In	O
spite	O
of	O
medical	O
help	O
:	O
the	O
puzzle	O
of	O
an	O
eighteenth	O
-	O
century	O
Prime	O
Minister	O
's	O
illness	O
.	O

Abstract	O
Medical	O
History	O
,	O
1990	O
,	O
34	O
:	O
178	O
-	O
184	O
.	O

IN	O
SPITE	O
OF	O
MEDICAL	O
HELP	O
:	O
THE	O
PUZZLE	O
OF	O
AN	O
EIGHTEENTH	O
-	O
CENTURY	O
PRIME	O
MINISTER	O
'S	O
ILLNESS	O
by	O
MARJORIE	O
BLOY	O
*	O
Charles	O
Watson	O
Wentworth	O
,	O
second	O
Marquis	O
of	O
Rockingham	O
,	O
died	O
suddenly	O
and	O
unexpectedly	O
on	O
1	O
July	O
1782	O
,	O
when	O
he	O
was	O
only	O
52	O
years	O
old	O
.	O

He	O
had	O
suffered	O
-	O
or	O
enjoyed	O
-	O
ill	O
health	O
all	O
his	O
life	O
but	O
in	O
1782	O
appeared	O
to	O
be	O
no	O
worse	O
than	O
he	O
had	O
ever	O
been	O
.	O

His	O
death	O
in	O
London	O
terminated	O
his	O
second	O
period	O
of	O
office	O
as	O
Prime	O
Minister	O
,	O
to	O
which	O
he	O
had	O
been	O
appointed	O
only	O
14	O
weeks	O
earlier	O
.	O

In	O
May	O
he	O
had	O
reported	O
to	O
the	O
Duke	O
of	O
Portland	O
that	O
he	O
had	O
""""	O
for	O
some	O
weeks	O
past	O
undergone	O
much	O
Pain	O
and	O
much	O
inconvenience	O
from	O
something	O
similar	O
to	O
my	O
old	O
Complaint	O
in	O
my	O
Side	O
and	O
Stomach	O
""""	O
but	O
that	O
he	O
felt	O
much	O
better	O
than	O
he	O
had	O
.	O
'	O

By	O
17	O
June	O
he	O
was	O
recovering	O
from	O
both	O
influenza	O
and	O
his	O
""""	O
old	O
"complaint"".2"	O
On	O
1	O
July	O
he	O
died	O
and	O
on	O
the	O
20th	O
he	O
was	O
interred	O
in	O
York	O
Minster	O
.	O

The	O
first	O
recorded	O
bout	O
of	O
illness	O
suffered	O
by	O
the	O
marquis	O
,	O
then	O
Lord	O
Higham	O
,	O
was	O
in	O
July	O
1741	O
when	O
the	O
11-year	O
-	O
old	O
was	O
""""	O
a	O
little	O
indisposed	O
,	O
something	O

Feaverish	O

I	O
guess	O
it	O
proceeds	O
from	O
Worms	O
and	O
will	O
Soon	O
be	O
"removed"".3"	O

He	O
also	O
had	O
a	O
rash	O
and	O
it	O
was	O
thought	O
that	O
the	O
cause	O
of	O
the	O
problem	O
was	O
that	O
the	O
boy	O
had	O
overheated	O
himself.4	O
He	O
was	O
still	O
ill	O
at	O
the	O
beginning	O
of	O
August	O
:	O
he	O
had	O
been	O
""""	O
much	O
out	O
of	O
order	O
""""	O
for	O
a	O
long	O
time	O
but	O
had	O
been	O
recommended	O
to	O
take	O
warm	O
baths	O
by	O
Dr	O
Wilmot	O
and	O
Mr	O
Ranby	O
when	O
they	O
were	O
consulted	O
in	O
London.5	O
Charles	O
's	O
aunt	O
,	O
Lady	O
Isabella	O
Finch	O
,	O
was	O
sure	O
that	O
the	O
baths	O
""""	O
and	O
other	O
Things	O
They	O
'll	O
prescribe	O
will	O
in	O
a	O
short	O
Time	O
entirely	O
Cure	O
his	O
Complaints	O
w	O
[	O
hic	O
]	O
h	O
neither	O
of	O
Them	O
thought	O
proceed	O
from	O
any	O
dangerous	O
"Causes"".6"	O
In	O
spite	O
of	O
Lady	O
Isabella	O
's	O
hopes	O
,	O
Charles	O
did	O
not	O
greatly	O
improve	O
,	O
even	O
though	O
his	O
mother	O
believed	O
that	O
he	O
continued	O
mending	O
every	O
day	O
.	O

The	O
main	O
reason	O
that	O
Higham	O
and	O
his	O
mother	O
had	O
gone	O
to	O
London	O
to	O
consult	O
Dr	O
Wilmot	O
and	O
Mr	O
*	O

Marjorie	O
Bloy	O
,	O
Ph.D.	O
,	O
18	O
Farm	O
View	O
Road	O
,	O
Kimberworth	O
,	O
Rotherham	O
,	O
S.	O
Yorks	O
.	O

S61	O
2BA	O
.	O

The	O
Rockingham	O
Papers	O
are	O
in	O
the	O
holdings	O
of	O
the	O
Wentworth	O
Woodhouse	O
Muniments	O
at	O
Sheffield	O
City	O
Archives	O
Department	O
,	O
Sheffield	O
City	O
Library	O
.	O

I	O
am	O
grateful	O
to	O
Dr	O
R.	O
S.	O
Morton	O
for	O
his	O
advice	O
and	O
help	O
with	O
the	O
diagnostic	O
sections	O
of	O
this	O
essay	O
.	O

'	O
WWM	O
,	O
RI-2094	O
.	O

Rockingham	O
to	O
Portland	O
,	O
25	O
May	O
1782	O
.	O

2WWM	O
,	O
RI-2094	O
.	O

Rockingham	O
to	O
Charlemont	O
,	O
17	O
June	O
1782	O
.	O

3	O
WWM	O
,	O
M8	O
-	O
25	O
.	O

Malton	O
to	O
Nottingham	O
,	O
after	O
16	O
June	O
1741	O
.	O

4	O
WWM	O
,	O
M8	O
-	O
26	O
.	O

Lady	O
Finch	O
to	O
Lady	O
Malton	O
,	O
30	O
July	O
1741	O
.	O

5	O
WWM	O
,	O
M8	O
-	O
28	O
.	O

Winchelsea	O
to	O
Malton	O
,	O
7	O
August	O
1741	O
.	O

6	O
WWM	O
,	O
M8	O
-	O
29	O
.	O

Lady	O
Finch	O
to	O
Malton	O
,	O
7	O
August	O
1741	O
.	O

178	O
An	O
eighteenth	O
-	O
century	O
Prime	O
Minister	O
's	O
illness	O
Ranby	O
was	O
his	O
mother	O
's	O
concern	O
about	O
a	O
""""	O
swelling	O
in	O
a	O
certain	O
part	O
which	O
was	O
larger	O
than	O
when	O
we	O
left	O
Wentworth	O
""""	O
.	O

The	O
doctors	O
hoped	O
that	O
it	O
would	O
burst	O
outwards	O
""""	O
which	O
they	O
assure	O
me	O
will	O
be	O
the	O
safest	O
way	O
and	O
give	O
the	O
poor	O
Monkey	O
but	O
very	O
little	O
pain	O
'	O
7	O
On	O
20	O
August	O
Lord	O
Winchelsea	O
,	O
Higham	O
's	O
uncle	O
,	O
surprised	O
to	O
see	O
the	O
boy	O
so	O
well	O
and	O
brisk	O
,	O
hoped	O
that	O
Charles	O
was	O
""""	O
now	O
safe	O
from	O
this	O
complaint	O
"""-"	O
the	O
same	O
one	O
from	O
which	O
he	O
had	O
suffered	O
in	O
1738	O
-	O
39-but	O
thought	O
that	O
he	O
would	O
never	O
be	O
safe	O
""""	O
if	O
he	O
continues	O
the	O
practice	O
of	O
overheating	O
himself	O
and	O
then	O
drinking	O
Cold	O
Water	O
""""	O
.	O

He	O
said	O
that	O
Charles	O
was	O
of	O
a	O
""""	O
pretty	O
healthy	O
strong	O
"Constitution"";8"	O
Lady	O
Malton	O
was	O
not	O
so	O
sure	O
.	O

The	O
same	O
day	O
she	O
wrote	O
a	O
progress	O
report	O
to	O
her	O
husband	O
saying	O
that	O
Charles	O
's	O
swelling	O
continued	O
to	O
grow	O
,	O
as	O
did	O
the	O
pain	O
""""	O
in	O
that	O
part	O
(	O
but	O
not	O
the	O
lease	O
[	O
sic	O
]	O
trouble	O
in	O
making	O
Water	O
or	O
going	O
to	O
Stool	O
)	O
&	O
less	O
Fever	O
than	O
c	O
[	O
oulJd	O
be	O
imagined	O
where	O
Matter	O
is	O
as	O
they	O
now	O
imagine	O
certainly	O
gathering	O
and	O
must	O
end	O
in	O
an	O
operation	O
""""	O
.	O

In	O
spite	O
of	O
it	O
all	O
,	O
Charles	O
was	O
in	O

fine	O
spirits.9	O
Lady	O
Malton	O
dosed	O
the	O
boy	O
with	O
cinchona	B
bark	O
,	O
which	O
removed	O
the	O
pains	O
in	O
his	O
legs	O
and	O
reduced	O
his	O
fever	O
,	O
and	O
she	O
was	O
convinced	O
that	O
they	O
would	O
soon	O
have	O
""""	O
a	O
clear	O
Stage	O
to	O
act	O
in	O
a	O
proper	O
manner	O
a	O
[	O
bou	O
]	O
t	O
his	O
other	O
Complaints	O
w	O
[	O
hic	O
]	O
h	O
the	O
Learned	O
assure	O
me	O
are	O
to	O
be	O
conquered	O
also	O
""""	O
.	O

10	O
Charles	O
was	O
soon	O
allowed	O
to	O
eat	O
meat	O
and	O
Mr	O
Ranby	O
still	O
assured	O
her	O
that	O
the	O
swelling	O
would	O
break	O
outwards	O
.	O

1	O
""""	O
Three	O
days	O
later	O
he	O
decided	O
to	O
lance	O
it	O
,	O
even	O
though	O
Dr	O
Bourne	O
disagreed	O
.	O

The	O
boy	O
's	O
mother	O
was	O
puzzled	O
because	O
the	O
swelling	O
""""	O
sometimes	O
pushes	O
forward	O
very	O
fast	O
then	O
retires	O
a	O
little	O
""""	O
but	O
the	O
doctor	O
and	O
Ranby	O
seemed	O
happy	O
with	O
his	O
condition.'2	O
At	O
this	O
point	O
the	O
letters	O
cease	O
,	O
presumably	O
because	O
Malton	O
arrived	O
in	O
London	O
with	O
his	O
daughters	O
,	O
to	O
have	O
them	O
inoculated	O
against	O
smallpox	B
,	O
but	O
a	O
later	O
letter	O
states	O
that	O
surgery	O
to	O
open	O
the	O
swelling	O
was	O
not	O
undertaken	O
.	O

13	O
By	O
the	O
end	O
of	O
October	O
the	O
correspondence	O
had	O
recommenced	O
.	O

Charles	O
was	O
ill	O
again	O
.	O

He	O
was	O
just	O
the	O
same	O
as	O
when	O
he	O
left	O
Kensington	O
,	O
so	O
John	O
Bourne	O
had	O
bled	O
him	O
and	O
the	O
child	O
had	O
started	O
on	O
Sir	O
Edward	O
Hulse	O
's	O
prescription	O
,	O
unfortunately	O
not	O
defined	O
in	O
the	O
letter	O
,	O
but	O
which	O
was	O
apparently	O
as	O
bad	O
as	O
the	O
last	O
one	O
,	O
if	O
not	O
worse	O
.	O

Lady	O
Malton	O
thought	O
that	O
""""	O
with	O
such	O
a	O
State	O
of	O
Blood	O
the	O
Continuation	O
of	O
Health	O
can	O
not	O
be	O
expected	O
""""	O
but	O
was	O
hopeful	O
that	O
the	O
""""	O
Cinnabar	O
may	O
prove	O
a	O
more	O
Efficacious	O
remedie	O
than	O
any	O
than	O
has	O
been	O
tryed	O
"yet"""".""4"	O
That	O
night	O
she	O
applied	O
""""	O
a	O
Blister	O
...	O
without	O
the	O
least	O
Symptom	O
or	O
tendency	O
to	O
anything	O
like	O
Strangury	O
""""	O
.	O

He	O
bore	O
the	O
treatment	O
well	O
,	O
as	O
he	O
had	O
done	O
three	O
years	O
previously	O
,	O
and	O
it	O
seemed	O
so	O
successful	O
that	O
Lady	O
Malton	O
was	O
""""	O
determined	O
to	O
keep	O
it	O
running	O
full	O
as	O
long	O
as	O
I	O
did	O
last	O
time	O
by	O
the	O
help	O
of	O
John	O
Borne	O
[	O
sic	O
]	O
with	O
much	O
ease	O
to	O
the	O
Dear	O
"Child"".'5"	O
She	O
7	O
WWM	O
,	O
M7	O
-	O
51	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
18	O
August	O
1741	O
.	O

8	O
WWM	O
,	O
M2	O
-	O
84	O
.	O

Winchelsea	O
to	O
Malton	O
,	O
20	O
August	O
1741	O
.	O

9	O
WWM	O
,	O
M7	O
-	O
52	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
20	O
August	O
1741	O
.	O
'	O

0	O
WWM	O
,	O
M7	O
-	O
53	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
25	O
August	O
1741	O
.	O

WWM	O
,	O
M7	O
-	O
54	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
29	O
August	O
1741	O
.	O

WWM	O
,	O
M7	O
-	O
55	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
1	O
September	O
1741	O
.	O

3	O
WWM	O
,	O
R170	O
-	O
20	O
.	O

Nicol6	O

Scanagati	O
of	O
Padua	O
,	O
20	O
July	O
1750	O
.	O

I	O
am	O
grateful	O
to	O
Fr	O
John	O
McMahon	O
and	O
Dr	O
Stephen	O
Bemrose	O
for	O
their	O
translations	O
of	O
this	O
letter	O
.	O

4	O
WWM	O
,	O
M7	O
-	O
14	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
31	O
October	O
1741	O
.	O

5	O
WWM	O
,	O
M7	O
-	O
19	O
.	O

Lady	O
Malton	O
to	O
Lady	O
Finch	O
,	O
2	O
November	O
1741	O
.	O

179	O
Marjorie	O
Bloy	O
continued	O
with	O
the	O
blister	O
and	O
applied	O
""""	O
ointment	O
with	O
flyes	O
""""	O
,	O
apparently	O
some	O
sort	O
of	O
irritant	O
potion	O
,	O
with	O
no	O
sign	O
of	O
strangury	O
.	O

Charles	O
found	O
her	O
treatment	O
""""	O
not	O
near	O
the	O
pain	O
he	O
expected	O
""""	O
and	O
she	O
was	O
""""	O
full	O
of	O
hopes	O
that	O
he	O
will	O
rec	O
[	O
eiv	O
]	O
e	O
great	O
benefit	O
from	O
"it"".1"	O
Apart	O
from	O
his	O
other	O
troubles	O
,	O
one	O
of	O
Charles	O
's	O
knees	O
had	O
swollen	O
but	O
this	O
had	O
much	O
abated	O
since	O
the	O
application	O
of	O
the	O
blisters	O
which	O
Lady	O
Malton	O
believed	O
""""	O
must	O
be	O
acting	O
upon	O
the	O
whole	O
Mass	O
of	O
Blood	O
""""	O
since	O
it	O
had	O
""""	O
reached	O
the	O
remote	O
part	O
""""	O
.	O

She	O
thought	O
that	O
Sir	O
Edward	O
Hulse	O
's	O
powders	O
were	O
too	O
slow	O
in	O
taking	O
effect	O
although	O
the	O
boy	O
took	O
them	O
very	O
quietly.'7	O
Sir	O
Edward	O
did	O
not	O
""""	O
apprehend	O
any	O
great	O
danger	O
from	O
the	O
Siziness	O
[	O
thickness	O
]	O
of	O
Charles	O
'	O
blood	O
""""	O
;	O
Lady	O
Malton	O
thought	O
that	O
the	O
condition	O
was	O
the	O
cause	O
of	O
all	O
the	O
child	O
's	O
problems	O
,	O
which	O
would	O
not	O
end	O
until	O
it	O
was	O
set	O
to	O
rights	O
.	O

At	O
any	O
rate	O
,	O
he	O
was	O
fit	O
enough	O
to	O
go	O
hunting.'8	O
Charles	O
continued	O
in	O
the	O
same	O
state	O
of	O
health	O
.	O

He	O
slept	O
well	O
at	O
night	O
,	O
ate	O
more	O
than	O
his	O
mother	O
thought	O
was	O
good	O
for	O
him	O
,	O
and	O
was	O
able	O
to	O
exercise	O
strenuously	O
without	O
tiring	O
.	O

He	O
put	O
on	O
no	O
weight	O
though	O
,	O
and	O
""""	O
as	O
for	O
them	O
swellings	O
at	O
his	O
throat	O
,	O
they	O
are	O
almost	O
gone	O
one	O
day	O
and	O
rise	O
the	O
next	O
""""	O
.	O

His	O
mother	O
did	O
not	O
expect	O
a	O
speedy	O
recovery	O
and	O
""""	O
if	O
the	O
D	O
[	O
octo	O
]	O
rs	O
think	O
him	O
in	O
a	O
good	O
state	O
of	O
health	O
now	O
,	O
I	O
s	O
[	O
houl	O
]	O
d	O
be	O
glad	O
to	O
see	O
him	O
in	O
a	O
"better"".'9"	O
He	O
began	O
to	O
improve	O
and	O
by	O
the	O
end	O
of	O
November	O
even	O
she	O
thought	O
he	O
was	O
on	O
the	O
mend	O
and	O
gaining	O
weight.20	O
Unfortunately	O
,	O
Lady	O
Malton	O
again	O
had	O
cause	O
for	O
concern	O
over	O
his	O
health	O
in	O
January	O
1742	O
when	O
he	O
began	O
to	O
suffer	O
from	O
an	O
intermittent	O
hoarseness.2	O
'	O
Otherwise	O
he	O
was	O
as	O
well	O
as	O
one	O
could	O
expect	O
,	O
with	O
no	O
other	O
complaints.22	O
It	O
was	O
not	O
to	O
last	O
.	O

In	O
May	O
1742	O
Charles	O
and	O
his	O
mother	O
were	O
again	O
in	O
Bristol	O
,	O
taking	O
the	O
waters	O
because	O
he	O
had	O
been	O
indisposed	O
.	O

Lady	O
Malton	O
thought	O
the	O
waters	O
were	O
doing	O
them	O
good	O
because	O
they	O
were	O
both	O
being	O
violently	O
sick.23	O
However	O
,	O
Charles	O
had	O
had	O
no	O
dinner	O
on	O
25	O
or	O
26	O
May	O
and	O
was	O
hot	O
,	O
lazy	O
,	O
and	O
inclined	O
to	O
stir	O
,	O
""""	O
from	O
which	O
I	O
conclude	O
he	O
is	O
not	O
well	O
,	O
.	O
.	O
.	O

and	O
therefore	O
Intend	O
to	O
give	O
him	O
a	O
gentle	O
Vomit	O
...	O
and	O
to	O
let	O
him	O
take	O
his	O
old	O
Remedie	O
the	O
Salt	O
Draughts	O
for	O
a	O
few	O
Daies	O
which	O
I	O
dare	O
say	O
will	O
set	O
him	O
quite	O
to	O
"rights"".24"	O
By	O
29	O
May	O
Dr	O
Boume	O
had	O
bled	O
the	O
boy	O
""""	O
which	O
succeeded	O
very	O
well	O
but	O
...	O
found	O
it	O
[	O
his	O
blood	O
]	O
as	O
bad	O
as	O
ever	O
""""	O
.	O

The	O
waters	O
were	O
not	O
working	O
""""	O
but	O
there	O
is	O
a	O
great	O
deal	O
for	O
them	O
to	O
do	O
which	O
grant	O
God	O
they	O
may	O
effect	O
""""	O
.	O

The	O
weather	O
had	O
turned	O
warm	O
so	O
Lady	O
Malton	O
had	O
""""	O
shorn	O
him	O
...	O
which	O
has	O
display'd	O
a	O
most	O
scabby	O
head	O
and	O
indeed	O
several	O
other	O
untoward	O
Blotches	O
he	O
has	O
out	O
upon	O
other	O
parts	O
of	O
his	O
Body	O
""""	O
,	O
which	O
made	O
her	O
uneasy.25	O
The	O
blotches	O
on	O
his	O
head	O
were	O
not	O
numerous	O
""""	O
yet	O
they	O
made	O
up	O
in	O
quality	O
for	O
so	O
virulent	O
a	O
Corrosive	O
Humour	O
is	O
not	O
easily	O
conceived	O
without	O
seeing	O
it	O
""""	O
.	O

The	O
pustules	O
on	O
his	O
body	O
were	O
of	O
the	O
same	O
sort	O
16	O
WWM	O
,	O
M7	O
-	O
17	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
4	O
November	O
1741	O
.	O

7	O
WWM	O
,	O
M7	O
-	O
18	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
4	O
November	O
1741	O
.	O

18	O
WWM	O
,	O
M7	O
-	O
16	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
7	O
November	O
1741	O
.	O
'	O

9WWM	O
,	O
M7	O
-	O
15	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
9	O
November	O
1741	O
.	O

20	O
WWM	O
,	O
M7	O
-	O
22	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
25	O
November	O
1741	O
.	O

21	O
WWM	O
,	O
M7	O
-	O
1	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
25	O
January	O
1742	O
.	O

22	O
WWM	O
,	O
M7	O
-	O
4	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
8	O
February	O
1742	O
and	O
WWM	O
,	O
M7	O
-	O
9	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
22	O
February	O
1742	O
.	O

23	O
WWM	O
,	O
M7	O
-	O
29	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
12	O
May	O
1742	O
.	O

24	O
WWM	O
,	O
M7	O
-	O
35	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
26	O
May	O
1742	O
.	O

25	O
WWM	O
,	O
M7	O
-	O
36	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
29	O
May	O
1742	O
.	O

180	O
An	O
eighteenth	O
-	O
century	O
Prime	O
Minister	O
's	O
illness	O
and	O
his	O
mother	O
intended	O
to	O
put	O
plasters	O
on	O
them	O
to	O
prevent	O
them	O
from	O
spreading	O
.	O

Charles	O
was	O
also	O
feverish	O
;	O
his	O
glands	O
were	O
swollen	O
and	O
his	O
pulse	O
was	O
erratic	O
""""	O
but	O
out	O
of	O
compassion	O
to	O
you	O

I	O
must	O
tell	O
you	O
that	O
he	O
is	O
with	O
me	O
as	O
Brisk	O
and	O
lively	O
as	O
you	O
ever	O
Saw	O
him	O
""""	O
.	O

Lady	O
Malton	O
had	O
called	O
in	O
two	O
eminent	O
Bristol	O
men	O
,	O
Dr	O
Logan	O
and	O
Mr	O
Pye	O
,	O
to	O
treat	O
the	O
boy	O
;	O
Mr	O
Pye	O
prescribed	O
""""	O
the	O
Precipitate	O
Per	O
se	O
""""	O
as	O
the	O
cure	O
for	O
the	O
""""	O
hectic	O
""""	O
.	O

Pye	O
made	O
it	O
himself	O
and	O
said	O
that	O
it	O
was	O
the	O
only	O
remedy	O
that	O
would	O
work	O
.	O

Clearly	O
Charles	O
was	O
impatient	O
to	O
be	O
cured	O
because	O
he	O
told	O
his	O
mother	O
to	O
give	O
him	O
the	O
medicine	O
""""	O
to	O
cure	O
me	O
which	O
I	O
am	O
sure	O
it	O
will	O
do	O
or	O
shoot	O
me	O
through	O
the	O
head	O
at	O
once	O
""""	O
.	O

She	O
thought	O
that	O
this	O
attitude	O
was	O
""""	O
odd	O
from	O
one	O
of	O
his	O
Age	O
and	O
[	O
it	O
]	O
does	O
not	O
a	O
little	O
"disturb"".26"	O
The	O
blotches	O
began	O
to	O
burst	O
and	O
indent	O
but	O
the	O
doctor	O
thought	O
that	O
all	O
would	O
be	O
well	O
in	O
the	O
end.27	O
Meanwhile	O
,	O
Charles	O
was	O
still	O
losing	O
weight	O
even	O
though	O
""""	O
he	O
had	O
none	O
to	O
spare	O
before	O
""""	O
and	O
he	O
was	O
inclined	O
to	O
be	O
lazy	O
which	O
was	O
not	O
his	O
natural	O
turn	O
.	O

His	O
father	O
recommended	O
some	O
unknown	O
cure	O
which	O
he	O
called	O
Gascoin	O
's	O
Powder	O
-	O
a	O
dose	O
of	O
five	O
grains	O
made	O
up	O
with	O
syrup	O
into	O
a	O
pill	O
-	O
every	O
night	O
.	O

To	O
make	O
matters	O
worse	O
,	O
the	O
doctors	O
disagreed	O
about	O
the	O
treatment	O
.	O
""""	O

Dr	O
Pye	O
is	O
Vehemently	O
for	O
the	O
P.	O
Per	O
se	O
,	O
Dr	O
Logan	O
saies	O
that	O
it	O
is	O
a	O
Medicine	O
that	O
may	O
prove	O
too	O
rough	O
in	O
its	O
operation	O
for	O
his	O
Constitution	O
&	O
therefore	O
begs	O
a	O
tryal	O
of	O
Beazor	O
mineral	O
[	O
gall	O
stones	O
from	O
a	O
goat	B
]	O
and	O
Viper	O
Broth	O
""""	O
.	O

The	O
Bristol	O
water	O
had	O
not	O
yet	O
acted	O
""""	O
because	O
his	O
case	O
is	O
of	O
too	O
obstinate	O
a	O
Nature	O
""""	O
and	O
Lady	O
Malton	O
herself	O
was	O
satisfied	O
that	O
since	O
nothing	O
else	O
had	O
worked	O
to	O
cure	O
the	O
boy	O
,	O
the	O
time	O
had	O
come	O
to	O
try	O
mercurials	O
,	O
even	O
though	O
she	O
knew	O
that	O
they	O
were	O
""""	O
powerful	O
and	O
perhaps	O
in	O
some	O
cases	O
hazardous	O
"medicines"".28"	O

She	O
wanted	O
to	O
see	O
some	O
remedy	O
succeed	O
but	O
was	O
""""	O
afraid	O
of	O
violent	O
ones	O
and	O
at	O
the	O
same	O
time	O
vastly	O
distrustfull	O
[	O
sic	O
]	O
of	O
mild	O
ones	O
""""	O
.	O

It	O
would	O
appear	O
that	O
the	O
""""	O
precipitate	O
Per	O
se	O
""""	O
,	O
probably	O
mercury	O
-	O
based	O
,	O
could	O
be	O
a	O
kill	O
-	O
or	O
-	O
cure	O
remedy	O
.	O

Her	O
""""	O
terrors	O
""""	O
did	O
not	O
arise	O
from	O
any	O
immediate	O
danger	O
to	O
her	O
son	O
,	O
and	O
her	O
""""	O
perfect	O
Knowledge	O
""""	O
of	O
his	O
disorder	O
convinced	O
her	O
that	O
whatever	O
remedies	O
he	O
took	O
,	O
the	O
cure	O
was	O
in	O
the	O
hands	O
of	O
God.29	O
To	O
add	O
to	O
Charles	O
'	O
disorders	O
,	O
on	O
12	O
June	O
he	O
developed	O
a	O
""""	O
very	O
inflamed	O
bad	O
Eye	O
...	O
the	O
same	O
Eye	O
that	O
...	O
he	O
did	O
not	O
see	O
so	O
well	O
of	O
[	O
as	O
]	O
the	O
other	O
...	O

He	O
sais	O
[	O
sic	O
]	O
that	O
from	O
that	O
eye	O
Alone	O
he	O
can	O
Scarcely	O
distinguish	O
anything	O
""""	O
.	O

The	O
doctors	O
suggested	O
bathing	O
the	O
eye	O
:	O
Lady	O
Malton	O
knew	O
that	O
the	O
""""	O
frightful	O
symptoms	O
""""	O
which	O
were	O
""""	O
shocking	O
to	O
behold	O
""""	O
were	O
a	O
result	O
of	O
""""	O
the	O
Same	O
as	O
produces	O
all	O
the	O
rest	O
of	O
his	O
complaints	O
in	O
whichever	O
Shape	O
they	O
appear	O
""""	O
.	O

30	O
The	O
eye	O
was	O
very	O
bloodshot	O
and	O
inflamed	O
;	O
the	O
eyelid	O
was	O
swollen	O
so	O
he	O
could	O
hardly	O
open	O
it	O
.	O

The	O
other	O
eye	O
was	O
dull	O
and	O
""""	O
he	O
had	O
very	O
little	O
sight	O
of	O
"it"".31"	O
By	O
14	O
June	O
the	O
eye	O
problem	O
had	O
eased	O
somewhat	O
but	O
Lady	O
Malton	O
could	O
find	O
no	O
cause	O
to	O
attribute	O
the	O
improvement	O
to	O
any	O
of	O
the	O
""""	O
cures	O
""""	O
.	O

Charles	O
was	O
still	O
being	O
subjected	O
to	O
Bristol	O
water	O
,	O
Beazor	O
mineral	O
,	O
Viper	O
broth	O
,	O
cinnabar	O
and	O
the	O
precipitate	O
per	O
se.32	O
She	O
decided	O
to	O
take	O
the	O
boy	O
home	O
to	O
Wentworth	O
because	O
he	O
was	O
26	O
WWM	O
,	O
M7	O
-	O
38	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
1	O
June	O
1742	O
.	O

27	O
WWM	O
,	O
M7	O
-	O
39	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
2	O
June	O
1742	O
.	O

28	O
WWM	O
,	O
M7	O
-	O
41	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
5	O
June	O
1742	O
.	O

29	O
WWM	O
,	O
M7	O
-	O
43	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
7	O
June	O
1742	O
.	O

30	O
WWM	O
,	O
M7	O
-	O
45	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
12	O
June	O
1742	O
.	O

31	O
WWM	O
,	O
M7	O
-	O
56	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
undated	O
:	O
12	O
June	O
?	O
1742	O
.	O

32	O
WWM	O
,	O
M7	O
-	O
46	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
14	O
June	O
?	O
1742	O
.	O

181	O
Marjorie	O
Bloy	O
more	O
likely	O
to	O
recover	O
there	O
than	O
anywhere	O
else.33	O
He	O
still	O
ate	O
and	O
slept	O
well	O
and	O
was	O
""""	O
pretty	O
cheerful	O
but	O
his	O
looks	O
are	O
bitter	O
bad	O
still	O
.	O

The	O
flesh	O
he	O
lost	O
in	O
the	O
Accidental	O
Feavour	O
he	O
has	O
not	O
Recover'd	O
and	O
his	O
complexion	O
is	O
of	O
the	O
most	O
sickly	O
sort	O
his	O
hands	O
of	O
the	O
same	O
Hue	O
his	O
legs	O
are	O
tollerable	O
[	O
sic	O
]	O
"well"".34"	O
They	O
returned	O
to	O
Wentworth	O
in	O
short	O
stages	O
and	O
by	O
6	O
September	O
Higham	O
was	O
""""	O
perfectly	O
recovered	O
.	O
.	O
.	O

after	O
the	O
long	O
and	O
successful	O
Care	O
that	O
Lady	O
Malton	O
has	O
taken	O
""""	O
of	O
him.35	O
In	O
May	O
1743	O
he	O
was	O
inoculated	O
against	O
smallpox	B
and	O
made	O
a	O
perfect	O
recovery	O
after	O
which	O
he	O
caught	O
cold	O
""""	O
by	O
stripping	O
when	O
He	O
was	O
"hot"".36"	O
Lord	O
Higham	O
does	O
not	O
seem	O
to	O
have	O
been	O
seriously	O
ill	O
after	O
that	O
until	O
,	O
at	O
the	O
age	O
of	O
19	O
,	O
he	O
undertook	O
his	O
Grand	O
Tour	O
in	O
1749	O
.	O

In	O
July	O
1750	O
,	O
by	O
then	O
Lord	O
Malton	O
,	O
he	O
had	O
cause	O
to	O
consult	O
Nicolo	O
Scanagati	O
in	O
Padua	O
for	O
the	O
treatment	O
of	O
gonorrhoea	O
.	O

Scanagati	O
produced	O
a	O
lengthy	O
medical	O
report	O
of	O
Malton	O
's	O
treatment	O
,	O
presumably	O
for	O
his	O
English	O
doctor	O
's	O
enlightenment.37	O
The	O
initial	O
treatment	O
was	O
an	O
""""	O
electuary	O
,	O
consisting	O
of	O
three	O
ounces	O
of	O
emollient	O
,	O
three	O
drams	O
of	O
powdered	O
jalap	B
,	O
a	O
half	O
[	O
dram	O
]	O
of	O
purified	O
nitre	O
,	O
bound	O
together	O
with	O
lemon	B
juice	O
taken	O
twice	O
a	O
day	O
""""	O
.	O

The	O
result	O
was	O
satisfactory	O
:	O
""""	O
The	O
dark	O
greenish	O
poison	O
was	O
oozing	O
slowly	O
from	O
his	O
penis	O
,	O
which	O
was	O
all	O
contracted	O
and	O
the	O
sharp	O
and	O
constant	O
pain	O
extended	O
from	O
the	O
perineum	O
up	O
to	O
the	O
urinary	O
bladder	O
,	O
producing	O
small	O
swellings	O
now	O
in	O
this	O
place	O
,	O
now	O
in	O
that	O
.	O
""""	O

There	O
was	O
a	O
fierce	O
burning	O
sensation	O
in	O
the	O
glands	O
,	O
which	O
prevented	O
him	O
from	O
sleeping	O
.	O

Because	O
of	O
this	O
,	O
it	O
seemed	O
reasonable	O
to	O
bathe	O
that	O
part	O
in	O
tepid	O
water	O
and	O
milk	O
,	O
and	O
to	O
apply	O
poultices	O
to	O
the	O
areas	O
affected	O
by	O
swelling	O
and	O
contractions	O
,	O
together	O
with	O
cold	O
drinks	O
and	O
a	O
few	O
grains	O
of	O
laudanum	O
at	O
night	O
.	O

Malton	O
was	O
blooded	O
regularly	O
besides	O
being	O
given	O
purgatives	O
;	O
the	O
treatment	O
then	O
moved	O
on	O
to	O
the	O
administration	O
of	O
mercury	O
,	O
both	O
internal	O
and	O
on	O
the	O
gums	O
,	O
since	O
it	O
was	O
widely	O
believed	O
at	O
the	O
time	O
that	O
gonorrhoea	O
and	O
syphilis	O
were	O
steps	O
of	O
the	O
same	O
disease	O
,	O
""""	O
the	O
Venereal	O
""""	O
.	O

Scanagati	O
at	O
this	O
point	O
ruled	O
out	O
the	O
suggestion	O
of	O
syphilitic	O
chancre	O
because	O
Malton	O
's	O
urine	O
was	O
fine	O
and	O
light	O
with	O
a	O
pungent	O
odour	O
.	O

Scanagati	O
did	O
ask	O
if	O
Malton	O
had	O
previously	O
ever	O
had	O
a	O
similar	O
peculiarity	O
of	O
his	O
urine	O
.	O

Malton	O
replied	O
that	O
when	O
he	O
was	O
very	O
young	O
and	O
still	O
inexperienced	O
sexually	O
,	O
for	O
some	O
time	O
following	O
a	O
fever	O
he	O
had	O
had	O
the	O
same	O
unusual	O
urine	O
,	O
and	O
indeed	O
that	O
on	O
one	O
occasion	O
this	O
symptom	O
coincided	O
with	O
certain	O
tumours	O
on	O
the	O
testicles	O
.	O

It	O
was	O
only	O
by	O
chance	O
that	O
he	O
had	O
not	O
had	O
recourse	O
to	O
surgery	O
,	O
the	O
reason	O
being	O
that	O
he	O
was	O
also	O
afflicted	O
with	O
a	O
throat	O
infection	O
-	O
to	O
which	O
he	O
was	O
prone	O
-	O
and	O
therefore	O
had	O
his	O
vein	O
opened	O
four	O
times	O
.	O

Thereupon	O
the	O
inflammation	O
subsided	O
,	O
and	O
equally	O
the	O
tumours	O
and	O
sediment	O
disappeared	O
.	O

He	O
told	O
me	O
that	O
as	O
a	O
youth	O
he	O
had	O
sometimes	O
experienced	O
some	O
difficulty	O
and	O
a	O
burning	O
sensation	O
when	O
urinating	O
,	O
which	O
subsided	O
when	O
his	O
blood	O
was	O
let	O
and	O
with	O
the	O
application	O
of	O
poultices	O
.	O

I	O
observed	O
that	O
from	O
time	O
to	O
time	O
his	O
face	O
and	O
body	O
were	O
covered	O
with	O
purplish	O
spots	O
,	O
which	O
,	O
having	O
produced	O
a	O
little	O
fluid	O
,	O
would	O
disappearas	O
indeed	O
happened	O
in	O
the	O
course	O
of	O
the	O
cure	O
,	O
at	O
the	O
end	O
of	O
which	O
his	O
face	O
was	O
entirely	O
33	O
WWM	O
,	O
M7	O
-	O
47	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
15	O
June	O
1742	O
.	O

34	O
WWM	O
,	O
M7	O
-	O
48	O
.	O

Lady	O
to	O
Lord	O
Malton	O
,	O
16	O
June	O
1742	O
.	O

35	O
WWM	O
,	O
M2	O
-	O
104	O
/	O
5	O
.	O

Lady	O
Finch	O
to	O
Lady	O
Malton	O
,	O
6	O
September	O
1742	O
.	O

36	O
WWM	O
,	O
M2	O
-	O
135	O
.	O

Lady	O
Finch	O
to	O
Malton	O
,	O
18	O
June	O
1742	O
.	O

37	O
WWM	O
,	O
R170	O
-	O
20	O
.	O

Nicol6	O
Scanagati	O
's	O
report	O
.	O

182	O
An	O
eighteenth	O
-	O
century	O
Prime	O
Minister	O
's	O
illness	O
free	O
from	O
these	O
spots	O
.	O

From	O
this	O
observation	O
,	O
it	O
seemed	O
to	O
me	O
simple	O
to	O
deduce	O
both	O
the	O
original	O
cause	O
and	O
the	O
more	O
immediate	O
cause	O
of	O
the	O
said	O
sediment	O
:	O
namely	O
a	O
natural	O
complexion	O
of	O
humours	O
which	O
are	O
exacerbated	O
by	O
muriatic	O
[	O
i.e.	O
,	O
acidic	O
]	O
sourness	O
,	O
together	O
with	O
the	O
marked	O
inflammation	O
of	O
the	O
blood	O
and	O
the	O
motion	O
of	O
the	O
contracted	O
poison	O
.	O

Scanagati	O
then	O
recommended	O
the	O
continuation	O
of	O
the	O
electuary	O
made	O
of	O
emollient	O
,	O
guaiacum	O
resin	O
,	O
balsam	O
,	O
rhubarb	B
,	O
and	O
nitre	O
.	O

What	O
does	O
all	O
this	O
add	O
up	O
to	O
in	O
terms	O
of	O
diagnosis	O
?	O

The	O
early	O
illness	O
is	O
a	O
mystery	O
.	O

Did	O
he	O
have	O
an	O
inguinal	O
hernia	O
;	O
or	O
perhaps	O
mumps	O
or	O
epididymitis	O
?	O

His	O
was	O
a	O
childless	O
marriage	O
.	O

He	O
seems	O
to	O
have	O
been	O
too	O
fit	O
for	O
the	O
illness	O
to	O
have	O
been	O
rheumatic	O
fever	O
.	O

Cystitis	O
was	O
not	O
uncommon	O
and	O
this	O
could	O
certainly	O
lead	O
to	O
""""	O
strangury	O
""""	O
.	O

Perhaps	O
Rockingham	O
suffered	O
from	O
a	O
congenital	O
defect	O
of	O
his	O
urinogenitary	O
system	O
which	O
would	O
result	O
in	O
recurrent	O
attacks	O
of	O
cystitis	O
and	O
might	O
cause	O
long	O
-	O
term	O
damage	O
to	O
the	O
urinary	O
tract	O
and	O
eventual	O
destruction	O
of	O
the	O
kidneys	O
,	O
precipitating	O
sudden	O
and	O
unexpected	O
death	O
.	O

Another	O
possibility	O
might	O
be	O
diabetes	O
.	O

Rockingham	O
had	O
a	O
urinary	O
infection	O
and	O
certainly	O
suffered	O
from	O
recurrent	O
skin	O
infections	O
,	O
although	O
it	O
appears	O
from	O
Scanagati	O
's	O
report	O
that	O
these	O
cleared	O
up	O
when	O
mercury	O
was	O
administered	O
.	O

Certainly	O
the	O
marquis	O
complained	O
often	O
about	O
pains	O
in	O
his	O
side	O
and	O
stomach	O
and	O
made	O
no	O
secret	O
of	O
his	O
""""	O
old	O
complaint	O
""""	O
.	O

He	O
was	O
noticeably	O
less	O
physically	O
active	O
as	O
he	O
moved	O
into	O
his	O
thirties	O
and	O
only	O
occasionally	O
exerted	O
himself	O
by	O
riding	O
any	O
distance	O
,	O
even	O
though	O
he	O
had	O
enjoyed	O
hunting	O
when	O
he	O
was	O
younger	O
.	O

He	O
found	O
the	O
pains	O
caused	O
by	O
his	O
""""	O
old	O
complaint	O
""""	O
made	O
him	O
feel	O
so	O
ill	O
that	O
he	O
was	O
unable	O
to	O
concentrate	O
on	O
""""	O
any	O
Manner	O
of	O
Business	O
""""	O
and	O
on	O
occasion	O
it	O
seemed	O
likely	O
to	O
prevent	O
him	O
from	O
attending	O
Parliament.38	O
He	O
may	O
well	O
have	O
suffered	O
from	O
a	O
problem	O
with	O
gallstones	O
from	O
an	O
early	O
age.39	O
He	O
appears	O
to	O
have	O
suffered	O
from	O
a	O
nervous	O
disorder	O
which	O
manifested	O
itself	O
in	O
severe	O
palpitations	O
,	O
trembling	O
,	O
and	O
other	O
types	O
of	O
physical	O
discomforts	O
such	O
as	O
boils	O
and	O
headaches	O
with	O
which	O
he	O
was	O
frequently	O
afflicted.40	O
He	O
probably	O
had	O
constipation	O
too	O
,	O
since	O
he	O
was	O
always	O
dosing	O
himself	O
with	O
purgatives	O
.	O

In	O
fact	O
in	O
April	O
1772	O
the	O
Duke	O
of	O
Richmond	O
decided	O
that	O
Rockingham	O
's	O
real	O
problem	O
was	O
a	O
""""	O
surfeit	O
of	O
"physick""41"	O
although	O
Edmund	O
Burke	O
noted	O
in	O
June	O
1772	O
that	O
the	O
marquis	O
had	O
had	O
a	O
long	O
and	O
severe	O
illness.42	O
Whatever	O
his	O
many	O
and	O
varied	O
ailments	O
,	O
Rockingham	O
survived	O
until	O
he	O
was	O
52	O
in	O
spite	O
of	O
the	O
attentions	O
of	O
both	O
doctors	O
and	O
quacks	O
and	O
that	O
,	O
for	O
the	O
mid	O
-	O
eighteenth	O
century	O
,	O
was	O
a	O
good	O
age	O
.	O

The	O
mystery	O
still	O
remains	O
,	O
however	O
.	O

Contemporary	O
opinion	O
had	O
it	O
that	O
he	O
died	O
of	O
pneumonia	O
but	O
it	O
must	O
have	O
struck	O
38	O
WWM	O
,	O
R153	O
-	O
1	O
.	O

Rockingham	O
to	O
Burke	O
,	O
31	O
October	O
1767	O
;	O
WWM	O
,	O
RI-1238	O
.	O

Rockingham	O
to	O
Dowdeswell	O
,	O
20	O
October	O
1769	O
;	O
WWM	O
,	O
RI-1928	O
.	O

Rockingham	O
to	O
Savile	O
,	O
September	O
1780	O
.	O

39	O
Ross	O
J.	O
S.	O
Hoffman	O
,	O
The	O
Marquis	O
.	O

A	O
study	O
of	O
Lord	O
Rockingham	O
,	O
1730	O
-	O
1782	O
,	O
New	O
York	O
,	O
Fordham	O
University	O
Press	O
,	O
1973	O
,	O
p.	O
35	O
.	O

This	O
is	O
the	O
only	O
recent	O
biography	O
of	O
the	O
second	O
Marquis	O
of	O
Rockingham	O
,	O
and	O
does	O
not	O
deal	O
with	O
his	O
illnesses	O
.	O

Although	O
he	O
does	O
not	O
give	O
the	O
source	O
of	O
his	O
information	O
,	O
Hoffman	O
asserts	O
that	O
Rockingham	O
was	O
in	O
Bath	O
between	O
March	O
and	O
August	O
1761	O
suffering	O
from	O
gallstones	O
.	O

The	O
marquis	O
would	O
then	O
have	O
been	O
31	O
years	O
old	O
.	O

40	O
Historical	O
Manuscripts	O
Commission	O
,	O
Lindley	O
Wood	O
,	O
p.	O
184	O
.	O

41	O
WWM	O
,	O
RI-1403	O
.	O

Richmond	O
to	O
Rockingham	O
,	O
26	O
April	O
1772	O
.	O

42	O
Burke	O
to	O
James	O
de	O
Lancey	O
,	O
30	O
June	O
1772	O
.	O

The	O
correspondence	O
of	O
Edmund	O
Burke	O
,	O
vol	O
.	O

2	O
,	O
ed	O
.	O

T.	O
W.	O
Copeland	O
and	O
others	O
,	O
Cambridge	O
University	O
Press	O
,	O
1958	O
-	O
1978	O
,	O
p.	O
311	O
.	O

183	O
Marjorie	O
Bloy	O
suddenly	O

:	O
it	O
was	O
only	O
two	O
weeks	O
from	O
him	O
""""	O
recovering	O
""""	O
to	O
dying	O
.	O

Another	O
almost	O
contemporary	O
account	O
of	O
the	O
marquis	O
's	O
death	O
came	O
from	O
the	O
Earl	O
of	O
Albemarle	O
.	O

He	O
noted	O
that	O
Rockingham	O
had	O
""""	O
for	O
some	O
time	O
past	O
been	O
afflicted	O
with	O
water	O
on	O
the	O
chest	O
:	O
and	O
to	O
this	O
well	O
-	O
known	O
malady	O
was	O
superadded	O
the	O
then	O
novel	O
disease	O
of	O
"influenza"".43"	O
This	O
conceivably	O
could	O
be	O
an	O
uninformed	O
account	O
,	O
handed	O
down	O
orally	O
by	O
surviving	O
members	O
of	O
the	O
marquis	O
's	O
family	O
,	O
of	O
emphysema	O
.	O

More	O
fascinating	O
than	O
the	O
diagnosis	O
of	O
the	O
cause	O
of	O
death	O
,	O
however	O
,	O
is	O
-	O
what	O
was	O
wrong	O
with	O
him	O
during	O
his	O
lifetime	O
?	O

Or	O
is	O
it	O
yet	O
another	O
example	O
of	O
the	O
""""	O
English	O
disease	O
""""	O
:	O
hypochondria	O
?	O

43Albemarle	O
,	O
George	O
Thomas	O
,	O
Earl	O
of	O
,	O
Memoirs	O
of	O
the	O
Marquis	O
of	O
Rockingham	O
and	O
his	O
contemporaries	O
,	O
London	O
,	O
Richard	O
Bentley	O
,	O
2	O
vols	O
.	O
,	O
1852	O
,	O
vol	O
.	O

2	O
,	O
p.	O
483	O
.	O

This	O
is	O
the	O
only	O
contemporary	O
work	O
concerning	O
Rockingham	O
,	O
but	O
does	O
not	O
mention	O
his	O
early	O
life	O
and	O
illnesses	O
.	O

184	O

Tissue	O
-	O
dependent	O
isoforms	O
of	O
mammalian	O
Fox-1	O
homologs	O
are	O
associated	O
with	O
tissue	O
-	O
specific	O
splicing	O
activities	O
Abstract	O
An	O
intronic	O
hexanucleotide	O
UGCAUG	O
has	O
been	O
shown	O
to	O
play	O
a	O
critical	O
role	O
in	O
the	O
regulation	O
of	O
tissue	O
-	O
specific	O
alternative	O
splicing	O
of	O
pre	O
-	O
mRNAs	O
in	O
a	O
wide	O
range	O
of	O
tissues	O
.	O

Vertebrate	O
Fox-1	O
has	O
been	O
shown	O
to	O
bind	O
to	O
this	O
element	O
,	O
in	O
a	O
highly	O
sequence	O
-	O
specific	O
manner	O
,	O
through	O
its	O
RNA	O
recognition	O
motif	O
(	O
RRM	O
)	O
.	O

In	O
mammals	O
,	O
there	O
are	O
at	O
least	O
two	O
Fox-1-related	O
genes	O
,	O
ataxin-2	O
binding	O
protein	O
1	O
(	O
A2BP1	O
)	O
/	O
Fox-1	O
and	O
Fxh	O
/	O
Rbm9	O
,	O
which	O
encode	O
an	O
identical	O
RRM	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
both	O
mouse	B
Fxh	O
and	O
A2BP1	O
transcripts	O
undergo	O
tissue	O
-	O
specific	O
alternative	O
splicing	O
,	O
generating	O
protein	O
isoforms	O
specific	O
to	O
brain	O
and	O
muscle	O
.	O

These	O
tissue	O
-	O
specific	O
isoforms	O
are	O
characterized	O
for	O
their	O
abilities	O
to	O
regulate	O
neural	O
cell	O
-	O
specific	O
alternative	O
splicing	O
of	O
a	O
cassette	O
exon	O
,	O
N30	O
,	O
in	O
the	O
non	O
-	O
muscle	O
myosin	O
heavy	O
chain	O
II	O
-	O
B	O
pre	O
-	O
mRNA	O
,	O
previously	O
shown	O
to	O
be	O
regulated	O
through	O
an	O
intronic	O
distal	O
downstream	O
enhancer	O
(	O
IDDE	O
)	O
.	O

All	O
Fxh	O
and	O
A2BP1	O
isoforms	O
with	O
the	O
RRM	O
are	O
capable	O
of	O
binding	O
to	O
the	O
IDDE	O
in	O
vitro	O
through	O
the	O
UGCAUG	O
elements	O
.	O

Each	O
isoform	O
,	O
however	O
,	O
shows	O
quantitative	O
differences	O
in	O
splicing	O
activity	O
and	O
nuclear	O
distribution	O
in	O
transfected	O
cells	O
.	O

All	O
Fxh	O
isoforms	O
and	O
a	O
brain	O
isoform	O
of	O
A2BP1	O
show	O
a	O
predominant	O
nuclear	O
localization	O
.	O

Brain	O
isoforms	O
of	O
both	O
Fxh	O
and	O
A2BP1	O
promote	O
N30	O
splicing	O
much	O
more	O
efficiently	O
than	O
do	O
the	O
muscle	O
-	O
specific	O
isoforms	O
.	O

Skeletal	O
muscles	O
express	O
additional	O
isoforms	O
that	O
lack	O
a	O
part	O
of	O
the	O
RRM	O
.	O

These	O
isoforms	O
are	O
incapable	O
of	O
activating	O
neural	O
cell	O
-	O
specific	O
splicing	O
and	O
,	O
moreover	O
,	O
can	O
inhibit	O
UGCAUG	O
-	O
dependent	O
N30	O
splicing	O
.	O

These	O
findings	O
suggest	O
that	O
tissue	O
-	O
specific	O
isoforms	O
of	O
Fxh	O
and	O
A2BP1	O
play	O
an	O
important	O
role	O
in	O
determining	O
tissue	O
specificity	O
of	O
UGCAUG	O
-	O
mediated	O
alternative	O
splicing	O
.	O

INTRODUCTION	O
Alternative	O
splicing	O
of	O
pre	O
-	O
mRNA	O
is	O
one	O
of	O
the	O
fundamental	O
mechanisms	O
for	O
the	O
regulation	O
of	O
gene	O
expression	O
in	O
higher	O
eukaryotes	O
(	O
1,2	O
)	O
.	O

Developmentally	O
regulated	O
,	O
cell	O
type-	O
or	O
tissue	O
-	O
specific	O
,	O
and	O
signal	O
-	O
induced	O
alternative	O
splicing	O
of	O
pre	O
-	O
mRNAs	O
takes	O
place	O
in	O
multicellular	O
organisms	O
throughout	O
their	O
lifetimes	O
.	O

Misregulation	O
or	O
abnormalities	O
in	O
pre	O
-	O
mRNA	O
splicing	O
,	O
in	O
some	O
instances	O
,	O
leads	O
to	O
cellular	O
dysfunctions	O
found	O
in	O
human	B
and	O
animal	O
diseases	O
(	O
3–5	O
)	O
.	O

Using	O
various	O
model	O
systems	O
of	O
regulated	O
alternative	O
splicing	O
,	O
a	O
number	O
of	O
pre	O
-	O
mRNA	O
features	O
that	O
influence	O
alternative	O
splice	O
site	O
selection	O
have	O
been	O
defined	O
(	O
1,2	O
)	O
.	O

These	O
include	O
enhancer	O
and	O
repressor	O
RNA	O
sequences	O
located	O
in	O
exons	O
and	O
introns	O
.	O

Identification	O
of	O
RNA	O
-	O
binding	O
proteins	O
targeting	O
these	O
cis	O
-	O
regulatory	O
elements	O
is	O
currently	O
in	O
progress	O
.	O

In	O
vertebrates	O
,	O
participation	O
of	O
the	O
SR	O
family	O
proteins	O
and	O
hnRNP	O
proteins	O
,	O
such	O
as	O
PTB	O
and	O
hnRNPA1	O
,	O
in	O
alternative	O
splicing	O
regulation	O
via	O
binding	O
to	O
the	O
cis	O
-	O
regulatory	O
elements	O
have	O
been	O
shown	O
in	O
many	O
tissue	O
-	O
specific	O
splicing	O
models	O
(	O
6,7	O
)	O
.	O

Although	O
these	O
RNA	O
-	O
binding	O
proteins	O
are	O
ubiquitously	O
expressed	O
,	O
their	O
different	O
abundance	O
in	O
different	O
cells	O
,	O
differences	O
in	O
their	O
post	O
-	O
translational	O
modifications	O
in	O
different	O
cellular	O
contexts	O
and	O
their	O
different	O
abilities	O
to	O
assemble	O
multiprotein	O
complexes	O
in	O
different	O
pre	O
-	O
mRNA	O
contexts	O
are	O
thought	O
to	O
contribute	O
to	O
the	O
determination	O
of	O
cell	O
type	O
-	O
specific	O
patterns	O
of	O
alternative	O
splicing	O
.	O

For	O
the	O
last	O
few	O
years	O
,	O
tissue	O
-	O
specific	O
and	O
tissue	O
-	O
enriched	O
RNA	O
-	O
binding	O
proteins	O
have	O
begun	O
to	O
be	O
identified	O
as	O
splicing	O
regulators	O
.	O

These	O
include	O
brain	O
-	O
specific	O
(	O
or	O
enriched	O
)	O
Nova-1	O
,	O
nPTB	O
(	O
brPTB	O
)	O
and	O
some	O
of	O
the	O
CELF	O
family	O
proteins	O
(	O
8–12	O
)	O
.	O

Discovery	O
of	O
these	O
proteins	O
has	O
had	O
a	O
great	O
impact	O
on	O
studies	O
aimed	O
at	O
understanding	O
the	O
molecular	O
mechanisms	O
of	O
alternative	O
splicing	O
regulation	O
.	O

One	O
of	O
the	O
intronic	O
cis	O
-	O
elements	O
,	O
which	O
are	O
involved	O
in	O
tissue	O
-	O
specific	O
or	O
differentiation	O
stage	O
-	O
dependent	O
regulation	O
of	O
alternative	O
splicing	O
,	O
is	O
the	O
hexanucleotide	O
UGCAUG	O
.	O

The	O
importance	O
of	O
this	O
element	O
was	O
originally	O
recognized	O
in	O
fibronectin	O
pre	O
-	O
mRNA	O
by	O
Huh	O
and	O
Hynes	O
(	O
13	O
)	O
.	O

Since	O
then	O
,	O
alternative	O
splicing	O
specific	O
to	O
a	O
variety	O
of	O
tissues	O
or	O
cell	O
types	O
,	O
including	O
neural	O
cells	O
,	O
muscles	O
,	O
epithelial	O
cells	O
and	O
erythrocytes	O
,	O
has	O
been	O
shown	O
to	O
be	O
modulated	O
via	O
this	O
element	O
(	O
14–21	O
)	O
.	O

Recently	O
,	O
Jin	O
et	O
al.	O
(	O
21	O
)	O
discovered	O
that	O
a	O
zebrafish	B
homolog	O
of	O
Caenorhabditis	B
elegans	I
Fox-1	O
(	O
22	O
)	O
could	O
bind	O
specifically	O
to	O
the	O
pentanucleotide	O
GCAUG	O
by	O
in	O
vitro	O
selection	O
from	O
randomized	O
RNA	O
sequences	O
.	O

This	O
pentanucleotide	O
is	O
almost	O
identical	O
to	O
the	O
hexanucleotide	O
UGCAUG	O
except	O
for	O
the	O
first	O
U.	O
Moreover	O
,	O
the	O
zebrafish	B
Fox-1	O
homolog	O
,	O
as	O
well	O
as	O
the	O
mouse	B
Fox-1	O
homolog	O
,	O
are	O
capable	O
of	O
repressing	O
the	O
inclusion	O
of	O
an	O
alternative	O
cassette	O
exon	O
of	O
the	O
ATP	O
synthase	O
F1γ	O
pre	O
-	O
mRNA	O
via	O
binding	O
to	O
GCAUG	O
,	O
which	O
mimics	O
muscle	O
-	O
specific	O
exclusion	O
of	O
this	O
exon	O
.	O

This	O
mouse	B
homolog	O
is	O
identical	O
to	O
the	O
ataxin-2	O
binding	O
protein	O
1	O
(	O
A2BP1	O
)	O
,	O
which	O
has	O
been	O
previously	O
cloned	O
in	O
humans	B
and	O
mice	B
as	O
the	O
cDNA	O
encoding	O
a	O
protein	O
,	O
which	O
interacts	O
with	O
ataxin-2	O
,	O
the	O
product	O
of	O
the	O
causative	O
gene	O
for	O
spinocerebellar	O
ataxia	O
type	O
2	O
(	O
23,24	O
)	O
.	O

In	O
addition	O
to	O
A2BP1	O
/	O
Fox-1	O
,	O
another	O
mouse	B
homolog	O
of	O
C.elegans	B
Fox-1	O
,	O
Fxh	O
,	O
has	O
been	O
independently	O
cloned	O
as	O
a	O
cDNA	O
,	O
which	O
is	O
induced	O
by	O
androgen	O
in	O
motor	O
neurons	O
(	O
25	O
)	O
.	O

Of	O
note	O
is	O
that	O
A2BP1	O
/	O
Fox-1	O
and	O
Fxh	O
share	O
an	O
identical	O
RNA	O
recognition	O
motif	O
(	O
RRM	O
)	O
at	O
the	O
amino	O
acid	O
level	O
.	O

Therefore	O
,	O
two	O
genes	O
in	O
the	O
mouse	B
genome	O
encode	O
homologs	O
of	O
nematode	O
Fox-1	O
.	O

According	O
to	O
the	O
names	O
given	O
by	O
the	O
first	O
cDNA	O
cloning	O
,	O
we	O
used	O
the	O
nomenclature	O
of	O
A2BP1	O
and	O
Fxh	O
in	O
this	O
report	O
.	O

A2BP1	O
and	O
Fxh	O
have	O
been	O
named	O
A2BP1	O
and	O
Rbm9	O
,	O
respectively	O
,	O
in	O
the	O
human	B
and	O
mouse	B
genomes	O
.	O

We	O
have	O
been	O
studying	O
regulatory	O
mechanisms	O
of	O
neural	O
cell	O
-	O
specific	O
alternative	O
splicing	O
using	O
the	O
non	O
-	O
muscle	O
myosin	O
heavy	O
chain	O
II	O
-	O
B	O
(	O
NMHC	O
-	O
B	O
)	O
gene	O
as	O
a	O
model	O
system	O
(	O
14,26	O
)	O
.	O

NMHC	O
-	O
B	O
mRNA	O
is	O
expressed	O
ubiquitously	O
.	O

However	O
,	O
an	O
alternative	O
exon	O
,	O
N30	O
,	O
which	O
encodes	O
a	O
30	O
nt	O
coding	O
sequence	O
,	O
is	O
included	O
in	O
the	O
mRNAs	O
from	O
some	O
neural	O
cells	O
,	O
but	O
is	O
skipped	O
in	O
those	O
from	O
all	O
other	O
cells	O
in	O
mammals	O
and	O
birds	O
(	O
27,28	O
)	O
.	O

In	O
cultured	O
cells	O
,	O
a	O
switch	O
in	O
N30	O
splicing	O
from	O
exclusion	O
to	O
inclusion	O
can	O
be	O
seen	O
in	O
neural	O
retinoblastoma	O
Y79	O
cells	O
during	O
the	O
post	O
-	O
mitotic	O
and	O
differentiated	O
stages	O
triggered	O
by	O
butyrate	O
treatment	O
.	O

We	O
have	O
previously	O
defined	O
an	O
intronic	O
distal	O
downstream	O
enhancer	O
(	O
IDDE	O
)	O
,	O
which	O
confers	O
neural	O
cell	O
specificity	O
on	O
N30	O
inclusion	O
,	O
using	O
this	O
cell	O
line	O
(	O
14	O
)	O
.	O

The	O
IDDE	O
includes	O
two	O
copies	O
of	O
UGCAUG	O
.	O

Mutation	O
of	O
these	O
hexanucleotides	O
results	O
in	O
N30	O
skipping	O
in	O
post	O
-	O
mitotic	O
differentiated	O
Y79	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
possible	O
involvement	O
of	O
A2BP1	O
and	O
Fxh	O
in	O
the	O
regulation	O
of	O
N30	O
splicing	O
.	O

To	O
this	O
end	O
,	O
we	O
have	O
isolated	O
cDNA	O
clones	O
for	O
A2BP1	O
and	O
Fxh	O
from	O
brain	O
and	O
muscles	O
.	O

cDNA	O
cloning	O
revealed	O
the	O
existence	O
of	O
tissue	O
-	O
specific	O
(	O
enriched	O
)	O
isoforms	O
of	O
both	O
A2BP1	O
and	O
Fxh	O
.	O

Of	O
importance	O
,	O
different	O
isoforms	O
of	O
A2BP1	O
and	O
Fxh	O
show	O
different	O
activities	O
with	O
respect	O
to	O
N30	O
splicing	O
as	O
well	O
as	O
different	O
subcellular	O
localizations	O
.	O

MATERIALS	O
AND	O
METHODS	O
Database	O
disposition	O
The	O
sequences	O
reported	O
in	O
this	O
paper	O
have	O
been	O
deposited	O
in	O
the	O
GenBank	O
database	O
with	O
accession	O
numbers	O
AY659951	O
(	O
F011	O
)	O
,	O
AY659952	O
(	O
F411	O
)	O
,	O
AY659953	O
(	O
F402	O
)	O
,	O
AY659954	O
(	O
A016	O
)	O
,	O
AY659955	O
(	O
A030	O
)	O
,	O
AY659956	O
(	O
A713	O
)	O
,	O
AY659957	O
(	O
A715	O
)	O
and	O
AY659958	O
(	O
A704	O
)	O
.	O

RNA	O
preparation	O
and	O
RT	O
–	O
PCR	O
Total	O
RNAs	O
were	O
isolated	O
from	O
mouse	B
tissues	O
and	O
cultured	O
cells	O
using	O
an	O
RNA	O
isolation	O
kit	O
(	O
Stratagene	O
)	O
or	O
an	O
RNeasy	O
mini	O
kit	O
(	O
Qiagen	O
)	O
.	O

To	O
obtain	O
the	O
full	O
-	O
length	O
coding	O
regions	O
of	O
cDNAs	O
for	O
Fxh	O
and	O
A2BP1	O
,	O
RT	O
–	O
PCRs	O
were	O
performed	O
using	O
Superscript	O
II	O
RNase	O
H−	O
reverse	O
transcriptase	O
(	O
Invitrogen	O
)	O
and	O
Pfu	O
Turbo	O
DNA	O
polymerase	O
(	O
Stratagene	O
)	O
.	O

The	O
PCR	O
primers	O
used	O
to	O
obtain	O
all	O
Fxh	O
cDNAs	O
were	O
5′-ctcaggcctccactagttATGGAGAAAAAGAAAATGGTAACTC-3′	O
and	O
5′-ctcaggcctcctctagaaGTAGGGGGCAAATCGGCTGTA-3′.	O
The	O
upstream	O
primers	O
for	O
the	O
brain	O
(	O
A016	O
and	O
A030	O
)	O
and	O
muscle	O
(	O
A713	O
,	O
A715	O
and	O
A704	O
)	O
A2BP1	O
cDNAs	O
were	O
5′-ctcaggcctccactagtgATGAATTGTGAAAGAGAGCAGCT-3′	O
and	O
5′-ctcaggcctccactagtcATGTTGGCGTCGCAAGGAGTCC-3′	O
,	O
respectively	O
,	O
and	O
the	O
downstream	O
primer	O
for	O
all	O
A2BP1	O
cDNAs	O
was	O
5′-ctcaggcctcctctagagATATGGAGCAAAACGGTTGTATCC-3′.	O
Lower	O
case	O
letters	O
represent	O
adapter	O
sequences	O
including	O
restriction	O
enzyme	O
sites	O
.	O

5′	O
Rapid	O
amplification	O
of	O
cDNA	O
ends	O
(	O
RACE	O
)	O
was	O
performed	O
using	O
Marathon	O
-	O
Ready	O
cDNA	O
(	O
BD	O
Biosciences	O
Clontech	O
)	O
.	O

For	O
the	O
analysis	O
of	O
minigene	O
and	O
NMHC	O
-	O
B	O
mRNAs	O
,	O
RT	O
–	O
PCRs	O
were	O
performed	O
as	O
described	O
previously	O
(	O
14,26	O
)	O
.	O

Sequences	O
of	O
primers	O
P1–P9	O
shown	O
in	O
Figures	O
1	O
,	O
4	O
and	O
6	O
are	O
as	O
follows	O
:	O
P1	O
,	O
5′-AATTCACCCAGCAACCAGAAT-3′	O
;	O
P2	O
,	O
5′-TAGAGGGATGTAAGTGTTGATGCC-3′	O
;	O
P3	O
,	O
5′-CAGAGGGCGGACAGTGTATGGT-3′	O
;	O
P4	O
,	O
5′-GGCGGCAGGGGCGAGGGCAT-3′	O
;	O
P5	O
,	O
5′-CCGTGGTCGCACCGTGTACAAC-3′	O
;	O
P6	O
,	O
5′-CAGCGGCAGTGGCAGGGGTG-3′	O
;	O
P7	O
,	O
5′-AGGAAGAAAGGACCATAATATTCC-3′	O
;	O
P8	O
,	O
5′-CCTCCACCCAGCTCCAGTTGT-3′	O
;	O
and	O
P9	O
,	O
5′-CCTGTAGTTATTAAATCCTTCAAG-3′.	O
Preparation	O
of	O
expression	O
constructs	O
and	O
minigenes	O
The	O
cDNAs	O
of	O
Fxh	O
and	O
A2BP1	O
were	O
introduced	O
into	O
a	O
plasmid	O
pCS3	O
+	O
MT	O
,	O
which	O
contains	O
a	O
myc	O
-	O
epitope	O
,	O
and	O
its	O
modified	O
version	O
pCS3	O
+	O
MT	O
+	O
NLS	O
,	O
which	O
in	O
addition	O
contains	O
the	O
nuclear	O
localization	O
signal	O
(	O
NLS	O
)	O
of	O
the	O
SV40	B
large	O
T	O
antigen	O
(	O
26	O
)	O
.	O

Minigenes	O
G	O
,	O
J	O
without	O
the	O
IDDE	O
,	O
and	O
H	O
with	O
the	O
wild	O
-	O
type	O
IDDE	O
are	O
the	O
same	O
as	O
minigenes	O
W	O
,	O
D4	O
and	O
Cm0	O
,	O
respectively	O
in	O
ref	O
.	O

(	O
14	O
)	O
.	O

The	O
201	O
nt	O
IDDEs	O
with	O
mutations	O
were	O
generated	O
by	O
recombinant	O
PCR	O
using	O
the	O
appropriate	O
primers	O
,	O
which	O
included	O
mutated	O
sequences	O
.	O

The	O
hexanucleotide	O
TGCATG	O
sequences	O
at	O
the	O
5′	O
and	O
3′	O
sides	O
were	O
changed	O
to	O
GTTACT	O
and	O
ACCTAC	O
,	O
respectively	O
.	O

Electrophoresis	O
mobility	O
shift	O
assay	O
Template	O
DNAs	O
for	O
in	O
vitro	O
RNA	O
transcription	O
were	O
prepared	O
by	O
PCR	O
using	O
the	O
wild	O
-	O
type	O
and	O
mutant	O
IDDEs	O
in	O
the	O
minigenes	O
as	O
templates	O
and	O
an	O
upstream	O
primer	O
that	O
included	O
the	O
T7	O
promoter	O
sequence	O
at	O
the	O
5′	O
end	O
.	O

The	O
probe	O
and	O
competitor	O
RNAs	O
were	O
transcribed	O
by	O
T7	O
RNA	O
polymerase	O
in	O
the	O
presence	O
of	O
[	O
α-32P	O
]	O
UTP	O
and	O
a	O
trace	O
amount	O
of	O
[	O
35S	O
]	O
UTPαS	O
,	O
respectively	O
,	O
using	O
a	O
MAXIscript	O
kit	O
(	O
Ambion	O
)	O
.	O

Mole	O
concentrations	O
of	O
synthesized	O
RNAs	O
were	O
estimated	O
by	O
radioactivities	O
.	O

Fxh	O
and	O
A2BP1	O
proteins	O
with	O
a	O
myc	O
tag	O
were	O
synthesized	O
in	O
vitro	O
by	O
using	O
a	O
TNT	O
quick	O
-	O
coupled	O
transcription	O
/	O
translation	O
system	O
(	O
Promega	O
)	O
from	O
pCS3	O
+	O
MT	O
constructs	O
,	O
which	O
include	O
the	O
SP6	O
promoter	O
.	O

Binding	O
reactions	O
were	O
carried	O
out	O
in	O
a	O
10	O
μl	O
mixture	O
that	O
contains	O
10	O
mM	O
HEPES	O
(	O
pH	O
7.9	O
)	O
,	O
2	O
mM	O
MgCl2	O
,	O
50	O
mM	O
KCl	O
,	O
5	O
%	O
glycerol	O
,	O
0.5	O
mM	O
DTT	O
,	O
5	O
μg	O
tRNA	O
,	O
1	O
μl	O
reticulocyte	O
lysate	O
reaction	O
mixture	O
and	O
15	O
fmol	O
of	O
probe	O
,	O
on	O
ice	O
for	O
20–30	O
min	O
.	O

An	O
aliquot	O
of	O
5	O
μg	O
of	O
heparin	O
was	O
added	O
to	O
the	O
reaction	O
10	O
min	O
before	O
gel	O
electrophoresis	O
.	O

The	O
reaction	O
mixtures	O
were	O
analyzed	O
by	O
electrophoresis	O
in	O
a	O
6	O
%	O
polyacrylamide	O
gel	O
using	O
a	O
0.5	O
×	O
TBE	O
buffer	O
(	O
Invitrogen	O
)	O
.	O

Cell	O
culture	O
and	O
transfection	O
The	O
human	B
retinoblastoma	O
cell	O
line	O
Y79	O
was	O
cultured	O
and	O
transfected	O
with	O
DNAs	O
as	O
described	O
previously	O
(	O
14,26	O
)	O
.	O

Total	O
amounts	O
of	O
transfected	O
DNAs	O
were	O
adjusted	O
to	O
be	O
constant	O
by	O
addition	O
of	O
the	O
empty	O
vector	O
.	O

Either	O
Lipofectin	O
(	O
Invitrogen	O
)	O
or	O
Effectene	O
transfection	O
reagent	O
(	O
Qiagen	O
)	O
was	O
used	O
for	O
the	O
transfection	O
.	O

For	O
stable	O
transfection	O
,	O
the	O
pCS3+MT	O
expression	O
constructs	O
were	O
co	O
-	O
transfected	O
with	O
a	O
plasmid	O
carrying	O
a	O
neomycin	O
resistant	O
gene	O
and	O
selected	O
by	O
0.2	O
mM	O
geneticin	O
(	O
Invitrogen	O
)	O
.	O

For	O
differentiation	O
of	O
Y79	O
cells	O
,	O
cells	O
were	O
plated	O
on	O
the	O
poly	O
-	O
d	O
-	O
lysine	O
-	O
coated	O
plates	O
and	O
then	O
treated	O
with	O
2.0–2.5	O
mM	O
sodium	O
butyrate	O
for	O
4–5	O
days	O
.	O

HeLa	O
cells	O
were	O
cultured	O
as	O
described	O
and	O
transfected	O
with	O
DNA	O
using	O
Effectene	O
reagent	O
(	O
14,26	O
)	O
.	O

Immunoblot	O
analysis	O
Samples	O
that	O
required	O
both	O
protein	O
and	O
mRNA	O
analysis	O
were	O
split	O
upon	O
harvesting	O
.	O

Total	O
cell	O
proteins	O
were	O
subjected	O
to	O
SDS	O
–	O
PAGE	O
and	O
blotted	O
as	O
described	O
previously	O
(	O
26	O
)	O
.	O

The	O
primary	O
antibodies	O
used	O
are	O
monoclonal	O
antibodies	O
to	O
a	O
myc	O
-	O
epitope	O
(	O
Invitrogen	O
)	O
and	O
green	O
fluorescent	O
protein	O
(	O
GFP	O
)	O
(	O
Clontech	O
)	O
.	O

Binding	O
of	O
antibodies	O
was	O
detected	O
with	O
the	O
SuperSignal	O
System	O
(	O
Pierce	O
)	O
or	O
ECL	O
(	O
Amersham	O
)	O
.	O

Immunofluorescent	O
microscopy	O
HeLa	O
or	O
Y79	O
cells	O
grown	O
in	O
a	O
four	O
-	O
chamber	O
glass	O
slide	O
were	O
transfected	O
as	O
described	O
above	O
.	O

Cells	O
were	O
fixed	O
with	O
10	O
%	O
formaldehyde	O
24–48	O
h	O
after	O
transfection	O
,	O
and	O
permealized	O
with	O
0.5	O
%	O
Triton	O
X-100	O
then	O
blocked	O
with	O
5	O
%	O
goat	B
serum	O
.	O

Primary	O
antibodies	O
used	O
were	O
mouse	B
anti	O
-	O
myc	O
(	O
Invitrogen	O
)	O
,	O
rabbit	B
anti	O
-	O
NMHC	O
-	O
B	O
(	O
29	O
)	O
.	O

Secondary	O
antibodies	O
were	O
Alexa	O
Fluor	O
594	O
goat	B
anti	O
-	O
mouse	B
IgG	O
and	O
Alexa	O
Fluor	O
488	O
goat	B
anti	O
-	O
rabbit	B
IgG	O
(	O
Molecular	O
Probes	O
)	O
.	O

DAPI	O
was	O
used	O
for	O
DNA	O
staining	O
.	O

Specimens	O
were	O
mounted	O
in	O
ProLong	O
antifed	O
kit	O
(	O
Molecular	O
Probe	O
)	O
.	O

The	O
images	O
were	O
collected	O
using	O
Leica	O
SP	O
confocal	O
microscopy	O
(	O
Leica	O
)	O
.	O

RESULTS	O
Tissue	O
-	O
dependent	O
isoforms	O
of	O
Fxh	O
and	O
A2BP1	O
and	O
their	O
subcellular	O
distribution	O
The	O
A2BP1	O
mRNAs	O
are	O
detected	O
almost	O
exclusively	O
in	O
brain	O
and	O
striated	O
muscles	O
(	O
heart	O
and	O
skeletal	O
muscles	O
)	O
in	O
adult	O
mice	B
,	O
whereas	O
the	O
Fxh	O
mRNAs	O
are	O
expressed	O
in	O
a	O
wide	O
variety	O
of	O
tissues	O
with	O
the	O
highest	O
expression	O
in	O
brain	O
and	O
heart	O
[	O
(	O
21,25	O
)	O
and	O
S.	O
Kawamoto	O
,	O
unpublished	O
data	O
]	O
.	O

These	O
expression	O
profiles	O
prompted	O
us	O
to	O
characterize	O
the	O
mRNAs	O
of	O
A2BP1	O
and	O
Fxh	O
in	O
brain	O
and	O
muscles	O
.	O

We	O
have	O
cloned	O
cDNAs	O
for	O
two	O
gene	O
transcripts	O
from	O
brain	O
,	O
heart	O
and	O
skeletal	O
muscles	O
by	O
RT	O
–	O
PCR	O
and	O
5′	O
RACE	O
.	O

The	O
isolated	O
cDNAs	O
are	O
schematically	O
presented	O
with	O
genomic	O
structures	O
in	O
Figure	O
1	O
(	O
for	O
amino	O
acid	O
sequences	O
see	O
also	O
Figure	O
8)	O
.	O

Both	O
gene	O
transcripts	O
are	O
found	O
to	O
undergo	O
tissue	O
-	O
specific	O
alternative	O
splicing	O
.	O

In	O
both	O
cases	O
,	O
brain	O
and	O
striated	O
muscles	O
express	O
unique	O
splice	O
variants	O
generated	O
by	O
mutually	O
exclusive	O
splicing	O
of	O
exons	O
B40	O
and	O
M43	O
,	O
respectively	O
,	O
which	O
provide	O
different	O
coding	O
sequences	O
in	O
the	O
middle	O
of	O
the	O
carboxyl	O
half	O
of	O
the	O
molecules	O
.	O

Southern	O
blot	O
analysis	O
of	O
the	O
RT	O
–	O
PCR	O
products	O
of	O
the	O
Fxh	O
mRNAs	O
from	O
the	O
different	O
tissues	O
probed	O
by	O
oligonucleotides	O
corresponding	O
to	O
B40	O
and	O
M43	O
shows	O
that	O
M43	O
is	O
exclusively	O
used	O
in	O
heart	O
and	O
skeletal	O
muscles	O
,	O
while	O
B40	O
is	O
predominantly	O
used	O
in	O
brain	O
(	O
Figure	O
2A	O
)	O
.	O

Digestion	O
of	O
the	O
RT	O
–	O
PCR	O
products	O
of	O
the	O
A2BP1	O
mRNAs	O
with	O
restriction	O
enzymes	O
unique	O
to	O
B40	O
and	O
M43	O
demonstrates	O
that	O
B40	O
and	O
M43	O
are	O
used	O
almost	O
exclusively	O
in	O
brain	O
and	O
muscles	O
,	O
respectively	O
(	O
Figure	O
2B	O
)	O
.	O

A2BP1	O
contains	O
an	O
additional	O
cassette	O
type	O
alternative	O
exon	O
A53	O
,	O
consisting	O
of	O
53	O
nt	O
.	O

Inclusion	O
and	O
exclusion	O
of	O
exon	O
A53	O
results	O
in	O
two	O
different	O
amino	O
acid	O
sequences	O
at	O
the	O
C	O
-	O
terminal	O
region	O
owing	O
to	O
a	O
frame	O
shift	O
.	O

In	O
the	O
case	O
of	O
the	O
A2BP1	O
gene	O
,	O
moreover	O
,	O
it	O
appears	O
that	O
brain	O
and	O
striated	O
muscle	O
utilize	O
alternative	O
promoters	O
,	O
resulting	O
in	O
different	O
amino	O
acid	O
sequences	O
at	O
the	O
N	O
-	O
terminus	O
.	O

The	O
5′	O
RACE	O
of	O
skeletal	O
muscle	O
mRNAs	O
yielded	O
essentially	O
a	O
single	O
species	O
of	O
sequence	O
with	O
29	O
unique	O
N	O
-	O
terminal	O
amino	O
acids	O
.	O

The	O
5′	O
RACE	O
using	O
brain	O
mRNAs	O
;	O
however	O
,	O
yielded	O
multiple	O
products	O
with	O
multiple	O
deduced	O
amino	O
acid	O
sequences	O
,	O
all	O
of	O
which	O
differ	O
from	O
the	O
muscle	O
amino	O
acid	O
sequence	O
at	O
the	O
very	O
N	O
-	O
terminus	O
.	O

Here	O
,	O
we	O
focus	O
our	O
analysis	O
on	O
a	O
clone	O
containing	O
nine	O
unique	O
amino	O
acids	O
at	O
the	O
N	O
-	O
terminus	O
,	O
which	O
was	O
obtained	O
most	O
frequently	O
.	O

Exon	O
–	O
intron	O
organization	O
of	O
Fxh	O
and	O
A2BP1	O
shows	O
remarkable	O
similarities	O
and	O
a	O
RRM	O
is	O
encoded	O
in	O
four	O
exons	O
(	O
Figure	O
1B	O
)	O
.	O

Of	O
note	O
is	O
that	O
the	O
significant	O
amounts	O
of	O
Fxh	O
and	O
A2BP1	O
mRNAs	O
from	O
skeletal	O
muscles	O
are	O
missing	O
a	O
part	O
of	O
the	O
RRM	O
by	O
exon	O
skipping	O
.	O

Typically	O
,	O
as	O
shown	O
in	O
Figure	O
2C	O
,	O
they	O
lack	O
the	O
93	O
nt	O
exon	O
that	O
encodes	O
RNP1	O
,	O
one	O
of	O
the	O
two	O
most	O
critical	O
motifs	O
of	O
the	O
RRM	O
(	O
30	O
)	O
.	O

Some	O
of	O
them	O
lack	O
almost	O
the	O
entire	O
RRM	O
(	O
e.g.	O
F402	O
in	O
Figure	O
1A	O
)	O
.	O

To	O
examine	O
the	O
subcellular	O
distribution	O
of	O
each	O
isoform	O
of	O
Fxh	O
and	O
A2BP1	O
,	O
myc	O
-	O
tagged	O
proteins	O
were	O
transiently	O
expressed	O
in	O
cultured	O
cells	O
and	O
immunostained	O
with	O
an	O
anti	O
-	O
myc	O
antibody	O
.	O

Initially	O
,	O
HeLa	O
cells	O
were	O
used	O
to	O
investigate	O
subcellular	O
localization	O
,	O
since	O
these	O
cells	O
are	O
more	O
suited	O
for	O
these	O
studies	O
.	O

Representative	O
confocal	O
images	O
are	O
shown	O
in	O
Figure	O
3A	O
.	O

DAPI	O
and	O
anti	O
-	O
NMHC	O
-	O
B	O
antibodies	O
serve	O
as	O
markers	O
for	O
nuclei	O
and	O
cytoplasm	O
,	O
respectively	O
.	O

As	O
noted	O
,	O
the	O
ratio	O
of	O
protein	O
distributed	O
between	O
nuclei	O
and	O
cytoplasm	O
differs	O
among	O
the	O
proteins	O
.	O

All	O
isoforms	O
of	O
Fxh	O
have	O
a	O
predominant	O
nuclear	O
localization	O
.	O

The	O
brain	O
isoform	O
of	O
A2BP1	O
without	O
the	O
A53	O
exon	O
(	O
A016	O
)	O
localizes	O
to	O
both	O
nuclei	O
and	O
cytoplasm	O
,	O
whereas	O
the	O
other	O
brain	O
isoform	O
with	O
the	O
A53	O
exon	O
(	O
A030	O
)	O
localizes	O
predominantly	O
to	O
cytoplasm	O
with	O
only	O
a	O
minimum	O
being	O
in	O
the	O
nuclei	O
.	O

The	O
relative	O
amounts	O
of	O
both	O
muscle	O
isoforms	O
of	O
A2BP1	O
(	O
A713	O
and	O
A715	O
)	O
are	O
somewhat	O
between	O
the	O
amounts	O
of	O
the	O
two	O
brain	O
isoforms	O
.	O

These	O
data	O
are	O
summarized	O
in	O
Figure	O
1A	O
.	O

The	O
subcellular	O
distribution	O
of	O
representative	O
isoforms	O
(	O
F011	O
,	O
A016	O
and	O
A030	O
)	O
was	O
also	O
examined	O
in	O
retinoblastoma	O
Y79	O
cells	O
,	O
which	O
were	O
used	O
as	O
host	O
cells	O
for	O
the	O
transfection	O
experiments	O
in	O
order	O
to	O
characterize	O
splicing	O
activities	O
of	O
Fxh	O
and	O
A2BP	O
proteins	O
(	O
see	O
below	O
)	O
.	O

Although	O
Y79	O
cells	O
have	O
a	O
spherical	O
shape	O
and	O
have	O
only	O
thin	O
cytoplasm	O
,	O
exogenously	O
expressed	O
isoforms	O
of	O
Fxh	O
and	O
A2BP1	O
show	O
a	O
similar	O
subcellular	O
distribution	O
as	O
in	O
HeLa	O
cells	O
(	O
Figure	O
3B	O
)	O
.	O

F011	O
localizes	O
predominantly	O
to	O
nuclei	O
,	O
A016	O
to	O
both	O
nuclei	O
and	O
cytoplasm	O
and	O
A030	O
predominantly	O
to	O
cytoplasm	O
.	O

Specific	O
interaction	O
of	O
Fxh	O
and	O
A2BP1	O
with	O
IDDE	O
via	O
a	O
hexanucleotide	O
UGCAUG	O
Fxh	O
and	O
A2BP1	O
share	O
an	O
identical	O
RRM	O
and	O
A2BP1	O
has	O
been	O
reported	O
to	O
bind	O
specifically	O
to	O
the	O
pentanucleotide	O
GCAUG	O
through	O
this	O
RRM	O
(	O
21	O
)	O
.	O

We	O
have	O
previously	O
reported	O
that	O
the	O
IDDE	O
of	O
the	O
NMHC	O
-	O
B	O
transcript	O
,	O
which	O
is	O
indispensable	O
for	O
the	O
regulation	O
of	O
neural	O
cell	O
-	O
specific	O
cassette	O
type	O
exon	O
N30	O
splicing	O
,	O
has	O
two	O
copies	O
of	O
GCAUG	O
(	O
14	O
)	O
.	O

Therefore	O
,	O
we	O
investigated	O
whether	O
Fxh	O
and/or	O
A2BP1	O
bound	O
to	O
the	O
IDDE	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
were	O
carried	O
out	O
using	O
labeled	O
IDDE	O
and	O
in	O
vitro	O
transcribed	O
and	O
translated	O
Fxh	O
and	O
A2BP1	O
,	O
which	O
include	O
a	O
myc	O
-	O
epitope	O
.	O

Since	O
all	O
Fxh	O
and	O
A2BP1	O
isoforms	O
,	O
except	O
F402	O
and	O
A704	O
,	O
contain	O
the	O
identical	O
RRM	O
,	O
representative	O
isoforms	O
were	O
analyzed	O
.	O

The	O
expression	O
of	O
F011	O
in	O
reticulocyte	O
lysate	O
causes	O
the	O
formation	O
of	O
a	O
RNA	O
–	O
protein	O
complex	O
whose	O
migration	O
shift	O
distinguishes	O
it	O
from	O
those	O
of	O
the	O
control	O
reticulocyte	O
lysate	O
(	O
C	O
in	O
Figure	O
4B	O
,	O
lanes	O
3	O
and	O
10	O
)	O
.	O

The	O
unlabeled	O
wild	O
-	O
type	O
IDDE	O
competes	O
with	O
the	O
probe	O
efficiently	O
for	O
the	O
formation	O
of	O
the	O
specific	O
complex	O
C	O
(	O
Figure	O
4B	O
,	O
lane	O
4	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
mutant	O
mc	O
(	O
Figure	O
4A	O
)	O
,	O
which	O
has	O
a	O
mutation	O
in	O
both	O
copies	O
of	O
UGCAUG	O
,	O
does	O
not	O
(	O
Figure	O
4B	O
,	O
lane	O
7	O
)	O
.	O

The	O
mutant	O
ma	O
,	O
which	O
has	O
a	O
mutation	O
in	O
the	O
hexanucleotide	O
at	O
the	O
5′	O
side	O
,	O
shows	O
less	O
efficient	O
competition	O
,	O
compared	O
with	O
mb	O
,	O
which	O
has	O
a	O
mutation	O
in	O
the	O
3′	O
side	O
of	O
the	O
hexanucleotide	O
(	O
Figure	O
4B	O
,	O
lanes	O
5	O
and	O
6	O
)	O
,	O
indicating	O
that	O
the	O
nucleotides	O
at	O
the	O
5′	O
side	O
are	O
more	O
important	O
than	O
those	O
at	O
the	O
3′	O
side	O
.	O

The	O
presence	O
of	O
an	O
anti	O
-	O
myc	O
antibody	O
,	O
but	O
not	O
a	O
non	O
-	O
specific	O
antibody	O
,	O
inhibits	O
the	O
formation	O
of	O
the	O
specific	O
complex	O
(	O
Figure	O
4B	O
,	O
lane	O
8)	O
.	O

Synthesis	O
of	O
the	O
full	O
-	O
length	O
F011	O
protein	O
using	O
a	O
reticulocyte	O
lysate	O
and	O
specificity	O
of	O
the	O
myc	O
antibody	O
for	O
the	O
expressed	O
protein	O
are	O
verified	O
by	O
immunoblot	O
analysis	O
(	O
Figure	O
4B	O
,	O
lanes	O
11	O
and	O
12	O
)	O
.	O

A016	O
and	O
A030	O
show	O
essentially	O
identical	O
results	O
to	O
those	O
with	O
F011	O
(	O
data	O
not	O
shown	O
)	O
.	O

These	O
results	O
indicate	O
that	O
Fxh	O
and	O
A2BP1	O
can	O
bind	O
to	O
the	O
IDDE	O
and	O
that	O
the	O
hexanucleotide	O
UGCAUG	O
is	O
required	O
for	O
their	O
binding	O
.	O

Fxh	O
and	O
A2BP1	O
enhance	O
N30	O
inclusion	O
in	O
a	O
UGCAUG	O
-	O
dependent	O
manner	O
To	O
study	O
whether	O
Fxh	O
and	O
A2BP1	O
regulate	O
neural	O
cell	O
-	O
specific	O
splicing	O
via	O
binding	O
to	O
UGCAUG	O
,	O
the	O
Fxh	O
and	O
A2BP1	O
expression	O
constructs	O
were	O
co	O
-	O
transfected	O
into	O
retinoblastoma	O
Y79	O
cells	O
with	O
a	O
number	O
of	O
the	O
reporter	O
minigene	O
constructs	O
,	O
which	O
include	O
the	O
wild	O
-	O
type	O
or	O
a	O
mutant	O
version	O
of	O
UGCAUG	O
in	O
the	O
IDDE	O
(	O
Figure	O
4A	O
)	O
.	O

Minigenes	O
H	O
and	O
J	O
consist	O
of	O
the	O
exons	O
E5	O
,	O
N30	O
and	O
E6	O
and	O
their	O
flanking	O
introns	O
with	O
some	O
deletions	O
in	O
the	O
introns	O
.	O

The	O
IDDE	O
with	O
or	O
without	O
mutations	O
in	O
the	O
hexanucleotide	O
is	O
included	O
or	O
excluded	O
between	O
N30	O
and	O
E6	O
.	O

As	O
described	O
above	O
,	O
each	O
isoform	O
of	O
Fxh	O
and	O
A2BP1	O
enters	O
the	O
nucleus	O
to	O
a	O
different	O
extent	O
.	O

To	O
see	O
the	O
effects	O
of	O
different	O
proteins	O
on	O
N30	O
splicing	O
itself	O
,	O
independent	O
of	O
their	O
differential	O
properties	O
in	O
nuclear	O
localization	O
,	O
an	O
exogenous	O
NLS	O
was	O
added	O
to	O
the	O
expressed	O
proteins	O
.	O

Since	O
Fxh	O
and	O
A2BP1	O
proteins	O
contain	O
the	O
identical	O
RRM	O
,	O
and	O
F011	O
,	O
A016	O
and	O
A030	O
all	O
show	O
the	O
same	O
UGCAUG	O
-	O
dependent	O
binding	O
to	O
the	O
IDDE	O
in	O
vitro	O
,	O
F011	O
and	O
A030	O
were	O
used	O
for	O
these	O
experiments	O
.	O

Host	O
cells	O
Y79	O
at	O
the	O
proliferating	O
stage	O
exclude	O
the	O
N30	O
exon	O
in	O
∼90	O
%	O
of	O
the	O
endogenous	O
NMHC	O
-	O
B	O
mRNAs	O
(	O
e.g.	O
see	O
Figure	O
6A	O
,	O
lane	O
1	O
)	O
.	O

As	O
shown	O
in	O
Figure	O
4C	O
,	O
the	O
mRNAs	O
derived	O
from	O
minigene	O
J	O
exclude	O
N30	O
without	O
exogenous	O
expression	O
of	O
Fxh	O
or	O
A2BP1	O
in	O
Y79	O
cells	O
,	O
similar	O
to	O
the	O
endogenous	O
NMHC	O
-	O
B	O
mRNAs	O
(	O
Figure	O
4C	O
,	O
upper	O
panel	O
,	O
lanes	O
1–5	O
)	O
.	O

However	O
,	O
in	O
the	O
presence	O
of	O
exogenous	O
expression	O
of	O
F011	O
and	O
A030	O
,	O
the	O
N30	O
inclusion	O
is	O
increased	O
(	O
Figure	O
4C	O
,	O
upper	O
panel	O
,	O
lanes	O
7	O
and	O
12	O
)	O
.	O

The	O
N30	O
inclusion	O
is	O
absolutely	O
dependent	O
on	O
the	O
presence	O
of	O
the	O
IDDE	O
(	O
Figure	O
4C	O
,	O
upper	O
panel	O
,	O
lanes	O
6	O
and	O
11	O
)	O
.	O

Moreover	O
,	O
mutation	O
of	O
either	O
one	O
of	O
the	O
two	O
copies	O
of	O
UGCAUG	O
(	O
ma	O
,	O
mb	O
)	O
abolishes	O
the	O
inclusion	O
of	O
N30	O
(	O
Figure	O
4C	O
,	O
upper	O
panel	O
,	O
lanes	O
8–10	O
,	O
13–15	O
)	O
.	O

In	O
the	O
context	O
of	O
minigene	O
H	O
,	O
which	O
contains	O
shorter	O
introns	O
,	O
the	O
larger	O
extent	O
of	O
N30	O
inclusion	O
is	O
induced	O
by	O
either	O
F011	O
or	O
A030	O
overexpression	O
(	O
Figure	O
4C	O
,	O
middle	O
panel	O
,	O
lanes	O
7	O
and	O
12	O
)	O
.	O

The	O
N30	O
inclusion	O
of	O
the	O
minigene	O
H	O
mRNAs	O
also	O
depends	O
on	O
the	O
presence	O
of	O
the	O
IDDE	O
(	O
Figure	O
4C	O
,	O
middle	O
panel	O
,	O
lanes	O
6	O
and	O
11	O
)	O
.	O

Mutation	O
of	O
both	O
copies	O
of	O
UGCAUG	O
(	O
mc	O
)	O
results	O
in	O
a	O
complete	O
loss	O
of	O
N30	O
inclusion	O
(	O
Figure	O
4C	O
,	O
middle	O
panel	O
,	O
lanes	O
10	O
and	O
15	O
)	O
.	O

The	O
mutant	O
ma	O
shows	O
stronger	O
inhibition	O
of	O
N30	O
inclusion	O
compared	O
with	O
mb	O
(	O
Figure	O
4C	O
,	O
middle	O
panel	O
,	O
lanes	O
8	O
and	O
9	O
)	O
.	O

This	O
observation	O
is	O
consistent	O
with	O
the	O
competition	O
experiments	O
of	O
the	O
EMSA	O
shown	O
in	O
Figure	O
4B	O
,	O
indicating	O
that	O
the	O
5′	O
hexanucleotide	O
is	O
more	O
important	O
than	O
the	O
3′	O
hexanucleotide	O
for	O
binding	O
of	O
Fxh	O
or	O
A2BP1	O
to	O
the	O
IDDE	O
as	O
well	O
as	O
an	O
activation	O
of	O
N30	O
splicing	O
.	O

Comparable	O
amounts	O
of	O
F011	O
and	O
A030	O
are	O
expressed	O
in	O
each	O
transfection	O
as	O
verified	O
by	O
immunoblots	O
using	O
an	O
anti	O
-	O
myc	O
antibody	O
(	O
Figure	O
4C	O
,	O
lower	O
panel	O
,	O
lanes	O
6–17	O
)	O
.	O

Since	O
minigenes	O
J	O
and	O
H	O
lack	O
a	O
portion	O
of	O
the	O
intron	O
between	O
exons	O
N30	O
and	O
E6	O
and	O
,	O
therefore	O
,	O
the	O
IDDE	O
is	O
located	O
∼100	O
nt	O
downstream	O
of	O
N30	O
,	O
instead	O
of	O
1.5	O
kb	O
as	O
in	O
the	O
native	O
gene	O
,	O
we	O
also	O
analyzed	O
the	O
effects	O
of	O
Fxh	O
and	O
A2BP1	O
on	O
the	O
N30	O
splicing	O
of	O
the	O
wild	O
-	O
type	O
minigene	O
G	O
,	O
which	O
includes	O
full	O
-	O
length	O
introns	O
among	O
E5	O
,	O
N30	O
and	O
E6	O
(	O
Figure	O
4A	O
)	O
.	O

As	O
shown	O
in	O
Figure	O
4C	O
(	O
right	O
panel	O
)	O
,	O
both	O
F011	O
and	O
A030	O
are	O
capable	O
of	O
promoting	O
N30	O
inclusion	O
,	O
with	O
F011	O
showing	O
a	O
higher	O
activity	O
(	O
Figure	O
4C	O
,	O
lanes	O
16	O
and	O
17	O
)	O
.	O

Although	O
A030	O
can	O
promote	O
N30	O
inclusion	O
as	O
efficiently	O
as	O
F011	O
in	O
the	O
contexts	O
of	O
the	O
minigene	O
J	O
and	O
H	O
transcripts	O
,	O
it	O
can	O
do	O
so	O
less	O
efficiently	O
than	O
F011	O
in	O
the	O
context	O
of	O
the	O
minigene	O
G	O
transcript	O
.	O

Interpretation	O
of	O
this	O
observation	O
will	O
be	O
discussed	O
below	O
.	O

Taken	O
together	O
,	O
Fxh	O
and	O
A2BP1	O
can	O
activate	O
N30	O
inclusion	O
in	O
an	O
IDDE	O
-	O
dependent	O
manner	O
.	O

The	O
hexanucleotide	O
motif	O
UGCAUG	O
is	O
indispensable	O
for	O
this	O
activation	O
.	O

Differential	O
activities	O
of	O
alternatively	O
spliced	O
isoforms	O
of	O
Fxh	O
and	O
A2BP1	O
in	O
promoting	O
N30	O
inclusion	O
Both	O
Fxh	O
and	O
A2BP1	O
mRNAs	O
are	O
expressed	O
in	O
brain	O
and	O
A2BP1	O
is	O
also	O
expressed	O
in	O
striated	O
muscles	O
and	O
Fxh	O
is	O
expressed	O
in	O
an	O
even	O
wider	O
variety	O
of	O
tissues	O
.	O

As	O
demonstrated	O
above	O
,	O
however	O
,	O
both	O
Fxh	O
and	O
A2BP1	O
transcripts	O
undergo	O
tissue	O
-	O
dependent	O
alternative	O
splicing	O
,	O
producing	O
muscle	O
-	O
specific	O
and	O
brain	O
-	O
enriched	O
isoforms	O
.	O

Therefore	O
,	O
the	O
relative	O
activity	O
of	O
individual	O
isoform	O
of	O
Fxh	O
and	O
A2BP1	O
in	O
promoting	O
N30	O
inclusion	O
was	O
compared	O
using	O
minigene	O
G.	O
First	O
,	O
in	O
order	O
to	O
evaluate	O
the	O
relative	O
specific	O
activity	O
of	O
each	O
isoform	O
in	O
the	O
splicing	O
reaction	O
separately	O
from	O
its	O
ability	O
to	O
localize	O
to	O
nuclei	O
,	O
an	O
exogenous	O
NLS	O
was	O
included	O
in	O
the	O
expressed	O
protein	O
to	O
equalize	O
the	O
nuclear	O
concentration	O
of	O
the	O
expressed	O
protein	O
in	O
these	O
experiments	O
.	O

Essentially	O
,	O
all	O
of	O
the	O
expressed	O
proteins	O
with	O
the	O
exogenous	O
NLS	O
are	O
localized	O
to	O
the	O
nucleus	O
(	O
data	O
not	O
shown	O
)	O
.	O

Therefore	O
,	O
the	O
relative	O
nuclear	O
concentrations	O
of	O
the	O
expressed	O
proteins	O
can	O
be	O
estimated	O
easily	O
by	O
immunoblots	O
.	O

As	O
shown	O
in	O
immunoblots	O
in	O
Figure	O
5A	O
,	O
similar	O
quantities	O
of	O
proteins	O
are	O
expressed	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Expression	O
of	O
the	O
brain	O
isoform	O
F011	O
causes	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
N30	O
inclusion	O
and	O
the	O
extent	O
of	O
N30	O
inclusion	O
reaches	O
a	O
plateau	O
with	O
∼85	O
%	O
of	O
the	O
mRNAs	O
including	O
N30	O
.	O

In	O
contrast	O
,	O
inclusion	O
of	O
N30	O
promoted	O
by	O
F411	O
,	O
the	O
predominant	O
isoform	O
from	O
skeletal	O
muscles	O
,	O
reaches	O
a	O
plateau	O
with	O
only	O
40	O
%	O
of	O
the	O
mRNAs	O
.	O

With	O
respect	O
to	O
A2BP1	O
,	O
the	O
brain	O
isoform	O
A030	O
shows	O
higher	O
activity	O
in	O
N30	O
inclusion	O
than	O
the	O
muscle	O
isoform	O
A715	O
,	O
which	O
shows	O
almost	O
no	O
activation	O
,	O
as	O
shown	O
in	O
Figure	O
5A	O
.	O

Including	O
additional	O
isoforms	O
,	O
the	O
activities	O
of	O
individual	O
isoforms	O
with	O
an	O
exogenous	O
NLS	O
in	O
promoting	O
N30	O
inclusion	O
are	O
shown	O
in	O
Figure	O
5B	O
(	O
lanes	O
8–13	O
)	O
and	O
are	O
also	O
summarized	O
in	O
Figure	O
1A	O
(	O
nls	O
)	O
.	O

Special	O
care	O
was	O
taken	O
to	O
ensure	O
that	O
a	O
similar	O
quantity	O
of	O
each	O
protein	O
was	O
expressed	O
and	O
,	O
if	O
not	O
,	O
different	O
amounts	O
were	O
tested	O
to	O
obtain	O
comparable	O
expression	O
.	O

In	O
the	O
presence	O
of	O
the	O
exogenous	O
NLS	O
(	O
nls	O
)	O
,	O
F011	O
and	O
A016	O
show	O
the	O
highest	O
activities	O
among	O
all	O
isoforms	O
tested	O
.	O

A30	O
shows	O
a	O
considerably	O
lower	O
activity	O
than	O
A016	O
.	O

Each	O
of	O
the	O
muscle	O
isoforms	O
(	O
F411	O
,	O
A713	O
and	O
A715	O
)	O
has	O
a	O
lower	O
activity	O
than	O
that	O
of	O
their	O
brain	O
counterparts	O
(	O
F011	O
,	O
A016	O
and	O
A030	O
,	O
respectively	O
)	O
.	O

As	O
expected	O
,	O
isoforms	O
lacking	O
a	O
part	O
or	O
all	O
of	O
the	O
RRM	O
(	O
F402	O
and	O
A704	O
)	O
have	O
no	O
activity	O
for	O
N30	O
inclusion	O
.	O

Next	O
,	O
the	O
splicing	O
activities	O
of	O
the	O
wild	O
-	O
type	O
proteins	O
without	O
an	O
exogenous	O
NLS	O
were	O
examined	O
.	O

Representative	O
data	O
are	O
shown	O
in	O
Figure	O
5B	O
(	O
lanes	O
2–7	O
)	O
and	O
the	O
relative	O
activities	O
are	O
summarized	O
in	O
Figure	O
1A	O
(	O
wt	O
)	O
.	O

The	O
protein	O
amounts	O
detected	O
by	O
immunoblots	O
in	O
these	O
experiments	O
represent	O
the	O
total	O
amounts	O
of	O
the	O
proteins	O
distributed	O
to	O
both	O
the	O
nuclei	O
and	O
the	O
cytoplasm	O
.	O

The	O
splicing	O
activities	O
of	O
the	O
wild	O
-	O
type	O
proteins	O
are	O
consistent	O
with	O
the	O
activities	O
that	O
combine	O
the	O
splicing	O
activities	O
of	O
the	O
proteins	O
with	O
the	O
exogenous	O
NLS	O
and	O
the	O
activities	O
of	O
the	O
native	O
proteins	O
to	O
localize	O
to	O
nuclei	O
.	O

In	O
the	O
absence	O
of	O
the	O
exogenous	O
NLS	O
(	O
wt	O
)	O
,	O
the	O
brain	O
isoforms	O
F011	O
,	O
and	O
A016	O
to	O
a	O
lesser	O
extent	O
,	O
are	O
still	O
capable	O
of	O
activating	O
N30	O
inclusion	O
efficiently	O
.	O

The	O
muscle	O
isoforms	O
for	O
both	O
Fxh	O
and	O
A2BP1	O
(	O
F411	O
,	O
A713	O
and	O
A715	O
)	O
,	O
as	O
well	O
as	O
the	O
brain	O
isoform	O
A030	O
,	O
show	O
only	O
minimal	O
activities	O
.	O

Therefore	O
,	O
F011	O
and	O
A016	O
appear	O
to	O
have	O
the	O
most	O
physiological	O
relevance	O
to	O
N30	O
splicing	O
activation	O
.	O

Overexpression	O
of	O
Fxh	O
and	O
A2BP1	O
activates	O
N30	O
inclusion	O
of	O
endogenous	O
NMHC	O
-	O
B	O
mRNAs	O
The	O
human	B
NMHC	O
-	O
B	O
gene	O
consists	O
of	O
41	O
constitutive	O
exons	O
and	O
3	O
alternative	O
exons	O
.	O

Its	O
pre	O
-	O
mRNA	O
is	O
∼156	O
kb	O
in	O
length	O
and	O
it	O
is	O
much	O
more	O
complex	O
than	O
the	O
pre	O
-	O
mRNA	O
from	O
the	O
minigenes	O
.	O

In	O
addition	O
,	O
the	O
minigene	O
pre	O
-	O
mRNAs	O
are	O
driven	O
by	O
a	O
heterologous	O
promoter	O
.	O

Therefore	O
,	O
we	O
next	O
examined	O
if	O
Fxh	O
and	O
A2BP1	O
were	O
capable	O
of	O
promoting	O
N30	O
inclusion	O
of	O
the	O
endogenous	O
transcript	O
.	O

Y79	O
cells	O
were	O
stably	O
transfected	O
with	O
the	O
expression	O
construct	O
for	O
F011	O
or	O
A016	O
.	O

Both	O
F011	O
and	O
A016	O
are	O
enriched	O
in	O
the	O
brain	O
and	O
show	O
higher	O
activation	O
of	O
N30	O
inclusion	O
in	O
the	O
minigene	O
transcripts	O
.	O

mRNAs	O
encoding	O
endogenous	O
NMHC	O
-	O
B	O
were	O
analyzed	O
by	O
using	O
RT	O
–	O
PCR	O
.	O

As	O
shown	O
in	O
Figure	O
6	O
,	O
the	O
inclusion	O
of	O
exon	O
N30	O
with	O
and	O
without	O
another	O
alternative	O
exon	O
,	O
R18	O
,	O
in	O
the	O
endogenous	O
mRNAs	O
is	O
markedly	O
increased	O
in	O
the	O
clones	O
which	O
were	O
stably	O
transfected	O
with	O
the	O
construct	O
for	O
F011	O
or	O
A016	O
containing	O
an	O
exogenous	O
NLS	O
(	O
Figure	O
6	O
,	O
lanes	O
4	O
and	O
5	O
)	O
.	O

Although	O
to	O
a	O
lesser	O
extent	O
,	O
transfection	O
of	O
the	O
wild	O
-	O
type	O
constructs	O
without	O
an	O
exogenous	O
NLS	O
also	O
results	O
in	O
a	O
significant	O
increase	O
in	O
N30	O
inclusion	O
(	O
Figure	O
6	O
,	O
lanes	O
2	O
and	O
3	O
)	O
.	O

Thus	O
,	O
exogenously	O
expressed	O
Fxh	O
and	O
A2BP1	O
are	O
capable	O
of	O
activating	O
N30	O
inclusion	O
not	O
only	O
in	O
the	O
transcripts	O
from	O
the	O
minigenes	O
,	O
but	O
also	O
in	O
those	O
from	O
the	O
native	O
NMHC	O
-	O
B	O
gene	O
in	O
Y79	O
cells	O
.	O

Fxh	O
may	O
cooperate	O
with	O
other	O
factor	O
(	O
s	O
)	O
to	O
promote	O
N30	O
inclusion	O
To	O
address	O
the	O
role	O
of	O
endogenous	O
Fxh	O
and	O
its	O
potential	O
interaction	O
with	O
other	O
proteins	O
in	O
promoting	O
N30	O
inclusion	O
,	O
we	O
made	O
use	O
of	O
an	O
isoform	O
of	O
Fxh	O
,	O
F402	O
,	O
which	O
lacks	O
the	O
RRM	O
.	O

The	O
mutant	O
proteins	O
lacking	O
an	O
RRM	O
for	O
other	O
RNA	O
-	O
binding	O
proteins	O
have	O
previously	O
been	O
reported	O
to	O
function	O
in	O
a	O
dominant	O
-	O
negative	O
fashion	O
and	O
inhibit	O
the	O
activities	O
of	O
the	O
wild	O
-	O
type	O
proteins	O
(	O
26,31	O
)	O
.	O

Therefore	O
,	O
the	O
effects	O
of	O
F402	O
on	O
the	O
N30	O
inclusion	O
of	O
minigene	O
H	O
mRNAs	O
were	O
examined	O
in	O
the	O
context	O
of	O
the	O
Y79	O
cells	O
treated	O
with	O
butyrate	O
.	O

Upon	O
butyrate	O
treatment	O
,	O
as	O
reported	O
previously	O
,	O
Y79	O
cells	O
enter	O
in	O
a	O
post	O
-	O
mitotic	O
and	O
differentiated	O
stage	O
,	O
and	O
importantly	O
,	O
the	O
endogenous	O
as	O
well	O
as	O
the	O
minigene	O
mRNAs	O
in	O
those	O
cells	O
include	O
N30	O
to	O
a	O
large	O
extent	O
,	O
unlike	O
those	O
in	O
the	O
untreated	O
cells	O
that	O
predominantly	O
exclude	O
N30	O
(	O
14	O
)	O
.	O

As	O
shown	O
in	O
Figure	O
7	O
,	O
in	O
the	O
absence	O
of	O
exogenous	O
expression	O
of	O
F402	O
,	O
large	O
quantities	O
of	O
the	O
mRNAs	O
derived	O
from	O
minigene	O
H	O
-	O
wt	O
,	O
which	O
contains	O
the	O
wild	O
-	O
type	O
IDDE	O
,	O
include	O
N30	O
(	O
Figure	O
7	O
,	O
upper	O
panel	O
,	O
lane	O
4	O
)	O
.	O

In	O
contrast	O
,	O
only	O
small	O
quantities	O
of	O
N30	O
inclusion	O
are	O
detected	O
in	O
the	O
mRNAs	O
from	O
minigene	O
H	O
-	O
mc	O
,	O
which	O
has	O
mutations	O
in	O
both	O
copies	O
of	O
UGCAUG	O
in	O
the	O
IDDE	O
(	O
Figure	O
7	O
,	O
upper	O
panel	O
,	O
lane	O
8)	O
.	O

Therefore	O
,	O
the	O
butyrate	O
-	O
treated	O
Y79	O
cells	O
contain	O
factor	O
(	O
s	O
)	O
,	O
which	O
are	O
capable	O
of	O
activating	O
the	O
UGCAUG	O
-	O
dependent	O
N30	O
inclusion	O
.	O

Co	O
-	O
transfection	O
of	O
the	O
wild	O
-	O
type	O
minigene	O
H	O
-	O
wt	O
with	O
the	O
F402	O
expression	O
construct	O
causes	O
a	O
dose	O
-	O
dependent	O
inhibition	O
of	O
N30	O
inclusion	O
(	O
Figure	O
7	O
,	O
lanes	O
1–3	O
)	O
,	O
indicating	O
that	O
F402	O
has	O
an	O
antagonistic	O
effect	O
on	O
the	O
endogenous	O
factors	O
with	O
respect	O
to	O
N30	O
inclusion	O
.	O

Notably	O
,	O
the	O
UGCAUG	O
-	O
independent	O
N30	O
inclusion	O
seen	O
in	O
the	O
mutant	O
minigene	O
H	O
-	O
mc	O
is	O
not	O
affected	O
by	O
the	O
co	O
-	O
expression	O
of	O
F402	O
(	O
Figure	O
7	O
,	O
lanes	O
5–7	O
)	O
,	O
indicating	O
that	O
the	O
inhibitory	O
activity	O
of	O
F402	O
depends	O
on	O
the	O
UGCAUG	O
element	O
.	O

The	O
parallel	O
experiment	O
with	O
the	O
F011	O
expression	O
construct	O
does	O
not	O
show	O
a	O
significant	O
effect	O
on	O
N30	O
splicing	O
in	O
either	O
the	O
wild	O
-	O
type	O
or	O
mutant	O
minigene	O
(	O
Figure	O
7	O
,	O
lanes	O
9–16	O
)	O
.	O

This	O
may	O
be	O
due	O
to	O
the	O
fact	O
that	O
N30	O
inclusion	O
of	O
the	O
wild	O
-	O
type	O
minigene	O
mRNAs	O
has	O
already	O
reached	O
a	O
maximal	O
level	O
and	O
is	O
consistent	O
with	O
the	O
idea	O
that	O
butyrate	O
-	O
treated	O
Y79	O
cells	O
contain	O
sufficient	O
amounts	O
of	O
protein	O
(	O
s	O
)	O
functionally	O
equivalent	O
to	O
F011	O
,	O
which	O
can	O
promote	O
N30	O
inclusion	O
in	O
a	O
UGCAUG	O
-	O
dependent	O
manner	O
.	O

Since	O
F402	O
does	O
not	O
bind	O
to	O
the	O
UGCAUG	O
element	O
,	O
and	O
has	O
a	O
UGCAUG	O
-	O
dependent	O
antagonistic	O
effect	O
on	O
N30	O
splicing	O
,	O
it	O
most	O
probably	O
disrupts	O
protein	O
–	O
protein	O
interactions	O
of	O
the	O
endogenous	O
proteins	O
that	O
are	O
required	O
for	O
the	O
UGCAUG	O
-	O
dependent	O
activation	O
of	O
N30	O
splicing	O
.	O

Endogenous	O
Fxh	O
(	O
and/or	O
A2BP1	O
)	O
would	O
be	O
a	O
good	O
candidate	O
whose	O
function	O
could	O
be	O
antagonized	O
by	O
exogenously	O
expressed	O
F402	O
.	O

Thus	O
,	O
this	O
observation	O
suggests	O
that	O
the	O
endogenous	O
Fxh	O
has	O
an	O
effect	O
on	O
the	O
activation	O
of	O
N30	O
splicing	O
and	O
that	O
other	O
proteins	O
cooperate	O
with	O
Fxh	O
for	O
N30	O
activation	O
.	O

Since	O
muscle	O
cells	O
express	O
the	O
RRM	O
-	O
defective	O
isoforms	O
to	O
a	O
significant	O
extent	O
(	O
Figure	O
2C	O
)	O
and	O
the	O
wild	O
-	O
type	O
F402	O
localize	O
to	O
nuclei	O
efficiently	O
,	O
this	O
also	O
raises	O
the	O
possibility	O
that	O
the	O
RRM	O
-	O
defective	O
isoforms	O
may	O
have	O
an	O
inhibitory	O
function	O
on	O
the	O
N30	O
splicing	O
in	O
muscle	O
cells	O
.	O

DISCUSSION	O
Two	O
major	O
findings	O
are	O
described	O
in	O
this	O
report	O
.	O

First	O
,	O
Fxh	O
and	O
A2BP1	O
facilitate	O
neural	O
cell	O
-	O
specific	O
inclusion	O
of	O
the	O
cassette	O
-	O
type	O
exon	O
via	O
binding	O
to	O
the	O
specific	O
intronic	O
sequence	O
UGCAUG	O
.	O

In	O
addition	O
to	O
a	O
minigene	O
model	O
system	O
,	O
Fxh	O
and	O
A2BP1	O
are	O
capable	O
of	O
facilitating	O
N30	O
inclusion	O
of	O
the	O
endogenous	O
pre	O
-	O
mRNA	O
.	O

This	O
result	O
provides	O
an	O
important	O
demonstration	O
of	O
physiological	O
relevance	O
and	O
supports	O
the	O
notion	O
that	O
the	O
NMHC	O
-	O
B	O
pre	O
-	O
mRNA	O
is	O
likely	O
to	O
be	O
the	O
true	O
target	O
for	O
Fxh	O
or	O
A2BP1-mediated	O
regulation	O
.	O

However	O
,	O
whether	O
the	O
endogenous	O
Fxh	O
or	O
A2BP1	O
regulates	O
endogenous	O
NMHC	O
-	O
B	O
pre	O
-	O
mRNA	O
splicing	O
needs	O
to	O
be	O
determined	O
in	O
a	O
future	O
study	O
.	O

In	O
vertebrates	O
,	O
small	O
interfering	O
RNAs	O
and	O
gene	O
targeting	O
strategies	O
have	O
recently	O
been	O
used	O
successfully	O
to	O
address	O
the	O
roles	O
of	O
endogenous	O
splicing	O
regulators	O
in	O
alternative	O
splicing	O
of	O
endogenous	O
target	O
pre	O
-	O
mRNAs	O
(	O
8,32–36	O
)	O
.	O

A	O
second	O
and	O
more	O
novel	O
finding	O
is	O
the	O
identification	O
of	O
tissue	O
-	O
specific	O
isoforms	O
of	O
Fxh	O
and	O
A2BP1	O
with	O
different	O
splicing	O
activities	O
as	O
well	O
as	O
different	O
subcellular	O
localizations	O
.	O

This	O
finding	O
raises	O
the	O
possibility	O
that	O
the	O
products	O
of	O
the	O
Fxh	O
and	O
A2BP1	O
genes	O
can	O
contribute	O
to	O
a	O
mechanism	O
as	O
to	O
how	O
tissue	O
specificity	O
of	O
alternative	O
splicing	O
is	O
achieved	O
.	O

Many	O
splicing	O
factors	O
are	O
detected	O
not	O
only	O
in	O
the	O
nuclei	O
,	O
but	O
also	O
in	O
the	O
cytoplasm	O
(	O
37	O
)	O
.	O

They	O
are	O
shuttling	O
between	O
the	O
nucleus	O
and	O
the	O
cytoplasm	O
and	O
,	O
in	O
some	O
instances	O
,	O
extracellular	O
stimuli	O
trigger	O
changes	O
in	O
subcellular	O
distribution	O
of	O
these	O
proteins	O
.	O

Such	O
translocations	O
have	O
been	O
reported	O
for	O
hnRNPA1	O
and	O
PTB	O
(	O
38,39	O
)	O
.	O

Moreover	O
,	O
a	O
number	O
of	O
RNA	O
-	O
binding	O
proteins	O
have	O
been	O
demonstrated	O
to	O
play	O
a	O
role	O
in	O
multiple	O
steps	O
during	O
gene	O
expression	O
in	O
different	O
subcellular	O
compartments	O
,	O
such	O
as	O
pre	O
-	O
mRNA	O
processing	O
in	O
nuclei	O
,	O
mRNA	O
export	O
from	O
nuclei	O
to	O
cytoplasm	O
and	O
mRNA	O
localization	O
,	O
stability	O
and	O
translation	O
in	O
cytoplasm	O
(	O
37,40	O
)	O
.	O

Therefore	O
,	O
not	O
surprisingly	O
,	O
Fxh	O
and	O
A2BP1	O
isoforms	O
were	O
found	O
to	O
be	O
distributed	O
in	O
both	O
the	O
nuclei	O
and	O
the	O
cytoplasm	O
in	O
HeLa	O
and	O
Y79	O
cells	O
.	O

However	O
,	O
the	O
relative	O
ratios	O
of	O
proteins	O
distributed	O
between	O
the	O
two	O
subcellular	O
compartments	O
at	O
steady	O
-	O
state	O
differ	O
among	O
the	O
isoforms	O
.	O

In	O
agreement	O
with	O
Jin	O
et	O
al.	O
(	O
21	O
)	O
,	O
substantial	O
amounts	O
of	O
the	O
brain	O
isoform	O
A016	O
are	O
detected	O
in	O
nuclei	O
.	O

Other	O
A2BP1	O
isoforms	O
,	O
the	O
brain	O
isoform	O
A030	O
and	O
the	O
muscle	O
isoforms	O
A713	O
and	O
A715	O
,	O
are	O
only	O
poorly	O
detected	O
in	O
nuclei	O
.	O

This	O
observation	O
is	O
consistent	O
with	O
the	O
reports	O
where	O
endogenous	O
A2BP1	O
in	O
cerebellar	O
Purkinje	O
cells	O
,	O
hippocampus	O
neurons	O
and	O
cardiac	O
myocytes	O
were	O
shown	O
to	O
be	O
localized	O
essentially	O
to	O
the	O
cytoplasm	O
(	O
23,24	O
)	O
.	O

Thus	O
,	O
inclusion	O
and	O
exclusion	O
of	O
A53	O
and	O
differences	O
in	O
the	O
very	O
N	O
-	O
terminal	O
sequences	O
results	O
in	O
A2BP1	O
isoforms	O
with	O
a	O
distinct	O
subcellular	O
localization	O
.	O

It	O
is	O
likely	O
that	O
A2BP1	O
proteins	O
have	O
multiple	O
roles	O
,	O
involving	O
both	O
nuclear	O
and	O
cytoplasmic	O
events	O
.	O

In	O
contrast	O
,	O
all	O
three	O
Fxh	O
isoforms	O
predominantly	O
localized	O
to	O
the	O
nuclei	O
.	O

Therefore	O
,	O
in	O
terms	O
of	O
their	O
localization	O
,	O
Fxh	O
proteins	O
are	O
better	O
candidates	O
for	O
regulators	O
of	O
the	O
pre	O
-	O
mRNA	O
splicing	O
that	O
takes	O
place	O
in	O
nuclei	O
.	O

Of	O
note	O
,	O
however	O
,	O
our	O
preliminary	O
results	O
of	O
5′	O
RACE	O
,	O
as	O
well	O
as	O
the	O
EST	O
database	O
,	O
detect	O
multiple	O
5′	O
end	O
sequences	O
for	O
both	O
Fxh	O
and	O
A2BP1	O
mRNAs	O
,	O
which	O
are	O
presumably	O
generated	O
by	O
alternative	O
promoters	O
and	O
alternative	O
splicing	O
.	O

The	O
diversity	O
of	O
the	O
5′	O
end	O
cDNA	O
sequences	O
leads	O
to	O
the	O
generation	O
of	O
a	O
number	O
of	O
unique	O
N	O
-	O
terminal	O
amino	O
acid	O
sequences	O
.	O

Therefore	O
,	O
this	O
study	O
does	O
not	O
exclude	O
the	O
possible	O
existence	O
of	O
other	O
isoforms	O
with	O
different	O
subcellular	O
localizations	O
for	O
both	O
Fxh	O
and	O
A2BP1	O
.	O

Our	O
study	O
also	O
does	O
not	O
exclude	O
the	O
possibility	O
that	O
some	O
of	O
the	O
isoforms	O
translocate	O
between	O
the	O
nucleus	O
and	O
the	O
cytoplasm	O
following	O
stimuli	O
.	O

The	O
main	O
aim	O
of	O
this	O
study	O
is	O
to	O
determine	O
the	O
relative	O
activities	O
of	O
tissue	O
-	O
dependent	O
isoforms	O
of	O
Fxh	O
and	O
A2BP1	O
in	O
neural	O
cell	O
-	O
specific	O
and	O
UGCAUG	O
element	O
-	O
dependent	O
alternative	O
splicing	O
.	O

To	O
obtain	O
an	O
indication	O
of	O
the	O
relative	O
specific	O
activity	O
of	O
each	O
isoform	O
in	O
transfected	O
cells	O
,	O
the	O
same	O
amounts	O
of	O
the	O
expressed	O
proteins	O
should	O
be	O
available	O
for	O
the	O
splicing	O
reaction	O
in	O
the	O
nuclei	O
.	O

For	O
this	O
reason	O
,	O
an	O
exogenous	O
NLS	O
was	O
included	O
in	O
the	O
expressed	O
proteins	O
.	O

Essentially	O
,	O
all	O
of	O
the	O
expressed	O
proteins	O
with	O
the	O
exogenous	O
NLS	O
localized	O
to	O
nuclei	O
.	O

Thus	O
,	O
the	O
amounts	O
of	O
the	O
expressed	O
proteins	O
determined	O
by	O
immunoblots	O
represent	O
the	O
nuclear	O
concentrations	O
.	O

The	O
analysis	O
using	O
the	O
proteins	O
expressed	O
with	O
the	O
exogenous	O
NLS	O
allowed	O
us	O
to	O
compare	O
directly	O
the	O
splicing	O
activities	O
of	O
these	O
proteins	O
.	O

Furthermore	O
,	O
this	O
analysis	O
also	O
allowed	O
us	O
to	O
define	O
the	O
critical	O
regions	O
of	O
the	O
proteins	O
for	O
splicing	O
activation	O
.	O

As	O
shown	O
in	O
Figure	O
5	O
,	O
the	O
splicing	O
activities	O
of	O
the	O
various	O
isoforms	O
of	O
Fxh	O
and	O
A2BP1	O
are	O
intrinsically	O
different	O
,	O
regardless	O
of	O
the	O
subcellular	O
localization	O
properties	O
of	O
the	O
wild	O
-	O
type	O
proteins	O
.	O

Among	O
the	O
isoforms	O
tested	O
in	O
this	O
study	O
,	O
F011	O
and	O
A016	O
,	O
which	O
include	O
B40	O
,	O
are	O
found	O
to	O
have	O
higher	O
activities	O
in	O
promoting	O
N30	O
inclusion	O
.	O

When	O
the	O
primary	O
amino	O
acid	O
sequences	O
,	O
outside	O
of	O
the	O
RRM	O
,	O
of	O
these	O
two	O
proteins	O
are	O
compared	O
,	O
the	O
C	O
-	O
terminal	O
regions	O
(	O
amino	O
acids	O
190–377	O
of	O
F011	O
)	O
show	O
a	O
higher	O
homology	O
with	O
71	O
%	O
identity	O
,	O
whereas	O
the	O
N	O
-	O
terminal	O
regions	O
(	O
amino	O
acids	O
1–112	O
of	O
F011	O
)	O
show	O
only	O
53	O
%	O
identity	O
.	O

The	O
C	O
-	O
terminal	O
region	O
includes	O
four	O
subregions	O
of	O
nearly	O
identical	O
stretches	O
of	O
amino	O
acids	O
(	O
Figure	O
8	O
,	O
I	O
–	O
IV	O
)	O
.	O

One	O
subregion	O
(	O
II	O
)	O
includes	O
13	O
amino	O
acids	O
encoded	O
by	O
exon	O
B40	O
.	O

Substitution	O
of	O
this	O
subregion	O
with	O
exon	O
M43	O
in	O
Fxh	O
causes	O
substantial	O
changes	O
in	O
amino	O
acid	O
sequences	O
resulting	O
in	O
only	O
a	O
21	O
%	O
identity	O
in	O
this	O
region	O
between	O
F011	O
and	O
F411	O
.	O

Another	O
subregion	O
(	O
IV	O
)	O
is	O
located	O
at	O
the	O
C	O
-	O
terminal	O
end	O
and	O
A030	O
lacks	O
this	O
homologous	O
region	O
by	O
the	O
inclusion	O
of	O
exon	O
A53	O
,	O
which	O
results	O
in	O
a	O
frame	O
shift	O
.	O

Since	O
F411	O
and	O
A030	O
show	O
poor	O
splicing	O
activation	O
compared	O
with	O
F011	O
and	O
A016	O
,	O
respectively	O
,	O
these	O
two	O
subregions	O
of	O
F011	O
and	O
A016	O
appear	O
to	O
serve	O
as	O
activation	O
domains	O
,	O
presumably	O
by	O
interacting	O
with	O
other	O
proteins	O
.	O

This	O
notion	O
is	O
supported	O
by	O
the	O
finding	O
that	O
the	O
RRM	O
-	O
lacking	O
isoform	O
F402	O
,	O
which	O
includes	O
the	O
same	O
subregions	O
II	O
and	O
IV	O
as	O
F011	O
,	O
functions	O
apparently	O
as	O
a	O
dominant	O
-	O
negative	O
mutant	O
to	O
the	O
wild	O
-	O
type	O
Fxh	O
,	O
consistent	O
with	O
the	O
interpretation	O
that	O
the	O
mutant	O
and	O
wild	O
-	O
type	O
are	O
competing	O
to	O
interact	O
with	O
other	O
protein	O
(	O
s	O
)	O
.	O

To	O
date	O
,	O
Fyn	O
tyrosine	O
kinase	O
and	O
estrogen	O
receptor	O
-	O
α	O
have	O
been	O
reported	O
to	O
interact	O
with	O
Fxh	O
,	O
and	O
ataxin-2	O
with	O
A2BP1	O
(	O
23,41,42	O
)	O
.	O

Whether	O
these	O
proteins	O
participate	O
in	O
the	O
regulation	O
of	O
pre	O
-	O
mRNA	O
splicing	O
is	O
currently	O
unknown	O
.	O

Of	O
interest	O
,	O
A030	O
with	O
the	O
exogenous	O
NLS	O
activates	O
N30	O
splicing	O
as	O
efficiently	O
as	O
F011	O
in	O
the	O
pre	O
-	O
mRNAs	O
derived	O
from	O
minigenes	O
J	O
and	O
H	O
,	O
which	O
contain	O
the	O
shorter	O
intron	O
,	O
whereas	O
this	O
isoform	O
poorly	O
activates	O
N30	O
splicing	O
in	O
the	O
pre	O
-	O
mRNA	O
from	O
minigene	O
G	O
,	O
which	O
contains	O
the	O
full	O
-	O
length	O
intron	O
.	O

This	O
observation	O
implies	O
that	O
the	O
interactions	O
of	O
A030	O
with	O
different	O
factors	O
are	O
required	O
in	O
the	O
different	O
pre	O
-	O
mRNA	O
contexts	O
.	O

Therefore	O
,	O
the	O
isoforms	O
of	O
Fxh	O
and	O
A2BP1	O
described	O
here	O
may	O
have	O
different	O
effects	O
on	O
other	O
UGCAUG	O
-	O
regulated	O
alternative	O
splicing	O
.	O

The	O
involvement	O
of	O
the	O
hexanucleotide	O
UGCAUG	O
in	O
regulated	O
alternative	O
splicing	O
has	O
been	O
experimentally	O
demonstrated	O
in	O
a	O
number	O
of	O
neural	O
cell	O
-	O
specific	O
,	O
as	O
well	O
as	O
other	O
tissue	O
-	O
specific	O
,	O
model	O
systems	O
(	O
13–21	O
)	O
.	O

This	O
hexanucleotide	O
element	O
plays	O
a	O
role	O
,	O
in	O
most	O
cases	O
,	O
as	O
an	O
enhancer	O
in	O
regulating	O
alternative	O
splicing	O
of	O
cassette	O
-	O
type	O
exons	O
as	O
well	O
as	O
mutually	O
exclusive	O
exons	O
.	O

Furthermore	O
,	O
computational	O
analysis	O
has	O
revealed	O
that	O
UGCAUG	O
is	O
over	O
-	O
represented	O
in	O
the	O
introns	O
in	O
which	O
splicing	O
is	O
regulated	O
,	O
compared	O
with	O
the	O
constitutively	O
spliced	O
introns	O
(	O
43	O
)	O
.	O

This	O
analysis	O
also	O
pointed	O
to	O
the	O
UGCAUG	O
element	O
as	O
playing	O
a	O
role	O
in	O
the	O
regulation	O
of	O
tissue	O
-	O
specific	O
alternative	O
splicing	O
in	O
a	O
wide	O
range	O
of	O
tissues	O
,	O
but	O
not	O
in	O
specific	O
tissues	O
.	O

To	O
date	O
,	O
KH	O
-	O
type	O
splicing	O
regulatory	O
protein	O
(	O
KSRP	O
)	O
(	O
44	O
)	O
,	O
A2BP1	O
(	O
21	O
)	O
and	O
Fxh	O
(	O
this	O
study	O
)	O
are	O
known	O
to	O
be	O
capable	O
of	O
binding	O
to	O
UGCAUG	O
.	O

KSRP	O
is	O
expressed	O
ubiquitously	O
and	O
tissue	O
-	O
specific	O
variants	O
of	O
this	O
gene	O
have	O
not	O
been	O
described	O
so	O
far	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
described	O
the	O
existence	O
of	O
tissue	O
-	O
dependent	O
isoforms	O
of	O
Fxh	O
and	O
A2BP1	O
,	O
which	O
,	O
while	O
not	O
identical	O
in	O
some	O
areas	O
of	O
the	O
molecule	O
,	O
may	O
contain	O
the	O
same	O
RRM	O
.	O

The	O
physiological	O
relevance	O
of	O
these	O
isoforms	O
is	O
that	O
they	O
have	O
different	O
splicing	O
activities	O
and	O
different	O
subcellular	O
localizations	O
.	O

The	O
brain	O
isoforms	O
promote	O
N30	O
inclusion	O
more	O
efficiently	O
than	O
the	O
muscle	O
isoforms	O
of	O
both	O
Fxh	O
and	O
A2BP1	O
.	O

The	O
isoforms	O
lacking	O
the	O
RRM	O
are	O
normally	O
expressed	O
to	O
a	O
significant	O
extent	O
in	O
skeletal	O
muscles	O
.	O

This	O
isoform	O
is	O
incapable	O
of	O
activating	O
N30	O
splicing	O
and	O
,	O
moreover	O
,	O
can	O
inhibit	O
N30	O
inclusion	O
.	O

The	O
properties	O
of	O
these	O
isoforms	O
are	O
consistent	O
with	O
Fxh	O
and	O
A2BP1	O
acting	O
as	O
regulators	O
for	O
N30	O
splicing	O
,	O
since	O
N30	O
is	O
included	O
in	O
neuronal	O
cells	O
,	O
but	O
excluded	O
in	O
muscles	O
.	O

Therefore	O
,	O
despite	O
the	O
tissue	O
-	O
independent	O
occurrence	O
of	O
UGCAUG	O
as	O
a	O
regulatory	O
element	O
,	O
given	O
the	O
tissue	O
-	O
dependent	O
isoforms	O
of	O
the	O
UGCAUG	O
-	O
binding	O
proteins	O
(	O
Fxh	O
and	O
A2BP1	O
)	O
with	O
different	O
activities	O
,	O
the	O
hexanucleotide	O
UGCAUG	O
could	O
confer	O
tissue	O
specificity	O
on	O
regulated	O
splicing	O
.	O

One	O
of	O
the	O
major	O
problems	O
in	O
understanding	O
the	O
mechanisms	O
responsible	O
for	O
alternative	O
pre	O
-	O
mRNA	O
splicing	O
is	O
the	O
manner	O
in	O
which	O
tissue	O
specificity	O
is	O
determined	O
.	O

In	O
vertebrates	O
,	O
to	O
date	O
,	O
only	O
a	O
few	O
tissue	O
-	O
specific	O
proteins	O
have	O
been	O
identified	O
as	O
splicing	O
regulators	O
(	O
8–12	O
)	O
.	O

Here	O
,	O
we	O
have	O
shown	O
that	O
the	O
tissue	O
-	O
dependent	O
isoforms	O
of	O
the	O
sequence	O
-	O
specific	O
RNA	O
-	O
binding	O
proteins	O
,	O
which	O
themselves	O
are	O
generated	O
by	O
alternative	O
splicing	O
,	O
have	O
different	O
activities	O
in	O
tissue	O
-	O
specific	O
alternative	O
splicing	O
of	O
target	O
pre	O
-	O
mRNA	O
.	O

Therefore	O
,	O
these	O
isoforms	O
play	O
a	O
role	O
in	O
the	O
determination	O
of	O
tissue	O
specificity	O
of	O
target	O
pre	O
-	O
mRNA	O
splicing	O
.	O

The	O
discovery	O
of	O
these	O
tissue	O
-	O
dependent	O
isoforms	O
of	O
the	O
UGCAUG	O
-	O
binding	O
proteins	O
with	O
different	O
splicing	O
activities	O
adds	O
an	O
important	O
new	O
dimension	O
to	O
the	O
molecular	O
mechanisms	O
responsible	O
for	O
regulating	O
tissue	O
-	O
dependent	O
alternative	O
splicing	O
mediated	O
via	O
UGCAUG	O
.	O

Epigenetic	O
inactivation	O
and	O
aberrant	O
transcription	O
of	O
CSMD1	O
in	O
squamous	O
cell	O
carcinoma	O
cell	O
lines	O
Abstract	O
Background	O
The	O
p23.2	O
region	O
of	O
human	B
chromosome	O
8	O
is	O
frequently	O
deleted	O
in	O
several	O
types	O
of	O
epithelial	O
cancer	O
and	O
those	O
deletions	O
appear	O
to	O
be	O
associated	O
with	O
poor	O
prognosis	O
.	O

Cub	O
and	O
Sushi	O
Multiple	O
Domains	O
1	O
(	O
CSMD1	O
)	O
was	O
positionally	O
cloned	O
as	O
a	O
candidate	O
for	O
the	O
8p23	O
suppressor	O
but	O
point	O
mutations	O
in	O
this	O
gene	O
are	O
rare	O
relative	O
to	O
the	O
frequency	O
of	O
allelic	O
loss	O
.	O

In	O
an	O
effort	O
to	O
identify	O
alternative	O
mechanisms	O
of	O
inactivation	O
,	O
we	O
have	O
characterized	O
CSMD1	O
expression	O
and	O
epigenetic	O
modifications	O
in	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
cell	O
lines	O
.	O

Results	O
Only	O
one	O
of	O
the	O
20	O
cell	O
lines	O
examined	O
appears	O
to	O
express	O
a	O
structurally	O
normal	O
CSMD1	O
transcript	O
.	O

The	O
rest	O
express	O
transcripts	O
which	O
either	O
lack	O
internal	O
exons	O
,	O
terminate	O
abnormally	O
or	O
initiate	O
at	O
cryptic	O
promoters	O
.	O

None	O
of	O
these	O
truncated	O
transcripts	O
is	O
predicted	O
to	O
encode	O
a	O
functional	O
CSMD1	O
protein	O
.	O

Cell	O
lines	O
that	O
express	O
little	O
or	O
no	O
CSMD1	O
RNA	O
exhibit	O
DNA	O
methylation	O
of	O
a	O
specific	O
region	O
of	O
the	O
CpG	O
island	O
surrounding	O
CSMD1	O
's	O
first	O
exon	O
.	O

Conclusion	O
Correlating	O
methylation	O
patterns	O
and	O
expression	O
suggests	O
that	O
it	O
is	O
modification	O
of	O
the	O
genomic	O
DNA	O
preceding	O
the	O
first	O
exon	O
that	O
is	O
associated	O
with	O
gene	O
silencing	O
and	O
that	O
methylation	O
of	O
CpG	O
dinucleotides	O
further	O
3	O
'	O
does	O
not	O
contribute	O
to	O
inactivation	O
of	O
the	O
gene	O
.	O

Taken	O
together	O
,	O
the	O
cell	O
line	O
data	O
suggest	O
that	O
epigenetic	O
silencing	O
and	O
aberrant	O
splicing	O
rather	O
than	O
point	O
mutations	O
may	O
be	O
contributing	O
to	O
the	O
reduction	O
in	O
CSMD1	O
expression	O
in	O
squamous	O
cancers	O
.	O

These	O
mechanisms	O
can	O
now	O
serve	O
as	O
a	O
focus	O
for	O
further	O
analysis	O
of	O
primary	O
squamous	O
cancers	O
.	O

Background	O
CUB	O
and	O
Sushi	O
Multiple	O
Domains	O
1	O
(	O
CSMD1	O
)	O
was	O
cloned	O
as	O
a	O
candidate	O
tumor	O
suppressor	O
or	O
progression	O
gene	O
from	O
a	O
region	O
of	O
human	B
chromosome	O
8	O
deleted	O
in	O
tumors	O
of	O
the	O
upper	O
aerodigestive	O
tract	O
,	O
prostate	O
,	O
ovary	O
and	O
bladder	O
[	O
1	O
-	O
7	O
]	O
.	O

Deletion	O
of	O
8p23.2	O
or	O
reduced	O
expression	O
of	O
CSMD1	O
has	O
been	O
associated	O
with	O
poor	O
prognosis	O
in	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinomas	O
and	O
in	O
prostate	O
cancers	O
[	O
2,5,8	O
]	O
.	O

CSMD1	O
,	O
consisting	O
of	O
70	O
exons	O
spread	O
over	O
two	O
megabases	O
of	O
8p23.2	O
,	O
encodes	O
a	O
rare	O
11.5	O
kb	O
transcript	O
most	O
abundantly	O
expressed	O
in	O
the	O
brain	O
[	O
1	O
]	O
.	O

It	O
is	O
the	O
founding	O
member	O
of	O
a	O
novel	O
,	O
evolutionarily	O
highly	O
conserved	O
gene	O
family	O
whose	O
proteins	O
contain	O
multiple	O
domains	O
thought	O
to	O
be	O
sites	O
of	O
protein	O
-	O
protein	O
or	O
protein	O
-	O
ligand	O
interactions	O
and	O
whose	O
structure	O
suggests	O
that	O
they	O
may	O
be	O
transmembrane	O
receptors	O
or	O
adhesion	O
proteins	O
[	O
9,10	O
]	O
.	O

Tumor	O
suppressor	O
genes	O
are	O
expected	O
to	O
be	O
inactivated	O
in	O
cancers	O
either	O
genetically	O
by	O
mutations	O
or	O
epigenetically	O
by	O
modification	O
of	O
their	O
promoters	O
.	O

While	O
CSMD1	O
transcripts	O
are	O
detectable	O
in	O
upper	O
aerodigestive	O
tract	O
epithelium	O
,	O
preliminary	O
analysis	O
of	O
several	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
cell	O
lines	O
suggested	O
that	O
CSMD1	O
expression	O
was	O
lost	O
in	O
these	O
lines	O
[	O
1	O
]	O
.	O

Although	O
the	O
region	O
containing	O
CSMD1	O
is	O
frequently	O
deleted	O
in	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinomas	O
and	O
prostatic	O
adenocarcinomas	O
[	O
3,11	O
-	O
15	O
]	O
,	O
point	O
mutations	O
in	O
the	O
gene	O
are	O
relatively	O
rare	O
in	O
primary	O
squamous	O
cancers	O
[	O
16	O
]	O
and	O
in	O
squamous	O
cell	O
carcinoma	O
cell	O
lines	O
(	O
Schmidt	O
,	O
Richter	O
and	O
Scholnick	O
,	O
unpublished	O
)	O
.	O

Nonsense	O
or	O
splice	O
junction	O
mutations	O
in	O
CSMD1	O
have	O
not	O
been	O
reported	O
and	O
not	O
enough	O
is	O
known	O
about	O
the	O
function	O
of	O
the	O
protein	O
to	O
accurately	O
assess	O
the	O
effect	O
of	O
the	O
few	O
missense	O
mutations	O
that	O
have	O
been	O
detected	O
.	O

Thus	O
,	O
if	O
CSMD1	O
is	O
inactivated	O
in	O
tumors	O
,	O
alternative	O
mechanisms	O
for	O
gene	O
silencing	O
must	O
be	O
operating	O
.	O

In	O
this	O
paper	O
,	O
we	O
demonstrate	O
that	O
while	O
most	O
squamous	O
cell	O
carcinoma	O
cell	O
lines	O
do	O
not	O
express	O
full	O
length	O
CSMD1	O
transcripts	O
,	O
nearly	O
all	O
produce	O
abnormal	O
transcripts	O
unlikely	O
to	O
encode	O
functional	O
CSMD1	O
proteins	O
.	O

Methylation	O
of	O
the	O
DNA	O
preceding	O
CSMD1	O
's	O
first	O
exon	O
is	O
correlated	O
with	O
reduction	O
in	O
the	O
level	O
of	O
expression	O
and	O
cell	O
lines	O
expressing	O
at	O
low	O
levels	O
do	O
not	O
appear	O
to	O
elongate	O
the	O
full	O
11.5	O
kb	O
transcript	O
.	O

Other	O
anomalies	O
of	O
expression	O
include	O
incorrect	O
splicing	O
and	O
the	O
use	O
of	O
cryptic	O
promoters	O
.	O

Our	O
data	O
suggest	O
that	O
activation	O
of	O
these	O
promoters	O
may	O
result	O
from	O
the	O
global	O
demethylation	O
of	O
the	O
genome	O
associated	O
with	O
tumorigenesis	O
(	O
reviewed	O
by	O
Ehrlich	O
[	O
17	O
]	O
)	O
.	O

Taken	O
together	O
these	O
data	O
demonstrate	O
that	O
mechanisms	O
other	O
than	O
point	O
mutation	O
are	O
responsible	O
for	O
the	O
aberrant	O
CSMD1	O
expression	O
in	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
cell	O
lines	O
,	O
and	O
these	O
data	O
suggest	O
potential	O
targets	O
for	O
further	O
investigation	O
in	O
primary	O
tumors	O
.	O

Results	O
CSMD1	O
promoter	O
methylation	O
in	O
HNSCC	O
cell	O
lines	O
is	O
correlated	O
with	O
expression	O
levels	O
Preliminary	O
evidence	O
suggested	O
that	O
CSMD1	O
expression	O
is	O
lost	O
in	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinomas	O
[	O
1	O
]	O
but	O
that	O
point	O
mutations	O
were	O
rare	O
[	O
[	O
16	O
]	O
,	O
and	O
Schmidt	O
,	O
Richter	O
and	O
Scholnick	O
,	O
unpublished	O
]	O
.	O

To	O
date	O
,	O
only	O
two	O
of	O
the	O
20	O
cell	O
lines	O
we	O
have	O
tested	O
for	O
CSMD1	O
expression	O
,	O
UPCI	O
:	O
SCC066	O
and	O
PCI-13	O
,	O
express	O
large	O
transcripts	O
initiated	O
at	O
the	O
normal	O
CSMD1	O
promoter	O
.	O

These	O
data	O
suggest	O
that	O
a	O
mechanism	O
(	O
s	O
)	O
other	O
than	O
point	O
mutation	O
must	O
be	O
responsible	O
for	O
the	O
loss	O
of	O
expression	O
.	O

CSMD1	O
's	O
first	O
exon	O
is	O
embedded	O
in	O
a	O
3.7	O
kb	O
CpG	O
island	O
(	O
data	O
from	O
the	O
UCSC	O
genome	O
browser	O
[	O
18	O
]	O
)	O
suggesting	O
that	O
promoter	O
methylation	O
might	O
epigenetically	O
silence	O
the	O
gene	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
surveyed	O
32	O
head	O
and	O
neck	O
cancer	O
cell	O
lines	O
for	O
CSMD1	O
promoter	O
methylation	O
using	O
the	O
Combined	O
Bisulfite	O
Restriction	O
Analysis	O
(	O
COBRA	O
)	O
technique	O
described	O
by	O
Xiong	O
and	O
Laird	O
(	O
Methods	O
)	O
[	O
19	O
]	O
.	O

COBRA	O
analysis	O
of	O
the	O
three	O
amplicons	O
diagrammed	O
in	O
Figure	O
1	O
suggested	O
that	O
28	O
of	O
the	O
cell	O
lines	O
(	O
87	O
%	O
)	O
had	O
more	O
promoter	O
methylation	O
than	O
did	O
normal	O
upper	O
aerodigestive	O
epithelium	O
(	O
data	O
not	O
shown	O
)	O
.	O

We	O
selected	O
nine	O
of	O
these	O
cell	O
lines	O
for	O
high	O
resolution	O
analysis	O
of	O
promoter	O
methylation	O
by	O
sequencing	O
of	O
clones	O
from	O
bisulfite	O
converted	O
genomic	O
DNA	O
.	O

This	O
approach	O
has	O
the	O
distinct	O
advantage	O
of	O
allowing	O
determination	O
of	O
the	O
state	O
of	O
all	O
the	O
CpG	O
dinucleotides	O
within	O
an	O
amplicon	O
on	O
an	O
allele	O
by	O
allele	O
basis	O
.	O

Amplicons	O
1	O
and	O
2	O
have	O
19	O
and	O
20	O
CpG	O
dinucleotides	O
,	O
respectively	O
.	O

Amplicon	O
3	O
could	O
not	O
be	O
examined	O
by	O
this	O
technique	O
because	O
it	O
is	O
unclonable	O
after	O
bisulfite	O
conversion	O
.	O

The	O
methylation	O
data	O
were	O
correlated	O
to	O
CSMD1	O
expression	O
levels	O
as	O
measured	O
by	O
quantitative	O
RT	O
-	O
PCR	O
using	O
an	O
amplicon	O
spanning	O
exons	O
1	O
and	O
2	O
(	O
Methods	O
)	O
.	O

A	O
pool	O
of	O
cDNA	O
from	O
five	O
normal	O
oropharyngeal	O
epithelium	O
specimens	O
served	O
as	O
a	O
basis	O
for	O
comparison	O
to	O
the	O
cell	O
lines	O
.	O

Our	O
data	O
from	O
amplicon	O
1	O
demonstrate	O
a	O
clear	O
relationship	O
between	O
methylation	O
and	O
the	O
level	O
of	O
expression	O
(	O
Figure	O
2	O
)	O
.	O

The	O
bisulfite	O
sequencing	O
data	O
confirm	O
that	O
there	O
is	O
relatively	O
little	O
promoter	O
methylation	O
in	O
normal	O
tissue	O
(	O
clones	O
1–20	O
,	O
Figure	O
2A	O
)	O
.	O

This	O
is	O
also	O
the	O
case	O
in	O
cell	O
line	O
UPCI	O
:	O
SCC066	O
which	O
expresses	O
a	O
large	O
CSMD1	O
transcript	O
from	O
the	O
normal	O
promoter	O
at	O
a	O
level	O
approximately	O
33	O
%	O
of	O
that	O
of	O
normal	O
tissue	O
(	O
clones	O
32–39	O
,	O
Figure	O
2B	O
)	O
.	O

PCI-13	O
,	O
our	O
highest	O
expressing	O
line	O
at	O
125	O
%	O
of	O
normal	O
epithelium	O
,	O
displays	O
two	O
distinct	O
patterns	O
of	O
promoter	O
methylation	O
with	O
some	O
clones	O
heavily	O
methylated	O
(	O
clones	O
21–24	O
,	O
and	O
30	O
)	O
and	O
others	O
with	O
no	O
methylation	O
(	O
clones	O
25–39	O
and	O
31	O
;	O
Figure	O
2B	O
)	O
.	O

This	O
pattern	O
is	O
consistent	O
with	O
either	O
heterozygosity	O
for	O
methylation	O
or	O
the	O
co	O
-	O
existence	O
of	O
2	O
distinct	O
populations	O
within	O
the	O
cell	O
line	O
,	O
one	O
heavily	O
methylated	O
and	O
one	O
unmethylated	O
.	O

We	O
can	O
not	O
distinguish	O
between	O
these	O
two	O
possibilities	O
using	O
the	O
currently	O
available	O
data	O
.	O

The	O
remaining	O
cell	O
lines	O
express	O
CSMD1	O
at	O
a	O
level	O
half	O
that	O
of	O
UPCI	O
:	O
SCC066	O
or	O
less	O
(	O
ranging	O
from	O
17	O
%	O
to	O
1	O
%	O
of	O
normal	O
epithelium	O
)	O
and	O
they	O
exhibit	O
considerably	O
greater	O
methylation	O
of	O
amplicon	O
1	O
(	O
clones	O
40–76	O
,	O
Figure	O
2C	O
)	O
.	O

Cell	O
lines	O
with	O
more	O
amplicon	O
1	O
methylation	O
tend	O
to	O
express	O
the	O
gene	O
at	O
lower	O
levels	O
but	O
the	O
relationship	O
is	O
not	O
strictly	O
quantitative	O
(	O
Figure	O
2C	O
)	O
.	O

In	O
contrast	O
,	O
our	O
data	O
revealed	O
no	O
relationship	O
between	O
expression	O
level	O
and	O
methylation	O
of	O
amplicon	O
2	O
(	O
located	O
towards	O
the	O
3	O
'	O
end	O
of	O
exon	O
1	O
,	O
Figure	O
1	O
)	O
.	O

For	O
example	O
,	O
all	O
of	O
the	O
10	O
clones	O
of	O
amplicon	O
2	O
sequenced	O
from	O
PCI-13	O
were	O
methylated	O
at	O
19	O
or	O
20	O
of	O
their	O
20	O
CpG	O
dinucleotides	O
.	O

UPCI	O
:	O
SCC066	O
,	O
on	O
the	O
other	O
hand	O
,	O
has	O
nearly	O
no	O
methylation	O
in	O
amplicon	O
2	O
with	O
only	O
a	O
single	O
methylated	O
CpG	O
dinucleotide	O
detected	O
in	O
one	O
clone	O
out	O
of	O
the	O
nine	O
sequenced	O
.	O

Amplicon	O
2	O
ranges	O
from	O
completely	O
unmethylated	O
to	O
heavily	O
methylated	O
in	O
the	O
seven	O
remaining	O
cell	O
lines	O
(	O
data	O
not	O
shown	O
)	O
.	O

Low	O
transcript	O
levels	O
are	O
accompanied	O
by	O
a	O
failure	O
to	O
elongate	O
the	O
full	O
CSMD1	O
transcript	O
On	O
the	O
surface	O
,	O
the	O
quantitative	O
RT	O
-	O
PCR	O
data	O
presented	O
in	O
Figure	O
2	O
suggest	O
that	O
the	O
cell	O
lines	O
we	O
consider	O
low	O
expressing	O
might	O
still	O
have	O
up	O
to	O
17	O
%	O
of	O
the	O
normal	O
level	O
of	O
CSMD1	O
transcript	O
.	O

A	O
survey	O
of	O
20	O
cell	O
lines	O
using	O
a	O
battery	O
of	O
RT	O
-	O
PCR	O
primer	O
pairs	O
located	O
throughout	O
the	O
11.5	O
kb	O
transcript	O
reveals	O
that	O
this	O
is	O
not	O
the	O
case	O
.	O

These	O
lines	O
included	O
OKF6-TERT1	O
,	O
a	O
TERT	O
immortalized	O
,	O
p16	O
deficient	O
but	O
untransformed	O
oral	O
keratinocyte	O
cell	O
line	O
[	O
20	O
]	O
.	O

Our	O
data	O
suggest	O
that	O
the	O
low	O
expressing	O
cell	O
lines	O
shown	O
in	O
Figure	O
2C	O
express	O
considerably	O
more	O
of	O
the	O
5	O
'	O
end	O
of	O
the	O
11.5	O
kb	O
transcript	O
than	O
they	O
do	O
exons	O
further	O
3	O
'	O
,	O
a	O
phenomenon	O
well	O
illustrated	O
by	O
cell	O
line	O
PCI-100	O
.	O

This	O
line	O
expresses	O
the	O
exon	O
1	O
/	O
exon	O
2	O
amplicon	O
at	O
approximately	O
15	O
%	O
of	O
the	O
level	O
of	O
normal	O
epithelium	O
.	O

In	O
contrast	O
,	O
we	O
had	O
previously	O
reported	O
that	O
CSMD1	O
transcripts	O
were	O
not	O
detectable	O
in	O
this	O
line	O
by	O
combined	O
RT	O
-	O
PCR	O
and	O
Southern	O
blotting	O
using	O
three	O
sets	O
of	O
intron	O
spanning	O
primers	O
[	O
1	O
]	O
.	O

The	O
most	O
5	O
'	O
of	O
those	O
amplicons	O
spans	O
exons	O
9	O
through	O
26	O
.	O

Analysis	O
with	O
additional	O
primer	O
pairs	O
resolves	O
this	O
apparent	O
paradox	O
by	O
demonstrating	O
that	O
the	O
amount	O
of	O
transcript	O
declines	O
sharply	O
and	O
reproducibly	O
as	O
one	O
examines	O
progressively	O
more	O
3	O
'	O
exons	O
(	O
Figure	O
3	O
)	O
.	O

The	O
same	O
effect	O
is	O
seen	O
using	O
either	O
oligo	O
-	O
dT	O
or	O
random	O
hexamer	O
primed	O
cDNA	O
.	O

No	O
transcript	O
of	O
this	O
structure	O
has	O
been	O
detected	O
in	O
normal	O
epithelium	O
nor	O
have	O
we	O
detected	O
any	O
sequence	O
alterations	O
in	O
PCI-100	O
that	O
would	O
explain	O
why	O
the	O
full	O
transcript	O
is	O
not	O
expressed	O
.	O

It	O
is	O
not	O
clear	O
whether	O
PCI-100	O
produces	O
a	O
small	O
number	O
of	O
discrete	O
size	O
classes	O
of	O
transcript	O
,	O
if	O
individual	O
transcripts	O
terminate	O
at	O
random	O
points	O
within	O
the	O
very	O
large	O
introns	O
in	O
this	O
part	O
of	O
the	O
gene	O
(	O
the	O
first	O
10	O
introns	O
average	O
~150	O
kb	O
in	O
length	O
)	O
,	O
or	O
if	O
the	O
short	O
transcripts	O
result	O
from	O
the	O
elevated	O
activity	O
of	O
a	O
previously	O
undetected	O
posttranscriptional	O
control	O
mechanism	O
.	O

Inactivation	O
of	O
CSMD1	O
by	O
aberrant	O
splicing	O
Two	O
cell	O
lines	O
,	O
UPCI	O
:	O
SCC066	O
and	O
PCI-13	O
,	O
express	O
large	O
CSMD1	O
transcripts	O
initiated	O
at	O
the	O
normal	O
promoter	O
.	O

Subsequent	O
finer	O
scale	O
analysis	O
demonstrates	O
that	O
PCI-13	O
's	O
transcript	O
lacks	O
exons	O
4	O
and	O
5	O
,	O
resulting	O
in	O
a	O
frameshift	O
-	O
induced	O
nonsense	O
codon	O
in	O
exon	O
6	O
(	O
Figure	O
4	O
)	O
.	O

Sequencing	O
of	O
the	O
PCI-13	O
RT	O
-	O
PCR	O
product	O
demonstrates	O
the	O
direct	O
juxtaposition	O
of	O
wildtype	O
exons	O
3	O
and	O
6	O
and	O
that	O
the	O
transcript	O
contains	O
no	O
novel	O
sequences	O
or	O
splices	O
that	O
would	O
prevent	O
the	O
frameshift	O
.	O

UPCI	O
:	O
SCC066	O
produces	O
two	O
transcripts	O
,	O
a	O
normal	O
one	O
that	O
includes	O
exons	O
4	O
and	O
5	O
and	O
another	O
that	O
lacks	O
them	O
(	O
Figure	O
4	O
)	O
.	O

RT	O
-	O
PCR	O
of	O
human	B
fetal	O
brain	O
cDNA	O
reveals	O
very	O
low	O
levels	O
of	O
an	O
RT	O
-	O
PCR	O
product	O
corresponding	O
in	O
size	O
to	O
that	O
expected	O
from	O
the	O
internally	O
deleted	O
transcript	O
.	O

This	O
band	O
is	O
not	O
readily	O
visible	O
at	O
the	O
exposure	O
used	O
for	O
Figure	O
4A	O
.	O

We	O
have	O
not	O
detected	O
a	O
similar	O
sized	O
PCR	O
product	O
in	O
RNA	O
from	O
oropharyngeal	O
epithelium	O
but	O
this	O
may	O
reflect	O
the	O
fact	O
that	O
CSMD1	O
transcripts	O
are	O
~10x	O
less	O
abundant	O
in	O
oropharyngeal	O
epithelium	O
than	O
they	O
are	O
in	O
fetal	O
brain	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
transcripts	O
lacking	O
exons	O
4	O
and	O
5	O
appear	O
to	O
result	O
from	O
aberrant	O
splicing	O
rather	O
than	O
somatic	O
deletion	O
of	O
these	O
two	O
exons	O
or	O
mutations	O
of	O
their	O
splicing	O
consensus	O
sequences	O
.	O

Exons	O
4	O
and	O
5	O
can	O
be	O
amplified	O
from	O
PCI-13	O
genomic	O
DNA	O
and	O
sequencing	O
of	O
those	O
PCR	O
products	O
demonstrates	O
that	O
both	O
their	O
coding	O
sequences	O
and	O
consensus	O
splice	O
sites	O
are	O
wildtype	O
.	O

Activation	O
of	O
cryptic	O
promoters	O
in	O
cancer	O
cell	O
lines	O
The	O
RT	O
-	O
PCR	O
survey	O
revealed	O
a	O
second	O
transcriptional	O
anomaly	O
exhibited	O
by	O
4	O
cell	O
lines	O
:	O
SCC9	O
,	O
041	O
,	O
PCI-1	O
and	O
PCI-2	O
.	O

Like	O
PCI-100	O
,	O
these	O
lines	O
express	O
low	O
levels	O
of	O
the	O
very	O
5	O
'	O
end	O
of	O
the	O
transcript	O
and	O
even	O
lower	O
levels	O
of	O
more	O
3	O
'	O
exons	O
within	O
the	O
first	O
half	O
of	O
the	O
transcript	O
.	O

However	O
,	O
these	O
lines	O
are	O
distinct	O
in	O
expressing	O
higher	O
levels	O
of	O
the	O
3	O
'	O
half	O
of	O
the	O
transcript	O
,	O
suggesting	O
that	O
alternative	O
promoters	O
in	O
the	O
middle	O
of	O
the	O
gene	O
may	O
be	O
used	O
.	O

SCC9	O
was	O
chosen	O
for	O
further	O
study	O
because	O
it	O
expresses	O
the	O
3	O
'	O
half	O
of	O
the	O
transcript	O
at	O
a	O
level	O
dramatically	O
higher	O
than	O
normal	O
for	O
oropharyngeal	O
epithelium	O
.	O

Northern	O
blotting	O
detects	O
a	O
comparatively	O
abundant	O
6.4	O
kb	O
truncated	O
transcript	O
as	O
well	O
as	O
smaller	O
amounts	O
of	O
an	O
8.7	O
kb	O
transcript	O
in	O
SCC9	O
(	O
Figure	O
5A	O
)	O
.	O

The	O
other	O
three	O
cell	O
lines	O
express	O
their	O
truncated	O
CSMD1	O
transcripts	O
at	O
lower	O
levels	O
(	O
data	O
not	O
shown	O
)	O
.	O

Sequence	O
analysis	O
of	O
CSMD1	O
cDNA	O
clones	O
from	O
SCC9	O
demonstrates	O
that	O
many	O
transcripts	O
are	O
improperly	O
spliced	O
,	O
resulting	O
in	O
retention	O
of	O
intronic	O
sequences	O
and/or	O
deletion	O
of	O
exonic	O
sequences	O
(	O
data	O
not	O
shown	O
)	O
.	O

In	O
particular	O
,	O
retention	O
of	O
sequences	O
from	O
intron	O
40	O
is	O
common	O
.	O

The	O
high	O
frequency	O
of	O
faulty	O
splicing	O
may	O
explain	O
the	O
broadness	O
of	O
the	O
6.4	O
kb	O
CSMD1	O
band	O
in	O
Figure	O
5A	O
and	O
suggests	O
that	O
the	O
8.7	O
kb	O
transcript	O
may	O
also	O
be	O
incompletely	O
or	O
improperly	O
spliced	O
.	O

5	O
'	O
RACE	O
[	O
21	O
]	O
reveals	O
that	O
the	O
SCC9	O
message	O
is	O
initiated	O
just	O
upstream	O
of	O
an	O
Alu	O
element	O
in	O
intron	O
36	O
(	O
Figure	O
5B	O
)	O
.	O

Only	O
the	O
5'-most	O
120	O
base	O
pairs	O
of	O
the	O
Alu	O
element	O
are	O
present	O
in	O
the	O
genome	O
.	O

RT	O
-	O
PCR	O
using	O
a	O
forward	O
primer	O
specific	O
for	O
the	O
novel	O
sequences	O
of	O
the	O
SCC9	O
transcript	O
(	O
prm1904	O
,	O
cgtttagttcgacacacttcatgt	O
)	O
demonstrates	O
that	O
cell	O
lines	O
041	O
,	O
PCI-1	O
and	O
PCI-2	O
do	O
not	O
initiate	O
their	O
CSMD1	O
transcripts	O
at	O
the	O
same	O
point	O
,	O
suggesting	O
that	O
other	O
cryptic	O
promoters	O
are	O
active	O
in	O
these	O
lines	O
.	O

The	O
sequence	O
of	O
this	O
novel	O
exon	O
has	O
been	O
entered	O
in	O
Genbank	O
as	O
accession	O
number	O
DQ093422	O
.	O

DNA	O
methyltransferase	O
inhibitors	O
activate	O
the	O
same	O
cryptic	O
promoter	O
used	O
in	O
cell	O
line	O
SCC9	O
Expression	O
from	O
epigenetically	O
silenced	O
promoters	O
can	O
sometimes	O
be	O
restored	O
by	O
treatment	O
with	O
inhibitors	O
of	O
DNA	O
methyltransferase	O
or	O
histone	O
deacetylase	O
activity	O
(	O
[	O
22	O
]	O
)	O
.	O

We	O
selected	O
two	O
low	O
expressing	O
cell	O
lines	O
with	O
promoter	O
methylation	O
,	O
UPCI	O
:	O
SCC104	O
and	O
094	O
,	O
for	O
treatment	O
with	O
various	O
concentrations	O
of	O
5-azacytidine	O
or	O
5-aza-2'-deoxycytidine	O
(	O
5-aza	O
-	O
dC	O
)	O
as	O
well	O
as	O
combinations	O
of	O
either	O
of	O
those	O
drugs	O
with	O
the	O
histone	O
deacetylase	O
inhibitor	O
trichostatin	O
A.	O
These	O
treatments	O
did	O
not	O
reactivate	O
the	O
silenced	O
CSMD1	O
promoter	O
.	O

COBRA	O
analysis	O
of	O
genomic	O
DNA	O
from	O
the	O
treated	O
cells	O
suggested	O
that	O
the	O
drugs	O
did	O
not	O
robustly	O
affect	O
methylation	O
of	O
the	O
CSMD1	O
promoter	O
even	O
at	O
levels	O
high	O
enough	O
to	O
be	O
toxic	O
to	O
the	O
cells	O
.	O

These	O
experiments	O
did	O
however	O
shed	O
light	O
on	O
the	O
cryptic	O
promoter	O
used	O
in	O
SCC9	O
cells	O
and	O
on	O
the	O
interpretation	O
of	O
experiments	O
using	O
methyltransferase	O
inhibitors	O
.	O

Treatment	O
of	O
cell	O
line	O
094	O
with	O
relatively	O
high	O
doses	O
of	O
5aza	O
-	O
dC	O
results	O
in	O
the	O
expression	O
of	O
the	O
3	O
'	O
end	O
of	O
the	O
CSMD1	O
transcript	O
.	O

This	O
transcript	O
was	O
not	O
detected	O
in	O
control	O
094	O
cells	O
undergoing	O
mock	O
drug	O
treatment	O
(	O
Figure	O
6	O
)	O
nor	O
was	O
it	O
detected	O
in	O
094	O
cells	O
growing	O
under	O
normal	O
culture	O
conditions	O
(	O
data	O
not	O
shown	O
)	O
.	O

RT	O
-	O
PCR	O
of	O
cDNA	O
from	O
drug	O
-	O
treated	O
094	O
cells	O
using	O
the	O
primer	O
developed	O
from	O
the	O
novel	O
5	O
'	O
exon	O
of	O
SCC9	O
's	O
truncated	O
transcript	O
(	O
prm1904	O
,	O
see	O
above	O
)	O
yielded	O
a	O
product	O
identical	O
in	O
size	O
to	O
that	O
amplified	O
from	O
SCC9	O
cDNA	O
(	O
Figure	O
6	O
)	O
.	O

The	O
identity	O
of	O
the	O
product	O
was	O
confirmed	O
by	O
DNA	O
sequencing	O
which	O
also	O
revealed	O
that	O
the	O
drug	O
-	O
induced	O
094	O
transcript	O
was	O
more	O
faithfully	O
spliced	O
than	O
the	O
transcript	O
expressed	O
in	O
SCC9	O
(	O
data	O
not	O
shown	O
)	O
.	O

Discussion	O
Our	O
data	O
clearly	O
demonstrate	O
that	O
expression	O
of	O
normal	O
CSMD1	O
transcripts	O
is	O
rare	O
in	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
cell	O
lines	O
.	O

Of	O
the	O
HNSCC	O
cell	O
lines	O
examined	O
,	O
only	O
UPCI	O
:	O
SCC066	O
appears	O
to	O
express	O
a	O
normal	O
transcript	O
from	O
the	O
expected	O
promoter	O
.	O

Even	O
that	O
cell	O
line	O
produces	O
a	O
second	O
species	O
of	O
aberrantly	O
spliced	O
transcript	O
lacking	O
internal	O
exons	O
.	O

Our	O
data	O
suggest	O
that	O
epigenetic	O
modification	O
of	O
the	O
DNA	O
5	O
'	O
of	O
the	O
transcription	O
start	O
site	O
may	O
contribute	O
to	O
the	O
down	O
-	O
regulation	O
of	O
CSMD1	O
.	O

In	O
addition	O
,	O
a	O
low	O
level	O
of	O
expression	O
appears	O
to	O
be	O
associated	O
with	O
production	O
of	O
prematurely	O
terminated	O
transcripts	O
.	O

This	O
degree	O
of	O
complexity	O
might	O
be	O
expected	O
from	O
a	O
2	O
megabase	O
,	O
70	O
exon	O
gene	O
.	O

Methylation	O
of	O
a	O
specific	O
region	O
of	O
the	O
CpG	O
island	O
,	O
-395	O
to	O
-112	O
bp	O
relative	O
to	O
the	O
transcriptional	O
start	O
site	O
(	O
amplicon	O
1	O
)	O
,	O
appears	O
to	O
be	O
correlated	O
with	O
the	O
activity	O
of	O
the	O
normal	O
CSMD1	O
promoter	O
.	O

In	O
contrast	O
,	O
methylation	O
of	O
amplicon	O
2	O
,	O
located	O
within	O
the	O
first	O
exon	O
,	O
shows	O
no	O
such	O
relationship	O
.	O

Our	O
data	O
suggest	O
that	O
the	O
relationship	O
between	O
the	O
amount	O
of	O
methylation	O
in	O
amplicon	O
1	O
and	O
the	O
level	O
of	O
expression	O
may	O
not	O
be	O
strictly	O
quantitative	O
.	O

Differences	O
between	O
cell	O
lines	O
with	O
amplicon	O
1	O
methylation	O
could	O
arise	O
through	O
a	O
number	O
of	O
mechanisms	O
,	O
for	O
example	O
,	O
variations	O
in	O
the	O
levels	O
of	O
transcription	O
factors	O
between	O
cell	O
lines	O
.	O

In	O
cases	O
where	O
there	O
is	O
considerable	O
heterogeneity	O
in	O
the	O
methylation	O
pattern	O
within	O
a	O
cell	O
line	O
like	O
PCI-100	O
,	O
alleles	O
with	O
less	O
methylation	O
may	O
be	O
expressed	O
at	O
higher	O
levels	O
than	O
those	O
more	O
heavily	O
methylated	O
(	O
compare	O
clones	O
51	O
and	O
52	O
to	O
clone	O
58	O
in	O
Figure	O
2C	O
)	O
.	O

Alternatively	O
,	O
the	O
presence	O
of	O
methylation	O
in	O
amplicon	O
1	O
could	O
be	O
a	O
qualitative	O
but	O
not	O
strictly	O
quantitative	O
indicator	O
of	O
methylation	O
of	O
a	O
critical	O
segment	O
of	O
the	O
promoter	O
not	O
discovered	O
in	O
this	O
study	O
.	O

The	O
normal	O
CSMD1	O
promoter	O
was	O
not	O
reactivated	O
by	O
drugs	O
that	O
inhibit	O
DNA	O
methyltransferases	O
and	O
histone	O
deacetylases	O
,	O
nor	O
did	O
the	O
drugs	O
abolish	O
CSMD1	O
promoter	O
methylation	O
,	O
even	O
at	O
toxic	O
doses	O
.	O

Not	O
all	O
genes	O
with	O
promoter	O
methylation	O
respond	O
to	O
such	O
treatments	O
[	O
23	O
]	O
.	O

These	O
drug	O
treatments	O
did	O
,	O
however	O
,	O
provide	O
a	O
potential	O
explanation	O
for	O
the	O
use	O
of	O
a	O
normally	O
cryptic	O
promoter	O
by	O
cell	O
line	O
SCC9	O
.	O

The	O
CSMD1	O
transcript	O
in	O
this	O
line	O
is	O
initiated	O
near	O
a	O
partial	O
Alu	O
element	O
.	O

5-aza	O
-	O
dC	O
treatment	O
of	O
cell	O
line	O
094	O
activates	O
the	O
same	O
cryptic	O
promoter	O
.	O

This	O
suggests	O
that	O
cryptic	O
promoters	O
may	O
be	O
naturally	O
activated	O
by	O
general	O
hypomethylation	O
of	O
the	O
genome	O
in	O
cancer	O
cells	O
and	O
the	O
subsequent	O
release	O
of	O
repetitive	O
elements	O
from	O
epigenetic	O
repression	O
(	O
reviewed	O
by	O
Ehrlich	O
[	O
17	O
]	O
)	O
.	O

The	O
SCC9	O
transcript	O
does	O
not	O
appear	O
to	O
encode	O
a	O
functional	O
protein	O
but	O
,	O
with	O
a	O
very	O
large	O
gene	O
like	O
CSMD1	O
,	O
there	O
is	O
a	O
potential	O
for	O
some	O
abnormally	O
initiated	O
transcripts	O
to	O
encode	O
truncated	O
proteins	O
with	O
dominant	O
negative	O
properties	O
.	O

The	O
second	O
ramification	O
of	O
this	O
finding	O
is	O
for	O
the	O
interpretation	O
of	O
data	O
obtained	O
by	O
treating	O
cells	O
with	O
methyltransferase	O
inhibitors	O
.	O

Detection	O
of	O
CSMD1	O
transcripts	O
solely	O
with	O
primers	O
mapping	O
to	O
the	O
3	O
'	O
end	O
of	O
the	O
gene	O
could	O
have	O
been	O
erroneously	O
interpreted	O
as	O
representing	O
reactivation	O
of	O
the	O
normal	O
promoter	O
.	O

It	O
seems	O
imperative	O
that	O
such	O
experiments	O
demonstrate	O
that	O
transcripts	O
detected	O
after	O
drug	O
treatment	O
are	O
actually	O
initiated	O
at	O
the	O
normal	O
promoter	O
.	O

Aberrant	O
splicing	O
also	O
appears	O
to	O
play	O
a	O
role	O
in	O
the	O
production	O
of	O
defective	O
CSMD1	O
transcripts	O
.	O

Loss	O
of	O
splicing	O
fidelity	O
has	O
been	O
proposed	O
as	O
a	O
characteristic	O
of	O
cancer	O
cells	O
[	O
24,25	O
]	O
and	O
this	O
would	O
be	O
consistent	O
with	O
the	O
variety	O
of	O
misspliced	O
transcripts	O
we	O
detected	O
from	O
SCC9	O
.	O

However	O
,	O
the	O
removal	O
of	O
exons	O
4	O
and	O
5	O
from	O
the	O
CSMD1	O
transcript	O
in	O
PCI-13	O
may	O
reflect	O
a	O
more	O
specific	O
phenomenon	O
than	O
a	O
general	O
inability	O
to	O
splice	O
large	O
introns	O
;	O
this	O
line	O
is	O
still	O
capable	O
of	O
splicing	O
large	O
introns	O
as	O
evidenced	O
by	O
its	O
successful	O
splicing	O
of	O
exon	O
3	O
to	O
exon	O
6	O
,	O
eliminating	O
an	O
intron	O
of	O
over	O
666	O
kb	O
.	O

The	O
failure	O
to	O
include	O
exons	O
4	O
and	O
5	O
may	O
be	O
due	O
to	O
inactivation	O
of	O
a	O
splicing	O
enhancer	O
in	O
intron	O
3	O
,	O
or	O
to	O
less	O
efficient	O
splicing	O
due	O
to	O
the	O
fact	O
that	O
exons	O
4	O
and	O
5	O
do	O
not	O
begin	O
with	O
the	O
consensus	O
G	O
residue	O
(	O
Figure	O
4B	O
)	O
[	O
26	O
]	O
.	O

Conclusion	O
Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
CSMD1	O
function	O
is	O
lost	O
in	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
cell	O
lines	O
through	O
a	O
variety	O
of	O
mechanisms	O
other	O
than	O
point	O
mutagenesis	O
.	O

Epigenetic	O
modifications	O
of	O
amplicon	O
1	O
and	O
defective	O
splicing	O
appear	O
to	O
be	O
fruitful	O
areas	O
to	O
explore	O
in	O
primary	O
head	O
and	O
neck	O
squamous	O
cancers	O
.	O

Methods	O
Cell	O
lines	O
and	O
tissue	O
samples	O
DNA	O
from	O
HNSCC	O
cell	O
lines	O
UMSCC9	O
,	O
UMSCC35	O
,	O
UMSCC37	O
,	O
UMSCC38	O
,	O
UMSCC45	O
,	O
UMSCC49	O
,	O
UMSCC65	O
,	O
UMSCC68	O
,	O
and	O
UMSCC76	O
was	O
provided	O
by	O
Dr.	O
Thomas	O
Carey	O
,	O
University	O
of	O
Michigan	O
[	O
27	O
]	O
.	O

Dr.	O
Ruud	O
Brakenhoff	O
,	O
Vrije	O
Universitat	O
,	O
provided	O
cell	O
lines	O
040	O
,	O
041	O
,	O
and	O
094	O
[	O
28	O
]	O
;	O
Dr.	O
Theresa	O
Whiteside	O
,	O
University	O
of	O
Pittsburgh	O
,	O
provided	O
cell	O
lines	O
PCI-1	O
,	O
PCI-2	O
,	O
PCI-4B	O
,	O
PCI-13	O
,	O
PCI-30	O
,	O
PCI-50	O
,	O
PCI-51	O
,	O
PCI-52	O
,	O
PCI-100	O
[	O
29	O
]	O
,	O
SCC4	O
,	O
SCC9	O
[	O
30,31	O
]	O
,	O
and	O
UPCI	O
:	O
SCC068	O
,	O
UPCI	O
:	O
SCC74	O
,	O
UPCI	O
:	O
SCC104	O
,	O
UPCI	O
:	O
SCC182	O
,	O
UPCI	O
:	O
SCC203	O
,	O
and	O
UPCI	O
:	O
SCC220	O
[	O
developed	O
by	O
Dr.	O
Susanne	O
Gollin	O
,	O
University	O
of	O
Pittsburgh	O
,	O
32	O
]	O
.	O

Dr.	O
Gollin	O
provided	O
cell	O
lines	O
UPCI	O
:	O
SCC056	O
,	O
UPCI	O
:	O
SCC066	O
,	O
and	O
UPCI	O
:	O
SCC114	O
[	O
14,16,32	O
]	O
.	O

The	O
immortal	O
but	O
untransformed	O
keratinocyte	O
line	O
OKF6-TERT1	O
was	O
obtained	O
from	O
Dr.	O
James	O
Rheinwald	O
,	O
Harvard	O
University	O
[	O
20	O
]	O
.	O

Normal	O
oropharyngeal	O
epithelium	O
was	O
isolated	O
from	O
discarded	O
tissue	O
from	O
uvulopalatopharyngoplasties	O
(	O
UPPP	O
)	O
collected	O
anonymously	O
with	O
the	O
approval	O
of	O
the	O
Washington	O
University	O
Human	B
Studies	O
Committee	O
.	O

Cell	O
Culture	O
and	O
Tissue	O
Preparation	O
Squamous	O
cell	O
carcinoma	O
cell	O
lines	O
were	O
grown	O
in	O
DMEM	O
or	O
DMEM	O
:	O
F-12	O
,	O
1:1	O
Mixture	O
(	O
BioWhittaker	O
)	O
containing	O
10	O
%	O
fetal	O
bovine	B
serum	O
(	O
Sigma	O
)	O
.	O

DMEM	O
medium	O
was	O
supplemented	O
with	O
1X	O
MEM	O
Nonessential	O
Amino	O
Acids	O
(	O
BioWhittaker	O
)	O
.	O

Upper	O
aerodigestive	O
tract	O
epithelium	O
was	O
separated	O
from	O
the	O
rest	O
of	O
the	O
UPPP	O
specimen	O
by	O
digestion	O
with	O
Dispase	O
II	O
(	O
Roche	O
)	O
using	O
a	O
protocol	O
adapted	O
from	O
Oda	O
and	O
Watson	O
[	O
33	O
]	O
.	O

Nucleic	O
acid	O
preparation	O
and	O
bisulfite	O
conversion	O
Genomic	O
DNA	O
was	O
isolated	O
by	O
using	O
either	O
Nucleospin	O
Tissue	O
kits	O
(	O
Clontech	O
)	O
,	O
QIAamp	O
DNA	O
Blood	O
Mini	O
kits	O
(	O
Qiagen	O
)	O
or	O
Trizol	O
(	O
Invitrogen	O
)	O
according	O
to	O
the	O
manufacturers	O
'	O
instructions	O
.	O

Total	O
RNA	O
isolation	O
,	O
synthesis	O
of	O
first	O
strand	O
cDNA	O
,	O
RT	O
-	O
PCR	O
and	O
5	O
'	O
RACE	O
PCR	O
were	O
performed	O
essentially	O
as	O
previously	O
described	O
[	O
1	O
]	O
.	O

Poly	O
-	O
A+	O
RNA	O
for	O
Northern	O
blotting	O
was	O
selected	O
from	O
total	O
RNA	O
using	O
Oligotex	O
beads	O
(	O
Qiagen	O
)	O
.	O

Northern	O
blotting	O
and	O
hybridization	O
were	O
performed	O
as	O
previously	O
described	O
[	O
1	O
]	O
.	O

cDNA	O
synthesis	O
was	O
primed	O
using	O
oligo	O
dT	O
or	O
random	O
primers	O
and	O
extended	O
by	O
either	O
Thermoscript	O
or	O
Superscript	O
III	O
reverse	O
transcriptase	O
(	O
Invitrogen	O
)	O
.	O

PCR	O
was	O
run	O
in	O
Perkin	O
-	O
Elmer	O
480	O
or	O
Applied	O
Biosystems	O
9700	O
thermal	O
cyclers	O
for	O
35	O
cycles	O
unless	O
otherwise	O
noted	O
.	O

Images	O
of	O
ethidium	O
bromide	O
stained	O
gels	O
were	O
captured	O
with	O
a	O
Gel	O
-	O
Doc	O
imaging	O
station	O
(	O
Biorad	O
)	O
.	O

Quantitative	O
PCR	O
was	O
run	O
in	O
an	O
Applied	O
Biosystems	O
5700	O
thermal	O
cycler	O
using	O
SYBR	O
Green	O
Master	O
Mix	O
(	O
Applied	O
Biosystems	O
)	O
.	O

Primers	O
prm2426	O
(	O
gtgtggagtatctgcagacatga	O
)	O
and	O
prm2427	O
(	O
ctggactaagcctccacagttct	O
)	O
were	O
used	O
to	O
amplify	O
a	O
132	O
base	O
segment	O
spanning	O
CSMD1	O
's	O
first	O
and	O
second	O
exons	O
.	O

An	O
amplicon	O
from	O
human	B
18S	O
RNA	O
was	O
used	O
as	O
a	O
basis	O
for	O
comparisons	O
across	O
cell	O
lines	O
(	O
primers	O
prm2396	O
,	O
ttcggaactgaggccatgat	O
and	O
prm2397	O
,	O
tttcgctctggtccgtcttg	O
)	O
.	O

Calculations	O
were	O
performed	O
using	O
the	O
ΔΔCt	O
method	O
in	O
GeneAmp	O
5700	O
SDS	O
software	O
(	O
version	O
1.3	O
)	O
and	O
Microsoft	O
Excel	O
.	O

Quantitation	O
was	O
based	O
on	O
the	O
average	O
values	O
obtained	O
from	O
duplicate	O
reactions	O
.	O

The	O
level	O
of	O
CSMD1	O
expression	O
in	O
normal	O
oropharyngeal	O
epithelium	O
was	O
determined	O
from	O
pooled	O
cDNA	O
from	O
five	O
UPPP	O
specimens	O
.	O

We	O
used	O
the	O
CpGenome	O
DNA	O
Modification	O
kit	O
(	O
Intergen	O
)	O
for	O
bisulfite	O
conversion	O
of	O
the	O
genomic	O
DNA	O
according	O
to	O
the	O
manufacturer	O
's	O
protocol	O
,	O
with	O
the	O
following	O
exception	O
.	O

Incubation	O
of	O
the	O
conversion	O
reaction	O
was	O
carried	O
out	O
in	O
a	O
thermal	O
cycler	O
for	O
six	O
cycles	O
each	O
consisting	O
of	O
three	O
minutes	O
at	O
94	O
°	O
C	O
followed	O
by	O
three	O
hours	O
at	O
50	O
°	O
C	O
(	O
Christina	O
Menke	O
and	O
Paul	O
Goodfellow	O
,	O
personal	O
communication	O
)	O
.	O

Analysis	O
of	O
CSMD1	O
Promoter	O
Methylation	O
Methylation	O
of	O
three	O
segments	O
of	O
the	O
CSMD1	O
CpG	O
island	O
was	O
examined	O
using	O
the	O
Combined	O
Bisulfite	O
Restriction	O
Analysis	O
technique	O
(	O
COBRA	O
)	O
[	O
19	O
]	O
.	O

All	O
three	O
segments	O
were	O
amplified	O
by	O
using	O
the	O
nested	O
primers	O
and	O
PCR	O
conditions	O
listed	O
in	O
Table	O
1	O
.	O

Amplicon	O
1	O
extends	O
from	O
-395	O
to	O
-112	O
bp	O
,	O
amplicon	O
2	O
from	O
+	O
175	O
to	O
+	O
396	O
bp	O
,	O
and	O
amplicon	O
3	O
from	O
+	O
398	O
to	O
+	O
718	O
bp	O
relative	O
to	O
the	O
first	O
base	O
of	O
the	O
transcript	O
.	O

A	O
small	O
region	O
surrounding	O
the	O
transcription	O
start	O
site	O
(	O
-111	O
to	O
+	O
174	O
bp	O
)	O
could	O
not	O
be	O
examined	O
because	O
no	O
PCR	O
primers	O
could	O
be	O
designed	O
from	O
its	O
extremely	O
GC	O
-	O
rich	O
sequence	O
.	O

The	O
first	O
round	O
PCR	O
used	O
2	O
μl	O
of	O
bisulfite	O
converted	O
genomic	O
DNA	O
in	O
a	O
final	O
volume	O
of	O
10	O
μl	O
.	O

Subsequent	O
amplifications	O
with	O
nested	O
primers	O
used	O
4	O
μl	O
of	O
first	O
round	O
product	O
as	O
template	O
in	O
reactions	O
with	O
a	O
final	O
volume	O
of	O
20	O
μl	O
.	O

All	O
PCR	O
was	O
carried	O
out	O
for	O
35	O
cycles	O
.	O

A	O
portion	O
of	O
the	O
second	O
round	O
PCR	O
product	O
was	O
run	O
on	O
a	O
1.5	O
%	O
agarose	O
gel	O
,	O
stained	O
with	O
ethidium	O
bromide	O
,	O
and	O
quantified	O
using	O
the	O
ImageQuant	O
software	O
package	O
(	O
v1.2	O
for	O
Macintosh	O
,	O
Molecular	O
Dynamics	O
)	O
so	O
that	O
equal	O
amounts	O
of	O
each	O
could	O
be	O
used	O
in	O
restriction	O
digests	O
.	O

Restriction	O
digests	O
for	O
COBRA	O
were	O
performed	O
with	O
either	O
BstU	O
I	O
or	O
Taqα	O
I	O
(	O
5	O
or	O
10	O
units	O
per	O
reaction	O
,	O
respectively	O
;	O
New	O
England	O
Biolabs	O
)	O
for	O
4	O
hours	O
in	O
a	O
final	O
volume	O
of	O
10	O
μl	O
.	O

Taqα	O
I	O
digests	O
were	O
performed	O
only	O
when	O
no	O
methylation	O
was	O
detected	O
with	O
BstU	O
I.	O
BstU	O
I	O
digests	O
also	O
included	O
an	O
internal	O
control	O
DNA	O
fragment	O
to	O
confirm	O
complete	O
digestion	O
.	O

This	O
DNA	O
fragment	O
contains	O
a	O
single	O
BstU	O
I	O
site	O
and	O
was	O
amplified	O
from	O
a	O
cloned	O
CSMD1	O
cDNA	O
using	O
primers	O
prm2020	O
(	O
agatcccccagtgtctccctgtgt	O
)	O
and	O
prm2021	O
(	O
actgctggtgccgtggtaatgact	O
)	O
.	O

The	O
control	O
PCR	O
product	O
is	O
1019	O
bp	O
long	O
and	O
is	O
digested	O
to	O
two	O
fragments	O
of	O
605	O
and	O
414	O
bp	O
by	O
BstU	O
I.	O
Digestion	O
products	O
were	O
fractionated	O
on	O
a	O
10	O
%	O
polyacrylamide	O
gel	O
,	O
stained	O
with	O
ethidium	O
bromide	O
,	O
and	O
visualized	O
with	O
a	O
Gel	O
-	O
Doc	O
video	O
imaging	O
workstation	O
(	O
Bio	O
-	O
Rad	O
)	O
.	O

High	O
resolution	O
analysis	O
of	O
methylation	O
was	O
performed	O
by	O
sequence	O
analysis	O
of	O
individual	O
clones	O
from	O
amplicons	O
1	O
and	O
2	O
.	O

DNA	O
from	O
amplicon	O
3	O
proved	O
unclonable	O
and	O
gel	O
electrophoresis	O
suggests	O
that	O
its	O
very	O
AT	O
rich	O
sequence	O
results	O
in	O
a	O
bent	O
DNA	O
configuration	O
.	O

PCR	O
products	O
were	O
purified	O
using	O
the	O
Nucleospin	O
Extraction	O
columns	O
(	O
Clontech	O
)	O
and	O
inserted	O
into	O
the	O
pCR2.1-TOPO	O
vector	O
using	O
the	O
TOPO	O
TA	O
Cloning	O
kit	O
(	O
Invitrogen	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
.	O

Plasmid	O
DNA	O
from	O
individual	O
colonies	O
was	O
isolated	O
using	O
the	O
Nucleospin	O
Plus	O
Plasmid	O
Miniprep	O
kit	O
(	O
Clontech	O
)	O
and	O
sequenced	O
with	O
a	O
reverse	O
vector	O
primer	O
(	O
agcggataacaatttcacacagga	O
)	O
using	O
fluorescence	O
based	O
sequencing	O
with	O
Big	O
Dye	O
Terminator	O
mix	O
(	O
Applied	O
Biosystems	O
)	O
.	O

Treatment	O
of	O
cultured	O
cells	O
with	O
DNA	O
methyltransferase	O
inhibitors	O
Cell	O
line	O
094	O
was	O
treated	O
with	O
5-aza-2'-deoxycytidine	O
(	O
5aza	O
-	O
dC	O
)	O
(	O
Sigma	O
)	O
dissolved	O
in	O
DMSO	O
.	O

Two	O
100	O
mm	O
cell	O
culture	O
dishes	O
containing	O
5	O
×	O
105	O
cells	O
were	O
established	O
for	O
each	O
of	O
the	O
drug	O
concentrations	O
tested	O
.	O

Cells	O
were	O
grown	O
for	O
72	O
hours	O
in	O
media	O
containing	O
DMEM	O
:	O
F-12	O
,	O
1:1	O
Mixture	O
(	O
BioWhittaker	O
)	O
with	O
1X	O
MEM	O
Nonessential	O
Amino	O
Acids	O
(	O
BioWhittaker	O
)	O
and	O
10	O
%	O
fetal	O
bovine	B
serum	O
and	O
then	O
switched	O
to	O
media	O
containing	O
5aza	O
-	O
dC	O
at	O
concentrations	O
of	O
0	O
μm	O
,	O
5	O
μM	O
,	O
25	O
μM	O
,	O
or	O
100	O
μM.	O
Cells	O
were	O
fed	O
daily	O
for	O
4–5	O
days	O
and	O
then	O
both	O
plates	O
were	O
harvested	O
in	O
3	O
ml	O
of	O
Trizol	O
(	O
Invitrogen	O
)	O
for	O
isolation	O
of	O
RNA	O
and	O
DNA	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
.	O

RT	O
-	O
PCR	O
used	O
for	O
detection	O
of	O
CSMD1	O
transcripts	O
in	O
these	O
treated	O
cells	O
was	O
run	O
for	O
40	O
cycles	O
.	O

Abbreviations	O
5aza	O
-	O
dC	O
=	O
5-aza-2'deoxycytidine	O
,	O
COBRA	O
=	O
Combined	O
Bisulfite	O
Restriction	O
Analysis	O
,	O
CSMD1	O
=	O
Cub	O
and	O
sushi	O
multiple	O
domains	O
1	O
,	O
HNSCC	O
=	O
head	O
&	O
neck	O
squamous	O
cell	O
carcinoma	O
,	O
RT	O
-	O
PCR	O
=	O
reverse	O
transcription	O
–	O
polymerase	O
chain	O
reaction	O
,	O
SCC	O
=	O
squamous	O
cell	O
carcinoma	O
,	O
UPPP	O
=	O
uvulopalatopharyngoplasty	O
.	O

Competing	O
interests	O
The	O
author	O
(	O
s	O
)	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
Authors	O
'	O
contributions	O
TMR	O
performed	O
the	O
DNA	O
methylation	O
analysis	O
,	O
and	O
parts	O
of	O
the	O
transcript	O
survey	O
.	O

BDT	O
cloned	O
and	O
characterized	O
the	O
novel	O
first	O
exon	O
expressed	O
in	O
cell	O
line	O
SCC9	O
.	O

SBS	O
performed	O
parts	O
of	O
the	O
transcript	O
survey	O
and	O
characterized	O
the	O
deletion	O
of	O
exons	O
4	O
and	O
5	O
in	O
PCI-13	O
.	O

All	O
three	O
authors	O
participated	O
in	O
the	O
analysis	O
of	O
the	O
data	O
and	O
in	O
the	O
writing	O
of	O
the	O
manuscript	O
.	O

Identification	O
of	O
kinectin	O
as	O
a	O
novel	O
Behçet	O
's	O
disease	O
autoantigen	O
Abstract	O
There	O
has	O
been	O
some	O
evidence	O
that	O
Behçet	O
's	O
disease	O
(	O
BD	O
)	O
has	O
a	O
significant	O
autoimmune	O
component	O
but	O
the	O
molecular	O
identity	O
of	O
putative	O
autoantigens	O
has	O
not	O
been	O
well	O
characterized	O
.	O

In	O
the	O
initial	O
analysis	O
of	O
the	O
autoantibody	O
profile	O
in	O
39	O
Chinese	O
BD	O
patients	O
,	O
autoantibodies	O
to	O
cellular	O
proteins	O
were	O
uncovered	O
in	O
23	O
%	O
as	O
determined	O
by	O
immunoblotting	O
.	O

We	O
have	O
now	O
identified	O
one	O
of	O
the	O
major	O
autoantibody	O
specificities	O
using	O
expression	O
cloning	O
.	O

Serum	O
from	O
a	O
BD	O
patient	O
was	O
used	O
as	O
a	O
probe	O
to	O
immunoscreen	O
a	O
λZAP	O
expression	O
cDNA	O
library	O
.	O

Candidate	O
autoantigen	O
cDNAs	O
were	O
characterized	O
by	O
direct	O
nucleotide	O
sequencing	O
and	O
their	O
expressed	O
products	O
were	O
examined	O
for	O
reactivity	O
to	O
the	O
entire	O
panel	O
of	O
BD	O
sera	O
using	O
immunoprecipitation	O
.	O

Reactivity	O
was	O
also	O
examined	O
with	O
normal	O
control	O
sera	O
and	O
disease	O
control	O
sera	O
from	O
patients	O
with	O
lupus	O
and	O
Sjögren	O
's	O
syndrome	O
.	O

Six	O
independent	O
candidate	O
clones	O
were	O
isolated	O
from	O
the	O
cDNA	O
library	O
screen	O
and	O
were	O
identified	O
as	O
overlapping	O
partial	O
human	B
kinectin	O
cDNAs	O
.	O

The	O
finding	O
that	O
kinectin	O
was	O
an	O
autoantigen	O
was	O
verified	O
in	O
9	O
out	O
of	O
39	O
(	O
23	O
%	O
)	O
BD	O
patient	O
sera	O
by	O
immunoprecipitation	O
of	O
the	O
in	O
vitro	O
translation	O
products	O
.	O

Sera	O
from	O
controls	O
showed	O
no	O
reactivity	O
.	O

The	O
significance	O
of	O
kinectin	O
as	O
a	O
participant	O
in	O
autoimmune	O
pathogenesis	O
in	O
BD	O
and	O
the	O
potential	O
use	O
of	O
autoantibody	O
to	O
kinectin	O
in	O
serodiagnostics	O
are	O
discussed	O
.	O

Introduction	O
Behçet	O
's	O
disease	O
(	O
BD	O
)	O
is	O
a	O
systemic	O
vasculitic	O
disease	O
typified	O
by	O
a	O
triad	O
of	O
symptoms	O
including	O
recurrent	O
oral	O
ulcers	O
,	O
genital	O
ulcers	O
and	O
uveitis	O
.	O

In	O
addition	O
,	O
skin	O
,	O
joint	O
,	O
large	O
vessels	O
,	O
nervous	O
system	O
and	O
gastrointestinal	O
systems	O
may	O
be	O
involved	O
.	O

BD	O
is	O
a	O
global	O
disease	O
but	O
has	O
the	O
highest	O
prevalence	O
in	O
the	O
region	O
along	O
the	O
ancient	O
'	O
Silk	O
Road	O
'	O
in	O
China	O
.	O

The	O
etiopathogenesis	O
of	O
the	O
disease	O
remains	O
unclear	O
but	O
microbial	O
agent	O
triggers	O
,	O
environmental	O
factors	O
,	O
genetic	O
predisposition	O
,	O
neutrophil	O
hyperfunction	O
,	O
endothelial	O
cell	O
dysfunction	O
and	O
immunological	O
abnormalities	O
involving	O
both	O
T	O
and	O
B	O
cells	O
have	O
been	O
implicated	O
.	O

Increasing	O
amounts	O
of	O
research	O
evidence	O
supports	O
the	O
possibility	O
that	O
it	O
is	O
an	O
immune	O
-	O
mediated	O
vasculitis	O
,	O
and	O
that	O
abnormal	O
T	O
-	O
cell	O
and	O
B	O
-	O
cell	O
reactions	O
and	O
autoantigen	O
-	O
driven	O
autoimmunity	O
play	O
pivotal	O
roles	O
[	O
1	O
]	O
.	O

Systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
is	O
the	O
prototypic	O
systemic	O
autoimmune	O
rheumatic	O
disease	O
with	O
autoantibodies	O
against	O
cellular	O
(	O
particularly	O
nuclear	O
)	O
antigens	O
,	O
some	O
of	O
which	O
are	O
critically	O
implicated	O
in	O
the	O
autoimmune	O
pathology	O
while	O
others	O
provide	O
valuable	O
serodiagnostic	O
markers	O
for	O
the	O
disease	O
.	O

Unlike	O
the	O
picture	O
in	O
SLE	O
and	O
other	O
related	O
rheumatic	O
diseases	O
,	O
in	O
BD	O
,	O
antinuclear	O
antibodies	O
and	O
antibodies	O
to	O
neutrophil	O
cytoplasmic	O
antigens	O
etc	O
.	O
are	O
not	O
present	O
.	O

To	O
date	O
,	O
since	O
neither	O
a	O
specific	O
autoantibody	O
nor	O
pathognomonic	O
pathological	O
index	O
is	O
available	O
to	O
help	O
establish	O
the	O
diagnosis	O
of	O
BD	O
,	O
it	O
is	O
largely	O
or	O
solely	O
based	O
on	O
clinical	O
manifestations	O
[	O
2	O
]	O
,	O
and	O
a	O
dilemma	O
in	O
diagnosis	O
is	O
not	O
a	O
rare	O
occurrence	O
in	O
clinical	O
practice	O
.	O

Nevertheless	O
,	O
since	O
the	O
1960s	O
,	O
there	O
have	O
been	O
reports	O
of	O
autoantibodies	O
against	O
certain	O
unknown	O
components	O
of	O
human	B
oral	O
mucosa	O
in	O
sera	O
of	O
patients	O
with	O
BD	O
.	O

Since	O
then	O
,	O
sporadic	O
reports	O
on	O
findings	O
of	O
autoantibodies	O
in	O
this	O
disease	O
have	O
been	O
described	O
,	O
such	O
as	O
antibodies	O
to	O
retinal	O
antigen	O
(	O
s	O
)	O
,	O
heat	O
shock	O
protein	O
(	O
HSP	O
)	O
of	O
some	O
strains	O
of	O
Streptococcus	B
sanguis	I
cross	O
-	O
reactive	O
with	O
human	B
HSP	O
polypeptide	O
[	O
3	O
]	O
,	O
antibodies	O
to	O
endothelial	O
cell	O
antigens	O
(	O
AECA	O
)	O
and	O
antibodies	O
to	O
α	O
-	O
tropomyosin	O
[	O
4,5	O
]	O
,	O
attesting	O
to	O
the	O
complicated	O
humoral	O
immune	O
disorders	O
in	O
this	O
disease	O
.	O

This	O
investigation	O
was	O
aimed	O
at	O
defining	O
target	O
cellular	O
autoantigens	O
using	O
time	O
-	O
tested	O
and	O
well	O
-	O
established	O
molecular	O
techniques	O
.	O

Immunoscreening	O
of	O
expression	O
libraries	O
using	O
BD	O
sera	O
was	O
used	O
since	O
this	O
approach	O
has	O
been	O
successfully	O
employed	O
in	O
the	O
characterization	O
of	O
many	O
clinically	O
relevant	O
antigens	O
in	O
systemic	O
rheumatic	O
diseases	O
such	O
as	O
SS	O
-	O
A	O
/	O
Ro	O
[	O
6	O
-	O
9	O
]	O
and	O
SS	O
-	O
B	O
/	O
La	O
[	O
10	O
]	O
antigens	O
in	O
Sjögren	O
's	O
syndrome	O
(	O
SjS	O
)	O
and	O
centromere	O
antigen	O
CENP	O
-	O
B	O
[	O
11	O
]	O
in	O
scleroderma	O
.	O

In	O
addition	O
,	O
we	O
have	O
been	O
successful	O
in	O
using	O
this	O
strategy	O
to	O
identify	O
interesting	O
autoantigens	O
that	O
have	O
other	O
biological	O
significance	O
.	O

Examples	O
of	O
these	O
include	O
NOR90	O
/	O
hUBF	O
[	O
12	O
]	O
,	O
p80-coilin	O
[	O
13	O
]	O
,	O
Golgi	O
autoantigens	O
[	O
14	O
-	O
16	O
]	O
and	O
,	O
more	O
recently	O
,	O
GW182	O
[	O
17	O
]	O
.	O

Materials	O
and	O
methods	O
Patients	O
and	O
sera	O
The	O
currently	O
used	O
empirical	O
criteria	O
for	O
the	O
diagnosis	O
of	O
BD	O
in	O
this	O
study	O
were	O
the	O
criteria	O
proposed	O
by	O
the	O
International	O
Study	O
Group	O
for	O
BD	O
(	O
abbreviated	O
as	O
'	O
International	O
Criteria	O
'	O
)	O
[	O
2	O
]	O
.	O

The	O
study	O
subjects	O
of	O
39	O
Chinese	O
BD	O
patients	O
comprised	O
17	O
males	O
and	O
22	O
females	O
,	O
mean	O
age	O
37	O
±	O
11.3	O
years	O
old	O
,	O
who	O
were	O
divided	O
into	O
two	O
subgroups	O
:	O
25	O
typical	O
BD	O
patients	O
(	O
Group	O
I	O
,	O
satisfying	O
the	O
International	O
Criteria	O
)	O
and	O
14	O
clinically	O
diagnosed	O
BD	O
patients	O
who	O
had	O
recurrent	O
oral	O
ulcers	O
and	O
one	O
of	O
the	O
symptoms	O
of	O
genital	O
ulcers	O
,	O
eye	O
symptoms	O
or	O
skin	O
lesions	O
as	O
defined	O
by	O
the	O
International	O
Criteria	O
,	O
as	O
well	O
as	O
additional	O
symptom	O
(	O
s	O
)	O
closely	O
related	O
to	O
BD	O
as	O
listed	O
in	O
the	O
International	O
Criteria	O
,	O
that	O
is	O
,	O
gastrointestinal	O
ulcerations	O
,	O
deep	O
vein	O
thrombosis	O
or	O
arthralgia	O
/	O
arthritis	O
without	O
evidence	O
that	O
the	O
latter	O
symptoms	O
might	O
be	O
related	O
to	O
any	O
other	O
disease	O
(	O
Group	O
II	O
,	O
defined	O
as	O
'	O
probable	O
BD	O
'	O
in	O
this	O
study	O
)	O
.	O

Disease	O
controls	O
included	O
10	O
patients	O
with	O
SLE	O
and	O
10	O
with	O
SjS	O
,	O
all	O
satisfying	O
corresponding	O
international	O
classification	O
criteria	O
.	O

All	O
BD	O
patients	O
and	O
disease	O
controls	O
involved	O
in	O
the	O
study	O
were	O
patients	O
treated	O
at	O
the	O
Rheumatology	O
Department	O
of	O
Ren	O
Ji	O
Hospital	O
,	O
Shanghai	O
,	O
China	O
,	O
where	O
their	O
clinical	O
data	O
and	O
serum	O
samples	O
were	O
collected	O
.	O

Twenty	O
normal	O
control	O
sera	O
were	O
randomly	O
selected	O
from	O
healthy	O
blood	O
donors	O
working	O
in	O
the	O
same	O
hospital	O
.	O

This	O
study	O
was	O
approved	O
by	O
the	O
institution	O
review	O
board	O
of	O
Ren	O
Ji	O
Hospital	O
which	O
is	O
affiliated	O
with	O
Shanghai	O
Second	O
Medical	O
University	O
,	O
and	O
each	O
patient	O
involved	O
gave	O
informed	O
consent	O
.	O

All	O
serum	O
samples	O
were	O
preserved	O
at	O
-20	O
°	O
C	O
or	O
-70	O
°	O
C	O
until	O
use	O
.	O

Cell	O
lines	O
and	O
cell	O
extracts	O
HeLa	O
(	O
ATCC	O
CCL	O
2.2	O
)	O
and	O
T24	O
(	O
human	B
transitional	O
cell	O
bladder	O
carcinoma	O
)	O
were	O
obtained	O
from	O
the	O
American	O
Type	O
Culture	O
Collection	O
(	O
Rockville	O
,	O
MD	O
,	O
USA	O
)	O
.	O

A	O
bovine	B
aortic	O
endothelial	O
cell	O
line	O
was	O
kindly	O
provided	O
by	O
Dr	O
Eugene	O
G	O
Levin	O
from	O
the	O
Scripps	O
Research	O
Institute	O
(	O
La	O
Jolla	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Cells	O
were	O
cultured	O
in	O
DMEM	O
containing	O
10	O
%	O
calf	O
serum	O
,	O
harvested	O
and	O
extracted	O
in	O
Buffer	O
A	O
(	O
150	O
mM	O
NaCl	O
,	O
10	O
mM	O
Tris	O
-	O
HCl	O
,	O
pH7.2	O
,	O
0.5	O
%	O
Nonidet	O
P-40	O
)	O
with	O
protease	O
inhibitor	O
(	O
Complete	O
™	O
;	O
Boehringer	O
Mannheim	O
,	O
Indianapolis	O
,	O
IN	O
,	O
USA	O
)	O
.	O

For	O
the	O
preparation	O
of	O
whole	O
cell	O
extract	O
,	O
10	O
volumes	O
of	O
Laemmli	O
gel	O
sample	O
buffer	O
[	O
18	O
]	O
were	O
added	O
to	O
the	O
cell	O
pellet	O
,	O
boiled	O
for	O
3	O
min	O
and	O
stored	O
at	O
-20	O
°	O
C	O
until	O
use	O
.	O

Western	O
blot	O
Whole	O
cell	O
lysates	O
from	O
bovine	B
aortic	O
endothelial	O
cell	O
,	O
HeLa	O
and	O
T24	O
cells	O
were	O
resolved	O
individually	O
by	O
discontinuous	O
7.5	O
%	O
gel	O
SDS	O
-	O
PAGE	O
according	O
to	O
Laemmli	O
's	O
method	O
[	O
18	O
]	O
.	O

Immunoblotting	O
was	O
performed	O
as	O
described	O
by	O
Towbin	O
et	O
al.	O
[	O
19	O
]	O
with	O
modifications	O
.	O

Nitrocellulose	O
strips	O
were	O
blocked	O
with	O
3	O
%	O
nonfat	O
milk	O
in	O
PBS	O
containing	O
0.05	O
%	O
Tween-20	O
(	O
PBS	O
-	O
T	O
)	O
and	O
then	O
incubated	O
with	O
BD	O
patient	O
sera	O
and	O
normal	O
control	O
sera	O
(	O
1:100	O
dilution	O
)	O
at	O
room	O
temperature	O
for	O
1	O
h.	O
Filters	O
were	O
washed	O
extensively	O
with	O
PBS	O
-	O
T	O
to	O
remove	O
any	O
unbound	O
antibodies	O
.	O

Bound	O
antibodies	O
were	O
detected	O
with	O
polyvalent	O
,	O
peroxidase	O
-	O
conjugated	O
goat	B
anti	O
-	O
human	B
Ig	O
and	O
visualized	O
by	O
incubating	O
the	O
nitrocellulose	O
strips	O
in	O
chemiluminescent	O
reagents	O
(	O
NEN	O
Life	O
Science	O
Products	O
Inc.	O
,	O
Boston	O
,	O
MA	O
,	O
USA	O
)	O
and	O
exposing	O
to	O
Kodak	O
XAR-5	O
films	O
.	O

Screening	O
of	O
phage	O
cDNA	O
expression	O
library	O
with	O
antibody	O
probes	O
Serum	O
from	O
a	O
BD	O
patient	O
showing	O
the	O
highest	O
antibody	O
titer	O
in	O
immunoblotting	O
was	O
selected	O
as	O
a	O
probe	O
and	O
used	O
at	O
a	O
dilution	O
of	O
1:300	O
for	O
initial	O
immunoscreening	O
of	O
approximately	O
106	O
recombinants	O
from	O
a	O
T24	O
cDNA	O
expression	O
library	O
.	O

The	O
latter	O
was	O
constructed	O
in	O
λZAPExpress	O
vector	O
(	O
Stratagene	O
,	O
La	O
Jolla	O
,	O
CA	O
,	O
USA	O
)	O
and	O
screened	O
as	O
previously	O
described	O
[	O
20	O
-	O
22	O
]	O
.	O

All	O
screenings	O
were	O
performed	O
on	O
duplicate	O
isopropyl	O
β	O
-	O
D	O
-	O
thiogalactoside	O
(	O
IPTG	O
)	O
pre	O
-	O
impregnated	O
nitrocellulose	O
filters	O
,	O
and	O
immunoreactive	O
clones	O
were	O
detected	O
by	O
chemiluminescence	O
.	O

Positive	O
phages	O
were	O
subsequently	O
plaque	O
purified	O
to	O
100	O
%	O
by	O
two	O
repeated	O
rounds	O
of	O
screening	O
at	O
low	O
plaque	O
densities	O
.	O

Before	O
screening	O
the	O
cDNA	O
library	O
,	O
the	O
BD	O
serum	O
was	O
extensively	O
adsorbed	O
against	O
bacteria	O
and	O
wild	O
-	O
type	O
λZAP	O
phage	O
mixture	O
to	O
reduce	O
background	O
binding	O
.	O

Analysis	O
of	O
candidate	O
cDNAs	O
Purified	O
candidate	O
plaques	O
were	O
subcloned	O
in	O
vivo	O
into	O
pBK	O
-	O
CMV	O
plasmids	O
using	O
ExAssist	O
™	O
helper	O
phage	O
as	O
recommended	O
in	O
the	O
manufacturer	O
's	O
instructions	O
(	O
Stratagene	O
)	O
.	O

The	O
recombinant	O
pBK	O
-	O
CMV	O
plasmids	O
were	O
then	O
purified	O
using	O
QIAprep	O
Spin	O
Minprep	O
Kit	O
(	O
Qiagen	O
,	O
Valencia	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Restriction	O
enzyme	O
digestion	O
of	O
plasmids	O
with	O
EcoRI	O
and	O
XhoI	O
and	O
electrophoresis	O
in	O
a	O
standard	O
1.0	O
%	O
agarose	O
gel	O
was	O
used	O
to	O
analyze	O
the	O
length	O
of	O
cDNA	O
insert	O
of	O
each	O
candidate	O
plasmid	O
.	O

The	O
complete	O
nucleotide	O
sequence	O
was	O
determined	O
using	O
Bigdye	O
terminator	O
sequencing	O
and	O
a	O
semi	O
-	O
automated	O
sequencer	O
model	O
377	O
(	O
ABI	O
,	O
Foster	O
City	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Both	O
nucleotide	O
and	O
deduced	O
amino	O
acid	O
sequences	O
were	O
analyzed	O
for	O
similarity	O
with	O
known	O
sequences	O
using	O
BLAST	O
search	O
[	O
23	O
]	O
and	O
ExPASy	O
Proteomics	O
tools	O
.	O

Secondary	O
structure	O
analysis	O
for	O
coiled	O
-	O
coil	O
motifs	O
was	O
conducted	O
with	O
the	O
software	O
program	O
COILS	O
[	O
24	O
]	O
.	O

Immunoprecipitation	O
of	O
in	O
vitro	O
translation	O
products	O
Candidate	O
cDNA	O
clones	O
were	O
used	O
as	O
templates	O
for	O
in	O
vitro	O
transcription	O
and	O
translation	O
and	O
the	O
products	O
were	O
used	O
as	O
substrates	O
for	O
immunoprecipitation	O
to	O
confirm	O
the	O
specificity	O
of	O
reaction	O
with	O
BD	O
sera	O
.	O

In	O
brief	O
,	O
1	O
μg	O
of	O
the	O
pBK	O
-	O
CMV	O
plasmid	O
identified	O
in	O
the	O
screening	O
outlined	O
above	O
was	O
added	O
as	O
template	O
in	O
a	O
50-μl	O
reaction	O
for	O
the	O
coupled	O
in	O
vitro	O
transcription	O
and	O
translation	O
reaction	O
with	O
a	O
rabbit	B
reticulocyte	O
lysate	O
system	O
(	O
Promega	O
,	O
Madison	O
,	O
WI	O
,	O
USA	O
)	O
in	O
the	O
presence	O
of	O
35S	O
-	O
methionine	O
(	O
Trans-35S	O
label	O
;	O
ICN	O
Biochemicals	O
,	O
Costa	O
Mesa	O
,	O
CA	O
,	O
USA	O
)	O
and	O
RNasin	O
®	O
Ribonuclease	O
Inhibitor	O
(	O
Stratagene	O
)	O
as	O
recommended	O
by	O
the	O
manufacturer	O
(	O
Promega	O
)	O
.	O

Translation	O
was	O
carried	O
out	O
at	O
30	O
°	O
C	O
for	O
1.5	O
h.	O
Products	O
were	O
analyzed	O
in	O
a	O
12.5	O
%	O
gel	O
SDS	O
-	O
PAGE	O
and	O
stored	O
at	O
-80	O
°	O
C	O
for	O
further	O
immunoprecipitation	O
analysis	O
.	O

The	O
in	O
vitro	O
translation	O
proteins	O
were	O
examined	O
for	O
reactivity	O
by	O
sera	O
using	O
immunoprecipitation	O
described	O
[	O
8,25	O
]	O
.	O

Results	O
and	O
discussion	O
Autoantibody	O
detection	O
in	O
sera	O
from	O
BD	O
patients	O
Initial	O
examination	O
of	O
a	O
group	O
of	O
39	O
BD	O
patients	O
using	O
indirect	O
immunofluorescence	O
(	O
IIF	O
)	O
on	O
a	O
HEp-2	O
cell	O
substrate	O
did	O
not	O
yield	O
any	O
characteristic	O
nuclear	O
or	O
cytoplasmic	O
staining	O
patterns	O
.	O

BD	O
is	O
thought	O
by	O
some	O
to	O
be	O
a	O
vasculitic	O
disease	O
involving	O
pathophysiology	O
of	O
endothelial	O
cells	O
,	O
and	O
antibody	O
to	O
endothelial	O
cell	O
antigen	O
(	O
AECA	O
)	O
has	O
been	O
reported	O
.	O

Reports	O
on	O
the	O
prevalence	O
of	O
AECA	O
have	O
varied	O
largely	O
and	O
alpha	O
-	O
enolase	O
was	O
reported	O
as	O
one	O
of	O
the	O
putative	O
target	O
antigens	O
[	O
26	O
]	O
.	O

In	O
this	O
study	O
,	O
the	O
use	O
of	O
bovine	B
aortic	O
endothelial	O
cells	O
as	O
substrate	O
for	O
IIF	O
did	O
not	O
provide	O
any	O
additional	O
data	O
.	O

However	O
,	O
Western	O
blot	O
analysis	O
of	O
the	O
BD	O
sera	O
began	O
to	O
show	O
some	O
interesting	O
autoreactivity	O
using	O
cell	O
lysates	O
from	O
both	O
HeLa	O
and	O
bovine	B
aortic	O
endothelial	O
cells	O
.	O

HeLa	O
cells	O
were	O
initially	O
used	O
for	O
this	O
analysis	O
because	O
they	O
are	O
commonly	O
used	O
in	O
the	O
laboratory	O
as	O
Western	O
blot	O
substrate	O
.	O

Fig.	O
1	O
illustrates	O
the	O
common	O
reactivity	O
to	O
49	O
kDa	O
and	O
120	O
kDa	O
proteins	O
in	O
the	O
endothelial	O
cell	O
lysates	O
.	O

These	O
antigens	O
were	O
also	O
detected	O
in	O
HeLa	O
and	O
T24	O
cells	O
;	O
the	O
latter	O
cell	O
line	O
was	O
analyzed	O
because	O
our	O
laboratory	O
at	O
The	O
Scripps	O
Research	O
Institute	O
has	O
produced	O
an	O
excellent	O
expression	O
cDNA	O
library	O
from	O
the	O
T24	O
line	O
and	O
the	O
positive	O
result	O
with	O
the	O
T24	O
cell	O
extracts	O
allowed	O
us	O
to	O
screen	O
the	O
T24	O
library	O
.	O

Ig	O
isotype	O
analysis	O
showed	O
that	O
all	O
reactivity	O
was	O
largely	O
IgG	O
antibodies	O
.	O

Since	O
the	O
49	O
kDa	O
and	O
120	O
kDa	O
bands	O
were	O
observed	O
in	O
cell	O
extracts	O
from	O
bovine	B
as	O
well	O
as	O
human	B
cell	O
lines	O
,	O
these	O
autoantigens	O
might	O
be	O
evolutionarily	O
conserved	O
.	O

In	O
total	O
,	O
nine	O
out	O
of	O
39	O
BD	O
sera	O
(	O
23	O
%	O
)	O
had	O
autoantibody	O
to	O
the	O
49	O
kDa	O
antigen	O
and	O
eight	O
(	O
20	O
%	O
)	O
to	O
the	O
120	O
kDa	O
antigen	O
.	O

Four	O
BD	O
sera	O
(	O
10	O
%	O
)	O
reacted	O
with	O
both	O
proteins	O
.	O

Additionally	O
,	O
sera	O
that	O
showed	O
common	O
reactivity	O
to	O
the	O
120	O
kDa	O
protein	O
also	O
demonstrated	O
a	O
common	O
band	O
that	O
migrated	O
at	O
~150	O
kDa	O
,	O
although	O
it	O
appeared	O
weaker	O
than	O
the	O
120	O
kDa	O
band	O
.	O

These	O
antigens	O
appeared	O
to	O
have	O
different	O
molecular	O
weights	O
than	O
those	O
of	O
the	O
known	O
autoantigens	O
in	O
systemic	O
rheumatic	O
diseases	O
.	O

In	O
addition	O
,	O
other	O
reactive	O
bands	O
were	O
detected	O
but	O
they	O
were	O
not	O
as	O
commonly	O
shared	O
as	O
the	O
49	O
kDa	O
and	O
120	O
kDa	O
bands	O
.	O

The	O
49	O
kDa	O
protein	O
was	O
shown	O
to	O
be	O
distinct	O
from	O
48	O
kDa	O
SS	O
-	O
B	O
/	O
La	O
or	O
50	O
kDa	O
Jo-1	O
proteins	O
(	O
Fig.	O
1	O
)	O
.	O

The	O
120	O
kDa	O
antigen	O
was	O
also	O
shown	O
to	O
migrate	O
differently	O
from	O
alanyl	O
tRNA	O
synthetase	O
in	O
another	O
Western	O
blot	O
analysis	O
(	O
data	O
not	O
shown	O
)	O
and	O
did	O
not	O
share	O
any	O
apparent	O
crossreactive	O
epitopes	O
with	O
the	O
49	O
kDa	O
antigen	O
.	O

Western	O
blot	O
analyses	O
of	O
20	O
normal	O
control	O
sera	O
did	O
not	O
show	O
the	O
reactivities	O
observed	O
with	O
BD	O
sera	O
.	O

In	O
order	O
to	O
further	O
characterize	O
these	O
autoreactivities	O
,	O
a	O
serum	O
sample	O
from	O
the	O
Group	O
I	O
definitive	O
BD	O
patients	O
with	O
the	O
strongest	O
reactivity	O
to	O
49	O
kDa	O
and	O
120	O
kDa	O
antigens	O
(	O
Fig.	O
1	O
,	O
lane	O
2	O
)	O
was	O
selected	O
as	O
antibody	O
probe	O
for	O
expression	O
library	O
screening	O
.	O

Kinectin	O
identified	O
as	O
a	O
novel	O
BD	O
autoantigen	O
After	O
screening	O
500,000	O
clones	O
from	O
the	O
T24	O
cell	O
λZAPExpress	O
expression	O
library	O
,	O
seven	O
immunoreactive	O
clones	O
were	O
isolated	O
and	O
plaque	O
purified	O
in	O
two	O
to	O
three	O
rounds	O
to	O
achieve	O
100	O
%	O
homogeneity	O
.	O

The	O
cDNA	O
inserts	O
were	O
subcloned	O
in	O
vivo	O
into	O
pBK	O
-	O
CMV	O
plasmids	O
,	O
analyzed	O
by	O
restriction	O
digestion	O
using	O
EcoRI	O
and	O
XhoI	O
enzymes	O
,	O
and	O
submitted	O
to	O
direct	O
nucleotide	O
sequencing	O
across	O
the	O
polylinker	O
arms	O
.	O

The	O
cDNA	O
inserts	O
represented	O
six	O
independent	O
clones	O
designated	O
BD41	O
(	O
identical	O
to	O
BD44	O
)	O
,	O
BD481	O
,	O
BD42	O
,	O
BD47	O
,	O
BD482	O
and	O
BD49	O
.	O

Their	O
identities	O
were	O
established	O
as	O
overlapping	O
partial	O
cDNAs	O
of	O
human	B
kinectin	O
,	O
ranging	O
from	O
1.9	O
kb	O
to	O
3	O
kb	O
(	O
Fig.	O
2a	O
)	O
.	O

The	O
full	O
-	O
length	O
human	B
kinectin	O
(	O
GenBank	O
accession	O
number	O
NM_182926	O
[	O
27	O
]	O
)	O
has	O
4,816	O
bases	O
containing	O
an	O
open	O
reading	O
frame	O
coding	O
1,357	O
amino	O
acid	O
residues	O
with	O
molecular	O
mass	O
156	O
kDa	O
.	O

All	O
six	O
cDNAs	O
lacked	O
the	O
5	O
'	O
portion	O
of	O
the	O
kinectin	O
sequence	O
to	O
different	O
degrees	O
but	O
spanned	O
a	O
sequence	O
of	O
kinectin	O
that	O
extended	O
to	O
the	O
3'-untranslated	O
region	O
.	O

Secondary	O
structure	O
analysis	O
of	O
kinectin	O
protein	O
using	O
the	O
program	O
COILS	O
identified	O
a	O
long	O
region	O
of	O
α	O
-	O
helical	O
coiled	O
-	O
coil	O
domain	O
that	O
extended	O
from	O
amino	O
acid	O
residue	O
327	O
to	O
the	O
C	O
-	O
terminus	O
(	O
Fig.	O
2a	O
,	O
hatched	O
boxes	O
)	O
.	O

In	O
vitro	O
coupled	O
transcription	O
and	O
translation	O
of	O
BD44	O
and	O
BD42	O
clones	O
directed	O
the	O
synthesis	O
of	O
[	O
35S	O
]	O
-methionine	O
-	O
labeled	O
polypeptides	O
that	O
migrated	O
at	O
95	O
and	O
60	O
kDa	O
,	O
respectively	O
,	O
in	O
addition	O
to	O
smaller	O
polypeptides	O
(	O
Fig.	O
2b	O
)	O
.	O

These	O
products	O
had	O
predicted	O
molecular	O
weights	O
of	O
103	O
kDa	O
and	O
75	O
kDa	O
.	O

Kinectin	O
was	O
initially	O
identified	O
in	O
chick	O
embryo	O
brain	O
microsome	O
as	O
an	O
integral	O
membrane	O
protein	O
anchored	O
in	O
endoplasmic	O
reticulum	O
and	O
involved	O
in	O
kinesin	O
-	O
driven	O
vesicle	O
motility	O
along	O
microtubules	O
[	O
28,29	O
]	O
.	O

Kinectin	O
consists	O
of	O
a	O
120-kDa	O
and	O
a	O
160-kDa	O
polypeptide	O
interacting	O
through	O
the	O
α	O
-	O
helical	O
coiled	O
-	O
coil	O
domain	O
to	O
form	O
a	O
heterodimer	O
[	O
30	O
]	O
.	O

The	O
full	O
-	O
length	O
kinectin	O
is	O
the	O
160	O
kDa	O
polypeptide	O
containing	O
an	O
N	O
-	O
terminal	O
transmembrane	O
helix	O
followed	O
by	O
a	O
bipartite	O
nuclear	O
localization	O
sequence	O
and	O
two	O
C	O
-	O
terminal	O
leucine	O
zipper	O
motifs	O
.	O

We	O
presume	O
that	O
the	O
120	O
kDa	O
polypeptide	O
detected	O
in	O
Western	O
blot	O
(	O
Fig.	O
1	O
)	O
is	O
the	O
truncated	O
version	O
of	O
the	O
160-kDa	O
polypeptide	O
,	O
lacking	O
the	O
N	O
-	O
terminal	O
first	O
232	O
amino	O
acids	O
[	O
30	O
]	O
.	O

The	O
N	O
-	O
terminus	O
of	O
the	O
160-kDa	O
polypeptide	O
consists	O
of	O
a	O
transmembrane	O
domain	O
that	O
anchors	O
kinectin	O
to	O
endoplasmic	O
reticulum	O
[	O
30,31	O
]	O
.	O

This	O
120	O
kDa	O
polypeptide	O
is	O
probably	O
the	O
predominant	O
form	O
detected	O
in	O
the	O
Western	O
blot	O
analysis	O
(	O
Fig.	O
1	O
)	O
because	O
of	O
its	O
preferential	O
solubility	O
due	O
to	O
the	O
omission	O
of	O
the	O
N	O
-	O
terminal	O
transmembrane	O
domain	O
.	O

Other	O
functions	O
for	O
kinectin	O
have	O
been	O
reported	O
.	O

Yeast	B
two	O
-	O
hybrid	O
screen	O
studies	O
from	O
several	O
laboratories	O
have	O
revealed	O
the	O
interaction	O
of	O
the	O
Rho	O
family	O
of	O
GTPase	O
with	O
kinectin	O
,	O
and	O
have	O
shown	O
the	O
functional	O
links	O
among	O
RhoG	O
,	O
kinectin	O
and	O
kinesin	O
,	O
with	O
kinectin	O
as	O
a	O
key	O
effector	O
of	O
RhoG	O
microtubule	O
-	O
dependent	O
cellular	O
activity	O
[	O
32	O
]	O
.	O

Kinectin	O
was	O
also	O
identified	O
as	O
an	O
important	O
constituent	O
of	O
integrin	O
-	O
based	O
adhesion	O
complexes	O
,	O
which	O
link	O
integrins	O
to	O
the	O
cytoskeleton	O
and	O
recruit	O
signaling	O
molecules	O
[	O
33	O
]	O
.	O

A	O
new	O
study	O
reported	O
that	O
a	O
kinectin	O
isoform	O
lacking	O
a	O
major	O
portion	O
of	O
the	O
kinesin	O
-	O
binding	O
domain	O
is	O
very	O
probably	O
the	O
most	O
conservative	O
form	O
of	O
kinectin	O
;	O
it	O
does	O
not	O
bind	O
kinesin	O
but	O
act	O
as	O
a	O
membrane	O
anchor	O
for	O
the	O
translation	O
elongation	O
factor-1	O
delta	O
in	O
the	O
endoplasmic	O
reticulum	O
[	O
34	O
]	O
.	O

Prevalence	O
and	O
specificity	O
of	O
anti	O
-	O
kinectin	O
autoantibodies	O
The	O
in	O
vitro	O
[	O
35S	O
]	O
-methionine	O
-	O
labeled	O
translation	O
product	O
of	O
BD44	O
,	O
representing	O
the	O
largest	O
recombinant	O
kinectin	O
fragment	O
available	O
,	O
was	O
used	O
as	O
the	O
antigen	O
substrate	O
in	O
an	O
immunoprecipitation	O
assay	O
.	O

Out	O
of	O
39	O
BD	O
patient	O
sera	O
,	O
nine	O
(	O
23	O
%	O
)	O
recognized	O
the	O
BD44	O
translation	O
product	O
(	O
Fig.	O
3	O
)	O
,	O
whereas	O
sera	O
from	O
20	O
normal	O
controls	O
,	O
10	O
SLE	O
and	O
10	O
SjS	O
patients	O
did	O
not	O
show	O
reactivity	O
.	O

Among	O
the	O
nine	O
anti	O
-	O
kinectin	O
positive	O
patients	O
,	O
six	O
(	O
6	O
/	O
25	O
,	O
24	O
%	O
)	O
were	O
from	O
Group	O
I	O
(	O
definitive	O
BD	O
)	O
including	O
the	O
BD	O
patient	O
whose	O
serum	O
was	O
used	O
in	O
the	O
immunoscreening	O
of	O
expression	O
cDNA	O
library	O
,	O
and	O
three	O
(	O
3	O
/	O
14	O
,	O
21.4	O
%	O
)	O
patients	O
were	O
from	O
the	O
Group	O
II	O
(	O
probable	O
BD	O
)	O
in	O
this	O
study	O
.	O

According	O
to	O
the	O
Fisher	O
Exact	O
Probability	O
calculation	O
(	O
P	O
=	O
1.00	O
)	O
,	O
there	O
is	O
no	O
statistically	O
significant	O
difference	O
for	O
antibody	O
to	O
kinectin	O
between	O
the	O
two	O
groups	O
.	O

The	O
combined	O
data	O
substantiated	O
the	O
finding	O
that	O
kinectin	O
is	O
an	O
autoantigen	O
that	O
can	O
be	O
recognized	O
by	O
sera	O
from	O
23	O
%	O
of	O
Chinese	O
BD	O
patients	O
in	O
this	O
study	O
with	O
at	O
least	O
one	O
immunoreactive	O
region	O
or	O
autoepitope	O
residing	O
within	O
the	O
BD44	O
encoded	O
polypeptide	O
.	O

Currently	O
,	O
there	O
are	O
more	O
than	O
six	O
diagnostic	O
/	O
classification	O
criteria	O
for	O
BD	O
,	O
among	O
which	O
the	O
International	O
Criteria	O
have	O
been	O
applied	O
most	O
extensively	O
due	O
to	O
its	O
relatively	O
high	O
sensitivity	O
(	O
91	O
%	O
)	O
and	O
specificity	O
(	O
96	O
%	O
)	O
[	O
2	O
]	O
.	O

As	O
discussed	O
above	O
,	O
differential	O
diagnosis	O
of	O
BD	O
might	O
be	O
confusing	O
in	O
clinical	O
practice	O
since	O
no	O
specific	O
laboratory	O
test	O
is	O
available	O
,	O
and	O
some	O
patients	O
may	O
have	O
symptoms	O
and	O
signs	O
strongly	O
suggestive	O
of	O
BD	O
but	O
do	O
not	O
fully	O
satisfy	O
the	O
International	O
Criteria	O
,	O
as	O
in	O
the	O
Group	O
II	O
(	O
probable	O
BD	O
)	O
patients	O
in	O
our	O
study	O
group	O
.	O

A	O
number	O
of	O
investigators	O
have	O
pointed	O
out	O
that	O
a	O
comprehensive	O
analysis	O
of	O
the	O
clinical	O
data	O
for	O
a	O
given	O
patient	O
is	O
very	O
important	O
for	O
correct	O
clinical	O
diagnosis	O
of	O
BD	O
,	O
and	O
that	O
classification	O
/	O
diagnosis	O
criteria	O
,	O
including	O
the	O
International	O
Criteria	O
,	O
should	O
be	O
followed	O
but	O
should	O
not	O
be	O
exclusive	O
.	O

The	O
observation	O
that	O
three	O
out	O
of	O
14	O
patients	O
in	O
the	O
probable	O
BD	O
group	O
also	O
had	O
antibody	O
to	O
kinectin	O
and	O
the	O
similar	O
percentage	O
of	O
positive	O
reactors	O
between	O
this	O
group	O
and	O
Group	O
I	O
(	O
21.4	O
%	O
versus	O
24	O
%	O
)	O
supports	O
this	O
notion	O
.	O

The	O
further	O
use	O
of	O
non	O
-	O
clinical	O
parameters	O
such	O
as	O
immunological	O
biomarkers	O
as	O
adjuncts	O
to	O
identify	O
BD	O
patients	O
could	O
be	O
of	O
help	O
in	O
the	O
classification	O
of	O
this	O
disease	O
entity	O
While	O
our	O
work	O
was	O
ongoing	O
,	O
anti	O
-	O
kinectin	O
antibodies	O
were	O
reported	O
in	O
sera	O
from	O
patients	O
with	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
[	O
35,36	O
]	O
and	O
aplastic	O
anemia	O
[	O
37,38	O
]	O
.	O

The	O
first	O
HCC	O
report	O
[	O
35	O
]	O
identified	O
kinectin	O
as	O
a	O
tumor	O
-	O
associated	O
antigen	O
from	O
the	O
screening	O
of	O
an	O
autologous	O
cDNA	O
library	O
constructed	O
from	O
the	O
cancer	O
of	O
a	O
30-year	O
-	O
old	O
patient	O
from	O
Guangxi	O
,	O
China	O
.	O

This	O
report	O
stated	O
that	O
four	O
out	O
of	O
five	O
HCC	O
patients	O
tested	O
were	O
positive	O
for	O
anti	O
-	O
kinectin	O
antibody	O
[	O
35	O
]	O
.	O

In	O
2004	O
,	O
another	O
laboratory	O
also	O
reported	O
the	O
cloning	O
of	O
kinectin	O
as	O
a	O
tumor	O
-	O
associated	O
antigen	O
from	O
a	O
(	O
presumably	O
)	O
different	O
30-year	O
-	O
old	O
Chinese	O
HCC	O
patient	O
[	O
36	O
]	O
.	O

In	O
contrast	O
,	O
anti	O
-	O
kinectin	O
antibodies	O
were	O
not	O
detected	O
in	O
other	O
studies	O
of	O
HCC	O
patients	O
associated	O
with	O
our	O
laboratory	O
[	O
39,40	O
]	O
.	O

The	O
reports	O
of	O
anti	O
-	O
kinectin	O
antibodies	O
in	O
aplastic	O
anemia	O
are	O
also	O
very	O
interesting	O
[	O
37,38	O
]	O
.	O

The	O
initial	O
report	O
by	O
Hirano	O
et	O
al.	O
identified	O
kinectin	O
by	O
screening	O
an	O
aplastic	O
anemia	O
patient	O
for	O
candidate	O
antigens	O
using	O
a	O
Clontech	O
human	B
fetal	O
liver	O
cDNA	O
expression	O
library	O
and	O
it	O
was	O
concluded	O
that	O
seven	O
out	O
of	O
18	O
aplastic	O
anemia	O
patients	O
were	O
positive	O
for	O
anti	O
-	O
kinectin	O
while	O
none	O
of	O
the	O
normal	O
or	O
disease	O
controls	O
had	O
this	O
antibody	O
[	O
37	O
]	O
.	O

In	O
their	O
recent	O
report	O
,	O
Hirano	O
et	O
al.	O
reported	O
that	O
anti	O
-	O
kinectin	O
antibodies	O
were	O
found	O
in	O
39	O
%	O
of	O
aplastic	O
anemia	O
patients	O
from	O
the	O
United	O
States	O
but	O
only	O
in	O
three	O
out	O
of	O
30	O
(	O
10	O
%	O
)	O
cases	O
in	O
Japan	O
[	O
38	O
]	O
.	O

In	O
our	O
study	O
reported	O
here	O
,	O
kinectin	O
antibodies	O
were	O
only	O
detected	O
in	O
BD	O
patients	O
and	O
not	O
in	O
normal	O
controls	O
and	O
SLE	O
and	O
SjS	O
disease	O
controls	O
.	O

None	O
of	O
the	O
BD	O
patients	O
with	O
anti	O
-	O
kinectin	O
had	O
signs	O
of	O
HCC	O
or	O
aplastic	O
anemia	O
at	O
the	O
time	O
of	O
diagnosis	O
and	O
at	O
up	O
to	O
4	O
years	O
of	O
follow	O
-	O
up	O
.	O

Mapping	O
of	O
epitope	O
(	O
s	O
)	O
recognized	O
by	O
anti	O
-	O
kinectin	O
antibodies	O
may	O
shed	O
light	O
on	O
the	O
question	O
of	O
whether	O
different	O
autoepitopes	O
reside	O
within	O
the	O
kinectin	O
molecule	O
recognized	O
by	O
sera	O
from	O
different	O
diseases	O
.	O

Kinectin	O
–	O
a	O
new	O
member	O
of	O
coiled	O
-	O
coil	O
cytoplasmic	O
autoantigens	O
We	O
have	O
recently	O
reviewed	O
the	O
literature	O
on	O
the	O
growing	O
number	O
of	O
cytoplasmic	O
autoantigens	O
rich	O
in	O
α	O
-	O
helical	O
coiled	O
-	O
coil	O
domains	O
as	O
typified	O
from	O
our	O
study	O
of	O
Golgi	O
autoantigens	O
[	O
41	O
]	O
.	O

Golgi	O
autoantigens	O
are	O
generally	O
high	O
molecular	O
weight	O
proteins	O
between	O
100	O
and	O
350	O
kDa	O
and	O
rich	O
in	O
coiled	O
-	O
coil	O
domains	O
in	O
the	O
central	O
region	O
with	O
non	O
-	O
coiled	O
-	O
coil	O
or	O
globular	O
domains	O
at	O
both	O
N	O
and	O
C	O
termini	O
.	O

Golgi	O
autoantigens	O
are	O
displayed	O
on	O
the	O
cytoplasmic	O
face	O
of	O
the	O
Golgi	O
complex	O
and	O
are	O
not	O
localized	O
to	O
apoptotic	O
blebs	O
during	O
apoptosis	O
[	O
42	O
]	O
.	O

Giantin	O
,	O
the	O
highest	O
molecular	O
weight	O
Golgi	O
autoantigen	O
reported	O
,	O
is	O
the	O
predominant	O
target	O
of	O
human	B
anti	O
-	O
Golgi	O
complex	O
antibodies	O
and	O
multiple	O
non	O
-	O
cross	O
-	O
reactive	O
epitopes	O
have	O
been	O
mapped	O
spanning	O
the	O
350	O
kDa	O
protein	O
[	O
43	O
]	O
.	O

Other	O
high	O
molecular	O
weight	O
autoantigens	O
with	O
similar	O
features	O
have	O
been	O
reported	O
in	O
cytoplasmic	O
and	O
mitotic	O
organelles	O
suggesting	O
that	O
these	O
selected	O
proteins	O
become	O
autoimmunogenic	O
based	O
on	O
their	O
subcellular	O
association	O
and	O
molecular	O
features	O
[	O
41	O
]	O
.	O

For	O
example	O
,	O
in	O
the	O
endosomal	O
compartment	O
,	O
the	O
two	O
known	O
autoantigens	O
are	O
early	O
endosomal	O
protein	O
EEA1	O
(	O
180	O
kDa	O
)	O
[	O
44	O
]	O
and	O
CLIP-170	O
(	O
170	O
kDa	O
)	O
[	O
45	O
]	O
.	O

There	O
is	O
also	O
a	O
series	O
of	O
centrosomal	O
autoantigens	O
identified	O
as	O
coiled	O
-	O
coil	O
-	O
rich	O
proteins	O
including	O
pericentrin	O
,	O
a	O
220	O
kDa	O
protein	O
[	O
46	O
]	O
,	O
ninein	O
,	O
a	O
protein	O
with	O
alternatively	O
spliced	O
products	O
of	O
245	O
and	O
249	O
kDa	O
[	O
47	O
]	O
,	O
Cep250	O
(	O
250	O
kDa	O
)	O
and	O
Cep110	O
(	O
110	O
kDa	O
)	O
[	O
48	O
]	O
.	O

Centromere	O
autoantigens	O
have	O
been	O
described	O
but	O
the	O
two	O
interesting	O
ones	O
related	O
to	O
this	O
discussion	O
are	O
CENP	O
-	O
E	O
[	O
49	O
]	O
and	O
CENP	O
-	O
F	O
[	O
50	O
]	O
;	O
both	O
are	O
high	O
molecular	O
weight	O
proteins	O
(	O
312	O
to	O
400	O
kDa	O
)	O
and	O
have	O
the	O
same	O
type	O
of	O
overall	O
structure	O
as	O
discussed	O
above	O
.	O

NuMA	O
is	O
another	O
large	O
coiled	O
-	O
coil	O
protein	O
located	O
at	O
the	O
mitotic	O
spindle	O
pole	O
and	O
is	O
the	O
most	O
common	O
target	O
autoantigen	O
in	O
sera	O
with	O
mitotic	O
spindle	O
apparatus	O
staining	O
[	O
51	O
]	O
.	O

Non	O
-	O
muscle	O
myosin	O
(	O
~200	O
kDa	O
)	O
is	O
a	O
cytoskeletal	O
autoantigen	O
[	O
52	O
]	O
that	O
falls	O
in	O
the	O
same	O
group	O
of	O
high	O
molecular	O
weight	O
and	O
coiled	O
-	O
coil	O
-	O
rich	O
autoantigens	O
.	O

These	O
endosomal	O
,	O
centrosomal	O
,	O
mitotic	O
apparatus	O
and	O
intracellular	O
autoantigens	O
are	O
,	O
like	O
the	O
golgins	O
,	O
proteins	O
with	O
high	O
molecular	O
weights	O
and	O
an	O
overall	O
high	O
content	O
of	O
coiled	O
-	O
coil	O
domains	O
.	O

The	O
combination	O
of	O
these	O
two	O
physical	O
features	O
in	O
autoantigens	O
may	O
contribute	O
to	O
the	O
induction	O
and	O
production	O
of	O
autoimmune	O
antibodies	O
in	O
certain	O
disease	O
states	O
.	O

Kinectin	O
is	O
an	O
integral	O
membrane	O
protein	O
largely	O
confined	O
to	O
the	O
endoplasmic	O
reticulum	O
[	O
28,31	O
]	O
and	O
it	O
fits	O
into	O
this	O
new	O
category	O
of	O
autoantigens	O
that	O
are	O
large	O
coiled	O
-	O
coil	O
rich	O
proteins	O
(	O
≥100	O
kDa	O
)	O
in	O
the	O
cytoplasm	O
.	O

Conclusion	O
Here	O
we	O
report	O
the	O
detection	O
of	O
kinectin	O
autoantibody	O
in	O
23	O
%	O
of	O
Chinese	O
patients	O
with	O
BD	O
.	O

The	O
identity	O
of	O
kinectin	O
as	O
a	O
BD	O
-	O
related	O
autoantigen	O
has	O
not	O
been	O
reported	O
to	O
date	O
.	O

Autoantibody	O
reaction	O
against	O
kinectin	O
in	O
BD	O
observed	O
in	O
this	O
study	O
further	O
confirms	O
the	O
autoimmune	O
involvement	O
in	O
BD	O
and	O
may	O
provide	O
new	O
inroads	O
into	O
elucidating	O
the	O
immunopathogenesis	O
of	O
the	O
disease	O
.	O

In	O
an	O
effort	O
to	O
clarify	O
the	O
association	O
of	O
BD	O
with	O
antibody	O
to	O
kinectin	O
,	O
it	O
is	O
essential	O
to	O
measure	O
antibody	O
to	O
kinectin	O
in	O
larger	O
patient	O
populations	O
including	O
both	O
BD	O
,	O
probable	O
BD	O
and	O
important	O
autoimmune	O
rheumatic	O
diseases	O
such	O
as	O
SLE	O
,	O
SjS	O
,	O
rheumatoid	O
arthritis	O
etc	O
.	O
,	O
as	O
well	O
as	O
those	O
diseases	O
not	O
easily	O
differentiated	O
from	O
BD	O
,	O
such	O
as	O
recurrent	O
aphthous	O
oral	O
ulcer	O
,	O
Reiter	O
's	O
syndrome	O
,	O
inflammatory	O
bowel	O
diseases	O
etc	O
.	O

On	O
the	O
other	O
hand	O
,	O
further	O
analysis	O
of	O
the	O
association	O
of	O
anti	O
-	O
kinectin	O
antibody	O
with	O
different	O
manifestations	O
or	O
disease	O
'	O
subtypes	O
'	O
of	O
BD	O
is	O
another	O
important	O
project	O
.	O

Anti	O
-	O
kinectin	O
is	O
clearly	O
only	O
one	O
of	O
the	O
antigen	O
-	O
antibody	O
systems	O
identified	O
because	O
there	O
were	O
many	O
other	O
antibodies	O
observed	O
in	O
the	O
Western	O
blot	O
analysis	O
of	O
BD	O
sera	O
.	O

Using	O
other	O
sera	O
for	O
immunoscreening	O
would	O
probably	O
lead	O
to	O
the	O
identification	O
of	O
other	O
potentially	O
important	O
antigen	O
-	O
antibody	O
systems	O
.	O

Abbreviations	O
AECA	O
=	O
antibody	O
to	O
endothelial	O
cell	O
antigen	O
;	O
BD	O
=	O
Behçet	O
's	O
disease	O
;	O
DMEM	O
=	O
Dulbecco	O
's	O
modified	O
Eagle	O
's	O
medium	O
;	O
HCC	O
=	O
hepatocellular	O
carcinoma	O
;	O
HSP	O
=	O
heat	O
shock	O
protein	O
;	O
IIF	O
=	O
indirect	O
immunofluorescence	O
;	O
PBS	O
=	O
phosphate	O
buffered	O
saline	O
;	O
SjS	O
=	O
Sjögren	O
's	O
syndrome	O
;	O
SLE	O
=	O
systemic	O
lupus	O
erythematosus	O
.	O

Competing	O
interests	O
The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O
YL	O
performed	O
the	O
study	O
and	O
drafted	O
the	O
manuscript	O
.	O

PY	O
provided	O
technical	O
help	O
throughout	O
the	O
study	O
.	O

SLC	O
and	O
EMT	O
conceived	O
the	O
study	O
,	O
participated	O
in	O
the	O
design	O
and	O
helped	O
in	O
the	O
analysis	O
of	O
the	O
data	O
.	O

EKLC	O
participated	O
in	O
the	O
design	O
of	O
the	O
study	O
,	O
interpreted	O
data	O
and	O
helped	O
to	O
draft	O
the	O
manuscript	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Gene	O
expression	O
studies	O
in	O
isolated	O
mitochondria	O
:	O
Solanum	B
tuberosum	I
rps10	O
is	O
recognized	O
by	O
cognate	O
potato	B
but	O
not	O
by	O
the	O
transcription	O
,	O
splicing	O
and	O
editing	O
machinery	O
of	O
wheat	B
mitochondria	O
Abstract	O
The	O
complex	O
gene	O
expression	O
mechanisms	O
that	O
occur	O
in	O
plant	O
mitochondria	O
,	O
such	O
as	O
RNA	O
editing	O
and	O
splicing	O
,	O
are	O
not	O
yet	O
well	O
understood	O
.	O

RNA	O
editing	O
in	O
higher	O
plant	O
mitochondria	O
is	O
a	O
highly	O
specific	O
process	O
which	O
modifies	O
mRNA	O
sequences	O
by	O
C	O
-	O
to	O
-	O
U	O
conversions	O
.	O

It	O
has	O
been	O
suggested	O
that	O
in	O
some	O
cases	O
this	O
process	O
is	O
required	O
for	O
splicing	O
.	O

Here	O
,	O
we	O
use	O
an	O
experimental	O
model	O
based	O
on	O
the	O
introduction	O
of	O
DNA	O
into	O
isolated	O
mitochondria	O
by	O
electroporation	O
to	O
study	O
organellar	O
gene	O
expression	O
events	O
.	O

Our	O
aim	O
was	O
to	O
compare	O
processing	O
and	O
editing	O
of	O
potato	B
small	O
ribosomal	O
protein	O
10	O
gene	O
(	O
rps10	O
)	O
transcripts	O
in	O
heterologous	O
(	O
wheat	B
mitochondria	O
)	O
and	O
homologous	O
(	O
potato	B
mitochondria	O
)	O
contexts	O
.	O

rps10	O
is	O
a	O
suitable	O
model	O
because	O
it	O
contains	O
a	O
group	O
II	O
intron	O
,	O
is	O
absent	O
in	O
wheat	B
mitochondria	O
but	O
is	O
actively	O
expressed	O
in	O
potato	B
mitochondria	O
,	O
where	O
transcripts	O
are	O
spliced	O
and	O
undergo	O
five	O
C	O
-	O
to	O
-	O
U	O
editing	O
events	O
.	O

For	O
this	O
purpose	O
,	O
conditions	O
for	O
electroporating	O
isolated	O
potato	B
mitochondria	O
were	O
established	O
.	O

rps10	O
was	O
placed	O
under	O
the	O
control	O
of	O
either	O
potato	B
or	O
wheat	B
cox2	O
promoters	O
.	O

We	O
found	O
that	O
rps10	O
was	O
only	O
transcribed	O
under	O
the	O
control	O
of	O
a	O
cognate	O
promoter	O
.	O

In	O
wheat	B
mitochondria	O
,	O
rps10	O
transcripts	O
were	O
neither	O
spliced	O
nor	O
edited	O
while	O
they	O
are	O
correctly	O
processed	O
in	O
potato	B
mitochondria	O
.	O

Interestingly	O
,	O
a	O
wheat	B
editing	O
site	O
grafted	O
into	O
rps10	O
was	O
not	O
recognized	O
by	O
wheat	B
mitochondria	O
but	O
was	O
correctly	O
edited	O
in	O
potato	B
mitochondria	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
editing	O
might	O
occur	O
only	O
when	O
the	O
transcripts	O
are	O
engaged	O
in	O
processing	O
and	O
that	O
they	O
would	O
not	O
be	O
available	O
to	O
editing	O
factors	O
outside	O
of	O
a	O
putative	O
RNA	O
maturation	O
machinery	O
complex	O
.	O

INTRODUCTION	O
Gene	O
expression	O
in	O
plant	O
mitochondria	O
is	O
a	O
complex	O
process	O
involving	O
multiple	O
steps	O
such	O
as	O
transcription	O
,	O
cis-	O
and	O
trans	O
-	O
splicing	O
,	O
RNA	O
trimming	O
and	O
RNA	O
editing	O
on	O
the	O
way	O
to	O
translation	O
(	O
1	O
)	O
.	O

RNA	O
editing	O
has	O
been	O
found	O
in	O
a	O
variety	O
of	O
organisms	O
and	O
occurs	O
through	O
different	O
mechanisms	O
such	O
as	O
insertion	O
or	O
deletion	O
of	O
nucleotides	O
,	O
or	O
base	O
conversions	O
[	O
for	O
details	O
see	O
reference	O
(	O
2	O
)	O
]	O
.	O

In	O
higher	O
plant	O
organelles	O
,	O
RNA	O
editing	O
is	O
an	O
important	O
post	O
-	O
transcriptional	O
event	O
characterized	O
by	O
C	O
-	O
to	O
-	O
U	O
changes	O
via	O
a	O
deamination	O
mechanism	O
(	O
3–5	O
)	O
.	O

In	O
Arabidopsis	B
thaliana	I
456	O
C	O
-	O
to	O
-	O
U	O
editing	O
events	O
have	O
been	O
described	O
(	O
6	O
)	O
.	O

RNA	O
editing	O
occurs	O
mostly	O
in	O
the	O
coding	O
regions	O
which	O
alter	O
the	O
identity	O
of	O
the	O
encoded	O
amino	O
acid	O
,	O
but	O
some	O
editing	O
events	O
occur	O
in	O
highly	O
structured	O
regions	O
of	O
introns	O
(	O
7,8	O
)	O
.	O

Like	O
other	O
maturation	O
processes	O
,	O
RNA	O
editing	O
is	O
an	O
essential	O
post	O
-	O
transcriptional	O
event	O
in	O
plant	O
mitochondrial	O
gene	O
expression	O
(	O
9–11	O
)	O
required	O
for	O
the	O
synthesis	O
of	O
functional	O
proteins	O
(	O
12,13	O
)	O
.	O

The	O
introduction	O
of	O
foreign	O
DNA	O
into	O
isolated	O
mitochondria	O
is	O
a	O
novel	O
experimental	O
model	O
which	O
has	O
provided	O
important	O
information	O
on	O
RNA	O
editing	O
and	O
RNA	O
splicing	O
enabling	O
the	O
use	O
of	O
a	O
site	O
-	O
directed	O
mutagenesis	O
approach	O
(	O
14,15	O
)	O
.	O

Using	O
a	O
cognate	O
cox2	O
chimeric	O
gene	O
construct	O
,	O
the	O
cis	O
-	O
recognition	O
elements	O
required	O
for	O
plant	O
mitochondria	O
RNA	O
editing	O
have	O
been	O
determined	O
(	O
16,17	O
)	O
.	O

Using	O
the	O
same	O
approach	O
,	O
Staudinger	O
and	O
Kempken	O
(	O
18	O
)	O
have	O
reported	O
that	O
transcripts	O
from	O
A.thaliana	B
cox2	O
,	O
but	O
not	O
Sorghum	B
bicolor	I
atp6	O
,	O
are	O
edited	O
when	O
the	O
genes	O
are	O
introduced	O
into	O
maize	B
mitochondria	O
.	O

Interestingly	O
,	O
higher	O
plant	O
mitochondrial	O
genomes	O
differ	O
in	O
their	O
gene	O
contents	O
due	O
to	O
an	O
evolutionary	O
information	O
transfer	O
from	O
the	O
organelle	O
to	O
the	O
nucleus	O
(	O
19	O
)	O
.	O

Of	O
particular	O
interest	O
is	O
the	O
situation	O
of	O
the	O
small	O
ribosomal	O
protein	O
10	O
gene	O
(	O
rps10	O
)	O
,	O
a	O
group	O
II	O
intron	O
-	O
bearing	O
gene	O
which	O
is	O
encoded	O
in	O
Solanum	B
tuberosum	I
mitochondrial	O
DNA	O
but	O
is	O
absent	O
from	O
the	O
wheat	B
mitochondrial	O
genome	O
(	O
20	O
)	O
.	O

Higher	O
plant	O
mitochondria	O
contain	O
group	O
II	O
introns	O
either	O
in	O
cis-	O
or	O
trans-	O
configuration	O
(	O
1	O
)	O
which	O
can	O
be	O
folded	O
in	O
a	O
characteristic	O
secondary	O
structure	O
(	O
21	O
)	O
.	O

Intron	O
removal	O
in	O
plant	O
mitochondrial	O
mRNAs	O
is	O
not	O
well	O
documented	O
because	O
such	O
introns	O
are	O
unable	O
to	O
self	O
-	O
splice	O
.	O

Previously	O
,	O
we	O
described	O
that	O
electroporated	O
cox2	O
constructs	O
were	O
a	O
good	O
model	O
for	O
the	O
study	O
of	O
the	O
splicing	O
process	O
.	O

Using	O
this	O
model	O
,	O
we	O
found	O
that	O
editing	O
and	O
splicing	O
of	O
cox2	O
transcripts	O
were	O
not	O
linked	O
in	O
wheat	B
mitochondria	O
(	O
15	O
)	O
.	O

To	O
challenge	O
the	O
ability	O
of	O
mitochondrial	O
gene	O
expression	O
machinery	O
to	O
recognize	O
genetic	O
information	O
which	O
has	O
been	O
lost	O
during	O
evolution	O
,	O
we	O
decided	O
to	O
introduce	O
the	O
S.tuberosum	B
non	O
-	O
cognate	O
rps10	O
gene	O
into	O
wheat	B
mitochondria	O
.	O

Five	O
C	O
residues	O
are	O
changed	O
to	O
U	O
in	O
potato	B
mitochondria	O
rps10	O
transcripts	O
by	O
editing	O
.	O

Two	O
of	O
them	O
have	O
been	O
postulated	O
as	O
being	O
necessary	O
for	O
acquisition	O
of	O
a	O
proper	O
secondary	O
and/or	O
tertiary	O
structure	O
for	O
splicing	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
it	O
was	O
necessary	O
to	O
set	O
up	O
the	O
conditions	O
for	O
electroporation	O
of	O
foreign	O
DNA	O
into	O
S.tuberosum	B
mitochondria	O
.	O

Here	O
,	O
we	O
show	O
that	O
a	O
potato	B
rps10	O
construct	O
is	O
transcribed	O
when	O
introduced	O
into	O
wheat	B
mitochondria	O
,	O
but	O
transcripts	O
are	O
not	O
recognized	O
by	O
the	O
post	O
-	O
transcriptional	O
processing	O
machinery	O
.	O

In	O
contrast	O
,	O
a	O
rps10	O
construct	O
is	O
correctly	O
expressed	O
and	O
processed	O
in	O
cognate	O
potato	B
mitochondria	O
.	O

Moreover	O
,	O
we	O
present	O
evidence	O
that	O
transcript	O
editing	O
might	O
be	O
linked	O
to	O
overall	O
RNA	O
processing	O
.	O

This	O
is	O
the	O
first	O
report	O
on	O
DNA	O
electroporation	O
into	O
potato	B
mitochondria	O
.	O

MATERIALS	O
AND	O
METHODS	O
Plasmids	O
All	O
plasmids	O
used	O
in	O
this	O
study	O
are	O
based	O
on	O
the	O
previously	O
described	O
pCOXII	O
vector	O
(	O
14	O
)	O
.	O

An	O
NsiI	O
restriction	O
site	O
was	O
introduced	O
at	O
the	O
initiation	O
codon	O
of	O
the	O
wheat	B
cox2	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
.	O

Then	O
,	O
NsiI	O
was	O
used	O
in	O
combination	O
with	O
a	O
SpeI	O
restriction	O
site	O
present	O
in	O
the	O
original	O
vector	O
after	O
the	O
stop	O
codon	O
,	O
to	O
produce	O
the	O
chimeric	O
vectors	O
.	O

S.tuberosum	B
cox2	O
gene	O
,	O
including	O
a	O
727	O
bp	O
non	O
-	O
coding	O
upstream	O
region	O
,	O
was	O
isolated	O
by	O
PCR	O
from	O
total	O
DNA	O
using	O
the	O
primer	O
A	O
designed	O
from	O
partial	O
sequences	O
reported	O
by	O
Löessl	O
et	O
al.	O
(	O
22	O
)	O
,	O
accession	O
no.	O
AF096321	O
,	O
containing	O
the	O
KpnI	O
restriction	O
sequence	O
,	O
and	O
primer	O
B	O
derived	O
from	O
Triticum	B
timopheevi	I
cox2	O
(	O
AF336134	O
)	O
.	O

A	O
fragment	O
of	O
2888	O
bp	O
was	O
obtained	O
and	O
cloned	O
on	O
pGEM	O
-	O
T	O
vector	O
.	O

The	O
complete	O
sequence	O
of	O
the	O
S.tuberosum	B
cox2	O
was	O
determined	O
(	O
accession	O
no.	O
DQ18064	O
)	O
.	O

To	O
generate	O
the	O
plasmid	O
pCOXIISt	O
containing	O
the	O
S.tuberosum	B
cox2	O
gene	O
,	O
a	O
KpnI	O
/	O
SpeI	O
fragment	O
containing	O
the	O
727	O
bp	O
upstream	O
region	O
and	O
the	O
complete	O
coding	O
region	O
was	O
used	O
to	O
replace	O
the	O
wheat	B
gene	O
from	O
pCOXII	O
.	O

As	O
for	O
pCOXII	O
,	O
a	O
NsiI	O
site	O
was	O
inserted	O
at	O
the	O
ATG	O
start	O
codon	O
and	O
a	O
23	O
bp	O
fragment	O
was	O
inserted	O
at	O
position	O
−20	O
.	O

This	O
23	O
bp	O
insertion	O
provides	O
a	O
specific	O
sequence	O
allowing	O
isolation	O
of	O
potato	B
cox2	O
transcripts	O
originating	O
from	O
the	O
introduced	O
DNA	O
by	O
RT	O
–	O
PCR	O
.	O

The	O
chimeric	O
wheat	B
/	O
potato	B
cox2	O
gene	O
was	O
constructed	O
by	O
replacing	O
727	O
bp	O
KpnI	O
/	O
NsiI	O
promoter	O
sequence	O
from	O
pCOXIISt	O
with	O
the	O
880	O
bp	O
wheat	B
upstream	O
region	O
from	O
pCOXII	O
.	O

The	O
vectors	O
pRPS10W	O
and	O
the	O
pRPS10St	O
derivative	O
,	O
containing	O
wheat	B
and	O
potato	B
cox2	O
promoters	O
,	O
respectively	O
,	O
were	O
constructed	O
by	O
inserting	O
the	O
1178	O
bp	O
rps10	O
sequence	O
containing	O
two	O
exons	O
separated	O
by	O
a	O
777	O
bp	O
intronic	O
sequence	O
[	O
(	O
23	O
)	O
,	O
accession	O
no.	O
X74826	O
]	O
.	O

The	O
coding	O
region	O
was	O
isolated	O
from	O
total	O
S.tuberosum	B
DNA	O
by	O
PCR	O
using	O
primers	O
D1	O
and	O
D2	O
containing	O
the	O
restriction	O
sites	O
NsiI	O
and	O
SpeI	O
,	O
respectively	O
.	O

The	O
fragment	O
NsiI	O
/	O
SpeI	O
was	O
purified	O
and	O
cloned	O
into	O
pCOXII	O
and	O
pCOXIISt	O
,	O
replacing	O
the	O
respective	O
cox2	O
coding	O
regions	O
.	O

Since	O
all	O
vectors	O
used	O
here	O
were	O
based	O
on	O
pCOXII	O
,	O
they	O
contain	O
the	O
downstream	O
region	O
from	O
the	O
wheat	B
cob	O
gene	O
(	O
Ir	O
-	O
cob	O
)	O
(	O
accession	O
no.	O
AF337547	O
)	O
(	O
14	O
)	O
.	O

This	O
sequence	O
,	O
combined	O
with	O
the	O
23	O
bp	O
upstream	O
insert	O
sequence	O
served	O
to	O
distinguish	O
,	O
using	O
primers	O
1a	O
and	O
1b	O
,	O
foreign	O
from	O
endogenous	O
transcripts	O
.	O

All	O
mutants	O
were	O
obtained	O
using	O
QuickChange	O
®	O
Site	O
-	O
Directed	O
Mutagenesis	O
kit	O
(	O
Stratagene	O
)	O
.	O

PCR	O
product	O
purifications	O
were	O
carried	O
out	O
with	O
the	O
Wizard	O
®	O
Clean	O
-	O
Up	O
System	O
(	O
Promega	O
)	O
.	O

PCR	O
primers	O
used	O
Oligonucleotides	O
sequences	O
are	O
in	O
5′	O
to	O
3′	O
orientation	O
.	O

(	O
1a	O
)	O
,	O
GCGGTGCAGTCATACAGATCTGC	O
;	O
(	O
1b	O
)	O
,	O
TATCCAGATTTGGTACCAAAC	O
;	O
(	O
2a	O
)	O
,	O
GCAGTCATACAGATCTGCCAAAG	O
;	O
(	O
2b	O
)	O
,	O
AGATTTGGTACCAAACCCGGG	O
;	O
(	O
A	O
)	O
,	O
TATAGGTACCTCTCAGGTGTCAAAGTGTGGATTT	O
;	O
(	O
B	O
)	O
,	O
TATAACTAGTTTAAGCTTCCCCG	O
;	O
(	O
D1	O
)	O
,	O
TATAATGCATAGACAAAGGAGAGCACTTA	O
;	O
(	O
D2	O
)	O
,	O
TATAACTAGTTCAGGAAAGGGTCAACGCAA	O
.	O

Restriction	O
sites	O
are	O
underlined	O
.	O

Mutagenesis	O
primers	O
(	O
only	O
sense	O
primers	O
in	O
5′–3′	O
orientation	O
are	O
indicated	O
)	O
Single	O
C2	O
,	O
C3	O
and	O
C2+C3	O
double	O
mutant	O
plasmids	O
were	O
constructed	O
with	O
primers	O
(	O
C2	O
)	O
AAGAAGTTCTTTTGGTTAAAACGCC	O
and	O
(	O
C3	O
)	O
CGCCGTGCGACTTGGAGGACATAAG	O
.	O

NsiI	O
-	O
pCOXII	O
:	O
GGAAATCCAATGCATCTTCGTTCATT	O
and	O
NsiI	O
-	O
pCOXIISt	O
:	O
CCAAACCAAATGCATGTTCTAGAATG	O
.	O

Construct	O
pCOXIISt	O
containing	O
a	O
23	O
nt	O
insertion	O
in	O
the	O
promoter	O
region	O
,	O
was	O
carried	O
out	O
into	O
two	O
consecutive	O
insertions	O
using	O
primers	O
:	O
TGGGGGGAGCAGAGCAGTGCGGTGCAGTCACAAAGAATGAACCAAACC	O
and	O
GCAGTGCGGTGCAGTCATACAGATCTGCCAAAGAATGAACCAAACC	O
.	O

For	O
constructs	O
MA	O
and	O
MAB	O
containing	O
the	O
wheat	B
cox2	O
C259	O
editing	O
site	O
,	O
two	O
consecutive	O
insertions	O
were	O
carried	O
out	O
using	O
primers	O
:	O
GGAAGATTGGATTACTATCGAAATTGCCCTGAATCA	O
and	O
TACTATCGAAATTATTCGGACCATGCCCTGAATCA	O
.	O

For	O
ME6	O
and	O
ME6b	O
constructs	O
,	O
primers	O
CCGCGAGGAATCAACTACTATCGAAATTATTGCCGGTGCTGAC	O
and	O
CAACTACTATCGAAATTATTCGGACCATATTGCCGGTGCTGAC	O
were	O
used	O
.	O

Inserted	O
nucleotides	O
are	O
underlined	O
and	O
the	O
modified	O
residues	O
are	O
indicated	O
in	O
bold	O
.	O

Mitochondria	O
purification	O
S.tuberosum	B
cv	O
.	O

Rosevalt	O
tubers	O
and	O
T.aestivum	B
var	I
Fortal	I
seeds	O
were	O
used	O
.	O

Potato	B
mitochondria	O
were	O
prepared	O
from	O
2	O
kg	O
of	O
tubers	O
in	O
batches	O
of	O
200	O
g	O
with	O
200	O
ml	O
of	O
a	O
homogenization	O
buffer	O
containing	O
0.4	O
M	O
mannitol	O
,	O
25	O
mM	O
MOPS	O
(	O
pH	O
7.8	O
)	O
,	O
1	O
mM	O
EGTA	O
,	O
8	O
mM	O
cysteine	O
and	O
1	O
mg	O
/	O
ml	O
fatty	O
acid	O
-	O
free	O
BSA	O
.	O

Homogenization	O
was	O
carried	O
out	O
for	O
15	O
s	O
in	O
a	O
Waring	O
blendor	O
at	O
full	O
speed	O
.	O

Homogenate	O
was	O
centrifuged	O
in	O
a	O
Sorvall	O
GSA	O
rotor	O
at	O
1500	O
g	O
for	O
10	O
min	O
at	O
4	O
°	O
C	O
.	O

Supernatant	O
was	O
centrifuged	O
in	O
a	O
GSA	O
rotor	O
at	O
12	O
000	O
g	O
for	O
15	O
min	O
.	O

The	O
mitochondrial	O
pellet	O
was	O
resuspended	O
in	O
50	O
ml	O
of	O
homogenization	O
buffer	O
and	O
centrifuged	O
at	O
1500	O
g.	O

The	O
supernatant	O
was	O
centrifuged	O
in	O
a	O
Sorvall	O
SS-34	O
rotor	O
at	O
15	O
000	O
g	O
for	O
10	O
min	O
,	O
the	O
pellet	O
was	O
resuspended	O
in	O
12	O
ml	O
of	O
homogenization	O
buffer	O
and	O
mitochondria	O
were	O
purified	O
by	O
centrifugation	O
on	O
a	O
sucrose	O
gradient	O
essentially	O
as	O
described	O
for	O
wheat	B
embryo	O
mitochondria	O
(	O
14	O
)	O
.	O

Electroporation	O
Electrotransfer	O
experiments	O
were	O
carried	O
out	O
with	O
1	O
mg	O
of	O
purified	O
wheat	B
embryo	O
or	O
potato	B
tuber	O
mitochondria	O
in	O
50	O
µl	O
of	O
0.33	O
M	O
sucrose	O
and	O
1	O
µg	O
of	O
recombinant	O
plasmid	O
as	O
described	O
(	O
14	O
)	O
.	O

The	O
electroporated	O
mitochondria	O
were	O
incubated	O
for	O
18	O
h	O
at	O
25	O
°	O
C	O
,	O
then	O
recovered	O
by	O
centrifugation	O
in	O
a	O
Sigma	O
N	O
°	O
12024	O
rotor	O
(	O
Sigma	O
1K15	O
refrigerated	O
centrifuge	O
)	O
at	O
15	O
000	O
g	O
for	O
15	O
min	O
at	O
4	O
°	O
C	O
.	O

In	O
the	O
case	O
of	O
potato	B
mitochondria	O
the	O
incubation	O
mixture	O
was	O
supplemented	O
with	O
1	O
mg	O
/	O
ml	O
of	O
fatty	O
acid	O
-	O
free	O
BSA	O
.	O

RNA	O
was	O
purified	O
with	O
200	O
µl	O
of	O
TRIzol	O
™	O
reagent	O
(	O
Gibco	O
-	O
BRL	O
)	O
according	O
to	O
the	O
supplier	O
's	O
protocol	O
.	O

DNAse	O
I	O
protection	O
assay	O
and	O
DNA	O
purification	O
After	O
electroporation	O
and	O
centrifugation	O
,	O
the	O
mitochondrial	O
pellet	O
was	O
resuspended	O
in	O
100	O
µl	O
of	O
buffer	O
[	O
10	O
mM	O
Tris	O
–	O
HCl	O
(	O
pH	O
7.5	O
)	O
,	O
2	O
mM	O
magnesium	O
acetate	O
and	O
0.33	O
M	O
sucrose	O
]	O
containing	O
60	O
U	O
of	O
DNase	O
I	O
(	O
Gibco	O
-	O
BRL	O
)	O
and	O
incubated	O
for	O
1	O
h	O
at	O
room	O
temperature	O
.	O

The	O
DNase	O
reaction	O
was	O
stopped	O
by	O
adding	O
4	O
µl	O
of	O
0.5	O
M	O
EDTA	O
and	O
then	O
heating	O
for	O
10	O
min	O
at	O
65	O
°	O
C	O
.	O

Mitochondria	O
were	O
incubated	O
with	O
100	O
µg	O
of	O
Proteinase	O
K	O
(	O
Merck	O
)	O
for	O
4	O
h	O
at	O
37	O
°	O
C	O
.	O

One	O
microliter	O
of	O
20	O
%	O
SDS	O
was	O
added	O
to	O
achieve	O
mitochondrial	O
lysis	O
and	O
the	O
DNA	O
was	O
extracted	O
with	O
phenol	O
/	O
chloroform	O
,	O
precipitated	O
with	O
0.1	O
vol	O
of	O
3	O
M	O
Sodium	O
Acetate	O
(	O
pH	O
5.2	O
)	O
,	O
3	O
vol	O
of	O
100	O
%	O
ethanol	O
and	O
100	O
ng	O
of	O
carrier	O
yeast	B
tRNA	O
and	O
left	O
overnight	O
at	O
−20	O
°	O
C	O
.	O

After	O
centrifugation	O
,	O
the	O
DNA	O
pellet	O
was	O
resuspended	O
in	O
TE	O
buffer	O
[	O
10	O
mM	O
Tris	O
–	O
HCl	O
(	O
pH	O
8)	O
and	O
1	O
mM	O
EDTA	O
]	O
.	O

RT	O
–	O
PCR	O
RNA	O
(	O
1	O
µg	O
)	O
was	O
treated	O
with	O
2	O
U	O
of	O
Amplification	O
grade	O
DNase	O
I	O
(	O
Promega	O
)	O
.	O

cDNA	O
synthesis	O
was	O
performed	O
with	O
200	O
U	O
of	O
Superscript	O
II	O
RT	O
using	O
100	O
ng	O
of	O
random	O
hexamers	O
.	O

The	O
PCR	O
were	O
performed	O
with	O
primers	O
1a	O
and	O
1b	O
using	O
Advantage	O
®	O
2	O
Polymerase	O
Mix	O
(	O
Clontech	O
)	O
as	O
follows	O
:	O
95	O
°	O
C	O
,	O
1	O
min	O
;	O
5	O
cycles	O
at	O
95	O
°	O
C	O
for	O
30	O
s	O
and	O
68	O
°	O
C	O
for	O
1	O
min	O
;	O
30	O
cycles	O
at	O
95	O
°	O
C	O
for	O
30	O
s	O
,	O
58	O
°	O
C	O
for	O
30	O
s	O
and	O
68	O
°	O
C	O
for	O
30	O
s	O
,	O
and	O
finally	O
68	O
°	O
C	O
for	O
1	O
min	O
.	O

Primers	O
2a	O
and	O
2b	O
were	O
used	O
for	O
nested	O
PCR	O
from	O
1	O
µl	O
of	O
the	O
first	O
PCR	O
.	O

No	O
RT	O
–	O
PCR	O
amplification	O
products	O
were	O
obtained	O
with	O
RNA	O
from	O
non	O
-	O
electroporated	O
mitochondria	O
.	O

DNA	O
sequencing	O
Sequence	O
analyses	O
were	O
performed	O
directly	O
on	O
the	O
RT	O
–	O
PCR	O
product	O
using	O
an	O
automatic	O
DNA	O
sequencing	O
equipment	O
with	O
the	O
BigDye	O
®	O
Terminator	O
Cycle	O
Sequencing	O
Kit	O
(	O
Applied	O
Biosystem	O
)	O
.	O

RESULTS	O
S.tuberosum	B
rps10	O
transcripts	O
are	O
not	O
processed	O
in	O
wheat	B
mitochondria	O
The	O
S.tuberosum	B
rps10	O
construct	O
under	O
control	O
of	O
a	O
wheat	B
cox2	O
promoter	O
(	O
Figure	O
1A	O
)	O
was	O
incorporated	O
into	O
purified	O
wheat	B
mitochondria	O
by	O
electroporation	O
as	O
indicated	O
in	O
Materials	O
and	O
Methods	O
.	O

After	O
electroporation	O
and	O
incubation	O
in	O
expression	O
medium	O
,	O
mitochondrial	O
RNA	O
was	O
extracted	O
and	O
analysed	O
by	O
RT	O
–	O
PCR	O
.	O

The	O
primers	O
used	O
allowed	O
detection	O
of	O
the	O
transcripts	O
generated	O
by	O
the	O
constructs	O
introduced	O
and	O
excluded	O
any	O
product	O
from	O
endogenous	O
cox2	O
(	O
or	O
rps10	O
in	O
the	O
potato	B
system	O
)	O
.	O

Two	O
bands	O
of	O
1204	O
and	O
427	O
bp	O
were	O
expected	O
from	O
precursor	O
and	O
mature	O
rps10	O
mRNAs	O
,	O
respectively	O
.	O

Only	O
precursor	O
rps10	O
molecules	O
were	O
detected	O
(	O
Figure	O
1B	O
)	O
.	O

As	O
a	O
control	O
,	O
a	O
cognate	O
cox2	O
construct	O
(	O
16	O
)	O
was	O
used	O
.	O

In	O
this	O
case	O
,	O
the	O
2048	O
and	O
827	O
bp	O
RT	O
–	O
PCR	O
bands	O
representing	O
the	O
precursor	O
and	O
spliced	O
cox2	O
products	O
,	O
respectively	O
were	O
observed	O
(	O
Figure	O
1B	O
)	O
.	O

In	O
all	O
cases	O
,	O
the	O
PCR	O
bands	O
actually	O
represent	O
transcription	O
products	O
since	O
when	O
PCR	O
was	O
performed	O
without	O
the	O
RT	O
step	O
we	O
observed	O
no	O
amplification	O
products	O
.	O

Previously	O
,	O
five	O
C	O
residues	O
,	O
two	O
in	O
exon	O
1	O
,	O
one	O
in	O
the	O
intron	O
and	O
two	O
in	O
exon	O
2	O
have	O
been	O
reported	O
to	O
be	O
changed	O
to	O
U	O
by	O
editing	O
in	O
potato	B
mitochondria	O
(	O
23	O
)	O
.	O

To	O
determine	O
if	O
the	O
non	O
-	O
cognate	O
transcript	O
could	O
be	O
recognized	O
by	O
the	O
wheat	B
RNA	O
editing	O
machinery	O
,	O
the	O
1204	O
bp	O
RT	O
–	O
PCR	O
product	O
was	O
sequenced	O
.	O

While	O
wheat	B
cox2	O
editing	O
sites	O
were	O
correctly	O
edited	O
in	O
control	O
as	O
expected	O
(	O
Figure	O
1C	O
,	O
only	O
site	O
C77	O
is	O
shown	O
)	O
,	O
all	O
five	O
editable	O
residues	O
in	O
potato	B
rps10	O
transcript	O
remain	O
unchanged	O
.	O

cox2	O
C77	O
editing	O
sites	O
are	O
identical	O
in	O
potato	B
and	O
wheat	B
.	O

Failure	O
of	O
rps10	O
transcript	O
splicing	O
in	O
wheat	B
mitochondria	O
is	O
not	O
linked	O
to	O
the	O
absence	O
of	O
editing	O
It	O
has	O
been	O
suggested	O
that	O
residues	O
C2	O
and	O
C3	O
participate	O
in	O
the	O
secondary	O
structure	O
of	O
the	O
intron	O
necessary	O
for	O
splicing	O
(	O
23	O
)	O
.	O

A	O
possible	O
explanation	O
to	O
the	O
failure	O
observed	O
in	O
precursor	O
rps10	O
splicing	O
could	O
be	O
that	O
the	O
absence	O
of	O
edition	O
of	O
C2	O
and	O
C3	O
prevent	O
the	O
intron	O
from	O
organizing	O
itself	O
in	O
a	O
catalytically	O
competent	O
conformation	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
single	O
C2	O
and	O
C3	O
mutants	O
and	O
a	O
C2+C3	O
double	O
mutant	O
were	O
constructed	O
by	O
changing	O
the	O
C	O
residues	O
to	O
T.	O
Neither	O
single	O
nor	O
double	O
mutants	O
were	O
able	O
to	O
undergo	O
splicing	O
(	O
Figure	O
2	O
)	O
.	O

Electroporation	O
of	O
S.tuberosum	B
mitochondria	O
Since	O
two	O
important	O
post	O
-	O
transcriptional	O
processes	O
,	O
RNA	O
editing	O
and	O
splicing	O
,	O
were	O
inoperative	O
when	O
S.tuberosum	B
rps10	O
was	O
expressed	O
in	O
wheat	B
mitochondria	O
,	O
we	O
decided	O
to	O
verify	O
whether	O
the	O
negative	O
results	O
were	O
inherent	O
to	O
the	O
rps10	O
chimeric	O
constructs	O
or	O
due	O
to	O
the	O
lack	O
of	O
trans	O
-	O
recognition	O
elements	O
in	O
wheat	B
mitochondria	O
.	O

For	O
this	O
purpose	O
,	O
it	O
was	O
necessary	O
to	O
set	O
up	O
an	O
electroporation	O
protocol	O
adapted	O
to	O
S.tuberosum	B
mitochondria	O
.	O

Purified	O
organelles	O
were	O
prepared	O
from	O
potato	B
tubers	O
as	O
indicated	O
in	O
Materials	O
and	O
Methods	O
.	O

Electric	O
pulses	O
in	O
the	O
range	O
between	O
8	O
and	O
20	O
kV	O
were	O
performed	O
.	O

Internalization	O
of	O
exogenous	O
DNA	O
was	O
measured	O
by	O
DNAse	O
protection	O
assays	O
(	O
14	O
)	O
.	O

Potato	B
mitochondria	O
show	O
a	O
broad	O
range	O
response	O
with	O
a	O
maximum	O
around	O
13	O
kV	O
(	O
Figure	O
3	O
)	O
.	O

This	O
voltage	O
setting	O
was	O
therefore	O
used	O
for	O
further	O
experiments	O
.	O

S.tuberosum	B
mitochondria	O
does	O
not	O
recognize	O
the	O
wheat	B
cox2	O
promoter	O
To	O
ascertain	O
the	O
ability	O
of	O
electroporated	O
mitochondria	O
to	O
perform	O
expression	O
of	O
the	O
exogenous	O
gene	O
construct	O
,	O
we	O
used	O
a	O
plasmid	O
containing	O
the	O
potato	B
cox2	O
gene	O
controlled	O
either	O
by	O
T.aestivum	B
or	O
S.tuberosum	B
promoters	O
.	O

As	O
shown	O
in	O
Figure	O
4	O
,	O
the	O
construct	O
containing	O
the	O
wheat	B
or	O
potato	B
promoters	O
was	O
transcribed	O
only	O
in	O
cognate	O
mitochondria	O
.	O

In	O
potato	B
,	O
the	O
mature	O
product	O
is	O
barely	O
detectable	O
.	O

In	O
contrast	O
to	O
wheat	B
mitochondria	O
,	O
the	O
821	O
nt	O
mature	O
transcript	O
was	O
only	O
detected	O
when	O
the	O
electroporated	O
potato	B
mitochondria	O
were	O
incubated	O
in	O
the	O
presence	O
of	O
fatty	O
acid	O
-	O
free	O
BSA	O
.	O

A	O
cognate	O
rps10	O
construct	O
is	O
correctly	O
expressed	O
,	O
edited	O
and	O
processed	O
in	O
potato	B
mitochondria	O
The	O
construct	O
expressing	O
potato	B
rps10	O
under	O
the	O
control	O
of	O
potato	B
cox2	O
promoter	O
was	O
introduced	O
into	O
S.tuberosum	B
isolated	O
mitochondria	O
.	O

After	O
incubation	O
,	O
the	O
precursor	O
and	O
mature	O
transcripts	O
were	O
amplified	O
by	O
RT	O
–	O
PCR	O
(	O
Figure	O
5A	O
)	O
and	O
sequenced	O
.	O

As	O
shown	O
in	O
Figure	O
5B	O
,	O
the	O
four	O
editing	O
sites	O
C1	O
,	O
C2	O
,	O
C4	O
and	O
C5	O
,	O
described	O
previously	O
in	O
endogenous	O
transcripts	O
,	O
were	O
found	O
edited	O
in	O
mature	O
mRNA	O
.	O

The	O
presence	O
of	O
spliced	O
molecules	O
containing	O
unedited	O
residues	O
(	O
Figure	O
5B	O
)	O
indicates	O
that	O
rps10	O
transcripts	O
could	O
be	O
spliced	O
before	O
editing	O
.	O

To	O
confirm	O
this	O
observation	O
,	O
the	O
PCR	O
product	O
was	O
cloned	O
and	O
sequenced	O
.	O

One	O
half	O
of	O
the	O
individual	O
clones	O
were	O
found	O
edited	O
at	O
sites	O
C1	O
and	O
C2	O
;	O
65	O
%	O
were	O
edited	O
at	O
site	O
C4	O
and	O
25	O
%	O
were	O
edited	O
at	O
site	O
C5	O
.	O

A	O
cognate	O
editing	O
site	O
in	O
a	O
non	O
-	O
native	O
context	O
is	O
not	O
recognized	O
by	O
wheat	B
mitochondria	O
but	O
is	O
recognized	O
in	O
heterologous	O
mitochondria	O
To	O
test	O
whether	O
wheat	B
mitochondria	O
are	O
able	O
to	O
edit	O
a	O
cognate	O
site	O
when	O
placed	O
in	O
the	O
context	O
of	O
a	O
potato	B
transcript	O
,	O
we	O
introduced	O
the	O
C259	O
−16	O
/	O
+6	O
region	O
from	O
wheat	B
cox2	O
into	O
potato	B
rps10	O
exon	O
1	O
or	O
intron	O
(	O
Figure	O
6A	O
,	O
construct	O
MA	O
and	O
ME6	O
,	O
respectively	O
)	O
.	O

As	O
reported	O
previously	O
,	O
the	O
23	O
nt	O
region	O
forming	O
the	O
C259	O
editing	O
site	O
from	O
wheat	B
cox2	O
was	O
efficiently	O
edited	O
when	O
grafted	O
into	O
a	O
different	O
context	O
in	O
a	O
wheat	B
transcript	O
(	O
17	O
)	O
.	O

Wild	O
-	O
type	O
rps10	O
(	O
pRPS10W	O
)	O
and	O
the	O
MA	O
and	O
ME6	O
mutants	O
were	O
expressed	O
in	O
wheat	B
mitochondria	O
but	O
no	O
splicing	O
was	O
observed	O
(	O
Figure	O
6B	O
)	O
.	O

Unexpectedly	O
,	O
wheat	B
mitochondria	O
appear	O
to	O
be	O
unable	O
to	O
edit	O
the	O
cognate	O
C259	O
site	O
when	O
the	O
−16	O
/	O
+6	O
region	O
is	O
located	O
on	O
a	O
potato	B
rps10	O
precursor	O
.	O

The	O
control	O
CM	O
construct	O
,	O
containing	O
the	O
C259	O
site	O
grafted	O
in	O
a	O
different	O
context	O
but	O
in	O
its	O
own	O
cox2	O
gene	O
,	O
was	O
expressed	O
,	O
spliced	O
and	O
edited	O
as	O
expected	O
[	O
(	O
17	O
)	O
,	O
Figure	O
6B	O
and	O
D	O
]	O
.	O

To	O
compare	O
the	O
editing	O
status	O
of	O
RNAs	O
at	O
the	O
same	O
stage	O
of	O
processing	O
,	O
the	O
editing	O
status	O
of	O
the	O
inserted	O
C259	O
site	O
in	O
precursor	O
cox2	O
transcripts	O
is	O
shown	O
(	O
Figure	O
6D	O
)	O
.	O

The	O
analogous	O
MAb	O
and	O
ME6b	O
constructs	O
,	O
containing	O
the	O
S.tuberosum	B
cox2	O
promoter	O
and	O
the	O
C259	O
region	O
inserted	O
into	O
rps10	O
exon	O
1	O
and	O
intron	O
were	O
used	O
to	O
electroporate	O
potato	B
mitochondria	O
.	O

As	O
shown	O
in	O
Figure	O
6C	O
,	O
MAb	O
and	O
ME6b	O
were	O
expressed	O
and	O
spliced	O
at	O
the	O
same	O
level	O
as	O
the	O
control	O
in	O
the	O
homologous	O
context	O
,	O
indicating	O
that	O
insertion	O
does	O
not	O
affect	O
the	O
splicing	O
process	O
.	O

Interestingly	O
,	O
while	O
C259	O
insertion	O
was	O
not	O
recognized	O
in	O
wheat	B
mitochondria	O
(	O
Figure	O
6D	O
)	O
,	O
the	O
potato	B
RNA	O
editing	O
machinery	O
edited	O
the	O
inserted	O
C259	O
region	O
(	O
Figure	O
6E	O
)	O
.	O

The	O
C259	O
region	O
inserted	O
in	O
the	O
rps10	O
intron	O
(	O
construct	O
ME6b	O
)	O
was	O
also	O
edited	O
,	O
although	O
at	O
a	O
very	O
low	O
level	O
,	O
showing	O
that	O
editing	O
may	O
precede	O
intron	O
removal	O
(	O
not	O
shown	O
)	O
.	O

DISCUSSION	O
Plant	O
mitochondria	O
undergo	O
complex	O
expression	O
mechanisms	O
which	O
are	O
poorly	O
understood	O
.	O

Most	O
studies	O
are	O
based	O
on	O
analysis	O
of	O
in	O
vivo	O
mature	O
or	O
intermediate	O
gene	O
products	O
giving	O
clues	O
on	O
possible	O
mechanisms	O
and	O
suggesting	O
pathways	O
operating	O
in	O
gene	O
expression	O
.	O

Direct	O
tests	O
using	O
in	O
vitro	O
approaches	O
have	O
been	O
fruitful	O
(	O
4,5,24	O
)	O
,	O
but	O
are	O
hampered	O
by	O
the	O
difficulty	O
of	O
obtaining	O
active	O
mitochondrial	O
extracts	O
.	O

Previously	O
,	O
we	O
devised	O
an	O
experimental	O
model	O
based	O
on	O
electroporation	O
of	O
isolated	O
mitochondria	O
that	O
allows	O
us	O
to	O
test	O
gene	O
expression	O
of	O
wild	O
-	O
type	O
and	O
mutant	O
genes	O
.	O

This	O
approach	O
has	O
been	O
very	O
useful	O
in	O
elucidating	O
the	O
process	O
of	O
RNA	O
maturation	O
in	O
plant	O
mitochondria	O
,	O
in	O
particular	O
splicing	O
and	O
editing	O
(	O
14,15	O
)	O
.	O

The	O
aim	O
of	O
this	O
work	O
was	O
to	O
analyse	O
different	O
gene	O
expression	O
events	O
when	O
a	O
foreign	O
gene	O
was	O
expressed	O
in	O
a	O
heterologous	O
context	O
.	O

rps10	O
was	O
chosen	O
precisely	O
because	O
this	O
genetic	O
information	O
is	O
lacking	O
in	O
wheat	B
mitochondria	O
but	O
is	O
active	O
in	O
potato	B
mitochondria	O
(	O
20,23,25	O
)	O
.	O

Moreover	O
,	O
rps10	O
transcripts	O
undergo	O
five	O
C	O
-	O
to	O
-	O
U	O
editing	O
events	O
in	O
potato	B
mitochondria	O
and	O
rps10	O
contains	O
an	O
intron	O
,	O
thus	O
facilitating	O
the	O
analysis	O
of	O
post	O
-	O
transcriptional	O
processing	O
.	O

To	O
best	O
evaluate	O
the	O
expression	O
of	O
rps10	O
in	O
the	O
non	O
-	O
cognate	O
mitochondria	O
,	O
it	O
was	O
necessary	O
to	O
set	O
up	O
electroporation	O
conditions	O
for	O
introducing	O
foreign	O
DNA	O
into	O
S.tuberosum	B
mitochondria	O
.	O

Potato	B
tuber	O
mitochondria	O
were	O
able	O
to	O
incorporate	O
DNA	O
essentially	O
under	O
the	O
same	O
conditions	O
described	O
for	O
wheat	B
embryo	O
organelles	O
(	O
14	O
)	O
,	O
except	O
that	O
the	O
optimal	O
voltage	O
range	O
was	O
larger	O
.	O

A	O
major	O
difference	O
to	O
wheat	B
was	O
that	O
isolated	O
potato	B
mitochondria	O
were	O
viable	O
for	O
3–4	O
h	O
as	O
measured	O
by	O
oxygen	O
consumption	O
(	O
data	O
not	O
shown	O
)	O
.	O

Thus	O
,	O
to	O
observe	O
transcript	O
maturation	O
after	O
electroporation	O
the	O
incubation	O
mixture	O
needed	O
to	O
be	O
supplemented	O
with	O
fatty	O
acid	O
-	O
free	O
BSA	O
(	O
see	O
Figure	O
4	O
)	O
.	O

This	O
behaviour	O
probably	O
reflects	O
the	O
uncoupling	O
of	O
oxidative	O
phosphorylation	O
by	O
fatty	O
acids	O
during	O
incubation	O
of	O
potato	B
mitochondria	O
(	O
26	O
)	O
.	O

In	O
fact	O
,	O
previously	O
we	O
found	O
that	O
proper	O
gene	O
expression	O
in	O
isolated	O
mitochondria	O
requires	O
a	O
functional	O
organelle	O
able	O
to	O
generate	O
ATP	O
from	O
ADP	O
and	O
succinate	O
(	O
14	O
)	O
.	O

An	O
interesting	O
observation	O
was	O
that	O
neither	O
the	O
wheat	B
nor	O
the	O
potato	B
cox2	O
promoters	O
were	O
recognized	O
in	O
a	O
heterologous	O
context	O
(	O
Figure	O
4A	O
and	O
B	O
)	O
.	O

This	O
situation	O
might	O
by	O
explained	O
by	O
the	O
fact	O
that	O
potato	B
and	O
wheat	B
promoter	O
sequences	O
have	O
no	O
recognizable	O
homologous	O
motifs	O
.	O

Plant	O
mitochondria	O
promoters	O
are	O
characterized	O
by	O
a	O
conserved	O
core	O
CRTA	O
sequence	O
with	O
differences	O
in	O
the	O
extent	O
and	O
the	O
composition	O
of	O
sequences	O
around	O
the	O
consensus	O
motif	O
(	O
27,28	O
)	O
.	O

While	O
the	O
transcription	O
initiation	O
site	O
in	O
wheat	B
mitochondria	O
is	O
located	O
at	O
position	O
−170	O
(	O
29	O
)	O
,	O
the	O
potato	B
promoter	O
has	O
not	O
yet	O
been	O
described	O
.	O

Transcription	O
may	O
be	O
initiated	O
at	O
numerous	O
sites	O
suggesting	O
a	O
relaxed	O
promoter	O
recognition	O
by	O
the	O
transcription	O
machinery	O
(	O
28	O
)	O
.	O

However	O
,	O
the	O
lack	O
of	O
crossed	O
recognition	O
of	O
cox2	O
promoters	O
in	O
wheat	B
and	O
potato	B
is	O
not	O
a	O
general	O
situation	O
since	O
the	O
A.thaliana	B
cox2	O
gene	O
is	O
expressed	O
and	O
spliced	O
when	O
introduced	O
into	O
maize	B
mitochondria	O
,	O
indicating	O
that	O
the	O
Arabidopsis	B
gene	O
shares	O
some	O
signals	O
with	O
maize	B
cox2	O
promoter	O
that	O
are	O
sufficient	O
for	O
transcription	O
(	O
18	O
)	O
.	O

The	O
sites	O
required	O
for	O
transcript	O
initiation	O
have	O
been	O
recently	O
described	O
in	O
A.thaliana	B
mitochondrial	O
genes	O
(	O
28	O
)	O
.	O

Three	O
regions	O
were	O
described	O
as	O
important	O
for	O
transcription	O
initiation	O
.	O

We	O
found	O
no	O
such	O
homologous	O
sequences	O
in	O
the	O
potato	B
cox2	O
upstream	O
region	O
indicating	O
that	O
the	O
two	O
dicot	O
promoters	O
do	O
not	O
have	O
the	O
same	O
origin	O
.	O

This	O
in	O
turn	O
may	O
reflect	O
the	O
natural	O
history	O
of	O
this	O
particular	O
mitochondrial	O
gene	O
evolving	O
in	O
its	O
own	O
context	O
.	O

It	O
should	O
be	O
mentioned	O
that	O
the	O
presence	O
of	O
a	O
conserved	O
sequence	O
is	O
not	O
sufficient	O
for	O
expression	O
since	O
a	O
region	O
that	O
acts	O
as	O
promoter	O
in	O
Arabidopsis	B
,	O
potato	B
and	O
Oenothera	O
is	O
inactive	O
in	O
vivo	O
in	O
pea	B
(	O
30	O
)	O
.	O

Further	O
studies	O
will	O
be	O
required	O
to	O
understand	O
the	O
transcriptional	O
events	O
in	O
plant	O
mitochondria	O
.	O

Electroporation	O
of	O
foreign	O
DNA	O
into	O
isolated	O
mitochondria	O
provides	O
an	O
interesting	O
functional	O
model	O
,	O
complementary	O
to	O
in	O
vitro	O
transcription	O
assay	O
,	O
for	O
answering	O
these	O
questions	O
.	O

The	O
potato	B
rps10	O
gene	O
controlled	O
by	O
a	O
T.aestivum	B
promoter	O
(	O
Figure	O
1A	O
)	O
was	O
transcribed	O
as	O
a	O
1204	O
nt	O
precursor	O
in	O
wheat	B
mitochondria	O
,	O
but	O
no	O
traces	O
of	O
mature	O
RNA	O
were	O
observed	O
.	O

Moreover	O
,	O
the	O
five	O
C	O
residues	O
reported	O
as	O
RNA	O
editing	O
targets	O
in	O
vivo	O
(	O
23	O
)	O
remain	O
unchanged	O
,	O
indicating	O
that	O
rps10	O
transcript	O
was	O
not	O
recognized	O
by	O
the	O
wheat	B
splicing	O
and	O
editing	O
machinery	O
.	O

A	O
control	O
using	O
the	O
cognate	O
cox2	O
construct	O
demonstrates	O
that	O
electroporated	O
organelles	O
were	O
competent	O
for	O
splicing	O
and	O
editing	O
(	O
Figure	O
1B	O
and	O
C	O
)	O
.	O

Some	O
editing	O
events	O
occur	O
in	O
highly	O
structured	O
domains	O
of	O
introns	O
.	O

Because	O
in	O
some	O
cases	O
,	O
editing	O
corrects	O
A	O
-	O
C	O
mispairing	O
improving	O
conformation	O
of	O
the	O
intron	O
,	O
it	O
has	O
been	O
proposed	O
that	O
the	O
C	O
-	O
to	O
-	O
U	O
change	O
might	O
be	O
necessary	O
for	O
efficient	O
splicing	O
(	O
8,9,23,31	O
)	O
.	O

Based	O
on	O
the	O
canonical	O
structure	O
of	O
group	O
II	O
mitochondrial	O
introns	O
(	O
21	O
)	O
,	O
two	O
editing	O
sites	O
,	O
C2	O
located	O
at	O
the	O
Intron	O
Binding	O
Site	O
2	O
(	O
IBS2	O
)	O
and	O
C3	O
located	O
in	O
the	O
intron	O
,	O
nine	O
residues	O
downstream	O
from	O
the	O
end	O
of	O
exon	O
1	O
in	O
S.tuberosum	B
rps10	O
are	O
of	O
particular	O
interest	O
.	O

It	O
has	O
been	O
predicted	O
that	O
both	O
edited	O
residues	O
participate	O
in	O
base	O
-	O
pair	O
interactions	O
in	O
the	O
putative	O
secondary	O
structure	O
.	O

Of	O
particular	O
interest	O
is	O
the	O
site	O
C3	O
located	O
in	O
intron	O
domain	O
I	O
(	O
23	O
)	O
.	O

This	O
position	O
may	O
be	O
crucial	O
for	O
splicing	O
as	O
inferred	O
from	O
mutants	O
of	O
a	O
yeast	B
mitochondrial	O
intron	O
(	O
32	O
)	O
.	O

We	O
addressed	O
this	O
question	O
by	O
introducing	O
rps10	O
mutant	O
genes	O
presenting	O
C2	O
,	O
C3	O
or	O
both	O
positions	O
in	O
the	O
edited	O
form	O
into	O
mitochondria	O
.	O

As	O
shown	O
in	O
Figure	O
2	O
,	O
transcription	O
was	O
as	O
efficient	O
as	O
for	O
the	O
cognate	O
cox2	O
construct	O
but	O
neither	O
wild	O
-	O
type	O
rps10	O
nor	O
the	O
C	O
-	O
U	O
mutants	O
underwent	O
splicing	O
.	O

These	O
results	O
clearly	O
demonstrate	O
that	O
C2	O
and	O
C3	O
editing	O
is	O
not	O
sufficient	O
for	O
splicing	O
of	O
rps10	O
precursor	O
in	O
wheat	B
mitochondria	O
and	O
lead	O
us	O
to	O
conclude	O
that	O
splicing	O
failure	O
is	O
probably	O
linked	O
to	O
the	O
lack	O
of	O
trans	O
-	O
recognition	O
elements	O
.	O

One	O
may	O
speculate	O
that	O
these	O
trans	O
-	O
acting	O
factors	O
,	O
for	O
instance	O
nuclear	O
-	O
encoded	O
maturases	O
,	O
were	O
lost	O
after	O
rps10	O
was	O
transferred	O
to	O
the	O
nucleus	O
in	O
monocots	O
(	O
20,25	O
)	O
.	O

The	O
C	O
-	O
to	O
-	O
U	O
mutants	O
were	O
also	O
tested	O
in	O
potato	B
mitochondria	O
;	O
no	O
significant	O
differences	O
were	O
detected	O
in	O
splicing	O
efficiency	O
when	O
compared	O
to	O
the	O
unedited	O
construct	O
(	O
D.	O
Choury	O
,	O
unpublished	O
data	O
)	O
.	O

It	O
should	O
be	O
noted	O
that	O
the	O
lack	O
of	O
splicing	O
in	O
wheat	B
mitochondria	O
is	O
not	O
a	O
general	O
feature	O
of	O
potato	B
introns	O
,	O
since	O
the	O
potato	B
cox2	O
intron	O
is	O
removed	O
efficiently	O
(	O
Figure	O
4B	O
)	O
.	O

This	O
is	O
consistent	O
with	O
the	O
hypothesis	O
that	O
potato	B
and	O
wheat	B
mitochondria	O
have	O
similar	O
trans	O
-	O
acting	O
factors	O
for	O
cox2	O
intron	O
removal	O
.	O

A	O
possible	O
link	O
between	O
intron	O
removal	O
and	O
editing	O
has	O
been	O
proposed	O
for	O
splicing	O
of	O
nad1e	O
and	O
nad5III	O
trans	O
-	O
introns	O
where	O
domain	O
six	O
may	O
require	O
editing	O
to	O
be	O
structured	O
in	O
a	O
catalytic	O
competent	O
secondary	O
conformation	O
(	O
8)	O
.	O

In	O
rice	B
,	O
failure	O
of	O
RNA	O
maturation	O
and	O
editing	O
has	O
been	O
correlated	O
with	O
cytoplasmic	O
male	O
sterile	O
phenotype	O
.	O

In	O
this	O
model	O
,	O
the	O
absence	O
of	O
the	O
nuclear	O
gene	O
Rf-1	O
affects	O
B	O
-	O
atp6	O
RNA	O
cleavage	O
and	O
editing	O
(	O
33	O
)	O
.	O

In	O
organello	O
studies	O
have	O
shown	O
that	O
S.bicolor	B
atp6	O
-	O
1	O
gene	O
was	O
transcribed	O
but	O
not	O
edited	O
when	O
introduced	O
into	O
maize	B
mitochondria	O
(	O
18	O
)	O
.	O

However	O
,	O
partially	O
edited	O
molecules	O
were	O
detected	O
in	O
sorghum	B
-	O
maize	B
atp6	O
chimeric	O
transcripts	O
when	O
they	O
included	O
the	O
maize	B
atp6	O
5′-untranslated	O
sequence	O
,	O
suggesting	O
that	O
the	O
5′	O
non	O
-	O
coding	O
region	O
provides	O
a	O
structural	O
motif	O
or	O
binding	O
site	O
for	O
a	O
transcript	O
-	O
specific	O
editing	O
factor	O
(	O
34	O
)	O
.	O

Unfortunately	O
,	O
no	O
data	O
on	O
atp6	O
processing	O
was	O
reported	O
to	O
determine	O
whether	O
this	O
region	O
is	O
directly	O
involved	O
in	O
editing	O
or	O
some	O
other	O
maturation	O
event	O
.	O

Since	O
wheat	B
mitochondria	O
do	O
not	O
have	O
rps10	O
encoded	O
in	O
the	O
mitochondrial	O
genome	O
(	O
20	O
)	O
,	O
it	O
was	O
interesting	O
to	O
test	O
whether	O
wheat	B
mitochondria	O
were	O
able	O
to	O
recognize	O
editing	O
sites	O
which	O
had	O
been	O
lost	O
during	O
evolution	O
.	O

In	O
other	O
words	O
,	O
whether	O
the	O
mitochondrial	O
trans	O
-	O
recognition	O
elements	O
are	O
specific	O
for	O
each	O
site	O
or	O
whether	O
they	O
are	O
operating	O
on	O
a	O
subset	O
of	O
editing	O
sites	O
.	O

This	O
question	O
is	O
important	O
since	O
to	O
date	O
the	O
factors	O
responsible	O
for	O
RNA	O
editing	O
in	O
plant	O
mitochondria	O
remain	O
unknown	O
.	O

Solving	O
this	O
issue	O
may	O
provide	O
clues	O
to	O
uncover	O
such	O
factors	O
.	O

As	O
described	O
above	O
,	O
the	O
rps10	O
transcript	O
was	O
not	O
processed	O
in	O
wheat	B
but	O
it	O
was	O
correctly	O
spliced	O
in	O
cognate	O
mitochondria	O
(	O
Figure	O
5A	O
)	O
.	O

Indeed	O
,	O
the	O
mature	O
transcript	O
had	O
identical	O
exon1	O
and	O
exon2	O
junction	O
as	O
found	O
in	O
endogenous	O
rps10	O
mRNA	O
(	O
data	O
not	O
shown	O
)	O
.	O

More	O
importantly	O
,	O
all	O
editing	O
sites	O
,	O
C1	O
,	O
C2	O
,	O
C4	O
and	O
C5	O
were	O
significantly	O
converted	O
to	O
Us	O
(	O
Figure	O
5B	O
)	O
.	O

The	O
fact	O
that	O
the	O
four	O
editing	O
sites	O
were	O
found	O
either	O
edited	O
or	O
unedited	O
in	O
spliced	O
rps10	O
mRNA	O
is	O
an	O
indication	O
that	O
editing	O
does	O
not	O
precede	O
splicing	O
as	O
was	O
previously	O
found	O
for	O
cox2	O
in	O
wheat	B
(	O
15	O
)	O
.	O

It	O
may	O
be	O
argued	O
that	O
the	O
absence	O
of	O
splicing	O
precluded	O
editing	O
.	O

This	O
possibility	O
can	O
be	O
discarded	O
since	O
potato	B
rps10	O
precursor	O
mRNA	O
was	O
found	O
to	O
be	O
edited	O
in	O
vivo	O
(	O
23	O
)	O
.	O

These	O
data	O
clearly	O
show	O
that	O
splicing	O
is	O
not	O
required	O
for	O
rps10	O
editing	O
,	O
similar	O
to	O
previous	O
findings	O
for	O
cox2	O
mRNA	O
and	O
also	O
in	O
cox2	O
mutant	O
derivatives	O
unable	O
to	O
remove	O
the	O
intron	O
(	O
15	O
)	O
.	O

This	O
led	O
us	O
to	O
postulate	O
that	O
the	O
inability	O
of	O
wheat	B
mitochondria	O
to	O
recognize	O
rps10	O
editing	O
sites	O
is	O
likely	O
due	O
to	O
the	O
fact	O
that	O
wheat	B
mitochondria	O
have	O
lost	O
the	O
editing	O
trans	O
-	O
recognition	O
elements	O
which	O
become	O
dispensable	O
after	O
transfer	O
of	O
rps10	O
to	O
the	O
nucleus	O
.	O

To	O
test	O
this	O
possibility	O
,	O
rps10	O
chimeric	O
plasmids	O
containing	O
editing	O
site	O
C259	O
from	O
wheat	B
cox2	O
inserted	O
either	O
in	O
exon1	O
or	O
the	O
intron	O
were	O
constructed	O
.	O

Site	O
C259	O
is	O
formed	O
by	O
23	O
nt	O
corresponding	O
to	O
the	O
−16	O
/	O
+6	O
sequence	O
embedding	O
the	O
target	O
C.	O
Previously	O
we	O
found	O
that	O
this	O
small	O
region	O
could	O
be	O
recognized	O
by	O
the	O
RNA	O
editing	O
machinery	O
when	O
placed	O
outside	O
of	O
its	O
natural	O
context	O
(	O
16,17	O
)	O
.	O

The	O
wheat	B
C259	O
editing	O
site	O
in	O
the	O
chimeric	O
construct	O
was	O
correctly	O
edited	O
by	O
potato	B
mitochondria	O
.	O

This	O
result	O
is	O
not	O
unexpected	O
since	O
the	O
corresponding	O
region	O
in	O
endogenous	O
potato	B
cox2	O
mRNA	O
,	O
which	O
presents	O
two	O
differences	O
at	O
positions	O
−3	O
(	O
C	O
instead	O
of	O
A	O
)	O
and	O
−7	O
(	O
G	O
instead	O
of	O
A	O
)	O
,	O
is	O
edited	O
.	O

Furthermore	O
,	O
these	O
positions	O
were	O
not	O
crucial	O
for	O
editing	O
of	O
C259	O
(	O
17	O
)	O
.	O

Surprisingly	O
,	O
the	O
C259	O
editing	O
site	O
grafted	O
in	O
rps10	O
was	O
not	O
recognized	O
by	O
the	O
wheat	B
editing	O
machinery	O
.	O

We	O
can	O
not	O
exclude	O
the	O
possibility	O
that	O
editing	O
efficiency	O
in	O
precursor	O
molecules	O
is	O
very	O
low	O
and	O
so	O
is	O
undetectable	O
when	O
sequencing	O
RT	O
–	O
PCR	O
products	O
representing	O
a	O
pool	O
of	O
transcripts	O
.	O

However	O
,	O
analysis	O
of	O
the	O
same	O
region	O
in	O
cox2	O
precursors	O
indicates	O
that	O
this	O
was	O
not	O
the	O
case	O
since	O
significant	O
C	O
-	O
to	O
-	O
U	O
conversion	O
was	O
observed	O
(	O
Figure	O
6D	O
)	O
.	O

These	O
observations	O
lead	O
us	O
to	O
postulate	O
that	O
editing	O
is	O
occurring	O
only	O
when	O
the	O
transcript	O
is	O
engaged	O
in	O
post	O
-	O
transcriptional	O
processing	O
,	O
suggesting	O
that	O
rps10	O
transcripts	O
are	O
not	O
available	O
to	O
editing	O
factors	O
independently	O
of	O
the	O
RNA	O
maturation	O
machinery	O
.	O

The	O
fact	O
that	O
the	O
wheat	B
editing	O
site	O
C259	O
inserted	O
in	O
chimeric	O
rps10	O
transcripts	O
was	O
not	O
recognized	O
by	O
wheat	B
mitochondria	O
is	O
a	O
strong	O
argument	O
for	O
this	O
hypothesis	O
.	O

One	O
might	O
speculate	O
that	O
in	O
plant	O
mitochondria	O
,	O
transcripts	O
have	O
to	O
be	O
engaged	O
in	O
a	O
kind	O
of	O
multiprotein	O
processing	O
complex	O
.	O

A	O
failure	O
to	O
be	O
recognized	O
at	O
some	O
early	O
stage	O
will	O
lead	O
to	O
their	O
accumulation	O
as	O
unmodified	O
precursors	O
.	O

EndoNet	O
:	O
an	O
information	O
resource	O
about	O
endocrine	O
networks	O
Abstract	O
EndoNet	O
is	O
a	O
new	O
database	O
that	O
provides	O
information	O
about	O
the	O
components	O
of	O
endocrine	O
networks	O
and	O
their	O
relations	O
.	O

It	O
focuses	O
on	O
the	O
endocrine	O
cell	O
-	O
to	O
-	O
cell	O
communication	O
and	O
enables	O
the	O
analysis	O
of	O
intercellular	O
regulatory	O
pathways	O
in	O
humans	B
.	O

In	O
the	O
EndoNet	O
data	O
model	O
,	O
two	O
classes	O
of	O
components	O
span	O
a	O
bipartite	O
directed	O
graph	O
.	O

One	O
class	O
represents	O
the	O
hormones	O
(	O
in	O
the	O
broadest	O
sense	O
)	O
secreted	O
by	O
defined	O
donor	O
cells	O
.	O

The	O
other	O
class	O
consists	O
of	O
the	O
acceptor	O
or	O
target	O
cells	O
expressing	O
the	O
corresponding	O
hormone	O
receptors	O
.	O

The	O
identity	O
and	O
anatomical	O
environment	O
of	O
cell	O
types	O
,	O
tissues	O
and	O
organs	O
is	O
defined	O
through	O
references	O
to	O
the	O
CYTOMER	O
®	O
ontology	O
.	O

With	O
the	O
EndoNet	O
user	O
interface	O
,	O
it	O
is	O
possible	O
to	O
query	O
the	O
database	O
for	O
hormones	O
,	O
receptors	O
or	O
tissues	O
and	O
to	O
combine	O
several	O
items	O
from	O
different	O
search	O
rounds	O
in	O
one	O
complex	O
result	O
set	O
,	O
from	O
which	O
a	O
network	O
can	O
be	O
reconstructed	O
and	O
visualized	O
.	O

For	O
each	O
entity	O
,	O
a	O
detailed	O
characteristics	O
page	O
is	O
available	O
.	O

Some	O
well	O
-	O
established	O
endocrine	O
pathways	O
are	O
offered	O
as	O
showcases	O
in	O
the	O
form	O
of	O
predefined	O
result	O
sets	O
.	O

These	O
sets	O
can	O
be	O
used	O
as	O
a	O
starting	O
point	O
for	O
a	O
more	O
complex	O
query	O
or	O
for	O
obtaining	O
a	O
quick	O
overview	O
.	O

The	O
EndoNet	O
database	O
is	O
accessible	O
at	O
.	O

INTRODUCTION	O
Theoretical	O
analyses	O
in	O
the	O
post	O
-	O
sequencing	O
era	O
,	O
in	O
particular	O
in	O
the	O
context	O
of	O
systems	O
biology	O
approaches	O
,	O
increasingly	O
investigate	O
the	O
properties	O
of	O
all	O
kinds	O
of	O
pathways	O
and	O
networks	O
such	O
as	O
metabolic	O
and	O
signaling	O
pathways	O
.	O

It	O
is	O
commonly	O
accepted	O
that	O
we	O
need	O
formal	O
descriptions	O
of	O
these	O
networks	O
to	O
make	O
systematic	O
use	O
of	O
the	O
overwhelming	O
body	O
of	O
facts	O
gathered	O
over	O
decades	O
of	O
laboratory	O
work	O
both	O
in	O
narrow	O
or	O
global	O
scale	O
.	O

Corresponding	O
databases	O
have	O
been	O
created	O
and	O
are	O
available	O
now	O
for	O
metabolic	O
networks	O
(	O
KEGG	O
)	O
(	O
1,2	O
)	O
,	O
protein	O
interaction	O
networks	O
(	O
BIND	O
and	O
DIP	O
)	O
(	O
3,4	O
)	O
and	O
signaling	O
pathways	O
(	O
CSNDB	O
,	O
Patika	O
and	O
TRANSPATH	O
®	O
)	O
(	O
5–8	O
)	O
,	O
just	O
to	O
name	O
a	O
few	O
.	O

So	O
far	O
,	O
however	O
,	O
their	O
main	O
focus	O
is	O
on	O
intracellular	O
processes	O
.	O

Intercellular	O
signaling	O
is	O
addressed	O
only	O
insofar	O
as	O
usually	O
the	O
pathways	O
modeled	O
start	O
with	O
extracellular	O
ligands	O
,	O
and	O
as	O
there	O
exist	O
catalogs	O
and	O
databases	O
about	O
secreted	O
proteins	O
,	O
or	O
the	O
'	O
secretome	O
'	O
,	O
of	O
certain	O
systems	O
(	O
9–12	O
)	O
.	O

This	O
shortcoming	O
is	O
part	O
of	O
the	O
more	O
comprehensive	O
problem	O
,	O
the	O
genotype	O
–	O
phenotype	O
gap	O
:	O
from	O
a	O
certain	O
genotype	O
,	O
we	O
are	O
able	O
to	O
infer	O
a	O
'	O
molecular	O
phenotype	O
'	O
,	O
but	O
for	O
correlating	O
it	O
with	O
a	O
more	O
complex	O
phenotype	O
such	O
as	O
a	O
biological	O
process	O
,	O
or	O
even	O
a	O
certain	O
disease	O
and	O
its	O
clinical	O
appearance	O
,	O
we	O
still	O
depend	O
largely	O
on	O
the	O
mere	O
description	O
of	O
an	O
observed	O
correlation	O
.	O

There	O
is	O
no	O
way	O
to	O
infer	O
such	O
a	O
phenotype	O
through	O
all	O
the	O
different	O
layers	O
of	O
increasing	O
complexity	O
between	O
genomic	O
DNA	O
sequences	O
and	O
the	O
physiological	O
function	O
of	O
whole	O
organs	O
and	O
their	O
interplay	O
within	O
an	O
organism	O
.	O

There	O
may	O
be	O
principal	O
barriers	O
preventing	O
such	O
an	O
inference	O
across	O
different	O
complexity	O
levels	O
,	O
but	O
even	O
to	O
explore	O
these	O
limits	O
,	O
we	O
have	O
to	O
make	O
attempts	O
to	O
bridge	O
the	O
genotype	O
–	O
phenotype	O
gap	O
.	O

We	O
have	O
to	O
do	O
the	O
next	O
step	O
towards	O
modeling	O
intercellular	O
networks	O
that	O
are	O
inextricably	O
linked	O
to	O
the	O
physiology	O
of	O
multicellular	O
organisms	O
(	O
13	O
)	O
.	O

Being	O
one	O
of	O
the	O
most	O
complex	O
constructs	O
in	O
the	O
body	O
,	O
the	O
endocrine	O
system	O
comprises	O
numerous	O
cells	O
and	O
tissues	O
that	O
secrete	O
hormones	O
which	O
pass	O
through	O
the	O
body	O
,	O
activate	O
specific	O
receptors	O
of	O
target	O
cells	O
and	O
initiate	O
there	O
multiple	O
intracellular	O
signaling	O
pathways	O
.	O

Here	O
,	O
we	O
present	O
a	O
new	O
database	O
,	O
EndoNet	O
,	O
which	O
provides	O
information	O
about	O
the	O
components	O
of	O
endocrine	O
networks	O
and	O
their	O
relations	O
,	O
and	O
enables	O
the	O
analysis	O
of	O
intercellular	O
regulatory	O
pathways	O
in	O
humans	B
.	O

The	O
EndoNet	O
database	O
is	O
accessible	O
at	O
.	O

RESULTS	O
The	O
biological	O
schema	O
of	O
endocrine	O
actions	O
Development	O
and	O
function	O
of	O
different	O
organs	O
as	O
well	O
as	O
the	O
response	O
of	O
a	O
whole	O
multicellular	O
organism	O
to	O
its	O
environment	O
is	O
coordinated	O
through	O
a	O
complex	O
communication	O
system	O
between	O
specialized	O
cells	O
that	O
are	O
part	O
of	O
its	O
organs	O
.	O

This	O
communication	O
is	O
mostly	O
mediated	O
by	O
hormones	O
.	O

In	O
a	O
broader	O
sense	O
,	O
this	O
functional	O
class	O
of	O
biomolecules	O
also	O
comprises	O
growth	O
factors	O
,	O
cytokines	O
,	O
chemokines	O
and	O
other	O
signal	O
transmitters	O
.	O

This	O
generic	O
view	O
is	O
supported	O
,	O
for	O
instance	O
,	O
by	O
the	O
definition	O
given	O
for	O
'	O
hormone	O
activity	O
'	O
by	O
Gene	O
Ontology	O
(	O
GO	O
)	O
(	O
14	O
)	O
:	O
'	O
Any	O
substance	O
formed	O
in	O
very	O
small	O
amounts	O
in	O
one	O
specialized	O
organ	O
or	O
group	O
of	O
cells	O
and	O
carried	O
(	O
sometimes	O
in	O
the	O
bloodstream	O
)	O
to	O
another	O
organ	O
or	O
group	O
of	O
cells	O
,	O
in	O
the	O
same	O
organism	O
,	O
upon	O
which	O
it	O
has	O
a	O
specific	O
regulatory	O
action	O
'	O
.	O

This	O
definition	O
is	O
also	O
broad	O
enough	O
to	O
include	O
modes	O
of	O
hormonal	O
actions	O
as	O
diverse	O
as	O
endocrine	O
,	O
paracrine	O
and	O
autocrine	O
effects	O
.	O

Accordingly	O
,	O
with	O
the	O
term	O
'	O
hormone	O
'	O
one	O
might	O
refer	O
to	O
any	O
extracellular	O
substance	O
that	O
induces	O
specific	O
responses	O
in	O
target	O
cell	O
and	O
helps	O
to	O
coordinate	O
growth	O
,	O
differentiation	O
,	O
gene	O
expression	O
and	O
metabolic	O
activities	O
of	O
various	O
cells	O
,	O
tissues	O
and	O
organs	O
in	O
multicellular	O
organisms	O
(	O
15	O
)	O
.	O

Hormones	O
can	O
be	O
classified	O
based	O
on	O
their	O
chemical	O
nature	O
,	O
solubility	O
,	O
the	O
distance	O
over	O
which	O
the	O
signal	O
acts	O
and	O
so	O
on	O
(	O
15,16	O
)	O
.	O

From	O
the	O
viewpoint	O
of	O
genome	O
–	O
phenotype	O
relations	O
,	O
it	O
is	O
reasonable	O
to	O
distinguish	O
between	O
polypeptide	O
,	O
thus	O
,	O
genome	O
-	O
encoded	O
hormones	O
,	O
on	O
one	O
hand	O
,	O
and	O
those	O
low	O
-	O
molecular	O
weight	O
hormones	O
such	O
as	O
steroids	O
,	O
with	O
only	O
the	O
machinery	O
of	O
their	O
synthesis	O
being	O
genome	O
-	O
encoded	O
,	O
on	O
the	O
other	O
hand	O
.	O

Another	O
classification	O
of	O
hormones	O
,	O
which	O
seems	O
to	O
be	O
overlapping	O
with	O
the	O
previous	O
one	O
refers	O
to	O
the	O
intracellular	O
location	O
of	O
their	O
receptors	O
and	O
,	O
thus	O
,	O
how	O
the	O
subsequent	O
signal	O
is	O
further	O
transduced	O
:	O
membrane	O
-	O
bound	O
receptors	O
usually	O
trigger	O
more	O
or	O
less	O
complex	O
signaling	O
cascades	O
towards	O
the	O
nucleus	O
,	O
whereas	O
nuclear	O
receptors	O
,	O
mainly	O
bound	O
by	O
low	O
-	O
molecular	O
weight	O
hormones	O
,	O
have	O
a	O
very	O
short	O
signaling	O
pathway	O
downstream	O
since	O
they	O
act	O
as	O
transcription	O
factors	O
themselves	O
(	O
15,16	O
)	O
.	O

In	O
intercellular	O
communication	O
,	O
we	O
can	O
basically	O
differentiate	O
between	O
two	O
kinds	O
of	O
cells	O
:	O
donor	O
cells	O
which	O
synthesize	O
and	O
secrete	O
a	O
hormone	O
,	O
and	O
acceptor	O
cells	O
which	O
express	O
a	O
hormone	O
receptor	O
(	O
Figure	O
1a	O
)	O
.	O

Donor	O
cells	O
become	O
active	O
under	O
the	O
influence	O
of	O
an	O
external	O
,	O
mostly	O
environmental	O
,	O
stimulus	O
.	O

In	O
the	O
acceptor	O
cell	O
,	O
binding	O
of	O
the	O
hormone	O
to	O
a	O
receptor	O
triggers	O
an	O
intracellular	O
signal	O
transduction	O
cascade	O
with	O
different	O
kinds	O
of	O
end	O
nodes	O
and	O
effects	O
:	O
transcription	O
factors	O
affecting	O
the	O
gene	O
expression	O
program	O
of	O
the	O
acceptor	O
cell	O
,	O
metabolic	O
enzymes	O
controlling	O
the	O
cell	O
's	O
metabolism	O
,	O
structural	O
components	O
which	O
define	O
the	O
acceptor	O
's	O
morphological	O
features	O
,	O
or	O
components	O
of	O
the	O
secretory	O
apparatus	O
regulating	O
the	O
release	O
of	O
other	O
extracellular	O
molecules	O
.	O

If	O
synthesis	O
and	O
secretion	O
of	O
another	O
hormone	O
is	O
among	O
the	O
effects	O
exerted	O
by	O
receptor	O
activation	O
,	O
the	O
acceptor	O
is	O
turned	O
into	O
a	O
donor	O
cell	O
,	O
thus	O
becoming	O
an	O
internal	O
node	O
of	O
the	O
organism	O
's	O
endocrine	O
network	O
.	O

Acceptor	O
cells	O
which	O
do	O
not	O
become	O
producers	O
of	O
another	O
hormone	O
are	O
called	O
'	O
terminal	O
target	O
cells	O
'	O
of	O
the	O
endocrine	O
network	O
,	O
but	O
finally	O
constitute	O
the	O
overall	O
physiological	O
effect	O
of	O
the	O
respective	O
hormonal	O
pathway	O
,	O
or	O
simply	O
the	O
phenotype	O
(	O
Figure	O
1a	O
)	O
.	O

The	O
EndoNet	O
data	O
model	O
In	O
the	O
EndoNet	O
data	O
model	O
,	O
two	O
classes	O
of	O
entities	O
—	O
hormones	O
(	O
in	O
the	O
broadest	O
sense	O
)	O
and	O
their	O
acceptor	O
or	O
target	O
cells	O
expressing	O
the	O
corresponding	O
receptors	O
—	O
span	O
a	O
bipartite	O
directed	O
graph	O
.	O

Since	O
one	O
and	O
the	O
same	O
hormone	O
may	O
be	O
secreted	O
by	O
multiple	O
cell	O
types	O
(	O
donor	O
cells	O
)	O
,	O
each	O
such	O
secretion	O
event	O
is	O
represented	O
by	O
a	O
hormone	O
node	O
on	O
its	O
own	O
.	O

Similarly	O
,	O
each	O
cell	O
type	O
known	O
to	O
express	O
a	O
hormone	O
receptor	O
(	O
acceptor	O
cell	O
)	O
leads	O
to	O
an	O
individual	O
node	O
.	O

The	O
graph	O
's	O
edges	O
represent	O
hormone	O
transport	O
and	O
binding	O
to	O
a	O
receptor	O
(	O
intercellular	O
edges	O
)	O
,	O
on	O
one	O
hand	O
,	O
and	O
triggering	O
or	O
inhibition	O
of	O
hormone	O
secretion	O
by	O
a	O
receptor	O
activated	O
by	O
hormone	O
binding	O
(	O
intracellular	O
edges	O
)	O
,	O
on	O
the	O
other	O
hand	O
.	O

Optionally	O
,	O
an	O
edge	O
representing	O
the	O
transport	O
of	O
a	O
hormone	O
can	O
be	O
subdivided	O
by	O
introducing	O
the	O
transport	O
medium	O
(	O
usually	O
blood	O
)	O
as	O
an	O
additional	O
,	O
intermediary	O
node	O
.	O

Thus	O
,	O
in	O
the	O
conceptual	O
schema	O
of	O
the	O
EndoNet	O
database	O
(	O
Figure	O
1b	O
)	O
,	O
the	O
links	O
between	O
cells	O
/	O
organs	O
and	O
hormone	O
define	O
donor	O
cells	O
(	O
'	O
D	O
'	O
)	O
,	O
those	O
between	O
cells	O
/	O
organs	O
and	O
receptors	O
acceptor	O
cells	O
(	O
'	O
A	O
'	O
)	O
.	O

If	O
an	O
acceptor	O
cell	O
synthesizes	O
another	O
hormone	O
in	O
response	O
to	O
an	O
incoming	O
signal	O
,	O
it	O
becomes	O
an	O
internal	O
node	O
in	O
the	O
emerging	O
hormonal	O
network	O
.	O

In	O
EndoNet	O
,	O
the	O
pathway	O
between	O
a	O
hormone	O
receptor	O
expressed	O
in	O
an	O
acceptor	O
cell	O
and	O
a	O
hormone	O
synthesized	O
in	O
the	O
same	O
cell	O
(	O
intracellular	O
edge	O
)	O
is	O
handled	O
as	O
a	O
black	O
box	O
.	O

In	O
case	O
of	O
genome	O
-	O
encoded	O
peptide	O
hormones	O
,	O
cross	O
-	O
references	O
to	O
entries	O
in	O
the	O
TRANSPATH	O
®	O
database	O
,	O
which	O
describe	O
the	O
signaling	O
cascade	O
starting	O
from	O
the	O
hormone	O
's	O
receptor	O
and	O
ending	O
at	O
the	O
hormone	O
's	O
gene	O
,	O
are	O
provided	O
,	O
if	O
available	O
.	O

Datasets	O
on	O
non	O
-	O
peptide	O
hormones	O
will	O
in	O
future	O
be	O
enriched	O
by	O
a	O
specific	O
metabolic	O
add	O
-	O
on	O
which	O
will	O
include	O
references	O
to	O
the	O
databases	O
KEGG	O
(	O
1	O
)	O
and	O
BRENDA	O
(	O
17	O
)	O
,	O
allowing	O
for	O
further	O
characterization	O
of	O
the	O
steps	O
performed	O
during	O
the	O
hormone	O
's	O
synthesis	O
and	O
the	O
regulation	O
of	O
both	O
activity	O
and	O
expression	O
of	O
the	O
enzymes	O
involved	O
.	O

By	O
now	O
,	O
the	O
EndoNet	O
structure	O
already	O
allows	O
for	O
including	O
descriptions	O
of	O
the	O
physiological	O
effects	O
induced	O
by	O
hormone	O
binding	O
(	O
see	O
below	O
,	O
Future	O
Developments	O
)	O
.	O

The	O
contents	O
of	O
EndoNet	O
In	O
the	O
present	O
version	O
of	O
EndoNet	O
,	O
and	O
as	O
a	O
first	O
approach	O
,	O
we	O
consider	O
the	O
endocrine	O
(	O
hormonal	O
)	O
network	O
of	O
the	O
human	B
body	O
.	O

For	O
each	O
molecule	O
(	O
hormone	O
or	O
receptor	O
)	O
,	O
a	O
primary	O
name	O
and	O
synonyms	O
are	O
given	O
.	O

In	O
case	O
of	O
peptide	O
hormones	O
,	O
the	O
sequence	O
of	O
the	O
processed	O
polypeptide	O
,	O
rather	O
than	O
that	O
of	O
the	O
protein	O
precursor	O
,	O
is	O
specified	O
.	O

For	O
a	O
multimeric	O
protein	O
hormone	O
,	O
the	O
subunit	O
composition	O
as	O
well	O
as	O
the	O
sequences	O
of	O
all	O
subunits	O
are	O
stored	O
;	O
the	O
same	O
holds	O
true	O
for	O
hormone	O
receptors	O
.	O

Additionally	O
,	O
all	O
peptide	O
hormone	O
and	O
receptor	O
datasets	O
have	O
links	O
to	O
HumanPSD	O
™	O
(	O
18	O
)	O
and	O
to	O
the	O
Swiss	O
-	O
Prot	O
database	O
,	O
The	O
structures	O
of	O
non	O
-	O
peptide	O
hormones	O
can	O
be	O
accessed	O
through	O
the	O
corresponding	O
hyperlinks	O
to	O
the	O
KEGG	O
COMPOUND	O
section	O
.	O

Finally	O
,	O
all	O
molecules	O
may	O
have	O
links	O
to	O
the	O
TRANSPATH	O
®	O
database	O
.	O

As	O
described	O
,	O
EndoNet	O
utilizes	O
data	O
about	O
the	O
tissues	O
from	O
which	O
hormones	O
are	O
secreted	O
and	O
in	O
which	O
receptors	O
are	O
expressed	O
to	O
define	O
donor	O
and	O
acceptor	O
cells	O
,	O
respectively	O
.	O

The	O
identity	O
and	O
anatomical	O
environment	O
of	O
cell	O
types	O
,	O
tissues	O
and	O
organs	O
is	O
defined	O
through	O
references	O
to	O
the	O
CYTOMER	O
®	O
ontology	O
(	O
19,20	O
)	O
;	O
in	O
the	O
numerous	O
cases	O
where	O
the	O
receptors	O
are	O
ubiquitously	O
expressed	O
,	O
just	O
the	O
root	O
term	O
'	O
human	B
body	O
'	O
is	O
linked	O
.	O

Data	O
on	O
whether	O
a	O
hormone	O
's	O
synthesis	O
is	O
triggered	O
or	O
inhibited	O
by	O
another	O
hormone	O
through	O
its	O
respective	O
receptor	O
in	O
a	O
particular	O
cell	O
was	O
obtained	O
by	O
manual	O
selection	O
from	O
textbooks	O
[	O
e.g.	O
(	O
16	O
)	O
,	O
]	O
,	O
monographies	O
(	O
21	O
)	O
,	O
original	O
literature	O
,	O
the	O
EST	O
library	O
information	O
and	O
the	O
linked	O
databases	O
(	O
TRANSPATH	O
®	O
,	O
HumanPSD	O
™	O
and	O
Swiss	O
-	O
Prot	O
)	O
.	O

The	O
contents	O
of	O
EndoNet	O
are	O
summarized	O
in	O
Table	O
1	O
.	O

Web	O
interface	O
,	O
queries	O
and	O
visualization	O
EndoNet	O
can	O
be	O
accessed	O
through	O
the	O
WWW	O
via	O
a	O
JSP	O
-	O
based	O
web	O
interface	O
.	O

Hormones	O
,	O
receptors	O
and	O
tissues	O
can	O
be	O
queried	O
for	O
their	O
names	O
,	O
and	O
detailed	O
information	O
on	O
all	O
identified	O
components	O
is	O
available	O
through	O
individual	O
characteristics	O
pages	O
.	O

Each	O
hormone	O
's	O
individual	O
entry	O
page	O
displays	O
its	O
source	O
and	O
target	O
tissues	O
(	O
donor	O
and	O
acceptor	O
cells	O
)	O
as	O
well	O
as	O
its	O
receptors	O
,	O
along	O
with	O
some	O
molecular	O
data	O
.	O

Similarly	O
,	O
each	O
receptor	O
entry	O
exhibits	O
the	O
tissues	O
in	O
which	O
the	O
receptor	O
is	O
expressed	O
,	O
and	O
the	O
hormones	O
it	O
interacts	O
with	O
.	O

Finally	O
,	O
each	O
tissue	O
entry	O
lists	O
the	O
hormone	O
receptors	O
that	O
are	O
found	O
in	O
,	O
as	O
well	O
as	O
the	O
hormones	O
that	O
are	O
synthesized	O
and	O
secreted	O
by	O
the	O
tissue	O
.	O

It	O
is	O
also	O
indicated	O
whether	O
the	O
corresponding	O
tissue	O
exerts	O
gender	O
-	O
specific	O
properties	O
;	O
additional	O
information	O
based	O
on	O
the	O
CYTOMER	O
®	O
ontology	O
is	O
available	O
through	O
the	O
corresponding	O
link	O
on	O
the	O
tissue	O
detail	O
page	O
.	O

Instead	O
of	O
searching	O
for	O
a	O
name	O
of	O
a	O
hormone	O
,	O
one	O
can	O
also	O
browse	O
the	O
hierarchical	O
hormone	O
classification	O
featured	O
by	O
EndoNet	O
(	O
available	O
at	O
the	O
'	O
Search	O
'	O
page	O
)	O
.	O

Each	O
query	O
result	O
can	O
be	O
used	O
as	O
starting	O
point	O
for	O
an	O
extended	O
query	O
.	O

Different	O
items	O
of	O
interest	O
can	O
be	O
selected	O
and	O
added	O
to	O
a	O
common	O
result	O
set	O
.	O

Since	O
several	O
search	O
results	O
can	O
be	O
combined	O
,	O
it	O
is	O
possible	O
to	O
create	O
sets	O
with	O
multiple	O
search	O
parameters	O
.	O

At	O
any	O
step	O
of	O
this	O
incremental	O
retrieval	O
process	O
,	O
the	O
sets	O
of	O
hormones	O
,	O
receptors	O
and	O
tissues	O
obtained	O
so	O
far	O
can	O
be	O
used	O
as	O
starting	O
points	O
for	O
reconstructing	O
a	O
network	O
by	O
a	O
depth	O
-	O
first	O
graph	O
traversal	O
algorithm	O
.	O

The	O
maximum	O
number	O
of	O
steps	O
can	O
be	O
selected	O
separately	O
for	O
the	O
upstream	O
and	O
downstream	O
part	O
of	O
the	O
reconstruction	O
process	O
.	O

Subsequently	O
,	O
the	O
graph	O
will	O
be	O
displayed	O
using	O
a	O
Graphviz	O
-	O
based	O
visualization	O
method	O
[	O
(	O
22	O
)	O
,	O
]	O
.	O

In	O
the	O
resulting	O
image	O
,	O
hormones	O
and	O
receptors	O
are	O
represented	O
as	O
nodes	O
grouped	O
together	O
into	O
subgraphs	O
representing	O
the	O
tissues	O
(	O
cells	O
/	O
organs	O
)	O
they	O
are	O
secreted	O
from	O
or	O
expressed	O
in	O
,	O
respectively	O
(	O
Figure	O
2	O
)	O
.	O

Autocrine	O
loops	O
(	O
donor	O
and	O
acceptor	O
cell	O
being	O
identical	O
)	O
are	O
treated	O
specially	O
for	O
visualization	O
.	O

On	O
demand	O
,	O
the	O
hormones	O
'	O
transport	O
media	O
can	O
be	O
included	O
in	O
the	O
visualization	O
of	O
intercellular	O
edges	O
,	O
enabling	O
the	O
user	O
to	O
choose	O
between	O
different	O
complexities	O
of	O
output	O
.	O

Intracellular	O
edges	O
,	O
which	O
connect	O
a	O
receptor	O
to	O
a	O
hormone	O
,	O
represent	O
the	O
influence	O
of	O
a	O
receptor	O
's	O
activation	O
on	O
the	O
secretion	O
of	O
a	O
hormone	O
from	O
the	O
same	O
cell	O
and	O
are	O
displayed	O
differently	O
,	O
depending	O
on	O
whether	O
this	O
influence	O
is	O
triggering	O
or	O
inhibitory	O
in	O
nature	O
.	O

The	O
graph	O
is	O
displayed	O
as	O
a	O
clickable	O
image	O
map	O
,	O
linking	O
each	O
entity	O
to	O
its	O
detailed	O
characteristics	O
page	O
,	O
thus	O
making	O
the	O
database	O
entries	O
accessible	O
from	O
the	O
graphical	O
overview	O
of	O
a	O
network	O
,	O
too	O
.	O

The	O
graph	O
is	O
available	O
in	O
two	O
different	O
formats	O
:	O
PNG	O
and	O
SVG	O
.	O

While	O
virtually	O
every	O
browser	O
supports	O
PNG	O
(	O
a	O
'	O
pixel	O
'	O
or	O
'	O
bitmap	O
'	O
format	O
)	O
,	O
only	O
a	O
few	O
of	O
them	O
provide	O
a	O
zoom	O
functionality	O
for	O
bitmap	O
pictures	O
.	O

Scalable	O
vector	O
graphics	O
,	O
(	O
SVG	O
)	O
provides	O
more	O
functionality	O
(	O
including	O
perfect	O
image	O
quality	O
throughout	O
all	O
zoom	O
factors	O
)	O
,	O
but	O
until	O
now	O
most	O
browsers	O
do	O
not	O
support	O
SVG	O
natively	O
and	O
require	O
an	O
SVG	O
plugin	O
(	O
)	O
for	O
displaying	O
this	O
vector	O
-	O
based	O
format	O
.	O

Some	O
well	O
-	O
established	O
endocrine	O
pathways	O
are	O
offered	O
as	O
showcases	O
in	O
the	O
form	O
of	O
predefined	O
result	O
sets	O
.	O

For	O
instance	O
,	O
sets	O
representing	O
the	O
hypothalamic	O
–	O
hypophyseal	O
axis	O
with	O
a	O
focus	O
on	O
either	O
thyroid	O
hormones	O
,	O
adrenal	O
hormones	O
,	O
growth	O
hormones	O
or	O
prolactin	O
are	O
provided	O
.	O

These	O
predefined	O
sets	O
can	O
be	O
used	O
for	O
obtaining	O
a	O
quick	O
overview	O
or	O
as	O
starting	O
points	O
for	O
more	O
complex	O
queries	O
.	O

FUTURE	O
DEVELOPMENTS	O
Among	O
the	O
important	O
improvements	O
of	O
EndoNet	O
which	O
we	O
are	O
currently	O
working	O
on	O
is	O
the	O
possibility	O
to	O
represent	O
intercellular	O
communication	O
at	O
different	O
levels	O
of	O
the	O
hierarchical	O
organization	O
of	O
organs	O
,	O
tissues	O
and	O
cells	O
in	O
the	O
organism	O
,	O
as	O
well	O
as	O
to	O
distinguish	O
between	O
such	O
communications	O
in	O
male	O
and	O
female	O
organisms	O
.	O

These	O
options	O
will	O
be	O
introduced	O
by	O
a	O
tighter	O
integration	O
with	O
the	O
CYTOMER	O
-	O
based	O
ontology	O
(	O
19,20	O
)	O
.	O

The	O
next	O
step	O
will	O
be	O
to	O
expand	O
the	O
contents	O
of	O
EndoNet	O
towards	O
the	O
details	O
of	O
the	O
processes	O
occurring	O
in	O
the	O
transport	O
medium	O
,	O
usually	O
the	O
blood	O
.	O

Since	O
not	O
all	O
hormones	O
are	O
transported	O
as	O
free	O
molecules	O
and	O
some	O
hydrophobic	O
hormones	O
(	O
e.g.	O
steroids	O
and	O
thyroids	O
)	O
need	O
to	O
be	O
bound	O
to	O
specific	O
carrier	O
proteins	O
,	O
proper	O
description	O
of	O
such	O
transporters	O
and	O
their	O
interaction	O
with	O
the	O
corresponding	O
hormones	O
will	O
be	O
required	O
.	O

It	O
is	O
planned	O
to	O
involve	O
quantitative	O
data	O
about	O
the	O
regular	O
or	O
pathological	O
levels	O
of	O
the	O
hormones	O
,	O
the	O
overall	O
kinetics	O
of	O
each	O
hormone	O
in	O
the	O
blood	O
(	O
monotonous	O
decay	O
,	O
oscillating	O
concentrations	O
,	O
increase	O
in	O
response	O
to	O
certain	O
stimuli	O
,	O
etc	O
.	O
)	O
,	O
its	O
turnover	O
and	O
metabolic	O
products	O
,	O
etc	O
.	O

That	O
will	O
allow	O
utilization	O
of	O
EndoNet	O
contents	O
for	O
diagnostic	O
purposes	O
.	O

In	O
future	O
,	O
the	O
EndoNet	O
data	O
model	O
will	O
be	O
extended	O
in	O
order	O
to	O
incorporate	O
external	O
stimuli	O
(	O
e.g.	O
light	O
)	O
and	O
physiological	O
states	O
(	O
stress	O
,	O
age	O
,	O
etc	O
.	O
)	O
in	O
a	O
formalized	O
manner	O
,	O
allowing	O
to	O
determine	O
whether	O
or	O
not	O
and	O
in	O
which	O
quantity	O
a	O
hormone	O
will	O
be	O
secreted	O
under	O
the	O
given	O
circumstances	O
.	O

EndoNet	O
will	O
then	O
link	O
the	O
physiological	O
effects	O
of	O
hormones	O
with	O
the	O
intracellular	O
molecular	O
processes	O
leading	O
to	O
its	O
synthesis	O
and	O
secretion	O
in	O
the	O
donor	O
cells	O
,	O
and	O
to	O
the	O
effects	O
on	O
its	O
acceptor	O
cells	O
.	O

At	O
many	O
places	O
of	O
these	O
intracellular	O
and	O
intercellular	O
networks	O
,	O
genetically	O
determined	O
aberrations	O
may	O
cause	O
specific	O
,	O
sometimes	O
pathological	O
phenotypes	O
.	O

Thus	O
,	O
EndoNet	O
will	O
enable	O
to	O
bridge	O
the	O
gap	O
between	O
known	O
genotypes	O
and	O
their	O
molecular	O
and	O
clinical	O
phenotypes	O
in	O
this	O
area	O
of	O
medical	O
research	O
and	O
its	O
applications	O
.	O

DISCUSSION	O
At	O
its	O
present	O
state	O
,	O
EndoNet	O
provides	O
a	O
high	O
coverage	O
of	O
molecules	O
that	O
are	O
conventionally	O
considered	O
as	O
hormones	O
as	O
well	O
as	O
other	O
molecules	O
that	O
are	O
involved	O
in	O
intercellular	O
communication	O
,	O
such	O
as	O
growth	O
factors	O
,	O
lymphokines	O
and	O
chemokines	O
and	O
their	O
known	O
receptors	O
.	O

The	O
aim	O
of	O
the	O
database	O
is	O
to	O
provide	O
a	O
useful	O
resource	O
for	O
studying	O
the	O
principal	O
features	O
of	O
hormonal	O
networks	O
in	O
a	O
comprehensive	O
way	O
,	O
as	O
it	O
was	O
done	O
more	O
exemplarily	O
in	O
the	O
past	O
for	O
these	O
kinds	O
of	O
networks	O
(	O
23	O
)	O
,	O
but	O
was	O
done	O
globally	O
for	O
many	O
other	O
intracellular	O
network	O
types	O
,	O
such	O
as	O
metabolic	O
,	O
protein	O
interaction	O
and	O
transcription	O
networks	O
[	O
reviewed	O
in	O
(	O
24,25	O
)	O
]	O
.	O

EndoNet	O
database	O
certainly	O
is	O
not	O
yet	O
complete	O
but	O
will	O
grow	O
rapidly	O
.	O

Plasma	O
D	O
-	O
dimer	O
concentration	O
in	O
patients	O
with	O
systemic	O
sclerosis	O
Abstract	O
Background	O
Systemic	O
sclerosis	O
(	O
SSc	O
)	O
is	O
an	O
autoimmune	O
disorder	O
of	O
the	O
connective	O
tissue	O
characterized	O
by	O
widespread	O
vascular	O
lesions	O
and	O
fibrosis	O
.	O

Little	O
is	O
known	O
so	O
far	O
on	O
the	O
activation	O
of	O
the	O
hemostatic	O
and	O
fibrinolytic	O
systems	O
in	O
SSc	O
,	O
and	O
most	O
preliminary	O
evidences	O
are	O
discordant	O
.	O

Methods	O
To	O
verify	O
whether	O
SSc	O
patients	O
might	O
display	O
a	O
prothrombotic	O
condition	O
,	O
plasma	O
D	O
-	O
dimer	O
was	O
assessed	O
in	O
28	O
consecutive	O
SSc	O
patients	O
and	O
in	O
33	O
control	O
subjects	O
,	O
matched	O
for	O
age	O
,	O
sex	O
and	O
environmental	O
habit	O
.	O

Results	O
and	O
discussion	O
When	O
compared	O
to	O
healthy	O
controls	O
,	O
geometric	O
mean	O
and	O
95	O
%	O
confidence	O
interval	O
(	O
IC95	O
%	O
)	O
of	O
plasma	O
D	O
-	O
dimer	O
were	O
significantly	O
increased	O
in	O
SSc	O
patients	O
(	O
362	O
ng	O
/	O
mL	O
,	O
IC	O
95	O
%	O
:	O
361–363	O
ng	O
/	O
mL	O
vs	O
229	O
ng	O
/	O
mL	O
,	O
IC95	O
%	O
:	O
228–231	O
ng	O
/	O
mL	O
,	O
p	O
=	O
0.005	O
)	O
.	O

After	O
stratifying	O
SSc	O
patients	O
according	O
to	O
disease	O
subset	O
,	O
no	O
significant	O
differences	O
were	O
observed	O
between	O
those	O
with	O
limited	O
cutaneous	O
pattern	O
and	O
controls	O
,	O
whereas	O
patients	O
with	O
diffuse	O
cutaneous	O
pattern	O
displayed	O
substantially	O
increased	O
values	O
.	O

No	O
correlation	O
was	O
found	O
between	O
plasma	O
D	O
-	O
dimer	O
concentration	O
and	O
age	O
,	O
sex	O
,	O
autoantibody	O
pattern	O
,	O
serum	O
creatinine	O
,	O
erythrosedimentation	O
rate	O
,	O
nailfold	O
videocapillaroscopic	O
pattern	O
and	O
pulmonary	O
involvement	O
.	O

Conclusion	O
We	O
demonstrated	O
that	O
SSc	O
patients	O
with	O
diffuse	O
subset	O
are	O
characterized	O
by	O
increased	O
plasma	O
D	O
-	O
dimer	O
values	O
,	O
reflecting	O
a	O
potential	O
activation	O
of	O
both	O
the	O
hemostatic	O
and	O
fibrinolytic	O
cascades	O
,	O
which	O
might	O
finally	O
predispose	O
these	O
patients	O
to	O
thrombotic	O
complications	O
.	O

Background	O
Systemic	O
sclerosis	O
(	O
SSc	O
)	O
is	O
an	O
autoimmune	O
disorder	O
of	O
the	O
connective	O
tissue	O
characterized	O
by	O
widespread	O
vascular	O
lesions	O
and	O
fibrosis	O
.	O

In	O
SSc	O
,	O
vasospasm	O
causes	O
frequent	O
episodes	O
of	O
reperfusion	O
injury	O
and	O
free	O
radical	O
-	O
mediated	O
endothelial	O
dysfunction	O
,	O
which	O
might	O
finally	O
influence	O
the	O
onset	O
of	O
local	O
thrombotic	O
complications	O
.	O

The	O
characteristic	O
vascular	O
involvement	O
affects	O
primarily	O
small	O
arteries	O
and	O
capillaries	O
,	O
causing	O
reduced	O
blood	O
flow	O
and	O
tissue	O
ischemia	O
and	O
supporting	O
the	O
typical	O
clinical	O
manifestations	O
of	O
this	O
unique	O
autoimmune	O
disorder	O
[	O
1	O
]	O
.	O

However	O
,	O
mechanisms	O
involved	O
in	O
the	O
endothelial	O
injury	O
are	O
as	O
yet	O
elusive	O
and	O
most	O
biochemical	O
evidences	O
are	O
often	O
inconclusive	O
or	O
controversial	O
.	O

Some	O
earlier	O
investigations	O
suggested	O
that	O
SSc	O
patients	O
might	O
be	O
characterized	O
by	O
a	O
procoagulant	O
state	O
,	O
reporting	O
depressed	O
basal	O
and	O
stimulated	O
fibrinolytic	O
activity	O
,	O
while	O
others	O
studies	O
have	O
reported	O
normal	O
plasma	O
fibrinolytic	O
activity	O
and	O
normal	O
skin	O
and	O
plasma	O
tissue	O
plasminogen	O
activator	O
(	O
tPA	O
)	O
levels	O
[	O
2	O
-	O
4	O
]	O
.	O

It	O
has	O
been	O
also	O
reported	O
that	O
the	O
lack	O
of	O
a	O
consistent	O
and	O
homogenous	O
increase	O
of	O
some	O
fibrinolytic	O
markers	O
,	O
in	O
the	O
presence	O
of	O
normal	O
levels	O
of	O
antithrombin	O
,	O
might	O
indirectly	O
highlight	O
an	O
impairment	O
of	O
the	O
heparan	O
sulphate	O
-	O
antithrombin	O
system	O
,	O
which	O
would	O
finally	O
promote	O
thrombin	O
generation	O
[	O
3	O
]	O
.	O

Conversely	O
,	O
Cerinic	O
and	O
colleagues	O
provided	O
evidence	O
that	O
fibrinolysis	O
might	O
be	O
impaired	O
in	O
SSc	O
,	O
as	O
shown	O
by	O
reduced	O
D	O
-	O
dimer	O
and	O
decreased	O
levels	O
of	O
plasminogen	O
activator	O
inhibitor	O
[	O
4	O
]	O
.	O

In	O
synthesis	O
,	O
there	O
are	O
no	O
conclusive	O
evidences	O
on	O
the	O
activity	O
of	O
the	O
hemostatic	O
and	O
fibrinolytic	O
pathways	O
in	O
SSc	O
so	O
far	O
.	O

D	O
-	O
dimer	O
,	O
a	O
breakdown	O
product	O
of	O
cross	O
-	O
linked	O
fibrin	O
,	O
was	O
proven	O
useful	O
for	O
the	O
diagnostic	O
evaluation	O
of	O
several	O
thrombotic	O
disorders	O
.	O

Moreover	O
,	O
an	O
increased	O
D	O
-	O
dimer	O
value	O
in	O
plasma	O
is	O
a	O
reliable	O
marker	O
of	O
a	O
systemic	O
prothrombotic	O
state	O
,	O
likely	O
superior	O
to	O
alternative	O
fibrinolytic	O
markers	O
,	O
and	O
its	O
measurement	O
might	O
be	O
helpful	O
in	O
predicting	O
or	O
preventing	O
thrombotic	O
events	O
in	O
the	O
single	O
patient	O
[	O
5	O
]	O
.	O

Therefore	O
,	O
to	O
investigate	O
whether	O
SSc	O
patients	O
might	O
be	O
characterized	O
by	O
a	O
potential	O
prothrombotic	O
condition	O
,	O
plasma	O
D	O
-	O
dimer	O
vales	O
were	O
measured	O
in	O
a	O
subset	O
of	O
SSc	O
patients	O
,	O
compared	O
with	O
those	O
of	O
a	O
healthy	O
matched	O
control	O
population	O
and	O
further	O
associated	O
with	O
SSc	O
disease	O
subset	O
.	O

Methods	O
Plasma	O
D	O
-	O
dimer	O
was	O
measured	O
in	O
28	O
consecutive	O
SSc	O
patients	O
(	O
2	O
males	O
and	O
26	O
females	O
;	O
mean	O
age	O
50	O
±	O
15	O
years	O
,	O
17	O
with	O
limited	O
and	O
11	O
with	O
diffuse	O
disease	O
patterns	O
)	O
,	O
who	O
fulfilled	O
the	O
American	O
Rheumatism	O
Association	O
's	O
criteria	O
for	O
the	O
diagnosis	O
of	O
SSc	O
[	O
6	O
]	O
and	O
in	O
33	O
control	O
subjects	O
,	O
matched	O
for	O
age	O
(	O
48	O
±	O
13	O
years	O
)	O
,	O
sex	O
(	O
3	O
males	O
,	O
30	O
females	O
)	O
and	O
environmental	O
habit	O
,	O
recruited	O
among	O
healthy	O
hospital	O
personnel	O
.	O

Samples	O
were	O
collected	O
in	O
the	O
morning	O
;	O
all	O
subjects	O
were	O
in	O
a	O
fasted	O
state	O
.	O

The	O
research	O
was	O
carried	O
out	O
according	O
to	O
the	O
principles	O
of	O
the	O
Declaration	O
of	O
Helsinki	O
and	O
an	O
informed	O
consent	O
for	O
testing	O
was	O
received	O
from	O
all	O
individuals	O
recruited	O
to	O
the	O
study	O
.	O

Blood	O
was	O
collected	O
after	O
an	O
overnight	O
fast	O
into	O
siliconized	O
vacuum	O
tubes	O
,	O
containing	O
0.105	O
mol	O
/	O
l	O
sodium	O
citrate	O
(	O
Becton	O
-	O
Dickinson	O
,	O
Oxford	O
,	O
UK	O
)	O
.	O

Samples	O
were	O
gently	O
mixed	O
and	O
centrifuged	O
for	O
10	O
min	O
at	O
15	O
°	O
C	O
at	O
1500	O
×	O
g	O
;	O
plasma	O
was	O
separated	O
and	O
stored	O
in	O
aliquots	O
at	O
-70	O
°	O
C	O
until	O
measurement	O
.	O

Plasma	O
D	O
-	O
dimer	O
was	O
measured	O
employing	O
Vidas	O
DD	O
,	O
a	O
rapid	O
and	O
quantitative	O
automated	O
enzyme	O
linked	O
immunosorbent	O
assay	O
with	O
fluorescent	O
detection	O
,	O
on	O
the	O
Mini	O
Vidas	O
immunoanalyzer	O
(	O
bioMerieux	O
,	O
Marcy	O
l'Etoile	O
,	O
France	O
)	O
.	O

Analytical	O
imprecision	O
,	O
expressed	O
in	O
terms	O
of	O
mean	O
inter	O
-	O
assay	O
coefficient	O
of	O
variation	O
(	O
CV	O
)	O
,	O
was	O
quoted	O
by	O
the	O
manufacturer	O
as	O
being	O
lower	O
than	O
5	O
%	O
.	O

Significance	O
of	O
differences	O
between	O
samples	O
was	O
assessed	O
,	O
following	O
logarithmic	O
conversion	O
of	O
data	O
,	O
by	O
parametric	O
tests	O
(	O
Student	O
's	O
t	O
-	O
test	O
,	O
ANOVA	O
test	O
,	O
Pearson	O
's	O
correlation	O
)	O
;	O
the	O
level	O
of	O
statistical	O
significance	O
was	O
set	O
at	O
p	O
<	O
0.05	O
.	O

Results	O
and	O
discussion	O
When	O
compared	O
to	O
healthy	O
controls	O
,	O
geometric	O
mean	O
and	O
95	O
%	O
confidence	O
interval	O
(	O
IC95	O
%	O
)	O
of	O
plasma	O
D	O
-	O
dimer	O
concentration	O
appeared	O
significantly	O
increased	O
in	O
SSc	O
patients	O
(	O
362	O
ng	O
/	O
mL	O
,	O
IC	O
95	O
%	O
:	O
361–363	O
ng	O
/	O
mL	O
vs	O
229	O
ng	O
/	O
mL	O
,	O
IC95	O
%	O
:	O
228–231	O
ng	O
/	O
mL	O
,	O
p	O
=	O
0.005	O
)	O
.	O

After	O
stratifying	O
SSc	O
patients	O
according	O
to	O
disease	O
subset	O
,	O
no	O
significant	O
differences	O
were	O
observed	O
between	O
those	O
with	O
limited	O
cutaneous	O
pattern	O
(	O
lcSSc	O
)	O
and	O
controls	O
(	O
geometric	O
mean	O
plasma	O
D	O
-	O
dimer	O
:	O
283	O
ng	O
/	O
mL	O
,	O
IC95	O
%	O
:	O
282–285	O
ng	O
/	O
mL	O
;	O
p	O
=	O
0.61	O
)	O
,	O
whereas	O
patients	O
with	O
diffuse	O
cutaneous	O
pattern	O
(	O
dcSSc	O
)	O
displayed	O
substantially	O
increased	O
values	O
(	O
geometric	O
mean	O
plasma	O
D	O
-	O
dimer	O
:	O
538	O
ng	O
/	O
mL	O
,	O
IC95	O
%	O
:	O
536–539	O
ng	O
/	O
mL	O
;	O
p	O
<	O
0.001	O
)	O
.	O

Additionally	O
,	O
patients	O
with	O
active	O
disease	O
,	O
as	O
evaluated	O
according	O
to	O
the	O
European	O
Scleroderma	O
Study	O
Group	O
criteria	O
[	O
7	O
]	O
,	O
displayed	O
higher	O
D	O
-	O
dimer	O
levels	O
as	O
compared	O
to	O
patients	O
with	O
inactive	O
disease	O
(	O
p	O
=	O
0.027	O
)	O
.	O

As	O
further	O
shown	O
in	O
table	O
1	O
,	O
D	O
-	O
dimer	O
concentration	O
correlated	O
significantly	O
with	O
the	O
modified	O
Rodnan	O
total	O
skin	O
score	O
(	O
TSS	O
)	O
and	O
the	O
forced	O
vital	O
capacity	O
(	O
FVC	O
)	O
.	O

No	O
correlation	O
was	O
observed	O
between	O
plasma	O
D	O
-	O
dimer	O
concentration	O
and	O
age	O
,	O
sex	O
,	O
autoantibody	O
pattern	O
,	O
serum	O
creatinine	O
,	O
erythrosedimentation	O
rate	O
,	O
nailfold	O
videocapillaroscopic	O
pattern	O
and	O
pulmonary	O
involvement	O
,	O
ascertained	O
according	O
to	O
the	O
score	O
proposed	O
by	O
Medsger	O
et	O
al	O
[	O
8	O
]	O
.	O

The	O
pathogenesis	O
of	O
the	O
endothelial	O
injury	O
in	O
SSc	O
is	O
as	O
yet	O
elusive	O
and	O
most	O
biochemical	O
evidences	O
are	O
often	O
inconclusive	O
or	O
controversial	O
.	O

Although	O
endothelial	O
cell	O
apoptosis	O
and	O
impaired	O
angiogenesis	O
have	O
received	O
major	O
attention	O
among	O
the	O
mechanisms	O
involved	O
in	O
the	O
characteristic	O
vascular	O
dysfunction	O
,	O
recent	O
studies	O
provided	O
clear	O
evidence	O
of	O
a	O
significant	O
activation	O
of	O
the	O
coagulation	O
cascade	O
,	O
resulting	O
in	O
a	O
procoagulant	O
state	O
that	O
might	O
finally	O
raise	O
the	O
relative	O
risk	O
of	O
thrombotic	O
events	O
in	O
these	O
patients	O
.	O

In	O
SSc	O
,	O
the	O
peculiar	O
vascular	O
lesions	O
and	O
fibrosis	O
were	O
claimed	O
to	O
impair	O
endothelial	O
function	O
,	O
as	O
suggested	O
by	O
impairment	O
of	O
fibrinolysis	O
and	O
activation	O
of	O
the	O
coagulation	O
pathway	O
.	O

The	O
following	O
loss	O
of	O
the	O
balance	O
between	O
fibrinolysis	O
and	O
coagulation	O
might	O
finally	O
contribute	O
to	O
vessel	O
engulfment	O
with	O
fibrin	O
and	O
breakdown	O
of	O
vessel	O
patency	O
,	O
symptomatic	O
of	O
a	O
tendency	O
to	O
the	O
development	O
of	O
thrombotic	O
complications	O
in	O
this	O
particular	O
autoimmune	O
disorder	O
[	O
4	O
]	O
.	O

D	O
-	O
dimer	O
is	O
a	O
heterogeneous	O
class	O
of	O
end	O
-	O
stage	O
degradation	O
products	O
that	O
directly	O
reflect	O
the	O
level	O
of	O
lysed	O
cross	O
-	O
linked	O
fibrin	O
,	O
occurring	O
in	O
vivo	O
with	O
a	O
wide	O
range	O
of	O
molecular	O
weights	O
.	O

Therefore	O
,	O
D	O
-	O
dimer	O
is	O
a	O
well	O
-	O
recognized	O
marker	O
of	O
a	O
systemic	O
prothrombotic	O
state	O
[	O
5,9	O
]	O
and	O
appears	O
a	O
strong	O
,	O
consistent	O
predictor	O
of	O
cardiovascular	O
events	O
in	O
the	O
general	O
population	O
,	O
in	O
patients	O
with	O
cardiovascular	O
disease	O
and	O
in	O
other	O
pathologies	O
characterized	O
by	O
an	O
increased	O
risk	O
of	O
thrombosis	O
[	O
10	O
-	O
12	O
]	O
.	O

Accordingly	O
,	O
D	O
-	O
dimer	O
measurement	O
could	O
be	O
reliably	O
used	O
as	O
an	O
initial	O
screening	O
test	O
in	O
patients	O
with	O
clinically	O
suspected	O
thrombosis	O
,	O
as	O
its	O
high	O
negative	O
predictive	O
value	O
enables	O
to	O
validly	O
rule	O
out	O
ongoing	O
thrombotic	O
complications	O
[	O
12	O
]	O
.	O

Little	O
is	O
known	O
on	O
the	O
thrombotic	O
tendency	O
of	O
SSc	O
patients	O
so	O
far	O
[	O
13	O
]	O
.	O

At	O
variance	O
with	O
previous	O
investigations	O
[	O
2	O
-	O
4	O
]	O
,	O
we	O
demonstrated	O
that	O
SSc	O
patients	O
with	O
diffuse	O
subset	O
are	O
characterized	O
by	O
increased	O
plasma	O
D	O
-	O
dimer	O
values	O
,	O
reflecting	O
a	O
potential	O
activation	O
of	O
both	O
the	O
coagulation	O
and	O
fibrinolytic	O
pathways	O
.	O

Conclusion	O
Although	O
increased	O
D	O
-	O
dimer	O
values	O
in	O
SSc	O
patients	O
were	O
occasionally	O
observed	O
in	O
earlier	O
studies	O
,	O
the	O
association	O
between	O
plasma	O
D	O
-	O
dimer	O
and	O
disease	O
subset	O
is	O
likely	O
an	O
original	O
and	O
innovative	O
issue	O
.	O

The	O
significant	O
correlation	O
observed	O
with	O
disease	O
activity	O
,	O
cutaneous	O
involvement	O
and	O
forced	O
vital	O
capacity	O
,	O
further	O
suggests	O
that	O
SSc	O
patients	O
,	O
especially	O
those	O
with	O
diffuse	O
subset	O
,	O
display	O
a	O
hypercoagulable	O
state	O
,	O
which	O
might	O
finally	O
predispose	O
this	O
peculiar	O
subset	O
of	O
patients	O
to	O
the	O
development	O
of	O
thrombotic	O
complications	O
.	O

Authors	O
'	O
contributions	O
GL	O
:	O
conceived	O
of	O
the	O
study	O
,	O
participated	O
in	O
its	O
design	O
and	O
coordination	O
and	O
drafted	O
the	O
manuscript	O
;	O
AV	O
:	O
participated	O
in	O
the	O
design	O
of	O
the	O
study	O
,	O
performed	O
the	O
statistical	O
analysis	O
and	O
helped	O
to	O
draft	O
the	O
manuscript	O
;	O
PC	O
:	O
participated	O
in	O
the	O
design	O
and	O
coordination	O
of	O
the	O
study	O
;	O
GLS	O
:	O
participated	O
in	O
the	O
design	O
of	O
the	O
study	O
;	O
MM	O
:	O
participated	O
in	O
the	O
design	O
and	O
coordination	O
of	O
the	O
study	O
and	O
performed	O
the	O
measurement	O
;	O
GCG	O
:	O
participated	O
in	O
the	O
design	O
and	O
coordination	O
of	O
the	O
study	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Molecular	O
cloning	O
of	O
four	O
novel	O
murine	O
ribonuclease	O
genes	O
:	O
unusual	O
expansion	O
within	O
the	O
ribonuclease	O
A	O
gene	O
family	O
.	O

Abstract	O
We	O
have	O
characterized	O
four	O
novel	O
murine	O
ribonuclease	O
genes	O
that	O
,	O
together	O
with	O
the	O
murine	O
eosinophil	O
-	O
associated	O
ribonucleases	O
1	O
and	O
2	O
,	O
form	O
a	O
distinct	O
and	O
unusual	O
cluster	O
within	O
the	O
RNase	O
A	O
gene	O
superfamily	O
.	O

Three	O
of	O
these	O
genes	O
(	O
mR-3	O
,	O
mR-4	O
,	O
mR-5	O
)	O
include	O
complete	O
open	O
reading	O
frames	O
,	O
encoding	O
ribonucleases	O
with	O
eight	O
cysteines	O
and	O
appropriately	O
spaced	O
histidines	O
(	O
His11	O
and	O
His124	O
)	O
and	O
lysine	O
(	O
Lys35	O
)	O
that	O
are	O
characteristic	O
of	O
this	O
enlarging	O
protein	O
family	O
;	O
the	O
fourth	O
sequence	O
encodes	O
a	O
non	O
-	O
functional	O
pseudogene	O
(	O
mR-6P	O
)	O
.	O

Although	O
the	O
amino	O
acid	O
sequence	O
similarities	O
among	O
these	O
murine	O
ribonucleases	O
varies	O
from	O
60	O
to	O
94	O
%	O
,	O
they	O
form	O
a	O
unique	O
cluster	O
,	O
as	O
each	O
sequence	O
is	O
found	O
to	O
be	O
more	O
closely	O
related	O
to	O
another	O
of	O
this	O
group	O
than	O
to	O
either	O
murine	O
angiogenin	O
or	O
to	O
murine	O
pancreatic	O
ribonuclease	O
.	O

Interestingly	O
,	O
the	O
relationship	O
between	O
the	O
six	O
genes	O
in	O
this	O
'	O
mR	O
cluster	O
'	O
and	O
the	O
defined	O
lineages	O
of	O
the	O
RNase	O
A	O
gene	O
family	O
could	O
not	O
be	O
determined	O
by	O
amino	O
acid	O
sequence	O
homology	O
,	O
suggesting	O
the	O
possibility	O
that	O
there	O
are	O
one	O
or	O
more	O
additional	O
ribonuclease	O
lineages	O
that	O
have	O
yet	O
to	O
be	O
defined	O
.	O

Although	O
the	O
nature	O
of	O
the	O
evolutionary	O
constraints	O
promoting	O
this	O
unusual	O
expansion	O
and	O
diversification	O
remain	O
unclear	O
,	O
the	O
implications	O
with	O
respect	O
to	O
function	O
are	O
intriguing	O
.	O

�	O
1997	O
Oxford	O
University	O
Press	O
Nucleic	O
Acids	O
Research	O
,	O
1997	O
,	O
Vol	O
.	O

25	O
,	O
No.	O
21	O
4235	O
�	O
4239	O
Molecular	O
cloning	O
of	O
four	O
novel	O
murine	O
ribonuclease	O
genes	O
:	O
unusual	O
expansion	O
within	O
the	O
Ribonuclease	O
A	O
gene	O
family	O
Dean	O
Batten+	O
,	O
Kimberly	O
D.	O
Dyer	O
,	O
Joseph	O
B.	O
Domachowske	O
�	O
and	O
Helene	O
F.	O
Rosenberg	O

*	O
The	O
Laboratory	O
of	O
Host	O
Defenses	O
,	O
Building	O
10	O
,	O
Room	O
11N104	O
,	O
National	O
Institute	O
of	O
Allergy	O
and	O
Infectious	O
Diseases	O
,	O
National	O
Institutes	O
of	O
Health	O
,	O
9000	O
Rockville	O
Pike	O
,	O
Bethesda	O
,	O
MD	O
20892	O
,	O
USA	O
Received	O
August	O
4	O
,	O
1997	O
;	O
Revised	O
and	O
Accepted	O
September	O
17	O
,	O
1997	O
DDBJ	O
/	O
EMBL	O
/	O
GenBank	O
accession	O
numbers	O
:	O
U72031	O
,	O
U72032	O
,	O
AF017258	O
�	O
AF017261	O
ABSTRACT	O
We	O
have	O
characterized	O
four	O
novel	O
murine	O
ribonuclease	O
genes	O
that	O
,	O
together	O
with	O
the	O
murine	O
eosinophilassociated	O
ribonucleases	O
1	O
and	O
2	O
,	O
form	O
a	O
distinct	O
and	O
unusual	O
cluster	O
within	O
the	O
RNase	O
A	O
gene	O
superfamily	O
.	O

Three	O
of	O
these	O
genes	O
(	O
mR-3	O
,	O
mR-4	O
,	O
mR-5	O
)	O
include	O
complete	O
open	O
reading	O
frames	O
,	O
encoding	O
ribonucleases	O
with	O
eight	O
cysteines	O
and	O
appropriately	O
spaced	O
histidines	O
(	O
His11	O
and	O
His124	O
)	O
and	O
lysine	O
(	O
Lys35	O
)	O
that	O
are	O
characteristic	O
of	O
this	O
enlarging	O
protein	O
family	O
;	O
the	O
fourth	O
sequence	O
encodes	O
a	O
non	O
-	O
functional	O
pseudogene	O
(	O
mR-6P	O
)	O
.	O

Although	O
the	O
amino	O
acid	O
sequence	O
similarities	O
among	O
these	O
murine	O
ribonucleases	O
varies	O
from	O
60	O
to	O
94	O
%	O
,	O
they	O
form	O
a	O
unique	O
cluster	O
,	O
as	O
each	O
sequence	O
is	O
found	O
to	O
be	O
more	O
closely	O
related	O
to	O
another	O
of	O
this	O
group	O
than	O
to	O
either	O
murine	O
angiogenin	O
or	O
to	O
murine	O
pancreatic	O
ribonuclease	O
.	O

Interestingly	O
,	O
the	O
relationship	O
between	O
the	O
six	O
genes	O
in	O
this	O
`	O
mR	O
cluster	O
'	O
and	O
the	O
defined	O
lineages	O
of	O
the	O
RNase	O
A	O
gene	O
family	O
could	O
not	O
be	O
determined	O
by	O
amino	O
acid	O
sequence	O
homology	O
,	O
suggesting	O
the	O
possibility	O
that	O
there	O
are	O
one	O
or	O
more	O
additional	O
ribonuclease	O
lineages	O
that	O
have	O
yet	O
to	O
be	O
defined	O
.	O

Although	O
the	O
nature	O
of	O
the	O
evolutionary	O
constraints	O
promoting	O
this	O
unusual	O
expansion	O
and	O
diversification	O
remain	O
unclear	O
,	O
the	O
implications	O
with	O
respect	O
to	O
function	O
are	O
intriguing	O
.	O

INTRODUCTION	O
Ribonuclease	O
A	O
(	O
RNase	O
A	O
,	O
bovine	B
pancreatic	O
ribonuclease	O
)	O
is	O
the	O
prototype	O
of	O
an	O
enlarging	O
family	O
of	O
proteins	O
defined	O
by	O
distinctive	O
elements	O
of	O
conserved	O
primary	O
structure	O
and	O
enzymatic	O
activity	O
(	O
1,2	O
)	O
.	O

The	O
features	O
shared	O
by	O
all	O
members	O
of	O
the	O
RNase	O
A	O
family	O
include	O
six	O
to	O
eight	O
cysteines	O
and	O
specific	O
histidine	O
and	O
lysine	O
residues	O
that	O
form	O
the	O
ribonuclease	O
active	O
site	O
.	O

To	O
date	O
,	O
several	O
distinct	O
lineages	O
within	O
the	O
RNase	O
A	O
superfamily	O
have	O
been	O
identified	O
.	O

Pancreatic	O
ribonucleases	O
(	O
RNases	O
1	O
)	O
have	O
been	O
isolated	O
from	O
an	O
extensive	O
array	O
of	O
mammalian	O
species	O
(	O
3,4	O
)	O
,	O
and	O
mRNA	O
encoding	O
human	B
pancreatic	O
ribonuclease	O
has	O
been	O
detected	O
in	O
numerous	O
somatic	O
tissues	O
in	O
addition	O
to	O
pancreas	O
(	O
5	O
)	O
.	O

RNases	O
2	O
and	O
3	O
,	O
eosinophil	O
-	O
derived	O
neurotoxin	O
(	O
EDN	O
)	O
and	O
eosinophil	O
cationic	O
protein	O
(	O
ECP	O
)	O
,	O
respectively	O
,	O
have	O
been	O
characterized	O
primarily	O
with	O
respect	O
to	O
eosinophil	O
function	O
(	O
6,7	O
)	O
,	O
although	O
expression	O
of	O
EDN	O
[	O
also	O
known	O
as	O
RNase	O
Us	O
(	O
8)	O
or	O
human	B
liver	O
ribonuclease	O
(	O
9	O
)	O
]	O
is	O
also	O
widespread	O
(	O
5	O
)	O
.	O

Angiogenin	O
(	O
RNase	O
5	O
)	O
,	O
a	O
structurally	O
atypical	O
member	O
of	O
this	O
family	O
,	O
was	O
originally	O
identified	O
as	O
an	O
agent	O
promoting	O
blood	O
vessel	O
growth	O
and	O
development	O
(	O
10,11	O
)	O
.	O

RNase	O
4	O
(	O
12,13	O
)	O
and	O
RNase	O
k6	O
(	O
14	O
)	O
are	O
also	O
members	O
of	O
the	O
RNase	O
A	O
superfamily	O
,	O
although	O
their	O
functions	O
are	O
currently	O
obscure	O
.	O

Recently	O
,	O
Larson	O
and	O
colleagues	O
(	O
15	O
)	O
described	O
cDNAs	O
encoding	O
two	O
highly	O
homologous	O
murine	O
ribonucleases	O
,	O
the	O
murine	O
eosinophil	O
-	O
associated	O
ribonucleases	O
(	O
mEAR	O
)	O
1	O
and	O
2	O
,	O
which	O
were	O
cloned	O
and	O
identified	O
via	O
tryptic	O
peptides	O
isolated	O
from	O
murine	O
eosinophil	O
proteins	O
.	O

Although	O
Southern	O
analysis	O
demonstrated	O
that	O
multiple	O
copies	O
of	O
sequence	O
homologous	O
to	O
mEAR-1	O
and	O
mEAR-2	O
were	O
present	O
in	O
murine	O
genomic	O
DNA	O
,	O
the	O
precise	O
nature	O
of	O
these	O
copies	O
--	O
as	O
pseudogenes	O
,	O
polymorphisms	O
,	O
or	O
distinct	O
functional	O
genes	O
--	O
was	O
unclear	O
.	O

In	O
this	O
work	O
,	O
we	O
have	O
identified	O
four	O
of	O
these	O
homologous	O
sequences	O
,	O
three	O
encoding	O
novel	O
ribonucleases	O
,	O
and	O
one	O
encoding	O
a	O
pseudogene	O
.	O

Together	O
with	O
mEAR-1	O
and	O
mEAR-2	O
,	O
these	O
six	O
ribonuclease	O
genes	O
form	O
an	O
`	O
mR	O
cluster	O
,	O
'	O
whose	O
members	O
are	O
more	O
closely	O
related	O
to	O
one	O
another	O
than	O
they	O
are	O
to	O
other	O
murine	O
ribonucleases	O
,	O
yet	O
whose	O
position	O
with	O
respect	O
to	O
the	O
defined	O
RNase	O
A	O
lineages	O
remains	O
unclear	O
.	O

MATERIALS	O
AND	O
METHODS	O
Isolation	O
of	O
genomic	O
fragments	O
encoding	O
murine	O
ribonucleases	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
Genomic	O
DNA	O
was	O
isolated	O
from	O
cells	O
of	O
the	O
murine	O
3T3	O
fibroblast	O
cell	O
line	O
.	O

The	O
mR-3	O
,	O
mR-5	O
and	O
mR-6P	O
sequences	O
were	O
amplified	O
using	O
oligonucleotide	O
primers	O
derived	O
from	O
the	O
published	O
coding	O
sequence	O
of	O
mEAR-1	O
as	O
follows	O
:	O
5-CAA	O
ACC	O
CTT	O
TCC	O
CAG	O
AAG	O
TTT	O
GCC-3	O
(	O
amino	O
acids	O
28	O
�	O
33	O
)	O
;	O
5-AAA	O
TGT	O
CCC	O
ATC	O
CAA	O
GTG	O
AAC	O
TGG	O
ACC-3	O
(	O
amino	O
acids	O
156	O
�	O
148	O
)	O
(	O
15	O
)	O
.	O

The	O
PCR	O
reactions	O
were	O
performed	O
as	O
described	O
previously	O
(	O
14	O
)	O
,	O
and	O
the	O
multiple	O
products	O
present	O
in	O
the	O
single	O
400	O
bp	O
product	O
were	O
identified	O
by	O
dideoxy	O
*	O
To	O
whom	O
correspondence	O
should	O
be	O
addressed	O
.	O

Tel	O
:	O
+	O
1	O
301	O
402	O
9131	O
;	O
Fax	O
:	O
+	O
1	O
301	O
402	O
4369	O
;	O
Email	O
:	O
hr2k@nih.gov	O
Present	O
addresses	O
:	O
+	O
Duke	O
University	O
School	O
of	O
Medicine	O
,	O
Durham	O
,	O
NC	O
27701	O
,	O
USA	O
and	O
�	O
Department	O
of	O
Pediatrics	O
,	O
State	O
University	O
of	O
New	O
York	O
-	O
Health	O
Sciences	O
Center	O
at	O
Syracuse	O
,	O
Syracuse	O
,	O
NY	O
13210	O
,	O
USA	O
4236	O
Nucleic	O
Acids	O
Research	O
,	O
1997	O
,	O
Vol	O
.	O

25	O
,	O
No.	O
21	O
Figure	O
1	O
.	O
(	O
A	O
)	O
Alignment	O
of	O
amino	O
acid	O
sequences	O
encoded	O
by	O
six	O
related	O
murine	O
ribonuclease	O
genes	O
.	O

Regions	O
of	O
amino	O
acid	O
sequence	O
identity	O
among	O
the	O
five	O
functional	O
genes	O
are	O
enclosed	O
in	O
boxes	O
;	O
the	O
boxes	O
enclosing	O
the	O
active	O
site	O
residues	O
(	O
His11	O
,	O
Lys35	O
,	O
His124	O
)	O
and	O
eight	O
cysteines	O
conserved	O
in	O
all	O
members	O
of	O
the	O
RNase	O
A	O
superfamily	O
are	O
shaded	O
.	O

(	O
B	O
)	O
Percent	O
similarities	O
between	O
amino	O
acid	O
sequences	O
determined	O
via	O
the	O
BESTFIT	O
algorithm	O
of	O
the	O
Wisconsin	O
Genetics	O
Computer	O
Group	O
(	O
WGCG	O
)	O
program	O
on	O
-	O
line	O
at	O
the	O
National	O
Institutes	O
of	O
Health	O
.	O

GenBank	O
accession	O
numbers	O
:	O
mEAR	O
(	O
murine	O
eosinophil	O
-	O
associated	O
ribonuclease	O
)	O
-1	O
,	O
U72032	O
;	O
mEAR-2	O
,	O
U72031	O
;	O
mR	O
(	O
murine	O
ribonuclease	O
)	O
-3	O
,	O
AF017258	O
;	O
mR-4	O
,	O
AF017259	O
;	O
mR-5	O
,	O
AF017260	O
;	O
mR-6P	O
(	O
pseudogene	O
)	O
,	O
AF017261	O
.	O

sequencing	O
of	O
individual	O
plasmids	O
after	O
subcloning	O
into	O
the	O
pCR	O
II	O
TA	O
cloning	O
vector	O
(	O
Invitrogen	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
.	O

The	O
complete	O
open	O
reading	O
frames	O
were	O
obtained	O
by	O
extension	O
in	O
both	O
5	O
and	O
3	O
directions	O
by	O
uni	O
-	O
directional	O
PCR	O
(	O
Genome	O
Walker	O
kit	O
,	O
Clontech	O
,	O
Palo	O
Alto	O
,	O
CA	O
)	O
,	O
involving	O
two	O
amplifications	O
with	O
nested	O
primers	O
and	O
Tth	O
polymerase	O
as	O
described	O
previously	O
(	O
14	O
)	O
.	O

The	O
nested	O
gene	O
-	O
specific	O
primer	O
pairs	O
were	O
as	O
follows	O
:	O
for	O
5	O
extension	O
of	O
mR-3	O
,	O
5-CTG	O
GAA	O
CCA	O
CTG	O
GAT	O
ACG	O
TGG	O
GAC	O
TGT	O
CCT-3	O
and	O
5-ACG	O
TGG	O
GAC	O
TGT	O
CCT	O
GTG	O
GAG	O
TTC	O
TGG	O
GTT-3	O
;	O
for	O
3	O
extension	O
of	O
mR-3	O
,	O
5-ATG	O
CTG	O
TTG	O
GTG	O
TGT	O
GTG	O
GAA	O
ATC	O
CAA	O
GTG-3	O
and	O
5-GCT	O
TGT	O
GCA	O
GTG	O
ACA	O
ATA	O
TAA	O
GTC	O
AAA	O
ACT-3	O
;	O
for	O
5	O
extension	O
of	O
mR-5	O
,	O
5-GGT	O
GGG	O
ACG	O
GTC	O
CTT	O
TGG	O
AGT	O
TCT	O
GGG	O
GTT	O
ACA-3	O
and	O
5-GGG	O
GTT	O
ACA	O
GGC	O
AAC	O
TGT	O
GTA	O
GGA	O
CTT	O
CTT	O
TCC-3	O
;	O
for	O
3	O
extension	O
of	O
mR-5	O
,	O
5-GAT	O
GTT	O
GTC	O
CGT	O
GTG	O
TGT	O
CAC	O
AAT	O
CCA	O
CCC-3	O
and	O
5-AAG	O
ACT	O
TGC	O
AAA	O
GAC	O
GGG	O
ACA	O
AGT	O
CCA	O
AAT-3	O
;	O
for	O
5	O
extension	O
of	O
mR-6P	O
,	O
5-TTG	O
TTG	O
TTT	O
TGC	O
ATC	O
TGC	O
ATT	O
GTG	O
CAT	O
AAC	O
TGC-3	O
and	O
5-TTC	O
TGC	O
ATA	O
ACT	O
GCT	O
TGC	O
TGA	O
ACT	O
TGT	O
GAG	O
TGA-3	O
;	O
for	O
3	O
extension	O
of	O
mR-6P	O
,	O
5-ATG	O
TGA	O
TAA	O
TGC	O
AAT	O
GCT	O
GTC	O
TCT	O
TAG	O
CAG	O
TTA-3	O
and	O
5-TAC	O
AAG	O
AGT	O
ATG	O
TAA	O
GCC	O
ATT	O
GAA	O
TCA	O
TTT	O
TCT-3	O
.	O

The	O
products	O
of	O
these	O
reactions	O
were	O
likewise	O
subcloned	O
into	O
the	O
PCR	O
II	O
TA	O
vector	O
and	O
evaluated	O
by	O
dideoxy	O
-	O
sequencing	O
.	O

The	O
mR-4	O
sequence	O
was	O
amplified	O
with	O
a	O
36	O
bp	O
primer	O
derived	O
from	O
sequence	O
encoding	O
the	O
amino	O
-	O
terminal	O
signal	O
sequence	O
of	O
mEAR-1	O
;	O
5-ATG	O
GGT	O
CCG	O
AAG	O
CTG	O
CTT	O
GAG	O
TCC	O
CGA	O
CTT	O
TGT	O
CTC-3	O
with	O
the	O
carboxy	O
-	O
primer	O
described	O
above	O
.	O

Northern	O
analysis	O
The	O
murine	O
multi	O
-	O
tissue	O
Northern	O
blot	O
was	O
purchased	O
from	O
Clontech	O
,	O
and	O
pre	O
-	O
hybridized	O
and	O
hybridized	O
as	O
per	O
manufacturer	O
's	O
instructions	O
with	O
radiolabelled	O
oligonucleotide	O
probes	O
.	O

The	O
membrane	O
was	O
washed	O
with	O
5	O
�	O
SSPE	O
with	O
0.1	O
%	O
SDS	O
for	O
1	O
h	O
at	O
37_C	O
and	O
the	O
autoradiogram	O
developed	O
after	O
exposure	O
to	O
film	O
at	O
�	O
80_C.	O
The	O
mEAR-1	O
/	O
mEAR-2	O
/	O
mR-3	O
probe	O
:	O
5-CTC	O
TTG	O
TCA	O
CTG	O
CAC	O
AAG	O
CCA	O
CTT	O
GGA	O
TTT	O
CC-3	O
,	O
the	O
mR-5	O
probe	O
:	O
5-GTC	O
CCG	O
TCT	O
TTG	O
CAA	O
GTC	O
TTG	O
GGT	O
GGA	O
TTG	O
TG-3	O
,	O
and	O
the	O
actin	O
probe	O
:	O
5-GCA	O
CAT	O
GCC	O
GGA	O
GCC	O
GTT	O
GTC	O
GAC	O
GAC	O
GAG	O
CGC	O
GGC	O
GAT	O
ATC	O
ATC	O
ATC-3	O
(	O
16	O
)	O
.	O

4237	O
Nucleic	O
Acids	O
Research	O
,	O
1997	O
,	O
Vol	O
.	O

25	O
,	O
No.	O
Nucleic	O
Acids	O
Research	O
,	O
1994	O
,	O
Vol	O
.	O

22	O
,	O
No.	O
121	O
4237	O
Figure	O
2	O
.	O

(	O
A	O
)	O
Dendrogram	O
depicting	O
relationships	O
among	O
the	O
eight	O
characterized	O
murine	O
ribonucleases	O
as	O
determined	O
by	O
a	O
modified	O
UPGMA	O
method	O
(	O
17	O
)	O
.	O

Abbreviations	O
are	O
as	O
in	O
Figure	O
1A	O
,	O
also	O
mPR	O
(	O
murine	O
pancreatic	O
ribonuclease	O
,	O
sw	O
:	O
rnp_mouse	O
)	O
,	O
mANG	O
(	O
murine	O
angiogenin	O
,	O
U72672	O
)	O
,	O
hEDN	O
(	O
human	B
eosinophil	O
-	O
derived	O
neurotoxin	O
,	O
M24157	O
)	O
,	O
hECP	O
(	O
human	B
eosinophil	O
cationic	O
protein	O
,	O
X15161	O
)	O
,	O
hRK6	O
(	O
human	B
ribonuclease	O
k6	O
,	O
U64998	O
)	O
,	O
pRK6	O
(	O
porcine	O
kidney	O
ribonuclease	O
(	O
24	O
)	O
,	O
and	O
bRK6	O
(	O
bovine	B
kidney	O
ribonuclease	O
,	O
sw	O
:	O
rnkd_bovin	O
)	O
.	O

(	O
B	O
)	O
Calculated	O
isoelectric	O
points	O
from	O
amino	O
acid	O
sequences	O
in	O
(	O
A	O
)	O
as	O
determined	O
via	O
the	O
PEPTIDESORT	O
algorithm	O
of	O
WGCG	O
.	O

Table	O
1	O
.	O

Amino	O
acid	O
sequence	O
comparisons	O
of	O
murine	O
and	O
human	B
ribonucleases	O
Sequence	O
analysis	O
All	O
DNA	O
sequence	O
analysis	O
and	O
comparisons	O
were	O
performed	O
with	O
the	O
assistance	O
of	O
the	O
Wisconsin	O
Genetics	O
Computer	O
Group	O
and	O
Sequencher	O
(	O
Gene	O
Codes	O
Corporation	O
)	O
programs	O
available	O
at	O
the	O
National	O
Institutes	O
of	O
Health	O
.	O

The	O
dendrogram	O
in	O
Figure	O
2A	O
was	O
constructed	O
by	O
a	O
modified	O
version	O
of	O
the	O
unweighted	O
pair	O
group	O
method	O
with	O
arithmetic	O
mean	O
(	O
UPGMA	O
)	O
(	O
17	O
)	O
,	O
constructed	O
using	O
four	O
initial	O
pairings	O
,	O
mEAR-2	O
to	O
mR-3	O
,	O
mR-5	O
to	O
mR-6P	O
,	O
hEDN	O
to	O
hECP	O
and	O
bRK6	O
to	O
pRK6	O
.	O

RESULTS	O
Isolation	O
of	O
genomic	O
fragments	O
encoding	O
novel	O
murine	O
ribonucleases	O
The	O
alignment	O
in	O
Figure	O
1A	O
displays	O
the	O
amino	O
acid	O
sequences	O
encoded	O
by	O
the	O
six	O
related	O
ribonuclease	O
genes	O
.	O

Murine	O
eosinophil	O
-	O
associated	O
ribonucleases-1	O
and	O
-2	O
(	O
mEAR-1	O
and	O
mEAR-2	O
)	O
are	O
the	O
predicted	O
amino	O
acid	O
sequences	O
from	O
two	O
genes	O
described	O
previously	O
by	O
Larson	O
and	O
colleagues	O
(	O
15	O
)	O
;	O
murine	O
ribonucleases	O
3	O
,	O
4	O
,	O
5	O
and	O
6-pseudogene	O
(	O
mR-3	O
,	O
mR-4	O
,	O
mR-5	O
and	O
mR-6P	O
)	O
,	O
are	O
the	O
predicted	O
amino	O
acid	O
sequences	O
encoded	O
by	O
novel	O
DNA	O
hEDN	O
mEAR-1	O
mEAR-2	O
mR-3	O
mR-4	O
mR-5	O
mANG	O
mPR	O
56	O
56	O
54	O
60	O
60	O
43	O
53	O
hECP	O
59	O
59	O
57	O
59	O
58	O
49	O
52	O
hRK6	O
58	O
59	O
59	O
53	O
56	O
49	O
59	O
hPR	O
47	O
48	O
49	O
48	O
57	O
55	O
79	O
hR4	O
50	O
53	O
51	O
52	O
54	O
57	O
66	O
hANG	O
49	O
48	O
51	O
47	O
47	O
80	O
60	O
Values	O
are	O
expressed	O
as	O
percent	O
similarity	O
between	O
pairs	O
of	O
amino	O
acid	O
sequences	O
as	O
determined	O
by	O
the	O
BESTFIT	O
algorithm	O
of	O
the	O
Wisconsin	O
Genetics	O
Computer	O
Group	O
program	O
on	O
-	O
line	O
at	O
the	O
National	O
Institutes	O
of	O
Health	O
.	O

Value	O
representing	O
the	O
highest	O
degree	O
of	O
sequence	O
homology	O
in	O
each	O
row	O
is	O
indicated	O
in	O
boldface	O
.	O

Abbreviations	O
are	O
as	O
defined	O
in	O
Figures	O
1	O
and	O
2	O
,	O
and	O
also	O
include	O
hR4	O
(	O
human	B
ribonuclease	O
4	O
,	O
sw	O
:	O
rnl4_human	O
)	O
,	O
hANG	O
(	O
human	B
angiogenin	O
,	O
M11567	O
)	O
,	O
and	O
hPR	O
(	O
human	B
pancreatic	O
ribonuclease	O
,	O
X62946	O
)	O
.	O

4238	O
Nucleic	O
Acids	O
Research	O
,	O
1997	O
,	O
Vol	O
.	O

25	O
,	O
No.	O
21	O
fragments	O
amplified	O
from	O
murine	O
genomic	O
DNA	O
.	O

All	O
five	O
functional	O
genes	O
encode	O
amino	O
acid	O
sequences	O
with	O
eight	O
cysteines	O
and	O
appropriately	O
spaced	O
catalytic	O
histidines	O
and	O
lysine	O
that	O
are	O
conserved	O
among	O
the	O
members	O
of	O
the	O
RNase	O
A	O
superfamily	O
.	O

The	O
predicted	O
coding	O
sequence	O
of	O
the	O
non	O
-	O
functional	O
pseudogene	O
(	O
mR-6P	O
)	O
includes	O
two	O
aberrant	O
stop	O
codons	O
(	O
positions	O
19	O
and	O
100	O
)	O
as	O
well	O
as	O
a	O
point	O
mutation	O
resulting	O
in	O
the	O
destruction	O
of	O
the	O
cysteine	O
at	O
position	O
78	O
.	O

Each	O
genomic	O
fragment	O
also	O
encodes	O
a	O
28	O
residue	O
amino	O
terminal	O
signal	O
sequence	O
(	O
not	O
shown	O
)	O
.	O

The	O
amino	O
acid	O
sequences	O
are	O
displayed	O
in	O
order	O
of	O
decreasing	O
similarity	O
to	O
mEAR-1	O
(	O
Fig.	O
1B	O
)	O
.	O

Genomic	O
fragments	O
encoding	O
mEAR-1	O
and	O
mEAR-2	O
were	O
also	O
detected	O
.	O

Relationships	O
among	O
the	O
murine	O
ribonucleases	O
A	O
dendrogram	O
depicting	O
the	O
relationships	O
among	O
several	O
of	O
the	O
murine	O
and	O
human	B
ribonucleases	O
is	O
shown	O
in	O
Figure	O
2A	O
.	O

The	O
mEAR-1	O
,	O
mEAR-2	O
,	O
and	O
mR-3	O
sequences	O
form	O
a	O
closely	O
related	O
sub	O
-	O
group	O
,	O
with	O
only	O
nine	O
amino	O
acid	O
sequence	O
differences	O
noted	O
between	O
mEAR-2	O
and	O
mR-3	O
,	O
and	O
12	O
and	O
17	O
between	O
these	O
two	O
and	O
mEAR-1	O
,	O
respectively	O
.	O

The	O
mR-4	O
,	O
mR-5	O
,	O
and	O
mR-6P	O
sequences	O
diverge	O
from	O
this	O
subgroup	O
and	O
from	O
one	O
another	O
as	O
well	O
.	O

These	O
six	O
sequences	O
are	O
more	O
closely	O
related	O
to	O
one	O
another	O
than	O
they	O
are	O
to	O
either	O
murine	O
pancreatic	O
ribonuclease	O
(	O
mPR	O
)	O
or	O
to	O
murine	O
angiogenin	O
(	O
mANG	O
)	O
or	O
to	O
any	O
of	O
the	O
three	O
human	B
ribonucleases	O
shown	O
(	O
hEDN	O
,	O
hECP	O
or	O
hRK6	O
)	O
.	O

Isoelectric	O
points	O
The	O
isoelectric	O
points	O
of	O
all	O
six	O
related	O
ribonucleases	O
range	O
from	O
8	O
�	O
11	O
,	O
as	O
is	O
typical	O
for	O
members	O
of	O
the	O
RNase	O
A	O
superfamily	O
(	O
Fig.	O
2B	O
)	O
.	O

Interestingly	O
,	O
the	O
isoelectric	O
points	O
within	O
the	O
mEAR-1	O
/	O
mEAR-2	O
/	O
mR-3	O
subgroup	O
vary	O
by	O
a	O
full	O
1.0	O
unit	O
(	O
mEAR-1	O
at	O
9.2	O
to	O
mEAR-2	O
at	O
10.2	O
)	O
in	O
response	O
to	O
only	O
12	O
discrepancies	O
in	O
amino	O
acid	O
sequence	O
.	O

As	O
increased	O
charge	O
has	O
been	O
associated	O
with	O
increased	O
toxicity	O
in	O
other	O
branches	O
of	O
the	O
RNase	O
A	O
gene	O
family	O
(	O
18	O
)	O
,	O
this	O
finding	O
has	O
potential	O
consequences	O
with	O
respect	O
to	O
the	O
function	O
of	O
these	O
proteins	O
(	O
see	O
Discussion	O
)	O
.	O

Northern	O
analysis	O
Tissue	O
-	O
specific	O
expression	O
of	O
mRNA	O
encoding	O
these	O
murine	O
ribonucleases	O
is	O
shown	O
in	O
Figure	O
3	O
.	O

The	O
probe	O
complementary	O
to	O
all	O
three	O
sequences	O
of	O
the	O
mEAR-1	O
/	O
mEAR-2	O
/	O
mR-3	O
subgroup	O
hybridizes	O
to	O
an	O
1.4	O
kb	O
mRNA	O
isolated	O
from	O
renal	O
tissue	O
(	O
Fig.	O
3A	O
)	O
.	O

As	O
the	O
probe	O
can	O
not	O
distinguish	O
among	O
the	O
three	O
genes	O
,	O
it	O
is	O
not	O
possible	O
to	O
conclude	O
whether	O
the	O
band	O
detected	O
represents	O
mRNA	O
encoding	O
one	O
,	O
two	O
,	O
or	O
all	O
three	O
of	O
the	O
ribonucleases	O
of	O
this	O
subgroup	O
.	O

In	O
contrast	O
,	O
the	O
probe	O
complementary	O
to	O
the	O
mR-5	O
genomic	O
fragment	O
hybridizes	O
to	O
two	O
prominent	O
mRNA	O
species	O
in	O
hepatic	O
tissue	O
,	O
one	O
at	O
1.4	O
kb	O
,	O
and	O
a	O
second	O
at	O
2.0	O
kb	O
.	O

A	O
prominent	O
mRNA	O
of	O
1.8	O
kb	O
was	O
also	O
detected	O
in	O
mRNA	O
isolated	O
from	O
murine	O
testicular	O
tissue	O
;	O
fainter	O
hybridizing	O
mRNAs	O
of	O
varying	O
size	O
were	O
detected	O
in	O
lung	O
and	O
skeletal	O
muscle	O
.	O

The	O
size	O
variation	O
may	O
represent	O
differential	O
splicing	O
of	O
the	O
mR-5-encoding	O
mRNA	O
,	O
or	O
may	O
represent	O
mRNAs	O
encoding	O
one	O
or	O
more	O
as	O
yet	O
undiscovered	O
murine	O
ribonucleases	O
that	O
are	O
more	O
closely	O
related	O
to	O
mR-5	O
than	O
those	O
whose	O
sequences	O
are	O
reported	O
here	O
.	O

Figure	O
3	O
.	O
(	O
A	O
)	O
Murine	O
RNA	O
probed	O
with	O
a	O
32	O
bp	O
oligonucleotide	O
complementary	O
to	O
mEAR-1	O
,	O
mEAR-2	O
and	O
mR-3	O
coding	O
sequences	O
.	O

Tissue	O
source	O
of	O
each	O
RNA	O
is	O
indicated	O
above	O
each	O
lane	O
.	O

(	O
B	O
)	O
Same	O
as	O
in	O
(	O
A	O
)	O
,	O
probed	O
with	O
a	O
32	O
bp	O
oligonucleotide	O
complementary	O
to	O
mR-5	O
.	O

(	O
C	O
)	O
Same	O
as	O
in	O
(	O
A	O
)	O
,	O
probed	O
with	O
a	O
48	O
bp	O
oligonucleotide	O
complementary	O
to	O
human	B
actin	O
(	O
16	O
)	O
,	O
demonstrating	O
relative	O
loading	O
of	O
each	O
lane	O
.	O

Relationship	O
to	O
human	B
ribonucleases	O
The	O
data	O
in	O
Table	O
1	O
denote	O
the	O
amino	O
acid	O
sequence	O
similarity	O
between	O
pairs	O
of	O
murine	O
and	O
human	B
ribonucleases	O
of	O
the	O
RNase	O
A	O
superfamily	O
.	O

Overall	O
,	O
the	O
similarities	O
within	O
the	O
identified	O
cluster	O
range	O
from	O
47	O
to	O
60	O
%	O
,	O
with	O
remarkably	O
little	O
variation	O
among	O
the	O
pairs	O
.	O

Although	O
the	O
sequences	O
of	O
the	O
mEAR-1	O
/	O
mEAR-2	O
/	O
mR-3	O
subgroup	O
are	O
slightly	O
more	O
similar	O
to	O
ECP	O
and	O
RNase	O
k6	O
,	O
and	O
mR-4	O
and	O
mR-5	O
,	O
to	O
EDN	O
and	O
ECP	O
,	O
the	O
orthologous	O
relationships	O
of	O
these	O
murine	O
ribonucleases	O
can	O
not	O
be	O
discerned	O
from	O
these	O
data	O
.	O

This	O
stands	O
in	O
direct	O
contrast	O
to	O
mPR	O
and	O
mANG	O
,	O
whose	O
human	B
orthologs	O
can	O
be	O
clearly	O
distinguished	O
on	O
the	O
basis	O
of	O
their	O
amino	O
acid	O
sequence	O
homologies	O
.	O

DISCUSSION	O
In	O
this	O
work	O
,	O
we	O
have	O
identified	O
four	O
novel	O
murine	O
ribonuclease	O
genes	O
that	O
,	O
together	O
with	O
mEAR-1	O
and	O
mEAR-2	O
defined	O
by	O
Larson	O
and	O
colleagues	O
(	O
15	O
)	O
,	O
form	O
an	O
unusual	O
cluster	O
within	O
the	O
RNase	O
A	O
gene	O
superfamily	O
.	O

The	O
six	O
genes	O
within	O
this	O
cluster	O
have	O
varying	O
amino	O
acid	O
sequence	O
homologies	O
to	O
one	O
another	O
,	O
but	O
are	O
clearly	O
more	O
closely	O
related	O
to	O
one	O
another	O
than	O
to	O
either	O
murine	O
pancreatic	O
ribonuclease	O
(	O
mPR	O
)	O
or	O
angiogenin	O
(	O
mANG	O
)	O
,	O
or	O
to	O
any	O
of	O
the	O
human	B
ribonucleases	O
of	O
the	O
RNase	O
A	O
family	O
.	O

These	O
results	O
suggest	O
that	O
the	O
`	O
mR	O
cluster	O
'	O
emerged	O
via	O
multiple	O
duplications	O
of	O
a	O
gene	O
that	O
had	O
already	O
diverged	O
from	O
those	O
encoding	O
the	O
other	O
murine	O
ribonucleases	O
.	O

Although	O
this	O
type	O
of	O
expansion	O
is	O
unusual	O
in	O
this	O
gene	O
family	O
,	O
it	O
is	O
actually	O
not	O
unique	O
;	O
similar	O
expansion	O
has	O
occurred	O
in	O
bovine	B
species	O
,	O
with	O
gene	O
duplication	O
resulting	O
in	O
the	O
three	O
closely	O
-	O
related	O
bovine	B
pancreatic	O
,	O
bovine	B
brain	O
(	O
19,20	O
)	O
and	O
bovine	B
seminal	O
(	O
21	O
)	O
ribonucleases	O
.	O

One	O
interesting	O
feature	O
of	O
the	O
mR	O
cluster	O
is	O
that	O
its	O
relationship	O
to	O
any	O
of	O
to	O
the	O
six	O
known	O
human	B
RNase	O
A	O
-	O
type	O
genes	O
can	O
not	O
be	O
4239	O
Nucleic	O
Acids	O
Research	O
,	O
1997	O
,	O
Vol	O
.	O

25	O
,	O
No.	O
Nucleic	O
Acids	O
Research	O
,	O
1994	O
,	O
Vol	O
.	O

22	O
,	O
No.	O
121	O
determined	O
from	O
their	O
respective	O
amino	O
acid	O
sequence	O
homologies	O
.	O

Although	O
the	O
amino	O
acid	O
sequences	O
encoded	O
by	O
mEAR-1	O
and	O
mEAR-2	O
match	O
those	O
of	O
tryptic	O
peptides	O
derived	O
from	O
murine	O
eosinophil	O
proteins	O
(	O
15	O
)	O
,	O
the	O
homology	O
data	O
do	O
not	O
stand	O
in	O
overwhelming	O
support	O
of	O
a	O
unique	O
relationship	O
between	O
any	O
of	O
the	O
mR	O
cluster	O
ribonucleases	O
and	O
the	O
human	B
eosinophil	O
ribonucleases	O
EDN	O
and	O
ECP	O
.	O

The	O
existence	O
of	O
an	O
additional	O
,	O
as	O
yet	O
unidentified	O
human	B
ribonuclease	O
(	O
or	O
ribonucleases	O
)	O
more	O
closely	O
related	O
to	O
those	O
of	O
the	O
mR	O
cluster	O
can	O
not	O
be	O
ruled	O
out	O
.	O

Perhaps	O
the	O
most	O
important	O
issue	O
raised	O
by	O
this	O
work	O
is	O
the	O
question	O
of	O
why	O
so	O
much	O
evolutionary	O
energy	O
has	O
been	O
devoted	O
to	O
enlarging	O
and	O
diversifying	O
the	O
RNase	O
A	O
gene	O
superfamily	O
.	O

To	O
date	O
,	O
this	O
superfamily	O
now	O
includes	O
several	O
distinct	O
lineages	O
,	O
two	O
species	O
-	O
limited	O
clusters	O
,	O
and	O
the	O
two	O
most	O
rapidly	O
evolving	O
functional	O
coding	O
sequences	O
known	O
among	O
primates	O
(	O
22	O
)	O
.	O

The	O
question	O
of	O
evolutionary	O
energy	O
takes	O
on	O
particular	O
significance	O
here	O
,	O
where	O
five	O
functional	O
ribonucleases	O
have	O
emerged	O
in	O
what	O
appears	O
to	O
be	O
a	O
remarkably	O
short	O
period	O
of	O
evolutionary	O
time	O
(	O
15	O
)	O
.	O

It	O
is	O
conceivable	O
that	O
each	O
of	O
these	O
ribonucleases	O
might	O
serve	O
a	O
unique	O
but	O
related	O
function	O
.	O

On	O
this	O
point	O
,	O
a	O
number	O
of	O
studies	O
have	O
suggested	O
a	O
distinct	O
role	O
for	O
the	O
human	B
ribonuclease	O
ECP	O
in	O
eosinophil	O
-	O
mediated	O
host	O
defense	O
(	O
6,7	O
)	O
;	O
in	O
addition	O
,	O
we	O
have	O
recently	O
shown	O
that	O
eosinophil	O
ribonucleases	O
can	O
inhibit	O
retroviral	O
transduction	O
of	O
human	B
target	O
cells	O
(	O
23	O
)	O
.	O

The	O
possibility	O
that	O
certain	O
ribonucleases	O
have	O
diverged	O
to	O
promote	O
distinct	O
and	O
specific	O
host	O
defense	O
-	O
related	O
activities	O
remains	O
an	O
intriguing	O
hypothesis	O
.	O

ACKNOWLEDGEMENTS	O
We	O
would	O
like	O
to	O
thank	O
Dr	O
Jianzhi	O
Zhang	O
for	O
helpful	O
discussions	O
,	O
and	O
Drs	O
Harry	O
L.	O
Malech	O
and	O
John	O
I.	O
Gallin	O
for	O
their	O
ongoing	O
suppport	O
of	O
the	O
work	O
in	O
our	O
laboratory	O
.	O

D.B.	O
is	O
a	O
Howard	O
Hughes	O
Medical	O
Institute	O
-	O
National	O
Institutes	O
of	O
Health	O
Research	O
Scholar	O
REFERENCES	O
1	O
D'Alessio	O
,	O
G.	O
and	O
Riordan	O
,	O
J.F.	O
(	O
1997	O
)	O
In	O
D'Alessio	O
,	O
G.	O
and	O
Riordan	O
,	O
J.F.	O
(	O
eds	O
)	O
Ribonucleases	O
:	O
structure	O
and	O
function	O
.	O

Academic	O
Press	O
,	O
Inc.	O
,	O
New	O
York	O
,	O
NY	O
.	O

2	O
Sorrentino	O
,	O
S.	O
and	O
Libonati	O
,	O
M.	O
(	O
1997	O
)	O
FEBS	O
Lett	O
.	O

404	O
,	O
1	O
�	O
5	O
.	O
21	O
22	O
23	O
24	O
3	O
4	O
5	O
6	O
7	O
8	O
9	O
10	O
11	O
12	O
13	O
14	O
15	O
16	O
17	O
18	O
19	O
20	O
4239	O
Beintema	O
,	O
J.J.	O
,	O
Breukelman	O
,	O
H.J	O
,	O
Carsana	O
,	O
A.	O
,	O
and	O
Furia	O
,	O
A.	O
(	O
1997	O
)	O
In	O
D'Alessio	O
,	O
G.	O
and	O
Riordan	O
,	O
J.F.	O
(	O
eds	O
)	O
Ribonucleases	O
:	O
structure	O
and	O
function	O
.	O

Academic	O
Press	O
,	O
Inc.	O
,	O
New	O
York	O
,	O
NY	O
.	O

Confalone	O
,	O
E.	O
,	O
Beintema	O
,	O
J.J.	O
,	O
Sasso	O
,	O
M.P.	O
Carsana	O
,	O
A.	O
,	O
Palmieria	O
,	O
M.	O
,	O
Vento	O
,	O
M.T.	O
and	O
Furia	O
A.	O
(	O
1995	O
)	O
J.	O
Mol	O
.	O

Evol	O
.	O

41	O
,	O
850	O
�	O
858	O
.	O

Futami	O
,	O
J.	O
,	O
Tsushima	O
,	O
Y.	O
,	O
Murato	O
,	O
U	O
,	O
Tada	O
,	O
H.	O
,	O
Sasaki	O
,	O
J.	O
,	O
Seno	O
,	O
M.	O
,	O
and	O
Yamada	O
,	O
H.	O
(	O
1997	O
)	O
DNA	O
Cell	O
Biol	O
.	O

16	O
,	O
413	O
�	O
419	O
.	O

Ackerman	O
,	O
S.J.	O
(	O
1993	O
)	O
In	O
Makino	O
,	O
S.	O
and	O
Fukuda	O
,	O
T.	O
(	O
eds	O
)	O
Eosinophils	O
:	O
biological	O
and	O
clinical	O
aspects	O
.	O

CRC	O
Press	O
,	O
Inc.	O
,	O
Boca	O
Raton	O
,	O
FL	O
Spry	O
,	O
C.J.F.	O
(	O
1988	O
)	O
Eosinophils	O
:	O
a	O
comprehensive	O
review	O
and	O
guide	O
to	O
the	O
scientific	O
and	O
medical	O
literature	O
.	O

Oxford	O
University	O
Press	O
,	O
Oxford	O
,	O
UK	O
.	O

Beintema	O
,	O
J.J.	O
,	O
Hofsteenge	O
,	O
J.	O
,	O
Iwama	O
,	O
M.	O
,	O
Morita	O
,	O
T.	O
,	O
Ohgi	O
,	O
K.	O
,	O
Irie	O
,	O
M.	O
,	O
Sugiyama	O
,	O
R.H.	O
,	O
Schieven	O
G.L.	O
,	O
Dekker	O
,	O
C.A.	O
,	O
and	O
Glitz	O
,	O
D.G.	O
(	O
1988	O
)	O
Biochemistry	O
27	O
,	O
4530	O
�	O
4538	O
.	O

Sorrentino	O
,	O
S.	O
,	O
Tucker	O
,	O
G.K.	O
,	O
and	O
Glitz	O
,	O
D.G.	O
(	O
1988	O
)	O
J.	O
Biol	O
.	O

Chem	O
.	O

263	O
,	O
16125	O
�	O
16131	O
.	O

Vallee	O
,	O
B.L.	O
and	O
Riordan	O
,	O
J.F.	O
(	O
1988	O
)	O
Adv	O
.	O

Exp	O
.	O

Med	O
.	O

Biol	O
.	O

234	O
,	O
41	O
�	O
53	O
.	O

Moroianu	O
,	O
J.	O
and	O
Riordan	O
,	O
J.F.	O
(	O
1994	O
)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

USA	O
91	O
,	O
1677	O
�	O
1681	O
.	O

Seno	O
,	O
M.	O
,	O
Futami	O
,	O
J.	O
,	O
Tsushima	O
,	O
Y.	O
,	O
Akutagawa	O
,	O
K.	O
,	O
Kosaka	O
,	O
M.	O
,	O
Tada	O
,	O
H.	O
and	O
Yamada	O
,	O
H.	O
(	O
1995	O
)	O
Bioch	O
.	O

Biophys	O
.	O

Acta	O
1261	O
,	O
424	O
�	O
426	O
.	O

Rosenberg	O
,	O
H.F.	O
and	O
Dyer	O
,	O
K.D.	O
(	O
1995	O
)	O
Nucleic	O
Acids	O
Res	O
.	O

23	O
,	O
4290	O
�	O
4295	O
.	O

Rosenberg	O
,	O
H.F.	O
and	O
Dyer	O
,	O
K.D.	O
(	O
1996	O
)	O
Nucleic	O
Acids	O
Res	O
.	O

24	O
,	O
3507	O
�	O
3513	O
.	O

Larson	O
,	O
K.A.	O
,	O
Olson	O
,	O
E.V.	O
,	O
Madden	O
,	O
B.J.	O
,	O
Gleich	O
,	O
G.J.	O
,	O
Lee	O
,	O
N.A.	O
and	O
Lee	O
,	O
J.J.	O
(	O
1997	O
)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

USA	O
93	O
,	O
12370	O
�	O
12375	O
.	O

Nakajima	O
-	O
Iyima	O
,	O
S.	O
,	O
Hamada	O
,	O
H.	O
,	O
Reddy	O
,	O
P.	O
and	O
Kakanaga	O
,	O
T.	O
(	O
1985	O
)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

USA	O
82	O
,	O
6133	O
�	O
6137	O
.	O

Li	O
,	O
W	O
.-	O
H.	O
and	O
Graur	O
,	O
D.	O
(	O
1991	O
)	O
Fundamentals	O
of	O
Molecular	O
Evolution	O
.	O

Sinauer	O
Associates	O
,	O
Sunderland	O
,	O
MA	O
.	O

Rosenberg	O
,	O
H.F.	O
and	O
Dyer	O
,	O
K.D.	O
(	O
1995	O
)	O
J.	O
Biol	O
.	O

Chem	O
.	O
270	O
,	O
21539	O
�	O
21544	O
.	O

Watanabe	O
,	O
H.	O
,	O
Katoh	O
,	O
H	O
,	O
Ishii	O
,	O
M.	O
,	O
Komoda	O
,	O
Y.	O
,	O
Sanda	O
,	O
A.	O
,	O
Takizawa	O
,	O
Y.	O
,	O
Ohgi	O
,	O
K.	O
and	O
Irie	O
,	O
M.	O
(	O
1988	O
)	O
J.	O
Biochem	O
.	O

104	O
,	O
939	O
�	O
945	O
.	O

Sasso	O
,	O
M.P.	O
,	O
Carsana	O
,	O
A.	O
,	O
Confalone	O
,	O
E.	O
,	O
Cosi	O
,	O
C.	O
,	O
Sorrentino	O
,	O
S.	O
,	O
Viola	O
,	O
M.	O
,	O
Palmieri	O
,	O
M.	O
,	O
Russo	O
,	O
E.	O
and	O
Furia	O
,	O
A.	O
(	O
1991	O
)	O
Nucleic	O
Acids	O
Res	O
.	O

19	O
,	O
6469	O
�	O
6474	O
.	O

Palmieri	O
,	O
M.	O
,	O
Carsana	O
,	O
A.	O
,	O
Furia	O
,	O
A.	O
and	O
Libonati	O
,	O
M.	O
(	O
1985	O
)	O
Eur	O
.	O

J.	O
Biochem	O
.	O

152	O
,	O
275	O
�	O
277	O
.	O

Rosenberg	O
,	O
H.F.	O
,	O
Dyer	O
,	O
K.D.	O
,	O
Tiffany	O
,	O
H.L.	O
and	O
Gonzalez	O
,	O
M.	O
(	O
1995	O
)	O
Nature	O
Genet	O
.	O

10	O
,	O
219	O
�	O
223	O
.	O

Domachowske	O
,	O
J.B.	O
and	O
Rosenberg	O
,	O
H.F.	O
(	O
1997	O
)	O
J.	O
Leukoc	O
.	O

Biol	O
.	O
,	O
62	O
,	O
363	O
�	O
368	O
.	O

Iwama	O
,	O
M.	O
,	O
Sanda	O
,	O
A.	O
,	O
Ohgi	O
,	O
K.	O
,	O
Hofsteenge	O
,	O
J.	O
,	O
and	O
Irie	O
,	O
M.	O
(	O
1993	O
)	O
Biosci	O
.	O

Biotech	O
.	O

Biochem	O
.	O

57	O
,	O
2133	O
�	O
2138	O
.	O

Rap1p	O
and	O
other	O
transcriptional	O
regulators	O
can	O
function	O
in	O
defining	O
distinct	O
domains	O
of	O
gene	O
expression	O
Abstract	O
Barrier	O
elements	O
that	O
are	O
able	O
to	O
block	O
the	O
propagation	O
of	O
transcriptional	O
silencing	O
in	O
yeast	B
are	O
functionally	O
similar	O
to	O
chromatin	O
boundary	O
/	O
insulator	O
elements	O
in	O
metazoans	O
that	O
delimit	O
functional	O
chromosomal	O
domains	O
.	O

We	O
show	O
that	O
the	O
upstream	O
activating	O
sequences	O
of	O
many	O
highly	O
expressed	O
ribosome	O
protein	O
genes	O
and	O
glycolytic	O
genes	O
exhibit	O
barrier	O
activity	O
.	O

Analyses	O
of	O
these	O
barriers	O
indicate	O
that	O
binding	O
sites	O
for	O
transcriptional	O
regulators	O
Rap1p	O
,	O
Abf1p	O
,	O
Reb1p	O
,	O
Adr1p	O
and	O
Gcn4p	O
may	O
participate	O
in	O
barrier	O
function	O
.	O

We	O
also	O
present	O
evidence	O
suggesting	O
that	O
Rap1p	O
is	O
directly	O
involved	O
in	O
barrier	O
activity	O
,	O
and	O
its	O
barrier	O
function	O
correlates	O
with	O
local	O
changes	O
in	O
chromatin	O
structure	O
.	O

We	O
further	O
demonstrate	O
that	O
tethering	O
the	O
transcriptional	O
activation	O
domain	O
of	O
Rap1p	O
to	O
DNA	O
is	O
sufficient	O
to	O
recapitulate	O
barrier	O
activity	O
.	O

Moreover	O
,	O
targeting	O
the	O
activation	O
domain	O
of	O
Adr1p	O
or	O
Gcn4p	O
also	O
establishes	O
a	O
barrier	O
to	O
silencing	O
.	O

These	O
results	O
support	O
the	O
notion	O
that	O
transcriptional	O
regulators	O
could	O
also	O
participate	O
in	O
delimiting	O
functional	O
domains	O
in	O
the	O
genome	O
.	O

INTRODUCTION	O
The	O
eukaryotic	O
genome	O
is	O
organized	O
into	O
discrete	O
functional	O
domains	O
in	O
which	O
gene	O
expression	O
is	O
either	O
permitted	O
or	O
repressed	O
.	O

Domains	O
permissive	O
for	O
gene	O
expression	O
are	O
usually	O
defined	O
as	O
euchromatin	O
or	O
active	O
chromatin	O
,	O
and	O
domains	O
that	O
repress	O
gene	O
expression	O
heterochromatin	O
or	O
silent	O
chromatin	O
.	O

The	O
HML	O
and	O
HMR	O
loci	O
in	O
Saccharomyces	B
cerevisiae	I
are	O
silent	O
chromatin	O
domains	O
(	O
1	O
)	O
.	O

Compared	O
to	O
active	O
chromatin	O
,	O
silent	O
chromatin	O
is	O
more	O
compact	O
and	O
its	O
histone	O
components	O
are	O
hypoacetylated	O
(	O
2	O
)	O
.	O

The	O
SIR	O
complex	O
consisting	O
of	O
Sir2p	O
through	O
Sir4p	O
is	O
an	O
integral	O
part	O
of	O
yeast	B
silent	O
chromatin	O
.	O

Sir3p	O
and	O
Sir4p	O
interact	O
with	O
the	O
N	O
-	O
terminal	O
tails	O
of	O
histones	O
H3	O
and	O
H4	O
providing	O
the	O
structural	O
basis	O
of	O
silent	O
chromatin	O
(	O
1	O
)	O
.	O

Sir2p	O
was	O
recently	O
found	O
to	O
be	O
an	O
NAD	O
-	O
dependent	O
histone	O
deacetylase	O
and	O
was	O
suggested	O
to	O
be	O
responsible	O
for	O
histone	O
hypoacetylation	O
in	O
silent	O
chromatin	O
(	O
3	O
)	O
.	O

Silent	O
chromatin	O
is	O
initiated	O
at	O
small	O
cis	O
-	O
acting	O
DNA	O
elements	O
known	O
as	O
the	O
E	O
and	O
I	O
silencers	O
flanking	O
each	O
of	O
the	O
HM	O
loci	O
(	O
4	O
)	O
.	O

Increasing	O
evidence	O
indicates	O
that	O
histone	O
deacetylation	O
is	O
key	O
to	O
the	O
propagation	O
of	O
silent	O
chromatin	O
(	O
4	O
)	O
.	O

In	O
vertebrates	O
and	O
fission	O
yeast	B
,	O
spread	O
of	O
silent	O
chromatin	O
involves	O
a	O
chain	O
of	O
events	O
of	O
histone	O
H3	O
deacetylation	O
→	O
H3	O
methylation	O
→	O
binding	O
of	O
methylated	O
H3	O
by	O
HP1	O
(	O
heterochromatin	O
protein	O
1	O
)	O
or	O
swi6	O
(	O
4	O
)	O
.	O

In	O
S.cerevisiae	B
,	O
there	O
is	O
evidence	O
that	O
Sir3p	O
(	O
hence	O
the	O
SIR	O
complex	O
)	O
has	O
much	O
higher	O
affinity	O
to	O
unacetylated	O
histone	O
H4	O
than	O
acetylated	O
H4	O
(	O
5	O
)	O
.	O

Based	O
on	O
this	O
and	O
the	O
fact	O
that	O
Sir2p	O
is	O
a	O
histone	O
deacetylase	O
,	O
a	O
refined	O
model	O
for	O
the	O
propagation	O
of	O
silent	O
chromatin	O
can	O
be	O
proposed	O
.	O

In	O
this	O
model	O
,	O
Sir2p	O
recruited	O
to	O
the	O
silencer	O
deacetylates	O
histones	O
in	O
an	O
adjacent	O
nucleosome	O
enabling	O
it	O
to	O
bind	O
another	O
SIR	O
complex	O
with	O
high	O
affinity	O
.	O

The	O
nucleosome	O
-	O
bound	O
SIR	O
complex	O
in	O
turn	O
deacetylates	O
the	O
neighboring	O
nucleosome	O
allowing	O
it	O
to	O
recruit	O
a	O
new	O
SIR	O
complex	O
.	O

In	O
this	O
manner	O
,	O
the	O
SIR	O
complex	O
promotes	O
its	O
own	O
propagation	O
along	O
an	O
array	O
of	O
nucleosomes	O
(	O
4	O
)	O
.	O

The	O
fact	O
that	O
transcriptionally	O
silent	O
chromatin	O
can	O
encroach	O
upon	O
active	O
chromatin	O
poses	O
the	O
question	O
of	O
how	O
interspersed	O
domains	O
of	O
silent	O
and	O
active	O
chromatin	O
are	O
demarcated	O
.	O

Studies	O
of	O
the	O
Drosophila	O
and	O
vertebrate	O
genomes	O
demonstrated	O
that	O
some	O
domains	O
are	O
delimited	O
by	O
boundary	O
or	O
insulator	O
elements	O
(	O
6	O
)	O
.	O

These	O
elements	O
are	O
specialized	O
DNA	O
sequences	O
that	O
act	O
as	O
barriers	O
to	O
enhancers	O
and/or	O
silent	O
chromatin	O
.	O

One	O
of	O
the	O
best	O
characterized	O
insulators	O
is	O
the	O
chicken	B
HS4	O
insulator	O
at	O
the	O
β	O
-	O
globin	O
locus	O
.	O

Histones	O
surrounding	O
this	O
insulator	O
are	O
hyperacetylated	O
indicating	O
the	O
presence	O
of	O
histone	O
acetyltransferase	O
(	O
HAT	O
)	O
activity	O
at	O
the	O
insulator	O
(	O
6	O
)	O
.	O

Recently	O
,	O
sequences	O
that	O
could	O
block	O
the	O
spread	O
of	O
silent	O
chromatin	O
have	O
been	O
discovered	O
in	O
S.cerevisiae	B
(	O
7,8	O
)	O
.	O

These	O
sequences	O
(	O
referred	O
to	O
as	O
silent	O
chromatin	O
barriers	O
)	O
include	O
sub	O
-	O
telomeric	O
anti	O
-	O
silencing	O
regions	O
(	O
STARs	O
)	O
,	O
the	O
right	O
boundary	O
of	O
HMR	O
,	O
and	O
the	O
upstream	O
activating	O
sequence	O
(	O
UAS	O
)	O
of	O
the	O
highly	O
expressed	O
TEF2	O
gene	O
(	O
9–11	O
)	O
.	O

The	O
mechanisms	O
underlying	O
barrier	O
functions	O
in	O
yeast	B
are	O
not	O
known	O
.	O

TEF2-UAS	O
contains	O
three	O
tandem	O
repressor	O
activator	O
protein	O
1	O
(	O
Rap1p	O
)	O
-binding	O
sites	O
that	O
are	O
necessary	O
and	O
sufficient	O
for	O
its	O
barrier	O
function	O
(	O
11	O
)	O
.	O

Rap1p	O
is	O
an	O
abundant	O
sequence	O
-	O
specific	O
DNA	O
-	O
binding	O
protein	O
(	O
12	O
)	O
.	O

Variants	O
of	O
the	O
13	O
bp	O
consensus	O
sequence	O
for	O
Rap1p	O
binding	O
(	O
ACACC	O
CRYACAYM	O
)	O
(	O
13	O
)	O
lie	O
not	O
only	O
in	O
the	O
UASs	O
of	O
numerous	O
genes	O
but	O
also	O
in	O
the	O
silencers	O
of	O
the	O
HM	O
loci	O
and	O
in	O
telomeric	O
C1–3A	O
repeats	O
.	O

Accordingly	O
,	O
Rap1p	O
functions	O
as	O
a	O
global	O
regulator	O
of	O
transcriptional	O
activation	O
and	O
repression	O
,	O
silencing	O
,	O
as	O
well	O
as	O
telomere	O
length	O
(	O
12	O
)	O
.	O

Rap1p	O
performs	O
these	O
diverse	O
functions	O
by	O
interacting	O
with	O
different	O
factors	O
in	O
respective	O
contexts	O
.	O

As	O
an	O
activator	O
,	O
Rap1p	O
binds	O
to	O
the	O
promoters	O
of	O
362	O
ORFs	O
(	O
13	O
)	O
and	O
can	O
function	O
via	O
at	O
least	O
three	O
mechanisms	O
.	O

First	O
,	O
Rap1p	O
binding	O
can	O
'	O
open	O
up	O
'	O
local	O
chromatin	O
structure	O
at	O
a	O
promoter	O
to	O
help	O
another	O
activator	O
to	O
bind	O
(	O
14	O
)	O
.	O

Secondly	O
,	O
Rap1p	O
bound	O
to	O
DNA	O
can	O
help	O
Gcr1p	O
bind	O
to	O
an	O
adjacent	O
site	O
in	O
the	O
promoter	O
through	O
physical	O
interaction	O
(	O
15	O
)	O
.	O

Thirdly	O
,	O
Rap1p	O
is	O
involved	O
in	O
the	O
recruitment	O
of	O
the	O
NuA4	O
HAT	O
complex	O
and	O
TFIID	O
to	O
ribosome	O
protein	O
genes	O
(	O
RPGs	O
)	O
(	O
16,17	O
)	O
.	O

As	O
a	O
silencing	O
factor	O
,	O
Rap1p	O
binds	O
to	O
silencers	O
or	O
telomeric	O
repeats	O
and	O
recruits	O
Sir3p	O
/	O
Sir4p	O
through	O
direct	O
interactions	O
(	O
18	O
)	O
.	O

Rap1p	O
also	O
interacts	O
with	O
telomere	O
-	O
specific	O
proteins	O
in	O
executing	O
its	O
role	O
in	O
regulating	O
telomere	O
length	O
(	O
19	O
)	O
.	O

It	O
is	O
puzzling	O
that	O
a	O
protein	O
that	O
helps	O
establish	O
silent	O
chromatin	O
could	O
also	O
act	O
as	O
a	O
barrier	O
to	O
its	O
propagation	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
in	O
addition	O
to	O
TEF2-UAS	O
,	O
UASs	O
of	O
many	O
yeast	B
genes	O
exhibit	O
barrier	O
activity	O
.	O

Analyses	O
of	O
these	O
UASs	O
indicate	O
that	O
binding	O
sites	O
for	O
transcriptional	O
regulators	O
Abf1p	O
,	O
Reb1p	O
,	O
Adr1p	O
,	O
Gcn4p	O
,	O
as	O
well	O
as	O
Rap1p	O
,	O
may	O
participate	O
in	O
barrier	O
function	O
.	O

These	O
UASs	O
are	O
dispersed	O
across	O
the	O
genome	O
and	O
might	O
play	O
a	O
role	O
in	O
defining	O
functional	O
chromosomal	O
domains	O
.	O

Moreover	O
,	O
we	O
demonstrated	O
that	O
targeting	O
the	O
activation	O
domain	O
of	O
Rap1p	O
,	O
Adr1p	O
or	O
Gcn4p	O
alone	O
,	O
led	O
to	O
barrier	O
function	O
.	O

Since	O
the	O
activation	O
domain	O
of	O
an	O
activator	O
was	O
usually	O
involved	O
in	O
interacting	O
with	O
co	O
-	O
activators	O
and/or	O
components	O
of	O
the	O
transcriptional	O
machinery	O
,	O
these	O
data	O
indicated	O
that	O
other	O
factors	O
might	O
also	O
be	O
involved	O
in	O
barrier	O
function	O
.	O

MATERIALS	O
AND	O
METHODS	O
Plasmids	O
and	O
strains	O
Plasmids	O
1–53	O
were	O
used	O
to	O
make	O
strains	O
1–53	O
,	O
respectively	O
(	O
see	O
Figs	O
1–6	O
)	O
.	O

Plasmid	O
1	O
was	O
previously	O
named	O
pMB22-a	O
that	O
contained	O
a	O
HindIII	O
–	O
BamHI	O
fragment	O
of	O
chromosome	O
III	O
(	O
coordinates	O
14838–16263	O
)	O
with	O
a	O
URA3	O
gene	O
inserted	O
at	O
its	O
EcoRV	O
site	O
(	O
20	O
)	O
.	O

Plasmid	O
2	O
was	O
derived	O
from	O
1	O
by	O
inserting	O
TEF2-UAS	O
(	O
–511	O
to	O
–407	O
bp	O
relative	O
to	O
the	O
translation	O
start	O
codon	O
)	O
at	O
the	O
SnaBI	O
site	O
.	O

Plasmids	O
3–38	O
were	O
identical	O
to	O
2	O
except	O
that	O
different	O
fragments	O
from	O
various	O
promoters	O
(	O
see	O
Figs	O
1	O
and	O
2	O
)	O
were	O
inserted	O
at	O
the	O
SnaBI	O
site	O
.	O

Plasmid	O
29	O
had	O
a	O
sequence	O
of	O
chromosome	O
III	O
(	O
295327–295713	O
)	O
containing	O
the	O
HMR	O
-	O
tRNA	O
gene	O
(	O
21	O
)	O
inserted	O
at	O
the	O
SnaBI	O
site	O
of	O
plasmid	O
1	O
.	O

Plasmids	O
39	O
and	O
40	O
were	O
previously	O
named	O
pYXB26	O
and	O
pYXB59	O
,	O
respectively	O
(	O
11	O
)	O
.	O

Plasmid	O
41	O
was	O
identical	O
to	O
pYXB59	O
except	O
bearing	O
mutations	O
illustrated	O
in	O
Figure	O
3A	O
.	O

Plasmids	O
42–48	O
were	O
previously	O
described	O
as	O
pYXB29	O
,	O
48	O
,	O
28	O
,	O
27	O
,	O
59	O
,	O
31	O
and	O
37	O
,	O
respectively	O
(	O
11	O
)	O
.	O

Plasmid	O
50	O
was	O
derived	O
from	O
plasmid	O
1	O
by	O
inserting	O
two	O
copies	O
of	O
a	O
sequence	O
bearing	O
the	O
consensus	O
binding	O
sequence	O
of	O
LexA	O
(	O
bold	O
)	O
(	O
22	O
)	O
,	O
GGGGTACGTACTGTATGTACATACAGGATATCGGGG	O
,	O
at	O
the	O
SnaBI	O
site	O
.	O

Plasmid	O
51	O
was	O
identical	O
to	O
50	O
except	O
having	O
only	O
one	O
copy	O
of	O
the	O
LexA	O
-	O
binding	O
sequence	O
.	O

Plasmid	O
52	O
was	O
derived	O
from	O
pYXB26	O
(	O
11	O
)	O
by	O
inserting	O
a	O
SpeI	O
-	O
ADE2-AvrII	O
sequence	O
at	O
the	O
SpeI	O
site	O
.	O

Plasmid	O
53	O
was	O
derived	O
from	O
plasmid	O
52	O
by	O
inserting	O
TEF2-UAS	O
(	O
–511	O
to	O
–407	O
bp	O
relative	O
to	O
the	O
translation	O
start	O
codon	O
)	O
at	O
the	O
SpeI	O
site	O
.	O

Plasmid	O
L1	O
(	O
see	O
Fig.	O
5A	O
)	O
was	O
made	O
by	O
inserting	O
LEU2	O
into	O
pBTM116	O
(	O
23	O
)	O
carrying	O
the	O
LexA	O
gene	O
flanked	O
by	O
the	O
promoter	O
and	O
terminator	O
of	O
ADH1	O
.	O

L2	O
through	O
L8	O
were	O
derived	O
from	O
L1	O
by	O
fusing	O
various	O
sequences	O
to	O
LexA	O
(	O
see	O
Fig.	O
5A	O
and	O
B	O
)	O
.	O

Plasmid	O
pRS425	O
(	O
24	O
)	O
carried	O
the	O
2	O
µm	O
origin	O
and	O
LEU2	O
.	O

Strain	O
YXB76	O
was	O
MATa	O
ura3	O
-	O
52	O
leu2	O
-	O
3,112	O
ade2	O
-	O
1	O
lys1	O
-	O
1	O
his5	O
-	O
2	O
can1	O
-	O
100	O
,	O
E	O
-	O
HMLα	O
-	O
Iinverted	O
(	O
20	O
)	O
.	O

Y2047b	O
was	O
MATa	O
HMRa	O
HMLα	O
EΔ79–113::SUP4-o	O
IΔ242	O
LEU2-GAL10-FLP1	O
ura3	O
-	O
52	O
ade2	O
-	O
1	O
lys1	O
-	O
1	O
his5	O
-	O
1	O
can1	O
-	O
100	O
[	O
cir0	O
]	O
(	O
25	O
)	O
.	O

Strain	O
1	O
was	O
made	O
by	O
transforming	O
YXB76	O
to	O
Ura+	O
with	O
HindIII	O
+	O
BamHI	O
digested	O
plasmid	O
1	O
.	O

Strains	O
2–38	O
,	O
50	O
and	O
51	O
were	O
similarly	O
made	O
with	O
corresponding	O
plasmids	O
,	O
respectively	O
(	O
e.g.	O
strain	O
2	O
was	O
made	O
with	O
plasmid	O
2	O
)	O
.	O

Strains	O
39	O
,	O
40	O
and	O
42–48	O
were	O
previously	O
described	O
as	O
YXB26	O
,	O
48	O
,	O
29	O
,	O
48	O
,	O
28	O
,	O
27	O
,	O
59	O
,	O
31	O
and	O
37	O
,	O
respectively	O
(	O
11	O
)	O
.	O

Strains	O
41	O
,	O
52	O
and	O
53	O
(	O
see	O
Figs	O
3C	O
and	O
6	O
)	O
were	O
made	O
by	O
transforming	O
Y2047b	O
to	O
canavanine	O
-	O
resistant	O
by	O
BamHI	O
-	O
digested	O
plasmids	O
41	O
,	O
52	O
and	O
53	O
,	O
respectively	O
.	O

Strains	O
40′–48′	O
were	O
sir3::URA3	O
derivatives	O
of	O
strains	O
40–48	O
,	O
respectively	O
.	O

The	O
relevant	O
genotypes	O
of	O
all	O
the	O
strains	O
were	O
confirmed	O
by	O
Southern	O
blotting	O
.	O

Quantitative	O
mating	O
assay	O
Quantitative	O
mating	O
was	O
performed	O
as	O
described	O
(	O
11	O
)	O
.	O

Electrophoresis	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
Rap1p	O
was	O
expressed	O
in	O
Escherichia	B
coli	I
BL21	I
(	I
DE3	I
)	I
from	O
pL3S5	O
,	O
a	O
pET	O
vector	O
carrying	O
the	O
RAP1	O
gene	O
downstream	O
of	O
a	O
T7	O
promoter	O
(	O
26	O
)	O
.	O

Crude	O
protein	O
extracts	O
were	O
prepared	O
from	O
40	O
ml	O
cultures	O
harvested	O
after	O
3	O
h	O
of	O
IPTG	O
induction	O
and	O
resuspended	O
in	O
1	O
ml	O
of	O
lysis	O
buffer	O
(	O
50	O
mM	O
NaH2PO4	O
,	O
300	O
mM	O
NaCl	O
,	O
pH	O
8.0	O
)	O
.	O

A	O
control	O
extract	O
was	O
prepared	O
from	O
a	O
culture	O
without	O
IPTG	O
induction	O
.	O

Western	O
blotting	O
revealed	O
that	O
Rap1p	O
protein	O
was	O
present	O
in	O
the	O
induced	O
extract	O
but	O
not	O
the	O
uninduced	O
one	O
(	O
data	O
not	O
shown	O
)	O
.	O

DNA	O
fragments	O
of	O
26	O
bp	O
in	O
length	O
(	O
see	O
Fig.	O
3A	O
)	O
were	O
end	O
-	O
labeled	O
with	O
32P	O
-	O
phosphate	O
.	O

Fifteen	O
microliter	O
binding	O
reactions	O
were	O
prepared	O
,	O
each	O
consisting	O
of	O
20	O
000	O
c.p.m	O
.	O

radiolabeled	O
DNA	O
probe	O
,	O
5	O
µg	O
of	O
crude	O
protein	O
extract	O
,	O
non	O
-	O
specific	O
competitor	O
DNAs	O
(	O
0.3	O
µg	O
of	O
yeast	B
tRNA	O
,	O
0.3	O
µg	O
of	O
salmon	B
sperm	O
DNA	O
and	O
0.5	O
µg	O
of	O
E.coli	B
DNA	O
)	O
,	O
10	O
µg	O
of	O
BSA	O
,	O
10	O
mM	O
Tris	O
–	O
HCl	O
(	O
pH	O
8.0	O
)	O
,	O
10	O
mM	O
MgCl2	O
and	O
8	O
%	O
glycerol	O
.	O

The	O
reactions	O
were	O
incubated	O
at	O
25	O
°	O
C	O
for	O
20	O
min	O
and	O
loaded	O
onto	O
non	O
-	O
denaturing	O
polyacrylamide	O
gels	O
(	O
4–5	O
%	O
)	O
.	O

Gels	O
were	O
run	O
at	O
40	O
mA	O
for	O
1	O
h	O
in	O
0.5	O
×	O
TBE	O
buffer	O
.	O

Analysis	O
of	O
the	O
supercoiling	O
of	O
DNA	O
circles	O
Cells	O
were	O
grown	O
in	O
YPR	O
(	O
yeast	B
extract	O
+	O
bacto	O
peptone	O
+	O
2	O
%	O
raffinose	O
)	O
to	O
early	O
log	O
phase	O
.	O

Galactose	O
(	O
2	O
%	O
)	O
was	O
then	O
added	O
to	O
the	O
culture	O
to	O
induce	O
the	O
expression	O
of	O
FLP1	O
.	O

After	O
2.5	O
h	O
of	O
incubation	O
,	O
nucleic	O
acid	O
was	O
isolated	O
using	O
the	O
glass	O
bead	O
method	O
and	O
fractionated	O
on	O
agarose	O
gels	O
with	O
30	O
µg	O
/	O
ml	O
chloroquine	O
.	O

DNA	O
circles	O
were	O
detected	O
by	O
Southern	O
blotting	O
.	O

RESULTS	O
UASs	O
of	O
many	O
highly	O
expressed	O
genes	O
can	O
function	O
as	O
barriers	O
to	O
the	O
spread	O
of	O
silencing	O
We	O
have	O
previously	O
shown	O
that	O
TEF2-UAS	O
was	O
able	O
to	O
block	O
the	O
spread	O
of	O
silencing	O
in	O
a	O
silencer	O
-	O
blocking	O
assay	O
(	O
11	O
)	O
.	O

Such	O
an	O
assay	O
tested	O
if	O
a	O
sequence	O
had	O
the	O
ability	O
to	O
prevent	O
a	O
silencer	O
from	O
silencing	O
a	O
reporter	O
gene	O
when	O
it	O
was	O
positioned	O
between	O
the	O
silencer	O
and	O
the	O
reporter	O
.	O

In	O
this	O
report	O
we	O
used	O
a	O
new	O
silencer	O
-	O
blocking	O
assay	O
to	O
identify	O
more	O
barrier	O
elements	O
.	O

This	O
assay	O
employed	O
the	O
URA3	O
gene	O
and	O
an	O
inverted	O
HML	O
-	O
I	O
that	O
could	O
silence	O
sequences	O
to	O
the	O
right	O
of	O
HML	O
(	O
20	O
)	O
(	O
Fig.	O
1	O
,	O
strain	O
1	O
)	O
.	O

URA3	O
expression	O
makes	O
cells	O
sensitive	O
to	O
5-fluoroorotic	O
acid	O
(	O
FOA	O
)	O
thus	O
URA3	O
silencing	O
could	O
be	O
measured	O
by	O
cell	O
growth	O
on	O
FOA	O
medium	O
(	O
Fig.	O
1	O
,	O
strain	O
1	O
)	O
.	O

As	O
expected	O
,	O
TEF2-UAS	O
and	O
another	O
known	O
barrier	O
element	O
,	O
HMR	O
-	O
tRNA	O
gene	O
(	O
21	O
)	O
exhibited	O
barrier	O
activity	O
in	O
this	O
assay	O
as	O
indicated	O
by	O
the	O
lack	O
of	O
silencing	O
of	O
URA3	O
in	O
strains	O
2	O
and	O
29	O
(	O
Fig.	O
1	O
)	O
.	O

TEF2	O
encoding	O
translation	O
elongation	O
factor	O
1α	O
is	O
one	O
of	O
the	O
most	O
highly	O
expressed	O
genes	O
in	O
yeast	B
(	O
27	O
)	O
.	O

Other	O
highly	O
expressed	O
genes	O
include	O
ribosome	O
protein	O
genes	O
(	O
RPGs	O
)	O
and	O
genes	O
coding	O
for	O
glycolytic	O
enzymes	O
(	O
27	O
)	O
.	O

The	O
coordinated	O
regulation	O
of	O
most	O
of	O
these	O
genes	O
requires	O
the	O
so	O
-	O
called	O
general	O
regulatory	O
factors	O
Rap1p	O
,	O
Abf1p	O
and	O
Reb1p	O
(	O
28,29	O
)	O
.	O

Using	O
the	O
above	O
silencer	O
-	O
blocking	O
assay	O
,	O
we	O
tested	O
if	O
the	O
UASs	O
of	O
other	O
highly	O
expressed	O
genes	O
could	O
also	O
block	O
URA3	O
silencing	O
(	O
Fig.	O
1	O
)	O
.	O

Seventeen	O
new	O
barrier	O
elements	O
were	O
identified	O
from	O
a	O
total	O
of	O
26	O
UASs	O
tested	O
.	O

These	O
17	O
elements	O
were	O
UASs	O
of	O
eight	O
RPGs	O
(	O
see	O
Fig.	O
1	O
,	O
strains	O
3–10	O
)	O
,	O
eight	O
glycolytic	O
genes	O
(	O
strains	O
18–25	O
)	O
and	O
the	O
HIS3	O
gene	O
(	O
strain	O
26	O
)	O
.	O

All	O
17	O
elements	O
except	O
ADH2-UAS	O
and	O
HIS3-UAS	O
exhibited	O
very	O
strong	O
barrier	O
activity	O
as	O
evidenced	O
by	O
the	O
absence	O
of	O
URA3-silencing	O
in	O
strains	O
3–10	O
and	O
18–24	O
(	O
Fig.	O
1	O
)	O
.	O

Seven	O
of	O
the	O
eight	O
RPG	O
-	O
UASs	O
that	O
had	O
barrier	O
activity	O
,	O
contained	O
a	O
single	O
or	O
a	O
pair	O
of	O
tandem	O
Rap1p	O
-	O
binding	O
sites	O
(	O
Fig.	O
1	O
,	O
strains	O
3–9	O
)	O
.	O

Three	O
of	O
them	O
also	O
contained	O
an	O
Abf1p	O
or	O
Reb1p	O
site	O
(	O
strains	O
6	O
,	O
8	O
and	O
9	O
)	O
.	O

One	O
barrier	O
RPG	O
-	O
UAS	O
(	O
strain	O
10	O
)	O
had	O
only	O
a	O
predicted	O
Abf1p	O
site	O
.	O

Of	O
the	O
seven	O
RPG	O
-	O
UASs	O
that	O
had	O
no	O
barrier	O
activity	O
(	O
Fig.	O
1	O
,	O
11–17	O
)	O
,	O
only	O
two	O
bore	O
no	O
site	O
for	O
Rap1p	O
,	O
Abf1p	O
or	O
Reb1p	O
(	O
11	O
and	O
12	O
)	O
.	O

The	O
remaining	O
five	O
each	O
contained	O
one	O
to	O
three	O
Rap1p	O
sites	O
(	O
strains	O
13–17	O
)	O
.	O

RPL15A	O
-	O
UAS	O
(	O
17	O
)	O
also	O
contained	O
an	O
Abf1p	O
site	O
.	O

For	O
most	O
of	O
the	O
15	O
RPG	O
-	O
UASs	O
tested	O
(	O
3–17	O
)	O
,	O
the	O
presence	O
or	O
absence	O
of	O
predicted	O
Rap1p	O
sites	O
correlated	O
with	O
the	O
presence	O
or	O
absence	O
of	O
Rap1p	O
association	O
in	O
vivo	O
as	O
previously	O
examined	O
by	O
chromatin	O
immunoprecipitation	O
assays	O
(	O
13	O
)	O
.	O

Exceptions	O
were	O
the	O
UASs	O
of	O
RPS24B	O
,	O
RPS28A	O
and	O
RPL15A	O
(	O
13	O
)	O
.	O

Of	O
the	O
eight	O
UASs	O
of	O
glycolytic	O
genes	O
tested	O
(	O
Fig.	O
1	O
,	O
strains	O
18–25	O
)	O
,	O
seven	O
exhibited	O
strong	O
barrier	O
activity	O
(	O
18–24	O
)	O
and	O
one	O
had	O
weaker	O
but	O
detectable	O
barrier	O
activity	O
(	O
strain	O
25	O
)	O
.	O

Glycolytic	O
genes	O
are	O
among	O
the	O
most	O
highly	O
expressed	O
genes	O
and	O
their	O
high	O
expression	O
depends	O
on	O
the	O
functions	O
of	O
Rap1p	O
,	O
Abf1p	O
or	O
Reb1p	O
as	O
well	O
as	O
Gcr1p	O
(	O
29,30	O
)	O
.	O

The	O
seven	O
strong	O
glycolytic	O
barriers	O
all	O
consist	O
of	O
one	O
or	O
two	O
Rap1p	O
sites	O
plus	O
one	O
or	O
two	O
Reb1p	O
or	O
Abf1p	O
sites	O
(	O
Fig.	O
1	O
,	O
strains	O
18–24	O
)	O
.	O

In	O
addition	O
,	O
one	O
or	O
more	O
Gcr1p	O
-	O
binding	O
sites	O
are	O
found	O
adjacent	O
to	O
each	O
Rap1p	O
site	O
.	O

It	O
was	O
proposed	O
that	O
the	O
function	O
of	O
Rap1p	O
was	O
to	O
facilitate	O
the	O
binding	O
of	O
Gcr1p	O
to	O
the	O
UAS	O
(	O
15	O
)	O
.	O

Abf1p	O
or	O
Reb1p	O
was	O
shown	O
to	O
play	O
a	O
role	O
similar	O
to	O
that	O
of	O
Rap1p	O
in	O
activating	O
glycolytic	O
genes	O
(	O
31–33	O
)	O
.	O

Although	O
the	O
above	O
data	O
reinforced	O
the	O
notion	O
that	O
certain	O
Rap1p	O
-	O
binding	O
UASs	O
could	O
serve	O
as	O
barriers	O
to	O
silencing	O
,	O
they	O
raised	O
new	O
questions	O
about	O
the	O
essential	O
components	O
of	O
a	O
barrier	O
element	O
.	O

For	O
example	O
,	O
some	O
of	O
the	O
UASs	O
that	O
contained	O
only	O
a	O
single	O
Rap1p	O
site	O
had	O
barrier	O
activity	O
(	O
e.g.	O
RPL19B	O
-	O
UAS	O
,	O
strain	O
3	O
)	O
whereas	O
others	O
that	O
contained	O
two	O
or	O
three	O
sites	O
had	O
no	O
activity	O
(	O
e.g.	O
RPL39	O
,	O
strain	O
16	O
)	O
.	O

One	O
explanation	O
was	O
that	O
sequences	O
flanking	O
the	O
Rap1p	O
site	O
(	O
s	O
)	O
in	O
a	O
particular	O
UAS	O
could	O
positively	O
or	O
negatively	O
influence	O
barrier	O
function	O
.	O

Moreover	O
,	O
the	O
presence	O
of	O
Abf1p	O
or	O
Reb1p	O
sites	O
in	O
11	O
of	O
the	O
17	O
new	O
barriers	O
made	O
us	O
wonder	O
if	O
they	O
also	O
participated	O
in	O
barrier	O
function	O
.	O

We	O
began	O
to	O
address	O
these	O
issues	O
by	O
analyzing	O
three	O
new	O
barrier	O
elements	O
(	O
Fig.	O
2	O
)	O
.	O

RPS10A	O
-	O
UAS	O
containing	O
an	O
Abf1p	O
-	O
binding	O
site	O
and	O
a	O
pair	O
of	O
Rap1p	O
sites	O
was	O
divided	O
into	O
three	O
fragments	O
that	O
were	O
tested	O
in	O
a	O
silencer	O
-	O
blocking	O
assay	O
(	O
Fig.	O
2	O
,	O
strains	O
30–32	O
)	O
.	O

It	O
was	O
clear	O
that	O
only	O
the	O
fragment	O
containing	O
Rap1p	O
sites	O
functioned	O
as	O
a	O
barrier	O
(	O
strain	O
31	O
)	O
.	O

TPI1-UAS	O
bearing	O
a	O
Reb1p	O
site	O
and	O
a	O
Rap1p	O
site	O
was	O
divided	O
into	O
two	O
parts	O
with	O
one	O
containing	O
the	O
Rap1p	O
site	O
(	O
Fig.	O
2	O
,	O
strain	O
34	O
)	O
and	O
the	O
other	O
Reb1p	O
site	O
(	O
strain	O
33	O
)	O
.	O

Neither	O
of	O
these	O
fragments	O
alone	O
retained	O
barrier	O
activity	O
indicating	O
that	O
concerted	O
action	O
of	O
Reb1p	O
and	O
Rap1p	O
was	O
required	O
for	O
barrier	O
activity	O
.	O

Duplicating	O
the	O
Reb1p	O
-	O
bearing	O
part	O
of	O
TPI1-UAS	O
did	O
n't	O
restore	O
barrier	O
activity	O
(	O
strain	O
35	O
)	O
.	O

However	O
,	O
triplicating	O
the	O
Rap1p	O
-	O
containing	O
part	O
did	O
re	O
-	O
create	O
barrier	O
function	O
(	O
strain	O
36	O
)	O
.	O

RPS28A	O
-	O
UAS	O
bore	O
,	O
in	O
addition	O
to	O
a	O
Rap1p	O
site	O
,	O
an	O
Abf1p	O
site	O
and	O
an	O
adjacent	O
T	O
-	O
rich	O
region	O
that	O
are	O
required	O
for	O
efficient	O
transcription	O
of	O
RPS28A	O
(	O
34	O
)	O
.	O

A	O
sequence	O
of	O
RPS28A	O
-	O
UAS	O
deleted	O
for	O
a	O
fragment	O
bearing	O
the	O
Rap1p	O
site	O
lost	O
the	O
barrier	O
activity	O
(	O
Fig.	O
2	O
,	O
strain	O
37	O
)	O
.	O

However	O
,	O
duplicating	O
this	O
sequence	O
restored	O
barrier	O
activity	O
(	O
strain	O
38	O
)	O
.	O

The	O
above	O
results	O
indicated	O
again	O
that	O
Rap1p	O
sites	O
could	O
form	O
barriers	O
(	O
strains	O
31	O
and	O
36	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
they	O
also	O
suggested	O
that	O
synergistic	O
actions	O
of	O
Abf1p	O
sites	O
(	O
strain	O
38	O
)	O
,	O
Reb1p	O
site	O
+	O
Rap1p	O
site	O
(	O
strain	O
18	O
)	O
,	O
or	O
Abf1p	O
site	O
+	O
Rap1p	O
site	O
(	O
strain	O
16	O
)	O
could	O
all	O
lead	O
to	O
barrier	O
function	O
.	O

This	O
was	O
not	O
very	O
surprising	O
since	O
Rap1p	O
,	O
Abf1p	O
and	O
Reb1p	O
could	O
perform	O
similar	O
and	O
sometimes	O
interchangeable	O
functions	O
in	O
gene	O
regulation	O
(	O
16,35,36	O
)	O
.	O

Note	O
,	O
however	O
,	O
we	O
have	O
n't	O
ruled	O
out	O
the	O
possibility	O
that	O
other	O
factors	O
(	O
e.g.	O
Gcr1p	O
)	O
or	O
structure	O
features	O
of	O
DNA	O
(	O
e.g.	O
T	O
-	O
tracks	O
)	O
were	O
also	O
involved	O
in	O
barrier	O
function	O
.	O

It	O
was	O
interesting	O
that	O
ADH2-UAS	O
and	O
HIS3-UAS	O
bearing	O
no	O
site	O
for	O
Rap1p	O
,	O
Abf1p	O
or	O
Reb1p	O
exhibited	O
detectable	O
barrier	O
activity	O
(	O
Fig.	O
1	O
,	O
strains	O
25	O
and	O
26	O
)	O
.	O

However	O
,	O
binding	O
sites	O
for	O
other	O
transcriptional	O
activators	O
existed	O
in	O
these	O
UASs	O
.	O

The	O
major	O
regulator	O
that	O
binds	O
to	O
ADH2-UAS	O
is	O
Adr1p	O
(	O
37	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
Gcn4p	O
binds	O
to	O
multiple	O
sites	O
in	O
HIS3-UAS	O
and	O
activates	O
HIS3	O
transcription	O
(	O
38	O
)	O
.	O

The	O
possible	O
involvement	O
of	O
Adr1p	O
or	O
Gcn4p	O
in	O
barrier	O
function	O
was	O
examined	O
below	O
.	O

Note	O
Adr1p	O
function	O
was	O
subject	O
to	O
glucose	O
repression	O
(	O
37	O
)	O
,	O
which	O
might	O
explain	O
why	O
ADH2-UAS	O
only	O
exhibited	O
limited	O
barrier	O
activity	O
since	O
glucose	O
was	O
used	O
in	O
the	O
media	O
used	O
in	O
our	O
assay	O
.	O

Effect	O
of	O
mutating	O
Rap1p	O
-	O
binding	O
sites	O
in	O
TEF2-UAS	O
on	O
barrier	O
function	O
Although	O
we	O
had	O
shown	O
that	O
the	O
three	O
Rap1p	O
-	O
binding	O
sites	O
in	O
TEF2-UAS	O
were	O
necessary	O
and	O
sufficient	O
for	O
its	O
barrier	O
activity	O
(	O
11	O
)	O
,	O
we	O
had	O
not	O
shown	O
if	O
binding	O
of	O
Rap1p	O
to	O
these	O
sites	O
was	O
required	O
.	O

To	O
address	O
this	O
we	O
performed	O
mutational	O
analysis	O
of	O
TEF2-UAS	O
.	O

As	O
shown	O
in	O
Figure	O
3A	O
and	O
B	O
,	O
the	O
three	O
Rap1p	O
-	O
binding	O
sites	O
in	O
TEF2-UAS	O
(	O
designated	O
as	O
R1	O
,	O
R2	O
and	O
R3	O
)	O
were	O
all	O
able	O
to	O
bind	O
Rap1p	O
in	O
an	O
EMSA	O
(	O
Fig.	O
3B	O
)	O
.	O

Single	O
or	O
double	O
C→A	O
mutations	O
were	O
introduced	O
into	O
R1	O
,	O
R2	O
and	O
R3	O
resulting	O
in	O
m1	O
,	O
m2	O
and	O
m3	O
,	O
respectively	O
(	O
Fig.	O
3A	O
)	O
.	O

The	O
m2	O
and	O
m3	O
sites	O
had	O
both	O
lost	O
the	O
ability	O
to	O
bind	O
Rap1p	O
,	O
whereas	O
m1	O
still	O
bound	O
Rap1p	O
(	O
Fig.	O
3B	O
)	O
,	O
which	O
could	O
be	O
predicted	O
from	O
the	O
specific	O
mutations	O
in	O
each	O
site	O
(	O
Fig.	O
3A	O
,	O
compare	O
m1	O
,	O
m2	O
and	O
m3	O
to	O
the	O
consensus	O
sequence	O
)	O
.	O

We	O
then	O
tested	O
a	O
mutated	O
TEF2-UAS	O
containing	O
m1	O
,	O
m2	O
and	O
m3	O
in	O
a	O
silencer	O
-	O
blocking	O
assay	O
using	O
the	O
HML	O
-	O
E	O
silencer	O
and	O
the	O
HMLα	O
genes	O
(	O
Fig.	O
3C	O
)	O
.	O

In	O
this	O
assay	O
,	O
the	O
HML	O
-	O
I	O
silencer	O
was	O
deleted	O
but	O
the	O
HML	O
-	O
E	O
silencer	O
was	O
sufficient	O
to	O
silence	O
the	O
HMLα	O
genes	O
(	O
Fig.	O
3C	O
,	O
strain	O
39	O
)	O
(	O
11	O
)	O
.	O

Silencing	O
in	O
strain	O
39	O
(	O
a	O
-	O
type	O
)	O
was	O
measured	O
by	O
its	O
ability	O
to	O
mate	O
with	O
an	O
α	O
-	O
type	O
strain	O
(	O
Fig.	O
3C	O
)	O
.	O

As	O
predicted	O
,	O
the	O
wild	O
-	O
type	O
TEF2-UAS	O
blocked	O
HMLα	O
silencing	O
(	O
11	O
)	O
(	O
Fig.	O
3C	O
,	O
strain	O
40	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
mutated	O
TEF2-UAS	O
containing	O
m1	O
,	O
m2	O
and	O
m3	O
had	O
lost	O
barrier	O
activity	O
(	O
Fig.	O
3C	O
,	O
compare	O
the	O
mating	O
efficiencies	O
of	O
strains	O
41	O
and	O
40	O
)	O
.	O

Therefore	O
,	O
mutations	O
that	O
prevented	O
Rap1p	O
from	O
binding	O
two	O
of	O
the	O
three	O
sites	O
in	O
TEF2-UAS	O
abolished	O
its	O
barrier	O
activity	O
,	O
indicating	O
that	O
association	O
of	O
Rap1p	O
with	O
TEF2-UAS	O
at	O
more	O
than	O
one	O
site	O
was	O
required	O
for	O
barrier	O
function	O
.	O

The	O
barrier	O
TEF2-UAS	O
alters	O
local	O
chromatin	O
structure	O
In	O
eukaryotic	O
cells	O
,	O
the	O
topology	O
of	O
local	O
DNA	O
reflects	O
the	O
chromatin	O
structure	O
in	O
which	O
it	O
resides	O
.	O

We	O
had	O
previously	O
developed	O
a	O
DNA	O
topology	O
-	O
based	O
assay	O
to	O
examine	O
chromatin	O
structure	O
in	O
vivo	O
,	O
which	O
involved	O
excising	O
a	O
chromosomal	O
region	O
of	O
interest	O
from	O
its	O
genomic	O
location	O
as	O
a	O
circle	O
using	O
site	O
-	O
specific	O
recombination	O
(	O
39	O
)	O
.	O

Using	O
this	O
strategy	O
,	O
we	O
demonstrated	O
that	O
DNA	O
in	O
silenced	O
chromatin	O
was	O
more	O
negatively	O
supercoiled	O
than	O
that	O
in	O
active	O
chromatin	O
(	O
39	O
)	O
.	O

In	O
this	O
report	O
we	O
used	O
the	O
topology	O
assay	O
to	O
address	O
if	O
barrier	O
elements	O
altered	O
local	O
chromatin	O
structure	O
as	O
Drosophila	B
or	O
chicken	B
insulators	O
did	O
(	O
40,41	O
)	O
.	O

Various	O
sequences	O
(	O
designated	O
X	O
)	O
from	O
UASs	O
of	O
TEF2	O
,	O
AgTEF	O
(	O
TEF	O
gene	O
from	O
Ashbya	B
gossypii	I
)	O
and	O
ADE2	O
were	O
inserted	O
between	O
HML	O
-	O
E	O
and	O
HMLα	O
at	O
HMLΔI	O
(	O
HML	O
locus	O
deleted	O
for	O
the	O
I	O
silencer	O
)	O
flanked	O
by	O
the	O
FRT	O
sites	O
for	O
the	O
Flp1p	O
site	O
-	O
specific	O
recombinase	O
(	O
Fig.	O
4A	O
and	O
B	O
)	O
.	O

The	O
FLP1	O
gene	O
was	O
under	O
the	O
control	O
of	O
the	O
inducible	O
GAL10	O
promoter	O
(	O
39	O
)	O
.	O

The	O
mating	O
efficiency	O
of	O
each	O
strain	O
measured	O
silencing	O
of	O
HMLα	O
(	O
Fig.	O
4C	O
)	O
.	O

In	O
strains	O
40	O
,	O
42	O
,	O
44	O
and	O
47	O
,	O
silencing	O
was	O
restricted	O
to	O
the	O
left	O
of	O
the	O
X	O
insertions	O
and	O
HMLα	O
was	O
derepressed	O
(	O
Fig.	O
4C	O
)	O
.	O

Consistently	O
,	O
the	O
proportion	O
of	O
silent	O
chromatin	O
in	O
the	O
region	O
flanked	O
by	O
the	O
FRT	O
sites	O
in	O
each	O
of	O
these	O
strains	O
was	O
decreased	O
,	O
as	O
indicated	O
by	O
the	O
reduced	O
negative	O
supercoiling	O
of	O
the	O
excised	O
circle	O
(	O
11	O
)	O
(	O
data	O
not	O
shown	O
)	O
.	O

Note	O
that	O
the	O
above	O
effect	O
of	O
a	O
barrier	O
on	O
HML	O
chromatin	O
reflected	O
both	O
change	O
in	O
the	O
scope	O
of	O
silencing	O
caused	O
by	O
the	O
barrier	O
activity	O
and	O
alteration	O
(	O
if	O
any	O
)	O
in	O
chromatin	O
structure	O
at	O
the	O
barrier	O
independent	O
of	O
the	O
silencing	O
state	O
of	O
the	O
locus	O
.	O

To	O
exclusively	O
examine	O
the	O
latter	O
,	O
we	O
analyzed	O
the	O
topology	O
of	O
HML	O
DNA	O
in	O
a	O
silencing	O
-	O
deficient	O
background	O
.	O

The	O
SIR3	O
gene	O
in	O
strains	O
described	O
in	O
Figure	O
4B	O
was	O
disrupted	O
rendering	O
them	O
defective	O
in	O
silencing	O
(	O
strains	O
40′–48′	O
in	O
Fig.	O
4D	O
)	O
.	O

Recombination	O
mediated	O
by	O
Flp1p	O
in	O
these	O
strains	O
led	O
to	O
the	O
excision	O
of	O
a	O
group	O
of	O
chromosomal	O
circles	O
that	O
differed	O
only	O
in	O
the	O
X	O
insertion	O
.	O

The	O
supercoiling	O
of	O
these	O
circles	O
was	O
analyzed	O
as	O
a	O
function	O
of	O
the	O
length	O
of	O
the	O
insertion	O
(	O
Fig.	O
4D	O
)	O
.	O

If	O
an	O
insertion	O
simply	O
lengthened	O
a	O
circle	O
without	O
causing	O
abnormal	O
changes	O
in	O
nucleosomal	O
structure	O
and/or	O
density	O
,	O
the	O
topoisomers	O
of	O
this	O
circle	O
would	O
migrate	O
slower	O
relative	O
to	O
those	O
of	O
a	O
similar	O
circle	O
with	O
a	O
smaller	O
size	O
.	O

Otherwise	O
,	O
migration	O
of	O
the	O
topoisomers	O
would	O
deviate	O
from	O
that	O
predicted	O
based	O
on	O
the	O
size	O
of	O
the	O
circle	O
.	O

As	O
shown	O
in	O
Figure	O
4D	O
,	O
the	O
circle	O
from	O
strain	O
40′	O
bearing	O
a	O
104	O
bp	O
barrier	O
element	O
migrated	O
faster	O
rather	O
than	O
slower	O
than	O
the	O
circle	O
from	O
strain	O
46′	O
bearing	O
a	O
91	O
bp	O
non	O
-	O
barrier	O
element	O
.	O

Circles	O
bearing	O
other	O
barrier	O
elements	O
also	O
exhibited	O
unexpected	O
faster	O
migration	O
(	O
compare	O
strains	O
44′	O
to	O
45′	O
,	O
47′	O
to	O
43′	O
,	O
42′	O
to	O
48′	O
,	O
respectively	O
)	O
.	O

Therefore	O
,	O
these	O
data	O
indicated	O
that	O
barrier	O
function	O
correlated	O
with	O
altered	O
topology	O
of	O
local	O
DNA	O
.	O

This	O
was	O
further	O
demonstrated	O
by	O
that	O
mutations	O
in	O
TEF2-UAS	O
that	O
abolished	O
its	O
barrier	O
activity	O
also	O
abolished	O
its	O
effect	O
on	O
DNA	O
topology	O
(	O
Fig.	O
4D	O
,	O
compare	O
41′	O
to	O
40′	O
;	O
note	O
that	O
circles	O
from	O
both	O
strains	O
had	O
the	O
same	O
size	O
)	O
.	O

Since	O
in	O
our	O
gel	O
assay	O
more	O
negatively	O
supercoiled	O
DNA	O
migrate	O
slower	O
,	O
we	O
concluded	O
that	O
every	O
fragment	O
with	O
barrier	O
activity	O
caused	O
a	O
reduction	O
in	O
negative	O
supercoiling	O
of	O
approximately	O
one	O
to	O
two	O
turns	O
in	O
HMLΔI	O
DNA	O
(	O
Fig.	O
4D	O
,	O
compare	O
the	O
centers	O
of	O
distributions	O
of	O
topoisomers	O
in	O
pairs	O
of	O
lanes	O
,	O
e.g.	O
40′	O
and	O
41′	O
)	O
.	O

The	O
topology	O
of	O
eukaryotic	O
DNA	O
reflects	O
mainly	O
the	O
wrapping	O
of	O
DNA	O
into	O
nucleosomes	O
(	O
approximately	O
one	O
negative	O
superhelical	O
turn	O
is	O
associated	O
with	O
each	O
nucleosome	O
)	O
(	O
42	O
)	O
.	O

Therefore	O
,	O
removal	O
of	O
one	O
nucleosome	O
would	O
eliminate	O
approximately	O
one	O
turn	O
.	O

On	O
the	O
other	O
hand	O
,	O
histone	O
acetylation	O
can	O
reduce	O
negative	O
supercoiling	O
associated	O
with	O
a	O
nucleosome	O
by	O
approximately	O
0.2	O
turns	O
(	O
43	O
)	O
.	O

Therefore	O
,	O
acetylating	O
five	O
nucleosomes	O
would	O
reduce	O
negative	O
supercoiling	O
by	O
approximately	O
one	O
turn	O
.	O

Consequently	O
,	O
the	O
linking	O
number	O
change	O
of	O
one	O
to	O
two	O
brought	O
about	O
by	O
TEF2-UAS	O
can	O
be	O
accounted	O
for	O
by	O
either	O
the	O
loss	O
of	O
one	O
to	O
two	O
nucleosomes	O
or	O
acetylation	O
of	O
five	O
to	O
10	O
nucleosomes	O
.	O

Further	O
experiments	O
are	O
under	O
way	O
to	O
clarify	O
the	O
nature	O
of	O
change	O
in	O
chromatin	O
induced	O
by	O
a	O
barrier	O
.	O

Targeting	O
the	O
transcription	O
activation	O
domain	O
of	O
Rap1p	O
recapitulates	O
its	O
barrier	O
activity	O
The	O
multifunctional	O
Rap1p	O
can	O
be	O
divided	O
into	O
at	O
least	O
four	O
functional	O
domains	O
(	O
Fig.	O
5A	O
)	O
(	O
12	O
)	O
.	O

We	O
were	O
interested	O
in	O
defining	O
which	O
of	O
these	O
domains	O
might	O
be	O
involved	O
in	O
the	O
barrier	O
activity	O
of	O
Rap1p	O
.	O

To	O
this	O
end	O
,	O
we	O
fused	O
various	O
parts	O
of	O
Rap1p	O
to	O
the	O
bacterial	O
LexA	O
protein	O
and	O
tested	O
if	O
targeting	O
any	O
of	O
the	O
fusion	O
proteins	O
to	O
LexA	O
-	O
binding	O
sites	O
could	O
re	O
-	O
create	O
a	O
barrier	O
to	O
silencing	O
(	O
Fig.	O
5A	O
)	O
.	O

The	O
LexA	O
-	O
RAP1	O
fusion	O
genes	O
were	O
carried	O
on	O
2	O
µm	O
based	O
plasmids	O
marked	O
by	O
LEU2	O
(	O
designated	O
L1–L6	O
,	O
Fig.	O
5A	O
)	O
.	O

When	O
introduced	O
into	O
strain	O
50	O
in	O
which	O
two	O
LexA	O
-	O
binding	O
sites	O
had	O
been	O
inserted	O
between	O
the	O
inverted	O
HML	O
-	O
I	O
and	O
URA3	O
,	O
LexA	O
alone	O
had	O
no	O
effect	O
on	O
URA3	O
silencing	O
(	O
Fig.	O
5A	O
,	O
plasmid	O
L1	O
)	O
.	O

Targeting	O
the	O
DNA	O
binding	O
domain	O
,	O
DNA	O
bending	O
domain	O
,	O
silencing	O
domain	O
,	O
or	O
the	O
activating	O
+	O
silencing	O
domain	O
of	O
Rap1p	O
also	O
did	O
not	O
affect	O
URA3	O
silencing	O
(	O
L2–L5	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
targeting	O
the	O
activation	O
domain	O
alone	O
recapitulated	O
the	O
barrier	O
activity	O
of	O
Rap1p	O
(	O
L6	O
)	O
.	O

These	O
results	O
indicated	O
that	O
the	O
activation	O
domain	O
of	O
Rap1p	O
was	O
involved	O
in	O
barrier	O
activity	O
.	O

The	O
inability	O
of	O
the	O
Rap1p	O
-	O
silencing	O
domain	O
to	O
block	O
URA3	O
silencing	O
in	O
our	O
assay	O
did	O
not	O
necessarily	O
mean	O
that	O
this	O
domain	O
had	O
no	O
barrier	O
function	O
,	O
since	O
such	O
a	O
function	O
might	O
be	O
suppressed	O
by	O
much	O
stronger	O
silencing	O
activity	O
associated	O
with	O
the	O
silencing	O
domain	O
.	O

Was	O
the	O
lack	O
of	O
barrier	O
function	O
of	O
fusion	O
constructs	O
L2–L5	O
due	O
to	O
a	O
lack	O
of	O
expression	O
of	O
these	O
proteins	O
?	O

To	O
address	O
this	O
possibility	O
,	O
we	O
examined	O
the	O
levels	O
of	O
L1–L6	O
proteins	O
as	O
well	O
as	O
L7	O
and	O
L8	O
proteins	O
described	O
in	O
Figure	O
5B	O
by	O
western	O
blotting	O
using	O
an	O
antibody	O
against	O
LexA.	O
As	O
shown	O
in	O
Figure	O
5C	O
,	O
L5	O
was	O
expressed	O
at	O
a	O
level	O
comparable	O
to	O
L6	O
,	O
and	O
L4	O
was	O
expressed	O
at	O
a	O
higher	O
level	O
than	O
L6	O
.	O

Therefore	O
,	O
the	O
lack	O
of	O
barrier	O
function	O
of	O
L4	O
and	O
L6	O
was	O
not	O
the	O
result	O
of	O
their	O
lack	O
of	O
expression	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
level	O
of	O
L2	O
or	O
L3	O
was	O
significantly	O
lower	O
than	O
that	O
of	O
L6	O
,	O
hence	O
the	O
lack	O
of	O
barrier	O
function	O
of	O
L2	O
and	O
L3	O
might	O
be	O
due	O
to	O
their	O
insufficient	O
expression	O
.	O

As	O
an	O
important	O
control	O
for	O
the	O
above	O
targeting	O
experiments	O
,	O
we	O
showed	O
that	O
plasmids	O
L1–L6	O
(	O
Fig.	O
5A	O
)	O
as	O
well	O
as	O
L7	O
and	O
L8	O
(	O
Fig.	O
5B	O
)	O
bearing	O
LexA	O
-	O
fusion	O
genes	O
had	O
no	O
effect	O
on	O
URA3	O
silencing	O
in	O
strain	O
1	O
(	O
Fig.	O
1	O
)	O
in	O
which	O
there	O
was	O
no	O
binding	O
site	O
for	O
LexA	O
present	O
between	O
HML	O
-	O
I	O
and	O
URA3	O
(	O
data	O
not	O
shown	O
)	O
.	O

Hence	O
,	O
the	O
effect	O
of	O
the	O
fusion	O
proteins	O
on	O
URA3	O
silencing	O
was	O
the	O
result	O
of	O
their	O
targeting	O
to	O
specific	O
loci	O
,	O
not	O
the	O
consequence	O
of	O
non	O
-	O
specific	O
,	O
indirect	O
functions	O
(	O
if	O
any	O
)	O
of	O
these	O
proteins	O
.	O

Targeted	O
activation	O
domain	O
of	O
Adr1p	O
or	O
Gcn4p	O
can	O
also	O
act	O
as	O
a	O
barrier	O
factor	O
We	O
have	O
shown	O
above	O
that	O
ADH2-UAS	O
bearing	O
Adr1p	O
-	O
binding	O
sites	O
and	O
HIS3-UAS	O
bearing	O
Gcn4p	O
sites	O
both	O
had	O
detectable	O
barrier	O
activity	O
(	O
Fig.	O
1	O
,	O
strains	O
25	O
and	O
26	O
)	O
.	O

Given	O
that	O
tethering	O
the	O
activation	O
domain	O
of	O
Rap1p	O
is	O
sufficient	O
for	O
barrier	O
function	O
,	O
we	O
tested	O
if	O
targeting	O
the	O
activation	O
domain	O
of	O
Adr1p	O
or	O
Gcn4p	O
could	O
also	O
establish	O
a	O
barrier	O
.	O

Adr1p	O
contains	O
four	O
separate	O
activation	O
domains	O
(	O
TADI	O
–	O
TADIV	O
)	O
that	O
can	O
contact	O
Ada2p	O
,	O
Gcn5p	O
and/or	O
TFIIB	O
(	O
45	O
)	O
.	O

TAD	O
III	O
(	O
415–467	O
)	O
interacts	O
with	O
only	O
Gcn5p	O
but	O
not	O
Ada2p	O
or	O
TFIIB	O
.	O

We	O
fused	O
this	O
domain	O
of	O
Adr1p	O
and	O
the	O
activation	O
domain	O
of	O
Gcn4p	O
(	O
102–149	O
)	O
to	O
LexA	O
,	O
respectively	O
(	O
Fig.	O
5B	O
,	O
L7	O
and	O
L8	O
)	O
.	O

Targeting	O
these	O
fusion	O
proteins	O
to	O
two	O
LexA	O
-	O
binding	O
sites	O
between	O
HML	O
-	O
I	O
and	O
URA3	O
in	O
strain	O
50	O
dramatically	O
reduced	O
URA3	O
silencing	O
(	O
Fig.	O
5B	O
,	O
compare	O
L7	O
and	O
L8	O
to	O
L1	O
)	O
.	O

Therefore	O
,	O
like	O
LexA	O
-	O
Rap1p	O
(	O
627–695	O
)	O
,	O
both	O
LexA	O
-	O
Adr1p	O
(	O
415–467	O
)	O
and	O
LexA	O
-	O
Gcn4p	O
(	O
102–149	O
)	O
also	O
had	O
barrier	O
activity	O
.	O

Barrier	O
function	O
of	O
these	O
fusion	O
proteins	O
was	O
significantly	O
decreased	O
in	O
strain	O
51	O
in	O
which	O
only	O
one	O
LexA	O
site	O
was	O
inserted	O
between	O
HML	O
-	O
I	O
and	O
URA3	O
(	O
compare	O
strains	O
50	O
and	O
51	O
carrying	O
plasmid	O
L7	O
)	O
,	O
indicating	O
that	O
the	O
potency	O
of	O
such	O
barriers	O
was	O
dependent	O
on	O
the	O
amount	O
of	O
tethered	O
fusion	O
proteins	O
.	O

DISCUSSION	O
We	O
have	O
shown	O
in	O
this	O
report	O
that	O
UASs	O
of	O
many	O
highly	O
expressed	O
genes	O
could	O
function	O
as	O
barriers	O
to	O
the	O
spread	O
of	O
transcriptional	O
silencing	O
.	O

These	O
newly	O
identified	O
barrier	O
elements	O
together	O
with	O
previously	O
described	O
barrier	O
elements	O
(	O
STARs	O
,	O
HMR	O
-	O
tRNA	O
gene	O
,	O
TEF2-UAS	O
and	O
CHA1-UAS	O
)	O
(	O
9–11,21	O
)	O
are	O
scattered	O
across	O
the	O
yeast	B
genome	O
and	O
may	O
play	O
a	O
role	O
in	O
dividing	O
the	O
genome	O
into	O
functional	O
domains	O
.	O

Analyses	O
of	O
the	O
barrier	O
UASs	O
suggest	O
that	O
binding	O
sites	O
for	O
transcriptional	O
regulators	O
Rap1p	O
,	O
Abf1p	O
,	O
Reb1p	O
,	O
Adr1p	O
and	O
Gcn4p	O
can	O
participate	O
in	O
barrier	O
function	O
.	O

Barrier	O
activity	O
often	O
requires	O
concerted	O
actions	O
of	O
more	O
than	O
one	O
factor	O
-	O
binding	O
site	O
.	O

Our	O
mutational	O
analysis	O
of	O
TEF2-UAS	O
suggests	O
a	O
direct	O
involvement	O
of	O
Rap1p	O
in	O
its	O
barrier	O
function	O
.	O

It	O
is	O
noteworthy	O
that	O
not	O
all	O
UASs	O
of	O
highly	O
expressed	O
genes	O
have	O
barrier	O
activity	O
.	O

Many	O
non	O
-	O
barrier	O
UASs	O
also	O
consist	O
of	O
multiple	O
regulator	O
binding	O
sites	O
,	O
therefore	O
other	O
unknown	O
factors	O
might	O
determine	O
whether	O
a	O
UAS	O
could	O
act	O
as	O
a	O
barrier	O
.	O

How	O
Rap1p	O
and	O
the	O
other	O
transcriptional	O
regulators	O
act	O
to	O
block	O
silencing	O
is	O
not	O
clear	O
.	O

Since	O
they	O
can	O
all	O
act	O
as	O
transcriptional	O
activators	O
,	O
one	O
natural	O
explanation	O
is	O
that	O
they	O
may	O
overcome	O
the	O
silencing	O
effect	O
of	O
a	O
silencer	O
and	O
directly	O
activate	O
the	O
reporter	O
gene	O
.	O

However	O
,	O
it	O
has	O
been	O
well	O
documented	O
that	O
Rap1p	O
and	O
the	O
other	O
transcriptional	O
regulators	O
usually	O
act	O
at	O
relatively	O
short	O
distances	O
(	O
less	O
than	O
∼600	O
bp	O
upstream	O
of	O
the	O
translation	O
start	O
codon	O
)	O
(	O
28,29,46	O
)	O
,	O
but	O
the	O
binding	O
sites	O
for	O
these	O
regulators	O
were	O
>	O
800	O
bp	O
from	O
the	O
translation	O
start	O
codon	O
in	O
most	O
of	O
the	O
silencing	O
-	O
blocking	O
tests	O
in	O
this	O
report	O
(	O
Figs	O
1	O
and	O
2	O
)	O
.	O

In	O
the	O
test	O
shown	O
in	O
Figure	O
6	O
,	O
TEF2-UAS	O
blocked	O
ADE2	O
silencing	O
when	O
it	O
was	O
∼2	O
kb	O
downstream	O
from	O
the	O
translation	O
start	O
codon	O
of	O
the	O
gene	O
.	O

Moreover	O
,	O
Fourel	O
et	O
al.	O
(	O
44	O
)	O
demonstrated	O
that	O
the	O
barrier	O
function	O
(	O
or	O
anti	O
-	O
silencing	O
function	O
)	O
of	O
an	O
activator	O
was	O
independent	O
of	O
its	O
role	O
in	O
activating	O
transcription	O
.	O

Therefore	O
,	O
it	O
is	O
unlikely	O
that	O
the	O
ability	O
of	O
a	O
UAS	O
to	O
prevent	O
gene	O
silencing	O
is	O
due	O
to	O
its	O
direct	O
activation	O
of	O
the	O
gene	O
.	O

In	O
light	O
of	O
this	O
,	O
our	O
results	O
are	O
in	O
agreement	O
with	O
the	O
notion	O
that	O
transcriptional	O
regulators	O
can	O
also	O
participate	O
in	O
defining	O
the	O
boundaries	O
of	O
functional	O
chromosomal	O
domains	O
.	O

A	O
few	O
models	O
have	O
been	O
proposed	O
for	O
the	O
barrier	O
functions	O
of	O
transcriptional	O
regulators	O
.	O

One	O
model	O
proposed	O
that	O
binding	O
of	O
a	O
regulator	O
to	O
a	O
barrier	O
led	O
to	O
the	O
formation	O
of	O
a	O
nucleosome	O
-	O
free	O
region	O
thereby	O
disrupting	O
a	O
continuous	O
nucleosome	O
array	O
(	O
11	O
)	O
.	O

Since	O
the	O
SIR	O
complexes	O
spread	O
by	O
self	O
-	O
interaction	O
and	O
interacting	O
with	O
adjacent	O
nucleosmes	O
in	O
a	O
stepwise	O
fashion	O
(	O
4	O
)	O
,	O
a	O
nucleosome	O
-	O
free	O
gap	O
could	O
present	O
a	O
barrier	O
to	O
the	O
spreading	O
SIR	O
complex	O
.	O

This	O
'	O
nucleosome	O
gap	O
'	O
hypothesis	O
is	O
consistent	O
with	O
that	O
certain	O
barrier	O
factors	O
such	O
as	O
Rap1p	O
and	O
Reb1p	O
could	O
indeed	O
prevent	O
nucleosome	O
formation	O
around	O
their	O
binding	O
sites	O
(	O
14	O
)	O
and	O
the	O
barrier	O
function	O
of	O
TEF2-UAS	O
correlated	O
with	O
its	O
ability	O
to	O
alter	O
local	O
chromatin	O
structure	O
(	O
this	O
report	O
)	O
.	O

In	O
fact	O
,	O
many	O
insulator	O
/	O
boundary	O
elements	O
in	O
higher	O
organisms	O
have	O
also	O
been	O
shown	O
to	O
alter	O
local	O
chromatin	O
structure	O
.	O

For	O
instance	O
,	O
the	O
chicken	B
β	O
-	O
globin	O
insulator	O
was	O
linked	O
to	O
changes	O
in	O
nucleosome	O
positioning	O
,	O
and	O
the	O
Drosophila	B
scs	O
and	O
scs′	O
boundary	O
elements	O
are	O
associated	O
with	O
unusual	O
chromatin	O
structures	O
that	O
are	O
hypersensitive	O
to	O
nucleases	O
(	O
40,41	O
)	O
.	O

However	O
,	O
it	O
is	O
not	O
clear	O
whether	O
any	O
chromatin	O
change	O
associated	O
with	O
barrier	O
function	O
in	O
yeast	B
or	O
insulator	O
function	O
in	O
higher	O
cells	O
is	O
the	O
cause	O
or	O
effect	O
of	O
the	O
function	O
.	O

Another	O
model	O
for	O
barrier	O
action	O
proposed	O
by	O
R.	O
Kamakaka	O
and	O
colleagues	O
(	O
21	O
)	O
proposed	O
that	O
barrier	O
factors	O
recruit	O
chromatin	O
modifying	O
and/or	O
remodeling	O
complexes	O
to	O
counteract	O
the	O
more	O
compact	O
,	O
hypoacetylated	O
silent	O
chromatin	O
.	O

In	O
agreement	O
with	O
this	O
hypothesis	O
,	O
targeted	O
HATs	O
SAS2	O
,	O
GCN5	O
and	O
ESA1	O
all	O
had	O
barrier	O
activity	O
(	O
21	O
;	O
Y	O
.-	O
H.	O
Chiu	O
,	O
Q.	O
Yu	O
and	O
X.	O
Bi	O
,	O
unpublished	O
results	O
)	O
.	O

Interestingly	O
,	O
Rap1p	O
,	O
Adr1p	O
,	O
Gcn4p	O
and	O
Abf1p	O
share	O
the	O
ability	O
to	O
recruit	O
HAT	O
complexes	O
NuA4	O
and/or	O
SAGA	O
to	O
target	O
genes	O
(	O
16,45,47–49	O
)	O
.	O

Therefore	O
,	O
these	O
factors	O
that	O
are	O
capable	O
of	O
binding	O
to	O
the	O
newly	O
identified	O
barriers	O
may	O
function	O
as	O
barrier	O
factors	O
by	O
recruiting	O
HAT	O
complexes	O
.	O

In	O
fact	O
,	O
recruitment	O
of	O
HAT	O
activity	O
has	O
also	O
been	O
suggested	O
to	O
be	O
the	O
mechanism	O
underlying	O
the	O
function	O
of	O
the	O
chicken	B
β	O
-	O
globin	O
insulator	O
(	O
6	O
)	O
,	O
although	O
it	O
was	O
not	O
known	O
what	O
HAT	O
might	O
be	O
involved	O
.	O

Our	O
demonstration	O
that	O
tethering	O
the	O
activation	O
domain	O
of	O
Rap1p	O
,	O
Adr1p	O
or	O
Gcn4p	O
alone	O
recapitulates	O
barrier	O
activity	O
is	O
consistent	O
with	O
the	O
above	O
HAT	O
model	O
for	O
barrier	O
function	O
,	O
since	O
at	O
least	O
the	O
activation	O
domain	O
of	O
Adr1p	O
has	O
been	O
shown	O
to	O
directly	O
interact	O
with	O
HAT	O
complexes	O
(	O
45	O
)	O
.	O

However	O
,	O
we	O
have	O
n't	O
ruled	O
out	O
the	O
possibility	O
that	O
the	O
barrier	O
function	O
of	O
the	O
targeted	O
activation	O
domain	O
of	O
Rap1p	O
,	O
Adr1p	O
or	O
Gcn4p	O
is	O
not	O
related	O
to	O
the	O
barrier	O
function	O
of	O
the	O
native	O
protein	O
.	O

Note	O
that	O
the	O
'	O
nucleosome	O
gap	O
'	O
model	O
and	O
the	O
HAT	O
model	O
are	O
not	O
mutually	O
exclusive	O
since	O
the	O
nucleosome	O
gap	O
could	O
result	O
from	O
destabilization	O
of	O
nucelosomes	O
caused	O
by	O
HAT	O
function	O
.	O

A	O
recent	O
intriguing	O
study	O
showed	O
that	O
targeting	O
proteins	O
of	O
the	O
nuclear	O
pore	O
complex	O
(	O
NPC	O
)	O
could	O
also	O
establish	O
a	O
boundary	O
for	O
silent	O
chromatin	O
,	O
and	O
that	O
tethering	O
to	O
NPC	O
was	O
required	O
for	O
boundary	O
activity	O
(	O
50	O
)	O
.	O

This	O
led	O
to	O
a	O
revisit	O
to	O
the	O
looping	O
model	O
for	O
the	O
function	O
of	O
boundary	O
/	O
insulator	O
elements	O
(	O
51	O
)	O
.	O

However	O
,	O
an	O
alternative	O
explanation	O
was	O
that	O
the	O
NPC	O
compartment	O
could	O
simply	O
be	O
rich	O
in	O
transcriptional	O
activating	O
factors	O
or	O
poor	O
in	O
silencing	O
factors	O
like	O
the	O
SIR	O
proteins	O
(	O
50	O
)	O
.	O

In	O
summary	O
,	O
results	O
from	O
this	O
and	O
other	O
studies	O
indicate	O
that	O
factors	O
previously	O
identified	O
as	O
positive	O
and/or	O
negative	O
regulators	O
of	O
gene	O
activation	O
could	O
also	O
function	O
in	O
demarcating	O
distinct	O
domains	O
of	O
gene	O
activity	O
.	O

How	O
these	O
factors	O
carry	O
out	O
their	O
boundary	O
function	O
is	O
not	O
resolved	O
but	O
recruitment	O
of	O
other	O
factors	O
(	O
e.g.	O
chromatin	O
modifying	O
complexes	O
)	O
is	O
likely	O
to	O
be	O
involved	O
.	O

NOTE	O
ADDED	O
IN	O
PROOF	O
After	O
this	O
work	O
was	O
completed	O
and	O
submitted	O
for	O
publication	O
the	O
first	O
time	O
,	O
Fourel	O
et	O
al.	O
(	O
52	O
)	O
reported	O
that	O
targeted	O
activation	O
domains	O
of	O
Rap1p	O
and	O
Abf1p	O
had	O
insulating	O
capacity	O
.	O

Peculiarities	O
of	O
carcinogenesis	O
under	O
simultaneous	O
oral	O
administration	O
of	O
benzo	O
(	O
a	O
)	O
pyrene	O
and	O
o	O
-	O
cresol	O
in	O
mice	B
.	O

Abstract	O
A	O
modifying	O
influence	O
of	O
ortho	O
-	O
cresol	O
(	O
o	O
-	O
cresol	O
)	O
on	O
the	O
carcinogenic	O
effect	O
of	O
benzo	O
(	O
a	O
)	O
pyrene	O
(	O
BaP	O
)	O
with	O
combined	O
oral	O
administration	O
to	O
CC57Br	O
mice	B
had	O
been	O
found	O
.	O

During	O
simultaneous	O
administration	O
of	O
o	O
-	O
cresol	O
(	O
1	O
mg	O
)	O
and	O
BaP	O
(	O
1	O
mg	O
)	O
,	O
the	O
incidence	O
of	O
tumors	O
,	O
the	O
multiplicity	O
of	O
tumors	O
,	O
and	O
the	O
degree	O
of	O
malignancy	O
all	O
increased	O
,	O
but	O
the	O
latency	O
was	O
shortened	O
.	O

When	O
o	O
-	O
cresol	O
was	O
administered	O
before	O
or	O
after	O
BaP	O
(	O
in	O
identical	O
doses	O
)	O
,	O
the	O
carcinogenic	O
effect	O
was	O
weakened	O
.	O

When	O
o	O
-	O
cresol	O
(	O
10	O
mg	O
)	O
and	O
BaP	O
(	O
5	O
mg	O
)	O
were	O
administered	O
simultaneously	O
,	O
the	O
incidence	O
of	O
malignant	O
tumors	O
was	O
similar	O
to	O
controls	O
receiving	O
BaP	O
only	O
(	O
13.8	O
%	O
)	O
,	O
indicating	O
inhibition	O
of	O
carcinogenesis	O
.	O

Environnmental	O
Health	O
Perspectives	O
Supplements	O
Vol	O
.	O

101	O
(	O
Suppl	O
.	O

3	O
)	O
:	O
341	O
-	O
344	O
(	O
1993	O
)	O
Peculiarities	O
of	O
Carcinogenesis	O
under	O
Simultaneous	O
Oral	O
Administration	O
of	O
Benzo	O
(	O
a	O
)	O
Pyrene	O
and	O
o	O
-	O
Cresol	O
in	O
Mice	B
by	O
N.	O
Ya	O
.	O

Yanysheva	O
,	O
'	O
N.	O
V.	O
Balenko	O
,	O
1	O
.	O
A.	O
Chernichenko,1	O
and	O
V.	O
F.	O
Babiy	O
'	O
A	O
modifying	O
influence	O
of	O
ortho	O
-	O
cresol	O
(	O
o	O
-	O
cresol	O
)	O
on	O
the	O
carcinogenic	O
effect	O
of	O
benzo	O
(	O
a	O
)	O
pyrene	O
(	O
BaP	O
)	O
with	O
combined	O
oral	O
administration	O
to	O
CC57Br	O
mice	B
had	O
been	O
found	O
.	O

During	O
simultaneous	O
administration	O
of	O
o	O
-	O
cresol	O
(	O
1	O
mg	O
)	O
and	O
BaP	O
(	O
1	O
mg	O
)	O
,	O
the	O
incidence	O
of	O
tumors	O
,	O
the	O
multiplicity	O
of	O
tumors	O
,	O
and	O
the	O
degree	O
of	O
malignancy	O
all	O
increased	O
,	O
but	O
the	O
latency	O
was	O
shortened	O
.	O

When	O
o	O
-	O
cresol	O
was	O
administered	O
before	O
or	O
after	O
BaP	O
(	O
in	O
identical	O
doses	O
)	O
,	O
the	O
carcinogenic	O
effect	O
was	O
weakened	O
.	O

When	O
o	O
-	O
cresol	O
(	O
10	O
mg	O
)	O
and	O
BaP	O
(	O
5	O
mg	O
)	O
were	O
administered	O
simultaneously	O
,	O
the	O
incidence	O
of	O
malignant	O
tumors	O
was	O
similar	O
to	O
controls	O
receiving	O
BaP	O
only	O
(	O
13.8	O
%	O
)	O
,	O
indicating	O
inhibition	O
of	O
carcinogenesis	O
.	O

Introduction	O
Numerous	O
experiments	O
have	O
shown	O
a	O
modifying	O
influence	O
of	O
different	O
chemicals	O
on	O
benzo	O
(	O
a	O
)	O
pyrene	O
(	O
BaP	O
)	O
induced	O
carcinogenic	O
effects	O
.	O

Both	O
enhancing	O
or	O
weakening	O
effects	O
have	O
been	O
seen	O
(	O
1	O
-	O
12	O
)	O
.	O

In	O
some	O
experiments	O
ubiquitious	O
environmental	O
carcinogenic	O
and	O
toxic	O
chemical	O
pollutants	O
were	O
used	O
(	O
13	O
-	O
17	O
)	O
.	O

The	O
stimulating	O
effect	O
of	O
phenol	O
,	O
nitrogen	O
oxides	O
,	O
and	O
sulfur	O
dioxide	O
upon	O
BaP	O
's	O
blastogenic	O
action	O
on	O
the	O
respiratory	O
tract	O
and	O
phenol	O
on	O
the	O
digestive	O
tract	O
(	O
forestomach	O
)	O
have	O
been	O
reported	O
(	O
12	O
-	O
18	O
)	O
.	O

We	O
have	O
established	O
the	O
relationship	O
between	O
the	O
doses	O
of	O
carcinogenic	O
and	O
toxic	O
agents	O
and	O
their	O
modifying	O
effects	O
(	O
17,18	O
)	O
.	O

The	O
maximal	O
enhancing	O
effect	O
was	O
observed	O
after	O
BaP	O
(	O
2.5	O
mg	O
)	O
and	O
NO2	O
(	O
0.87	O
mg	O
/	O
m3	O
)	O
were	O
exposed	O
to	O
rat	B
respiratory	O
tract	O
.	O

The	O
effect	O
weakened	O
with	O
decreasing	O
dose	O
.	O

At	O
concentrations	O
at	O
the	O
MPC	O
level	O
(	O
MPC	O
BaP	O
,	O
1	O
ng	O
/	O
m3	O
,	O
MPC	O
NO2	O
,	O
0.04	O
mg	O
/	O
m3	O
)	O
no	O
effect	O
was	O
seen	O
.	O

Phenol	O
at	O
1	O
mg	O
orally	O
to	O
CC57Br	O
mice	B
enhanced	O
the	O
BaP	O
(	O
1	O
mg	O
)	O
effect	O
,	O
but	O
no	O
effect	O
was	O
seen	O
at	O
0.02	O
mg	O
.	O

Phenolic	O
compounds	O
showed	O
either	O
enhancing	O
or	O
inhibiting	O
effects	O
on	O
carcinogenesis	O
depending	O
on	O
their	O
chemical	O
structure	O
(	O
16,18	O
-	O
25	O
)	O
.	O

This	O
report	O
presents	O
the	O
results	O
of	O
combined	O
oral	O
administration	O
of	O
BaP	O
and	O
artho	O
-	O
cresol	O
(	O
o	O
-	O
cresol	O
)	O
in	O
mice	B
,	O
'	O
Ukrainian	O
State	O
Medical	O
Center	O
for	O
Environmental	O
Health	O
,	O
Kiev	O
,	O
Ukraine	O
.	O

Address	O
reprint	O
requests	O
to	O
N.	O
Y.	O
Yanysheva	O
,	O
Ukrainian	O
State	O
Medical	O
Center	O
for	O
Environmental	O
Health	O
,	O
Popudrenko	O
St.	O
50	O
,	O
253660	O
Kiev-94	O
,	O
Ukraine	O
.	O

chemicals	O
commonly	O
found	O
in	O
ambient	O
water	O
because	O
of	O
their	O
industrial	O
use	O
(	O
coke	O
chemistry	O
,	O
oil	O
processing	O
,	O
shale	O
processing	O
,	O
and	O
other	O
industries	O
)	O
(	O
27	O
-	O
30	O
)	O
.	O

Materials	O
and	O
Methods	O
The	O
experiment	O
was	O
conducted	O
on	O
CC57Br	O
female	O
mice	B
weighing	O
12	O
-	O
14	O
g.	O
Animals	O
were	O
divided	O
in	O
15	O
groups	O
.	O

This	O
experiment	O
included	O
three	O
types	O
of	O
sequential	O
combinations	O
for	O
the	O
introduction	O
of	O
compounds	O
:	O
a	O
)	O
simultaneous	O
BaP	O
and	O
o	O
-	O
cresol	O
administration	O
;	O
b	O
)	O
BaP	O
after	O
o	O
-	O
cresol	O
(	O
stage	O
1	O
)	O
;	O
and	O
c	O
)	O
BaP	O
before	O
o	O
-	O
cresol	O
(	O
stage	O
2	O
)	O
.	O

Appropriate	O
controls	O
were	O
included	O
(	O
Table	O
1	O
)	O
.	O

The	O
chemicals	O
were	O
administered	O
twice	O
per	O
week	O
(	O
for	O
a	O
total	O
of	O
10	O
,	O
20	O
,	O
and	O
40	O
doses	O
)	O
using	O
a	O
syringe	O
and	O
a	O
needle	O
with	O
a	O
soldered	O
olive	O
on	O
its	O
tip	O
.	O

BaP	O
(	O
1	O
or	O
5	O
mg	O
)	O
or	O
o	O
-	O
cresol	O
(	O
0.02	O
,	O
1	O
,	O
or	O
10	O
mg	O
)	O
was	O
placed	O
in	O
triethylene	O
glycol	O
(	O
TEG	O
)	O
and	O
administered	O
as	O
0.1-mL	O
water	O
solutions	O
.	O

The	O
evaluation	O
of	O
o	O
-	O
cresol	O
's	O
modifying	O
effect	O
on	O
the	O
incidence	O
of	O
tumors	O
,	O
especially	O
malignant	O
tumors	O
,	O
the	O
tumor	O
latency	O
period	O
(	O
tl	O
)	O
,	O
and	O
the	O
average	O
time	O
(	O
ta	O
)	O
of	O
the	O
appearance	O
of	O
tumors	O
,	O
as	O
well	O
as	O
the	O
multiplicity	O
index	O
,	O
M	O
(	O
the	O
average	O
number	O
of	O
tumors	O
per	O
animal	O
for	O
tumor	O
-	O
bearing	O
animals	O
)	O
was	O
recorded	O
.	O

Because	O
the	O
M	O
could	O
be	O
identified	O
at	O
the	O
initial	O
stage	O
of	O
carcinogenesis	O
by	O
the	O
third	O
month	O
after	O
the	O
beginning	O
of	O
the	O
trial	O
when	O
neoplasms	O
began	O
to	O
emerge	O
,	O
moribund	O
animals	O
were	O
killed	O
by	O
ether	O
inhalation	O
if	O
they	O
did	O
not	O
die	O
spontaneously	O
.	O

The	O
experiments	O
with	O
large	O
chemical	O
doses	O
(	O
BaP	O
,	O
5	O
mg	O
;	O
o	O
-	O
cresol	O
,	O
10	O
mg	O
)	O
lasted	O
for	O
30	O
weeks	O
.	O

Some	O
animals	O
were	O
killed	O
after	O
the	O
1st	O
,	O
3rd	O
,	O
5th	O
,	O
and	O
10th	O
procedures	O
for	O
the	O
YANYSHEVA	O
ET	O
AL	O
.	O

evaluation	O
of	O
initial	O
stages	O
of	O
carcinogenesis	O
;	O
others	O
were	O
killed	O
at	O
26	O
and	O
30	O
weeks	O
.	O

The	O
stomachs	O
were	O
distended	O
with	O
formalin	O
solution	O
and	O
the	O
mucosa	O
examined	O
macroscopically	O
.	O

All	O
tumors	O
>	O
1	O
mm	O
in	O
diameter	O
were	O
recorded	O
.	O

Organs	O
and	O
tissues	O
were	O
fised	O
in	O
10	O
%	O
neutral	O
formalin	O
solution	O
,	O
embedded	O
in	O
paraffin	O
and	O
routine	O
histological	O
slides	O
prepared	O
.	O

Microscopic	O
data	O
were	O
processed	O
according	O
to	O
Mostkovoy	O
(	O
30	O
)	O
.	O

Results	O
The	O
data	O
from	O
this	O
study	O
demonstrate	O
the	O
modifying	O
influence	O
of	O
o	O
-	O
cresol	O
on	O
BaP	O
-	O
induced	O
carcinogenesis	O
with	O
combined	O
oral	O
exposure	O
.	O

The	O
combined	O
exposure	O
and	O
BaP	O
alone	O
caused	O
benign	O
and	O
malignant	O
epithelial	O
tumors	O
of	O
the	O
forestomach	O
.	O

The	O
benign	O
neoplasms	O
were	O
papillomas	O
,	O
and	O
the	O
malignant	O
neoplasms	O
were	O
invasive	O
carcinomas	O
.	O

The	O
combined	O
administration	O
of	O
BaP	O
and	O
o	O
-	O
cresol	O
showed	O
different	O
results	O
depending	O
on	O
doses	O
and	O
sequential	O
combinations	O
of	O
both	O
chemicals	O
.	O

As	O
shown	O
in	O
Table	O
2	O
,	O
the	O
simultaneous	O
administration	O
of	O
BaP	O
(	O
1	O
mg	O
)	O
and	O
o	O
-	O
cresol	O
(	O
1	O
mg	O
)	O
affected	O
all	O
parameters	O
of	O
carcinogenesis	O
that	O
were	O
measured	O
.	O

This	O
included	O
a	O
significant	O
increase	O
in	O
the	O
incidence	O
of	O
tumors	O
,	O
shortening	O
of	O
the	O
time	O
to	O
the	O
appearance	O
of	O
the	O
first	O
tumor	O
,	O
and	O
the	O
mean	O
time	O
of	O
tumor	O
development	O
as	O
compared	O
to	O
animals	O
that	O
received	O
1	O
mg	O
of	O
BaP	O
alone	O
and	O
had	O
tumors	O
.	O

One	O
hundred	O
percent	O
of	O
the	O
mice	B
that	O
received	O
5	O
mg	O
of	O
BaP	O
alone	O
had	O
tumors	O
.	O

Shortening	O
of	O
the	O
time	O
to	O
appearance	O
of	O
malignant	O
tumors	O
was	O
also	O
observed	O
:	O
the	O
mice	B
with	O
forestomach	O
cancer	O
died	O
between	O
23	O
and	O
26.2	O
weeks	O
after	O
the	O
beginning	O
of	O
experiment	O
,	O
but	O
the	O
controls	O
survived	O
to	O
58.5	O
weeks	O
.	O

Muliple	O
small	O
metastases	O
in	O
the	O
lungs	O
and	O
mediastinum	O
were	O
found	O
in	O
42.8	O
%	O
of	O
mice	B
,	O
which	O
signifies	O
a	O
high	O
degree	O
of	O
malignancy	O
.	O

o	O
-	O
Cresol	O
at	O
0.02	O
mg	O
did	O
not	O
modify	O
carcinogenesis	O
in	O
comparison	O
to	O
the	O
control	O
.	O

o	O
-	O
Cresol	O
administration	O
before	O
or	O
after	O
BaP	O
did	O
not	O
modify	O
tumor	O
incidence	O
or	O
the	O
multiplicity	O
index	O
as	O
compared	O
to	O
control	O
,	O
but	O
the	O
latency	O
period	O
was	O
longer	O
(	O
Table	O
2	O
)	O
.	O

When	O
o	O
-	O
cresol	O
was	O
administered	O
after	O
BaP	O
(	O
stage	O
2	O
)	O
,	O
there	O
was	O
an	O
absence	O
of	O
malignant	O
tumors	O
.	O

Besides	O
the	O
quantitative	O
aspects	O
,	O
other	O
peculiarities	O
of	O
carcinogenesis	O
in	O
mice	B
simultaneously	O
administered	O
BaP	O
and	O
o	O
-	O
cresol	O
should	O
be	O
noted	O
.	O

The	O
combined	O
chemical	O
administration	O
resulted	O
in	O
diffuse	O
verrucosa	O
vegetations	O
over	O
the	O
forestomach	O
surface	O
,	O
especially	O
near	O
the	O
greater	O
curvature	O
.	O

Highly	O
aggressive	O
malignant	O
neoplasms	O
developed	O
earlier	O
with	O
more	O
metastases	O
as	O
compared	O
to	O
control	O
.	O

Many	O
mice	B
were	O
emaciated	O
,	O
and	O
the	O
tumors	O
could	O
be	O
Table	O
1	O
.	O

Scheme	O
of	O
BaP	O
and	O
o	O
-	O
cresol	O
combined	O
action	O
under	O
different	O
regimes	O
of	O
oral	O
administration	O
.	O

Theatmenta	O
No.	O
of	O
mice	B
Stage	O
1	O
Stage	O
2	O
Groups	O
of	O
in	O
each	O
No.	O
of	O
No.	O
of	O
animals	O
group	O
Substances	O
Dose	O
,	O
mg	O
applications	O
Substances	O
Dose	O
,	O
mg	O
applications	O
1	O
55	O
BaP	O
,	O
o	O
-	O
cresol	O
5	O
+	O
10	O
10	O
-	O
-	O
2	O
45	O
BaP	O
5	O
10	O
-	O
-	O
3	O
40	O
TEG	O
la	O
10	O
-	O
-	O
4	O
45	O
TEG	O
,	O
o	O
-	O
cresol	O
1b	O
+	O
10	O
10	O
-	O
-	O
5	O
30	O
BaP	O
,	O
o	O
-	O
cresol	O
1	O
+	O
1	O
20	O
-	O
-	O
6	O
30	O
BaP	O
,	O
o	O
-	O
cresol	O
1	O
+	O
0.02	O
20	O
-	O
-	O
7	O
30	O
o	O
-	O
Cresol	O
1	O
20	O
BaP	O
1	O
20	O
8	O
30	O
BaP	O
1	O
20	O
o	O
-	O
Cresol	O
1	O
20	O
9	O
30	O
BaP	O
1	O
20	O
-	O
10	O
30	O
-	O
-	O
-	O
BaP	O
1	O
20	O
11	O
30	O
o	O
-	O
Cresol	O
1	O
20	O
-	O
12	O
30	O
-	O
-	O
-	O
o	O
-	O
Cresol	O
1	O
20	O
13	O
30	O
o	O
-	O
Cresol	O
+	O
TEG	O
1	O
+	O
2	O
'	O
20	O
-	O
14	O
30	O
o	O
-	O
Cresol	O
+	O
TEG	O
0.02	O
+	O
2b	O
20	O
15	O
30	O
TEG	O
2b	O
20	O
-	O
-	O
Abbreviations	O
:	O
BaP	O
,	O
benzo	O
[	O
a	O
]	O
pyrene	O
;	O
TEG	O
,	O
triethylene	O
glycol	O
.	O

Table	O
2	O
.	O

Occurrence	O
of	O
forestomach	O
tumors	O
in	O
CC57Br	O
mice	B
after	O
combined	O
oral	O
administration	O
of	O
BaP	O
and	O
o	O
-	O
cresol	O
.	O

Number	O
of	O
animals	O
with	O
forestomach	O
tumors	O
Order	O
of	O
administration	O
of	O
substances	O
Total	O
Benign	O
Malignant	O
(	O
dose	O
,	O
mg	O
)	O
Absolute	O
%	O
%	O
M	O
t	O
,	O
ta	O
%	O
t	O
,	O
ta	O
BaP	O
(	O
5	O
)	O
,	O
o	O
-	O
cresol	O
(	O
10	O
)	O
29	O
100.0	O
86.2	O
ND	O
ND	O
ND	O
13.8	O
ND	O
ND	O
BaP	O
(	O
1	O
)	O
,	O
o	O
-	O
cresol	O
(	O
1	O
)	O
19	O
95.0	O
60.0	O
9.6	O
10.7	O
16.3	O
35.0	O
23.0	O
25.2	O
BaP	O
(	O
1	O
)	O
,	O
o	O
-	O
cresol	O
(	O
0.02	O
)	O
7	O
35.0	O
30.0	O
1.6	O
13.5	O
19.8	O
5.0	O
56.8	O
56.8	O
BaP	O
(	O
1	O
)	O
,	O
stage	O
1	O
,	O
o	O
-	O
cresol	O
(	O
1	O
)	O
,	O
stage	O
2	O
7	O
31.8	O
31.8	O
1.4	O
16.2	O
31.1	O
0	O
0	O
0	O
BaP	O
(	O
1	O
)	O
,	O
stage	O
2	O
6	O
35.3	O
29.4	O
2.8	O
15.8	O
41.2	O
5.9	O
24.8	O
24.8	O
BaP	O
(	O
5	O
)	O
,	O
stage	O
1	O
18	O
100.0	O
50.0	O
ND	O
ND	O
ND	O
50.0	O
ND	O
ND	O
BaP	O
(	O
1	O
)	O
,	O
stage	O
1	O
8	O
33.3	O
28.7	O
1.4	O
14.0	O
21.3	O
4.6	O
58.5	O
58.5	O
BaP	O
(	O
1	O
)	O
,	O
stage	O
2	O
7	O
36.8	O
31.6	O
2.8	O
10.0	O
13.3	O
5.2	O
55.7	O
55.7	O
Abbreviations	O
:	O
BaP	O
,	O
benzo	O
[	O
a	O
]	O
pyrene	O
;	O
0	O
,	O
not	O
observed	O
;	O
ND	O
,	O
not	O
determined	O
;	O
t1	O
,	O
time	O
of	O
the	O
first	O
tumor	O
appearance	O
in	O
weeks	O
;	O
ta	O
,	O
mean	O
time	O
of	O
tumor	O
development	O
in	O
weeks	O
;	O
M	O
,	O
multiplicity	O
.	O

342	O
CARCINOGENESIS	O
OF	O
BaP	O
AND	O
o	O
-	O
CRESOL	O
343	O
palpated	O
through	O
the	O
abdominal	O
wall	O
.	O

At	O
autopsy	O
,	O
enlargement	O
of	O
the	O
stomach	O
with	O
tuberculous	O
white	O
superficial	O
vegetations	O
were	O
observed	O
.	O

The	O
forestomach	O
and	O
glandular	O
part	O
of	O
the	O
stomach	O
was	O
often	O
obliterated	O
by	O
tumor	O
masses	O
.	O

The	O
stomach	O
was	O
often	O
adhered	O
to	O
the	O
pancreas	O
,	O
liver	O
,	O
and	O
mesentery	O
.	O

Hemmorrhage	O
and	O
inflammation	O
were	O
found	O
in	O
tumors	O
foci	O
.	O

When	O
o	O
-	O
cresol	O
was	O
introduced	O
before	O
BaP	O
,	O
the	O
tumors	O
were	O
more	O
frequently	O
found	O
closer	O
to	O
the	O
small	O
curvature	O
of	O
the	O
stomach	O
between	O
the	O
forestomach	O
and	O
esophageal	O
entrance	O
.	O

Over	O
the	O
large	O
curvature	O
less	O
prominent	O
mucosal	O
folds	O
were	O
observed	O
.	O

Microscopically	O
,	O
a	O
decrease	O
in	O
mucosa	O
papillae	O
,	O
epithelial	O
atrophy	O
(	O
one	O
to	O
two	O
cullular	O
layers	O
)	O
,	O
decreased	O
keratonization	O
,	O
and	O
nuclear	O
pycnosis	O
were	O
observed	O
.	O

With	O
the	O
simultaneous	O
administration	O
of	O
large	O
doses	O
of	O
o	O
-	O
cresol	O
and	O
BaP	O
,	O
the	O
final	O
carcinogenic	O
effect	O
(	O
30	O
weeks	O
after	O
the	O
first	O
dose	O
)	O
was	O
similar	O
to	O
BaP	O
alone	O
but	O
differences	O
were	O
observed	O
at	O
the	O
earlier	O
stages	O
(	O
after	O
the	O
1st	O
,	O
3rd	O
,	O
5th	O
,	O
and	O
10th	O
exposures	O
)	O
.	O

In	O
the	O
BaP	O
control	O
,	O
multiple	O
forestomach	O
epithelial	O
proliferative	O
and	O
hyperplastic	O
changes	O
were	O
found	O
after	O
the	O
third	O
dose	O
.	O

Multiple	O
papillomas	O
occurred	O
(	O
9	O
-	O
15	O
in	O
each	O
mouse	B
)	O
.	O

The	O
stomach	O
's	O
mucosal	O
folds	O
appeared	O
thickened	O
diffusely	O
,	O
then	O
papillomas	O
appeared	O
and	O
finally	O
merged	O
together	O
.	O

Approximately	O
half	O
of	O
the	O
tumors	O
were	O
malignant	O
.	O

The	O
neoplasms	O
filled	O
almost	O
the	O
whole	O
forestomach	O
cavity	O
and	O
infiltrated	O
the	O
wall	O
with	O
tuberculous	O
vegetations	O
,	O
which	O
were	O
visible	O
on	O
the	O
serosal	O
surface	O
.	O

Thmor	O
infiltration	O
in	O
the	O
liver	O
,	O
pancreas	O
,	O
and	O
wide	O
dissemination	O
of	O
peritoneum	O
were	O
also	O
observed	O
.	O

In	O
mice	B
simultaneously	O
administered	O
BaP	O
and	O
o	O
-	O
cresol	O
,	O
the	O
proliferative	O
alterations	O
of	O
forestomach	O
epithelium	O
were	O
seen	O
after	O
the	O
third	O
dose	O
.	O

However	O
,	O
they	O
occurred	O
as	O
the	O
single	O
foci	O
at	O
damaged	O
mucosa	O
and	O
even	O
in	O
the	O
later	O
stages	O
were	O
not	O
diffuse	O
.	O

Adjacent	O
to	O
the	O
hyperplastic	O
foci	O
,	O
the	O
mucosa	O
was	O
atrophied	O
with	O
decreased	O
keratonization	O
.	O

The	O
epithelial	O
cells	O
also	O
showed	O
cytoplasm	O
coagulation	O
and	O
nuclear	O
pycnosis	O
.	O

Edema	O
,	O
inflammation	O
of	O
the	O
mucosa	O
,	O
submucosa	O
microabscesses	O
,	O
and	O
erosion	O
were	O
seen	O
.	O

There	O
were	O
fewer	O
papillomas	O
per	O
mouse	B
(	O
four	O
to	O
eight	O
in	O
each	O
mouse	B
)	O
than	O
in	O
the	O
control	O
group	O
.	O

Even	O
in	O
the	O
late	O
stages	O
the	O
papillomas	O
were	O
isolated	O
and	O
elevated	O
on	O
the	O
atrophied	O
mucosal	O
folds	O
.	O

In	O
the	O
final	O
experiment	O
the	O
papillomas	O
prevailed	O
as	O
compared	O
to	O
the	O
previous	O
experiments	O
.	O

Only	O
4	O
out	O
of	O
29	O
mice	B
(	O
13.8	O
%	O
)	O
developed	O
malignant	O
tumors	O
.	O

Neoplasms	O
were	O
smaller	O
and	O
appeared	O
as	O
single	O
verrucosa	O
vegetations	O
5	O
-	O
10	O
mm	O
in	O
diameter	O
.	O

Thus	O
,	O
the	O
toxic	O
dose	O
of	O
o	O
-	O
cresol	O
inhibits	O
the	O
carcinogenic	O
process	O
of	O
induced	O
forestomach	O
tumors	O
by	O
decreasing	O
multiplicity	O
,	O
frequency	O
,	O
and	O
percentage	O
of	O
malignant	O
tumors	O
.	O

Discussion	O
Our	O
results	O
and	O
the	O
literature	O
suggest	O
a	O
hypothesis	O
on	O
modifying	O
carcinogenesis	O
mechanisms	O
.	O

The	O
primary	O
effect	O
of	O
the	O
toxic	O
agents	O
,	O
including	O
carcinogenic	O
agents	O
,	O
may	O
relate	O
to	O
cellular	O
membrane	O
damage	O
with	O
the	O
subsequent	O
increased	O
permeability	O
(	O
31	O
-	O
35	O
)	O
,	O
which	O
may	O
be	O
the	O
mechanism	O
of	O
the	O
o	O
-	O
cresol	O
.	O

With	O
simultaneous	O
introduction	O
of	O
o	O
-	O
cresol	O
at	O
low	O
toxic	O
doses	O
and	O
BaP	O
there	O
may	O
be	O
increased	O
carcinogen	O
penetration	O
to	O
the	O
target	O
cells	O
.	O

In	O
addition	O
,	O
membrane	O
damage	O
may	O
alter	O
other	O
cellular	O
systems	O
responsible	O
for	O
energy	O
and	O
xenobiotic	O
detoxication	O
.	O

Damage	O
of	O
these	O
processes	O
may	O
activate	O
free	O
-	O
radical	O
reactions	O
,	O
glycolysis	O
,	O
or	O
alter	O
carcinogenic	O
metabolism	O
,	O
which	O
promotes	O
the	O
oncogenic	O
effect	O
.	O

The	O
o	O
-	O
cresol	O
effect	O
on	O
these	O
systems	O
was	O
confirmed	O
by	O
our	O
previous	O
investigations	O
on	O
cytochrome	O
P450	O
,	O
ferrosulfuric	O
nonhemic	O
proteins	O
,	O
and	O
semiquinon	O
radical	O
content	O
affected	O
by	O
the	O
combined	O
action	O
of	O
BaP	O
and	O
o	O
-	O
cresol	O
(	O
36	O
)	O
.	O

Another	O
effect	O
was	O
obtained	O
with	O
BaP	O
exposure	O
after	O
o	O
-	O
cresol	O
.	O

The	O
atrophic	O
alterations	O
in	O
the	O
stomach	O
induced	O
by	O
2.5	O
months	O
of	O
o	O
-	O
cresol	O
administration	O
might	O
decrease	O
the	O
natural	O
conditions	O
of	O
retention	O
(	O
muscosal	O
folds	O
,	O
frontier	O
torn	O
)	O
,	O
and	O
thus	O
shorten	O
the	O
contact	O
of	O
BaP	O
with	O
the	O
forestomach	O
.	O

In	O
our	O
opinion	O
,	O
this	O
explains	O
the	O
decreased	O
carcinogenic	O
effect	O
seen	O
after	O
o	O
-	O
cresol	O
exposure	O
.	O

Considering	O
the	O
toxic	O
effect	O
of	O
o	O
-	O
cresol	O
at	O
low	O
toxic	O
doses	O
(	O
1	O
mg	O
)	O
after	O
BaP	O
and	O
the	O
effect	O
of	O
a	O
super	O
toxic	O
dose	O
(	O
10	O
mg	O
)	O
simultaneously	O
with	O
BaP	O
administration	O
,	O
it	O
is	O
possible	O
that	O
the	O
inhibition	O
of	O
carcinogenesis	O
in	O
both	O
trials	O
was	O
related	O
to	O
the	O
toxic	O
effects	O
of	O
o	O
-	O
cresol	O
.	O

Cytotoxicity	O
may	O
not	O
only	O
hamper	O
tumor	O
growth	O
,	O
but	O
also	O
promote	O
the	O
regression	O
of	O
inducible	O
and	O
spontaneous	O
neoplasms	O
(	O
37	O
-	O
39	O
)	O
.	O

There	O
is	O
also	O
a	O
possibility	O
that	O
BaP	O
damages	O
metabolic	O
systems	O
and	O
decreases	O
resistance	O
to	O
carcinogenesis	O
.	O

Conclusions	O
The	O
data	O
obtained	O
demonstrate	O
that	O
simultaneous	O
administration	O
of	O
BaP	O
modifies	O
the	O
induced	O
carcinogenesis	O
depending	O
on	O
the	O
dose	O
and	O
the	O
sequence	O
of	O
administration	O
.	O

Administered	O
with	O
BaP	O
(	O
1	O
mg	O
)	O
,	O
a	O
low	O
toxic	O
o	O
-	O
cresol	O
dose	O
(	O
about	O
minimally	O
effective	O
)	O
produces	O
an	O
enhanced	O
cocarcinogenic	O
effect	O
reflected	O
in	O
the	O
incidence	O
,	O
frequency	O
,	O
multiplicity	O
,	O
and	O
degree	O
of	O
malignancy	O
of	O
forestomach	O
tumors	O
.	O

o	O
-	O
Cresol	O
administration	O
at	O
low	O
toxic	O
doses	O
before	O
or	O
after	O
BaP	O
at	O
the	O
same	O
dose	O
level	O
(	O
1	O
mg	O
)	O
and	O
its	O
administration	O
at	O
super	O
toxic	O
doses	O
(	O
10	O
mg	O
)	O
with	O
the	O
BaP	O
optimal	O
dose	O
(	O
5	O
mg	O
)	O
may	O
inhibit	O
carcinogenesis	O
.	O

Simultaneous	O
introduction	O
of	O
a	O
noneffective	O
o	O
-	O
cresol	O
dose	O
(	O
0.02	O
mg	O
)	O
with	O
the	O
BaP	O
(	O
1	O
mg	O
)	O
does	O
not	O
change	O
its	O
carcinogenic	O
activity	O
.	O

Controlling	O
both	O
chemicals	O
in	O
the	O
environment	O
is	O
the	O
most	O
effective	O
measure	O
of	O
preventing	O
potential	O
risk	O
and	O
is	O
undoubtedly	O
of	O
paramount	O
significance	O
.	O

REFERENCES	O
1	O
.	O

Bingham	O
,	O
E.	O
,	O
and	O
Falk	O
,	O
H.	O
L.	O
Environmental	O
carcinogenesis	O
.	O

The	O
modifying	O
effect	O
of	O
cocarcinogens	O
on	O
the	O
threshold	O
response	O
.	O

Arch	O
.	O

Environ	O
.	O

Health	O
19	O
:	O
779	O
-	O
783	O
(	O
1969	O
)	O
.	O

2	O
.	O

Goldschmidt	O
,	O
B.	O
M.	O
,	O
Katz	O
,	O
C.	O
,	O
and	O
Van	O
Duuren	O
,	O
B.	O
L.	O

The	O
cocar	O
cinogenic	O
activity	O
of	O
non	O
-	O
carcinogenic	O
aromatic	O
hydrocarbons	O
.	O

Proc	O
.	O

Am	O
.	O

Assoc	O
.	O

Cancer	O
Res	O
.	O

17	O
:	O
84	O
(	O
1973	O
)	O
.	O

3	O
.	O

Kaufman	O
,	O
D.	O
C.	O
,	O
and	O
Madison	O
,	O
R.	O
M.	O
Synergistic	O
effects	O
of	O
benzo	O
(	O
a	O
)	O
pyrene	O
and	O
N	O
-	O
methyl	O
-	O
N	O
-	O
nitrosourea	O
respirators	O
carcinogenesis	O
in	O
Syrian	B
golden	I
hamsters	I
.	O

In	O
:	O
Proceedings	O
of	O
the	O
Sym	O
344	O
YANYSHEVA	O
ET	O
AL	O
.	O

posium	O
on	O
Epithelial	O
Respiratory	O
Carcinogenesis	O
and	O
Bioassays	O
.	O

Batelle	O
Seattle	O
Research	O
Center	O
,	O
Seattle	O
,	O
WA	O
,	O
1974	O
,	O
p.	O
17	O
.	O

4	O
.	O

Montesano	O
,	O
R.	O
,	O
Saffiotti	O
,	O
U	O
,	O
Ferrero	O
,	O
A	O
,	O
and	O
Kaufman	O
,	O
D.	O
Synergistic	O
effects	O
of	O
benzo	O
(	O
a	O
)	O
pyrene	O
and	O
diethylnitrosamine	O
on	O
respiratory	O
carcinogenesis	O
in	O
hamsters	O
.	O

J.	O
Natl	O
.	O

Cancer	O
.	O

Inst	O
.	O

5	O
:	O
1395	O
-	O
1397	O
(	O
1974	O
)	O
.	O

5	O
.	O

Pfeiffer	O
,	O
E.	O
H.	O
Investigations	O
of	O
the	O
carcinogenic	O
burden	O
by	O
air	O
pollution	O
in	O
man	B
.	O

VII	O
.	O

Studies	O
on	O
the	O
ontogenetic	O
interaction	O
of	O
polycyclic	O
aromatic	O
hydrocarbons	O
.	O

Zbl	O
.	O

Bakteriol	O
.	O

Parasitenk	O
.	O

Infektion	O
.	O

Hyg	O
.	O

Abt	O
.	O

B	O
158	O
(	O
1	O
)	O
:	O
69	O
-	O
83	O
(	O
1973	O
)	O
.	O

6	O
.	O

Slaga	O
,	O
T.	O
J.	O
,	O
Jecker	O
,	O
L.	O
,	O
Bracken	O
,	O
W.	O
M.	O
,	O
and	O
Weeks	O
,	O
C.	O
E.	O
The	O
effects	O
of	O
weak	O
or	O
non	O
-	O
carcinogenic	O
polycyclic	O
hydrocarbons	O
on	O
7,12-dimethylbenz	O
(	O
a	O
)	O
anthracene	O
and	O
benzo	O
(	O
a	O
)	O
pyrene	O
skin	O
tumor	O
-	O
initiation	O
.	O

Cancer	O
Lett	O
.	O

7	O
:	O
51	O
-	O
59	O
(	O
1979	O
)	O
.	O

7	O
.	O

Topping	O
,	O
D.	O
C.	O
,	O
Martin	O
,	O
D.	O
H.	O
,	O
and	O
Nettesheim	O
,	O
P.	O
Determination	O
of	O
cocarcinogenic	O
activity	O
of	O
benzo	O
(	O
a	O
)	O
pyrene	O
for	O
respiratory	O
tract	O
mucosa	O
.	O

Cancer	O
Lett	O
.	O

11	O
:	O
315	O
-	O
321	O
(	O
1981	O
)	O
.	O

8	O
.	O

Ilnitsky	O
,	O
A.	O
P.	O
,	O
Voronin	O
,	O
V.	O
M.	O
,	O
and	O
Solenova	O
,	O
M.	O
G.	O
Carcinogenic	O
effect	O
of	O
benzo	O
(	O
a	O
)	O
pyrene	O
and	O
its	O
combinations	O
with	O
other	O
carbohydrates	O
at	O
their	O
oral	O
intake	O
[	O
in	O
Russian	O
]	O
.	O

Voprosy	O
Onkol	O
.	O

10	O
:	O
71	O
-	O
75	O
(	O
1974	O
)	O
.	O

9	O
.	O

Kurljandsky	O
,	O
B.	O
A.	O
,	O
Medvedovsky	O
,	O
A.	O
G.	O
,	O
and	O
Mashbits	O
,	O
F.	O
D.	O
On	O
cocarcinogenic	O
effect	O
of	O
toxic	O
factors	O
of	O
low	O
intensity	O
[	O
in	O
Russian	O
]	O
.	O

Gig	O
.	O

Sanit	O
.	O

10	O
:	O
83	O
-	O
85	O
(	O
1972	O
)	O
.	O

10	O
.	O

Thrusov	O
,	O
V.	O
S.	O
,	O
and	O
Andrianov	O
,	O
L.	O
A.	O
On	O
combined	O
effect	O
on	O
the	O
skin	O
of	O
single	O
application	O
of	O
7,12-dimethylbenz	O
(	O
a	O
)	O
anthracene	O
and	O
repeated	O
applications	O
of	O
benz	O
(	O
a	O
)	O
pyrene	O
[	O
in	O
Russian	O
]	O
.	O

Bull	O
.	O

Eksper	O
.	O

Biol	O
.	O

Med	O
.	O

3	O
:	O
80	O
-	O
83	O
(	O
1972	O
)	O
.	O

11	O
.	O

Yanysheva	O
,	O
N.	O
Ya	O
.	O
,	O
Chernichenko	O
,	O
I.	O
A.	O
,	O
Balenko	O
,	O
N.	O
V	O
,	O
and	O
Kireeva	O
,	O
I.	O
S.	O
Carcinogenic	O
substances	O
and	O
their	O
hygienic	O
standardization	O
in	O
the	O
environment	O
[	O
in	O
Russian	O
]	O
.	O

Zdorovja	O
,	O
Kiev	O
,	O
1977	O
.	O

12	O
.	O

Laskin	O
,	O
S.	O
,	O
Kushner	O
,	O
M.	O
,	O
and	O
Drew	O
,	O
R.	O
T.	O
Studies	O
in	O
pulmonary	O
careinogenesis	O
.	O

In	O
:	O
Inhalation	O
Carcinogenesis	O
(	O
M.	O
G.	O
Hanna	O
,	O
P.	O
Nettesheim	O
,	O
and	O
J.	O
R.	O
Gillbert	O
,	O
Eds	O
.	O
)	O

U.S.	O
Atomic	O
Energy	O
Commission	O
Symposium	O
,	O
Series	O
18	O
,	O
1970	O
,	O
p.	O
321	O
.	O

13	O
.	O

Laskin	O
,	O
S.	O
,	O
Kuschner	O
,	O
M.	O
,	O
and	O
Drew	O
,	O
R.	O
T.	O
Inhalation	O
exposure	O
to	O
sulphur	O
dioxide	O
and	O
benzo	O
(	O
a	O
)	O
pyrene	O
.	O

Oak	O
Ridge	O
National	O
Laboratory	O
,	O
Gatlinburg	O
,	O
TN	O
,	O
1970	O
,	O
pp	O
.	O

322	O
-	O
351	O
.	O

14	O
.	O

Kuschner	O
,	O
M.	O
,	O
and	O
Laskin	O
,	O
S.	O
Experimental	O
models	O
in	O
environmental	O
carcinogenesis	O
.	O

Am	O
.	O

J.	O
Pathol	O
.	O

1	O
:	O
183	O
-	O
196	O
(	O
1971	O
)	O
.	O

15	O
.	O

Komine	O
,	O
T.	O
Influences	O
of	O
sulfur	O
dioxide	O
and	O
3,4-benzpyrene	O
on	O
the	O
respiratory	O
organ	O
of	O
rats	B
.	O

Hokkaido	O
Igaku	O
Zasshi	O
3	O
:	O
189	O
-	O
203	O
(	O
1977	O
)	O
.	O

16	O
.	O

Skvortsova	O
,	O
N.	O
N.	O
Role	O
of	O
some	O
common	O
atmospheric	O
pollutions	O
in	O
lung	O
blastomogenesis	O
[	O
in	O
Russian	O
]	O
.	O

In	O
:	O
Handbook	O
of	O
Hygiene	O
of	O
Atmospheric	O
Air	O
(	O
K.	O
A.	O
Bushtueva	O
,	O
Ed	O
.	O
)	O
,	O
Meditsina	O
,	O
Moscow	O
,	O
1976	O
,	O
pp	O
.	O

384	O
-	O
391	O
.	O

17	O
.	O

Yanysheva	O
,	O
N.	O
Ya	O
.	O
,	O
Balenko	O
,	O
N.	O
V	O
,	O
Chernichenko	O
,	O
I.	O
A	O
,	O
and	O
Babiy	O
,	O
V.	O
F.	O
Quantitation	O
of	O
modified	O
effects	O
of	O
nitrogen	O
oxides	O
on	O
carcinogenicity	O
of	O
benz	O
(	O
a	O
)	O
pyrene	O
effect	O
[	O
in	O
Rusian	O
]	O
.	O

Gig	O
.	O

Sanit	O
.	O

7	O
:	O
7	O
-	O
9	O
(	O
1986	O
)	O
.	O

18	O
.	O

Yanysheva	O
,	O
N.	O
Ya	O
.	O
,	O
Balenko	O
,	O
N.	O
V.	O
,	O
Chernichenko	O
,	O
I.	O
A.	O
,	O
Babiy	O
,	O
V.	O
F.	O
,	O
Bakanova	O
,	O
G.	O
N.	O
,	O
and	O
Lemeshko	O
,	O
L.	O
P.	O
Peculiarities	O
of	O
manifestation	O
of	O
carcinogenesis	O
at	O
combined	O
effect	O
of	O
benz	O
(	O
a	O
)	O
pyrene	O
and	O
phenol	O
depending	O
on	O
regimen	O
of	O
intake	O
into	O
the	O
organism	O
[	O
in	O
Russian	O
]	O
.	O

Gig	O
.	O

Sanit	O
.	O

4	O
:	O
29	O
-	O
33	O
(	O
1988	O
)	O
.	O

19	O
.	O

Van	O
Duuren	O
,	O
B.	O
L.	O
,	O
Katz	O
,	O
C.	O
,	O
and	O
Goldschmidt	O
,	O
B.	O
M.	O
Brief	O
communica	O
tion	O
:	O
cocarcinogenic	O
agents	O
in	O
tobacco	B
carcinogenesis	O
.	O

J.	O
Natl	O
.	O

Cancer	O
Inst	O
.	O

51	O
:	O
703	O
-	O
705	O
(	O
1973	O
)	O
.	O

20	O
.	O

Van	O
Duuren	O
,	O
B.	O
L.	O
,	O
and	O
Goldschmidt	O
,	O
B.	O
M.	O
Cocarcinogenic	O
and	O
tumor	O
-	O
promoting	O
agents	O
in	O
tobacco	B
carcinogenesis	O
.	O

J.	O
Natl	O
.	O

Cancer	O
Inst	O
.	O

56	O
:	O
1237	O
-	O
1242	O
(	O
1976	O
)	O
.	O

21	O
.	O

Wattenberg	O
,	O
L.	O
W.	O
,	O
Coccia	O
,	O
J.	O
B.	O
,	O
and	O
Lam	O
,	O
L.	O
K.	O
Inhibitory	O
effects	O
of	O
phenolic	O
compounds	O
on	O
benzo	O
(	O
a	O
)	O
pyrene	O
-	O
induced	O
neoplasia	O
.	O

Cancer	O
Res	O
.	O

8	O
:	O
2820	O
-	O
2823	O
(	O
1980	O
)	O
.	O

22	O
.	O

Bogovski	O
,	O
P.	O
A	O
,	O
and	O
Mirme	O
,	O
H.	O
Yu	O
.	O

Cocarcinogenicity	O
of	O
phenols	O
from	O
Estonian	O
shale	O
tars	O
(	O
oils	O
)	O
.	O

Environ	O
.	O

Health	O
Perspect	O
.	O

30	O
:	O
177	O
-	O
178	O
(	O
1979	O
)	O
.	O

23	O
.	O

Gubergritz	O
,	O
M.	O
Ya	O
.	O
,	O
and	O
Kirso	O
,	O
U.	O
E.	O
Carcinogenic	O
properties	O
,	O
struc	O
ture	O
and	O
reactive	O
capacity	O
of	O
phenols	O
[	O
in	O
Russian	O
]	O
.	O

Voprosy	O
Onkol	O
.	O

8	O
:	O
96	O
-	O
100	O
(	O
1970	O
)	O
.	O

24	O
.	O

Mirme	O
,	O
H.	O
Yu	O
.	O

Modifying	O
effect	O
of	O
water	O
-	O
soluble	O
shale	O
phenols	O
upon	O
carcinogenesis	O
[	O
in	O
Russian	O
]	O
.	O

In	O
:	O
Problems	O
of	O
Prevention	O
of	O
Pollution	O
of	O
Environment	O
by	O
Carcinogenic	O
Substances	O
(	O
M.	O
M.	O
Shabad	O
,	O
Ed	O
.	O
)	O
,	O
Tallinn	O
,	O
Valgus	O
,	O
1972	O
,	O
pp	O
.	O

16	O
-	O
18	O
.	O

25	O
.	O

Kirso	O
,	O
U.	O
E.	O
,	O
Pashin	O
,	O
Yu	O
.	O

V.	O
,	O
Bakhitova	O
,	O
L.	O
M.	O
,	O
and	O
Kjung	O
,	O
A.	O
I.	O
Effect	O
of	O
antioxidants	O
on	O
carcinogenic	O
and	O
mutagenic	O
activity	O
of	O
benzo	O
(	O
a	O
)	O
pyrene	O
[	O
in	O
Russian	O
]	O
.	O

Voprosy	O
Onkol	O
.	O

4	O
:	O
70	O
-	O
75	O
(	O
1985	O
)	O
.	O

26	O
.	O

Veldre	O
,	O
I.	O
A.	O
Comparative	O
assessment	O
of	O
toxic	O
effect	O
of	O
some	O
water	O
soluble	O
phenols	O
[	O
in	O
Russian	O
]	O
.	O

In	O
:	O
Proceedings	O
of	O
the	O
Scientific	O
Conference	O
on	O
Urgent	O
Problems	O
Related	O
with	O
Decrease	O
of	O
Infectious	O
Diseases	O
Morbidity	O
and	O
with	O
Hygienic	O
Problems	O
.	O

Tallinn	O
,	O
1968	O
,	O
pp	O
.	O

200	O
-	O
202	O
.	O

27	O
.	O

Substances	O
possessing	O
cocarcinogenic	O
effect	O
.	O

In	O
:	O
Carcinogenic	O
Sub	O
stances	O
in	O
the	O
Environment	O
of	O
Man	B
(	O
L.	O
M.	O
Shabad	O
and	O
A.	O
P.	O
Ilnitsky	O
,	O
Eds	O
.	O
)	O
,	O
Budapest	O
,	O
1979	O
,	O
pp	O
.	O
111	O
-	O
113	O
.	O

28	O
.	O

Djatlovitskaya	O
,	O
F.	O
G.	O
,	O
and	O
Maktas	O
,	O
E.	O
D.	O
Separate	O
determination	O
of	O
fly	O
phenols	O
in	O
water	O
using	O
thin	O
-	O
layer	O
chromatography	O
[	O
in	O
Russian	O
]	O
.	O

Gig	O
.	O

Sanit	O
.	O

6	O
:	O
60	O
-	O
63	O
(	O
1965	O
)	O
.	O

29	O
.	O

Kostovetsky	O
,	O
Ya	O
.	O
I.	O
,	O
and	O
Zholdakova	O
,	O
Z.	O
I.	O
About	O
hygienic	O
rate	O
setting	O
of	O
phenol	O
in	O
the	O
water	O
of	O
waterpools	O
[	O
in	O
Russian	O
]	O
.	O

Gig	O
.	O

Sanit	O
.	O

7	O
:	O
7	O
-	O
10	O
(	O
1971	O
)	O
.	O

30	O
.	O

Mostkovoy	O
,	O
M.	O
I.	O
Practicum	O
on	O
variational	O
-	O
statistical	O
processing	O
of	O
clinical	O
material	O
[	O
in	O
Russian	O
]	O
.	O

Ashkhabad	O
,	O
1954	O
,	O
p.	O
132	O
.	O

31	O
.	O

Weinstein	O
,	O
I.	O
B.	O
The	O
scientific	O
basis	O
for	O
carcinogen	O
detection	O
and	O
primary	O
cancer	O
prevention	O
.	O

Cancer	O
47	O
:	O
1133	O
-	O
1141	O
(	O
1981	O
)	O
.	O

32	O
.	O

Merkulov	O
,	O
A.	O
I	O
,	O
and	O
Skvortsova	O
,	O
R.	O
I.	O
About	O
toxic	O
effect	O
of	O
phenol	O
[	O
in	O
Russian	O
]	O
.	O

Gig	O
.	O

Sanit	O
.	O

1	O
:	O
79	O
-	O
80	O
(	O
1984	O
)	O
.	O

33	O
.	O

Weinstein	O
,	O
I.	O
B.	O
,	O
Mufson	O
,	O
R.	O
A.	O
,	O
Lee	O
,	O
L.	O
S.	O
,	O
et	O
al.	O
Membrane	O
and	O
other	O
biochemical	O
effects	O
of	O
the	O
phorbol	O
esters	O
and	O
their	O
relevance	O
to	O
tumor	O
promotion	O
.	O

In	O
:	O
Carcinogenesis	O
.	O

Fundamental	O
Mechanisms	O
and	O
Environmental	O
Effects	O
.	O

London	O
,	O
1980	O
,	O
pp	O
.	O

543	O
-	O
563	O
.	O

34	O
.	O

Yamasaki	O
,	O
H.	O
,	O
and	O
Weinstein	O
,	O
I.	O
B.	O
Cellular	O
and	O
molecular	O
mecha	O
nisms	O
of	O
tumor	O
promotion	O
and	O
their	O
implications	O
for	O
risk	O
assessment	O
.	O

In	O
:	O
Methods	O
for	O
Estimating	O
Risk	O
of	O
Chemical	O
Injury	O
:	O
Human	B
and	O
Non	O
-	O
human	B
Biota	O
and	O
Ecosystems	O
(	O
V.	O
B.	O
Vouk	O
,	O
G.	O
C.	O
Butler	O
,	O
D.	O
G.	O
Hoel	O
,	O
and	O
D.	O
B.	O
Peakall	O
,	O
Eds	O
.	O
)	O
,	O
SCOPE	O
,	O
1985	O
,	O
pp	O
.	O
155	O
-	O
180	O
.	O

35	O
.	O

Karu	O
,	O
T	O
,	O
Kirso	O
,	O
U.	O
E.	O
,	O
and	O
Andrianov	O
,	O
L.	O
A.	O
Dynamics	O
of	O
resorption	O
of	O
3,4-benzpyrene	O
with	O
phenols	O
from	O
mouse	B
skin	O
[	O
in	O
Russian	O
]	O
.	O

Voprosy	O
Onkol	O
.	O

5	O
:	O
80	O
-	O
84	O
(	O
1973	O
)	O
.	O

36	O
.	O

Yanysheva	O
,	O
N.	O
Ya	O
.	O
,	O
Yurkovskaya	O
,	O
T.	O
N.	O
,	O
Beregovskaya	O
,	O
N.	O
N.	O
,	O
et	O
al.	O
Metalloenzymic	O
complexes	O
of	O
energetic	O
and	O
detoxicating	O
systems	O
of	O
cell	O
during	O
benz	O
(	O
a	O
)	O
pyrene	O
-	O
induced	O
carcinogenesis	O
.	O

In	O
:	O
Proceedings	O
of	O
the	O
4th	O
National	O
Congress	O
of	O
Oncology	O
with	O
International	O
Participation	O
.	O

Sofia	O
,	O
1985	O
,	O
p.	O
102	O
.	O

37	O
.	O

Mizell	O
,	O
M.	O
Anuran	O
(	O
Lucke	O
)	O
tumor	O
breakdown	O
in	O
regenerating	O
anuran	O
tadpole	O
tails	O
.	O

Anat	O
.	O

Res	O
.	O

137	O
:	O
382	O
-	O
383	O
(	O
1960	O
)	O
.	O

38	O
.	O

Sheremetieva	O
,	O
E.	O
N.	O
Spontaneous	O
melanoma	O
in	O
regenerating	O
tails	O
of	O
axolotis	O
.	O

J.	O
Exp	O
.	O

Zool	O
.	O

158	O
:	O
101	O
-	O
122	O
(	O
1965	O
)	O
.	O

39	O
.	O

Tsonis	O
,	O
P.	O
A	O
,	O
and	O
Eguchi	O
,	O
G.	O
Carcinogens	O
on	O
regeneration	O
.	O

Effects	O
on	O
N	O
-	O
methyl	O
-	O
N	O
-	O
nitro	O
-	O
N	O
-	O
nitrosoguanidine	O
and	O
4-nitrogninoline-1-oxide	O
on	O
limb	O
regeneration	O
in	O
adult	O
newts	O
.	O

Differentiation	O
20	O
:	O
52	O
-	O
60	O
(	O
1981	O
)	O
.	O

Comparison	O
of	O
age	O
-	O
specific	O
cataract	O
prevalence	O
in	O
two	O
population	O
-	O
based	O
surveys	O
6	O
years	O
apart	O
Abstract	O
Background	O
In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
compare	O
age	O
-	O
specific	O
cortical	O
,	O
nuclear	O
and	O
posterior	O
subcapsular	O
(	O
PSC	O
)	O
cataract	O
prevalence	O
in	O
two	O
surveys	O
6	O
years	O
apart	O
.	O

Methods	O

The	O
Blue	O
Mountains	O
Eye	O
Study	O
examined	O
3654	O
participants	O
(	O
82.4	O
%	O
of	O
those	O
eligible	O
)	O
in	O
cross	O
-	O
section	O
I	O
(	O
1992–4	O
)	O
and	O
3509	O
participants	O
(	O
75.1	O
%	O
of	O
survivors	O
and	O
85.2	O
%	O
of	O
newly	O
eligible	O
)	O
in	O
cross	O
-	O
section	O
II	O
(	O
1997–2000	O
,	O
66.5	O
%	O
overlap	O
with	O
cross	O
-	O
section	O
I	O
)	O
.	O

Cataract	O
was	O
assessed	O
from	O
lens	O
photographs	O
following	O
the	O
Wisconsin	O
Cataract	O
Grading	O
System	O
.	O

Cortical	O
cataract	O
was	O
defined	O
if	O
cortical	O
opacity	O
comprised	O
≥	O
5	O
%	O
of	O
lens	O
area	O
.	O

Nuclear	O
cataract	O
was	O
defined	O
if	O
nuclear	O
opacity	O
≥	O

Wisconsin	O
standard	O
4	O
.	O

PSC	O
was	O
defined	O
if	O
any	O
present	O
.	O

Any	O
cataract	O
was	O
defined	O
to	O
include	O
persons	O
who	O
had	O
previous	O
cataract	O
surgery	O
.	O

Weighted	O
kappa	O
for	O
inter	O
-	O
grader	O
reliability	O
was	O
0.82	O
,	O
0.55	O
and	O
0.82	O
for	O
cortical	O
,	O
nuclear	O
and	O
PSC	O
cataract	O
,	O
respectively	O
.	O

We	O
assessed	O
age	O
-	O
specific	O
prevalence	O
using	O
an	O
interval	O
of	O
5	O
years	O
,	O
so	O
that	O
participants	O
within	O
each	O
age	O
group	O
were	O
independent	O
between	O
the	O
two	O
surveys	O
.	O

Results	O
Age	O
and	O
gender	O
distributions	O
were	O
similar	O
between	O
the	O
two	O
populations	O
.	O

The	O
age	O
-	O
specific	O
prevalence	O
of	O
cortical	O
(	O
23.8	O
%	O
in	O
1st	O
,	O
23.7	O
%	O
in	O
2nd	O
)	O
and	O
PSC	O
cataract	O
(	O
6.3	O
%	O
,	O
6.0	O
%	O
)	O
was	O
similar	O
.	O

The	O
prevalence	O
of	O
nuclear	O
cataract	O
increased	O
slightly	O
from	O
18.7	O
%	O
to	O
23.9	O
%	O
.	O

After	O
age	O
standardization	O
,	O
the	O
similar	O
prevalence	O
of	O
cortical	O
(	O
23.8	O
%	O
,	O
23.5	O
%	O
)	O
and	O
PSC	O
cataract	O
(	O
6.3	O
%	O
,	O
5.9	O
%	O
)	O
,	O
and	O
the	O
increased	O
prevalence	O
of	O
nuclear	O
cataract	O
(	O
18.7	O
%	O
,	O
24.2	O
%	O
)	O
remained	O
.	O

Conclusion	O
In	O
two	O
surveys	O
of	O
two	O
population	O
-	O
based	O
samples	O
with	O
similar	O
age	O
and	O
gender	O
distributions	O
,	O
we	O
found	O
a	O
relatively	O
stable	O
cortical	O
and	O
PSC	O
cataract	O
prevalence	O
over	O
a	O
6-year	O
period	O
.	O

The	O
increased	O
prevalence	O
of	O
nuclear	O
cataract	O
deserves	O
further	O
study	O
.	O

Background	O
Age	O
-	O
related	O
cataract	O
is	O
the	O
leading	O
cause	O
of	O
reversible	O
visual	O
impairment	O
in	O
older	O
persons	O
[	O
1	O
-	O
6	O
]	O
.	O

In	O
Australia	O
,	O
it	O
is	O
estimated	O
that	O
by	O
the	O
year	O
2021	O
,	O
the	O
number	O
of	O
people	O
affected	O
by	O
cataract	O
will	O
increase	O
by	O
63	O
%	O
,	O
due	O
to	O
population	O
aging	O
[	O
7	O
]	O
.	O

Surgical	O
intervention	O
is	O
an	O
effective	O
treatment	O
for	O
cataract	O
and	O
normal	O
vision	O
(	O
>	O
20	O
/	O
40	O
)	O
can	O
usually	O
be	O
restored	O
with	O
intraocular	O
lens	O
(	O
IOL	O
)	O
implantation	O
.	O

Cataract	O
surgery	O
with	O
IOL	O
implantation	O
is	O
currently	O
the	O
most	O
commonly	O
performed	O
,	O
and	O
is	O
,	O
arguably	O
,	O
the	O
most	O
cost	O
effective	O
surgical	O
procedure	O
worldwide	O
.	O

Performance	O
of	O
this	O
surgical	O
procedure	O
has	O
been	O
continuously	O
increasing	O
in	O
the	O
last	O
two	O
decades	O
.	O

Data	O
from	O
the	O
Australian	O
Health	O
Insurance	O
Commission	O
has	O
shown	O
a	O
steady	O
increase	O
in	O
Medicare	O
claims	O
for	O
cataract	O
surgery	O
[	O
8	O
]	O
.	O

A	O
2.6-fold	O
increase	O
in	O
the	O
total	O
number	O
of	O
cataract	O
procedures	O
from	O
1985	O
to	O
1994	O
has	O
been	O
documented	O
in	O
Australia	O
[	O
9	O
]	O
.	O

The	O
rate	O
of	O
cataract	O
surgery	O
per	O
thousand	O
persons	O
aged	O
65	O
years	O
or	O
older	O
has	O
doubled	O
in	O
the	O
last	O
20	O
years	O
[	O
8,9	O
]	O
.	O

In	O
the	O
Blue	O
Mountains	O
Eye	O
Study	O
population	O
,	O
we	O
observed	O
a	O
one	O
-	O
third	O
increase	O
in	O
cataract	O
surgery	O
prevalence	O
over	O
a	O
mean	O
6-year	O
interval	O
,	O
from	O
6	O
%	O
to	O
nearly	O
8	O
%	O
in	O
two	O
cross	O
-	O
sectional	O
population	O
-	O
based	O
samples	O
with	O
a	O
similar	O
age	O
range	O
[	O
10	O
]	O
.	O

Further	O
increases	O
in	O
cataract	O
surgery	O
performance	O
would	O
be	O
expected	O
as	O
a	O
result	O
of	O
improved	O
surgical	O
skills	O
and	O
technique	O
,	O
together	O
with	O
extending	O
cataract	O
surgical	O
benefits	O
to	O
a	O
greater	O
number	O
of	O
older	O
people	O
and	O
an	O
increased	O
number	O
of	O
persons	O
with	O
surgery	O
performed	O
on	O
both	O
eyes	O
.	O

Both	O
the	O
prevalence	O
and	O
incidence	O
of	O
age	O
-	O
related	O
cataract	O
link	O
directly	O
to	O
the	O
demand	O
for	O
,	O
and	O
the	O
outcome	O
of	O
,	O
cataract	O
surgery	O
and	O
eye	O
health	O
care	O
provision	O
.	O

This	O
report	O
aimed	O
to	O
assess	O
temporal	O
changes	O
in	O
the	O
prevalence	O
of	O
cortical	O
and	O
nuclear	O
cataract	O
and	O
posterior	O
subcapsular	O
cataract	O
(	O
PSC	O
)	O
in	O
two	O
cross	O
-	O
sectional	O
population	O
-	O
based	O
surveys	O
6	O
years	O
apart	O
.	O

Methods	O
The	O
Blue	O
Mountains	O
Eye	O
Study	O
(	O
BMES	O
)	O
is	O
a	O
population	O
-	O
based	O
cohort	O
study	O
of	O
common	O
eye	O
diseases	O
and	O
other	O
health	O
outcomes	O
.	O

The	O
study	O
involved	O
eligible	O
permanent	O
residents	O
aged	O
49	O
years	O
and	O
older	O
,	O
living	O
in	O
two	O
postcode	O
areas	O
in	O
the	O
Blue	O
Mountains	O
,	O
west	O
of	O
Sydney	O
,	O
Australia	O
.	O

Participants	O
were	O
identified	O
through	O
a	O
census	O
and	O
were	O
invited	O
to	O
participate	O
.	O

The	O
study	O
was	O
approved	O
at	O
each	O
stage	O
of	O
the	O
data	O
collection	O
by	O
the	O
Human	B
Ethics	O
Committees	O
of	O
the	O
University	O
of	O
Sydney	O
and	O
the	O
Western	O
Sydney	O
Area	O
Health	O
Service	O
and	O
adhered	O
to	O
the	O
recommendations	O
of	O
the	O
Declaration	O
of	O
Helsinki	O
.	O

Written	O
informed	O
consent	O
was	O
obtained	O
from	O
each	O
participant	O
.	O

Details	O
of	O
the	O
methods	O
used	O
in	O
this	O
study	O
have	O
been	O
described	O
previously	O
[	O
11	O
]	O
.	O

The	O
baseline	O
examinations	O
(	O
BMES	O
cross	O
-	O
section	O
I	O
)	O
were	O
conducted	O
during	O
1992–1994	O
and	O
included	O
3654	O
(	O
82.4	O
%	O
)	O
of	O
4433	O
eligible	O
residents	O
.	O

Follow	O
-	O
up	O
examinations	O
(	O
BMES	O
IIA	O
)	O
were	O
conducted	O
during	O
1997–1999	O
,	O
with	O
2335	O
(	O
75.0	O
%	O
of	O
BMES	O
cross	O
section	O
I	O
survivors	O
)	O
participating	O
.	O

A	O
repeat	O
census	O
of	O
the	O
same	O
area	O
was	O
performed	O
in	O
1999	O
and	O
identified	O
1378	O
newly	O
eligible	O
residents	O
who	O
moved	O
into	O
the	O
area	O
or	O
the	O
eligible	O
age	O
group	O
.	O

During	O
1999–2000	O
,	O
1174	O
(	O
85.2	O
%	O
)	O
of	O
this	O
group	O
participated	O
in	O
an	O
extension	O
study	O
(	O
BMES	O
IIB	O
)	O
.	O

BMES	O
cross	O
-	O
section	O
II	O
thus	O
includes	O
BMES	O
IIA	O
(	O
66.5	O
%	O
)	O
and	O
BMES	O
IIB	O
(	O
33.5	O
%	O
)	O
participants	O
(	O
n	O
=	O
3509	O
)	O
.	O

Similar	O
procedures	O
were	O
used	O
for	O
all	O
stages	O
of	O
data	O
collection	O
at	O
both	O
surveys	O
.	O

A	O
questionnaire	O
was	O
administered	O
including	O
demographic	O
,	O
family	O
and	O
medical	O
history	O
.	O

A	O
detailed	O
eye	O
examination	O
included	O
subjective	O
refraction	O
,	O
slit	O
-	O
lamp	O
(	O
Topcon	O
SL-7e	O
camera	O
,	O
Topcon	O
Optical	O
Co	O
,	O
Tokyo	O
,	O
Japan	O
)	O
and	O
retroillumination	O
(	O
Neitz	O
CT	O
-	O
R	O
camera	O
,	O
Neitz	O
Instrument	O
Co	O
,	O
Tokyo	O
,	O
Japan	O
)	O
photography	O
of	O
the	O
lens	O
.	O

Grading	O
of	O
lens	O
photographs	O
in	O
the	O
BMES	O
has	O
been	O
previously	O
described	O
[	O
12	O
]	O
.	O

Briefly	O
,	O
masked	O
grading	O
was	O
performed	O
on	O
the	O
lens	O
photographs	O
using	O
the	O
Wisconsin	O
Cataract	O
Grading	O
System	O
[	O
13	O
]	O
.	O

Cortical	O
cataract	O
and	O
PSC	O
were	O
assessed	O
from	O
the	O
retroillumination	O
photographs	O
by	O
estimating	O
the	O
percentage	O
of	O
the	O
circular	O
grid	O
involved	O
.	O

Cortical	O
cataract	O
was	O
defined	O
when	O
cortical	O
opacity	O
involved	O
at	O
least	O
5	O
%	O
of	O
the	O
total	O
lens	O
area	O
.	O

PSC	O
was	O
defined	O
when	O
opacity	O
comprised	O
at	O
least	O
1	O
%	O
of	O
the	O
total	O
lens	O
area	O
.	O

Slit	O
-	O
lamp	O
photographs	O
were	O
used	O
to	O
assess	O
nuclear	O
cataract	O
using	O
the	O
Wisconsin	O
standard	O
set	O
of	O
four	O
lens	O
photographs	O
[	O
13	O
]	O
.	O

Nuclear	O
cataract	O
was	O
defined	O
when	O
nuclear	O
opacity	O
was	O
at	O
least	O
as	O
great	O
as	O
the	O
standard	O
4	O
photograph	O
.	O

Any	O
cataract	O
was	O
defined	O
to	O
include	O
persons	O
who	O
had	O
previous	O
cataract	O
surgery	O
as	O
well	O
as	O
those	O
with	O
any	O
of	O
three	O
cataract	O
types	O
.	O

Inter	O
-	O
grader	O
reliability	O
was	O
high	O
,	O
with	O
weighted	O
kappa	O
0.82	O
for	O
cortical	O
cataract	O
,	O
0.55	O
(	O
simple	O
kappa	O
0.75	O
)	O
for	O
nuclear	O
cataract	O
and	O
0.82	O
for	O
PSC	O
grading	O
.	O

The	O
intra	O
-	O
grader	O
reliability	O
for	O
nuclear	O
cataract	O
was	O
assessed	O
with	O
simple	O
kappa	O
0.83	O
for	O
the	O
senior	O
grader	O
who	O
graded	O
nuclear	O
cataract	O
at	O
both	O
surveys	O
.	O

All	O
PSC	O
cases	O
were	O
confirmed	O
by	O
an	O
ophthalmologist	O
(	O
PM	O
)	O
.	O

In	O
cross	O
-	O
section	O
I	O
,	O
219	O
persons	O
(	O
6.0	O
%	O
)	O
had	O
missing	O
or	O
ungradable	O
Neitz	O
photographs	O
,	O
leaving	O
3435	O
with	O
photographs	O
available	O
for	O
cortical	O
cataract	O
and	O
PSC	O
assessment	O
,	O
while	O
1153	O
(	O
31.6	O
%	O
)	O
had	O
randomly	O
missing	O
or	O
ungradable	O
Topcon	O
photographs	O
due	O
to	O
a	O
camera	O
malfunction	O
,	O
leaving	O
2501	O
with	O
photographs	O
available	O
for	O
nuclear	O
cataract	O
assessment	O
.	O

Comparison	O
of	O
characteristics	O
between	O
participants	O
with	O
and	O
without	O
Neitz	O
or	O
Topcon	O
photographs	O
in	O
cross	O
-	O
section	O
I	O
showed	O
no	O
statistically	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
,	O
as	O
reported	O
previously	O
[	O
12	O
]	O
.	O

In	O
cross	O
-	O
section	O
II	O
,	O
441	O
persons	O
(	O
12.5	O
%	O
)	O
had	O
missing	O
or	O
ungradable	O
Neitz	O
photographs	O
,	O
leaving	O
3068	O
for	O
cortical	O
cataract	O
and	O
PSC	O
assessment	O
,	O
and	O
648	O
(	O
18.5	O
%	O
)	O
had	O
missing	O
or	O
ungradable	O
Topcon	O
photographs	O
,	O
leaving	O
2860	O
for	O
nuclear	O
cataract	O
assessment	O
.	O

Data	O
analysis	O
was	O
performed	O
using	O
the	O
Statistical	O
Analysis	O
System	O
(	O
SAS	O
,	O
SAS	O
Institute	O
,	O
Cary	O
,	O
NC	O
,	O
USA	O
)	O
.	O

Age	O
-	O
adjusted	O
prevalence	O
was	O
calculated	O
using	O
direct	O
standardization	O
of	O
the	O
cross	O
-	O
section	O
II	O
population	O
to	O
the	O
cross	O
-	O
section	O
I	O
population	O
.	O

We	O
assessed	O
age	O
-	O
specific	O
prevalence	O
using	O
an	O
interval	O
of	O
5	O
years	O
,	O
so	O
that	O
participants	O
within	O
each	O
age	O
group	O
were	O
independent	O
between	O
the	O
two	O
cross	O
-	O
sectional	O
surveys	O
.	O

Results	O
Characteristics	O
of	O
the	O
two	O
survey	O
populations	O
have	O
been	O
previously	O
compared	O
[	O
14	O
]	O
and	O
showed	O
that	O
age	O
and	O
sex	O
distributions	O
were	O
similar	O
.	O

Table	O
1	O
compares	O
participant	O
characteristics	O
between	O
the	O
two	O
cross	O
-	O
sections	O
.	O

Cross	O
-	O
section	O
II	O
participants	O
generally	O
had	O
higher	O
rates	O
of	O
diabetes	O
,	O
hypertension	O
,	O
myopia	O
and	O
more	O
users	O
of	O
inhaled	O
steroids	O
.	O

Cataract	O
prevalence	O
rates	O
in	O
cross	O
-	O
sections	O
I	O
and	O
II	O
are	O
shown	O
in	O
Figure	O
1	O
.	O

The	O
overall	O
prevalence	O
of	O
cortical	O
cataract	O
was	O
23.8	O
%	O
and	O
23.7	O
%	O
in	O
cross	O
-	O
sections	O
I	O
and	O
II	O
,	O
respectively	O
(	O
age	O
-	O
sex	O
adjusted	O
P	O
=	O
0.81	O
)	O
.	O

Corresponding	O
prevalence	O
of	O
PSC	O
was	O
6.3	O
%	O
and	O
6.0	O
%	O
for	O
the	O
two	O
cross	O
-	O
sections	O
(	O
age	O
-	O
sex	O
adjusted	O
P	O
=	O
0.60	O
)	O
.	O

There	O
was	O
an	O
increased	O
prevalence	O
of	O
nuclear	O
cataract	O
,	O
from	O
18.7	O
%	O
in	O
cross	O
-	O
section	O
I	O
to	O
23.9	O
%	O
in	O
cross	O
-	O
section	O
II	O
over	O
the	O
6-year	O
period	O
(	O
age	O
-	O
sex	O
adjusted	O
P	O
<	O
0.001	O
)	O
.	O

Prevalence	O
of	O
any	O
cataract	O
(	O
including	O
persons	O
who	O
had	O
cataract	O
surgery	O
)	O
,	O
however	O
,	O
was	O
relatively	O
stable	O
(	O
46.9	O
%	O
and	O
46.8	O
%	O
in	O
cross	O
-	O
sections	O
I	O
and	O
II	O
,	O
respectively	O
)	O
.	O

After	O
age	O
-	O
standardization	O
,	O
these	O
prevalence	O
rates	O
remained	O
stable	O
for	O
cortical	O
cataract	O
(	O
23.8	O
%	O
and	O
23.5	O
%	O
in	O
the	O
two	O
surveys	O
)	O
and	O
PSC	O
(	O
6.3	O
%	O
and	O
5.9	O
%	O
)	O
.	O

The	O
slightly	O
increased	O
prevalence	O
of	O
nuclear	O
cataract	O
(	O
from	O
18.7	O
%	O
to	O
24.2	O
%	O
)	O
was	O
not	O
altered	O
.	O

Table	O
2	O
shows	O
the	O
age	O
-	O
specific	O
prevalence	O
rates	O
for	O
cortical	O
cataract	O
,	O
PSC	O
and	O
nuclear	O
cataract	O
in	O
cross	O
-	O
sections	O
I	O
and	O
II	O
.	O

A	O
similar	O
trend	O
of	O
increasing	O
cataract	O
prevalence	O
with	O
increasing	O
age	O
was	O
evident	O
for	O
all	O
three	O
types	O
of	O
cataract	O
in	O
both	O
surveys	O
.	O

Comparing	O
the	O
age	O
-	O
specific	O
prevalence	O
between	O
the	O
two	O
surveys	O
,	O
a	O
reduction	O
in	O
PSC	O
prevalence	O
in	O
cross	O
-	O
section	O
II	O
was	O
observed	O
in	O
the	O
older	O
age	O
groups	O
(	O
≥	O
75	O
years	O
)	O
.	O

In	O
contrast	O
,	O
increased	O
nuclear	O
cataract	O
prevalence	O
in	O
cross	O
-	O
section	O
II	O
was	O
observed	O
in	O
the	O
older	O
age	O
groups	O
(	O
≥	O
70	O
years	O
)	O
.	O

Age	O
-	O
specific	O
cortical	O
cataract	O
prevalence	O
was	O
relatively	O
consistent	O
between	O
the	O
two	O
surveys	O
,	O
except	O
for	O
a	O
reduction	O
in	O
prevalence	O
observed	O
in	O
the	O
80–84	O
age	O
group	O
and	O
an	O
increasing	O
prevalence	O
in	O
the	O
older	O
age	O
groups	O
(	O
≥	O
85	O
years	O
)	O
.	O

Similar	O
gender	O
differences	O
in	O
cataract	O
prevalence	O
were	O
observed	O
in	O
both	O
surveys	O
(	O
Table	O
3	O
)	O
.	O

Higher	O
prevalence	O
of	O
cortical	O
and	O
nuclear	O
cataract	O
in	O
women	O
than	O
men	O
was	O
evident	O
but	O
the	O
difference	O
was	O
only	O
significant	O
for	O
cortical	O
cataract	O
(	O
age	O
-	O
adjusted	O
odds	O
ratio	O
,	O
OR	O
,	O
for	O
women	O
1.3	O
,	O
95	O
%	O
confidence	O
intervals	O
,	O
CI	O
,	O
1.1–1.5	O
in	O
cross	O
-	O
section	O
I	O
and	O
OR	O
1.4	O
,	O
95	O
%	O
CI	O
1.1–1.6	O
in	O
cross	O
-	O
section	O
II	O
)	O
.	O

In	O
contrast	O
,	O
men	O
had	O
slightly	O
higher	O
PSC	O
prevalence	O
than	O
women	O
in	O
both	O
cross	O
-	O
sections	O
but	O
the	O
difference	O
was	O
not	O
significant	O
(	O
OR	O
1.1	O
,	O
95	O
%	O
CI	O
0.8–1.4	O
for	O
men	O
in	O
cross	O
-	O
section	O
I	O
and	O
OR	O
1.2	O
,	O
95	O
%	O
0.9–1.6	O
in	O
cross	O
-	O
section	O
II	O
)	O
.	O

Discussion	O
Findings	O
from	O
two	O
surveys	O
of	O
BMES	O
cross	O
-	O
sectional	O
populations	O
with	O
similar	O
age	O
and	O
gender	O
distribution	O
showed	O
that	O
the	O
prevalence	O
of	O
cortical	O
cataract	O
and	O
PSC	O
remained	O
stable	O
,	O
while	O
the	O
prevalence	O
of	O
nuclear	O
cataract	O
appeared	O
to	O
have	O
increased	O
.	O

Comparison	O
of	O
age	O
-	O
specific	O
prevalence	O
,	O
with	O
totally	O
independent	O
samples	O
within	O
each	O
age	O
group	O
,	O
confirmed	O
the	O
robustness	O
of	O
our	O
findings	O
from	O
the	O
two	O
survey	O
samples	O
.	O

Although	O
lens	O
photographs	O
taken	O
from	O
the	O
two	O
surveys	O
were	O
graded	O
for	O
nuclear	O
cataract	O
by	O
the	O
same	O
graders	O
,	O
who	O
documented	O
a	O
high	O
inter-	O
and	O
intra	O
-	O
grader	O
reliability	O
,	O
we	O
can	O
not	O
exclude	O
the	O
possibility	O
that	O
variations	O
in	O
photography	O
,	O
performed	O
by	O
different	O
photographers	O
,	O
may	O
have	O
contributed	O
to	O
the	O
observed	O
difference	O
in	O
nuclear	O
cataract	O
prevalence	O
.	O

However	O
,	O
the	O
overall	O
prevalence	O
of	O
any	O
cataract	O
(	O
including	O
cataract	O
surgery	O
)	O
was	O
relatively	O
stable	O
over	O
the	O
6-year	O
period	O
.	O

Although	O
different	O
population	O
-	O
based	O
studies	O
used	O
different	O
grading	O
systems	O
to	O
assess	O
cataract	O
[	O
15	O
]	O
,	O
the	O
overall	O
prevalence	O
of	O
the	O
three	O
cataract	O
types	O
were	O
similar	O
across	O
different	O
study	O
populations	O
[	O
12,16	O
-	O
23	O
]	O
.	O

Most	O
studies	O
have	O
suggested	O
that	O
nuclear	O
cataract	O
is	O
the	O
most	O
prevalent	O
type	O
of	O
cataract	O
,	O
followed	O
by	O
cortical	O
cataract	O
[	O
16	O
-	O
20	O
]	O
.	O

Ours	O
and	O
other	O
studies	O
reported	O
that	O
cortical	O
cataract	O
was	O
the	O
most	O
prevalent	O
type	O
[	O
12,21	O
-	O
23	O
]	O
.	O

Our	O
age	O
-	O
specific	O
prevalence	O
data	O
show	O
a	O
reduction	O
of	O
15.9	O
%	O
in	O
cortical	O
cataract	O
prevalence	O
for	O
the	O
80–84	O
year	O
age	O
group	O
,	O
concordant	O
with	O
an	O
increase	O
in	O
cataract	O
surgery	O
prevalence	O
by	O
9	O
%	O
in	O
those	O
aged	O
80	O
+	O
years	O
observed	O
in	O
the	O
same	O
study	O
population	O
[	O
10	O
]	O
.	O

Although	O
cortical	O
cataract	O
is	O
thought	O
to	O
be	O
the	O
least	O
likely	O
cataract	O
type	O
leading	O
to	O
a	O
cataract	O
surgery	O
,	O
this	O
may	O
not	O
be	O
the	O
case	O
in	O
all	O
older	O
persons	O
.	O

A	O
relatively	O
stable	O
cortical	O
cataract	O
and	O
PSC	O
prevalence	O
over	O
the	O
6-year	O
period	O
is	O
expected	O
.	O

We	O
can	O
not	O
offer	O
a	O
definitive	O
explanation	O
for	O
the	O
increase	O
in	O
nuclear	O
cataract	O
prevalence	O
.	O

A	O
possible	O
explanation	O
could	O
be	O
that	O
a	O
moderate	O
level	O
of	O
nuclear	O
cataract	O
causes	O
less	O
visual	O
disturbance	O
than	O
the	O
other	O
two	O
types	O
of	O
cataract	O
,	O
thus	O
for	O
the	O
oldest	O
age	O
groups	O
,	O
persons	O
with	O
nuclear	O
cataract	O
could	O
have	O
been	O
less	O
likely	O
to	O
have	O
surgery	O
unless	O
it	O
is	O
very	O
dense	O
or	O
co	O
-	O
existing	O
with	O
cortical	O
cataract	O
or	O
PSC	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
functional	O
vision	O
and	O
reading	O
performance	O
were	O
high	O
in	O
patients	O
undergoing	O
cataract	O
surgery	O
who	O
had	O
nuclear	O
cataract	O
only	O
compared	O
to	O
those	O
with	O
mixed	O
type	O
of	O
cataract	O
(	O
nuclear	O
and	O
cortical	O
)	O
or	O
PSC	O
[	O
24,25	O
]	O
.	O

In	O
addition	O
,	O
the	O
overall	O
prevalence	O
of	O
any	O
cataract	O
(	O
including	O
cataract	O
surgery	O
)	O
was	O
similar	O
in	O
the	O
two	O
cross	O
-	O
sections	O
,	O
which	O
appears	O
to	O
support	O
our	O
speculation	O
that	O
in	O
the	O
oldest	O
age	O
group	O
,	O
nuclear	O
cataract	O
may	O
have	O
been	O
less	O
likely	O
to	O
be	O
operated	O
than	O
the	O
other	O
two	O
types	O
of	O
cataract	O
.	O

This	O
could	O
have	O
resulted	O
in	O
an	O
increased	O
nuclear	O
cataract	O
prevalence	O
(	O
due	O
to	O
less	O
being	O
operated	O
)	O
,	O
compensated	O
by	O
the	O
decreased	O
prevalence	O
of	O
cortical	O
cataract	O
and	O
PSC	O
(	O
due	O
to	O
these	O
being	O
more	O
likely	O
to	O
be	O
operated	O
)	O
,	O
leading	O
to	O
stable	O
overall	O
prevalence	O
of	O
any	O
cataract	O
.	O

Possible	O
selection	O
bias	O
arising	O
from	O
selective	O
survival	O
among	O
persons	O
without	O
cataract	O
could	O
have	O
led	O
to	O
underestimation	O
of	O
cataract	O
prevalence	O
in	O
both	O
surveys	O
.	O

We	O
assume	O
that	O
such	O
an	O
underestimation	O
occurred	O
equally	O
in	O
both	O
surveys	O
,	O
and	O
thus	O
should	O
not	O
have	O
influenced	O
our	O
assessment	O
of	O
temporal	O
changes	O
.	O

Measurement	O
error	O
could	O
also	O
have	O
partially	O
contributed	O
to	O
the	O
observed	O
difference	O
in	O
nuclear	O
cataract	O
prevalence	O
.	O

Assessment	O
of	O
nuclear	O
cataract	O
from	O
photographs	O
is	O
a	O
potentially	O
subjective	O
process	O
that	O
can	O
be	O
influenced	O
by	O
variations	O
in	O
photography	O
(	O
light	O
exposure	O
,	O
focus	O
and	O
the	O
slit	O
-	O
lamp	O
angle	O
when	O
the	O
photograph	O
was	O
taken	O
)	O
and	O
grading	O
.	O

Although	O
we	O
used	O
the	O
same	O
Topcon	O
slit	O
-	O
lamp	O
camera	O
and	O
the	O
same	O
two	O
graders	O
who	O
graded	O
photos	O
from	O
both	O
surveys	O
,	O
we	O
are	O
still	O
not	O
able	O
to	O
exclude	O
the	O
possibility	O
of	O
a	O
partial	O
influence	O
from	O
photographic	O
variation	O
on	O
this	O
result	O
.	O

A	O
similar	O
gender	O
difference	O
(	O
women	O
having	O
a	O
higher	O
rate	O
than	O
men	O
)	O
in	O
cortical	O
cataract	O
prevalence	O
was	O
observed	O
in	O
both	O
surveys	O
.	O

Our	O
findings	O
are	O
in	O
keeping	O
with	O
observations	O
from	O
the	O
Beaver	O
Dam	O
Eye	O
Study	O
[	O
18	O
]	O
,	O
the	O
Barbados	O
Eye	O
Study	O
[	O
22	O
]	O
and	O
the	O
Lens	O
Opacities	O
Case	O
-	O
Control	O
Group	O
[	O
26	O
]	O
.	O

It	O
has	O
been	O
suggested	O
that	O
the	O
difference	O
could	O
be	O
related	O
to	O
hormonal	O
factors	O
[	O
18,22	O
]	O
.	O

A	O
previous	O
study	O
on	O
biochemical	O
factors	O
and	O
cataract	O
showed	O
that	O
a	O
lower	O
level	O
of	O
iron	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
cortical	O
cataract	O
[	O
27	O
]	O
.	O

No	O
interaction	O
between	O
sex	O
and	O
biochemical	O
factors	O
were	O
detected	O
and	O
no	O
gender	O
difference	O
was	O
assessed	O
in	O
this	O
study	O
[	O
27	O
]	O
.	O

The	O
gender	O
difference	O
seen	O
in	O
cortical	O
cataract	O
could	O
be	O
related	O
to	O
relatively	O
low	O
iron	O
levels	O
and	O
low	O
hemoglobin	O
concentration	O
usually	O
seen	O
in	O
women	O
[	O
28	O
]	O
.	O

Diabetes	O
is	O
a	O
known	O
risk	O
factor	O
for	O
cortical	O
cataract	O
but	O
in	O
this	O
particular	O
population	O
diabetes	O
is	O
more	O
prevalent	O
in	O
men	O
than	O
women	O
in	O
all	O
age	O
groups	O
[	O
29	O
]	O
.	O

Differential	O
exposures	O
to	O
cataract	O
risk	O
factors	O
or	O
different	O
dietary	O
or	O
lifestyle	O
patterns	O
between	O
men	O
and	O
women	O
may	O
also	O
be	O
related	O
to	O
these	O
observations	O
and	O
warrant	O
further	O
study	O
.	O

Conclusion	O
In	O
summary	O
,	O
in	O
two	O
population	O
-	O
based	O
surveys	O
6	O
years	O
apart	O
,	O
we	O
have	O
documented	O
a	O
relatively	O
stable	O
prevalence	O
of	O
cortical	O
cataract	O
and	O
PSC	O
over	O
the	O
period	O
.	O

The	O
observed	O
overall	O
increased	O
nuclear	O
cataract	O
prevalence	O
by	O
5	O
%	O
over	O
a	O
6-year	O
period	O
needs	O
confirmation	O
by	O
future	O
studies	O
,	O
and	O
reasons	O
for	O
such	O
an	O
increase	O
deserve	O
further	O
study	O
.	O

Competing	O
interests	O
The	O
author	O
(	O
s	O
)	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O
AGT	O
graded	O
the	O
photographs	O
,	O
performed	O
literature	O
search	O
and	O
wrote	O
the	O
first	O
draft	O
of	O
the	O
manuscript	O
.	O

JJW	O
graded	O
the	O
photographs	O
,	O
critically	O
reviewed	O
and	O
modified	O
the	O
manuscript	O
.	O

ER	O
performed	O
the	O
statistical	O
analysis	O
and	O
critically	O
reviewed	O
the	O
manuscript	O
.	O

PM	O
designed	O
and	O
directed	O
the	O
study	O
,	O
adjudicated	O
cataract	O
cases	O
and	O
critically	O
reviewed	O
and	O
modified	O
the	O
manuscript	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Pre	O
-	O
publication	O
history	O
The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O

B	O
lymphocyte	O
stimulator	O
(	O
BLyS	O
)	O
isoforms	O
in	O
systemic	O
lupus	O
erythematosus	O
:	O
disease	O
activity	O
correlates	O
better	O
with	O
blood	O
leukocyte	O
BLyS	O
mRNA	O
levels	O
than	O
with	O
plasma	O
BLyS	O
protein	O
levels	O
Abstract	O
Considerable	O
evidence	O
points	O
to	O
a	O
role	O
for	O
B	O
lymphocyte	O
stimulator	O
(	O
BLyS	O
)	O
overproduction	O
in	O
murine	O
and	O
human	B
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
.	O

Nevertheless	O
,	O
the	O
correlation	O
between	O
circulating	O
levels	O
of	O
BLyS	O
protein	O
and	O
disease	O
activity	O
in	O
human	B
SLE	O
is	O
modest	O
at	O
best	O
.	O

This	O
may	O
be	O
due	O
to	O
an	O
inadequacy	O
of	O
the	O
former	O
to	O
reflect	O
endogenous	O
BLyS	O
overproduction	O
faithfully	O
,	O
in	O
that	O
steady	O
-	O
state	O
protein	O
levels	O
are	O
affected	O
not	O
just	O
by	O
production	O
rates	O
but	O
also	O
by	O
rates	O
of	O
peripheral	O
utilization	O
and	O
excretion	O
.	O

Increased	O
levels	O
of	O
BLyS	O
mRNA	O
may	O
better	O
reflect	O
increased	O
in	O
vivo	O
BLyS	O
production	O
,	O
and	O
therefore	O
they	O
may	O
correlate	O
better	O
with	O
biologic	O
and	O
clinical	O
sequelae	O
of	O
BLyS	O
overexpression	O
than	O
do	O
circulating	O
levels	O
of	O
BLyS	O
protein	O
.	O

Accordingly	O
,	O
we	O
assessed	O
peripheral	O
blood	O
leukocyte	O
levels	O
of	O
BLyS	O
mRNA	O
isoforms	O
(	O
full	O
-	O
length	O
BLyS	O
and	O
ΔBLyS	O
)	O
and	O
plasma	O
BLyS	O
protein	O
levels	O
in	O
patients	O
with	O
SLE	O
,	O
and	O
correlated	O
these	O
levels	O
with	O
laboratory	O
and	O
clinical	O
features	O
.	O

BLyS	O
protein	O
,	O
full	O
-	O
length	O
BLyS	O
mRNA	O
,	O
and	O
ΔBLyS	O
mRNA	O
levels	O
were	O
greater	O
in	O
SLE	O
patients	O
(	O
n	O
=	O
60	O
)	O
than	O
in	O
rheumatoid	O
arthritis	O
patients	O
(	O
n	O
=	O
60	O
)	O
or	O
normal	O
control	O
individuals	O
(	O
n	O
=	O
30	O
)	O
.	O

Although	O
full	O
-	O
length	O
BLyS	O
and	O
ΔBLyS	O
mRNA	O
levels	O
correlated	O
significantly	O
with	O
BLyS	O
protein	O
levels	O
in	O
the	O
SLE	O
cohort	O
,	O
BLyS	O
mRNA	O
levels	O
were	O
more	O
closely	O
associated	O
with	O
serum	O
immunoglobulin	O
levels	O
and	O
SLE	O
Disease	O
Activity	O
Index	O
scores	O
than	O
were	O
BLyS	O
protein	O
levels	O
.	O

Moreover	O
,	O
changes	O
in	O
SLE	O
Disease	O
Activity	O
Index	O
scores	O
were	O
more	O
closely	O
associated	O
with	O
changes	O
in	O
BLyS	O
mRNA	O
levels	O
than	O
with	O
changes	O
in	O
BLyS	O
protein	O
levels	O
among	O
the	O
37	O
SLE	O
patients	O
from	O
whom	O
repeat	O
blood	O
samples	O
were	O
obtained	O
.	O

Thus	O
,	O
full	O
-	O
length	O
BLyS	O
and	O
ΔBLyS	O
mRNA	O
levels	O
are	O
elevated	O
in	O
SLE	O
and	O
are	O
more	O
closely	O
associated	O
with	O
disease	O
activity	O
than	O
are	O
BLyS	O
protein	O
levels	O
.	O

BLyS	O
mRNA	O
levels	O
may	O
be	O
a	O
helpful	O
biomarker	O
in	O
the	O
clinical	O
monitoring	O
of	O
SLE	O
patients	O
.	O

Introduction	O
B	O
lymphocyte	O
stimulator	O
(	O
BLyS	O
;	O
a	O
trademark	O
of	O
Human	B
Genome	O
Sciences	O
,	O
Inc.	O
,	O
Rockville	O
,	O
MD	O
,	O
USA	O
)	O
is	O
a	O
285-amino	O
-	O
acid	O
member	O
of	O
the	O
tumor	O
necrosis	O
factor	O
ligand	O
superfamily	O
[	O
1	O
-	O
3	O
]	O
.	O

A	O
causal	O
relation	O
between	O
constitutive	O
overproduction	O
of	O
BLyS	O
and	O
development	O
of	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
-like	O
illness	O
has	O
incontrovertibly	O
been	O
established	O
in	O
mice	B
.	O

BLyS	O
-	O
transgenic	O
mice	B
often	O
develop	O
SLE	O
-	O
like	O
features	O
as	O
they	O
age	O
[	O
3	O
-	O
5	O
]	O
,	O
and	O
SLE	O
-	O
prone	O
(	O
NZB	O
×	O
NZW	O
)	O
F1	O
(	O
BWF1	O
)	O
and	O
MRL	O
-	O
lpr	O
/	O
lpr	O
mice	B
respond	O
clinically	O
to	O
treatment	O
with	O
BLyS	O
antagonists	O
(	O
decreased	O
disease	O
progression	O
and	O
improved	O
survival	O
)	O
[	O
3,6	O
]	O
.	O

Considerable	O
inferential	O
evidence	O
points	O
to	O
a	O
role	O
for	O
BLyS	O
overproduction	O
in	O
human	B
SLE	O
as	O
well	O
.	O

Cross	O
-	O
sectional	O
studies	O
have	O
demonstrated	O
elevated	O
circulating	O
levels	O
of	O
BLyS	O
in	O
20–30	O
%	O
of	O
human	B
SLE	O
patients	O
tested	O
at	O
a	O
single	O
point	O
in	O
time	O
[	O
7,8	O
]	O
.	O

Moreover	O
,	O
a	O
12-month	O
longitudinal	O
study	O
documented	O
persistently	O
elevated	O
serum	O
BLyS	O
levels	O
in	O
about	O
25	O
%	O
of	O
SLE	O
patients	O
and	O
intermittently	O
elevated	O
serum	O
BLyS	O
levels	O
in	O
an	O
additional	O
25	O
%	O
of	O
patients	O
[	O
9	O
]	O
.	O

Remarkably	O
,	O
circulating	O
BLyS	O
levels	O
did	O
not	O
correlate	O
with	O
disease	O
activity	O
(	O
measured	O
using	O
the	O
SLE	O
Disease	O
Activity	O
Index	O
[	O
SLEDAI	O
]	O
)	O
in	O
these	O
cross	O
-	O
sectional	O
or	O
longitudinal	O
studies	O
[	O
7	O
-	O
9	O
]	O
.	O

Although	O
a	O
statistically	O
significant	O
correlation	O
between	O
circulating	O
BLyS	O
levels	O
and	O
SLEDAI	O
has	O
been	O
appreciated	O
in	O
a	O
more	O
recent	O
24-month	O
longitudinal	O
study	O
of	O
245	O
SLE	O
patients	O
(	O
with	O
>	O
1,700	O
plasma	O
samples	O
analyzed	O
)	O
[	O
10	O
]	O
,	O
the	O
correlation	O
remains	O
weak	O
.	O

The	O
limited	O
correlation	O
between	O
circulating	O
BLyS	O
protein	O
levels	O
and	O
disease	O
activity	O
in	O
these	O
studies	O
may	O
have	O
exposed	O
an	O
inadequacy	O
of	O
the	O
former	O
to	O
reflect	O
faithfully	O
endogenous	O
BLyS	O
overproduction	O
.	O

In	O
addition	O
to	O
the	O
rate	O
of	O
BLyS	O
protein	O
production	O
,	O
several	O
other	O
factors	O
(	O
for	O
example	O
,	O
utilization	O
and	O
excretion	O
)	O
can	O
affect	O
circulating	O
BLyS	O
protein	O
levels	O
.	O

Although	O
there	O
are	O
no	O
practicable	O
means	O
of	O
directly	O
measuring	O
in	O
vivo	O
BLyS	O
production	O
per	O
se	O
in	O
humans	B
,	O
the	O
level	O
of	O
BLyS	O
mRNA	O
may	O
serve	O
as	O
a	O
better	O
surrogate	O
marker	O
of	O
in	O
vivo	O
BLyS	O
production	O
than	O
does	O
the	O
level	O
of	O
BLyS	O
protein	O
.	O

Candidate	O
BLyS	O
mRNA	O
isoforms	O
include	O
the	O
full	O
-	O
length	O
BLyS	O
mRNA	O
isoform	O
,	O
which	O
encodes	O
the	O
full	O
-	O
length	O
protein	O
,	O
and	O
the	O
alternatively	O
spliced	O
ΔBLyS	O
mRNA	O
isoform	O
,	O
which	O
encodes	O
a	O
protein	O
with	O
a	O
small	O
peptide	O
deletion	O
[	O
11	O
]	O
.	O

(	O
ΔBLyS	O
does	O
not	O
bind	O
to	O
cells	O
expressing	O
BLyS	O
receptors	O
,	O
and	O
therefore	O
it	O
has	O
no	O
agonistic	O
activity	O
.	O

Moreover	O
,	O
ΔBLyS	O
can	O
form	O
heterotrimers	O
with	O
full	O
-	O
length	O
BLyS	O
,	O
thereby	O
actually	O
functioning	O
as	O
a	O
dominant	O
-	O
negative	O
antagonist	O
of	O
BLyS	O
activity	O
.	O
)	O
In	O
this	O
report	O
we	O
demonstrate	O
that	O
peripheral	O
blood	O
leukocytes	O
from	O
SLE	O
patients	O
express	O
elevated	O
mRNA	O
levels	O
of	O
both	O
full	O
-	O
length	O
BLyS	O
and	O
ΔBLyS	O
relative	O
to	O
those	O
levels	O
expressed	O
by	O
patients	O
with	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
or	O
by	O
normal	O
control	O
individuals	O
.	O

In	O
the	O
SLE	O
patients	O
,	O
both	O
full	O
-	O
length	O
BLyS	O
and	O
ΔBLyS	O
mRNA	O
levels	O
are	O
more	O
closely	O
associated	O
with	O
disease	O
activity	O
(	O
SLEDAI	O
)	O
than	O
are	O
BLyS	O
protein	O
levels	O
.	O

Accordingly	O
,	O
BLyS	O
mRNA	O
levels	O
may	O
be	O
a	O
helpful	O
biomarker	O
in	O
the	O
clinical	O
monitoring	O
of	O
SLE	O
patients	O
.	O

Materials	O
and	O
methods	O
General	O
details	O
This	O
study	O
was	O
approved	O
by	O
the	O
institutional	O
review	O
boards	O
of	O
the	O
University	O
of	O
Southern	O
California	O
and	O
the	O
Scripps	O
Research	O
Institute	O
.	O

All	O
participants	O
gave	O
their	O
written	O
informed	O
consent	O
before	O
participation	O
in	O
this	O
study	O
.	O

Participants	O
Patients	O
receiving	O
outpatient	O
medical	O
care	O
at	O
the	O
rheumatology	O
clinics	O
of	O
the	O
Los	O
Angeles	O
County	O
+	O
University	O
of	O
Southern	O
California	O
Medical	O
Center	O
were	O
recruited	O
into	O
the	O
study	O
.	O

Diagnoses	O
of	O
SLE	O
(	O
n	O
=	O
60	O
)	O
or	O
RA	O
(	O
n	O
=	O
60	O
)	O
were	O
based	O
on	O
established	O
clinical	O
criteria	O
[	O
12	O
]	O
.	O

Healthy	O
control	O
individuals	O
(	O
n	O
=	O
30	O
)	O
were	O
recruited	O
from	O
Los	O
Angeles	O
County	O
+	O
University	O
of	O
Southern	O
California	O
Medical	O
Center	O
and	O
University	O
of	O
Southern	O
California	O
Keck	O
School	O
of	O
Medicine	O
personnel	O
.	O

No	O
exclusions	O
were	O
made	O
on	O
any	O
basis	O
other	O
than	O
an	O
inability	O
to	O
give	O
informed	O
consent	O
.	O

Each	O
patient	O
's	O
sex	O
,	O
race	O
,	O
age	O
,	O
and	O
medications	O
at	O
the	O
time	O
of	O
the	O
phlebotomy	O
were	O
recorded	O
(	O
Table	O
1	O
)	O
.	O

Based	O
solely	O
on	O
the	O
patient	O
's	O
willingness	O
to	O
donate	O
a	O
second	O
blood	O
sample	O
,	O
repeat	O
blood	O
samples	O
were	O
collected	O
from	O
37	O
of	O
the	O
SLE	O
patients	O
147–511	O
days	O
(	O
median	O
371	O
days	O
)	O
after	O
collection	O
of	O
the	O
first	O
samples	O
.	O

These	O
patients	O
were	O
not	O
selected	O
on	O
the	O
basis	O
of	O
any	O
demographic	O
,	O
clinical	O
,	O
or	O
laboratory	O
feature	O
.	O

Clinical	O
disease	O
activity	O
for	O
the	O
SLE	O
patients	O
was	O
assessed	O
using	O
the	O
SLEDAI	O
[	O
13	O
]	O
and	O
using	O
a	O
modified	O
SLEDAI	O
that	O
excludes	O
the	O
contribution	O
of	O
anti	O
-	O
double	O
-	O
stranded	O
DNA	O
(	O
anti	O
-	O
dsDNA	O
)	O
antibodies	O
from	O
the	O
total	O
score	O
.	O

Each	O
patient	O
's	O
medical	O
chart	O
was	O
reviewed	O
for	O
results	O
of	O
standard	O
clinical	O
laboratory	O
tests	O
within	O
the	O
previous	O
or	O
subsequent	O
1-month	O
period	O
.	O

Plasma	O
BLyS	O
determination	O
Whole	O
venous	O
blood	O
was	O
centrifuged	O
to	O
yield	O
plasma	O
and	O
a	O
buffy	O
coat	O
.	O

The	O
plasma	O
was	O
harvested	O
,	O
stored	O
at	O
-70	O
°	O
C	O
,	O
and	O
assayed	O
for	O
BLyS	O
levels	O
by	O
ELISA	O
[	O
8,14	O
]	O
using	O
Fab	O
fragments	O
of	O
the	O
capture	O
antibody	O
rather	O
than	O
the	O
whole	O
antibody	O
to	O
reduce	O
assay	O
interference	O
by	O
rheumatoid	O
factor	O
.	O

The	O
lower	O
limit	O
of	O
detection	O
in	O
this	O
assay	O
is	O
0.3	O
ng	O
/	O
ml	O
.	O

For	O
statistical	O
purposes	O
,	O
plasma	O
samples	O
with	O
BLyS	O
concentrations	O
below	O
the	O
lower	O
limit	O
of	O
detection	O
were	O
assigned	O
a	O
value	O
of	O
0.25	O
ng	O
/	O
ml	O
.	O

Blood	O
BLyS	O
mRNA	O
determination	O
The	O
buffy	O
coat	O
from	O
centrifuged	O
whole	O
blood	O
was	O
harvested	O
,	O
added	O
to	O
RNAlater	O
™	O
(	O
Ambion	O
,	O
Austin	O
,	O
TX	O
,	O
USA	O
)	O
at	O
a	O
1:4	O
vol	O
/	O
vol	O
ratio	O
for	O
RNA	O
stabilization	O
,	O
stored	O
at	O
-70	O
°	O
C	O
,	O
and	O
assayed	O
for	O
full	O
-	O
length	O
BLyS	O
and	O
ΔBLyS	O
mRNA	O
levels	O
by	O
real	O
-	O
time	O
PCR	O
.	O

Total	O
RNA	O
was	O
purified	O
from	O
buffy	O
coat	O
samples	O
using	O
RNAeasy	O
miniprep	O
kits	O
(	O
Qiagen	O
,	O
Valencia	O
,	O
CA	O
,	O
USA	O
)	O
,	O
and	O
contaminating	O
genomic	O
DNA	O
was	O
removed	O
by	O
DNAse	O
-	O
I	O
digestion	O
.	O

One	O
-	O
tenth	O
volume	O
of	O
total	O
RNA	O
was	O
used	O
as	O
template	O
in	O
the	O
first	O
-	O
strand	O
cDNA	O
reaction	O
using	O
oligo	O
-	O
dT	O
and	O
the	O
Superscript	O
III	O
first	O
-	O
strand	O
synthesis	O
system	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Duplicate	O
samples	O
of	O
cDNA	O
were	O
amplified	O
with	O
primers	O
against	O
β	O
-	O
actin	O
,	O
full	O
-	O
length	O
BLyS	O
,	O
or	O
ΔBLyS	O
:	O
β	O
-	O
actin	O
sense	O
5'-CGAGAAGATGACCCAGATCATGT-3	O
'	O
;	O
β	O
-	O
actin	O
anti	O
-	O
sense	O
5'-GGCATACCCCTCGTAGATGG-3	O
'	O
;	O
full	O
-	O
length	O
BLyS	O
sense	O
5'-GCAGACAGTGAAACACCAACTATAC-3	O
'	O
;	O
ΔBLyS	O
sense	O
5'-CAGAAGAAACAGGATCTTACACAT-3	O
'	O
;	O
and	O
full	O
-	O
length	O
BLyS	O
/	O
ΔBLyS	O
anti	O
-	O
sense	O
5'-TGCCAGCTGAATAGCAGGAATTAT-3	O
'	O
.	O

A	O
165	O
bp	O
amplicon	O
for	O
β	O
-	O
actin	O
was	O
PCR	O
-	O
amplified	O
using	O
the	O
7900	O
HT	O
ABI	O
Prism	O
machine	O
(	O
Qiagen	O
)	O
with	O
annealing	O
at	O
65	O
°	O
C	O
.	O

A	O
296	O
bp	O
amplicon	O
for	O
full	O
-	O
length	O
BLyS	O
was	O
PCR	O
-	O
amplified	O
,	O
with	O
annealing	O
at	O
64	O
°	O
C	O
.	O

A	O
270	O
bp	O
amplicon	O
for	O
ΔBLyS	O
was	O
PCR	O
-	O
amplified	O
with	O
annealing	O
at	O
61	O
°	O
C	O
.	O

The	O
annealing	O
conditions	O
for	O
full	O
-	O
length	O
BLyS	O
and	O
ΔBLyS	O
were	O
determined	O
so	O
that	O
each	O
primer	O
set	O
remained	O
specific	O
to	O
the	O
respective	O
BLyS	O
isoform	O
and	O
yielded	O
a	O
PCR	O
efficiency	O
similar	O
to	O
those	O
of	O
cloned	O
cDNA	O
standards	O
.	O

Melting	O
curve	O
analysis	O
revealed	O
a	O
single	O
peak	O
for	O
each	O
gene	O
amplified	O
.	O

The	O
threshold	O
cycle	O
(	O
Ct	O
)	O
values	O
for	O
each	O
reaction	O
were	O
determined	O
using	O
Sequence	O
Detection	O
System	O
software	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Results	O
are	O
presented	O
as	O
ratios	O
of	O
full	O
-	O
length	O
BLyS	O
or	O
ΔBLyS	O
mRNA	O
to	O
β	O
-	O
actin	O
mRNA	O
,	O
which	O
were	O
calculated	O
using	O
the	O
following	O
formulae	O
:	O
2	O
exp	O
(	O
Ctβ	O
-	O
actin	O
-	O
Ctfull	O
-	O
length	O
BLyS	O
)	O
2	O
exp	O
(	O
Ctβ	O
-	O
actin	O
-	O
CtΔBLyS	O
)	O
Determination	O
of	O
anti	O
-	O
BLyS	O
autoantibodies	O
BLyS	O
was	O
bound	O
to	O
microtiter	O
plates	O
by	O
first	O
coating	O
the	O
plates	O
with	O
streptavidin	O
and	O
then	O
adding	O
biotinylated	O
recombinant	O
BLyS.	O
Using	O
these	O
plates	O
as	O
the	O
capture	O
reagent	O
,	O
plasma	O
samples	O
were	O
incubated	O
,	O
and	O
horseradish	B
peroxidase	O
-	O
conjugated	O
anti	O
-	O
human	B
IgA	O
/	O
IgM	O
/	O
IgG	O
(	O
Southern	O
Biotechnology	O
Associates	O
,	O
Birmingham	O
,	O
AL	O
,	O
USA	O
;	O
1:20,000	O
final	O
dilution	O
)	O
or	O
horseradish	B
peroxidase	O
-	O
conjugated	O
anti	O
-	O
human	B
IgG	O
(	O
Southern	O
Biotechnology	O
;	O
1:10,000	O
final	O
dilution	O
)	O
were	O
used	O
as	O
the	O
detector	O
reagents	O
.	O

Statistical	O
analysis	O
All	O
analyses	O
were	O
performed	O
using	O
SigmaStat	O
software	O
(	O
SPSS	O
,	O
Chicago	O
,	O
IL	O
,	O
USA	O
)	O
.	O

Results	O
that	O
did	O
not	O
follow	O
a	O
normal	O
distribution	O
were	O
log	O
-	O
transformed	O
to	O
achieve	O
normality	O
.	O

Parametric	O
testing	O
between	O
two	O
matched	O
or	O
unmatched	O
groups	O
was	O
performed	O
using	O
the	O
paired	O
or	O
unpaired	O
t	O
test	O
,	O
respectively	O
.	O

Parametric	O
testing	O
among	O
three	O
or	O
more	O
groups	O
was	O
performed	O
using	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
.	O

When	O
log	O
-	O
transformation	O
failed	O
to	O
generate	O
normally	O
distributed	O
data	O
or	O
the	O
equal	O
variance	O
test	O
was	O
not	O
satisfied	O
,	O
nonparametric	O
testing	O
was	O
performed	O
using	O
the	O
Mann	O
–	O
Whitney	O
rank	O
sum	O
test	O
between	O
two	O
groups	O
and	O
by	O
Kruskal	O
–	O
Wallis	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
on	O
ranks	O
among	O
three	O
or	O
more	O
groups	O
.	O

Correlations	O
were	O
determined	O
using	O
Pearson	O
product	O
moment	O
correlation	O
for	O
interval	O
data	O
and	O
using	O
Spearman	O
rank	O
order	O
correlation	O
for	O
ordinal	O
data	O
or	O
for	O
interval	O
data	O
that	O
did	O
not	O
follow	O
a	O
normal	O
distribution	O
.	O

Nominal	O
data	O
were	O
analyzed	O
using	O
χ2	O
analysis	O
-	O
of	O
-	O
contingency	O
tables	O
.	O

Results	O
Elevated	O
plasma	O
BLyS	O
levels	O
and	O
blood	O
levels	O
of	O
full	O
-	O
length	O
BLyS	O
and	O
ΔBLyS	O
mRNA	O
isoforms	O
in	O
systemic	O
lupus	O
erythematosus	O
patients	O
Previous	O
reports	O
of	O
elevated	O
circulating	O
BLyS	O
levels	O
in	O
SLE	O
patients	O
were	O
based	O
on	O
a	O
BLyS	O
ELISA	O
that	O
utilized	O
a	O
whole	O
(	O
unfragmented	O
)	O
capture	O
anti	O
-	O
BLyS	O
monoclonal	O
antibody	O
[	O
7	O
-	O
9	O
]	O
.	O

Since	O
the	O
publication	O
of	O
these	O
reports	O
,	O
it	O
has	O
been	O
recognized	O
that	O
the	O
presence	O
of	O
rheumatoid	O
factor	O
can	O
potentially	O
interfere	O
with	O
the	O
assay	O
and	O
lead	O
to	O
spurious	O
overestimation	O
of	O
the	O
true	O
circulating	O
BLyS	O
levels	O
(	O
Human	B
Genome	O
Sciences	O
,	O
Inc.	O
;	O
unpublished	O
observations	O
)	O
.	O

To	O
mitigate	O
potential	O
interference	O
from	O
rheumatoid	O
factor	O
,	O
the	O
BLyS	O
ELISA	O
has	O
been	O
modified	O
and	O
the	O
capture	O
anti	O
-	O
BLyS	O
monoclonal	O
antibody	O
is	O
now	O
utilized	O
as	O
a	O
Fab	O
fragment	O
.	O

Despite	O
the	O
changes	O
in	O
the	O
ELISA	O
format	O
,	O
our	O
findings	O
are	O
entirely	O
consistent	O
with	O
those	O
of	O
the	O
previous	O
reports	O
.	O

Plasma	O
BLyS	O
levels	O
were	O
significantly	O
greater	O
in	O
the	O
SLE	O
group	O
than	O
in	O
either	O
RA	O
or	O
normal	O
control	O
group	O
(	O
P	O
<	O
0.001	O
;	O
Figure	O
1a	O
)	O
.	O

Arbitrary	O
assignment	O
of	O
the	O
95th	O
percentile	O
value	O
among	O
the	O
normal	O
control	O
individuals	O
as	O
the	O
upper	O
limit	O
of	O
'	O
normal	O
'	O
revealed	O
that	O
two	O
of	O
the	O
30	O
normal	O
control	O
individuals	O
,	O
15	O
of	O
the	O
60	O
RA	O
patients	O
,	O
and	O
29	O
of	O
the	O
60	O
SLE	O
patients	O
harbored	O
elevated	O
plasma	O
BLyS	O
levels	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Overexpression	O
of	O
BLyS	O
in	O
SLE	O
patients	O
was	O
also	O
established	O
by	O
measuring	O
BLyS	O
mRNA	O
levels	O
normalized	O
to	O
β	O
-	O
actin	O
mRNA	O
levels	O
in	O
peripheral	O
blood	O
leukocytes	O
(	O
buffy	O
coats	O
)	O
.	O

The	O
geometric	O
mean	O
full	O
-	O
length	O
BLyS	O
mRNA	O
and	O
ΔBLyS	O
mRNA	O
levels	O
among	O
the	O
SLE	O
patients	O
were	O
each	O
significantly	O
greater	O
than	O
those	O
among	O
the	O
RA	O
patients	O
and	O
normal	O
control	O
individuals	O
,	O
respectively	O
(	O
P	O
<	O
0.001	O
for	O
each	O
;	O
Figure	O
1b	O
,	O
c	O
)	O
.	O

Arbitrary	O
assignment	O
of	O
the	O
95th	O
percentile	O
values	O
for	O
full	O
-	O
length	O
BLyS	O
and	O
ΔBLyS	O
mRNA	O
levels	O
among	O
the	O
normal	O
control	O
individuals	O
as	O
the	O
upper	O
limits	O
of	O
'	O
normal	O
'	O
revealed	O
that	O
two	O
of	O
the	O
30	O
normal	O
control	O
individuals	O
,	O
four	O
of	O
the	O
60	O
RA	O
patients	O
,	O
and	O
20	O
of	O
the	O
60	O
SLE	O
patients	O
had	O
elevated	O
full	O
-	O
length	O
BLyS	O
mRNA	O
levels	O
(	O
P	O
<	O
0.001	O
)	O
,	O
and	O
that	O
two	O
of	O
the	O
30	O
normal	O
control	O
individuals	O
,	O
three	O
of	O
the	O
60	O
RA	O
patients	O
,	O
and	O
19	O
of	O
the	O
60	O
SLE	O
patients	O
had	O
elevated	O
ΔBLyS	O
mRNA	O
levels	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Levels	O
of	O
full	O
-	O
length	O
BLyS	O
and	O
ΔBLyS	O
mRNA	O
strongly	O
correlated	O
with	O
each	O
other	O
(	O
r	O
=	O
0.703	O
;	O
P	O
<	O
0.001	O
)	O
in	O
the	O
SLE	O
cohort	O
,	O
and	O
plasma	O
BLyS	O
levels	O
also	O
correlated	O
significantly	O
with	O
levels	O
of	O
each	O
BLyS	O
isoform	O
(	O
r	O
=	O
0.429	O
,	O
P	O
<	O
0.001	O
;	O
and	O
r	O
=	O
0.290	O
,	O
P	O
=	O
0.024	O
,	O
respectively	O
)	O
.	O

Among	O
these	O
SLE	O
patients	O
,	O
none	O
of	O
the	O
measured	O
BLyS	O
parameters	O
correlated	O
with	O
patient	O
age	O
,	O
sex	O
,	O
race	O
,	O
or	O
daily	O
dose	O
of	O
corticosteroids	O
(	O
data	O
not	O
shown	O
)	O
.	O

Because	O
the	O
racial	O
composition	O
of	O
the	O
normal	O
cohort	O
was	O
not	O
as	O
predominantly	O
Hispanic	O
as	O
were	O
those	O
of	O
the	O
RA	O
and	O
SLE	O
cohorts	O
,	O
we	O
assessed	O
the	O
BLyS	O
parameters	O
in	O
the	O
respective	O
Hispanic	O
subpopulations	O
.	O

As	O
for	O
the	O
entire	O
populations	O
,	O
values	O
for	O
SLE	O
were	O
significantly	O
greater	O
than	O
those	O
for	O
either	O
RA	O
or	O
normal	O
controls	O
(	O
P	O
≤	O
0.004	O
;	O
data	O
not	O
shown	O
)	O
.	O

Correlations	O
between	O
BLyS	O
parameters	O
and	O
plasma	O
immunoglobulin	O
levels	O
BLyS	O
is	O
a	O
potent	O
B	O
cell	O
survival	O
factor	O
[	O
15	O
-	O
21	O
]	O
,	O
and	O
administration	O
of	O
exogenous	O
BLyS	O
to	O
mice	B
leads	O
to	O
B	O
cell	O
expansion	O
and	O
hypergammaglobulinemia	O
[	O
1	O
]	O
.	O

Previous	O
studies	O
with	O
numbers	O
of	O
SLE	O
patients	O
greater	O
than	O
were	O
included	O
in	O
the	O
present	O
study	O
documented	O
a	O
modest	O
but	O
significant	O
correlation	O
between	O
serum	O
levels	O
of	O
BLyS	O
and	O
IgG	O
[	O
8,10	O
]	O
.	O

In	O
our	O
SLE	O
cohort	O
of	O
limited	O
size	O
,	O
plasma	O
BLyS	O
levels	O
failed	O
to	O
show	O
significant	O
correlations	O
with	O
plasma	O
levels	O
of	O
total	O
immunoglobulin	O
,	O
IgG	O
,	O
or	O
IgA.	O
In	O
contrast	O
,	O
full	O
-	O
length	O
BLyS	O
and	O
ΔBLyS	O
mRNA	O
levels	O
correlated	O
significantly	O
with	O
each	O
(	O
Figure	O
2	O
)	O
.	O

(	O
None	O
of	O
the	O
BLyS	O
parameters	O
correlated	O
with	O
plasma	O
IgM	O
levels	O
.	O
)	O

The	O
absence	O
of	O
significant	O
correlation	O
between	O
plasma	O
BLyS	O
levels	O
and	O
the	O
immunoglobulin	O
parameters	O
also	O
persisted	O
when	O
just	O
the	O
53	O
patients	O
with	O
detectable	O
plasma	O
BLyS	O
levels	O
were	O
considered	O
(	O
r	O
=	O
-0.133	O
,	O
P	O
=	O
0.346	O
for	O
total	O
immunoglobulin	O
;	O
r	O
=	O
-0.048	O
,	O
P	O
=	O
0.734	O
for	O
IgG	O
;	O
and	O
r	O
=	O
0.033	O
,	O
P	O
=	O
0.817	O
for	O
IgA	O
)	O
.	O

Correlations	O
between	O
BLyS	O
parameters	O
and	O
disease	O
activity	O
Previous	O
studies	O
either	O
have	O
failed	O
to	O
demonstrate	O
a	O
significant	O
correlation	O
between	O
disease	O
activity	O
and	O
circulating	O
BLyS	O
levels	O
[	O
7	O
-	O
9	O
]	O
or	O
have	O
detected	O
only	O
a	O
weak	O
correlation	O
between	O
the	O
two	O
[	O
10	O
]	O
.	O

Consonant	O
with	O
those	O
studies	O
,	O
we	O
identified	O
no	O
significant	O
correlation	O
between	O
plasma	O
BLyS	O
levels	O
and	O
SLEDAI	O
in	O
our	O
cohort	O
of	O
60	O
SLE	O
patients	O
(	O
Figure	O
3a	O
)	O
.	O

The	O
failure	O
to	O
demonstrate	O
a	O
significant	O
correlation	O
can	O
not	O
be	O
attributed	O
to	O
a	O
skewing	O
of	O
the	O
results	O
by	O
the	O
patients	O
in	O
whom	O
plasma	O
BLyS	O
levels	O
were	O
below	O
the	O
limit	O
of	O
detection	O
,	O
because	O
no	O
significant	O
correlation	O
was	O
detected	O
among	O
the	O
53	O
SLE	O
patients	O
in	O
whom	O
plasma	O
BLyS	O
levels	O
were	O
in	O
the	O
detectable	O
range	O
(	O
r	O
=	O
0.185	O
,	O
P	O
=	O
0.183	O
)	O
.	O

In	O
contrast	O
,	O
a	O
significant	O
correlation	O
between	O
SLEDAI	O
and	O
full	O
-	O
length	O
BLyS	O
mRNA	O
levels	O
was	O
readily	O
discernible	O
(	O
Figure	O
3b	O
)	O
.	O

A	O
trend	O
toward	O
a	O
correlation	O
between	O
SLEDAI	O
and	O
ΔBLyS	O
mRNA	O
levels	O
was	O
also	O
observed	O
,	O
although	O
it	O
did	O
not	O
achieve	O
statistical	O
significance	O
(	O
Figure	O
3c	O
)	O
.	O

A	O
component	O
of	O
the	O
SLEDAI	O
is	O
the	O
presence	O
of	O
circulating	O
anti	O
-	O
dsDNA	O
antibodies	O
.	O

Because	O
circulating	O
BLyS	O
levels	O
may	O
affect	O
the	O
presence	O
and/or	O
titers	O
of	O
circulating	O
anti	O
-	O
dsDNA	O
antibodies	O
[	O
7	O
-	O
10	O
]	O
,	O
we	O
assessed	O
correlations	O
between	O
the	O
individual	O
BLyS	O
parameters	O
and	O
a	O
modified	O
SLEDAI	O
that	O
excludes	O
any	O
consideration	O
of	O
anti	O
-	O
dsDNA	O
antibodies	O
.	O

As	O
with	O
the	O
unmodified	O
SLEDAI	O
,	O
the	O
modified	O
SLEDAI	O
did	O
not	O
correlate	O
with	O
plasma	O
BLyS	O
levels	O
(	O
Figure	O
3d	O
)	O
either	O
among	O
the	O
SLE	O
cohort	O
overall	O
or	O
among	O
the	O
53	O
patients	O
in	O
whom	O
plasma	O
BLyS	O
levels	O
were	O
in	O
the	O
detectable	O
range	O
(	O
r	O
=	O
0.160	O
,	O
P	O
=	O
0.252	O
)	O
,	O
but	O
it	O
significantly	O
correlated	O
with	O
full	O
-	O
length	O
BLyS	O
mRNA	O
levels	O
(	O
Figure	O
3e	O
)	O
and	O
exhibited	O
a	O
trend	O
toward	O
correlation	O
with	O
ΔBLyS	O
mRNA	O
levels	O
(	O
Figure	O
3f	O
)	O
.	O

Thus	O
,	O
the	O
stronger	O
correlations	O
between	O
BLyS	O
mRNA	O
levels	O
and	O
disease	O
activity	O
can	O
not	O
solely	O
be	O
explained	O
by	O
any	O
effects	O
that	O
BLyS	O
may	O
have	O
on	O
anti	O
-	O
dsDNA	O
antibodies	O
per	O
se	O
.	O

Moreover	O
,	O
among	O
the	O
37	O
SLE	O
patients	O
who	O
were	O
evaluated	O
on	O
two	O
separate	O
occasions	O
,	O
trends	O
toward	O
correlation	O
were	O
appreciated	O
between	O
changes	O
in	O
the	O
unmodified	O
or	O
modified	O
SLEDAI	O
and	O
changes	O
in	O
full	O
-	O
length	O
BLyS	O
or	O
ΔBLyS	O
mRNA	O
levels	O
but	O
not	O
changes	O
in	O
plasma	O
BLyS	O
levels	O
(	O
Figure	O
4	O
)	O
.	O

These	O
results	O
can	O
not	O
be	O
ascribed	O
to	O
changes	O
in	O
medications	O
taken	O
by	O
the	O
patients	O
,	O
because	O
changes	O
in	O
neither	O
disease	O
activity	O
nor	O
in	O
any	O
of	O
the	O
BLyS	O
parameters	O
correlated	O
with	O
changes	O
in	O
the	O
doses	O
of	O
corticosteroids	O
or	O
cytotoxics	O
taken	O
by	O
the	O
patients	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
failure	O
to	O
demonstrate	O
a	O
meaningful	O
association	O
between	O
changes	O
in	O
SLEDAI	O
score	O
and	O
changes	O
in	O
plasma	O
BLyS	O
protein	O
levels	O
can	O
not	O
be	O
attributed	O
to	O
a	O
skewing	O
of	O
the	O
results	O
by	O
the	O
patients	O
in	O
whom	O
plasma	O
BLyS	O
levels	O
were	O
below	O
the	O
limit	O
of	O
detection	O
,	O
because	O
the	O
absence	O
of	O
association	O
between	O
the	O
two	O
persisted	O
among	O
the	O
27	O
SLE	O
patients	O
in	O
whom	O
plasma	O
BLyS	O
levels	O
were	O
in	O
the	O
detectable	O
range	O
in	O
both	O
samples	O
(	O
r	O
=	O
-0.069	O
,	O
P	O
=	O
0.727	O
for	O
plasma	O
BLyS	O
versus	O
unmodified	O
SLEDAI	O
;	O
r	O
=	O
-0.020	O
,	O
P	O
=	O
0.919	O
for	O
plasma	O
BLyS	O
versus	O
modified	O
SLEDAI	O
)	O
.	O

Lack	O
of	O
correlation	O
between	O
levels	O
of	O
BLyS	O
mRNA	O
isoforms	O
and	O
percentages	O
of	O
individual	O
leukocyte	O
cell	O
types	O
Among	O
cells	O
in	O
peripheral	O
blood	O
,	O
BLyS	O
is	O
predominantly	O
expressed	O
by	O
cells	O
of	O
the	O
myeloid	O
lineage	O
(	O
monocytes	O
and	O
neutrophils	O
)	O
[	O
1,14,22,23	O
]	O
.	O

Accordingly	O
,	O
a	O
shift	O
in	O
the	O
differential	O
leukocyte	O
count	O
away	O
from	O
lymphocytes	O
to	O
monocytes	O
and/or	O
neutrophils	O
could	O
substantially	O
alter	O
BLyS	O
mRNA	O
results	O
.	O

Because	O
of	O
the	O
limited	O
amount	O
of	O
blood	O
we	O
were	O
permitted	O
to	O
obtain	O
from	O
the	O
SLE	O
patients	O
(	O
consequent	O
to	O
the	O
high	O
prevalence	O
of	O
anemia	O
among	O
these	O
patients	O
)	O
,	O
we	O
were	O
unable	O
to	O
purify	O
the	O
individual	O
leukocyte	O
populations	O
for	O
BLyS	O
mRNA	O
analysis	O
.	O

Nevertheless	O
,	O
to	O
demonstrate	O
that	O
the	O
elevated	O
BLyS	O
mRNA	O
levels	O
in	O
SLE	O
did	O
not	O
simply	O
reflect	O
a	O
shift	O
in	O
differential	O
leukocyte	O
count	O
,	O
we	O
assessed	O
the	O
correlations	O
between	O
the	O
individual	O
BLyS	O
parameters	O
on	O
the	O
one	O
hand	O
and	O
the	O
percentages	O
of	O
blood	O
neutrophils	O
,	O
monocytes	O
,	O
and	O
lymphocytes	O
on	O
the	O
other	O
.	O

No	O
correlations	O
were	O
appreciated	O
(	O
Figure	O
5	O
)	O
.	O

Presence	O
of	O
anti	O
-	O
BLyS	O
autoantibodies	O
in	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
The	O
poorer	O
correlation	O
between	O
plasma	O
BLyS	O
protein	O
levels	O
and	O
disease	O
activity	O
compared	O
with	O
that	O
between	O
BLyS	O
mRNA	O
levels	O
and	O
disease	O
activity	O
was	O
striking	O
.	O

Patients	O
with	O
SLE	O
frequently	O
develop	O
autoantibodies	O
against	O
self	O
-	O
antigens	O
,	O
and	O
so	O
some	O
of	O
the	O
SLE	O
patients	O
might	O
have	O
harbored	O
autoantibodies	O
to	O
BLyS.	O
Such	O
autoantibodies	O
could	O
have	O
complexed	O
with	O
BLyS	O
and	O
enhanced	O
its	O
clearance	O
,	O
thereby	O
masking	O
BLyS	O
overproduction	O
.	O

Alternatively	O
,	O
such	O
autoantibodies	O
might	O
have	O
sterically	O
blocked	O
the	O
epitopes	O
recognized	O
by	O
the	O
detecting	O
antibodies	O
in	O
the	O
in	O
vitro	O
ELISA	O
.	O

In	O
this	O
case	O
,	O
measured	O
BLyS	O
levels	O
would	O
have	O
been	O
spuriously	O
reduced	O
,	O
again	O
masking	O
BLyS	O
overproduction	O
.	O

In	O
our	O
cohort	O
,	O
IgA	O
/	O
IgM	O
/	O
IgG	O
anti	O
-	O
BLyS	O
antibodies	O
were	O
detected	O
in	O
six	O
out	O
of	O
the	O
60	O
SLE	O
patients	O
.	O

Such	O
autoantibodies	O
were	O
also	O
detected	O
in	O
two	O
out	O
of	O
60	O
RA	O
patients	O
and	O
in	O
one	O
out	O
of	O
30	O
normal	O
control	O
individuals	O
,	O
demonstrating	O
that	O
anti	O
-	O
BLyS	O
autoantibodies	O
are	O
not	O
restricted	O
to	O
SLE	O
patients	O
.	O

IgG	O
anti	O
-	O
BLyS	O
autoantibodies	O
were	O
detected	O
in	O
3	O
SLE	O
patients	O
but	O
in	O
no	O
RA	O
patients	O
or	O
normal	O
control	O
individuals	O
.	O

Discussion	O
Elevated	O
blood	O
levels	O
of	O
BLyS	O
protein	O
and	O
mRNA	O
are	O
well	O
described	O
features	O
of	O
human	B
SLE	O
[	O
7	O
-	O
9	O
]	O
.	O

We	O
confirmed	O
these	O
observations	O
in	O
our	O
study	O
and	O
extended	O
them	O
by	O
documenting	O
increases	O
not	O
just	O
in	O
levels	O
of	O
full	O
-	O
length	O
BLyS	O
mRNA	O
but	O
also	O
in	O
levels	O
of	O
ΔBLyS	O
mRNA	O
(	O
Figure	O
1	O
)	O
.	O

Of	O
note	O
,	O
BLyS	O
mRNA	O
levels	O
were	O
elevated	O
in	O
SLE	O
but	O
not	O
in	O
RA	O
,	O
raising	O
the	O
possibility	O
that	O
BLyS	O
overproduction	O
in	O
SLE	O
is	O
systemic	O
whereas	O
BLyS	O
overproduction	O
in	O
RA	O
may	O
be	O
more	O
focused	O
to	O
the	O
affected	O
arthritic	O
joints	O
[	O
24	O
]	O
.	O

The	O
modestly	O
elevated	O
plasma	O
BLyS	O
protein	O
levels	O
in	O
RA	O
patients	O
may	O
reflect	O
,	O
at	O
least	O
in	O
part	O
,	O
release	O
of	O
locally	O
overproduced	O
BLyS	O
into	O
the	O
circulation	O
.	O

The	O
relationship	O
between	O
circulating	O
BLyS	O
protein	O
levels	O
and	O
disease	O
activity	O
was	O
addressed	O
in	O
several	O
previous	O
studies	O
,	O
but	O
significant	O
correlations	O
between	O
the	O
two	O
measures	O
did	O
not	O
emerge	O
[	O
7	O
-	O
9	O
]	O
.	O

In	O
the	O
largest	O
study	O
to	O
date	O
,	O
a	O
2-year	O
longitudinal	O
study	O
of	O
245	O
patients	O
in	O
which	O
more	O
than	O
1,700	O
plasma	O
samples	O
were	O
analyzed	O
,	O
a	O
significant	O
but	O
weak	O
correlation	O
between	O
the	O
two	O
was	O
appreciated	O
[	O
10	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
a	O
significant	O
correlation	O
between	O
plasma	O
BLyS	O
protein	O
levels	O
and	O
disease	O
activity	O
was	O
again	O
not	O
realized	O
(	O
Figure	O
3a	O
,	O
d	O
)	O
.	O

The	O
weak	O
,	O
at	O
best	O
,	O
correlation	O
between	O
circulating	O
BLyS	O
levels	O
and	O
disease	O
activity	O
is	O
seemingly	O
rather	O
surprising	O
.	O

There	O
is	O
a	O
clear	O
-	O
cut	O
association	O
in	O
BlyS	O
transgenic	O
mice	B
between	O
BLyS	O
overexpression	O
and	O
development	O
of	O
SLE	O
-	O
like	O
features	O
[	O
3	O
-	O
5	O
]	O
,	O
and	O
treatment	O
of	O
SLE	O
-	O
prone	O
mice	B
with	O
BLyS	O
antagonists	O
retards	O
the	O
progression	O
of	O
disease	O
and	O
improves	O
survival	O
[	O
3,6	O
]	O
.	O

Moreover	O
,	O
development	O
of	O
precocious	O
glomerular	O
pathology	O
in	O
autoimmune	O
-	O
prone	O
mice	B
correlates	O
strongly	O
with	O
circulating	O
BLyS	O
levels	O
[	O
25	O
]	O
.	O

The	O
likely	O
explanation	O
for	O
the	O
weak	O
correlation	O
between	O
circulating	O
BLyS	O
levels	O
and	O
disease	O
activity	O
in	O
human	B
SLE	O
is	O
not	O
that	O
disease	O
activity	O
in	O
SLE	O
patients	O
is	O
insensitive	O
to	O
the	O
degree	O
of	O
BLyS	O
overproduction	O
.	O

Rather	O
,	O
a	O
more	O
tenable	O
explanation	O
is	O
that	O
circulating	O
BLyS	O
levels	O
in	O
human	B
SLE	O
do	O
not	O
always	O
accurately	O
reflect	O
excessive	O
endogenous	O
BLyS	O
production	O
.	O

We	O
can	O
identify	O
at	O
least	O
three	O
nonmutually	O
exclusive	O
mechanisms	O
to	O
explain	O
a	O
dissociation	O
between	O
the	O
two	O
.	O

First	O
,	O
SLE	O
patients	O
frequently	O
develop	O
autoantibodies	O
to	O
a	O
myriad	O
of	O
self	O
-	O
targets	O
(	O
for	O
example	O
,	O
erythrocytes	O
,	O
lymphocytes	O
)	O
.	O

Indeed	O
,	O
we	O
detected	O
circulating	O
IgA	O
/	O
IgM	O
/	O
IgG	O
anti	O
-	O
BLyS	O
autoantibodies	O
in	O
10	O
%	O
(	O
6	O
/	O
60	O
)	O
of	O
the	O
tested	O
SLE	O
patients	O
,	O
and	O
we	O
detected	O
circulating	O
IgG	O
anti	O
-	O
BLyS	O
autoantibodies	O
in	O
5	O
%	O
(	O
3	O
/	O
60	O
)	O
.	O

These	O
percentages	O
may	O
be	O
underestimates	O
of	O
the	O
true	O
prevalence	O
of	O
anti	O
-	O
BLyS	O
autoantibodies	O
,	O
because	O
some	O
of	O
these	O
autoantibodies	O
may	O
be	O
saturated	O
in	O
vivo	O
with	O
circulating	O
BLyS	O
,	O
rendering	O
them	O
incapable	O
of	O
binding	O
to	O
BLyS	O
in	O
the	O
in	O
vitro	O
detection	O
assay	O
.	O

We	O
do	O
not	O
yet	O
know	O
whether	O
the	O
anti	O
-	O
BLyS	O
autoantibodies	O
are	O
functionally	O
neutralizing	O
but	O
,	O
regardless	O
,	O
such	O
autoantibodies	O
could	O
enhance	O
the	O
clearance	O
of	O
BLyS	O
and/or	O
interfere	O
with	O
in	O
vitro	O
detection	O
of	O
BLyS	O
,	O
thereby	O
masking	O
endogenous	O
BLyS	O
overproduction	O
.	O

Second	O
,	O
increased	O
urinary	O
excretion	O
of	O
BLyS	O
has	O
been	O
reported	O
in	O
SLE	O
patients	O
,	O
especially	O
among	O
those	O
with	O
clinically	O
overt	O
renal	O
involvement	O
[	O
26	O
]	O
.	O

At	O
least	O
four	O
of	O
the	O
patients	O
we	O
studied	O
manifested	O
nephrotic	O
-	O
range	O
proteinuria	O
(	O
≥3	O
g	O
/	O
24	O
hours	O
)	O
,	O
and	O
so	O
urinary	O
loss	O
of	O
BLyS	O
was	O
probably	O
substantial	O
in	O
at	O
least	O
these	O
patients	O
.	O

A	O
validated	O
assay	O
for	O
urinary	O
BLyS	O
detection	O
has	O
not	O
yet	O
been	O
developed	O
so	O
we	O
were	O
unable	O
to	O
quantify	O
urinary	O
BLyS	O
levels	O
.	O

Once	O
an	O
assay	O
for	O
urinary	O
BLyS	O
levels	O
is	O
validated	O
,	O
we	O
should	O
be	O
able	O
to	O
assess	O
the	O
effect	O
of	O
urinary	O
BLyS	O
excretion	O
on	O
circulating	O
BLyS	O
levels	O
.	O

Third	O
,	O
BLyS	O
promotes	O
in	O
vivo	O
expansion	O
of	O
B	O
cells	O
[	O
1	O
]	O
.	O

Freshly	O
isolated	O
SLE	O
B	O
cells	O
,	O
despite	O
intact	O
surface	O
expression	O
of	O
BLyS	O
receptors	O
,	O
bind	O
less	O
biotinylated	O
BLyS	O
ex	O
vivo	O
than	O
do	O
freshly	O
isolated	O
normal	O
B	O
cells	O
[	O
27	O
]	O
.	O

Although	O
other	O
interpretations	O
are	O
possible	O
,	O
the	O
most	O
likely	O
explanation	O
is	O
that	O
BLyS	O
receptors	O
on	O
B	O
cells	O
in	O
SLE	O
patients	O
are	O
occupied	O
in	O
vivo	O
by	O
soluble	O
BLyS.	O
Accordingly	O
,	O
it	O
is	O
likely	O
that	O
BLyS	O
receptors	O
expressed	O
by	O
the	O
expanded	O
B	O
cell	O
population	O
do	O
bind	O
BLyS	O
and	O
remove	O
it	O
from	O
the	O
circulation	O
,	O
resulting	O
in	O
a	O
homeostatic	O
pathway	O
that	O
modulates	O
the	O
effects	O
of	O
BLyS	O
overproduction	O
on	O
circulating	O
BLyS	O
levels	O
.	O

Indeed	O
,	O
circulating	O
levels	O
of	O
BLyS	O
rise	O
with	O
peripheral	O
blood	O
B	O
cell	O
depletion	O
and	O
fall	O
with	O
re	O
-	O
emergence	O
of	O
peripheral	O
blood	O
B	O
cells	O
in	O
rituximab	O
-	O
treated	O
RA	O
or	O
SLE	O
patients	O
[	O
28,29	O
]	O
,	O
highlighting	O
this	O
inverse	O
relationship	O
between	O
circulating	O
BLyS	O
levels	O
and	O
B	O
cell	O
load	O
.	O

Moreover	O
,	O
one	O
of	O
the	O
hallmarks	O
of	O
active	O
disease	O
in	O
human	B
SLE	O
is	O
the	O
increased	O
percentages	O
of	O
activated	O
B	O
cells	O
and	O
plasma	O
cells	O
in	O
peripheral	O
blood	O
[	O
30	O
-	O
34	O
]	O
,	O
probably	O
reflecting	O
increased	O
systemic	O
numbers	O
of	O
activated	O
B	O
cells	O
and	O
plasma	O
cells	O
.	O

Although	O
not	O
yet	O
formally	O
tested	O
,	O
differential	O
BLyS	O
receptor	O
expression	O
by	O
these	O
cells	O
compared	O
with	O
expression	O
by	O
nonactivated	O
B	O
cells	O
may	O
result	O
in	O
increased	O
peripheral	O
BLyS	O
utilization	O
,	O
further	O
dampening	O
the	O
effects	O
of	O
BLyS	O
overproduction	O
on	O
circulating	O
protein	O
levels	O
.	O

To	O
circumvent	O
these	O
confounding	O
processes	O
,	O
we	O
used	O
BLyS	O
mRNA	O
levels	O
as	O
a	O
surrogate	O
marker	O
of	O
endogenous	O
BLyS	O
production	O
.	O

Overall	O
,	O
the	O
correlations	O
between	O
disease	O
activity	O
and	O
either	O
full	O
-	O
length	O
BLyS	O
or	O
ΔBLyS	O
mRNA	O
levels	O
were	O
much	O
stronger	O
than	O
that	O
between	O
disease	O
activity	O
and	O
BLyS	O
protein	O
levels	O
(	O
Figures	O
3	O
and	O
4	O
)	O
.	O

This	O
was	O
the	O
case	O
regardless	O
of	O
whether	O
we	O
used	O
the	O
standard	O
SLEDAI	O
or	O
the	O
modified	O
SLEDAI	O
as	O
a	O
measure	O
of	O
disease	O
activity	O
.	O

These	O
correlations	O
were	O
not	O
spurious	O
ones	O
consequent	O
to	O
shifts	O
in	O
percentages	O
of	O
leukocyte	O
subpopulations	O
in	O
peripheral	O
blood	O
,	O
because	O
BLyS	O
mRNA	O
levels	O
did	O
not	O
correlate	O
with	O
percentages	O
of	O
blood	O
neutrophils	O
,	O
monocytes	O
,	O
or	O
lymphocytes	O
(	O
Figure	O
5	O
)	O
.	O

A	O
similar	O
pattern	O
was	O
observed	O
between	O
plasma	O
immunoglobulin	O
levels	O
and	O
the	O
BLyS	O
parameters	O
,	O
with	O
plasma	O
levels	O
of	O
total	O
immunoglobulin	O
,	O
IgG	O
,	O
and	O
IgA	O
correlating	O
significantly	O
with	O
full	O
-	O
length	O
BLyS	O
and	O
ΔBLyS	O
mRNA	O
levels	O
but	O
not	O
with	O
plasma	O
BLyS	O
levels	O
(	O
Figure	O
2	O
)	O
.	O

These	O
significant	O
correlations	O
between	O
full	O
-	O
length	O
BLyS	O
or	O
ΔBLyS	O
mRNA	O
levels	O
and	O
plasma	O
immunoglobulin	O
levels	O
again	O
highlight	O
the	O
greater	O
ability	O
of	O
BLyS	O
mRNA	O
levels	O
,	O
compared	O
with	O
plasma	O
BLyS	O
protein	O
levels	O
,	O
to	O
reflect	O
ongoing	O
BLyS	O
overproduction	O
.	O

At	O
present	O
,	O
it	O
is	O
not	O
known	O
whether	O
soluble	O
ΔBLyS	O
protein	O
is	O
present	O
in	O
the	O
circulation	O
of	O
SLE	O
patients	O
or	O
of	O
normal	O
individuals	O
.	O

Although	O
full	O
-	O
length	O
BLyS	O
protein	O
is	O
readily	O
cleaved	O
and	O
released	O
from	O
cells	O
transfected	O
with	O
a	O
vector	O
containing	O
murine	O
full	O
-	O
length	O
BLyS	O
,	O
ΔBLyS	O
protein	O
is	O
not	O
cleaved	O
or	O
released	O
from	O
murine	O
ΔBLyS	O
transfectants	O
[	O
11	O
]	O
.	O

Given	O
the	O
strong	O
similarities	O
between	O
murine	O
and	O
human	B
full	O
-	O
length	O
BLyS	O
and	O
ΔBLyS	O
,	O
it	O
is	O
likely	O
that	O
human	B
soluble	O
ΔBLyS	O
protein	O
is	O
also	O
not	O
cleaved	O
from	O
the	O
cell	O
surface	O
and	O
released	O
into	O
the	O
circulation	O
.	O

Moreover	O
,	O
soluble	O
ΔBLyS	O
protein	O
is	O
not	O
released	O
from	O
cells	O
transfected	O
with	O
a	O
vector	O
containing	O
just	O
the	O
extracellular	O
domain	O
of	O
human	B
ΔBLyS	O
(	O
which	O
encodes	O
the	O
soluble	O
protein	O
;	O
A.L.	O
Gavin	O
,	O
unpublished	O
observations	O
)	O
.	O

Whether	O
this	O
reflects	O
rapid	O
intracellular	O
degradation	O
of	O
soluble	O
ΔBLyS	O
or	O
some	O
other	O
impediment	O
to	O
its	O
release	O
remains	O
unknown	O
.	O

Regardless	O
,	O
if	O
the	O
inability	O
to	O
release	O
soluble	O
ΔBLyS	O
in	O
vitro	O
faithfully	O
recapitulates	O
in	O
vivo	O
biology	O
,	O
then	O
the	O
stronger	O
associations	O
between	O
SLE	O
disease	O
activity	O
and	O
full	O
-	O
length	O
BLyS	O
or	O
ΔBLyS	O
mRNA	O
levels	O
compared	O
with	O
that	O
between	O
SLE	O
disease	O
activity	O
and	O
BLyS	O
protein	O
levels	O
could	O
not	O
be	O
attributable	O
to	O
interference	O
by	O
biologically	O
inactive	O
(	O
inhibitory	O
)	O
ΔBLyS	O
protein	O
in	O
the	O
BLyS	O
protein	O
detection	O
ELISA	O
.	O

Importantly	O
,	O
even	O
if	O
soluble	O
ΔBLyS	O
protein	O
is	O
present	O
in	O
the	O
circulation	O
and	O
is	O
detected	O
by	O
the	O
BLyS	O
protein	O
detection	O
ELISA	O
,	O
then	O
the	O
stronger	O
correlations	O
between	O
SLE	O
disease	O
activity	O
and	O
full	O
-	O
length	O
BLyS	O
or	O
ΔBLyS	O
mRNA	O
levels	O
than	O
that	O
between	O
disease	O
activity	O
and	O
total	O
BLyS	O
(	O
including	O
ΔBLyS	O
)	O
protein	O
levels	O
suggest	O
that	O
full	O
-	O
length	O
BLyS	O
and/or	O
ΔBLyS	O
mRNA	O
levels	O
may	O
operationally	O
serve	O
as	O
useful	O
biomarkers	O
of	O
disease	O
activity	O
in	O
SLE	O
.	O

Although	O
the	O
complexity	O
and	O
labor	O
intensiveness	O
associated	O
with	O
quantitative	O
real	O
-	O
time	O
PCR	O
may	O
render	O
measurement	O
of	O
BLyS	O
mRNA	O
levels	O
impracticable	O
for	O
routine	O
clinical	O
practice	O
,	O
such	O
measurement	O
could	O
readily	O
be	O
incorporated	O
into	O
clinical	O
trials	O
and	O
yield	O
valuable	O
information	O
.	O

Longitudinal	O
observations	O
in	O
large	O
numbers	O
of	O
SLE	O
patients	O
will	O
be	O
necessary	O
to	O
establish	O
or	O
refute	O
the	O
utility	O
of	O
full	O
-	O
length	O
BLyS	O
and/or	O
ΔBLyS	O
mRNA	O
to	O
subserve	O
this	O
clinically	O
vital	O
function	O
.	O

Although	O
expression	O
of	O
the	O
two	O
major	O
BLyS	O
isoforms	O
was	O
highly	O
coordinate	O
among	O
SLE	O
patients	O
,	O
there	O
were	O
several	O
patients	O
in	O
whom	O
ΔBLyS	O
mRNA	O
levels	O
were	O
markedly	O
greater	O
than	O
or	O
less	O
than	O
the	O
expected	O
values	O
based	O
on	O
full	O
-	O
length	O
BLyS	O
mRNA	O
levels	O
(	O
data	O
not	O
shown	O
)	O
.	O

This	O
raises	O
the	O
possibility	O
that	O
dysregulation	O
of	O
ΔBLyS	O
may	O
contribute	O
to	O
overall	O
BLyS	O
dysregulation	O
in	O
at	O
least	O
some	O
SLE	O
patients	O
.	O

It	O
is	O
known	O
that	O
interferon	O
-	O
γ	O
,	O
interleukin-10	O
,	O
interferon	O
-	O
α	O
,	O
and	O
CD154	O
can	O
upregulate	O
full	O
-	O
length	O
BLyS	O
mRNA	O
levels	O
[	O
14,22,35	O
]	O
,	O
but	O
it	O
is	O
not	O
known	O
what	O
effects	O
these	O
or	O
other	O
cytokines	O
/	O
cell	O
-	O
surface	O
structures	O
have	O
on	O
ΔBLyS	O
expression	O
.	O

Further	O
investigation	O
of	O
the	O
regulation	O
of	O
ΔBLyS	O
and	O
the	O
differential	O
expression	O
of	O
BLyS	O
isoforms	O
is	O
certainly	O
warranted	O
.	O

Although	O
the	O
associations	O
between	O
full	O
-	O
length	O
BLyS	O
and/or	O
ΔBLyS	O
mRNA	O
levels	O
and	O
disease	O
activity	O
in	O
SLE	O
were	O
usually	O
strong	O
when	O
the	O
SLE	O
cohort	O
was	O
analyzed	O
in	O
aggregate	O
,	O
there	O
were	O
several	O
SLE	O
patients	O
in	O
whom	O
BLyS	O
mRNA	O
levels	O
were	O
quite	O
high	O
despite	O
little	O
objective	O
ongoing	O
disease	O
activity	O
,	O
and	O
there	O
were	O
several	O
SLE	O
patients	O
in	O
whom	O
BLyS	O
mRNA	O
levels	O
were	O
low	O
despite	O
considerable	O
ongoing	O
disease	O
activity	O
.	O

One	O
must	O
recognize	O
that	O
the	O
bulk	O
of	O
the	O
pathogenic	O
autoimmune	O
responses	O
probably	O
takes	O
place	O
in	O
the	O
spleen	O
and	O
lymph	O
nodes	O
,	O
rather	O
than	O
in	O
the	O
peripheral	O
blood	O
,	O
where	O
myeloid	O
lineage	O
cells	O
(	O
for	O
example	O
,	O
dendritic	O
cells	O
)	O
produce	O
BLyS	O
and	O
support	O
B	O
cell	O
survival	O
and	O
expansion	O
[	O
36	O
]	O
.	O

Local	O
BLyS	O
production	O
in	O
the	O
secondary	O
lymphoid	O
tissues	O
will	O
be	O
more	O
important	O
to	O
the	O
development	O
and	O
maintenance	O
of	O
an	O
autoimmune	O
response	O
than	O
will	O
remote	O
BLyS	O
levels	O
in	O
the	O
circulation	O
.	O

Because	O
at	O
least	O
some	O
autoreactive	O
B	O
cells	O
may	O
be	O
more	O
sensitive	O
to	O
BLyS	O
-	O
mediated	O
survival	O
signals	O
than	O
non	O
-	O
autoreactive	O
B	O
cells	O
[	O
37,38	O
]	O
,	O
local	O
increases	O
in	O
BLyS	O
production	O
could	O
preferentially	O
promote	O
expansion	O
of	O
autoreactive	O
B	O
cells	O
.	O

These	O
cells	O
,	O
in	O
turn	O
,	O
could	O
activate	O
autoreactive	O
T	O
cells	O
by	O
presenting	O
autoantigen	O
to	O
them	O
,	O
and	O
some	O
of	O
the	O
autoreactive	O
B	O
cells	O
would	O
respond	O
to	O
T	O
cell	O
derived	O
signals	O
and	O
mature	O
into	O
(	O
pathogenic	O
)	O
autoantibody	O
secreting	O
plasma	O
cells	O
.	O

In	O
contrast	O
to	O
murine	O
studies	O
,	O
in	O
which	O
investigators	O
can	O
readily	O
harvest	O
and	O
analyze	O
lymphoid	O
and	O
myeloid	O
lineage	O
cells	O
from	O
any	O
site	O
(	O
for	O
example	O
,	O
spleen	O
,	O
bone	O
marrow	O
)	O
,	O
such	O
is	O
not	O
the	O
case	O
for	O
human	B
studies	O
.	O

Peripheral	O
blood	O
is	O
the	O
only	O
site	O
readily	O
accessible	O
for	O
human	B
studies	O
,	O
and	O
it	O
is	O
possible	O
that	O
,	O
at	O
least	O
in	O
some	O
patients	O
,	O
BLyS	O
mRNA	O
levels	O
in	O
circulating	O
leukocytes	O
do	O
not	O
reflect	O
local	O
BLyS	O
production	O
in	O
the	O
secondary	O
lymphoid	O
tissues	O
.	O

One	O
must	O
also	O
recognize	O
that	O
disease	O
activity	O
in	O
SLE	O
is	O
not	O
solely	O
driven	O
by	O
B	O
cells	O
.	O

Systemic	O
inflammation	O
and	O
SLE	O
flares	O
can	O
be	O
triggered	O
via	O
B	O
cell	O
independent	O
means	O
.	O

Not	O
all	O
SLE	O
patients	O
treated	O
with	O
a	O
B	O
cell	O
depleting	O
course	O
of	O
rituximab	O
experience	O
clinical	O
remission	O
[	O
39	O
]	O
,	O
strongly	O
pointing	O
to	O
the	O
importance	O
of	O
non	O
-	O
B	O
cells	O
in	O
disease	O
pathogenesis	O
/	O
maintenance	O
.	O

Conversely	O
,	O
not	O
all	O
pathogenic	O
B	O
cells	O
necessarily	O
require	O
high	O
levels	O
of	O
BLyS	O
to	O
effect	O
their	O
pathogenicity	O
.	O

Murine	O
studies	O
have	O
unequivocally	O
documented	O
B	O
cell	O
subpopulations	O
that	O
do	O
not	O
depend	O
upon	O
BLyS	O
for	O
their	O
survival	O
[	O
40	O
-	O
42	O
]	O
.	O

Although	O
mice	B
completely	O
devoid	O
of	O
BLyS	O
have	O
reduced	O
numbers	O
of	O
mature	O
B	O
cells	O
and	O
harbor	O
reduced	O
levels	O
of	O
immunoglobulin	O
,	O
these	O
reductions	O
are	O
incomplete	O
.	O

Thus	O
,	O
it	O
is	O
possible	O
that	O
some	O
SLE	O
patients	O
harbor	O
pathogenic	O
B	O
cells	O
that	O
are	O
relatively	O
insensitive	O
to	O
BLyS	O
and	O
could	O
drive	O
considerable	O
disease	O
activity	O
even	O
in	O
the	O
context	O
of	O
low	O
endogenous	O
BLyS	O
production	O
.	O

Conversely	O
,	O
patients	O
with	O
high	O
BLyS	O
mRNA	O
levels	O
may	O
be	O
those	O
patients	O
whose	O
disease	O
is	O
strongly	O
driven	O
by	O
BLyS	O
and	O
may	O
be	O
especially	O
helped	O
by	O
BLyS	O
antagonist	O
therapy	O
.	O

Future	O
clinical	O
trials	O
should	O
be	O
able	O
to	O
establish	O
whether	O
the	O
BLyS	O
mRNA	O
levels	O
are	O
good	O
predictors	O
of	O
response	O
to	O
such	O
agents	O
.	O

Conclusion	O
Plasma	O
total	O
immunoglobulin	O
,	O
IgG	O
,	O
and	O
IgA	O
levels	O
and	O
disease	O
activity	O
(	O
as	O
measured	O
by	O
SLEDAI	O
)	O
in	O
SLE	O
patients	O
correlate	O
more	O
closely	O
with	O
peripheral	O
blood	O
leukocyte	O
levels	O
of	O
BLyS	O
mRNA	O
than	O
with	O
plasma	O
levels	O
of	O
BLyS	O
protein	O
.	O

These	O
findings	O
suggest	O
that	O
BLyS	O
mRNA	O
levels	O
better	O
reflect	O
in	O
vivo	O
BLyS	O
production	O
than	O
do	O
circulating	O
BLyS	O
protein	O
levels	O
,	O
and	O
may	O
be	O
a	O
useful	O
biomarker	O
in	O
the	O
clinical	O
monitoring	O
of	O
SLE	O
patients	O
.	O

These	O
findings	O
also	O
support	O
the	O
premise	O
that	O
BLyS	O
overexpression	O
not	O
only	O
promotes	O
development	O
of	O
disease	O
but	O
also	O
actively	O
contributes	O
to	O
the	O
ongoing	O
maintenance	O
of	O
disease	O
in	O
SLE	O
patients	O
.	O

This	O
reinforces	O
the	O
rationale	O
underlying	O
clinical	O
trials	O
with	O
BLyS	O
antagonists	O
in	O
SLE	O
.	O

Abbreviations	O
anti	O
-	O
dsDNA	O
=	O
anti	O
-	O
double	O
-	O
stranded	O
DNA	O
;	O
BLyS	O
=	O
B	O
lymphocyte	O
stimulator	O
;	O
bp	O
=	O
base	O
pairs	O
;	O
Ct	O
=	O
threshold	O
cycle	O
;	O
ELISA	O
=	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
;	O
PCR	O
=	O
polymerase	O
chain	O
reaction	O
;	O
RA	O
=	O
rheumatoid	O
arthritis	O
;	O
SLE	O
=	O
systemic	O
lupus	O
erythematosus	O
;	O
SLEDAI	O
=	O
SLE	O
Disease	O
Activity	O
Index	O
.	O

Competing	O
interests	O
TSM	O
and	O
DMH	O
were	O
employees	O
of	O
Human	B
Genome	O
Sciences	O
(	O
HGS	O
)	O
at	O
the	O
time	O
the	O
investigation	O
was	O
conducted	O
.	O

(	O
DMH	O
has	O
since	O
left	O
the	O
company	O
.	O
)	O

WS	O
has	O
received	O
research	O
support	O
from	O
HGS	O
and	O
has	O
served	O
as	O
a	O
consultant	O
to	O
HGS	O
(	O
<	O
$	O
10,000	O
)	O
.	O

CEC	O
,	O
ALG	O
,	O
and	O
DN	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O
CEC	O
identified	O
and	O
recruited	O
all	O
participants	O
;	O
collected	O
all	O
the	O
blood	O
samples	O
and	O
reviewed	O
all	O
the	O
medical	O
charts	O
;	O
and	O
wrote	O
the	O
initial	O
working	O
draft	O
of	O
this	O
manuscript	O
.	O

ALG	O
developed	O
and	O
performed	O
all	O
the	O
real	O
-	O
time	O
PCR	O
assays	O
and	O
assisted	O
in	O
the	O
interpretation	O
of	O
the	O
results	O
and	O
in	O
writing	O
the	O
final	O
version	O
of	O
the	O
manuscript	O
.	O

TSM	O
performed	O
the	O
plasma	O
BLyS	O
protein	O
and	O
anti	O
-	O
BLyS	O
assays	O
and	O
assisted	O
in	O
the	O
interpretation	O
of	O
the	O
results	O
and	O
in	O
writing	O
the	O
final	O
version	O
of	O
the	O
manuscript	O
.	O

DMH	O
assisted	O
in	O
the	O
design	O
in	O
the	O
study	O
,	O
in	O
the	O
interpretation	O
of	O
the	O
results	O
,	O
and	O
in	O
writing	O
the	O
final	O
version	O
of	O
the	O
manuscript	O
.	O

DN	O
assisted	O
in	O
the	O
design	O
in	O
the	O
study	O
,	O
in	O
the	O
interpretation	O
of	O
the	O
results	O
,	O
and	O
in	O
writing	O
the	O
final	O
version	O
of	O
the	O
manuscript	O
.	O

WS	O
conceived	O
the	O
study	O
,	O
supervised	O
the	O
recruitment	O
of	O
participants	O
,	O
performed	O
the	O
statistical	O
analyses	O
,	O
assisted	O
in	O
the	O
interpretation	O
of	O
the	O
results	O
,	O
and	O
supervised	O
the	O
editing	O
of	O
the	O
manuscript	O
to	O
its	O
final	O
form	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
version	O
.	O

QGRS	O
Mapper	O
:	O
a	O
web	O
-	O
based	O
server	O
for	O
predicting	O
G	O
-	O
quadruplexes	O
in	O
nucleotide	O
sequences	O
Abstract	O
The	O
quadruplex	O
structures	O
formed	O
by	O
guanine	O
-	O
rich	O
nucleic	O
acid	O
sequences	O
have	O
received	O
significant	O
attention	O
recently	O
because	O
of	O
growing	O
evidence	O
for	O
their	O
role	O
in	O
important	O
biological	O
processes	O
and	O
as	O
therapeutic	O
targets	O
.	O

G	O
-	O
quadruplex	O
DNA	O
has	O
been	O
suggested	O
to	O
regulate	O
DNA	O
replication	O
and	O
may	O
control	O
cellular	O
proliferation	O
.	O

Sequences	O
capable	O
of	O
forming	O
G	O
-	O
quadruplexes	O
in	O
the	O
RNA	O
have	O
been	O
shown	O
to	O
play	O
significant	O
roles	O
in	O
regulation	O
of	O
polyadenylation	O
and	O
splicing	O
events	O
in	O
mammalian	O
transcripts	O
.	O

Whether	O
quadruplex	O
structure	O
directly	O
plays	O
a	O
role	O
in	O
regulating	O
RNA	O
processing	O
requires	O
investigation	O
.	O

Computational	O
approaches	O
to	O
study	O
G	O
-	O
quadruplexes	O
allow	O
detailed	O
analysis	O
of	O
mammalian	O
genomes	O
.	O

There	O
are	O
no	O
known	O
easily	O
accessible	O
user	O
-	O
friendly	O
tools	O
that	O
can	O
compute	O
G	O
-	O
quadruplexes	O
in	O
the	O
nucleotide	O
sequences	O
.	O

We	O
have	O
developed	O
a	O
web	O
-	O
based	O
server	O
,	O
QGRS	O
Mapper	O
,	O
that	O
predicts	O
quadruplex	O
forming	O
G	O
-	O
rich	O
sequences	O
(	O
QGRS	O
)	O
in	O
nucleotide	O
sequences	O
.	O

It	O
is	O
a	O
user	O
-	O
friendly	O
application	O
that	O
provides	O
many	O
options	O
for	O
defining	O
and	O
studying	O
G	O
-	O
quadruplexes	O
.	O

It	O
performs	O
analysis	O
of	O
the	O
user	O
provided	O
genomic	O
sequences	O
,	O
e.g.	O
promoter	O
and	O
telomeric	O
regions	O
,	O
as	O
well	O
as	O
RNA	O
sequences	O
.	O

It	O
is	O
also	O
useful	O
for	O
predicting	O
G	O
-	O
quadruplex	O
structures	O
in	O
oligonucleotides	O
.	O

The	O
program	O
provides	O
options	O
to	O
search	O
and	O
retrieve	O
desired	O
gene	O
/	O
nucleotide	O
sequence	O
entries	O
from	O
NCBI	O
databases	O
for	O
mapping	O
G	O
-	O
quadruplexes	O
in	O
the	O
context	O
of	O
RNA	O
processing	O
sites	O
.	O

This	O
feature	O
is	O
very	O
useful	O
for	O
investigating	O
the	O
functional	O
relevance	O
of	O
G	O
-	O
quadruplex	O
structure	O
,	O
in	O
particular	O
its	O
role	O
in	O
regulating	O
the	O
gene	O
expression	O
by	O
alternative	O
processing	O
.	O

In	O
addition	O
to	O
providing	O
data	O
on	O
composition	O
and	O
locations	O
of	O
QGRS	O
relative	O
to	O
the	O
processing	O
sites	O
in	O
the	O
pre	O
-	O
mRNA	O
sequence	O
,	O
QGRS	O
Mapper	O
features	O
interactive	O
graphic	O
representation	O
of	O
the	O
data	O
.	O

The	O
user	O
can	O
also	O
use	O
the	O
graphics	O
module	O
to	O
visualize	O
QGRS	O
distribution	O
patterns	O
among	O
all	O
the	O
alternative	O
RNA	O
products	O
of	O
a	O
gene	O
simultaneously	O
on	O
a	O
single	O
screen	O
.	O

QGRS	O
Mapper	O
can	O
be	O
accessed	O
at	O
.	O

INTRODUCTION	O
The	O
quadruplex	O
structures	O
formed	O
by	O
guanine	O
-	O
rich	O
nucleic	O
acid	O
sequences	O
have	O
received	O
significant	O
attention	O
recently	O
because	O
of	O
increasing	O
evidence	O
for	O
their	O
role	O
in	O
important	O
biological	O
processes	O
and	O
as	O
therapeutic	O
targets	O
(	O
1–5	O
)	O
.	O

The	O
G	O
-	O
quadruplex	O
structure	O
,	O
also	O
known	O
as	O
a	O
G	O
-	O
quartet	O
,	O
is	O
formed	O
by	O
repeated	O
folding	O
of	O
either	O
the	O
single	O
polynucleotide	O
molecule	O
or	O
by	O
association	O
of	O
two	O
or	O
four	O
molecules	O
.	O

The	O
structure	O
consists	O
of	O
stacked	O
G	O
-	O
tetrads	O
,	O
which	O
are	O
square	O
co	O
-	O
planar	O
arrays	O
of	O
four	O
guanine	O
bases	O
each	O
(	O
6	O
)	O
.	O

G	O
-	O
quadruplex	O
is	O
stabilized	O
with	O
cyclic	O
Hoogsteen	O
hydrogen	O
bonding	O
between	O
the	O
four	O
guanines	O
within	O
each	O
tetrad	O
.	O

The	O
present	O
work	O
focuses	O
only	O
on	O
the	O
unimolecular	O
quadruplexes	O
,	O
since	O
it	O
is	O
more	O
likely	O
to	O
be	O
encountered	O
in	O
physiological	O
conditions	O
(	O
7,8	O
)	O
.	O

Guanine	O
-	O
rich	O
sequences	O
capable	O
of	O
forming	O
G	O
-	O
quadruplexes	O
are	O
found	O
in	O
telomeres	O
,	O
promoter	O
regions	O
,	O
transcribed	O
and	O
other	O
biologically	O
important	O
regions	O
of	O
the	O
mammalian	O
genomes	O
.	O

G	O
-	O
quadruplex	O
DNA	O
has	O
been	O
suggested	O
to	O
regulate	O
DNA	O
replication	O
in	O
retinoblastoma	O
susceptibility	O
gene	O
(	O
Rb	O
)	O
region	O
(	O
9	O
)	O
.	O

This	O
structure	O
may	O
control	O
cellular	O
proliferation	O
at	O
telomeric	O
level	O
and	O
by	O
transcriptional	O
regulation	O
of	O
oncogenes	O
like	O
c	O
-	O
myc	O
(	O
2,10,11	O
)	O
and	O
c	O
-	O
kit	O
(	O
12	O
)	O
.	O

Formation	O
of	O
G	O
-	O
quadruplex	O
seems	O
to	O
be	O
regulated	O
through	O
interactions	O
with	O
cellular	O
proteins	O
.	O

While	O
some	O
proteins	O
help	O
stabilize	O
the	O
structure	O
(	O
13	O
)	O
,	O
others	O
are	O
known	O
to	O
resolve	O
it	O
(	O
1,4,14,15	O
)	O
.	O

Proteins	O
and	O
chemicals	O
that	O
stabilize	O
the	O
G	O
-	O
quadruplex	O
structure	O
can	O
inhibit	O
telomerase	O
action	O
and	O
,	O
therefore	O
,	O
are	O
being	O
evaluated	O
as	O
anticancer	O
therapeutic	O
agents	O
(	O
16–20	O
)	O
.	O

Chemical	O
compounds	O
that	O
inhibit	O
G	O
-	O
quadruplex	O
helicase	O
activity	O
may	O
also	O
be	O
capable	O
of	O
regulating	O
cellular	O
proliferation	O
(	O
4	O
)	O
.	O

G	O
-	O
quadruplexes	O
are	O
also	O
being	O
eyed	O
as	O
potential	O
antimicrobial	O
agents	O
due	O
to	O
their	O
ability	O
to	O
transport	O
monovalent	O
anions	O
(	O
21	O
)	O
.	O

G	O
-	O
quadruplex	O
motifs	O
in	O
the	O
RNA	O
have	O
been	O
shown	O
to	O
play	O
significant	O
roles	O
in	O
mRNA	O
turnover	O
(	O
1	O
)	O
,	O
FMRP	O
binding	O
(	O
22	O
)	O
,	O
translation	O
initiation	O
(	O
23	O
)	O
as	O
well	O
as	O
repression	O
(	O
24	O
)	O
.	O

We	O
have	O
shown	O
previously	O
that	O
a	O
G	O
-	O
rich	O
sequence	O
(	O
GRS	O
)	O
can	O
mediate	O
3′	O
end	O
processing	O
of	O
mammalian	O
pre	O
-	O
mRNAs	O
by	O
interacting	O
with	O
DSEF-1	O
/	O
hnRNPH	O
/	O
H′	O
protein	O
(	O
25–27	O
)	O
.	O

Members	O
of	O
the	O
hnRNP	O
H	O
protein	O
family	O
recognize	O
G	O
-	O
rich	O
motifs	O
capable	O
of	O
forming	O
G	O
-	O
quadruplexes	O
and	O
are	O
known	O
to	O
regulate	O
polyadenylation	O
and	O
splicing	O
events	O
in	O
mammalian	O
transcripts	O
(	O
28–30	O
)	O
.	O

Regulated	O
RNA	O
processing	O
is	O
an	O
essential	O
component	O
of	O
differential	O
gene	O
expression	O
which	O
is	O
central	O
to	O
many	O
important	O
biologically	O
processes	O
.	O

More	O
than	O
half	O
of	O
human	B
genes	O
are	O
known	O
to	O
have	O
alternative	O
polyadenylation	O
(	O
31	O
)	O
.	O

Over	O
two	O
-	O
thirds	O
of	O
human	B
genes	O
are	O
thought	O
to	O
undergo	O
alternative	O
splicing	O
(	O
32	O
)	O
.	O

Sequences	O
capable	O
of	O
forming	O
G	O
-	O
quadruplexes	O
found	O
in	O
the	O
vicinity	O
of	O
polyadenylation	O
and	O
splice	O
sites	O
act	O
as	O
regulators	O
by	O
interacting	O
with	O
hnRNP	O
F	O
and	O
H	O
proteins	O
(	O
25–27,30,33	O
)	O
.	O

Whether	O
quadruplex	O
structure	O
directly	O
plays	O
a	O
role	O
in	O
regulating	O
RNA	O
processing	O
events	O
requires	O
investigation	O
.	O

Computational	O
approaches	O
to	O
study	O
G	O
-	O
quadruplexes	O
in	O
the	O
mammalian	O
genomes	O
allow	O
large	O
-	O
scale	O
and	O
detailed	O
analysis	O
of	O
mammalian	O
genes	O
.	O

Although	O
,	O
G	O
-	O
quadruplexes	O
have	O
been	O
surveyed	O
in	O
the	O
human	B
genome	O
with	O
such	O
techniques	O
(	O
34,35	O
)	O
,	O
there	O
are	O
no	O
known	O
user	O
-	O
friendly	O
computational	O
tools	O
easily	O
accessible	O
to	O
the	O
public	O
.	O

We	O
had	O
previously	O
built	O
a	O
database	O
of	O
mapped	O
G	O
-	O
quadruplex	O
sequences	O
in	O
selected	O
alternatively	O
processed	O
human	B
and	O
mouse	B
genes	O
(	O
36	O
)	O
.	O

Our	O
preliminary	O
analysis	O
of	O
the	O
database	O
suggests	O
prevalence	O
of	O
such	O
motifs	O
near	O
alternative	O
splice	O
and	O
poly	O
(	O
A	O
)	O
sites	O
.	O

We	O
have	O
now	O
developed	O
a	O
web	O
-	O
based	O
server	O
,	O
QGRS	O
Mapper	O
,	O
that	O
generates	O
detailed	O
information	O
on	O
composition	O
and	O
distribution	O
of	O
putative	O
quadruplex	O
forming	O
G	O
-	O
rich	O
sequences	O
(	O
QGRS	O
)	O
in	O
any	O
NCBI	O
nucleotide	O
sequence	O
identified	O
or	O
provided	O
by	O
the	O
user	O
.	O

The	O
program	O
is	O
also	O
designed	O
to	O
handle	O
the	O
analysis	O
of	O
mammalian	O
pre	O
-	O
mRNA	O
sequences	O
,	O
including	O
those	O
that	O
are	O
alternatively	O
processed	O
(	O
alternatively	O
spliced	O
or	O
alternatively	O
polyadenylated	O
)	O
.	O

Researchers	O
interested	O
in	O
predicting	O
the	O
ability	O
of	O
a	O
nucleotide	O
sequence	O
to	O
form	O
G	O
-	O
quadruplex	O
structure	O
will	O
find	O
QGRS	O
Mapper	O
to	O
be	O
a	O
user	O
-	O
friendly	O
application	O
that	O
provides	O
many	O
options	O
for	O
analysis	O
.	O

The	O
user	O
can	O
define	O
the	O
minimum	O
number	O
of	O
tetrads	O
,	O
maximum	O
length	O
of	O
the	O
G	O
-	O
quadruplex	O
motif	O
,	O
and	O
size	O
as	O
well	O
as	O
composition	O
of	O
the	O
loops	O
.	O

The	O
program	O
can	O
map	O
unimolecular	O
QGRS	O
in	O
the	O
entire	O
nucleotide	O
sequence	O
provided	O
in	O
the	O
raw	O
or	O
FASTA	O
format	O
by	O
the	O
user	O
.	O

This	O
method	O
can	O
be	O
used	O
for	O
the	O
analysis	O
of	O
genomic	O
sequences	O
,	O
e.g.	O
promoter	O
and	O
telomeric	O
regions	O
,	O
as	O
well	O
as	O
RNA	O
sequences	O
.	O

It	O
is	O
also	O
useful	O
for	O
predicting	O
G	O
-	O
quadruplex	O
structures	O
in	O
oligonucleotides	O
.	O

Alternatively	O
,	O
the	O
program	O
provides	O
options	O
to	O
search	O
the	O
entire	O
NCBI	O
Gene	O
Entrez	O
,	O
RefSeq	O
and	O
GenBank	O
databases	O
in	O
order	O
to	O
retrieve	O
the	O
desired	O
gene	O
/	O
nucleotide	O
sequence	O
entries	O
for	O
analysis	O
of	O
their	O
transcribed	O
regions	O
.	O

Furthermore	O
,	O
QGRS	O
Mapper	O
is	O
a	O
unique	O
tool	O
for	O
mapping	O
G	O
-	O
quadruplex	O
forming	O
sequences	O
in	O
the	O
context	O
of	O
RNA	O
processing	O
sites	O
.	O

This	O
feature	O
is	O
very	O
useful	O
for	O
investigating	O
the	O
functional	O
relevance	O
of	O
G	O
-	O
quadruplex	O
structure	O
,	O
in	O
particular	O
its	O
role	O
in	O
regulating	O
the	O
gene	O
expression	O
by	O
alternative	O
processing	O
.	O

In	O
addition	O
to	O
providing	O
data	O
on	O
composition	O
and	O
locations	O
of	O
QGRS	O
relative	O
to	O
the	O
processing	O
sites	O
in	O
the	O
pre	O
-	O
mRNA	O
sequence	O
,	O
QGRS	O
Mapper	O
offers	O
interactive	O
graphic	O
representation	O
of	O
the	O
data	O
.	O

The	O
user	O
can	O
also	O
use	O
a	O
graphics	O
module	O
to	O
visualize	O
QGRS	O
distribution	O
patterns	O
among	O
all	O
the	O
alternative	O
RNA	O
products	O
of	O
a	O
gene	O
simultaneously	O
on	O
a	O
single	O
screen	O
.	O

METHODS	O
QGRS	O
definition	O
The	O
main	O
goal	O
of	O
the	O
QGRS	O
Mapper	O
program	O
is	O
to	O
predict	O
the	O
presence	O
of	O
QGRS	O
in	O
nucleotide	O
entries	O
.	O

These	O
putative	O
G	O
-	O
quadruplexes	O
are	O
identified	O
using	O
the	O
following	O
motif	O
.	O

GxNy1GxNy2GxNy3Gx	O
Here	O
x	O
=	O
number	O
of	O
guanine	O
tetrads	O
in	O
the	O
G	O
-	O
quadruplex	O
and	O
y1,y2,y3	O
=	O
length	O
of	O
gaps	O
(	O
i.e.	O
the	O
length	O
of	O
the	O
loops	O
connecting	O
the	O
guanine	O
tetrads	O
)	O
.	O

The	O
motif	O
consists	O
of	O
four	O
equal	O
length	O
sets	O
of	O
guanines	O
(	O
which	O
we	O
call	O
G	O
-	O
groups	O
)	O
,	O
separated	O
by	O
arbitrary	O
nucleotide	O
sequences	O
,	O
with	O
the	O
following	O
restrictions	O
.	O

The	O
sequence	O
must	O
contain	O
at	O
least	O
two	O
tetrads	O
(	O
i.e.	O
x	O
≥	O
2	O
)	O
.	O

Although	O
structures	O
with	O
three	O
or	O
more	O
G	O
-	O
tetrads	O
are	O
considered	O
to	O
be	O
more	O
stable	O
,	O
many	O
nucleotide	O
sequences	O
are	O
known	O
to	O
form	O
quadruplexes	O
with	O
two	O
G	O
-	O
tetrads	O
(	O
37,38	O
)	O
.	O

QGRS	O
Mapper	O
is	O
meant	O
to	O
be	O
a	O
flexible	O
and	O
comprehensive	O
tool	O
for	O
investigating	O
G	O
-	O
quadruplexes	O
;	O
hence	O
it	O
considers	O
sequences	O
with	O
two	O
tetrads	O
.	O

By	O
default	O
,	O
only	O
QGRS	O
of	O
maximum	O
length	O
of	O
30	O
bases	O
are	O
considered	O
.	O

However	O
,	O
the	O
program	O
gives	O
the	O
user	O
the	O
option	O
to	O
search	O
for	O
sequences	O
up	O
to	O
45	O
bases	O
.	O

This	O
restriction	O
on	O
the	O
length	O
of	O
the	O
sequences	O
being	O
considered	O
is	O
in	O
agreement	O
with	O
recent	O
literature	O
(	O
34,35	O
)	O
.	O

The	O
maximum	O
length	O
of	O
30	O
bases	O
restricts	O
G	O
-	O
groups	O
to	O
a	O
maximum	O
size	O
of	O
6.The	O
gaps	O
or	O
loops	O
between	O
the	O
G	O
-	O
groups	O
may	O
be	O
arbitrary	O
in	O
composition	O
or	O
length	O
(	O
within	O
the	O
overall	O
restrictions	O
on	O
the	O
length	O
of	O
QGRS	O
)	O
.	O

The	O
program	O
gives	O
the	O
user	O
the	O
option	O
to	O
search	O
for	O
QGRS	O
having	O
loops	O
with	O
a	O
specified	O
length	O
range	O
(	O
e.g.	O
the	O
user	O
can	O
search	O
for	O
QGRS	O
with	O
loops	O
of	O
lengths	O
between	O
1	O
and	O
4	O
)	O
.	O

The	O
user	O
can	O
also	O
specify	O
a	O
string	O
that	O
one	O
or	O
more	O
loops	O
of	O
each	O
QGRS	O
must	O
contain	O
.	O

This	O
string	O
can	O
be	O
given	O
as	O
a	O
regular	O
expression	O
.	O

For	O
example	O
,	O
entering	O
the	O
regular	O
expression	O
'	O
T	O
{	O
3,5	O
}	O
'	O
will	O
search	O
for	O
QGRS	O
having	O
one	O
or	O
more	O
loops	O
that	O
contain	O
three	O
to	O
five	O
consecutive	O
T	O
's	O
.	O

Also	O
,	O
at	O
most	O
one	O
of	O
the	O
gaps	O
is	O
allowed	O
to	O
be	O
of	O
zero	O
length	O
Table	O
1	O
shows	O
some	O
examples	O
of	O
valid	O
QGRS	O
.	O

The	O
guanine	O
groups	O
which	O
form	O
the	O
tetrads	O
are	O
underlined	O
.	O

The	O
first	O
sequence	O
has	O
four	O
tetrads	O
and	O
equal	O
length	O
gaps	O
.	O

This	O
would	O
seem	O
to	O
provide	O
a	O
G	O
-	O
quadruplex	O
that	O
is	O
the	O
most	O
stable	O
of	O
the	O
three	O
sequences	O
.	O

The	O
second	O
sequence	O
is	O
notable	O
for	O
the	O
significant	O
differences	O
in	O
the	O
size	O
of	O
its	O
loops	O
.	O

The	O
third	O
sequence	O
has	O
two	O
tetrads	O
,	O
even	O
though	O
three	O
of	O
the	O
G	O
-	O
groups	O
could	O
have	O
included	O
another	O
G	O
(	O
since	O
all	O
G	O
-	O
groups	O
must	O
be	O
equal	O
in	O
size	O
)	O
.	O

G	O
-	O
scores	O
We	O
have	O
devised	O
a	O
scoring	O
system	O
that	O
evaluates	O
a	O
QGRS	O
for	O
its	O
likelihood	O
to	O
form	O
a	O
stable	O
G	O
-	O
quadruplex	O
.	O

Higher	O
scoring	O
sequences	O
will	O
make	O
better	O
candidates	O
for	O
G	O
-	O
quadruplexes	O
.	O

The	O
scoring	O
method	O
uses	O
the	O
following	O
principles	O
which	O
are	O
based	O
on	O
previous	O
studies	O
(	O
34,35,39–42	O
)	O
.	O

Shorter	O
loops	O
are	O
more	O
common	O
than	O
longer	O
loops	O
.	O

G	O
-	O
quadruplexes	O
tend	O
to	O
have	O
loops	O
roughly	O
equal	O
in	O
size	O
.	O

The	O
greater	O
the	O
number	O
of	O
guanine	O
tetrads	O
,	O
the	O
more	O
stable	O
the	O
quadruplex	O
.	O

The	O
computed	O
G	O
-	O
scores	O
are	O
dependent	O
on	O
the	O
user	O
selected	O
maximum	O
QGRS	O
length	O
.	O

The	O
highest	O
possible	O
G	O
-	O
score	O
,	O
using	O
the	O
default	O
maximum	O
QGRS	O
length	O
of	O
30	O
,	O
is	O
105	O
.	O

Here	O
is	O
a	O
sequence	O
attaining	O
that	O
score	O
:	O
GGGGGGTGGGGGGTGGGGGGTGGGGGG	O
.	O

Eliminating	O
QGRS	O
overlaps	O
Two	O
QGRS	O
are	O
said	O
to	O
overlap	O
if	O
their	O
positions	O
in	O
the	O
nucleotide	O
sequence	O
overlap	O
.	O

QGRS	O
Mapper	O
will	O
start	O
with	O
a	O
nucleotide	O
sequence	O
,	O
find	O
all	O
QGRS	O
occurring	O
in	O
the	O
sequence	O
and	O
then	O
produce	O
a	O
non	O
-	O
overlapping	O
set	O
of	O
QGRS	O
.	O

Overlaps	O
are	O
eliminated	O
by	O
selecting	O
the	O
higher	O
scoring	O
QGRS	O
.	O

In	O
the	O
non	O
-	O
overlapping	O
view	O
,	O
only	O
this	O
sequence	O
will	O
be	O
displayed	O
,	O
although	O
the	O
user	O
can	O
request	O
that	O
all	O
overlapping	O
sequences	O
be	O
displayed	O
.	O

Please	O
see	O
supplementary	O
materials	O
at	O
NAR	O
online	O
for	O
more	O
details	O
on	O
the	O
elimination	O
of	O
overlapping	O
QGRS	O
.	O

FEATURES	O
Design	O
and	O
implementation	O
QGRS	O
Mapper	O
is	O
a	O
web	O
-	O
based	O
program	O
,	O
written	O
in	O
PHP	O
,	O
with	O
Java	O
being	O
used	O
for	O
some	O
of	O
its	O
graphics	O
.	O

The	O
program	O
takes	O
a	O
nucleotide	O
sequence	O
from	O
NCBI	O
(	O
or	O
as	O
provided	O
by	O
the	O
user	O
)	O
and	O
analyzes	O
it	O
for	O
the	O
presence	O
of	O
putative	O
G	O
-	O
quadruplexes	O
.	O

The	O
structure	O
of	O
QGRS	O
Mapper	O
is	O
summarized	O
in	O
Table	O
2	O
.	O

Search	O
and	O
analysis	O
QGRS	O
Mapper	O
allows	O
the	O
user	O
to	O
search	O
for	O
putative	O
G	O
-	O
quadruplexes	O
in	O
a	O
variety	O
of	O
ways	O
.	O

It	O
is	O
possible	O
to	O
enter	O
a	O
nucleotide	O
sequence	O
in	O
raw	O
or	O
FASTA	O
format	O
for	O
analysis	O
.	O

One	O
can	O
search	O
and	O
analyze	O
gene	O
sequences	O
by	O
Gene	O
ID	O
,	O
Gene	O
name	O
or	O
symbol	O
,	O
accession	O
number	O
or	O
GI	O
number	O
for	O
an	O
NCBI	O
nucleotide	O
sequence	O
entry	O
.	O

The	O
user	O
can	O
opt	O
to	O
change	O
the	O
maximum	O
length	O
of	O
QGRS	O
that	O
will	O
be	O
searched	O
for	O
(	O
the	O
default	O
maximum	O
length	O
being	O
30	O
)	O
and	O
change	O
the	O
minimum	O
sized	O
G	O
-	O
group	O
(	O
which	O
is	O
two	O
by	O
default	O
)	O
.	O

Also	O
,	O
the	O
user	O
can	O
specify	O
that	O
the	O
loops	O
in	O
the	O
QGRS	O
fall	O
within	O
a	O
given	O
size	O
range	O
and	O
that	O
one	O
or	O
more	O
loops	O
of	O
the	O
QGRS	O
contain	O
a	O
given	O
string	O
(	O
for	O
which	O
the	O
user	O
may	O
enter	O
a	O
regular	O
expression	O
)	O
.	O

The	O
web	O
page	O
for	O
QGRS	O
analysis	O
can	O
be	O
seen	O
in	O
Figure	O
1	O
.	O

After	O
entering	O
a	O
sequence	O
in	O
raw	O
or	O
FASTA	O
format	O
,	O
QGRS	O
Mapper	O
will	O
search	O
the	O
sequence	O
for	O
occurrences	O
of	O
QGRS	O
.	O

The	O
user	O
may	O
enter	O
any	O
combination	O
of	O
the	O
letters	O
A	O
,	O
C	O
,	O
T	O
,	O
G	O
,	O
U	O
,	O
N.	O
The	O
Gene	O
ID	O
field	O
allows	O
the	O
user	O
to	O
search	O
the	O
NCBI	O
Entrez	O
Gene	O
database	O
.	O

QGRS	O
Mapper	O
will	O
connect	O
to	O
NCBI	O
,	O
download	O
and	O
parse	O
the	O
gene	O
entry	O
,	O
and	O
then	O
analyze	O
the	O
transcribed	O
region	O
of	O
its	O
nucleotide	O
sequence	O
for	O
the	O
presence	O
of	O
QGRS	O
.	O

For	O
example	O
,	O
entering	O
the	O
gene	O
ID	O
403437	O
results	O
in	O
downloading	O
the	O
Brca1	O
gene	O
sequence	O
for	O
Canis	B
familiaris	I
.	O

Using	O
the	O
default	O
QGRS	O
search	O
parameters	O
,	O
QGRS	O
Mapper	O
finds	O
156	O
non	O
-	O
overlapping	O
QGRS	O
and	O
3394	O
overlapping	O
QGRS	O
in	O
the	O
transcribed	O
region	O
of	O
this	O
gene	O
.	O

The	O
Gene	O
Name	O
or	O
Gene	O
Symbol	O
field	O
also	O
allows	O
the	O
user	O
to	O
search	O
the	O
NCBI	O
databases	O
for	O
all	O
such	O
genes	O
.	O

Entering	O
the	O
gene	O
name	O
Bcl2	O
results	O
in	O
nine	O
different	O
hits	O
which	O
are	O
displayed	O
in	O
Table	O
3	O
.	O

All	O
nine	O
of	O
these	O
entries	O
can	O
be	O
analyzed	O
for	O
the	O
occurrence	O
of	O
QGRS	O
.	O

Clicking	O
on	O
the	O
Gene	O
ID	O
takes	O
the	O
user	O
to	O
the	O
respective	O
Entrez	O
Gene	O
entry	O
.	O

Clicking	O
on	O
the	O
last	O
column	O
initiates	O
analysis	O
of	O
the	O
selection	O
by	O
QGRS	O
Mapper	O
.	O

Similarly	O
,	O
the	O
user	O
can	O
also	O
enter	O
an	O
NCBI	O
accession	O
number	O
to	O
search	O
for	O
gene	O
sequences	O
.	O

For	O
example	O
,	O
searching	O
the	O
accession	O
number	O
AF312033	O
results	O
in	O
12	O
hits	O
being	O
displayed	O
for	O
this	O
GenBank	O
nucleotide	O
sequence	O
entry	O
.	O

The	O
search	O
phase	O
of	O
the	O
program	O
is	O
followed	O
by	O
an	O
analysis	O
of	O
the	O
QGRS	O
contained	O
in	O
the	O
query	O
sequence	O
.	O

In	O
this	O
phase	O
of	O
QGRS	O
Mapper	O
,	O
the	O
sequence	O
data	O
downloaded	O
previously	O
is	O
analyzed	O
to	O
identify	O
and	O
map	O
all	O
QGRS	O
relative	O
to	O
locations	O
such	O
as	O
splice	O
sites	O
in	O
exons	O
/	O
introns	O
,	O
and	O
poly	O
(	O
A	O
)	O
site	O
(	O
if	O
these	O
locations	O
are	O
known	O
)	O
.	O

Furthermore	O
the	O
QGRS	O
are	O
scored	O
by	O
the	O
method	O
described	O
above	O
.	O

The	O
computed	O
G	O
-	O
score	O
is	O
used	O
to	O
eliminate	O
overlapping	O
QGRS	O
.	O

At	O
times	O
,	O
QGRS	O
Mapper	O
must	O
analyze	O
a	O
considerable	O
amount	O
of	O
data	O
.	O

For	O
example	O
,	O
the	O
mouse	B
version	O
of	O
the	O
gene	O
PTPRU	O
,	O
which	O
is	O
69822	O
bases	O
long	O
,	O
contains	O
94681	O
QGRS	O
of	O
length	O
up	O
to	O
45	O
bases	O
.	O

QGRS	O
Mapper	O
will	O
find	O
,	O
analyze	O
and	O
map	O
all	O
of	O
these	O
sequences	O
.	O

During	O
this	O
analysis	O
a	O
message	O
is	O
displayed	O
indicating	O
the	O
estimated	O
time	O
left	O
to	O
completion	O
.	O

QGRS	O
Mapper	O
output	O
After	O
the	O
analysis	O
of	O
overlaps	O
is	O
completed	O
,	O
QGRS	O
Mapper	O
displays	O
a	O
summary	O
of	O
its	O
findings	O
,	O
in	O
the	O
Gene	O
View	O
.	O

This	O
summary	O
includes	O
basic	O
gene	O
information	O
such	O
as	O
the	O
gene	O
ID	O
,	O
gene	O
symbol	O
,	O
gene	O
name	O
,	O
a	O
link	O
to	O
the	O
NCBI	O
entry	O
,	O
organism	O
name	O
,	O
chromosome	O
number	O
and	O
number	O
of	O
products	O
and	O
poly	O
(	O
A	O
)	O
signals	O
.	O

Information	O
is	O
also	O
given	O
for	O
each	O
product	O
,	O
such	O
as	O
the	O
number	O
of	O
exons	O
and	O
introns	O
,	O
number	O
of	O
QGRS	O
(	O
non	O
-	O
overlapping	O
and	O
overlapping	O
)	O
,	O
number	O
of	O
QGRS	O
found	O
near	O
RNA	O
processing	O
sites	O
,	O
and	O
a	O
visual	O
map	O
of	O
the	O
product	O
.	O

As	O
an	O
example	O
,	O
the	O
Gene	O
View	O
for	O
the	O
human	B
GREB1	O
is	O
displayed	O
in	O
Figure	O
2	O
,	O
showing	O
the	O
table	O
of	O
gene	O
information	O
and	O
product	O
information	O
for	O
the	O
first	O
product	O
(	O
the	O
output	O
for	O
all	O
products	O
may	O
be	O
seen	O
in	O
the	O
supplementary	O
material	O
)	O
.	O

At	O
this	O
stage	O
in	O
the	O
analysis	O
the	O
user	O
can	O
choose	O
among	O
three	O
further	O
displays	O
:	O
'	O
Data	O
View	O
'	O
,	O
'	O
Data	O
View	O
(	O
with	O
overlaps	O
)	O
'	O
and	O
'	O
Graphics	O
View	O
'	O
.	O

This	O
can	O
be	O
done	O
for	O
the	O
entire	O
gene	O
or	O
for	O
any	O
particular	O
product	O
.	O

In	O
the	O
Data	O
View	O
,	O
a	O
table	O
is	O
displayed	O
showing	O
information	O
for	O
each	O
of	O
the	O
set	O
of	O
non	O
-	O
overlapping	O
QGRS	O
.	O

This	O
table	O
displays	O
the	O
position	O
of	O
the	O
QGRS	O
,	O
which	O
exon	O
/	O
intron	O
it	O
appears	O
in	O
,	O
its	O
distance	O
from	O
3′	O
and	O
5′	O
splice	O
sites	O
,	O
the	O
QGRS	O
sequence	O
(	O
with	O
each	O
G	O
-	O
group	O
underlined	O
)	O
and	O
the	O
corresponding	O
G	O
-	O
score	O
.	O

Similar	O
display	O
is	O
also	O
shown	O
for	O
each	O
QGRS	O
mapped	O
to	O
poly	O
(	O
A	O
)	O
region	O
in	O
the	O
product	O
.	O

If	O
the	O
user	O
requests	O
the	O
Data	O
View	O
for	O
the	O
entire	O
gene	O
,	O
then	O
the	O
QGRS	O
information	O
is	O
shown	O
for	O
each	O
product	O
.	O

The	O
'	O
Data	O
View	O
(	O
with	O
overlaps	O
)	O
'	O
gives	O
the	O
same	O
information	O
but	O
shows	O
the	O
locations	O
of	O
all	O
QGRS	O
.	O

Figure	O
3	O
shows	O
the	O
Data	O
View	O
for	O
product	O
1	O
of	O
the	O
GREB1	O
gene	O
.	O

The	O
user	O
can	O
also	O
choose	O
the	O
Graphics	O
View	O
to	O
give	O
a	O
visual	O
display	O
of	O
the	O
location	O
of	O
QGRS	O
.	O

This	O
allows	O
the	O
user	O
to	O
see	O
the	O
location	O
of	O
QGRS	O
relative	O
to	O
exons	O
and	O
introns	O
(	O
if	O
that	O
information	O
is	O
available	O
)	O
.	O

The	O
Graphics	O
View	O
has	O
the	O
following	O
components	O
.	O

A	O
graphic	O
display	O
of	O
the	O
entire	O
gene	O
(	O
showing	O
the	O
location	O
of	O
the	O
exons	O
)	O
.	O

This	O
display	O
includes	O
a	O
sliding	O
window	O
that	O
can	O
be	O
used	O
to	O
focus	O
on	O
any	O
particular	O
segment	O
of	O
the	O
gene	O
.	O

This	O
window	O
may	O
be	O
dragged	O
to	O
the	O
left	O
or	O
right	O
to	O
change	O
position	O
within	O
the	O
gene	O
.	O

A	O
magnified	O
view	O
of	O
the	O
fragment	O
of	O
the	O
gene	O
within	O
the	O
sliding	O
window	O
.	O

A	O
graph	O
showing	O
the	O
location	O
of	O
QGRS	O
within	O
the	O
fragment	O
,	O
with	O
each	O
QGRS	O
being	O
displayed	O
by	O
a	O
bar	O
whose	O
height	O
represents	O
its	O
G	O
-	O
score	O
.	O

A	O
vertical	O
slider	O
that	O
allows	O
the	O
user	O
to	O
change	O
the	O
size	O
of	O
the	O
window	O
.	O

This	O
allows	O
the	O
user	O
to	O
zoom	O
in	O
or	O
out	O
on	O
any	O
part	O
of	O
the	O
gene	O
.	O

The	O
sliding	O
window	O
on	O
the	O
gene	O
expands	O
or	O
contracts	O
as	O
one	O
zooms	O
in	O
or	O
out	O
.	O

It	O
is	O
possible	O
to	O
see	O
the	O
nucleotide	O
sequence	O
of	O
the	O
product	O
at	O
maximum	O
zoom	O
levels	O
.	O

The	O
Graphics	O
View	O
for	O
the	O
entire	O
gene	O
shows	O
the	O
G	O
-	O
score	O
graph	O
together	O
with	O
an	O
exon	O
/	O
intron	O
map	O
for	O
each	O
product	O
.	O

This	O
allows	O
the	O
user	O
to	O
visually	O
compare	O
the	O
location	O
of	O
QGRS	O
for	O
each	O
product	O
relative	O
to	O
that	O
of	O
splice	O
sites	O
.	O

The	O
Graphics	O
View	O
for	O
the	O
first	O
product	O
of	O
the	O
GREB1	O
gene	O
is	O
represented	O
in	O
Figure	O
4	O
.	O

The	O
Graphics	O
View	O
for	O
the	O
entire	O
GREB1	O
gene	O
may	O
be	O
seen	O
in	O
the	O
Supplementary	O
Data	O
.	O

CONCLUSIONS	O
QGRS	O
Mapper	O
is	O
a	O
user	O
-	O
friendly	O
web	O
-	O
based	O
server	O
that	O
provides	O
computational	O
tools	O
for	O
prediction	O
of	O
Quadruplex	O
forming	O
G	O
-	O
rich	O
sequences	O
in	O
the	O
nucleotide	O
sequences	O
identified	O
or	O
provided	O
by	O
the	O
user	O
.	O

The	O
program	O
offers	O
many	O
options	O
,	O
including	O
user	O
-	O
defined	O
composition	O
of	O
the	O
quadruplex	O
.	O

It	O
can	O
analyze	O
DNA	O
or	O
RNA	O
sequence	O
provided	O
by	O
the	O
user	O
in	O
the	O
raw	O
or	O
FASTA	O
format	O
.	O

The	O
application	O
also	O
provides	O
tools	O
for	O
searching	O
and	O
retrieving	O
gene	O
/	O
nucleotide	O
entries	O
from	O
a	O
variety	O
of	O
NCBI	O
databases	O
.	O

There	O
are	O
several	O
options	O
for	O
data	O
output	O
format	O
,	O
including	O
an	O
interactive	O
graphic	O
module	O
.	O

Researchers	O
interested	O
in	O
evaluating	O
the	O
ability	O
of	O
nucleotide	O
sequences	O
to	O
form	O
unimolecular	O
G	O
-	O
quadruplexes	O
will	O
find	O
QGRS	O
Mapper	O
to	O
be	O
very	O
useful	O
.	O

Owing	O
to	O
the	O
flexible	O
and	O
comprehensive	O
nature	O
of	O
the	O
design	O
,	O
it	O
is	O
expected	O
to	O
serve	O
a	O
variety	O
of	O
scientists	O
.	O

The	O
application	O
will	O
be	O
especially	O
attractive	O
to	O
individuals	O
interested	O
in	O
exploring	O
the	O
role	O
of	O
G	O
-	O
quadruplexes	O
in	O
regulated	O
RNA	O
processing	O
.	O

We	O
are	O
using	O
the	O
server	O
to	O
perform	O
a	O
large	O
-	O
scale	O
analysis	O
of	O
alternatively	O
processed	O
mammalian	O
transcripts	O
.	O

We	O
are	O
particularly	O
interested	O
in	O
studying	O
the	O
composition	O
and	O
distribution	O
patterns	O
of	O
G	O
-	O
quadruplexes	O
in	O
the	O
transcribed	O
regions	O
of	O
mammalian	O
genes	O
.	O

SUPPLEMENTARY	O
DATA	O
Supplementary	O
Data	O
are	O
available	O
at	O
NAR	O
online	O
.	O

Travel	O
-	O
Related	O
Venous	O
Thrombosis	O
:	O
Results	O
from	O
a	O
Large	O
Population	O
-	O
Based	O
Case	O
Control	O
Study	O
(	O
MEGA	O
Study	O
)	O
Abstract	O
Background	O
Recent	O
studies	O
have	O
indicated	O
an	O
increased	O
risk	O
of	O
venous	O
thrombosis	O
after	O
air	O
travel	O
.	O

Nevertheless	O
,	O
questions	O
on	O
the	O
magnitude	O
of	O
risk	O
,	O
the	O
underlying	O
mechanism	O
,	O
and	O
modifying	O
factors	O
remain	O
unanswered	O
.	O

Methods	O
and	O
Findings	O
We	O
studied	O
the	O
effect	O
of	O
various	O
modes	O
and	O
duration	O
of	O
travel	O
on	O
the	O
risk	O
of	O
venous	O
thrombosis	O
in	O
a	O
large	O
ongoing	O
case	O
-	O
control	O
study	O
on	O
risk	O
factors	O
for	O
venous	O
thrombosis	O
in	O
an	O
unselected	O
population	O
(	O
MEGA	O
study	O
)	O
.	O

We	O
also	O
assessed	O
the	O
combined	O
effect	O
of	O
travel	O
and	O
prothrombotic	O
mutations	O
,	O
body	O
mass	O
index	O
,	O
height	O
,	O
and	O
oral	O
contraceptive	O
use	O
.	O

Since	O
March	O
1999	O
,	O
consecutive	O
patients	O
younger	O
than	O
70	O
y	O
with	O
a	O
first	O
venous	O
thrombosis	O
have	O
been	O
invited	O
to	O
participate	O
in	O
the	O
study	O
,	O
with	O
their	O
partners	O
serving	O
as	O
matched	O
control	O
individuals	O
.	O

Information	O
has	O
been	O
collected	O
on	O
acquired	O
and	O
genetic	O
risk	O
factors	O
for	O
venous	O
thrombosis	O
.	O

Of	O
1,906	O
patients	O
,	O
233	O
had	O
traveled	O
for	O
more	O
than	O
4	O
h	O
in	O
the	O
8	O
wk	O
preceding	O
the	O
event	O
.	O

Traveling	O
in	O
general	O
was	O
found	O
to	O
increase	O
the	O
risk	O
of	O
venous	O
thrombosis	O
2-fold	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
2.1	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
1.5–3.0	O
)	O
.	O

The	O
risk	O
of	O
flying	O
was	O
similar	O
to	O
the	O
risks	O
of	O
traveling	O
by	O
car	O
,	O
bus	O
,	O
or	O
train	O
.	O

The	O
risk	O
was	O
highest	O
in	O
the	O
first	O
week	O
after	O
traveling	O
.	O

Travel	O
by	O
car	O
,	O
bus	O
,	O
or	O
train	O
led	O
to	O
a	O
high	O
relative	O
risk	O
of	O
thrombosis	O
in	O
individuals	O
with	O
factor	O
V	O
Leiden	O
(	O
OR	O
8.1	O
;	O
95	O
%	O
CI	O
2.7–24.7	O
)	O
,	O
in	O
those	O
who	O
had	O
a	O
body	O
mass	O
index	O
of	O
more	O
than	O
30	O
kg	O
/	O
m2	O
(	O
OR	O
9.9	O
;	O
95	O
%	O
CI	O
3.6–27.6	O
)	O
,	O
in	O
those	O
who	O
were	O
more	O
than	O
1.90	O
m	O
tall	O
(	O
OR	O
4.7	O
;	O
95	O
%	O
CI	O
1.4–15.4	O
)	O
,	O
and	O
in	O
those	O
who	O
used	O
oral	O
contraceptives	O
(	O
estimated	O
OR	O
>	O
20	O
)	O
.	O

For	O
air	O
travel	O
these	O
synergistic	O
findings	O
were	O
more	O
apparent	O
,	O
while	O
people	O
shorter	O
than	O
1.60	O
m	O
had	O
an	O
increased	O
risk	O
of	O
thrombosis	O
after	O
air	O
travel	O
(	O
OR	O
4.9	O
;	O
95	O
%	O
CI	O
0.9–25.6	O
)	O
as	O
well	O
.	O

Conclusions	O
The	O
risk	O
of	O
venous	O
thrombosis	O
after	O
travel	O
is	O
moderately	O
increased	O
for	O
all	O
modes	O
of	O
travel	O
.	O

Subgroups	O
exist	O
in	O
which	O
the	O
risk	O
is	O
highly	O
increased	O
.	O

Background	O
.	O

Recently	O
there	O
has	O
been	O
increasing	O
concern	O
that	O
blood	O
clots	O
(	O
thromboses	O
)	O
in	O
the	O
leg	O
or	O
lungs	O
occur	O
with	O
greater	O
frequency	O
after	O
air	O
travel	O
.	O

Several	O
theories	O
have	O
been	O
put	O
forward	O
to	O
explain	O
why	O
this	O
increase	O
might	O
happen	O
,	O
including	O
the	O
fact	O
that	O
air	O
passengers	O
tend	O
to	O
not	O
move	O
around	O
much	O
,	O
or	O
possibly	O
that	O
reduced	O
amounts	O
of	O
oxygen	O
in	O
the	O
blood	O
make	O
the	O
blood	O
more	O
likely	O
to	O
clot	O
.	O

Understanding	O
what	O
causes	O
such	O
clots	O
is	O
important	O
as	O
it	O
would	O
help	O
us	O
come	O
up	O
with	O
suggestions	O
of	O
ways	O
to	O
prevent	O
them	O
.	O

Why	O
Was	O
This	O
Study	O
Done	O
?	O

It	O
is	O
not	O
possible	O
to	O
test	O
in	O
a	O
controlled	O
trial	O
whether	O
travel	O
causes	O
an	O
increase	O
in	O
blood	O
clots	O
,	O
so	O
the	O
next	O
best	O
way	O
of	O
studying	O
this	O
problem	O
is	O
to	O
do	O
a	O
case	O
-	O
control	O
study	O
,	O
in	O
which	O
people	O
with	O
blood	O
clots	O
(	O
cases	O
)	O
are	O
compared	O
with	O
similar	O
people	O
who	O
do	O
n't	O
have	O
a	O
blood	O
clot	O
(	O
controls	O
—	O
in	O
this	O
case	O
,	O
the	O
partners	O
of	O
the	O
cases	O
)	O
,	O
and	O
the	O
differences	O
in	O
a	O
number	O
of	O
contributing	O
factors	O
are	O
assessed	O
.	O

What	O
Did	O
the	O
Researchers	O
Do	O
and	O
Find	O
?	O

Since	O
1999	O
,	O
the	O
MEGA	O
(	O
Multiple	O
Environmental	O
and	O
Genetic	O
Assessment	O
of	O
Risk	O
Factors	O
for	O
Venous	O
Thrombosis	O
)	O
study	O
has	O
aimed	O
to	O
identify	O
all	O
people	O
in	O
an	O
area	O
of	O
the	O
Netherlands	O
who	O
develop	O
a	O
blood	O
clot	O
for	O
the	O
first	O
time	O
,	O
by	O
seeking	O
out	O
people	O
who	O
receive	O
treatment	O
for	O
blood	O
clots	O
.	O

At	O
the	O
time	O
of	O
this	O
report	O
,	O
1,906	O
people	O
with	O
clots	O
had	O
been	O
found	O
;	O
of	O
these	O
,	O
233	O
had	O
traveled	O
for	O
more	O
than	O
four	O
hours	O
in	O
the	O
eight	O
weeks	O
preceding	O
the	O
event	O
.	O

Traveling	O
in	O
general	O
was	O
found	O
to	O
increase	O
the	O
risk	O
of	O
clots	O
two	O
-	O
fold	O
,	O
and	O
the	O
risk	O
was	O
highest	O
in	O
the	O
week	O
after	O
traveling	O
.	O

The	O
risk	O
of	O
flying	O
was	O
similar	O
to	O
the	O
risk	O
of	O
traveling	O
by	O
car	O
,	O
bus	O
,	O
or	O
train	O
,	O
and	O
was	O
highest	O
in	O
the	O
first	O
week	O
after	O
traveling	O
.	O

Certain	O
other	O
factors	O
increased	O
the	O
risk	O
of	O
a	O
blood	O
clot	O
even	O
more	O
,	O
such	O
as	O
having	O
a	O
particular	O
mutation	O
(	O
known	O
as	O
factor	O
V	O
Leiden	O
)	O
in	O
a	O
gene	O
involved	O
in	O
blood	O
clotting	O
,	O
having	O
a	O
body	O
mass	O
index	O
of	O
more	O
than	O
30	O
kg	O
/	O
m2	O
(	O
over	O
30	O
kg	O
/	O
m2	O
is	O
defined	O
as	O
being	O
obese	O
)	O
,	O
being	O
more	O
than	O
1.90	O
meters	O
tall	O
,	O
and	O
using	O
oral	O
contraceptives	O
.	O

All	O
these	O
factors	O
made	O
the	O
risk	O
of	O
clots	O
especially	O
after	O
air	O
travel	O
worse	O
;	O
in	O
addition	O
,	O
people	O
shorter	O
than	O
1.60	O
meters	O
also	O
had	O
an	O
increased	O
risk	O
of	O
thrombosis	O
after	O
air	O
travel	O
.	O

However	O
,	O
it	O
should	O
be	O
borne	O
in	O
mind	O
that	O
the	O
number	O
of	O
cases	O
in	O
each	O
of	O
these	O
various	O
groups	O
was	O
quite	O
small	O
,	O
and	O
the	O
overall	O
risk	O
of	O
getting	O
a	O
thrombosis	O
is	O
still	O
low	O
.	O

What	O
Do	O
These	O
Findings	O
Mean	O
?	O

Since	O
the	O
risks	O
of	O
thrombosis	O
are	O
increased	O
for	O
all	O
types	O
of	O
long	O
travel	O
,	O
it	O
seems	O
that	O
the	O
main	O
factor	O
causing	O
the	O
thrombosis	O
is	O
immobility	O
.	O

However	O
,	O
since	O
the	O
risk	O
is	O
even	O
higher	O
for	O
air	O
travel	O
,	O
the	O
relative	O
lack	O
of	O
oxygen	O
may	O
also	O
play	O
a	O
part	O
.	O

One	O
interesting	O
aspect	O
of	O
this	O
study	O
is	O
that	O
the	O
researchers	O
used	O
partners	O
as	O
controls	O
;	O
in	O
order	O
to	O
be	O
sure	O
that	O
doing	O
this	O
did	O
not	O
make	O
the	O
results	O
invalid	O
,	O
the	O
researchers	O
had	O
to	O
carefully	O
adjust	O
for	O
differences	O
between	O
the	O
cases	O
and	O
controls	O
,	O
such	O
as	O
the	O
fact	O
that	O
partners	O
were	O
generally	O
of	O
the	O
opposite	O
sex	O
.	O

In	O
a	O
related	O
Perspective	O
(	O
DOI	O
:	O
10.1371	O
/	O
journal.pmed.0030300	O
)	O
,	O
Kenneth	O
Rothman	O
discusses	O
the	O
study	O
further	O
.	O

Additional	O
Information	O
.	O

Please	O
access	O
these	O
Web	O
sites	O
via	O
the	O
online	O
version	O
of	O
this	O
summary	O
at	O
http://dx.doi.org/10.1371/journal.pmed.0030307	O
.	O

Introduction	O
Interest	O
in	O
the	O
role	O
of	O
air	O
travel	O
in	O
the	O
pathogenesis	O
of	O
venous	O
thrombosis	O
has	O
heightened	O
in	O
the	O
past	O
5	O
y	O
[	O
1–5	O
]	O
.	O

Venous	O
thrombosis	O
was	O
first	O
linked	O
to	O
air	O
travel	O
in	O
1954	O
[	O
6	O
]	O
,	O
and	O
as	O
air	O
travel	O
has	O
become	O
more	O
and	O
more	O
common	O
,	O
many	O
case	O
reports	O
and	O
case	O
series	O
have	O
been	O
published	O
since	O
.	O

Several	O
clinical	O
studies	O
have	O
shown	O
an	O
association	O
between	O
air	O
travel	O
and	O
the	O
risk	O
of	O
venous	O
thrombosis	O
.	O

In	O
a	O
series	O
of	O
individuals	O
who	O
died	O
suddenly	O
at	O
Heathrow	O
Airport	O
,	O
death	O
occurred	O
far	O
more	O
often	O
in	O
the	O
arrival	O
than	O
in	O
the	O
departure	O
area	O
[	O
7	O
]	O
.	O

Two	O
similar	O
studies	O
described	O
a	O
""""	O
dose	O
-	O
response	O
""""	O
relation	O
:	O
the	O
risk	O
of	O
pulmonary	O
embolism	O
in	O
air	O
travelers	O
increased	O
with	O
the	O
distance	O
traveled	O
[	O
5,8	O
]	O
.	O

A	O
number	O
of	O
case	O
-	O
control	O
studies	O
,	O
however	O
,	O
have	O
shown	O
conflicting	O
results	O
[	O
9–11	O
]	O
.	O

More	O
recently	O
,	O
a	O
2-fold	O
increased	O
risk	O
in	O
patients	O
who	O
had	O
traveled	O
by	O
air	O
was	O
described	O
in	O
a	O
case	O
-	O
control	O
study	O
among	O
210	O
patients	O
and	O
210	O
controls	O
[	O
3	O
]	O
.	O

A	O
case	O
-	O
crossover	O
study	O
based	O
on	O
record	O
linking	O
in	O
Australia	O
described	O
a	O
4-fold	O
increased	O
risk	O
of	O
venous	O
thrombosis	O
in	O
the	O
first	O
2	O
wk	O
after	O
a	O
long	O
-	O
haul	O
flight	O
[	O
1	O
]	O
.	O

In	O
terms	O
of	O
absolute	O
risk	O
,	O
two	O
studies	O
found	O
similar	O
results	O
:	O
one	O
performed	O
in	O
New	O
Zealand	O
found	O
a	O
frequency	O
of	O
1	O
%	O
of	O
venous	O
thrombosis	O
in	O
878	O
individuals	O
who	O
had	O
traveled	O
by	O
air	O
for	O
at	O
least	O
10	O
h	O
[	O
2	O
]	O
,	O
and	O
a	O
German	O
study	O
found	O
venous	O
thrombotic	O
events	O
in	O
2.8	O
%	O
of	O
964	O
individuals	O
who	O
had	O
traveled	O
for	O
more	O
than	O
8	O
h	O
in	O
an	O
airplane	O
,	O
as	O
compared	O
to	O
1	O
%	O
in	O
1,213	O
controls	O
[	O
4	O
]	O
.	O

The	O
events	O
in	O
both	O
studies	O
were	O
mostly	O
asymptomatic	O
.	O

The	O
available	O
evidence	O
suggests	O
that	O
the	O
overall	O
risk	O
of	O
venous	O
thrombosis	O
is	O
moderately	O
increased	O
after	O
air	O
travel	O
.	O

Nevertheless	O
,	O
many	O
questions	O
remain	O
unanswered	O
:	O
the	O
exact	O
underlying	O
mechanism	O
is	O
still	O
unknown	O
,	O
and	O
,	O
related	O
to	O
this	O
,	O
it	O
is	O
not	O
clear	O
whether	O
the	O
risk	O
is	O
increased	O
after	O
air	O
travel	O
only	O
or	O
after	O
long	O
-	O
distance	O
travel	O
in	O
general	O
.	O

Furthermore	O
,	O
the	O
effect	O
of	O
the	O
combination	O
of	O
other	O
risk	O
factors	O
for	O
venous	O
thrombosis	O
and	O
travel	O
has	O
not	O
yet	O
been	O
systematically	O
studied	O
,	O
with	O
the	O
exception	O
of	O
a	O
study	O
by	O
Martinelli	O
et	O
al.	O
,	O
who	O
found	O
an	O
additionally	O
increased	O
risk	O
in	O
patients	O
with	O
thrombophilia	O
and	O
patients	O
who	O
used	O
oral	O
contraceptives	O
[	O
3	O
]	O
.	O

The	O
Multiple	O
Environmental	O
and	O
Genetic	O
Assessment	O
(	O
MEGA	O
)	O
study	O
of	O
risk	O
factors	O
for	O
venous	O
thrombosis	O
is	O
a	O
large	O
ongoing	O
case	O
-	O
control	O
study	O
aimed	O
at	O
assessing	O
the	O
combined	O
effect	O
of	O
genetic	O
and	O
acquired	O
risk	O
factors	O
for	O
venous	O
thrombosis	O
.	O

Cases	O
and	O
control	O
individuals	O
are	O
questioned	O
about	O
—	O
among	O
many	O
other	O
items	O
—	O
travel	O
that	O
occurred	O
shortly	O
before	O
the	O
event	O
.	O

This	O
provides	O
an	O
opportunity	O
to	O
assess	O
the	O
effect	O
of	O
travel	O
on	O
the	O
risk	O
of	O
thrombosis	O
in	O
an	O
unselected	O
population	O
,	O
as	O
well	O
as	O
the	O
effect	O
of	O
the	O
combination	O
of	O
travel	O
with	O
several	O
other	O
risk	O
factors	O
for	O
thrombosis	O
.	O

Methods	O
Study	O
Design	O

Since	O
March	O
1999	O
,	O
consecutive	O
patients	O
younger	O
than	O
70	O
y	O
with	O
a	O
first	O
deep	O
-	O
vein	O
thrombosis	O
(	O
DVT	O
)	O
or	O
pulmonary	O
embolism	O
(	O
PE	O
)	O
have	O
been	O
identified	O
at	O
six	O
regional	O
anticoagulation	O
clinics	O
in	O
the	O
Netherlands	O
.	O

Anticoagulant	O
clinics	O
monitor	O
the	O
anticoagulant	O
therapy	O
of	O
all	O
patients	O
in	O
a	O
well	O
-	O
defined	O
geographical	O
area	O
,	O
allowing	O
us	O
to	O
identify	O
consecutive	O
and	O
unselected	O
patients	O
with	O
thrombosis	O
.	O

Patients	O
who	O
were	O
unable	O
to	O
fill	O
in	O
the	O
questionnaire	O
(	O
because	O
of	O
language	O
or	O
severe	O
psychiatric	O
problems	O
)	O
,	O
as	O
well	O
as	O
those	O
who	O
died	O
soon	O
after	O
the	O
venous	O
thrombosis	O
or	O
who	O
were	O
in	O
the	O
end	O
stage	O
of	O
a	O
disease	O
and	O
for	O
that	O
reason	O
did	O
not	O
participate	O
,	O
were	O
not	O
included	O
.	O

All	O
others	O
were	O
considered	O
eligible	O
.	O

Partners	O
of	O
these	O
patients	O
were	O
invited	O
as	O
control	O
individuals	O
,	O
and	O
the	O
same	O
exclusion	O
criteria	O
were	O
applied	O
.	O

All	O
participants	O
filled	O
in	O
a	O
detailed	O
standardized	O
questionnaire	O
on	O
general	O
demographic	O
and	O
anthropomorphic	O
characteristics	O
,	O
as	O
well	O
as	O
risk	O
factors	O
for	O
venous	O
thrombosis	O
.	O

The	O
questionnaire	O
was	O
sent	O
to	O
all	O
participants	O
within	O
a	O
few	O
weeks	O
after	O
the	O
event	O
and	O
covered	O
the	O
period	O
of	O
1	O
y	O
prior	O
to	O
the	O
date	O
of	O
the	O
thrombotic	O
event	O
(	O
index	O
date	O
)	O
.	O

When	O
the	O
participant	O
was	O
unable	O
to	O
fill	O
in	O
the	O
questionnaire	O
we	O
asked	O
questions	O
by	O
phone	O
,	O
using	O
a	O
standardized	O
mini	O
-	O
questionnaire	O
.	O

Three	O
months	O
after	O
the	O
patients	O
had	O
discontinued	O
their	O
oral	O
anticoagulant	O
therapy	O
,	O
they	O
were	O
invited	O
with	O
their	O
partners	O
to	O
the	O
anticoagulation	O
clinic	O
for	O
a	O
blood	O
sample	O
.	O

In	O
those	O
patients	O
who	O
continued	O
to	O
take	O
oral	O
anticoagulant	O
therapy	O
for	O
more	O
than	O
1	O
y	O
after	O
the	O
event	O
,	O
blood	O
was	O
drawn	O
during	O
therapy	O
.	O

If	O
participants	O
were	O
unable	O
to	O
come	O
to	O
the	O
clinic	O
,	O
a	O
buccal	O
swab	O
was	O
sent	O
by	O
mail	O
to	O
replace	O
the	O
blood	O
sample	O
for	O
DNA	O
extraction	O
.	O

The	O
study	O
protocol	O
was	O
approved	O
by	O
the	O
Ethics	O
Committee	O
of	O
the	O
Leiden	O
University	O
Medical	O
Center	O
.	O

Written	O
informed	O
consent	O
was	O
obtained	O
from	O
all	O
participants	O
[	O
12	O
]	O
.	O

Validation	O
Study	O
of	O
Thrombosis	O
Diagnosis	O
Discharge	O
letters	O
or	O
diagnostic	O
reports	O
of	O
the	O
venous	O
thrombotic	O
event	O
were	O
obtained	O
for	O
a	O
sample	O
of	O
742	O
patients	O
who	O
had	O
their	O
first	O
thrombosis	O
between	O
March	O
1999	O
and	O
March	O
2000	O
.	O

The	O
diagnostic	O
management	O
of	O
the	O
patients	O
was	O
compared	O
to	O
the	O
diagnostic	O
procedure	O
as	O
described	O
in	O
the	O
Dutch	O
consensus	O
[	O
13	O
]	O
.	O

Diagnosis	O
of	O
clinically	O
suspected	O
DVT	O
of	O
the	O
leg	O
is	O
based	O
on	O
a	O
clinical	O
score	O
,	O
serial	O
compression	O
ultrasonography	O
,	O
and	O
D	O
-	O
dimer	O
assay	O
.	O

Objective	O
testing	O
of	O
clinically	O
suspected	O
pulmonary	O
embolism	O
is	O
based	O
on	O
perfusion	O
and	O
ventilation	O
scintigraphy	O
,	O
ultrasonography	O
of	O
the	O
leg	O
veins	O
,	O
pulmonary	O
angiography	O
,	O
or	O
helical	O
computed	O
tomography	O
.	O

Out	O
of	O
395	O
patients	O
with	O
DVT	O
of	O
the	O
leg	O
,	O
384	O
(	O
97	O
%	O
)	O
were	O
objectively	O
diagnosed	O
,	O
while	O
out	O
of	O
347	O
patients	O
with	O
PE	O
,	O
271	O
(	O
78	O
%	O
)	O
were	O
confirmed	O
with	O
objective	O
testing	O
as	O
certainly	O
having	O
PE	O
.	O

Since	O
the	O
diagnosis	O
appears	O
to	O
be	O
made	O
by	O
objective	O
methods	O
in	O
virtually	O
all	O
cases	O
of	O
DVT	O
,	O
while	O
being	O
more	O
ambiguous	O
for	O
PE	O
,	O
we	O
also	O
analyzed	O
these	O
two	O
manifestations	O
of	O
venous	O
thrombosis	O
separately	O
.	O

Current	O
Analysis	O
For	O
the	O
current	O
analysis	O
we	O
were	O
interested	O
in	O
the	O
effects	O
of	O
travel	O
,	O
and	O
its	O
combined	O
effect	O
with	O
other	O
common	O
risk	O
factors	O
for	O
venous	O
thrombosis	O
.	O

Patients	O
with	O
a	O
solitary	O
arm	O
thrombosis	O
were	O
excluded	O
from	O
this	O
analysis	O
.	O

Of	O
3,902	O
eligible	O
cases	O
,	O
diagnosed	O
up	O
to	O
May	O
2002	O
,	O
656	O
did	O
not	O
participate	O
for	O
various	O
reasons	O
(	O
such	O
as	O
not	O
willing	O
or	O
not	O
reachable	O
)	O
,	O
leading	O
to	O
a	O
response	O
of	O
83	O
%	O
.	O

A	O
further	O
3	O
%	O
responded	O
only	O
to	O
the	O
mini	O
-	O
questionnaire	O
,	O
taken	O
by	O
phone	O
,	O
which	O
did	O
not	O
contain	O
questions	O
about	O
travel	O
.	O

Of	O
the	O
remaining	O
3,111	O
cases	O
,	O
78	O
%	O
had	O
a	O
partner	O
,	O
77	O
%	O
of	O
whom	O
were	O
willing	O
to	O
participate	O
,	O
which	O
left	O
1,867	O
couples	O
.	O

Additionally	O
,	O
229	O
partners	O
were	O
identified	O
for	O
whom	O
the	O
corresponding	O
patient	O
originally	O
participated	O
but	O
was	O
later	O
found	O
not	O
to	O
be	O
eligible	O
(	O
aged	O
over	O
70	O
y	O
,	O
or	O
not	O
a	O
first	O
thrombotic	O
event	O
)	O
.	O

These	O
control	O
individuals	O
were	O
matched	O
on	O
sex	O
and	O
5-y	O
age	O
groups	O
to	O
one	O
of	O
the	O
557	O
patients	O
whose	O
partner	O
did	O
not	O
want	O
to	O
participate	O
,	O
so	O
an	O
extra	O
229	O
pairs	O
were	O
included	O
,	O
making	O
a	O
total	O
of	O
4,192	O
participants	O
(	O
2,096	O
pairs	O
)	O
.	O

As	O
part	O
of	O
the	O
general	O
questionnaire	O
,	O
questions	O
had	O
been	O
asked	O
about	O
whether	O
or	O
not	O
respondents	O
had	O
traveled	O
for	O
more	O
than	O
4	O
h	O
in	O
the	O
3	O
mo	O
before	O
the	O
index	O
date	O
,	O
about	O
the	O
travel	O
date	O
,	O
and	O
about	O
mode	O
and	O
duration	O
of	O
travel	O
.	O

We	O
assessed	O
the	O
occurrence	O
of	O
thrombosis	O
in	O
relation	O
to	O
the	O
period	O
of	O
time	O
that	O
had	O
passed	O
since	O
traveling	O
.	O

Travel	O
was	O
defined	O
in	O
the	O
analysis	O
as	O
at	O
least	O
one	O
journey	O
with	O
a	O
duration	O
of	O
at	O
least	O
four	O
uninterrupted	O
hours	O
during	O
the	O
8-wk	O
period	O
before	O
the	O
event	O
.	O

During	O
the	O
analysis	O
it	O
appeared	O
that	O
some	O
individuals	O
had	O
provided	O
dates	O
of	O
travel	O
after	O
the	O
event	O
instead	O
of	O
before	O
.	O

As	O
there	O
was	O
only	O
one	O
opportunity	O
to	O
fill	O
in	O
such	O
a	O
date	O
,	O
we	O
had	O
no	O
information	O
about	O
the	O
period	O
before	O
the	O
event	O
.	O

This	O
was	O
the	O
case	O
in	O
88	O
cases	O
and	O
146	O
controls	O
.	O

We	O
excluded	O
these	O
individuals	O
and	O
their	O
partners	O
,	O
which	O
left	O
3,812	O
participants	O
(	O
1,906	O
pairs	O
)	O
for	O
the	O
analysis	O
.	O

Because	O
we	O
selected	O
the	O
partners	O
of	O
the	O
cases	O
as	O
control	O
individuals	O
,	O
and	O
because	O
it	O
turned	O
out	O
,	O
as	O
expected	O
,	O
that	O
couples	O
tend	O
to	O
travel	O
together	O
,	O
we	O
performed	O
a	O
conditional	O
logistic	O
regression	O
analysis	O
to	O
calculate	O
odds	O
ratios	O
(	O
ORs	O
)	O
for	O
the	O
relation	O
between	O
travel	O
and	O
venous	O
thrombosis	O
.	O

This	O
method	O
fully	O
takes	O
this	O
matching	O
into	O
account	O
,	O
and	O
leads	O
to	O
unbiased	O
estimates	O
,	O
with	O
adjustment	O
for	O
all	O
factors	O
in	O
which	O
cases	O
and	O
controls	O
tend	O
to	O
be	O
similar	O
,	O
e.g.	O
,	O
socioeconomic	O
class	O
[	O
14	O
]	O
.	O

Details	O
of	O
this	O
method	O
can	O
be	O
found	O
in	O
Protocol	O
S1	O
.	O

The	O
95	O
%	O
confidence	O
intervals	O
(	O
CIs	O
)	O
were	O
derived	O
from	O
the	O
model	O
.	O

We	O
assessed	O
the	O
combined	O
effect	O
of	O
traveling	O
and	O
the	O
following	O
risk	O
factors	O
for	O
thrombosis	O
:	O
factor	O
V	O
Leiden	O
mutation	O
,	O
prothrombin	O
G20210A	O
mutation	O
,	O
body	O
mass	O
index	O
(	O
BMI	O
,	O
as	O
kg	O
/	O
m2	O
)	O
,	O
and	O
height	O
.	O

We	O
were	O
also	O
interested	O
in	O
the	O
combined	O
effect	O
of	O
oral	O
contraceptive	O
use	O
and	O
travel	O
.	O

However	O
,	O
as	O
the	O
control	O
individuals	O
were	O
nearly	O
always	O
of	O
the	O
opposite	O
sex	O
(	O
partners	O
of	O
the	O
cases	O
were	O
recruited	O
as	O
controls	O
)	O
,	O
it	O
was	O
not	O
possible	O
to	O
perform	O
a	O
matched	O
analysis	O
for	O
the	O
combination	O
of	O
oral	O
contraceptive	O
use	O
and	O
travel	O
.	O

Therefore	O
,	O
we	O
performed	O
a	O
case	O
-	O
only	O
analysis	O
[	O
15	O
]	O
.	O

This	O
method	O
allows	O
one	O
to	O
examine	O
the	O
association	O
between	O
two	O
exposures	O
among	O
case	O
individuals	O
only	O
.	O

ORs	O
are	O
interpreted	O
as	O
a	O
synergy	O
index	O
(	O
SI	O
)	O
on	O
a	O
multiplicative	O
scale	O
,	O
with	O
independence	O
assumed	O
between	O
the	O
exposures	O
.	O

As	O
this	O
analysis	O
depends	O
only	O
on	O
cases	O
,	O
it	O
was	O
possible	O
to	O
perform	O
it	O
in	O
all	O
consecutive	O
cases	O
,	O
therefore	O
also	O
including	O
those	O
without	O
a	O
partner	O
.	O

Laboratory	O
Measurements	O
Blood	O
was	O
collected	O
from	O
the	O
antecubital	O
vein	O
into	O
vacuum	O
tubes	O
containing	O
0.106	O
mol	O
/	O
l	O
trisodium	O
citrate	O
.	O

High	O
molecular	O
weight	O
DNA	O
was	O
isolated	O
from	O
leukocytes	O
using	O
a	O
standard	O
salting	O
-	O
out	O
procedure	O
[	O
16	O
]	O
and	O
stored	O
at	O
−20	O
°	O
C	O
.	O

When	O
a	O
blood	O
sample	O
was	O
not	O
available	O
,	O
DNA	O
was	O
extracted	O
from	O
buccal	O
swabs	O
.	O

Three	O
large	O
cotton	B
swabs	O
in	O
a	O
total	O
of	O
6	O
ml	O
of	O
SDS	O
–	O
proteinase	O
K	O
solution	O
(	O
100	O
mM	O
NaCl	O
,	O
10	O
mM	O
EDTA	O
,	O
10	O
mM	O
Tris	O
-	O
HCl	O
[	O
pH	O
8.0	O
]	O
,	O
0.5	O
%	O
SDS	O
,	O
0.1	O
mg	O
/	O
ml	O
proteinase	O
K	O
)	O
were	O
obtained	O
.	O

Upon	O
arrival	O
,	O
the	O
proteinase	O
K	O
concentration	O
was	O
raised	O
to	O
0.2	O
mg	O
/	O
ml	O
,	O
and	O
the	O
sample	O
was	O
incubated	O
for	O
2	O
h	O
at	O
65	O
°	O
C	O
.	O

Subsequently	O
,	O
the	O
solute	O
was	O
recovered	O
by	O
centrifugation	O
.	O

Potassium	O
acetate	O
was	O
added	O
to	O
the	O
supernatant	O
to	O
a	O
final	O
concentration	O
of	O
1.6	O
M.	O
After	O
15	O
min	O
incubation	O
on	O
ice	O
,	O
proteins	O
were	O
removed	O
using	O
chloroform	O
/	O
isomylalcohol	O
(	O
24:1	O
)	O
treatment	O
.	O

The	O
DNA	O
in	O
the	O
water	O
phase	O
was	O
subsequently	O
ethanol	O
precipitated	O
.	O

After	O
centrifugation	O
,	O
the	O
pellet	O
was	O
resuspended	O
in	O
200	O
μl	O
of	O
10	O
mM	O
Tris	O
-	O
HCl	O
and	O
10	O
mM	O
EDTA	O
(	O
pH	O
8.0	O
)	O
,	O
and	O
frozen	O
at	O
−20	O
°	O
C	O
until	O
further	O
analysis	O
.	O

The	O
factor	O
V	O
Leiden	O
mutation	O
(	O
G1691A	O
)	O
and	O
the	O
prothrombin	O
mutation	O
(	O
G20210A	O
)	O
were	O
simultaneously	O
detected	O
by	O
duplex	O
polymerase	O
chain	O
reaction	O
[	O
17,18	O
]	O
.	O

The	O
technician	O
was	O
blinded	O
concerning	O
the	O
origin	O
of	O
the	O
sample	O
,	O
i.e.	O
,	O
whether	O
it	O
was	O
from	O
a	O
patient	O
or	O
from	O
a	O
control	O
individual	O
.	O

Results	O
Venous	O
Thrombosis	O
in	O
Relation	O
to	O
Travel	O
Table	O
1	O
shows	O
general	O
characteristics	O
of	O
the	O
1,906	O
patients	O
.	O

They	O
ranged	O
in	O
age	O
from	O
18	O
to	O
69	O
y	O
(	O
median	O
50.4	O
y	O
)	O
;	O
51	O
%	O
were	O
men	O
.	O

Diagnosis	O
was	O
DVT	O
in	O
57	O
%	O
of	O
the	O
cases	O
,	O
PE	O
in	O
32	O
%	O
,	O
and	O
both	O
in	O
11	O
%	O
.	O

As	O
partners	O
of	O
the	O
cases	O
were	O
included	O
as	O
control	O
individuals	O
,	O
the	O
sex	O
distribution	O
of	O
the	O
control	O
individuals	O
was	O
the	O
opposite	O
;	O
the	O
age	O
distribution	O
differed	O
only	O
trivially	O
.	O

Of	O
the	O
patients	O
,	O
233	O
individuals	O
(	O
12	O
%	O
)	O
had	O
traveled	O
for	O
at	O
least	O
4	O
h	O
by	O
air	O
,	O
bus	O
,	O
car	O
,	O
or	O
train	O
within	O
the	O
8	O
wk	O
preceding	O
the	O
index	O
date	O
,	O
as	O
compared	O
to	O
182	O
of	O
the	O
control	O
individuals	O
(	O
9.5	O
%	O
)	O
.	O

As	O
the	O
cases	O
and	O
control	O
individuals	O
were	O
selected	O
as	O
couples	O
,	O
many	O
pairs	O
(	O
135	O
)	O
had	O
traveled	O
together	O
and	O
were	O
uninformative	O
:	O
as	O
a	O
consequence	O
,	O
145	O
pairs	O
in	O
which	O
either	O
the	O
patient	O
(	O
98	O
)	O
or	O
the	O
control	O
(	O
47	O
)	O
had	O
traveled	O
could	O
be	O
used	O
for	O
the	O
matched	O
analysis	O
(	O
Table	O
2	O
)	O
.	O

This	O
analysis	O
showed	O
a	O
2-fold	O
increased	O
risk	O
of	O
venous	O
thrombosis	O
for	O
all	O
modes	O
of	O
travel	O
combined	O
(	O
OR	O
2.1	O
;	O
95	O
%	O
CI	O
1.5–3.0	O
)	O
compared	O
to	O
not	O
traveling	O
.	O

For	O
air	O
travel	O
alone	O
,	O
49	O
individuals	O
(	O
31	O
cases	O
and	O
18	O
controls	O
)	O
had	O
traveled	O
without	O
their	O
partner	O
,	O
and	O
the	O
analysis	O
yielded	O
an	O
OR	O
of	O
1.7	O
(	O
95	O
%	O
CI	O
1.0–3.1	O
)	O
.	O

For	O
the	O
other	O
modes	O
of	O
travel	O
(	O
car	O
,	O
bus	O
,	O
and	O
train	O
)	O
the	O
relative	O
risks	O
were	O
essentially	O
similar	O
to	O
each	O
other	O
and	O
to	O
that	O
of	O
air	O
travel	O
(	O
Table	O
2	O
)	O
.	O

The	O
risk	O
of	O
venous	O
thrombosis	O
was	O
not	O
clearly	O
related	O
to	O
increased	O
duration	O
of	O
travel	O
(	O
Table	O
2	O
)	O
.	O

Of	O
the	O
233	O
events	O
that	O
occurred	O
within	O
8	O
wk	O
after	O
traveling	O
,	O
68	O
(	O
29	O
%	O
)	O
were	O
diagnosed	O
in	O
the	O
first	O
week	O
,	O
after	O
which	O
the	O
incidence	O
gradually	O
decreased	O
(	O
Figure	O
1	O
)	O
.	O

The	O
Effect	O
of	O
Other	O
Risk	O
Factors	O
Combined	O
with	O
Travel	O
Prothrombotic	O
mutations	O
.	O

Information	O
on	O
the	O
factor	O
V	O
Leiden	O
mutation	O
and	O
prothrombin	O
G20210A	O
genotype	O
was	O
available	O
for	O
1,713	O
patients	O
(	O
90	O
%	O
)	O
and	O
for	O
1,629	O
of	O
the	O
control	O
individuals	O
(	O
85	O
%	O
)	O
.	O

Factor	O
V	O
Leiden	O
was	O
present	O
in	O
259	O
cases	O
(	O
14	O
%	O
)	O
and	O
84	O
control	O
individuals	O
(	O
4	O
%	O
)	O
(	O
OR	O
3.1	O
;	O
95	O
%	O
CI	O
2.4–4.1	O
)	O
.	O

The	O
risk	O
of	O
venous	O
thrombosis	O
was	O
8-fold	O
increased	O
in	O
people	O
with	O
factor	O
V	O
Leiden	O
who	O
had	O
traveled	O
by	O
bus	O
,	O
car	O
,	O
or	O
train	O
(	O
modes	O
combined	O
)	O
as	O
compared	O
to	O
noncarriers	O
who	O
did	O
not	O
travel	O
(	O
OR	O
8.1	O
;	O
95	O
%	O
CI	O
2.7–24.7	O
)	O
.	O

For	O
the	O
combined	O
effect	O
of	O
air	O
travel	O
and	O
factor	O
V	O
Leiden	O
,	O
the	O
risk	O
seemed	O
even	O
slightly	O
higher	O
(	O
OR	O
13.6	O
;	O
95	O
%	O
CI	O
2.9–64.2	O
)	O
.	O

The	O
prothrombin	O
G20210A	O
mutation	O
was	O
found	O
in	O
83	O
cases	O
(	O
4	O
%	O
)	O
and	O
in	O
29	O
control	O
individuals	O
(	O
2	O
%	O
)	O
(	O
OR	O
2.7	O
;	O
95	O
%	O
CI	O
1.7–4.2	O
)	O
.	O

The	O
risk	O
in	O
individuals	O
with	O
this	O
mutation	O
who	O
had	O
traveled	O
was	O
difficult	O
to	O
interpret	O
because	O
of	O
the	O
small	O
numbers	O
but	O
appeared	O
not	O
to	O
increase	O
more	O
than	O
additively	O
(	O
Table	O
3	O
)	O
.	O

BMI	O
.	O

The	O
effect	O
of	O
BMI	O
was	O
studied	O
by	O
dividing	O
individuals	O
into	O
three	O
categories	O
with	O
the	O
following	O
BMI	O
values	O
:	O
<	O
25	O
,	O
25–30	O
,	O
and	O
>	O
30	O
kg	O
/	O
m2	O
[	O
19	O
]	O
.	O

A	O
BMI	O
of	O
25–30	O
kg	O
/	O
m2	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
venous	O
thrombosis	O
(	O
OR	O
1.4	O
;	O
95	O
%	O
CI	O
1.2–1.7	O
)	O
,	O
and	O
the	O
risk	O
was	O
slightly	O
higher	O
in	O
patients	O
with	O
a	O
BMI	O
of	O
30	O
kg	O
/	O
m2	O
or	O
more	O
(	O
OR	O
1.7	O
;	O
95	O
%	O
CI	O
1.4–2.1	O
)	O
.	O

The	O
combined	O
effect	O
of	O
a	O
higher	O
BMI	O
and	O
travel	O
was	O
the	O
sum	O
of	O
the	O
individual	O
risks	O
(	O
Table	O
3	O
)	O
,	O
with	O
the	O
exception	O
of	O
people	O
with	O
a	O
BMI	O
of	O
more	O
than	O
30	O
kg	O
/	O
m2	O
who	O
traveled	O
by	O
car	O
,	O
bus	O
,	O
or	O
train	O
,	O
for	O
whom	O
the	O
risk	O
was	O
10-fold	O
increased	O
(	O
OR	O
9.9	O
;	O
95	O
%	O
CI	O
3.6–27.6	O
)	O
.	O

This	O
increase	O
in	O
risk	O
was	O
not	O
found	O
in	O
people	O
who	O
traveled	O
by	O
air	O
.	O

Height	O
.	O

Particularly	O
short	O
or	O
tall	O
people	O
may	O
be	O
subjected	O
during	O
travel	O
to	O
even	O
more	O
unnatural	O
sitting	O
positions	O
than	O
individuals	O
with	O
average	O
height	O
.	O

Therefore	O
,	O
we	O
assessed	O
the	O
effect	O
of	O
extremes	O
of	O
heights	O
in	O
combination	O
with	O
travel	O
on	O
the	O
risk	O
of	O
venous	O
thrombosis	O
by	O
comparing	O
short	O
(	O
less	O
than	O
1.60	O
m	O
)	O
and	O
tall	O
individuals	O
(	O
more	O
than	O
1.90	O
m	O
)	O
with	O
people	O
of	O
average	O
height	O
(	O
1.60–1.90	O
m	O
)	O
.	O

Compared	O
to	O
people	O
of	O
average	O
height	O
,	O
the	O
risk	O
of	O
venous	O
thrombosis	O
was	O
lower	O
for	O
short	O
people	O
(	O
OR	O
0.7	O
;	O
95	O
%	O
CI	O
0.5–0.9	O
)	O
and	O
did	O
not	O
differ	O
for	O
very	O
tall	O
individuals	O
(	O
OR	O
0.9	O
;	O
95	O
%	O
CI	O
0.7–1.1	O
)	O
.	O

The	O
risk	O
was	O
found	O
to	O
be	O
increased	O
in	O
people	O
of	O
more	O
than	O
1.90	O
m	O
who	O
traveled	O
(	O
OR	O
4.7	O
;	O
95	O
%	O
CI	O
1.4–15.4	O
for	O
travel	O
by	O
car	O
,	O
bus	O
,	O
or	O
train	O
;	O
OR	O
6.8	O
;	O
95	O
%	O
CI	O
0.8–60.6	O
for	O
air	O
travel	O
)	O
compared	O
to	O
non	O
-	O
traveling	O
people	O
of	O
average	O
height	O
.	O

Interestingly	O
,	O
the	O
risk	O
of	O
venous	O
thrombosis	O
was	O
also	O
increased	O
in	O
short	O
people	O
but	O
only	O
after	O
air	O
travel	O
(	O
OR	O
4.9	O
;	O
95	O
%	O
CI	O
0.9–25.6	O
)	O
,	O
not	O
after	O
other	O
modes	O
of	O
travel	O
(	O
OR	O
1.0	O
;	O
95	O
%	O
CI	O
0.3–2.8	O
,	O
all	O
relative	O
to	O
non	O
-	O
traveling	O
people	O
of	O
average	O
height	O
)	O
.	O

Oral	O
contraception	O
.	O

To	O
study	O
the	O
association	O
between	O
oral	O
contraceptive	O
use	O
,	O
travel	O
,	O
and	O
the	O
risk	O
of	O
venous	O
thrombosis	O
,	O
we	O
performed	O
a	O
case	O
-	O
only	O
analysis	O
in	O
all	O
female	O
patients	O
who	O
were	O
less	O
than	O
50	O
y	O
of	O
age	O
.	O

As	O
we	O
needed	O
only	O
cases	O
,	O
it	O
was	O
also	O
possible	O
to	O
include	O
women	O
without	O
a	O
partner	O
for	O
this	O
analysis	O
,	O
which	O
led	O
to	O
a	O
total	O
of	O
1,025	O
women	O
aged	O
under	O
50	O
.	O

Non	O
-	O
users	O
who	O
did	O
not	O
travel	O
were	O
used	O
as	O
the	O
reference	O
group	O
.	O

The	O
case	O
-	O
only	O
estimate	O
of	O
the	O
SI	O
for	O
women	O
who	O
traveled	O
by	O
car	O
,	O
bus	O
,	O
or	O
train	O
was	O
2.4	O
(	O
95	O
%	O
CI	O
1.5–3.7	O
)	O
.	O

This	O
indicates	O
that	O
the	O
OR	O
for	O
the	O
combination	O
of	O
travel	O
and	O
oral	O
contraceptive	O
use	O
is	O
2.4	O
times	O
the	O
product	O
of	O
the	O
separate	O
ORs	O
.	O

As	O
oral	O
contraceptive	O
use	O
generally	O
increases	O
the	O
risk	O
of	O
venous	O
thrombosis	O
about	O
4-fold	O
[	O
20	O
]	O
,	O
the	O
combination	O
with	O
travel	O
by	O
car	O
,	O
bus	O
,	O
or	O
train	O
would	O
lead	O
to	O
an	O
estimated	O
OR	O
of	O
about	O
20	O
(	O
4	O
×	O
2	O
×	O
2.4	O
)	O
.	O

A	O
clearly	O
stronger	O
interaction	O
of	O
travel	O
by	O
air	O
with	O
oral	O
contraceptive	O
use	O
was	O
found	O
:	O
the	O
case	O
-	O
only	O
estimate	O
of	O
the	O
SI	O
was	O
4.9	O
(	O
95	O
%	O
CI	O
2.1–	O
11.4	O
)	O
,	O
which	O
would	O
result	O
in	O
an	O
OR	O
of	O
about	O
40	O
(	O
4	O
×	O
2	O
×	O
4.9	O
)	O
.	O

Effect	O
of	O
Risk	O
Factors	O
in	O
DVT	O
Patients	O
Only	O
Of	O
the	O
1,906	O
cases	O
,	O
1,082	O
were	O
diagnosed	O
with	O
DVT	O
.	O

As	O
the	O
diagnosis	O
was	O
more	O
unambiguous	O
in	O
these	O
patients	O
(	O
97	O
%	O
objectively	O
diagnosed	O
as	O
compared	O
to	O
78	O
%	O
of	O
the	O
PE	O
patients	O
)	O
,	O
we	O
repeated	O
the	O
analysis	O
in	O
these	O
patients	O
only	O
.	O

In	O
this	O
analysis	O
,	O
the	O
overall	O
effect	O
of	O
travel	O
on	O
the	O
risk	O
of	O
DVT	O
was	O
equal	O
to	O
the	O
effect	O
on	O
all	O
venous	O
thrombosis	O
(	O
DVT	O
and	O
PE	O
combined	O
)	O
.	O

However	O
,	O
here	O
we	O
found	O
a	O
stronger	O
risk	O
for	O
travel	O
by	O
air	O
(	O
OR	O
3.0	O
;	O
95	O
%	O
CI	O
1.3–7.1	O
)	O
then	O
for	O
travel	O
by	O
car	O
,	O
bus	O
,	O
or	O
train	O
(	O
OR	O
1.9	O
;	O
95	O
%	O
CI	O
1.1–3.2	O
)	O
(	O
Table	O
4	O
)	O
.	O

Also	O
,	O
the	O
analysis	O
of	O
the	O
combination	O
of	O
other	O
risk	O
factors	O
with	O
travel	O
resulted	O
in	O
more	O
clear	O
-	O
cut	O
effects	O
,	O
despite	O
the	O
smaller	O
number	O
of	O
cases	O
:	O
the	O
risk	O
of	O
DVT	O
was	O
still	O
clearly	O
synergistically	O
increased	O
in	O
patients	O
with	O
factor	O
V	O
Leiden	O
who	O
traveled	O
,	O
whereas	O
the	O
prothrombin	O
G20210A	O
mutation	O
did	O
not	O
further	O
increase	O
the	O
risk	O
of	O
travel	O
(	O
Table	O
4	O
)	O
.	O

Furthermore	O
,	O
a	O
BMI	O
of	O
more	O
than	O
30	O
kg	O
/	O
m2	O
in	O
combination	O
with	O
travel	O
yielded	O
high	O
ORs	O
for	O
DVT	O
both	O
in	O
people	O
who	O
traveled	O
by	O
car	O
,	O
bus	O
,	O
or	O
train	O
and	O
in	O
those	O
who	O
flew	O
.	O

Being	O
more	O
than	O
1.90	O
m	O
tall	O
in	O
combination	O
with	O
travel	O
resulted	O
in	O
higher	O
ORs	O
for	O
DVT	O
;	O
the	O
risk	O
for	O
short	O
people	O
was	O
more	O
increased	O
after	O
travel	O
by	O
air	O
(	O
OR	O
6.8	O
;	O
95	O
%	O
CI	O
1.1–43.5	O
)	O
(	O
Table	O
4	O
)	O
.	O

The	O
effect	O
of	O
oral	O
contraceptive	O
use	O
in	O
combination	O
with	O
travel	O
by	O
car	O
,	O
bus	O
,	O
or	O
train	O
on	O
the	O
risk	O
of	O
DVT	O
was	O
studied	O
in	O
589	O
women	O
and	O
was	O
somewhat	O
lower	O
than	O
the	O
effect	O
on	O
the	O
risk	O
of	O
all	O
venous	O
thrombosis	O
(	O
SI	O
1.9	O
;	O
95	O
%	O
CI	O
0.9–4.2	O
)	O
.	O

In	O
those	O
who	O
traveled	O
by	O
air	O
it	O
was	O
also	O
a	O
bit	O
lower	O
(	O
SI	O
3.4	O
;	O
95	O
%	O
CI	O
1.3–8.8	O
)	O
,	O
but	O
still	O
indicative	O
of	O
a	O
strong	O
synergistic	O
effect	O
.	O

Discussion	O
In	O
this	O
population	O
-	O
based	O
case	O
-	O
control	O
study	O
,	O
long	O
-	O
distance	O
traveling	O
increased	O
the	O
risk	O
of	O
venous	O
thrombosis	O
2-fold	O
.	O

Travel	O
by	O
air	O
increased	O
the	O
risk	O
to	O
the	O
same	O
extent	O
as	O
travel	O
by	O
car	O
,	O
bus	O
,	O
or	O
train	O
.	O

The	O
risk	O
was	O
highest	O
in	O
the	O
first	O
week	O
after	O
traveling	O
.	O

As	O
venous	O
thrombosis	O
is	O
a	O
disease	O
in	O
which	O
many	O
factors	O
(	O
genetic	O
and	O
acquired	O
)	O
interact	O
[	O
21	O
]	O
,	O
we	O
identified	O
groups	O
with	O
additional	O
risk	O
factors	O
in	O
which	O
the	O
risk	O
was	O
further	O
increased	O
.	O

This	O
was	O
the	O
case	O
for	O
individuals	O
with	O
factor	O
V	O
Leiden	O
,	O
obese	O
people	O
(	O
BMI	O
>	O
30	O
kg	O
/	O
m2	O
)	O
,	O
and	O
short	O
(	O
only	O
for	O
travel	O
by	O
air	O
)	O
and	O
tall	O
people	O
,	O
as	O
well	O
as	O
for	O
women	O
using	O
oral	O
contraceptives	O
.	O

Some	O
of	O
these	O
synergistic	O
effects	O
were	O
more	O
apparent	O
for	O
air	O
travel	O
.	O

Although	O
the	O
studies	O
that	O
have	O
been	O
published	O
so	O
far	O
have	O
not	O
yielded	O
entirely	O
consistent	O
results	O
,	O
those	O
that	O
did	O
report	O
an	O
increased	O
risk	O
of	O
venous	O
thrombosis	O
in	O
air	O
travelers	O
showed	O
similar	O
risk	O
estimates	O
of	O
a	O
2-	O
to	O
3-fold	O
increased	O
risk	O
(	O
even	O
in	O
one	O
with	O
asymptomatic	O
events	O
only	O
[	O
4	O
]	O
)	O
.	O

The	O
occurrence	O
of	O
venous	O
thrombosis	O
was	O
highest	O
in	O
the	O
first	O
week	O
after	O
travel	O
,	O
and	O
slowly	O
declined	O
afterwards	O
,	O
a	O
pattern	O
that	O
was	O
also	O
described	O
in	O
a	O
recent	O
record	O
-	O
linking	O
study	O
from	O
Australia	O
[	O
1	O
]	O
,	O
supporting	O
a	O
causal	O
relation	O
.	O

As	O
a	O
possible	O
mechanism	O
for	O
an	O
extra	O
risk	O
in	O
travelers	O
who	O
fly	O
,	O
an	O
effect	O
of	O
hypobaric	O
hypoxia	O
on	O
the	O
coagulation	O
system	O
was	O
postulated	O
,	O
which	O
has	O
already	O
been	O
studied	O
a	O
number	O
of	O
times	O
,	O
mainly	O
in	O
hypobaric	O
chambers	O
,	O
with	O
unclear	O
results	O
so	O
far	O
.	O

Our	O
study	O
showed	O
an	O
increased	O
risk	O
in	O
all	O
types	O
of	O
travel	O
,	O
which	O
suggests	O
that	O
the	O
increased	O
risk	O
of	O
flying	O
is	O
caused	O
mainly	O
by	O
immobilization	O
.	O

Additionally	O
,	O
the	O
risk	O
is	O
further	O
increased	O
in	O
short	O
and	O
tall	O
people	O
,	O
who	O
are	O
likely	O
to	O
experience	O
more	O
immobilization	O
and	O
venous	O
compression	O
than	O
other	O
travelers	O
.	O

However	O
,	O
as	O
some	O
of	O
our	O
findings	O
were	O
more	O
pronounced	O
for	O
air	O
travel	O
,	O
we	O
can	O
not	O
exclude	O
an	O
additional	O
effect	O
of	O
hypobaric	O
hypoxia	O
,	O
possibly	O
in	O
risk	O
groups	O
only	O
.	O

This	O
possibility	O
is	O
supported	O
by	O
a	O
recent	O
study	O
of	O
our	O
group	O
[	O
22	O
]	O
in	O
which	O
we	O
found	O
that	O
thrombin	O
generation	O
occurred	O
in	O
some	O
healthy	O
volunteers	O
after	O
flying	O
for	O
8	O
h	O
but	O
happened	O
to	O
a	O
far	O
lesser	O
extent	O
after	O
being	O
immobilized	O
for	O
8	O
h	O
in	O
a	O
cinema	O
.	O

The	O
high	O
response	O
in	O
the	O
fliers	O
was	O
associated	O
with	O
the	O
presence	O
of	O
risk	O
factors	O
for	O
thrombosis	O
,	O
i.e.	O
,	O
oral	O
contraceptive	O
use	O
,	O
the	O
factor	O
V	O
Leiden	O
mutation	O
,	O
and	O
the	O
combination	O
of	O
the	O
two	O
.	O

This	O
finding	O
indicates	O
an	O
effect	O
of	O
an	O
additional	O
factor	O
in	O
an	O
airplane	O
,	O
such	O
as	O
hypobaric	O
hypoxia	O
,	O
to	O
which	O
mainly	O
individuals	O
with	O
risk	O
factors	O
respond	O
.	O

None	O
of	O
the	O
studies	O
published	O
so	O
far	O
have	O
systematically	O
studied	O
the	O
effect	O
of	O
traveling	O
in	O
combination	O
with	O
other	O
risk	O
factors	O
,	O
with	O
the	O
exception	O
of	O
the	O
study	O
by	O
Martinelli	O
et	O
al.	O
[	O
3	O
]	O
.	O

In	O
an	O
analysis	O
of	O
210	O
patients	O
,	O
they	O
found	O
a	O
16-fold	O
increased	O
risk	O
for	O
patients	O
who	O
traveled	O
by	O
air	O
and	O
had	O
some	O
form	O
of	O
thrombophilia	O
,	O
as	O
well	O
as	O
a	O
14-fold	O
increased	O
risk	O
in	O
women	O
who	O
flew	O
and	O
used	O
oral	O
contraceptives	O
,	O
findings	O
that	O
confirm	O
both	O
the	O
results	O
of	O
the	O
present	O
study	O
and	O
our	O
finding	O
of	O
activated	O
coagulation	O
in	O
individuals	O
with	O
risk	O
factors	O
after	O
flying	O
[	O
22	O
]	O
.	O

The	O
finding	O
that	O
taller	O
and	O
shorter	O
people	O
had	O
an	O
increased	O
risk	O
of	O
venous	O
thrombosis	O
after	O
traveling	O
should	O
be	O
interpreted	O
with	O
some	O
caution	O
,	O
as	O
the	O
numbers	O
were	O
small	O
in	O
these	O
strata	O
.	O

On	O
the	O
other	O
hand	O
,	O
it	O
is	O
biologically	O
plausible	O
:	O
very	O
tall	O
people	O
are	O
subjected	O
to	O
even	O
more	O
cramped	O
seating	O
than	O
average	O
-	O
height	O
individuals	O
,	O
and	O
very	O
short	O
people	O
's	O
feet	O
may	O
not	O
touch	O
the	O
floor	O
,	O
which	O
would	O
lead	O
to	O
extra	O
compression	O
of	O
the	O
popliteal	O
veins	O
.	O

Interestingly	O
,	O
the	O
increased	O
risk	O
for	O
short	O
people	O
was	O
only	O
found	O
in	O
people	O
who	O
traveled	O
by	O
air	O
.	O

This	O
may	O
have	O
to	O
do	O
with	O
the	O
fact	O
that	O
seats	O
in	O
cars	O
are	O
generally	O
lower	O
,	O
and	O
more	O
individually	O
adjustable	O
,	O
than	O
those	O
in	O
airplanes	O
.	O

As	O
the	O
diagnosis	O
of	O
DVT	O
is	O
usually	O
more	O
unambiguous	O
than	O
that	O
of	O
PE	O
[	O
23	O
]	O
,	O
as	O
was	O
the	O
case	O
in	O
our	O
study	O
population	O
as	O
well	O
,	O
we	O
repeated	O
the	O
analysis	O
using	O
only	O
DVT	O
as	O
the	O
outcome	O
of	O
interest	O
(	O
97	O
%	O
objectively	O
diagnosed	O
)	O
.	O

In	O
this	O
analysis	O
,	O
despite	O
using	O
smaller	O
numbers	O
,	O
most	O
findings	O
were	O
either	O
similar	O
or	O
appeared	O
more	O
evident	O
,	O
and	O
inconsistencies	O
that	O
were	O
found	O
when	O
using	O
both	O
DVT	O
and	O
PE	O
as	O
endpoints	O
disappeared	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
large	O
population	O
-	O
based	O
case	O
-	O
control	O
study	O
in	O
which	O
the	O
effect	O
of	O
travel	O
on	O
the	O
risk	O
of	O
venous	O
thrombosis	O
has	O
been	O
studied	O
.	O

Because	O
the	O
control	O
individuals	O
were	O
closely	O
matched	O
,	O
being	O
partners	O
of	O
the	O
cases	O
,	O
and	O
couples	O
tend	O
to	O
travel	O
together	O
,	O
only	O
the	O
cases	O
and	O
control	O
individuals	O
who	O
had	O
not	O
traveled	O
together	O
could	O
be	O
used	O
for	O
the	O
analysis	O
.	O

Also	O
because	O
of	O
this	O
design	O
,	O
the	O
effect	O
of	O
sex	O
and	O
age	O
could	O
not	O
be	O
studied	O
.	O

It	O
has	O
to	O
be	O
noted	O
,	O
however	O
,	O
that	O
for	O
all	O
other	O
research	O
questions	O
on	O
the	O
effect	O
of	O
genetic	O
and	O
acquired	O
risk	O
factors	O
on	O
the	O
risk	O
of	O
venous	O
thrombosis	O
,	O
this	O
design	O
has	O
no	O
limitations	O
and	O
the	O
close	O
matching	O
of	O
cases	O
and	O
controls	O
renders	O
confounding	O
by	O
,	O
for	O
instance	O
,	O
lifestyle	O
and	O
socioeconomic	O
class	O
less	O
likely	O
than	O
in	O
previous	O
unmatched	O
studies	O
(	O
see	O
also	O
Protocol	O
S1	O
)	O
.	O

Another	O
advantage	O
of	O
this	O
approach	O
is	O
the	O
minimization	O
of	O
recall	O
bias	O
,	O
as	O
the	O
cases	O
and	O
controls	O
would	O
generally	O
fill	O
in	O
the	O
questionnaire	O
together	O
.	O

Many	O
questions	O
are	O
still	O
left	O
unanswered	O
that	O
necessitate	O
more	O
research	O
.	O

First	O
of	O
all	O
,	O
our	O
study	O
results	O
apply	O
only	O
to	O
people	O
younger	O
than	O
70	O
y	O
of	O
age	O
.	O

Furthermore	O
,	O
it	O
is	O
likely	O
that	O
other	O
characteristics	O
exist	O
that	O
also	O
increase	O
the	O
risk	O
—	O
person	O
-	O
specific	O
(	O
e.g.	O
,	O
other	O
drug	O
use	O
)	O
,	O
behavioral	O
(	O
e.g.	O
,	O
use	O
of	O
sleeping	O
pills	O
or	O
alcohol	O
consumption	O
)	O
,	O
and	O
flight	O
-	O
specific	O
(	O
e.g.	O
,	O
class	O
or	O
seating	O
)	O
—that	O
need	O
to	O
be	O
identified	O
.	O

These	O
further	O
variables	O
are	O
part	O
of	O
our	O
ongoing	O
study	O
as	O
part	O
of	O
the	O
World	O
Health	O
Organization	O
Research	O
Initiative	O
into	O
the	O
Global	O
Hazards	O
of	O
Travel	O
(	O
WRIGHT	O
study	O
)	O
.	O

For	O
those	O
who	O
have	O
an	O
increased	O
risk	O
,	O
such	O
as	O
oral	O
contraceptive	O
users	O
and	O
individuals	O
with	O
factor	O
V	O
Leiden	O
,	O
prevention	O
may	O
be	O
warranted	O
.	O

Prevention	O
may	O
vary	O
from	O
simple	O
measures	O
,	O
such	O
as	O
exercises	O
during	O
the	O
flight	O
,	O
to	O
measures	O
that	O
carry	O
a	O
risk	O
themselves	O
,	O
such	O
as	O
anticoagulants	O
.	O

Specific	O
studies	O
are	O
needed	O
to	O
assess	O
the	O
efficacy	O
of	O
these	O
measures	O
and	O
their	O
risk	O
–	O
benefit	O
ratio	O
.	O

It	O
can	O
be	O
concluded	O
that	O
the	O
risk	O
of	O
venous	O
thrombosis	O
is	O
2-fold	O
increased	O
for	O
all	O
travelers	O
and	O
to	O
the	O
same	O
extent	O
for	O
all	O
modes	O
of	O
travel	O
.	O

In	O
individuals	O
who	O
use	O
oral	O
contraceptives	O
,	O
are	O
carriers	O
of	O
the	O
factor	O
V	O
Leiden	O
mutation	O
,	O
or	O
are	O
particularly	O
tall	O
,	O
short	O
,	O
or	O
obese	O
,	O
this	O
risk	O
is	O
considerably	O
higher	O
,	O
to	O
such	O
an	O
extent	O
that	O
studies	O
into	O
the	O
efficacy	O
of	O
prophylactic	O
measures	O
are	O
required	O
.	O

Supporting	O
Information	O

Case	O
report	O
:	O
rapidly	O
fatal	O
bowel	O
ischaemia	O
on	O
clozapine	O
treatment	O
Abstract	O
Background	O
There	O
have	O
been	O
previous	O
reported	O
deaths	O
due	O
to	O
clozapine	O
-	O
induced	O
constipation	O
.	O

In	O
all	O
these	O
cases	O
patients	O
have	O
experienced	O
prior	O
abdominal	O
symptoms	O
over	O
a	O
period	O
of	O
weeks	O
or	O
months	O
.	O

Case	O
presentation	O
We	O
report	O
the	O
sudden	O
death	O
due	O
to	O
constipation	O
of	O
a	O
healthy	O
young	O
male	O
patient	O
on	O
clozapine	O
without	O
any	O
known	O
history	O
of	O
prior	O
abdominal	O
symptoms	O
.	O

Conclusion	O
Psychiatrists	O
need	O
to	O
be	O
alert	O
to	O
the	O
medical	O
emergencies	O
which	O
can	O
occur	O
in	O
the	O
context	O
of	O
clozapine	O
treatment	O
and	O
also	O
need	O
to	O
make	O
other	O
clinicians	O
who	O
may	O
have	O
contact	O
with	O
their	O
patients	O
aware	O
of	O
these	O
.	O

Background	O
There	O
have	O
been	O
six	O
previously	O
published	O
cases	O
of	O
death	O
secondary	O
to	O
clozapine	O
-	O
induced	O
constipation	O
[	O
1	O
-	O
3	O
]	O
.	O

Of	O
these	O
,	O
two	O
patients	O
died	O
from	O
faecal	O
peritonitis	O
,	O
two	O
from	O
aspiration	O
of	O
faeculent	O
vomitus	O
as	O
a	O
result	O
of	O
bowel	O
obstruction	O
and	O
two	O
from	O
bowel	O
necrosis	O
.	O

In	O
all	O
these	O
cases	O
there	O
had	O
been	O
prior	O
complaints	O
of	O
constipation	O
and/or	O
other	O
abdominal	O
symptoms	O
for	O
weeks	O
to	O
months	O
before	O
the	O
fatal	O
event	O
.	O

Here	O
we	O
describe	O
a	O
case	O
of	O
constipation	O
,	O
presumably	O
clozapine	O
-	O
induced	O
,	O
where	O
death	O
from	O
bowel	O
ischaemia	O
occured	O
within	O
2	O
days	O
from	O
the	O
first	O
complaint	O
of	O
constipation	O
and	O
without	O
any	O
prior	O
reported	O
abdominal	O
symptoms	O
which	O
might	O
have	O
provided	O
a	O
warning	O
to	O
the	O
clinicians	O
involved	O
.	O

Case	O
presentation	O
A	O
20-year	O
-	O
old	O
male	O
with	O
a	O
year	O
long	O
history	O
of	O
schizophrenia	O
which	O
had	O
been	O
unresponsive	O
to	O
trials	O
of	O
two	O
atypical	O
antipsychotic	O
drugs	O
was	O
commenced	O
on	O
clozapine	O
.	O

The	O
dose	O
was	O
titrated	O
over	O
the	O
next	O
year	O
to	O
900	O
mg	O
daily	O
.	O

Due	O
to	O
persisting	O
negative	O
symptoms	O
amisulpiride	O
400	O
mg	O
twice	O
daily	O
was	O
added	O
with	O
good	O
response	O
after	O
one	O
month	O
.	O

The	O
patient	O
was	O
reviewed	O
regularly	O
over	O
the	O
next	O
year	O
,	O
continued	O
to	O
improve	O
and	O
did	O
not	O
report	O
any	O
side	O
effects	O
to	O
members	O
of	O
the	O
multidisciplinary	O
mental	O
health	O
team	O
working	O
to	O
support	O
him	O
in	O
the	O
community	O
.	O

He	O
appeared	O
to	O
be	O
fit	O
and	O
healthy	O
.	O

Although	O
he	O
usually	O
lived	O
in	O
supported	O
accommodation	O
he	O
was	O
staying	O
temporarily	O
with	O
his	O
family	O
and	O
from	O
their	O
account	O
he	O
complained	O
of	O
having	O
constipation	O
for	O
2	O
days	O
before	O
presenting	O
to	O
his	O
GP	O
with	O
severe	O
abdominal	O
pain	O
.	O

He	O
was	O
prescribed	O
medication	O
and	O
returned	O
home	O
but	O
his	O
condition	O
deteriorated	O
further	O
and	O
a	O
few	O
hours	O
later	O
an	O
ambulance	O
was	O
called	O
.	O

He	O
collapsed	O
and	O
died	O
before	O
reaching	O
hospital	O
.	O

Post	O
mortem	O
examination	O
revealed	O
that	O
he	O
had	O
impacted	O
faeces	O
which	O
had	O
pressed	O
against	O
the	O
bowel	O
wall	O
causing	O
ischaemia	O
.	O

This	O
had	O
led	O
to	O
infarction	O
of	O
this	O
part	O
of	O
the	O
bowel	O
.	O

Conclusion	O
This	O
case	O
demonstrates	O
that	O
death	O
can	O
occur	O
over	O
a	O
very	O
short	O
time	O
course	O
from	O
constipation	O
,	O
in	O
this	O
case	O
presumably	O
induced	O
by	O
clozapine	O
.	O

Death	O
from	O
constipation	O
and	O
subsequent	O
bowel	O
infarction	O
is	O
relatively	O
common	O
in	O
elderly	O
patients	O
and	O
infarction	O
causes	O
a	O
far	O
more	O
rapid	O
and	O
dangerous	O
deterioration	O
than	O
does	O
intestinal	O
obstruction	O
.	O

In	O
the	O
present	O
case	O
this	O
meant	O
that	O
this	O
patient	O
did	O
not	O
have	O
any	O
contact	O
with	O
psychiatric	O
services	O
between	O
the	O
onset	O
of	O
his	O
symptoms	O
and	O
his	O
rapid	O
demise	O
,	O
in	O
spite	O
of	O
regular	O
follow	O
-	O
up	O
.	O

Although	O
the	O
risk	O
of	O
neutropenia	O
is	O
relatively	O
well	O
-	O
known	O
,	O
it	O
should	O
be	O
borne	O
in	O
mind	O
that	O
clozapine	O
is	O
reported	O
to	O
be	O
associated	O
with	O
a	O
number	O
of	O
other	O
syndromes	O
which	O
may	O
be	O
rapidly	O
fatal	O
including	O
not	O
only	O
constipation	O
and	O
obstruction	O
but	O
also	O
cardiovascular	O
collapse	O
,	O
seizures	O
and	O
ketoacidosis	O
.	O

Psychiatrists	O
working	O
with	O
such	O
patients	O
should	O
not	O
only	O
themselves	O
be	O
vigilant	O
regarding	O
such	O
complications	O
but	O
should	O
take	O
steps	O
to	O
see	O
that	O
other	O
clinicians	O
to	O
whom	O
the	O
patient	O
may	O
present	O
are	O
also	O
aware	O
of	O
them	O
.	O

Competing	O
interests	O
The	O
author	O
(	O
s	O
)	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O
Both	O
authors	O
were	O
equally	O
involved	O
in	O
the	O
preparation	O
of	O
this	O
manuscript	O
.	O

Pre	O
-	O
publication	O
history	O
The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O

Expression	O
of	O
C	O
-	O
terminal	O
deleted	O
p53	O
isoforms	O
in	O
neuroblastoma	O
Abstract	O
The	O
tumor	O
suppressor	O
gene	O
,	O
p53	O
,	O
is	O
rarely	O
mutated	O
in	O
neuroblastomas	O
(	O
NB	O
)	O
at	O
the	O
time	O
of	O
diagnosis	O
,	O
but	O
its	O
dysfunction	O
could	O
result	O
from	O
a	O
nonfunctional	O
conformation	O
or	O
cytoplasmic	O
sequestration	O
of	O
the	O
wild	O
-	O
type	O
p53	O
protein	O
.	O

However	O
,	O
p53	O
mutation	O
,	O
when	O
it	O
occurs	O
,	O
is	O
found	O
in	O
NB	O
tumors	O
with	O
drug	O
resistance	O
acquired	O
over	O
the	O
course	O
of	O
chemotherapy	O
.	O

As	O
yet	O
,	O
no	O
study	O
has	O
been	O
devoted	O
to	O
the	O
function	O
of	O
the	O
specific	O
p53	O
mutants	O
identified	O
in	O
NB	O
cells	O
.	O

This	O
study	O
includes	O
characterization	O
and	O
functional	O
analysis	O
of	O
p53	O
expressed	O
in	O
eight	O
cell	O
lines	O
:	O
three	O
wild	O
-	O
type	O
cell	O
lines	O
and	O
five	O
cell	O
lines	O
harboring	O
mutations	O
.	O

We	O
identified	O
two	O
transcription	O
-	O
inactive	O
p53	O
variants	O
truncated	O
in	O
the	O
C	O
-	O
terminus	O
,	O
one	O
of	O
which	O
corresponded	O
to	O
the	O
p53β	O
isoform	O
recently	O
identified	O
in	O
normal	O
tissue	O
by	O
Bourdon	O
et	O
al.	O
[	O
J.	O
C.	O
Bourdon	O
,	O
K.	O
Fernandes	O
,	O
F.	O
Murray	O
-	O
Zmijewski	O
,	O
G.	O
Liu	O
,	O
A.	O
Diot	O
,	O
D.	O
P.	O
Xirodimas	O
,	O
M.	O
K.	O
Saville	O
and	O
D.	O
P.	O
Lane	O
(	O
2005	O
)	O
Genes	O
Dev	O
.	O
,	O
19	O
,	O
2122–2137	O
]	O
.	O

Our	O
results	O
show	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
the	O
p53β	O
isoform	O
is	O
the	O
only	O
p53	O
species	O
to	O
be	O
endogenously	O
expressed	O
in	O
the	O
human	B
NB	O
cell	O
line	O
SK	O
-	O
N	O
-	O
AS	O
,	O
suggesting	O
that	O
the	O
C	O
-	O
terminus	O
truncated	O
p53	O
isoforms	O
may	O
play	O
an	O
important	O
role	O
in	O
NB	O
tumor	O
development	O
.	O

INTRODUCTION	O
The	O
p53	O
tumor	O
suppressor	O
gene	O
remains	O
the	O
most	O
frequently	O
altered	O
gene	O
in	O
human	B
tumors	O
.	O

Several	O
p53	O
mutation	O
databases	O
have	O
been	O
reported	O
previously	O
(	O
1–3	O
)	O
,	O
and	O
to	O
date	O
,	O
more	O
than	O
1500	O
different	O
p53	O
mutants	O
have	O
been	O
described	O
(	O
4	O
)	O
.	O

Functional	O
inactivation	O
of	O
p53	O
is	O
usually	O
due	O
to	O
gene	O
mutation	O
,	O
deletion	O
or	O
protein	O
degradation	O
.	O

In	O
general	O
,	O
the	O
majority	O
of	O
p53	O
mutations	O
in	O
human	B
neoplasia	O
are	O
missense	O
mutations	O
affecting	O
the	O
DNA	O
-	O
binding	O
domain	O
(	O
DBD	O
)	O
.	O

Unlike	O
other	O
human	B
cancers	O
,	O
p53	O
in	O
neuroblastoma	O
(	O
NB	O
)	O
is	O
rarely	O
mutated	O
in	O
the	O
primary	O
tumor	O
at	O
diagnosis	O
but	O
high	O
levels	O
of	O
wild	O
-	O
type	O
p53	O
(	O
wt	O
p53	O
)	O
protein	O
expression	O
have	O
been	O
found	O
in	O
the	O
cytoplasm	O
of	O
undifferentiated	O
tumors	O
(	O
5,6	O
)	O
.	O

More	O
recently	O
,	O
in	O
normal	O
unstressed	O
cells	O
,	O
wt	O
p53	O
protein	O
was	O
found	O
to	O
be	O
retained	O
in	O
the	O
cytoplasm	O
as	O
a	O
latent	O
form	O
,	O
in	O
huge	O
,	O
p53-associated	O
protein	O
complexes	O
known	O
as	O
'	O
Parc	O
'	O
(	O
7	O
)	O
.	O

The	O
steady	O
-	O
state	O
concentration	O
of	O
p53	O
in	O
normal	O
unstressed	O
cells	O
is	O
usually	O
very	O
low	O
because	O
of	O
the	O
short	O
half	O
-	O
life	O
of	O
the	O
wild	O
-	O
type	O
(	O
wt	O
)	O
protein	O
.	O

Overexpression	O
of	O
p53	O
in	O
most	O
of	O
the	O
transformed	O
cells	O
containing	O
a	O
missense	O
mutation	O
within	O
the	O
p53	O
gene	O
appears	O
to	O
be	O
due	O
to	O
the	O
increased	O
stability	O
of	O
mutated	O
p53	O
(	O
8)	O
.	O

In	O
unstressed	O
NB	O
cells	O
,	O
high	O
wt	O
p53	O
expression	O
may	O
reflect	O
the	O
embryonic	O
origin	O
of	O
NBs	O
,	O
in	O
which	O
precursor	O
cells	O
fail	O
to	O
mature	O
(	O
9	O
)	O
.	O

p53	O
mutations	O
are	O
unusual	O
in	O
human	B
NB	O
but	O
,	O
when	O
they	O
do	O
occur	O
,	O
are	O
found	O
in	O
post	O
-	O
chemotherapy	O
tumors	O
.	O

In	O
this	O
respect	O
,	O
Tweddle	O
et	O
al.	O
(	O
10	O
)	O
described	O
how	O
two	O
NB	O
cell	O
lines	O
derived	O
from	O
the	O
same	O
patient	O
can	O
elicit	O
a	O
different	O
p53	O
status	O
:	O
wt	O
p53	O
for	O
SK	O
-	O
N	O
-	O
BE	O
(	O
1a	O
)	O
established	O
before	O
treatment	O
,	O
and	O
mutated	O
p53	O
for	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2c	O
)	O
established	O
after	O
relapse	O
of	O
the	O
patient	O
under	O
treatment	O
with	O
cytotoxic	O
agents	O
such	O
as	O
cyclophosphamide	O
,	O
doxorubicin	O
,	O
vincristine	O
and	O
radiotherapy	O
.	O

In	O
NB	O
cell	O
lines	O
,	O
p53	O
mutation	O
has	O
been	O
found	O
in	O
multidrug	O
-	O
resistant	O
cells	O
(	O
11	O
)	O
.	O

Various	O
types	O
of	O
p53	O
mutation	O
have	O
been	O
detected	O
in	O
NB	O
cells	O
and	O
can	O
lead	O
to	O
inactivation	O
either	O
by	O
shut	O
-	O
down	O
of	O
protein	O
expression	O
or	O
production	O
of	O
aberrant	O
p53	O
products	O
.	O

Indeed	O
,	O
in	O
LAN-1	O
cells	O
,	O
p53	O
nonsense	O
mutation	O
at	O
cysteine	O
182	O
in	O
exon	O
5	O
leads	O
to	O
the	O
absence	O
of	O
protein	O
(	O
9	O
)	O
,	O
whereas	O
in	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
cells	O
,	O
missense	O
mutation	O
at	O
codon	O
135	O
(	O
C135F	O
)	O
leads	O
to	O
stable	O
overexpressed	O
protein	O
(	O
11	O
)	O
.	O

By	O
analyzing	O
IGR	O
-	O
N-91	O
,	O
a	O
cell	O
line	O
established	O
in	O
our	O
laboratory	O
from	O
the	O
bone	O
marrow	O
of	O
a	O
patient	O
with	O
metastatic	O
NB	O
after	O
unsuccessful	O
Adriamycin	O
–	O
vincristine	O
chemotherapy	O
(	O
12	O
)	O
,	O
we	O
identified	O
another	O
type	O
of	O
aberrant	O
protein	O
that	O
arises	O
from	O
the	O
duplication	O
of	O
exons	O
7	O
-	O
8	O
-	O
9	O
.	O

This	O
duplication	O
spans	O
from	O
amino	O
acids	O
225	O
to	O
331	O
,	O
which	O
represent	O
part	O
of	O
the	O
DBD	O
and	O
part	O
of	O
the	O
oligomerization	O
domain	O
(	O
13	O
)	O
.	O

However	O
,	O
each	O
p53	O
mutant	O
has	O
been	O
described	O
in	O
the	O
literature	O
as	O
a	O
case	O
report	O
,	O
and	O
so	O
far	O
,	O
no	O
comparative	O
study	O
has	O
been	O
undertaken	O
to	O
link	O
their	O
biochemical	O
features	O
with	O
functional	O
properties	O
.	O

In	O
the	O
present	O
study	O
we	O
report	O
two	O
novel	O
p53	O
C	O
-	O
terminus	O
mutants	O
identified	O
in	O
SK	O
-	O
N	O
-	O
AS	O
and	O
IGR	O
-	O
NB8	O
human	B
NB	O
cell	O
lines	O
.	O

The	O
biological	O
properties	O
of	O
these	O
two	O
new	O
variants	O
were	O
analyzed	O
in	O
comparison	O
with	O
p53	O
isolated	O
from	O
six	O
other	O
human	B
NB	O
lines	O
:	O
three	O
[	O
LAN-1	O
,	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
and	O
IGR	O
-	O
N-91	O
]	O
expressing	O
mutant	O
p53	O
and	O
three	O
(	O
SH	O
-	O
SY5Y	O
,	O
LAN-5	O
and	O
IMR-32	O
)	O
expressing	O
the	O
wt	O
protein	O
.	O

This	O
characterization	O
was	O
done	O
by	O
using	O
a	O
range	O
of	O
functional	O
assays	O
:	O
(	O
i	O
)	O
the	O
ability	O
of	O
the	O
protein	O
to	O
bind	O
with	O
p53	O
consensus	O
sequence	O
using	O
the	O
functional	O
analysis	O
of	O
separated	O
allele	O
in	O
yeast	B
(	O
FASAY	O
)	O
;	O
(	O
ii	O
)	O
the	O
ability	O
of	O
the	O
protein	O
to	O
transactivate	O
the	O
p53-responsive	O
element	O
(	O
RE	O
)	O
identified	O
either	O
in	O
the	O
promoter	O
of	O
p21	O
/	O
WAF1	O
or	O
in	O
the	O
first	O
intron	O
of	O
BAX	O
,	O
using	O
luciferase	O
reporter	O
assay	O
;	O
(	O
iii	O
)	O
the	O
induction	O
of	O
endogenous	O
p21	O
/	O
WAF1	O
gene	O
expression	O
under	O
stress	O
conditions	O
.	O

MATERIALS	O
AND	O
METHODS	O
Neuroblastoma	O
cell	O
lines	O
,	O
culture	O
and	O
drug	O
treatments	O
The	O
parental	O
human	B
NB	O
SH	O
-	O
SY5Y	O
,	O
SK	O
-	O
N	O
-	O
AS	O
,	O
IMR-32	O
and	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
cell	O
lines	O
were	O
purchased	O
from	O
the	O
European	O
Collection	O
of	O
Cell	O
Cultures	O
(	O
ECACC	O
,	O
Wiltshire	O
,	O
UK	O
)	O
.	O

The	O
human	B
IGR	O
-	O
NB8	O
cells	O
(	O
a	O
gift	O
of	O
Prof.	O
Gilles	O
Vassal	O
,	O
UPRES	O
EA	O
3535	O
,	O
Institut	O
Gustave	O
Roussy	O
,	O
Villejuif	O
)	O
were	O
derived	O
from	O
a	O
previously	O
untreated	O
localized	O
NB	O
(	O
14	O
)	O
.	O

The	O
LAN-1	O
and	O
LAN-5	O
cell	O
lines	O
were	O
provided	O
by	O
Dr	O
Nicole	O
Gross	O
(	O
Pediatric	O
Oncology	O
Research	O
,	O
Lausanne	O
,	O
Switzerland	O
)	O
.	O

The	O
human	B
IGR	O
-	O
N-91	O
cell	O
line	O
was	O
established	O
in	O
our	O
laboratory	O
from	O
the	O
bone	O
marrow	O
of	O
a	O
patient	O
with	O
metastatic	O
NB	O
after	O
unsuccessful	O
adriamycin	O
–	O
vincristin	O
chemotherapy	O
(	O
12	O
)	O
.	O

LAN-1	O
,	O
LAN-5	O
and	O
IMR-32	O
were	O
grown	O
in	O
RPMI	O
medium	O
supplemented	O
with	O
2	O
mM	O
l	O
-	O
glutamine	O
and	O
10	O
%	O
fetal	O
calf	O
serum	O
and	O
gentamicine	O
10	O
μg	O
/	O
ml	O
.	O

Others	O
cell	O
lines	O
were	O
cultured	O
in	O
DMEM	O
.	O

For	O
activation	O
of	O
endogenous	O
p53	O
,	O
cells	O
were	O
treated	O
with	O
cis	O
-	O
platinum	O
(	O
Sigma	O
)	O
(	O
10	O
μg	O
/	O
ml	O
)	O
for	O
24	O
h	O
then	O
lysed	O
for	O
western	O
blot	O
analysis	O
.	O

Western	O
blot	O
analysis	O
This	O
procedure	O
was	O
carried	O
out	O
as	O
described	O
previously	O
(	O
13	O
)	O
.	O

Protein	O
lysates	O
(	O
50	O
μg	O
)	O
were	O
submitted	O
to	O
10	O
%	O
SDS	O
–	O
PAGE	O
,	O
and	O
then	O
transferred	O
onto	O
nitrocellulose	O
filters	O
.	O

After	O
saturation	O
,	O
the	O
membranes	O
were	O
incubated	O
with	O
primary	O
antibody	O
diluted	O
in	O
0.1	O
%	O
phosphate	O
-	O
buffered	O
saline	O
,	O
Tween-20	O
and	O
3	O
%	O
skim	O
milk	O
.	O

The	O
primary	O
antibodies	O
used	O
were	O
anti	O
-	O
p53	O
monoclonal	O
antibody	O
(	O
clone	O
DO-7	O
,	O
1	O
/	O
1000	O
,	O
DAKO	O
)	O
,	O
anti	O
-	O
p21	O
/	O
WAF1	O
monoclonal	O
antibody	O
(	O
Ab-1	O
,	O
1	O
/	O
200	O
,	O
Oncogene	O
Research	O
)	O
and	O
anti	O
-	O
β	O
-	O
actin	O
monoclonal	O
antibody	O
(	O
1	O
/	O
1000	O
;	O
Chemicon	O
)	O
as	O
internal	O
control	O
.	O

Protein	O
bands	O
were	O
detected	O
by	O
ECL	O
system	O
(	O
Amersham	O
)	O
.	O

PCR	O
,	O
plasmids	O
cloning	O
Genomic	O
DNA	O
was	O
extracted	O
using	O
lysis	O
buffer	O
containing	O
20	O
mM	O
Tris	O
–	O
HCl	O
,	O
pH	O
7.5	O
;	O
0.4	O
M	O
NaCl	O
;	O
0.5	O
%	O
SDS	O
;	O
10	O
mM	O
EDTA	O
,	O
treated	O
with	O
proteinase	O
K	O
(	O
200	O
μg	O
/	O
μl	O
)	O
,	O
purified	O
with	O
phenol	O
/	O
chloroform	O
,	O
precipitated	O
with	O
ethanol	O
and	O
dissolved	O
in	O
DNase	O
free	O
water	O
.	O

Total	O
RNA	O
were	O
purified	O
using	O
RNAble	O
reagent	O
(	O
Eurobio	O
)	O
,	O
precipitated	O
with	O
isopropanol	O
and	O
dissolved	O
in	O
RNase	O
free	O
water	O
.	O

cDNA	O
was	O
obtained	O
by	O
reverse	O
transcription	O
of	O
1	O
μg	O
of	O
total	O
RNA	O
using	O
Superscript	O
II	O
™	O
RNase	O
H	O
-	O
Reverse	O
transcriptase	O
(	O
Invitrogen	O
)	O
and	O
Oligo	O
-	O
d	O
(	O
T	O
)	O
16	O
in	O
conditions	O
specified	O
by	O
the	O
manufacturer	O
.	O

Amplification	O
of	O
full	O
-	O
length	O
p53	O
coding	O
region	O
from	O
SH	O
-	O
SY5Y	O
,	O
IGR	O
-	O
N-91	O
,	O
IGR	O
-	O
NB8	O
and	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
cell	O
lines	O
was	O
performed	O
using	O
forward	O
primer	O
at	O
position	O
152	O
and	O
reverse	O
primer	O
at	O
position	O
1583	O
(	O
F1	O
and	O
R7	O
,	O
respectively	O
,	O
Table	O
1	O
;	O
GenBank	O
accession	O
no.	O
K03199	O
)	O
.	O

p53	O
cDNA	O
from	O
SK	O
-	O
N	O
-	O
AS	O
cells	O
for	O
cloning	O
was	O
obtained	O
from	O
RT	O
–	O
PCR	O
using	O
F1	O
and	O
reverse	O
primer	O
i9	O
+	O
:	O
5′-GCAAAGTCATAGAACCATTTTCAT-3′	O
(	O
nucleotide	O
position	O
14989	O
,	O
GenBank	O
accession	O
no.	O
X54156	O
)	O
primers	O
which	O
encompass	O
from	O
exon	O
1	O
to	O
exon	O
i9	O
+	O
first	O
identified	O
by	O
Flaman	O
et	O
al.	O
(	O
15	O
)	O
included	O
.	O

The	O
PCR	O
was	O
done	O
in	O
the	O
presence	O
of	O
pfu	O
Hotstart	O
DNA	O
polymerase	O
(	O
Stratagene	O
)	O
for	O
30	O
cycles	O
of	O
1	O
min	O
at	O
90	O
°	O
C	O
,	O
1	O
min	O
at	O
65	O
°	O
C	O
and	O
2	O
min	O
30	O
s	O
at	O
72	O
°	O
C	O
using	O
PTC-100	O
thermocycler	O
(	O
MJ	O
-	O
Research	O
)	O
.	O

The	O
p53	O
cDNA	O
from	O
SH	O
-	O
SY5Y	O
,	O
SK	O
-	O
N	O
-	O
AS	O
,	O
IGR	O
-	O
N-91	O
,	O
IGR	O
-	O
NB8	O
and	O
SK	O
-	O
N	O
-	O
AS	O
cells	O
were	O
then	O
cloned	O
into	O
pcDNA3.1	O
/	O
V5-His	O
-	O
Topo	O
vector	O
(	O
Invitrogen	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
instruction	O
.	O

The	O
p53	O
sequence	O
of	O
each	O
cell	O
line	O
was	O
investigated	O
by	O
sequencing	O
of	O
plasmids	O
after	O
cloning	O
.	O

Sequencing	O
was	O
performed	O
by	O
Genome	O
Express	O
(	O
Meylan	O
,	O
France	O
)	O
.	O

The	O
pDDm	O
-	O
TO	O
harboring	O
p53	O
dominant	O
negative	O
form	O
(	O
p53DD	O
)	O
pGL3-E1bTATA	O
and	O
the	O
pE1B	O
-	O
hWAF1	O
firefly	O
luciferase	O
reporter	O
containing	O
the	O
p53-responsive	O
element	O
of	O
the	O
p21	O
/	O
WAF1	O
promoter	O
were	O
described	O
previously	O
(	O
16,17	O
)	O
pE1B	O
-	O
BAXi	O
contains	O
the	O
p53RE	O
identified	O
in	O
the	O
intron	O
1	O
of	O
the	O
BAX	O
gene	O
[	O
(	O
18	O
)	O
and	O
D.	O
Munsch	O
,	O
personal	O
communication	O
]	O
.	O

Oligonucleotides	O
TCGAGGGCAGGCCCGGGCTTGTCG	O
and	O
CTAGCGACAAGCCCGGGCCTGCCC	O
were	O
annealed	O
and	O
cloned	O
into	O
pGL3-E1bTATA	O
digested	O
with	O
NheI	O
and	O
XhoI	O
to	O
obtain	O
pE1B	O
-	O
BAXi	O
.	O

The	O
pcDNA3-ΔNp73α	O
expression	O
plasmid	O
was	O
a	O
gift	O
of	O
Dr	O
Daniel	O
Caput	O
(	O
SANOFI	O
,	O
Labèges	O
,	O
France	O
)	O
.	O

Fluorescent	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
Cytogenetic	O
preparations	O
Metaphase	O
spreads	O
from	O
healthy	O
human	B
male	O
lymphocytes	O
and	O
tumor	O
cell	O
lines	O
were	O
prepared	O
as	O
described	O
previously	O
(	O
19	O
)	O
.	O

BAC	O
probe	O
RP11	O
-	O
199F11	O
,	O
containing	O
a	O
167	O
kb	O
region	O
spanning	O
TP53	O
gene	O
,	O
was	O
labeled	O
by	O
random	O
priming	O
in	O
the	O
presence	O
of	O
Alexa	O
594-dUTP	O
(	O
Molecular	O
Probes	O
)	O
.	O

A	O
commercial	O
probe	O
specific	O
for	O
chromosome	O
17	O
centromere	O
,	O
and	O
labeled	O
with	O
spectrum	O
green	O
,	O
was	O
obtained	O
from	O
Vysis	O
.	O

After	O
over	O
-	O
night	O
cohybridization	O
of	O
the	O
probes	O
in	O
the	O
presence	O
of	O
Cot-1	O
DNA	O
,	O
the	O
slides	O
were	O
washed	O
and	O
DNA	O
counterstained	O
with	O
DAPI	O
.	O

The	O
preparations	O
were	O
observed	O
with	O
an	O
epifluorescence	O
microscope	O
and	O
images	O
captured	O
with	O
a	O
Vysis	O
imaging	O
station	O
.	O

Between	O
3	O
and	O
14	O
metaphases	O
spreads	O
and	O
30–200	O
nuclei	O
were	O
examined	O
for	O
each	O
cell	O
line	O
.	O

Luciferase	O
reporter	O
assays	O
LAN-1	O
or	O
SH	O
-	O
SY5Y	O
cells	O
were	O
seeded	O
in	O
duplicates	O
onto	O
6-well	O
plates	O
at	O
a	O
density	O
of	O
2	O
×	O
104	O
cells	O
per	O
cm2	O
and	O
cotransfected	O
24	O
h	O
later	O
with	O
0.5	O
μg	O
(	O
2.5	O
μg	O
/	O
ml	O
)	O
of	O
pGL3	O
firefly	O
luciferase	O
reporter	O
gene	O
plasmid	O
under	O
the	O
control	O
of	O
either	O
pE1B	O
-	O
hWAF1	O
or	O
pE1B	O
-	O
BAX	O
using	O
lipofectamine	O
2000	O
and	O
1	O
μg	O
of	O
either	O
a	O
p53	O
expressing	O
plasmid	O
or	O
an	O
empty	O
vector	O
.	O

At	O
24	O
h	O
after	O
transfection	O
,	O
cells	O
were	O
lysed	O
with	O
200	O
μl	O
/	O
well	O
of	O
passive	O
lysis	O
buffer	O
provided	O
with	O
the	O
'	O
Luciferase	O
assay	O
kit	O
'	O
(	O
Promega	O
)	O
.	O

Luciferase	O
activity	O
was	O
measured	O
using	O
Microlumat	O
LB96P	O
luminometer	O
(	O
EG	O
&	O
G	O
Berthold	O
Instrument	O
)	O
.	O

Functional	O
assay	O
in	O
yeast	B
cDNA	O
was	O
obtained	O
by	O
RT	O
of	O
1	O
μg	O
of	O
total	O
RNA	O
using	O
Superscript	O
II	O
™	O
RNase	O
H	O
-	O
Reverse	O
transcriptase	O
(	O
Invitrogen	O
)	O
and	O
random	O
hexamers	O
to	O
prime	O
the	O
synthesis	O
in	O
conditions	O
specified	O
by	O
the	O
manufacturer	O
.	O

p53	O
cDNA	O
was	O
amplified	O
by	O
PCR	O
and	O
cotransformed	O
into	O
yeast	B
,	O
IG397	O
Ade2	O
strain	O
,	O
together	O
with	O
either	O
pRDI-22	O
vector	O
for	O
p53-standard	O
assay	O
or	O
pFW35	O
and	O
pFW34	O
plasmid	O
for	O
5′	O
or	O
3′	O
split	O
assay	O
,	O
respectively	O
,	O
carrying	O
the	O
ADE2	O
open	O
reading	O
frame	O
under	O
the	O
control	O
of	O
a	O
p53-responsive	O
promoter	O
(	O
20	O
)	O
.	O

In	O
a	O
selective	O
medium	O
lacking	O
leucine	O
,	O
wt	O
-	O
p53	O
activates	O
transcription	O
of	O
ADE2	O
gene	O
that	O
encodes	O
enzyme	O
—	O
phosphoribosylimidazole	O
carboxylase	O
—	O
implicated	O
in	O
adenine	O
biosynthesis	O
.	O

Therefore	O
,	O
a	O
colony	O
of	O
cells	O
that	O
expresses	O
ADE2	O
gene	O
is	O
white	O
whereas	O
the	O
one	O
composed	O
of	O
cells	O
where	O
ADE2	O
gene	O
is	O
not	O
expressed	O
owing	O
p53	O
mutation	O
is	O
red	O
.	O

RESULTS	O
P53	O
status	O
in	O
SK	O
-	O
N	O
-	O
AS	O
and	O
IGR	O
-	O
NB8	O
cells	O
We	O
first	O
compared	O
the	O
migration	O
profiles	O
of	O
p53	O
expressed	O
in	O
SK	O
-	O
N	O
-	O
AS	O
and	O
IGR	O
-	O
NB8	O
with	O
those	O
expressed	O
in	O
the	O
other	O
six	O
NB	O
cells	O
,	O
SH	O
-	O
SY5Y	O
,	O
LAN-5	O
,	O
LAN-1	O
,	O
IMR-32	O
,	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
and	O
IGR	O
-	O
N-91	O
.	O

Western	O
blots	O
from	O
50	O
μg	O
of	O
total	O
protein	O
extracts	O
were	O
revealed	O
with	O
p53	O
monoclonal	O
antibody	O
(	O
DO-7	O
)	O
.	O

A	O
range	O
of	O
profiles	O
was	O
identified	O
as	O
shown	O
in	O
Figure	O
1A	O
.	O

As	O
expected	O
,	O
p53	O
extracted	O
from	O
the	O
three	O
cell	O
lines	O
,	O
SH	O
-	O
SY5Y	O
,	O
LAN-5	O
and	O
IMR-32	O
,	O
expressing	O
wt	O
protein	O
(	O
13,21	O
)	O
migrated	O
at	O
the	O
wt	O
position	O
.	O

Of	O
particular	O
note	O
in	O
these	O
three	O
wt	O
p53	O
cell	O
lines	O
was	O
an	O
additional	O
faint	O
band	O
that	O
migrated	O
faster	O
than	O
the	O
full	O
-	O
length	O
protein	O
.	O

The	O
LAN-1	O
cells	O
were	O
found	O
to	O
be	O
p53	O
deficient	O
(	O
9	O
)	O
.	O

The	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
cell	O
line	O
showed	O
an	O
intense	O
band	O
reflecting	O
p53	O
stability	O
due	O
to	O
a	O
missense	O
mutation	O
at	O
codon	O
135	O
(	O
11	O
)	O
.	O

As	O
expected	O
,	O
due	O
to	O
the	O
previously	O
identified	O
duplication	O
of	O
exons	O
7	O
-	O
8	O
-	O
9	O
(	O
13	O
)	O
,	O
p53	O
protein	O
migration	O
was	O
delayed	O
in	O
the	O
IGR	O
-	O
N-91	O
cells	O
.	O

In	O
contrast	O
,	O
the	O
p53	O
protein	O
in	O
the	O
SK	O
-	O
N	O
-	O
AS	O
cell	O
line	O
migrated	O
noticeably	O
faster	O
than	O
the	O
wt	O
protein	O
,	O
indicating	O
that	O
it	O
was	O
smaller	O
in	O
size	O
.	O

The	O
p53	O
protein	O
in	O
the	O
IGR	O
-	O
NB8	O
cell	O
line	O
was	O
even	O
smaller	O
than	O
that	O
in	O
SK	O
-	O
N	O
-	O
AS	O
.	O

To	O
analyze	O
the	O
coding	O
region	O
of	O
each	O
of	O
the	O
p53	O
variants	O
,	O
RT	O
–	O
PCR	O
was	O
performed	O
using	O
p53-specific	O
F1-R7	O
primers	O
(	O
Table	O
1	O
and	O
Figure	O
1B	O
)	O
.	O

The	O
expected	O
1430	O
bp	O
for	O
full	O
-	O
length	O
p53	O
was	O
amplified	O
from	O
wt	O
p53-expressing	O
SH	O
-	O
SY5Y	O
,	O
LAN-5	O
and	O
IMR-32	O
cell	O
lines	O
.	O

As	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
harbors	O
a	O
single	O
point	O
mutation	O
at	O
codon	O
135	O
(	O
C135F	O
)	O
,	O
the	O
amplified	O
fragment	O
analyzed	O
by	O
electrophoresis	O
migrated	O
as	O
wt	O
p53	O
(	O
Figure	O
1B	O
)	O
.	O

The	O
longer	O
RT	O
–	O
PCR	O
fragment	O
from	O
the	O
mutated	O
IGR	O
-	O
N-91	O
cell	O
line	O
resulted	O
from	O
the	O
duplication	O
of	O
exons	O
7	O
-	O
8	O
-	O
9	O
,	O
as	O
shown	O
in	O
our	O
previous	O
data	O
(	O
13	O
)	O
,	O
which	O
corresponds	O
to	O
extra	O
nucleic	O
material	O
of	O
321	O
nt	O
.	O

For	O
the	O
LAN-1	O
cells	O
,	O
no	O
amplified	O
fragment	O
was	O
observed	O
in	O
accordance	O
with	O
published	O
data	O
,	O
which	O
demonstrates	O
the	O
extremely	O
low	O
levels	O
of	O
p53	O
mRNA	O
and	O
the	O
undetectable	O
level	O
of	O
protein	O
(	O
9	O
)	O
.	O

An	O
amplified	O
fragment	O
of	O
the	O
same	O
length	O
as	O
the	O
wt	O
protein	O
was	O
observed	O
in	O
the	O
IGR	O
-	O
NB8	O
cell	O
line	O
(	O
Figure	O
1B	O
)	O
.	O

Indeed	O
,	O
complete	O
gene	O
sequencing	O
revealed	O
a	O
point	O
mutation	O
E326STOP	O
leading	O
to	O
a	O
truncated	O
protein	O
at	O
C	O
-	O
terminus	O
.	O

No	O
fragment	O
,	O
however	O
,	O
was	O
amplified	O
from	O
SK	O
-	O
N	O
-	O
AS	O
with	O
F1-R7	O
primers	O
.	O

To	O
further	O
map	O
the	O
p53	O
mRNA	O
transcribed	O
in	O
these	O
cells	O
,	O
series	O
of	O
RT	O
–	O
PCR	O
tests	O
were	O
performed	O
using	O
the	O
forward	O
primer	O
,	O
F2	O
(	O
exon	O
8	O
position	O
1008th	O
according	O
to	O
GenBank	O
accession	O
no.	O
K03199	O
)	O
,	O
matched	O
with	O
different	O
reverse	O
primers	O
,	O
R3	O
(	O
at	O
the	O
junction	O
of	O
exon	O
8	O
/	O
9	O
,	O
nt	O
position	O
1124	O
)	O
,	O
R4	O
,	O
R5	O
(	O
in	O
exon	O
9	O
at	O
positions	O
1154	O
and	O
1184	O
,	O
respectively	O
)	O
,	O
and	O
R6	O
(	O
in	O
exon	O
10	O
,	O
at	O
position	O
1230	O
)	O
.	O

The	O
sequences	O
of	O
these	O
primers	O
are	O
given	O
in	O
Table	O
1	O
and	O
the	O
results	O
are	O
presented	O
in	O
Figure	O
2A	O
.	O

SK	O
-	O
N	O
-	O
AS	O
cDNA	O
gave	O
an	O
amplified	O
fragment	O
of	O
the	O
same	O
size	O
as	O
SH	O
-	O
SY5Y	O
cDNA	O
with	O
the	O
three	O
primer	O
pairs	O
,	O
F2	O
/	O
R3	O
,	O
F2	O
/	O
R4	O
and	O
F3	O
/	O
R5	O
.	O

However	O
,	O
in	O
contrast	O
to	O
SH	O
-	O
SY5Y	O
,	O
no	O
fragment	O
was	O
obtained	O
with	O
SK	O
-	O
N	O
-	O
AS	O
cDNA	O
using	O
the	O
F2	O
/	O
R6	O
primer	O
pair	O
,	O
which	O
suggests	O
the	O
absence	O
of	O
exon	O
10	O
in	O
SK	O
-	O
N	O
-	O
AS	O
mRNA	O
.	O

The	O
p53	O
protein	O
expressed	O
in	O
SK	O
-	O
N	O
-	O
AS	O
is	O
the	O
p53β	O
isoform	O
An	O
alternatively	O
spliced	O
form	O
of	O
human	B
p53	O
mRNA	O
with	O
an	O
additional	O
133	O
bp	O
exon	O
derived	O
from	O
intron	O
9	O
has	O
been	O
detected	O
in	O
normal	O
human	B
lymphocytes	O
(	O
15	O
)	O
.	O

This	O
spliced	O
variant	O
named	O
'	O
i9	O
+	O
'	O
encodes	O
a	O
truncated	O
protein	O
of	O
341	O
amino	O
acids	O
including	O
10	O
new	O
amino	O
acids	O
derived	O
from	O
the	O
novel	O
exon	O
,	O
the	O
p53β	O
isoform	O
according	O
to	O
Bourdon	O
et	O
al.	O
nomenclature	O
(	O
22	O
)	O
.	O

This	O
led	O
us	O
to	O
hypothesize	O
that	O
the	O
shorter	O
protein	O
expressed	O
by	O
the	O
SK	O
-	O
N	O
-	O
AS	O
cell	O
line	O
could	O
be	O
the	O
p53β	O
isoform	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
RT	O
–	O
PCRs	O
were	O
performed	O
using	O
primer	O
sets	O
designed	O
to	O
amplify	O
the	O
3′	O
region	O
of	O
p53	O
mRNA	O
encoding	O
either	O
the	O
specific	O
C	O
-	O
terminal	O
part	O
of	O
the	O
wt	O
protein	O
(	O
wt	O
C	O
-	O
ter	O
)	O
or	O
the	O
specific	O
C	O
-	O
terminal	O
part	O
of	O
the	O
β	O
isoform	O
(	O
β	O
C	O
-	O
ter	O
)	O
.	O

In	O
parallel	O
amplification	O
with	O
a	O
primer	O
pair	O
amplifying	O
the	O
DBD	O
was	O
used	O
as	O
control	O
.	O

The	O
sequences	O
of	O
these	O
oligonucleotides	O
are	O
given	O
in	O
Table	O
1	O
.	O

The	O
results	O
presented	O
in	O
Figure	O
2B	O
are	O
consistent	O
with	O
the	O
only	O
expression	O
of	O
the	O
p53β	O
isoform	O
in	O
SK	O
-	O
N	O
-	O
AS	O
as	O
no	O
band	O
was	O
observed	O
in	O
lane	O
using	O
specific	O
C	O
-	O
ter	O
primer	O
located	O
in	O
exon	O
10	O
.	O

Interestingly	O
,	O
RT	O
–	O
PCR	O
using	O
SH	O
-	O
SY5Y	O
(	O
SH	O
)	O
gave	O
an	O
amplified	O
fragment	O
not	O
only	O
with	O
the	O
primer	O
pair	O
specific	O
to	O
the	O
C	O
-	O
ter	O
domain	O
of	O
wt	O
p53	O
but	O
also	O
with	O
the	O
primer	O
pair	O
specific	O
to	O
the	O
p53β	O
isoform	O
.	O

This	O
result	O
,	O
combined	O
with	O
the	O
presence	O
of	O
an	O
additional	O
faint	O
band	O
migrating	O
faster	O
than	O
wt	O
p53	O
in	O
denaturing	O
polyacrylamide	O
gel	O
(	O
Figure	O
1A	O
)	O
,	O
strongly	O
suggests	O
that	O
both	O
the	O
p53	O
full	O
-	O
length	O
protein	O
and	O
the	O
β	O
isoform	O
were	O
expressed	O
in	O
the	O
SH	O
-	O
SY5Y	O
cells	O
.	O

The	O
full	O
-	O
length	O
SK	O
-	O
N	O
-	O
AS	O
p53	O
cDNA	O
was	O
then	O
amplified	O
with	O
the	O
forward	O
primer	O
F1	O
and	O
a	O
reverse	O
primer	O
located	O
within	O
the	O
novel	O
exon	O
i9	O
+	O
(	O
Table	O
1	O
)	O
.	O

This	O
amplified	O
fragment	O
was	O
cloned	O
in	O
pcDNA3	O
/	O
V5-His	O
-	O
Topo	O
,	O
as	O
described	O
in	O
Materials	O
and	O
Methods	O
.	O

Its	O
sequence	O
analysis	O
confirmed	O
that	O
the	O
truncated	O
p53	O
expressed	O
in	O
SK	O
-	O
N	O
-	O
AS	O
was	O
encoded	O
by	O
the	O
i9	O
+	O
splice	O
variant	O
described	O
previously	O
by	O
Flaman	O
et	O
al.	O
(	O
15	O
)	O
that	O
encodes	O
the	O
p53β	O
isoform	O
characterized	O
by	O
Bourdon	O
et	O
al.	O
(	O
22	O
)	O
.	O

A	O
series	O
of	O
genomic	O
amplifications	O
were	O
performed	O
to	O
identify	O
a	O
possible	O
deletion	O
within	O
the	O
intron	O
9	O
that	O
could	O
account	O
for	O
the	O
absence	O
of	O
normal	O
size	O
p53	O
in	O
SK	O
-	O
N	O
-	O
AS	O
cells	O
.	O

The	O
primer	O
sequences	O
are	O
given	O
in	O
Table	O
1	O
.	O

Amplifications	O
were	O
performed	O
in	O
parallel	O
with	O
total	O
DNA	O
extracted	O
from	O
SH	O
-	O
SY5Y	O
and	O
SK	O
-	O
N	O
-	O
AS	O
cells	O
.	O

Results	O
are	O
presented	O
in	O
Figure	O
3	O
.	O

Normal	O
size	O
fragments	O
that	O
encompass	O
the	O
acceptor	O
site	O
of	O
intron	O
9	O
were	O
amplified	O
with	O
SH	O
-	O
SY5Y	O
as	O
well	O
as	O
with	O
SK	O
-	O
N	O
-	O
AS	O
DNA	O
.	O

On	O
the	O
contrary	O
amplification	O
fragments	O
that	O
encompass	O
the	O
intron	O
9	O
donor	O
site	O
were	O
obtained	O
only	O
with	O
SH	O
-	O
SY5Y	O
but	O
not	O
with	O
SK	O
-	O
N	O
-	O
AS	O
DNA	O
.	O

These	O
results	O
identify	O
a	O
deletion	O
of	O
the	O
intron	O
9	O
/	O
exon	O
10	O
junction	O
within	O
the	O
SK	O
-	O
N	O
-	O
AS	O
p53	O
gene	O
.	O

A	O
yeast	B
functional	O
assay	O
confirmed	O
the	O
absence	O
of	O
p53	O
full	O
-	O
length	O
expression	O
in	O
SK	O
-	O
N	O
-	O
AS	O
and	O
IGR	O
-	O
NB8	O
It	O
is	O
possible	O
to	O
detect	O
p53	O
mutation	O
using	O
a	O
simple	O
yeast	B
colony	O
color	O
assay	O
as	O
described	O
by	O
Flaman	O
et	O
al.	O
(	O
23	O
)	O
.	O

When	O
the	O
strain	O
is	O
transformed	O
with	O
a	O
plasmid	O
-	O
encoding	O
wt	O
p53	O
,	O
the	O
cells	O
express	O
the	O
ADE2	O
gene	O
and	O
produce	O
white	O
colonies	O
(	O
Figure	O
4A	O
,	O
a	O
,	O
b2	O
and	O
c1	O
,	O
and	O
Figure	O
4B	O
,	O
dish	O
a	O
)	O
.	O

Cells	O
containing	O
mutant	O
p53	O
fail	O
to	O
express	O
ADE2	O
and	O
form	O
small	O
red	O
colonies	O
(	O
Figure	O
4A	O
,	O
b	O
and	O
b1	O
,	O
and	O
Figure	O
4B	O
,	O
dish	O
c	O
)	O
.	O

When	O
the	O
p53	O
cDNA	O
fragment	O
is	O
deleted	O
,	O
cells	O
are	O
unable	O
to	O
form	O
a	O
colony	O
(	O
Figure	O
4A	O
,	O
c	O
and	O
c2	O
)	O
.	O

As	O
shown	O
in	O
Table	O
2	O
,	O
FASAY	O
was	O
performed	O
as	O
a	O
p53-standard	O
test	O
with	O
full	O
-	O
length	O
cDNA	O
or	O
with	O
the	O
split	O
version	O
at	O
the	O
5′	O
and	O
3′	O
end	O
(	O
15	O
)	O
.	O

The	O
background	O
of	O
FASAY	O
experiments	O
is	O
around	O
10	O
%	O
.	O

p53	O
wt	O
expressing	O
SH	O
-	O
SY5Y	O
and	O
LAN-5	O
,	O
2	O
wt	O
cell	O
lines	O
,	O
yielded	O
∼92–97	O
%	O
of	O
white	O
colonies	O
(	O
Table	O
2	O
)	O
.	O

One	O
hundred	O
percent	O
of	O
the	O
colonies	O
carrying	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
p53	O
,	O
which	O
is	O
homozygous	O
for	O
the	O
C135F	O
mutation	O
,	O
turned	O
red	O
with	O
the	O
standard	O
or	O
5′	O
split	O
assay	O
,	O
whereas	O
94	O
%	O
of	O
the	O
colonies	O
turned	O
white	O
with	O
the	O
3′	O
split	O
assay	O
since	O
the	O
missense	O
mutation	O
does	O
not	O
extend	O
to	O
the	O
C′-terminus	O
of	O
the	O
gene	O
(	O
Table	O
2	O
and	O
Figure	O
4B	O
,	O
dish	O
c	O
)	O
.	O

No	O
colonies	O
were	O
observed	O
with	O
p53-deficient	O
LAN-1	O
cells	O
,	O
(	O
see	O
also	O
Figure	O
4A	O
,	O
c	O
and	O
c2	O
)	O
.	O

With	O
SK	O
-	O
N	O
-	O
AS	O
cells	O
,	O
the	O
split	O
5′	O
assay	O
gave	O
96	O
%	O
white	O
colonies	O
,	O
while	O
the	O
p53-standard	O
and	O
split	O
3′	O
assay	O
did	O
not	O
produce	O
any	O
colonies	O
(	O
Table	O
2	O
)	O
.	O

This	O
means	O
that	O
the	O
5′	O
terminus	O
was	O
intact	O
whereas	O
the	O
3′	O
terminus	O
had	O
been	O
deleted	O
,	O
as	O
was	O
confirmed	O
by	O
nucleotide	O
sequence	O
analysis	O
.	O

The	O
IGR	O
-	O
NB8	O
colonies	O
,	O
however	O
,	O
were	O
red	O
both	O
with	O
the	O
p53-standard	O
assay	O
and	O
the	O
split	O
3′	O
assay	O
.	O

In	O
the	O
IGR	O
-	O
N-91	O
cell	O
line	O
,	O
where	O
p53	O
harbors	O
two	O
contiguous	O
sets	O
of	O
exons	O
7–9	O
,	O
spanning	O
the	O
DBD	O
and	O
oligomerization	O
domain	O
,	O
it	O
is	O
interesting	O
to	O
note	O
that	O
the	O
yeast	B
colonies	O
were	O
predominantly	O
white	O
(	O
Figure	O
4B	O
,	O
dish	O
b	O
)	O
with	O
the	O
split	O
5′	O
and	O
the	O
split	O
3′	O
assay	O
(	O
96	O
and	O
87	O
%	O
of	O
white	O
colonies	O
,	O
respectively	O
)	O

This	O
suggests	O
that	O
the	O
cells	O
express	O
a	O
binding	O
ability	O
that	O
is	O
specific	O
to	O
wild	O
-	O
type	O
p53	O
rather	O
than	O
mutated	O
p53	O
(	O
Table	O
2	O
)	O
.	O

Transcription	O
activity	O
of	O
SH	O
-	O
SY5Y	O
,	O
IGR	O
-	O
N-91	O
,	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
,	O
SK	O
-	O
N	O
-	O
AS	O
and	O
IGR	O
-	O
NB8	O
p53	O
variants	O
in	O
mammalian	O
cells	O
To	O
determine	O
the	O
transactivation	O
ability	O
of	O
p53	O
variants	O
in	O
mammalian	O
cells	O
,	O
we	O
used	O
a	O
reporter	O
gene	O
strategy	O
.	O

The	O
p53RE	O
located	O
within	O
either	O
the	O
human	B
p21	O
/	O
WAF1	O
promoter	O
or	O
the	O
intron	O
1	O
of	O
the	O
mouse	B
and	O
human	B
BAX	O
gene	O
[	O
(	O
18	O
)	O
and	O
D.	O
Munsch	O
,	O
personnal	O
communication	O
)	O
were	O
cloned	O
in	O
a	O
luciferase	O
reporter	O
gene	O
plasmid	O
upstream	O
of	O
the	O
E1B	O
minimal	O
promoter	O
as	O
described	O
in	O
Materials	O
and	O
Methods	O
.	O

The	O
p53-negative	O
LAN-1	O
cells	O
were	O
cotransfected	O
with	O
the	O
p53	O
vectors	O
expressing	O
the	O
p53	O
cloned	O
from	O
either	O
SH	O
-	O
SY5Y	O
,	O
IGR	O
-	O
N-91	O
,	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
,	O
SK	O
-	O
N	O
-	O
AS	O
or	O
IGR	O
-	O
NB8	O
and	O
the	O
luciferase	O
reporter	O
plasmids	O
.	O

Both	O
p53RE	O
were	O
strongly	O
stimulated	O
in	O
cells	O
cotransfected	O
with	O
wt	O
p53	O
cloned	O
from	O
SH	O
-	O
SY5Y	O
,	O
as	O
compared	O
to	O
cells	O
cotransfected	O
with	O
an	O
empty	O
plasmid	O
.	O

In	O
contrast	O
,	O
none	O
of	O
the	O
p53	O
variants	O
was	O
able	O
to	O
transactivate	O
the	O
expression	O
of	O
luciferase	O
driven	O
by	O
either	O
p21	O
/	O
WAF1	O
or	O
BAX	O
p53RE	O
(	O
Figure	O
5	O
)	O
.	O

To	O
test	O
transactivation	O
capability	O
at	O
the	O
protein	O
level	O
,	O
each	O
variant	O
was	O
transfected	O
into	O
p53-negative	O
LAN-1	O
cells	O
and	O
the	O
stimulation	O
of	O
endogenous	O
p21	O
/	O
Waf1	O
gene	O
expression	O
was	O
analyzed	O
by	O
western	O
blotting	O
.	O

As	O
shown	O
in	O
Figure	O
6	O
,	O
in	O
contrast	O
to	O
wt	O
p53	O
,	O
none	O
of	O
the	O
p53	O
variants	O
was	O
able	O
to	O
induce	O
p21	O
protein	O
accumulation	O
.	O

We	O
then	O
tested	O
for	O
a	O
possible	O
dominant	O
negative	O
effect	O
of	O
these	O
various	O
mutants	O
on	O
wt	O
p53-dependent	O
transcriptional	O
activity	O
.	O

To	O
this	O
end	O
,	O
SH	O
-	O
SY5Y	O
cells	O
were	O
cotransfected	O
with	O
constructs	O
encoding	O
the	O
luciferase	O
gene	O
driven	O
by	O
either	O
the	O
p21	O
/	O
Waf1	O
or	O
BAX	O
p53RE	O
and	O
the	O
constructs	O
expressing	O
the	O
various	O
p53s	O
cloned	O
from	O
IGR	O
-	O
NB8	O
,	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
,	O
IGR	O
-	O
N-91	O
,	O
SK	O
-	O
N	O
-	O
AS	O
and	O
IGR	O
-	O
NB8	O
NB	O
cells	O
or	O
p53DD	O
,	O
a	O
dominant	O
negative	O
mutant	O
of	O
wt	O
p53	O
(	O
24	O
)	O
.	O

The	O
stress	O
induced	O
by	O
transfection	O
activated	O
the	O
transcriptional	O
activity	O
of	O
the	O
wt	O
p53	O
expressed	O
in	O
SH	O
-	O
SY5Y	O
,	O
leading	O
to	O
a	O
p53-dependent	O
expression	O
of	O
luciferase	O
as	O
illustrated	O
by	O
the	O
fact	O
that	O
coexpression	O
of	O
p53DD	O
led	O
to	O
a	O
substantial	O
decrease	O
in	O
luciferase	O
activity	O
when	O
compared	O
to	O
the	O
luciferase	O
activity	O
of	O
cells	O
cotransfected	O
with	O
an	O
empty	O
plasmid	O
(	O
Figure	O
5	O
)	O
.	O

Compared	O
to	O
p53DD	O
,	O
mutants	O
within	O
the	O
DBD	O
isolated	O
from	O
IGR	O
-	O
N-91	O
or	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
had	O
only	O
a	O
moderate	O
dominant	O
negative	O
effect	O
on	O
endogenous	O
wt	O
p53	O
transcriptional	O
activity	O
.	O

More	O
surprisingly	O
,	O
the	O
transfection	O
of	O
the	O
C	O
-	O
terminal	O
truncated	O
variant	O
IGR	O
-	O
NB8	O
enhanced	O
both	O
BAX	O
and	O
p21	O
/	O
WAF1	O
p53RE	O
activity	O
.	O

The	O
coexpression	O
of	O
p53β	O
cloned	O
from	O
SK	O
-	O
N	O
-	O
AS	O
also	O
enhanced	O
BAX	O
p53RE	O
activity	O
.	O

A	O
similar	O
effect	O
has	O
been	O
reported	O
already	O
for	O
p53β	O
by	O
Bourdon	O
et	O
al.	O
(	O
22	O
)	O
.	O

When	O
combined	O
,	O
these	O
results	O
show	O
that	O
all	O
the	O
p53	O
variants	O
isolated	O
from	O
the	O
NB	O
cells	O
had	O
lost	O
the	O
ability	O
to	O
specifically	O
transactivate	O
the	O
p53	O
target	O
genes	O
.	O

Their	O
effect	O
on	O
the	O
transcriptional	O
activity	O
of	O
endogenous	O
wt	O
p53	O
expressed	O
in	O
SH	O
-	O
SY5Y	O
cells	O
,	O
however	O
,	O
largely	O
depended	O
on	O
the	O
p53	O
domain	O
affected	O
by	O
the	O
modification	O
.	O

All	O
the	O
identified	O
p53	O
variants	O
inhibited	O
the	O
induction	O
of	O
endogenous	O
p21	O
/	O
WAF1	O
gene	O
expression	O
under	O
stress	O
conditions	O
We	O
further	O
examined	O
whether	O
the	O
four	O
p53	O
variants	O
,	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
,	O
IGR	O
-	O
N-91	O
,	O
SK	O
-	O
N	O
-	O
AS	O
and	O
IGR	O
-	O
NB8	O
,	O
had	O
loss	O
their	O
ability	O
to	O
stimulate	O
the	O
endogenous	O
expression	O
of	O
the	O
p21	O
/	O
WAF1	O
gene	O
,	O
the	O
archetypical	O
cell	O
cycle	O
inhibitor	O
and	O
the	O
true	O
target	O
of	O
p53	O
.	O

To	O
this	O
end	O
,	O
cellular	O
response	O
to	O
genotoxic	O
stress	O
was	O
analyzed	O
by	O
western	O
blot	O
following	O
treatment	O
of	O
the	O
various	O
cell	O
lines	O
with	O
cisplatin	O
,	O
one	O
of	O
the	O
most	O
potent	O
antitumor	O
agents	O
used	O
in	O
neuroblastoma	O
.	O

Results	O
are	O
presented	O
in	O
Figure	O
7	O
.	O

None	O
of	O
the	O
mutant	O
cells	O
,	O
regardless	O
of	O
the	O
type	O
of	O
mutation	O
,	O
was	O
able	O
to	O
induce	O
p21	O
/	O
WAF1	O
protein	O
accumulation	O
,	O
unlike	O
the	O
3	O
p53	O
wild	O
-	O
type	O
cells	O
(	O
SH	O
-	O
SY5Y	O
,	O
IMR-32	O
and	O
LAN-5	O
)	O
.	O

Genomic	O
status	O
of	O
TP53	O
region	O
in	O
the	O
various	O
cell	O
lines	O
According	O
to	O
Knudson	O
's	O
'	O
two	O
hit	O
'	O
model	O
of	O
tumor	O
suppressor	O
gene	O
functional	O
inactivation	O
,	O
the	O
mutation	O
of	O
one	O
allele	O
is	O
supposed	O
to	O
be	O
associated	O
with	O
a	O
deletion	O
of	O
the	O
second	O
allele	O
.	O

To	O
assess	O
this	O
genetic	O
mechanism	O
,	O
we	O
performed	O
FISH	O
experiments	O
to	O
search	O
for	O
deletions	O
of	O
one	O
copy	O
of	O
the	O
TP53	O
region	O
,	O
especially	O
in	O
cell	O
lines	O
with	O
a	O
mutated	O
TP53	O
gene	O
.	O

For	O
this	O
purpose	O
,	O
metaphase	O
preparations	O
of	O
the	O
studied	O
cell	O
lines	O
were	O
cohybridized	O
with	O
a	O
p53	O
DNA	O
probe	O
labeled	O
in	O
red	O
(	O
BAC	O
clone	O
RP11	O
-	O
199F11	O
)	O
as	O
described	O
previously	O
(	O
25	O
)	O
and	O
a	O
chromosome	O
17-specific	O
centromeric	O
probe	O
labeled	O
in	O
green	O
.	O

The	O
three	O
cell	O
lines	O
shown	O
previously	O
to	O
express	O
a	O
wt	O
p53	O
protein	O
(	O
LAN5	O
,	O
IMR32	O
and	O
SH	O
-	O
SY5Y	O
)	O
,	O
displayed	O
as	O
expected	O
two	O
signals	O
with	O
each	O
probe	O
,	O
confirming	O
the	O
presence	O
of	O
both	O
TP53	O
alleles	O
in	O
these	O
cells	O
(	O
Figure	O
8	O
and	O
Table	O
3	O
)	O
.	O

Conversely	O
,	O
IGR	O
-	O
N-91	O
and	O
SK	O
-	O
N	O
-	O
AS	O
cell	O
lines	O
displayed	O
only	O
one	O
fluorescent	O
signal	O
for	O
each	O
probe	O
,	O
suggesting	O
a	O
whole	O
chromosome	O
17	O
lost	O
,	O
or	O
at	O
least	O
losses	O
of	O
the	O
17p	O
arm	O
and	O
the	O
centromeric	O
region	O
.	O

The	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
cell	O
line	O
has	O
been	O
described	O
as	O
containing	O
only	O
one	O
chromosome	O
17	O
and	O
one	O
TP53	O
signal	O
(	O
10	O
)	O
.	O

In	O
our	O
analysis	O
,	O
only	O
10	O
%	O
of	O
the	O
cells	O
displayed	O
this	O
characteristic	O
,	O
whilst	O
most	O
of	O
the	O
cells	O
had	O
two	O
copies	O
of	O
both	O
(	O
Figure	O
8	O
and	O
Table	O
3	O
)	O
.	O

p53	O
sequencing	O
,	O
however	O
,	O
confirmed	O
the	O
previously	O
described	O
mutation	O
,	O
and	O
the	O
absence	O
of	O
a	O
normal	O
allele	O
,	O
suggesting	O
that	O
the	O
cells	O
used	O
in	O
our	O
study	O
had	O
acquired	O
,	O
during	O
culture	O
,	O
an	O
uniparental	O
disomy	O
for	O
the	O
TP53-mutated	O
chromosome	O
17	O
.	O

Finally	O
,	O
the	O
other	O
two	O
cell	O
lines	O
(	O
LAN-1	O
and	O
IGR	O
-	O
NB8	O
)	O
displayed	O
highly	O
variable	O
genetic	O
heterogeneity	O
from	O
one	O
cell	O
to	O
the	O
next	O
(	O
Table	O
3	O
)	O
.	O

Surprisingly	O
,	O
although	O
p53	O
transcripts	O
are	O
extremely	O
faintly	O
expressed	O
in	O
LAN-1	O
cell	O
line	O
,	O
all	O
cells	O
showed	O
several	O
FISH	O
signals	O
with	O
the	O
167	O
kb	O
BAC	O
probe	O
used	O
here	O
.	O

To	O
understand	O
this	O
apparent	O
contradiction	O
,	O
an	O
array	O
-	O
CGH	O
experiment	O
was	O
performed	O
on	O
an	O
oligo	O
-	O
array	O
Agilent	O
,	O
which	O
indicated	O
a	O
133	O
kb	O
interstitial	O
deletion	O
corresponding	O
to	O
the	O
p53	O
coding	O
region	O
and	O
the	O
97	O
kb	O
upstream	O
region	O
.	O

Accordingly	O
,	O
the	O
fluorescent	O
spots	O
observed	O
in	O
FISH	O
experiments	O
on	O
LAN-1	O
cells	O
should	O
be	O
related	O
to	O
the	O
hybridization	O
of	O
the	O
57	O
kb	O
region	O
downstream	O
of	O
p53	O
gene	O
present	O
in	O
the	O
BAC	O
probe	O
.	O

IGRN	O
-	O
B8	O
cell	O
line	O
displayed	O
a	O
number	O
of	O
signals	O
of	O
both	O
colors	O
ranging	O
from	O
0	O
to	O
4	O
,	O
with	O
87	O
%	O
of	O
cells	O
displaying	O
a	O
loss	O
for	O
one	O
TP53	O
allele	O
.	O

Despite	O
this	O
genomic	O
variability	O
,	O
analysis	O
of	O
the	O
p53	O
protein	O
showed	O
a	O
single	O
shortened	O
form	O
in	O
IGR	O
-	O
N	O
-	O
B8	O
cell	O
line	O
(	O
Figure	O
1	O
)	O
.	O

Consequently	O
,	O
and	O
as	O
suggested	O
for	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
cell	O
line	O
,	O
IGR	O
-	O
N	O
-	O
B8	O
cell	O
line	O
should	O
contain	O
a	O
variable	O
number	O
of	O
copies	O
of	O
chromosome	O
17	O
with	O
mutated	O
p53	O
.	O

DISCUSSION	O
The	O
p53	O
gene	O
,	O
the	O
'	O
genome	O
guardian	O
'	O
,	O
is	O
mutated	O
in	O
over	O
50	O
%	O
of	O
human	B
cancers	O
,	O
with	O
the	O
most	O
common	O
mutations	O
being	O
missense	O
mutations	O
(	O
>	O
2	O
/	O
3	O
of	O
mutations	O
)	O
(	O
26	O
)	O
.	O

In	O
human	B
neuroblastoma	O
tumors	O
,	O
p53	O
mutations	O
are	O
rarely	O
present	O
at	O
the	O
time	O
of	O
diagnosis	O
(	O
5,27	O
)	O
;	O
however	O
,	O
oncogenic	O
p53	O
mutations	O
can	O
be	O
found	O
in	O
advanced	O
neuroblastomas	O
that	O
often	O
relapse	O
following	O
high	O
-	O
dose	O
chemotherapy	O
(	O
10	O
)	O
.	O

In	O
contrast	O
,	O
in	O
breast	O
cancers	O
,	O
it	O
has	O
been	O
reported	O
that	O
p53	O
mutations	O
might	O
improve	O
response	O
to	O
high	O
-	O
dose	O
chemotherapy	O
including	O
therapy	O
with	O
epirubicin	O
and	O
cyclophosphamide	O
(	O
28	O
)	O
.	O

An	O
investigation	O
into	O
the	O
p53	O
genomic	O
status	O
and	O
functions	O
of	O
eight	O
human	B
NB	O
lines	O
revealed	O
that	O
all	O
five	O
of	O
the	O
mutated	O
cell	O
lines	O
had	O
distinct	O
genetic	O
characteristics	O
as	O
is	O
schematically	O
represented	O
in	O
Figure	O
9	O
:	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
with	O
a	O
single	O
missense	O
mutation	O
in	O
the	O
p53	O
gene	O
,	O
encoding	O
a	O
highly	O
stable	O
full	O
-	O
length	O
protein	O
.	O

SK	O
-	O
N	O
-	O
AS	O
and	O
IGR	O
-	O
NB8	O
proteins	O
,	O
although	O
they	O
have	O
intact	O
transactivation	O
and	O
DBDs	O
,	O
were	O
truncated	O
at	O
the	O
C	O
-	O
terminus	O
generating	O
341	O
and	O
326	O
amino	O
acids	O
respectively	O
;	O
they	O
therefore	O
lack	O
the	O
tetramerization	O
domain	O
that	O
is	O
essential	O
for	O
an	O
active	O
conformation	O
.	O

Very	O
recently	O
,	O
Bourdon	O
et	O
al.	O
(	O
22	O
)	O
reported	O
the	O
putative	O
occurrence	O
of	O
β	O
and	O
γ	O
isoforms	O
from	O
different	O
tissues	O
due	O
to	O
alternate	O
splicing	O
that	O
indicates	O
the	O
similarity	O
to	O
those	O
of	O
p73	O
and	O
p63	O
as	O
identified	O
previously	O
by	O
Daniel	O
Caput	O
and	O
co	O
-	O
workers	O
(	O
29	O
)	O
.	O

In	O
the	O
p53	O
isoforms	O
scheme	O
proposed	O
by	O
Bourdon	O
et	O
al.	O
(	O
22	O
)	O
,	O
the	O
SK	O
-	O
N	O
-	O
AS	O
cell	O
line	O
that	O
elicits	O
p53i9	O
protein	O
expression	O
is	O
consistent	O
with	O
the	O
p53β	O
isoform	O
.	O

Genomic	O
analysis	O
reveals	O
that	O
the	O
only	O
occurrence	O
of	O
the	O
p53β	O
isoform	O
in	O
SK	O
-	O
N	O
-	O
AS	O
results	O
from	O
a	O
deletion	O
spanning	O
the	O
intron	O
9	O
/	O
exon	O
10	O
junction	O
.	O

Similar	O
to	O
the	O
p53β	O
isoform	O
in	O
SK	O
-	O
N	O
-	O
AS	O
,	O
the	O
p53	O
in	O
IGR	O
-	O
NB8	O
that	O
lacks	O
67	O
amino	O
acids	O
at	O
C	O
-	O
terminus	O
was	O
,	O
alone	O
,	O
unable	O
to	O
induce	O
p21	O
/	O
WAF1	O
promoter	O
activation	O
except	O
with	O
endogenous	O
wt	O
-	O
p53	O
on	O
SH	O
-	O
SY5Y	O
cells	O
where	O
transfection	O
with	O
IGR	O
-	O
NB8	O
significantly	O
augmented	O
the	O
transcriptional	O
activation	O
of	O
the	O
p21	O
/	O
Waf-1	O
promoter	O
(	O
Figure	O
5A	O
)	O
.	O

Studies	O
by	O
other	O
authors	O
have	O
reported	O
the	O
interaction	O
between	O
the	O
C	O
-	O
terminal	O
domain	O
and	O
another	O
region	O
that	O
impedes	O
the	O
active	O
conformation	O
of	O
p53	O
,	O
suggesting	O
an	O
allosteric	O
model	O
for	O
p53	O
activity	O
regulation	O
(	O
30	O
)	O
.	O

Such	O
events	O
have	O
been	O
demonstrated	O
for	O
the	O
342-stop	O
mutant	O
,	O
generated	O
by	O
mutagenesis	O
,	O
which	O
can	O
modulate	O
transactivation	O
,	O
growth	O
and	O
apoptosis	O
(	O
31	O
)	O
.	O

Moreover	O
,	O
Harms	O
and	O
Chen	O
(	O
32	O
)	O
reported	O
that	O
the	O
C	O
-	O
terminal	O
basic	O
domain	O
inhibits	O
induction	O
of	O
the	O
proapoptotic	O
target	O
gene	O
insulin	O
-	O
like	O
growth	O
factor	O
binding	O
protein	O
3	O
,	O
suggesting	O
that	O
IGR	O
-	O
NB8	O
might	O
induce	O
this	O
gene	O
.	O

IGR	O
-	O
N-91	O
had	O
an	O
abnormally	O
high	O
molecular	O
weight	O
protein	O
due	O
to	O
the	O
duplication	O
of	O
wild	O
-	O
type	O
exons	O
7	O
-	O
8	O
-	O
9	O
,	O
thus	O
affecting	O
the	O
DBD	O
and	O
OD	O
;	O
and	O
LAN-1	O
,	O
with	O
a	O
mutation	O
at	O
codon	O
182	O
(	O
Cys→stop	O
)	O
concurred	O
with	O
an	O
earlier	O
report	O
showing	O
extremely	O
low	O
levels	O
of	O
mRNA	O
and	O
undetectable	O
protein	O
expression	O
(	O
9	O
)	O
.	O

Notably	O
,	O
all	O
the	O
p53	O
variants	O
,	O
including	O
SK	O
-	O
N	O
-	O
AS	O
(	O
β	O
isoform	O
)	O
and	O
IGR	O
-	O
NB8	O
(	O
C	O
-	O
terminal	O
truncated	O
p53	O
)	O
,	O
elicited	O
a	O
total	O
lack	O
of	O
p21	O
promoter	O
activation	O
.	O

In	O
particular	O
,	O
the	O
p53β	O
isoform	O
was	O
unable	O
to	O
induce	O
endogenous	O
p21	O
expression	O
in	O
SK	O
-	O
N	O
-	O
AS	O
(	O
Figure	O
6	O
)	O
,	O
concurring	O
with	O
data	O
obtained	O
from	O
in	O
vitro	O
transfection	O
experiments	O
in	O
H1299	O
cells	O
by	O
Bourdon	O
et	O
al.	O
(	O
22	O
)	O
.	O

For	O
the	O
IGR	O
-	O
N-91	O
cells	O
,	O
although	O
p53	O
was	O
mutated	O
and	O
unable	O
to	O
transactivate	O
the	O
p21	O
/	O
WAF1	O
promoter	O
,	O
the	O
FASAY	O
global	O
test	O
was	O
not	O
conclusive	O
since	O
∼80	O
%	O
of	O
colonies	O
were	O
white	O
and	O
nearly	O
20	O
%	O
(	O
see	O
also	O
Table	O
2	O
)	O
,	O
though	O
not	O
enough	O
,	O
were	O
red	O
.	O

Moreover	O
,	O
in	O
this	O
particular	O
line	O
,	O
standard	O
sequencing	O
on	O
cDNA	O
using	O
primers	O
located	O
within	O
each	O
exon	O
as	O
used	O
for	O
routine	O
tumor	O
analysis	O
was	O
unable	O
to	O
detect	O
any	O
anomalies	O
in	O
p53	O
genetic	O
status	O
(	O
data	O
not	O
shown	O
)	O
.	O

These	O
results	O
enlighten	O
the	O
limit	O
of	O
the	O
conventional	O
tests	O
to	O
detect	O
a	O
transcription	O
inactivation	O
of	O
p53	O
brought	O
by	O
duplication	O
within	O
the	O
DBD	O
.	O

Analysis	O
of	O
p53	O
genomic	O
status	O
was	O
explored	O
by	O
FISH	O
experiments	O
,	O
in	O
search	O
for	O
a	O
potential	O
biallelic	O
inactivation	O
of	O
p53	O
,	O
with	O
a	O
mutation	O
of	O
one	O
allele	O
and	O
a	O
deletion	O
of	O
the	O
second	O
one	O
.	O

This	O
situation	O
was	O
indeed	O
clearly	O
observed	O
in	O
IGR	O
-	O
N-91	O
and	O
SK	O
-	O
N	O
-	O
AS	O
cell	O
lines	O
,	O
with	O
an	O
unambiguous	O
loss	O
of	O
one	O
chromosome	O
17p	O
arm	O
in	O
all	O
cells	O
of	O
both	O
.	O

SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
,	O
LAN-1	O
and	O
IGR	O
-	O
NB-8	O
cell	O
lines	O
showed	O
a	O
more	O
complex	O
genomic	O
situation	O
which	O
should	O
be	O
relevant	O
of	O
variable	O
copy	O
numbers	O
of	O
chromosome	O
17	O
bearing	O
in	O
most	O
cases	O
(	O
LAN-1	O
)	O
or	O
in	O
all	O
cases	O
[	O
SKN	O
-	O
BE	O
(	O
2	O
)	O
,	O
IGR	O
-	O
NB8	O
]	O
the	O
mutated	O
characteristic	O
p53	O
allele	O
.	O

Our	O
data	O
therefore	O
clearly	O
demonstrate	O
that	O
each	O
technique	O
has	O
a	O
role	O
and	O
a	O
combination	O
of	O
techniques	O
is	O
required	O
in	O
order	O
to	O
correctly	O
define	O
the	O
p53	O
phenotype	O
and	O
genotype	O
in	O
tumor	O
and	O
particularly	O
in	O
NB	O
cells	O
.	O

Our	O
data	O
enlighten	O
a	O
high	O
frequency	O
of	O
the	O
C	O
-	O
terminal	O
abnormalities	O
(	O
3	O
/	O
5	O
mutated	O
)	O
in	O
NB	O
cell	O
lines	O
.	O

For	O
SK	O
-	O
N	O
-	O
AS	O
and	O
IGR	O
-	O
NB8	O
,	O
a	O
part	O
of	O
the	O
oligomerization	O
domain	O
was	O
lost	O
and	O
IGR	O
-	O
N-91	O
gained	O
an	O
extra	O
oligomerization	O
domain	O
.	O

According	O
to	O
FASAY	O
assay	O
the	O
p53	O
expressed	O
in	O
IGR	O
-	O
N-91	O
still	O
specifically	O
bind	O
DNA	O
but	O
not	O
the	O
p53	O
expressed	O
in	O
SK	O
-	O
N	O
-	O
AS	O
and	O
IGR	O
-	O
NB8	O
in	O
agreement	O
with	O
previous	O
published	O
data	O
obtained	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
(	O
33	O
)	O
.	O

With	O
regards	O
to	O
biological	O
relevance	O
,	O
different	O
mutants	O
within	O
the	O
DBD	O
vary	O
in	O
their	O
oncogenicity	O
.	O

They	O
are	O
classified	O
into	O
two	O
types	O
depending	O
of	O
the	O
location	O
of	O
the	O
mutation	O
,	O
mutations	O
of	O
class	O
I	O
occur	O
in	O
the	O
DNA	O
contact	O
areas	O
,	O
while	O
class	O
II	O
mutations	O
occur	O
in	O
areas	O
important	O
for	O
the	O
conformational	O
stability	O
of	O
p53	O
protein	O
(	O
30	O
)	O
.	O

Although	O
both	O
class	O
I	O
and	O
class	O
II	O
mutants	O
have	O
loss	O
its	O
ability	O
to	O
specifically	O
bind	O
DNA	O
,	O
class	O
II	O
mutations	O
have	O
been	O
shown	O
to	O
be	O
more	O
oncogenic	O
than	O
class	O
I.	O
However	O
,	O
to	O
our	O
knowledge	O
the	O
oncogenicity	O
of	O
mutant	O
affecting	O
the	O
C	O
-	O
terminal	O
domain	O
have	O
not	O
been	O
studied	O
.	O

The	O
biological	O
role	O
of	O
the	O
C	O
-	O
terminal	O
mutants	O
needs	O
now	O
to	O
be	O
thoroughly	O
investigated	O
in	O
NB	O
tumors	O
.	O

Presence	O
of	O
antibodies	O
against	O
cyclic	O
citrullinated	O
peptides	O
in	O
patients	O
with	O
'	O
rhupus	O
'	O
:	O
a	O
cross	O
-	O
sectional	O
study	O
Abstract	O
'	O
Rhupus	O
'	O
is	O
a	O
rare	O
condition	O
sharing	O
features	O
of	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
and	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
.	O

If	O
rhupus	O
is	O
a	O
distinctive	O
entity	O
,	O
an	O
overlap	O
between	O
RA	O
and	O
SLE	O
or	O
a	O
subset	O
of	O
SLE	O
is	O
currently	O
debated	O
.	O

This	O
study	O
was	O
performed	O
to	O
explore	O
the	O
prevalence	O
of	O
antibodies	O
against	O
cyclic	O
citrullinated	O
peptides	O
(	O
anti	O
-	O
CCP	O
antibodies	O
)	O
in	O
rhupus	O
.	O

Patients	O
meeting	O
American	O
College	O
of	O
Rheumatology	O
criteria	O
for	O
RA	O
,	O
SLE	O
,	O
or	O
both	O
were	O
included	O
.	O

Clinical	O
and	O
radiographic	O
features	O
were	O
recorded	O
and	O
sera	O
were	O
searched	O
for	O
anti	O
-	O
CCP	O
antibodies	O
,	O
rheumatoid	O
factor	O
,	O
antinuclear	O
antibodies	O
,	O
anti	O
-	O
extractable	O
nuclear	O
antigens	O
,	O
and	O
antibodies	O
against	O
double	O
-	O
stranded	O
DNA	O
(	O
anti	O
-	O
dsDNA	O
antibodies	O
)	O
.	O

Seven	O
patients	O
for	O
each	O
group	O
were	O
included	O
.	O

Clinical	O
and	O
serological	O
features	O
for	O
RA	O
or	O
SLE	O
were	O
similar	O
between	O
rhupus	O
and	O
RA	O
patients	O
,	O
and	O
between	O
rhupus	O
and	O
SLE	O
patients	O
,	O
respectively	O
.	O

Values	O
for	O
anti	O
-	O
CCP	O
antibodies	O
obtained	O
were	O
significantly	O
(	O
p	O
<	O
0.05	O
)	O
higher	O
in	O
RA	O
(	O
6	O
/	O
7	O
)	O
and	O
rhupus	O
(	O
4	O
/	O
7	O
)	O
than	O
in	O
SLE	O
patients	O
(	O
0	O
/	O
7	O
)	O
and	O
healthy	O
subjects	O
(	O
0	O
/	O
7	O
)	O
.	O

Our	O
data	O
support	O
the	O
possibility	O
that	O
rhupus	O
is	O
an	O
overlap	O
between	O
RA	O
and	O
SLE	O
,	O
because	O
highly	O
specific	O
autoantibodies	O
for	O
RA	O
(	O
anti	O
-	O
CCP	O
)	O
and	O
for	O
SLE	O
(	O
anti	O
-	O
dsDNA	O
and	O
anti	O
-	O
Sm	O
)	O
are	O
detected	O
in	O
coexistence	O
.	O

Introduction	O
The	O
clinical	O
coexistence	O
of	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
and	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
was	O
first	O
described	O
in	O
1969	O
by	O
Kantor	O
and	O
was	O
termed	O
'	O
rhupus	O
syndrome	O
'	O
by	O
Schur	O
(	O
both	O
cited	O
in	O
[	O
1	O
]	O
)	O
.	O

Since	O
then	O
,	O
fewer	O
than	O
100	O
cases	O
of	O
rhupus	O
have	O
been	O
published	O
[	O
1	O
-	O
3	O
]	O
.	O

In	O
an	O
epidemiological	O
study	O
including	O
about	O
7,000	O
new	O
patients	O
,	O
the	O
prevalence	O
of	O
RA	O
was	O
15	O
%	O
and	O
for	O
SLE	O
it	O
was	O
8.9	O
%	O
.	O

The	O
expected	O
coincidence	O
of	O
RA	O
and	O
SLE	O
by	O
chance	O
would	O
therefore	O
be	O
1.2	O
%	O
.	O

However	O
,	O
the	O
observed	O
prevalence	O
of	O
rhupus	O
was	O
0.09	O
%	O
,	O
less	O
than	O
one	O
-	O
tenth	O
of	O
that	O
expected	O
[	O
1	O
]	O
.	O

Previous	O
reports	O
have	O
shown	O
that	O
the	O
patients	O
with	O
rhupus	O
display	O
an	O
array	O
of	O
autoantibodies	O
including	O
anti	O
-	O
double	O
-	O
stranded	O
DNA	O
(	O
anti	O
-	O
dsDNA	O
)	O
,	O
anti	O
-	O
Sm	O
(	O
both	O
highly	O
specific	O
for	O
SLE	O
)	O
,	O
anti	O
-	O
SSA	O
,	O
anti	O
-	O
SSB	O
,	O
anti	O
-	O
ribonucleoprotein	O
,	O
antinuclear	O
antibodies	O
(	O
ANA	O
)	O
,	O
anti	O
-	O
cardiolipins	O
,	O
and	O
rheumatoid	O
factor	O
(	O
RF	O
)	O
[	O
1,2	O
]	O
.	O

However	O
,	O
no	O
study	O
has	O
yet	O
been	O
performed	O
to	O
investigate	O
the	O
presence	O
of	O
antibodies	O
against	O
cyclic	O
citrullinated	O
peptides	O
(	O
anti	O
-	O
CCP	O
antibodies	O
)	O
,	O
which	O
have	O
a	O
specificity	O
for	O
RA	O
of	O
96	O
to	O
98	O
%	O
(	O
for	O
second	O
-	O
generation	O
assays	O
(	O
anti	O
-	O
CCP2	O
)	O
)	O
[	O
4,5	O
]	O
.	O

Recent	O
data	O
have	O
confirmed	O
that	O
these	O
antibodies	O
are	O
rarely	O
if	O
ever	O
present	O
in	O
other	O
autoimmune	O
diseases	O
such	O
as	O
SLE	O
,	O
Sjögren	O
's	O
syndrome	O
(	O
SS	O
)	O
,	O
scleroderma	O
and	O
myositis	O
[	O
6	O
]	O
.	O

Nowadays	O
,	O
it	O
is	O
a	O
matter	O
of	O
debate	O
whether	O
rhupus	O
is	O
a	O
clinically	O
and	O
immunologically	O
distinctive	O
entity	O
[	O
2	O
]	O
,	O
a	O
true	O
overlap	O
between	O
SLE	O
and	O
RA	O
[	O
7	O
]	O
,	O
or	O
a	O
subgroup	O
of	O
patients	O
with	O
lupus	O
[	O
8	O
]	O
.	O

This	O
descriptive	O
,	O
cross	O
-	O
sectional	O
study	O
was	O
performed	O
to	O
investigate	O
the	O
frequency	O
of	O
anti	O
-	O
CCP	O
antibodies	O
in	O
a	O
cohort	O
of	O
patients	O
with	O
rhupus	O
.	O

Materials	O
and	O
methods	O
We	O
included	O
all	O
patients	O
fulfilling	O
American	O
College	O
of	O
Rheumatology	O
(	O
ACR	O
)	O
classification	O
criteria	O
for	O
both	O
RA	O
[	O
9	O
]	O
and	O
SLE	O
[	O
10	O
]	O
who	O
belonged	O
to	O
our	O
cohorts	O
of	O
patients	O
with	O
RA	O
and	O
with	O
SLE	O
.	O

Comparisons	O
were	O
made	O
with	O
age-	O
and	O
gender	O
-	O
matched	O
patients	O
with	O
RA	O
and	O
with	O
SLE	O
,	O
and	O
healthy	O
subjects	O
.	O

The	O
study	O
was	O
approved	O
by	O
the	O
local	O
ethics	O
committee	O
,	O
and	O
informed	O
consent	O
was	O
obtained	O
.	O

Serum	O
samples	O
were	O
obtained	O
and	O
stored	O
at	O
-75	O
°	O
C	O
until	O
use	O
.	O

Sera	O
were	O
analyzed	O
for	O
anti	O
-	O
CCP2	O
antibodies	O
by	O
ELISA	O
(	O
Inova	O
Diagnostics	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
with	O
a	O
cutoff	O
value	O
of	O
60	O
U	O
/	O
ml	O
.	O

Fine	O
antinuclear	O
reactivities	O
(	O
ELISA	O
;	O
Inova	O
Diagnostics	O
)	O
,	O
RF	O
(	O
nephelometry	O
)	O
,	O
ANA	O
(	O
indirect	O
immunofluorescence	O
on	O
HEp-2	O
slides	O
)	O
,	O
and	O
anti	O
-	O
dsDNA	O
(	O
indirect	O
immunofluorescence	O
on	O
Crithidia	O
luciliae	O
substrate	O
)	O
antibodies	O
were	O
also	O
determined	O
.	O

Except	O
for	O
healthy	O
individuals	O
,	O
standard	O
radiographs	O
of	O
hands	O
were	O
available	O
.	O

For	O
statistical	O
analysis	O
,	O
ANOVA	O
and	O
the	O
Mann	O
–	O
Whitney	O
U	O
test	O
were	O
performed	O
as	O
appropriate	O
with	O
GraphPad	O
Prism	O
4.0	O
software	O
(	O
GraphPad	O
Inc	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Results	O
Seven	O
female	O
patients	O
with	O
a	O
median	O
age	O
of	O
44	O
years	O
(	O
range	O
25	O
to	O
64	O
)	O
met	O
our	O
inclusion	O
criteria	O
.	O

The	O
major	O
clinical	O
and	O
laboratory	O
findings	O
are	O
presented	O
in	O
Table	O
1	O
.	O

Healthy	O
individuals	O
and	O
all	O
patients	O
belonged	O
to	O
cohorts	O
from	O
the	O
same	O
ethnic	O
group	O
(	O
Hispanic	O
mestizo	O
)	O
.	O

No	O
differences	O
in	O
demographic	O
data	O
were	O
found	O
between	O
groups	O
.	O

Mean	O
ACR	O
criteria	O
for	O
SLE	O
were	O
5.57	O
(	O
range	O
4	O
to	O
8)	O
in	O
the	O
SLE	O
group	O
,	O
and	O
5.57	O
(	O
4	O
to	O
8)	O
in	O
the	O
rhupus	O
group	O
.	O

In	O
the	O
same	O
way	O
,	O
mean	O
ACR	O
criteria	O
for	O
RA	O
were	O
6	O
(	O
4	O
to	O
7	O
)	O
in	O
the	O
RA	O
group	O
,	O
and	O
5.14	O
(	O
4	O
to	O
6	O
)	O
for	O
the	O
patients	O
with	O
rhupus	O
.	O

In	O
all	O
patients	O
with	O
rhupus	O
,	O
RA	O
was	O
presented	O
as	O
the	O
initial	O
disease	O
,	O
as	O
has	O
been	O
described	O
previously	O
[	O
2	O
]	O
.	O

In	O
accordance	O
with	O
another	O
report	O
,	O
in	O
two	O
patients	O
the	O
disease	O
started	O
during	O
their	O
childhood	O
as	O
juvenile	O
chronic	O
arthritis	O
[	O
1	O
]	O
.	O

Anti	O
-	O
CCP	O
antibodies	O
were	O
found	O
in	O
four	O
of	O
seven	O
(	O
57	O
%	O
)	O
patients	O
with	O
rhupus	O
,	O
and	O
in	O
six	O
of	O
seven	O
(	O
86	O
%	O
)	O
patients	O
with	O
RA	O
,	O
whereas	O
neither	O
patients	O
with	O
SLE	O
nor	O
healthy	O
individuals	O
showed	O
reactivity	O
.	O

When	O
the	O
concentrations	O
in	O
each	O
group	O
were	O
compared	O
,	O
a	O
statistical	O
significant	O
difference	O
between	O
groups	O
was	O
found	O
(	O
ANOVA	O
,	O
p	O
<	O
0.05	O
)	O
.	O

The	O
mean	O
concentration	O
of	O
anti	O
-	O
CCP	O
antibodies	O
was	O
584	O
U	O
/	O
ml	O
(	O
range	O
0	O
to	O
1,237	O
)	O
in	O
patients	O
with	O
rhupus	O
(	O
Figure	O
1	O
)	O
,	O
875	O
U	O
/	O
ml	O
(	O
0	O
to	O
1,178	O
)	O
in	O
the	O
RA	O
group	O
(	O
not	O
significant	O
compared	O
with	O
rhupus	O
)	O
,	O
1	O
U	O
/	O
ml	O
(	O
0	O
to	O
10	O
)	O
for	O
SLE	O
individuals	O
(	O
p	O
<	O
0.05	O
compared	O
with	O
rhupus	O
)	O
,	O
and	O
0	O
U	O
/	O
ml	O
(	O
0	O
to	O
2	O
)	O
for	O
healthy	O
controls	O
(	O
p	O
<	O
0.05	O
compared	O
with	O
rhupus	O
)	O
.	O

Two	O
of	O
three	O
patients	O
with	O
rhupus	O
who	O
were	O
negative	O
for	O
anti	O
-	O
CCP	O
antibodies	O
were	O
also	O
negative	O
for	O
anti	O
-	O
dsDNA	O
antibodies	O
,	O
RF	O
and	O
anti	O
-	O
extractable	O
nuclear	O
antigen	O
antibodies	O
,	O
although	O
both	O
patients	O
met	O
RA	O
and	O
SLE	O
classification	O
criteria	O
,	O
including	O
ANA	O
and	O
erosive	O
arthritis	O
.	O

Differences	O
in	O
ANA	O
,	O
anti	O
-	O
dsDNA	O
and	O
anti	O
-	O
extractable	O
nuclear	O
antigen	O
autoantibodies	O
between	O
patients	O
with	O
rhupus	O
and	O
those	O
with	O
SLE	O
were	O
not	O
found	O
.	O

We	O
also	O
found	O
no	O
difference	O
in	O
the	O
prevalence	O
of	O
RF	O
between	O
patients	O
with	O
rhupus	O
and	O
those	O
with	O
RA	O
.	O

Surprisingly	O
,	O
one	O
healthy	O
subject	O
was	O
positive	O
for	O
RF	O
,	O
ANA	O
and	O
anti	O
-	O
SSA	O
antibodies	O
,	O
although	O
she	O
was	O
asymptomatic	O
and	O
no	O
features	O
of	O
any	O
disease	O
were	O
found	O
.	O

Discussion	O
The	O
close	O
association	O
between	O
different	O
type	O
II	O
human	B
leukocyte	O
antigen	O
(	O
HLA	O
)	O
molecules	O
and	O
the	O
risk	O
of	O
RA	O
is	O
well	O
established	O
.	O

These	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
II	O
molecules	O
share	O
the	O
same	O
amino	O
acid	O
sequence	O
(	O
QKRAA	O
or	O
QRRAA	O
)	O
in	O
positions	O
69	O
to	O
74	O
of	O
the	O
β	O
-	O
chain	O
,	O
namely	O
the	O
'	O
shared	O
epitope	O
'	O
.	O

Recent	O
works	O
have	O
demonstrated	O
that	O
this	O
'	O
shared	O
epitope	O
'	O
preferentially	O
binds	O
peptides	O
containing	O
the	O
non	O
-	O
standard	O
amino	O
acid	O
citrulline	O
(	O
deiminated	O
arginine	O
)	O
[	O
11	O
]	O
.	O

In	O
addition	O
,	O
an	O
abnormally	O
increased	O
function	O
of	O
the	O
enzyme	O
peptidylarginine	O
deiminase	O
4	O
(	O
PAD4	O
;	O
responsible	O
for	O
the	O
deimination	O
of	O
arginine	O
)	O
and	O
an	O
elevated	O
anti	O
-	O
CCP	O
autoantibody	O
production	O
in	O
patients	O
with	O
RA	O
have	O
been	O
demonstrated	O
[	O
12	O
]	O
.	O

These	O
facts	O
have	O
built	O
the	O
first	O
bridge	O
between	O
cellular	O
and	O
humoral	O
autoimmunity	O
in	O
a	O
major	O
rheumatic	O
disease	O
,	O
supporting	O
a	O
pathogenetic	O
role	O
for	O
an	O
abnormal	O
metabolism	O
of	O
citrulline	O
in	O
the	O
development	O
of	O
RA	O
[	O
13,14	O
]	O
.	O

Patients	O
with	O
SLE	O
are	O
often	O
part	O
of	O
the	O
control	O
group	O
when	O
determining	O
the	O
specificity	O
of	O
anti	O
-	O
CCP	O
antibodies	O
for	O
RA	O
[	O
15	O
]	O
,	O
although	O
some	O
studies	O
have	O
been	O
performed	O
specifically	O
on	O
patients	O
with	O
SLE	O
.	O

These	O
studies	O
contribute	O
some	O
clues	O
to	O
the	O
role	O
of	O
anti	O
-	O
CCP	O
antibodies	O
in	O
rhupus	O
.	O

Mediwake	O
and	O
colleagues	O
[	O
16	O
]	O
,	O
in	O
a	O
study	O
exploring	O
the	O
predictive	O
value	O
of	O
anti	O
-	O
CCP	O
antibodies	O
to	O
distinguish	O
erosive	O
arthritis	O
in	O
SLE	O
,	O
found	O
ten	O
patients	O
(	O
out	O
of	O
231	O
)	O
with	O
erosive	O
arthritis	O
,	O
two	O
of	O
whom	O
had	O
anti	O
-	O
CCP	O
antibodies	O
.	O

In	O
concord	O
with	O
this	O
,	O
Hoffman	O
and	O
colleagues	O
[	O
15	O
]	O
demonstrate	O
that	O
three	O
patients	O
with	O
erosive	O
arthritis	O
,	O
included	O
in	O
a	O
cohort	O
of	O
235	O
patients	O
with	O
SLE	O
,	O
were	O
positive	O
for	O
anti	O
-	O
CCP	O
antibodies	O
.	O

These	O
authors	O
suggest	O
that	O
the	O
presence	O
of	O
anti	O
-	O
CCP	O
antibodies	O
can	O
predispose	O
for	O
a	O
chronic	O
RA	O
-	O
like	O
arthritis	O
in	O
patients	O
with	O
SLE	O
.	O

Additionally	O
Weissman	O
and	O
colleagues	O
[	O
17	O
]	O
demonstrated	O
that	O
patients	O
with	O
SLE	O
can	O
display	O
radiographic	O
abnormalities	O
similar	O
to	O
those	O
of	O
RA	O
,	O
although	O
the	O
presence	O
of	O
marginal	O
erosions	O
is	O
a	O
rare	O
finding	O
.	O

In	O
the	O
present	O
study	O
we	O
demonstrate	O
that	O
the	O
patients	O
with	O
rhupus	O
show	O
a	O
very	O
similar	O
arthritis	O
pattern	O
(	O
including	O
erosive	O
disease	O
)	O
and	O
similar	O
autoantibody	O
production	O
(	O
RF	O
and	O
anti	O
-	O
CCP	O
antibodies	O
)	O
to	O
those	O
in	O
patients	O
with	O
RA	O
.	O

In	O
addition	O
,	O
patients	O
with	O
rhupus	O
display	O
a	O
clinical	O
and	O
serological	O
profile	O
indistinguishable	O
from	O
patients	O
with	O
SLE	O
.	O

Moreover	O
,	O
the	O
presence	O
of	O
other	O
coexistent	O
autoimmune	O
diseases	O
was	O
similar	O
in	O
all	O
groups	O
of	O
patients	O
(	O
two	O
patients	O
with	O
rhupus	O
,	O
three	O
patients	O
with	O
RA	O
,	O
and	O
three	O
patients	O
with	O
SLE	O
also	O
had	O
SS	O
)	O
.	O

We	O
found	O
high	O
titers	O
of	O
anti	O
-	O
CCP	O
antibodies	O
in	O
four	O
of	O
seven	O
(	O
57	O
%	O
)	O
patients	O
with	O
rhupus	O
,	O
a	O
frequency	O
similar	O
to	O
that	O
reported	O
for	O
RA	O
[	O
4	O
]	O
.	O

This	O
finding	O
,	O
together	O
with	O
the	O
clinical	O
similarity	O
,	O
supports	O
the	O
contention	O
that	O
rhupus	O
belongs	O
to	O
the	O
RA	O
spectrum	O
.	O

The	O
high	O
prevalence	O
of	O
anti	O
-	O
CCP	O
antibodies	O
in	O
RA	O
found	O
in	O
our	O
study	O
could	O
be	O
explained	O
by	O
a	O
selection	O
bias	O
because	O
only	O
patients	O
with	O
RA	O
with	O
an	O
aggressive	O
disease	O
(	O
namely	O
erosive	O
arthritis	O
and	O
RF+	O
)	O
were	O
included	O
.	O

In	O
contrast	O
,	O
the	O
mean	O
ACR	O
criterion	O
for	O
SLE	O
was	O
similar	O
between	O
patients	O
with	O
rhupus	O
and	O
those	O
with	O
SLE	O
,	O
including	O
the	O
'	O
robust	O
'	O
features	O
of	O
SLE	O
such	O
as	O
renal	O
and	O
neurological	O
involvement	O
,	O
and	O
anti	O
-	O
dsDNA	O
and	O
anti	O
-	O
Sm	O
antibodies	O
.	O

These	O
clinical	O
and	O
serological	O
features	O
shared	O
between	O
patients	O
with	O
rhupus	O
and	O
those	O
with	O
SLE	O
also	O
place	O
rhupus	O
in	O
the	O
SLE	O
spectrum	O
.	O

Titration	O
of	O
anti	O
-	O
CCP	O
antibodies	O
in	O
the	O
rhupus	O
group	O
clearly	O
shows	O
a	O
bimodal	O
distribution	O
,	O
suggesting	O
the	O
existence	O
of	O
two	O
different	O
subpopulations	O
.	O

Because	O
of	O
the	O
small	O
number	O
of	O
patients	O
,	O
we	O
are	O
unable	O
to	O
define	O
the	O
differential	O
features	O
underlying	O
each	O
subset	O
.	O

However	O
,	O
two	O
of	O
three	O
patients	O
negative	O
for	O
anti	O
-	O
CCP	O
antibodies	O
were	O
also	O
negative	O
for	O
both	O
RF	O
and	O
anti	O
-	O
dsDNA	O
antibodies	O
.	O

Conclusion	O
On	O
the	O
basis	O
of	O
the	O
presence	O
of	O
shared	O
clinical	O
features	O
of	O
RA	O
(	O
mainly	O
erosive	O
arthritis	O
)	O
and	O
SLE	O
(	O
including	O
renal	O
and	O
neurological	O
involvement	O
)	O
along	O
with	O
the	O
presence	O
of	O
anti	O
-	O
dsDNA	O
and	O
anti	O
-	O
CCP	O
autoantibodies	O
in	O
our	O
patients	O
with	O
rhupus	O
,	O
our	O
findings	O
strongly	O
support	O
the	O
contention	O
that	O
rhupus	O
is	O
a	O
true	O
overlap	O
between	O
RA	O
and	O
SLE	O
,	O
not	O
merely	O
a	O
part	O
of	O
the	O
clinical	O
spectrum	O
of	O
the	O
articular	O
involvement	O
seen	O
in	O
SLE	O
.	O

Moreover	O
,	O
on	O
the	O
basis	O
of	O
the	O
mean	O
ACR	O
criteria	O
for	O
both	O
diseases	O
,	O
we	O
have	O
confirmed	O
that	O
patients	O
with	O
rhupus	O
have	O
more	O
RA	O
-	O
associated	O
and	O
less	O
SLE	O
-	O
associated	O
damage	O
,	O
an	O
issue	O
that	O
has	O
been	O
suggested	O
previously	O
[	O
2	O
]	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
exploring	O
the	O
prevalence	O
of	O
anti	O
-	O
CCP	O
antibodies	O
specifically	O
in	O
patients	O
with	O
rhupus	O
.	O

More	O
studies	O
are	O
needed	O
to	O
expand	O
the	O
pathogenetic	O
knowledge	O
of	O
this	O
overlap	O
syndrome	O
.	O

Abbreviations	O
ANA	O
=	O
antinuclear	O
antibodies	O
;	O
anti	O
-	O
CCP	O
antibodies	O
=	O
antibodies	O
against	O
cyclic	O
citrullinated	O
peptides	O
;	O
anti	O
-	O
dsDNA	O
antibodies	O
=	O
antibodies	O
against	O
double	O
-	O
stranded	O
DNA	O
;	O
ELISA	O
=	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
;	O
RA	O
=	O
rheumatoid	O
arthritis	O
;	O
RF	O
=	O
rheumatoid	O
factor	O
;	O
SLE	O
=	O
systemic	O
lupus	O
erythematosus	O
;	O
SS	O
=	O
Sjögren	O
's	O
syndrome	O
.	O

Competing	O
interests	O
The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O
LA	O
-	O
G	O
participated	O
in	O
the	O
conception	O
and	O
design	O
of	O
the	O
experiments	O
,	O
in	O
the	O
acquisition	O
,	O
analysis	O
and	O
interpretation	O
of	O
data	O
,	O
and	O
was	O
involved	O
in	O
drafting	O
the	O
manuscript	O
.	O

RS	O
performed	O
the	O
immunoassays	O
.	O

RM	O
-	O
V	O
participated	O
in	O
the	O
analysis	O
and	O
interpretation	O
of	O
data	O
and	O
performed	O
the	O
statistical	O
analysis	O
.	O

LG	O
-	O
G	O
participated	O
in	O
the	O
analysis	O
and	O
interpretation	O
of	O
data	O
.	O

AV	O
participated	O
in	O
the	O
recruitment	O
of	O
patients	O
and	O
the	O
acquisition	O
of	O
data	O
.	O

RB	O
participated	O
in	O
the	O
interpretation	O
of	O
data	O
,	O
revising	O
the	O
manuscript	O
for	O
intellectual	O
content	O
and	O
giving	O
the	O
final	O
approval	O
of	O
the	O
version	O
to	O
be	O
published	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Identification	O
of	O
a	O
human	B
peripheral	O
blood	O
monocyte	O
subset	O
that	O
differentiates	O
into	O
osteoclasts	O
Abstract	O
Increased	O
bone	O
resorption	O
mediated	O
by	O
osteoclasts	O
causes	O
various	O
diseases	O
such	O
as	O
osteoporosis	O
and	O
bone	O
erosion	O
in	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
.	O

Osteoclasts	O
are	O
derived	O
from	O
the	O
monocyte	O
/	O
macrophage	O
lineage	O
,	O
but	O
the	O
precise	O
origin	O
remains	O
unclear	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
show	O
that	O
the	O
purified	O
CD16-	O
human	B
peripheral	O
blood	O
monocyte	O
subset	O
,	O
but	O
not	O
the	O
CD16	O
+	O
monocyte	O
subset	O
,	O
differentiates	O
into	O
osteoclast	O
by	O
stimulation	O
with	O
receptor	O
activator	O
of	O
NF	O
-	O
κB	O
ligand	O
(	O
RANKL	O
)	O
in	O
combination	O
with	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
M	O
-	O
CSF	O
)	O
.	O

Integrin	O
-	O
β3	O
mRNA	O
and	O
the	O
integrin	O
-	O
αvβ3	O
heterodimer	O
were	O
only	O
expressed	O
on	O
CD16-	O
monocytes	O
,	O
when	O
they	O
were	O
stimulated	O
with	O
RANKL	O
+	O
M	O
-	O
CSF	O
.	O

Downregulation	O
of	O
β3-subunit	O
expression	O
by	O
small	O
interfering	O
RNA	O
targeting	O
β3	O
abrogated	O
osteoclastogenesis	O
from	O
the	O
CD16-	O
monocyte	O
subset	O
.	O

In	O
contrast	O
,	O
the	O
CD16	O
+	O
monocyte	O
subset	O
expressed	O
larger	O
amounts	O
of	O
tumor	O
necrosis	O
factor	O
alpha	O
and	O
IL-6	O
than	O
the	O
CD16-	O
subset	O
,	O
which	O
was	O
further	O
enhanced	O
by	O
RANKL	O
stimulation	O
.	O

Examination	O
of	O
RA	O
synovial	O
tissue	O
showed	O
accumulation	O
of	O
both	O
CD16	O
+	O
and	O
CD16-	O
macrophages	O
.	O

Our	O
results	O
suggest	O
that	O
peripheral	O
blood	O
monocytes	O
consist	O
of	O
two	O
functionally	O
heterogeneous	O
subsets	O
with	O
distinct	O
responses	O
to	O
RANKL	O
.	O

Osteoclasts	O
seem	O
to	O
originate	O
from	O
CD16-	O
monocytes	O
,	O
and	O
integrin	O
β3	O
is	O
necessary	O
for	O
osteoclastogenesis	O
.	O

Blockade	O
of	O
accumulation	O
and	O
activation	O
of	O
CD16-	O
monocytes	O
could	O
therefore	O
be	O
a	O
beneficial	O
approach	O
as	O
an	O
anti	O
-	O
bone	O
resorptive	O
therapy	O
,	O
especially	O
for	O
RA	O
.	O

Introduction	O
Rheumatoid	O
arthritis	O
(	O
RA	O
)	O
is	O
an	O
autoimmune	O
disease	O
characterized	O
by	O
chronic	O
inflammation	O
and	O
proliferation	O
of	O
the	O
synovium	O
in	O
multiple	O
joints	O
.	O

A	O
large	O
number	O
of	O
inflammatory	O
cells	O
,	O
including	O
T	O
cells	O
,	O
B	O
cells	O
,	O
macrophages	O
and	O
dendritic	O
cells	O
,	O
accumulate	O
in	O
the	O
affected	O
synovium	O
,	O
and	O
these	O
inflammatory	O
cells	O
,	O
together	O
with	O
fibroblast	O
-	O
like	O
synoviocytes	O
,	O
express	O
various	O
cytokines	O
,	O
such	O
as	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNFα	O
)	O
,	O
IL-6	O
and	O
receptor	O
activator	O
of	O
NF	O
-	O
κB	O
ligand	O
(	O
RANKL	O
)	O
,	O
which	O
are	O
known	O
to	O
induce	O
differentiation	O
and	O
activation	O
of	O
osteoclasts	O
.	O

The	O
inflammatory	O
synovial	O
tissue	O
,	O
known	O
as	O
pannus	O
,	O
invades	O
the	O
articular	O
bone	O
and	O
causes	O
focal	O
bone	O
erosion	O
,	O
which	O
is	O
the	O
hallmark	O
of	O
RA	O
.	O

Histopathologically	O
,	O
osteoclasts	O
are	O
present	O
at	O
the	O
interface	O
of	O
the	O
pannus	O
and	O
bone	O
.	O

Interestingly	O
,	O
the	O
deletion	O
of	O
RANKL	O
or	O
c	O
-	O
Fos	O
gene	O
,	O
which	O
is	O
important	O
for	O
osteoclastogenesis	O
,	O
results	O
in	O
minimal	O
bone	O
destruction	O
in	O
mouse	B
models	O
of	O
arthritis	O
[	O
1,2	O
]	O
.	O

Furthermore	O
,	O
other	O
studies	O
indicated	O
that	O
inhibition	O
of	O
osteoclastogenesis	O
by	O
osteoprotegerin	O
,	O
a	O
decoy	O
receptor	O
for	O
RANKL	O
,	O
limits	O
bone	O
destruction	O
in	O
experimental	O
models	O
of	O
arthritis	O
.	O

These	O
studies	O
suggest	O
that	O
osteoclasts	O
are	O
involved	O
in	O
focal	O
bone	O
erosion	O
in	O
RA	O
[	O
3	O
]	O
.	O

Osteoclasts	O
are	O
derived	O
from	O
the	O
monocyte	O
/	O
macrophage	O
lineage	O
.	O

It	O
is	O
reported	O
that	O
osteoclast	O
precursors	O
reside	O
in	O
human	B
peripheral	O
blood	O
monocytes	O
[	O
4,5	O
]	O
.	O

A	O
marked	O
increase	O
of	O
the	O
circulating	O
osteoclast	O
precursors	O
was	O
demonstrated	O
in	O
patients	O
with	O
erosive	O
psoriatic	O
arthritis	O
as	O
well	O
as	O
in	O
arthritic	O
TNFα	O
transgenic	O
mice	B
[	O
6,7	O
]	O
.	O

It	O
was	O
also	O
shown	O
that	O
peripheral	O
monocytes	O
differentiate	O
into	O
osteoclasts	O
when	O
seeded	O
on	O
RANKL	O
/	O
osteoclast	O
differentiation	O
factor	O
-	O
producing	O
RA	O
synovial	O
fibroblasts	O
[	O
8	O
]	O
.	O

In	O
addition	O
,	O
RA	O
synovial	O
macrophages	O
thought	O
to	O
originate	O
from	O
peripheral	O
blood	O
monocytes	O
were	O
shown	O
to	O
differentiate	O
into	O
osteoclasts	O
[	O
9,10	O
]	O
.	O

Monocytes	O
are	O
therefore	O
involved	O
not	O
only	O
in	O
synovial	O
inflammation	O
,	O
but	O
also	O
in	O
bone	O
remodeling	O
as	O
potential	O
precursors	O
for	O
synovial	O
macrophages	O
and	O
osteoclasts	O
.	O

Human	B
peripheral	O
blood	O
monocytes	O
consist	O
of	O
two	O
major	O
subsets	O
,	O
CD16	O
+	O
and	O
CD16-	O
,	O
comprising	O
5–10	O
%	O
and	O
90–95	O
%	O
of	O
the	O
monocytes	O
,	O
respectively	O
.	O

These	O
two	O
subsets	O
exhibit	O
different	O
chemotaxis	O
activities	O
and	O
potential	O
of	O
cytokine	O
production	O
[	O
11,12	O
]	O
.	O

Moreover	O
,	O
activation	O
of	O
the	O
Toll	O
-	O
like	O
receptor	O
induces	O
distinct	O
subsets	O
,	O
CD1b+	O
dendritic	O
cells	O
and	O
DC	O
-	O
SIGN+	O
(	O
dendritic	O
cell	O
-	O
specific	O
C	O
-	O
type	O
lectin	O
ICAM-3-grabbing	O
nonintegrin	O
)	O
macrophages	O
from	O
CD16	O
+	O
and	O
CD16-	O
monocytes	O
,	O
respectively	O
[	O
13	O
]	O
.	O

It	O
has	O
not	O
been	O
revealed	O
,	O
however	O
,	O
which	O
monocyte	O
subset	O
develops	O
into	O
osteoclasts	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
determined	O
the	O
human	B
peripheral	O
blood	O
monocyte	O
subset	O
that	O
differentiates	O
into	O
osteoclasts	O
,	O
and	O
revealed	O
that	O
each	O
subset	O
exhibits	O
a	O
different	O
response	O
for	O
osteoclastogenic	O
stimuli	O
.	O

Materials	O
and	O
methods	O
Purification	O
of	O
peripheral	O
blood	O
monocytes	O
Peripheral	O
blood	O
monocytes	O
from	O
healthy	O
donors	O
were	O
collected	O
using	O
Ficoll	O
-	O
Conray	O
(	O
Imuuno	O
-	O
Biological	O
Laboratories	O
,	O
Gunma	O
,	O
Japan	O
)	O
gradient	O
centrifugation	O
.	O

Negative	O
selection	O
of	O
monocytes	O
was	O
performed	O
using	O
MACS	O
microbeads	O
(	O
Miltenyi	O
Biotec	O
,	O
Auburn	O
,	O
CA	O
,	O
USA	O
)	O
according	O
to	O
the	O
protocol	O
supplied	O
by	O
the	O
manufacturer	O
.	O

The	O
purified	O
monocytes	O
were	O
separated	O
into	O
two	O
subsets	O
,	O
CD16	O
+	O
and	O
CD16-	O
monocytes	O
,	O
using	O
CD16	O
MicroBeads	O
(	O
Miltenyi	O
Biotec	O
)	O
.	O

Flow	O
cytometry	O
analysis	O
using	O
FITC	O
-	O
conjugated	O
mouse	B
anti	O
-	O
CD14	O
mAb	O
(	O
MY4	O
;	O
Bechman	O
Coulter	O
,	O
Fullerton	O
,	O
CA	O
,	O
USA	O
)	O
and	O
phycoerythin	O
-	O
conjugated	O
mouse	B
anti	O
-	O
CD16	O
mAb	O
(	O
3G8	O
;	O
BD	O
Biosciences	O
,	O
San	O
Jose	O
,	O
CA	O
,	O
USA	O
)	O
showed	O
that	O
the	O
purities	O
of	O
the	O
CD16	O
+	O
and	O
CD16-	O
monocytes	O
were	O
more	O
than	O
90	O
%	O
and	O
92	O
%	O
,	O
respectively	O
.	O

For	O
the	O
other	O
experiment	O
,	O
monocytes	O
were	O
purified	O
using	O
CD14	O
MicroBeads	O
(	O
Miltenyi	O
Biotec	O
)	O
,	O
and	O
then	O
stained	O
either	O
with	O
FITC	O
-	O
conjugated	O
mouse	B
anti	O
-	O
CD33	O
mAb	O
(	O
MY9	O
;	O
Bechman	O
Coulter	O
)	O
or	O
phycoerythin	O
-	O
conjugated	O
mouse	B
anti	O
-	O
CD16	O
mAb	O
(	O
3G8	O
)	O
.	O

Cell	O
sorting	O
of	O
the	O
stained	O
cells	O
was	O
performed	O
using	O
a	O
FACS	O
Vantage	O
cytometer	O
(	O
BD	O
Biosciences	O
)	O
or	O
a	O
MoFlo	O
cell	O
sorter	O
(	O
Dako	O
,	O
Glostrup	O
,	O
Denmark	O
)	O
.	O

Osteoclast	O
differentiation	O
Purified	O
CD16	O
+	O
and	O
CD16-	O
monocytes	O
(	O
5	O
×	O
104	O
cells	O
/	O
well	O
)	O
were	O
incubated	O
in	O
96-well	O
plates	O
in	O
αMEM	O
(	O
Sigma	O
,	O
St	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
with	O
heat	O
-	O
inactivated	O
10	O
%	O
fetal	O
bovine	B
serum	O
(	O
FBS	O
)	O
(	O
Sigma	O
)	O
or	O
with	O
Ultra	O
-	O
Low	O
IgG	O
FBS	O
(	O
IgG	O
<	O
5	O
μg	O
/	O
ml	O
;	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
)	O
,	O
and	O
where	O
indicated	O
with	O
M	O
-	O
CSF	O
+	O
RANKL	O
(	O
Peprotech	O
,	O
Rocky	O
Hill	O
,	O
NJ	O
,	O
USA	O
)	O
.	O

For	O
the	O
other	O
experiments	O
,	O
varied	O
numbers	O
of	O
CD16	O
+	O
monocytes	O
(	O
1	O
×	O
103	O
,	O
2.5	O
×	O
103	O
,	O
5	O
×	O
103	O
)	O
were	O
mixed	O
with	O
CD16-	O
monocytes	O
(	O
5	O
×	O
104	O
cells	O
/	O
well	O
)	O
,	O
and	O
were	O
cultured	O
in	O
96-well	O
plates	O
in	O
αMEM	O
with	O
heat	O
-	O
inactivated	O
10	O
%	O
FBS	O
.	O

The	O
medium	O
was	O
replaced	O
with	O
fresh	O
medium	O
3	O
days	O
later	O
,	O
and	O
after	O
incubation	O
for	O
7	O
days	O
the	O
cells	O
were	O
stained	O
for	O
tartrate	O
-	O
resistant	O
acid	O
phosphatase	O
(	O
TRAP	O
)	O
expression	O
using	O
a	O
commercial	O
kit	O
(	O
Hokudo	O
,	O
Sapporo	O
,	O
Japan	O
)	O
.	O

The	O
number	O
of	O
TRAP	O
-	O
positive	O
multinucleated	O
cells	O
(	O
MNC	O
)	O
in	O
three	O
randomly	O
selected	O
fields	O
examined	O
at	O
100	O
×	O
magnification	O
or	O
the	O
total	O
number	O
of	O
TRAP	O
-	O
positive	O
MNC	O
per	O
well	O
was	O
counted	O
under	O
light	O
microscopy	O
.	O

Resorption	O
assay	O
Monocytes	O
were	O
seeded	O
onto	O
plates	O
coated	O
with	O
calcium	O
phosphate	O
thin	O
films	O
(	O
Biocoat	O
Osteologic	O
;	O
BD	O
Biosciences	O
)	O
and	O
were	O
incubated	O
with	O
RANKL	O
(	O
40	O
ng	O
/	O
ml	O
)	O
+	O
M	O
-	O
CSF	O
(	O
25	O
ng	O
/	O
ml	O
)	O
for	O
7	O
days	O
.	O

The	O
cells	O
were	O
then	O
lysed	O
in	O
bleach	O
solution	O
(	O
6	O
%	O
NaOCl	O
,	O
5.2	O
%	O
NaCl	O
)	O
.	O

The	O
resorption	O
lacunae	O
were	O
examined	O
under	O
light	O
microscopy	O
.	O

Enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
Purified	O
monocytes	O
were	O
cultured	O
in	O
96-well	O
plates	O
where	O
indicated	O
either	O
with	O
RANKL	O
or	O
M	O
-	O
CSF	O
for	O
24	O
hours	O
.	O

Concentrations	O
of	O
TNFα	O
and	O
IL-6	O
in	O
the	O
culture	O
supernatant	O
were	O
measured	O
with	O
an	O
ELISA	O
kit	O
(	O
BioSourse	O
International	O
,	O
Camarillo	O
,	O
CA	O
,	O
USA	O
)	O
.	O

For	O
experiments	O
of	O
matrix	O
metalloproteinase	O
(	O
MMP	O
)	O
-9	O
and	O
TRAP-5b	O
,	O
culture	O
supernatants	O
were	O
collected	O
on	O
day	O
7	O
and	O
the	O
concentrations	O
of	O
these	O
enzymes	O
were	O
measured	O
using	O
an	O
MMP-9	O
ELISA	O
kit	O
(	O
Amersham	O
Biosciences	O
,	O
Piscataway	O
,	O
NJ	O
,	O
USA	O
)	O
or	O
a	O
TRAP-5b	O
ELISA	O
kit	O
(	O
Suomen	O
,	O
Turku	O
,	O
Finland	O
)	O
.	O

Reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
Monocytes	O
(	O
1	O
×	O
106	O
cells	O
/	O
well	O
)	O
were	O
cultured	O
in	O
six	O
-	O
well	O
plates	O
with	O
M	O
-	O
CSF	O
alone	O
or	O
with	O
M	O
-	O
CSF	O
+	O
RANKL	O
for	O
3	O
days	O
.	O

Total	O
RNA	O
was	O
extracted	O
using	O
RNeasy	O
Micro	O
(	O
Qiagen	O
,	O
Valencia	O
,	O
CA	O
,	O
USA	O
)	O
.	O

The	O
RNA	O
was	O
then	O
treated	O
with	O
DNase	O
I	O
(	O
Qiagen	O
)	O
.	O

The	O
oligo	O
(	O
dT	O
)	O
-primed	O
cDNA	O
was	O
synthesized	O
using	O
Superscript	O
II	O
reverse	O
transcriptase	O
(	O
Invitrogen	O
)	O
.	O

The	O
amount	O
of	O
cDNA	O
for	O
amplification	O
was	O
adjusted	O
by	O
the	O
amount	O
of	O
RNA	O
measured	O
by	O
an	O
optical	O
density	O
meter	O
and	O
also	O
by	O
β	O
-	O
actin	O
or	O
GAPDH	O
PCR	O
products	O
.	O

One	O
microliter	O
of	O
cDNA	O
was	O
amplified	O
in	O
a	O
50	O
μl	O
final	O
volume	O
containing	O
25	O
pmol	O
appropriate	O
primer	O
pair	O
,	O
10	O
pmol	O
each	O
of	O
the	O
four	O
deoxynucleotide	O
triphosphates	O
,	O
and	O
5	O
units	O
FastStart	O
Taq	O
DNA	O
Polymerase	O
(	O
Roche	O
,	O
Manheim	O
,	O
Germany	O
)	O
in	O
a	O
thermal	O
cycler	O
(	O
PTC-200	O
;	O
MJ	O
GeneWorks	O
,	O
Waltham	O
,	O
MA	O
,	O
USA	O
)	O
.	O

The	O
PCR	O
conditions	O
were	O
25–40	O
cycles	O
of	O
denaturation	O
(	O
95	O
°	O
C	O
for	O
30	O
s	O
)	O
,	O
annealing	O
(	O
60–62	O
°	O
C	O
for	O
1	O
min	O
)	O
and	O
extension	O
(	O
72	O
°	O
C	O
for	O
1	O
min	O
)	O
.	O

The	O
sequences	O
of	O
the	O
primers	O
are	O
presented	O
in	O
Table	O
1	O
.	O

The	O
PCR	O
products	O
were	O
separated	O
by	O
electrophoresis	O
through	O
2	O
%	O
agarose	O
gel	O
.	O

Western	O
immunoblot	O
analysis	O
Purified	O
monocytes	O
were	O
cultured	O
for	O
3	O
days	O
in	O
the	O
presence	O
of	O
40	O
ng	O
/	O
ml	O
M	O
-	O
CSF	O
with	O
or	O
without	O
25	O
ng	O
/	O
ml	O
RANKL	O
.	O

Cells	O
were	O
lysed	O
in	O
RIPA	O
Lysis	O
buffer	O
(	O
upstate	O
,	O
Lake	O
Placid	O
,	O
NY	O
,	O
USA	O
)	O
containing	O
protease	O
inhibitors	O
(	O
Roche	O
)	O
for	O
15	O
min	O
at	O
4	O
°	O
C	O
.	O

A	O
total	O
of	O
20	O
μg	O
protein	O
was	O
boiled	O
in	O
the	O
presence	O
of	O
6	O
×	O
sodium	O
dodecyl	O
sulfate	O
sample	O
buffer	O
,	O
and	O
was	O
separated	O
on	O
7.5	O
%	O
or	O
10	O
%	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
(	O
ATTO	O
,	O
Tokyo	O
,	O
Japan	O
)	O
.	O

Proteins	O
were	O
then	O
electrotransferred	O
to	O
a	O
polyvinylidene	O
fluoride	O
microporous	O
membrane	O
(	O
Millipore	O
,	O
Billerica	O
,	O
MA	O
,	O
USA	O
)	O
in	O
a	O
semidry	O
system	O
.	O

Membranes	O
were	O
incubated	O
in	O
10	O
%	O
skim	O
milk	O
prepared	O
in	O
phosphate	O
-	O
buffered	O
saline	O
(	O
PBS	O
)	O
containing	O
0.1	O
%	O
Tween	O
20	O
,	O
and	O
were	O
subjected	O
to	O
immunoblotting	O
.	O

Antibodies	O
used	O
were	O
goat	B
anti	O
-	O
RANK	O
antibody	O
(	O
Techne	O
Corporation	O
,	O
Minneapolis	O
,	O
MN	O
,	O
USA	O
)	O
,	O
goat	B
anti	O
-	O
c	O
-	O
fms	O
antibody	O
(	O
R&D	O
systems	O
,	O
Minneapolis	O
,	O
MN	O
,	O
USA	O
)	O
,	O
and	O
mouse	B
anti	O
-	O
β	O
-	O
actin	O
mAb	O
(	O
AC-15	O
;	O
Sigma	O
)	O
.	O

Peroxidase	O
-	O
conjugated	O
rabbit	B
anti	O
-	O
goat	B
IgG	O
antibody	O
(	O
Dako	O
)	O
or	O
peroxidase	O
-	O
conjugated	O
rabbit	B
anti	O
-	O
mouse	B
IgG	O
antibody	O
(	O
Dako	O
)	O
was	O
used	O
as	O
the	O
second	O
antibody	O
.	O

The	O
signals	O
were	O
visualized	O
by	O
chemiluminescence	O
reagent	O
(	O
ECL	O
;	O
Amersham	O
Biocsiences	O
,	O
Little	O
Chalfont	O
,	O
UK	O
)	O
.	O

Cell	O
surface	O
expression	O
of	O
c	O
-	O
fms	O
The	O
following	O
mAbs	O
were	O
used	O
for	O
analysis	O
of	O
c	O
-	O
fms	O
expression	O
:	O
Alexa	O
647-conjugated	O
anti	O
-	O
CD14	O
mAb	O
(	O
UCHM1	O
;	O
Serotec	O
,	O
Oxford	O
,	O
UK	O
)	O
,	O
FITC	O
-	O
conjugated	O
anti	O
-	O
CD16	O
mAb	O
(	O
3G8	O
;	O
Bechman	O
Coulter	O
)	O
and	O
phycoerythin	O
-	O
conjugated	O
anti	O
-	O
c	O
-	O
fms	O
mAb	O
(	O
61708	O
;	O
R&D	O
systems	O
)	O
.	O

Alexa	O
647-conjugated	O
mouse	B
IgG2a	O
(	O
Serotec	O
)	O
,	O
FITC	O
-	O
conjugated	O
mouse	B
IgG1	O
(	O
BD	O
Biosciences	O
)	O
and	O
phycoerythin	O
-	O
conjugated	O
mouse	B
IgG1	O
(	O
Bechman	O
Coulter	O
)	O
were	O
used	O
as	O
isotype	O
controls	O
.	O

Peripheral	O
blood	O
monocytes	O
(	O
1	O
×	O
105	O
cells	O
)	O
were	O
incubated	O
with	O
1	O
μg	O
human	B
IgG	O
for	O
15	O
minutes	O
,	O
and	O
were	O
then	O
stained	O
with	O
three	O
fluorochrome	O
-	O
labeled	O
mAbs	O
for	O
45	O
minutes	O
on	O
ice	O
.	O

The	O
stained	O
cells	O
were	O
analyzed	O
with	O
a	O
FACS	O
Calibur	O
(	O
BD	O
Biosciences	O
)	O
.	O

Immunofluorescent	O
staining	O
Monocytes	O
(	O
8	O
×	O
104	O
cells	O
/	O
well	O
)	O
were	O
allowed	O
to	O
adhere	O
on	O
96-well	O
plates	O
overnight	O
or	O
were	O
cultured	O
with	O
M	O
-	O
CSF	O
and	O
RANKL	O
for	O
2–4	O
days	O
.	O

The	O
cells	O
were	O
fixed	O
in	O
acetone	O
and	O
then	O
stained	O
with	O
anti	O
-	O
αvβ3	O
mAb	O
(	O
LM609	O
;	O
Chemicon	O
,	O
Temecula	O
,	O
CA	O
,	O
USA	O
)	O
or	O
mouse	B
IgG1	O
(	O
11711	O
;	O
R&D	O
Systems	O
)	O
as	O
an	O
isotype	O
-	O
matched	O
control	O
.	O

Alexa	O
fluor546-conjugated	O
goat	B
anti	O
-	O
mouse	B
IgG1	O
antibody	O
(	O
Molecular	O
Probes	O
,	O
Eugene	O
,	O
OR	O
,	O
USA	O
)	O
was	O
used	O
as	O
the	O
second	O
antibody	O
.	O

TOTO-3	O
(	O
Molecular	O
Probes	O
)	O
was	O
used	O
for	O
nuclear	O
staining	O
.	O

Flow	O
cytometric	O
analysis	O
of	O
p38	O
MAPK	O
and	O
ERK1	O
/	O
2	O
phosphorylation	O
Purified	O
monocytes	O
were	O
cultured	O
in	O
the	O
presence	O
of	O
25	O
ng	O
/	O
ml	O
M	O
-	O
CSF	O
for	O
3	O
days	O
,	O
and	O
were	O
either	O
left	O
unstimulated	O
or	O
were	O
stimulated	O
with	O
40	O
ng	O
/	O
ml	O
RANKL	O
at	O
37	O
°	O
C	O
.	O

Stimulations	O
were	O
stopped	O
by	O
adding	O
an	O
equal	O
volume	O
of	O
PhosFlow	O
Fix	O
Buffer	O
I	O
solution	O
(	O
BD	O
Biosciences	O
)	O
to	O
the	O
cell	O
culture	O
.	O

After	O
incubation	O
for	O
10	O
minutes	O
at	O
37	O
°	O
C	O
,	O
the	O
cells	O
were	O
permeabilized	O
by	O
washing	O
twice	O
at	O
room	O
temperature	O
in	O
PhosFlow	O
Perm	O
/	O
Wash	O
Buffer	O
I	O
(	O
BD	O
Biosciences	O
)	O
.	O

A	O
total	O
of	O
1	O
×	O
105	O
cells	O
was	O
then	O
Fc	O
blocked	O
with	O
1	O
μg	O
human	B
IgG	O
for	O
15	O
minutes	O
,	O
and	O
was	O
stained	O
with	O
Alexa	O
Fluor	O
647-conjugated	O
mAb	O
either	O
to	O
phospho	O
-	O
p38	O
MAPK	O
(	O
T180	O
/	O
Y182	O
)	O
or	O
to	O
phospho	O
-	O
ERK1	O
/	O
2	O
(	O
T202	O
/	O
Y204	O
)	O
(	O
BD	O
Biosciences	O
)	O
for	O
30	O
minutes	O
at	O
room	O
temperature	O
.	O

Alexa	O
Fluor	O
647-conjugated	O
mouse	B
IgG1	O
(	O
BD	O
Biosciences	O
)	O
was	O
used	O
as	O
an	O
isotype	O
control	O
.	O

The	O
cells	O
were	O
washed	O
in	O
PhosFlow	O
Perm	O
/	O
Wash	O
Buffer	O
I	O
,	O
and	O
were	O
analyzed	O
by	O
flow	O
cytometry	O
,	O
as	O
already	O
described	O
.	O

RNA	O
interference	O
RNA	O
oligonucleotides	O
(	O
iGENE	O
,	O
Tsukuba	O
,	O
Japan	O
)	O
were	O
designed	O
based	O
on	O
the	O
algorithm	O
that	O
incorporates	O
single	O
nucleotide	O
polymorphism	O
and	O
homology	O
screening	O
to	O
ensure	O
a	O
target	O
-	O
specific	O
RNA	O
interference	O
effect	O
.	O

The	O
following	O
sense	O
and	O
antisense	O
oligonucleotides	O
were	O
used	O
:	O
integrin	O
β3	O
,	O
5'-GCU	O
UCA	O
AUG	O
AGG	O
AAG	O
UGA	O
AGA	O
AGC	O
A	O
-	O
AG	O
and	O
3'-UA	O
-	O
CGA	O
AGU	O
UAC	O
UCC	O
UUC	O
ACU	O
UCU	O
UCG	O
U	O
;	O
randomized	O
control	O
,	O
5'-CGA	O
UUC	O
GCU	O
AGA	O
CCG	O
GCU	O
UCA	O
UUG	O
C	O
-	O
AG	O
and	O
3'-UA	O
-	O
GCU	O
AAG	O
CGA	O
UCU	O
GGC	O
CGA	O
AGU	O
AAC	O
G	O
;	O
and	O
lamin	O
,	O
5'-GAG	O
GAA	O
CUG	O
GAC	O
UUC	O
CAG	O
AAG	O
AAC	O
A	O
-	O
AG	O
and	O
3'-UA	O
-	O
CUC	O
CUU	O
GAC	O
CUG	O
AAG	O
GUC	O
UUC	O
UUG	O
U.	O
CD16-	O
monocytes	O
(	O
8	O
×	O
104	O
cells	O
/	O
well	O
)	O
were	O
incubated	O
in	O
96-well	O
plates	O
in	O
optimem	O
(	O
Invitrogen	O
)	O
.	O

After	O
1	O
hour	O
,	O
siRNAs	O
were	O
transfected	O
into	O
the	O
cells	O
using	O
oligofectamine	O
(	O
Qiagen	O
)	O
based	O
on	O
the	O
method	O
recommended	O
by	O
the	O
manufacturer	O
.	O

After	O
2	O
hours	O
,	O
the	O
cells	O
were	O
washed	O
once	O
with	O
PBS	O
,	O
followed	O
by	O
the	O
addition	O
of	O
αMEM	O
supplemented	O
with	O
10	O
%	O
FBS	O
,	O
M	O
-	O
CSF	O
and	O
RANKL	O
.	O

After	O
a	O
2-day	O
incubation	O
,	O
the	O
β3	O
mRNA	O
expression	O
was	O
analyzed	O
by	O
RT	O
-	O
PCR	O
with	O
different	O
PCR	O
cycles	O
,	O
as	O
described	O
earlier	O
.	O

Immunofluorescent	O
staining	O
for	O
the	O
αvβ3	O
heterodimer	O
was	O
also	O
performed	O
as	O
described	O
above	O
,	O
and	O
numbers	O
of	O
αvβ3-positive	O
cells	O
were	O
counted	O
in	O
randomly	O
selected	O
three	O
fields	O
at	O
100	O
×	O
magnification	O
.	O

Seven	O
days	O
after	O
the	O
transfection	O
of	O
siRNAs	O
,	O
the	O
number	O
of	O
TRAP	O
-	O
positive	O
MNC	O
in	O
five	O
fields	O
examined	O
at	O
100	O
×	O
magnification	O
was	O
counted	O
under	O
light	O
microscopy	O
.	O

Inhibition	O
of	O
osteoclastogenesis	O
with	O
cyclic	O
RGDfV	O
peptide	O
CD16-	O
monocytes	O
were	O
incubated	O
in	O
96-well	O
plates	O
with	O
M	O
-	O
CSF	O
+	O
RANKL	O
for	O
2	O
days	O
.	O

A	O
medium	O
containing	O
either	O
cyclic	O
RGDfV	O
peptide	O
(	O
Arg	O
-	O
Gly	O
-	O
Asp	O
-	O
D	O
-	O
Phe	O
-	O
Val	O
)	O
(	O
Calbiochem	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
or	O
dimethyl	O
sulfoxide	O
was	O
then	O
added	O
.	O

After	O
incubation	O
for	O
a	O
further	O
5	O
days	O
,	O
the	O
number	O
of	O
TRAP	O
-	O
positive	O
MNC	O
in	O
five	O
fields	O
examined	O
at	O
100	O
×	O
magnification	O
was	O
counted	O
under	O
light	O
microscopy	O
.	O

Immunohistochemistry	O
Synovial	O
tissue	O
samples	O
were	O
obtained	O
during	O
total	O
knee	O
joint	O
replacement	O
surgery	O
from	O
four	O
RA	O
patients	O
.	O

Signed	O
consent	O
forms	O
were	O
obtained	O
before	O
the	O
operation	O
.	O

The	O
experimental	O
protocol	O
was	O
approved	O
by	O
the	O
ethics	O
committee	O
of	O
the	O
Tokyo	O
Medical	O
and	O
Dental	O
University	O
.	O

RA	O
was	O
diagnosed	O
according	O
to	O
the	O
American	O
College	O
of	O
Rheumatology	O
criteria	O
[	O
14	O
]	O
.	O

Double	O
immunofluorescent	O
staining	O
for	O
CD68	O
and	O
CD16	O
antigens	O
was	O
conducted	O
on	O
optimal	O
cutting	O
temperature	O
-	O
embedded	O
sections	O
of	O
frozen	O
synovial	O
samples	O
.	O

Eight	O
-	O
micrometer	O
-	O
thick	O
cryostat	O
sections	O
of	O
RA	O
synovium	O
were	O
fixed	O
in	O
acetone	O
for	O
3	O
minutes	O
and	O
were	O
then	O
rehydrated	O
in	O
PBS	O
for	O
5	O
minutes	O
.	O

The	O
samples	O
were	O
incubated	O
in	O
5	O
μg	O
/	O
ml	O
proteinase	O
K	O
(	O
Roche	O
)	O
,	O
50	O
mM	O
ethylenediamine	O
tetraacetic	O
acid	O
,	O
100	O
mM	O
Tris	O
–	O
HCl	O
,	O
pH	O
8.0	O
,	O
for	O
15	O
minutes	O
at	O
room	O
temperature	O
followed	O
by	O
a	O
wash	O
in	O
PBS	O
.	O

The	O
samples	O
were	O
then	O
blocked	O
with	O
10	O
%	O
goat	B
serum	O
in	O
PBS	O
for	O
60	O
minutes	O
at	O
room	O
temperature	O
,	O
and	O
were	O
incubated	O
with	O
anti	O
-	O
CD16	O
mAb	O
(	O
3G8	O
;	O
Immunotech	O
,	O
Marseille	O
,	O
France	O
)	O
or	O
mouse	B
IgG1	O
(	O
11711	O
)	O
as	O
an	O
isotype	O
-	O
matched	O
control	O
in	O
1	O
%	O
bovine	B
serum	O
albumin	O
/	O
PBS	O
for	O
60	O
minutes	O
at	O
room	O
temperature	O
.	O

The	O
samples	O
were	O
then	O
washed	O
three	O
times	O
in	O
PBS	O
,	O
for	O
5	O
minutes	O
each	O
,	O
and	O
incubated	O
with	O
Alexa	O
fluor546-conjugated	O
goat	B
anti	O
-	O
mouse	B
IgG1	O
antibody	O
(	O
Molecular	O
Probes	O
)	O
in	O
1	O
%	O
bovine	B
serum	O
albumin	O
/	O
PBS	O
for	O
60	O
minutes	O
at	O
room	O
temperature	O
.	O

The	O
samples	O
were	O
then	O
sequentially	O
stained	O
for	O
CD68	O
antigen	O
in	O
a	O
manner	O
similar	O
to	O
that	O
used	O
for	O
CD16	O
staining	O
.	O

The	O
samples	O
were	O
stained	O
with	O
anti	O
-	O
CD68	O
mAb	O
(	O
PGM1	O
;	O
Immunotech	O
)	O
or	O
mouse	B
IgG3	O
(	O
6A3	O
;	O
MBL	O
,	O
Nagoya	O
,	O
Japan	O
)	O
followed	O
by	O
labeling	O
with	O
Alexa	O
fluor488-conjugated	O
goat	B
anti	O
-	O
mouse	B
IgG3	O
antibody	O
(	O
Molecular	O
Probes	O
)	O
.	O

The	O
samples	O
were	O
examined	O
by	O
confocal	O
laser	O
scanning	O
microscope	O
(	O
Olympus	O
,	O
Tokyo	O
,	O
Japan	O
)	O
.	O

Statistical	O
analysis	O
Data	O
are	O
expressed	O
as	O
the	O
mean	O
±	O
standard	O
error	O
of	O
the	O
mean	O
.	O

A	O
nonpaired	O
Student	O
's	O
t	O
test	O
was	O
used	O
for	O
comparison	O
,	O
using	O
the	O
StatView	O
program	O
(	O
Abacus	O
Concepts	O
,	O
Berkeley	O
,	O
CA	O
,	O
USA	O
)	O
.	O

P	O
<	O
0.05	O
was	O
considered	O
statistically	O
significant	O
.	O

Results	O
Induction	O
of	O
osteoclasts	O
from	O
CD16-	O
peripheral	O
blood	O
monocytes	O
To	O
identify	O
the	O
monocyte	O
subset	O
that	O
differentiates	O
into	O
osteoclasts	O
,	O
we	O
examined	O
osteoclast	O
formation	O
from	O
CD16	O
+	O
and	O
CD16-	O
human	B
peripheral	O
blood	O
monocytes	O
.	O

The	O
monocyte	O
subsets	O
were	O
purified	O
using	O
magnetic	O
beads	O
.	O

Incubation	O
with	O
M	O
-	O
CSF	O
alone	O
did	O
not	O
induce	O
osteoclast	O
formation	O
from	O
either	O
subset	O
(	O
Figure	O
1a	O
)	O
.	O

Culture	O
with	O
M	O
-	O
CSF	O
+	O
RANKL	O
induced	O
a	O
significant	O
number	O
of	O
TRAP	O
-	O
positive	O
MNC	O
from	O
the	O
CD16-	O
subset	O
,	O
whereas	O
only	O
few	O
CD16	O
+	O
monocytes	O
differentiated	O
into	O
TRAP	O
-	O
positive	O
MNC	O
(	O
Figure	O
1a	O
,	O
b	O
)	O
.	O

We	O
then	O
assessed	O
the	O
bone	O
resorptive	O
ability	O
by	O
culturing	O
cells	O
on	O
calcium	O
phosphate	O
-	O
coated	O
plates	O
with	O
M	O
-	O
CSF	O
+	O
RANKL	O
.	O

Resorption	O
lacunae	O
were	O
detected	O
only	O
in	O
the	O
CD16-	O
subset	O
(	O
Figure	O
1c	O
)	O
,	O
indicating	O
the	O
TRAP	O
-	O
positive	O
CD16	O
-	O
-derived	O
MNC	O
possessed	O
the	O
osteoclast	O
phenotype	O
.	O

Similar	O
results	O
were	O
obtained	O
using	O
purified	O
monocytes	O
by	O
FACS	O
sorting	O
(	O
purities	O
:	O
CD16	O
+	O
,	O
96	O
%	O
;	O
CD16-	O
,	O
97	O
%	O
)	O
.	O

The	O
number	O
of	O
TRAP	O
-	O
positive	O
MNC	O
induced	O
were	O
36	O
±	O
3	O
cells	O
/	O
well	O
and	O
348	O
±	O
13	O
cells	O
/	O
well	O
from	O
CD16	O
+	O
and	O
CD16-	O
monocytes	O
,	O
respectively	O
.	O

To	O
exclude	O
the	O
possibility	O
that	O
the	O
anti	O
-	O
CD16	O
antibody	O
used	O
for	O
isolation	O
of	O
CD16	O
+	O
monocytes	O
inhibits	O
osteoclast	O
formation	O
,	O
we	O
separated	O
the	O
two	O
subsets	O
,	O
CD33low	O
monocytes	O
and	O
CD33high	O
monocytes	O
,	O
using	O
anti	O
-	O
CD33	O
mAb	O
and	O
a	O
fluorescent	O
cell	O
sorter	O
,	O
since	O
it	O
was	O
reported	O
that	O
CD33low	O
monocytes	O
correspond	O
to	O
CD16	O
+	O
,	O
and	O
that	O
CD33high	O
correspond	O
to	O
CD16-	O
monocytes	O
[	O
15	O
]	O
.	O

On	O
average	O
,	O
the	O
CD33low	O
population	O
contained	O
CD16-	O
(	O
10.2%	O
)	O
/	O
CD16	O
+	O
(	O
89.8	O
%	O
)	O
monocytes	O
,	O
and	O
the	O
CD33high	O
population	O
contained	O
CD16-	O
(	O
86.3%	O
)	O
/	O
CD16	O
+	O
(	O
13.7	O
%	O
)	O
monocytes	O
.	O

Culture	O
with	O
M	O
-	O
CSF	O
+	O
RANKL	O
induced	O
TRAP	O
-	O
positive	O
MNC	O
from	O
CD33high	O
monocytes	O
,	O
whereas	O
no	O
or	O
few	O
CD33low	O
monocytes	O
differentiated	O
into	O
TRAP	O
-	O
positive	O
MNC	O
(	O
CD33low	O
vs	O
CD33high	O
,	O
2	O
±	O
1	O
vs	O
192	O
±	O
71	O
cells	O
/	O
well	O
;	O
n	O
=	O
3	O
)	O
.	O

TRAP-5b	O
and	O
MMP-9	O
in	O
the	O
culture	O
supernatants	O
,	O
both	O
of	O
which	O
are	O
known	O
to	O
be	O
produced	O
by	O
osteoclasts	O
,	O
were	O
measured	O
by	O
ELISA	O
.	O

The	O
concentrations	O
of	O
both	O
enzymes	O
were	O
significantly	O
higher	O
in	O
the	O
culture	O
supernatant	O
of	O
CD16-	O
monocytes	O
than	O
in	O
that	O
of	O
CD16	O
+	O
monocytes	O
(	O
Figure	O
1d	O
)	O
.	O

These	O
results	O
suggest	O
that	O
the	O
CD16-	O
peripheral	O
blood	O
monocyte	O
subset	O
,	O
but	O
not	O
the	O
CD16	O
+	O
subset	O
,	O
differentiate	O
into	O
osteoclasts	O
by	O
incubation	O
with	O
RANKL	O
+	O
M	O
-	O
CSF	O
.	O

CD16	O
+	O
monocytes	O
do	O
not	O
affect	O
the	O
osteoclastogenesis	O
from	O
CD16-	O
monocytes	O
To	O
examine	O
whether	O
CD16	O
+	O
monocytes	O
affect	O
osteoclastogenesis	O
from	O
CD16-	O
monocytes	O
,	O
varied	O
numbers	O
of	O
CD16	O
+	O
monocytes	O
were	O
mixed	O
with	O
CD16-	O
monocytes	O
(	O
5	O
×	O
104	O
cells	O
/	O
well	O
)	O
,	O
and	O
were	O
cultured	O
for	O
7	O
days	O
in	O
the	O
presence	O
of	O
M	O
-	O
CSF	O
+	O
RANKL	O
.	O

The	O
number	O
of	O
TRAP	O
-	O
positive	O
MNC	O
was	O
not	O
altered	O
by	O
the	O
presence	O
of	O
CD16	O
+	O
monocytes	O
(	O
Figure	O
2	O
)	O
.	O

The	O
results	O
indicated	O
that	O
CD16	O
+	O
monocytes	O
did	O
not	O
hamper	O
or	O
enhance	O
the	O
osteoclastogenesis	O
from	O
CD16-	O
monocytes	O
.	O

Differences	O
in	O
cytokine	O
production	O
by	O
RANKL	O
-	O
stimulated	O
or	O
M	O
-	O
CSF	O
-	O
stimulated	O
CD16	O
+	O
and	O
CD16-	O
monocytes	O
To	O
compare	O
the	O
biological	O
response	O
of	O
CD16	O
+	O
and	O
CD16-	O
subsets	O
with	O
either	O
RANKL	O
or	O
M	O
-	O
CSF	O
stimulation	O
,	O
we	O
measured	O
the	O
amount	O
of	O
TNFα	O
and	O
IL-6	O
production	O
after	O
exposure	O
of	O
cells	O
to	O
various	O
concentrations	O
of	O
RANKL	O
or	O
M	O
-	O
CSF	O
with	O
an	O
ELISA	O
.	O

Without	O
RANKL	O
the	O
CD16	O
+	O
subset	O
produced	O
a	O
significant	O
amount	O
of	O
TNFα	O
and	O
IL-6	O
,	O
whereas	O
the	O
CD16-	O
subset	O
produced	O
undetectable	O
levels	O
(	O
Figure	O
3a	O
)	O
.	O

RANKL	O
stimulation	O
increased	O
TNFα	O
production	O
from	O
both	O
subsets	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
although	O
the	O
CD16	O
+	O
subset	O
produced	O
more	O
TNFα	O
than	O
did	O
the	O
CD16-	O
subset	O
.	O

RANKL	O
stimulation	O
also	O
enhanced	O
IL-6	O
production	O
from	O
the	O
CD16	O
+	O
subset	O
,	O
but	O
not	O
from	O
the	O
CD16-	O
subset	O
.	O

M	O
-	O
CSF	O
stimulation	O
increased	O
TNFα	O
and	O
IL-6	O
production	O
from	O
both	O
subsets	O
,	O
although	O
the	O
CD16	O
+	O
subset	O
produced	O
more	O
than	O
the	O
CD16-	O
subset	O
(	O
Figure	O
3b	O
)	O
.	O

These	O
results	O
suggest	O
that	O
CD16	O
+	O
monocytes	O
also	O
respond	O
both	O
to	O
RANKL	O
and	O
M	O
-	O
CSF	O
stimulation	O
,	O
although	O
such	O
stimulation	O
does	O
not	O
result	O
in	O
differentiation	O
into	O
osteoclasts	O
.	O

CD16	O
+	O
monocytes	O
were	O
also	O
noted	O
to	O
express	O
higher	O
amounts	O
of	O
inflammatory	O
cytokines	O
compared	O
with	O
CD16-	O
monocytes	O
with	O
or	O
without	O
RANKL	O
or	O
M	O
-	O
CSF	O
stimulation	O
.	O

Comparison	O
of	O
expression	O
levels	O
of	O
molecules	O
involved	O
in	O
osteoclastogenesis	O
between	O
CD16	O
+	O
and	O
CD16-	O
monocytes	O
Diverse	O
molecules	O
are	O
involved	O
in	O
RANKL	O
/	O
RANK	O
and	O
its	O
costimulatory	O
signal	O
transduction	O
pathways	O
[	O
16	O
]	O
.	O

The	O
different	O
response	O
to	O
RANKL	O
+	O
M	O
-	O
CSF	O
stimulation	O
between	O
the	O
CD16	O
+	O
monocyte	O
subset	O
and	O
the	O
CD16-	O
monocytes	O
subset	O
might	O
be	O
explained	O
by	O
the	O
expression	O
profiles	O
of	O
these	O
molecules	O
.	O

We	O
therefore	O
examined	O
the	O
mRNA	O
levels	O
of	O
the	O
following	O
molecules	O
:	O
receptor	O
activator	O
of	O
NF	O
-	O
κB	O
(	O
RANK	O
)	O
,	O
the	O
receptor	O
for	O
RANKL	O
;	O
c	O
-	O
fms	O
,	O
the	O
receptor	O
for	O
M	O
-	O
CSF	O
;	O
tumor	O
necrosis	O
factor	O
receptor	O
-	O
associated	O
factor	O
6	O
(	O
TRAF-6	O
)	O
,	O
the	O
adaptor	O
protein	O
for	O
RANK	O
;	O
c	O
-	O
Fos	O
and	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
c1	O
(	O
NFATc1	O
)	O
,	O
transcription	O
factors	O
that	O
are	O
essential	O
for	O
osteoclastogenesis	O
;	O
DNAX	O
-	O
activation	O
protein	O
12	O
(	O
DAP12	O
)	O
and	O
Fc	O
receptor	O
γ	O
chain	O
(	O
FcRγ	O
)	O
,	O
adaptor	O
proteins	O
known	O
to	O
deliver	O
costimulatory	O
signals	O
in	O
RANKL	O
-	O
induced	O
osteoclastogenesis	O
;	O
signal	O
regulatory	O
protein	O
β1	O
(	O
SIRP	O
-	O
β1	O
)	O
,	O
triggering	O
receptor	O
expressed	O
on	O
myeloid	O
cells	O
2	O
(	O
TREM-2	O
)	O
and	O
osteoclast	O
-	O
associated	O
receptor	O
(	O
OSCAR	O
)	O
,	O
transmembrane	O
receptors	O
that	O
associate	O
with	O
either	O
DAP12	O
or	O
FcRγ	O
;	O
and	O
αv	O
and	O
β3	O
,	O
integrins	O
known	O
to	O
be	O
expressed	O
as	O
the	O
αvβ3	O
heterodimer	O
on	O
osteoclasts	O
.	O

The	O
mRNA	O
levels	O
of	O
RANK	O
,	O
c	O
-	O
fms	O
,	O
TRAF-6	O
,	O
DAP12	O
and	O
SIRP	O
-	O
β1	O
under	O
the	O
baseline	O
condition	O
(	O
no	O
stimulation	O
)	O
varied	O
between	O
the	O
donors	O
;	O
however	O
,	O
we	O
did	O
not	O
find	O
consistent	O
differences	O
in	O
the	O
mRNA	O
levels	O
of	O
these	O
molecules	O
between	O
the	O
CD16	O
+	O
monocyte	O
subset	O
and	O
the	O
CD16-	O
monocyte	O
subset	O
among	O
three	O
to	O
six	O
donors	O
(	O
Figure	O
4a	O
)	O
.	O

The	O
mRNA	O
levels	O
of	O
other	O
molecules	O
,	O
apart	O
from	O
integrin	O
β3	O
,	O
were	O
similar	O
between	O
the	O
two	O
subsets	O
under	O
the	O
no	O
-	O
stimulation	O
condition	O
.	O

Although	O
the	O
mRNA	O
levels	O
of	O
RANK	O
,	O
c	O
-	O
fms	O
,	O
DAP12	O
,	O
FcRγ	O
,	O
TREM-2	O
and	O
OSCAR	O
increased	O
in	O
response	O
to	O
M	O
-	O
CSF	O
alone	O
or	O
M	O
-	O
CSF	O
+	O
RANKL	O
in	O
both	O
subsets	O
,	O
the	O
expression	O
levels	O
were	O
not	O
significantly	O
different	O
between	O
the	O
two	O
subsets	O
.	O

Expressions	O
of	O
TRAF-6	O
,	O
c	O
-	O
Fos	O
and	O
SIRP	O
-	O
β1	O
mRNA	O
did	O
not	O
change	O
following	O
stimulation	O
with	O
M	O
-	O
CSF	O
+	O
RANKL	O
.	O

Of	O
note	O
,	O
the	O
expression	O
of	O
NFATc1	O
mRNA	O
was	O
enhanced	O
by	O
M	O
-	O
CSF	O
+	O
RANKL	O
treatment	O
only	O
in	O
the	O
CD16-	O
subset	O
.	O

Furthermore	O
,	O
expression	O
of	O
integrin	O
αv	O
in	O
both	O
subsets	O
was	O
enhanced	O
by	O
M	O
-	O
CSF	O
with	O
or	O
without	O
RANKL	O
;	O
however	O
,	O
the	O
expression	O
level	O
was	O
greater	O
in	O
the	O
CD16-	O
subset	O
.	O

It	O
was	O
noted	O
that	O
integrin	O
-	O
β3	O
mRNA	O
was	O
detected	O
only	O
in	O
the	O
CD16-	O
subset	O
and	O
was	O
increased	O
by	O
M	O
-	O
CSF	O
+	O
RANKL	O
stimulation	O
,	O
but	O
not	O
by	O
M	O
-	O
CSF	O
alone	O
.	O

The	O
protein	O
expression	O
of	O
RANK	O
under	O
the	O
baseline	O
condition	O
was	O
weakly	O
detected	O
in	O
both	O
subsets	O
,	O
and	O
the	O
levels	O
were	O
varied	O
between	O
donors	O
by	O
western	O
immunoblotting	O
.	O

The	O
protein	O
expression	O
of	O
c	O
-	O
fms	O
was	O
weakly	O
detected	O
in	O
unstimulated	O
CD16	O
+	O
monocytes	O
,	O
but	O
not	O
in	O
CD16-	O
monocytes	O
(	O
Figure	O
4b	O
)	O
.	O

Flow	O
cytometry	O
analysis	O
of	O
c	O
-	O
fms	O
in	O
fresh	O
monocytes	O
,	O
however	O
,	O
showed	O
that	O
both	O
subsets	O
express	O
the	O
molecule	O
on	O
the	O
cell	O
surface	O
(	O
Figure	O
4c	O
)	O
.	O

Expressions	O
of	O
both	O
RANK	O
and	O
c	O
-	O
fms	O
were	O
upregulated	O
by	O
M	O
-	O
CSF	O
alone	O
and	O
by	O
M	O
-	O
CSF	O
+	O
RANKL	O
,	O
and	O
we	O
did	O
not	O
find	O
consistent	O
differences	O
in	O
the	O
protein	O
levels	O
of	O
these	O
molecules	O
between	O
the	O
two	O
monocyte	O
subsets	O
.	O

The	O
profiles	O
of	O
expression	O
levels	O
of	O
molecules	O
involved	O
in	O
RANKL	O
/	O
RANK	O
and	O
its	O
costimulatory	O
pathways	O
are	O
similar	O
between	O
the	O
two	O
subsets	O
,	O
except	O
for	O
NFATc1	O
,	O
integrin	O
αv	O
and	O
integrin	O
β3	O
.	O

We	O
therefore	O
assumed	O
that	O
the	O
distinct	O
induction	O
of	O
NFATc1	O
,	O
integrin	O
αv	O
and	O
integrin	O
β3	O
in	O
response	O
to	O
RANKL	O
stimulation	O
among	O
the	O
two	O
monocyte	O
subsets	O
might	O
explain	O
the	O
differences	O
in	O
their	O
abilities	O
to	O
differentiate	O
into	O
osteoclasts	O
.	O

RANKL	O
stimulation	O
induces	O
αvβ3	O
expression	O
on	O
CD16-	O
monocytes	O
The	O
integrin	O
-	O
β3	O
subunit	O
binds	O
to	O
integrin	O
αv	O
only	O
and	O
is	O
expressed	O
as	O
the	O
heterodimeric	O
protein	O
αvβ3	O
on	O
monocytes	O
and	O
osteoclasts	O
[	O
17	O
]	O
.	O

We	O
examined	O
the	O
expression	O
of	O
αvβ3	O
on	O
CD16	O
+	O
and	O
CD16-	O
monocytes	O
by	O
immunofluorescent	O
staining	O
.	O

Neither	O
unstimulated	O
nor	O
M	O
-	O
CSF	O
-	O
stimulated	O
monocyte	O
subsets	O
expressed	O
αvβ3	O
(	O
Figure	O
4d	O
and	O
data	O
not	O
shown	O
)	O
.	O

After	O
48	O
and	O
72	O
hours	O
of	O
treatment	O
with	O
M	O
-	O
CSF	O
+	O
RANKL	O
,	O
αvβ3-positive	O
mononuclear	O
cells	O
were	O
observed	O
in	O
CD16-	O
monocyte	O
cultures	O
but	O
not	O
in	O
CD16	O
+	O
monocyte	O
cultures	O
.	O

At	O
96	O
hours	O
,	O
both	O
αvβ3-positive	O
mononuclear	O
cells	O
and	O
multinucleated	O
cells	O
were	O
present	O
in	O
the	O
CD16-	O
monocyte	O
culture	O
.	O

The	O
results	O
indicated	O
that	O
αvβ3	O
was	O
selectively	O
expressed	O
on	O
CD16-	O
monocytes	O
in	O
the	O
presence	O
of	O
M	O
-	O
CSF	O
+	O
RANKL	O
,	O
and	O
the	O
expression	O
was	O
revealed	O
before	O
the	O
cells	O
differentiate	O
into	O
typical	O
multinucleated	O
osteoclasts	O
.	O

RANKL	O
activates	O
ERK	O
and	O
p38	O
kinases	O
only	O
in	O
CD16-	O
monocytes	O
Since	O
ERK	O
and	O
p38	O
MAPK	O
are	O
essential	O
in	O
RANKL	O
-	O
induced	O
osteoclastogenesis	O
[	O
18	O
-	O
20	O
]	O
,	O
we	O
next	O
examined	O
whether	O
these	O
kinases	O
were	O
activated	O
differently	O
in	O
CD16	O
+	O
monocytes	O
and	O
in	O
CD16-	O
monocytes	O
.	O

Purified	O
monocytes	O
were	O
precultured	O
with	O
25	O
ng	O
/	O
ml	O
M	O
-	O
CSF	O
for	O
3	O
days	O
to	O
enhance	O
RANK	O
expression	O
,	O
and	O
were	O
then	O
treated	O
with	O
RANKL	O
.	O

The	O
RANKL	O
treatment	O
induced	O
phosphorylation	O
of	O
both	O
ERK	O
and	O
p38	O
MAPK	O
in	O
CD16-	O
monocytes	O
at	O
5	O
minutes	O
postexposure	O
,	O
although	O
the	O
p38	O
MAPK	O
phosphorylation	O
was	O
weak	O
.	O

Both	O
phosphorylations	O
declined	O
to	O
a	O
basal	O
level	O
within	O
20	O
minutes	O
(	O
Figure	O
5	O
)	O
.	O

In	O
contrast	O
,	O
ERK	O
and	O
p38	O
MAPK	O
were	O
not	O
detectably	O
phosphorylated	O
in	O
CD16	O
+	O
monocytes	O
with	O
RANKL	O
.	O

siRNA	O
targeting	O
integrin	O
β3	O
inhibits	O
osteoclastogenesis	O
from	O
CD16-	O
monocytes	O
The	O
integrin	O
-	O
β3	O
cytoplasmic	O
domain	O
is	O
essential	O
for	O
activation	O
of	O
intracellular	O
signals	O
from	O
αvβ3	O
heterodimers	O
[	O
17	O
]	O
.	O

We	O
therefore	O
examined	O
the	O
involvement	O
of	O
αvβ3	O
in	O
RANKL	O
+	O
M	O
-	O
CSF	O
-	O
induced	O
osteoclastogenesis	O
in	O
human	B
CD16-	O
monocytes	O
using	O
siRNA	O
targeting	O
the	O
integrin	O
-	O
β3	O
subunit	O
.	O

The	O
integrin	O
-	O
β3	O
siRNA	O
or	O
control	O
randomized	O
siRNA	O
were	O
transfected	O
into	O
CD16-	O
monocytes	O
.	O

At	O
48	O
hours	O
post	O
-	O
transfection	O
,	O
we	O
determined	O
the	O
integrin	O
-	O
β3	O
mRNA	O
level	O
and	O
αvβ3	O
heterodimer	O
protein	O
expression	O
.	O

The	O
integrin	O
-	O
β3	O
mRNA	O
level	O
was	O
reduced	O
in	O
the	O
integrin	O
-	O
β3	O
siRNA	O
-	O
transfected	O
monocytes	O
compared	O
with	O
control	O
siRNA	O
-	O
transfected	O
monocytes	O
(	O
Figure	O
6a	O
)	O
.	O

The	O
αvβ3	O
heterodimer	O
expression	O
was	O
evaluated	O
by	O
immunofluorescent	O
staining	O
.	O

The	O
number	O
of	O
αvβ3-positive	O
cells	O
was	O
significantly	O
decreased	O
in	O
integrin	O
-	O
β3	O
siRNA	O
-	O
transfected	O
monocytes	O
compared	O
with	O
that	O
in	O
control	O
siRNA	O
(	O
Figure	O
6b	O
)	O
.	O

After	O
7	O
days	O
of	O
incubation	O
,	O
the	O
number	O
of	O
TRAP	O
-	O
positive	O
MNC	O
was	O
counted	O
.	O

Transfection	O
with	O
integrin	O
-	O
β3	O
siRNA	O
significantly	O
reduced	O
the	O
number	O
of	O
TRAP	O
-	O
positive	O
MNC	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
compared	O
with	O
control	O
siRNA	O
transfection	O
(	O
Figure	O
6c	O
)	O
.	O

In	O
addition	O
,	O
the	O
use	O
of	O
siRNA	O
directed	O
toward	O
a	O
different	O
site	O
of	O
integrin	O
-	O
β3	O
mRNA	O
also	O
inhibited	O
osteoclast	O
formation	O
from	O
CD16-	O
monocytes	O
(	O
data	O
not	O
shown	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
siRNA	O
that	O
targeted	O
lamin	O
,	O
which	O
was	O
used	O
as	O
a	O
negative	O
control	O
,	O
did	O
not	O
inhibit	O
the	O
induction	O
of	O
osteoclasts	O
(	O
data	O
not	O
shown	O
)	O
.	O

These	O
results	O
indicate	O
the	O
importance	O
of	O
integrin	O
β3	O
in	O
RANKL	O
-	O
induced	O
osteoclast	O
formation	O
from	O
CD16-	O
peripheral	O
blood	O
monocytes	O
.	O

Cyclic	O
RGDfV	O
peptide	O
inhibits	O
the	O
osteoclastogenesis	O
from	O
CD16-	O
monocytes	O
Integrin	O
αvβ3	O
recognizes	O
a	O
common	O
tripeptide	O
sequence	O
,	O
RGD	O
(	O
Arg	O
-	O
Gly	O
-	O
Asp	O
)	O
,	O
which	O
is	O
present	O
in	O
bone	O
matrix	O
proteins	O
such	O
as	O
vitronectin	O
and	O
fibronectin	O
[	O
21	O
]	O
.	O

Cyclic	O
RGDfV	O
peptide	O
(	O
Arg	O
-	O
Gly	O
-	O
Asp	O
-	O
D	O
-	O
Phe	O
-	O
Val	O
)	O
inhibits	O
binding	O
of	O
the	O
RGD	O
-	O
containing	O
molecules	O
to	O
αvβ3	O
[	O
22	O
]	O
.	O

To	O
investigate	O
the	O
role	O
of	O
ligand	O
binding	O
to	O
the	O
αvβ3	O
heterodimer	O
in	O
the	O
osteoclastogenesis	O
,	O
we	O
examined	O
whether	O
cyclic	O
RGDfV	O
peptide	O
inhibits	O
the	O
formation	O
of	O
osteoclasts	O
.	O

Cyclic	O
RGDfV	O
peptide	O
significantly	O
reduced	O
the	O
number	O
of	O
TRAP	O
-	O
positive	O
MNC	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
Figure	O
6d	O
)	O
.	O

The	O
results	O
imply	O
possible	O
involvement	O
of	O
ligand	O
bindings	O
to	O
αvβ3	O
in	O
the	O
osteoclastogenesis	O
.	O

Knockdown	O
of	O
integrin	O
β3	O
did	O
not	O
affect	O
the	O
expression	O
of	O
NFATc1	O
mRNA	O
In	O
the	O
next	O
step	O
,	O
we	O
determined	O
whether	O
integrin	O
-	O
β3-siRNA	O
-	O
induced	O
inhibition	O
of	O
the	O
osteoclastogenesis	O
reflects	O
downregulation	O
of	O
NFATc1	O
,	O
which	O
is	O
a	O
key	O
transcription	O
factor	O
in	O
osteoclastogenesis	O
[	O
23	O
]	O
.	O

For	O
this	O
purpose	O
,	O
we	O
compared	O
NFATc1	O
mRNA	O
levels	O
between	O
integrin	O
β3	O
and	O
control	O
siRNA	O
-	O
transfected	O
monocytes	O
.	O

Interestingly	O
,	O
integrin	O
-	O
β3	O
knockdown	O
did	O
not	O
alter	O
the	O
NFATc1	O
mRNA	O
level	O
(	O
Figure	O
7	O
)	O
,	O
suggesting	O
that	O
signal	O
transduction	O
mediated	O
by	O
integrin	O
β3	O
does	O
not	O
affect	O
the	O
expression	O
of	O
NFATc1	O
.	O

Detection	O
of	O
CD16	O
+	O
and	O
CD16-	O
macrophages	O
in	O
synovium	O
of	O
RA	O
patients	O
RA	O
synovial	O
macrophages	O
are	O
derived	O
from	O
peripheral	O
blood	O
monocytes	O
,	O
and	O
their	O
recruitment	O
into	O
the	O
synovium	O
is	O
facilitated	O
by	O
various	O
adhesion	O
molecules	O
and	O
chemokines	O
[	O
24	O
]	O
.	O

To	O
analyze	O
CD16	O
expression	O
on	O
synovial	O
macrophages	O
,	O
RA	O
synovial	O
tissues	O
were	O
double	O
-	O
stained	O
for	O
CD16	O
and	O
a	O
macrophage	O
marker	O
,	O
CD68	O
.	O

CD16-	O
/	O
CD68	O
+	O
macrophages	O
were	O
widespread	O
in	O
the	O
synovium	O
.	O

Although	O
less	O
frequent	O
,	O
CD16+	O
/	O
CD68	O
+	O
macrophages	O
were	O
also	O
observed	O
both	O
in	O
the	O
synovial	O
intima	O
and	O
subintima	O
(	O
Figure	O
8)	O
.	O

The	O
presence	O
of	O
two	O
subsets	O
of	O
macrophages	O
,	O
CD16	O
+	O
and	O
CD16-	O
,	O
in	O
RA	O
synovium	O
indicates	O
that	O
both	O
CD16	O
+	O
and	O
CD16-	O
peripheral	O
blood	O
monocytes	O
are	O
recruited	O
into	O
the	O
synovium	O
.	O

Discussion	O
Human	B
peripheral	O
blood	O
monocytes	O
are	O
a	O
heterogeneous	O
population	O
,	O
and	O
they	O
are	O
divided	O
into	O
two	O
subsets	O
based	O
on	O
the	O
expression	O
of	O
CD16	O
.	O

The	O
CD16	O
+	O
and	O
CD16-	O
monocyte	O
subsets	O
show	O
functional	O
differences	O
in	O
migration	O
,	O
cytokine	O
production	O
and	O
differentiation	O
into	O
macrophages	O
or	O
dendritic	O
cells	O
[	O
11	O
-	O
13,15	O
]	O
.	O

We	O
focused	O
on	O
the	O
heterogeneity	O
of	O
the	O
monocytes	O
,	O
and	O
the	O
primary	O
question	O
addressed	O
in	O
this	O
study	O
was	O
which	O
monocyte	O
subset	O
could	O
be	O
the	O
source	O
of	O
osteoclasts	O
.	O

The	O
results	O
demonstrated	O
that	O
CD16-	O
peripheral	O
blood	O
monocytes	O
,	O
but	O
not	O
CD16	O
+	O
monocytes	O
,	O
differentiated	O
in	O
vitro	O
into	O
osteoclasts	O
by	O
treatment	O
with	O
RANKL	O
+	O
M	O
-	O
CSF	O
.	O

To	O
investigate	O
the	O
molecular	O
mechanisms	O
of	O
the	O
different	O
response	O
to	O
RANKL	O
and	O
the	O
differentiation	O
into	O
osteoclasts	O
between	O
CD16	O
+	O
and	O
CD16-	O
monocytes	O
,	O
we	O
examined	O
the	O
expression	O
of	O
molecules	O
known	O
to	O
be	O
involved	O
in	O
osteoclastogenesis	O
.	O

The	O
expression	O
profiles	O
of	O
integrin	O
αv	O
,	O
integrin	O
β3	O
and	O
NFATc1	O
were	O
different	O
between	O
the	O
two	O
subsets	O
.	O

Integrin	O
αvβ3	O
heterodimer	O
was	O
expressed	O
only	O
on	O
RANKL	O
and	O
M	O
-	O
CSF	O
-	O
stimulated	O
CD16-	O
monocytes	O
.	O

It	O
is	O
known	O
that	O
αvβ3	O
expressed	O
on	O
osteoclasts	O
is	O
important	O
in	O
bone	O
resorption	O
as	O
well	O
as	O
in	O
attachment	O
of	O
osteoclasts	O
to	O
the	O
bone	O
matrix	O
[	O
25	O
]	O
.	O

It	O
was	O
recently	O
reported	O
that	O
bone	O
marrow	O
macrophages	O
of	O
integrin	O
-	O
β3-deficient	O
mice	B
could	O
not	O
differentiate	O
into	O
mature	O
osteoclasts	O
in	O
vitro	O
,	O
suggesting	O
that	O
αvβ3	O
is	O
involved	O
not	O
only	O
in	O
activation	O
,	O
but	O
also	O
in	O
differentiation	O
,	O
of	O
osteoclasts	O
in	O
mice	B
[	O
26,27	O
]	O
.	O

The	O
authors	O
also	O
showed	O
that	O
αvβ3	O
and	O
c	O
-	O
fms	O
share	O
a	O
common	O
intracellular	O
signaling	O
pathway	O
,	O
including	O
the	O
activation	O
of	O
ERK	O
and	O
the	O
induction	O
of	O
c	O
-	O
Fos	O
[	O
27	O
]	O
,	O
both	O
of	O
which	O
are	O
essential	O
for	O
osteoclastogenesis	O
[	O
28,29	O
]	O
.	O

In	O
addition	O
,	O
it	O
was	O
reported	O
that	O
echistatin	O
,	O
an	O
αvβ3	O
antagonist	O
,	O
inhibited	O
osteoclast	O
formation	O
of	O
mouse	B
bone	O
marrow	O
cells	O
[	O
30	O
]	O
.	O

In	O
accordance	O
with	O
these	O
reports	O
,	O
our	O
data	O
showed	O
that	O
knockdown	O
of	O
integrin	O
-	O
β3	O
expression	O
resulted	O
in	O
downregulation	O
of	O
the	O
αvβ3	O
heterodimer	O
,	O
and	O
abrogated	O
osteoclastogenesis	O
from	O
human	B
peripheral	O
blood	O
CD16-	O
monocytes	O
.	O

We	O
also	O
showed	O
that	O
blocking	O
of	O
adhesive	O
ligands	O
to	O
bind	O
to	O
αvβ3	O
by	O
RGDfV	O
peptide	O
inhibited	O
osteoclast	O
formation	O
from	O
CD16-	O
monocytes	O
.	O

Taken	O
together	O
,	O
the	O
process	O
of	O
ligand	O
binding	O
to	O
αvβ3	O
may	O
be	O
involved	O
in	O
the	O
osteoclastogenesis	O
.	O

Blockade	O
of	O
αvβ3	O
could	O
therefore	O
be	O
a	O
therapeutically	O
beneficial	O
approach	O
to	O
modulate	O
osteoclastogenesis	O
.	O

Indeed	O
,	O
integrin	O
αvβ3	O
antagonists	O
effectively	O
treated	O
osteoporosis	O
in	O
mice	B
,	O
rats	B
and	O
humans	B
,	O
and	O
protected	O
bone	O
destruction	O
in	O
rat	O
adjuvant	O
-	O
induced	O
arthritis	O
in	O
vivo	O
[	O
31	O
-	O
34	O
]	O
.	O

Of	O
note	O
,	O
it	O
is	O
reported	O
that	O
patients	O
with	O
Iraqi	O
-	O
Jewish	O
-	O
type	O
Glanzmann	O
thrombasthenia	O
who	O
are	O
deficient	O
in	O
integrin	O
β3	O
do	O
not	O
develop	O
osteopetrosis	O
because	O
of	O
the	O
upregulation	O
of	O
α2β1	O
expression	O
on	O
osteoclasts	O
,	O
although	O
the	O
bone	O
-	O
resorptive	O
ability	O
of	O
the	O
osteoclasts	O
was	O
decreased	O
in	O
vitro	O
[	O
35	O
]	O
.	O

The	O
function	O
of	O
αvβ3	O
in	O
vivo	O
in	O
osteoclast	O
formation	O
and	O
resorptive	O
function	O
could	O
therefore	O
be	O
partially	O
compensated	O
by	O
other	O
integrins	O
.	O

Although	O
all	O
the	O
multinucleated	O
osteoclasts	O
expressed	O
αvβ3	O
(	O
Figure	O
4d	O
)	O
[	O
36	O
]	O
,	O
a	O
small	O
number	O
of	O
M	O
-	O
CSF	O
+	O
RANKL	O
-	O
stimulated	O
mononuclear	O
CD16-	O
monocytes	O
expressed	O
αvβ3	O
(	O
Figure	O
4d	O
)	O
.	O

Multinucleated	O
osteoclasts	O
are	O
formed	O
by	O
fusion	O
of	O
osteoclast	O
precursor	O
cells	O
[	O
37	O
]	O
.	O

It	O
was	O
reported	O
that	O
αvβ3	O
is	O
involved	O
in	O
the	O
migration	O
of	O
osteoclast	O
precursors	O
[	O
30	O
]	O
.	O

The	O
αvβ3-positive	O
cells	O
could	O
therefore	O
be	O
forced	O
to	O
migrate	O
by	O
the	O
ligands	O
and	O
may	O
fuse	O
with	O
closed	O
αvβ3-negative	O
cells	O
.	O

Alternatively	O
,	O
only	O
αvβ3-positive	O
cells	O
may	O
be	O
fused	O
with	O
each	O
other	O
.	O

It	O
is	O
possible	O
to	O
consider	O
that	O
signaling	O
from	O
CD16	O
by	O
anti	O
-	O
CD16	O
mAb	O
-	O
coated	O
magnetic	O
beads	O
,	O
which	O
were	O
used	O
for	O
the	O
cell	O
separation	O
,	O
or	O
by	O
IgG	O
contained	O
in	O
FBS	O
might	O
inhibit	O
osteoclastogenesis	O
from	O
CD16	O
+	O
monocytes	O
.	O

We	O
therefore	O
separated	O
the	O
two	O
subsets	O
using	O
anti	O
-	O
CD33	O
mAb	O
and	O
a	O
fluorescent	O
cell	O
sorter	O
,	O
and	O
stimulated	O
the	O
cells	O
with	O
M	O
-	O
CSF	O
+	O
RANKL	O
.	O

The	O
results	O
showed	O
that	O
CD33low	O
monocytes	O
,	O
which	O
correspond	O
to	O
CD16	O
+	O
monocytes	O
,	O
still	O
could	O
not	O
differentiate	O
into	O
osteoclasts	O
.	O

CD16	O
is	O
a	O
heterodimer	O
consisting	O
of	O
FcγIIIa	O
and	O
Fcγ	O
,	O
and	O
has	O
low	O
affinity	O
for	O
the	O
Fc	O
region	O
of	O
IgG.	O
Aggregation	O
of	O
CD16	O
by	O
immune	O
complexes	O
leads	O
to	O
transmission	O
of	O
activating	O
signals	O
via	O
the	O
immunoreceptor	O
tyrosine	O
-	O
based	O
activation	O
motif	O
in	O
the	O
γ	O
chain	O
[	O
38	O
]	O
.	O

We	O
also	O
assessed	O
osteoclastogenesis	O
from	O
the	O
two	O
monocyte	O
subsets	O
using	O
IgG	O
-	O
depleted	O
bovine	B
serum	O
.	O

Even	O
in	O
the	O
IgG	O
-	O
free	O
medium	O
,	O
CD16-	O
monocytes	O
but	O
not	O
CD16	O
+	O
monocytes	O
differentiated	O
into	O
osteoclasts	O
(	O
data	O
not	O
shown	O
)	O
.	O

We	O
could	O
therefore	O
exclude	O
the	O
possibility	O
that	O
signal	O
transduction	O
through	O
CD16	O
inhibits	O
osteoclastogenesis	O
from	O
CD16	O
+	O
monocytes	O
.	O

NFATc1	O
is	O
a	O
key	O
transcription	O
factor	O
in	O
osteoclastogenesis	O
[	O
16	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
stimulation	O
with	O
M	O
-	O
CSF	O
+	O
RANKL	O
increased	O
the	O
NFATc1	O
mRNA	O
expression	O
in	O
the	O
CD16-	O
subset	O
only	O
,	O
similar	O
to	O
integrin	O
αv	O
and	O
integrin	O
β3	O
.	O

The	O
differences	O
in	O
NFATc1	O
induction	O
might	O
therefore	O
also	O
explain	O
the	O
difference	O
in	O
osteoclastogenesis	O
between	O
the	O
two	O
monocyte	O
subsets	O
.	O

It	O
is	O
of	O
interest	O
that	O
knockdown	O
of	O
integrin	O
β3	O
did	O
not	O
lower	O
the	O
mRNA	O
level	O
of	O
NFATc1	O
.	O

This	O
result	O
supports	O
the	O
notion	O
that	O
NFATc1	O
is	O
located	O
upstream	O
of	O
integrin	O
-	O
β3	O
expression	O
[	O
39	O
]	O
.	O

It	O
is	O
also	O
possible	O
that	O
parallel	O
activation	O
of	O
two	O
signaling	O
pathways	O
mediated	O
by	O
integrin	O
β3	O
and	O
NFATc1	O
contributes	O
to	O
osteoclastogenesis	O
independently	O
or	O
cooperatively	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
determine	O
the	O
mechanisms	O
of	O
integrin	O
β3	O
involvement	O
in	O
RANKL	O
/	O
RANK	O
-	O
mediated	O
osteoclast	O
differentiation	O
.	O

It	O
has	O
been	O
demonstrated	O
that	O
MAPK	O
families	O
,	O
ERK	O
and	O
p38	O
MAPK	O
,	O
were	O
activated	O
by	O
RANKL	O
-	O
induced	O
intracellular	O
signalings	O
in	O
osteoclasts	O
and	O
osteoclast	O
precursors	O
[	O
18,19	O
]	O
.	O

In	O
addition	O
,	O
these	O
kinases	O
are	O
involved	O
in	O
the	O
differentiation	O
of	O
osteoclasts	O
[	O
20	O
]	O
.	O

We	O
showed	O
that	O
RANKL	O
stimulation	O
induced	O
phosphorylation	O
of	O
ERK	O
and	O
p38	O
MAPK	O
only	O
in	O
CD16-	O
monocytes	O
.	O

It	O
is	O
suggested	O
that	O
differential	O
activation	O
of	O
these	O
kinases	O
may	O
partially	O
explain	O
the	O
distinct	O
properties	O
of	O
the	O
two	O
monocyte	O
subsets	O
upon	O
RANKL	O
stimulation	O
.	O

Our	O
results	O
showed	O
that	O
CD16	O
+	O
monocytes	O
produce	O
higher	O
levels	O
of	O
inflammatory	O
cytokines	O
including	O
TNFα	O
and	O
IL-6	O
compared	O
with	O
CD16-	O
monocytes	O
.	O

These	O
results	O
are	O
consistent	O
with	O
the	O
previous	O
report	O
showing	O
that	O
CD16	O
+	O
monocytes	O
produced	O
larger	O
amounts	O
of	O
TNFα	O
upon	O
lipopolysaccharide	O
or	O
lipopeptide	O
stimulation	O
than	O
did	O
CD16-	O
monocytes	O
[	O
40	O
]	O
.	O

Interestingly	O
,	O
we	O
showed	O
that	O
stimulation	O
either	O
with	O
RANKL	O
or	O
M	O
-	O
CSF	O
upregulated	O
the	O
TNFα	O
and	O
IL-6	O
production	O
by	O
CD16	O
+	O
monocytes	O
.	O

A	O
marked	O
increase	O
of	O
CD16	O
+	O
monocytes	O
in	O
peripheral	O
blood	O
is	O
reported	O
in	O
inflammatory	O
diseases	O
,	O
such	O
as	O
infection	O
,	O
malignancy	O
,	O
Kawasaki	O
disease	O
and	O
RA	O
[	O
41	O
-	O
44	O
]	O
.	O

Taken	O
together	O
,	O
CD16	O
+	O
monocytes	O
may	O
be	O
an	O
important	O
source	O
of	O
inflammatory	O
cytokines	O
.	O

In	O
mice	B
,	O
peripheral	O
blood	O
Ly-6Chigh	O
monocytes	O
,	O
which	O
are	O
thought	O
to	O
correspond	O
to	O
human	B
CD16-	O
monocytes	O
,	O
increase	O
in	O
inflammatory	O
conditions	O
,	O
and	O
these	O
cells	O
are	O
recruited	O
into	O
sites	O
of	O
inflammation	O
[	O
45	O
]	O
.	O

In	O
contrast	O
,	O
Ly-6Clow	O
monocytes	O
,	O
which	O
are	O
thought	O
to	O
correspond	O
to	O
human	B
CD16	O
+	O
,	O
migrate	O
into	O
noninflamed	O
tissues	O
[	O
12	O
]	O
.	O

These	O
data	O
on	O
mouse	B
monocytes	O
seem	O
to	O
be	O
in	O
contrast	O
to	O
the	O
data	O
on	O
human	B
monocytes	O
,	O
which	O
show	O
expansion	O
of	O
CD16	O
+	O
monocytes	O
in	O
inflammatory	O
conditions	O
where	O
they	O
produce	O
larger	O
amounts	O
of	O
inflammatory	O
cytokines	O
.	O

At	O
present	O
,	O
it	O
is	O
not	O
clear	O
whether	O
mouse	B
monocyte	O
subsets	O
,	O
Ly-6Clow	O
/	O
Ly-6Chigh	O
,	O
represent	O
human	B
monocyte	O
subsets	O
,	O
CD16+	O
/	O
CD16-	O
monocytes	O
,	O
and	O
whether	O
the	O
biologic	O
functions	O
of	O
mouse	B
monocytes	O
are	O
analogous	O
to	O
those	O
of	O
human	B
monocytes	O
.	O

In	O
mice	B
,	O
blood	O
monocytes	O
newly	O
released	O
from	O
the	O
bone	O
marrow	O
are	O
exclusively	O
Ly-6Chigh	O
and	O
the	O
level	O
of	O
Ly-6C	O
is	O
downregulated	O
while	O
in	O
circulation	O
[	O
45	O
]	O
.	O

It	O
is	O
thus	O
suggested	O
that	O
in	O
mice	B
the	O
two	O
monocyte	O
subsets	O
differing	O
in	O
Ly-6C	O
expression	O
represent	O
different	O
stages	O
in	O
the	O
maturation	O
pathway	O
.	O

In	O
the	O
human	B
,	O
transition	O
from	O
CD16-	O
monocytes	O
to	O
CD16	O
+	O
monocytes	O
is	O
observed	O
upon	O
culture	O
with	O
IL-10	O
,	O
M	O
-	O
CSF	O
and	O
transforming	O
growth	O
factor	O
beta	O
in	O
vitro	O
[	O
42,46	O
]	O
.	O

Similar	O
to	O
mouse	B
monocytes	O
,	O
therefore	O
,	O
human	B
peripheral	O
blood	O
CD16-	O
monocytes	O
may	O
also	O
maturate	O
into	O
CD16	O
+	O
monocytes	O
.	O

It	O
is	O
reported	O
that	O
a	O
significant	O
number	O
of	O
RA	O
synovial	O
cells	O
in	O
the	O
intima	O
express	O
CD16	O
,	O
suggesting	O
that	O
CD16	O
+	O
cells	O
are	O
synovial	O
macrophages	O
[	O
47	O
]	O
.	O

We	O
confirmed	O
that	O
both	O
CD16	O
+	O
and	O
CD16-	O
macrophages	O
accumulate	O
in	O
the	O
RA	O
synovium	O
by	O
double	O
-	O
color	O
immunohistochemical	O
staining	O
for	O
CD68	O
and	O
CD16	O
.	O

A	O
number	O
of	O
chemokines	O
are	O
abundantly	O
expressed	O
in	O
the	O
RA	O
synovium	O
[	O
24,48	O
]	O
.	O

Among	O
these	O
cytokines	O
,	O
MCP-1	O
,	O
MIP-1α	O
,	O
SDF-1	O
,	O
RANTES	O
and	O
fractalkine	O
can	O
induce	O
migration	O
of	O
CD16-	O
monocytes	O
in	O
vitro	O
(	O
[	O
11,12	O
]	O
and	O
unpublished	O
data	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
migration	O
of	O
CD16	O
+	O
monocytes	O
is	O
induced	O
only	O
by	O
fractalkine	O
.	O

These	O
chemokines	O
therefore	O
seem	O
to	O
play	O
an	O
important	O
role	O
in	O
recruitment	O
of	O
CD16	O
+	O
and	O
CD16-	O
monocytes	O
from	O
the	O
circulating	O
pool	O
into	O
the	O
RA	O
synovium	O
.	O

The	O
osteoclast	O
inducers	O
are	O
also	O
produced	O
in	O
the	O
RA	O
synovium	O
.	O

RANKL	O
is	O
expressed	O
by	O
synovial	O
fibroblasts	O
and	O
activated	O
T	O
cells	O
[	O
49	O
-	O
51	O
]	O
,	O
while	O
M	O
-	O
CSF	O
is	O
expressed	O
on	O
RA	O
synovial	O
macrophages	O
and	O
fibroblasts	O
[	O
52,53	O
]	O
.	O

TNFα	O
and	O
IL-6	O
,	O
which	O
are	O
mainly	O
expressed	O
on	O
RA	O
synovial	O
macrophages	O
and	O
fibroblasts	O
,	O
respectively	O
,	O
could	O
also	O
enhance	O
osteoclast	O
differentiation	O
[	O
54	O
]	O
.	O

Collectively	O
,	O
it	O
is	O
probable	O
that	O
the	O
recruited	O
CD16-	O
monocytes	O
/	O
macrophages	O
differentiate	O
into	O
osteoclasts	O
in	O
the	O
RA	O
synovium	O
,	O
and	O
contribute	O
to	O
bone	O
destruction	O
.	O

On	O
the	O
other	O
hand	O
,	O
CD16	O
+	O
monocytes	O
/	O
macrophages	O
might	O
also	O
be	O
involved	O
in	O
RA	O
pathogenesis	O
by	O
producing	O
inflammatory	O
cytokines	O
including	O
TNFα	O
and	O
IL-6	O
.	O

Since	O
TNFα	O
and	O
IL-6	O
enhance	O
osteoclast	O
formation	O
[	O
54,55	O
]	O
,	O
CD16	O
+	O
monocytes	O
/	O
macrophages	O
may	O
also	O
contribute	O
to	O
osteoclastogenesis	O
in	O
RA	O
synovium	O
.	O

Conclusion	O
We	O
have	O
shown	O
that	O
human	B
peripheral	O
blood	O
monocytes	O
consist	O
of	O
two	O
functionally	O
heterogeneous	O
subsets	O
with	O
distinct	O
response	O
to	O
osteoclastogenic	O
stimuli	O
.	O

Osteoclasts	O
seem	O
to	O
originate	O
from	O
CD16-	O
monocytes	O
,	O
and	O
integrin	O
β3	O
is	O
necessary	O
for	O
the	O
osteoclastogenesis	O
.	O

The	O
blockade	O
of	O
accumulation	O
and	O
activation	O
of	O
CD16-	O
monocytes	O
could	O
therefore	O
be	O
a	O
beneficial	O
approach	O
as	O
an	O
anti	O
-	O
bone	O
resorptive	O
therapy	O
,	O
especially	O
for	O
RA	O
.	O

Abbreviations	O
DAP	O
=	O
DNAX	O
-	O
activation	O
protein	O
;	O
ELISA	O
=	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
;	O
FBS	O
=	O
fetal	O
bovine	B
serum	O
;	O
FcRγ	O
=	O
Fc	O
receptor	O
γ	O
chain	O
;	O
IL	O
=	O
interleukin	O
;	O
FITC	O
=	O
fluorescein	O
isothiocianate	O
;	O
mAb	O
,	O
monoclonal	O
antibody	O
;	O
M	O
-	O
CSF	O
=	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
;	O
MEM	O
=	O
modified	O
Eagle	O
's	O
medium	O
;	O
MMP	O
=	O
matrix	O
metalloproteinase	O
;	O
MNC	O
=	O
multinucleated	O
cells	O
;	O
NF	O
=	O
nuclear	O
factor	O
;	O
OSCAR	O
=	O
osteoclast	O
-	O
associated	O
receptor	O
;	O
PBS	O
=	O
phosphate	O
-	O
buffered	O
saline	O
;	O
PCR	O
=	O
polymerase	O
chain	O
reaction	O
;	O
RA	O
=	O
rheumatoid	O
arthritis	O
;	O
RANK	O
=	O
receptor	O
activator	O
of	O
NF	O
-	O
κB	O
;	O
RANKL	O
=	O
receptor	O
activator	O
of	O
NF	O
-	O
κB	O
ligand	O
;	O
RT	O
=	O
reverse	O
transcriptase	O
;	O
siRNA	O
=	O
small	O
interfering	O
RNA	O
;	O
SIRP	O
-	O
β1	O
=	O
signal	O
regulatory	O
protein	O
-	O
β1	O
;	O
TNFα	O
=	O
tumor	O
necrosis	O
factor	O
alpha	O
;	O
TRAF	O
=	O
tumor	O
necrosis	O
factor	O
receptor	O
-	O
associated	O
factor	O
;	O
TRAP	O
=	O
tartrate	O
-	O
resistant	O
acid	O
phosphatase	O
;	O
TREM	O
=	O
triggering	O
receptor	O
expressed	O
on	O
myeloid	O
cells	O
.	O

Competing	O
interests	O
The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O
YK	O
participated	O
in	O
the	O
design	O
of	O
the	O
study	O
,	O
carried	O
out	O
the	O
experiments	O
and	O
statistical	O
analysis	O
,	O
and	O
drafted	O
the	O
manuscript	O
.	O

KH	O
and	O
KT	O
participated	O
in	O
the	O
design	O
of	O
the	O
study	O
and	O
its	O
coordination	O
.	O

TN	O
and	O
NM	O
conceived	O
of	O
the	O
study	O
,	O
participated	O
in	O
its	O
design	O
and	O
coordination	O
,	O
and	O
helped	O
to	O
draft	O
the	O
manuscript	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

MUC1	O
alters	O
oncogenic	O
events	O
and	O
transcription	O
in	O
human	B
breast	O
cancer	O
cells	O
Abstract	O
Introduction	O
MUC1	O
is	O
an	O
oncoprotein	O
whose	O
overexpression	O
correlates	O
with	O
aggressiveness	O
of	O
tumors	O
and	O
poor	O
survival	O
of	O
cancer	O
patients	O
.	O

Many	O
of	O
the	O
oncogenic	O
effects	O
of	O
MUC1	O
are	O
believed	O
to	O
occur	O
through	O
interaction	O
of	O
its	O
cytoplasmic	O
tail	O
with	O
signaling	O
molecules	O
.	O

As	O
expected	O
for	O
a	O
protein	O
with	O
oncogenic	O
functions	O
,	O
MUC1	O
is	O
linked	O
to	O
regulation	O
of	O
proliferation	O
,	O
apoptosis	O
,	O
invasion	O
,	O
and	O
transcription	O
.	O

Methods	O
To	O
clarify	O
the	O
role	O
of	O
MUC1	O
in	O
cancer	O
,	O
we	O
transfected	O
two	O
breast	O
cancer	O
cell	O
lines	O
(	O
MDA	O
-	O
MB-468	O
and	O
BT-20	O
)	O
with	O
small	O
interfering	O
(	O
si	O
)	O
RNA	O
directed	O
against	O
MUC1	O
and	O
analyzed	O
transcriptional	O
responses	O
and	O
oncogenic	O
events	O
(	O
proliferation	O
,	O
apoptosis	O
and	O
invasion	O
)	O
.	O

Results	O
Transcription	O
of	O
several	O
genes	O
was	O
altered	O
after	O
transfection	O
of	O
MUC1	O
siRNA	O
,	O
including	O
decreased	O
MAP2K1	O
(	O
MEK1	O
)	O
,	O
JUN	O
,	O
PDGFA	O
,	O
CDC25A	O
,	O
VEGF	O
and	O
ITGAV	O
(	O
integrin	O
αv	O
)	O
,	O
and	O
increased	O
TNF	O
,	O
RAF1	O
,	O
and	O
MMP2	O
.	O

Additional	O
changes	O
were	O
seen	O
at	O
the	O
protein	O
level	O
,	O
such	O
as	O
increased	O
expression	O
of	O
c	O
-	O
Myc	O
,	O
heightened	O
phosphorylation	O
of	O
AKT	O
,	O
and	O
decreased	O
activation	O
of	O
MEK1	O
/	O
2	O
and	O
ERK1	O
/	O
2	O
.	O

These	O
were	O
correlated	O
with	O
cellular	O
events	O
,	O
as	O
MUC1	O
siRNA	O
in	O
the	O
MDA	O
-	O
MB-468	O
line	O
decreased	O
proliferation	O
and	O
invasion	O
,	O
and	O
increased	O
stress	O
-	O
induced	O
apoptosis	O
.	O

Intriguingly	O
,	O
BT-20	O
cells	O
displayed	O
similar	O
levels	O
of	O
apoptosis	O
regardless	O
of	O
siRNA	O
,	O
and	O
actually	O
increased	O
proliferation	O
after	O
MUC1	O
siRNA	O
.	O

Conclusion	O
These	O
results	O
further	O
the	O
growing	O
knowledge	O
of	O
the	O
role	O
of	O
MUC1	O
in	O
transcription	O
,	O
and	O
suggest	O
that	O
the	O
regulation	O
of	O
MUC1	O
in	O
breast	O
cancer	O
may	O
be	O
more	O
complex	O
than	O
previously	O
appreciated	O
.	O

The	O
differences	O
between	O
these	O
two	O
cell	O
lines	O
emphasize	O
the	O
importance	O
of	O
understanding	O
the	O
context	O
of	O
cell	O
-	O
specific	O
signaling	O
events	O
when	O
analyzing	O
the	O
oncogenic	O
functions	O
of	O
MUC1	O
,	O
and	O
caution	O
against	O
generalizing	O
the	O
results	O
of	O
individual	O
cell	O
lines	O
without	O
adequate	O
confirmation	O
in	O
intact	O
biological	O
systems	O
.	O

Introduction	O
MUC1	O
is	O
the	O
founding	O
member	O
of	O
the	O
mucin	O
family	O
:	O
proteins	O
characterized	O
by	O
heavy	O
O	O
-	O
glycosylation	O
centering	O
around	O
a	O
variable	O
number	O
of	O
tandem	O
repeats	O
that	O
are	O
rich	O
in	O
serine	O
and	O
threonine	O
residues	O
[	O
1,2	O
]	O
.	O

MUC1	O
is	O
a	O
transmembrane	O
heterodimer	O
with	O
one	O
subunit	O
solely	O
extracellular	O
(	O
MUC1-EX	O
)	O
,	O
and	O
the	O
other	O
subunit	O
composed	O
of	O
a	O
short	O
extracellular	O
stem	O
,	O
a	O
single	O
transmembrane	O
domain	O
,	O
and	O
the	O
cytoplasmic	O
tail	O
(	O
together	O
called	O
the	O
MUC1-CT	O
)	O
.	O

MUC1	O
possesses	O
both	O
pro-	O
and	O
anti	O
-	O
adhesive	O
capacities	O
,	O
as	O
the	O
MUC1-EX	O
provides	O
binding	O
sites	O
for	O
a	O
variety	O
of	O
adhesion	O
proteins	O
,	O
while	O
its	O
large	O
size	O
and	O
extended	O
structure	O
prevents	O
cell	O
-	O
cell	O
contact	O
[	O
3	O
-	O
5	O
]	O
.	O

Initially	O
described	O
as	O
a	O
tumor	O
antigen	O
overexpressed	O
in	O
>	O
90	O
%	O
of	O
breast	O
cancers	O
,	O
MUC1	O
is	O
now	O
known	O
to	O
be	O
an	O
oncogene	O
with	O
roles	O
in	O
both	O
tumor	O
formation	O
and	O
progression	O
[	O
1,6	O
]	O
.	O

Mouse	B
studies	O
have	O
been	O
integral	O
to	O
the	O
current	O
understanding	O
of	O
MUC1	O
in	O
cancer	O
.	O

Muc1	O
knockout	O
mice	B
(	O
Muc1-	O
/	O
-	O
;	O
MUC1	O
is	O
human	B
;	O
Muc1	O
is	O
mouse	B
)	O
show	O
a	O
reduction	O
in	O
tumorigenic	O
phenotype	O
when	O
crossed	O
onto	O
mice	B
overexpressing	O
the	O
Wnt-1	O
[	O
7	O
]	O
or	O
polyomavirus	O
middle	O
T	O
antigen	O
[	O
8	O
]	O
oncogenes	O
in	O
the	O
mammary	O
gland	O
.	O

In	O
contrast	O
,	O
MUC1	O
overexpression	O
in	O
the	O
mammary	O
gland	O
drives	O
tumor	O
formation	O
[	O
9	O
]	O
,	O
indicating	O
that	O
MUC1	O
is	O
a	O
true	O
oncogene	O
.	O

Many	O
of	O
the	O
oncogenic	O
effects	O
of	O
MUC1	O
stem	O
from	O
its	O
cytoplasmic	O
tail	O
,	O
which	O
binds	O
to	O
several	O
proteins	O
implicated	O
in	O
cancer	O
,	O
including	O
c	O
-	O
Src	O
[	O
10,11	O
]	O
and	O
the	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
family	O
[	O
12,13	O
]	O
.	O

MUC1	O
stimulates	O
mitogen	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
signaling	O
through	O
the	O
extracellular	O
signal	O
regulated	O
kinases	O
(	O
ERK1	O
/	O
2	O
)	O
[	O
12,14	O
]	O
;	O
this	O
can	O
occur	O
through	O
MUC1	O
association	O
with	O
Grb2	O
and	O
son	O
of	O
sevenless	O
to	O
activate	O
Ras	O
[	O
15	O
]	O
.	O

ERK1	O
/	O
2	O
signaling	O
is	O
commonly	O
stimulated	O
by	O
the	O
Ras	O
-	O
Raf	O
-	O
MEK	O
(	O
MAPK	O
and	O
ERK	O
kinase	O
)	O
cascade	O
downstream	O
of	O
mitogens	O
such	O
as	O
EGFR	O
[	O
16	O
]	O
,	O
and	O
regulates	O
transcription	O
via	O
factors	O
like	O
the	O
activator	O
protein-1	O
complex	O
.	O

Loss	O
of	O
MUC1	O
can	O
reduce	O
EGFR	O
expression	O
[	O
17	O
]	O
,	O
providing	O
another	O
means	O
of	O
affecting	O
MAPK	O
signaling	O
.	O

Our	O
results	O
describe	O
a	O
novel	O
mechanism	O
by	O
which	O
MUC1	O
regulates	O
the	O
ERK1	O
/	O
2	O
pathway	O
,	O
through	O
modulating	O
transcription	O
of	O
the	O
genes	O
encoding	O
MEK1	O
,	O
Raf-1	O
,	O
and	O
c	O
-	O
Jun	O
.	O

MUC1	O
expression	O
correlates	O
with	O
increased	O
survival	O
in	O
response	O
to	O
cytotoxic	O
or	O
oxidative	O
agents	O
[	O
18	O
-	O
21	O
]	O
,	O
and	O
can	O
activate	O
the	O
phosphoinositol-3	O
kinase	O
-	O
AKT	O
pathway	O
as	O
part	O
of	O
an	O
anti	O
-	O
apoptotic	O
response	O
[	O
18	O
]	O
.	O

MUC1	O
has	O
also	O
recently	O
been	O
linked	O
to	O
transcription	O
,	O
as	O
the	O
MUC1-CT	O
localizes	O
to	O
the	O
nucleus	O
[	O
22	O
]	O
and	O
affects	O
transcription	O
by	O
β	O
-	O
catenin	O
[	O
22,23	O
]	O
,	O
FOXO3a	O
[	O
21	O
]	O
,	O
p53	O
[	O
24	O
]	O
,	O
and	O
estrogen	O
receptor	O
α	O
[	O
25	O
]	O
.	O

However	O
,	O
there	O
are	O
indications	O
that	O
the	O
role	O
of	O
MUC1	O
in	O
oncogenesis	O
is	O
regulated	O
by	O
cell	O
type	O
and	O
signaling	O
context	O
.	O

For	O
example	O
,	O
MUC1	O
can	O
stimulate	O
Fas	O
-	O
mediated	O
apoptosis	O
[	O
26	O
]	O
,	O
while	O
Muc1	O
is	O
specifically	O
down	O
-	O
regulated	O
in	O
c	O
-	O
neu	O
-	O
induced	O
mammary	O
tumors	O
[	O
27	O
]	O
.	O

This	O
report	O
emphasizes	O
the	O
complexity	O
of	O
MUC1	O
signaling	O
in	O
breast	O
cancer	O
by	O
contrasting	O
results	O
from	O
two	O
established	O
breast	O
cancer	O
cell	O
lines	O
.	O

To	O
understand	O
MUC1	O
function	O
in	O
cells	O
with	O
high	O
endogenous	O
expression	O
,	O
that	O
is	O
,	O
cells	O
likely	O
to	O
have	O
evolved	O
with	O
active	O
MUC1	O
signaling	O
,	O
we	O
used	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
to	O
knock	O
down	O
MUC1	O
in	O
MDA	O
-	O
MB-468	O
and	O
BT-20	O
cells	O
.	O

We	O
then	O
analyzed	O
transcription	O
of	O
84	O
genes	O
involved	O
in	O
cancer	O
,	O
as	O
well	O
as	O
the	O
effects	O
upon	O
cellular	O
events	O
linked	O
to	O
oncogenesis	O
,	O
such	O
as	O
apoptosis	O
and	O
proliferation	O
.	O

Though	O
the	O
cell	O
lines	O
show	O
some	O
similarity	O
in	O
transcriptional	O
alterations	O
after	O
transfection	O
with	O
MUC1	O
siRNA	O
,	O
their	O
phenotypes	O
are	O
quite	O
dissimilar	O
:	O
MDA	O
-	O
MB-468	O
increases	O
apoptosis	O
and	O
reduces	O
proliferation	O
and	O
invasion	O
,	O
while	O
BT-20	O
proliferates	O
more	O
rapidly	O
after	O
loss	O
of	O
MUC1	O
.	O

This	O
last	O
may	O
reflect	O
the	O
striking	O
amount	O
of	O
active	O
AKT	O
in	O
BT-20	O
;	O
AKT	O
activity	O
is	O
increased	O
in	O
both	O
cell	O
lines	O
after	O
MUC1	O
siRNA	O
,	O
which	O
agrees	O
with	O
a	O
previous	O
study	O
of	O
MUC1	O
siRNA	O
[	O
21	O
]	O
,	O
but	O
disagrees	O
with	O
results	O
from	O
3Y1	O
fibroblasts	O
[	O
18	O
]	O
.	O

Recent	O
studies	O
have	O
emphasized	O
the	O
complex	O
and	O
context	O
-	O
specific	O
regulation	O
of	O
even	O
such	O
classic	O
oncogenes	O
as	O
AKT	O
[	O
28	O
]	O
.	O

The	O
differences	O
between	O
the	O
two	O
breast	O
cancer	O
cell	O
lines	O
in	O
this	O
study	O
suggest	O
that	O
MUC1	O
oncogenic	O
functions	O
are	O
also	O
subject	O
to	O
cell	O
-	O
specific	O
regulation	O
,	O
and	O
stress	O
the	O
need	O
for	O
understanding	O
the	O
cellular	O
signaling	O
context	O
when	O
interpreting	O
results	O
.	O

Materials	O
and	O
methods	O
Cell	O
culture	O
and	O
siRNA	O
transfection	O
MDA	O
-	O
MB-468	O
and	O
BT-20	O
cells	O
(	O
American	O
Type	O
Culture	O
Collection	O
)	O
were	O
cultured	O
in	O
Dulbecco	O
's	O
modified	O
Eagle	O
's	O
medium	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
)	O
plus	O
10	O
%	O
fetal	O
calf	O
serum	O
,	O
1	O
%	O
Glutamax	O
(	O
Invitrogen	O
)	O
and	O
1	O
%	O
penicillin	O
/	O
streptomycin	O
.	O

Stable	O
cell	O
lines	O
(	O
468.Neo	O
and	O
468.MUC1Δ8	O
)	O
were	O
selected	O
with	O
0.5	O
mg	O
/	O
ml	O
G418	O
.	O

For	O
epidermal	O
growth	O
factor	O
(	O
EGF	O
)	O
stimulation	O
,	O
MDA	O
-	O
MB-468	O
cells	O
were	O
serum	O
-	O
starved	O
overnight	O
and	O
treated	O
for	O
10	O
minutes	O
at	O
37	O
°	O
C	O
with	O
100	O
ng	O
/	O
ml	O
EGF	O
.	O

Transient	O
siRNA	O
transfection	O
was	O
performed	O
with	O
Lipofectamine2000	O
(	O
Invitrogen	O
)	O
and	O
100	O
nM	O
siRNA	O
oligonucleotides	O
.	O

The	O
commercially	O
available	O
siRNA	O
constructs	O
(	O
all	O
from	O
Dharmacon	O
,	O
Lafayette	O
,	O
CO	O
,	O
USA	O
)	O
were	O
scrambled	O
(	O
siCONTROL	O
non	O
-	O
targeting	O
siRNA	O
#	O
1	O
)	O
,	O
or	O
directed	O
against	O
firefly	O
luciferase	O
(	O
siCONTROL	O
non	O
-	O
targeting	O
siRNA	O
#	O
2	O
)	O
or	O
MUC1	O
(	O
siGENOME	O
smartpool	O
)	O
.	O

The	O
independent	O
oligonucleotides	O
designed	O
in	O
our	O
laboratory	O
target	O
sequences	O
beginning	O
at	O
MUC1	O
codons	O
882	O
and	O
956	O
,	O
and	O
have	O
been	O
described	O
previously	O
[	O
29	O
]	O
.	O

The	O
scrambled	O
siRNA	O
construct	O
was	O
used	O
only	O
in	O
BT-20	O
cells	O
as	O
it	O
causes	O
a	O
non	O
-	O
specific	O
knockdown	O
of	O
MUC1	O
in	O
the	O
MDA	O
-	O
MB-468	O
line	O
.	O

Cloning	O
of	O
MUC1	O
WT	O
vector	O
and	O
stable	O
transfection	O
Two	O
silent	O
mutations	O
(	O
G891A	O
and	O
T894C	O
)	O
were	O
introduced	O
into	O
the	O
MUC1	O
cDNA	O
(	O
called	O
MUC1Δ8	O
)	O
to	O
make	O
it	O
resistant	O
to	O
the	O
882	O
siRNA	O
that	O
targets	O
that	O
region	O
of	O
the	O
mRNA	O
.	O

The	O
mutant	O
cDNA	O
was	O
cloned	O
into	O
the	O
pLNCX.1	O
vector	O
with	O
neomycin	O
resistance	O
(	O
gift	O
of	O
Joseph	O
Loftus	O
,	O
Mayo	O
Clinic	O
,	O
Arizona	O
,	O
USA	O
)	O
.	O

Stable	O
transfection	O
was	O
performed	O
with	O
Lipofectamine2000	O
;	O
cells	O
were	O
selected	O
beginning	O
24	O
hours	O
post	O
-	O
transfection	O
and	O
maintained	O
as	O
a	O
polyclonal	O
population	O
.	O

Western	O
blots	O
and	O
antibodies	O
Cells	O
were	O
lysed	O
in	O
buffer	O
(	O
20	O
mM	O
HEPES	O
pH	O
8.0	O
,	O
150	O
mM	O
sodium	O
chloride	O
,	O
1	O
%	O
Triton	O
X-100	O
,	O
2	O
mM	O
EDTA	O
)	O
with	O
commercial	O
protease	O
(	O
Complete	O
inhibitor	O
cocktail	O
,	O
Roche	O
,	O
Pleasanton	O
,	O
CA	O
,	O
USA	O
)	O
and	O
phosphatase	O
inhibitors	O
(	O
10	O
mM	O
sodium	O
fluoride	O
,	O
2	O
mM	O
sodium	O
vanadate	O
,	O
50	O
μM	O
ammonium	O
molybdate	O
)	O
.	O

Protein	O
concentration	O
was	O
determined	O
by	O
BCA	O
(	O
Pierce	O
,	O
Rockford	O
,	O
IL	O
,	O
USA	O
)	O
;	O
50	O
μg	O
of	O
lysate	O
were	O
loaded	O
on	O
SDS	O
-	O
PAGE	O
gels	O
for	O
each	O
experiment	O
,	O
except	O
for	O
the	O
pMEK1	O
/	O
2	O
blot	O
in	O
MDA	O
-	O
MB-468	O
,	O
where	O
150	O
μg	O
were	O
used	O
.	O

Non	O
-	O
commercial	O
antibodies	O
used	O
were	O
:	O
BC2	O
,	O
a	O
mouse	B
monoclonal	O
to	O
the	O
MUC1-EX	O
(	O
gift	O
of	O
Dr	O
McGuckin	O
,	O
Queensland	O
University	O
,	O
Queensland	O
,	O
Australia	O
)	O
,	O
and	O
CT2	O
,	O
an	O
Armenian	B
hamster	I
monoclonal	O
to	O
the	O
MUC1-CT	O
developed	O
in	O
our	O
lab	O
[	O
12	O
]	O
.	O

Antibodies	O
to	O
pMEK1	O
/	O
2	O
,	O
MEK1	O
/	O
2	O
,	O
ERK1	O
/	O
2	O
,	O
Myc	O
,	O
pAKT	O
,	O
AKT	O
,	O
β	O
-	O
tubulin	O
(	O
all	O
Cell	O
Signaling	O
,	O
Danvers	O
,	O
MA	O
,	O
USA	O
)	O
,	O
β	O
-	O
actin	O
and	O
dpERK1	O
/	O
2	O
(	O
both	O
Sigma	O
,	O
St.	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
were	O
used	O
according	O
to	O
manufacturers	O
'	O
recommendations	O
.	O

All	O
antibodies	O
except	O
β	O
-	O
actin	O
(	O
1:2,500	O
)	O
and	O
dpERK1	O
/	O
2	O
(	O
1:10,000	O
)	O
were	O
used	O
at	O
1:1,000	O
dilution	O
for	O
western	O
blots	O
.	O

Flow	O
cytometric	O
analysis	O
of	O
MUC1	O
was	O
done	O
with	O
HMPV	O
-	O
FITC	O
,	O
which	O
recognizes	O
the	O
core	O
peptide	O
of	O
the	O
MUC1-EX	O
tandem	O
repeats	O
(	O
Pharmingen	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Bromodeoxyuridine	O
(	O
BrdU	O
)	O
staining	O
was	O
performed	O
with	O
a	O
fluorescently	O
conjugated	O
antibody	O
to	O
BrdU	O
(	O
BrdU	O
-	O
PE	O
,	O
BD	O
Biosciences	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
as	O
described	O
below	O
.	O

Densitometry	O
was	O
performed	O
using	O
the	O
public	O
domain	O
ImageJ	O
program	O
(	O
developed	O
at	O
the	O
NIH	O
and	O
available	O
at	O
[	O
30	O
]	O
.	O

Each	O
band	O
was	O
measured	O
in	O
three	O
places	O
;	O
the	O
results	O
were	O
averaged	O
and	O
normalized	O
to	O
tubulin	O
to	O
control	O
for	O
loading	O
.	O

Transwell	O
invasion	O
assays	O
Cells	O
were	O
serum	O
-	O
starved	O
beginning	O
24	O
hours	O
post	O
-	O
siRNA	O
transfection	O
.	O

Cells	O
were	O
re	O
-	O
plated	O
in	O
serum	O
-	O
free	O
medium	O
48	O
hours	O
post	O
-	O
transfection	O
at	O
50,000	O
cells	O
per	O
insert	O
(	O
sized	O
for	O
24-well	O
plates	O
)	O
,	O
with	O
serum	O
-	O
containing	O
medium	O
in	O
the	O
bottom	O
of	O
the	O
growth	O
well	O
as	O
an	O
attractant	O
.	O

Transwell	O
inserts	O
(	O
BD	O
Biosciences	O
)	O
pre	O
-	O
coated	O
with	O
laminin	O
,	O
fibronectin	O
,	O
collagen	O
IV	O
,	O
or	O
control	O
(	O
no	O
matrix	O
)	O
were	O
used	O
,	O
and	O
cells	O
were	O
permitted	O
to	O
invade	O
for	O
48	O
hours	O
.	O

At	O
this	O
point	O
(	O
96	O
hours	O
post	O
-	O
transfection	O
)	O
,	O
visual	O
inspection	O
of	O
the	O
growth	O
wells	O
confirmed	O
that	O
negligible	O
numbers	O
of	O
cells	O
went	O
through	O
to	O
the	O
bottom	O
of	O
the	O
plate	O
.	O

Non	O
-	O
invaded	O
cells	O
were	O
swabbed	O
from	O
the	O
tops	O
of	O
half	O
of	O
the	O
inserts	O
(	O
'	O
samples	O
'	O
,	O
containing	O
only	O
invaded	O
cells	O
)	O
,	O
and	O
retained	O
in	O
the	O
others	O
(	O
'	O
controls	O
'	O
,	O
all	O
cells	O
)	O
.	O

Inserts	O
were	O
stained	O
for	O
10	O
minutes	O
with	O
crystal	O
violet	O
(	O
0.5	O
%	O
in	O
20	O
%	O
methanol	O
)	O
and	O
washed	O
with	O
water	O
.	O

Membranes	O
were	O
cut	O
out	O
and	O
destained	O
for	O
10	O
minutes	O
in	O
10	O
%	O
acetic	O
acid	O
in	O
a	O
96-well	O
plate	O
;	O
membranes	O
were	O
removed	O
and	O
absorbance	O
was	O
read	O
at	O
570	O
nm	O
.	O

Percent	O
invasion	O
is	O
defined	O
as	O
(	O
absorbance	O
of	O
samples	O
/	O
absorbance	O
of	O
controls	O
)	O
×	O
100	O
.	O

[	O
3H	O
]	O
Thymidine	O
incorporation	O
assays	O
Cells	O
were	O
re	O
-	O
plated	O
in	O
quadruplicate	O
24	O
hours	O
post	O
-	O
siRNA	O
transfection	O
at	O
15,000	O
cells	O
/	O
well	O
(	O
96-well	O
plate	O
)	O
with	O
[	O
3H	O
]	O
thymidine	O
(	O
1	O
μCi	O
/	O
well	O
)	O
,	O
then	O
incubated	O
in	O
normal	O
conditions	O
for	O
24	O
hours	O
.	O

At	O
this	O
time	O
(	O
48	O
hours	O
post	O
-	O
siRNA	O
transfection	O
)	O
excess	O
radioactivity	O
was	O
washed	O
off	O
and	O
the	O
cells	O
were	O
harvested	O
and	O
read	O
on	O
a	O
TopCount	O
plate	O
reader	O
.	O

Statistical	O
analysis	O
was	O
performed	O
using	O
JMP	O
5.1.2	O
software	O
(	O
SAS	O
Institute	O
,	O
Inc.	O
,	O
Cary	O
,	O
NC	O
,	O
USA	O
)	O
;	O
the	O
student	O
's	O
t	O
test	O
was	O
used	O
to	O
determine	O
p	O
values	O
and	O
significance	O
was	O
confirmed	O
with	O
Wilcoxon	O
rank	O
sum	O
and	O
Pearson	O
chi	O
squared	O
analyses	O
.	O

BrdU	O
incorporation	O
BrdU	O
(	O
50	O
μM	O
)	O
was	O
given	O
to	O
cells	O
48	O
hours	O
post	O
-	O
siRNA	O
transfection	O
and	O
permitted	O
to	O
incorporate	O
for	O
1.5	O
hours	O
.	O

Cells	O
were	O
then	O
washed	O
with	O
PBS	O
,	O
trypsinized	O
,	O
and	O
washed	O
again	O
.	O

BrdU	O
staining	O
was	O
performed	O
according	O
to	O
an	O
adaptation	O
of	O
the	O
manufacturer	O
's	O
protocol	O
:	O
cells	O
were	O
re	O
-	O
suspended	O
in	O
PBS	O
,	O
mixed	O
1:1	O
with	O
-20	O
°	O
C	O
neat	O
ethanol	O
,	O
and	O
incubated	O
1	O
hour	O
at	O
-20	O
°	O
C	O
to	O
fix	O
.	O

Fixed	O
cells	O
were	O
then	O
washed	O
gently	O
and	O
denatured	O
in	O
2	O
M	O
HCl	O
for	O
20	O
minutes	O
at	O
room	O
temperature	O
.	O

Following	O
washing	O
and	O
2	O
minute	O
's	O
incubation	O
with	O
0.1	O
M	O
Tris	O
to	O
neutralize	O
the	O
acid	O
,	O
cells	O
were	O
re	O
-	O
suspended	O
in	O
FACS	O
buffer	O
(	O
0.5	O
%	O
fetal	O
calf	O
serum	O
in	O
PBS	O
)	O
and	O
stained	O
with	O
Phycoerythrin	O
(	O
PE	O
)	O
-conjugated	O
anti	O
-	O
BrdU	O
according	O
to	O
the	O
manufacturer	O
's	O
protocol	O
for	O
flow	O
cytometry	O
analysis	O
on	O
a	O
FACScan	O
instrument	O
.	O

Apoptosis	O
and	O
trypan	O
blue	O
staining	O
Apoptosis	O
was	O
measured	O
using	O
a	O
kit	O
(	O
BD	O
Biosciences	O
)	O
containing	O
propidium	O
iodide	O
(	O
PI	O
)	O
and	O
FITC	O
-	O
conjugated	O
annexin	O
V.	O
Cells	O
were	O
stained	O
according	O
to	O
the	O
manufacturer	O
's	O
protocol	O
and	O
the	O
level	O
of	O
apoptosis	O
determined	O
by	O
flow	O
cytometry	O
.	O

Quadrants	O
are	O
:	O
early	O
apoptosis	O
(	O
annexin	O
V+	O
/	O
PI-	O
,	O
lower	O
right	O
)	O
late	O
apoptosis	O
(	O
annexin	O
V+	O
/	O
PI+	O
,	O
upper	O
right	O
)	O
and	O
non	O
-	O
apoptotic	O
cell	O
death	O
(	O
annexin	O
V-	O
/	O
PI+	O
,	O
upper	O
left	O
)	O
.	O

Treatments	O
for	O
the	O
stress	O
panel	O
were	O
:	O
no	O
treatment	O
(	O
control	O
)	O
;	O
DMSO	O
as	O
a	O
control	O
for	O
celecoxib	O
;	O
20	O
mM	O
celecoxib	O
,	O
brand	O
name	O
Celebrex	O
™	O
(	O
dissolved	O
in	O
DMSO	O
)	O
[	O
31	O
]	O
;	O
0.2	O
mM	O
H2O2	O
[	O
32	O
]	O
;	O
or	O
1	O
mg	O
/	O
mL	O
G418	O
(	O
Pfizer	O
,	O
New	O
York	O
,	O
NY	O
,	O
USA	O
)	O
.	O

Real	O
-	O
time	O
PCR	O
arrays	O
Transcriptional	O
analysis	O
using	O
Cancer	O
PathwayFinder	O
RT2	O
profiler	O
arrays	O
(	O
SuperArray	O
,	O
Frederick	O
,	O
MD	O
,	O
USA	O
)	O
was	O
performed	O
according	O
to	O
the	O
manufacturer	O
's	O
protocol	O
.	O

Briefly	O
,	O
total	O
RNA	O
was	O
isolated	O
using	O
an	O
RNeasy	O
extraction	O
kit	O
(	O
Qiagen	O
,	O
Valencia	O
,	O
CA	O
,	O
USA	O
)	O
;	O
1	O
μg	O
of	O
RNA	O
was	O
reverse	O
transcribed	O
with	O
the	O
cDNA	O
synthesis	O
kit	O
(	O
SuperArray	O
)	O
and	O
cDNA	O
was	O
subjected	O
to	O
real	O
-	O
time	O
PCR	O
using	O
SYBR	O
green	O
to	O
detect	O
product	O
.	O

Arrays	O
were	O
performed	O
independently	O
at	O
least	O
twice	O
for	O
each	O
cell	O
line	O
;	O
all	O
PCR	O
products	O
were	O
checked	O
on	O
agarose	O
gels	O
.	O

Values	O
were	O
obtained	O
for	O
the	O
threshold	O
cycle	O
(	O
Ct	O
)	O
for	O
each	O
gene	O
and	O
normalized	O
using	O
the	O
average	O
of	O
four	O
housekeeping	O
genes	O
on	O
the	O
same	O
array	O
(	O
HPRT1	O
,	O
RPL13A	O
,	O
GAPD	O
,	O
ACTB	O
)	O
.	O

Ct	O
values	O
for	O
housekeeping	O
genes	O
and	O
a	O
dilution	O
series	O
of	O
ACTB	O
were	O
monitored	O
for	O
consistency	O
between	O
arrays	O
.	O

Change	O
(	O
ΔCt	O
)	O
between	O
MUC1	O
siRNA	O
and	O
control	O
siRNA	O
was	O
found	O
by	O
:	O
ΔCt	O
=	O
Ct	O
(	O
MUC1	O
siRNA	O
)	O
-	O
Ct	O
(	O
control	O
siRNA	O
)	O
and	O
fold	O
change	O
by	O
:	O
Fold	O
change	O
=	O
2	O
(	O
-ΔCt	O
)	O
Values	O
are	O
given	O
as	O
fold	O
change	O
;	O
only	O
genes	O
showing	O
two	O
-	O
fold	O
or	O
greater	O
change	O
were	O
considered	O
.	O

Both	O
luciferase	O
and	O
scrambled	O
siRNA	O
controls	O
were	O
used	O
in	O
BT-20	O
;	O
only	O
genes	O
showing	O
consistent	O
alteration	O
with	O
both	O
controls	O
were	O
included	O
in	O
the	O
results	O
reported	O
here	O
.	O

The	O
scrambled	O
siRNA	O
could	O
be	O
not	O
used	O
in	O
MDA	O
-	O
MB-468	O
as	O
these	O
cells	O
decrease	O
MUC1	O
expression	O
in	O
response	O
to	O
this	O
construct	O
.	O

Results	O
siRNA	O
transfection	O
decreases	O
MUC1	O
expression	O
in	O
breast	O
cancer	O
cell	O
lines	O
Two	O
human	B
breast	O
cancer	O
cell	O
lines	O
,	O
MDA	O
-	O
MB-468	O
and	O
BT-20	O
,	O
were	O
transiently	O
transfected	O
with	O
a	O
pool	O
of	O
four	O
siRNA	O
oligonucleotides	O
directed	O
against	O
the	O
MUC1	O
mRNA	O
(	O
468.siMUC1	O
and	O
BT.siMUC1	O
)	O
,	O
or	O
a	O
control	O
oligonucleotide	O
directed	O
against	O
luciferase	O
(	O
468.siLuc	O
and	O
BT.siLuc	O
)	O
.	O

Both	O
cell	O
lines	O
express	O
high	O
levels	O
of	O
MUC1	O
,	O
making	O
them	O
promising	O
targets	O
for	O
this	O
analysis	O
.	O

Western	O
blots	O
(	O
Figure	O
1a	O
)	O
show	O
successful	O
knockdown	O
of	O
both	O
the	O
extracellular	O
domain	O
and	O
cytoplasmic	O
tail	O
fragments	O
of	O
MUC1	O
;	O
luciferase	O
siRNA	O
does	O
not	O
substantially	O
change	O
the	O
level	O
of	O
MUC1	O
compared	O
to	O
parental	O
cells	O
.	O

468.siMUC1	O
show	O
a	O
substantial	O
decrease	O
in	O
the	O
amount	O
of	O
MUC1-CT	O
,	O
while	O
BT.siMUC1	O
show	O
slightly	O
less	O
knockdown	O
of	O
MUC1-CT	O
.	O

Both	O
MDA	O
-	O
MB-468	O
and	O
BT-20	O
display	O
a	O
less	O
dramatic	O
decrease	O
of	O
MUC1	O
extracellular	O
domain	O
compared	O
to	O
MUC1-CT	O
(	O
Figure	O
1a	O
)	O
;	O
this	O
likely	O
represents	O
protein	O
synthesized	O
prior	O
to	O
transfection	O
,	O
and	O
may	O
reflect	O
differences	O
in	O
the	O
turnover	O
rates	O
of	O
the	O
two	O
subunits	O
.	O

Analysis	O
of	O
the	O
MUC1	O
extracellular	O
domain	O
by	O
flow	O
cytometry	O
confirms	O
that	O
both	O
cell	O
lines	O
substantially	O
decrease	O
MUC1	O
expression	O
after	O
siRNA	O
(	O
Figure	O
1b	O
)	O
.	O

By	O
flow	O
cytometry	O
,	O
468.siMUC1	O
averaged	O
75	O
%	O
knockdown	O
of	O
MUC1	O
compared	O
to	O
468.siLuc	O
;	O
and	O
BT.siMUC1	O
averaged	O
50	O
%	O
knockdown	O
relative	O
to	O
BT.siLuc	O
.	O

These	O
effects	O
could	O
be	O
titrated	O
with	O
the	O
concentration	O
of	O
siRNA	O
,	O
were	O
seen	O
as	O
early	O
as	O
24	O
hours	O
post	O
-	O
transfection	O
(	O
data	O
not	O
shown	O
)	O
and	O
lasted	O
to	O
at	O
least	O
96	O
h	O
post	O
-	O
transfection	O
(	O
Figure	O
1b	O
)	O
.	O

All	O
experiments	O
were	O
conducted	O
within	O
48	O
to	O
96	O
hours	O
after	O
siRNA	O
transfection	O
.	O

Similar	O
results	O
were	O
obtained	O
using	O
two	O
independent	O
oligonucleotides	O
designed	O
in	O
our	O
lab	O
(	O
data	O
not	O
shown	O
)	O
,	O
designated	O
'	O
882	O
'	O
and	O
'	O
956	O
'	O
for	O
the	O
initial	O
codon	O
recognized	O
by	O
each	O
.	O

Transcriptional	O
changes	O
are	O
seen	O
after	O
MUC1	O
siRNA	O
Recent	O
work	O
indicates	O
that	O
MUC1	O
may	O
affect	O
transcription	O
both	O
directly	O
via	O
interaction	O
with	O
transcription	O
factors	O
and	O
indirectly	O
(	O
for	O
example	O
,	O
through	O
modulating	O
signaling	O
)	O
.	O

To	O
study	O
the	O
effects	O
of	O
MUC1	O
knockdown	O
in	O
breast	O
cancer	O
cell	O
lines	O
,	O
real	O
-	O
time	O
PCR	O
arrays	O
were	O
used	O
to	O
analyze	O
transcription	O
of	O
84	O
genes	O
implicated	O
in	O
cancer	O
.	O

Only	O
genes	O
with	O
greater	O
than	O
two	O
-	O
fold	O
change	O
were	O
considered	O
.	O

Three	O
genes	O
(	O
MAP2K1	O
,	O
VEGF	O
,	O
PDGFA	O
)	O
were	O
altered	O
two	O
-	O
fold	O
or	O
more	O
after	O
MUC1	O
siRNA	O
in	O
both	O
MDA	O
-	O
MB-468	O
and	O
BT-20	O
cells	O
(	O
Figure	O
2	O
)	O
;	O
two	O
genes	O
(	O
ITGAV	O
,	O
MMP2	O
)	O
changed	O
only	O
in	O
468.siMUC1	O
;	O
and	O
five	O
genes	O
(	O
TIMP3	O
,	O
RAF1	O
,	O
JUN	O
,	O
TNF	O
,	O
CDC25A	O
)	O
only	O
in	O
BT.siMUC1	O
.	O

This	O
list	O
represents	O
all	O
genes	O
affected	O
greater	O
than	O
two	O
-	O
fold	O
after	O
MUC1	O
siRNA	O
,	O
rather	O
than	O
a	O
select	O
group	O
.	O

Three	O
genes	O
whose	O
transcription	O
was	O
changed	O
by	O
less	O
than	O
two	O
-	O
fold	O
are	O
shown	O
,	O
two	O
of	O
which	O
(	O
PDGFB	O
and	O
ITGB1	O
)	O
are	O
listed	O
because	O
they	O
relate	O
closely	O
to	O
genes	O
altered	O
by	O
two	O
-	O
fold	O
(	O
PDGFA	O
and	O
ITGAV	O
)	O
.	O

The	O
third	O
,	O
MYC	O
,	O
is	O
included	O
because	O
western	O
blots	O
confirmed	O
a	O
substantial	O
change	O
at	O
the	O
protein	O
level	O
(	O
Figure	O
3a	O
)	O
that	O
may	O
reflect	O
both	O
transcriptional	O
and	O
post	O
-	O
transcriptional	O
regulation	O
.	O

Interestingly	O
,	O
transcription	O
of	O
MAP2K1	O
was	O
decreased	O
in	O
both	O
cell	O
lines	O
after	O
MUC1	O
siRNA	O
.	O

This	O
gene	O
encodes	O
MEK1	O
,	O
one	O
of	O
the	O
primary	O
regulators	O
of	O
the	O
ERK1	O
/	O
2	O
MAPK	O
pathway	O
[	O
33	O
]	O
,	O
a	O
network	O
that	O
has	O
been	O
linked	O
several	O
times	O
to	O
MUC1	O
[	O
12,34	O
-	O
36	O
]	O
.	O

We	O
examined	O
MEK1	O
and	O
MEK2	O
levels	O
by	O
western	O
blot	O
to	O
confirm	O
decreased	O
protein	O
in	O
MUC1	O
siRNA	O
-	O
treated	O
cells	O
(	O
Figure	O
3a	O
)	O
,	O
and	O
found	O
that	O
not	O
only	O
were	O
total	O
MEK1	O
/	O
2	O
levels	O
lower	O
in	O
468.siMUC1	O
and	O
BT.siMUC1	O
compared	O
to	O
controls	O
(	O
0.48	O
and	O
0.68	O
relative	O
to	O
siLuc	O
,	O
respectively	O
)	O
,	O
but	O
so	O
were	O
the	O
basal	O
amounts	O
of	O
active	O
(	O
phosphorylated	O
)	O
MEK1	O
/	O
2	O
(	O
pMEK1	O
/	O
2	O
;	O
0.12	O
and	O
0.42	O
relative	O
to	O
siLuc	O
,	O
respectively	O
)	O
.	O

Both	O
468.siMUC1	O
and	O
BT.siMUC1	O
also	O
showed	O
reduced	O
activation	O
of	O
ERK1	O
/	O
2	O
(	O
dpERK1	O
/	O
2	O
;	O
0.21	O
and	O
0.27	O
relative	O
to	O
siLuc	O
,	O
respectively	O
)	O
,	O
as	O
would	O
be	O
expected	O
with	O
diminished	O
signaling	O
through	O
MEK1	O
/	O
2	O
;	O
total	O
ERK1	O
/	O
2	O
levels	O
remain	O
unchanged	O
.	O

As	O
both	O
lines	O
have	O
high	O
levels	O
of	O
EGFR	O
and	O
thus	O
activate	O
the	O
MEK	O
-	O
ERK	O
cascade	O
intensely	O
when	O
stimulated	O
with	O
EGF	O
[	O
37	O
]	O
,	O
siRNA	O
-	O
transfected	O
cells	O
were	O
treated	O
with	O
EGF	O
.	O

Notably	O
,	O
MUC1	O
siRNA	O
impairs	O
this	O
important	O
oncogenic	O
pathway	O
in	O
MDA	O
-	O
MB-468	O
cells	O
,	O
as	O
468.siMUC1	O
display	O
less	O
pMEK1	O
/	O
2	O
in	O
response	O
to	O
EGF	O
than	O
do	O
468.siLuc	O
(	O
Figure	O
3b	O
)	O
.	O

Interestingly	O
,	O
EGF	O
treatment	O
of	O
BT-20	O
cells	O
results	O
in	O
slightly	O
higher	O
pMEK1	O
/	O
2	O
levels	O
in	O
BT.siMUC1	O
compared	O
to	O
BT.siLuc	O
.	O

Though	O
this	O
result	O
seems	O
paradoxical	O
in	O
light	O
of	O
decreased	O
MAP2K1	O
transcription	O
in	O
BT.siMUC1	O
,	O
it	O
likely	O
results	O
from	O
differential	O
functions	O
of	O
Raf	O
isoforms	O
in	O
combination	O
with	O
the	O
increased	O
RAF1	O
transcription	O
(	O
Figure	O
2	O
)	O
and	O
protein	O
level	O
(	O
Figure	O
3a	O
)	O
in	O
these	O
cells	O
.	O

Specifically	O
,	O
B	O
-	O
Raf	O
is	O
thought	O
to	O
be	O
the	O
main	O
activator	O
of	O
MEK	O
under	O
normal	O
conditions	O
;	O
Raf-1	O
activates	O
MEK	O
in	O
response	O
to	O
stimulus	O
[	O
38	O
]	O
.	O

Thus	O
,	O
it	O
appears	O
that	O
basal	O
pMEK1	O
/	O
2	O
levels	O
are	O
not	O
greatly	O
affected	O
by	O
Raf-1	O
overexpression	O
in	O
BT.siMUC1	O
cells	O
,	O
likely	O
because	O
MEK	O
is	O
regulated	O
primarily	O
by	O
B	O
-	O
Raf	O
under	O
normal	O
growth	O
conditions	O
.	O

In	O
contrast	O
,	O
when	O
the	O
cells	O
are	O
stimulated	O
(	O
EGF	O
)	O
,	O
increased	O
Raf-1	O
levels	O
in	O
BT.siMUC1	O
leads	O
to	O
heightened	O
pMEK1	O
/	O
2	O
(	O
Figure	O
3b	O
)	O
.	O

MUC1	O
siRNA	O
increases	O
apoptosis	O
in	O
MDA	O
-	O
MB-468	O
but	O
not	O
BT-20	O
We	O
next	O
examined	O
whether	O
MUC1	O
knockdown	O
and	O
its	O
associated	O
transcriptional	O
alterations	O
would	O
affect	O
overall	O
cellular	O
events	O
.	O

As	O
several	O
of	O
the	O
genes	O
shown	O
in	O
Figure	O
2	O
are	O
important	O
in	O
regulating	O
proliferation	O
and	O
survival	O
,	O
and	O
because	O
of	O
the	O
recently	O
described	O
role	O
of	O
MUC1	O
in	O
modulating	O
apoptosis	O
in	O
response	O
to	O
cellular	O
stresses	O
[	O
20,21,24	O
]	O
,	O
we	O
first	O
analyzed	O
whether	O
MUC1	O
siRNA	O
would	O
alter	O
apoptosis	O
in	O
these	O
lines	O
.	O

Although	O
there	O
was	O
no	O
change	O
in	O
basal	O
apoptosis	O
in	O
either	O
line	O
(	O
Figure	O
4a	O
)	O
,	O
we	O
observed	O
that	O
the	O
cell	O
lines	O
responded	O
differently	O
when	O
trypsinized	O
for	O
re	O
-	O
plating	O
24	O
hours	O
after	O
transfection	O
(	O
Figure	O
4b	O
)	O
.	O

Interestingly	O
,	O
468.siMUC1	O
cells	O
show	O
greater	O
apoptosis	O
after	O
trypsinization	O
than	O
do	O
468.siLuc	O
(	O
49.8	O
%	O
versus	O
34.0	O
%	O
,	O
respectively	O
)	O
,	O
while	O
BT-20	O
cells	O
from	O
both	O
siRNA	O
treatments	O
display	O
similar	O
levels	O
of	O
apoptosis	O
(	O
around	O
22	O
%	O
)	O
.	O

To	O
examine	O
whether	O
this	O
phenomenon	O
is	O
specific	O
to	O
trypsin	O
treatment	O
or	O
part	O
of	O
a	O
general	O
stress	O
response	O
involving	O
MUC1	O
,	O
we	O
subjected	O
cells	O
to	O
a	O
panel	O
of	O
stresses	O
and	O
measured	O
cell	O
death	O
.	O

In	O
agreement	O
with	O
the	O
patterns	O
seen	O
with	O
trypsinization	O
,	O
BT.siLuc	O
and	O
BT.siMUC1	O
respond	O
similarly	O
to	O
all	O
treatments	O
(	O
data	O
not	O
shown	O
)	O
,	O
while	O
468.siMUC1	O
die	O
more	O
readily	O
than	O
468.siLuc	O
in	O
response	O
to	O
trypsin	O
,	O
G418	O
,	O
hydrogen	O
peroxide	O
,	O
or	O
celecoxib	O
,	O
a	O
chemotherapeutic	O
that	O
targets	O
the	O
cyclooxygenase-2	O
(	O
COX-2	O
)	O
pathway	O
(	O
Figure	O
4c	O
)	O
;	O
these	O
data	O
were	O
confirmed	O
with	O
two	O
independent	O
siRNA	O
constructs	O
(	O
data	O
not	O
shown	O
)	O
.	O

Like	O
the	O
MAPK	O
pathway	O
,	O
AKT	O
signaling	O
has	O
been	O
linked	O
to	O
MUC1	O
in	O
cancer	O
.	O

Although	O
transcription	O
of	O
AKT	O
was	O
not	O
altered	O
in	O
MUC1	O
siRNA	O
-	O
treated	O
cells	O
,	O
the	O
results	O
of	O
our	O
apoptosis	O
studies	O
prompted	O
us	O
to	O
investigate	O
levels	O
of	O
AKT	O
further	O
.	O

As	O
expected	O
,	O
the	O
total	O
AKT	O
protein	O
level	O
is	O
not	O
greatly	O
changed	O
after	O
MUC1	O
siRNA	O
in	O
either	O
cell	O
line	O
,	O
though	O
the	O
active	O
form	O
(	O
pAKT	O
)	O
is	O
increased	O
in	O
both	O
468.siMUC1	O
and	O
BT.siMUC1	O
compared	O
to	O
controls	O
(	O
Figure	O
3a	O
)	O
.	O

This	O
result	O
disagrees	O
with	O
MUC1	O
activation	O
of	O
the	O
AKT	O
pathway	O
in	O
rat	B
3Y1	O
cells	O
[	O
18	O
]	O
,	O
and	O
may	O
reflect	O
regulation	O
more	O
appropriate	O
to	O
breast	O
cancer	O
cells	O
;	O
this	O
is	O
supported	O
by	O
activation	O
of	O
AKT	O
in	O
response	O
to	O
MUC1	O
siRNA	O
in	O
other	O
lines	O
[	O
21	O
]	O
.	O

In	O
addition	O
,	O
there	O
is	O
a	O
striking	O
difference	O
in	O
the	O
relative	O
amounts	O
of	O
AKT	O
and	O
pAKT	O
in	O
the	O
two	O
cell	O
lines	O
(	O
Figure	O
4d	O
)	O
.	O

When	O
lysates	O
from	O
both	O
lines	O
are	O
exposed	O
to	O
film	O
for	O
the	O
same	O
length	O
of	O
time	O
(	O
overexposure	O
masks	O
the	O
differences	O
between	O
BT.siLuc	O
and	O
BT.siMUC1	O
that	O
are	O
apparent	O
in	O
Figure	O
3a	O
)	O
,	O
it	O
is	O
clear	O
that	O
pAKT	O
levels	O
are	O
much	O
higher	O
in	O
BT-20	O
than	O
in	O
MDA	O
-	O
MB-468	O
,	O
despite	O
lower	O
total	O
AKT	O
expression	O
.	O

This	O
difference	O
in	O
AKT	O
activation	O
between	O
MDA	O
-	O
MB-468	O
and	O
BT-20	O
likely	O
contributes	O
to	O
the	O
disparity	O
in	O
their	O
sensitivity	O
to	O
the	O
increased	O
apoptosis	O
expected	O
with	O
loss	O
of	O
MUC1	O
.	O

MUC1	O
siRNA	O
alters	O
proliferation	O
and	O
invasion	O
As	O
MUC1	O
is	O
involved	O
in	O
apoptosis	O
,	O
we	O
next	O
analyzed	O
its	O
effects	O
on	O
proliferation	O
.	O

BrdU	O
and	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
were	O
used	O
to	O
analyze	O
proliferation	O
after	O
MUC1	O
siRNA	O
.	O

468.siMUC1	O
cells	O
show	O
a	O
significant	O
decrease	O
in	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
compared	O
to	O
468.siLuc	O
,	O
while	O
intriguingly	O
,	O
BT.siMUC1	O
cells	O
show	O
a	O
significant	O
increase	O
in	O
proliferation	O
(	O
Figure	O
5a	O
)	O
.	O

Growth	O
curves	O
mirror	O
these	O
results	O
,	O
as	O
do	O
experiments	O
with	O
the	O
two	O
independent	O
MUC1	O
siRNA	O
oligonucleotides	O
(	O
data	O
not	O
shown	O
)	O
.	O

Note	O
that	O
these	O
assays	O
require	O
trypsinizing	O
cells	O
24	O
hours	O
post	O
-	O
transfection	O
;	O
therefore	O
,	O
the	O
results	O
in	O
the	O
MDA	O
-	O
MB-468	O
line	O
could	O
stem	O
from	O
the	O
changes	O
in	O
apoptosis	O
described	O
in	O
the	O
previous	O
section	O
,	O
rather	O
than	O
a	O
true	O
effect	O
on	O
proliferation	O
.	O

To	O
control	O
for	O
this	O
,	O
we	O
incubated	O
non	O
-	O
trypsinized	O
,	O
siRNA	O
-	O
transfected	O
cells	O
at	O
similar	O
confluence	O
with	O
BrdU	O
to	O
measure	O
incorporation	O
.	O

The	O
'	O
clumped	O
'	O
profile	O
of	O
cells	O
(	O
contrast	O
to	O
Figure	O
4b	O
)	O
is	O
likely	O
a	O
result	O
of	O
the	O
acid	O
denaturation	O
(	O
recommended	O
by	O
the	O
antibody	O
manufacturer	O
)	O
,	O
as	O
it	O
occurs	O
uniformly	O
in	O
these	O
experiments	O
.	O

BrdU	O
incorporation	O
(	O
Figure	O
5b	O
)	O
confirms	O
that	O
the	O
[	O
3H	O
]	O
thymidine	O
results	O
are	O
not	O
solely	O
due	O
to	O
alterations	O
in	O
apoptosis	O
,	O
as	O
468.siMUC1	O
cells	O
incorporate	O
less	O
BrdU	O
than	O
468.siLuc	O
;	O
once	O
again	O
,	O
BT.siMUC1	O
cells	O
show	O
increased	O
proliferation	O
over	O
BT.siLuc	O
.	O

Given	O
the	O
role	O
of	O
MUC1	O
in	O
adhesion	O
,	O
we	O
examined	O
whether	O
MUC1	O
siRNA	O
affects	O
cellular	O
invasion	O
.	O

In	O
transwell	O
assays	O
,	O
BT-20	O
cells	O
invaded	O
poorly	O
,	O
regardless	O
of	O
the	O
siRNA	O
used	O
(	O
data	O
not	O
shown	O
)	O
.	O

However	O
,	O
MDA	O
-	O
MB-468	O
cells	O
invade	O
more	O
readily	O
,	O
and	O
were	O
analyzed	O
on	O
a	O
panel	O
of	O
three	O
different	O
extracellular	O
matrix	O
proteins	O
.	O

Interestingly	O
,	O
468.siMUC1	O
cells	O
display	O
somewhat	O
decreased	O
invasion	O
on	O
collagen	O
IV	O
,	O
laminin	O
,	O
and	O
fibronectin	O
matrices	O
,	O
and	O
on	O
a	O
no	O
-	O
matrix	O
control	O
(	O
Figure	O
5c	O
)	O
,	O
which	O
is	O
in	O
agreement	O
with	O
the	O
trend	O
towards	O
decreased	O
metastasis	O
observed	O
in	O
Muc1-	O
/	O
-	O
×	O
MMTV	B
-	O
PyV	O
MT	O
mice	B
[	O
8	O
]	O
.	O

Transfection	O
of	O
MUC1	O
rescues	O
the	O
468.siMUC1	O
phenotype	O
To	O
determine	O
if	O
the	O
above	O
effects	O
are	O
specific	O
to	O
MUC1	O
,	O
we	O
created	O
stable	O
transfectants	O
of	O
the	O
MDA	O
-	O
MB-468	O
line	O
using	O
empty	O
vector	O
(	O
468.Neo	O
)	O
or	O
a	O
full	O
-	O
length	O
MUC1	O
construct	O
(	O
468.MUC1Δ8	O
)	O
that	O
is	O
resistant	O
to	O
one	O
of	O
the	O
independent	O
MUC1-directed	O
oligonucleotides	O
(	O
'	O
882	O
'	O
)	O
.	O

These	O
cells	O
were	O
maintained	O
in	O
G418-containing	O
medium	O
to	O
retain	O
transgene	O
selection	O
.	O

As	O
expected	O
,	O
468.MUC1Δ8	O
cells	O
show	O
higher	O
levels	O
of	O
both	O
the	O
MUC1	O
extracellular	O
domain	O
and	O
the	O
MUC1-CT	O
than	O
do	O
468.Neo	O
(	O
Figure	O
6a	O
)	O
.	O

Note	O
that	O
468.Neo	O
have	O
MUC1	O
expression	O
comparable	O
to	O
parental	O
MDA	O
-	O
MB-468	O
;	O
the	O
exposures	O
in	O
Figure	O
6a	O
are	O
lighter	O
than	O
those	O
in	O
Figure	O
1a	O
,	O
in	O
order	O
to	O
clearly	O
show	O
the	O
relative	O
levels	O
of	O
MUC1	O
in	O
the	O
stable	O
transfectants	O
.	O

After	O
MUC1	O
siRNA	O
,	O
468.MUC1Δ8	O
lose	O
some	O
MUC1	O
(	O
likely	O
endogenous	O
protein	O
,	O
which	O
is	O
not	O
siRNA	O
-	O
resistant	O
)	O
but	O
retain	O
high	O
-	O
level	O
expression	O
,	O
while	O
468.Neo	O
show	O
a	O
decrease	O
in	O
MUC1	O
levels	O
similar	O
to	O
parental	O
468.siMUC1	O
cells	O
(	O
Figures	O
6a	O
,	O
b	O
)	O
.	O

The	O
difference	O
in	O
the	O
amount	O
of	O
MUC1	O
knockdown	O
between	O
468.Neo	O
and	O
468.MUC1Δ8	O
is	O
highlighted	O
by	O
the	O
purple	O
shading	O
in	O
Figure	O
6b	O
.	O

BrdU	O
incorporation	O
(	O
Figure	O
6c	O
)	O
indicates	O
that	O
468.Neo	O
show	O
decreased	O
nucleotide	O
incorporation	O
after	O
MUC1	O
siRNA	O
compared	O
to	O
control	O
(	O
3.3	O
%	O
versus	O
25.0	O
%	O
,	O
respectively	O
)	O
;	O
this	O
is	O
not	O
seen	O
in	O
468.MUC1Δ8	O
cells	O
,	O
which	O
show	O
similar	O
levels	O
of	O
BrdU	O
incorporation	O
regardless	O
of	O
the	O
siRNA	O
used	O
(	O
21.5	O
%	O
for	O
luciferase	O
,	O
23.9	O
%	O
for	O
MUC1	O
)	O
.	O

468.Neo	O
cells	O
display	O
a	O
more	O
dramatic	O
decrease	O
in	O
BrdU	O
incorporation	O
after	O
MUC1	O
siRNA	O
than	O
what	O
is	O
seen	O
in	O
parental	O
468.siMUC1	O
cells	O
,	O
which	O
may	O
reflect	O
the	O
additional	O
stress	O
of	O
being	O
maintained	O
in	O
G418-containing	O
medium	O
.	O

Similarly	O
,	O
analysis	O
of	O
apoptosis	O
in	O
trypsinized	O
cells	O
indicates	O
that	O
the	O
increased	O
apoptosis	O
seen	O
in	O
parental	O
468.siMUC1	O
cells	O
is	O
also	O
present	O
in	O
the	O
468.Neo	O
line	O
after	O
MUC1	O
siRNA	O
(	O
Figure	O
6d	O
;	O
43.6	O
%	O
in	O
control	O
versus	O
59.6	O
%	O
in	O
MUC1	O
siRNA	O
)	O
.	O

However	O
,	O
in	O
468.MUC1Δ8	O
cells	O
,	O
the	O
level	O
of	O
apoptosis	O
after	O
luciferase	O
siRNA	O
(	O
34.1	O
%	O
)	O
is	O
lower	O
than	O
that	O
in	O
468.Neo	O
cells	O
;	O
MUC1	O
siRNA	O
increases	O
the	O
amount	O
of	O
apoptosis	O
slightly	O
(	O
42.8	O
%	O
)	O
,	O
restoring	O
it	O
to	O
a	O
level	O
similar	O
to	O
that	O
seen	O
in	O
luciferase	O
siRNA	O
-	O
treated	O
468.Neo	O
cells	O
.	O

Together	O
,	O
these	O
studies	O
suggest	O
that	O
the	O
above	O
-	O
described	O
results	O
are	O
specific	O
to	O
MUC1	O
,	O
as	O
stable	O
transfection	O
of	O
an	O
siRNA	O
-	O
resistant	O
MUC1	O
rescues	O
the	O
phenotype	O
seen	O
in	O
468.siMUC1	O
cells	O
.	O

Discussion	O
This	O
report	O
describes	O
both	O
the	O
transcriptional	O
alterations	O
seen	O
after	O
transfection	O
with	O
MUC1	O
siRNA	O
in	O
human	B
breast	O
cancer	O
cells	O
and	O
the	O
effects	O
on	O
events	O
such	O
as	O
apoptosis	O
and	O
proliferation	O
.	O

The	O
two	O
cell	O
lines	O
used	O
(	O
MDA	O
-	O
MB-468	O
and	O
BT-20	O
)	O
were	O
chosen	O
for	O
high	O
expression	O
of	O
MUC1	O
and	O
a	O
substantial	O
(	O
50	O
%	O
to	O
75	O
%	O
)	O
,	O
consistent	O
decrease	O
in	O
MUC1	O
expression	O
after	O
siRNA	O
.	O

Both	O
lines	O
have	O
epithelial	O
morphology	O
,	O
form	O
tumors	O
slowly	O
in	O
nude	B
mice	I
[	O
37	O
]	O
,	O
have	O
mutant	O
p53	O
[	O
39,40	O
]	O
,	O
express	O
EGFR	O
[	O
37	O
]	O
,	O
and	O
lack	O
estrogen	O
receptor	O
α	O
[	O
41	O
]	O
.	O

One	O
striking	O
difference	O
between	O
these	O
lines	O
,	O
however	O
,	O
is	O
their	O
response	O
to	O
MUC1	O
siRNA	O
.	O

MDA	O
-	O
MB-468	O
cells	O
behave	O
as	O
expected	O
for	O
loss	O
of	O
an	O
oncogene	O
:	O
MUC1	O
siRNA	O
correlates	O
with	O
increased	O
apoptosis	O
in	O
response	O
to	O
stress	O
,	O
decreased	O
proliferation	O
,	O
and	O
reduced	O
invasion	O
.	O

In	O
contrast	O
,	O
BT.siMUC1	O
cells	O
proliferate	O
more	O
rapidly	O
than	O
BT.siLuc	O
cells	O
with	O
little	O
effect	O
on	O
apoptosis	O
.	O

Much	O
of	O
the	O
phenotype	O
of	O
these	O
cells	O
can	O
be	O
understood	O
in	O
light	O
of	O
protein	O
levels	O
and	O
transcriptional	O
activity	O
after	O
MUC1	O
siRNA	O
.	O

As	O
mentioned	O
,	O
both	O
MDA	O
-	O
MB-468	O
and	O
BT-20	O
display	O
increased	O
pAKT	O
after	O
MUC1	O
siRNA	O
,	O
but	O
the	O
ratio	O
of	O
active	O
to	O
total	O
AKT	O
is	O
considerably	O
higher	O
in	O
the	O
BT-20	O
line	O
,	O
which	O
may	O
help	O
these	O
cells	O
resist	O
the	O
increased	O
apoptosis	O
expected	O
with	O
loss	O
of	O
MUC1	O
.	O

Myc	O
levels	O
are	O
also	O
higher	O
in	O
both	O
cell	O
lines	O
after	O
MUC1	O
siRNA	O
,	O
although	O
the	O
ability	O
of	O
Myc	O
to	O
promote	O
proliferation	O
and	O
apoptosis	O
in	O
different	O
cellular	O
contexts	O
[	O
42	O
]	O
complicates	O
the	O
interpretation	O
of	O
this	O
finding	O
.	O

Both	O
cell	O
lines	O
show	O
reduced	O
transcription	O
of	O
VEGF	O
,	O
PDGFA	O
,	O
PDGFB	O
,	O
and	O
MAP2K1	O
(	O
MEK1	O
)	O
after	O
MUC1	O
siRNA	O
.	O

The	O
genes	O
encoding	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
and	O
the	O
A	O
and	O
B	O
chains	O
of	O
platelet	O
-	O
derived	O
growth	O
factor	O
(	O
PDGF	O
-	O
A	O
and	O
PDGF	O
-	O
B	O
)	O
are	O
interesting	O
as	O
these	O
proteins	O
have	O
been	O
heavily	O
implicated	O
in	O
angiogenesis	O
,	O
suggesting	O
a	O
novel	O
function	O
for	O
MUC1	O
in	O
regulating	O
this	O
process	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
expression	O
in	O
cancer	O
is	O
linked	O
to	O
tumor	O
growth	O
and	O
metastasis	O
[	O
43,44	O
]	O
;	O
platelet	O
-	O
derived	O
growth	O
factor	O
is	O
also	O
angiogenic	O
,	O
but	O
has	O
an	O
additional	O
role	O
in	O
stimulating	O
desmoplasia	O
[	O
45	O
]	O
.	O

Reduced	O
transcription	O
of	O
these	O
genes	O
after	O
MUC1	O
siRNA	O
suggests	O
that	O
MUC1	O
may	O
foster	O
angiogenesis	O
and	O
stromal	O
proliferation	O
,	O
although	O
this	O
must	O
be	O
confirmed	O
in	O
a	O
more	O
appropriate	O
model	O
system	O
.	O

Decreased	O
MAP2K1	O
(	O
MEK1	O
)	O
transcription	O
after	O
MUC1	O
siRNA	O
provides	O
a	O
novel	O
mechanism	O
by	O
which	O
MUC1	O
can	O
affect	O
the	O
ERK1	O
/	O
2	O
MAPK	O
pathway	O
.	O

MUC1	O
has	O
often	O
been	O
linked	O
to	O
the	O
Ras	O
-	O
Raf	O
-	O
MEK	O
-	O
ERK	O
cascade	O
[	O
12,34	O
-	O
36,46	O
]	O
,	O
and	O
at	O
least	O
two	O
mechanisms	O
by	O
which	O
MUC1	O
can	O
alter	O
MAPK	O
signaling	O
have	O
been	O
described	O
:	O
MUC1	O
interaction	O
with	O
and	O
phosphorylation	O
by	O
the	O
EGFR	O
family	O
[	O
12,13	O
]	O
,	O
and	O
MUC1	O
binding	O
to	O
the	O
Grb2	O
/	O
Sos	O
complex	O
that	O
activates	O
Ras	O
[	O
46	O
]	O
.	O

Reduction	O
of	O
MEK1	O
levels	O
after	O
MUC1	O
siRNA	O
agrees	O
with	O
the	O
role	O
of	O
MUC1	O
in	O
strengthening	O
MAPK	O
signaling	O
,	O
and	O
indicates	O
that	O
MUC1	O
can	O
regulate	O
both	O
the	O
transcription	O
and	O
activity	O
of	O
members	O
of	O
this	O
pathway	O
.	O

Two	O
additional	O
MAPK	O
pathway	O
members	O
are	O
altered	O
specifically	O
in	O
BT.siMUC1	O
,	O
with	O
no	O
corresponding	O
change	O
in	O
468.siMUC1	O
cells	O
.	O

These	O
genes	O
are	O
RAF1	O
and	O
JUN	O
which	O
are	O
increased	O
and	O
decreased	O
,	O
respectively	O
,	O
after	O
MUC1	O
siRNA	O
.	O

Raf-1	O
and	O
c	O
-	O
Jun	O
both	O
function	O
outside	O
of	O
the	O
ERK1	O
/	O
2	O
MAPK	O
pathway	O
,	O
which	O
may	O
explain	O
the	O
seeming	O
paradox	O
of	O
increased	O
RAF1	O
transcription	O
with	O
simultaneous	O
decreases	O
in	O
MAP2K1	O
and	O
JUN	O
.	O

Specifically	O
,	O
Raf-1	O
can	O
inhibit	O
ASK1	O
(	O
apoptosis	O
signal	O
-	O
regulated	O
kinase	O
1	O
)	O
upstream	O
of	O
p38	O
and	O
JNK	O
(	O
Jun	O
N	O
-	O
terminal	O
kinase	O
)	O
[	O
38	O
]	O
.	O

ASK1	O
phosphorylates	O
JNK	O
in	O
response	O
to	O
stress	O
,	O
resulting	O
in	O
activation	O
of	O
c	O
-	O
Jun	O
and	O
stimulation	O
of	O
apoptosis	O
[	O
47	O
]	O
,	O
indicating	O
that	O
the	O
coordinate	O
up	O
-	O
regulation	O
of	O
RAF1	O
and	O
down	O
-	O
regulation	O
of	O
JUN	O
may	O
provide	O
a	O
potent	O
anti	O
-	O
apoptotic	O
effect	O
in	O
BT.siMUC1	O
.	O

Regulation	O
of	O
life	O
and	O
death	O
is	O
also	O
a	O
hallmark	O
of	O
the	O
CDC25A	O
and	O
TNF	O
gene	O
products	O
.	O

CDC25A	O
is	O
a	O
phosphatase	O
that	O
stimulates	O
cell	O
cycle	O
progression	O
[	O
48	O
]	O
,	O
thus	O
the	O
effects	O
of	O
its	O
decrease	O
in	O
BT.siMUC1	O
are	O
unclear	O
in	O
light	O
of	O
the	O
increased	O
proliferation	O
of	O
these	O
cells	O
.	O

However	O
,	O
the	O
CDC25	O
proteins	O
(	O
A	O
,	O
B	O
,	O
and	O
C	O
)	O
were	O
recently	O
shown	O
to	O
have	O
greater	O
functional	O
overlap	O
than	O
was	O
previously	O
thought	O
[	O
49	O
]	O
,	O
suggesting	O
that	O
the	O
other	O
two	O
isoforms	O
may	O
compensate	O
for	O
reduced	O
CDC25A	O
levels	O
.	O

TNF	O
encodes	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
α	O
,	O
known	O
for	O
its	O
potent	O
,	O
cell	O
type	O
-	O
specific	O
control	O
of	O
life	O
and	O
death	O
.	O

In	O
tumor	O
cells	O
,	O
TNFα	O
expression	O
can	O
promote	O
proliferation	O
and	O
inhibit	O
apoptosis	O
[	O
50	O
]	O
,	O
suggesting	O
that	O
increased	O
TNF	O
transcription	O
in	O
BT.siMUC1	O
could	O
contribute	O
to	O
the	O
increased	O
proliferation	O
seen	O
in	O
these	O
cells	O
.	O

Interestingly	O
,	O
the	O
increase	O
in	O
TNF	O
is	O
accompanied	O
by	O
decreased	O
transcription	O
of	O
TIMP3	O
,	O
encoding	O
tissue	O
inhibitor	O
of	O
metalloproteinases	O
(	O
TIMP	O
)	O
3	O
.	O

The	O
TIMP	O
family	O
disrupts	O
the	O
function	O
of	O
matrix	O
metalloproteinases	O
(	O
MMPs	O
)	O
,	O
generally	O
resulting	O
in	O
decreased	O
invasion	O
[	O
51	O
]	O
.	O

TIMP3	O
is	O
unique	O
in	O
that	O
it	O
can	O
also	O
inhibit	O
TNFα	O
converting	O
enzyme	O
(	O
TACE	O
)	O
,	O
which	O
activates	O
TNFα	O
by	O
cleaving	O
it	O
from	O
the	O
cell	O
surface	O
[	O
50	O
]	O
.	O

Reduced	O
expression	O
of	O
TIMP3	O
would	O
,	O
therefore	O
,	O
foster	O
signaling	O
through	O
TNFα	O
by	O
releasing	O
inhibition	O
of	O
TNFα	O
converting	O
enzyme	O
.	O

In	O
agreement	O
with	O
this	O
,	O
TIMP3	O
can	O
promote	O
apoptosis	O
[	O
52	O
]	O
;	O
thus	O
,	O
its	O
down	O
-	O
regulation	O
in	O
BT.siMUC1	O
provides	O
another	O
mechanism	O
by	O
which	O
these	O
cells	O
are	O
able	O
to	O
resist	O
the	O
increased	O
apoptosis	O
expected	O
with	O
loss	O
of	O
MUC1	O
.	O

Another	O
TIMP	O
target	O
responds	O
to	O
MUC1	O
siRNA	O
,	O
as	O
468.siMUC1	O
cells	O
show	O
significantly	O
increased	O
expression	O
of	O
MMP2	O
(	O
encoding	O
MMP-2	O
/	O
gelatinase	O
A	O
)	O
,	O
the	O
product	O
of	O
which	O
degrades	O
type	O
IV	O
collagen	O
[	O
52	O
]	O
.	O

In	O
breast	O
cancer	O
,	O
the	O
ratio	O
of	O
active	O
to	O
latent	O
MMP-2	O
increases	O
with	O
tumor	O
progression	O
;	O
MMP-2	O
may	O
facilitate	O
both	O
angiogenesis	O
and	O
metastasis	O
[	O
52	O
]	O
.	O

Its	O
increase	O
after	O
loss	O
of	O
MUC1	O
is	O
,	O
therefore	O
,	O
unexpected	O
,	O
but	O
at	O
least	O
two	O
factors	O
may	O
clarify	O
this	O
result	O
.	O

First	O
,	O
though	O
MMP-2	O
levels	O
are	O
increased	O
in	O
mouse	B
mammary	O
tumors	O
,	O
its	O
expression	O
is	O
confined	O
to	O
the	O
stroma	O
[	O
53	O
]	O
,	O
suggesting	O
that	O
increased	O
MMP2	O
transcription	O
after	O
loss	O
of	O
the	O
epithelium	O
-	O
specific	O
MUC1	O
might	O
reflect	O
a	O
shift	O
towards	O
a	O
more	O
mesenchymal	O
phenotype	O
.	O

Second	O
,	O
MMP-2	O
levels	O
are	O
increased	O
by	O
overexpression	O
of	O
erbB2	O
[	O
52	O
]	O
;	O
previous	O
studies	O
have	O
shown	O
that	O
erbB2	O
and	O
Muc1	O
expression	O
are	O
mutually	O
exclusive	O
in	O
mammary	O
tumors	O
[	O
27	O
]	O
,	O
implying	O
that	O
MMP2	O
might	O
be	O
part	O
of	O
a	O
transcriptional	O
profile	O
linked	O
to	O
low	O
MUC1	O
levels	O
.	O

It	O
is	O
intriguing	O
that	O
,	O
despite	O
increased	O
MMP2	O
transcription	O
,	O
invasion	O
is	O
decreased	O
in	O
468.siMUC1	O
cells	O
,	O
even	O
on	O
collagen	O
IV	O
.	O

This	O
may	O
reflect	O
insufficient	O
activation	O
of	O
MMP-2	O
,	O
as	O
the	O
precursor	O
protein	O
must	O
be	O
cleaved	O
for	O
enzymatic	O
function	O
[	O
52	O
]	O
.	O

Alternatively	O
,	O
the	O
slowed	O
invasion	O
of	O
these	O
cells	O
may	O
relate	O
to	O
impaired	O
adhesion	O
resulting	O
from	O
decreased	O
transcription	O
of	O
ITGAV	O
and	O
ITGB1	O
(	O
αv	O
and	O
β1	O
integrins	O
,	O
respectively	O
)	O
.	O

Integrin	O
signaling	O
is	O
tied	O
to	O
life	O
-	O
or	O
-	O
death	O
decisions	O
in	O
epithelial	O
cells	O
,	O
and	O
integrin	O
expression	O
is	O
vital	O
for	O
processes	O
from	O
wound	O
healing	O
to	O
metastasis	O
[	O
54	O
]	O
.	O

Integrin	O
αvβ3	O
is	O
implicated	O
in	O
facilitating	O
metastasis	O
of	O
breast	O
cancer	O
cells	O
to	O
bone	O
[	O
55	O
]	O
;	O
decreased	O
transcription	O
of	O
ITGAV	O
after	O
MUC1	O
siRNA	O
may	O
,	O
therefore	O
,	O
suggest	O
that	O
MUC1	O
is	O
involved	O
in	O
this	O
lethal	O
process	O
as	O
well	O
.	O

The	O
MUC1	O
oncogene	O
has	O
been	O
linked	O
to	O
apoptosis	O
[	O
18,20,26	O
]	O
,	O
proliferation	O
[	O
17	O
]	O
,	O
and	O
transcription	O
[	O
21,23	O
-	O
25	O
]	O
in	O
cancer	O
.	O

However	O
,	O
the	O
two	O
cell	O
lines	O
chosen	O
for	O
our	O
study	O
display	O
very	O
different	O
responses	O
to	O
MUC1	O
siRNA	O
,	O
indicating	O
that	O
regulation	O
of	O
MUC1	O
in	O
breast	O
cancer	O
is	O
likely	O
quite	O
complex	O
and	O
cautioning	O
against	O
over	O
-	O
generalization	O
of	O
results	O
from	O
individual	O
cell	O
lines	O
.	O

Previous	O
reports	O
suggest	O
that	O
,	O
though	O
most	O
studies	O
outline	O
a	O
clearly	O
oncogenic	O
role	O
for	O
MUC1	O
in	O
breast	O
cancer	O
,	O
the	O
exact	O
details	O
may	O
vary	O
depending	O
on	O
factors	O
such	O
as	O
cell	O
type	O
and	O
signaling	O
context	O
.	O

For	O
example	O
,	O
MUC1	O
stimulates	O
Fas	O
-	O
mediated	O
apoptosis	O
in	O
CHO	O
cells	O
[	O
26	O
]	O
,	O
quite	O
unlike	O
the	O
inhibition	O
of	O
apoptosis	O
seen	O
in	O
other	O
cell	O
lines	O
.	O

Similarly	O
,	O
though	O
MUC1	O
drives	O
mammary	O
oncogenesis	O
in	O
its	O
own	O
right	O
[	O
9	O
]	O
and	O
facilitates	O
tumorigenesis	O
driven	O
by	O
other	O
oncogenes	O
[	O
7,8	O
]	O
,	O
Muc1	O
is	O
selectively	O
down	O
-	O
regulated	O
in	O
c	O
-	O
neu	O
-	O
induced	O
mouse	B
mammary	O
tumors	O
[	O
27	O
]	O
,	O
indicating	O
that	O
the	O
context	O
of	O
oncogenic	O
signaling	O
is	O
vital	O
to	O
understanding	O
the	O
function	O
of	O
MUC1	O
.	O

Thus	O
,	O
it	O
is	O
important	O
to	O
consider	O
the	O
relative	O
levels	O
of	O
knockdown	O
of	O
MUC1	O
in	O
the	O
two	O
cell	O
lines	O
:	O
BT-20	O
cells	O
reduce	O
MUC1	O
expression	O
after	O
siRNA	O
less	O
strongly	O
than	O
do	O
MDA	O
-	O
MB-468	O
(	O
50	O
%	O
versus	O
75	O
%	O
knockdown	O
,	O
respectively	O
)	O
.	O

As	O
MUC1	O
serves	O
as	O
a	O
scaffold	O
[	O
11	O
]	O
,	O
overexpression	O
of	O
MUC1	O
relative	O
to	O
its	O
associated	O
signaling	O
proteins	O
might	O
create	O
a	O
dilution	O
effect	O
,	O
sequestering	O
signal	O
transducers	O
away	O
from	O
each	O
other	O
;	O
this	O
would	O
be	O
relieved	O
by	O
MUC1	O
siRNA	O
.	O

Thus	O
,	O
enough	O
MUC1	O
may	O
be	O
retained	O
in	O
BT.siMUC1	O
cells	O
for	O
its	O
oncogenic	O
effects	O
,	O
while	O
signaling	O
complex	O
formation	O
would	O
be	O
enhanced	O
by	O
lowering	O
the	O
amount	O
of	O
MUC1	O
relative	O
to	O
other	O
signaling	O
proteins	O
.	O

Conclusion	O
The	O
contrast	O
between	O
the	O
MDA	O
-	O
MB-468	O
and	O
BT-20	O
lines	O
in	O
response	O
to	O
MUC1	O
siRNA	O
serves	O
as	O
a	O
reminder	O
that	O
simplified	O
models	O
such	O
as	O
cell	O
lines	O
fail	O
to	O
encompass	O
the	O
complexity	O
of	O
intact	O
biological	O
systems	O
.	O

This	O
report	O
describes	O
transcriptional	O
alterations	O
seen	O
after	O
MUC1	O
knockdown	O
:	O
decreased	O
transcription	O
of	O
MAP2K1	O
,	O
VEGF	O
,	O
PDGFA	O
,	O
ITGAV	O
,	O
TIMP3	O
,	O
CDC25A	O
,	O
and	O
JUN	O
,	O
and	O
increased	O
transcription	O
of	O
MMP2	O
,	O
TNF	O
,	O
and	O
RAF1	O
.	O

The	O
alterations	O
in	O
MAP2K1	O
,	O
RAF1	O
,	O
and	O
JUN	O
represent	O
a	O
novel	O
means	O
by	O
which	O
MUC1	O
can	O
affect	O
ERK1	O
/	O
2	O
signaling	O
:	O
transcriptional	O
regulation	O
of	O
MAPK	O
pathway	O
members	O
.	O

Oncogenic	O
events	O
are	O
also	O
altered	O
in	O
both	O
cell	O
lines	O
after	O
MUC1	O
siRNA	O
.	O

These	O
results	O
strengthen	O
the	O
growing	O
ties	O
linking	O
MUC1	O
and	O
transcriptional	O
regulation	O
,	O
and	O
suggest	O
that	O
the	O
role	O
of	O
MUC1	O
in	O
breast	O
cancer	O
may	O
be	O
more	O
complex	O
than	O
a	O
direct	O
correlation	O
between	O
MUC1	O
level	O
and	O
oncogenic	O
function	O
.	O

Abbreviations	O
BrdU	O
=	O
bromodeoxyuridine	O
;	O
EGF	O
=	O
epidermal	O
growth	O
factor	O
;	O
EGFR	O
=	O
epidermal	O
growth	O
factor	O
receptor	O
;	O
ERK	O
=	O
extracellular	O
signal	O
regulated	O
kinase	O
;	O
MAPK	O
=	O
mitogen	O
activated	O
protein	O
kinase	O
;	O
MEK	O
=	O
MAPK	O
and	O
ERK	O
kinase	O
;	O
MMP	O
=	O
matrix	O
metalloproteinases	O
;	O
MUC1-CT	O
=	O
MUC1	O
cytoplasmic	O
tail	O
;	O
MUC1-EX	O
=	O
MUC1	O
extracellular	O
subunit	O
;	O
PBS	O
=	O
phosphate	O
-	O
buffered	O
saline	O
;	O
PI	O
=	O
propidium	O
iodide	O
;	O
siRNA	O
=	O
small	O
interfering	O
RNA	O
;	O
TIMP	O
=	O
tissue	O
inhibitor	O
of	O
metalloproteinases	O
;	O
TNF	O
=	O
tumor	O
necrosis	O
factor	O
.	O

Competing	O
interests	O
The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O
CLH	O
performed	O
all	O
studies	O
and	O
composed	O
the	O
manuscript	O
.	O

SJG	O
participated	O
in	O
the	O
design	O
and	O
coordination	O
of	O
the	O
studies	O
and	O
contributed	O
strongly	O
to	O
the	O
revision	O
of	O
the	O
manuscript	O
.	O

Both	O
authors	O
have	O
read	O
and	O
approved	O
the	O
manuscript	O
.	O

Video	O
analysis	O
of	O
the	O
escape	O
flight	O
of	O
Pileated	B
Woodpecker	I
Dryocopus	B
pileatus	I
:	O
does	O
the	O
Ivory	B
-	I
billed	I
Woodpecker	I
Campephilus	B
principalis	I
persist	O
in	O
continental	O
North	O
America	O
?	O

Abstract	O
Background	O
The	O
apparent	O
rediscovery	O
of	O
the	O
Ivory	B
-	I
billed	I
Woodpecker	I
Campephilus	B
principalis	I
in	O
Arkansas	O
,	O
USA	O
,	O
previously	O
feared	O
extinct	O
,	O
was	O
supported	O
by	O
video	O
evidence	O
of	O
a	O
single	O
bird	O
in	O
flight	O
(	O
Fitzpatrick	O
et	O
al	O
,	O
Science	O
2005	O
,	O
308:1460–1462	O
)	O
.	O

Plumage	O
patterns	O
and	O
wingbeat	O
frequency	O
of	O
the	O
putative	O
Ivory	B
-	I
billed	I
Woodpecker	I
were	O
said	O
to	O
be	O
incompatible	O
with	O
the	O
only	O
possible	O
confusion	O
species	O
native	O
to	O
the	O
area	O
,	O
the	O
Pileated	B
Woodpecker	I
Dryocopus	B
pileatus	I
.	O

Results	O
New	O
video	O
analysis	O
of	O
Pileated	B
Woodpeckers	I
in	O
escape	O
flights	O
comparable	O
to	O
that	O
of	O
the	O
putative	O
Ivory	B
-	I
billed	I
Woodpecker	I
filmed	O
in	O
Arkansas	O
shows	O
that	O
Pileated	B
Woodpeckers	I
can	O
display	O
a	O
wingbeat	O
frequency	O
equivalent	O
to	O
that	O
of	O
the	O
Arkansas	O
bird	O
during	O
escape	O
flight	O
.	O

The	O
critical	O
frames	O
from	O
the	O
Arkansas	O
video	O
that	O
were	O
used	O
to	O
identify	O
the	O
bird	O
as	O
an	O
Ivory	B
-	I
billed	I
Woodpecker	I
are	O
shown	O
to	O
be	O
equally	O
,	O
or	O
more	O
,	O
compatible	O
with	O
the	O
Pileated	B
Woodpecker	I
.	O

Conclusion	O
The	O
identification	O
of	O
the	O
bird	O
filmed	O
in	O
Arkansas	O
in	O
April	O
2004	O
as	O
an	O
Ivory	B
-	I
billed	I
Woodpecker	I
is	O
best	O
regarded	O
as	O
unsafe	O
.	O

The	O
similarities	O
between	O
the	O
Arkansas	O
bird	O
and	O
known	O
Pileated	B
Woodpeckers	I
suggest	O
that	O
it	O
was	O
most	O
likely	O
a	O
Pileated	B
Woodpecker	I
.	O

Background	O
The	O
reported	O
rediscovery	O
of	O
the	O
Ivory	B
-	I
billed	I
Woodpecker	I
in	O
2004–5	O
in	O
the	O
Big	O
Woods	O
of	O
Arkansas	O
gave	O
new	O
impetus	O
to	O
efforts	O
to	O
conserve	O
the	O
mature	O
bottomland	O
woodlands	O
of	O
the	O
south	O
-	O
eastern	O
USA	O
.	O

Several	O
sightings	O
have	O
been	O
reported	O
without	O
photographic	O
evidence	O
being	O
obtained	O
[	O
1	O
]	O
.	O

Unless	O
sightings	O
are	O
,	O
however	O
,	O
independently	O
verifiable	O
on	O
the	O
basis	O
of	O
photographic	O
or	O
other	O
recorded	O
evidence	O
,	O
the	O
possibility	O
that	O
mistakes	O
have	O
been	O
made	O
can	O
not	O
be	O
eliminated	O
.	O

Crucial	O
to	O
the	O
scientific	O
case	O
for	O
the	O
persistence	O
of	O
the	O
Ivory	B
-	I
billed	I
Woodpecker	I
was	O
a	O
4	O
s	O
video	O
of	O
a	O
large	O
woodpecker	O
in	O
flight	O
recorded	O
by	O
M.D.	O
Luneau	O
on	O
25	O
April	O
2004	O
(	O
henceforth	O
referred	O
to	O
as	O
the	O
'	O
Luneau	O
video	O
'	O
)	O
and	O
published	O
in	O
2005	O
[	O
1	O
]	O
,	O
which	O
was	O
claimed	O
to	O
be	O
inconsistent	O
with	O
the	O
plumage	O
patterns	O
of	O
the	O
superficially	O
similar	O
Pileated	B
Woodpecker	I
(	O
a	O
common	O
resident	O
bird	O
of	O
the	O
area	O
)	O
.	O

Both	O
species	O
are	O
large	O
,	O
black	O
-	O
and	O
-	O
white	O
woodpeckers	O
[	O
2	O
]	O
.	O

The	O
upperwing	O
of	O
the	O
Ivory	B
-	I
billed	I
Woodpecker	I
is	O
black	O
,	O
with	O
white	O
secondary	O
feathers	O
and	O
white	O
on	O
some	O
inner	O
primary	O
feathers	O
.	O

Pileated	B
Woodpeckers	I
have	O
a	O
largely	O
black	O
upperwing	O
,	O
with	O
white	O
restricted	O
to	O
the	O
'	O
wrist	O
'	O
due	O
to	O
white	O
bases	O
to	O
the	O
primary	O
feathers	O
.	O

The	O
underwing	O
of	O
Pileated	B
Woodpecker	I
has	O
all	O
-	O
white	O
underwing	O
coverts	O
,	O
giving	O
an	O
appearance	O
of	O
a	O
white	O
underwing	O
with	O
a	O
broad	O
black	O
outline	O
(	O
the	O
black	O
flight	O
feathers	O
)	O
.	O

These	O
plumage	O
differences	O
result	O
in	O
the	O
Ivory	B
-	I
billed	I
Woodpecker	I
having	O
a	O
white	O
trailing	O
edge	O
to	O
the	O
wings	O
(	O
upper	O
and	O
lower	O
sides	O
)	O
,	O
whereas	O
the	O
Pileated	B
Woodpecker	I
has	O
a	O
black	O
trailing	O
edge	O
to	O
the	O
wings	O
.	O

Both	O
species	O
have	O
black	O
wing	O
-	O
tips	O
.	O

These	O
and	O
other	O
plumage	O
characteristics	O
are	O
shown	O
in	O
[	O
1,2	O
]	O
.	O

The	O
wingbeat	O
frequency	O
of	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
was	O
measured	O
at	O
8.6	O
beats	O
s-1	O
,	O
similar	O
to	O
that	O
inferred	O
from	O
archival	O
sound	O
recording	O
of	O
a	O
single	O
Ivory	B
-	I
billed	I
Woodpecker	I
,	O
but	O
claimed	O
to	O
be	O
outside	O
the	O
range	O
of	O
Pileated	B
Woodpeckers	I
(	O
which	O
generally	O
have	O
slower	O
wingbeats	O
)	O
[	O
1,3	O
]	O
.	O

Sibley	O
et	O
al	O
[	O
4	O
]	O
questioned	O
the	O
video	O
evidence	O
,	O
in	O
particular	O
providing	O
alternative	O
explanations	O
for	O
the	O
plumage	O
patterns	O
of	O
the	O
Luneau	O
bird	O
in	O
flight	O
and	O
at	O
rest	O
.	O

They	O
pointed	O
out	O
individual	O
frames	O
of	O
the	O
Luneau	O
video	O
that	O
appear	O
to	O
show	O
three	O
features	O
that	O
are	O
each	O
inconsistent	O
with	O
Ivory	B
-	I
billed	I
Woodpecker	I
:	O
(	O
1	O
)	O
apparently	O
black	O
secondary	O
feathers	O
on	O
the	O
upper	O
surface	O
of	O
the	O
left	O
wing	O
,	O
(	O
2	O
)	O
particularly	O
bright	O
white	O
primary	O
bases	O
,	O
and	O
(	O
3	O
)	O
a	O
black	O
band	O
curving	O
smoothly	O
round	O
the	O
wing	O
tip	O
(	O
see	O
Figure	O
3	O
in	O
[	O
4	O
]	O
)	O
.	O

They	O
hypothesized	O
that	O
flexing	O
of	O
a	O
Pileated	B
Woodpecker	I
's	O
wings	O
during	O
flight	O
could	O
produce	O
the	O
appearance	O
of	O
white	O
trailing	O
edges	O
on	O
both	O
wings	O
in	O
low	O
-	O
quality	O
videos	O
[	O
4	O
]	O
.	O

They	O
offered	O
,	O
however	O
,	O
no	O
direct	O
evidence	O
to	O
show	O
that	O
this	O
could	O
cause	O
a	O
video	O
of	O
a	O
Pileated	B
Woodpecker	I
to	O
look	O
like	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
.	O

Fitzpatrick	O
et	O
al	O
[	O
5	O
]	O
in	O
turn	O
rebutted	O
some	O
aspects	O
of	O
the	O
hypothesis	O
of	O
Sibley	O
et	O
al	O
[	O
4	O
]	O
,	O
publishing	O
video	O
stills	O
of	O
Pileated	B
Woodpeckers	I
,	O
and	O
a	O
model	O
of	O
a	O
Pileated	B
Woodpecker	I
,	O
that	O
appeared	O
to	O
show	O
a	O
black	O
trailing	O
edge	O
to	O
the	O
wings	O
inconsistent	O
with	O
Ivory	B
-	I
billed	I
Woodpecker	I
and	O
the	O
Luneau	O
video	O
.	O

Fitzpatrick	O
et	O
al	O
[	O
5	O
]	O
neither	O
rebutted	O
nor	O
discussed	O
the	O
three	O
key	O
inconsistencies	O
described	O
above	O
.	O

Without	O
further	O
evidence	O
,	O
this	O
became	O
largely	O
a	O
theoretical	O
debate	O
over	O
interpretation	O
of	O
field	O
characters	O
that	O
were	O
barely	O
visible	O
in	O
the	O
very	O
small	O
images	O
originally	O
obtained	O
.	O

On	O
one	O
hand	O
,	O
as	O
pointed	O
out	O
in	O
Sibley	O
et	O
al	O
[	O
4	O
]	O
,	O
some	O
of	O
the	O
frames	O
of	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
do	O
appear	O
to	O
be	O
inconsistent	O
with	O
Ivory	B
-	I
billed	I
Woodpecker	I
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
flight	O
pattern	O
of	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
is	O
asserted	O
to	O
be	O
atypical	O
for	O
Pileated	B
Woodpecker	I
(	O
but	O
matching	O
anecdotal	O
descriptions	O
of	O
Ivory	B
-	I
billed	I
Woodpecker	I
)	O
.	O

Furthermore	O
,	O
the	O
general	O
impression	O
of	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
was	O
that	O
there	O
is	O
far	O
too	O
much	O
white	O
in	O
the	O
wings	O
for	O
it	O
to	O
be	O
a	O
Pileated	B
Woodpecker	I
,	O
and	O
that	O
if	O
it	O
was	O
a	O
Pileated	O
,	O
then	O
it	O
must	O
be	O
an	O
aberrant	O
one	O
with	O
abnormally	O
extensive	O
white	O
plumage	O
.	O

Such	O
birds	O
occasionally	O
occur	O
,	O
and	O
have	O
been	O
observed	O
in	O
the	O
Arkansas	O
study	O
area	O
[	O
6	O
]	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
determine	O
whether	O
the	O
flight	O
and	O
plumage	O
of	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
really	O
was	O
inconsistent	O
with	O
either	O
a	O
normal	O
or	O
partial	O
albino	O
Pileated	B
Woodpecker	I
.	O

Independent	O
analyses	O
of	O
the	O
plumage	O
patterns	O
and	O
wingbeat	O
frequencies	O
observable	O
in	O
Pileated	B
Woodpeckers	I
are	O
presented	O
,	O
and	O
it	O
is	O
concluded	O
that	O
the	O
identification	O
of	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
as	O
definite	O
Ivory	B
-	I
billed	I
Woodpecker	I
is	O
probably	O
unsafe	O
.	O

Results	O
On	O
January	O
28	O
and	O
February	O
5	O
,	O
2006	O
,	O
David	O
Nolin	O
(	O
DN	O
)	O
video	O
-	O
recorded	O
Pileated	B
Woodpeckers	I
Dryocopus	B
pileatus	I
at	O
a	O
bird	O
-	O
feeder	O
in	O
Dayton	O
,	O
Ohio	O
,	O
USA	O
.	O

A	O
Hi-8	O
Sony	O
Handycam	O
was	O
used	O
,	O
hand	O
-	O
held	O
,	O
at	O
approximately	O
5	O
m	O
from	O
the	O
feeder	O
.	O

Birds	O
on	O
the	O
tree	O
trunk	O
were	O
alarmed	O
by	O
movement	O
,	O
and	O
their	O
escape	O
flights	O
recorded	O
.	O

Four	O
escape	O
flights	O
were	O
captured	O
that	O
approximate	O
to	O
that	O
recorded	O
for	O
the	O
putative	O
Ivory	B
-	I
billed	I
Woodpecker	I
Campephilus	B
principalis	I
by	O
Luneau	O
in	O
April	O
2004	O
and	O
published	O
in	O
Fitzpatrick	O
et	O
al	O
[	O
1	O
]	O
.	O

The	O
videos	O
are	O
not	O
directly	O
equivalent	O
because	O
the	O
Pileated	B
Woodpeckers	I
made	O
only	O
short	O
escape	O
flights	O
to	O
nearby	O
trees	O
,	O
whereas	O
the	O
putative	O
Ivory	B
-	I
billed	I
Woodpecker	I
in	O
the	O
Luneau	O
video	O
showed	O
little	O
sign	O
of	O
coming	O
to	O
rest	O
before	O
being	O
lost	O
from	O
view	O
.	O

Nevertheless	O
,	O
interesting	O
comparisons	O
can	O
be	O
made	O
.	O

Wingbeat	O
frequency	O
of	O
Pileated	B
Woodpecker	I
The	O
woodpecker	O
in	O
the	O
Luneau	O
video	O
maintains	O
a	O
steady	O
rapid	O
wingbeat	O
rate	O
of	O
8.6	O
beats	O
s-1	O
for	O
at	O
least	O
8	O
wingbeats	O
[	O
1	O
]	O
,	O
a	O
figure	O
that	O
was	O
confirmed	O
by	O
independent	O
analysis	O
during	O
preparation	O
of	O
this	O
paper	O
.	O

The	O
Pileated	B
woodpeckers	I
in	O
DN	O
's	O
video	O
do	O
not	O
do	O
this	O
–	O
after	O
initial	O
rapid	O
flapping	O
immediately	O
after	O
take	O
-	O
off	O
,	O
they	O
settle	O
into	O
a	O
more	O
relaxed	O
level	O
flight	O
.	O

As	O
shown	O
in	O
Tables	O
1	O
and	O
2	O
,	O
although	O
the	O
mean	O
wingbeat	O
frequencies	O
of	O
the	O
Pileated	B
Woodpeckers	I
in	O
DN	O
's	O
video	O
are	O
slower	O
than	O
the	O
8.6	O
s-1	O
recorded	O
for	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
[	O
1,3,5	O
]	O
the	O
first	O
four	O
wingbeats	O
,	O
the	O
initial	O
escape	O
response	O
,	O
are	O
faster	O
than	O
those	O
claimed	O
for	O
Pileated	B
Woodpeckers	I
in	O
the	O
literature	O
[	O
1,3,5	O
]	O
.	O

For	O
the	O
four	O
escape	O
flights	O
,	O
the	O
mean	O
frequency	O
values	O
for	O
the	O
first	O
four	O
wingbeats	O
are	O
7.1	O
,	O
6.7	O
,	O
8.6	O
,	O
and	O
8.0	O
s-1	O
,	O
respectively	O
.	O

The	O
8.6	O
beats	O
s-1	O
of	O
the	O
bird	O
identified	O
in	O
the	O
Luneau	O
video	O
,	O
while	O
consistent	O
with	O
the	O
limited	O
data	O
(	O
n	O
=	O
1	O
;	O
see	O
Discussion	O
)	O
for	O
Ivory	B
-	I
billed	I
Woodpecker	I
,	O
is	O
equally	O
consistent	O
with	O
Pileated	B
Woodpecker	I
in	O
its	O
initial	O
escape	O
flight	O
.	O

The	O
bird	O
in	O
the	O
Luneau	O
video	O
maintains	O
a	O
frequency	O
of	O
8.6	O
s-1	O
for	O
the	O
next	O
four	O
wingbeats	O
too	O
,	O
whereas	O
the	O
Pileated	B
Woodpeckers	I
recorded	O
here	O
all	O
slowed	O
their	O
flight	O
as	O
they	O
prepared	O
to	O
land	O
in	O
nearby	O
trees	O
.	O

There	O
are	O
no	O
data	O
to	O
suggest	O
whether	O
Pileated	B
Woodpeckers	I
can	O
maintain	O
a	O
wingbeat	O
frequency	O
approaching	O
8.6	O
s-1	O
for	O
eight	O
or	O
more	O
wingbeats	O
,	O
like	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
.	O

It	O
remains	O
possible	O
that	O
the	O
flight	O
pattern	O
of	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
is	O
unusual	O
for	O
Pileated	B
Woodpecker	I
,	O
but	O
a	O
frequency	O
of	O
8.6	O
s-1	O
is	O
consistent	O
with	O
a	O
Pileated	B
Woodpecker	I
gaining	O
initial	O
speed	O
and	O
height	O
in	O
escape	O
flight	O
,	O
and	O
by	O
itself	O
can	O
not	O
be	O
taken	O
as	O
strong	O
evidence	O
that	O
the	O
Luneau	O
video	O
bird	O
was	O
an	O
Ivory	B
-	I
billed	I
Woodpecker	I
.	O

This	O
is	O
discussed	O
further	O
below	O
.	O

Plumage	O
pattern	O
of	O
Pileated	B
Woodpeckers	I
in	O
flight	O
The	O
video	O
of	O
Pileated	B
Woodpeckers	I
in	O
flight	O
was	O
obtained	O
in	O
avi	O
format	O
,	O
decompiled	O
and	O
examined	O
frame	O
by	O
frame	O
.	O

Comparisons	O
of	O
Pileated	B
Woodpecker	I
images	O
with	O
key	O
images	O
of	O
Luneau	O
video	O
are	O
shown	O
in	O
Figures	O
1	O
and	O
2	O
,	O
and	O
suggest	O
a	O
genuine	O
resemblance	O
between	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
and	O
a	O
Pileated	B
Woodpecker	I
.	O

Analysis	O
is	O
complicated	O
by	O
the	O
different	O
digital	O
processing	O
of	O
the	O
two	O
videos	O
,	O
and	O
in	O
the	O
case	O
of	O
the	O
Nolin	O
videos	O
it	O
is	O
important	O
to	O
concentrate	O
only	O
on	O
those	O
frames	O
or	O
part	O
-	O
frames	O
where	O
apparent	O
plumage	O
features	O
are	O
not	O
an	O
artifact	O
of	O
blurred	O
images	O
.	O

Thirty	O
-	O
six	O
frames	O
from	O
the	O
fourth	O
example	O
of	O
Pileated	O
escape	O
flight	O
,	O
which	O
most	O
resembled	O
the	O
flight	O
path	O
of	O
the	O
Luneau	O
video	O
bird	O
,	O
were	O
analysed	O
systematically	O
frame	O
by	O
frame	O
.	O

They	O
represent	O
seven	O
complete	O
wingbeats	O
(	O
1.20	O
s	O
from	O
the	O
middle	O
of	O
the	O
second	O
wingbeat	O
to	O
middle	O
of	O
wingbeat	O
9	O
)	O
and	O
were	O
directly	O
compared	O
frame	O
-	O
by	O
-	O
frame	O
with	O
the	O
equivalent	O
fields	O
(	O
middle	O
wingbeat	O
2	O
–	O
middle	O
wingbeat	O
9	O
)	O
of	O
the	O
Luneau	O
video	O
.	O

This	O
comparison	O
is	O
shown	O
in	O
Figure	O
3	O
.	O

The	O
images	O
of	O
the	O
birds	O
are	O
not	O
identical	O
,	O
but	O
in	O
every	O
frame	O
of	O
the	O
36	O
frames	O
available	O
,	O
there	O
are	O
sufficient	O
similarities	O
to	O
suggest	O
that	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
is	O
consistent	O
with	O
the	O
known	O
Pileated	B
Woodpecker	I
.	O

Further	O
comparisons	O
of	O
the	O
Luneau	O
bird	O
with	O
the	O
other	O
three	O
Pileated	B
escape	O
flights	O
recorded	O
are	O
presented	O
in	O
the	O
supplementary	O
material	O
(	O
see	O
Additional	O
file	O
1	O
)	O
.	O

Key	O
findings	O
of	O
the	O
video	O
analysis	O
are	O
:	O
1	O
.	O

Pileated	B
Woodpeckers	I
flying	O
near	O
-	O
horizontally	O
away	O
from	O
the	O
observer	O
show	O
much	O
more	O
white	O
in	O
poor	O
-	O
quality	O
video	O
than	O
would	O
be	O
expected	O
from	O
their	O
general	O
plumage	O
pattern	O
.	O

They	O
present	O
an	O
appearance	O
of	O
a	O
black	O
-	O
bodied	O
bird	O
with	O
largely	O
white	O
wings	O
and	O
black	O
wingtips	O
,	O
very	O
similar	O
to	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
;	O
compare	O
in	O
particular	O
Figure	O
1B	O
,	O
frame	O
758	O
,	O
with	O
Figure	O
1A	O
,	O
frame	O
283.3	O
.	O

The	O
expected	O
appearance	O
of	O
the	O
upperwing	O
of	O
Pileated	B
Woodpecker	I
–	O
mostly	O
black	O
with	O
a	O
small	O
white	O
patch	O
at	O
the	O
base	O
of	O
the	O
primaries	O
–	O
is	O
often	O
not	O
seen	O
,	O
and	O
is	O
only	O
clearly	O
resolvable	O
when	O
birds	O
are	O
flying	O
near	O
-	O
vertically	O
before	O
landing	O
on	O
a	O
tree	O
trunk	O
;	O
something	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
did	O
not	O
do	O
.	O

2	O
.	O

The	O
black	O
trailing	O
edge	O
to	O
the	O
underwing	O
of	O
Pileated	B
Woodpecker	I
is	O
often	O
very	O
inconspicuous	O
and	O
may	O
disappear	O
completely	O
.	O

Due	O
to	O
motion	O
and	O
flexion	O
of	O
the	O
wing	O
,	O
the	O
black	O
trailing	O
edge	O
is	O
much	O
more	O
obvious	O
towards	O
the	O
wingtips	O
.	O

This	O
produces	O
an	O
apparent	O
plumage	O
pattern	O
that	O
matches	O
the	O
patterns	O
shown	O
by	O
the	O
Luneau	O
video	O
bird	O
(	O
compare	O
Figure	O
1B	O
,	O
frames	O
175	O
and	O
457	O
with	O
Figure	O
1A	O
,	O
frames	O
300	O
and	O
416.7	O
)	O
.	O

In	O
many	O
frames	O
of	O
Pileated	B
Woodpecker	I
,	O
a	O
black	O
trailing	O
edge	O
to	O
the	O
wing	O
is	O
discernable	O
(	O
though	O
due	O
to	O
bleeding	O
of	O
white	O
as	O
a	O
video	O
artifact	O
,	O
it	O
appears	O
narrower	O
than	O
it	O
really	O
is	O
)	O
.	O

However	O
,	O
analysis	O
of	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
in	O
light	O
of	O
images	O
of	O
known	O
Pileated	B
Woodpeckers	I
confirms	O
that	O
a	O
similar	O
black	O
trailing	O
edge	O
to	O
the	O
wing	O
is	O
discernable	O
in	O
some	O
frames	O
of	O
the	O
Luneau	O
video	O
(	O
compare	O
Figure	O
1B	O
,	O
frame	O
775	O
with	O
Figure	O
1A	O
,	O
frame	O
366.7	O
:	O
the	O
apparent	O
plumage	O
patterns	O
are	O
similar	O
,	O
and	O
inconsistent	O
with	O
Ivory	B
-	I
billed	I
Woodpecker	I
)	O
.	O

It	O
is	O
argued	O
here	O
that	O
the	O
hypothesis	O
put	O
forward	O
in	O
Sibley	O
et	O
al	O
[	O
4	O
]	O
is	O
correct	O
,	O
and	O
that	O
the	O
black	O
trailing	O
edge	O
of	O
the	O
underwing	O
of	O
Pileated	B
Woodpecker	I
can	O
indeed	O
,	O
due	O
to	O
flexion	O
of	O
the	O
wings	O
during	O
the	O
downstroke	O
,	O
be	O
misinterpreted	O
as	O
the	O
black	O
leading	O
edge	O
and	O
wingtips	O
of	O
the	O
upperwing	O
of	O
an	O
Ivory	B
-	I
billed	I
Woodpecker	I
.	O

3	O
.	O

Figure	O
3	O
shows	O
that	O
the	O
plumage	O
patterns	O
shown	O
by	O
the	O
Luneau	O
bird	O
,	O
throughout	O
several	O
wingbeat	O
cycles	O
,	O
are	O
compatible	O
with	O
Pileated	B
Woodpecker	I
.	O

The	O
three	O
plumage	O
features	O
described	O
in	O
Sibley	O
et	O
al	O
[	O
4	O
]	O
that	O
are	O
incompatible	O
with	O
Ivory	B
-	I
billed	I
Woodpecker	I
(	O
black	O
secondary	O
feathers	O
on	O
upper	O
surface	O
of	O
left	O
wing	O
,	O
brighter	O
white	O
primary	O
bases	O
,	O
and	O
a	O
black	O
band	O
curling	O
round	O
the	O
wing	O
tip	O
)	O
are	O
seen	O
consistently	O
in	O
the	O
Luneau	O
video	O
and	O
are	O
recapitulated	O
throughout	O
the	O
video	O
of	O
Pileated	B
Woodpecker	I
.	O

Discussion	O
Evidence	O
is	O
presented	O
here	O
to	O
show	O
that	O
the	O
distinctive	O
plumage	O
features	O
of	O
Pileated	B
Woodpecker	I
are	O
surprisingly	O
difficult	O
to	O
resolve	O
in	O
poor	O
-	O
quality	O
video	O
of	O
birds	O
in	O
escape	O
flight	O
away	O
from	O
the	O
camera	O
,	O
and	O
that	O
they	O
can	O
show	O
apparent	O
plumage	O
patterns	O
that	O
might	O
more	O
readily	O
be	O
associated	O
with	O
Ivory	B
-	I
billed	I
Woodpecker	I
.	O

Irrespective	O
of	O
the	O
identity	O
of	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
,	O
this	O
knowledge	O
will	O
be	O
critical	O
to	O
assessment	O
of	O
further	O
claims	O
of	O
Ivory	B
-	I
billed	I
Woodpeckers	I
during	O
the	O
current	O
intensive	O
search	O
effort	O
.	O

It	O
is	O
,	O
however	O
,	O
suggested	O
here	O
that	O
critical	O
frames	O
used	O
for	O
identification	O
of	O
the	O
Luneau	O
video	O
woodpecker	O
as	O
an	O
Ivory	B
-	I
billed	I
Woodpecker	I
are	O
also	O
consistent	O
with	O
Pileated	B
Woodpecker	I
.	O

The	O
wingbeat	O
frequency	O
of	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
is	O
also	O
perhaps	O
consistent	O
with	O
Pileated	B
Woodpecker	I
,	O
at	O
least	O
for	O
short	O
periods	O
of	O
flight	O
.	O

Analysis	O
of	O
the	O
videos	O
of	O
Pileated	B
Woodpecker	I
has	O
supported	O
the	O
hypothesised	O
interpretations	O
of	O
key	O
frames	O
of	O
the	O
Luneau	O
video	O
by	O
Sibley	O
et	O
al	O
[	O
4	O
]	O
.	O

Although	O
the	O
rebuttal	O
of	O
that	O
comment	O
in	O
Fitzpatrick	O
et	O
al	O
[	O
5	O
]	O
asserted	O
that	O
flexion	O
and	O
motion	O
of	O
wings	O
of	O
Pileated	B
Woodpeckers	I
could	O
not	O
produce	O
the	O
images	O
seen	O
in	O
the	O
Luneau	O
video	O
,	O
it	O
has	O
been	O
shown	O
here	O
that	O
they	O
can	O
.	O

The	O
Luneau	O
video	O
as	O
presented	O
in	O
Fitzpatrick	O
et	O
al	O
[	O
1	O
]	O
,	O
shows	O
features	O
that	O
are	O
consistent	O
with	O
Pileated	B
Woodpecker	I
,	O
and	O
inconsistent	O
with	O
Ivory	B
-	I
billed	I
Woodpecker	I
.	O

It	O
is	O
argued	O
in	O
this	O
paper	O
that	O
,	O
in	O
fact	O
,	O
the	O
black	O
trailing	O
edge	O
of	O
the	O
wing	O
of	O
a	O
Pileated	B
Woodpecker	I
is	O
seen	O
clearly	O
in	O
the	O
Luneau	O
video	O
,	O
during	O
the	O
downstroke	O
of	O
the	O
wingbeat	O
cycle	O
,	O
but	O
that	O
it	O
has	O
been	O
misinterpreted	O
as	O
black	O
wingtips	O
(	O
Figure	O
1	O
,	O
2	O
,	O
3	O
)	O
.	O

A	O
fuller	O
analysis	O
of	O
the	O
Luneau	O
video	O
by	O
the	O
Cornell	O
University	O
team	O
is	O
presented	O
online	O
[	O
7	O
]	O
.	O

Although	O
it	O
is	O
not	O
peer	O
-	O
reviewed	O
,	O
the	O
points	O
this	O
article	O
makes	O
should	O
be	O
taken	O
into	O
account	O
.	O

The	O
authors	O
summarise	O
nine	O
diagnostic	O
traits	O
from	O
their	O
analysis	O
of	O
the	O
Luneau	O
video	O
that	O
identify	O
the	O
bird	O
as	O
Ivory	B
-	I
billed	I
Woodpecker	I
.	O

These	O
are	O
listed	O
and	O
discussed	O
point	O
-	O
by	O
point	O
below	O
.	O

1	O
.	O
'	O

The	O
underwing	O
pattern	O
in	O
flight	O
consistently	O
appears	O
largely	O
white	O
,	O
giving	O
the	O
appearance	O
of	O
having	O
black	O
wingtips	O
but	O
lacking	O
any	O
black	O
along	O
the	O
rear	O
,	O
or	O
trailing	O
edge	O
.	O
'	O

Data	O
presented	O
in	O
this	O
paper	O
show	O
that	O
this	O
statement	O
is	O
not	O
wholly	O
supported	O
,	O
and	O
in	O
any	O
case	O
the	O
underwing	O
of	O
Pileated	B
Woodpeckers	I
can	O
present	O
the	O
same	O
appearance	O
.	O

2	O
.	O
'	O

The	O
upperwing	O
pattern	O
in	O
flight	O
consistently	O
shows	O
a	O
broad	O
,	O
white	O
trailing	O
edge	O
,	O
with	O
no	O
frames	O
demonstrating	O
the	O
conspicuous	O
dark	O
rear	O
border	O
to	O
be	O
expected	O
of	O
normal	O
Pileated	B
Woodpeckers	I
.	O
'	O

Notwithstanding	O
that	O
certain	O
frames	O
of	O
the	O
Luneau	O
video	O
(	O
e.g.	O
frame	O
350	O
)	O
do	O
appear	O
to	O
show	O
a	O
black	O
trailing	O
edge	O
to	O
the	O
upperwing	O
,	O
data	O
presented	O
in	O
this	O
paper	O
shows	O
that	O
,	O
at	O
this	O
angle	O
of	O
view	O
and	O
resolution	O
of	O
video	O
,	O
Pileated	B
Woodpeckers	I
also	O
may	O
fail	O
to	O
show	O
this	O
feature	O
.	O

This	O
analysis	O
has	O
shown	O
that	O
the	O
hypothesis	O
presented	O
in	O
Sibley	O
et	O
al	O
[	O
4	O
]	O
is	O
plausible	O
,	O
i.e.	O
that	O
some	O
of	O
the	O
frames	O
interpreted	O
by	O
[	O
1	O
]	O
to	O
show	O
the	O
upperwing	O
of	O
an	O
Ivory	B
-	I
billed	I
Woodpecker	I
may	O
in	O
fact	O
show	O
large	O
amounts	O
of	O
white	O
and	O
the	O
black	O
trailing	O
edge	O
from	O
the	O
underwing	O
of	O
a	O
Pileated	B
Woodpecker	I
.	O

3	O
.	O
'	O

The	O
wings	O
are	O
longer	O
relative	O
to	O
the	O
body	O
diameter	O
than	O
in	O
Pileated	B
Woodpecker	I
and	O
consistent	O
with	O
the	O
wing	O
shape	O
of	O
Ivory	B
-	I
billed	I
Woodpecker	I
.	O
'	O

Fitzpatrick	O
et	O
al	O
[	O
5	O
]	O
agreed	O
that	O
accurate	O
measurements	O
were	O
not	O
possible	O
from	O
the	O
video	O
images	O
presented	O
in	O
their	O
original	O
paper	O
[	O
1	O
]	O
,	O
and	O
it	O
seems	O
unlikely	O
that	O
much	O
confidence	O
can	O
be	O
placed	O
in	O
the	O
wing	O
-	O
length	O
measurements	O
of	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
.	O

Comparison	O
of	O
,	O
for	O
example	O
,	O
Figure	O
1A	O
,	O
frame	O
283.3	O
with	O
Figure	O
1B	O
,	O
frame	O
578	O
suggests	O
that	O
any	O
differences	O
will	O
be	O
very	O
difficult	O
to	O
prove	O
.	O

4	O
.	O
'	O

Reenactment	O
of	O
the	O
scene	O
using	O
life	O
-	O
sized	O
,	O
realistically	O
painted	O
,	O
dynamically	O
flapping	O
models	O
produced	O
images	O
remarkably	O
similar	O
to	O
those	O
of	O
the	O
Luneau	O
video	O
using	O
the	O
Ivory	B
-	I
billed	I
Woodpecker	I
model	O
,	O
and	O
images	O
clearly	O
identifiable	O
as	O
Pileated	B
Woodpecker	I
using	O
a	O
model	O
of	O
that	O
species	O
.	O
'	O

Interpretation	O
of	O
model	O
re	O
-	O
enactments	O
is	O
hampered	O
by	O
the	O
fact	O
that	O
the	O
stiff	O
,	O
flat	O
-	O
winged	O
models	O
can	O
not	O
reflect	O
the	O
wing	O
flexion	O
and	O
curvature	O
of	O
real	O
birds	O
.	O

Reenactment	O
of	O
the	O
scene	O
using	O
real	O
Pileated	B
Woodpeckers	I
has	O
produced	O
images	O
remarkably	O
similar	O
to	O
the	O
Luneau	O
video	O
.	O

5	O
.	O
'	O

The	O
wingbeat	O
frequency	O
is	O
8.6	O
beats	O
per	O
second	O
,	O
which	O
is	O
almost	O
identical	O
to	O
that	O
recorded	O
for	O
Ivory	B
-	I
billed	I
Woodpecker	I
(	O
as	O
documented	O
by	O
one	O
acoustic	O
record	O
from	O
1935	O
)	O
.	O

The	O
wing	O
-	O
beat	O
frequencies	O
of	O
Pileated	B
Woodpecker	I
are	O
not	O
known	O
to	O
exceed	O
7.5	O
beats	O
per	O
second	O
,	O
and	O
more	O
typically	O
range	O
between	O
3	O
and	O
6	O
beats	O
per	O
second	O
.	O
'	O

The	O
fact	O
that	O
in	O
only	O
four	O
recorded	O
escape	O
flights	O
of	O
Pileated	B
Woodpecker	I
,	O
two	O
were	O
recorded	O
for	O
which	O
the	O
initial	O
escape	O
flight	O
wingbeat	O
frequency	O
(	O
8.0	O
s-1	O
and	O
8.6	O
s-1	O
)	O
exceeded	O
that	O
previously	O
recorded	O
for	O
this	O
species	O
shows	O
that	O
previous	O
datasets	O
were	O
too	O
limited	O
to	O
make	O
this	O
conclusion	O
.	O

Birds	O
flap	O
more	O
rapidly	O
at	O
take	O
off	O
to	O
gain	O
altitude	O
and	O
speed	O
than	O
they	O
do	O
in	O
sustained	O
level	O
flight	O
:	O
Pileated	B
Woodpecker	I
flight	O
data	O
in	O
the	O
literature	O
[	O
1,4,5	O
]	O
was	O
derived	O
from	O
the	O
work	O
of	O
Tobalske	O
[	O
8	O
]	O
,	O
which	O
explicitly	O
excluded	O
the	O
initial	O
take	O
-	O
off	O
period	O
,	O
and	O
therefore	O
can	O
not	O
be	O
used	O
to	O
support	O
the	O
elimination	O
of	O
Pileated	B
Woodpecker	I
in	O
the	O
Luneau	O
video	O
.	O

Furthermore	O
,	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
is	O
consistently	O
gaining	O
height	O
from	O
a	O
low	O
position	O
above	O
water	O
and	O
,	O
whatever	O
its	O
species	O
,	O
might	O
be	O
expected	O
to	O
flap	O
more	O
rapidly	O
than	O
if	O
it	O
were	O
in	O
level	O
flight	O
.	O

Tanner	O
[	O
9	O
]	O
noted	O
that	O
Pileated	B
Woodpeckers	I
can	O
maintain	O
extended	O
fast	O
direct	O
flight	O
.	O

He	O
was	O
of	O
the	O
opinion	O
that	O
flight	O
pattern	O
was	O
not	O
a	O
useful	O
character	O
for	O
separating	O
the	O
two	O
species	O
in	O
the	O
field	O
,	O
and	O
that	O
Pileated	B
Woodpeckers	I
frequently	O
fly	O
in	O
a	O
manner	O
that	O
was	O
in	O
no	O
way	O
different	O
to	O
Ivory	B
-	I
billed	I
Woodpeckers	I
.	O

The	O
figure	O
of	O
8.6	O
wingbeats	O
per	O
second	O
for	O
the	O
Luneau	O
bird	O
(	O
data	O
reanalysed	O
here	O
)	O
is	O
taken	O
as	O
consistent	O
with	O
Ivory	B
-	I
billed	I
Woodpecker	I
on	O
the	O
basis	O
of	O
analysis	O
of	O
a	O
single	O
archival	O
audio	O
recording	O
[	O
3	O
]	O
.	O

The	O
Ivory	B
-	I
billed	I
Woodpecker	I
in	O
that	O
audio	O
tape	O
is	O
clearly	O
flapping	O
its	O
wings	O
,	O
but	O
without	O
accompanying	O
visual	O
confirmation	O
it	O
is	O
not	O
clear	O
that	O
it	O
is	O
in	O
flight	O
.	O

In	O
general	O
,	O
larger	O
birds	O
are	O
expected	O
to	O
flap	O
their	O
wings	O
more	O
slowly	O
than	O
smaller	O
birds	O
of	O
comparable	O
wing	O
morphology	O
.	O

Tobalske	O
[	O
8	O
]	O
showed	O
that	O
,	O
across	O
species	O
,	O
smaller	O
woodpeckers	O
tend	O
to	O
flap	O
more	O
quickly	O
than	O
larger	O
ones	O
,	O
and	O
that	O
there	O
was	O
considerable	O
intraspecific	O
variation	O
.	O

The	O
assertion	O
that	O
Ivory	B
-	I
billed	I
Woodpeckers	I
flap	O
their	O
wings	O
more	O
quickly	O
than	O
Pileated	B
Woodpeckers	I
is	O
therefore	O
counterintuitive	O
.	O

Further	O
comment	O
is	O
conjecture	O
:	O
while	O
the	O
flight	O
pattern	O
and	O
wing	O
posture	O
of	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
may	O
be	O
unusual	O
,	O
it	O
has	O
not	O
been	O
shown	O
that	O
it	O
is	O
outside	O
the	O
range	O
of	O
variability	O
of	O
Pileated	B
Woodpecker	I
,	O
and	O
can	O
not	O
therefore	O
be	O
used	O
to	O
eliminate	O
the	O
possibility	O
that	O
it	O
was	O
the	O
commoner	O
species	O
.	O

6	O
.	O
'	O

White	O
plumage	O
on	O
the	O
back	O
is	O
visible	O
on	O
the	O
retreating	O
bird	O
as	O
it	O
begins	O
to	O
gain	O
altitude	O
.	O

Ivory	B
-	I
billed	I
Woodpecker	I
has	O
white	O
on	O
the	O
back	O
;	O
Pileated	B
Woodpecker	I
has	O
entirely	O
black	O
back	O
.	O
'	O

This	O
was	O
discussed	O
by	O
Sibley	O
et	O
al	O
[	O
4	O
]	O
,	O
who	O
argued	O
that	O
the	O
images	O
thought	O
to	O
show	O
white	O
on	O
the	O
dorsum	O
were	O
too	O
small	O
to	O
be	O
accepted	O
uncritically	O
.	O

In	O
all	O
the	O
frames	O
of	O
the	O
Luneau	O
video	O
that	O
appear	O
to	O
show	O
white	O
on	O
the	O
dorsum	O
,	O
the	O
bird	O
is	O
distant	O
(	O
dorsal	O
white	O
is	O
not	O
visible	O
on	O
the	O
higher	O
resolution	O
images	O
earlier	O
in	O
the	O
video	O
)	O
and	O
partially	O
obscured	O
,	O
making	O
it	O
difficult	O
to	O
distinguish	O
dorsum	O
from	O
wing	O
.	O

Spurious	O
areas	O
of	O
white	O
pixels	O
appear	O
as	O
artifacts	O
in	O
both	O
videos	O
.	O

Nevertheless	O
,	O
this	O
remains	O
the	O
best	O
evidence	O
that	O
the	O
Luneau	O
bird	O
was	O
not	O
a	O
standard	O
Pileated	B
Woodpecker	I
.	O

7	O
.	O
'	O

The	O
dorsal	O
view	O
of	O
the	O
right	O
wing	O
as	O
it	O
begins	O
to	O
unfold	O
shows	O
a	O
triangle	O
of	O
white	O
that	O
matches	O
in	O
size	O
and	O
position	O
the	O
white	O
on	O
the	O
folded	O
wing	O
of	O
an	O
Ivory	B
-	I
billed	I
Woodpecker	I
beginning	O
to	O
launch	O
into	O
flight	O
.	O
'	O

No	O
further	O
comment	O
is	O
provided	O
here	O
.	O

An	O
alternative	O
explanation	O
was	O
offered	O
by	O
Sibley	O
et	O
al	O
[	O
4	O
]	O
and	O
rebutted	O
by	O
Fitzpatrick	O
et	O
al	O
[	O
5	O
]	O
.	O

The	O
statement	O
requires	O
a	O
degree	O
of	O
certainty	O
about	O
the	O
position	O
of	O
the	O
wing	O
.	O

(	O
8)	O
'	O
The	O
distance	O
between	O
the	O
wrist	O
area	O
and	O
the	O
tip	O
of	O
the	O
tail	O
(	O
32–36	O
cm	O
,	O
as	O
measured	O
when	O
the	O
bird	O
begins	O
to	O
take	O
flight	O
)	O
is	O
comparable	O
to	O
known	O
measurements	O
of	O
Ivory	B
-	I
billed	I
Woodpecker	I
and	O
considerably	O
larger	O
than	O
even	O
the	O
largest	O
Pileated	B
Woodpecker	I
we	O
measured	O
.	O
'	O

As	O
stated	O
under	O
(	O
3	O
)	O
,	O
above	O
,	O
there	O
is	O
general	O
agreement	O
that	O
accurate	O
measurements	O
are	O
not	O
possible	O
from	O
the	O
Luneau	O
video	O
because	O
too	O
many	O
uncontrolled	O
variables	O
are	O
involved	O
[	O
4,5	O
]	O
.	O

9	O
.	O
'	O

Only	O
20	O
seconds	O
before	O
the	O
woodpecker	O
flees	O
,	O
a	O
bird	O
with	O
the	O
size	O
and	O
color	O
pattern	O
of	O
an	O
Ivory	B
-	I
billed	I
Woodpecker	I
was	O
perched	O
within	O
3	O
m	O
of	O
the	O
site	O
from	O
which	O
the	O
woodpecker	O
took	O
flight	O
.	O
'	O

This	O
would	O
be	O
a	O
strong	O
argument	O
if	O
it	O
could	O
be	O
shown	O
that	O
the	O
object	O
in	O
question	O
was	O
a	O
bird	O
and	O
not	O
,	O
as	O
is	O
now	O
apparently	O
thought	O
likely	O
,	O
a	O
section	O
of	O
branch	O
or	O
tree	O
stump	O
[	O
10	O
]	O
.	O

The	O
Luneau	O
video	O
reveals	O
several	O
white	O
triangular	O
patches	O
apparently	O
visible	O
on	O
or	O
around	O
tree	O
trunks	O
,	O
most	O
or	O
all	O
of	O
which	O
must	O
therefore	O
be	O
images	O
of	O
tree	O
topography	O
or	O
video	O
artifacts	O
.	O

This	O
was	O
discussed	O
in	O
the	O
literature	O
(	O
see	O
[	O
4,5	O
]	O
)	O
.	O

Central	O
to	O
the	O
identification	O
of	O
the	O
flying	O
bird	O
seen	O
in	O
the	O
Luneau	O
video	O
was	O
the	O
evidence	O
that	O
plumage	O
and	O
flight	O
patterns	O
were	O
inconsistent	O
with	O
Pileated	B
Woodpecker	I
.	O

A	O
very	O
basic	O
video	O
analysis	O
presented	O
here	O
has	O
suggested	O
that	O
this	O
may	O
not	O
be	O
the	O
case	O
,	O
and	O
that	O
further	O
research	O
is	O
needed	O
.	O

Any	O
identification	O
of	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
as	O
an	O
Ivory	B
-	I
bill	I
must	O
take	O
into	O
account	O
the	O
data	O
presented	O
here	O
and	O
in	O
Sibley	O
et	O
al	O
[	O
4	O
]	O
,	O
which	O
shows	O
it	O
is	O
largely	O
consistent	O
with	O
Pileated	B
Woodpecker	I
and	O
points	O
out	O
apparent	O
inconsistencies	O
with	O
Ivory	B
-	I
billed	I
Woodpecker	I
.	O

This	O
does	O
not	O
of	O
course	O
necessarily	O
imply	O
that	O
the	O
Ivory	B
-	I
billed	I
Woodpecker	I
is	O
extinct	O
,	O
nor	O
indeed	O
entirely	O
rule	O
out	O
the	O
possibility	O
that	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
was	O
one	O
.	O

There	O
appears	O
to	O
be	O
no	O
reason	O
to	O
question	O
the	O
anecdotal	O
sight	O
records	O
of	O
Ivory	B
-	I
billed	I
Woodpecker	I
presented	O
in	O
Fitzpatrick	O
et	O
al	O
[	O
1	O
]	O
(	O
or	O
in	O
many	O
online	O
sources	O
)	O
,	O
because	O
some	O
of	O
them	O
appear	O
credible	O
,	O
albeit	O
brief	O
.	O

Audio	O
evidence	O
has	O
since	O
been	O
published	O
[	O
11	O
]	O
although	O
this	O
too	O
is	O
far	O
from	O
conclusive	O
.	O

However	O
,	O
to	O
regard	O
the	O
Luneau	O
video	O
by	O
itself	O
as	O
presenting	O
anything	O
other	O
than	O
an	O
unidentified	O
woodpecker	O
falls	O
below	O
the	O
standards	O
of	O
proof	O
normally	O
required	O
for	O
scientific	O
publication	O
:	O
the	O
images	O
are	O
not	O
good	O
enough	O
.	O

The	O
Ivory	B
-	I
billed	I
Woodpecker	I
may	O
persist	O
in	O
continental	O
North	O
America	O
,	O
and	O
there	O
is	O
enough	O
anecdotal	O
evidence	O
to	O
make	O
this	O
a	O
possibility	O
,	O
but	O
the	O
Luneau	O
video	O
does	O
not	O
support	O
the	O
case	O
.	O

The	O
balance	O
of	O
evidence	O
would	O
suggest	O
that	O
the	O
bird	O
in	O
the	O
Luneau	O
video	O
is	O
more	O
likely	O
to	O
have	O
been	O
a	O
Pileated	B
Woodpecker	I
,	O
but	O
the	O
search	O
for	O
Ivory	B
-	I
billed	I
Woodpecker	I
should	O
continue	O
.	O

While	O
this	O
paper	O
was	O
under	O
review	O
,	O
a	O
report	O
of	O
sight	O
records	O
and	O
sound	O
recordings	O
of	O
Ivory	B
-	I
billed	I
Woodpeckers	I
was	O
published	O
from	O
a	O
location	O
in	O
Florida	O
[	O
12	O
]	O
.	O

This	O
very	O
exciting	O
claim	O
is	O
strengthened	O
by	O
reports	O
of	O
sighting	O
of	O
the	O
white	O
dorsal	O
stripes	O
on	O
one	O
bird	O
in	O
flight	O
.	O

Unfortunately	O
,	O
several	O
sightings	O
were	O
made	O
without	O
optical	O
aids	O
and	O
can	O
not	O
be	O
considered	O
proven	O
.	O

The	O
'	O
kent	O
'	O
calls	O
recorded	O
from	O
the	O
Florida	O
location	O
are	O
spectrographically	O
similar	O
to	O
the	O
'	O
bleat	O
'	O
calls	O
of	O
young	O
White	B
-	I
tailed	I
Deer	I
,	O
as	O
described	O
in	O
Richardson	O
et	O
al	O
[	O
13	O
]	O
.	O

A	O
clear	O
photograph	O
will	O
be	O
required	O
from	O
this	O
location	O
too	O
before	O
the	O
presence	O
of	O
Ivory	B
-	I
billed	I
Woodpeckers	I
can	O
be	O
considered	O
confirmed	O
.	O

It	O
is	O
hoped	O
that	O
this	O
paper	O
will	O
help	O
with	O
assessment	O
of	O
any	O
further	O
low	O
quality	O
photographs	O
or	O
videos	O
.	O

Conclusion	O
Flight	O
and	O
plumage	O
patterns	O
of	O
the	O
putative	O
Ivory	B
-	I
billed	I
Woodpecker	I
recorded	O
in	O
Arkansas	O
in	O
2005	O
are	O
recapitulated	O
by	O
confirmed	O
Pileated	B
Woodpeckers	I
.	O

The	O
bird	O
in	O
the	O
Arkansas	O
video	O
is	O
best	O
regarded	O
as	O
not	O
fully	O
identified	O
,	O
and	O
is	O
probably	O
a	O
Pileated	B
Woodpecker	I
.	O

Methods	O
Video	O
recording	O
Pileated	B
Woodpeckers	I
were	O
attracted	O
to	O
a	O
bird	O
feeder	O
containing	O
suet	O
at	O
Grants	O
Trail	O
,	O
Dayton	O
,	O
OH	O
45459	O
.	O

The	O
suet	O
feeder	O
was	O
placed	O
approximately	O
2.1	O
m	O
high	O
on	O
a	O
tree	O
trunk	O
,	O
and	O
the	O
distance	O
to	O
the	O
suet	O
feeder	O
from	O
the	O
observation	O
point	O
was	O
approximately	O
5	O
m.	O
Birds	O
on	O
the	O
feeder	O
were	O
startled	O
by	O
movement	O
of	O
window	O
blinds	O
on	O
January	O
28	O
and	O
February	O
5	O
,	O
2006	O
,	O
and	O
their	O
escape	O
flights	O
were	O
filmed	O
using	O
a	O
Sony	O
Hi-8	O
SteadyShot	O
video	O
camera	O
at	O
29.97	O
frames	O
s-1	O
.	O

At	O
least	O
two	O
birds	O
feature	O
in	O
the	O
videos	O
,	O
male	O
and	O
female	O
.	O

Analogue	O
tape	O
was	O
converted	O
to	O
digital	O
by	O
connecting	O
the	O
Hi-8	O
camera	O
directly	O
to	O
a	O
Sony	O
DCR	O
-	O
HC30	O
digital	O
video	O
camera	O
and	O
recording	O
onto	O
that	O
camera	O
's	O
mini	O
dv	O
cassette	O
.	O

The	O
resulting	O
images	O
were	O
converted	O
to	O
an	O
avi	O
file	O
using	O
Windows	O
Movie	O
Maker	O
on	O
a	O
Windows	O
XP	O
PC	O
.	O

The	O
video	O
is	O
freely	O
available	O
in	O
wmv	O
format	O
[	O
14	O
]	O
and	O
in	O
avi	O
format	O
from	O
the	O
author	O
or	O
David	O
Nolin	O
(	O
via	O
the	O
author	O
)	O
.	O

The	O
video	O
was	O
decompiled	O
using	O
Blaze	O
Media	O
Pro	O
(	O
Mystik	O
Media	O
,	O
Hampstead	O
,	O
NC	O
,	O
USA	O
)	O
for	O
a	O
detailed	O
analysis	O
.	O

Import	O
into	O
Avid	O
®	O
Xpress	O
Pro	O
HD	O
for	O
deinterlacing	O
did	O
not	O
reduce	O
the	O
wing	O
flicker	O
seen	O
in	O
the	O
images	O
,	O
and	O
further	O
professional	O
processing	O
could	O
not	O
improve	O
the	O
resolution	O
,	O
so	O
the	O
original	O
decompiled	O
file	O
was	O
used	O
for	O
analysis	O
.	O

Hence	O
some	O
frames	O
contain	O
two	O
overlaid	O
images	O
,	O
which	O
may	O
lower	O
the	O
resolution	O
in	O
some	O
cases	O
.	O

The	O
decompiled	O
file	O
was	O
examined	O
frame	O
by	O
frame	O
and	O
compared	O
to	O
the	O
decompiled	O
images	O
of	O
the	O
putative	O
Ivory	B
-	I
billed	I
Woodpecker	I
presented	O
in	O
Fitzpatrick	O
et	O
al	O
[	O
1	O
]	O
.	O

Wingbeat	O
frequencies	O
were	O
calculated	O
by	O
noting	O
the	O
frame	O
number	O
of	O
the	O
midpoint	O
of	O
the	O
downstroke	O
of	O
each	O
wingbeat	O
(	O
e.g.	O
Figure	O
1B	O
,	O
frame	O
758	O
)	O
and	O
calculating	O
the	O
length	O
of	O
time	O
taken	O
per	O
wingbeat	O
as	O
(	O
number	O
of	O
frames	O
between	O
downstroke	O
midpoints	O
)	O
/	O
29.97	O
.	O

Authors	O
'	O
contributions	O
JMC	O
performed	O
the	O
data	O
analysis	O
and	O
drafted	O
the	O
manuscript	O
.	O

Supplementary	O
Material	O

Estrogen	O
receptor	O
alpha	O
(	O
ERα	O
)	O
mRNA	O
copy	O
numbers	O
in	O
immunohistochemically	O
ERα	O
-	O
positive-	O
,	O
and	O
negative	O
breast	O
cancer	O
tissues	O
Abstract	O
Background	O
The	O
presence	O
of	O
ERα	O
is	O
the	O
basis	O
for	O
treating	O
breast	O
cancer	O
patients	O
with	O
targeted	O
molecular	O
therapies	O
that	O
block	O
estrogen	O
stimulation	O
of	O
breast	O
cancer	O
cell	O
division	O
.	O

To	O
select	O
patients	O
for	O
the	O
above	O
therapies	O
,	O
currently	O
,	O
the	O
ERα	O
presence	O
in	O
breast	O
cancer	O
tissues	O
is	O
determined	O
in	O
clinical	O
laboratories	O
by	O
microscopically	O
scoring	O
the	O
slides	O
subjected	O
to	O
immunohistochemistry	O
(	O
IHC	O
)	O
.	O

This	O
method	O
is	O
not	O
quantitative	O
,	O
highly	O
subjective	O
and	O
requires	O
large	O
amount	O
of	O
tumor	O
tissue	O
,	O
therefore	O
,	O
can	O
not	O
be	O
applied	O
to	O
sterotactic	O
and	O
ultrasound	O
guided	O
biopsy	O
samples	O
.	O

To	O
circumvent	O
these	O
problems	O
,	O
we	O
previously	O
developed	O
quantitative	O
real	O
-	O
time	O
PCR	O
based	O
molecular	O
assay	O
that	O
can	O
be	O
applied	O
to	O
determine	O
mRNA	O
copies	O
of	O
ERα	O
in	O
picogram	O
amounts	O
of	O
total	O
RNA	O
from	O
tumor	O
samples	O
.	O

However	O
,	O
it	O
is	O
not	O
known	O
how	O
the	O
mRNA	O
copy	O
numbers	O
correlate	O
to	O
IHC	O
positive	O
and	O
negative	O
status	O
.	O

Methods	O
In	O
the	O
current	O
study	O
we	O
determined	O
the	O
copy	O
numbers	O
of	O
ERα	O
mRNA	O
by	O
Q	O
RTPCR	O
in	O
breast	O
cancer	O
tissues	O
that	O
were	O
graded	O
as	O
ERα	O
-	O
positive	O
and	O
negative	O
by	O
1	O
)	O
IHC	O
and	O
2	O
)	O
functional	O
estrogen	O
binding	O
assay	O
and	O
statistically	O
analyzed	O
the	O
data	O
.	O

Results	O
We	O
demonstrate	O
here	O
that	O
ERα	O
mRNA	O
copy	O
numbers	O
are	O
not	O
significantly	O
different	O
in	O
tissues	O
that	O
are	O
graded	O
as	O
positive	O
by	O
IHC	O
and	O
ligand	O
binding	O
assays	O
.	O

We	O
establish	O
here	O
a	O
cut	O
of	O
value	O
of	O
5	O
×	O
106	O
copies	O
per	O
1010	O
mRNA	O
copies	O
of	O
GAPDH	O
with	O
an	O
Odds	O
Radio	O
of	O
39.4	O
,	O
Sensitivity	O
of	O
0.81	O
and	O
Specificity	O
of	O
0.90	O
in	O
breast	O
cancer	O
tissues	O
that	O
are	O
negative	O
for	O
ERα	O
protein	O
by	O
IHC	O
and	O
estrogen	O
binding	O
assays	O
.	O

ROC	O
analysis	O
of	O
the	O
data	O
gave	O
an	O
area	O
of	O
0.8967	O
under	O
the	O
curve	O
.	O

Conclusion	O
We	O
expect	O
that	O
the	O
cut	O
off	O
values	O
determined	O
here	O
will	O
be	O
highly	O
significant	O
for	O
applying	O
molecular	O
assay	O
in	O
the	O
place	O
of	O
IHC	O
in	O
clinical	O
laboratories	O
for	O
evaluating	O
the	O
presence	O
of	O
ERα	O
for	O
prognostic	O
and	O
therapeutic	O
purposes	O
.	O

Background	O
Breast	O
cancer	O
is	O
the	O
most	O
diagnosed	O
and	O
the	O
second	O
leading	O
cause	O
of	O
cancer	O
deaths	O
for	O
women	O
in	O
the	O
United	O
States	O
striking	O
about	O
300,000	O
and	O
killing	O
about	O
40,000	O
women	O
a	O
year	O
[	O
1	O
]	O
.	O

A	O
substantial	O
body	O
of	O
epidemiological	O
,	O
experimental	O
and	O
clinical	O
evidence	O
indicated	O
that	O
unopposed	O
stimulation	O
of	O
breast	O
epithelial	O
cells	O
by	O
the	O
natural	O
hormone	O
,	O
estrogen	O
,	O
plays	O
a	O
major	O
role	O
in	O
the	O
progression	O
of	O
breast	O
cancers	O
[	O
2	O
]	O
.	O

Because	O
endogenous	O
estrogens	O
directly	O
promote	O
the	O
growth	O
of	O
breast	O
cancer	O
cells	O
,	O
estrogen	O
deprivation	O
either	O
by	O
inhibiting	O
its	O
biosynthesis	O
(	O
aromatase	O
inhibitors	O
)	O
or	O
blocking	O
estrogen	O
-	O
mediated	O
gene	O
transcription	O
(	O
tamoxifen	O
)	O
through	O
its	O
high	O
affinity	O
receptor	O
,	O
the	O
estrogen	O
receptor	O
alpha	O
(	O
ERα	O
)	O
,	O
are	O
the	O
primary	O
lines	O
of	O
therapy	O
for	O
breast	O
cancer	O
patients	O
.	O

In	O
most	O
cases	O
,	O
the	O
efficacy	O
of	O
the	O
above	O
treatments	O
has	O
correlated	O
with	O
the	O
presence	O
of	O
ERα	O
in	O
the	O
tumor	O
tissues	O
.	O

Currently	O
,	O
only	O
those	O
patients	O
who	O
express	O
ERα	O
in	O
their	O
tumors	O
are	O
chosen	O
for	O
aromatase	O
inhibitor	O
or	O
tamoxifen	O
therapies	O
.	O

In	O
addition	O
to	O
being	O
a	O
therapeutic	O
target	O
,	O
ERα	O
was	O
also	O
shown	O
to	O
be	O
the	O
most	O
important	O
factor	O
to	O
predict	O
breast	O
cancer	O
prognosis	O
.	O

The	O
patients	O
who	O
express	O
ERα	O
in	O
their	O
tumors	O
have	O
an	O
overall	O
longer	O
cancer	O
-	O
free	O
survival	O
and	O
lower	O
recurrence	O
rates	O
than	O
patients	O
who	O
do	O
not	O
express	O
this	O
receptor	O
[	O
3	O
]	O
.	O

To	O
predict	O
prognosis	O
and	O
identify	O
patients	O
for	O
the	O
above	O
two	O
anti	O
-	O
estrogen	O
therapies	O
,	O
every	O
breast	O
cancer	O
tissue	O
is	O
currently	O
screened	O
for	O
the	O
presence	O
of	O
ERα	O
before	O
a	O
treatment	O
regimen	O
is	O
selected	O
for	O
any	O
breast	O
cancer	O
patient	O
.	O

The	O
presence	O
of	O
ERα	O
in	O
breast	O
tumors	O
was	O
originally	O
determined	O
in	O
clinical	O
labs	O
by	O
estrogen	O
binding	O
assay	O
for	O
about	O
20	O
years	O
.	O

However	O
,	O
when	O
the	O
tumors	O
were	O
detected	O
at	O
comparatively	O
smaller	O
sizes	O
and	O
highly	O
specific	O
monoclonal	O
antibodies	O
were	O
developed	O
that	O
could	O
detect	O
ERα	O
both	O
in	O
the	O
fresh	O
frozen	O
as	O
well	O
as	O
formalin	O
fixed	O
paraffin	O
-	O
embedded	O
tissues	O
,	O
the	O
clinical	O
labs	O
switched	O
to	O
immunohistochemistry	O
(	O
IHC	O
)	O
from	O
estrogen	O
binding	O
assay	O
for	O
determining	O
the	O
presence	O
of	O
ERα	O
.	O

Currently	O
ERα	O
is	O
determined	O
in	O
the	O
clinical	O
laboratories	O
from	O
rough	O
estimates	O
yielded	O
by	O
microscopically	O
scoring	O
the	O
slides	O
subjected	O
to	O
IHC	O
technique	O
using	O
antibodies	O
against	O
the	O
N	O
-	O
terminal	O
A	O
/	O
B	O
region	O
of	O
ERα	O
.	O

Although	O
this	O
procedure	O
is	O
used	O
for	O
over	O
ten	O
years	O
,	O
it	O
has	O
several	O
limitations	O
including	O
not	O
quantitative	O
,	O
highly	O
subjective	O
,	O
variations	O
due	O
to	O
antibody	O
preparations	O
,	O
variations	O
from	O
one	O
clinical	O
lab	O
to	O
other	O
and	O
comparatively	O
large	O
sample	O
size	O
requirement	O
.	O

In	O
recent	O
times	O
,	O
due	O
to	O
increased	O
awareness	O
and	O
substantially	O
improved	O
screening	O
methods	O
,	O
breast	O
cancers	O
are	O
detected	O
at	O
very	O
early	O
stages	O
and	O
excised	O
,	O
in	O
a	O
large	O
majority	O
of	O
cases	O
,	O
by	O
stereotactic	O
and	O
ultrasound	O
guided	O
techniques	O
.	O

In	O
these	O
cases	O
the	O
limited	O
amount	O
of	O
tumor	O
tissue	O
that	O
remains	O
after	O
histological	O
testing	O
restricts	O
determining	O
ERα	O
status	O
for	O
prognostic	O
and	O
therapeutic	O
purposes	O
by	O
IHC	O
.	O

In	O
many	O
cases	O
,	O
ERα	O
status	O
is	O
not	O
determined	O
due	O
to	O
insufficient	O
amount	O
of	O
tumor	O
tissue	O
.	O

For	O
these	O
reasons	O
there	O
is	O
an	O
urgent	O
need	O
to	O
switch	O
to	O
a	O
procedure	O
that	O
can	O
detect	O
ERα	O
in	O
a	O
very	O
small	O
amount	O
of	O
tumor	O
tissue	O
obtained	O
by	O
the	O
above	O
methods	O
.	O

There	O
is	O
a	O
general	O
consensus	O
that	O
ERα	O
mRNA	O
quantification	O
is	O
a	O
more	O
suited	O
technique	O
for	O
detecting	O
its	O
presence	O
in	O
tumor	O
tissues	O
.	O

Several	O
PCR	O
based	O
approaches	O
have	O
been	O
described	O
for	O
detecting	O
the	O
presence	O
of	O
ERα	O
in	O
breast	O
cancer	O
tissues	O
[	O
4,5	O
]	O
.	O

We	O
recently	O
developed	O
a	O
highly	O
sensitive	O
real	O
-	O
time	O
PCR	O
based	O
quantitative	O
molecular	O
assay	O
that	O
can	O
detect	O
and	O
quantify	O
as	O
low	O
as	O
50–100	O
copies	O
of	O
ERα	O
mRNA	O
from	O
as	O
small	O
as	O
40	O
picograms	O
of	O
total	O
RNA	O
from	O
breast	O
cancer	O
tissues	O
.	O

Because	O
quantitative	O
real	O
-	O
time	O
PCR	O
is	O
a	O
high	O
through	O
-	O
put	O
method	O
,	O
it	O
could	O
be	O
automated	O
to	O
apply	O
in	O
clinical	O
laboratories	O
.	O

However	O
,	O
it	O
is	O
not	O
known	O
how	O
the	O
ERα	O
mRNA	O
copy	O
numbers	O
correlate	O
to	O
ERα	O
positivity	O
and	O
negativity	O
by	O
IHC	O
assay	O
.	O

Establishing	O
a	O
cut	O
off	O
value	O
in	O
IHC	O
negative	O
tissues	O
is	O
required	O
for	O
the	O
application	O
of	O
molecular	O
assay	O
in	O
the	O
place	O
of	O
IHC	O
assay	O
.	O

To	O
determine	O
the	O
cut	O
off	O
value	O
,	O
we	O
have	O
profiled	O
ERα	O
mRNA	O
copy	O
numbers	O
in	O
breast	O
cancer	O
tissues	O
which	O
have	O
been	O
graded	O
as	O
ERα	O
positive	O
and	O
negative	O
by	O
IHC	O
and	O
estrogen	O
binding	O
assays	O
.	O

We	O
demonstrate	O
here	O
that	O
ERα	O
mRNA	O
copy	O
numbers	O
are	O
not	O
significantly	O
different	O
in	O
tissues	O
that	O
were	O
graded	O
as	O
positive	O
by	O
IHC	O
and	O
ligand	O
binding	O
assays	O
.	O

However	O
,	O
ERα	O
positive	O
tissues	O
,	O
either	O
by	O
IHC	O
or	O
estrogen	O
binding	O
assays	O
,	O
express	O
significantly	O
higher	O
mRNA	O
copy	O
numbers	O
than	O
the	O
negative	O
tissues	O
.	O

We	O
have	O
determined	O
the	O
cut	O
off	O
values	O
of	O
ERα	O
mRNA	O
copy	O
numbers	O
by	O
molecular	O
assay	O
that	O
correlate	O
to	O
ERα	O
negativity	O
by	O
both	O
IHC	O
and	O
ligand	O
binding	O
assays	O
using	O
CART	O
program	O
(	O
Classification	O
And	O
Regression	O
Tree	O
)	O
.	O

We	O
expect	O
that	O
the	O
cut	O
off	O
values	O
determined	O
here	O
will	O
be	O
highly	O
significant	O
for	O
applying	O
molecular	O
assay	O
in	O
the	O
place	O
of	O
IHC	O
in	O
clinical	O
laboratories	O
for	O
determining	O
the	O
ERα	O
status	O
for	O
prognostic	O
and	O
therapeutic	O
purposes	O
.	O

Methods	O
All	O
the	O
primers	O
used	O
in	O
the	O
current	O
study	O
were	O
synthesized	O
by	O
Gibco	O
-	O
BRL	O
Life	O
Technologies	O
.	O

TaqMan	O
Universal	O
PCR	O
Master	O
Mix	O
(	O
Cat	O
#	O
4304437	O
)	O
was	O
from	O
Applied	O
Biosystems	O
.	O

5'FAM	O
and	O
3'TAMARA	O
labeled	O
oligonucleotide	O
probes	O
were	O
synthesized	O
by	O
Applied	O
Biosystems	O
and	O
available	O
from	O
previous	O
studies	O
.	O

PCR	O
quality	O
water	O
and	O
Tris	O
-	O
EDTA	O
buffer	O
were	O
from	O
BioWhittaker	O
.	O

Breast	O
tumor	O
samples	O
Breast	O
cancer	O
tissues	O
with	O
known	O
ERα	O
status	O
by	O
IHC	O
and	O
ligand	O
binding	O
assay	O
were	O
available	O
from	O
previous	O
studies	O
[	O
6	O
-	O
9	O
]	O
.	O

Briefly	O
,	O
the	O
tumor	O
samples	O
were	O
collected	O
from	O
either	O
biopsy	O
or	O
mastectomies	O
immediately	O
after	O
surgery	O
and	O
stored	O
at	O
-80	O
°	O
C	O
until	O
use	O
.	O

Fresh	O
tumor	O
tissue	O
samples	O
for	O
ERα	O
quantification	O
were	O
routinely	O
harvested	O
immediately	O
adjacent	O
to	O
the	O
histologic	O
/	O
diagnostic	O
sections	O
and	O
considered	O
to	O
be	O
representative	O
of	O
the	O
tissue	O
used	O
for	O
diagnosis	O
.	O

All	O
the	O
samples	O
were	O
examined	O
by	O
a	O
pathologist	O
and	O
tissues	O
containing	O
>	O
80	O
%	O
cancer	O
cells	O
were	O
excised	O
and	O
used	O
for	O
ERα	O
mRNA	O
quantification	O
.	O

The	O
ERα	O
-	O
status	O
for	O
the	O
samples	O
used	O
in	O
this	O
study	O
was	O
determined	O
either	O
by	O
IHC	O
using	O
monoclonal	O
antibodies	O
against	O
NH2-terminal	O
portion	O
of	O
the	O
molecule	O
at	O
Oncotech	O
Laboratories	O
,	O
Irwine	O
,	O
CA	O
,	O
or	O
by	O
ligand	O
binding	O
assay	O
as	O
described	O
[	O
10	O
]	O
.	O

The	O
tumor	O
tissues	O
were	O
considered	O
positive	O
for	O
ERα	O
by	O
IHC	O
if	O
>	O
5	O
%	O
of	O
cancer	O
cells	O
showed	O
positive	O
nuclear	O
staining	O
.	O

The	O
tumor	O
tissues	O
that	O
were	O
diagnosed	O
as	O
ERα	O
positive	O
by	O
estrogen	O
binding	O
assay	O
had	O
>	O
3	O
fmol	O
of	O
ER	O
/	O
mg	O
of	O
total	O
tissue	O
extract	O
.	O

A	O
total	O
of	O
70	O
samples	O
positive	O
by	O
IHC	O
,	O
33	O
positive	O
by	O
estrogen	O
binding	O
assay	O
,	O
43	O
negative	O
by	O
IHC	O
and	O
20	O
negative	O
by	O
estrogen	O
binding	O
assay	O
were	O
included	O
in	O
the	O
current	O
study	O
(	O
Tables	O
1	O
,	O
2	O
,	O
3	O
and	O
4	O
respectively	O
)	O
.	O

The	O
tumor	O
tissues	O
were	O
processed	O
to	O
isolate	O
total	O
RNA	O
and	O
cDNAs	O
prepared	O
as	O
previously	O
described	O
[	O
6	O
-	O
9	O
]	O
.	O

Howard	O
University	O
Institutional	O
Review	O
Board	O
granted	O
the	O
ethical	O
approval	O
of	O
Tumor	O
collection	O
procedures	O
for	O
the	O
study	O
.	O

Absolute	O
quantification	O
of	O
ERα	O
mRNA	O
copy	O
numbers	O
by	O
quantitative	O
real	O
-	O
time	O
PCR	O
Absolute	O
quantification	O
of	O
ERα	O
transcript	O
copy	O
numbers	O
was	O
achieved	O
by	O
quantitative	O
real	O
-	O
time	O
PCR	O
in	O
ABI	O
Prism	O
GeneAmp	O
7900	O
HT	O
Sequence	O
Detection	O
System	O
as	O
described	O
previously	O
(	O
9	O
)	O
.	O

Briefly	O
,	O
a	O
typical	O
real	O
-	O
time	O
PCR	O
reaction	O
mixture	O
contained	O
cDNA	O
prepared	O
from	O
reverse	O
transcription	O
of	O
0.5	O
–	O
5	O
nanograms	O
of	O
tumor	O
tissue	O
total	O
RNA	O
,	O
0.04	O
micromolar	O
each	O
of	O
sense	O
and	O
anti	O
-	O
sense	O
primers	O
,	O
0.05	O
micromolar	O
5'FAM	O
and	O
3'TAMARA	O
labeled	O
oligonucleotide	O
probe	O
and	O
1	O
×	O
Taqman	O
Universal	O
PCR	O
Mix	O
in	O
a	O
total	O
volume	O
of	O
25	O
μl	O
.	O

PCR	O
conditions	O
were	O
initial	O
hold	O
at	O
50	O
°	O
C	O
for	O
two	O
minutes	O
,	O
followed	O
by	O
denaturation	O
for	O
ten	O
minutes	O
at	O
95	O
°	O
C	O
,	O
and	O
denaturation	O
for	O
15	O
seconds	O
at	O
95	O
°	O
C	O
in	O
the	O
subsequent	O
cycles	O
and	O
annealing	O
and	O
extension	O
for	O
1	O
min	O
at	O
60	O
°	O
C	O
for	O
40	O
cycles	O
.	O

The	O
ERα	O
mRNA	O
copy	O
numbers	O
in	O
tumor	O
tissues	O
were	O
determined	O
in	O
comparison	O
with	O
a	O
standard	O
graph	O
constructed	O
simultaneously	O
using	O
102	O
,	O
103	O
,	O
104	O
,	O
105	O
,	O
106	O
,	O
107	O
,	O
108	O
,	O
and	O
109	O
copies	O
of	O
reverse	O
transcribed	O
cRNA	O
of	O
ERα	O
.	O

All	O
the	O
samples	O
were	O
amplified	O
in	O
triplicate	O
and	O
real	O
-	O
time	O
PCRs	O
were	O
repeated	O
four	O
times	O
.	O

The	O
ERα	O
mRNA	O
copy	O
numbers	O
in	O
tumor	O
tissues	O
were	O
normalized	O
to	O
mRNA	O
copy	O
numbers	O
of	O
the	O
house	O
keeping	O
gene	O
,	O
glyceraldehyde	O
3-	O
phosphate	O
dehydrogenase	O
(	O
GAPDH	O
)	O
.	O

GAPDH	O
copy	O
numbers	O
were	O
determined	O
as	O
previously	O
described	O
[	O
11,12	O
]	O
.	O

The	O
sense	O
,	O
and	O
anti	O
-	O
sense	O
primers	O
and	O
probe	O
for	O
quantifying	O
the	O
mRNA	O
copy	O
numbers	O
of	O
ERα	O
were	O
5	O
'	O
caagcccgctcatgatcaa	O
3	O
'	O
(	O
position	O
,	O
exon	O
4	O
,	O
bp	O
1110–1128	O
)	O
,	O
5'ctgatcatggagggtcaaatccac3	O
'	O
(	O
position	O
,	O
exon	O
5	O
,	O
bp	O
1358–1338	O
)	O
and	O
FAM	O
5'agaacagcctggccttgtccctg3'TAMARA	O
(	O
position	O
,	O
exon	O
4	O
,	O
bp	O
1140–1162	O
)	O
respectively	O
.	O

The	O
sense	O
and	O
anti	O
-	O
sense	O
primers	O
and	O
probe	O
for	O
quantifying	O
GAPDH	O
mRNA	O
copy	O
numbers	O
were	O
5'ttccagg	O
agcgag	O
atccct3	O
'	O
(	O
position	O
,	O
bp	O
304–322	O
)	O
,	O
5'ggctgttgtcatacttctcatgg3	O
'	O
(	O
position	O
,	O
bp	O
483–505	O
)	O
and	O
FAM	O
5	O
'	O
tgctggcgctgagtacgtcgtg3	O
'	O
TAMARA	O
(	O
position	O
,	O
bp	O
342–363	O
)	O
respectively	O
.	O

Primer	O
positions	O
of	O
ERα	O
and	O
GAPDH	O
nucleotide	O
sequences	O
were	O
as	O
described	O
[	O
13,14	O
]	O
.	O

Statistical	O
analysis	O
Wilcoxon	O
-	O
rank	O
-	O
sum	O
test	O
and	O
standard	O
two	O
-	O
sample	O
t	O
-	O
test	O
were	O
used	O
to	O
determine	O
whether	O
the	O
mRNA	O
copy	O
numbers	O
were	O
significantly	O
different	O
in	O
breast	O
cancer	O
tissues	O
that	O
were	O
1	O
)	O
ERα	O
-	O
positive	O
and	O
ERα	O
-	O
negative	O
by	O
IHC	O
,	O
2	O
)	O
ERα	O
-	O
positive	O
and	O
ERα	O
-	O
negative	O
by	O
estrogen	O
binding	O
assays	O
,	O
3	O
)	O
ERα	O
positive	O
by	O
IHC	O
and	O
estrogen	O
binding	O
assays	O
,	O
and	O
4	O
)	O
ERα	O
-	O
negative	O
by	O
IHC	O
and	O
estrogen	O
binding	O
assays	O
.	O

Test	O
results	O
were	O
considered	O
significant	O
if	O
P	O
≤	O
0	O
.	O
05	O
.	O

To	O
determine	O
the	O
cut	O
-	O
off	O
value	O
/	O
maximum	O
level	O
of	O
mRNA	O
copy	O
numbers	O
in	O
the	O
samples	O
which	O
were	O
negative	O
by	O
IHC	O
and	O
estrogen	O
binding	O
assays	O
,	O
we	O
used	O
CART	O
(	O
Classification	O
Regression	O
Tree	O
)	O
[	O
15,16	O
]	O
program	O
.	O

The	O
data	O
consisting	O
of	O
103	O
ERα	O
positive	O
and	O
63	O
ERα	O
negative	O
samples	O
which	O
had	O
a	O
predictive	O
variable	O
,	O
mRNA	O
copy	O
numbers	O
,	O
were	O
partitioned	O
into	O
two	O
groups	O
using	O
CART	O
program	O
.	O

This	O
program	O
determines	O
the	O
best	O
cut	O
-	O
off	O
value	O
copy	O
numbers	O
in	O
the	O
sense	O
that	O
the	O
OR	O
(	O
Odds	O
Ratio	O
,	O
ERα	O
positive	O
to	O
ERα	O
negative	O
in	O
our	O
case	O
)	O
of	O
the	O
two	O
groups	O
(	O
with	O
copy	O
number	O
greater	O
than	O
the	O
cut	O
-	O
off	O
value	O
in	O
one	O
group	O
and	O
less	O
or	O
equal	O
to	O
the	O
cut	O
-	O
off	O
value	O
in	O
the	O
other	O
)	O
is	O
maximized	O
.	O

Receiver	O
Operating	O
Characteristic	O
(	O
ROC	O
)	O
analysis	O
was	O
performed	O
to	O
determine	O
the	O
sensitivity	O
and	O
specificity	O
of	O
the	O
RNA	O
based	O
molecular	O
assay	O
.	O

The	O
ROC	O
curves	O
were	O
generated	O
by	O
connecting	O
all	O
the	O
points	O
determined	O
by	O
the	O
copy	O
numbers	O
in	O
all	O
the	O
samples	O
in	O
an	O
increasing	O
order	O
.	O

Since	O
data	O
on	O
IHC	O
grading	O
as	O
percent	O
positive	O
cells	O
were	O
available	O
on	O
some	O
of	O
the	O
samples	O
,	O
the	O
correlation	O
between	O
the	O
IHC	O
grading	O
and	O
the	O
mRNA	O
copy	O
number	O
was	O
determined	O
both	O
in	O
the	O
original	O
scale	O
and	O
in	O
logarithmic	O
transformations	O
scale	O
using	O
S	O
-	O
PLUS	O
software	O
.	O

Results	O
We	O
have	O
undertaken	O
the	O
current	O
study	O
to	O
determine	O
ERα	O
mRNA	O
copy	O
numbers	O
in	O
breast	O
cancer	O
tissues	O
that	O
were	O
positive	O
and	O
negative	O
by	O
two	O
conventional	O
methods	O
of	O
assaying	O
ERα	O
protein	O
,	O
IHC	O
and	O
estrogen	O
binding	O
.	O

The	O
rational	O
for	O
undertaking	O
this	O
study	O
is	O
that	O
once	O
we	O
establish	O
a	O
threshold	O
value	O
in	O
IHC	O
negative	O
tissues	O
,	O
then	O
the	O
molecular	O
assay	O
could	O
be	O
applied	O
in	O
clinical	O
laboratories	O
in	O
the	O
place	O
of	O
currently	O
used	O
IHC	O
assay	O
for	O
determining	O
the	O
status	O
of	O
ERα	O
for	O
prognostic	O
and	O
therapeutic	O
purposes	O
.	O

Our	O
rational	O
for	O
establishing	O
a	O
cut	O
off	O
value	O
is	O
that	O
any	O
patient	O
who	O
expresses	O
above	O
the	O
cut	O
off	O
level	O
could	O
be	O
selected	O
as	O
a	O
candidate	O
for	O
anti	O
-	O
estrogen	O
therapies	O
and	O
could	O
be	O
considered	O
to	O
have	O
good	O
prognosis	O
.	O

We	O
first	O
profiled	O
ERα	O
mRNA	O
copy	O
numbers	O
in	O
70	O
samples	O
positive	O
by	O
IHC	O
,	O
43	O
negative	O
by	O
IHC	O
,	O
33	O
positive	O
by	O
estrogen	O
binding	O
assay	O
and	O
20	O
negative	O
by	O
estrogen	O
binding	O
assay	O
.	O

The	O
data	O
are	O
presented	O
in	O
Tables	O
1	O
,	O
3	O
,	O
2	O
and	O
4	O
respectively	O
.	O

A	O
box	O
plot	O
drawn	O
for	O
the	O
copy	O
numbers	O
(	O
logarithm	O
base	O
2	O
scale	O
)	O
in	O
the	O
four	O
groups	O
(	O
positive	O
and	O
negative	O
by	O
IHC	O
and	O
by	O
estrogen	O
binding	O
assay	O
)	O
using	O
S	O
-	O
PLUS	O
software	O
is	O
shown	O
in	O
Figure	O
1	O
.	O

We	O
next	O
compared	O
the	O
quantitative	O
data	O
on	O
mRNA	O
copy	O
numbers	O
among	O
samples	O
as	O
described	O
below	O
.	O

1	O
)	O
We	O
tested	O
whether	O
the	O
two	O
conventional	O
assays	O
,	O
the	O
IHC	O
and	O
estrogen	O
binding	O
assays	O
,	O
correlate	O
in	O
terms	O
of	O
mRNA	O
copy	O
numbers	O
in	O
70	O
and	O
33	O
positive	O
tissues	O
(	O
Tables	O
1	O
and	O
2	O
respectively	O
)	O
using	O
Wilcoxon	O
-	O
rank	O
-	O
sum	O
test	O
and	O
standard	O
two	O
-	O
sample	O
t	O
-	O
tests	O
.	O

By	O
these	O
two	O
tests	O
,	O
we	O
did	O
not	O
find	O
significant	O
differences	O
in	O
the	O
ERα	O
mRNA	O
copy	O
numbers	O
in	O
samples	O
that	O
were	O
ERα	O
positive	O
by	O
IHC	O
and	O
estrogen	O
binding	O
assays	O
(	O
p	O
>	O
0.28	O
by	O
both	O
tests	O
)	O
.	O

2	O
)	O
We	O
also	O
compared	O
the	O
mRNA	O
copy	O
numbers	O
in	O
43	O
samples	O
negative	O
by	O
IHC	O
with	O
20	O
samples	O
negative	O
by	O
estrogen	O
binding	O
assay	O
and	O
did	O
not	O
find	O
significant	O
differences	O
(	O
Tables	O
3	O
and	O
4	O
respectively	O
)	O
(	O
p	O
>	O
0.25	O
by	O
the	O
above	O
two	O
tests	O
)	O
.	O

However	O
,	O
3	O
)	O
we	O
found	O
significant	O
differences	O
in	O
mRNA	O
copy	O
numbers	O
in	O
the	O
breast	O
tumors	O
that	O
were	O
IHC	O
positive	O
from	O
those	O
which	O
were	O
IHC	O
negative	O
(	O
Tables	O
1	O
and	O
3	O
respectively	O
)	O
(	O
p	O
=	O
1.3e-6	O
by	O
standard	O
two	O
-	O
sample	O
t	O
-	O
test	O
and	O
p	O
=	O
2.7e-18	O
by	O
Wilcoxon	O
-	O
rank	O
-	O
sum	O
test	O
)	O
.	O

And	O
4	O
)	O
we	O
also	O
found	O
significant	O
differences	O
in	O
the	O
samples	O
that	O
were	O
positive	O
and	O
negative	O
by	O
estrogen	O
binding	O
assay	O
(	O
Tables	O
2	O
and	O
4	O
respectively	O
)	O
(	O
p	O
=	O
7.6e-3	O
by	O
standard	O
two	O
-	O
sample	O
t	O
-	O
test	O
and	O
p	O
=	O
3.6e-7	O
by	O
Wilcoxon	O
-	O
rank	O
-	O
sum	O
test	O
)	O
.	O

After	O
establishing	O
that	O
ERα	O
-	O
positive	O
tissues	O
express	O
significantly	O
higher	O
levels	O
of	O
mRNA	O
copy	O
numbers	O
compared	O
to	O
negative	O
tumor	O
samples	O
,	O
we	O
next	O
determined	O
the	O
maximum	O
level	O
of	O
expression	O
in	O
ERα	O
-	O
negative	O
samples	O
using	O
CART	O
program	O
.	O

By	O
using	O
this	O
program	O
,	O
we	O
found	O
the	O
maximum	O
level	O
of	O
expression	O
of	O
mRNA	O
copy	O
numbers	O
/	O
cut	O
-	O
off	O
value	O
to	O
be	O
5	O
×	O
106	O
per	O
1010copies	O
of	O
GAPDH	O
mRNA	O
.	O

Of	O
the	O
total	O
106	O
positive	O
(	O
70	O
by	O
IHC	O
and	O
33	O
by	O
estrogen	O
binding	O
assay	O
)	O
samples	O
in	O
our	O
study	O
,	O
83	O
samples	O
showed	O
higher	O
level	O
of	O
expression	O
than	O
5	O
×	O
106	O
copies	O
per	O
1010	O
copies	O
of	O
GAPDH	O
.	O

It	O
is	O
possible	O
that	O
the	O
samples	O
that	O
showed	O
less	O
than	O
the	O
above	O
cut	O
off	O
value	O
copy	O
numbers	O
could	O
be	O
due	O
to	O
false	O
positivity	O
by	O
the	O
above	O
methods	O
.	O

In	O
a	O
total	O
of	O
63	O
negative	O
samples	O
(	O
43	O
by	O
IHC	O
and	O
20	O
by	O
estrogen	O
binding	O
assay	O
)	O
only	O
6	O
samples	O
showed	O
higher	O
expression	O
than	O
5	O
×	O
106	O
copies	O
per	O
1010GAPDH	O
copies	O
.	O

It	O
is	O
also	O
possible	O
that	O
the	O
samples	O
that	O
showed	O
higher	O
than	O
the	O
cut	O
off	O
copy	O
numbers	O
could	O
be	O
false	O
negative	O
.	O

The	O
OR	O
(	O
Odds	O
Ratio	O
)	O
in	O
the	O
two	O
groups	O
is	O
about	O
39.4	O
,	O
an	O
extremely	O
high	O
OR	O
value	O
.	O

The	O
counts	O
of	O
the	O
ERα	O
-	O
positive	O
(	O
80	O
,	O
23	O
)	O
and	O
ERα	O
-	O
negative	O
(	O
6	O
,	O
66	O
)	O
in	O
the	O
two	O
groups	O
produce	O
a	O
chi	O
-	O
square	O
value	O
of	O
88.2544	O
with	O
1	O
degree	O
of	O
freedom	O
,	O
which	O
is	O
consistent	O
with	O
our	O
T	O
-	O
test	O
and	O
Wilcoxon	O
-	O
rank	O
-	O
sum	O
test	O
results	O
.	O

We	O
applied	O
the	O
above	O
cut	O
off	O
value	O
and	O
determined	O
the	O
Sensitivity	O
(	O
percentage	O
of	O
samples	O
that	O
showed	O
higher	O
copy	O
numbers	O
than	O
the	O
cut	O
off	O
value	O
of	O
5	O
×	O
106	O
copies	O
per	O
1010	O
GAPDH	O
copies	O
in	O
IHC	O
positive	O
tissues	O
)	O
and	O
Specificity	O
(	O
percentage	O
of	O
samples	O
that	O
showed	O
less	O
than	O
5	O
×	O
106	O
copies	O
per	O
1010	O
GAPDH	O
copies	O
in	O
IHC	O
negative	O
tissues	O
)	O
and	O
the	O
values	O
obtained	O
were	O
0.81	O
and	O
0.90	O
respectively	O
.	O

We	O
also	O
determined	O
Receiver	O
Operating	O
Characteristics	O
using	O
S	O
-	O
PLUS	O
software	O
and	O
the	O
ROC	O
curve	O
generated	O
is	O
shown	O
in	O
Figure	O
2	O
.	O

The	O
area	O
under	O
the	O
ROC	O
curve	O
,	O
0.89675	O
,	O
shows	O
that	O
the	O
molecular	O
assay	O
clearly	O
distinguishes	O
the	O
positives	O
by	O
IHC	O
or	O
estrogen	O
binding	O
from	O
the	O
negative	O
tissues	O
.	O

Since	O
we	O
have	O
the	O
grading	O
score	O
as	O
percent	O
positive	O
cells	O
for	O
about	O
50	O
samples	O
(	O
Table	O
1	O
)	O
,	O
we	O
tested	O
if	O
a	O
correlation	O
exits	O
between	O
the	O
percent	O
positive	O
cells	O
by	O
IHC	O
and	O
the	O
mRNA	O
copy	O
numbers	O
using	O
S	O
-	O
PLUS	O
software	O
.	O

We	O
obtained	O
a	O
correlation	O
coefficient	O
of	O
0.02	O
.	O

When	O
we	O
used	O
the	O
logarithmic	O
transformations	O
scale	O
,	O
we	O
obtained	O
a	O
correlation	O
coefficient	O
of	O
0.037	O
.	O

These	O
results	O
indicated	O
that	O
there	O
is	O
no	O
correlation	O
between	O
the	O
percent	O
positive	O
cells	O
and	O
the	O
level	O
of	O
ERα	O
mRNA	O
copy	O
numbers	O
.	O

These	O
observations	O
could	O
be	O
due	O
to	O
qualitative	O
nature	O
of	O
IHC	O
assay	O
.	O

The	O
IHC	O
data	O
only	O
show	O
the	O
number	O
of	O
positive	O
cells	O
but	O
not	O
quantitative	O
to	O
determine	O
the	O
level	O
of	O
ERα	O
expression	O
.	O

The	O
molecular	O
assay	O
based	O
on	O
RNA	O
is	O
quantitative	O
to	O
determine	O
the	O
level	O
of	O
ERα	O
expression	O
.	O

Discussion	O
and	O
conclusion	O
Previously	O
ERα	O
mRNA	O
levels	O
in	O
immunohistochemically	O
positive	O
and	O
negative	O
tissues	O
were	O
evaluated	O
in	O
breast	O
cancer	O
tissues	O
by	O
several	O
groups	O
using	O
conventional	O
RT	O
PCR	O
.	O

Cullen	O
et	O
al	O
[	O
17	O
]	O
determined	O
mRNA	O
levels	O
by	O
conventional	O
PCR	O
in	O
107	O
breast	O
cancer	O
tissues	O
.	O

They	O
reported	O
that	O
ERα	O
mRNA	O
was	O
more	O
frequently	O
detected	O
in	O
ERα	O
protein	O
positive	O
tissues	O
than	O
ERα	O
protein	O
negative	O
tissues	O
.	O

Jarzabek	O
et	O
al	O
[	O
18	O
]	O
studied	O
ERα	O
mRNA	O
levels	O
and	O
protein	O
levels	O
in	O
41	O
primary	O
breast	O
cancer	O
tissues	O
.	O

They	O
reported	O
the	O
presence	O
of	O
ERα	O
mRNA	O
in	O
all	O
the	O
tissues	O
,	O
where	O
as	O
the	O
protein	O
was	O
present	O
only	O
in	O
70	O
%	O
of	O
tumor	O
tissues	O
by	O
Western	O
blotting	O
and	O
67	O
%	O
showed	O
positive	O
by	O
immunohistochemistry	O
.	O

They	O
concluded	O
that	O
lack	O
of	O
ERα	O
protein	O
is	O
not	O
due	O
to	O
lack	O
of	O
ERα	O
gene	O
expression	O
or	O
methylation	O
of	O
its	O
promoter	O
,	O
but	O
may	O
be	O
due	O
to	O
post	O
-	O
transcriptional	O
or	O
post	O
-	O
translational	O
mechanisms	O
.	O

Alkarain	O
et	O
al	O
[	O
19	O
]	O
reported	O
the	O
presence	O
of	O
ERα	O
mRNA	O
in	O
immunohistochemically	O
ERα	O
-	O
negative	O
tissues	O
.	O

However	O
,	O
none	O
of	O
the	O
above	O
studies	O
has	O
evaluated	O
the	O
threshold	O
levels	O
of	O
ERα	O
mRNA	O
levels	O
in	O
immunohistochemically	O
negative	O
tissues	O
or	O
those	O
negative	O
by	O
ligand	O
binding	O
assays	O
.	O

Our	O
quantitative	O
analysis	O
of	O
ERα	O
mRNA	O
copy	O
numbers	O
demonstrate	O
that	O
breast	O
cancer	O
tissues	O
that	O
are	O
negative	O
by	O
both	O
IHC	O
and	O
ligand	O
binding	O
express	O
significant	O
levels	O
of	O
ERα	O
mRNA	O
.	O

The	O
reasons	O
why	O
the	O
mRNA	O
is	O
not	O
translated	O
to	O
detectable	O
protein	O
are	O
not	O
clear	O
.	O

Our	O
previous	O
studies	O
on	O
ERβ	O
mRNA	O
copy	O
numbers	O
[	O
9	O
]	O
in	O
breast	O
cancer	O
tissues	O
have	O
shown	O
that	O
at	O
the	O
5	O
×	O
106	O
copies	O
per	O
1010	O
mRNA	O
copies	O
of	O
GAPDH	O
levels	O
ERβ	O
protein	O
is	O
translated	O
.	O

It	O
is	O
possible	O
that	O
either	O
ERα	O
mRNA	O
is	O
not	O
translated	O
or	O
the	O
translated	O
protein	O
is	O
degraded	O
to	O
undetectable	O
levels	O
in	O
these	O
tissues	O
.	O

The	O
results	O
and	O
the	O
analysis	O
presented	O
above	O
clearly	O
demonstrate	O
that	O
the	O
ERα	O
positive	O
tissues	O
by	O
IHC	O
or	O
estrogen	O
binding	O
assay	O
express	O
significantly	O
higher	O
mRNA	O
copy	O
numbers	O
than	O
5	O
×	O
106	O
copies	O
per	O
1010	O
GAPDH	O
copies	O
.	O

An	O
extremely	O
high	O
Odds	O
Ratio	O
,	O
high	O
sensitivity	O
and	O
specificity	O
demonstrate	O
that	O
the	O
molecular	O
assay	O
could	O
be	O
used	O
in	O
the	O
place	O
of	O
currently	O
used	O
IHC	O
in	O
the	O
clinical	O
laboratories	O
.	O

Based	O
on	O
our	O
data	O
above	O
any	O
patient	O
who	O
has	O
more	O
than	O
5	O
×	O
106	O
copies	O
per	O
1010	O
GAPDH	O
copies	O
in	O
her	O
tumor	O
tissue	O
could	O
be	O
considered	O
positive	O
for	O
ERα	O
,	O
could	O
be	O
selected	O
for	O
anti	O
-	O
estrogen	O
therapies	O
and	O
considered	O
to	O
have	O
good	O
prognosis	O
.	O

However	O
,	O
the	O
above	O
described	O
approach	O
has	O
some	O
limitations	O
in	O
that	O
it	O
needs	O
to	O
be	O
verified	O
on	O
a	O
defined	O
set	O
of	O
biopsy	O
samples	O
and	O
with	O
reference	O
to	O
another	O
house	O
keeping	O
gene	O
.	O

Therefore	O
,	O
the	O
results	O
should	O
be	O
interpreted	O
with	O
caution	O
and	O
undoubtedly	O
will	O
require	O
confirmation	O
by	O
a	O
larger	O
prospective	O
multi	O
-	O
centered	O
clinical	O
study	O
with	O
a	O
more	O
accurate	O
design	O
to	O
bring	O
the	O
technology	O
to	O
the	O
clinic	O
.	O

The	O
current	O
study	O
is	O
a	O
first	O
step	O
in	O
that	O
direction	O
.	O

We	O
expect	O
that	O
the	O
cost	O
effective	O
,	O
extremely	O
sensitive	O
,	O
high	O
though	O
-	O
put	O
molecular	O
assay	O
which	O
requires	O
only	O
a	O
few	O
cancer	O
cells	O
could	O
be	O
an	O
assay	O
of	O
choice	O
to	O
replace	O
IHC	O
in	O
clinical	O
labs	O
for	O
determining	O
ERα	O
status	O
in	O
breast	O
cancer	O
tissues	O
once	O
established	O
in	O
a	O
multi	O
-	O
centered	O
prospective	O
clinical	O
study	O
.	O

Abbreviations	O
FAM	O
,	O
carboxy	O
-	O
fluorescein	O
;	O
TAMARA	O
,	O
6-carboxy	O
tetraethyl	O
-	O
rhodamine	O
;	O
GAPDH	O
,	O
Glyceraldehyde-3	O
phosphate	O
dehydrogenase	O
;	O
ERα	O
,	O
estrogen	O
receptor	O
alpha	O
;	O
IHC	O
,	O
Immunohistochemistry	O
;	O
CART	O
,	O
Classification	O
And	O
Regression	O
Tree	O
;	O
and	O
OR	O
,	O
Odds	O
Ratio	O
and	O
ROC	O
,	O
Receiver	O
Operating	O
Characteristics	O
.	O

Competing	O
interests	O
The	O
author	O
(	O
s	O
)	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O
I.	O
P	O
conceived	O
the	O
study	O
,	O
participated	O
in	O
the	O
design	O
of	O
the	O
study	O
,	O
performed	O
the	O
real	O
-	O
time	O
PCR	O
quantifications	O
of	O
ERalph	O
mRNA	O
copy	O
numbers	O
and	O
drafted	O
the	O
manuscript	O
.	O

Q.Y	O
participated	O
in	O
performing	O
the	O
statistical	O
analysis	O
of	O
the	O
data	O
.	O

Both	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Pre	O
-	O
publication	O
history	O
The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O

Human	B
growth	O
hormone	O
(	O
GH1	O
)	O
gene	O
polymorphism	O
map	O
in	O
a	O
normal	O
-	O
statured	O
adult	O
population	O
Abstract	O
Objective	O
GH1	O
gene	O
presents	O
a	O
complex	O
map	O
of	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
the	O
entire	O
promoter	O
,	O
coding	O
and	O
noncoding	O
regions	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
establish	O
the	O
complete	O
map	O
of	O
GH1	O
gene	O
SNPs	O
in	O
our	O
control	O
normal	O
population	O
and	O
to	O
analyse	O
its	O
association	O
with	O
adult	O
height	O
.	O

Design	O
,	O
subjects	O
and	O
measurements	O
A	O
systematic	O
GH1	O
gene	O
analysis	O
was	O
designed	O
in	O
a	O
control	O
population	O
of	O
307	O
adults	O
of	O
both	O
sexes	O
with	O
height	O
normally	O
distributed	O
within	O
normal	O
range	O
for	O
the	O
same	O
population	O
:	O
−2	O
standard	O
deviation	O
scores	O
(	O
SDS	O
)	O
to	O
+	O
2	O
SDS	O
.	O

An	O
analysis	O
was	O
performed	O
on	O
individual	O
and	O
combined	O
genotype	O
associations	O
with	O
adult	O
height	O
.	O

Results	O
Twenty	O
-	O
five	O
SNPs	O
presented	O
a	O
frequency	O
over	O
1	O
%	O
:	O
11	O
in	O
the	O
promoter	O
(	O
P1	O
to	O
P11	O
)	O
,	O
three	O
in	O
the	O
5′UTR	O
region	O
(	O
P12	O
to	O
P14	O
)	O
,	O
one	O
in	O
exon	O
1	O
(	O
P15	O
)	O
,	O
three	O
in	O
intron	O
1	O
(	O
P16	O
to	O
P18	O
)	O
,	O
two	O
in	O
intron	O
2	O
(	O
P19	O
and	O
P20	O
)	O
,	O
two	O
in	O
exon	O
4	O
(	O
P21	O
and	O
P22	O
)	O
and	O
three	O
in	O
intron	O
4	O
(	O
P23	O
to	O
P25	O
)	O
.	O

Twenty	O
-	O
nine	O
additional	O
changes	O
with	O
frequencies	O
under	O
1	O
%	O
were	O
found	O
in	O
29	O
subjects	O
.	O

P8	O
,	O
P19	O
,	O
P20	O
and	O
P25	O
had	O
not	O
been	O
previously	O
described	O
.	O

P6	O
,	O
P12	O
,	O
P17	O
and	O
P25	O
accounted	O
for	O
6·2	O
%	O
of	O
the	O
variation	O
in	O
adult	O
height	O
(	O
P	O
=	O
0·0007	O
)	O
in	O
this	O
population	O
with	O
genotypes	O
A	O
/	O
G	O
at	O
P6	O
,	O
G	O
/	O
G	O
at	O
P6	O
and	O
A	O
/	O
G	O
at	O
P12	O
decreasing	O
height	O
SDS	O
(	O
−0·063	O
±	O
0·031	O
,	O
−0·693	O
±	O
0·350	O
and	O
−0·489	O
±	O
0·265	O
,	O
Mean	O
±	O
SE	O
)	O
and	O
genotypes	O
A	O
/	O
T	O
at	O
P17	O
and	O
T	O
/	O
G	O
at	O
P25	O
increasing	O
height	O
SDS	O
(	O
+	O
1·094	O
±	O
0·456	O
and	O
+	O
1·184	O
±	O
0·432	O
)	O
.	O

Conclusions	O
This	O
study	O
established	O
the	O
GH1	O
gene	O
sequence	O
variation	O
map	O
in	O
a	O
normal	O
adult	O
height	O
control	O
population	O
confirming	O
the	O
high	O
density	O
of	O
SNPs	O
in	O
a	O
relatively	O
small	O
gene	O
.	O

Our	O
study	O
shows	O
that	O
the	O
more	O
frequent	O
SNPs	O
did	O
not	O
significantly	O
contribute	O
to	O
height	O
determination	O
,	O
while	O
only	O
one	O
promoter	O
and	O
two	O
intronic	O
SNPs	O
contributed	O
significantly	O
to	O
it	O
.	O

Studies	O
in	O
larger	O
populations	O
will	O
have	O
to	O
confirm	O
the	O
associations	O
and	O
in	O
vitro	O
functional	O
studies	O
will	O
elucidate	O
the	O
mechanisms	O
involved	O
.	O

Systematic	O
GH1	O
gene	O
analysis	O
in	O
patients	O
with	O
growth	O
delay	O
and	O
suspected	O
GH	O
deficiency	O
/	O
insufficiency	O
will	O
clarify	O
whether	O
different	O
SNP	O
frequencies	O
and/or	O
the	O
presence	O
of	O
different	O
sequence	O
changes	O
may	O
be	O
associated	O
with	O
phenotypes	O
in	O
them	O
.	O

Introduction	O
Human	B
skeletal	O
growth	O
and	O
final	O
height	O
attainment	O
are	O
a	O
result	O
of	O
a	O
multifactorial	O
regulation	O
involving	O
systemic	O
and	O
local	O
hormones	O
,	O
growth	O
and	O
nutritional	O
factors	O
,	O
lifestyle	O
and	O
genetic	O
factors	O
.	O

Heritability	O
estimates1	O
and	O
genome	O
-	O
wide	O
linkage	O
analysis2	O
have	O
shown	O
that	O
genetic	O
factors	O
play	O
a	O
major	O
role	O
in	O
determining	O
stature	O
.	O

Among	O
these	O
factors	O
,	O
the	O
GH	O
-	O
IGF	O
-	O
I	O
axis	O
plays	O
an	O
important	O
role	O
during	O
postnatal	O
life	O
,	O
and	O
associations	O
between	O
structural	O
variations	O
in	O
its	O
genes	O
and	O
height	O
are	O
currently	O
under	O
study.3	O
Although	O
growth	O
hormone	O
(	O
GH	O
)	O
deficiency	O
is	O
a	O
well	O
-	O
known	O
cause	O
of	O
growth	O
retardation	O
,	O
which	O
responds	O
to	O
GH	O
replacement	O
therapy	O
,	O
the	O
diagnosis	O
and	O
physiopathological	O
mechanisms	O
for	O
the	O
so	O
-	O
called	O
'	O
idiopathic	O
isolated	O
GH	O
deficiency	O
'	O
(	O
IIGHD	O
)	O
require	O
further	O
clarification	O
.	O

In	O
addition	O
,	O
GH	O
secretion	O
levels	O
and	O
markers	O
of	O
GH	O
biological	O
activity	O
have	O
been	O
demonstrated	O
to	O
be	O
specific	O
and	O
sensitive	O
only	O
in	O
major	O
deficiency	O
states.4,5	O
Genetic	O
causes	O
of	O
GH	O
deficiency	O
within	O
the	O
GH1	O
gene	O
have	O
been	O
established	O
;	O
however	O
,	O
they	O
are	O
rarely	O
recognized	O
and	O
only	O
sought	O
in	O
major	O
GH	O
deficiency	O
states	O
during	O
childhood	O
and	O
in	O
family	O
studies.3	O
GH1	O
gene	O
,	O
located	O
at	O
17q22–24	O
,	O
is	O
a	O
component	O
of	O
the	O
GH	O
gene	O
cluster	O
in	O
which	O
five	O
genes	O
evolving	O
from	O
a	O
common	O
ancestor	O
are	O
91–99	O
%	O
sequence	O
conserved	O
(	O
paralogues	O
)	O
.6	O
GH1	O
is	O
more	O
abundantly	O
expressed	O
in	O
pituitary	O
cells	O
,	O
while	O
the	O
other	O
four	O
genes	O
are	O
expressed	O
in	O
placental	O
tissue	O
.	O

Large	O
deletions	O
within	O
the	O
GH1	O
gene	O
cluster	O
were	O
described	O
first	O
followed	O
by	O
point	O
mutations	O
,	O
the	O
majority	O
of	O
which	O
affect	O
introns	O
3	O
or	O
4	O
,	O
provoke	O
skipping	O
of	O
exon	O
3	O
product	O
and	O
exert	O
a	O
dominant	O
effect.3,7,8	O
More	O
recently	O
,	O
the	O
presence	O
of	O
single	O
nucleotide	O
polymorphic	O
points	O
(	O
SNPs	O
)	O
in	O
the	O
promoter	O
region	O
or	O
in	O
intron	O
4	O
of	O
the	O
GH1	O
gene	O
have	O
been	O
described9–12	O
and	O
associations	O
with	O
promoter	O
allele	O
activities	O
or	O
with	O
GH	O
secretion	O
efficacy	O
and	O
circulating	O
IGF	O
-	O
I	O
levels	O
in	O
growth	O
-	O
retarded	O
patients	O
have	O
also	O
been	O
described.11,12	O
Other	O
studies	O
have	O
analysed	O
several	O
GH1	O
gene	O
SNP	O
genotypes	O
as	O
related	O
to	O
the	O
incidence	O
of	O
neoplasia	O
,	O
with	O
a	O
positive	O
association	O
with	O
colorectal	O
neoplasia	O
for	O
intron	O
4	O
SNP,13	O
a	O
negative	O
result	O
for	O
breast	O
carcinoma14,15	O
or	O
a	O
positive	O
one	O
for	O
breast	O
cancer	O
risk.16,17	O
In	O
addition	O
,	O
a	O
recent	O
study	O
in	O
a	O
cohort	O
of	O
adults	O
over	O
ages	O
60	O
years	O
detected	O
a	O
significant	O
association	O
between	O
genotypes	O
at	O
one	O
SNP	O
in	O
the	O
GH1	O
gene	O
promoter	O
region	O
and	O
at	O
the	O
intron	O
4	O
SNP	O
described	O
by	O
Hasegawa	O
et	O
al.11	O
with	O
baseline	O
bone	O
density	O
and	O
accelerated	O
bone	O
loss	O
together	O
with	O
an	O
interaction	O
with	O
weight	O
at	O
1	O
year.18	O
Intron	O
4	O
SNP	O
described	O
by	O
Hasegawa	O
et	O
al.11	O
has	O
also	O
been	O
associated	O
,	O
in	O
women	O
,	O
with	O
shorter	O
body	O
height	O
and	O
reduced	O
mortality,19	O
whereas	O
another	O
intron	O
4	O
SNP	O
(	O
T1169A	O
)	O
has	O
been	O
associated	O
in	O
both	O
sexes	O
with	O
a	O
favourable	O
metabolic	O
profile.20	O
A	O
systematic	O
SNP	O
study	O
was	O
conducted	O
by	O
Adkins	O
et	O
al.21	O
in	O
GH1	O
promoter	O
,	O
coding	O
and	O
noncoding	O
regions	O
in	O
DNAs	O
from	O
placental	O
tissues	O
,	O
and	O
analysis	O
of	O
associations	O
between	O
genotypes	O
and	O
birth	O
weight	O
revealed	O
an	O
association	O
between	O
an	O
alternate	O
nucleotide	O
at	O
−1	O
and	O
+	O
3	O
of	O
translation	O
initiation	O
site	O
and	O
fetal	O
growth	O
restriction	O
.	O

However	O
,	O
no	O
systematic	O
GH1	O
gene	O
analysis	O
in	O
the	O
entire	O
promoter	O
,	O
coding	O
and	O
noncoding	O
regions	O
has	O
been	O
conducted	O
in	O
adults	O
to	O
establish	O
the	O
map	O
of	O
structural	O
variation	O
and	O
its	O
possible	O
association	O
with	O
height	O
.	O

The	O
relatively	O
short	O
size	O
of	O
the	O
entire	O
gene	O
permits	O
a	O
complete	O
analysis	O
which	O
is	O
,	O
nevertheless	O
,	O
hampered	O
by	O
the	O
need	O
to	O
avoid	O
amplification	O
of	O
any	O
other	O
of	O
the	O
GH	O
cluster	O
genes	O
(	O
paralogues	O
)	O
and	O
the	O
high	O
density	O
of	O
sequence	O
variations	O
.	O

To	O
obtain	O
normative	O
data	O
for	O
subsequent	O
analysis	O
of	O
GH1	O
gene	O
contribution	O
to	O
IIGHD	O
in	O
children	O
,	O
a	O
systematic	O
GH1	O
gene	O
structural	O
analysis	O
was	O
designed	O
in	O
a	O
normal	O
adult	O
control	O
population	O
to	O
establish	O
the	O
GH1	O
gene	O
SNP	O
map	O
in	O
adults	O
from	O
our	O
population	O
with	O
heights	O
within	O
the	O
normal	O
range	O
,	O
determine	O
the	O
genotype	O
frequencies	O
and	O
analyse	O
possible	O
associations	O
between	O
individual	O
and	O
combined	O
SNPs	O
with	O
height	O
.	O

Subjects	O
and	O
methods	O
Subjects	O
A	O
total	O
of	O
307	O
adult	O
subjects	O
of	O
both	O
sexes	O
(	O
164	O
women	O
and	O
143	O
men	O
)	O
were	O
recruited	O
from	O
hospital	O
personnel	O
and	O
parents	O
of	O
patients	O
with	O
no	O
history	O
of	O
growth	O
retardation	O
.	O

Subjects	O
had	O
to	O
fulfil	O
the	O
following	O
criteria	O
:	O
Iberian	O
Peninsular	O
(	O
except	O
Basque	O
)	O
family	O
origin	O
and	O
no	O
family	O
history	O
of	O
pathological	O
short	O
stature	O
.	O

A	O
single	O
subject	O
per	O
family	O
was	O
included	O
.	O

The	O
protocol	O
was	O
approved	O
by	O
the	O
Hospital	O
Vall	O
d'Hebron	O
Ethics	O
Committee	O
and	O
written	O
informed	O
consent	O
was	O
obtained	O
from	O
each	O
participant	O
.	O

Height	O
standard	O
deviation	O
scores	O
(	O
height	O
SDS	O
)	O
were	O
calculated	O
according	O
to	O
sex	O
-	O
specific	O
reference	O
growth	O
charts	O
for	O
the	O
Spanish	O
population	O
(	O
Carrascosa	O
et	O
al.22	O
charts	O
were	O
used	O
for	O
subjects	O
under	O
ages	O
30	O
years	O
and	O
Hernández	O
et	O
al.23	O
for	O
subjects	O
aged	O
30–50	O
years	O
)	O
.	O

Only	O
individuals	O
with	O
height	O
SDS	O
between	O
−2	O
and	O
+	O
2	O
SDS	O
were	O
included	O
in	O
the	O
study	O
(	O
mean	O
−0·016	O
;	O
32	O
women	O
and	O
28	O
men	O
between	O
−2·000	O
and	O
−1·010	O
;	O
99	O
women	O
and	O
80	O
men	O
between	O
−1·000	O
and	O
+	O
0·910	O
;	O
33	O
women	O
and	O
35	O
men	O
between	O
+	O
1·010	O
and	O
+	O
1·980	O
)	O
and	O
sample	O
size	O
was	O
adjusted	O
for	O
normal	O
sex	O
and	O
height	O
SDS	O
distribution	O
.	O

Height	O
and	O
weight	O
were	O
recorded	O
in	O
the	O
morning	O
by	O
a	O
single	O
observer	O
.	O

Height	O
was	O
measured	O
with	O
a	O
Harpenden	O
stadiometer	O
.	O

Four	O
millilitres	O
of	O
peripheral	O
venous	O
blood	O
were	O
drawn	O
into	O
EDTA	O
-	O
containing	O
tubes	O
for	O
molecular	O
genetic	O
analysis	O
.	O

Genomic	O
DNA	O
study	O
Genomic	O
DNA	O
was	O
obtained	O
from	O
peripheral	O
blood	O
following	O
the	O
method	O
described	O
by	O
Lahiri	O
and	O
Nurnberger.24	O
DNA	O
was	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
using	O
a	O
nested	O
strategy	O
.	O

Briefly	O
,	O
50	O
ng	O
of	O
genomic	O
DNA	O
were	O
added	O
to	O
a	O
10	O
µl	O
reaction	O
mixture	O
of	O
1	O
mm	O
Mg	O
(	O
OAc	O
)	O
2	O
,	O
0·6	O
mm	O
dNTPs	O
,	O
0·3	O
µm	O
of	O
each	O
primer	O
,	O
and	O
0·4	O
U	O
r	O
Tth	O
DNA	O
polymerase	O
XL	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
,	O
USA	O
)	O
.	O

The	O
sense	O
and	O
antisense	O
primers	O
used	O
corresponded	O
to	O
nucleotides	O
4156–5′ACGGTCCGCCACTACGCCCAGC-3′	O
and	O
the	O
complement	O
of	O
6948–5′TGCAGTGAGCCAAGATTGTGCC-3′	O
of	O
the	O
GH	O
gene	O
cluster.6	O
The	O
PCR	O
reaction	O
mix	O
was	O
denatured	O
for	O
5	O
min	O
at	O
94	O
°	O
C	O
and	O
cycled	O
40	O
times	O
(	O
94	O
°	O
C	O
,	O
1	O
min	O
;	O
72	O
°	O
C	O
,	O
3	O
min	O
30	O
s	O
)	O
followed	O
by	O
a	O
7-min	O
extension	O
at	O
72	O
°	O
C	O
.	O

The	O
resulting	O
GH1	O
PCR	O
products	O
(	O
2893	O
bp	O
)	O
were	O
used	O
as	O
templates	O
for	O
five	O
nested	O
reactions	O
(	O
AN	O
,	O
BL	O
,	O
CK	O
,	O
DI	O
,	O
FP	O
)	O
,	O
carried	O
out	O
as	O
follows	O
:	O
1	O
µl	O
of	O
each	O
GH1	O
PCR	O
product	O
was	O
added	O
to	O
a	O
20	O
µl	O
reaction	O
mixture	O
of	O
1·5	O
mm	O
MgCl2	O
,	O
0·2	O
mm	O
dNTPs	O
,	O
0·3	O
µm	O
of	O
each	O
primer	O
and	O
0·4	O
U	O
Eco	O
Taq	O
DNA	O
polymerase	O
(	O
Ecogen	O
S.R.L.	O
,	O
Barcelona	O
,	O
Spain	O
)	O
.	O

Reaction	O
mixtures	O
were	O
denatured	O
for	O
5	O
min	O
at	O
94	O
°	O
C	O
,	O
cycled	O
40	O
times	O
(	O
94	O
°	O
C	O
,	O
1	O
min	O
;	O
58	O
°	O
C	O
,	O
1	O
min	O
;	O
and	O
72	O
°	O
C	O
,	O
1	O
min	O
)	O
,	O
followed	O
by	O
a	O
7-min	O
extension	O
at	O
72	O
°	O
C	O
.	O

Sense	O
and	O
antisense	O
primers	O
were	O
as	O
follows	O
:	O
Sequencing	O
from	O
both	O
ends	O
was	O
performed	O
by	O
the	O
dideoxy	O
method	O
using	O
ABI	O
PRISM	O
BigDye	O
Terminator	O
version	O
3·1	O
Cycle	O
Sequencing	O
Kit	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
,	O
USA	O
)	O
.	O

GH1	O
gene	O
nucleotide	O
sequence	O
published	O
by	O
Chen	O
et	O
al.6	O
was	O
used	O
as	O
control	O
.	O

For	O
each	O
DNA	O
,	O
the	O
five	O
segments	O
from	O
the	O
nested	O
PCR	O
were	O
assembled	O
with	O
the	O
SeqEscape	O
programme	O
(	O
Applied	O
Biosystems	O
)	O
and	O
interpretation	O
was	O
made	O
visually	O
and	O
simultaneously	O
by	O
two	O
observers	O
.	O

Antisense	O
sequencing	O
was	O
performed	O
to	O
confirm	O
each	O
nucleotide	O
sequence	O
change	O
up	O
to	O
the	O
establishment	O
of	O
the	O
more	O
frequent	O
SNP	O
map	O
(	O
frequency	O
over	O
1	O
%	O
)	O
,	O
whereas	O
less	O
frequent	O
single	O
or	O
multiple	O
nucleotide	O
changes	O
were	O
reconfirmed	O
in	O
each	O
DNA	O
by	O
antisense	O
sequence	O
and	O
resequencing	O
after	O
a	O
new	O
nested	O
PCR	O
from	O
original	O
DNA	O
was	O
performed	O
.	O

Single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
genotyping	O
The	O
sequences	O
for	O
the	O
five	O
genes	O
of	O
the	O
GH	O
cluster	O
identified	O
by	O
Chen	O
et	O
al.6	O
and	O
reported	O
as	O
the	O
GI	O
sequence	O
183148	O
were	O
aligned	O
using	O
the	O
Multalin	O
program.25	O
SNPs	O
and	O
other	O
sequence	O
changes	O
identified	O
were	O
indicated	O
using	O
their	O
position	O
corresponding	O
to	O
GH1	O
.	O

Genotypes	O
were	O
deduced	O
by	O
the	O
combination	O
of	O
genetic	O
variation	O
at	O
the	O
polymorphic	O
positions	O
.	O

Statistical	O
analysis	O
Standardized	O
height	O
was	O
investigated	O
for	O
normal	O
distribution	O
(	O
Kolmogorov	O
-	O
Smirnov	O
test	O
:	O
c2	O
=	O
2·882	O
,	O
P	O
=	O
0·4733	O
)	O
.	O

Hardy	O
–	O
Weinberg	O
equilibrium	O
was	O
tested	O
for	O
SNPs	O
presenting	O
three	O
alternate	O
genotypes	O
according	O
to	O
standard	O
procedures	O
using	O
χ2-analysis	O
.	O

anova	O
test	O
was	O
applied	O
to	O
investigate	O
individual	O
and	O
combined	O
SNP	O
association	O
with	O
adult	O
height	O
SDS	O
;	O
significance	O
assessment	O
was	O
adjusted	O
for	O
multiple	O
testing	O
using	O
Fisher	O
's	O
PLSD	O
test	O
setting	O
Pcritical	O
=	O
0·05	O
or	O
the	O
Bonferroni	O
–	O
Dunn	O
test	O
setting	O
Pcritical	O
=	O
0·05	O
/	O
n	O
(	O
n	O
=	O
number	O
of	O
comparisons	O
carried	O
out	O
)	O
.	O

Stepwise	O
regression	O
analysis	O
was	O
applied	O
to	O
predict	O
the	O
contribution	O
of	O
SNPs	O
to	O
adult	O
height	O
SDS	O
.	O

Statview	O
4·5	O
program	O
(	O
Abacus	O
Concepts	O
Inc.	O
,	O
Berkeley	O
,	O
CA	O
,	O
USA	O
)	O
was	O
used	O
for	O
statistical	O
analyses	O
.	O

Results	O
GH1	O
gene	O
sequence	O
variation	O
GH1	O
gene	O
sequence	O
comparison	O
with	O
the	O
GI-183148	O
sequence	O
published	O
by	O
Chen	O
et	O
al.6	O
yielded	O
a	O
total	O
of	O
54	O
single	O
or	O
multiple	O
nucleotide	O
changes	O
.	O

Twenty	O
-	O
five	O
SNPs	O
presented	O
a	O
frequency	O
over	O
1	O
%	O
(	O
genotypes	O
and	O
frequencies	O
are	O
listed	O
in	O
Table	O
1	O
)	O
.	O

SNPs	O
which	O
presented	O
the	O
three	O
alternate	O
genotypes	O
(	O
P2	O
to	O
P4	O
,	O
P6	O
,	O
P7	O
,	O
P10	O
and	O
P24	O
)	O
were	O
in	O
Hardy	O
–	O
Weinberg	O
equilibrium	O
(	O
data	O
not	O
shown	O
)	O
.	O

Twenty	O
-	O
nine	O
additional	O
changes	O
were	O
found	O
with	O
a	O
frequency	O
under	O
1	O
%	O
or	O
involving	O
more	O
than	O
one	O
nucleotide	O
and	O
thus	O
could	O
be	O
considered	O
as	O
rare	O
variant	O
SNPs	O
(	O
R1	O
to	O
R29	O
)	O
(	O
Table	O
2	O
)	O
.	O

These	O
changes	O
were	O
found	O
in	O
29	O
of	O
307	O
subjects	O
(	O
9·4	O
%	O
)	O
,	O
all	O
in	O
heterozygosity	O
.	O

GH1-paralogue	O
alignment	O
A	O
sequence	O
alignment	O
was	O
performed	O
to	O
study	O
possible	O
sequence	O
recombinations	O
among	O
paralogues	O
of	O
the	O
five	O
GH1-gene	O
cluster	O
(	O
Fig.	O
1	O
)	O
.	O

This	O
alignment	O
showed	O
that	O
9	O
of	O
25	O
SNPs	O
(	O
36	O
%	O
)	O
in	O
the	O
GH1	O
gene	O
did	O
not	O
correspond	O
to	O
any	O
of	O
the	O
paralogues	O
.	O

Among	O
the	O
29	O
rare	O
SNPs	O
found	O
,	O
six	O
(	O
20·7	O
%	O
)	O
did	O
not	O
correspond	O
to	O
any	O
of	O
the	O
paralogues	O
:	O
two	O
were	O
located	O
in	O
the	O
5′UTR	O
region	O
(	O
R9	O
and	O
R10	O
)	O
,	O
two	O
in	O
intron	O
1	O
(	O
positions	O
5300	O
=	O
R14	O
and	O
5302	O
=	O
R17	O
)	O
,	O
one	O
in	O
intron	O
2	O
(	O
position	O
5679	O
=	O
R21	O
)	O
and	O
one	O
in	O
intron	O
4	O
(	O
position	O
6344	O
=	O
R23	O
)	O
(	O
Table	O
2	O
)	O
.	O

Equivalence	O
with	O
previously	O
reported	O
GH1	O
changes	O
Equivalence	O
with	O
changes	O
and	O
SNPs	O
previously	O
reported	O
by	O
other	O
authors	O
are	O
shown	O
in	O
Table	O
3	O
.	O

The	O
majority	O
found	O
a	O
high	O
density	O
of	O
SNPs	O
in	O
the	O
promoter	O
and	O
5′UTR	O
regions	O
in	O
control	O
populations.10,12,21	O
Several	O
sequence	O
changes	O
have	O
been	O
reported	O
in	O
patients	O
with	O
familial	O
or	O
idiopathic	O
short	O
stature,11,26,27	O
whereas	O
P8	O
,	O
P19	O
,	O
P20	O
and	O
P25	O
(	O
at	O
positions	O
5165	O
,	O
5681	O
,	O
5686	O
and	O
6358	O
,	O
respectively	O
,	O
in	O
the	O
Genebank	O
accession	O
GI	O
183148	O
)	O
located	O
in	O
the	O
promoter	O
,	O
intron	O
2	O
and	O
intron	O
4	O
regions	O
,	O
respectively	O
,	O
had	O
not	O
been	O
previously	O
described	O
.	O

GH1	O
genotypes	O
and	O
associations	O
with	O
height	O
SDS	O
Associations	O
between	O
genotypes	O
and	O
standardized	O
height	O
were	O
first	O
studied	O
in	O
the	O
subpopulation	O
of	O
278	O
controls	O
carrying	O
only	O
the	O
25	O
most	O
frequent	O
SNPs	O
in	O
the	O
GH1	O
gene	O
(	O
c2	O
=	O
2·59	O
;	O
P	O
=	O
0·5458	O
for	O
normality	O
of	O
height	O
distribution	O
)	O
.	O

Three	O
individual	O
SNPs	O
showed	O
a	O
statistically	O
significant	O
association	O
with	O
height	O
SDS	O
:	O
at	O
positions	O
5286	O
(	O
P16	O
)	O
,	O
5290	O
(	O
P17	O
)	O
and	O
6358	O
(	O
P25	O
)	O
.	O

Subjects	O
with	O
heterozygous	O
genotypes	O
presented	O
statistically	O
significant	O
taller	O
stature	O
than	O
the	O
corresponding	O
homozygous	O
genotypes	O
(	O
P	O
=	O
0·016	O
for	O
P16	O
,	O
P	O
=	O
0·015	O
for	O
P17	O
and	O
P	O
=	O
0·023	O
for	O
P25	O
)	O
(	O
Fig.	O
2a	O
,	O
b	O
,	O
c	O
)	O
.	O

P16	O
and	O
P17	O
were	O
in	O
linkage	O
disequilibrium	O
(	O
LD	O
)	O
(	O
r2	O
=	O
0·831	O
)	O
,	O
while	O
P25	O
was	O
carried	O
by	O
six	O
subjects	O
homozygous	O
at	O
P16	O
and	O
P17	O
.	O

GH1	O
gene	O
genotypes	O
were	O
defined	O
by	O
genetic	O
variation	O
in	O
the	O
25	O
polymorphic	O
positions	O
.	O

We	O
found	O
163	O
different	O
combinations	O
.	O

Only	O
two	O
genotypes	O
presented	O
a	O
frequency	O
over	O
5	O
%	O
(	O
Table	O
4	O
)	O
.	O

Height	O
SDS	O
in	O
the	O
two	O
more	O
frequent	O
genotypes	O
did	O
not	O
differ	O
significantly	O
and	O
covered	O
the	O
whole	O
height	O
range	O
.	O

Genotype	O
1	O
presented	O
four	O
heterozygous	O
variations	O
and	O
Genotype	O
2	O
was	O
the	O
corresponding	O
homozygous	O
genotype	O
.	O

Heterozygous	O
positions	O
corresponded	O
to	O
SNPs	O
with	O
the	O
highest	O
frequency	O
variation	O
(	O
4886	O
(	O
P4	O
)	O
,	O
5107	O
(	O
P7	O
)	O
,	O
5157	O
(	O
P10	O
)	O
and	O
6331	O
(	O
P24	O
)	O
)	O
.	O

In	O
addition	O
,	O
DNAs	O
exhibited	O
a	O
different	O
genotype	O
in	O
each	O
of	O
129	O
subjects	O
(	O
46·4	O
%	O
)	O
.	O

The	O
11	O
SNPs	O
found	O
in	O
the	O
promoter	O
region	O
(	O
Table	O
1	O
)	O
were	O
grouped	O
in	O
94	O
genotypes	O
and	O
analysed	O
for	O
association	O
with	O
adult	O
height	O
SDS	O
.	O

The	O
four	O
more	O
frequent	O
combinations	O
are	O
listed	O
in	O
Table	O
4	O
:	O
height	O
SDS	O
of	O
these	O
four	O
genotypes	O
did	O
not	O
differ	O
statistically	O
although	O
Genotype	O
3	O
tended	O
to	O
have	O
a	O
shorter	O
height	O
.	O

Genotype	O
3	O
differed	O
from	O
Genotype	O
1	O
in	O
the	O
SNP	O
located	O
at	O
position	O
5089	O
(	O
P6	O
)	O
,	O
corresponding	O
to	O
Pit	O
1	O
proximal	O
responsive	O
element	O
for	O
GH1	O
gene	O
promoter	O
.	O

Genotype	O
4	O
is	O
heterozygous	O
at	O
positions	O
4856	O
(	O
P2	O
)	O
,	O
4863	O
(	O
P3	O
)	O
and	O
5107	O
(	O
P7	O
)	O
.	O

In	O
addition	O
,	O
19	O
%	O
of	O
cases	O
exhibited	O
a	O
genotype	O
in	O
the	O
promoter	O
region	O
carried	O
by	O
only	O
one	O
subject	O
.	O

Combination	O
of	O
the	O
three	O
SNPs	O
in	O
the	O
5′UTR	O
region	O
of	O
GH1	O
gene	O
resulted	O
in	O
five	O
different	O
genotypes	O
.	O

SNPs	O
at	O
positions	O
5178	O
(	O
P12	O
)	O
and	O
5187	O
(	O
P13	O
)	O
were	O
in	O
LD	O
(	O
r2	O
=	O
0·88	O
)	O
.	O

Mean	O
height	O
SDS	O
comparison	O
among	O
these	O
genotypes	O
was	O
not	O
statistically	O
significant	O
,	O
although	O
mean	O
height	O
SDS	O
of	O
alternate	O
nucleotide	O
carriers	O
at	O
position	O
5178	O
(	O
P12	O
)	O
tended	O
to	O
be	O
shorter	O
(	O
Table	O
4	O
)	O
.	O

An	O
anova	O
analysis	O
was	O
conducted	O
to	O
investigate	O
the	O
interaction	O
between	O
two	O
or	O
more	O
SNPs	O
and	O
height	O
SDS	O
.	O

SNPs	O
at	O
positions	O
5286	O
(	O
P16	O
)	O
and	O
5290	O
(	O
P17	O
)	O
were	O
in	O
LD	O
(	O
r2	O
=	O
0·83	O
)	O
:	O
the	O
heterozygous	O
genotype	O
AG	O
/	O
AT	O
for	O
these	O
SNPs	O
was	O
associated	O
with	O
taller	O
stature	O
(	O
shown	O
above	O
)	O
.	O

SNP	O
at	O
position	O
6358	O
(	O
P25	O
)	O
increased	O
the	O
expected	O
height	O
SDS	O
for	O
individual	O
carriers	O
of	O
the	O
G	O
allele	O
at	O
5089	O
(	O
P6	O
)	O
SNP	O
as	O
shown	O
in	O
Fig.	O
2	O
(	O
d	O
)	O
:	O
subjects	O
heterozygous	O
at	O
6358	O
(	O
P25	O
)	O
were	O
taller	O
than	O
the	O
mean	O
,	O
and	O
mean	O
height	O
SDS	O
of	O
subjects	O
with	O
GG	O
/	O
TG	O
combined	O
genotype	O
was	O
significantly	O
higher	O
than	O
the	O
corresponding	O
GG	O
/	O
TT	O
genotype	O
(	O
P	O
=	O
0·0021	O
)	O
,	O
suggesting	O
an	O
interaction	O
between	O
these	O
two	O
SNPs	O
as	O
they	O
were	O
not	O
in	O
LD	O
.	O

Analysis	O
of	O
height	O
SDS	O
association	O
with	O
the	O
most	O
frequent	O
single	O
and	O
combined	O
SNPs	O
and	O
with	O
rare	O
variant	O
SNPs	O
was	O
performed	O
in	O
the	O
29	O
individuals	O
carrying	O
the	O
rare	O
SNPs	O
(	O
Table	O
2	O
)	O
.	O

None	O
of	O
them	O
carried	O
any	O
of	O
the	O
three	O
SNPs	O
(	O
P16	O
,	O
P17	O
and	O
P25	O
)	O
related	O
to	O
taller	O
stature	O
in	O
the	O
population	O
of	O
278	O
controls	O
with	O
only	O
the	O
frequent	O
SNPs	O
.	O

In	O
these	O
29	O
,	O
mean	O
height	O
SDS	O
(	O
0·000	O
±	O
0·987	O
,	O
from	O
−1·930	O
to	O
+	O
1·870	O
)	O
did	O
not	O
differ	O
from	O
that	O
of	O
the	O
278	O
controls	O
(	O
−0·018	O
±	O
1·041	O
,	O
from	O
−2·000	O
to	O
+	O
1·980	O
)	O
.	O

Analysis	O
of	O
associations	O
between	O
individual	O
SNP	O
genotypes	O
and	O
height	O
SDS	O
revealed	O
that	O
SNPs	O
at	O
positions	O
5089	O
(	O
P6	O
)	O
,	O
5178	O
(	O
P12	O
)	O
and	O
5187	O
(	O
P13	O
)	O
were	O
associated	O
with	O
significantly	O
shorter	O
stature	O
(	O
Fig.	O
2e	O
)	O
.	O

Only	O
two	O
sequence	O
changes	O
considered	O
as	O
rare	O
SNPs	O
were	O
carried	O
by	O
individuals	O
in	O
the	O
lower	O
normal	O
height	O
range	O
(	O
between	O
−1·500	O
and	O
−2·000	O
SDS	O
)	O
(	O
Table	O
2	O
)	O
:	O
R4	O
(	O
4979	O
C	O
>	O
T	O
)	O
in	O
the	O
promoter	O
region	O
and	O
R14	O
(	O
5300	O
C	O
>	O
T	O
)	O
in	O
intron	O
1	O
.	O

Predicted	O
single	O
amino	O
acid	O
changes	O
located	O
in	O
exon	O
5	O
(	O
R25	O
to	O
R27	O
)	O
were	O
not	O
associated	O
with	O
short	O
stature	O
.	O

In	O
the	O
entire	O
population	O
of	O
307	O
controls	O
,	O
stepwise	O
regression	O
analysis	O
between	O
height	O
SDS	O
and	O
genotypes	O
at	O
the	O
25	O
SNPs	O
showed	O
that	O
genotypes	O
at	O
5089	O
(	O
P6	O
)	O
,	O
5178	O
(	O
P12	O
)	O
,	O
5290	O
(	O
P17	O
)	O
and	O
6358	O
(	O
P25	O
)	O
were	O
significantly	O
correlated	O
with	O
height	O
SDS	O
(	O
r2	O
=	O
0·062	O
,	O
P	O
=	O
0·0007	O
)	O
with	O
genotypes	O
A	O
/	O
G	O
at	O
P6	O
,	O
G	O
/	O
G	O
at	O
P6	O
and	O
A	O
/	O
G	O
at	O
P12	O
decreasing	O
height	O
SDS	O
(	O
−0·063	O
±	O
0·031	O
,	O
−0·693	O
±	O
0·350	O
and	O
−0·489	O
±	O
0·265	O
,	O
respectively	O
,	O
Mean	O
±	O
SE	O
)	O
and	O
genotypes	O
A	O
/	O
T	O
at	O
P17	O
and	O
T	O
/	O
G	O
at	O
P25	O
increasing	O
height	O
SDS	O
(	O
+	O
1·094	O
±	O
0·456	O
and	O
+	O
1·184	O
±	O
0·432	O
,	O
respectively	O
)	O
.	O

Discussion	O
Genetic	O
variations	O
within	O
human	B
GH1	O
gene	O
have	O
been	O
described	O
by	O
several	O
authors.9–12,21	O
The	O
populations	O
described	O
to	O
date	O
comprised	O
small	O
numbers	O
of	O
normal	O
-	O
stature	O
individuals,9	O
male	O
adults	O
with	O
narrow	O
height	O
range12	O
or	O
growth	O
-	O
retarded	O
patients	O
with	O
/	O
without	O
GHD	O
before	O
achievement	O
of	O
adult	O
height.9,11,12	O
Our	O
study	O
was	O
designed	O
to	O
characterize	O
the	O
GH1	O
gene	O
sequence	O
variation	O
in	O
individuals	O
within	O
the	O
whole	O
range	O
of	O
normal	O
adult	O
height	O
(	O
between	O
−2	O
and	O
+	O
2	O
SDS	O
)	O
according	O
to	O
the	O
standards	O
for	O
our	O
population	O
.	O

Height	O
was	O
normally	O
distributed	O
,	O
both	O
sexes	O
were	O
equally	O
represented	O
and	O
the	O
GI-183148	O
homozygous	O
sequence6	O
was	O
used	O
for	O
comparison	O
.	O

A	O
nested	O
PCR	O
with	O
specific	O
primers	O
for	O
GH1	O
gene	O
was	O
designed	O
,	O
thus	O
avoiding	O
amplification	O
of	O
any	O
other	O
GH	O
gene	O
paralogue	O
of	O
the	O
GH	O
gene	O
cluster	O
.	O

Our	O
results	O
establish	O
a	O
map	O
of	O
25	O
SNPs	O
as	O
present	O
in	O
over	O
1	O
%	O
of	O
individuals	O
,	O
whereas	O
29	O
other	O
sequence	O
changes	O
(	O
single	O
or	O
multiple	O
nucleotide	O
)	O
are	O
present	O
in	O
less	O
than	O
1	O
%	O
of	O
subjects	O
.	O

More	O
than	O
50	O
%	O
(	O
n	O
=	O
14	O
)	O
of	O
SNPs	O
are	O
located	O
in	O
the	O
promoter	O
and	O
5′UTR	O
regions	O
,	O
thus	O
confirming	O
previous	O
reports	O
:	O
Giordano	O
et	O
al.9	O
reported	O
eight	O
SNPs	O
in	O
the	O
promoter	O
and	O
5′UTR	O
regions	O
,	O
Wagner	O
et	O
al.10	O
16	O
SNPs	O
from	O
the	O
promoter	O
to	O
intron	O
1	O
and	O
Horan	O
et	O
al.12	O
identified	O
36	O
haplotypes	O
in	O
control	O
subjects	O
of	O
the	O
British	O
population	O
,	O
which	O
would	O
result	O
from	O
the	O
combination	O
of	O
15	O
of	O
the	O
previously	O
reported	O
SNPs	O
.	O

Our	O
results	O
confirm	O
the	O
presence	O
of	O
13	O
of	O
those	O
points	O
;	O
SNP	O
at	O
5165	O
(	O
R11	O
in	O
the	O
present	O
study	O
and	O
+	O
3	O
in	O
references9,12	O
)	O
was	O
present	O
in	O
less	O
than	O
1	O
%	O
of	O
subjects	O
and	O
a	O
new	O
SNP	O
is	O
described	O
(	O
P8	O
at	O
5116	O
in	O
the	O
VDR	O
/	O
RA	O
/	O
T3	O
responsive	O
element	O
sequence	O
)	O
.	O

The	O
remaining	O
SNPs	O
(	O
from	O
P15	O
to	O
P25	O
,	O
n	O
=	O
11	O
)	O
are	O
distributed	O
in	O
introns	O
1	O
,	O
2	O
and	O
4	O
,	O
and	O
among	O
coding	O
regions	O
only	O
exon	O
1	O
and	O
exon	O
4	O
bear	O
a	O
total	O
of	O
three	O
SNPs	O
,	O
two	O
of	O
which	O
predict	O
an	O
amino	O
acid	O
change	O
(	O
P15	O
and	O
P21	O
)	O
.	O

These	O
two	O
latter	O
SNPs	O
had	O
been	O
described	O
by	O
Millar	O
et	O
al.26	O
and	O
the	O
more	O
frequent	O
SNP	O
in	O
intron	O
4	O
(	O
P24	O
)	O
has	O
been	O
described	O
by	O
Hasegawa	O
et	O
al.11	O
together	O
with	O
the	O
two	O
more	O
frequent	O
SNPs	O
in	O
the	O
promoter	O
region	O
(	O
P4	O
and	O
P7	O
in	O
our	O
map	O
)	O
.	O

Three	O
new	O
SNPs	O
are	O
described	O
(	O
P19	O
and	O
P20	O
in	O
intron	O
2	O
and	O
P25	O
in	O
intron	O
4	O
)	O
,	O
all	O
outside	O
the	O
splice	O
sites	O
.	O

Only	O
SNPs	O
presenting	O
high	O
frequency	O
are	O
present	O
in	O
homozygous	O
alternate	O
state	O
and	O
this	O
accounts	O
mostly	O
for	O
the	O
majority	O
of	O
the	O
promoter	O
and	O
5′UTR	O
SNPs	O
and	O
in	O
the	O
intron	O
4	O
more	O
frequent	O
SNP	O
(	O
P24	O
)	O
described	O
by	O
Hasegawa	O
et	O
al.11	O
In	O
conclusion	O
,	O
in	O
the	O
entire	O
coding	O
and	O
noncoding	O
GH1	O
gene	O
sequence	O
,	O
only	O
P24	O
is	O
present	O
in	O
homozygous	O
alternate	O
state	O
.	O

Our	O
results	O
show	O
that	O
the	O
GI	O
183148	O
homozygous	O
sequence	O
is	O
present	O
in	O
our	O
population	O
except	O
for	O
SNP	O
P14	O
in	O
the	O
5′UTR	O
region	O
which	O
is	O
only	O
present	O
as	O
the	O
alternate	O
nucleotide	O
in	O
homozygous	O
or	O
heterozygous	O
states	O
.	O

As	O
described	O
by	O
several	O
authors9,10,12,21	O
several	O
promoter	O
SNPs	O
affected	O
functional	O
sequences	O
and	O
P6	O
is	O
located	O
in	O
the	O
Pit	O
1	O
proximal	O
responsive	O
element	O
,	O
P7	O
and	O
P8	O
in	O
the	O
VDR	O
/	O
RA	O
/	O
T3	O
responsive	O
element	O
and	O
P9	O
(	O
G	O
del	O
)	O
in	O
the	O
TATA	O
box	O
.	O

The	O
mechanisms	O
by	O
which	O
the	O
high	O
density	O
of	O
SNPs	O
in	O
the	O
GH1	O
gene	O
is	O
generated	O
has	O
been	O
proposed	O
to	O
be	O
recombination	O
and	O
gene	O
conversion	O
with	O
any	O
other	O
(	O
s	O
)	O
of	O
the	O
GH	O
cluster	O
genes.9,12,28	O
Alignment	O
of	O
the	O
25	O
SNPs	O
with	O
the	O
other	O
GH1	O
gene	O
paralogues	O
demonstrated	O
in	O
our	O
results	O
that	O
this	O
mechanism	O
is	O
possible	O
for	O
64	O
%	O
of	O
SNPs	O
.	O

Familial	O
SNP	O
transmission	O
pattern	O
analysis	O
will	O
be	O
of	O
interest	O
to	O
support	O
the	O
hypothesis	O
of	O
GH	O
gene	O
recombination	O
.	O

In	O
addition	O
,	O
29	O
of	O
307	O
individuals	O
(	O
9·4	O
%	O
)	O
bore	O
additional	O
GH1	O
sequence	O
changes	O
with	O
frequencies	O
under	O
1	O
%	O
.	O

As	O
for	O
SNPs	O
,	O
they	O
are	O
located	O
along	O
the	O
whole	O
gene	O
with	O
higher	O
density	O
in	O
the	O
promoter	O
and	O
5′UTR	O
regions	O
.	O

Interestingly	O
,	O
intron	O
3	O
and	O
exon	O
5	O
present	O
several	O
of	O
these	O
less	O
frequent	O
changes	O
.	O

Intron	O
3	O
has	O
been	O
shown	O
to	O
carry	O
the	O
majority	O
of	O
single	O
nucleotide	O
mutations	O
causing	O
the	O
dominant	O
form	O
of	O
GH	O
deficiency.3	O
The	O
two	O
single	O
nucleotide	O
changes	O
detected	O
in	O
intron	O
3	O
(	O
R15	O
at	O
6056	O
and	O
R16	O
at	O
6061	O
)	O
are	O
in	O
perfect	O
LD	O
(	O
r2	O
=	O
1·0	O
)	O
and	O
located	O
within	O
the	O
enhancer	O
splice	O
site	O
element	O
(	O
ESE	O
)	O
described	O
by	O
Ryther	O
et	O
al.29,30	O
Studies	O
in	O
additional	O
normal	O
or	O
growth	O
-	O
retarded	O
populations	O
will	O
permit	O
description	O
of	O
their	O
possible	O
clinical	O
implications	O
.	O

Five	O
single	O
nucleotide	O
changes	O
are	O
located	O
in	O
exon	O
5	O
;	O
of	O
these	O
five	O
,	O
three	O
predict	O
an	O
amino	O
acid	O
change	O
,	O
and	O
one	O
of	O
the	O
three	O
(	O
Ile179Met	O
)	O
has	O
been	O
described	O
by	O
Lewis	O
et	O
al.27	O
in	O
a	O
paediatric	O
patient	O
with	O
familial	O
short	O
stature	O
and	O
the	O
other	O
two	O
,	O
as	O
yet	O
undescribed	O
,	O
are	O
contiguous	O
in	O
a	O
single	O
individual	O
(	O
Pro133Hys	O
and	O
Arg134Leu	O
)	O
.	O

Polynucleotide	O
changes	O
are	O
mostly	O
located	O
in	O
the	O
promoter	O
region	O
corresponding	O
to	O
the	O
VDR	O
/	O
RA	O
/	O
T3	O
response	O
element	O
.	O

As	O
for	O
frequent	O
SNPs	O
,	O
the	O
majority	O
of	O
the	O
sequence	O
changes	O
with	O
frequencies	O
under	O
1	O
%	O
may	O
have	O
been	O
generated	O
by	O
recombination	O
within	O
the	O
GH	O
gene	O
cluster	O
as	O
19	O
of	O
24	O
(	O
79	O
%	O
)	O
may	O
correspond	O
to	O
one	O
or	O
more	O
of	O
the	O
GH1	O
gene	O
paralogues	O
.	O

Our	O
results	O
now	O
show	O
the	O
diversity	O
and	O
complexity	O
of	O
SNP	O
genotypes	O
,	O
as	O
previously	O
highlighted	O
by	O
other	O
authors9,10,12,21	O
in	O
a	O
normal	O
adult	O
height	O
control	O
population	O
.	O

Our	O
initial	O
aim	O
when	O
designing	O
the	O
present	O
study	O
was	O
to	O
establish	O
the	O
map	O
of	O
GH1	O
gene	O
SNPs	O
in	O
our	O
adult	O
control	O
population	O
with	O
heights	O
normally	O
distributed	O
within	O
the	O
entire	O
normal	O
range	O
for	O
further	O
comparison	O
with	O
genotypes	O
in	O
our	O
paediatric	O
population	O
with	O
growth	O
delay	O
,	O
variable	O
response	O
to	O
GH	O
secretion	O
tests	O
and	O
adequate	O
response	O
to	O
GH	O
therapy	O
.	O

Analysis	O
of	O
SNP	O
association	O
with	O
adult	O
height	O
was	O
subsequently	O
performed	O
to	O
establish	O
a	O
body	O
of	O
knowledge	O
useful	O
for	O
comparing	O
patient	O
genotypes	O
and	O
phenotypes	O
.	O

This	O
analysis	O
was	O
first	O
performed	O
in	O
controls	O
bearing	O
only	O
frequent	O
SNPs	O
(	O
90·5	O
%	O
of	O
the	O
total	O
population	O
)	O
.	O

We	O
demonstrate	O
that	O
the	O
four	O
SNPs	O
with	O
the	O
highest	O
allelic	O
variation	O
frequencies	O
(	O
P4	O
,	O
P7	O
,	O
P10	O
and	O
P24	O
)	O
do	O
not	O
significantly	O
contribute	O
to	O
adult	O
height	O
determination	O
,	O
with	O
the	O
heterozygous	O
genotype	O
being	O
the	O
most	O
frequent	O
followed	O
by	O
the	O
corresponding	O
homozygous	O
genotype	O
in	O
the	O
whole	O
sequence	O
,	O
and	O
heights	O
are	O
normally	O
distributed	O
over	O
the	O
entire	O
height	O
range	O
.	O

The	O
third	O
most	O
frequent	O
combined	O
genotype	O
in	O
the	O
promoter	O
region	O
in	O
our	O
population	O
presented	O
,	O
in	O
addition	O
,	O
in	O
heterozygosity	O
,	O
the	O
SNP	O
at	O
P6	O
in	O
the	O
sequence	O
regulated	O
by	O
Pit	O
1	O
and	O
although	O
mean	O
height	O
of	O
individuals	O
(	O
6·1	O
%	O
)	O
bearing	O
this	O
genotype	O
was	O
around	O
−0·5	O
SDS	O
,	O
this	O
was	O
not	O
statistically	O
significant	O
.	O

Analysis	O
of	O
single	O
SNP	O
genotype	O
association	O
with	O
adult	O
height	O
yielded	O
few	O
clues	O
as	O
to	O
the	O
contribution	O
of	O
GH1	O
gene	O
variation	O
to	O
adult	O
height	O
determination	O
.	O

Only	O
three	O
SNPs	O
(	O
P16	O
,	O
P17	O
and	O
P25	O
)	O
,	O
present	O
with	O
low	O
frequency	O
and	O
only	O
in	O
heterozygous	O
state	O
,	O
were	O
individually	O
significantly	O
associated	O
with	O
taller	O
stature	O
and	O
none	O
was	O
individually	O
associated	O
with	O
shorter	O
stature	O
.	O

P16	O
and	O
P17	O
(	O
in	O
LD	O
,	O
r2	O
=	O
0·83	O
)	O
are	O
located	O
in	O
intron	O
1	O
and	O
P25	O
in	O
intron	O
4	O
.	O

The	O
resulting	O
sequence	O
for	O
the	O
presence	O
of	O
P16	O
and	O
P17	O
corresponded	O
to	O
the	O
paralogue	O
GH2	O
and	O
generated	O
a	O
responsive	O
element	O
for	O
a	O
core	O
-	O
binding	O
protein	O
(	O
Matinspector	O
Programme	O
,	O
Geometrix	O
Software	O
GmbH	O
,	O
München	O
,	O
Germany	O
)	O
with	O
three	O
Kruppel	O
-	O
type	O
zinc	O
fingers	O
which	O
could	O
increase	O
the	O
efficacy	O
of	O
GH1	O
gene	O
transcription;31,32	O
moreover	O
,	O
Kruppel	O
-	O
like	O
proteins	O
have	O
recently	O
been	O
described	O
in	O
the	O
brain.33	O
Stepwise	O
regression	O
analysis	O
demonstrated	O
that	O
P17	O
and	O
P25	O
contribute	O
,	O
separately	O
,	O
to	O
an	O
increase	O
of	O
almost	O
1·0	O
height	O
SDS	O
.	O

P16	O
and	O
P17	O
had	O
been	O
described	O
by	O
Adkins	O
et	O
al.21	O
although	O
they	O
found	O
no	O
association	O
with	O
fetal	O
growth	O
,	O
whereas	O
P25	O
had	O
not	O
previously	O
been	O
described	O
.	O

The	O
mechanisms	O
by	O
which	O
they	O
may	O
determine	O
taller	O
final	O
height	O
should	O
be	O
established	O
by	O
in	O
vitro	O
studies	O
analysing	O
GH1	O
gene	O
transcription	O
and	O
GH	O
protein	O
translation	O
efficiencies	O
.	O

Analysis	O
of	O
interaction	O
effect	O
between	O
SNPs	O
detected	O
that	O
variation	O
at	O
P25	O
masked	O
an	O
effect	O
of	O
P6	O
.	O

Individuals	O
homozygous	O
at	O
P25	O
(	O
TT	O
)	O
present	O
a	O
significant	O
association	O
between	O
P6	O
genotype	O
and	O
height	O
with	O
the	O
homozygous	O
alternate	O
genotype	O
at	O
P6	O
(	O
GG	O
)	O
being	O
associated	O
with	O
shorter	O
stature	O
.	O

This	O
was	O
further	O
confirmed	O
in	O
the	O
subpopulation	O
of	O
29	O
individuals	O
bearing	O
rare	O
SNPs	O
who	O
,	O
in	O
the	O
absence	O
of	O
heterozygous	O
change	O
at	O
P25	O
,	O
presented	O
significantly	O
shorter	O
stature	O
in	O
the	O
heterozygous	O
alternate	O
nucleotide	O
change	O
at	O
P6	O
(	O
AG	O
)	O
.	O

P6	O
,	O
located	O
at	O
Pit	O
1	O
proximal	O
responsive	O
element	O
of	O
the	O
GH1	O
gene	O
promoter	O
,	O
was	O
first	O
described	O
by	O
Wagner	O
et	O
al.10	O
and	O
Giordano	O
et	O
al.9	O
and	O
further	O
by	O
Horan	O
et	O
al.12	O
Six	O
of	O
nine	O
GH1	O
gene	O
promoter	O
haplotypes	O
bearing	O
the	O
alternate	O
G	O
at	O
P6	O
presented	O
lower	O
transcriptional	O
activities	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
detected	O
differential	O
protein	O
binding	O
strength	O
,	O
although	O
in	O
vitro	O
studies	O
were	O
unable	O
to	O
identify	O
this	O
SNP	O
as	O
a	O
major	O
determinant	O
of	O
GH1	O
gene	O
expression	O
level.12	O
A	O
recent	O
study	O
from	O
Giordano	O
et	O
al.34	O
has	O
shown	O
a	O
twofold	O
reduced	O
luciferase	O
activity	O
for	O
the	O
G	O
nucleotide	O
bearing	O
promoter	O
haplotype	O
in	O
transfected	O
rat	B
pituitary	O
cells	O
.	O

Genotypes	O
at	O
P6	O
had	O
also	O
been	O
associated	O
with	O
decreased	O
breast	O
cancer	O
risk	O
through	O
its	O
association	O
with	O
lower	O
GH	O
secretion	O
and	O
IGF	O
-	O
I	O
circulating	O
levels.16,17	O
In	O
our	O
results	O
,	O
GH1	O
gene	O
polymorphic	O
structural	O
variation	O
accounted	O
for	O
only	O
6·2	O
%	O
of	O
adult	O
height	O
determination	O
in	O
the	O
entire	O
adult	O
population	O
studied	O
and	O
genome	O
-	O
wide	O
linkage	O
analysis	O
of	O
stature	O
in	O
multiple	O
populations	O
revealed	O
no	O
linkage	O
with	O
chromosome	O
17	O
GH	O
gene	O
cluster.2,35	O
As	O
only	O
some	O
of	O
the	O
less	O
frequent	O
SNPs	O
are	O
statistically	O
associated	O
with	O
height	O
,	O
and	O
in	O
view	O
of	O
the	O
high	O
density	O
of	O
SNPs	O
,	O
our	O
study	O
may	O
be	O
hampered	O
by	O
selection	O
bias36	O
and	O
would	O
ideally	O
have	O
required	O
a	O
wider	O
sampling	O
of	O
some	O
2	O
000	O
individuals	O
;	O
however	O
,	O
this	O
was	O
a	O
highly	O
laborious	O
strategy	O
when	O
the	O
complete	O
sequencing	O
technique	O
is	O
applied	O
.	O

The	O
high	O
density	O
of	O
SNPs	O
and	O
their	O
proximity	O
hamper	O
other	O
genotyping	O
strategies	O
for	O
rapid	O
determination	O
of	O
the	O
complete	O
GH1	O
SNP	O
map	O
in	O
large	O
control	O
and	O
patient	O
populations	O
.	O

Individual	O
SNP	O
associations	O
with	O
height	O
or	O
other	O
GH	O
secretion	O
-	O
related	O
phenotypic	O
traits	O
will	O
require	O
further	O
confirmation	O
by	O
studies	O
in	O
larger	O
populations	O
and	O
by	O
in	O
vitro	O
functional	O
studies	O
.	O

In	O
conclusion	O
,	O
our	O
study	O
established	O
the	O
GH1	O
gene	O
sequence	O
variation	O
map	O
in	O
an	O
adult	O
control	O
population	O
with	O
heights	O
normally	O
distributed	O
within	O
the	O
normal	O
range	O
.	O

SNPs	O
and	O
other	O
sequence	O
change	O
contributions	O
to	O
skeletal	O
growth	O
as	O
observed	O
at	O
adult	O
height	O
demonstrated	O
that	O
,	O
despite	O
the	O
high	O
frequency	O
of	O
variation	O
and	O
diversity	O
and	O
complexity	O
of	O
combinations	O
,	O
only	O
some	O
of	O
the	O
less	O
frequent	O
SNPs	O
were	O
associated	O
with	O
taller	O
stature	O
(	O
P17	O
in	O
intron	O
1	O
and	O
P25	O
in	O
intron	O
4	O
)	O
,	O
even	O
masking	O
the	O
SNP	O
contribution	O
to	O
a	O
shorter	O
one	O
(	O
P6	O
in	O
the	O
promoter	O
and	O
P12	O
in	O
the	O
5′UTR	O
regions	O
,	O
respectively	O
)	O
.	O

Systematic	O
GH1	O
gene	O
analysis	O
in	O
patients	O
with	O
growth	O
delay	O
and	O
suspected	O
GH	O
deficiency	O
/	O
insufficiency	O
will	O
clarify	O
whether	O
different	O
SNP	O
frequencies	O
and/or	O
the	O
presence	O
of	O
different	O
sequence	O
changes	O
may	O
be	O
associated	O
with	O
phenotypes	O
in	O
them	O
.	O

A	O
global	O
gene	O
evolution	O
analysis	O
on	O
Vibrionaceae	O
family	O
using	O
phylogenetic	O
profile	O
Abstract	O
Background	O
Vibrionaceae	O
represent	O
a	O
significant	O
portion	O
of	O
the	O
cultivable	O
heterotrophic	O
sea	O
bacteria	O
;	O
they	O
strongly	O
affect	O
nutrient	O
cycling	O
and	O
some	O
species	O
are	O
devastating	O
pathogens	O
.	O

In	O
this	O
work	O
we	O
propose	O
an	O
improved	O
phylogenetic	O
profile	O
analysis	O
on	O
14	O
Vibrionaceae	O
genomes	O
,	O
to	O
study	O
the	O
evolution	O
of	O
this	O
family	O
on	O
the	O
basis	O
of	O
gene	O
content	O
.	O

The	O
phylogenetic	O
profile	O
is	O
based	O
on	O
the	O
observation	O
that	O
genes	O
involved	O
in	O
the	O
same	O
process	O
(	O
e.g.	O
metabolic	O
pathway	O
or	O
structural	O
complex	O
)	O
tend	O
to	O
be	O
concurrently	O
present	O
or	O
absent	O
within	O
different	O
genomes	O
.	O

This	O
allows	O
the	O
prediction	O
of	O
hypothetical	O
functions	O
on	O
the	O
basis	O
of	O
a	O
shared	O
phylogenetic	O
profiles	O
.	O

Moreover	O
this	O
approach	O
is	O
useful	O
to	O
identify	O
putative	O
laterally	O
transferred	O
elements	O
on	O
the	O
basis	O
of	O
their	O
presence	O
on	O
distantly	O
phylogenetically	O
related	O
bacteria	O
.	O

Results	O
Vibrionaceae	O
ORFs	O
were	O
aligned	O
against	O
all	O
the	O
available	O
bacterial	O
proteomes	O
.	O

Phylogenetic	O
profile	O
is	O
defined	O
as	O
an	O
array	O
of	O
distances	O
,	O
based	O
on	O
aminoacid	O
substitution	O
matrixes	O
,	O
from	O
single	O
genes	O
to	O
all	O
their	O
orthologues	O
.	O

Final	O
phylogenetic	O
profiles	O
,	O
derived	O
from	O
non	O
-	O
redundant	O
list	O
of	O
all	O
ORFs	O
,	O
was	O
defined	O
as	O
the	O
median	O
of	O
all	O
the	O
profiles	O
belonging	O
to	O
the	O
cluster	O
.	O

The	O
resulting	O
phylogenetic	O
profiles	O
matrix	O
contains	O
gene	O
clusters	O
on	O
the	O
rows	O
and	O
organisms	O
on	O
the	O
columns	O
.	O

Cluster	O
analysis	O
identified	O
groups	O
of	O
""""	O
core	O
genes	O
""""	O
with	O
a	O
widespread	O
high	O
similarity	O
across	O
all	O
the	O
organisms	O
and	O
several	O
clusters	O
that	O
contain	O
genes	O
homologous	O
only	O
to	O
a	O
limited	O
set	O
of	O
organisms	O
.	O

On	O
each	O
of	O
these	O
clusters	O
,	O
COG	O
class	O
enrichment	O
has	O
been	O
calculated	O
.	O

The	O
analysis	O
reveals	O
that	O
clusters	O
of	O
core	O
genes	O
have	O
the	O
highest	O
number	O
of	O
enriched	O
classes	O
,	O
while	O
the	O
others	O
are	O
enriched	O
just	O
for	O
few	O
of	O
them	O
like	O
DNA	O
replication	O
,	O
recombination	O
and	O
repair	O
.	O

Conclusion	O
We	O
found	O
that	O
mobile	O
elements	O
have	O
heterogeneous	O
profiles	O
not	O
only	O
across	O
the	O
entire	O
set	O
of	O
organisms	O
,	O
but	O
also	O
within	O
Vibrionaceae	O
;	O
this	O
confirms	O
their	O
great	O
influence	O
on	O
bacteria	O
evolution	O
even	O
inside	O
the	O
same	O
family	O
.	O

Furthermore	O
,	O
several	O
hypothetical	O
proteins	O
highly	O
correlate	O
with	O
mobile	O
elements	O
profiles	O
suggesting	O
a	O
possible	O
horizontal	O
transfer	O
mechanism	O
for	O
the	O
evolution	O
of	O
these	O
genes	O
.	O

Finally	O
,	O
we	O
suggested	O
the	O
putative	O
role	O
of	O
some	O
ORFs	O
having	O
an	O
unknown	O
function	O
on	O
the	O
basis	O
of	O
their	O
phylogenetic	O
profile	O
similarity	O
to	O
well	O
characterized	O
genes	O
.	O

Background	O
Over	O
the	O
past	O
ten	O
years	O
,	O
a	O
great	O
number	O
of	O
microbial	O
genomes	O
have	O
been	O
sequenced	O
covering	O
a	O
wide	O
representation	O
of	O
prokaryots	O
as	O
well	O
as	O
multiple	O
strains	O
of	O
some	O
species	O
.	O

The	O
study	O
of	O
these	O
genomes	O
both	O
by	O
computational	O
and	O
experimental	O
approaches	O
has	O
highly	O
improved	O
our	O
understanding	O
on	O
physiology	O
,	O
phylogenetic	O
relationship	O
and	O
pathogenicity	O
of	O
many	O
organisms	O
.	O

Furthermore	O
,	O
it	O
has	O
provided	O
new	O
knowledge	O
on	O
microbial	O
genome	O
evolution	O
,	O
revealing	O
a	O
gene	O
core	O
shared	O
by	O
the	O
great	O
majority	O
of	O
bacteria	O
,	O
genes	O
characteristic	O
of	O
particular	O
groups	O
and	O
""""	O
novel	O
""""	O
genes	O
that	O
possibly	O
originated	O
by	O
lateral	O
gene	O
transfer	O
from	O
some	O
unknown	O
source	O
.	O

Analysis	O
performed	O
on	O
closely	O
related	O
genomes	O
revealed	O
that	O
a	O
substantial	O
fraction	O
of	O
genes	O
in	O
any	O
genome	O
seem	O
to	O
be	O
strain	O
specific	O
.	O

These	O
genes	O
might	O
sometime	O
arise	O
by	O
gene	O
duplication	O
followed	O
by	O
a	O
rapid	O
divergence	O
,	O
or	O
by	O
lineage	O
-	O
specific	O
loss	O
of	O
genes	O
in	O
one	O
strain	O
,	O
resulting	O
in	O
a	O
unique	O
gene	O
in	O
other	O
strains	O
.	O

However	O
,	O
there	O
are	O
several	O
lines	O
of	O
evidence	O
indicating	O
that	O
lateral	O
gene	O
transfer	O
may	O
be	O
the	O
main	O
mechanism	O
to	O
acquire	O
novel	O
genes	O
.	O

Indeed	O
,	O
this	O
could	O
be	O
one	O
of	O
the	O
main	O
forces	O
driving	O
bacterial	O
adaptation	O
and	O
evolution	O
.	O

Phage	O
DNA	O
is	O
thought	O
to	O
be	O
one	O
of	O
the	O
main	O
vectors	O
for	O
lateral	O
gene	O
transfer	O
among	O
bacteria	O
[	O
1	O
]	O
and	O
many	O
virulence	O
factors	O
from	O
bacterial	O
pathogen	O
are	O
phage	O
encoded	O
[	O
2	O
]	O
.	O

For	O
example	O
,	O
the	O
genes	O
for	O
CT	O
,	O
the	O
most	O
important	O
virulence	O
factor	O
of	O
V.	B
cholerae	I
,	O
are	O
encoded	O
in	O
the	O
genome	O
of	O
phage	O
CTXφ	O
,	O
integrated	O
in	O
the	O
bacterial	O
chromosome	O
1	O
.	O

Since	O
lateral	O
gene	O
transfer	O
plays	O
a	O
relevant	O
role	O
in	O
bacterial	O
evolution	O
,	O
the	O
reconstruction	O
of	O
phylogeny	O
is	O
very	O
complex	O
and	O
phylogenetic	O
trees	O
built	O
by	O
standard	O
sequence	O
analysis	O
may	O
not	O
lead	O
to	O
a	O
reliable	O
picture	O
of	O
the	O
evolutionary	O
history	O
.	O

In	O
fact	O
,	O
alternative	O
trees	O
can	O
be	O
obtained	O
when	O
different	O
proteins	O
are	O
considered	O
.	O

For	O
many	O
aspects	O
the	O
classification	O
of	O
bacteria	O
on	O
the	O
basis	O
of	O
their	O
global	O
gene	O
content	O
may	O
give	O
a	O
better	O
description	O
of	O
their	O
evolutionary	O
history	O
.	O

This	O
may	O
be	O
particularly	O
important	O
when	O
bacteria	O
of	O
the	O
same	O
group	O
are	O
compared	O
,	O
since	O
newly	O
acquired	O
genes	O
could	O
be	O
relevant	O
to	O
confer	O
peculiar	O
features	O
that	O
allows	O
the	O
exploitation	O
of	O
different	O
ecological	O
niches	O
.	O

In	O
this	O
study	O
we	O
propose	O
a	O
bioinformatic	O
procedure	O
to	O
investigate	O
bacterial	O
genome	O
evolution	O
,	O
taking	O
into	O
account	O
the	O
global	O
gene	O
content	O
,	O
as	O
well	O
as	O
sequence	O
similarity	O
.	O

We	O
based	O
our	O
analysis	O
on	O
modified	O
phylogenetic	O
profiles	O
[	O
3	O
]	O
;	O
however	O
,	O
we	O
do	O
not	O
consider	O
only	O
the	O
presence	O
/	O
absence	O
of	O
orthologue	O
genes	O
,	O
but	O
also	O
their	O
distance	O
,	O
based	O
on	O
a	O
substitution	O
matrix	O
.	O

A	O
phylogenetic	O
profile	O
is	O
a	O
non	O
-	O
sequence	O
-	O
homology	O
-	O
based	O
method	O
developed	O
to	O
infer	O
a	O
possible	O
functional	O
relationship	O
between	O
genes	O
.	O

It	O
is	O
based	O
on	O
the	O
idea	O
that	O
proteins	O
that	O
are	O
involved	O
in	O
the	O
same	O
metabolic	O
pathway	O
or	O
structural	O
complex	O
are	O
likely	O
to	O
evolve	O
in	O
a	O
correlate	O
fashion	O
and	O
during	O
evolution	O
appear	O
phylogenetically	O
linked	O
,	O
showing	O
a	O
tendency	O
to	O
be	O
either	O
preserved	O
or	O
eliminated	O
as	O
a	O
whole	O
.	O

Therefore	O
,	O
genes	O
showing	O
similar	O
phylogenetic	O
profiles	O
are	O
likely	O
to	O
be	O
functionally	O
related	O
.	O

We	O
extended	O
the	O
use	O
of	O
phylogenetic	O
profiles	O
to	O
produce	O
an	O
evolutionary	O
tree	O
based	O
on	O
a	O
hierarchical	O
clusterization	O
of	O
organisms	O
with	O
similar	O
phylogenetic	O
profiles	O
.	O

For	O
this	O
study	O
we	O
took	O
the	O
whole	O
gene	O
dataset	O
of	O
320	O
prokaryotic	O
genomes	O
,	O
however	O
,	O
we	O
limited	O
the	O
analysis	O
to	O
the	O
orthologous	O
groups	O
that	O
are	O
present	O
in	O
at	O
least	O
one	O
of	O
the	O
14	O
considered	O
species	O
of	O
the	O
Vibrionaceae	O
family	O
.	O

These	O
bacteria	O
belong	O
to	O
the	O
Gammaproteobacteria	O
group	O
and	O
are	O
highly	O
abundant	O
in	O
aquatic	O
environment	O
,	O
they	O
strongly	O
influence	O
nutrient	O
cycling	O
and	O
various	O
species	O
are	O
also	O
devastating	O
pathogens	O
.	O

Since	O
we	O
focused	O
our	O
analysis	O
on	O
this	O
particular	O
group	O
,	O
the	O
aim	O
of	O
this	O
study	O
is	O
not	O
the	O
construction	O
of	O
a	O
global	O
evolutionary	O
tree	O
,	O
but	O
rather	O
a	O
Vibrionaceae	O
perspective	O
of	O
bacterial	O
diversity	O
,	O
based	O
on	O
phylogenetic	O
profiles	O
.	O

Results	O
and	O
discussion	O
Phylogenetic	O
matrix	O
The	O
analysis	O
was	O
performed	O
on	O
14	O
bacteria	O
belonging	O
to	O
the	O
Vibrionaceae	O
family	O
(	O
Table	O
1	O
)	O
.	O

The	O
redundant	O
list	O
of	O
Vibrionaceae	O
ORFs	O
was	O
clustered	O
to	O
reduce	O
the	O
number	O
of	O
proteins	O
to	O
analyze	O
and	O
the	O
phylogenetic	O
profile	O
for	O
each	O
cluster	O
was	O
calculated	O
as	O
described	O
in	O
the	O
Method	O
section	O
.	O

Many	O
authors	O
proposed	O
and	O
successfully	O
applied	O
different	O
measure	O
methods	O
to	O
calculate	O
the	O
phylogenetic	O
profile	O
values	O
.	O

Pellegrini	O
et	O
al.	O
[	O
3	O
]	O
firstly	O
proposed	O
a	O
phylogenetic	O
profile	O
described	O
as	O
a	O
string	O
of	O
bits	O
,	O
each	O
bit	O
representing	O
the	O
absence	O
or	O
presence	O
of	O
an	O
homologous	O
gene	O
in	O
a	O
given	O
genome	O
.	O

This	O
method	O
lacks	O
a	O
weighting	O
procedure	O
,	O
giving	O
the	O
same	O
weight	O
(	O
value	O
1	O
)	O
to	O
all	O
the	O
sequences	O
that	O
are	O
considered	O
homologous	O
given	O
a	O
similarity	O
threshold	O
.	O

Enault	O
and	O
colleagues	O
proposed	O
an	O
improved	O
phylogenetic	O
profile	O
based	O
on	O
a	O
normalized	O
Blastp	O
bit	O
score	O
[	O
4	O
]	O
.	O

This	O
method	O
,	O
compared	O
to	O
the	O
approach	O
implemented	O
by	O
Pellegrini	O
,	O
allows	O
weighting	O
each	O
point	O
of	O
the	O
profile	O
proportionally	O
to	O
the	O
length	O
and	O
the	O
quality	O
of	O
the	O
alignment	O
.	O

Jingchun	O
and	O
colleagues	O
optimized	O
the	O
phylogenetic	O
profiles	O
method	O
by	O
integrating	O
phylogenetic	O
relationships	O
among	O
reference	O
organisms	O
and	O
sequence	O
homology	O
information	O
,	O
based	O
on	O
E	O
-	O
value	O
score	O
,	O
to	O
improve	O
prediction	O
accuracy	O
[	O
5	O
]	O
.	O

The	O
measure	O
index	O
I	O
proposed	O
in	O
this	O
work	O
is	O
similar	O
to	O
the	O
others	O
described	O
above	O
,	O
taking	O
into	O
account	O
both	O
the	O
quality	O
and	O
the	O
length	O
of	O
the	O
alignment	O
using	O
a	O
substitution	O
matrix	O
.	O

Moreover	O
our	O
approach	O
considers	O
also	O
the	O
total	O
length	O
of	O
the	O
sequences	O
,	O
penalizing	O
good	O
alignments	O
occurring	O
between	O
ORFs	O
having	O
different	O
lengths	O
and	O
taking	O
into	O
consideration	O
that	O
ORFs	O
could	O
differentiate	O
mainly	O
for	O
the	O
presence	O
of	O
functional	O
domains	O
.	O

The	O
final	O
phylogenetic	O
profile	O
for	O
each	O
cluster	O
was	O
defined	O
as	O
the	O
median	O
of	O
all	O
the	O
profiles	O
belonging	O
to	O
the	O
cluster	O
,	O
named	O
""""	O
meta	O
-	O
profile	O
""""	O
,	O
which	O
describes	O
the	O
profile	O
of	O
conserved	O
ORFs	O
belonging	O
to	O
an	O
entire	O
family	O
.	O

Hierarchical	O
cluster	O
analysis	O
A	O
hierarchical	O
cluster	O
analysis	O
was	O
performed	O
on	O
the	O
entire	O
phylogenetic	O
profile	O
matrix	O
and	O
it	O
was	O
calculated	O
a	O
statistical	O
support	O
based	O
on	O
bootstrap	O
method	O
for	O
the	O
nodes	O
of	O
the	O
columns	O
tree	O
(	O
Fig	O
1	O
)	O
.	O

The	O
branch	O
tree	O
colors	O
represent	O
the	O
bootstrap	O
percentage	O
support	O
.	O

This	O
constitutes	O
a	O
phylogenetic	O
tree	O
based	O
on	O
gene	O
content	O
using	O
Vibrionaceae	O
ORFs	O
as	O
a	O
reference	O
.	O

Genomes	O
belonging	O
to	O
the	O
same	O
taxonomic	O
group	O
tend	O
to	O
cluster	O
together	O
and	O
the	O
Vibrionaceae	O
species	O
are	O
closely	O
related	O
.	O

As	O
expected	O
,	O
according	O
to	O
the	O
Vibrionaceae	O
branch	O
lengths	O
it	O
is	O
evident	O
that	O
variability	O
within	O
this	O
group	O
is	O
higher	O
compared	O
to	O
the	O
other	O
groups	O
.	O

The	O
dataset	O
used	O
for	O
phylogenetic	O
matrix	O
calculation	O
is	O
indeed	O
composed	O
by	O
Vibrionaceae	O
ORFs	O
.	O

This	O
implies	O
that	O
the	O
similarity	O
measures	O
between	O
these	O
ORFs	O
and	O
the	O
corresponding	O
orthologues	O
will	O
be	O
nearly	O
zero	O
in	O
most	O
of	O
the	O
other	O
species	O
and	O
significantly	O
higher	O
in	O
the	O
Vibrionaceae	O
family	O
,	O
increasing	O
the	O
variability	O
into	O
this	O
group	O
.	O

Moreover	O
the	O
average	O
percentage	O
of	O
clusters	O
shared	O
by	O
the	O
Vibrionaceae	O
members	O
is	O
only	O
47.5	O
%	O
(	O
average	O
number	O
of	O
shared	O
clusters	O
divided	O
by	O
the	O
total	O
number	O
of	O
clusters	O
)	O
that	O
again	O
indicates	O
a	O
high	O
variability	O
inside	O
this	O
family	O
.	O

It	O
is	O
also	O
interesting	O
to	O
note	O
that	O
organisms	O
belonging	O
to	O
the	O
same	O
or	O
closely	O
related	O
taxa	O
split	O
into	O
different	O
subgroups	O
.	O

This	O
highlights	O
the	O
existence	O
of	O
a	O
high	O
variability	O
among	O
lineages	O
,	O
due	O
to	O
genetic	O
and	O
evolutionary	O
processes	O
such	O
as	O
lateral	O
gene	O
transfer	O
,	O
concerted	O
evolution	O
and	O
gene	O
duplication	O
[	O
6	O
]	O
.	O

In	O
terms	O
of	O
gene	O
content	O
,	O
the	O
organisms	O
more	O
related	O
to	O
the	O
Vibrionaceae	O
belong	O
to	O
the	O
gamma	O
and	O
beta	O
proteobacteria	O
.	O

In	O
particular	O
Altermonadales	O
,	O
Enterobacteriales	O
and	O
Burkholderiales	O
are	O
closely	O
related	O
to	O
Vibrionaceae	O
,	O
and	O
share	O
the	O
higher	O
number	O
of	O
cluster	O
of	O
genes	O
(	O
average	O
percentage	O
of	O
20	O
%	O
)	O
.	O

As	O
expected	O
,	O
Archea	O
are	O
the	O
most	O
distant	O
group	O
sharing	O
just	O
3.8	O
%	O
of	O
clusters	O
.	O

Clusters	O
and	O
genes	O
distribution	O
,	O
as	O
shown	O
in	O
Fig	O
2	O
,	O
reveals	O
that	O
the	O
number	O
of	O
clusters	O
and	O
genes	O
shared	O
by	O
the	O
organisms	O
decreases	O
as	O
the	O
number	O
of	O
organisms	O
considered	O
increases	O
.	O

The	O
analysis	O
was	O
performed	O
considering	O
for	O
each	O
cluster	O
profile	O
the	O
number	O
of	O
organisms	O
sharing	O
the	O
same	O
numbers	O
of	O
clusters	O
(	O
and	O
genes	O
)	O
.	O

The	O
majority	O
of	O
gene	O
cluster	O
groups	O
no	O
more	O
than	O
21	O
species	O
on	O
a	O
total	O
of	O
320	O
.	O

The	O
highest	O
blue	O
spike	O
corresponds	O
to	O
the	O
higher	O
number	O
of	O
genes	O
shared	O
by	O
105	O
groups	O
of	O
14	O
organisms	O
.	O

Among	O
these	O
groups	O
,	O
as	O
expected	O
,	O
Vibrionaceae	O
are	O
highly	O
represented	O
.	O

Other	O
species	O
represented	O
are	O
Colwellia	B
psychrerythraea	I
34H	I
and	O
Shewanella	B
oneidensis	I
,	O
that	O
belong	O
to	O
the	O
Alteromonadales	O
family	O
.	O

The	O
cluster	O
analysis	O
performed	O
on	O
genes	O
is	O
shown	O
in	O
Fig.	O
3	O
.	O

From	O
now	O
on	O
,	O
to	O
avoid	O
confusing	O
interpretation	O
between	O
clusters	O
derived	O
from	O
the	O
cluster	O
analysis	O
and	O
cluster	O
derived	O
from	O
the	O
ORFs	O
clustering	O
we	O
will	O
use	O
the	O
term	O
""""	O
gene	O
""""	O
in	O
place	O
of	O
cluster	O
of	O
ORFs	O
.	O

The	O
different	O
gradient	O
of	O
color	O
,	O
from	O
bright	O
to	O
dark	O
red	O
,	O
represents	O
decreasing	O
similarity	O
values	O
.	O

The	O
cluster	O
analysis	O
allows	O
the	O
detection	O
of	O
three	O
main	O
groups	O
of	O
genes	O
.	O

The	O
first	O
one	O
(	O
Fig	O
3	O
,	O
panel	O
B	O
)	O
contains	O
the	O
most	O
conserved	O
and	O
established	O
genes	O
shared	O
almost	O
by	O
all	O
the	O
organisms	O
.	O

These	O
core	O
genes	O
can	O
be	O
defined	O
as	O
the	O
set	O
of	O
all	O
genes	O
shared	O
as	O
orthologous	O
by	O
all	O
members	O
of	O
an	O
evolutionary	O
coherent	O
group	O
.	O

In	O
our	O
analysis	O
we	O
identify	O
four	O
clusters	O
,	O
for	O
a	O
total	O
of	O
145	O
genes	O
,	O
shared	O
by	O
all	O
the	O
320	O
organisms	O
.	O

The	O
ORFs	O
belonging	O
to	O
these	O
clusters	O
are	O
predicted	O
to	O
codify	O
for	O
the	O
ATP	O
binding	O
subunit	O
of	O
ABC	O
transporters	O
(	O
annotated	O
as	O
ABC	O
-	O
type	O
polar	O
amino	O
acid	O
transport	O
system	O
,	O
ABC	O
-	O
type	O
antimicrobial	O
peptide	O
transport	O
system	O
,	O
ABC	O
-	O
type	O
histidine	O
transport	O
system	O
and	O
ABC	O
-	O
type	O
transport	O
system	O
involved	O
in	O
lysophospholipase	O
L1	O
biosynthesis	O
)	O
.	O

This	O
finding	O
is	O
surprising	O
since	O
this	O
is	O
the	O
first	O
report	O
where	O
these	O
ORFs	O
are	O
assigned	O
to	O
the	O
core	O
genes	O
.	O

Anyway	O
two	O
different	O
explanations	O
can	O
be	O
traced	O
.	O

First	O
,	O
it	O
is	O
known	O
that	O
the	O
ABC	O
transporters	O
represent	O
an	O
essential	O
transport	O
system	O
in	O
the	O
prokaryotes	O
and	O
that	O
their	O
ATP	O
binding	O
subunits	O
are	O
apparently	O
overrepresented	O
compared	O
to	O
the	O
other	O
two	O
subunits	O
(	O
ligand	O
binding	O
and	O
permease	O
subunit	O
)	O
in	O
all	O
genomes	O
sequenced	O
thus	O
far	O
[	O
7	O
]	O
.	O

Second	O
,	O
one	O
organism	O
,	O
Buchnera	B
aphidicola	I
,	O
presents	O
these	O
genes	O
with	O
a	O
similarity	O
just	O
below	O
the	O
cut	O
-	O
off	O
used	O
for	O
the	O
analysis	O
,	O
but	O
they	O
have	O
been	O
considered	O
since	O
it	O
is	O
well	O
known	O
that	O
in	O
this	O
mutualistic	O
endosymbiont	O
the	O
accelerated	O
evolution	O
and	O
AT	O
bias	O
affect	O
all	O
its	O
genes	O
,	O
including	O
the	O
16S	O
rRNA	O
[	O
8,9	O
]	O
.	O

The	O
dataset	O
used	O
for	O
the	O
analysis	O
includes	O
genomes	O
in	O
draft	O
quality	O
(	O
Vibrio	B
cholerae	I
0395	I
,	O
Vibrio	B
cholerae	I
MO10	I
,	O
Vibrio	B
cholerae	I
RC385	I
,	O
Vibrio	B
cholerae	I
V51	I
,	O
Vibrio	B
cholerae	I
V52	I
,	O
Photobacterium	B
profundum	I
3TCK	I
,	O
Vibrio	B
MED222	I
,	O
Vibrio	B
splendidus12B01	I
)	O
.	O

Wrong	O
ORFs	O
prediction	O
or	O
missing	O
genes	O
due	O
to	O
incomplete	O
genome	O
sequences	O
can	O
explain	O
the	O
low	O
number	O
of	O
core	O
genes	O
identified	O
.	O

To	O
avoid	O
such	O
problems	O
we	O
repeated	O
the	O
analysis	O
excluding	O
the	O
draft	O
genomes	O
and	O
thus	O
considering	O
312	O
genomes	O
.	O

The	O
results	O
,	O
reported	O
in	O
Table	O
2	O
,	O
show	O
an	O
increased	O
number	O
of	O
the	O
core	O
genes	O
and	O
in	O
particular	O
ribosomal	O
proteins	O
and	O
tRNA	O
synthetase	O
,	O
as	O
reported	O
by	O
Charlesbois	O
and	O
Doolittle	O
[	O
10	O
]	O
.	O

This	O
could	O
be	O
considered	O
as	O
a	O
sort	O
of	O
""""	O
minimal	O
genome	O
""""	O
containing	O
the	O
group	O
of	O
genes	O
that	O
are	O
necessary	O
to	O
maintain	O
a	O
free	O
-	O
living	O
organism	O
.	O

The	O
low	O
number	O
of	O
genes	O
shared	O
by	O
all	O
the	O
organisms	O
can	O
be	O
due	O
to	O
many	O
factors	O
.	O

First	O
of	O
all	O
we	O
used	O
the	O
Vibrionaceae	O
ORFs	O
as	O
a	O
reference	O
,	O
limiting	O
the	O
number	O
of	O
genes	O
we	O
were	O
able	O
to	O
identify	O
.	O

It	O
was	O
further	O
demonstrated	O
that	O
the	O
core	O
gene	O
size	O
decreases	O
as	O
more	O
genome	O
sequences	O
are	O
analyzed	O
[	O
10	O
]	O
.	O

Genes	O
that	O
are	O
considered	O
to	O
belong	O
to	O
the	O
core	O
set	O
when	O
close	O
organisms	O
are	O
compared	O
,	O
are	O
classified	O
as	O
flexible	O
genes	O
when	O
distantly	O
related	O
genomes	O
are	O
analyzed	O
[	O
6	O
]	O
.	O

Finally	O
,	O
genes	O
within	O
core	O
genomes	O
might	O
be	O
transferred	O
or	O
replaced	O
,	O
introducing	O
new	O
versions	O
of	O
existing	O
genes	O
into	O
genomes	O
.	O

Such	O
transfers	O
can	O
replace	O
even	O
highly	O
conserved	O
genes	O
by	O
non	O
-	O
homologous	O
counterparts	O
but	O
the	O
advantages	O
provided	O
are	O
difficult	O
to	O
explain	O
.	O

It	O
is	O
also	O
to	O
take	O
into	O
consideration	O
that	O
many	O
symbiotic	O
and	O
parasitic	O
bacteria	O
undergo	O
a	O
reduction	O
of	O
their	O
genomes	O
,	O
loosing	O
many	O
genes	O
required	O
by	O
free	O
-	O
living	O
cell	O
.	O

The	O
second	O
group	O
(	O
Fig	O
3	O
,	O
panel	O
C	O
)	O
represents	O
genes	O
shared	O
mainly	O
among	O
Vibrionaceae	O
and	O
other	O
gamma	O
proteobacteria	O
(	O
as	O
Altermonadales	O
,	O
Burkholderiales	O
and	O
Enterobactidiales	O
)	O
.	O

Finally	O
,	O
the	O
third	O
group	O
(	O
Fig.	O
3	O
,	O
panel	O
D	O
)	O
is	O
composed	O
by	O
genes	O
that	O
are	O
mainly	O
specific	O
to	O
the	O
Vibrionaceae	O
.	O

k	O
-	O
mean	O
cluster	O
analysis	O
and	O
cluster	O
enrichment	O
We	O
performed	O
a	O
k	O
-	O
means	O
cluster	O
analysis	O
,	O
setting	O
the	O
k	O
value	O
to	O
14	O
.	O

As	O
shown	O
in	O
Fig.	O
4	O
,	O
the	O
clusters	O
3	O
,	O
4	O
,	O
11	O
,	O
13	O
and	O
14	O
contain	O
the	O
higher	O
percentage	O
of	O
genes	O
,	O
accounting	O
for	O
more	O
that	O
50	O
%	O
of	O
the	O
total	O
genes	O
,	O
while	O
clusters	O
9	O
and	O
10	O
contain	O
the	O
lower	O
number	O
of	O
ORFs	O
(	O
3	O
%	O
of	O
genes	O
)	O
.	O

The	O
variance	O
in	O
each	O
k	O
-	O
means	O
cluster	O
is	O
very	O
low	O
(	O
Fig.	O
4	O
)	O
,	O
meaning	O
that	O
the	O
clusters	O
contain	O
genes	O
with	O
compact	O
and	O
similar	O
profiles	O
.	O

As	O
described	O
in	O
Fig.	O
4	O
,	O
the	O
majority	O
of	O
the	O
clusters	O
(	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
,	O
6	O
,	O
7	O
,	O
9	O
,	O
12	O
,	O
13	O
)	O
contains	O
genes	O
with	O
a	O
similar	O
profile	O
,	O
with	O
the	O
average	O
values	O
(	O
red	O
line	O
)	O
near	O
zero	O
,	O
except	O
for	O
the	O
presence	O
of	O
some	O
spikes	O
correspondent	O
to	O
an	O
increasing	O
similarity	O
with	O
some	O
isolated	O
organisms	O
.	O

As	O
shown	O
in	O
Table	O
3	O
,	O
clusters	O
1	O
,	O
3	O
,	O
4	O
,	O
5	O
,	O
and	O
9	O
contains	O
genes	O
that	O
have	O
a	O
high	O
similarity	O
in	O
a	O
small	O
subset	O
of	O
organisms	O
.	O

The	O
majority	O
of	O
these	O
ORFs	O
are	O
annotated	O
as	O
hypothetical	O
proteins	O
or	O
phage	O
related	O
proteins	O
.	O

Clusters	O
8	O
,	O
10	O
and	O
14	O
present	O
genes	O
shared	O
among	O
almost	O
all	O
the	O
organisms	O
.	O

In	O
particular	O
cluster	O
10	O
is	O
composed	O
by	O
the	O
core	O
genes	O
described	O
before	O
having	O
an	O
high	O
value	O
of	O
similarity	O
widespread	O
among	O
all	O
the	O
organisms	O
;	O
cluster	O
8	O
contains	O
genes	O
shared	O
mainly	O
by	O
gamma	O
proteobacteria	O
and	O
cluster	O
14	O
is	O
composed	O
of	O
genes	O
in	O
common	O
between	O
Vibrionaceae	O
and	O
Enterobacteriaceae	O
.	O

A	O
functional	O
annotation	O
has	O
been	O
performed	O
on	O
each	O
gene	O
cluster	O
using	O
COG	O
(	O
Cluster	O
of	O
Orthologous	O
Genes	O
)	O
,	O
KEGG	O
pathway	O
map	O
and	O
GO	O
databases	O
.	O

For	O
each	O
k	O
-	O
mean	O
cluster	O
the	O
enrichment	O
probability	O
with	O
respect	O
to	O
the	O
total	O
number	O
of	O
clusters	O
has	O
been	O
obtained	O
with	O
the	O
hypergeometric	O
distribution	O
.	O

Fig.	O
5	O
shows	O
COG	O
enrichment	O
results	O
for	O
each	O
cluster	O
.	O

As	O
expected	O
clusters	O
represented	O
by	O
conserved	O
genes	O
(	O
cluster	O
8	O
,	O
10	O
and	O
14	O
)	O
have	O
the	O
higher	O
number	O
of	O
enriched	O
COG	O
codes	O
,	O
while	O
cluster	O
specific	O
of	O
few	O
organisms	O
are	O
characterized	O
by	O
a	O
small	O
number	O
of	O
enriched	O
COGs	O
.	O

The	O
majority	O
of	O
clusters	O
presents	O
COG	O
codes	O
enrichment	O
for	O
S	O
(	O
function	O
unknown	O
)	O
,	O
R	O
(	O
poorly	O
characterized	O
)	O
and	O
–	O
(	O
absence	O
of	O
COG	O
code	O
)	O
categories	O
.	O

This	O
is	O
due	O
to	O
the	O
large	O
abundance	O
of	O
unknown	O
and	O
hypothetical	O
proteins	O
presents	O
in	O
the	O
Vibrionaceae	O
proteomes	O
.	O

It	O
is	O
worth	O
noting	O
that	O
cluster	O
3	O
,	O
mainly	O
represented	O
by	O
Photobacterium	B
profundum	I
SS9	I
ORFs	O
,	O
is	O
enriched	O
only	O
by	O
C	O
(	O
Energy	O
production	O
and	O
conversion	O
)	O
,	O
L	O
(	O
DNA	O
replication	O
,	O
recombination	O
and	O
repair	O
)	O
and	O
M	O
(	O
Cell	O
envelope	O
biogenesis	O
,	O
outer	O
membrane	O
)	O
.	O

Probably	O
the	O
L	O
class	O
overrepresentation	O
is	O
determined	O
by	O
the	O
high	O
number	O
of	O
transposons	O
that	O
are	O
present	O
in	O
the	O
SS9	O
genome	O
[	O
11	O
]	O
.	O

The	O
role	O
played	O
by	O
these	O
transposable	O
elements	O
in	O
the	O
survival	O
of	O
this	O
deep	O
-	O
sea	O
bacterium	O
it	O
is	O
still	O
a	O
matter	O
of	O
debate	O
[	O
12	O
]	O
.	O

In	O
addition	O
V.	B
vulnificus	I
YJ016	I
and	O
V.	B
vulnificus	I
CMCP6	I
(	O
cluster	O
13	O
)	O
seem	O
to	O
share	O
genes	O
belonging	O
to	O
the	O
enriched	O
COG	O
classes	O
K	O
(	O
Transcription	O
)	O
,	O
L	O
and	O
T	O
(	O
Signal	O
transduction	O
mechanisms	O
)	O
.	O

It	O
was	O
previously	O
reported	O
an	O
enrichment	O
in	O
genes	O
belonging	O
to	O
the	O
transcription	O
class	O
in	O
the	O
genome	O
of	O
V.	B
vulnificus	I
respect	O
to	O
the	O
V.	B
cholerae	I
genome	O
[	O
13	O
]	O
.	O

This	O
class	O
is	O
clearly	O
related	O
to	O
the	O
T	O
class	O
and	O
seems	O
to	O
indicate	O
that	O
this	O
organism	O
is	O
able	O
to	O
receive	O
and	O
translate	O
in	O
a	O
transcriptional	O
response	O
specific	O
environmental	O
signals	O
.	O

Despite	O
this	O
,	O
the	O
large	O
majority	O
of	O
the	O
genes	O
in	O
clusters	O
3	O
and	O
13	O
lacks	O
COG	O
annotation	O
.	O

Cluster	O
7	O
,	O
as	O
shown	O
in	O
Table	O
3	O
,	O
accounts	O
organisms	O
with	O
large	O
genome	O
size	O
(	O
see	O
Table	O
1	O
)	O
.	O

This	O
can	O
explain	O
the	O
fact	O
the	O
this	O
cluster	O
contains	O
almost	O
all	O
the	O
COG	O
class	O
enriched	O
and	O
suggests	O
a	O
more	O
complex	O
and	O
flexible	O
life	O
-	O
style	O
of	O
these	O
organisms	O
compared	O
to	O
the	O
other	O
Vibrionaceae	O
members	O
.	O

KEGG	O
annotation	O
is	O
limited	O
to	O
metabolic	O
or	O
structural	O
complex	O
network	O
and	O
so	O
a	O
reduced	O
number	O
of	O
genes	O
have	O
a	O
KEGG	O
entry	O
.	O

This	O
causes	O
the	O
presence	O
of	O
clusters	O
without	O
enriched	O
map	O
(	O
cluster	O
2–5	O
,	O
7	O
,	O
13	O
,	O
see	O
Fig	O
5	O
)	O
.	O

Also	O
in	O
this	O
case	O
,	O
the	O
clusters	O
presenting	O
the	O
higher	O
number	O
of	O
significant	O
KEGG	O
map	O
are	O
those	O
containing	O
the	O
conserved	O
genes	O
.	O

The	O
most	O
enriched	O
KEGG	O
clusters	O
are	O
cluster	O
14	O
,	O
10	O
and	O
8	O
accounting	O
for	O
the	O
majority	O
of	O
the	O
metabolic	O
pathways	O
.	O

Cluster	O
1	O
is	O
enriched	O
for	O
map3080	O
(	O
type	O
IV	O
secretion	O
system	O
)	O
.	O

In	O
fact	O
V.	B
fischeri	I
genome	O
contains	O
10	O
separate	O
pilus	O
gene	O
clusters	O
,	O
including	O
eight	O
type	O
-	O
IV	O
pilus	O
loci	O
.	O

The	O
presence	O
of	O
multiple	O
pilus	O
gene	O
clusters	O
suggests	O
that	O
different	O
pili	O
may	O
be	O
expressed	O
in	O
different	O
environments	O
or	O
during	O
multiple	O
stages	O
of	O
its	O
development	O
as	O
a	O
symbiont	O
[	O
14	O
]	O
.	O

Cluster	O
11	O
is	O
enriched	O
for	O
map3090	O
(	O
type	O
II	O
secretion	O
system	O
)	O
.	O

The	O
type	O
II	O
pathway	O
is	O
conserved	O
among	O
gram	O
-	O
negative	O
bacteria	O
,	O
including	O
many	O
pathogens	O
,	O
and	O
secretes	O
a	O
variety	O
of	O
virulence	O
factors	O
and	O
degradative	O
enzymes	O
[	O
15	O
]	O
.	O

Cluster	O
9	O
is	O
enriched	O
for	O
map	O
00860	O
(	O
Porphyrin	O
and	O
chlorophyll	O
metabolism	O
)	O
.	O

These	O
genes	O
are	O
involved	O
in	O
the	O
cobalamin	O
(	O
coenzyme	O
B12	O
)	O
biosynthetic	O
pathway	O
[	O
16	O
]	O
.	O

Some	O
organisms	O
,	O
such	O
as	O
Salmonella	B
typhimurium	I
and	O
Klebsiella	B
pneumoniae	I
,	O
can	O
synthesize	O
cobalamin	O
de	O
novo	O
[	O
17	O
]	O
,	O
while	O
E.	B
coli	I
and	O
large	O
part	O
of	O
the	O
Vibrionaceae	O
perform	O
cobalamin	O
biosynthesis	O
only	O
when	O
provided	O
with	O
cobinamide	O
.	O

It	O
is	O
interesting	O
to	O
observe	O
that	O
the	O
genes	O
belonging	O
to	O
the	O
de	O
novo	O
pathway	O
are	O
only	O
shared	O
by	O
Archea	O
,	O
some	O
other	O
organisms	O
like	O
Salmonella	O
,	O
Pseudomonas	O
and	O
Vibrio	B
MED222	I
.	O

Finally	O
cluster	O
6	O
is	O
enriched	O
by	O
map2010	O
(	O
ABC	O
transporter	O
)	O
,	O
map2020	O
(	O
two	O
-	O
component	O
system	O
)	O
,	O
map2030	O
and	O
map2031	O
(	O
bacterial	O
chemotaxis	O
)	O
,	O
map2040	O
(	O
Flagellar	O
assembly	O
)	O
and	O
map3090	O
(	O
type	O
II	O
secretion	O
system	O
)	O
.	O

This	O
cluster	O
contains	O
genes	O
shared	O
with	O
a	O
high	O
similarity	O
by	O
all	O
Vibrio	O
and	O
with	O
a	O
lower	O
similarity	O
with	O
Photobacterium	B
profundum	I
species	O
.	O

Among	O
the	O
Vibrio	O
species	O
the	O
organisms	O
showing	O
the	O
highest	O
similarity	O
(	O
Tab	O
.	O
3	O
)	O
are	O
V.	B
cholerae	I
strains	O
.	O

Vibrionaceae	O
specific	O
genes	O
We	O
identify	O
1940	O
clusters	O
specific	O
to	O
the	O
Vibrionaceae	O
.	O

All	O
the	O
Vibrionaceae	O
considered	O
in	O
the	O
analysis	O
share	O
108	O
clusters	O
.	O

Among	O
these	O
genes	O
we	O
identify	O
ToxR	O
and	O
ToxS	O
genes	O
.	O

ToxR	O
gene	O
encodes	O
a	O
transmembrane	O
regulatory	O
protein	O
firstly	O
identified	O
in	O
V.	B
cholerae	I
,	O
in	O
which	O
it	O
co	O
-	O
ordinates	O
many	O
virulence	O
factors	O
in	O
response	O
to	O
several	O
environmental	O
parameters	O
[	O
18	O
]	O
.	O

V.	B
cholerae	I
ToxR	O
activity	O
is	O
enhanced	O
by	O
a	O
second	O
transmembrane	O
protein	O
,	O
ToxS	O
,	O
encoded	O
downstream	O
toxR	O
[	O
19	O
]	O
.	O

This	O
family	O
of	O
proteins	O
is	O
involved	O
in	O
response	O
to	O
temperature	O
,	O
pH	O
,	O
osmolarity	O
and	O
in	O
Photobacterium	B
profundum	I
SS9	I
,	O
a	O
piezophilic	O
bacterium	O
,	O
to	O
hydrostatic	O
pressure	O
[	O
20	O
]	O
.	O

The	O
widespread	O
presence	O
of	O
these	O
genes	O
among	O
the	O
Vibrionaceae	O
suggests	O
their	O
importance	O
in	O
regulatory	O
mechanisms	O
.	O

We	O
identify	O
two	O
other	O
noteworthy	O
groups	O
of	O
genes	O
composed	O
by	O
257	O
and	O
160	O
genes	O
respectively	O
shared	O
just	O
by	O
two	O
strains	O
,	O
mainly	O
annotated	O
as	O
""""	O
hypothetical	O
protein	O
""""	O
.	O

The	O
first	O
group	O
of	O
genes	O
is	O
shared	O
between	O
Photobacterium	B
profundum	I
SS9	I
and	O
Photobacterium	B
profundum	I
3TCK	I
,	O
while	O
the	O
second	O
is	O
shared	O
between	O
V.	B
vulnificus	I
CMCP6	I
and	O
YJ016	B
.	O

These	O
strains	O
are	O
closely	O
related	O
and	O
this	O
explains	O
the	O
high	O
number	O
of	O
shared	O
genes	O
;	O
while	O
,	O
inside	O
the	O
Vibrionaceae	O
family	O
,	O
the	O
number	O
of	O
specific	O
shared	O
genes	O
highly	O
decreases	O
,	O
showing	O
a	O
high	O
inter	O
-	O
species	O
variability	O
(	O
Fig.	O
6	O
)	O
Prophages	O
and	O
transposases	O
Prophages	O
recover	O
different	O
biological	O
roles	O
both	O
as	O
quantitatively	O
important	O
genetic	O
elements	O
of	O
the	O
bacterial	O
chromosome	O
,	O
and	O
as	O
vectors	O
of	O
lateral	O
gene	O
transfer	O
among	O
bacteria	O
,	O
due	O
to	O
their	O
characters	O
of	O
mobile	O
DNA	O
elements	O
.	O

Indeed	O
,	O
numerous	O
virulence	O
factors	O
from	O
bacterial	O
pathogens	O
are	O
phage	O
encoded	O
.	O

It	O
was	O
postulated	O
that	O
this	O
role	O
of	O
prophages	O
is	O
not	O
limited	O
to	O
pathogenic	O
bacteria	O
but	O
some	O
adaptations	O
of	O
nonpathogenic	O
strains	O
to	O
their	O
ecological	O
niche	O
might	O
also	O
be	O
mediated	O
by	O
prophages	O
acquisition	O
[	O
21	O
]	O
.	O

To	O
better	O
understand	O
the	O
importance	O
of	O
mobile	O
elements	O
within	O
Vibrionaceae	O
family	O
,	O
we	O
performed	O
a	O
hierarchical	O
cluster	O
analysis	O
using	O
gene	O
profiles	O
annotated	O
as	O
""""	O
phage	O
protein	O
""""	O
and	O
""""	O
transposase	O
""""	O
,	O
for	O
a	O
total	O
of	O
172	O
clusters	O
of	O
genes	O
(	O
Fig	O
7	O
)	O
.	O

We	O
found	O
that	O
a	O
high	O
inter	O
-	O
strain	O
genetic	O
variability	O
exists	O
and	O
phages	O
and	O
transposases	O
are	O
both	O
shared	O
by	O
almost	O
all	O
Vibrionaceae	O
,	O
and	O
specific	O
to	O
just	O
some	O
organisms	O
.	O

We	O
identified	O
five	O
major	O
clusters	O
of	O
mobile	O
elements	O
that	O
are	O
specific	O
to	O
a	O
single	O
organism	O
.	O

A	O
group	O
composed	O
by	O
26	O
clusters	O
containing	O
both	O
transposase	O
and	O
phage	O
proteins	O
seem	O
to	O
be	O
unique	O
to	O
V.	B
splendiduds	I
12B01	I
(	O
Fig	O
7	O
)	O
.	O

Another	O
one	O
composed	O
by	O
16	O
clusters	O
is	O
specific	O
of	O
V.	B
vulnificus	I
CMCP6	I
(	O
Fig	O
7	O
)	O
while	O
V.	B
parahaemoliticus	I
has	O
a	O
cluster	O
of	O
11	O
genes	O
(	O
Fig	O
7	O
)	O
.	O

Moreover	O
there	O
is	O
another	O
group	O
of	O
transposases	O
and	O
phage	O
genes	O
shared	O
mainly	O
by	O
V.	B
cholerae	I
0395	O
,	O
Shewanella	B
oneidensis	I
and	O
V.	B
cholerae	I
V51	O
(	O
Fig	O
7	O
)	O
.	O

Finally	O
a	O
big	O
cluster	O
of	O
almost	O
30	O
genes	O
,	O
all	O
predicted	O
to	O
codify	O
for	O
transposases	O
,	O
was	O
found	O
in	O
P.	B
profundum	I
SS9	I
genome	O
(	O
Fig.	O
7	O
)	O
.	O

The	O
high	O
presence	O
of	O
transposases	O
in	O
this	O
bacterium	O
seems	O
to	O
correlate	O
with	O
its	O
deep	O
-	O
sea	O
habitat	O
,	O
a	O
feature	O
presumably	O
shared	O
with	O
other	O
deep	O
-	O
sea	O
microorganisms	O
[	O
12	O
]	O
.	O

As	O
shown	O
in	O
Fig	O
7	O
,	O
many	O
of	O
the	O
clusters	O
well	O
conserved	O
in	O
an	O
organism	O
,	O
are	O
partially	O
shared	O
with	O
a	O
low	O
similarity	O
by	O
other	O
organisms	O
.	O

This	O
agrees	O
with	O
the	O
idea	O
that	O
prophages	O
are	O
not	O
maintained	O
in	O
the	O
genome	O
over	O
a	O
long	O
period	O
of	O
time	O
and	O
part	O
of	O
their	O
genes	O
may	O
be	O
deleted	O
from	O
the	O
chromosome	O
.	O

Moreover	O
,	O
microarray	O
analysis	O
and	O
PCR	O
scanning	O
demonstrated	O
that	O
prophages	O
are	O
frequently	O
strain	O
specific	O
within	O
a	O
given	O
bacterial	O
species	O
[	O
22	O
-	O
24	O
]	O
.	O

According	O
to	O
the	O
modular	O
theory	O
of	O
phage	O
evolution	O
,	O
phage	O
genomes	O
are	O
mosaics	O
of	O
modules	O
,	O
groups	O
of	O
genes	O
functionally	O
related	O
,	O
that	O
are	O
free	O
to	O
recombine	O
in	O
genetic	O
exchanges	O
between	O
distinct	O
phages	O
infecting	O
the	O
same	O
cell	O
[	O
21	O
]	O
.	O

This	O
can	O
result	O
in	O
the	O
occurrences	O
of	O
different	O
part	O
of	O
phage	O
distributed	O
in	O
far	O
related	O
genomes	O
.	O

Phylogenetic	O
profile	O
of	O
some	O
transposases	O
is	O
similar	O
to	O
the	O
phage	O
ones	O
,	O
suggesting	O
a	O
possible	O
transfer	O
mechanism	O
phage	O
-	O
mediated	O
for	O
such	O
mobile	O
elements	O
.	O

Conclusion	O
In	O
this	O
work	O
we	O
propose	O
an	O
improved	O
phylogenetic	O
profile	O
analysis	O
on	O
14	O
Vibrionaceae	O
genomes	O
,	O
to	O
study	O
this	O
family	O
on	O
the	O
basis	O
of	O
gene	O
content	O
.	O

Using	O
a	O
phylogenetic	O
profile	O
for	O
each	O
cluster	O
of	O
genes	O
defined	O
as	O
the	O
median	O
of	O
all	O
the	O
profiles	O
belonging	O
to	O
the	O
cluster	O
(	O
meta	O
-	O
profile	O
)	O
we	O
investigate	O
the	O
evolution	O
of	O
groups	O
of	O
ORFs	O
belonging	O
to	O
the	O
entire	O
family	O
.	O

A	O
two	O
-	O
way	O
cluster	O
analysis	O
allows	O
us	O
to	O
identify	O
similarity	O
structures	O
on	O
the	O
entire	O
phylogenetic	O
matrix	O
composed	O
by	O
8,239	O
clusters	O
of	O
genes	O
and	O
320	O
organisms	O
.	O

The	O
phylogenetic	O
tree	O
obtained	O
with	O
the	O
cluster	O
analysis	O
does	O
not	O
reflect	O
the	O
global	O
evolutionary	O
tree	O
because	O
of	O
the	O
Vibrionaceae	O
ORFs	O
dataset	O
used	O
for	O
the	O
analysis	O
,	O
but	O
rather	O
can	O
be	O
considered	O
as	O
the	O
Vibrionaceae	O
perspective	O
of	O
bacterial	O
diversity	O
.	O

The	O
phylogenetic	O
tree	O
reflects	O
the	O
evolutionary	O
processes	O
that	O
shape	O
genomes	O
,	O
as	O
lateral	O
gene	O
transfer	O
,	O
genes	O
genesis	O
and	O
loss	O
.	O

In	O
this	O
context	O
,	O
the	O
tree	O
allows	O
to	O
group	O
together	O
genomes	O
on	O
the	O
base	O
of	O
their	O
global	O
gene	O
content	O
.	O

We	O
found	O
that	O
genomes	O
belonging	O
to	O
the	O
same	O
taxonomic	O
group	O
tend	O
to	O
cluster	O
together	O
and	O
that	O
Vibrionaceae	O
species	O
are	O
closely	O
related	O
.	O

Moreover	O
organisms	O
belonging	O
to	O
the	O
same	O
or	O
closely	O
related	O
taxa	O
split	O
into	O
different	O
subgroups	O
,	O
confirming	O
the	O
existence	O
of	O
a	O
high	O
variability	O
among	O
lineages	O
,	O
due	O
to	O
genetic	O
and	O
evolutionary	O
process	O
such	O
as	O
lateral	O
gene	O
transfer	O
,	O
concerted	O
evolution	O
and	O
genes	O
duplication	O
.	O

On	O
the	O
other	O
hand	O
several	O
groups	O
of	O
genes	O
characterised	O
by	O
different	O
homogeneous	O
profiles	O
have	O
been	O
identified	O
.	O

In	O
particular	O
we	O
found	O
,	O
1	O
)	O
a	O
set	O
of	O
conserved	O
genes	O
(	O
with	O
a	O
high	O
similarity	O
values	O
across	O
all	O
organisms	O
)	O
that	O
reflects	O
the	O
""""	O
minimal	O
genome	O
""""	O
composition	O
defined	O
in	O
other	O
previous	O
works	O
;	O
2	O
)	O
a	O
set	O
of	O
genes	O
mainly	O
shared	O
by	O
Vibrionaceae	O
and	O
other	O
Gamma	O
proteobacteria	O
and	O
3	O
)	O
genes	O
specific	O
to	O
different	O
sets	O
of	O
Vibrionaceae	O
.	O

Finally	O
a	O
further	O
analysis	O
on	O
prophage	O
and	O
transposase	O
has	O
confirmed	O
the	O
high	O
inter	O
-	O
strain	O
genetic	O
variability	O
even	O
among	O
closely	O
related	O
species	O
.	O

The	O
increasing	O
number	O
of	O
genomes	O
included	O
in	O
this	O
type	O
of	O
analysis	O
surely	O
add	O
new	O
sorces	O
of	O
variability	O
and	O
noise	O
,	O
anyway	O
we	O
think	O
that	O
the	O
use	O
of	O
meta	O
-	O
profiles	O
can	O
be	O
useful	O
for	O
complexity	O
reduction	O
and	O
data	O
analysis	O
to	O
study	O
global	O
gene	O
evolution	O
.	O

Methods	O
Datasets	O
The	O
Vibrionaceae	O
species	O
used	O
in	O
this	O
analysis	O
were	O
selected	O
among	O
the	O
freely	O
available	O
complete	O
and	O
draft	O
genome	O
sequences	O
.	O

The	O
proteomes	O
of	O
V.	B
cholerae	I
N16961	I
,	O
V.	B
parahaemolyticus	I
,	O
V.	B
vulnificus	I
YJ016	I
,	O
V.	B
vulnificus	I
CMCP6	I
,	O
V.	B
fischeri	I
ES114	I
,	O
Photobacterium	B
profundum	I
SS9	I
were	O
downloaded	O
from	O
the	O
NCBI	O
ftp	O
site	O
[	O
25	O
]	O
.	O

Protein	O
sequences	O
of	O
Vibrio	B
cholerae	I
MO10	I
,	O
Vibrio	B
cholerae	I
0395	I
,	O
Vibrio	B
cholerae	I
RC385	I
,	O
Vibrio	B
cholerae	I
V51	I
,	O
Vibrio	B
cholerae	I
V52	I
were	O
downloaded	O
from	O
the	O
NCBI	O
genome	O
database	O
,	O
while	O
sequences	O
of	O
Vibrio	B
MED222	I
,	O
Vibrio	B
splendidus	I
12B01	I
,	O
Photobacterium	B
profundum	I
3TCK	I
from	O
the	O
J.	O
Craig	O
Venter	O
Institute	O
web	O
site	O
.	O

The	O
320	O
complete	O
genomes	O
update	O
at	O
03	O
/	O
06	O
were	O
downloaded	O
from	O
the	O
NCBI	O
ftp	O
site	O
.	O

Similarity	O
search	O
and	O
phylogenetic	O
profile	O
construction	O
All	O
the	O
Vibrionaceae	O
ORFs	O
were	O
merged	O
generating	O
a	O
redundant	O
list	O
of	O
59,669	O
proteins	O
and	O
were	O
compared	O
to	O
all	O
open	O
reading	O
frame	O
from	O
320	O
bacterial	O
and	O
archeal	O
genomes	O
using	O
Blastp	O
.	O

To	O
determine	O
the	O
presence	O
of	O
an	O
orthologous	O
we	O
used	O
a	O
combination	O
of	O
three	O
different	O
thresholds	O
;	O
a	O
similarity	O
value	O
equal	O
to	O
or	O
higher	O
than	O
30	O
%	O
,	O
an	O
alignment	O
length	O
equal	O
or	O
higher	O
than	O
70	O
%	O
and	O
an	O
Evalue	O
score	O
lower	O
than	O
or	O
equal	O
to	O
e-6	O
.	O

After	O
determining	O
the	O
presence	O
of	O
an	O
orthologous	O
gene	O
,	O
we	O
computed	O
a	O
similarity	O
index	O
I	O
for	O
each	O
pair	O
of	O
orthologous	O
(	O
a	O
point	O
of	O
the	O
phylogenetic	O
profile	O
)	O
as	O
follow	O
:	O

I	O
=	O
SqsSqq⋅min⁡	O
(	O
lq	O
,	O
ls	O
)	O
max⁡	O
(	O
lq	O
,	O
ls	O
)	O
MathType@MTEF@5@5@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacqWGjbqscqGH9aqpdaWcaaqaaiabdofatnaaBaaaleaacqWGXbqCcqWGZbWCaeqaaaGcbaGaem4uam1aaSbaaSqaaiabdghaXjabdghaXbqabaaaaOGaeyyXIC9aaSaaaeaacyGGTbqBcqGGPbqAcqGGUbGBcqGGOaakcqWGSbaBdaWgaaWcbaGaemyCaehabeaakiabcYcaSiabdYgaSnaaBaaaleaacqWGZbWCaeqaaOGaeiykaKcabaGagiyBa0MaeiyyaeMaeiiEaGNaeiikaGIaemiBaW2aaSbaaSqaaiabdghaXbqabaGccqGGSaalcqWGSbaBdaWgaaWcbaGaem4CamhabeaakiabcMcaPaaaaaa@532D@	O
where	O
lq	O
and	O
ls	O
are	O
the	O
query	O
and	O
subject	O
length	O
sequence	O
respectively	O
and	O
Sqs	O
is	O
the	O
similarity	O
score	O
between	O
the	O
query	O
and	O
the	O
subject	O
sequence	O
.	O

Sqs	O
is	O
defined	O
as	O
follow	O
:	O
Sqs=∑i=1MαAqi	O
,	O
Asi+GP	O
MathType@MTEF@5@5@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacqWGtbWudaWgaaWcbaGaemyCaeNaem4Camhabeaakiabg2da9maaqahabaacciGae8xSde2aaSbaaSqaaiabdgeabjabdghaXjabdMgaPjabcYcaSiabdgeabjabdohaZjabdMgaPbqabaaabaGaemyAaKMaeyypa0JaeGymaedabaGaemyta0eaniabggHiLdGccqGHRaWkcqWGhbWrcqWGqbauaaa@4620@	O
where	O
M	O
is	O
the	O
match	O
length	O
between	O
the	O
query	O
and	O
subject	O
sequence	O
;	O
Aqi	O
and	O
Asi	O
respectively	O
the	O
query	O
and	O
subject	O
amino	O
acid	O
in	O
position	O
i	O
;	O
α	O
the	O
BLOSUM	O
substitution	O
matrix	O
value	O
for	O
amino	O
acid	O
pair	O
Aqi	O
,	O
Asi	O
and	O
GP	O
the	O
gap	O
penalty	O
.	O

GP	O
is	O
defined	O
as	O
follow	O
:	O
GP	O
=	O
GOP+GEP	O
(	O
k-1	O
)	O
where	O
GOP	O
is	O
the	O
Gap	O
Open	O
Penalty	O
set	O
to	O
-11	O
,	O
GEP	O
the	O
Gap	O
Extension	O
Penalty	O
set	O
to	O
-1	O
and	O
k	O
the	O
gap	O
length	O
.	O

Sqq	O
represents	O
the	O
score	O
of	O
the	O
self	O
-	O
aligned	O
query	O
sequence	O
.	O

Sqs	O
is	O
always	O
smaller	O
than	O
Sqq	O
and	O
the	O
score	O
S	O
range	O
between	O
0	O
and	O
1	O
.	O

In	O
order	O
to	O
take	O
into	O
account	O
also	O
the	O
different	O
sequence	O
lengths	O
,	O
we	O
multiplied	O
the	O
score	O
S	O
by	O
the	O
ratio	O
between	O
the	O
minimum	O
length	O
between	O
query	O
and	O
subject	O
and	O
the	O
maximum	O
length	O
between	O
query	O
and	O
subjects	O
.	O

In	O
this	O
way	O
the	O
total	O
score	O
is	O
weighted	O
on	O
the	O
base	O
of	O
the	O
length	O
,	O
resulting	O
in	O
a	O
lower	O
similarity	O
value	O
if	O
the	O
lengths	O
of	O
the	O
sequences	O
are	O
different	O
.	O

The	O
phylogenetic	O
profile	O
for	O
each	O
ORF	O
is	O
an	O
array	O
of	O
index	O
I	O
with	O
length	O
equal	O
to	O
the	O
number	O
of	O
genomes	O
considered	O
(	O
320	O
)	O
.	O

ORFs	O
clustering	O
The	O
redundant	O
list	O
of	O
59,669	O
Vibrionaceae	O
ORFs	O
contained	O
multiple	O
copies	O
of	O
the	O
same	O
genes	O
due	O
to	O
the	O
presence	O
of	O
conserved	O
genes	O
in	O
the	O
considered	O
genomes	O
.	O

In	O
order	O
to	O
reduce	O
the	O
redundancy	O
,	O
we	O
clustered	O
proteins	O
using	O
a	O
two	O
-	O
step	O
approach	O
.	O

The	O
first	O
step	O
is	O
based	O
on	O
COG	O
(	O
Cluster	O
of	O
Othologous	O
Genes	O
)	O
annotation	O
.	O

COG	O
classifies	O
conserved	O
genes	O
according	O
to	O
their	O
homologous	O
relationships	O
.	O

All	O
the	O
Vibrionaceae	O
ORFs	O
were	O
annotated	O
using	O
COG	O
clusters	O
and	O
proteins	O
sharing	O
the	O
same	O
COG	O
code	O
were	O
considered	O
belonging	O
to	O
the	O
same	O
cluster	O
.	O

In	O
particular	O
,	O
the	O
annotation	O
process	O
consists	O
of	O
a	O
similarity	O
search	O
of	O
all	O
the	O
ORFs	O
against	O
the	O
COG	O
proteins	O
using	O
blast	O
and	O
considering	O
the	O
best	O
hit	O
for	O
each	O
protein	O
.	O

43,024	O
ORFs	O
presented	O
a	O
similarity	O
with	O
a	O
COG	O
entry	O
,	O
producing	O
2,463	O
different	O
clusters	O
.	O

In	O
the	O
second	O
step	O
,	O
the	O
remaining	O
16,645	O
ORFs	O
without	O
similarity	O
with	O
any	O
COG	O
entry	O
were	O
clustered	O
using	O
CD	O
-	O
HIT	O
software	O
[	O
26	O
]	O
.	O

CD	O
-	O
HIT	O
program	O
clusters	O
protein	O
sequence	O
database	O
at	O
high	O
sequence	O
identity	O
threshold	O
and	O
efficiently	O
removes	O
high	O
sequence	O
redundancy	O
.	O

This	O
last	O
clustering	O
process	O
produced	O
9,613	O
different	O
groups	O
of	O
similar	O
proteins	O
.	O

Finally	O
from	O
the	O
12,076	O
total	O
clusters	O
obtained	O
by	O
this	O
methodology	O
,	O
those	O
composed	O
by	O
ORFs	O
that	O
do	O
not	O
have	O
any	O
ortologous	O
genes	O
(	O
with	O
a	O
phylogenetic	O
profile	O
composed	O
by	O
an	O
array	O
with	O
all	O
zero	O
values	O
except	O
for	O
one	O
position	O
match	O
with	O
itself	O
)	O
were	O
eliminated	O
,	O
resulting	O
in	O
a	O
dataset	O
composed	O
by	O
8,239	O
distinct	O
clusters	O
.	O

The	O
final	O
phylogenetic	O
profile	O
for	O
each	O
cluster	O
(	O
meta	O
-	O
profile	O
)	O
was	O
defined	O
as	O
the	O
median	O
of	O
all	O
the	O
profiles	O
belonging	O
to	O
the	O
cluster	O
.	O

At	O
the	O
end	O
of	O
these	O
procedures	O
the	O
final	O
phylogenetic	O
matrix	O
was	O
composed	O
by	O
8,239	O
rows	O
(	O
cluster	O
of	O
genes	O
)	O
and	O
320	O
columns	O
(	O
organisms	O
)	O
.	O

In	O
each	O
cell	O
the	O
median	O
of	O
the	O
index	O
in	O
the	O
cluster	O
was	O
reported	O
.	O

Cluster	O
analysis	O
Several	O
clustering	O
techniques	O
have	O
been	O
used	O
to	O
identify	O
the	O
similarity	O
structure	O
underneath	O
our	O
data	O
.	O

A	O
k	O
-	O
means	O
and	O
a	O
two	O
-	O
way	O
hierarchical	O
cluster	O
analysis	O
with	O
Euclidean	O
distance	O
and	O
complete	O
linkage	O
were	O
performed	O
on	O
the	O
phylogenetic	O
matrix	O
.	O

The	O
goal	O
of	O
a	O
cluster	O
analysis	O
is	O
to	O
partition	O
the	O
elements	O
into	O
subsets	O
without	O
any	O
constrains	O
or	O
a	O
priori	O
information	O
,	O
so	O
that	O
two	O
criteria	O
are	O
satisfied	O
:	O
homogeneity	O
,	O
elements	O
inside	O
a	O
cluster	O
are	O
highly	O
similar	O
to	O
each	O
other	O
;	O
and	O
separation	O
,	O
elements	O
from	O
different	O
clusters	O
have	O
low	O
similarity	O
to	O
each	O
other	O
.	O

The	O
Figure	O
of	O
Merit	O
(	O
FOM	O
)	O
is	O
a	O
measure	O
of	O
fit	O
of	O
the	O
expression	O
patterns	O
for	O
the	O
clusters	O
produced	O
by	O
a	O
particular	O
algorithm	O
that	O
estimates	O
the	O
predictive	O
power	O
of	O
a	O
clustering	O
algorithm	O
.	O

It	O
is	O
computed	O
by	O
removing	O
each	O
sample	O
in	O
turn	O
from	O
the	O
data	O
set	O
,	O
clustering	O
genes	O
based	O
on	O
the	O
remaining	O
data	O
,	O
and	O
calculating	O
the	O
fit	O
of	O
the	O
withheld	O
sample	O
to	O
the	O
clustering	O
pattern	O
obtained	O
from	O
the	O
other	O
samples	O
.	O

On	O
our	O
data	O
FOM	O
analysis	O
identified	O
the	O
best	O
number	O
of	O
k	O
-	O
means	O
clusters	O
between	O
10	O
and	O
15	O
.	O

We	O
decided	O
to	O
set	O
k	O
(	O
in	O
the	O
k	O
-	O
means	O
analysis	O
)	O
equal	O
to	O
14	O
.	O

In	O
each	O
of	O
these	O
14	O
clusters	O
subsequent	O
hierarchical	O
cluster	O
analysis	O
was	O
performed	O
with	O
bootstrap	O
cluster	O
assessment	O
.	O

All	O
the	O
previous	O
analyses	O
were	O
performed	O
with	O
TMEV	O
software	O
[	O
27	O
]	O
,	O
freely	O
available	O
at	O
[	O
28	O
]	O
.	O

Enrichment	O
categories	O
Each	O
cluster	O
of	O
genes	O
has	O
been	O
annotated	O
according	O
to	O
COG	O
code	O
,	O
GO	O
terms	O
and	O
KEGG	O
pathway	O
maps	O
.	O

Class	O
enrichment	O
(	O
with	O
respect	O
to	O
the	O
entire	O
matrix	O
)	O
has	O
been	O
calculated	O
according	O
to	O
the	O
hypergeometric	O
distribution	O
that	O
was	O
used	O
to	O
obtain	O
the	O
chance	O
probability	O
of	O
observing	O
the	O
number	O
of	O
genes	O
annotated	O
with	O
a	O
particular	O
COG	O
,	O
GO	O
and	O
KEGG	O
category	O
among	O
the	O
selected	O
cluster	O
.	O

The	O
probability	O
P	O
of	O
observing	O
at	O
least	O
k	O
genes	O
of	O
a	O
functional	O
category	O
within	O
a	O
group	O
of	O
n	O
genes	O
is	O
given	O
by	O
:	O
P=∑i	O
=	O
kn	O
(	O
fi	O
)	O
(	O
g−fn−i	O
)	O
(	O
gn	O
)	O
MathType@MTEF@5@5@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacqWGqbaucqGH9aqpdaaeWbqaamaalaaabaWaaeWaaeaafaqabeGabaaabaGaemOzaygabaGaemyAaKgaaaGaayjkaiaawMcaamaabmaabaqbaeqabiqaaaqaaiabdEgaNjabgkHiTiabdAgaMbqaaiabd6gaUjabgkHiTiabdMgaPbaaaiaawIcacaGLPaaaaeaadaqadaqaauaabeqaceaaaeaacqWGNbWzaeaacqWGUbGBaaaacaGLOaGaayzkaaaaaaWcbaGaemyAaKMaeyypa0Jaem4AaSgabaGaemOBa4ganiabggHiLdaaaa@47C6@	O
where	O
f	O
is	O
the	O
total	O
number	O
of	O
genes	O
with	O
the	O
same	O
category	O
(	O
in	O
the	O
matrix	O
)	O
and	O
g	O
is	O
the	O
total	O
number	O
of	O
genes	O
in	O
our	O
matrix	O
.	O

Dynein	O
Modifiers	O
in	O
C.	B
elegans	I
:	O

Light	O
Chains	O
Suppress	O
Conditional	O
Heavy	O
Chain	O
Mutants	O
Abstract	O
Cytoplasmic	O
dynein	O
is	O
a	O
microtubule	O
-	O
dependent	O
motor	O
protein	O
that	O
functions	O
in	O
mitotic	O
cells	O
during	O
centrosome	O
separation	O
,	O
metaphase	O
chromosome	O
congression	O
,	O
anaphase	O
spindle	O
elongation	O
,	O
and	O
chromosome	O
segregation	O
.	O

Dynein	O
is	O
also	O
utilized	O
during	O
interphase	O
for	O
vesicle	O
transport	O
and	O
organelle	O
positioning	O
.	O

While	O
numerous	O
cellular	O
processes	O
require	O
cytoplasmic	O
dynein	O
,	O
the	O
mechanisms	O
that	O
target	O
and	O
regulate	O
this	O
microtubule	O
motor	O
remain	O
largely	O
unknown	O
.	O

By	O
screening	O
a	O
conditional	O
Caenorhabditis	B
elegans	I
cytoplasmic	O
dynein	O
heavy	O
chain	O
mutant	O
at	O
a	O
semipermissive	O
temperature	O
with	O
a	O
genome	O
-	O
wide	O
RNA	O
interference	O
library	O
to	O
reduce	O
gene	O
functions	O
,	O
we	O
have	O
isolated	O
and	O
characterized	O
twenty	O
dynein	O
-	O
specific	O
suppressor	O
genes	O
.	O

When	O
reduced	O
in	O
function	O
,	O
these	O
genes	O
suppress	O
dynein	O
mutants	O
but	O
not	O
other	O
conditionally	O
mutant	O
loci	O
,	O
and	O
twelve	O
of	O
the	O
20	O
specific	O
suppressors	O
do	O
not	O
exhibit	O
sterile	O
or	O
lethal	O
phenotypes	O
when	O
their	O
function	O
is	O
reduced	O
in	O
wild	O
-	O
type	O
worms	B
.	O

Many	O
of	O
the	O
suppressor	O
proteins	O
,	O
including	O
two	O
dynein	O
light	O
chains	O
,	O
localize	O
to	O
subcellular	O
sites	O
that	O
overlap	O
with	O
those	O
reported	O
by	O
others	O
for	O
the	O
dynein	O
heavy	O
chain	O
.	O

Furthermore	O
,	O
knocking	O
down	O
any	O
one	O
of	O
four	O
putative	O
dynein	O
accessory	O
chains	O
suppresses	O
the	O
conditional	O
heavy	O
chain	O
mutants	O
,	O
suggesting	O
that	O
some	O
accessory	O
chains	O
negatively	O
regulate	O
heavy	O
chain	O
function	O
.	O

We	O
also	O
identified	O
29	O
additional	O
genes	O
that	O
,	O
when	O
reduced	O
in	O
function	O
,	O
suppress	O
conditional	O
mutations	O
not	O
only	O
in	O
dynein	O
but	O
also	O
in	O
loci	O
required	O
for	O
unrelated	O
essential	O
processes	O
.	O

In	O
conclusion	O
,	O
we	O
have	O
identified	O
twenty	O
genes	O
that	O
in	O
many	O
cases	O
are	O
not	O
essential	O
themselves	O
but	O
are	O
conserved	O
and	O
when	O
reduced	O
in	O
function	O
can	O
suppress	O
conditionally	O
lethal	O
C.	B
elegans	I
cytoplasmic	O
dynein	O
heavy	O
chain	O
mutants	O
.	O

We	O
conclude	O
that	O
conserved	O
but	O
nonessential	O
genes	O
contribute	O
to	O
dynein	O
function	O
during	O
the	O
essential	O
process	O
of	O
mitosis	O
.	O

Microtubules	O
and	O
microtubule	O
-	O
dependent	O
motor	O
proteins	O
segregate	O
chromosomes	O
during	O
mitosis	O
and	O
also	O
promote	O
cellular	O
organization	O
in	O
nondividing	O
cells	O
.	O

An	O
essential	O
motor	O
protein	O
complex	O
called	O
cytoplasmic	O
dynein	O
powers	O
many	O
aspects	O
of	O
microtubule	O
-	O
dependent	O
transport	O
,	O
but	O
it	O
is	O
currently	O
unclear	O
how	O
dynein	O
is	O
regulated	O
such	O
that	O
it	O
can	O
execute	O
different	O
processes	O
.	O

We	O
have	O
performed	O
a	O
genome	O
-	O
wide	O
screen	O
to	O
isolate	O
genes	O
that	O
are	O
involved	O
in	O
dynein	O
-	O
dependent	O
processes	O
.	O

We	O
determined	O
that	O
20	O
of	O
the	O
49	O
genes	O
we	O
identified	O
specifically	O
influenced	O
the	O
viability	O
of	O
dynein	O
mutant	O
strains	O
but	O
not	O
the	O
viability	O
of	O
other	O
C.	B
elegans	I
mutants	O
.	O

Many	O
of	O
the	O
proteins	O
that	O
specifically	O
influence	O
dynein	O
localized	O
to	O
subcellular	O
sites	O
where	O
the	O
dynein	O
heavy	O
chain	O
has	O
been	O
reported	O
by	O
others	O
to	O
be	O
found	O
.	O

Additionally	O
,	O
we	O
identified	O
four	O
dynein	O
components	O
that	O
appear	O
to	O
negatively	O
regulate	O
the	O
force	O
-	O
generating	O
dynein	O
heavy	O
chain	O
.	O

The	O
identification	O
and	O
initial	O
characterization	O
of	O
this	O
group	O
of	O
genes	O
represents	O
a	O
route	O
to	O
identify	O
genes	O
that	O
are	O
not	O
themselves	O
essential	O
but	O
do	O
participate	O
in	O
essential	O
processes	O
.	O

Introduction	O
The	O
microtubule	O
motor	O
called	O
cytoplasmic	O
dynein	O
has	O
roles	O
in	O
diverse	O
cellular	O
processes	O
including	O
meiotic	O
and	O
mitotic	O
spindle	O
assembly	O
and	O
function	O
,	O
neuronal	O
transport	O
,	O
and	O
organelle	O
positioning	O
[	O
1	O
]	O
.	O

Cytoplasmic	O
dynein	O
is	O
composed	O
of	O
a	O
dimer	O
of	O
heavy	O
chains	O
(	O
HCs	O
)	O
,	O
along	O
with	O
several	O
accessory	O
chains	O
(	O
ACs	O
:	O
intermediate	O
,	O
light	O
intermediate	O
,	O
and	O
light	O
chains	O
)	O
.	O

Other	O
dynein	O
-	O
interacting	O
proteins	O
,	O
such	O
as	O
dynactin	O
and	O
LIS1	O
,	O
are	O
likely	O
present	O
at	O
substoichiometric	O
levels	O
and	O
further	O
modulate	O
dynein	O
function	O
.	O

The	O
HCs	O
contain	O
both	O
ATPase	O
and	O
microtubule	O
binding	O
activities	O
and	O
are	O
sufficient	O
for	O
microtubule	O
-	O
based	O
motility	O
in	O
vitro	O
,	O
moving	O
toward	O
the	O
minus	O
,	O
or	O
slow	O
-	O
growing	O
,	O
end	O
of	O
microtubules	O
[	O
2	O
]	O
.	O

The	O
dynein	O
ACs	O
provide	O
cargo	O
docking	O
sites	O
and	O
often	O
are	O
encoded	O
by	O
multigene	O
families	O
in	O
any	O
one	O
species	O
[	O
reviewed	O
in	O
1,3	O
]	O
.	O

In	O
C.	B
elegans	I
,	O
a	O
single	O
gene	O
called	O
dhc-1	O
encodes	O
a	O
cytoplasmic	O
dynein	O
1	O
HC	O
,	O
while	O
11	O
other	O
genes	O
encode	O
five	O
classes	O
of	O
predicted	O
dynein	O
ACs	O
[	O
3,4	O
]	O
.	O

The	O
early	O
C.	B
elegans	I
embryo	O
is	O
an	O
excellent	O
system	O
for	O
investigating	O
gene	O
contributions	O
for	O
essential	O
cellular	O
processes	O
,	O
including	O
cytoskeletal	O
functions	O
[	O
5	O
]	O
.	O

The	O
C.	B
elegans	I
dynein	O
HC	O
DHC-1	O
is	O
essential	O
and	O
required	O
for	O
multiple	O
microtubule	O
-	O
dependent	O
events	O
during	O
early	O
embryogenesis	O
[	O
6–9	O
]	O
.	O

Depletion	O
of	O
DHC-1	O
by	O
RNA	O
interference	O
(	O
RNAi	O
)	O
in	O
early	O
C.	B
elegans	I
embryos	O
produces	O
defects	O
in	O
female	O
meiotic	O
divisions	O
,	O
migration	O
of	O
the	O
oocyte	O
and	O
sperm	O
pronuclei	O
after	O
fertilization	O
,	O
and	O
centrosome	O
separation	O
during	O
mitotic	O
spindle	O
assembly	O
[	O
6	O
]	O
.	O

Analysis	O
of	O
fast	O
-	O
acting	O
dhc-1	O
temperature	O
-	O
sensitive	O
(	O
ts	O
)	O
mutants	O
has	O
further	O
revealed	O
that	O
dynein	O
is	O
required	O
for	O
chromosome	O
congression	O
to	O
the	O
metaphase	O
plate	O
during	O
mitosis	O
,	O
as	O
well	O
as	O
for	O
mitotic	O
spindle	O
positioning	O
[	O
10	O
]	O
.	O

While	O
many	O
requirements	O
for	O
cytoplasmic	O
dynein	O
are	O
known	O
,	O
our	O
knowledge	O
of	O
the	O
molecular	O
mechanisms	O
that	O
target	O
and	O
regulate	O
dynein	O
remains	O
limited	O
.	O

Clearly	O
,	O
the	O
multiple	O
ACs	O
can	O
couple	O
the	O
dynein	O
HC	O
to	O
particular	O
substrates	O
[	O
11	O
]	O
,	O
including	O
vesicles	O
,	O
nuclei	O
,	O
viruses	O
,	O
kinetochores	O
,	O
and	O
rhodopsin	O
[	O
see	O
table	O
in	O
1	O
]	O
.	O

However	O
,	O
reducing	O
the	O
function	O
of	O
only	O
four	O
of	O
the	O
eleven	O
dynein	O
ACs	O
in	O
C.	B
elegans	I
produces	O
lethal	O
phenotypes	O
[	O
12	O
]	O
.	O

Thus	O
,	O
it	O
remains	O
unclear	O
how	O
ACs	O
influence	O
the	O
different	O
essential	O
requirements	O
for	O
dynein	O
.	O

Another	O
potential	O
route	O
for	O
dynein	O
regulation	O
involves	O
the	O
phosphorylation	O
state	O
of	O
the	O
different	O
dynein	O
chains	O
,	O
which	O
in	O
some	O
cases	O
confers	O
distinctive	O
functional	O
properties	O
to	O
the	O
motor	O
.	O

While	O
many	O
examples	O
of	O
dynein	O
phosphorylation	O
exist	O
,	O
and	O
cell	O
cycle	O
dependent	O
changes	O
in	O
phosphorylation	O
have	O
been	O
described	O
[	O
13–15	O
]	O
,	O
few	O
if	O
any	O
studies	O
have	O
demonstrated	O
a	O
requirement	O
for	O
such	O
modification	O
during	O
mitosis	O
.	O

Large	O
-	O
scale	O
forward	O
genetic	O
screens	O
have	O
identified	O
genes	O
with	O
requirements	O
similar	O
to	O
those	O
for	O
dynein	O
,	O
but	O
many	O
of	O
these	O
encode	O
core	O
components	O
of	O
the	O
microtubule	O
cytoskeleton	O
and	O
few	O
are	O
known	O
to	O
directly	O
influence	O
dynein	O
itself	O
[	O
12,16	O
]	O
.	O

Genes	O
that	O
do	O
influence	O
dynein	O
function	O
might	O
also	O
have	O
other	O
essential	O
roles	O
,	O
leading	O
to	O
pleiotropic	O
mutant	O
phenotypes	O
that	O
obscure	O
their	O
relationship	O
to	O
dynein	O
[	O
17–19	O
]	O
.	O

Moreover	O
,	O
redundancy	O
within	O
the	O
multigene	O
dynein	O
subunit	O
families	O
,	O
and	O
also	O
perhaps	O
between	O
the	O
different	O
ACs	O
,	O
may	O
complicate	O
the	O
identification	O
of	O
single	O
gene	O
requirements	O
that	O
are	O
important	O
for	O
dynein	O
function	O
.	O

Thus	O
far	O
,	O
reducing	O
the	O
function	O
of	O
individual	O
genes	O
has	O
not	O
provided	O
substantial	O
insight	O
into	O
the	O
mechanisms	O
that	O
regulate	O
and	O
mediate	O
the	O
many	O
different	O
requirements	O
for	O
cytoplasmic	O
dynein	O
during	O
mitosis	O
.	O

To	O
identify	O
potential	O
regulators	O
of	O
cytoplasmic	O
dynein	O
,	O
we	O
have	O
used	O
a	O
sensitized	O
genetic	O
background	O
to	O
conduct	O
a	O
genome	O
-	O
wide	O
screen	O
for	O
modifiers	O
of	O
dynein	O
function	O
in	O
C.	B
elegans	I
.	O

Other	O
groups	O
have	O
successfully	O
used	O
RNAi	O
modifier	O
screens	O
to	O
identify	O
genes	O
that	O
function	O
in	O
particular	O
pathways	O
[	O
20–23	O
]	O
;	O
we	O
have	O
used	O
RNAi	O
to	O
screen	O
for	O
genes	O
that	O
,	O
when	O
reduced	O
in	O
function	O
,	O
suppress	O
the	O
embryonic	O
lethality	O
associated	O
with	O
a	O
temperature	O
-	O
sensitive	O
(	O
ts	O
)	O
allele	O
of	O
the	O
dhc-1	O
dynein	O
HC	O
gene	O
.	O

Using	O
the	O
dhc-1ts	O
genetic	O
background	O
,	O
we	O
found	O
49	O
genes	O
that	O
,	O
when	O
depleted	O
,	O
suppress	O
the	O
partial	O
loss	O
of	O
HC	O
function	O
.	O

Twenty	O
of	O
these	O
genes	O
suppress	O
conditional	O
dynein	O
HC	O
mutants	O
but	O
not	O
other	O
conditional	O
mutants	O
with	O
unrelated	O
defects	O
.	O

Finally	O
,	O
we	O
show	O
that	O
some	O
of	O
these	O
dynein	O
-	O
specific	O
suppressors	O
encode	O
proteins	O
that	O
may	O
overlap	O
with	O
the	O
dynein	O
HC	O
in	O
subcellular	O
localization	O
.	O

Results	O
To	O
identify	O
dynein	O
suppressors	O
,	O
we	O
used	O
three	O
different	O
conditional	O
and	O
recessive	O
dhc-1	O
mutants	O
that	O
were	O
identified	O
previously	O
[	O
7	O
]	O
.	O

These	O
ts	O
alleles	O
of	O
dhc-1	O
(	O
or195	O
,	O
or283	O
,	O
and	O
or352	O
)	O
produce	O
similar	O
defects	O
at	O
the	O
restrictive	O
temperature	O
of	O
26	O
°	O
C	O
,	O
including	O
incomplete	O
mitotic	O
spindle	O
assembly	O
in	O
one	O
-	O
cell	O
embryos	O
and	O
embryonic	O
lethality	O
[	O
7	O
]	O
.	O

We	O
sequenced	O
the	O
dhc-1	O
locus	O
in	O
the	O
three	O
mutants	O
.	O

The	O
independently	O
isolated	O
or195	O
and	O
or283	O
alleles	O
each	O
change	O
a	O
conserved	O
serine	O
to	O
leucine	O
at	O
codon	O
3200	O
,	O
within	O
the	O
coiled	O
-	O
coil	O
region	O
of	O
the	O
microtubule	O
-	O
binding	O
stalk	O
domain	O
(	O
Figure	O
1A	O
and	O
1C	O
)	O
.	O

The	O
or352	O
allele	O
replaces	O
a	O
conserved	O
glycine	O
with	O
aspartic	O
acid	O
at	O
codon	O
2158	O
,	O
in	O
the	O
ATP	O
-	O
binding	O
walker	O
A	O
motif	O
of	O
the	O
second	O
AAA	O
ATPase	O
domain	O
(	O
Figure	O
1B	O
and	O
1C	O
)	O
.	O

As	O
both	O
missense	O
mutations	O
affect	O
conserved	O
residues	O
,	O
they	O
may	O
prove	O
useful	O
for	O
engineering	O
ts	O
alleles	O
in	O
other	O
organisms	O
.	O

The	O
temperature	O
versus	O
viability	O
curves	O
of	O
the	O
dynein	O
ts	O
mutants	O
feature	O
a	O
steep	O
central	O
transition	O
zone	O
ideal	O
for	O
modifier	O
screening	O
because	O
subtle	O
changes	O
in	O
temperature	O
produce	O
large	O
changes	O
in	O
embryonic	O
viability	O
(	O
Figure	O
2A	O
)	O
.	O

To	O
identify	O
genes	O
that	O
,	O
when	O
reduced	O
in	O
function	O
,	O
can	O
suppress	O
conditional	O
dhc-1	O
mutants	O
,	O
we	O
developed	O
a	O
high	O
-	O
throughput	O
RNAi	O
-	O
based	O
screen	O
(	O
Figure	O
2B	O
)	O
.	O

To	O
reduce	O
gene	O
function	O
we	O
used	O
a	O
library	O
of	O
16,757	O
bacterial	O
strains	O
that	O
each	O
express	O
a	O
dsRNA	O
corresponding	O
to	O
exon	O
-	O
rich	O
gene	O
sequences	O
[	O
17,19	O
]	O
.	O

We	O
then	O
tested	O
over	O
99	O
%	O
of	O
the	O
bacterial	O
strains	O
in	O
this	O
library	O
for	O
RNAi	O
-	O
mediated	O
suppression	O
of	O
dhc-1	O
(	O
or195	O
)	O
embryonic	O
lethality	O
at	O
23	O
°	O
C	O
,	O
after	O
raising	O
synchronized	O
L1	O
larvae	O
to	O
adulthood	O
on	O
dsRNA	O
-	O
expressing	O
bacterial	O
lawns	O
in	O
48-well	O
agar	O
plates	O
.	O

This	O
screening	O
procedure	O
should	O
work	O
to	O
identify	O
nonessential	O
and	O
essential	O
suppressor	O
genes	O
,	O
because	O
RNAi	O
does	O
not	O
always	O
fully	O
reduce	O
gene	O
function	O
[	O
24,25	O
]	O
,	O
and	O
even	O
if	O
RNAi	O
does	O
produce	O
lethality	O
,	O
cosuppression	O
could	O
restore	O
viability	O
.	O

Nevertheless	O
,	O
essential	O
genes	O
may	O
be	O
missed	O
due	O
to	O
earlier	O
requirements	O
that	O
produce	O
strong	O
larval	O
arrest	O
,	O
sterile	O
,	O
or	O
embryonic	O
lethal	O
phenotypes	O
.	O

Using	O
this	O
screening	O
procedure	O
,	O
we	O
identified	O
49	O
bacterial	O
clones	O
that	O
consistently	O
increased	O
embryonic	O
viability	O
at	O
the	O
semipermissive	O
temperature	O
.	O

The	O
dsRNA	O
-	O
producing	O
plasmids	O
were	O
then	O
sequenced	O
to	O
verify	O
gene	O
identity	O
.	O

Quantification	O
of	O
embryonic	O
viability	O
using	O
dhc-1	O
(	O
or195	O
)	O
animals	O
showed	O
that	O
the	O
RNAi	O
-	O
mediated	O
depletion	O
of	O
suppressor	O
gene	O
function	O
increased	O
viability	O
to	O
5%–100	O
%	O
,	O
compared	O
to	O
less	O
than	O
2	O
%	O
in	O
unsuppressed	O
controls	O
(	O
Figure	O
3A	O
;	O
Table	O
S1	O
)	O
.	O

The	O
proteins	O
encoded	O
by	O
the	O
suppressor	O
genes	O
we	O
identified	O
are	O
summarized	O
in	O
Figure	O
4	O
.	O

As	O
a	O
more	O
direct	O
assay	O
for	O
dynein	O
activity	O
in	O
the	O
suppressed	O
dhc-1	O
embryos	O
,	O
we	O
measured	O
spindle	O
length	O
and	O
cytokinesis	O
success	O
:	O
dhc-1	O
mutant	O
embryos	O
have	O
severe	O
spindle	O
assembly	O
defects	O
and	O
subsequent	O
cytokinesis	O
failures	O
[	O
6,7,10	O
]	O
.	O

We	O
shifted	O
dhc-1	O
adult	O
hermaphrodites	O
from	O
23	O
°	O
C	O
to	O
the	O
fully	O
restrictive	O
temperature	O
of	O
26	O
°	O
C	O
for	O
3–5	O
hours	O
and	O
made	O
time	O
-	O
lapse	O
video	O
micrographs	O
using	O
Nomarski	O
optics	O
to	O
monitor	O
the	O
first	O
embryonic	O
cell	O
division	O
.	O

This	O
procedure	O
results	O
in	O
dhc-1	O
(	O
or195	O
)	O
embryos	O
with	O
P0	O
spindles	O
30	O
%	O
the	O
length	O
of	O
wild	O
-	O
type	O
spindles	O
(	O
Figure	O
S1	O
)	O
.	O

In	O
the	O
suppressed	O
dhc-1	O
(	O
or195	O
)	O
backgrounds	O
,	O
spindle	O
lengths	O
ranged	O
from	O
30%–83	O
%	O
of	O
wild	O
-	O
type	O
lengths	O
(	O
Figure	O
S1	O
)	O
.	O

Similarly	O
,	O
cytokinesis	O
failed	O
in	O
unsuppressed	O
dhc-1	O
(	O
or195	O
)	O
embryos	O
89	O
%	O
of	O
the	O
time	O
,	O
but	O
most	O
of	O
the	O
suppressors	O
rescued	O
this	O
phenotype	O
(	O
Figure	O
S1	O
)	O
.	O

These	O
results	O
indicate	O
that	O
most	O
of	O
the	O
suppressors	O
influence	O
dynein	O
-	O
dependent	O
cellular	O
processes	O
,	O
as	O
expected	O
given	O
their	O
ability	O
to	O
restore	O
viability	O
when	O
reduced	O
in	O
function	O
.	O

Specificity	O
of	O
Suppression	O
Because	O
RNAi	O
can	O
reduce	O
the	O
function	O
of	O
unintended	O
targets	O
(	O
so	O
-	O
called	O
""""	O
off	O
-	O
target	O
effects	O
""""	O
[	O
26,27	O
]	O
)	O
,	O
we	O
also	O
used	O
available	O
mutations	O
in	O
some	O
of	O
the	O
suppressor	O
genes	O
we	O
identified	O
to	O
reduce	O
their	O
function	O
.	O

We	O
constructed	O
double	O
mutant	O
strains	O
using	O
dhc-1	O
(	O
or195	O
)	O
and	O
viable	O
deletion	O
alleles	O
for	O
two	O
suppressor	O
genes	O
,	O
dylt-1	O
(	O
ok417	O
)	O
and	O
ufd-2	O
(	O
tm1380	O
)	O
,	O
and	O
examined	O
embryonic	O
viability	O
(	O
Figure	O
3B	O
)	O
.	O

The	O
deletion	O
alleles	O
of	O
dylt-1	O
(	O
encoding	O
a	O
Tctex1-type	O
dynein	O
light	O
chain	O
)	O
,	O
and	O
ufd-2	O
(	O
encoding	O
a	O
ubiquitin	O
conjugating	O
enzyme	O
)	O
both	O
recapitulated	O
the	O
suppression	O
produced	O
by	O
RNAi	O
knockdown	O
(	O
Figure	O
3B	O
)	O
.	O

The	O
dpy-3	O
(	O
e27	O
)	O
and	O
dpy-10	O
(	O
e128	O
)	O
point	O
mutation	O
alleles	O
[	O
28	O
]	O
also	O
suppressed	O
embryonic	O
lethality	O
in	O
double	O
mutants	O
(	O
Figure	O
3B	O
)	O
.	O

Based	O
on	O
this	O
small	O
sampling	O
,	O
and	O
because	O
RNAi	O
in	O
C.	B
elegans	I
appears	O
to	O
be	O
highly	O
gene	O
specific	O
in	O
the	O
absence	O
of	O
close	O
paralogs	O
[	O
12,19	O
]	O
,	O
we	O
conclude	O
that	O
many	O
of	O
the	O
suppressors	O
we	O
have	O
identified	O
will	O
prove	O
to	O
be	O
suppressor	O
locus	O
specific	O
.	O

The	O
dsRNA	O
-	O
expressing	O
bacterial	O
clones	O
we	O
used	O
to	O
deplete	O
two	O
of	O
the	O
dynein	O
suppressors	O
(	O
tag-300	O
and	O
ZK1127.10	O
)	O
probably	O
also	O
knock	O
down	O
expression	O
of	O
one	O
close	O
paralog	O
for	O
each	O
locus	O
[	O
29	O
]	O
.	O

We	O
next	O
asked	O
whether	O
the	O
suppressors	O
are	O
specific	O
for	O
dynein	O
function	O
or	O
if	O
their	O
depletion	O
more	O
generally	O
stabilizes	O
ts	O
proteins	O
.	O

We	O
tested	O
for	O
specificity	O
using	O
two	O
conditional	O
mutants	O
with	O
cell	O
fate	O
patterning	O
defects	O
unrelated	O
to	O
dynein	O
function	O
,	O
lit-1	O
(	O
or131	O
)	O
and	O
spn-4	O
(	O
or191	O
)	O
.	O

The	O
lit-1	O
gene	O
encodes	O
a	O
MAP	O
kinase	O
-	O
related	O
protein	O
[	O
30	O
]	O
,	O
while	O
spn-4	O
encodes	O
a	O
protein	O
with	O
an	O
RNA	O
binding	O
motif	O
[	O
31	O
]	O
.	O

We	O
found	O
that	O
ten	O
of	O
the	O
dhc-1-interacting	O
genes	O
significantly	O
increased	O
embryonic	O
viability	O
in	O
both	O
lit-1	O
and	O
spn-4	O
mutants	O
,	O
while	O
18	O
others	O
suppressed	O
one	O
or	O
the	O
other	O
of	O
these	O
two	O
conditional	O
mutants	O
when	O
reduced	O
in	O
function	O
using	O
the	O
same	O
RNAi	O
protocol	O
as	O
that	O
used	O
for	O
dhc-1ts	O
mutants	O
(	O
Figure	O
4	O
,	O
right	O
two	O
columns	O
;	O
Table	O
S1	O
)	O
.	O

Therefore	O
,	O
about	O
half	O
of	O
the	O
suppressors	O
appear	O
to	O
act	O
nonspecifically	O
on	O
multiple	O
ts	O
mutants	O
to	O
restore	O
embryonic	O
viability	O
.	O

From	O
here	O
on	O
,	O
we	O
will	O
refer	O
to	O
the	O
suppressors	O
that	O
only	O
acted	O
on	O
dhc-1	O
,	O
and	O
not	O
on	O
lit-1	O
and	O
spn-4	O
ts	O
mutants	O
,	O
as	O
dynein	O
-	O
specific	O
suppressors	O
.	O

Because	O
many	O
ts	O
mutations	O
exert	O
their	O
effect	O
via	O
protein	O
assembly	O
or	O
unfolding	O
mechanisms	O
[	O
32	O
]	O
,	O
suppressor	O
genes	O
reduced	O
in	O
function	O
by	O
RNAi	O
might	O
not	O
be	O
expected	O
to	O
exhibit	O
allele	O
specificity	O
with	O
most	O
ts	O
mutations	O
.	O

To	O
determine	O
if	O
the	O
dynein	O
suppressors	O
are	O
either	O
allele	O
or	O
strain	O
specific	O
,	O
we	O
tested	O
the	O
two	O
other	O
conditional	O
dhc-1	O
strains	O
(	O
containing	O
the	O
or283	O
and	O
or352	O
alleles	O
)	O
.	O

Although	O
the	O
or283	O
allele	O
is	O
identical	O
to	O
or195	O
,	O
it	O
provides	O
a	O
useful	O
control	O
for	O
the	O
presence	O
of	O
background	O
mutations	O
because	O
the	O
two	O
strains	O
were	O
isolated	O
independently	O
.	O

In	O
most	O
cases	O
,	O
depletion	O
of	O
the	O
dynein	O
-	O
specific	O
suppressors	O
also	O
restored	O
viability	O
to	O
the	O
other	O
two	O
ts	O
dhc-1	O
alleles	O
.	O

Y40B1B.5	O
,	O
a	O
putative	O
translation	O
initiation	O
factor	O
,	O
suppressed	O
only	O
one	O
conditional	O
dhc-1	O
strain	O
,	O
and	O
we	O
consider	O
this	O
as	O
an	O
example	O
of	O
a	O
nonspecific	O
interaction	O
(	O
Figure	O
4	O
,	O
left	O
three	O
columns	O
;	O
Table	O
S1	O
)	O
.	O

Two	O
dsRNAs	O
that	O
do	O
not	O
suppress	O
lit-1	O
or	O
spn-4	O
mutants	O
produced	O
suppression	O
in	O
the	O
dhc-1	O
(	O
or195	O
)	O
and	O
dhc-1	O
(	O
or283	O
)	O
strains	O
,	O
but	O
not	O
in	O
the	O
dhc-1	O
(	O
or352	O
)	O
strain	O
,	O
perhaps	O
indicating	O
allele	O
specificity	O
or	O
variability	O
in	O
the	O
RNAi	O
treatments	O
.	O

We	O
conclude	O
that	O
strain	O
background	O
differences	O
are	O
relatively	O
rare	O
,	O
and	O
that	O
the	O
majority	O
of	O
the	O
suppressors	O
are	O
allele	O
-	O
independent	O
.	O

To	O
summarize	O
,	O
we	O
have	O
identified	O
20	O
genes	O
that	O
when	O
reduced	O
in	O
function	O
specifically	O
suppress	O
multiple	O
dynein	O
ts	O
strains	O
but	O
not	O
unrelated	O
ts	O
loci	O
.	O

Survey	O
of	O
Putative	O
Dynein	O
Accessory	O
Chains	O
We	O
were	O
surprised	O
to	O
discover	O
that	O
depleting	O
two	O
predicted	O
dynein	O
ACs	O
specifically	O
suppressed	O
the	O
partial	O
loss	O
of	O
HC	O
function	O
,	O
because	O
most	O
dynein	O
accessory	O
subunits	O
are	O
presumed	O
to	O
promote	O
dynein	O
function	O
by	O
aiding	O
dynein	O
complex	O
formation	O
or	O
mediating	O
cargo	O
attachment	O
[	O
3,11,33	O
]	O
.	O

Depletion	O
of	O
either	O
dylt-1	O
(	O
encoding	O
a	O
Tctex1-type	O
light	O
chain	O
)	O
or	O
dyrb-1	O
(	O
encoding	O
a	O
roadblock	O
-	O
type	O
light	O
chain	O
)	O
suppressed	O
embryonic	O
lethality	O
in	O
all	O
three	O
ts	O
dynein	O
HC	O
mutant	O
strains	O
(	O
Figure	O
4	O
)	O
.	O

To	O
extend	O
this	O
observation	O
,	O
we	O
surveyed	O
all	O
genes	O
encoding	O
predicted	O
dynein	O
components	O
for	O
suppression	O
of	O
the	O
three	O
ts	O
dhc-1	O
mutants	O
(	O
Figure	O
5A	O
;	O
Table	O
S2	O
)	O
.	O

We	O
reasoned	O
that	O
some	O
dynein	O
subunit	O
genes	O
could	O
have	O
been	O
missed	O
in	O
the	O
primary	O
screening	O
and	O
several	O
dynein	O
AC	O
genes	O
were	O
not	O
represented	O
in	O
the	O
E.	B
coli	I
RNAi	O
library	O
.	O

After	O
using	O
RNAi	O
to	O
reduce	O
their	O
function	O
,	O
we	O
found	O
that	O
one	O
of	O
three	O
Tctex1	O
homologs	O
(	O
dylt-1	O
)	O
,	O
one	O
of	O
four	O
LC8	O
homologs	O
(	O
dlc-1	O
)	O
,	O
one	O
of	O
two	O
light	O
intermediate	O
chains	O
(	O
dli-1	O
)	O
,	O
as	O
well	O
as	O
the	O
sole	O
roadblock	O
homolog	O
(	O
dyrb-1	O
)	O
each	O
strongly	O
suppressed	O
the	O
three	O
conditional	O
dynein	O
mutants	O
.	O

Lower	O
-	O
level	O
suppression	O
was	O
also	O
seen	O
for	O
the	O
second	O
light	O
intermediate	O
chain	O
,	O
xbx-1	O
,	O
when	O
its	O
function	O
was	O
reduced	O
.	O

Thus	O
,	O
one	O
gene	O
of	O
each	O
of	O
four	O
subunit	O
classes	O
restores	O
viability	O
to	O
the	O
three	O
dhc-1	O
mutant	O
strains	O
when	O
depleted	O
by	O
RNAi	O
.	O

The	O
only	O
subunit	O
class	O
not	O
found	O
to	O
suppress	O
was	O
the	O
intermediate	O
chain	O
,	O
encoded	O
by	O
a	O
single	O
gene	O
in	O
C.	B
elegans	I
,	O
dyci-1	O
.	O

When	O
reduced	O
in	O
function	O
by	O
RNAi	O
,	O
dyci-1	O
produces	O
a	O
larval	O
arrest	O
phenotype	O
like	O
that	O
observed	O
for	O
dhc-1	O
(	O
RNAi	O
)	O
;	O
this	O
phenotype	O
precludes	O
any	O
suppression	O
of	O
the	O
conditional	O
embryonic	O
lethality	O
(	O
shown	O
as	O
""""	O
la	O
""""	O
in	O
Figure	O
5A	O
)	O
.	O

In	O
contrast	O
,	O
knockdown	O
of	O
either	O
dlc-1	O
or	O
dli-1	O
suppresses	O
embryonic	O
lethality	O
in	O
the	O
dhc-1ts	O
mutants	O
,	O
even	O
though	O
reducing	O
their	O
function	O
in	O
otherwise	O
wild	O
-	O
type	O
embryos	O
produces	O
dhc-1-like	O
defects	O
,	O
including	O
embryonic	O
lethality	O
[	O
12,34	O
]	O
(	O
see	O
Figure	O
5B	O
and	O
Discussion	O
)	O
.	O

The	O
suppressing	O
cytoplasmic	O
dynein	O
subunits	O
and	O
DYCI-1	O
are	O
shown	O
in	O
a	O
putative	O
complex	O
in	O
Figure	O
5E	O
.	O

We	O
performed	O
several	O
genetic	O
assays	O
to	O
better	O
understand	O
how	O
the	O
suppressor	O
genes	O
may	O
be	O
operating	O
.	O

First	O
,	O
suppression	O
of	O
dhc-1	O
lethality	O
by	O
reducing	O
AC	O
function	O
may	O
indicate	O
that	O
our	O
dhc-1	O
alleles	O
express	O
a	O
neomorphic	O
and	O
toxic	O
DHC-1	O
protein	O
:	O
if	O
the	O
suppressor	O
dynein	O
AC	O
subunits	O
positively	O
function	O
in	O
dynein	O
processes	O
,	O
depleting	O
them	O
might	O
suppress	O
any	O
neomorphic	O
effects	O
.	O

This	O
explanation	O
is	O
perhaps	O
unlikely	O
,	O
because	O
the	O
dhc-1ts	O
alleles	O
are	O
all	O
recessive	O
,	O
but	O
remained	O
a	O
possibility	O
in	O
dhc-1	O
homozygotes	O
.	O

We	O
therefore	O
reduced	O
dynein	O
function	O
using	O
RNAi	O
in	O
animals	O
that	O
had	O
passed	O
through	O
the	O
larval	O
arrest	O
points	O
for	O
dhc-1	O
(	O
RNAi	O
)	O
and	O
dyci-1	O
(	O
RNAi	O
)	O
.	O

Specifically	O
,	O
we	O
transferred	O
dhc-1	O
(	O
or195	O
)	O

L4	O
hermaphrodites	O
to	O
plates	O
with	O
bacteria	O
expressing	O
dhc-1	O
or	O
dyci-1	O
dsRNA	O
.	O

As	O
control	O
we	O
performed	O
dylt-1	O
(	O
RNAi	O
)	O
using	O
the	O
same	O
procedure	O
.	O

We	O
observed	O
substantial	O
suppression	O
with	O
dylt-1	O
in	O
this	O
assay	O
,	O
but	O
we	O
saw	O
no	O
suppression	O
with	O
the	O
heavy	O
or	O
intermediate	O
chains	O
(	O
Figure	O
5C	O
)	O
.	O

This	O
suggests	O
that	O
the	O
DHC-1ts	O
protein	O
is	O
not	O
toxic	O
and	O
that	O
dyci-1	O
acts	O
more	O
like	O
dhc-1	O
than	O
the	O
other	O
suppressing	O
ACs	O
because	O
it	O
does	O
not	O
suppress	O
the	O
heavy	O
chain	O
mutant	O
.	O

To	O
further	O
examine	O
the	O
nature	O
of	O
the	O
AC	O
suppression	O
,	O
we	O
asked	O
if	O
depletion	O
of	O
the	O
suppressor	O
chains	O
could	O
bypass	O
the	O
requirement	O
for	O
dhc-1	O
.	O

We	O
transferred	O
wild	O
-	O
type	O
L4	O
larvae	O
to	O
plates	O
with	O
bacteria	O
expressing	O
dsRNA	O
corresponding	O
to	O
both	O
the	O
suppressor	O
ACs	O
and	O
dhc-1	O
.	O

We	O
did	O
not	O
observe	O
any	O
suppression	O
in	O
these	O
double	O
RNAi	O
assays	O
(	O
Figure	O
5D	O
)	O
,	O
suggesting	O
that	O
dhc-1ts	O
suppression	O
requires	O
the	O
residual	O
activity	O
of	O
the	O
defective	O
DHC-1	O
protein	O
.	O

We	O
conclude	O
that	O
the	O
dynein	O
AC	O
suppressors	O
inhibit	O
or	O
somehow	O
oppose	O
the	O
function	O
of	O
the	O
DHC-1ts	O
protein	O
,	O
and	O
that	O
the	O
dhc-1	O
(	O
or195ts	O
)	O
mutation	O
does	O
not	O
produce	O
a	O
toxic	O
gene	O
product	O
but	O
simply	O
reduces	O
DHC-1	O
activity	O
to	O
a	O
low	O
,	O
but	O
non	O
-	O
null	O
,	O
level	O
.	O

Localization	O
of	O
the	O
Dynein	O
Suppressor	O
Proteins	O
To	O
further	O
explore	O
how	O
the	O
suppressor	O
proteins	O
function	O
,	O
we	O
examined	O
the	O
subcellular	O
localization	O
of	O
nine	O
of	O
them	O
as	O
stably	O
expressed	O
N	O
-	O
terminal	O
GFP::S	O
fusions	O
.	O

We	O
chose	O
to	O
first	O
focus	O
on	O
the	O
suppressor	O
genes	O
that	O
were	O
conserved	O
but	O
poorly	O
characterized	O
in	O
any	O
system	O
,	O
or	O
were	O
conserved	O
but	O
uncharacterized	O
during	O
early	O
C.	B
elegans	I
embryogenesis	O
.	O

Prior	O
dynein	O
immunocytochemistry	O
-	O
based	O
localization	O
studies	O
serve	O
as	O
a	O
comparison	O
[	O
6,10,35	O
]	O
.	O

As	O
in	O
other	O
species	O
,	O
C.	B
elegans	I
DHC-1	O
is	O
associated	O
with	O
mitotic	O
spindles	O
,	O
centrosomes	O
,	O
the	O
nuclear	O
envelope	O
,	O
the	O
cell	O
cortex	O
,	O
the	O
midbody	O
,	O
and	O
throughout	O
the	O
cytoplasm	O
.	O

Most	O
of	O
the	O
suppressor	O
proteins	O
we	O
examined	O
localized	O
to	O
sites	O
where	O
DHC-1	O
is	O
known	O
to	O
act	O
or	O
localize	O
(	O
Figure	O
6	O
)	O
.	O

However	O
,	O
the	O
nearly	O
ubiquitous	O
distribution	O
of	O
DHC-1	O
in	O
early	O
embryonic	O
cells	O
makes	O
colocalization	O
likely	O
but	O
not	O
necessarily	O
meaningful	O
,	O
and	O
biochemical	O
studies	O
are	O
needed	O
to	O
conclusively	O
address	O
any	O
direct	O
or	O
indirect	O
physical	O
associations	O
.	O

Four	O
suppressor	O
GFP	O
fusion	O
proteins	O
localized	O
to	O
nuclear	O
membranes	O
and	O
to	O
spindle	O
poles	O
or	O
pericentrosomal	O
regions	O
.	O

The	O
DYLT-1	O
and	O
DYRB-1	O
dynein	O
light	O
chains	O
were	O
associated	O
with	O
nuclear	O
envelopes	O
and	O
centrosomes	O
,	O
as	O
well	O
as	O
meiotic	O
and	O
mitotic	O
spindle	O
poles	O
(	O
Figure	O
6A–6H	O
;	O
Videos	O
S1	O
and	O
S2	O
)	O
.	O

The	O
potential	O
coiled	O
-	O
coil	O
protein	O
K04F10.3	O
was	O
present	O
on	O
the	O
nuclear	O
envelope	O
and	O
in	O
a	O
pericentrosomal	O
position	O
during	O
mitosis	O
,	O
similar	O
to	O
endoplasmic	O
reticulum	O
proteins	O
[	O
36	O
]	O
(	O
Figure	O
6I–6L	O
;	O
Video	O
S3	O
)	O
.	O

K04F10.3	O
was	O
also	O
highly	O
enriched	O
at	O
meiotic	O
spindle	O
poles	O
(	O
Figure	O
6I	O
)	O
,	O
which	O
has	O
been	O
observed	O
for	O
other	O
endoplasmic	O
reticulum	O
proteins	O
[	O
36	O
]	O
.	O

The	O
NPP-22	O
transmembrane	O
nucleoporin	O
was	O
found	O
at	O
nuclear	O
envelopes	O
(	O
Figure	O
6M–6P	O
;	O
Video	O
S4	O
)	O
,	O
as	O
previously	O
reported	O
for	O
later	O
stage	O
embryos	O
[	O
37	O
]	O
,	O
and	O
it	O
also	O
surrounded	O
centrosomes	O
during	O
mitosis	O
.	O

Two	O
splice	O
isoforms	O
of	O
the	O
pleckstrin	O
homology	O
domain	O
–	O
containing	O
EFA-6	O
/	O
Y55D9A.1	O
,	O
an	O
ARF	O
guanine	O
nucleotide	O
exchange	O
factor	O
,	O
were	O
enriched	O
cortically	O
both	O
in	O
the	O
anterior	O
portion	O
of	O
the	O
one	O
-	O
cell	O
zygote	O
and	O
at	O
the	O
blastomere	O
boundary	O
in	O
two	O
-	O
cell	O
embryos	O
(	O
Figure	O
6Q–6	O
T	O
;	O
Videos	O
S5	O
and	O
S6	O
)	O
.	O

The	O
conserved	O
Mo25	O
homolog	O
MOP-25.2	O
/	O
Y53C12A.4	O
was	O
found	O
enriched	O
in	O
a	O
single	O
spot	O
after	O
cytokinesis	O
that	O
appears	O
to	O
correspond	O
to	O
the	O
midbody	O
(	O
Figure	O
6U–6X	O
;	O
Video	O
S7	O
)	O
.	O

F10E7.8	O
,	O
a	O
highly	O
conserved	O
ortholog	O
of	O
S.	B
cerevisiae	I
Far11	O
,	O
appears	O
nuclear	O
(	O
Figure	O
6Y–6B′	O
and	O
Video	O
S8	O
)	O
.	O

Finally	O
,	O
the	O
nonspecific	O
suppressor	O
protein	O
STAR-2	O
,	O
a	O
predicted	O
RNA	O
binding	O
protein	O
,	O
appears	O
to	O
be	O
associated	O
with	O
P	O
-	O
granules	O
(	O
like	O
its	O
homolog	O
GLD-1	O
)	O
,	O
where	O
dynein	O
is	O
neither	O
localized	O
nor	O
known	O
to	O
function	O
(	O
Figure	O
6C′–6F′	O
)	O
.	O

DLYT-1	O
and	O
DYRB-1	O
:	O
Dynein	O
Light	O
Chain	O
Localization	O
The	O
C.	B
elegans	I
dynein	O
HC	O
protein	O
weakly	O
localizes	O
to	O
spindle	O
poles	O
during	O
early	O
embryonic	O
cell	O
cycles	O
[	O
6,10	O
]	O
,	O
and	O
so	O
did	O
DYRB-1	O
and	O
DYLT-1	O
(	O
Videos	O
S9	O
and	O
S10	O
)	O
.	O

However	O
,	O
ts	O
mutant	O
forms	O
of	O
the	O
DHC-1	O
protein	O
(	O
including	O
DHC-1	O
encoded	O
by	O
the	O
or195	O
allele	O
)	O
strongly	O
localize	O
to	O
centrosomes	O
when	O
shifted	O
to	O
the	O
non	O
-	O
permissive	O
temperature	O
[	O
10	O
]	O
.	O

The	O
mechanism	O
underlying	O
this	O
enhanced	O
localization	O
is	O
not	O
known	O
,	O
but	O
it	O
may	O
represent	O
trapping	O
of	O
the	O
defective	O
protein	O
at	O
a	O
normally	O
transient	O
location	O
.	O

We	O
exploited	O
this	O
behavior	O
of	O
the	O
mutant	O
DHC-1	O
protein	O
to	O
determine	O
whether	O
redistribution	O
of	O
the	O
putative	O
DYRB-1	O
and	O
DYLT-1	O
dynein	O
light	O
chains	O
also	O
occurred	O
in	O
the	O
dhc-1	O
(	O
or195	O
)	O
background	O
.	O

We	O
found	O
that	O
the	O
cellular	O
distributions	O
of	O
DYRB-1	O
and	O
DYLT-1	O
were	O
dramatically	O
altered	O
in	O
dhc-1	O
(	O
or195	O
)	O
mutant	O
embryos	O
.	O

After	O
shifting	O
the	O
parental	O
worms	B
to	O
the	O
restrictive	O
temperature	O
for	O
3–5	O
h	O
prior	O
to	O
collecting	O
embryos	O
,	O
these	O
two	O
proteins	O
were	O
prominently	O
localized	O
to	O
centrosomes	O
and	O
to	O
spindle	O
poles	O
that	O
did	O
not	O
separate	O
in	O
one	O
-	O
cell	O
stage	O
embryos	O
(	O
Figure	O
7	O
;	O
Videos	O
S11	O
and	O
S12	O
)	O
.	O

The	O
spindle	O
pole	O
to	O
cytoplasmic	O
fluorescence	O
ratio	O
during	O
late	O
anaphase	O
was	O
5-fold	O
higher	O
in	O
both	O
of	O
the	O
dhc-1	O
homozygous	O
mutant	O
strains	O
when	O
compared	O
to	O
wild	O
-	O
type	O
embryos	O
expressing	O
the	O
GFP	O
fusions	O
.	O

We	O
also	O
assayed	O
localization	O
of	O
the	O
two	O
putative	O
dynein	O
light	O
chains	O
after	O
short	O
temperature	O
shifts	O
to	O
the	O
nonpermissive	O
temperature	O
in	O
the	O
dhc-1	O
(	O
or195	O
)	O

mutant	O
background	O
,	O
which	O
yields	O
mitotic	O
spindles	O
with	O
an	O
overall	O
wild	O
-	O
type	O
appearance	O
and	O
function	O
.	O

These	O
short	O
temperature	O
shifts	O
also	O
resulted	O
in	O
robust	O
localization	O
of	O
these	O
two	O
dynein	O
light	O
chains	O
to	O
centrosomes	O
(	O
unpublished	O
data	O
)	O
.	O

Finally	O
,	O
we	O
examined	O
the	O
localization	O
of	O
GFP::DYRB-1	O
and	O
GFP::DYLT-1	O
in	O
embryos	O
from	O
dhc-1	O
(	O
or195	O
)	O
−	O
/	O
+	O
worms	B
grown	O
at	O
the	O
dhc-1	O
(	O
or195	O
)	O

permissive	O
temperature	O
of	O
15	O
°	O
C	O
.	O

Even	O
though	O
embryos	O
from	O
mothers	O
heterozygous	O
for	O
this	O
recessive	O
mutation	O
are	O
viable	O
and	O
develop	O
normally	O
,	O
even	O
at	O
26	O
°	O
C	O
[	O
7	O
]	O
,	O
we	O
observed	O
a	O
substantial	O
increase	O
in	O
both	O
GFP	O
fusion	O
proteins	O
at	O
the	O
mitotic	O
spindle	O
poles	O
in	O
early	O
embryos	O
(	O
Figure	O
7	O
;	O
Videos	O
S13	O
and	O
S14	O
)	O
.	O

Importantly	O
,	O
localization	O
of	O
DYLT-1	O
and	O
DYRB-1	O
to	O
centrosomes	O
does	O
not	O
occur	O
in	O
embryos	O
depleted	O
for	O
DHC-1	O
with	O
RNAi	O
(	O
our	O
unpublished	O
results	O
)	O
,	O
indicating	O
that	O
these	O
proteins	O
require	O
the	O
mutant	O
DHC-1	O
polypeptide	O
for	O
centrosomal	O
targeting	O
in	O
the	O
dhc-1	O
(	O
or195	O
)	O
embryos	O
.	O

In	O
summary	O
,	O
the	O
DYRB-1	O
and	O
DYLT-1	O
proteins	O
localize	O
to	O
sites	O
where	O
the	O
DHC-1	O
HC	O
is	O
also	O
found	O
in	O
wild	O
-	O
type	O
embryos	O
,	O
and	O
all	O
three	O
proteins	O
respond	O
similarly	O
to	O
mutational	O
alterations	O
in	O
DHC-1	O
.	O

Genetic	O
Characterization	O
of	O
the	O
DYLT-1	O
and	O
DYRB-1	O
Dynein	O
Light	O
Chains	O
We	O
obtained	O
putative	O
null	O
alleles	O
to	O
determine	O
if	O
dylt-1	O
and	O
dyrb-1	O
function	O
in	O
dynein	O
-	O
dependent	O
processes	O
.	O

DYLT-1	O
is	O
40	O
%	O
identical	O
to	O
human	B
DYNLT3	O
and	O
38	O
%	O
identical	O
to	O
Drosophila	B
Dlc90F	O
(	O
see	O
alignment	O
in	O
Figure	O
8A	O
)	O
.	O

Two	O
other	O
C.	B
elegans	I
genes	O
,	O
dylt-2	O
and	O
dylt-3	O
,	O
encode	O
more	O
divergent	O
members	O
of	O
this	O
protein	O
family	O
.	O

DYRB-1	O
is	O
49	O
%	O
identical	O
to	O
both	O
human	B
DYNLRB1	O
and	O
Drosophila	B
Robl	O
(	O
see	O
alignment	O
in	O
Figure	O
8A	O
)	O
.	O

There	O
do	O
not	O
appear	O
to	O
be	O
other	O
Roadblock	O
genes	O
in	O
the	O
C.	B
elegans	I
genome	O
[	O
3	O
]	O
.	O

Deletion	O
alleles	O
for	O
both	O
dylt-1	O
and	O
dyrb-1	O
have	O
been	O
isolated	O
(	O
Figure	O
8B	O
)	O
.	O

The	O
dylt-1	O
(	O
ok417	O
)	O
deletion	O
removes	O
the	O
entire	O
DYLT-1	O
open	O
reading	O
frame	O
and	O
does	O
not	O
affect	O
adjacent	O
coding	O
regions	O
.	O

The	O
dyrb-1	O
(	O
tm2645	O
)	O
deletion	O
removes	O
69	O
%	O
of	O
the	O
dyrb-1	O
coding	O
region	O
,	O
leaving	O
29	O
predicted	O
N	O
-	O
terminal	O
amino	O
acids	O
,	O
and	O
does	O
not	O
affect	O
adjacent	O
coding	O
regions	O
.	O

Both	O
deletions	O
are	O
currently	O
annotated	O
as	O
homozygous	O
viable	O
[	O
29	O
]	O
.	O

However	O
,	O
we	O
found	O
that	O
the	O
dyrb-1	O
(	O
tm2645	O
)	O
strain	O
was	O
in	O
fact	O
heterozygous	O
for	O
the	O
deletion	O
and	O
that	O
most	O
embryos	O
produced	O
by	O
dyrb-1	O
(	O
tm2645	O
)	O
homozygous	O
animals	O
failed	O
to	O
hatch	O
(	O
Figure	O
8C	O
)	O
.	O

Homozygous	O
dyrb-1	O
(	O
tm2645	O
)	O
worms	B
also	O
showed	O
an	O
egg	O
-	O
laying	O
defect	O
and	O
produced	O
small	O
broods	O
(	O
unpublished	O
data	O
)	O
.	O

To	O
determine	O
if	O
the	O
dyrb-1	O
deletion	O
was	O
responsible	O
for	O
the	O
embryonic	O
lethality	O
,	O
we	O
crossed	O
the	O
GFP::dyrb-1	O
transgene	O
into	O
the	O
deletion	O
background	O
.	O

The	O
presence	O
of	O
the	O
transgene	O
fully	O
rescued	O
the	O
embryonic	O
lethality	O
(	O
Figure	O
8C	O
)	O
,	O
but	O
not	O
the	O
egg	O
-	O
laying	O
defect	O
:	O
the	O
transgene	O
is	O
driven	O
from	O
a	O
germline	O
-	O
specific	O
promoter	O
and	O
so	O
would	O
not	O
be	O
expected	O
to	O
rescue	O
zygotic	O
phenotypes	O
.	O

The	O
embryonic	O
lethality	O
exhibited	O
by	O
dyrb-1	O
(	O
tm2645	O
)	O
mutants	O
is	O
consistent	O
with	O
RNAi	O
studies	O
performed	O
by	O
injection	O
or	O
soaking	O
[	O
12,38	O
]	O
.	O

In	O
contrast	O
,	O
homozygous	O
dylt-1	O
deletion	O
mutants	O
did	O
not	O
exhibit	O
any	O
larval	O
or	O
embryonic	O
lethality	O
(	O
Figure	O
8C	O
)	O
.	O

To	O
determine	O
if	O
these	O
dynein	O
light	O
chain	O
mutants	O
exhibit	O
dynein	O
HC	O
-	O
like	O
phenotypes	O
,	O
we	O
observed	O
the	O
completion	O
of	O
meiotic	O
polar	O
body	O
extrusion	O
and	O
the	O
first	O
two	O
mitotic	O
cell	O
divisions	O
in	O
mutant	O
embryos	O
(	O
Figure	O
8D	O
)	O
.	O

The	O
dylt-1	O
embryos	O
appeared	O
wild	O
type	O
for	O
completion	O
of	O
meiosis	O
,	O
pronuclear	O
migration	O
,	O
and	O
spindle	O
assembly	O
and	O
function	O
.	O

However	O
,	O
the	O
dyrb-1	O
embryos	O
occasionally	O
contained	O
extra	O
female	O
pronuclei	O
(	O
observed	O
in	O
four	O
of	O
12	O
recordings	O
,	O
Figure	O
8D	O
)	O
,	O
suggesting	O
that	O
polar	O
body	O
extrusion	O
was	O
defective	O
,	O
and	O
pronuclear	O
migration	O
was	O
often	O
slow	O
compared	O
to	O
wild	O
-	O
type	O
embryos	O
.	O

Once	O
formed	O
,	O
spindles	O
appeared	O
functional	O
using	O
Nomarski	O
optics	O
,	O
although	O
they	O
were	O
frequently	O
positioned	O
improperly	O
and	O
had	O
large	O
spindle	O
poles	O
,	O
as	O
has	O
also	O
been	O
observed	O
after	O
RNAi	O
knockdown	O
[	O
12	O
]	O
.	O

Thus	O
,	O
these	O
two	O
genes	O
are	O
not	O
strictly	O
essential	O
,	O
but	O
the	O
DYRB-1	O
protein	O
clearly	O
is	O
required	O
for	O
dynein	O
-	O
dependent	O
processes	O
.	O

Discussion	O
By	O
using	O
the	O
suppressor	O
screening	O
method	O
outlined	O
in	O
Figure	O
2B	O
,	O
we	O
have	O
isolated	O
and	O
characterized	O
49	O
genes	O
that	O
when	O
reduced	O
in	O
function	O
can	O
suppress	O
a	O
partial	O
loss	O
of	O
dynein	O
HC	O
function	O
.	O

This	O
screening	O
procedure	O
takes	O
advantage	O
of	O
sensitized	O
genetic	O
backgrounds	O
using	O
conditional	O
mutants	O
,	O
can	O
be	O
completed	O
for	O
one	O
mutant	O
in	O
less	O
than	O
5	O
wk	O
,	O
and	O
is	O
scalable	O
so	O
that	O
many	O
mutants	O
can	O
be	O
screened	O
in	O
parallel	O
.	O

In	O
fact	O
,	O
we	O
have	O
performed	O
15	O
such	O
screens	O
in	O
different	O
sensitized	O
backgrounds	O
(	O
unpublished	O
data	O
)	O
.	O

By	O
using	O
three	O
dhc-1ts	O
mutant	O
strains	O
,	O
we	O
found	O
that	O
strain	O
background	O
differences	O
and	O
allele	O
specificity	O
are	O
minimal	O
because	O
most	O
of	O
these	O
genes	O
suppress	O
all	O
three	O
dynein	O
mutants	O
when	O
reduced	O
in	O
function	O
using	O
RNAi	O
.	O

Furthermore	O
,	O
by	O
using	O
two	O
unrelated	O
ts	O
mutants	O
to	O
assay	O
for	O
specificity	O
,	O
we	O
found	O
that	O
57	O
%	O
of	O
the	O
suppressor	O
genes	O
suppress	O
multiple	O
unrelated	O
mutant	O
loci	O
.	O

Thus	O
,	O
it	O
is	O
clear	O
that	O
assaying	O
the	O
specificity	O
of	O
suppression	O
is	O
critical	O
for	O
evaluating	O
the	O
functional	O
significance	O
of	O
these	O
RNAi	O
interactions	O
.	O

Eliminating	O
the	O
analysis	O
of	O
these	O
nonspecific	O
genes	O
in	O
future	O
screens	O
will	O
save	O
time	O
and	O
resources	O
.	O

Most	O
of	O
the	O
specific	O
suppressor	O
proteins	O
we	O
examined	O
appear	O
to	O
overlap	O
in	O
subcellular	O
localization	O
with	O
the	O
dynein	O
HC	O
,	O
based	O
on	O
previous	O
studies	O
of	O
DHC-1	O
,	O
while	O
one	O
nonspecific	O
suppressor	O
protein	O
,	O
STAR-2	O
,	O
localized	O
to	O
germline	O
P	O
-	O
granules	O
,	O
where	O
dynein	O
is	O
not	O
known	O
to	O
function	O
.	O

Many	O
of	O
the	O
20	O
genes	O
that	O
specifically	O
suppress	O
multiple	O
dhc-1ts	O
alleles	O
are	O
nonessential	O
in	O
C.	B
elegans	I
but	O
well	O
conserved	O
nonetheless	O
.	O

Six	O
of	O
eight	O
deletion	O
alleles	O
available	O
for	O
the	O
20	O
specific	O
suppressor	O
genes	O
are	O
homozygous	O
viable	O
,	O
and	O
six	O
additional	O
specific	O
genes	O
do	O
not	O
display	O
lethal	O
phenotypes	O
when	O
reduced	O
in	O
function	O
by	O
RNAi	O
in	O
wild	O
-	O
type	O
worms	B
[	O
29	O
]	O
.	O

Thus	O
,	O
our	O
genetic	O
screening	O
has	O
identified	O
roles	O
in	O
an	O
essential	O
process	O
for	O
at	O
least	O
12	O
apparently	O
nonessential	O
genes	O
.	O

Fourteen	O
of	O
the	O
specific	O
dynein	O
suppressor	O
genes	O
have	O
human	B
orthologs	O
as	O
determined	O
by	O
best	O
reciprocal	O
BLAST	O
hits	O
(	O
Table	O
1	O
)	O
,	O
while	O
mop-25.2	O
has	O
a	O
conserved	O
human	B
homolog	O
but	O
also	O
a	O
paralog	O
in	O
C.	B
elegans	I
.	O

Eleven	O
of	O
these	O
conserved	O
genes	O
are	O
nonessential	O
in	O
C.	B
elegans	I
.	O

Interestingly	O
,	O
eight	O
of	O
the	O
conserved	O
genes	O
in	O
Table	O
1	O
have	O
been	O
implicated	O
in	O
human	B
disease	O
etiology	O
,	O
with	O
three	O
of	O
them	O
identified	O
as	O
the	O
causative	O
gene	O
[	O
39–41	O
]	O
.	O

Thus	O
,	O
using	O
sensitized	O
genetic	O
backgrounds	O
for	O
genome	O
-	O
wide	O
modifier	O
screens	O
can	O
identify	O
roles	O
for	O
nonessential	O
but	O
conserved	O
genes	O
and	O
thereby	O
provide	O
insights	O
into	O
human	B
disease	O
.	O

Nonspecific	O
Suppression	O
of	O
Conditional	O
Mutants	O
We	O
examined	O
the	O
predicted	O
molecular	O
functions	O
of	O
the	O
suppressor	O
proteins	O
to	O
better	O
understand	O
the	O
basis	O
for	O
the	O
nonspecific	O
suppression	O
phenomenon	O
.	O

Strikingly	O
,	O
many	O
of	O
the	O
nonspecific	O
suppressor	O
genes	O
encode	O
proteins	O
with	O
predicted	O
roles	O
in	O
mitochondrial	O
,	O
ribosomal	O
,	O
and	O
collagen	O
function	O
(	O
18	O
of	O
29	O
genes	O
,	O
or	O
62	O
%	O
)	O
,	O
while	O
only	O
two	O
such	O
genes	O
appeared	O
to	O
specifically	O
suppress	O
dhc-1	O
(	O
2	O
of	O
20	O
genes	O
or	O
10	O
%	O
)	O
.	O

It	O
is	O
possible	O
that	O
stress	O
produced	O
by	O
RNAi	O
knockdown	O
of	O
these	O
suppressor	O
genes	O
triggers	O
the	O
activity	O
of	O
molecular	O
chaperones	O
that	O
can	O
generally	O
restore	O
function	O
to	O
ts	O
proteins	O
.	O

Indeed	O
,	O
mutation	O
of	O
dpy-10	O
is	O
known	O
to	O
suppress	O
three	O
other	O
ts	O
mutants	O
:	O
glp-1	O
,	O
emb-5	O
,	O
and	O
mup-1	O
[	O
42–44	O
]	O
.	O

Furthermore	O
,	O
RNAi	O
reduction	O
of	O
dpy-10	O
,	O
star-2	O
,	O
osr-1	O
,	O
or	O
C50D2.1	O
(	O
all	O
suppressors	O
of	O
dhc-1	O
,	O
lit-1	O
,	O
and	O
spn-4	O
ts	O
alleles	O
)	O
induces	O
the	O
glycerol	O
biosynthetic	O
gene	O
gpdh-2	O
,	O
while	O
dpy-10	O
and	O
osr-1	O
mutants	O
exhibit	O
increased	O
glycerol	O
levels	O
,	O
a	O
condition	O
that	O
promotes	O
protein	O
stability	O
[	O
45	O
]	O
.	O

We	O
suggest	O
that	O
partial	O
loss	O
of	O
central	O
metabolic	O
processes	O
can	O
invoke	O
stress	O
responses	O
that	O
nonspecifically	O
alleviate	O
protein	O
-	O
folding	O
problems	O
in	O
ts	O
proteins	O
.	O

Filtering	O
out	O
these	O
nonspecific	O
interactions	O
by	O
testing	O
unrelated	O
conditional	O
mutants	O
increases	O
the	O
likelihood	O
that	O
the	O
remaining	O
suppressor	O
genes	O
are	O
more	O
directly	O
involved	O
with	O
dynein	O
function	O
.	O

However	O
,	O
ts	O
mutants	O
likely	O
differ	O
in	O
their	O
susceptibility	O
to	O
nonspecific	O
suppression	O
mechanisms	O
,	O
and	O
some	O
apparently	O
unrelated	O
ts	O
mutants	O
might	O
share	O
common	O
cofactors	O
such	O
that	O
both	O
mutants	O
are	O
suppressed	O
by	O
depletion	O
of	O
the	O
same	O
cofactor	O
.	O

Nevertheless	O
,	O
we	O
expect	O
that	O
more	O
extensive	O
testing	O
for	O
specificity	O
will	O
prove	O
very	O
useful	O
for	O
judging	O
the	O
significance	O
of	O
modifier	O
interactions	O
.	O

Possible	O
Relevance	O
of	O
Suppressor	O
Proteins	O
to	O
Dynein	O
Function	O

We	O
examined	O
the	O
localization	O
of	O
a	O
number	O
of	O
GFP	O
fusions	O
to	O
suppressor	O
proteins	O
to	O
gain	O
insight	O
into	O
their	O
functional	O
relationship	O
to	O
dynein	O
.	O

In	O
several	O
cases	O
,	O
the	O
subcellular	O
distribution	O
of	O
the	O
suppressor	O
proteins	O
overlapped	O
in	O
different	O
ways	O
with	O
the	O
known	O
and	O
nearly	O
ubiquitous	O
distribution	O
of	O
cytoplasmic	O
dynein	O
in	O
the	O
early	O
C.	B
elegans	I
embryo	O
.	O

In	O
fact	O
,	O
the	O
only	O
specific	O
suppressor	O
that	O
did	O
not	O
display	O
dynein	O
-	O
like	O
localization	O
was	O
F10E7.8	O
,	O
a	O
homolog	O
of	O
yeast	B
Far11	O
of	O
unknown	O
function	O
[	O
46	O
]	O
,	O
which	O
was	O
nuclear	O
.	O

The	O
one	O
nonspecific	O
suppressor	O
protein	O
we	O
examined	O
did	O
not	O
show	O
any	O
dynein	O
-	O
like	O
localization	O
patterns	O
.	O

The	O
subcellular	O
localizations	O
of	O
the	O
GFP::suppressor	O
protein	O
fusions	O
are	O
intriguing	O
.	O

However	O
,	O
given	O
the	O
nearly	O
ubiquitous	O
distribution	O
of	O
dynein	O
in	O
early	O
embryonic	O
cells	O
,	O
biochemical	O
tests	O
for	O
direct	O
association	O
are	O
needed	O
to	O
address	O
the	O
significance	O
of	O
any	O
colocalization	O
detected	O
using	O
light	O
microscopy	O
.	O

We	O
are	O
particularly	O
interested	O
in	O
suppressor	O
proteins	O
that	O
localize	O
to	O
mitotic	O
spindle	O
poles	O
:	O
the	O
association	O
of	O
the	O
DYLT-1	O
and	O
DYRB-1	O
predicted	O
dynein	O
light	O
chains	O
with	O
centrosomes	O
and	O
spindle	O
poles	O
suggests	O
that	O
they	O
may	O
be	O
components	O
of	O
cytoplasmic	O
dynein	O
in	O
C.	B
elegans	I
.	O

Localization	O
of	O
cytoplasmic	O
dynein	O
to	O
centrosomes	O
and	O
spindle	O
poles	O
is	O
well	O
established	O
[	O
47,48	O
]	O
,	O
and	O
the	O
inhibition	O
of	O
dynein	O
function	O
prevents	O
centrosome	O
separation	O
,	O
centrosome	O
attachment	O
to	O
nuclei	O
,	O
and	O
the	O
formation	O
of	O
bipolar	O
spindles	O
[	O
6,10,49,50	O
]	O
.	O

Moreover	O
,	O
the	O
centrosomal	O
localization	O
of	O
DHC-1	O
,	O
DYLT-1	O
,	O
and	O
DYRB-1	O
are	O
all	O
greatly	O
enhanced	O
in	O
dhc-1ts	O
mutant	O
embryos	O
:	O
this	O
dependence	O
of	O
the	O
light	O
chain	O
distribution	O
on	O
the	O
HC	O
further	O
suggests	O
they	O
reside	O
in	O
the	O
same	O
motor	O
complex	O
(	O
Figure	O
7	O
and	O
[	O
10	O
]	O
)	O
.	O

Furthermore	O
,	O
roadblock	O
light	O
chains	O
are	O
well	O
-	O
established	O
components	O
of	O
dynein	O
,	O
and	O
all	O
of	O
the	O
roadblock	O
protein	O
in	O
mammalian	O
liver	O
extracts	O
is	O
dynein	O
associated	O
[	O
51,52	O
]	O
.	O

Finally	O
,	O
a	O
DYLT-1	O
homolog	O
in	O
vertebrates	O
is	O
a	O
stoichiometric	O
subunit	O
of	O
cytoplasmic	O
dynein	O
[	O
53	O
]	O
.	O

The	O
presence	O
of	O
these	O
two	O
light	O
chains	O
in	O
a	O
dynein	O
complex	O
is	O
consistent	O
with	O
them	O
having	O
either	O
positive	O
or	O
negative	O
roles	O
in	O
the	O
regulation	O
of	O
HC	O
function	O
(	O
see	O
below	O
)	O
.	O

Cytoplasmic	O
dynein	O
is	O
found	O
on	O
the	O
nuclear	O
envelope	O
where	O
it	O
is	O
thought	O
to	O
regulate	O
nuclear	O
membrane	O
breakdown	O
during	O
mitosis	O
[	O
54	O
]	O
,	O
and	O
dynein	O
plays	O
roles	O
during	O
the	O
trafficking	O
of	O
endoplasmic	O
reticulum	O
components	O
[	O
55,56	O
]	O
.	O

Therefore	O
,	O
the	O
nuclear	O
envelope	O
/	O
endoplasmic	O
reticulum	O
proteins	O
NPP-22	O
and	O
K04F10.3	O
could	O
couple	O
dynein	O
activity	O
to	O
either	O
of	O
these	O
structures	O
.	O

The	O
anc-1	O
gene	O
was	O
also	O
isolated	O
in	O
our	O
screening	O
and	O
ANC-1	O
is	O
localized	O
to	O
the	O
nuclear	O
envelope	O
where	O
it	O
maintains	O
nuclear	O
positioning	O
in	O
postembryonic	O
cells	O
[	O
57	O
]	O
.	O

Reducing	O
the	O
function	O
of	O
these	O
three	O
genes	O
may	O
suppress	O
partial	O
loss	O
of	O
dynein	O
HC	O
mutants	O
by	O
reducing	O
the	O
need	O
for	O
dynein	O
during	O
nuclear	O
envelope	O
breakdown	O
,	O
through	O
constitutive	O
partial	O
destabilization	O
of	O
the	O
nuclear	O
envelope	O
.	O

The	O
distribution	O
of	O
the	O
cytoplasmic	O
dynein	O
HC	O
includes	O
sites	O
other	O
than	O
spindle	O
poles	O
and	O
nuclear	O
envelopes	O
in	O
C.	B
elegans	I
,	O
for	O
example	O
,	O
at	O
the	O
cell	O
cortex	O
and	O
at	O
the	O
cell	O
division	O
remnant	O
called	O
the	O
midbody	O
[	O
6,10	O
]	O
.	O

The	O
MOP-25.2	O
protein	O
was	O
found	O
at	O
the	O
midbody	O
and	O
faintly	O
at	O
spindle	O
poles	O
.	O

The	O
MOP-25.2	O
ortholog	O
in	O
S.	B
pombe	I
,	O
Pmo25	O
,	O
is	O
also	O
present	O
at	O
the	O
cell	O
division	O
site	O
and	O
on	O
spindle	O
poles	O
[	O
58	O
]	O
.	O

Mammalian	O
MOP-25.2	O
homologs	O
stimulate	O
the	O
kinase	O
activity	O
of	O
the	O
LKB1	O
tumor	O
suppressor	O
(	O
the	O
C.	B
elegans	I
ortholog	O
is	O
PAR-4	O
)	O
,	O
which	O
in	O
turn	O
activates	O
MARK	O
microtubule	O
-	O
destabilizing	O
kinases	O
[	O
59,60	O
]	O
.	O

The	O
C.	B
elegans	I
MARK	O
ortholog	O
,	O
PAR-1	O
,	O
controls	O
cell	O
polarity	O
during	O
embryogenesis	O
,	O
and	O
orthologs	O
have	O
been	O
implicated	O
in	O
regulation	O
of	O
microtubule	O
dynamics	O
from	O
yeast	B
to	O
humans	B
[	O
61–64	O
]	O
.	O

Lastly	O
,	O
the	O
two	O
splice	O
isoforms	O
of	O
EFA-6	O
were	O
associated	O
with	O
the	O
anterior	O
cell	O
cortex	O
in	O
late	O
one	O
-	O
cell	O
embryos	O
.	O

Cortically	O
localized	O
dynein	O
may	O
have	O
important	O
roles	O
in	O
applying	O
forces	O
to	O
astral	O
microtubules	O
that	O
influence	O
mitotic	O
spindle	O
positioning	O
and	O
chromosome	O
separation	O
during	O
anaphase	O
[	O
10,65,66	O
]	O
.	O

EFA6	O
ARF	O
guanine	O
nucleotide	O
exchange	O
factors	O
require	O
their	O
pleckstrin	O
homology	O
domain	O
for	O
cortical	O
targeting	O
,	O
and	O
are	O
known	O
to	O
regulate	O
cortical	O
actin	O
dynamics	O
in	O
vertebrate	O
cells	O
by	O
promoting	O
guanine	O
nucleotide	O
exchange	O
on	O
ARF6	O
[	O
67,68	O
]	O
.	O

Our	O
results	O
identifying	O
efa-6	O
as	O
a	O
dynein	O
HC	O
suppressor	O
suggest	O
a	O
functional	O
linkage	O
of	O
the	O
actin	O
and	O
microtubule	O
cytoskeletons	O
at	O
the	O
cell	O
cortex	O
.	O

Interestingly	O
,	O
two	O
yeast	B
pleckstrin	O
homology	O
domain	O
proteins	O
,	O
Num1	O
and	O
mcp5	O
+	O
,	O
localize	O
to	O
the	O
cell	O
cortex	O
and	O
direct	O
astral	O
microtubule	O
and	O
dynein	O
function	O
,	O
although	O
they	O
do	O
not	O
contain	O
a	O
Sec7	O
domain	O
like	O
EFA-6	O
does	O
[	O
69–71	O
]	O
.	O

Function	O
of	O
Dynein	O
Intermediate	O
,	O
Light	O
Intermediate	O
,	O
and	O
Light	O
Chains	O
The	O
dynein	O
chains	O
in	O
C.	B
elegans	I
exhibit	O
strikingly	O
different	O
functional	O
requirements	O
.	O

The	O
DYRB-1	O
roadblock	O
light	O
chain	O
is	O
required	O
for	O
completion	O
of	O
meiosis	O
and	O
pronuclear	O
migration	O
,	O
but	O
an	O
at	O
least	O
partially	O
functional	O
mitotic	O
spindle	O
forms	O
in	O
the	O
absence	O
of	O
DYRB-1	O
(	O
Figure	O
8)	O
.	O

The	O
DLI-1	O
light	O
intermediate	O
chain	O
is	O
required	O
for	O
multiple	O
dynein	O
-	O
dependent	O
functions	O
:	O
pronuclear	O
migration	O
,	O
centrosome	O
separation	O
,	O
and	O
meiotic	O
and	O
mitotic	O
spindle	O
function	O
[	O
12,34	O
]	O
.	O

DLI-1	O
may	O
promote	O
nuclear	O
envelope	O
targeting	O
of	O
both	O
centrosomes	O
and	O
DHC-1	O
by	O
interacting	O
with	O
the	O
nuclear	O
envelope	O
protein	O
ZYG-12	O
[	O
35	O
]	O
.	O

The	O
second	O
worm	O
light	O
intermediate	O
chain	O
gene	O
,	O
xbx-1	O
,	O
is	O
required	O
for	O
cilia	O
function	O
but	O
not	O
early	O
embryonic	O
development	O
[	O
12,72	O
]	O
.	O

RNAi	O
knockdown	O
of	O
DLC-1	O
,	O
one	O
of	O
three	O
LC8	O
proteins	O
in	O
C.	B
elegans	I
,	O
produces	O
defects	O
similar	O
to	O
dli-1	O
but	O
knockdown	O
of	O
the	O
other	O
two	O
LC8-related	O
genes	O
does	O
not	O
result	O
in	O
any	O
phenotypes	O
[	O
12	O
]	O
.	O

RNAi	O
depletion	O
of	O
dyci-1	O
results	O
in	O
severe	O
meiotic	O
,	O
pronuclear	O
migration	O
,	O
and	O
mitotic	O
spindle	O
assembly	O
defects	O
[	O
12	O
]	O
and	O
in	O
our	O
feeding	O
RNAi	O
regimen	O
dyci-1	O
(	O
RNAi	O
)	O
produces	O
a	O
larval	O
arrest	O
phenotype	O
similar	O
to	O
that	O
observed	O
for	O
dhc-1	O
.	O

Finally	O
,	O
the	O
three	O
Tctex1	O
proteins	O
in	O
C.	B
elegans	I
,	O
DYLT-1	O
,	O
2	O
,	O
and	O
3	O
,	O
are	O
not	O
essential	O
for	O
dynein	O
-	O
related	O
functions	O
[	O
12	O
]	O
.	O

As	O
the	O
dyrb-1	O
,	O
dlc-1	O
,	O
and	O
dli-1	O
dynein	O
AC	O
genes	O
display	O
some	O
dhc-1-like	O
requirements	O
,	O
they	O
positively	O
influence	O
dynein	O
function	O
.	O

However	O
,	O
because	O
reducing	O
their	O
function	O
suppresses	O
dhc-1ts	O
mutants	O
,	O
they	O
may	O
also	O
exert	O
negative	O
regulation	O
(	O
along	O
with	O
dylt-1	O
)	O
on	O
the	O
heavy	O
chain	O
.	O

Negative	O
Regulation	O
of	O
Dynein	O
HC	O
by	O
Light	O
Chain	O
Subunits	O
Finding	O
that	O
reducing	O
the	O
function	O
of	O
light	O
and	O
light	O
intermediate	O
dynein	O
chains	O
suppressed	O
the	O
partial	O
loss	O
of	O
HC	O
function	O
was	O
a	O
striking	O
result	O
.	O

One	O
member	O
of	O
each	O
of	O
four	O
subunit	O
classes	O
can	O
suppress	O
the	O
embryonic	O
lethality	O
associated	O
with	O
three	O
dhc-1	O
ts	O
mutants	O
(	O
Figure	O
5	O
)	O
.	O

We	O
have	O
considered	O
two	O
different	O
models	O
to	O
explain	O
how	O
RNAi	O
-	O
mediated	O
depletion	O
of	O
these	O
dynein	O
ACs	O
can	O
suppress	O
reduced	O
HC	O
function	O
.	O

First	O
,	O
these	O
dynein	O
subunits	O
could	O
be	O
in	O
functional	O
complexes	O
with	O
,	O
and	O
exert	O
negative	O
regulation	O
on	O
,	O
the	O
DHC-1	O
HC	O
(	O
Figure	O
5B	O
)	O
.	O

The	O
suppression	O
mechanism	O
in	O
this	O
case	O
proposes	O
that	O
removal	O
of	O
the	O
suppressing	O
ACs	O
increases	O
residual	O
mutant	O
DHC-1	O
activity	O
.	O

The	O
other	O
,	O
nonsuppressing	O
,	O
accessory	O
subunits	O
might	O
then	O
function	O
in	O
nonmitotic	O
cellular	O
processes	O
such	O
as	O
neuronal	O
transport	O
or	O
organelle	O
positioning	O
.	O

In	O
support	O
of	O
this	O
view	O
,	O
physical	O
removal	O
of	O
the	O
intermediate	O
chains	O
of	O
rat	B
cytoplasmic	O
dynein	O
increased	O
HC	O
ATPase	O
activity	O
by	O
about	O
4-fold	O
(	O
light	O
chains	O
were	O
not	O
monitored	O
in	O
this	O
study	O
but	O
were	O
likely	O
removed	O
as	O
well	O
)	O
[	O
73	O
]	O
.	O

Thus	O
,	O
at	O
least	O
with	O
respect	O
to	O
ATPase	O
activity	O
,	O
some	O
dynein	O
ACs	O
do	O
act	O
as	O
biochemical	O
negative	O
regulators	O
of	O
HC	O
function	O
.	O

An	O
Assortment	O
of	O
Essential	O
and	O
Nonessential	O
Dynein	O
Complexes	O
Alternatively	O
,	O
an	O
assortment	O
of	O
dynein	O
complexes	O
(	O
with	O
different	O
ACs	O
)	O
could	O
coexist	O
within	O
early	O
embryonic	O
cells	O
,	O
with	O
only	O
a	O
subset	O
required	O
for	O
the	O
essential	O
mitotic	O
functions	O
that	O
require	O
DHC-1	O
.	O

In	O
this	O
case	O
,	O
suppression	O
might	O
result	O
from	O
the	O
release	O
of	O
DHC-1	O
HCs	O
from	O
less	O
essential	O
motor	O
complexes	O
,	O
allowing	O
more	O
of	O
the	O
functionally	O
compromised	O
HCs	O
to	O
participate	O
in	O
the	O
essential	O
process	O
of	O
mitosis	O
.	O

We	O
currently	O
disfavor	O
this	O
hypothesis	O
because	O
two	O
of	O
the	O
suppressing	O
light	O
chains	O
(	O
DYLT-1	O
and	O
DYRB-1	O
)	O
can	O
indeed	O
localize	O
to	O
meiotic	O
and	O
mitotic	O
spindles	O
(	O
Figures	O
6	O
and	O
7	O
)	O
,	O
sites	O
where	O
DHC-1	O
has	O
been	O
shown	O
by	O
others	O
to	O
localize	O
and	O
function	O
.	O

Furthermore	O
,	O
the	O
distribution	O
of	O
DYRB-1	O
and	O
DYLT-1	O
closely	O
resembles	O
the	O
distribution	O
of	O
the	O
HC	O
in	O
dhc-1	O
(	O
or195	O
)	O
embryos	O
,	O
suggesting	O
that	O
these	O
two	O
light	O
chains	O
associate	O
with	O
the	O
HC	O
during	O
mitosis	O
(	O
Figure	O
7	O
and	O
[	O
10	O
]	O
)	O
.	O

Finally	O
,	O
dhc-1-like	O
phenotypes	O
result	O
from	O
mutation	O
or	O
RNAi	O
knockdown	O
of	O
three	O
suppressing	O
ACs	O
in	O
otherwise	O
wild	O
-	O
type	O
worms	B
,	O
indicating	O
that	O
they	O
share	O
at	O
least	O
some	O
common	O
and	O
essential	O
requirements	O
.	O

Regardless	O
of	O
the	O
suppression	O
mechanism	O
,	O
our	O
identification	O
of	O
ACs	O
that	O
genetically	O
interact	O
with	O
the	O
DHC-1	O
HC	O
provides	O
a	O
basis	O
for	O
functionally	O
classifying	O
the	O
paralogs	O
of	O
these	O
dynein	O
subunit	O
gene	O
families	O
,	O
and	O
for	O
further	O
investigation	O
of	O
dynein	O
composition	O
and	O
function	O
.	O

Nonessential	O
Dynein	O
Subunits	O
and	O
Negative	O
Regulation	O
of	O
the	O
HC	O
Some	O
ACs	O
are	O
nonessential	O
,	O
supporting	O
the	O
view	O
that	O
some	O
cytoplasmic	O
dynein	O
subunits	O
could	O
function	O
by	O
exerting	O
negative	O
regulation	O
on	O
the	O
HC	O
,	O
rather	O
than	O
positively	O
influencing	O
essential	O
HC	O
function	O
.	O

For	O
example	O
,	O
DYRB-1	O
is	O
not	O
absolutely	O
required	O
for	O
viability	O
because	O
worms	B
lacking	O
this	O
protein	O
can	O
be	O
propagated	O
,	O
although	O
they	O
are	O
extremely	O
sick	O
and	O
do	O
exhibit	O
two	O
dhc-1-like	O
phenotypes	O
(	O
Figure	O
8)	O
.	O

Also	O
,	O
homozygous	O
dylt-1	O
deletion	O
mutants	O
appear	O
fully	O
viable	O
(	O
Figure	O
8)	O
.	O

The	O
two	O
additional	O
Tctex1	O
C.	B
elegans	I
genes	O
could	O
be	O
functionally	O
redundant	O
with	O
DYLT-1	O
,	O
but	O
simultaneously	O
reducing	O
the	O
function	O
of	O
DYLT-2	O
and	O
DYLT-3	O
by	O
RNAi	O
in	O
the	O
dylt-1	O
deletion	O
strain	O
did	O
not	O
cause	O
lethality	O
(	O
unpublished	O
data	O
)	O
.	O

Because	O
RNAi	O
does	O
not	O
always	O
completely	O
reduce	O
function	O
,	O
the	O
question	O
of	O
redundancy	O
in	O
the	O
Tctex1	O
C.	B
elegans	I
gene	O
family	O
remains	O
unresolved	O
.	O

However	O
,	O
Drosophila	B
contains	O
only	O
a	O
single	O
Tctex1	O
gene	O
,	O
Dlc90F	O
[	O
74,75	O
]	O
.	O

A	O
Dlc90F	O
null	O
allele	O
that	O
deletes	O
80	O
%	O
of	O
the	O
open	O
reading	O
frame	O
is	O
essential	O
only	O
for	O
sperm	O
production	O
but	O
not	O
for	O
viability	O
of	O
male	O
or	O
female	O
flies	O
,	O
despite	O
the	O
wild	O
-	O
type	O
protein	O
being	O
incorporated	O
into	O
dynein	O
motors	O
and	O
expressed	O
in	O
various	O
Drosophila	B
tissues	O
[	O
74	O
]	O
.	O

Thus	O
,	O
at	O
least	O
in	O
Drosophila	B
,	O
the	O
Tctex1	O
dynein	O
light	O
chain	O
family	O
is	O
not	O
required	O
for	O
cell	O
division	O
processes	O
like	O
the	O
HC	O
is	O
.	O

Interestingly	O
,	O
budding	O
yeast	B
does	O
not	O
possess	O
genes	O
for	O
the	O
Tctex1	O
or	O
roadblock	O
ACs	O
,	O
indicating	O
that	O
functional	O
cytoplasmic	O
dynein	O
does	O
not	O
require	O
these	O
subunits	O
that	O
are	O
conserved	O
in	O
many	O
other	O
organisms	O
.	O

The	O
AC	O
genes	O
that	O
yeast	B
does	O
posses	O
are	O
not	O
required	O
for	O
HC	O
motility	O
in	O
vitro	O
because	O
dynein	O
purified	O
from	O
yeast	B
with	O
mutations	O
in	O
these	O
genes	O
remains	O
fully	O
active	O
[	O
2	O
]	O
.	O

Thus	O
,	O
dynein	O
function	O
in	O
several	O
contexts	O
does	O
not	O
require	O
AC	O
subunits	O
,	O
and	O
we	O
suggest	O
that	O
in	O
some	O
cases	O
they	O
may	O
have	O
negative	O
regulatory	O
roles	O
.	O

Negative	O
regulation	O
of	O
cytoplasmic	O
dynein	O
may	O
be	O
redundant	O
with	O
other	O
modes	O
of	O
HC	O
regulation	O
or	O
only	O
required	O
during	O
special	O
circumstances	O
.	O

Further	O
studies	O
of	O
subunit	O
localization	O
,	O
and	O
in	O
vitro	O
studies	O
of	O
C.	B
elegans	I
dynein	O
motility	O
,	O
may	O
provide	O
further	O
insight	O
into	O
the	O
modes	O
of	O
AC	O
regulation	O
and	O
function	O
.	O

Materials	O
and	O
Methods	O
C.	B
elegans	I
strains	O
and	O
culture	O
.	O

Strains	O
were	O
cultured	O
according	O
to	O
standard	O
procedures	O
[	O
28	O
]	O
.	O

ts	O
mutants	O
were	O
maintained	O
at	O
15	O
°	O
C	O
and	O
GFP	O
-	O
expressing	O
strains	O
in	O
a	O
wild	O
-	O
type	O
background	O
were	O
maintained	O
in	O
a	O
23	O
°	O
C	O
incubator	O
.	O

dhc-1	O
(	O
or195	O
)	O
was	O
outcrossed	O
six	O
times	O
to	O
the	O
N2	O
Bristol	O
wild	O
-	O
type	O
strain	O
and	O
the	O
or283	O
and	O
or352	O
dhc-1	O
mutants	O
were	O
each	O
outcrossed	O
four	O
times	O
with	O
N2	O
.	O

For	O
sequencing	O
mutant	O
dhc-1	O
loci	O
,	O
genomic	O
DNA	O
was	O
amplified	O
as	O
overlapping	O
∼1-kb	O
fragments	O
from	O
the	O
start	O
codon	O
to	O
the	O
stop	O
codon	O
and	O
sequenced	O
at	O
the	O
University	O
of	O
Oregon	O
DNA	O
sequencing	O
laboratory	O
.	O

For	O
double	O
mutant	O
constructions	O
,	O
the	O
dhc-1	O
(	O
or195	O
)	O
mutation	O
was	O
monitored	O
by	O
sequencing	O
or	O
by	O
assaying	O
a	O
restriction	O
fragment	O
length	O
polymorphism	O
caused	O
by	O
the	O
mutation	O
with	O
Hpy188I	O
(	O
New	O
England	O
Biolabs	O
,	O
http://www.neb.com	O
)	O
,	O
following	O
PCR	O
amplification	O
of	O
the	O
mutated	O
region	O
.	O

The	O
dylt-1	O
(	O
ok417	O
)	O
and	O
ufd-2	O
(	O
tm1380	O
)	O
alleles	O
were	O
monitored	O
by	O
PCR	O
amplification	O
of	O
genomic	O
sequence	O
encompassing	O
the	O
deletions	O
and	O
assaying	O
product	O
size	O
by	O
agarose	O
gel	O
electrophoresis	O
.	O

GFP	O
imaging	O
.	O

Visualization	O
of	O
GFP	O
fusion	O
protein	O
localization	O
was	O
accomplished	O
by	O
mounting	O
embryos	O
on	O
M9	O
+	O
3	O
%	O
agarose	O
pads	O
on	O
microscope	O
slides	O
covered	O
with	O
a	O
coverslip	O
.	O

Time	O
-	O
lapse	O
videos	O
were	O
obtained	O
on	O
a	O
spinning	O
disk	O
Nikon	O
Eclipse	O
TE2000-U	O
microscope	O
(	O
Nikon	O
Instruments	O
,	O
http://www.nikon.com	O
)	O
fitted	O
with	O
an	O
ORCA	O
-	O
ER	O
digital	O
camera	O
(	O
Hamamatsu	O
Photonics	O
,	O
http://www.hamamatsu.com	O
)	O
using	O
a	O
Nikon	O
60	O
×	O
,	O
1.4	O
NA	O
Plan	O
Apo	O
oil	O
objective	O
lens	O
.	O

Videos	O
were	O
adjusted	O
for	O
contrast	O
in	O
ImageJ	O
(	O
National	O
Institutes	O
of	O
Health	O
,	O
http://rsb.info.nih.gov/ij/	O
)	O
[	O
76	O
]	O
,	O
images	O
were	O
adjusted	O
for	O
levels	O
in	O
Adobe	O
Photoshop	O
(	O
http://www.adobe.com/	O
)	O
.	O

RNAi	O
screening	O
.	O

After	O
obtaining	O
the	O
E.	B
coli	I
RNAi	O
library	O
from	O
the	O
MRC	O
Geneservice	O
(	O
Cambridge	O
,	O
UK	O
)	O
[	O
17,19	O
]	O
,	O
we	O
rearrayed	O
it	O
into	O
a	O
48-well	O
microplate	O
format	O
using	O
a	O
liquid	O
-	O
handling	O
Qiagen	O
BioRobot	O
8000	O
(	O
http://www.qiagen.com	O
)	O
.	O

E.	B
coli	I
strains	O
were	O
thawed	O
from	O
−80	O
°	O
C	O
storage	O
and	O
inoculated	O
into	O
1	O
ml	O
of	O
LB	O
+	O
100	O
mg	O
/	O
ml	O
ampicillin	O
-	O
containing	O
96-well	O
growth	O
plates	O
(	O
Whatman	O
,	O
http://www.whatman.com	O
)	O
and	O
covered	O
with	O
microporous	O
sealing	O
film	O
(	O
USA	O
Scientific	O
,	O
http://www.usascientific.com	O
)	O
.	O

Only	O
48	O
wells	O
of	O
the	O
96-well	O
growth	O
plates	O
were	O
filled	O
with	O
media	O
,	O
corresponding	O
to	O
the	O
rearrayed	O
E.	B
coli	I
library	O
.	O

After	O
overnight	O
shaking	O
incubation	O
at	O
37	O
°	O
C	O
,	O
20	O
μl	O
of	O
the	O
cultures	O
were	O
dispensed	O
with	O
a	O
24-channel	O
electronic	O
repeating	O
pipette	O
(	O
Rainin	O
,	O
http://www.rainin.com	O
)	O
onto	O
48-well	O
plates	O
(	O
Nunc	O
,	O
http://www.nuncbrand.com/	O
)	O
containing	O
NGM	O
agar	O
,	O
100	O
μg	O
/	O
ml	O
ampicillin	O
,	O
and	O
1	O
mM	O
IPTG	O
and	O
allowed	O
to	O
dry	O
and	O
induce	O
dsRNA	O
at	O
37	O
°	O
C	O
overnight	O
.	O

The	O
48-well	O
agar	O
plates	O
were	O
filled	O
with	O
a	O
Wheaton	O
Unispense	O
peristaltic	O
pump	O
(	O
http://www.wheaton.com	O
)	O
equipped	O
with	O
a	O
custom	O
-	O
made	O
adaptor	O
(	O
University	O
of	O
Oregon	O
Technical	O
Science	O
Administration	O
)	O
that	O
allowed	O
simultaneous	O
filling	O
of	O
eight	O
wells	O
with	O
the	O
agar	O
solution	O
.	O

Approximately	O
15	O
hypochlorite	O
-	O
synchronized	O
L1	O
mutant	O
larvae	O
were	O
pipetted	O
into	O
each	O
well	O
of	O
the	O
48-well	O
plates	O
with	O
a	O
multichannel	O
pipette	O
and	O
allowed	O
to	O
produce	O
broods	O
.	O

Screening	O
for	O
F1	O
viability	O
was	O
performed	O
by	O
visual	O
examination	O
with	O
a	O
dissecting	O
microscope	O
.	O

Phenotypes	O
were	O
recorded	O
on	O
an	O
Excel	O
spreadsheet	O
(	O
http://www.microsoft.com	O
)	O
and	O
organized	O
in	O
a	O
FileMaker	O
Pro	O
(	O
http://www.filemaker.com	O
)	O
database	O
.	O

We	O
qualitatively	O
identified	O
295	O
initial	O
positive	O
suppressing	O
E.	B
coli	I
strains	O
,	O
for	O
which	O
we	O
repeated	O
the	O
assay	O
on	O
60-mm	O
plates	O
with	O
E.	B
coli	I
again	O
thawed	O
from	O
the	O
library	O
(	O
not	O
streak	O
purified	O
)	O
.	O

If	O
the	O
observed	O
phenotypes	O
reproduced	O
,	O
the	O
assay	O
was	O
performed	O
with	O
three	O
streak	O
-	O
purified	O
E.	B
coli	I
colonies	O
,	O
and	O
a	O
single	O
isolate	O
that	O
again	O
displayed	O
the	O
interaction	O
was	O
kept	O
for	O
further	O
analysis	O
.	O

Embryonic	O
viability	O
quantitation	O
methods	O
.	O

To	O
quantitate	O
embryonic	O
viability	O
we	O
used	O
the	O
following	O
procedure	O
.	O

Cultures	O
of	O
dsRNA	O
-	O
producing	O
bacteria	O
were	O
grown	O
overnight	O
in	O
LB	O
+	O
100	O
μg	O
/	O
ml	O
ampicillin	O
.	O

Cultures	O
(	O
0.2	O
ml	O
)	O
were	O
seeded	O
onto	O
60-mm	O
NGM	O
agar	O
plates	O
containing	O
100	O
μg	O
/	O
ml	O
ampicillin	O
and	O
1	O
mM	O
IPTG	O
and	O
allowed	O
to	O
induce	O
dsRNAs	O
overnight	O
at	O
room	O
temperature	O
.	O

The	O
L4440	O
control	O
vector	O
-	O
containing	O
strain	O
was	O
used	O
as	O
the	O
bacterial	O
lawn	O
for	O
the	O
experiments	O
shown	O
in	O
Figures	O
2A	O
and	O
3B	O
.	O

Approximately	O
80	O
synchronized	O
L1	O
larvae	O
(	O
obtained	O
from	O
hypochlorite	O
-	O
treated	O
worms	B
)	O
were	O
pipetted	O
onto	O
the	O
plates	O
and	O
allowed	O
to	O
grow	O
to	O
young	O
adulthood	O
.	O

Five	O
gravid	O
worms	B
were	O
transferred	O
to	O
prepared	O
NGM	O
agar	O
plates	O
supplemented	O
with	O
100	O
μg	O
/	O
ml	O
ampicillin	O
and	O
1	O
mM	O
IPTG	O
containing	O
a	O
small	O
RNAi	O
bacterial	O
lawn	O
produced	O
from	O
∼5	O
μl	O
of	O
overnight	O
E.	B
coli	I
culture	O
.	O

After	O
producing	O
broods	O
,	O
the	O
adult	O
worms	B
were	O
removed	O
and	O
the	O
embryos	O
were	O
allowed	O
to	O
develop	O
for	O
at	O
least	O
24	O
h.	O
Embryos	O
and	O
larvae	O
were	O
then	O
counted	O
immediately	O
or	O
after	O
storage	O
at	O
4	O
°	O
C	O
.	O

We	O
considered	O
only	O
suppressor	O
dsRNAs	O
that	O
increased	O
embryonic	O
viability	O
greater	O
than	O
3-fold	O
above	O
the	O
background	O
viability	O
observed	O
with	O
the	O
L4440	O
control	O
vector	O
(	O
in	O
the	O
dhc-1	O
(	O
or195	O
)	O
)	O
screen	O
to	O
be	O
significant	O
enough	O
for	O
continued	O
study	O
.	O

Molecular	O
biology	O
.	O

We	O
introduced	O
a	O
polylinker	O
site	O
containing	O
six	O
unique	O
restriction	O
enzyme	O
recognition	O
sites	O
into	O
the	O
pIC26	O
GFP	O
-	O
S	O
protein	O
plasmid	O
by	O
using	O
phosphorylated	O
and	O
PAGE	O
-	O
purified	O
synthetic	O
oligonucleotides	O
[	O
77	O
]	O
.	O

Following	O
ligation	O
,	O
the	O
new	O
plasmid	O
was	O
sequence	O
verified	O
.	O

The	O
modified	O
vector	O
,	O
pSO26	O
,	O
allows	O
the	O
use	O
of	O
additional	O
restriction	O
enzymes	O
and	O
directional	O
cloning	O
for	O
inserting	O
genes	O
of	O
interest	O
(	O
Figure	O
S2	O
)	O
.	O

The	O
SpeI	O
site	O
was	O
recreated	O
at	O
the	O
5′	O
end	O
of	O
the	O
polylinker	O
but	O
not	O
at	O
the	O
3′	O
end	O
.	O

We	O
amplified	O
N2	O
genomic	O
DNA	O
or	O
cDNA	O
(	O
Invitrogen	O
,	O
http://www.invitrogen.com	O
)	O
with	O
Pfu	O
Turbo	O
polymerase	O
(	O
Stratagene	O
,	O
http://www.stratagene.com	O
)	O
,	O
and	O
cloned	O
A	O
-	O
tailed	O
PCR	O
products	O
into	O
either	O
pGEM	O
-	O
T	O
or	O
pGEM	O
-	O
T	O
-	O
easy	O
shuttle	O
vectors	O
(	O
Promega	O
,	O
http://www.promega.com	O
)	O
.	O

Inserted	O
genes	O
were	O
sequence	O
verified	O
at	O
the	O
University	O
of	O
Oregon	O
DNA	O
sequencing	O
laboratory	O
prior	O
to	O
cleavage	O
and	O
ligation	O
to	O
pSO26	O
(	O
see	O
Table	O
S3	O
for	O
restriction	O
sites	O
and	O
primer	O
sequences	O
used	O
)	O
.	O

All	O
of	O
the	O
constructs	O
used	O
in	O
this	O
study	O
were	O
cloned	O
as	O
SpeI	O
-	O
AsiSI	O
or	O
AscI	O
-	O
AsiSI	O
fragments	O
,	O
except	O
for	O
the	O
STAR-2	O
gene	O
,	O
which	O
was	O
amplified	O
as	O
a	O
SpeI	O
fragment	O
and	O
cloned	O
into	O
pIC26	O
.	O

To	O
construct	O
dynein	O
subunit	O
dsRNA	O
-	O
expressing	O
plasmids	O
not	O
available	O
in	O
the	O
RNAi	O
library	O
,	O
gene	O
fragments	O
were	O
amplified	O
from	O
N2	O
genomic	O
DNA	O
with	O
the	O
following	O
primers	O
:	O
F41G4.1	O
:	O
5′-AAGATATCACCCAAAATGGTCCAAAACAAAG-3′	O
and	O
5′-CGGATATCTCGACTGAAGCTGGTTCTGA-3′	O
,	O
xbx-1	O
:	O
5′-AAGATATCTACGACGATGGAAGTTTGAAG-3′	O
and	O
5′-CGGATATCCGTGCCTCTGCAGC-3′	O
,	O
dlc-3	O
:	O
5′-AAGATATCAATTTCAGGTGGACACTGGC-3′	O
and	O
5′-CGGATATCAGCACACTTGCATCATCTGAA-3′.	O
The	O
PCR	O
products	O
were	O
cut	O
with	O
EcoRV	O
,	O
ligated	O
to	O
EcoRV	O
-	O
digested	O
L4440	O
,	O
and	O
sequence	O
verified	O
.	O

Isolation	O
of	O
transgenic	O
worms	B
.	O

GFP	O
fusion	O
plasmids	O
were	O
bombarded	O
into	O
unc-119	O
(	O
ed3	O
)	O
worms	B
as	O
previously	O
described	O
except	O
with	O
the	O
following	O
two	O
changes	O
[	O
78	O
]	O
.	O

Three	O
milligrams	O
of	O
gold	O
particles	O
were	O
used	O
per	O
hepta	O
adaptor	O
bombardment	O
.	O

Also	O
,	O
we	O
briefly	O
sonicated	O
the	O
gold	O
particles	O
(	O
prior	O
to	O
DNA	O
coating	O
and	O
while	O
suspended	O
in	O
50	O
%	O
glycerol	O
)	O
with	O
a	O
Branson	O
sonifier	O
450	O
(	O
http://www.sonifier.com/	O
)	O
fitted	O
with	O
a	O
small	O
tip	O
set	O
to	O
power	O
level	O
1	O
,	O
to	O
disrupt	O
gold	O
aggregates	O
.	O

Non	O
-	O
Unc	O
worms	B
were	O
picked	O
to	O
new	O
plates	O
and	O
allowed	O
to	O
produce	O
broods	O
,	O
which	O
were	O
assayed	O
for	O
GFP	O
fluorescence	O
with	O
a	O
Zeiss	O
axioskop	O
microscope	O
(	O
http://www.zeiss.com/	O
)	O
fitted	O
with	O
an	O
X	O
-	O
Cite	O
120	O
illumination	O
system	O
(	O
EXFO	O
life	O
sciences	O
,	O
Mississauga	O
,	O
Ontario	O
,	O
Canada	O
)	O
.	O

For	O
each	O
fluorescent	O
line	O
,	O
12	O
GFP	O
-	O
positive	O
worms	B
were	O
singled	O
to	O
new	O
plates	O
to	O
determine	O
if	O
the	O
constructs	O
were	O
integrated	O
or	O
were	O
carried	O
as	O
extrachromosomal	O
arrays	O
.	O

Supporting	O
Information	O
Accession	O
Numbers	O
The	O
National	O
Center	O
for	O
Biotechnology	O
Information	O
(	O
NCBI	O
)	O
database	O
(	O
http://www.ncbi.nlm.nih.gov/gquery/gquery.fcgi?itool=toolbar	O
)	O
accession	O
numbers	O
for	O
the	O
dhc-1	O
homologs	O
discussed	O
in	O
this	O
paper	O
are	O
C.	B
elegans	I
,	O
NP_491363	O
;	O
Dictyostelium	B
discoideum	I
,	O
XP_643185	O
;	O
Drosophila	B
melanogaster	I
,	O
AAA60323	O
;	O
Homo	B
sapiens	I
,	O
NP_001367	O
;	O
Mus	B
musculus	I
,	O
NP_084514	O
;	O
Saccharomyces	B
cerevisiae	I
,	O
NP_012980	O
;	O
and	O
Schizosaccharomyces	B
pombe	I
,	O
NP_001018285	O
.	O

The	O
NCBI	O
accession	O
numbers	O
for	O
the	O
Drosophila	B
and	O
human	B
DYLT-1	O
and	O
DYRB-1	O
protein	O
homologues	O
,	O
respectively	O
,	O
are	O
Dlc90F	O
,	O
NP_477356	O
;	O
DYNLT3	O
,	O
NP_006511	O
;	O
DYNLRB1	O
,	O
NP_054902	O
;	O
and	O
robl	O
,	O
NP_523771	O
.	O

Identification	O
of	O
Two	O
Independent	O
Risk	O
Factors	O
for	O
Lupus	O
within	O
the	O
MHC	O
in	O
United	O
Kingdom	O
Families	O
Abstract	O
The	O
association	O
of	O
the	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
with	O
SLE	O
is	O
well	O
established	O
yet	O
the	O
causal	O
variants	O
arising	O
from	O
this	O
region	O
remain	O
to	O
be	O
identified	O
,	O
largely	O
due	O
to	O
inadequate	O
study	O
design	O
and	O
the	O
strong	O
linkage	O
disequilibrium	O
demonstrated	O
by	O
genes	O
across	O
this	O
locus	O
.	O

The	O
majority	O
of	O
studies	O
thus	O
far	O
have	O
identified	O
strong	O
association	O
with	O
classical	O
class	O
II	O
alleles	O
,	O
in	O
particular	O
HLA	O
-	O
DRB1	O
*	O
0301	O
and	O
HLA	O
-	O
DRB1	O
*	O
1501	O
.	O

Additional	O
associations	O
have	O
been	O
reported	O
with	O
class	O
III	O
alleles	O
;	O
specifically	O
,	O
complement	O
C4	O
null	O
alleles	O
and	O
a	O
tumor	O
necrosis	O
factor	O
promoter	O
SNP	O
(	O
TNF-308G	O
/	O
A	O
)	O
.	O

However	O
,	O
the	O
relative	O
effects	O
of	O
these	O
class	O
II	O
and	O
class	O
III	O
variants	O
have	O
not	O
been	O
determined	O
.	O

We	O
have	O
thus	O
used	O
a	O
family	O
-	O
based	O
approach	O
to	O
map	O
association	O
signals	O
across	O
the	O
MHC	O
class	O
II	O
and	O
class	O
III	O
regions	O
in	O
a	O
cohort	O
of	O
314	O
complete	O
United	O
Kingdom	O
Caucasian	O
SLE	O
trios	O
by	O
typing	O
tagging	O
SNPs	O
together	O
with	O
classical	O
typing	O
of	O
the	O
HLA	O
-	O
DRB1	O
locus	O
.	O

Using	O
TDT	O
and	O
conditional	O
regression	O
analyses	O
,	O
we	O
have	O
demonstrated	O
the	O
presence	O
of	O
two	O
distinct	O
and	O
independent	O
association	O
signals	O
in	O
SLE	O
:	O
HLA	O
-	O
DRB1	O
*	O
0301	O
(	O
nominal	O
p	O
=	O
4.9	O
×	O
10−8	O
,	O
permuted	O
p	O
<	O
0.0001	O
,	O
OR	O
=	O
2.3	O
)	O
and	O
the	O
T	O
allele	O
of	O
SNP	O
rs419788	O
(	O
nominal	O
p	O
=	O
4.3	O
×	O
10−8	O
,	O
permuted	O
p	O
<	O
0.0001	O
,	O
OR	O
=	O
2.0	O
)	O
in	O
intron	O
6	O
of	O
the	O
class	O
III	O
region	O
gene	O
SKIV2L	O
.	O

Assessment	O
of	O
genotypic	O
risk	O
demonstrates	O
a	O
likely	O
dominant	O
model	O
of	O
inheritance	O
for	O
HLA	O
-	O
DRB1	O
*	O
0301	O
,	O
while	O
rs419788-T	O
confers	O
susceptibility	O
in	O
an	O
additive	O
manner	O
.	O

Furthermore	O
,	O
by	O
comparing	O
transmitted	O
and	O
untransmitted	O
parental	O
chromosomes	O
,	O
we	O
have	O
delimited	O
our	O
class	O
II	O
signal	O
to	O
a	O
180	O
kb	O
region	O
encompassing	O
the	O
alleles	O
HLA	O
-	O
DRB1	O
*	O
0301-HLA	O
-	O
DQA1	O

*	O
0501-HLA	O
-	O
DQB1	O
*	O
0201	O
alone	O
.	O

Our	O
class	O
III	O
signal	O
importantly	O
excludes	O
independent	O
association	O
at	O
the	O
TNF	O
promoter	O
polymorphism	O
,	O
TNF-308G	O
/	O
A	O
,	O
in	O
our	O
SLE	O
cohort	O
and	O
provides	O
a	O
potentially	O
novel	O
locus	O
for	O
future	O
genetic	O
and	O
functional	O
studies	O
.	O

Systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
/	O
lupus	O
)	O
is	O
a	O
complex	O
autoimmune	O
disease	O
in	O
which	O
the	O
body	O
's	O
immune	O
system	O
attacks	O
its	O
own	O
tissues	O
,	O
causing	O
inflammation	O
in	O
a	O
variety	O
of	O
different	O
organs	O
such	O
as	O
the	O
skin	O
,	O
joints	O
,	O
and	O
kidneys	O
.	O

The	O
cause	O
of	O
lupus	O
is	O
not	O
known	O
,	O
but	O
genes	O
play	O
a	O
significant	O
role	O
in	O
the	O
predisposition	O
to	O
disease	O
.	O

The	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
on	O
Chromosome	O
6	O
contains	O
at	O
least	O
100	O
different	O
genes	O
that	O
affect	O
the	O
immune	O
system	O
,	O
including	O
the	O
genes	O
with	O
the	O
strongest	O
effect	O
on	O
lupus	O
susceptibility	O
.	O

Despite	O
the	O
importance	O
of	O
the	O
MHC	O
in	O
SLE	O
,	O
the	O
identity	O
of	O
the	O
actual	O
genes	O
in	O
the	O
MHC	O
region	O
that	O
cause	O
SLE	O
has	O
remained	O
elusive	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
used	O
the	O
latest	O
set	O
of	O
genetic	O
markers	O
present	O
at	O
the	O
MHC	O
in	O
lupus	O
families	O
to	O
identify	O
the	O
actual	O
genes	O
that	O
affect	O
the	O
disease	O
.	O

To	O
our	O
knowledge	O
,	O
we	O
have	O
shown	O
for	O
the	O
first	O
time	O
that	O
two	O
separate	O
groups	O
of	O
genes	O
are	O
involved	O
in	O
SLE	O
.	O

One	O
group	O
of	O
genes	O
alters	O
how	O
the	O
immune	O
system	O
may	O
inappropriately	O
target	O
its	O
own	O
tissues	O
in	O
the	O
disease	O
.	O

How	O
the	O
second	O
set	O
of	O
genes	O
predisposes	O
to	O
SLE	O
is	O
the	O
subject	O
of	O
ongoing	O
study	O
.	O

Introduction	O
Since	O
the	O
early	O
1970s	O
,	O
the	O
human	B
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
a	O
number	O
of	O
autoimmune	O
,	O
inflammatory	O
,	O
and	O
infectious	O
diseases	O
,	O
and	O
it	O
continues	O
to	O
be	O
the	O
focus	O
of	O
intense	O
research	O
[	O
1	O
]	O
.	O

The	O
recently	O
defined	O
extended	O
MHC	O
(	O
xMHC	O
)	O
encompasses	O
7.6	O
Mb	O
of	O
genome	O
on	O
6p21.3	O
and	O
is	O
divided	O
into	O
five	O
subregions	O
from	O
telomere	O
to	O
centromere	O
:	O
extended	O
class	O
I	O
,	O
classical	O
class	O
I	O
,	O
classical	O
class	O
III	O
,	O
classical	O
class	O
II	O
,	O
and	O
extended	O
class	O
II	O
.	O

In	O
addition	O
,	O
the	O
MHC	O
contains	O
two	O
hypervariable	O
regions	O
,	O
the	O
RCCX	O
module	O
in	O
class	O
III	O
(	O
spanning	O
complement	O
C4	O
)	O
and	O
the	O
HLA	O
-	O
DRB	O
genes	O
in	O
class	O
II	O
,	O
that	O
both	O
exhibit	O
copy	O
number	O
polymorphism	O
.	O

Examination	O
of	O
the	O
sequence	O
across	O
the	O
extended	O
MHC	O
reveals	O
the	O
presence	O
of	O
421	O
genes	O
,	O
and	O
over	O
252	O
(	O
60	O
%	O
)	O
are	O
thought	O
to	O
be	O
expressed	O
[	O
2	O
]	O
.	O

Around	O
40	O
%	O
of	O
genes	O
expressed	O
within	O
the	O
classical	O
MHC	O
encode	O
proteins	O
with	O
putative	O
immunomodulatory	O
function	O
[	O
3	O
]	O
.	O

The	O
classical	O
class	O
I	O
and	O
class	O
II	O
loci	O
encode	O
the	O
human	B
leucocyte	O
antigen	O
(	O
HLA	O
)	O
proteins	O
involved	O
in	O
antigen	O
presentation	O
to	O
T	O
cells	O
,	O
initiating	O
the	O
adaptive	O
immune	O
response	O
.	O

The	O
class	O
III	O
region	O
contains	O
the	O
greatest	O
density	O
of	O
genes	O
in	O
the	O
genome	O
(	O
58	O
expressed	O
genes	O
)	O
,	O
which	O
are	O
often	O
found	O
in	O
functionally	O
related	O
clusters	O
[	O
2	O
]	O
.	O

A	O
major	O
obstacle	O
in	O
the	O
identification	O
of	O
disease	O
-	O
specific	O
causal	O
variants	O
within	O
the	O
MHC	O
has	O
been	O
the	O
strong	O
linkage	O
disequilibrium	O
(	O
LD	O
)	O
exhibited	O
by	O
certain	O
alleles	O
in	O
this	O
region	O
,	O
resulting	O
in	O
the	O
existence	O
of	O
long	O
-	O
range	O
,	O
conserved	O
,	O
extended	O
haplotypes	O
[	O
4	O
]	O
,	O
also	O
known	O
as	O
ancestral	O
haplotypes	O
[	O
5	O
]	O
,	O
sometimes	O
spanning	O
more	O
than	O
2	O
Mb	O
[	O
6	O
]	O
.	O

Thus	O
,	O
for	O
many	O
MHC	O
-	O
associated	O
diseases	O
,	O
it	O
has	O
only	O
been	O
possible	O
to	O
delimit	O
association	O
signals	O
to	O
a	O
particular	O
extended	O
haplotype	O
or	O
segment	O
of	O
one	O
.	O

Systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
/	O
lupus	O
,	O
[	O
Online	O
Mendelian	O
Inheritance	O
in	O
Man	B
152700	O
,	O
http://www.ncbi.nlm.nih.gov/sites/entrez?db=OMIM&TabCmd=Limits	O
]	O
)	O
is	O
a	O
chronic	O
,	O
multi	O
-	O
system	O
autoimmune	O
disease	O
affecting	O
young	O
women	O
ten	O
times	O
more	O
commonly	O
than	O
men	O
.	O

The	O
worldwide	O
prevalence	O
of	O
SLE	O
is	O
estimated	O
at	O
between	O
12	O
and	O
124	O
cases	O
per	O
100,000	O
individuals	O
[	O
7	O
]	O
.	O

SLE	O
is	O
characterized	O
by	O
the	O
presence	O
of	O
pathogenic	O
autoantibodies	O
to	O
nuclear	O
and	O
cell	O
-	O
surface	O
antigens	O
that	O
show	O
affinity	O
maturation	O
.	O

The	O
consequent	O
immune	O
complexes	O
deposit	O
in	O
tissues	O
,	O
causing	O
inflammation	O
and	O
damage	O
.	O

It	O
is	O
well	O
established	O
that	O
there	O
is	O
a	O
complex	O
genetic	O
component	O
to	O
lupus	O
aetiology	O
,	O
with	O
hormonal	O
and	O
environmental	O
influences	O
also	O
contributing	O
to	O
disease	O
susceptibility	O
[	O
8,9	O
]	O
.	O

The	O
MHC	O
has	O
been	O
the	O
most	O
consistently	O
confirmed	O
genetic	O
risk	O
factor	O
for	O
SLE	O
,	O
and	O
multiple	O
different	O
genes	O
within	O
the	O
region	O
have	O
been	O
significantly	O
implicated	O
with	O
disease	O
susceptibility	O
.	O

For	O
example	O
,	O
hereditary	O
and	O
acquired	O
deficiencies	O
of	O
the	O
early	O
classical	O
complement	O
component	O
C4	O
,	O
located	O
within	O
the	O
MHC	O
class	O
III	O
locus	O
,	O
leads	O
to	O
a	O
lupus	O
-	O
like	O
syndrome	O
.	O

A	O
role	O
for	O
another	O
class	O
III	O
gene	O
,	O
tumour	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
)	O
,	O
in	O
SLE	O
was	O
suggested	O
following	O
the	O
observation	O
that	O
the	O
lupus	O
-	O
prone	O
New	O
Zealand	O
F1	O
mouse	B
hybrid	O
exhibits	O
constitutively	O
low	O
TNF	O
expression	O
[	O
10	O
]	O
.	O

Recently	O
,	O
the	O
development	O
of	O
antinuclear	O
antibodies	O
in	O
patients	O
treated	O
with	O
TNF	O
antagonists	O
has	O
also	O
stimulated	O
interest	O
in	O
the	O
possible	O
role	O
of	O
TNF	O
in	O
SLE	O
[	O
11–13	O
]	O
.	O

Murine	O
and	O
human	B
candidate	O
gene	O
studies	O
,	O
together	O
with	O
genome	O
-	O
wide	O
linkage	O
screens	O
,	O
provide	O
further	O
support	O
that	O
multiple	O
genetic	O
loci	O
,	O
including	O
the	O
mouse	B
MHC	O
complex	O
H2	O
and	O
the	O
human	B
MHC	O
locus	O
,	O
contribute	O
to	O
disease	O
susceptibility	O
[	O
14–17	O
]	O
.	O

It	O
should	O
be	O
noted	O
that	O
the	O
human	B
MHC	O
was	O
first	O
associated	O
with	O
SLE	O
in	O
1971	O
,	O
when	O
studies	O
demonstrated	O
that	O
lupus	O
probands	O
were	O
enriched	O
for	O
the	O
class	O
I	O
alleles	O
HL	O
-	O
A8	O
(	O
now	O
known	O
as	O
HLA	O
-	O
B8	O
)	O
and	O
HLA	O
-	O
W15	O
(	O
now	O
known	O
as	O
HLA	O
-	O
B15	O
)	O
when	O
compared	O
with	O
healthy	O
controls	O
[	O
18,19	O
]	O
.	O

Further	O
case	O
control	O
association	O
studies	O
were	O
small	O
,	O
performed	O
in	O
ethnically	O
diverse	O
populations	O
,	O
and	O
tested	O
only	O
a	O
small	O
number	O
of	O
the	O
classical	O
HLA	O
and	O
complement	O
C4	O
alleles	O
.	O

The	O
most	O
consistent	O
findings	O
reported	O
to	O
date	O
are	O
associations	O
with	O
the	O
class	O
II	O
alleles	O
HLA	O
-	O
DR2	O
(	O
DRB1	O
*	O
1501	O
)	O
and	O
HLA	O
-	O
DR3	O
(	O
DRB1	O
*	O
0301	O
)	O
and	O
their	O
respective	O
haplotypes	O
in	O
Caucasian	O
populations	O
.	O

The	O
complement	O
C4A	O
null	O
allele	O
(	O
C4A*Q0	O
)	O
has	O
shown	O
inconsistent	O
association	O
with	O
lupus	O
in	O
a	O
number	O
of	O
studies	O
—	O
a	O
situation	O
that	O
may	O
reflect	O
genetic	O
heterogeneity	O
in	O
disease	O
susceptibility	O
[	O
20–23	O
]	O
.	O

In	O
addition	O
,	O
a	O
recent	O
study	O
has	O
demonstrated	O
that	O
low	O
C4A	O
copy	O
number	O
is	O
a	O
risk	O
factor	O
for	O
lupus	O
in	O
a	O
European	O
American	O
cohort	O
[	O
24	O
]	O
.	O

However	O
,	O
the	O
C4A	O
null	O
allele	O
lies	O
on	O
the	O
lupus	O
-	O
associated	O
DR3	O
""""	O
autoimmune	O
""""	O
extended	O
haplotype	O
(	O
AH8.1	O
)	O
,	O
which	O
exhibits	O
extremely	O
strong	O
LD	O
[	O
6	O
]	O
.	O

It	O
therefore	O
remains	O
to	O
be	O
definitively	O
established	O
whether	O
this	O
locus	O
constitutes	O
a	O
distinct	O
susceptibility	O
allele	O
to	O
that	O
of	O
the	O
class	O
II	O
association	O
or	O
is	O
merely	O
in	O
LD	O
with	O
it	O
.	O

Similarly	O
,	O
certain	O
TNF	O
promoter	O
polymorphisms	O
,	O
including	O
the	O
much	O
-	O
studied	O
SNP	O
TNF-308G	O
/	O
A	O
,	O
have	O
shown	O
association	O
with	O
SLE	O
;	O
but	O
again	O
,	O
many	O
of	O
these	O
variants	O
are	O
carried	O
on	O
the	O
highly	O
conserved	O
8.1	O
ancestral	O
haplotype	O
,	O
thus	O
restricting	O
interpretation	O
of	O
these	O
data	O
.	O

In	O
2002	O
,	O
a	O
family	O
-	O
based	O
study	O
employing	O
microsatellites	O
as	O
surrogate	O
markers	O
for	O
HLA	O
-	O
DRB1	O
haplotypes	O
in	O
Caucasian	O
lupus	O
families	O
demonstrated	O
association	O
with	O
DR3-	O
,	O
DR2-	O
,	O
and	O
DR8	O
(	O
DRB1	O
*	O
0801	O
)	O
-containing	O
haplotypes	O
.	O

In	O
that	O
study	O
,	O
Graham	O
and	O
colleagues	O
reported	O
that	O
,	O
taking	O
advantage	O
of	O
recombinant	O
chromosomes	O
,	O
the	O
disease	O
risk	O
region	O
could	O
be	O
limited	O
to	O
a	O
1	O
Mb	O
region	O
encompassing	O
classical	O
class	O
II	O
and	O
class	O
III	O
[	O
25	O
]	O
.	O

We	O
have	O
performed	O
a	O
medium	O
resolution	O
association	O
mapping	O
study	O
of	O
the	O
MHC	O
in	O
lupus	O
families	O
,	O
utilizing	O
a	O
combination	O
of	O
SNPs	O
and	O
four	O
-	O
digit	O
typing	O
at	O
the	O
HLA	O
-	O
DRB1	O
locus	O
in	O
order	O
to	O
anchor	O
haplotypes	O
.	O

Sixty	O
-	O
eight	O
SNPs	O
were	O
successfully	O
genotyped	O
across	O
a	O
2.4	O
Mb	O
region	O
of	O
the	O
MHC	O
,	O
from	O
the	O
class	O
I	O
locus	O
KIAA1949	O
to	O
the	O
class	O
II	O
gene	O
HLA	O
-	O
DPB2	O
,	O
in	O
314	O
UK	O
Caucasian	O
SLE	O
trios	O
.	O

We	O
used	O
these	O
data	O
to	O
perform	O
a	O
family	O
-	O
based	O
association	O
study	O
in	O
an	O
attempt	O
to	O
distinguish	O
the	O
relative	O
effects	O
of	O
the	O
class	O
II	O
and	O
class	O
III	O
regions	O
of	O
the	O
MHC	O
in	O
lupus	O
susceptibility	O
.	O

In	O
addition	O
,	O
we	O
employed	O
the	O
long	O
-	O
range	O
haplotype	O
test	O
to	O
search	O
for	O
the	O
presence	O
of	O
high	O
-	O
frequency	O
,	O
extended	O
haplotypes	O
indicative	O
of	O
recent	O
positive	O
selection	O
[	O
26	O
]	O
.	O

We	O
have	O
also	O
used	O
family	O
-	O
based	O
and	O
case	O
-	O
control	O
strategies	O
to	O
examine	O
genotypic	O
risk	O
at	O
HLA	O
-	O
DRB1	O
and	O
rs419788	O
.	O

Results	O
Association	O
Testing	O
of	O
HLA	O
-	O
DRB1	O
and	O
MHC	O
Region	O
SNPs	O
In	O
order	O
to	O
define	O
the	O
causal	O
variation	O
within	O
the	O
MHC	O
region	O
,	O
we	O
typed	O
314	O
complete	O
SLE	O
trios	O
for	O
the	O
HLA	O
-	O
DRB1	O
gene	O
as	O
well	O
as	O
for	O
86	O
SNPs	O
across	O
a	O
2.4	O
Mb	O
region	O
encompassing	O
the	O
HLA	O
class	O
I	O
locus	O
HLA	O
-	O
B	O
to	O
HLA	O
-	O
DPB2	O
.	O

High	O
-	O
quality	O
genotype	O
data	O
was	O
obtained	O
for	O
HLA	O
-	O
DRB1	O
and	O
68	O
MHC	O
SNPs	O
(	O
see	O
Table	O
S1	O
for	O
quality	O
control	O
data	O
)	O
.	O

Association	O
testing	O
of	O
the	O
HLA	O
-	O
DRB1	O
gene	O
revealed	O
a	O
significant	O
association	O
with	O
HLA	O
-	O
DRB1	O
*	O
0301	O
(	O
nominal	O
p	O
=	O
4.9	O
×	O
10−8	O
,	O
permuted	O
p	O
<	O
0.0001	O
,	O
T	O
:	O
U	O
=	O
129:55	O
)	O
in	O
our	O
lupus	O
cohort	O
(	O
Table	O
1	O
)	O
.	O

There	O
was	O
also	O
a	O
trend	O
for	O
under	O
transmission	O
of	O
the	O
HLA	O
-	O
DRB1	O
*	O
0701	O
allele	O
(	O
nominal	O
p	O
=	O
0.0013	O
,	O
T	O
:	O
U	O
42:77	O
)	O
;	O
however	O
,	O
this	O
association	O
was	O
no	O
longer	O
significant	O
after	O
correction	O
for	O
multiple	O
testing	O
as	O
determined	O
by	O
10,000	O
permutations	O
of	O
the	O
dataset	O
(	O
permuted	O
p	O
=	O
0.09	O
)	O
.	O

Furthermore	O
,	O
we	O
did	O
not	O
find	O
evidence	O
of	O
association	O
with	O
HLA	O
-	O
DRB1	O
*	O
1501	O
(	O
nominal	O
p	O
=	O
1.0	O
,	O
T	O
:	O
U	O
70:70	O
)	O
or	O
HLA	O
-	O
DRB1	O
*	O
0801	O
(	O
nominal	O
p	O
=	O
1.0	O
,	O
T	O
:	O
U	O
=	O
11:11	O
)	O
in	O
our	O
cohort	O
(	O
see	O
Table	O
S2	O
for	O
complete	O
HLA	O
-	O
DRB1	O
association	O
data	O
)	O
;	O
alleles	O
previously	O
suggested	O
by	O
microsatellite	O
typing	O
of	O
a	O
US	O
lupus	O
cohort	O
[	O
25	O
]	O
.	O

Association	O
testing	O
of	O
the	O
MHC	O
region	O
SNPs	O
also	O
identified	O
significant	O
evidence	O
of	O
association	O
to	O
SLE	O
(	O
Table	O
1	O
for	O
associated	O
markers	O
and	O
Table	O
S3	O
for	O
all	O
MHC	O
SNPs	O
)	O
.	O

The	O
SNP	O
with	O
the	O
most	O
significant	O
association	O
,	O
rs419788	O
(	O
nominal	O
p	O
=	O
4.3	O
×	O
10−8	O
,	O
permuted	O
p	O
<	O
0.0001	O
)	O
was	O
of	O
similar	O
strength	O
to	O
that	O
of	O
the	O
HLA	O
-	O
DRB1	O
*	O
0301	O
allele	O
,	O
with	O
odds	O
ratios	O
(	O
ORs	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
CIs	O
)	O
of	O
2.0	O
(	O
1.6–2.6	O
)	O
and	O
2.3	O
(	O
1.7–3.2	O
)	O
,	O
respectively	O
.	O

This	O
SNP	O
is	O
located	O
within	O
intron	O
6	O
of	O
the	O
class	O
III	O
gene	O
,	O
superkiller	O
viralicidic	O
activity	O
2-like	O
(	O
Saccharomyces	B
cerevisiae	I
)	O
(	O
SKIV2L	O
)	O
,	O
and	O
is	O
located	O
approximately	O
500	O
kb	O
telomeric	O
to	O
the	O
HLA	O
-	O
DRB1	O
gene	O
.	O

Of	O
the	O
other	O
12	O
SNPs	O
that	O
were	O
significantly	O
associated	O
with	O
SLE	O
(	O
nominal	O
p	O
=	O
4.0	O
×	O
10−4	O
to	O
2.5	O
×	O
10−7	O
;	O
permuted	O
p	O
=	O
0.03	O
to	O
<	O
0.0001	O
)	O
,	O
one	O
was	O
located	O
in	O
the	O
class	O
I	O
region	O
between	O
HLA	O
-	O
B	O
and	O
MICA	O
,	O
seven	O
were	O
located	O
in	O
the	O
class	O
III	O
region	O
,	O
and	O
four	O
were	O
situated	O
in	O
the	O
class	O
II	O
region	O
(	O
Table	O
1	O
;	O
Figure	O
S1	O
)	O
.	O

Specifically	O
,	O
the	O
seven	O
associated	O
class	O
III	O
SNPs	O
were	O
located	O
in	O
or	O
close	O
to	O
the	O
following	O
genes	O
:	O
the	O
TNF	O
promoter	O
,	O
BAT3	O
,	O
SLC44A4	O
,	O
EHMT2	O
,	O
TNXB	O
,	O
GPSM3	O
,	O
and	O
NOTCH4	O
.	O

One	O
of	O
the	O
four	O
class	O
II	O
associated	O
SNPs	O
was	O
close	O
to	O
HLA	O
-	O
DRA	O
,	O
two	O
were	O
between	O
HLA	O
-	O
DRB1	O
and	O
HLA	O
-	O
DQA1	O
and	O
one	O
was	O
in	O
intron	O
1	O
of	O
HLA	O
-	O
DQA1	O
.	O

The	O
correlation	O
between	O
all	O
68	O
SNPs	O
and	O
HLA	O
-	O
DRB1	O
in	O
our	O
UK	O
SLE	O
cohort	O
is	O
illustrated	O
in	O
Figure	O
1	O
.	O

The	O
markers	O
showing	O
significant	O
association	O
are	O
highlighted	O
.	O

Conditional	O
Analyses	O
Identify	O
Two	O
Independent	O
Association	O
Signals	O
in	O
the	O
MHC	O
In	O
order	O
to	O
establish	O
whether	O
the	O
two	O
most	O
associated	O
signals	O
identified	O
in	O
this	O
association	O
-	O
mapping	O
experiment	O
are	O
likely	O
to	O
represent	O
a	O
single	O
causal	O
allele	O
or	O
independent	O
risk	O
factors	O
,	O
we	O
first	O
examined	O
the	O
association	O
data	O
conditioned	O
upon	O
the	O
presence	O
of	O
the	O
HLA	O
-	O
DRB1	O
*	O
0301	O
allele	O
.	O

We	O
found	O
that	O
four	O
of	O
the	O
13	O
associated	O
SNPs	O
showed	O
evidence	O
of	O
signals	O
independent	O
of	O
HLA	O
-	O
DRB1	O
*	O
0301	O
in	O
our	O
dataset	O
,	O
the	O
strongest	O
of	O
which	O
was	O
rs419788	O
(	O
Table	O
1	O
)	O
.	O

We	O
therefore	O
conditioned	O
the	O
three	O
remaining	O
SNPs	O
(	O
rs2523589	O
,	O
rs1052486	O
,	O
and	O
rs605203	O
)	O
on	O
rs419788	O
to	O
assess	O
whether	O
these	O
signals	O
are	O
truly	O
independent	O
of	O
each	O
other	O
or	O
show	O
association	O
due	O
to	O
LD	O
with	O
rs419788	O
.	O

In	O
addition	O
,	O
we	O
included	O
HLA	O
-	O
DRB1	O
in	O
stepwise	O
conditional	O
regression	O
analyses	O
performed	O
on	O
the	O
SNPs	O
showing	O
association	O
independent	O
of	O
HLA	O
-	O
DRB1	O
(	O
unpublished	O
data	O
)	O
.	O

These	O
analyses	O
demonstrated	O
that	O
the	O
observed	O
association	O
signals	O
at	O
rs2523589	O
,	O
rs1052486	O
,	O
and	O
rs605203	O
were	O
predominantly	O
dependent	O
upon	O
the	O
association	O
at	O
rs419788	O
,	O
and	O
suggested	O
that	O
there	O
are	O
two	O
major	O
independent	O
association	O
signals	O
in	O
the	O
MHC	O
in	O
UK	O
SLE	O
:	O
HLA	O
-	O
DRB1	O
and	O
rs419788	O
.	O

The	O
independence	O
of	O
the	O
association	O
signals	O
at	O
HLA	O
-	O
DRB1	O
and	O
rs419788	O
is	O
further	O
supported	O
by	O
the	O
observation	O
that	O
there	O
is	O
only	O
modest	O
LD	O
between	O
these	O
two	O
(	O
r2	O
=	O
0.24	O
)	O
.	O

There	O
was	O
no	O
association	O
with	O
any	O
other	O
HLA	O
-	O
DRB1	O
allele	O
and	O
the	O
four	O
SNPs	O
independent	O
of	O
HLA	O
-	O
DRB1	O
*	O
0301	O
(	O
TRANSMIT	O
,	O
unpublished	O
data	O
)	O
.	O

The	O
association	O
of	O
the	O
tumour	O
necrosis	O
factor	O
gene	O
promoter	O
SNP	O
TNF-308G	O
/	O
A	O
with	O
SLE	O
is	O
lost	O
after	O
conditioning	O
for	O
HLA	O
-	O
DRB1	O
*	O
0301	O
in	O
our	O
cohort	O
.	O

If	O
we	O
perform	O
the	O
reverse	O
analysis	O
and	O
condition	O
HLA	O
-	O
DRB1	O
*	O
0301	O
on	O
the	O
presence	O
of	O
the	O
TNF	O
promoter	O
SNP	O
,	O
we	O
find	O
that	O
the	O
association	O
remains	O
,	O
confirming	O
that	O
our	O
TNF	O
association	O
is	O
secondary	O
to	O
that	O
of	O
HLA	O
-	O
DRB1	O
*	O
0301	O
.	O

Genotypic	O
Risk	O
for	O
Class	O
II	O
and	O
Class	O
III	O
Association	O
Signals	O

Having	O
established	O
independent	O
association	O
at	O
the	O
allelic	O
level	O
with	O
HLA	O
-	O
DRB1	O
*	O
0301	O
and	O
rs419788-T	O
in	O
our	O
UK	O
SLE	O
cohort	O
,	O
we	O
wanted	O
to	O
further	O
determine	O
the	O
genotypic	O
risk	O
conferred	O
by	O
these	O
variants	O
and	O
hence	O
gain	O
insight	O
into	O
their	O
underlying	O
mode	O
of	O
inheritance	O
in	O
lupus	O
.	O

We	O
used	O
case	O
-	O
control	O
and	O
family	O
-	O
based	O
analyses	O
to	O
assess	O
genotypic	O
risk	O
at	O
HLA	O
-	O
DRB1	O
,	O
while	O
the	O
family	O
-	O
based	O
test	O
alone	O
was	O
used	O
for	O
rs419788	O
.	O

Common	O
family	O
-	O
based	O
tests	O
of	O
LD	O
,	O
such	O
as	O
those	O
used	O
in	O
this	O
study	O
(	O
Genehunter	O
)	O
,	O
measure	O
transmission	O
distortion	O
based	O
on	O
allele	O
counts	O
rather	O
than	O
genotype	O
counts	O
;	O
the	O
former	O
has	O
been	O
shown	O
to	O
be	O
more	O
powerful	O
under	O
additive	O
models	O
,	O
while	O
the	O
latter	O
has	O
greater	O
power	O
under	O
recessive	O
or	O
dominant	O
genetic	O
models	O
[	O
27	O
]	O
.	O

The	O
genotype	O
-	O
pedigree	O
disequilibrium	O
test	O
(	O
geno	O
-	O
PDT	O
)	O
determines	O
LD	O
between	O
a	O
locus	O
genotype	O
and	O
disease	O
by	O
comparing	O
genotypes	O
that	O
are	O
transmitted	O
from	O
parent	O
to	O
proband	O
with	O
those	O
that	O
are	O
not	O
[	O
27	O
]	O
.	O

We	O
used	O
the	O
geno	O
-	O
PDT	O
to	O
assess	O
genotypic	O
risk	O
for	O
our	O
class	O
II	O
and	O
class	O
III	O
association	O
signals	O
:	O
HLA	O
-	O
DRB1	O
and	O
the	O
SNP	O
rs419788	O
.	O

In	O
the	O
case	O
-	O
control	O
analysis	O
for	O
HLA	O
-	O
DRB1	O
,	O
ORs	O
with	O
95	O
%	O
CI	O
were	O
calculated	O
and	O
Fisher	O
's	O
exact	O
test	O
employed	O
to	O
assess	O
statistically	O
significant	O
differences	O
between	O
HLA	O
-	O
DRB1	O
genotypes	O
in	O
lupus	O
probands	O
and	O
healthy	O
controls	O
.	O

For	O
HLA	O
-	O
DRB1	O
,	O
the	O
alleles	O
were	O
coded	O
as	O
follows	O
:	O
HLA	O
-	O
DRB1	O
*	O
0301	O
,	O
HLA	O
-	O
DRB1	O
*	O
1501	O
,	O
HLA	O
-	O
DRB1*X	O
where	O
X	O
represents	O
all	O
HLA	O
-	O
DRB1	O
alleles	O
other	O
than	O
HLA	O
-	O
DRB1	O
*	O
0301	O
,	O
and	O
HLA	O
-	O
DRB1	O
*	O
1501	O
.	O

We	O
included	O
HLA	O
-	O
DRB1	O
*	O
1501	O
in	O
the	O
analysis	O
,	O
even	O
though	O
we	O
find	O
no	O
allelic	O
association	O
in	O
our	O
cohort	O
,	O
because	O
previous	O
studies	O
have	O
shown	O
a	O
greater	O
risk	O
for	O
lupus	O
in	O
individuals	O
who	O
are	O
compound	O
heterozygotes	O
for	O
HLA	O
-	O
DRB1	O
*	O
0301-	O
and	O
HLA	O
-	O
DRB1	O
*	O
1501-containing	O
haplotypes	O
[	O
25,28	O
]	O
.	O

Overall	O
the	O
results	O
are	O
consistent	O
with	O
a	O
dominant	O
effect	O
from	O
HLA	O
-	O
DRB1	O
*	O
0301	O
(	O
Table	O
2	O
)	O
and	O
a	O
dose	O
-	O
dependent	O
(	O
additive	O
)	O
effect	O
from	O
rs419788-T	O
(	O
Table	O
3	O
)	O
.	O

Specifically	O
,	O
both	O
case	O
-	O
control	O
and	O
geno	O
-	O
PDT	O
demonstrate	O
that	O
there	O
is	O
no	O
dose	O
-	O
dependent	O
increase	O
in	O
disease	O
risk	O
for	O
HLA	O
-	O
DRB1	O
*	O
0301	O
.	O

Rather	O
,	O
it	O
appears	O
that	O
the	O
presence	O
of	O
a	O
single	O
copy	O
of	O
HLA	O
-	O
DRB1	O
*	O
0301	O
alone	O
is	O
sufficient	O
to	O
increase	O
susceptibility	O
to	O
disease	O
.	O

Moreover	O
the	O
0301	O
/	O
X	O
genotypes	O
constitute	O
the	O
greatest	O
risk	O
in	O
our	O
cohort	O
rather	O
than	O
the	O
0301	O
/	O
1501	O
heterozygotes	O
.	O

Genotypes	O
containing	O
HLA	O
-	O
DRB1	O
*	O
1501	O
in	O
the	O
absence	O
of	O
HLA	O
-	O
DRB1	O
*	O
0301	O
revealed	O
no	O
significant	O
association	O
in	O
our	O
cohort	O
.	O

All	O
three	O
rs419788	O
genotypes	O
demonstrated	O
significant	O
association	O
in	O
our	O
lupus	O
families	O
(	O
Table	O
3	O
)	O
.	O

The	O
common	O
CC	O
genotype	O
was	O
significantly	O
under	O
transmitted	O
,	O
while	O
the	O
rare	O
T	O
allele	O
displayed	O
dose	O
-	O
dependent	O
over	O
transmission	O
to	O
lupus	O
probands	O
.	O

Characterization	O
of	O
HLA	O
-	O
DRB1	O
*	O
0301	O
Risk	O
Haplotype	O

Next	O
,	O
we	O
wanted	O
to	O
further	O
delimit	O
the	O
MHC	O
class	O
II	O
association	O
signal	O
that	O
we	O
have	O
detected	O
at	O
HLA	O
-	O
DRB1	O
.	O

We	O
used	O
phased	O
parental	O
genotype	O
data	O
to	O
compare	O
the	O
allelic	O
composition	O
of	O
HLA	O
-	O
DRB1	O
*	O
0301-bearing	O
haplotypes	O
that	O
were	O
transmitted	O
(	O
T	O
)	O
to	O
affected	O
probands	O
to	O
those	O
that	O
were	O
not	O
transmitted	O
(	O
or	O
untransmitted	O
,	O
UT	O
)	O
with	O
the	O
aim	O
of	O
identifying	O
differences	O
that	O
could	O
delineate	O
the	O
lupus	O
susceptibility	O
interval	O
(	O
s	O
)	O
arising	O
from	O
this	O
haplotype	O
(	O
summarized	O
in	O
Figures	O
2A	O
,	O
2B	O
,	O
and	O
S2	O
)	O
.	O

We	O
observed	O
a	O
striking	O
difference	O
between	O
transmitted	O
and	O
untransmitted	O
chromosomes	O
within	O
the	O
class	O
II	O
region	O
:	O
nearly	O
all	O
transmitted	O
HLA	O
-	O
DRB1	O
*	O
0301	O
haplotypes	O
(	O
99	O
%	O
)	O
are	O
identical	O
across	O
a	O
180	O
kb	O
region	O
defined	O
by	O
eight	O
SNPs	O
,	O
whereas	O
the	O
corresponding	O
region	O
within	O
untransmitted	O
HLA	O
-	O
DRB1	O
*	O
0301	O
haplotypes	O
exhibits	O
significant	O
recombination	O
.	O

These	O
data	O
strongly	O
suggest	O
the	O
existence	O
of	O
a	O
risk	O
haplotype	O
that	O
,	O
interestingly	O
,	O
contains	O
only	O
three	O
expressed	O
genes	O
:	O
HLA	O
-	O
DRB1	O
,	O
HLA	O
-	O
DQA1	O
,	O
and	O
HLA	O
-	O
DQB1	O
.	O

Furthermore	O
,	O
we	O
can	O
confidently	O
define	O
the	O
allelic	O
composition	O
of	O
this	O
risk	O
haplotype	O
,	O
as	O
these	O
three	O
genes	O
are	O
in	O
strong	O
LD	O
and	O
occur	O
in	O
one	O
common	O
haplotype	O
in	O
Caucasians	O
:	O
HLA	O
-	O
DRB1	O
*	O
0301-HLA	O
-	O
DQA1	O

*	O
0501-HLA	O
-	O
DQB1	O
*	O
0201	O
.	O

Thus	O
,	O
we	O
hypothesize	O
that	O
the	O
specific	O
combination	O
of	O
all	O
three	O
alleles	O
is	O
required	O
to	O
confer	O
disease	O
risk	O
in	O
lupus	O
or	O
that	O
disease	O
susceptibility	O
lies	O
with	O
either	O
HLA	O
-	O
DRB1	O
*	O
0301	O
or	O
the	O
HLA	O
-	O
DQ	O
alleles	O
.	O

We	O
do	O
not	O
have	O
sufficient	O
numbers	O
of	O
recombinant	O
chromosomes	O
in	O
this	O
risk	O
region	O
to	O
further	O
delimit	O
this	O
signal	O
:	O
2	O
/	O
176	O
(	O
1.1	O
%	O
)	O
transmitted	O
HLA	O
-	O
DRB1	O
*	O
0301	O
haplotypes	O
are	O
recombinant	O
at	O
HLA	O
-	O
DQA1-HLA	O
-	O
DQB1	O
;	O
3	O
/	O
178	O
(	O
1.7	O
%	O
)	O
transmitted	O
haplotypes	O
identical	O
across	O
HLA	O
-	O
DQA1-HLA	O
-	O
DQB1	O
do	O
not	O
possess	O
HLA	O
-	O
DRB1	O
*	O
0301	O
.	O

The	O
composite	O
relative	O
extended	O
haplotype	O
homozygosity	O
(	O
REHH	O
)	O
versus	O
frequency	O
plot	O
for	O
UK	O
SLE	O
;	O
Utah	O
residents	O
with	O
ancestry	O
from	O
northern	O
and	O
western	O
Europe	O
(	O
CEPH	O
)	O
;	O
and	O
Yoruba	O
in	O
Ibadan	O
,	O
Nigeria	O
(	O
Yoruba	O
)	O
populations	O
is	O
shown	O
in	O
Figure	O
3A	O
.	O

We	O
can	O
only	O
comment	O
on	O
evidence	O
for	O
positive	O
selection	O
in	O
CEPH	O
individuals	O
,	O
as	O
we	O
have	O
used	O
this	O
population	O
alone	O
to	O
assess	O
background	O
variation	O
on	O
Chromosome	O
6	O
.	O

The	O
SLE	O
and	O
Yoruba	O
cohorts	O
are	O
shown	O
for	O
comparative	O
purposes	O
.	O

We	O
find	O
no	O
evidence	O
of	O
positive	O
selection	O
for	O
HLA	O
-	O
DRB1	O
*	O
0301	O
in	O
the	O
CEPH	O
population	O
.	O

However	O
,	O
this	O
allele	O
is	O
enriched	O
in	O
our	O
lupus	O
cohort	O
(	O
21	O
%	O
of	O
parental	O
chromosomes	O
)	O
and	O
displays	O
greater	O
extended	O
homozygosity	O
when	O
compared	O
with	O
HLA	O
-	O
DRB1	O
*	O
0301-bearing	O
haplotypes	O
in	O
CEPH	O
and	O
Yoruba	O
.	O

Hence	O
,	O
the	O
HLA	O
-	O
DRB1	O
*	O
0301	O
allele	O
in	O
lupus	O
is	O
observed	O
as	O
an	O
outlier	O
on	O
the	O
plot	O
when	O
compared	O
to	O
background	O
variation	O
in	O
CEPH	O
.	O

These	O
data	O
support	O
our	O
previous	O
observations	O
(	O
outlined	O
above	O
)	O
of	O
the	O
highly	O
conserved	O
nature	O
of	O
HLA	O
-	O
DRB1	O
*	O
0301	O
haplotypes	O
in	O
lupus	O
.	O

In	O
addition	O
,	O
the	O
haplotype	O
bifurcation	O
plots	O
centered	O
on	O
HLA	O
-	O
DRB1	O
*	O
0301	O
for	O
UK	O
SLE	O
,	O
CEPH	O
,	O
and	O
Yoruba	O
populations	O
in	O
Figure	O
3B	O
illustrate	O
preservation	O
of	O
the	O
common	O
HLA	O
-	O
DRB1	O
*	O
0301	O
haplotype	O
in	O
CEPH	O
and	O
UK	O
SLE	O
,	O
while	O
that	O
seen	O
in	O
the	O
Yoruba	O
is	O
significantly	O
different	O
.	O

The	O
class	O
II	O
regions	O
of	O
all	O
three	O
populations	O
are	O
essentially	O
identical	O
across	O
our	O
chosen	O
SNPs	O
;	O
the	O
main	O
differences	O
lie	O
in	O
class	O
III	O
.	O

The	O
difference	O
in	O
African	O
populations	O
in	O
the	O
class	O
III	O
region	O
is	O
one	O
possible	O
explanation	O
for	O
the	O
lack	O
of	O
evidence	O
for	O
an	O
association	O
between	O
HLA	O
-	O
DRB1	O
*	O
0301	O
and	O
SLE	O
in	O
African	O
or	O
African	O
American	O
populations	O
.	O

However	O
,	O
HLA	O
-	O
DRB1	O
*	O
0301	O
has	O
a	O
lower	O
frequency	O
(	O
∼7%–10	O
%	O
)	O
in	O
African	O
populations	O
compared	O
with	O
Europeans	O
(	O
∼13	O
%	O
)	O
,	O
and	O
the	O
number	O
of	O
HLA	O
association	O
studies	O
conducted	O
in	O
African	O
populations	O
is	O
very	O
limited	O
.	O

Characterization	O
of	O
Class	O
III	O
Region	O
Risk	O
Haplotype	O
Our	O
data	O
reveal	O
a	O
second	O
independent	O
signal	O
at	O
the	O
MHC	O
in	O
SLE	O
arising	O
from	O
the	O
T	O
allele	O
of	O
SNP	O
rs419788	O
in	O
intron	O
6	O
of	O
the	O
class	O
III	O
gene	O
,	O
SKIV2L	O
.	O

Further	O
evidence	O
supporting	O
the	O
independence	O
of	O
the	O
rs419788-T	O
and	O
HLA	O
-	O
DRB1	O
*	O
0301	O
alleles	O
is	O
provided	O
by	O
the	O
moderate	O
LD	O
between	O
these	O
two	O
variants	O
(	O
r2	O
=	O
0.24	O
)	O
coupled	O
with	O
our	O
data	O
demonstrating	O
that	O
only	O
47	O
%	O
of	O
rs419788-T	O
allele	O
-	O
bearing	O
haplotypes	O
contain	O
HLA	O
-	O
DRB1	O
*	O
0301	O
.	O

The	O
structure	O
and	O
composition	O
of	O
T	O
and	O
UT	O
haplotypes	O
anchored	O
at	O
rs419788-T	O
were	O
essentially	O
identical	O
(	O
Figures	O
2C	O
,	O
2D	O
,	O
and	O
S2	O
)	O
,	O
and	O
hence	O
not	O
informative	O
in	O
delimiting	O
our	O
class	O
III	O
signal	O
.	O

Therefore	O
,	O
we	O
examined	O
the	O
LD	O
structure	O
around	O
our	O
associated	O
class	O
III	O
SNP	O
to	O
better	O
define	O
our	O
disease	O
risk	O
interval	O
.	O

In	O
our	O
lupus	O
dataset	O
the	O
rs419788-T	O
allele	O
resides	O
on	O
three	O
of	O
seven	O
haplotypes	O
present	O
within	O
a	O
large	O
block	O
of	O
six	O
SNPs	O
exhibiting	O
strong	O
LD	O
.	O

This	O
haplotype	O
block	O
encompasses	O
roughly	O
270	O
kb	O
containing	O
class	O
III	O
genes	O
from	O
SLC44A4	O
to	O
AGER	O
,	O
including	O
the	O
RCCX	O
module	O
.	O

Next	O
,	O
we	O
analyzed	O
the	O
haplotype	O
block	O
structure	O
of	O
this	O
region	O
in	O
CEPH	O
families	O
using	O
SNP	O
data	O
dumped	O
from	O
the	O
International	O
HapMap	O
Project	O
(	O
http://www.hapmap.org/	O
)	O
.	O

The	O
greater	O
density	O
of	O
SNP	O
typing	O
available	O
in	O
the	O
HapMap	O
CEPH	O
population	O
compared	O
to	O
our	O
current	O
UK	O
SLE	O
map	O
allowed	O
us	O
to	O
potentially	O
refine	O
our	O
signal	O
by	O
exploring	O
correlations	O
between	O
our	O
associated	O
SNP	O
and	O
those	O
surrounding	O
it	O
.	O

Analysis	O
of	O
these	O
data	O
(	O
Figure	O
4	O
)	O
suggests	O
the	O
presence	O
of	O
short	O
-	O
range	O
LD	O
around	O
our	O
associated	O
variant	O
,	O
rs419788	O
,	O
in	O
CEPH	O
families	O
,	O
encompassing	O
approximately	O
40	O
kb	O
of	O
the	O
genome	O
which	O
includes	O
the	O
five	O
genes	O
:	O
complement	O
factor	O
B	O
(	O
CFB	O
)	O
,	O
RD	O
RNA	O
binding	O
protein	O
(	O
RDBP	O
)	O
,	O
SKIV2L	O
,	O
dom-3	O
homolg	O
Z	O
(	O
C.	B
elegans	I
)	O
(	O
DOM3Z	O
)	O
,	O
and	O
serine	O
/	O
threonine	O
kinase	O
19	O
(	O
STK19	O
)	O
,	O
and	O
does	O
not	O
include	O
the	O
complement	O
C4	O
locus	O
.	O

Furthermore	O
,	O
assessment	O
of	O
marker	O
association	O
in	O
our	O
lupus	O
dataset	O
demonstrates	O
that	O
after	O
conditioning	O
for	O
HLA	O
-	O
DRB1	O
*	O
0301	O
,	O
the	O
only	O
markers	O
that	O
retain	O
association	O
signals	O
are	O
telomeric	O
of	O
SKIV2L	O
,	O
suggesting	O
that	O
complement	O
C4	O
,	O
which	O
is	O
centromeric	O
to	O
this	O
gene	O
,	O
may	O
not	O
be	O
responsible	O
for	O
our	O
independent	O
class	O
III	O
signal	O
.	O

Subphenotype	O
Analysis	O
In	O
order	O
to	O
gain	O
further	O
insight	O
into	O
disease	O
pathogenesis	O
,	O
we	O
examined	O
common	O
lupus	O
subphenotypes	O
.	O

Such	O
subsets	O
are	O
more	O
homogeneous	O
than	O
lupus	O
per	O
se	O
and	O
thus	O
maybe	O
enriched	O
for	O
specific	O
predisposing	O
variants	O
.	O

In	O
addition	O
,	O
one	O
might	O
expect	O
a	O
close	O
association	O
between	O
MHC	O
class	O
II	O
alleles	O
and	O
autoantibody	O
subsets	O
in	O
lupus	O
if	O
these	O
are	O
indeed	O
causal	O
variants	O
,	O
given	O
their	O
role	O
in	O
antigen	O
presentation	O
and	O
subsequent	O
humoral	O
immunity	O
.	O

We	O
therefore	O
tested	O
our	O
two	O
main	O
MHC	O
association	O
signals	O
,	O
HLA	O
-	O
DRB1	O
*	O
0301	O
and	O
rs419788	O
,	O
for	O
association	O
with	O
renal	O
disease	O
and	O
autoantibody	O
subsets	O
in	O
our	O
lupus	O
cohort	O
.	O

We	O
found	O
that	O
HLA	O
-	O
DRB1	O
*	O
0301	O
was	O
associated	O
with	O
the	O
presence	O
of	O
anti	O
-	O
Ro	O
and	O
anti	O
-	O
La	O
antibodies	O
in	O
our	O
UK	O
SLE	O
cohort	O
,	O
with	O
the	O
latter	O
showing	O
the	O
greatest	O
evidence	O
of	O
association	O
(	O
anti	O
-	O
La	O
nominal	O
p	O
<	O
0.001	O
compared	O
with	O
anti	O
-	O
Ro	O
nominal	O
p	O
<	O
0.025	O
)	O
.	O

We	O
found	O
no	O
association	O
of	O
HLA	O
-	O
DRB1	O
*	O
0301	O
with	O
renal	O
disease	O
or	O
any	O
other	O
autoantibody	O
subsets	O
in	O
our	O
dataset	O
(	O
see	O
Table	O
S4	O
for	O
detailed	O
results	O
)	O
.	O

Genotypes	O
of	O
the	O
SNP	O
rs419788	O
were	O
not	O
associated	O
with	O
any	O
of	O
the	O
tested	O
lupus	O
subphenotypes	O
after	O
controlling	O
for	O
the	O
effect	O
of	O
HLA	O
-	O
DRB1	O
*	O
0301	O
(	O
unpublished	O
data	O
)	O
.	O

Discussion	O
We	O
present	O
the	O
first	O
family	O
-	O
based	O
SNP	O
association	O
study	O
of	O
the	O
MHC	O
in	O
SLE	O
.	O

We	O
have	O
genotyped	O
69	O
markers	O
(	O
HLA	O
-	O
DRB1	O
and	O
68	O
SNPs	O
)	O
across	O
2.4	O
Mb	O
of	O
the	O
MHC	O
,	O
encompassing	O
class	O
III	O
and	O
class	O
II	O
,	O
in	O
a	O
cohort	O
of	O
314	O
UK	O
Caucasian	O
SLE	O
trios	O
.	O

Transmission	O
disequilibrium	O
testing	O
of	O
these	O
data	O
has	O
shown	O
predominant	O
association	O
with	O
the	O
alleles	O
HLA	O
-	O
DRB1	O
*	O
0301	O
and	O
rs419788-T	O
,	O
together	O
with	O
12	O
other	O
MHC	O
SNPs	O
.	O

Moreover	O
,	O
using	O
conditional	O
analyses	O
,	O
we	O
have	O
shown	O
that	O
the	O
two	O
primary	O
signals	O
of	O
association	O
at	O
the	O
MHC	O
are	O
independent	O
of	O
each	O
other	O
.	O

Specifically	O
,	O
one	O
signal	O
arises	O
from	O
HLA	O
-	O
DRB1	O
*	O
0301	O
in	O
class	O
II	O
and	O
the	O
other	O
from	O
the	O
T	O
allele	O
of	O
SNP	O
rs419788	O
in	O
the	O
class	O
III	O
gene	O
SKIV2L	O
.	O

Examination	O
of	O
bifurcation	O
plots	O
for	O
T	O
and	O
UT	O
HLA	O
-	O
DRB1	O
*	O
0301-containing	O
haplotypes	O
has	O
enabled	O
delineation	O
of	O
our	O
class	O
II	O
association	O
signal	O
to	O
a	O
180	O
kb	O
region	O
encompassing	O
HLA	O
-	O
DRB1	O
*	O
0301-HLA	O
-	O
DQA1	O

*	O
0501-HLA	O
-	O
DQB1	O
*	O
0201	O
.	O

These	O
data	O
substantially	O
refine	O
that	O
previously	O
published	O
by	O
Graham	O
et	O
al.	O
in	O
2002	O
[	O
25	O
]	O
,	O
where	O
the	O
lupus	O
susceptibility	O
interval	O
within	O
HLA	O
-	O
DRB1	O
*	O
0301-containing	O
haplotypes	O
could	O
only	O
be	O
delimited	O
to	O
a	O
1	O
Mb	O
region	O
encompassing	O
class	O
II	O
and	O
class	O
III	O
.	O

The	O
precise	O
causal	O
variant	O
(	O
s	O
)	O
within	O
this	O
region	O
remains	O
to	O
be	O
determined	O
,	O
as	O
the	O
three	O
implicated	O
alleles	O
exhibit	O
strong	O
LD	O
with	O
few	O
recombination	O
events	O
separating	O
them	O
(	O
two	O
out	O
of	O
176	O
transmitted	O
HLA	O
-	O
DRB1	O
*	O
0301	O
chromosomes	O
in	O
our	O
dataset	O
)	O
.	O

However	O
,	O
all	O
three	O
allelic	O
variants	O
represent	O
attractive	O
functional	O
candidates	O
in	O
lupus	O
susceptibility	O
for	O
their	O
role	O
in	O
antigen	O
presentation	O
and	O
stimulation	O
of	O
the	O
adaptive	O
immune	O
response	O
.	O

Our	O
association	O
of	O
HLA	O
-	O
DRB1	O
*	O
0301	O
with	O
lupus	O
concurs	O
with	O
published	O
data	O
in	O
Caucasian	O
cohorts	O
and	O
is	O
well	O
established	O
[	O
16	O
]	O
.	O

While	O
our	O
lack	O
of	O
association	O
with	O
HLA	O
-	O
DRB1	O
*	O
1501	O
and	O
HLA	O
-	O
DRB1	O
*	O
0801	O
is	O
consistent	O
with	O
previous	O
data	O
from	O
the	O
UK	O
[	O
29	O
]	O
,	O
Spain	O
[	O
30	O
]	O
,	O
the	O
Netherlands	O
[	O
31	O
]	O
,	O
Sweden	O
[	O
32	O
]	O
,	O
Mexico	O
[	O
33	O
]	O
,	O
and	O
the	O
US	O
[	O
34	O
]	O
,	O
it	O
conflicts	O
with	O
that	O
of	O
other	O
US	O
groups	O
[	O
25,35	O
]	O
.	O

Interestingly	O
,	O
we	O
demonstrate	O
a	O
trend	O
,	O
though	O
not	O
statistically	O
significant	O
,	O
for	O
undertransmission	O
of	O
HLA	O
-	O
DRB1	O
*	O
0701—a	O
result	O
also	O
observed	O
in	O
prior	O
UK	O
and	O
Canadian	O
lupus	O
studies	O
[	O
29,36	O
]	O
.	O

Moreover	O
,	O
a	O
negative	O
association	O
of	O
HLA	O
-	O
DRB1	O
*	O
0701	O
has	O
been	O
reported	O
in	O
other	O
autoimmune	O
diseases	O
including	O
Graves	O
disease	O
[	O
37,38	O
]	O
,	O
type	O
1	O
diabetes	O
[	O
39	O
]	O
,	O
and	O
rheumatoid	O
arthritis	O
[	O
40	O
]	O
.	O

It	O
appears	O
that	O
the	O
conflicting	O
results	O
between	O
UK	O
SLE	O
and	O
previous	O
US	O
(	O
Minnesota	O
[	O
MN	O
]	O
)	O
[	O
25	O
]	O
SLE	O
data	O
stem	O
from	O
differences	O
in	O
HLA	O
-	O
DRB1	O
allele	O
frequency	O
in	O
the	O
probands	O
of	O
each	O
cohort	O
.	O

The	O
reason	O
for	O
this	O
is	O
unclear	O
.	O

A	O
comparison	O
between	O
UK	O
and	O
MN	O
SLE	O
cohorts	O
(	O
Table	O
4	O
)	O
reveals	O
that	O
UK	O
SLE	O
cases	O
are	O
enriched	O
for	O
HLA	O
-	O
DRB1	O
*	O
0301	O
but	O
not	O
HLA	O
-	O
DRB1	O
*	O
0801	O
or	O
HLA	O
-	O
DRB1	O
*	O
1501	O
when	O
compared	O
to	O
a	O
UK	O
control	O
population	O
.	O

In	O
contrast	O
,	O
MN	O
SLE	O
cases	O
are	O
enriched	O
for	O
HLA	O
-	O
DRB1	O
*	O
0301-DQB1	O
*	O
0201	O
,	O
DRB1	O
*	O
0801-DQB1	O
*	O
0402	O
,	O
and	O
DRB1	O

*	O
1501-DQB1	O
*	O
0602	O
inferred	O
haplotypes	O
when	O
compared	O
to	O
MN	O
controls	O
[	O
25	O
]	O
.	O

There	O
is	O
no	O
statistically	O
significant	O
difference	O
in	O
the	O
aforementioned	O
HLA	O
class	O
II	O
alleles	O
/	O
haplotypes	O
between	O
UK	O
and	O
MN	O
control	O
populations	O
that	O
could	O
account	O
for	O
the	O
disparity	O
seen	O
in	O
the	O
respective	O
lupus	O
cohorts	O
.	O

Differences	O
in	O
disease	O
severity	O
and	O
subphenotype	O
frequency	O
between	O
the	O
two	O
populations	O
could	O
account	O
for	O
the	O
observed	O
discrepancy	O
.	O

From	O
the	O
limited	O
data	O
available	O
we	O
found	O
that	O
the	O
presence	O
of	O
renal	O
disease	O
appears	O
to	O
be	O
similar	O
in	O
both	O
cohorts	O
(	O
UK	O
SLE	O
36	O
%	O
compared	O
with	O
MN	O
SLE	O
40	O
%	O
)	O
,	O
while	O
the	O
gender	O
ratios	O
are	O
significantly	O
different	O
(	O
female	O
:	O
male	O
UK	O
SLE	O
11:1	O
compared	O
with	O
MN	O
SLE	O
57:1	O
,	O
Chi	O
square	O
p	O
value	O
<	O
0.001	O
)	O
.	O

We	O
were	O
unable	O
to	O
compare	O
other	O
lupus	O
subphenotypes	O
.	O

Furthermore	O
,	O
closer	O
inspection	O
of	O
these	O
data	O
reveals	O
that	O
microsatellite	O
-	O
inference	O
of	O
HLA	O
-	O
DRB1	O
alleles	O
in	O
the	O
MN	O
SLE	O
dataset	O
may	O
underestimate	O
the	O
frequency	O
of	O
HLA	O
-	O
DRB1	O
*	O
0301	O
and	O
overestimate	O
that	O
of	O
HLA	O
-	O
DRB1	O
*	O
1501	O
,	O
thus	O
diminishing	O
the	O
effect	O
of	O
the	O
former	O
and	O
enhancing	O
that	O
of	O
the	O
latter	O
.	O

It	O
is	O
also	O
possible	O
that	O
the	O
MN	O
SLE	O
cohort	O
shows	O
greater	O
racial	O
heterogeneity	O
in	O
comparison	O
to	O
our	O
UK	O
SLE	O
cohort	O
,	O
despite	O
both	O
being	O
characterized	O
as	O
Caucasian	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
increased	O
risk	O
for	O
lupus	O
in	O
individuals	O
carrying	O
particular	O
combinations	O
of	O
microsatellite	O
-	O
inferred	O
HLA	O
-	O
DRB1-HLA	O
-	O
DQB1	O
haplotypes	O
[	O
25,28	O
]	O
.	O

The	O
highest	O
risk	O
genotype	O
was	O
found	O
to	O
be	O
the	O
compound	O
heterozygote	O
HLA	O
-	O
DRB1	O
*	O
0301-DQB1	O
*	O
0201	O
/	O
HLA	O
-	O
DRB1	O

*	O
1501-DQB1	O
*	O
0602	O
,	O
while	O
HLA	O
-	O
DRB1	O
*	O
0301-DQB1	O
*	O
0201-containing	O
genotypes	O
demonstrated	O
a	O
dose	O
-	O
dependent	O
effect	O
in	O
increasing	O
lupus	O
susceptibility	O
[	O
25,28	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
examined	O
genotypic	O
risk	O
at	O
the	O
classically	O
typed	O
HLA	O
-	O
DRB1	O
locus	O
and	O
in	O
contrast	O
to	O
the	O
aforementioned	O
data	O
of	O
Graham	O
et	O
al.	O
[	O
25,28	O
]	O
we	O
have	O
shown	O
a	O
likely	O
dominant	O
effect	O
of	O
the	O
associated	O
allele	O
,	O
HLA	O
-	O
DRB1	O
*	O
0301	O
.	O

The	O
case	O
-	O
control	O
and	O
family	O
-	O
based	O
analyses	O
for	O
HLA	O
-	O
DRB1	O
also	O
show	O
the	O
greater	O
power	O
of	O
the	O
former	O
to	O
detect	O
significant	O
association	O
(	O
Table	O
2	O
)	O
.	O

Specifically	O
,	O
all	O
genotypes	O
containing	O
HLA	O
-	O
DRB1	O
*	O
0301	O
show	O
increased	O
transmission	O
to	O
lupus	O
probands	O
;	O
however	O
,	O
homozygotes	O
show	O
no	O
greater	O
risk	O
compared	O
with	O
heterozygotes	O
,	O
as	O
would	O
be	O
expected	O
under	O
additive	O
or	O
multiplicative	O
models	O
.	O

Thus	O
,	O
a	O
dominant	O
model	O
of	O
inheritance	O
,	O
requiring	O
the	O
presence	O
of	O
a	O
single	O
copy	O
of	O
the	O
disease	O
-	O
predisposing	O
variant	O
alone	O
,	O
likely	O
underlies	O
the	O
susceptibility	O
conferred	O
by	O
HLA	O
-	O
DRB1	O
*	O
0301	O
in	O
UK	O
SLE	O
.	O

Such	O
a	O
model	O
would	O
fit	O
an	O
antigen	O
presentation	O
hypothesis	O
where	O
susceptible	O
individuals	O
carrying	O
an	O
HLA	O
-	O
DRB1	O
*	O
0301	O
allele	O
are	O
able	O
to	O
present	O
auto	O
-	O
antigens	O
to	O
CD4	O
+	O
lymphocytes	O
,	O
thus	O
stimulating	O
an	O
autoimmune	O
response	O
.	O

The	O
differences	O
between	O
our	O
UK	O
SLE	O
and	O
the	O
previously	O
published	O
US	O
SLE	O
data	O
may	O
reflect	O
disease	O
,	O
ethnic	O
,	O
and	O
haplotypic	O
heterogeneity	O
.	O

Interestingly	O
,	O
analysis	O
of	O
genotypic	O
risk	O
at	O
the	O
associated	O
class	O
III	O
marker	O
,	O
rs419788	O
,	O
suggests	O
an	O
additive	O
(	O
dose	O
-	O
dependent	O
)	O
pattern	O
of	O
inheritance	O
for	O
the	O
rare	O
T	O
allele	O
,	O
where	O
one	O
copy	O
confers	O
a	O
low	O
risk	O
of	O
disease	O
and	O
two	O
copies	O
results	O
in	O
greater	O
susceptibility	O
.	O

The	O
different	O
inheritance	O
patterns	O
for	O
our	O
class	O
II	O
and	O
class	O
III	O
association	O
signals	O
provide	O
further	O
evidence	O
for	O
their	O
independence	O
.	O

A	O
variety	O
of	O
HLA	O
-	O
DR	O
and	O
HLA	O
-	O
DQ	O
alleles	O
have	O
been	O
associated	O
with	O
autoantibody	O
subsets	O
in	O
ethnically	O
diverse	O
populations	O
of	O
lupus	O
.	O

The	O
strongest	O
associations	O
have	O
been	O
demonstrated	O
between	O
anti	O
-	O
Ro	O
and	O
anti	O
-	O
La	O
antibodies	O
and	O
HLA	O
-	O
DR3	O
and	O
HLA	O
-	O
DQ2	O
(	O
HLA	O
-	O
DQB1	O
*	O
0201	O
)	O
,	O
which	O
are	O
in	O
strong	O
LD	O
[	O
41–45	O
]	O
in	O
case	O
-	O
control	O
studies	O
.	O

Here	O
,	O
we	O
confirm	O
the	O
association	O
of	O
HLA	O
-	O
DRB1	O
*	O
0301	O
with	O
anti	O
-	O
Ro	O
and	O
anti	O
-	O
La	O
antibody	O
production	O
in	O
our	O
family	O
-	O
based	O
cohort	O
.	O

Examination	O
of	O
LD	O
structure	O
around	O
our	O
second	O
independent	O
association	O
,	O
rs419788-T	O
in	O
class	O
III	O
,	O
coupled	O
with	O
the	O
results	O
of	O
our	O
conditional	O
analysis	O
,	O
suggests	O
that	O
this	O
signal	O
could	O
also	O
be	O
delimited	O
to	O
a	O
relatively	O
narrow	O
genomic	O
interval	O
of	O
about	O
40	O
kb	O
given	O
further	O
SNP	O
mapping	O
in	O
our	O
cohort	O
.	O

This	O
region	O
includes	O
the	O
genes	O
CFB	O
,	O
RDBP	O
,	O
SKIV2L	O
,	O
DOM3Z	O
,	O
and	O
STK19	O
,	O
but	O
does	O
not	O
include	O
complement	O
C4	O
.	O

Thus	O
,	O
complement	O
C4	O
null	O
alleles	O
,	O
which	O
have	O
been	O
implicated	O
in	O
lupus	O
pathogenesis	O
,	O
may	O
not	O
be	O
responsible	O
for	O
our	O
class	O
III	O
signal	O
.	O

We	O
conclude	O
,	O
therefore	O
,	O
that	O
our	O
family	O
-	O
based	O
mapping	O
study	O
has	O
potentially	O
revealed	O
a	O
hitherto	O
unknown	O
lupus	O
susceptibility	O
interval	O
in	O
the	O
class	O
III	O
region	O
of	O
the	O
MHC	O
.	O

However	O
,	O
we	O
can	O
not	O
conclusively	O
exclude	O
association	O
at	O
complement	O
C4	O
/	O
RCCX	O
without	O
direct	O
determination	O
of	O
C4	O
polymorphism	O
/	O
copy	O
number	O
in	O
our	O
cohort	O
.	O

With	O
respect	O
to	O
the	O
genes	O
implicated	O
in	O
our	O
study	O
,	O
CFB	O
is	O
a	O
vital	O
component	O
of	O
the	O
alternate	O
complement	O
pathway	O
and	O
disregulation	O
may	O
clearly	O
affect	O
the	O
inflammatory	O
response	O
[	O
46	O
]	O
.	O

RD	O
and	O
Skiv2l	O
are	O
proteins	O
potentially	O
involved	O
in	O
RNA	O
processing	O
.	O

The	O
RD	O
protein	O
forms	O
part	O
of	O
a	O
negative	O
elongation	O
factor	O
(	O
NELF	O
)	O
complex	O
that	O
represses	O
RNA	O
polymerase	O
II	O
transcript	O
elongation	O
,	O
while	O
Skiv2l	O
is	O
a	O
DEAD	O
box	O
protein	O
with	O
possible	O
function	O
as	O
an	O
RNA	O
helicase	O
.	O

The	O
function	O
of	O
Dom3z	O
is	O
currently	O
unknown	O
,	O
although	O
the	O
homologous	O
yeast	B
protein	O
binds	O
nuclear	O
exoribonuclease	O
.	O

Moreover	O
,	O
its	O
ubiquitous	O
expression	O
suggests	O
a	O
housekeeping	O
role	O
.	O

STK19	O
is	O
a	O
protein	O
kinase	O
of	O
unknown	O
function	O
with	O
primary	O
nuclear	O
localization	O
[	O
47	O
]	O
.	O

Interestingly	O
,	O
RDBP	O
and	O
SKIV2L	O
are	O
found	O
to	O
be	O
highly	O
expressed	O
in	O
T	O
lymphocytes	O
,	O
B	O
lymphocytes	O
,	O
and	O
dendritic	O
cells	O
(	O
SymAtlas	O
,	O
http://symatlas.gnf.org/SymAtlas/	O
)	O
.	O

A	O
number	O
of	O
studies	O
have	O
demonstrated	O
conflicting	O
evidence	O
for	O
and	O
against	O
association	O
with	O
various	O
TNF	O
locus	O
polymorphisms	O
in	O
SLE	O
[	O
48	O
]	O
.	O

A	O
recent	O
meta	O
-	O
analysis	O
of	O
the	O
TNF-308G	O
/	O
A	O
promoter	O
polymorphism	O
in	O
SLE	O
[	O
48	O
]	O
revealed	O
evidence	O
of	O
association	O
for	O
the	O
minor	O
allele	O
(	O
A	O
)	O
in	O
European	O
populations	O
;	O
however	O
,	O
this	O
study	O
did	O
not	O
account	O
for	O
LD	O
with	O
class	O
II	O
alleles	O
.	O

On	O
conditioning	O
our	O
dataset	O
for	O
HLA	O
-	O
DRB1	O
*	O
0301	O
,	O
we	O
find	O
that	O
the	O
TNF	O
promoter	O
signal	O
is	O
lost	O
,	O
suggesting	O
that	O
this	O
association	O
is	O
not	O
independent	O
and	O
is	O
due	O
to	O
LD	O
with	O
HLA	O
-	O
DRB1	O
*	O
0301	O
(	O
or	O
another	O
variant	O
in	O
LD	O
with	O
HLA	O
-	O
DRB1	O
*	O
0301	O
)	O
.	O

In	O
summary	O
,	O
we	O
have	O
found	O
association	O
with	O
two	O
distinct	O
and	O
independent	O
variants	O
within	O
the	O
class	O
II	O
(	O
HLA	O
-	O
DRB1	O
*	O
0301	O
)	O
and	O
class	O
III	O
(	O
SKIV2L	O
)	O
regions	O
of	O
the	O
MHC	O
in	O
UK	O
SLE	O
trios	O
.	O

We	O
can	O
delimit	O
our	O
class	O
II	O
signal	O
in	O
lupus	O
to	O
three	O
genetic	O
variants	O
(	O
HLA	O
-	O
DRB1	O
*	O
0301-HLA	O
-	O
DQA1	O
*	O
0501-HLA	O
-	O
DQB1	O
*	O
0201	O
)	O
that	O
may	O
confer	O
disease	O
risk	O
in	O
combination	O
or	O
as	O
separate	O
signals	O
.	O

Our	O
class	O
III	O
signal	O
importantly	O
excludes	O
independent	O
association	O
at	O
the	O
TNF	O
promoter	O
polymorphism	O
TNF-308G	O
/	O
A	O
and	O
potentially	O
provides	O
a	O
novel	O
locus	O
for	O
further	O
study	O
.	O

Materials	O
and	O
Methods	O
Study	O
cohorts	O
.	O

SLE	O
families	O
.	O

The	O
cohort	O
comprises	O
314	O
complete	O
SLE	O
trios	O
(	O
that	O
is	O
,	O
mother	O
,	O
father	O
,	O
and	O
affected	O
lupus	O
proband	O
)	O
collected	O
as	O
previously	O
described	O
[	O
49	O
]	O
.	O

All	O
study	O
participants	O
are	O
European	O
Caucasian	O
on	O
the	O
basis	O
of	O
grandparental	O
origin	O
.	O

All	O
314	O
lupus	O
probands	O
(	O
288	O
female	O
,	O
26	O
male	O
)	O
fulfill	O
the	O
revised	O
American	O
College	O
of	O
Rheumatology	O
(	O
ACR	O
)	O
criteria	O
for	O
SLE	O
[	O
50	O
]	O
,	O
36	O
%	O
of	O
whom	O
have	O
a	O
diagnosis	O
of	O
lupus	O
nephritis	O
.	O

Written	O
consent	O
was	O
obtained	O
from	O
all	O
study	O
participants	O
and	O
ethical	O
approval	O
for	O
this	O
study	O
was	O
obtained	O
from	O
the	O
Multi	O
-	O
Centre	O
Research	O
Ethics	O
Committee	O
(	O
MREC	O
2	O
June	O
1998	O
)	O
.	O

Healthy	O
controls	O
.	O

The	O
control	O
population	O
for	O
the	O
HLA	O
-	O
DRB1	O
genotypic	O
risk	O
case	O
-	O
control	O
analysis	O
constitutes	O
1,667	O
healthy	O
males	O
of	O
Northern	O
European	O
origin	O
.	O

The	O
individuals	O
are	O
potential	O
hematopoietic	O
stem	O
cell	O
donors	O
and	O
were	O
typed	O
to	O
four	O
digits	O
for	O
HLA	O
-	O
DRB1	O
at	O
the	O
Anthony	O
Nolan	O
Trust	O
,	O
UK	O
for	O
this	O
purpose	O
.	O

The	O
level	O
of	O
resolution	O
used	O
for	O
the	O
typing	O
of	O
HLA	O
-	O
DRB1	O
*	O
15	O
alleles	O
in	O
these	O
healthy	O
controls	O
resulted	O
in	O
the	O
ambiguous	O
allele	O
string	O
HLA	O
-	O
DRB1	O
*	O
1501	O
/	O
1502	O
/	O
1504	O
/	O
1506	O
.	O

However	O
,	O
it	O
is	O
likely	O
that	O
the	O
great	O
majority	O
are	O
HLA	O
-	O
DRB1	O
*	O
1501	O
.	O

There	O
is	O
no	O
gender	O
bias	O
in	O
HLA	O
-	O
DRB1	O
allele	O
frequencies	O
,	O
so	O
although	O
we	O
have	O
used	O
a	O
male	O
control	O
cohort	O
,	O
the	O
frequencies	O
would	O
be	O
expected	O
to	O
be	O
the	O
same	O
in	O
a	O
similar	O
female	O
cohort	O
(	O
Steven	O
Marsh	O
,	O
personal	O
communication	O
)	O
.	O

SNP	O
genotyping	O
.	O

Eighty	O
-	O
six	O
SNPs	O
were	O
chosen	O
for	O
genotyping	O
in	O
our	O
mapping	O
study	O
.	O

Specifically	O
,	O
we	O
selected	O
40	O
MHC	O
class	O
II	O
and	O
class	O
III	O
haplotype	O
tagging	O
SNPs	O
from	O
a	O
preliminary	O
MHC	O
SNP	O
map	O
[	O
51	O
]	O
that	O
had	O
previously	O
shown	O
robust	O
genotyping	O
efficacy	O
.	O

In	O
addition	O
,	O
we	O
typed	O
36	O
MHC	O
class	O
II	O
tag	O
SNPs	O
from	O
a	O
subsequent	O
high	O
-	O
resolution	O
MHC	O
study	O
[	O
52	O
]	O
.	O

We	O
also	O
included	O
the	O
TNF-308G	O
/	O
A	O
promoter	O
SNP	O
,	O
together	O
with	O
nine	O
further	O
SNPs	O
in	O
the	O
region	O
of	O
HLA	O
-	O
B	O
and	O
MICA	O
obtained	O
from	O
the	O
database	O
,	O
dbSNP	O
(	O
http://www.ncbi.nlm.nih.gov/projects/SNP/	O
)	O
.	O

The	O
latter	O
SNPs	O
had	O
not	O
been	O
well	O
characterized	O
.	O

All	O
variants	O
were	O
typed	O
in	O
the	O
entire	O
cohort	O
(	O
n	O
=	O
942	O
)	O
.	O

The	O
SNPs	O
span	O
approximately	O
2.4	O
Mb	O
of	O
the	O
MHC	O
from	O
the	O
class	O
I	O
gene	O
,	O
KIAA1949	O
to	O
the	O
class	O
II	O
pseudogene	O
,	O
HLA	O
-	O
DPB2	O
and	O
thus	O
encompass	O
MHC	O
class	O
III	O
and	O
class	O
II	O
.	O

SNP	O
genotyping	O
was	O
performed	O
at	O
the	O
Broad	O
Institute	O
of	O
MIT	O
and	O
Harvard	O
and	O
at	O
Imperial	O
College	O
London	O
by	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
/	O
ionisation	O
time	O
-	O
of	O
-	O
flight	O
(	O
MALDI	O
-	O
TOF	O
)	O
mass	O
spectrometry	O
using	O
the	O
Sequenom	O
MassARRAY	O
platform	O
as	O
previously	O
described	O
[	O
53	O
]	O
.	O

SNPs	O
that	O
failed	O
Sequenom	O
typing	O
were	O
retyped	O
by	O
KBiosciences	O
(	O
http://www.kbioscience.co.uk/	O
)	O
using	O
their	O
in	O
-	O
house	O
SNP	O
genotyping	O
methodology	O
,	O
KASPar	O
(	O
http://www.kbioscience.co.uk/genotyping/index.htm	O
)	O
,	O
a	O
competitive	O
allele	O
-	O
specific	O
PCR	O
technique	O
.	O

HLA	O
-	O
DRB1	O
genotyping	O
.	O

HLA	O
-	O
DRB1	O
typing	O
was	O
performed	O
at	O
the	O
Anthony	O
Nolan	O
Trust	O
,	O
UK	O
.	O

All	O
samples	O
(	O
n	O
=	O
942	O
UK	O
SLE	O
trios	O
and	O
n	O
=	O
1,667	O
controls	O
)	O
were	O
genotyped	O
using	O
LABType	O
SSO	O
(	O
sequence	O
-	O
specific	O
oligonucleotide	O
)	O
typing	O
technology	O
according	O
to	O
the	O
manufacturer	O
's	O
written	O
recommendations	O
(	O
http://www.onelambda.com	O
)	O
.	O

Briefly	O
,	O
a	O
locus	O
-	O
specific	O
biotinylated	O
PCR	O
amplicon	O
is	O
produced	O
,	O
denatured	O
,	O
and	O
rehybridized	O
to	O
complementary	O
oligonucleotide	O
probes	O
conjugated	O
to	O
fluorescently	O
coded	O
beads	O
.	O

The	O
bound	O
biotinylated	O
PCR	O
product	O
can	O
be	O
detected	O
using	O
R	O
-	O
phycoerythrin	O
-	O
conjugated	O
streptavidin	O
.	O

A	O
flow	O
analyzer	O
identifies	O
the	O
fluorescent	O
intensity	O
of	O
phycoerythrin	O
on	O
each	O
bead	O
.	O

The	O
assignment	O
of	O
HLA	O
type	O
is	O
based	O
on	O
the	O
reaction	O
pattern	O
compared	O
to	O
patterns	O
associated	O
with	O
known	O
sequences	O
.	O

High	O
resolution	O
testing	O
was	O
performed	O
using	O
the	O
Dynal	O
AllSet+	O
SSP	O
(	O
sequence	O
-	O
specific	O
primers	O
)	O
DRB1	O
assay	O
according	O
to	O
the	O
manufacturer	O
's	O
protocol	O
(	O
Invitrogen	O
)	O
for	O
SLE	O
families	O
only	O
.	O

The	O
presence	O
or	O
absence	O
of	O
PCR	O
amplification	O
was	O
detected	O
in	O
a	O
gel	O
electrophoresis	O
step	O
using	O
visualization	O
by	O
ethidium	O
bromide	O
incorporation	O
.	O

Genotypes	O
were	O
determined	O
using	O
SSPTool	O
software	O
.	O

Samples	O
that	O
could	O
not	O
be	O
resolved	O
to	O
four	O
digits	O
using	O
SSO	O
and	O
PCR	O
-	O
SSP	O
were	O
analyzed	O
by	O
DNA	O
sequencing	O
of	O
exon	O
2	O
of	O
HLA	O
-	O
DRB1	O
.	O

Primers	O
,	O
reagents	O
,	O
and	O
protocols	O
were	O
provided	O
by	O
The	O
Anthony	O
Nolan	O
Trust	O
,	O
UK	O
(	O
primer	O
sequences	O
are	O
available	O
on	O
request	O
)	O
.	O

Specific	O
HLA	O
-	O
DRB1	O
alleles	O
were	O
assigned	O
by	O
comparing	O
the	O
resultant	O
sequence	O
with	O
reference	O
sequence	O
from	O
the	O
IMGT	O
/	O
HLA	O
Database	O
[	O
54	O
]	O
.	O

Data	O
analysis	O
.	O

Mendelian	O
inconsistencies	O
were	O
removed	O
using	O
PedCheck	O
[	O
55	O
]	O
.	O

Families	O
in	O
which	O
more	O
than	O
eight	O
markers	O
demonstrated	O
Mendel	O
errors	O
were	O
removed	O
from	O
further	O
analysis	O
.	O

Markers	O
with	O
less	O
than	O
80	O
%	O
genotyping	O
efficiency	O
and	O
markers	O
where	O
more	O
than	O
eight	O
families	O
showed	O
Mendel	O
errors	O
were	O
also	O
excluded	O
from	O
analysis	O
.	O

Two	O
markers	O
located	O
within	O
the	O
SLE	O
associated	O
class	O
II	O
region	O
(	O
rs2239802	O
in	O
intron	O
4	O
of	O
HLA	O
-	O
DRA	O
and	O
rs6457594	O
in	O
the	O
region	O
between	O
HLA	O
-	O
DRB9	O
and	O
HLA	O
-	O
DRB5	O
)	O
show	O
deviation	O
from	O
Hardy	O
–	O
Weinberg	O
equilibrium	O
(	O
HWE	O
)	O
,	O
which	O
may	O
reflect	O
an	O
undetected	O
SLE	O
association	O
or	O
systematic	O
genotyping	O
error	O
.	O

HWE	O
was	O
assessed	O
in	O
parental	O
samples	O
in	O
our	O
cohort	O
.	O

There	O
is	O
currently	O
no	O
uniform	O
opinion	O
in	O
the	O
community	O
regarding	O
the	O
inclusion	O
or	O
exclusion	O
of	O
SNPs	O
that	O
show	O
deviation	O
from	O
HWE	O
,	O
hence	O
we	O
elected	O
to	O
include	O
these	O
markers	O
in	O
the	O
final	O
analysis	O
.	O

Sixty	O
-	O
eight	O
out	O
of	O
the	O
total	O
86	O
SNPs	O
passed	O
our	O
quality	O
-	O
control	O
measures	O
(	O
see	O
Table	O
S1	O
for	O
details	O
)	O
.	O

In	O
summary	O
,	O
one	O
SNP	O
was	O
monomorphic	O
in	O
our	O
dataset	O
,	O
four	O
SNPs	O
yielded	O
low	O
genotyping	O
efficiency	O
,	O
and	O
13	O
SNPs	O
were	O
excluded	O
for	O
unacceptable	O
Mendel	O
error	O
rate	O
.	O

The	O
mean	O
call	O
rate	O
for	O
all	O
markers	O
post	O
-	O
quality	O
control	O
was	O
94	O
%	O
(	O
range	O
83	O
%	O
to	O
99	O
%	O
)	O
.	O

Family	O
-	O
based	O
association	O
testing	O
was	O
performed	O
using	O
Genehunter	O
TDT	O
(	O
version	O
2.1	O
)	O
[	O
56	O
]	O
and	O
TRANSMIT	O
(	O
version	O
2.5	O
)	O
[	O
57	O
]	O
.	O

Haplotypes	O
were	O
constructed	O
and	O
permutation	O
testing	O
performed	O
using	O
Haploview	O
(	O
version	O
3.32	O
)	O
[	O
58	O
]	O
.	O

Significance	O
of	O
association	O
signals	O
in	O
all	O
analyses	O
was	O
based	O
on	O
permutation	O
testing	O
(	O
10,000	O
permutations	O
)	O
.	O

The	O
data	O
are	O
represented	O
both	O
as	O
nominal	O
and	O
permuted	O
p	O
values	O
.	O

ORs	O
with	O
95	O
%	O
CI	O
for	O
family	O
-	O
based	O
analyses	O
were	O
calculated	O
in	O
PLINK	O
(	O
http://pngu.mgh.harvard.edu/purcell/plink/	O
)	O
[	O
59	O
]	O
.	O

Conditional	O
regression	O
analyses	O
were	O
undertaken	O
using	O
WHAP	O
[	O
60	O
]	O
.	O

The	O
geno	O
-	O
PDT	O
was	O
performed	O
using	O
PDT	O
version	O
5.1	O
with	O
default	O
settings	O
[	O
27	O
]	O
.	O

The	O
HLA	O
-	O
DRB1	O
alleles	O
were	O
coded	O
into	O
three	O
groups	O
for	O
the	O
geno	O
-	O
PDT	O
and	O
the	O
case	O
-	O
control	O
analysis	O
:	O
HLA	O
-	O
DRB1	O
*	O
0301	O
,	O
HLA	O
-	O
DRB1	O
*	O
1501	O
and	O
HLA	O
-	O
DRX	O
where	O
HLA	O
-	O
DRX	O
includes	O
all	O
HLA	O
-	O
DRB1	O
alleles	O
other	O
than	O
HLA	O
-	O
DRB1	O
*	O
0301	O
or	O
HLA	O
-	O
DRB1	O
*	O
1501	O
.	O

The	O
HLA	O
-	O
DRB1	O
*	O
1501	O
code	O
in	O
the	O
healthy	O
controls	O
represents	O
the	O
allele	O
string	O
HLA	O
-	O
DRB1	O
*	O
1501	O
/	O
1502	O
/	O
1504	O
/	O
1506	O
,	O
as	O
described	O
previously	O
.	O

The	O
HLA	O
-	O
DRB1	O
*	O
1501	O
code	O
in	O
the	O
lupus	O
probands	O
represents	O
the	O
alleles	O
HLA	O
-	O
DRB1	O
*	O
1501	O
(	O
84	O
out	O
of	O
91	O
*	O
1501	O
and	O
*	O
1502	O
alleles	O
)	O
and	O
HLA	O
-	O
DRB1	O
*	O
1502	O
(	O
7	O
/	O
91	O
*	O
1501	O
and	O
*	O
1502	O
alleles	O
)	O
,	O
as	O
*	O
1504	O
and	O

*	O
1506	O
were	O
not	O
present	O
in	O
this	O
population	O
.	O

Fisher	O
's	O
exact	O
test	O
was	O
used	O
to	O
assess	O
significance	O
of	O
association	O
in	O
the	O
case	O
-	O
control	O
analysis	O
.	O

Subphenotype	O
analysis	O
.	O

We	O
looked	O
for	O
association	O
of	O
the	O
HLA	O
-	O
DRB1	O
*	O
0301	O
allele	O
with	O
autoantibody	O
subsets	O
and	O
renal	O
disease	O
in	O
our	O
cohort	O
using	O
the	O
Chi	O
-	O
square	O
test	O
.	O

We	O
compared	O
cases	O
with	O
and	O
without	O
the	O
subphenotype	O
of	O
interest	O
with	O
DRB1	O
*	O
0301	O
homozygosity	O
,	O
heterozygosity	O
,	O
combined	O
homozygosity	O
and	O
heterozygosity	O
,	O
and	O
non	O
-	O
DRB1	O
*	O
0301	O
status	O
.	O

We	O
performed	O
the	O
same	O
analyses	O
for	O
homozygous	O
and	O
heterozygous	O
genotypes	O
of	O
the	O
associated	O
SNP	O
rs419788	O
.	O

The	O
autoantibody	O
subsets	O
compared	O
were	O
anti	O
-	O
C1q	O
,	O
IgG	O
,	O
and	O
IgM	O
anti	O
-	O
cardiolipin	O
antibodies	O
(	O
ACLG	O
and	O
ACLM	O
)	O
,	O
anti	O
-	O
Ro	O
,	O
anti	O
-	O
La	O
,	O
anti	O
-	O
RNP	O
,	O
anti	O
-	O
Sm	O
,	O
and	O
anti	O
-	O
dsDNA	O
.	O

Delineation	O
of	O
associated	O
MHC	O
haplotypes	O
and	O
evidence	O
for	O
positive	O
selection	O
.	O

We	O
looked	O
for	O
positively	O
selected	O
alleles	O
in	O
our	O
dataset	O
using	O
the	O
long	O
-	O
range	O
haplotype	O
test	O
as	O
measured	O
by	O
extended	O
haplotype	O
homozygosity	O
(	O
EHH	O
)	O
,	O
previously	O
described	O
by	O
Sabeti	O
et	O
al.	O
[	O
26	O
]	O
.	O

Essentially	O
,	O
such	O
an	O
analysis	O
allows	O
assessment	O
of	O
positive	O
selection	O
by	O
mining	O
datasets	O
for	O
high	O
frequency	O
extended	O
haplotypes	O
in	O
comparison	O
to	O
the	O
other	O
core	O
haplotypes	O
at	O
a	O
locus	O
.	O

EHH	O
is	O
defined	O
as	O
the	O
probability	O
that	O
two	O
randomly	O
chosen	O
chromosomes	O
carrying	O
the	O
core	O
haplotype	O
of	O
interest	O
will	O
be	O
identical	O
by	O
descent	O
(	O
homozygosity	O
at	O
all	O
SNPs	O
)	O
for	O
the	O
entire	O
interval	O
from	O
the	O
core	O
to	O
a	O
distance	O
x.	O

The	O
REHH	O
is	O
the	O
ratio	O
of	O
the	O
EHH	O
on	O
the	O
tested	O
core	O
haplotype	O
compared	O
with	O
the	O
combined	O
EHH	O
of	O
all	O
the	O
other	O
core	O
haplotypes	O
at	O
the	O
region	O
excluding	O
the	O
tested	O
core	O
;	O
as	O
such	O
,	O
REHH	O
accounts	O
for	O
local	O
variation	O
in	O
recombination	O
rate	O
while	O
EHH	O
does	O
not	O
[	O
26	O
]	O
.	O

The	O
program	O
emphase	O
was	O
employed	O
to	O
assign	O
the	O
phase	O
of	O
parental	O
genotype	O
data	O
and	O
reconstruct	O
missing	O
information	O
.	O

Emphase	O
is	O
a	O
simple	O
phaser	O
similar	O
to	O
the	O
phaser	O
of	O
Excoffier	O
and	O
Slatkin	O
[	O
61	O
]	O
.	O

It	O
is	O
very	O
fast	O
,	O
especially	O
on	O
large	O
datasets	O
,	O
and	O
sufficiently	O
accurate	O
for	O
most	O
genetic	O
applications	O
.	O

EHH	O
analysis	O
was	O
performed	O
on	O
the	O
phased	O
parental	O
data	O
using	O
the	O
software	O
program	O
SWEEP	O
(	O
http://www.broad.mit.edu/mpg/sweep/index.html	O
)	O
.	O

Haplotype	O
bifurcation	O
plots	O
.	O

We	O
represent	O
the	O
breakdown	O
of	O
LD	O
on	O
core	O
haplotypes	O
using	O
haplotype	O
bifurcation	O
diagrams	O
generated	O
in	O
the	O
program	O
TREE	O
[	O
62	O
]	O
(	O
also	O
explained	O
in	O
[	O
52	O
]	O
)	O
.	O

REHH	O
versus	O
frequency	O
plots	O
.	O

Fifty	O
-	O
three	O
SNPs	O
(	O
identified	O
in	O
Figure	O
1	O
)	O
are	O
common	O
to	O
our	O
dataset	O
and	O
the	O
CEPH	O
and	O
Yoruba	O
HapMap	O
[	O
63	O
]	O
populations	O
.	O

These	O
three	O
datasets	O
,	O
together	O
with	O
CEPH	O
SNP	O
data	O
for	O
Chromosome	O
6	O
in	O
its	O
entirety	O
,	O
were	O
used	O
to	O
generate	O
separate	O
REHH	O
versus	O
frequency	O
plots	O
in	O
SWEEP	O
.	O

The	O
plots	O
from	O
the	O
four	O
cohorts	O
were	O
combined	O
for	O
visual	O
,	O
not	O
statistical	O
,	O
comparison	O
.	O

Evidence	O
for	O
positive	O
selection	O
was	O
quantitatively	O
assessed	O
in	O
CEPH	O
individuals	O
,	O
as	O
this	O
population	O
alone	O
was	O
used	O
to	O
assess	O
background	O
variation	O
on	O
Chromosome	O
6	O
.	O

The	O
UK	O
SLE	O
and	O
Yoruba	O
cohort	O
data	O
are	O
shown	O
for	O
comparison	O
.	O

The	O
95th	O
percentile	O
based	O
on	O
total	O
CEPH	O
Chromosome	O
6	O
SNP	O
data	O
is	O
shown	O
.	O

Supporting	O
Information	O
Accession	O
Numbers	O
The	O
Online	O
Mendelian	O
Inheritance	O
in	O
Man	B
(	O
OMIM	O
,	O
http://www.ncbi.nlm.nih.gov/sites/entrez?db=omim	O
)	O
accession	O
numbers	O
for	O
the	O
genes	O
described	O
in	O
this	O
study	O
are	O
as	O
follows	O
:	O
AGER	O
,	O
600214	O
;	O
BAT3	O
,	O
142590	O
;	O
C4A	O
,	O
120810	O
;	O
C4B	O
,	O
120820	O
;	O
CFB	O
,	O
138470	O
;	O
DOM3Z	O
,	O
605996	O
;	O
DOM3Z	O
,	O
605996	O
;	O
EHMT2	O
,	O
604599	O
;	O
HLA	O
-	O
B	O
,	O
142830	O
;	O
HLA	O
-	O
DPB2	O
,	O
120290	O
;	O
HLA	O
-	O
DQA1	O
,	O
146880	O
;	O
HLA	O
-	O
DQB1	O
,	O
604305	O
;	O
HLA	O
-	O
DRA	O
,	O
142860	O
;	O
HLA	O
-	O
DRB1	O
,	O
142857	O
;	O
KIAA1949	O
,	O
610990	O
;	O
MICA	O
,	O
600169	O
;	O
NOTCH4	O
,	O
164951	O
;	O
RDBP	O
,	O
154040	O
;	O
RDBP	O
,	O
154040	O
;	O
SKIV2L	O
,	O
600478	O
;	O
SLC44A4	O
,	O
606107	O
;	O
STK19	O
,	O
604977	O
;	O
STK19	O
,	O
604977	O
;	O
TNF	O
,	O
191160	O
;	O
and	O
TNXB	O
,	O
600985	O
.	O

SuperCAT	O
:	O
a	O
supertree	O
database	O
for	O
combined	O
and	O
integrative	O
multilocus	O
sequence	O
typing	O
analysis	O
of	O
the	O
Bacillus	B
cereus	I
group	I
of	O
bacteria	O
(	O
including	O
B.	B
cereus	I
,	O
B.	B
anthracis	I
and	O
B.	B
thuringiensis	I
)	O
Abstract	O
The	O
Bacillus	B
cereus	I
group	I
of	O
bacteria	O
is	O
an	O
important	O
group	O
including	O
mammalian	O
and	O
insect	O
pathogens	O
,	O
such	O
as	O
B.	B
anthracis	I
,	O
the	O
anthrax	B
bacterium	O
,	O
B.	B
thuringiensis	I
,	O
used	O
as	O
a	O
biological	O
pesticide	O
and	O
B.	B
cereus	I
,	O
often	O
involved	O
in	O
food	O
poisoning	O
incidents	O
.	O

To	O
characterize	O
the	O
population	O
structure	O
and	O
epidemiology	O
of	O
these	O
bacteria	O
,	O
five	O
separate	O
multilocus	O
sequence	O
typing	O
(	O
MLST	O
)	O
schemes	O
have	O
been	O
developed	O
,	O
which	O
makes	O
results	O
difficult	O
to	O
compare	O
.	O

Therefore	O
,	O
we	O
have	O
developed	O
a	O
database	O
that	O
compiles	O
and	O
integrates	O
MLST	O
data	O
from	O
all	O
five	O
schemes	O
for	O
the	O
B.	B
cereus	I
group	I
,	O
accessible	O
at	O
http://mlstoslo.uio.no/.	O
Supertree	O
techniques	O
were	O
used	O
to	O
combine	O
the	O
phylogenetic	O
information	O
from	O
analysis	O
of	O
all	O
schemes	O
and	O
datasets	O
,	O
in	O
order	O
to	O
produce	O
an	O
integrated	O
view	O
of	O
the	O
B.	B
cereus	I
group	I
population	O
.	O

The	O
database	O
currently	O
contains	O
strain	O
information	O
and	O
sequence	O
data	O
for	O
1029	O
isolates	O
and	O
26	O
housekeeping	O
gene	O
fragments	O
,	O
which	O
can	O
be	O
searched	O
by	O
keywords	O
,	O
MLST	O
scheme	O
,	O
or	O
sequence	O
similarity	O
.	O

Supertrees	O
can	O
be	O
browsed	O
according	O
to	O
various	O
criteria	O
such	O
as	O
species	O
,	O
isolate	O
source	O
,	O
or	O
genetic	O
distance	O
,	O
and	O
subtrees	O
containing	O
strains	O
of	O
interest	O
can	O
be	O
extracted	O
.	O

Besides	O
analysis	O
of	O
the	O
available	O
data	O
,	O
the	O
user	O
has	O
the	O
possibility	O
to	O
enter	O
her	O
/	O
his	O
own	O
sequences	O
and	O
compare	O
them	O
to	O
the	O
database	O
and/or	O
include	O
them	O
into	O
the	O
supertree	O
reconstructions	O
.	O

INTRODUCTION	O
Multilocus	O
sequence	O
typing	O
(	O
MLST	O
)	O
is	O
a	O
tool	O
that	O
is	O
widely	O
used	O
for	O
phylogenetic	O
typing	O
of	O
bacteria	O
.	O

MLST	O
is	O
based	O
on	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplification	O
and	O
sequencing	O
of	O
internal	O
fragments	O
of	O
usually	O
seven	O
essential	O
or	O
housekeeping	O
genes	O
spread	O
around	O
the	O
bacterial	O
chromosome	O
.	O

The	O
genetic	O
relatedness	O
among	O
isolates	O
is	O
then	O
determined	O
by	O
comparison	O
of	O
the	O
nucleotide	O
sequence	O
types	O
(	O
1,2	O
)	O
.	O

MLST	O
is	O
thus	O
a	O
method	O
that	O
is	O
unambiguous	O
and	O
truly	O
portable	O
among	O
laboratories	O
.	O

Since	O
the	O
initial	O
development	O
of	O
this	O
technique	O
for	O
Neisseria	B
meningitidis	I
in	O
1998	O
,	O
MLST	O
schemes	O
have	O
been	O
developed	O
for	O
about	O
30	O
species	O
including	O
some	O
of	O
the	O
most	O
important	O
bacterial	O
pathogens	O
,	O
e.g.	O
Streptococcus	B
pneumoniae	I
,	O
Streptococcus	B
pyogenes	I
,	O
Haemophilus	B
influenzae	I
,	O
Staphylococcus	B
aureus	I
,	O
Campylobacter	B
jejuni	I
,	O
Enterococcus	B
faecium	I
,	O
Burkholderia	B
pseudomallei	I
,	O
Escherichia	B
coli	I
,	O
Salmonella	B
enterica	I
and	O
the	O
Bacillus	B
cereus	I
group	I
(	O
see	O
(	O
1	O
)	O
for	O
a	O
recent	O
review	O
)	O
.	O

These	O
MLST	O
schemes	O
have	O
been	O
used	O
successfully	O
to	O
explore	O
the	O
population	O
structure	O
of	O
bacteria	O
,	O
to	O
study	O
the	O
evolution	O
of	O
their	O
virulence	O
properties	O
,	O
to	O
identify	O
antibiotic	O
-	O
resistant	O
strains	O
and	O
epidemic	O
clones	O
,	O
and	O
for	O
epidemiological	O
surveillance	O
.	O

The	O
B.	B
cereus	I
group	I
includes	O
bacterial	O
species	O
that	O
are	O
of	O
medical	O
and/or	O
economic	O
importance	O
,	O
such	O
as	O
B.	B
anthracis	I
,	O
an	O
obligate	O
mammalian	O
pathogen	O
causing	O
the	O
lethal	O
disease	O
anthrax	B
,	O
B.	B
cereus	I
,	O
an	O
opportunistic	O
human	B
pathogen	O
involved	O
in	O
food	O
-	O
poisoning	O
incidents	O
and	O
contaminations	O
in	O
hospitals	O
,	O
B.	B
thuringiensis	I
,	O
an	O
insect	O
pathogen	O
and	O
one	O
of	O
the	O
world	O
's	O
most	O
widely	O
used	O
biopesticide	O
and	O
B.	B
weihenstephanensis	I
,	O
a	O
cold	O
-	O
tolerant	O
species	O
known	O
for	O
contaminating	O
dairies	O
.	O

These	O
species	O
are	O
genetically	O
very	O
closely	O
related	O
and	O
may	O
be	O
considered	O
as	O
one	O
species	O
based	O
on	O
genetic	O
and	O
genomic	O
evidence	O
(	O
3–5	O
)	O
.	O

Unlike	O
other	O
bacterial	O
species	O
that	O
are	O
typed	O
using	O
a	O
single	O
MLST	O
scheme	O
,	O
five	O
separate	O
schemes	O
have	O
been	O
developed	O
for	O
the	O
B.	B
cereus	I
group	I
,	O
based	O
on	O
different	O
sets	O
of	O
genes	O
and	O
isolates	O
(	O
5–10	O
)	O
.	O

The	O
Priest	O
scheme	O
(	O
8)	O
is	O
currently	O
the	O
most	O
widely	O
used	O
.	O

Studies	O
with	O
the	O
various	O
schemes	O
have	O
independently	O
indicated	O
that	O
the	O
B.	B
cereus	I
group	I
population	O
is	O
divided	O
into	O
three	O
main	O
phylogenetic	O
clusters	O
and	O
that	O
species	O
are	O
usually	O
intermixed	O
within	O
the	O
groups	O
.	O

One	O
cluster	O
contains	O
the	O
monomorphic	O
B.	B
anthracis	I
isolates	O
and	O
a	O
number	O
of	O
B.	B
cereus	I
and	O
B.	B
thuringiensis	I
strains	O
,	O
many	O
of	O
which	O
are	O
from	O
clinical	O
sources	O
.	O

A	O
second	O
heterogeneous	O
cluster	O
includes	O
B.	B
cereus	I
and	O
B.	B
thuringiensis	I
isolates	O
from	O
various	O
origins	O
,	O
while	O
cold	O
-	O
tolerant	O
B.	B
weihenstephanensis	I
and	O
B.	B
cereus	I
isolates	O
belong	O
to	O
the	O
third	O
group	O
.	O

The	O
separate	O
MLST	O
analyses	O
have	O
also	O
revealed	O
that	O
the	O
B.	B
cereus	I
group	I
population	O
is	O
weakly	O
clonal	O
overall	O
due	O
to	O
numerous	O
clinical	O
and	O
virulent	O
isolates	O
emerging	O
from	O
different	O
phylogenetic	O
positions	O
(	O
5–8,11–14	O
)	O
,	O
with	O
the	O
exception	O
of	O
the	O
'	O
cold	O
-	O
tolerant	O
'	O
cluster	O
that	O
seems	O
to	O
exhibit	O
a	O
panmictic	O
(	O
or	O
sexual	O
)	O
population	O
structure	O
,	O
i.e.	O
with	O
frequent	O
genetic	O
exchanges	O
between	O
strains	O
(	O
9	O
)	O
.	O

Despite	O
the	O
overall	O
congruence	O
between	O
the	O
various	O
MLST	O
studies	O
,	O
the	O
use	O
of	O
separate	O
schemes	O
with	O
no	O
gene	O
overlap	O
and	O
very	O
little	O
strain	O
overlap	O
has	O
produced	O
a	O
confusing	O
situation	O
and	O
makes	O
the	O
results	O
difficult	O
to	O
compare	O
directly	O
.	O

Therefore	O
,	O
we	O
recently	O
proposed	O
a	O
combined	O
scheme	O
based	O
on	O
genes	O
taken	O
from	O
three	O
of	O
the	O
four	O
schemes	O
available	O
by	O
then	O
and	O
for	O
which	O
we	O
created	O
a	O
web	O
-	O
based	O
database	O
accessible	O
at	O
the	O
University	O
of	O
Oslo	O
's	O
MLST	O
server	O
,	O
http://mlstoslo.uio.no/	O
(	O
5	O
)	O
.	O

Here	O
,	O
in	O
order	O
to	O
provide	O
the	O
B.	B
cereus	I
group	I
research	O
community	O
with	O
a	O
common	O
MLST	O
resource	O
,	O
we	O
have	O
developed	O
on	O
the	O
same	O
website	O
a	O
database	O
,	O
SuperCAT	O
,	O
that	O
compiles	O
and	O
integrates	O
MLST	O
data	O
from	O
all	O
the	O
published	O
B.	B
cereus	I
group	I
schemes	O
.	O

In	O
addition	O
,	O
we	O
applied	O
supertree	O
reconstruction	O
methods	O
to	O
build	O
an	O
integrated	O
view	O
of	O
the	O
B.	B
cereus	I
group	I
population	O
and	O
phylogeny	O
.	O

Below	O
we	O
describe	O
the	O
content	O
and	O
main	O
features	O
of	O
the	O
new	O
database	O
as	O
well	O
as	O
the	O
process	O
of	O
supertree	O
building	O
.	O

DATABASE	O
CONTENT	O
AND	O
IMPLEMENTATION	O
The	O
SuperCAT	O
database	O
provides	O
information	O
,	O
sequence	O
and	O
phylogenetic	O
data	O
for	O
all	O
bacterial	O
isolates	O
that	O
have	O
been	O
typed	O
using	O
any	O
of	O
the	O
five	O
published	O
MLST	O
schemes	O
for	O
the	O
B.	B
cereus	I
group	I
(	O
Table	O
1	O
)	O
.	O

Strain	O
information	O
,	O
when	O
known	O
,	O
includes	O
isolate	O
description	O
,	O
source	O
and	O
geographical	O
location	O
of	O
isolation	O
,	O
and	O
the	O
scheme	O
(	O
s	O
)	O
used	O
for	O
typing	O
.	O

The	O
sequence	O
data	O
include	O
the	O
nucleotide	O
sequences	O
of	O
the	O
MLST	O
loci	O
examined	O
in	O
a	O
given	O
strain	O
.	O

SuperCAT	O
also	O
contains	O
the	O
phylogenetic	O
supertree	O
of	O
the	O
B.	B
cereus	I
group	I
reconstructed	O
by	O
combining	O
the	O
sequence	O
data	O
from	O
all	O
five	O
schemes	O
,	O
as	O
well	O
as	O
supertrees	O
built	O
for	O
individual	O
schemes	O
.	O

Information	O
and	O
sequences	O
for	O
isolates	O
typed	O
by	O
the	O
Priest	O
and	O
Tourasse	O
–	O
Helgason	O
schemes	O
were	O
retrieved	O
from	O
the	O
databases	O
devoted	O
to	O
these	O
schemes	O
at	O
http://pubmlst.org/bcereus	O
and	O
http://mlstoslo.uio.no/	O
,	O
respectively	O
.	O

MLST	O
data	O
for	O
additional	O
strains	O
not	O
available	O
in	O
the	O
pubmlst.org	O
repository	O
(	O
strains	O
from	O
(	O
15	O
)	O
are	O
missing	O
therein	O
)	O
and	O
for	O
the	O
Helgason	O
,	O
Ko	O
,	O
and	O
Candelon	O
–	O
Sorokin	O
schemes	O
were	O
taken	O
from	O
the	O
published	O
literature	O
and	O
the	O
Genbank	O
nucleotide	O
sequence	O
database	O
(	O
Table	O
1	O
)	O
.	O

In	O
addition	O
,	O
sequences	O
of	O
all	O
MLST	O
loci	O
were	O
extracted	O
from	O
the	O
complete	O
genomes	O
of	O
the	O
21	O
sequenced	O
B.	B
cereus	I
group	I
strains	O
available	O
in	O
Genbank	O
.	O

Altogether	O
,	O
SuperCAT	O
currently	O
contains	O
data	O
for	O
1029	O
isolates	O
and	O
26	O
gene	O
fragments	O
from	O
25	O
different	O
genes	O
.	O

However	O
,	O
since	O
most	O
strains	O
have	O
been	O
typed	O
using	O
only	O
6	O
or	O
7	O
of	O
the	O
26	O
loci	O
,	O
about	O
one	O
-	O
third	O
of	O
the	O
complete	O
set	O
of	O
sequences	O
are	O
included	O
.	O

The	O
26	O
loci	O
,	O
only	O
available	O
for	O
the	O
completely	O
sequenced	O
strains	O
,	O
sum	O
up	O
to	O
10	O
619	O
bp	O
.	O

All	O
these	O
genes	O
are	O
located	O
on	O
the	O
chromosome	O
,	O
thus	O
the	O
database	O
provides	O
no	O
information	O
about	O
extrachromosomal	O
plasmids	O
even	O
though	O
most	O
of	O
the	O
strains	O
do	O
carry	O
one	O
or	O
several	O
small	O
and/or	O
large	O
plasmids	O
.	O

Unlike	O
scheme	O
-	O
specific	O
MLST	O
databases	O
,	O
SuperCAT	O
does	O
not	O
contain	O
allele	O
and	O
sequence	O
type	O
(	O
ST	O
)	O
numbers	O
.	O

Since	O
isolates	O
in	O
SuperCAT	O
have	O
been	O
typed	O
by	O
different	O
subsets	O
of	O
loci	O
,	O
complete	O
allelic	O
profiles	O
are	O
unavailable	O
and	O
therefore	O
STs	O
can	O
not	O
be	O
assigned	O
for	O
most	O
strains	O
,	O
except	O
the	O
fully	O
sequenced	O
ones	O
.	O

Table	O
1.The	O
five	O
MLST	O
schemes	O
designed	O
for	O
typing	O
bacteria	O
of	O
the	O
B.	B
cereus	I
groupSchemeGenesTotal	I
sequence	O
length	O
(	O
bp	O
)	O
Total	O
number	O
of	O
isolateseUsed	O
in	O
(	O
references	O
)	O
Helgasonadk	O
,	O
ccpA	O
,	O
ftsA	O
,	O
glpT	O
,	O
pyre	O
,	O
recF	O
and	O
sucC2	O
938120	O
(	O
6,12,46	O
)	O
Candelon	O
–	O
Sorokina	O
,	O
cclpC	O
,	O
dinB	O
,	O
gdpD	O
,	O
panC	O
,	O
purF	O
and	O
yhfL2	O
850149	O
(	O
9,10	O
)	O
Kob	O
,	O
cgyrB	O
,	O
mbl	O
,	O
mdh	O
,	O
mutS	O
,	O
pycA	O
(	O
1	O
)	O
and	O
rpoB2	O
00265	O
(	O
7	O
)	O
Priesta	O
,	O
bglpF	O
,	O
gmk	O
,	O
ilvD	O
,	O
pta	O
,	O
purH	O
,	O
pycA	O
(	O
2	O
)	O
and	O
tpi2	O
829721	O
(	O
8,11,13–15,46–48	O
)	O
Tourasse	O
–	O
Helgasona	O
,	O
b	O
,	O
dadk	O
,	O
ccpA	O
,	O
glpF	O
,	O
glpT	O
,	O
panC	O
,	O
pta	O
and	O
pycA	O
(	O
2	O
)	O
2	O
658172	O
(	O
5	O
)	O
aSpecific	O
databases	O
for	O
the	O
Priest	O
and	O
Tourasse	O
–	O
Helgason	O
schemes	O
are	O
accessible	O
at	O
http://pubmlst.org/bcereus/	O
and	O
http://mlstoslo.uio.no/	O
,	O
respectively	O
.	O

A	O
BLAST	O
database	O
for	O
the	O
Candelon	O
–	O
Sorokin	O
scheme	O
is	O
available	O
at	O
http://spock.jouy.inra.fr/cgi-bin/bacilliMLSopen.cgi.bWhile	O
the	O
Tourasse	O
–	O
Helgason	O
and	O
Priest	O
schemes	O
use	O
the	O
same	O
gene	O
fragment	O
for	O
the	O
pycA	O
gene	O
,	O
the	O
Ko	O
scheme	O
is	O
based	O
on	O
a	O
different	O
and	O
non	O
-	O
overlapping	O
gene	O
region.cThe	O
B.	B
cereus	I
group	I
-	O
specific	O
transcriptional	O
regulator	O
plcR	O
was	O
originally	O
included	O
in	O
the	O
Candelon	O
–	O
Sorokin	O
and	O
Ko	O
schemes	O
.	O

However	O
,	O
plcR	O
follows	O
a	O
phylogeny	O
different	O
from	O
the	O
other	O
MLST	O
loci	O
(	O
7,10	O
)	O
and	O
is	O
no	O
longer	O
used	O
for	O
MLST	O
;	O
therefore	O
,	O
it	O
is	O
not	O
included	O
in	O
SuperCAT.dThe	O
Tourasse	O
–	O
Helgason	O
scheme	O
is	O
a	O
combined	O
scheme	O
based	O
on	O
3	O
genes	O
from	O
the	O
Helgason	O
scheme	O
(	O
adk	O
,	O
ccpA	O
,	O
and	O
glpT	O
)	O
,	O
3	O
genes	O
from	O
the	O
Priest	O
scheme	O
(	O
glpF	O
,	O
pta	O
and	O
pycA	O
(	O
2	O
)	O
)	O
,	O
and	O
the	O
panC	O
gene	O
from	O
the	O
Candelon	O
–	O
Sorokin	O
scheme.eIncluding	O
strains	O
with	O
fully	O
sequenced	O
genomes	O
.	O

SuperCAT	O
is	O
built	O
as	O
a	O
relational	O
database	O
using	O
the	O
PostgreSQL	O
management	O
system	O
,	O
and	O
data	O
are	O
accessible	O
through	O
a	O
graphical	O
web	O
interface	O
.	O

User	O
queries	O
and	O
results	O
pages	O
are	O
processed	O
and	O
created	O
on	O
-	O
the	O
-	O
fly	O
via	O
a	O
highly	O
modified	O
version	O
of	O
the	O
mlstdbNet	O
software	O
(	O
16	O
)	O
written	O
in	O
PERL	O
and	O
based	O
on	O
the	O
DataBase	O
Interface	O
(	O
DBI	O
)	O
and	O
Common	O
Gateway	O
Interface	O
(	O
CGI	O
)	O
modules	O
.	O

The	O
database	O
is	O
implemented	O
on	O
a	O
Linux	O
Apache	O
web	O
server	O
maintained	O
through	O
the	O
facilities	O
and	O
support	O
provided	O
by	O
the	O
Norwegian	O
EMBnet	O
node	O
.	O

Some	O
large	O
supertree	O
computations	O
are	O
run	O
on	O
a	O
Linux	O
supercomputer	O
at	O
the	O
University	O
of	O
Oslo	O
.	O

The	O
ATV	O
(	O
A	O
Tree	O
Viewer	O
)	O
Java	O
applet	O
is	O
used	O
for	O
phylogenetic	O
tree	O
display	O
(	O
17	O
)	O
.	O

ATV	O
notably	O
supports	O
horizontal	O
and	O
vertical	O
zooming	O
capabilities	O
that	O
are	O
suitable	O
for	O
browsing	O
large	O
trees	O
.	O

The	O
Jalview	O
editor	O
Java	O
applet	O
is	O
also	O
implemented	O
in	O
SuperCAT	O
for	O
advanced	O
multiple	O
sequence	O
alignment	O
display	O
(	O
18	O
)	O
.	O

SUPERTREE	O
RECONSTRUCTION	O
Supertree	O
techniques	O
allow	O
to	O
combine	O
the	O
phylogenetic	O
information	O
from	O
different	O
datasets	O
into	O
a	O
common	O
phylogenetic	O
tree	O
and	O
several	O
studies	O
have	O
shown	O
that	O
meaningful	O
supertrees	O
can	O
be	O
obtained	O
even	O
when	O
taxon	O
overlap	O
is	O
very	O
sparse	O
(	O
see	O
(	O
19,20	O
)	O
for	O
reviews	O
)	O
.	O

Supertree	O
analysis	O
has	O
thus	O
become	O
increasingly	O
popular	O
for	O
taking	O
advantage	O
and	O
combining	O
the	O
massive	O
amount	O
of	O
sequence	O
data	O
available	O
in	O
public	O
databases	O
for	O
reconstructing	O
large	O
-	O
scale	O
organismal	O
phylogenies	O
with	O
the	O
ultimate	O
goal	O
of	O
building	O
the	O
tree	O
of	O
life	O
(	O
21–24	O
)	O
.	O

In	O
this	O
study	O
,	O
the	O
21	O
B.	B
cereus	I
group	I
strains	O
that	O
have	O
been	O
completely	O
sequenced	O
,	O
and	O
for	O
which	O
the	O
sequences	O
at	O
all	O
26	O
MLST	O
loci	O
are	O
thus	O
available	O
,	O
can	O
be	O
used	O
to	O
join	O
all	O
five	O
schemes	O
and	O
provide	O
the	O
strain	O
overlap	O
necessary	O
for	O
supertree	O
analysis	O
.	O

The	O
global	O
B.	B
cereus	I
group	I
supertree	O
,	O
containing	O
1029	O
isolates	O
,	O
was	O
reconstructed	O
according	O
to	O
the	O
widely	O
used	O
matrix	O
representation	O
by	O
parsimony	O
(	O
MRP	O
)	O
procedure	O
(	O
Figure	O
1	O
;	O
(	O
19,25,26	O
)	O
)	O
.	O

Scheme	O
-	O
specific	O
supertrees	O
were	O
also	O
reconstructed	O
for	O
each	O
of	O
the	O
five	O
MLST	O
schemes	O
by	O
the	O
same	O
technique	O
.	O

Briefly	O
,	O
a	O
phylogenetic	O
tree	O
is	O
built	O
for	O
every	O
gene	O
separately	O
by	O
the	O
maximum	O
likelihood	O
method	O
with	O
the	O
PHYML_aLRT	O
program	O
(	O
27	O
)	O
.	O

Then	O
,	O
each	O
gene	O
tree	O
is	O
recoded	O
into	O
a	O
binary	O
matrix	O
representing	O
the	O
branching	O
order	O
(	O
i.e.	O
the	O
phylogenetic	O
groupings	O
)	O
following	O
standard	O
MRP	O
coding	O
using	O
the	O
SuperMRP.pl	O
script	O
(	O
28	O
)	O
.	O

All	O
gene	O
tree	O
matrices	O
are	O
concatenated	O
into	O
a	O
supermatrix	O
,	O
in	O
which	O
isolates	O
missing	O
from	O
a	O
particular	O
tree	O
are	O
coded	O
using	O
the	O
'	O
?	O
'	O
character	O
representing	O
unknown	O
data	O
.	O

In	O
this	O
supermatrix	O
,	O
the	O
sequence	O
of	O
0	O
's	O
,	O
1	O
's	O
and	O
?	O

's	O
defines	O
the	O
branching	O
profile	O
of	O
a	O
strain	O
.	O

Closely	O
related	O
strains	O
have	O
similar	O
branching	O
profiles	O
.	O

Supertrees	O
are	O
then	O
generated	O
from	O
the	O
supermatrix	O
by	O
the	O
maximum	O
parsimony	O
technique	O
using	O
the	O
program	O
MIX	O
from	O
the	O
PHYLIP	O
package	O
(	O
29	O
)	O
run	O
with	O
default	O
parameters	O
.	O

The	O
maximum	O
parsimony	O
step	O
infers	O
the	O
trees	O
that	O
would	O
require	O
the	O
minimum	O
number	O
of	O
changes	O
between	O
the	O
branching	O
profiles	O
of	O
all	O
isolates	O
,	O
where	O
the	O
unknown	O
characters	O
can	O
take	O
any	O
of	O
the	O
two	O
possible	O
states	O
0	O
or	O
1	O

(	O
they	O
are	O
not	O
treated	O
as	O
missing	O
gaps	O
)	O
.	O

As	O
many	O
trees	O
were	O
equally	O
parsimonious	O
,	O
the	O
final	O
supertree	O
was	O
taken	O
as	O
the	O
strict	O
consensus	O
of	O
all	O
parsimony	O
trees	O
with	O
the	O
CONSENSE	O
program	O
of	O
PHYLIP	O
.	O

In	O
order	O
to	O
obtain	O
branch	O
lengths	O
that	O
are	O
proportional	O
to	O
the	O
amount	O
of	O
nucleotide	O
changes	O
,	O
we	O
added	O
an	O
additional	O
step	O
in	O
which	O
branch	O
lengths	O
and	O
statistical	O
support	O
for	O
groupings	O
are	O
estimated	O
from	O
the	O
concatenated	O
sequences	O
by	O
the	O
maximum	O
likelihood	O
method	O
employing	O
approximate	O
likelihood	O
-	O
ratio	O
tests	O
(	O
aLRTs	O
)	O
for	O
branches	O
using	O
PHYML_aLRT	O
with	O
Shimodaira	O
-	O
Hasegawa	O
-	O
like	O
support	O
values	O
(	O
27,30	O
)	O
.	O

aLRTs	O
provide	O
a	O
fast	O
way	O
of	O
testing	O
branch	O
support	O
without	O
requirement	O
of	O
multiple	O
replicates	O
like	O
traditional	O
bootstrap	O
procedures	O
.	O

The	O
Felsenstein-1984	O
nucleotide	O
substitution	O
model	O
supplemented	O
with	O
a	O
gamma	O
distribution	O
(	O
F84+Γ	O
)	O
was	O
used	O
in	O
maximum	O
likelihood	O
computations	O
for	O
individual	O
gene	O
trees	O
and	O
the	O
supertree	O
(	O
31	O
)	O
.	O

This	O
model	O
allows	O
for	O
unequal	O
base	O
frequencies	O
,	O
transition	O
/	O
transversion	O
rate	O
bias	O
,	O
and	O
gamma	O
-	O
distributed	O
substitution	O
rate	O
variation	O
among	O
sites	O
.	O

It	O
was	O
empirically	O
chosen	O
as	O
a	O
consensus	O
from	O
exploratory	O
model	O
testing	O
using	O
ModelTest	O
(	O
32,33	O
)	O
,	O
which	O
indicated	O
that	O
models	O
including	O
these	O
three	O
factors	O
were	O
most	O
appropriate	O
for	O
the	O
MLST	O
loci	O
studied	O
,	O
although	O
models	O
for	O
individual	O
loci	O
differed	O
slightly	O
.	O

Note	O
that	O
the	O
maximum	O
likelihood	O
technique	O
also	O
allows	O
for	O
uneven	O
rates	O
of	O
nucleotide	O
substitution	O
between	O
strains	O
,	O
which	O
allows	O
to	O
accommodate	O
slow-	O
and	O
fast	O
-	O
evolving	O
isolates	O
.	O

To	O
reduce	O
the	O
size	O
of	O
the	O
binary	O
supermatrix	O
and	O
speed	O
up	O
computations	O
,	O
individual	O
gene	O
trees	O
and	O
the	O
supertree	O
were	O
built	O
using	O
only	O
one	O
representative	O
from	O
a	O
set	O
of	O
strains	O
having	O
identical	O
sequences	O
.	O

The	O
remaining	O
identical	O
isolates	O
were	O
graphically	O
added	O
to	O
the	O
tree	O
afterwards	O
when	O
drawing	O
the	O
final	O
supertree	O
.	O

Figure	O
1.Schematic	O
overview	O
of	O
the	O
B.	B
cereus	I
group	I
supertree	O
reconstruction	O
procedure	O
using	O
Matrix	O
Representation	O
by	O
Parsimony	O
(	O
MRP	O
)	O
.	O

See	O
text	O
for	O
details	O
.	O

It	O
should	O
be	O
noted	O
that	O
the	O
global	O
1029-strain	O
supertree	O
retains	O
the	O
phylogenetic	O
signals	O
from	O
the	O
individual	O
schemes	O
and	O
contains	O
the	O
three	O
main	O
clusters	O
of	O
the	O
B.	B
cereus	I
group	I
population	O
described	O
in	O
the	O
section	O
'	O
Introduction	O
'	O
.	O

The	O
integrated	O
SuperCAT	O
system	O
may	O
also	O
allow	O
to	O
infer	O
new	O
relationships	O
between	O
strains	O
that	O
were	O
analyzed	O
with	O
different	O
gene	O
sets	O
.	O

Even	O
though	O
the	O
26	O
loci	O
sequences	O
are	O
available	O
for	O
only	O
21	O
isolates	O
,	O
they	O
apparently	O
provide	O
enough	O
overlap	O
information	O
for	O
building	O
the	O
main	O
branches	O
of	O
the	O
supertree	O
.	O

These	O
21	O
isolates	O
cover	O
all	O
three	O
clusters	O
,	O
although	O
the	O
majority	O
of	O
them	O
are	O
B.	B
anthracis	I
strains	O
or	O
clinical	O
strains	O
closely	O
related	O
to	O
B.	B
anthracis	I
due	O
to	O
the	O
focus	O
of	O
genome	O
sequencing	O
projects	O
,	O
making	O
the	O
part	O
of	O
the	O
supertree	O
containing	O
these	O
isolates	O
likely	O
to	O
be	O
more	O
accurate	O
than	O
the	O
rest	O
of	O
the	O
tree	O
.	O

Furthermore	O
,	O
111	O
other	O
isolates	O
have	O
been	O
typed	O
by	O
10	O
genes	O
or	O
more	O
,	O
providing	O
additional	O
overlap	O
(	O
see	O
the	O
'	O
Gene	O
Distribution	O
'	O
page	O
)	O
.	O

Although	O
about	O
two	O
-	O
thirds	O
of	O
the	O
sequence	O
data	O
are	O
missing	O
overall	O
,	O
it	O
has	O
been	O
shown	O
for	O
other	O
organisms	O
that	O
relevant	O
supertrees	O
could	O
be	O
reconstructed	O
with	O
datasets	O
containing	O
more	O
than	O
90	O
%	O
of	O
missing	O
data	O
,	O
especially	O
when	O
the	O
characters	O
that	O
are	O
present	O
are	O
informative	O
(	O
20,22,23,34	O
)	O
.	O

Empirical	O
and	O
simulation	O
studies	O
have	O
indicated	O
that	O
this	O
behavior	O
may	O
be	O
due	O
to	O
the	O
fact	O
that	O
the	O
characters	O
which	O
are	O
present	O
are	O
more	O
important	O
for	O
the	O
tree	O
-	O
building	O
process	O
than	O
those	O
which	O
are	O
absent	O
(	O
see	O
(	O
20,34	O
)	O
and	O
references	O
therein	O
)	O
.	O

Precise	O
within	O
-	O
cluster	O
groupings	O
may	O
contain	O
more	O
uncertainty	O
,	O
as	O
indicated	O
by	O
the	O
large	O
number	O
of	O
unresolved	O
multifurcations	O
in	O
the	O
B.	B
cereus	I
group	I
supertree	O
.	O

Finally	O
,	O
it	O
is	O
also	O
worth	O
mentioning	O
that	O
the	O
branching	O
orders	O
of	O
the	O
scheme	O
-	O
specific	O
MRP	O
supertrees	O
are	O
highly	O
correlated	O
to	O
those	O
of	O
the	O
published	O
trees	O
built	O
with	O
concatenated	O
sequences	O
and	O
other	O
phylogenetic	O
algorithms	O
.	O

DATA	O
ACCESS	O
AND	O
MANIPULATION	O
The	O
complete	O
list	O
of	O
isolates	O
included	O
in	O
SuperCAT	O
(	O
currently	O
1029	O
)	O
with	O
strain	O
description	O
,	O
source	O
and	O
country	O
of	O
origin	O
is	O
available	O
at	O
the	O
database	O
home	O
page	O
.	O

By	O
default	O
all	O
isolates	O
in	O
the	O
database	O
are	O
used	O
in	O
the	O
analysis	O
tools	O
provided	O
,	O
but	O
the	O
user	O
can	O
select	O
strains	O
of	O
interest	O
by	O
keywords	O
,	O
MLST	O
scheme	O
,	O
entering	O
a	O
list	O
of	O
strain	O
identifiers	O
,	O
or	O
choosing	O
isolates	O
individually	O
via	O
checkboxes	O
.	O

All	O
subsequent	O
analyses	O
will	O
be	O
based	O
on	O
the	O
selected	O
strain	O
subset	O
and	O
their	O
loci	O
.	O

The	O
keyword	O
search	O
will	O
look	O
for	O
matches	O
in	O
any	O
of	O
the	O
strain	O
,	O
description	O
,	O
source	O
,	O
location	O
and	O
scheme	O
fields	O
.	O

Complex	O
keyword	O
queries	O
with	O
several	O
logical	O
operators	O
can	O
be	O
formulated	O
in	O
the	O
'	O
advanced	O
search	O
'	O
page	O
.	O

Note	O
that	O
many	O
isolates	O
were	O
referred	O
by	O
alternative	O
names	O
in	O
different	O
MLST	O
schemes	O
and	O
publications	O
,	O
therefore	O
synonyms	O
have	O
been	O
included	O
in	O
the	O
strain	O
descriptions	O
that	O
allow	O
a	O
particular	O
isolate	O
to	O
be	O
looked	O
up	O
using	O
any	O
of	O
its	O
alternative	O
identifiers	O
.	O

A	O
sequence	O
search	O
is	O
also	O
possible	O
using	O
BLASTN	O
(	O
35	O
)	O
,	O
in	O
order	O
to	O
select	O
isolates	O
that	O
have	O
allele	O
sequences	O
identical	O
to	O
user	O
-	O
entered	O
query	O
sequences	O
.	O

Throughout	O
SuperCAT	O
,	O
clicking	O
on	O
a	O
strain	O
name	O
will	O
pop	O
up	O
an	O
isolate	O
-	O
specific	O
window	O
showing	O
all	O
relevant	O
information	O
and	O
giving	O
access	O
to	O
the	O
nucleotide	O
sequences	O
of	O
individual	O
loci	O
for	O
that	O
isolate	O
.	O

Detailed	O
information	O
about	O
the	O
MLST	O
schemes	O
(	O
e.g.	O
loci	O
names	O
and	O
lengths	O
,	O
genomic	O
coordinates	O
,	O
literature	O
references	O
)	O
and	O
their	O
overlap	O
,	O
the	O
distribution	O
of	O
available	O
loci	O
among	O
the	O
isolates	O
,	O
and	O
the	O
supertree	O
reconstruction	O
procedure	O
can	O
be	O
obtained	O
by	O
clicking	O
the	O
relevant	O
links	O
in	O
the	O
header	O
line	O
present	O
at	O
the	O
top	O
of	O
every	O
page	O
.	O

Apart	O
from	O
the	O
basic	O
functions	O
for	O
selecting	O
and	O
accessing	O
strain	O
information	O
and	O
sequence	O
data	O
for	O
all	O
five	O
B.	B
cereus	I
group	I
MLST	O
schemes	O
,	O
the	O
main	O
features	O
of	O
SuperCAT	O
relate	O
to	O
the	O
manipulation	O
of	O
the	O
supertrees	O
constructed	O
by	O
the	O
MRP	O
approach	O
.	O

The	O
global	O
supertree	O
based	O
on	O
the	O
combination	O
of	O
all	O
five	O
B.	B
cereus	I
group	I
MLST	O
schemes	O
as	O
well	O
as	O
the	O
five	O
scheme	O
-	O
specific	O
supertrees	O
can	O
be	O
browsed	O
according	O
to	O
various	O
user	O
-	O
chosen	O
criteria	O
(	O
Figure	O
2	O
)	O
.	O

Isolates	O
in	O
the	O
supertrees	O
can	O
be	O
colored	O
by	O
species	O
or	O
source	O
of	O
isolation	O
.	O

It	O
is	O
also	O
possible	O
to	O
specifically	O
mark	O
in	O
red	O
the	O
current	O
subset	O
of	O
strains	O
that	O
has	O
been	O
selected	O
by	O
the	O
user	O
and	O
to	O
extract	O
from	O
the	O
supertrees	O
the	O
subtree	O
containing	O
only	O
those	O
isolates	O
.	O

In	O
the	O
case	O
of	O
the	O
multi	O
-	O
scheme	O
supertree	O
highlighting	O
of	O
the	O
strains	O
can	O
be	O
based	O
on	O
genetic	O
distance	O
.	O

With	O
this	O
option	O
the	O
user	O
can	O
mark	O
on	O
and/or	O
extract	O
from	O
the	O
tree	O
the	O
isolates	O
that	O
are	O
genetically	O
closely	O
related	O
to	O
strains	O
of	O
her	O
/	O
his	O
choice	O
.	O

The	O
user	O
can	O
either	O
select	O
strains	O
that	O
share	O
one	O
or	O
several	O
identical	O
allele	O
sequences	O
with	O
her	O
/	O
his	O
query	O
isolate	O
(	O
s	O
)	O
or	O
that	O
are	O
at	O
a	O
specified	O
genetic	O
distance	O
.	O

Distances	O
between	O
isolates	O
are	O
computed	O
by	O
summing	O
up	O
the	O
lengths	O
of	O
the	O
branches	O
(	O
in	O
average	O
number	O
of	O
nucleotide	O
substitutions	O
per	O
site	O
)	O
connecting	O
the	O
isolates	O
in	O
the	O
supertree	O
(	O
known	O
as	O
patristic	O
distances	O
;	O
(	O
36	O
)	O
)	O
.	O

The	O
genetic	O
relatedness	O
search	O
functions	O
are	O
also	O
available	O
in	O
a	O
separate	O
page	O
for	O
the	O
user	O
to	O
find	O
closely	O
related	O
isolates	O
without	O
tree	O
manipulation	O
.	O

SuperCAT	O
allows	O
to	O
compare	O
the	O
scheme	O
-	O
specific	O
MLST	O
supertrees	O
with	O
each	O
other	O
and	O
with	O
the	O
global	O
supertree	O
by	O
using	O
the	O
subset	O
of	O
isolates	O
that	O
are	O
common	O
to	O
all	O
selected	O
schemes	O
.	O

Common	O
isolates	O
can	O
either	O
be	O
highlighted	O
in	O
red	O
or	O
be	O
extracted	O
as	O
subtrees	O
from	O
each	O
supertree	O
,	O
which	O
can	O
be	O
used	O
for	O
comparing	O
the	O
positions	O
of	O
the	O
common	O
strains	O
in	O
the	O
various	O
MLST	O
trees	O
.	O

For	O
all	O
supertree	O
-	O
related	O
options	O
,	O
detailed	O
tree	O
navigation	O
can	O
be	O
achieved	O
using	O
the	O
various	O
functions	O
in	O
the	O
ATV	O
tree	O
window	O
when	O
the	O
trees	O
are	O
displayed	O
(	O
17	O
)	O
.	O

Figure	O
2.Examples	O
of	O
supertree	O
browsing	O
and	O
manipulation	O
in	O
SuperCAT	O
.	O

A	O
,	O
supertree	O
colored	O
by	O
species	O
;	O
B	O
,	O
specific	O
highlighting	O
of	O
user	O
-	O
selected	O
strains	O
(	O
in	O
red	O
)	O
;	O
C	O
,	O
extracted	O
subtree	O
containing	O
only	O
the	O
strains	O
highlighted	O
in	O
B.	O
Trees	O
are	O
displayed	O
using	O
ATV	O
(	O
17	O
)	O
.	O

Besides	O
the	O
manipulation	O
of	O
the	O
precomputed	O
supertrees	O
,	O
SuperCAT	O
offers	O
the	O
user	O
the	O
possibility	O
to	O
compute	O
new	O
supertrees	O
by	O
MRP	O
using	O
any	O
combination	O
of	O
strains	O
,	O
schemes	O
and	O
genes	O
.	O

Supertree	O
computations	O
may	O
be	O
extremely	O
time	O
consuming	O
,	O
ranging	O
from	O
a	O
few	O
minutes	O
to	O
2–3	O
days	O
with	O
the	O
complete	O
database	O
.	O

Users	O
are	O
therefore	O
requested	O
to	O
enter	O
their	O
e	O
-	O
mail	O
addresses	O
and	O
will	O
receive	O
a	O
notification	O
containing	O
a	O
link	O
to	O
the	O
results	O
page	O
when	O
the	O
supertree	O
is	O
ready	O
.	O

Note	O
that	O
when	O
building	O
a	O
supertree	O
for	O
a	O
user	O
-	O
selected	O
subset	O
of	O
strains	O
,	O
the	O
computation	O
will	O
first	O
include	O
all	O
database	O
isolates	O
.	O

A	O
subtree	O
containing	O
only	O
the	O
user	O
-	O
selected	O
isolates	O
will	O
then	O
be	O
extracted	O
from	O
the	O
supertree	O
of	O
all	O
strains	O
.	O

Although	O
more	O
time	O
consuming	O
,	O
this	O
strategy	O
allows	O
:	O
(	O
i	O
)	O
to	O
avoid	O
sampling	O
artefacts	O
as	O
phylogenies	O
built	O
with	O
different	O
isolate	O
sets	O
may	O
vary	O
and	O
(	O
ii	O
)	O
to	O
obtain	O
relationships	O
even	O
if	O
the	O
selected	O
isolates	O
have	O
been	O
typed	O
using	O
non	O
-	O
overlapping	O
gene	O
sets	O
,	O
as	O
the	O
supertree	O
of	O
all	O
isolates	O
can	O
always	O
be	O
built	O
owing	O
to	O
the	O
completely	O
sequenced	O
strains	O
that	O
are	O
common	O
to	O
all	O
schemes	O
.	O

Another	O
main	O
feature	O
of	O
the	O
SuperCAT	O
database	O
is	O
that	O
the	O
user	O
can	O
enter	O
her	O
/	O
his	O
own	O
private	O
sequences	O
and	O
conduct	O
several	O
sequence	O
analyses	O
(	O
Figure	O
3	O
)	O
.	O

These	O
analyses	O
include	O
:	O
(	O
a	O
)	O
building	O
new	O
supertrees	O
containing	O
user	O
isolates	O
and	O
sequences	O
;	O
(	O
b	O
)	O
finding	O
database	O
isolates	O
having	O
sequences	O
most	O
similar	O
to	O
the	O
user	O
's	O
query	O
sequences	O
using	O
an	O
on	O
-	O
line	O
BLASTN	O
(	O
35	O
)	O
service	O
;	O
and	O
(	O
c	O
)	O
aligning	O
user	O
sequences	O
to	O
database	O
genes	O
using	O
the	O
multiple	O
sequence	O
alignment	O
program	O
CLUSTALW	O
(	O
37	O
)	O
.	O

For	O
the	O
last	O
option	O
,	O
the	O
Jalview	O
editor	O
(	O
18	O
)	O
is	O
provided	O
for	O
advanced	O
multiple	O
alignment	O
display	O
.	O

All	O
user	O
-	O
entered	O
data	O
must	O
be	O
in	O
FASTA	O
format	O
and	O
can	O
be	O
either	O
copied	O
and	O
pasted	O
into	O
the	O
query	O
forms	O
or	O
uploaded	O
from	O
text	O
files	O
stored	O
locally	O
on	O
the	O
user	O
's	O
computer	O
.	O

Figure	O
3.Examples	O
of	O
query	O
results	O
in	O
SuperCAT	O
.	O

A	O
,	O
multi	O
-	O
scheme	O
BLAST	O
search	O
with	O
sequence	O
alignment	O
;	O
B	O
,	O
multi	O
-	O
scheme	O
genetic	O
search	O
showing	O
the	O
list	O
of	O
isolates	O
sharing	O
one	O
or	O
more	O
sequences	O
with	O
a	O
query	O
strain	O
;	O
C	O
,	O
multiple	O
sequence	O
alignment	O
using	O
Jalview	O
(	O
18	O
)	O
.	O

All	O
strain	O
information	O
data	O
,	O
sequences	O
and	O
phylogenetic	O
trees	O
,	O
including	O
user	O
-	O
made	O
supertrees	O
and	O
extracted	O
subtrees	O
,	O
can	O
be	O
saved	O
and	O
downloaded	O
freely	O
from	O
the	O
database	O
.	O

Users	O
wishing	O
to	O
have	O
their	O
MLST	O
data	O
included	O
as	O
part	O
of	O
the	O
SuperCAT	O
release	O
(	O
and/or	O
the	O
Tourasse	O
–	O
Helgason	O
scheme	O
-	O
specific	O
database	O
)	O
are	O
welcome	O
to	O
contact	O
N.J.T.	O
or	O
A	O
.-	O
B.K.	O
at	O
the	O
e	O
-	O
mail	O
addresses	O
given	O
on	O
the	O
Oslo	O
MLST	O
server	O
front	O
page	O
.	O

DISCUSSION	O
AND	O
FUTURE	O
DEVELOPMENTS	O
SuperCAT	O
is	O
a	O
newly	O
created	O
database	O
devoted	O
to	O
the	O
B.	B
cereus	I
group	I
of	O
bacteria	O
whose	O
main	O
objectives	O
are	O
to	O
provide	O
a	O
common	O
MLST	O
repository	O
and	O
means	O
for	O
building	O
a	O
comprehensive	O
genetic	O
analysis	O
of	O
the	O
group	O
that	O
has	O
been	O
typed	O
by	O
five	O
separate	O
schemes	O
.	O

The	O
database	O
is	O
publicly	O
and	O
freely	O
available	O
at	O
http://mlstoslo.uio.no/	O
,	O
along	O
with	O
the	O
database	O
specific	O
for	O
the	O
combined	O
scheme	O
of	O
(	O
5	O
)	O
.	O

We	O
plan	O
to	O
update	O
SuperCAT	O
quarterly	O
.	O

Future	O
developments	O
of	O
the	O
database	O
may	O
deal	O
with	O
refining	O
the	O
supertree	O
-	O
building	O
procedure	O
.	O

In	O
particular	O
,	O
a	O
new	O
improved	O
method	O
has	O
recently	O
been	O
developed	O
for	O
taking	O
into	O
account	O
both	O
nucleotide	O
substitutions	O
and	O
recombination	O
events	O
in	O
phylogenies	O
,	O
as	O
part	O
of	O
the	O
ClonalFrame	O
software	O
,	O
which	O
has	O
been	O
applied	O
to	O
the	O
B.	B
cereus	I
group	I
and	O
the	O
Priest	O
scheme	O
(	O
38	O
)	O
.	O

It	O
would	O
therefore	O
be	O
of	O
interest	O
to	O
examine	O
the	O
suitability	O
of	O
ClonalFrame	O
in	O
the	O
supertree	O
context	O
.	O

It	O
is	O
also	O
tempting	O
to	O
extend	O
the	O
supertree	O
analysis	O
beyond	O
MLST	O
data	O
,	O
by	O
incorporating	O
the	O
phylogenies	O
obtained	O
previously	O
from	O
large	O
-	O
scale	O
multilocus	O
enzyme	O
electrophoresis	O
(	O
MLEE	O
;	O
(	O
3,39–41	O
)	O
)	O
and	O
amplified	O
fragment	O
length	O
polymorphism	O
(	O
AFLP	O
;	O
(	O
42–45	O
)	O
)	O
studies	O
.	O

The	O
MRP	O
framework	O
is	O
ideal	O
since	O
it	O
allows	O
to	O
integrate	O
trees	O
that	O
can	O
be	O
built	O
from	O
different	O
methods	O
and	O
data	O
.	O

As	O
MLEE	O
,	O
AFLP	O
and	O
MLST	O
have	O
different	O
levels	O
of	O
resolution	O
,	O
one	O
can	O
hope	O
that	O
combining	O
them	O
might	O
provide	O
an	O
even	O
more	O
robust	O
supertree	O
for	O
the	O
B.	B
cereus	I
group	I
.	O

Discovery	O
of	O
genes	O
implicated	O
in	O
whirling	O
disease	O
infection	O
and	O
resistance	O
in	O
rainbow	B
trout	I
using	O
genome	O
-	O
wide	O
expression	O
profiling	O
Abstract	O
Background	O
Whirling	O
disease	O
,	O
caused	O
by	O
the	O
pathogen	O
Myxobolus	B
cerebralis	I
,	O
afflicts	O
several	O
salmonid	O
species	O
.	O

Rainbow	B
trout	I
are	O
particularly	O
susceptible	O
and	O
may	O
suffer	O
high	O
mortality	O
rates	O
.	O

The	O
disease	O
is	O
persistent	O
and	O
spreading	O
in	O
hatcheries	O
and	O
natural	O
waters	O
of	O
several	O
countries	O
,	O
including	O
the	O
U.S.A.	O
,	O
and	O
the	O
economic	O
losses	O
attributed	O
to	O
whirling	O
disease	O
are	O
substantial	O
.	O

In	O
this	O
study	O
,	O
genome	O
-	O
wide	O
expression	O
profiling	O
using	O
cDNA	O
microarrays	O
was	O
conducted	O
for	O
resistant	O
Hofer	O
and	O
susceptible	O
Trout	O
Lodge	O
rainbow	B
trout	I
strains	O
following	O
pathogen	O
exposure	O
with	O
the	O
primary	O
objective	O
of	O
identifying	O
specific	O
genes	O
implicated	O
in	O
whirling	O
disease	O
resistance	O
.	O

Results	O
Several	O
genes	O
were	O
significantly	O
up	O
-	O
regulated	O
in	O
skin	O
following	O
pathogen	O
exposure	O
for	O
both	O
the	O
resistant	O
and	O
susceptible	O
rainbow	B
trout	I
strains	O
.	O

For	O
both	O
strains	O
,	O
response	O
to	O
infection	O
appears	O
to	O
be	O
linked	O
with	O
the	O
interferon	O
system	O
.	O

Expression	O
profiles	O
for	O
three	O
genes	O
identified	O
with	O
microarrays	O
were	O
confirmed	O
with	O
qRT	O
-	O
PCR	O
.	O

Ubiquitin	O
-	O
like	O
protein	O
1	O
was	O
up	O
-	O
regulated	O
over	O
100	O
fold	O
and	O
interferon	O
regulating	O
factor	O
1	O
was	O
up	O
-	O
regulated	O
over	O
15	O
fold	O
following	O
pathogen	O
exposure	O
for	O
both	O
strains	O
.	O

Expression	O
of	O
metallothionein	O
B	O
,	O
which	O
has	O
known	O
roles	O
in	O
inflammation	O
and	O
immune	O
response	O
,	O
was	O
up	O
-	O
regulated	O
over	O
5	O
fold	O
in	O
the	O
resistant	O
Hofer	O
strain	O
but	O
was	O
unchanged	O
in	O
the	O
susceptible	O
Trout	O
Lodge	O
strain	O
following	O
pathogen	O
exposure	O
.	O

Conclusion	O
The	O
present	O
study	O
has	O
provided	O
an	O
initial	O
view	O
into	O
the	O
genetic	O
basis	O
underlying	O
immune	O
response	O
and	O
resistance	O
of	O
rainbow	B
trout	I
to	O
the	O
whirling	O
disease	O
parasite	O
.	O

The	O
identified	O
genes	O
have	O
allowed	O
us	O
to	O
gain	O
insight	O
into	O
the	O
molecular	O
mechanisms	O
implicated	O
in	O
salmonid	O
immune	O
response	O
and	O
resistance	O
to	O
whirling	O
disease	O
infection	O
.	O

Background	O
Whirling	O
disease	O
was	O
first	O
described	O
among	O
farmed	O
rainbow	B
trout	I
(	O
Oncorhynchus	B
mykiss	I
)	O
,	O
a	O
native	O
North	O
American	O
salmonid	O
species	O
,	O
introduced	O
to	O
Germany	O
as	O
a	O
food	O
fish	O
in	O
the	O
late	O
1800s	O
[	O
1	O
]	O
.	O

Whirling	O
disease	O
is	O
associated	O
with	O
systemic	O
infections	O
by	O
the	O
myxozoan	O
Myxobolus	B
cerebralis	I
,	O
a	O
parasite	O
with	O
presumed	O
origins	O
among	O
salmonid	O
fish	O
in	O
Eurasia	O
[	O
2,3	O
]	O
.	O

Rainbow	B
trout	I
are	O
highly	O
susceptible	O
to	O
whirling	O
disease	O
and	O
the	O
introduction	O
of	O
the	O
parasite	O
to	O
the	O
U.S.A.	O
in	O
the	O
1950s	O
had	O
immediate	O
economic	O
impacts	O
on	O
salmonid	O
hatcheries	O
in	O
both	O
eastern	O
and	O
western	O
states	O
[	O
2	O
]	O
.	O

The	O
parasite	O
has	O
a	O
broad	O
worldwide	O
distribution	O
and	O
has	O
been	O
identified	O
in	O
25	O
states	O
in	O
the	O
U.S.A.	O
where	O
salmonid	O
fish	O
are	O
present	O
[	O
4	O
]	O
.	O

Salmonid	O
hatcheries	O
throughout	O
the	O
U.S.A	O
have	O
suffered	O
drastic	O
economic	O
losses	O
due	O
to	O
whirling	O
disease	O
outbreaks	O
.	O

The	O
disease	O
has	O
more	O
recently	O
been	O
recognized	O
as	O
the	O
principal	O
cause	O
of	O
major	O
population	O
declines	O
among	O
wild	O
rainbow	B
trout	I
populations	O
in	O
the	O
intermountain	O
region	O
of	O
the	O
U.S.A	O
with	O
serious	O
negative	O
impacts	O
on	O
sportfishing	O
and	O
allied	O
industries	O
[	O
5	O
-	O
7	O
]	O
.	O

Additionally	O
,	O
concerns	O
continue	O
over	O
the	O
potential	O
negative	O
ecologic	O
impacts	O
of	O
whirling	O
disease	O
on	O
wild	O
salmonid	O
populations	O
,	O
particularly	O
threatened	O
or	O
endangered	O
salmonids	O
such	O
as	O
bull	B
trout	I
(	O
Salvelinus	B
confluentus	I
)	O
,	O
cutthroat	B
trout	I
(	O
Oncorhynchus	B
clarki	I
)	O
,	O
and	O
steelhead	B
(	O
Oncorhynchus	B
mykiss	I
)	O
[	O
8,9	O
]	O
.	O

Myxobolus	B
cerebralis	I
has	O
a	O
complex	O
life	O
cycle	O
that	O
includes	O
two	O
alternate	O
hosts	O
,	O
a	O
salmonid	O
fish	O
and	O
an	O
oligochaete	O
worm	O
,	O
Tubifex	B
tubifex	I
[	O
10,11	O
]	O
.	O

Infection	O
in	O
the	O
salmonid	O
host	O
begins	O
when	O
microscopic	O
waterborne	O
actinospore	O
stages	O
of	O
M.	B
cerebralis	I
are	O
released	O
from	O
the	O
worm	O
and	O
contact	O
the	O
skin	O
of	O
the	O
fish	O
host	O
.	O

Actinospores	O
,	O
also	O
referred	O
to	O
as	O
triactinomyxons	O
for	O
M.	B
cerebralis	I
,	O
attach	O
preferentially	O
to	O
fins	O
and	O
the	O
buccal	O
cavity	O
where	O
they	O
release	O
one	O
or	O
more	O
of	O
three	O
coiled	O
polar	O
filaments	O
which	O
penetrate	O
and	O
then	O
anchor	O
them	O
to	O
the	O
epidermis	O
[	O
12	O
]	O
.	O

Within	O
minutes	O
the	O
sporoplasm	O
,	O
which	O
contains	O
64	O
internal	O
cells	O
,	O
migrates	O
from	O
the	O
triactinomxyon	O
to	O
deeper	O
layers	O
of	O
the	O
epidermis	O
,	O
an	O
action	O
that	O
may	O
be	O
facilitated	O
by	O
parasite	O
proteases	O
[	O
13	O
-	O
15	O
]	O
.	O

Aggregates	O
and	O
single	O
cells	O
from	O
the	O
sporoplasm	O
then	O
begin	O
mitotic	O
replication	O
within	O
two	O
h	O
of	O
initial	O
infection	O
,	O
alternating	O
between	O
inter	O
and	O
intracellular	O
locations	O
,	O
a	O
process	O
that	O
may	O
also	O
depend	O
upon	O
parasite	O
coded	O
protease	O
activity	O
[	O
15,16	O
]	O
.	O

Over	O
the	O
next	O
10	O
h	O
at	O
water	O
temperatures	O
of	O
15	O
°	O
C	O
,	O
parasites	O
within	O
host	O
epithelial	O
cells	O
further	O
divide	O
by	O
the	O
process	O
of	O
endogeny	O
or	O
cell	O
within	O
cell	O
replication	O
prior	O
to	O
release	O
and	O
then	O
penetration	O
of	O
new	O
host	O
cells	O
.	O

Between	O
12	O
and	O
20	O
h	O
post	O
infection	O
,	O
the	O
number	O
of	O
parasite	O
cells	O
present	O
in	O
the	O
epidermis	O
steadily	O
declines	O
until	O
new	O
stages	O
are	O
observed	O
in	O
the	O
subcutis	O
at	O
48	O
h.	O
Degenerative	O
stages	O
observed	O
in	O
the	O
epidermis	O
between	O
12	O
and	O
20	O
h	O
are	O
suspected	O
to	O
be	O
a	O
result	O
of	O
the	O
action	O
of	O
the	O
host	O
immune	O
response	O
,	O
although	O
the	O
cellular	O
and	O
or	O
humoral	O
factors	O
involved	O
are	O
not	O
currently	O
known	O
.	O

After	O
a	O
brief	O
residence	O
in	O
the	O
subcutis	O
,	O
parasite	O
stages	O
are	O
presumed	O
to	O
migrate	O
to	O
proximal	O
nervous	O
tissues	O
,	O
initially	O
in	O
peripheral	O
and	O
then	O
more	O
central	O
locations	O
[	O
16	O
]	O
.	O

Migration	O
and	O
potential	O
replication	O
of	O
parasite	O
stages	O
in	O
nervous	O
tissue	O
ensues	O
over	O
the	O
next	O
16	O
d	O
with	O
the	O
first	O
parasites	O
exiting	O
to	O
invade	O
cartilage	O
observed	O
at	O
20	O
d	O
post	O
infection	O
[	O
16	O
]	O
.	O

Feeding	O
on	O
cartilage	O
may	O
induce	O
a	O
host	O
inflammatory	O
response	O
that	O
constricts	O
the	O
spinal	O
cord	O
,	O
brain	O
stem	O
,	O
and	O
caudal	O
nerves	O
resulting	O
in	O
the	O
erratic	O
swimming	O
behavior	O
(	O
whirling	O
)	O
and	O
black	O
tail	O
observed	O
among	O
fish	O
with	O
acute	O
whirling	O
disease	O
[	O
17	O
]	O
.	O

An	O
additional	O
impact	O
of	O
cartilage	O
destruction	O
are	O
permanent	O
deformities	O
to	O
the	O
skeletal	O
system	O
that	O
may	O
increase	O
vulnerability	O
to	O
predation	O
and	O
impair	O
ability	O
to	O
forage	O
for	O
food	O
[	O
1	O
]	O
.	O

The	O
final	O
developmental	O
stages	O
of	O
the	O
parasite	O
in	O
the	O
fish	O
are	O
environmentally	O
resistant	O
spore	O
stages	O
(	O
myxospores	O
)	O
which	O
remained	O
trapped	O
in	O
cartilage	O
or	O
bone	O
[	O
18	O
]	O
.	O

Death	O
of	O
infected	O
fish	O
or	O
ingestion	O
by	O
fish	O
or	O
avian	O
predators	O
releases	O
myxospores	O
from	O
the	O
fish	O
tissues	O
and	O
they	O
may	O
be	O
ingested	O
by	O
the	O
second	O
host	O
,	O
the	O
benthic	O
dwelling	O
oligochaete	O
T.	B
tubifex	I
[	O
19	O
]	O
.	O

A	O
second	O
developmental	O
cycle	O
then	O
occurs	O
under	O
the	O
mucosal	O
lining	O
of	O
the	O
intestine	O
that	O
results	O
in	O
the	O
release	O
of	O
thousands	O
of	O
the	O
actinospore	O
(	O
triactinomyxon	O
)	O
stages	O
potentially	O
over	O
the	O
entire	O
lifetime	O
of	O
the	O
individual	O
oligochaete	O
[	O
20	O
]	O
.	O

Susceptibility	O
to	O
whirling	O
disease	O
in	O
U.S.	O
rainbow	B
trout	I
strains	O
is	O
pervasive	O
with	O
only	O
two	O
of	O
the	O
tested	O
native	O
strains	O
displaying	O
any	O
degree	O
of	O
resistance	O
,	O
which	O
may	O
be	O
inconsistent	O
and	O
relatively	O
moderate	O
[	O
21,22	O
]	O
.	O

Hatchery	O
rainbow	B
trout	I
in	O
Germany	O
(	O
Hofer	O
strain	O
)	O
,	O
however	O
,	O
have	O
acquired	O
a	O
degree	O
of	O
resistance	O
to	O
whirling	O
disease	O
that	O
is	O
consistently	O
much	O
higher	O
than	O
any	O
domestic	O
rainbow	O
strains	O
and	O
comparable	O
to	O
that	O
of	O
brown	B
trout	I
(	O
Salmon	B
trutta	I
)	O
,	O
which	O
are	O
native	O
to	O
Europe	O
and	O
typically	O
asymptomatic	O
following	O
infection	O
[	O
23	O
]	O
.	O

Laboratory	O
tests	O
comparing	O
rainbow	B
trout	I
strains	O
under	O
the	O
same	O
environmental	O
conditions	O
and	O
pathogen	O
exposure	O
indicate	O
that	O
the	O
Hofer	O
strain	O
's	O
ability	O
to	O
combat	O
M.	B
cerebralis	I
infection	O
has	O
a	O
genetic	O
basis	O
.	O

Recently	O
,	O
controlled	O
crosses	O
of	O
the	O
Hofer	O
strain	O
and	O
a	O
susceptible	O
strain	O
(	O
Colorado	O
River	O
rainbow	B
trout	I
[	O
CRR	O
]	O
)	O
demonstrated	O
that	O
resistance	O
to	O
whirling	O
disease	O
was	O
inherited	O
by	O
progeny	O
[	O
24	O
]	O
and	O
heritability	O
estimates	O
are	O
currently	O
underway	O
.	O

The	O
discovery	O
of	O
the	O
resistant	O
Hofer	O
strain	O
allowed	O
us	O
to	O
conduct	O
an	O
intraspecific	O
comparison	O
of	O
susceptible	O
and	O
resistant	O
rainbow	B
trout	I
in	O
order	O
to	O
gain	O
insight	O
into	O
the	O
genetic	O
basis	O
underlying	O
whirling	O
disease	O
susceptibility	O
for	O
this	O
species	O
.	O

Gene	O
expression	O
profiling	O
,	O
through	O
the	O
use	O
of	O
microarrays	O
,	O
is	O
an	O
extremely	O
high	O
-	O
throughput	O
method	O
to	O
discover	O
specific	O
genes	O
and	O
pathways	O
involved	O
in	O
a	O
disease	O
phenotype	O
without	O
the	O
bias	O
of	O
a	O
candidate	O
gene	O
approach	O
.	O

In	O
this	O
study	O
,	O
microarray	O
analysis	O
was	O
used	O
to	O
examine	O
expression	O
changes	O
in	O
a	O
resistant	O
and	O
susceptible	O
strain	O
of	O
rainbow	B
trout	I
following	O
exposure	O
to	O
M.	B
cerebralis	I
,	O
the	O
pathogen	O
causing	O
whirling	O
disease	O
.	O

We	O
have	O
found	O
several	O
genes	O
significantly	O
up	O
-	O
regulated	O
in	O
both	O
the	O
resistant	O
and	O
susceptible	O
strain	O
that	O
appear	O
to	O
be	O
involved	O
in	O
host	O
response	O
to	O
infection	O
.	O

We	O
have	O
also	O
found	O
a	O
gene	O
which	O
is	O
significantly	O
up	O
-	O
regulated	O
in	O
the	O
resistant	O
but	O
remains	O
unchanged	O
in	O
the	O
susceptible	O
rainbow	B
trout	I
strain	O
following	O
pathogen	O
exposure	O
that	O
is	O
a	O
likely	O
candidate	O
gene	O
for	O
involvement	O
in	O
conferring	O
whirling	O
disease	O
resistance	O
.	O

Results	O
and	O
Discussion	O
Quantitative	O
PCR	O
conducted	O
on	O
caudal	O
fin	O
tissues	O
at	O
two	O
hours	O
post	O
exposure	O
to	O
M.	B
cerebralis	I
demonstrated	O
each	O
fish	O
strain	O
had	O
similar	O
initial	O
pathogen	O
loads	O
,	O
although	O
there	O
was	O
substantial	O
variation	O
between	O
individual	O
fish	O
within	O
each	O
strain	O
.	O

The	O
mean	O
parasite	O
copy	O
numbers	O
per	O
host	O
cell	O
were	O
1.20	O
×	O
106	O
(	O
SD	O
1.53	O
×	O
106	O
)	O
for	O
the	O
Hofer	O
and	O
1.04	O
×	O
106	O
(	O
SD	O
0.91	O
×	O
106	O
)	O
for	O
the	O
Trout	O
Lodge	O
.	O

These	O
mean	O
values	O
and	O
standard	O
deviations	O
are	O
similar	O
to	O
those	O
obtained	O
in	O
additional	O
studies	O
of	O
susceptible	O
rainbow	B
trout	I
when	O
examined	O
at	O
early	O
time	O
points	O
post	O
TAM	O
exposure	O
(	O
unpublished	O
data	O
)	O
.	O

In	O
order	O
to	O
study	O
genes	O
involved	O
in	O
whirling	O
disease	O
response	O
,	O
resistant	O
and	O
susceptible	O
rainbow	B
trout	I
strains	O
were	O
exposed	O
to	O
M.	B
cerebralis	I
and	O
RNA	O
from	O
skin	O
tissue	O
was	O
converted	O
to	O
cDNA	O
and	O
hybridized	O
onto	O
microarrays	O
.	O

Relative	O
gene	O
expression	O
for	O
exposed	O
and	O
unexposed	O
controls	O
for	O
each	O
strain	O
was	O
compared	O
and	O
the	O
list	O
of	O
differentially	O
expressed	O
genes	O
for	O
both	O
strains	O
is	O
found	O
in	O
Table	O
1	O
.	O

A	O
combined	O
total	O
of	O
17	O
genes	O
or	O
features	O
(	O
14	O
annotated	O
genes	O
,	O
3	O
unknown	O
features	O
)	O
were	O
differentially	O
expressed	O
in	O
one	O
or	O
both	O
strains	O
following	O
pathogen	O
exposure	O
and	O
are	O
involved	O
with	O
rainbow	B
trout	I
infection	O
response	O
to	O
whirling	O
disease	O
exposure	O
.	O

Several	O
of	O
these	O
genes	O
were	O
found	O
in	O
different	O
locations	O
on	O
the	O
array	O
as	O
unique	O
expressed	O
sequence	O
tag	O
(	O
EST	O
)	O
clones	O
and	O
their	O
repeated	O
presence	O
on	O
the	O
significance	O
gene	O
lists	O
provides	O
additional	O
support	O
for	O
their	O
involvement	O
in	O
the	O
whirling	O
disease	O
phenotype	O
.	O

The	O
small	O
number	O
of	O
genes	O
found	O
potentially	O
indicates	O
that	O
only	O
a	O
few	O
genes	O
contribute	O
to	O
the	O
phenotypic	O
differences	O
found	O
between	O
resistant	O
Hofer	O
and	O
susceptible	O
Trout	O
Lodge	O
,	O
at	O
least	O
in	O
terms	O
of	O
differential	O
gene	O
expression	O
,	O
during	O
early	O
disease	O
progression	O
in	O
the	O
skin	O
.	O

In	O
the	O
microarray	O
statistical	O
analysis	O
,	O
when	O
the	O
delta	O
value	O
was	O
adjusted	O
even	O
slightly	O
lower	O
,	O
the	O
FDR	O
estimate	O
increases	O
from	O
0	O
%	O
to	O
~78	O
%	O
.	O

Since	O
increasing	O
the	O
FDR	O
cut	O
-	O
off	O
to	O
such	O
a	O
high	O
percentage	O
would	O
dramatically	O
reduce	O
power	O
,	O
we	O
chose	O
to	O
leave	O
the	O
gene	O
list	O
small	O
with	O
an	O
estimated	O
FDR	O
of	O
0	O
%	O
.	O

This	O
type	O
of	O
dramatic	O
increase	O
in	O
FDR	O
estimation	O
is	O
additional	O
support	O
that	O
there	O
are	O
not	O
many	O
genes	O
differentially	O
expressed	O
in	O
response	O
to	O
whirling	O
disease	O
infection	O
for	O
our	O
chosen	O
tissue	O
and	O
time	O
points	O
.	O

Different	O
salmonid	O
microarray	O
platforms	O
,	O
such	O
as	O
those	O
available	O
from	O
Oregon	O
State	O
University	O
and	O
Michigan	O
State	O
University	O
,	O
or	O
different	O
tissues	O
and	O
time	O
points	O
may	O
produce	O
additional	O
candidate	O
genes	O
.	O

A	O
recent	O
time	O
course	O
study	O
used	O
a	O
candidate	O
gene	O
approach	O
to	O
identify	O
four	O
genes	O
(	O
TGF	O
-	O
β	O
,	O
IL-1β1	O
,	O
IL-1β2	O
,	O
and	O
COX-2	O
)	O
that	O
were	O
significantly	O
up	O
-	O
regulated	O
by	O
both	O
Hofer	O
and	O
Trout	O
Lodge	O
in	O
response	O
to	O
whirling	O
disease	O
infection	O
[	O
25	O
]	O
.	O

These	O
genes	O
and	O
their	O
downstream	O
effectors	O
were	O
not	O
identified	O
in	O
the	O
current	O
microarray	O
study	O
,	O
likely	O
due	O
to	O
many	O
differences	O
in	O
experimental	O
design	O
between	O
the	O
two	O
studies	O
(	O
e.g.	O
,	O
pathogen	O
exposure	O
levels	O
,	O
tissue	O
types	O
,	O
water	O
temperatures	O
,	O
age	O
of	O
fish	O
at	O
exposure	O
,	O
etc	O
.	O
)	O
.	O

While	O
downstream	O
effectors	O
of	O
these	O
genes	O
were	O
present	O
on	O
the	O
microarray	O
,	O
only	O
one	O
of	O
the	O
four	O
genes	O
(	O
COX-2	O
)	O
was	O
actually	O
present	O
on	O
the	O
microarray	O
.	O

It	O
is	O
our	O
hope	O
that	O
future	O
genome	O
sequencing	O
will	O
enable	O
the	O
construction	O
of	O
more	O
comprehensive	O
microarray	O
platforms	O
for	O
economically	O
important	O
aquaculture	O
species	O
,	O
such	O
as	O
Atlantic	B
salmon	I
and	O
rainbow	B
trout	I
.	O

All	O
significant	O
genes	O
identified	O
by	O
the	O
current	O
microarray	O
study	O
were	O
up	O
-	O
regulated	O
following	O
pathogen	O
exposure	O
for	O
one	O
or	O
both	O
strains	O
.	O

Therefore	O
,	O
it	O
appears	O
that	O
both	O
strains	O
are	O
undergoing	O
transcriptional	O
activation	O
to	O
defend	O
against	O
whirling	O
disease	O
infection	O
and	O
thus	O
,	O
are	O
exclusively	O
employing	O
positive	O
regulation	O
for	O
the	O
genes	O
examined	O
in	O
skin	O
during	O
early	O
disease	O
progression	O
.	O

The	O
normal	O
caveats	O
that	O
apply	O
for	O
microarray	O
studies	O
(	O
gene	O
discovery	O
is	O
limited	O
by	O
transcripts	O
on	O
arrays	O
,	O
differences	O
at	O
transcriptional	O
level	O
may	O
not	O
cause	O
phenotypic	O
differences	O
,	O
results	O
are	O
dependent	O
upon	O
tissue	O
type	O
and	O
time	O
point	O
chosen	O
,	O
etc	O
.	O
)	O
apply	O
for	O
this	O
study	O
.	O

Additionally	O
,	O
the	O
comparison	O
of	O
two	O
rainbow	B
trout	I
strains	O
(	O
i.e.	O
,	O
resistant	O
versus	O
susceptible	O
)	O
added	O
another	O
layer	O
of	O
complexity	O
to	O
the	O
analysis	O
.	O

We	O
chose	O
to	O
not	O
directly	O
compare	O
the	O
two	O
strains	O
because	O
there	O
could	O
be	O
expression	O
differences	O
between	O
them	O
,	O
due	O
to	O
divergence	O
following	O
strain	O
isolation	O
,	O
that	O
are	O
unrelated	O
to	O
the	O
whirling	O
disease	O
phenotype	O
.	O

With	O
that	O
in	O
mind	O
,	O
the	O
two	O
strains	O
were	O
first	O
compared	O
entirely	O
separately	O
from	O
each	O
other	O
to	O
discover	O
expression	O
differences	O
in	O
response	O
to	O
pathogen	O
exposure	O
for	O
each	O
strain	O
.	O

Only	O
the	O
genes	O
responding	O
to	O
infection	O
,	O
and	O
therefore	O
implicated	O
in	O
the	O
whirling	O
disease	O
phenotype	O
,	O
were	O
compared	O
between	O
the	O
two	O
strains	O
for	O
differential	O
gene	O
expression	O
(	O
Figure	O
1	O
)	O
.	O

A	O
limitation	O
of	O
this	O
approach	O
to	O
our	O
study	O
is	O
that	O
constitutively	O
expressed	O
transcripts	O
which	O
are	O
differentially	O
expressed	O
between	O
the	O
two	O
strains	O
that	O
contribute	O
to	O
the	O
whirling	O
disease	O
phenotype	O
can	O
not	O
be	O
identified	O
.	O

Microarray	O
analysis	O
of	O
genes	O
differentially	O
expressed	O
in	O
the	O
resistant	O
Hofer	O
strain	O
in	O
response	O
to	O
pathogen	O
exposure	O
A	O
total	O
of	O
16	O
genes	O
or	O
features	O
(	O
13	O
annotated	O
genes	O
,	O
3	O
unknown	O
features	O
)	O
were	O
up	O
-	O
regulated	O
in	O
the	O
resistant	O
Hofer	O
strain	O
following	O
pathogen	O
exposure	O
.	O

All	O
13	O
annotated	O
genes	O
have	O
been	O
previously	O
implicated	O
in	O
host	O
immune	O
response	O
for	O
other	O
infectious	O
diseases	O
.	O

Viral	B
Hemorrhagic	I
Septicemia	I
Virus	I
(	O
VHSV	B
)	O
induced	O
protein	O
and	O
neighbor	O
of	O
COX-4	O
are	O
the	O
only	O
annotated	O
genes	O
without	O
known	O
molecular	O
functions	O
.	O

A	O
common	O
link	O
between	O
the	O
majority	O
of	O
annotated	O
genes	O
with	O
known	O
molecular	O
functions	O
is	O
an	O
involvement	O
in	O
the	O
interferon	O
system	O
.	O

The	O
interferon	O
system	O
is	O
one	O
of	O
the	O
first	O
lines	O
of	O
host	O
defense	O
against	O
invading	O
pathogens	O
for	O
vertebrates	O
(	O
for	O
review	O
see	O
[	O
26	O
]	O
)	O
,	O
including	O
teleost	B
fish	I
(	O
for	O
review	O
see	O
[	O
27	O
]	O
)	O
.	O

Other	O
economically	O
important	O
salmonid	O
pathogens	O
,	O
such	O
as	O
infectious	B
pancreatic	I
necrosis	I
virus	I
and	O
infectious	B
salmon	I
anaemia	I
virus	I
have	O
been	O
found	O
to	O
activate	O
both	O
type	O
I	O
and	O
type	O
II	O
interferon	O
(	O
IFN	O
)	O
responses	O
in	O
the	O
Atlantic	B
salmon	I
host	O
following	O
infection	O
[	O
28	O
]	O
.	O

Interferons	O
are	O
cytokine	O
proteins	O
that	O
are	O
secreted	O
following	O
infection	O
and	O
play	O
a	O
critical	O
role	O
in	O
both	O
innate	O
and	O
adaptive	O
immunity	O
.	O

The	O
IFN	O
system	O
has	O
been	O
most	O
widely	O
researched	O
in	O
mammals	O
and	O
studies	O
have	O
found	O
that	O
type	O
I	O
IFN	O
(	O
mammalian	O
IFN	O
-	O
α	O
/	O
β	O
)	O
are	O
secreted	O
by	O
the	O
pathogen	O
-	O
infected	O
cells	O
as	O
part	O
of	O
a	O
rapid	O
initial	O
immune	O
response	O
while	O
Type	O
II	O
IFN	O
(	O
mammalian	O
IFN	O
-	O
γ	O
)	O
is	O
secreted	O
by	O
natural	O
killer	O
(	O
NK	O
)	O
and	O
T	O
cells	O
and	O
plays	O
a	O
more	O
central	O
role	O
in	O
the	O
second	O
wave	O
of	O
immune	O
response	O
.	O

To	O
cope	O
with	O
the	O
myriad	O
of	O
host	O
infections	O
,	O
the	O
interferon	O
system	O
is	O
highly	O
complex	O
and	O
involves	O
the	O
regulation	O
of	O
hundreds	O
of	O
genes	O
[	O
29,30	O
]	O
.	O

Specifically	O
,	O
type	O
I	O
IFN	O
acts	O
to	O
increase	O
MHC	O
class	O
I	O
expression	O
for	O
antigen	O
presentation	O
[	O
31	O
]	O
,	O
promote	O
T	O
cell	O
survival	O
[	O
32	O
]	O
,	O
inhibit	O
cell	O
proliferation	O
[	O
33	O
]	O
,	O
mediate	O
apoptosis	O
[	O
26	O
]	O
,	O
and	O
increase	O
NK	O
cell	O
activity	O
[	O
34	O
]	O
.	O

Type	O
II	O
IFN	O
acts	O
to	O
increase	O
both	O
MHC	O
class	O
I	O
and	O
II	O
expression	O
for	O
antigen	O
presentation	O
[	O
29	O
]	O
,	O
stimulate	O
macrophages	O
to	O
kill	O
engulfed	O
pathogens	O
[	O
35	O
]	O
,	O
induce	O
apoptosis	O
[	O
36	O
]	O
,	O
and	O
regulate	O
leukocyte	O
-	O
endothelium	O
interactions	O
[	O
37	O
]	O
in	O
addition	O
to	O
many	O
other	O
immune	O
-	O
related	O
activities	O
.	O

It	O
is	O
informative	O
to	O
examine	O
the	O
functional	O
roles	O
of	O
each	O
gene	O
's	O
encoded	O
protein	O
specifically	O
to	O
better	O
understand	O
the	O
part	O
each	O
plays	O
,	O
both	O
individually	O
and	O
as	O
interconnected	O
components	O
,	O
in	O
host	O
immune	O
response	O
.	O

Expression	O
of	O
the	O
interferon	O
-	O
induced	O
35	O
kDa	O
protein	O
is	O
induced	O
by	O
IFN	O
and	O
it	O
is	O
involved	O
in	O
cytokine	O
signalling	O
[	O
38	O
]	O
.	O

Interferon	O
regulatory	O
factor	O
1	O
(	O
IRF-1	O
)	O
and	O
interferon	O
regulatory	O
factor	O
7	O
(	O
IRF-7	O
)	O
are	O
transcription	O
factors	O
that	O
induce	O
expression	O
of	O
IFN	O
responsive	O
genes	O
[	O
39,40	O
]	O
.	O

Additionally	O
,	O
IRF-1	O
is	O
involved	O
in	O
apoptosis	O
and	O
cell	O
cycle	O
regulation	O
related	O
to	O
tumor	O
suppression	O
[	O
41	O
]	O
.	O

Similarly	O
,	O
cyclin	O
-	O
dependent	O
kinase	O
4	O
inhibitor	O
B	O
(	O
p15-INK4b	O
)	O
plays	O
a	O
role	O
in	O
apoptosis	O
[	O
42	O
]	O
,	O
cell	O
cycle	O
regulation	O
[	O
42	O
]	O
,	O
and	O
tumor	O
suppression	O
[	O
43	O
]	O
and	O
can	O
be	O
induced	O
by	O
the	O
cytokine	O
TGF	O
-	O
β	O
[	O
44	O
]	O
.	O

Gig2	O
is	O
an	O
interferon	O
-	O
inducible	O
protein	O
that	O
is	O
likely	O
part	O
of	O
the	O
JAK	O
-	O
STAT	O
signal	O
transduction	O
pathway	O
[	O
45	O
]	O
.	O

Ubiquitin	O
and	O
the	O
proteasome	O
subunit	O
beta	O
type	O
8	O
precursor	O
are	O
both	O
members	O
of	O
the	O
ubiquitin	O
-	O
proteasome	O
system	O
(	O
for	O
review	O
see	O
[	O
26	O
]	O
)	O
,	O
which	O
serves	O
to	O
degrade	O
proteins	O
via	O
proteolysis	O
.	O

These	O
degraded	O
proteins	O
can	O
originate	O
from	O
an	O
invading	O
pathogen	O
and	O
are	O
displayed	O
on	O
MHC	O
class	O
I	O
proteins	O
.	O

The	O
beta-2-microglobulin	O
is	O
an	O
integral	O
component	O
of	O
MHC	O
class	O
I	O
proteins	O
and	O
is	O
therefore	O
involved	O
in	O
antigen	O
processing	O
and	O
presentation	O
to	O
cytotoxic	O
T	O
cells	O
[	O
46	O
]	O
.	O

Haptoglobin	O
binds	O
hemoglobin	O
and	O
limits	O
its	O
availability	O
to	O
infectious	O
bacteria	O
,	O
thus	O
preventing	O
bacterial	O
proliferation	O
in	O
a	O
wound	O
[	O
47	O
]	O
.	O

The	O
PPAR	O
-	O
α	O
-	O
interacting	O
complex	O
protein	O
285	O
is	O
a	O
transcriptional	O
co	O
-	O
activator	O
with	O
helicase	O
activity	O
[	O
48	O
]	O
and	O
has	O
sequence	O
similarity	O
to	O
a	O
rainbow	B
trout	I
VHSV	B
-	O
induced	O
protein	O
.	O

Gene	O
expression	O
of	O
metallothionein	O
B	O
(	O
MT	O
-	O
B	O
)	O
is	O
induced	O
by	O
several	O
metal	O
ions	O
[	O
49	O
]	O
,	O
cytokines	O
[	O
50	O
-	O
52	O
]	O
,	O
and	O
stress	O
hormones	O
[	O
53	O
-	O
55	O
]	O
.	O

MT	O
proteins	O
are	O
believed	O
to	O
play	O
diverse	O
functional	O
roles	O
in	O
inflammation	O
,	O
immune	O
response	O
,	O
apoptosis	O
,	O
tumor	O
suppression	O
,	O
and	O
detoxification	O
(	O
for	O
reviews	O
see	O
[	O
55,56	O
]	O
)	O
.	O

Microarray	O
analysis	O
of	O
genes	O
differentially	O
expressed	O
in	O
the	O
susceptible	O
Trout	O
Lodge	O
strain	O
in	O
response	O
to	O
pathogen	O
exposure	O
A	O
total	O
of	O
six	O
genes	O
or	O
features	O
(	O
five	O
annotated	O
genes	O
,	O
one	O
unknown	O
feature	O
)	O
were	O
up	O
-	O
regulated	O
in	O
the	O
susceptible	O
Trout	O
Lodge	O
strain	O
following	O
pathogen	O
exposure	O
.	O

Only	O
one	O
of	O
the	O
significant	O
genes	O
for	O
Trout	O
Lodge	O
,	O
which	O
has	O
sequence	O
similarity	O
to	O
CC	O
chemokine	O
SCYA113	O
,	O
was	O
not	O
also	O
differentially	O
expressed	O
in	O
Hofer	O
in	O
response	O
to	O
pathogen	O
exposure	O
.	O

The	O
CC	O
chemokine	O
SCYA113	O
gene	O
is	O
a	O
member	O
of	O
the	O
CC	O
chemokine	O
family	O
,	O
which	O
guides	O
leukocytes	O
to	O
sites	O
of	O
infection	O
and	O
inflammation	O
(	O
for	O
review	O
see	O
[	O
57	O
]	O
)	O
.	O

The	O
fewer	O
number	O
of	O
significant	O
genes	O
found	O
for	O
Trout	O
Lodge	O
relative	O
to	O
Hofer	O
may	O
indicate	O
a	O
decrease	O
in	O
transcriptional	O
activation	O
for	O
this	O
susceptible	O
strain	O
.	O

There	O
is	O
,	O
however	O
,	O
likely	O
some	O
degree	O
of	O
overlap	O
in	O
both	O
strains	O
'	O
response	O
to	O
pathogen	O
exposure	O
due	O
to	O
the	O
fact	O
that	O
several	O
genes	O
were	O
up	O
-	O
regulated	O
in	O
both	O
Hofer	O
and	O
Trout	O
Lodge	O
(	O
i.e.	O
,	O
ubiquitin	O
-	O
like	O
protein	O
1	O
,	O
IRF-1	O
,	O
and	O
PPAR	O
-	O
α	O
-	O
interacting	O
protein	O
Gig2	O
)	O
.	O

A	O
critical	O
phase	O
in	O
the	O
early	O
stages	O
of	O
M.	B
cerebralis	I
infection	O
in	O
trout	O
is	O
invasion	O
and	O
intracellular	O
replication	O
,	O
processes	O
that	O
begin	O
as	O
early	O
as	O
one	O
hour	O
post	O
exposure	O
to	O
triactinomyxons	O
[	O
16	O
]	O
.	O

A	O
role	O
for	O
accumulated	O
ubiquinated	O
proteins	O
in	O
the	O
lysosome	O
in	O
the	O
killing	O
of	O
Mycobacterium	B
tuberculosis	I
has	O
recently	O
been	O
described	O
that	O
has	O
implications	O
for	O
a	O
range	O
of	O
intracellular	O
infections	O
[	O
58	O
]	O
and	O
some	O
similar	O
responses	O
to	O
infection	O
may	O
be	O
occurring	O
for	O
both	O
resistant	O
and	O
susceptible	O
strains	O
.	O

Microarray	O
analysis	O
of	O
genes	O
differentially	O
expressed	O
between	O
resistant	O
and	O
susceptible	O
strains	O
in	O
response	O
to	O
pathogen	O
exposure	O
Of	O
the	O
genes	O
differentially	O
expressed	O
in	O
response	O
to	O
pathogen	O
exposure	O
for	O
both	O
strains	O
,	O
only	O
metallothionein	O
B	O
shows	O
a	O
statistically	O
significant	O
difference	O
in	O
expression	O
between	O
the	O
two	O
strains	O
(	O
Table	O
2	O
)	O
.	O

MT	O
-	O
B	O
was	O
found	O
to	O
be	O
up	O
-	O
regulated	O
in	O
the	O
resistant	O
Hofer	O
strain	O
following	O
pathogen	O
exposure	O
but	O
remained	O
unchanged	O
in	O
the	O
susceptible	O
Trout	O
Lodge	O
strain	O
.	O

As	O
previously	O
noted	O
,	O
metallothionein	O
has	O
been	O
implicated	O
in	O
a	O
broad	O
range	O
of	O
functional	O
capacities	O
,	O
including	O
inflammatory	O
and	O
immune	O
responses	O
.	O

Several	O
cytokines	O
can	O
induce	O
metallothionein	O
expression	O
including	O
IFN	O
[	O
59	O
-	O
61	O
]	O
,	O
interleukin-1	O
[	O
50	O
]	O
,	O
interleukin-6	O
[	O
51	O
]	O
,	O
and	O
tumor	O
necrosis	O
factor	O
-	O
α	O
[	O
52	O
]	O
.	O

Metallothionein	O
has	O
been	O
shown	O
to	O
mediate	O
leukocyte	O
chemotaxis	O
and	O
has	O
been	O
hypothesized	O
to	O
serve	O
as	O
an	O
early	O
""""	O
danger	O
signal	O
""""	O
during	O
times	O
of	O
stress	O
or	O
infection	O
to	O
activate	O
an	O
immune	O
response	O
[	O
62	O
]	O
.	O

The	O
functional	O
similarities	O
between	O
metallothionein	O
and	O
CC	O
chemokine	O
SCYA113	O
,	O
at	O
least	O
in	O
terms	O
of	O
leukocyte	O
chemotaxis	O
,	O
are	O
certainly	O
of	O
interest	O
since	O
these	O
genes	O
displayed	O
quite	O
distinct	O
expression	O
profiles	O
.	O

Metallothionein	O
was	O
up	O
-	O
regulated	O
in	O
the	O
resistant	O
Hofer	O
strain	O
and	O
CC	O
chemokine	O
SCYA113	O
was	O
up	O
-	O
regulated	O
in	O
the	O
susceptible	O
Trout	O
Lodge	O
strain	O
(	O
although	O
CC	O
chemokine	O
SCYA113	O
did	O
not	O
pass	O
the	O
significance	O
cut	O
-	O
off	O
to	O
be	O
considered	O
differentially	O
expressed	O
between	O
the	O
two	O
strains	O
)	O
.	O

This	O
distinction	O
between	O
two	O
genes	O
,	O
capable	O
of	O
similar	O
biological	O
roles	O
,	O
may	O
indicate	O
that	O
leukocyte	O
movements	O
to	O
,	O
and	O
their	O
activities	O
once	O
at	O
,	O
the	O
infection	O
site	O
are	O
key	O
factors	O
in	O
determining	O
resistance	O
versus	O
susceptibility	O
to	O
whirling	O
disease	O
.	O

Evaluations	O
by	O
light	O
microscopy	O
and	O
qPCR	O
for	O
M.	B
cerebralis	I
genomic	O
DNA	O
of	O
Hofer	O
and	O
Trout	O
Lodge	O
rainbow	B
trout	I
exposed	O
to	O
triactinomyxons	O
demonstrates	O
Hofer	O
more	O
efficiently	O
eliminates	O
invading	O
parasites	O
in	O
the	O
skin	O
(	O
M.	O
Adkison	O
,	O
pers	O
.	O

comm	O
.	O
)	O
.	O

While	O
the	O
parasite	O
effectively	O
penetrates	O
the	O
epidermis	O
in	O
both	O
strains	O
,	O
significantly	O
fewer	O
parasites	O
survive	O
the	O
migration	O
from	O
the	O
skin	O
to	O
the	O
nerves	O
as	O
evaluated	O
at	O
10	O
d	O
post	O
exposure	O
.	O

A	O
role	O
for	O
host	O
immune	O
factors	O
in	O
the	O
elimination	O
of	O
invading	O
parasites	O
,	O
even	O
in	O
susceptible	O
rainbow	B
trout	I
strains	O
,	O
is	O
suggested	O
by	O
several	O
prior	O
light	O
and	O
electron	O
microscopy	O
studies	O
that	O
demonstrate	O
an	O
increase	O
in	O
degenerative	O
stages	O
in	O
the	O
skin	O
beginning	O
as	O
early	O
as	O
12	O
h	O
and	O
then	O
their	O
elimination	O
by	O
24	O
h	O
post	O
-	O
exposure	O
to	O
triactinomyxons	O
[	O
12,16,63	O
]	O
.	O

The	O
difference	O
in	O
metallothionein	O
expression	O
may	O
be	O
due	O
to	O
an	O
alternative	O
immune	O
response	O
pathway	O
since	O
the	O
protein	O
has	O
known	O
involvement	O
in	O
diverse	O
functional	O
capacities	O
.	O

For	O
instance	O
,	O
metallothionein	O
's	O
role	O
as	O
a	O
zinc	O
-	O
finger	O
transcriptional	O
regulator	O
[	O
64	O
]	O
may	O
dramatically	O
alter	O
the	O
expression	O
profiles	O
between	O
resistant	O
and	O
susceptible	O
rainbow	B
trout	I
.	O

All	O
biological	O
roles	O
of	O
this	O
diverse	O
protein	O
should	O
be	O
considered	O
when	O
examining	O
the	O
complexities	O
of	O
host	O
immune	O
response	O
.	O

Additionally	O
,	O
upstream	O
regulators	O
of	O
metallothionein	O
expression	O
could	O
be	O
the	O
true	O
underlying	O
cause	O
of	O
the	O
whirling	O
disease	O
phenotype	O
since	O
a	O
gene	O
expression	O
study	O
alone	O
can	O
not	O
determine	O
if	O
a	O
gene	O
is	O
directly	O
contributing	O
to	O
a	O
phenotype	O
(	O
i.e.	O
,	O
cause	O
versus	O
downstream	O
effect	O
)	O
.	O

Validation	O
of	O
microarray	O
results	O
by	O
qRT	O
-	O
PCR	O
Quantitative	O
RT	O
-	O
PCR	O
(	O
qRT	O
-	O
PCR	O
)	O
confirmed	O
the	O
microarrays	O
results	O
for	O
two	O
of	O
the	O
genes	O
up	O
-	O
regulated	O
in	O
both	O
Hofer	O
and	O
Trout	O
Lodge	O
following	O
infection	O
,	O
ubiquitin	O
and	O
IRF-1	O
,	O
and	O
the	O
metallothionein	O
gene	O
(	O
MT	O
-	O
B	O
)	O
,	O
which	O
was	O
up	O
-	O
regulated	O
in	O
Hofer	O
but	O
remained	O
unchanged	O
in	O
Trout	O
Lodge	O
following	O
infection	O
(	O
Figure	O
2	O
)	O
.	O

The	O
qRT	O
-	O
PCR	O
results	O
for	O
IRF-1	O
and	O
metallothionein	O
were	O
quite	O
similar	O
to	O
the	O
microarray	O
results	O
for	O
each	O
gene	O
,	O
in	O
terms	O
of	O
relative	O
expression	O
changes	O
in	O
response	O
to	O
infection	O
.	O

MT	O
-	O
B	O
was	O
found	O
to	O
once	O
again	O
be	O
significantly	O
up	O
-	O
regulated	O
in	O
the	O
resistant	O
Hofer	O
strain	O
following	O
pathogen	O
exposure	O
but	O
remained	O
unchanged	O
in	O
the	O
susceptible	O
Trout	O
Lodge	O
.	O

This	O
difference	O
in	O
MT	O
-	O
B	O
gene	O
expression	O
between	O
the	O
two	O
strains	O
was	O
statistically	O
significant	O
(	O
P	O
~	O
0.001	O
)	O
.	O

The	O
relative	O
degree	O
of	O
up	O
-	O
regulation	O
for	O
ubiquitin	O
following	O
pathogen	O
exposure	O
was	O
considerably	O
higher	O
in	O
the	O
qRT	O
-	O
PCR	O
(	O
~9	O
–	O
17	O
fold	O
greater	O
up	O
-	O
regulation	O
in	O
qRT	O
-	O
PCR	O
versus	O
microarrays	O
)	O
.	O

Many	O
other	O
studies	O
have	O
also	O
observed	O
this	O
pattern	O
of	O
greater	O
sensitivity	O
in	O
qRT	O
-	O
PCR	O
versus	O
microarray	O
results	O
(	O
for	O
examples	O
see	O
[	O
65,66	O
]	O
,	O
which	O
is	O
often	O
attributed	O
to	O
the	O
more	O
gene	O
-	O
specific	O
optimized	O
conditions	O
of	O
the	O
qRT	O
-	O
PCR	O
approach	O
.	O

Given	O
the	O
high	O
degree	O
of	O
statistical	O
support	O
and	O
biological	O
relevance	O
of	O
the	O
candidate	O
genes	O
,	O
we	O
believe	O
this	O
study	O
provides	O
initial	O
insight	O
into	O
rainbow	B
trout	I
genes	O
and	O
pathways	O
responding	O
to	O
whirling	O
disease	O
infection	O
and	O
identifies	O
the	O
first	O
candidate	O
genes	O
for	O
whirling	O
disease	O
resistance	O
.	O

Potential	O
future	O
studies	O
While	O
the	O
interferon	O
system	O
appears	O
to	O
be	O
a	O
likely	O
candidate	O
system	O
for	O
further	O
study	O
,	O
many	O
of	O
the	O
significant	O
genes	O
are	O
found	O
in	O
alternative	O
pathways	O
and	O
have	O
distinct	O
roles	O
and	O
functions	O
in	O
other	O
systems	O
.	O

Furthermore	O
,	O
it	O
is	O
increasingly	O
apparent	O
that	O
epistatic	O
interactions	O
and	O
the	O
interplay	O
between	O
pathways	O
/	O
networks	O
previously	O
classified	O
as	O
discrete	O
can	O
have	O
enormous	O
phenotypic	O
effects	O
on	O
quantitative	O
traits	O
[	O
67	O
]	O
.	O

Multiple	O
avenues	O
of	O
research	O
should	O
be	O
examined	O
in	O
future	O
studies	O
,	O
using	O
the	O
candidate	O
genes	O
presented	O
here	O
as	O
an	O
initial	O
guide	O
,	O
due	O
to	O
the	O
complex	O
relationships	O
between	O
hosts	O
and	O
pathogens	O
.	O

For	O
instance	O
,	O
the	O
migration	O
of	O
leukocytes	O
and	O
their	O
subsequent	O
activity	O
in	O
the	O
skin	O
are	O
likely	O
a	O
critical	O
part	O
of	O
the	O
early	O
immune	O
and	O
inflammatory	O
host	O
response	O
after	O
pathogen	O
infection	O
.	O

Additionally	O
,	O
it	O
is	O
quite	O
feasible	O
that	O
the	O
difference	O
in	O
metallothionein	O
expression	O
is	O
due	O
to	O
an	O
alternative	O
immune	O
response	O
pathway	O
since	O
the	O
protein	O
has	O
known	O
involvement	O
in	O
diverse	O
functional	O
capacities	O
.	O

For	O
instance	O
,	O
metallothionein	O
's	O
role	O
as	O
a	O
zinc	O
-	O
finger	O
transcriptional	O
regulator	O
[	O
64	O
]	O
may	O
dramatically	O
alter	O
the	O
expression	O
profiles	O
between	O
resistant	O
and	O
susceptible	O
rainbow	B
trout	I
.	O

All	O
biological	O
roles	O
of	O
this	O
diverse	O
protein	O
should	O
be	O
considered	O
when	O
examining	O
the	O
complexities	O
of	O
host	O
immune	O
response	O
.	O

Finally	O
,	O
upstream	O
regulators	O
of	O
metallothionein	O
expression	O
could	O
be	O
the	O
true	O
underlying	O
cause	O
of	O
the	O
whirling	O
disease	O
phenotype	O
since	O
a	O
gene	O
expression	O
study	O
alone	O
can	O
not	O
determine	O
if	O
a	O
gene	O
is	O
directly	O
contributing	O
to	O
a	O
phenotype	O
(	O
i.e.	O
,	O
cause	O
versus	O
downstream	O
effect	O
)	O
.	O

The	O
expression	O
profiles	O
of	O
a	O
variety	O
of	O
metallothionein	O
upstream	O
regulators	O
,	O
such	O
as	O
cytokines	O
and	O
metal	O
transcription	O
factor	O
(	O
MTF-1	O
)	O
,	O
could	O
be	O
evaluated	O
in	O
a	O
time	O
course	O
study	O
during	O
early	O
disease	O
progression	O
to	O
identify	O
additional	O
candidate	O
genes	O
.	O

A	O
QTL	O
mapping	O
approach	O
could	O
also	O
be	O
used	O
to	O
identify	O
particular	O
chromosomal	O
regions	O
directly	O
contributing	O
to	O
the	O
disease	O
phenotype	O
.	O

Conclusion	O
The	O
present	O
study	O
has	O
provided	O
the	O
first	O
examination	O
into	O
the	O
genetic	O
basis	O
underlying	O
rainbow	B
trout	I
's	O
immune	O
response	O
and	O
resistance	O
to	O
the	O
whirling	O
disease	O
pathogen	O
.	O

Several	O
genes	O
were	O
significantly	O
up	O
-	O
regulated	O
in	O
skin	O
following	O
pathogen	O
exposure	O
for	O
both	O
the	O
resistant	O
Hofer	O
and	O
susceptible	O
Trout	O
Lodge	O
rainbow	B
trout	I
strains	O
.	O

For	O
both	O
strains	O
,	O
response	O
to	O
infection	O
appears	O
to	O
be	O
linked	O
with	O
the	O
interferon	O
system	O
.	O

Metallothionein	O
B	O
is	O
differentially	O
expressed	O
between	O
the	O
resistant	O
and	O
susceptible	O
strains	O
and	O
is	O
a	O
good	O
candidate	O
for	O
future	O
whirling	O
disease	O
resistance	O
studies	O
.	O

The	O
identified	O
genes	O
have	O
allowed	O
us	O
to	O
gain	O
initial	O
insight	O
into	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
a	O
salmonid	O
host	O
's	O
immune	O
response	O
and	O
resistance	O
to	O
whirling	O
disease	O
infection	O
.	O

Methods	O
Animal	O
care	O
,	O
pathogen	O
exposure	O
,	O
and	O
RNA	O
preparation	O
Hofer	O
and	O
Trout	O
Lodge	O
rainbow	B
trout	I
strains	O
were	O
reared	O
in	O
35	O
gallon	O
aquaria	O
with	O
15	O
°	O
C	O
flow	O
-	O
through	O
well	O
water	O
for	O
nine	O
weeks	O
post	O
-	O
hatch	O
,	O
with	O
each	O
fish	O
weighing	O
approximately	O
6.5	O
grams	O
prior	O
to	O
pathogen	O
exposure	O
.	O

Individuals	O
from	O
each	O
strain	O
(	O
n	O
=	O
60	O
)	O
were	O
exposed	O
to	O
2,000	O
triactinomyxons	O
(	O
TAMs	O
)	O
per	O
fish	O
for	O
one	O
hour	O
.	O

Additional	O
fish	O
(	O
n	O
=	O
60	O
)	O
from	O
both	O
strains	O
served	O
as	O
unexposed	O
controls	O
,	O
which	O
were	O
treated	O
identically	O
to	O
exposed	O
fish	O
at	O
all	O
experimental	O
stages	O
other	O
than	O
their	O
lack	O
of	O
pathogen	O
exposure	O
.	O

Fish	O
were	O
then	O
kept	O
under	O
standard	O
aquaculture	O
conditions	O
until	O
euthanized	O
.	O

TaqMan	O
PCR	O
for	O
the	O
quantitative	O
evaluation	O
of	O
genomic	O
parasite	O
DNA	O
was	O
employed	O
to	O
confirm	O
that	O
fish	O
in	O
both	O
the	O
Hofer	O
and	O
Trout	O
Lodge	O
groups	O
received	O
equal	O
amounts	O
of	O
parasite	O
exposure	O
.	O

At	O
two	O
hours	O
post	O
TAM	O
exposure	O
,	O
6	O
fish	O
in	O
each	O
exposed	O
group	O
were	O
removed	O
and	O
euthanized	O
with	O
an	O
overdose	O
of	O
benzocaine	O
at	O
a	O
concentration	O
of	O
500	O
mg	O
/	O
L.	O
Caudal	O
fins	O
were	O
removed	O
posterior	O
to	O
the	O
peduncle	O
and	O
used	O
as	O
the	O
tissue	O
for	O
a	O
quantiative	O
TaqMan	O
assay	O
following	O
procedures	O
described	O
by	O
Kelley	O
et	O
al.	O
[	O
68	O
]	O
.	O

Microarray	O
studies	O
examining	O
skin	O
four	O
hours	O
after	O
pathogen	O
exposure	O
did	O
not	O
identify	O
any	O
genes	O
differentially	O
expressed	O
between	O
Trout	O
Lodge	O
and	O
Hofer	O
strains	O
(	O
data	O
not	O
shown	O
)	O
.	O

Therefore	O
,	O
we	O
chose	O
a	O
later	O
time	O
point	O
(	O
24	O
hours	O
after	O
exposure	O
)	O
so	O
that	O
early	O
host	O
immune	O
response	O
was	O
more	O
likely	O
to	O
be	O
fully	O
underway	O
and	O
significant	O
expression	O
changes	O
could	O
be	O
detected	O
.	O

After	O
the	O
24	O
hour	O
incubation	O
period	O
,	O
all	O
fish	O
were	O
euthanized	O
with	O
an	O
overdose	O
of	O
benzocaine	O
at	O
a	O
concentration	O
of	O
500	O
mg	O
/	O
L.	O
Each	O
fish	O
was	O
euthanized	O
individually	O
and	O
the	O
caudal	O
fin	O
(	O
largely	O
comprised	O
of	O
skin	O
tissue	O
)	O
was	O
removed	O
posterior	O
to	O
the	O
peduncle	O
.	O

The	O
fin	O
was	O
immediately	O
placed	O
into	O
2	O
×	O
Nucleic	O
Acid	O
Purification	O
Lysis	O
Solution	O
supplied	O
with	O
ABI	O
's	O
TransPrep	O
Chemistry	O
kit	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
)	O
to	O
stop	O
further	O
gene	O
expression	O
changes	O
.	O

Total	O
RNA	O
was	O
extracted	O
from	O
the	O
fin	O
of	O
each	O
individual	O
using	O
the	O
ABI	O
Prism	O
™	O
TransPrep	O
system	O
with	O
the	O
ABI	O
Prism	O
™	O
6100	O
Nucleic	O
Acid	O
PrepStation	O
according	O
to	O
manufacturer	O
instructions	O
.	O

RNA	O
quality	O
was	O
assessed	O
by	O
agarose	O
gel	O
electrophoresis	O
and	O
RNA	O
concentrations	O
were	O
measured	O
using	O
a	O
ND-1000	O
spectrophotometer	O
(	O
NanoDrop	O
Technologies	O
,	O
Wilmington	O
,	O
DE	O
)	O
.	O

Starting	O
total	O
RNA	O
yields	O
were	O
not	O
sufficient	O
for	O
microarray	O
hybridizations	O
due	O
to	O
the	O
small	O
amount	O
of	O
caudal	O
fin	O
tissue	O
present	O
on	O
these	O
young	O
fish	O
.	O

Therefore	O
,	O
250	O
–	O
1000	O
ng	O
of	O
total	O
RNA	O
was	O
used	O
as	O
the	O
starting	O
material	O
to	O
create	O
amplified	O
RNA	O
(	O
aRNA	O
)	O
indirectly	O
labeled	O
with	O
Cy3	O
or	O
Cy5	O
fluorescent	O
dyes	O
(	O
GE	O
Healthcare	O
,	O
Buckinghamshire	O
,	O
UK	O
)	O
using	O
the	O
Amino	O
Allyl	O
MessageAmp	O
™	O
II	O
aRNA	O
Amplification	O
kit	O
according	O
to	O
manufacturer	O
instructions	O
(	O
Ambion	O
,	O
Austin	O
,	O
TX	O
)	O
.	O

Microarray	O
hybridization	O
and	O
data	O
analysis	O
Salmonid	O
cDNA	O
microarrays	O
(	O
GRASP16k	O
v2.0	O
)	O
were	O
obtained	O
from	O
consortium	O
for	O
Genomic	O
Research	O
on	O
Atlantic	O
Salmon	O
(	O
cGRASP	O
)	O
and	O
details	O
of	O
microarray	O
development	O
and	O
fabrication	O
can	O
be	O
found	O
in	O
von	O
Schalburg	O
et	O
al.	O
[	O
69	O
]	O
.	O

These	O
arrays	O
contain	O
13,421	O
Atlantic	B
salmon	I
and	O
2,576	O
rainbow	B
trout	I
cDNA	O
features	O
and	O
have	O
been	O
successfully	O
used	O
for	O
several	O
previous	O
rainbow	B
trout	I
gene	O
expression	O
studies	O
[	O
70	O
-	O
73	O
]	O
.	O

For	O
each	O
rainbow	B
trout	I
strain	O
,	O
competitive	O
hybridization	O
was	O
conducted	O
on	O
every	O
array	O
using	O
equal	O
amounts	O
(	O
8	O
μg	O
)	O
of	O
differentially	O
labeled	O
aRNA	O
from	O
one	O
control	O
fish	O
and	O
one	O
exposed	O
fish	O
.	O

Four	O
biological	O
replicates	O
were	O
performed	O
for	O
each	O
experimental	O
condition	O
and	O
dye	O
-	O
sample	O
coupling	O
was	O
swapped	O
between	O
biological	O
replicates	O
in	O
a	O
balanced	O
block	O
design	O
.	O

Prehybridization	O
washes	O
for	O
all	O
microarrays	O
included	O
:	O
2	O
×	O
5	O
min	O
in	O
0.1	O
%	O
SDS	O
,	O
5	O
×	O
1	O
min	O
in	O
NANOpure	O
H2O	O
with	O
0.5	O
mM	O
dithiothreotol	O
,	O
1	O
min	O
in	O
near	O
boiling	O
nanopure	O
H2O	O
,	O
centrifugation	O
for	O
2	O
min	O
at	O
1500	O
RPM	O
.	O

To	O
reduce	O
background	O
,	O
the	O
microarrays	O
were	O
next	O
incubated	O
for	O
90	O
min	O
in	O
5	O
×	O
SSC	O
,	O
0.1	O
%	O
SDS	O
,	O
3	O
%	O
BSA	O
(	O
Fraction	O
V	O
)	O
at	O
49	O
°	O
C	O
,	O
washed	O
3	O
×	O
20	O
s	O
in	O
nanopure	O
H2O	O
,	O
and	O
dried	O
by	O
centrifugation	O
for	O
5	O
min	O
at	O
1500	O
RPM	O
.	O

The	O
labeled	O
aRNA	O
samples	O
were	O
competitively	O
hybridized	O
to	O
microarrays	O
prewarmed	O
to	O
49	O
°	O
C	O
for	O
16	O
hours	O
in	O
a	O
formamide	O
-	O
based	O
buffer	O
(	O
Genisphere	O
,	O
Hatfield	O
,	O
PA	O
)	O
with	O
LNA	O
dT	O
blocker	O
(	O
Genisphere	O
)	O
.	O

Posthybridization	O
washes	O
for	O
all	O
microarrays	O
included	O
:	O
1	O
×	O
10	O
min	O
in	O
2	O
×	O
SSC	O
,	O
0.1	O
%	O
SDS	O
prewarmed	O
to	O
49	O
°	O
C	O
,	O
2	O
×	O
5	O
min	O
in	O
2	O
×	O
SSC	O
,	O
0.1	O
%	O
SDS	O
at	O
room	O
temperature	O
,	O
2	O
×	O
5	O
min	O
1	O
×	O
SSC	O
at	O
room	O
temperature	O
,	O
2	O
×	O
5	O
min	O
0.1	O
×	O
SSC	O
at	O
room	O
temperature	O
.	O

Slides	O
were	O
then	O
dried	O
by	O
centrifugation	O
and	O
immediately	O
scanned	O
using	O
an	O
Agilent	O
G2565BA	O
Microarray	O
Scanner	O
(	O
Agilent	O
Technologies	O
,	O
Santa	O
Clara	O
,	O
CA	O
)	O
.	O

Data	O
underwent	O
local	O
background	O
subtraction	O
and	O
LOWESS	O
normalization	O
using	O
Agilent	O
's	O
Feature	O
Extraction	O
software	O
.	O

Raw	O
and	O
processed	O
gene	O
expression	O
data	O
have	O
been	O
deposited	O
into	O
the	O
NCBI	O
Gene	O
Expression	O
Omnibus	O
[	O
74	O
]	O
(	O
series	O
GSE8631	O
)	O
and	O
are	O
in	O
compliance	O
with	O
MIAME	O
guidelines	O
.	O

The	O
Significance	O
Analysis	O
of	O
Microarrays	O
(	O
SAM	O
)	O
software	O
package	O
[	O
75	O
]	O
was	O
used	O
to	O
identify	O
differentially	O
expressed	O
genes	O
between	O
exposed	O
and	O
unexposed	O
control	O
fish	O
for	O
each	O
rainbow	B
trout	I
strain	O
.	O

Both	O
a	O
Wilcoxon	O
rank	O
sum	O
and	O
a	O
modified	O
t	O
-	O
test	O
were	O
conducted	O
with	O
1,000	O
permutations	O
and	O
the	O
minimum	O
fold	O
change	O
cut	O
-	O
off	O
was	O
set	O
to	O
2.0	O
up-	O
or	O
down	O
-	O
regulated	O
.	O

A	O
false	O
discovery	O
rate	O
(	O
FDR	O
)	O
of	O
0.00	O
%	O
was	O
estimated	O
for	O
both	O
strains	O
.	O

To	O
determine	O
statistically	O
significant	O
differences	O
between	O
the	O
Hofer	O
and	O
Trout	O
Lodge	O
strains	O
,	O
a	O
Welch	O
's	O
t	O
-	O
test	O
(	O
P	O
-	O
value	O
<	O
0.01	O
)	O
was	O
implemented	O
in	O
Microsoft	O
Excel	O
between	O
the	O
log	O
ratios	O
(	O
exposed	O
/	O
control	O
)	O
for	O
each	O
strain	O
for	O
all	O
genes	O
that	O
were	O
significant	O
for	O
at	O
least	O
one	O
strain	O
in	O
the	O
SAM	O
program	O
.	O

Quantitative	O
RT	O
-	O
PCR	O
Microarray	O
expression	O
results	O
were	O
validated	O
by	O
qRT	O
-	O
PCR	O
for	O
several	O
identified	O
genes	O
.	O

Prior	O
to	O
qRT	O
-	O
PCR	O
,	O
80	O
ng	O
of	O
total	O
RNA	O
was	O
reverse	O
transcribed	O
from	O
each	O
biological	O
replicate	O
used	O
for	O
the	O
microarray	O
study	O
along	O
with	O
two	O
additional	O
samples	O
(	O
total	O
n	O
=	O
6	O
per	O
experimental	O
condition	O
)	O
using	O
the	O
QuantiScript	O
Reverse	O
Transcriptase	O
kit	O
(	O
Qiagen	O
,	O
Valencia	O
,	O
CA	O
)	O
according	O
to	O
manufacturer	O
instructions	O
.	O

In	O
contrast	O
to	O
the	O
microarray	O
experiments	O
,	O
the	O
template	O
RNA	O
was	O
not	O
amplified	O
before	O
cDNA	O
synthesis	O
.	O

EST	O
clone	O
sequences	O
from	O
the	O
cGRASP	O
microarray	O
were	O
used	O
to	O
design	O
primers	O
for	O
genes	O
undergoing	O
validation	O
,	O
along	O
with	O
a	O
β	O
-	O
actin	O
reference	O
gene	O
used	O
for	O
normalization	O
,	O
with	O
Primer3	O
software	O
[	O
76	O
]	O
and	O
the	O
sequence	O
for	O
each	O
primer	O
pair	O
is	O
shown	O
in	O
Table	O
3	O
.	O

The	O
Quantitect	O
™	O
SYBR	O
®	O
Green	O
RT	O
-	O
PCR	O
kit	O
(	O
Qiagen	O
)	O
was	O
used	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
except	O
the	O
final	O
PCR	O
volume	O
was	O
reduced	O
to	O
25	O
μl	O
.	O

The	O
PCR	O
conditions	O
used	O
on	O
a	O
Chromo4	O
Real	O
Time	O
PCR	O
Detection	O
System	O
(	O
Bio	O
-	O
Rad	O
,	O
Hercules	O
,	O
CA	O
)	O
were	O
as	O
follows	O
:	O
HotStarTaq	O
DNA	O
polymerase	O
activation	O
at	O
95	O
°	O
C	O
for	O
15	O
min	O
,	O
45	O
cycles	O
of	O
15	O
s	O
denaturation	O
at	O
94	O
°	O
C	O
,	O
30	O
s	O
annealing	O
at	O
58	O
°	O
C	O
,	O
30	O
s	O
extension	O
at	O
72	O
°	O
C	O
,	O
followed	O
by	O
a	O
melting	O
curve	O
to	O
ensure	O
that	O
a	O
single	O
PCR	O
product	O
was	O
produced	O
for	O
each	O
reaction	O
.	O

For	O
each	O
gene	O
,	O
the	O
relative	O
amount	O
of	O
gene	O
expression	O
was	O
calculated	O
using	O
the	O
ΔΔCT	O
method	O
[	O
77	O
]	O
and	O
significance	O
was	O
determined	O
using	O
a	O
nonparametric	O
Mann	O
-	O
Whitney	O
U	O
test	O
and	O
multiple	O
linear	O
regression	O
in	O
JMP	O
.	O

Authors	O
'	O
contributions	O
MRB	O
participated	O
in	O
study	O
conception	O
and	O
design	O
,	O
conducted	O
gene	O
expression	O
experiments	O
and	O
data	O
analysis	O
,	O
and	O
drafted	O
the	O
manuscript	O
.	O

ABW	O
participated	O
in	O
study	O
design	O
,	O
data	O
analysis	O
,	O
and	O
manuscript	O
revision	O
.	O

RPH	O
and	O
BPM	O
participated	O
in	O
study	O
conception	O
and	O
design	O
,	O
supervision	O
of	O
research	O
activities	O
,	O
and	O
manuscript	O
revision	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Port	O
site	O
herniation	O
of	O
the	O
small	O
bowel	O
following	O
laparoscopy	O
-	O
assisted	O
distal	O
gastrectomy	O
:	O
a	O
case	O
report	O
Abstract	O
Introduction	O
Port	O
-	O
site	O
herniation	O
is	O
a	O
rare	O
but	O
potentially	O
dangerous	O
complication	O
after	O
laparoscopic	O
surgery	O
.	O

Closure	O
of	O
port	O
sites	O
,	O
especially	O
those	O
measuring	O
10	O
mm	O
or	O
more	O
,	O
has	O
been	O
recommended	O
to	O
avoid	O
such	O
an	O
event	O
.	O

Case	O
presentation	O
We	O
herein	O
report	O
the	O
only	O
case	O
of	O
a	O
port	O
site	O
hernia	O
among	O
a	O
series	O
52	O
consecutive	O
cases	O
of	O
laparoscopy	O
-	O
assisted	O
distal	O
gastrectomy	O
(	O
LADG	O
)	O
carried	O
out	O
by	O
our	O
unit	O
between	O
July	O
2002	O
and	O
March	O
2007	O
.	O

In	O
this	O
case	O
the	O
small	O
bowel	O
herniated	O
and	O
incarcerated	O
through	O
the	O
port	O
site	O
on	O
day	O
4	O
after	O
LADG	O
despite	O
closure	O
of	O
the	O
fascia	O
.	O

Initial	O
manifestations	O
experienced	O
by	O
the	O
patient	O
,	O
possibly	O
due	O
to	O
obstruction	O
,	O
and	O
including	O
mild	O
abdominal	O
pain	O
and	O
nausea	O
,	O
occurred	O
on	O
the	O
third	O
day	O
postoperatively	O
.	O

The	O
definitive	O
diagnosis	O
was	O
made	O
on	O
day	O
4	O
based	O
on	O
symptoms	O
related	O
to	O
leakage	O
from	O
the	O
duodenal	O
stump	O
,	O
which	O
was	O
considered	O
to	O
have	O
developed	O
after	O
severe	O
obstruction	O
of	O
the	O
bowel	O
.	O

Re	O
-	O
operation	O
for	O
reduction	O
of	O
the	O
incarcerated	O
bowel	O
and	O
tube	O
duodenostomy	O
with	O
peritoneal	O
drainage	O
were	O
required	O
to	O
manage	O
this	O
complication	O
.	O

Conclusion	O
We	O
present	O
this	O
case	O
report	O
and	O
review	O
of	O
literature	O
to	O
discuss	O
further	O
regarding	O
methods	O
of	O
fascial	O
closure	O
after	O
laparoscopic	O
surgery	O
.	O

Introduction	O
Bowel	O
herniation	O
through	O
the	O
fascial	O
defect	O
created	O
by	O
the	O
entry	O
of	O
trocars	O
is	O
now	O
recognized	O
as	O
a	O
rare	O
but	O
potentially	O
serious	O
complication	O
of	O
laparoscopic	O
surgery	O
[	O
1	O
]	O
.	O

Although	O
port	O
site	O
herniation	O
is	O
an	O
infrequent	O
complication	O
,	O
there	O
are	O
still	O
some	O
reports	O
of	O
port	O
site	O
herniation	O
after	O
these	O
procedures	O
,	O
even	O
with	O
closure	O
of	O
trocar	O
sites	O
[	O
1,2	O
]	O
.	O

The	O
following	O
report	O
describes	O
a	O
case	O
of	O
a	O
trocar	O
site	O
hernia	O
that	O
evolved	O
into	O
leakage	O
from	O
the	O
duodenal	O
stump	O
after	O
laparoscopy	O
-	O
assisted	O
distal	O
gastrectomy	O
(	O
LADG	O
)	O
.	O

Progression	O
occurred	O
because	O
of	O
complete	O
obstruction	O
of	O
the	O
incarcerated	O
bowel	O
after	O
a	O
Roux	O
-	O
en	O
-	O
Y	O
reconstruction	O
.	O

We	O
describe	O
the	O
significance	O
of	O
complete	O
closure	O
of	O
the	O
fascial	O
defect	O
at	O
the	O
trocar	O
site	O
including	O
the	O
peritoneum	O
in	O
the	O
prevention	O
of	O
this	O
condition	O
,	O
as	O
well	O
as	O
the	O
importance	O
of	O
early	O
diagnosis	O
to	O
avoid	O
serious	O
subsequent	O
events	O
.	O

Case	O
presentation	O
An	O
80-year	O
-	O
old	O
man	B
was	O
found	O
to	O
have	O
early	O
gastric	O
cancer	O
during	O
his	O
yearly	O
check	O
-	O
up	O
by	O
gastrointestinal	O
endoscopy	O
.	O

He	O
was	O
158	O
cm	O
in	O
height	O
and	O
weighed	O
62	O
kg	O
.	O

Gastrointestinal	O
endoscopy	O
showed	O
a	O
depressed	O
lesion	O
that	O
was	O
diagnosed	O
as	O
early	O
gastric	O
cancer	O
by	O
pathological	O
examination	O
of	O
biopsy	O
specimens	O
.	O

He	O
underwent	O
LADG	O
with	O
regional	O
lymph	O
node	O
dissection	O
(	O
D1	O
including	O
the	O
nodes	O
surrounding	O
the	O
origin	O
of	O
left	O
gastric	O
artery	O
)	O
.	O

A	O
12-mm	O
trocar	O
for	O
the	O
laparoscope	O
was	O
placed	O
in	O
the	O
umbilicus	O
.	O

Pneumoperitoneum	O
was	O
then	O
established	O
with	O
carbon	O
dioxide	O
and	O
the	O
intraperitoneal	O
pressure	O
was	O
maintained	O
at	O
10	O
mm	O
Hg	O
.	O

Two	O
more	O
12-mm	O
trocars	O
were	O
inserted	O
in	O
the	O
midclavicular	O
line	O
below	O
the	O
costal	O
margin	O
and	O
2	O
cm	O
above	O
the	O
umbilicus	O
on	O
each	O
of	O
both	O
flanks	O
and	O
were	O
used	O
for	O
active	O
surgical	O
instruments	O
.	O

All	O
trocars	O
used	O
were	O
the	O
non	O
-	O
bladed	O
type	O
.	O

The	O
specimen	O
was	O
removed	O
through	O
a	O
small	O
medial	O
incision	O
which	O
was	O
55	O
mm	O
in	O
length	O
placed	O
after	O
resection	O
of	O
the	O
stomach	O
,	O
and	O
then	O
Roux	O
-	O
en	O
-	O
Y	O
reconstruction	O
(	O
RY	O
)	O
was	O
carried	O
out	O
(	O
Fig.	O
1	O
)	O
.	O

A	O
tubular	O
shaped	O
drainage	O
tube	O
10	O
mm	O
in	O
diameter	O
was	O
inserted	O
and	O
placed	O
through	O
the	O
upper	O
trocar	O
site	O
made	O
on	O
the	O
right	O
flank	O
.	O

Wound	O
defect	O
at	O
the	O
umbilical	O
port	O
site	O
was	O
sutured	O
completely	O
including	O
the	O
peritoneum	O
with	O
0	O
absorbable	O
suture	O
and	O
fascial	O
incisions	O
at	O
all	O
other	O
trocar	O
insertion	O
sites	O
were	O
closed	O
with	O
2	O
-	O
0	O
absorbable	O
sutures	O
.	O

Surgical	O
duration	O
was	O
263	O
min	O
,	O
and	O
the	O
volume	O
of	O
blood	O
loss	O
was	O
less	O
than	O
50	O
mL	O
with	O
no	O
blood	O
transfusion	O
.	O

Postoperatively	O
,	O
the	O
patient	O
complained	O
of	O
an	O
acidic	O
feeling	O
in	O
his	O
stomach	O
;	O
however	O
,	O
there	O
were	O
no	O
remarkable	O
abnormalities	O
on	O
biochemical	O
examination	O
of	O
serum	O
.	O

Radiological	O
findings	O
did	O
not	O
suggest	O
bowel	O
obstruction	O
until	O
3	O
days	O
postoperatively	O
,	O
although	O
mild	O
symptoms	O
such	O
as	O
general	O
malaise	O
and	O
vague	O
abdominal	O
pain	O
were	O
reported	O
on	O
day	O
three	O
.	O

However	O
,	O
on	O
day	O
4	O
,	O
the	O
patient	O
started	O
to	O
complain	O
of	O
upper	O
abdominal	O
pain	O
and	O
developed	O
a	O
high	O
grade	O
fever	O
(	O
38	O
°	O
C	O
)	O
.	O

Complete	O
obstruction	O
of	O
the	O
small	O
bowel	O
and	O
leakage	O
of	O
contrast	O
media	O
were	O
demonstrated	O
by	O
Gastrografin	O
swallow	O
and	O
subsequent	O
abdominal	O
computed	O
tomography	O
(	O
CT	O
)	O
.	O

CT	O
also	O
showed	O
a	O
mass	O
lesion	O
at	O
the	O
trocar	O
insertion	O
site	O
on	O
the	O
upper	O
left	O
flank	O
,	O
suggesting	O
herniation	O
through	O
the	O
port	O
site	O
(	O
Fig.	O
2	O
)	O
.	O

Marked	O
dilatation	O
of	O
the	O
duodenum	O
including	O
the	O
horizontal	O
part	O
and	O
second	O
portion	O
was	O
observed	O
.	O

A	O
diagnosis	O
of	O
staple	O
failure	O
of	O
the	O
stump	O
of	O
the	O
duodenum	O
and	O
port	O
-	O
site	O
herniation	O
of	O
the	O
small	O
bowel	O
was	O
made	O
,	O
and	O
exploratory	O
laparotomy	O
was	O
carried	O
out	O
.	O

A	O
small	O
medial	O
incision	O
that	O
had	O
been	O
made	O
at	O
the	O
initial	O
surgery	O
was	O
extended	O
downward	O
to	O
the	O
umbilicus	O
to	O
open	O
the	O
peritoneal	O
cavity	O
.	O

As	O
we	O
expected	O
,	O
the	O
small	O
bowel	O
was	O
incarcerated	O
into	O
the	O
peritoneal	O
defect	O
in	O
the	O
abdominal	O
wall	O
created	O
by	O
the	O
trocar	O
placed	O
in	O
the	O
left	O
upper	O
flank	O
leading	O
to	O
complete	O
obstruction	O
of	O
the	O
bowel	O
(	O
Fig.	O
3	O
)	O
.	O

Part	O
of	O
the	O
jejunum	O
30	O
cm	O
distal	O
from	O
the	O
ligament	O
of	O
Treitz	O
herniated	O
around	O
the	O
fascial	O
stitch	O
,	O
which	O
still	O
existed	O
at	O
the	O
time	O
of	O
the	O
re	O
-	O
exploration	O
.	O

The	O
peritoneal	O
cavity	O
was	O
contaminated	O
with	O
intestinal	O
juice	O
.	O

Close	O
examination	O
after	O
reduction	O
of	O
the	O
incarcerated	O
bowel	O
did	O
not	O
demonstrate	O
necrosis	O
of	O
the	O
intestine	O
,	O
and	O
thus	O
,	O
we	O
decided	O
not	O
to	O
resect	O
this	O
lesion	O
.	O

Leakage	O
of	O
intestinal	O
juice	O
through	O
a	O
pinhole	O
fistula	O
at	O
the	O
duodenal	O
stump	O
was	O
also	O
observed	O
.	O

Tube	O
duodenostomy	O
was	O
performed	O
with	O
an	O
omental	O
patch	O
used	O
for	O
closure	O
of	O
the	O
fistula	O
.	O

The	O
peritoneal	O
defect	O
was	O
also	O
closed	O
.	O

The	O
postoperative	O
course	O
was	O
fairly	O
good	O
without	O
high	O
output	O
of	O
the	O
intestinal	O
juice	O
leakage	O
or	O
sepsis	O
.	O

The	O
patient	O
remained	O
in	O
the	O
intensive	O
care	O
unit	O
for	O
5	O
days	O
after	O
re	O
-	O
operation	O
,	O
and	O
was	O
then	O
transferred	O
to	O
the	O
general	O
ward	O
.	O

Discussion	O
Port	O
-	O
site	O
herniation	O
,	O
which	O
is	O
one	O
of	O
the	O
major	O
complications	O
after	O
laparoscopic	O
procedures	O
[	O
1	O
]	O
,	O
sometimes	O
develops	O
into	O
serious	O
complications	O
,	O
such	O
as	O
bowel	O
obstruction	O
due	O
to	O
incarceration	O
into	O
the	O
fascial	O
defect	O
at	O
the	O
port	O
site	O
.	O

Boughey	O
et	O
al.	O
have	O
reported	O
four	O
cases	O
of	O
Richter	O
's	O
hernia	O
that	O
occurred	O
at	O
a	O
port	O
site	O
after	O
laparoscopic	O
surgery	O
[	O
1	O
]	O
.	O

They	O
reviewed	O
previous	O
reports	O
and	O
found	O
the	O
incidence	O
to	O
be	O
0.2	O
to	O
3	O
%	O
.	O

A	O
report	O
describes	O
the	O
incidence	O
of	O
hernia	O
as	O
0.23	O
%	O
for	O
10-mm	O
trocar	O
use	O
,	O
rising	O
to	O
3.1	O
%	O
for	O
the	O
12-mm	O
trocar	O
[	O
2	O
]	O
suggesting	O
that	O
the	O
wound	O
created	O
by	O
a	O
larger	O
port	O
carries	O
a	O
greater	O
risk	O
of	O
herniation	O
.	O

Most	O
surgeons	O
now	O
routinely	O
close	O
the	O
fascia	O
of	O
port	O
sites	O
to	O
prevent	O
this	O
complication	O
[	O
2	O
]	O
.	O

According	O
to	O
previous	O
reports	O
,	O
port	O
site	O
herniation	O
apparently	O
happens	O
more	O
often	O
with	O
the	O
use	O
of	O
bladed	O
type	O
trocars	O
than	O
non	O
-	O
bladed	O
type	O
trocars	O
[	O
3	O
]	O
.	O

Indeed	O
,	O
Kolata	O
demonstrated	O
that	O
the	O
wounds	O
made	O
by	O
the	O
non	O
-	O
bladed	O
trocar	O
were	O
narrower	O
than	O
those	O
created	O
by	O
cutting	O
tip	O
trocars	O
in	O
a	O
pig	B
experimental	O
model	O
[	O
4	O
]	O
.	O

Several	O
reports	O
even	O
concluded	O
that	O
port	O
sites	O
created	O
by	O
non	O
-	O
bladed	O
trocars	O
do	O
not	O
require	O
fascial	O
closure	O
[	O
3	O
]	O
.	O

However	O
,	O
the	O
current	O
case	O
suggests	O
that	O
thick	O
preperitoneum	O
is	O
a	O
potential	O
space	O
that	O
allows	O
for	O
the	O
development	O
of	O
bowel	O
herniation	O
even	O
with	O
the	O
use	O
of	O
non	O
-	O
bladed	O
type	O
trocars	O
.	O

A	O
previous	O
report	O
also	O
described	O
port	O
-	O
site	O
herniation	O
,	O
despite	O
the	O
closure	O
of	O
the	O
superficial	O
layer	O
of	O
the	O
fascial	O
defect	O
[	O
5	O
]	O
.	O

The	O
current	O
case	O
did	O
not	O
demonstrate	O
any	O
of	O
the	O
risk	O
factors	O
suggested	O
previously	O
[	O
6	O
]	O
;	O
1	O
)	O
enlargement	O
of	O
a	O
port	O
site	O
to	O
remove	O
specimen	O
;	O
2	O
)	O
glucose	O
intolerance	O
;	O
3	O
)	O
obesity	O
;	O
or	O
4	O
)	O
extensive	O
manipulation	O
of	O
the	O
trocar	O
during	O
relatively	O
prolonged	O
surgical	O
duration	O
,	O
which	O
might	O
have	O
enlarged	O
the	O
trocar	O
site	O
and	O
thus	O
induced	O
bowel	O
herniation	O
.	O

Therefore	O
,	O
we	O
recommend	O
closing	O
the	O
fascial	O
defect	O
,	O
including	O
the	O
peritoneum	O
,	O
especially	O
if	O
the	O
trocar	O
size	O
is	O
more	O
than	O
10-mm	O
and	O
in	O
the	O
presence	O
of	O
any	O
of	O
the	O
risk	O
factors	O
described	O
above	O
.	O

However	O
,	O
it	O
is	O
sometimes	O
difficult	O
to	O
completely	O
close	O
the	O
defect	O
,	O
including	O
the	O
peritoneum	O
,	O
especially	O
in	O
obese	O
patients	O
.	O

Shaher	O
reviewed	O
different	O
wound	O
closure	O
techniques	O
by	O
a	O
literature	O
search	O
[	O
7	O
]	O
.	O

In	O
this	O
review	O
,	O
old	O
methods	O
using	O
classical	O
instruments	O
including	O
Deschamps	O
needle	O
are	O
also	O
useful	O
as	O
well	O
as	O
special	O
wound	O
devices	O
designed	O
for	O
port	O
site	O
closure	O
.	O

Elashry	O
et	O
al.	O
described	O
a	O
prospective	O
randomized	O
study	O
demonstrating	O
that	O
the	O
Carter	O
-	O
Thomason	O
device	O
was	O
faster	O
and	O
resulted	O
in	O
fewer	O
port	O
-	O
closure	O
-	O
related	O
complications	O
among	O
eight	O
different	O
techniques	O
tested	O
[	O
8	O
]	O
.	O

Insertion	O
of	O
a	O
SURGICEL	O
plug	O
into	O
the	O
muscular	O
layer	O
of	O
trocar	O
wounds	O
has	O
also	O
been	O
proposed	O
by	O
Chiu	O
et	O
al	O
[	O
9	O
]	O
.	O

Alternatively	O
,	O
tangential	O
insertion	O
of	O
a	O
trocar	O
through	O
the	O
abdominal	O
wall	O
might	O
be	O
effective	O
in	O
reducing	O
the	O
size	O
of	O
fascial	O
defects	O
.	O

Moreover	O
,	O
recent	O
publications	O
have	O
demonstrated	O
that	O
radially	O
expanding	O
type	O
trocars	O
could	O
be	O
useful	O
to	O
avoid	O
the	O
necessity	O
of	O
closing	O
the	O
fascial	O
defect	O
[	O
10	O
]	O
.	O

Symptoms	O
of	O
trocar	O
-	O
site	O
herniation	O
vary	O
depending	O
on	O
the	O
severity	O
of	O
bowel	O
obstruction	O
.	O

Mild	O
symptoms	O
such	O
as	O
slight	O
nausea	O
and	O
vague	O
abdominal	O
pain	O
,	O
both	O
of	O
which	O
are	O
most	O
frequently	O
seen	O
in	O
the	O
early	O
normal	O
postoperative	O
course	O
after	O
abdominal	O
surgery	O
,	O
could	O
be	O
the	O
first	O
and	O
only	O
complaints	O
at	O
the	O
early	O
stage	O
of	O
this	O
complication	O
.	O

Thus	O
,	O
the	O
diagnosis	O
may	O
be	O
delayed	O
.	O

In	O
our	O
case	O
,	O
mild	O
abdominal	O
pain	O
with	O
general	O
malaise	O
might	O
have	O
been	O
symptoms	O
related	O
to	O
the	O
early	O
stage	O
of	O
the	O
onset	O
.	O

Abdominal	O
CT	O
showing	O
the	O
enlarged	O
duodenum	O
also	O
suggested	O
that	O
leakage	O
from	O
the	O
duodenal	O
stump	O
occurred	O
due	O
to	O
the	O
obstruction	O
of	O
the	O
distal	O
bowel	O
.	O

Thus	O
,	O
severe	O
complication	O
might	O
have	O
been	O
avoided	O
,	O
if	O
early	O
diagnosis	O
had	O
been	O
made	O
.	O

Although	O
the	O
benefit	O
of	O
Roux	O
-	O
en	O
-	O
Y	O
is	O
apparent	O
[	O
11	O
]	O
,	O
the	O
duodenal	O
stump	O
could	O
be	O
vulnerable	O
to	O
leakage	O
due	O
to	O
increased	O
intrabowel	O
pressure	O
.	O

Therefore	O
,	O
careful	O
management	O
of	O
the	O
postoperative	O
course	O
is	O
warranted	O
,	O
especially	O
after	O
procedures	O
involving	O
division	O
of	O
the	O
bowel	O
such	O
as	O
LADG	O
.	O

Moreover	O
,	O
special	O
attention	O
should	O
be	O
paid	O
in	O
patients	O
with	O
risk	O
factors	O
for	O
port	O
site	O
hernia	O
such	O
as	O
obesity	O
,	O
aggressive	O
manipulation	O
through	O
the	O
port	O
sites	O
,	O
and	O
prolonged	O
surgery	O
.	O

Conclusion	O
Port	O
-	O
site	O
herniation	O
is	O
a	O
potentially	O
dangerous	O
complication	O
after	O
laparoscopic	O
procedures	O
.	O

Careful	O
management	O
of	O
the	O
postoperative	O
course	O
is	O
recommended	O
especially	O
for	O
patients	O
with	O
risk	O
factors	O
such	O
as	O
obesity	O
and	O
extensive	O
manipulation	O
of	O
the	O
trocar	O
during	O
prolonged	O
surgical	O
duration	O
.	O

Competing	O
interests	O
The	O
author	O
(	O
s	O
)	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O
TI	O
,	O
NF	O
,	O
HT	O
and	O
TK	O
performed	O
the	O
first	O
and	O
second	O
operation	O
.	O

TI	O
and	O
KK	O
were	O
responsible	O
for	O
the	O
postoperative	O
management	O
.	O

TI	O
,	O
HT	O
,	O
TW	O
,	O
and	O
KN	O
were	O
involved	O
in	O
editing	O
the	O
manuscript	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Consent	O
Written	O
informed	O
consent	O
was	O
obtained	O
from	O
the	O
patient	O
for	O
publication	O
of	O
this	O
case	O
report	O
and	O
any	O
accompanying	O
images	O
.	O

A	O
copy	O
of	O
the	O
written	O
consent	O
is	O
available	O
for	O
review	O
by	O
the	O
Editor	O
-	O
in	O
-	O
Chief	O
of	O
this	O
journal	O
.	O

Borrelia	B
burgdorferi	I
membranes	O
are	O
the	O
primary	O
targets	O
of	O
reactive	O
oxygen	O
species	O
Abstract	O
Spirochetes	O
living	O
in	O
an	O
oxygen	O
-	O
rich	O
environment	O
or	O
when	O
challenged	O
by	O
host	O
immune	O
cells	O
are	O
exposed	O
to	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
.	O

These	O
species	O
can	O
harm	O
/	O
destroy	O
cysteinyl	O
residues	O
,	O
iron	O
-	O
sulphur	O
clusters	O
,	O
DNA	O
and	O
polyunsaturated	O
lipids	O
,	O
leading	O
to	O
inhibition	O
of	O
growth	O
or	O
cell	O
death	O
.	O

Because	O
Borrelia	B
burgdorferi	I
contains	O
no	O
intracellular	O
iron	O
,	O
DNA	O
is	O
most	O
likely	O
not	O
a	O
major	O
target	O
for	O
ROS	O
via	O
Fenton	O
reaction	O
.	O

In	O
support	O
of	O
this	O
,	O
growth	O
of	O
B.	B
burgdorferi	I
in	O
the	O
presence	O
of	O
5	O
mM	O
H2O2	O
had	O
no	O
effect	O
on	O
the	O
DNA	O
mutation	O
rate	O
(	O
spontaneous	O
coumermycin	O
A1	O
resistance	O
)	O
,	O
and	O
cells	O
treated	O
with	O
10	O
mM	O
t	O
-	O
butyl	O
hydroperoxide	O
or	O
10	O
mM	O
H2O2	O
show	O
no	O
increase	O
in	O
DNA	O
damage	O
.	O

Unlike	O
most	O
bacteria	O
,	O
B.	B
burgdorferi	I
incorporates	O
ROS	O
-	O
susceptible	O
polyunsaturated	O
fatty	O
acids	O
from	O
the	O
environment	O
into	O
their	O
membranes	O
.	O

Analysis	O
of	O
lipoxidase	O
-	O
treated	O
B.	B
burgdorferi	I
cells	O
by	O
Electron	O
Microscopy	O
showed	O
significant	O
irregularities	O
indicative	O
of	O
membrane	O
damage	O
.	O

Fatty	O
acid	O
analysis	O
of	O
cells	O
treated	O
with	O
lipoxidase	O
indicated	O
that	O
host	O
-	O
derived	O
linoleic	O
acid	O
had	O
been	O
dramatically	O
reduced	O
(	O
50-fold	O
)	O
in	O
these	O
cells	O
,	O
with	O
a	O
corresponding	O
increase	O
in	O
the	O
levels	O
of	O
malondialdehyde	O
by	O
-	O
product	O
(	O
fourfold	O
)	O
.	O

These	O
data	O
suggest	O
that	O
B.	B
burgdorferi	I
membrane	O
lipids	O
are	O
targets	O
for	O
attack	O
by	O
ROS	O
encountered	O
in	O
the	O
various	O
stages	O
of	O
the	O
infective	O
cycle	O
.	O

Introduction	O
Borrelia	B
burgdorferi	I
,	O
the	O
causative	O
agent	O
of	O
Lyme	O
disease	O
,	O
survives	O
and	O
proliferates	O
in	O
distinctly	O
different	O
niches	O
,	O
including	O
its	O
arthropod	O
vector	O
and	O
various	O
mammalian	O
hosts	O
.	O

These	O
'	O
micro	O
'	O
environments	O
provide	O
their	O
own	O
distinct	O
sets	O
of	O
advantages	O
and	O
challenges	O
to	O
B.	B
burgdorferi	I
.	O

For	O
example	O
,	O
during	O
the	O
initial	O
stages	O
of	O
infection	O
of	O
the	O
mammalian	O
host	O
,	O
immune	O
cells	O
attempt	O
to	O
prevent	O
B.	B
burgdorferi	I
from	O
establishing	O
an	O
infection	O
using	O
several	O
systems	O
including	O
those	O
generating	O
bacteriocidal	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
[	O
e.g.	O
superoxide	O
radicals	O
(	O
O2-	O
)	O
,	O
hydrogen	O
peroxide	O
(	O
H2O2	O
)	O
and	O
hydroxyl	O
radicals	O
(	O
OH	O
)	O
]	O
and	O
reactive	O
nitrogen	O
species	O
(	O
RNS	O
)	O
[	O
e.g.	O
nitric	O
oxide	O
(	O
NO	O
)	O
and	O
peroxynitrite	O
]	O
(	O
Storz	O
and	O
Imlay	O
,	O
1999	O
)	O
.	O

In	O
order	O
for	O
B.	B
burgdorferi	I
to	O
successfully	O
colonize	O
a	O
new	O
host	O
and	O
cause	O
disease	O
,	O
they	O
must	O
overcome	O
the	O
challenges	O
posed	O
by	O
the	O
innate	O
immune	O
system	O
including	O
the	O
deleterious	O
effects	O
of	O
ROS	O
/	O
RNS	O
compounds	O
.	O

The	O
effects	O
of	O
ROS	O
/	O
RNS	O
on	O
cells	O
have	O
been	O
extensively	O
investigated	O
.	O

These	O
highly	O
reactive	O
compounds	O
have	O
been	O
shown	O
to	O
damage	O
cellular	O
macromolecules	O
including	O
DNA	O
,	O
proteins	O
and	O
cellular	O
membranes	O
.	O

The	O
damage	O
to	O
membranes	O
can	O
arise	O
through	O
either	O
lipid	O
or	O
membrane	O
protein	O
damage	O
.	O

In	O
eukaryotes	O
,	O
membrane	O
lipids	O
are	O
a	O
major	O
target	O
of	O
ROS	O
.	O

Free	O
radicals	O
attack	O
polyunsaturated	O
fatty	O
acids	O
in	O
membranes	O
and	O
initiate	O
lipid	O
peroxidation	O
.	O

A	O
primary	O
effect	O
of	O
this	O
is	O
a	O
decrease	O
in	O
membrane	O
fluidity	O
which	O
affects	O
the	O
physical	O
properties	O
of	O
the	O
membrane	O
altering	O
the	O
function	O
of	O
membrane	O
-	O
associated	O
proteins	O
.	O

Once	O
lipid	O
peroxides	O
form	O
,	O
they	O
react	O
with	O
adjacent	O
polyunsaturated	O
lipids	O
causing	O
an	O
amplification	O
of	O
the	O
damage	O
.	O

Lipid	O
peroxides	O
undergo	O
further	O
oxidation	O
to	O
a	O
variety	O
of	O
products	O
,	O
including	O
aldehydes	O
,	O
which	O
subsequently	O
react	O
with	O
and	O
damage	O
membrane	O
proteins	O
.	O

However	O
,	O
in	O
bacteria	O
,	O
it	O
is	O
assumed	O
that	O
lipids	O
are	O
not	O
subject	O
to	O
the	O
oxidative	O
damage	O
observed	O
in	O
eukaryotic	O
cells	O
.	O

Only	O
certain	O
polyunsaturated	O
lipids	O
,	O
such	O
as	O
linoleic	O
acid	O
and	O
linolenic	O
acid	O
,	O
are	O
susceptible	O
to	O
oxidation	O
(	O
Gutteridge	O
and	O
Halliwell	O
,	O
1990	O
)	O
,	O
and	O
it	O
is	O
clear	O
that	O
most	O
bacteria	O
do	O
not	O
synthesize	O
or	O
incorporate	O
these	O
types	O
of	O
lipids	O
in	O
their	O
cell	O
membrane	O
.	O

Two	O
notable	O
exceptions	O
are	O
the	O
photosynthetic	O
bacteria	O
which	O
synthesize	O
and	O
incorporate	O
significant	O
levels	O
of	O
linoleic	O
acid	O
in	O
their	O
membrane	O
(	O
Tasaka	O
et	O
al.	O
,	O
1996	O
)	O
and	O
Helicobacter	B
pylori	I
membranes	O
which	O
contain	O
between	O
0.5	O
%	O
and	O
3	O
%	O
linoleic	O
acid	O
(	O
Ursini	O
and	O
Bindoli	O
,	O
1987	O
)	O
.	O

Instead	O
,	O
it	O
has	O
been	O
shown	O
that	O
the	O
most	O
damaging	O
effects	O
of	O
ROS	O
in	O
bacteria	O
result	O
from	O
the	O
interactions	O
of	O
H2O2	O
with	O
'	O
free	O
'	O
Fe2	O
+	O
(	O
Imlay	O
,	O
2003	O
)	O
,	O
generating	O
very	O
reactive	O
OH	O
(	O
Fenton	O
reaction	O
)	O
.	O

Because	O
of	O
this	O
reactivity	O
,	O
the	O
effect	O
on	O
any	O
given	O
biomolecule	O
will	O
depend	O
largely	O
upon	O
proximity	O
to	O
the	O
target	O
.	O

Because	O
Fe2	O
+	O
localizes	O
along	O
the	O
phosphodiester	O
backbone	O
of	O
nucleic	O
acid	O
,	O
DNA	O
is	O
a	O
major	O
target	O
of	O
OH	O
.	O

This	O
reactive	O
species	O
can	O
pull	O
electrons	O
from	O
either	O
the	O
base	O
or	O
sugar	O
moieties	O
,	O
producing	O
a	O
variety	O
of	O
lesions	O
including	O
single-	O
and	O
double	O
-	O
stranded	O
breaks	O
in	O
the	O
backbone	O
and	O
chemical	O
cross	O
-	O
links	O
to	O
other	O
molecules	O
.	O

These	O
strand	O
breaks	O
and	O
other	O
lesions	O
block	O
DNA	O
replication	O
and	O
contribute	O
to	O
OH	O
toxicity	O
and	O
cell	O
death	O
.	O

Other	O
base	O
damage	O
,	O
which	O
does	O
not	O
hinder	O
replication	O
,	O
may	O
result	O
in	O
a	O
significant	O
increase	O
in	O
mutation	O
rates	O
.	O

The	O
intracellular	O
biochemistry	O
of	O
B.	B
burgdorferi	I
suggests	O
that	O
the	O
primary	O
cellular	O
target	O
of	O
ROS	O
may	O
be	O
distinct	O
from	O
that	O
described	O
in	O
other	O
bacteria	O
such	O
as	O
Escherichia	B
coli	I
.	O

In	O
E.	B
coli	I
,	O
the	O
extent	O
of	O
DNA	O
damage	O
due	O
to	O
H2O2	O
and	O
Fenton	O
chemistry	O
is	O
directly	O
proportional	O
to	O
Fe	O
metabolism	O
and	O
the	O
free	O
Fe	O
concentration	O
within	O
the	O
cell	O
(	O
10	O
µM	O
)	O
(	O
Keyer	O
and	O
Imlay	O
,	O
1996	O
)	O
.	O

As	O
the	O
intracellular	O
Fe	O
concentrations	O
of	O
B.	B
burgdorferi	I
are	O
estimated	O
to	O
be	O
<	O
10	O
atoms	O
per	O
cell	O
(	O
Posey	O
and	O
Gherardini	O
,	O
2000	O
)	O
,	O
it	O
seems	O
unlikely	O
that	O
DNA	O
is	O
a	O
primary	O
target	O
for	O
ROS	O
.	O

Therefore	O
,	O
the	O
purpose	O
of	O
this	O
study	O
is	O
to	O
determine	O
the	O
biochemical	O
effects	O
of	O
ROS	O
on	O
B.	B
burgdorferi	I
,	O
including	O
growth	O
effects	O
and	O
biological	O
/	O
physical	O
damage	O
.	O

Results	O
Effect	O
of	O
ROS	O
on	O
B.	B
burgdorferi	I
cells	O
In	O
order	O
to	O
determine	O
what	O
the	O
cellular	O
targets	O
of	O
ROS	O
in	O
B.	B
burgdorferi	I
are	O
,	O
we	O
first	O
needed	O
to	O
determine	O
the	O
sensitivity	O
of	O
Borrelia	O
cells	O
to	O
various	O
oxidants	O
.	O

Microaerobic	O
cultures	O
of	O
B.	B
burgdorferi	I
strain	O
B31A3	O
were	O
grown	O
to	O
a	O
cell	O
density	O
of	O
5	O
×	O
107	O
cells	O
ml−1	O
,	O
treated	O
with	O
varying	O
concentrations	O
of	O
H2O2	O
(	O
0–50	O
mM	O
)	O
or	O
t	O
-	O
butyl	O
hydroperoxide	O
(	O
0–50	O
mM	O
)	O
and	O
the	O
number	O
of	O
surviving	O
cells	O
determined	O
by	O
plating	O
.	O

The	O
results	O
are	O
shown	O
in	O
Fig.	O
1	O
.	O

When	O
cells	O
were	O
exposed	O
to	O
10	O
mM	O
t	O
-	O
butyl	O
hydroperoxide	O
,	O
approximately	O
50	O
%	O
of	O
the	O
cells	O
survive	O
(	O
Fig.	O
1A	O
)	O
.	O

In	O
contrast	O
,	O
when	O
E.	B
coli	I
cells	O
were	O
exposed	O
to	O
1	O
mM	O
t	O
-	O
butyl	O
hydroperoxide	O
,	O
approximately	O
1	O
%	O
of	O
the	O
cells	O
survive	O
.	O

B.	B
burgdorferi	I
cells	O
were	O
much	O
more	O
resistant	O
to	O
t	O
-	O
butyl	O
hydroperoxide	O
than	O
E.	B
coli	I
cells	O
,	O
with	O
a	O
survival	O
rate	O
of	O
approximately	O
100	O
%	O
at	O
1	O
mM	O
t	O
-	O
butyl	O
hydroperoxide	O
.	O

This	O
trend	O
was	O
observed	O
when	O
cells	O
were	O
exposed	O
to	O
H2O2	O
.	O

E.	B
coli	I
cells	O
exposed	O
to	O
1	O
mM	O
H2O2	O
have	O
approximately	O
10	O
%	O
survivability	O
,	O
while	O
100	O
%	O
of	O
the	O
B.	B
burgdorferi	I
cells	O
survive	O
at	O
this	O
concentration	O
,	O
and	O
approximately	O
80	O
%	O
survive	O
when	O
exposed	O
to	O
10	O
mM	O
H2O2	O
(	O
Fig.	O
1B	O
)	O
.	O

Similar	O
results	O
were	O
obtained	O
when	O
cells	O
were	O
exposed	O
in	O
HN	O
(	O
Hepes	O
-	O
NaCl	O
)	O
buffer	O
,	O
suggesting	O
that	O
the	O
high	O
-	O
level	O
resistance	O
to	O
ROS	O
was	O
not	O
due	O
to	O
the	O
interaction	O
of	O
ROS	O
with	O
components	O
of	O
Barbour	O
-	O
Stoenner	O
-	O
Kelly	O
(	O
BSK	O
-	O
II	O
)	O
growth	O
medium	O
.	O

Taken	O
together	O
,	O
these	O
data	O
indicated	O
that	O
B.	B
burgdorferi	I
strain	O
B31A3	O
was	O
highly	O
resistant	O
to	O
exposure	O
to	O
both	O
t	O
-	O
butyl	O
peroxide	O
and	O
H2O2	O
.	O

Borrelia	B
burgdorferi	I
DNA	O
is	O
not	O
the	O
primary	O
target	O
of	O
ROS	O
For	O
most	O
bacteria	O
,	O
DNA	O
is	O
the	O
major	O
target	O
of	O
ROS	O
causing	O
a	O
wide	O
variety	O
of	O
DNA	O
lesions	O
.	O

This	O
is	O
in	O
part	O
due	O
to	O
the	O
localization	O
of	O
'	O
free	O
'	O
Fe2	O
+	O
along	O
the	O
phosphodiester	O
backbone	O
of	O
nucleic	O
acids	O
,	O
putting	O
the	O
DNA	O
in	O
close	O
proximity	O
to	O
the	O
active	O
species	O
formed	O
via	O
the	O
Fenton	O
reaction	O
.	O

However	O
,	O
B.	B
burgdorferi	I
has	O
been	O
shown	O
to	O
harbour	O
few	O
genes	O
encoding	O
orthologues	O
of	O
known	O
iron	O
-	O
containing	O
proteins	O
,	O
does	O
not	O
require	O
Fe	O
for	O
growth	O
and	O
has	O
intracellular	O
Fe	O
concentrations	O
estimated	O
to	O
be	O
<	O
10	O
atoms	O
per	O
cell	O
(	O
Posey	O
and	O
Gherardini	O
,	O
2000	O
)	O
.	O

Taken	O
together	O
,	O
these	O
observations	O
strongly	O
suggest	O
that	O
B.	B
burgdorferi	I
DNA	O
is	O
not	O
a	O
major	O
target	O
for	O
ROS	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
different	O
techniques	O
were	O
used	O
to	O
measure	O
DNA	O
damage	O
in	O
B.	B
burgdorferi	I
cells	O
after	O
exposure	O
to	O
ROS	O
.	O

One	O
reliable	O
indicator	O
of	O
DNA	O
damage	O
by	O
ROS	O
in	O
a	O
cell	O
is	O
an	O
increase	O
in	O
the	O
spontaneous	O
mutation	O
rate	O
.	O

In	O
B.	B
burgdorferi	I
,	O
mutations	O
that	O
confer	O
resistance	O
to	O
coumermycin	O
A1	O
,	O
which	O
targets	O
the	O
β	O
subunit	O
of	O
DNA	O
gyrase	O
,	O
have	O
been	O
mapped	O
to	O
gyrB	O
,	O
the	O
gene	O
encoding	O
DNA	O
gyrase	O
B	O
(	O
Samuels	O
et	O
al.	O
,	O
1994	O
)	O
.	O

In	O
each	O
case	O
,	O
a	O
single	O
point	O
mutation	O
correlated	O
with	O
this	O
drug	O
resistance	O
.	O

To	O
determine	O
if	O
exposure	O
to	O
oxidants	O
increases	O
DNA	O
damage	O
by	O
increasing	O
point	O
mutations	O
,	O
B.	B
burgdorferi	I
B31A3	O
cells	O
grown	O
under	O
microaerobic	O
conditions	O
were	O
treated	O
with	O
5	O
mM	O
H2O2	O
and	O
plated	O
in	O
the	O
presence	O
and	O
absence	O
of	O
250	O
ng	O
ml−1	O
coumermycin	O
A1	O
.	O

The	O
mutation	O
frequency	O
was	O
calculated	O
as	O
the	O
number	O
of	O
colonies	O
that	O
are	O
CouR	O
per	O
total	O
number	O
of	O
cells	O
plated	O
.	O

The	O
spontaneous	O
resistance	O
frequency	O
of	O
treated	O
cells	O
was	O
approximately	O
equivalent	O
to	O
that	O
of	O
untreated	O
cells	O
,	O
8.8	O
×	O
10−8	O
and	O
1.33	O
×	O
10−7	O
,	O
respectively	O
,	O
indicating	O
no	O
increase	O
in	O
the	O
number	O
of	O
point	O
mutations	O
(	O
Fig.	O
2A	O
)	O
.	O

Also	O
,	O
no	O
increase	O
in	O
point	O
mutations	O
was	O
observed	O
when	O
cells	O
were	O
treated	O
with	O
higher	O
concentrations	O
of	O
H2O2	O
(	O
10	O
mM	O
)	O
or	O
when	O
treated	O
with	O
t	O
-	O
butyl	O
hydroperoxide	O
(	O
5	O
and	O
10	O
mM	O
)	O
(	O
data	O
not	O
shown	O
)	O
.	O

Another	O
effective	O
way	O
to	O
determine	O
DNA	O
damage	O
is	O
by	O
measuring	O
the	O
number	O
of	O
apurinic	O
/	O
apyrimidinic	O
sites	O
(	O
AP	O
)	O
.	O

AP	O
sites	O
in	O
DNA	O
,	O
where	O
the	O
DNA	O
base	O
is	O
lost	O
,	O
can	O
be	O
generated	O
spontaneously	O
under	O
physiological	O
conditions	O
by	O
hydrolysis	O
of	O
the	O
N	O
-	O
glycosylic	O
bond	O
,	O
or	O
can	O
also	O
be	O
formed	O
by	O
DNA	O
-	O
damaging	O
agents	O
(	O
Lindahl	O
and	O
Nyberg	O
,	O
1972	O
)	O
,	O
such	O
as	O
UV	O
,	O
alkylating	O
agents	O
or	O
OH	O
.	O

They	O
are	O
also	O
intermediates	O
in	O
the	O
base	O
excision	O
repair	O
pathway	O
(	O
BER	O
)	O
(	O
Weiss	O
and	O
Grossman	O
,	O
1987	O
;	O
Friedberg	O
and	O
Hanawalt	O
,	O
1988	O
;	O
Wallace	O
,	O
1988	O
)	O
.	O

Thus	O
,	O
the	O
cellular	O
steady	O
state	O
level	O
of	O
AP	O
sites	O
would	O
increase	O
as	O
a	O
consequence	O
of	O
base	O
modifications	O
and	O
their	O
subsequent	O
repair	O
.	O

As	O
AP	O
sites	O
are	O
bypassed	O
inefficiently	O
by	O
DNA	O
polymerase	O
in	O
bacterial	O
cells	O
,	O
DNA	O
lesions	O
can	O
result	O
in	O
a	O
significant	O
block	O
in	O
DNA	O
replication	O
.	O

Therefore	O
,	O
the	O
number	O
of	O
AP	O
sites	O
can	O
serve	O
as	O
a	O
sensitive	O
indicator	O
of	O
DNA	O
damage	O
resulting	O
from	O
oxidative	O
stress	O
(	O
Kubo	O
et	O
al.	O
,	O
1992	O
)	O
.	O

To	O
determine	O
whether	O
ROS	O
can	O
damage	O
B.	B
burgdorferi	I
DNA	O
,	O
strain	O
B31A3	O
cells	O
grown	O
under	O
microaerobic	O
conditions	O
were	O
treated	O
with	O
H2O2	O
(	O
1	O
or	O
10	O
mM	O
)	O
,	O
t	O
-	O
butyl	O
hydroperoxide	O
(	O
1	O
or	O
10	O
mM	O
)	O
or	O
lipoxidase	O
(	O
an	O
enzyme	O
which	O
specifically	O
catalyses	O
the	O
hydroperoxidation	O
of	O
lipids	O
containing	O
a	O
cis	O
,	O
cis	O
-	O
pentadiene	O
structure	O
,	O
such	O
as	O
linoleic	O
acid	O
)	O
.	O

The	O
DNA	O
was	O
isolated	O
and	O
assayed	O
for	O
AP	O
sites	O
.	O

The	O
results	O
are	O
shown	O
in	O
Fig.	O
2B	O
.	O

In	O
all	O
cases	O
,	O
the	O
numbers	O
of	O
AP	O
sites	O
per	O
105	O
bp	O
DNA	O
were	O
equivalent	O
,	O
indicating	O
that	O
the	O
addition	O
of	O
oxidants	O
did	O
not	O
increase	O
the	O
number	O
of	O
DNA	O
base	O
lesions	O
.	O

In	O
contrast	O
,	O
when	O
E.	B
coli	I
strain	O
TA4315	O
cells	O
(	O
ahpCF	O
)	O
(	O
Storz	O
et	O
al.	O
,	O
1989	O
)	O
were	O
treated	O
with	O
100	O
µM	O
H2O2	O
,	O
the	O
number	O
of	O
AP	O
sites	O
increased	O
∼10-fold	O
over	O
untreated	O
cells	O
.	O

These	O
data	O
suggest	O
that	O
B.	B
burgdorferi	I
DNA	O
was	O
not	O
a	O
major	O
target	O
for	O
oxidative	O
damage	O
under	O
these	O
conditions	O
.	O

It	O
is	O
of	O
note	O
to	O
mention	O
that	O
the	O
total	O
number	O
of	O
AP	O
sites	O
per	O
105	O
bp	O
DNA	O
is	O
approximately	O
10-fold	O
higher	O
in	O
untreated	O
Borrelia	O
B31A3	O
DNA	O
than	O
in	O
untreated	O
E.	B
coli	I
DNA	O
.	O

The	O
Borrelia	O
genome	O
consists	O
of	O
a	O
linear	O
chromosome	O
and	O
multiple	O
linear	O
and	O
circular	O
plasmids	O
.	O

Numerous	O
observations	O
indicate	O
that	O
functional	O
telomeres	O
require	O
interaction	O
with	O
DNA	O
damage	O
repair	O
proteins	O
,	O
suggesting	O
that	O
the	O
DNA	O
damage	O
repair	O
machinery	O
,	O
including	O
the	O
BER	O
,	O
is	O
involved	O
in	O
replication	O
of	O
telomeres	O
and	O
protection	O
of	O
functional	O
chromosome	O
ends	O
(	O
Verdun	O
and	O
Karlseder	O
,	O
2007	O
)	O
.	O

An	O
important	O
intermediate	O
in	O
BER	O
is	O
the	O
apurinic	O
or	O
abasic	O
site	O
.	O

Therefore	O
,	O
it	O
was	O
possible	O
that	O
the	O
higher	O
numbers	O
of	O
AP	O
sites	O
in	O
untreated	O
Borrelia	O
DNA	O
was	O
due	O
to	O
the	O
number	O
of	O
telomeres	O
present	O
in	O
the	O
genome	O
.	O

The	O
B.	B
burgdorferi	I
strain	O
B31A3	O
harbours	O
11	O
linear	O
plasmids	O
and	O
a	O
linear	O
chromosome	O
with	O
∼100	O
unpaired	O
bases	O
in	O
the	O
telomere	O
loops	O
per	O
genome	O
or	O
10	O
bases	O
per	O
105	O
bp	O
DNA	O
(	O
Hinnebusch	O
and	O
Barbour	O
,	O
1991	O
;	O
Chaconas	O
,	O
2005	O
)	O
.	O

Untreated	O
Borrelia	O
B31A3	O
contains	O
11	O
±	O
3.8	O
AP	O
sites	O
per	O
105	O
bp	O
DNA	O
,	O
suggesting	O
that	O
the	O
elevated	O
number	O
of	O
AP	O
sites	O
in	O
Borrelia	O
was	O
due	O
to	O
the	O
number	O
of	O
telomeres	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
the	O
AP	O
sites	O
were	O
measured	O
in	O
DNA	O
isolated	O
from	O
untreated	O
B.	B
burgdorferi	I
strain	O
B314	O
which	O
harbours	O
no	O
linear	O
plasmids	O
(	O
Sadziene	O
et	O
al.	O
,	O
1993	O
)	O
.	O

The	O
number	O
of	O
unpaired	O
bases	O
in	O
the	O
telomere	O
loops	O
per	O
genome	O
was	O
estimated	O
to	O
be	O
10	O
,	O
which	O
corresponds	O
to	O
1	O
base	O
per	O
105	O
bp	O
DNA	O
,	O
and	O
only	O
3.6	O
±	O
0.2	O
AP	O
sites	O
per	O
105	O
bp	O
DNA	O
were	O
detected	O
,	O
supporting	O
the	O
hypothesis	O
that	O
the	O
high	O
number	O
of	O
AP	O
sites	O
in	O
untreated	O
Borrelia	O
DNA	O
was	O
due	O
to	O
the	O
number	O
of	O
unpaired	O
bases	O
in	O
the	O
telomeres	O
.	O

The	O
analyses	O
of	O
the	O
AP	O
sites	O
strongly	O
suggested	O
that	O
B.	B
burgdorferi	I
DNA	O
was	O
not	O
the	O
major	O
target	O
for	O
oxidative	O
damage	O
.	O

In	O
addition	O
to	O
the	O
generation	O
of	O
abasic	O
sites	O
,	O
oxygen	O
radicals	O
often	O
damage	O
DNA	O
through	O
the	O
formation	O
of	O
8-oxoguanine	O
lesions	O
(	O
Nakamura	O
et	O
al.	O
,	O
2000	O
)	O
.	O

8-Oxoguanine	O
,	O
through	O
its	O
ability	O
to	O
mispair	O
with	O
bases	O
other	O
than	O
cytosine	O
,	O
likely	O
plays	O
a	O
role	O
in	O
DNA	O
mutagenesis	O
.	O

Consequently	O
,	O
8-oxoguanine	O
is	O
often	O
used	O
as	O
a	O
marker	O
of	O
oxidized	O
DNA	O
damage	O
.	O

To	O
determine	O
whether	O
ROS	O
can	O
damage	O
B.	B
burgdorferi	I
DNA	O
and	O
cause	O
8-oxoguanine	O
lesions	O
,	O
strain	O
B31A3	O
cells	O
grown	O
under	O
microaerobic	O
conditions	O
were	O
treated	O
with	O
H2O2	O
(	O
5	O
or	O
10	O
mM	O
)	O
,	O
t	O
-	O
butyl	O
hydroperoxide	O
(	O
5	O
or	O
10	O
mM	O
)	O
or	O
lipoxidase	O
.	O

The	O
DNA	O
was	O
isolated	O
and	O
assayed	O
for	O
8-oxoguanine	O
using	O
an	O
Enzyme	O
-	O
Linked	O
ImmunoSorbent	O
Assay	O
.	O

The	O
results	O
are	O
shown	O
in	O
Fig.	O
2C	O
.	O

In	O
all	O
cases	O
,	O
the	O
amount	O
of	O
8-oxoguanine	O
in	O
Borrelia	O
cells	O
was	O
below	O
the	O
detection	O
limit	O
of	O
the	O
assay	O
.	O

In	O
contrast	O
,	O
when	O
a	O
MutM	O
(	O
the	O
specific	O
glycosylase	O
that	O
removes	O
the	O
8-oxoguanine	O
)	O
-deficient	O
E.	B
coli	I
strain	O
was	O
treated	O
with	O
100	O
µM	O
H2O2	O
,	O
the	O
amount	O
of	O
8-oxoguanine	O
sites	O
increased	O
∼fivefold	O
over	O
untreated	O
cells	O
.	O

It	O
is	O
important	O
to	O
point	O
out	O
that	O
no	O
MutM	O
homologue	O
has	O
been	O
identified	O
in	O
the	O
genome	O
of	O
B.	B
burgdorferi	I
.	O

Taken	O
together	O
,	O
these	O
data	O
suggested	O
that	O
B.	B
burgdorferi	I
DNA	O
was	O
not	O
a	O
major	O
target	O
for	O
oxidative	O
damage	O
under	O
these	O
conditions	O
.	O

The	O
membranes	O
of	O
B.	B
burgdorferi	I
are	O
targeted	O
during	O
oxidative	O
stress	O
In	O
eukaryotes	O
,	O
membrane	O
lipids	O
are	O
a	O
major	O
target	O
of	O
ROS	O
.	O

Free	O
radicals	O
can	O
attack	O
polyunsaturated	O
fatty	O
acids	O
,	O
such	O
as	O
linoleic	O
acid	O
and	O
linolenic	O
acid	O
,	O
in	O
membranes	O
and	O
initiate	O
lipid	O
peroxidation	O
.	O

This	O
reaction	O
can	O
cascade	O
throughout	O
the	O
membrane	O
to	O
adjacent	O
polyunsaturated	O
fatty	O
acids	O
,	O
decreasing	O
membrane	O
fluidity	O
and	O
generating	O
more	O
toxic	O
products	O
such	O
as	O
aldehydes	O
(	O
Imlay	O
,	O
2003	O
)	O
.	O

Because	O
most	O
bacterial	O
membranes	O
contain	O
saturated	O
and	O
monounsaturated	O
fatty	O
acids	O
rather	O
than	O
'	O
reactive	O
'	O
polyunsaturated	O
lipids	O
,	O
peroxidation	O
of	O
lipids	O
in	O
bacterial	O
membranes	O
is	O
not	O
considered	O
a	O
problem	O
.	O

As	O
B.	B
burgdorferi	I
can	O
not	O
synthesize	O
their	O
own	O
lipids	O
,	O
they	O
must	O
instead	O
scavenge	O
them	O
.	O

Therefore	O
,	O
it	O
seems	O
likely	O
that	O
their	O
membrane	O
composition	O
would	O
reflect	O
the	O
host	O
's	O
lipid	O
profile	O
or	O
that	O
of	O
their	O
growth	O
medium	O
(	O
Barbour	O
,	O
1984	O
;	O
Fraser	O
et	O
al.	O
,	O
1997	O
)	O
and	O
would	O
contain	O
some	O
polyunsaturated	O
fatty	O
acids	O
.	O

To	O
determine	O
if	O
B.	B
burgdorferi	I
contains	O
polyunsaturated	O
lipids	O
,	O
B.	B
burgdorferi	I
strain	O
B31A3	O
was	O
grown	O
under	O
anaerobic	O
conditions	O
and	O
analysed	O
for	O
fatty	O
acid	O
composition	O
by	O
Lipid	O
Technologies	O
(	O
Austin	O
,	O
MN	O
)	O
.	O

The	O
results	O
are	O
shown	O
in	O
Table	O
1	O
and	O
are	O
reported	O
as	O
percentage	O
of	O
total	O
fatty	O
acid	O
content	O
.	O

Linoleic	O
acid	O
comprised	O
∼10	O
%	O
of	O
the	O
total	O
lipid	O
content	O
and	O
the	O
linolenic	O
acid	O
content	O
was	O
measured	O
to	O
be	O
∼1	O
%	O
,	O
indicating	O
that	O
Borrelia	O
cells	O
do	O
contain	O
lipids	O
that	O
are	O
susceptible	O
to	O
ROS	O
damage	O
.	O

The	O
amount	O
of	O
linoleic	O
acid	O
and	O
linolenic	O
acid	O
present	O
in	O
Borrelia	O
reflected	O
the	O
amount	O
present	O
in	O
the	O
media	O
.	O

Therefore	O
,	O
these	O
results	O
suggested	O
that	O
the	O
amount	O
of	O
these	O
fatty	O
acids	O
in	O
the	O
membranes	O
would	O
vary	O
as	O
availability	O
varies	O
.	O

To	O
determine	O
if	O
Borrelia	O
polyunsaturated	O
lipids	O
can	O
undergo	O
lipid	O
peroxidation	O
,	O
B.	B
burgdorferi	I
B31A3	O
cells	O
grown	O
microaerobically	O
were	O
treated	O
with	O
1	O
mM	O
t	O
-	O
butyl	O
hydroperoxide	O
or	O
250	O
mg	O
of	O
lipoxidase	O
,	O
and	O
the	O
cell	O
pellets	O
were	O
analysed	O
for	O
fatty	O
acid	O
composition	O
(	O
Industrial	O
Laboratory	O
)	O
.	O

The	O
results	O
are	O
shown	O
in	O
Table	O
2	O
and	O
are	O
reported	O
as	O
the	O
percentage	O
of	O
total	O
cell	O
mass	O
.	O

The	O
per	O
cent	O
of	O
linoleic	O
acid	O
in	O
the	O
total	O
cell	O
mass	O
decreased	O
with	O
treatment	O
,	O
while	O
the	O
levels	O
of	O
oleic	O
acid	O
(	O
c18:1n9	O
)	O
and	O
pentadecanoic	O
acid	O
(	O
c15:0	O
)	O
remained	O
relatively	O
constant	O
.	O

Untreated	O
cells	O
contained	O
0.04	O
%	O
linoleic	O
acid	O
,	O
while	O
cells	O
treated	O
with	O
t	O
-	O
butyl	O
hydroperoxide	O
contained	O
10-fold	O
less	O
(	O
0.004	O
%	O
)	O
linoleic	O
acid	O
and	O
cells	O
treated	O
with	O
lipoxidase	O
had	O
no	O
detectable	O
linoleic	O
acid	O
present	O
in	O
the	O
sample	O
.	O

These	O
data	O
indicated	O
that	O
the	O
linoleic	O
acid	O
present	O
in	O
B.	B
burgdorferi	I
membranes	O
can	O
be	O
oxidized	O
by	O
ROS	O
.	O

Malondialdehyde	O
(	O
MDA	O
)	O
is	O
generated	O
as	O
a	O
relatively	O
stable	O
end	O
-	O
product	O
from	O
the	O
oxidative	O
degradation	O
of	O
polyunsaturated	O
fatty	O
acids	O
.	O

MDA	O
has	O
thus	O
been	O
used	O
as	O
an	O
indicator	O
of	O
lipid	O
peroxidation	O
(	O
Gutteridge	O
and	O
Halliwell	O
,	O
1990	O
;	O
Esterbauer	O
et	O
al.	O
,	O
1991	O
)	O
.	O

To	O
further	O
demonstrate	O
that	O
Borrelia	O
lipids	O
can	O
undergo	O
lipid	O
peroxidation	O
,	O
B31A3	O
cells	O
grown	O
microaerobically	O
were	O
treated	O
with	O
5	O
mM	O
AAPH	O
(	O
free	O
radical	O
generator	O
)	O
or	O
250	O
mg	O
of	O
lipoxidase	O
and	O
MDA	O
measured	O
(	O
Seljeskog	O
et	O
al.	O
,	O
2006	O
)	O
.	O

The	O
results	O
are	O
shown	O
in	O
Fig.	O
3	O
.	O

Untreated	O
cells	O
contained	O
∼16.5	O
µM	O
of	O
MDA	O
per	O
mg	O
of	O
protein	O
.	O

When	O
the	O
cells	O
were	O
treated	O
with	O
AAPH	O
or	O
lipoxidase	O
,	O
the	O
amount	O
of	O
MDA	O
increased	O
∼1.5-fold	O
(	O
27.3	O
µM	O
of	O
MDA	O
per	O
mg	O
of	O
protein	O
)	O
and	O
approximately	O
twofold	O
(	O
33	O
µM	O
of	O
MDA	O
per	O
mg	O
of	O
protein	O
)	O
respectively	O
(	O
Fig.	O
3A	O
)	O
.	O

As	O
a	O
control	O
,	O
eukaryotic	O
cells	O
(	O
mouse	B
myeloma	O
cells	O
SP2	O
)	O
were	O
treated	O
with	O
AAPH	O
and	O
MDA	O
measured	O
(	O
Fig.	O
3B	O
)	O
.	O

Mouse	B
myeloma	O
cells	O
have	O
been	O
used	O
as	O
a	O
model	O
system	O
for	O
the	O
determination	O
of	O
phospholipid	O
hydroperoxides	O
(	O
Chotimarkorn	O
et	O
al.	O
,	O
2005	O
)	O
.	O

In	O
this	O
case	O
,	O
the	O
amount	O
of	O
MDA	O
increased	O
approximately	O
threefold	O
(	O
36.3	O
µM	O
of	O
MDA	O
per	O
mg	O
of	O
protein	O
)	O
in	O
the	O
treated	O
cells	O
versus	O
untreated	O
cells	O
(	O
11.7	O
µM	O
of	O
MDA	O
per	O
mg	O
of	O
protein	O
)	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggested	O
that	O
,	O
like	O
eukaryotic	O
membranes	O
,	O
Borrelia	O
membrane	O
lipids	O
were	O
capable	O
of	O
undergoing	O
lipid	O
peroxidation	O
.	O

As	O
shown	O
in	O
Fig.	O
3A	O
,	O
there	O
is	O
a	O
measurable	O
quantity	O
of	O
MDA	O
present	O
even	O
in	O
untreated	O
cells	O
,	O
suggesting	O
that	O
the	O
membrane	O
lipids	O
are	O
damaged	O
without	O
the	O
addition	O
of	O
exogenous	O
ROS	O
.	O

Oxidative	O
damage	O
is	O
an	O
unavoidable	O
by	O
-	O
product	O
of	O
growth	O
in	O
an	O
oxygen	O
environment	O
because	O
superoxide	O
anions	O
and	O
H2O2	O
are	O
formed	O
whenever	O
molecular	O
oxygen	O
chemically	O
oxidizes	O
electron	O
carriers	O
.	O

To	O
determine	O
if	O
the	O
Borrelia	O
lipids	O
are	O
damaged	O
from	O
growth	O
in	O
an	O
oxygen	O
environment	O
,	O
B.	B
burgdorferi	I
B31A3	O
cells	O
were	O
grown	O
under	O
anaerobic	O
,	O
microaerobic	O
and	O
aerobic	O
conditions	O
and	O
MDA	O
measured	O
.	O

Figure	O
3C	O
demonstrates	O
that	O
as	O
the	O
oxygen	O
concentration	O
increased	O
,	O
the	O
amount	O
of	O
MDA	O
increased	O
.	O

Cells	O
grown	O
under	O
anaerobic	O
conditions	O
contained	O
the	O
lowest	O
amount	O
of	O
MDA	O
(	O
7.6	O
µM	O
of	O
MDA	O
per	O
mg	O
of	O
protein	O
)	O
,	O
approximately	O
twofold	O
less	O
than	O
the	O
measured	O
amount	O
in	O
microaerobic	O
cells	O
(	O
16.5	O
µM	O
of	O
MDA	O
per	O
mg	O
of	O
protein	O
)	O
.	O

Aerobically	O
grown	O
cells	O
contained	O
the	O
highest	O
amount	O
of	O
MDA	O
,	O
∼1.5-fold	O
greater	O
than	O
that	O
observed	O
in	O
microaerobic	O
cells	O
(	O
28.8	O
µM	O
of	O
MDA	O
per	O
mg	O
of	O
protein	O
)	O
and	O
∼3.7-fold	O
greater	O
than	O
that	O
observed	O
in	O
anaerobically	O
grown	O
cells	O
.	O

These	O
data	O
suggested	O
that	O
Borrelia	O
lipids	O
can	O
be	O
damaged	O
during	O
aerobic	O
growth	O
.	O

Our	O
High	O
Performance	O
Liquid	O
Chromatography	O
analyses	O
of	O
the	O
MDA	O
present	O
in	O
anaerobically	O
grown	O
B.	B
burgdorferi	I
cells	O
showed	O
a	O
small	O
peak	O
with	O
a	O
retention	O
time	O
similar	O
to	O
that	O
of	O
the	O
MDA	O
standard	O
.	O

This	O
was	O
puzzling	O
as	O
little	O
or	O
no	O
lipid	O
peroxidation	O
should	O
occur	O
under	O
these	O
conditions	O
.	O

To	O
further	O
characterize	O
this	O
'	O
MDA	O
'	O
peak	O
,	O
a	O
three	O
-	O
dimensional	O
diode	O
array	O
spectra	O
was	O
generated	O
by	O
scanning	O
each	O
sample	O
during	O
the	O
elution	O
of	O
the	O
peak	O
(	O
Fig.	O
4	O
,	O
lower	O
sections	O
)	O
.	O

An	O
authentic	O
MDA	O
standard	O
was	O
also	O
scanned	O
as	O
a	O
control	O
(	O
Fig.	O
4A	O
,	O
lower	O
section	O
)	O
.	O

In	O
the	O
anaerobically	O
grown	O
cells	O
,	O
the	O
spectrum	O
shows	O
that	O
two	O
compounds	O
with	O
different	O
absorbance	O
maximums	O
(	O
Fig.	O
4B	O
,	O
lower	O
section	O
)	O
comprised	O
the	O
single	O
retention	O
time	O
peak	O
from	O
the	O
HPLC	O
chromatogram	O
(	O
Fig.	O
4B	O
,	O
upper	O
section	O
)	O
.	O

Based	O
on	O
this	O
spectrum	O
,	O
the	O
amount	O
of	O
actual	O
MDA	O
contributed	O
<	O
15	O
%	O
of	O
the	O
total	O
amount	O
of	O
material	O
detected	O
in	O
the	O
HPLC	O
peak	O
while	O
the	O
second	O
contaminating	O
peak	O
contributed	O
>	O
85	O
%	O
.	O

Therefore	O
,	O
the	O
amount	O
of	O
MDA	O
in	O
untreated	O
anaerobically	O
grown	O
cells	O
was	O
considerably	O
less	O
than	O
the	O
7.6	O
µM	O
of	O
MDA	O
per	O
mg	O
of	O
protein	O
actually	O
measured	O
.	O

However	O
,	O
in	O
cells	O
grown	O
under	O
microaerobic	O
conditions	O
,	O
the	O
MDA	O
peak	O
contributed	O
more	O
to	O
the	O
overall	O
retention	O
time	O
peak	O
when	O
compared	O
with	O
the	O
anaerobic	O
spectrum	O
,	O
while	O
the	O
second	O
contaminating	O
peak	O
stays	O
relatively	O
constant	O
(	O
Fig.	O
4C	O
,	O
lower	O
section	O
)	O
.	O

These	O
spectra	O
demonstrated	O
that	O
the	O
increase	O
in	O
the	O
MDA	O
retention	O
time	O
peak	O
between	O
anaerobically	O
and	O
aerobically	O
grown	O
cells	O
was	O
due	O
to	O
the	O
increase	O
in	O
the	O
amount	O
of	O
authentic	O
MDA	O
present	O
.	O

The	O
fluorescent	O
probe	O
diphenyl-1-pyrenylphophine	O
(	O
DPPP	O
)	O
has	O
been	O
used	O
for	O
detection	O
of	O
lipid	O
hydroperoxides	O
in	O
cell	O
membranes	O
(	O
Okimoto	O
et	O
al.	O
,	O
2000	O
;	O
Takahashi	O
et	O
al.	O
,	O
2001	O
)	O
.	O

In	O
this	O
method	O
,	O
the	O
hydroperoxides	O
are	O
reduced	O
with	O
DPPP	O
,	O
resulting	O
in	O
the	O
formation	O
of	O
the	O
fluorescent	O
arylphosphine	O
oxide	O
.	O

To	O
visualize	O
the	O
lipid	O
hydroperoxides	O
,	O
B.	B
burgdorferi	I
B31A3	O
cells	O
were	O
labelled	O
with	O
DPPP	O
and	O
observed	O
by	O
fluorescence	O
microscopy	O
(	O
Fig.	O
5B	O
)	O
.	O

E.	B
coli	I
Top10	O
cells	O
and	O
mouse	B
myeloma	O
SP2	O
cells	O
were	O
also	O
labelled	O
and	O
visualized	O
to	O
serve	O
as	O
negative	O
and	O
positive	O
controls	O
respectively	O
(	O
Fig.	O
5A	O
and	O
C	O
)	O
.	O

Red	O
Fluorescent	O
dye	O
was	O
used	O
to	O
visualize	O
the	O
cell	O
membranes	O
.	O

A	O
strong	O
fluorescence	O
of	O
DPPP	O
was	O
observed	O
for	O
B31A3	O
cells	O
(	O
Fig.	O
5B	O
)	O
and	O
for	O
the	O
mouse	B
myeloma	O
cells	O
(	O
Fig.	O
5C	O
)	O
,	O
but	O
not	O
for	O
the	O
E.	B
coli	I
cells	O
(	O
Fig.	O
5A	O
)	O
.	O

An	O
overlay	O
of	O
the	O
two	O
dyes	O
demonstrates	O
that	O
the	O
DPPP	O
fluorescence	O
of	O
both	O
the	O
Borrelia	O
and	O
myeloma	O
cells	O
corresponds	O
to	O
the	O
areas	O
of	O
red	O
fluorescence	O
.	O

This	O
indicated	O
that	O
lipid	O
hydroperoxides	O
were	O
present	O
on	O
the	O
Borrelia	O
cell	O
membranes	O
and	O
suggested	O
that	O
the	O
membranes	O
were	O
damaged	O
.	O

To	O
further	O
demonstrate	O
Borrelia	O
membrane	O
damage	O
,	O
B.	B
burgdorferi	I
B31A3	O
cells	O
were	O
grown	O
under	O
anaerobic	O
and	O
microaerobic	O
conditions	O
and	O
visualized	O
by	O
negative	O
stain	O
using	O
an	O
electron	O
microscope	O
.	O

Additionally	O
,	O
cells	O
grown	O
under	O
microaerobic	O
conditions	O
were	O
treated	O
with	O
250	O
mg	O
of	O
lipoxidase	O
and	O
visualized	O
by	O
Electron	O
Microscopy	O
.	O

Intact	O
membranes	O
were	O
observed	O
in	O
cultures	O
of	O
B31A3	O
grown	O
under	O
anaerobic	O
and	O
microaerobic	O
conditions	O
(	O
Fig.	O
6A	O
and	O
B	O
respectively	O
)	O
.	O

However	O
,	O
in	O
cultures	O
treated	O
with	O
lipoxidase	O
(	O
Fig.	O
6C	O
)	O
,	O
a	O
significant	O
number	O
of	O
membrane	O
blebs	O
were	O
seen	O
surrounding	O
the	O
spirochetes	O
,	O
indicating	O
membrane	O
damage	O
.	O

Taken	O
together	O
,	O
these	O
data	O
indicated	O
that	O
Borrelia	O
membranes	O
were	O
a	O
target	O
for	O
oxidative	O
stress	O
.	O

Discussion	O
Most	O
bacterial	O
pathogens	O
are	O
faced	O
with	O
the	O
challenge	O
of	O
overcoming	O
ROS	O
generated	O
by	O
the	O
host	O
immune	O
system	O
.	O

These	O
radicals	O
can	O
cause	O
a	O
great	O
deal	O
of	O
damage	O
to	O
biological	O
molecules	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

The	O
potential	O
cellular	O
targets	O
for	O
ROS	O
damage	O
in	O
bacteria	O
include	O
DNA	O
,	O
RNA	O
,	O
proteins	O
and	O
lipids	O
,	O
and	O
extensive	O
work	O
has	O
been	O
done	O
to	O
determine	O
the	O
cellular	O
targets	O
of	O
ROS	O
that	O
affect	O
bacterial	O
survival	O
.	O

To	O
date	O
,	O
the	O
most	O
definitive	O
work	O
has	O
been	O
done	O
on	O
E.	B
coli	I
.	O

It	O
seems	O
clear	O
from	O
several	O
studies	O
that	O
the	O
most	O
physiologically	O
relevant	O
target	O
of	O
ROS	O
in	O
E.	B
coli	I
is	O
DNA	O
.	O

The	O
exposure	O
to	O
µM	O
concentrations	O
of	O
ROS	O
(	O
i.e.	O
H2O2	O
)	O
is	O
sufficient	O
to	O
cause	O
DNA	O
damage	O
,	O
inhibit	O
DNA	O
replication	O
,	O
increase	O
the	O
mutation	O
rate	O
and	O
often	O
lead	O
to	O
cell	O
death	O
.	O

This	O
process	O
leading	O
to	O
DNA	O
damage	O
begins	O
with	O
formation	O
of	O
O2-	O
and	O
H2O2	O
from	O
the	O
oxidation	O
of	O
flavoproteins	O
and/or	O
the	O
diffusion	O
of	O
these	O
reactive	O
species	O
from	O
the	O
extracellular	O
milieu	O
.	O

The	O
subsequent	O
oxidation	O
of	O
Fe	O
-	O
S	O
proteins	O
by	O
ROS	O
(	O
e.g.	O
O2-	O
)	O
leads	O
to	O
an	O
increase	O
in	O
intracellular	O
'	O
free	O
'	O
Fe2	O
+	O
which	O
triggers	O
the	O
reduction	O
of	O
H2O2	O
to	O
OH	O
(	O
Fenton	O
reaction	O
)	O
.	O

The	O
highly	O
reactive	O
nature	O
of	O
OH	O
limits	O
its	O
diffusion	O
so	O
that	O
it	O
generally	O
reacts	O
with	O
molecules	O
in	O
close	O
proximity	O
to	O
its	O
origin	O
(	O
e.g.	O
the	O
Fe2	O
+	O
associated	O
with	O
DNA	O
)	O
.	O

In	O
DNA	O
,	O
OH	O
oxidizes	O
sugar	O
and	O
base	O
moieties	O
,	O
producing	O
radicals	O
which	O
ultimately	O
generate	O
lesions	O
,	O
including	O
base	O
modifications	O
,	O
strand	O
breaks	O
and	O
chemical	O
cross	O
-	O
links	O
to	O
other	O
molecules	O
.	O

Base	O
modifications	O
lead	O
to	O
mismatching	O
and	O
increased	O
mutation	O
frequencies	O
while	O
more	O
severe	O
damage	O
,	O
such	O
as	O
strand	O
breaks	O
,	O
prevents	O
DNA	O
replication	O
,	O
contributing	O
to	O
OH	O
toxicity	O
and	O
cell	O
death	O
.	O

Critical	O
to	O
this	O
chemical	O
process	O
in	O
vivo	O
is	O
the	O
presence	O
of	O
iron	O
.	O

No	O
other	O
metal	O
or	O
non	O
-	O
metal	O
electron	O
carrier	O
appears	O
to	O
be	O
able	O
to	O
univalently	O
reduce	O
H2O2	O
to	O
OH	O
in	O
vivo	O
(	O
Macomber	O
et	O
al.	O
,	O
2007	O
)	O
.	O

These	O
observations	O
are	O
critical	O
in	O
beginning	O
to	O
understand	O
the	O
oxidative	O
damage	O
/	O
targets	O
in	O
B.	B
burgdorferi	I
.	O

It	O
has	O
been	O
shown	O
in	O
E.	B
coli	I
that	O
the	O
free	O
-	O
iron	O
pool	O
size	O
determines	O
the	O
rate	O
of	O
oxidative	O
DNA	O
damage	O
.	O

For	O
example	O
,	O
in	O
wild	O
-	O
type	O
E.	B
coli	I
,	O
free	O
iron	O
levels	O
are	O
estimated	O
to	O
be	O
10	O
µM	O
,	O
yet	O
H2O2	O
is	O
only	O
mildly	O
genotoxic	O
(	O
Keyer	O
and	O
Imlay	O
,	O
1996	O
)	O
.	O

However	O
,	O
in	O
E.	B
coli	I
Fur-	O
mutants	O
,	O
intracellular	O
iron	O
concentration	O
increases	O
eightfold	O
while	O
survival	O
is	O
10-fold	O
lower	O
when	O
cells	O
are	O
exposed	O
to	O
H2O2	O
.	O

Because	O
B.	B
burgdorferi	I
cells	O
do	O
not	O
contain	O
detectable	O
levels	O
of	O
intracellular	O
Fe	O
,	O
it	O
seems	O
unlikely	O
that	O
DNA	O
is	O
a	O
major	O
target	O
for	O
damage	O
via	O
the	O
Fenton	O
reaction	O
in	O
this	O
bacterium	O
(	O
Posey	O
and	O
Gherardini	O
,	O
2000	O
)	O
.	O

The	O
experimental	O
data	O
present	O
in	O
this	O
report	O
suggested	O
that	O
this	O
was	O
the	O
case	O
.	O

When	O
B.	B
burgdorferi	I
cells	O
were	O
exposed	O
to	O
high	O
concentrations	O
of	O
ROS	O
(	O
e.g.	O
H2O2	O
)	O
,	O
there	O
was	O
no	O
effect	O
on	O
the	O
spontaneous	O
mutation	O
rate	O
(	O
Fig.	O
2A	O
)	O
or	O
the	O
number	O
of	O
DNA	O
lesions	O
(	O
AP	O
sites	O
or	O
8-oxoguanine	O
)	O
(	O
Fig.	O
2B	O
and	O
C	O
)	O
.	O

It	O
should	O
be	O
noted	O
that	O
in	O
these	O
experiments	O
,	O
a	O
wild	O
-	O
type	O
strain	O
of	O
B.	B
burgdorferi	I
was	O
used	O
and	O
presumably	O
all	O
of	O
the	O
endogenous	O
oxidative	O
stress	O
enzymes	O
were	O
expressed	O
.	O

Therefore	O
,	O
it	O
is	O
possible	O
that	O
no	O
DNA	O
damage	O
was	O
observed	O
because	O
these	O
enzymes	O
are	O
capable	O
of	O
detoxifying	O
the	O
cell	O
and	O
protecting	O
nucleic	O
acids	O
from	O
oxidation	O
via	O
the	O
Fenton	O
reaction	O
.	O

However	O
,	O
we	O
do	O
not	O
believe	O
this	O
to	O
be	O
the	O
case	O
as	O
the	O
concentration	O
of	O
oxidants	O
used	O
in	O
these	O
experiments	O
were	O
significantly	O
higher	O
than	O
concentrations	O
known	O
to	O
cause	O
DNA	O
damage	O
in	O
E.	B
coli	I
and	O
other	O
pathogenic	O
bacteria	O
.	O

The	O
lack	O
of	O
detectable	O
DNA	O
damage	O
in	O
B.	B
burgdorferi	I
cells	O
under	O
the	O
conditions	O
tested	O
could	O
be	O
the	O
result	O
of	O
very	O
efficient	O
DNA	O
repair	O
systems	O
.	O

Bacteria	O
,	O
such	O
as	O
E.	B
coli	I
,	O
harbour	O
genes	O
encoding	O
repair	O
enzymes	O
(	O
i.e.	O
MutM	O
,	O
MutY	O
,	O
Ung	O
,	O
AlkA	O
,	O
MutS	O
,	O
MutL	O
,	O
ExoIII	O
,	O
EndoVIII	O
,	O
PolI	O
,	O
RecJ	O
)	O
.	O

Key	O
enzymes	O
in	O
the	O
repair	O
of	O
8-oxoguanine	O
lesions	O
resulting	O
from	O
the	O
oxidation	O
of	O
DNA	O
are	O
the	O
bifunctional	O
glycosylases	O
,	O
such	O
as	O
MutM	O
,	O
MutY	O
or	O
EndoVIII	O
.	O

The	O
first	O
activity	O
of	O
these	O
enzymes	O
is	O
to	O
remove	O
oxidized	O
or	O
ring	O
-	O
saturated	O
bases	O
while	O
the	O
second	O
activity	O
is	O
to	O
remove	O
the	O
resulting	O
deoxyribose	O
residue	O
,	O
generating	O
a	O
3′-phosphate	O
end	O
(	O
Krwawicz	O
et	O
al.	O
,	O
2007	O
)	O
.	O

This	O
3′-P	O
is	O
converted	O
to	O
a	O
3′-OH	O
by	O
various	O
enzymes	O
/	O
pathways	O
and	O
the	O
lesion	O
is	O
repaired	O
by	O
enzymes	O
(	O
e.g.	O
ExoIII	O
,	O
PolI	O
,	O
LigI	O
etc	O
.	O
)	O
in	O
the	O
short	O
or	O
long	O
BER	O
pathways	O
(	O
S	O
-	O
BER	O
,	O
L	O
-	O
BER	O
)	O
.	O

Interestingly	O
,	O
the	O
B.	B
burgdorferi	I
genome	O
does	O
not	O
contain	O
genes	O
encoding	O
homologues	O
of	O
MutM	O
,	O
MutY	O
or	O
EndoVIII	O
,	O
suggesting	O
that	O
it	O
would	O
be	O
difficult	O
for	O
the	O
cells	O
to	O
efficiently	O
repair	O
8-oxoguanine	O
sites	O
using	O
this	O
pathway	O
.	O

B.	B
burgdorferi	I
does	O
harbour	O
the	O
genes	O
encoding	O
the	O
enzymes	O
Ung	O
(	O
monofunctional	O
gylcosylase	O
,	O
BB0053	O
)	O
,	O
MutS	O
(	O
BB0797	O
,	O
BB0098	O
)	O
,	O
MutL	O
(	O
BB0211	O
)	O
,	O
ExoIII	O
(	O
BB0114	O
)	O
,	O
PolI	O
(	O
BB0548	O
)	O
,	O
LigI	O
(	O
BB0552	O
)	O
and	O
RecJ	O
(	O
BB0254	O
)	O
(	O
Fraser	O
et	O
al.	O
,	O
1997	O
)	O
which	O
are	O
involved	O
in	O
excision	O
and	O
repair	O
,	O
via	O
S	O
-	O
BER	O
or	O
L	O
-	O
BER	O
,	O
of	O
deaminated	O
,	O
alkylated	O
,	O
methylated	O
or	O
mismatched	O
bases	O
.	O

Clearly	O
,	O
these	O
repair	O
systems	O
in	O
B.	B
burgdorferi	I
do	O
not	O
seem	O
as	O
robust	O
at	O
defending	O
against	O
oxidation	O
of	O
DNA	O
as	O
those	O
described	O
in	O
E.	B
coli	I
.	O

The	O
lack	O
of	O
key	O
repair	O
enzymes	O
in	O
this	O
system	O
may	O
indicate	O
that	O
B.	B
burgdorferi	I
DNA	O
is	O
not	O
subjected	O
to	O
the	O
same	O
challenge	O
from	O
ROS	O
as	O
is	O
E.	B
coli	I
.	O

In	O
most	O
bacteria	O
,	O
ROS	O
-	O
mediated	O
damage	O
to	O
lipids	O
(	O
lipid	O
peroxidation	O
)	O
is	O
very	O
unlikely	O
because	O
of	O
the	O
lack	O
of	O
polyunsaturated	O
fatty	O
acids	O
(	O
e.g.	O
linoleic	O
acid	O
)	O
(	O
Imlay	O
,	O
2003	O
)	O
.	O

When	O
it	O
does	O
occur	O
,	O
lipid	O
peroxidation	O
is	O
initiated	O
by	O
the	O
attack	O
of	O
free	O
radicals	O
on	O
polyunsaturated	O
fatty	O
acids	O
which	O
decreases	O
the	O
membrane	O
fluidity	O
and	O
,	O
if	O
these	O
reactions	O
propagate	O
,	O
lipid	O
peroxides	O
and	O
their	O
degradation	O
products	O
(	O
e.g.	O
aldehydes	O
)	O
in	O
turn	O
could	O
damage	O
proteins	O
(	O
Gutteridge	O
and	O
Halliwell	O
,	O
1990	O
)	O
.	O

This	O
would	O
dramatically	O
affect	O
the	O
function	O
of	O
transmembrane	O
proteins	O
and	O
membrane	O
-	O
bound	O
lipoproteins	O
involved	O
in	O
the	O
maintenance	O
of	O
membrane	O
potential	O
and	O
solute	O
transport	O
,	O
decreasing	O
cell	O
survivability	O
.	O

In	O
contrast	O
to	O
most	O
bacteria	O
,	O
B.	B
burgdorferi	I
membranes	O
contained	O
significant	O
levels	O
of	O
unsaturated	O
fatty	O
acids	O
,	O
such	O
as	O
linoleic	O
acid	O
and	O
linolenic	O
acid	O
,	O
which	O
were	O
derived	O
from	O
the	O
growth	O
media	O
(	O
Table	O
1	O
)	O
.	O

Thus	O
,	O
it	O
seemed	O
possible	O
that	O
lipids	O
and/or	O
proteins	O
rather	O
than	O
DNA	O
are	O
the	O
primary	O
targets	O
of	O
ROS	O
in	O
B.	B
burgdorferi	I
.	O

When	O
Borrelia	O
cells	O
are	O
treated	O
with	O
oxidants	O
,	O
the	O
levels	O
of	O
linoleic	O
acid	O
decreased	O
while	O
other	O
fatty	O
acids	O
remain	O
unaffected	O
(	O
Table	O
2	O
)	O
.	O

In	O
addition	O
,	O
HPLC	O
-	O
based	O
assays	O
demonstrated	O
that	O
,	O
as	O
linoleic	O
acid	O
concentrations	O
decrease	O
,	O
MDA	O
(	O
a	O
toxic	O
lipid	O
peroxide	O
intermediate	O
)	O
increased	O
(	O
Fig.	O
3	O
)	O
.	O

When	O
these	O
cells	O
were	O
examined	O
by	O
electron	O
microscopy	O
,	O
damage	O
to	O
the	O
membranes	O
(	O
membrane	O
'	O
blebs	O
'	O
)	O
was	O
observed	O
(	O
Fig.	O
6	O
)	O
.	O

These	O
data	O
indicated	O
that	O
unlike	O
most	O
other	O
bacteria	O
,	O
Borrelia	O
membranes	O
were	O
damaged	O
by	O
oxygen	O
radicals	O
.	O

As	O
B.	B
burgdorferi	I
may	O
be	O
exposed	O
to	O
potentially	O
harmful	O
oxygen	O
species	O
at	O
different	O
stages	O
of	O
the	O
infective	O
cycle	O
,	O
the	O
ability	O
to	O
protect	O
its	O
membrane	O
lipids	O
from	O
ROS	O
should	O
be	O
required	O
for	O
survival	O
in	O
the	O
different	O
host	O
environments	O
.	O

In	O
eukaryotic	O
cells	O
,	O
where	O
lipid	O
peroxidation	O
is	O
a	O
major	O
consequence	O
of	O
oxidative	O
attack	O
,	O
proteins	O
which	O
protect	O
membranes	O
have	O
been	O
well	O
studied	O
.	O

For	O
example	O
,	O
phospholipid	O
hydroperoxide	O
glutathione	O
peroxidase	O
,	O
a	O
member	O
of	O
the	O
glutathione	O
peroxidase	O
family	O
,	O
has	O
been	O
identified	O
in	O
a	O
variety	O
of	O
higher	O
organisms	O
.	O

These	O
enzymes	O
are	O
capable	O
of	O
reducing	O
an	O
assortment	O
of	O
hydroperoxy	O
lipids	O
,	O
including	O
oxidized	O
phospholipids	O
and	O
cholesterol	O
esters	O
(	O
Ursini	O
and	O
Bindoli	O
,	O
1987	O
)	O
,	O
and	O
protect	O
complex	O
membranes	O
from	O
oxidative	O
damage	O
.	O

Much	O
less	O
is	O
known	O
about	O
the	O
enzyme	O
(	O
s	O
)	O
responsible	O
for	O
protecting	O
unsaturated	O
lipids	O
from	O
ROS	O
in	O
prokaryotes	O
.	O

In	O
H.	B
pylori	I
,	O
lipid	O
hydroperoxide	O
levels	O
in	O
ahpC	O
mutants	O
are	O
approximately	O
three	O
times	O
higher	O
than	O
in	O
wild	O
-	O
type	O
cells	O
,	O
suggesting	O
a	O
role	O
for	O
AhpC	O
in	O
reducing	O
organic	O
peroxides	O
(	O
Wang	O
et	O
al.	O
,	O
2006a	O
,	O
b	O
)	O
.	O

In	O
addition	O
,	O
purified	O
AhpC	O
has	O
been	O
shown	O
to	O
reduce	O
linoleic	O
acid	O
hydroperoxide	O
in	O
vitro	O
(	O
Baker	O
et	O
al.	O
,	O
2001	O
)	O
.	O

Because	O
these	O
antioxidant	O
enzymes	O
promote	O
the	O
in	O
vivo	O
survival	O
of	O
cells	O
when	O
challenged	O
with	O
ROS	O
,	O
enzymes	O
for	O
the	O
reduction	O
of	O
lipid	O
peroxides	O
in	O
Borrelia	O
need	O
to	O
be	O
identified	O
.	O

Interestingly	O
,	O
Borrelia	O
cells	O
grown	O
aerobically	O
showed	O
signs	O
of	O
membrane	O
damage	O
similar	O
to	O
those	O
observed	O
in	O
cells	O
exposed	O
to	O
various	O
oxidants	O
.	O

The	O
amount	O
of	O
MDA	O
in	O
untreated	O
aerobically	O
grown	O
cells	O
was	O
equivalent	O
to	O
that	O
observed	O
in	O
treated	O
cells	O
(	O
Fig.	O
3	O
)	O
.	O

Also	O
,	O
EM	O
indicated	O
that	O
cells	O
grown	O
microaerobically	O
or	O
aerobically	O
had	O
significantly	O
more	O
membrane	O
damage	O
than	O
cells	O
grown	O
anaerobically	O
(	O
Fig.	O
6	O
)	O
.	O

This	O
indicated	O
that	O
Borrelia	O
membranes	O
can	O
be	O
damaged	O
simply	O
by	O
exposure	O
to	O
physiologically	O
relevant	O
concentrations	O
of	O
dissolved	O
oxygen	O
.	O

In	O
exponentially	O
growing	O
E.	B
coli	I
,	O
Imlay	O
and	O
Fridovich	O
(	O
1991	O
)	O
have	O
shown	O
that	O
both	O
O2-	O
and	O
H2O2	O
are	O
generated	O
by	O
the	O
autoxidation	O
of	O
components	O
of	O
the	O
respiratory	O
chain	O
during	O
oxygen	O
metabolism	O
.	O

In	O
contrast	O
,	O
B.	B
burgdorferi	I
is	O
very	O
metabolically	O
limited	O
and	O
has	O
no	O
enzymes	O
for	O
the	O
TCA	O
cycle	O
or	O
respiration	O
.	O

Therefore	O
,	O
it	O
seems	O
more	O
likely	O
that	O
sources	O
of	O
ROS	O
are	O
exogenous	O
(	O
e.g.	O
innate	O
immune	O
response	O
in	O
the	O
mammalian	O
host	O
)	O
rather	O
than	O
endogenous	O
.	O

In	O
addition	O
,	O
the	O
current	O
practice	O
of	O
growing	O
B.	B
burgdorferi	I
under	O
atmospheric	O
oxygen	O
could	O
itself	O
be	O
unintentionally	O
compromising	O
cell	O
integrity	O
during	O
in	O
vitro	O
manipulations	O
.	O

Analyses	O
of	O
the	O
B.	B
burgdorferi	I
genome	O
indicates	O
that	O
only	O
a	O
few	O
genes	O
encoding	O
putative	O
oxidative	O
stress	O
/	O
intracellular	O
redox	O
proteins	O
(	O
SodA	O
,	O
NapA	O
,	O
BosR	O
,	O
CoADR	O
,	O
Trx	O
and	O
TrxR	O
)	O
(	O
Fraser	O
et	O
al.	O
,	O
1997	O
)	O
are	O
present	O
,	O
compared	O
with	O
other	O
bacterial	O
pathogens	O
,	O
including	O
other	O
pathogenic	O
spirochetes	O
(	O
e.g.	O
Treponema	O
,	O
Leptospira	O
)	O
.	O

Despite	O
this	O
apparent	O
'	O
deficiency	O
'	O
in	O
the	O
number	O
of	O
ROS	O
-	O
protective	O
enzymes	O
,	O
B.	B
burgdorferi	I
cells	O
appear	O
to	O
be	O
able	O
to	O
cope	O
with	O
physiologically	O
relevant	O
levels	O
of	O
ROS	O
.	O

There	O
are	O
several	O
factors	O
that	O
would	O
contribute	O
to	O
this	O
phenomenon	O
:	O
(	O
i	O
)	O
as	O
B.	B
burgdorferi	I
does	O
not	O
harbour	O
the	O
genes	O
encoding	O
respiratory	O
enzymes	O
nor	O
metabolize	O
oxygen	O
,	O
it	O
seems	O
unlikely	O
that	O
significant	O
levels	O
of	O
ROS	O
are	O
generated	O
via	O
the	O
incomplete	O
reduction	O
of	O
O2	O
during	O
cellular	O
metabolism	O
.	O

This	O
would	O
suggest	O
that	O
potential	O
ROS	O
challenges	O
to	O
B.	B
burgdorferi	I
would	O
come	O
almost	O
completely	O
from	O
extracellular	O
sources	O
with	O
little	O
contribution	O
from	O
intracellularly	O
generated	O
ROS	O
;	O
(	O
ii	O
)	O
owing	O
to	O
a	O
lack	O
of	O
understanding	O
of	O
the	O
physiological	O
conditions	O
in	O
vector	O
and	O
host	O
tissues	O
infected	O
with	O
B.	B
burgdorferi	I
,	O
it	O
is	O
difficult	O
to	O
assess	O
the	O
levels	O
and/or	O
sites	O
of	O
the	O
potential	O
ROS	O
challenge	O
during	O
the	O
infective	O
cycle	O
and	O
(	O
iii	O
)	O
most	O
importantly	O
,	O
analyses	O
of	O
the	O
potential	O
targets	O
for	O
ROS	O
in	O
B.	B
burgdorferi	I
strongly	O
suggested	O
that	O
the	O
major	O
targets	O
of	O
oxidative	O
damage	O
are	O
different	O
and	O
perhaps	O
less	O
extensive	O
in	O
this	O
bacterium	O
than	O
in	O
other	O
bacterial	O
pathogens	O
(	O
e.g.	O
E.	B
coli	I
)	O
.	O

Taken	O
together	O
,	O
this	O
suggests	O
that	O
B.	B
burgdorferi	I
would	O
be	O
innately	O
more	O
resistant	O
to	O
ROS	O
and	O
require	O
a	O
less	O
extensive	O
repertoire	O
of	O
enzymes	O
to	O
protect	O
the	O
cells	O
from	O
oxidative	O
damage	O
.	O

Experimental	O
procedures	O
Strains	O
,	O
growth	O
conditions	O
and	O
reagents	O
Borrelia	B
burgdorferi	I
strain	O
B31A3	O
and	O
strain	O
B314	O
(	O
Sadziene	O
et	O
al.	O
,	O
1993	O
)	O
were	O
grown	O
in	O
modified	O
BSK	O
-	O
II	O
(	O
Barbour	O
,	O
1984	O
)	O
medium	O
at	O
34	O
°	O
C	O
under	O
an	O
atmosphere	O
of	O
0–20	O
%	O
O2	O
with	O
5	O
%	O
CO2	O
and	O
the	O
balance	O
N2	O
.	O

Cells	O
density	O
was	O
determined	O
using	O
a	O
dark	O
-	O
field	O
microscope	O
.	O

All	O
reagents	O
were	O
purchased	O
from	O
Sigma	O
Chemicals	O
,	O
St.	O
Louis	O
,	O
MO	O
unless	O
stated	O
otherwise	O
.	O

E.	B
coli	I
strain	O
Top10	O
,	O
strain	O
TA4315	O
(	O
ahpCF	O
)	O
(	O
Storz	O
et	O
al.	O
,	O
1989	O
)	O
and	O
CM1319	O
(	O
mutM	O
)	O
(	O
Bridges	O
et	O
al.	O
,	O
1996	O
)	O
were	O
grown	O
in	O
Luria	O
–	O
Bertani	O
(	O
LB	O
)	O
at	O
37	O
°	O
C	O
with	O
shaking	O
.	O

Per	O
cent	O
survivability	O
assays	O
Borrelia	B
burgdorferi	I
strain	O
B31A3	O
was	O
grown	O
to	O
a	O
cell	O
density	O
of	O
5	O
×	O
107	O
cells	O
ml−1	O
in	O
BSK	O
II	O
under	O
microaerobic	O
(	O
3	O
%	O
O2	O
)	O
conditions	O
,	O
the	O
culture	O
split	O
and	O
the	O
cells	O
treated	O
with	O
varying	O
concentrations	O
of	O
oxidants	O
(	O
0–50	O
mM	O
t	O
-	O
butyl	O
hydroperoxide	O
or	O
H2O2	O
)	O
at	O
34	O
°	O
C	O
for	O
4	O
h.	O
After	O
the	O
incubation	O
,	O
cells	O
were	O
diluted	O
in	O
fresh	O
BSK	O
II	O
,	O
plated	O
on	O
BSK	O
plates	O
and	O
incubated	O
7–14	O
days	O
at	O
34	O
°	O
C	O
.	O

Per	O
cent	O
survivability	O
was	O
calculated	O
as	O
the	O
number	O
of	O
colonies	O
on	O
the	O
treated	O
plates	O
versus	O
the	O
number	O
of	O
colonies	O
on	O
the	O
untreated	O
plates	O
.	O

Determination	O
of	O
the	O
spontaneous	O
mutation	O
rate	O
To	O
determine	O
spontaneous	O
resistance	O
to	O
coumermycin	O
A1	O
,	O
B.	B
burgdorferi	I
B31A3	O
cells	O
were	O
grown	O
under	O
microaerobic	O
conditions	O
to	O
a	O
cell	O
density	O
of	O
5	O
×	O
107	O
cells	O
ml−1	O
and	O
treated	O
with	O
5	O
mM	O
H2O2	O
for	O
1	O
h	O
at	O
34	O
°	O
C	O
.	O

The	O
cells	O
were	O
plated	O
on	O
BSK	O
plates	O
containing	O
0	O
or	O
250	O
ng	O
ml−1	O
coumermycin	O
A1	O
and	O
incubated	O
7–14	O
days	O
at	O
34	O
°	O
C	O
.	O

The	O
resistance	O
frequency	O
was	O
calculated	O
as	O
the	O
number	O
of	O
colonies	O
that	O
are	O
CouR	O
per	O
total	O
number	O
of	O
cells	O
plated	O
.	O

Measurement	O
of	O
DNA	O
base	O
lesions	O
Borrelia	B
burgdorferi	I
B31A3	O
cells	O
were	O
grown	O
in	O
BSK	O
-	O
II	O
under	O
microaerobic	O
conditions	O
to	O
a	O
cell	O
density	O
of	O
5	O
×	O
107	O
cells	O
ml−1	O
,	O
treated	O
with	O
various	O
oxidants	O
(	O
1	O
or	O
10	O
mM	O
t	O
-	O
butyl	O
hydroperoxide	O
,	O
1	O
or	O
10	O
mM	O
H2O2	O
,	O
10	O
mM	O
paraquat	O
or	O
lipoxidase	O
)	O
for	O
4	O
h	O
and	O
total	O
DNA	O
was	O
isolated	O
using	O
Wizard	O
Genomic	O
DNA	O
Purification	O
Kit	O
(	O
Promega	O
Corp.	O
,	O
Madison	O
,	O
WI	O
)	O
.	O

The	O
number	O
of	O
base	O
lesions	O
was	O
determined	O
using	O
the	O
DNA	O
Damage	O
Quantification	O
Colorimetric	O
Assay	O
kit	O
(	O
Oxford	O
Biomedical	O
Research	O
,	O
Oxford	O
,	O
MI	O
)	O
following	O
the	O
manufacturer	O
's	O
protocol	O
.	O

Briefly	O
,	O
500	O
ng	O
of	O
DNA	O
was	O
mixed	O
with	O
an	O
equal	O
volume	O
of	O
10	O
mM	O
biotinylated	O
aldehyde	O
reactive	O
probe	O
(	O
ARP	O
)	O
reagent	O
and	O
incubated	O
for	O
1	O
h	O
at	O
37	O
°	O
C	O
.	O

The	O
DNA	O
-	O
ARP	O
product	O
was	O
ethanol	O
-	O
precipitated	O
using	O
glycogen	O
as	O
a	O
carrier	O
,	O
washed	O
three	O
times	O
with	O
70	O
%	O
ethanol	O
and	O
resuspended	O
in	O
Tris	O
-	O
EDTA	O
to	O
give	O
a	O
final	O
concentration	O
of	O
0.5	O
µg	O
ml−1	O
.	O

The	O
DNA	O
-	O
ARP	O
product	O
was	O
allowed	O
to	O
bind	O
to	O
the	O
wells	O
of	O
96-well	O
microplate	O
overnight	O
at	O
37	O
°	O
C	O
.	O

After	O
the	O
binding	O
,	O
the	O
wells	O
were	O
washed	O
four	O
times	O
with	O
TPBS	O
(	O
137	O
mM	O
NaCl	O
,	O
2.7	O
mM	O
KCl	O
,	O
10	O
mM	O
Na3HPO4	O
,	O
2	O
mM	O
KH2PO4	O
,	O
0.5	O
%	O
Tween	O
20	O
,	O
pH	O
7.4	O
)	O
.	O

The	O
HRP	O
-	O
streptavidin	O
conjugate	O
was	O
diluted	O
to	O
0.5	O
µg	O
ml−1	O
in	O
Assay	O
Buffer	O
(	O
0.15	O
M	O
NaCl	O
,	O
10	O
mM	O
NasHPO4	O
,	O
1.5	O
mM	O
KH2PO4	O
,	O
2.5	O
mM	O
KCl	O
,	O
5	O
mg	O
ml−1	O
BSA	O
,	O
0.1	O
%	O
Tween	O
,	O
pH	O
7.5	O
)	O
,	O
100	O
µl	O
was	O
added	O
to	O
each	O
well	O
and	O
the	O
plate	O
incubated	O
at	O
100	O
r.p.m	O
.	O

for	O
1	O
h	O
at	O
room	O
temperature	O
(	O
RT	O
)	O
.	O

After	O
incubation	O
,	O
the	O
wells	O
were	O
washed	O
four	O
times	O
with	O
TPBS	O
,	O
100	O
µl	O
of	O
substrate	O
was	O
added	O
to	O
each	O
well	O
and	O
incubated	O
for	O
1	O
h	O
at	O
37	O
°	O
C	O
.	O

The	O
reaction	O
was	O
then	O
quenched	O
with	O
100	O
µl	O
of	O
1	O
M	O
sulphuric	O
acid	O
and	O
the	O
reaction	O
was	O
monitored	O
at	O
450	O
nm	O
.	O

The	O
number	O
of	O
aldehyde	O
reactive	O
probe	O
(	O
DNA	O
base	O
lesions	O
)	O
per	O
105	O
bp	O
DNA	O
was	O
determined	O
using	O
a	O
standard	O
curve	O
.	O

As	O
a	O
control	O
,	O
E.	B
coli	I
TA4315	O
cells	O
were	O
grown	O
in	O
minimal	O
media	O
to	O
OD600	O
of	O
0.4	O
,	O
treated	O
with	O
0	O
or	O
100	O
µM	O
H2O2	O
for	O
30	O
min	O
and	O
DNA	O
isolated	O
.	O

The	O
number	O
of	O
base	O
lesions	O
was	O
determined	O
as	O
described	O
above	O
.	O

B.	B
burgdorferi	I
strain	O
B314	O
cells	O
were	O
grown	O
under	O
microaerobic	O
conditions	O
and	O
DNA	O
isolated	O
.	O

The	O
number	O
of	O
DNA	O
lesions	O
was	O
determined	O
as	O
described	O
.	O

To	O
determine	O
the	O
amount	O
of	O
8-oxoguanine	O
in	O
B.	B
burgdorferi	I
DNA	O
,	O
cells	O
were	O
grown	O
and	O
treated	O
as	O
described	O
above	O
and	O
DNA	O
isolated	O
.	O

The	O
DNA	O
was	O
converted	O
to	O
single	O
-	O
stranded	O
DNA	O
by	O
boiling	O
the	O
sample	O
for	O
5	O
min	O
followed	O
by	O
rapid	O
chill	O
on	O
ice	O
.	O

The	O
DNA	O
was	O
then	O
digested	O
with	O
nuclease	O
P1	O
for	O
2	O
h	O
and	O
then	O
treated	O
with	O
alkaline	O
phosphatase	O
for	O
1	O
h	O
following	O
manufacturer	O
's	O
protocols	O
.	O

The	O
resultant	O
mixture	O
was	O
then	O
centrifuged	O
for	O
5	O
min	O
at	O
6000	O
g	O
and	O
the	O
supernatant	O
used	O
for	O
the	O
8-oxoguanine	O
ELISA	O
assay	O
(	O
Oxford	O
Biomedical	O
Research	O
,	O
Oxford	O
,	O
MI	O
)	O
.	O

As	O
a	O
control	O
,	O
E.	B
coli	I
CM1319	O
(	O
mutM	O
)	O
cells	O
were	O
grown	O
in	O
LB	O
to	O
OD600	O
of	O
0.4	O
,	O
treated	O
with	O
0	O
or	O
100	O
µM	O
H2O2	O
for	O
1	O
h	O
and	O
DNA	O
isolated	O
.	O

The	O
concentration	O
of	O
8-oxoguanine	O
was	O
determined	O
as	O
above	O
.	O

Lipid	O
analyses	O
To	O
determine	O
fatty	O
acid	O
content	O
in	O
B.	B
burgdorferi	I
total	O
membranes	O
,	O
B.	B
burgdorferi	I
strain	O
B31A3	O
was	O
grown	O
under	O
anaerobic	O
conditions	O
to	O
a	O
cell	O
density	O
of	O
5	O
×	O
107	O
cells	O
ml−1	O
,	O
harvested	O
by	O
centrifugation	O
(	O
5000	O
g	O
,	O
15	O
min	O
,	O
4	O
°	O
C	O
)	O
and	O
washed	O
two	O
times	O
with	O
HN	O
(	O
20	O
mM	O
NaCl	O
,	O
50	O
mM	O
Hepes	O
,	O
pH	O
7.6	O
)	O
buffer	O
.	O

Cell	O
pellets	O
were	O
analysed	O
for	O
fatty	O
acid	O
composition	O
by	O
fatty	O
acid	O
methyl	O
ester	O
(	O
FAME	O
)	O
gas	O
chromatography	O
(	O
Lipid	O
Technologies	O
,	O
Austin	O
,	O
MN	O
)	O
and	O
results	O
are	O
reported	O
as	O
percentage	O
of	O
total	O
fatty	O
acid	O
content	O
.	O

To	O
determine	O
the	O
effects	O
of	O
oxidants	O
on	O
fatty	O
acid	O
composition	O
,	O
a	O
1.5	O
l	O
culture	O
of	O
B.	B
burgdorferi	I
strain	O
B31A3	O
was	O
grown	O
under	O
microaerobic	O
conditions	O
to	O
a	O
cell	O
density	O
of	O
5	O
×	O
107	O
cells	O
ml−1	O
.	O

The	O
culture	O
was	O
split	O
into	O
500	O
ml	O
aliquots	O
,	O
the	O
first	O
was	O
treated	O
with	O
1	O
mM	O
t	O
-	O
butyl	O
hydroperoxide	O
,	O
the	O
second	O
with	O
0.25	O
mg	O
of	O
lipoxidase	O
(	O
17	O
700	O
units	O
)	O
and	O
the	O
third	O
was	O
untreated	O
.	O

All	O
cultures	O
were	O
incubated	O
for	O
12	O
h	O
at	O
34	O
°	O
C	O
.	O

Cells	O
were	O
harvested	O
by	O
centrifugation	O
(	O
5000	O
g	O
,	O
4	O
°	O
C	O
,	O
15	O
min	O
)	O
and	O
washed	O
three	O
times	O
with	O
HN	O
buffer	O
.	O

The	O
fatty	O
acids	O
present	O
in	O
the	O
cell	O
pellets	O
were	O
analysed	O
by	O
FAME	O
gas	O
chromatography	O
(	O
Industrial	O
Laboratory	O
,	O
Wheat	O
Ridge	O
,	O
CO	O
)	O
.	O

Fatty	O
acids	O
were	O
reported	O
as	O
percentage	O
of	O
total	O
cell	O
mass	O
.	O

Measurement	O
of	O
MDA	O
Borrelia	B
burgdorferi	I
strain	O
B31A3	O
was	O
grown	O
aerobically	O
,	O
microaerobically	O
and	O
anaerobically	O
as	O
described	O
above	O
to	O
a	O
cell	O
density	O
of	O
5	O
×	O
107	O
cells	O
ml−1	O
.	O

The	O
microaerobic	O
culture	O
was	O
split	O
and	O
treated	O
with	O
either	O
5	O
mM	O
AAPH	O
[	O
2,2′-azobis	O
(	O
2-methylpropionamidine	O
)	O
dihydrochloride	O
]	O
or	O
250	O
mg	O
of	O
lipoxidase	O
for	O
4	O
h	O
at	O
34	O
°	O
C	O
.	O

To	O
measure	O
the	O
amount	O
of	O
MDA	O
,	O
the	O
cells	O
were	O
derivatized	O
with	O
thiobarbituric	O
acid	O
and	O
analysed	O
by	O
HPLC	O
as	O
described	O
by	O
Seljeskog	O
et	O
al.	O
(	O
2006	O
)	O
.	O

After	O
the	O
incubation	O
,	O
all	O
cells	O
were	O
harvested	O
by	O
centrifugation	O
(	O
1000	O
g	O
,	O
5	O
min	O
,	O
4	O
°	O
C	O
)	O
and	O
washed	O
three	O
times	O
with	O
HN	O
buffer	O
.	O

Each	O
sample	O
was	O
resuspended	O
in	O
50	O
µl	O
of	O
HN	O
,	O
mixed	O
with	O
150	O
µl	O
of	O
0.1	O
N	O
perchloric	O
acid	O
,	O
150	O
µl	O
of	O
40	O
mM	O
thiobarbituric	O
acid	O
and	O
35	O
µl	O
of	O
20	O
%	O
SDS	O
,	O
vortexed	O
and	O
heated	O
at	O
97	O
°	O
C	O
for	O
60	O
min	O
.	O

After	O
cooling	O
at	O
−20	O
°	O
C	O
for	O
20	O
min	O
,	O
300	O
µl	O
of	O
methanol	O
and	O
100	O
µl	O
of	O
20	O
%	O
trichloroacetic	O
acid	O
was	O
added	O
and	O
the	O
samples	O
were	O
mixed	O
vigorously	O
and	O
centrifuged	O
(	O
13	O
000	O
g	O
,	O
6	O
min	O
)	O
.	O

The	O
samples	O
(	O
10	O
µl	O
)	O
were	O
then	O
analysed	O
with	O
an	O
Agilent	O
Technologies	O
1200	O
series	O
HPLC	O
system	O
using	O
a	O
C18	O
4.6	O
×	O
150	O
mm	O
column	O
with	O
mobile	O
phase	O
72:17:11	O
(	O
50	O
mM	O
KPO4	O
,	O
pH	O
6.8	O
:	O
methanol	O
:	O
acetonitrile	O
)	O
.	O

Absorbance	O
was	O
monitored	O
at	O
532	O
nm	O
.	O

Pure	O
MDA	O
standards	O
(	O
0–10	O
µM	O
)	O
were	O
prepared	O
in	O
methanol	O
for	O
comparison	O
.	O

As	O
a	O
negative	O
control	O
,	O
E.	B
coli	I
Top10	O
cells	O
were	O
grown	O
to	O
OD600	O
of	O
0.4	O
,	O
treated	O
with	O
0	O
or	O
5	O
mM	O
AAPH	O
for	O
30	O
min	O
and	O
MDA	O
measured	O
as	O
above	O
.	O

As	O
a	O
positive	O
control	O
,	O
mouse	B
myeloma	O
SP2	O
/	O
O	O
cells	O
were	O
cultured	O
with	O
HYQ	O
-	O
CCM1	O
(	O
HyClone	O
)	O
medium	O
at	O
37	O
°	O
C	O
in	O
a	O
humidified	O
5	O
%	O
CO2	O
atmosphere	O
,	O
treated	O
with	O
1	O
mM	O
AAPH	O
at	O
37	O
°	O
C	O
for	O
4	O
h	O
(	O
Chotimarkorn	O
et	O
al.	O
,	O
2005	O
)	O
and	O
MDA	O
measured	O
as	O
above	O
.	O

Identification	O
of	O
lipid	O
damage	O
using	O
Diphenyl-1-pyrenylphosphine	O
fluorescent	O
stain	O
Borrelia	B
burgdorferi	I
strain	O
B31A3	O
cells	O
were	O
grown	O
microaerobically	O
as	O
described	O
above	O
until	O
a	O
cell	O
density	O
of	O
5	O
×	O
107	O
cells	O
ml−1	O
was	O
obtained	O
.	O

The	O
culture	O
was	O
divided	O
into	O
two	O
equal	O
aliquots	O
and	O
the	O
cells	O
treated	O
with	O
5	O
mM	O
AAPH	O
for	O
4	O
h	O
at	O
34	O
°	O
C	O
.	O

After	O
the	O
incubation	O
,	O
all	O
cells	O
were	O
harvested	O
by	O
centrifugation	O
(	O
1000	O
g	O
,	O
5	O
min	O
,	O
4	O
°	O
C	O
)	O
and	O
washed	O
three	O
times	O
with	O
HN	O
buffer	O
.	O

To	O
visualize	O
Borrelia	O
cells	O
,	O
the	O
cells	O
were	O
stained	O
with	O
PKH26	O
Red	O
Fluorescent	O
Cell	O
Linker	O
Dye	O
(	O
Sigma	O
Aldrich	O
)	O
following	O
the	O
manufacturer	O
's	O
protocol	O
.	O

To	O
visualize	O
the	O
lipid	O
hydroperoxides	O
in	O
the	O
cell	O
membrane	O
,	O
the	O
cells	O
were	O
counterstained	O
with	O
DPPP	O
(	O
Cayman	O
Chemicals	O
,	O
MI	O
)	O
(	O
Okimoto	O
et	O
al.	O
,	O
2000	O
)	O
.	O

Briefly	O
,	O
after	O
cells	O
were	O
stained	O
with	O
the	O
Red	O
Fluorescent	O
dye	O
,	O
2	O
ml	O
of	O
rabbit	B
serum	O
was	O
added	O
to	O
stop	O
the	O
reaction	O
and	O
the	O
mixture	O
incubated	O
for	O
1	O
min	O
at	O
RT	O
.	O

Next	O
,	O
4	O
ml	O
of	O
HN	O
buffer	O
was	O
added	O
,	O
the	O
cells	O
harvested	O
by	O
centrifugation	O
(	O
1000	O
g	O
,	O
10	O
min	O
,	O
RT	O
)	O
and	O
washed	O
three	O
times	O
with	O
HN	O
buffer	O
.	O

The	O
cells	O
were	O
then	O
resuspended	O
in	O
1	O
ml	O
of	O
HN	O
buffer	O
,	O
incubated	O
at	O
34	O
°	O
C	O
for	O
5	O
min	O
and	O
30	O
µl	O
of	O
2.5	O
mM	O
DPPP	O
was	O
added	O
.	O

The	O
incubation	O
was	O
then	O
continued	O
at	O
34	O
°	O
C	O
for	O
5	O
min	O
in	O
the	O
dark	O
.	O

After	O
incubation	O
,	O
the	O
mixture	O
was	O
centrifuged	O
(	O
1000	O
g	O
,	O
10	O
min	O
,	O
RT	O
)	O
and	O
the	O
cells	O
washed	O
three	O
times	O
with	O
HN	O
buffer	O
.	O

The	O
cells	O
were	O
then	O
resuspended	O
in	O
100	O
µl	O
HN	O
buffer	O
and	O
observed	O
by	O
fluorescence	O
microscopy	O
with	O
excitation	O
wavelengths	O
551	O
nm	O
(	O
Red	O
Fluorescent	O
)	O
and	O
351	O
nm	O
(	O
DPPP	O
)	O
,	O
and	O
emission	O
wavelengths	O
567	O
nm	O
(	O
Red	O
Fluorescent	O
)	O
and	O
380	O
nm	O
(	O
DPPP	O
)	O
.	O

As	O
a	O
positive	O
control	O
,	O
mouse	B
myeloma	O
SP2	O
/	O
O	O
cells	O
were	O
cultured	O
with	O
HYQ	O
-	O
CCM1	O
(	O
HyClone	O
)	O
medium	O
at	O
37	O
°	O
C	O
in	O
a	O
humidified	O
5	O
%	O
CO2	O
atmosphere	O
,	O
treated	O
with	O
1	O
mM	O
AAPH	O
at	O
37	O
°	O
C	O
for	O
4	O
h	O
(	O
Chotimarkorn	O
et	O
al.	O
,	O
2005	O
)	O
and	O
stained	O
as	O
described	O
above	O
.	O

As	O
a	O
negative	O
control	O
,	O
E.	B
coli	I
Top10	O
cells	O
were	O
grown	O
to	O
OD600	O
of	O
0.4	O
,	O
treated	O
with	O
0	O
or	O
5	O
mM	O
AAPH	O
for	O
30	O
min	O
and	O
stained	O
as	O
described	O
above	O
.	O

Electron	O
microscopy	O
Borrelia	B
burgdorferi	I
cells	O
were	O
grown	O
under	O
microaerobic	O
or	O
anaerobic	O
conditions	O
to	O
a	O
cell	O
density	O
of	O
5	O
×	O
107	O
cells	O
ml−1	O
.	O

The	O
microaerobic	O
cultures	O
were	O
split	O
and	O
treated	O
with	O
lipoxidase	O
for	O
4	O
h	O
at	O
34	O
°	O
C	O
.	O

Cells	O
were	O
harvested	O
by	O
centrifugation	O
(	O
5000	O
g	O
,	O
10	O
min	O
,	O
4	O
°	O
C	O
)	O
,	O
washed	O
and	O
resuspended	O
in	O
HBSS	O
(	O
Lonza	O
Group	O
Ltd	O
,	O
Switzerland	O
)	O
.	O

The	O
cells	O
were	O
fixed	O
with	O
Karnovsky	O
's	O
phosphate	O
for	O
5	O
min	O
at	O
RT	O
adsorbed	O
to	O
Formvar	O
/	O
carbon	O
-	O
coated	O
grids	O
(	O
Ted	O
Pella	O
,	O
Redding	O
,	O
CA	O
)	O
for	O
5	O
min	O
and	O
washed	O
three	O
times	O
in	O
H2O	O
.	O

The	O
grids	O
were	O
stained	O
with	O
1	O
%	O
ammonium	O
molybdate	O
and	O
allowed	O
to	O
air	O
-	O
dry	O
.	O

Samples	O
were	O
examined	O
using	O
a	O
Hitachi	O
H7500	O
electron	O
microscope	O
(	O
Hitachi	O
High	O
Technologies	O
America	O
,	O
Pleasanton	O
,	O
CA	O
)	O
.	O

Cytotoxic	O
Activity	O
of	O
Silyl-	O
and	O
Germyl	O
-	O
Substituted	O
4,4-Dioxo-3a,6a	O
-	O
Dihydrothieno	O
[	O
2,3−d	O
]	O
isoxazolines-2	O
Abstract	O
The	O
[	O
2	O
+	O
3	O
]	O
dipolar	O
cycloaddition	O
of	O
nitrile	O
oxides	O
to	O
the	O
double	O
C	O
=	O
C	O
bonds	O
of	O
thiophene-1	O
,	O
1-dioxides	O
leads	O
to	O
formation	O
of	O
the	O
fused	O
isoxazolines-2	O
(	O
1	O
,	O
2	O
)	O
.	O

Tumor	O
growth	O
inhibition	O
of	O
these	O
compounds	O
strongly	O
depends	O
on	O
the	O
nature	O
of	O
group	O
IV	O
A	O
element	O
increasing	O
from	O
slightly	O
active	O
tert	O
-	O
butyl	O
derivatives	O
to	O
silicon	O
and	O
germanium	O
containing	O
analogues	O
.	O

The	O
products	O
of	O
benzonitrile	O
oxide	O
cycloaddition	O
have	O
greater	O
cytotoxic	O
effect	O
than	O
the	O
compounds	O
obtained	O
from	O
the	O
cycloaddition	O
reaction	O
of	O
2	O
,	O
5-disubstituted	O
thiophene-1	O
,	O
1-dioxides	O
with	O
acetonitrile	O
oxide	O
.	O

Fused	O
silyl	O
substituted	O
isoxazolines-2	O
are	O
stronger	O
NO	O
-	O
inducers	O
than	O
their	O
germyl	O
and	O
tert	O
-	O
butyl	O
analogues	O
.	O

CYTOTOXIC	O
ACTIVITY	O
OF	O
SILYL-	O
AND	O
GERMYL	O
-	O
SUBSTITUTED	O
4,4-DIOXO-3a,6a	O
-	O
DIHYDROTHIENO	O
[	O
2,3-d	O
]	O
ISOXAZOLINES-2	O
E.	O
Lukevics	O
*	O
,	O
P.	O
Arsenyan	O
,	O
I.	O
Shestakova	O
,	O
O.	O
Zharkova	O
,	O
I.	O
Kanepe	O
,	O
R.	O
Mezapuke	O
,	O
and	O
O.	O
Pudova	O
Latvian	O
Institute	O
of	O
Organic	O
Synthesis	O
,	O
Aizkraukles	O
21	O
,	O
Riga	O
,	O
LV-1006	O
,	O
Latvia	O
ABSTRACT	O

The	O
[	O
2	O
+	O
3	O
]	O
dipolar	O
cycloaddition	O
of	O
nitrile	O
oxides	O
to	O
the	O
double	O
(	O
3=	O
(	O
3	O
bonds	O
of	O
thiophene	O
-	O
l	O
,	O
l	O
-	O
dioides	O
leads	O
to	O
formation	O
of	O
the	O
fused	O
isoxazolines-2	O
(	O
1	O
,	O
2	O
)	O
.	O

Tumor	O
growth	O
inhibition	O
of	O
these	O
compounds	O
strongly	O
depends	O
on	O
the	O
nature	O
of	O
group	O
IV	O
A	O
element	O
increasing	O
from	O
slightly	O
active	O
ert	O
-	O
butyl	O
derivatives	O
to	O
silicon	O
and	O
germanium	O
containing	O
analogues	O
.	O

The	O
products	O
of	O
benzonitdle	O
oxide	O
cycloaddition	O
have	O
greater	O
cytotoic	O
effect	O
than	O
the	O
compounds	O
obtained	O
from	O
he	O
cycloaddition	O
reaction	O
of	O
2,5-disubstituted	O
thiophene	O
-	O
l	O
,	O
l	O
-	O
dioxides	O
with	O
acetonitrile	O
oxide	O
.	O

Fused	O
silyl	O
substituted	O
isoxazolines-2	O
are	O
stronger	O
NO	O
-	O
inducers	O
than	O
their	O
germyl	O
and	O
tert	O
-	O
butyl	O
analogues	O
.	O

INTRODUCTION	O
The	O
interest	O
in	O
silyl	O
substituted	O
thiophene	O
-	O
l	O
,	O
l	O
-	O
dioxides	O
stems	O
from	O
the	O
fact	O
that	O
they	O
are	O
useful	O
synthetic	O
intermediates	O
for	O
the	O
preparation	O
of	O
various	O
types	O
of	O
organic	O
compounds	O
by	O
Diels	O
-	O
Alder	O
cycloaddition	O
[	O
1	O
]	O
,	O
amine	O
induced	O
ring	O
-	O
opening	O
reaction	O
[	O
2	O
]	O
,	O
or	O
coupling	O
of	O
bromothiophene	O
-	O
l	O
,	O
l	O
-	O
dioxides	O
with	O
thienyl	O
stannanes	O
in	O
the	O
presence	O
of	O
a	O
palladium	O
(	O
0	O
)	O
catalyst	O
[	O
3	O
]	O
.	O

It	O
has	O
been	O
shown	O
that	O
unsubstituted	O
thiophene	O
-	O
l	O
,	O
l	O
-	O
dioxide	O
prepared	O
in	O
situ	O
is	O
a	O
quite	O
reactive	O
dipolarophile	O
in	O
the	O
[	O
2	O
+	O
3	O
]	O
cycloaddition	O
reactions	O
with	O
N	O
,	O
o	O
-	O
diphenylnitrone	O
[	O
4	O
]	O
,	O
benzonitrile	O
[	O
4	O
,	O
5	O
]	O
and	O
mesitonitrile	O
[	O
4	O
,	O
5	O
]	O
oxides	O
yielding	O
mono-	O
and	O
diisoxazolines-2	O
and	O
N	O
-	O
substituted	O
isoxazolidines	O
.	O

Moreover	O
,	O
our	O
recent	O
studies	O
indicate	O
that	O
silyl-	O
and	O
germylcontaining	O
isoxazolines	O
have	O
gained	O
a	O
great	O
deal	O
of	O
attention	O
as	O
compounds	O
possessing	O
a	O
wide	O
spectrum	O
of	O
the	O
biological	O
properties	O
.	O

The	O
vasodilating	O
,	O
anticoagulant	O
and	O
cardioprotective	O
activity	O
of	O
5-Si-	O
(	O
Ge	O
)	O
substituted	O
isoxazolines-2	O
has	O
been	O
studied	O
in	O
vitro	O
and	O
in	O
vivo	O
[	O
6	O
,	O
7	O
]	O
.	O

The	O
most	O
active	O
isoxazoline	O
-3-	O
(	O
"5""-triethylgermyl-3""-isoxazolino"	O
)	O
pyridine	O
hydrochloride	O
protected	O
the	O
heart	O
from	O
rhythm	O
disturbances	O
and	O
lethality	O
during	O
ischemiareperfusion	O
[	O
7	O
]	O
.	O

It	O
has	O
been	O
shown	O
that	O
silylisoxazolines-2	O
are	O
more	O
potent	O
in	O
protection	O
against	O
hypoxia	O
and	O
corazole	O
convulsions	O
than	O
germanium	O
analogues	O
.	O

However	O
,	O
germylisoxazolines-2	O
are	O
stronger	O
tumor	O
growth	O
inhibitors	O
and	O
NO	O
-	O
inducers	O
than	O
their	O
silicon	O
analogue	O
[	O
8	O
]	O
.	O

This	O
work	O
presents	O
the	O
results	O
of	O
cytotoxic	O
activity	O
for	O
fused	O
isoxazolines-2	O
bearing	O
a	O
group	O
14	O
element	O
as	O
substituent	O
(	O
1	O
,	O
2	O
)	O
in	O
function	O
of	O
the	O
nature	O
of	O
the	O
group	O
14	O
element	O
.	O

M	O
e3M.CH3	O
N	O
-0\	O
R	O
O\	O
M	O
e3	O
M	O
S	O
N	O
02	O
02	O
2	O
1	O
MATERIALS	O
AND	O
METHODS	O
CHEMISTRY	O
Seven	O
tert	O
-	O
butyl-	O
,	O
trimethylsilyl-	O
,	O
and	O
trimethylgermyl	O
-	O
substituted	O
4,4-dioxo-3a,6adihydrothieno	O
[	O
2,3-d	O
]	O
isoxazoline-2	O
1	O
and	O
2	O
(	O
Table	O
1	O
)	O
were	O
prepared	O
by	O
the	O
[	O
2	O
+	O
3	O
]	O
dipolar	O
63	O
Vol	O
.	O

7	O
,	O
No.	O
2	O
,	O
2000	O
Cytotoxic	O
Activity	O
ofSilyl	O
-	O
and	O
Germyl	O
-	O
Substituted	O
4	O
,	O
4-dioxo-3a	O
,	O
6a	O
-	O
Dihydrothieno	O
[	O
2	O
,	O
3-d	O
]	O
Isoxazolines-2	O
cycloaddition	O
of	O
aceto-	O
and	O
benzonitrile	O
oxides	O
to	O
2,5-disubstituted	O
thiophene	O
-	O
l	O
,	O
l	O
-	O
dioxides	O
.	O

Their	O
synthesis	O
and	O
characterization	O
are	O
given	O
in	O
ref	O
.	O

[	O
9	O
]	O
.	O

_	O
,	O
,	O
/0\N	O
Me3	O
M	O
M'Me3	O
Me3	O
M	O
02	O
M	O
,	O
M'=C	O
,	O
Si	O
,	O
Ge	O
;	O
R	O
=	O
Me	O
,	O
Ph	O
;	O
R'=H	O
,	O
Me3Ge	O
Table	O
1	O
.	O
Me3C	O
,	O
MeSi	O
,	O
Investigated	O
dihydrothieno	O
[	O
2,3-d	O
]	O
isoxazolines-2	O
02	O
Me3Ge	O
substituted	O
%	O
,	O
\R	O
4,4-dioxo-3a,6a	O
Compound	O
'	O
Type	O
la	O
M	O
R	O
H	O
Me3Ge	O
Me3Ge	O
Yield	O
4,4-dioxo-3	O
"methyl""5-tert"	O
-	O
butyl-3a,6adihydrothieno	O
[	O
2,3-d	O
]	O
isoxazoline-2	O
(	O
3	O
'	O
C	O
Si	O
(	O
%	O
)	O
80	O
4,4-dioxo-3-methyl-3a	O
-	O
trimethylgermyl-5-tert	O
-	O
butyl3a	O
,	O
6a	O
-	O
d	O
ihyd	O
rothieno	O
[	O
2,3-d	O
]	O
isoxazoli	O
ne-2	O
4,4-dioxo-3-methyl-3a	O
-	O
trimethyigermyl-5tri	O
methylsilyl-3a	O
,	O
6a	O
-	O
d	O
hyd	O
roth	O
ien	O
o	O
[	O
2,3d	O
]	O
isoxazoline-2	O
4,4-d	O
io	O
x	O
o-3-	O
meth	O
y	O
I-3a	O
,	O
5-	O
b	O
s	O
tri	O
m	O
ethy	O
Ig	O
e	O
rmy	O
I	O
)	O
3a	O
,	O
6a	O
-	O
d	O
hyd	O
rothieno	O
[	O
2,3-d	O
]	O
isoxazo	O
ne-2	O
4,4-d	O
ioxo-3-ph	O
en	O
y	O
I-5-tert	O
-	O
b	O
uty	O
I-3a	O
,	O
6adihydrothieno	O
[	O
2,3-d	O
]	O
isoxazoline-2	O
4,4-d	O
ioxo-3-p	O
h	O
e	O
ny	O
I-5-tri	O
meth	O
y	O
si	O
ly	O
I-3a	O
,	O
6adihydrothieno	O
[	O
2,3-d	O
]	O
isoxazoline-2	O
4,4-d	O
ioxo-3-p	O
h	O
e	O
n	O
y	O
I-5-tri	O
methy	O
Ig	O
e	O
rmy	O
I-3a	O
,	O
6adi	O
,	O
hydr0thieno	O
[	O
2,3	O
,	O
d	O
]	O
isoxazoline-2	O
lb	O
lc	O
58	O
45	O
67	O
84	O
ld	O
2a	O
2b	O
Ge	O
Me3Ge	O
C	O
Si	O
77	O
85	O
2c	O
Ge	O
IN	O
VITRO	O
CYTOTOXITY	O
ASSAY	O
Monolayer	O
cells	O
lines	O
were	O
cultivated	O
for	O
72	O
h	O
in	O
DMEM	O
standard	O
medium	O
without	O
an	O
indicator	O
and	O
antibiotics	O
.	O

After	O
the	O
ampoule	O
was	O
defreezed	O
not	O
more	O
than	O
four	O
passa4ges	O
were	O
performed	O
.	O

The	O
control	O
cells	O
and	O
cells	O
with	O
tested	O
substances	O
in	O
the	O
range	O
of	O
2	O
-	O
5	O
10	O
cell	O
/	O
mL	O
concentration	O
(	O
depending	O
on	O
line	O
nature	O
)	O
were	O
placed	O
on	O
a	O
separate	O
96	O
wells	O
plates	O
.	O

Solutions	O
containing	O
test	O
compounds	O
were	O
diluted	O
and	O
added	O
in	O
wells	O
to	O
give	O
the	O
final	O
concentrations	O
of	O
50	O
,	O
25	O
,	O
12.5	O
,	O
and	O
6.25	O
#	O
g	O
/	O
mL	O
Control	O
cells	O
were	O
treated	O
in	O
the	O
same	O
manner	O
only	O
in	O
the	O
absence	O
of	O
test	O
compounds	O
.	O

Plates	O
were	O
cultivated	O
for	O
72	O
h.	O
A	O
quantity	O
of	O
survived	O
cells	O
was	O
determined	O
using	O
crystal	O
violet	O
(	O
CV	O
)	O
or	O
3-	O
(	O
4,5-dimethylthiazol-2-yl	O
)	O
-2,5diphenyltetrazolinium	O
bromide	O
(	O
MTT	O
)	O
coloration	O
which	O
was	O
assayed	O
by	O
multiscan	O
spectrofotometer	O
.	O

The	O
quantity	O
of	O
alive	O
cells	O
on	O
control	O
plate	O
was	O
taken	O
in	O
calculations	O
for	O
100	O
%	O
[	O
10	O
,	O
11	O
]	O
.	O

Concentration	O
of	O
NO	O
was	O
determined	O
according	O
to	O
[	O
10	O
]	O
.	O

RESULTS	O
AND	O
DISCUSSION	O
Potential	O
cytotoxic	O
activity	O
of	O
synthesized	O
fused	O
isoxazolines	O
1	O
and	O
2	O
was	O
tested	O
in	O
vitro	O
on	O
four	O
monolayer	O
tumor	O
cell	O
lines	O
:	O
MG-22A	O
(	O
mouse	B
hepatoma	O
)	O
,	O
HT-1080	O
(	O
human	B
fibroblastoma	O
)	O
,	O
B16	O
(	O
mouse	B
melanoma	O
)	O
,	O
Neuro	O
2A	O
(	O
mouse	B
neiroblastoma	O
)	O
.	O

Concentrations	O
providing	O
50	O
%	O
of	O
tumor	O
death	O
effect	O
were	O
determined	O
according	O
to	O
the	O
known	O
procedure	O
[	O
12	O
]	O
using	O
96	O
well	O
plates	O
.	O

The	O
experimental	O
evaluation	O
of	O
cytotoxicity	O
properties	O
is	O
presented	O
in	O
Table	O
2	O
.	O

A	O
preliminary	O
analysis	O
of	O
the	O
structure	O
-	O
activity	O
relationship	O
for	O
the	O
cytotoxic	O
action	O
clearly	O
indicates	O
the	O
strong	O
influence	O
of	O
the	O
MeM	O
(	O
M	O
=	O
C	O
,	O
Si	O
,	O
Ge	O
)	O
group	O
in	O
position	O
5	O
of	O
fused	O
isoxazolines	O
1	O
and	O
2	O
.	O

Derivatives	O
bearing	O
tert	O
-	O
butyl	O
substituent	O
(	O
la	O
,	O
b	O
and	O
2a	O
)	O
have	O
a	O
slight	O
cytotoxic	O
effect	O
(	O
>	O
10	O
#	O
g	O
/	O
mL	O
)	O
.	O

The	O
substitution	O
of	O
the	O
tert	O
-	O
butyl	O
group	O
by	O
trimethylsilyl	O
or	O
64	O
E.	O
Lukevics	O
et	O
al.	O
Metal	O
-	O
Based	O
Drugs	O
A	O
oO	O
{	O
D	O
0	O
0	O
65	O
Vol	O
.	O

7	O
,	O
No.	O
2	O
,	O
2000	O
Cytotoxic	O
Activity	O
ofSilyl	O
-	O
and	O
Germyl	O
-	O
Substituted	O
4	O
,	O
4-dioxo-3a	O
,	O
6a	O
-	O
Dihydrothieno	O
[	O
2	O
,	O
3-d	O
]	O
Isoxazolines-2	O
trimethylgermyl	O
ones	O
leads	O
to	O
considerable	O
increase	O
of	O
cytotoxicity	O
.	O

It	O
must	O
be	O
noted	O
that	O
the	O
activity	O
of	O
silicon-	O
and	O
germanium	O
-	O
containing	O
compounds	O
(	O
1	O
and	O
l	O
d	O
)	O
depends	O
on	O
the	O
tumor	O
type	O
.	O

5-Trimethylsilyl	O
-	O
substituted	O
fused	O
isoxazoline	O
le	O
is	O
more	O
active	O
than	O
the	O
germanium	O
analogue	O
l	O
d	O
in	O
tests	O
on	O
HP-1080	O
and	O
MG-22A	O
cell	O
lines	O
.	O

However	O
,	O
the	O
germanium	O
compound	O
ld	O
has	O
greater	O
cytotoxic	O
effect	O
on	O
Neuro	O
2A	O
and	O
B16	O
cell	O
lines	O
than	O
the	O
silicon	O
derivative	O
lc	O
.	O

Comparison	O
of	O
the	O
tumor	O
growth	O
inhibition	O
for	O
derivatives	O
1	O
and	O
2	O
shows	O
a	O
higher	O
activity	O
of	O
the	O
condensed	O
isoxazolines	O
2	O
containing	O
a	O
phenyl	O
group	O
in	O
position	O
3	O
with	O
respect	O
to	O
4,4-dioxo-3-methyl-3a	O
-	O
trimethylgermyl-5-MeM-3a,6a	O
-	O
dihyd	O
rothieno	O
[	O
2,3d	O
]	O
isoxazolines	O
l	O
b	O
-	O
d	O
.	O

Silyl-	O
and	O
germyl	O
-	O
substituted	O
fused	O
isoxazolines	O
have	O
a	O
medium	O
NOinduction	O
ability	O
,	O
4,4-dioxo-3-phenyl-5-trimethylsilyl-3a,6a	O
-	O
dihydrothieno	O
[	O
2,3-d	O
]	O
isoxazoline-2	O
(	O
2b	O
)	O
being	O
the	O
most	O
active	O
(	O
250	O
%	O
in	O
the	O
MG-22A	O
test	O
)	O
.	O

ACKNOWLEGMENT	O
We	O
are	O
grateful	O
to	O
Latvian	O
Taiho	O
Foundation	O
for	O
financial	O
support	O
.	O

REFERENCES	O
1	O
.	O
A.	O
R.	O
M.	O
Donovan	O
,	O
M.	O
K.	O
Shepherd	O
,	O
Tetrahedron	O
Lett	O
.	O
,	O
35	O
(	O
1994	O
)	O
4425	O
.	O

2	O
.	O
S.	O
Gronowitz	O
,	O
A	O
.-	O
B.	O
H0rnfeldt	O
,	O
E.	O
Lukevics	O
,	O
O.	O
Pudova	O
,	O
Synthesis	O
,	O
(	O
1994	O
)	O
40	O
.	O

3	O
.	O
G.	O
Barbarella	O
,	O
L.	O
Favaretto	O
,	O
G.	O
Sotgiu	O
,	O
M.	O
Zambianchi	O
,	O
L.	O
Antolini	O
,	O
O.	O
Pudova	O
,	O
A.	O
Bongini	O
,	O
J.	O
Org	O
.	O

Chem	O
.	O
,	O
63	O
(	O
1998	O
)	O
5497	O
.	O

4	O
.	O
A.	O
Bened	O
,	O
R.	O
Durand	O
,	O
D.	O
Pioch	O
,	O
P.	O
Geneste	O
,	O
J.	O
P.	O
Declerq	O
,	O
G.	O
Germain	O
,	O
J.	O
Rambaud	O
,	O
R.	O
Roques	O
,	O
J.	O
Org	O
.	O

Chem	O
.	O
,	O
46	O
(	O
1981	O
)	O
3502	O
.	O

5	O
.	O
F.	O
M.	O
Albini	O
,	O
P.	O
Ceva	O
,	O
A.	O
Mascherpa	O
,	O
E.	O
Albini	O
,	O
P.	O
Caramella	O
,	O
Tetrahedron	O
,	O
38	O
(	O
1982	O
)	O
6	O
.	O
7	O
.	O
8	O
.	O

9	O
.	O
10	O
.	O
11	O
.	O
12	O
.	O
3629	O
.	O

E.	O
Lukevics	O
,	O
M.	O
Veveris	O
,	O
V.	O
Dirnens	O
,	O
Appl	O
.	O

Organomet	O
.	O

Chem	O
.	O
,	O
11	O
(	O
1997	O
)	O
805	O
.	O

E.	O
Lukevics	O
,	O
P.	O
Arsenyan	O
,	O
M.	O
Veveris	O
,	O
Metal	O
Based	O
Drugs	O
,	O
5	O
(	O
1998	O
)	O
251	O
.	O

E.	O
Lukevics	O
,	O
P.	O
Arsenyan	O
,	O
S.	O
Germane	O
,	O
I.	O
Shestakova	O
,	O
Applied	O
Organomet	O
.	O

Chem	O
.	O
,	O
13	O
(	O
1999	O
)	O
795	O
.	O

E.	O
Lukevics	O
,	O
P.	O
Arsenyan	O
,	O
S.	O
Belyakov	O
,	O
J.	O
Popelis	O
,	O
O.	O
Pudova	O
,	O
Organometallics	O
,	O
18	O
(	O
1999	O
)	O
3187	O
.	O

D.J.	O
Fast	O
,	O
R.C.	O
Lynch	O
,	O
R.W.	O
Leu	O
,	O
J.	O
Leuckocyt	O
.	O

Biol	O
.	O
,	O
52	O
(	O
1992	O
)	O
255	O
.	O

P.J.	O
Freshney	O
,	O
Culture	O
of	O
Animal	O
Cells	O
(	O
A	O
Manual	O
of	O
Basic	O
Technique	O
)	O
,	O
Wiley	O
-	O
Liss	O
,	O
New	O
York	O
,	O
1994	O
,	O
pp	O
.	O

296	O
-	O
297	O
.	O

R.	O
J.	O
Riddell	O
,	O
R.	O
H.	O
Clothier	O
,	O
M.	O
Fd	O
.	O

Balls	O
,	O
Chem	O
.	O

Toxicol	O
.	O
,	O
24	O
(	O
1986	O
)	O
469	O
.	O

Received	O
:	O
January	O
21	O
,	O
2000	O
Accepted	O
:	O
February	O
1	O
,	O
2000	O
Received	O
in	O
revised	O
camera	O
-	O
ready	O
format	O
""""	O
February	O
2	O
,	O
2000	O
66	O

Synthesis	O
,	O
Characterization	O
and	O
Antitumour	O
Activity	O
of	O
Some	O
Butyltin	O
(	O
IV	O
)	O
Cysteaminates	O
and	O
N	O
,	O
N	O
-	O
Dimethylcysteaminates	O
Abstract	O
The	O
synthesis	O
and	O
characterization	O
of	O
four	O
di-	O
and	O
tri	O
-	O
n	O
-	O
butyltin	O
cysteaminates	O
and	O
N	O
,	O
N	O
-	O
dimethylcysteaminates	O
and	O
three	O
protonated	O
/	O
quaternized	O
derivatives	O
are	O
reported	O
.	O

They	O
all	O
exhibit	O
moderate	O
or	O
high	O
in	O
vitro	O
cytotoxic	O
activity	O
.	O

Six	O
of	O
seven	O
compounds	O
presented	O
in	O
this	O
work	O
are	O
more	O
active	O
than	O
cisplatin	O
,	O
etoposide	O
and	O
5-fluorouracil	O
,	O
but	O
less	O
active	O
than	O
methotrexate	O
and	O
doxorubicin	O
.	O

Metal	O
Based	O
Drugs	O
Vol	O
.	O

7	O
,	O
Nr	O
.	O

5	O
,	O
2000	O
SYNTHESIS	O
,	O
CHARACTERIZATION	O
AND	O
ANTITUMOUR	O
ACTITY	O
OF	O
SOME	O
BUTYLTIN	O
(	O
IV	O
)	O
CYSTEAMINATES	O
AND	O
N	O
,	O
N	O
-	O
DIMETHYLCYSTEAMINATES	O
Marcel	O
Gielen	O
Karel	O
Handlir.2	O
,	O
Martin	O
Hollein	O
and	O
Dick	O
de	O
Vos	O
2	O
3	O
Departement	O
of	O
General	O
and	O
Organic	O
Chemistry	O
AOSC	O
,	O
Faculty	O
of	O
Applied	O
Sciences	O
,	O
Free	O
University	O
of	O
Brussels	O
VUV	O
,	O
Pleinlaan	O
2	O
,	O
B-1050	O
Brussels	O
,	O
Belgium	O
Departement	O
of	O
General	O
and	O
Inorganic	O
Chemistry	O
,	O
Faculty	O
of	O
Chemical	O
Technology	O
,	O
University	O
of	O
Pafdubice	O
,	O
Nam	O
.	O

Cs	O
.	O

legii	O
565	O
,	O
53210	O
Pardubice	O
,	O
Czech	O
Republic	O
Pharmachemie	O
B.	O
V.	O
,	O
Haarlem	O
,	O
the	O
Netherlands	O
Abstract	O
.	O

The	O
synthesis	O
and	O
characterization	O
of	O
four	O
di-	O
and	O
tri	O
-	O
n	O
-	O
butyltin	O
cysteaminates	O
and	O
_	O
N	O
,	O
N	O
-	O
dimethylcysteaminates	O
and	O
three	O
protonated	O
/	O
quaternized	O
derivatives	O
are	O
reported	O
.	O

They	O
all	O
exhibit	O
moderate	O
or	O
high	O
in	O
vitro	O
cytotoxic	O
activity	O
.	O

Six	O
of	O
seven	O
compounds	O
presented	O
in	O
this	O
work	O
are	O
more	O
active	O
than	O
cisplatin	O
,	O
etoposide	O
and	O
5-fluorouracil	O
,	O
but	O
less	O
active	O
than	O
methotrexate	O
and	O
doxorubiein	O
.	O

Introduction	O
.	O

Several	O
organotin	O
cysteaminates	O
(	O
aminoethylthiolates	O
)	O
have	O
been	O
studied	O
1	O
-	O
4	O
as	O
compounds	O
with	O
potentially	O
high	O
biological	O
activity	O
,	O
but	O
little	O
is	O
known	O
about	O
their	O
cytotoxic	O
effect	O
.	O

The	O
present	O
paper	O
reports	O
the	O
synthesis	O
and	O
characterization	O
of	O
di-	O
and	O
tri	O
-	O
n	O
-	O
butyltin	O
cysteaminates	O
and	O
their	O
N	O
,	O
N	O
-	O
dimethyl	O
analogues	O
and	O
their	O
in	O
vitro	O
cytotoxicity	O
.	O

It	O
is	O
shown	O
that	O
a	O
correct	O
evaluation	O
of	O
the	O
biological	O
activity	O
of	O
organotin	O
compounds	O
remains	O
5	O
often	O
hampered	O
by	O
their	O
low	O
water	O
solubility	O
.	O

Therefore	O
,	O
we	O
focused	O
on	O
the	O
synthesis	O
of	O
derivatives	O
with	O
potentially	O
higher	O
water	O
solubility	O
by	O
introducing	O
ionic	O
groups	O
into	O
the	O
molecule	O
by	O
protonation	O
or	O
quatemization	O
of	O
a	O
nitrogen	O
atom	O
.	O

Results	O
and	O
discussion	O
.	O

3	O
2	O
4	O
(	O
n	O
-	O
Bu	O
)	O
n	O
Sn	O
[	O
SCH2-CH2-NHm	O
(	O
CH3	O
)	O
2-m	O
]	O
4-n	O
n=3	O
,	O
n=3	O
,	O
n=2	O
,	O
n=2	O
,	O
m=2	O
m	O
=	O
O	O
m=2	O
m	O
=	O
O	O
(	O
1	O
)	O
(	O
2	O
)	O
(	O
3	O
)	O
(	O
4	O
)	O
3	O
2	O
4	O
(	O
n	O
-	O
Bu	O
)	O
3	O
Sn	O
S	O
-	O
CH2-CH2-NHm	O
(	O
CH3	O
)	O
3.m	O
X	O
m=3	O
,	O
x	O
=	O
cn3so3	O
(	O
5	O
)	O
m	O
1	O
,	O
X	O
=	O
CH3SO3	O
(	O
6	O
)	O
m	O
0	O
,	O
X	O
I	O
(	O
7	O
)	O
n	O
-	O
Bu	O
CH3-CH2-CH2-CH2	O
(	O
2	O
)	O
,	O
di	O
-	O
nTri	O
-	O
n	O
-	O
butyltin	O
cysteaminate	O
(	O
1	O
)	O
,	O
tri	O
-	O
n	O
-	O
butyltin	O
N	O
,	O
N	O
-	O
dimethylcysteaminate	O
butyltin	O
bis	O
(	O
cysteaminate	O
)	O
(	O
3	O
)	O
and	O
di	O
-	O
n	O
-	O
butyltin	O
bis	O
(	O
N	O
,	O
N	O
-	O
dimethylcysteaminate	O
)	O
(	O
4	O
)	O
were	O
prepared	O
by	O
the	O
reaction	O
of	O
the	O
sodium	O
cysteaminate	O
(	O
prepared	O
in	O
situ	O
by	O
the	O
reaction	O
of	O
sodium	O
methylate	O
with	O
the	O
hydrochloride	O
of	O
eysteamine	O
)	O
with	O
the	O
suitable	O
di	O
-	O
or	O
tri	O
-	O
n	O
-	O
butyltin	O
chloride	O
in	O
chloroform	O
following	O
reference	O
by	O
the	O
reactions	O
of	O
the	O
The	O
methanesulphonates	O
5	O
and	O
6	O
were	O
respectively	O
synthesized	O
equimolar	O
amount	O
of	O
methane	O
sulphonic	O
acid	O
in	O
unprotonated	O
analogs	O
1	O
and	O
2	O
with	O
an	O
chloroform	O
.	O

After	O
purification	O
on	O
a	O
short	O
column	O
of	O
alumina	O
and	O
evaporation	O
of	O
the	O
solvent	O
,	O
colourless	O
viscous	O
oils	O
were	O
obtained	O
.	O

The	O
quaternized	O
methyl	O
derivative	O
of	O
2	O
,	O
the	O
methiodide	O
(	O
7	O
)	O
,	O
was	O
prepared	O
by	O
its	O
reaction	O
with	O
methyl	O
iodide	O
in	O
benzene	O
and	O
purified	O
by	O
recrystalization	O
from	O
chloroform	O
.	O

233	O
M.	O
Gielen	O
,	O
K.	O
Handlir	O
,	O
M.	O
Hollein	O
and	O
D.	O
de	O
Vos	O
Synthesis	O
,	O
Characterization	O
and	O
Antitumor	O
Activity	O
ofSome	O
Butyltin	O
(	O
IV	O
)	O
Cysteaminates	O
and	O
N	O
,	O
N	O
-	O
Dimethylcysteaminates	O
86	O
77	O
85	O
3	O
(	O
C4H9	O
)	O
2Sn	O
(	O
SCH2CH2NH2	O
)	O
2	O
90	O
4	O
(	O
C4Hg	O
)	O
zSn	O
(	O
SCH2CHzN	O
(	O
CH3	O
)	O
2	O
)	O
2	O
92	O
oil	O
5	O
(	O
C4H9	O
)	O
3	O
SnSCH2CH2NH3	O
CH3SO3	O
94	O
6	O
oil	O
(	O
C4H9	O
)	O
3	O
SnSCH2CH2NH	O
(	O
CH3	O
)	O
2	O
CH3SO3	O
118	O
-	O
120	O
74	O
7	O
(	O
C4H9	O
)	O
.SnSCH.CH.N	O
(	O
CH3	O
)	O
31	O
The	O
elemental	O
analyses	O
(	O
C	O
,	O
H	O
,	O
N	O
,	O
Sn	O
)	O
agree	O
satisfactorily	O
with	O
the	O
proposed	O
formul	O
Table	O
1	O
.	O

Melting	O
points	O
and	O
yields	O
for	O
..	O
c0mP0unds	O
1	O
(	O
)	O
rmula	O
,	O
2	O
comp	O
.	O

1	O
(	O
C4H9	O
)	O
3SnSCHzCH2NH2	O
2	O
(	O
C4H9	O
)	O
3SnSCHzCH2N	O
(	O
CH3	O
)	O
2	O
7	O
.	O

m.p	O
.	O
,	O
..	O
b.p	O
..	O
,	O
.C	O
120	O
-	O
123	O
/	O
40	O
Pa	O
129	O
-	O
131	O
/	O
35	O
Pa	O
167	O
-	O
169	O
/	O
35	O
Pa	O
172	O
-	O
174	O
/	O
40	O
Pa	O
'	O
o	O
'	O
yield,.%	O
Compounds	O
1-	O
4	O
,	O
and	O
7	O
,	O
are	O
poorly	O
soluble	O
in	O
aqueous	O
solutions	O
(	O
<	O
mg	O
/	O
mL	O
)	O
.	O

Compounds	O
5	O
and	O
6	O
exhibit	O
higher	O
water	O
solubilities	O
(	O
ca	O
.	O

2	O
mg	O
/	O
mL	O
)	O
.	O

Compounds	O
1	O
7	O
are	O
soluble	O
in	O
a	O
therapeutic	O
solution	O
(	O
0,103	O
M	O
solution	O
of	O
NaCl	O
in	O
water	O
/	O
DMSO	O
1	O
/	O
9	O
)	O
.	O

A	O
white	O
turbidity	O
appears	O
in	O
these	O
solutions	O
only	O
after	O
several	O
hours	O
due	O
to	O
slow	O
hydrolysis	O
.	O

Compounds	O
1	O
7	O
were	O
characterized	O
by	O
multinuclear	O
NMR	O
spectroscopy	O
.	O

The	O
NMR	O
parameters	O
are	O
given	O
in	O
Table	O
2	O
.	O

Table	O
2	O
.	O

Resonances	O
of	O
13C	O
,	O
(	O
ca	O
20	O
%	O
sol	O
.	O

v	O
/	O
v	O
)	O
1	O
'	O
compound	O
SN	O
and	O
ll9Sn	O
NMR	O
spectra	O
of	O
2	O
the	O
compounds	O
1	O
-	O
7	O
in	O
CDCI3	O
5	O
86.3	O
13.45	O
6	O
'	O
'	O
S'n	O
)	O
,	O
""""	O
ppm	O
6	O
(	O
3c	O
)	O
a	O
,	O
ppm	O
x	O
77.6	O
12.3	O
77.5	O
12.75	O
3	O
-28.9	O
22.38	O
38	O
.	O
'	O

18.78	O
4	O
6	O
'	O
'	O
89.5	O
13.45	O
7	O
93.2	O
13.60	O
(	O
332	O
)	O
27.93	O
(	O
331	O
)	O
27.97	O
(	O
495	O
)	O
28.27	O
(	O
438	O
)	O
27.51	O
(	O
322	O
)	O
28.30	O
(	O
350	O
)	O
28.34	O
(	O
339	O
)	O
28.47	O
(	O
21.3	O
)	O
26.32	O
(	O
21.1	O
)	O
26.38	O
(	O
28.4	O
)	O
26.42	O
(	O
26.4	O
)	O
25.90	O
(	O
21.4	O
)	O
26.85	O
(	O
21.3	O
)	O
26.81	O
(	O
22.0	O
)	O
26.91	O
(	O
59.6	O
)	O
12.89	O
(	O
59.8	O
)	O
12.95	O
(	O
87.1	O
)	O
13.35	O
(	O
83.8	O
)	O
12.82	O
(	O
62.7	O
)	O
13.45	O
(	O
61.4	O
)	O
13.58	O
62.2	O
)	O
14.00	O
(	O
-	O
)	O
30.31	O
45.02	O
(	O
-	O
)	O
23.59	O
63.12	O
44.71	O
(	O
-	O
)	O
30.04	O
44.44	O
(	O
-	O
)	O

23.84	O
61.84	O
44.46	O
(	O
-	O
)	O
23.92	O
43.08	O
(-;	O
(	O
-	O
)	O
20.94	O

19.70	O
60.94	O
69.49	O
43.42	O
54.18	O
39.15	O
39.16	O
-360.4	O
-354.0	O
-355.3	O
-354.4	O
-349.4	O
-344.2	O
-325.8	O
1.1	O
6.2	O
1.5	O
1.5	O
12.7	O
11.7	O
30.1	O
13	O
a'values	O
of	O
nJ	O
(	O
n	O
J	O
9	O
Sn	O
,	O
,	O
C	O
)	O
c0uplihg	O
constants	O
in	O
Hz'for	O
Carbon	O
ato	O
]	O
ns	O
in	O
parentlee	O
's	O
difference	O
btween	O
(	O
N	O
)	O
for	O
the	O
organo.i	O
compound	O
and	O
free	O
cysteamine	O
,	O
6	O
(	O
N	O
)	O
361.5	O
ppm	O
;	O
N	O
,	O
N	O
-	O
dimethylcysteamine	O
,	O
5	O
(	O
N	O
)	O
-355.9	O
ppm	O
)	O
not	O
observed	O
C	O
resonances	O
were	O
assigned	O
on	O
the	O
basis	O
of	O
the	O
values	O
of	O
n	O
J	O
(	O
119	O
Sn	O
,	O
13	O
C	O
)	O
coupling	O
constants	O
and	O
standard	O
13	O
C-	O
APT	O
techniques	O
utilization	O
in	O
agreement	O
with	O
ref	O
..	O

The	O
values	O
of	O
119	O
Sn	O
chemical	O
shifts	O
are	O
found	O
in	O
the	O
interval	O
characteristic	O
for	O
fourcoordinated	O
tin	O
6,7	O
.	O

The	O
values	O
of	O
the	O
coupling	O
constants	O
j	O
(	O
1	O
lqSn,13C	O
)	O
agree	O
with	O
the	O
structure	O
proposed	O
.	O

Compound	O
3	O
is	O
characterized	O
by	O
a	O
somewhat	O
larger	O
upfield	O
shift	O
,	O
close	O
to	O
the	O
upper	O
limit	O
of	O
the	O
above	O
mentioned	O
interval	O
,	O
together	O
with	O
a	O
high	O
value	O
of	O
1j	O
(	O
l	O
lqSn,13C	O
)	O
(	O
495	O
Hz	O
)	O
.	O

67	O
The	O
C	O
-	O
Sn	O
-	O
C	O
angle	O
,	O
est'mated	O
,	O
from	O
this	O
value	O
of	O
coupling	O
constant	O
is	O
124	O
According	O
to	O
ref	O
.	O

this	O
behaviour	O
can	O
be	O
due	O
to	O
intermolecular	O
association	O
increasing	O
the	O
coordinatitn	O
number	O
of	O
tin	O
in	O
concentrated	O
solutions	O
,	O
as	O
suggested	O
by	O
the	O
concentration	O
dependence	O
of	O
tS	O
(	O
Sn	O
)	O
and	O
cryoscopic	O
measurements	O
in	O
benzene	O
.	O

The	O
values	O
of	O
the	O
6	O
(	O
SN	O
)	O
chemical	O
shifts	O
of	O
compounds	O
1	O
,	O
2	O
and	O
4	O
only	O
slightly	O
differ	O
from	O
the	O
(	O
15N	O
)	O
values	O
of	O
the	O
free	O
cysteamine	O
.	O

The	O
significantly	O
larger	O
i	O
(	O
15N	O
)	O
chemical	O
shift	O
of	O
compound	O
3	O
is	O
however	O
much	O
lower	O
than	O
those	O
of	O
compounds	O
5	O
,	O
6	O
and	O
7	O
containing	O
a	O
N	O
interaction	O
in	O
compounds	O
1	O
tetracoordinated	O
nitrogen	O
atom	O
.	O

It	O
can	O
be	O
stated	O
that	O
the	O
Sn	O
4	O
is	O
negligible	O
or	O
only	O
very	O
weak	O
in	O
chlorofom	O
solutions	O
.	O

This	O
conclusion	O
is	O
not	O
in	O
contradiction	O
with	O
the	O
proved	O
Sn	O
N	O
interaction	O
found	O
in	O
the	O
solid	O
state	O
8	O
.	O

13	O
.	O

,	O
234	O
Metal	O
Based	O
Drugs	O
Vol	O
.	O

7	O
,	O
Nr	O
.	O

5	O
,	O
2000	O
Antitumour	O
activity	O
.	O

The	O
results	O
of	O
the	O
in	O
vitro	O
antitumour	O
tests	O
of	O
compounds	O
1	O
7	O
are	O
given	O
in	O
Table	O
3	O
as	O
the	O
inhibition	O
doses	O
IDs0	O
observed	O
against	O
a	O
panel	O
of	O
seven	O
human	O
tumour	O
cell	O
lines	O
,	O
MCF-7	O
and	O
EVSA	O
-	O
T	O
,	O
two	O
breast	O
cancers	O
,	O
WiDr	O
,	O
a	O
colon	O
cancer	O
,	O
IGROV	O
,	O
an	O
ovarian	O
cancer	O
,	O
M19	O
MEL	O
,	O
a	O
melanoma	O
,	O
A248	O
,	O
a	O
renal	O
cancer	O
,	O
and	O
H226	O
,	O
a	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
.	O

The	O
antitumour	O
tests	O
results	O
are	O
compared	O
with	O
those	O
obtained	O
for	O
clinically	O
used	O
reference	O
compounds9	O
like	O
cisplatin	O
,	O
doxorubicin	O
,	O
etoposide	O
,	O
5-fluorouracil	O
and	O
methotrexate	O
.	O

Table	O
3	O
.	O

Inhibition	O
doses	O
comp	O
.	O

1	O
2	O
3	O
4	O
5	O
6	O
7	O
MF-7	O
41	O
41	O
51	O
78	O
30	O
90	O
385	O
699	O
10	O
2	O
594	O
750	O
18	O
EVSA	O
-	O
T	O
33	O
35	O
45	O
65	O
<3	O
57	O
367	O
IDs0	O
of	O
compounds	O
WiDr	O
39	O
39	O
211	O
331	O
19	O
40	O
339	O
1-	O
7	O
and	O
of	O
five	O
reference	O
compounds	O
.	O

IGROV	O
M19MEL	O
A498	O
H226	O
67	O
44	O
85	O
39	O
46	O
78	O
88	O
39	O
68	O
70	O
118	O
72	O
110	O
129	O
108	O
112	O
31	O
29	O
36	O
42	O
83	O
133	O
77	O
111	O
327	O
758	O
576	O
411	O
169	O
60	O
580	O
297	O
7	O
558	O
16	O
505	O
442	O
23	O
cisplatin	O
doxorubicin	O
etoposide	O
5-fluorouracil	O
422	O
8	O
317	O
475	O
5	O
methotrexate	O
967	O
11	O
150	O
225	O
<3	O
2	O
253	O
90	O
314	O
143	O
37	O
3	O
369	O
199	O
3	O
934	O
340	O
2	O
287	O
It	O
is	O
evident	O
from	O
Table	O
3	O
that	O
all	O
studied	O
compounds	O
exhibit	O
excellent	O
cytostatic	O
activities	O
,	O
except	O
compound	O
7	O
showing	O
only	O
moderate	O
activity	O
.	O

Compounds	O
1	O
6	O
are	O
more	O
active	O
than	O
cisplatin	O
and	O
,	O
in	O
most	O
cases	O
,	O
than	O
etoposide	O
and	O
5-fluorouracil	O
.	O

Their	O
activity	O
is	O
lower	O
than	O
that	O
of	O
doxorubicin	O
and	O
methotrexate	O
in	O
most	O
cases	O
for	O
the	O
studied	O
cancer	O
cell	O
lines	O
.	O

The	O
very	O
limited	O
set	O
of	O
acquired	O
activity	O
values	O
show	O
that	O
the	O
activity	O
of	O
tri	O
-	O
n	O
-	O
butyltin	O
are	O
higher	O
than	O
those	O
of	O
di	O
-	O
n	O
-	O
butyl	O
analogues	O
(	O
1>3	O
,	O
2>4	O
)	O
for	O
all	O
cell	O
lines	O
,	O
especially	O
compounds	O
against	O
WiDr	O
.	O

The	O
N	O
,	O
N	O
-	O
dimethyl	O
derivatives	O
exhibit	O
an	O
activity	O
comparable	O
to	O
or	O
somewhat	O
higher	O
than	O
that	O
of	O
unmethylated	O
compounds	O
.	O

Compound	O
8	O
,	O
with	O
a	O
quaternized	O
nitrogen	O
,	O
exhibits	O
the	O
lowest	O
cytotoxic	O
activities	O
,	O
approximatively	O
9	O
times	O
lower	O
than	O
compound	O
2	O
.	O

It	O
might	O
be	O
underlined	O
that	O
the	O
ionic	O
more	O
water	O
-	O
soluble	O
compounds	O
5	O
and	O
6	O
are	O
not	O
more	O
active	O
than	O
the	O
uncharged	O
analogs	O
1	O
-	O
4	O
,	O
whereas	O
the	O
hydrophilic	O
organotin	O
polyoxacarboxylates	O
exhibit	O
much	O
higher	O
in	O
vitro	O
activities	O
than	O
other	O
organotin	O
carxylates	O
51	O
Compounds	O
5	O
and	O
6	O
(	O
with	O
a	O
protonated	O
nitrogen	O
)	O
exhibit	O
activities	O
comparable	O
or	O
even	O
considerably	O
higher	O
(	O
compound	O
5	O
)	O
against	O
EVSA	O
-	O
T	O
than	O
the	O
corresponding	O
unprotonated	O
compounds	O
.	O

Compound	O
7	O
(	O
with	O
a	O
quaternized	O
nitrogen	O
)	O
exhibits	O
the	O
lowest	O
cytostatic	O
activities	O
,	O
approximately	O
9	O
times	O
should	O
however	O
be	O
mentioned	O
that	O
another	O
ionic	O
organotin	O
lower	O
than	O
compound	O
2	O
.	O

It	O
compound	O
,	O
bis	O
(	O
dicyclohexyl	O
)	O
ammonium	O
bis	O
(	O
2,6-pyridinecarboxyla	O
,	O
to	O
)	O
di	O
-	O
n	O
-	O
butylstannate	O
,	O
where	O
the	O
organotin	O
moiety	O
is	O
this	O
time	O
anionic	O
,	O
is	O
also	O
as	O
active	O
as	O
the	O
uncharged	O
analog	O

l.	O

All	O
NMR	O
spectra	O
were	O
recorded	O
on	O
a	O
Bruker	O
AMX	O
360	O
instrument	O
using	O
a	O
5	O
mm	O
multinuclear	O
tuneable	O
probe	O
.	O

The	O
residual	O
CHCI3	O
resonance	O
at	O
7.24	O
ppm	O
was	O
used	O
as	O
reference	O
for	O
the	O
H	O
soectra	O
and	O
the	O
central	O
13CDCI3	O
resonance	O
at	O
77.0	O
ppm	O
,	O
for	O
the	O
13C	O
spectra	O
.	O

The	O
119	O
Sn	O
chemical	O
shifts	O
were	O
refered	O
to	O
the	O
external	O
tetramethyltin	O
[	O
6	O
(	O
119	O
Sn	O
)	O
0.0	O
]	O
.	O

The	O
15N	O
NMR	O
spectra	O
were	O
measur;l	O
using	O
the	O
INEPT	O
technique	O
or	O
in	O
inverse	O
-	O
gated	O
mode	O
.	O

(	O
reference	O
:	O
Instrumentation	O
.	O

external	O
nitromethane	O
,	O
[	O
5	O
(	O
'N	O
)	O
0.0	O
]	O
)	O
.	O

The	O
protocol	O
followed	O
for	O
the	O
in	O
vitro	O
antitumour	O
screenings	O
has	O
been	O
already	O
reported	O
10	O
.	O

Acknowledgements	O
.	O

K.	O
H.	O
and	O
M	O
H.	O
thank	O
the	O
Grant	O
Agency	O
of	O
the	O
Czech	O
Republic	O
(	O
Grant	O
No.	O
203	O
/	O
00	O
/	O
0920	O
)	O
and	O
the	O
Ministry	O
o	O
""""	O
Education	O
,	O
Youth	O
and	O
Sport	O
of	O
the	O
Czech	O
republic	O
,	O
associated	O
with	O
EU	O
in	O
the	O
COST	O
8.20	O
program	O
for	O
financial	O
support	O
of	O
this	O
work	O
.	O

We	O
are	O
grateful	O
to	O
Mr.	O
R.	O
G.	O
Experimental	O
Oostrum	O
,	O
Dr.	O
J.	O
verweij	O
,	O
Prof.	O
Dr.	O
G.	O
Stoter	O
,	O
r.	O

K.	O
Nooter	O
,	O
Laboratory	O
of	O
Chemotherapy	O
and	O
Pharmacology	O
,	O
Department	O
of	O
Medical	O
Oncology	O
,	O
Rotterdam	O
Cancer	O
235	O
M.	O
Gielen	O
,	O
K.	O
Handlir	O
,	O
M.	O
HoHein	O
and	O
D.	O
de	O
Vos	O
Synthesis	O
,	O
Characterization	O
and	O
Antitumor	O
Activity	O
ofSome	O
Butyltin	O
(	O
IV	O
)	O
Cysteaminates	O
and	O
N	O
,	O
N	O
-	O
Dimethylcysteaminates	O
Institute	O
,	O
NL	O
3008	O
AE	O
,	O
Rotterdam	O
,	O
The	O
Netherlands	O
,	O
for	O
performing	O
the	O
in	O
vitro	O
tests	O
.	O

This	O
research	O
was	O
supported	O
by	O
the	O
Fund	O
for	O
Scientific	O
Research	O
Flanders	O
(	O
Belgium	O
)	O
,	O
grant	O
nr	O
G.0074.00	O
,	O
M.	O
G.	O
)	O
.	O

References	O
.	O

1	O
.	O

B.S.	O
Saraswat	O
,	O
J.	O
Mason	O
,	O
Polyhedron	O
(	O
9	O
)	O
,	O
5	O
(	O
1986	O
)	O
,	O
1449	O
.	O

2	O
.	O

G.	O
Domazetis	O
,	O
R.	O
J.	O
Magee	O
,	O
B.	O
D.	O
James	O
,	O
J.	O
Organomet	O
.	O

Chem	O
,	O
162	O
(	O
1978	O
)	O
,	O
239	O
.	O
3	O
.	O

J.D.	O
Cashion	O
,	O
G.	O
Domazetis	O
,	O
B.	O
D.	O
James	O
,	O
J.	O
Organomet	O
.	O

Chem	O
,	O
185	O
(	O
1980	O
)	O
,	O
433	O
.	O
4	O
.	O

G.	O
Domazetis	O
,	O
R.	O
J.	O
Magee	O
,	O
B.	O
D.	O
James	O
,	O
J.	O
Organomet	O
.	O

Chem	O
,	O
148	O
(	O
1978	O
)	O
,	O
339	O
.	O
5	O
.	O

G.	O
Atassi	O
,	O
Rev.	O
Si	O
Ge	O
Sn	O
Pb	O
Cpds	O
,	O
8	O
(	O
1985	O
)	O
,	O
219	O
;	O
M.	O
Kemmer	O
,	O
M.	O
Gielen	O
,	O
M.	O
Biesemans	O
,	O
D.	O
de	O
Vos	O
,	O
R.	O
Willem	O
,	O
Metal	O
-	O
Based	O
Drugs	O
5	O
(	O
1998	O
)	O
,	O
189	O
;	O
M.	O
Gielen	O
,	O
M.	O
Biesemans	O
,	O
D.	O
de	O
Vos	O
,	O
R.	O
Willem	O
,	O
J.	O
Inorg	O
.	O

Biochem	O
.	O
,	O
79	O
(	O
2000	O
)	O
,	O
139	O
.	O
6	O
.	O

J.	O
Holecek	O
,	O
A.	O
Lycka	O
,	O
Inorg	O
.	O

Chim	O
.	O

Acta	O
,	O
118	O
(	O
1986	O
)	O
,	O
L	O
15	O
.	O
7	O
.	O

J.	O
Holecek	O
,	O
M.	O
Nadvomik	O
,	O
K.	O
Handlir	O
,	O
A.	O
Lycka	O
,	O
J.	O
Organomet	O
.	O

Chem	O
.	O
,	O
315	O
(	O
1986	O
)	O
,	O
299	O
.	O
8	O
.	O

B.D.	O
James	O
,	O
R.	O
J.	O
Magee	O
,	O
W.	O
C.	O
Patalinghug	O
,	O
B.	O
W.	O
Skelton	O
,	O
A.	O
H.	O
White	O
,	O
J.	O
Organomet	O
.	O

Chem	O
,	O
467	O
(	O
1994	O
)	O
,	O
51	O
9	O
.	O

P.	O
Skehan	O
,	O
R.	O
Storeng	O
,	O
D.	O
Scudiero	O
,	O
A.	O
Monks	O
,	O
J.	O
McMahon	O
,	O
D.	O
Vistica	O
,	O
J.	O
T.	O
Warren	O
,	O
H.	O
Bokesh	O
,	O
S.	O
Kenney	O
,	O
M.	O
R.	O
Boyd	O
,	O
J	O
..	O
Natl	O
.	O

Cancer	O
lnst	O
.	O
,	O
82	O
(	O
1990	O
)	O
,	O
1107	O
.	O
10	O
.	O

Y.	O
P.	O
Kepers	O
,	O
G.	O
J.	O
Peters	O
,	O
J.	O
Van	O
Ark	O
-	O
Otte	O
,	O
B.	O
Winograd	O
,	O
H.	O
M.	O
Pinedo	O
,	O
Eur	O
.	O

J.	O
Cancer	O
,	O
27	O
(	O
1991	O
)	O
,	O
897	O
.	O
11	O
.	O

M.	O
Kemmer	O
,	O
L.	O
Ghys	O
,	O
M.	O
Gielen	O
,	O
M.	O
Biesemans	O
,	O
E.	O
R.	O
T.	O
Tiekink	O
,	O
R.	O
Willem	O
,	O
J.	O
Organomet	O
.	O

Chem	O
.	O
582	O
(	O
1999	O
)	O
,	O
195	O
.	O
12	O
.	O

S.	O
W.	O
Ng	O
,	O
V.	O
G.	O
Kumar	O
Das	O
,	O
J.	O
Holecek	O
,	O
A.	O
Lycka	O
,	O
M.	O
Gielen	O
,	O
M.	O
G.	O
B.	O
Drew	O
,	O
Appl	O
.	O

Organomet	O
.	O

Chem	O
.	O
11	O
(	O
1997	O
)	O
,	O
3	O
9	O
.	O

Received	O
""""	O
September	O
22	O
,	O
2000	O
Accepted-	O
October	O
19	O
,	O
2000	O
Received	O
in	O
revised	O
camera	O
-	O
ready	O
format-	O
October	O
20	O
,	O
2000	O
236	O

IL-5	O
drives	O
eosinophils	O
from	O
bone	O
marrow	O
to	O
blood	O
and	O
tissues	O
in	O
a	O
guinea	O
-	O
pig	O
model	O
of	O
visceral	O
larva	O
migrans	O
syndrome	O
Abstract	O
This	O
study	O
was	O
undertaken	O
to	O
evaluate	O
the	O
role	O
of	O
IL-5	O
in	O
eosinophil	O
migration	O
and	O
in	O
the	O
maintenance	O
of	O
eosinophilia	O
in	O
a	O
guinea	O
-	O
pig	O
model	O
of	O
visceral	O
larva	O
migrans	O
syndrome	O
.	O

The	O
results	O
show	O
that	O
the	O
infection	O
of	O
animals	O
with	O
Toxocara	B
canis	I
induced	O
an	O
early	O
increase	O
in	O
serum	O
IL-5	O
levels	O
that	O
might	O
be	O
essential	O
for	O
eosinophil	O
differentiation	O
and	O
proliferation	O
and	O
for	O
the	O
development	O
of	O
eosinophilia	O
.	O

When	O
infected	O
guinea	O
-	O
pigs	O
were	O
treated	O
with	O
mAb	O
anti	O
-	O
IL-5	O
(	O
TRFK-5	O
)	O
given	O
at	O
the	O
same	O
time	O
or	O
1	O
or	O
3	O
days	O
after	O
infection	O
,	O
there	O
was	O
a	O
high	O
percentage	O
of	O
reduction	O
of	O
eosinophil	O
counts	O
18	O
days	O
after	O
infection	O
.	O

However	O
,	O
when	O
the	O
mAb	O
was	O
administered	O
during	O
the	O
peak	O
of	O
eosinophilia	O
,	O
there	O
was	O
high	O
inhibition	O
in	O
blood	O
,	O
no	O
inhibition	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
or	O
peritoneum	O
and	O
an	O
increase	O
in	O
eosinophil	O
numbers	O
in	O
bone	O
marrow	O
.	O

Thus	O
,	O
a	O
basic	O
level	O
of	O
IL-5	O
may	O
be	O
essential	O
to	O
drive	O
eosinophils	O
from	O
bone	O
marrow	O
to	O
blood	O
and	O
tissues	O
,	O
and	O
for	O
the	O
maintenance	O
of	O
eosinophilia	O
in	O
infected	O
animals	O
.	O

We	O
may	O
also	O
conclude	O
that	O
when	O
eosinophils	O
have	O
already	O
migrated	O
to	O
the	O
lungs	O
,	O
TRFK-5	O
has	O
no	O
power	O
to	O
inhibit	O
eosinophilia	O
,	O
which	O
is	O
also	O
under	O
control	O
of	O
local	O
lung	O
cells	O
producing	O
IL-5	O
.	O

In	O
this	O
way	O
,	O
only	O
one	O
later	O
TRFK-5	O
treatment	O
may	O
not	O
be	O
sufficient	O
to	O
modify	O
the	O
lung	O
parenchyma	O
microenvironment	O
,	O
since	O
T.	B
canis	I
antigens	O
had	O
already	O
stimulated	O
some	O
cell	O
populations	O
to	O
produce	O
IL-5	O
.	O

Research	O
Paper	O
Mediators	O
of	O
Inflammation	O
5	O
,	O
24	O
-	O
31	O
(	O
1996	O
)	O
Tins	O
study	O
was	O
undertaken	O
to	O
evaluate	O
the	O
role	O
of	O
11	O
-	O
5	O
in	O
eosinophil	O
migration	O
and	O
in	O
the	O
maintenance	O
of	O
eosinophilia	O
in	O
a	O
guinea	O
-	O
pig	O
model	O
of	O
visceral	O
larva	O
migrans	O
syndrome	O
.	O

The	O
results	O
show	O
that	O
the	O
infection	O
of	O
animals	O
with	O
Toxocara	B
canis	I
induced	O
an	O
early	O
increase	O
in	O
serum	O
11	O
-	O
5	O
levels	O
that	O
might	O
be	O
essential	O
for	O
eosi	O
IL-5	O
drives	O
eosinophils	O
from	O
bone	O
marrow	O
to	O
blood	O
and	O
tissues	O
in	O
a	O
guinea	O
-	O
pig	O
model	O
of	O
visceral	O
larva	O
migrans	O
syndrome	O
L.	O
H.	O
Faccioli	O
,	O
"1""cA"	O
V.	O
F.	O
Mokwa	O
,	O
C.	O
L.	O
Silva	O
,	O
G.	O
M.	O
Rocha	O
,	O
J.	O
I.	O
Araujo	O
,	O
M.	O
A.	O
Nahori	O
2	O
and	O
B.	O
B.	O
Vargaftig	O
2	O
nophil	O
differentiation	O
and	O
proliferation	O
and	O
for	O
the	O
development	O
of	O
eosinophilia	O
.	O

When	O
infected	O
guinea	O
-	O
pigs	O
were	O
treated	O
with	O
mAb	O
anti-11	O
-	O
5	O
(	O
TRFK-5	O
)	O
given	O
at	O
the	O
same	O
time	O
or	O
1	O
or	O
3	O
days	O
after	O
infection	O
,	O
there	O
was	O
a	O
high	O
percentage	O
of	O
reduction	O
of	O
eosinophil	O
counts	O
18	O
days	O
after	O
infection	O
.	O

However	O
,	O
when	O
the	O
mAb	O
was	O
administered	O
during	O
the	O
peak	O
of	O
eosinophilia	O
,	O
there	O
was	O
high	O
inhibition	O
in	O
blood	O
,	O
no	O
inhibition	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
or	O
peritoneum	O
and	O
an	O
increase	O
in	O
eosinophil	O
numbers	O
in	O
bone	O
marrow	O
.	O

Thus	O
,	O
a	O
basic	O
level	O
of	O
11	O
-	O
5	O
may	O
be	O
essential	O
to	O
drive	O
eosinophils	O
from	O
bone	O
marrow	O
to	O
blood	O
and	O
tissues	O
,	O
and	O
for	O
the	O
maintenance	O
of	O
eosinophilia	O
in	O
infected	O
animals	O
.	O

We	O
may	O
also	O
conclude	O
that	O
when	O
eosinophils	O
have	O
already	O
migrated	O
to	O
the	O
lungs	O
,	O
TRFK-5	O
has	O
no	O
power	O
to	O
inhibit	O
eosinophilia	O
,	O
which	O
is	O
also	O
under	O
control	O
of	O
local	O
lung	O
cells	O
producing	O
11	O
-	O
5	O
.	O

In	O
this	O
way	O
,	O
only	O
one	O
later	O
TRFK-5	O
treatment	O
may	O
not	O
be	O
sufficient	O
to	O
modify	O
the	O
lung	O
parenchyma	O
microenvironment	O
,	O
since	O
T.	B
canis	I
antigens	O
had	O
already	O
stimulated	O
some	O
cell	O
populations	O
to	O
produce	O
11	O
-	O
5	O
.	O

1Department	O
of	O
Parasitology	O
,	O
Microbiology	O
and	O
Immunology	O
,	O
School	O
of	O
Medicine	O
of	O
Ribeir,5o	O
Preto	O
,	O
14049	O
-	O
900	O
,	O
Ribeiro	O
Preto	O
,	O
SP	O
,	O
Brazil	O
.	O

Fax	O
:	O
(	O
+	O
55	O
)	O
16	O
633	O
6631	O
2Unit	O
de	O
Pharmacologie	O
Cellulaire	O
,	O
Unit	O
Associe	O
Institut	O
Pasteur	O
/	O
INSERM	O
n.	O
285	O
,	O
Paris	O
,	O
France	O
.	O

CACorresponding	O
Author	O
Key	O
words	O
:	O
Eosinophil	O
,	O
Eosinophilia	O
by	O
Toxocara	B
canis	I
,	O
IL-5	O
in	O
eosinophilia	O
,	O
Toxocara	B
canis	I
Introduction	O
treatment	O
in	O
mice	B
infected	O
with	O
Eosinophilia	O
has	O
been	O
associated	O
with	O
parasitic	O
diseases	O
,	O
particularly	O
when	O
the	O
parasites	O
invade	O
the	O
tissues	O
or	O
injure	O
the	O
mucosal	O
surfaces	O
.	O

Toxocara	B
canis	I
is	O
an	O
intestinal	O
parasite	O
of	O
dogs	B
,	O
and	O
is	O
the	O
most	O
common	O
aetiologic	O
agent	O
of	O
visceral	O
larva	O
migrans	O
syndrome	O
(	O
VLMS	O
)	O
.	O

In	O
humans	B
,	O
VLMS	O
results	O
from	O
the	O
ingestion	O
of	O
embryonated	O
eggs	O
of	O
T.	B
canis	I
,	O
that	O
eclode	O
in	O
the	O
small	O
intesfine	O
.	O

The	O
infective	O
larvae	O
invade	O
the	O
mucosa	O
,	O
move	O
into	O
the	O
liver	O
via	O
the	O
portal	O
circulation	O
,	O
and	O
from	O
there	O
to	O
the	O
lungs	O
.	O

2	O
Beaver	O
et	O
al.	O
,	O
3	O
who	O
were	O
the	O
first	O
to	O
describe	O
this	O
syndrome	O
,	O
noted	O
the	O
intense	O
eosinophilia	O
which	O
reaches	O
more	O
than	O
90	O
%	O
of	O
total	O
leucocyte	O
counts	O
.	O

However	O
,	O
there	O
are	O
few	O
studies	O
regarding	O
the	O
mechanisms	O
involved	O
in	O
the	O
blood	O
and	O
tissue	O
eosinophilia	O
obseeeed	O
in	O
VLMS	O
.	O

Several	O
investigators	O
have	O
suggested	O
a	O
direct	O
correlation	O
between	O
eosinophilia	O
and	O
interleukin5	O
(	O
IL-5	O
)	O
in	O
human	B
helminth	O
infections4'5	O
and	O
in	O
experimental	O
animal	O
models	O
.	O

67	O
Inhibition	O
of	O
eosinophilia	O
has	O
been	O
demonstrated	O
by	O
anti	O
-	O
IL-5	O
24	O
Mediators	O
of	O
Inflammation	O
Vol	O
5	O
brasiliensis	O
,	O
8	O
$	O
chistosoma	O
mansoni	O
,	O
Toxocara	B
canis7	I
and	O
Heligmosomoidespolygyrus	B
.	O

1	O
IL-5	O
has	O
also	O
been	O
shown	O
to	O
support	O
the	O
terminal	O
differentiation	O
,	O
proliferation	O
of	O
eosinophil	O
precursors	O
11'12	O
and	O
eosinophil	O
activation	O
.	O

13	O
Although	O
IL-5	O
does	O
not	O
demonstrate	O
eosinophil	O
chemotactic	O
activity	O
in	O
vivo14	O
there	O
is	O
some	O
evidence	O
suggesting	O
that	O
this	O
cytokine	O
may	O
modulate	O
a	O
selective	O
eosinophil	O
accumulation	O
at	O
the	O
site	O
of	O
inflammation	O
.	O

Moreover	O
,	O
Sehmi	O
et	O
a	O
/	O
.15	O
reported	O
that	O
IL-5	O
has	O
a	O
selective	O
priming	O
effect	O
on	O
eosinophil	O
migratory	O
response	O
to	O
nonselective	O
chemoattractant	O
mediators	O
in	O
vitro	O
.	O

Also	O
,	O
Moser	O
et	O
a	O
/	O
.	O
16	O
have	O
demonstrated	O
that	O
in	O
order	O
to	O
acquire	O
the	O
ability	O
to	O
transmigrate	O
,	O
eosinophils	O
must	O
be	O
primed	O
with	O
IL-5	O
,	O
IL-3	O
and	O
GM	O
-	O
CSF	O
.	O

Thus	O
,	O
the	O
involvement	O
of	O
IL-5	O
in	O
eosinophilia	O
is	O
not	O
fully	O
understood	O
.	O

In	O
the	O
present	O
study	O
we	O
have	O
used	O
a	O
guinea	O
-	O
pig	O
model	O
of	O
VLMS	O
to	O
investigate	O
the	O
involvement	O
of	O
IL-5	O
in	O
eosinophil	O
migration	O
and	O
in	O
the	O
maintenance	O
of	O
eosinophilia	O
in	O
blood	O
,	O
bone	O
marrow	O
,	O
lung	O
and	O
peritoneal	O
cavity	O
.	O

(	O
C	O
)	O
1996	O
Rapid	O
Science	O
Publishers	O
Nipostrongylus	O
1996	O
IL-5	O
drives	O
eosinophils	O
in	O
guinea	O
-	O
pig	O
Materials	O
and	O
Methods	O
Animals	O
:	O

Outbred	O
albino	O
weighing	O
300	O
-	O
400	O
g	O
at	O
the	O
ments	O
were	O
obtained	O
from	O
the	O
School	O
of	O
Medicine	O
of	O
versity	O
of	O
So	O
Paulo	O
,	O
Brazil	O
.	O

female	O
guinea	O
-	O
pigs	O
start	O
of	O
the	O
experi	O
were	O
routinely	O
processed	O
,	O
embedded	O
in	O
paraffin	O
,	O
sectioned	O
at	O
4-61.tm	O
,	O
and	O
stained	O
with	O
Chromothope	O
2R	O
and	O
haematoxylin	O
,	O
for	O
examination	O
by	O
light	O
microscopy	O
.	O

Determination	O
oflL-5	O
in	O
serum	O
:	O
The	O
IL-5	O
level	O
in	O
the	O
serum	O
of	O
guinea	O
-	O
pigs	O
was	O
measured	O
using	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
.	O

Briefly	O
,	O
ELISA	O
plates	O
(	O
96-well	O
Immunoplate	O
MaxiSorp	O
,	O
Nunc	O
,	O
Roskilde	O
,	O
Denmark	O
)	O
were	O
coated	O
with	O
IL-5-specific	O
monoclonal	O
antibody	O
(	O
TRFK-5	O
,	O
5	O
lag	O
/	O
ml	O
in	O
phosphate	O
buffered	O
saline	O
,	O
pH	O
7.4	O
,	O
PBS	O
,	O
100	O
l.tl/well	O
)	O
.	O

After	O
2	O
h	O
of	O
incubation	O
at	O
37C	O
,	O
the	O
wells	O
were	O
washed	O
four	O
times	O
with	O
PBS	O
containing	O
0.1	O
%	O
Tween	O
20	O
(	O
PBS	O
-	O
T	O
)	O
.	O

Then	O
,	O
100	O
btl	O
of	O
samples	O
or	O
recombinant	O
murine	O
IL-5	O
standards	O
(	O
0.15	O
-	O
200ng	O
/	O
ml	O
)	O
in	O
PBS	O
-	O
T	O
and	O
2	O
%	O
BSA	O
(	O
PBSTBSA	O
)	O
were	O
added	O
to	O
each	O
well	O
.	O

After	O
incubation	O
for	O
l	O
h	O
at	O
37C	O
,	O
the	O
wells	O
were	O
washed	O
three	O
times	O
and	O
100	O
l.tl	O
of	O
biotinylated	O
rat	B
anti	O
-	O
murine	O
IL-5	O
(	O
biotinylated	O
-	O
TRFK-5	O
,	O
1	O
lag	O
/	O
ml	O
in	O
PBS	O
-	O
TBSA	O
)	O
was	O
added	O
.	O

After	O
incubation	O
for	O
1	O
h	O
at	O
37C	O
,	O
the	O
wells	O
were	O
washed	O
again	O
three	O
times	O
and	O
100	O
of	O
peroxidase	O
-	O
labelled	O
streptavidin	O
(	O
1	O
/	O
1000	O
,	O
Kirkegaard	O
&	O
Perry	O
Laboratories	O
Inc.	O
,	O
Maryland	O
,	O
USA	O
)	O
were	O
added	O
to	O
each	O
well	O
.	O

Following	O
incubation	O
for	O
l	O
h	O
at	O
37C	O
and	O
further	O
washing	O
,	O
the	O
enzyme	O
was	O
developed	O
using	O
the	O
TMB	O
substrate	O
peroxidase	O
for	O
5	O
min	O
.	O

The	O
reaction	O
was	O
stopped	O
by	O
adding	O
501.tl	O
of	O
2.0	O
N	O
HCl	O
,	O
and	O
the	O
optical	O
densities	O
were	O
read	O
at	O
490	O
nm	O
using	O
an	O
automated	O
plate	O
reader	O
.	O

The	O
sensitivity	O
of	O
the	O
assay	O
was	O
0.15	O
ng	O
/	O
ml	O
and	O
the	O
upper	O
limit	O
100ng	O
/	O
ml	O
.	O

the	O
animal	O
house	O
of	O
Ribeiro	O
Preto	O
,	O
Uni	O
Infection	O
of	O
animals	O
:	O
T.	B
canis	I
eggs	O
were	O
obtained	O
by	O
the	O
methods	O
of	O
Olson	O
and	O
Schulz	O
,	O
17	O
with	O
minor	O
modifications	O
.	O

Briefly	O
,	O
gravid	O
female	O
worms	O
were	O
recovered	O
from	O
dogs	B
,	O
and	O
the	O
eggs	O
were	O
rescued	O
from	O
the	O
uterus	O
,	O
washed	O
and	O
allowed	O
to	O
develop	O
to	O
the	O
infective	O
stage	O
in	O
shallow	O
dishes	O
containing	O
0.5	O
%	O
formalin	O
at	O
37C	O
.	O

Under	O
light	O
ether	O
anaesthesia	O
,	O
the	O
animals	O
were	O
infected	O
with	O
I	O
ml	O
saline	O
containing	O
500	O
T.	B
canis	I
eggs	O
,	O
by	O
gastric	O
intubation	O
using	O
a	O
metal	O
cannula	O
.	O

Blood	O
cell	O
counts	O
:	O
Guinea	O
-	O
pigs	O
were	O
anaesthetized	O
with	O
sodium	O
pentobarbitone	O
(	O
30mg	O
/	O
kg	O
,	O
i.v	O
.	O
)	O
and	O
blood	O
samples	O
were	O
collected	O
by	O
cardiac	O
puncture	O
with	O
10	O
%	O
EDTA	O
.	O

Total	O
cell	O
counts	O
were	O
carried	O
out	O
using	O
diluting	O
fluid	O
in	O
a	O
Neubauer	O
chamber	O
.	O

Differential	O
countings	O
were	O
obtained	O
using	O
Rosenfeld	O
-	O
stained	O
cytocentrifuge	O
preparations	O
,	O
Bronchoalveolar	O
lavage	O
fluid	O
.	O

The	O
guinea	O
-	O
pigs	O
were	O
killed	O
by	O
an	O
overdose	O
of	O
sodium	O
pentobarbitone	O
and	O
5ml	O
of	O
phosphate	O
-	O
buffered	O
saline	O
(	O
PBS	O
)	O
containing	O
0.5	O
%	O
sodium	O
citrate	O
(	O
PBS	O
/	O
SC	O
)	O
,	O
at	O
room	O
temperature	O
,	O
were	O
instilled	O
through	O
a	O
polyethylene	O
cannula	O
introduced	O
into	O
the	O
trachea	O
.	O

The	O
cells	O
present	O
in	O
the	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
were	O
recovered	O
immediately	O
.	O

The	O
procedure	O
was	O
repeated	O
once	O
.	O

The	O
leucocyte	O
counts	O
in	O
the	O
BAI	O
_	O
were	O
determined	O
as	O
described	O
above	O
,	O
Peritoneal	O
cells	O
:	O
The	O
cells	O
from	O
the	O
peritoneal	O
cavities	O
were	O
harvested	O
by	O
injection	O
of	O
10ml	O
of	O
PBS	O
/	O
SC	O
into	O
the	O
peritoneum	O
.	O

Only	O
5	O
-	O
8	O
ml	O
of	O
the	O
fluid	O
was	O
withdrawn	O
for	O
cell	O
counts	O
,	O
as	O
described	O
above	O
,	O
Monoclonal	O
antibodies	O
:	O
The	O
rat	B
monoclonal	O
antibody	O
TRFK-5	O
was	O
a	O
generous	O
gift	O
from	O
Dr	O
P.	O
Minoprio	O
,	O
Institut	O
Pasteur	O
,	O
Paris	O
.	O

The	O
neutralizing	O
antibody	O
was	O
purified	O
by	O
precipitation	O
with	O
ammonium	O
sulfate	O
(	O
45	O
%	O
)	O
from	O
ascites	O
prepared	O
in	O
CD1	O
nude	B
mice	I
(	O
Charles	O
River	O
,	O
St	O
Aubin	O
les	O
Elbeuf	O
,	O
France	O
)	O
inoculated	O
1	O
week	O
before	O
the	O
injection	O
of	O
hybridoma	O
cells	O
,	O
with	O
I	O
ml	O
of	O
pristane	O
(	O
Sigma	O
)	O
.	O

After	O
precipitation	O
and	O
dialysis	O
of	O
the	O
ascite	O
fluid	O
overnight	O
against	O
PBS	O
,	O
the	O
dialysate	O
was	O
further	O
purified	O
on	O
a	O
Protein	O
G1	O
column	O
(	O
HiTrapTM	O
,	O
Pharmacia	O
Upsala	O
,	O
Sweden	O
)	O
.	O

Bone	O
marrow	O
cells	O
:	O
Bone	O
marrow	O
cells	O
were	O
collected	O
by	O
flushing	O
the	O
contents	O
of	O
the	O
guinea	O
-	O
pig	O
femur	O
with	O
10	O
ml	O
of	O
PBS	O
/	O
SC	O
.	O

Total	O
cell	O
numbers	O
were	O
determined	O
as	O
above	O
.	O

In	O
the	O
differential	O
cell	O
counts	O
the	O
cell	O
populations	O
were	O
divided	O
into	O
mature	O
neutrophils	O
,	O
mature	O
eosinophils	O
and	O
others	O
(	O
mainly	O
precursors	O
and	O
mononuclear	O
cells	O
)	O
,	O
Histopathological	O
studies	O
:	O
Tissues	O
were	O
removed	O
from	O
guinea	O
-	O
pigs	O
at	O
various	O
times	O
post	O
-	O
infection	O
and	O
immediately	O
fixed	O
in	O
10	O
%	O
formalin	O
.	O

Tissues	O
Eosinophil	O
and	O
cytokine	O
depletion	O
:	O
Guinea	O
-	O
pigs	O
were	O
injected	O
i.p	O
.	O

with	O
TRFK-5	O
or	O
with	O
the	O
irrelevant	O
antibody	O
(	O
rat	B
IgG	O
against	O
total	O
anti	O
-	O
human	B
IgG	O
)	O
once	O
,	O
2mg	O
/	O
animal	O
,	O
at	O
the	O
time	O
of	O
infection	O
or	O
at	O
different	O
intervals	O
(	O
1	O
,	O
3	O
,	O
12	O
or	O
17	O
days	O
)	O
thereafter	O
.	O

The	O
animals	O
in	O
this	O
group	O
were	O
sacririced	O
18	O
days	O
after	O
infection	O
.	O

liver	O
:	O
One	O
lobule	O
of	O
was	O
used	O
to	O
determine	O
the	O
larval	O
each	O
liver	O
counts	O
from	O
infected	O
guinea	O
-	O
pigs	O
.	O

Larval	O
recovery	O
Recovery	O
of	O
larvae	O
from	O
Mediators	O
of	O
Inflammation	O
Vol	O
5	O
1996	O
25	O
L.	O
H.	O
Faccioli	O
et	O
al.	O
was	O
evaluated	O
as	O
described	O
by	O
Kayes	O
and	O
Oaks	O
,	O
18	O
with	O
minor	O
modifications	O
.	O

Briefly	O
,	O
the	O
tissue	O
was	O
chopped	O
and	O
digested	O
with	O
pepsin	O
-	O
HC1	O
(	O
pH	O
1.5	O
1.8	O
)	O
for	O
2h	O
at	O
37C	O
.	O

Larval	O
counts	O
for	O
each	O
sample	O
were	O
performed	O
after	O
centrifugation	O
and	O
examination	O
of	O
three	O
100-l.tl	O
samples	O
under	O
the	O
light	O
microscope	O
.	O

Statistical	O
analysis	O
:	O
Data	O
are	O
presented	O
as	O
the	O
mean	O
_	O
+	O
S.E.M.	O
and	O
were	O
analysed	O
statistically	O
using	O
the	O
Mann	O
-	O
Whitney	O
test	O
for	O
unpaired	O
data	O
.	O

A	O
p	O
<	O
0.05	O
value	O
was	O
considered	O
to	O
be	O
statistically	O
significant	O
.	O

Results	O
of	O
eosinophil	O
counts	O
in	O
blood	O
bone	O
marrow	O
,	O
BALF	O
and	O
peritoneum	O
:	O
Guinea	O
-	O
pigs	O
infected	O
with	O
T.	B
canis	I
eggs	O
showed	O
a	O
timedependent	O
blood	O
,	O
bone	O
-	O
marrow	O
,	O
BAUV	O
and	O
peritoneal	O
eosinophilia	O
(	O
Fig.	O
1	O
)	O
.	O

The	O
results	O
represent	O
the	O
mean	O
of	O
nine	O
animals	O
obtained	O
in	O
three	O
different	O
experiments	O
.	O

The	O
eosinophil	O
number	O
Kinetics	O
16	O
increased	O
significantly	O
from	O
0.55	O
+	O
_	O
0.37	O
x	O
105	O
at	O
the	O
beginning	O
of	O
experiment	O
to	O
6.0	O
+	O
_	O
_	O
1.03	O
x	O
105	O
at	O
6	O
days	O
post	O
-	O
infection	O
,	O
peaked	O
at	O
day	O
18	O
(	O
12.0	O
_	O
+	O
2.31	O
x	O
105	O
)	O
,	O
and	O
decreased	O
by	O
day	O
24	O
(	O
8.11	O
2.85	O
x	O
105	O
)	O
(	O
Fig.	O
1A	O
)	O
.	O

A	O
rise	O
in	O
the	O
percentage	O
of	O
mature	O
eosinophils	O
in	O
bone	O
marrow	O
""""	O
was	O
observed	O
12	O
days	O
after	O
infection	O
(	O
ranging	O
from	O
6	O
2	O
%	O
to	O
14	O
2	O
%	O
)	O
and	O
peaked	O
at	O
18	O
days	O
(	O
17	O
2	O
%	O
)	O
(	O
Fig.	O
1B	O
)	O
.	O

As	O
in	O
blood	O
,	O
the	O
number	O
of	O
eosinophils	O
in	O
BALF	O
increased	O
significantly	O
from	O
0.14	O
0.06	O
x	O
105	O
to	O
1.37	O
_	O
+	O
0.35	O
x	O
105	O
at	O
6	O
days	O
after	O
infection	O
,	O
reaching	O
a	O
peak	O
at	O
18	O
days	O
(	O
10.23	O
2.62	O
x	O
105	O
)	O
with	O
an	O
increase	O
in	O
relative	O
number	O
of	O
as	O
much	O
as	O
90	O
%	O
in	O
eosinophil	O
counts	O
in	O
relation	O
to	O
controls	O
,	O
and	O
was	O
still	O
elevated	O
at	O
day	O
24	O
(	O
9.07	O
_	O
_	O
_	O
3.47	O
x	O
10	O
s	O
)	O
(	O
Fig.	O
1C	O
)	O
.	O

The	O
remaining	O
cells	O
in	O
the	O
BALF	O
were	O
alveolar	O
macrophages	O
,	O
lymphocytes	O
,	O
mast	O
cells	O
and	O
ciliated	O
cells	O
.	O

In	O
contrast	O
to	O
blood	O
and	O
BALF	O
,	O
the	O
number	O
of	O
eosinophils	O
in	O
the	O
peritoneal	O
cavity	O
increased	O
significantl	O
only	O
at	O
day	O
12	O
post	O
-	O
infection	O
(	O
onset	O
,	O
2.06	O
1.04	O
x	O
105	O
;	O
day	O
6	O
,	O
3.68	O
_	O
+	O
0.82	O
x	O
105	O
;	O
day	O
12	O
,	O
5.77	O
+	O
_	O
1.12	O
x	O
10	O
>	O
;	O
and	O
increased	O
progres	O
_	O
_	O
_	O
_	O
_	O
.	O

(	O
B	O
)	O
(	O
AI	O
Blood	O
24	O
20	O
""""	O
Bone	O
Marrow	O
1612	O
8	O
4	O
O0	O
3	O
6	O
9	O
12	O
15	O
111	O
21	O
24	O
16	O
(	O
c	O
)	O
BALF	O
16	O
ID	O
)	O
Peritoneum	O
12	O
_	O
_	O
o	O
12	O
8	O
4	O
0	O
3	O
O6	O
9	O
12	O
15	O
16	O
21	O
24	O
Days	O
postinfoction	O
FIG	O
.	O

1	O
.	O
Number	O
of	O
eosinophils	O
in	O
blood	O
,	O
BALF	O
and	O
peritoneal	O
cavity	O
,	O
and	O
percentage	O
,	O
of	O
eosinophils	O
in	O
bone	O
marrow	O
of	O
T.	B
canisqnfected	I
guinea	O
-	O
pigs	O
.	O

Values	O
are	O
the	O
mean	O
-t	O
-	O
S.E.M.	O
(	O
n=8	O
to	O
9	O
)	O
.	O

Asterisks	O
indicate	O
a	O
significant	O
difference	O
between	O
infected	O
and	O
noninfected	O
animals	O
(	O
n	O
5	O
6	O
)	O
.	O

*	O
p	O
<	O
0.05	O
and	O

*	O
*	O
p	O
<	O
0.01	O
.	O

26	O
Mediators	O
of	O
Inflammation	O
Vol	O
5	O
1996	O
IL-5	O
drives	O
eosinophils	O
in	O
guinea	O
-	O
pig	O
sively	O
until	O
day	O
24	O
,	O
12.44	O
4-	O
2.72	O
x	O
105	O
)	O
(	O
Fig.	O
1D	O
)	O
.	O

The	O
percentage	O
of	O
eosinophils	O
in	O
some	O
animals	O
reached	O
55	O
%	O
at	O
the	O
peak	O
of	O
infection	O
.	O

No	O
increase	O
in	O
the	O
number	O
of	O
mononuclear	O
cells	O
was	O
seen	O
in	O
any	O
compartment	O
analysed	O
.	O

Larval	O
counts	O
:	O
The	O
percentage	O
of	O
inoculated	O
T.	B
canis	I
larvae	O
recovered	O
by	O
peptic	O
digestion	O
of	O
the	O
liver	O
of	O
experimental	O
animals	O
4	O
h	O
and	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
9	O
,	O
12	O
and	O
18	O
days	O
after	O
inoculation	O
of	O
500	O
eggs	O
per	O
animal	O
is	O
shown	O
in	O
Fig.	O
2	O
.	O

Most	O
of	O
the	O
larvae	O
were	O
recovered	O
2	O
to	O
4	O
days	O
after	O
infection	O
and	O
10	O
%	O
recovery	O
was	O
also	O
observed	O
on	O
day	O
18	O
in	O
the	O
liver	O
of	O
the	O
animals	O
.	O

150	O
120	O
IL-5	O
level	O
in	O
serum	O
of	O
infected	O
animals	O
:	O
IL-5	O
was	O
measured	O
in	O
the	O
serum	O
of	O
infected	O
and	O
normal	O
guinea	O
-	O
pigs	O
.	O

Each	O
time	O
point	O
in	O
Fig.	O
3	O
represents	O
the	O
mean	O
of	O
results	O
from	O
three	O
to	O
five	O
infected	O
animals	O
,	O
and	O
from	O
six	O
controls	O
.	O

Two	O
peaks	O
of	O
IL5	O
were	O
present	O
in	O
the	O
serum	O
of	O
infected	O
guineapigs	B
1	O
day	O
after	O
infection	O
(	O
102	O
_	O
_	O
+	O
22	O
pg	O
/	O
ml	O
)	O
,	O
and	O
18	O
days	O
later	O
(	O
59	O
7	O
pg	O
/	O
ml	O
)	O
.	O

The	O
level	O
of	O
IL-5	O
in	O
the	O
controls	O
was	O
31	O
4-	O
4	O
pg	O
/	O
ml	O
.	O

Eosinophil	O
numbers	O
in	O
infected	O
animals	O
treated	O
with	O
TRFK-5	O
:	O
When	O
guinea	O
-	O
pigs	O
received	O
an	O
i.p	O
.	O

injection	O
of	O
TRFK-5	O
,	O
the	O
monoclonal	O
antibody	O
against	O
IL-5	O
,	O
at	O
the	O
time	O
of	O
egg	O
administration	O
or	O
1	O
day	O
later	O
,	O
the	O
number	O
of	O
eosinophils	O
in	O
blood	O
,	O
BALF	O
,	O
peritoneal	O
cavity	O
and	O
bone	O
marrow	O
was	O
_	O
30	O
0	O
0	O
3	O
6	O
12	O
18	O
Days	O
postinfection	O
FIG	O
.	O

3	O
.	O

IL-5	O
concentration	O
in	O
serum	O
of	O
T.	B
caniinfected	I
guineapigs	B
(	O
n	O
3	O
-	O
5	O
)	O
.	O

Basal	O
IL-5	O
concentrations	O
were	O
of	O
31	O
4	O
pg	O
/	O
ml	O
(	O
n=	O
12	O
)	O
.	O

_	O
24	O
60	O
50	O
40	O
0	O
""""	O
T	O
""""	O
1	O
""""	O
0	O
3	O
6	O
9	O
12	O
15	O
18	O
21	O
24	O
Days	O
postinfection	O
FIG	O
.	O

2	O
.	O

Percentage	O
of	O
T.	B
canis	I
larvae	O
recovered	O
from	O
liver	O
of	O
guinea	O
-	O
pigs	O
studied	O
at	O
various	O
times	O
post	O
-	O
infection	O
.	O

Data	O
obtained	O
from	O
five	O
animals	O
.	O

drastically	O
reduced	O
,	O
even	O
when	O
determined	O
18	O
days	O
after	O
infection	O
(	O
Table	O
1	O
)	O
.	O

No	O
inhibition	O
of	O
eosinophil	O
counts	O
was	O
observed	O
when	O
the	O
animals	O
were	O
inoculated	O
with	O
the	O
irrelevant	O
antibody	O
at	O
the	O
time	O
of	O
infection	O
(	O
Table	O
1	O
)	O
.	O

Fig.	O
4	O
shows	O
the	O
comparative	O
results	O
of	O
eosinophilia	O
obtained	O
when	O
the	O
antibody	O
was	O
given	O
3	O
days	O
or	O
17	O
days	O
after	O
egg	O
inoculation	O
.	O

The	O
antibody	O
given	O
at	O
3	O
days	O
after	O
infection	O
induced	O
a	O
high	O
percentage	O
of	O
inhibition	O
in	O
eosinophil	O
counts	O
in	O
all	O
the	O
compartments	O
analysed	O
18	O
days	O
after	O
infection	O
(	O
Fig.	O
4A	O
)	O
.	O

However	O
,	O
when	O
TRFK-5	O
was	O
administered	O
to	O
the	O
infected	O
animals	O
on	O
day	O
17	O
post	O
-	O
infection	O
(	O
thus	O
1	O
day	O
before	O
sacrifice	O
)	O
,	O
a	O
significant	O
inhibition	O
in	O
number	O
and	O
percentage	O
of	O
eosinophils	O
was	O
observed	O
only	O
in	O
the	O
blood	O
(	O
p=0.030	O
)	O
(	O
Fig.	O
4B	O
)	O
.	O

A	O
small	O
non	O
-	O
significant	O
decrease	O
was	O
seen	O
in	O
BALF	O
(	O
p	O
0.790	O
)	O
and	O
peritoneum	O
(	O
p=	O
0.222	O
)	O
.	O

Moreover	O
,	O
the	O
number	O
of	O
mature	O
eosinophils	O
in	O
bone	O
marrow	O
increased	O
by	O
140	O
%	O
(	O
p	O
0.038	O
)	O
.	O

As	O
demonstrated	O
in	O
Fig.	O
4B	O
,	O
the	O
behaviour	O
of	O
eosinotShilia	O
in	O
BALF	O
was	O
completely	O
different	O
from	O
that	O
observed	O
in	O
blood	O
.	O

Thus	O
,	O
to	O
better	O
understand	O
the	O
eosinophilia	O
in	O
the	O
lungs	O
of	O
infected	O
animals	O
,	O
we	O
monitored	O
eosinophil	O
numbers	O
in	O
BALF	O
after	O
administration	O
of	O
TRFK-5	O
at	O
the	O
same	O
time	O
,	O
or	O
1	O
,	O
3	O
,	O
12	O
or	O
17	O
days	O
after	O
infection	O
.	O

The	O
animals	O
were	O
sacrificed	O
18	O
days	O
after	O
infection	O
.	O

In	O
another	O
group	O
,	O
TRFK-5	O
was	O
administered	O
18	O
days	O
post	O
-	O
infection	O
and	O
the	O
animals	O
were	O
sacrificed	O
6	O
days	O
later	O
.	O

When	O
the	O
mAb	O
was	O
administered	O
at	O
the	O
same	O
time	O
or	O
1	O
or	O
3	O
days	O
postinfection	O
there	O
was	O
a	O
significant	O
inhibition	O
in	O
the	O
number	O
of	O
eosinophils	O
(	O
Fig.	O
5	O
)	O
.	O

These	O
data	O
show	O
Mediators	O
of	O
Inflammation	O
Vol	O
5	O
1996	O
27	O
L.	O
H.	O
Faccioli	O
et	O
al.	O
Table	O
1	O
.	O

Eosinophils	O
in	O
T.	O
caniinfected	O
guinea	O
-	O
pigs	O
treated	O
or	O
untreated	O
with	O
TRFK-5	O
Compartment	O
Time	O
of	O
sacrifice	O
(	O
days	O
)	O
Non18	O
24	O
18	O
24	O
18	O
24	O
18	O
24	O
treated	O
Blood	O
12.18	O
5.28	O
10.08	O
-t-	O
2.85	O
16.50	O

4.42	O
6.57	O
+	O
_	O
_	O
1.68	O
BALF	O
Peritoneal	O
cavity	O
12.31	O
-I-	O
2.35	O
12.44	O
2.33	O
9	O
6	O
Bone	O
marrow	O
_	O
_	O
_	O
_	O
_	O
_	O
_	O
_	O
_	O
_	O
_	O
_	O
_	O
_	O
_	O
_	O
Days	O
of	O
treatment	O
with	O
TRFK-5	O
after	O
egg	O
administration	O
Irrelevant	O
Ab	O
at	O
the	O
time	O
of	O
infection	O
0	O
3	O
12	O
17	O
18	O
(	O
n	O
6	O
)	O
(	O
n=4	O
)	O
(	O
n=4	O
)	O
(	O
n	O
5	O
)	O
(	O
n	O
5	O
)	O
(	O
n=4	O
)	O
0.14	O
-t-	O
0.14	O
""""	O
0.26	O
0.79	O
0.26	O
*	O
0.24	O
*	O
0.17	O
_	O
-t-	O
0.17	O
""""	O
0.15	O
0.15	O
""""	O
2.59	O
0.80	O
*	O
4.36	O
2.21	O
13.32	O
4.54	O
O.	O
15	O
0.15	O
*	O
0.36	O
0.10	O
""""	O
1.22	O
-t-	O
0.50	O
*	O
7.07	O
-t-	O
2.39	O
15.24	O
29.31	O
_	O
+	O
15.90	O
16.09	O
10.33	O
_	O
+	O
4.10	O
3.79	O
1.47	O
-t-	O
0.76	O
*	O
3	O
0.48	O
_	O
+	O
0.35	O
*	O
0.46	O
2.6	O
0.27	O
*	O
1.3	O
""""	O
2.89	O
0.94	O
*	O
10.42	O
4.00	O
1.58	O
""""	O
-+	O
1	O
""""	O
1.25	O
-I-	O
0.25	O
*	O
+	O
5	O
15	O
-t-	O
2	O
9_+1	O
2	O
0.7	O
*	O
In	O
blood	O
BALF	O
and	O
peritoneal	O
cavity	O
the	O
values	O
represent	O
mean	O
-t-	O
_	O
S.E.M.	O
x	O
10	O
eosinophils	O
.	O

*	O
p	O
<	O
0.05	O
.	O

ml-1	O
and	O
in	O
bone	O
marrow	O
mean	O
-t-	O
_	O
S.E.M.	O
of	O
the	O
percentage	O
of	O
mature	O
that	O
the	O
inhibition	O
of	O
the	O
first	O
peak	O
of	O
IL-5	O
which	O
appeared	O
at	O
1	O
to	O
3	O
days	O
after	O
infection	O
as	O
shown	O
in	O
Fig.	O
3	O
,	O
is	O
also	O
very	O
important	O
for	O
the	O
establishment	O
of	O
eosinophilia	O
in	O
the	O
lungs	O
.	O

However	O
,	O
24-	O
(	O
A	O
)	O
when	O
the	O
mAb	O
was	O
administered	O
12	O
,	O
17	O
or	O
18	O
days	O
after	O
infection	O
there	O
was	O
no	O
significant	O
inhibition	O
in	O
the	O
numbers	O
of	O
eosinophils	O
in	O
BALF	O
(	O
Fig.	O
5	O
)	O
,	O
showing	O
that	O
once	O
established	O
,	O
the	O
eosi18	O
15x	O
16	O
12	O
.	O

_	O
.	O

0	O
12	O
o	O
BIo	O
o	O
d	O
BALF	O
P	O

e	O
rit	O
oneum	O
Bone	O
marrow	O
24-	O
(	O
Is	O
)	O
1815	O
E	O
x	O
20	O
16	O
o	O
12	O
/	O
/	O
/	O
.	O
o	O
=	O
o	O
12	O
0	O
Blood	O
O	O
""""	O
BALF	O
Peritoneum	O
Bone	O
marrow	O
FIG	O
.	O

4	O
.	O
Number	O
of	O
eosinophils	O
in	O
blood	O
,	O
BALF	O
and	O
peritoneum	O
and	O
percentage	O
of	O
eosinophils	O
in	O
bone	O
marrow	O
of	O
T.	B
caniinfected	I
guinea	O
-	O
pigs	O
submitted	O
or	O
not	O
to	O
treatment	O
with	O
TRFK-5	O
.	O

(	O
A	O
)	O
2	O
mg	O
/	O
animal	O
at	O
3	O
days	O
post	O
-	O
infection	O
;	O
(	O
B	O
)	O
2	O
mg	O
/	O
animal	O
17	O
days	O
post	O
-	O
infection	O
.	O

The	O
treated	O
and	O
control	O
animals	O
were	O
sacrificed	O
18	O
days	O
after	O
infection	O
.	O

Asterisks	O
indicate	O
a	O
significant	O
difference	O
from	O
infected	O
controls	O
(	O
n=5	O
-	O
6	O
)	O
and	O
from	O
animals	O
treated	O
with	O
TRFK-5	O
(	O
n=4-	O
5	O
)	O
.	O

*	O
p	O
<	O
0.05	O
and	O

*	O
*	O
p	O
<	O
0.01	O
.	O

28	O
Mediators	O
of	O
Inflammation	O
Vol	O
5	O
1996	O
IL-5	O
drives	O
eosinophils	O
in	O
guinea	O
-	O
pig	O
24	O
E	O
20	O
heart	O
;	O
data	O
not	O
shown	O
)	O
and	O
muscle	O
,	O
as	O
reported	O
by	O
other	O
investigators	O
,	O
8	O
were	O
infiltrated	O
.	O

The	O
factors	O
responsible	O
for	O
in	O
vivo	O
eosinophil	O
accumulation	O
at	O
inflammatory	O
sites	O
have	O
been	O
0	O
TRFK-5	O
i.p	O
.	O

0	O
3	O
12	O
17	O
A	O
B	O
FIG	O
.	O

5	O
.	O
Number	O
of	O
eosinophils	O
in	O
BALF	O
of	O
T.	O
caniinfected	O
guinea	O
-	O
pigs	O
submitted	O
or	O
not	O
to	O
treatment	O
with	O
TRFK-5	O
.	O

(	O
A	O
)	O
animals	O
were	O
sacrificed	O
18	O
days	O
post	O
-	O
infection	O
and	O
(	O
B	O
)	O
24	O
days	O
after	O
infection	O
.	O

Asterisks	O
indicate	O
a	O
significant	O
difference	O
from	O
infected	O
control	O
and	O
from	O
animals	O
treated	O
with	O
TRFK-5	O
(	O
p	O
<	O
0.01	O
)	O
.	O

nophilia	O
persists	O
in	O
lungs	O
,	O
probably	O
by	O
the	O
secretion	O
of	O
IL-5	O
from	O
cells	O
localized	O
in	O
the	O
lung	O
microenvironment	O
,	O
Histopathological	O
analysis	O
:	O
The	O
treatment	O
of	O
T.	B
canis	I
-	O
infected	O
animals	O
with	O
irrelevant	O
antibody	O
showed	O
a	O
widespread	O
eosinophilic	O
infiltration	O
as	O
in	O
untreated	O
animals	O
(	O
Fig.	O
6A	O
,	O
B	O
)	O
.	O

However	O
,	O
the	O
treatment	O
of	O
animals	O
with	O
TRFK-5	O
at	O
the	O
same	O
time	O
of	O
infection	O
,	O
or	O
1	O
day	O
or	O
3	O
days	O
later	O
ted	O
to	O
a	O
complete	O
inhibition	O
of	O
eosinophil	O
infiltration	O
in	O
the	O
lung	O
parenchyma	O
(	O
Fig.	O
6C	O
)	O
.	O

By	O
contrast	O
,	O
the	O
mononuclear	O
cell	O
infiltration	O
in	O
the	O
lungs	O
was	O
not	O
modified	O
.	O

When	O
the	O
infected	O
guinea	O
-	O
pigs	O
received	O
TRFK-5	O
1	O
day	O
before	O
sacrifice	O
(	O
or	O
17	O
days	O
post	O
-	O
infection	O
)	O
,	O
eosinophil	O
infiltration	O
in	O
the	O
lung	O
parenchyma	O
was	O
also	O
inhibited	O
(	O
Fig.	O
6D	O
)	O
but	O
not	O
to	O
the	O
same	O
extent	O
as	O
observed	O
in	O
the	O
group	O
receiving	O
TRFK-5	O
given	O
at	O
the	O
time	O
of	O
infection	O
or	O
3	O
days	O
later	O
.	O

Thus	O
,	O
the	O
histological	O
determination	O
of	O
eosinophil	O
infiltration	O
in	O
these	O
lungs	O
corroborates	O
a	O
reduction	O
but	O
not	O
a	O
sizeable	O
inhibition	O
of	O
eosinophil	O
numbers	O
as	O
observed	O
in	O
the	O
BALF	O
of	O
the	O
same	O
infected	O
animals	O
,	O
poorly	O
defined	O
,	O
although	O
T	O
lymphocytes	O
and	O
mast	O
cells	O
appear	O
to	O
be	O
involved	O
in	O
eosinophilia	O
.	O

9'2	O
IL-5	O
,	O
a	O
T	O
cell	O
-	O
derived	O
factor	O
that	O
regulates	O
B	O
cell	O
functions	O
,	O
is	O
an	O
eosinophil	O
differentiation	O
factor11	O
as	O
well	O
as	O
a	O
stimulating	O
and	O
survival	O
-	O
prolonging	O
factor	O
specific	O
for	O
eosinophils	O
in	O
vitro	O
.	O

2	O
Also	O
,	O
several	O
investigators	O
have	O
demonstrated	O
that	O
sTstemic	O
eosinophilia	O
in	O
mice	B
infected	O
with	O
parasites	O
is	O
mediated	O
by	O
IL-5	O
produced	O
in	O
response	O
to	O
the	O
infection	O
.	O

2'22	O
In	O
the	O
present	O
study	O
,	O
the	O
i.p	O
.	O

administration	O
of	O
the	O
TRFK-5	O
antibody	O
markedly	O
inhibited	O
the	O
widespread	O
eosinophilia	O
observed	O
in	O
T.	B
canis	I
-	O
infected	O
guinea	O
-	O
pigs	O
,	O
indicating	O
that	O
IL5	O
participated	O
in	O
a	O
guinea	O
-	O
pig	O
model	O
of	O
VLMS	O
eosinophJlia	O
.	O

Most	O
of	O
the	O
T.	B
canis	I
larvae	O
which	O
penetrated	O
the	O
intestinal	O
wall	O
had	O
migrated	O
into	O
the	O
liver	O
within	O
72h	O
after	O
inoculation	O
as	O
demonstrated	O
here	O
and	O
elsewhere	O
.	O

2	O

It	O
is	O
apparently	O
during	O
this	O
interval	O
that	O
the	O
worm	O
provides	O
the	O
signals	O
to	O
cytokine	O
-	O
producing	O
cells	O
,	O
which	O
in	O
turn	O
trigger	O
increased	O
serum	O
levels	O
of	O
specific	O
cytokine	O
as	O
demonstrated	O
here	O
for	O
IL-5	O
,	O
24	O
to	O
72	O
h	O
after	O
infection	O
.	O

The	O
signals	O
may	O
be	O
provided	O
directly	O
by	O
the	O
invading	O
parasite	O
or	O
by	O
cells	O
in	O
response	O
to	O
the	O
parasite	O
.	O

The	O
cytokine	O
pattern	O
that	O
develops	O
at	O
this	O
early	O
stage	O
,	O
probably	O
induced	O
by	O
a	O
T	O
-	O
cell	O
independent	O
pathway	O
,	O
may	O
also	O
influence	O
the	O
pattern	O
of	O
T	O
cell	O
differentiation	O
into	O
a	O
Th2	O
type	O
,	O
which	O
may	O
be	O
responsible	O
for	O
the	O
second	O
peak	O
of	O
IL-5	O
observed	O
in	O
our	O
experimental	O
model	O
(	O
Fig.	O
3	O
)	O
,	O
although	O
a	O
second	O
cycle	O
of	O
larval	O
invasion	O
(	O
Fig.	O
2	O
)	O
with	O
a	O
rapid	O
peak	O
of	O
IL-5	O
liberation	O
can	O
not	O
be	O
ruled	O
out	O
.	O

Discussion	O
The	O
results	O
of	O
the	O
present	O
study	O
show	O
that	O
in	O
our	O
experimental	O
model	O
widespread	O
eosinophilia	O
follows	O
the	O
infection	O
of	O
guinea	O
-	O
pigs	O
with	O
second	O
stage	O
eggs	O
from	O
T.	B
canis	I
,	O
as	O
also	O
noted	O
in	O
humans	B
and	O
in	O
other	O
experimental	O
animals	O
.	O

7'7	O
T.	B
canis	I
is	O
a	O
potent	O
stimulus	O
for	O
systemic	O
eosinophilia	O
,	O
since	O
blood	O
,	O
BALF	O
,	O
peritoneum	O
and	O
all	O
tissues	O
examined	O
(	O
kidney	O
,	O
eyes	O
,	O
spleen	O
,	O
thymus	O
,	O
Thus	O
,	O
our	O
results	O
suggest	O
that	O
the	O
eosinophilia	O
against	O
helminth	O
larvae	O
may	O
be	O
initiated	O
by	O
the	O
release	O
of	O
IL-5	O
when	O
the	O
parasites	O
migrate	O
from	O
the	O
intestine	O
to	O
the	O
liver	O
by	O
stimulation	O
of	O
specific	O
cell	O
populations	O
.	O

Then	O
,	O
an	O
early	O
release	O
of	O
IL-5	O
quickly	O
induces	O
eosinophil	O
recruitment	O
,	O
probably	O
first	O
from	O
the	O
stored	O
mature	O
eosinophil	O
pool	O
from	O
vascular	O
endothelium	O
or	O
by	O
the	O
mobilization	O
of	O
eosinophils	O
from	O
extravascular	O
sites	O
to	O
the	O
blood	O
.	O

This	O
fact	O
could	O
explain	O
why	O
we	O
found	O
increased	O
eosinophils	O
first	O
in	O
blood	O
and	O
later	O
in	O
other	O
compartments	O
.	O

The	O
early	O
IL-5	O
release	O
may	O
also	O
serve	O
as	O
a	O
signal	O
for	O
eosinophil	O
differentiation	O
and	O
maturation	O
in	O
bone	O
marrow	O
.	O

The	O
time	O
inteeeal	O
observed	O
between	O
the	O
first	O
peak	O
of	O
IL-5	O
release	O
and	O
the	O
increase	O
of	O
eosinophils	O
in	O
blood	O
coincides	O
with	O
that	O
reported	O
to	O
be	O
necessary	O
for	O
eosinophil	O
differentiation	O
and	O
maturation	O
in	O
vitro	O
.	O

12Increased	O
eosinophil	O
production	O
and	O
liberation	O
into	O
blood	O
and	O
other	O
tissues	O
occurs	O
Mediators	O
of	O
Inflammation	O
Vol	O
5	O
1996	O
29	O
L.	O
H.	O
Faccioli	O
et	O
al.	O
FIG	O
.	O

6	O
.	O
(	O
A	O
)	O
photomicrographs	O
of	O
lung	O
parenchyma	O
from	O
guinea	O
-	O
pigs	O
infected	O
for	O
18	O
days	O
with	O
T.	B
cani	I
,	O
,	O
(	O
B	O
)	O
infected	O
animals	O
which	O
were	O
treated	O
with	O
irrelevant	O
antibody	O
at	O
the	O
time	O
of	O
infection	O
;	O
(	O
C	O
)	O
infected	O
animals	O
which	O
were	O
treated	O
with	O
the	O
mAb	O
TRFK-5	O
at	O
3	O
days	O
after	O
infection	O
;	O
(	O
D	O
)	O
mAb	O
administration	O
17	O
days	O
after	O
infection	O
.	O

The	O
animals	O
were	O
sacrificed	O
18	O
days	O
after	O
infection	O
.	O

Note	O
the	O
intense	O
eosinophil	O
infiltration	O
into	O
the	O
lung	O
in	O
A	O
and	O
B	O
,	O
the	O
inhibition	O
of	O
eosinophils	O
in	O
C	O
and	O
the	O
reduction	O
of	O
eosinophils	O
in	O
D.	O
thereafter	O
.	O

Thus	O
,	O
early	O
and	O
later	O
IL-5	O
release	O
provides	O
a	O
necessary	O
level	O
of	O
this	O
cytokine	O
,	O
which	O
is	O
involved	O
in	O
the	O
maintenance	O
of	O
eosinophilia	O
.	O

We	O
may	O
assume	O
that	O
the	O
inhibition	O
of	O
the	O
first	O
peak	O
of	O
IL-5	O
release	O
by	O
TRFK-5	O
does	O
not	O
permit	O
the	O
subsequent	O
T	O
cell	O
stimulation	O
and	O
differentiation	O
.	O

This	O
may	O
explain	O
the	O
long	O
-	O
lasting	O
effect	O
of	O
TRFK5	O
treatment	O
observed	O
here	O
and	O
also	O
reported	O
by	O
others	O
.	O

8	O
In	O
agreement	O
with	O
our	O
results	O
,	O
there	O
is	O
an	O
important	O
observation	O
of	O
Svetic	O
et	O
al.	O
24	O
showing	O
that	O
a	O
specific	O
and	O
highly	O
reproducible	O
IL-5	O
gene	O
expression	O
pattern	O
is	O
detectable	O
in	O
Peyer	O
's	O
patches	O
by	O
6	O
to	O
12h	O
after	O
Heligmosomoides	B
polygyrus	I
infection	O
.	O

The	O
early	O
increase	O
in	O
IL-5	O
gene	O
expression	O
after	O
infection	O
was	O
probably	O
T	O
cell	O
-	O
independent	O
,	O
inasmuch	O
as	O
it	O
was	O
obseeeed	O
in	O
Peyer	O
's	O
patches	O
of	O
congenitally	O
athymic	O
mice	B
and	O
of	O
conventional	O
mice	B
treated	O
with	O
anti	O
-	O
CD4	O
30	O
Mediators	O
of	O
Inflammation	O
Vol	O
5	O
and	O
anti	O
-	O
CD8	O
mAb	O
.	O

Moreover	O
,	O
Kusama	O
eta	O
/	O
.	O
25	O
have	O
observed	O
two	O
peaks	O
of	O
eosinophilia	O
in	O
normal	O
and	O
athymic	O
mice	B
,	O
and	O
suggested	O
that	O
IL-5	O
observed	O
in	O
the	O
first	O
peak	O
was	O
produced	O
by	O
cells	O
other	O
than	O
CD4	O
T	O
cells	O
,	O
since	O
anti	O
-	O
CD4	O
and	O
anti	O
-	O
CD3	O
mAb	O
reduced	O
only	O
the	O
second	O
peak	O
of	O
eosinophilia	O
in	O
normal	O
mice	B
and	O
slightly	O
reduced	O
the	O
first	O
peak	O
of	O
eosinophilia	O
in	O
both	O
normal	O
and	O
nu	O
/	O
nu	O
mice	B
.	O

The	O
local	O
lung	O
cells	O
producing	O
IL-5	O
may	O
also	O
help	O
us	O
to	O
explain	O
the	O
reason	O
why	O
12	O
,	O
17	O
or	O
18	O
days	O
post	O
-	O
infection	O
TRFK-5	O
treatment	O
only	O
partially	O
inhibits	O
,	O
or	O
does	O
not	O
inhibit	O
eosinophil	O
infiltration	O
into	O
the	O
lungs	O
,	O
as	O
demonstrated	O
in	O
Figs	O
5	O
and	O
6	O
.	O

We	O
may	O
suggest	O
that	O
when	O
eosinophils	O
have	O
already	O
migrated	O
to	O
the	O
lungs	O
,	O
TRFK-5	O
has	O
no	O
power	O
to	O
inhibit	O
eosinophilia	O
,	O
which	O
is	O
also	O
under	O
control	O
of	O
local	O
lung	O
cells	O
producing	O
IL-5	O
.	O

In	O
this	O
way	O
,	O
only	O
one	O
later	O
TRFK	O
1996	O
IL-5	O
drives	O
eosinophils	O
in	O
guinea	O
-	O
pig	O
5	O
treatment	O
may	O
not	O
be	O
sufficient	O
to	O
modify	O
the	O
lung	O
parenchyma	O
microenvironment	O
,	O
since	O
T.	B
canis	I
antigens	O
have	O
already	O
stimulated	O
some	O
cell	O
populations	O
to	O
produce	O
IL-5	O
,	O
as	O
demonstrated	O
by	O
Kusama	O
et	O
aL25These	O
results	O
suggest	O
that	O
eosinophilia	O
in	O
lungs	O
is	O
under	O
the	O
control	O
of	O
different	O
factors	O
when	O
compared	O
to	O
that	O
observed	O
in	O
blood	O
and	O
the	O
peritoneal	O
cavity	O
.	O

One	O
of	O
the	O
most	O
important	O
results	O
obtained	O
here	O
was	O
the	O
inhibition	O
of	O
circulating	O
eosinophil	O
numbers	O
by	O
the	O
different	O
mAb	O
treatments	O
,	O
even	O
when	O
the	O
antibody	O
was	O
given	O
at	O
the	O
peak	O
of	O
blood	O
eosinophilia	O
,	O
which	O
was	O
accompanied	O
by	O
an	O
increase	O
of	O
mature	O
eosinophils	O
in	O
bone	O
marrow	O
.	O

This	O
suggests	O
that	O
IL-5	O
,	O
apart	O
from	O
being	O
required	O
for	O
the	O
terminal	O
differentiation	O
of	O
eosinophils	O
in	O
bone	O
marrow	O
,	O
26	O
is	O
also	O
likely	O
to	O
drive	O
eosinophils	O
from	O
the	O
bone	O
marrow	O
to	O
the	O
blood	O
and	O
then	O
to	O
the	O
tissues	O
,	O
probably	O
by	O
upregulating	O
VLA-4	O
expression	O
in	O
eosinophils	O
.	O

Moser	O
et	O
aL	O
have	O
demonstrated	O
that	O
in	O
order	O
to	O
acquire	O
the	O
ability	O
to	O
transmigrate	O
,	O
eosinophils	O
must	O
be	O
primed	O
with	O
cytokines	O
such	O
as	O
IL-5	O
,	O
IL-3	O
or	O
GM	O
-	O
CSF	O
for	O
expression	O
of	O
adhesion	O
molecules	O
such	O
as	O
VI-4	O
.	O

Recently	O
,	O
Pretolani	O
et	O
al.	O
27	O
have	O
indeed	O
shown	O
that	O
an	O
anti	O
-	O
VLA-4	O
antibody	O
suppresses	O
eosinophil	O
recruitment	O
to	O
lung	O
in	O
the	O
guinea	O
-	O
pig	O
and	O
,	O
as	O
a	O
consequence	O
,	O
inhibits	O
the	O
accompanying	O
bronchopulmonary	O
hyperresponsiveness	O
.	O

tant	O
in	O
protective	O
immunity	O
to	O
a	O
gastrointestinal	O
nematode	O
infection	O
in	O
mice	B
.	O

Proc	O
Natl	O
Acad	O
Sci	O
USA	O
1991	O
;	O
88=	O
5513	O
-	O
5517	O
.	O

11	O
.	O

Yamaguchi	O
A	O
,	O
Suda	O
T	O
,	O
Suda	O
J	O
,	O
et	O
al.	O
Purified	O
interleukin	O
(	O
IL-5	O
)	O
supports	O
the	O
terminal	O
differentiation	O
and	O
proliferation	O
of	O
murine	O
eosinophilic	O
precursors	O
.	O

J	O
Exp	O
Med	O
1988	O
;	O
16'7	O
:	O
43	O
-	O
56	O
.	O
12	O
.	O

Yamaguchi	O
Y	O
,	O
Hayashi	O
Y	O
,	O
Sugama	O
Y	O
,	O
et	O
al.	O
Highly	O
purified	O
murine	O
interleukin	O
(	O
IL-5	O
)	O
stimulates	O
eosinophil	O
function	O
and	O
prolongs	O
in	O
vitro	O
survival	O
.	O

IL-5	O
as	O
an	O
eosinophil	O
chemotactic	O
factor	O
.	O

J	O
Exp	O
Med	O
1988	O
;	O
16'7	O
:	O
17371752	O
.	O
13	O
.	O

Rothenberg	O
ME	O
,	O
Petersen	O
J	O
,	O
Stevens	O
RL	O
,	O
Silberstein	O
DS	O
,	O
McKenzie	O
DT	O
,	O
Austen	O
KF	O
,	O
Owen	O
WF	O
.	O

IL-5-dependent	O
conversion	O
of	O
normodense	O
human	B
eosinophils	O
to	O
the	O
hypodense	O
phenotype	O
uses	O
3T3	O
fibroblasts	O
for	O
enhanced	O
viability	O
,	O
accelerated	O
hypodensity	O
,	O
and	O
sustained	O
antibodydependent	O
cytotoxicity	O
.	O

J	O
Immuno11989	O
;	O
143	O
;	O
2311	O
-	O
2316	O
.	O
14	O
.	O

Collins	O
PD	O
,	O
Weg	O
VB	O
,	O
Faccioli	O
LH	O
,	O
Watson	O
ML	O
,	O
Moqbel	O
R	O
,	O
Williams	O
TJ	O
.	O

Eosinophil	O
accumulation	O
induced	O
by	O
human	B
interleukin-8	O
in	O
the	O
guinea	B
pig	I
in	O
vivo	O
.	O

Immunology	O
1993	O
;	O
'	O
7	O
}	O
;	O
312	O
-	O
318	O
.	O
15	O
.	O

Sehmi	O
R	O
,	O
Wardlavo	O
AJ	O
,	O
Cromwell	O
O	O
,	O
Kurihara	O
K	O
,	O
Waltmann	O
P	O
,	O
Kay	O
AB	O
.	O

Interleukin-5	O
selectively	O
enhances	O
the	O
chemotactic	O
response	O
of	O
eosinophils	O
obtained	O
from	O
normal	O
but	O
not	O
eosinophilic	O
subjects	O
.	O

Blood	O
1992	O
;	O
'	O
79	O
;	O
2952	O
-	O
2959	O
.	O

16	O
.	O

Moser	O
R	O
,	O
Fehr	O
J	O
,	O
Bruijnzeel	O
PLB	O
.	O

IL-4	O
controls	O
the	O
selective	O
endotheliumdriven	O
transmigration	O
of	O
eosinophils	O
from	O
allergic	O
individuals	O
.	O

J	O
Immunol	O
1992	O
;	O
149	O
:	O
1432	O
-	O
1438	O
.	O

17	O
.	O

Olson	O
LJ	O
,	O
Schulz	O
CW	O
.	O

Nematode	O
induced	O
hypersensitivity	O
reactions	O
in	O
guinea	B
pigs	I
:	O
onset	O
of	O
eosinophilia	O
and	O
positive	O
Schultz	O
-	O
Dale	O
reactions	O
following	O
graded	O
infection	O
with	O
Toxocara	B
canis	I
.	O

Ann	O
N	O
Y	O
Acad	O
Sci	O
1963	O
;	O
113	O
;	O
440	O
-	O
455	O
.	O
18	O
.	O

Kayes	O
SG	O
,	O
Oaks	O
JA	O
.	O

Development	O
of	O
the	O
granulomatous	O
response	O
in	O
murine	O
toxocariasis	O
.	O

I.	O
Initial	O
events	O
.	O

Am	O
J	O
Patho11978	O
;	O
,	O
}	O
3	O
;	O
277	O
-	O
294	O
.	O
19	O
.	O

Basten	O
A	O
,	O
Beeson	O
PB	O
.	O

Mechanisms	O
of	O
eosinophilia	O
.	O

II	O
.	O

Role	O
of	O
the	O
lymphocyte	O
.	O

J	O
Exp	O
Med	O
1970	O
;	O
131	O
;	O
1288	O
-	O
1305	O
.	O

20	O
.	O

Plaut	O
M	O
,	O
Pierce	O
JH	O
,	O
Watson	O
CJ	O
,	O
Hanley	O
-	O
Hyde	O
J	O
,	O
Nordan	O
RP	O
,	O
Paul	O
WE	O
.	O

Mast	O
cell	O
lines	O
produce	O
lymphokines	O
in	O
response	O
to	O
cross	O
-	O
linkage	O
of	O
Fc	O
epsilon	O
RI	O
or	O
to	O
calcium	O
ionophoras	O
.	O

Nature	O
1989	O
;	O
339	O
:	O
64	O
-	O
67	O
.	O
is	O
21	O
.	O

Sher	O
A	O
,	O
Coffman	O
RL	O
,	O
Hieny	O
S	O
,	O
Scott	O
P	O
,	O
Cheever	O
AW	O
.	O

Interleukin	O
required	O
for	O
the	O
blood	O
and	O
tissue	O
eosinophilia	O
but	O
not	O
granuloma	O
formation	O
induced	O
by	O
infection	O
with	O
Schistosoma	B
mansoni	I
.	O

Proc	O
Natl	O
Acad	O
Sci	O
USA	O
1990	O
;	O
8'7	O
;	O
61	O
-	O
65	O
.	O
22	O
.	O

Herndon	O
FJ	O
,	O
Kayes	O
SG	O
.	O

Depletion	O
of	O
eosinophils	O
by	O
anti	O
-	O
IL-5	O
monoclonal	O
antibody	O
treatment	O
of	O
mice	B
infected	O
with	O
Trichinella	B
spiralis	I
does	O
not	O
alter	O
parasite	O
burden	O
or	O
immunologic	O
resistance	O
to	O
reinfection	O
.	O

J	O
Immuno11992	O
;	O
149	O
:	O
3642	O
-	O
3647	O
.	O

23	O
.	O

Oshima	O
T.	O
Standardization	O
of	O
techniques	O
for	O
infecting	O
mice	B
with	O
Tox24	O
.	O

ocara	O
canis	O
and	O
observations	O
on	O
the	O
normal	O
migration	O
routes	O
of	O
the	O
larvae	O
.	O

J	O
Parasito11961	O
;	O
4'7=	O
652	O
.	O

Svetic	O
A	O
,	O
Madden	O
KB	O
,	O
Zhou	O
XD	O
,	O
et	O
al.	O
A	O
primary	O
intestinal	O
helminthic	O
infection	O
rapidly	O
induces	O
a	O
gut	O
-	O
associated	O
elevation	O
of	O
Th2-associated	O
cytokines	O
and	O
IL-3	O
.	O

J	O
Immuno11993	O
;	O
150	O
:	O
3434	O
-	O
3441	O
.	O

Kusama	O
Y	O
,	O
Takamoto	O
M	O
,	O
Kasahara	O
T	O
,	O
Takatsu	O
K	O
,	O
Nariuchi	O
H	O
,	O
Sugane	O
K.	O
Mechanisms	O
of	O
eosinophilia	O
in	O
BALB	O
/	O
c	O
-	O
nu	O
/	O
+	O
and	O
congenitally	O
athymic	O
BALB	O
/	O
c	O
-	O
nu	O
/	O
nu	O
mice	B
infected	O
with	O
Toxocara	B
canis	I
.	O

Immunology	O
1995	O
;	O
84	O
;	O
461	O
-	O
468	O
.	O

Rennick	O
DM	O
,	O
Thompson	O
-	O
Snipes	O
L	O
,	O
Coffman	O
RL	O
,	O
Seymour	O
BWP	O
,	O
Jackson	O
JD	O
,	O
Hudak	O
S.	O
In	O
vivo	O
administration	O
of	O
antibody	O
to	O
interleukin-5	O
inhibits	O
increased	O
generation	O
of	O
eosinophils	O
and	O
their	O
progenitors	O
in	O
bone	O
marrow	O
of	O
parasitized	O
mice	B
.	O

Blood	O
1990	O
;	O
'	O
76	O
:	O
312	O
-	O
316	O
.	O

Petrolani	O
M	O
,	O
Ruffle	O
C	O
,	O
Lapa	O
e	O
Silva	O
JR	O
,	O
Joseph	O
D	O
,	O
Lobb	O
RR	O
,	O
Boris	O
Vargaftig	O
B.	O
Antibody	O
to	O
very	O
late	O
activation	O
antigen	O
4	O
prevents	O
antigen	O
-	O
induced	O
bronchial	O
hyperreactivity	O
and	O
cellular	O
infiltration	O
in	O
guinea	B
pig	I
airways	O
.	O

J	O
Exp	O
Med	O
1994	O
;	O
180=	O
795	O
-	O
805	O
.	O

References	O
25	O
.	O
1	O
.	O

Nutman	O
2	O
.	O

3	O
.	O
4	O
.	O
5	O
.	O
6	O
.	O
7	O
.	O
8	O
.	O
9	O
.	O

TB	O
,	O
Ottesen	O
EA	O
,	O
Cohen	O
SG	O
.	O

The	O
eosinophil	O
,	O
eosinophilia	O
,	O
and	O
eosinophil	O
-	O
related	O
disorders	O
.	O

Allergy	O
Proc	O
1989	O
;	O
10	O
;	O
47	O
-	O
62	O
.	O

Glickman	O
LT	O
,	O
Schantz	O
PM	O
.	O

Epidemiology	O
and	O
pathogenesis	O
of	O
zoonotic	O
toxocariasis	O
.	O

Epidem	O
Rev	O
1981	O
;	O
3=	O
230	O
-	O
250	O
.	O

Beaver	O
P	O
,	O
Snyder	O
H	O
,	O
Carrera	O
G	O
,	O
Dent	O
J	O
,	O
Lafferty	O
J.	O
Chronic	O
eosinophilia	O
due	O
to	O
visceral	O
larva	O
migrans	O
.	O

Pediatrics	O
1952	O
;	O
9	O
:	O
7	O
-	O
19	O
.	O

Limaye	O
AP	O
,	O
Abrams	O
JS	O
,	O
Silver	O
JE	O
,	O
Ottesen	O
EA	O
,	O
Nutman	O
TB	O
.	O

Regulation	O
of	O
parasite	O
-	O
induced	O
eosinophilia	O
:	O
selectively	O
increased	O
interleukin	O
production	O
in	O
helminth	O
-	O
infected	O
patients	O
.	O

J	O
Exp	O
Med	O
1990	O
;	O
l'7	O
:	O
a	O
;	O
399	O
-	O
402	O
.	O

Steel	O
C	O
,	O
Nutman	O
TB	O
.	O

Regulation	O
of	O
IL-5	O
in	O
onchocerciasis	O
:	O
a	O
critical	O
role	O
for	O
IL-2	O
.	O

J	O
Immuno11993	O
;	O
15	O
{	O
}	O
;	O
5511	O
-	O
5518	O
.	O

Yamaguchi	O
Y	O
,	O
Matsui	O
T	O
,	O
Kasahara	O
T	O
,	O
et	O
al.	O
In	O
vivo	O
changes	O
of	O
hemapoietic	O
progenitors	O
and	O
the	O
expression	O
of	O
the	O
interleukin	O
gene	O
in	O
eosinophilic	O
mice	B
infected	O
with	O
Toxocara	B
canis	I
.	O

Exp	O
Hemato11990	O
;	O
18	O
;	O
1152	O
-	O
1157	O
.	O

Parsons	O
JC	O
,	O
Coffman	O
RL	O
,	O
Grieve	O
RB	O
.	O

Antibody	O
to	O
interleukin	O
prevents	O
blood	O
and	O
tissue	O
eosinophilia	O
but	O
not	O
liver	O
trapping	O
in	O
murine	O
larval	O
toxocariasis	O
.	O

Parasite	O
Immuno11993	O
;	O
15	O
:	O
501	O
-	O
508	O
.	O

Coffman	O
RL	O
,	O
Seymour	O
BWP	O
,	O
Hudak	O
S	O
,	O
Jackson	O
J	O
,	O
Rennick	O
D.	O
Antibody	O
to	O
interleukin-5	O
inhibits	O
helminth	O
-	O
induced	O
eosinophilia	O
in	O
mice	B
.	O

Science	O
1989	O
;	O
245	O
;	O
308	O
-	O
310	O
.	O

Sher	O
A	O
,	O
Coffman	O
RL	O
,	O
Hieny	O
S	O
,	O
Cheever	O
AW	O
.	O

Ablation	O
of	O
eosinophil	O
and	O
IgE	O
responses	O
with	O
anti	O
-	O
IL-5	O
or	O
anti	O
-	O
IL-4	O
antibodies	O
fails	O
to	O
affect	O
immunity	O
against	O
Schistosoma	B
mansoni	I
in	O
the	O
mouse	B
.	O

J	O
Immuno11990	O
;	O
145	O
:	O
3911	O
26	O
.	O

27	O
.	O

ACKNOWLEDGEMENTS	O
.	O

This	O
work	O
was	O
funded	O
by	O
grant	O
300652	O
/	O
85	O
-	O
2	O
from	O
Conselho	O
Nacional	O
de	O
Desenvolvimento	O
Cientifico	O
e	O
Tecnol6gico	O
(	O
CNPq	O
)	O
and	O
Grant	O
92	O
/	O
5105	O
-	O
7	O
from	O
Fundago	O
de	O
Amparo	O
ft	O
Pesquisa	O
do	O
Estado	O
de	O
So	O
Paulo	O
(	O
FAPESP	O
)	O
.	O

We	O
wish	O
to	O
thank	O
Mrs	O
M.A.	O
Fernandes	O
for	O
technical	O
assistance	O
,	O
Mrs	O
M.M.O.	O
Rossi	O
for	O
the	O
histological	O
sections	O
,	O
M.	O
Costa	O
Gongalves	O
for	O
the	O
photography	O
artwork	O
,	O
and	O
Dr	O
P.	O
Minoprio	O
,	O
Institut	O
Pasteur	O
,	O
for	O
kindly	O
providing	O
TRFK-5	O
.	O

3916	O
.	O

10	O
.	O

Urban	O
Jr	O
JF	O
,	O
Katona	O
IM	O
,	O
Paul	O
WE	O
,	O
Finkelman	O
FD	O
.	O

Interleukin	O
4	O
is	O
impor	O
Received	O
12	O
October	O
1995	O
;	O
accepted	O
17	O
November	O
1995	O
Mediators	O
of	O
Inflammation	O
Vol	O
5	O
1996	O
31	O

Comparison	O
of	O
strategies	O
for	O
identification	O
of	O
regulatory	O
quantitative	O
trait	O
loci	O
of	O
transcript	O
expression	O
traits	O
Abstract	O
In	O
order	O
to	O
identify	O
regulatory	O
genes	O
,	O
we	O
determined	O
the	O
heritability	O
of	O
gene	O
transcripts	O
,	O
performed	O
linkage	O
analysis	O
to	O
identify	O
quantitative	O
trait	O
loci	O
(	O
QTLs	O
)	O
,	O
and	O
evaluated	O
the	O
evidence	O
for	O
shared	O
genetic	O
effects	O
among	O
transcripts	O
with	O
co	O
-	O
localized	O
QTLs	O
in	O
non	O
-	O
diseased	O
participants	O
from	O
14	O
CEPH	O
(	O
Centre	O
d'Etude	O
du	O
Polymorphisme	O
Humain	O
)	O
Utah	O
families	O
.	O

Seventy	O
-	O
six	O
percent	O
of	O
transcripts	O
had	O
a	O
significant	O
heritability	O
and	O
54	O
%	O
of	O
them	O
had	O
LOD	O
score	O
≥	O
1.8	O
.	O

Bivariate	O
genetic	O
analysis	O
of	O
15	O
transcripts	O
that	O
had	O
co	O
-	O
localized	O
QTLs	O
on	O
4q28.2-q31.1	O
identified	O
significant	O
genetic	O
correlation	O
among	O
some	O
transcripts	O
although	O
no	O
improvement	O
in	O
the	O
magnitude	O
of	O
LOD	O
scores	O
in	O
this	O
region	O
was	O
noted	O
.	O

Similar	O
results	O
were	O
found	O
in	O
analysis	O
of	O
12	O
transcripts	O
,	O
that	O
had	O
co	O
-	O
localized	O
QTLs	O
in	O
the	O
13q34	O
region	O
.	O

Principal	O
-	O
component	O
analyses	O
did	O
not	O
improve	O
the	O
ability	O
to	O
identify	O
chromosomal	O
regions	O
of	O
co	O
-	O
localized	O
gene	O
expressions	O
.	O

Background	O
There	O
is	O
a	O
breadth	O
of	O
information	O
being	O
generated	O
by	O
the	O
Human	B
Genome	O
Project	O
and	O
the	O
interpretation	O
of	O
these	O
data	O
has	O
been	O
a	O
major	O
area	O
of	O
research	O
.	O

For	O
simple	O
Mendelian	O
disorders	O
,	O
the	O
identification	O
of	O
genetic	O
effects	O
is	O
fairly	O
straightforward	O
due	O
to	O
understanding	O
the	O
biology	O
that	O
drives	O
these	O
disorders	O
.	O

However	O
,	O
for	O
complex	O
oligogenic	O
or	O
polygenic	O
disorders	O
,	O
understanding	O
all	O
the	O
interconnections	O
between	O
genes	O
influencing	O
a	O
trait	O
is	O
a	O
difficult	O
task	O
because	O
the	O
understanding	O
of	O
the	O
biology	O
of	O
many	O
of	O
these	O
disorders	O
is	O
still	O
evolving	O
.	O

Multiple	O
gene	O
×	O
gene	O
and	O
gene	O
×	O
environment	O
interactions	O
can	O
influence	O
the	O
expression	O
of	O
phenotypes	O
.	O

Genes	O
can	O
interact	O
by	O
modifying	O
the	O
expression	O
of	O
other	O
genes	O
and	O
therefore	O
function	O
as	O
regulatory	O
genes	O
[	O
1	O
]	O
.	O

In	O
an	O
effort	O
to	O
dissect	O
some	O
of	O
these	O
complexities	O
,	O
we	O
performed	O
linkage	O
analysis	O
of	O
gene	O
expression	O
transcripts	O
of	O
members	O
of	O
Centre	O
d'Etude	O
du	O
Polymorphisme	O
Humain	O
(	O
CEPH	O
)	O
Utah	O
families	O
to	O
determine	O
the	O
heritability	O
of	O
transcripts	O
and	O
the	O
evidence	O
for	O
regulatory	O
quantitative	O
trait	O
loci	O
(	O
QTLs	O
)	O
and	O
we	O
performed	O
pairwise	O
bivariate	O
linkage	O
analysis	O
and	O
principal	O
-	O
component	O
analysis	O
(	O
PCA	O
)	O
for	O
data	O
-	O
reduction	O
to	O
evaluate	O
the	O
evidence	O
for	O
shared	O
genetic	O
effects	O
.	O

The	O
ability	O
to	O
assess	O
gene	O
expression	O
traits	O
simultaneously	O
and	O
to	O
link	O
them	O
to	O
QTLs	O
offers	O
the	O
possibility	O
of	O
identifying	O
previously	O
unknown	O
underlying	O
molecular	O
processes	O
for	O
future	O
investigation	O
.	O

Methods	O
Population	O
and	O
phenotypes	O
We	O
used	O
the	O
Genetic	O
Analysis	O
Workshop	O
15	O
(	O
GAW	O
15	O
)	O
Problem	O
1	O
microarray	O
gene	O
expression	O
profiles	O
for	O
the	O
analyses	O
.	O

Data	O
were	O
available	O
for	O
14	O
three	O
-	O
generation	O
CEPH	O
Utah	O
families	O
.	O

Expression	O
levels	O
of	O
genes	O
were	O
obtained	O
from	O
lymphoblastoid	O
cells	O
using	O
the	O
Affymetrix	O
Human	B
Focus	O
Arrays	O
[	O
2	O
]	O
.	O

We	O
were	O
provided	O
with	O
data	O
on	O
3554	O
transcripts	O
that	O
showed	O
greater	O
variation	O
between	O
individuals	O
than	O
within	O
the	O
same	O
individual	O
.	O

Family	O
members	O
were	O
genotyped	O
for	O
2882	O
autosomal	O
and	O
X	O
-	O
linked	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNP	O
)	O
generated	O
by	O
the	O
SNP	O
Consortium	O
.	O

Genetic	O
map	O
positions	O
were	O
obtained	O
using	O
the	O
SNP	O
Mapping	O
web	O
application	O
developed	O
by	O
the	O
University	O
College	O
Dublin	O
Conway	O
Institute	O
of	O
Biomolecular	O
and	O
Biomedical	O
Research	O
,	O
which	O
uses	O
the	O
Rutgers	O
Combined	O
Linkage	O
-	O
Physical	O
Map	O
of	O
the	O
Human	B
Genome	O
and	O
data	O
taken	O
from	O
the	O
NCBI	O
dbSNP	O
Build	O
123	O
(	O
in	O
Kosambi	O
centimorgans	O
)	O
.	O

This	O
information	O
was	O
used	O
to	O
calculate	O
multipoint	O
identity	O
by	O
descent	O
matrices	O
(	O
MIBDs	O
)	O
with	O
Merlin	O
and	O
Minx	O
[	O
3	O
]	O
,	O
after	O
removal	O
of	O
Mendelian	O
inconsistencies	O
and	O
double	O
recombinants	O
with	O
Preswalk	O
(	O
based	O
on	O
Simwalk	O
mistyping	O
probabilities	O
)	O
[	O
4	O
]	O
.	O

MIBDs	O
were	O
used	O
for	O
linkage	O
analyses	O
.	O

Transcript	O
distributions	O
were	O
normalized	O
using	O
an	O
inverse	O
normalization	O
transformation	O
of	O
z	O
-	O
scores	O
of	O
individual	O
transcripts	O
regressed	O
on	O
the	O
mean	O
individual	O
transcript	O
level	O
.	O

We	O
further	O
adjusted	O
for	O
the	O
effects	O
of	O
age	O
,	O
age2	O
,	O
sex	O
,	O
age	O
×	O
sex	O
and	O
age2	O
×	O
sex	O
interaction	O
using	O
predictive	O
linear	O
regression	O
models	O
in	O
SAS	O
9.1	O
(	O
Cary	O
,	O
NC	O
)	O
.	O

We	O
generated	O
these	O
residuals	O
as	O
part	O
of	O
our	O
processing	O
of	O
the	O
transcripts	O
for	O
linkage	O
analyses	O
.	O

Heritability	O
estimation	O
and	O
linkage	O
analysis	O
Heritability	O
was	O
estimated	O
using	O
maximum	O
likelihood	O
variance	O
decomposition	O
methods	O
in	O
SOLAR	O
[	O
5,6	O
]	O
.	O

Genome	O
scans	O
were	O
performed	O
using	O
multipoint	O
variance	O
-	O
components	O
models	O
that	O
test	O
for	O
linkage	O
between	O
traits	O
and	O
genetic	O
variants	O
by	O
partitioning	O
the	O
variance	O
of	O
the	O
expression	O
level	O
into	O
its	O
additive	O
genetic	O
and	O
environmental	O
variance	O
components	O
[	O
7	O
]	O
.	O

For	O
transcripts	O
with	O
co	O
-	O
localized	O
QTLs	O
,	O
we	O
performed	O
bivariate	O
linkage	O
analysis	O
to	O
identify	O
shared	O
genetic	O
effects	O
.	O

The	O
bivariate	O
polygenic	O
model	O
estimates	O
correlations	O
caused	O
by	O
residual	O
additive	O
genetic	O
effects	O
(	O
ρG	O
)	O
and	O
correlations	O
caused	O
by	O
random	O
environmental	O
effects	O
(	O
ρE	O
)	O
[	O
8	O
]	O
.	O

To	O
test	O
for	O
additive	O
genetic	O
correlation	O
among	O
pairs	O
of	O
traits	O
,	O
the	O
log	O
likelihood	O
of	O
a	O
model	O
in	O
which	O
ρG	O
is	O
constrained	O
to	O
0	O
(	O
null	O
hypothesis	O
,	O
no	O
correlation	O
)	O
or	O
ρG	O
=	O
1	O
(	O
null	O
hypothesis	O
,	O
complete	O
shared	O
genetic	O
effect	O
)	O
is	O
compared	O
to	O
that	O
of	O
a	O
model	O
in	O
which	O
ρG	O
is	O
estimated	O
for	O
the	O
traits	O
.	O

Significant	O
differences	O
among	O
the	O
models	O
(	O
ρG	O
≠	O
0	O
)	O
suggest	O
that	O
some	O
of	O
the	O
same	O
genes	O
influence	O
both	O
traits	O
.	O

We	O
also	O
performed	O
linkage	O
analysis	O
using	O
the	O
factors	O
obtained	O
from	O
the	O
PCA	O
in	O
a	O
sample	O
of	O
transcripts	O
with	O
co	O
-	O
localized	O
QTLs	O
.	O

Principal	O
-	O
component	O
analysis	O
PCA	O
was	O
used	O
to	O
reduce	O
the	O
number	O
of	O
expression	O
profiles	O
into	O
statistically	O
meaningful	O
groups	O
while	O
retaining	O
the	O
original	O
total	O
variance	O
using	O
all	O
the	O
expression	O
profiles	O
[	O
9,10	O
]	O
.	O

We	O
selected	O
two	O
different	O
chromosomal	O
regions	O
of	O
a	O
length	O
of	O
10	O
to	O
12	O
MB	O
in	O
which	O
the	O
QTLs	O
of	O
at	O
least	O
10	O
transcripts	O
were	O
co	O
-	O
localized	O
.	O

Only	O
transcripts	O
of	O
genes	O
that	O
were	O
not	O
located	O
in	O
these	O
selected	O
chromosomal	O
regions	O
were	O
included	O
in	O
the	O
analyses	O
(	O
trans	O
-	O
regulatory	O
genes	O
)	O
.	O

Because	O
of	O
the	O
small	O
number	O
of	O
individuals	O
in	O
the	O
study	O
and	O
concerns	O
of	O
overfitting	O
the	O
model	O
,	O
a	O
maximum	O
sample	O
of	O
50	O
transcript	O
values	O
were	O
considered	O
at	O
one	O
time	O
[	O
11	O
]	O
.	O

The	O
number	O
of	O
factors	O
was	O
determined	O
using	O
the	O
eigenvalue	O
-	O
one	O
requirement	O
[	O
11	O
]	O
.	O

Factors	O
are	O
interpreted	O
by	O
examining	O
the	O
varimax	O
-	O
rotated	O
factor	O
loadings	O
,	O
which	O
are	O
the	O
correlations	O
between	O
each	O
phenotype	O
and	O
the	O
factor	O
in	O
question	O
.	O

Factor	O
loadings	O
greater	O
than	O
or	O
equal	O
to	O
0.40	O
in	O
absolute	O
value	O
were	O
used	O
to	O
interpret	O
factors	O
and	O
to	O
characterize	O
the	O
factor	O
structures	O
;	O
this	O
criterion	O
ensures	O
that	O
the	O
individual	O
factor	O
variables	O
share	O
at	O
least	O
15	O
%	O
of	O
their	O
variance	O
with	O
the	O
given	O
factor	O
[	O
9	O
]	O
.	O

The	O
principle	O
components	O
were	O
obtained	O
by	O
calculating	O
the	O
eigenvalues	O
of	O
the	O
sample	O
covariance	O
matrix	O
,	O
which	O
represent	O
the	O
amount	O
of	O
variance	O
contributed	O
by	O
each	O
factor	O
.	O

Only	O
factors	O
with	O
eigenvalues	O
higher	O
than	O
1	O
were	O
considered	O
for	O
linkage	O
analysis	O
.	O

Integrating	O
data	O
from	O
linkage	O
analysis	O
for	O
gene	O
co	O
-	O
expression	O
Linkage	O
signals	O
of	O
individual	O
transcript	O
expressions	O
were	O
recorded	O
and	O
the	O
location	O
of	O
QTLs	O
was	O
compared	O
to	O
the	O
location	O
of	O
the	O
transcript	O
gene	O
in	O
order	O
to	O
identify	O
trans	O
-	O
regulatory	O
sites	O
.	O

In	O
addition	O
,	O
the	O
location	O
and	O
LOD	O
scores	O
of	O
QTLs	O
identified	O
in	O
single	O
individual	O
transcript	O
analysis	O
(	O
univariate	O
analysis	O
)	O
were	O
compared	O
with	O
the	O
location	O
of	O
the	O
QTLs	O
identified	O
using	O
bivariate	O
analysis	O
or	O
factors	O
of	O
the	O
PCA	O
.	O

This	O
allowed	O
a	O
determination	O
of	O
whether	O
the	O
bivariate	O
analysis	O
or	O
PCA	O
data	O
reduction	O
analysis	O
improved	O
our	O
evidence	O
for	O
linkage	O
,	O
and	O
if	O
so	O
,	O
a	O
more	O
in	O
-	O
depth	O
examination	O
of	O
the	O
transcripts	O
included	O
in	O
the	O
principal	O
components	O
needs	O
to	O
be	O
examined	O
for	O
biologic	O
interactions	O
on	O
complex	O
disorders	O
.	O

Results	O
Among	O
194	O
individuals	O
from	O
14	O
families	O
,	O
17	O
individuals	O
with	O
missing	O
information	O
on	O
age	O
were	O
excluded	O
.	O

Seventy	O
-	O
six	O
percent	O
(	O
n	O
=	O
2688	O
)	O
of	O
the	O
transcripts	O
had	O
significant	O
heritability	O
(	O
p	O
<	O
0.05	O
)	O
and	O
were	O
considered	O
for	O
the	O
linkage	O
analysis	O
.	O

Of	O
this	O
,	O
1448	O
(	O
54	O
%	O
)	O
transcripts	O
displayed	O
suggestive	O
evidence	O
of	O
linkage	O
(	O
had	O
a	O
maximum	O
LOD	O
score	O
≥	O
1.8	O
[	O
12	O
]	O
)	O
.	O

The	O
QTLs	O
of	O
1661	O
transcripts	O
(	O
759	O
of	O
which	O
with	O
LOD	O
≥	O
1.8	O
)	O
were	O
localized	O
in	O
a	O
different	O
region	O
than	O
the	O
gene	O
transcript	O
(	O
trans	O
-	O
regulatory	O
sites	O
)	O
.	O

We	O
used	O
two	O
different	O
chromosomal	O
regions	O
with	O
co	O
-	O
localized	O
transcript	O
QTLs	O
,	O
chromosomes	O
4q28.2-q31.1	O
and	O
13q34	O
,	O
for	O
more	O
in	O
-	O
depth	O
analyses	O
.	O

Chromosome	O
4q28.2-q31.1	O
region	O
Table	O
1	O
reports	O
the	O
results	O
for	O
the	O
chromosome	O
4q28.2-q31.1	O
region	O
.	O

Fifteen	O
transcripts	O
co	O
-	O
localized	O
in	O
this	O
region	O
in	O
the	O
univariate	O
linkage	O
analysis	O
,	O
and	O
the	O
LOD	O
scores	O
ranged	O
from	O
1.17	O
to	O
3.72	O
.	O

The	O
strongest	O
linkage	O
signals	O
were	O
observed	O
for	O
the	O
transcripts	O
of	O
the	O
MX2	O
,	O
NUCB2	O
,	O
and	O
SNX4	O
genes	O
.	O

Using	O
PCA	O
,	O
we	O
obtained	O
five	O
factors	O
from	O
the	O
15	O
transcripts	O
with	O
eigenvalues	O
greater	O
than	O
1	O
.	O

Only	O
one	O
factor	O
,	O
with	O
a	O
high	O
positive	O
loading	O
for	O
the	O
MX2	O
gene	O
transcript	O
,	O
had	O
a	O
significant	O
heritability	O
and	O
a	O
LOD	O
score	O
≥	O
1.8	O
.	O

The	O
linkage	O
analysis	O
using	O
this	O
factor	O
identified	O
the	O
chromosome	O
region	O
for	O
the	O
MX2	O
gene	O
,	O
but	O
the	O
LOD	O
score	O
was	O
lower	O
than	O
the	O
one	O
obtained	O
by	O
single	O
linkage	O
analysis	O
of	O
the	O
MX2	O
transcript	O
.	O

We	O
then	O
performed	O
bivariate	O
analysis	O
of	O
all	O
pairwise	O
co	O
-	O
localized	O
transcripts	O
on	O
4q28.2-q31.1	O
and	O
found	O
evidence	O
for	O
genetic	O
correlation	O
of	O
co	O
-	O
localized	O
genes	O
,	O
although	O
without	O
much	O
increase	O
in	O
the	O
magnitude	O
of	O
the	O
LOD	O
score	O
(	O
Figure	O
1	O
)	O
.	O

This	O
analysis	O
identified	O
two	O
networks	O
of	O
gene	O
expressions	O
(	O
Figure	O
1	O
)	O
.	O

We	O
obtained	O
two	O
factors	O
using	O
PCA	O
of	O
the	O
first	O
network	O
(	O
Group	O
1	O
,	O
SNX4	O
,	O
YWHAQ	O
,	O
ASS	O
,	O
MX2	O
,	O
and	O
ISGF3	O
G	O
gene	O
transcripts	O
)	O
.	O

Both	O
factors	O
had	O
significant	O
heritability	O
;	O
however	O
,	O
only	O
Factor	O
1	O
,	O
loading	O
heavily	O
on	O
the	O
MX2	O
gene	O
,	O
localized	O
to	O
the	O
4q28.2-q31.1	O
region	O
(	O
Table	O
1	O
)	O
,	O
and	O
the	O
magnitude	O
of	O
the	O
LOD	O
score	O
was	O
lower	O
than	O
that	O
of	O
the	O
univariate	O
MX2	O
gene	O
transcript	O
analysis	O
(	O
LOD	O
=	O
2.28	O
)	O
.	O

The	O
heritability	O
of	O
one	O
factor	O
obtained	O
using	O
PCA	O
for	O
Group	O
2	O
transcripts	O
was	O
not	O
significant	O
and	O
further	O
analysis	O
was	O
not	O
performed	O
.	O

Chromosome	O
13q34	O
region	O
We	O
performed	O
analysis	O
in	O
an	O
additional	O
chromosome	O
region	O
of	O
co	O
-	O
localized	O
transcripts	O
,	O
13q34	O
region	O
,	O
and	O
noted	O
similar	O
results	O
.	O

Using	O
univariate	O
analysis	O
,	O
12	O
transcripts	O
co	O
-	O
localized	O
in	O
this	O
region	O
;	O
and	O
bivariate	O
analysis	O
revealed	O
an	O
intricate	O
network	O
of	O
correlated	O
traits	O
(	O
Table	O
2	O
and	O
Figure	O
2	O
)	O
.	O

Using	O
PCA	O
,	O
we	O
obtained	O
five	O
factors	O
,	O
three	O
of	O
them	O
with	O
significant	O
heritability	O
.	O

Similar	O
to	O
our	O
previous	O
findings	O
on	O
chomosome	O
4	O
,	O
PCA	O
factors	O
did	O
not	O
improve	O
the	O
magnitude	O
of	O
the	O
LOD	O
scores	O
when	O
compared	O
to	O
univariate	O
analysis	O
.	O

Discussion	O
In	O
this	O
study	O
,	O
we	O
identified	O
co	O
-	O
localized	O
QTLs	O
of	O
individual	O
transcripts	O
and	O
compared	O
the	O
univariate	O
and	O
bivariate	O
linkage	O
results	O
using	O
single	O
transcripts	O
to	O
those	O
using	O
factors	O
obtained	O
from	O
PCA	O
.	O

By	O
using	O
factors	O
that	O
accounted	O
for	O
the	O
variance	O
of	O
multiple	O
transcripts	O
with	O
co	O
-	O
localized	O
QTLs	O
,	O
we	O
attempted	O
to	O
reduce	O
the	O
number	O
of	O
linkage	O
analyses	O
performed	O
as	O
well	O
as	O
possibly	O
identifying	O
previously	O
unknown	O
patterns	O
of	O
associated	O
gene	O
expression	O
profiles	O
.	O

The	O
PCA	O
did	O
in	O
fact	O
reduce	O
the	O
number	O
of	O
linkage	O
analyses	O
performed	O
,	O
but	O
it	O
did	O
not	O
improve	O
the	O
magnitude	O
of	O
signals	O
in	O
the	O
target	O
QTLs	O
as	O
compared	O
with	O
univariate	O
or	O
bivariate	O
analyses	O
.	O

In	O
fact	O
,	O
in	O
at	O
least	O
one	O
case	O
,	O
PCA	O
was	O
unable	O
to	O
detect	O
a	O
linkage	O
signal	O
for	O
the	O
main	O
gene	O
transcript	O
loading	O
in	O
the	O
factor	O
(	O
Table	O
1	O
,	O
Group	O
1	O
,	O
Factor	O
2	O
)	O
.	O

We	O
also	O
performed	O
pairwise	O
bivariate	O
genetic	O
analysis	O
on	O
those	O
transcripts	O
that	O
co	O
-	O
localized	O
to	O
the	O
same	O
genomic	O
region	O
,	O
presumably	O
because	O
this	O
area	O
of	O
the	O
genome	O
harbored	O
genes	O
involved	O
in	O
the	O
regulation	O
of	O
these	O
transcripts	O
[	O
2	O
]	O
.	O

We	O
detected	O
significant	O
genetic	O
correlation	O
of	O
these	O
co	O
-	O
localized	O
transcripts	O
,	O
indicating	O
potential	O
gene	O
networks	O
operating	O
in	O
these	O
regions	O
.	O

However	O
,	O
in	O
most	O
cases	O
,	O
bivariate	O
linkage	O
analysis	O
did	O
not	O
improve	O
the	O
magnitude	O
of	O
the	O
LOD	O
score	O
compared	O
to	O
univariate	O
analysis	O
.	O

Most	O
traits	O
were	O
highly	O
correlated	O
(	O
ρG	O
>	O
0.60	O
)	O
,	O
and	O
therefore	O
they	O
may	O
provide	O
redundant	O
information	O
that	O
may	O
reduce	O
the	O
power	O
for	O
detection	O
of	O
the	O
bivariate	O
signal	O
[	O
8	O
]	O
.	O

In	O
addition	O
,	O
because	O
ρG	O
is	O
a	O
test	O
of	O
the	O
overall	O
additive	O
genetic	O
correlation	O
among	O
two	O
traits	O
and	O
not	O
the	O
QTL	O
-	O
specific	O
pleiotropy	O
,	O
it	O
is	O
possible	O
that	O
the	O
co	O
-	O
localized	O
linkage	O
signals	O
are	O
not	O
in	O
fact	O
genetically	O
correlated	O
.	O

Further	O
analysis	O
is	O
required	O
to	O
address	O
these	O
issues	O
.	O

The	O
chromosome	O
regions	O
selected	O
for	O
detailed	O
analyses	O
were	O
arbitrarily	O
chosen	O
as	O
we	O
identified	O
multiple	O
other	O
regions	O
with	O
co	O
-	O
localized	O
linkage	O
of	O
gene	O
expressions	O
.	O

The	O
results	O
from	O
our	O
univariate	O
genome	O
scan	O
differ	O
markedly	O
from	O
those	O
reported	O
by	O
Morley	O
et	O
al.	O
[	O
2	O
]	O
because	O
we	O
included	O
a	O
smaller	O
sample	O
of	O
individuals	O
so	O
that	O
adjustment	O
for	O
covariate	O
effects	O
of	O
age	O
could	O
be	O
made	O
.	O

Our	O
analysis	O
strategy	O
also	O
adjusted	O
for	O
the	O
effects	O
of	O
age	O
and	O
sex	O
,	O
which	O
could	O
also	O
add	O
to	O
the	O
observed	O
differences	O
[	O
13	O
]	O
.	O

Finally	O
,	O
our	O
definition	O
of	O
genome	O
window	O
size	O
for	O
co	O
-	O
localized	O
gene	O
expressions	O
was	O
twice	O
larger	O
than	O
the	O
one	O
described	O
in	O
the	O
study	O
of	O
Morley	O
et	O
al.	O
Conclusion	O
We	O
identified	O
several	O
chromosomal	O
regions	O
of	O
co	O
-	O
localized	O
trans	O
-	O
regulatory	O
genes	O
with	O
significant	O
heritability	O
.	O

Some	O
of	O
these	O
regulatory	O
genes	O
displayed	O
strong	O
additive	O
genetic	O
correlations	O
,	O
and	O
may	O
be	O
part	O
of	O
genetic	O
networks	O
.	O

However	O
,	O
when	O
compared	O
to	O
univariate	O
analysis	O
,	O
linkage	O
analysis	O
of	O
bivariate	O
phenotypes	O
and	O
factor	O
scores	O
obtained	O
from	O
PCA	O
did	O
not	O
improve	O
the	O
ability	O
to	O
identify	O
chromosomal	O
regions	O
of	O
co	O
-	O
localized	O
gene	O
expressions	O
.	O

List	O
of	O
Abbreviations	O
CEPH	O
:	O

Centre	O
d'Etude	O
du	O
Polymorphisme	O
Humain	O
GAW	O
:	O

Genetic	O
Analysis	O
Workshop	O
H2	O
:	O
heritability	O
LOD	O
:	O
logarithm	O
of	O
the	O
odds	O
MIBD	O
:	O
multipoint	O
identity	O
-	O
by	O
-	O
descent	O
matrices	O
N	O
/	O
A	O
:	O
not	O
apply	O
NCBI	O
:	O
National	O
Center	O
for	O
Biotechnology	O
Information	O
PCA	O
:	O
principal	O
-	O
component	O
analysis	O
QTL	O
:	O
quantitative	O
trait	O
loci	O
SE	O
:	O
standard	O
error	O
of	O
the	O
mean	O
SNP	O
:	O
single	O
-	O
nucleotide	O
polymorphism	O
SOLAR	O
:	O
Sequential	O
Oligogenic	O
Linkage	O
Analysis	O
Routines	O
Competing	O
interests	O
The	O
author	O
(	O
s	O
)	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Modeling	O
the	O
effect	O
of	O
PTPN22	O
in	O
rheumatoid	O
arthritis	O
Abstract	O
In	O
order	O
to	O
model	O
the	O
effect	O
of	O
PTPN22	O
on	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
,	O
we	O
determined	O
the	O
combination	O
of	O
single	O
-	O
nucleotide	O
-	O
polymorphisms	O
(	O
SNPs	O
)	O
showing	O
the	O
strongest	O
association	O
with	O
RA	O
.	O

Three	O
SNPs	O
(	O
rs2476601-rs12730735-rs11102685	O
)	O
were	O
selected	O
for	O
which	O
we	O
estimated	O
the	O
genotypic	O
relative	O
risks	O
(	O
GRRs	O
)	O
of	O
the	O
corresponding	O
genotypes	O
.	O

On	O
the	O
basis	O
of	O
these	O
GRRs	O
we	O
defined	O
four	O
at	O
-	O
risk	O
genotypic	O
classes	O
.	O

Relative	O
to	O
the	O
class	O
of	O
reference	O
risk	O
,	O
individuals	O
had	O
a	O
risk	O
approximately	O
multiplied	O
by	O
two	O
,	O
three	O
,	O
or	O
four	O
.	O

This	O
classification	O
was	O
confirmed	O
by	O
the	O
excess	O
of	O
identity	O
-	O
by	O
-	O
descent	O
(	O
IBD	O
)	O
sharing	O
(	O
IBD	O
=	O
2	O
)	O
for	O
the	O
sibs	O
of	O
an	O
index	O
in	O
the	O
high	O
-	O
risk	O
class	O
and	O
by	O
excess	O
of	O
non	O
-	O
IBD	O
sharing	O
(	O
IBD	O
=	O
0	O
)	O
when	O
the	O
index	O
belonged	O
to	O
the	O
low	O
-	O
risk	O
class	O
.	O

The	O
observed	O
data	O
could	O
not	O
be	O
explained	O
by	O
the	O
role	O
of	O
a	O
single	O
variant	O
but	O
were	O
compatible	O
either	O
with	O
a	O
joint	O
effect	O
of	O
the	O
three	O
typed	O
SNPs	O
of	O
PTPN22	O
on	O
RA	O
or	O
with	O
the	O
role	O
of	O
two	O
untyped	O
variants	O
.	O

Background	O
The	O
single	O
-	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
R620W	O
,	O
also	O
denoted	O
rs2476601	O
,	O
is	O
located	O
within	O
the	O
hematopoietic	O
-	O
specific	O
protein	O
tyrosine	O
phosphatase	O
gene	O
,	O
PTPN22	O
.	O

This	O
SNP	O
(	O
C	O
/	O
T	O
)	O
codes	O
for	O
an	O
amino	O
-	O
acid	O
change	O
and	O
the	O
frequency	O
of	O
its	O
minor	O
allele	O
T	O
has	O
been	O
recently	O
and	O
repeatedly	O
shown	O
to	O
be	O
increased	O
in	O
patients	O
with	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
[	O
1	O
]	O
.	O

The	O
allele	O
T	O
confers	O
1.7-	O
to	O
1.9-fold	O
increased	O
risk	O
to	O
heterozygote	O
and	O
higher	O
risks	O
to	O
homozygote	O
carriers	O
[	O
2	O
]	O
compared	O
to	O
the	O
non	O
-	O
carrier	O
individuals	O
.	O

This	O
variant	O
is	O
also	O
well	O
known	O
to	O
be	O
associated	O
with	O
several	O
other	O
autoimmune	O
diseases	O
[	O
3	O
]	O
,	O
such	O
as	O
systemic	O
lupus	O
erythematosus	O
and	O
type	O
1	O
diabetes	O
.	O

Recently	O
,	O
Carlton	O
et	O
al.	O
[	O
2	O
]	O
studied	O
the	O
PTPN22	O
genetic	O
variations	O
in	O
the	O
North	O
American	O
Rheumatoid	O
Arthritis	O
Consortium	O
(	O
NARAC	O
)	O
data	O
.	O

Using	O
the	O
information	O
on	O
several	O
SNPs	O
typed	O
in	O
PTPN22	O
,	O
they	O
compared	O
the	O
haplotype	O
distributions	O
in	O
NARAC	O
patients	O
and	O
controls	O
.	O

They	O
demonstrated	O
that	O
SNP	O
R620W	O
does	O
not	O
fully	O
explain	O
the	O
association	O
between	O
PTPN22	O
and	O
RA	O
and	O
suggested	O
the	O
effect	O
of	O
at	O
least	O
one	O
additional	O
variant	O
in	O
the	O
PTPN22	O
gene	O
.	O

We	O
propose	O
here	O
to	O
reanalyze	O
the	O
NARAC	O
data	O
using	O
both	O
association	O
and	O
linkage	O
information	O
for	O
modeling	O
the	O
role	O
of	O
PTPN22	O
in	O
RA	O
.	O

Methods	O
Data	O

We	O
selected	O
from	O
the	O
NARAC	O
data	O
the	O
511	O
families	O
with	O
affected	O
sib	O
pairs	O
typed	O
for	O
14	O
SNPs	O
of	O
PTPN22	O
,	O
and	O
1404	O
unrelated	O
controls	O
also	O
typed	O
for	O
all	O
these	O
SNPs	O
.	O

For	O
each	O
affected	O
sib	O
pair	O
we	O
considered	O
the	O
proband	O
as	O
an	O
index	O
RA	O
patient	O
.	O

The	O
R620W	O
SNP	O
is	O
one	O
of	O
the	O
14	O
SNPs	O
in	O
PTPN22	O
.	O

It	O
is	O
located	O
at	O
the	O
ninth	O
position	O
,	O
so	O
it	O
will	O
be	O
subsequently	O
denoted	O
as	O
SNP	O
9	O
.	O

A	O
preliminary	O
study	O
of	O
linkage	O
disequilibrium	O
(	O
LD	O
)	O
among	O
the	O
14	O
SNPs	O
was	O
examined	O
in	O
the	O
1404	O
controls	O
.	O

The	O
LD	O
analysis	O
lead	O
us	O
to	O
exclude	O
3	O
SNPs	O
(	O
SNP	O
2	O
,	O
SNP	O
12	O
,	O
SNP	O
13	O
)	O
,	O
which	O
are	O
in	O
complete	O
LD	O
with	O
one	O
(	O
or	O
more	O
)	O
other	O
SNP	O
(	O
s	O
)	O
.	O

Selection	O
of	O
associated	O
SNPs	O
The	O
combination	O
test	O
[	O
4	O
]	O
was	O
used	O
on	O
the	O
11	O
remaining	O
SNPs	O
to	O
select	O
the	O
subset	O
of	O
SNPs	O
showing	O
a	O
significant	O
difference	O
in	O
the	O
genotypic	O
distribution	O
between	O
RA	O
index	O
patients	O
and	O
controls	O
.	O

Its	O
principle	O
consists	O
in	O
testing	O
all	O
possible	O
combinations	O
of	O
SNPs	O
within	O
a	O
gene	O
.	O

Here	O
,	O
there	O
are	O
(	O
211	O
-	O
1	O
)	O
possible	O
combinations	O
.	O

Such	O
a	O
systematic	O
testing	O
of	O
all	O
SNPs	O
and	O
all	O
SNP	O
combinations	O
raises	O
the	O
problem	O
of	O
multiple	O
and	O
non	O
-	O
independent	O
tests	O
.	O

This	O
problem	O
is	O
generally	O
solved	O
by	O
the	O
implementation	O
of	O
a	O
permutation	O
procedure	O
that	O
allows	O
estimation	O
of	O
corrected	O
p	O
-	O
values	O
.	O

Here	O
,	O
associated	O
combinations	O
are	O
very	O
significant	O
and	O
the	O
number	O
of	O
permutations	O
necessary	O
to	O
discriminate	O
them	O
would	O
be	O
extremely	O
high	O
and	O
almost	O
unreachable	O
.	O

Nevertheless	O
,	O
the	O
chi	O
-	O
square	O
values	O
of	O
the	O
genotypic	O
association	O
test	O
are	O
so	O
high	O
that	O
even	O
the	O
conservative	O
Bonferroni	O
correction	O
can	O
be	O
used	O
.	O

We	O
selected	O
the	O
most	O
associated	O
and	O
parsimonious	O
subset	O
of	O
SNPs	O
by	O
nested	O
chi	O
-	O
square	O
tests	O
(	O
NCST	O
)	O
in	O
a	O
forward	O
procedure	O
.	O

The	O
NCST	O
compares	O
the	O
strength	O
of	O
association	O
between	O
nested	O
significant	O
subsets	O
.	O

Genotypic	O
relative	O
-	O
risk	O
estimation	O
For	O
the	O
selected	O
subset	O
of	O
SNPs	O
,	O
we	O
used	O
the	O
marker	O
association	O
segregation	O
chi	O
-	O
square	O
(	O
MASC	O
)	O
method	O
[	O
5	O
]	O
to	O
compute	O
the	O
genotypic	O
relative	O
risk	O
(	O
GRR	O
)	O
of	O
each	O
genotype	O
.	O

The	O
genotype	O
distributions	O
of	O
index	O
and	O
controls	O
was	O
conditional	O
on	O
the	O
fact	O
that	O
the	O
index	O
has	O
an	O
affected	O
sib	O
.	O

Stratified	O
sib	O
pair	O
IBD	O
estimation	O
Conditional	O
on	O
each	O
marker	O
genotype	O
of	O
the	O
index	O
cases	O
,	O
the	O
number	O
of	O
parental	O
alleles	O
identical	O
by	O
descent	O
(	O
IBD	O
)	O
shared	O
by	O
the	O
index	O
case	O
and	O
one	O
affected	O
sib	O
were	O
estimated	O
on	O
PTPN22	O
with	O
the	O
MERLIN	O
software	O
[	O
6	O
]	O
.	O

MERLIN	O
is	O
able	O
to	O
take	O
into	O
account	O
LD	O
between	O
SNPs	O
during	O
the	O
IBD	O
computation	O
.	O

So	O
the	O
estimated	O
IBD	O
distributions	O
are	O
computed	O
on	O
the	O
overall	O
set	O
of	O
SNPs	O
even	O
if	O
they	O
are	O
in	O
LD	O
.	O

The	O
fit	O
of	O
a	O
model	O
to	O
the	O
IBD	O
distributions	O
stratified	O
on	O
index	O
marker	O
genotypes	O
[	O
7	O
]	O
may	O
then	O
be	O
tested	O
by	O
the	O
MASC	O
method	O
.	O

Modeling	O
PTPN22	O
effect	O
We	O
applied	O
the	O
MASC	O
method	O
[	O
5	O
]	O
to	O
find	O
the	O
most	O
parsimonious	O
model	O
explaining	O
the	O
overall	O
observations	O
,	O
i.e.	O
,	O
the	O
genotype	O
and	O
the	O
stratified	O
sib	O
-	O
pair	O
IBD	O
distributions	O
.	O

To	O
do	O
this	O
,	O
MASC	O
requires	O
the	O
haplotype	O
frequencies	O
in	O
the	O
general	O
population	O
,	O
which	O
were	O
estimated	O
on	O
the	O
unrelated	O
controls	O
by	O
the	O
MERLIN	O
software	O
.	O

The	O
MASC	O
method	O
computes	O
the	O
expected	O
genotype	O
marker	O
distribution	O
and	O
the	O
expected	O
sib	O
-	O
pair	O
IBD	O
distributions	O
stratified	O
on	O
marker	O
genotypes	O
for	O
a	O
given	O
genetic	O
model	O
.	O

Here	O
,	O
the	O
computation	O
of	O
the	O
genotypic	O
distribution	O
is	O
conditioned	O
on	O
the	O
fact	O
that	O
index	O
cases	O
have	O
an	O
affected	O
sib	O
.	O

The	O
global	O
expected	O
likelihood	O
of	O
the	O
genetic	O
model	O
given	O
the	O
observed	O
data	O
is	O
then	O
computed	O
as	O
the	O
product	O
of	O
the	O
likelihoods	O
of	O
each	O
expected	O
distribution	O
,	O
and	O
is	O
maximized	O
on	O
the	O
model	O
parameters	O
.	O

The	O
fit	O
of	O
the	O
model	O
to	O
the	O
observed	O
data	O
is	O
tested	O
by	O
a	O
likelihood	O
ratio	O
test	O
(	O
LRT	O
)	O
between	O
global	O
expected	O
likelihood	O
and	O
the	O
likelihood	O
of	O
the	O
saturated	O
model	O
.	O

Results	O
Selection	O
of	O
associated	O
SNPs	O
Many	O
subsets	O
of	O
SNPs	O
show	O
significant	O
associations	O
.	O

Table	O
1	O
presents	O
a	O
selection	O
of	O
the	O
most	O
associated	O
combinations	O
of	O
one	O
,	O
two	O
,	O
and	O
three	O
SNPs	O
.	O

When	O
considering	O
only	O
the	O
effect	O
of	O
a	O
single	O
SNP	O
,	O
the	O
only	O
significant	O
associated	O
one	O
after	O
correction	O
for	O
multiple	O
testing	O
is	O
SNP	O
9	O
.	O

The	O
combination	O
of	O
SNPs	O
9–10	O
is	O
the	O
one	O
which	O
,	O
among	O
the	O
combination	O
of	O
two	O
SNPs	O
,	O
best	O
improves	O
the	O
association	O
shown	O
by	O
the	O
SNP	O
9	O
alone	O
(	O
p	O
=	O
0.017	O
)	O
.	O

The	O
subset	O
SNPs	O
9	O
-	O
10	O
-	O
11	O
(	O
rs2476601-rs12730735-rs11102685	O
)	O
is	O
the	O
only	O
one	O
that	O
improves	O
significantly	O
the	O
association	O
shown	O
by	O
the	O
SNPs	O
9–10	O
(	O
p	O
=	O
0.038	O
)	O
.	O

Adding	O
another	O
SNP	O
to	O
this	O
subset	O
does	O
not	O
significantly	O
improve	O
the	O
association	O
.	O

Consequently	O
,	O
all	O
the	O
subsequent	O
analyses	O
have	O
been	O
done	O
considering	O
SNPs	O
9	O
-	O
10	O
-	O
11	O
and	O
their	O
ten	O
corresponding	O
genotypes	O
.	O

GRR	O
estimation	O
Table	O
2	O
displays	O
the	O
genotypes	O
and	O
the	O
corresponding	O
GRRs	O
for	O
SNP	O
9	O
taken	O
alone	O
(	O
columns	O
1	O
and	O
2	O
)	O
and	O
for	O
the	O
set	O
of	O
the	O
three	O
SNPs	O
9	O
-	O
10	O
-	O
11	O
(	O
columns	O
3	O
and	O
4	O
)	O
.	O

The	O
GRRs	O
vary	O
from	O
1	O
to	O
2.7	O
when	O
considering	O
only	O
SNP	O
9	O
,	O
whereas	O
the	O
variation	O
ranges	O
from	O
1	O
to	O
4.7	O
when	O
the	O
information	O
on	O
the	O
three	O
SNPs	O
is	O
taken	O
into	O
account	O
.	O

Interestingly	O
,	O
the	O
CC	O
genotype	O
of	O
the	O
SNP	O
9	O
can	O
be	O
subdivided	O
in	O
several	O
genotypes	O
when	O
taking	O
into	O
account	O
the	O
genotypes	O
for	O
SNPs	O
10	O
and	O
11	O
(	O
rows	O
1	O
to	O
6	O
)	O
with	O
GRRs	O
ranging	O
from	O
1	O
(	O
CC	O
-	O
GG	O
-	O
AA	O
)	O
to	O
3.6	O
(	O
CC	O
-	O
AA	O
-	O
GG	O
)	O
.	O

This	O
observation	O
demonstrates	O
the	O
importance	O
of	O
using	O
the	O
additional	O
information	O
on	O
SNPs	O
10–11	O
.	O

Sib	O
pair	O
IBD	O
estimation	O
The	O
proportion	O
of	O
RA	O
sibs	O
sharing	O
0	O
,	O
1	O
,	O
or	O
2	O
parental	O
alleles	O
for	O
PTPN22	O
is	O
0.26	O
(	O
181	O
pairs	O
)	O
,	O
0.51	O
(	O
362	O
pairs	O
)	O
,	O
and	O
0.23	O
(	O
167	O
pairs	O
)	O
,	O
respectively	O
,	O
and	O
does	O
not	O
differ	O
from	O
the	O
IBD	O
distribution	O
0.25	O
;	O
0.5	O
;	O
0.25	O
expected	O
under	O
no	O
linkage	O
.	O

However	O
,	O
if	O
our	O
GRRs	O
correctly	O
reflect	O
the	O
differential	O
risk	O
of	O
RA	O
,	O
we	O
expect	O
to	O
see	O
differences	O
in	O
the	O
IBD	O
vectors	O
stratified	O
on	O
the	O
genotypes	O
of	O
the	O
subset	O
of	O
SNPs	O
9	O
-	O
10	O
-	O
11	O
[	O
7	O
]	O
.	O

To	O
avoid	O
cells	O
with	O
small	O
numbers	O
of	O
individuals	O
we	O
pooled	O
sib	O
pairs	O
with	O
the	O
index	O
genotypes	O
(	O
SNP	O
9	O
-	O
10	O
-	O
11	O
)	O
that	O
have	O
similar	O
risk	O
.	O

We	O
thus	O
defined	O
four	O
arbitrary	O
at	O
risk	O
genotypic	O
classes	O
:	O
the	O
low	O
risk	O
class	O
(	O
L	O
;	O
GRR	O
=	O
1	O
;	O
19	O
pairs	O
)	O
,	O
the	O
intermediate	O
risk	O
class	O
1	O
(	O
I1	O
;	O
1	O
<	O
GRR	O
≤	O
2	O
;	O
295	O
pairs	O
)	O
,	O
the	O
intermediate	O
risk	O
class	O
2	O
(	O
I2	O
;	O
2	O
<	O
GRR	O
≤	O
3	O
;	O
157	O
pairs	O
)	O
,	O
and	O
the	O
high	O
risk	O
class	O
(	O
H	O
;	O
GRR	O
>	O
3	O
;	O
34	O
pairs	O
)	O
.	O

Table	O
3	O
shows	O
that	O
the	O
proportion	O
of	O
IBD	O
=	O
0	O
decreases	O
from	O
0.47	O
to	O
0.09	O
according	O
to	O
the	O
fact	O
that	O
the	O
index	O
belongs	O
to	O
class	O
L	O
or	O
class	O
H	O
and	O
conversely	O
,	O
the	O
proportion	O
of	O
IBD	O
=	O
2	O
increases	O
from	O
0.11	O
to	O
0.26	O
.	O

These	O
stratified	O
IBD	O
distributions	O
are	O
consistent	O
with	O
the	O
risk	O
genotypic	O
classes	O
.	O

In	O
contrast	O
,	O
the	O
IBD	O
sharing	O
distributions	O
stratified	O
only	O
on	O
SNP	O
9	O
genotypes	O
are	O
not	O
consistent	O
with	O
the	O
GRR	O
estimates	O
on	O
this	O
SNP	O
(	O
Table	O
4	O
)	O
.	O

Modeling	O
PTPN22	O
effect	O
We	O
apply	O
the	O
MASC	O
method	O
in	O
using	O
the	O
genotype	O
distribution	O
only	O
on	O
the	O
SNP	O
9	O
and	O
the	O
IBD	O
stratified	O
on	O
the	O
SNP	O
9	O
genotypes	O
.	O

In	O
that	O
case	O
,	O
the	O
single	O
and	O
causal	O
effect	O
of	O
the	O
SNP	O
9	O
is	O
not	O
rejected	O
(	O
p	O
=	O
0.29	O
)	O
.	O

Then	O
,	O
we	O
model	O
the	O
effect	O
of	O
PTPN22	O
using	O
the	O
four	O
genotypic	O
groups	O
of	O
risk	O
defined	O
on	O
the	O
genotypes	O
of	O
the	O
combination	O
of	O
the	O
SNPs	O
9	O
-	O
10	O
-	O
11	O
and	O
the	O
IBD	O
information	O
stratified	O
on	O
them	O
.	O

In	O
this	O
case	O
,	O
we	O
reject	O
the	O
direct	O
effect	O
of	O
SNP	O
9	O
(	O
p	O
=	O
0.005	O
)	O
.	O

We	O
also	O
reject	O
the	O
effect	O
of	O
a	O
single	O
untyped	O
SNP	O
(	O
p	O
=	O
0.04	O
)	O
.	O

However	O
,	O
we	O
do	O
not	O
reject	O
the	O
interactive	O
effect	O
of	O
the	O
3	O
SNPs	O
(	O
p	O
=	O
0.53	O
)	O
or	O
the	O
interactive	O
effect	O
of	O
two	O
untyped	O
SNPs	O
.	O

Discussion	O
The	O
involvement	O
of	O
PTPN22	O
and	O
HLA	O
in	O
RA	O
susceptibility	O
is	O
no	O
longer	O
disputed	O
.	O

However	O
,	O
as	O
shown	O
by	O
Carlton	O
et	O
al.	O
and	O
confirmed	O
in	O
this	O
study	O
,	O
the	O
role	O
of	O
PTPN22	O
can	O
not	O
be	O
explained	O
only	O
by	O
the	O
R620W	O
SNP	O
.	O

A	O
correct	O
modeling	O
of	O
PTPN22	O
is	O
important	O
and	O
shows	O
that	O
the	O
genotypic	O
risk	O
varies	O
much	O
more	O
(	O
1	O
to	O
4.7	O
)	O
than	O
reported	O
in	O
the	O
literature	O
(	O
1	O
to	O
2.7	O
)	O
[	O
4	O
]	O
.	O

In	O
this	O
study	O
we	O
proposed	O
,	O
for	O
the	O
first	O
time	O
,	O
a	O
model	O
for	O
the	O
effect	O
of	O
PTPN22	O
,	O
taking	O
into	O
account	O
both	O
association	O
and	O
linkage	O
information	O
.	O

Another	O
method	O
,	O
called	O
LAMP	O
[	O
8	O
]	O
was	O
recently	O
proposed	O
for	O
joint	O
modeling	O
of	O
linkage	O
and	O
association	O
[	O
8	O
]	O
.	O

The	O
linkage	O
information	O
used	O
by	O
the	O
LAMP	O
method	O
is	O
the	O
global	O
IBD	O
sharing	O
of	O
affected	O
sib	O
pairs	O
.	O

However	O
,	O
it	O
is	O
very	O
important	O
to	O
note	O
that	O
the	O
power	O
of	O
model	O
discrimination	O
strongly	O
depends	O
on	O
the	O
association	O
and	O
linkage	O
information	O
that	O
is	O
used	O
.	O

As	O
shown	O
here	O
,	O
the	O
information	O
on	O
SNP	O
9	O
alone	O
and	O
on	O
the	O
global	O
IBD	O
is	O
very	O
poor	O
as	O
compared	O
with	O
that	O
of	O
the	O
three	O
SNPs	O
9	O
-	O
10	O
-	O
11	O
and	O
to	O
the	O
stratified	O
IBD	O
distributions	O
on	O
the	O
four	O
at	O
-	O
risk	O
genotype	O
groups	O
.	O

In	O
conclusion	O
,	O
we	O
applied	O
a	O
four	O
-	O
step	O
strategy	O
to	O
model	O
the	O
effect	O
of	O
a	O
candidate	O
gene	O
covered	O
by	O
several	O
SNPs	O
:	O
1	O
)	O
to	O
select	O
the	O
most	O
associated	O
set	O
of	O
SNPs	O
;	O
2	O
)	O
to	O
group	O
the	O
corresponding	O
genotypes	O
according	O
their	O
GRRs	O
;	O
3	O
)	O
to	O
stratify	O
IBD	O
sharing	O
information	O
on	O
the	O
at	O
-	O
risk	O
genotype	O
groups	O
;	O
4	O
)	O
to	O
model	O
the	O
effect	O
of	O
the	O
candidate	O
gene	O
while	O
taking	O
into	O
account	O
both	O
linkage	O
and	O
association	O
information	O
.	O

This	O
strategy	O
allowed	O
better	O
modeling	O
of	O
the	O
effect	O
of	O
PTPN22	O
in	O
RA	O
susceptibility	O
.	O

Recently	O
,	O
du	O
Montcel	O
et	O
al.	O
[	O
9	O
]	O
refined	O
the	O
modeling	O
of	O
HLA	O
in	O
RA	O
susceptibility	O
.	O

A	O
next	O
step	O
will	O
be	O
to	O
use	O
simultaneously	O
the	O
PTPN22	O
and	O
HLA	O
information	O
to	O
evaluate	O
their	O
joint	O
effects	O
while	O
taking	O
into	O
account	O
important	O
covariables	O
such	O
as	O
age	O
and	O
gender	O
.	O

Competing	O
interests	O
The	O
author	O
(	O
s	O
)	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Comparative	O
Genome	O
Analysis	O
of	O
Filamentous	O
Fungi	O
Reveals	O
Gene	O
Family	O
Expansions	O
Associated	O
with	O
Fungal	O
Pathogenesis	O
Abstract	O
Fungi	O
and	O
oomycetes	O
are	O
the	O
causal	O
agents	O
of	O
many	O
of	O
the	O
most	O
serious	O
diseases	O
of	O
plants	O
.	O

Here	O
we	O
report	O
a	O
detailed	O
comparative	O
analysis	O
of	O
the	O
genome	O
sequences	O
of	O
thirty	O
-	O
six	O
species	O
of	O
fungi	O
and	O
oomycetes	O
,	O
including	O
seven	O
plant	O
pathogenic	O
species	O
,	O
that	O
aims	O
to	O
explore	O
the	O
common	O
genetic	O
features	O
associated	O
with	O
plant	O
disease	O
-	O
causing	O
species	O
.	O

The	O
predicted	O
translational	O
products	O
of	O
each	O
genome	O
have	O
been	O
clustered	O
into	O
groups	O
of	O
potential	O
orthologues	O
using	O
Markov	O
Chain	O
Clustering	O
and	O
the	O
data	O
integrated	O
into	O
the	O
e	O
-	O
Fungi	O
object	O
-	O
oriented	O
data	O
warehouse	O
(	O
http://www.e-fungi.org.uk/	O
)	O
.	O

Analysis	O
of	O
the	O
species	O
distribution	O
of	O
members	O
of	O
these	O
clusters	O
has	O
identified	O
proteins	O
that	O
are	O
specific	O
to	O
filamentous	O
fungal	O
species	O
and	O
a	O
group	O
of	O
proteins	O
found	O
only	O
in	O
plant	O
pathogens	O
.	O

By	O
comparing	O
the	O
gene	O
inventories	O
of	O
filamentous	O
,	O
ascomycetous	O
phytopathogenic	O
and	O
free	O
-	O
living	O
species	O
of	O
fungi	O
,	O
we	O
have	O
identified	O
a	O
set	O
of	O
gene	O
families	O
that	O
appear	O
to	O
have	O
expanded	O
during	O
the	O
evolution	O
of	O
phytopathogens	O
and	O
may	O
therefore	O
serve	O
important	O
roles	O
in	O
plant	O
disease	O
.	O

We	O
have	O
also	O
characterised	O
the	O
predicted	O
set	O
of	O
secreted	O
proteins	O
encoded	O
by	O
each	O
genome	O
and	O
identified	O
a	O
set	O
of	O
protein	O
families	O
which	O
are	O
significantly	O
over	O
-	O
represented	O
in	O
the	O
secretomes	O
of	O
plant	O
pathogenic	O
fungi	O
,	O
including	O
putative	O
effector	O
proteins	O
that	O
might	O
perturb	O
host	O
cell	O
biology	O
during	O
plant	O
infection	O
.	O

The	O
results	O
demonstrate	O
the	O
potential	O
of	O
comparative	O
genome	O
analysis	O
for	O
exploring	O
the	O
evolution	O
of	O
eukaryotic	O
microbial	O
pathogenesis	O
.	O

Introduction	O
Fungi	O
and	O
oomycetes	O
are	O
responsible	O
for	O
many	O
of	O
the	O
world	O
's	O
most	O
devastating	O
plant	O
diseases	O
including	O
late	O
blight	O
disease	O
of	O
potato	B
,	O
caused	O
by	O
the	O
oomycete	O
pathogen	O
Phytophthora	B
infestans	I
and	O
rice	B
blast	O
disease	O
caused	O
by	O
the	O
ascomycete	O
fungus	O
Magnaporthe	B
grisea	I
,	O
both	O
of	O
which	O
are	O
responsible	O
for	O
very	O
significant	O
harvest	O
losses	O
each	O
year	O
.	O

The	O
enormous	O
diversity	O
of	O
crop	O
diseases	O
caused	O
by	O
these	O
eukaryotic	O
micro	O
-	O
organisms	O
poses	O
a	O
difficult	O
challenge	O
to	O
the	O
development	O
of	O
durable	O
disease	O
control	O
strategies	O
.	O

Identifying	O
common	O
underlying	O
molecular	O
mechanisms	O
necessary	O
for	O
pathogenesis	O
in	O
a	O
wide	O
range	O
of	O
pathogenic	O
species	O
is	O
therefore	O
a	O
major	O
goal	O
of	O
current	O
research	O
.	O

Approximately	O
100,000	O
species	O
of	O
fungi	O
have	O
so	O
far	O
been	O
described	O
,	O
but	O
only	O
a	O
very	O
small	O
proportion	O
of	O
these	O
are	O
pathogenic	O
[	O
1	O
]	O
.	O

Phylogenetic	O
studies	O
have	O
,	O
meanwhile	O
,	O
shown	O
that	O
disease	O
-	O
causing	O
pathogens	O
are	O
not	O
necessarily	O
closely	O
-	O
related	O
to	O
each	O
other	O
,	O
and	O
in	O
fact	O
are	O
spread	O
throughout	O
all	O
taxonomic	O
groups	O
of	O
fungi	O
,	O
often	O
showing	O
a	O
close	O
evolutionary	O
relationship	O
to	O
non	O
-	O
pathogenic	O
species	O
[	O
2	O
]	O
,	O
[	O
3	O
]	O
.	O

It	O
therefore	O
seems	O
likely	O
that	O
phytopathogenicity	O
has	O
evolved	O
as	O
a	O
trait	O
many	O
times	O
during	O
fungal	O
and	O
oomycete	O
evolution	O
[	O
1	O
]	O
and	O
in	O
some	O
groups	O
may	O
be	O
ancestral	O
to	O
the	O
more	O
recent	O
emergence	O
of	O
saprotrophic	O
species	O
.	O

A	O
significant	O
effort	O
has	O
gone	O
into	O
the	O
identification	O
of	O
pathogenicity	O
determinants–	O
individual	O
genes	O
that	O
are	O
essential	O
for	O
a	O
pathogen	O
to	O
invade	O
a	O
host	O
plant	O
successfully	O
,	O
but	O
which	O
are	O
dispensable	O
for	O
saprophytic	O
growth	O
[	O
4	O
]	O
,	O
[	O
5	O
]	O
.	O

However	O
,	O
far	O
from	O
being	O
novel	O
proteins	O
encoded	O
only	O
by	O
the	O
genomes	O
of	O
pathogenic	O
fungi	O
,	O
many	O
of	O
the	O
genes	O
identified	O
so	O
far	O
encode	O
components	O
of	O
conserved	O
signalling	O
pathways	O
that	O
are	O
found	O
in	O
all	O
species	O
of	O
fungi	O
,	O
such	O
as	O
the	O
mitogen	O
activated	O
protein	O
(	O
MAP	O
)	O
kinases	O
[	O
6	O
]	O
,	O
adenylate	O
cyclase	O
[	O
7	O
]	O
and	O
G	O
-	O
protein	O
subunits	O
[	O
8	O
]	O
.	O

The	O
MAP	O
kinase	O
pathways	O
,	O
for	O
example	O
,	O
have	O
been	O
studied	O
extensively	O
in	O
the	O
budding	O
yeast	B
Saccharomyces	B
cerevisiae	I
and	O
trigger	O
morphological	O
and	O
biochemical	O
changes	O
in	O
response	O
to	O
external	O
stimuli	O
such	O
as	O
starvation	O
stress	O
or	O
hyperosmotic	O
conditions	O
[	O
9	O
]	O
.	O

In	O
pathogenic	O
fungi	O
,	O
components	O
of	O
these	O
pathways	O
have	O
evolved	O
instead	O
to	O
regulate	O
the	O
morphological	O
changes	O
associated	O
with	O
plant	O
infection	O
.	O

For	O
example	O
,	O
appressorium	O
formation	O
in	O
the	O
rice	B
blast	I
fungus	I
Magnaporthe	B
grisea	I
,	O
stimulated	O
by	O
hard	O
,	O
hydrophobic	O
surfaces	O
is	O
regulated	O
by	O
a	O
MAP	O
kinase	O
cascade	O
[	O
10	O
]	O
.	O

This	O
pathway	O
deploys	O
novel	O
classes	O
of	O
G	O
-	O
protein	O
coupled	O
receptors	O
not	O
found	O
in	O
the	O
genome	O
of	O
S.	B
cerevisiae	I
[	O
11	O
]	O
,	O
but	O
the	O
inductive	O
signal	O
is	O
transmitted	O
via	O
a	O
MAP	O
kinase	O
,	O
Pmk1	O
,	O
that	O
is	O
a	O
functional	O
homologue	O
of	O
the	O
yeast	B
Fus3	O
MAP	O
kinase	O
where	O
it	O
serves	O
a	O
role	O
in	O
pheromone	O
signalling	O
[	O
10	O
]	O
.	O

Similarly	O
,	O
conserved	O
metabolic	O
pathways	O
such	O
as	O
the	O
glyoxylate	O
cycle	O
and	O
amino	O
acid	O
biosynthesis	O
are	O
also	O
important	O
for	O
pathogenesis	O
[	O
12	O
]	O
–	O
[	O
14	O
]	O
.	O

This	O
may	O
in	O
some	O
cases	O
reflect	O
the	O
nutritional	O
environment	O
the	O
pathogen	O
encounters	O
when	O
growing	O
in	O
the	O
host	O
plant	O
tissue	O
,	O
and	O
in	O
others	O
shows	O
the	O
importance	O
of	O
simple	O
metabolites	O
for	O
pathogenic	O
processes	O
,	O
such	O
as	O
the	O
role	O
of	O
glycerol	O
as	O
a	O
compatible	O
solute	O
for	O
generating	O
turgor	O
pressure	O
in	O
the	O
appressorium	O
of	O
M.	B
grisea	I
[	O
15	O
]	O
.	O

It	O
is	O
undoubtedly	O
the	O
case	O
,	O
however	O
,	O
that	O
identification	O
of	O
such	O
genes	O
has	O
also	O
been	O
a	O
consequence	O
of	O
the	O
manner	O
in	O
which	O
these	O
studies	O
have	O
been	O
carried	O
out	O
,	O
often	O
using	O
yeast	B
as	O
a	O
model	O
organism	O
to	O
test	O
hypotheses	O
concerning	O
the	O
developmental	O
biology	O
and	O
biochemistry	O
of	O
plant	O
pathogenic	O
species	O
.	O

Other	O
pathogenicity	O
factors	O
identified	O
to	O
date	O
have	O
been	O
shown	O
to	O
be	O
involved	O
in	O
functions	O
associated	O
with	O
host	O
infection	O
,	O
such	O
as	O
plant	O
cell	O
wall	O
degradation	O
,	O
toxin	O
biosynthesis	O
and	O
protection	O
against	O
plant	O
defences	O
[	O
reviewed	O
in	O
5	O
]	O
.	O

Identification	O
of	O
a	O
pathogenicity	O
factor	O
generally	O
involves	O
making	O
a	O
mutant	O
fungal	O
strain	O
with	O
a	O
non	O
-	O
functioning	O
version	O
of	O
the	O
gene	O
by	O
targeted	O
gene	O
deletion	O
and	O
assaying	O
the	O
ability	O
of	O
the	O
mutant	O
to	O
cause	O
disease	O
.	O

Therefore	O
,	O
most	O
pathogenicity	O
factors	O
identified	O
so	O
far	O
,	O
have	O
been	O
validated	O
in	O
only	O
a	O
small	O
number	O
of	O
genetically	O
tractable	O
pathogenic	O
fungi	O
,	O
such	O
as	O
M.	B
grisea	I
and	O
the	O
corn	B
smut	O
Ustilago	B
maydis	I
and	O
many	O
of	O
the	O
advances	O
in	O
understanding	O
the	O
developmental	O
biology	O
of	O
plant	O
infection	O
have	O
occurred	O
in	O
these	O
model	O
pathogens	O
[	O
16	O
]	O
,	O
[	O
17	O
]	O
.	O

However	O
,	O
there	O
are	O
severe	O
limitations	O
to	O
studying	O
pathogenicity	O
by	O
mutating	O
one	O
gene	O
at	O
a	O
time	O
and	O
working	O
predominantly	O
with	O
a	O
hypothesis	O
-	O
driven	O
,	O
reverse	O
genetics	O
approach	O
.	O

Many	O
virulence	O
-	O
associated	O
processes	O
,	O
for	O
instance	O
,	O
such	O
as	O
the	O
development	O
of	O
infection	O
structures	O
and	O
haustoria	O
,	O
are	O
likely	O
to	O
involve	O
a	O
large	O
number	O
of	O
gene	O
products	O
and	O
so	O
there	O
is	O
likely	O
to	O
be	O
redundancy	O
in	O
gene	O
function	O
.	O

One	O
example	O
of	O
this	O
is	O
cutinase	O
,	O
a	O
type	O
of	O
methyl	O
esterase	O
that	O
hydrolyses	O
the	O
protective	O
cutin	O
layer	O
present	O
on	O
the	O
outside	O
of	O
the	O
plant	O
epidermis	O
.	O

Cutinase	O
was	O
excluded	O
as	O
a	O
pathogencity	O
factor	O
for	O
M.	B
grisea	I
on	O
the	O
basis	O
that	O
a	O
mutant	O
strain	O
containing	O
a	O
non	O
-	O
functional	O
cutinase	O
-	O
encoding	O
gene	O
was	O
still	O
able	O
to	O
cause	O
rice	B
blast	O
disease	O
[	O
18	O
]	O
.	O

However	O
,	O
sequencing	O
of	O
the	O
M.	B
grisea	I
genome	O
has	O
shown	O
the	O
presence	O
of	O
eight	O
potential	O
cutinase	O
-	O
encoding	O
genes	O
implicated	O
in	O
virulence	O
[	O
19	O
]	O
.	O

Additionally	O
,	O
targeted	O
gene	O
deletion	O
is	O
not	O
feasible	O
in	O
many	O
important	O
pathogens	O
and	O
the	O
normal	O
definition	O
of	O
fungal	O
pathogenicity	O
can	O
not	O
be	O
applied	O
in	O
the	O
case	O
of	O
obligate	O
biotrophs	O
,	O
such	O
as	O
the	O
powdery	O
mildew	O
fungus	O
Blumeria	B
graminis	I
,	O
which	O
can	O
not	O
be	O
cultured	O
away	O
from	O
living	O
host	O
plants	O
.	O

Therefore	O
,	O
new	O
approaches	O
are	O
needed	O
to	O
identify	O
genes	O
that	O
are	O
vital	O
for	O
the	O
process	O
of	O
pathogenicity	O
.	O

These	O
include	O
high	O
-	O
throughput	O
methods	O
such	O
as	O
microarray	O
analysis	O
,	O
serial	O
analysis	O
of	O
gene	O
expression	O
(	O
SAGE	O
)	O
,	O
insertional	O
mutagenesis	O
,	O
proteomics	O
and	O
metabolomics	O
[	O
19	O
]	O
,	O
[	O
20	O
]	O
and	O
are	O
dependent	O
on	O
the	O
availability	O
of	O
genome	O
sequence	O
information	O
.	O

After	O
the	O
initial	O
release	O
of	O
the	O
genome	O
of	O
the	O
budding	O
yeast	B
S.	B
cerevisiae	I
in	O
1996	O
[	O
21	O
]	O
,	O
the	O
number	O
of	O
publicly	O
available	O
sequenced	O
fungal	O
genomes	O
has	O
recently	O
risen	O
very	O
quickly	O
.	O

A	O
large	O
number	O
of	O
fungal	O
genome	O
sequences	O
are	O
now	O
publicly	O
available	O
,	O
including	O
those	O
from	O
several	O
phytopathogenic	O
fungi	O
,	O
including	O
M.	B
grisea	I
[	O
22	O
]	O
,	O
Ustilago	B
maydis	I
[	O
23	O
]	O
,	O
Gibberella	B
zeae	I
[	O
24	O
]	O
(	O
the	O
causal	O
agent	O
of	O
head	O
blight	O
of	O
wheat	B
and	O
barley	B
)	O
,	O
Stagonospora	B
nodorum	I
[	O
25	O
]	O
(	O
the	O
causal	O
agent	O
of	O
glume	O
blotch	O
of	O
wheat	B
)	O
,	O
the	O
grey	O
mould	O
fungus	O
Botrytis	B
cinerea	I
and	O
the	O
white	O
mould	O
fungus	O
Sclerotinia	B
sclerotiorum	I
[	O
reviewed	O
in	O
19	O
]	O
.	O

Comparison	O
of	O
gene	O
inventories	O
of	O
pathogenic	O
and	O
non	O
-	O
pathogenic	O
organisms	O
offers	O
the	O
most	O
direct	O
means	O
of	O
providing	O
new	O
information	O
concerning	O
the	O
mechanisms	O
involved	O
in	O
fungal	O
and	O
oomycete	O
pathogenicity	O
.	O

In	O
this	O
report	O
,	O
we	O
have	O
developed	O
and	O
utilized	O
the	O
e	O
-	O
Fungi	O
object	O
-	O
oriented	O
data	O
warehouse	O
[	O
26	O
]	O
,	O
which	O
contains	O
data	O
from	O
36	O
species	O
of	O
fungi	O
and	O
oomycetes	O
and	O
deploys	O
a	O
range	O
of	O
querying	O
tools	O
to	O
allow	O
interrogation	O
of	O
a	O
significant	O
amount	O
of	O
genome	O
data	O
in	O
unparalleled	O
detail	O
.	O

We	O
report	O
the	O
identification	O
of	O
new	O
gene	O
families	O
that	O
are	O
over	O
represented	O
in	O
the	O
genomes	O
of	O
filamentous	O
ascomycete	O
phytopathogens	O
and	O
define	O
gene	O
sets	O
that	O
are	O
specific	O
to	O
diverse	O
fungal	O
pathogen	O
species	O
.	O

We	O
also	O
report	O
the	O
putatively	O
secreted	O
protein	O
sets	O
which	O
are	O
produced	O
by	O
plant	O
pathogenic	O
fungi	O
and	O
which	O
may	O
play	O
significant	O
roles	O
in	O
plant	O
infection	O
.	O

Results	O
Identification	O
of	O
orthologous	O
gene	O
sets	O
from	O
fungal	O
and	O
oomcyete	O
genomes	O
Genome	O
sequences	O
and	O
sets	O
of	O
predicted	O
proteins	O
were	O
analysed	O
from	O
34	O
species	O
of	O
fungi	O
and	O
2	O
species	O
of	O
oomycete	O
(	O
Table	O
1	O
)	O
.	O

In	O
order	O
to	O
compare	O
such	O
a	O
large	O
number	O
of	O
genomes	O
,	O
an	O
object	O
-	O
oriented	O
data	O
warehouse	O
has	O
been	O
constructed	O
known	O
as	O
e	O
-	O
Fungi	O
[	O
26	O
]	O
which	O
integrates	O
genomic	O
data	O
with	O
a	O
variety	O
of	O
functional	O
data	O
and	O
has	O
a	O
powerful	O
set	O
of	O
queries	O
that	O
enables	O
sophisticated	O
,	O
whole	O
-	O
genome	O
comparisons	O
to	O
be	O
performed	O
.	O

To	O
compare	O
genome	O
inventories	O
,	O
the	O
entire	O
set	O
of	O
predicted	O
proteins	O
from	O
the	O
36	O
species	O
(	O
348,787	O
proteins	O
)	O
were	O
clustered	O
using	O
Markov	O
Chain	O
Clustering	O
[	O
27	O
]	O
as	O
described	O
previously	O
[	O
28	O
]	O
,	O
[	O
29	O
]	O
.	O

A	O
total	O
of	O
282,061	O
predicted	O
proteins	O
were	O
grouped	O
into	O
23,724	O
clusters	O
,	O
each	O
cluster	O
representing	O
a	O
group	O
of	O
putative	O
orthologues	O
.	O

The	O
remaining	O
66,934	O
sequences	O
were	O
singletons	O
,	O
the	O
products	O
of	O
unique	O
genes	O
.	O

A	O
total	O
of	O
165	O
clusters	O
contained	O
proteins	O
from	O
all	O
36	O
species	O
used	O
in	O
this	O
study	O
(	O
Table	O
S1	O
)	O
.	O

Not	O
surprisingly	O
,	O
they	O
included	O
many	O
proteins	O
involved	O
in	O
basic	O
cellular	O
processes	O
,	O
such	O
as	O
ribosomal	O
proteins	O
,	O
components	O
of	O
transcription	O
,	O
translation	O
and	O
DNA	O
replication	O
apparatus	O
,	O
cytoskeletal	O
proteins	O
,	O
histones	O
,	O
proteins	O
involved	O
in	O
the	O
secretory	O
pathway	O
,	O
protein	O
folding	O
,	O
protein	O
sorting	O
and	O
ubiquitin	O
-	O
mediated	O
proteolysis	O
and	O
enzymes	O
involved	O
in	O
primary	O
metabolism	O
.	O

Only	O
16	O
clusters	O
contained	O
proteins	O
that	O
were	O
found	O
in	O
all	O
34	O
species	O
of	O
fungi	O
,	O
but	O
which	O
were	O
absent	O
from	O
the	O
two	O
species	O
of	O
oomycete	O
(	O
Table	O
S2	O
)	O
.	O

This	O
number	O
of	O
fungal	O
-	O
specific	O
clusters	O
is	O
surprisingly	O
low	O
considering	O
the	O
phylogenetic	O
distance	O
between	O
the	O
oomycetes	O
and	O
fungi	O
[	O
30	O
]	O
.	O

The	O
list	O
however	O
,	O
is	O
consistent	O
with	O
the	O
fundamental	O
differences	O
in	O
biology	O
between	O
fungi	O
and	O
oomycetes	O
and	O
included	O
proteins	O
involved	O
in	O
fungal	O
septation	O
,	O
glycosylation	O
,	O
transcriptional	O
regulation	O
,	O
cell	O
signalling	O
,	O
as	O
well	O
as	O
two	O
amino	O
-	O
acyl	O
tRNA	O
synthetases	O
.	O

The	O
obligate	O
mammalian	O
pathogen	O
Encephalitozoon	B
cuniculi	I
,	O
a	O
microsporidian	O
fungus	O
,	O
has	O
a	O
reduced	O
genome	O
that	O
codes	O
only	O
for	O
1,997	O
proteins	O
and	O
lacks	O
genes	O
encoding	O
enzymes	O
of	O
many	O
primary	O
metabolic	O
pathways	O
such	O
as	O
the	O
tricarboxylic	O
acid	O
cycle	O
,	O
fatty	O
acid	O
β	O
-	O
oxidation	O
,	O
biosynthetic	O
enzymes	O
of	O
the	O
vast	O
majority	O
of	O
amino	O
acids	O
,	O
fatty	O
acids	O
and	O
nucleotides	O
,	O
as	O
well	O
as	O
components	O
of	O
the	O
respiratory	O
electron	O
transport	O
chain	O
and	O
F1-F0	O
ATP	O
synthase	O
.	O

It	O
also	O
lacks	O
mitochondria	O
and	O
peroxisomes	O
[	O
31	O
]	O
.	O

Therefore	O
,	O
we	O
reasoned	O
that	O
the	O
inclusion	O
of	O
this	O
species	O
in	O
the	O
analysis	O
of	O
MCL	O
clusters	O
is	O
likely	O
to	O
result	O
in	O
underestimation	O
of	O
the	O
number	O
of	O
groups	O
of	O
conserved	O
proteins	O
.	O

By	O
discarding	O
E.	B
cuniculi	I
,	O
there	O
are	O
377	O
clusters	O
that	O
contained	O
proteins	O
from	O
35	O
species	O
of	O
fungi	O
and	O
oomycetes	O
(	O
Table	O
S3	O
)	O
.	O

This	O
relatively	O
small	O
number	O
of	O
fungal	O
-	O
conserved	O
clusters	O
reflects	O
the	O
large	O
evolutionary	O
distance	O
between	O
members	O
of	O
the	O
fungal	O
kingdom	O
,	O
as	O
well	O
as	O
complex	O
patterns	O
of	O
gene	O
gains	O
and	O
losses	O
during	O
the	O
evolution	O
of	O
fungi	O
.	O

Basidiomycetes	O
and	O
ascomycetes	O
are	O
thought	O
to	O
have	O
diverged	O
nearly	O
1,000	O
million	O
years	O
ago	O
[	O
32	O
]	O
and	O
the	O
Saccharomycotina	O
alone	O
are	O
more	O
evolutionarily	O
diverged	O
than	O
the	O
Chordate	O
phylum	O
of	O
the	O
animal	O
kingdom	O
[	O
33	O
]	O
.	O

Since	O
the	O
divergence	O
of	O
Saccharomycotina	O
(	O
hemiascomycetes	O
)	O
and	O
Pezizomycotina	O
(	O
euascomycetes	O
)	O
,	O
the	O
genomes	O
of	O
the	O
latter	O
have	O
greatly	O
increased	O
in	O
size	O
,	O
partly	O
due	O
to	O
the	O
appearance	O
of	O
novel	O
genes	O
related	O
to	O
the	O
filamentous	O
lifestyle	O
.	O

Lineage	O
-	O
specific	O
gene	O
losses	O
have	O
also	O
been	O
shown	O
in	O
a	O
number	O
of	O
hemiascomycete	O
species	O
[	O
34	O
]	O
.	O

As	O
well	O
as	O
the	O
groups	O
of	O
proteins	O
mentioned	O
above	O
(	O
Table	O
S1	O
)	O
,	O
the	O
fungal	O
-	O
conserved	O
clusters	O
included	O
those	O
containing	O
enzymes	O
from	O
primary	O
metabolic	O
pathways	O
not	O
present	O
in	O
E.	B
cuniculi	I
,	O
such	O
as	O
the	O
tricarboxylic	O
acid	O
cycle	O
,	O
amino	O
acid	O
metabolism	O
,	O
fatty	O
acid	O
biosynthesis	O
,	O
cholesterol	O
biosynthesis	O
and	O
nucleotide	O
metabolism	O
,	O
as	O
well	O
as	O
components	O
of	O
the	O
respiratory	O
electron	O
transport	O
chain	O
and	O
F1-F0	O
ATP	O
synthase	O
.	O

The	O
conserved	O
protein	O
clusters	O
also	O
include	O
a	O
number	O
of	O
transporters	O
(	O
including	O
mitochondrial	O
transporters	O
)	O
,	O
enzymes	O
involved	O
in	O
haem	O
biosynthesis	O
,	O
autophagy	O
-	O
related	O
proteins	O
,	O
those	O
involved	O
in	O
protein	O
targeting	O
to	O
the	O
peroxisome	O
and	O
vacuole	O
and	O
additional	O
groups	O
of	O
proteins	O
involved	O
in	O
signal	O
transduction	O
that	O
are	O
not	O
present	O
in	O
E.	B
cuniculi	I
(	O
including	O
those	O
involved	O
in	O
inosine	O
triphosphate	O
and	O
leukotriene	O
metabolism	O
)	O
.	O

The	O
analysis	O
also	O
showed	O
there	O
were	O
105	O
clusters	O
that	O
contained	O
proteins	O
from	O
33	O
species	O
of	O
fungi	O
(	O
excluding	O
E.	B
cuniculi	I
)	O
,	O
but	O
not	O
from	O
the	O
two	O
species	O
of	O
oomycete	O
(	O
see	O
Table	O
S4	O
)	O
.	O

As	O
well	O
as	O
those	O
mentioned	O
previously	O
(	O
Table	O
S2	O
)	O
,	O
the	O
group	O
includes	O
a	O
number	O
of	O
clusters	O
of	O
transporters	O
that	O
are	O
conserved	O
in	O
fungi	O
but	O
not	O
found	O
in	O
oomycetes	O
,	O
as	O
well	O
as	O
proteins	O
involved	O
in	O
fungal	O
cell	O
wall	O
synthesis	O
,	O
and	O
lipid	O
metabolism	O
.	O

It	O
may	O
be	O
the	O
case	O
that	O
the	O
genomes	O
of	O
oomycete	O
species	O
do	O
not	O
possess	O
orthologues	O
of	O
the	O
fungal	O
genes	O
in	O
these	O
clusters	O
,	O
or	O
alternatively	O
,	O
the	O
large	O
evolutionary	O
distance	O
between	O
the	O
oomycetes	O
and	O
fungi	O
mean	O
that	O
the	O
corresponding	O
orthologues	O
from	O
each	O
Kingdom	O
cluster	O
separately	O
.	O

Comparative	O
analysis	O
of	O
yeasts	O
and	O
filamentous	O
fungi	O
One	O
striking	O
difference	O
in	O
the	O
morphology	O
of	O
species	O
of	O
fungi	O
is	O
between	O
those	O
that	O
have	O
a	O
filamentous	O
,	O
multi	O
-	O
cellular	O
growth	O
habit	O
and	O
those	O
that	O
grow	O
as	O
single	O
yeast	B
cells	O
.	O

There	O
is	O
some	O
overlap	O
between	O
these	O
two	O
groups	O
;	O
because	O
some	O
fungi	O
are	O
dimorphic	O
or	O
even	O
pleiomorphic	O
,	O
switching	O
between	O
different	O
growth	O
forms	O
depending	O
on	O
environmental	O
conditions	O
or	O
the	O
stage	O
of	O
their	O
life	O
cycle	O
.	O

For	O
example	O
,	O
the	O
corn	B
-	O
smut	O
fungus	O
Ustilago	B
maydis	I
can	O
exist	O
saprophytically	O
as	O
haploid	O
yeast	B
-	O
like	O
cells	O
,	O
but	O
needs	O
to	O
form	O
a	O
dikaryotic	O
filamentous	O
growth	O
form	O
in	O
order	O
to	O
infect	O
the	O
host	O
plant	O
[	O
23	O
]	O
.	O

Generally	O
the	O
genomes	O
of	O
the	O
filamentous	O
fungi	O
contain	O
more	O
protein	O
-	O
encoding	O
genes	O
(	O
9,000–17,000	O
)	O
than	O
those	O
from	O
unicellular	O
yeasts	O
(	O
5,000–7,000	O
)	O
,	O
perhaps	O
reflecting	O
their	O
greater	O
morphological	O
complexity	O
and	O
secondary	O
metabolic	O
capacity	O
.	O

U.	B
maydis	I
,	O
however	O
,	O
has	O
6,522	O
protein	O
encoding	O
genes	O
,	O
perhaps	O
reflecting	O
its	O
lack	O
of	O
extensive	O
secondary	O
metabolic	O
pathways	O
and	O
its	O
potential	O
usefulness	O
in	O
defining	O
the	O
minimal	O
gene	O
sets	O
associated	O
with	O
biotrophic	O
growth	O
[	O
23	O
]	O
.	O

The	O
increase	O
in	O
proteome	O
size	O
in	O
filamentous	O
ascomycetes	O
may	O
be	O
due	O
to	O
the	O
expansion	O
of	O
certain	O
gene	O
families	O
or	O
the	O
presence	O
of	O
novel	O
genes	O
that	O
are	O
essential	O
for	O
the	O
filamentous	O
lifestyle	O
.	O

For	O
the	O
purposes	O
of	O
this	O
study	O
,	O
the	O
filamentous	O
fungi	O
were	O
defined	O
as	O
the	O
filamentous	O
ascomycetes	O
(	O
subphylum	O
Pezizomycotina	O
)	O
,	O
basidiomycetes	O
and	O
zygomycetes	O
and	O
the	O
unicellular	O
fungi	O
were	O
defined	O
as	O
the	O
budding	O
yeasts	O
(	O
order	O
Saccharomycetales	O
)	O
,	O
the	O
archiascomycete	O
Schizosaccharomyces	B
pombe	I
and	O
the	O
microsporidian	O
fungus	O
Encephalitozoon	B
cuniculi	I
.	O

A	O
total	O
of	O
37	O
MCL	O
clusters	O
contained	O
proteins	O
from	O
all	O
species	O
of	O
filamentous	O
fungi	O
,	O
but	O
no	O
species	O
of	O
unicellular	O
fungi	O
(	O
Table	O
2	O
)	O
.	O

Interestingly	O
,	O
eight	O
of	O
these	O
clusters	O
also	O
contained	O
proteins	O
from	O
both	O
species	O
of	O
oomycete	O
represented	O
in	O
e	O
-	O
Fungi	O
.	O

The	O
filamentous	O
-	O
fungal	O
specific	O
clusters	O
included	O
a	O
number	O
of	O
proteins	O
that	O
are	O
involved	O
in	O
cytoskeletal	O
rearrangements	O
(	O
dedicator	O
of	O
cytokinesis	O
protein	O
,	O
integrin	O
beta-1-binding	O
protein	O
,	O
dynactin	O
p62	O
family	O
,	O
dynein	O
light	O
intermediate	O
chain	O
2	O
)	O
,	O
it	O
seems	O
likely	O
that	O
these	O
are	O
required	O
for	O
the	O
complex	O
morphological	O
changes	O
that	O
filamentous	O
fungi	O
undergo	O
during	O
their	O
lifecycle	O
and	O
the	O
production	O
of	O
differentiated	O
cells	O
,	O
such	O
as	O
spores	O
,	O
fruiting	O
bodies	O
and	O
infection	O
structures	O
.	O

The	O
results	O
also	O
suggest	O
that	O
filamentous	O
fungal	O
species	O
make	O
a	O
greater	O
use	O
of	O
lipids	O
as	O
signalling	O
molecules	O
than	O
yeast	B
species	O
.	O

For	O
example	O
,	O
the	O
occurrence	O
of	O
filamentous	O
fungal	O
-	O
specific	O
clusters	O
representing	O
two	O
groups	O
of	O
lysophospholipases	O
,	O
as	O
well	O
as	O
ceramidases	O
that	O
are	O
involved	O
in	O
sphingolipid	O
signalling	O
[	O
35	O
]	O
and	O
linoleate	O
diol	O
synthases	O
that	O
can	O
catalyse	O
the	O
formation	O
of	O
leukotrienes	O
[	O
36	O
]	O
.	O

Interestingly	O
,	O
one	O
of	O
the	O
products	O
of	O
linoleate	O
diol	O
synthase	O
has	O
been	O
shown	O
to	O
be	O
a	O
sporulation	O
hormone	O
in	O
Aspergillus	B
nidulans	I
[	O
37	O
]	O
.	O

There	O
is	O
also	O
a	O
cluster	O
that	O
represents	O
homologues	O
of	O
a	O
novel	O
human	B
gene	O
(	O
LRP16	O
)	O
that	O
acts	O
downstream	O
of	O
a	O
steroid	O
receptor	O
and	O
promotes	O
cell	O
proliferation	O
[	O
38	O
]	O
.	O

Two	O
clusters	O
of	O
filamentous	O
fungal	O
-	O
specific	O
proteins	O
represent	O
enzymes	O
involved	O
in	O
molypterin	O
biosynthesis	O
(	O
MCL2420	O
,	O
MCL2581	O
)	O
.	O

Molypterin	O
is	O
a	O
molybdenum	O
-	O
containing	O
co	O
-	O
factor	O
for	O
nitrate	O
reductase	O
,	O
an	O
enzyme	O
that	O
is	O
known	O
to	O
be	O
absent	O
from	O
the	O
species	O
of	O
yeast	B
used	O
in	O
this	O
study	O
[	O
39	O
]	O
.	O

Both	O
these	O
clusters	O
are	O
also	O
found	O
in	O
oomycetes	O
.	O

There	O
are	O
other	O
clusters	O
representing	O
proteins	O
important	O
for	O
activities	O
specific	O
to	O
filamentous	O
fungi	O
,	O
such	O
as	O
homologues	O
of	O
Pro11	O
(	O
striatin	O
)	O
which	O
regulates	O
fruiting	O
body	O
formation	O
in	O
Sordaria	B
macrospora	I
[	O
40	O
]	O
,	O
the	O
vegetatible	O
incompatibility	O
protein	O
HET	O
-	O
E-1	O
,	O
which	O
prevents	O
the	O
formation	O
of	O
heterokaryons	O
between	O
incompatible	O
fungal	O
strains	O
in	O
Podospora	B
anserina	I
[	O
41	O
]	O
,	O
anucleate	O
primary	O
sterigmata	O
protein	O
A	O
from	O
Aspergillus	B
nidulans	I
,	O
which	O
is	O
essential	O
for	O
nuclear	O
migration	O
and	O
conidiophore	O
development	O
[	O
42	O
]	O
and	O
cytochrome	O
P450	O
and	O
polyketide	O
synthase	O
-	O
encoding	O
genes	O
,	O
both	O
of	O
which	O
are	O
involved	O
in	O
a	O
number	O
of	O
secondary	O
metabolic	O
pathways	O
including	O
toxin	O
biosynthesis	O
[	O
43	O
]	O
.	O

Pathogenicity	O
-	O
associated	O
gene	O
functions	O
in	O
fungi	O
As	O
the	O
selected	O
set	O
of	O
fungi	O
includes	O
both	O
saprotrophic	O
and	O
pathogenic	O
species	O
,	O
this	O
allows	O
us	O
to	O
compare	O
the	O
gene	O
inventories	O
of	O
phytopathogenic	O
and	O
closely	O
related	O
non	O
-	O
pathogenic	O
fungi	O
to	O
look	O
for	O
genes	O
that	O
are	O
unique	O
to	O
phytopathogens	O
.	O

Analysis	O
of	O
MCL	O
clusters	O
showed	O
that	O
there	O
were	O
no	O
clusters	O
that	O
contained	O
proteins	O
from	O
all	O
species	O
of	O
fungal	O
phytopathogen	O
in	O
e	O
-	O
Fungi	O
(	O
namely	O
B.	B
cinerea	I
,	O
Eremothecium	B
gossypii	I
,	O
G.	B
zeae	I
,	O
M.	B
grisea	I
,	O
S.	B
sclerotiorum	I
,	O
S.	B
nodorum	I
and	O
U.	B
maydis	I
)	O
but	O
did	O
not	O
contain	O
proteins	O
from	O
non	O
-	O
pathogenic	O
species	O
.	O

There	O
were	O
,	O
however	O
,	O
four	O
clusters	O
that	O
were	O
exclusive	O
to	O
filamentous	O
ascomycete	O
phytopathogens	O
(	O
namely	O
B.	B
cinerea	I
,	O
G.	B
zeae	I
,	O
M.	B
grisea	I
,	O
S.	B
sclerotiorum	I
,	O
S.	B
nodorum	I
as	O
shown	O
in	O
Table	O
3	O
)	O
.	O

Significantly	O
,	O
none	O
of	O
the	O
members	O
of	O
these	O
clusters	O
had	O
homology	O
to	O
any	O
known	O
proteins	O
or	O
contained	O
motifs	O
from	O
the	O
Pfam	O
database	O
[	O
44	O
]	O
,	O
so	O
we	O
were	O
unable	O
to	O
predict	O
their	O
function	O
,	O
although	O
two	O
of	O
the	O
clusters	O
(	O
MCL4854	O
and	O
MCL8229	O
)	O
consisted	O
entirely	O
of	O
proteins	O
that	O
were	O
predicted	O
to	O
be	O
secreted	O
.	O

Taken	O
together	O
,	O
the	O
observations	O
indicate	O
that	O
a	O
battery	O
of	O
completely	O
novel	O
secreted	O
proteins	O
may	O
be	O
associated	O
with	O
ascomycete	O
fungal	O
pathogens	O
.	O

Pathogenicity	O
factors	O
have	O
been	O
defined	O
as	O
genes	O
that	O
are	O
essential	O
for	O
successful	O
completion	O
of	O
the	O
pathogen	O
lifecycle	O
but	O
dispensable	O
for	O
saprophytic	O
growth	O
[	O
4	O
]	O
.	O

This	O
is	O
an	O
experimental	O
definition	O
based	O
on	O
whether	O
null	O
mutations	O
of	O
a	O
given	O
gene	O
reduce	O
the	O
virulence	O
of	O
the	O
pathogen	O
on	O
its	O
host	O
.	O

We	O
wished	O
to	O
ascertain	O
whether	O
homologues	O
of	O
previously	O
characterised	O
and	O
experimentally	O
-	O
validated	O
pathogenicity	O
factors	O
were	O
limited	O
to	O
the	O
genomes	O
of	O
pathogenic	O
species	O
.	O

A	O
search	O
was	O
therefore	O
made	O
for	O
pathogenicity	O
factors	O
that	O
have	O
been	O
identified	O
experimentally	O
for	O
the	O
species	O
of	O
phytopathogens	O
represented	O
in	O
e	O
-	O
Fungi	O
using	O
PHI	O
-	O
base	O
,	O
the	O
plant	O
-	O
host	O
interaction	O
database	O
[	O
45	O
]	O
.	O

The	O
matching	O
locus	O
was	O
identified	O
for	O
each	O
pathogenicity	O
factor	O
in	O
the	O
corresponding	O
genome	O
sequence	O
by	O
comparing	O
a	O
published	O
protein	O
sequence	O
with	O
sets	O
of	O
predicted	O
proteins	O
for	O
each	O
genome	O
using	O
BLASTP	O
.	O

This	O
produced	O
a	O
list	O
of	O
105	O
pathogenicity	O
factors	O
,	O
although	O
corresponding	O
loci	O
could	O
not	O
be	O
found	O
in	O
genome	O
sequences	O
for	O
all	O
the	O
published	O
genes	O
(	O
see	O
Table	O
S5	O
)	O
.	O

MCL	O
clusters	O
containing	O
these	O
proteins	O
were	O
identified	O
(	O
76	O
unique	O
clusters	O
)	O
and	O
the	O
species	O
distribution	O
of	O
members	O
of	O
these	O
clusters	O
analysed	O
.	O

In	O
total	O
,	O
29	O
of	O
the	O
MCL	O
clusters	O
contained	O
pathogenicity	O
factors	O
with	O
members	O
from	O
at	O
least	O
34	O
of	O
the	O
36	O
species	O
represented	O
in	O
e	O
-	O
Fungi	O
(	O
Table	O
4	O
)	O
.	O

Not	O
surprisingly	O
,	O
many	O
of	O
these	O
clusters	O
contain	O
conserved	O
components	O
of	O
signalling	O
pathways	O
such	O
as	O
protein	O
kinases	O
,	O
adenylate	O
cyclases	O
,	O
G	O
-	O
proteins	O
and	O
cell	O
cycle	O
regulators	O
.	O

Cellular	O
morphogenesis	O
is	O
known	O
to	O
be	O
important	O
for	O
infection	O
of	O
the	O
host	O
plant	O
by	O
many	O
phytopathogens	O
,	O
for	O
example	O
,	O
in	O
appressorium	O
formation	O
in	O
Magnaporthe	B
grisea	I
[	O
46	O
]	O
or	O
the	O
switch	O
in	O
the	O
growth	O
form	O
of	O
Ustilago	B
maydis	I
from	O
yeast	B
-	O
like	O
growth	O
to	O
filamentous	O
invasive	O
growth	O
[	O
47	O
]	O
.	O

Links	O
between	O
successful	O
plant	O
infection	O
and	O
cell	O
cycle	O
control	O
have	O
also	O
been	O
demonstrated	O
[	O
48	O
]	O
.	O

It	O
seems	O
likely	O
that	O
conserved	O
signalling	O
pathways	O
that	O
control	O
activities	O
,	O
such	O
as	O
mating	O
and	O
morphogenesis	O
in	O
all	O
fungi	O
,	O
have	O
evolved	O
to	O
control	O
processes	O
essential	O
for	O
pathogencity	O
in	O
phytopathogens	O
.	O

Other	O
conserved	O
pathogenicity	O
factors	O
encode	O
enzymes	O
of	O
metabolic	O
pathways	O
that	O
are	O
present	O
in	O
nearly	O
all	O
fungi	O
,	O
but	O
seem	O
to	O
be	O
important	O
for	O
the	O
life	O
cycle	O
of	O
particular	O
pathogenic	O
species	O
,	O
for	O
example	O
,	O
enzymes	O
involved	O
in	O
beta	O
-	O
oxidation	O
of	O
fatty	O
acids	O
,	O
the	O
glyoxylate	O
shunt	O
,	O
amino	O
acid	O
metabolism	O
and	O
the	O
utilisation	O
of	O
stored	O
sugars	O
.	O

When	O
considered	O
together	O
,	O
this	O
may	O
indicate	O
that	O
nutritional	O
conditions	O
which	O
fungi	O
encounter	O
when	O
invading	O
host	O
plant	O
tissue	O
require	O
mobilisation	O
of	O
stored	O
lipids	O
prior	O
to	O
nutrition	O
being	O
extracted	O
from	O
the	O
host	O
plant	O
.	O

Seventeen	O
of	O
the	O
MCL	O
clusters	O
containing	O
pathogenicity	O
factors	O
were	O
specific	O
to	O
filamentous	O
ascomycetes	O
(	O
Table	O
5	O
)	O
.	O

These	O
include	O
a	O
number	O
of	O
enzymes	O
involved	O
in	O
secondary	O
metabolism	O
,	O
such	O
as	O
those	O
involved	O
in	O
the	O
synthesis	O
of	O
the	O
fungal	O
toxin	O
trichothecene	O
in	O
G.	B
zeae	I
[	O
43	O
]	O
and	O
those	O
involved	O
in	O
melanin	O
biosynthesis	O
[	O
49	O
]	O
,	O
as	O
well	O
as	O
structural	O
proteins	O
,	O
some	O
of	O
which	O
are	O
components	O
of	O
differentiated	O
cell	O
types	O
not	O
seen	O
in	O
yeasts	O
,	O
for	O
example	O
,	O
hydrophobins	O
which	O
are	O
components	O
of	O
aerial	O
structures	O
such	O
as	O
fruiting	O
bodies	O
[	O
50	O
]	O
but	O
are	O
also	O
involved	O
in	O
pathogenicity	O
[	O
16	O
]	O
.	O

There	O
also	O
seems	O
to	O
be	O
a	O
number	O
of	O
filamentous	O
ascomycete	O
specific	O
receptor	O
proteins	O
(	O
transducin	O
beta	O
-	O
subunit	O
,	O
G	O
-	O
protein	O
coupled	O
receptor	O
,	O
tetraspanins	O
)	O
that	O
have	O
evolved	O
in	O
pathogens	O
to	O
be	O
used	O
in	O
sensing	O
environmental	O
cues	O
that	O
are	O
essential	O
for	O
successful	O
infection	O
of	O
the	O
host	O
[	O
51	O
]	O
.	O

The	O
Woronin	O
body	O
is	O
a	O
structure	O
found	O
only	O
in	O
filamentous	O
ascomycetes	O
,	O
and	O
has	O
been	O
shown	O
to	O
be	O
essential	O
for	O
pathogenicity	O
in	O
M.	B
grisea	I
[	O
52	O
]	O
.	O

A	O
major	O
constituent	O
of	O
the	O
woronin	O
body	O
,	O
encoded	O
by	O
MVP1	O
,	O
is	O
a	O
pathogenicity	O
factor	O
for	O
M.	B
grisea	I
,	O
but	O
also	O
has	O
homologues	O
in	O
nearly	O
all	O
species	O
of	O
filamentous	O
ascomycetes	O
.	O

Two	O
proteins	O
that	O
were	O
initially	O
discovered	O
as	O
being	O
highly	O
expressed	O
in	O
the	O
appressoria	O
of	O
M.	B
grisea	I
and	O
essential	O
for	O
pathogenicity	O
(	O
Mas1	O
and	O
Mas3	O
)	O
[	O
53	O
]	O
also	O
have	O
homologues	O
in	O
a	O
number	O
of	O
species	O
of	O
filamentous	O
fungi	O
(	O
Table	O
5	O
)	O
.	O

Thus	O
,	O
many	O
innovations	O
that	O
have	O
allowed	O
filamentous	O
ascomycetes	O
to	O
have	O
a	O
more	O
complex	O
morphology	O
than	O
unicellular	O
yeasts	O
have	O
also	O
evolved	O
to	O
be	O
essential	O
for	O
plant	O
infection	O
by	O
phytopathogenic	O
species	O
.	O

Interestingly	O
,	O
none	O
of	O
the	O
MCL	O
clusters	O
containing	O
known	O
pathogenicity	O
factors	O
contained	O
members	O
only	O
from	O
phytopathogenic	O
fungi	O
,	O
apart	O
from	O
those	O
that	O
were	O
restricted	O
to	O
just	O
one	O
species	O
.	O

These	O
are	O
therefore	O
likely	O
to	O
represent	O
highly	O
-	O
specialised	O
proteins	O
that	O
have	O
evolved	O
for	O
the	O
specific	O
lifecycle	O
of	O
just	O
one	O
species	O
of	O
phytopathogen	O
,	O
for	O
example	O
the	O
Pwl	O
proteins	O
involved	O
in	O
determining	O
host	O
range	O
of	O
different	O
strains	O
of	O
M.	B
grisea	I
[	O
54	O
]	O
.	O

Two	O
of	O
the	O
proteins	O
specific	O
to	O
M.	B
grisea	I
,	O
the	O
metallothionein	O
Mmt1	O
[	O
55	O
]	O
and	O
the	O
hydrophobin	O
Mpg1	O
[	O
56	O
]	O
are	O
small	O
polypeptides	O
and	O
are	O
members	O
of	O
highly	O
divergent	O
gene	O
families	O
,	O
other	O
members	O
of	O
which	O
do	O
not	O
cluster	O
together	O
using	O
BLASTP	O
.	O

Comparative	O
analysis	O
of	O
plant	O
-	O
pathogenic	O
and	O
saprotrophic	O
filamentous	O
ascomycetes	O
Based	O
on	O
the	O
analysis	O
reported	O
,	O
it	O
is	O
likely	O
that	O
in	O
general	O
there	O
are	O
a	O
large	O
number	O
of	O
differences	O
in	O
gene	O
inventories	O
between	O
filamentous	O
and	O
yeast	B
-	O
like	O
fungi	O
.	O

Therefore	O
,	O
in	O
order	O
to	O
compare	O
the	O
genomes	O
of	O
phytopathogens	O
and	O
saprotrophs	O
,	O
we	O
focused	O
on	O
filamentous	O
ascomycetes	O
in	O
order	O
to	O
resolve	O
in	O
greater	O
detail	O
the	O
distinct	O
differences	O
in	O
gene	O
sets	O
between	O
these	O
two	O
ecologically	O
separate	O
groups	O
of	O
fungi	O
.	O

In	O
this	O
way	O
differences	O
due	O
to	O
phylogeny	O
between	O
the	O
species	O
would	O
be	O
minimised	O
.	O

We	O
compared	O
the	O
gene	O
inventories	O
of	O
the	O
phytopathogens	O
B.	B
cinerea	I
,	O
G.	B
zeae	I
,	O
M.	B
grisea	I
,	O
S.	B
sclerotiorum	I
,	O
S.	B
nodorum	I
with	O
the	O
non	O
-	O
pathogens	O
Aspergillus	B
nidulans	I
,	O
Chaetomium	B
globosum	I
,	O
Neurospora	B
crassa	I
and	O
Trichoderma	B
reesei	I
.	O

Phylogenetic	O
analysis	O
suggests	O
that	O
the	O
phytopathogenic	O
species	O
do	O
not	O
form	O
a	O
separate	O
clade	O
from	O
the	O
pathogenic	O
species	O
(	O
Figure	O
1	O
)	O
,	O
[	O
3	O
]	O
and	O
we	O
assumed	O
that	O
differences	O
in	O
gene	O
inventory	O
should	O
therefore	O
reflect	O
lifestyle	O
rather	O
than	O
evolutionary	O
distance	O
.	O

In	O
order	O
for	O
such	O
a	O
comparison	O
to	O
be	O
considered	O
valid	O
,	O
the	O
completeness	O
and	O
quality	O
of	O
the	O
fungal	O
genome	O
sequences	O
used	O
should	O
,	O
however	O
,	O
also	O
be	O
comparable	O
.	O

Table	O
S6	O
summarises	O
the	O
available	O
data	O
about	O
genome	O
sequence	O
coverage	O
,	O
genome	O
size	O
and	O
the	O
number	O
of	O
predicted	O
proteins	O
for	O
each	O
species	O
.	O

This	O
shows	O
that	O
the	O
genome	O
coverage	O
is	O
greater	O
than	O
5x	O
and	O
the	O
number	O
of	O
predicted	O
proteins	O
in	O
the	O
range	O
of	O
10,000–16,000	O
for	O
all	O
genomes	O
used	O
,	O
suggesting	O
a	O
high	O
level	O
of	O
equivalence	O
between	O
species	O
with	O
regard	O
to	O
sequence	O
quality	O
.	O

From	O
our	O
work	O
it	O
seems	O
unlikely	O
that	O
there	O
are	O
pathogenicity	O
factors	O
conserved	O
in	O
,	O
and	O
specific	O
to	O
,	O
all	O
species	O
of	O
phytopathogen	O
.	O

It	O
may	O
,	O
for	O
instance	O
,	O
be	O
the	O
case	O
that	O
differences	O
in	O
the	O
gene	O
inventories	O
are	O
due	O
to	O
the	O
expansion	O
of	O
certain	O
gene	O
families	O
in	O
the	O
genomes	O
of	O
phytopathogenic	O
species	O
associated	O
with	O
functions	O
necessary	O
for	O
pathogenesis	O
.	O

To	O
define	O
protein	O
families	O
,	O
we	O
used	O
the	O
Pfam	O
database	O
which	O
contains	O
protein	O
family	O
models	O
based	O
on	O
Hidden	O
Markov	O
Models	O
[	O
44	O
]	O
,	O
[	O
57	O
]	O
.	O

Sets	O
of	O
predicted	O
proteins	O
for	O
each	O
fungal	O
species	O
in	O
e	O
-	O
Fungi	O
were	O
analysed	O
for	O
the	O
occurrence	O
of	O
Pfam	O
motifs	O
and	O
the	O
number	O
of	O
proteins	O
containing	O
each	O
domain	O
across	O
fungal	O
species	O
ascertained	O
.	O

The	O
sets	O
of	O
predicted	O
protein	O
sequences	O
used	O
in	O
this	O
study	O
have	O
been	O
automatically	O
predicted	O
as	O
part	O
of	O
each	O
individual	O
genome	O
project	O
and	O
are	O
likely	O
to	O
contain	O
a	O
number	O
of	O
artefactual	O
sequences	O
.	O

The	O
use	O
of	O
Pfam	O
motifs	O
to	O
define	O
gene	O
families	O
in	O
this	O
study	O
reduces	O
the	O
likelihood	O
of	O
such	O
sequences	O
affecting	O
the	O
data	O
,	O
since	O
Pfam	O
motifs	O
are	O
based	O
on	O
multiple	O
sequence	O
alignments	O
of	O
well	O
-	O
studied	O
proteins	O
.	O

A	O
small	O
number	O
of	O
Pfam	O
motifs	O
were	O
not	O
found	O
in	O
the	O
proteomes	O
of	O
the	O
filamentous	O
ascomycete	O
non	O
-	O
pathogens	O
,	O
but	O
were	O
found	O
in	O
the	O
proteomes	O
of	O
at	O
least	O
three	O
species	O
of	O
filamentous	O
ascomycete	O
phytopathogens	O
(	O
Table	O
6	O
)	O
.	O

These	O
include	O
the	O
Cas1p	O
-	O
like	O
motif	O
(	O
PF07779	O
)	O
,	O
found	O
in	O
4	O
species	O
of	O
phytopathogen	O
,	O
including	O
five	O
copies	O
in	O
G.	B
zeae	I
,	O
and	O
the	O
Yeast	B
cell	O
wall	O
synthesis	O
protein	O
KRE9	O
/	O
KNH1	O
motif	O
(	O
PF05390	O
)	O
,	O
which	O
was	O
found	O
in	O
three	O
species	O
of	O
phytopathogen	O
.	O

Cas1p	O
is	O
a	O
membrane	O
protein	O
necessary	O
for	O
the	O
O	O
-	O
acetylation	O
of	O
the	O
capsular	O
polysaccharide	O
of	O
the	O
basidiomycete	O
animal	O
pathogen	O
Cryptococcus	B
neoformans	I
[	O
58	O
]	O
.	O

KRE9	O
and	O
KNH1	O
are	O
involved	O
in	O
the	O
synthesis	O
of	O
cell	O
surface	O
polysaccharides	O
in	O
S.	B
cerevisiae	I
[	O
59	O
]	O
.	O

Taken	O
together	O
this	O
suggests	O
that	O
synthesis	O
of	O
cell	O
surface	O
polysaccharides	O
is	O
important	O
for	O
phytopathogens	O
,	O
perhaps	O
helping	O
to	O
shroud	O
the	O
fungus	O
from	O
plant	O
defences	O
.	O

The	O
function	O
of	O
the	O
YDG	O
/	O
SRA	O
domain	O
motif	O
(	O
PF02182	O
)	O
is	O
unknown	O
,	O
but	O
is	O
found	O
in	O
a	O
novel	O
mouse	B
cell	O
proliferation	O
protein	O
Np95	O
,	O
in	O
which	O
the	O
domain	O
is	O
important	O
both	O
for	O
the	O
interaction	O
with	O
histones	O
and	O
for	O
chromatin	O
binding	O
in	O
vivo	O
[	O
60	O
]	O
.	O

As	O
well	O
as	O
domains	O
of	O
unknown	O
function	O
,	O
the	O
list	O
of	O
phytopathogen	O
-	O
specific	O
Pfam	O
motifs	O
includes	O
Allophanate	O
hydrolase	O
(	O
PF02682	O
)	O
which	O
is	O
found	O
in	O
an	O
enzyme	O
involved	O
in	O
the	O
ATP	O
-	O
dependent	O
urea	O
degradation	O
pathway	O
[	O
61	O
]	O
,	O
a	O
peptidase	O
motif	O
,	O
an	O
opioid	O
growth	O
receptor	O
motif	O
(	O
PF04664	O
)	O
and	O
Mnd1	O
(	O
PF03962	O
)	O
,	O
which	O
is	O
involved	O
in	O
recombination	O
and	O
meiotic	O
nuclear	O
division	O
[	O
62	O
]	O
.	O

To	O
detect	O
potential	O
gene	O
family	O
expansion	O
,	O
we	O
decided	O
to	O
identify	O
Pfam	O
motifs	O
that	O
were	O
present	O
in	O
both	O
phytopathogenic	O
and	O
non	O
-	O
pathogenic	O
species	O
of	O
filamentous	O
ascomycetes	O
,	O
but	O
that	O
were	O
more	O
common	O
in	O
the	O
genomes	O
of	O
the	O
former	O
.	O

The	O
Pfam	O
motifs	O
were	O
ranked	O
on	O
the	O
ratio	O
of	O
the	O
mean	O
number	O
of	O
proteins	O
containing	O
each	O
motif	O
in	O
phytopathogens	O
,	O
when	O
compared	O
to	O
non	O
-	O
pathogens	O
(	O
Table	O
7	O
)	O
.	O

The	O
tables	O
only	O
show	O
ratios	O
of	O
greater	O
than	O
or	O
equal	O
to	O
2.5	O
.	O

Pfam	O
motifs	O
that	O
were	O
more	O
common	O
in	O
the	O
proteomes	O
of	O
pathogens	O
,	O
include	O
some	O
found	O
in	O
enzymes	O
involved	O
in	O
secondary	O
metabolic	O
pathways	O
.	O

These	O
include	O
novel	O
enzymes	O
that	O
have	O
only	O
previously	O
been	O
studied	O
in	O
non	O
-	O
fungal	O
species	O
,	O
such	O
as	O
the	O
chalcone	O
synthases	O
;	O
type	O
III	O
polyketide	O
synthases	O
involved	O
in	O
the	O
biosynthesis	O
of	O
flavonoids	O
in	O
plants	O
[	O
63	O
]	O
and	O
lipoxygenases	O
;	O
components	O
of	O
metabolic	O
pathways	O
resulting	O
in	O
the	O
synthesis	O
of	O
physiologically	O
-	O
active	O
compounds	O
such	O
as	O
eicosanoids	O
in	O
mammals	O
[	O
64	O
]	O
and	O
jasmonic	O
acid	O
in	O
plants	O
[	O
65	O
]	O
as	O
well	O
as	O
antibiotic	O
synthesis	O
monooxygenases	O
.	O

It	O
seems	O
likely	O
that	O
secondary	O
metabolism	O
is	O
essential	O
in	O
phytopathogenic	O
species	O
for	O
the	O
synthesis	O
of	O
mycotoxins	O
,	O
antibiotics	O
,	O
siderophores	O
and	O
pigments	O
[	O
66	O
]	O
,	O
but	O
it	O
may	O
also	O
offer	O
fungal	O
pathogens	O
a	O
distinct	O
alternative	O
means	O
of	O
perturbing	O
host	O
metabolism	O
,	O
cell	O
signalling	O
or	O
plant	O
defence	O
,	O
in	O
contrast	O
to	O
bacterial	O
pathogens	O
that	O
rely	O
on	O
protein	O
secretion	O
to	O
achieve	O
this	O
.	O

There	O
also	O
seems	O
to	O
be	O
number	O
of	O
protease	O
and	O
peptidase	O
domains	O
that	O
are	O
more	O
common	O
in	O
the	O
genomes	O
of	O
phytopathogens	O
as	O
well	O
as	O
domains	O
from	O
two	O
classes	O
of	O
cell	O
-	O
wall	O
degrading	O
enzymes	O
:	O
namely	O
cutinase	O
(	O
PF01083	O
)	O
and	O
Glycosyl	O
hydrolase	O
family	O
53	O
(	O
PF07745	O
)	O
which	O
is	O
found	O
in	O
arabinogalactan	O
endo-1,4-beta	O
-	O
galactosidases	O
that	O
hydrolyze	O
the	O
galactan	O
side	O
chains	O
that	O
form	O
part	O
of	O
the	O
complex	O
carbohydrate	O
structure	O
of	O
pectin	O
[	O
67	O
]	O
.	O

Two	O
other	O
domains	O
found	O
in	O
enzymes	O
involved	O
in	O
pectin	O
degradation	O
,	O
pectinesterase	O
(	O
PF01095	O
)	O
and	O
Glycosyl	O
hydrolases	O
family	O
28	O
(	O
PF00295	O
)	O
are	O
both	O
more	O
than	O
twice	O
as	O
common	O
in	O
the	O
genomes	O
of	O
phytopathogens	O
than	O
saprotrophs	O
.	O

In	O
contrast	O
,	O
domains	O
found	O
in	O
cellulases	O
have	O
fairly	O
equal	O
distribution	O
between	O
the	O
proteomes	O
of	O
phytopathogens	O
and	O
non	O
-	O
pathogens	O
(	O
data	O
not	O
shown	O
)	O
.	O

Therefore	O
,	O
for	O
phytopathogens	O
the	O
most	O
essential	O
enzymes	O
for	O
pathogenesis	O
may	O
well	O
be	O
those	O
that	O
allow	O
the	O
fungus	O
to	O
penetrate	O
the	O
protective	O
cutin	O
layer	O
of	O
the	O
plant	O
epidermis	O
and	O
disrupt	O
the	O
pectin	O
matrix	O
of	O
the	O
plant	O
cell	O
wall	O
in	O
which	O
cellulose	O
fibrils	O
are	O
embedded	O
.	O

Pectin	O
-	O
degrading	O
enzymes	O
have	O
already	O
been	O
shown	O
to	O
be	O
pathogenicity	O
factors	O
in	O
a	O
number	O
of	O
fungi	O
[	O
68	O
]	O
.	O

NPP1	O
motifs	O
are	O
characteristic	O
of	O
a	O
group	O
of	O
proteins	O
called	O
NLPs	O
(	O
Nep1-like	O
proteins	O
)	O
that	O
trigger	O
defence	O
responses	O
,	O
necrosis	O
and	O
cell	O
death	O
in	O
plants	O
and	O
may	O
act	O
as	O
virulence	O
factors	O
[	O
69	O
]	O
.	O

The	O
NLPs	O
are	O
more	O
common	O
in	O
the	O
genomes	O
of	O
phytopathogenic	O
,	O
when	O
compared	O
to	O
non	O
-	O
pathogenic	O
ascomycetes	O
,	O
but	O
are	O
even	O
more	O
numerous	O
in	O
the	O
proteomes	O
of	O
the	O
oomycetes	O
(	O
64	O
proteins	O
in	O
Phytophthora	B
ramorum	I
and	O
75	O
in	O
Phytophthora	B
sojae	I
)	O
.	O

Proteins	O
containing	O
the	O
Chitin	O
recognition	O
protein	O
domain	O
(	O
PF00187	O
)	O
are	O
also	O
very	O
common	O
in	O
the	O
proteomes	O
of	O
phytopathogens	O
(	O
18	O
in	O
M.	B
grisea	I
and	O
16	O
in	O
S.	B
nodorum	I
)	O
.	O

A	O
role	O
for	O
chitin	O
-	O
binding	O
proteins	O
has	O
been	O
proposed	O
in	O
protecting	O
the	O
fungal	O
cell	O
wall	O
from	O
chitinases	O
produced	O
by	O
host	O
plants	O
[	O
70	O
]	O
.	O

There	O
are	O
also	O
two	O
other	O
Pfam	O
motifs	O
,	O
which	O
are	O
more	O
common	O
in	O
the	O
proteomes	O
of	O
phytopathogens	O
,	O
that	O
are	O
found	O
in	O
enzymes	O
involved	O
in	O
the	O
catabolism	O
of	O
toxic	O
compounds	O
,	O
namely	O
arylesterase	O
(	O
PF01731	O
)	O
and	O
EthD	O
protein	O
(	O
PF07110	O
)	O
which	O
breakdown	O
organophosphorus	O
esters	O
[	O
71	O
]	O
and	O
ethyl	O
tert	O
-	O
butyl	O
ether	O
[	O
72	O
]	O
,	O
respectively	O
.	O

Comparative	O
secretome	O
analysis	O
of	O
phytopathogenic	O
and	O
saprotrophic	O
filamentous	O
ascomycetes	O
Studies	O
in	O
bacterial	O
pathogens	O
and	O
oomycetes	O
have	O
shown	O
that	O
a	O
range	O
of	O
secreted	O
proteins	O
known	O
as	O
effectors	O
are	O
important	O
for	O
establishing	O
infection	O
of	O
the	O
host	O
plant	O
[	O
73	O
]	O
,	O
[	O
74	O
]	O
.	O

These	O
secreted	O
proteins	O
may	O
disable	O
plant	O
defences	O
and	O
subvert	O
cellular	O
processes	O
to	O
suit	O
the	O
needs	O
of	O
invading	O
pathogens	O
.	O

Therefore	O
,	O
we	O
decided	O
also	O
to	O
compare	O
gene	O
family	O
size	O
in	O
the	O
secretomes	O
of	O
phytopathogens	O
and	O
non	O
-	O
pathogens	O
.	O

There	O
are	O
a	O
number	O
of	O
programs	O
available	O
that	O
predict	O
whether	O
a	O
protein	O
is	O
likely	O
to	O
be	O
secreted	O
,	O
although	O
the	O
predictions	O
they	O
give	O
significantly	O
differ	O
from	O
each	O
other	O
.	O

Therefore	O
we	O
defined	O
the	O
secretome	O
of	O
each	O
fungal	O
species	O
based	O
on	O
those	O
proteins	O
that	O
are	O
predicted	O
to	O
be	O
secreted	O
by	O
two	O
different	O
programs	O
:	O
SignalP	O
3.0	O
[	O
75	O
]	O
and	O
WoLFPSORT	O
[	O
76	O
]	O
.	O

The	O
size	O
of	O
each	O
secretome	O
is	O
summarised	O
in	O
Figure	O
2	O
.	O

Even	O
when	O
using	O
two	O
programs	O
,	O
the	O
sizes	O
of	O
predicted	O
secretomes	O
can	O
vary	O
greatly	O
.	O

For	O
example	O
,	O
a	O
similar	O
analysis	O
for	O
M.	B
grisea	I
using	O
SignalP	O
and	O
ProtComp	O
(	O
www.Softberry.com	O
)	O
predicted	O
only	O
739	O
secreted	O
proteins	O
(	O
out	O
of	O
a	O
proteome	O
of	O
11,109	O
)	O
compared	O
to	O
our	O
prediction	O
of	O
1,546	O
secreted	O
proteins	O
(	O
out	O
of	O
a	O
proteome	O
of	O
12,841	O
)	O
[	O
22	O
]	O
.	O

The	O
size	O
of	O
the	O
secretomes	O
for	O
each	O
species	O
varied	O
from	O
5%–12	O
%	O
of	O
the	O
total	O
proteome	O
.	O

Overall	O
,	O
the	O
size	O
of	O
the	O
secretomes	O
from	O
phytopathogens	O
did	O
not	O
differ	O
greatly	O
from	O
that	O
of	O
non	O
-	O
pathogens	O
.	O

Table	O
8	O
shows	O
a	O
list	O
of	O
Pfam	O
motifs	O
,	O
not	O
found	O
in	O
the	O
secretomes	O
of	O
non	O
-	O
pathogenic	O
filamentous	O
ascomycetes	O
,	O
that	O
were	O
present	O
in	O
at	O
least	O
three	O
phytopathogenic	O
fungal	O
species	O
.	O

The	O
Isochorismatase	O
motif	O
(	O
PF00857	O
)	O
was	O
found	O
in	O
the	O
secretomes	O
of	O
all	O
five	O
species	O
of	O
phytopathogen	O
.	O

Isochorismatase	O
catalyses	O
the	O
conversion	O
of	O
isochorismate	O
to	O
2,3-dihydroxybenzoate	O
and	O
pyruvate	O
.	O

It	O
has	O
been	O
implicated	O
in	O
the	O
synthesis	O
of	O
the	O
anti	O
-	O
microbial	O
compound	O
phenazine	O
by	O
Pseudomonas	B
aeruginosa	I
[	O
77	O
]	O
and	O
the	O
siderophore	O
,	O
enterobactin	O
,	O
by	O
Escherichia	B
coli	I
[	O
78	O
]	O
.	O

The	O
isochorismatase	O
motif	O
is	O
also	O
found	O
in	O
a	O
number	O
of	O
hydrolases	O
,	O
such	O
as	O
nicotinamidase	O
that	O
converts	O
nicotinamide	O
to	O
nicotinic	O
acid	O
[	O
79	O
]	O
.	O

Members	O
of	O
this	O
family	O
are	O
found	O
in	O
all	O
filamentous	O
ascomycetes	O
,	O
but	O
interestingly	O
they	O
are	O
only	O
secreted	O
in	O
phytopathogens	O
.	O

Salicylic	O
acid	O
is	O
synthesised	O
in	O
plants	O
in	O
response	O
to	O
pathogen	O
attack	O
and	O
mediates	O
plant	O
defences	O
.	O

As	O
isochorismate	O
is	O
a	O
precursor	O
of	O
salicyclic	O
acid	O
[	O
80	O
]	O
,	O
it	O
may	O
be	O
worth	O
speculating	O
that	O
isochorismatases	O
secreted	O
by	O
fungi	O
could	O
act	O
to	O
reduce	O
salicylic	O
acid	O
accumulation	O
in	O
response	O
to	O
pathogen	O
attack	O
and	O
thus	O
inhibit	O
plant	O
defence	O
responses	O
.	O

The	O
secreted	O
isochorismatases	O
(	O
apart	O
from	O
one	O
of	O
the	O
proteins	O
from	O
S.	B
nodorum	I
)	O
all	O
show	O
sequence	O
similarity	O
to	O
ycaC	O
from	O
E.	B
coli	I
,	O
an	O
octameric	O
hydrolase	O
of	O
unknown	O
function	O
[	O
81	O
]	O
.	O

Pfam	O
motifs	O
found	O
in	O
the	O
secretomes	O
of	O
at	O
least	O
three	O
species	O
of	O
phytopathogens	O
,	O
but	O
not	O
in	O
any	O
of	O
the	O
non	O
-	O
pathogens	O
also	O
include	O
those	O
found	O
in	O
enzymes	O
potentially	O
involved	O
in	O
detoxification	O
,	O
such	O
as	O
arylesterase	O
and	O
amidohydrolase	O
,	O
and	O
also	O
beta	O
-	O
ketoacyl	O
synthase	O
,	O
which	O
catalyses	O
the	O
condensation	O
of	O
malonyl	O
-	O
ACP	O
with	O
a	O
growing	O
fatty	O
acid	O
chain	O
and	O
is	O
found	O
as	O
a	O
component	O
of	O
a	O
number	O
of	O
enzyme	O
systems	O
,	O
including	O
fatty	O
acid	O
synthases	O
and	O
polyketide	O
synthases	O
[	O
82	O
]	O
,	O
[	O
83	O
]	O
.	O

Table	O
9	O
shows	O
a	O
list	O
of	O
Pfam	O
motifs	O
that	O
are	O
more	O
common	O
in	O
the	O
secretomes	O
of	O
phytopathogens	O
as	O
compared	O
to	O
saprotrophs	O
.	O

These	O
include	O
a	O
number	O
of	O
secreted	O
proteases	O
,	O
transcription	O
factors	O
and	O
components	O
of	O
signal	O
transduction	O
pathways	O
.	O

The	O
Kelch	O
domain	O
(	O
PF01344	O
)	O
shows	O
the	O
most	O
striking	O
difference	O
in	O
distribution	O
between	O
phytopathogenic	O
and	O
non	O
-	O
pathogenic	O
genomes	O
.	O

This	O
50-residue	O
domain	O
is	O
found	O
in	O
a	O
number	O
of	O
actin	O
-	O
binding	O
proteins	O
[	O
84	O
]	O
,	O
as	O
well	O
as	O
enzymes	O
such	O
as	O
galactose	O
oxidase	O
and	O
neuraminidase	O
.	O

The	O
putative	O
function	O
of	O
each	O
secreted	O
Kelch	O
domain	O
-	O
containing	O
protein	O
was	O
ascertained	O
by	O
performing	O
a	O
BLAST	O
search	O
against	O
the	O
NCBI	O
non	O
-	O
redundant	O
protein	O
database	O
(	O
Table	O
10	O
)	O
.	O

A	O
number	O
of	O
these	O
seem	O
to	O
be	O
galactose	O
oxidases	O
,	O
enzymes	O
which	O
catalyse	O
the	O
oxidation	O
of	O
a	O
range	O
of	O
primary	O
alcohols	O
,	O
including	O
galactose	O
,	O
to	O
the	O
corresponding	O
aldehyde	O
with	O
the	O
concomitant	O
reduction	O
of	O
oxygen	O
to	O
hydrogen	O
peroxide	O
(	O
H2O2	O
)	O
[	O
85	O
]	O
.	O

Galactose	O
oxidase	O
shares	O
a	O
copper	O
radical	O
oxidase	O
motif	O
with	O
the	O
hydrogen	O
peroxide	O
-	O
generating	O
glyoxal	O
oxidases	O
involved	O
in	O
lignin	O
-	O
degradation	O
in	O
Phanerochaete	B
chrysosporium	I
[	O
86	O
]	O
.	O

H2O2-producing	O
copper	O
oxidases	O
have	O
been	O
shown	O
to	O
have	O
roles	O
in	O
morphogenesis	O
,	O
in	O
the	O
corn	B
-	O
smut	O
fungus	O
Ustilago	B
maydis	I
for	O
example	O
,	O
a	O
glyoxal	O
oxidase	O
is	O
required	O
for	O
filamentous	O
growth	O
and	O
pathogenicity	O
[	O
87	O
]	O
and	O
a	O
galactose	O
oxidase	O
is	O
involved	O
in	O
fruiting	O
body	O
formation	O
in	O
the	O
gram	O
-	O
negative	O
bacterium	O
Stigmatella	B
aurantiaca	I
[	O
88	O
]	O
.	O

Interestingly	O
,	O
the	O
list	O
of	O
Pfam	O
motifs	O
more	O
common	O
in	O
the	O
secretomes	O
of	O
phytopathogens	O
also	O
includes	O
those	O
found	O
in	O
copper	O
amine	O
oxidases	O
,	O
H2O2-generating	O
enzymes	O
that	O
catalyse	O
the	O
oxidative	O
deamination	O
of	O
primary	O
amines	O
to	O
the	O
corresponding	O
aldehydes	O
[	O
89	O
]	O
and	O
peroxidases	O
,	O
haem	O
-	O
containing	O
enzymes	O
that	O
use	O
hydrogen	O
peroxide	O
as	O
the	O
electron	O
acceptor	O
to	O
catalyse	O
a	O
number	O
of	O
oxidative	O
reactions	O
.	O

Secreted	O
fungal	O
peroxidases	O
include	O
enzymes	O
involved	O
in	O
lignin	O
breakdown	O
by	O
the	O
white	O
rot	O
fungus	O
Phanerochaete	B
chrysosporium	I
[	O
90	O
]	O
,	O
but	O
in	O
plants	O
they	O
generate	O
reactive	O
oxygen	O
species	O
and	O
are	O
involved	O
in	O
defence	O
responses	O
and	O
growth	O
induction	O
[	O
91	O
]	O
.	O

A	O
number	O
of	O
other	O
secreted	O
Kelch	O
domain	O
-	O
containing	O
proteins	O
have	O
similarity	O
to	O
proteins	O
of	O
unknown	O
function	O
from	O
species	O
of	O
the	O
bacterial	O
phytopathogen	O
Xanthomonas	O
.	O

Many	O
Kelch	O
domain	O
-	O
containing	O
proteins	O
are	O
involved	O
in	O
cytoskeletal	O
rearrangement	O
and	O
cell	O
morphology	O
[	O
92	O
]	O
,	O
[	O
93	O
]	O
.	O

It	O
may	O
be	O
worth	O
speculating	O
that	O
secreted	O
Kelch	O
domain	O
-	O
containing	O
proteins	O
could	O
act	O
as	O
effectors	O
,	O
causing	O
changes	O
in	O
the	O
arrangement	O
of	O
the	O
cytoskeleton	O
of	O
infected	O
plants	O
to	O
aid	O
the	O
proliferation	O
of	O
fungal	O
hyphae	O
.	O

It	O
has	O
recently	O
been	O
shown	O
,	O
for	O
example	O
,	O
that	O
M.	B
grisea	I
co	O
-	O
opts	O
plasmodesmata	O
to	O
move	O
from	O
cell	O
to	O
cell	O
in	O
infected	O
rice	B
leaves	O
[	O
94	O
]	O
and	O
would	O
therefore	O
need	O
to	O
peturb	O
cytoskeletal	O
organisation	O
in	O
rice	B
epidermal	O
cells	O
.	O

There	O
are	O
other	O
Pfam	O
domains	O
that	O
are	O
more	O
common	O
in	O
the	O
secretomes	O
of	O
phytopathogens	O
that	O
may	O
potentially	O
be	O
found	O
in	O
effectors	O
such	O
as	O
the	O
PAN	O
domain	O
(	O
PF00024	O
)	O
,	O
that	O
mediates	O
protein	O
-	O
protein	O
and	O
protein	O
-	O
carbohydrate	O
interactions	O
[	O
95	O
]	O
and	O
the	O
F5	O
/	O
8	O
type	O
C	O
domain	O
(	O
PF00754	O
)	O
,	O
found	O
in	O
the	O
discoidin	O
family	O
of	O
proteins	O
involved	O
in	O
cell	O
-	O
adhesion	O
or	O
developmental	O
processes	O
[	O
96	O
]	O
.	O

Discussion	O
One	O
of	O
the	O
most	O
fundamental	O
aims	O
in	O
plant	O
pathology	O
research	O
is	O
to	O
define	O
precisely	O
the	O
difference	O
between	O
pathogenic	O
and	O
non	O
-	O
pathogenic	O
microorganisms	O
.	O

The	O
answer	O
can	O
not	O
be	O
one	O
of	O
simple	O
phylogeny	O
,	O
because	O
phytopathogenic	O
species	O
are	O
found	O
in	O
all	O
taxonomic	O
divisions	O
of	O
fungi	O
and	O
are	O
often	O
closely	O
related	O
to	O
non	O
-	O
pathogenic	O
species	O
[	O
3	O
]	O
.	O

Before	O
the	O
availability	O
of	O
genomic	O
sequences	O
and	O
high	O
throughput	O
approaches	O
to	O
study	O
gene	O
function	O
[	O
20	O
]	O
,	O
research	O
was	O
concentrated	O
on	O
the	O
search	O
for	O
single	O
pathogenicity	O
factors	O
;	O
genes	O
that	O
are	O
dispensable	O
for	O
saprophytic	O
growth	O
but	O
essential	O
for	O
successful	O
infection	O
of	O
the	O
host	O
plant	O
[	O
4	O
]	O
,	O
[	O
97	O
]	O
.	O

However	O
,	O
rather	O
than	O
encoding	O
novel	O
proteins	O
found	O
only	O
in	O
phytopathogens	O
,	O
the	O
majority	O
of	O
pathogenicity	O
factors	O
discovered	O
in	O
this	O
way	O
have	O
been	O
found	O
to	O
be	O
involved	O
in	O
signalling	O
cascades	O
and	O
metabolic	O
pathways	O
and	O
hence	O
are	O
conserved	O
in	O
most	O
species	O
of	O
fungi	O
[	O
5	O
]	O
.	O

Components	O
of	O
signalling	O
cascades	O
that	O
in	O
the	O
budding	O
yeast	B
S.	B
cerevisiae	I
are	O
responsible	O
for	O
responses	O
to	O
pheromones	O
,	O
nutritional	O
starvation	O
and	O
osmotic	O
stress	O
[	O
9	O
]	O
have	O
in	O
many	O
cases	O
evolved	O
different	O
roles	O
in	O
the	O
life	O
cycle	O
of	O
pathogens	O
,	O
such	O
as	O
controlling	O
appressorium	O
formation	O
,	O
dimorphism	O
and	O
growth	O
[	O
10	O
]	O
.	O

Although	O
the	O
central	O
components	O
of	O
signalling	O
are	O
conserved	O
between	O
phytopathogens	O
and	O
S.	B
cerevisiae	I
,	O
the	O
receptors	O
are	O
often	O
different	O
,	O
reflecting	O
the	O
different	O
environmental	O
cues	O
to	O
which	O
the	O
pathogen	O
needs	O
to	O
respond	O
[	O
11	O
]	O
,	O
[	O
98	O
]	O
.	O

Analysis	O
of	O
all	O
available	O
genome	O
sequences	O
from	O
a	O
wider	O
range	O
of	O
fungal	O
species	O
has	O
for	O
the	O
first	O
time	O
allowed	O
us	O
to	O
address	O
the	O
differences	O
between	O
phytopathogens	O
and	O
non	O
-	O
pathogens	O
at	O
a	O
whole	O
genome	O
level	O
.	O

For	O
this	O
purpose	O
,	O
the	O
e	O
-	O
Fungi	O
data	O
warehouse	O
provides	O
a	O
means	O
to	O
interrogate	O
the	O
vast	O
amounts	O
of	O
genomic	O
and	O
functional	O
data	O
available	O
in	O
a	O
simple	O
integrated	O
manner	O
[	O
26	O
]	O
.	O

Previous	O
research	O
,	O
in	O
which	O
EST	O
datasets	O
were	O
compared	O
with	O
genomic	O
sequences	O
,	O
suggested	O
that	O
the	O
expressed	O
gene	O
inventories	O
of	O
phytopathogenic	O
species	O
were	O
not	O
significantly	O
more	O
similar	O
to	O
one	O
another	O
than	O
to	O
those	O
of	O
saprotrophic	O
filamentous	O
fungi	O
[	O
99	O
]	O
.	O

We	O
clustered	O
sets	O
of	O
predicted	O
proteins	O
from	O
36	O
different	O
species	O
of	O
fungi	O
and	O
oomycetes	O
into	O
groups	O
of	O
potential	O
orthologues	O
and	O
the	O
species	O
distribution	O
of	O
members	O
of	O
each	O
cluster	O
was	O
ascertained	O
.	O

There	O
were	O
no	O
clusters	O
that	O
were	O
completely	O
specific	O
to	O
phytopathogenic	O
species	O
across	O
both	O
fungi	O
and	O
oomycetes	O
,	O
suggesting	O
that	O
the	O
presence	O
of	O
novel	O
,	O
universal	O
pathogenicity	O
factors	O
in	O
the	O
genomes	O
of	O
phytopathogens	O
is	O
unlikely	O
.	O

This	O
was	O
confirmed	O
by	O
looking	O
at	O
clusters	O
containing	O
empirically	O
defined	O
pathogenicity	O
factors	O
,	O
where	O
homologues	O
of	O
many	O
of	O
these	O
were	O
found	O
in	O
all	O
species	O
studied	O
and	O
none	O
were	O
conserved	O
in	O
the	O
genomes	O
only	O
of	O
phytopathogens	O
.	O

A	O
small	O
number	O
were	O
only	O
found	O
in	O
a	O
single	O
species	O
of	O
fungus	O
and	O
probably	O
represented	O
proteins	O
that	O
are	O
highly	O
specialised	O
for	O
a	O
particular	O
role	O
in	O
a	O
specific	O
pathogenic	O
species	O
,	O
for	O
example	O
in	O
host	O
-	O
plant	O
recognition	O
[	O
54	O
]	O
.	O

Previous	O
research	O
also	O
suggested	O
that	O
the	O
gene	O
inventories	O
of	O
filamentous	O
fungi	O
were	O
more	O
similar	O
to	O
each	O
other	O
than	O
to	O
those	O
of	O
unicellular	O
yeasts	O
[	O
99	O
]	O
.	O

Analysis	O
of	O
the	O
clusters	O
of	O
similar	O
proteins	O
show	O
some	O
clusters	O
that	O
are	O
found	O
in	O
all	O
species	O
of	O
filamentous	O
fungi	O
(	O
including	O
ascomycetes	O
,	O
basidiomycetes	O
and	O
zygomycetes	O
)	O
but	O
are	O
not	O
present	O
in	O
the	O
genomes	O
of	O
yeasts	O
,	O
consistent	O
with	O
the	O
original	O
conclusion	O
.	O

These	O
contain	O
a	O
number	O
of	O
proteins	O
that	O
are	O
likely	O
to	O
be	O
involved	O
in	O
morphological	O
changes	O
associated	O
with	O
the	O
more	O
complex	O
filamentous	O
lifestyle	O
,	O
as	O
well	O
those	O
involved	O
in	O
secondary	O
metabolism	O
and	O
signalling	O
cascades	O
that	O
are	O
not	O
found	O
in	O
yeasts	O
.	O

In	O
particular	O
,	O
our	O
results	O
suggest	O
that	O
filamentous	O
fungi	O
use	O
a	O
wider	O
variety	O
of	O
lipid	O
molecules	O
for	O
the	O
purpose	O
of	O
signalling	O
.	O

Some	O
of	O
these	O
may	O
act	O
as	O
pheromones	O
,	O
or	O
hormones–	O
chemical	O
messengers	O
diffusing	O
from	O
one	O
cell	O
to	O
another	O
to	O
elicit	O
a	O
physiological	O
or	O
developmental	O
response	O
[	O
37	O
]	O
.	O

A	O
number	O
of	O
these	O
innovations	O
to	O
the	O
filamentous	O
lifestyle	O
may	O
serve	O
important	O
roles	O
in	O
pathogenesis	O
as	O
well	O
,	O
because	O
homologues	O
of	O
a	O
number	O
of	O
pathogenicity	O
factors	O
are	O
found	O
only	O
in	O
filamentous	O
ascomycetes	O
.	O

The	O
distribution	O
of	O
filamentous	O
fungi	O
-	O
specific	O
proteins	O
,	O
such	O
as	O
involved	O
in	O
those	O
cytoskeletal	O
rearrangements	O
and	O
fruiting	O
body	O
formation	O
,	O
throughout	O
the	O
fungal	O
kingdom	O
(	O
and	O
in	O
some	O
cases	O
in	O
oomycetes	O
as	O
well	O
)	O
,	O
suggests	O
that	O
the	O
last	O
common	O
ancestral	O
fungus	O
may	O
well	O
have	O
been	O
multi	O
-	O
cellular	O
and	O
the	O
evolution	O
of	O
uni	O
-	O
cellular	O
fungi	O
was	O
likely	O
associated	O
with	O
massive	O
gene	O
loss	O
.	O

For	O
example	O
,	O
it	O
has	O
been	O
shown	O
that	O
early	O
in	O
ascomycete	O
evolution	O
there	O
was	O
a	O
proliferation	O
of	O
subtilase	O
-	O
type	O
protease	O
-	O
encoding	O
genes	O
that	O
have	O
been	O
retained	O
in	O
some	O
filamentous	O
ascomycete	O
lineages	O
,	O
but	O
lost	O
in	O
the	O
yeast	B
lineage	O
[	O
100	O
]	O
.	O

It	O
has	O
previously	O
been	O
speculated	O
that	O
the	O
evolution	O
of	O
phytopathogenesis	O
was	O
associated	O
with	O
the	O
expansion	O
of	O
certain	O
gene	O
families	O
[	O
1	O
]	O
.	O

Duplication	O
of	O
an	O
ancestral	O
gene	O
,	O
followed	O
by	O
mutation	O
allows	O
members	O
of	O
the	O
family	O
to	O
take	O
on	O
new	O
functions	O
[	O
101	O
]	O
.	O

For	O
example	O
,	O
genomes	O
of	O
the	O
filamentous	O
ascomycetes	O
studied	O
here	O
have	O
between	O
40	O
and	O
140	O
cytochrome	O
P450-encoding	O
genes	O
(	O
data	O
not	O
shown	O
)	O
that	O
are	O
involved	O
in	O
toxin	O
biosynthesis	O
,	O
lipid	O
metabolism	O
,	O
alkane	O
assimilation	O
and	O
detoxification	O
[	O
102	O
]	O
and	O
which	O
probably	O
arose	O
via	O
gene	O
duplication	O
and	O
functional	O
diversification	O
.	O

In	O
contrast	O
,	O
the	O
genome	O
of	O
the	O
budding	O
yeast	B
S.	B
cerevisiae	I
has	O
only	O
three	O
cytochrome	O
P450-encoding	O
enzymes	O
.	O

We	O
have	O
shown	O
here	O
that	O
there	O
are	O
likely	O
to	O
be	O
large	O
differences	O
in	O
the	O
gene	O
inventories	O
of	O
filamentous	O
fungi	O
compared	O
to	O
unicellular	O
yeasts	O
.	O

To	O
study	O
the	O
differences	O
between	O
phytopathogenic	O
and	O
saprophytic	O
fungi	O
,	O
we	O
concentrated	O
on	O
the	O
filamentous	O
ascomycetes	O
where	O
there	O
are	O
a	O
number	O
of	O
phytopathogenic	O
species	O
genomes	O
have	O
been	O
sequenced	O
along	O
with	O
closely	O
related	O
non	O
-	O
pathogens	O
.	O

Protein	O
families	O
were	O
defined	O
using	O
Pfam	O
motifs	O
[	O
57	O
]	O
and	O
the	O
predicted	O
protein	O
sets	O
for	O
each	O
species	O
analysed	O
in	O
order	O
to	O
identify	O
domains	O
that	O
were	O
specific	O
to	O
or	O
more	O
common	O
in	O
the	O
genomes	O
of	O
phytopathogens	O
.	O

Not	O
surprisingly	O
,	O
many	O
of	O
the	O
protein	O
families	O
we	O
identified	O
are	O
likely	O
to	O
be	O
associated	O
with	O
pathogenic	O
processes	O
such	O
as	O
plant	O
cell	O
wall	O
degradation	O
,	O
toxin	O
biosynthesis	O
,	O
formation	O
of	O
reactive	O
oxygen	O
species	O
and	O
detoxification	O
[	O
5	O
]	O
.	O

Studies	O
of	O
bacterial	O
phytopathogens	O
have	O
shown	O
the	O
importance	O
of	O
effectors	O
,	O
secreted	O
proteins	O
that	O
disable	O
plant	O
defences	O
and	O
subvert	O
metabolic	O
and	O
morphological	O
processes	O
for	O
the	O
benefit	O
of	O
the	O
invading	O
pathogen	O
and	O
which	O
require	O
delivery	O
via	O
a	O
type	O
III	O
secretion	O
system	O
that	O
are	O
often	O
deployed	O
during	O
pathogenesis	O
[	O
73	O
]	O
.	O

Bacterial	O
type	O
III	O
secreted	O
effectors	O
(	O
T3SEs	O
)	O
have	O
been	O
shown	O
to	O
target	O
salicyclic	O
acid	O
and	O
abscisic	O
acid	O
-	O
dependent	O
defences	O
,	O
host	O
vesicle	O
trafficking	O
,	O
transcription	O
and	O
RNA	O
metabolism	O
,	O
and	O
several	O
components	O
of	O
the	O
plant	O
defence	O
signalling	O
networks	O
[	O
103	O
]	O
.	O

Very	O
recently	O
,	O
potential	O
effector	O
-	O
encoding	O
genes	O
have	O
been	O
identified	O
in	O
the	O
genomes	O
of	O
several	O
species	O
of	O
oomycete	O
pathogens	O
and	O
are	O
defined	O
by	O
the	O
presence	O
of	O
a	O
conserved	O
RXLR	O
-	O
EER	O
motif	O
downstream	O
of	O
the	O
signal	O
peptide	O
sequence	O
[	O
74	O
]	O
.	O

The	O
RXLR	O
-	O
EER	O
motif	O
is	O
necessary	O
for	O
delivery	O
of	O
effector	O
proteins	O
into	O
host	O
plant	O
cells	O
and	O
is	O
therefore	O
critical	O
to	O
their	O
biological	O
activity	O
[	O
74	O
]	O
.	O

To	O
identify	O
potential	O
fungal	O
effectors	O
,	O
we	O
compared	O
Pfam	O
motif	O
frequency	O
between	O
the	O
secretomes	O
of	O
phytopathogens	O
and	O
non	O
-	O
pathogens	O
.	O

This	O
analysis	O
identified	O
potential	O
effector	O
-	O
encoding	O
genes	O
,	O
including	O
secreted	O
proteases	O
,	O
transcription	O
factors	O
and	O
proteins	O
that	O
may	O
be	O
involved	O
in	O
cytoskeletal	O
rearrangements	O
(	O
such	O
as	O
Kelch	O
-	O
domain	O
containing	O
proteins	O
)	O
and	O
protein	O
-	O
protein	O
interactions	O
,	O
as	O
well	O
as	O
a	O
group	O
of	O
pathogen	O
-	O
specific	O
secreted	O
isochorisimatases	O
that	O
potentially	O
could	O
suppress	O
salicyclic	O
acid	O
-	O
dependent	O
host	O
plant	O
defences	O
.	O

Bacterial	O
T3SEs	O
are	O
injected	O
directly	O
into	O
the	O
host	O
cytoplasm	O
via	O
the	O
type	O
III	O
secretion	O
injection	O
apparatus	O
[	O
73	O
]	O
.	O

In	O
contrast	O
,	O
the	O
potential	O
fungal	O
effectors	O
identified	O
in	O
this	O
study	O
appear	O
to	O
be	O
secreted	O
by	O
the	O
normal	O
cellular	O
secretory	O
pathway	O
via	O
the	O
endoplasmic	O
reticulum	O
and	O
the	O
mechanism	O
by	O
which	O
fungal	O
effectors	O
might	O
be	O
taken	O
up	O
by	O
plant	O
cells	O
and	O
enter	O
into	O
the	O
host	O
cytoplasm	O
is	O
currently	O
unknown	O
.	O

Although	O
the	O
evolution	O
of	O
phytopathogenicity	O
is	O
likely	O
to	O
have	O
happened	O
several	O
times	O
and	O
the	O
lifestyles	O
of	O
these	O
fungi	O
are	O
diverse	O
,	O
a	O
comparison	O
of	O
gene	O
inventories	O
of	O
a	O
number	O
of	O
species	O
using	O
a	O
powerful	O
resource	O
,	O
such	O
as	O
e	O
-	O
Fungi	O
,	O
has	O
allowed	O
us	O
to	O
pinpoint	O
new	O
gene	O
families	O
that	O
may	O
serve	O
important	O
roles	O
in	O
the	O
virulence	O
of	O
phytopathogens	O
,	O
allowing	O
their	O
selection	O
for	O
gene	O
functional	O
studies	O
,	O
that	O
are	O
currently	O
in	O
progress	O
.	O

The	O
analyses	O
deployed	O
here	O
may	O
also	O
offer	O
a	O
blueprint	O
for	O
the	O
types	O
of	O
larger	O
,	O
more	O
comprehensive	O
studies	O
that	O
will	O
be	O
necessary	O
to	O
interpret	O
the	O
large	O
flow	O
of	O
genetic	O
data	O
that	O
will	O
result	O
from	O
next	O
generation	O
DNA	O
sequence	O
analysis	O
utilizing	O
both	O
a	O
much	O
wider	O
variety	O
of	O
fungal	O
pathogen	O
species	O
and	O
also	O
large	O
sets	O
of	O
individual	O
isolates	O
of	O
existing	O
species	O
.	O

Materials	O
and	O
Methods	O
Clustering	O
of	O
sequences	O
Sets	O
of	O
predicted	O
proteins	O
were	O
downloaded	O
for	O
each	O
of	O
the	O
36	O
genomes	O
from	O
respective	O
sequencing	O
project	O
websites	O
(	O
Table	O
1	O
)	O
.	O

Proteins	O
less	O
than	O
40	O
amino	O
acids	O
in	O
length	O
were	O
not	O
included	O
in	O
this	O
analysis	O
.	O

Proteins	O
were	O
clustered	O
using	O
""""	O
all	O
against	O
all	O
""""	O
BLASTP	O
[	O
104	O
]	O
followed	O
by	O
Markov	O
Chain	O
Clustering	O
(	O
MCL	O
)	O
[	O
27	O
]	O
with	O
2.5	O
as	O
a	O
moderate	O
inflation	O
value	O
and	O
10−10	O
as	O
an	O
E	O
-	O
value	O
cut	O
-	O
off	O
,	O
as	O
described	O
previously	O
[	O
28	O
]	O
,	O
[	O
29	O
]	O
.	O

Clusters	O
were	O
annotated	O
based	O
on	O
best	O
hit	O
against	O
Swiss	O
-	O
Prot	O
protein	O
database	O
[	O
105	O
]	O
of	O
members	O
of	O
that	O
cluster	O
(	O
e	O
-	O
value	O
<	O
10−20	O
using	O
BLASTP	O
)	O
,	O
or	O
Pfam	O
motifs	O
contained	O
in	O
proteins	O
from	O
the	O
cluster	O
in	O
the	O
absence	O
of	O
Swiss	O
-	O
Prot	O
hits	O
.	O

Identification	O
of	O
Pfam	O
motifs	O
The	O
Pfam	O
-	O
A	O
library	O
from	O
release	O
18.0	O
of	O
the	O
Pfam	O
database	O
was	O
downloaded	O
from	O
the	O
Pfam	O
website	O
(	O
http://www.sanger.ac.uk/Software/Pfam/	O
)	O
.	O

This	O
library	O
contains	O
7973	O
protein	O
models	O
constructed	O
from	O
manually	O
curated	O
multiple	O
alignments	O
and	O
covers	O
75	O
%	O
of	O
proteins	O
in	O
UniProt	O
[	O
44	O
]	O
,	O
[	O
57	O
]	O
.	O

This	O
library	O
was	O
used	O
to	O
analyse	O
the	O
sequences	O
of	O
predicted	O
proteins	O
for	O
all	O
36	O
fungal	O
genomes	O
to	O
identify	O
the	O
Pfam	O
motifs	O
that	O
each	O
protein	O
contains	O
.	O

The	O
analysis	O
was	O
performed	O
using	O
the	O
""""	O
pfam_scan	O
""""	O
perl	O
script	O
(	O
version	O
0.5	O
)	O
downloaded	O
from	O
the	O
Pfam	O
website	O
and	O
HMMER	O
software	O
(	O
downloaded	O
from	O
http://hmmer.wustl.edu/	O
)	O
.	O

Default	O
thresholds	O
were	O
used	O
,	O
which	O
are	O
hand	O
-	O
curated	O
for	O
every	O
family	O
and	O
designed	O
to	O
minimise	O
false	O
positives	O
[	O
44	O
]	O
.	O

Identification	O
of	O
secreted	O
proteins	O
The	O
N	O
-	O
terminal	O
sequence	O
of	O
each	O
predicted	O
protein	O
from	O
the	O
36	O
fungal	O
genomes	O
used	O
in	O
this	O
study	O
was	O
analysed	O
for	O
the	O
presence	O
of	O
a	O
signal	O
peptide	O
using	O
SignalP	O
3.0	O
[	O
75	O
]	O
and	O
sub	O
-	O
cellular	O
localisation	O
was	O
predicted	O
using	O
WoLF	O
PSORT	O
[	O
76	O
]	O
.	O

Both	O
these	O
programs	O
were	O
installed	O
locally	O
.	O

SignalP	O
3.0	O
uses	O
two	O
different	O
algorithms	O
to	O
identify	O
signal	O
sequences	O
.	O

The	O
secretome	O
for	O
each	O
fungal	O
species	O
was	O
defined	O
as	O
containing	O
those	O
proteins	O
that	O
were	O
predicted	O
have	O
a	O
signal	O
peptide	O
by	O
both	O
prediction	O
algorithms	O
from	O
SignalP	O
3.0	O
and	O
also	O
predicted	O
to	O
be	O
extracellular	O
by	O
WoLF	O
PSORT	O
.	O

Data	O
analysis	O
All	O
the	O
data	O
produced	O
,	O
as	O
described	O
above	O
,	O
was	O
stored	O
in	O
the	O
e	O
-	O
Fungi	O
data	O
warehouse	O
[	O
26	O
]	O
from	O
which	O
it	O
can	O
be	O
accessed	O
via	O
a	O
web	O
-	O
interface	O
(	O
http://www.e-fungi.org.uk/	O
)	O
.	O

Analyses	O
described	O
in	O
this	O
study	O
were	O
performed	O
using	O
the	O
e	O
-	O
Fungi	O
database	O
.	O

Supporting	O
Information	O

Minocycline	O
attenuates	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-induced	O
neuroinflammation	O
,	O
sickness	O
behavior	O
,	O
and	O
anhedonia	O
Abstract	O
Background	O
Activation	O
of	O
the	O
peripheral	O
innate	O
immune	O
system	O
stimulates	O
the	O
secretion	O
of	O
CNS	O
cytokines	O
that	O
modulate	O
the	O
behavioral	O
symptoms	O
of	O
sickness	O
.	O

Excessive	O
production	O
of	O
cytokines	O
by	O
microglia	O
,	O
however	O
,	O
may	O
cause	O
long	O
-	O
lasting	O
behavioral	O
and	O
cognitive	O
complications	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
minocycline	O
,	O
an	O
anti	O
-	O
inflammatory	O
agent	O
and	O
purported	O
microglial	O
inhibitor	O
,	O
attenuates	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-induced	O
neuroinflammation	O
,	O
sickness	O
behavior	O
,	O
and	O
anhedonia	O
.	O

Methods	O
In	O
the	O
first	O
set	O
of	O
experiments	O
the	O
effect	O
of	O
minocycline	O
pretreatment	O
on	O
LPS	O
-	O
induced	O
microglia	O
activation	O
was	O
assessed	O
in	O
BV-2	O
microglia	O
cell	O
cultures	O
.	O

In	O
the	O
second	O
study	O
,	O
adult	O
(	O
3–6	O
m	O
)	O
BALB	O
/	O
c	O
mice	B
received	O
an	O
intraperitoneal	O
(	O
i.p	O
.	O
)	O
injection	O
of	O
vehicle	O
or	O
minocycline	O
(	O
50	O
mg	O
/	O
kg	O
)	O
for	O
three	O
consecutive	O
days	O
.	O

On	O
the	O
third	O
day	O
,	O
mice	B
were	O
also	O
injected	O
(	O
i.p	O
.	O
)	O
with	O
saline	O
or	O
Escherichia	B
coli	I
LPS	O
(	O
0.33	O
mg	O
/	O
kg	O
)	O
and	O
behavior	O
(	O
i.e.	O
,	O
sickness	O
and	O
anhedonia	O
)	O
and	O
markers	O
of	O
neuroinflammation	O
(	O
i.e.	O
,	O
microglia	O
activation	O
and	O
inflammatory	O
cytokines	O
)	O
were	O
determined	O
.	O

In	O
the	O
final	O
study	O
,	O
adult	O
and	O
aged	O
BALB	O
/	O
c	O
mice	B
were	O
treated	O
with	O
the	O
same	O
minocycline	O
and	O
LPS	O
injection	O
regimen	O
and	O
markers	O
of	O
neuroinflammation	O
were	O
determined	O
.	O

All	O
data	O
were	O
analyzed	O
using	O
Statistical	O
Analysis	O
Systems	O
General	O
Linear	O
Model	O
procedures	O
and	O
were	O
subjected	O
to	O
one-	O
,	O
two-	O
,	O
or	O
three	O
-	O
way	O
ANOVA	O
to	O
determine	O
significant	O
main	O
effects	O
and	O
interactions	O
.	O

Results	O
Minocycline	O
blocked	O
LPS	O
-	O
stimulated	O
inflammatory	O
cytokine	O
secretion	O
in	O
the	O
BV-2	O
microglia	O
-	O
derived	O
cell	O
line	O
and	O
reduced	O
LPS	O
-	O
induced	O
Toll	O
-	O
like	O
-	O
receptor-2	O
(	O
TLR2	O
)	O
surface	O
expression	O
on	O
brain	O
microglia	O
.	O

Moreover	O
,	O
minocycline	O
facilitated	O
the	O
recovery	O
from	O
sickness	O
behavior	O
(	O
i.e.	O
,	O
anorexia	O
,	O
weight	O
loss	O
,	O
and	O
social	O
withdrawal	O
)	O
and	O
prevented	O
anhedonia	O
in	O
adult	O
mice	B
challenged	O
with	O
LPS	O
.	O

Furthermore	O
,	O
the	O
minocycline	O
associated	O
recovery	O
from	O
LPS	O
-	O
induced	O
sickness	O
behavior	O
was	O
paralleled	O
by	O
reduced	O
mRNA	O
levels	O
of	O
Interleukin	O
(	O
IL	O
)	O
-1β	O
,	O
IL-6	O
,	O
and	O
indoleamine	O
2	O
,	O
3	O
dioxygenase	O
(	O
IDO	O
)	O
in	O
the	O
cortex	O
and	O
hippocampus	O
.	O

Finally	O
,	O
in	O
aged	O
mice	B
,	O
where	O
exaggerated	O
neuroinflammation	O
was	O
elicited	O
by	O
LPS	O
,	O
minocycline	O
pretreatment	O
was	O
still	O
effective	O
in	O
markedly	O
reducing	O
mRNA	O
levels	O
of	O
IL-1β	O
,	O
TLR2	O
and	O
IDO	O
in	O
the	O
hippocampus	O
.	O

Conclusion	O
These	O
data	O
indicate	O
that	O
minocycline	O
mitigates	O
neuroinflammation	O
in	O
the	O
adult	O
and	O
aged	O
brain	O
and	O
modulates	O
the	O
cytokine	O
-	O
associated	O
changes	O
in	O
motivation	O
and	O
behavior	O
.	O

Background	O
The	O
bi	O
-	O
directional	O
communication	O
between	O
the	O
immune	O
system	O
and	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
is	O
necessary	O
for	O
mounting	O
the	O
appropriate	O
immunological	O
,	O
physiological	O
,	O
and	O
behavioral	O
responses	O
to	O
immune	O
stimulation	O
[	O
1	O
]	O
.	O

CNS	O
innate	O
immune	O
cells	O
including	O
microglia	O
and	O
macrophages	O
play	O
integral	O
roles	O
in	O
receiving	O
and	O
propagating	O
inflammatory	O
signals	O
that	O
are	O
initiated	O
at	O
the	O
periphery	O
.	O

Activation	O
of	O
peripheral	O
innate	O
immune	O
cells	O
elicits	O
the	O
secretion	O
of	O
inflammatory	O
cytokines	O
,	O
including	O
interleukin	O
(	O
IL	O
)	O
-1	O
,	O
IL-6	O
,	O
and	O
tumor	O
necrosis	O
factor	O
-	O
α	O
(	O
TNFα	O
.	O
)	O
,	O
that	O
use	O
neural	O
[	O
2,3	O
]	O
,	O
humoral	O
[	O
4	O
]	O
and	O
blood	O
brain	O
barrier	O
pathways	O
[	O
5	O
]	O
to	O
relay	O
this	O
signal	O
to	O
the	O
CNS	O
.	O

This	O
inflammatory	O
signal	O
,	O
in	O
turn	O
,	O
induces	O
CNS	O
macrophages	O
and	O
microglia	O
to	O
produce	O
the	O
same	O
cytokines	O
[	O
6	O
]	O
,	O
which	O
target	O
neuronal	O
substrates	O
and	O
elicit	O
a	O
sickness	O
behavior	O
syndrome	O
that	O
is	O
normally	O
adaptive	O
and	O
beneficial	O
to	O
the	O
host	O
[	O
1	O
]	O
.	O

An	O
amplified	O
or	O
excessive	O
inflammatory	O
cytokine	O
response	O
in	O
the	O
brain	O
,	O
however	O
,	O
is	O
associated	O
with	O
a	O
myriad	O
of	O
complications	O
including	O
cognitive	O
dysfunction	O
[	O
7	O
-	O
10	O
]	O
,	O
prolonged	O
sickness	O
behavior	O
[	O
11	O
-	O
14	O
]	O
,	O
and	O
depressive	O
-	O
like	O
behavior	O
[	O
15	O
]	O
.	O

Microglia	O
are	O
primarily	O
involved	O
in	O
immune	O
surveillance	O
[	O
16,17	O
]	O
,	O
but	O
when	O
activated	O
have	O
macrophage	O
-	O
like	O
capabilities	O
including	O
phagocytosis	O
,	O
inflammatory	O
cytokine	O
production	O
,	O
and	O
antigen	O
presentation	O
[	O
18	O
]	O
.	O

Normally	O
these	O
neuroinflammatory	O
changes	O
are	O
transient	O
with	O
microglia	O
returning	O
to	O
a	O
resting	O
state	O
as	O
the	O
immune	O
stimulus	O
is	O
resolved	O
.	O

Aging	O
or	O
neurological	O
disease	O
,	O
however	O
,	O
may	O
provide	O
a	O
brain	O
environment	O
where	O
microglia	O
are	O
more	O
""""	O
reactive	O
or	O
primed	O
""""	O
to	O
a	O
peripheral	O
immune	O
challenge	O
[	O
19	O
]	O
.	O

Recent	O
findings	O
indicate	O
that	O
several	O
markers	O
of	O
glial	O
activation	O
such	O
as	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
II	O
,	O
complement	O
receptors	O
,	O
and	O
scavenger	O
receptors	O
are	O
increased	O
in	O
brain	O
during	O
normal	O
aging	O
[	O
13,20	O
-	O
26	O
]	O
.	O

Furthermore	O
,	O
we	O
and	O
others	O
have	O
reported	O
that	O
a	O
biological	O
consequence	O
of	O
this	O
reactive	O
glial	O
profile	O
is	O
an	O
exaggerated	O
neuroinflammatory	O
response	O
to	O
innate	O
immune	O
challenge	O
[	O
9,10,12	O
-	O
14,27,28	O
]	O
.	O

Active	O
microglia	O
and	O
CNS	O
macrophages	O
also	O
contribute	O
to	O
the	O
production	O
of	O
oxidative	O
and	O
neuroactive	O
mediators	O
that	O
may	O
influence	O
behavior	O
.	O

For	O
instance	O
,	O
inflammatory	O
cytokines	O
in	O
the	O
CNS	O
upregulate	O
the	O
enzyme	O
IDO	O
[	O
29,30	O
]	O
,	O
which	O
metabolizes	O
tryptophan	O
(	O
TRP	O
)	O
into	O
L	O
-	O
kynurenine	O
(	O
KYN	O
)	O
[	O
31	O
]	O
.	O

TRP	O
degradation	O
to	O
KYN	O
can	O
reduce	O
TRP	O
levels	O
that	O
are	O
required	O
for	O
serotonin	O
synthesis	O
[	O
32	O
]	O
and	O
can	O
lead	O
to	O
the	O
production	O
of	O
neuroactive	O
mediators	O
including	O
3-hydroxykynurenine	O
(	O
3HK	O
)	O
and	O
quinolinic	O
acid	O
(	O
QUIN	O
)	O
[	O
31	O
]	O
.	O

High	O
levels	O
of	O
3HK	O
and	O
QUIN	O
induce	O
neuronal	O
damage	O
through	O
oxidative	O
stress	O
[	O
33	O
]	O
and	O
over	O
stimulation	O
of	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	O
)	O
receptors	O
[	O
34,35	O
]	O
.	O

A	O
recent	O
study	O
indicates	O
that	O
while	O
several	O
cell	O
types	O
in	O
the	O
CNS	O
express	O
IDO	O
,	O
only	O
microglia	O
maintain	O
all	O
the	O
enzymes	O
required	O
to	O
produce	O
3HK	O
and	O
QUIN	O
[	O
36	O
]	O
.	O

Because	O
IDO	O
mediated	O
TRP	O
degradation	O
impacts	O
both	O
serotonergic	O
and	O
glutamatergic	O
pathways	O
,	O
this	O
may	O
be	O
an	O
important	O
mechanism	O
underlying	O
mood	O
and	O
behavior	O
complications	O
concomitant	O
with	O
inflammation	O
[	O
37	O
-	O
39	O
]	O
.	O

Because	O
activated	O
microglia	O
are	O
suspected	O
to	O
cause	O
or	O
exacerbate	O
several	O
neurodegenerative	O
diseases	O
,	O
pharmacological	O
strategies	O
to	O
suppress	O
microglial	O
activity	O
are	O
being	O
explored	O
as	O
therapies	O
.	O

Minocycline	O
is	O
a	O
tetracycline	O
derived	O
antibiotic	O
that	O
has	O
anti	O
-	O
inflammatory	O
properties	O
in	O
the	O
CNS	O
that	O
are	O
separate	O
from	O
its	O
antimicrobial	O
action	O
[	O
40	O
]	O
.	O

Minocycline	O
readily	O
crosses	O
the	O
blood	O
brain	O
barrier	O
and	O
attenuates	O
inflammation	O
associated	O
with	O
microglial	O
activation	O
.	O

For	O
example	O
,	O
minocycline	O
blocks	O
the	O
deleterious	O
effects	O
of	O
neuroinflammation	O
on	O
neurogenesis	O
,	O
long	O
-	O
term	O
potentiation	O
,	O
and	O
neuronal	O
survival	O
[	O
41	O
-	O
43	O
]	O
.	O

The	O
mechanism	O
of	O
action	O
is	O
unclear	O
,	O
but	O
recent	O
studies	O
indicate	O
that	O
minocycline	O
abrogates	O
MAPkinase	O
and	O
NFκB	O
dependent	O
signaling	O
pathways	O
in	O
primary	O
microglia	O
and	O
microglia	O
cell	O
cultures	O
[	O
44	O
]	O
.	O

Moreover	O
,	O
in	O
the	O
brain	O
of	O
rats	B
,	O
minocycline	O
abrogates	O
microglial	O
expression	O
of	O
CD11b	O
and	O
MHC	O
II	O
through	O
a	O
protein	O
kinase	O
-	O
c	O
dependent	O
mechanism	O
[	O
45	O
]	O
.	O

This	O
is	O
relevant	O
because	O
minocycline	O
attenuates	O
neuroinflammation	O
in	O
several	O
rodent	O
models	O
of	O
disease	O
including	O
Amyotrophic	O
Lateral	O
Sclerosis	O
[	O
46	O
]	O
,	O
Experimental	O
Autoimmune	O
Encephalomyelitis	O
(	O
EAE	O
)	O
[	O
45	O
]	O
and	O
MPTP	O
-	O
induced	O
Parkinson	O
's	O
disease	O
[	O
47	O
]	O
.	O

However	O
,	O
the	O
extent	O
to	O
which	O
minocycline	O
facilitates	O
the	O
recovery	O
from	O
cytokine	O
-	O
mediated	O
sickness	O
behavior	O
is	O
unknown	O
.	O

The	O
present	O
study	O
investigated	O
the	O
degree	O
to	O
which	O
minocycline	O
–	O
an	O
anti	O
-	O
inflammatory	O
agent	O
and	O
purported	O
microglial	O
inhibitor	O
–	O
reduced	O
LPS	O
-	O
induced	O
neuroinflammation	O
and	O
sickness	O
behavior	O
.	O

We	O
show	O
that	O
minocycline	O
blocked	O
LPS	O
-	O
stimulated	O
inflammatory	O
cytokine	O
secretion	O
in	O
the	O
BV-2	O
microglia	O
-	O
derived	O
cell	O
line	O
and	O
reduced	O
LPS	O
-	O
induced	O
Toll	O
-	O
like	O
-	O
receptor-2	O
(	O
TLR2	O
)	O
surface	O
expression	O
on	O
brain	O
microglia	O
.	O

Moreover	O
,	O
our	O
data	O
show	O
that	O
minocycline	O
pretreatment	O
attenuated	O
LPS	O
-	O
induced	O
weight	O
loss	O
,	O
social	O
withdrawal	O
,	O
and	O
anhedonia	O
in	O
adult	O
mice	B
.	O

The	O
attenuation	O
of	O
sickness	O
behavior	O
was	O
paralleled	O
with	O
minocycline	O
dependent	O
decrease	O
in	O
markers	O
of	O
neuroinflammation	O
(	O
IL-1β	O
,	O
TLR2	O
,	O
and	O
IDO	O
)	O
in	O
adult	O
and	O
aged	O
mice	B
.	O

These	O
findings	O
support	O
our	O
hypothesis	O
that	O
the	O
ability	O
to	O
mitigate	O
cytokine	O
expression	O
in	O
the	O
brain	O
during	O
systemic	O
inflammatory	O
events	O
may	O
be	O
useful	O
in	O
preventing	O
cognitive	O
and	O
behavioral	O
deficits	O
.	O

Methods	O
Animals	O
Male	O
BALB	O
/	O
c	O
mice	B
,	O
adults	O
(	O
3	O
month	O
old	O
)	O
and	O
juvenile	O
(	O
3–4	O
week	O
old	O
)	O
were	O
purchased	O
from	O
Harlan	O
(	O
Indianapolis	O
,	O
IN	O
)	O
.	O

For	O
age	O
comparisons	O
,	O
male	O
BALB	O
/	O
c	O
mice	B
(	O
3–4	O
and	O
20–22	O
month	O
old	O
)	O
were	O
purchased	O
from	O
the	O
National	O
Institute	O
on	O
Aging	O
specific	O
pathogen	O
free	O
colony	O
.	O

Upon	O
arrival	O
,	O
mice	B
were	O
individually	O
housed	O
in	O
polypropylene	O
cages	O
and	O
maintained	O
at	O
21	O
°	O
C	O
under	O
a	O
12	O
h	O
light	O
:	O
12	O
h	O
dark	O
cycle	O
with	O
ad	O
libitum	O
access	O
to	O
water	O
and	O
rodent	O
chow	O
.	O

At	O
the	O
end	O
of	O
each	O
study	O
,	O
mice	B
were	O
examined	O
postmortem	O
for	O
gross	O
signs	O
of	O
disease	O
(	O
e.g.	O
,	O
splenomeglia	O
or	O
tumors	O
)	O
.	O

Data	O
from	O
mice	B
determined	O
to	O
be	O
unhealthy	O
were	O
excluded	O
from	O
analysis	O
(	O
<	O
5	O
%	O
)	O
.	O

All	O
procedures	O
were	O
in	O
accordance	O
with	O
the	O
National	O
Institute	O
of	O
Health	O
Guidelines	O
for	O
the	O
Care	O
and	O
Use	O
of	O
Laboratory	O
Animals	O
and	O
were	O
approved	O
by	O
The	O
Ohio	O
State	O
University	O
Institutional	O
Laboratory	O
Animal	O
Care	O
and	O
Use	O
Committee	O
.	O

Cell	O
culture	O
BV-2	O
microglia	O
cell	O
lines	O
were	O
cultured	O
in	O
growth	O
medium	O
(	O
DMEM	O
supplemented	O
with	O
10	O
%	O
FBS	O
,	O
sodium	O
bicarbonate	O
3.7	O
g	O
/	O
l	O
,	O
200	O
mM	O
glutamine	O
,	O
100	O
U	O
/	O
ml	O
penicillin	O
G	O
,	O
100	O
μg	O
/	O
ml	O
streptomycin	O
,	O
0.25	O
μg	O
/	O
ml	O
fungizone	O
)	O
as	O
previously	O
described	O
[	O
12	O
]	O
.	O

Cultures	O
were	O
maintained	O
at	O
37	O
°	O
C	O
with	O
95	O
%	O
humidity	O
and	O
5	O
%	O
CO2	O
and	O
growth	O
medium	O
was	O
replenished	O
every	O
third	O
day	O
until	O
confluence	O
.	O

Cultures	O
were	O
washed	O
twice	O
and	O
supplemented	O
with	O
warm	O
growth	O
medium	O
containing	O
experimental	O
treatments	O
.	O

Cell	O
viability	O
was	O
measured	O
by	O
the	O
MTS	O
cell	O
proliferation	O
assay	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
(	O
Promega	O
,	O
Madison	O
,	O
WI	O
)	O
.	O

CNS	O
macrophage	O
/	O
microglia	O
isolation	O
CNS	O
macrophages	O
and	O
microglia	O
were	O
collected	O
from	O
whole	O
brain	O
homogenates	O
as	O
described	O
previously	O
[	O
48	O
]	O
,	O
but	O
with	O
several	O
modifications	O
.	O

Mice	B
were	O
euthanized	O
by	O
CO2	O
asphyxiation	O
and	O
whole	O
brains	O
were	O
collected	O
.	O

Brains	O
were	O
homogenized	O
in	O
Hank	O
's	O
balanced	O
salt	O
solution	O
(	O
HBSS	O
)	O
pH	O
7.4	O
.	O

Brain	O
homogenates	O
were	O
passed	O
through	O
a	O
70	O
μm	O
nylon	O
cell	O
strainer	O
and	O
centrifuged	O
at	O
400	O
×	O
g	O
for	O
10	O
min	O
.	O

Supernatants	O
were	O
removed	O
and	O
cell	O
pellets	O
were	O
re	O
-	O
suspended	O
in	O
70	O
%	O
isotonic	O
Percoll	O
(	O
GE	O
-	O
healthcare	O
,	O
Uppsala	O
,	O
Sweden	O
)	O
at	O
room	O
temperature	O
.	O

A	O
discontinuous	O
Percoll	O
density	O
gradient	O
was	O
set	O
up	O
as	O
follows	O
:	O
70	O
%	O
,	O
35	O
%	O
,	O
and	O
0	O
%	O
isotonic	O
Percoll	O
.	O

This	O
suspension	O
was	O
centrifuged	O
for	O
30	O
minutes	O
at	O
400	O
×	O
g.	O
A	O
mixed	O
population	O
of	O
CNS	O
macrophages	O
and	O
microglia	O
was	O
collected	O
from	O
the	O
interphase	O
between	O
the	O
70	O
%	O
and	O
35	O
%	O
Percoll	O
layers	O
.	O

Cells	O
were	O
washed	O
and	O
then	O
re	O
-	O
suspended	O
in	O
sterile	O
HBSS	O
.	O

The	O
number	O
of	O
viable	O
cells	O
was	O
determined	O
using	O
a	O
hemacytometer	O
and	O
0.2	O
%	O
trypan	O
blue	O
staining	O
.	O

Flow	O
cytometry	O
Flow	O
cytometric	O
analysis	O
of	O
microglial	O
cell	O
surface	O
markers	O
was	O
performed	O
as	O
described	O
previously	O
,	O
but	O
with	O
a	O
few	O
modifications	O
[	O
48	O
]	O
.	O

In	O
brief	O
,	O
Fc	O
receptors	O
on	O
macrophages	O
and	O
microglia	O
were	O
blocked	O
with	O
anti	O
-	O
CD16	O
/	O
CD32	O
antibody	O
(	O
eBiosciences	O
,	O
CA	O
)	O
.	O

Next	O
,	O
cells	O
were	O
incubated	O
with	O
either	O
Panel-1	O
(	O
anti	O
-	O
CD11b	O
APC	O
,	O
anti	O
-	O
CD45	O
FITC	O
,	O
and	O
anti	O
-	O
MHC	O
II	O
PE	O
from	O
eBiosciences	O
,	O
CA	O
)	O
or	O
Panel-2	O
antibodies	O
(	O
anti	O
-	O
CD11b	O
APC	O
,	O
anti	O
-	O
CD45	O
FITC	O
,	O
and	O
anti	O
-	O
TLR2	O
PE	O
from	O
eBiosciences	O
,	O
CA	O
)	O
.	O

Expression	O
of	O
these	O
surface	O
receptors	O
was	O
determined	O
by	O
flow	O
cytometry	O
using	O
a	O
Becton	O
-	O
Dickinson	O
FACSCaliber	O
four	O
color	O
Cytometer	O
.	O

Thirty	O
thousand	O
events	O
were	O
collected	O
and	O
microglia	O
were	O
differentiated	O
from	O
macrophages	O
based	O
on	O
the	O
levels	O
of	O
CD11b	O
and	O
CD45	O
surface	O
expression	O
.	O

Microglia	O
stain	O
CD11b+	O
/	O
CD45low	O
and	O
macrophages	O
stain	O
CD11b+	O
/	O
CD45high	O
[	O
48,49	O
]	O
.	O

Flow	O
data	O
were	O
analyzed	O
using	O
FlowJo	O
software	O
(	O
Tree	O
Star	O
,	O
San	O
Carlos	O
,	O
CA	O
)	O
.	O

Behavior	O
tests	O
Social	O
exploratory	O
behavior	O
To	O
assess	O
the	O
motivation	O
to	O
engage	O
in	O
social	O
exploratory	O
behavior	O
,	O
a	O
novel	O
juvenile	O
conspecific	O
was	O
introduced	O
into	O
the	O
test	O
subject	O
's	O
home	O
cage	O
for	O
a	O
10-min	O
period	O
.	O

Behavior	O
was	O
video	O
taped	O
and	O
the	O
cumulative	O
amount	O
of	O
time	O
the	O
subject	O
engaged	O
in	O
social	O
investigation	O
was	O
determined	O
from	O
the	O
video	O
records	O
by	O
a	O
trained	O
observer	O
who	O
was	O
blind	O
to	O
the	O
experimental	O
treatments	O
.	O

Baseline	O
social	O
behavior	O
was	O
measured	O
at	O
time	O
0	O
for	O
all	O
experimental	O
treatments	O
.	O

Social	O
behavior	O
was	O
determined	O
as	O
the	O
amount	O
of	O
time	O
that	O
the	O
experimental	O
subject	O
spent	O
investigating	O
(	O
e.g.	O
,	O
anogenital	O
sniffing	O
,	O
trailing	O
)	O
the	O
juvenile	O
.	O

Results	O
are	O
expressed	O
as	O
percent	O
decrease	O
in	O
time	O
engaged	O
in	O
social	O
behavior	O
compared	O
to	O
respective	O
baseline	O
measures	O
.	O

Sucrose	O
preference	O
To	O
assess	O
sucrose	O
preference	O
,	O
mice	B
were	O
provided	O
two	O
solutions	O
,	O
water	O
or	O
water	O
supplemented	O
with	O
2	O
%	O
sucrose	O
,	O
in	O
50	O
ml	O
conical	O
tubes	O
with	O
stoppers	O
fitted	O
with	O
ball	O
-	O
type	O
sipper	O
tubes	O
.	O

Prior	O
to	O
testing	O
conditions	O
,	O
all	O
mice	B
were	O
acclimated	O
to	O
the	O
two	O
bottle	O
test	O
choice	O
.	O

All	O
mice	B
drank	O
both	O
the	O
water	O
and	O
the	O
2	O
%	O
sucrose	O
solution	O
,	O
but	O
preferred	O
drinking	O
the	O
sucrose	O
over	O
the	O
water	O
(	O
data	O
not	O
shown	O
)	O
.	O

On	O
the	O
day	O
of	O
testing	O
,	O
mice	B
were	O
fluid	O
and	O
food	O
deprived	O
for	O
2	O
h	O
prior	O
to	O
testing	O
[	O
50	O
]	O
.	O

At	O
the	O
start	O
of	O
the	O
dark	O
phase	O
of	O
the	O
photoperiod	O
,	O
drinking	O
water	O
and	O
the	O
2	O
%	O
sucrose	O
solution	O
were	O
placed	O
in	O
the	O
home	O
cage	O
overnight	O
(	O
15	O
h	O
)	O
.	O

At	O
the	O
end	O
of	O
each	O
testing	O
period	O
the	O
fluid	O
content	O
of	O
the	O
conical	O
tubes	O
was	O
measured	O
and	O
sucrose	O
preference	O
was	O
determined	O
using	O
the	O
equation	O
:	O

Sucrose	O
intake	O
/	O
Total	O
fluid	O
intake	O
(	O
water	O
+	O
sucrose	O
intake	O
)	O
×	O
100	O
[	O
51	O
]	O
.	O

Plasma	O
cytokine	O
measurement	O
IL-6	O
and	O
IL-1β	O
were	O
measured	O
in	O
the	O
plasma	O
as	O
previously	O
described	O
[	O
52	O
]	O
.	O

In	O
brief	O
,	O
mice	B
were	O
euthanized	O
by	O
CO2	O
asphyxiation	O
and	O
blood	O
was	O
collected	O
by	O
cardiac	O
puncture	O
into	O
EDTA	O
coated	O
syringes	O
.	O

Samples	O
were	O
centrifuged	O
(	O
6000	O
×	O
g	O
for	O
15	O
min	O
at	O
4	O
°	O
C	O
)	O
and	O
plasma	O
was	O
collected	O
and	O
stored	O
frozen	O
(	O
-80	O
°	O
C	O
)	O
until	O
assaying	O
.	O

Plasma	O
samples	O
were	O
assayed	O
for	O
IL-6	O
using	O
a	O
customized	O
ELISA	O
that	O
we	O
have	O
described	O
in	O
detail	O
[	O
52	O
]	O
and	O
for	O
IL-1β	O
using	O
a	O
commercial	O
ELISA	O
kit	O
(	O
R&D	O
Systems	O
,	O
Minneapolis	O
,	O
MN	O
)	O
.	O

Assays	O
were	O
sensitive	O
to	O
8	O
pg	O
/	O
ml	O
of	O
IL-6	O
and	O
1.5	O
pg	O
/	O
ml	O
of	O
IL-1β	O
,	O
and	O
inter-	O
and	O
intra	O
-	O
assay	O
coefficients	O
of	O
variation	O
were	O
less	O
than	O
10	O
%	O
.	O

Real	O
time	O
PCR	O
Total	O
RNA	O
was	O
isolated	O
from	O
brain	O
using	O
the	O
Tri	O
Reagent	O
protocol	O
(	O
Sigma	O
,	O
St.	O
Louis	O
,	O
MO	O
)	O
.	O

RNA	O
samples	O
were	O
subjected	O
to	O
a	O
DNase	O
I	O
digestion	O
procedure	O
and	O
then	O
reverse	O
transcribed	O
to	O
cDNA	O
using	O
a	O
RT	O
RETROscript	O
kit	O
(	O
Ambion	O
,	O
Austin	O
,	O
TX	O
)	O
.	O

Quantitative	O
real	O
time	O
PCR	O
was	O
performed	O
using	O
the	O
Applied	O
Biosystems	O
(	O
Foster	O
,	O
CA	O
)	O
Assay	O
-	O
on	O
Demand	O
Gene	O
Expression	O
protocol	O
as	O
previously	O
described	O
[	O
13	O
]	O
.	O

In	O
brief	O
,	O
cDNA	O
was	O
amplified	O
by	O
real	O
time	O
PCR	O
where	O
a	O
target	O
cDNA	O
(	O
IL-1β	O
,	O
IL-6	O
,	O
MHC	O
II	O
,	O
TLR2	O
,	O
or	O
IDO	O
)	O
and	O
a	O
reference	O
cDNA	O
(	O
glyceraldehyde-3-phosphate	O
dehydrogenase	O
)	O
were	O
amplified	O
simultaneously	O
using	O
an	O
oligonucleotide	O
probe	O
with	O
a	O
5	O
'	O
fluorescent	O
reporter	O
dye	O
(	O
6-FAM	O
)	O
and	O
a	O
3	O
'	O
quencher	O
dye	O
(	O
NFQ	O
)	O
.	O

Fluorescence	O
was	O
determined	O
on	O
an	O
ABI	O
PRISM	O
7300-sequence	O
detection	O
system	O
(	O
Applied	O
Biosystems	O
,	O
CA	O
)	O
.	O

Data	O
were	O
analyzed	O
using	O
the	O
comparative	O
threshold	O
cycle	O
(	O
Ct	O
)	O
method	O
and	O
results	O
are	O
expressed	O
as	O
fold	O
difference	O
.	O

Experimental	O
protocols	O
For	O
the	O
cell	O
culture	O
studies	O
,	O
minocycline	O
was	O
prepared	O
in	O
dimethyl	O
sulfoxide	O
(	O
DMSO	O
)	O
and	O
BV-2	O
cells	O
were	O
washed	O
and	O
replenished	O
with	O
growth	O
mediumsupplemented	O
with	O
0	O
,	O
25	O
,	O
50	O
,	O
100	O
,	O
200	O
,	O
or	O
400	O
μg	O
/	O
ml	O
minocycline	O
.	O

After	O
30	O
min	O
,	O
LPS	O
at	O
10	O
ng	O
/	O
ml	O
was	O
added	O
to	O
the	O
culture	O
medium	O
.	O

Supernatants	O
were	O
collected	O
4	O
h	O
later	O
and	O
IL-6	O
and	O
IL-1β	O
concentrations	O
were	O
determined	O
by	O
ELISA	O
.	O

Total	O
proteins	O
were	O
determined	O
from	O
cell	O
culture	O
homogenates	O
by	O
the	O
Bio	O
-	O
Rad	O
Dc	O
protein	O
assay	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
(	O
Bio	O
-	O
Rad	O
Lboratories	O
,	O
Hercules	O
,	O
CA	O
)	O
.	O

Each	O
treatment	O
was	O
replicated	O
a	O
minimum	O
of	O
four	O
times	O
.	O

Cell	O
viability	O
was	O
confirmed	O
by	O
the	O
MTS	O
cell	O
proliferation	O
assay	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
(	O
Promega	O
,	O
Madison	O
,	O
WI	O
)	O
.	O

For	O
all	O
mouse	B
studies	O
,	O
minocycline	O
(	O
Sigma	O
,	O
St.	O
Louis	O
,	O
MO	O
)	O
was	O
dissolved	O
in	O
sterile	O
water	O
and	O
sonicated	O
to	O
ensure	O
complete	O
solubilization	O
.	O

In	O
the	O
first	O
mouse	B
study	O
,	O
adult	O
male	O
BALB	O
/	O
c	O
mice	B
received	O
an	O
intraperitoneal	O
(	O
i.p	O
.	O
)	O
injection	O
of	O
vehicle	O
or	O
minocycline	O
(	O
50	O
mg	O
/	O
kg	O
)	O
for	O
three	O
consecutive	O
days	O
.	O

On	O
the	O
3rd	O
day	O
,	O
mice	B
were	O
also	O
injected	O
i.p	O
.	O
with	O
saline	O
or	O
Escherichia	B
coli	I
LPS	O
(	O
0.33	O
mg	O
/	O
kg	O
;	O
serotype	O
0127	O
:	O
B8	O
,	O
Sigma	O
,	O
St.	O
Louis	O
,	O
MO	O
)	O
and	O
were	O
euthanized	O
by	O
CO2	O
asphyxiation	O
24	O
h	O
later	O
(	O
n	O
=	O
6	O
)	O
.	O

The	O
LPS	O
dosage	O
was	O
selected	O
because	O
it	O
elicits	O
a	O
proinflammatory	O
cytokine	O
response	O
in	O
the	O
brain	O
resulting	O
in	O
mild	O
transient	O
sickness	O
behavior	O
in	O
adult	O
mice	B
[	O
13,53	O
]	O
.	O

Macrophage	O
/	O
microglial	O
cells	O
were	O
isolated	O
from	O
whole	O
brain	O
homogenates	O
and	O
TLR2	O
and	O
MHC	O
II	O
surface	O
expression	O
were	O
determined	O
by	O
flow	O
cytometry	O
.	O

The	O
minocycline	O
injection	O
regimen	O
and	O
dosage	O
was	O
selected	O
because	O
a	O
repeated	O
pretreatment	O
course	O
with	O
minocycline	O
is	O
necessary	O
to	O
attenuate	O
neuroinflammation	O
[	O
41	O
-	O
43,45	O
]	O
.	O

In	O
the	O
second	O
study	O
,	O
adult	O
male	O
BALB	O
/	O
c	O
mice	B
received	O
an	O
i.p	O
.	O

injection	O
with	O
vehicle	O
or	O
minocycline	O
for	O
three	O
consecutive	O
days	O
.	O

On	O
the	O
third	O
day	O
,	O
motivation	O
to	O
engage	O
in	O
social	O
behavior	O
was	O
determined	O
immediately	O
before	O
i.p	O
.	O

injection	O
of	O
saline	O
or	O
LPS	O
(	O
0.33	O
mg	O
/	O
kg	O
)	O
and	O
again	O
2	O
,	O
4	O
,	O
8	O
,	O
12	O
,	O
and	O
24	O
h	O
later	O
(	O
n	O
=	O
8)	O
.	O

Body	O
weight	O
and	O
food	O
intake	O
were	O
measured	O
at	O
each	O
time	O
point	O
over	O
the	O
24	O
h	O
period	O
.	O

In	O
a	O
related	O
,	O
but	O
separate	O
study	O
,	O
adult	O
mice	B
were	O
treated	O
with	O
minocycline	O
and	O
LPS	O
as	O
described	O
and	O
anhedonia	O
was	O
assessed	O
24–39	O
h	O
following	O
i.p	O
.	O

injection	O
of	O
saline	O
or	O
LPS	O
(	O
0.33	O
mg	O
/	O
kg	O
)	O
(	O
n	O
=	O
15	O
)	O
.	O

Body	O
weight	O
,	O
food	O
intake	O
,	O
water	O
intake	O
,	O
and	O
sucrose	O
intake	O
were	O
determined	O
over	O
the	O
testing	O
period	O
.	O

In	O
the	O
third	O
study	O
,	O
adult	O
BALB	O
/	O
c	O
mice	B
were	O
treated	O
with	O
minocycline	O
and	O
then	O
LPS	O
as	O
described	O
.	O

Mice	B
were	O
euthanized	O
by	O
CO2	O
asphyxiation	O
4	O
later	O
.	O

Brains	O
were	O
removed	O
and	O
dissected	O
to	O
collect	O
different	O
brain	O
regions	O
.	O

Brain	O
regions	O
were	O
stored	O
at	O
-20	O
°	O
C	O
in	O
RNAlater	O
(	O
Qiagen	O
,	O
CA	O
)	O
.	O

Total	O
RNA	O
was	O
isolated	O
from	O
brain	O
samples	O
and	O
assayed	O
using	O
quantitative	O
PCR	O
(	O
n	O
=	O
8)	O
.	O

Plasma	O
was	O
also	O
collected	O
and	O
stored	O
(	O
-80	O
°	O
C	O
)	O
until	O
assaying	O
.	O

In	O
a	O
final	O
study	O
,	O
adult	O
(	O
3–4	O
month	O
old	O
)	O
or	O
aged	O
(	O
20–22	O
month	O
old	O
)	O
male	O
BALB	O
/	O
c	O
mice	B
were	O
treated	O
with	O
minocycline	O
and	O
LPS	O
as	O
described	O
and	O
euthanized	O
4	O
h	O
later	O
.	O

Brains	O
were	O
dissected	O
to	O
collect	O
different	O
brain	O
regions	O
and	O
were	O
stored	O
at	O
-20	O
°	O
C	O
in	O
RNAlater	O
(	O
Qiagen	O
,	O
CA	O
)	O
.	O

Total	O
RNA	O
was	O
isolated	O
from	O
the	O
hippocampus	O
and	O
assayed	O
using	O
quantitative	O
PCR	O
(	O
n	O
=	O
8)	O
.	O

Statistical	O
analysis	O
All	O
data	O
were	O
analyzed	O
using	O
Statistical	O
Analysis	O
Systems	O
(	O
SAS	O
)	O
General	O
Linear	O
Model	O
procedures	O
.	O

Data	O
were	O
subjected	O
to	O
one	O
,	O
two-	O
(	O
Mino	O
×	O
LPS	O
,	O
Age	O
×	O
LPS	O
,	O
Mino	O
×	O
Age	O
)	O
or	O
three	O
-	O
way	O
(	O
Mino	O
×	O
LPS	O
×	O
Time	O
,	O
Mino	O
×	O
LPS	O
×	O
Age	O
)	O
ANOVA	O
to	O
determine	O
significant	O
main	O
effects	O
and	O
interactions	O
between	O
main	O
factors	O
.	O

When	O
appropriate	O
,	O
differences	O
between	O
treatment	O
means	O
were	O
evaluated	O
by	O
an	O
F	O
-	O
protected	O
t	O
-	O
test	O
using	O
the	O
Least	O
-	O
Significant	O
Difference	O
procedure	O
of	O
SAS	O
.	O

All	O
data	O
are	O
expressed	O
as	O
treatment	O
means	O
±	O
standard	O
error	O
of	O
the	O
mean	O
(	O
SEM	O
)	O
.	O

Results	O
Minocycline	O
attenuates	O
LPS	O
-	O
induced	O
cytokine	O
production	O
in	O
BV-2	O
microglia	O
Minocycline	O
is	O
a	O
tetracycline	O
-	O
type	O
antibiotic	O
that	O
has	O
anti	O
-	O
inflammatory	O
properties	O
in	O
the	O
CNS	O
[	O
41	O
-	O
43,45	O
]	O
.	O

To	O
determine	O
the	O
degree	O
to	O
which	O
minocycline	O
suppresses	O
microglia	O
activation	O
,	O
BV-2	O
microglia	O
-	O
derived	O
cell	O
lines	O
were	O
used	O
.	O

In	O
the	O
first	O
experiment	O
,	O
BV-2	O
cells	O
were	O
treated	O
with	O
LPS	O
and	O
IL-6	O
production	O
was	O
determined	O
4	O
h	O
later	O
.	O

Fig.	O
1A	O
shows	O
that	O
LPS	O
increased	O
IL-6	O
production	O
in	O
a	O
dose	O
dependent	O
manner	O
F	O
(	O
5	O
,	O
23	O
)	O
=	O
101	O
,	O
P	O
<	O
0.001	O
)	O
.	O

In	O
the	O
second	O
experiment	O
,	O
BV-2	O
cells	O
were	O
incubated	O
with	O
DMSO	O
or	O
minocycline	O
and	O
then	O
stimulated	O
with	O
LPS	O
.	O

Minocycline	O
reduced	O
LPS	O
-	O
induced	O
IL-6	O
secretion	O
in	O
a	O
dose	O
dependent	O
manner	O
(	O
Mino	O
×	O
LPS	O
interaction	O
,	O
F	O
(	O
4	O
,	O
23	O
)	O
=	O
16.87	O
,	O
P	O
<	O
0.001	O
,	O
Fig.	O
1B	O
)	O
.	O

Minocycline	O
pretreatment	O
had	O
a	O
similar	O
anti	O
-	O
inflammatory	O
effect	O
on	O
LPS	O
-	O
stimulated	O
IL-1β	O
secretion	O
(	O
Fig.	O
1C	O
)	O
.	O

In	O
a	O
third	O
experiment	O
,	O
minocycline	O
suppressed	O
LPS	O
-	O
induced	O
MHC	O
II	O
,	O
TLR2	O
,	O
IL-1β	O
,	O
and	O
IL-6	O
mRNA	O
levels	O
(	O
P	O
<	O
0.05	O
,	O
for	O
each	O
,	O
Fig.	O
1D	O
)	O
.	O

The	O
MTS	O
assay	O
verified	O
that	O
neither	O
cell	O
survival	O
nor	O
proliferation	O
was	O
affected	O
by	O
the	O
experimental	O
treatments	O
(	O
data	O
not	O
shown	O
)	O
.	O

LPS	O
-	O
induced	O
TLR2	O
surface	O
expression	O
on	O
microglia	O
is	O
reduced	O
by	O
minocycline	O
Because	O
minocycline	O
attenuated	O
LPS	O
-	O
induced	O
cytokine	O
secretion	O
and	O
TLR2	O
mRNA	O
expression	O
in	O
BV-2	O
cells	O
we	O
next	O
sought	O
to	O
determine	O
if	O
minocycline	O
suppresses	O
markers	O
of	O
microglial	O
activation	O
in	O
the	O
brain	O
of	O
mice	B
.	O

Mice	B
were	O
injected	O
i.p	O
.	O

with	O
vehicle	O
or	O
minocycline	O
for	O
3	O
consecutive	O
days	O
then	O
challenged	O
with	O
saline	O
or	O
LPS	O
i.p	O
.	O

Markers	O
of	O
activation	O
,	O
TLR2	O
and	O
MHC	O
II	O
,	O
were	O
determined	O
on	O
microglia	O
collected	O
24	O
h	O
later	O
.	O

The	O
representative	O
bivariate	O
density	O
plot	O
in	O
Fig.	O
2A	O
shows	O
that	O
there	O
were	O
two	O
populations	O
of	O
CD11b	O
/	O
CD45	O
positive	O
cells	O
and	O
that	O
more	O
cells	O
stained	O
CD11b+	O
/	O
CD45low	O
(	O
microglia	O
)	O
than	O
CD11b+	O
/	O
CD45high	O
(	O
CNS	O
macrophages	O
)	O
.	O

ANOVA	O
revealed	O
that	O
LPS	O
injection	O
increased	O
TLR2	O
surface	O
expression	O
on	O
microglia	O
(	O
F	O
(	O
1	O
,	O
20	O
)	O
=	O
17.6	O
,	O
P	O
<	O
0.004	O
,	O
Fig.	O
2B&D	O
)	O
,	O
but	O
this	O
induction	O
was	O
abrogated	O
by	O
minocycline	O
pretreatment	O
(	O
Tendency	O
for	O
Mino	O
×	O
LPS	O
interaction	O
,	O
F	O
(	O
1	O
,	O
20	O
)	O
=	O
2.66	O
,	O
P	O
=	O
0.10	O
,	O
Fig.	O
2C&D	O
)	O
.	O

It	O
is	O
important	O
to	O
note	O
that	O
because	O
minocycline	O
and	O
saline	O
controls	O
did	O
not	O
differ	O
in	O
their	O
TLR2	O
expression	O
,	O
these	O
data	O
were	O
grouped	O
together	O
as	O
the	O
Control	O
group	O
(	O
Fig.	O
2B&C	O
)	O
.	O

In	O
addition	O
,	O
neither	O
minocycline	O
nor	O
LPS	O
treatment	O
had	O
a	O
significant	O
main	O
effect	O
on	O
MHC	O
class	O
II	O
surface	O
expression	O
on	O
microglia	O
(	O
data	O
not	O
shown	O
)	O
.	O

These	O
data	O
indicate	O
that	O
minocycline	O
attenuated	O
LPS	O
-	O
induced	O
TLR2	O
expression	O
on	O
microglia	O
.	O

Minocycline	O
facilitates	O
the	O
recovery	O
from	O
LPS	O
-	O
induced	O
sickness	O
behavior	O
CNS	O
macrophages	O
and	O
microglia	O
produce	O
inflammatory	O
cytokines	O
and	O
secondary	O
messengers	O
that	O
modulate	O
behavioral	O
responses	O
.	O

Therefore	O
,	O
we	O
next	O
investigated	O
if	O
minocycline	O
reduced	O
the	O
sickness	O
response	O
associated	O
with	O
peripheral	O
LPS	O
injection	O
.	O

In	O
this	O
experiment	O
,	O
adult	O
mice	B
were	O
treated	O
with	O
minocycline	O
and	O
LPS	O
as	O
described	O
.	O

Social	O
exploratory	O
behavior	O
was	O
measured	O
before	O
i.p	O
.	O

LPS	O
injection	O
and	O
again	O
2	O
,	O
4	O
,	O
8	O
,	O
and	O
24	O
h	O
later	O
.	O

Fig.	O
3A	O
shows	O
that	O
LPS	O
injection	O
caused	O
a	O
reduction	O
in	O
social	O
exploratory	O
behavior	O
(	O
F	O
(	O
1,57	O
)	O
=	O
218	O
,	O
P	O
<	O
0.001	O
)	O
that	O
was	O
time	O
dependent	O
(	O
F	O
(	O
4,57	O
)	O
=	O
66.5	O
,	O
P	O
<	O
0.001	O
)	O
.	O

Moreover	O
,	O
the	O
LPS	O
-	O
associated	O
reduction	O
in	O
social	O
exploration	O
was	O
attenuated	O
by	O
minocycline	O
(	O
Mino	O
×	O
LPS	O
interaction	O
,	O
F	O
(	O
1,57	O
)	O
=	O
7.5	O
,	O
P	O
<	O
0.007	O
)	O
.	O

For	O
example	O
,	O
at	O
8	O
h	O
post	O
LPS	O
,	O
social	O
exploration	O
was	O
reduced	O
by	O
35	O
%	O
in	O
minocycline	O
pretreated	O
mice	B
given	O
LPS	O
compared	O
to	O
a	O
67	O
%	O
reduction	O
in	O
vehicle	O
pretreated	O
mice	B
given	O
LPS	O
(	O
P	O
<	O
0.001	O
)	O
.	O

While	O
minocycline	O
administration	O
alone	O
reduced	O
food	O
intake	O
and	O
body	O
weight	O
in	O
control	O
mice	B
(	O
P	O
<	O
0.05	O
,	O
for	O
each	O
)	O
,	O
it	O
also	O
protected	O
against	O
LPS	O
-	O
associated	O
anorexia	O
(	O
Mino	O
×	O
LPS	O
interaction	O
,	O
F	O
(	O
1	O
,	O
60	O
)	O
=	O
70.0	O
,	O
P	O
<	O
0.001	O
,	O
Fig.	O
3B	O
)	O
and	O
weight	O
loss	O
(	O
Mino	O
×	O
LPS	O
interaction	O
,	O
F	O
(	O
1	O
,	O
60	O
)	O
=	O
29.7	O
,	O
P	O
<	O
0.001	O
,	O
Fig.	O
3C	O
)	O
.	O

Because	O
sickness	O
can	O
also	O
be	O
associated	O
with	O
longer	O
lasting	O
changes	O
in	O
motivation	O
[	O
38	O
]	O
,	O
we	O
next	O
sought	O
to	O
determine	O
if	O
minocycline	O
abrogated	O
LPS	O
-	O
induced	O
anhedonia	O
[	O
54,55	O
]	O
.	O

In	O
this	O
experiment	O
,	O
mice	B
were	O
subjected	O
to	O
the	O
same	O
minocycline	O
injection	O
regimen	O
and	O
LPS	O
challenge	O
as	O
above	O
and	O
sucrose	O
preference	O
was	O
assessed	O
24–39	O
h	O
post	O
LPS	O
injection	O
.	O

By	O
24	O
h	O
post	O
LPS	O
injection	O
,	O
food	O
and	O
water	O
intake	O
returned	O
to	O
baseline	O
and	O
LPS	O
treated	O
mice	B
still	O
exhibited	O
a	O
marked	O
reduction	O
in	O
sucrose	O
preference	O
from	O
24–39	O
h	O
(	O
F	O
(	O
1,59	O
)	O
=	O
14.3	O
,	O
P	O
<	O
0.003	O
)	O
.	O

Moreover	O
,	O
this	O
LPS	O
-	O
dependent	O
reduction	O
in	O
sucrose	O
preference	O
was	O
prevented	O
by	O
minocycline	O
pretreatment	O
(	O
Mino	O
×	O
LPS	O
interaction	O
,	O
F	O
(	O
1	O
,	O
59	O
)	O
=	O
9.9	O
,	O
P	O
<	O
0.004	O
,	O
Fig.	O
4	O
)	O
.	O

For	O
example	O
,	O
minocycline	O
pretreated	O
mice	B
injected	O
with	O
LPS	O
maintained	O
the	O
same	O
strong	O
preference	O
for	O
sucrose	O
as	O
saline	O
and	O
minocycline	O
controls	O
(	O
i.e.	O
,	O
approximately	O
85	O
%	O
preference	O
)	O
.	O

These	O
data	O
can	O
be	O
interpreted	O
to	O
indicate	O
that	O
minocycline	O
blocks	O
anhedonia	O
associated	O
with	O
peripheral	O
LPS	O
challenge	O
.	O

Minocycline	O
reduces	O
LPS	O
-	O
induced	O
neuroinflammation	O
Pro	O
-	O
inflammatory	O
cytokines	O
in	O
the	O
CNS	O
are	O
partially	O
responsible	O
for	O
the	O
behavioral	O
symptoms	O
of	O
sickness	O
(	O
e.g.	O
,	O
anorexia	O
,	O
social	O
withdrawal	O
,	O
and	O
anhedonia	O
)	O
[	O
1	O
]	O
.	O

Therefore	O
,	O
we	O
investigated	O
the	O
degree	O
to	O
which	O
minocycline	O
reduces	O
neuroinflammation	O
(	O
IL-1β	O
,	O
IL-6	O
,	O
and	O
IDO	O
)	O
after	O
peripheral	O
injection	O
of	O
LPS	O
.	O

In	O
this	O
experiment	O
,	O
mice	B
were	O
subjected	O
to	O
the	O
minocycline	O
injection	O
regimen	O
and	O
LPS	O
challenge	O
as	O
above	O
and	O
cytokine	O
mRNA	O
levels	O
were	O
determined	O
in	O
the	O
cortex	O
and	O
hippocampus	O
4	O
h	O
after	O
LPS	O
injection	O
.	O

In	O
mice	B
pretreated	O
with	O
vehicle	O
,	O
LPS	O
markedly	O
increased	O
IL-1β	O
mRNA	O
levels	O
in	O
the	O
hippocampus	O
(	O
F	O
(	O
1,31	O
)	O
=	O
62	O
,	O
P	O
<	O
0.0001	O
)	O
and	O
cortex	O
(	O
F	O
(	O
1,31	O
)	O
=	O
17.25	O
,	O
P	O
<	O
0.0003	O
)	O
.	O

The	O
LPS	O
-	O
induced	O
IL-1β	O
mRNA	O
expression	O
was	O
reduced	O
in	O
both	O
brain	O
regions	O
in	O
mice	B
receiving	O
minocycline	O
prior	O
to	O
LPS	O
injection	O
:	O
(	O
hippocampus	O
,	O
F	O
(	O
1,31	O
)	O
=	O
9.63	O
,	O
P	O
<	O
0.01	O
)	O
and	O
cortex	O
,	O
F	O
(	O
1,31	O
)	O
=	O
7.23	O
,	O
P	O
=	O
0.08	O
,	O
Fig.	O
5A	O
)	O
.	O

LPS	O
caused	O
a	O
similar	O
induction	O
of	O
IL-6	O
mRNA	O
levels	O
in	O
the	O
hippocampus	O
(	O
F	O
(	O
1,31	O
)	O
=	O
37.2	O
,	O
P	O
<	O
0.001	O
)	O
and	O
cortex	O
(	O
F	O
(	O
1,31	O
)	O
=	O
22.5	O
,	O
P	O
<	O
0.001	O
)	O
,	O
but	O
minocycline	O
pretreatment	O
only	O
significantly	O
attenuated	O
LPS	O
-	O
induced	O
IL-6	O
mRNA	O
levels	O
in	O
the	O
hippocampus	O
(	O
F	O
(	O
1,31	O
)	O
=	O
10.27	O
,	O
P	O
<	O
0.004	O
,	O
Fig.	O
5B	O
)	O
.	O

IDO	O
mRNA	O
levels	O
were	O
determined	O
from	O
the	O
same	O
RNA	O
pool	O
.	O

Fig.	O
6D	O
shows	O
that	O
LPS	O
injection	O
increased	O
IDO	O
mRNA	O
expression	O
in	O
the	O
hippocampus	O
(	O
F	O
(	O
1,31	O
)	O
=	O
11.69	O
,	O
P	O
<	O
0.002	O
)	O
and	O
cortex	O
(	O
F	O
(	O
1,31	O
)	O
=	O
5.26	O
,	O
P	O
<	O
0.03	O
)	O
.	O

This	O
LPS	O
-	O
induced	O
IDO	O
mRNA	O
expression	O
was	O
attenuated	O
by	O
minocycline	O
in	O
the	O
hippocampus	O
(	O
F	O
(	O
1,31	O
)	O
=	O
11.69	O
,	O
P	O
<	O
0.002	O
)	O
and	O
cortex	O
(	O
F	O
(	O
1,31	O
)	O
=	O
5.26	O
,	O
P	O
<	O
0.03	O
)	O
.	O

It	O
is	O
important	O
to	O
note	O
that	O
IDO	O
mRNA	O
was	O
undetected	O
in	O
saline	O
treated	O
mice	B
.	O

Therefore	O
,	O
the	O
fold	O
IDO	O
change	O
was	O
relative	O
to	O
the	O
IDO	O
mRNA	O
levels	O
in	O
mice	B
receiving	O
minocycline	O
prior	O
to	O
LPS	O
.	O

Minocycline	O
reduces	O
LPS	O
-	O
induced	O
IL-6	O
,	O
but	O
not	O
IL-1β	O
,	O
in	O
the	O
plasma	O
Because	O
cytokine	O
signals	O
can	O
be	O
relayed	O
from	O
the	O
periphery	O
to	O
the	O
brain	O
by	O
humoral	O
pathways	O
[	O
56	O
]	O
,	O
plasma	O
cytokine	O
levels	O
of	O
IL-6	O
and	O
IL-1β	O
were	O
determined	O
4	O
h	O
post	O
LPS	O
injection	O
.	O

As	O
expected	O
,	O
LPS	O
injection	O
caused	O
a	O
marked	O
increase	O
in	O
plasma	O
IL-1β	O
(	O
F	O
(	O
1,36	O
)	O
=	O
52.5	O
,	O
P	O
<	O
0.001	O
)	O
and	O
IL-6	O
levels	O
(	O
F	O
(	O
1,36	O
)	O
34.01	O
,	O
P	O
<	O
0.01	O
)	O
.	O

Minocycline	O
pretreatment	O
reduced	O
LPS	O
-	O
induced	O
IL-6	O
levels	O
in	O
the	O
plasma	O
(	O
F	O
(	O
1,36	O
)	O
6.68	O
,	O
P	O
<	O
0.01	O
)	O
but	O
had	O
no	O
significant	O
main	O
effect	O
on	O
LPS	O
-	O
induced	O
IL-1β	O
levels	O
(	O
Fig.	O
6	O
)	O
.	O

Minocycline	O
attenuates	O
LPS	O
-	O
induced	O
exaggerated	O
neuroinflammation	O
in	O
aged	O
mice	B
Aged	O
BALB	O
/	O
c	O
mice	B
(	O
22–24	O
m	O
)	O
have	O
an	O
exaggerated	O
neuroinflammatory	O
response	O
to	O
LPS	O
injection	O
[	O
10,13,14	O
]	O
.	O

Therefore	O
,	O
we	O
next	O
sought	O
to	O
determine	O
if	O
the	O
heightened	O
inflammatory	O
response	O
in	O
the	O
brain	O
of	O
aged	O
mice	B
was	O
reduced	O
by	O
minocycline	O
.	O

In	O
this	O
experiment	O
,	O
adult	O
and	O
aged	O
mice	B
were	O
subjected	O
to	O
the	O
minocycline	O
injection	O
regimen	O
and	O
LPS	O
challenge	O
as	O
above	O
.	O

As	O
we	O
have	O
reported	O
previously	O
,	O
MHC	O
II	O
mRNA	O
expression	O
was	O
increased	O
by	O
age	O
(	O
P	O
<	O
0.03	O
,	O
Fig.	O
7A	O
)	O
[	O
13,14	O
]	O
,	O
but	O
MHC	O
II	O
levels	O
were	O
unaffected	O
by	O
either	O
LPS	O
or	O
minocycline	O
treatment	O
(	O
not	O
shown	O
)	O
.	O

Consistent	O
with	O
the	O
data	O
presented	O
in	O
Fig.	O
2	O
,	O
ANOVA	O
revealed	O
a	O
significant	O
main	O
effect	O
of	O
LPS	O
injection	O
on	O
TLR2	O
mRNA	O
expression	O
in	O
the	O
hippocampus	O
(	O
F	O
(	O
1,63	O
)	O
=	O
85.5	O
,	O
P	O
<	O
0.001	O
)	O
.	O

Moreover	O
,	O
LPS	O
caused	O
a	O
greater	O
increase	O
in	O
TLR2	O
mRNA	O
in	O
the	O
hippocampus	O
of	O
aged	O
mice	B
compared	O
to	O
adults	O
(	O
LPS	O
×	O
Age	O
interaction	O
,	O
F	O
(	O
1,63	O
)	O
=	O
12.70	O
,	O
P	O
<	O
0.01	O
)	O
.	O

Furthermore	O
,	O
minocycline	O
pretreatment	O
attenuated	O
LPS	O
-	O
induced	O
TLR2	O
mRNA	O
levels	O
in	O
both	O
adult	O
and	O
aged	O
mice	B
(	O
Mino	O
×	O
LPS	O
interaction	O
,	O
F	O
(	O
1,63	O
)	O
=	O
9.02	O
,	O
P	O
<	O
0.004	O
)	O
.	O

Parallel	O
to	O
the	O
results	O
for	O
TLR2	O
,	O
LPS	O
caused	O
a	O
greater	O
increase	O
in	O
IL-1β	O
and	O
IDO	O
mRNA	O
levels	O
in	O
hippocampus	O
of	O
aged	O
mice	B
compared	O
to	O
adults	O
(	O
Age	O
×	O
LPS	O
,	O
F	O
(	O
1,60	O
)	O
=	O
8.64	O
,	O
P	O
<	O
0.01	O
for	O
IL-1β	O
and	O
F	O
(	O
1,60	O
)	O
=	O
4.0	O
,	O
P	O
<	O
0.05	O
for	O
IDO	O
)	O
.	O

Minocycline	O
pretreatment	O
attenuated	O
LPS	O
-	O
induced	O
mRNA	O
levels	O
of	O
IL-1β	O
(	O
Mino	O
×	O
LPS	O
,	O
F	O
(	O
1,60	O
)	O
=	O
8.76	O
,	O
P	O
<	O
0.01	O
,	O
Fig.	O
7C	O
)	O
and	O
IDO	O
(	O
Mino	O
×	O
LPS	O
,	O
F	O
(	O
1,60	O
)	O
=	O
9.7	O
,	O
P	O
<	O
0.003	O
,	O
Fig.	O
7D	O
)	O
.	O

While	O
LPS	O
induced	O
higher	O
IL-6	O
mRNA	O
levels	O
in	O
the	O
hippocampus	O
of	O
both	O
adult	O
and	O
aged	O
mice	B
(	O
F	O
(	O
1,59	O
)	O
=	O
44.5	O
,	O
P	O
<	O
0.001	O
)	O
,	O
there	O
was	O
not	O
an	O
Age	O
×	O
LPS	O
interaction	O
.	O

Minocycline	O
pretreatment	O
attenuated	O
the	O
LPS	O
-	O
induced	O
increase	O
in	O
hippocampal	O
IL-6	O
mRNA	O
(	O
Mino	O
×	O
LPS	O
,	O
F	O
(	O
1,59	O
)	O
=	O
5.4	O
,	O
P	O
<	O
0.02	O
,	O
Fig.	O
7E	O
)	O
.	O

Taken	O
together	O
these	O
data	O
indicate	O
that	O
minocycline	O
pretreatment	O
was	O
effective	O
in	O
attenuating	O
the	O
exaggerated	O
neuroinflammation	O
in	O
aged	O
mice	B
.	O

Discussion	O
In	O
the	O
elderly	O
,	O
systemic	O
infection	O
is	O
associated	O
with	O
an	O
increased	O
frequency	O
of	O
behavioral	O
and	O
cognitive	O
complications	O
[	O
57,58	O
]	O
.	O

We	O
have	O
reported	O
that	O
stimulation	O
of	O
the	O
peripheral	O
immune	O
system	O
in	O
older	O
(	O
20–24	O
m	O
)	O
BALB	O
/	O
c	O
mice	B
causes	O
exaggerated	O
neuroinflammation	O
that	O
is	O
paralleled	O
by	O
prolonged	O
sickness	O
[	O
13	O
]	O
,	O
impaired	O
working	O
memory	O
[	O
10	O
]	O
,	O
and	O
depressive	O
-	O
like	O
behaviors	O
[	O
15	O
]	O
.	O

Therefore	O
,	O
it	O
is	O
important	O
to	O
understand	O
the	O
mechanisms	O
that	O
can	O
modulate	O
cytokine	O
-	O
mediated	O
pathways	O
in	O
the	O
brain	O
.	O

Here	O
we	O
show	O
that	O
minocycline	O
treatment	O
reduced	O
LPS	O
-	O
induced	O
TLR2	O
expression	O
in	O
BV-2	O
cells	O
and	O
on	O
microglia	O
isolated	O
from	O
adult	O
mice	B
.	O

Moreover	O
,	O
we	O
demonstrate	O
that	O
minocycline	O
was	O
effective	O
in	O
facilitating	O
the	O
recovery	O
from	O
LPS	O
-	O
induced	O
sickness	O
and	O
preventing	O
anhedonia	O
in	O
adult	O
mice	B
.	O

Furthermore	O
,	O
we	O
show	O
that	O
minocycline	O
attenuated	O
LPS	O
-	O
induced	O
neuroinflammation	O
in	O
adults	O
and	O
normalized	O
the	O
exaggerated	O
neuroinflammation	O
in	O
aged	O
mice	B
.	O

Our	O
findings	O
,	O
using	O
cell	O
culture	O
and	O
animal	O
experiments	O
,	O
support	O
the	O
notion	O
that	O
minocycline	O
attenuates	O
microglial	O
activation	O
and	O
limits	O
production	O
of	O
inflammatory	O
mediators	O
.	O

For	O
instance	O
,	O
minocycline	O
pretreatment	O
of	O
BV-2	O
cultures	O
decreased	O
LPS	O
-	O
stimulated	O
cytokine	O
production	O
in	O
a	O
dose	O
dependent	O
manner	O
(	O
Fig.	O
1A	O
)	O
.	O

In	O
BV-2	O
cells	O
,	O
minocycline	O
also	O
attenuated	O
mRNA	O
expression	O
of	O
inflammatory	O
genes	O
including	O
IL-6	O
,	O
IL-1β	O
,	O
MHC	O
II	O
,	O
and	O
TLR2	O
(	O
Fig.	O
1D	O
)	O
.	O

These	O
data	O
are	O
consistent	O
with	O
other	O
studies	O
using	O
minocycline	O
and	O
LPS	O
in	O
BV-2	O
cells	O
[	O
44,59	O
]	O
.	O

Based	O
on	O
these	O
data	O
we	O
next	O
investigated	O
if	O
microglial	O
activation	O
could	O
be	O
attenuated	O
in	O
the	O
brain	O
.	O

Because	O
LPS	O
increases	O
brain	O
cytokine	O
production	O
we	O
expected	O
that	O
MHC	O
II	O
expression	O
would	O
also	O
be	O
increased	O
.	O

Contrary	O
to	O
our	O
predictions	O
,	O
neither	O
MHC	O
II	O
mRNA	O
levels	O
(	O
Fig.	O
7	O
)	O
in	O
the	O
brain	O
nor	O
MHC	O
II	O
surface	O
expression	O
on	O
microglia	O
(	O
CD11b+	O
/	O
CD45low	O
)	O
(	O
data	O
not	O
shown	O
)	O
were	O
increased	O
by	O
LPS	O
injection	O
.	O

In	O
an	O
EAE	O
model	O
,	O
minocycline	O
reduced	O
microglial	O
expression	O
of	O
MHC	O
II	O
[	O
45	O
]	O
,	O
but	O
one	O
key	O
difference	O
from	O
our	O
study	O
is	O
that	O
the	O
induction	O
of	O
EAE	O
pathology	O
requires	O
functional	O
antigen	O
presentation	O
on	O
MHC	O
II	O
[	O
60	O
]	O
.	O

It	O
is	O
postulated	O
that	O
microglia	O
have	O
several	O
activation	O
states	O
that	O
depend	O
on	O
the	O
specific	O
inflammatory	O
stimulus	O
[	O
61	O
]	O
.	O

Thus	O
,	O
in	O
situations	O
of	O
transient	O
peripheral	O
innate	O
immune	O
stimulation	O
,	O
markers	O
in	O
the	O
CNS	O
such	O
as	O
Toll	O
-	O
Like	O
receptors	O
[	O
6	O
]	O
may	O
be	O
indicative	O
of	O
microglia	O
activation	O
.	O

In	O
support	O
of	O
this	O
premise	O
,	O
our	O
data	O
show	O
that	O
LPS	O
injection	O
increases	O
TLR2	O
surface	O
expression	O
on	O
microglia	O
(	O
CD11b+	O
/	O
CD45low	O
)	O
,	O
which	O
is	O
inhibited	O
by	O
minocycline	O
pretreatment	O
(	O
Fig.	O
2	O
)	O
.	O

These	O
data	O
are	O
consistent	O
with	O
other	O
studies	O
showing	O
that	O
central	O
or	O
peripheral	O
LPS	O
challenge	O
increases	O
TLR2	O
mRNA	O
in	O
the	O
brain	O
[	O
6,14	O
]	O
.	O

Taken	O
together	O
our	O
findings	O
can	O
be	O
interpreted	O
to	O
suggest	O
that	O
minocycline	O
attenuates	O
pathways	O
associated	O
with	O
microglia	O
activation	O
following	O
peripheral	O
LPS	O
challenge	O
.	O

One	O
of	O
the	O
important	O
findings	O
of	O
this	O
study	O
was	O
that	O
reduction	O
of	O
neuroinflammation	O
by	O
minocycline	O
was	O
associated	O
with	O
facilitated	O
recovery	O
from	O
LPS	O
-	O
induced	O
sickness	O
behavior	O
.	O

These	O
results	O
are	O
akin	O
to	O
our	O
previous	O
work	O
with	O
the	O
anti	O
-	O
oxidant	O
,	O
α	O
-	O
tocopherol	O
[	O
52	O
]	O
,	O
and	O
an	O
NFKB	O
decoy	O
inhibitor	O
[	O
62	O
]	O
.	O

Consistent	O
with	O
our	O
previous	O
studies	O
[	O
52,53,62,63	O
]	O
,	O
reductions	O
in	O
neuroinflammatory	O
cytokines	O
(	O
Fig.	O
5	O
)	O
did	O
not	O
prevent	O
the	O
induction	O
of	O
the	O
LPS	O
-	O
induced	O
sickness	O
response	O
(	O
2–4	O
h	O
)	O
,	O
but	O
rather	O
facilitated	O
the	O
recovery	O
from	O
sickness	O
(	O
8–24	O
h	O
)	O
(	O
Fig.	O
3A	O
)	O
.	O

Recovery	O
may	O
be	O
a	O
critical	O
issue	O
because	O
brain	O
cytokines	O
and	O
the	O
corresponding	O
physiological	O
and	O
behavioral	O
responses	O
are	O
beneficial	O
to	O
the	O
host	O
[	O
1	O
]	O
.	O

The	O
potential	O
risk	O
for	O
a	O
maladaptive	O
response	O
occurs	O
when	O
the	O
normally	O
transient	O
neuroinflammatory	O
response	O
is	O
amplified	O
or	O
protracted	O
[	O
64	O
]	O
.	O

Therefore	O
pharmacological	O
agents	O
,	O
similar	O
to	O
minocycline	O
,	O
that	O
attenuate	O
neuroinflammatory	O
responses	O
,	O
but	O
do	O
not	O
completely	O
inhibit	O
them	O
,	O
may	O
be	O
important	O
in	O
preventing	O
the	O
development	O
of	O
more	O
severe	O
and	O
long	O
-	O
lasting	O
cognitive	O
and	O
behavioral	O
complications	O
.	O

The	O
results	O
of	O
the	O
sucrose	O
preference	O
experiments	O
support	O
the	O
idea	O
that	O
limiting	O
exposure	O
to	O
neuroinflammation	O
decreases	O
the	O
duration	O
of	O
behavioral	O
responses	O
.	O

For	O
example	O
,	O
while	O
minocycline	O
did	O
not	O
inhibit	O
cytokine	O
expression	O
(	O
Fig.	O
5	O
)	O
or	O
the	O
induction	O
of	O
sickness	O
(	O
Fig.	O
3A	O
)	O
,	O
minocycline	O
pretreatment	O
completely	O
reversed	O
the	O
reduction	O
in	O
sucrose	O
preference	O
(	O
i.e.	O
,	O
anhedonia	O
)	O
associated	O
with	O
LPS	O
injection	O
(	O
Fig.	O
4	O
)	O
.	O

It	O
is	O
also	O
important	O
to	O
mention	O
that	O
while	O
LPS	O
-	O
associated	O
sickness	O
and	O
anhedonia	O
are	O
interrelated	O
,	O
these	O
behaviors	O
can	O
be	O
differentiated	O
from	O
one	O
another	O
.	O

For	O
instance	O
,	O
reduced	O
social	O
exploration	O
was	O
evident	O
2–24	O
h	O
post	O
injection	O
(	O
Fig.	O
3A	O
)	O
,	O
but	O
only	O
decreased	O
sucrose	O
preference	O
was	O
exhibited	O
24	O
to	O
39	O
h	O
later	O
(	O
Fig.	O
4	O
)	O
.	O

This	O
separation	O
between	O
behaviors	O
is	O
consistent	O
with	O
other	O
studies	O
investigating	O
sickness	O
and	O
longer	O
-	O
lasting	O
changes	O
in	O
motivation	O
[	O
15,65,66	O
]	O
.	O

IDO	O
mediated	O
TRP	O
metabolism	O
represents	O
a	O
potential	O
connection	O
between	O
activation	O
of	O
CNS	O
innate	O
immune	O
cells	O
and	O
longer	O
lasting	O
behavioral	O
responses	O
.	O

IDO	O
mediated	O
TRP	O
metabolism	O
in	O
the	O
brain	O
may	O
affect	O
behavior	O
by	O
impacting	O
both	O
serotonin	O
and	O
glutamate	O
pathways	O
[	O
39	O
]	O
.	O

We	O
have	O
reported	O
that	O
IDO	O
induction	O
and	O
activity	O
is	O
amplified	O
in	O
the	O
brain	O
of	O
aged	O
mice	B
and	O
is	O
associated	O
with	O
prolonged	O
depressive	O
-	O
like	O
behavior	O
[	O
15	O
]	O
.	O

Here	O
we	O
show	O
that	O
IDO	O
mRNA	O
induction	O
is	O
blocked	O
by	O
minocycline	O
in	O
the	O
brain	O
of	O
both	O
adult	O
and	O
aged	O
mice	B
(	O
Figs.	O
5&7	O
)	O
.	O

These	O
data	O
are	O
consistent	O
with	O
a	O
recent	O
report	O
showing	O
a	O
causal	O
relationship	O
between	O
IDO	O
activity	O
and	O
acute	O
depressive	O
effects	O
in	O
adult	O
CD-1	O
mice	B
.	O

In	O
this	O
study	O
,	O
O'Connor	O
et	O
al.	O
report	O
that	O
both	O
1-methyl	O
tryptophan	O
(	O
a	O
competitive	O
inhibitor	O
of	O
IDO	O
)	O
and	O
minocycline	O
blocked	O
IDO	O
induction	O
and	O
prevented	O
depressive	O
-	O
like	O
immobility	O
in	O
the	O
tail	O
suspension	O
and	O
forced	O
swimming	O
tests	O
[	O
66	O
]	O
.	O

Thus	O
,	O
in	O
the	O
present	O
study	O
,	O
the	O
minocycline	O
blockade	O
of	O
IDO	O
induction	O
may	O
explain	O
the	O
abrogation	O
of	O
LPS	O
-	O
induced	O
anhedonia	O
.	O

Another	O
interesting	O
finding	O
was	O
that	O
while	O
minocycline	O
pretreatment	O
in	O
adult	O
mice	B
attenuated	O
LPS	O
-	O
induced	O
brain	O
IL-1β	O
at	O
4	O
h	O
(	O
Fig.	O
5	O
)	O
,	O
it	O
had	O
no	O
effect	O
on	O
plasma	O
IL-1β	O
levels	O
(	O
Fig.	O
6	O
)	O
.	O

Because	O
IL-1β	O
signals	O
can	O
be	O
relayed	O
from	O
the	O
periphery	O
to	O
the	O
brain	O
by	O
humoral	O
pathways	O
[	O
5	O
]	O
,	O
these	O
findings	O
suggest	O
that	O
minocycline	O
has	O
anti	O
-	O
inflammatory	O
properties	O
within	O
the	O
brain	O
.	O

These	O
data	O
are	O
consistent	O
with	O
related	O
findings	O
that	O
minocycline	O
readily	O
crosses	O
the	O
blood	O
brain	O
barrier	O
to	O
elicit	O
an	O
anti	O
-	O
inflammatory	O
effect	O
[	O
41	O
-	O
43	O
]	O
.	O

With	O
regard	O
to	O
IL-6	O
,	O
minocycline	O
pretreatment	O
attenuated	O
both	O
brain	O
and	O
plasma	O
levels	O
at	O
4	O
h	O
post	O
LPS	O
injection	O
.	O

Because	O
circulating	O
IL-6	O
levels	O
can	O
be	O
increased	O
by	O
CNS	O
mediated	O
pathways	O
including	O
activation	O
of	O
the	O
hypothalamus	O
-	O
pituitary	O
-	O
adrenal	O
(	O
HPA	O
)	O
axis	O
[	O
67	O
]	O
and	O
the	O
sympathetic	O
nervous	O
system	O
[	O
68	O
]	O
,	O
the	O
specific	O
reduction	O
in	O
plasma	O
IL-6	O
by	O
minocycline	O
may	O
reflect	O
the	O
reduction	O
in	O
brain	O
inflammation	O
at	O
4	O
h	O
(	O
Fig.	O
5	O
)	O
.	O

In	O
support	O
of	O
this	O
notion	O
,	O
we	O
and	O
others	O
have	O
reported	O
that	O
i.c.v	O
.	O

injection	O
of	O
LPS	O
or	O
IL-1β	O
increase	O
plasma	O
IL-6	O
levels	O
,	O
but	O
not	O
IL-1β	O
levels	O
[	O
14,68,69	O
]	O
.	O

The	O
final	O
critical	O
finding	O
of	O
this	O
study	O
was	O
that	O
minocycline	O
was	O
effective	O
in	O
attenuating	O
neuroinflammation	O
independent	O
of	O
age	O
.	O

Consistent	O
with	O
other	O
aging	O
and	O
neuroinflammation	O
studies	O
,	O
our	O
data	O
show	O
that	O
LPS	O
caused	O
exaggerated	O
neuroinflammation	O
in	O
aged	O
mice	B
compared	O
to	O
adults	O
[	O
10,13	O
-	O
15	O
]	O
.	O

It	O
is	O
important	O
to	O
mention	O
that	O
while	O
there	O
was	O
an	O
age	O
-	O
related	O
difference	O
in	O
MHC	O
II	O
expression	O
in	O
the	O
hippocampus	O
of	O
saline	O
treated	O
mice	B
(	O
Fig.	O
7A	O
)	O
there	O
was	O
not	O
an	O
age	O
-	O
related	O
difference	O
in	O
IL-1β	O
and	O
IL-6	O
mRNA	O
levels	O
.	O

These	O
data	O
differ	O
from	O
a	O
previous	O
report	O
using	O
BALB	O
/	O
c	O
mice	B
showing	O
an	O
increase	O
in	O
IL-6	O
in	O
older	O
mice	B
[	O
70	O
]	O
.	O

This	O
may	O
be	O
because	O
the	O
mice	B
used	O
in	O
the	O
present	O
study	O
were	O
approximately	O
4	O
months	O
younger	O
than	O
the	O
mice	B
used	O
previously	O
.	O

Nonetheless	O
,	O
microglia	O
can	O
be	O
primed	O
or	O
reactive	O
with	O
increased	O
MHC	O
II	O
expression	O
,	O
but	O
do	O
not	O
necessarily	O
produce	O
inflammatory	O
cytokines	O
in	O
this	O
state	O
[	O
19	O
]	O
.	O

The	O
key	O
results	O
are	O
that	O
peripheral	O
LPS	O
injection	O
causes	O
a	O
greater	O
induction	O
of	O
TLR2	O
,	O
IL-1β	O
,	O
and	O
IDO	O
mRNA	O
in	O
the	O
aged	O
brain	O
than	O
in	O
the	O
adult	O
brain	O
and	O
that	O
minocycline	O
pretreatment	O
normalizes	O
this	O
age	O
-	O
related	O
exaggerated	O
neuroinflammation	O
(	O
Fig.	O
7	O
)	O
.	O

These	O
findings	O
are	O
also	O
important	O
because	O
an	O
amplified	O
neuroinflammatory	O
response	O
in	O
the	O
aged	O
brain	O
is	O
a	O
precursor	O
to	O
complications	O
including	O
deficits	O
in	O
working	O
memory	O
,	O
memory	O
consolidation	O
,	O
and	O
depressive	O
-	O
like	O
behavior	O
[	O
9,10,15	O
]	O
.	O

Based	O
on	O
the	O
biochemical	O
and	O
behavioral	O
data	O
obtained	O
from	O
this	O
study	O
,	O
we	O
predict	O
that	O
minocycline	O
will	O
abrogate	O
the	O
prolonged	O
LPS	O
-	O
induced	O
sickness	O
[	O
13	O
]	O
and	O
depressive	O
-	O
like	O
behavior	O
exhibited	O
by	O
aged	O
BALB	O
/	O
c	O
mice	B
[	O
15	O
]	O
.	O

We	O
acknowledge	O
,	O
however	O
,	O
that	O
future	O
studies	O
are	O
necessary	O
to	O
test	O
these	O
predictions	O
.	O

Conclusion	O
The	O
present	O
study	O
demonstrates	O
that	O
minocycline	O
reduces	O
LPS	O
-	O
induced	O
microglial	O
activation	O
,	O
CNS	O
cytokine	O
production	O
,	O
and	O
behavioral	O
symptoms	O
of	O
sickness	O
(	O
e.g.	O
,	O
social	O
withdrawal	O
and	O
anhedonia	O
)	O
.	O

These	O
findings	O
are	O
potentially	O
important	O
because	O
they	O
indicate	O
that	O
minocycline	O
can	O
be	O
used	O
to	O
mitigate	O
cytokine	O
expression	O
in	O
the	O
brain	O
and	O
have	O
a	O
beneficial	O
affect	O
on	O
behavioral	O
responses	O
.	O

Taken	O
together	O
,	O
these	O
data	O
support	O
the	O
idea	O
that	O
pharmacological	O
strategies	O
aimed	O
at	O
decreasing	O
neuroinflammation	O
associated	O
with	O
microglial	O
activation	O
are	O
important	O
for	O
improving	O
recovery	O
from	O
sickness	O
and	O
reducing	O
the	O
frequency	O
of	O
neurobehavioral	O
complications	O
.	O

List	O
of	O
abbreviations	O
3-Hydroxy	O
-	O
L	O
-	O
Kynuriene	O
(	O
3HK	O
)	O
,	O
Allophycocyanin	O
(	O
APC	O
)	O
,	O
Analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
,	O
Central	O
Nervous	O
System	O
(	O
CNS	O
)	O
,	O
Dulbecco	O
's	O
Modified	O
Eagle	O
's	O
Medium	O
(	O
DMEM	O
)	O
,	O
Dimethyl	O
Sulfoxide	O
(	O
DMSO	O
)	O
,	O
Experimental	O
Autoimmune	O
Encephalomyelitis	O
(	O
EAE	O
)	O
,	O
Enzyme	O
Linked	O
Immmunosorbent	O
Assay	O
(	O
ELISA	O
)	O
,	O
Fluorescein	O
Isothiocyanate	O
(	O
FITC	O
)	O
,	O
Fetal	O
Bovine	B
Serum	O
(	O
FBS	O
)	O
,	O
Hank	O
's	O
Balanced	O
Salt	O
Solution	O
(	O
HBSS	O
)	O
,	O
Indoleamine	O
2	O
,	O
3	O
dioxygenase	O
(	O
IDO	O
)	O
,	O
Intraperitoneal	O
(	O
i.p	O
.	O
)	O
,	O
Intracerebroventricular	O
(	O
i.c.v	O
.	O
)	O
,	O
Interleukin	O
(	O
IL	O
)	O
,	O
Kynurenine	O
(	O
KYN	O
)	O
,	O
Lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
Major	O
Histocompatibility	O
Complex	O
class	O
II	O
(	O
MHC	O
II	O
)	O
,	O
Mitogen	O
Activated	O
Protein	O
Kinase	O
(	O
MAP	O
-	O
kinase	O
)	O
,	O
Nuclear	O
factor	O
kappa	O
B	O
(	O
NFκB	O
)	O
,	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	O
)	O
,	O
R	O
-	O
Phycoerthrin	O
(	O
PE	O
)	O
,	O
Quinolinic	O
acid	O
(	O
QUIN	O
)	O
,	O
Statistical	O
Analysis	O
Systems	O
(	O
SAS	O
)	O
,	O
Standard	O
Error	O
of	O
the	O
Mean	O
(	O
SEM	O
)	O
,	O
Toll	O
-	O
like	O
Receptor-2	O
(	O
TLR2	O
)	O
,	O
and	O
Tryptophan	O
(	O
TRP	O
)	O
.	O

Competing	O
interests	O
The	O
authors	O
of	O
this	O
manuscript	O
declare	O
that	O
there	O
are	O
no	O
actual	O
or	O
potential	O
conflicts	O
of	O
interest	O
.	O

The	O
authors	O
affirm	O
that	O
there	O
are	O
no	O
financial	O
,	O
personal	O
or	O
other	O
relationships	O
with	O
other	O
people	O
or	O
organizations	O
that	O
have	O
inappropriately	O
influenced	O
or	O
biased	O
their	O
research	O
.	O

Authors	O
'	O
contributions	O
CJH	O
was	O
involved	O
in	O
research	O
experimentation	O
,	O
completion	O
of	O
statistical	O
analysis	O
,	O
and	O
writing	O
of	O
the	O
manuscript	O
.	O

YH	O
,	O
AW	O
,	O
MH	O
and	O
JH	O
assisted	O
with	O
experimentation	O
and	O
data	O
analysis	O
.	O

MB	O
and	O
JFS	O
contributed	O
to	O
the	O
design	O
of	O
the	O
experiments	O
and	O
assisted	O
in	O
editing	O
the	O
manuscript	O
.	O

JPG	O
directed	O
all	O
aspects	O
of	O
this	O
research	O
project	O
including	O
the	O
experimental	O
design	O
,	O
research	O
experimentation	O
,	O
completion	O
of	O
statistical	O
analysis	O
,	O
and	O
writing	O
of	O
the	O
manuscript	O
.	O

A	O
novel	O
,	O
non	O
-	O
invasive	O
,	O
online	O
-	O
monitoring	O
,	O
versatile	O
and	O
easy	O
plant	O
-	O
based	O
probe	O
for	O
measuring	O
leaf	O
water	O
status	O
Abstract	O
A	O
high	O
-	O
precision	O
pressure	O
probe	O
is	O
described	O
which	O
allows	O
non	O
-	O
invasive	O
online	O
-	O
monitoring	O
of	O
the	O
water	O
relations	O
of	O
intact	O
leaves	O
.	O

Real	O
-	O
time	O
recording	O
of	O
the	O
leaf	O
water	O
status	O
occurred	O
by	O
data	O
transfer	O
to	O
an	O
Internet	O
server	O
.	O

The	O
leaf	O
patch	O
clamp	O
pressure	O
probe	O
measures	O
the	O
attenuated	O
pressure	O
,	O
Pp	O
,	O
of	O
a	O
leaf	O
patch	O
in	O
response	O
to	O
a	O
constant	O
clamp	O
pressure	O
,	O
Pclamp	O
.	O

Pp	O
is	O
sensed	O
by	O
a	O
miniaturized	O
silicone	O
pressure	O
sensor	O
integrated	O
into	O
the	O
device	O
.	O

The	O
magnitude	O
of	O
Pp	O
is	O
dictated	O
by	O
the	O
transfer	O
function	O
of	O
the	O
leaf	O
,	O
Tf	O
,	O
which	O
is	O
a	O
function	O
of	O
leaf	O
patch	O
volume	O
and	O
ultimately	O
of	O
cell	O
turgor	O
pressure	O
,	O
Pc	O
,	O
as	O
shown	O
theoretically	O
.	O

The	O
power	O
function	O
Tf	O
=	O
f	O
(	O
Pc	O
)	O
theoretically	O
derived	O
was	O
experimentally	O
confirmed	O
by	O
concomitant	O
Pp	O
and	O
Pc	O
measurements	O
on	O
intact	O
leaflets	O
of	O
the	O
liana	O
Tetrastigma	B
voinierianum	I
under	O
greenhouse	O
conditions	O
.	O

Simultaneous	O
Pp	O
recordings	O
on	O
leaflets	O
up	O
to	O
10	O
m	O
height	O
above	O
ground	O
demonstrated	O
that	O
changes	O
in	O
Tf	O
induced	O
by	O
Pc	O
changes	O
due	O
to	O
changes	O
of	O
microclimate	O
and/or	O
of	O
the	O
irrigation	O
regime	O
were	O
sensitively	O
reflected	O
in	O
corresponding	O
changes	O
of	O
Pp	O
.	O

Analysis	O
of	O
the	O
data	O
show	O
that	O
transpirational	O
water	O
loss	O
during	O
the	O
morning	O
hours	O
was	O
associated	O
with	O
a	O
transient	O
rise	O
in	O
turgor	O
pressure	O
gradients	O
within	O
the	O
leaflets	O
.	O

Subsequent	O
recovery	O
of	O
turgescence	O
during	O
the	O
afternoon	O
was	O
much	O
faster	O
than	O
the	O
preceding	O
transpiration	O
-	O
induced	O
water	O
loss	O
if	O
the	O
plants	O
were	O
well	O
irrigated	O
.	O

Our	O
data	O
show	O
the	O
enormous	O
potential	O
of	O
the	O
leaf	O
patch	O
clamp	O
pressure	O
probe	O
for	O
leaf	O
water	O
studies	O
including	O
unravelling	O
of	O
the	O
hydraulic	O
communication	O
between	O
neighbouring	O
leaves	O
and	O
over	O
long	O
distances	O
within	O
tall	O
plants	O
(	O
trees	O
)	O
.	O

Introduction	O
Optimum	O
water	O
supply	O
,	O
particularly	O
at	O
peak	O
needs	O
of	O
the	O
plants	O
,	O
is	O
an	O
important	O
issue	O
for	O
greenhouse	O
and	O
field	O
vegetable	O
production	O
.	O

In	O
a	O
greenhouse	O
on	O
a	O
sunny	O
day	O
,	O
evaporation	O
and	O
transpiration	O
(	O
so	O
-	O
called	O
evapotranspiration	O
)	O
can	O
occur	O
so	O
rapidly	O
that	O
water	O
loss	O
can	O
cause	O
plant	O
damage	O
before	O
wilting	O
symptoms	O
are	O
visible	O
.	O

Even	O
at	O
lower	O
temperatures	O
the	O
restricted	O
rooting	O
in	O
greenhouses	O
leads	O
frequently	O
to	O
plant	O
water	O
deficiency	O
.	O

Thus	O
,	O
no	O
matter	O
how	O
slight	O
,	O
drought	O
stress	O
will	O
result	O
in	O
a	O
significant	O
reduction	O
in	O
growth	O
and	O
,	O
in	O
turn	O
,	O
of	O
harvest	O
yield	O
.	O

On	O
the	O
other	O
hand	O
,	O
over	O
-	O
irrigation	O
must	O
be	O
avoided	O
and	O
the	O
appropriate	O
method	O
of	O
watering	O
must	O
be	O
selected	O
because	O
wet	O
soils	O
and	O
permanent	O
moisture	O
on	O
plant	O
organs	O
promote	O
the	O
incidence	O
of	O
root	O
mould	O
,	O
grey	O
mould	O
(	O
Botrytis	O
blight	O
)	O
,	O
formation	O
of	O
leaf	O
oedema	O
,	O
and	O
other	O
plant	O
diseases	O
(	O
Sherf	O
and	O
MacNab	O
,	O
1986	O
)	O
.	O

Conservation	O
of	O
water	O
is	O
another	O
important	O
issue	O
in	O
semi	O
-	O
arid	O
and	O
arid	O
regions	O
where	O
water	O
is	O
scarce	O
.	O

The	O
advent	O
of	O
(	O
subsurface	O
)	O
drip	O
irrigation	O
has	O
considerably	O
reduced	O
water	O
consumption	O
of	O
agricultural	O
,	O
horticultural	O
,	O
and	O
greenhouse	O
crops	O
,	O
but	O
has	O
also	O
highlighted	O
the	O
need	O
for	O
sensors	O
monitoring	O
water	O
deficiency	O
of	O
plants	O
directly	O
and	O
online	O
(	O
Jones	O
,	O
2004	O
)	O
.	O

In	O
plant	O
physiology	O
and	O
agriculture	O
the	O
pressure	O
bomb	O
technique	O
pioneered	O
by	O
Scholander	O
et	O
al.	O
(	O
1965	O
)	O
is	O
a	O
widely	O
accepted	O
reference	O
technique	O
for	O
measuring	O
leaf	O
water	O
status	O
.	O

However	O
,	O
the	O
method	O
is	O
massively	O
invasive	O
,	O
slow	O
,	O
labour	O
-	O
intensive	O
(	O
and	O
therefore	O
expensive	O
)	O
,	O
unsuitable	O
for	O
automation	O
,	O
and	O
gives	O
only	O
spot	O
measurements	O
.	O

Furthermore	O
,	O
interpretation	O
of	O
the	O
data	O
is	O
still	O
a	O
matter	O
of	O
debate	O
(	O
Zimmermann	O
U	O
et	O
al.	O
,	O
2004	O
;	O
Zimmermann	O
D	O
et	O
al.	O
,	O
2007	O
)	O
.	O

Leaf	O
thickness	O
is	O
also	O
sometimes	O
used	O
as	O
an	O
indicator	O
for	O
water	O
stress	O
(	O
Burquez	O
,	O
1987	O
;	O
McBurney	O
,	O
1992	O
;	O
Malone	O
,	O
1993	O
)	O
.	O

Leaf	O
thickness	O
monitoring	O
devices	O
are	O
commercially	O
available	O
.	O

They	O
are	O
non	O
-	O
invasive	O
and	O
suitable	O
for	O
online	O
measurements	O
,	O
but	O
have	O
the	O
disadvantage	O
that	O
changes	O
in	O
water	O
status	O
are	O
frequently	O
not	O
reflected	O
sensitively	O
in	O
changes	O
of	O
leaf	O
thickness	O
.	O

The	O
pressure	O
probe	O
technique	O
pioneered	O
by	O
Zimmermann	O
,	O
Tomos	O
,	O
and	O
others	O
(	O
Zimmermann	O
et	O
al.	O
,	O
1969	O
,	O
2004	O
;	O
Tomos	O
,	O
1988	O
;	O
Balling	O
and	O
Zimmermann	O
,	O
1990	O
)	O
,	O
on	O
the	O
other	O
hand	O
,	O
is	O
a	O
well	O
established	O
technology	O
for	O
measuring	O
turgor	O
and	O
xylem	O
pressure	O
on	O
the	O
levels	O
of	O
individual	O
cells	O
and	O
xylem	O
vessels	O
,	O
respectively	O
.	O

This	O
technique	O
is	O
not	O
suitable	O
for	O
automation	O
.	O

Moreover	O
,	O
the	O
probe	O
technique	O
requires	O
rather	O
sophisticated	O
equipment	O
and	O
a	O
high	O
level	O
of	O
technical	O
skill	O
.	O

These	O
disadvantages	O
are	O
also	O
shared	O
by	O
the	O
ball	O
tonometry	O
,	O
a	O
method	O
which	O
allows	O
non	O
-	O
invasive	O
monitoring	O
of	O
cell	O
turgor	O
pressure	O
by	O
application	O
of	O
an	O
external	O
pressure	O
(	O
Lintilhac	O
et	O
al.	O
,	O
2000	O
;	O
Geitmann	O
,	O
2006	O
)	O
.	O

Other	O
water	O
stress	O
monitoring	O
devices	O
are	O
described	O
in	O
the	O
literature	O
,	O
but	O
all	O
of	O
them	O
have	O
various	O
disadvantages	O
which	O
prevented	O
their	O
implementation	O
for	O
leaf	O
water	O
status	O
measurements	O
in	O
greenhouses	O
or	O
in	O
the	O
field	O
(	O
see	O
,	O
for	O
example	O
,	O
the	O
review	O
article	O
of	O
Jones	O
,	O
2004	O
,	O
and	O
also	O
Grant	O
et	O
al.	O
,	O
2007	O
)	O
.	O

In	O
this	O
communication	O
a	O
novel	O
,	O
non	O
-	O
invasive	O
,	O
online	O
-	O
monitoring	O
plant	O
-	O
based	O
probe	O
is	O
described	O
that	O
meets	O
the	O
demands	O
of	O
controlling	O
horticultural	O
and	O
agricultural	O
water	O
applications	O
.	O

The	O
probe	O
is	O
characterized	O
by	O
high	O
precision	O
,	O
operating	O
convenience	O
,	O
minimum	O
costs	O
,	O
and	O
by	O
automation	O
suitability	O
.	O

Data	O
can	O
be	O
transferred	O
wireless	O
to	O
a	O
personal	O
computer	O
or	O
to	O
an	O
Internet	O
server	O
via	O
a	O
mobile	O
phone	O
network	O
for	O
real	O
-	O
time	O
evaluation	O
and	O
for	O
the	O
automatic	O
regulation	O
of	O
irrigation	O
.	O

The	O
technology	O
includes	O
a	O
miniaturized	O
silicone	O
pressure	O
sensor	O
integrated	O
into	O
a	O
spring	O
clamp	O
that	O
is	O
clamped	O
to	O
a	O
patch	O
of	O
an	O
intact	O
plant	O
leaf	O
.	O

The	O
patch	O
clamp	O
pressure	O
probe	O
measures	O
the	O
attenuated	O
pressure	O
response	O
of	O
the	O
leaf	O
patch	O
upon	O
the	O
application	O
of	O
a	O
constant	O
,	O
clamped	O
pressure	O
.	O

The	O
attenuation	O
of	O
the	O
applied	O
pressure	O
depends	O
on	O
the	O
transfer	O
function	O
of	O
the	O
leaf	O
.	O

The	O
magnitude	O
of	O
the	O
transfer	O
function	O
depends	O
on	O
two	O
terms	O
,	O
a	O
turgor	O
pressure	O
-	O
independent	O
term	O
(	O
related	O
to	O
the	O
compression	O
of	O
the	O
cuticle	O
,	O
cell	O
walls	O
,	O
and	O
other	O
structural	O
elements	O
)	O
and	O
a	O
turgor	O
pressure	O
-	O
dependent	O
term	O
.	O

Theory	O
shows	O
that	O
the	O
turgor	O
pressure	O
-	O
dependent	O
part	O
of	O
the	O
transfer	O
function	O
Tf	O
is	O
a	O
power	O
function	O
of	O
the	O
cell	O
turgor	O
pressure	O
,	O
Pc	O
,	O
and	O
predicts	O
that	O
Tf	O
assumes	O
values	O
close	O
to	O
zero	O
if	O
Pc	O
is	O
high	O
and	O
,	O
vice	O
versa	O
,	O
values	O
close	O
to	O
unity	O
if	O
Pc	O
is	O
low	O
.	O

This	O
could	O
be	O
verified	O
by	O
combined	O
turgor	O
pressure	O
probe	O
and	O
leaf	O
patch	O
clamp	O
pressure	O
probe	O
measurements	O
on	O
leaflets	O
of	O
the	O
liana	O
Tetrastigma	B
voinierianum	I
.	O

The	O
10-m	O
tall	O
liana	O
growing	O
in	O
a	O
tropical	O
greenhouse	O
was	O
selected	O
for	O
the	O
first	O
studies	O
because	O
a	O
comprehensive	O
data	O
set	O
about	O
diurnal	O
changes	O
in	O
xylem	O
and	O
turgor	O
pressure	O
gradients	O
under	O
various	O
environmental	O
conditions	O
existed	O
for	O
this	O
greenhouse	O
plant	O
(	O
Benkert	O
et	O
al.	O
,	O
1995	O
;	O
Thürmer	O
et	O
al.	O
,	O
1999	O
;	O
see	O
also	O
Zimmermann	O
et	O
al.	O
,	O
2004	O
)	O
.	O

Measurements	O
of	O
diurnal	O
changes	O
of	O
the	O
patch	O
clamp	O
pressure	O
performed	O
here	O
yielded	O
results	O
which	O
were	O
consistent	O
with	O
the	O
previous	O
pressure	O
probe	O
work	O
on	O
the	O
liana	O
.	O

The	O
data	O
also	O
demonstrated	O
that	O
changes	O
in	O
the	O
irrigation	O
regime	O
and	O
in	O
microclimate	O
can	O
be	O
sensed	O
by	O
this	O
novel	O
probe	O
very	O
sensitively	O
and	O
that	O
use	O
of	O
several	O
probes	O
allowed	O
the	O
study	O
of	O
the	O
diurnal	O
water	O
transport	O
at	O
multiple	O
scales	O
from	O
single	O
leaves	O
to	O
the	O
whole	O
organism	O
(	O
Meinzer	O
et	O
al.	O
,	O
2001	O
)	O
.	O

This	O
can	O
be	O
done	O
without	O
knowledge	O
of	O
the	O
turgor	O
pressure	O
because	O
the	O
transfer	O
function	O
is	O
a	O
direct	O
measure	O
of	O
leaf	O
water	O
status	O
.	O

Materials	O
and	O
methods	O
Plant	O
material	O
Experiments	O
were	O
performed	O
on	O
two	O
specimens	O
of	O
the	O
liana	O
Tetrastigma	B
voinierianum	I
,	O
growing	O
in	O
the	O
c.	O
12	O
m	O
tall	O
tropical	O
greenhouse	O
of	O
the	O
University	O
of	O
Salzburg	O
,	O
Austria	O
.	O

The	O
ground	O
ascended	O
by	O
about	O
5	O
m	O
towards	O
the	O
backstage	O
of	O
the	O
greenhouse	O
.	O

The	O
height	O
of	O
the	O
plant	O
in	O
this	O
area	O
was	O
about	O
4.5	O
m	O
,	O
whereas	O
the	O
height	O
of	O
the	O
plant	O
in	O
the	O
front	O
area	O
reached	O
10	O
m.	O
However	O
,	O
the	O
stem	O
and	O
the	O
branches	O
of	O
the	O
two	O
plants	O
were	O
considerably	O
longer	O
,	O
because	O
the	O
plants	O
had	O
grown	O
vertically	O
upwards	O
and	O
then	O
part	O
of	O
the	O
way	O
downwards	O
.	O

First	O
measurements	O
were	O
performed	O
during	O
the	O
last	O
week	O
of	O
May	O
,	O
2007	O
.	O

This	O
week	O
was	O
very	O
sunny	O
and	O
warm	O
.	O

Experiments	O
were	O
repeated	O
during	O
the	O
last	O
week	O
of	O
August	O
and	O
the	O
first	O
week	O
of	O
September	O
,	O
2007	O
.	O

At	O
this	O
time	O
of	O
the	O
year	O
the	O
weather	O
conditions	O
were	O
quite	O
poor	O
.	O

The	O
weeks	O
were	O
rainy	O
,	O
sunshine	O
occurred	O
only	O
occasionally	O
.	O

On	O
average	O
,	O
the	O
sky	O
was	O
very	O
cloudy	O
.	O

Due	O
to	O
the	O
variable	O
weather	O
conditions	O
the	O
ambient	O
temperature	O
,	O
T	O
,	O
in	O
the	O
greenhouse	O
usually	O
varied	O
between	O
19	O
°	O
C	O
and	O
27	O
°	O
C	O
.	O

By	O
contrast	O
,	O
during	O
the	O
hot	O
week	O
in	O
May	O
temperatures	O
at	O
the	O
top	O
of	O
the	O
plants	O
could	O
reach	O
up	O
to	O
44	O
°	O
C	O
.	O

The	O
greenhouse	O
was	O
illuminated	O
between	O
07.30	O
h	O
and	O
19.00	O
h	O
(	O
CET	O
=	O
Central	O
European	O
Time	O
)	O
.	O

During	O
the	O
day	O
-	O
time	O
,	O
the	O
artificial	O
illumination	O
was	O
switched	O
off	O
automatically	O
once	O
the	O
natural	O
irradiance	O
exceeded	O
about	O
45	O
μmol	O
photons	O
m−2	O
s−1	O
at	O
ground	O
level	O
.	O

At	O
full	O
sunshine	O
,	O
the	O
light	O
intensity	O
was	O
limited	O
by	O
automatically	O
operating	O
blinds	O
.	O

The	O
relative	O
humidity	O
(	O
r.h	O
.	O
)	O
of	O
the	O
air	O
was	O
regulated	O
by	O
overhead	O
misters	O
.	O

Despite	O
attempts	O
to	O
keep	O
the	O
r.h	O
.	O

above	O
60–70	O
%	O
large	O
axial	O
r.h	O
.	O

gradients	O
along	O
the	O
stem	O
of	O
the	O
liana	O
were	O
observed	O
during	O
sunny	O
days	O
(	O
see	O
below	O
)	O
.	O

The	O
ambient	O
temperature	O
and	O
relative	O
humidity	O
at	O
the	O
measuring	O
sites	O
were	O
determined	O
by	O
using	O
thermistors	O
(	O
Tinytag	O
;	O
RS	O
Components	O
GmbH	O
,	O
Mörfelden	O
-	O
Walldorf	O
,	O
Germany	O
)	O
.	O

Leaf	O
patch	O
clamp	O
pressure	O
probe	O
and	O
data	O
acquisition	O
The	O
pressure	O
sensor	O
chip	O
allows	O
pressure	O
measurements	O
up	O
to	O
100	O
kPa	O
.	O

The	O
sensor	O
consists	O
of	O
a	O
miniature	O
piezoresistive	O
Wheatstone	O
bridge	O
.	O

The	O
sensors	O
used	O
in	O
this	O
work	O
were	O
purchased	O
from	O
the	O
company	O
'	O
Raumedic	O
'	O
(	O
Helmbrechts	O
,	O
Germany	O
)	O
and	O
from	O
the	O
company	O
'	O
Keller	O
'	O
(	O
AG	O
,	O
Druckmesstechnik	O
;	O
Winterthur	O
,	O
Switzerland	O
)	O
.	O

However	O
,	O
it	O
has	O
to	O
be	O
pointed	O
out	O
that	O
any	O
other	O
miniaturized	O
pressure	O
or	O
force	O
sensor	O
could	O
be	O
used	O
.	O

The	O
sensor	O
chip	O
was	O
integrated	O
into	O
one	O
of	O
the	O
planar	O
circular	O
pads	O
of	O
a	O
spring	O
clamp	O
shown	O
schematically	O
in	O
Fig.	O
1	O
.	O

The	O
spring	O
clamp	O
consisted	O
of	O
two	O
curved	O
arms	O
bridged	O
by	O
a	O
spring	O
in	O
the	O
middle	O
(	O
Wolfcraft	O
GmbH	O
;	O
microfix	O
S	O
(	O
B3630Fz60	O
)	O
,	O
Kempenich	O
,	O
Germany	O
)	O
.	O

The	O
clamp	O
pressure	O
exerted	O
by	O
the	O
spring	O
on	O
the	O
leaf	O
,	O
Pclamp	O
,	O
could	O
be	O
varied	O
by	O
a	O
stiff	O
strap	O
(	O
made	O
of	O
synthetic	O
material	O
)	O
spanned	O
between	O
the	O
arms	O
of	O
the	O
spring	O
clip	O
at	O
the	O
handhold	O
site	O
(	O
Fig.	O
1	O
)	O
.	O

The	O
length	O
of	O
the	O
strap	O
and	O
thus	O
the	O
spring	O
load	O
acting	O
on	O
the	O
leaflet	O
between	O
the	O
two	O
pads	O
could	O
be	O
varied	O
by	O
regularly	O
punched	O
holes	O
(	O
as	O
in	O
a	O
belt	O
)	O
.	O

Calibration	O
of	O
the	O
sensor	O
chips	O
was	O
performed	O
by	O
pressurization	O
in	O
a	O
pressure	O
chamber	O
equipped	O
with	O
an	O
integrated	O
manometer	O
(	O
LEO	O
1	O
,	O
Keller	O
AG	O
,	O
Winterthur	O
,	O
Switzerland	O
)	O
.	O

The	O
readings	O
of	O
all	O
sensors	O
used	O
in	O
this	O
study	O
increased	O
linearly	O
with	O
pressure	O
in	O
the	O
range	O
between	O
0	O
kPa	O
and	O
100	O
kPa	O
.	O

The	O
pressure	O
sensitivity	O
of	O
the	O
various	O
sensors	O
was	O
found	O
to	O
be	O
almost	O
identical	O
for	O
all	O
probes	O
.	O

Before	O
use	O
the	O
probes	O
were	O
also	O
tested	O
for	O
temperature	O
-	O
sensitivity	O
in	O
an	O
accessible	O
climate	O
chamber	O
because	O
it	O
is	O
well	O
-	O
known	O
that	O
silicone	O
-	O
embedded	O
sensors	O
tend	O
to	O
become	O
temperature	O
-	O
sensitive	O
during	O
storage	O
.	O

Probes	O
were	O
subject	O
to	O
temperature	O
regimes	O
ranging	O
from	O
10	O
°	O
C	O
to	O
35	O
°	O
C	O
.	O

Probes	O
were	O
not	O
used	O
if	O
the	O
temperature	O
treatment	O
induced	O
a	O
pressure	O
change	O
larger	O
than	O
0.5	O
kPa	O
.	O

The	O
signals	O
of	O
the	O
leaf	O
patch	O
clamp	O
pressure	O
probe	O
were	O
transmitted	O
by	O
a	O
telemetry	O
system	O
(	O
teleBITcom	O
gmbh	O
,	O
Teltow	O
,	O
Germany	O
)	O
.	O

The	O
operating	O
distance	O
between	O
the	O
battery	O
-	O
powered	O
wireless	O
telemetric	O
transmitter	O
and	O
the	O
receiver	O
base	O
station	O
was	O
up	O
to	O
400	O
m.	O
Each	O
transmitter	O
read	O
,	O
amplified	O
,	O
and	O
converted	O
the	O
analogue	O
signals	O
of	O
the	O
pressure	O
sensor	O
into	O
digitalized	O
signals	O
.	O

The	O
data	O
were	O
sent	O
together	O
with	O
the	O
transmitter	O
ID	O
-	O
code	O
every	O
90	O
s	O
via	O
the	O
ISM	O
band	O
of	O
433	O
MHz	O
to	O
the	O
receiver	O
base	O
station	O
which	O
logged	O
and	O
transferred	O
the	O
data	O
to	O
a	O
personal	O
computer	O
or	O
to	O
a	O
GPRS	O
modem	O
linked	O
to	O
an	O
Internet	O
server	O
(	O
NTBB	O
Systemtechnik	O
GmbH	O
,	O
Zeuthen	O
,	O
Germany	O
)	O
for	O
analysis	O
and	O
archival	O
storage	O
.	O

For	O
sensor	O
calibration	O
and	O
data	O
recording	O
the	O
SENBIT	O
software	O
(	O
teleBITcom	O
gmbh	O
,	O
Teltow	O
,	O
Germany	O
)	O
was	O
used	O
.	O

The	O
software	O
allowed	O
communication	O
with	O
up	O
to	O
32	O
sensors	O
at	O
regular	O
short	O
intervals	O
(	O
90	O
s	O
to	O
5	O
min	O
)	O
.	O

In	O
this	O
study	O
,	O
up	O
to	O
10	O
sensor	O
/	O
transmitter	O
units	O
were	O
installed	O
at	O
different	O
heights	O
on	O
the	O
two	O
lianas	O
.	O

Data	O
transfer	O
to	O
the	O
Internet	O
server	O
operated	O
without	O
any	O
problem	O
during	O
the	O
entire	O
experimental	O
period	O
.	O

However	O
,	O
for	O
safety	O
reasons	O
hard	O
-	O
wired	O
conventional	O
data	O
acquisition	O
was	O
also	O
performed	O
using	O
dataloggers	O
(	O
Raumedic	O
,	O
Helmbrechts	O
,	O
Germany	O
)	O
.	O

The	O
dataloggers	O
were	O
controlled	O
by	O
a	O
computer	O
program	O
that	O
provided	O
functions	O
for	O
data	O
storage	O
and	O
sensor	O
calibration	O
.	O

Data	O
were	O
transferred	O
regularly	O
from	O
the	O
dataloggers	O
to	O
a	O
personal	O
computer	O
.	O

Cell	O
turgor	O
pressure	O
probe	O
Turgor	O
pressure	O
measurements	O
were	O
performed	O
on	O
leaflets	O
of	O
the	O
10-m	O
tall	O
liana	O
at	O
c.	O
0.2	O
m	O
height	O
above	O
the	O
roots	O
.	O

The	O
construction	O
and	O
function	O
of	O
the	O
cell	O
turgor	O
pressure	O
probe	O
has	O
been	O
described	O
elsewhere	O
(	O
Zimmermann	O
et	O
al.	O
,	O
1969	O
,	O
2004	O
)	O
.	O

Briefly	O
,	O
the	O
microcapillary	O
was	O
filled	O
with	O
oil	O
up	O
to	O
the	O
very	O
tip	O
and	O
was	O
then	O
inserted	O
into	O
the	O
upper	O
leaflet	O
surface	O
between	O
the	O
main	O
vein	O
and	O
the	O
leaflet	O
edge	O
.	O

Insertion	O
was	O
made	O
under	O
a	O
small	O
overpressure	O
(	O
about	O
20	O
kPa	O
)	O
achieved	O
by	O
appropriate	O
displacement	O
of	O
the	O
metal	O
rod	O
in	O
the	O
probe	O
in	O
order	O
to	O
avoid	O
tip	O
clogging	O
.	O

Penetration	O
was	O
stopped	O
upon	O
reaching	O
the	O
mesophyll	O
cell	O
layer	O
and	O
formation	O
of	O
a	O
stable	O
oil	O
/	O
sap	O
meniscus	O
within	O
the	O
tip	O
region	O
of	O
the	O
microcapillary	O
of	O
the	O
probe	O
.	O

During	O
the	O
measurements	O
it	O
was	O
regularly	O
proved	O
whether	O
the	O
tip	O
was	O
clogged	O
or	O
not	O
by	O
appropriate	O
displacement	O
of	O
the	O
metal	O
rod	O
.	O

Theoretical	O
background	O
The	O
input	O
pressure	O
,	O
Pin	O
,	O
experienced	O
by	O
the	O
cells	O
in	O
a	O
leaf	O
patch	O
is	O
equal	O
to	O
the	O
clamp	O
pressure	O
,	O
Pclamp	O
,	O
only	O
if	O
the	O
pressure	O
signal	O
is	O
transferred	O
lossless	O
to	O
the	O
cells	O
in	O
the	O
leaves	O
.	O

However	O
,	O
losses	O
usually	O
occur	O
due	O
to	O
the	O
compressibility	O
and	O
the	O
deformability	O
of	O
the	O
silicone	O
of	O
the	O
pressure	O
sensor	O
as	O
well	O
as	O
of	O
the	O
compressibility	O
of	O
the	O
cuticle	O
and	O
other	O
structural	O
elements	O
of	O
the	O
leaf	O
.	O

Therefore	O
,	O
theory	O
shows	O
that	O
only	O
a	O
fraction	O
of	O
Pclamp	O
may	O
arrive	O
at	O
the	O
cells	O
,	O
i.e.	O
that	O
the	O
attenuation	O
factor	O
,	O
Fa	O
=	O
Pin	O
/	O
Pclamp	O
,	O
is	O
smaller	O
than	O
unity	O
.	O

Fa	O
depends	O
on	O
the	O
individual	O
leaf	O
properties	O
.	O

Fa	O
can	O
be	O
assumed	O
to	O
be	O
constant	O
(	O
and	O
leaf	O
thickness	O
changes	O
are	O
negligible	O
)	O
if	O
the	O
structural	O
elements	O
are	O
completely	O
pre	O
-	O
compressed	O
by	O
application	O
of	O
an	O
appropriate	O
Pclamp	O
.	O

If	O
Pclamp	O
is	O
kept	O
constant	O
during	O
the	O
following	O
experimental	O
period	O
,	O
Pin	O
is	O
constant	O
and	O
the	O
output	O
pressure	O
,	O
Pp	O
,	O
is	O
only	O
determined	O
by	O
the	O
cell	O
transfer	O
function	O
,	O
Tf	O
(	O
V	O
)	O
,	O
where	O
V	O
is	O
the	O
leaf	O
patch	O
volume	O
.	O

In	O
other	O
words	O
,	O
Tf	O
(	O
V	O
)	O
determines	O
the	O
fraction	O
of	O
Pin	O
sensed	O
by	O
the	O
probe	O
.	O

It	O
is	O
dimensionless	O
and	O
assumes	O
values	O
between	O
zero	O
and	O
unity:	O
(	O
1	O
)	O
Tf	O
depends	O
on	O
the	O
volume	O
of	O
the	O
leaf	O
patch	O
,	O
V	O
,	O
at	O
constant	O
ambient	O
temperature	O
,	O
T:	O
(	O
2	O
)	O
δV	O
depends	O
on	O
changes	O
in	O
cell	O
turgor	O
pressure	O
,	O
δPc	O
,	O
as	O
follows:	O
(	O
3	O
)	O
where	O
op	O
is	O
the	O
average	O
volumetric	O
elastic	O
modulus	O
of	O
the	O
clamped	O
tissue	O
(	O
Philip	O
,	O
1958	O
)	O
.	O

op	O
is	O
a	O
very	O
complex	O
parameter	O
and	O
will	O
be	O
dictated	O
by	O
the	O
turgor	O
pressure	O
in	O
the	O
turgescent	O
state	O
.	O

For	O
a	O
first	O
approximation	O
it	O
is	O
assumed	O
that	O
op	O
increases	O
linearly	O
with	O
Pc	O
(	O
support	O
for	O
this	O
assumption	O
is	O
given	O
by	O
Zimmermann	O
and	O
Steudle	O
,	O
1978	O
;	O
Zimmermann	O
and	O
Hüsken	O
,	O
1980	O
;	O

Wendler	O
et	O
al.	O
,	O
1983	O
)	O
:	O
(	O
4	O
)	O
where	O
a	O
and	O
b	O
are	O
constants	O
for	O
individual	O
leaf	O
properties	O
.	O

Because	O
of	O
the	O
viscoelastic	O
properties	O
of	O
the	O
cell	O
wall	O
,	O
the	O
magnitude	O
of	O
the	O
constants	O
depends	O
on	O
the	O
duration	O
of	O
the	O
external	O
pressure	O
application	O
(	O
Zimmermann	O
and	O
Hüsken	O
,	O
1980	O
)	O
.	O

The	O
constants	O
are	O
relatively	O
large	O
if	O
rapid	O
turgor	O
pressure	O
changes	O
are	O
induced	O
(	O
e.g.	O
by	O
using	O
the	O
cell	O
turgor	O
pressure	O
probe	O
)	O
,	O
whereas	O
slow	O
turgor	O
pressure	O
changes	O
(	O
e.g.	O
under	O
transpirational	O
conditions	O
)	O
result	O
in	O
small	O
values	O
.	O

Combining	O
equations	O
2–4	O
leads	O
to	O
equation	O
5.	O
(	O
5	O
)	O
Equation	O
5	O
can	O
be	O
integrated	O
by	O
assuming	O
for	O
a	O
first	O
approximation	O
that	O
at	O
Pc=0	O
Tf=1	O
and	O
that	O
the	O
internal	O
osmotic	O
pressure	O
of	O
the	O
cells	O
remained	O
constant	O
.	O

After	O
appropriate	O
re	O
-	O
arrangements	O
equation	O
6	O
is	O
obtained:	O
(	O
6	O
)	O
and	O
,	O
respectively	O
,	O
if	O
the	O
denominator	O
is	O
replaced	O
by	O
equation	O
4:	O
(	O
7	O
)	O
Introducing	O
equation	O
6	O
into	O
equation	O
1	O
yields	O
the	O
wanted	O
relationship	O
between	O
the	O
parameters	O
Pp	O
and	O
Pin:	O
(	O
8	O
)	O
Equation	O
8	O
can	O
be	O
verified	O
experimentally	O
.	O

Inspection	O
of	O
the	O
equation	O
shows	O
that	O
the	O
patch	O
clamp	O
pressure	O
,	O
Pp	O
,	O
is	O
a	O
power	O
function	O
of	O
the	O
turgor	O
pressure	O
,	O
Pc	O
.	O

The	O
exponent	O
of	O
the	O
function	O
is	O
equal	O
to	O
or	O
smaller	O
than	O
unity	O
.	O

If	O
a=1	O
and	O
b	O
<	O
<	O
Pc	O
,	O
equation	O
8	O
turns	O
into	O
Pp	O
=	O
b	O
/	O
Pc	O
,	O
i.e.	O
both	O
parameters	O
are	O
directly	O
reciprocally	O
coupled	O
with	O
each	O
other	O
.	O

Thus	O
Tf	O
assumes	O
low	O
values	O
if	O
Pc	O
is	O
high	O
and	O
,	O
vice	O
versa	O
,	O
a	O
value	O
close	O
to	O
unity	O
if	O
Pc	O
is	O
close	O
to	O
zero	O
.	O

Using	O
appropriate	O
values	O
for	O
a	O
and	O
b	O
for	O
a	O
given	O
leaf	O
(	O
see	O
below	O
)	O
it	O
can	O
be	O
shown	O
that	O
below	O
Pc=100	O
kPa	O
,	O
Pp	O
increases	O
dramatically	O
.	O

This	O
means	O
that	O
the	O
transfer	O
function	O
responds	O
very	O
sensitively	O
upon	O
loss	O
of	O
complete	O
turgor	O
pressure	O
.	O

In	O
the	O
derivation	O
of	O
equation	O
8	O
it	O
was	O
assumed	O
that	O
op	O
is	O
temperature	O
-	O
independent	O
.	O

However	O
,	O
temperature	O
effects	O
on	O
cell	O
elasticity	O
are	O
well	O
-	O
known	O
,	O
although	O
they	O
are	O
not	O
very	O
large	O
in	O
the	O
temperature	O
range	O
investigated	O
here	O
(	O
see	O
,	O
for	O
example	O
,	O
Petersen	O
et	O
al.	O
,	O
1982	O
;	O
Niklas	O
,	O
1992	O
;	O
Hogan	O
and	O
Niklas	O
,	O
2004	O
;	O
Edelmann	O
et	O
al.	O
,	O
2005	O
)	O
.	O

Temperature	O
effects	O
on	O
op	O
can	O
not	O
be	O
excluded	O
if	O
different	O
values	O
for	O
the	O
Pclamp	O
,	O
and	O
,	O
in	O
turn	O
,	O
for	O
the	O
input	O
pressure	O
,	O
Pin	O
,	O
are	O
selected	O
,	O
as	O
well	O
as	O
if	O
significantly	O
different	O
values	O
for	O
the	O
constants	O
a	O
and	O
b	O
are	O
assumed	O
for	O
optimum	O
fitting	O
of	O
the	O
Pp	O
=	O
f	O
(	O
Pc	O
)	O
curves	O
.	O

Therefore	O
,	O
in	O
the	O
case	O
of	O
large	O
temperature	O
gradients	O
as	O
observed	O
here	O
(	O
see	O
Figs	O
2	O
and	O
3	O
)	O
only	O
the	O
relative	O
,	O
but	O
not	O
the	O
absolute	O
changes	O
in	O
Pp	O
measured	O
at	O
the	O
different	O
heights	O
can	O
be	O
compared	O
with	O
each	O
other	O
.	O

However	O
,	O
Pp	O
values	O
measured	O
at	O
the	O
same	O
height	O
are	O
still	O
comparable	O
and	O
give	O
information	O
about	O
the	O
turgescence	O
,	O
i.e.	O
about	O
the	O
water	O
status	O
of	O
the	O
leaf	O
cells	O
.	O

Results	O
The	O
leaf	O
patch	O
clamp	O
pressure	O
probe	O
was	O
clamped	O
about	O
2	O
cm	O
away	O
from	O
the	O
edge	O
of	O
a	O
leaflet	O
of	O
the	O
compound	O
leaves	O
.	O

Leaflets	O
of	O
similar	O
size	O
(	O
176±58	O
cm2	O
,	O
n=12	O
)	O
were	O
used	O
.	O

Inspection	O
of	O
the	O
leaf	O
patches	O
after	O
removal	O
of	O
the	O
probes	O
under	O
the	O
microscope	O
revealed	O
no	O
changes	O
in	O
leaflet	O
appearance	O
beneath	O
the	O
pads	O
,	O
even	O
after	O
several	O
weeks	O
.	O

Lesions	O
on	O
the	O
leaves	O
were	O
never	O
found	O
.	O

Only	O
occasionally	O
were	O
very	O
slight	O
impressions	O
of	O
the	O
pads	O
on	O
the	O
leaflet	O
surface	O
observed	O
.	O

Clamping	O
of	O
the	O
leaves	O
could	O
be	O
performed	O
at	O
any	O
time	O
of	O
the	O
day	O
.	O

Clamp	O
pressures	O
,	O
Pclamp	O
,	O
applied	O
to	O
the	O
leaves	O
were	O
of	O
the	O
order	O
of	O
80–200	O
kPa	O
.	O

The	O
optimum	O
value	O
for	O
Pclamp	O
of	O
a	O
given	O
leaf	O
has	O
to	O
be	O
found	O
empirically	O
.	O

Experience	O
shows	O
that	O
Pclamp	O
values	O
could	O
be	O
considered	O
as	O
optimal	O
if	O
the	O
output	O
pressure	O
Pp	O
assumed	O
values	O
between	O
10	O
kPa	O
and	O
25	O
kPa	O
upon	O
clamping	O
in	O
the	O
early	O
morning	O
(	O
when	O
turgor	O
pressure	O
was	O
high	O
)	O
or	O
between	O
50	O
kPa	O
and	O
70	O
kPa	O
upon	O
clamping	O
around	O
noon	O
or	O
towards	O
early	O
afternoon	O
(	O
when	O
turgor	O
pressure	O
was	O
usually	O
low	O
)	O
.	O

The	O
magnitude	O
of	O
Pp	O
depended	O
on	O
the	O
compressibility	O
and	O
deformability	O
properties	O
of	O
the	O
individual	O
leaves	O
which	O
may	O
vary	O
considerably	O
due	O
to	O
age	O
,	O
morphology	O
,	O
leaf	O
thickness	O
,	O
abiotic	O
factors	O
etc	O
.	O

The	O
magnitude	O
of	O
Pclamp	O
had	O
no	O
effect	O
on	O
the	O
diurnal	O
profiles	O
of	O
Pp	O
,	O
in	O
response	O
to	O
changes	O
in	O
microclimate	O
and/or	O
changes	O
in	O
the	O
irrigation	O
regime	O
.	O

Probes	O
clamped	O
on	O
the	O
same	O
leaflet	O
or	O
nearby	O
leaflets	O
of	O
leaves	O
responded	O
almost	O
identically	O
upon	O
temporary	O
changes	O
in	O
transpiration	O
and/or	O
water	O
supply	O
even	O
if	O
the	O
Pclamp	O
values	O
were	O
different	O
due	O
to	O
different	O
leaf	O
thickness	O
as	O
well	O
as	O
local	O
compressibility	O
and	O
deformability	O
properties	O
(	O
data	O
not	O
shown	O
)	O
.	O

This	O
was	O
found	O
over	O
the	O
entire	O
height	O
of	O
the	O
plants	O
.	O

Screening	O
experiments	O
proved	O
further	O
that	O
a	O
high	O
surface	O
roughness	O
prevented	O
a	O
uniform	O
contact	O
between	O
the	O
pads	O
of	O
the	O
probe	O
and	O
the	O
leaf	O
.	O

Non	O
-	O
uniform	O
contact	O
resulted	O
in	O
a	O
reduced	O
pressure	O
response	O
of	O
the	O
probe	O
(	O
data	O
not	O
shown	O
)	O
.	O

Thus	O
,	O
in	O
order	O
to	O
obtain	O
maximum	O
resolution	O
of	O
microclimate	O
-	O
induced	O
and/or	O
plant	O
-	O
based	O
effects	O
on	O
the	O
Pp	O
values	O
,	O
it	O
was	O
crucial	O
that	O
the	O
probe	O
was	O
placed	O
on	O
relatively	O
smooth	O
areas	O
,	O
i.e.	O
preferentially	O
between	O
the	O
veins	O
rather	O
than	O
on	O
the	O
veins	O
in	O
order	O
to	O
guarantee	O
a	O
uniform	O
pressure	O
transmission	O
.	O

It	O
also	O
turned	O
out	O
that	O
areas	O
with	O
lesions	O
or	O
covered	O
with	O
dust	O
should	O
be	O
avoided	O
.	O

Probably	O
due	O
to	O
the	O
absence	O
of	O
dust	O
,	O
high	O
resolution	O
results	O
were	O
obtained	O
when	O
the	O
sensor	O
-	O
containing	O
pad	O
faced	O
the	O
abaxial	O
side	O
,	O
but	O
not	O
the	O
adaxial	O
side	O
of	O
the	O
leaf	O
.	O

Diurnal	O
changes	O
in	O
the	O
patch	O
clamp	O
pressure	O
Figure	O
2A	O
represents	O
Pp	O
recordings	O
conducted	O
on	O
the	O
10	O
m	O
tall	O
liana	O
on	O
24	O
May	O
and	O
25	O
May	O
,	O
2007	O
.	O

The	O
plant	O
was	O
well	O
-	O
watered	O
before	O
the	O
beginning	O
of	O
the	O
measurements	O
(	O
22	O
May	O
)	O
and	O
was	O
also	O
watered	O
regularly	O
during	O
the	O
experimental	O
period	O
.	O

The	O
sufficient	O
supply	O
of	O
the	O
leaves	O
with	O
water	O
was	O
indicated	O
by	O
high	O
turgor	O
pressure	O
values	O
of	O
c.	O
500	O
kPa	O
at	O
predawn	O
and	O
guttation	O
up	O
to	O
a	O
height	O
of	O
6	O
m	O
around	O
sunrise	O
(	O
see	O
also	O
Thürmer	O
et	O
al.	O
,	O
1999	O
)	O
.	O

Diurnal	O
changes	O
of	O
the	O
Pp	O
values	O
were	O
recorded	O
simultaneously	O
at	O
0.2	O
m	O
,	O
6	O
m	O
,	O
and	O
10	O
m	O
height	O
.	O

The	O
corresponding	O
diurnal	O
changes	O
in	O
the	O
ambient	O
temperature	O
,	O
T	O
,	O
and	O
relative	O
humidity	O
,	O
r.h	O
.	O
,	O
measured	O
close	O
to	O
the	O
sites	O
of	O
the	O
patch	O
clamp	O
pressure	O
probes	O
,	O
are	O
given	O
in	O
Fig.	O
2B	O
and	O
C.	O
It	O
was	O
very	O
sunny	O
on	O
24	O
May	O
resulting	O
in	O
a	O
rapid	O
heating	O
-	O
up	O
of	O
the	O
greenhouse	O
,	O
particularly	O
in	O
the	O
upper	O
part	O
.	O

This	O
led	O
to	O
the	O
development	O
of	O
large	O
vertical	O
gradients	O
in	O
T	O
and	O
r.h	O
.	O

along	O
the	O
stem	O
of	O
the	O
liana	O
(	O
Fig.	O
2B	O
,	O
C	O
)	O
.	O

Because	O
sunlight	O
was	O
dimmed	O
by	O
operation	O
of	O
the	O
automatic	O
blinds	O
at	O
noon	O
(	O
see	O
Materials	O
and	O
methods	O
)	O
the	O
gradients	O
did	O
not	O
reach	O
maximum	O
values	O
before	O
the	O
afternoon	O
.	O

Between	O
15.30	O
h	O
and	O
16.30	O
h	O
an	O
ambient	O
temperature	O
of	O
44	O
°	O
C	O
and	O
a	O
relative	O
humidity	O
of	O
20	O
%	O
were	O
recorded	O
at	O
the	O
top	O
of	O
the	O
liana	O
,	O
whereas	O
at	O
0.2	O
m	O
height	O
T	O
and	O
r.h	O
.	O
were	O
27	O
°	O
C	O
and	O
70	O
%	O
,	O
respectively	O
.	O

The	O
gradients	O
in	O
T	O
and	O
r.h	O
.	O

disappeared	O
at	O
c.	O
22.00	O
h.	O
Due	O
to	O
the	O
dense	O
foliage	O
of	O
the	O
plant	O
above	O
c.	O
7	O
m	O
and	O
due	O
to	O
light	O
dimming	O
by	O
the	O
blinds	O
,	O
leaves	O
closer	O
to	O
the	O
ground	O
only	O
became	O
exposed	O
to	O
direct	O
sunshine	O
towards	O
the	O
early	O
afternoon	O
.	O

In	O
contrast	O
to	O
24	O
May	O
,	O
the	O
following	O
day	O
was	O
cloudy	O
until	O
noon	O
.	O

Thus	O
,	O
leaves	O
in	O
the	O
upper	O
part	O
of	O
the	O
liana	O
became	O
fully	O
exposed	O
to	O
bright	O
sunshine	O
first	O
around	O
14.00	O
h	O
as	O
indicated	O
by	O
the	O
rapid	O
increase	O
in	O
T	O
and	O
the	O
corresponding	O
decrease	O
of	O
r.h	O
.	O

above	O
a	O
height	O
of	O
6	O
m	O
(	O
Fig.	O
2B	O
,	O
C	O
)	O
.	O

Despite	O
the	O
strongly	O
delayed	O
exposure	O
of	O
the	O
leaves	O
to	O
sunshine	O
,	O
comparable	O
maximum	O
values	O
for	O
T	O
and	O
r.h	O
.	O

at	O
the	O
three	O
measuring	O
sites	O
,	O
as	O
well	O
as	O
vertical	O
gradients	O
in	O
T	O
and	O
r.h	O
.	O

of	O
comparable	O
size	O
,	O
were	O
measured	O
between	O
15.30	O
h	O
and	O
16.30	O
h	O
as	O
on	O
the	O
day	O
before	O
.	O

Inspection	O
of	O
Fig.	O
2	O
shows	O
that	O
the	O
diurnal	O
changes	O
of	O
T	O
and	O
r.h	O
.	O

at	O
the	O
three	O
measuring	O
sites	O
are	O
reflected	O
in	O
corresponding	O
changes	O
of	O
Pp	O
.	O

During	O
the	O
nights	O
the	O
Pp	O
values	O
were	O
low	O
.	O

After	O
sunrise	O
at	O
04.24	O
h	O
the	O
Pp	O
values	O
remained	O
low	O
for	O
further	O
4–5	O
h	O
,	O
except	O
at	O
6	O
m	O
height	O
where	O
a	O
slight	O
and	O
continuous	O
increase	O
in	O
the	O
Pp	O
values	O
was	O
very	O
often	O
recorded	O
.	O

After	O
about	O
09.00	O
h	O
the	O
Pp	O
values	O
increased	O
over	O
the	O
entire	O
height	O
of	O
the	O
liana	O
.	O

Peaking	O
of	O
the	O
Pp	O
values	O
occurred	O
between	O
15.30	O
h	O
and	O
16.30	O
h	O
at	O
all	O
heights	O
when	O
the	O
T	O
and	O
r.h	O
.	O

gradients	O
reached	O
maximum	O
values	O
.	O

Towards	O
the	O
evening	O
the	O
Pp	O
values	O
decreased	O
again	O
in	O
order	O
to	O
reach	O
the	O
original	O
low	O
values	O
at	O
c.	O
22.00	O
h.	O
Until	O
peaking	O
in	O
the	O
afternoon	O
,	O
more	O
or	O
less	O
pronounced	O
fluctuations	O
of	O
the	O
Pp	O
values	O
were	O
seen	O
.	O

A	O
part	O
of	O
these	O
fluctuations	O
seemed	O
to	O
be	O
correlated	O
with	O
changes	O
in	O
the	O
local	O
ambient	O
temperature	O
,	O
relative	O
humidity	O
and/or	O
with	O
a	O
temporary	O
exposure	O
of	O
the	O
clamped	O
leaflet	O
to	O
sunshine	O
(	O
compare	O
Fig.	O
2A	O
with	O
Fig.	O
2B	O
,	O
C	O
)	O
.	O

However	O
,	O
there	O
was	O
also	O
a	O
considerable	O
number	O
of	O
fluctuations	O
which	O
could	O
not	O
be	O
traced	O
back	O
to	O
changes	O
in	O
the	O
microclimate	O
.	O

An	O
example	O
can	O
be	O
found	O
in	O
Fig.	O
2A	O
(	O
arrow	O
)	O
.	O

The	O
peaking	O
of	O
the	O
Pp	O
value	O
measured	O
at	O
a	O
height	O
of	O
0.2	O
m	O
around	O
14.00	O
h	O
is	O
obviously	O
not	O
induced	O
by	O
changes	O
in	O
the	O
local	O
temperature	O
and	O
relative	O
humidity	O
or	O
by	O
exposure	O
to	O
sunshine	O
.	O

Similar	O
diurnal	O
changes	O
in	O
Pp	O
,	O
T	O
,	O
and	O
r.h	O
.	O
were	O
also	O
found	O
for	O
the	O
4.5	O
m	O
tall	O
liana	O
in	O
the	O
backstage	O
of	O
the	O
greenhouse	O
(	O
data	O
not	O
shown	O
)	O
.	O

Figure	O
3	O
shows	O
long	O
-	O
term	O
Pp	O
,	O
T	O
,	O
and	O
r.h	O
.	O

measurements	O
performed	O
at	O
0.2	O
m	O
,	O
6	O
m	O
,	O
and	O
10	O
m	O
height	O
in	O
late	O
summer	O
2007	O
.	O

In	O
contrast	O
to	O
the	O
experimental	O
conditions	O
in	O
late	O
spring	O
(	O
Fig.	O
2	O
)	O
the	O
liana	O
had	O
been	O
watered	O
only	O
sporadically	O
during	O
the	O
weeks	O
before	O
the	O
measurements	O
.	O

The	O
soil	O
was	O
extremely	O
dry	O
and	O
no	O
guttation	O
was	O
observed	O
at	O
predawn	O
,	O
even	O
at	O
0.2	O
m	O
height	O
.	O

Turgor	O
pressure	O
measurements	O
performed	O
at	O
0.2	O
m	O
height	O
yielded	O
values	O
below	O
250	O
kPa	O
at	O
predawn	O
.	O

Continuous	O
irrigation	O
was	O
started	O
at	O
10.00	O
h	O
on	O
28	O
August	O
(	O
c.	O
400	O
l	O
d−1	O
)	O
.	O

Guttation	O
occurred	O
at	O
0.2	O
m	O
height	O
,	O
but	O
not	O
at	O
6	O
m	O
height	O
on	O
1	O
September	O
.	O

At	O
sunrise	O
(	O
05.25	O
h	O
)	O
,	O
turgor	O
pressures	O
of	O
c.	O
500	O
kPa	O
were	O
recorded	O
at	O
the	O
base	O
of	O
the	O
liana	O
.	O

Guttation	O
at	O
6	O
m	O
height	O
was	O
still	O
not	O
observed	O
on	O
3	O
September	O
indicating	O
that	O
the	O
hydration	O
state	O
of	O
the	O
plant	O
was	O
still	O
less	O
than	O
in	O
the	O
last	O
week	O
of	O
May.	O
The	O
T	O
and	O
r.h	O
.	O

profiles	O
during	O
the	O
end	O
of	O
summer	O
were	O
also	O
different	O
to	O
those	O
in	O
late	O
spring	O
(	O
compare	O
Fig.	O
2B	O
,	O
C	O
with	O
Fig.	O
3B	O
,	O
C	O
)	O
.	O

On	O
28	O
August	O
when	O
irrigation	O
started	O
it	O
was	O
sunny	O
.	O

Similarly	O
to	O
May	O
,	O
peak	O
values	O
of	O
T	O
and	O
r.h	O
.	O
were	O
reached	O
at	O
c.	O
15.30	O
h.	O
However	O
,	O
temperatures	O
at	O
the	O
top	O
of	O
the	O
plant	O
did	O
not	O
exceed	O
35	O
°	O
C	O
and	O
r.h	O
.	O
did	O
not	O
drop	O
below	O
40	O
%	O
.	O

Accordingly	O
,	O
the	O
vertical	O
T	O
and	O
r.h	O
.	O

gradients	O
were	O
smaller	O
than	O
those	O
measured	O
at	O
the	O
end	O
of	O
May.	O
On	O
29	O
August	O
,	O
when	O
it	O
became	O
very	O
rainy	O
and	O
light	O
irradiance	O
dropped	O
dramatically	O
,	O
gradients	O
in	O
T	O
and	O
r.h	O
.	O

of	O
slightly	O
decreased	O
size	O
were	O
still	O
recorded	O
.	O

Peaking	O
of	O
T	O
and	O
r.h	O
.	O

occurred	O
at	O
c.	O
14.30	O
h.	O
T	O
and	O
r.h	O
.	O

gradients	O
did	O
not	O
develop	O
in	O
the	O
following	O
three	O
days	O
which	O
were	O
very	O
cloudy	O
and	O
rainy	O
.	O

An	O
almost	O
constant	O
temperature	O
of	O
c.	O
25	O
°	O
C	O
and	O
a	O
relative	O
humidity	O
of	O
80	O
%	O
were	O
measured	O
on	O
the	O
ground	O
and	O
at	O
the	O
top	O
of	O
the	O
greenhouse	O
throughout	O
the	O
day	O
;	O
light	O
irradiance	O
did	O
not	O
exceed	O
40	O
μmol	O
photons	O
m−2	O
s−1	O
.	O

Only	O
on	O
31	O
August	O
,	O
did	O
the	O
rain	O
stop	O
and	O
the	O
upper	O
part	O
of	O
the	O
liana	O
was	O
exposed	O
to	O
sunshine	O
for	O
1–2	O
h	O
and	O
thus	O
small	O
T	O
and	O
r.h	O
.	O

gradients	O
developed	O
.	O

The	O
following	O
days	O
of	O
2	O
and	O
3	O
September	O
were	O
partly	O
cloudy	O
and	O
sunny	O
and	O
the	O
peaking	O
of	O
T	O
and	O
r.h	O
.	O

occurred	O
at	O
c.	O
13.00	O
h.	O
The	O
upper	O
,	O
but	O
not	O
the	O
lower	O
part	O
of	O
the	O
liana	O
was	O
exposed	O
to	O
sunshine	O
for	O
several	O
hours	O
.	O

This	O
resulted	O
in	O
the	O
formation	O
of	O
T	O
and	O
r.h	O
.	O

gradients	O
.	O

The	O
size	O
of	O
the	O
gradients	O
was	O
similar	O
to	O
that	O
measured	O
on	O
29	O
August	O
.	O

Inspection	O
of	O
Fig.	O
3A	O
indicates	O
that	O
peaking	O
of	O
the	O
Pp	O
values	O
coincided	O
with	O
peaking	O
of	O
r.h	O
.	O

and	O
T	O
in	O
Fig.	O
3B	O
and	O
C.	O
Figure	O
3A	O
shows	O
further	O
that	O
the	O
peak	O
amplitude	O
of	O
the	O
Pp	O
values	O
recorded	O
at	O
the	O
three	O
measuring	O
sites	O
decreased	O
continuously	O
from	O
28	O
August	O
whereas	O
the	O
low	O
Pp	O
values	O
at	O
the	O
nights	O
remained	O
unaltered	O
.	O

The	O
peak	O
amplitude	O
measured	O
on	O
29	O
August	O
was	O
only	O
slightly	O
lower	O
than	O
that	O
measured	O
on	O
the	O
day	O
before	O
,	O
the	O
peak	O
amplitude	O
was	O
rather	O
low	O
on	O
30	O
August	O
.	O

It	O
remained	O
at	O
this	O
low	O
level	O
until	O
2	O
September	O
,	O
except	O
that	O
on	O
31	O
August	O
the	O
peak	O
amplitude	O
at	O
the	O
three	O
measuring	O
sites	O
increased	O
slightly	O
,	O
presumably	O
because	O
of	O
the	O
short	O
-	O
time	O
exposure	O
of	O
the	O
upper	O
leaves	O
to	O
sun	O
(	O
see	O
above	O
)	O
.	O

Comparison	O
of	O
the	O
diurnal	O
changes	O
in	O
the	O
Pp	O
values	O
with	O
the	O
corresponding	O
T	O
and	O
r.h	O
.	O

changes	O
in	O
Fig.	O
3B	O
and	O
C	O
indicates	O
that	O
part	O
of	O
the	O
changes	O
in	O
the	O
peak	O
amplitude	O
of	O
the	O
Pp	O
values	O
were	O
induced	O
by	O
changes	O
in	O
the	O
environmental	O
parameters	O
.	O

However	O
,	O
part	O
of	O
the	O
changes	O
must	O
obviously	O
be	O
attributed	O
to	O
irrigation	O
.	O

This	O
conclusion	O
can	O
be	O
drawn	O
if	O
,	O
for	O
example	O
,	O
the	O
peaking	O
of	O
Pp	O
on	O
2	O
and	O
3	O
September	O
is	O
compared	O
with	O
the	O
peaking	O
of	O
Pp	O
on	O
29	O
August	O
.	O

Despite	O
the	O
comparable	O
size	O
of	O
the	O
T	O
and	O
r.h	O
.	O

gradients	O
,	O
the	O
peak	O
Pp	O
values	O
were	O
much	O
smaller	O
,	O
particularly	O
at	O
0.2	O
m	O
height	O
,	O
on	O
2	O
and	O
3	O
September	O
compared	O
with	O
29	O
August	O
.	O

Plots	O
of	O
the	O
Pp	O
values	O
measured	O
at	O
6	O
m	O
and	O
10	O
m	O
height	O
on	O
24	O
May	O
,	O
28	O
August	O
,	O
and	O
2	O
September	O
against	O
r.h	O
.	O

(	O
or	O
against	O
T	O
since	O
both	O
parameters	O
were	O
usually	O
closely	O
related	O
)	O
also	O
support	O
the	O
view	O
that	O
the	O
local	O
microclimate	O
is	O
not	O
the	O
only	O
factor	O
which	O
determined	O
the	O
magnitude	O
of	O
the	O
Pp	O
values	O
at	O
the	O
three	O
measuring	O
sites	O
.	O

Figure	O
4	O
shows	O
that	O
the	O
Pp	O
values	O
recorded	O
at	O
6	O
m	O
and	O
10	O
m	O
height	O
increased	O
with	O
decreasing	O
r.h	O
.	O

from	O
c.	O
09.00	O
h	O
until	O
r.h	O
.	O
reached	O
the	O
minimum	O
value	O
(	O
and	O
T	O
the	O
maximum	O
value	O
,	O
respectively	O
)	O
,	O
when	O
with	O
the	O
progression	O
of	O
the	O
day	O
r.h	O
.	O

increased	O
and	O
T	O
decreased	O
,	O
Pp	O
decreased	O
again	O
.	O

This	O
decrease	O
was	O
much	O
faster	O
than	O
expected	O
in	O
the	O
light	O
of	O
the	O
preceding	O
r.h	O
.-	O
induced	O
increase	O
of	O
Pp	O
if	O
the	O
plant	O
was	O
well	O
-	O
watered	O
(	O
24	O
May	O
;	O
Fig.	O
4A	O
,	O
B	O
)	O
.	O

Refilling	O
of	O
the	O
leaf	O
cells	O
was	O
apparently	O
enhanced	O
by	O
the	O
high	O
hydration	O
state	O
of	O
the	O
plant	O
.	O

By	O
contrast	O
,	O
when	O
the	O
liana	O
had	O
not	O
been	O
irrigated	O
well	O
(	O
28	O
August	O
,	O
Fig.	O
4C	O
,	O
D	O
)	O
both	O
kinetics	O
of	O
the	O
changes	O
of	O
Pp	O
with	O
r.h	O
.	O
were	O
comparable	O
.	O

The	O
low	O
hydration	O
state	O
of	O
the	O
plant	O
apparently	O
delayed	O
cell	O
refilling	O
.	O

After	O
4	O
d	O
irrigation	O
(	O
2	O
September	O
)	O
,	O
the	O
low	O
value	O
of	O
Pp	O
recovered	O
at	O
relatively	O
low	O
r.h	O
.	O

as	O
in	O
May	O
at	O
10	O
m	O
height	O
(	O
Fig.	O
4F	O
)	O
,	O
but	O
not	O
at	O
6	O
m	O
height	O
(	O
Fig.	O
4E	O
)	O
.	O

Recovery	O
of	O
the	O
low	O
Pp	O
values	O
at	O
this	O
height	O
occurred	O
,	O
however	O
,	O
at	O
significantly	O
lower	O
r.h	O
.	O

than	O
on	O
28	O
August	O
,	O
indicating	O
that	O
rehydration	O
of	O
the	O
leaves	O
at	O
this	O
height	O
had	O
not	O
been	O
completed	O
.	O

Evaluation	O
of	O
other	O
data	O
sets	O
yielded	O
similar	O
results	O
(	O
not	O
shown	O
)	O
.	O

Patch	O
clamp	O
pressure	O
versus	O
cell	O
turgor	O
pressure	O
measurements	O
The	O
leaf	O
patch	O
clamp	O
pressure	O
probe	O
measures	O
the	O
pressure	O
transfer	O
function	O
of	O
a	O
defined	O
leaflet	O
area	O
.	O

The	O
above	O
theoretical	O
considerations	O
have	O
shown	O
that	O
the	O
transfer	O
function	O
is	O
mainly	O
determined	O
by	O
turgor	O
pressure	O
provided	O
that	O
the	O
structural	O
elements	O
do	O
not	O
contribute	O
or	O
constantly	O
contribute	O
to	O
the	O
pressure	O
signal	O
transfer	O
.	O

In	O
order	O
to	O
prove	O
the	O
theory	O
parallel	O
measurements	O
of	O
leaf	O
patch	O
clamp	O
pressure	O
(	O
Pp	O
)	O
and	O
cell	O
turgor	O
pressure	O
(	O
Pc	O
)	O
were	O
performed	O
on	O
a	O
leaflet	O
at	O
0.2	O
m	O
height	O
(	O
Fig.	O
5A	O
)	O
.	O

Simultaneously	O
,	O
the	O
Pp	O
values	O
were	O
recorded	O
at	O
6	O
m	O
and	O
10	O
m	O
height	O
(	O
Fig.	O
5B	O
,	O
C	O
)	O
.	O

Measurements	O
were	O
performed	O
after	O
several	O
days	O
of	O
irrigation	O
.	O

In	O
these	O
experiments	O
,	O
the	O
microcapillary	O
of	O
the	O
turgor	O
pressure	O
probe	O
was	O
inserted	O
into	O
parenchymal	O
cells	O
located	O
close	O
to	O
the	O
main	O
vein	O
on	O
the	O
abaxial	O
side	O
of	O
a	O
leaflet	O
,	O
i.e.	O
c.	O
10	O
cm	O
away	O
from	O
the	O
leaf	O
patch	O
clamp	O
pressure	O
probe	O
near	O
the	O
leaflet	O
periphery	O
.	O

Turgor	O
pressure	O
measurements	O
on	O
leaf	O
cells	O
of	O
T.	B
voinierianum	I
were	O
difficult	O
to	O
perform	O
because	O
of	O
the	O
presence	O
of	O
mucilage	O
.	O

Mucilage	O
resulted	O
in	O
clogging	O
of	O
the	O
tip	O
of	O
the	O
microcapillary	O
of	O
the	O
cell	O
turgor	O
pressure	O
probe	O
.	O

For	O
this	O
reason	O
,	O
measurements	O
with	O
the	O
Scholander	O
pressure	O
chamber	O
were	O
not	O
very	O
reliable	O
.	O

It	O
was	O
extremely	O
difficult	O
to	O
determine	O
exactly	O
the	O
balancing	O
pressure	O
at	O
which	O
water	O
appears	O
at	O
the	O
cut	O
end	O
of	O
the	O
petiole	O
of	O
the	O
leaf	O
.	O

In	O
Fig.	O
5A	O
the	O
average	O
turgor	O
pressure	O
values	O
are	O
plotted	O
which	O
were	O
calculated	O
from	O
3–8	O
min	O
long	O
measurements	O
.	O

Inspection	O
of	O
Fig.	O
5A	O
–	O
C	O
shows	O
that	O
Pc	O
exhibited	O
similar	O
diurnal	O
changes	O
as	O
the	O
Pp	O
values	O
at	O
0.2	O
m	O
,	O
6	O
m	O
,	O
and	O
10	O
m	O
height	O
.	O

Changes	O
in	O
Pc	O
after	O
sunrise	O
preceded	O
changes	O
in	O
Pp	O
,	O
most	O
likely	O
due	O
to	O
the	O
different	O
measuring	O
sites	O
on	O
the	O
leaflets	O
.	O

After	O
the	O
onset	O
of	O
transpiration	O
the	O
loss	O
of	O
turgor	O
pressure	O
of	O
cells	O
located	O
at	O
the	O
periphery	O
of	O
the	O
leaflets	O
(	O
where	O
Pp	O
is	O
recorded	O
)	O
is	O
apparently	O
immediately	O
compensated	O
by	O
water	O
shifting	O
from	O
the	O
xylem	O
and	O
the	O
cells	O
located	O
close	O
to	O
the	O
main	O
vein	O
(	O
where	O
Pc	O
is	O
measured	O
)	O
.	O

Consistent	O
with	O
this	O
explanation	O
,	O
towards	O
the	O
afternoon	O
when	O
all	O
cells	O
throughout	O
the	O
leaflets	O
exhibit	O
low	O
turgor	O
pressure	O
,	O
the	O
increase	O
in	O
Pc	O
and	O
the	O
decrease	O
in	O
Pp	O
occurred	O
nearly	O
concomitantly	O
.	O

Interestingly	O
,	O
the	O
delay	O
between	O
the	O
response	O
of	O
Pc	O
and	O
Pp	O
upon	O
changes	O
in	O
T	O
and	O
r.h	O
.	O

in	O
the	O
early	O
morning	O
hours	O
decreased	O
from	O
about	O
2.5	O
h	O
at	O
0.2	O
m	O
height	O
to	O
1.5	O
h	O
at	O
6	O
m	O
height	O
,	O
and	O
to	O
1	O
h	O
at	O
10	O
m	O
height	O
.	O

In	O
Fig.	O
5D	O
the	O
Pp	O
values	O
measured	O
at	O
the	O
three	O
heights	O
are	O
plotted	O
against	O
the	O
corresponding	O
Pc	O
values	O
(	O
i.e.	O
neglecting	O
the	O
delayed	O
response	O
of	O
Pp	O
)	O
.	O

The	O
curves	O
could	O
be	O
fitted	O
quite	O
well	O
by	O
equation	O
8	O
.	O

Fitting	O
of	O
the	O
curves	O
required	O
the	O
assumption	O
of	O
different	O
values	O
for	O
the	O
constants	O
a	O
and	O
b	O
in	O
equation	O
4	O
(	O
see	O
legend	O
to	O
Fig.	O
5	O
)	O
indicating	O
that	O
the	O
elastic	O
properties	O
of	O
the	O
leaves	O
were	O
different	O
,	O
presumably	O
due	O
to	O
changes	O
of	O
the	O
ambient	O
temperature	O
with	O
height	O
(	O
see	O
above	O
)	O
.	O

Turgor	O
pressure	O
measurements	O
at	O
5	O
m	O
height	O
failed	O
because	O
of	O
abundant	O
mucilage	O
in	O
the	O
leaflet	O
tissue	O
at	O
this	O
time	O
of	O
the	O
year	O
.	O

Mucilage	O
in	O
the	O
cells	O
and	O
xylem	O
vessels	O
was	O
less	O
abundant	O
when	O
turgor	O
pressure	O
measurements	O
were	O
performed	O
during	O
the	O
summer	O
of	O
1999	O
.	O

Plot	O
of	O
the	O
Pc	O
data	O
measured	O
by	O
Thürmer	O
et	O
al.	O
(	O
1999	O
)	O
at	O
5	O
m	O
height	O
against	O
online	O
recordings	O
of	O
Pp	O
in	O
May	O
2007	O
revealed	O
very	O
good	O
agreement	O
between	O
both	O
parameters	O
,	O
even	O
though	O
the	O
microcapillary	O
was	O
inserted	O
into	O
cells	O
located	O
on	O
the	O
upper	O
leaflet	O
surface	O
between	O
the	O
main	O
vein	O
and	O
the	O
leaflet	O
edge	O
(	O
Fig.	O
6	O
)	O
.	O

On	O
both	O
measuring	O
days	O
in	O
1999	O
and	O
2007	O
,	O
similar	O
environmental	O
conditions	O
existed	O
.	O

Inspection	O
of	O
Fig.	O
6	O
shows	O
that	O
Pp	O
measured	O
at	O
6	O
m	O
height	O
was	O
delayed	O
by	O
c.	O
1.5	O
h.	O
A	O
plot	O
of	O
the	O
Pp	O
values	O
against	O
the	O
Pc	O
values	O
according	O
to	O
Fig.	O
5D	O
could	O
also	O
be	O
fitted	O
very	O
well	O
by	O
equation	O
8	O
(	O
see	O
inset	O
of	O
Fig.	O
6	O
)	O
indicating	O
the	O
validity	O
of	O
equation	O
8	O
to	O
describe	O
properly	O
the	O
relationship	O
between	O
Pp	O
and	O
Pc	O
.	O

Discussion	O
The	O
results	O
presented	O
here	O
demonstrate	O
that	O
the	O
novel	O
patch	O
clamp	O
pressure	O
probe	O
is	O
a	O
very	O
sensitive	O
,	O
versatile	O
,	O
and	O
easy	O
-	O
to	O
-	O
handle	O
plant	O
-	O
based	O
tool	O
for	O
online	O
monitoring	O
of	O
the	O
effects	O
of	O
evapotranspiration	O
and/or	O
of	O
irrigation	O
regimes	O
on	O
the	O
water	O
relations	O
of	O
leaves	O
(	O
Figs	O
2	O
,	O
3	O
)	O
.	O

The	O
probe	O
measures	O
the	O
output	O
signal	O
upon	O
application	O
of	O
a	O
constantly	O
clamped	O
pressure	O
,	O
i.e.	O
the	O
pressure	O
transfer	O
function	O
of	O
leaf	O
patches	O
.	O

Since	O
the	O
application	O
of	O
the	O
probe	O
is	O
not	O
restricted	O
to	O
special	O
leaves	O
,	O
patch	O
clamp	O
pressure	O
measurements	O
will	O
readily	O
show	O
which	O
crop	O
varieties	O
can	O
be	O
grown	O
with	O
the	O
least	O
water	O
for	O
the	O
most	O
yield	O
.	O

It	O
has	O
also	O
been	O
demonstated	O
here	O
that	O
the	O
plant	O
-	O
based	O
data	O
can	O
be	O
sent	O
by	O
small	O
telemetric	O
units	O
connected	O
to	O
the	O
patch	O
clamp	O
pressure	O
probes	O
to	O
a	O
receiver	O
base	O
station	O
which	O
logs	O
and	O
stores	O
the	O
data	O
pending	O
transfer	O
to	O
a	O
GPRS	O
modem	O
linked	O
to	O
an	O
Internet	O
server	O
.	O

The	O
telemetric	O
systems	O
operated	O
faultlessly	O
.	O

This	O
is	O
a	O
very	O
important	O
result	O
because	O
there	O
is	O
agreement	O
between	O
scientists	O
and	O
growers	O
(	O
Jones	O
,	O
2004	O
)	O
that	O
control	O
of	O
irrigation	O
must	O
be	O
tied	O
to	O
remote	O
sensing	O
devices	O
in	O
order	O
to	O
reduce	O
manpower	O
and	O
to	O
conserve	O
water	O
.	O

The	O
patch	O
clamp	O
pressure	O
probe	O
technique	O
introduced	O
here	O
meets	O
these	O
demands	O
.	O

A	O
further	O
advantage	O
is	O
that	O
the	O
probe	O
is	O
cheap	O
and	O
easy	O
to	O
handle	O
.	O

Some	O
care	O
is	O
required	O
only	O
when	O
clamping	O
the	O
leaf	O
.	O

Leaves	O
must	O
be	O
clean	O
and	O
any	O
rough	O
surface	O
topography	O
must	O
be	O
avoided	O
.	O

This	O
implies	O
that	O
the	O
dimensions	O
of	O
the	O
pads	O
of	O
the	O
spring	O
clamp	O
must	O
be	O
adjusted	O
to	O
the	O
size	O
of	O
the	O
intercostal	O
area	O
since	O
non	O
-	O
uniform	O
contact	O
between	O
leaf	O
surface	O
and	O
pads	O
lowered	O
the	O
output	O
pressure	O
signal	O
.	O

Experience	O
collected	O
with	O
patch	O
clamp	O
pressure	O
measurements	O
on	O
T.	B
voinierianum	I
and	O
on	O
preliminary	O
results	O
of	O
other	O
plants	O
(	O
e.g.	O
grapevines	O
,	O
bananas	B
,	O
Eucalyptus	O
,	O
and	O
Arabidopsis	O
)	O
showed	O
that	O
a	O
smooth	O
intercostal	O
leaf	O
area	O
for	O
clamping	O
can	O
readily	O
be	O
found	O
.	O

Equally	O
,	O
optimum	O
values	O
for	O
the	O
clamp	O
pressure	O
can	O
also	O
be	O
relatively	O
quickly	O
selected	O
empirically	O
if	O
the	O
guidelines	O
mentioned	O
above	O
are	O
followed	O
.	O

For	O
many	O
purposes	O
calibration	O
of	O
the	O
leaf	O
patch	O
clamp	O
pressure	O
probe	O
against	O
the	O
cell	O
turgor	O
pressure	O
probe	O
is	O
not	O
stringent	O
.	O

It	O
may	O
be	O
sufficient	O
to	O
know	O
that	O
the	O
transfer	O
function	O
assumes	O
small	O
values	O
at	O
full	O
turgescence	O
and	O
is	O
nearly	O
unity	O
at	O
low	O
turgescence	O
.	O

However	O
,	O
for	O
scientific	O
reasons	O
and	O
for	O
the	O
application	O
of	O
the	O
probe	O
in	O
basic	O
research	O
,	O
the	O
dependency	O
of	O
the	O
transfer	O
function	O
on	O
cell	O
turgor	O
pressure	O
might	O
be	O
of	O
great	O
interest	O
.	O

The	O
theoretical	O
considerations	O
have	O
demonstrated	O
that	O
the	O
relationship	O
between	O
the	O
transfer	O
function	O
and	O
the	O
turgor	O
pressure	O
can	O
obviously	O
be	O
described	O
by	O
equation	O
8	O
,	O
i.e.	O
by	O
a	O
power	O
function	O
.	O

Concomitant	O
measurements	O
of	O
turgor	O
pressure	O
and	O
patch	O
clamp	O
pressure	O
have	O
confirmed	O
the	O
theoretical	O
considerations	O
(	O
Fig.	O
5	O
)	O
.	O

Analogous	O
recordings	O
of	O
turgor	O
pressure	O
and	O
patch	O
clamp	O
pressure	O
on	O
grapevines	O
,	O
bananas	B
,	O
and	O
Eucalyptus	B
trees	O
also	O
yielded	O
results	O
(	O
D	O
Zimmermann	O
,	O
unpublished	O
results	O
)	O
which	O
were	O
consistent	O
with	O
the	O
predictions	O
of	O
equation	O
8	O
.	O

Patch	O
clamp	O
pressure	O
measurements	O
allow	O
,	O
therefore	O
,	O
calculation	O
of	O
turgor	O
pressures	O
if	O
the	O
constants	O
a	O
and	O
b	O
defined	O
by	O
equation	O
4	O
are	O
known	O
.	O

These	O
parameters	O
can	O
be	O
obtained	O
by	O
numerical	O
fitting	O
of	O
Pp	O
versus	O
Pc	O
curves	O
.	O

Online	O
patch	O
clamp	O
pressure	O
measurements	O
open	O
up	O
new	O
possibilities	O
to	O
unravel	O
the	O
hydraulic	O
communication	O
among	O
leaves	O
,	O
including	O
tall	O
trees	O
.	O

It	O
is	O
shown	O
here	O
that	O
the	O
patch	O
clamp	O
pressure	O
can	O
simultaneously	O
be	O
monitored	O
in	O
shaded	O
or	O
sun	O
-	O
exposed	O
leaflets	O
at	O
different	O
heights	O
under	O
greenhouse	O
conditions	O
by	O
using	O
several	O
probes	O
.	O

It	O
was	O
even	O
possible	O
to	O
measure	O
the	O
turgor	O
pressure	O
at	O
different	O
sites	O
on	O
the	O
leaf	O
.	O

Therefore	O
,	O
water	O
shifting	O
between	O
leaf	O
cells	O
via	O
the	O
apoplastic	O
and	O
symplastic	O
pathways	O
can	O
be	O
studied	O
.	O

Physically	O
sound	O
theories	O
are	O
available	O
(	O
Molz	O
and	O
Ikenberry	O
,	O
1974	O
;	O
Molz	O
et	O
al.	O
,	O
1979	O
)	O
,	O
but	O
experimental	O
facts	O
are	O
not	O
available	O
or	O
are	O
mainly	O
based	O
on	O
speculations	O
(	O
Steudle	O
and	O
French	O
,	O
1996	O
)	O
.	O

The	O
first	O
evidence	O
for	O
the	O
dynamics	O
of	O
the	O
hydraulic	O
communication	O
between	O
leaflets	O
at	O
different	O
height	O
and	O
within	O
leaflets	O
is	O
given	O
here	O
.	O

Thürmer	O
et	O
al.	O
(	O
1999	O
)	O
have	O
shown	O
by	O
using	O
the	O
xylem	O
and	O
turgor	O
pressure	O
probe	O
that	O
the	O
decrease	O
in	O
local	O
xylem	O
pressure	O
after	O
daybreak	O
from	O
positive	O
,	O
sub	O
-	O
atmospheric	O
or	O
slightly	O
above	O
-	O
atmospheric	O
values	O
to	O
negative	O
values	O
was	O
associated	O
with	O
an	O
almost	O
1:1	O
decrease	O
in	O
turgor	O
pressure	O
of	O
the	O
cells	O
located	O
close	O
to	O
the	O
main	O
vein	O
of	O
the	O
leaflets	O
(	O
see	O
also	O
Zimmermann	O
et	O
al.	O
,	O
2004	O
)	O
.	O

Similarly	O
,	O
in	O
the	O
afternoon	O
,	O
the	O
increase	O
of	O
xylem	O
pressure	O
in	O
non	O
-	O
cavitated	O
vessels	O
towards	O
more	O
positive	O
values	O
correlated	O
with	O
a	O
1:1	O
increase	O
in	O
cell	O
turgor	O
pressure	O
.	O

Obviously	O
,	O
changes	O
in	O
transpiration	O
resulted	O
in	O
a	O
very	O
rapid	O
establishment	O
of	O
a	O
new	O
local	O
water	O
equilibrium	O
state	O
between	O
the	O
xylem	O
and	O
the	O
turgor	O
pressure	O
of	O
the	O
adjacent	O
cells	O
.	O

The	O
turgor	O
pressure	O
measurements	O
of	O
Thürmer	O
et	O
al.	O
(	O
1999	O
)	O
were	O
performed	O
at	O
1	O
m	O
and	O
5	O
m	O
height	O
.	O

No	O
significant	O
differences	O
in	O
the	O
turgor	O
pressure	O
values	O
were	O
found	O
over	O
the	O
day	O
.	O

The	O
turgor	O
pressure	O
measurements	O
at	O
0.2	O
m	O
height	O
reported	O
here	O
confirmed	O
the	O
finding	O
of	O
Thürmer	O
et	O
al.	O
(	O
1999	O
)	O
that	O
the	O
turgor	O
pressure	O
in	O
the	O
cells	O
located	O
near	O
the	O
main	O
vein	O
dropped	O
immediately	O
upon	O
daybreak	O
.	O

However	O
,	O
our	O
patch	O
clamp	O
pressure	O
measurements	O
at	O
the	O
periphery	O
of	O
the	O
leaflets	O
imply	O
that	O
the	O
turgor	O
pressure	O
of	O
these	O
cells	O
apparently	O
had	O
a	O
significantly	O
delayed	O
response	O
upon	O
the	O
onset	O
of	O
transpiration	O
.	O

This	O
finding	O
can	O
be	O
taken	O
as	O
evidence	O
that	O
turgor	O
pressure	O
gradients	O
are	O
temporarily	O
generated	O
within	O
the	O
leaf	O
during	O
the	O
early	O
morning	O
hours	O
.	O

This	O
delay	O
in	O
the	O
response	O
of	O
patch	O
clamp	O
pressure	O
after	O
daybreak	O
was	O
c.	O
1	O
h	O
for	O
leaves	O
at	O
the	O
top	O
,	O
but	O
c.	O
2.5	O
h	O
for	O
leaves	O
at	O
the	O
base	O
.	O

The	O
data	O
suggest	O
that	O
with	O
progression	O
of	O
the	O
day	O
the	O
gradients	O
collapsed	O
first	O
at	O
the	O
top	O
of	O
the	O
liana	O
,	O
where	O
transpiration	O
was	O
high	O
,	O
before	O
it	O
occurred	O
in	O
leaves	O
further	O
down	O
.	O

During	O
the	O
afternoon	O
hours	O
the	O
increase	O
in	O
the	O
turgor	O
pressure	O
values	O
measured	O
close	O
to	O
the	O
main	O
vein	O
coincided	O
with	O
the	O
values	O
measured	O
by	O
the	O
patch	O
clamp	O
pressure	O
probe	O
(	O
Fig.	O
5	O
)	O
.	O

The	O
unbalanced	O
osmotic	O
pressure	O
throughout	O
the	O
leaflets	O
obviously	O
favoured	O
simultaneous	O
turgor	O
pressure	O
regeneration	O
in	O
all	O
leaflet	O
cells	O
.	O

The	O
process	O
seemed	O
to	O
be	O
very	O
similar	O
to	O
the	O
refilling	O
of	O
the	O
cells	O
of	O
the	O
resurrection	O
plant	O
Myrothamnus	B
flabellifolia	I
with	O
water	O
after	O
desiccation	O
(	O
Wagner	O
et	O
al.	O
,	O
2000	O
)	O
.	O

Uniform	O
radial	O
refilling	O
of	O
cells	O
with	O
water	O
in	O
this	O
species	O
is	O
also	O
driven	O
by	O
the	O
unbalanced	O
osmotic	O
pressure	O
throughout	O
the	O
tissue	O
.	O

As	O
indicated	O
by	O
Fig.	O
4A	O
and	O
B	O
,	O
restoration	O
of	O
full	O
turgescence	O
in	O
T.	B
voinierianum	I
was	O
faster	O
than	O
the	O
preceding	O
turgor	O
pressure	O
loss	O
if	O
the	O
lianas	O
were	O
well	O
-	O
watered	O
.	O

By	O
contrast	O
,	O
limitations	O
in	O
water	O
supply	O
resulted	O
in	O
the	O
coincidence	O
of	O
the	O
phases	O
of	O
turgor	O
pressure	O
loss	O
and	O
regeneration	O
.	O

Interestingly	O
,	O
watering	O
of	O
the	O
lianas	O
after	O
non	O
-	O
irrigation	O
seemed	O
to	O
lead	O
preferentially	O
to	O
water	O
shifting	O
to	O
the	O
top	O
of	O
the	O
plant	O
,	O
because	O
,	O
after	O
3	O
d	O
of	O
irrigation	O
,	O
turgor	O
pressure	O
regeneration	O
during	O
the	O
afternoon	O
was	O
very	O
fast	O
again	O
at	O
10	O
m	O
height	O
(	O
Fig.	O
4F	O
)	O
,	O
but	O
not	O
at	O
5	O
m	O
height	O
(	O
Fig.	O
4E	O
)	O
.	O

Rapid	O
water	O
movement	O
to	O
the	O
top	O
is	O
expected	O
if	O
hydrostatic	O
pressure	O
,	O
osmotic	O
pressure	O
,	O
and/or	O
gel	O
-	O
based	O
gradients	O
throughout	O
the	O
vessels	O
exist	O
or	O
are	O
generated	O
rapidly	O
in	O
the	O
afternoon	O
when	O
cavitation	O
has	O
occurred	O
.	O

This	O
was	O
demonstrated	O
by	O
Benkert	O
et	O
al.	O
(	O
1995	O
)	O
and	O
Thürmer	O
et	O
al.	O
(	O
1999	O
)	O
by	O
using	O
the	O
xylem	O
pressure	O
probe	O
.	O

Continuous	O
xylem	O
pressure	O
gradients	O
during	O
the	O
morning	O
hours	O
can	O
also	O
explain	O
why	O
changes	O
in	O
Pp	O
at	O
lower	O
heights	O
were	O
frequently	O
found	O
which	O
could	O
not	O
be	O
correlated	O
with	O
changes	O
in	O
local	O
temperature	O
or	O
relative	O
humidity	O
.	O

Water	O
loss	O
at	O
the	O
top	O
of	O
the	O
plant	O
induces	O
a	O
drop	O
in	O
xylem	O
pressure	O
which	O
is	O
transferred	O
rapidly	O
to	O
the	O
basal	O
leaves	O
where	O
it	O
induces	O
a	O
temporary	O
turgor	O
pressure	O
loss	O
that	O
is	O
soon	O
compensated	O
by	O
water	O
uptake	O
from	O
the	O
roots	O
(	O
arrow	O
in	O
Fig.	O
2	O
)	O
.	O

Even	O
though	O
more	O
work	O
is	O
required	O
,	O
the	O
present	O
study	O
shows	O
that	O
the	O
leaf	O
patch	O
clamp	O
pressure	O
probe	O
is	O
a	O
promising	O
tool	O
to	O
elucidate	O
short-	O
and	O
long	O
-	O
distance	O
water	O
transport	O
in	O
T.	B
voinierianum	I
and	O
other	O
plants	O
.	O

CHEK2	O
Mutations	O
Affecting	O
Kinase	O
Activity	O

Together	O
With	O
Mutations	O
in	O
TP53	O
Indicate	O
a	O
Functional	O
Pathway	O
Associated	O
with	O
Resistance	O
to	O
Epirubicin	O
in	O
Primary	O
Breast	O
Cancer	O
Abstract	O
Background	O
Chemoresistance	O
is	O
the	O
main	O
obstacle	O
to	O
cure	O
in	O
most	O
malignant	O
diseases	O
.	O

Anthracyclines	O
are	O
among	O
the	O
main	O
drugs	O
used	O
for	O
breast	O
cancer	O
therapy	O
and	O
in	O
many	O
other	O
malignant	O
conditions	O
.	O

Single	O
parameter	O
analysis	O
or	O
global	O
gene	O
expression	O
profiles	O
have	O
failed	O
to	O
identify	O
mechanisms	O
causing	O
in	O
vivo	O
resistance	O
to	O
anthracyclines	O
.	O

While	O
we	O
previously	O
found	O
TP53	O
mutations	O
in	O
the	O
L2	O
/	O
L3	O
domains	O
to	O
be	O
associated	O
with	O
drug	O
resistance	O
,	O
some	O
tumors	O
harboring	O
wild	O
-	O
type	O
TP53	O
were	O
also	O
therapy	O
resistant	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
;	O
1	O
)	O
To	O
explore	O
alterations	O
in	O
the	O
TP53	O
gene	O
with	O
respect	O
to	O
resistance	O
to	O
a	O
regular	O
dose	O
epirubicin	O
regimen	O
(	O
90	O
mg	O
/	O
m2	O
every	O
3	O
week	O
)	O
in	O
patients	O
with	O
primary	O
,	O
locally	O
advanced	O
breast	O
cancer	O
;	O
2	O
)	O
Identify	O
critical	O
mechanisms	O
activating	O
p53	O
in	O
response	O
to	O
DNA	O
damage	O
in	O
breast	O
cancer	O
;	O
3	O
)	O
Evaluate	O
in	O
vitro	O
function	O
of	O
Chk2	O
and	O
p14	O
proteins	O
corresponding	O
to	O
identified	O
mutations	O
in	O
the	O
CHEK2	O
and	O
p14	O
(	O
ARF	O
)	O
genes	O
;	O
and	O
4	O
)	O
Explore	O
potential	O
CHEK2	O
or	O
p14	O
(	O
ARF	O
)	O
germline	O
mutations	O
with	O
respect	O
to	O
family	O
cancer	O
incidence	O
.	O

Methods	O
and	O
Findings	O
Snap	O
-	O
frozen	O
biopsies	O
from	O
109	O
patients	O
collected	O
prior	O
to	O
epirubicin	O
(	O
as	O
preoperative	O
therapy	O
were	O
investigated	O
for	O
TP53	O
,	O
CHEK2	O
and	O
p14	O
(	O
ARF	O
)	O
mutations	O
by	O
sequencing	O
the	O
coding	O
region	O
and	O
p14	O
(	O
ARF	O
)	O
promoter	O
methylations	O
.	O

TP53	O
mutastions	O
were	O
associated	O
with	O
chemoresistance	O
,	O
defined	O
as	O
progressive	O
disease	O
on	O
therapy	O
(	O
p	O
=	O
0.0358	O
;	O
p	O
=	O
0.0136	O
for	O
mutations	O
affecting	O
p53	O
loop	O
domains	O
L2	O
/	O
L3	O
)	O
.	O

Germline	O
CHEK2	O
mutations	O
(	O
n	O
=	O
3	O
)	O
were	O
associated	O
with	O
therapy	O
resistance	O
(	O
p	O
=	O
0.0226	O
)	O
.	O

Combined	O
,	O
mutations	O
affecting	O
either	O
CHEK2	O
or	O
TP53	O
strongly	O
predicted	O
therapy	O
resistance	O
(	O
p	O
=	O
0.0101	O
;	O
TP53	O
mutations	O
restricted	O
to	O
the	O
L2	O
/	O
L3	O
domains	O
:	O
p	O
=	O
0.0032	O
)	O
.	O

Two	O
patients	O
progressing	O
on	O
therapy	O
harbored	O
the	O
CHEK2	O
mutation	O
,	O
Arg95Ter	O
,	O
completely	O
abrogating	O
Chk2	O
protein	O
dimerization	O
and	O
kinase	O
activity	O
.	O

One	O
patient	O
(	O
Epi132	O
)	O
revealed	O
family	O
cancer	O
occurrence	O
resembling	O
families	O
harboring	O
CHEK2	O
mutations	O
in	O
general	O
,	O
the	O
other	O
patient	O
(	O
epi203	O
)	O
was	O
non	O
-	O
conclusive	O
.	O

No	O
mutation	O
or	O
promoter	O
hypermethylation	O
in	O
p14	O
(	O
ARF	O
)	O
were	O
detected	O
.	O

Conclusion	O
This	O
study	O
is	O
the	O
first	O
reporting	O
an	O
association	O
between	O
CHEK2	O
mutations	O
and	O
therapy	O
resistance	O
in	O
human	B
cancers	O
and	O
to	O
document	O
mutations	O
in	O
two	O
genes	O
acting	O
direct	O
up	O
/	O
down	O
-	O
stream	O
to	O
each	O
other	O
to	O
cause	O
therapy	O
failure	O
,	O
emphasizing	O
the	O
need	O
to	O
investigate	O
functional	O
cascades	O
in	O
future	O
studies	O
.	O

Introduction	O
Chemoresistance	O
is	O
the	O
main	O
obstacle	O
to	O
cure	O
in	O
most	O
malignancies	O
,	O
including	O
breast	O
cancer	O
.	O

While	O
adjuvant	O
chemotherapy	O
may	O
reduce	O
the	O
hazard	O
rate	O
of	O
relapse	O
by	O
about	O
one	O
third	O
in	O
breast	O
cancer	O
patients	O
[	O
1	O
]	O
,	O
the	O
majority	O
among	O
patients	O
harboring	O
micro-	O
metastases	O
are	O
not	O
cured	O
by	O
today	O
's	O
standards	O
.	O

Considering	O
patients	O
harboring	O
distant	O
metastases	O
,	O
resistance	O
and	O
therapy	O
failure	O
inevitably	O
occurs	O
,	O
in	O
general	O
over	O
a	O
time	O
period	O
of	O
less	O
than	O
one	O
year	O
for	O
each	O
individual	O
regimen	O
[	O
2	O
]	O
.	O

Despite	O
extensive	O
experimental	O
research	O
[	O
3	O
]	O
,	O
little	O
data	O
are	O
available	O
considering	O
chemoresistance	O
in	O
vivo	O
.	O

For	O
anthracycline	O
therapy	O
in	O
breast	O
cancer	O
,	O
topoisomerase	O
-	O
II	O
amplifications	O
have	O
been	O
associated	O
with	O
a	O
dose	O
-	O
responsiveness	O
different	O
from	O
what	O
is	O
observed	O
in	O
non	O
-	O
amplified	O
tumors	O
4	O
,	O
5	O
.	O

Several	O
studies	O
have	O
tried	O
to	O
generate	O
""""	O
prediction	O
profiles	O
""""	O
based	O
on	O
gene	O
expression	O
microarrays	O
[	O
6	O
]	O
,	O
[	O
7	O
]	O
,	O
[	O
8	O
]	O
,	O
however	O
,	O
none	O
of	O
the	O
different	O
profiles	O
generated	O
expressed	O
a	O
sensitivity	O
suitable	O
for	O
clinical	O
applications	O
,	O
or	O
have	O
been	O
successfully	O
reproduced	O
by	O
others	O
(	O
see	O
references	O
to	O
original	O
works	O
in	O
[	O
9	O
]	O
and	O
[	O
10	O
]	O
)	O
.	O

p53	O
(	O
the	O
protein	O
encoded	O
by	O
the	O
TP53	O
gene	O
)	O
plays	O
a	O
key	O
role	O
in	O
executing	O
DNA	O
-	O
damage	O
induced	O
apoptosis	O
and	O
growth	O
arrest	O
[	O
11	O
]	O
.	O

Previously	O
,	O
our	O
group	O
reported	O
mutations	O
in	O
the	O
zink	O
-	O
binding	O
domains	O
L2	O
(	O
codons	O
163–195	O
)	O
and	O
L3	O
(	O
codons	O
236–251	O
)	O
of	O
p53	O
critical	O
to	O
DNA	O
binding	O
[	O
12	O
]	O
to	O
be	O
associated	O
with	O
but	O
not	O
fully	O
predictive	O
for	O
resistance	O
to	O
chemotherapy	O
with	O
a	O
low	O
-	O
dose	O
weekly	O
anthracycline	O
[	O
13	O
]	O
or	O
a	O
mitomycin	O
plus	O
5-fluoro	O
-	O
uracil	O
containing	O
[	O
14	O
]	O
regimen	O
.	O

Similar	O
findings	O
were	O
reported	O
by	O
another	O
group	O
[	O
15	O
]	O
.	O

In	O
contrast	O
,	O
others	O
reported	O
TP53	O
mutations	O
to	O
predict	O
sensitivity	O
to	O
a	O
dose	O
-	O
dense	O
epirubicin	O
-	O
cyclophosphamide	O
regimen	O
[	O
16	O
]	O
.	O

The	O
finding	O
that	O
some	O
tumors	O
harboring	O
wild	O
-	O
type	O
TP53	O
may	O
be	O
resistant	O
to	O
anthracycline	O
therapy	O
lead	O
us	O
to	O
postulate	O
that	O
other	O
genes	O
involved	O
in	O
the	O
p53	O
pathway	O
could	O
be	O
mutated	O
in	O
these	O
tumors	O
[	O
3	O
]	O
.	O

p53	O
is	O
activated	O
by	O
post	O
-	O
translational	O
modifications	O
,	O
and	O
the	O
protein	O
is	O
phosphorylated	O
at	O
multiple	O
amino	O
acids	O
[	O
17	O
]	O
.	O

Phosphorylation	O
at	O
Ser	O
20	O
(	O
Ser	O
23	O
in	O
mice	B
)	O
by	O
the	O
Chk2	O
protein	O
(	O
coded	O
by	O
the	O
CHEK2	O
gene	O
)	O
in	O
response	O
to	O
DNA	O
damage	O
activates	O
p53	O
by	O
inhibiting	O
binding	O
to	O
,	O
and	O
deactivation	O
by	O
,	O
the	O
MDM2	O
(	O
Mouse	B
Minute	O
2	O
homolog	O
;	O
HDM2	O
)	O
protein	O
[	O
18	O
]	O
,	O
[	O
19	O
]	O
,	O
[	O
20	O
]	O
.	O

While	O
experimental	O
studies	O
have	O
suggested	O
a	O
critical	O
role	O
of	O
Chk2	O
in	O
activating	O
p53	O
apoptotic	O
response	O
to	O
genotoxic	O
stress	O
[	O
21	O
]	O
,	O
[	O
22	O
]	O
,	O
others	O
claim	O
Chk2	O
to	O
be	O
dispensable	O
for	O
p53	O
activation	O
with	O
respect	O
to	O
apoptosis	O
as	O
well	O
as	O
growth	O
arrest	O
[	O
23	O
]	O
.	O

Following	O
an	O
initial	O
report	O
of	O
a	O
CHEK2	O
germline	O
mutation	O
in	O
a	O
family	O
filling	O
the	O
characteristics	O
of	O
a	O
Li	O
-	O
Fraumeni	O
syndrome	O
(	O
LFS	O
)	O
[	O
24	O
]	O
,	O
recent	O
papers	O
have	O
suggested	O
germline	O
mutations	O
in	O
CHEK2	O
to	O
be	O
associated	O
with	O
a	O
moderately	O
increased	O
risk	O
of	O
breast	O
and	O
colon	O
cancers	O
(	O
see	O
references	O
in	O
[	O
25	O
]	O
)	O
.	O

Recently	O
,	O
we	O
discovered	O
a	O
somatic	O
,	O
nonsense	O
CHEK2	O
mutation	O
in	O
a	O
single	O
patient	O
expressing	O
resistance	O
to	O
doxorubicin	O
low	O
dose	O
therapy	O
[	O
26	O
]	O
.	O

A	O
second	O
mechanism	O
of	O
p53	O
activation	O
is	O
through	O
p14	O
(	O
ARF	O
)	O
(	O
p19	O
in	O
mice	B
)	O
function	O
.	O

p14	O
(	O
ARF	O
)	O
does	O
not	O
phosphorylate	O
p53	O
,	O
but	O
inhibits	O
MDM2	O
dependent	O
p53	O
degradation	O
through	O
direct	O
MDM2	O
binding	O
.	O

While	O
p14	O
(	O
ARF	O
)	O
-mediated	O
p53	O
activation	O
has	O
been	O
linked	O
to	O
oncogene	O
-	O
induced	O
p53	O
activation	O
and	O
,	O
in	O
general	O
,	O
considered	O
not	O
involved	O
in	O
response	O
to	O
DNA	O
damage	O
(	O
see	O
references	O
in	O
[	O
27	O
]	O
)	O
,	O
p14	O
(	O
ARF	O
)	O
may	O
be	O
activated	O
through	O
the	O
E2F1	O
/	O
retinoblastoma	O
pathway	O
[	O
28	O
]	O
.	O

Importantly	O
,	O
two	O
recent	O
studies	O
revealed	O
lack	O
of	O
p19	O
(	O
mouse	B
homologue	O
of	O
human	B
p14	O
(	O
ARF	O
)	O
)	O
function	O
in	O
mice	B
to	O
inhibit	O
p53	O
tumor	O
suppressor	O
function	O
in	O
response	O
to	O
ionizing	O
radiation	O
as	O
well	O
as	O
DNA	O
damaging	O
agents	O
[	O
29	O
]	O
,	O
[	O
30	O
]	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
1	O
)	O
to	O
explore	O
alterations	O
in	O
the	O
TP53	O
gene	O
with	O
respect	O
to	O
resistance	O
to	O
a	O
regular	O
dose	O
epirubicin	O
regimen	O
(	O
90	O
mg	O
/	O
m2	O
body	O
surface	O
every	O
3	O
week	O
)	O
in	O
patient	O
with	O
primary	O
,	O
locally	O
advanced	O
,	O
breast	O
cancer	O
;	O
2	O
)	O
To	O
explore	O
defects	O
in	O
potential	O
mechanisms	O
activating	O
p53	O
in	O
response	O
to	O
DNA	O
damage	O
in	O
breast	O
cancer	O
as	O
a	O
cause	O
of	O
drug	O
resistance	O
in	O
wild	O
-	O
type	O
tumors	O
.	O

To	O
do	O
so	O
,	O
we	O
sequenced	O
the	O
complete	O
coding	O
regions	O
for	O
the	O
CHEK2	O
and	O
p14	O
(	O
ARF	O
)	O
genes	O
and	O
analyzed	O
for	O
p14	O
(	O
ARF	O
)	O
promoter	O
hypermetylations	O
;	O
3	O
)	O
Evaluate	O
in	O
vitro	O
function	O
of	O
potential	O
Chk2	O
and	O
p14	O
(	O
ARF	O
)	O
protein	O
translates	O
corresponding	O
to	O
identified	O
mutations	O
in	O
the	O
CHEK2	O
and	O
p14	O
(	O
ARF	O
)	O
genes	O
;	O
4	O
)	O
Identify	O
potential	O
TP53	O
,	O
CHEK2	O
and	O
p14	O
(	O
ARF	O
)	O
mutations	O
to	O
be	O
germline	O
,	O
explore	O
the	O
incidence	O
of	O
different	O
cancers	O
among	O
affected	O
relatives	O
with	O
respect	O
to	O
specific	O
mutations	O
.	O

By	O
comparing	O
in	O
vitro	O
characteristics	O
of	O
specific	O
mutations	O
to	O
drug	O
sensitivity	O
and	O
family	O
cancer	O
risk	O
syndromes	O
,	O
this	O
may	O
add	O
to	O
our	O
understanding	O
of	O
the	O
importance	O
of	O
these	O
gene	O
cascades	O
executing	O
response	O
to	O
DNA	O
damage	O
versus	O
tumor	O
suppression	O
activity	O
.	O

Analyzing	O
tumor	O
samples	O
from	O
a	O
total	O
of	O
109	O
primary	O
locally	O
advanced	O
breast	O
cancer	O
patients	O
treated	O
with	O
epirubicin	O
90mg	O
/	O
3	O
weekly	O
,	O
we	O
found	O
TP53	O
mutations	O
affecting	O
the	O
L2	O
/	O
L3	O
domains	O
or	O
protein	O
dimerization	O
,	O
as	O
well	O
as	O
non	O
-	O
functional	O
CHEK2	O
mutations	O
abrogating	O
dimerization	O
and	O
phosphorylation	O
,	O
to	O
be	O
associated	O
with	O
therapy	O
resistance	O
;	O
no	O
mutation	O
or	O
promoter	O
hypermethylations	O
of	O
the	O
p14	O
(	O
ARF	O
)	O
gene	O
was	O
discovered	O
.	O

Our	O
findings	O
suggest	O
a	O
critical	O
role	O
for	O
Chk2	O
with	O
respect	O
to	O
DNA	O
-	O
damage	O
-	O
dependent	O
p53	O
activation	O
and	O
resistance	O
to	O
anthracycline	O
therapy	O
in	O
human	B
breast	O
cancer	O
.	O

Materials	O
and	O
Methods	O
Patients	O
A	O
total	O
of	O
223	O
patients	O
with	O
locally	O
advanced	O
non	O
-	O
inflammatory	O
breast	O
cancer	O
(	O
T3	O
-	O
4	O
and/or	O
N2	O
)	O
were	O
randomly	O
allocated	O
to	O
primary	O
treatment	O
either	O
with	O
epirubicin	O
90	O
mg	O
/	O
m2	O
or	O
paclitaxel	O
200	O
mg	O
/	O
m2	O
.	O

The	O
primary	O
aim	O
of	O
the	O
study	O
was	O
identification	O
of	O
markers	O
predicting	O
drug	O
resistance	O
to	O
the	O
regimens	O
.	O

Thus	O
,	O
the	O
reason	O
for	O
randomizing	O
patients	O
was	O
not	O
for	O
effect	O
comparison	O
,	O
but	O
to	O
achieve	O
similar	O
patient	O
cohorts	O
in	O
the	O
two	O
arms	O
.	O

Based	O
on	O
the	O
findings	O
of	O
a	O
clinical	O
lack	O
of	O
cross	O
-	O
resistance	O
between	O
anthracyclines	O
and	O
taxane	O
therapies	O
in	O
breast	O
cancer	O
[	O
31	O
]	O
,	O
we	O
hypothesized	O
the	O
mechanisms	O
of	O
resistance	O
to	O
be	O
different	O
between	O
the	O
two	O
compounds	O
.	O

While	O
the	O
analysis	O
of	O
tumor	O
samples	O
from	O
the	O
paclitaxel	O
is	O
ongoing	O
,	O
we	O
here	O
report	O
our	O
findings	O
from	O
the	O
patients	O
allocated	O
to	O
the	O
epirubicin	O
arm	O
.	O

The	O
epirubicin	O
arm	O
included	O
a	O
total	O
of	O
109	O
patients	O
(	O
age	O
28	O
to	O
70	O
years	O
,	O
median	O
51	O
years	O
)	O
.	O

Two	O
patients	O
were	O
analyzed	O
for	O
gene	O
mutations	O
but	O
omitted	O
from	O
statistical	O
analysis	O
as	O
protocol	O
violators	O
;	O
histopathological	O
examination	O
revealed	O
one	O
patient	O
(	O
Epi089	O
)	O
to	O
harbor	O
a	O
sarcomatoid	O
tumor	O
,	O
while	O
one	O
patient	O
Epi232	O
was	O
erroneously	O
enrolled	O
with	O
stage	O
II	O
disease	O
.	O

The	O
study	O
protocol	O
was	O
approved	O
by	O
the	O
Regional	O
Ethical	O
Committee	O
(	O
Norwegian	O
Health	O
Region	O
III	O
)	O
,	O
including	O
formal	O
Biobank	O
registration	O
in	O
accordance	O
to	O
Norwegian	O
law	O
.	O

The	O
study	O
and	O
protocol	O
is	O
registered	O
under	O
the	O
Norwegian	O
Social	O
Science	O
Data	O
services	O
(	O
(	O
www.nsd/uib/personvern/database/	O
)	O
,	O
University	O
of	O
Bergen	O
project	O
no	O
16297	O
and	O
Helse	O
Bergen	O
project	O
no	O
13025	O
)	O
.	O

Each	O
patient	O
gave	O
written	O
informed	O
consent	O
.	O

Tissue	O
Sampling	O
Before	O
commencing	O
chemotherapy	O
,	O
each	O
patient	O
had	O
an	O
incisional	O
tumor	O
biopsy	O
as	O
described	O
previously	O
[	O
14	O
]	O
.	O

All	O
tissue	O
samples	O
were	O
snap	O
-	O
frozen	O
immediately	O
on	O
removal	O
in	O
the	O
theatre	O
.	O

Treatment	O
Regime	O
and	O
Staging	O
Primary	O
treatment	O
consisted	O
of	O
epirubicin	O
(	O
90	O
mg	O
/	O
m2	O
)	O
administered	O
as	O
a	O
3-weekly	O
schedule	O
.	O

Treatment	O
was	O
scheduled	O
for	O
four	O
cycles	O
unless	O
progression	O
occurred	O
at	O
an	O
earlier	O
stage	O
.	O

Clinical	O
response	O
was	O
assessed	O
before	O
each	O
treatment	O
cycle	O
,	O
and	O
the	O
final	O
response	O
evaluated	O
3	O
weeks	O
after	O
the	O
4th	O
cycle	O
for	O
overall	O
response	O
classification	O
.	O

Because	O
the	O
protocol	O
was	O
implemented	O
by	O
October	O
1997	O
with	O
patients	O
enrolled	O
between	O
November	O
1997	O
and	O
December	O
2003	O
,	O
responses	O
were	O
consistently	O
graded	O
by	O
the	O
UICC	O
system	O
[	O
32	O
]	O
and	O
not	O
the	O
more	O
recently	O
implemented	O
""""	O
RECIST	O
""""	O
criteria	O
[	O
33	O
]	O
.	O

Thus	O
,	O
responses	O
were	O
classified	O
as	O
CR	O
(	O
Complete	O
Response	O
,	O
complete	O
disappearance	O
of	O
all	O
tumor	O
lesions	O
)	O
,	O
PR	O
(	O
Partial	O
Response	O
,	O
reduction	O
≥50	O
%	O
in	O
the	O
sum	O
of	O
all	O
tumor	O
lesions	O
,	O
calculated	O
for	O
each	O
as	O
the	O
product	O
of	O
the	O
largest	O
diameter	O
and	O
the	O
one	O
perpendicular	O
to	O
it	O
)	O
,	O
PD	O
(	O
Progressive	O
Disease	O
,	O
increase	O
in	O
the	O
diameter	O
product	O
of	O
any	O
individual	O
tumor	O
lesion	O
by	O
≥25	O
%	O
)	O
,	O
and	O
SD	O
(	O
Stable	O
Disease	O
,	O
anything	O
between	O
PR	O
and	O
PD	O
)	O
.	O

To	O
analyze	O
for	O
the	O
predictive	O
value	O
of	O
the	O
different	O
parameters	O
,	O
similar	O
to	O
our	O
previous	O
studies	O
[	O
13	O
]	O
,	O
[	O
14	O
]	O
we	O
compared	O
PD	O
tumors	O
(	O
non	O
responders	O
)	O
with	O
the	O
combined	O
group	O
of	O
tumors	O
classified	O
as	O
SD	O
/	O
PR	O
/	O
CR	O
(	O
responders	O
)	O
;	O
the	O
reason	O
for	O
this	O
approach	O
is	O
discussed	O
in	O
detail	O
elsewhere	O
[	O
34	O
]	O
.	O

Median	O
follow	O
-	O
up	O
time	O
was	O
defined	O
from	O
patient	O
inclusion	O
in	O
the	O
study	O
up	O
to	O
October	O
31	O
,	O
2006	O
.	O

Deaths	O
attributable	O
to	O
causes	O
other	O
than	O
breast	O
cancer	O
were	O
treated	O
as	O
censored	O
observations	O
.	O

All	O
patient	O
records	O
were	O
subject	O
to	O
central	O
audit	O
for	O
response	O
classification	O
(	O
by	O
E.L.	O
,	O
B.Ø.	O
and	O
P.E.L.	O
)	O
.	O

Response	O
classifications	O
were	O
completed	O
and	O
approved	O
without	O
any	O
knowledge	O
about	O
result	O
from	O
laboratory	O
analysis	O
.	O

RNA	O
Purification	O
Total	O
RNA	O
was	O
purified	O
by	O
Trizol	O
(	O
Life	O
Technologies	O
,	O
Inc.	O
)	O
extraction	O
from	O
snap	O
-	O
frozen	O
tissue	O
samples	O
according	O
to	O
manufacturer	O
's	O
instructions	O
.	O

After	O
extraction	O
,	O
the	O
RNA	O
was	O
dissolved	O
in	O
100	O
µl	O
of	O
DEPC	O
treated	O
ddH2O	O
.	O

cDNA	O
was	O
synthesized	O
by	O
reverse	O
transcription	O
using	O
Transcriptor	O
reverse	O
transcriptase	O
(	O
Roche	O
)	O
,	O
according	O
to	O
the	O
manufacturer	O
's	O
protocol	O
.	O

DNA	O
Purification	O
Genomic	O
DNA	O
from	O
tumor	O
biopsies	O
and	O
blood	O
lymphocytes	O
was	O
isolated	O
using	O
QIAamp	O
DNA	O
Mini	O
kit	O
(	O
Qiagen	O
,	O
Chatsworth	O
,	O
CA	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
protocol	O
.	O

Mutation	O
Analysis	O
All	O
mutational	O
analysis	O
was	O
performed	O
blinded	O
to	O
clinical	O
data	O
.	O

Mutations	O
in	O
TP53	O
,	O
CHEK2	O
and	O
p14	O
(	O
ARF	O
)	O
genes	O
were	O
analyzed	O
by	O
PCR	O
(	O
or	O
nested	O
PCR	O
)	O
amplification	O
and	O
sequencing	O
of	O
PCR	O
product	O
,	O
or	O
by	O
cloning	O
of	O
PCR	O
products	O
and	O
sequencing	O
of	O
the	O
resulting	O
plasmids	O
(	O
all	O
primers	O
described	O
in	O
Table	O
1	O
)	O
.	O

Cloning	O
was	O
performed	O
using	O
the	O
TOPO	O
TA	O
Cloning	O
kit	O
(	O
Invitrogen	O
)	O
.	O

Sequencing	O
of	O
clones	O
was	O
performed	O
until	O
at	O
least	O
10	O
different	O
sequences	O
covered	O
all	O
parts	O
of	O
the	O
CHEK2	O
coding	O
sequence	O
.	O

DNA	O
sequencing	O
was	O
carried	O
out	O
directly	O
on	O
1	O
µl	O
PCR	O
product	O
or	O
plasmid	O
using	O
Big	O
Dye	O
terminator	O
mix	O
(	O
Applied	O
Biosystems	O
)	O
.	O

Capillary	O
gel	O
electrophoresis	O
,	O
data	O
collection	O
,	O
and	O
sequence	O
analysis	O
were	O
done	O
on	O
an	O
automated	O
DNA	O
sequencer	O
(	O
ABI	O
3700	O
)	O
.	O

When	O
a	O
mutation	O
was	O
detected	O
,	O
the	O
relevant	O
exon	O
was	O
amplified	O
by	O
PCR	O
from	O
genomic	O
tumor	O
DNA	O
and	O
DNA	O
from	O
blood	O
lymphocytes	O
and	O
sequenced	O
for	O
verification	O
and	O
germline	O
detection	O
.	O

(	O
Primers	O
described	O
in	O
Table	O
1	O
)	O
.	O

Loss	O
of	O
Heterozygosity	O
(	O
LOH	O
)	O
Loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
in	O
tumors	O
with	O
mutations	O
in	O
CHEK2	O
was	O
assessed	O
using	O
the	O
microsatellite	O
marker	O
,	O
D22S275	O
,	O
which	O
maps	O
to	O
intron	O
4	O
of	O
CHEK2	O
.	O

LOH	O
in	O
tumors	O
with	O
mutation	O
in	O
TP53	O
was	O
assessed	O
using	O
two	O
markers	O
,	O
one	O
variable	O
number	O
tandem	O
repeat	O
in	O
intron	O
1	O
[	O
35	O
]	O
and	O
a	O
CA	O
repeat	O
close	O
to	O
the	O
TP53	O
gene	O
[	O
36	O
]	O
.	O

Fluorescently	O
end	O
-	O
labeled	O
primers	O
were	O
used	O
in	O
the	O
PCR	O
,	O
and	O
the	O
PCR	O
products	O
were	O
analyzed	O
on	O
an	O
ABI	O
3700	O
.	O

LOH	O
was	O
evaluated	O
by	O
comparing	O
the	O
allele	O
peak	O
-	O
height	O
ratios	O
from	O
blood	O
DNA	O
and	O
tumor	O
DNA	O
.	O

A	O
sample	O
was	O
scored	O
as	O
having	O
AI	O
(	O
Allelic	O
Imbalance	O
)	O
when	O
a	O
reduction	O
in	O
peak	O
height	O
of	O
one	O
allele	O
in	O
tumor	O
sample	O
was	O
at	O
least	O
18	O
%	O
compared	O
with	O
that	O
of	O
blood	O
DNA	O
from	O
the	O
same	O
patient	O
[	O
37	O
]	O
.	O

Analysis	O
of	O
p14	O
(	O
ARF	O
)	O
promoter	O
methylation	O
Genomic	O
DNA	O
was	O
subjected	O
to	O
bisulphate	O
conversion	O
using	O
the	O
CpGenome	O
DNA	O
Modification	O
Kit	O
(	O
Intergen	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
protocol	O
.	O

Both	O
the	O
unmethylated-	O
and	O
methylated	O
-	O
specific	O
PCRs	O
were	O
performed	O
in	O
50	O
µl	O
reaction	O
mixes	O
containing	O
2.5	O
U	O
AmpliTaq	O
Gold	O
DNA	O
Polymerase	O
(	O
Applied	O
Biosystems	O
)	O
,	O
1	O
×	O
PCR	O
buffer	O
,	O
1.5	O
mM	O
MgCl2	O
,	O
0.1	O
mM	O
of	O
each	O
deoxynucleotide	O
triphosphate	O
,	O
0.2	O
µM	O
of	O
each	O
primer	O
(	O
Table	O
1	O
)	O
and	O
2	O
µl	O
of	O
modified	O
genomic	O
DNA	O
.	O

Thermocycling	O
conditions	O
for	O
both	O
the	O
unmethylated-	O
and	O
methylated	O
-	O
specific	O
PCRs	O
were	O
an	O
initial	O
step	O
of	O
5	O
minutes	O
at	O
95	O
°	O
C	O
followed	O
by	O
35	O
cycles	O
of	O
30	O
sec.	O
at	O
94	O
°	O
C	O
,	O
30	O
sec.	O
at	O
60.5	O
°	O
C	O
and	O
60	O
sec.	O
at	O
72	O
°	O
C	O
before	O
a	O
final	O
elongation	O
step	O
at	O
72	O
°	O
C	O
for	O
7	O
min	O
.	O

Chk2	O
Dimerisation	O
Chk2	O
mutant	O
's	O
ability	O
to	O
form	O
dimers	O
with	O
the	O
wild	O
-	O
type	O
protein	O
was	O
investigated	O
by	O
immunoprecipitation	O
.	O

U-2-OS	O
cells	O
were	O
co	O
-	O
transfected	O
with	O
expression	O
vectors	O
expressing	O
wild	O
-	O
type	O
Chk2	O
with	O
N	O
-	O
terminal	O
Xpr	O
-	O
tag	O
(	O
pcDNA4	O
/	O
HisMax	O
,	O
Invitrogen	O
)	O
and	O
mutated	O
Chk2	O
forms	O
with	O
C	O
-	O
terminal	O
V5-tag	O
(	O
pcDNA3.1	O
/	O
V5-His	O
,	O
Invitrogen	O
)	O
.	O

Transfection	O
was	O
performed	O
using	O
FuGene	O
6.0	O
transfection	O
reagent	O
(	O
Roche	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
.	O

Cells	O
were	O
harvested	O
in	O
lysisbuffer	O
(	O
50	O
mM	O
TrisHCl	O
pH	O
8.0	O
,	O
150	O
mM	O
NaCl	O
,	O
0.5	O
%	O
NP40	O
,	O
5	O
mM	O
EDTA	O
pH	O
8.0	O
)	O
48	O
hours	O
after	O
transfection	O
.	O

An	O
aliquote	O
of	O
the	O
cell	O
lysate	O
was	O
harvested	O
for	O
subsequent	O
Chk2-mutant	O
-	O
V5	O
transfection	O
verification	O
.	O

Samples	O
were	O
further	O
incubated	O
with	O
A	O
/	O
G	O
Pluss	O
Agarose	O
beads	O
(	O
Santa	O
Cruz	O
Biotechnology	O
)	O
at	O
4	O
°	O
C	O
for	O
25	O
minutes	O
before	O
the	O
beads	O
were	O
removed	O
by	O
centrifugation	O
at	O
5000	O
g	O
for	O
4	O
minutes	O
and	O
the	O
samples	O
were	O
incubated	O
with	O
1.5	O
µg	O
anti	O
-	O
V5	O
(	O
Invitrogen	O
)	O
at	O
4	O
°	O
C	O
for	O
90	O
minutes	O
.	O

Fresh	O
A	O
/	O
G	O
Pluss	O
Agarose	O
beads	O
were	O
added	O
and	O
the	O
samples	O
were	O
incubated	O
for	O
another	O
90	O
minutes	O
at	O
4	O
°	O
C	O
.	O

The	O
beads	O
were	O
washed	O
three	O
times	O
with	O
1	O
×	O
PBS	O
,	O
before	O
being	O
separated	O
on	O
a	O
10	O
%	O
polyacrylamide	O
gel	O
and	O
blotted	O
on	O
to	O
a	O
nitrocellulose	O
membrane	O
.	O

Chk2-wild	O
-	O
type	O
-	O
Xpr	O
co	O
-	O
precipitated	O
with	O
Chk2-mutant	O
-	O
V5	O
was	O
detected	O
through	O
incubations	O
with	O
anti	O
-	O
Xpr	O
antibody	O
(	O
Invitrogen	O
)	O
,	O
HRP	O
-	O
conjugated	O
secondary	O
antibody	O
and	O
ECL	O
detection	O
reagent	O
(	O
GE	O
Healthcare	O
)	O
.	O

Kinase	O
Activity	O
Chk2	O
mutant	O
's	O
ability	O
to	O
function	O
as	O
kinases	O
was	O
investigated	O
through	O
an	O
in	O
vitro	O
kinase	O
assay	O
.	O

The	O
V5	O
expression	O
vectors	O
used	O
for	O
the	O
dimerisation	O
study	O
were	O
also	O
used	O
to	O
express	O
Chk2	O
mutants	O
in	O
the	O
kinase	O
assay	O
.	O

U-2-OS	O
cells	O
were	O
transfected	O
using	O
the	O
FuGene	O
6.0	O
transfection	O
reagent	O
(	O
Roche	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
.	O

Cells	O
were	O
then	O
incubated	O
at	O
37	O
°	O
C	O
in	O
5	O
%	O
CO2	O
and	O
humidified	O
atmosphere	O
.	O

After	O
24	O
hours	O
doxorubicin	O
(	O
Nycomed	O
Pharma	O
)	O
was	O
added	O
to	O
the	O
media	O
to	O
a	O
final	O
concentration	O
of	O
50ng	O
/	O
ml	O
and	O
the	O
cells	O
were	O
further	O
incubated	O
for	O
24	O
hours	O
before	O
harvest	O
.	O

75	O
cm2	O
of	O
90	O
%	O
confluent	O
cells	O
were	O
harvested	O
in	O
500	O
µl	O
lysis	O
buffer	O
(	O
50	O
mM	O
HEPES	O
,	O
150	O
mM	O
NaCl	O
,	O
10	O
%	O
glycerol	O
,	O
0.5	O
%	O
Triton	O
X-100	O
,	O
2	O
mM	O
MgCl2	O
,	O
5	O
mM	O
EDTA	O
)	O
,	O
and	O
the	O
cytosol	O
was	O
incubated	O
for	O
90	O
minutes	O
at	O
4	O
°	O
C	O
with	O
50	O
µl	O
50	O
%	O
Glutathione	O
Sepharose	O
beads	O
(	O
Amersham	O
Biosciences	O
)	O
linked	O
to	O
anti	O
-	O
V5	O
antibody	O
(	O
Invitrogen	O
)	O
.	O

The	O
beads	O
were	O
then	O
washed	O
twice	O
with	O
lysisbuffer	O
containing	O
500	O
mM	O
NaCl	O
and	O
twice	O
with	O
kinase	O
assay	O
buffer	O
(	O
50	O
mM	O
HEPES	O
,	O
10	O
mM	O
MgCl2	O
,	O
5	O
mM	O
MnCl2	O
,	O
2.5	O
mM	O
EGTA	O
)	O
.	O

The	O
beads	O
received	O
30	O
µl	O
kinase	O
assay	O
buffer	O
with	O
7.5	O
µM	O
cold	O
ATP	O
,	O
10	O
µCi	O
32P	O
-	O
gamma	O
-	O
ATP	O
(	O
GE	O
Healthcare	O
)	O
and	O
2	O
µg	O
isolated	O
Cdc25C	O
peptide	O
,	O
and	O
was	O
incubated	O
at	O
30	O
°	O
C	O
for	O
30	O
minutes	O
.	O

Samples	O
were	O
separated	O
on	O
a	O
12.5	O
%	O
polyacrylamide	O
gel	O
and	O
blotted	O
on	O
to	O
a	O
nitrocellulose	O
membrane	O
.	O

A	O
radiosensitive	O
imaging	O
plate	O
was	O
exposed	O
to	O
the	O
membrane	O
and	O
the	O
plate	O
was	O
read	O
in	O
a	O
FLA200	O
imager	O
(	O
Fuji	O
)	O
.	O

The	O
kinase	O
assay	O
described	O
above	O
was	O
also	O
used	O
to	O
determine	O
the	O
Chk2	O
mutants	O
'	O
kinase	O
activity	O
after	O
co	O
-	O
transfection	O
of	O
each	O
Chk2	O
mutant	O
and	O
wild	O
-	O
type	O
Chk2	O
in	O
equal	O
amounts	O
.	O

Statistical	O
Analysis	O
Statistical	O
analysis	O
was	O
performed	O
using	O
the	O
Primer	O
of	O
Biostatistics	O
system	O
,	O
version	O
5.0	O
[	O
38	O
]	O
.	O

The	O
differences	O
in	O
the	O
distribution	O
of	O
TP53	O
and	O
CHEK2	O
mutations	O
among	O
patients	O
revealing	O
a	O
PD	O
and	O
the	O
responders	O
were	O
analyzed	O
with	O
use	O
of	O
Fisher	O
's	O
exact	O
test	O
.	O

P	O
-	O
values	O
are	O
reported	O
as	O
accumulated	O
two	O
-	O
sided	O
.	O

Because	O
of	O
the	O
limited	O
time	O
of	O
the	O
follow	O
-	O
up	O
,	O
no	O
formal	O
statistical	O
assessment	O
of	O
overall	O
survival	O
was	O
performed	O
.	O

Relapse	O
-	O
free	O
survival	O
was	O
analyzed	O
by	O
the	O
log	O
-	O
rank	O
test	O
.	O

Details	O
regarding	O
outcome	O
in	O
individual	O
patients	O
with	O
mutations	O
are	O
shown	O
in	O
Table	O
2	O
and	O
3	O
to	O
make	O
them	O
available	O
to	O
the	O
reader	O
.	O

Results	O
TP53	O
Mutations	O
and	O
Response	O
to	O
Therapy	O
The	O
TP53	O
mutations	O
identified	O
in	O
the	O
tumors	O
of	O
the	O
patients	O
treated	O
with	O
epirubicin	O
together	O
with	O
the	O
clinical	O
response	O
to	O
therapy	O
and	O
follow	O
-	O
up	O
data	O
are	O
presented	O
in	O
Table	O
2	O
.	O

Somatic	O
TP53	O
mutations	O
were	O
identified	O
in	O
23	O
(	O
21.5	O
%	O
)	O
of	O
the	O
patients	O
.	O

Normal	O
tissue	O
(	O
WBC	O
)	O
was	O
available	O
from	O
18	O
of	O
these	O
for	O
germline	O
characterization	O
,	O
revealing	O
none	O
of	O
the	O
mutations	O
identified	O
to	O
be	O
germline	O
alterations	O
.	O

Of	O
the	O
23	O
mutations	O
detected	O
,	O
20	O
were	O
missense	O
and	O
3	O
were	O
nonsense	O
.	O

One	O
mutation	O
(	O
del483CAT	O
)	O
has	O
not	O
been	O
reported	O
previously	O
either	O
in	O
breast	O
cancer	O
or	O
in	O
any	O
other	O
tumor	O
type	O
(	O
IARC	O
database	O
:	O
http://www.iarc.fr/p53/	O
)	O
.	O

Twelve	O
of	O
the	O
mutations	O
directly	O
or	O
indirectly	O
affected	O
the	O
L2	O
/	O
L3	O
domains	O
of	O
the	O
p53	O
protein	O
(	O
Table	O
2	O
)	O
previous	O
found	O
to	O
predict	O
a	O
poor	O
prognosis	O
[	O
39	O
]	O
and	O
drug	O
resistance	O
[	O
14	O
]	O
,	O
[	O
40	O
]	O
.	O

For	O
statistical	O
comparison	O
,	O
mutation	O
Gly325Ter	O
(	O
patient	O
Epi215	O
)	O
located	O
to	O
the	O
tetramerization	O
domain	O
is	O
grouped	O
together	O
with	O
the	O
mutations	O
affecting	O
the	O
L2	O
/	O
L3	O
domain	O
,	O
since	O
this	O
mutation	O
leads	O
to	O
truncation	O
of	O
the	O
protein	O
and	O
with	O
loss	O
of	O
tetramerization	O
and	O
functional	O
defects	O
similar	O
to	O
L2	O
/	O
L3	O
mutations	O
[	O
41	O
]	O
.	O

There	O
was	O
a	O
statistical	O
significant	O
correlation	O
between	O
TP53	O
mutation	O
status	O
and	O
lack	O
of	O
treatment	O
response	O
(	O
PD	O
)	O
(	O
Table	O
4	O
;	O
p	O
=	O
0.0358	O
;	O
Fisher	O
exact	O
test	O
)	O
.	O

When	O
tumors	O
harboring	O
TP53	O
mutations	O
affecting	O
the	O
p53	O
L2	O
/	O
L3	O
DNA	O
-	O
binding	O
domains	O
were	O
compared	O
to	O
those	O
with	O
wild	O
-	O
type	O
TP53	O
or	O
TP53	O
mutations	O
outside	O
the	O
L2	O
/	O
L3	O
domains	O
,	O
this	O
correlation	O
was	O
further	O
strengthened	O
(	O
p	O
=	O
0.0136	O
)	O
.	O

The	O
previously	O
described	O
TP53	O
polymorphism	O
,	O
Arg72Pro	O
[	O
42	O
]	O
was	O
detected	O
in	O
31	O
(	O
29	O
%	O
)	O
of	O
our	O
patients	O
.	O

No	O
correlation	O
was	O
found	O
between	O
this	O
polymorphism	O
and	O
lack	O
of	O
treatment	O
response	O
(	O
p	O
=	O
0.2750	O
;	O
Fisher	O
exact	O
test	O
)	O
or	O
TP53	O
mutational	O
status	O
(	O
p	O
=	O
0.2024	O
)	O
.	O

CHEK2	O
Mutations	O
and	O
Response	O
to	O
Therapy	O
Table	O
3	O
presents	O
the	O
patients	O
with	O
detected	O
CHEK2	O
mutations	O
together	O
with	O
a	O
description	O
of	O
the	O
clinical	O
response	O
and	O
follow	O
up	O
-	O
data	O
.	O

CHEK2	O
mutations	O
were	O
identified	O
in	O
three	O
out	O
of	O
the	O
109	O
patients	O
(	O
2.8	O
%	O
)	O
.	O

Notably	O
,	O
each	O
of	O
the	O
CHEK2	O
mutations	O
identified	O
was	O
also	O
present	O
in	O
patient	O
lymphocyte	O
DNA	O
,	O
confirming	O
a	O
germline	O
origin	O
.	O

The	O
Arg95Ter	O
(	O
C283	O
T	O
)	O
mutation	O
is	O
novel	O
.	O

This	O
mutation	O
was	O
present	O
in	O
two	O
patients	O
(	O
Epi132	O
and	O
Epi203	O
)	O
living	O
in	O
different	O
parts	O
of	O
Norway	O
with	O
no	O
known	O
family	O
relationship	O
.	O

However	O
,	O
linkage	O
analysis	O
using	O
microsatellite	O
markers	O
(	O
D22S275	O
,	O
D22S272	O
,	O
D22S1172	O
and	O
D22S423	O
)	O
suggested	O
a	O
common	O
founder	O
mutation	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
C283	O
T	O
transition	O
generates	O
a	O
novel	O
stop	O
codon	O
in	O
exon	O
1	O
of	O
CHEK2	O
,	O
leading	O
to	O
truncation	O
of	O
the	O
Chk2	O
protein	O
.	O

LOH	O
analysis	O
indicated	O
loss	O
of	O
the	O
wild	O
-	O
type	O
CHEK2	O
allele	O
in	O
the	O
both	O
tumors	O
from	O
the	O
two	O
patients	O
harboring	O
this	O
mutation	O
(	O
Epi132	O
and	O
Epi203	O
)	O
.	O

Both	O
these	O
tumors	O
were	O
non	O
-	O
responsive	O
to	O
epirubicin	O
therapy	O
(	O
PD	O
)	O
.	O

In	O
contrast	O
,	O
the	O
third	O
patient	O
with	O
a	O
germline	O
CHEK2	O
mutation	O
(	O
patient	O
Epi151	O
;	O
point	O
mutation	O
at	O
T1091C	O
,	O
Ile364Thr	O
)	O
had	O
a	O
partial	O
response	O
to	O
epirubicin	O
therapy	O
.	O

This	O
tumor	O
was	O
non	O
-	O
informative	O
with	O
respect	O
to	O
LOH	O
.	O

Taking	O
all	O
CHEK2	O
mutations	O
together	O
,	O
they	O
predicted	O
resistance	O
to	O
epirubicin	O
(	O
p	O
=	O
0.0226	O
)	O
.	O

The	O
previously	O
described	O
silent	O
Glu84Glu	O
(	O
A252	O
G	O
)	O
polymorphism	O
[	O
24	O
]	O
,	O
[	O
43	O
]	O
in	O
exon	O
1	O
was	O
detected	O
in	O
two	O
(	O
1.9	O
%	O
)	O
patients	O
.	O

No	O
association	O
between	O
this	O
polymorphism	O
and	O
treatment	O
response	O
was	O
recorded	O
.	O

One	O
of	O
the	O
tumors	O
(	O
Epi203	O
)	O
harboring	O
the	O
C283	O
T	O
substitution	O
(	O
Arg95Ter	O
)	O
also	O
harbored	O
a	O
somatic	O
TP53	O
mutation	O
in	O
codon	O
175	O
,	O
Arg175His	O
,	O
located	O
in	O
the	O
L2	O
domain	O
of	O
p53	O
(	O
Table	O
2	O
)	O
.	O

This	O
mutation	O
was	O
detected	O
in	O
another	O
four	O
of	O
our	O
patients	O
treated	O
with	O
epirubicin	O
(	O
Table	O
2	O
)	O
.	O

In	O
addition	O
,	O
TP53	O
Arg175His	O
mutation	O
was	O
recorded	O
in	O
one	O
patient	O
of	O
our	O
previous	O
study	O
evaluating	O
response	O
to	O
doxorubicin	O
[	O
13	O
]	O
.	O

The	O
fact	O
that	O
none	O
of	O
the	O
Arg175His	O
patients	O
presented	O
here	O
or	O
in	O
our	O
previous	O
study	O
revealed	O
resistance	O
to	O
therapy	O
(	O
PD	O
)	O
suggests	O
this	O
mutation	O
may	O
not	O
cause	O
resistance	O
to	O
anthracyclines	O
in	O
breast	O
cancers	O
in	O
vivo	O
.	O

Omitting	O
the	O
tumor	O
harboring	O
both	O
a	O
CHEK2	O
and	O
a	O
TP53	O
mutation	O
(	O
patient	O
Epi203	O
)	O
from	O
statistical	O
analysis	O
,	O
Chk2	O
mutations	O
(	O
n	O
=	O
2	O
)	O
were	O
non	O
-	O
significantly	O
associated	O
with	O
therapy	O
resistance	O
(	O
p	O
=	O
0.1633	O
)	O
.	O

In	O
a	O
previous	O
study	O
[	O
26	O
]	O
,	O
however	O
,	O
we	O
analyzed	O
for	O
CHEK2	O
mutation	O
status	O
in	O
relation	O
to	O
therapy	O
outcome	O
in	O
a	O
cohort	O
of	O
patients	O
from	O
doxorubicin	O
study	O
[	O
13	O
]	O
.	O

In	O
that	O
study	O
[	O
26	O
]	O
,	O
we	O
detected	O
the	O
previously	O
identified	O
mutation	O
Ile157Thr	O
.	O

In	O
addition	O
,	O
we	O
detected	O
a	O
novel	O
nonsense	O
somatic	O
mutation	O
(	O
1368InsA	O
)	O
.	O

This	O
mutation	O
was	O
associated	O
with	O
lack	O
of	O
function	O
in	O
vitro	O
;	O
moreover	O
,	O
it	O
was	O
associated	O
with	O
drug	O
resistance	O
in	O
vivo	O
.	O

Analyzing	O
our	O
material	O
and	O
this	O
cohort	O
[	O
26	O
]	O
together	O
,	O
(	O
n	O
=	O
160	O
)	O
,	O
CHEK2	O
mutations	O
(	O
n	O
=	O
5	O
in	O
total	O
)	O
predicted	O
for	O
resistance	O
to	O
doxorubicin	O
and	O
epirubicin	O
therapy	O
(	O
p	O
=	O
0.0123	O
)	O
.	O

Even	O
though	O
,	O
excluding	O
patient	O
Epi203	O
(	O
harboring	O
TP53	O
Arg175His	O
and	O
Arg95Ter	O
CHEK2	O
mutation	O
)	O
as	O
well	O
as	O
other	O
patients	O
harboring	O
TP53	O
L2	O
/	O
L3	O
mutations	O
(	O
n	O
=	O
129	O
)	O
,	O
CHEK2	O
mutations	O
(	O
n	O
=	O
4	O
in	O
total	O
)	O
predicted	O
for	O
resistance	O
to	O
doxorubicin	O
and	O
epirubicin	O
therapy	O
(	O
p	O
=	O
0.030	O
)	O
.	O

TP53	O
and	O
CHEK2	O
Mutations	O
Combined	O
and	O
Response	O
to	O
Therapy	O
Assuming	O
that	O
TP53	O
and	O
CHEK2	O
mutations	O
may	O
substitute	O
for	O
each	O
other	O
,	O
we	O
analyzed	O
for	O
the	O
predictive	O
effect	O
of	O
mutations	O
in	O
both	O
genes	O
.	O

The	O
occurrence	O
of	O
a	O
mutation	O
affecting	O
either	O
CHEK2	O
or	O
TP53	O
strongly	O
predicted	O
therapy	O
resistance	O
(	O
p	O
=	O
0.0101	O
;	O
Fisher	O
exact	O
test	O
)	O
.	O

When	O
tumors	O
harboring	O
TP53-L2	O
/	O
L3	O
mutations	O
and	O
CHEK2	O
mutations	O
were	O
compared	O
with	O
those	O
wild	O
-	O
type	O
or	O
TP53	O
mutations	O
outside	O
the	O
L2	O
/	O
L3	O
domain	O
,	O
the	O
correlation	O
was	O
further	O
strengthened	O
(	O
p	O
=	O
0.0032	O
;	O
Fisher	O
exact	O
test	O
)	O
.	O

The	O
significance	O
was	O
preserved	O
when	O
comparing	O
patients	O
with	O
a	O
PD	O
to	O
objective	O
responders	O
(	O
CR	O
and	O
PR	O
)	O
excluding	O
patients	O
with	O
stable	O
disease	O
(	O
SD	O
)	O
from	O
the	O
statistical	O
analysis	O
(	O
Table	O
4	O
)	O
.	O

p14	O
(	O
ARF	O
)	O
Mutations	O
and	O
Promoter	O
Methylations	O
Neither	O
mutations	O
nor	O
polymorphisms	O
in	O
the	O
coding	O
region	O
of	O
p14	O
(	O
ARF	O
)	O
were	O
observed	O
among	O
the	O
107	O
patients	O
analyzed	O
.	O

Likewise	O
,	O
no	O
promoter	O
methylations	O
were	O
detected	O
.	O

Influence	O
of	O
CHEK2	O
and	O
TP53	O
Mutation	O
Status	O
on	O
Relapse	O
-	O
Free	O
Survival	O
Because	O
of	O
the	O
limited	O
time	O
of	O
the	O
follow	O
-	O
up	O
,	O
no	O
formal	O
statistical	O
assessment	O
of	O
overall	O
survival	O
was	O
performed	O
.	O

Details	O
regarding	O
outcome	O
for	O
individual	O
patients	O
with	O
mutations	O
are	O
described	O
in	O
Table	O
2	O
and	O
3	O
to	O
make	O
these	O
data	O
available	O
to	O
the	O
reader	O
.	O

Relapse	O
-	O
free	O
survival	O
is	O
depicted	O
in	O
(	O
Figure	O
1	O
)	O
.	O

Figure	O
1A	O
shows	O
relapse	O
-	O
free	O
survival	O
for	O
the	O
patients	O
with	O
TP53	O
and	O
CHEK2	O
mutations	O
(	O
all	O
mutations	O
found	O
)	O
compared	O
to	O
patients	O
without	O
any	O
TP53	O
or	O
CHEK2	O
mutations	O
,	O
no	O
difference	O
in	O
relapse	O
-	O
free	O
survival	O
was	O
observed	O
.	O

Similar	O
,	O
no	O
difference	O
was	O
seen	O
when	O
grouping	O
TP53	O
mutations	O
outside	O
L2	O
/	O
L3	O
and	O
CHEK2	O
mutation	O
not	O
affecting	O
kinase	O
function	O
(	O
Ile364Thr	O
)	O
as	O
wild	O
-	O
type	O
(	O
Figure	O
1B	O
)	O
.	O

Grouping	O
tumors	O
harboring	O
a	O
mutation	O
in	O
L2	O
/	O
L3	O
together	O
with	O
CHEK2	O
mutations	O
affecting	O
kinase	O
domain	O
(	O
Arg95Ter	O
)	O
in	O
one	O
group	O
,	O
mutations	O
outside	O
TP53	O
L2	O
/	O
L3	O
and	O
Ile364Thr	O
as	O
one	O
group	O
and	O
tumors	O
without	O
any	O
found	O
mutations	O
in	O
TP53	O
and	O
CHEK2	O
separately	O
,	O
again	O
no	O
noticeably	O
difference	O
in	O
relapse	O
-	O
free	O
survival	O
were	O
seen	O
(	O
Figure	O
1C	O
)	O
.	O

Notably	O
,	O
in	O
addition	O
to	O
a	O
short	O
median	O
follow	O
-	O
up	O
time	O
,	O
a	O
total	O
of	O
35	O
patients	O
with	O
a	O
sub	O
-	O
optimal	O
response	O
to	O
epirubicin	O
received	O
subsequent	O
treatment	O
with	O
paclitaxel	O
,	O
which	O
may	O
have	O
influenced	O
the	O
outcome	O
.	O

CHEK2	O
Mutant	O
's	O
Capability	O
to	O
Form	O
Dimers	O
To	O
investigate	O
whether	O
the	O
identified	O
CHEK2	O
mutations	O
affect	O
the	O
ability	O
of	O
the	O
Chk2	O
protein	O
to	O
form	O
dimers	O
,	O
co	O
-	O
transfection	O
and	O
immunopresipitation	O
of	O
V5-tagged	O
mutants	O
and	O
Xpress	O
-	O
tagged	O
wild	O
-	O
type	O
Chk2	O
were	O
performed	O
using	O
CHEK2	O
low	O
-	O
expressing	O
U-2-OS	O
cells	O
.	O

As	O
we	O
identified	O
the	O
previously	O
characterized	O
CHEK2	O
germline	O
mutants	O
variants	O
Arg117His	O
(	O
n	O
=	O
2	O
and	O
Ile157Thr	O
(	O
n	O
=	O
1	O
)	O
among	O
patients	O
allocated	O
to	O
primary	O
treatment	O
with	O
paclitaxel	O
in	O
our	O
ongoing	O
study	O
,	O
these	O
mutants	O
were	O
evaluated	O
together	O
with	O
Arg95Ter	O
and	O
Ile364Thr	O
.	O

The	O
results	O
presented	O
in	O
Figure	O
2	O
show	O
that	O
all	O
Chk2	O
variants	O
carrying	O
a	O
point	O
mutation	O
were	O
able	O
to	O
form	O
dimers	O
with	O
wild	O
-	O
type	O
Chk2	O
,	O
whereas	O
the	O
Arg95Ter	O
variant	O
was	O
not	O
.	O

Kinase	O
Activity	O
of	O
CHEK2	O
Mutants	O
To	O
investigate	O
whether	O
the	O
identified	O
CHEK2	O
mutants	O
retained	O
the	O
wild	O
-	O
type	O
kinase	O
activity	O
,	O
an	O
in	O
vitro	O
Chk2	O
kinase	O
assay	O
with	O
respect	O
to	O
Chk2	O
autophosphorylation	O
and	O
Cdc25	O
substrate	O
phosphorylation	O
was	O
performed	O
.	O

The	O
U-2-OS	O
cells	O
were	O
preferred	O
for	O
this	O
assay	O
because	O
they	O
were	O
previously	O
found	O
to	O
express	O
only	O
low	O
levels	O
of	O
endogenous	O
Chk2	O
[	O
44	O
]	O
.	O

This	O
was	O
confirmed	O
by	O
us	O
using	O
an	O
antibody	O
recognizing	O
endogenous	O
protein	O
(	O
data	O
not	O
shown	O
)	O
.	O

These	O
cells	O
have	O
previously	O
been	O
used	O
by	O
other	O
investigators	O
to	O
study	O
Chk2	O
kinase	O
activity	O
[	O
44	O
]	O
,	O
[	O
45	O
]	O
,	O
[	O
46	O
]	O
.	O

The	O
two	O
mutants	O
Arg117Gly	O
and	O
Ile157Thr	O
were	O
previously	O
tested	O
for	O
in	O
vitro	O
kinase	O
activity	O
[	O
47	O
]	O
,	O
but	O
were	O
both	O
included	O
here	O
,	O
together	O
with	O
wild	O
-	O
type	O
CHEK2	O
as	O
controls	O
.	O

Compared	O
to	O
wild	O
-	O
type	O
Chk2	O
,	O
the	O
Ile157Thr	O
mutant	O
retained	O
wild	O
-	O
type	O
kinase	O
activity	O
.	O

The	O
mutant	O
Ile364Thr	O
showed	O
partially	O
reduced	O
kinase	O
activity	O
both	O
in	O
term	O
of	O
Cdc25-phosphorylation	O
and	O
autophosphorylation	O
(	O
Figure	O
3	O
)	O
.	O

In	O
contrast	O
,	O
the	O
mutant	O
Arg117Gly	O
showed	O
strongly	O
reduced	O
kinase	O
activity	O
while	O
the	O
Arg95Ter	O
mutant	O
was	O
totally	O
devoid	O
of	O
any	O
Chk2	O
kinase	O
activity	O
.	O

The	O
activity	O
recorded	O
for	O
Ile157Thr	O
and	O
Arg117Gly	O
was	O
consistent	O
with	O
previously	O
reported	O
results	O
for	O
these	O
two	O
mutants	O
[	O
47	O
]	O
.	O

Notably	O
,	O
there	O
was	O
an	O
internal	O
consistency	O
with	O
respect	O
to	O
percentage	O
activity	O
reduction	O
comparing	O
individual	O
mutants	O
with	O
respect	O
to	O
autophosphorylation	O
and	O
phosphorylation	O
of	O
Cdc25	O
(	O
Figure	O
3	O
)	O
.	O

Since	O
enzymatically	O
active	O
Chk2	O
exists	O
as	O
dimers	O
,	O
it	O
was	O
important	O
to	O
determine	O
the	O
effect	O
of	O
Chk2	O
mutants	O
on	O
wild	O
-	O
type	O
/	O
mutant	O
heterodimer	O
kinase	O
activity	O
.	O

The	O
effect	O
on	O
Chk2	O
kinase	O
activities	O
(	O
Chk2	O
autophosphorylation	O
and	O
Cdc25	O
substrate	O
phosphorylation	O
)	O
of	O
the	O
individual	O
mutants	O
were	O
therefore	O
determined	O
after	O
co	O
-	O
transfection	O
with	O
wild	O
-	O
type	O
Chk2	O
as	O
described	O
in	O
Materials	O
and	O
Methods	O
.	O

The	O
results	O
from	O
this	O
co	O
-	O
transfection	O
-	O
kinase	O
assay	O
(	O
Figure	O
4	O
)	O
were	O
similar	O
to	O
those	O
of	O
the	O
single	O
-	O
transfection	O
assay	O
(	O
Figure	O
3	O
)	O
except	O
in	O
the	O
case	O
of	O
the	O
Arg117Gly	O
mutant	O
,	O
which	O
expressed	O
a	O
substantial	O
kinase	O
activity	O
when	O
complexed	O
with	O
wild	O
-	O
type	O
Chk2	O
.	O

This	O
is	O
consistent	O
with	O
previous	O
data	O
indicating	O
that	O
the	O
Arg117Gly	O
mutant	O
has	O
neglectable	O
kinase	O
activity	O
itself	O
but	O
dimerizes	O
efficiently	O
to	O
Chk2	O
wild	O
-	O
type	O
without	O
strongly	O
affecting	O
the	O
wild	O
-	O
type	O
Chk2	O
activity	O
.	O

Hence	O
,	O
the	O
activity	O
detected	O
is	O
probably	O
caused	O
by	O
the	O
co	O
-	O
transfected	O
and	O
co	O
-	O
precipitated	O
wild	O
-	O
type	O
protein	O
.	O

To	O
rule	O
out	O
the	O
possibility	O
that	O
endogenously	O
expressed	O
wild	O
-	O
type	O
Chk2	O
contributed	O
to	O
observed	O
Arg117Gly	O
kinase	O
activity	O
shown	O
in	O
Figure	O
4	O
,	O
we	O
compared	O
the	O
Arg117Gly	O
variant	O
activity	O
in	O
the	O
presence	O
or	O
absence	O
of	O
co	O
-	O
transfected	O
wild	O
-	O
type	O
Chk2	O
to	O
the	O
activities	O
of	O
Arg95Ter	O
under	O
the	O
same	O
conditions	O
.	O

The	O
Arg95Ter	O
variant	O
does	O
not	O
form	O
dimers	O
with	O
wild	O
-	O
type	O
Chk2	O
.	O

As	O
seen	O
in	O
Figure	O
5	O
,	O
Arg117Gly	O
,	O
which	O
forms	O
dimers	O
with	O
Chk2	O
wild	O
-	O
type	O
,	O
allows	O
increased	O
activity	O
when	O
co	O
-	O
transfected	O
with	O
wild	O
-	O
type	O
as	O
compared	O
to	O
the	O
corresponding	O
activity	O
for	O
the	O
Arg95Ter	O
mutant	O
.	O

The	O
fact	O
that	O
Arg117Gly	O
,	O
when	O
transfected	O
alone	O
,	O
displays	O
very	O
similar	O
activity	O
as	O
Arg95Ter	O
or	O
negative	O
control	O
(	O
background	O
levels	O
)	O
,	O
strongly	O
indicates	O
that	O
the	O
contribution	O
of	O
endogenous	O
Chk2	O
,	O
which	O
,	O
similarly	O
to	O
exogenously	O
expressed	O
wild	O
-	O
type	O
Chk2	O
co	O
-	O
precipitate	O
with	O
Arg117Gly	O
is	O
non	O
-	O
significant	O
.	O

Family	O
Cancer	O
Incidence	O
in	O
Relation	O
to	O
CHEK2	O
Germline	O
Mutations	O
Following	O
an	O
initial	O
report	O
of	O
a	O
family	O
with	O
a	O
CHEK2	O
germline	O
mutation	O
expressing	O
an	O
increased	O
cancer	O
incidence	O
resembling	O
the	O
Li	O
-	O
Fraumeni	O
syndrome	O
[	O
24	O
]	O
,	O
recent	O
studies	O
have	O
revealed	O
the	O
more	O
common	O
CHEK2	O
mutations	O
to	O
be	O
associated	O
with	O
a	O
moderately	O
increased	O
risk	O
of	O
breast	O
and	O
colorectal	O
cancers	O
.	O

We	O
hypothesized	O
that	O
CHEK2	O
mutations	O
having	O
a	O
detrimental	O
effect	O
on	O
drug	O
sensitivity	O
could	O
be	O
associated	O
with	O
a	O
more	O
aggressive	O
,	O
Li	O
-	O
Fraumeni	O
or	O
a	O
Li	O
-	O
Fraumeni	O
-	O
like	O
(	O
LFL	O
)	O
cancer	O
syndrome	O
[	O
48	O
]	O
.	O

Except	O
from	O
the	O
patient	O
harboring	O
the	O
Ile364Thr	O
mutation	O
who	O
did	O
not	O
have	O
any	O
known	O
congestion	O
of	O
cancer	O
disease	O
in	O
the	O
family	O
,	O
a	O
detailed	O
assessment	O
of	O
family	O
cancer	O
history	O
was	O
performed	O
for	O
each	O
patient	O
harboring	O
a	O
germline	O
CHEK2	O
mutation	O
.	O

The	O
family	O
cancer	O
pedigrees	O
are	O
depicted	O
in	O
Figure	O
6	O
.	O

While	O
patients	O
harboring	O
CHEK2	O
germline	O
mutations	O
revealed	O
different	O
types	O
of	O
cancers	O
(	O
mainly	O
breast	O
and	O
tumors	O
of	O
the	O
gastrointestinal	O
area	O
)	O
in	O
their	O
family	O
,	O
surprisingly	O
,	O
no	O
distinct	O
pattern	O
discriminating	O
families	O
harboring	O
the	O
Arg95Ter	O
mutation	O
from	O
the	O
other	O
CHEK2	O
mutated	O
families	O
could	O
be	O
identified	O
.	O

One	O
of	O
them	O
(	O
Epi203	O
)	O
,	O
who	O
inherited	O
the	O
mutation	O
from	O
her	O
father	O
's	O
side	O
of	O
the	O
family	O
,	O
had	O
no	O
accumulation	O
of	O
either	O
breast	O
or	O
colorectal	O
cancer	O
on	O
that	O
side	O
.	O

It	O
should	O
be	O
noted	O
,	O
however	O
,	O
that	O
two	O
brothers	O
of	O
her	O
fathers	O
mother	O
had	O
prostate	O
cancer	O
,	O
and	O
two	O
siblings	O
of	O
his	O
father	O
having	O
hepatocellular	O
carcinoma	O
and	O
bladder	O
cancer	O
,	O
respectively	O
)	O
,	O
while	O
the	O
other	O
expressed	O
a	O
disease	O
pattern	O
resembling	O
what	O
has	O
been	O
seen	O
with	O
the	O
more	O
common	O
CHEK2	O
mutations	O
,	O
like	O
del1100C	O
[	O
25	O
]	O
.	O

Discussion	O
TP53	O
plays	O
a	O
key	O
role	O
as	O
a	O
tumor	O
suppressor	O
gene	O
.	O

Its	O
protein	O
product	O
activates	O
processes	O
such	O
as	O
growth	O
arrest	O
,	O
DNA	O
repair	O
,	O
apoptosis	O
and/or	O
senescence	O
in	O
response	O
to	O
genotoxic	O
damage	O
as	O
well	O
as	O
oncogene	O
activity	O
[	O
49	O
]	O
,	O
[	O
50	O
]	O
.	O

Despite	O
being	O
extensively	O
studied	O
,	O
critical	O
issues	O
regarding	O
regulation	O
of	O
the	O
p53	O
protein	O
remain	O
poorly	O
understood	O
,	O
and	O
conflicting	O
evidence	O
obtained	O
in	O
different	O
experimental	O
systems	O
make	O
the	O
clinical	O
relevance	O
of	O
experimental	O
data	O
questionable	O
.	O

Chemoresistance	O
is	O
the	O
main	O
obstacle	O
to	O
cancer	O
cure	O
in	O
most	O
malignancies	O
,	O
including	O
breast	O
cancer	O
.	O

Previously	O
,	O
we	O
found	O
TP53	O
mutations	O
affecting	O
the	O
L2	O
/	O
L3	O
DNA	O
binding	O
domain	O
to	O
be	O
associated	O
with	O
lack	O
of	O
responsiveness	O
to	O
doxorubicin	O
monotherapy	O
[	O
13	O
]	O
as	O
well	O
as	O
mitomycin	O
and	O
5-fluoro	O
-	O
uracil	O
in	O
concert	O
[	O
14	O
]	O
.	O

However	O
,	O
some	O
tumors	O
revealed	O
therapy	O
resistance	O
despite	O
harboring	O
wild	O
-	O
type	O
TP53	O
.	O

Postulating	O
that	O
these	O
tumors	O
may	O
harbor	O
genetic	O
disturbances	O
in	O
genes	O
playing	O
a	O
key	O
role	O
in	O
the	O
p53	O
pathway	O
,	O
we	O
here	O
sequenced	O
TP53	O
along	O
with	O
CHEK2	O
and	O
p14	O
(	O
ARF	O
)	O
,	O
the	O
latter	O
two	O
known	O
to	O
play	O
a	O
critical	O
role	O
as	O
p53	O
activators	O
,	O
in	O
tumors	O
from	O
109	O
patients	O
treated	O
with	O
epirubicin	O
monotherapy	O
.	O

Our	O
results	O
confirm	O
TP53	O
mutations	O
,	O
in	O
particular	O
those	O
affecting	O
the	O
L2	O
/	O
L3	O
domains	O
,	O
to	O
be	O
associated	O
with	O
drug	O
resistance	O
.	O

Most	O
importantly	O
,	O
we	O
also	O
found	O
CHEK2	O
mutations	O
generating	O
a	O
non	O
-	O
functional	O
protein	O
in	O
our	O
in	O
vitro	O
assays	O
to	O
be	O
associated	O
with	O
drug	O
resistance	O
.	O

In	O
contrast	O
,	O
none	O
of	O
our	O
tumors	O
harbored	O
either	O
mutations	O
or	O
expressed	O
promoter	O
hypermethylations	O
affecting	O
the	O
p14	O
.	O

Based	O
on	O
in	O
vitro	O
assays	O
,	O
we	O
were	O
able	O
to	O
classify	O
the	O
different	O
Chk2	O
mutants	O
with	O
respect	O
to	O
dimerization	O
capability	O
as	O
well	O
as	O
kinase	O
activity	O
(	O
Chk2	O
autophosphorylation	O
and	O
Cdc25	O
substrate	O
phosphorylation	O
)	O
.	O

In	O
addition	O
,	O
the	O
kinase	O
activities	O
of	O
the	O
Chk2	O
wild	O
-	O
type	O
/	O
mutant	O
complexes	O
were	O
monitored	O
in	O
co	O
-	O
transfection	O
experiments	O
.	O

Notably	O
,	O
each	O
point	O
mutation	O
(	O
except	O
for	O
Arg117Gly	O
)	O
revealed	O
similar	O
relative	O
kinase	O
efficacy	O
whether	O
co	O
-	O
transfected	O
with	O
wild	O
-	O
type	O
Chk2	O
or	O
not	O
(	O
Figure	O
3	O
and	O
4	O
)	O
.	O

Cells	O
co	O
-	O
transfected	O
with	O
Arg117Gly	O
and	O
wild	O
-	O
type	O
Chk2	O
revealed	O
kinase	O
activity	O
,	O
probably	O
due	O
to	O
the	O
contribution	O
of	O
the	O
wild	O
type	O
protein	O
in	O
Chk2	O
mutant	O
–	O
wild	O
-	O
type	O
heterodimers	O
.	O

In	O
contrast	O
,	O
cells	O
transfected	O
with	O
Arg95Ter	O
revealed	O
no	O
kinase	O
activity	O
whether	O
co	O
-	O
transfected	O
with	O
wild	O
-	O
type	O
Chk2	O
or	O
not	O
,	O
clearly	O
distinguishing	O
this	O
mutation	O
from	O
the	O
others	O
(	O
Figure	O
3	O
and	O
5	O
)	O
.	O

All	O
in	O
vitro	O
assays	O
were	O
based	O
on	O
transfection	O
of	O
the	O
U-2-OS	O
cell	O
line	O
,	O
a	O
cell	O
line	O
known	O
to	O
express	O
wild	O
-	O
type	O
Chk2	O
at	O
low	O
levels	O
,	O
and	O
previously	O
used	O
by	O
other	O
investigators	O
to	O
study	O
Chk2	O
activity	O
[	O
44	O
]	O
,	O
[	O
45	O
]	O
,	O
[	O
46	O
]	O
.	O

Since	O
we	O
were	O
not	O
able	O
to	O
obtain	O
satisfactory	O
technical	O
quality	O
of	O
the	O
kinase	O
assay	O
in	O
cell	O
lines	O
negative	O
for	O
Chk2	O
(	O
HCT	O
15	O
and	O
HCT	O
116	O
)	O
,	O
we	O
assessed	O
potential	O
background	O
kinase	O
activity	O
due	O
to	O
endogenous	O
Chk2	O
by	O
performing	O
western	O
blot	O
analysis	O
revealing	O
the	O
endogenous	O
levels	O
of	O
Chk2	O
in	O
U-2-OS	O
cells	O
to	O
be	O
non	O
-	O
significant	O
compared	O
to	O
the	O
exogenously	O
expressed	O
Chk2	O
levels	O
(	O
data	O
not	O
shown	O
)	O
.	O

We	O
also	O
performed	O
a	O
separate	O
kinase	O
assay	O
,	O
directly	O
comparing	O
the	O
effect	O
of	O
binding	O
partners	O
for	O
the	O
dimerizing	O
Arg117Gly	O
and	O
the	O
non	O
-	O
dimerizing	O
Arg95Ter	O
.	O

This	O
assay	O
also	O
revealed	O
the	O
contribution	O
of	O
endogenous	O
Chk2	O
to	O
be	O
non	O
-	O
significant	O
(	O
Figure	O
5	O
)	O
.	O

Taking	O
our	O
in	O
vitro	O
findings	O
together	O
with	O
in	O
vivo	O
observations	O
,	O
our	O
present	O
data	O
confirm	O
that	O
the	O
functionally	O
defective	O
CHEK2	O
Arg95Ter	O
mutation	O
,	O
together	O
with	O
LOH	O
,	O
is	O
associated	O
with	O
resistance	O
to	O
anthracycline	O
therapy	O
.	O

In	O
contrast	O
,	O
the	O
patient	O
harboring	O
the	O
Ile364Thr	O
mutation	O
,	O
moderately	O
reducing	O
phosphorylation	O
activity	O
,	O
responded	O
well	O
to	O
therapy	O
.	O

The	O
other	O
missense	O
mutations	O
;	O
Arg117Gly	O
and	O
Ile157Thr	O
were	O
observed	O
among	O
patients	O
receiving	O
paclitaxel	O
therapy	O
only	O
;	O
thus	O
,	O
their	O
influence	O
on	O
anthracycline	O
sensitivity	O
in	O
vivo	O
could	O
not	O
be	O
addressed	O
.	O

Yet	O
,	O
based	O
on	O
the	O
finding	O
that	O
the	O
Arg117Gly	O
mutant	O
expressed	O
no	O
intrinsic	O
activity	O
,	O
but	O
readily	O
dimerized	O
to	O
the	O
wild	O
-	O
type	O
protein	O
without	O
abolishing	O
its	O
activity	O
,	O
we	O
hypothesize	O
that	O
this	O
mutation	O
and	O
,	O
probably	O
,	O
other	O
yet	O
unidentified	O
CHEK2	O
mutations	O
with	O
a	O
similar	O
lack	O
of	O
intrinsic	O
kinase	O
activity	O
,	O
may	O
cause	O
resistance	O
to	O
anthracycline	O
therapy	O
if	O
combined	O
with	O
LOH	O
in	O
breast	O
cancer	O
.	O

Our	O
present	O
findings	O
have	O
two	O
major	O
implications	O
.	O

First	O
,	O
we	O
confirm	O
that	O
mutations	O
in	O
genes	O
encoding	O
proteins	O
located	O
within	O
the	O
same	O
functional	O
pathway	O
may	O
substitute	O
for	O
each	O
other	O
with	O
respect	O
to	O
drug	O
sensitivity	O
,	O
revealing	O
for	O
the	O
first	O
time	O
a	O
functional	O
pathway	O
critical	O
to	O
chemotherapy	O
response	O
in	O
vivo	O
.	O

Second	O
,	O
the	O
identification	O
of	O
mutations	O
in	O
the	O
CHEK2	O
but	O
not	O
in	O
the	O
p14	O
(	O
ARF	O
)	O
gene	O
in	O
resistant	O
tumors	O
suggests	O
that	O
Chk2	O
mediated	O
phosphorylation	O
of	O
p53	O
is	O
a	O
critical	O
event	O
in	O
executing	O
anti	O
-	O
tumor	O
effect	O
as	O
a	O
response	O
to	O
DNA	O
damaging	O
agents	O
in	O
breast	O
cancer	O
.	O

This	O
adds	O
to	O
our	O
understanding	O
not	O
only	O
of	O
the	O
function	O
of	O
p53	O
but	O
Chk2	O
as	O
well	O
.	O

p53	O
undergoes	O
phosphorylation	O
at	O
multiple	O
sites	O
by	O
different	O
kinases	O
,	O
including	O
Chk2	O
[	O
51	O
]	O
.	O

While	O
activation	O
of	O
the	O
ATM	O
leading	O
to	O
direct	O
(	O
Ser	O
15	O
)	O
and	O
Chk2-mediated	O
(	O
Ser	O
20	O
)	O
phosphorylation	O
of	O
p53	O
is	O
considered	O
an	O
important	O
mechanism	O
for	O
triggering	O
p53	O
activation	O
in	O
response	O
to	O
DNA	O
damage	O
[	O
52	O
]	O
,	O
some	O
reports	O
suggest	O
ATM	O
[	O
53	O
]	O
and	O
even	O
Chk2	O
[	O
23	O
]	O
to	O
be	O
redundant	O
to	O
this	O
function	O
.	O

Importantly	O
,	O
Chk2	O
has	O
been	O
shown	O
capable	O
of	O
inducing	O
ATM	O
-	O
independent	O
apoptosis	O
in	O
vitro	O
[	O
21	O
]	O
.	O

While	O
Chk2	O
phosphorylates	O
p53	O
at	O
Ser	O
20	O
,	O
thereby	O
stabilizing	O
p53	O
by	O
preventing	O
MDM2	O
binding	O
[	O
19	O
]	O
,	O
Chk2	O
also	O
phosphorylates	O
p53	O
at	O
six	O
additional	O
sites	O
,	O
including	O
Ser	O
313	O
and	O
Ser	O
314	O
located	O
in	O
the	O
nuclear	O
localization	O
signal	O
domain	O
of	O
p53	O
[	O
51	O
]	O
.	O

In	O
addition	O
,	O
Chk2	O
phosphorylates	O
other	O
important	O
targets	O
like	O
BRCA1	O
,	O
Cdc25A	O
and	O
Cdc25C	O
involved	O
in	O
DNA	O
repair	O
,	O
G1	O
and	O
G2	O
arrest	O
,	O
respectively	O
[	O
54	O
]	O
.	O

Despite	O
the	O
wide	O
range	O
of	O
known	O
Chk2	O
substrates	O
relevant	O
for	O
DNA	O
repair	O
and	O
cell	O
cycle	O
control	O
,	O
our	O
present	O
findings	O
that	O
CHEK2	O
mutations	O
leading	O
to	O
non	O
-	O
functional	O
Chk2	O
protein	O
may	O
substitute	O
for	O
p53	O
mutations	O
strongly	O
advocate	O
a	O
role	O
for	O
Chk2	O
with	O
respect	O
to	O
drug	O
sensitivity	O
executed	O
through	O
p53	O
activation	O
.	O

Notably	O
,	O
one	O
of	O
the	O
tumors	O
(	O
Epi203	O
)	O
with	O
the	O
Arg95Ter	O
CHEK2	O
mutation	O
in	O
addition	O
harbored	O
a	O
somatic	O
TP53	O
mutation	O
,	O
Arg175His	O
,	O
with	O
allelic	O
imbalance	O
for	O
the	O
TP53	O
gene	O
(	O
Table	O
2	O
)	O
.	O

Importantly	O
,	O
among	O
another	O
four	O
patients	O
in	O
this	O
study	O
(	O
Epi063	O
,	O
Epi071	O
,	O
Epi087	O
,	O
Epi153	O
)	O
and	O
one	O
patient	O
from	O
our	O
previous	O
doxorubicin	O
protocol	O
[	O
13	O
]	O
harboring	O
the	O
Arg175His	O
mutation	O
together	O
with	O
allelic	O
imbalance	O
for	O
TP53	O
,	O
all	O
five	O
of	O
these	O
patients	O
responded	O
to	O
anthracycline	O
therapy	O
either	O
with	O
a	O
partial	O
response	O
or	O
stable	O
disease	O
.	O

In	O
contrast	O
,	O
Epi132	O
and	O
the	O
only	O
patient	O
for	O
whom	O
we	O
previously	O
identified	O
a	O
non	O
-	O
functional	O
CHEK2	O
mutation	O
(	O
1368InsA	O
;	O
coding	O
for	O
a	O
non	O
-	O
functional	O
protein	O
translate	O
with	O
cytoplasmic	O
location	O
[	O
26	O
]	O
)	O
expressed	O
resistance	O
to	O
epirubicin	O
and	O
doxorubicin	O
,	O
respectively	O
.	O

Arg175His	O
is	O
a	O
p53	O
""""	O
hot	O
-	O
spot	O
""""	O
structural	O
mutation	O
reported	O
to	O
have	O
defects	O
with	O
respect	O
to	O
transcriptional	O
activation	O
and	O
also	O
to	O
negatively	O
interact	O
with	O
wild	O
-	O
type	O
p53	O
[	O
55	O
]	O
.	O

While	O
this	O
mutation	O
has	O
been	O
shown	O
to	O
enhance	O
chemoresistance	O
upon	O
transfection	O
into	O
p53	O
null	O
Saos-2	O
cells	O
[	O
56	O
]	O
,	O
these	O
osteosarcoma	O
-	O
derived	O
cells	O
may	O
not	O
necessarily	O
be	O
representative	O
for	O
breast	O
cancers	O
in	O
vivo	O
.	O

Recent	O
evidence	O
strongly	O
support	O
p53	O
to	O
be	O
involved	O
also	O
in	O
non	O
-	O
transcriptional	O
mediated	O
apoptosis	O
by	O
interacting	O
with	O
the	O
Bcl-2	O
/	O
Bax	O
system	O
[	O
57	O
]	O
,	O
and	O
transcription	O
-	O
defect	O
structural	O
p53	O
mutants	O
have	O
been	O
shown	O
to	O
execute	O
non	O
-	O
transcriptional	O
apoptosis	O
in	O
experimental	O
systems	O
[	O
58	O
]	O
.	O

Concomitant	O
inactivation	O
of	O
Chk2	O
and	O
p53	O
in	O
breast	O
cancer	O
has	O
been	O
recorded	O
by	O
others	O
[	O
59	O
]	O
,	O
and	O
the	O
finding	O
that	O
a	O
somatic	O
mutation	O
may	O
generate	O
a	O
""""	O
growth	O
advantage	O
""""	O
in	O
tumor	O
cells	O
already	O
harboring	O
a	O
germline	O
CHEK2	O
mutation	O
may	O
not	O
implicate	O
an	O
effect	O
on	O
drug	O
sensitivity	O
in	O
tumors	O
not	O
yet	O
exposed	O
to	O
cytotoxic	O
compounds	O
.	O

Rather	O
,	O
it	O
may	O
indicate	O
a	O
growth	O
advantage	O
,	O
probably	O
related	O
to	O
loss	O
of	O
p21	O
function	O
.	O

Notably	O
,	O
in	O
a	O
previous	O
study	O
we	O
found	O
the	O
p21	O
polymorphism	O
G251A	O
to	O
be	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
developing	O
large	O
breast	O
cancers	O
but	O
to	O
have	O
no	O
effect	O
on	O
drug	O
sensitivity	O
[	O
60	O
]	O
,	O
indicating	O
that	O
growth	O
rate	O
and	O
drug	O
resistance	O
may	O
be	O
regulated	O
independently	O
.	O

Taken	O
together	O
,	O
we	O
believe	O
our	O
findings	O
advocate	O
a	O
role	O
for	O
Chk2	O
in	O
executing	O
cellular	O
response	O
to	O
anthracycline	O
-	O
induced	O
DNA	O
damage	O
.	O

As	O
mentioned	O
above	O
,	O
removing	O
TP53	O
mutated	O
tumors	O
including	O
the	O
double	O
-	O
mutated	O
Epi203	O
from	O
statistical	O
analysis	O
,	O
CHEK2	O
mutation	O
status	O
still	O
predicted	O
for	O
resistance	O
to	O
anthracycline	O
therapy	O
.	O

In	O
addition	O
,	O
removing	O
the	O
tumors	O
harboring	O
the	O
Arg175His	O
mutation	O
from	O
the	O
p53	O
""""	O
L2	O
/	O
L3	O
""""	O
group	O
strengthened	O
the	O
correlation	O
to	O
lack	O
of	O
treatment	O
response	O
to	O
epirubicin	O
(	O
p	O
=	O
0.0005	O
)	O
.	O

Comparing	O
the	O
effects	O
of	O
mutations	O
in	O
the	O
CHEK2	O
gene	O
to	O
TP53	O
mutations	O
indirectly	O
underlines	O
the	O
importance	O
of	O
the	O
role	O
of	O
Chk2	O
to	O
chemoresistance	O
.	O

Our	O
present	O
findings	O
as	O
well	O
as	O
results	O
from	O
our	O
previous	O
studies	O
[	O
13	O
]	O
,	O
[	O
14	O
]	O
revealed	O
that	O
about	O
50	O
%	O
of	O
the	O
patients	O
with	O
tumors	O
harboring	O
TP53	O
L2	O
/	O
L3	O
mutations	O
to	O
be	O
non	O
-	O
responders	O
to	O
primary	O
therapy	O
.	O

In	O
contrast	O
,	O
all	O
our	O
three	O
patients	O
harboring	O
a	O
non	O
-	O
functional	O
CHEK2	O
mutation	O
(	O
the	O
two	O
Arg95Ter	O
mutated	O
patients	O
here	O
and	O
our	O
previous	O
patient	O
harboring	O
the	O
1368InsA	O
)	O
expressed	O
primary	O
resistance	O
to	O
therapy	O
.	O

We	O
previously	O
hypothesized	O
that	O
therapy	O
response	O
in	O
tumors	O
harboring	O
TP53	O
L2	O
/	O
L3	O
mutations	O
could	O
be	O
due	O
to	O
redundant	O
pathways	O
acting	O
in	O
concert	O
[	O
3	O
]	O
.	O

Although	O
no	O
definite	O
conclusion	O
should	O
be	O
drawn	O
from	O
a	O
limited	O
number	O
of	O
observation	O
,	O
the	O
fact	O
that	O
Chk2	O
not	O
only	O
phosphorylates	O
p53	O
but	O
also	O
phosphorylates	O
other	O
substrates	O
such	O
as	O
Cdc25A	O
and	O
Cdc25C	O
[	O
54	O
]	O
and	O
E2F1	O
in	O
response	O
to	O
etoposide	O
-	O
induced	O
DNA	O
damage	O
[	O
61	O
]	O
may	O
indicate	O
that	O
inactivation	O
of	O
redundant	O
pathways	O
could	O
take	O
place	O
in	O
parallel	O
.	O

The	O
literature	O
remains	O
inconsistent	O
with	O
respect	O
to	O
whether	O
the	O
border	O
amino	O
acids	O
163	O
,	O
195	O
,	O
236	O
and	O
251	O
should	O
be	O
included	O
in	O
the	O
p53	O
L2	O
and	O
L3	O
domains	O
[	O
12	O
]	O
.	O

Taking	O
a	O
conservative	O
approach	O
,	O
we	O
classified	O
patient	O
Epi56	O
,	O
harboring	O
a	O
mutation	O
in	O
codon	O
163	O
,	O
as	O
a	O
L2	O
/	O
L3	O
mutant	O
.	O

The	O
patient	O
harboring	O
this	O
mutation	O
responded	O
to	O
therapy	O
(	O
PR	O
)	O
.	O

If	O
this	O
mutation	O
was	O
classified	O
as	O
outside	O
the	O
L2	O
domain	O
,	O
our	O
p	O
-	O
value	O
had	O
been	O
strengthened	O
from	O
p	O
=	O
0.0136	O
to	O
p	O
=	O
0.0096	O
.	O

Germline	O
mutations	O
in	O
TP53	O
cause	O
the	O
Li	O
-	O
Fraumeni	O
and	O
Li	O
-	O
Fraumeni	O
-	O
like	O
cancer	O
disposition	O
syndromes	O
.	O

However	O
,	O
while	O
the	O
germline	O
and	O
somatic	O
mutations	O
associated	O
with	O
these	O
syndromes	O
reveal	O
a	O
preference	O
for	O
the	O
same	O
codons	O
[	O
48	O
]	O
,	O
TP53	O
mutations	O
affecting	O
the	O
DNA	O
-	O
binding	O
domains	O
seem	O
associated	O
with	O
a	O
poor	O
prognosis	O
[	O
62	O
]	O
,	O
[	O
63	O
]	O
,	O
[	O
64	O
]	O
and	O
,	O
in	O
particular	O
,	O
drug	O
resistance	O
[	O
14	O
]	O
,	O
[	O
40	O
]	O
in	O
breast	O
cancer	O
.	O

Thus	O
,	O
tumor	O
suppression	O
and	O
tumor	O
cell	O
response	O
to	O
chemotherapeutics	O
may	O
involve	O
different	O
parts	O
of	O
p53	O
protein	O
function	O
.	O

Following	O
an	O
initial	O
report	O
identifying	O
a	O
CHEK2	O
mutation	O
in	O
a	O
family	O
expressing	O
characteristics	O
of	O
the	O
Li	O
-	O
Fraumeni	O
syndrome	O
[	O
65	O
]	O
,	O
recent	O
evidence	O
has	O
linked	O
CHEK2	O
founder	O
mutations	O
to	O
a	O
moderately	O
increased	O
risk	O
of	O
breast-	O
and	O
colorectal	O
cancers	O
with	O
some	O
additional	O
disposition	O
for	O
other	O
malignancies	O
as	O
well	O
[	O
66	O
]	O
.	O

However	O
,	O
cancer	O
incidence	O
and	O
phenotypes	O
did	O
not	O
reveal	O
an	O
aggressive	O
Li	O
-	O
Fraumeni	O
or	O
Li	O
-	O
Fraumeni	O
-	O
like	O
tumor	O
pattern	O
.	O

Similar	O
to	O
the	O
two	O
patients	O
in	O
our	O
paclitaxel	O
treatment	O
arm	O
harboring	O
the	O
rare	O
but	O
previously	O
characterized	O
mutation	O
Arg117Gly	O
and	O
the	O
patient	O
with	O
the	O
Ile157Thr	O
mutation	O
,	O
they	O
expressed	O
a	O
moderately	O
increased	O
risk	O
of	O
breast	O
and	O
gastrointestinal	O
cancers	O
(	O
Fig.	O
6	O
)	O
.	O

Thus	O
,	O
CHEK2	O
resembles	O
TP53	O
in	O
as	O
much	O
as	O
there	O
seems	O
to	O
be	O
no	O
direct	O
correlation	O
between	O
effects	O
of	O
individual	O
mutations	O
with	O
respect	O
to	O
tumor	O
suppression	O
and	O
drug	O
resistance	O
.	O

Our	O
finding	O
that	O
TP53	O
mutations	O
located	O
to	O
the	O
DNA	O
-	O
binding	O
domains	O
predicts	O
drug	O
resistance	O
may	O
indicate	O
transcriptional	O
mechanisms	O
to	O
be	O
involved	O
in	O
drug	O
-	O
induced	O
cell	O
death	O
.	O

p53	O
induced	O
apoptosis	O
has	O
been	O
associated	O
with	O
transcriptional	O
induction	O
of	O
genes	O
including	O
Puma	O
and	O
Noxa	O
as	O
well	O
as	O
Bax	O
in	O
experimental	O
systems	O
[	O
55	O
]	O
,	O
[	O
67	O
]	O
,	O
[	O
68	O
]	O
.	O

Yet	O
,	O
recent	O
evidence	O
has	O
revealed	O
p53	O
to	O
induce	O
apoptosis	O
through	O
non	O
-	O
transcriptional	O
mechanisms	O
by	O
direct	O
protein	O
interactions	O
with	O
members	O
of	O
the	O
Bcl-2	O
/	O
Bax	O
system	O
and	O
mitochondrial	O
release	O
of	O
cytochrom	O
c	O
[	O
57	O
]	O
,	O
[	O
69	O
]	O
.	O

In	O
deed	O
,	O
there	O
is	O
evidence	O
that	O
the	O
DNA	O
-	O
binding	O
domains	O
,	O
in	O
particular	O
the	O
L3	O
part	O
of	O
the	O
protein	O
,	O
may	O
be	O
critical	O
also	O
to	O
transcriptional	O
-	O
independent	O
apoptosis	O
[	O
70	O
]	O
.	O

Of	O
particular	O
note	O
is	O
the	O
finding	O
that	O
Chk2	O
may	O
regulate	O
transcriptional	O
-	O
independent	O
p53-mediated	O
apoptosis	O
in	O
response	O
to	O
DNA	O
-	O
damage	O
created	O
through	O
ionizing	O
irradiation	O
[	O
71	O
]	O
.	O

Interestingly	O
,	O
Krajewski	O
et	O
al	O
[	O
72	O
]	O
reported	O
low	O
expression	O
of	O
Bax	O
assessed	O
by	O
immunostaining	O
to	O
be	O
associated	O
with	O
a	O
low	O
response	O
to	O
chemotherapy	O
in	O
metastatic	O
breast	O
cancer	O
.	O

Although	O
no	O
conclusion	O
should	O
be	O
drawn	O
at	O
this	O
stage	O
,	O
together	O
these	O
findings	O
are	O
consistent	O
with	O
the	O
challenging	O
hypothesis	O
that	O
transcription	O
-	O
independent	O
activation	O
of	O
Bax	O
following	O
Chk2-phosphorylation	O
may	O
represent	O
a	O
key	O
pathway	O
in	O
p53	O
dependent	O
cell	O
death	O
in	O
breast	O
cancer	O
in	O
vivo	O
.	O

p14	O
acts	O
by	O
releasing	O
p53	O
from	O
MDM2	O
binding	O
,	O
and	O
has	O
been	O
related	O
to	O
oncogene	O
-	O
induced	O
p53	O
activation	O
[	O
73	O
]	O
.	O

Recently	O
,	O
p14	O
was	O
shown	O
to	O
affect	O
p53	O
by	O
additional	O
mechanisms	O
,	O
including	O
acetylations	O
[	O
74	O
]	O
,	O
response	O
to	O
ionizing	O
radiation	O
in	O
human	B
fibroblasts	O
[	O
75	O
]	O
,	O
and	O
tumor	O
-	O
suppression	O
following	O
ionizing	O
radiation	O
in	O
mice	B
[	O
76	O
]	O
,	O
[	O
77	O
]	O
.	O

These	O
findings	O
further	O
links	O
the	O
retinoblastoma	O
and	O
p53	O
pathways	O
[	O
28	O
]	O
.	O

As	O
such	O
,	O
we	O
believe	O
the	O
negative	O
finding	O
with	O
respect	O
to	O
its	O
role	O
in	O
chemoresistance	O
adds	O
important	O
information	O
.	O

Contrasting	O
earlier	O
findings	O
by	O
us	O
and	O
others	O
[	O
15	O
]	O
,	O
a	O
recent	O
study	O
revealed	O
TP53	O
mutations	O
to	O
be	O
associated	O
with	O
increased	O
likelihood	O
of	O
having	O
a	O
complete	O
response	O
to	O
chemotherapy	O
[	O
16	O
]	O
.	O

These	O
results	O
may	O
not	O
necessarily	O
be	O
at	O
conflict	O
.	O

In	O
the	O
latter	O
study	O
,	O
patients	O
received	O
treatment	O
with	O
a	O
""""	O
dose	O
-	O
dense	O
""""	O
chemotherapy	O
regimen	O
;	O
if	O
confirmed	O
,	O
the	O
combined	O
data	O
may	O
outline	O
a	O
therapeutic	O
indication	O
for	O
aggressive	O
dose	O
-	O
dense	O
therapy	O
based	O
on	O
tumor	O
TP53	O
/	O
CHEK2	O
status	O
.	O

So	O
far	O
attempts	O
to	O
identify	O
single	O
markers	O
and	O
,	O
more	O
recently	O
,	O
gene	O
expression	O
arrays	O
predicting	O
chemoresistance	O
have	O
not	O
proved	O
successful	O
(	O
see	O
refs	O
in	O
[	O
9	O
]	O
,	O
[	O
10	O
]	O
)	O
.	O

The	O
findings	O
presented	O
here	O
reveal	O
for	O
the	O
first	O
time	O
defects	O
in	O
a	O
functional	O
gene	O
cascade	O
to	O
be	O
associated	O
with	O
drug	O
resistance	O
in	O
a	O
human	B
cancer	O
in	O
vivo	O
.	O

Moreover	O
,	O
the	O
findings	O
are	O
made	O
in	O
breast	O
cancer	O
,	O
the	O
most	O
frequent	O
malignant	O
disease	O
among	O
women	O
in	O
the	O
industrialized	O
world	O
,	O
and	O
relate	O
to	O
resistance	O
to	O
anthracyclines	O
,	O
the	O
type	O
of	O
cytotoxic	O
compounds	O
most	O
frequently	O
employed	O
for	O
this	O
malignancy	O
.	O

While	O
the	O
only	O
study	O
we	O
are	O
aware	O
of	O
comparing	O
TP53	O
mutation	O
status	O
in	O
primaries	O
and	O
their	O
distant	O
metastases	O
suggested	O
an	O
increasing	O
fraction	O
of	O
tumors	O
to	O
express	O
mutated	O
TP53	O
during	O
progression	O
[	O
78	O
]	O
,	O
we	O
do	O
not	O
know	O
the	O
potential	O
contribution	O
of	O
either	O
TP53	O
or	O
CHEK2	O
mutations	O
to	O
drug	O
resistance	O
in	O
micrometastases	O
or	O
in	O
metastatic	O
disease	O
.	O

Yet	O
the	O
finding	O
that	O
one	O
of	O
our	O
non	O
-	O
functional	O
CHEK2	O
mutations	O
associated	O
with	O
chemoresistance	O
(	O
1368InsA	O
)	O
occurred	O
as	O
a	O
somatic	O
,	O
not	O
germline	O
mutation	O
,	O
suggest	O
such	O
mutations	O
may	O
be	O
selected	O
for	O
during	O
tumor	O
progression	O
.	O

We	O
propose	O
the	O
findings	O
presented	O
here	O
provide	O
important	O
beacons	O
identifying	O
a	O
functional	O
pathway	O
[	O
3	O
]	O
likely	O
to	O
be	O
disturbed	O
through	O
different	O
mechanisms	O
in	O
relation	O
to	O
therapy	O
resistance	O
in	O
advanced	O
disease	O
.	O

In	O
conclusion	O
,	O
we	O
believe	O
our	O
findings	O
here	O
that	O
mutations	O
in	O
the	O
TP53	O
and	O
CHEK2	O
genes	O
each	O
may	O
cause	O
resistance	O
to	O
anthracycline	O
therapy	O
in	O
primary	O
tumors	O
to	O
have	O
wide	O
implications	O
to	O
future	O
research	O
in	O
this	O
area	O
.	O

While	O
results	O
from	O
experimental	O
systems	O
are	O
mandatory	O
generating	O
hypotheses	O
,	O
conflicting	O
data	O
from	O
in	O
vitro	O
studies	O
underlines	O
the	O
pivotal	O
role	O
of	O
identifying	O
defects	O
associated	O
with	O
therapy	O
resistance	O
in	O
vivo	O
.	O

Either	O
through	O
mutations	O
of	O
the	O
genes	O
themselves	O
,	O
or	O
inactivation	O
of	O
this	O
functional	O
cascade	O
through	O
co	O
-	O
factors	O
,	O
we	O
believe	O
identification	O
of	O
the	O
Chk2	O
–	O
p53	O
axis	O
as	O
critical	O
to	O
anthracycline	O
therapy	O
response	O
provides	O
a	O
functional	O
clue	O
for	O
further	O
investigations	O
in	O
this	O
area	O
.	O

A	O
case	O
of	O
demand	O
ischemia	O
from	O
phendimetrazine	O
Abstract	O
Introduction	O
Phendimetrazine	O
is	O
a	O
medication	O
currently	O
being	O
used	O
to	O
help	O
patients	O
with	O
weight	O
loss	O
.	O

It	O
shares	O
a	O
chemical	O
structure	O
with	O
amphetamines	O
.	O

As	O
such	O
,	O
it	O
shares	O
some	O
of	O
the	O
same	O
toxicities	O
,	O
which	O
can	O
include	O
cardiac	O
toxicity	O
.	O

This	O
case	O
highlights	O
this	O
principle	O
.	O

Case	O
presentation	O
a	O
54	O
year	O
old	O
Caucasian	O
female	O
presented	O
to	O
our	O
urgent	O
care	O
facility	O
with	O
complaints	O
of	O
chest	O
pains	O
and	O
other	O
symptoms	O
suggestive	O
of	O
acute	O
coronary	O
syndrome	O
.	O

Ultimately	O
,	O
she	O
was	O
transferred	O
to	O
the	O
emergency	O
room	O
.	O

After	O
evaluation	O
there	O
,	O
it	O
appeared	O
she	O
was	O
having	O
demand	O
ischemia	O
from	O
prescription	O
diet	O
pills	O

Conclusion	O
This	O
case	O
report	O
demonstrates	O
the	O
potential	O
dangers	O
of	O
amphetamine	O
based	O
diet	O
pills	O
.	O

There	O
have	O
been	O
other	O
cases	O
of	O
cardiomyopathies	O
related	O
to	O
phendimetrazine	O
,	O
but	O
it	O
is	O
something	O
that	O
is	O
rarely	O
recognized	O
in	O
an	O
outpatient	O
setting	O
.	O

A	O
case	O
such	O
as	O
this	O
demonstrates	O
the	O
importance	O
of	O
obtaining	O
a	O
careful	O
medication	O
history	O
in	O
all	O
patients	O
and	O
in	O
recognizing	O
diet	O
pills	O
with	O
an	O
amphetamine	O
base	O
can	O
cause	O
cardiac	O
toxicity	O
.	O

Case	O
presentation	O
A	O
54	O
year	O
-	O
old	O
Caucasian	O
female	O
presented	O
to	O
our	O
urgent	O
care	O
facility	O
complaining	O
of	O
nausea	O
and	O
vomiting	O
,	O
sense	O
of	O
impending	O
doom	O
and	O
vague	O
chest	O
pain	O
radiating	O
toward	O
her	O
left	O
side	O
for	O
about	O
five	O
hours	O
.	O

She	O
never	O
had	O
similar	O
symptoms	O
in	O
the	O
past	O
.	O

She	O
also	O
denied	O
anything	O
that	O
could	O
have	O
precipitated	O
these	O
symptoms	O
.	O

Her	O
only	O
past	O
medical	O
history	O
was	O
significant	O
for	O
spina	O
bifida	O
.	O

Her	O
medications	O
included	O
occasional	O
Fiorinal	O
(	O
unknown	O
dose	O
)	O
,	O
Xanax	O
0.5	O
mg	O
as	O
needed	O
,	O
and	O
Phendimetrazine	O
(	O
unclear	O
dose	O
)	O
.	O

Her	O
social	O
history	O
was	O
significant	O
for	O
smoking	O
1	O
/	O
2	O
pack	O
per	O
day	O
cigarette	O
use	O
.	O

She	O
denied	O
alcohol	O
use	O
.	O

Family	O
history	O
was	O
non	O
contributory	O
.	O

She	O
worked	O
from	O
home	O
.	O

Her	O
physical	O
exam	O
showed	O
a	O
tachycardia	O
of	O
around	O
100	O
beats	O
per	O
minute	O
,	O
respiratory	O
rate	O
of	O
16	O
,	O
temperature	O
of	O
98.1	O
,	O
and	O
O2	O
saturation	O
of	O
100	O
%	O
on	O
room	O
air	O
.	O

She	O
was	O
approximately	O
5'7	O
""""	O
and	O
145	O
pounds	O
.	O

In	O
general	O
,	O
she	O
was	O
an	O
anxious	O
appearing	O
,	O
diaphoretic	O
woman	O
in	O
moderate	O
distress	O
,	O
she	O
had	O
no	O
elevated	O
JVD	O
at	O
30	O
degrees	O
,	O
her	O
heart	O
was	O
tachycardic	O
,	O
but	O
otherwise	O
without	O
murmur	O
,	O
gallops	O
,	O
or	O
rubs	O
,	O
her	O
lungs	O
were	O
clear	O
,	O
abdomen	O
soft	O
,	O
and	O
she	O
had	O
no	O
peripheral	O
edema	O
.	O

An	O
EKG	O
was	O
checked	O
which	O
appears	O
below	O
(	O
figure	O
1	O
)	O
.	O

After	O
examination	O
,	O
there	O
was	O
concern	O
for	O
acute	O
coronary	O
syndrome	O
(	O
ACS	O
)	O
.	O

She	O
was	O
given	O
nitroglycerin	O
with	O
relief	O
of	O
her	O
chest	O
discomfort	O
.	O

She	O
was	O
also	O
given	O
aspirin	O
to	O
chew	O
.	O

EMS	O
was	O
called	O
and	O
she	O
was	O
transferred	O
to	O
a	O
local	O
emergency	O
room	O
.	O

She	O
was	O
hospitalized	O
there	O
for	O
three	O
days	O
and	O
after	O
her	O
discharge	O
,	O
we	O
got	O
permission	O
from	O
her	O
to	O
request	O
records	O
.	O

While	O
hospitalized	O
,	O
she	O
was	O
ruled	O
out	O
for	O
ACS	O
with	O
negative	O
troponins	O
.	O

She	O
was	O
also	O
given	O
beta	O
blockade	O
which	O
resolved	O
her	O
tachycardia	O
and	O
her	O
T	O
wave	O
changes	O
on	O
EKG	O
.	O

The	O
next	O
morning	O
,	O
she	O
had	O
an	O
adenosine	O
stress	O
test	O
which	O
revealed	O
normal	O
uptake	O
with	O
no	O
areas	O
of	O
ischemia	O
and	O
an	O
ejection	O
fraction	O
of	O
55	O
%	O
.	O

She	O
was	O
monitored	O
for	O
one	O
more	O
day	O
and	O
then	O
discharged	O
with	O
instructions	O
to	O
discontinue	O
her	O
diet	O
pills	O
.	O

Discussion	O
Phendimetrazine	O
is	O
a	O
medication	O
currently	O
being	O
used	O
for	O
weight	O
loss	O
,	O
with	O
potential	O
for	O
illicit	O
use	O
.	O

It	O
has	O
a	O
similar	O
chemical	O
composition	O
of	O
amphetamines	O
,	O
which	O
is	O
thought	O
to	O
account	O
for	O
its	O
clinical	O
actions	O
[	O
1	O
]	O
.	O

Amphetamines	O
are	O
well	O
recognized	O
as	O
an	O
etiology	O
of	O
cardiac	O
ischemia	O
,	O
however	O
phendimetrazine	O
is	O
more	O
rarely	O
described	O
in	O
the	O
literature	O
as	O
causing	O
cardiac	O
events	O
.	O

[	O
2,3	O
]	O
.	O

Acute	O
effects	O
include	O
hyperpyrexia	O
,	O
mydriasis	O
,	O
chest	O
pain	O
,	O
arrhytmias	O
,	O
delirium	O
,	O
and	O
,	O
rhabdomylosis	O
,	O
among	O
others	O
[	O
2	O
]	O
.	O

Long	O
term	O
use	O
has	O
been	O
associated	O
with	O
dilated	O
cardiomyopathies	O
,	O
some	O
of	O
which	O
have	O
resolved	O
with	O
discontinuation	O
of	O
the	O
medication	O
[	O
3	O
]	O
.	O

In	O
this	O
particular	O
case	O
,	O
it	O
appears	O
she	O
may	O
have	O
developed	O
a	O
demand	O
ischemia	O
from	O
the	O
medication	O
.	O

It	O
is	O
not	O
known	O
how	O
much	O
of	O
the	O
drug	O
she	O
was	O
taking	O
.	O

Initially	O
,	O
she	O
was	O
resistant	O
to	O
accepting	O
that	O
phendimetrazine	O
could	O
induce	O
side	O
effects	O
,	O
and	O
there	O
was	O
suspicion	O
that	O
she	O
could	O
have	O
been	O
taking	O
more	O
of	O
the	O
drug	O
that	O
recommended	O
.	O

In	O
addition	O
,	O
she	O
was	O
not	O
prescribed	O
the	O
medication	O
and	O
would	O
not	O
admit	O
to	O
where	O
she	O
obtained	O
it	O
.	O

As	O
the	O
public	O
seems	O
to	O
have	O
more	O
focus	O
on	O
using	O
medications	O
to	O
induce	O
weight	O
loss	O
,	O
this	O
may	O
be	O
a	O
more	O
recognized	O
complication	O
and	O
heart	O
conditions	O
should	O
likely	O
be	O
monitored	O
prior	O
to	O
starting	O
amphetamine	O
based	O
weight	O
loss	O
pills	O
.	O

Conclusion	O
Due	O
to	O
potentially	O
detrimental	O
effects	O
of	O
this	O
medication	O
,	O
phendimetrazine	O
should	O
be	O
used	O
cautiously	O
in	O
many	O
situations	O
.	O

As	O
it	O
shares	O
its	O
chemical	O
structure	O
with	O
amphetamines	O
,	O
it	O
also	O
shares	O
many	O
of	O
the	O
side	O
effects	O
and	O
the	O
potential	O
for	O
abuse	O
/	O
addiction	O
.	O

There	O
have	O
been	O
other	O
reports	O
in	O
literature	O
describing	O
adverse	O
outcomes	O
from	O
phendimetrazine	O
as	O
well	O
as	O
other	O
weight	O
loss	O
medications	O
.	O

Therefore	O
,	O
cautious	O
use	O
is	O
warranted	O
.	O

Abbreviations	O
ACS	O
:	O
Acute	O
Coronary	O
Syndrome	O
.	O

Competing	O
interests	O
The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O
DL	O
,	O
JJ	O
,	O
GG	O
have	O
all	O
been	O
involved	O
in	O
and	O
approve	O
of	O
the	O
writing	O
of	O
this	O
case	O
presentation	O
.	O

Consent	O
Written	O
informed	O
consent	O
was	O
obtained	O
from	O
the	O
patient	O
for	O
publication	O
purposes	O
.	O

A	O
copy	O
can	O
be	O
obtained	O
if	O
requested	O
by	O
the	O
Editor	O
in	O
Chief	O
of	O
this	O
journal	O
.	O

Are	O
there	O
sensitive	O
subgroups	O
for	O
the	O
effects	O
of	O
airborne	O
particles	O
?	O

Abstract	O
Recent	O
studies	O
have	O
shown	O
that	O
particulate	O
air	O
pollution	O
is	O
a	O
risk	O
factor	O
for	O
hospitalization	O
for	O
heart	O
and	O
lung	O
disease	O
;	O
however	O
,	O
little	O
is	O
known	O
about	O
what	O
subpopulations	O
are	O
most	O
sensitive	O
to	O
this	O
pollutant	O
.	O

We	O
analyzed	O
Medicare	O
hospital	O
admissions	O
for	O
heart	O
disease	O
,	O
chronic	O
obstructive	O
pulmonary	O
disorders	O
(	O
COPD	O
)	O
and	O
pneumonia	O
in	O
Chicago	O
,	O
Cook	O
County	O
,	O
Illinois	O
,	O
between	O
1985	O
and	O
1994	O
.	O

We	O
examined	O
whether	O
previous	O
admissions	O
or	O
secondary	O
diagnoses	O
for	O
selected	O
conditions	O
predisposed	O
persons	O
to	O
having	O
a	O
greater	O
risk	O
from	O
air	O
pollution	O
.	O

We	O
also	O
considered	O
effect	O
modification	O
by	O
age	O
,	O
sex	O
,	O
and	O
race	O
.	O

We	O
found	O
that	O
the	O
air	O
-	O
pollution	O
-	O
associated	O
increase	O
in	O
hospital	O
admissions	O
for	O
cardiovascular	O
diseases	O
was	O
almost	O
doubled	O
in	O
subjects	O
with	O
concurrent	O
respiratory	O
infections	O
.	O

The	O
risk	O
was	O
also	O
increased	O
by	O
a	O
previous	O
admission	O
for	O
conduction	O
disorders	O
.	O

For	O
COPD	O
and	O
pneumonia	O
admissions	O
,	O
diagnosis	O
of	O
conduction	O
disorders	O
or	O
dysrhythmias	O
increased	O
the	O
risk	O
of	O
particulate	O
matter	O
<	O
10	O
microm	O
in	O
aerodynamic	O
diameter	O
(	O
PM	O
(	O
10	O
)	O
)	O
-associated	O
admissions	O
.	O

Persons	O
with	O
asthma	O
had	O
twice	O
the	O
risk	O
of	O
a	O
PM	O
(	O
10	O
)	O
-associated	O
pneumonia	O
admission	O
and	O
persons	O
with	O
heart	O
failure	O
had	O
twice	O
the	O
risk	O
of	O
PM	O
(	O
10	O
)	O
-induced	O
COPD	O
admissions	O
.	O

The	O
PM	O
(	O
10	O
)	O
effect	O
did	O
not	O
vary	O
by	O
sex	O
,	O
age	O
,	O
and	O
race	O
.	O

These	O
results	O
suggest	O
that	O
patients	O
with	O
acute	O
respiratory	O
infections	O
or	O
defects	O
in	O
the	O
electrical	O
control	O
of	O
the	O
heart	O
are	O
a	O
risk	O
group	O
for	O
particulate	O
matter	O
effects	O
.	O

Articles	O
Are	O
There	O
Sensitive	O
Subgroups	O
for	O
the	O
Effects	O
of	O
Airborne	O
Particles	O
?	O

Antonella	O
Zanobetti,1	O
Joel	O
Schwartz,1,2	O
and	O
Diane	O
Gold1,2	O

1Environmental	O
Epidemiology	O
Program	O
,	O
Department	O
of	O
Environmental	O
Health	O
,	O
Harvard	O
School	O
of	O
Public	O
Health	O
,	O
Boston	O
,	O
Massachusetts	O
,	O
USA	O
;	O
2Channing	O
Laboratory	O
,	O
Department	O
of	O
Medicine	O
,	O
Harvard	O
Medical	O
School	O
and	O
Brigham	O
and	O
Women	O
's	O
Hospital	O
,	O
Boston	O
,	O
Massachusetts	O
,	O
USA	O
Recent	O
studies	O
have	O
shown	O
that	O
particulate	O
air	O
pollution	O
is	O
a	O
risk	O
factor	O
for	O
hospitalization	O
for	O
heart	O
and	O
lung	O
disease	O
;	O
however	O
,	O
little	O
is	O
known	O
about	O
what	O
subpopulations	O
are	O
most	O
sensitive	O
to	O
this	O
pollutant	O
.	O

We	O
analyzed	O
Medicare	O
hospital	O
admissions	O
for	O
heart	O
disease	O
,	O
chronic	O
obstructive	O
pulmonary	O
disorders	O
(	O
COPD	O
)	O
and	O
pneumonia	O
in	O
Chicago	O
,	O
Cook	O
County	O
,	O
Illinois	O
,	O
between	O
1985	O
and	O
1994	O
.	O

We	O
examined	O
whether	O
previous	O
admissions	O
or	O
secondary	O
diagnoses	O
for	O
selected	O
conditions	O
predisposed	O
persons	O
to	O
having	O
a	O
greater	O
risk	O
from	O
air	O
pollution	O
.	O

We	O
also	O
considered	O
effect	O
modification	O
by	O
age	O
,	O
sex	O
,	O
and	O
race	O
.	O

We	O
found	O
that	O
the	O
air	O
-	O
pollution	O
-	O
associated	O
increase	O
in	O
hospital	O
admissions	O
for	O
cardiovascular	O
diseases	O
was	O
almost	O
doubled	O
in	O
subjects	O
with	O
concurrent	O
respiratory	O
infections	O
.	O

The	O
risk	O
was	O
also	O
increased	O
by	O
a	O
previous	O
admission	O
for	O
conduction	O
disorders	O
.	O

For	O
COPD	O
and	O
pneumonia	O
admissions	O
,	O
diagnosis	O
of	O
conduction	O
disorders	O
or	O
dysrhythmias	O
increased	O
the	O
risk	O
of	O
particulate	O
matter	O
<	O
10	O
�	O
m	O
in	O
aerodynamic	O
diameter	O
(	O
PM10	O
)	O
-associated	O
admissions	O
.	O

Persons	O
with	O
asthma	O
had	O
twice	O
the	O
risk	O
of	O
a	O
PM10-associated	O
pneumonia	O
admission	O
and	O
persons	O
with	O
heart	O
failure	O
had	O
twice	O
the	O
risk	O
of	O
PM10-induced	O
COPD	O
admissions	O
.	O

The	O
PM10	O
effect	O
did	O
not	O
vary	O
by	O
sex	O
,	O
age	O
,	O
and	O
race	O
.	O

These	O
results	O
suggest	O
that	O
patients	O
with	O
acute	O
respiratory	O
infections	O
or	O
defects	O
in	O
the	O
electrical	O
control	O
of	O
the	O
heart	O
are	O
a	O
risk	O
group	O
for	O
particulate	O
matter	O
effects	O
.	O

Key	O
words	O
:	O
effect	O
modification	O
,	O
hospital	O
admissions	O
,	O
particulate	O
air	O
pollution	O
.	O

Environ	O
Health	O
Perspect	O
108:841	O
�	O
845	O
(	O
2000	O
)	O
.	O

[	O
Online	O
28	O
July	O
2000	O
]	O

http://ehpnet1.niehs.nih.gov/docs/2000/108p841-845zanobetti/abstract.html	O
Particulate	O
air	O
pollution	O
has	O
been	O
associated	O
with	O
increases	O
in	O
daily	O
deaths	O
and	O
hospital	O
admissions	O
in	O
studies	O
all	O
over	O
the	O
world	O
(	O
1	O
�	O
15	O
)	O
.	O

These	O
associations	O
are	O
now	O
well	O
documented	O
but	O
little	O
is	O
known	O
,	O
as	O
yet	O
,	O
of	O
the	O
characteristics	O
of	O
persons	O
that	O
put	O
them	O
at	O
increased	O
risk	O
of	O
adverse	O
events	O
related	O
to	O
particulate	O
air	O
pollution	O
.	O

This	O
has	O
been	O
identified	O
as	O
a	O
key	O
data	O
gap	O
(	O
16	O
)	O
.	O

Schwartz	O
and	O
Dockery	O
(	O
17	O
)	O
reported	O
that	O
persons	O
older	O
than	O
65	O
years	O
of	O
age	O
had	O
a	O
somewhat	O
increased	O
risk	O
of	O
death	O
,	O
and	O
this	O
has	O
been	O
confirmed	O
in	O
other	O
studies	O
(	O
18	O
)	O
.	O

A	O
more	O
detailed	O
examination	O
of	O
particulate	O
matter	O
-	O
related	O
risk	O
by	O
deciles	O
of	O
age	O
(	O
19	O
)	O
showed	O
the	O
risk	O
beginning	O
to	O
increase	O
at	O
approximately	O
40	O
years	O
of	O
age	O
and	O
reaching	O
its	O
maximum	O
for	O
those	O
75	O
years	O
of	O
age	O
and	O
older	O
.	O

In	O
addition	O
to	O
age	O
,	O
several	O
studies	O
suggest	O
that	O
persons	O
with	O
respiratory	O
illness	O
are	O
at	O
increased	O
risk	O
for	O
cardiovascular	O
effects	O
associated	O
with	O
air	O
pollution	O
.	O

An	O
examination	O
of	O
death	O
certificates	O
on	O
high-	O
and	O
low	O
-	O
air	O
pollution	O
days	O
reported	O
a	O
substantial	O
difference	O
in	O
the	O
proportion	O
of	O
deaths	O
from	O
cardiovascular	O
causes	O
that	O
had	O
respiratory	O
disease	O
as	O
a	O
contributing	O
cause	O
of	O
death	O
(	O
19	O
)	O
.	O

A	O
recent	O
follow	O
-	O
up	O
study	O
of	O
a	O
cohort	O
of	O
persons	O
with	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
in	O
Barcelona	O
,	O
Spain	O
,	O
found	O
an	O
association	O
between	O
particulate	O
air	O
pollution	O
and	O
all	O
-	O
cause	O
mortality	O
in	O
the	O
cohort	O
(	O
20	O
)	O
.	O

The	O
magnitude	O
of	O
the	O
risk	O
per	O
microgram	O
per	O
cubic	O
meter	O
of	O
exposure	O
was	O
substantially	O
greater	O
than	O
that	O
for	O
the	O
general	O
population	O
.	O

Environmental	O
Health	O
Perspectives	O
Controlled	O
exposure	O
of	O
animals	O
with	O
chronic	O
bronchitis	O
and	O
control	O
animals	O
to	O
concentrated	O
air	O
particles	O
also	O
demonstrated	O
a	O
potentiating	O
effect	O
of	O
chronic	O
lung	O
disease	O
in	O
the	O
response	O
to	O
airborne	O
particles	O
(	O
21	O
)	O
.	O

This	O
has	O
led	O
to	O
the	O
hypothesis	O
that	O
the	O
cardiovascular	O
effects	O
of	O
air	O
pollution	O
are	O
predominantly	O
in	O
persons	O
with	O
chronic	O
lung	O
disease	O
.	O

There	O
has	O
been	O
even	O
less	O
done	O
to	O
examine	O
potential	O
modifiers	O
of	O
the	O
effects	O
of	O
airborne	O
particles	O
on	O
hospital	O
admissions	O
.	O

The	O
existing	O
literature	O
on	O
comorbidity	O
shows	O
that	O
comorbidity	O
per	O
se	O
seems	O
to	O
increase	O
the	O
risk	O
of	O
adverse	O
outcomes	O
(	O
22	O
�	O
30	O
)	O
.	O

Little	O
is	O
known	O
about	O
the	O
role	O
of	O
these	O
comorbidities	O
as	O
effect	O
modifiers	O
for	O
the	O
effects	O
of	O
air	O
pollution	O
.	O

This	O
study	O
uses	O
data	O
from	O
the	O
Medicare	O
system	O
to	O
examine	O
potential	O
short	O
-	O
term	O
and	O
long	O
-	O
term	O
medical	O
conditions	O
that	O
may	O
increase	O
a	O
person	O
's	O
risk	O
of	O
hospital	O
admissions	O
associated	O
with	O
particulate	O
air	O
pollution	O
.	O

In	O
addition	O
,	O
we	O
examine	O
potential	O
effect	O
modification	O
by	O
age	O
,	O
race	O
,	O
and	O
sex	O
.	O

Materials	O
and	O
Methods	O
Health	O
data	O
.	O

The	O
Health	O
Care	O
Financing	O
Administration	O
(	O
Baltimore	O
,	O
MD	O
)	O
maintains	O
records	O
of	O
every	O
hospital	O
admission	O
for	O
Medicare	O
participants	O
in	O
the	O
United	O
States	O
.	O

Persons	O
in	O
this	O
database	O
have	O
a	O
unique	O
identifier	O
.	O

Using	O
this	O
identifier	O
,	O
we	O
traced	O
every	O
hospital	O
admission	O
for	O
heart	O
and	O
lung	O
disease	O
for	O
each	O
person	O
in	O
Cook	O
County	O
,	O
Illinois	O
,	O
between	O
1985	O
and	O
1994	O
.	O

We	O
chose	O
Cook	O
County	O
because	O
it	O
is	O
the	O
most	O
populous	O
county	O
in	O
the	O
United	O
States	O
with	O
daily	O
monitoring	O
for	O
particulate	O
matter	O
with	O
aerodynamic	O
diameter	O
<	O
10	O
�	O
m	O
(	O
PM10	O
)	O
.	O

The	O
data	O
were	O
then	O
analyzed	O
to	O
look	O
at	O
effect	O
modification	O
by	O
concurrent	O
and	O
preexisting	O
conditions	O
as	O
well	O
as	O
by	O
age	O
,	O
race	O
,	O
and	O
sex	O
.	O

To	O
establish	O
a	O
baseline	O
risk	O
,	O
we	O
computed	O
daily	O
counts	O
of	O
hospital	O
admissions	O
for	O
cardiovascular	O
disease	O
(	O
CVD	O
)	O
[	O
International	O
Classification	O
of	O
Disease	O
,	O
9th	O
edition	O
,	O
World	O
Health	O
Organization	O
,	O
Geneva	O
(	O
ICD-9	O
)	O
code	O
390	O
�	O
429	O
]	O
,	O
pneumonia	O
(	O
ICD-9	O
code	O
480	O
�	O
487	O
)	O
,	O
and	O
COPD	O
(	O
ICD-9	O
code	O
490	O
�	O
496	O
,	O
excluding	O
493	O
)	O
.	O

The	O
association	O
between	O
these	O
daily	O
counts	O
and	O
PM10	O
was	O
examined	O
for	O
the	O
years	O
1988	O
�	O
1994	O
,	O
when	O
daily	O
PM10	O
monitoring	O
data	O
were	O
available	O
in	O
Chicago	O
.	O

Once	O
our	O
baseline	O
risks	O
were	O
established	O
,	O
we	O
examined	O
three	O
classes	O
of	O
potential	O
effect	O
modifiers	O
.	O

First	O
,	O
we	O
looked	O
at	O
whether	O
previous	O
admissions	O
for	O
selected	O
conditions	O
predisposed	O
persons	O
to	O
having	O
a	O
greater	O
risk	O
from	O
air	O
pollution	O
.	O

For	O
each	O
of	O
the	O
three	O
admission	O
categories	O
(	O
CVD	O
,	O
pneumonia	O
,	O
and	O
COPD	O
)	O
,	O
we	O
considered	O
10	O
causes	O
(	O
defined	O
by	O
a	O
previous	O
admission	O
)	O
as	O
effect	O
modifiers	O
:	O
COPD	O
(	O
ICD-9	O
code	O
490	O
�	O
496	O
except	O
493	O
)	O
,	O
asthma	O
(	O
ICD-9	O
code	O
493	O
)	O
,	O
acute	O
bronchitis	O
(	O
ICD-9	O
code	O
466	O
)	O
,	O
acute	O
respiratory	O
illness	O
(	O
ICD-9	O
code	O
460	O
�	O
466	O
)	O
,	O
pneumonia	O
(	O
ICD-9	O
code	O
480	O
�	O
487	O
)	O
,	O
CVD	O
(	O
ICD-9	O
code	O
390	O
�	O
429	O
)	O
,	O
myocardial	O
infarction	O
(	O
ICD-9	O
code	O
410	O
)	O
,	O
congestive	O
heart	O
failure	O
(	O
ICD-9	O
code	O
428	O
)	O
,	O
conduction	O
disorders	O
(	O
ICD-9	O
code	O
426	O
)	O
,	O
and	O
dysrhythmias	O
(	O
ICD9	O
code	O
427	O
)	O
.	O

To	O
test	O
the	O
hypothesis	O
that	O
persons	O
with	O
these	O
conditions	O
had	O
higher	O
risks	O
of	O
subsequent	O
PM10-related	O
admissions	O
,	O
we	O
computed	O
separate	O
daily	O
counts	O
of	O
admissions	O
for	O
our	O
three	O
target	O
causes	O
,	O
stratified	O
by	O
whether	O
or	O
not	O
the	O
person	O
admitted	O
had	O
been	O
previously	O
admitted	O
for	O
the	O
hypothesized	O
predisposing	O
condition	O
.	O

Separate	O
analyses	O
were	O
then	O
performed	O
within	O
each	O
strata	O
to	O
see	O
if	O
the	O
effects	O
of	O
PM10	O
differed	O
by	O
strata	O
.	O

Address	O
correspondence	O
to	O
A.	O
Zanobetti	O
,	O
Department	O
of	O
Environmental	O
Health	O
,	O
Environmental	O
Epidemiology	O
Program	O
,	O
Harvard	O
School	O
of	O
Public	O
Health	O
,	O
665	O
Huntington	O
Avenue	O
,	O
Boston	O
,	O
MA	O
02115	O
USA	O
.	O

Telephone	O
:	O
(	O
617	O
)	O
4324642	O
.	O

Fax	O
:	O
(	O
617	O
)	O
277	O
-	O
2382	O
.	O

E	O
-	O
mail	O
:	O
azanob@	O
sparc6a.harvard.edu	O
Supported	O
by	O
NIEHS	O
grant	O
ES07937	O
.	O

Received	O
18	O
January	O
2000	O
;	O
accepted	O
18	O
April	O
2000	O
.	O

�	O
VOLUME	O
108	O
|	O
NUMBER	O
9	O
|	O
September	O
2000	O
841	O
Articles	O
�	O
Zanobetti	O
et	O
al.	O
The	O
second	O
set	O
of	O
potential	O
predisposing	O
conditions	O
included	O
secondary	O
diagnoses	O
associated	O
with	O
the	O
index	O
admission	O
.	O

These	O
could	O
represent	O
the	O
presence	O
of	O
a	O
chronic	O
condition	O
(	O
e.g.	O
,	O
COPD	O
)	O
that	O
has	O
not	O
resulted	O
in	O
a	O
previous	O
hospital	O
admission	O
.	O

They	O
could	O
also	O
represent	O
acute	O
conditions	O
that	O
may	O
have	O
increased	O
the	O
subjects	O
'	O
sensitivity	O
to	O
air	O
pollution	O
.	O

For	O
example	O
,	O
if	O
respiratory	O
infections	O
modified	O
the	O
effect	O
of	O
particulate	O
matter	O
on	O
the	O
cardiovascular	O
health	O
of	O
persons	O
with	O
underlying	O
heart	O
disease	O
,	O
then	O
the	O
risk	O
of	O
a	O
hospital	O
admission	O
for	O
heart	O
disease	O
might	O
be	O
different	O
in	O
persons	O
with	O
infections	O
.	O

If	O
this	O
were	O
true	O
,	O
then	O
the	O
risk	O
ratio	O
of	O
a	O
10-	O
�	O
g	O
/	O
m3	O
increase	O
of	O
PM10	O
on	O
cardiovascular	O
admissions	O
of	O
persons	O
with	O
a	O
concurrent	O
respiratory	O
infection	O
would	O
be	O
different	O
from	O
the	O
ratio	O
in	O
persons	O
without	O
respiratory	O
infection	O
.	O

To	O
test	O
these	O
hypotheses	O
,	O
we	O
computed	O
separate	O
daily	O
counts	O
of	O
admissions	O
for	O
events	O
with	O
and	O
without	O
the	O
concurrent	O
conditions	O
hypothesized	O
to	O
increase	O
sensitivity	O
to	O
air	O
pollution	O
.	O

These	O
were	O
taken	O
as	O
the	O
same	O
10	O
conditions	O
in	O
the	O
first	O
analysis	O
with	O
certain	O
exclusions	O
for	O
pairing	O
that	O
would	O
be	O
illogical	O
.	O

That	O
is	O
,	O
the	O
concurrent	O
diagnosis	O
of	O
a	O
specific	O
cardiac	O
condition	O
was	O
not	O
treated	O
as	O
an	O
effect	O
modifier	O
for	O
admissions	O
for	O
any	O
cardiovascular	O
condition	O
.	O

Likewise	O
,	O
pneumonia	O
and	O
COPD	O
were	O
not	O
possible	O
concurrent	O
conditions	O
for	O
each	O
other	O
.	O

The	O
third	O
set	O
of	O
predisposing	O
conditions	O
considered	O
was	O
being	O
older	O
than	O
75	O
years	O
of	O
age	O
,	O
nonwhite	O
,	O
and	O
female	O
.	O

These	O
were	O
examined	O
for	O
all	O
three	O
outcomes	O
.	O

We	O
obtained	O
weather	O
data	O
for	O
O'Hare	O
Airport	O
from	O
the	O
EarthInfo	O
CD	O
-	O
ROM	O
(	O
EarthInfo	O
CD	O
NCDC	O
Surface	O
Airways	O
,	O
EarthInfo	O
Inc.	O
,	O
Boulder	O
,	O
CO	O
)	O
,	O
and	O
we	O
obtained	O
air	O
pollution	O
data	O
from	O
the	O
U.S.	O
Environmental	O
Protection	O
Agency	O
Aerometric	O
Information	O
Retrieval	O
System	O
network	O
(	O
31	O
)	O
.	O

running	O
-	O
line	O
smoother	O
,	O
loess	O
(	O
35	O
)	O
,	O
was	O
chosen	O
to	O
estimate	O
the	O
smooth	O
function	O
.	O

To	O
control	O
for	O
weather	O
variables	O
and	O
day	O
of	O
the	O
week	O
,	O
we	O
chose	O
the	O
smoothing	O
parameter	O
that	O
minimized	O
the	O
Akaike	O
's	O
information	O
criterion	O
(	O
36	O
)	O
.	O

To	O
model	O
seasonality	O
we	O
chose	O
the	O
smoothing	O
parameter	O
that	O
minimized	O
the	O
sum	O
of	O
the	O
autocorrelation	O
of	O
the	O
residuals	O
while	O
removing	O
seasonal	O
patterns	O
.	O

Two	O
autoregressive	O
terms	O
(	O
37	O
)	O
were	O
added	O
in	O
the	O
model	O
to	O
eliminate	O
the	O
remaining	O
serial	O
correlation	O
from	O
the	O
residuals	O
.	O

We	O
used	O
the	O
mean	O
of	O
PM10	O
on	O
the	O
day	O
of	O
the	O
admission	O
and	O
the	O
day	O
before	O
the	O
admission	O
as	O
our	O
exposure	O
variable	O
.	O

This	O
gives	O
results	O
that	O
are	O
similar	O
to	O
those	O
obtained	O
fitting	O
a	O
full	O
distributed	O
lag	O
model	O
(	O
38	O
)	O
.	O

PM10	O
was	O
treated	O
linearly	O
.	O

Our	O
baseline	O
models	O
used	O
the	O
daily	O
counts	O
of	O
CVD	O
,	O
pneumonia	O
,	O
and	O
COPD	O
admissions	O
as	O
outcomes	O
.	O

We	O
then	O
subdivided	O
those	O
counts	O
by	O
the	O
presence	O
or	O
absence	O
of	O
the	O
potential	O
effect	O
modifier	O
and	O
reestimated	O
our	O
regressions	O
on	O
those	O
subgroups	O
.	O

We	O
considered	O
effect	O
modification	O
to	O
be	O
indicated	O
when	O
the	O
estimates	O
of	O
PM10	O
in	O
the	O
group	O
with	O
the	O
condition	O
was	O
outside	O
of	O
the	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
of	O
the	O
effect	O
estimate	O
in	O
persons	O
without	O
the	O
condition	O
.	O

Results	O
Table	O
1	O
shows	O
the	O
mean	O
daily	O
admissions	O
for	O
COPD	O
,	O
cardiovascular	O
,	O
and	O
pneumonia	O
both	O
overall	O
and	O
in	O
the	O
presence	O
of	O
the	O
potential	O
effect	O
modifiers	O
.	O

For	O
some	O
effect	O
modifiers	O
such	O
as	O
conduction	O
disorders	O
or	O
myocardial	O
infarctions	O
,	O
the	O
counts	O
in	O
conjunction	O
with	O
our	O
respiratory	O
outcomes	O
are	O
low	O
,	O
which	O
limits	O
power	O
.	O

In	O
general	O
,	O
the	O
numbers	O
are	O
lower	O
for	O
examining	O
effect	O
modification	O
by	O
previous	O
admissions	O
than	O
for	O
effect	O
modification	O
by	O
concurrent	O
diagnosis	O
.	O

This	O
is	O
as	O
expected	O
because	O
many	O
clinically	O
relevant	O
comorbidities	O
may	O
never	O
have	O
resulted	O
in	O
a	O
hospital	O
admission	O
.	O

Table	O
2	O
shows	O
the	O
25th	O
,	O
50th	O
,	O
and	O
75th	O
percentile	O
values	O
for	O
the	O
environmental	O
variables	O
.	O

The	O
mean	O
value	O
for	O
PM10	O
is	O
33	O
�	O
g	O
/	O
m3	O
.	O

The	O
daily	O
values	O
for	O
PM10	O
were	O
computed	O
as	O
the	O
average	O
of	O
10	O
monitors	O
,	O
two	O
of	O
which	O
measured	O
PM10	O
almost	O
every	O
day	O
and	O
the	O
others	O
less	O
frequently	O
(	O
38	O
)	O
.	O

Table	O
3	O
shows	O
the	O
mean	O
daily	O
counts	O
of	O
CVD	O
,	O
COPD	O
,	O
and	O
pneumonia	O
by	O
sex	O
,	O
age	O
groups	O
,	O
and	O
race	O
.	O

The	O
distribution	O
by	O
sex	O
is	O
almost	O
even	O
,	O
although	O
the	O
counts	O
of	O
admissions	O
for	O
males	O
are	O
generally	O
lower	O
(	O
approximately	O
10	O
%	O
)	O
than	O
for	O
females	O
,	O
particularly	O
for	O
cardiovascular	O
diseases	O
.	O

The	O
counts	O
of	O
CVD	O
,	O
COPD	O
,	O
and	O
pneumonia	O
admissions	O
were	O
similar	O
for	O
people	O
65	O
�	O
75	O
or	O
75	O
years	O
of	O
age	O
and	O
older	O
.	O

Tables	O
4	O
�	O
6	O
show	O
the	O
results	O
for	O
the	O
effect	O
PM10	O
overall	O
and	O
stratifying	O
by	O
concurrent	O
diagnosis	O
and	O
previous	O
admissions	O
.	O

These	O
are	O
expressed	O
as	O
the	O
percentage	O
increase	O
for	O
10	O
�	O
g	O
/	O
m3	O
PM10	O
.	O

Table	O
4	O
shows	O
the	O
results	O
for	O
CVD	O
.	O

A	O
10-	O
�	O
g	O
/	O
m3	O
increase	O
in	O
PM10	O
was	O
associated	O
with	O
a	O
1.31	O
%	O
(	O
5	O
%	O
CI	O
,	O
0.97	O
%	O
;	O
95	O
%	O
CI	O
,	O
1.66	O
%	O
)	O
increase	O
in	O
hospital	O
admissions	O
for	O
heart	O
disease	O
in	O
all	O
elderly	O
persons	O
.	O

A	O
concurrent	O
(	O
not	O
previous	O
)	O
diagnosis	O
of	O
COPD	O
modified	O
the	O
risk	O
of	O
PM10-associated	O
admissions	O
for	O
heart	O
disease	O
.	O

However	O
,	O
significant	O
associations	O
were	O
still	O
seen	O
between	O
PM10	O
Table	O
1	O
.	O

Mean	O
daily	O
counts	O
of	O
admissions	O
,	O
Chicago	O
1986	O
�	O
1994	O
,	O
for	O
COPD	O
,	O
CVD	O
,	O
and	O
pneumonia	O
overall	O
and	O
by	O
concurrent	O
diagnosis	O
and	O
by	O
previous	O
admissions	O
.	O

By	O
concurrent	O
diagnosis	O
COPD	O
CVD	O
Pneumonia	O
Overall	O
Respiratory	O
disease	O
Acute	O
bronchitis	O
Acute	O
respiratory	O
infections	O
Pneumonia	O
Asthma	O
COPD	O
Cardiovascular	O
disease	O
CVD	O
Conduction	O
disorders	O
Cardiac	O
dysrhythmias	O
Congestive	O
heart	O
failure	O
Myocardial	O
infarction	O
NA	O
,	O
not	O
applicable	O
.	O

By	O
previous	O
admissions	O
COPD	O
CVD	O
Pneumonia	O
7.8	O
0.8	O
0.9	O
1.6	O
0.9	O
2.7	O
2.1	O
0.0	O
0.4	O
0.9	O
0.3	O
102.1	O
1.6	O
1.8	O
7.3	O
1.5	O
2.0	O
54.7	O
1.0	O
9.9	O
24.2	O
11.4	O
26.5	O
0.9	O
1.0	O
6.4	O
0.7	O
1.4	O
7.2	O
0.2	O
1.5	O
3.1	O
1.0	O
Methods	O

We	O
analyzed	O
the	O
data	O
with	O
a	O
generalized	O
additive	O
robust	O
Poisson	O
regression	O
model	O
(	O
32	O
)	O
.	O

This	O
approach	O
has	O
become	O
the	O
norm	O
in	O
such	O
studies	O
(	O
14,33,34	O
)	O
.	O

In	O
the	O
generalized	O
additive	O
model	O
the	O
outcome	O
is	O
assumed	O
to	O
depend	O
on	O
a	O
sum	O
of	O
nonparametric	O
smooth	O
functions	O
for	O
each	O
variable	O
that	O
models	O
the	O
potential	O
nonlinear	O
dependence	O
of	O
daily	O
admission	O
on	O
weather	O
and	O
season	O
.	O

The	O
model	O
is	O
of	O
the	O
form	O
:	O
log	O
[	O
E	O
(	O
Yt	O
)	O
]	O
=	O
0	O
+	O
S1	O
(	O
X1	O
)	O
+	O
...	O
+	O
Sp	O
(	O
Xp	O
)	O
where	O
E	O
(	O
Yt	O
)	O
is	O
the	O
expected	O
value	O
of	O
the	O
daily	O
count	O
of	O
admissions	O
Yt	O
and	O
Si	O
are	O
the	O
smooth	O
functions	O
of	O
the	O
covariates	O
Xi	O
.	O

We	O
examined	O
temperature	O
,	O
previous	O
day	O
's	O
temperature	O
,	O
relative	O
humidity	O
,	O
barometric	O
pressure	O
,	O
and	O
day	O
of	O
week	O
covariates	O
.	O

The	O
locally	O
weighted	O
7.8	O
0.1	O
0.3	O
0.4	O
0.1	O
NA	O
4.7	O
0.2	O
1.4	O
1.8	O
0.1	O
102.1	O
0.9	O
1.3	O
4.0	O
1.8	O
13.4	O
NA	O
NA	O
NA	O
NA	O
NA	O
26.5	O
0.3	O
0.3	O
NA	O
0.9	O
6.9	O
14.7	O
0.6	O
4.6	O
7.3	O
0.4	O
Table	O
2	O
.	O

25th	O
,	O
50th	O
,	O
and	O
75th	O
percentile	O
values	O
for	O
the	O
environmental	O
variables	O
in	O
Chicago	O
,	O
1988	O
�	O
1994	O
.	O

Temperature	O
(	O
�	O
F	O
)	O
35	O
51	O
67	O
Relative	O
humidity	O
62	O
70	O
79	O
Barometric	O
pressure	O
29.2	O
29.3	O
29.4	O
PM10	O
(	O
�	O
g	O
/	O
m3	O
)	O
23	O
33	O
46	O
Table	O
3	O
.	O

Mean	O
daily	O
counts	O
of	O
admissions	O
by	O
sex	O
,	O
race	O
,	O
and	O
age	O
groups	O
,	O
Chicago	O
,	O
1986	O
�	O
1994	O
.	O

Group	O
Overall	O
Female	O
Nonwhite	O
Age	O
>	O
75	O
years	O
COPD	O
7.8	O
4.2	O
1.6	O
3.7	O
CVD	O

102.1	O
59.4	O
21.0	O
55.1	O
Pneumonia	O
26.5	O
14.7	O
5.2	O
17.4	O
842	O
VOLUME	O
108	O
|	O
NUMBER	O
9	O
|	O
September	O
2000	O
�	O
Environmental	O
Health	O
Perspectives	O
Articles	O
�	O
Effects	O
of	O
particles	O
on	O
sensitive	O
subgroups	O
and	O
heart	O
disease	O
admissions	O
in	O
persons	O
without	O
COPD	O
listed	O
as	O
either	O
a	O
comorbidity	O
or	O
a	O
cause	O
of	O
previous	O
admission	O
(	O
Table	O
4	O
)	O
.	O

A	O
significant	O
association	O
was	O
also	O
seen	O
in	O
persons	O
without	O
any	O
respiratory	O
disease	O
as	O
a	O
concurrent	O
diagnosis	O
,	O
although	O
the	O
risk	O
is	O
much	O
lower	O
than	O
in	O
persons	O
with	O
respiratory	O
disease	O
.	O

However	O
,	O
the	O
risk	O
associated	O
with	O
PM10	O
was	O
roughly	O
doubled	O
in	O
subjects	O
with	O
concurrent	O
respiratory	O
infections	O
and	O
the	O
risk	O
estimates	O
in	O
those	O
subjects	O
were	O
outside	O
the	O
95	O
%	O
CI	O
of	O
the	O
risk	O
in	O
patients	O
without	O
concurrent	O
respiratory	O
infections	O
.	O

A	O
previous	O
admission	O
for	O
conduction	O
disorders	O
(	O
e.g.	O
,	O
heart	O
block	O
)	O
increased	O
the	O
risk	O
of	O
a	O
PM10-related	O
subsequent	O
admission	O
for	O
any	O
heart	O
condition	O
,	O
and	O
a	O
weaker	O
indication	O
of	O
effect	O
modification	O
was	O
seen	O
for	O
persons	O
with	O
previous	O
admission	O
for	O
dysrhythmias	O
.	O

In	O
contrast	O
heart	O
failure	O
and	O
previous	O
myocardial	O
infarctions	O
were	O
highly	O
insignificant	O
as	O
effect	O
modifiers	O
.	O

Table	O
5	O
shows	O
the	O
results	O
for	O
COPD	O
.	O

Overall	O
,	O
there	O
is	O
a	O
1.89	O
%	O
(	O
95	O
%	O
CI	O
,	O
0.8	O
�	O
3.0	O
)	O
increase	O
in	O
COPD	O
admissions	O
for	O
a	O
10	O
�	O
g	O
/	O
m3	O
increase	O
in	O
PM10	O
.	O

The	O
results	O
of	O
the	O
stratified	O
analysis	O
suggest	O
that	O
preexisting	O
heart	O
disease	O
modifies	O
Table	O
4	O
.	O

Percentage	O
increase	O
in	O
hospital	O
admissions	O
for	O
CVD	O
in	O
all	O
persons	O
and	O
by	O
concurrent	O
diagnosis	O
and	O
previous	O
admissions	O
.	O

PM10	O
2.5	O
%	O
CI	O
97.5	O
%	O
CI	O
All	O
persons	O
1.31	O
By	O
concurrent	O
diagnosis	O
Respiratory	O
disease	O
All	O
respiratory	O
disease	O
With	O
1.65	O
Without	O
0.98	O
Acute	O
bronchitis	O
With	O
2.50	O
Without	O
1.07	O
Acute	O
respiratory	O
infections	O
With	O
2.71	O
Without	O
1.06	O
Pneumonia	O
With	O
1.95	O
Without	O
1.03	O
COPD	O
With	O
1.59	O
Without	O
1.08	O
By	O
previous	O
admissions	O
Respiratory	O
disease	O
All	O
respiratory	O
disease	O
With	O
1.18	O
Without	O
1.08	O
COPD	O
With	O
1.48	O
Without	O
1.09	O
Asthma	O
With	O
1.71	O
Without	O
1.08	O
Cardiovascular	O
disease	O
Conduction	O
disorders	O
With	O
2.89	O
Without	O
1.07	O
Cardiac	O
dyshrethmias	O
With	O
1.61	O
Without	O
1.04	O
0.97	O
1.66	O
the	O
risk	O
of	O
COPD	O
admissions	O
on	O
high	O
particle	O
days	O
.	O

Previous	O
admissions	O
for	O
any	O
cardiovascular	O
disease	O
increased	O
the	O
risk	O
of	O
a	O
PM10associated	O
COPD	O
admission	O
approximately	O
2.5-fold	O
.	O

A	O
previous	O
heart	O
failure	O
admission	O
caused	O
an	O
even	O
more	O
striking	O
increase	O
in	O
the	O
PM10	O
effect	O
.	O

Previous	O
admissions	O
for	O
dysrhythmias	O
and	O
conduction	O
defects	O
were	O
rare	O
(	O
Table	O
1	O
)	O
with	O
no	O
power	O
to	O
examine	O
effect	O
modifications	O
.	O

Listings	O
as	O
concurrent	O
diagnoses	O
were	O
more	O
common	O
and	O
here	O
they	O
joined	O
heart	O
failure	O
in	O
increasing	O
the	O
risk	O
of	O
PM	O
10	O
-associated	O
COPD	O
admissions	O
.	O

For	O
COPD	O
there	O
was	O
also	O
some	O
indication	O
that	O
concurrent	O
pneumonia	O
or	O
an	O
acute	O
respiratory	O
infection	O
admission	O
in	O
the	O
last	O
year	O
increased	O
risk	O
.	O

The	O
low	O
numbers	O
made	O
these	O
estimates	O
less	O
precise	O
,	O
however	O
.	O

The	O
percentage	O
increase	O
in	O
pneumonia	O
admission	O
(	O
Table	O
6	O
)	O
for	O
10	O
�	O
g	O
/	O
m3	O
PM10	O
is	O
higher	O
than	O
for	O
COPD	O
or	O
CVD	O
with	O
an	O
increase	O
of	O
2.34	O
%	O
(	O
95	O
%	O
CI	O
,	O
1.66	O
�	O
3.0	O
)	O
.	O

As	O
with	O
COPD	O
,	O
persons	O
with	O
heart	O
disease	O
appeared	O
at	O
higher	O
risk	O
of	O
pneumonia	O
hospital	O
admissions	O
associated	O
with	O
particulate	O
air	O
pollution	O
.	O

Here	O
diagnoses	O
suggestive	O
of	O
impaired	O
autonomic	O
control	O
of	O
the	O
heart	O
,	O
such	O
as	O
conduction	O
disorders	O
or	O
dysrhythmias	O
,	O
were	O
associated	O
with	O
increased	O
risk	O
for	O
PM	O
10	O
effects	O
on	O
pneumonia	O
admissions	O
.	O

Unlike	O
COPD	O
,	O
no	O
difference	O
was	O
seen	O
for	O
congestive	O
heart	O
failure	O
.	O

Persons	O
with	O
asthma	O
Table	O
5	O
.	O

Percentage	O
increase	O
in	O
hospital	O
admissions	O
for	O
COPD	O
in	O
all	O
persons	O
and	O
by	O
concurrent	O
diagnosis	O
and	O
previous	O
admissions	O
.	O

PM10	O
2.5	O
%	O
CI	O
97.5	O
%	O
CI	O
All	O
persons	O
1.89	O
By	O
concurrent	O
diagnosis	O
Respiratory	O
disease	O
Pneumonia	O
With	O
4.00	O
Without	O
1.51	O
Cardiovascular	O
disease	O
Conduction	O
disorders	O
With	O
2.34	O
Without	O
1.60	O
Cardiac	O
dysrhythmias	O
With	O
3.09	O
Without	O
1.43	O
Congestive	O
heart	O
failure	O
With	O
2.90	O
Without	O
1.39	O
By	O
previous	O
admissions	O
Respiratory	O
disease	O
Acute	O
respiratory	O
infections	O
With	O
3.20	O
Without	O
1.70	O
Cardiovascular	O
disease	O
CVD	O
With	O
2.90	O
Without	O
1.18	O
Congestive	O
heart	O
failure	O
With	O
4.37	O
Without	O
1.14	O
Within	O
1	O
year	O
6.04	O
0.80	O
2.99	O
had	O
twice	O
the	O
risk	O
of	O
a	O
PM10-induced	O
pneumonia	O
admission	O
as	O
persons	O
without	O
asthma	O
.	O

Table	O
7	O
shows	O
the	O
results	O
by	O
sex	O
,	O
age	O
,	O
and	O
race	O
.	O

None	O
of	O
the	O
effect	O
size	O
estimates	O
for	O
any	O
of	O
the	O
stratification	O
variables	O
were	O
outside	O
of	O
the	O
95	O
%	O
CI	O
for	O
the	O
opposite	O
strata	O
.	O

There	O
was	O
a	O
tendency	O
for	O
the	O
effect	O
of	O
PM10	O
on	O
CVD	O
admissions	O
to	O
be	O
higher	O
for	O
females	O
,	O
whereas	O
the	O
effect	O
on	O
pneumonia	O
admissions	O
was	O
higher	O
for	O
males	O
.	O

In	O
general	O
,	O
we	O
found	O
somewhat	O
larger	O
effects	O
on	O
whites	O
compared	O
to	O
nonwhites	O
,	O
and	O
for	O
persons	O
older	O
than	O
75	O
years	O
of	O
age	O
compared	O
to	O
younger	O
persons	O
.	O

Discussion	O
In	O
this	O
analysis	O
we	O
examined	O
whether	O
the	O
effect	O
of	O
PM10	O
on	O
the	O
risk	O
of	O
hospital	O
admission	O
for	O
heart	O
and	O
lung	O
disease	O
was	O
different	O
depending	O
on	O
the	O
presence	O
of	O
comorbidities	O
.	O

We	O
found	O
that	O
PM10	O
was	O
associated	O
with	O
hospital	O
admissions	O
for	O
all	O
three	O
causes	O
(	O
CVD	O
,	O
COPD	O
,	O
and	O
pneumonia	O
)	O
and	O
we	O
found	O
not	O
a	O
general	O
increase	O
in	O
PM10	O
related	O
risk	O
with	O
comorbidities	O
,	O
but	O
a	O
specific	O
pattern	O
that	O
is	O
suggestive	O
of	O
potential	O
mechanisms	O
and	O
consistent	O
with	O
other	O
recent	O
epidemiologic	O
and	O
toxicologic	O
findings	O
.	O

One	O
major	O
finding	O
of	O
this	O
study	O
is	O
that	O
preexisting	O
cardiovascular	O
disease	O
,	O
particularly	O
impaired	O
autonomic	O
control	O
(	O
conduction	O
defects	O
and	O
dysrhythmias	O
)	O
and	O
heart	O
failure	O
,	O
substantially	O
increased	O
the	O
risk	O
of	O
respiratory	O
admissions	O
associated	O
with	O
airborne	O
particles	O
.	O

In	O
fact	O
,	O
recent	O
human	B
studies	O
have	O
shown	O
that	O
exposure	O
to	O
particulate	O
air	O
pollution	O
is	O
a	O
risk	O
factor	O
for	O
reduced	O
heart	O
rate	O
variability	O
(	O
39	O
�	O
41	O
)	O
.	O

Reduced	O
heart	O
rate	O
variability	O
is	O
an	O
adverse	O
response	O
and	O
a	O
risk	O
factor	O
for	O
arrhythmia	O
.	O

A	O
new	O
study	O
of	O
defibrillator	O
discharges	O
in	O
patients	O
with	O
implanted	O
cardioverter	O
defibrillators	O
found	O
that	O
discharges	O
were	O
associated	O
with	O
air	O
pollution	O
(	O
42	O
)	O
.	O

Exposure	O
to	O
combustion	O
Table	O
6	O
.	O

Percentage	O
increase	O
in	O
hospital	O
admissions	O
for	O
pneumonia	O
in	O
all	O
persons	O
and	O
by	O
concurrent	O
diagnosis	O
and	O
previous	O
admissions	O
.	O

PM10	O
All	O
persons	O
By	O
concurrent	O
diagnosis	O
Respiratory	O
disease	O
Asthma	O
With	O
Without	O
Cardiovascular	O
disease	O
Conduction	O
disorders	O

With	O
Without	O
Cardiac	O
dysrhythmias	O

With	O
Without	O

By	O
previous	O
admissions	O
Cardiovascular	O
disease	O
Cardiac	O
dysrhythmias	O
With	O
Without	O
2.34	O
2.5	O
%	O
CI	O
97.5	O
%	O
CI	O
1.66	O
3.02	O
1.10	O
0.64	O
�	O
0.47	O
0.76	O
0.18	O
0.76	O
0.55	O
0.72	O
0.85	O
0.75	O
2.20	O
1.33	O
5.55	O
1.37	O
5.30	O
1.37	O
3.36	O
1.35	O
2.34	O
1.41	O
�	O
0.45	O
0.47	O
�	O
4.42	O
0.58	O
0.64	O
0.33	O
0.77	O
0.24	O
8.65	O
2.57	O
9.59	O
2.64	O
5.60	O
2.55	O
5.08	O
2.55	O
0.45	O
0.76	O
�	O
0.40	O
0.78	O
�	O
0.43	O
0.77	O
0.22	O
0.76	O
0.75	O
0.72	O
1.91	O
1.41	O
3.40	O
1.40	O
3.89	O

1.39	O
5.63	O
1.38	O
2.48	O
1.36	O
4.18	O
2.07	O
7.92	O
1.99	O
�	O
�	O
1.01	O
1.46	O
4.28	O
1.37	O
�	O
�	O
7.46	O
2.69	O
11.69	O
2.61	O
�	O
�	O
�	O
1.38	O
0.66	O
0.99	O
�	O
0.01	O
1.43	O
0.05	O
2.10	O
8.01	O
2.76	O
4.85	O
2.39	O
7.40	O
2.24	O
10.14	O
3.47	O
2.08	O
1.21	O
1.45	O
5.79	O
2.71	O
Increases	O
are	O
for	O
a	O
10-	O
�	O
g	O
/	O
m3	O
increase	O
in	O
PM10	O
.	O

Increases	O
are	O
for	O
a	O
10-	O
�	O
g	O
/	O
m3	O
increase	O
in	O
PM10	O
.	O

Increases	O
are	O
for	O
a	O
10-	O
�	O
g	O
/	O
m3	O
increase	O
in	O
PM10	O
.	O

Environmental	O
Health	O
Perspectives	O
�	O
VOLUME	O
108	O
|	O
NUMBER	O
9	O
|	O
September	O
2000	O
843	O
Articles	O
�	O
Zanobetti	O
et	O
al.	O
Table	O
7	O
.	O

Effect	O
modification	O
by	O
sex	O
,	O
race	O
,	O
and	O
age	O
groups	O
for	O
10	O
�	O
g	O
/	O
m3	O
PM10	O
.	O

%	O
All	O
persons	O
Male	O
Female	O
White	O
Non	O
-	O
white	O
Age	O
>	O
75	O
Age	O
75	O
1.89	O
1.34	O
2.19	O
1.65	O
1.07	O
2.20	O
1.33	O
COPD	O
(	O
95	O
%	O
CI	O
)	O
(	O
0.80	O
,	O
2.99	O
)	O
(	O
�	O
0.14	O
,	O
2.84	O
)	O
(	O
0.81	O
,	O
3.59	O
)	O
(	O
0.51	O
,	O
2.81	O
)	O
(	O
�	O
1.11	O
,	O
3.3	O
)	O
(	O
0.72	O
,	O
3.69	O
)	O
(	O
0.03	O
,	O
2.65	O
)	O
%	O
1.31	O
1.07	O
1.21	O
1.20	O
0.70	O
1.28	O
0.93	O
CVD	O
(	O
95	O
%	O
CI	O
)	O
(	O
0.97	O
,	O
1.66	O
)	O
(	O
0.62	O
,	O
1.51	O
)	O
(	O
0.83	O
,	O
1.6	O
)	O
(	O
0.86	O
,	O
1.55	O
)	O
(	O
0.1	O
,	O
1.3	O
)	O
(	O
0.88	O
,	O
1.69	O
)	O
(	O
0.51	O
,	O
1.35	O
)	O
%	O
2.34	O
2.65	O
1.91	O
2.45	O
1.91	O
2.12	O
2.52	O
Pneumonia	O
(	O
95	O
%	O
CI	O
)	O
(	O
1.66	O
,	O
3.02	O
)	O
(	O
1.81	O
,	O
3.5	O
)	O
(	O
1.11	O
,	O
2.72	O
)	O
(	O
1.77	O
,	O
3.14	O
)	O
(	O
0.69	O
,	O
3.14	O
)	O
(	O
1.38	O
,	O
2.86	O
)	O
(	O
1.57	O
,	O
3.48	O
)	O
Figures	O
shown	O
are	O
the	O
percentage	O
increase	O
in	O
admissions	O
(	O
95	O
%	O
CI	O
)	O
.	O

particles	O
has	O
also	O
been	O
associated	O
with	O
arrhythmia	O
in	O
an	O
animal	O
model	O
(	O
43	O
)	O
and	O
changes	O
in	O
ST	O
segments	O
have	O
been	O
noted	O
as	O
well	O
(	O
44	O
)	O
.	O

This	O
is	O
the	O
first	O
study	O
to	O
suggest	O
persons	O
with	O
defects	O
in	O
the	O
electrical	O
control	O
of	O
the	O
heart	O
are	O
also	O
at	O
higher	O
risk	O
of	O
respiratory	O
illness	O
after	O
exposure	O
to	O
airborne	O
particles	O
.	O

These	O
data	O
also	O
suggest	O
that	O
persons	O
admitted	O
to	O
hospitals	O
for	O
pneumonia	O
during	O
an	O
air	O
pollution	O
episode	O
may	O
be	O
at	O
high	O
risk	O
for	O
clinically	O
significant	O
conduction	O
disorders	O
during	O
that	O
hospital	O
admission	O
.	O

Patients	O
with	O
congestive	O
heart	O
failure	O
were	O
at	O
greater	O
risk	O
of	O
hospital	O
admissions	O
for	O
COPD	O
in	O
association	O
with	O
airborne	O
particles	O
.	O

Heart	O
failure	O
and	O
COPD	O
is	O
not	O
an	O
uncommon	O
combination	O
.	O

The	O
finding	O
that	O
these	O
patients	O
are	O
at	O
higher	O
risk	O
for	O
admissions	O
associated	O
with	O
particulate	O
air	O
pollution	O
is	O
new	O
but	O
is	O
also	O
consistent	O
with	O
several	O
other	O
recent	O
reports	O
.	O

The	O
spontaneous	O
hypertensive	O
rat	B
develops	O
a	O
model	O
of	O
heart	O
failure	O
,	O
and	O
recent	O
studies	O
have	O
reported	O
greater	O
sensitivity	O
to	O
particulate	O
air	O
pollution	O
in	O
these	O
rats	B
.	O

These	O
include	O
both	O
electrocardiogram	O
abnormalities	O
(	O
44	O
)	O
and	O
pulmonary	O
toxicity	O
(	O
45,46	O
)	O
.	O

Similarly	O
,	O
in	O
an	O
epidemiologic	O
study	O
,	O
Hoek	O
et	O
al.	O
(	O
47	O
)	O
,	O
found	O
a	O
higher	O
relative	O
risk	O
of	O
death	O
with	O
an	O
increase	O
in	O
PM10	O
for	O
congestive	O
heart	O
failure	O
deaths	O
than	O
other	O
deaths	O
.	O

The	O
potential	O
role	O
of	O
COPD	O
in	O
those	O
heart	O
failure	O
deaths	O
was	O
not	O
examined	O
.	O

Another	O
consistent	O
pattern	O
in	O
our	O
data	O
is	O
of	O
acute	O
respiratory	O
infections	O
increasing	O
susceptibility	O
to	O
airborne	O
particles	O
.	O

Acute	O
bronchitis	O
,	O
or	O
more	O
generally	O
acute	O
upper	O
respiratory	O
illnesses	O
,	O
as	O
well	O
as	O
pneumonia	O
,	O
increased	O
susceptibility	O
to	O
particle	O
-	O
associated	O
admissions	O
for	O
CVD	O
and	O
COPD	O
.	O

The	O
notion	O
that	O
air	O
pollution	O
exacerbates	O
acute	O
respiratory	O
infections	O
is	O
well	O
supported	O
by	O
studies	O
which	O
report	O
associations	O
between	O
airborne	O
particles	O
and	O
hospital	O
admissions	O
for	O
respiratory	O
infections	O
(	O
48,49	O
)	O
.	O

Zelikoff	O
et	O
al.	O
(	O
50	O
)	O
exposed	O
rats	B
infected	O
with	O
streptococcus	O
to	O
concentrated	O
air	O
particles	O
and	O
reported	O
a	O
significant	O
increase	O
in	O
bacterial	O
burdens	O
and	O
in	O
the	O
extent	O
of	O
pneumonia	O
compared	O
to	O
animals	O
exposed	O
to	O
filtrated	O
air	O
.	O

This	O
suggests	O
an	O
impaired	O
immune	O
response	O
.	O

Similarly	O
,	O
exposure	O
to	O
combustion	O
particles	O
enhances	O
influenza	O
infections	O
in	O
mice	B
(	O
51	O
)	O
.	O

An	O
impaired	O
defense	O
to	O
respiratory	O
infection	O
is	O
a	O
major	O
reason	O
that	O
persons	O
with	O
COPD	O
require	O
hospital	O
admission	O
.	O

If	O
airborne	O
particles	O
result	O
in	O
further	O
impairment	O
the	O
effect	O
modification	O
we	O
observe	O
makes	O
good	O
sense	O
.	O

The	O
effect	O
modification	O
for	O
heart	O
disease	O
admissions	O
is	O
more	O
relevant	O
.	O

This	O
modification	O
is	O
consistent	O
with	O
the	O
earlier	O
report	O
of	O
Schwartz	O
(	O
19	O
)	O
,	O
who	O
found	O
greater	O
reports	O
of	O
respiratory	O
complications	O
on	O
death	O
certificates	O
with	O
an	O
underlying	O
cause	O
of	O
heart	O
disease	O
if	O
the	O
death	O
occurred	O
on	O
a	O
day	O
with	O
high	O
levels	O
of	O
airborne	O
particles	O
.	O

Although	O
airborne	O
particle	O
exposure	O
has	O
been	O
associated	O
with	O
increased	O
exacerbation	O
of	O
asthma	O
(	O
2,12,48,52	O
�	O
59	O
)	O
,	O
this	O
paper	O
is	O
the	O
first	O
to	O
suggest	O
that	O
asthmatics	O
are	O
more	O
susceptible	O
to	O
PM10-induced	O
pneumonia	O
exacerbation	O
or	O
to	O
cardiovascular	O
effects	O
.	O

The	O
effects	O
on	O
pneumonia	O
admissions	O
are	O
plausible	O
,	O
given	O
the	O
impaired	O
ability	O
to	O
fight	O
off	O
infections	O
in	O
asthmatics	O
with	O
mucus	O
plugs	O
and	O
the	O
evidence	O
the	O
airborne	O
particles	O
impair	O
the	O
lungs	O
'	O
ability	O
to	O
fight	O
off	O
bacterial	O
and	O
viral	O
infections	O
,	O
as	O
noted	O
earlier	O
.	O

The	O
increased	O
cardiovascular	O
sensitivity	O
,	O
albeit	O
weaker	O
,	O
is	O
interesting	O
.	O

If	O
airborne	O
particles	O
affect	O
the	O
cardiovascular	O
system	O
via	O
the	O
role	O
of	O
the	O
lung	O
in	O
autonomic	O
control	O
,	O
it	O
is	O
possible	O
that	O
asthmatics	O
would	O
be	O
more	O
sensitive	O
to	O
those	O
effects	O
.	O

Animal	O
models	O
of	O
asthma	O
showed	O
that	O
combustion	O
particles	O
enhance	O
the	O
asthmatic	O
response	O
to	O
aeroallergen	O
challenges	O
(	O
59	O
)	O
.	O

This	O
suggests	O
an	O
enhancement	O
of	O
pulmonary	O
response	O
in	O
asthmatics	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
diagnosis	O
of	O
asthma	O
is	O
problematic	O
in	O
the	O
elderly	O
,	O
and	O
crossover	O
with	O
COPD	O
is	O
possible	O
.	O

The	O
possibility	O
that	O
this	O
explains	O
our	O
results	O
is	O
reduced	O
by	O
our	O
failure	O
to	O
find	O
previous	O
hospital	O
admission	O
for	O
COPD	O
was	O
an	O
effect	O
modifier	O
for	O
the	O
effect	O
of	O
particles	O
on	O
cardiovascular	O
admissions	O
.	O

We	O
must	O
acknowledge	O
several	O
potential	O
limitations	O
of	O
this	O
study	O
.	O

First	O
,	O
we	O
considered	O
only	O
previous	O
admissions	O
that	O
occurred	O
within	O
Cook	O
County	O
.	O

Hence	O
persons	O
with	O
previous	O
admissions	O
elsewhere	O
would	O
be	O
misclassified	O
to	O
our	O
reference	O
group	O
.	O

The	O
effect	O
of	O
this	O
would	O
be	O
to	O
reduce	O
the	O
difference	O
in	O
PM	O
10	O
effect	O
between	O
the	O
two	O
groups	O
.	O

VOLUME	O
Nevertheless	O
,	O
we	O
identified	O
some	O
interesting	O
interactions	O
.	O

We	O
can	O
not	O
exclude	O
the	O
possibility	O
that	O
there	O
are	O
areas	O
we	O
missed	O
for	O
this	O
reason	O
.	O

We	O
also	O
examined	O
interactions	O
in	O
a	O
log	O
relative	O
risk	O
model	O
,	O
which	O
is	O
inherently	O
multiplicative	O
.	O

Although	O
we	O
believe	O
this	O
is	O
justified	O
because	O
doubling	O
the	O
population	O
exposed	O
would	O
be	O
expected	O
to	O
double	O
the	O
pollution	O
associated	O
admissions	O
,	O
it	O
results	O
in	O
a	O
more	O
conservative	O
definition	O
of	O
interaction	O
than	O
would	O
an	O
additive	O
risk	O
model	O
.	O

Finally	O
,	O
our	O
exposure	O
is	O
clearly	O
measured	O
with	O
error	O
.	O

Most	O
of	O
this	O
error	O
is	O
Berkson	O
error	O
(	O
60	O
)	O
and	O
hence	O
will	O
introduce	O
no	O
bias	O
,	O
and	O
Zeger	O
et	O
al.	O
(	O
60	O
)	O
showed	O
that	O
the	O
remaining	O
error	O
would	O
have	O
to	O
have	O
pathologic	O
correlations	O
with	O
other	O
variables	O
to	O
result	O
in	O
an	O
upward	O
bias	O
.	O

Another	O
important	O
result	O
from	O
this	O
study	O
,	O
of	O
course	O
,	O
is	O
an	O
estimate	O
of	O
the	O
magnitude	O
of	O
the	O
effect	O
of	O
airborne	O
particles	O
on	O
public	O
health	O
.	O

The	O
PM10	O
concentrations	O
in	O
Chicago	O
during	O
this	O
period	O
were	O
associated	O
with	O
approximately	O
1,600	O
additional	O
admissions	O
per	O
year	O
for	O
heart	O
disease	O
,	O
740	O
additional	O
admissions	O
per	O
year	O
for	O
pneumonia	O
,	O
and	O
170	O
additional	O
admissions	O
per	O
year	O
for	O
COPD	O
.	O

These	O
are	O
not	O
trivial	O
increases	O
in	O
serious	O
morbidity	O
.	O

The	O
results	O
of	O
our	O
study	O
should	O
be	O
replicated	O
in	O
additional	O
cities	O
,	O
although	O
they	O
do	O
begin	O
to	O
fill	O
in	O
some	O
missing	O
information	O
about	O
the	O
effects	O
of	O
airborne	O
particles	O
on	O
health	O
.	O

More	O
generally	O
airborne	O
particles	O
have	O
been	O
associated	O
with	O
a	O
broad	O
range	O
of	O
systemic	O
changes	O
including	O
heart	O
rate	O
variability	O
(	O
39	O
�	O
41	O
)	O
,	O
increased	O
peripheral	O
neutrophils	O
(	O
61	O
�	O
63	O
)	O
,	O
increased	O
plasma	O
viscosity	O
(	O
64	O
)	O
,	O
an	O
increase	O
in	O
blood	O
pressure	O
(	O
65	O
)	O
,	O
and	O
the	O
outcomes	O
mentioned	O
previously	O
.	O

The	O
role	O
of	O
these	O
systemic	O
changes	O
as	O
potential	O
sources	O
of	O
the	O
specific	O
effect	O
modifications	O
we	O
have	O
seen	O
should	O
be	O
an	O
area	O
of	O
fruitful	O
research	O
in	O
the	O
future	O
.	O

REFERENCES	O
AND	O
NOTES	O
1	O
.	O

Katsouyanni	O
K	O
,	O
Touloumi	O
G	O
,	O
Spix	O
C	O
,	O
Schwartz	O
J	O
,	O
Balducci	O
F	O
,	O
Medina	O
S	O
,	O
Rossi	O
G	O
,	O
Wojtyniak	O
D	O
,	O
Sunyer	O
J	O
,	O
Bacharova	O
L	O
,	O
et	O
al.	O
Short	O
term	O
effects	O
of	O
ambient	O
sulphur	O
dioxide	O
and	O
particulate	O
matter	O
on	O
mortality	O
in	O
12	O
European	O
cities	O
:	O
results	O
from	O
time	O
series	O
data	O
from	O
the	O
APHEA	O
project	O
.	O

Br	O
Med	O
J	O
314:1658	O
�	O
1663	O
(	O
1997	O
)	O
.	O

Pope	O
CA	O
,	O
Dockery	O
DW	O
,	O
Schwartz	O
J.	O
Review	O
of	O
epidemiologic	O
evidence	O
of	O
health	O
effects	O
of	O
particulate	O
air	O
pollution	O
.	O

Inhal	O
Toxicol	O
7:1	O
�	O
18	O
(	O
1995	O
)	O
.	O

Schwartz	O
J.	O
Air	O
pollution	O
and	O
daily	O
mortality	O
:	O
a	O
review	O
and	O
meta	O
analysis	O
.	O

Environ	O
Res	O
64:36	O
�	O
52	O
(	O
1994	O
)	O
.	O

Dominici	O
F	O
,	O
Samet	O
J	O
,	O
Zeger	O
SL	O
.	O

Combining	O
evidence	O
on	O
air	O
pollution	O
and	O
daily	O
mortality	O
from	O
the	O
largest	O
20	O
US	O
cities	O
:	O
a	O
hierarchical	O
modeling	O
strategy	O
.	O

R	O
Stat	O
Soc	O
Ser	O
A	O
,	O
in	O
press	O
.	O

Burnett	O
RT	O
,	O
Dales	O
RE	O
,	O
Raizenne	O
ME	O
,	O
Krewski	O
D	O
,	O
Summers	O
PW	O
,	O
Roberts	O
GR	O
,	O
Raad	O
-	O
Young	O
M	O
,	O
Dann	O
T	O
,	O
Brooke	O
T.	O
Effects	O
of	O
low	O
ambient	O
levels	O
of	O
ozone	O
and	O
sulfates	O
on	O
the	O
frequency	O
of	O
respiratory	O
admissions	O
to	O
Ontario	O
hospitals	O
.	O

Environ	O
Res	O
65:172	O
�	O
194	O
(	O
1994	O
)	O
.	O

Anderson	O
HR	O
,	O
Spix	O
C	O
,	O
Medina	O
S	O
,	O
Schouten	O
JP	O
,	O
Castellsague	O
J	O
,	O
Rossi	O
G	O
,	O
Zmirou	O
D	O
,	O
Touloumi	O
G	O
,	O
Wojtyniak	O
B	O
,	O
Ponka	O
A	O
,	O
et	O
al.	O
Air	O
pollution	O
and	O
daily	O
admissions	O
for	O
2	O
.	O

3	O
.	O

4	O
.	O
5	O
.	O
6	O
.	O
844	O
108	O
|	O
NUMBER	O
9	O
|	O
September	O
2000	O
�	O
Environmental	O
Health	O
Perspectives	O
Articles	O
�	O
Effects	O
of	O
particles	O
on	O
sensitive	O
subgroups	O
7	O
.	O

8	O
.	O
9	O
.	O
10	O
.	O
11	O
.	O

12	O
.	O

13	O
.	O

14	O
.	O

15	O
.	O

16	O
.	O

17	O
.	O

18	O
.	O

19	O
.	O
20	O
.	O

21	O
.	O

22	O
.	O

23	O
.	O

24	O
.	O

25	O
.	O

26	O
.	O

27	O
.	O

28	O
.	O

29	O
.	O

30	O
.	O

chronic	O
obstructive	O
pulmonary	O
disease	O
in	O
6	O
European	O
cities	O
:	O
results	O
from	O
the	O
APHEA	O
project	O
.	O

Eur	O
Respir	O
J	O
10:1064	O
�	O
1071	O
(	O
1997	O
)	O
.	O

Schwartz	O
J.	O
Short	O
term	O
fluctuations	O
in	O
air	O
pollution	O
and	O
hospital	O
admissions	O
of	O
the	O
elderly	O
for	O
respiratory	O
disease	O
.	O

Thorax	O
50:531	O
�	O
538	O
(	O
1995	O
)	O
.	O

Schwartz	O
J.	O
Air	O
pollution	O
and	O
hospital	O
admissions	O
for	O
heart	O
disease	O
in	O
eight	O
U.S.	O
counties	O
.	O

Epidemiology	O
10:17	O
�	O
22	O
(	O
1999	O
)	O
.	O

Schwartz	O
J.	O
Air	O
pollution	O
and	O
hospital	O
admissions	O
for	O
the	O
elderly	O
in	O
Minneapolis	O
.	O

Arch	O
Environ	O
Health	O
49:366	O
�	O
374	O
(	O
1994	O
)	O
.	O

Schwartz	O
J.	O
Air	O
pollution	O
and	O
hospital	O
admissions	O
for	O
the	O
elderly	O
in	O
Birmingham	O
,	O
Alabama	O
.	O

Am	O
J	O
Epidemiol	O
139:589	O
�	O
598	O
(	O
1994	O
)	O
.	O

Schwartz	O
J.	O
Air	O
pollution	O
and	O
hospital	O
admissions	O
for	O
the	O
elderly	O
in	O
Detroit	O
,	O
MI	O
.	O

Am	O
J	O
Respir	O
Crit	O
Care	O
Med	O
150:648	O
�	O
655	O
(	O
1994	O
)	O
.	O

Pope	O
CA	O
III	O
.	O

Respiratory	O
disease	O
associated	O
with	O
community	O
air	O
pollution	O
and	O
a	O
steel	O
mill	O
,	O
Utah	O
valley	O
.	O

Am	O
J	O
Public	O
Health	O
79:623	O
�	O
628	O
(	O
1989	O
)	O
.	O

Saldiva	O
PH	O
,	O
Pope	O
CA	O
,	O
Schwartz	O
J	O
,	O
Dockery	O
DW	O
,	O
Lichtenfels	O
AJ	O
,	O
Salge	O
JM	O
,	O
Barone	O
I	O
,	O
Bohm	O
GM	O
.	O

Air	O
pollution	O
and	O
mortality	O
in	O
elderly	O
people	O
:	O
a	O
time	O
series	O
study	O
in	O
Sao	O
Paulo	O
,	O
Brazil	O
.	O

Arch	O
Environ	O
Health	O
50:159	O
�	O
163	O
(	O
1995	O
)	O
.	O

Schwartz	O
,	O
J.	O
Air	O
pollution	O
and	O
hospital	O
admissions	O
for	O
cardiovascular	O
disease	O
in	O
Tucson	O
.	O

Epidemiology	O
8:371	O
�	O
177	O
(	O
1997	O
)	O
.	O

Delfino	O
RJ	O
,	O
Murphy	O
Moulton	O
AM	O
,	O
Becklake	O
MR	O
.	O

Emergency	O
room	O
visits	O
for	O
respiratory	O
illnesses	O
among	O
the	O
elderly	O
in	O
Montreal	O
:	O
association	O
with	O
low	O
level	O
ozone	O
exposure	O
.	O

Environ	O
Res	O
76:67	O
�	O
77	O
(	O
1998	O
)	O
.	O

National	O
Research	O
Council	O
.	O

Research	O
Priorities	O
for	O
Airborne	O
Particulate	O
Matter	O
.	O

Washington	O
,	O
DC	O
:	O
National	O
Academy	O
Press	O
,	O
1998	O
.	O

Schwartz	O
J	O
,	O
Dockery	O
DW	O
.	O

Increased	O
mortality	O
in	O
Philadelphia	O
associated	O
with	O
daily	O
air	O
pollution	O
concentrations	O
.	O

Am	O
Rev	O
Respir	O
Dis	O
145:600	O
�	O
604	O
(	O
1992	O
)	O
.	O

Samet	O
JM	O
,	O
Zeger	O
SL	O
,	O
Berhane	O
K.	O

The	O
association	O
of	O
mortality	O
and	O
particulate	O
air	O
pollution	O
.	O

In	O
:	O
Particulate	O
Air	O
Pollution	O
and	O
Daily	O
Mortality	O
.	O

The	O
Phase	O
I	O
Report	O
of	O
the	O
Particle	O
Epidemiology	O
Evaluation	O
Project	O
.	O

Boston	O
,	O
MA	O
:	O
Health	O
Effects	O
Institute	O
,	O
1995	O
.	O

Schwartz	O
J.	O

What	O
are	O
people	O
dying	O
of	O
on	O
high	O
air	O
pollution	O
days	O
?	O

Environ	O
Res	O
64:26	O
�	O
35	O
(	O
1994	O
)	O
.	O

Sunyer	O
J	O
,	O
Schwartz	O
J	O
,	O
Tobias	O
A	O
,	O
MacFarlane	O
D	O
,	O
Garcia	O
J	O
,	O
Anto	O
JM	O
.	O

Patients	O
with	O
chronic	O
obstructive	O
pulmonary	O
disease	O
are	O
a	O
susceptible	O
population	O
of	O
dying	O
due	O
to	O
urban	O
particles	O
.	O

Am	O
J	O
Epidemiol	O
151	O
(	O
1	O
)	O
:50	O
�	O
56	O
(	O
2000	O
)	O
.	O

Godleski	O
JJ	O
,	O
Sioutas	O
C	O
,	O
Katler	O
M	O
,	O
Koutrakis	O
P.	O
Death	O
from	O
inhalation	O
of	O
concentrated	O
air	O
particles	O
in	O
animal	O
models	O
of	O
pulmonary	O
disease	O
.	O

Am	O
J	O
Respir	O
Crit	O
Care	O
Med	O
153	O
:	O
A15	O
(	O
1996	O
)	O
.	O

Matsui	O
K	O
,	O
Goldman	O
L.	O
Comorbidity	O
as	O
a	O
correlate	O
of	O
length	O
of	O
stay	O
for	O
hospitalized	O
patients	O
with	O
acute	O
chest	O
pain	O
.	O

J	O
Gen	O
Intern	O
Med	O
11:262	O
�	O
268	O
(	O
1996	O
)	O
.	O

Charlson	O
M	O
,	O
Szatrowshi	O
TP	O
,	O
Peterson	O
J	O
,	O
Gold	O
J.	O
Validation	O
of	O
a	O
combined	O
comorbidity	O
index	O
.	O

J	O
Clin	O
Epidemiol	O
47:1245	O
�	O
1251	O
(	O
1994	O
)	O
.	O

Monane	O
M	O
,	O
Kanter	O
DS	O
,	O
Glynn	O
RJ	O
,	O
Avorn	O
J.	O
Variability	O
in	O
length	O
of	O
hospitalization	O
for	O
stroke	O
.	O

The	O
role	O
of	O
managed	O
care	O
in	O
an	O
elderly	O
population	O
.	O

Arch	O
Neurol	O
53:848	O
(	O
1996	O
)	O
.	O

Hallstrom	O
AP	O
,	O
Cobb	O
LA	O
,	O
Yu	O
BH	O
.	O

Influence	O
of	O
comorbidity	O
on	O
the	O
outcome	O
of	O
patients	O
treated	O
for	O
out	O
-	O
of	O
-	O
hospital	O
ventricular	O
fibrillation	O
.	O

Circulation	O
93:2019	O
�	O
2022	O
(	O
1996	O
)	O
.	O

Malenka	O
DJ	O
,	O
Mclerran	O
D	O
,	O
Roos	O
N	O
,	O
Fisher	O
ES	O
,	O
Wennberg	O
JE	O
.	O

Using	O
administrative	O
data	O
to	O
describe	O
case	O
-	O
mix	O
:	O
a	O
comparison	O
with	O
the	O
medical	O
record	O
.	O

J	O
Clin	O
Epidemiol	O
47:1027	O
�	O
1032	O
(	O
1994	O
)	O
.	O

Romano	O
PS	O
,	O
Roos	O
LL	O
,	O
Jollis	O
JG	O
.	O

Adapting	O
a	O
clinical	O
comorbidity	O
index	O
for	O
use	O
with	O
ICD-9-CM	O
administrative	O
data	O
:	O
differing	O
perspectives	O
.	O

J	O
Clin	O
Epidemiol	O
46:1075	O
�	O
1079	O
(	O
1993	O
)	O
.	O

Deyo	O
RA	O
,	O
Cherkin	O
DC	O
,	O
Ciol	O
MA	O
.	O

Adapting	O
a	O
clinical	O
comorbidity	O
index	O
for	O
use	O
with	O
ICD-9CM	O
administrative	O
databases	O
.	O

J	O
Clin	O
Epidemiol	O
45:613	O
�	O
619	O
(	O
1992	O
)	O
.	O

Charlson	O
ME	O
,	O
Pompei	O
P	O
,	O
Ales	O
KL	O
,	O
MacKenzie	O
CR	O
.	O

A	O
new	O
method	O
of	O
classifying	O
prognostic	O
comorbidity	O
in	O
longitudinal	O
studies	O
:	O
development	O
and	O
validation	O
.	O

J	O
Chronic	O
Dis	O
40:373	O
�	O
383	O
(	O
1987	O
)	O
.	O

Librero	O
J	O
,	O
Peir	O
�	O
S	O
,	O
Ordi	O
�	O
ana	O
R.	O
Chronic	O
comorbidity	O
and	O
outcomes	O
of	O
hospital	O
care	O
:	O
length	O
of	O
stay	O
,	O
mortality	O
,	O
and	O
readmission	O
at	O
30	O
and	O
365	O
days	O
.	O

J	O
Clin	O
Epidemiol	O
52:171	O
�	O
179	O
(	O
1999	O
)	O
.	O

31	O
.	O

Nehls	O
GJ	O
,	O
Akland	O
GG	O
.	O

Procedures	O
for	O
handling	O
aerometric	O
data	O
.	O

J	O
Air	O
Pollut	O
Control	O
Assoc	O
23:180	O
�	O
184	O
(	O
1973	O
)	O
.	O

32	O
.	O

Hastie	O
T	O
,	O
Tibshirani	O
R.	O
Generalized	O
Additive	O
Models	O
.	O

London	O
:	O
Chapman	O
and	O
Hall	O
,	O
1990	O
.	O
33	O
.	O

Schwartz	O
J.	O
Generalized	O
additive	O
models	O
in	O
epidemiology	O
.	O

In	O
:	O
International	O
Biometric	O
Society	O
,	O
Invited	O
Papers	O
.	O

17th	O
International	O
Biometric	O
Conference	O
,	O
8	O
�	O
12	O
August	O
1994	O
,	O
Hamilton	O
,	O
Ontario	O
,	O
Canada	O
.	O

Washington	O
,	O
DC	O
:	O
International	O
Biometric	O
Society	O
,	O
1994;55	O
�	O
80	O
.	O
34	O
.	O

Rossi	O
G	O
,	O
Vigotti	O
MA	O
,	O
Zanobetti	O
A	O
,	O
Repetto	O
F	O
,	O
Giannelle	O
V	O
,	O
Schwartz	O
J.	O
Air	O
pollution	O
and	O
cause	O
specific	O
mortality	O
in	O
Milan	O
,	O
Italy	O
,	O
1980	O
�	O
1989	O
.	O

Arch	O
Environ	O
Health	O
54:158	O
�	O
164	O
(	O
1999	O
)	O
.	O

35	O
.	O

Cleveland	O
WS	O
,	O
Devlin	O
SJ	O
.	O

Robust	O
locally	O
-	O
weighted	O
regression	O
and	O
smoothing	O
scatterplots	O
.	O

J	O
Am	O
Stat	O
Assoc	O
74:829	O
�	O
836	O
(	O
1988	O
)	O
.	O

36	O
.	O

Akaike	O
H.	O
Information	O
theory	O
and	O
an	O
extension	O
of	O
the	O
maximum	O
likelihood	O
principal	O
.	O

In	O
:	O
2nd	O
International	O
Symposium	O
on	O
Information	O
Theory	O
(	O
Petrov	O
BN	O
,	O
Csaki	O
F	O
,	O
eds	O
)	O
.	O

Budapest	O
:	O
Akademiai	O
Kaiado	O
,	O
1973;267	O
�	O
281	O
.	O
37	O
.	O

Brumback	O
BA	O
,	O
Ryan	O
LM	O
,	O
Schwartz	O
J	O
,	O
Neas	O
LM	O
,	O
Stark	O
PC	O
,	O
Burge	O
HA	O
.	O

Transitional	O
regression	O
models	O
with	O
application	O
to	O
environmental	O
time	O
series	O
.	O

J	O
Acoust	O
Soc	O
Am	O
95	O
(	O
449	O
)	O
:16	O
�	O
28	O
(	O
2000	O
)	O
.	O

38	O
.	O

Schwartz	O
J.	O

The	O
distributed	O
lag	O
between	O
air	O
pollution	O
and	O
daily	O
deaths	O
.	O

Epidemiology	O
11:320	O
�	O
326	O
(	O
2000	O
)	O
.	O

39	O
.	O

Pope	O
CA	O
III	O
,	O
Verrier	O
RL	O
,	O
Lovett	O
EG	O
,	O
Larson	O
AC	O
,	O
Raizenne	O
ME	O
,	O
Kanner	O
RE	O
,	O
Schwartz	O
J	O
,	O
Villegas	O
GM	O
,	O
Dockery	O
DW	O
.	O

Heart	O
rate	O
variability	O
associated	O
with	O
particulate	O
air	O
pollution	O
.	O

Am	O
Heart	O
J	O
138:890	O
�	O
899	O
(	O
1999	O
)	O
.	O

40	O
.	O

Gold	O
DR	O
,	O
Litonjua	O
A	O
,	O
Schwartz	O
J	O
,	O
Lovett	O
E	O
,	O
Larson	O
A	O
,	O
Nearing	O
B	O
,	O
Allen	O
G	O
,	O
Verrier	O
M	O
,	O
Cherry	O
R	O
,	O
Verrier	O
R.	O
Ambient	O
pollution	O
and	O
heart	O
rate	O
variability	O
.	O

Circulation	O
101	O
(	O
11	O
)	O
:1267	O
�	O
1273	O
(	O
2000	O
)	O
.	O

41	O
.	O

Liao	O
D	O
,	O
Creason	O
J	O
,	O
Shy	O
C	O
,	O
Williams	O
R	O
,	O
Watts	O
R	O
,	O
Zweidinger	O
R.	O
Daily	O
variation	O
of	O
particulate	O
air	O
pollution	O
and	O
poor	O
cardiac	O
autonomic	O
control	O
in	O
the	O
elderly	O
.	O

Environ	O
Health	O
Perspect	O
107:521	O
�	O
525	O
(	O
1999	O
)	O
.	O

42	O
.	O

Peters	O
A	O
,	O
Liu	O
E	O
,	O
Verrier	O
RL	O
,	O
Schwartz	O
J	O
,	O
Gold	O
DR	O
,	O
Mittelman	O
M	O
,	O
Baliff	O
J	O
,	O
Allen	O
G	O
,	O
Monahan	O
K	O
,	O
Dockery	O
DW	O
.	O

Air	O
pollution	O
and	O
incidences	O
of	O
cardiac	O
arrhythmia	O
.	O

Epidemiology	O
11	O
(	O
1	O
)	O
:11	O
�	O
17	O
(	O
2000	O
)	O
.	O

43	O
.	O

Godleski	O
JJ	O
,	O
Verrier	O
RL	O
,	O
Koutrakis	O
P	O
,	O
Catalano	O
P.	O
Mechanisms	O
of	O
Morbidity	O
and	O
Mortality	O
from	O
Exposure	O
to	O
Ambient	O
Air	O
Particles	O
.	O

Health	O
Effects	O
Institute	O
Research	O
Report	O
91	O
.	O

Cambridge	O
,	O
MA	O
:	O
Health	O
Effects	O
Institute	O
,	O
2000	O
.	O
44	O
.	O

Watkinson	O
WP	O
,	O
Campen	O
MJ	O
,	O
Kodavanti	O
UP	O
,	O
Ledbetter	O
AD	O
,	O
Costa	O
DL	O
.	O

Effects	O
of	O
inhaled	O
residual	O
oil	O
fly	O
ash	O
particles	O
on	O
electrocardiographic	O
and	O
thermoregulatory	O
parameters	O
in	O
normal	O
and	O
compromised	O
rats	B
[	O
Abstract	O
]	O
.	O

Am	O
J	O
Respir	O
Crit	O
Care	O
Med	O
157	O
:	O
A150	O
(	O
1998	O
)	O
.	O

45	O
.	O

Watkinson	O
WP	O
,	O
Campen	O
MJ	O
,	O
Costa	O
DL	O
.	O

Cardiac	O
arrhythmia	O
induction	O
after	O
exposure	O
to	O
residual	O
oil	O
fly	O
ash	O
particles	O
in	O
a	O
rodent	O
model	O
of	O
pulmonary	O
hypertension	O
.	O

Toxicol	O
Sci	O
41:209	O
�	O
216	O
(	O
1998	O
)	O
.	O

46	O
.	O

Kodavanti	O
UP	O
,	O
Jackson	O
MC	O
,	O
Richards	O
J	O
,	O
Ledbetter	O
A	O
,	O
Costa	O
DL	O
.	O

Differential	O
pulmonary	O
responses	O
to	O
inhaled	O
emission	O
particulate	O
matter	O
(	O
PM	O
)	O
in	O
systemically	O
hypertensive	O
vs.	O
normotensive	O
rats	B
[	O
Abstract	O
]	O
.	O

Am	O
J	O
Respir	O
Crit	O
Care	O
Med	O
157	O
:	O
A260	O
(	O
1998	O
)	O
.	O

47	O
.	O

Hoek	O
G	O
,	O
Brunekreef	O
B	O
,	O
van	O
Wijnen	O
JH	O
.	O

Cardiovascular	O
mortality	O
response	O
to	O
air	O
pollution	O
is	O
strongest	O
for	O
heart	O
failure	O
and	O
thrombotic	O
causes	O
of	O
death	O
[	O
Abstract	O
]	O
.	O

Epidemiology	O
10	O
:	O
S177	O
(	O
1999	O
)	O
.	O

48	O
.	O

Bates	O
DV	O
,	O
Szito	O
R.	O
Hospital	O
admissions	O
and	O
air	O
pollutants	O
in	O
southern	O
Ontario	O
:	O
the	O
acid	O
summer	O
haze	O
effect	O
.	O

Environ	O
Res	O
43:317	O
�	O
331	O
(	O
1987	O
)	O
.	O

49	O
.	O

Pope	O
CA	O
III	O
.	O

Respiratory	O
disease	O
associated	O
with	O
community	O
air	O
pollution	O
and	O
a	O
steel	O
mill	O
,	O
Utah	O
valley	O
.	O

Am	O
J	O
Public	O
Health	O
79:623	O
�	O
628	O
(	O
1989	O
)	O
.	O

50	O
.	O

Zelikoff	O
JT	O
,	O
Nadziejko	O
C	O
,	O
Fang	O
T	O
,	O
Gordon	O
C	O
,	O
Premdass	O
C	O
,	O
Cohen	O
MD	O
.	O

Short	O
term	O
,	O
low	O
-	O
dose	O
inhalation	O
of	O
ambient	O
particulate	O
matter	O
exacerbates	O
ongoing	O
pneumococcal	O
infections	O
in	O
Streptococcus	O
Pneumoniae	O
-	O
infected	O
rates	O
.	O

In	O
:	O
Proceedings	O
of	O
the	O
Third	O
Colloquium	O
on	O
Particulate	O
Air	O
Pollution	O
and	O
Human	B
Health	O
(	O
Phalen	O
RF	O
,	O
Bell	O
YM	O
,	O
eds	O
)	O
.	O

Irvine	O
,	O
CA	O
:	O
Air	O
Pollution	O
Health	O
Effects	O
Laboratory	O
,	O
University	O
of	O
California	O
,	O
1999;8	O
-	O
94	O
�	O
8	O
-	O
101	O
.	O
51	O
.	O

Clarke	O
RW	O
,	O
Hemenway	O
DR	O
,	O
Frank	O
R	O
,	O
Kleeberger	O
SR	O
,	O
Longphre	O
MV	O
,	O
Jakab	O
GJ	O
.	O

Particle	O
associated	O
sulfate	O
exposure	O
enhances	O
murine	O
influenza	O
mortality	O
[	O
Abstract	O
]	O
.	O

Am	O
J	O
Respir	O
Crit	O
Care	O
Med	O
155	O
:	O
A245	O
(	O
1997	O
)	O
.	O

52	O
.	O

Pope	O
CA	O
,	O
Dockery	O
DW	O
,	O
Spengler	O
JD	O
,	O
Raizenne	O
ME	O
.	O

Respiratory	O
health	O
and	O
PM10	O
pollution	O
:	O
a	O
daily	O
time	O
series	O
analysis	O
.	O

Am	O
Rev	O
Respir	O
Dis	O
144:668	O
�	O
674	O
(	O
1991	O
)	O
.	O

53	O
.	O

Schwartz	O
J	O
,	O
Koenig	O
J	O
,	O
Slater	O
D	O
,	O
Larson	O
T.	O
Particulate	O
air	O
pollution	O
and	O
hospital	O
emergency	O
visits	O
for	O
asthma	O
in	O
Seattle	O
.	O

Am	O
Rev	O
Respir	O
Dis	O
147:826	O
�	O
831	O
(	O
1993	O
)	O
.	O

54	O
.	O

Thurston	O
GD	O
,	O
Ito	O
K	O
,	O
Lippman	O
M	O
,	O
Hayes	O
CG	O
,	O
Bates	O
DV	O
.	O

Respiratory	O
hospital	O
admissions	O
and	O
summertime	O
haze	O
air	O
pollution	O
in	O
Toronto	O
,	O
Ontario	O
:	O
consideration	O
of	O
the	O
role	O
of	O
acid	O
aerosols	O
.	O

Environ	O
Res	O
65:271	O
�	O
290	O
(	O
1994	O
)	O
.	O

55	O
.	O

Norris	O
G	O
,	O
YoungPong	O
SN	O
,	O
Koenig	O
JQ	O
,	O
Larson	O
TV	O
,	O
Sheppard	O
L	O
,	O
Stout	O
JW	O
.	O

An	O
association	O
between	O
fine	O
particles	O
and	O
asthma	O
emergency	O
department	O
visits	O
for	O
children	O
in	O
Seattle	O
.	O

Environ	O
Health	O
Perspect	O
107:489	O
�	O
493	O
(	O
1999	O
)	O
.	O

56	O
.	O

Hamada	O
K	O
,	O
Goldsmith	O
CW	O
,	O
Kobzik	O
L.	O
Air	O
pollutant	O
aerosols	O
allow	O
airway	O
sensitization	O
to	O
allergen	O
in	O
juvenile	O
mice	B
.	O

Am	O
J	O
Resp	O
Crit	O
Care	O
Med	O
A28	O
(	O
1999	O
)	O
.	O

57	O
.	O

Lambert	O
AL	O
,	O
Selgrade	O
M	O
,	O
Dong	O
W	O
,	O
Winsett	O
D	O
,	O
Gilmour	O
M.	O
Enhanced	O
allergic	O
sensitization	O
by	O
residual	O
oil	O
fly	O
ash	O
particles	O
is	O
mediated	O
by	O
soluble	O
metal	O
constituents	O
[	O
Abstract	O
]	O
.	O

Am	O
J	O
Respir	O
Crit	O
Care	O
Med	O
159	O
:	O
A26	O
(	O
1999	O
)	O
.	O

58	O
.	O

Dailey	O
LA	O
,	O
Madden	O
MC	O
,	O
Devlin	O
RB	O
.	O

Do	O
airway	O
epithelial	O
cells	O
from	O
normal	O
and	O
asthmatic	O
donors	O
respond	O
differently	O
to	O
an	O
in	O
vitro	O
challenge	O
with	O
a	O
particulate	O
pollutant	O
?	O

[	O
Abstract	O
]	O
.	O

Am	O
J	O
Respir	O
Crit	O
Care	O
Med	O
157	O
:	O
A598	O
(	O
1998	O
)	O
.	O

59	O
.	O

Gilmour	O
MI	O
,	O
Winsett	O
D	O
,	O
Selgrade	O
MJ	O
,	O
Costa	O
DL	O
.	O

Residual	O
oil	O
fly	O
ash	O
exposure	O
enhances	O
allergic	O
sensitization	O
to	O
house	O
dust	O
mite	O
in	O
rats	B
and	O
augments	O
immune	O
-	O
mediated	O
inflammation	O
[	O
Abstract	O
]	O
.	O

Am	O
J	O
Respir	O
Crit	O
Care	O
Med	O
155	O
:	O
A244	O
(	O
1997	O
)	O
.	O

60	O
.	O

Zeger	O
SL	O
,	O
Thomas	O
D	O
,	O
Dominici	O
F	O
,	O
Samet	O
JM	O
,	O
Schwartz	O
JM	O
,	O
Dockery	O
D	O
,	O
Cohen	O
A.	O
Exposure	O
measurement	O
error	O
in	O
time	O
�	O
series	O
studies	O
of	O
air	O
pollution	O
:	O
concepts	O
and	O
consequences	O
.	O

Environ	O
Health	O
Perspect	O
108:419	O
�	O
426	O
(	O
2000	O
)	O
.	O

61	O
.	O

Salvi	O
S	O
,	O
Blomberg	O
A	O
,	O
Rudell	O
B	O
,	O
Kelly	O
F	O
,	O
Sandstrom	O
T	O
,	O
Holgate	O
ST	O
,	O
Frew	O
A.	O
Acute	O
inflammatory	O
responses	O
in	O
the	O
airways	O
and	O
peripheral	O
blood	O
after	O
short	O
-	O
term	O
exposure	O
to	O
diesel	O
exhaust	O
in	O
healthy	O
human	B
volunteers	O
.	O

Am	O
J	O
Respir	O
Crit	O
Care	O
Med	O
159:702	O
�	O
709	O
(	O
1999	O
)	O
.	O

62	O
.	O

Tan	O
WC	O
,	O
van	O
Eeden	O
S	O
,	O
Qiu	O
DW	O
,	O
Liam	O
BL	O
,	O
Dyachokova	O
Y	O
,	O
Hogg	O
JL	O
.	O

Particulate	O
air	O
pollution	O
,	O
bone	O
marrow	O
stimulation	O
and	O
the	O
pathogenesis	O
of	O
excess	O
cardiovascular	O
and	O
pulmonary	O
deaths	O
.	O

Am	O
J	O
Respir	O
Crit	O
Care	O
Med	O
155:1441	O
�	O
1447	O
(	O
1997	O
)	O
.	O

63	O
.	O

Gordon	O
T	O
,	O
Nadziejko	O
C	O
,	O
Schlesinger	O
R	O
,	O
Chen	O
LC	O
.	O

Pulmonary	O
and	O
cardiovascular	O
effects	O
of	O
acute	O
exposure	O
to	O
concentrated	O
ambient	O
particulate	O
matter	O
in	O
rats	B
.	O

Toxicol	O
Lett	O
96	O
�	O
97:285	O
�	O
288	O
(	O
1998	O
)	O
.	O

64	O
.	O

Peters	O
A	O
,	O
Doering	O
A	O
,	O
Wichmann	O
HE	O
,	O
Koenig	O
W.	O
Increased	O
plasma	O
viscosity	O
during	O
an	O
air	O
pollution	O
episode	O
:	O
a	O
link	O
to	O
mortality	O
?	O

Lancet	O
349	O
(	O
9065	O
)	O
:1582	O
�	O
1587	O
(	O
1997	O
)	O
.	O

65	O
.	O

Peters	O
A	O
,	O
Stieberv	O
J	O
,	O
Doering	O
A	O
,	O
Wichmann	O
HE	O
.	O

Is	O
systolic	O
blood	O
pressure	O
associated	O
with	O
air	O
pollution	O
?	O

[	O
Abstract	O
]	O
.	O

Epidemiology	O
10	O
(	O
4	O
)	O
:S177	O
(	O
1999	O
)	O
.	O

Environmental	O
Health	O
Perspectives	O
�	O
VOLUME	O
108	O
|	O
NUMBER	O

9	O
|	O
September	O
2000	O
845	O

Host	O
immunity	O
in	O
the	O
protective	O
response	O
to	O
vaccination	O
with	O
heat	O
-	O
killed	O
Burkholderia	B
mallei	I
Abstract	O
Background	O
We	O
performed	O
initial	O
cell	O
,	O
cytokine	O
and	O
complement	O
depletion	O
studies	O
to	O
investigate	O
the	O
possible	O
role	O
of	O
these	O
effectors	O
in	O
response	O
to	O
vaccination	O
with	O
heat	O
-	O
killed	O
Burkholderia	B
mallei	I
in	O
a	O
susceptible	O
BALB	O
/	O
c	O
mouse	B
model	O
of	O
infection	O
.	O

Results	O
While	O
protection	O
with	O
heat	O
-	O
killed	O
bacilli	O
did	O
not	O
result	O
in	O
sterilizing	O
immunity	O
,	O
limited	O
protection	O
was	O
afforded	O
against	O
an	O
otherwise	O
lethal	O
infection	O
and	O
provided	O
insight	O
into	O
potential	O
host	O
protective	O
mechanisms	O
.	O

Our	O
results	O
demonstrated	O
that	O
mice	B
depleted	O
of	O
either	O
B	O
cells	O
,	O
TNF	O
-	O
α	O
or	O
IFN	O
-	O
γ	O
exhibited	O
decreased	O
survival	O
rates	O
,	O
indicating	O
a	O
role	O
for	O
these	O
effectors	O
in	O
obtaining	O
partial	O
protection	O
from	O
a	O
lethal	O
challenge	O
by	O
the	O
intraperitoneal	O
route	O
.	O

Additionally	O
,	O
complement	O
depletion	O
had	O
no	O
effect	O
on	O
immunoglobulin	O
production	O
when	O
compared	O
to	O
non	O
-	O
complement	O
depleted	O
controls	O
infected	O
intranasally	O
.	O

Conclusion	O
The	O
data	O
provide	O
a	O
basis	O
for	O
future	O
studies	O
of	O
protection	O
via	O
vaccination	O
using	O
either	O
subunit	O
or	O
whole	O
-	O
organism	O
vaccine	O
preparations	O
from	O
lethal	O
infection	O
in	O
the	O
experimental	O
BALB	O
/	O
c	O
mouse	B
model	O
.	O

The	O
results	O
of	O
this	O
study	O
demonstrate	O
participation	O
of	O
B220	O
+	O
cells	O
and	O
pro	O
-	O
inflammatory	O
cytokines	O
IFN	O
-	O
γ	O
and	O
TNF	O
-	O
α	O
in	O
protection	O
following	O
HK	O
vaccination	O
.	O

Background	O
Burkholderia	B
mallei	I
,	O
the	O
etiologic	O
agent	O
of	O
glanders	O
,	O
is	O
a	O
gram	O
-	O
negative	O
,	O
capsulated	O
,	O
non	O
-	O
motile	O
,	O
facultative	O
intracelluar	O
bacterium	O
.	O

Most	O
known	O
members	O
of	O
the	O
Burkholderiaceae	O
are	O
resident	O
in	O
the	O
soil	O
;	O
however	O
,	O
B.	B
mallei	I
is	O
thought	O
to	O
be	O
an	O
obligate	O
mammalian	O
pathogen	O
.	O

Horses	B
are	O
highly	O
susceptible	O
to	O
infection	O
and	O
considered	O
the	O
natural	O
reservoir	O
for	O
infection	O
,	O
although	O
mules	B
and	O
donkeys	B
are	O
also	O
susceptible	O
[	O
1	O
]	O
.	O

Clinically	O
,	O
glanders	O
in	O
solipeds	O
can	O
present	O
as	O
either	O
a	O
chronic	O
(	O
horses	B
)	O
or	O
acute	O
(	O
mules	B
and	O
donkeys	B
)	O
form	O
.	O

Naturally	O
acquired	O
human	B
infection	O
with	O
B.	B
mallei	I
,	O
although	O
not	O
seen	O
in	O
the	O
United	O
States	O
since	O
1945	O
,	O
has	O
occurred	O
rarely	O
and	O
sporadically	O
among	O
laboratory	O
workers	O
and	O
those	O
in	O
direct	O
contact	O
with	O
infected	O
animals	O
[	O
2	O
]	O
.	O

However	O
,	O
glanders	O
is	O
endemic	O
among	O
domestic	O
animals	O
in	O
Africa	O
,	O
Asia	O
,	O
the	O
Middle	O
East	O
,	O
and	O
Central	O
and	O
South	O
America	O
.	O

The	O
course	O
of	O
infection	O
is	O
dependent	O
on	O
the	O
route	O
of	O
exposure	O
.	O

Direct	O
contact	O
with	O
the	O
skin	O
can	O
lead	O
to	O
a	O
systemic	O
infection	O
.	O

Inhalation	O
of	O
aerosol	O
or	O
dust	O
containing	O
B.	B
mallei	I
can	O
lead	O
to	O
septicemic	O
,	O
pulmonary	O
,	O
or	O
chronic	O
infections	O
of	O
the	O
muscle	O
,	O
liver	O
and	O
spleen	O
.	O

The	O
disease	O
has	O
a	O
95	O
%	O
case	O
fatality	O
rate	O
for	O
untreated	O
septicemic	O
infections	O
and	O
a	O
50	O
%	O
case	O
fatality	O
rate	O
in	O
antibiotic	O
-	O
treated	O
individuals	O
[	O
3	O
]	O
.	O

There	O
is	O
no	O
human	B
or	O
animal	O
vaccine	O
available	O
for	O
glanders	O
,	O
and	O
development	O
of	O
a	O
partial	O
or	O
fully	O
protective	O
adaptive	O
host	O
response	O
to	O
the	O
organism	O
has	O
not	O
been	O
well	O
-	O
defined	O
.	O

Previous	O
studies	O
with	O
B.	B
mallei	I
and	O
the	O
host	O
response	O
have	O
shown	O
that	O
a	O
mixed	O
immune	O
response	O
consisting	O
of	O
both	O
Th1	O
and	O
Th2-associated	O
cytokines	O
with	O
a	O
predominant	O
IgG1	O
subclass	O
does	O
not	O
correlate	O
with	O
protection	O
[	O
4	O
]	O
.	O

Additional	O
studies	O
with	O
passive	O
transfer	O
of	O
monoclonal	O
antibodies	O
specific	O
for	O
B.	B
mallei	I
have	O
correlated	O
with	O
early	O
protection	O
from	O
infection	O
[	O
5	O
]	O
.	O

Recent	O
studies	O
have	O
also	O
shown	O
the	O
Th1	O
cytokine	O
IL-12	O
to	O
mediate	O
partial	O
protection	O
to	O
non	O
-	O
viable	O
B.	B
mallei	I
-	O
vaccinated	O
mice	B
[	O
6	O
]	O
.	O

Thus	O
,	O
full	O
correlates	O
of	O
protection	O
mediated	O
by	O
the	O
adaptive	O
immune	O
system	O
against	O
B.	B
mallei	I
remain	O
to	O
be	O
fully	O
elucidated	O
.	O

In	O
this	O
series	O
of	O
studies	O
,	O
we	O
sought	O
to	O
address	O
the	O
impact	O
of	O
depletion	O
of	O
the	O
major	O
effector	O
lymphoid	O
cell	O
populations	O
(	O
B220	O
+	O
B	O
cells	O
,	O
CD4	O
+	O
or	O
CD8	O
+	O
T	O
cells	O
)	O
and	O
key	O
pro	O
-	O
inflammatory	O
/	O
Type	O
1	O
cytokines	O
(	O
IFN	O
-	O
γ	O
or	O
TNF	O
-	O
α	O
)	O
on	O
survival	O
in	O
BALB	O
/	O
c	O
mice	B
vaccinated	O
with	O
heat	O
killed	O
(	O
HK	O
)	O
bacilli	O
followed	O
by	O
an	O
intraperitoneal	O
(	O
i.p	O
.	O
)	O
challenge	O
with	O
live	O
organism	O
.	O

In	O
addition	O
,	O
studies	O
investigating	O
the	O
effect	O
of	O
complement	O
on	O
opsonization	O
of	O
organism	O
and	O
antibody	O
production	O
were	O
assessed	O
.	O

Heat	O
killed	O
bacteria	O
were	O
used	O
as	O
a	O
model	O
of	O
vaccination	O
to	O
allow	O
evaluation	O
of	O
B.	B
mallei	I
specific	O
immune	O
responses	O
.	O

The	O
results	O
of	O
this	O
study	O
demonstrate	O
participation	O
of	O
B220	O
+	O
cells	O
and	O
pro	O
-	O
inflammatory	O
cytokines	O
IFN	O
-	O
γ	O
and	O
TNF	O
-	O
α	O
in	O
protection	O
following	O
HK	O
vaccination	O
.	O

Results	O
Heat	O
-	O
killed	O
B.	B
mallei	I
vaccination	O
mediates	O
partial	O
protection	O
from	O
lethal	O
challenge	O
To	O
begin	O
to	O
address	O
this	O
issue	O
in	O
an	O
animal	O
model	O
of	O
acute	O
infection	O
,	O
we	O
established	O
that	O
immunologically	O
naive	O
BALB	O
/	O
c	O
mice	B
challenged	O
i.p	O
.	O
with	O
2	O
×	O
107	O
CFU	O
resulted	O
in	O
death	O
by	O
day	O
4–6	O
,	O
while	O
i.p	O
.	O

immunization	O
with	O
1	O
×	O
105	O
heat	O
killed	O
(	O
HK	O
)	O
bacteria	O
provided	O
partial	O
protection	O
against	O
a	O
subsequent	O
challenge	O
.	O

Two	O
independent	O
experiments	O
resulted	O
in	O
similar	O
findings	O
of	O
40	O
%	O
survival	O
for	O
HK	O
-	O
vaccinated	O
mice	B
with	O
a	O
mean	O
survival	O
time	O
(	O
MST	O
)	O
of	O
8	O
days	O
versus	O
4	O
days	O
in	O
naïve	O
mice	B
(	O
Fig.	O
1	O
)	O
.	O

The	O
administration	O
of	O
vaccines	O
for	O
B.	B
mallei	I
during	O
an	O
outbreak	O
would	O
mandate	O
relatively	O
rapid	O
onset	O
of	O
protection	O
for	O
human	B
or	O
veterinary	O
use	O
.	O

Based	O
on	O
non	O
-	O
routine	O
use	O
and	O
vaccine	O
implementation	O
in	O
the	O
course	O
of	O
an	O
outbreak	O
,	O
a	O
14	O
day	O
window	O
was	O
chosen	O
for	O
assessment	O
of	O
protection	O
.	O

Our	O
results	O
indicate	O
that	O
HK	O
vaccination	O
can	O
afford	O
partial	O
protection	O
to	O
an	O
otherwise	O
lethal	O
challenge	O
of	O
B.	B
mallei	I
by	O
the	O
i.p	O
.	O

route	O
.	O

Effects	O
of	O
cell	O
depletion	O
on	O
HK	O
-	O
vaccinated	O
survival	O
To	O
dissect	O
the	O
cellular	O
basis	O
for	O
protection	O
mediated	O
by	O
HK	O
vaccination	O
,	O
13	O
days	O
after	O
immunization	O
with	O
HK	O
bacteria	O
(	O
day	O
-1	O
)	O
,	O
and	O
at	O
day	O
of	O
challenge	O
,	O
mice	B
were	O
dosed	O
with	O
antibodies	O
to	O
deplete	O
CD4	O
+	O
,	O
CD8	O
+	O
or	O
B220	O
+	O
cells	O
.	O

Antibody	O
depletion	O
of	O
CD4	O
+	O
,	O
CD8	O
+	O
,	O
or	O
B220	O
+	O
cells	O
in	O
these	O
mice	B
was	O
confirmed	O
by	O
flow	O
cytometric	O
analysis	O
with	O
depletion	O
efficiencies	O
for	O
CD4	O
,	O
CD8	O
,	O
and	O
B220	O
populations	O
at	O
99.7	O
%	O
,	O
96	O
%	O
,	O
and	O
95	O
%	O
,	O
respectively	O
,	O
relative	O
to	O
mice	B
treated	O
with	O
isotype	O
control	O
monoclonal	O
antibodies	O
(	O
data	O
not	O
shown	O
)	O
.	O

Our	O
results	O
demonstrated	O
decreased	O
survival	O
rates	O
in	O
B220	O
(	O
p	O
=	O
0.3418	O
)	O
,	O
CD4	O
+	O
(	O
p	O
=	O
0.5417	O
)	O
and	O
CD8	O
+	O
(	O
p	O
=	O
0.4684	O
)	O
antibody	O
depleted	O
mice	B
,	O
compared	O
to	O
isotype	O
control	O
antibody	O
,	O
a	O
finding	O
that	O
indicated	O
a	O
possible	O
role	O
for	O
vaccine	O
induced	O
antibody	O
production	O
.	O

When	O
challenged	O
with	O
2	O
×	O
107	O
CFU	O
/	O
mouse	B
by	O
the	O
i.p	O
.	O

route	O
,	O
loss	O
of	O
T	O
cells	O
resulted	O
in	O
reduced	O
survival	O
(	O
50	O
%	O
)	O
relative	O
to	O
the	O
non	O
-	O
specific	O
isotype	O
control	O
(	O
Fig.	O
2	O
)	O
.	O

In	O
contrast	O
to	O
the	O
loss	O
of	O
T	O
cells	O
,	O
depletion	O
of	O
B220	O
+	O
cells	O
resulted	O
in	O
100	O
%	O
mortality	O
relative	O
to	O
the	O
non	O
-	O
specific	O
isotype	O
control	O
(	O
Fig.	O
2	O
)	O
.	O

To	O
further	O
evaluate	O
the	O
necessity	O
of	O
these	O
effector	O
cells	O
in	O
providing	O
protection	O
following	O
HK	O
vaccination	O
,	O
relatively	O
resistant	O
C57BL	O
/	O
6	O
mice	B
,	O
deficient	O
in	O
mature	O
B	O
-	O
cells	O
(	O
μMT	O
)	O
,	O
CD4	O
T	O
-	O
cells	O
(	O
CD4-	O
/	O
-	O
)	O
or	O
CD8	O
T	O
-	O
cells	O
(	O
CD8-	O
/	O
-	O
)	O
were	O
subjected	O
to	O
an	O
identical	O
HK	O
vaccination	O
and	O
challenge	O
regimen	O
.	O

Mature	O
,	O
B	O
-	O
cell	O
-	O
deficient	O
mice	B
demonstrated	O
a	O
50	O
%	O
decreased	O
survival	O
(	O
p	O
=	O
0.0888	O
)	O
compared	O
to	O
the	O
wild	O
-	O
type	O
mice	B
with	O
an	O
MST	O
of	O
35.5	O
days	O
(	O
Fig.	O
3	O
)	O
.	O

CD4-	O
/	O
-	O
and	O
CD8-	O
/	O
-	O
mice	B
exhibited	O
a	O
60	O
%	O
(	O
p	O
=	O
0.1343	O
)	O
and	O
0	O
%	O
reduced	O
survival	O
,	O
respectively	O
(	O
Fig.	O
3	O
)	O
.	O

Effects	O
of	O
cytokine	O
depletion	O
on	O
HK	O
vaccination	O
Similar	O
studies	O
were	O
performed	O
to	O
determine	O
the	O
role	O
of	O
IFN	O
-	O
γ	O
or	O
TNF	O
-	O
α	O
in	O
acute	O
infection	O
in	O
BALB	O
/	O
c	O
mice	B
immunized	O
with	O
HK	O
bacteria	O
.	O

Six	O
hours	O
before	O
challenge	O
,	O
mice	B
were	O
dosed	O
with	O
antibodies	O
that	O
neutralize	O
IFN	O
-	O
γ	O
or	O
TNF	O
-	O
α	O
.	O

Individual	O
depletion	O
of	O
either	O
TNF	O
-	O
α	O
(	O
p	O
=	O
0.0145	O
)	O
or	O
IFN	O
-	O
γ	O
(	O
p	O
=	O
0.0446	O
)	O
resulted	O
in	O
100	O
%	O
mortality	O
with	O
an	O
MST	O
of	O
3	O
and	O
2	O
days	O
,	O
respectively	O
,	O
compared	O
to	O
the	O
HK	O
-	O
vaccinated	O
isotype	O
control	O
mice	B
(	O
Fig.	O
4	O
)	O
.	O

In	O
contrast	O
,	O
40	O
%	O
of	O
HK	O
-	O
vaccinated	O
,	O
isotype	O
control	O
mice	B
survived	O
to	O
at	O
least	O
12	O
days	O
post	O
-	O
challenge	O
(	O
Fig	O
4	O
)	O
.	O

To	O
further	O
evaluate	O
the	O
host	O
TNF	O
-	O
α	O
response	O
during	O
an	O
established	O
B.	B
mallei	I
chronic	O
infection	O
,	O
we	O
infected	O
12	O
BALB	O
/	O
c	O
mice	B
by	O
the	O
i.p	O
.	O

route	O
with	O
1	O
×	O
106	O
CFU	O
B.	B
mallei	I
.	O

One	O
animal	O
was	O
terminally	O
ill	O
on	O
day	O
37	O
post	O
-	O
infection	O
.	O

On	O
day	O
42	O
post	O
-	O
infection	O
,	O
the	O
remaining	O
11	O
mice	B
were	O
dosed	O
with	O
either	O
anti	O
-	O
TNF	O
-	O
α	O
(	O
n	O
=	O
6	O
)	O
,	O
or	O
control	O
mAb	O
(	O
AFRC	O
Mac	O
49	O
)	O
(	O
n	O
=	O
5	O
)	O
.	O

No	O
further	O
deaths	O
were	O
observed	O
in	O
the	O
control	O
mAb	O
-	O
treated	O
mice	B
.	O

Rapid	O
mortality	O
was	O
observed	O
in	O
the	O
anti	O
-	O
TNF	O
-	O
α	O
-	O
treated	O
group	O
,	O
with	O
all	O
mice	B
dying	O
within	O
7	O
days	O
of	O
treatment	O
(	O
p	O
=	O
0.0023	O
)	O
relative	O
to	O
the	O
isotype	O
-	O
treated	O
controls	O
(	O
Fig.	O
5	O
)	O
.	O

J774A.1	O
uptake	O
of	O
serum	O
treated	O
B.	B
mallei	I
Complement	O
mediated	O
uptake	O
assays	O
were	O
performed	O
to	O
evaluate	O
opsonization	O
.	O

Results	O
indicated	O
enhanced	O
bacterial	O
uptake	O
in	O
J774A.1	O
phagocytes	O
inoculated	O
with	O
serum	O
treated	O
B.	B
mallei	I
(	O
p	O
=	O
.0082	O
)	O
,	O
compared	O
to	O
B.	B
mallei	I
alone	O
,	O
while	O
heat	O
-	O
inactivated	O
serum	O
produced	O
uptake	O
percentages	O
similar	O
to	O
those	O
prior	O
to	O
serum	O
addition	O
(	O
Fig.	O
6	O
)	O
.	O

Taken	O
together	O
,	O
these	O
results	O
imply	O
an	O
active	O
role	O
for	O
complement	O
components	O
in	O
the	O
uptake	O
of	O
organism	O
by	O
macrophages	O
.	O

Immunoglobulin	O
production	O
in	O
HK	O
vaccinated	O
BALB	O
/	O
c	O
mice	B
We	O
further	O
characterized	O
the	O
ability	O
of	O
HK	O
vaccination	O
to	O
induce	O
a	O
predominant	O
IgG	O
isotype	O
by	O
determining	O
IgG2a	O
/	O
IgG1	O
ratios	O
in	O
i.p	O
.	O
and	O
i.n	O
.	O

vaccinated	O
BALB	O
/	O
c	O
mice	B
.	O

Pre	O
(	O
day	O
14	O
post	O
vaccination	O
)	O
and	O
post	O
(	O
day	O
2	O
post	O
infection	O
)	O
exposure	O
serum	O
samples	O
were	O
obtained	O
and	O
evaluated	O
for	O
IgG	O
isotype	O
concentrations	O
(	O
Table	O
1	O
)	O
.	O

No	O
appreciable	O
differences	O
in	O
IgG	O
pre	O
-	O
exposure	O
levels	O
were	O
seen	O
when	O
comparing	O
i.n	O
.	O

to	O
i.p	O
.	O

vaccination	O
.	O

In	O
addition	O
,	O
cobra	O
venom	O
factor	O
-	O
treated	O
animals	O
showed	O
no	O
significant	O
differences	O
to	O
non	O
-	O
cobra	O
venom	O
factor	O
-	O
treated	O
animals	O
in	O
IgG	O
pre	O
-	O
exposure	O
(	O
challenge	O
)	O
levels	O
.	O

Conversely	O
,	O
isotype	O
switching	O
in	O
the	O
cobra	O
venom	O
factor	O
treated	O
animals	O
was	O
enhanced	O
in	O
post	O
-	O
exposure	O
serum	O
IgG2a	O
(	O
Table	O
1	O
)	O
.	O

Discussion	O
Recent	O
studies	O
have	O
shown	O
a	O
key	O
role	O
in	O
protection	O
from	O
lethal	O
challenge	O
for	O
IFN	O
-	O
γ	O
in	O
non	O
-	O
vaccinated	O
mice	B
from	O
either	O
NK	O
and/or	O
NKT	O
cells	O
following	O
experimental	O
exposure	O
to	O
B.	B
mallei	I
and	O
B.	B
pseudomallei	I
[	O
7,8	O
]	O
.	O

A	O
similar	O
protective	O
role	O
in	O
the	O
innate	O
response	O
to	O
infection	O
has	O
been	O
demonstrated	O
for	O
TNF	O
-	O
α	O
in	O
B.	B
pseudomallei	I
infection	O
[	O
8	O
]	O
.	O

The	O
studies	O
presented	O
here	O
are	O
consistent	O
with	O
the	O
essential	O
role	O
of	O
these	O
factors	O
in	O
the	O
relative	O
levels	O
of	O
protection	O
conferred	O
by	O
vaccination	O
with	O
heat	O
-	O
killed	O
B.	B
pseudomallei	I
and	O
would	O
appear	O
to	O
be	O
viable	O
early	O
markers	O
for	O
protection	O
from	O
lethal	O
acute	O
infection	O
[	O
9	O
]	O
.	O

Currently	O
,	O
there	O
are	O
no	O
fully	O
protective	O
vaccines	O
against	O
B.	B
mallei	I
or	O
B.	B
pseudomallei	I
in	O
a	O
murine	O
model	O
,	O
particularly	O
for	O
the	O
sensitive	O
BALB	O
/	O
c	O
versus	O
C57BL6	O
models	O
.	O

Previous	O
studies	O
have	O
also	O
demonstrated	O
that	O
both	O
the	O
humoral	O
and	O
cell	O
-	O
mediated	O
arms	O
are	O
essential	O
for	O
protection	O
from	O
B.	B
pseudomallei	I
infection	O
[	O
10	O
]	O
.	O

Thus	O
,	O
loss	O
or	O
reduction	O
of	O
TNF	O
-	O
α	O
and	O
IFN	O
-	O
γ	O
levels	O
result	O
in	O
significantly	O
reduced	O
survival	O
rates	O
,	O
substantiating	O
previous	O
reports	O
of	O
the	O
role	O
of	O
these	O
factors	O
in	O
protection	O
against	O
B.	B
mallei	I
[	O
7	O
]	O
.	O

Moreover	O
,	O
we	O
demonstrate	O
a	O
role	O
for	O
sustained	O
TNF	O
-	O
α	O
production	O
in	O
the	O
maintenance	O
of	O
host	O
survival	O
throughout	O
the	O
course	O
of	O
B.	B
mallei	I
infection	O
.	O

Mice	B
with	O
an	O
established	O
B.	B
mallei	I
chronic	O
infection	O
rapidly	O
lost	O
the	O
ability	O
to	O
control	O
the	O
growth	O
of	O
the	O
bacillus	O
upon	O
neutralization	O
of	O
TNF	O
-	O
α	O
.	O

This	O
would	O
suggest	O
a	O
potential	O
role	O
for	O
TNF	O
-	O
α	O
in	O
the	O
maintenance	O
of	O
productive	O
granulomas	O
which	O
may	O
limit	O
the	O
spread	O
of	O
bacteria	O
in	O
chronically	O
infected	O
hosts	O
,	O
or	O
,	O
alternatively	O
,	O
in	O
direct	O
or	O
indirect	O
microbicidal	O
or	O
bacteriostatic	O
activities	O
at	O
the	O
sites	O
of	O
infection	O
.	O

Additional	O
studies	O
are	O
underway	O
to	O
determine	O
more	O
precisely	O
the	O
role	O
of	O
TNF	O
-	O
α	O
in	O
host	O
protection	O
to	O
B.	B
mallei	I
.	O

Multiple	O
innate	O
and	O
adaptive	O
cell	O
types	O
may	O
contribute	O
to	O
the	O
production	O
of	O
IFN	O
-	O
γ	O
in	O
response	O
to	O
infection	O
with	O
B.	B
mallei	I
following	O
vaccination	O
.	O

Our	O
results	O
with	O
individual	O
depletion	O
of	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
cells	O
suggests	O
that	O
both	O
cell	O
types	O
may	O
compensate	O
for	O
the	O
functional	O
loss	O
of	O
the	O
other	O
effector	O
cell	O
type	O
in	O
the	O
production	O
of	O
this	O
key	O
cytokine	O
.	O

The	O
effector	O
role	O
for	O
IFN	O
-	O
γ	O
in	O
mediating	O
protection	O
against	O
B.	B
mallei	I
may	O
include	O
both	O
immunoregulatory	O
and	O
non	O
-	O
regulatory	O
functions	O
.	O

Regardless	O
,	O
the	O
requirement	O
of	O
IFN	O
-	O
γ	O
,	O
as	O
demonstrated	O
by	O
administration	O
of	O
neutralizing	O
antibody	O
prior	O
to	O
infection	O
,	O
indicates	O
that	O
stimulation	O
of	O
IFN	O
-	O
γ	O
response	O
is	O
a	O
desirable	O
goal	O
for	O
a	O
B.	B
mallei	I
vaccine	O
.	O

Similarly	O
,	O
B220-positive	O
cells	O
appear	O
to	O
play	O
a	O
role	O
in	O
protection	O
following	O
vaccination	O
with	O
heat	O
-	O
killed	O
B.	B
mallei	I
.	O

Interestingly	O
,	O
this	O
protective	O
immunity	O
,	O
occurring	O
in	O
other	O
intracellular	O
pathogens	O
,	O
is	O
not	O
exclusively	O
dependent	O
on	O
B	O
cells	O
[	O
11	O
]	O
.	O

Passive	O
protection	O
has	O
been	O
demonstrated	O
against	O
acute	O
Burkholderia	O
infection	O
by	O
monoclonal	O
antibodies	O
[	O
5,12	O
]	O
.	O

Protection	O
against	O
B.	B
pseudomallei	I
infection	O
by	O
anti	O
-	O
LPS	O
,	O
capsular	O
polysaccharide	O
and	O
proteins	O
has	O
been	O
short	O
-	O
lived	O
,	O
suggesting	O
that	O
antibody	O
production	O
offers	O
limited	O
protection	O
in	O
the	O
initial	O
stages	O
of	O
infection	O
by	O
an	O
as	O
-	O
yet	O
-	O
undefined	O
mechanism	O
[	O
12	O
]	O
.	O

We	O
have	O
shown	O
that	O
following	O
depletion	O
of	O
B220	O
+	O
cells	O
,	O
survival	O
rates	O
decreased	O
as	O
much	O
as	O
100	O
%	O
relative	O
to	O
non	O
-	O
depleted	O
controls	O
and	O
individual	O
CD4	O
/	O
CD8-depleted	O
mice	B
via	O
the	O
intraperitoneal	O
route	O
.	O

Results	O
from	O
C57BL	O
/	O
6	O
mice	B
deficient	O
in	O
mature	O
B	O
-	O
cells	O
(	O
μMT	O
)	O
,	O
CD4	O
T	O
-	O
cells	O
(	O
CD4-	O
/	O
-	O
)	O
or	O
CD8	O
T	O
-	O
cells	O
(	O
CD8-	O
/	O
-	O
)	O
substantiate	O
the	O
requirement	O
for	O
B	O
-	O
cell	O
involvement	O
by	O
evidence	O
of	O
μMT	O
and	O
CD4-	O
/	O
-	O
decreased	O
survival	O
.	O

The	O
lack	O
of	O
an	O
effective	O
CTL	O
response	O
to	O
vaccination	O
did	O
not	O
appear	O
to	O
alter	O
survival	O
in	O
what	O
would	O
appear	O
to	O
be	O
a	O
CD4	O
/	O
B	O
-	O
cell	O
(	O
humoral	O
)	O
-driven	O
response	O
.	O

In	O
CD4-deficient	O
mice	B
,	O
we	O
have	O
the	O
additional	O
potential	O
variable	O
that	O
a	O
CD4-dependent	O
antibody	O
response	O
might	O
also	O
be	O
inhibited	O
during	O
the	O
vaccination	O
phase	O
relative	O
to	O
mice	B
treated	O
with	O
antibody	O
immediately	O
prior	O
to	O
and	O
during	O
the	O
early	O
phases	O
of	O
infection	O
.	O

Although	O
not	O
statistically	O
significant	O
,	O
we	O
did	O
observe	O
a	O
decrease	O
in	O
survival	O
in	O
μMT	O
(	O
mature	O
B	O
cell	O
)	O
deficient	O
mice	B
as	O
early	O
as	O
day	O
9	O
post	O
challenge	O
,	O
whereas	O
CD4-deficient	O
mice	B
produced	O
similar	O
results	O
at	O
day	O
32	O
post	O
challenge	O
,	O
indicating	O
a	O
role	O
for	O
B	O
cells	O
independent	O
of	O
CD4	O
T	O
cell	O
help	O
,	O
perhaps	O
through	O
a	O
T	O
-	O
independent	O
mechanism	O
of	O
antibody	O
production	O
.	O

Although	O
CD8-	O
/	O
-	O
C57BL	O
/	O
6	O
demonstrated	O
no	O
decreased	O
survival	O
in	O
our	O
HK	O
-	O
vaccinated	O
model	O
,	O
a	O
lack	O
of	O
potential	O
endogenous	O
protein	O
production	O
by	O
HK	O
B.	B
mallei	I
may	O
have	O
contributed	O
to	O
limited	O
MHC	O
-	O
I	O
presentation	O
.	O

Complement	O
associated	O
studies	O
revealed	O
increased	O
J774A.1	O
uptake	O
of	O
serum	O
-	O
treated	O
B.	B
mallei	I
.	O

Complement	O
-	O
mediated	O
uptake	O
studies	O
of	O
B.	B
pseudomallei	I
by	O
polymorphonuclear	O
leukocytes	O
(	O
PMNs	O
)	O
suggest	O
that	O
capsule	O
production	O
contributes	O
to	O
resistance	O
of	O
phagocytosis	O
by	O
reducing	O
C3b	O
bacterial	O
deposition	O
[	O
13	O
]	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
a	O
polysaccharide	O
capsule	O
is	O
present	O
in	O
B.	B
mallei	I
,	O
[	O
14,15	O
]	O
although	O
in	O
the	O
present	O
study	O
enhanced	O
uptake	O
with	O
serum	O
-	O
treated	O
B.	B
mallei	I
was	O
observed	O
.	O

Intracellular	O
survival	O
assays	O
of	O
complement	O
mediated	O
uptake	O
of	O
organisms	O
were	O
not	O
performed	O
in	O
the	O
present	O
study	O
,	O
thus	O
,	O
the	O
role	O
of	O
complement	O
opsonization	O
on	O
intracellular	O
survival	O
is	O
not	O
fully	O
resolved	O
.	O

Previous	O
reports	O
have	O
demonstrated	O
the	O
ability	O
of	O
B.	B
mallei	I
to	O
survive	O
within	O
macrophage	O
without	O
the	O
aid	O
of	O
serum	O
coating	O
organisms	O
[	O
16	O
]	O
.	O

Conversely	O
,	O
the	O
idea	O
of	O
antibody	O
mediated	O
opsonization	O
to	O
facilitate	O
macrophage	O
activation	O
and	O
clearance	O
of	O
intracellular	O
organisms	O
may	O
offer	O
support	O
to	O
the	O
role	O
of	O
B	O
cells	O
in	O
an	O
effective	O
immune	O
response	O
.	O

A	O
possible	O
protective	O
mechanism	O
may	O
include	O
HK	O
vaccination	O
induced	O
production	O
of	O
opsonizing	O
antibodies	O
which	O
may	O
aid	O
in	O
complement	O
mediated	O
uptake	O
,	O
thereby	O
limiting	O
the	O
initial	O
bacterial	O
threshold	O
below	O
a	O
lethal	O
level	O
.	O

Immunoglobulin	O
responses	O
to	O
HK	O
vaccination	O
resulted	O
in	O
modest	O
levels	O
of	O
IgG1	O
following	O
2	O
weeks	O
post	O
vaccination	O
,	O
while	O
post	O
-	O
exposure	O
levels	O
were	O
indicative	O
of	O
efficient	O
class	O
switching	O
to	O
a	O
favorable	O
IgG2a	O
isotype	O
.	O

Importantly	O
,	O
cobra	O
venom	O
factor	O
treatment	O
of	O
animals	O
at	O
time	O
of	O
vaccination	O
did	O
not	O
alter	O
their	O
ability	O
to	O
produce	O
immunoglobulin	O
.	O

In	O
fact	O
,	O
cobra	O
venom	O
factor	O
treated	O
animals	O
resulted	O
in	O
higher	O
IgG2a	O
levels	O
when	O
compared	O
to	O
non	O
-	O
treated	O
.	O

Complement	O
activation	O
can	O
modulate	O
both	O
the	O
primary	O
and	O
secondary	O
immune	O
responses	O
and	O
has	O
been	O
shown	O
to	O
enhance	O
secondary	O
immune	O
responses	O
to	O
vaccination	O
[	O
17	O
]	O
.	O

The	O
current	O
results	O
suggest	O
that	O
cobra	O
venom	O
factor	O
treatment	O
may	O
affect	O
the	O
modulation	O
of	O
the	O
immune	O
response	O
to	O
B.	B
mallei	I
infection	O
through	O
B	O
cell	O
activation	O
and/or	O
memory	O
B	O
cell	O
generation	O
.	O

Conclusion	O
In	O
summary	O
,	O
our	O
results	O
provide	O
a	O
basis	O
for	O
future	O
studies	O
of	O
protection	O
via	O
vaccination	O
using	O
either	O
subunit	O
or	O
whole	O
-	O
organism	O
vaccine	O
preparations	O
from	O
lethal	O
infection	O
in	O
the	O
experimental	O
BALB	O
/	O
c	O
mouse	B
model	O
.	O

Understanding	O
and	O
defining	O
the	O
role	O
of	O
B	O
cells	O
in	O
adaptive	O
B.	B
mallei	I
immunity	O
will	O
likely	O
be	O
fundamental	O
to	O
the	O
design	O
of	O
an	O
efficacious	O
vaccine	O
and	O
important	O
goals	O
of	O
future	O
research	O
.	O

Methods	O
Bacterial	O
strain	O
and	O
mice	B
B.	B
mallei	I
strain	O
ATCC	O
23344	O
(	O
China	O
7	O
)	O
was	O
cultured	O
on	O
Luria	O
-	O
Bertani	O
agar	O
supplemented	O
with	O
4	O
%	O
glycerol	O
(	O
LB+4%G	O
)	O
agar	O
plates	O
for	O
48	O
h	O
at	O
37	O
°	O
C	O
.	O

Isolated	O
colonies	O
were	O
sub	O
-	O
cultured	O
to	O
LB+4%G	O
broth	O
,	O
and	O
cultures	O
were	O
incubated	O
at	O
37	O
°	O
C	O
until	O
optical	O
density	O
readings	O
at	O
600	O
nm	O
(	O
OD600	O
)	O
reached	O
an	O
exponential	O
phase	O
of	O
growth	O
.	O

Bacteria	O
were	O
pelleted	O
by	O
centrifugation	O
,	O
washed	O
and	O
re	O
-	O
suspended	O
in	O
sterile	O
1	O
×	O
phosphate	O
-	O
buffered	O
saline	O
(	O
PBS	O
,	O
pH	O
7.4	O
)	O
to	O
obtain	O
the	O
desired	O
CFU	O
/	O
ml	O
.	O

To	O
obtain	O
HK	O
inoculums	O
,	O
bacterial	O
suspensions	O
were	O
incubated	O
at	O
85	O
°	O
C	O
for	O
3	O
h	O
and	O
stored	O
at	O
4	O
°	O
C	O
until	O
use	O
.	O

The	O
absence	O
of	O
live	O
B.	B
mallei	I
organisms	O
in	O
the	O
HK	O
preparations	O
was	O
confirmed	O
after	O
plating	O
10	O
%	O
of	O
the	O
total	O
inoculums	O
(	O
v	O
/	O
v	O
)	O
and	O
incubating	O
these	O
at	O
37	O
°	O
C	O
for	O
48	O
h.	O
All	O
procedures	O
were	O
performed	O
under	O
a	O
class	O
II	O
biosafety	O
cabinet	O
in	O
a	O
biosafety	O
level	O
3	O
laboratory	O
.	O

Female	O
,	O
6-	O
to	O
8-week	O
-	O
old	O
,	O
BALB	O
/	O
c	O
mice	B
(	O
n	O
=	O
5–7	O
)	O
were	O
obtained	O
from	O
Harlan	O
Sprague	O
Dawley	O
,	O
Inc.	O
(	O
Indianapolis	O
,	O
Indiana	O
)	O
.	O

Female	O
,	O
6-	O
to	O
8-week	O
-	O
old	O
,	O
C57BL	O
/	O
6	O
mice	B
deficient	O
in	O
mature	O
B	O
-	O
cells	O
(	O
μMT	O
)	O
,	O
CD4	O
T	O
-	O
cells	O
(	O
CD4-	O
/	O
-	O
)	O
and	O
CD8	O
T	O
-	O
cells	O
(	O
CD8-	O
/	O
-	O
)	O
and	O
wild	O
-	O
type	O
mice	B
were	O
obtained	O
from	O
The	O
Jackson	O
Laboratory	O
(	O
Bar	O
Harbor	O
,	O
Maine	O
)	O
.	O

Vaccination	O
and	O
challenge	O
BALB	O
/	O
c	O
and	O
C57BL	O
/	O
6	O
mice	B
were	O
grouped	O
and	O
vaccinated	O
with	O
0.5	O
μg	O
of	O
HK	O
B.	B
mallei	I
(	O
without	O
adjuvant	O
)	O
by	O
i.p	O
.	O

injection	O
using	O
a	O
25-gauge	O
syringe	O
.	O

Two	O
weeks	O
post	O
HK	O
vaccination	O
mice	B
were	O
injected	O
i.p	O
.	O
with	O
2	O
×	O
107	O
CFU	O
/	O
100	O
μl	O
of	O
live	O
B.	B
mallei	I
(	O
~20	O
LD50	O
)	O
[	O
18	O
]	O
.	O

Complement	O
depleted	O
animals	O
were	O
challenged	O
with	O
2.5	O
×	O
104	O
CFU	O
/	O
50	O
μl	O
(	O
~0.25	O
LD50	O
)	O
by	O
intranasal	O
(	O
i.n	O
.	O
)	O
route	O
.	O

Aliquots	O
from	O
the	O
inoculums	O
were	O
plated	O
to	O
confirm	O
the	O
infecting	O
dose	O
.	O

All	O
procedures	O
and	O
animal	O
protocols	O
used	O
in	O
this	O
study	O
were	O
approved	O
by	O
the	O
Biosafety	O
and	O
IACUC	O
committees	O
at	O
UTMB	O
and	O
conducted	O
in	O
either	O
BSL-3	O
or	O
ABSL-3	O
laboratories	O
.	O

Cell	O
and	O
cytokine	O
depletions	O
Acute	O
in	O
vivo	O
cell	O
/	O
cytokine	O
depletion	O
was	O
performed	O
with	O
monoclonal	O
rat	B
anti	O
-	O
mouse	B
CD4	O
(	O
GK1.5	O
)	O
,	O
CD8α	O
(	O
53	O
-	O
6.7	O
)	O
or	O
B220	O
(	O
RA3	O
-	O
6B2	O
)	O
obtained	O
from	O
R&D	O
Systems	O
,	O
Inc.	O
(	O
Minneapolis	O
,	O
MN	O
)	O
by	O
methods	O
similar	O
to	O
those	O
we	O
have	O
previously	O
described	O
[	O
19	O
]	O
.	O

Functional	O
grade	O
purified	O
rat	B
anti	O
-	O
mouse	B
interferon	O
-	O
gamma	O
(	O
IFN	O
-	O
γ	O
,	O
AN-18	O
)	O
was	O
obtained	O
from	O
eBioscience	O
(	O
San	O
Diego	O
,	O
CA	O
)	O
and	O
purified	O
anti	O
-	O
mouse	B
tumor	O
necrosis	O
factor	O
(	O
TNF	O
-	O
α	O
,	O
MP6-XT3	O
)	O
from	O
BD	O
Pharmingen	O
(	O
San	O
Diego	O
,	O
CA	O
)	O
.	O

IFN	O
-	O
γ	O
and	O
TNF	O
-	O
α	O
antibodies	O
were	O
injected	O
i.p	O
.	O

6	O
h	O
prior	O
to	O
challenge	O
,	O
200	O
μg	O
per	O
mouse	B
in	O
200	O
μl	O
PBS	O
or	O
at	O
later	O
time	O
points	O
as	O
indicated	O
.	O

Rat	B
IgG	O
isotype	O
control	O
was	O
obtained	O
from	O
Southern	O
Biotech	O
(	O
Birmingham	O
,	O
AL	O
)	O
and	O
administered	O
i.p	O
.	O

on	O
day	O
of	O
challenge	O
,	O
200	O
μg	O
/	O
mouse	B
.	O

Rat	B
anti	O
-	O
mouse	B
CD4	O
,	O
CD8α	O
and	O
B220	O
were	O
injected	O
i.p	O
.	O

twice	O
,	O
1	O
day	O
prior	O
to	O
challenge	O
and	O
on	O
day	O
of	O
challenge	O
,	O
with	O
an	O
equivalent	O
dosage	O
sufficient	O
to	O
deplete	O
T	O
or	O
B	O
cells	O
from	O
6	O
×	O
108	O
bone	O
marrow	O
cells	O
per	O
injection	O
.	O

The	O
efficiency	O
of	O
depletion	O
at	O
time	O
of	O
infection	O
for	O
CD4	O
+	O
,	O
CD8	O
+	O
,	O
and	O
B220	O
+	O
cells	O
was	O
confirmed	O
by	O
flow	O
cytometry	O
analysis	O
immediately	O
prior	O
to	O
infection	O
.	O

Complement	O
depletion	O
with	O
cobra	O
venom	O
factor	O
Mice	B
,	O
six	O
to	O
seven	O
per	O
group	O
,	O
were	O
vaccinated	O
i.p	O
.	O
with	O
1	O
×	O
105	O
CFU	O
of	O
nonviable	O
B.	B
mallei	I
cell	O
preparation	O
in	O
a	O
total	O
volume	O
of	O
0.1	O
ml	O
.	O

Two	O
weeks	O
later	O
,	O
24	O
h	O
and	O
1	O
h	O
before	O
challenge	O
,	O
complement	O
depleted	O
mice	B
were	O
treated	O
i.p	O
.	O
with	O
12.5	O
units	O
total	O
cobra	O
venom	O
factor	O
(	O
Quidel	O
Corporation	O
Speciality	O
Products	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
in	O
0.1	O
ml	O
of	O
PBS	O
.	O

Complement	O
depletion	O
was	O
confirmed	O
prior	O
to	O
challenge	O
by	O
micro	O
-	O
titer	O
hemolytic	O
complement	O
activity	O
(	O
CH50	O
)	O
assay	O
as	O
previously	O
described	O
[	O
20	O
]	O
.	O

B.	B
mallei	I
J774A.1	O
uptake	O
assays	O
J774A.1	O
cells	O
were	O
seeded	O
(	O
5	O
×	O
105	O
)	O
onto	O
Corning	O
costar	O
24	O
well	O
plates	O
(	O
Corning	O
,	O
NY	O
)	O
with	O
DMEM	O
and	O
incubated	O
overnight	O
at	O
37	O
°	O
C	O
with	O
5	O
%	O
CO2	O
.	O

Bacterial	O
suspensions	O
were	O
incubated	O
at	O
37	O
°	O
C	O
for	O
45	O
minutes	O
supplemented	O
with	O
2	O
%	O
mouse	B
serum	O
from	O
Sigma	O
-	O
Aldrich	O
(	O
St.	O
Louis	O
,	O
MO	O
.	O
)	O
,	O
heat	O
inactivated	O
mouse	B
serum	O
(	O
56	O
°	O
C	O
30	O
minutes	O
)	O
,	O
or	O
bacteria	O
alone	O
and	O
then	O
added	O
at	O
an	O
MOI	O
of	O
10:1	O
to	O
J774A.1	O
cells	O
in	O
triplicate	O
.	O

Inoculated	O
wells	O
were	O
centrifuged	O
at	O
800	O
g	O
for	O
2	O
minutes	O
and	O
incubated	O
for	O
2	O
hours	O
at	O
37	O
°	O
C	O
with	O
5	O
%	O
CO2	O
followed	O
by	O
a	O
PBS	O
wash	O
(	O
×2	O
)	O
and	O
2	O
hour	O
incubation	O
with	O
250	O
μg	O
/	O
ml	O
kanamycin	O
.	O

Wells	O
were	O
washed	O
twice	O
with	O
PBS	O
and	O
lysed	O
with	O
0.1	O
%	O
Triton	O
X-100	O
,	O
followed	O
by	O
serial	O
10-fold	O
dilutions	O
plated	O
on	O
LBG	O
plates	O
and	O
incubated	O
at	O
37	O
°	O
C	O
for	O
2	O
days	O
.	O

Colony	O
forming	O
units	O
were	O
enumerated	O
and	O
uptake	O
expressed	O
as	O
a	O
percentage	O
of	O
initial	O
inoculating	O
dose	O
±	O
SEM	O
.	O

Antibodies	O
and	O
flow	O
cytometry	O
Flow	O
cytometric	O
analysis	O
was	O
performed	O
on	O
0.1-ml	O
blood	O
samples	O
transferred	O
to	O
micro	O
centrifuge	O
tubes	O
containing	O
90	O
μl	O
of	O
acid	O
citrate	O
dextrose	O
(	O
ACD	O
)	O
solution	O
.	O

Red	O
blood	O
cells	O
were	O
lysed	O
using	O
ACK	O
-	O
lysing	O
buffer	O
(	O
Biosource	O
International	O
,	O
Inc.	O
,	O
Camarillo	O
,	O
CA	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
instruction	O
.	O

Antibodies	O
used	O
for	O
analysis	O
of	O
surface	O
markers	O
included	O
:	O
FITC	O
-	O
conjugated	O
rat	B
anti	O
-	O
mouse	B
CD45R	O
/	O
B220	O
(	O
RA3	O
-	O
6B2	O
,	O
BD	O
Pharmingen	O
San	O
Diego	O
,	O
CA	O
)	O
for	O
B	O
cells	O
;	O
FITC	O
-	O
conjugated	O
rat	B
anti	O
-	O
mouse	B
CD8α	O
(	O
53	O
-	O
6.7	O
)	O
and	O
CD4	O
(	O
GK1.5	O
,	O
BD	O
Pharmingen	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
for	O
CD8	O
+	O
or	O
CD4	O
+	O
cells	O
,	O
respectively	O
.	O

Samples	O
evaluated	O
for	O
CD4	O
+	O
and	O
CD8α+	O
cells	O
were	O
also	O
incubated	O
with	O
biotin	O
-	O
conjugated	O
hamster	O
anti	O
-	O
mouse	B
CD3e	O
(	O
145	O
-	O
2C11	O
)	O
monoclonal	O
antibody	O
(	O
BD	O
Pharmingen	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
and	O
subsequently	O
with	O
streptavidin	O
APC	O
Cy7	O
.	O

Isotype	O
-	O
matched	O
,	O
non	O
-	O
specific	O
controls	O
were	O
assayed	O
in	O
parallel	O
(	O
BD	O
Pharmingen	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
.	O

Surface	O
staining	O
was	O
performed	O
according	O
to	O
previously	O
published	O
protocols	O
[	O
21	O
]	O
.	O

Following	O
cell	O
staining	O
,	O
the	O
samples	O
were	O
fixed	O
with	O
2	O
%	O
buffered	O
paraformaldehyde	O
overnight	O
prior	O
to	O
analysis	O
by	O
flow	O
cytometry	O
.	O

Samples	O
were	O
analyzed	O
using	O
a	O
FACSCalibur	O
flow	O
cytometer	O
with	O
BD	O
CellQuest	O
Pro	O
software	O
.	O

Antibody	O
assays	O
Immunoglobulin	O
subclass	O
IgG1	O
and	O
IgG2a	O
titers	O
in	O
mice	B
were	O
determined	O
by	O
a	O
whole	O
bacterial	O
cell	O
ELISA	O
performed	O
in	O
96-well	O
,	O
Immulon	O
2	O
HB	O
,	O
round	O
-	O
bottom	O
plates	O
(	O
Dynex	O
Technologies	O
)	O
.	O

B.	B
mallei	I
antigen	O
was	O
diluted	O
in	O
0.1	O
M	O
carbonate	O
buffer	O
(	O
pH	O
9.5	O
)	O
and	O
50	O
μl	O
of	O
diluted	O
cells	O
placed	O
into	O
wells	O
.	O

Plates	O
were	O
stored	O
overnight	O
at	O
4	O
°	O
C	O
.	O

The	O
plates	O
were	O
washed	O
with	O
washing	O
solution	O
(	O
1	O
×	O
PBS	O
,	O
0.05	O
%	O
Tween	O
20	O
)	O
,	O
and	O
incubated	O
with	O
100	O
μl	O
of	O
blocking	O
solution	O
(	O
1	O
×	O
PBS	O
,	O
1	O
%	O
bovine	B
serum	O
albumin	O
,	O
0.05	O
%	O
Tween	O
20	O
)	O
for	O
1	O
h	O
at	O
37	O
°	O
C	O
.	O

Dilutions	O
of	O
mouse	B
sera	O
were	O
made	O
with	O
blocking	O
solution	O
in	O
duplicate	O
and	O
plates	O
were	O
incubated	O
for	O
1	O
h	O
at	O
37	O
°	O
C	O
.	O

Following	O
incubation	O
,	O
plates	O
were	O
washed	O
and	O
50	O
μl	O
of	O
anti	O
-	O
Ig	O
-	O
horseradish	B
peroxidase	O
subclass	O
conjugate	O
,	O
diluted	O
accordingly	O
to	O
manufacturer	O
's	O
instructions	O
(	O
Southern	O
Biotechnology	O
Associates	O
,	O
Inc.	O
Birmingham	O
,	O
Ala.	O
)	O
,	O
was	O
added	O
to	O
each	O
well	O
and	O
incubated	O
for	O
1	O
h	O
at	O
37	O
°	O
C	O
.	O

After	O
washing	O
,	O
50	O
μl	O
of	O
2,2'-azino	O
-	O
di-	O
(	O
3-ethylbenzthizoline	O
)	O
-6-sulfonate	O
(	O
ABTS	O
)	O
peroxidase	O
substrate	O
(	O
KPL	O
,	O
Inc.	O
,	O
Gaithersburg	O
,	O
Maryland	O
)	O
was	O
added	O
to	O
each	O
well	O
and	O
plates	O
incubated	O
for	O
25	O
min	O
at	O
room	O
temperature	O
.	O

The	O
amount	O
of	O
bound	O
antibody	O
was	O
determined	O
colorimetrically	O
by	O
absorbance	O
at	O
405	O
nm	O
.	O

Statistical	O
analysis	O
Survival	O
curves	O
were	O
calculated	O
by	O
Kaplan	O
Meier	O
survival	O
analysis	O
with	O
log	O
-	O
rank	O
tests	O
between	O
groups	O
using	O
GraphPad	O
Prism	O
(	O
V.4.03	O
for	O
windows	O
)	O
.	O

Statistical	O
analysis	O
was	O
generally	O
performed	O
with	O
the	O
paired	O
Student	O
's	O
t	O
-	O
test	O
.	O

P	O
value	O
≤	O
0.05	O
was	O
considered	O
significant	O
.	O

Abbreviations	O
HK	O
:	O
Heat	O
-	O
killed	O
;	O
i.p	O
.	O

:	O
intraperitoneal	O
;	O
i.n	O
.	O
:	O
intranasal	O
.	O

Authors	O
'	O
contributions	O
GCW	O
designed	O
and	O
conducted	O
experiments	O
and	O
drafted	O
the	O
manuscript	O
.	O

BMJ	O
carried	O
out	O
the	O
immunoassays	O
and	O
animal	O
work	O
.	O

SP	O
provided	O
analysis	O
of	O
data	O
and	O
contributed	O
to	O
design	O
and	O
animal	O
work	O
.	O

RAL	O
participated	O
in	O
the	O
generation	O
and	O
analysis	O
of	O
chronic	O
TNF	O
-	O
α	O
data	O
.	O

DME	O
conceived	O
the	O
study	O
,	O
and	O
participated	O
in	O
its	O
design	O
and	O
coordination	O
and	O
helped	O
to	O
draft	O
the	O
manuscript	O
.	O

AGT	O
participated	O
in	O
the	O
bacterial	O
work	O
and	O
drafting	O
of	O
the	O
manuscript	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Syndrome	O
of	O
arachnomelia	O
in	O
Simmental	O
cattle	B
Abstract	O
Background	O
The	O
syndrome	O
of	O
arachnomelia	O
is	O
an	O
inherited	O
malformation	O
mainly	O
of	O
limbs	O
,	O
back	O
and	O
head	O
in	O
cattle	B
.	O

At	O
present	O
the	O
arachnomelia	O
syndrome	O
has	O
been	O
well	O
known	O
mainly	O
in	O
Brown	O
Swiss	O
cattle	B
.	O

Nevertheless	O
,	O
the	O
arachnomelia	O
syndrome	O
had	O
been	O
observed	O
in	O
the	O
Hessian	O
Simmental	O
population	O
during	O
the	O
decade	O
1964–1974	O
.	O

Recently	O
,	O
stillborn	O
Simmental	O
calves	O
were	O
observed	O
having	O
a	O
morphology	O
similar	O
to	O
the	O
arachnomelia	O
syndrome	O
.	O

The	O
goal	O
of	O
this	O
work	O
was	O
the	O
characterization	O
of	O
the	O
morphology	O
and	O
genealogy	O
of	O
the	O
syndrome	O
in	O
Simmental	O
to	O
establish	O
the	O
basis	O
for	O
an	O
effective	O
management	O
of	O
the	O
disease	O
.	O

Results	O
The	O
first	O
pathologically	O
confirmed	O
arachnomelia	O
syndrome	O
-	O
cases	O
in	O
the	O
current	O
Simmental	O
population	O
appeared	O
in	O
the	O
year	O
2005	O
.	O

By	O
2007	O
,	O
an	O
additional	O
140	O
calves	O
with	O
the	O
arachnomelia	O
syndrome	O
were	O
identified	O
.	O

The	O
major	O
pathological	O
findings	O
were	O
malformed	O
bones	O
affecting	O
the	O
head	O
,	O
long	O
bones	O
of	O
the	O
legs	O
and	O
the	O
vertebral	O
column	O
.	O

It	O
could	O
be	O
shown	O
that	O
,	O
with	O
the	O
exception	O
of	O
two	O
cases	O
that	O
were	O
considered	O
as	O
phenocopies	O
,	O
all	O
of	O
the	O
paternal	O
and	O
about	O
two	O
-	O
third	O
of	O
the	O
maternal	O
pedigrees	O
of	O
the	O
affected	O
calves	O
could	O
be	O
traced	O
back	O
to	O
one	O
common	O
founder	O
.	O

Together	O
with	O
the	O
data	O
from	O
experimental	O
matings	O
,	O
the	O
pedigree	O
data	O
support	O
an	O
autosomal	O
recessive	O
mutation	O
being	O
the	O
etiology	O
of	O
the	O
arachnomelia	O
syndrome	O
.	O

The	O
frequency	O
of	O
the	O
mutation	O
in	O
the	O
current	O
population	O
was	O
estimated	O
to	O
be	O
3.32	O
%	O
.	O

Conclusion	O
We	O
describe	O
the	O
repeated	O
occurrence	O
of	O
the	O
arachnomelia	O
syndrome	O
in	O
Simmental	O
calves	O
.	O

It	O
resembles	O
completely	O
the	O
same	O
defect	O
occurring	O
in	O
the	O
Brown	O
Swiss	O
breed	O
.	O

The	O
mutation	O
became	O
relatively	O
widespread	O
amongst	O
the	O
current	O
population	O
.	O

Therefore	O
,	O
a	O
control	O
system	O
has	O
to	O
be	O
established	O
and	O
it	O
is	O
highly	O
desirable	O
to	O
map	O
the	O
disease	O
and	O
develop	O
a	O
genetic	O
test	O
system	O
.	O

Background	O
In	O
the	O
year	O
2006	O
a	O
syndrome	O
was	O
described	O
in	O
the	O
German	O
and	O
Austrian	O
Simmental	O
(	O
Fleckvieh	O
,	O
as	O
it	O
is	O
locally	O
called	O
,	O
is	O
the	O
main	O
dual	O
-	O
purpose	O
breed	O
in	O
Germany	O
,	O
in	O
short	O
called	O
Simmental	O
in	O
the	O
further	O
text	O
)	O
population	O
,	O
that	O
was	O
pathologically	O
similar	O
to	O
the	O
arachnomelia	O
syndrome	O
in	O
Brown	O
Swiss	O
cattle	B
[	O
1	O
]	O
.	O

The	O
congenital	O
arachnomelia	O
syndrome	O
(	O
AS	O
,	O
OMIA	O
Phene	O
ID	O
139	O
,	O
Group	O
000059	O
)	O
is	O
mainly	O
a	O
malformation	O
of	O
the	O
skeletal	O
system	O
in	O
cattle	B
that	O
was	O
initially	O
described	O
by	O
Rieck	O
and	O
Schade	O
[	O
2	O
]	O
in	O
Holstein	O
Friesian	O
,	O
Red	O
Holstein	O
and	O
Simmental	O
.	O

The	O
main	O
pathological	O
changes	O
are	O
skeletal	O
malformations	O
of	O
the	O
legs	O
,	O
the	O
spinal	O
column	O
and	O
the	O
skull	O
.	O

The	O
legs	O
are	O
thinner	O
and	O
appear	O
longer	O
than	O
normal	O
(	O
dolichostenomelia	O
,	O
arachnomelia	O
)	O
since	O
the	O
diameter	O
of	O
the	O
diaphyses	O
is	O
reduced	O
.	O

These	O
long	O
bones	O
are	O
more	O
fragile	O
and	O
,	O
in	O
combination	O
with	O
stiffened	O
joints	O
,	O
they	O
tend	O
to	O
fracture	O
during	O
calving	O
.	O

The	O
fetlock	O
joints	O
are	O
deformed	O
,	O
often	O
stiffened	O
and	O
show	O
hyperextension	O
.	O

The	O
malformation	O
of	O
the	O
spinal	O
column	O
leads	O
to	O
kyphosis	O
and	O
scoliosis	O
.	O

The	O
skull	O
malformations	O
are	O
characterized	O
by	O
a	O
shortened	O
lower	O
jaw	O
(	O
brachygnathia	O
inferior	O
)	O
,	O
convex	O
rounding	O
of	O
the	O
frontal	O
bone	O
leading	O
to	O
a	O
marked	O
stop	O
(	O
""""	O
pointer	O
head	O
""""	O
)	O
and	O
rotation	O
of	O
the	O
anterior	O
cranium	O
.	O

In	O
some	O
cases	O
,	O
additional	O
malformations	O
like	O
hydrocephalus	O
externus	O
develop	O
[	O
2	O
-	O
5	O
]	O
.	O

Since	O
the	O
report	O
of	O
Rieck	O
and	O
Schade	O
[	O
2	O
]	O
no	O
further	O
cases	O
were	O
reported	O
in	O
Simmental	O
cattle	B
,	O
but	O
in	O
the	O
1980s	O
the	O
syndrome	O
was	O
dispersed	O
in	O
another	O
breed	O
,	O
the	O
European	O
Brown	O
Swiss	O
cattle	B
,	O
by	O
the	O
use	O
of	O
American	O
Brown	O
Swiss	O
sires	O
[	O
4,6	O
]	O
.	O

In	O
Brown	O
Swiss	O
an	O
autosomal	O
recessive	O
mode	O
of	O
inheritance	O
was	O
supposed	O
and	O
a	O
control	O
program	O
based	O
on	O
the	O
identification	O
of	O
carriers	O
by	O
pedigree	O
analyses	O
was	O
established	O
[	O
5	O
]	O
.	O

Recently	O
,	O
four	O
cases	O
of	O
arachnomelia	O
syndrome	O
were	O
reported	O
in	O
Italy	O
[	O
3	O
]	O
.	O

In	O
this	O
study	O
,	O
we	O
present	O
the	O
data	O
of	O
152	O
pathologically	O
confirmed	O
cases	O
of	O
arachnomelia	O
syndrome	O
in	O
Simmental	O
that	O
were	O
collected	O
from	O
October	O
2005	O
to	O
March	O
2007	O
.	O

We	O
describe	O
the	O
pathological	O
findings	O
,	O
the	O
familial	O
occurrence	O
and	O
an	O
estimate	O
of	O
the	O
frequency	O
of	O
the	O
diseases	O
allele	O
in	O
Simmental	O
cattle	B
.	O

Additional	O
support	O
for	O
the	O
mode	O
of	O
inheritance	O
and	O
the	O
genetic	O
basis	O
of	O
the	O
arachnomelia	O
syndrome	O
is	O
given	O
by	O
the	O
result	O
of	O
experimental	O
matings	O
of	O
obligate	O
carriers	O
.	O

Results	O
and	O
discussion	O
AS	O
has	O
not	O
been	O
reported	O
again	O
in	O
Simmental	O
since	O
its	O
first	O
description	O
in	O
the	O
1970s	O
,	O
more	O
than	O
thirteen	O
years	O
ago	O
.	O

In	O
autumn	O
2004	O
a	O
number	O
of	O
stillborn	O
calves	O
with	O
similar	O
malformations	O
of	O
the	O
legs	O
and	O
head	O
were	O
recorded	O
within	O
the	O
monitoring	O
system	O
of	O
anomalies	O
in	O
Simmental	O
.	O

Some	O
of	O
these	O
calves	O
were	O
sent	O
to	O
the	O
veterinary	O
service	O
laboratory	O
for	O
examination	O
,	O
and	O
in	O
December	O
2005	O
the	O
first	O
15	O
cases	O
of	O
AS	O
were	O
pathologically	O
confirmed	O
.	O

Subsequently	O
,	O
farmers	O
and	O
veterinarians	O
had	O
been	O
encouraged	O
to	O
report	O
cases	O
by	O
an	O
information	O
leaflet	O
and	O
various	O
articles	O
in	O
local	O
trade	O
journals	O
.	O

An	O
increasing	O
number	O
of	O
suspected	O
cases	O
was	O
reported	O
and	O
an	O
additional	O
136	O
affected	O
calves	O
were	O
identified	O
by	O
pathological	O
examination	O
by	O
June	O
2007	O
.	O

Familial	O
occurrence	O
and	O
case	O
presentation	O
of	O
the	O
syndrome	O
of	O
arachnomelia	O
The	O
geographical	O
origins	O
of	O
the	O
cases	O
were	O
the	O
southern	O
part	O
of	O
Germany	O
and	O
Austria	O
,	O
reflecting	O
the	O
regional	O
distribution	O
of	O
the	O
Simmental	O
breed	O
.	O

Both	O
sexes	O
were	O
equally	O
represented	O
in	O
the	O
152	O
(	O
80	O
male	O
,	O
72	O
female	O
,	O
χ2	O
=	O
0.21	O
,	O
p	O
=	O
0.64	O
)	O
affected	O
calves	O
.	O

The	O
largest	O
number	O
of	O
cases	O
was	O
registered	O
in	O
2006	O
(	O
Figure	O
1	O
)	O
.	O

In	O
retrospect	O
,	O
it	O
could	O
be	O
shown	O
that	O
the	O
main	O
reason	O
for	O
the	O
rapid	O
increase	O
of	O
cases	O
in	O
the	O
years	O
2005	O
and	O
2006	O
was	O
the	O
high	O
popularity	O
of	O
certain	O
sires	O
carrying	O
the	O
AS	O
mutation	O
(	O
ROMEL	O
,	O
ISO	O
-	O
Nr	O
.	O
276000911043667	O
,	O
born	O
in	O
1995	O
;	O
EGEL	O
,	O
276000915512806	O
,	O
1985	O
;	O
REXON	O
,	O
276000913008210	O
,	O
1989	O
)	O
.	O

The	O
latter	O
two	O
sires	O
represent	O
the	O
key	O
-	O
nodes	O
of	O
the	O
pedigree	O
pathways	O
of	O
the	O
mutation	O
from	O
the	O
founder	O
into	O
the	O
current	O
population	O
(	O
Figure	O
2	O
)	O
.	O

ROMEL	O
,	O
for	O
example	O
,	O
sired	O
more	O
than	O
40,000	O
cows	B
4	O
to	O
6	O
years	O
ago	O
.	O

Furthermore	O
,	O
115	O
sons	O
of	O
ROMEL	O
born	O
from	O
2001	O
to	O
2005	O
are	O
registered	O
and	O
listed	O
in	O
the	O
breeding	O
database	O
[	O
7	O
]	O
.	O

These	O
progeny	O
were	O
now	O
mated	O
to	O
ROMEL	O
and	O
sons	O
or	O
grandsons	O
of	O
EGEL	O
and	O
REXON	O
resulting	O
in	O
a	O
high	O
probability	O
for	O
the	O
occurrence	O
of	O
affected	O
calves	O
.	O

Increasing	O
awareness	O
of	O
the	O
disease	O
and	O
abandoning	O
of	O
selling	O
the	O
semen	O
from	O
carriers	O
led	O
to	O
a	O
sharp	O
drop	O
of	O
cases	O
in	O
2007	O
.	O

The	O
disease	O
was	O
successfully	O
managed	O
by	O
efficient	O
collaboration	O
of	O
the	O
Institute	O
for	O
Animal	O
Breeding	O
of	O
the	O
Bavarian	O
State	O
Research	O
Centre	O
for	O
Agriculture	O
(	O
LfL	O
)	O
,	O
the	O
Landeskuratorium	O
der	O
Erzeugerringe	O
für	O
tierische	O
Veredelung	O
in	O
Bayern	O
e.	O

V	O
(	O
LKV	O
)	O
,	O
the	O
Bavarian	O
Animal	O
Health	O
Service	O
(	O
TGD	O
)	O
and	O
breeding	O
organizations	O
.	O

Pathological	O
findings	O
Calves	O
under	O
suspicion	O
of	O
the	O
arachnomelia	O
syndrome	O
were	O
sent	O
to	O
the	O
pathology	O
department	O
of	O
the	O
TGD	O
for	O
macroscopic	O
examination	O
.	O

The	O
observed	O
major	O
pathological	O
findings	O
were	O
(	O
1	O
)	O
facial	O
deformation	O
,	O
including	O
brachygnathia	O
inferior	O
and	O
concave	O
rounding	O
of	O
the	O
maxilla	O
forming	O
a	O
dent	O
(	O
'	O
pointer	O
-	O
head	O
'	O
)	O
;	O
(	O
2	O
)	O
abnormally	O
thin	O
diaphyses	O
of	O
the	O
long	O
bones	O
(	O
the	O
outer	O
diameter	O
of	O
the	O
diaphyses	O
is	O
diminished	O
,	O
whereas	O
the	O
width	O
of	O
the	O
substantia	O
compacta	O
is	O
normal	O
)	O
leading	O
to	O
frequent	O
fractures	O
of	O
the	O
metacarpus	O
and	O
metatarsus	O
in	O
the	O
course	O
of	O
forced	O
birth	O
assistance	O
(	O
'	O
spider	O
-	O
legs	O
'	O
,	O
dolichostenomelia	O
)	O
.	O

The	O
deformations	O
of	O
other	O
bones	O
of	O
the	O
legs	O
were	O
less	O
apparent	O
and	O
the	O
scapula	O
was	O
usually	O
unaffected	O
;	O
(	O
3	O
)	O
angular	O
deformations	O
of	O
the	O
distal	O
parts	O
of	O
the	O
legs	O
characterized	O
by	O
bilateral	O
stiff	O
and	O
hyperextended	O
fetlocks	O
with	O
the	O
extremity	O
of	O
the	O
toe	O
forward	O
and	O
parallel	O
to	O
the	O
trunk	O
of	O
the	O
body	O
;	O
and	O
(	O
4	O
)	O
defects	O
of	O
the	O
vertebral	O
column	O
(	O
kyphosis	O
and	O
scoliosis	O
)	O
,	O
but	O
not	O
of	O
the	O
ribs	O
(	O
Figure	O
3A	O
–	O
C	O
)	O
.	O

Additionally	O
,	O
inconsistent	O
pathological	O
findings	O
included	O
cerebral	O
herniation	O
combined	O
with	O
a	O
malformed	O
foramen	O
magnum	O
,	O
microphthalmia	O
,	O
and	O
external	O
and	O
internal	O
hydrocephalus	O
.	O

The	O
latter	O
seem	O
to	O
develop	O
secondarily	O
,	O
due	O
to	O
the	O
enlarged	O
foramen	O
magnum	O
.	O

Histological	O
examination	O
of	O
selected	O
cases	O
revealed	O
the	O
presence	O
of	O
hemorrhages	O
at	O
the	O
osteochondral	O
junction	O
of	O
the	O
epiphysis	O
and	O
an	O
abrupt	O
transmission	O
from	O
chondral	O
to	O
osteogenic	O
tissue	O
.	O

Cases	O
never	O
showed	O
isolated	O
malformations	O
,	O
e.g.	O
of	O
the	O
head	O
or	O
legs	O
,	O
but	O
usually	O
a	O
combination	O
of	O
all	O
pathological	O
findings	O
that	O
are	O
characteristic	O
for	O
the	O
syndrome	O
.	O

Nevertheless	O
,	O
the	O
degree	O
of	O
the	O
lesions	O
ranged	O
from	O
obvious	O
spider	O
-	O
leg	O
cases	O
to	O
moderate	O
or	O
mild	O
changes	O
,	O
making	O
a	O
definite	O
diagnosis	O
difficult	O
.	O

The	O
latter	O
cases	O
(	O
3	O
)	O
were	O
excluded	O
from	O
the	O
initial	O
pedigree	O
analyses	O
.	O

Meanwhile	O
,	O
an	O
indirect	O
gene	O
test	O
is	O
available	O
that	O
has	O
been	O
developed	O
at	O
the	O
Institute	O
for	O
Animal	O
Breeding	O
of	O
the	O
Bavarian	O
State	O
Research	O
Centre	O
for	O
Agriculture	O
(	O
ITZ	O
)	O
and	O
it	O
could	O
be	O
shown	O
that	O
these	O
cases	O
are	O
most	O
probably	O
not	O
genetically	O
affected	O
(	O
Buitkamp	O
et	O
al.	O
,	O
in	O
preparation	O
)	O
.	O

Carrier	O
identification	O
Two	O
criteria	O
were	O
used	O
for	O
carrier	O
identification	O
.	O

The	O
first	O
was	O
the	O
presence	O
of	O
a	O
calf	O
that	O
was	O
diagnosed	O
by	O
pathological	O
investigation	O
.	O

In	O
many	O
cases	O
more	O
than	O
one	O
affected	O
calf	O
per	O
sire	O
was	O
identified	O
[	O
8	O
]	O
.	O

Some	O
sires	O
had	O
only	O
one	O
affected	O
calf	O
,	O
but	O
a	O
large	O
number	O
of	O
risk	O
-	O
matings	O
.	O

In	O
these	O
cases	O
a	O
second	O
criterion	O
,	O
the	O
statistical	O
evaluation	O
of	O
risk	O
-	O
matings	O
,	O
was	O
used	O
to	O
identify	O
potential	O
phenocopies	O
.	O

For	O
this	O
purpose	O
,	O
the	O
probability	O
of	O
observing	O
only	O
a	O
single	O
affected	O
calf	O
among	O
a	O
certain	O
number	O
of	O
risk	O
-	O
matings	O
of	O
the	O
sire	O
in	O
question	O
was	O
calculated	O
.	O

Risk	O
-	O
matings	O
were	O
defined	O
as	O
matings	O
with	O
direct	O
progenies	O
of	O
identified	O
AS	O
carriers	O
.	O

The	O
probability	O
of	O
observing	O
an	O
affected	O
calf	O
depends	O
also	O
on	O
the	O
probability	O
that	O
such	O
a	O
calf	O
is	O
reported	O
to	O
the	O
LKV	O
.	O

We	O
assumed	O
this	O
probability	O
to	O
be	O
50	O
%	O
.	O

Under	O
these	O
conditions	O
,	O
the	O
probability	O
of	O
observing	O
only	O
one	O
affected	O
calf	O
is	O
lower	O
than	O
1.0	O
percent	O
,	O
if	O
at	O
least	O
104	O
risk	O
-	O
matings	O
are	O
given	O
for	O
a	O
single	O
sire	O
.	O

In	O
this	O
case	O
it	O
is	O
very	O
likely	O
that	O
the	O
single	O
affected	O
calf	O
is	O
a	O
phenocopy	O
.	O

In	O
2006	O
and	O
2007	O
this	O
was	O
the	O
case	O
for	O
two	O
sires	O
used	O
for	O
artificial	O
insemination	O
that	O
had	O
no	O
pedigree	O
connection	O
to	O
SEMPER	O
(	O
see	O
below	O
)	O
.	O

Experimental	O
matings	O
of	O
obligate	O
carriers	O
Four	O
out	O
of	O
seven	O
cows	B
that	O
were	O
known	O
AS	O
carriers	O
brought	O
to	O
the	O
facilities	O
of	O
the	O
ITZ	O
were	O
used	O
for	O
embryo	O
transfer	O
(	O
Table	O
1	O
)	O
.	O

33	O
of	O
the	O
60	O
recipients	O
(	O
55	O
%	O
)	O
were	O
confirmed	O
pregnant	O
on	O
day	O
35	O
.	O

Four	O
of	O
the	O
33	O
pregnant	O
heifers	O
(	O
12	O
%	O
)	O
aborted	O
between	O
days	O
36	O
and	O
49	O
of	O
pregnancy	O
.	O

Of	O
the	O
remaining	O
29	O
recipients	O
,	O
6	O
were	O
slaughtered	O
on	O
day	O
150	O
,	O
6	O
on	O
day	O
200	O
,	O
and	O
17	O
animals	O
on	O
day	O
225	O
of	O
pregnancy	O
(	O
Table	O
1	O
)	O
.	O

Four	O
fetuses	O
(	O
three	O
male	O
and	O
one	O
female	O
)	O
out	O
of	O
29	O
(	O
14	O
%	O
)	O
showed	O
the	O
typical	O
pathological	O
changes	O
of	O
the	O
arachnomelia	O
syndrome	O
as	O
described	O
above	O
(	O
Figure	O
4C	O
,	O
D	O
)	O
.	O

All	O
other	O
fetuses	O
showed	O
no	O
signs	O
of	O
AS	O
(	O
Figure	O
4A	O
,	O
B	O
)	O
.	O

Male	O
fetuses	O
represented	O
76	O
%	O
(	O
22	O
of	O
29	O
)	O
of	O
pregnancies	O
(	O
χ2	O
=	O
3.123	O
,	O
p	O
=	O
0.077	O
,	O
Yates	O
corrected	O
for	O
sample	O
size	O
<	O
30	O
)	O
.	O

Female	O
weight	O
(	O
Table	O
2	O
)	O
,	O
crown	O
-	O
rump	O
length	O
at	O
day	O
225	O
and	O
chest	O
circumference	O
at	O
day	O
225	O
of	O
normal	O
fetuses	O
were	O
lower	O
than	O
that	O
of	O
male	O
fetuses	O
.	O

Fetuses	O
that	O
were	O
affected	O
by	O
the	O
arachnomelia	O
syndrome	O
showed	O
lower	O
weight	O
than	O
normal	O
fetuses	O
.	O

The	O
affected	O
and	O
the	O
normal	O
fetuses	O
had	O
similar	O
crown	O
-	O
rump	O
length	O
,	O
but	O
the	O
chest	O
circumference	O
of	O
affected	O
fetuses	O
was	O
higher	O
than	O
that	O
of	O
normal	O
fetuses	O
(	O
Table	O
2	O
)	O
.	O

Due	O
to	O
the	O
small	O
number	O
of	O
affected	O
female	O
fetuses	O
,	O
a	O
comparison	O
with	O
unaffected	O
animals	O
for	O
sex	O
was	O
not	O
possible	O
.	O

To	O
compare	O
unaffected	O
and	O
affected	O
animals	O
in	O
total	O
,	O
the	O
data	O
were	O
analyzed	O
for	O
statistical	O
differences	O
by	O
the	O
non	O
parametric	O
Mann	O
-	O
Whitney	O
-	O
Test	O
.	O

The	O
only	O
trait	O
that	O
was	O
significantly	O
different	O
between	O
unaffected	O
and	O
affected	O
fetuses	O
was	O
the	O
chest	O
circumference	O
(	O
p	O
=	O
0.004	O
,	O
Table	O
2	O
)	O
.	O

The	O
body	O
weight	O
of	O
AS	O
affected	O
calves	O
was	O
tendentially	O
lower	O
than	O
that	O
of	O
normal	O
calves	O
.	O

Since	O
affected	O
calves	O
did	O
not	O
have	O
different	O
crown	O
-	O
rump	O
-	O
length	O
and	O
their	O
chest	O
circumference	O
was	O
even	O
higher	O
,	O
this	O
can	O
best	O
be	O
explained	O
by	O
a	O
reduced	O
bone	O
mass	O
.	O

Pedigree	O
Analysis	O
and	O
mode	O
of	O
inheritance	O
Eight	O
-	O
generation	O
pedigrees	O
of	O
all	O
cases	O
were	O
extracted	O
from	O
the	O
joint	O
German	O
and	O
Austria	O
pedigree	O
data	O
and	O
screened	O
for	O
common	O
ancestors	O
.	O

The	O
pedigree	O
of	O
the	O
majority	O
of	O
affected	O
calves	O
(	O
paternal	O
line	O
150	O
,	O
maternal	O
line	O
106	O
out	O
of	O
152	O
,	O
Table	O
3	O
)	O
could	O
be	O
traced	O
back	O
to	O
one	O
founder	O
,	O
SEMPER	O
(	O
ISO	O
-	O
Nr	O
.	O
27000979299305	O
)	O
,	O
a	O
sire	O
born	O
in	O
1964	O
,	O
6–9	O
generations	O
before	O
the	O
affected	O
calves	O
were	O
born	O
(	O
Figure	O
2	O
)	O
.	O

Most	O
of	O
the	O
affected	O
calves	O
inherited	O
the	O
AS	O
mutation	O
via	O
REXON	O
or	O
EGEL	O
(	O
Table	O
3	O
,	O
Figure	O
2	O
)	O
.	O

In	O
44	O
cases	O
the	O
maternal	O
paths	O
were	O
not	O
linked	O
to	O
the	O
common	O
pedigree	O
(	O
Table	O
3	O
)	O
.	O

One	O
explanation	O
would	O
be	O
the	O
existence	O
of	O
additional	O
,	O
hereto	O
unknown	O
origins	O
of	O
the	O
mutation	O
.	O

This	O
could	O
happen	O
if	O
the	O
AS	O
mutation	O
is	O
much	O
more	O
ancient	O
and	O
additional	O
pedigree	O
paths	O
exist	O
or	O
if	O
an	O
independent	O
mutation	O
event	O
happened	O
leading	O
to	O
the	O
same	O
phenotype	O
.	O

An	O
alternative	O
,	O
more	O
plausible	O
explanation	O
could	O
be	O
the	O
occurrence	O
of	O
misparentages	O
.	O

It	O
is	O
well	O
known	O
that	O
in	O
the	O
pre	O
parentage	O
-	O
test	O
era	O
,	O
the	O
frequency	O
of	O
false	O
paternity	O
,	O
especially	O
of	O
the	O
cows	B
,	O
was	O
reasonable	O
high	O
(	O
up	O
to	O
23	O
%	O
[	O
9	O
]	O
)	O
.	O

Therefore	O
,	O
there	O
is	O
a	O
good	O
chance	O
of	O
a	O
false	O
registry	O
within	O
6–9	O
generations	O
.	O

There	O
is	O
strong	O
support	O
for	O
the	O
assumption	O
that	O
the	O
AS	O
is	O
regulated	O
by	O
a	O
single	O
autosomal	O
locus	O
acting	O
in	O
a	O
recessive	O
manner	O
.	O

First	O
of	O
all	O
,	O
the	O
pedigree	O
structure	O
of	O
the	O
affected	O
calves	O
in	O
Simmental	O
can	O
best	O
be	O
explained	O
by	O
a	O
recessive	O
mode	O
of	O
inheritance	O
.	O

The	O
paternal	O
branch	O
of	O
the	O
pedigree	O
could	O
be	O
traced	O
back	O
to	O
one	O
sire	O
,	O
SEMPER	O
,	O
for	O
all	O
affected	O
calves	O
,	O
the	O
maternal	O
branch	O
in	O
the	O
majority	O
of	O
the	O
cases	O
.	O

Inbreeding	O
loops	O
over	O
a	O
few	O
generations	O
are	O
present	O
in	O
several	O
pedigrees	O
of	O
affected	O
calves	O
,	O
e.g.	O
cases	O
P3364	O
and	O
P1787	O
(	O
Figure	O
2	O
)	O
.	O

Sex	O
-	O
dependent	O
inheritance	O
can	O
obviously	O
be	O
excluded	O
and	O
a	O
dominant	O
mode	O
with	O
reduced	O
penetrance	O
seems	O
to	O
be	O
unlikely	O
.	O

Secondly	O
,	O
the	O
experimental	O
matings	O
resulted	O
in	O
4	O
affected	O
and	O
25	O
unaffected	O
fetuses	O
,	O
a	O
result	O
that	O
most	O
closely	O
resembles	O
the	O
expectation	O
of	O
a	O
recessive	O
mode	O
of	O
inheritance	O
.	O

Thirdly	O
,	O
the	O
occurrence	O
of	O
cases	O
corresponded	O
well	O
with	O
the	O
numbers	O
expected	O
under	O
the	O
assumption	O
of	O
a	O
recessively	O
acting	O
mutation	O
.	O

We	O
tested	O
this	O
on	O
the	O
progeny	O
of	O
ROMEL	O
,	O
the	O
largest	O
dataset	O
available	O
from	O
one	O
carrier	O
.	O

We	O
analyzed	O
the	O
period	O
from	O
the	O
beginning	O
of	O
the	O
recording	O
system	O
for	O
malformations	O
to	O
May	O
2007	O
.	O

In	O
that	O
period	O
44,170	O
calves	O
were	O
born	O
that	O
were	O
sired	O
by	O
ROMEL	O
.	O

From	O
these	O
,	O
662	O
were	O
considered	O
as	O
risk	O
pairings	O
,	O
i.e.	O
the	O
mother	O
had	O
a	O
risk	O
of	O
0.5	O
to	O
be	O
a	O
carrier	O
(	O
i.e.	O
one	O
of	O
the	O
grandparents	O
was	O
an	O
obligate	O
carrier	O
)	O
and	O
35	O
calves	O
out	O
of	O
these	O
were	O
diagnosed	O
as	O
affected	O
.	O

Since	O
it	O
is	O
expected	O
that	O
about	O
1	O
/	O
2	O
to	O
1	O
/	O
3	O
of	O
the	O
affected	O
calves	O
were	O
recorded	O
,	O
this	O
result	O
is	O
very	O
close	O
to	O
the	O
expected	O
1:7	O
ratio	O
of	O
affected	O
to	O
unaffected	O
calves	O
.	O

Moreover	O
,	O
these	O
findings	O
are	O
concordant	O
with	O
the	O
historical	O
description	O
of	O
the	O
arachnomelia	O
syndrome	O
in	O
Simmental	O
[	O
2	O
]	O
and	O
the	O
analyses	O
of	O
cases	O
in	O
Brown	O
Swiss	O
[	O
5	O
]	O
.	O

Finally	O
,	O
when	O
applying	O
linkage	O
analyses	O
using	O
microsatellite	O
markers	O
,	O
evaluations	O
with	O
a	O
model	O
assuming	O
recessive	O
autosomal	O
inheritance	O
gave	O
the	O
highest	O
lod	O
scores	O
(	O
Buitkamp	O
et	O
al.	O
,	O
in	O
preparation	O
)	O
.	O

Allelic	O
frequency	O
of	O
carriers	O
in	O
the	O
present	O
Simmental	O
cow	B
population	O
Since	O
the	O
arachnomelia	O
syndrome	O
-	O
allele	O
was	O
passed	O
to	O
the	O
current	O
population	O
through	O
two	O
parental	O
lines	O
(	O
REXON	O
and	O
EGEL	O
)	O
and	O
the	O
main	O
carriers	O
are	O
known	O
,	O
it	O
is	O
possible	O
to	O
estimate	O
the	O
frequency	O
of	O
the	O
disease	O
allele	O
by	O
an	O
allele	O
-	O
counting	O
method	O
[	O
10	O
]	O
.	O

The	O
allelic	O
frequency	O
was	O
calculated	O
for	O
all	O
cows	B
from	O
the	O
breeding	O
population	O
who	O
were	O
alive	O
in	O
June	O
2007	O
.	O

In	O
10.4	O
percent	O
of	O
the	O
pedigrees	O
of	O
540,725	O
cows	B
an	O
identified	O
carrier	O
was	O
found	O
and	O
the	O
probability	O
that	O
individual	O
cows	B
were	O
carrier	O
of	O
the	O
arachnomelia	O
syndrome	O
-	O
allele	O
was	O
calculated	O
.	O

E.g.	O
in	O
14,740	O
and	O
41,032	O
cases	O
a	O
known	O
carrier	O
appeared	O
as	O
sire	O
and	O
grandsire	O
,	O
respectively	O
.	O

In	O
these	O
cases	O
the	O
probability	O
of	O
transmitting	O
the	O
allele	O
is	O
50	O
and	O
25	O
percent	O
,	O
respectively	O
,	O
if	O
no	O
further	O
carrier	O
is	O
present	O
in	O
the	O
two	O
generation	O
pedigree	O
.	O

The	O
averaged	O
rate	O
of	O
the	O
arachnomelia	O
syndrome	O
carriers	O
based	O
on	O
known	O
carriers	O
over	O
all	O
cows	B
alive	O
in	O
Bavarian	O
Simmental	O
was	O
3.32	O
percent	O
.	O

Using	O
this	O
approach	O
,	O
the	O
frequency	O
of	O
carriers	O
was	O
calculated	O
for	O
each	O
year	O
(	O
always	O
based	O
on	O
the	O
actual	O
datasets	O
from	O
August	O
2008	O
)	O
from	O
2003	O
to	O
2008	O
(	O
Figure	O
1	O
)	O
.	O

The	O
calculations	O
were	O
done	O
twice	O
,	O
considering	O
all	O
known	O
carriers	O
together	O
,	O
and	O
also	O
by	O
using	O
only	O
ROMEL	O
as	O
a	O
carrier	O
to	O
show	O
the	O
numeric	O
contribution	O
of	O
his	O
progeny	O
(	O
Figure	O
1	O
)	O
.	O

For	O
these	O
analyses	O
,	O
the	O
sires	O
that	O
are	O
designated	O
to	O
be	O
non	O
-	O
carriers	O
by	O
the	O
number	O
of	O
risk	O
pairings	O
without	O
having	O
a	O
case	O
or	O
the	O
indirect	O
gene	O
test	O
are	O
set	O
as	O
non	O
-	O
carrier	O
.	O

Therefore	O
,	O
these	O
frequencies	O
are	O
slightly	O
lower	O
than	O
the	O
initial	O
frequency	O
estimate	O
of	O
3.32	O
percent	O
.	O

Conclusion	O
The	O
cases	O
of	O
malformed	O
Simmental	O
calves	O
presented	O
here	O
showed	O
the	O
same	O
morphology	O
described	O
in	O
the	O
arachnomelia	O
syndrome	O
in	O
Brown	O
Swiss	O
[	O
e.g.	O
[	O
3	O
]	O
]	O
,	O
even	O
though	O
there	O
is	O
a	O
certain	O
morphological	O
variation	O
from	O
mild	O
to	O
severe	O
malformations	O
.	O

The	O
main	O
findings	O
,	O
brachygnathia	O
inferior	O
and	O
convex	O
frontal	O
bone	O
of	O
the	O
face	O
,	O
deformation	O
of	O
vertebrae	O
,	O
and	O
dysplasia	O
of	O
the	O
limbs	O
,	O
namely	O
the	O
diaphyses	O
of	O
metatarsus	O
and	O
-carpus	O
and	O
the	O
fetlocks	O
,	O
can	O
best	O
be	O
explained	O
by	O
irregularly	O
developed	O
bone	O
structure	O
at	O
the	O
corresponding	O
locations	O
.	O

Without	O
pathological	O
examination	O
it	O
is	O
difficult	O
to	O
distinguish	O
the	O
arachnomelia	O
syndrome	O
from	O
other	O
malformations	O
of	O
the	O
limbs	O
.	O

Therefore	O
,	O
low	O
numbers	O
of	O
cases	O
in	O
Simmental	O
probably	O
passed	O
unrecognized	O
before	O
2005	O
.	O

In	O
that	O
year	O
the	O
allelic	O
frequency	O
of	O
the	O
disease	O
in	O
the	O
cow	B
population	O
increased	O
sharply	O
because	O
some	O
sires	O
that	O
had	O
been	O
carriers	O
of	O
the	O
mutation	O
had	O
become	O
very	O
popular	O
2–4	O
years	O
before	O
.	O

The	O
identification	O
of	O
a	O
common	O
ancestor	O
,	O
the	O
results	O
from	O
the	O
experimental	O
matings	O
and	O
the	O
analyses	O
of	O
numbers	O
of	O
cases	O
from	O
risk	O
matings	O
strongly	O
support	O
the	O
hypothesis	O
of	O
an	O
autosomal	O
recessively	O
inherited	O
disease	O
.	O

Furthermore	O
,	O
this	O
assumption	O
is	O
concordant	O
with	O
the	O
historical	O
description	O
of	O
the	O
syndrome	O
in	O
Simmental	O
and	O
Brown	O
Swiss	O
.	O

The	O
allelic	O
frequency	O
of	O
the	O
arachnomelia	O
syndrome	O
in	O
the	O
current	O
population	O
is	O
well	O
above	O
3	O
percent	O
and	O
a	O
substantial	O
number	O
of	O
progeny	O
from	O
known	O
carriers	O
with	O
superior	O
genetic	O
merit	O
shall	O
be	O
used	O
as	O
sires	O
during	O
the	O
next	O
years	O
.	O

Therefore	O
,	O
a	O
control	O
system	O
has	O
to	O
be	O
established	O
and	O
the	O
arachnomelia	O
syndrome	O
-	O
gene	O
should	O
be	O
mapped	O
as	O
a	O
prerequisite	O
for	O
the	O
development	O
of	O
an	O
indirect	O
gene	O
test	O
for	O
carrier	O
identification	O
.	O

The	O
availability	O
of	O
pathologically	O
well	O
characterized	O
cases	O
from	O
the	O
field	O
and	O
from	O
the	O
ET	O
-	O
generated	O
full	O
-	O
sib	O
families	O
will	O
be	O
an	O
excellent	O
material	O
for	O
a	O
genetic	O
mapping	O
procedure	O
.	O

Methods	O
Recording	O
system	O
for	O
congenital	O
malformations	O
A	O
system	O
for	O
monitoring	O
inherited	O
congenital	O
malformations	O
in	O
Bavarian	O
cattle	B
populations	O
was	O
established	O
by	O
the	O
Institute	O
for	O
Animal	O
Breeding	O
of	O
the	O
Bavarian	O
State	O
Research	O
Centre	O
for	O
Agriculture	O
(	O
ITZ	O
)	O
in	O
cooperation	O
with	O
the	O
Bavarian	O
milk	O
recording	O
organization	O
(	O
LKV	O
)	O
[	O
11	O
]	O
.	O

In	O
short	O
,	O
a	O
questionnaire	O
was	O
developed	O
for	O
detailed	O
recording	O
of	O
malformed	O
calves	O
.	O

The	O
malformation	O
was	O
described	O
according	O
to	O
its	O
location	O
(	O
e.g.	O
head	O
,	O
legs	O
)	O
and	O
its	O
characteristics	O
(	O
e.g.	O
hernia	O
)	O
.	O

The	O
standardized	O
data	O
were	O
stored	O
in	O
a	O
database	O
at	O
the	O
LKV	O
,	O
that	O
is	O
evaluated	O
monthly	O
for	O
a	O
potential	O
genetic	O
background	O
of	O
malformations	O
.	O

Sires	O
that	O
fit	O
into	O
the	O
pedigree	O
(	O
progeny	O
of	O
REXON	O
or	O
EGEL	O
)	O
with	O
at	O
least	O
one	O
affected	O
calf	O
with	O
confirmed	O
paternity	O
were	O
defined	O
as	O
obligate	O
carriers	O
and	O
marked	O
in	O
the	O
breeding	O
information	O
system	O
[	O
7	O
]	O
.	O

In	O
cases	O
without	O
connection	O
to	O
the	O
pedigree	O
and	O
only	O
one	O
recorded	O
calf	O
the	O
number	O
of	O
""""	O
risk	O
pairings	O
""""	O
(	O
matings	O
to	O
cows	B
where	O
at	O
least	O
one	O
parent	O
is	O
a	O
known	O
carrier	O
,	O
enabling	O
the	O
calculation	O
of	O
the	O
probability	O
for	O
the	O
occurrence	O
of	O
cases	O
)	O
was	O
calculated	O
.	O

When	O
the	O
probability	O
that	O
a	O
case	O
occurs	O
was	O
above	O
99	O
%	O
for	O
the	O
sire	O
in	O
question	O
the	O
case	O
was	O
considered	O
to	O
be	O
a	O
phenocopy	O
.	O

The	O
number	O
of	O
calves	O
affected	O
by	O
the	O
arachnomelia	O
syndrome	O
and	O
their	O
parentage	O
is	O
routinely	O
published	O
[	O
8	O
]	O
.	O

Pathological	O
examinations	O
Pathological	O
examinations	O
followed	O
standard	O
procedures	O
.	O

Calves	O
were	O
photographed	O
and	O
size	O
and	O
weight	O
measurements	O
were	O
recorded	O
.	O

Tissue	O
specimens	O
from	O
the	O
condyle	O
(	O
epiphysis	O
)	O
and	O
from	O
the	O
diaphysis	O
of	O
the	O
femur	O
were	O
collected	O
for	O
histological	O
examination	O
.	O

Specimens	O
were	O
fixed	O
in	O
10	O
%	O
formalin	O
and	O
kept	O
in	O
a	O
decalcifying	O
solution	O
(	O
Ossafixonafor	O
)	O
for	O
24	O
hours	O
.	O

Thereafter	O
,	O
specimens	O
were	O
processed	O
in	O
an	O
automated	O
embedding	O
system	O
,	O
sectioned	O
at	O
4–6	O
microns	O
and	O
finally	O
stained	O
with	O
haematoxyline	O
and	O
eosin	O
.	O

Experimental	O
matings	O
and	O
embryo	O
transfer	O
Known	O
carriers	O
of	O
the	O
arachnomelia	O
syndrome	O
(	O
seven	O
cows	B
that	O
had	O
produced	O
at	O
least	O
one	O
affected	O
calf	O
)	O
were	O
brought	O
to	O
the	O
facilities	O
of	O
the	O
ITZ	O
for	O
embryo	O
transfer	O
(	O
Table	O
1	O
)	O
.	O

Late	O
morulae	O
and	O
blastocysts	O
collected	O
on	O
day	O
7	O
(	O
day	O
0	O
=	O
estrus	O
)	O
from	O
superovulated	O
donor	O
cows	B
were	O
nonsurgically	O
transferred	O
to	O
heifers	O
[	O
12	O
]	O
.	O

Mode	O
of	O
inheritance	O
and	O
allele	O
frequency	O
The	O
pedigree	O
of	O
all	O
cases	O
was	O
constructed	O
from	O
the	O
pedigree	O
that	O
is	O
used	O
for	O
the	O
joint	O
breeding	O
evaluation	O
of	O
Germany	O
and	O
Austria	O
.	O

The	O
graphical	O
presentation	O
of	O
the	O
pedigree	O
was	O
performed	O
with	O
the	O
Pedigraph	O
TM	O
software	O
[	O
13	O
]	O
.	O

The	O
allelic	O
frequency	O
of	O
the	O
AS	O
mutation	O
in	O
the	O
current	O
cow	B
population	O
was	O
estimated	O
from	O
ancestors	O
with	O
known	O
genotypes	O
following	O
the	O
allele	O
-	O
counting	O
method	O
[	O
10	O
]	O
.	O

For	O
this	O
reason	O
two	O
generation	O
pedigrees	O
of	O
herd	O
book	O
cows	B
in	O
Bavarian	O
Simmental	O
were	O
analyzed	O
for	O
obligate	O
carriers	O
.	O

We	O
considered	O
all	O
cows	B
that	O
were	O
alive	O
in	O
June	O
2007	O
and	O
included	O
in	O
the	O
herd	O
book	O
.	O

All	O
animals	O
were	O
bred	O
by	O
the	O
use	O
of	O
artificial	O
insemination	O
.	O

Statistical	O
analyses	O
The	O
non	O
parametric	O
Mann	O
-	O
Whitney	O
-	O
Test	O
was	O
performed	O
using	O
SPSS	O
Version	O
14.0	O
,	O
the	O
Chi	O
-	O
square	O
test	O
was	O
performed	O
using	O
R	O
2.4.0	O
[	O
14	O
]	O
.	O

Authors	O
'	O
contributions	O
JB	O
drafted	O
the	O
manuscript	O
and	O
analyzed	O
the	O
pedigrees	O
.	O

BL	O
conceived	O
the	O
monitoring	O
system	O
for	O
inherited	O
diseases	O
.	O

RE	O
extracted	O
the	O
data	O
from	O
the	O
database	O
and	O
estimated	O
the	O
allelic	O
frequencies	O
of	O
the	O
arachnomelia	O
syndrome	O
.	O

HR	O
and	O
MW	O
performed	O
the	O
embryo	O
collection	O
,	O
transfer	O
and	O
recorded	O
the	O
morpho	O
-	O
metrical	O
data	O
of	O
the	O
experimental	O
matings	O
.	O

BS	O
examined	O
the	O
calves	O
pathologically	O
.	O

NM	O
and	O
KG	O
participated	O
in	O
study	O
design	O
and	O
coordination	O
and	O
critically	O
revised	O
the	O
manuscript	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Foamy	O
Macrophages	O
from	O
Tuberculous	O
Patients	O
'	O
Granulomas	O
Constitute	O
a	O
Nutrient	O
-	O
Rich	O
Reservoir	O
for	O
M.	B
tuberculosis	I
Persistence	O
Abstract	O
Tuberculosis	O
(	O
TB	O
)	O
is	O
characterized	O
by	O
a	O
tight	O
interplay	O
between	O
Mycobacterium	B
tuberculosis	I
and	O
host	O
cells	O
within	O
granulomas	O
.	O

These	O
cellular	O
aggregates	O
restrict	O
bacterial	O
spreading	O
,	O
but	O
do	O
not	O
kill	O
all	O
the	O
bacilli	O
,	O
which	O
can	O
persist	O
for	O
years	O
.	O

In	O
-	O
depth	O
investigation	O
of	O
M.	B
tuberculosis	I
interactions	O
with	O
granuloma	O
-	O
specific	O
cell	O
populations	O
are	O
needed	O
to	O
gain	O
insight	O
into	O
mycobacterial	O
persistence	O
,	O
and	O
to	O
better	O
understand	O
the	O
physiopathology	O
of	O
the	O
disease	O
.	O

We	O
have	O
analyzed	O
the	O
formation	O
of	O
foamy	O
macrophages	O
(	O
FMs	O
)	O
,	O
a	O
granuloma	O
-	O
specific	O
cell	O
population	O
characterized	O
by	O
its	O
high	O
lipid	O
content	O
,	O
and	O
studied	O
their	O
interaction	O
with	O
the	O
tubercle	O
bacillus	O
.	O

Within	O
our	O
in	O
vitro	O
human	B
granuloma	O
model	O
,	O
M.	B
tuberculosis	I
long	O
chain	O
fatty	O
acids	O
,	O
namely	O
oxygenated	O
mycolic	O
acids	O
(	O
MA	O
)	O
,	O
triggered	O
the	O
differentiation	O
of	O
human	B
monocyte	O
-	O
derived	O
macrophages	O
into	O
FMs	O
.	O

In	O
these	O
cells	O
,	O
mycobacteria	O
no	O
longer	O
replicated	O
and	O
switched	O
to	O
a	O
dormant	O
non	O
-	O
replicative	O
state	O
.	O

Electron	O
microscopy	O
observation	O
of	O
M.	B
tuberculosis	I
–	O
infected	O
FMs	O
showed	O
that	O
the	O
mycobacteria	O
-	O
containing	O
phagosomes	O
migrate	O
towards	O
host	O
cell	O
lipid	O
bodies	O
(	O
LB	O
)	O
,	O
a	O
process	O
which	O
culminates	O
with	O
the	O
engulfment	O
of	O
the	O
bacillus	O
into	O
the	O
lipid	O
droplets	O
and	O
with	O
the	O
accumulation	O
of	O
lipids	O
within	O
the	O
microbe	O
.	O

Altogether	O
,	O
our	O
results	O
suggest	O
that	O
oxygenated	O
mycolic	O
acids	O
from	O
M.	B
tuberculosis	I
play	O
a	O
crucial	O
role	O
in	O
the	O
differentiation	O
of	O
macrophages	O
into	O
FMs	O
.	O

These	O
cells	O
might	O
constitute	O
a	O
reservoir	O
used	O
by	O
the	O
tubercle	O
bacillus	O
for	O
long	O
-	O
term	O
persistence	O
within	O
its	O
human	B
host	O
,	O
and	O
could	O
provide	O
a	O
relevant	O
model	O
for	O
the	O
screening	O
of	O
new	O
antimicrobials	O
against	O
non	O
-	O
replicating	O
persistent	O
mycobacteria	O
.	O

Introduction	O
Tuberculosis	O
caused	O
by	O
Mycobacterium	B
tuberculosis	I
(	O
M.tb	B
)	O
remains	O
one	O
of	O
the	O
leading	O
causes	O
of	O
mortality	O
in	O
the	O
world	O
,	O
with	O
around	O
2	O
million	O
deaths	O
each	O
year	O
[	O
1	O
]	O
.	O

Most	O
individuals	O
remain	O
asymptomatic	O
after	O
the	O
primary	O
infection	O
with	O
only	O
10	O
%	O
at	O
risk	O
of	O
developing	O
an	O
active	O
disease	O
during	O
their	O
life	O
[	O
2	O
]	O
.	O

In	O
asymptomatic	O
individuals	O
,	O
the	O
bacilli	O
are	O
not	O
cleared	O
but	O
rather	O
persist	O
in	O
a	O
dormant	O
state	O
,	O
from	O
which	O
they	O
may	O
reactivate	O
and	O
induce	O
clinical	O
disease	O
at	O
later	O
stages	O
[	O
3	O
]	O
.	O

The	O
prognosis	O
of	O
the	O
disease	O
depends	O
on	O
the	O
host	O
's	O
efficiency	O
to	O
constrain	O
the	O
bacilli	O
at	O
the	O
site	O
of	O
infection	O
.	O

When	O
inhaled	O
M.tb	B
reach	O
the	O
lungs	O
,	O
they	O
are	O
internalized	O
by	O
lung	O
macrophages	O
.	O

The	O
latter	O
trigger	O
the	O
accumulation	O
at	O
the	O
infectious	O
site	O
of	O
macrophages	O
,	O
lymphocytes	O
and	O
dendritic	O
cells	O
,	O
to	O
form	O
a	O
granuloma	O
,	O
which	O
is	O
a	O
major	O
histo	O
-	O
pathological	O
feature	O
of	O
TB	O
.	O

Within	O
granulomas	O
,	O
macrophages	O
differentiate	O
into	O
epithelioïd	O
cells	O
(	O
differentiated	O
macrophages	O
)	O
,	O
and/or	O
fuse	O
to	O
form	O
multinucleated	O
giant	O
cells	O
(	O
MGC	O
)	O
.	O

Macrophages	O
with	O
large	O
numbers	O
of	O
lipid	O
-	O
free	O
vacuoles	O
,	O
as	O
well	O
as	O
macrophages	O
filled	O
with	O
lipid	O
-	O
containing	O
bodies	O
,	O
also	O
called	O
foamy	O
macrophages	O
(	O
FM	O
)	O
are	O
also	O
found	O
within	O
granulomatous	O
structures	O
in	O
both	O
experimental	O
animal	O
models	O
and	O
human	B
disease	O
[	O
4	O
]	O
,	O
[	O
5	O
]	O
.	O

The	O
above	O
cells	O
are	O
surrounded	O
by	O
a	O
rim	O
of	O
lymphocytes	O
,	O
and	O
at	O
later	O
stages	O
,	O
a	O
tight	O
coat	O
of	O
fibroblasts	O
encloses	O
the	O
structure	O
[	O
6	O
]	O
.	O

Although	O
the	O
structure	O
and	O
cell	O
composition	O
of	O
granulomas	O
are	O
well	O
known	O
,	O
the	O
biology	O
of	O
these	O
inflammatory	O
structures	O
and	O
,	O
more	O
specifically	O
,	O
the	O
role	O
of	O
granuloma	O
-	O
specific	O
cell	O
types	O
,	O
remain	O
largely	O
unknown	O
.	O

We	O
have	O
previously	O
developed	O
an	O
in	O
vitro	O
model	O
of	O
human	B
tuberculous	O
granulomas	O
to	O
gain	O
insight	O
into	O
the	O
survival	O
strategies	O
of	O
the	O
tubercle	O
bacillus	O
within	O
its	O
human	B
host	O
.	O

This	O
model	O
now	O
enables	O
the	O
characterization	O
of	O
granuloma	O
-	O
specific	O
cell	O
types	O
,	O
and	O
their	O
modulation	O
by	O
M.tb	B
[	O
7	O
]	O
.	O

The	O
main	O
advantage	O
of	O
this	O
model	O
over	O
in	O
vivo	O
animal	O
models	O
or	O
ex	O
vivo	O
human	B
biopsy	O
samples	O
,	O
is	O
the	O
availability	O
of	O
live	O
granuloma	O
cells	O
which	O
facilitates	O
analysis	O
of	O
their	O
cell	O
biology	O
.	O

Using	O
this	O
model	O
we	O
have	O
recently	O
shown	O
that	O
,	O
within	O
granulomas	O
,	O
large	O
multinucleated	O
giant	O
cells	O
,	O
also	O
known	O
as	O
Langhans	O
giant	O
cells	O
,	O
result	O
from	O
the	O
induction	O
of	O
granuloma	O
macrophage	O
fusion	O
by	O
M.tb	B
glycolipids	O
[	O
8	O
]	O
.	O

We	O
have	O
shown	O
that	O
these	O
cells	O
have	O
lost	O
the	O
ability	O
to	O
mediate	O
bacterial	O
uptake	O
upon	O
maturation	O
,	O
but	O
have	O
conserved	O
their	O
ability	O
to	O
mediate	O
antigen	O
presentation	O
[	O
9	O
]	O
.	O

The	O
differentiation	O
of	O
macrophages	O
into	O
FMs	O
has	O
been	O
particularly	O
well	O
described	O
in	O
individuals	O
developing	O
a	O
postprimary	O
,	O
also	O
known	O
as	O
secondary	O
or	O
adult	O
,	O
TB	O
.	O

These	O
postprimary	O
infections	O
are	O
considered	O
to	O
be	O
the	O
result	O
of	O
re	O
-	O
infection	O
or	O
reactivation	O
of	O
a	O
primary	O
TB	O
[	O
10	O
]	O
.	O

FMs	O
have	O
been	O
described	O
in	O
leprosy	O
patients	O
or	O
M.	B
avium	I
-	O
infected	O
AIDS	O
(	O
Acquired	O
ImmunoDeficiency	O
Syndrome	O
)	O
patients	O
,	O
and	O
in	O
chronic	O
stages	O
of	O
M.tb	B
infection	O
in	O
mice	B
[	O
4	O
]	O
,	O
[	O
11	O
]	O
,	O
[	O
12	O
]	O
.	O

The	O
foamy	O
aspect	O
of	O
these	O
macrophages	O
is	O
the	O
result	O
of	O
intracellular	O
lipid	O
accumulation	O
within	O
lipid	O
bodies	O
,	O
also	O
called	O
lipid	O
droplets	O
or	O
lipid	O
vacuoles	O
[	O
13	O
]	O
,	O
[	O
14	O
]	O
,	O
[	O
15	O
]	O
.	O

In	O
an	O
experimental	O
model	O
of	O
leukocyte	O
infection	O
,	O
it	O
was	O
recently	O
suggested	O
that	O
BCG	O
(	O
Bacille	O
Calmette	O
Guerin	O
)	O
infection	O
can	O
induce	O
,	O
in	O
a	O
TLR2-dependent	O
fashion	O
,	O
the	O
rapid	O
formation	O
of	O
lipid	O
bodies	O
carrying	O
out	O
part	O
of	O
the	O
eicosanoïd	O
biosynthesis	O
that	O
usually	O
accompanies	O
the	O
infection	O
,	O
thus	O
pointing	O
to	O
an	O
active	O
role	O
for	O
lipid	O
bodies	O
during	O
the	O
course	O
of	O
infection	O
[	O
16	O
]	O
.	O

However	O
,	O
the	O
mechanisms	O
regulating	O
this	O
lipid	O
accumulation	O
during	O
mycobacterial	O
infection	O
and	O
their	O
significance	O
in	O
the	O
physiopathology	O
of	O
tuberculosis	O
are	O
not	O
understood	O
.	O

Most	O
of	O
the	O
studies	O
on	O
TB	O
granulomas	O
have	O
focused	O
on	O
the	O
contribution	O
of	O
host	O
components	O
,	O
but	O
very	O
little	O
is	O
known	O
about	O
the	O
role	O
played	O
by	O
bacterial	O
constituents	O
in	O
terms	O
of	O
granuloma	O
formation	O
and	O
progression	O
.	O

The	O
present	O
work	O
was	O
aimed	O
at	O
deciphering	O
the	O
role	O
of	O
FMs	O
in	O
M.tb	B
survival	O
within	O
human	B
granulomas	O
.	O

To	O
test	O
our	O
working	O
hypothesis	O
according	O
to	O
which	O
FMs	O
constitute	O
a	O
nutrient	O
-	O
rich	O
reservoir	O
for	O
M.tb	B
persistence	O
,	O
we	O
used	O
our	O
in	O
vitro	O
model	O
of	O
human	B
granulomas	O
to	O
analyze	O
the	O
formation	O
of	O
FMs	O
and	O
their	O
role	O
during	O
M.tb	B
infection	O
.	O

We	O
showed	O
that	O
only	O
highly	O
virulent	O
mycobacteria	O
(	O
M.tb	B
,	O
M.	B
avium	I
)	O
and	O
not	O
saprophytic	O
ones	O
(	O
M.	B
smegmatis	I
)	O
could	O
induce	O
the	O
formation	O
of	O
FMs	O
in	O
mature	O
granulomas	O
.	O

Moreover	O
,	O
we	O
demonstrated	O
that	O
oxygenated	O
mycolic	O
acids	O
specifically	O
produced	O
by	O
the	O
above	O
pathogenic	O
species	O
were	O
responsible	O
for	O
FMs	O
formation	O
.	O

Once	O
differentiated	O
,	O
FMs	O
were	O
unable	O
to	O
mediate	O
phagocytosis	O
of	O
new	O
bacilli	O
and	O
their	O
microbicidal	O
activity	O
was	O
reduced	O
.	O

M.tb	B
was	O
not	O
killed	O
in	O
FMs	O
but	O
instead	O
persisted	O
in	O
a	O
non	O
-	O
replicating	O
state	O
,	O
and	O
over	O
-	O
expressed	O
dormancy	O
genes	O
.	O

Noteworthy	O
,	O
in	O
foamy	O
macrophages	O
,	O
M.tb	B
-	O
containing	O
phagosomes	O
were	O
shown	O
to	O
migrate	O
towards	O
lipid	O
bodies	O
which	O
they	O
progressively	O
surrounded	O
and	O
engulfed	O
.	O

As	O
a	O
result	O
,	O
bacteria	O
were	O
freed	O
into	O
lipid	O
bodies	O
,	O
thus	O
favoring	O
the	O
bacilli	O
's	O
access	O
to	O
nutrients	O
.	O

From	O
these	O
data	O
,	O
we	O
propose	O
that	O
FMs	O
could	O
form	O
a	O
secure	O
reservoir	O
for	O
the	O
tubercle	O
bacilli	O
.	O

Methods	O
Human	B
samples	O
Human	B
blood	O
samples	O
,	O
purchased	O
from	O
the	O
French	O
National	O
Blood	O
provider	O
of	O
Toulouse	O
,	O
were	O
collected	O
from	O
fully	O
anonymized	O
non	O
-	O
tuberculous	O
control	O
donors	O
,	O
an	O
ethical	O
committee	O
approval	O
was	O
,	O
therefore	O
,	O
not	O
necessary	O
.	O

This	O
study	O
was	O
conducted	O
according	O
to	O
the	O
principles	O
expressed	O
in	O
the	O
Helsinki	O
Declaration	O
,	O
with	O
informed	O
consent	O
obtained	O
from	O
each	O
donor	O
.	O

We	O
chose	O
to	O
work	O
on	O
lymph	O
node	O
samples	O
rather	O
than	O
lung	O
biopsies	O
,	O
which	O
are	O
usually	O
only	O
paraffin	O
-	O
embedded	O
,	O
because	O
staining	O
for	O
lipids	O
can	O
only	O
be	O
performed	O
on	O
frozen	O
samples	O
.	O

Lymph	O
node	O
biopsies	O
were	O
taken	O
for	O
diagnosis	O
purposes	O
,	O
in	O
ten	O
non	O
-	O
HIV	B
patients	O
.	O

For	O
each	O
biopsy	O
,	O
a	O
fragment	O
was	O
sent	O
to	O
the	O
microbiology	O
laboratory	O
,	O
another	O
was	O
frozen	O
in	O
liquid	O
nitrogen	O
and	O
the	O
main	O
part	O
was	O
fixed	O
in	O
formalin	O
and	O
paraffin	O
-	O
embedded	O
for	O
histological	O
examination	O
.	O

M.tb	B
was	O
identified	O
in	O
9	O
lymph	O
node	O
biopsies	O
and	O
from	O
the	O
lung	O
aspiration	O
in	O
the	O
last	O
patient	O
.	O

This	O
latter	O
case	O
showed	O
no	O
signs	O
of	O
necrosis	O
,	O
and	O
no	O
FMs	O
were	O
found	O
in	O
the	O
lymph	O
node	O
biopsy	O
.	O

This	O
study	O
complies	O
with	O
the	O
guidelines	O
of	O
the	O
declaration	O
of	O
Helsinki	O
.	O

Bacterial	O
strains	O
and	O
culture	O
conditions	O
Wild	O
-	O
type	O
M.	B
smegmatis	I
and	O
M.	B
smegmatis	I
/	O
hma	O
strains	O
were	O
previously	O
described	O
[	O
17	O
]	O
,	O
M.	B
tuberculosis	I
-	O
GFP	O
were	O
a	O
kind	O
gift	O
from	O
Dr.	O
C.	O
Guilhot	O
(	O
CNRS	O
-	O
IPBS	O
,	O
Toulouse	O
France	O
)	O
.	O

Bacilli	O
were	O
grown	O
in	O
Middlebrook	O
7H9	O
medium	O
(	O
Difco	O
)	O
supplemented	O
with	O
10	O
%	O
albumin	O
–	O
dextrose	O
–	O
catalase	O
(	O
Difco	O
)	O
.	O

Fluorescent	O
M.	B
smegmatis	I
and	O
M.	B
smegmatis	I
/	O
hma	O
were	O
obtained	O
by	O
FITC	O
labelling	O
as	O
described	O
in	O
[	O
18	O
]	O
.	O

Isolation	O
of	O
RNA	O
from	O
intraphagosomal	O
M.tb	B
Six	O
and	O
12	O
days	O
post	O
-	O
infection	O
(	O
MOI	O
10	O
)	O
,	O
macrophages	O
and	O
FMs	O
(	O
5	O
×	O
106	O
)	O
were	O
washed	O
twice	O
with	O
PBS	O
,	O
scraped	O
off	O
the	O
cell	O
dishes	O
and	O
recovered	O
by	O
centrifugation	O
.	O

The	O
cell	O
pellets	O
were	O
lysed	O
with	O
lysis	O
buffer	O
(	O
RNEasy	O
mini	O
kit	O
,	O
Quiagen	O
)	O
and	O
transferred	O
to	O
2	O
ml	O
Eppendorf	O
-	O
tubes	O
containing	O
a	O
0.5	O
ml	O
suspension	O
of	O
0.1	O
mm	O
-	O
diameter	O
glass	O
beads	O
(	O
Biospec	O
)	O
.	O

Mycobacteria	O
were	O
disrupted	O
using	O
a	O
bead	O
beater	O
(	O
Retsch	O
)	O
followed	O
by	O
a	O
5	O
min	O
centrifugation	O
at	O
14	O
000	O
g	O
.	O

RNA	O
contained	O
in	O
the	O
supernatant	O
was	O
then	O
column	O
-	O
purified	O
according	O
to	O
the	O
manufacturer	O
's	O
conditions	O
using	O
the	O
RNEasy	O
mini	O
kit	O
(	O
Qiagen	O
)	O
and	O
quantified	O
.	O

Quantitative	O
Real	O
-	O
Time	O
RT	O
-	O
PCR	O
In	O
RNA	O
samples	O
DNA	O
contamination	O
was	O
excluded	O
by	O
DNAse	O
I	O
treatment	O
(	O
Ambion	O
)	O
.	O

1	O
µg	O
total	O
RNA	O
was	O
reverse	O
-	O
transcribed	O
using	O
random	O
hexamer	O
primers	O
(	O
Ambion	O
)	O
and	O
Superscript	O
III	O
reverse	O
transcriptase	O
(	O
Invitrogen	O
)	O
.	O

Real	O
-	O
time	O
PCR	O
was	O
performed	O
on	O
cDNA	O
using	O
the	O
SYBR	O
green	O
essay	O
(	O
Applied	O
Biosystems	O
)	O
.	O

Reverse	O
and	O
forward	O
primers	O
used	O
are	O
listed	O
below	O
in	O
Table	O
1	O
.	O

Fluorescence	O
was	O
measured	O
by	O
ABIPrism	O
7300	O
(	O
Applied	O
Biosystems	O
)	O
.	O

The	O
calculated	O
threshold	O
cycle	O
(	O
Ct	O
)	O
value	O
for	O
each	O
gene	O
of	O
interest	O
was	O
normalized	O
to	O
the	O
Ct	O
value	O
for	O
16S	O
and	O
the	O
fold	O
expression	O
was	O
calculated	O
using	O
the	O
formula	O
:	O
fold	O
change	O
=	O
2−Δ.	O
(	O
ΔCt	O
)	O
[	O
19	O
]	O
.	O

Real	O
-	O
time	O
PCR	O
conditions	O
include	O
initial	O
activation	O
at	O
94	O
°	O
C	O
for	O
5	O
min	O
,	O
followed	O
by	O
40	O
cycles	O
of	O
denaturation	O
at	O
94	O
°	O
C	O
for	O
30	O
sec	O
,	O
annealing	O
and	O
extension	O
at	O
65	O
°	O
C	O
for	O
1	O
min	O
.	O

The	O
gene	O
induction	O
ratios	O
were	O
obtained	O
by	O
comparing	O
gene	O
expression	O
levels	O
in	O
intracellular	O
bacilli	O
with	O
those	O
of	O
log	O
-	O
phase	O
in	O
vitro	O
-	O
grown	O
bacilli	O
.	O

RNAs	O
were	O
isolated	O
from	O
two	O
independent	O
macrophage	O
infections	O
.	O

In	O
vitro	O
human	B
granuloma	O
formation	O
In	O
vitro	O
granulomas	O
were	O
obtained	O
as	O
previously	O
described	O
[	O
7	O
]	O
.	O

Briefly	O
,	O
1	O
×	O
106	O
freshly	O
isolated	O
Peripheral	O
Blood	O
Mononuclear	O
Cells	O
(	O
PBMCs	O
)	O
were	O
incubated	O
with	O
1	O
×	O
104	O
viable	O
M.tb	B
,	O
or	O
1	O
×	O
103	O
viable	O
M.	B
smegmatis	I
or	O
M.	B
smegmatis	I
/	O
hma	O
.	O

The	O
culture	O
medium	O
was	O
RPMI-1640+Glutamax	O
(	O
Difco	O
)	O
,	O
containing	O
7.5	O
%	O
human	B
AB	O
serum	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
.	O

Macrophage	O
differentiation	O
2.5	O
×	O
106	O
PBMCs	O
prepared	O
in	O
RPMI-1640+Glutamax	O
(	O
Difco	O
)	O
were	O
plated	O
over	O
coverslips	O
in	O
24-well	O
plates	O
.	O

After	O
2	O
h	O
culture	O
at	O
37	O
°	O
C	O
,	O
cells	O
were	O
washed	O
3	O
times	O
with	O
PBS	O
and	O
then	O
refed	O
with	O
RPMI-1640+Glutamax	O
(	O
Difco	O
)	O
,	O
containing	O
7.5	O
%	O
human	B
AB	O
serum	O
.	O

After	O
6	O
days	O
of	O
culturing	O
,	O
macrophages	O
were	O
differentiated	O
.	O

Respiratory	O
burst	O
assay	O
with	O
Nitroblue	O
tetrazolium	O
(	O
NBT	O
)	O
Human	B
monocyte	O
derived	O
macrophages	O
were	O
stimulated	O
with	O
M.	B
smegmatis	I
/	O
hma	O
for	O
2	O
h	O
at	O
37	O
°	O
C	O
,	O
washed	O
and	O
reincubated	O
in	O
mycobacterium	O
-	O
free	O
medium	O
.	O

After	O
2	O
days	O
of	O
differentiation	O
into	O
FMs	O
,	O
macrophages	O
were	O
co	O
-	O
stained	O
with	O
NBT	O
(	O
2	O
mg	O
/	O
ml	O
Sigma	O
-	O
Aldrich	O
)	O
and	O
Nile	O
red	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
for	O
30	O
min	O
at	O
37	O
°	O
C	O
.	O

Stained	O
cells	O
were	O
fixed	O
and	O
then	O
analysed	O
with	O
an	O
inverted	O
microscope	O
(	O
Nikon	O
TE	O
300	O
)	O
.	O

Phagocytosis	O
and	O
Survival	O
test	O
For	O
phagocytosis	O
assays	O
,	O
differentiated	O
macrophages	O
were	O
incubated	O
with	O
M.	B
smegmatis	I
/	O
hma	O
mycolic	O
acids	O
for	O
2	O
days	O
and	O
then	O
infected	O
with	O
1	O
×	O
108	O
labeled	O
mycobacteria	O
per	O
well	O
for	O
90	O
min	O
,	O
washed	O
3	O
times	O
with	O
PBS	O
and	O
chased	O
for	O
3	O
h	O
in	O
fresh	O
culture	O
medium	O
.	O

For	O
survival	O
experiments	O
,	O
macrophages	O
were	O
infected	O
with	O
M.	B
tuberculosis	I
-	O
GFP	O
(	O
10	O
bacteria	O
/	O
cell	O
)	O
,	O
washed	O
3	O
times	O
with	O
PBS	O
(	O
Gibco	O
)	O
and	O
re	O
-	O
incubated	O
in	O
fresh	O
culture	O
medium	O
.	O

At	O
selected	O
time	O
points	O
thereafter	O
(	O
1	O
,	O
3	O
,	O
6	O
,	O
10	O
and	O
14	O
days	O
)	O
cells	O
were	O
labeled	O
with	O
Nile	O
red	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
,	O
fixed	O
and	O
observed	O
under	O
a	O
confocal	O
microscope	O
.	O

The	O
amount	O
of	O
mycobacteria	O
per	O
cells	O
was	O
evaluated	O
.	O

(	O
100	O
cells	O
were	O
analyzed	O
for	O
each	O
time	O
point	O
)	O
.	O

Lipid	O
body	O
staining	O
and	O
immunostaining	O
Granuloma	O
cells	O
were	O
collected	O
and	O
plated	O
onto	O
glass	O
coverslips	O
with	O
a	O
cytospin	O
(	O
Thermo	O
Shandon	O
)	O
fixed	O
for	O
30	O
min	O
in	O
PBS	O
-	O
PFA	O
4	O
%	O
and	O
stained	O
with	O
Oil	O
red	O
-	O
O	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
as	O
described	O
[	O
20	O
]	O
.	O

The	O
slides	O
were	O
then	O
counterstained	O
with	O
haematoxylin	O
(	O
Dako	O
Cytomation	O
)	O
and	O
observed	O
under	O
an	O
inverted	O
microscope	O
(	O
Nikon	O
TE	O
300	O
)	O
.	O

For	O
fluorescence	O
analysis	O
,	O
granuloma	O
cells	O
or	O
macrophages	O
were	O
collected	O
in	O
PBS	O
,	O
lipid	O
bodies	O
were	O
stained	O
with	O
Nile	O
red	O
(	O
Sigma	O
-	O
Aldrich	O
,	O
0.1	O
µg	O
/	O
ml	O
,	O
from	O
a	O
stock	O
solution	O
in	O
methanol	O
)	O
for	O
15	O
min	O
washed	O
with	O
PBS	O
,	O
fixed	O
for	O
30	O
min	O
in	O
PBS	O
-	O
PFA	O
4	O
%	O
,	O
mounted	O
with	O
the	O
fluorescent	O
mounting	O
medium	O
(	O
Dako	O
Cytomation	O
)	O
and	O
observed	O
under	O
a	O
confocal	O
microscope	O
.	O

In	O
order	O
to	O
distinguish	O
the	O
lipids	O
contained	O
within	O
lipid	O
bodies	O
,	O
from	O
those	O
of	O
the	O
cell	O
membrane	O
,	O
we	O
used	O
the	O
fluorescent	O
emission	O
spectrum	O
properties	O
of	O
Nile	O
red	O
which	O
depend	O
upon	O
the	O
kind	O
of	O
lipid	O
associated	O
with	O
Nile	O
red	O
,	O
i.e.	O
for	O
triacylglycerol	O
:	O
λmax	O
em	O
=	O
590	O
nm	O
,	O
for	O
phospholipids	O
:	O
λmax	O
em	O
=	O
640	O
nm	O
(	O
Molecular	O
Probes	O
handbook	O
)	O
.	O

On	O
confocal	O
microscopy	O
pictures	O
,	O
the	O
phospholipid	O
background	O
of	O
both	O
macrophages	O
and	O
FM	O
appears	O
in	O
red	O
and	O
the	O
triacylglycerol	O
-	O
rich	O
lipid	O
bodies	O
appear	O
in	O
white	O
.	O

Cells	O
were	O
considered	O
to	O
be	O
positive	O
for	O
Nile	O
red	O
staining	O
when	O
more	O
than	O
50	O
%	O
of	O
the	O
cell	O
surface	O
was	O
stained	O
(	O
see	O
Figure	O
S2	O
)	O
.	O

Mycolic	O
acid	O
isolation	O
Bacterial	O
residues	O
obtained	O
after	O
lipid	O
extraction	O
with	O
organic	O
solvents	O
[	O
17	O
]	O
were	O
saponified	O
with	O
a	O
mixture	O
of	O
40	O
%	O
KOH	O
aqueous	O
solution	O
and	O
methoxyethanol	O
(	O
1∶7	O
,	O
v	O
/	O
v	O
)	O
at	O
110	O
°	O
C	O
for	O
3	O
hours	O
in	O
a	O
screw	O
-	O
capped	O
tube	O
.	O

After	O
acidification	O
,	O
fatty	O
acids	O
were	O
extracted	O
with	O
diethylether	O
,	O
derivatised	O
into	O
methyl	O
esters	O
with	O
diazomethane	O
and	O
analyzed	O
by	O
analytical	O
thin	O
-	O
layer	O
chromatography	O
on	O
silica	O
Gel	O
60	O
(	O
Silica	O
Gel	O
60	O
Macherey	O
-	O
Nagel	O
)	O
using	O
either	O
dicholoromethane	O
or	O
petroleum	O
ether	O
/	O
diethylether	O
(	O
9∶1	O
,	O
v	O
/	O
v	O
,	O
five	O
runs	O
)	O
.	O

Visualization	O
of	O
lipid	O
spots	O
was	O
performed	O
by	O
spraying	O
the	O
plates	O
with	O
molybdophosphoric	O
acid	O
(	O
10	O
%	O
in	O
ethanol	O
)	O
,	O
followed	O
by	O
charring	O
.	O

Processing	O
for	O
electron	O
microscopy	O
Granulomas	O
were	O
fixed	O
for	O
1	O
hour	O
at	O
room	O
temperature	O
with	O
2.5	O
%	O
glutaraldehyde	O
in	O
0.1	O
M	O
cacodylate	O
buffer	O
,	O
pH	O
7.2	O
,	O
containing	O
0.1	O
M	O
sucrose	O
,	O
5	O
mM	O
CaCl2	O
and	O
5	O
mM	O
MgCl2	O
.	O

After	O
two	O
successive	O
15-min	O
washes	O
with	O
the	O
same	O
buffer	O
,	O
the	O
granulomas	O
were	O
postfixed	O
for	O
1	O
hour	O
at	O
RT	O
with	O
1	O
%	O
osmium	O
tetroxide	O
(	O
Electron	O
Microscopy	O
Science	O
)	O
in	O
the	O
same	O
buffer	O
devoid	O
of	O
sucrose	O
.	O

The	O
granulomas	O
were	O
scraped	O
off	O
the	O
culture	O
dishes	O
with	O
a	O
rubber	O
policeman	O
and	O
concentrated	O
in	O
1	O
%	O
agarose	O
in	O
the	O
same	O
buffer	O
.	O

After	O
a	O
one	O
hour	O
treatment	O
at	O
room	O
temperature	O
with	O
1	O
%	O
uranyl	O
acetate	O
in	O
Veronal	O
buffer	O
,	O
the	O
samples	O
were	O
dehydrated	O
in	O
a	O
graded	O
series	O
of	O
ethanol	O
and	O
embedded	O
in	O
Spurr	O
resin	O
.	O

Thin	O
sections	O
were	O
stained	O
with	O
uranyl	O
acetate	O
and	O
lead	O
citrate	O
.	O

Image	O
acquisition	O
in	O
confocal	O
microscopy	O
The	O
images	O
were	O
obtained	O
using	O
a	O
Leica	O
confocal	O
fluorescence	O
microscope	O
(	O
SP2	O
)	O
equipped	O
with	O
a	O
Plan	O
Apo	O
40	O
×	O
1.4	O
Ph	O
6	O
objective	O
(	O
Olympus	O
Optical	O
)	O
and	O
CoolSNAP	O
-	O
Pro	O
CF	O
digital	O
camera	O
in	O
conjunction	O
with	O
Image	O
-	O
Pro	O
Plus	O
version	O
4.5.1.3	O
software	O
(	O
Media	O
Cybernetics	O
)	O
.	O

The	O
images	O
were	O
edited	O
using	O
Adobe	O
Photoshop	O
CS2	O
9	O
software	O
(	O
Adobe	O
Systems	O
)	O
.	O

Results	O
Foamy	O
macrophages	O
are	O
strongly	O
associated	O
with	O
necrotic	O
lesions	O
and	O
often	O
contain	O
M.	B
tuberculosis	I
We	O
analyzed	O
lymph	O
node	O
biopsies	O
from	O
10	O
tuberculous	O
patients	O
as	O
a	O
first	O
step	O
for	O
evaluating	O
the	O
role	O
of	O
FMs	O
within	O
tuberculous	O
granulomas	O
.	O

A	O
section	O
through	O
a	O
representative	O
biopsy	O
is	O
shown	O
in	O
Figure	O
1	O
.	O

Well	O
-	O
circumscribed	O
and	O
-differentiated	O
granulomatous	O
structures	O
were	O
observed	O
in	O
all	O
the	O
samples	O
(	O
Figure	O
1A	O
)	O
.	O

Classically	O
,	O
lesions	O
display	O
a	O
necrotic	O
center	O
(	O
N	O
)	O
,	O
an	O
interface	O
area	O
between	O
the	O
necrotic	O
center	O
and	O
the	O
histiocytes	O
(	O
I	O
)	O
,	O
and	O
some	O
peripheral	O
granulomas	O
(	O
G	O
)	O
.	O

Only	O
seven	O
out	O
of	O
ten	O
patients	O
presented	O
lesions	O
displaying	O
central	O
necrosis	O
(	O
Table	O
2	O
)	O
.	O

Staining	O
of	O
the	O
histology	O
samples	O
with	O
Oil	O
red	O
-	O
O	O
,	O
a	O
classic	O
lipid	O
stain	O
,	O
confirmed	O
the	O
presence	O
of	O
FMs	O
within	O
the	O
granulomatous	O
structures	O
in	O
six	O
out	O
of	O
seven	O
samples	O
presenting	O
necrosis	O
(	O
Figure	O
1B	O
)	O
,	O
whereas	O
no	O
FMs	O
were	O
found	O
in	O
the	O
three	O
non	O
-	O
necrotic	O
lesions	O
(	O
Table	O
2	O
)	O
.	O

Noteworthy	O
,	O
in	O
samples	O
with	O
necrotic	O
areas	O
,	O
FMs	O
were	O
always	O
found	O
in	O
the	O
interface	O
region	O
flanking	O
the	O
central	O
necrosis	O
(	O
Figure	O
1B	O
)	O
.	O

These	O
observations	O
firstly	O
confirmed	O
the	O
presence	O
of	O
FMs	O
in	O
most	O
TB	O
patients	O
'	O
lesions	O
thereby	O
suggesting	O
that	O
these	O
cells	O
play	O
an	O
important	O
role	O
in	O
the	O
formation	O
/	O
maintenance	O
of	O
such	O
lesions	O
.	O

Second	O
,	O
FMs	O
seem	O
to	O
be	O
associated	O
with	O
necrosis	O
,	O
which	O
is	O
a	O
hallmark	O
of	O
TB	O
lesions	O
,	O
since	O
they	O
were	O
observed	O
only	O
in	O
lesions	O
with	O
a	O
necrotic	O
center	O
and	O
preferentially	O
located	O
around	O
the	O
necrotic	O
area	O
.	O

Interestingly	O
,	O
staining	O
,	O
in	O
parallel	O
,	O
of	O
serial	O
thin	O
sections	O
from	O
a	O
patient	O
's	O
lesion	O
biopsy	O
with	O
Oil	O
red	O
-	O
O	O
(	O
Figure	O
1C	O
)	O
and	O
Ziehl	O
Nielsen	O
(	O
Figure	O
1D	O
)	O
,	O
showed	O
that	O
most	O
of	O
the	O
bacilli	O
(	O
arrow	O
)	O
were	O
located	O
in	O
the	O
same	O
area	O
as	O
FMs	O
,	O
thus	O
suggesting	O
a	O
strong	O
association	O
between	O
the	O
persisting	O
tubercle	O
bacilli	O
and	O
FMs	O
within	O
granulomas	O
.	O

M.	B
tuberculosis	I
induces	O
the	O
formation	O
of	O
FMs	O
within	O
in	O
vitro	O
human	B
tuberculous	O
granulomas	O
To	O
further	O
characterize	O
the	O
role	O
of	O
FMs	O
in	O
the	O
granulomatous	O
response	O
,	O
we	O
assessed	O
whether	O
FM	O
formation	O
in	O
granulomatous	O
structures	O
was	O
triggered	O
only	O
by	O
pathogenic	O
mycobacterial	O
species	O
(	O
M.tb	B
)	O
,	O
or	O
by	O
low	O
virulent	O
ones	O
(	O
M.	B
smegmatis	I
)	O
as	O
well	O
.	O

PBMCs	O
from	O
non	O
-	O
tuberculous	O
control	O
individuals	O
were	O
infected	O
with	O
M.tb	B
or	O
M.	B
smegmatis	I
,	O
following	O
the	O
procedure	O
previously	O
described	O
for	O
the	O
induction	O
of	O
granulomatous	O
structures	O
(	O
[	O
7	O
]	O
,	O
[	O
9	O
]	O
and	O
Figure	O
S1	O
)	O
.	O

Granuloma	O
cells	O
collected	O
at	O
days	O
3	O
and	O
11	O
were	O
stained	O
with	O
Oil	O
red	O
-	O
O	O
to	O
visualize	O
the	O
lipid	O
droplets	O
within	O
FMs	O
under	O
the	O
light	O
microscope	O
(	O
Figure	O
2	O
)	O
.	O

At	O
day	O
3	O
,	O
several	O
M.tb	B
-	O
induced	O
granuloma	O
cells	O
already	O
showed	O
lipid	O
bodies	O
(	O
Figure	O
2A	O
)	O
.	O

In	O
contrast	O
,	O
the	O
cells	O
collected	O
from	O
M.	B
smegmatis	I
-	O
induced	O
granulomas	O
were	O
seldom	O
(	O
5	O
%	O
)	O
positively	O
stained	O
(	O
Figure	O
2B	O
)	O
.	O

Interestingly	O
,	O
M.	B
avium	I
induced	O
FM	O
formation	O
in	O
a	O
similar	O
way	O
to	O
M.tb	B
(	O
not	O
shown	O
)	O
.	O

By	O
day	O
11	O
,	O
the	O
amount	O
of	O
positively	O
stained	O
cells	O
had	O
increased	O
in	O
M.tb	B
-	O
induced	O
granulomas	O
,	O
but	O
not	O
in	O
M.	B
smegmatis	I
-	O
induced	O
ones	O
.	O

In	O
addition	O
,	O
the	O
number	O
of	O
lipid	O
bodies	O
per	O
cell	O
increased	O
dramatically	O
with	O
time	O
,	O
as	O
depited	O
in	O
the	O
enlarged	O
views	O
(	O
Figures	O
2A	O
,	O
C	O
)	O
.	O

The	O
quantitative	O
evaluation	O
of	O
the	O
percentage	O
of	O
FMs	O
within	O
granulomas	O
induced	O
by	O
both	O
strains	O
confirmed	O
the	O
differences	O
observed	O
under	O
the	O
light	O
microscope	O
,	O
and	O
showed	O
a	O
seven	O
-	O
fold	O
difference	O
(	O
44	O
%	O
vs	O
6	O
%	O
respectively	O
)	O
between	O
M.tb	B
and	O
M.	B
smegmatis	I
in	O
terms	O
of	O
their	O
ability	O
to	O
induce	O
FM	O
formation	O
(	O
Figure	O
2D	O
)	O
.	O

Our	O
results	O
therefore	O
show	O
that	O
virulent	O
species	O
such	O
as	O
M.tb	B
and	O
M.	B
avium	I
,	O
contrary	O
to	O
poorly	O
or	O
avirulent	O
ones	O
such	O
as	O
M.	B
smegmatis	I
,	O
are	O
able	O
to	O
induce	O
the	O
formation	O
of	O
FMs	O
within	O
our	O
experimental	O
model	O
.	O

Oxygenated	O
mycolic	O
acids	O
induce	O
the	O
maturation	O
of	O
macrophages	O
into	O
FMs	O
Mycolic	O
acids	O
from	O
M.tb	B
incorporated	O
into	O
liposomes	O
were	O
recently	O
shown	O
to	O
trigger	O
the	O
differentiation	O
of	O
mice	B
peritoneal	O
macrophages	O
into	O
foamy	O
-	O
like	O
cells	O
[	O
21	O
]	O
.	O

Interestingly	O
,	O
both	O
M.tb	B
and	O
M.	B
avium	I
,	O
which	O
induce	O
FM	O
formation	O
,	O
express	O
a	O
family	O
of	O
oxygenated	O
mycolic	O
acids	O
,	O
especially	O
ketomycolic	O
acids	O
,	O
which	O
are	O
not	O
produced	O
by	O
M.	B
smegmatis	I
(	O
Figure	O
3A	O
)	O
.	O

In	O
this	O
context	O
,	O
inactivation	O
of	O
the	O
M.tb	B
hma	O
gene	O
(	O
mmaA4-Rv0642c	O
)	O
was	O
shown	O
to	O
abolish	O
the	O
synthesis	O
of	O
oxygenated	O
keto-	O
and	O
hydroxyl	O
-	O
mycolic	O
acid	O
in	O
the	O
mutant	O
strain	O
[	O
17	O
]	O
.	O

Conversely	O
,	O
transforming	O
M.	B
smegmatis	I
with	O
the	O
hma	O
gene	O
induced	O
the	O
production	O
of	O
both	O
keto-	O
and	O
hydroxyl	O
-	O
mycolic	O
acids	O
[	O
22	O
]	O
,	O
(	O
Figures	O
3B	O
,	O
C	O
)	O
.	O

In	O
the	O
light	O
of	O
both	O
data	O
,	O
we	O
anticipated	O
that	O
oxygenated	O
mycolic	O
acids	O
specifically	O
produced	O
by	O
M.tb	B
and	O
M.	B
avium	I
,	O
under	O
the	O
control	O
of	O
hma	O
,	O
are	O
responsible	O
for	O
FM	O
formation	O
within	O
human	B
granulomas	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
compared	O
FM	O
formation	O
after	O
infection	O
of	O
PBMCs	O
with	O
either	O
the	O
wild	O
-	O
type	O
,	O
or	O
the	O
hma	O
-	O
expressing	O
M.	B
smegmatis	I
strain	O
(	O
M.	B
smegmatis	I
/	O
hma	O
)	O
.	O

Granulomas	O
cells	O
were	O
collected	O
3	O
days	O
later	O
and	O
stained	O
with	O
Oil	O
red	O
-	O
O	O
to	O
visualize	O
lipid	O
bodies	O
.	O

Wild	O
-	O
type	O
M.	B
smegmatis	I
-	O
induced	O
granulomas	O
displayed	O
only	O
5.5	O
%	O
of	O
FM	O
,	O
whereas	O
the	O
hma	O
gene	O
-	O
expressing	O
strain	O
induced	O
granulomas	O
bearing	O
a	O
majority	O
(	O
67	O
%	O
)	O
of	O
brightly	O
stained	O
Oil	O
red	O
-	O
O	O
positive	O
cells	O
(	O
Figures	O
4A	O
,	O
B	O
,	O
C	O
)	O
.	O

Induction	O
of	O
FM	O
formation	O
was	O
even	O
greater	O
if	O
isolated	O
macrophages	O
were	O
directly	O
infected	O
with	O
either	O
strain	O
.	O

After	O
only	O
4	O
hours	O
of	O
infection	O
,	O
M.	B
smegmatis	I
/	O
hma	O
had	O
already	O
transformed	O
64	O
%	O
of	O
the	O
infected	O
macrophages	O
into	O
lipid	O
body	O
-	O
positive	O
cells	O
(	O
see	O
Figure	O
S2	O
for	O
Nile	O
red	O
positive	O
cells	O
)	O
,	O
whereas	O
only	O
9	O
%	O
of	O
the	O
cells	O
contained	O
lipid	O
bodies	O
after	O
infection	O
with	O
the	O
wild	O
-	O
type	O
strain	O
(	O
Figures	O
4D	O
,	O
E	O
,	O
F	O
)	O
.	O

To	O
confirm	O
the	O
specific	O
role	O
of	O
hma	O
-	O
dependent	O
oxygenated	O
mycolic	O
acids	O
in	O
FM	O
formation	O
,	O
and	O
to	O
rule	O
out	O
a	O
possible	O
combined	O
effect	O
of	O
oxygenated	O
mycolic	O
-	O
acids	O
with	O
other	O
mycobacterial	O
components	O
,	O
mycolic	O
acids	O
isolated	O
from	O
wild	O
-	O
type	O
M.	B
smegmatis	I
or	O
M.	B
smegmatis	I
/	O
hma	O
were	O
incubated	O
with	O
isolated	O
macrophages	O
.	O

With	O
mycolic	O
acids	O
isolated	O
from	O
the	O
wild	O
-	O
type	O
strain	O
,	O
only	O
13	O
%	O
of	O
the	O
macrophages	O
were	O
transformed	O
into	O
FM	O
whereas	O
66	O
%	O
of	O
the	O
macrophages	O
incubated	O
with	O
mycolic	O
acids	O
isolated	O
from	O
M.	B
smegmatis	I
/	O
hma	O
were	O
strongly	O
stained	O
for	O
lipid	O
bodies	O
(	O
Figures	O
4	O
G	O
,	O
H	O
,	O
I	O
)	O
.	O

These	O
results	O
therefore	O
indicate	O
that	O
oxygenated	O
mycolic	O
acids	O
play	O
a	O
leading	O
role	O
in	O
M.tb	B
-	O
induced	O
FM	O
formation	O
.	O

The	O
phagocytic	O
and	O
bactericidal	O
activities	O
are	O
arrested	O
in	O
FMs	O
To	O
assess	O
the	O
function	O
of	O
granuloma	O
FM	O
,	O
we	O
first	O
evaluated	O
the	O
ability	O
of	O
such	O
cells	O
to	O
mediate	O
phagocytosis	O
.	O

For	O
this	O
purpose	O
,	O
macrophages	O
isolated	O
from	O
PBMCs	O
were	O
exposed	O
to	O
M.	B
smegmatis	I
/	O
hma	O
-	O
derived	O
mycolic	O
acids	O
to	O
induce	O
FM	O
formation	O
.	O

Two	O
days	O
later	O
,	O
the	O
cell	O
population	O
contained	O
a	O
mixture	O
of	O
FM	O
(	O
50–70	O
%	O
)	O
and	O
macrophages	O
(	O
30–50	O
%	O
)	O
,	O
as	O
assessed	O
by	O
Nile	O
red	O
staining	O
(	O
not	O
shown	O
)	O
.	O

The	O
mixed	O
cell	O
population	O
was	O
infected	O
with	O
FITC	O
-	O
labelled	O
M.	B
smegmatis	I
.	O

Intracellular	O
bacilli	O
were	O
found	O
only	O
within	O
Nile	O
red	O
-	O
negative	O
macrophages	O
thereby	O
indicating	O
that	O
FMs	O
are	O
unable	O
to	O
ingest	O
bacteria	O
(	O
Figure	O
5A	O
)	O
.	O

This	O
result	O
was	O
reproduced	O
using	O
other	O
mycobacterial	O
strains	O
,	O
such	O
as	O
M.tb	B
and	O
M.	B
bovis	I
BCG	I
,	O
for	O
infection	O
(	O
not	O
shown	O
)	O
.	O

These	O
results	O
further	O
suggest	O
that	O
the	O
bacilli	O
found	O
in	O
granuloma	O
FMs	O
were	O
internalized	O
by	O
macrophages	O
prior	O
to	O
their	O
transformation	O
into	O
FMs	O
.	O

To	O
assess	O
whether	O
FMs	O
are	O
able	O
to	O
develop	O
a	O
respiratory	O
burst	O
,	O
which	O
is	O
a	O
major	O
intracellular	O
bactericidal	O
activity	O
,	O
the	O
ability	O
of	O
Nile	O
red	O
positive	O
cells	O
(	O
i.e.	O
FMs	O
)	O
to	O
mediate	O
NBT	O
reduction	O
was	O
determined	O
.	O

As	O
shown	O
in	O
Figure	O
5D	O
,	O
only	O
8	O
%	O
of	O
the	O
NBT	O
-	O
positive	O
cells	O
(	O
Figure	O
5B	O
)	O
were	O
Nile	O
red	O
positive	O
FMs	O
(	O
Figure	O
5C	O
)	O
.	O

This	O
strongly	O
suggests	O
that	O
once	O
macrophages	O
have	O
differentiated	O
into	O
FMs	O
,	O
they	O
lose	O
the	O
ability	O
to	O
mediate	O
intracellular	O
bactericidal	O
activity	O
.	O

We	O
postulate	O
that	O
FMs	O
could	O
,	O
therefore	O
,	O
form	O
a	O
secure	O
reservoir	O
for	O
the	O
tubercle	O
bacilli	O
.	O

M.	B
tuberculosis	I
persists	O
in	O
a	O
dormant	O
non	O
-	O
replicative	O
state	O
in	O
FMs	O
To	O
evaluate	O
the	O
validity	O
of	O
the	O
above	O
hypothesis	O
,	O
we	O
analyzed	O
the	O
ability	O
of	O
M.tb	B
to	O
replicate	O
within	O
FMs	O
.	O

For	O
this	O
purpose	O
,	O
isolated	O
macrophages	O
were	O
infected	O
with	O
M.tb	B
.	O

At	O
selected	O
intervals	O
post	O
-	O
infection	O
,	O
the	O
amount	O
of	O
bacilli	O
per	O
cell	O
was	O
compared	O
in	O
both	O
non	O
-	O
differentiated	O
macrophages	O
and	O
FMs	O
(	O
Figure	O
5E	O
)	O
.	O

Until	O
day	O
6	O
,	O
M.tb	B
replicated	O
in	O
a	O
similar	O
fashion	O
in	O
both	O
cell	O
types	O
.	O

In	O
contrast	O
,	O
after	O
day	O
6	O
post	O
-	O
infection	O
,	O
the	O
amount	O
of	O
bacilli	O
remained	O
stationary	O
in	O
FMs	O
,	O
whereas	O
it	O
continued	O
to	O
increase	O
in	O
macrophages	O
.	O

It	O
is	O
interesting	O
to	O
note	O
that	O
arrest	O
of	O
bacterial	O
replication	O
coincided	O
with	O
completion	O
of	O
macrophage	O
differentiation	O
into	O
FM	O
,	O
i.e.	O
starting	O
from	O
day	O
3	O
post	O
-	O
infection	O
.	O

Our	O
data	O
suggest	O
,	O
that	O
the	O
bacilli	O
found	O
in	O
granuloma	O
FMs	O
were	O
internalized	O
by	O
macrophages	O
prior	O
to	O
their	O
differentiation	O
into	O
FMs	O
and	O
also	O
that	O
bacilli	O
can	O
terminate	O
their	O
replication	O
cycle	O
while	O
macrophages	O
are	O
being	O
transformed	O
into	O
FM	O
,	O
but	O
that	O
replication	O
comes	O
to	O
a	O
halt	O
as	O
soon	O
as	O
the	O
maturation	O
process	O
is	O
complete	O
.	O

We	O
next	O
determined	O
whether	O
the	O
non	O
-	O
replicative	O
bacilli	O
observed	O
in	O
FMs	O
were	O
still	O
alive	O
.	O

For	O
this	O
purpose	O
,	O
we	O
analyzed	O
the	O
expression	O
of	O
a	O
series	O
of	O
genes	O
known	O
to	O
be	O
up	O
-	O
regulated	O
when	O
bacilli	O
are	O
in	O
a	O
persistent	O
non	O
-	O
replicating	O
state	O
[	O
23	O
]	O
,	O
[	O
24	O
]	O
.	O

RNA	O
was	O
,	O
therefore	O
,	O
prepared	O
from	O
both	O
in	O
vitro	O
-	O
grown	O
M.tb	B
and	O
intracellular	O
bacilli	O
at	O
day	O
6	O
and	O
12	O
post	O
-	O
infection	O
.	O

The	O
respective	O
amounts	O
of	O
RNA	O
corresponding	O
to	O
isocitrate	O
lyase	O
,	O
α	O
-	O
cristallin	O
,	O
a	O
very	O
hypothetical	O
7.6	O
kDa	O
protein	O
,	O
CHP	O
and	O
DosR	O
proteins	O
were	O
then	O
quantified	O
by	O
RT	O
-	O
PCR	O
.	O

As	O
shown	O
in	O
Table	O
3	O
,	O
the	O
dormancy	O
genes	O
were	O
all	O
strongly	O
up	O
-	O
regulated	O
in	O
intracellular	O
bacilli	O
at	O
day	O
12	O
post	O
-	O
infection	O
.	O

These	O
results	O
further	O
demonstrate	O
that	O
the	O
bacilli	O
are	O
not	O
killed	O
in	O
FMs	O
,	O
but	O
rather	O
persist	O
in	O
a	O
dormant	O
,	O
and	O
therefore	O
non	O
-	O
replicative	O
stage	O
[	O
25	O
]	O
.	O

Interestingly	O
,	O
the	O
dormancy	O
genes	O
were	O
not	O
as	O
strongly	O
expressed	O
at	O
day	O
6	O
,	O
time	O
at	O
which	O
bacteria	O
were	O
still	O
able	O
to	O
replicate	O
in	O
macrophages	O
undergoing	O
differentiation	O
into	O
FMs	O
.	O

Characterization	O
of	O
M.tb	B
survival	O
within	O
FMs	O
and	O
interaction	O
with	O
lipid	O
bodies	O
To	O
gain	O
further	O
insight	O
into	O
the	O
morphological	O
appearance	O
of	O
M.tb	B
within	O
FM	O
and	O
into	O
the	O
interactions	O
between	O
FM	O
lipid	O
bodies	O
(	O
LB	O
)	O
and	O
M.tb	B
-	O
containing	O
phagosomes	O
,	O
granulomas	O
were	O
fixed	O
and	O
processed	O
for	O
conventional	O
electron	O
microscopy	O
at	O
days	O
3	O
and	O
11	O
post	O
-	O
infection	O
.	O

Whatever	O
the	O
time	O
point	O
at	O
which	O
granuloma	O
cells	O
were	O
observed	O
,	O
bacteria	O
were	O
all	O
enclosed	O
in	O
phagosomes	O
,	O
most	O
of	O
which	O
contained	O
a	O
single	O
bacterium	O
.	O

None	O
of	O
them	O
(	O
over	O
a	O
thousand	O
which	O
were	O
examined	O
under	O
the	O
electron	O
microscope	O
)	O
were	O
free	O
in	O
the	O
cytoplasm	O
and	O
only	O
one	O
was	O
enclosed	O
in	O
a	O
classical	O
autophagic	O
vacuole	O
.	O

At	O
day	O
3	O
post	O
-	O
infection	O
,	O
FMs	O
profiles	O
(	O
thin	O
sections	O
)	O
were	O
scarce	O
,	O
representing	O
at	O
most	O
9	O
%	O
of	O
the	O
total	O
population	O
of	O
macrophage	O
profiles	O
observed	O
under	O
the	O
electron	O
microscope	O
(	O
Figure	O
6A	O
)	O
.	O

In	O
addition	O
,	O
86	O
%	O
of	O
the	O
FM	O
profiles	O
displayed	O
at	O
most	O
5	O
small	O
LBs	O
(	O
Figure	O
6B	O
)	O
.	O

At	O
this	O
stage	O
of	O
granuloma	O
formation	O
,	O
bacteria	O
were	O
infrequent	O
in	O
FM	O
,	O
but	O
were	O
found	O
in	O
other	O
types	O
of	O
macrophages	O
.	O

One	O
of	O
these	O
displayed	O
large	O
numbers	O
of	O
vacuoles	O
containing	O
flocculent	O
material	O
and	O
often	O
one	O
or	O
two	O
LBs	O
.	O

Over	O
95	O
%	O
of	O
the	O
bacteria	O
located	O
in	O
the	O
different	O
granuloma	O
macrophages	O
were	O
morphologically	O
intact	O
,	O
and	O
therefore	O
alive	O
[	O
26	O
]	O
.	O

Intact	O
bacteria	O
present	O
no	O
breaks	O
in	O
the	O
cell	O
wall	O
or	O
cytoplasmic	O
membrane	O
and	O
their	O
cytoplasm	O
has	O
preserved	O
its	O
ultrastructural	O
organization	O
and	O
electron	O
opacity	O
.	O

Furthermore	O
,	O
they	O
display	O
no	O
electron	O
translucent	O
intracytoplasmic	O
lipid	O
inclusions	O
(	O
ILI	O
)	O
.	O

Bacteria	O
were	O
also	O
observed	O
in	O
between	O
cells	O
,	O
probably	O
as	O
a	O
result	O
of	O
cell	O
lysis	O
within	O
granulomas	O
.	O

These	O
bacteria	O
were	O
also	O
morphologically	O
intact	O
and	O
devoid	O
of	O
ILI	O
(	O
not	O
shown	O
)	O
.	O

At	O
day	O
11	O
post	O
-	O
infection	O
,	O
M.tb	B
-	O
containing	O
macrophages	O
displaying	O
large	O
numbers	O
of	O
vacuoles	O
with	O
flocculent	O
material	O
were	O
less	O
frequently	O
observed	O
.	O

Interestingly	O
,	O
the	O
amount	O
of	O
such	O
vacuoles	O
had	O
strongly	O
decreased	O
in	O
most	O
of	O
these	O
cells	O
while	O
the	O
number	O
of	O
LBs	O
had	O
increased	O
.	O

The	O
percentage	O
of	O
FM	O
had	O
increased	O
to	O
reach	O
41	O
%	O
of	O
the	O
total	O
population	O
of	O
macrophage	O
profiles	O
within	O
the	O
granulomas	O
(	O
Figure	O
6A	O
)	O
.	O

From	O
these	O
observations	O
,	O
it	O
is	O
tempting	O
to	O
assume	O
that	O
the	O
highly	O
vesiculated	O
macrophages	O
give	O
rise	O
to	O
FMs	O
.	O

Within	O
FMs	O
,	O
the	O
size	O
and	O
amount	O
of	O
LBs	O
had	O
also	O
increased	O
with	O
time	O
since	O
48	O
%	O
of	O
the	O
FM	O
profiles	O
now	O
displayed	O
more	O
than	O
5	O
LB	O
per	O
FM	O
thin	O
section	O
(	O
Figure	O
6B	O
)	O
,	O
randomly	O
distributed	O
within	O
the	O
cells	O
(	O
Figure	O
6C	O
)	O
.	O

About	O
30	O
%	O
of	O
the	O
FM	O
profiles	O
displayed	O
between	O
1	O
and	O
20	O
bacteria	O
,	O
which	O
were	O
morphologically	O
intact	O
and	O
enclosed	O
within	O
phagosomes	O
(	O
Figure	O
6C	O
,	O
enlarged	O
view	O
)	O
.	O

The	O
interaction	O
between	O
these	O
bacteria	O
and	O
the	O
cellular	O
LBs	O
was	O
next	O
examined	O
at	O
day	O
11	O
.	O

Sixty	O
percent	O
of	O
the	O
bacilli	O
were	O
scattered	O
throughout	O
the	O
FMs	O
and	O
displayed	O
no	O
obvious	O
signs	O
of	O
interaction	O
with	O
the	O
cellular	O
LBs	O
.	O

A	O
small	O
fraction	O
of	O
the	O
bacteria	O
(	O
21	O
%	O
)	O
,	O
however	O
,	O
were	O
observed	O
in	O
the	O
close	O
vicinity	O
of	O
cellular	O
LBs	O
.	O

The	O
membrane	O
of	O
the	O
phagosomes	O
in	O
which	O
they	O
were	O
enclosed	O
clearly	O
interacted	O
with	O
cellular	O
LBs	O
(	O
Figures	O
6C	O
,	O
7A	O
,	O
7B	O
,	O
arrows	O
)	O
and	O
became	O
tightly	O
apposed	O
to	O
an	O
increasingly	O
larger	O
surface	O
area	O
of	O
the	O
LB	O
.	O

As	O
a	O
result	O
,	O
the	O
phagosomes	O
started	O
to	O
surround	O
LBs	O
in	O
a	O
zippering	O
fashion	O
(	O
Figures	O
7E	O
,	O
F	O
)	O
.	O

Ultimately	O
,	O
bacilli	O
(	O
19	O
%	O
)	O
were	O
translocated	O
to	O
cellular	O
LBs	O
(	O
Figure	O
7C	O
)	O
.	O

From	O
these	O
observations	O
,	O
it	O
is	O
tempting	O
to	O
assume	O
that	O
M.tb	B
-	O
containing	O
phagosomes	O
engulf	O
cellular	O
LBs	O
rather	O
than	O
fusing	O
with	O
them	O
.	O

This	O
process	O
,	O
which	O
is	O
reminiscent	O
of	O
autophagy	O
,	O
resulted	O
in	O
the	O
transfer	O
of	O
free	O
bacteria	O
into	O
the	O
lumen	O
of	O
cellular	O
LBs	O
(	O
Figure	O
7C	O
)	O
,	O
some	O
of	O
which	O
displayed	O
up	O
to	O
21	O
bacteria	O
(	O
Figure	O
7	O
G	O
)	O
.	O

Interestingly	O
,	O
only	O
altered	O
M.tb	B
found	O
within	O
FM	O
lipid	O
bodies	O
exhibited	O
electron	O
translucent	O
ILIs	O
(	O
Figures	O
7D	O
,	O
G	O
)	O
,	O
thereby	O
suggesting	O
that	O
they	O
are	O
able	O
to	O
accumulate	O
host	O
cell	O
lipids	O
.	O

In	O
previous	O
work	O
,	O
the	O
term	O
altered	O
bacteria	O
had	O
been	O
used	O
to	O
define	O
live	O
bacteria	O
that	O
had	O
acquired	O
ILIs	O
[	O
26	O
]	O
.	O

Since	O
the	O
presence	O
of	O
ILIs	O
within	O
the	O
cytoplasm	O
of	O
M.tb	B
is	O
typical	O
for	O
non	O
-	O
replicating	O
bacteria	O
in	O
a	O
state	O
of	O
dormancy	O
[	O
27	O
]	O
,	O
this	O
further	O
confirms	O
that	O
these	O
bacteria	O
are	O
dormant	O
.	O

Discussion	O
Studies	O
carried	O
out	O
several	O
decades	O
ago	O
suggested	O
that	O
postprimary	O
tuberculosis	O
starts	O
as	O
a	O
lipid	O
pneumonia	O
[	O
28	O
]	O
,	O
[	O
29	O
]	O
.	O

Indeed	O
,	O
following	O
a	O
first	O
inflammatory	O
process	O
leading	O
to	O
exudates	O
of	O
mononuclear	O
cells	O
within	O
alveolar	O
spaces	O
,	O
early	O
pathologists	O
observed	O
an	O
accumulation	O
of	O
lipid	O
droplets	O
in	O
alveolar	O
macrophages	O
of	O
TB	O
patients	O
.	O

Tubercle	O
bacilli	O
were	O
shown	O
to	O
reside	O
in	O
these	O
lipid	O
-	O
rich	O
macrophages	O
which	O
were	O
named	O
foamy	O
macrophages	O
(	O
FMs	O
)	O
[	O
30	O
]	O
.	O

Recently	O
,	O
histo	O
-	O
pathological	O
analysis	O
of	O
biopsies	O
from	O
patients	O
with	O
untreated	O
tuberculosis	O
confirmed	O
the	O
century	O
-	O
old	O
histological	O
descriptions	O
of	O
postprimary	O
tuberculosis	O
[	O
10	O
]	O
.	O

In	O
this	O
study	O
,	O
Hunter	O
et	O
al	O
showed	O
that	O
postprimary	O
tuberculosis	O
begins	O
as	O
a	O
lipid	O
pneumonia	O
with	O
the	O
accumulation	O
of	O
large	O
amounts	O
of	O
lipid	O
-	O
rich	O
FMs	O
,	O
accompanied	O
by	O
bronchial	O
obstruction	O
.	O

It	O
was	O
also	O
shown	O
that	O
in	O
alveolar	O
foamy	O
macrophages	O
,	O
the	O
bacilli	O
were	O
mainly	O
found	O
within	O
lipid	O
droplets	O
.	O

All	O
these	O
observations	O
underline	O
the	O
important	O
,	O
yet	O
often	O
neglected	O
,	O
role	O
of	O
lipid	O
accumulation	O
,	O
and	O
more	O
precisely	O
FM	O
formation	O
,	O
at	O
the	O
infectious	O
site	O
in	O
the	O
physiopathology	O
of	O
TB	O
.	O

In	O
murine	O
experimental	O
models	O
,	O
FMs	O
accumulate	O
within	O
the	O
outermost	O
layer	O
of	O
granulomatous	O
structures	O
occupying	O
the	O
alveolar	O
spaces	O
during	O
the	O
chronic	O
phase	O
of	O
infection	O
.	O

This	O
strongly	O
suggests	O
that	O
FMs	O
could	O
be	O
involved	O
in	O
lesion	O
cleaning	O
via	O
phagocytic	O
uptake	O
of	O
cellular	O
debris	O
generated	O
by	O
the	O
local	O
inflammatory	O
response	O
.	O

Once	O
filled	O
with	O
debris	O
,	O
FMs	O
would	O
leave	O
the	O
parenchyma	O
through	O
the	O
alveolar	O
spaces	O
up	O
to	O
the	O
superior	O
bronchial	O
tree	O
,	O
to	O
be	O
finally	O
swallowed	O
and	O
digested	O
in	O
the	O
stomach	O
[	O
31	O
]	O
.	O

In	O
fact	O
,	O
this	O
process	O
is	O
very	O
well	O
known	O
,	O
and	O
is	O
a	O
crucial	O
factor	O
for	O
TB	O
diagnosis	O
in	O
children	O
.	O

As	O
infants	O
do	O
not	O
usually	O
generate	O
cavitary	O
lesions	O
,	O
and	O
because	O
it	O
is	O
difficult	O
to	O
detect	O
bacilli	O
in	O
the	O
sputum	O
,	O
the	O
diagnosis	O
is	O
linked	O
to	O
the	O
detection	O
of	O
bacilli	O
in	O
the	O
gastrointestinal	O
lavage	O
[	O
32	O
]	O
.	O

We	O
show	O
that	O
M.tb	B
-	O
induced	O
the	O
transformation	O
of	O
in	O
vitro	O
-	O
grown	O
human	B
granuloma	O
macrophages	O
into	O
FMs	O
within	O
6	O
days	O
,	O
and	O
even	O
more	O
rapidly	O
(	O
3–4	O
hours	O
)	O
in	O
cultured	O
macrophages	O
.	O

Although	O
this	O
event	O
occurs	O
more	O
quickly	O
than	O
in	O
vivo	O
,	O
or	O
in	O
animal	O
models	O
,	O
our	O
data	O
are	O
consistent	O
with	O
the	O
above	O
in	O
vivo	O
observations	O
.	O

Within	O
FMs	O
,	O
bacilli	O
and	O
LBs	O
were	O
often	O
tightly	O
linked	O
,	O
to	O
the	O
point	O
that	O
a	O
non	O
-	O
negligible	O
amount	O
of	O
bacteria	O
were	O
ultimately	O
observed	O
within	O
LBs	O
.	O

Interestingly	O
,	O
some	O
of	O
the	O
bacilli	O
transferred	O
into	O
lipid	O
bodies	O
displayed	O
their	O
own	O
intracytoplasmic	O
lipid	O
inclusions	O
,	O
which	O
are	O
considered	O
to	O
be	O
one	O
of	O
the	O
hallmarks	O
of	O
non	O
-	O
replicating	O
(	O
dormant	O
)	O
M.tb	B
[	O
27	O
]	O
.	O

The	O
recent	O
observation	O
of	O
persistent	O
ILI	O
-	O
containing	O
tubercle	O
bacilli	O
within	O
adipocyte	O
LBs	O
[	O
33	O
]	O
is	O
in	O
good	O
agreement	O
with	O
our	O
observations	O
.	O

Since	O
bacilli	O
residing	O
in	O
phagosomes	O
that	O
do	O
not	O
interact	O
with	O
cellular	O
lipid	O
bodies	O
do	O
not	O
display	O
ILIs	O
,	O
it	O
is	O
tempting	O
to	O
assume	O
that	O
lipids	O
within	O
ILIs	O
are	O
of	O
cellular	O
origin	O
.	O

The	O
accumulation	O
of	O
lipids	O
within	O
bacilli	O
[	O
47	O
]	O
,	O
via	O
interaction	O
with	O
FM	O
lipid	O
bodies	O
could	O
,	O
therefore	O
,	O
be	O
crucial	O
to	O
M.tb	B
persistence	O
.	O

It	O
is	O
indeed	O
known	O
that	O
M.tb	B
accumulates	O
lipids	O
,	O
and	O
more	O
precisely	O
triacylglycerols	O
,	O
during	O
dormancy	O
[	O
34	O
]	O
,	O
[	O
35	O
]	O
from	O
which	O
it	O
derives	O
both	O
carbon	O
and	O
energy	O
for	O
its	O
own	O
metabolism	O
.	O

Intracellular	O
persistence	O
of	O
M.tb	B
is	O
also	O
critically	O
linked	O
to	O
the	O
acquisition	O
of	O
host	O
cholesterol	O
through	O
the	O
Mce4	O
transporter	O
system	O
[	O
36	O
]	O
.	O

The	O
question	O
that	O
arises	O
is	O
how	O
do	O
bacteria	O
gain	O
access	O
to	O
lipids	O
from	O
LB	O
?	O

Direct	O
fusion	O
of	O
phagosomes	O
with	O
FM	O
lipid	O
bodies	O
seems	O
unlikely	O
as	O
the	O
membranes	O
of	O
both	O
structures	O
are	O
quite	O
different	O
from	O
one	O
another	O
.	O

Our	O
observations	O
suggest	O
instead	O
that	O
once	O
M.tb	B
-	O
containing	O
phagosomes	O
have	O
established	O
close	O
contact	O
with	O
a	O
lipid	O
body	O
,	O
they	O
surround	O
and	O
engulf	O
the	O
latter	O
by	O
a	O
process	O
that	O
remains	O
to	O
be	O
deciphered	O
.	O

This	O
phenomenon	O
is	O
somewhat	O
reminiscent	O
of	O
autophagy	O
,	O
as	O
observed	O
under	O
conditions	O
of	O
cholesterol	O
depletion	O
in	O
macrophages	O
infected	O
with	O
M.	B
avium	I
[	O
37	O
]	O
.	O

After	O
degradation	O
of	O
the	O
resulting	O
inner	O
membrane	O
,	O
bacteria	O
would	O
be	O
freed	O
within	O
the	O
lipids	O
of	O
the	O
engulfed	O
LB	O
,	O
and	O
therefore	O
be	O
in	O
direct	O
contact	O
with	O
cellular	O
lipids	O
.	O

How	O
bacilli	O
translocate	O
the	O
cellular	O
lipids	O
to	O
their	O
own	O
cytoplasm	O
remains	O
to	O
be	O
established	O
.	O

Another	O
important	O
phenomenon	O
underlined	O
by	O
our	O
study	O
is	O
the	O
strong	O
correlation	O
between	O
the	O
presence	O
of	O
FMs	O
in	O
the	O
granulomatous	O
structures	O
and	O
the	O
development	O
of	O
necrosis	O
within	O
the	O
lesion	O
,	O
as	O
suggested	O
by	O
Pagel	O
over	O
80	O
years	O
ago	O
[	O
29	O
]	O
.	O

Interestingly	O
,	O
FMs	O
were	O
systematically	O
located	O
at	O
the	O
interface	O
region	O
between	O
the	O
histiocytes	O
and	O
the	O
central	O
necrosis	O
area	O
of	O
the	O
biopsied	O
lesions	O
.	O

Although	O
necrosis	O
formation	O
could	O
depend	O
on	O
an	O
indirect	O
effect	O
of	O
the	O
global	O
immune	O
response	O
,	O
our	O
data	O
indicate	O
that	O
the	O
formation	O
of	O
FMs	O
is	O
an	O
important	O
factor	O
favoring	O
the	O
appearance	O
of	O
necrosis	O
.	O

Analysis	O
of	O
larger	O
series	O
of	O
biopsy	O
samples	O
are	O
,	O
however	O
,	O
needed	O
to	O
definitely	O
demonstrate	O
our	O
actual	O
hypothesis	O
according	O
to	O
which	O
FMs	O
play	O
a	O
direct	O
and	O
unique	O
role	O
in	O
necrosis	O
formation	O
.	O

Consistent	O
with	O
this	O
hypothesis	O
,	O
we	O
observed	O
that	O
FMs	O
induced	O
from	O
M.tb	B
-	O
infected	O
macrophages	O
displayed	O
permanent	O
TNF	O
-	O
α	O
secretion	O
,	O
a	O
potent	O
pro	O
-	O
necrotic	O
factor	O
,	O
whereas	O
M.	B
smegmatis	I
-	O
infected	O
macrophages	O
were	O
poor	O
producers	O
of	O
TNF	O
-	O
α	O
.	O

At	O
day	O
4	O
post	O
-	O
infection	O
,	O
TNF	O
-	O
α	O
secretion	O
was	O
indeed	O
twofold	O
higher	O
in	O
macrophages	O
(	O
of	O
which	O
70	O
%	O
had	O
differentiated	O
into	O
FMs	O
)	O
infected	O
with	O
M.tb	B
than	O
in	O
those	O
infected	O
with	O
M.	B
smegmatis	I
,	O
as	O
measured	O
both	O
by	O
ELISA	O
and	O
RNA	O
quantification	O
(	O
Peyron	O
,	O
unpublished	O
observations	O
)	O
.	O

However	O
,	O
one	O
must	O
keep	O
in	O
mind	O
that	O
the	O
association	O
of	O
FMs	O
and	O
necrosis	O
may	O
be	O
the	O
consequence	O
of	O
the	O
FM	O
cleaning	O
process	O
of	O
lipoproteins	O
released	O
into	O
the	O
necrotic	O
tissue	O
,	O
as	O
observed	O
in	O
atherosclerosis	O
lesions	O
[	O
38	O
]	O
.	O

It	O
is	O
thus	O
tempting	O
to	O
propose	O
that	O
M.tb	B
mycolic	O
acids	O
may	O
be	O
responsible	O
for	O
the	O
development	O
of	O
necrotic	O
lesions	O
,	O
due	O
to	O
their	O
ability	O
to	O
induce	O
TNF	O
-	O
α	O
production	O
by	O
FMs	O
.	O

Whether	O
mycolic	O
acids	O
are	O
directly	O
involved	O
in	O
TNF	O
-	O
α	O
production	O
,	O
or	O
only	O
indirectly	O
by	O
inducing	O
FM	O
formation	O
,	O
remains	O
a	O
matter	O
of	O
debate	O
currently	O
under	O
study	O
.	O

Our	O
observations	O
are	O
strikingly	O
similar	O
to	O
the	O
phenomena	O
described	O
for	O
postprimary	O
tuberculosis	O
,	O
that	O
seems	O
to	O
begin	O
as	O
localized	O
foci	O
of	O
pneumonia	O
followed	O
by	O
massive	O
necrosis	O
leading	O
to	O
the	O
formation	O
of	O
pulmonary	O
cavities	O
[	O
10	O
]	O
.	O

If	O
this	O
proves	O
to	O
be	O
the	O
case	O
,	O
then	O
the	O
traditionally	O
admitted	O
phenomenon	O
of	O
cavitation	O
arising	O
from	O
the	O
erosion	O
of	O
caseating	O
granulomatous	O
structures	O
from	O
bronchi	O
can	O
be	O
ruled	O
out	O
[	O
39	O
]	O
.	O

In	O
our	O
study	O
,	O
we	O
successfully	O
induced	O
FM	O
formation	O
from	O
isolated	O
macrophages	O
infected	O
with	O
M.tb	B
,	O
i.e.	O
outside	O
a	O
granulomatous	O
structure	O
,	O
which	O
is	O
consistent	O
with	O
Hunter	O
's	O
recent	O
proposal	O
.	O

Until	O
now	O
,	O
mycolic	O
acids	O
have	O
been	O
considered	O
to	O
be	O
indirectly	O
involved	O
in	O
virulence	O
mechanisms	O
as	O
being	O
part	O
of	O
complex	O
molecules	O
of	O
the	O
mycobacterial	O
envelope	O
.	O

The	O
most	O
widely	O
studied	O
mycolic	O
acid	O
-	O
containing	O
mycobacterial	O
compound	O
trehalose	O
6,6′	O
dimycolate	O
(	O
TDM	O
)	O
,	O
has	O
been	O
extensively	O
analyzed	O
for	O
its	O
role	O
in	O
virulence	O
since	O
the	O
mid	O
-	O
fifties	O
[	O
40	O
]	O
.	O

Recently	O
,	O
it	O
was	O
shown	O
to	O
interfere	O
with	O
the	O
host	O
granulomatous	O
response	O
[	O
41	O
]	O
.	O

Overall	O
,	O
TDM	O
was	O
mainly	O
shown	O
to	O
mediate	O
macrophage	O
activation	O
and	O
a	O
Th1-type	O
response	O
to	O
M.tb	B
infection	O
(	O
for	O
review	O
,	O
see	O
[	O
25	O
]	O
)	O
.	O

Our	O
results	O
demonstrate	O
a	O
direct	O
role	O
of	O
oxygenated	O
mycolic	O
acids	O
for	O
FM	O
formation	O
,	O
independently	O
from	O
the	O
appearance	O
and	O
stage	O
of	O
the	O
disease	O
.	O

M.tb	B
-	O
specific	O
mycolic	O
acids	O
indeed	O
trigger	O
the	O
transformation	O
of	O
both	O
isolated	O
and	O
granuloma	O
macrophages	O
,	O
into	O
FM	O
.	O

Given	O
the	O
absence	O
of	O
FM	O
formation	O
in	O
M.	B
smegmatis	I
-	O
induced	O
granulomas	O
,	O
despite	O
the	O
induction	O
of	O
a	O
comparative	O
inflammatory	O
response	O
,	O
ascertained	O
by	O
the	O
similar	O
induction	O
of	O
granulomas	O
,	O
this	O
phenomenon	O
clearly	O
depends	O
upon	O
a	O
direct	O
contact	O
with	O
the	O
bacilli	O
,	O
and	O
not	O
to	O
the	O
inflammatory	O
response	O
.	O

Mycolic	O
acids	O
are	O
major	O
and	O
hallmark	O
components	O
of	O
the	O
mycobacterial	O
cell	O
wall	O
.	O

They	O
constitute	O
40–60	O
%	O
of	O
dry	O
weight	O
of	O
the	O
envelope	O
[	O
42	O
]	O
.	O

All	O
members	O
of	O
the	O
complex	O
(	O
e.g.	O
M.tb	B
,	O
Mycobacterium	B
africanum	I
,	O
Mycobacterium	B
bovis	I
and	O
Mycobacterium	B
microti	I
)	O
are	O
able	O
to	O
synthesize	O
the	O
same	O
combination	O
of	O
mycolic	O
acids	O
,	O
i.e.	O
cyclopropanated	O
α	O
-	O
mycolic	O
acids	O
,	O
ketomycolic	O
and	O
methoxymycolic	O
acids	O
[	O
17	O
]	O
,	O
which	O
are	O
not	O
synthesized	O
by	O
non	O
-	O
pathogenic	O
mycobacterial	O
species	O
[	O
43	O
]	O
.	O

These	O
structural	O
specificities	O
probably	O
account	O
for	O
part	O
of	O
the	O
pathogenicity	O
of	O
these	O
species	O
,	O
as	O
shown	O
by	O
the	O
impaired	O
virulence	O
of	O
mutant	O
strains	O
deprived	O
of	O
keto	O
and	O
methoxyl	O
groups	O
in	O
experimental	O
infections	O
[	O
17	O
]	O
,	O
[	O
44	O
]	O
,	O
[	O
45	O
]	O
.	O

Our	O
study	O
,	O
therefore	O
,	O
gives	O
the	O
first	O
proof	O
of	O
a	O
direct	O
role	O
of	O
isolated	O
mycolic	O
acids	O
in	O
the	O
interplay	O
between	O
M.tb	B
and	O
host	O
cells	O
.	O

Interestingly	O
,	O
this	O
effect	O
is	O
expressed	O
both	O
by	O
whole	O
bacilli	O
and	O
isolated	O
lipids	O
,	O
suggesting	O
that	O
oxygenated	O
mycolic	O
acids	O
are	O
either	O
secreted	O
by	O
the	O
bacilli	O
,	O
or	O
exposed	O
at	O
the	O
cell	O
wall	O
surface	O
in	O
a	O
manner	O
enabling	O
their	O
bioactivity	O
.	O

According	O
to	O
our	O
results	O
,	O
mycolic	O
acids	O
trigger	O
the	O
formation	O
,	O
within	O
granulomas	O
,	O
of	O
FMs	O
in	O
which	O
bacilli	O
can	O
hide	O
and	O
survive	O
.	O

Oxygenated	O
mycolic	O
acids	O
,	O
either	O
free	O
,	O
as	O
constituents	O
of	O
TDM	O
[	O
44	O
]	O
,	O
or	O
linked	O
to	O
the	O
cell	O
wall	O
arabinogalactan	O
[	O
46	O
]	O
,	O
[	O
47	O
]	O
,	O
should	O
,	O
therefore	O
,	O
be	O
considered	O
as	O
major	O
virulence	O
factors	O
enabling	O
M.tb	B
survival	O
for	O
long	O
periods	O
of	O
time	O
in	O
a	O
persistent	O
state	O
.	O

Being	O
an	O
inducer	O
of	O
host	O
lipid	O
accumulation	O
,	O
and	O
FM	O
formation	O
at	O
the	O
site	O
of	O
infection	O
,	O
these	O
oxygenated	O
mycolic	O
acids	O
could	O
,	O
therefore	O
,	O
also	O
be	O
responsible	O
for	O
the	O
induction	O
of	O
necrosis	O
within	O
lesions	O
,	O
thus	O
favoring	O
M.tb	B
dissemination	O
.	O

Interestingly	O
,	O
deletion	O
of	O
the	O
mmaA4	O
(	O
Rv0642c	O
)	O
gene	O
also	O
drastically	O
decreased	O
the	O
ability	O
of	O
M.tb	B
to	O
induce	O
the	O
differentiation	O
of	O
macrophages	O
into	O
FMs	O
(	O
data	O
not	O
shown	O
)	O
.	O

However	O
,	O
the	O
residual	O
ability	O
of	O
this	O
mutant	O
to	O
induce	O
FMs	O
suggests	O
that	O
other	O
mycobacterial	O
factors	O
might	O
partially	O
trigger	O
the	O
formation	O
of	O
FM	O
.	O

With	O
regard	O
to	O
the	O
mycolic	O
acid	O
methyltransferases	O
,	O
given	O
that	O
(	O
i	O
)	O
mmaA2	O
(	O
Rv0644c	O
)	O
and	O
mmaA3	O
(	O
Rv0643c	O
)	O
are	O
pseudogenes	O
in	O
M.	B
leprae	I
and	O
(	O
ii	O
)	O
mmaA4	O
KO	O
present	O
no	O
trans	O
cyclopropanation	O
[	O
45	O
]	O
,	O
thus	O
excluding	O
the	O
involvement	O
of	O
the	O
cmaA2	O
(	O
Rv0503c	O
)	O
gene	O
,	O
we	O
expect	O
that	O
at	O
least	O
pcaA	O
(	O
Rv0470c	O
)	O
,	O
which	O
introduces	O
cis	O
-	O
cyclopropane	O
,	O
may	O
play	O
the	O
same	O
role	O
.	O

Consistent	O
with	O
this	O
hypothesis	O
,	O
a	O
pcaA	O
null	O
mutant	O
is	O
unable	O
to	O
persist	O
within	O
infected	O
mice	B
[	O
46	O
]	O
,	O
thus	O
demonstrating	O
the	O
role	O
of	O
a	O
mycolic	O
acid	O
methyltransferase	O
in	O
the	O
chronic	O
stage	O
of	O
infection	O
.	O

Overall	O
,	O
our	O
study	O
has	O
shed	O
light	O
on	O
a	O
previously	O
uncharacterized	O
cell	O
population	O
participating	O
in	O
human	B
tuberculous	O
granulomas	O
,	O
namely	O
foamy	O
macrophages	O
.	O

We	O
propose	O
that	O
the	O
specific	O
induction	O
of	O
FM	O
by	O
M.tb	B
would	O
create	O
a	O
favourable	O
environment	O
for	O
persistent	O
bacteria	O
.	O

In	O
our	O
opinion	O
,	O
FMs	O
could	O
be	O
a	O
safe	O
shelter	O
because	O
they	O
preserve	O
bacilli	O
from	O
a	O
direct	O
contact	O
with	O
granuloma	O
lymphocytes	O
and	O
histiocytes	O
,	O
they	O
lose	O
one	O
of	O
the	O
major	O
macrophage	O
bactericidal	O
activities	O
and	O
they	O
constitute	O
an	O
important	O
source	O
of	O
nutrients	O
for	O
the	O
bacilli	O
thanks	O
to	O
the	O
fatty	O
acids	O
accumulated	O
in	O
their	O
lipid	O
granules	O
.	O

Supporting	O
Information	O

The	O
ineffectiveness	O
of	O
tobramycin	O
combination	O
therapy	O
in	O
Streptococcus	B
faecium	I
endocarditis	O
.	O

Abstract	O
A	O
patient	O
required	O
mitral	O
valve	O
replacement	O
following	O
ineffective	O
antibiotic	O
treatment	O
of	O
enterococcal	O
endocarditis	O
caused	O
by	O
Streptococcus	B
faecium	I
.	O

Endocarditis	O
had	O
relapsed	O
despite	O
therapy	O
with	O
ampicillin	O
and	O
tobramycin	O
for	O
six	O
weeks	O
.	O

A	O
second	O
relapse	O
had	O
occurred	O
following	O
treatment	O
with	O
penicillin	O
and	O
gentamicin	O
.	O

Initial	O
failure	O
of	O
antibiotic	O
therapy	O
may	O
be	O
related	O
to	O
the	O
known	O
lack	O
of	O
in	O
vitro	O
and	O
in	O
vivo	O
synergy	O
between	O
penicillin	O
and	O
tobramycin	O
against	O
S.	B
faecium	I
.	O

Effective	O
therapy	O
of	O
enterococcal	O
endocarditis	O
requires	O
considerations	O
of	O
bacterial	O
speciation	O
,	O
determination	O
of	O
high	O
-	O
level	O
aminoglycoside	O
resistance	O
,	O
and	O
preferably	O
adequate	O
antibiotic	O
synergy	O
studies	O
to	O
assure	O
effective	O
therapy	O
.	O

THE	O
YALE	O
JOURNAL	O
OF	O
BIOLOGY	O
AND	O
MEDICINE	O
56	O
(	O
1983	O
)	O
,	O
243	O
-	O
249	O
The	O
Ineffectiveness	O
of	O
Tobramycin	O
Combination	O
Therapy	O
in	O
Streptococcus	B
Faecium	I
Endocarditis	O
JUDITH	O
A.	O
GOLDSTEIN	O
,	O
M.D.,a	O
HOWARD	O
COHEN	O
,	O
M.D.,a	O
AND	O
FRANK	O
J.	O
BIA	O
,	O
M.D.	O
,	O
M.P.H.a	O
,	O
b	O
aInfectious	O
Disease	O
Section	O
of	O
the	O
Department	O
of	O
Medicine	O
,	O
and	O
bThe	O
Department	O
of	O
Laboratory	O
Medicine	O
,	O
Veterans	O
Administration	O
Medical	O
Center	O
,	O
West	O
Haven	O
,	O
and	O
Yale	O
University	O
School	O
of	O
Medicine	O
,	O
New	O
Haven	O
,	O
Connecticut	O
Received	O
July	O
11	O
,	O
1983	O
A	O
patient	O
required	O
mitral	O
valve	O
replacement	O
following	O
ineffective	O
antibiotic	O
treatment	O
of	O
enterococcal	O
endocarditis	O
caused	O
by	O
Streptococcusfaecium	B
.	O

Endocarditis	O
had	O
relapsed	O
despite	O
therapy	O
with	O
ampicillin	O
and	O
tobramycin	O
for	O
six	O
weeks	O
.	O

A	O
second	O
relapse	O
had	O
occurred	O
following	O
treatment	O
with	O
penicillin	O
and	O
gentamicin	O
.	O

Initial	O
failure	O
of	O
antibiotic	O
therapy	O
may	O
be	O
related	O
to	O
the	O
known	O
lack	O
of	O
in	O
vitro	O
and	O
in	O
vivo	O
synergy	O
between	O
penicillin	O
and	O
tobramycin	O
against	O
S.	B
faecium	I
.	O

Effective	O
therapy	O
of	O
enterococcal	O
endocarditis	O
requires	O
considerations	O
of	O
bacterial	O
speciation	O
,	O
determination	O
of	O
high	O
-	O
level	O
aminoglycoside	O
resistance	O
,	O
and	O
preferably	O
adequate	O
antibiotic	O
synergy	O
studies	O
to	O
assure	O
effective	O
therapy	O
.	O

INTRODUCTION	O
Enterococcal	O
endocarditis	O
requires	O
special	O
therapeutic	O
considerations	O
because	O
the	O
responsible	O
organisms	O
are	O
relatively	O
penicillin	O
-	O
resistant	O
streptococci	O
which	O
require	O
synergistic	O
combinations	O
of	O
antibiotics	O
to	O
achieve	O
acceptable	O
cure	O
rates	O
[	O
1,2	O
]	O
.	O

The	O
group	O
D	O
enterococci	O
include	O
three	O
main	O
species	O
S.	B
faecalis	I
,	O
S.	B
faecium	I
,	O
and	O
S.	B
durans	I
.	O

S.	B
faecium	I
cause	O
a	O
minority	O
of	O
all	O
cases	O
of	O
enterococcal	O
endocarditis	O
,	O
in	O
those	O
instances	O
in	O
which	O
enterococci	O
have	O
been	O
speciated	O
[	O
3	O
]	O
,	O
but	O
they	O
have	O
been	O
more	O
resistant	O
both	O
to	O
penicillin	O
and	O
penicillin	O
-	O
aminoglycoside	O
combinations	O
than	O
S.	B
faecalis	I
[	O
4,5,6	O
]	O
.	O

We	O
describe	O
a	O
64-year	O
-	O
old	O
man	B
with	O
S.	B
faecium	I
endocarditis	O
in	O
whom	O
a	O
six	O
-	O
week	O
course	O
of	O
ampicillin	O
and	O
tobramycin	O
,	O
followed	O
by	O
additional	O
courses	O
of	O
penicillin	O
and	O
other	O
aminoglycosides	O
,	O
failed	O
to	O
eradicate	O
the	O
organism	O
from	O
the	O
patient	O
's	O
mitral	O
valve	O
.	O

This	O
case	O
is	O
of	O
interest	O
because	O
therapeutic	O
failure	O
of	O
ampicillin	O
and	O
tobramycin	O
in	O
S.	B
faecium	I
endocarditis	O
has	O
not	O
been	O
reported	O
previously	O
,	O
but	O
might	O
have	O
been	O
predicted	O
on	O
the	O
basis	O
of	O
previous	O
in	O
vitro	O
and	O
in	O
vivo	O
studies	O
[	O
6	O
]	O
.	O

Although	O
the	O
need	O
for	O
both	O
a	O
penicillin	O
derivative	O
and	O
an	O
aminoglycoside	O
in	O
the	O
therapy	O
of	O
enterococcal	O
endocarditis	O
is	O
widely	O
known	O
,	O
it	O
is	O
important	O
to	O
distinguish	O
between	O
the	O
differing	O
efficacies	O
of	O
penicillin	O
-	O
aminoglycoside	O
combinations	O
for	O
treating	O
various	O
species	O
of	O
enterococci	O
such	O
as	O
S.	B
faecium	I
.	O

243	O
Address	O
reprint	O
requests	O
to	O
:	O
Judith	O
A.	O
Goldstein	O
,	O
M.D.	O
,	O
Section	O
of	O
Infectious	O
Diseases	O
,	O
Department	O
of	O
Medicine	O
,	O
Long	O
Island	O
Jewish	O
-	O
Hillside	O
Medical	O
Center	O
,	O
Queen	O
's	O
Hosp	O
.	O

Center	O
Affiliate	O
,	O
82	O
-	O
68	O
164th	O
Street	O
,	O
Jamaica	O
,	O
NY	O
11432	O

Copyright	O
c	O
1983	O
by	O
The	O
Yale	O
Journal	O
of	O
Biology	O
and	O
Medicine	O
,	O
Inc.	O

All	O
rights	O
of	O
reproduction	O
in	O
any	O
form	O
reserved	O
.	O

GOLDSTEIN	O
ET	O
AL	O
.	O

CASE	O
REPORT	O
A	O
64-year	O
-	O
old	O
male	O
was	O
in	O
good	O
health	O
until	O
December	O
1980	O
,	O
when	O
he	O
noted	O
intermittent	O
night	O
sweats	O
,	O
malaise	O
,	O
fever	O
,	O
and	O
fatigue	O
.	O

He	O
received	O
oral	O
erythromycin	O
for	O
14	O
days	O
with	O
transient	O
improvement	O
of	O
symptoms	O
.	O

However	O
,	O
after	O
completing	O
therapy	O
,	O
symptoms	O
reappeared	O
and	O
he	O
noted	O
a	O
15-pound	O
weight	O
loss	O
with	O
low	O
-	O
grade	O
fever	O
(	O
99	O
-	O
100.5?F	O
)	O
during	O
the	O
two	O
months	O
preceding	O
admission	O
.	O

There	O
was	O
no	O
previous	O
history	O
of	O
rheumatic	O
or	O
congenital	O
heart	O
disease	O
.	O

In	O
March	O
1981	O
,	O
the	O
patient	O
was	O
admitted	O
to	O
his	O
community	O
hospital	O
where	O
evaluation	O
revealed	O
a	O
new	O
apical	O
systolic	O
murmur	O
radiating	O
to	O
the	O
axilla	O
.	O

There	O
were	O
no	O
petechiae	O
,	O
Janeway	O
lesions	O
,	O
Osler	O
's	O
nodes	O
,	O
Roth	O
spots	O
,	O
or	O
splenomegaly	O
.	O

The	O
hematocrit	O
was	O
34.8	O
percent	O
,	O
WBC	O
count	O
9,300	O
cells	O
per	O
cu	O
mm	O
with	O
a	O
differential	O
count	O
of	O
67	O
segmented	O
forms	O
,	O
9	O
bands	O
,	O
15	O
lymphocytes	O
,	O
7	O
monocytes	O
,	O
1	O
eosinophil	O
,	O
and	O
1	O
basophil	O
.	O

The	O
erythrocyte	O
sedimentation	O
rate	O
(	O
ESR	O
)	O
was	O
62	O
mm	O
per	O
hour	O
(	O
nl	O
<	O
10	O
mm	O
per	O
hour	O
)	O
and	O
the	O
serum	O
rheumatoid	O
factor	O
titer	O
was	O
1:320	O
.	O

Chest	O
films	O
and	O
electrocardiogram	O
were	O
reportedly	O
normal	O
.	O

Group	O
D	O
streptococci	O
grew	O
from	O
three	O
sets	O
of	O
blood	O
cultures	O
.	O

Enterococcal	O
endocarditis	O
was	O
diagnosed	O
and	O
he	O
was	O
treated	O
with	O
six	O
weeks	O
of	O
parenteral	O
ampicillin	O
(	O
12	O
grams	O
per	O
day	O
)	O
and	O
tobramycin	O
(	O
3	O
mg	O
per	O
kg	O
per	O
day	O
)	O
.	O

Resolution	O
of	O
symptoms	O
occurred	O
within	O
several	O
days	O
after	O
antibiotics	O
were	O
begun	O
.	O

Serum	O
bactericidal	O
titers	O
against	O
the	O
organism	O
,	O
obtained	O
during	O
peak	O
antibiotic	O
levels	O
,	O
were	O
1:8	O
or	O
greater	O
on	O
several	O
occasions	O
,	O
and	O
blood	O
cultures	O
were	O
negative	O
while	O
the	O
patient	O
was	O
receiving	O
antibiotics	O
.	O

M	O
-	O
mode	O
echocardiography	O
demonstrated	O
left	O
atrial	O
enlargement	O
but	O
no	O
definable	O
abnormalities	O
of	O
the	O
mitral	O
or	O
aortic	O
valves	O
.	O

Intravenous	O
pyelogram	O
,	O
oral	O
cholecystogram	O
,	O
cystoscopy	O
,	O
liver	O
-	O
spleen	O
scan	O
,	O
and	O
upper	O
and	O
lower	O
gastrointestinal	O
series	O
were	O
normal	O
except	O
for	O
a	O
few	O
sigmoid	O
diverticuli	O
.	O

Flexible	O
signoidoscopy	O
demonstrated	O
both	O
a	O
small	O
perianal	O
fissure	O
and	O
hemorrhoids	O
.	O

Blood	O
cultures	O
two	O
weeks	O
after	O
therapy	O
were	O
negative	O
.	O

Second	O
Admission	O
(	O
June	O
19-August	O
4	O
,	O
1981	O
)	O
In	O
June	O
1981	O
,	O
he	O
again	O
noted	O
intermittent	O
fever	O
,	O
night	O
sweats	O
,	O
and	O
fatigue	O
.	O

Group	O
D	O
streptococci	O
grew	O
from	O
three	O
sets	O
of	O
blood	O
cultures	O
and	O
he	O
was	O
admitted	O
to	O
the	O
West	O
Haven	O
VA	O
Medical	O
Center	O
for	O
recurrent	O
endocarditis	O
.	O

On	O
examination	O
a	O
somewhat	O
louder	O
apical	O
systolic	O
murmur	O
was	O
noted	O
.	O

The	O
ESR	O
was	O
50	O
mm	O
/	O
hour	O
and	O
rheumatoid	O
factor	O
titer	O
was	O
1:320	O
.	O

Serum	O
complement	O
levels	O
were	O
normal	O
and	O
cryoglobulins	O
were	O
not	O
detectable	O
.	O

Chest	O
films	O
,	O
EKG	O
,	O
and	O
urinalysis	O
were	O
normal	O
.	O

Cardiac	O
M	O
-	O
mode	O
echocardiogram	O
revealed	O
a	O
globular	O
mass	O
attached	O
to	O
the	O
posterior	O
mitral	O
valve	O
leaflet	O
with	O
prolapse	O
into	O
a	O
slightly	O
enlarged	O
left	O
atrium	O
.	O

A	O
twodimensional	O
echocardiogram	O
confirmed	O
mitral	O
valve	O
prolapse	O
and	O
suggested	O
a	O
posterior	O
leaflet	O
vegetation	O
.	O

Gallium	O
citrate	O
scan	O
was	O
negative	O
.	O

Three	O
separate	O
morphologic	O
colony	O
variants	O
were	O
isolated	O
from	O
blood	O
,	O
each	O
identified	O
as	O
S.	B
faecium	I
by	O
Dr.	O
R.R.	O
Facklam	O
(	O
Center	O
for	O
Disease	O
Control	O
,	O
Atlanta	O
,	O
Georgia	O
)	O
.	O

The	O
patient	O
received	O
intravenous	O
penicillin	O
(	O
20	O
million	O
units	O
per	O
day	O
)	O
and	O
gentamicin	O
(	O
3	O
mg	O
per	O
kg	O
per	O
day	O
)	O
for	O
six	O
weeks	O
with	O
improvement	O
.	O

Peak	O
serum	O
bactericidal	O
titers	O
of	O
1:8	O
or	O
greater	O
were	O
achieved	O
against	O
two	O
of	O
the	O
colony	O
variants	O
;	O
however	O
,	O
against	O
the	O
large	O
colony	O
morphotype	O
,	O
a	O
titer	O
of	O
only	O
1:2	O
was	O
obtained	O
.	O

An	O
enlarged	O
left	O
atrium	O
with	O
intermittent	O
fluttering	O
and	O
prolapse	O
of	O
the	O
mitral	O
valve	O
was	O
noted	O
on	O
echocardiography	O
three	O
weeks	O
into	O
therapy	O
.	O

Multiple	O
blood	O
cultures	O
taken	O
while	O
the	O
patient	O
was	O
receiving	O
antibiotics	O
were	O
negative	O
,	O
as	O
were	O
those	O
obtained	O
48	O
and	O
72	O
hours	O
after	O
discontinuation	O
of	O
antibiotics	O
.	O

244	O
S.	B
FAECIUM	I
ENDOCARDITIS	O
Third	O
Admission	O
(	O
August	O
12-October	O
4	O
,	O
1981	O
)	O
Withing	O
a	O
week	O
following	O
discharge	O
,	O
the	O
patient	O
again	O
developed	O
fever	O
,	O
nocturnal	O
sweats	O
,	O
and	O
malaise	O
.	O

S.	B
faecium	I
(	O
large	O
colony	O
morphotype	O
,	O
and	O
poorly	O
growing	O
small	O
colony	O
morphotype	O
)	O
grew	O
from	O
six	O
sets	O
of	O
blood	O
cultures	O
obtained	O
on	O
admission	O
.	O

Penicillin	O
(	O
30	O
million	O
units	O
/	O
day	O
)	O
and	O
gentamicin	O
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
)	O
were	O
again	O
administered	O
,	O
initially	O
achieving	O
peak	O
serum	O
inhibitory	O
and	O
bactericidal	O
dilutions	O
of	O
1:16	O
and	O
1:8	O
against	O
the	O
organism	O
,	O
respectively	O
.	O

However	O
,	O
the	O
organism	O
had	O
a	O
lowlevel	O
resistance	O
to	O
streptomycin	O
(	O
MIC	O
<	O
125	O
/Ag	O
/	O
ml	O
)	O
,	O
and	O
streptomycin	O
(	O
2	O
grams	O
per	O
day	O
)	O
was	O
substituted	O
for	O
gentamicin	O
two	O
weeks	O
into	O
antibiotic	O
therapy	O
.	O

Repeat	O
echocardiograms	O
showed	O
irregular	O
and	O
shaggy	O
densities	O
of	O
both	O
mitral	O
valve	O
leaflets	O
with	O
partial	O
prolapse	O
.	O

Cardiac	O
catheterization	O
demonstrated	O
marked	O
mitral	O
valve	O
prolapse	O
with	O
mitral	O
regurgitation	O
.	O

A	O
radiolucent	O
filling	O
defect	O
was	O
noted	O
,	O
suggesting	O
a	O
coronary	O
artery	O
embolus	O
at	O
the	O
origin	O
of	O
the	O
left	O
anterior	O
descending	O
(	O
LAD	O
)	O
artery	O
,	O
causing	O
75	O
percent	O
occlusion	O
of	O
the	O
lumen	O
.	O

The	O
patient	O
underwent	O
mitral	O
valve	O
replacement	O
,	O
receiving	O
a	O
number	O
31	O
porcine	O
Hancock	O
bioprosthesis	O
and	O
bypass	O
graft	O
to	O
the	O
midportion	O
of	O
the	O
LAD	O
.	O

The	O
mitral	O
valve	O
was	O
thickened	O
with	O
several	O
ruptured	O
chordae	O
of	O
the	O
posterior	O
leaflet	O
noted	O
,	O
but	O
no	O
vegetations	O
.	O

The	O
aortic	O
valve	O
appeared	O
normal	O
,	O
with	O
no	O
visible	O
septal	O
or	O
ring	O
abscesses	O
.	O

The	O
occlusion	O
in	O
the	O
LAD	O
was	O
not	O
approached	O
to	O
avoid	O
embolizing	O
distal	O
fragments	O
.	O

Histopathologically	O
the	O
mitral	O
valve	O
showed	O
mild	O
fibrosis	O
and	O
myxoid	O
degeneration	O
without	O
inflammatory	O
changes	O
.	O

Bacterial	O
and	O
fungal	O
stains	O
were	O
negative	O
but	O
S.	B
faecium	I
grew	O
from	O
fragments	O
of	O
the	O
resected	O
valve	O
.	O

Following	O
surgery	O
the	O
patient	O
received	O
six	O
additional	O
weeks	O
parenteral	O
penicillin	O
and	O
streptomycin	O
.	O

Repeat	O
blood	O
cultures	O
on	O
this	O
regimen	O
and	O
following	O
therapy	O
were	O
negative	O
.	O

Evaluation	O
six	O
months	O
following	O
discontinuation	O
of	O
antibiotics	O
showed	O
no	O
evidence	O
of	O
recurrent	O
endocarditis	O
.	O

LABORATORY	O
EVALUATION	O
The	O
minimum	O
inhibitory	O
and	O
bactericidal	O
concentrations	O
of	O
penicillin	O
,	O
ampicillin	O
,	O
and	O
tobramycin	O
against	O
the	O
S.	B
faecium	I
isolated	O
from	O
the	O
patient	O
's	O
blood	O
cultures	O
TABLE	O
1	O
Minimum	O
Inhibitory	O
and	O
Bactericidal	O
Concentrations	O
of	O
Antibiotics	O
,	O
Against	O
Streptococcus	B
faecium	I
Isolates	O
from	O
Blood	O
Cultures	O
Date	O
Penicillin	O
Ampicillin	O
Tobramycin	O
Organism	O
Isolated	O
MIC	O
MIC	O
MBC	O
MIC	O
MBC	O
S.	B
faecium	I
,	O
prior	O
to	O
ampicillin	O
/	O
tobramycin	O
therapy	O
3	O
/	O
17	O
/	O
81	O
2	O
1	O
2	O
>	O
32	O
>	O
32	O
S.	B
faecium	I
,	O
after	O
ampicillin	O
/	O
tobramycin	O
therapy	O
a.	O

Large	O
colony	O
variant	O
6	O
/	O
16	O
/	O
81	O
2	O
1	O
1	O
>	O
32	O
>	O
32	O
b.	O
Medium	O
colony	O
variant	O
6	O
/	O
16	O
/	O
81	O
2	O
1	O
2	O
32	O
32	O
c.	O
Small	O
colony	O
variant	O
6	O
/	O
16	O
/	O
81	O
4	O
2	O
4	O
>	O
32	O
>	O
32	O
aMIC	O
and	O
MBC	O
are	O
minimum	O
inhibitory	O
and	O
bactericidal	O
concentrations	O
of	O
antibiotics	O
,	O
respectively	O
,	O
in	O
tig	O
/	O
ml	O
.	O

245	O
GOLDSTEIN	O
ET	O
AL	O
.	O

FIG	O
.	O

1	O
.	O

Time	O
-	O
kill	O
curve	O
demonstrat8	O
3-	O
\	O
""""	O
''	O
ing	O
the	O
effects	O
of	O
various	O
penicillinO	O
aminoglycoside	O
combinations	O
on	O
S.	O
{	O
73	O
2-	O
\	O
>	O
,	O
faecium	O
obtained	O
from	O
the	O
patient	O
's	O
blood	O
cultures	O
immediately	O
prior	O
to	O
mitral	O
valve	O
excision	O
.	O

Note	O
the	O
lack	O
of	O
4u	O
,	O
synergy	O
between	O
penicillin	O
and	O
tobra25kg	O
/	O
rm	O
Streporrrychn	O
t	O
mycin	O
against	O
this	O
organism	O
when	O
/0	O
units	O
/	O
mI	O
Penicillin	O
_	O
compared	O
to	O
synergistic	O
combinations	O
0	O
4	O
8	O
12	O
6	O
20	O
24	O
of	O
penicillin	O
-	O
gentamicin	O
and	O
penicillin	O
HOURS	O
streptomycin	O
.	O

after	O
initial	O
oral	O
erythromycin	O
therapy	O
,	O
and	O
prior	O
to	O
therapy	O
for	O
endocarditis	O
,	O
are	O
shown	O
in	O
Table	O
1	O
.	O

Following	O
combined	O
therapy	O
with	O
ampicillin	O
and	O
tobramycin	O
and	O
relapse	O
of	O
endocarditis	O
,	O
three	O
morphological	O
variants	O
were	O
isolated	O
from	O
blood	O
cultures	O
and	O
also	O
evaluated	O
.	O

Twenty	O
-	O
four	O
hour	O
time	O
-	O
kill	O
curves	O
for	O
penicillin	O
in	O
combination	O
with	O
various	O
aminoglycosides	O
were	O
performed	O
by	O
Dr.	O
Robert	O
Moellering	O
on	O
the	O
S.	B
faecium	I
isolated	O
from	O
the	O
patient	O
's	O
blood	O
immediately	O
prior	O
to	O
mitral	O
valve	O
excision	O
and	O
replacement	O
(	O
Fig.	O
1	O
)	O
.	O

Synergy	O
was	O
readily	O
demonstrable	O
against	O
this	O
organism	O
by	O
penicillin	O
-	O
streptomycin	O
and	O
penicillin	O
-	O
gentamicin	O
combinations	O
in	O
vitro	O
,	O
but	O
not	O
by	O
penicillin	O
-	O
tobramycin	O
.	O

DISCUSSION	O
Among	O
streptococci	O
,	O
the	O
enterococci	O
are	O
unusual	O
in	O
their	O
relative	O
resistance	O
to	O
a	O
broad	O
spectrum	O
of	O
antimicrobial	O
agents	O
,	O
and	O
single	O
-	O
agent	O
therapy	O
is	O
rarely	O
bactericidal	O
against	O
them	O
[	O
2	O
]	O
.	O

Since	O
Hunter	O
's	O
original	O
observations	O
in	O
1947	O
,	O
it	O
has	O
become	O
increasingly	O
clear	O
that	O
effective	O
synergistic	O
combinations	O
of	O
antibiotics	O
are	O
necessary	O
to	O
successfully	O
treat	O
enterococcal	O
endocarditis	O
[	O
1	O
]	O
.	O

Although	O
S.	B
faecalis	I
represents	O
the	O
majority	O
of	O
clinical	O
enterococcal	O
isolates	O
,	O
S.	B
faecium	I
nonetheless	O
comprises	O
5	O
-	O
10	O
percent	O
of	O
these	O
isolates	O
in	O
some	O
series	O
[	O
3,4	O
]	O
.	O

Moreover	O
,	O
major	O
differences	O
exist	O
in	O
antimicrobial	O
susceptibility	O
and	O
resistance	O
to	O
penicillin	O
-	O
aminoglycoside	O
synergism	O
between	O
these	O
two	O
enterococcal	O
species	O
.	O

The	O
MIC	O
of	O
penicillin	O
against	O
S.	B
faecium	I
is	O
higher	O
and	O
this	O
organism	O
is	O
more	O
resistant	O
to	O
a	O
number	O
of	O
different	O
combinations	O
of	O
penicillin	O
and	O
various	O
aminoglycosides	O
than	O
is	O
S.	B
faecalis	I
[	O
6	O
]	O
.	O

The	O
mechanisms	O
of	O
resistance	O
exhibited	O
by	O
enterococci	O
to	O
penicillin	O
-	O
aminoglycoside	O
synergy	O
have	O
been	O
investigated	O
.	O

Clinically	O
achievable	O
levels	O
of	O
amino	O
246	O
S.	B
FAECIUM	I
ENDOCARDITIS	O
glycosides	O
are	O
generally	O
ineffective	O
against	O
enterococci	O
.	O

This	O
intrinsic	O
low	O
-	O
level	O
resistance	O
(	O
MIC	O
c	O
250	O
isg	O
/	O
ml	O
)	O
is	O
thought	O
to	O
be	O
the	O
result	O
of	O
poor	O
antibiotic	O
penetration	O
of	O
the	O
bacterial	O
cell	O
wall	O
.	O

However	O
,	O
in	O
the	O
presence	O
of	O
antibiotics	O
that	O
interfere	O
with	O
cell	O
wall	O
synthesis	O
,	O
there	O
is	O
enhanced	O
aminoglycoside	O
uptake	O
[	O
7	O
]	O
.	O

In	O
concert	O
,	O
these	O
events	O
are	O
the	O
basis	O
for	O
penicillin	O
-	O
aminoglycoside	O
synergism	O
.	O

Ribosomal	O
resistance	O
of	O
the	O
30S	O
subunit	O
to	O
streptomycin	O
and	O
defective	O
uptake	O
of	O
gentamicin	O
in	O
the	O
presence	O
of	O
penicillin	O
have	O
been	O
reported	O
mechanisms	O
of	O
resistance	O
among	O
enterococcal	O
isolates	O
[	O
8,9	O
]	O
.	O

However	O
,	O
in	O
the	O
majority	O
of	O
instances	O
,	O
failure	O
of	O
synergy	O
involves	O
plasmid	O
-	O
mediated	O
production	O
of	O
aminoglycoside	O
-	O
modifying	O
enzymes	O
.	O

For	O
streptomycin	O
and	O
kanamycin	O
,	O
plasmid	O
-	O
mediated	O
enzymatic	O
inactivation	O
confers	O
high	O
-	O
level	O
resistance	O
(	O
MIC	O
>	O
2,000	O
Ag	O
/	O
ml	O
)	O
and	O
correlates	O
with	O
failure	O
of	O
these	O
aminoglycosides	O
to	O
exert	O
a	O
synergistic	O
effect	O
when	O
combined	O
with	O
penicillin	O
[	O
10,11	O
]	O
.	O

Plasmid	O
-	O
mediated	O
modifying	O
enzymes	O
have	O
been	O
found	O
in	O
both	O
S.	B
faecalis	I
and	O
S.	B
faecium	I
'	O
[	O
12	O
]	O
.	O

Currently	O
,	O
approximately	O
one	O
-	O
half	O
of	O
clinical	O
enterococcal	O
isolates	O
demonstrate	O
high	O
-	O
level	O
resistance	O
to	O
streptomycin	O
and	O
kanamycin	O
[	O
13	O
]	O
.	O

Combinations	O
of	O
penicillin	O
with	O
kanamycin	O
,	O
tobramycin	O
,	O
sisomicin	O
,	O
and	O
netilmicin	O
have	O
consistently	O
failed	O
to	O
demonstrate	O
synergistic	O
killing	O
of	O
S.	B
faecium	I
in	O
vitro	O
[	O
6	O
]	O
.	O

This	O
failure	O
of	O
synergy	O
occurs	O
even	O
when	O
high	O
-	O
level	O
resistance	O
to	O
these	O
aminoglycosides	O
is	O
not	O
present	O
.	O

The	O
mechanism	O
of	O
resistance	O
appears	O
to	O
be	O
related	O
to	O
the	O
production	O
of	O
an	O
inactivating	O
enzyme	O
that	O
acetylates	O
the	O
aminoglycoside	O
substrate	O
at	O
the	O
6	O
'	O
position1	O
[	O
14	O
]	O
.	O

The	O
genetic	O
basis	O
for	O
production	O
of	O
this	O
enzyme	O
has	O
not	O
been	O
well	O
-	O
defined	O
and	O
plasmid	O
transfer	O
experiments	O
have	O
thus	O
far	O
been	O
unsucessful	O
in	O
demonstrating	O
the	O
encodement	O
of	O
this	O
enzyme	O
by	O
extrachromosomal	O
DNA	O
[	O
14	O
]	O
.	O

Moellering	O
et	O
al.	O
demonstrated	O
in	O
vivo	O
,	O
utilizing	O
the	O
rabbit	B
model	O
of	O
endocarditis	O
,	O
that	O
penicillin	O
and	O
netilmicin	O
were	O
not	O
efficacious	O
in	O
the	O
treatment	O
of	O
endocarditis	O
caused	O
by	O
a	O
low	O
-	O
level	O
aminoglycoside	O
-	O
resistant	O
strain	O
of	O
S.	B
faecium	I
[	O
6	O
]	O
.	O

Although	O
combinations	O
of	O
penicillin	O
with	O
tobramycin	O
,	O
kanamycin	O
,	O
or	O
sisomicin	O
were	O
not	O
evaluated	O
,	O
the	O
authors	O
postulated	O
that	O
the	O
same	O
ineffectual	O
result	O
would	O
have	O
occurred	O
.	O

In	O
the	O
present	O
case	O
,	O
the	O
recurrence	O
of	O
S.	B
faecium	I
endocarditis	O
after	O
six	O
weeks	O
of	O
therapy	O
with	O
ampicillin	O
and	O
tobramycin	O
confirms	O
the	O
therapeutic	O
and	O
clinical	O
significance	O
of	O
their	O
data	O
,	O
and	O
emphasizes	O
that	O
tobramycin	O
is	O
not	O
an	O
aminoglycoside	O
to	O
be	O
used	O
for	O
treatment	O
of	O
serious	O
S.	B
faecium	I
infections	O
.	O

Bacterial	O
tolerance	O
has	O
been	O
suggested	O
as	O
a	O
possible	O
basis	O
for	O
therapeutic	O
failures	O
,	O
particularly	O
in	O
the	O
treatment	O
of	O
infections	O
caused	O
by	O
Staphylococcus	B
aureus	I
with	O
defects	O
in	O
the	O
production	O
of	O
autolysins	O
.	O

MBCs	O
are	O
generally	O
several	O
-	O
fold	O
higher	O
than	O
MICs	O
and	O
this	O
phenomenon	O
appears	O
to	O
be	O
associated	O
with	O
the	O
autolysin	O
defect	O
[	O
5	O
]	O
.	O

Lorian	O
has	O
also	O
described	O
the	O
formation	O
of	O
numerous	O
aberrant	O
cross	O
-	O
walls	O
by	O
S.	B
faecalis	I
grown	O
in	O
the	O
presence	O
of	O
subinhibitory	O
concentrations	O
of	O
penicillin	O
[	O
15	O
]	O
.	O

MBCs	O
were	O
only	O
slightly	O
higher	O
than	O
MICs	O
for	O
the	O
three	O
S.	B
faecium	I
variants	O
obtained	O
from	O
our	O
patient	O
,	O
and	O
they	O
did	O
not	O
appear	O
to	O
be	O
tolerant	O
strains	O
of	O
S.	B
faecium	I
.	O

There	O
was	O
no	O
evidence	O
that	O
any	O
of	O
the	O
morphological	O
variants	O
isolated	O
were	O
unusually	O
resistant	O
to	O
antibiotics	O
.	O

Therefore	O
,	O
subsequent	O
failure	O
of	O
therapy	O
could	O
not	O
be	O
explained	O
on	O
the	O
basis	O
of	O
antibiotic	O
resistance	O
patterns	O
.	O

The	O
initial	O
failure	O
of	O
ampicillin	O
and	O
tobramycin	O
therapy	O
may	O
have	O
allowed	O
the	O
infecting	O
organism	O
to	O
become	O
better	O
established	O
and	O
more	O
difficult	O
to	O
eradicate	O
from	O
the	O
valve	O
.	O

Alternatively	O
,	O
a	O
'	O
Wennersten	O
C	O
,	O
Moellering	O
RC	O
Jr	O
:	O
Mechanism	O
of	O
resistance	O
to	O
penicillin	O
-	O
aminoglycoside	O
synergism	O
in	O
Streptococcus	B
faecium	I
.	O

Proceedings	O
of	O
the	O
1th	O
International	O
Congress	O
of	O
Chemotherapy	O
and	O
19th	O
Interscience	O
Conference	O
on	O
Antimicrobial	O
Agents	O
and	O
Chemotherapy	O
1:710	O
-	O
711	O
,	O
1979	O
247	O
248	O
GOLDSTEIN	O
ET	O
AL	O
.	O

persistent	O
focus	O
of	O
infection	O
causing	O
the	O
LAD	O
lesion	O
seen	O
by	O
arteriography	O
may	O
have	O
slowly	O
resolved	O
and	O
accounted	O
for	O
the	O
apparent	O
failure	O
to	O
respond	O
to	O
synergistic	O
combinations	O
of	O
antibiotics	O
.	O

In	O
summary	O
,	O
our	O
patient	O
was	O
treated	O
for	O
Streptococcusfaecium	B
endocarditis	O
with	O
both	O
ampicillin	O
and	O
the	O
aminoglycoside	O
antibiotic	O
,	O
tobramycin	O
.	O

Relapse	O
of	O
endocarditis	O
might	O
have	O
been	O
anticipated	O
on	O
the	O
basis	O
of	O
previous	O
experimental	O
data	O
showing	O
lack	O
of	O
synergy	O
when	O
tobramycin	O
is	O
used	O
against	O
this	O
organism	O
.	O

This	O
case	O
graphically	O
illustrates	O
the	O
relevance	O
of	O
synergy	O
studies	O
to	O
therapeutic	O
considerations	O
in	O
the	O
treatment	O
of	O
endocarditis	O
.	O

However	O
,	O
subsequent	O
therapy	O
with	O
synergistic	O
combinations	O
of	O
antibiotics	O
did	O
not	O
result	O
in	O
cure	O
.	O

The	O
data	O
do	O
not	O
implicate	O
tolerant	O
organisms	O
as	O
a	O
cause	O
for	O
relapses	O
.	O

Failure	O
of	O
therapy	O
may	O
have	O
been	O
related	O
to	O
the	O
presence	O
of	O
protected	O
organisms	O
in	O
vegetations	O
which	O
were	O
seen	O
on	O
echocardiograms	O
,	O
and	O
also	O
suggested	O
by	O
the	O
presence	O
of	O
a	O
possible	O
coronary	O
artery	O
embolus	O
seen	O
on	O
coronary	O
arteriograms	O
.	O

In	O
conclusion	O
,	O
speciation	O
of	O
isolates	O
suspected	O
of	O
causing	O
endocarditis	O
and	O
adequate	O
synergy	O
studies	O
of	O
antibiotic	O
combinations	O
are	O
indicated	O
before	O
a	O
long	O
and	O
expensive	O
course	O
of	O
therapy	O
with	O
antimicrobial	O
agents	O
is	O
undertaken	O
for	O
this	O
disease	O
.	O

However	O
,	O
as	O
this	O
case	O
also	O
illustrates	O
,	O
demonstration	O
of	O
synergism	O
in	O
vitro	O
does	O
not	O
assure	O
clinical	O
cure	O
.	O

ACKNOWLEDGEMENTS	O
Dr.	O
Goldstein	O
was	O
supported	O
by	O
training	O
grant	O
Al	O
07033	O
-	O
05	O
from	O
the	O
National	O
Institute	O
of	O
Allergy	O
and	O
Infectious	O
Diseases	O
.	O

The	O
authors	O
gratefully	O
acknowledge	O
the	O
advice	O
,	O
laboratory	O
assistance	O
,	O
and	O
careful	O
review	O
of	O
this	O
manuscript	O
by	O
Dr.	O
Robert	O
C.	O
Moellering	O
,	O
Jr.	O
The	O
authors	O
also	O
wish	O
to	O
thank	O
Dr.	O
Howard	O
S.	O
Forster	O
for	O
referring	O
this	O
patient	O
to	O
us	O
,	O
Ms.	O
Mary	O
Murray	O
and	O
Deborah	O
Beauvais	O
for	O
manuscript	O
preparation	O
,	O
and	O
Ms.	O
Gertrude	O
Barden	O
,	O
MT	O
(	O
ASCP	O
)	O
,	O
MHS	O
,	O
for	O
technical	O
assistance	O
and	O
advice	O
in	O
evaluation	O
of	O
this	O
patient	O
.	O

REFERENCES	O
1	O
.	O

Hunter	O
TH	O
:	O
Use	O
of	O
streptomycin	O
in	O
the	O
treatment	O
of	O
bacterial	O
endocarditis	O
.	O

Am	O
J	O
Med	O
2:436	O
-	O
442	O
,	O
1947	O
2	O
.	O

Moellering	O
RC	O
Jr	O
,	O
Krogstad	O
DJ	O
:	O
Antibiotic	O
resistance	O
in	O
enterococci	O
.	O

Microbiology	O
293	O
-	O
298	O
,	O
1979	O
3	O
.	O

Facklam	O
RR	O
:	O
Recognition	O
of	O
group	O
D	O
streptococcal	O
species	O
of	O
human	B
origin	O
by	O
biochemical	O
and	O
physiological	O
tests	O
.	O

Appl	O
Microbiol	O
23:1131	O
-	O
1139	O
,	O
1972	O
4	O
.	O

Toala	O
P	O
,	O
McDonald	O
A	O
,	O
Wilcox	O
C	O
,	O
et	O
al	O
:	O
Susceptibility	O
of	O
group	O
D	O
streptococcus	O
(	O
enterococcus	O
)	O
to	O
21	O
antibiotics	O
in	O
vitro	O
,	O
with	O
special	O
reference	O
to	O
species	O
differences	O
.	O

Am	O
J	O
Med	O
Sci	O
258:416	O
-	O
430	O
,	O
1969	O
5	O
.	O

Shungu	O
DL	O
,	O
Cornett	O
JB	O
,	O
Shockman	O
GD	O
:	O
Morphological	O
and	O
physiological	O
study	O
of	O
autolytic	O
defective	O
Streptococcus	B
faecium	I
strains	O
.	O

J	O
Bacteriol	O
138:598	O
-	O
608	O
,	O
1979	O
6	O
.	O

Moellering	O
RC	O
Jr	O
,	O
Korzeniowski	O
OM	O
,	O
Sande	O
MA	O
,	O
et	O
al	O
:	O
Species	O
-	O
specific	O
resistance	O
to	O
antimicrobial	O
synergism	O
in	O
Streptococcusfaecium	B
and	O
Streptococcusfaecalis	B
.	O

J	O
Infect	O
Dis	O
140:203	O
-	O
208	O
,	O
1979	O
7	O
.	O

Moellering	O
RC	O
Jr	O
,	O
Weinberg	O
AN	O
:	O
Studies	O
on	O
antibiotic	O
synergism	O
against	O
enterococci	O
.	O

11	O
.	O

Effect	O
of	O
various	O
antibiotics	O
on	O
the	O
uptake	O
of	O
'	O
4C	O
-	O
labelled	O
streptomycin	O
by	O
enterococci	O
.	O

J	O
Clin	O
Invest	O
50:2580	O
-	O
2584	O
,	O
1971	O
8	O
.	O

Zimmermann	O
RA	O
,	O
Moellering	O
RC	O
Jr	O
,	O
Weinberg	O
AN	O
:	O
Mechanisms	O
of	O
resistance	O
to	O
antibiotic	O
synergism	O
in	O
enterococci	O
.	O

J	O
Bacteriol	O
105:873	O
-	O
879	O
,	O
1971	O
9	O
.	O

Moellering	O
RC	O
Jr	O
,	O
Murray	O
BE	O
,	O
Schoenbaum	O
SC	O
,	O
et	O
al	O
:	O
A	O
novel	O
mechanism	O
of	O
resistance	O
to	O
penicillin	O
gentamicin	O
synergism	O
in	O
S.	B
faecalis	I
.	O

J	O
Infect	O
Dis	O
141:81	O
-	O
86	O
,	O
1980	O
10	O
.	O

Krogstad	O
DJ	O
,	O
Korfhagen	O
TR	O
,	O
Moellering	O
RC	O
Jr	O
,	O
et	O
al	O
:	O
Plasmid	O
-	O
mediated	O
resistance	O
to	O
antibiotic	O
synergism	O
in	O
enterococci	O
.	O

J	O
Clin	O
Invest	O
61:1645	O
-	O
1653	O
,	O
1978	O
11	O
.	O

Krogstad	O
DJ	O
,	O
Korfhagen	O
TR	O
,	O
Moellering	O
RC	O
Jr	O
,	O
et	O
al	O
:	O
Aminoglycoside	O
-	O
inactivating	O
enzymes	O
in	O
clinical	O
isolates	O
of	O
Streptococcusfaecalis	B
:	O
An	O
explanation	O
for	O
resistance	O
to	O
antibiotic	O
synergism	O
.	O

J	O
Clin	O
Invest	O
62:480	O
-	O
486	O
,	O
1978	O
S.	B
FAECIUM	I
ENDOCARDITIS	O
249	O
12	O
.	O

Courvalin	O
PM	O
,	O
Shaw	O
WV	O
,	O
Jacob	O
AE	O
:	O
Plasmid	O
-	O
mediated	O
mechanisms	O
of	O
resistance	O
to	O
aminoglycoside	O
-	O
aminocyclitol	O
antibiotics	O
and	O
to	O
chloramphenicol	O
in	O
group	O
D	O
streptococci	O
.	O

Antimicrob	O
Agents	O
Chemother	O
13:716	O
-	O
725	O
,	O
1978	O
13	O
.	O

Calderwood	O
SA	O
,	O
Wennersten	O
C	O
,	O
Moellering	O
RC	O
Jr	O
,	O
et	O
al	O
:	O
Resistance	O
to	O
six	O
aminoglycosidic	O
aminocyclitol	O
antibiotics	O
among	O
enterococci	O
:	O
Prevalence	O
,	O
evolution	O
,	O
and	O
relationship	O
to	O
synergism	O
with	O
penicillin	O
.	O

Antimicrob	O
Agents	O
Chemother	O
12:401	O
-	O
405	O
,	O
1977	O
14	O
.	O

Bisno	O
AL	O
:	O
Treatment	O
of	O
infective	O
endocarditis	O
.	O

New	O
York	O
,	O
Grune	O
and	O
Stratton	O
,	O
1981	O
,	O
p	O
90	O
15	O
.	O

Lorian	O
V	O
:	O
Effects	O
of	O
subminimum	O
inhibitory	O
concentrations	O
of	O
antibiotics	O
on	O
bacteria	O
.	O

In	O
Antibiotics	O
in	O
Laboratory	O
Medicine	O
.	O

Edited	O
by	O
V	O
Lorian	O
.	O

Baltimore	O
,	O
Williams	O
and	O
Wilkins	O
,	O
1980	O
,	O
p	O
342	O

Suggestions	O
Concerning	O
the	O
Use	O
of	O
the	O
Subclavian	O
which	O
Arises	O
from	O
the	O
Aorta	O
in	O
the	O
Treatment	O
of	O
the	O
Tetralogy	O
of	O
Fallot	O
*	O
Abstract	O
Images	O

SUGGESTIONS	O
CONCERNING	O
THE	O
USE	O
OF	O
THE	O
SUBCLAVIAN	O
WHICH	O
ARISES	O
FROM	O
THE	O
AORTA	O
IN	O
THE	O
TREATMENT	O
OF	O
THE	O
TETRALOGY	O
OF	O
FALLOT	O
*	O
HARRIS	O
B.	O
SHUMACKER	O
,	O
JR	O
.	O

*	O

*	O
In	O
Blalock	O
's	O
early	O
experience	O
with	O
the	O
operative	O
treatment	O
of	O
the	O
tetralogy	O
of	O
Fallot	O
,	O
the	O
two	O
subclavian	O
,	O
the	O
innominate	O
,	O
and	O
carotid	O
arteries	O
were	O
all	O
used	O
for	O
anastomosis	O
to	O
the	O
pulmonary	O
artery	O
.	O

Soon	O
,	O
however	O
,	O
it	O
became	O
evident	O
that	O
use	O
of	O
the	O
innominate	O
or	O
carotid	O
was	O
followed	O
by	O
a	O
relatively	O
high	O
incidence	O
of	O
complications	O
resulting	O
from	O
cerebral	O
ischemia	O
.	O

Blalock	O
suggested	O
,	O
therefore	O
,	O
that	O
the	O
subclavian	O
be	O
used	O
by	O
preference	O
.	O

The	O
subclavian	O
branch	O
of	O
the	O
innominate	O
does	O
not	O
become	O
kinked	O
or	O
badly	O
angulated	O
when	O
it	O
is	O
turned	O
down	O
for	O
the	O
anastomosis	O
,	O
and	O
a	O
good	O
functional	O
result	O
almost	O
invariably	O
follows	O
the	O
completion	O
of	O
a	O
satisfactory	O
anastomosis	O
.	O

The	O
subclavian	O
which	O
arises	O
directly	O
from	O
the	O
aorta	O
,	O
on	O
the	O
other	O
hand	O
,	O
tends	O
to	O
form	O
a	O
bad	O
angle	O
when	O
it	O
is	O
brought	O
down	O
for	O
the	O
anastomosis	O
,	O
and	O
,	O
indeed	O
,	O
near	O
its	O
point	O
of	O
origin	O
it	O
may	O
be	O
so	O
flattened	O
out	O
against	O
the	O
relatively	O
rigid	O
aortic	O
wall	O
as	O
to	O
obstruct	O
all	O
blood	O
flow	O
through	O
it	O
.	O

These	O
considerations	O
led	O
Blalock	O
to	O
recommend	O
the	O
use	O
of	O
the	O
former	O
except	O
in	O
infants	O
under	O
two	O
years	O
of	O
age	O
in	O
whom	O
this	O
artery	O
may	O
be	O
too	O
small	O
and	O
in	O
adults	O
or	O
children	O
over	O
twelve	O
years	O
old	O
or	O
five	O
feet	O
tall	O
with	O
a	O
left	O
aortic	O
arch	O
in	O
whom	O
it	O
is	O
often	O
too	O
short	O
to	O
permit	O
a	O
satisfactory	O
anastomosis.7	O
'	O
In	O
contrast	O
,	O
Paine	O
and	O
Varco	O
,	O
'	O
Lam,6	O
Holman	O
,	O
'	O
Olim,7	O
and	O
others	O
have	O
preferred	O
to	O
use	O
the	O
subclavian	O
which	O
arises	O
from	O
the	O
aorta	O
and	O
have	O
obtained	O
generally	O
excellent	O
results	O
.	O

They	O
point	O
out	O
that	O
the	O
tendency	O
to	O
kinking	O
of	O
the	O
artery	O
is	O
more	O
a	O
theoretical	O
than	O
a	O
practical	O
disadvantage	O
,	O
that	O
the	O
exposure	O
and	O
dissection	O
of	O
both	O
the	O
pulmonary	O
artery	O
and	O
the	O
subclavian	O
are	O
easier	O
on	O
the	O
side	O
of	O
the	O
aortic	O
arch	O
,	O
that	O
both	O
vessels	O
are	O
generally	O
longer	O
than	O
on	O
the	O
opposite	O
side	O
and	O
that	O
,	O
as	O
a	O
general	O
rule	O
,	O
the	O
anastomosis	O
can	O
be	O
accomplished	O
more	O
readily	O
.	O

The	O
practical	O
usefulness	O
of	O
a	O
third	O
systemic	O
vessel	O
,	O
namely	O
the	O
aorta	O
,	O
was	O
demonstrated	O
by	O
the	O
development	O
of	O
a	O
technique	O
for	O
side	O
-	O
to	O
-	O
side	O
aortic	O
pulmonary	O
anastomosis	O
by	O
Potts	O
and	O
his	O
"associates.""0"	O
In	O
spite	O
of	O
the	O
preferences	O
held	O
by	O
individual	O
operators	O
for	O
use	O
of	O
one	O
vessel	O
or	O
another	O
,	O
the	O
fact	O
remains	O
,	O
as	O
Blalock	O
has	O
emphasized	O
,	O
that	O
there	O
is	O
always	O
present	O
a	O
usable	O
systemic	O
vessel	O
provided	O
a	O
suitable	O
pulmonary	O
artery	O
is	O
available	O
.	O

Nevertheless	O
,	O
the	O
choice	O
of	O
the	O
systemic	O
artery	O
in	O
each	O
individual	O
patient	O
is	O
important	O
since	O
in	O
certain	O
cases	O
one	O
or	O
another	O
is	O
unsuitable	O
.	O

*	O
From	O
the	O
Department	O
of	O
Surgery	O
,	O
the	O
Indiana	O
University	O
Medical	O
Center	O
,	O
Indianapolis	O
,	O
Indiana	O
.	O

Aided	O
by	O
a	O
contract	O
between	O
the	O
Office	O
of	O
Naval	O
Research	O
,	O
Department	O
of	O
the	O
Navy	O
,	O
and	O
Indiana	O
University	O
.	O

*	O

*	O
Resident	O
Surgeon	O
,	O
New	O
Haven	O
Hospital	O
,	O
1937	O
-	O
1938	O
.	O

Received	O
for	O
publication	O
April	O
26	O
,	O
1951	O
.	O

TREATMENT	O
OF	O
TETRALOGY	O
OF	O
FALLOT	O
It	O
has	O
been	O
my	O
custom	O
to	O
follow	O
a	O
policy	O
rather	O
similar	O
to	O
that	O
outlined	O
by	O
Blalock	O
.	O

The	O
subclavian	O
branch	O
of	O
the	O
innominate	O
has	O
generally	O
been	O
preferred	O
in	O
patients	O
ranging	O
between	O
two	O
and	O
twelve	O
years	O
of	O
age	O
and	O
in	O
older	O
individuals	O
in	O
whom	O
there	O
is	O
a	O
right	O
aortic	O
arch	O
.	O

In	O
others	O
the	O
thoracotomy	O
is	O
usually	O
made	O
on	O
the	O
side	O
of	O
the	O
aortic	O
arch	O
,	O
and	O
either	O
the	O
aorta	O
itself	O
or	O
the	O
subclavian	O
arising	O
from	O
the	O
aorta	O
is	O
used	O
for	O
the	O
anastomosis	O
.	O

My	O
experience	O
with	O
the	O
use	O
of	O
the	O
subclavian	O
originating	O
from	O
the	O
aorta	O
is	O
small	O
and	O
the	O
results	O
have	O
not	O
been	O
as	O
good	O
as	O
those	O
which	O
others	O
have	O
reported	O
.	O

One	O
eighteen	O
-	O
month	O
-	O
old	O
child	O
died	O
the	O
day	O
after	O
operation	O
and	O
was	O
found	O
at	O
post	O
-	O
mortem	O
examination	O
to	O
have	O
an	O
occluded	O
anastomosis	O
.	O

In	O
one	O
three	O
-	O
year	O
-	O
old	O
child	O
and	O
one	O
twenty	O
-	O
year	O
-	O
old	O
woman	O
a	O
poor	O
result	O
was	O
obtained	O
and	O
a	O
second	O
operation	O
upon	O
the	O
other	O
side	O
was	O
necessary	O
.	O

In	O
two	O
additional	O
cases	O
the	O
result	O
was	O
only	O
fair	O
.	O

Excluding	O
the	O
patients	O
mentioned	O
in	O
the	O
present	O
report	O
,	O
only	O
in	O
two	O
was	O
an	O
unquestionably	O
good	O
result	O
obtained	O
.	O

Recently	O
,	O
in	O
several	O
cases	O
in	O
which	O
failure	O
seemed	O
evident	O
a	O
modification	O
has	O
been	O
required	O
in	O
order	O
to	O
obtain	O
a	O
functioning	O
shunt	O
.	O

Since	O
these	O
modifications	O
proved	O
successful	O
and	O
since	O
these	O
threats	O
of	O
failure	O
tax	O
one	O
's	O
ingenuiity	O
at	O
the	O
time	O
of	O
operation	O
,	O
I	O
have	O
thought	O
it	O
might	O
be	O
helpful	O
to	O
describe	O
the	O
procedures	O
employed	O
and	O
to	O
illustrate	O
them	O
with	O
case	O
reports	O
.	O

One	O
is	O
a	O
method	O
which	O
obviously	O
has	O
very	O
limited	O
applicability	O
,	O
while	O
the	O
otlher	O
would	O
seem	O
to	O
be	O
rather	O
generally	O
applicable	O
.	O

The	O
first	O
consists	O
of	O
the	O
transplantation	O
of	O
the	O
origin	O
of	O
the	O
subclavian	O
to	O
a	O
more	O
suitable	O
portion	O
of	O
the	O
aorta	O
.	O

Case	O
report	O
The	O
patient	O
was	O
a	O
19-year	O
-	O
old	O
girl	O
who	O
had	O
been	O
cyanotic	O
since	O
the	O
age	O
of	O
six	O
months	O
.	O

She	O
had	O
developed	O
normally	O
but	O
was	O
always	O
limited	O
in	O
exercise	O
capacity	O
.	O

In	O
her	O
early	O
years	O
of	O
school	O
she	O
was	O
taken	O
to	O
school	O
by	O
her	O
parents	O
and	O
carried	O
to	O
and	O
from	O
her	O
seat	O
in	O
the	O
classroom	O
.	O

She	O
did	O
reasonably	O
well	O
in	O
high	O
school	O
,	O
being	O
driven	O
to	O
and	O
from	O
the	O
school	O
,	O
but	O
she	O
got	O
into	O
severe	O
difficulty	O
when	O
she	O
attempted	O
to	O
attend	O
college	O
.	O

The	O
longer	O
distances	O
between	O
classes	O
and	O
the	O
necessity	O
for	O
climbing	O
stairs	O
precipitated	O
a	O
downhill	O
course	O
,	O
with	O
increasing	O
dyspnea	O
,	O
more	O
marked	O
cyanosis	O
and	O
fatigue	O
,	O
and	O
the	O
onset	O
of	O
bouts	O
of	O
loss	O
of	O
consciousness	O
.	O

The	O
latter	O
occurred	O
several	O
times	O
daily	O
.	O

One	O
which	O
was	O
witnessed	O
by	O
her	O
physician	O
lasted	O
45	O
minutes	O
;	O
he	O
feared	O
it	O
would	O
prove	O
fatal	O
.	O

Ordinarily	O
,	O
she	O
could	O
not	O
walk	O
more	O
than	O
half	O
a	O
block	O
.	O

There	O
was	O
marked	O
cyanosis	O
of	O
the	O
nails	O
and	O
mucous	O
membranes	O
and	O
to	O
a	O
lesser	O
extent	O
of	O
the	O
skin	O
.	O

Clubbing	O
was	O
very	O
prominent	O
.	O

All	O
the	O
results	O
of	O
physical	O
and	O
laboratory	O
examination	O
fitted	O
in	O
with	O
a	O
diagnosis	O
of	O
tetralogy	O
of	O
Fallot	O
.	O

The	O
hematocrit	O
ranged	O
between	O
83	O
and	O
90	O
.	O

Oxygen	O
saturation	O
of	O
arterial	O
blood	O
was	O
65	O
per	O
cent	O
at	O
complete	O
rest	O
.	O

The	O
aortic	O
arch	O
was	O
on	O
the	O
left	O
side	O
.	O

On	O
October	O
26	O
,	O
1949	O
a	O
left	O
lateral	O
thoracotomy	O
was	O
performed	O
,	O
the	O
pleural	O
cavity	O
being	O
entered	O
through	O
the	O
bed	O
of	O
the	O
fifth	O
rib	O
.	O

There	O
was	O
evident	O
greatly	O
increased	O
collateral	O
circulation	O
in	O
the	O
mediastinum	O
and	O
hilum	O
.	O

The	O
pulmonary	O
artery	O
appeared	O
to	O
have	O
markedly	O
reduced	O
blood	O
flow	O
,	O
was	O
very	O
short	O
,	O
small	O
,	O
and	O
thin	O
-	O
walled	O
.	O

Its	O
diameter	O
was	O
less	O
than	O
5	O
mm	O
.	O

The	O
aorta	O
seemed	O
to	O
be	O
bowed	O
out	O
laterally	O
in	O
an	O
unusual	O
fashion	O
and	O
the	O
short	O
pulmonary	O
artery	O
could	O
not	O
possibly	O
be	O
brought	O
out	O
over	O
it	O
.	O

The	O
subclavian	O
artery	O
was	O
relatively	O
small	O
,	O
having	O
487	O
YALE	O
JOURNAL	O
OF	O
BIOLOGY	O
AND	O
MEDICINE	O
a	O
diameter	O
of	O
only	O
about	O
4	O
mm	O
.	O

but	O
it	O
seemed	O
rather	O
long	O
.	O

It	O
was	O
apparent	O
that	O
a	O
Pott	O
's	O
procedure	O
was	O
impossible	O
and	O
that	O
an	O
end	O
-	O
to	O
-	O
side	O
subclavian	O
pulmonary	O
artery	O
anastomosis	O
would	O
be	O
doomed	O
to	O
failure	O
.	O

Hence	O
,	O
the	O
subclavian	O
artery	O
was	O
divided	O
at	O
the	O
level	O
of	O
its	O
first	O
branch	O
,	O
the	O
pulmonary	O
artery	O
was	O
divided	O
proximally	O
,	O
and	O
an	O
end	O
-	O
to	O
-	O
end	O
subclavian	O
-	O
pulmonary	O
anastomosis	O
was	O
carried	O
out	O
.	O

This	O
was	O
done	O
with	O
ease	O
.	O

When	O
the	O
clamps	O
were	O
removed	O
,	O
however	O
,	O
no	O
blood	O
flowed	O
through	O
it	O
.	O

The	O
softwalled	O
subclavian	O
was	O
completely	O
flattened	O
out	O
against	O
the	O
relatively	O
rigid	O
aorta	O
(	O
Fig.	O
1	O
)	O
.	O

When	O
the	O
hilar	O
structures	O
were	O
forcibly	O
elevated	O
in	O
a	O
cephalad	O
direction	O
the	O
subclavian	O
immediately	O
filled	O
and	O
pulsated	O
normally	O
and	O
a	O
thrill	O
could	O
be	O
felt	O
.	O

Simple	O
expansion	O
of	O
the	O
lungs	O
,	O
however	O
,	O
failed	O
to	O
achieve	O
this	O
result	O
and	O
I	O
could	O
conceive	O
of	O
no	O
way	O
in	O
which	O
the	O
hilar	O
region	O
could	O
be	O
held	O
in	O
a	O
more	O
cephalad	O
direction	O
.	O

The	O
subclavian	O
was	O
then	O
ligated	O
at	O
the	O
point	O
where	O
it	O
came	O
off	O
the	O
aorta	O
and	O
its	O
proximal	O
end	O
was	O
anastomosed	O
end	O
-	O
to	O
-	O
side	O
to	O
the	O
descending	O
aorta	O
.	O

It	O
now	O
pulsated	O
vigorously	O
as	O
did	O
the	O
pulmonary	O
artery	O
.	O

In	O
spite	O
of	O
the	O
good	O
pulsation	O
no	O
thrill	O
was	O
palpable	O
.	O

The	O
patient	O
had	O
an	O
uneventful	O
but	O
disappointing	O
convalescence	O
.	O

She	O
remained	O
markedly	O
cyanotic	O
and	O
no	O
continuous	O
bruit	O
was	O
audible	O
.	O

When	O
she	O
left	O
the	O
hospital	O
14	O
days	O
after	O
operation	O
there	O
was	O
no	O
improvement	O
in	O
her	O
appearance	O
,	O
hematocrit	O
,	O
or	O
arterial	O
oxygen	O
saturation	O
.	O

Surprisingly	O
enough	O
she	O
reported	O
progress	O
on	O
each	O
follow	O
-	O
up	O
examination	O
.	O

By	O
the	O
end	O
of	O
seven	O
weeks	O
she	O
was	O
obviously	O
less	O
cyanotic	O
,	O
her	O
hematocrit	O
was	O
77	O
,	O
and	O
she	O
was	O
able	O
to	O
walk	O
a	O
number	O
of	O
blocks	O
and	O
to	O
climb	O
a	O
flight	O
of	O
stairs	O
without	O
difficulty	O
.	O

She	O
reported	O
that	O
she	O
had	O
danced	O
and	O
roller	O
-	O
skated	O
without	O
much	O
trouble	O
.	O

Shortly	O
thereafter	O
a	O
continuous	O
murmur	O
was	O
audible	O
in	O
the	O
left	O
chest	O
.	O

She	O
continued	O
to	O
improve	O
and	O
in	O
January	O
entered	O
a	O
southern	O
college	O
.	O

She	O
did	O
well	O
.	O

At	O
least	O
once	O
a	O
day	O
,	O
often	O
twice	O
,	O
she	O
walked	O
without	O
difficulty	O
from	O
the	O
campus	O
into	O
town	O
and	O
back	O
,	O
a	O
distance	O
of	O
ten	O
blocks	O
each	O
way	O
.	O

She	O
played	O
a	O
little	O
tennis	O
,	O
learned	O
to	O
swim	O
,	O
and	O
began	O
to	O
dance	O
,	O
including	O
jitterbugging	O
.	O

When	O
she	O
xvas	O
seen	O
in	O
June	O
,	O
her	O
color	O
was	O
good	O
,	O
although	O
there	O
was	O
still	O
slight	O
cyanosis	O
of	O
lips	O
and	O
nail	O
beds	O
.	O

There	O
was	O
a	O
very	O
loud	O
,	O
continuous	O
murmur	O
in	O
the	O
left	O
chest	O
.	O

The	O
following	O
fall	O
she	O
transferred	O
to	O
a	O
midwestern	O
university	O
.	O

She	O
got	O
along	O
reasonably	O
well	O
but	O
not	O
as	O
well	O
as	O
she	O
had	O
in	O
a	O
warmer	O
climate	O
and	O
on	O
more	O
level	O
terrain	O
.	O

She	O
walked	O
four	O
or	O
five	O
blocks	O
up	O
and	O
down	O
hills	O
between	O
classes	O
without	O
difficulty	O
in	O
good	O
weather	O
but	O
complained	O
of	O
some	O
dyspnea	O
and	O
fatigue	O
on	O
cold	O
,	O
windy	O
days	O
.	O

She	O
attended	O
dances	O
and	O
often	O
danced	O
each	O
number	O
throughout	O
the	O
evening	O
without	O
trouble	O
.	O

When	O
seen	O
in	O
December	O
she	O
looked	O
well	O
.	O

Her	O
color	O
was	O
good	O
and	O
clubbing	O
was	O
definitely	O
less	O
marked	O
than	O
it	O
had	O
been	O
previously	O
.	O

She	O
had	O
a	O
severe	O
cold	O
at	O
the	O
time	O
.	O

Her	O
oxygen	O
saturation	O
of	O
arterial	O
blood	O
was	O
75	O
per	O
cent	O
at	O
rest	O
and	O
it	O
did	O
not	O
fall	O
when	O
she	O
stood	O
or	O
still	O
-	O
walked	O
.	O

The	O
hematocrit	O
was	O
69	O
.	O

There	O
was	O
audible	O
the	O
same	O
loud	O
continuous	O
murmur	O
in	O
the	O
left	O
chest	O
.	O

Though	O
the	O
patient	O
has	O
been	O
markedly	O
improved	O
,	O
it	O
is	O
recognized	O
that	O
the	O
result	O
is	O
not	O
as	O
good	O
as	O
is	O
commonly	O
obtained	O
when	O
patients	O
with	O
more	O
adequate	O
pulmonary	O
arteries	O
are	O
treated	O
by	O
the	O
conventional	O
anastomosis	O
of	O
a	O
systemic	O
artery	O
to	O
the	O
side	O
of	O
the	O
pulmonary	O
artery	O
.	O

Nevertheless	O
,	O
the	O
patient	O
has	O
thus	O
far	O
been	O
given	O
such	O
good	O
health	O
and	O
relatively	O
normal	O
capacity	O
for	O
ordinary	O
activity	O
that	O
further	O
operation	O
has	O
seemed	O
unwarranted	O
,	O
though	O
the	O
possibility	O
of	O
some	O
future	O
attempt	O
at	O
creation	O
of	O
an	O
additional	O
shunt	O
is	O
being	O
kept	O
in	O
mind	O
.	O

The	O
second	O
procedure	O
embodies	O
the	O
cephalad	O
transplantation	O
of	O
the	O
pulmonary	O
artery	O
by	O
a	O
plastic	O
repair	O
of	O
the	O
incision	O
in	O
the	O
hilar	O
and	O
mediastinal	O
pleural	O
structures	O
.	O

488	O
FIG	O
.	O

1	O
.	O

Drawing	O
illustrating	O
the	O
condition	O
which	O
existed	O
in	O
the	O
first	O
case	O
after	O
completion	O
of	O
the	O
anastomosis	O
(	O
A	O
)	O
and	O
its	O
correction	O
by	O
transplantation	O
of	O
the	O
origin	O
of	O
the	O
subclavian	O
(	O
B	O
)	O
.	O

FIG	O
.	O

2	O
.	O

Drawing	O
illustrating	O
correction	O
of	O
obstruction	O
to	O
blood	O
flow	O
through	O
the	O
subclavian	O
artery	O
by	O
inverted	O
T	O
or	O
L	O
plastic	O
closure	O
of	O
the	O
defect	O
in	O
the	O
hilar	O
and	O
mediastinal	O
structures	O
.	O

TREATMENT	O
OF	O
TETRALOGY	O
OF	O
FALLOT	O
Case	O
reports	O
The	O
first	O
patient	O
was	O
a	O
fully	O
grown	O
young	O
man	B
of	O
17	O
with	O
tetralogy	O
of	O
Fallot	O
which	O
caused	O
considerable	O
incapacity	O
.	O

He	O
was	O
admitted	O
to	O
the	O
hospital	O
on	O
July	O
18	O
,	O
1950	O
and	O
was	O
operated	O
upon	O
two	O
days	O
later	O
.	O

He	O
was	O
known	O
to	O
have	O
a	O
left	O
aortic	O
arch	O
,	O
and	O
a	O
left	O
lateral	O
thoracotomy	O
was	O
performed	O
.	O

The	O
aorta	O
was	O
freed	O
for	O
a	O
side	O
-	O
to	O
-	O
side	O
anastomosis	O
with	O
the	O
pulmonary	O
artery	O
.	O

So	O
much	O
difficulty	O
was	O
encountered	O
,	O
however	O
,	O
in	O
placing	O
the	O
aortic	O
clamp	O
in	O
proper	O
position	O
for	O
making	O
a	O
satisfactory	O
incision	O
in	O
the	O
aorta	O
that	O
the	O
procedure	O
was	O
abandoned	O
and	O
an	O
end	O
-	O
to	O
-	O
side	O
subclavian	O
-	O
pulmonary	O
artery	O
anastomosis	O
accomplished	O
instead	O
.	O

The	O
pulmonary	O
artery	O
was	O
of	O
fair	O
size	O
,	O
having	O
an	O
estimated	O
diameter	O
of	O
1	O
cm	O
.	O

The	O
subclavian	O
artery	O
appeared	O
to	O
be	O
quite	O
long	O
and	O
it	O
was	O
of	O
very	O
satisfactory	O
size	O
,	O
having	O
a	O
diameter	O
of	O
about	O
6	O
mm	O
.	O

To	O
my	O
dismay	O
,	O
the	O
first	O
portion	O
of	O
the	O
soft	O
-	O
walled	O
subclavian	O
artery	O
was	O
completely	O
flattened	O
out	O
against	O
the	O
rather	O
rigid	O
wall	O
of	O
the	O
aorta	O
and	O
no	O
blood	O
flow	O
through	O
it	O
could	O
be	O
demonstrated	O
,	O
there	O
being	O
no	O
subclavian	O
pulsation	O
nor	O
thrill	O
in	O
the	O
pulmonary	O
artery	O
.	O

If	O
one	O
forcefully	O
elevated	O
the	O
hilum	O
of	O
the	O
lung	O
in	O
a	O
cephalad	O
direction	O
,	O
the	O
obstruction	O
disappeared	O
,	O
the	O
subclavian	O
artery	O
began	O
to	O
pulsate	O
,	O
and	O
a	O
thrill	O
could	O
be	O
palpated	O
.	O

When	O
the	O
lung	O
was	O
allowed	O
to	O
assume	O
its	O
usual	O
position	O
,	O
the	O
subclavian	O
obstruction	O
was	O
again	O
evident	O
and	O
could	O
not	O
be	O
prevented	O
by	O
full	O
expansion	O
of	O
the	O
lung	O
.	O

It	O
was	O
found	O
that	O
the	O
hilar	O
region	O
and	O
the	O
pulmonary	O
artery	O
could	O
be	O
maintained	O
in	O
a	O
satisfactory	O
cephalad	O
position	O
by	O
traction	O
upward	O
upon	O
the	O
cuff	O
of	O
hilar	O
pleura	O
and	O
the	O
adjacent	O
vascular	O
sheath	O
and	O
that	O
these	O
structures	O
were	O
sufficiently	O
strong	O
so	O
that	O
traction	O
could	O
be	O
maintained	O
upon	O
them	O
with	O
a	O
small	O
hemostat	O
.	O

The	O
defect	O
in	O
the	O
mediastinal	O
and	O
hilar	O
tissues	O
was	O
then	O
repaired	O
using	O
a	O
sort	O
of	O
inverted	O
T	O
-	O
plastic	O
closure	O
.	O

By	O
this	O
maneuver	O
success	O
was	O
achieved	O
in	O
elevating	O
the	O
pulmonary	O
artery	O
in	O
a	O
cephalad	O
direction	O
so	O
that	O
the	O
subclavian	O
obstruction	O
was	O
relieved	O
and	O
excellent	O
pulsation	O
was	O
evident	O
(	O
Fig.	O
2B	O
)	O
.	O

A	O
fairly	O
good	O
continuous	O
thrill	O
was	O
palpable	O
.	O

The	O
patient	O
had	O
an	O
uneventful	O
convalescence	O
.	O

When	O
last	O
seen	O
on	O
January	O
16	O
,	O
1951	O
he	O
had	O
excellent	O
color	O
without	O
any	O
visible	O
cyanosis	O
.	O

The	O
clubbing	O
seemed	O
to	O
have	O
decreased	O
somewhat	O
.	O

A	O
continuous	O
murmur	O
was	O
audible	O
.	O

He	O
stated	O
that	O
he	O
noted	O
no	O
limitation	O
of	O
exercise	O
capacity	O
.	O

In	O
outlining	O
his	O
activities	O
he	O
said	O
that	O
,	O
among	O
other	O
things	O
,	O
he	O
was	O
doing	O
a	O
great	O
deal	O
of	O
ice	O
-	O
skating	O
and	O
was	O
playing	O
ice	O
hockey	O
regularly	O
.	O

He	O
was	O
planning	O
to	O
start	O
college	O
work	O
the	O
following	O
month	O
.	O

The	O
second	O
patient	O
was	O
a	O
16-year	O
-	O
old	O
boy	O
who	O
had	O
been	O
cyanotic	O
since	O
birth	O
.	O

His	O
physical	O
development	O
was	O
somewhat	O
retarded	O
and	O
he	O
was	O
slow	O
in	O
learning	O
to	O
sit	O
and	O
walk	O
.	O

Until	O
he	O
had	O
grown	O
old	O
enough	O
to	O
be	O
self	O
-	O
conscious	O
about	O
it	O
he	O
had	O
always	O
squatted	O
when	O
he	O
was	O
tired	O
.	O

By	O
perseverance	O
he	O
had	O
managed	O
to	O
do	O
more	O
than	O
one	O
would	O
have	O
suspected	O
he	O
could	O
from	O
the	O
degree	O
of	O
his	O
cyanosis	O
.	O

He	O
could	O
walk	O
as	O
much	O
as	O
five	O
or	O
six	O
blocks	O
at	O
a	O
slow	O
pace	O
.	O

He	O
was	O
fond	O
of	O
drums	O
and	O
managed	O
to	O
play	O
occasionally	O
with	O
an	O
orchestra	O
in	O
a	O
somewhat	O
restricted	O
fashion	O
.	O

For	O
the	O
past	O
few	O
months	O
he	O
had	O
had	O
more	O
dyspnea	O
,	O
fatigability	O
,	O
and	O
seemed	O
to	O
be	O
going	O
downhill	O
generally	O
.	O

The	O
results	O
of	O
physical	O
and	O
laboratory	O
studies	O
were	O
rather	O
typical	O
of	O
the	O
tetralogy	O
of	O
Fallot	O
.	O

Clubbing	O
was	O
marked	O
,	O
the	O
nailbeds	O
and	O
mucous	O
membranes	O
were	O
a	O
rather	O
deep	O
purplish	O
-	O
blue	O
color	O
,	O
and	O
the	O
skin	O
had	O
a	O
dusky	O
cyanotic	O
tint	O
.	O

The	O
aortic	O
arch	O
was	O
determined	O
to	O
be	O
on	O
the	O
left	O
.	O

On	O
July	O
21	O
,	O
1950	O
a	O
left	O
lateral	O
thoracotomy	O
was	O
performed	O
,	O
the	O
pleural	O
cavity	O
being	O
entered	O
through	O
the	O
bed	O
of	O
the	O
fourth	O
rib	O
.	O

There	O
was	O
a	O
rather	O
marked	O
increase	O
in	O
the	O
collateral	O
circulation	O
in	O
the	O
mediastinum	O
and	O
the	O
hilar	O
region	O
.	O

The	O
pulmonary	O
artery	O
was	O
easily	O
dissected	O
free	O
.	O

It	O
was	O
fairly	O
long	O
and	O
was	O
about	O
1	O
cm	O
.	O

in	O
diameter	O
.	O

The	O
subclavian	O
artery	O
seemed	O
quite	O
long	O
and	O
was	O
of	O
adequate	O
size	O
,	O
having	O
a	O
diameter	O
of	O
about	O
5	O
mm	O
.	O

An	O
end	O
-	O
to	O
-	O
side	O
sub9lavian	O
pulmonary	O
anastomosis	O
was	O
performed	O
.	O

Again	O
in	O
this	O
case	O
,	O
however	O
,	O
the	O
first	O
part	O
of	O
the	O
subclavian	O
was	O
acutely	O
angulated	O
and	O
completely	O
flattened	O
out	O
against	O
the	O
aortic	O
wall	O
.	O

There	O
was	O
no	O
489	O
YALE	O
JOURNAL	O
OF	O
BIOLOGY	O
AND	O
MEDICINE	O
pulsation	O
in	O
the	O
subclavian	O
and	O
no	O
thrill	O
in	O
the	O
pulmonary	O
.	O

In	O
this	O
instance	O
also	O
,	O
good	O
blood	O
flow	O
through	O
the	O
subclavian	O
artery	O
was	O
evident	O
whenever	O
the	O
hilar	O
structures	O
were	O
elevated	O
in	O
a	O
cephalad	O
direction	O
but	O
no	O
pulsation	O
was	O
demonstrable	O
simply	O
by	O
expanding	O
fully	O
the	O
lung	O
.	O

Again	O
,	O
a	O
sort	O
of	O
inverted	O
T	O
-	O
plastic	O
closure	O
of	O
the	O
defect	O
in	O
the	O
hilum	O
and	O
mediastinum	O
brought	O
about	O
a	O
cephalad	O
elevation	O
of	O
the	O
pulmonary	O
artery	O
so	O
that	O
tension	O
was	O
released	O
and	O
there	O
was	O
excellent	O
pulsation	O
in	O
the	O
subclavian	O
artery	O
.	O

A	O
thrill	O
was	O
now	O
palpable	O
.	O

Convalescence	O
was	O
uneventful	O
.	O

Improvement	O
in	O
color	O
was	O
evident	O
within	O
a	O
few	O
days	O
and	O
his	O
color	O
was	O
excellent	O
by	O
the	O
time	O
he	O
was	O
discharged	O
from	O
the	O
hospital	O
on	O
the	O
thirteenth	O
postoperative	O
day	O
.	O

He	O
rapidly	O
found	O
that	O
he	O
was	O
now	O
able	O
to	O
lead	O
a	O
quite	O
normal	O
sort	O
of	O
life	O
.	O

When	O
he	O
was	O
seen	O
on	O
December	O
9	O
he	O
stated	O
that	O
he	O
had	O
no	O
limitation	O
in	O
exercise	O
capacity	O
.	O

He	O
could	O
walk	O
rapidly	O
without	O
fatigue	O
.	O

He	O
was	O
going	O
to	O
school	O
and	O
was	O
playing	O
the	O
drums	O
in	O
a	O
professional	O
orchestra	O
three	O
or	O
four	O
nights	O
each	O
week	O
.	O

There	O
was	O
some	O
diminution	O
in	O
the	O
clubbing	O
and	O
his	O
color	O
was	O
excellent	O
.	O

There	O
was	O
a	O
loud	O
continuous	O
bruit	O
audible	O
in	O
the	O
chest	O
.	O

On	O
March	O
27	O
the	O
arterial	O
oxygen	O
saturation	O
was	O
88.2	O
per	O
cent	O
.	O

When	O
I	O
first	O
used	O
this	O
procedure	O
I	O
was	O
rather	O
surprised	O
that	O
such	O
tissues	O
would	O
hold	O
sutures	O
and	O
serve	O
satisfactorily	O
to	O
elevate	O
the	O
hilum	O
.	O

On	O
occasions	O
I	O
had	O
previously	O
toyed	O
with	O
the	O
idea	O
of	O
suturing	O
hilar	O
pleura	O
to	O
the	O
mediastinal	O
pleura	O
but	O
had	O
abandoned	O
it	O
as	O
impractical	O
because	O
the	O
sutures	O
seemed	O
to	O
pull	O
out	O
whenever	O
there	O
was	O
any	O
tension	O
whatsoever	O
.	O

If	O
the	O
procedure	O
is	O
to	O
be	O
successful	O
,	O
it	O
is	O
essential	O
that	O
the	O
sutures	O
encompass	O
any	O
adjacent	O
areolar	O
and	O
fibrous	O
tissue	O
and	O
especially	O
the	O
so	O
-	O
called	O
vascular	O
sheath	O
which	O
surrounds	O
both	O
pulmonary	O
artery	O
and	O
aorta	O
and	O
is	O
dissected	O
free	O
during	O
the	O
course	O
of	O
the	O
operation	O
.	O

Fortunately	O
,	O
in	O
its	O
proximal	O
portion	O
the	O
sheath	O
about	O
the	O
pulmonary	O
artery	O
gains	O
added	O
strength	O
from	O
the	O
extension	O
into	O
it	O
of	O
a	O
reflection	O
of	O
the	O
fibrous	O
pericardium	O
.	O

Sutures	O
through	O
the	O
mediastinal	O
pleura	O
in	O
the	O
region	O
of	O
the	O
aortic	O
arch	O
purposely	O
include	O
the	O
perivascular	O
tissues	O
which	O
have	O
been	O
stripped	O
off	O
the	O
aorta	O
and	O
subclavian	O
artery	O
and	O
also	O
any	O
other	O
available	O
tissue	O
which	O
may	O
lend	O
strength	O
,	O
such	O
as	O
the	O
divided	O
ends	O
of	O
the	O
supreme	O
intercostal	O
vein	O
or	O
other	O
vessels	O
which	O
lhave	O
been	O
transected	O
and	O
ligated	O
.	O

The	O
exact	O
method	O
of	O
repair	O
will	O
vary	O
from	O
case	O
to	O
case	O
.	O

By	O
placing	O
the	O
sutures	O
properly	O
it	O
would	O
seem	O
possible	O
sometimes	O
to	O
displace	O
the	O
pulmonary	O
artery	O
laterally	O
as	O
well	O
as	O
in	O
a	O
cephalad	O
direction	O
if	O
such	O
a	O
maneuver	O
was	O
thought	O
to	O
be	O
desirable	O
(	O
Fig.	O
2C	O
)	O
.	O

On	O
occasions	O
one	O
would	O
close	O
the	O
pleural	O
defect	O
fairly	O
snugly	O
,	O
on	O
others	O
leave	O
it	O
wide	O
open	O
in	O
places	O
.	O

Discussion	O
Though	O
there	O
is	O
always	O
available	O
some	O
suitable	O
systemic	O
vessel	O
and	O
though	O
the	O
major	O
concern	O
in	O
the	O
operative	O
treatment	O
of	O
the	O
tetralogy	O
of	O
Fallot	O
is	O
the	O
adequacy	O
of	O
the	O
pulmonary	O
artery	O
,	O
from	O
time	O
to	O
time	O
one	O
may	O
find	O
the	O
achievement	O
of	O
a	O
satisfactory	O
result	O
thwarted	O
by	O
the	O
local	O
anatomical	O
characteristics	O
regardless	O
of	O
one	O
's	O
choice	O
of	O
procedure	O
.	O

Consequently	O
,	O
those	O
modifications	O
which	O
may	O
add	O
to	O
the	O
likelihood	O
of	O
a	O
successful	O
outcome	O
are	O
important	O
.	O

Blalock	O
""""	O
'	O
pointed	O
out	O
the	O
practicability	O
of	O
performing	O
an	O
end	O
-	O
toend	O
subclavian	O
-	O
pulmonary	O
artery	O
anastomosis	O
whenever	O
the	O
pulmonary	O
artery	O
is	O
judged	O
too	O
small	O
or	O
the	O
subclavian	O
too	O
short	O
for	O
a	O
satisfactory	O
end	O
490	O
TREATMENT	O
OF	O
TETRALOGY	O
OF	O
FALLOT	O
491	O
to	O
-	O
side	O
anastomosis	O
.	O

Holman	O
'	O
feels	O
that	O
a	O
poorly	O
functioning	O
shunt	O
after	O
end	O
-	O
to	O
-	O
side	O
anastomosis	O
can	O
usually	O
be	O
corrected	O
by	O
proximal	O
division	O
of	O
the	O
subclavian	O
artery	O
,	O
thus	O
in	O
effect	O
converting	O
the	O
procedure	O
into	O
an	O
end	O
-	O
to	O
-	O
end	O
anastomosis	O
.	O

If	O
a	O
satisfactory	O
end	O
-	O
to	O
-	O
side	O
suture	O
of	O
subclavian	O
and	O
pulmonary	O
arteries	O
or	O
side	O
-	O
to	O
-	O
side	O
aortic	O
pulmonary	O
anastomosis	O
seems	O
difficult	O
to	O
achieve	O
,	O
one	O
may	O
occasionally	O
find	O
it	O
useful	O
to	O
divide	O
the	O
upper	O
lobe	O
branch	O
of	O
the	O
pulmonary	O
artery	O
and	O
carry	O
out	O
an	O
end	O
-	O
to	O
-	O
end	O
suture	O
of	O
the	O
subclavian	O
and	O
the	O
proximal	O
end	O
of	O
the	O
upper	O
lobe	O
branch	O
.	O

Potts	O
and	O
Smith	O
'	O
performed	O
an	O
anastomosis	O
between	O
the	O
proximal	O
end	O
of	O
the	O
upper	O
lobe	O
branch	O
and	O
the	O
side	O
of	O
the	O
aorta	O
in	O
a	O
case	O
in	O
which	O
complete	O
temporary	O
occlusion	O
of	O
the	O
main	O
pulmonary	O
artery	O
was	O
withstood	O
poorly	O
.	O

I	O
have	O
found	O
this	O
principle	O
of	O
division	O
of	O
the	O
upper	O
lobe	O
branch	O
and	O
use	O
of	O
its	O
proximal	O
end	O
of	O
value	O
in	O
obtaining	O
a	O
suitable	O
subclavian	O
pulmonary	O
anastomosis	O
when	O
the	O
subclavian	O
seemed	O
to	O
have	O
inadequate	O
length	O
.	O

On	O
occasions	O
when	O
the	O
systemic	O
vessel	O
seems	O
too	O
short	O
,	O
one	O
may	O
elect	O
to	O
interpose	O
a	O
free	O
vascular	O
transplant,3	O
""""	O
'	O
a	O
modification	O
I	O
first	O
employed	O
in	O
1946	O
though	O
unfortunately	O
not	O
with	O
success	O
in	O
this	O
instance	O
.	O

The	O
operation	O
performed	O
in	O
my	O
first	O
patient	O
constitutes	O
in	O
reality	O
the	O
use	O
of	O
the	O
subclavian	O
artery	O
as	O
an	O
autogenous	O
graft	O
between	O
the	O
aorta	O
and	O
pulmonary	O
artery	O
.	O

It	O
will	O
obviously	O
not	O
often	O
be	O
the	O
procedure	O
of	O
choice	O
but	O
sometimes	O
may	O
be	O
found	O
a	O
useful	O
measure	O
in	O
converting	O
an	O
apparently	O
inadequate	O
functional	O
shunt	O
into	O
a	O
good	O
one	O
.	O

If	O
my	O
initial	O
experiences	O
with	O
the	O
plastic	O
repair	O
of	O
the	O
defect	O
in	O
the	O
mediastinal	O
and	O
hilar	O
structures	O
are	O
characteristic	O
of	O
what	O
may	O
be	O
expected	O
of	O
this	O
procedure	O
,	O
it	O
would	O
seem	O
to	O
have	O
wide	O
applicability	O
whenever	O
a	O
poorly	O
functioning	O
subclavian	O
-	O
pulmonary	O
shunt	O
seems	O
correctable	O
by	O
cephalad	O
transplantation	O
of	O
the	O
hilar	O
structures	O
and	O
the	O
consequent	O
release	O
of	O
tension	O
.	O

I	O
was	O
unaware	O
of	O
any	O
reference	O
in	O
the	O
literature	O
to	O
its	O
use	O
until	O
belatedly	O
I	O
discovered	O
that	O
I	O
had	O
overlooked	O
a	O
statement	O
in	O
the	O
legend	O
of	O
one	O
of	O
the	O
excellent	O
drawings	O
in	O
Blalock	O
's	O
paper	O
on	O
surgical	O
procedures	O
in	O
pulmonic	O
stenosis	O
.	O
'	O

Here	O
he	O
states	O
that	O
suture	O
of	O
the	O
pleura	O
of	O
the	O
superior	O
aspect	O
of	O
the	O
hilum	O
to	O
the	O
mediastinal	O
pleura	O
may	O
effectively	O
elevate	O
a	O
little	O
the	O
pulmonary	O
artery	O
.	O

Perhaps	O
our	O
more	O
detailed	O
consideration	O
of	O
this	O
maneuver	O
may	O
add	O
to	O
its	O
general	O
usefulness	O
.	O

REFERENCES	O
1	O
Blalock	O
,	O
A.	O
:	O
The	O
technique	O
of	O
creation	O
of	O
an	O
artificial	O
ductus	O
arteriosus	O
in	O
the	O
treatment	O
of	O
pulmonic	O
stenosis	O
.	O

J.	O
Thorac	O
.	O

Surg	O
.	O
,	O
1947	O
,	O
16	O
,	O
244	O
.	O

2	O
Blalock	O
,	O
A.	O
:	O
Surgical	O
procedures	O
employed	O
and	O
anatomical	O
variations	O
encountered	O
in	O
the	O
treatment	O
of	O
congenital	O
pulmonic	O
stenosis	O
.	O

Surg	O
.	O
,	O
Gyn	O
.	O

Obst	O
.	O
,	O
1948	O
,	O
87	O
,	O
385	O
.	O

3	O
Gross	O
,	O
R.	O
E.	O
,	O
Bill	O
,	O
A.	O
H.	O
,	O
Jr.	O
,	O
and	O
Pierce	O
,	O
E.	O
C.	O
:	O

Methods	O
for	O
preservation	O
and	O
transplantation	O
of	O
aortic	O
grafts	O
.	O

Observation	O
on	O
arterial	O
grafts	O
in	O
dogs	B
.	O

Report	O
of	O
transplantation	O
of	O
preserved	O
arterial	O
grafts	O
in	O
nine	O
human	B
cases	O
.	O

Surg	O
.	O
,	O
Gyn	O
.	O

Obst	O
.	O
,	O
1949	O
,	O
88	O
,	O
689	O
.	O

4	O
Holman	O
,	O
E.	O
:	O
The	O
surgery	O
of	O
pulmonary	O
stenosis	O
.	O

Experiences	O
with	O
left	O
subclavian	O
to	O
left	O
pulmonary	O
artery	O
anastomosis	O
.	O

J.	O
Thorac	O
.	O

Surg	O
.	O
,	O
1949	O
,	O
18	O
,	O
827	O
.	O

5	O
Johnson	O
,	O
J.	O
,	O
Kirby	O
,	O
C.	O
K.	O
,	O
Greifenstein	O
,	O
F.	O
E.	O
,	O
and	O
Costillo	O
,	O
A.	O
:	O
The	O
experimental	O
and	O
clinical	O
use	O
of	O
vein	O
grafts	O
to	O
replace	O
defects	O
of	O
large	O
arteries	O
.	O

Surgery	O
,	O
1949	O
,	O
26	O
,	O
945	O
.	O

492	O
YALE	O
JOURNAL	O
OF	O
BIOLOGY	O
AND	O
MEDICINE	O
6	O
Lam	O
,	O
C.	O
R.	O
:	O
The	O
choice	O
of	O
the	O
side	O
for	O
approach	O
in	O
operations	O
for	O
pulmonary	O
stenosis	O
.	O

J.	O
Thorac	O
.	O

Surg	O
.	O
,	O
1949	O
,	O
18	O
,	O
661	O
.	O

7	O
Olim	O
,	O
C.	O
B.	O
:	O
Experiences	O
in	O
the	O
surgical	O
treatment	O
of	O
congenital	O
pulmonary	O
stenosis	O
.	O

American	O
Surgeon	O
,	O
1951	O
,	O
17	O
,	O
245	O
.	O

8	O
Paine	O
,	O
J.	O
R.	O
and	O
Varco	O
,	O
R.	O
C.	O
:	O

Experiences	O
with	O
the	O
surgical	O
treatment	O
of	O
pul	O
monic	O
stenosis	O
.	O

Surgery	O
,	O
1948	O
,	O
24	O
,	O
355	O
.	O

9	O
Potts	O
,	O
W.	O
J.	O
and	O
Smith	O
,	O
S.	O
:	O
New	O
surgical	O
procedures	O
in	O
certain	O
cases	O
of	O
congenital	O
pulmonary	O
stenosis	O
.	O

Arch	O
.	O

Surg	O
.	O
,	O
1949	O
,	O
59	O
,	O
491	O
.	O

10	O
Potts	O
,	O
W.	O
J.	O
,	O
Smith	O
S.	O
,	O
and	O
Gibson	O
,	O
S.	O
:	O
Anastomosis	O
of	O
the	O
aorta	O
to	O
a	O
pulmonary	O
artery	O
;	O
certain	O
types	O
in	O
congenital	O
heart	O
disease	O
.	O

J.	O
Am	O
.	O

M.	O
Ass	O
.	O
,	O
1946	O
,	O
132	O
,	O
627	O
.	O

A	O
Case	O
-	O
Control	O
Study	O
to	O
Assess	O
the	O
Relationship	O
between	O
Poverty	O
and	O
Visual	O
Impairment	O
from	O
Cataract	O
in	O
Kenya	O
,	O
the	O
Philippines	O
,	O
and	O
Bangladesh	O
Abstract	O
Background	O
The	O
link	O
between	O
poverty	O
and	O
health	O
is	O
central	O
to	O
the	O
Millennium	O
Development	O
Goals	O
(	O
MDGs	O
)	O
.	O

Poverty	O
can	O
be	O
both	O
a	O
cause	O
and	O
consequence	O
of	O
poor	O
health	O
,	O
but	O
there	O
are	O
few	O
epidemiological	O
studies	O
exploring	O
this	O
complex	O
relationship	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
association	O
between	O
visual	O
impairment	O
from	O
cataract	O
and	O
poverty	O
in	O
adults	O
in	O
Kenya	O
,	O
Bangladesh	O
,	O
and	O
the	O
Philippines	O
.	O

Methods	O
and	O
Findings	O
A	O
population	O
-	O
based	O
case	O
–	O
control	O
study	O
was	O
conducted	O
in	O
three	O
countries	O
during	O
2005–2006	O
.	O

Cases	O
were	O
persons	O
aged	O
50	O
y	O
or	O
older	O
and	O
visually	O
impaired	O
due	O
to	O
cataract	O
(	O
visual	O
acuity	O
<	O
6	O
/	O
24	O
in	O
the	O
better	O
eye	O
)	O
.	O

Controls	O
were	O
persons	O
age-	O
and	O
sex	O
-	O
matched	O
to	O
the	O
case	O
participants	O
with	O
normal	O
vision	O
selected	O
from	O
the	O
same	O
cluster	O
.	O

Household	O
expenditure	O
was	O
assessed	O
through	O
the	O
collection	O
of	O
detailed	O
consumption	O
data	O
,	O
and	O
asset	O
ownership	O
and	O
self	O
-	O
rated	O
wealth	O
were	O
also	O
measured	O
.	O

In	O
total	O
,	O
596	O
cases	O
and	O
535	O
controls	O
were	O
included	O
in	O
these	O
analyses	O
(	O
Kenya	O
142	O
cases	O
,	O
75	O
controls	O
;	O
Bangladesh	O
216	O
cases	O
,	O
279	O
controls	O
;	O
Philippines	O
238	O
cases	O
,	O
180	O
controls	O
)	O
.	O

Case	O
participants	O
were	O
more	O
likely	O
to	O
be	O
in	O
the	O
lowest	O
quartile	O
of	O
per	O
capita	O
expenditure	O
(	O
PCE	O
)	O
compared	O
to	O
controls	O
in	O
Kenya	O
(	O
odds	O
ratio	O
=	O
2.3	O
,	O
95	O
%	O
confidence	O
interval	O
0.9–5.5	O
)	O
,	O
Bangladesh	O
(	O
1.9	O
,	O
1.1–3.2	O
)	O
,	O
and	O
the	O
Philippines	O
(	O
3.1	O
,	O
1.7–5.7	O
)	O
,	O
and	O
there	O
was	O
significant	O
dose	O
–	O
response	O
relationship	O
across	O
quartiles	O
of	O
PCE	O
.	O

These	O
associations	O
persisted	O
after	O
adjustment	O
for	O
self	O
-	O
rated	O
health	O
and	O
social	O
support	O
indicators	O
.	O

A	O
similar	O
pattern	O
was	O
observed	O
for	O
the	O
relationship	O
between	O
cataract	O
visual	O
impairment	O
with	O
asset	O
ownership	O
and	O
self	O
-	O
rated	O
wealth	O
.	O

There	O
was	O
no	O
consistent	O
pattern	O
of	O
association	O
between	O
PCE	O
and	O
level	O
of	O
visual	O
impairment	O
due	O
to	O
cataract	O
,	O
sex	O
,	O
or	O
age	O
among	O
the	O
three	O
countries	O
.	O

Conclusions	O
Our	O
data	O
show	O
that	O
people	O
with	O
visual	O
impairment	O
due	O
to	O
cataract	O
were	O
poorer	O
than	O
those	O
with	O
normal	O
sight	O
in	O
all	O
three	O
low	O
-	O
income	O
countries	O
studied	O
.	O

The	O
MDGs	O
are	O
committed	O
to	O
the	O
eradication	O
of	O
extreme	O
poverty	O
and	O
provision	O
of	O
health	O
care	O
to	O
poor	O
people	O
,	O
and	O
this	O
study	O
highlights	O
the	O
need	O
for	O
increased	O
provision	O
of	O
cataract	O
surgery	O
to	O
poor	O
people	O
,	O
as	O
they	O
are	O
particularly	O
vulnerable	O
to	O
visual	O
impairment	O
from	O
cataract	O
.	O

Background	O
.	O

Globally	O
,	O
about	O
45	O
million	O
people	O
are	O
blind	O
.	O

As	O
with	O
many	O
other	O
conditions	O
,	O
avoidable	O
blindness	O
(	O
preventable	O
or	O
curable	O
blindness	O
)	O
is	O
a	O
particular	O
problem	O
for	O
people	O
in	O
developing	O
countries—90	O
%	O
of	O
blind	O
people	O
live	O
in	O
poor	O
regions	O
of	O
the	O
world	O
.	O

Although	O
various	O
infections	O
and	O
disorders	O
can	O
cause	O
blindness	O
,	O
cataract	O
is	O
the	O
most	O
common	O
cause	O
.	O

In	O
cataract	O
,	O
which	O
is	O
responsible	O
for	O
half	O
of	O
all	O
cases	O
of	O
blindness	O
in	O
the	O
world	O
,	O
the	O
lens	O
of	O
the	O
eye	O
gradually	O
becomes	O
cloudy	O
.	O

Because	O
the	O
lens	O
focuses	O
light	O
to	O
produce	O
clear	O
,	O
sharp	O
images	O
,	O
as	O
cataract	O
develops	O
,	O
vision	O
becomes	O
increasingly	O
foggy	O
or	O
fuzzy	O
,	O
colors	O
become	O
less	O
intense	O
,	O
and	O
the	O
ability	O
to	O
see	O
shapes	O
against	O
a	O
background	O
declines	O
.	O

Eventually	O
,	O
vision	O
may	O
be	O
lost	O
completely	O
.	O

Cataract	O
can	O
be	O
treated	O
with	O
an	O
inexpensive	O
,	O
simple	O
operation	O
in	O
which	O
the	O
cloudy	O
lens	O
is	O
surgically	O
removed	O
and	O
an	O
artificial	O
lens	O
is	O
inserted	O
into	O
the	O
eye	O
to	O
restore	O
vision	O
.	O

In	O
developed	O
countries	O
,	O
this	O
operation	O
is	O
common	O
and	O
easily	O
accessible	O
but	O
many	O
poor	O
countries	O
lack	O
the	O
resources	O
to	O
provide	O
the	O
operation	O
to	O
everyone	O
who	O
needs	O
it	O
.	O

In	O
addition	O
,	O
blind	O
people	O
often	O
can	O
not	O
afford	O
to	O
travel	O
to	O
the	O
hospitals	O
where	O
the	O
operation	O
,	O
which	O
also	O
may	O
come	O
with	O
a	O
fee	O
,	O
is	O
done	O
.	O

Why	O
Was	O
This	O
Study	O
Done	O
?	O
Because	O
blindness	O
may	O
reduce	O
earning	O
potential	O
,	O
many	O
experts	O
believe	O
that	O
poverty	O
and	O
blindness	O
(	O
and	O
,	O
more	O
generally	O
,	O
poor	O
health	O
)	O
are	O
inextricably	O
linked	O
.	O

People	O
become	O
ill	O
more	O
often	O
in	O
poor	O
countries	O
than	O
in	O
wealthy	O
countries	O
because	O
they	O
have	O
insufficient	O
food	O
,	O
live	O
in	O
substandard	O
housing	O
,	O
and	O
have	O
limited	O
access	O
to	O
health	O
care	O
,	O
education	O
,	O
water	O
,	O
and	O
sanitation	O
.	O

Once	O
they	O
are	O
ill	O
,	O
their	O
ability	O
to	O
earn	O
money	O
may	O
be	O
reduced	O
,	O
which	O
increases	O
their	O
personal	O
poverty	O
and	O
slows	O
the	O
economic	O
development	O
of	O
the	O
whole	O
country	O
.	O

Because	O
of	O
this	O
potential	O
link	O
between	O
health	O
and	O
poverty	O
,	O
improvements	O
in	O
health	O
are	O
at	O
the	O
heart	O
of	O
the	O
United	O
Nations	O
Millennium	O
Development	O
Goals	O
,	O
a	O
set	O
of	O
eight	O
goals	O
established	O
in	O
2000	O
with	O
the	O
primary	O
aim	O
of	O
reducing	O
world	O
poverty	O
.	O

However	O
,	O
few	O
studies	O
have	O
actually	O
investigated	O
the	O
complex	O
relationship	O
between	O
poverty	O
and	O
health	O
.	O

Here	O
,	O
the	O
researchers	O
investigate	O
the	O
association	O
between	O
visual	O
impairment	O
from	O
cataract	O
and	O
poverty	O
among	O
adults	O
living	O
in	O
three	O
low	O
-	O
income	O
countries	O
.	O

What	O
Did	O
the	O
Researchers	O
Do	O
and	O
Find	O
?	O

The	O
researchers	O
identified	O
nearly	O
600	O
people	O
aged	O
50	O
y	O
or	O
more	O
with	O
severe	O
cataract	O
-	O
induced	O
visual	O
impairment	O
(	O
""""	O
cases	O
""""	O
)	O
primarily	O
through	O
a	O
survey	O
of	O
the	O
population	O
in	O
Kenya	O
,	O
Bangladesh	O
,	O
and	O
the	O
Philippines	O
.	O

They	O
matched	O
each	O
case	O
to	O
a	O
normally	O
sighted	O
(	O
""""	O
control	O
""""	O
)	O
person	O
of	O
similar	O
age	O
and	O
sex	O
living	O
nearby	O
.	O

They	O
then	O
assessed	O
a	O
proxy	O
for	O
the	O
income	O
level	O
,	O
measured	O
as	O
""""	O
per	O
capita	O
expenditure	O
""""	O
(	O
PCE	O
)	O
,	O
of	O
all	O
the	O
study	O
participants	O
(	O
people	O
with	O
cataracts	O
and	O
controls	O
)	O
by	O
collecting	O
information	O
about	O
what	O
their	O
households	O
consumed	O
.	O

The	O
participants	O
'	O
housing	O
conditions	O
and	O
other	O
assets	O
and	O
their	O
self	O
-	O
rated	O
wealth	O
were	O
also	O
measured	O
.	O

In	O
all	O
three	O
countries	O
,	O
cases	O
were	O
more	O
likely	O
to	O
be	O
in	O
the	O
lowest	O
quarter	O
(	O
quartile	O
)	O
of	O
the	O
range	O
of	O
PCEs	O
for	O
that	O
country	O
than	O
controls	O
.	O

In	O
the	O
Philippines	O
,	O
for	O
example	O
,	O
people	O
with	O
cataract	O
-	O
affected	O
vision	O
were	O
three	O
times	O
more	O
likely	O
than	O
normally	O
sighted	O
controls	O
to	O
have	O
a	O
PCE	O
in	O
the	O
lowest	O
quartile	O
than	O
in	O
the	O
highest	O
quartile	O
.	O

The	O
risk	O
of	O
cataract	O
-	O
related	O
visual	O
impairment	O
increased	O
as	O
PCE	O
decreased	O
in	O
all	O
three	O
countries	O
.	O

Similarly	O
,	O
severe	O
cataract	O
-	O
induced	O
visual	O
impairment	O
was	O
more	O
common	O
in	O
those	O
who	O
owned	O
fewer	O
assets	O
and	O
those	O
with	O
lower	O
self	O
-	O
rated	O
wealth	O
.	O

However	O
,	O
there	O
was	O
no	O
consistent	O
association	O
between	O
PCE	O
and	O
the	O
level	O
of	O
cataract	O
-	O
induced	O
visual	O
impairment	O
.	O

What	O
Do	O
These	O
Findings	O
Mean	O
?	O

These	O
findings	O
show	O
that	O
there	O
is	O
an	O
association	O
between	O
visual	O
impairment	O
caused	O
by	O
cataract	O
and	O
poverty	O
in	O
Kenya	O
,	O
Bangladesh	O
,	O
and	O
the	O
Philippines	O
.	O

However	O
,	O
because	O
the	O
financial	O
circumstances	O
of	O
the	O
people	O
in	O
this	O
study	O
were	O
assessed	O
after	O
cataracts	O
had	O
impaired	O
their	O
sight	O
,	O
this	O
study	O
does	O
not	O
prove	O
that	O
poverty	O
is	O
a	O
cause	O
of	O
visual	O
impairment	O
.	O

A	O
causal	O
connection	O
between	O
poverty	O
and	O
cataract	O
can	O
only	O
be	O
shown	O
by	O
determining	O
the	O
PCEs	O
of	O
normally	O
sighted	O
people	O
and	O
following	O
them	O
for	O
several	O
years	O
to	O
see	O
who	O
develops	O
cataract	O
.	O

Nevertheless	O
,	O
by	O
confirming	O
an	O
association	O
between	O
poverty	O
and	O
blindness	O
,	O
these	O
findings	O
highlight	O
the	O
need	O
for	O
increased	O
provision	O
of	O
cataract	O
surgery	O
to	O
poor	O
people	O
,	O
particularly	O
since	O
cataract	O
surgery	O
has	O
the	O
potential	O
to	O
improve	O
the	O
quality	O
of	O
life	O
for	O
many	O
people	O
in	O
developing	O
countries	O
at	O
a	O
relatively	O
low	O
cost	O
.	O

Additional	O
Information	O
.	O

Please	O
access	O
these	O
Web	O
sites	O
via	O
the	O
online	O
version	O
of	O
this	O
summary	O
at	O
http://dx.doi.org/10.1371/journal.pmed.0050244	O
.	O

Introduction	O
Improvements	O
in	O
health	O
are	O
at	O
the	O
heart	O
of	O
the	O
Millennium	O
Development	O
Goals	O
,	O
with	O
the	O
recognition	O
that	O
better	O
health	O
is	O
central	O
to	O
the	O
primary	O
aim	O
of	O
reducing	O
poverty	O
as	O
well	O
as	O
important	O
in	O
its	O
own	O
right	O
.	O

Empirical	O
data	O
are	O
needed	O
to	O
back	O
up	O
this	O
claim	O
.	O

Unravelling	O
the	O
relationship	O
between	O
blindness	O
and	O
poverty	O
therefore	O
has	O
important	O
implications	O
,	O
and	O
may	O
also	O
be	O
informative	O
for	O
the	O
association	O
between	O
poverty	O
and	O
other	O
disabilities	O
.	O

Blindness	O
is	O
a	O
common	O
condition	O
globally	O
,	O
affecting	O
approximately	O
45	O
million	O
people	O
,	O
and	O
more	O
than	O
a	O
third	O
of	O
blindness	O
is	O
caused	O
by	O
cataract	O
[	O
1,2	O
]	O
.	O

Globally	O
,	O
the	O
prevalence	O
of	O
blindness	O
is	O
five	O
-	O
fold	O
higher	O
in	O
poor	O
than	O
rich	O
countries	O
[	O
2	O
]	O
.	O

Limited	O
data	O
show	O
that	O
within	O
countries	O
the	O
poor	O
are	O
also	O
more	O
likely	O
to	O
be	O
blind	O
[	O
3,4	O
]	O
.	O

It	O
is	O
frequently	O
asserted	O
that	O
blindness	O
is	O
both	O
a	O
cause	O
and	O
consequence	O
of	O
poverty	O
,	O
but	O
there	O
are	O
few	O
empirical	O
data	O
to	O
support	O
this	O
claim	O
.	O

Poverty	O
may	O
cause	O
cataract	O
blindness	O
,	O
because	O
access	O
to	O
cataract	O
surgery	O
is	O
limited	O
in	O
low	O
-	O
income	O
countries	O
[	O
5	O
]	O
.	O

Furthermore	O
,	O
within	O
poor	O
countries	O
some	O
evidence	O
suggests	O
that	O
lack	O
of	O
money	O
is	O
a	O
major	O
barrier	O
to	O
uptake	O
of	O
cataract	O
surgery	O
by	O
individuals	O
[	O
6–8	O
]	O
.	O

Blindness	O
may	O
also	O
cause	O
poverty	O
,	O
as	O
the	O
blind	O
individual	O
,	O
or	O
the	O
household	O
members	O
who	O
care	O
for	O
them	O
,	O
have	O
a	O
reduced	O
earning	O
potential	O
[	O
4,9	O
]	O
.	O

This	O
complex	O
problem	O
could	O
have	O
serious	O
implications	O
;	O
estimates	O
from	O
The	O
Gambia	O
suggest	O
that	O
there	O
is	O
a	O
substantial	O
economic	O
burden	O
from	O
lost	O
productivity	O
among	O
blind	O
people	O
[	O
10	O
]	O
.	O

Therefore	O
,	O
blindness	O
prevention	O
may	O
ultimately	O
be	O
cost	O
saving	O
[	O
11	O
]	O
.	O

Extrapolations	O
on	O
a	O
global	O
level	O
indicate	O
that	O
a	O
successful	O
eye	O
care	O
programme	O
could	O
prevent	O
more	O
than	O
100	O
million	O
cases	O
of	O
blindness	O
between	O
2000	O
and	O
2020	O
,	O
and	O
consequently	O
save	O
at	O
least	O
US$	O
102	O
billion	O
,	O
which	O
would	O
otherwise	O
be	O
lost	O
to	O
reductions	O
in	O
productivity	O
associated	O
with	O
blindness	O
[	O
12	O
]	O
.	O

However	O
,	O
these	O
estimates	O
are	O
based	O
on	O
extrapolations	O
from	O
limited	O
data	O
and	O
were	O
not	O
based	O
on	O
individual	O
-	O
level	O
data	O
.	O

It	O
is	O
also	O
difficult	O
to	O
identify	O
the	O
component	O
of	O
productivity	O
loss	O
that	O
is	O
due	O
to	O
blindness	O
,	O
as	O
this	O
condition	O
mainly	O
affects	O
older	O
people	O
,	O
who	O
may	O
suffer	O
from	O
other	O
comorbidities	O
that	O
restrict	O
their	O
employment	O
opportunities	O
or	O
make	O
them	O
dependent	O
on	O
the	O
care	O
of	O
others	O
.	O

The	O
Cataract	O
Impact	O
Study	O
was	O
undertaken	O
to	O
assess	O
the	O
relationship	O
between	O
cataract	O
visual	O
impairment	O
and	O
""""	O
economic	O
poverty	O
""""	O
and	O
quality	O
of	O
life	O
,	O
and	O
to	O
estimate	O
the	O
impact	O
of	O
cataract	O
surgery	O
on	O
these	O
factors	O
in	O
three	O
low	O
-	O
income	O
countries	O
.	O

The	O
aim	O
of	O
the	O
current	O
paper	O
is	O
to	O
assess	O
the	O
association	O
at	O
baseline	O
between	O
visual	O
impairment	O
from	O
cataract	O
and	O
household	O
poverty	O
(	O
measured	O
through	O
consumption	O
,	O
asset	O
ownership	O
,	O
and	O
self	O
-	O
rated	O
wealth	O
)	O
in	O
a	O
population	O
-	O
based	O
case	O
–	O
control	O
study	O
in	O
Kenya	O
,	O
the	O
Philippines	O
,	O
and	O
Bangladesh	O
.	O

Methods	O
Setting	O
Case	O
and	O
control	O
participants	O
were	O
recruited	O
from	O
Nakuru	O
district	O
,	O
Kenya	O
(	O
January	O
–	O
February	O
,	O
2005	O
)	O
;	O
Negros	O
island	O
(	O
May	O
–	O
June	O
,	O
2005	O
)	O
and	O
Antique	O
district	O
(	O
April	O
–	O
May	O
,	O
2006	O
)	O
,	O
Philippines	O
;	O
and	O
Satkhira	O
district	O
,	O
Bangladesh	O
(	O
November	O
–	O
December	O
,	O
2005	O
)	O
.	O

Selection	O
of	O
Cases	O
and	O
Controls	O
Persons	O
with	O
cataract	O
visual	O
impairment	O
(	O
cases	O
)	O
and	O
persons	O
without	O
(	O
controls	O
)	O
were	O
primarily	O
recruited	O
through	O
a	O
population	O
-	O
based	O
survey	O
of	O
adults	O
aged	O
≥	O
50	O
y	O
[	O
6–8	O
]	O
.	O

Clusters	O
of	O
50	O
people	O
(	O
regardless	O
of	O
visual	O
impairment	O
)	O
aged	O
≥	O
50	O
y	O
were	O
selected	O
through	O
probability	O
-	O
proportionate	O
to	O
size	O
sampling	O
,	O
using	O
either	O
the	O
census	O
(	O
Philippines	O
and	O
Bangladesh	O
)	O
or	O
electoral	O
role	O
(	O
Kenya	O
)	O
as	O
the	O
sampling	O
frame	O
.	O

Households	O
within	O
clusters	O
were	O
selected	O
through	O
a	O
modification	O
of	O
compact	O
segment	O
sampling	O
,	O
whereby	O
a	O
map	O
was	O
drawn	O
of	O
the	O
enumeration	O
area	O
that	O
was	O
divided	O
into	O
segments	O
,	O
each	O
including	O
approximately	O
50	O
people	O
aged	O
≥	O
50	O
y	O
,	O
and	O
one	O
segment	O
was	O
chosen	O
at	O
random	O
[	O
13	O
]	O
.	O

Households	O
in	O
the	O
segment	O
were	O
included	O
sequentially	O
until	O
50	O
people	O
aged	O
≥	O
50	O
y	O
were	O
identified	O
.	O

The	O
surveys	O
included	O
3,503	O
(	O
93	O
%	O
response	O
rate	O
)	O
people	O
aged	O
≥	O
50	O
y	O
in	O
Kenya	O
,	O
4,868	O
(	O
92	O
%	O
)	O
in	O
Bangladesh	O
,	O
2,774	O
(	O
76	O
%	O
)	O
in	O
Negros	O
,	O
and	O
3,177	O
(	O
83	O
%	O
)	O
in	O
Antique	O
.	O

All	O
people	O
in	O
the	O
survey	O
aged	O
≥	O
50	O
y	O
underwent	O
visual	O
acuity	O
(	O
VA	O
)	O
testing	O
and	O
ophthalmic	O
examination	O
.	O

VA	O
was	O
measured	O
in	O
full	O
daylight	O
with	O
available	O
spectacle	O
correction	O
with	O
a	O
Snellen	O
tumbling	O
""""	O
E	O
""""	O
chart	O
using	O
optotype	O
size	O
6	O
/	O
18	O
(	O
20	O
/	O
60	O
)	O
on	O
one	O
side	O
and	O
size	O
6	O
/	O
60	O
(	O
20	O
/	O
200	O
)	O
on	O
the	O
other	O
side	O
at	O
6	O
or	O
3	O
metres	O
.	O

If	O
the	O
VA	O
was	O
<	O
6	O
/	O
18	O
in	O
either	O
eye	O
then	O
pinhole	O
vision	O
was	O
also	O
measured	O
.	O

Participants	O
with	O
pinhole	O
vision	O
<	O
6	O
/	O
18	O
but	O
>	O
6	O
/	O
60	O
in	O
the	O
better	O
eye	O
due	O
to	O
age	O
-	O
related	O
cataract	O
were	O
given	O
a	O
second	O
VA	O
test	O
using	O
an	O
""""	O
E	O
""""	O
of	O
size	O
6	O
/	O
24	O
.	O

The	O
ophthalmologist	O
examined	O
all	O
eyes	O
with	O
a	O
presenting	O
VA	O
<	O
6	O
/	O
18	O
with	O
a	O
torch	O
(	O
i.e.	O
,	O
flashlight	O
)	O
,	O
direct	O
ophthalmoscope	O
,	O
and/or	O
portable	O
slit	O
lamp	O
.	O

The	O
principal	O
cause	O
of	O
blindness	O
or	O
visual	O
impairment	O
was	O
recorded	O
,	O
according	O
to	O
the	O
WHO	O
convention	O
in	O
which	O
the	O
major	O
cause	O
is	O
assigned	O
to	O
the	O
primary	O
disorder	O
or	O
,	O
if	O
there	O
are	O
two	O
existing	O
primary	O
disorders	O
,	O
to	O
the	O
one	O
that	O
is	O
easiest	O
to	O
treat	O
[	O
14	O
]	O
.	O

Survey	O
participants	O
were	O
eligible	O
for	O
inclusion	O
as	O
cases	O
if	O
they	O
were	O
aged	O
≥	O
50	O
y	O
with	O
best	O
corrected	O
visual	O
acuity	O
<	O
6	O
/	O
24	O
in	O
the	O
better	O
eye	O
due	O
to	O
cataract	O
,	O
as	O
diagnosed	O
by	O
an	O
ophthalmologist	O
.	O

All	O
eligible	O
cases	O
identified	O
from	O
these	O
surveys	O
were	O
invited	O
to	O
participate	O
in	O
the	O
study	O
.	O

Participants	O
were	O
eligible	O
to	O
be	O
controls	O
if	O
they	O
were	O
aged	O
≥	O
50	O
y	O
,	O
did	O
not	O
have	O
VA	O
<	O
6	O
/	O
24	O
in	O
the	O
better	O
eye	O
due	O
to	O
cataract	O
and	O
did	O
not	O
live	O
in	O
the	O
same	O
household	O
as	O
a	O
case	O
.	O

During	O
the	O
survey	O
a	O
list	O
was	O
maintained	O
of	O
all	O
eligible	O
controls	O
,	O
by	O
age	O
group	O
(	O
50–54	O
,	O
55–59	O
,	O
60–64	O
,	O
65–69	O
,	O
and	O
>	O
70	O
)	O
and	O
sex	O
.	O

Whenever	O
a	O
case	O
was	O
identified	O
,	O
one	O
age-	O
and	O
sex	O
-	O
matched	O
control	O
was	O
randomly	O
selected	O
from	O
the	O
list	O
for	O
inclusion	O
(	O
or	O
up	O
to	O
two	O
controls	O
in	O
Bangladesh	O
)	O
.	O

If	O
no	O
matching	O
eligible	O
controls	O
had	O
been	O
identified	O
in	O
that	O
cluster	O
at	O
that	O
stage	O
of	O
the	O
survey	O
,	O
then	O
the	O
next	O
eligible	O
control	O
in	O
the	O
cluster	O
was	O
recruited	O
.	O

Because	O
of	O
logistical	O
and	O
time	O
constraints	O
,	O
additional	O
cases	O
were	O
also	O
included	O
through	O
community	O
-	O
based	O
case	O
detection	O
.	O

In	O
Kenya	O
and	O
Negros	O
(	O
Philippines	O
)	O
,	O
clusters	O
were	O
randomly	O
selected	O
through	O
probability	O
proportionate	O
to	O
size	O
using	O
the	O
same	O
cluster	O
sampling	O
procedure	O
after	O
completion	O
of	O
the	O
population	O
-	O
based	O
survey	O
.	O

Clusters	O
were	O
visited	O
in	O
advance	O
and	O
asked	O
that	O
all	O
people	O
≥	O
50	O
y	O
with	O
vision	O
problems	O
come	O
to	O
a	O
central	O
point	O
on	O
a	O
specified	O
day	O
,	O
and	O
that	O
a	O
list	O
be	O
made	O
of	O
people	O
unable	O
to	O
attend	O
(	O
e.g.	O
,	O
due	O
to	O
blindness	O
or	O
other	O
physical	O
disability	O
)	O
.	O

After	O
examining	O
patients	O
at	O
the	O
central	O
point	O
,	O
the	O
survey	O
team	O
then	O
visited	O
those	O
unable	O
to	O
leave	O
their	O
houses	O
.	O

Any	O
identified	O
eligible	O
cases	O
that	O
agreed	O
to	O
be	O
part	O
of	O
the	O
study	O
were	O
interviewed	O
in	O
their	O
homes	O
.	O

In	O
Bangladesh	O
and	O
Antique	O
(	O
Philippines	O
)	O
,	O
community	O
case	O
detection	O
was	O
carried	O
out	O
simultaneously	O
with	O
the	O
survey	O
by	O
two	O
of	O
the	O
four	O
teams	O
,	O
so	O
that	O
controls	O
were	O
included	O
for	O
these	O
cases	O
.	O

Within	O
each	O
cluster	O
from	O
the	O
survey	O
,	O
one	O
interviewer	O
was	O
asked	O
to	O
be	O
taken	O
to	O
two	O
community	O
members	O
aged	O
≥	O
50	O
y	O
with	O
eye	O
problems	O
,	O
living	O
within	O
the	O
cluster	O
boundaries	O
but	O
not	O
from	O
the	O
segments	O
selected	O
for	O
the	O
survey	O
.	O

If	O
VA	O
was	O
<	O
6	O
/	O
24	O
with	O
pinhole	O
in	O
the	O
better	O
eye	O
,	O
the	O
ophthalmologist	O
was	O
called	O
to	O
carry	O
out	O
the	O
full	O
eye	O
examination	O
,	O
and	O
eligible	O
cases	O
were	O
included	O
in	O
the	O
study	O
.	O

For	O
the	O
purposes	O
of	O
the	O
present	O
analyses	O
,	O
control	O
individuals	O
with	O
any	O
visual	O
impairment	O
(	O
VA	O
<	O
6	O
/	O
18	O
in	O
the	O
better	O
eye	O
)	O
were	O
excluded	O
(	O
n	O
=	O
14	O
in	O
Kenya	O
,	O
n	O
=	O
53	O
in	O
Bangladesh	O
,	O
n	O
=	O
24	O
in	O
the	O
Philippines	O
)	O
.	O

Case	O
and	O
control	O
participants	O
who	O
were	O
significantly	O
communication	O
impaired	O
(	O
e.g.	O
deafness	O
,	O
dementia	O
,	O
or	O
psychiatric	O
disease	O
)	O
were	O
excluded	O
(	O
fewer	O
than	O
five	O
per	O
country	O
)	O
,	O
and	O
one	O
case	O
was	O
excluded	O
in	O
the	O
Philippines	O
because	O
of	O
missing	O
age	O
data	O
.	O

One	O
household	O
had	O
two	O
eligible	O
cases	O
(	O
Kenya	O
)	O
,	O
and	O
one	O
of	O
these	O
participants	O
was	O
excluded	O
for	O
the	O
poverty	O
analyses	O
as	O
poverty	O
was	O
assessed	O
through	O
household	O
level	O
indicators	O
(	O
see	O
below	O
)	O
.	O

In	O
total	O
,	O
147	O
cases	O
(	O
82	O
from	O
the	O
survey	O
and	O
65	O
from	O
case	O
detection	O
)	O
and	O
79	O
controls	O
were	O
included	O
in	O
Kenya	O
;	O
217	O
cases	O
(	O
162	O
from	O
survey	O
and	O
55	O
from	O
case	O
detection	O
)	O
and	O
280	O
controls	O
in	O
Bangladesh	O
;	O
and	O
238	O
cases	O
(	O
146	O
survey	O
and	O
92	O
case	O
detection	O
)	O
and	O
180	O
controls	O
in	O
the	O
Philippines	O
.	O

Data	O
Collection	O
All	O
case	O
and	O
control	O
participants	O
were	O
interviewed	O
in	O
their	O
homes	O
by	O
trained	O
interviewers	O
in	O
the	O
local	O
language	O
.	O

Each	O
interview	O
lasted	O
approximately	O
1	O
h.	O
Measures	O
of	O
poverty	O
.	O

Poverty	O
was	O
measured	O
through	O
(	O
a	O
)	O
monthly	O
per	O
capita	O
expenditure	O
(	O
PCE	O
)	O
to	O
indicate	O
consumption	O
,	O
(	O
b	O
)	O
asset	O
ownership	O
,	O
and	O
(	O
c	O
)	O
self	O
-	O
rated	O
wealth	O
.	O

The	O
economic	O
part	O
of	O
the	O
questionnaires	O
was	O
adapted	O
through	O
interviews	O
,	O
focus	O
group	O
discussions	O
,	O
and	O
pilot	O
testing	O
in	O
each	O
country	O
to	O
ensure	O
local	O
relevance	O
.	O

The	O
person	O
primarily	O
responsible	O
for	O
household	O
finances	O
(	O
which	O
may	O
have	O
been	O
the	O
case	O
/	O
control	O
or	O
another	O
household	O
member	O
)	O
was	O
interviewed	O
to	O
assess	O
PCE	O
and	O
assets	O
.	O

PCE	O
was	O
measured	O
using	O
methods	O
based	O
on	O
the	O
World	O
Bank	O
's	O
Living	O
Standards	O
Measurement	O
Study	O
[	O
15	O
]	O
.	O

Items	O
were	O
included	O
on	O
food	O
(	O
42–52	O
items	O
per	O
country	O
)	O
,	O
education	O
(	O
three	O
items	O
)	O
,	O
health	O
(	O
five	O
items	O
)	O
,	O
household	O
expenses	O
(	O
nine	O
items	O
)	O
,	O
and	O
personal	O
expenses	O
(	O
21	O
or	O
22	O
items	O
)	O
.	O

In	O
total	O
,	O
85	O
items	O
were	O
included	O
in	O
the	O
questionnaire	O
in	O
Kenya	O
,	O
90	O
in	O
the	O
Philippines	O
,	O
and	O
79	O
in	O
Bangladesh	O
.	O

The	O
informant	O
was	O
asked	O
to	O
recall	O
the	O
monetary	O
value	O
of	O
food	O
that	O
was	O
purchased	O
,	O
consumed	O
from	O
home	O
production	O
,	O
or	O
received	O
as	O
payment	O
in	O
kind	O
or	O
as	O
gifts	O
.	O

Consumption	O
was	O
assessed	O
over	O
a	O
1-wk	O
period	O
for	O
frequently	O
consumed	O
items	O
,	O
and	O
this	O
was	O
scaled	O
up	O
to	O
estimate	O
monthly	O
consumption	O
.	O

The	O
amount	O
consumed	O
monthly	O
was	O
assessed	O
for	O
items	O
that	O
were	O
consumed	O
more	O
rarely	O
.	O

Monthly	O
rent	O
was	O
recorded	O
among	O
households	O
who	O
rented	O
,	O
and	O
households	O
who	O
owned	O
their	O
property	O
were	O
asked	O
to	O
estimate	O
the	O
amount	O
that	O
they	O
could	O
charge	O
in	O
rent	O
per	O
month	O
.	O

The	O
consumption	O
on	O
all	O
items	O
was	O
summed	O
to	O
calculate	O
total	O
monthly	O
household	O
consumption	O
,	O
and	O
this	O
was	O
converted	O
to	O
United	O
States	O
dollars	O
(	O
US$	O
)	O
at	O
the	O
2005	O
exchange	O
rate	O
(	O
$	O
1	O
=	O
76	O
Kenya	O
shillings	O
,	O
64	O
Bangladesh	O
taka	O
,	O
55	O
Philippine	O
pesos	O
)	O
.	O

Total	O
monthly	O
household	O
consumption	O
was	O
divided	O
by	O
the	O
number	O
of	O
household	O
members	O
to	O
calculate	O
monthly	O
PCE	O
for	O
the	O
household	O
.	O

The	O
household	O
informant	O
was	O
also	O
asked	O
about	O
the	O
number	O
and	O
type	O
of	O
context	O
-	O
specific	O
assets	O
owned	O
by	O
the	O
household	O
,	O
including	O
different	O
types	O
of	O
furniture	O
,	O
electrical	O
equipment	O
,	O
cattle	B
,	O
and	O
vehicles	O
.	O

Information	O
was	O
collected	O
on	O
household	O
characteristics	O
,	O
including	O
the	O
building	O
material	O
of	O
the	O
floor	O
,	O
roof	O
,	O
and	O
walls	O
;	O
type	O
of	O
toilet	O
;	O
and	O
the	O
number	O
of	O
rooms	O
.	O

Self	O
-	O
rated	O
wealth	O
was	O
assessed	O
by	O
asking	O
the	O
household	O
informant	O
to	O
rank	O
the	O
household	O
's	O
wealth	O
relative	O
to	O
others	O
in	O
the	O
community	O
on	O
a	O
scale	O
from	O
1	O
(	O
poorest	O
)	O
to	O
10	O
(	O
richest	O
)	O
.	O

Covariates	O
.	O

Case	O
and	O
control	O
individuals	O
were	O
interviewed	O
about	O
standard	O
sociodemographic	O
indicators	O
,	O
including	O
household	O
composition	O
,	O
education	O
,	O
and	O
employment	O
.	O

Information	O
was	O
collected	O
on	O
vision	O
-	O
related	O
quality	O
of	O
life	O
using	O
the	O
World	O
Health	O
Organization	O
Prevention	O
of	O
Blindness	O
and	O
Deafness	O
20-item	O
Visual	O
Functioning	O
Questionnaire	O
[	O
16,17	O
]	O
,	O
and	O
health	O
-	O
related	O
quality	O
of	O
life	O
was	O
assessed	O
using	O
items	O
from	O
the	O
European	O
Quality	O
of	O
Life	O
Questionnaire	O
[	O
18	O
]	O
.	O

Detailed	O
time	O
-	O
use	O
data	O
were	O
collected	O
using	O
methods	O
based	O
on	O
the	O
World	O
Bank	O
's	O
Living	O
Standards	O
Measurement	O
Study	O
[	O
15	O
]	O
.	O

Training	O
and	O
Fieldwork	O
Interviewers	O
were	O
trained	O
for	O
1	O
wk	O
,	O
including	O
2	O
d	O
of	O
pilot	O
testing	O
.	O

Attempts	O
were	O
made	O
to	O
minimise	O
measurement	O
bias	O
by	O
emphasising	O
the	O
need	O
for	O
consistency	O
in	O
data	O
collection	O
among	O
cases	O
and	O
controls	O
.	O

The	O
questionnaires	O
were	O
translated	O
into	O
the	O
local	O
languages	O
(	O
three	O
in	O
Kenya	O
,	O
three	O
in	O
the	O
Philippines	O
,	O
and	O
one	O
in	O
Bangladesh	O
)	O
and	O
back	O
-	O
translated	O
by	O
independent	O
translators	O
(	O
one	O
for	O
each	O
language	O
)	O
who	O
were	O
also	O
asked	O
to	O
comment	O
on	O
appropriateness	O
of	O
language	O
used	O
for	O
the	O
target	O
population	O
.	O

A	O
review	O
was	O
held	O
to	O
discuss	O
differences	O
in	O
translation	O
and	O
modify	O
accordingly	O
.	O

The	O
questionnaire	O
was	O
piloted	O
in	O
each	O
setting	O
and	O
small	O
modifications	O
to	O
wording	O
of	O
some	O
items	O
were	O
made	O
,	O
where	O
appropriate	O
,	O
to	O
ensure	O
local	O
understanding	O
.	O

Teams	O
were	O
accompanied	O
by	O
a	O
field	O
supervisor	O
at	O
least	O
1	O
d	O
per	O
wk	O
to	O
ensure	O
that	O
high	O
quality	O
was	O
maintained	O
and	O
interviews	O
were	O
observed	O
randomly	O
throughout	O
the	O
study	O
.	O

Statistical	O
Analysis	O
Microsoft	O
Access	O
was	O
used	O
for	O
data	O
entry	O
,	O
and	O
all	O
data	O
were	O
double	O
entered	O
and	O
validated	O
.	O

Analyses	O
were	O
undertaken	O
in	O
SAS	O
version	O
8.2	O
.	O

The	O
mean	O
and	O
range	O
of	O
each	O
expenditure	O
item	O
was	O
calculated	O
to	O
assess	O
whether	O
answers	O
were	O
plausible	O
,	O
and	O
to	O
identify	O
and	O
exclude	O
gross	O
outliers	O
(	O
none	O
identified	O
)	O
.	O

Rental	O
equivalents	O
were	O
imputed	O
based	O
on	O
household	O
characteristics	O
and	O
non	O
-	O
rent	O
expenditure	O
for	O
households	O
where	O
these	O
estimates	O
were	O
missing	O
or	O
unreasonably	O
low	O
(	O
<	O
$	O
1	O
per	O
mo	O
)	O
(	O
four	O
in	O
Kenya	O
,	O
three	O
in	O
Bangladesh	O
,	O
18	O
in	O
the	O
Philippines	O
)	O
.	O

Total	O
monthly	O
household	O
consumption	O
was	O
divided	O
by	O
the	O
number	O
of	O
household	O
members	O
to	O
calculate	O
per	O
capita	O
household	O
expenditure	O
.	O

Per	O
capita	O
household	O
expenditure	O
was	O
divided	O
into	O
quartiles	O
,	O
separately	O
for	O
each	O
country	O
,	O
based	O
on	O
the	O
distribution	O
of	O
the	O
data	O
for	O
the	O
case	O
and	O
control	O
participants	O
combined	O
.	O

Households	O
with	O
incomplete	O
expenditure	O
data	O
were	O
excluded	O
from	O
analyses	O
(	O
five	O
cases	O
and	O
four	O
controls	O
in	O
Kenya	O
;	O
one	O
case	O
and	O
one	O
control	O
in	O
Bangladesh	O
)	O
.	O

A	O
relative	O
index	O
of	O
household	O
assets	O
was	O
derived	O
using	O
principal	O
components	O
analysis	O
(	O
PCA	O
)	O
to	O
determine	O
weights	O
for	O
a	O
list	O
of	O
assets	O
and	O
wealth	O
indicators	O
[	O
19	O
]	O
.	O

Variables	O
entered	O
into	O
the	O
PCA	O
included	O
building	O
materials	O
of	O
the	O
house	O
,	O
ownership	O
of	O
ten	O
household	O
assets	O
,	O
animal	O
ownership	O
,	O
and	O
education	O
of	O
the	O
head	O
of	O
the	O
household	O
.	O

The	O
derived	O
index	O
was	O
divided	O
into	O
quartiles	O
from	O
poorest	O
(	O
lowest	O
socioeconomic	O
status	O
[	O
SES	O
]	O
index	O
)	O
to	O
least	O
poor	O
(	O
highest	O
SES	O
index	O
)	O
.	O

PCA	O
analyses	O
were	O
undertaken	O
separately	O
for	O
each	O
country	O
.	O

The	O
means	O
of	O
the	O
poverty	O
variables	O
were	O
first	O
compared	O
for	O
cases	O
recruited	O
through	O
the	O
two	O
different	O
methods	O
,	O
and	O
then	O
from	O
cases	O
and	O
controls	O
using	O
t	O
-	O
tests	O
for	O
continuous	O
variables	O
(	O
e.g.	O
,	O
PCE	O
and	O
assets	O
)	O
.	O

For	O
categorical	O
variables	O
(	O
e.g.	O
,	O
household	O
rank	O
)	O
we	O
used	O
the	O
Mann	O
-	O
Whitney	O
test	O
and	O
presented	O
medians	O
and	O
interquartile	O
ranges	O
.	O

PCE	O
was	O
highly	O
skewed	O
and	O
therefore	O
was	O
log	O
transformed	O
for	O
the	O
t	O
-	O
tests	O
.	O

The	O
two	O
-	O
way	O
correlations	O
were	O
calculated	O
between	O
PCE	O
,	O
assets	O
,	O
and	O
household	O
rank	O
,	O
in	O
turn	O
.	O

Logistic	O
regression	O
analyses	O
were	O
undertaken	O
separately	O
for	O
each	O
country	O
,	O
assessing	O
the	O
association	O
between	O
case	O
/	O
control	O
status	O
and	O
sociodemographic	O
and	O
poverty	O
variables	O
.	O

Conditional	O
logistic	O
regression	O
was	O
not	O
undertaken	O
,	O
since	O
the	O
matching	O
was	O
incomplete	O
,	O
so	O
all	O
analyses	O
were	O
adjusted	O
for	O
the	O
matching	O
variables	O
(	O
age	O
,	O
sex	O
,	O
and	O
rural	O
/	O
urban	O
location	O
)	O
.	O

Likelihood	O
ratio	O
tests	O
were	O
undertaken	O
to	O
assess	O
the	O
significance	O
of	O
adding	O
covariates	O
with	O
more	O
than	O
two	O
levels	O
(	O
e.g.	O
,	O
age	O
groups	O
,	O
self	O
-	O
rated	O
health	O
groups	O
)	O
to	O
the	O
model	O
.	O

Tests	O
for	O
trend	O
were	O
undertaken	O
across	O
quartiles	O
of	O
the	O
poverty	O
variables	O
and	O
assessed	O
using	O
the	O
p	O
-	O
value	O
for	O
trend	O
.	O

Analyses	O
were	O
also	O
conducted	O
adjusting	O
for	O
the	O
logistic	O
regression	O
analyses	O
for	O
poverty	O
by	O
social	O
support	O
indicators	O
(	O
marital	O
status	O
and	O
household	O
size	O
)	O
and	O
self	O
-	O
rated	O
health	O
,	O
since	O
these	O
variables	O
may	O
confound	O
the	O
association	O
between	O
cataract	O
visual	O
impairment	O
and	O
poverty	O
.	O

Analyses	O
from	O
the	O
Philippines	O
were	O
also	O
adjusted	O
for	O
study	O
site	O
,	O
since	O
data	O
were	O
obtained	O
from	O
two	O
settings	O
(	O
Negros	O
and	O
Antique	O
)	O
.	O

An	O
attempt	O
was	O
made	O
to	O
disentangle	O
the	O
relationship	O
between	O
poverty	O
and	O
cataract	O
by	O
stratifying	O
the	O
analyses	O
by	O
age	O
,	O
sex	O
,	O
and	O
level	O
of	O
visual	O
impairment	O
among	O
the	O
cases	O
.	O

Ethical	O
Approval	O
Informed	O
signed	O
or	O
thumb	O
-	O
printed	O
consent	O
was	O
obtained	O
from	O
all	O
cases	O
and	O
controls	O
.	O

In	O
Kenya	O
and	O
Bangladesh	O
all	O
cases	O
were	O
offered	O
free	O
cataract	O
surgery	O
at	O
the	O
local	O
hospital	O
,	O
with	O
free	O
transport	O
.	O

In	O
the	O
Philippines	O
,	O
patients	O
were	O
referred	O
for	O
surgery	O
,	O
which	O
was	O
subsidised	O
for	O
patients	O
who	O
could	O
not	O
afford	O
the	O
fee	O
.	O

Ethical	O
approval	O
for	O
this	O
study	O
was	O
obtained	O
from	O
the	O
ethics	O
committees	O
of	O
the	O
London	O
School	O
of	O
Hygiene	O
&	O
Tropical	O
Medicine	O
,	O
the	O
Kenya	O
Medical	O
Research	O
Institute	O
,	O
the	O
Bangladesh	O
Medical	O
Research	O
Council	O
,	O
and	O
the	O
University	O
of	O
St.	O
La	O
Salle	O
,	O
Bacolod	O
,	O
Philippines	O
.	O

This	O
study	O
complied	O
with	O
the	O
guidelines	O
of	O
the	O
Declaration	O
of	O
Helsinki	O
.	O

Results	O
Sociodemographic	O
Characteristics	O
of	O
Cases	O
and	O
Controls	O
Case	O
and	O
control	O
participants	O
were	O
matched	O
reasonably	O
closely	O
by	O
sex	O
and	O
location	O
.	O

However	O
,	O
within	O
the	O
age	O
category	O
≥	O
70	O
y	O
,	O
cases	O
tended	O
to	O
be	O
older	O
than	O
the	O
controls	O
,	O
so	O
that	O
cases	O
were	O
over	O
-	O
represented	O
in	O
the	O
oldest	O
age	O
groups	O
(	O
75–79	O
and	O
≥	O
80	O
y	O
)	O
compared	O
to	O
controls	O
(	O
Table	O
1	O
)	O
.	O

Cases	O
were	O
less	O
likely	O
to	O
be	O
married	O
than	O
controls	O
,	O
in	O
Kenya	O
(	O
OR	O
0.6	O
,	O
95	O
%	O
CI	O
0.3–1.1	O
)	O
,	O
Bangladesh	O
(	O
0.6	O
,	O
0.4–1.0	O
)	O
,	O
and	O
the	O
Philippines	O
(	O
0.7	O
,	O
0.4–1.0	O
)	O
,	O
although	O
this	O
only	O
reached	O
statistical	O
significance	O
in	O
Bangladesh	O
(	O
p	O
=	O
0.03	O
)	O
.	O

There	O
was	O
a	O
strong	O
protective	O
effect	O
of	O
literacy	O
and	O
education	O
on	O
cataract	O
in	O
Bangladesh	O
and	O
Kenya	O
that	O
was	O
not	O
evident	O
in	O
the	O
Philippines	O
.	O

Cases	O
were	O
substantially	O
less	O
likely	O
to	O
have	O
a	O
job	O
other	O
than	O
working	O
in	O
the	O
field	O
compared	O
to	O
controls	O
in	O
all	O
three	O
countries	O
.	O

Cases	O
reported	O
significantly	O
poorer	O
self	O
-	O
rated	O
health	O
than	O
controls	O
—	O
this	O
pattern	O
was	O
particularly	O
evident	O
in	O
the	O
Philippines	O
(	O
OR	O
for	O
lowest	O
versus	O
highest	O
quartile	O
of	O
self	O
-	O
rated	O
health	O
=	O
5.7	O
,	O
95	O
%	O
CI	O
3.0–10.7	O
)	O
but	O
also	O
apparent	O
in	O
Kenya	O
(	O
2.6	O
,	O
1.1–6.2	O
)	O
and	O
Bangladesh	O
(	O
3.3	O
,	O
2.1–5.3	O
)	O
.	O

Summary	O
Wealth	O
Measures	O
All	O
three	O
settings	O
were	O
poor	O
.	O

The	O
mean	O
PCE	O
was	O
less	O
than	O
US$	O
1	O
per	O
person	O
per	O
day	O
in	O
all	O
three	O
settings	O
:	O
US$	O
26.4	O
(	O
standard	O
deviation	O
[	O
SD	O
]	O
=	O
US$	O
34.9	O
)	O
in	O
Kenya	O
,	O
US$	O
21.7	O
(	O
US$	O
48.0	O
)	O
in	O
Bangladesh	O
and	O
US$	O
26.1	O
(	O
US$	O
23.5	O
)	O
in	O
the	O
Philippines	O
.	O

The	O
biggest	O
expense	O
was	O
food	O
in	O
all	O
three	O
settings	O
,	O
making	O
up	O
55	O
%	O
of	O
PCE	O
in	O
Kenya	O
,	O
47	O
%	O
in	O
Bangladesh	O
,	O
and	O
64	O
%	O
in	O
the	O
Philippines	O
,	O
followed	O
by	O
household	O
expenses	O
including	O
rent	O
(	O
21	O
%	O
in	O
Kenya	O
,	O
28	O
%	O
Bangladesh	O
,	O
and	O
22	O
%	O
Philippines	O
)	O
(	O
Figure	O
1	O
)	O
.	O

The	O
majority	O
of	O
food	O
consumption	O
was	O
from	O
direct	O
purchase	O
(	O
70	O
%	O
in	O
Kenya	O
,	O
75	O
%	O
in	O
Bangladesh	O
,	O
and	O
77	O
%	O
in	O
the	O
Philippines	O
)	O
or	O
home	O
-	O
grown	O
production	O
(	O
24	O
%	O
in	O
Kenya	O
,	O
22	O
%	O
in	O
Bangladesh	O
,	O
and	O
17	O
%	O
in	O
the	O
Philippines	O
)	O
,	O
and	O
little	O
was	O
from	O
gifts	O
or	O
payments	O
.	O

An	O
asset	O
score	O
was	O
created	O
through	O
PCA	O
in	O
the	O
three	O
settings	O
.	O

The	O
first	O
principal	O
component	O
explained	O
22	O
%	O
of	O
the	O
variability	O
in	O
asset	O
variables	O
in	O
Kenya	O
,	O
25	O
%	O
in	O
Bangladesh	O
,	O
and	O
24	O
%	O
in	O
the	O
Philippines	O
.	O

Self	O
-	O
perceived	O
wealth	O
of	O
the	O
household	O
clustered	O
around	O
the	O
average	O
with	O
a	O
large	O
proportion	O
of	O
households	O
in	O
Kenya	O
(	O
48	O
%	O
)	O
,	O
Bangladesh	O
(	O
43	O
%	O
)	O
,	O
and	O
the	O
Philippines	O
(	O
64	O
%	O
)	O
;	O
households	O
stating	O
that	O
they	O
were	O
ranked	O
between	O
4	O
and	O
6	O
,	O
on	O
a	O
scale	O
from	O
1	O
to	O
10	O
,	O
in	O
terms	O
of	O
wealth	O
in	O
their	O
community	O
.	O

The	O
three	O
measures	O
of	O
poverty	O
were	O
highly	O
correlated	O
,	O
each	O
showing	O
significant	O
correlation	O
(	O
p	O
<	O
0.001	O
)	O
with	O
the	O
other	O
measure	O
.	O

Economic	O
and	O
Household	O
Characteristics	O
of	O
Cases	O
and	O
Controls	O
There	O
were	O
no	O
significant	O
differences	O
in	O
PCE	O
,	O
assets	O
,	O
or	O
household	O
rank	O
between	O
cases	O
recruited	O
through	O
the	O
population	O
-	O
based	O
survey	O
and	O
those	O
recruited	O
through	O
case	O
detection	O
,	O
with	O
the	O
exception	O
that	O
the	O
case	O
-	O
detection	O
cases	O
had	O
lower	O
household	O
rank	O
in	O
Kenya	O
(	O
mean	O
=	O
3.7	O
versus	O
3.1	O
,	O
p	O
=	O
0.02	O
)	O
.	O

Consequently	O
,	O
cases	O
recruited	O
through	O
the	O
two	O
methods	O
were	O
combined	O
in	O
the	O
subsequent	O
analyses	O
.	O

Cases	O
were	O
poorer	O
than	O
controls	O
,	O
in	O
all	O
three	O
settings	O
according	O
to	O
all	O
three	O
poverty	O
measurements	O
(	O
Table	O
2	O
)	O
.	O

The	O
mean	O
PCE	O
was	O
20%–28	O
%	O
lower	O
for	O
members	O
of	O
households	O
with	O
a	O
case	O
than	O
for	O
control	O
households	O
,	O
and	O
this	O
difference	O
was	O
highly	O
significant	O
in	O
Bangladesh	O
and	O
the	O
Philippines	O
;	O
for	O
Kenya	O
it	O
was	O
lower	O
but	O
did	O
not	O
reach	O
significance	O
(	O
p	O
=	O
0.07	O
)	O
.	O

The	O
PCA	O
score	O
for	O
assets	O
was	O
significantly	O
lower	O
among	O
cases	O
than	O
controls	O
in	O
Kenya	O
and	O
Bangladesh	O
,	O
and	O
it	O
was	O
lower	O
in	O
the	O
Philippines	O
although	O
it	O
did	O
not	O
reach	O
significance	O
(	O
p	O
=	O
0.06	O
)	O
.	O

Self	O
-	O
perceived	O
wealth	O
was	O
significantly	O
lower	O
for	O
households	O
with	O
a	O
case	O
compared	O
to	O
control	O
households	O
in	O
Kenya	O
(	O
3.4	O
versus	O
4.5	O
)	O
and	O
Bangladesh	O
(	O
3.9	O
versus	O
4.6	O
)	O
,	O
though	O
not	O
in	O
the	O
Philippines	O
(	O
4.1	O
versus	O
4.3	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
size	O
of	O
the	O
households	O
of	O
cases	O
and	O
controls	O
in	O
any	O
of	O
the	O
three	O
settings	O
.	O

The	O
ratio	O
of	O
dependents	O
(	O
i.e.	O
,	O
household	O
member	O
aged	O
<	O
15	O
or	O
≥	O
50	O
y	O
)	O
to	O
independents	O
(	O
i.e.	O
,	O
household	O
member	O
aged	O
15–50	O
y	O
)	O
was	O
similar	O
between	O
cases	O
and	O
controls	O
in	O
Bangladesh	O
(	O
1.4	O
versus	O
1.4	O
)	O
,	O
but	O
the	O
dependency	O
ratio	O
was	O
higher	O
for	O
controls	O
than	O
cases	O
in	O
Kenya	O
(	O
2.1	O
versus	O
1.6	O
)	O
and	O
the	O
Philippines	O
(	O
1.7	O
versus	O
1.3	O
)	O
,	O
due	O
to	O
the	O
smaller	O
number	O
of	O
people	O
of	O
working	O
age	O
.	O

Patterns	O
of	O
Expenditure	O
in	O
Cases	O
and	O
Controls	O
Figure	O
1	O
shows	O
the	O
total	O
PCE	O
and	O
the	O
allocation	O
of	O
expenditure	O
within	O
quartiles	O
of	O
PCE	O
for	O
cases	O
and	O
controls	O
.	O

Monthly	O
PCE	O
was	O
similar	O
for	O
cases	O
and	O
controls	O
within	O
each	O
of	O
the	O
quartiles	O
of	O
expenditure	O
.	O

There	O
was	O
a	O
gradual	O
increase	O
in	O
PCE	O
between	O
the	O
first	O
three	O
quartiles	O
,	O
and	O
then	O
a	O
rapid	O
increase	O
between	O
the	O
third	O
and	O
the	O
richest	O
quartile	O
.	O

Within	O
the	O
first	O
three	O
quartiles	O
of	O
PCE	O
the	O
majority	O
of	O
expenditure	O
was	O
on	O
food	O
.	O

Substantial	O
expenditure	O
on	O
non	O
-	O
food	O
items	O
was	O
observed	O
only	O
in	O
the	O
highest	O
quartile	O
of	O
expenditure	O
,	O
where	O
about	O
half	O
of	O
expenditure	O
was	O
on	O
non	O
-	O
food	O
items	O
.	O

Similar	O
patterns	O
of	O
PCE	O
were	O
observed	O
for	O
cases	O
and	O
controls	O
in	O
Kenya	O
,	O
Bangladesh	O
,	O
and	O
the	O
Philippines	O
within	O
each	O
quartile	O
of	O
expenditure	O
.	O

These	O
results	O
demonstrate	O
that	O
cataract	O
visual	O
impairment	O
was	O
related	O
to	O
reduced	O
PCE	O
,	O
but	O
not	O
allocation	O
of	O
expenditure	O
.	O

Multivariate	O
Analyses	O
of	O
Poverty	O
and	O
Cataract	O
Visual	O
Impairment	O
Multivariate	O
analyses	O
showed	O
that	O
case	O
participants	O
were	O
consistently	O
poorer	O
than	O
controls	O
in	O
Kenya	O
,	O
Bangladesh	O
,	O
and	O
the	O
Philippines	O
,	O
using	O
three	O
different	O
measures	O
of	O
poverty	O
(	O
Table	O
3	O
)	O
.	O

Cases	O
were	O
more	O
likely	O
than	O
controls	O
to	O
be	O
in	O
the	O
lowest	O
quartile	O
of	O
PCE	O
rather	O
than	O
the	O
highest	O
quartile	O
in	O
Kenya	O
(	O
OR	O
2.3	O
,	O
95	O
%	O
CI	O
0.9–5.5	O
)	O
,	O
Bangladesh	O
(	O
1.9	O
,	O
1.1–3.2	O
)	O
and	O
the	O
Philippines	O
(	O
3.1	O
,	O
1.7–5.7	O
)	O
.	O

In	O
all	O
three	O
settings	O
these	O
associations	O
showed	O
significant	O
dose	O
–	O
response	O
as	O
assessed	O
by	O
the	O
p	O
-	O
value	O
for	O
trend	O
across	O
the	O
quartiles	O
,	O
with	O
decreasing	O
PCE	O
related	O
to	O
case	O
status	O
and	O
these	O
relationships	O
persisted	O
after	O
adjustment	O
for	O
self	O
-	O
rated	O
health	O
and	O
social	O
support	O
indicators	O
.	O

A	O
similar	O
pattern	O
was	O
observed	O
for	O
the	O
relationship	O
between	O
case	O
–	O
control	O
status	O
and	O
asset	O
ownership	O
.	O

Cases	O
were	O
significantly	O
more	O
likely	O
to	O
be	O
in	O
the	O
lowest	O
quartile	O
of	O
asset	O
ownership	O
rather	O
than	O
the	O
highest	O
quartile	O
compared	O
to	O
controls	O
in	O
Kenya	O
(	O
3.7	O
,	O
1.4–9.6	O
)	O
,	O
Bangladesh	O
(	O
2.6	O
,	O
1.5–4.4	O
)	O
,	O
and	O
the	O
Philippines	O
(	O
2.1	O
,	O
1.1–3.8	O
)	O
.	O

Cases	O
were	O
also	O
significantly	O
more	O
likely	O
to	O
be	O
in	O
the	O
lowest	O
quartile	O
of	O
household	O
rank	O
rather	O
than	O
the	O
highest	O
,	O
compared	O
to	O
controls	O
in	O
Kenya	O
(	O
3.5	O
,	O
1.5–8.0	O
)	O
,	O
Bangladesh	O
(	O
2.7	O
,	O
1.6–4.7	O
)	O
and	O
the	O
Philippines	O
(	O
2.3	O
,	O
1.1–4.8	O
)	O
.	O

The	O
associations	O
with	O
assets	O
and	O
household	O
rank	O
also	O
showed	O
a	O
significant	O
dose	O
–	O
response	O
relationship	O
,	O
and	O
the	O
associations	O
were	O
largely	O
unchanged	O
after	O
adjustment	O
for	O
self	O
-	O
rated	O
health	O
and	O
social	O
support	O
indicators	O
.	O

In	O
Kenya	O
and	O
Bangladesh	O
the	O
relationship	O
between	O
PCE	O
and	O
case	O
status	O
was	O
somewhat	O
weaker	O
than	O
for	O
the	O
other	O
measures	O
of	O
poverty	O
,	O
while	O
the	O
reverse	O
was	O
true	O
in	O
the	O
Philippines	O
.	O

Stratifying	O
the	O
association	O
between	O
PCE	O
and	O
cataract	O
visual	O
impairment	O
by	O
level	O
of	O
visual	O
impairment	O
showed	O
an	O
inconsistent	O
pattern	O
(	O
Table	O
4	O
)	O
.	O

In	O
Kenya	O
,	O
the	O
association	O
with	O
low	O
PCE	O
was	O
somewhat	O
stronger	O
comparing	O
cataract	O
blind	O
cases	O
to	O
controls	O
(	O
OR	O
3.1	O
,	O
95	O
%	O
CI	O
0.9–10.8	O
)	O
than	O
comparing	O
moderate	O
visually	O
impaired	O
cases	O
to	O
controls	O
(	O
1.8	O
,	O
0.6–5.4	O
)	O
,	O
while	O
this	O
pattern	O
was	O
reversed	O
in	O
Bangladesh	O
(	O
blind	O
cases	O
versus	O
controls	O
:	O
1.8	O
,	O
1.0–3.4	O
;	O
moderately	O
visually	O
impaired	O
cases	O
versus	O
controls	O
:	O
3.1	O
,	O
1.3–7.2	O
)	O
.	O

In	O
the	O
Philippines	O
the	O
association	O
with	O
low	O
PCE	O
was	O
strongest	O
comparing	O
severely	O
visually	O
impaired	O
cases	O
to	O
controls	O
(	O
5.9	O
,	O
2.0–17.6	O
)	O
.	O

The	O
association	O
between	O
cataract	O
visual	O
impairment	O
and	O
PCE	O
was	O
stronger	O
among	O
men	O
than	O
women	O
in	O
Bangladesh	O
and	O
the	O
Philippines	O
,	O
while	O
the	O
reverse	O
was	O
true	O
in	O
Kenya	O
(	O
Table	O
5	O
)	O
.	O

In	O
Kenya	O
and	O
the	O
Philippines	O
the	O
strongest	O
association	O
between	O
cataract	O
and	O
PCE	O
was	O
among	O
people	O
aged	O
70–79	O
y	O
,	O
while	O
in	O
Bangladesh	O
the	O
strongest	O
effect	O
was	O
in	O
people	O
aged	O
over	O
80	O
y.	O
Stratifying	O
the	O
association	O
between	O
assets	O
and	O
household	O
rank	O
with	O
cataract	O
by	O
level	O
of	O
visual	O
impairment	O
,	O
sex	O
,	O
or	O
age	O
broadly	O
repeated	O
these	O
findings	O
,	O
and	O
generally	O
supported	O
the	O
lack	O
of	O
consistent	O
pattern	O
(	O
unpublished	O
data	O
)	O
.	O

Discussion	O
This	O
large	O
,	O
multicentre	O
population	O
-	O
based	O
case	O
–	O
control	O
study	O
provides	O
evidence	O
that	O
people	O
with	O
visual	O
impairment	O
from	O
cataract	O
are	O
poorer	O
than	O
control	O
participants	O
with	O
normal	O
vision	O
matched	O
for	O
age	O
and	O
sex	O
.	O

This	O
pattern	O
was	O
evident	O
whether	O
poverty	O
was	O
measured	O
in	O
terms	O
of	O
PCE	O
,	O
assets	O
,	O
or	O
self	O
-	O
rated	O
wealth	O
.	O

Marital	O
status	O
seemed	O
to	O
be	O
protective	O
for	O
cataract	O
visual	O
impairment	O
,	O
possibly	O
indicating	O
the	O
role	O
of	O
social	O
support	O
in	O
health	O
-	O
seeking	O
behaviour	O
.	O

Reduced	O
self	O
-	O
rated	O
health	O
was	O
also	O
strongly	O
related	O
to	O
cataract	O
visual	O
impairment	O
.	O

This	O
demonstrates	O
the	O
impact	O
of	O
poor	O
vision	O
on	O
overall	O
assessments	O
of	O
health	O
and	O
supports	O
our	O
previous	O
finding	O
of	O
a	O
relationship	O
between	O
cataract	O
and	O
quality	O
of	O
life	O
[	O
17	O
]	O
.	O

Adjustment	O
for	O
marital	O
status	O
and	O
self	O
-	O
rated	O
health	O
did	O
not	O
entirely	O
explain	O
the	O
association	O
between	O
poverty	O
and	O
cataract	O
visual	O
impairment	O
,	O
suggesting	O
that	O
it	O
operated	O
through	O
other	O
pathways	O
.	O

Visual	O
impairment	O
could	O
cause	O
poverty	O
through	O
reduced	O
employment	O
opportunities	O
.	O

We	O
might	O
therefore	O
expect	O
to	O
see	O
a	O
stronger	O
relationship	O
between	O
cataract	O
and	O
poverty	O
among	O
the	O
blind	O
case	O
participants	O
who	O
may	O
have	O
fewer	O
employment	O
opportunities	O
than	O
among	O
those	O
less	O
impaired	O
(	O
i.e.	O
,	O
moderate	O
visual	O
impairment	O
)	O
.	O

Poverty	O
may	O
also	O
cause	O
visual	O
impairment	O
through	O
restricted	O
access	O
to	O
cataract	O
surgery	O
.	O

In	O
this	O
case	O
we	O
would	O
expect	O
to	O
see	O
a	O
stronger	O
relationship	O
between	O
poverty	O
and	O
less	O
severely	O
affected	O
cases	O
(	O
i.e.	O
,	O
moderate	O
visual	O
impairment	O
)	O
,	O
as	O
poor	O
families	O
may	O
allocate	O
money	O
for	O
surgery	O
on	O
members	O
who	O
are	O
blind	O
from	O
cataract	O
,	O
so	O
that	O
poverty	O
mainly	O
restricts	O
access	O
to	O
surgery	O
among	O
people	O
who	O
are	O
moderately	O
visually	O
impaired	O
.	O

The	O
relationships	O
that	O
we	O
observed	O
between	O
level	O
of	O
visual	O
impairment	O
and	O
cataract	O
were	O
inconsistent	O
across	O
the	O
three	O
settings	O
.	O

Perhaps	O
this	O
shows	O
that	O
both	O
pathways	O
were	O
operating	O
or	O
that	O
the	O
dynamics	O
of	O
the	O
relationship	O
between	O
poverty	O
and	O
blindness	O
vary	O
in	O
different	O
settings	O
.	O

Levels	O
of	O
literacy	O
and	O
education	O
were	O
lower	O
among	O
cases	O
than	O
controls	O
.	O

These	O
long	O
-	O
term	O
indicators	O
of	O
disadvantage	O
are	O
unlikely	O
to	O
have	O
changed	O
after	O
the	O
onset	O
of	O
cataract	O
.	O

This	O
observation	O
provides	O
some	O
evidence	O
that	O
poverty	O
preceded	O
blindness	O
in	O
our	O
study	O
participants	O
.	O

It	O
is	O
frequently	O
asserted	O
that	O
blindness	O
is	O
both	O
a	O
cause	O
and	O
consequence	O
of	O
poverty	O
,	O
but	O
there	O
are	O
few	O
empirical	O
data	O
to	O
support	O
this	O
claim	O
.	O

Globally	O
,	O
the	O
prevalence	O
of	O
blindness	O
is	O
five	O
-	O
fold	O
higher	O
in	O
poor	O
than	O
rich	O
countries	O
[	O
2	O
]	O
,	O
and	O
data	O
from	O
Pakistan	O
and	O
India	O
suggest	O
that	O
within	O
countries	O
the	O
poor	O
are	O
more	O
likely	O
to	O
be	O
blind	O
[	O
3	O
,	O
4	O
]	O
.	O

Some	O
blinding	O
conditions	O
are	O
a	O
direct	O
consequence	O
of	O
poverty	O
,	O
notably	O
trachoma	O
,	O
which	O
thrives	O
in	O
poor	O
areas	O
lacking	O
water	O
and	O
sanitation	O
[	O
20	O
]	O
.	O

Other	O
blinding	O
diseases	O
clearly	O
contribute	O
to	O
poverty	O
,	O
such	O
as	O
onchocerciasis	O
,	O
which	O
results	O
in	O
the	O
abandonment	O
of	O
the	O
fertile	O
areas	O
near	O
to	O
the	O
rivers	O
where	O
the	O
disease	O
vector	O
thrives	O
[	O
9	O
]	O
.	O

A	O
larger	O
literature	O
shows	O
that	O
poor	O
people	O
are	O
more	O
likely	O
to	O
be	O
ill	O
or	O
disabled	O
than	O
their	O
richer	O
compatriots	O
,	O
ranging	O
from	O
general	O
disability	O
in	O
India	O
,	O
Bulgaria	O
,	O
and	O
Ghana	O
[	O
21	O
]	O
;	O
common	O
mental	O
disorders	O
in	O
Brazil	O
,	O
Chile	O
,	O
India	O
,	O
and	O
Zimbabwe	O
[	O
22	O
]	O
;	O
deafness	O
in	O
Brazil	O
[	O
23	O
]	O
;	O
and	O
tuberculosis	O
in	O
China	O
[	O
24	O
]	O
.	O

There	O
are	O
also	O
some	O
exceptions	O
such	O
as	O
a	O
case	O
-	O
control	O
study	O
in	O
Rwanda	O
which	O
failed	O
to	O
show	O
an	O
association	O
between	O
PCE	O
and	O
musculoskeletal	O
impairment	O
,	O
perhaps	O
because	O
the	O
population	O
was	O
almost	O
universally	O
poor	O
[	O
25	O
]	O
.	O

Poverty	O
may	O
increase	O
the	O
incidence	O
of	O
disease	O
,	O
particularly	O
preventable	O
diseases	O
such	O
as	O
tuberculosis	O
.	O

Poverty	O
may	O
also	O
restrict	O
access	O
to	O
appropriate	O
health	O
care	O
and	O
so	O
prolong	O
the	O
duration	O
of	O
disease	O
.	O

A	O
study	O
in	O
rural	O
Tanzania	O
showed	O
that	O
care	O
-	O
seeking	O
behaviour	O
for	O
childhood	O
illness	O
is	O
worse	O
among	O
poorer	O
families	O
than	O
among	O
the	O
relatively	O
rich	O
families	O
[	O
26	O
]	O
.	O

Another	O
Tanzanian	O
study	O
found	O
that	O
people	O
with	O
higher	O
levels	O
of	O
asset	O
ownership	O
were	O
more	O
likely	O
to	O
obtain	O
antimalarials	O
even	O
though	O
they	O
were	O
less	O
likely	O
to	O
be	O
parasitaemic	O
[	O
27	O
]	O
.	O

With	O
respect	O
to	O
cataract	O
,	O
there	O
is	O
little	O
evidence	O
that	O
prevention	O
is	O
possible	O
,	O
and	O
so	O
the	O
main	O
pathway	O
from	O
poverty	O
to	O
blindness	O
is	O
likely	O
to	O
be	O
through	O
reduced	O
access	O
to	O
cataract	O
surgical	O
services	O
.	O

High	O
health	O
care	O
costs	O
may	O
also	O
exacerbate	O
poverty	O
.	O

A	O
study	O
in	O
rural	O
China	O
showed	O
that	O
ill	O
health	O
increases	O
medical	O
expenditure	O
significantly	O
,	O
which	O
detracts	O
from	O
expenditure	O
on	O
food	O
,	O
education	O
,	O
investment	O
in	O
farming	O
,	O
and	O
participation	O
in	O
social	O
activities	O
[	O
28	O
]	O
.	O

Inability	O
to	O
afford	O
cataract	O
surgery	O
is	O
cited	O
as	O
the	O
major	O
barrier	O
to	O
the	O
uptake	O
of	O
surgery	O
in	O
the	O
surveys	O
conducted	O
in	O
Kenya	O
,	O
the	O
Philippines	O
,	O
and	O
Bangladesh	O
[	O
6–8	O
]	O
.	O

This	O
indicates	O
that	O
the	O
cost	O
of	O
surgery	O
is	O
perceived	O
as	O
substantial	O
by	O
many	O
households	O
,	O
notwithstanding	O
the	O
problems	O
of	O
assessing	O
the	O
complex	O
issue	O
of	O
barriers	O
in	O
the	O
absence	O
of	O
in	O
-	O
depth	O
qualitative	O
interviews	O
.	O

Consequently	O
,	O
there	O
are	O
lower	O
rates	O
of	O
cataract	O
surgery	O
among	O
the	O
poor	O
[	O
3	O
]	O
.	O

Poverty	O
may	O
also	O
limit	O
the	O
employment	O
opportunities	O
of	O
the	O
person	O
with	O
disability	O
or	O
their	O
household	O
members	O
.	O

This	O
pattern	O
has	O
been	O
demonstrated	O
for	O
people	O
with	O
HIV	B
in	O
South	O
Africa	O
[	O
29	O
]	O
,	O
tuberculosis	O
in	O
China	O
[	O
24	O
]	O
,	O
or	O
disability	O
in	O
Sri	O
Lanka	O
[	O
22	O
]	O
.	O

An	O
impact	O
of	O
blindness	O
on	O
reduced	O
employment	O
or	O
income	O
has	O
been	O
observed	O
in	O
Guinea	O
[	O
9	O
]	O
and	O
India	O
[	O
4	O
]	O
.	O

A	O
belief	O
that	O
blindness	O
reduces	O
the	O
employment	O
opportunities	O
of	O
household	O
members	O
is	O
widespread	O
,	O
but	O
so	O
far	O
there	O
is	O
limited	O
supportive	O
evidence	O
.	O

There	O
is	O
a	O
further	O
complication	O
to	O
investigations	O
of	O
the	O
relationship	O
between	O
cataract	O
and	O
poverty	O
,	O
as	O
the	O
individuals	O
with	O
cataract	O
are	O
likely	O
to	O
be	O
elderly	O
and	O
facing	O
multiple	O
disabilities	O
.	O

Our	O
study	O
took	O
account	O
of	O
the	O
potential	O
impact	O
of	O
multiple	O
disabilities	O
,	O
as	O
we	O
adjusted	O
for	O
self	O
-	O
rated	O
health	O
,	O
which	O
is	O
closely	O
related	O
to	O
overall	O
health	O
,	O
and	O
this	O
adjustment	O
had	O
no	O
overall	O
impact	O
on	O
our	O
results	O
[	O
30	O
]	O
.	O

Study	O
Strengths	O
This	O
was	O
a	O
large	O
population	O
-	O
based	O
case	O
–	O
control	O
study	O
,	O
conducted	O
in	O
three	O
countries	O
,	O
allowing	O
international	O
comparisons	O
.	O

This	O
was	O
the	O
first	O
study	O
,	O
to	O
our	O
knowledge	O
,	O
to	O
relate	O
PCE	O
to	O
visual	O
impairment	O
.	O

We	O
also	O
measured	O
assets	O
,	O
which	O
reflects	O
long	O
-	O
term	O
access	O
to	O
resources	O
,	O
and	O
self	O
-	O
rated	O
wealth	O
.	O

We	O
used	O
expenditure	O
as	O
a	O
proxy	O
for	O
income	O
,	O
which	O
has	O
aided	O
both	O
academic	O
and	O
nonacademic	O
investigations	O
.	O

As	O
one	O
example	O
,	O
the	O
notorious	O
Chicago	O
gangster	O
Al	O
Capone	O
managed	O
to	O
escape	O
prosecution	O
for	O
smuggling	O
,	O
gambling	O
,	O
bootlegging	O
,	O
and	O
murder	O
for	O
years	O
,	O
but	O
was	O
eventually	O
convicted	O
of	O
tax	O
evasion	O
,	O
because	O
the	O
jury	O
was	O
convinced	O
that	O
his	O
exorbitant	O
expenses	O
on	O
clothes	O
,	O
furnishing	O
,	O
foods	O
,	O
and	O
gifts	O
were	O
inconsistent	O
with	O
his	O
claim	O
that	O
he	O
had	O
no	O
income	O
.	O

Expenditure	O
often	O
provides	O
a	O
better	O
measure	O
of	O
poverty	O
than	O
income	O
for	O
a	O
number	O
of	O
reasons	O
.	O

Income	O
may	O
be	O
variable	O
by	O
season	O
,	O
whereas	O
households	O
attempt	O
to	O
smooth	O
expenditure	O
over	O
the	O
year	O
.	O

People	O
are	O
more	O
comfortable	O
sharing	O
information	O
about	O
expenditure	O
than	O
income	O
,	O
and	O
it	O
may	O
be	O
a	O
more	O
meaningful	O
measure	O
than	O
income	O
in	O
an	O
agrarian	O
society	O
as	O
it	O
reflects	O
what	O
the	O
household	O
is	O
able	O
to	O
command	O
based	O
on	O
its	O
current	O
income	O
,	O
borrowing	O
ability	O
,	O
or	O
household	O
savings	O
[	O
31	O
]	O
.	O

PCE	O
also	O
has	O
advantages	O
over	O
assets	O
,	O
as	O
it	O
may	O
be	O
more	O
responsive	O
to	O
change	O
,	O
which	O
will	O
be	O
important	O
for	O
the	O
follow	O
-	O
up	O
analyses	O
of	O
the	O
study	O
participants	O
after	O
they	O
have	O
undergone	O
cataract	O
surgery	O
.	O

Study	O
Limitations	O
There	O
are	O
a	O
number	O
of	O
limitations	O
relating	O
to	O
the	O
measurement	O
of	O
poverty	O
in	O
this	O
study	O
.	O

Our	O
analyses	O
focus	O
on	O
monetary	O
indicators	O
of	O
poverty	O
,	O
while	O
we	O
acknowledge	O
that	O
health	O
,	O
education	O
,	O
and	O
housing	O
are	O
also	O
important	O
.	O

We	O
concede	O
that	O
it	O
is	O
difficult	O
to	O
measure	O
expenditure	O
accurately	O
[	O
32,33	O
]	O
,	O
but	O
this	O
also	O
true	O
for	O
the	O
measurement	O
of	O
diet	O
and	O
other	O
variables	O
,	O
which	O
is	O
standard	O
practise	O
in	O
many	O
epidemiological	O
studies	O
.	O

Furthermore	O
,	O
a	O
large	O
number	O
of	O
items	O
were	O
included	O
in	O
our	O
measure	O
of	O
expenditure	O
so	O
that	O
the	O
measure	O
was	O
comprehensive	O
[	O
33	O
]	O
.	O

Expenditure	O
data	O
were	O
not	O
validated	O
through	O
diaries	O
or	O
other	O
means	O
,	O
although	O
assets	O
and	O
self	O
-	O
rated	O
wealth	O
correlated	O
highly	O
with	O
PCE	O
.	O

Other	O
recent	O
estimates	O
of	O
expenditure	O
are	O
not	O
available	O
from	O
surveys	O
conducted	O
in	O
these	O
countries	O
to	O
allow	O
comparison	O
.	O

The	O
per	O
capita	O
estimates	O
of	O
monthly	O
gross	O
national	O
income	O
from	O
the	O
World	O
Development	O
Indicators	O
database	O
show	O
somewhat	O
higher	O
estimates	O
in	O
Kenya	O
(	O
US$	O
48	O
)	O
and	O
Bangladesh	O
(	O
US$	O
40	O
)	O
than	O
our	O
PCE	O
derived	O
estimates	O
,	O
and	O
far	O
higher	O
estimates	O
for	O
the	O
Philippines	O
(	O
US$	O
108	O
)	O
.	O

This	O
discrepancy	O
may	O
be	O
reasonable	O
,	O
as	O
the	O
World	O
Development	O
Indicators	O
reflect	O
national	O
averages	O
,	O
while	O
we	O
sampled	O
the	O
households	O
with	O
elderly	O
people	O
in	O
poor	O
regions	O
of	O
the	O
country	O
,	O
many	O
of	O
whom	O
were	O
visually	O
impaired	O
from	O
cataract	O
.	O

PCE	O
was	O
calculated	O
simply	O
by	O
dividing	O
the	O
total	O
household	O
expenditure	O
by	O
the	O
number	O
of	O
household	O
members	O
,	O
without	O
inclusion	O
of	O
economies	O
of	O
scale	O
or	O
equivalence	O
scales	O
.	O

There	O
is	O
no	O
widely	O
accepted	O
alternative	O
to	O
the	O
simple	O
equal	O
-	O
sharing	O
convention	O
,	O
and	O
the	O
majority	O
of	O
expenditure	O
was	O
on	O
food	O
which	O
does	O
not	O
allow	O
for	O
economies	O
of	O
scale	O
.	O

Furthermore	O
,	O
there	O
were	O
slightly	O
fewer	O
people	O
of	O
working	O
age	O
in	O
the	O
control	O
households	O
in	O
Kenya	O
and	O
the	O
Philippines	O
,	O
so	O
adjustment	O
for	O
equivalence	O
scores	O
would	O
be	O
unlikely	O
to	O
explain	O
the	O
higher	O
poverty	O
among	O
cases	O
.	O

The	O
case	O
and	O
control	O
households	O
were	O
of	O
similar	O
sizes	O
in	O
the	O
three	O
settings	O
,	O
so	O
economies	O
of	O
scales	O
are	O
unlikely	O
to	O
have	O
explained	O
the	O
differences	O
.	O

There	O
were	O
a	O
number	O
of	O
limitations	O
relating	O
to	O
study	O
design	O
.	O

Unfortunately	O
,	O
we	O
did	O
not	O
record	O
the	O
exact	O
numbers	O
of	O
cases	O
and	O
controls	O
who	O
refused	O
to	O
participate	O
or	O
were	O
unable	O
to	O
communicate	O
(	O
believed	O
to	O
be	O
fewer	O
than	O
five	O
in	O
each	O
country	O
)	O
,	O
so	O
the	O
response	O
rate	O
is	O
unknown	O
,	O
but	O
was	O
believed	O
to	O
be	O
high	O
.	O

A	O
variety	O
of	O
methods	O
were	O
used	O
for	O
case	O
recruitment	O
,	O
as	O
we	O
were	O
not	O
able	O
to	O
obtain	O
enough	O
cases	O
through	O
the	O
survey	O
alone	O
.	O

However	O
,	O
cases	O
recruited	O
through	O
the	O
population	O
-	O
based	O
survey	O
and	O
through	O
case	O
detection	O
had	O
similar	O
poverty	O
characteristics	O
.	O

Conclusions	O
Our	O
data	O
show	O
that	O
people	O
with	O
visual	O
impairment	O
due	O
to	O
cataract	O
were	O
poorer	O
than	O
controls	O
in	O
three	O
low	O
income	O
countries	O
,	O
Bangladesh	O
,	O
Kenya	O
,	O
and	O
the	O
Philippines	O
.	O

The	O
Millennium	O
Development	O
Goals	O
are	O
committed	O
to	O
the	O
eradication	O
of	O
extreme	O
poverty	O
and	O
provision	O
of	O
health	O
care	O
to	O
poor	O
people	O
.	O

This	O
study	O
confirms	O
an	O
association	O
between	O
poverty	O
and	O
blindness	O
and	O
highlights	O
the	O
need	O
for	O
increased	O
provision	O
of	O
cataract	O
surgery	O
to	O
poor	O
people	O
,	O
particularly	O
since	O
cataract	O
surgery	O
is	O
a	O
highly	O
cost	O
-	O
effective	O
intervention	O
in	O
these	O
settings	O
[	O
34	O
]	O
.	O

Human	B
genetic	O
selection	O
on	O
the	O
MTHFR	O
677C	O
>	O
T	O
polymorphism	O
Abstract	O
Background	O
The	O
prevalence	O
of	O
genotypes	O
of	O
the	O
677C	O
>	O
T	O
polymorphism	O
for	O
the	O
MTHFR	O
gene	O
varies	O
among	O
humans	B
.	O

In	O
previous	O
studies	O
,	O
we	O
found	O
changes	O
in	O
the	O
genotypic	O
frequencies	O
of	O
this	O
polymorphism	O
in	O
populations	O
of	O
different	O
ages	O
,	O
suggesting	O
that	O
this	O
could	O
be	O
caused	O
by	O
an	O
increase	O
in	O
the	O
intake	O
of	O
folate	O
and	O
multivitamins	O
by	O
women	O
during	O
the	O
periconceptional	O
period	O
.	O

The	O
aim	O
was	O
to	O
analyze	O
changes	O
in	O
the	O
allelic	O
frequencies	O
of	O
this	O
polymorphism	O
in	O
a	O
Spanish	O
population	O
,	O
including	O
samples	O
from	O
spontaneous	O
abortions	O
(	O
SA	O
)	O
.	O

Methods	O
A	O
total	O
of	O
1305	O
subjects	O
born	O
in	O
the	O
20th	O
century	O
were	O
genotyped	O
for	O
the	O
677C	O
>	O
T	O
polymorphism	O
using	O
allele	O
specific	O
real	O
-	O
time	O
PCR	O
with	O
Taqman	O
®	O
probes	O
.	O

A	O
section	O
of	O
our	O
population	O
(	O
n	O
=	O
276	O
)	O
born	O
in	O
1980–1989	O
was	O
compared	O
with	O
fetal	O
samples	O
(	O
n	O
=	O
344	O
)	O
from	O
SA	O
of	O
unknown	O
etiology	O
from	O
the	O
same	O
period	O
.	O

Results	O
An	O
increase	O
in	O
the	O
frequency	O
of	O
the	O
T	O
allele	O
(	O
0.38	O
vs	O
0.47	O
;	O
p	O
<	O
0.001	O
)	O
and	O
of	O
the	O
TT	O
genotype	O
(	O
0.14	O
vs	O
0.24	O
;	O
p	O
<	O
0.001	O
)	O
in	O
subjects	O
born	O
in	O
the	O
last	O
quarter	O
of	O
the	O
century	O
was	O
observed	O
.	O

In	O
the	O
1980–1989	O
period	O
,	O
the	O
results	O
show	O
that	O
the	O
frequency	O
of	O
the	O
wild	O
type	O
genotype	O
(	O
CC	O
)	O
is	O
about	O
tenfold	O
lower	O
in	O
the	O
SA	O
samples	O
than	O
in	O
the	O
controls	O
(	O
0.03	O
vs	O
0.33	O
;	O
p	O
<	O
0.001	O
)	O
and	O
that	O
the	O
frequency	O
of	O
the	O
TT	O
genotype	O
increases	O
in	O
the	O
controls	O
(	O
0.19	O
to	O
0.27	O
)	O
and	O
in	O
the	O
SA	O
samples	O
(	O
0.20	O
to	O
0.33	O
(	O
p	O
<	O
0.01	O
)	O
)	O
;	O
r	O
=	O
0.98	O
.	O

Conclusion	O
Selection	O
in	O
favor	O
of	O
the	O
T	O
allele	O
has	O
been	O
detected	O
.	O

This	O
selection	O
could	O
be	O
due	O
to	O
the	O
increased	O
fetal	O
viability	O
in	O
early	O
stages	O
of	O
embryonic	O
development	O
,	O
as	O
is	O
deduced	O
by	O
the	O
increase	O
of	O
mutants	O
in	O
both	O
living	O
and	O
SA	O
populations	O
.	O

Background	O
The	O
methylenetetrahydrofolate	O
reductase	O
enzyme	O
(	O
MTHFR	O
)	O
catalyzes	O
a	O
reaction	O
that	O
produces	O
5-methyltetrahydrofolate	O
(	O
5-methylTHF	O
)	O
,	O
the	O
methyl	O
donor	O
for	O
homocysteine	O
in	O
the	O
synthesis	O
of	O
methionine	O
.	O

The	O
677C	O
>	O
T	O
mutation	O
of	O
the	O
MTHFR	O
gene	O
has	O
been	O
associated	O
with	O
a	O
thermolabile	O
enzyme	O
with	O
decreased	O
activity	O
that	O
may	O
cause	O
an	O
increase	O
in	O
plasma	O
homocysteine	O
concentrations	O
[	O
1	O
]	O
when	O
folate	O
status	O
is	O
poor	O
.	O

This	O
polymorphism	O
is	O
one	O
of	O
the	O
most	O
widely	O
studied	O
clinically	O
relevant	O
polymorphisms	O
in	O
humans	B
,	O
as	O
it	O
is	O
related	O
to	O
cardiovascular	O
disease	O
[	O
2	O
]	O
and	O
neural	O
tube	O
defects	O
(	O
NTD	O
;	O
601634	O
)	O
[	O
3	O
]	O
.	O

A	O
large	O
number	O
of	O
studies	O
have	O
provided	O
a	O
broad	O
overview	O
of	O
the	O
prevalence	O
of	O
the	O
677C	O
>	O
T	O
polymorphism	O
in	O
different	O
human	B
populations	O
,	O
showing	O
that	O
the	O
distribution	O
of	O
frequencies	O
is	O
diverse	O
[	O
4	O
]	O
.	O

These	O
differences	O
have	O
been	O
also	O
observed	O
between	O
groups	O
of	O
different	O
ages	O
in	O
the	O
same	O
Spanish	O
population	O
(	O
older	O
and	O
younger	O
than	O
24	O
years	O
)	O
[	O
5	O
]	O
and	O
in	O
a	O
Swiss	O
population	O
(	O
older	O
and	O
younger	O
than	O
60	O
years	O
)	O
[	O
6	O
]	O
,	O
as	O
well	O
as	O
in	O
a	O
Japanese	O
population	O
[	O
7	O
]	O
.	O

In	O
some	O
populations	O
,	O
such	O
the	O
Toscanians	O
in	O
Italy	O
[	O
8	O
]	O
and	O
Mexicans	O
[	O
9	O
]	O
,	O
the	O
homozygous	O
mutated	O
genotype	O
(	O
TT	O
)	O
has	O
reached	O
frequencies	O
greater	O
than	O
30	O
%	O
.	O

On	O
the	O
other	O
hand	O
,	O
in	O
Africans	O
the	O
frequency	O
of	O
the	O
TT	O
genotype	O
is	O
very	O
low	O
(	O
less	O
than	O
1	O
%	O
)	O
[	O
10,11	O
]	O
,	O
but	O
,	O
in	O
African	O
-	O
Americans	O
,	O
it	O
has	O
already	O
reached	O
2	O
%	O
[	O
12	O
]	O
.	O

Studies	O
based	O
on	O
the	O
distribution	O
of	O
genotypic	O
and	O
allelic	O
frequencies	O
of	O
the	O
677C	O
>	O
T	O
polymorphism	O
and	O
the	O
1298A	O
>	O
C	O
polymorphism	O
in	O
the	O
MTHFR	O
gene	O
in	O
Israeli	O
,	O
Japanese	O
and	O
Ghanaian	O
Africans	O
populations	O
[	O
13	O
]	O
concluded	O
that	O
the	O
677	O
T	O
mutation	O
in	O
the	O
MTHFR	O
gene	O
emerged	O
as	O
a	O
founder	O
haplotype	O
with	O
some	O
selective	O
advantage	O
.	O

Recently	O
,	O
preliminary	O
evidence	O
of	O
genetic	O
selection	O
of	O
this	O
polymorphism	O
related	O
to	O
folate	O
intake	O
has	O
been	O
reported	O
[	O
14	O
]	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
is	O
to	O
analyze	O
the	O
changes	O
in	O
frequencies	O
of	O
the	O
677C	O
>	O
T	O
polymorphism	O
during	O
the	O
20th	O
century	O
and	O
particularly	O
the	O
evolution	O
of	O
the	O
frequencies	O
during	O
the	O
decade	O
of	O
1980–1989	O
,	O
by	O
comparing	O
the	O
genotype	O
frequencies	O
between	O
living	O
subjects	O
born	O
in	O
this	O
period	O
versus	O
samples	O
of	O
spontaneous	O
abortions	O
(	O
SA	O
)	O
that	O
occurred	O
during	O
in	O
the	O
same	O
time	O
period	O
.	O

Methods	O
Subjects	O
This	O
study	O
was	O
approved	O
by	O
the	O
Ethics	O
Committee	O
at	O
the	O
University	O
Hospital	O
""""	O
Virgen	O
de	O
la	O
Victoria	O
""""	O
(	O
Málaga	O
)	O
.	O

One	O
of	O
the	O
study	O
groups	O
consisted	O
of	O
344	O
fetal	O
tissue	O
samples	O
from	O
SA	O
,	O
obtained	O
from	O
the	O
Department	O
of	O
Pathology	O
of	O
the	O
University	O
Hospital	O
Carlos	O
Haya	O
(	O
Málaga	O
)	O
.	O

These	O
samples	O
were	O
selected	O
after	O
checking	O
the	O
clinical	O
history	O
and	O
by	O
the	O
inclusion	O
criteria	O
of	O
containing	O
histologically	O
confirmed	O
fetal	O
tissue	O
collected	O
in	O
the	O
1980s	O
from	O
SA	O
at	O
less	O
than	O
3	O
months	O
(	O
11	O
±	O
1.70	O
week	O
)	O
and	O
of	O
unknown	O
etiology	O
.	O

These	O
fetal	O
samples	O
were	O
compared	O
with	O
a	O
control	O
population	O
of	O
276	O
subjects	O
born	O
in	O
the	O
1980s	O
with	O
an	O
average	O
age	O
of	O
22	O
±	O
4.58	O
.	O

Another	O
population	O
of	O
subjects	O
born	O
in	O
the	O
south	O
of	O
Spain	O
in	O
the	O
20th	O
century	O
were	O
genotyped	O
(	O
1305	O
subjects	O
,	O
697	O
women	O
and	O
608	O
men	O
)	O
and	O
divided	O
into	O
four	O
groups	O
according	O
to	O
birth	O
date	O
:	O
1900	O
to	O
1925	O
(	O
n	O
=	O
206	O
)	O
;	O
1926	O
to	O
1950	O
(	O
n	O
=	O
320	O
)	O
,	O
1951	O
to	O
1975	O
(	O
n	O
=	O
408	O
)	O
,	O
1976	O
to	O
2000	O
(	O
n	O
=	O
371	O
)	O
.	O

Individuals	O
were	O
selected	O
randomly	O
from	O
different	O
areas	O
of	O
the	O
province	O
of	O
Malaga	O
,	O
in	O
southern	O
Spain	O
,	O
and	O
from	O
different	O
social	O
statuses	O
to	O
avoid	O
a	O
selection	O
bias	O
.	O

All	O
the	O
selected	O
individuals	O
were	O
Caucasian	O
and	O
residents	O
of	O
the	O
study	O
area	O
.	O

The	O
parents	O
of	O
all	O
subjects	O
included	O
in	O
the	O
study	O
were	O
also	O
Caucasian	O
and	O
born	O
in	O
Spain	O
.	O

The	O
possibility	O
of	O
a	O
founder	O
effect	O
or	O
genetic	O
drift	O
was	O
investigated	O
and	O
rejected	O
.	O

All	O
the	O
selected	O
individuals	O
were	O
also	O
genotyped	O
for	O
an	O
insertion	O
/	O
deletion	O
polymorphism	O
in	O
the	O
angiotensin	O
converting	O
enzyme	O
(	O
ACE	O
)	O
gene	O
and/or	O
the	O
2756A	O
>	O
G	O
polymorphism	O
in	O
the	O
methionine	O
synthase	O
gene	O
(	O
MTR	O
)	O
,	O
in	O
order	O
to	O
determine	O
whether	O
or	O
not	O
our	O
adult	O
and	O
young	O
populations	O
were	O
genetically	O
homogeneous	O
.	O

No	O
significant	O
differences	O
were	O
observed	O
in	O
allelic	O
or	O
genotypic	O
frequencies	O
for	O
these	O
genes	O
between	O
the	O
different	O
groups	O
.	O

The	O
population	O
studied	O
was	O
randomly	O
selected	O
according	O
to	O
age	O
.	O

Subjects	O
0–12	O
years	O
old	O
were	O
selected	O
from	O
dried	O
blood	O
spots	O
from	O
neonatal	O
screening	O
papers	O
;	O
subjects	O
10–24	O
years	O
old	O
were	O
recruited	O
from	O
students	O
in	O
primary	O
and	O
secondary	O
schools	O
and	O
in	O
university	O
;	O
subjects	O
25–50	O
years	O
old	O
and	O
>	O
51	O
years	O
old	O
were	O
recruited	O
using	O
their	O
Andalusia	O
Health	O
Service	O
identity	O
cards	O
.	O

After	O
approval	O
by	O
the	O
University	O
Hospital	O
Ethical	O
Committee	O
,	O
all	O
the	O
subjects	O
were	O
contacted	O
,	O
and	O
,	O
from	O
those	O
whose	O
written	O
consent	O
was	O
obtained	O
,	O
10	O
ml	O
of	O
blood	O
was	O
taken	O
.	O

The	O
investigation	O
in	O
this	O
study	O
conforms	O
to	O
the	O
principles	O
outlined	O
in	O
the	O
Declaration	O
of	O
Helsinki	O
.	O

Genetic	O
analysis	O
The	O
fetal	O
samples	O
were	O
extracted	O
from	O
the	O
archived	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
tissue	O
sections	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
fetal	O
tissue	O
using	O
the	O
method	O
described	O
by	O
Coombs	O
et	O
al.	O
(	O
1999	O
)	O
[	O
15	O
]	O
.	O

Genomic	O
DNA	O
of	O
the	O
second	O
and	O
third	O
groups	O
was	O
extracted	O
from	O
peripheral	O
leukocytes	O
using	O
the	O
AquaPure	O
Genomic	O
DNA	O
Blood	O
Kit	O
(	O
Bio	O
-	O
Rad	O
)	O
.	O

Genotyping	O
was	O
performed	O
using	O
Real	O
Time	O
PCR	O
with	O
allele	O
specific	O
Taqman	O
®	O
probes	O
and	O
primers	O
described	O
by	O
Ulvik	O
et	O
al.	O
(	O
2001	O
)	O
[	O
16	O
]	O
and	O
the	O
following	O
optimized	O
protocol	O
for	O
45	O
cycles	O
:	O
10	O
s	O
–	O
94	O
°	O
C	O
,	O
40	O
s	O
–	O
54	O
°	O
C	O
,	O
15	O
s	O
–	O
72	O
°	O
C	O
.	O

The	O
PCR	O
mix	O
(	O
25	O
μl	O
total	O
volume	O
)	O
consisted	O
of	O
5	O
μl	O
of	O
genomic	O
DNA	O
,	O
0.5	O
μl	O
of	O
sense	O
primer	O
,	O
0.62	O
μl	O
of	O
anti	O
-	O
sense	O
primer	O
,	O
0.85	O
μl	O
Taqman	O
®	O
probe	O
FAM	O
,	O
0.43	O
μl	O
Taqman	O
®	O
probe	O
TET	O
,	O
20	O
μl	O
PCR	O
-	O
buffer	O
iQ	O
-	O
SupermixTM	O
(	O
Bio	O
-	O
Rad	O
)	O
(	O
containing	O
100	O
mM	O
KCl	O
,	O
40	O
mM	O
Tris	O
-	O
HCl	O
,	O
(	O
pH	O
8.4	O
)	O
1.6	O
mM	O
dNTP	O
(	O
dATP	O
,	O
dCTP	O
,	O
dGTP	O
and	O
dTTP	O
)	O
,	O
iTaq	O
®	O
polymerase	O
(	O
50	O
units	O
/	O
mL	O
)	O
and	O
6	O
mM	O
MgCl2	O
)	O
and	O
17.75	O
μl	O
H2O	O
.	O

Statistical	O
and	O
mathematical	O
analysis	O
All	O
samples	O
were	O
genotyped	O
,	O
and	O
the	O
allelic	O
and	O
genotypic	O
frequencies	O
were	O
compared	O
.	O

Differences	O
were	O
analyzed	O
statistically	O
using	O
the	O
chi	O
-	O
square	O
test	O
or	O
Fisher	O
's	O
exact	O
test	O
.	O

Correlations	O
are	O
expressed	O
using	O
Pearson	O
's	O
coefficient	O
(	O
r	O
)	O
.	O

Compliance	O
of	O
genotype	O
distributions	O
with	O
Hardy	O
-	O
Weinberg	O
(	O
HW	O
)	O
equilibrium	O
was	O
evaluated	O
by	O
chi	O
-	O
square	O
analysis	O
.	O

For	O
all	O
tests	O
,	O
a	O
p	O
-	O
value	O
<	O
0.05	O
was	O
considered	O
to	O
be	O
statistically	O
significant	O
.	O

Values	O
are	O
expressed	O
as	O
the	O
mean	O
±	O
SD	O
.	O

The	O
genetic	O
selection	O
model	O
was	O
calculated	O
for	O
the	O
evolution	O
of	O
the	O
677C	O
>	O
T	O
genotypes	O
.	O

The	O
genetic	O
selection	O
could	O
be	O
classified	O
as	O
codominant	O
or	O
incompletely	O
dominant	O
and	O
directional	O
with	O
the	O
heterozygous	O
genotype	O
having	O
an	O
intermediate	O
fitness	O
.	O

For	O
this	O
kind	O
of	O
selection	O
,	O
the	O
most	O
appropriate	O
mathematical	O
model	O
is	O
dq	O
=	O
[	O
spq	O
(	O
2hp+q	O
-	O
h	O
)	O
]	O
/	O
[	O
p2	O
+	O
2pq	O
(	O
1-hs	O
)	O
+	O
q2	O
×	O
(	O
1-s	O
)	O
]	O
,	O
where	O
dq	O
is	O
the	O
change	O
of	O
frequency	O
of	O
the	O
allele	O
with	O
lower	O
fitness	O
,	O
s	O
is	O
the	O
fraction	O
of	O
that	O
genotype	O
lost	O
to	O
selection	O
,	O
h	O
is	O
the	O
degree	O
of	O
dominance	O
(	O
between	O
0	O
,	O
for	O
no	O
dominance	O
and	O
1	O
,	O
for	O
complete	O
dominance	O
)	O
,	O
and	O
p	O
is	O
the	O
frequency	O
of	O
the	O
allele	O
with	O
higher	O
fitness	O
.	O

Results	O
We	O
analyzed	O
the	O
genotype	O
frequencies	O
of	O
the	O
677C	O
>	O
T	O
polymorphism	O
in	O
a	O
population	O
born	O
during	O
the	O
20th	O
century	O
.	O

A	O
total	O
of	O
1305	O
subjects	O
were	O
divided	O
into	O
four	O
groups	O
of	O
25	O
years	O
according	O
to	O
birth	O
date	O
.	O

The	O
genotype	O
frequencies	O
were	O
compared	O
between	O
the	O
four	O
quarters	O
of	O
the	O
century	O
and	O
showed	O
very	O
significant	O
changes	O
(	O
p	O
<	O
0.001	O
)	O
in	O
the	O
group	O
born	O
in	O
the	O
last	O
quarter	O
of	O
the	O
20th	O
century	O
(	O
1976–2000	O
)	O
,	O
when	O
compared	O
to	O
any	O
of	O
the	O
other	O
groups	O
.	O

The	O
changes	O
show	O
a	O
decrease	O
of	O
the	O
CC	O
genotype	O
and	O
an	O
increase	O
of	O
the	O
TT	O
genotype	O
in	O
the	O
last	O
25	O
years	O
of	O
the	O
20th	O
century	O
.	O

(	O
Table	O
1	O
)	O

Considering	O
that	O
each	O
25	O
year	O
period	O
corresponds	O
to	O
a	O
generation	O
,	O
allelic	O
frequencies	O
did	O
not	O
change	O
during	O
the	O
first	O
75	O
years	O
of	O
the	O
century	O
(	O
HW	O
equilibrium	O
)	O
.	O

However	O
,	O
we	O
found	O
that	O
allelic	O
and	O
genotypic	O
frequencies	O
for	O
the	O
677C	O
>	O
T	O
polymorphism	O
in	O
the	O
last	O
quarter	O
of	O
the	O
century	O
are	O
significantly	O
different	O
compared	O
to	O
the	O
previous	O
generation	O
(	O
1951–1975	O
)	O
.	O

The	O
genotype	O
frequencies	O
in	O
the	O
last	O
quarter	O
of	O
the	O
century	O
are	O
not	O
the	O
expected	O
by	O
a	O
HW	O
calculation	O
using	O
the	O
allelic	O
frequencies	O
of	O
the	O
previous	O
generation	O
.	O

This	O
could	O
be	O
described	O
as	O
a	O
consequence	O
of	O
genetic	O
selection	O
found	O
in	O
this	O
population	O
,	O
in	O
the	O
absence	O
of	O
other	O
causes	O
.	O

Applying	O
the	O
mathematical	O
model	O
described	O
above	O
to	O
our	O
population	O
,	O
the	O
calculated	O
fitness	O
(	O
s	O
)	O
is	O
0.5	O
,	O
and	O
it	O
can	O
be	O
predicted	O
that	O
both	O
alleles	O
will	O
be	O
approximately	O
at	O
a	O
frequency	O
of	O
50	O
%	O
in	O
the	O
next	O
generation	O
and	O
allele	O
T	O
will	O
be	O
at	O
90	O
%	O
after	O
seven	O
generations	O
(	O
Figure	O
1A	O
)	O
.	O

Another	O
possibility	O
is	O
that	O
a	O
scenario	O
could	O
be	O
predicted	O
in	O
which	O
both	O
alleles	O
will	O
have	O
frequencies	O
of	O
about	O
50	O
%	O
in	O
the	O
next	O
generation	O
and	O
that	O
they	O
will	O
maintain	O
this	O
stability	O
while	O
conditions	O
remain	O
unchanged	O
.	O

(	O
Figure	O
1B	O
)	O
The	O
comparison	O
of	O
the	O
genotype	O
frequencies	O
between	O
a	O
group	O
of	O
fetal	O
samples	O
from	O
SA	O
that	O
occurred	O
during	O
the	O
1980–1989	O
decade	O
and	O
living	O
subjects	O
born	O
in	O
the	O
same	O
decade	O
showed	O
significant	O
differences	O
in	O
genotype	O
frequencies	O
(	O
p	O
<	O
0.001	O
)	O
.	O

CC	O
genotypes	O
were	O
almost	O
absent	O
in	O
abortion	O
samples	O
compared	O
to	O
living	O
subjects	O
(	O
0.03	O
vs	O
0.33	O
)	O
,	O
while	O
CT	O
and	O
TT	O
genotypes	O
were	O
overrepresented	O
in	O
the	O
same	O
group	O
.	O

When	O
3-year	O
periods	O
are	O
studied	O
in	O
the	O
decade	O
,	O
we	O
detected	O
a	O
significant	O
increase	O
of	O
the	O
mutated	O
subjects	O
during	O
the	O
decade	O
(	O
CT	O
p	O
<	O
0.05	O
;	O
TT	O
p	O
<	O
0.01	O
)	O
.	O

Allele	O
frequencies	O
showed	O
the	O
same	O
pattern	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Controls	O
showed	O
the	O
same	O
tendency	O
but	O
without	O
statistical	O
significance	O
.	O

(	O
Table	O
2	O
)	O

The	O
evolution	O
of	O
genotype	O
frequencies	O
during	O
the	O
1980–1989	O
decade	O
of	O
the	O
TT	O
genotypes	O
correlates	O
well	O
in	O
both	O
living	O
populations	O
as	O
well	O
as	O
fetal	O
samples	O
r	O
=	O
0.98	O
(	O
p	O
=	O
0.11	O
)	O
.	O

Discussion	O
Different	O
reports	O
show	O
that	O
the	O
prevalence	O
of	O
the	O
677C	O
>	O
T	O
polymorphism	O
of	O
the	O
MTHFR	O
gene	O
differs	O
dramatically	O
among	O
human	B
populations	O
.	O

Evidence	O
of	O
this	O
dynamism	O
can	O
be	O
observed	O
in	O
many	O
reports	O
:	O
frequency	O
variations	O
between	O
populations	O
that	O
are	O
geographically	O
very	O
close	O
,	O
even	O
in	O
the	O
same	O
country	O
[	O
8	O
]	O
;	O
changes	O
found	O
in	O
the	O
same	O
race	O
or	O
ethnic	O
group	O
such	O
as	O
Africans	O
[	O
10,11	O
]	O
and	O
African	O
-	O
Americans	O
[	O
12	O
]	O
;	O
the	O
high	O
prevalence	O
of	O
the	O
677C	O
>	O
T	O
poymorphism	O
in	O
populations	O
with	O
special	O
nutritional	O
features	O
such	O
as	O
Mexicans	O
[	O
9	O
]	O
and	O
Japanese	O
[	O
13	O
]	O
;	O
and	O
changes	O
in	O
frequencies	O
between	O
generations	O
of	O
the	O
same	O
population	O
,	O
as	O
has	O
been	O
observed	O
in	O
Spain	O
[	O
5	O
]	O
,	O
Switzerland	O
[	O
6	O
]	O
and	O
Japan	O
[	O
7	O
]	O
.	O

There	O
are	O
numerous	O
interpretations	O
of	O
this	O
great	O
diversity	O
,	O
and	O
most	O
tend	O
to	O
be	O
related	O
to	O
adaptation	O
to	O
external	O
conditions	O
such	O
as	O
climate	O
or	O
nutritional	O
status	O
.	O

Dependence	O
of	O
folate	O
degradation	O
on	O
skin	O
pigmentation	O
[	O
17	O
]	O
,	O
nutritional	O
habits	O
or	O
human	B
intervention	O
periconceptional	O
periods	O
could	O
explain	O
this	O
genetic	O
variation	O
.	O

Definitely	O
,	O
external	O
factors	O
in	O
combination	O
with	O
different	O
levels	O
of	O
MTHFR	O
enzyme	O
activity	O
,	O
conditioned	O
by	O
polymorphisms	O
,	O
could	O
influence	O
the	O
fetal	O
viability	O
of	O
certain	O
genotypes	O
.	O

In	O
1998	O
,	O
we	O
suggested	O
the	O
possibility	O
of	O
genetic	O
selection	O
in	O
Spain	O
in	O
favor	O
of	O
the	O
mutants	O
of	O
the	O
677C	O
>	O
T	O
polymorphism	O
in	O
the	O
MTHFR	O
gene	O
based	O
on	O
the	O
fact	O
that	O
treatment	O
with	O
vitamins	O
and	O
folates	O
during	O
pregnancy	O
increased	O
the	O
viability	O
of	O
fetuses	O
with	O
the	O
TT	O
homozygous	O
genotype	O
.	O

This	O
hypothesis	O
was	O
based	O
on	O
the	O
increase	O
in	O
the	O
number	O
of	O
mutated	O
individuals	O
found	O
in	O
our	O
population	O
since	O
the	O
mid-1970s	O
[	O
5	O
]	O
and	O
the	O
coincident	O
increased	O
intake	O
of	O
vitamins	O
and	O
folate	O
by	O
pregnant	O
women	O
in	O
Spain	O
[	O
18,19	O
]	O
.	O

In	O
2002	O
,	O
a	O
new	O
study	O
found	O
changes	O
in	O
genotype	O
frequencies	O
for	O
the	O
677C	O
>	O
T	O
and	O
1298A	O
>	O
C	O
polymorphisms	O
in	O
different	O
age	O
groups	O
.	O

Total	O
homocysteine	O
(	O
tHcy	O
)	O
levels	O
in	O
plasma	O
were	O
also	O
analyzed	O
according	O
to	O
the	O
different	O
genotype	O
interactions	O
[	O
20	O
]	O
.	O

That	O
study	O
hypothesized	O
about	O
fetal	O
viability	O
and	O
about	O
a	O
genetic	O
selection	O
model	O
on	O
the	O
basis	O
of	O
non	O
-	O
linkage	O
disequilibrium	O
between	O
both	O
polymorphisms	O
.	O

Recently	O
,	O
a	O
study	O
with	O
fetal	O
and	O
control	O
populations	O
showed	O
the	O
strong	O
influence	O
of	O
these	O
polymorphisms	O
,	O
though	O
mainly	O
of	O
the	O
677C	O
>	O
T	O
polymorphism	O
,	O
on	O
spontaneous	O
early	O
abortion	O
[	O
21	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
significant	O
changes	O
in	O
allelic	O
and	O
genotypic	O
frequencies	O
are	O
detected	O
,	O
as	O
is	O
Hardy	O
-	O
Weinberg	O
disequilibrium	O
,	O
at	O
the	O
677C	O
>	O
T	O
polymorphism	O
.	O

We	O
hypothesize	O
that	O
there	O
is	O
a	O
dynamic	O
process	O
of	O
genetic	O
selection	O
that	O
favors	O
the	O
T	O
allele	O
.	O

This	O
process	O
of	O
selection	O
started	O
during	O
the	O
last	O
quarter	O
of	O
the	O
20th	O
century	O
,	O
during	O
which	O
the	O
frequency	O
for	O
mutant	O
homozygous	O
(	O
TT	O
)	O
rose	O
significantly	O
from	O
14	O
%	O
to	O
24	O
%	O
.	O

We	O
propose	O
that	O
this	O
increase	O
in	O
mutants	O
is	O
due	O
to	O
the	O
inclusion	O
of	O
an	O
external	O
factor	O
that	O
enhances	O
mutant	O
fetal	O
viability	O
.	O

If	O
we	O
apply	O
the	O
mathematical	O
model	O
for	O
dynamic	O
selection	O
developed	O
for	O
diploid	O
organisms	O
with	O
sexual	O
reproduction	O
,	O
the	O
T	O
allele	O
could	O
reach	O
to	O
90	O
%	O
in	O
seven	O
generations	O
in	O
our	O
population	O
(	O
Figure	O
1A	O
)	O
.	O

However	O
,	O
this	O
model	O
assumes	O
selection	O
in	O
a	O
constant	O
environment	O
that	O
applies	O
to	O
all	O
individuals	O
in	O
the	O
population	O
studied	O
.	O

In	O
our	O
case	O
,	O
we	O
suggest	O
that	O
the	O
external	O
factor	O
is	O
related	O
to	O
an	O
increase	O
in	O
folate	O
and	O
vitamin	O
intake	O
in	O
women	O
in	O
periconceptional	O
period	O
and	O
does	O
not	O
affect	O
to	O
all	O
individuals	O
[	O
18,19	O
]	O
.	O

We	O
assume	O
that	O
prediction	O
of	O
a	O
classic	O
selection	O
model	O
in	O
this	O
case	O
is	O
only	O
theoretical	O
.	O

On	O
the	O
basis	O
of	O
a	O
competition	O
between	O
alleles	O
in	O
which	O
an	O
environmental	O
factor	O
favors	O
one	O
allele	O
versus	O
the	O
other	O
,	O
the	O
final	O
result	O
would	O
be	O
that	O
predicted	O
by	O
the	O
previous	O
mathematical	O
model	O
.	O

However	O
in	O
this	O
case	O
,	O
the	O
environment	O
is	O
not	O
selecting	O
against	O
the	O
wild	O
type	O
allele	O
but	O
rather	O
allowing	O
the	O
survival	O
of	O
more	O
mutated	O
alleles	O
.	O

Therefore	O
,	O
the	O
expected	O
result	O
would	O
be	O
not	O
a	O
systematic	O
increase	O
of	O
the	O
mutated	O
allele	O
but	O
the	O
creation	O
of	O
an	O
allelic	O
balance	O
dependent	O
on	O
vitamin	O
and	O
folate	O
abundance	O
conditions	O
.	O

In	O
this	O
case	O
,	O
the	O
mutation	O
would	O
have	O
a	O
lower	O
influence	O
on	O
fetal	O
viability	O
(	O
Figure	O
1B	O
)	O
.	O

The	O
results	O
showed	O
an	O
increase	O
in	O
mutated	O
genotypes	O
(	O
CT	O
and	O
TT	O
)	O
and	O
a	O
strong	O
protection	O
against	O
abortion	O
by	O
the	O
wild	O
type	O
genotype	O
(	O
CC	O
)	O
,	O
which	O
is	O
practically	O
non	O
-	O
existent	O
in	O
the	O
SA	O
group	O
.	O

The	O
frequency	O
of	O
the	O
CC	O
genotype	O
shows	O
no	O
change	O
over	O
the	O
decade	O
studied	O
(	O
1980–1989	O
)	O
,	O
which	O
indicates	O
that	O
folate	O
does	O
not	O
exert	O
a	O
visible	O
effect	O
on	O
this	O
genotype	O
.	O

However	O
,	O
the	O
frequency	O
of	O
the	O
mutated	O
allele	O
increases	O
during	O
this	O
decade	O
,	O
especially	O
in	O
fetuses	O
from	O
abortions	O
,	O
and	O
this	O
increase	O
correlated	O
with	O
the	O
increase	O
of	O
the	O
T	O
allele	O
in	O
the	O
control	O
population	O
.	O

This	O
finding	O
suggests	O
that	O
the	O
effect	O
of	O
folate	O
is	O
crucial	O
to	O
viability	O
during	O
the	O
early	O
stages	O
of	O
embryonic	O
development	O
,	O
but	O
,	O
even	O
with	O
folate	O
,	O
not	O
all	O
embryos	O
will	O
survive	O
until	O
birth	O
.	O

In	O
this	O
population	O
,	O
the	O
mutant	O
allele	O
with	O
lower	O
enzymatic	O
activity	O
has	O
higher	O
fitness	O
than	O
the	O
wild	O
type	O
.	O

In	O
the	O
folate	O
cycle	O
,	O
it	O
can	O
be	O
observed	O
that	O
5,10-methyleneTHF	O
availability	O
may	O
be	O
important	O
.	O

5,10-methyleneTHF	O
is	O
the	O
substrate	O
for	O
several	O
reactions	O
in	O
the	O
cycle	O
,	O
but	O
two	O
of	O
them	O
(	O
5-methylTHF	O
and	O
thymidilate	O
synthesis	O
)	O
might	O
be	O
essential	O
for	O
embryo	O
development	O
in	O
folate	O
deficiency	O
conditions	O
.	O

In	O
both	O
cases	O
,	O
complete	O
or	O
limited	O
MTHFR	O
activity	O
will	O
produce	O
higher	O
or	O
lower	O
5,10-methyleneTHF	O
availability	O
,	O
which	O
might	O
be	O
an	O
essential	O
factor	O
for	O
embryo	O
development	O
,	O
such	O
that	O
a	O
greater	O
folate	O
levels	O
can	O
compensate	O
the	O
lower	O
enzymatic	O
activity	O
of	O
the	O
mutant	O
.	O

The	O
implications	O
of	O
this	O
polymorphism	O
in	O
nucleotide	O
synthesis	O
have	O
not	O
yet	O
been	O
determined	O
,	O
but	O
certain	O
data	O
,	O
such	O
as	O
high	O
levels	O
of	O
uric	O
acid	O
found	O
in	O
mutated	O
subjects	O
[	O
22,23	O
]	O
,	O
suggest	O
that	O
there	O
are	O
different	O
turnover	O
rates	O
associated	O
with	O
different	O
polymorphisms	O
.	O

Conclusion	O
We	O
suggest	O
that	O
there	O
is	O
genetic	O
selection	O
in	O
our	O
population	O
for	O
the	O
T	O
allele	O
of	O
the	O
MTHFR	O
–	O
677C	O
>	O
T	O
polymorphism	O
,	O
whose	O
origin	O
could	O
be	O
an	O
increase	O
in	O
fetal	O
viability	O
during	O
the	O
early	O
stages	O
of	O
embryonic	O
development	O
because	O
of	O
an	O
increase	O
in	O
folate	O
and	O
vitamin	O
intake	O
by	O
women	O
in	O
the	O
periconceptional	O
period	O
that	O
began	O
to	O
be	O
established	O
in	O
Spain	O
in	O
the	O
last	O
quarter	O
of	O
the	O
20th	O
century	O
[	O
18,19	O
]	O
.	O

Higher	O
frequencies	O
for	O
the	O
T	O
allele	O
and	O
TT	O
genotype	O
in	O
our	O
population	O
are	O
observed	O
in	O
the	O
living	O
and	O
SA	O
populations	O
.	O

Competing	O
interests	O
The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O
AMO	O
performed	O
the	O
statistical	O
analysis	O
,	O
helped	O
to	O
draft	O
the	O
manuscript	O
and	O
revised	O
it	O
for	O
publication	O
.	O

GC	O
is	O
the	O
corresponding	O
author	O
,	O
participated	O
in	O
the	O
acquisition	O
of	O
samples	O
and	O
carried	O
out	O
the	O
genotyping	O
.	O

ARP	O
carried	O
out	O
the	O
bibliographic	O
search	O
and	O
helped	O
to	O
draft	O
the	O
manuscript	O
.	O

AJJ	O
participated	O
in	O
the	O
selection	O
and	O
the	O
processing	O
of	O
samples	O
.	O

MJG	O
coordinated	O
the	O
laboratory	O
work	O
and	O
selected	O
the	O
genotyping	O
method	O
.	O

AR	O
selected	O
the	O
control	O
subjects	O
and	O
designed	O
the	O
consent	O
form	O
.	O

MR	O
helped	O
in	O
the	O
interpretation	O
of	O
data	O
and	O
tables	O
performance	O
.	O

ARE	O
conceived	O
the	O
study	O
and	O
is	O
the	O
guarantor	O
of	O
this	O
work	O
and	O
the	O
general	O
coordinator	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Pre	O
-	O
publication	O
history	O
The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O

Protein	O
subfamily	O
assignment	O
using	O
the	O
Conserved	O
Domain	O
Database	O
Abstract	O
Background	O
Domains	O
,	O
evolutionarily	O
conserved	O
units	O
of	O
proteins	O
,	O
are	O
widely	O
used	O
to	O
classify	O
protein	O
sequences	O
and	O
infer	O
protein	O
function	O
.	O

Often	O
,	O
two	O
or	O
more	O
overlapping	O
domain	O
models	O
match	O
a	O
region	O
of	O
a	O
protein	O
sequence	O
.	O

Therefore	O
,	O
procedures	O
are	O
required	O
to	O
choose	O
appropriate	O
domain	O
annotations	O
for	O
the	O
protein	O
.	O

Here	O
,	O
we	O
propose	O
a	O
method	O
for	O
assigning	O
NCBI	O
-	O
curated	O
domains	O
from	O
the	O
Curated	O
Domain	O
Database	O
(	O
CDD	O
)	O
that	O
takes	O
into	O
account	O
the	O
organization	O
of	O
the	O
domains	O
into	O
hierarchies	O
of	O
homologous	O
domain	O
models	O
.	O

Findings	O
Our	O
analysis	O
of	O
alignment	O
scores	O
from	O
NCBI	O
-	O
curated	O
domain	O
assignments	O
suggests	O
that	O
identifying	O
the	O
correct	O
model	O
among	O
closely	O
related	O
models	O
is	O
more	O
difficult	O
than	O
choosing	O
between	O
non	O
-	O
overlapping	O
domain	O
models	O
.	O

We	O
find	O
that	O
simple	O
heuristics	O
based	O
on	O
sorting	O
scores	O
and	O
domain	O
-	O
specific	O
thresholds	O
are	O
effective	O
at	O
reducing	O
classification	O
error	O
.	O

In	O
fact	O
,	O
in	O
our	O
test	O
set	O
,	O
the	O
heuristics	O
result	O
in	O
almost	O
90	O
%	O
of	O
current	O
misclassifications	O
due	O
to	O
missing	O
domain	O
subfamilies	O
being	O
replaced	O
by	O
more	O
generic	O
domain	O
assignments	O
,	O
thereby	O
eliminating	O
a	O
significant	O
amount	O
of	O
error	O
within	O
the	O
database	O
.	O

Conclusion	O
Our	O
proposed	O
domain	O
subfamily	O
assignment	O
rule	O
has	O
been	O
incorporated	O
into	O
the	O
CD	O
-	O
Search	O
software	O
for	O
assigning	O
CDD	O
domains	O
to	O
query	O
protein	O
sequences	O
and	O
has	O
significantly	O
improved	O
pre	O
-	O
calculated	O
domain	O
annotations	O
on	O
protein	O
sequences	O
in	O
NCBI	O
's	O
Entrez	O
resource	O
.	O

Background	O
A	O
major	O
goal	O
in	O
the	O
post	O
-	O
genomic	O
world	O
is	O
to	O
infer	O
protein	O
function	O
from	O
sequence	O
information	O
.	O

One	O
popular	O
approach	O
is	O
to	O
classify	O
protein	O
families	O
or	O
domains	O
by	O
grouping	O
homologous	O
sequences	O
and	O
annotating	O
the	O
groups	O
with	O
properties	O
such	O
as	O
general	O
function	O
,	O
intracellular	O
location	O
,	O
three	O
-	O
dimensional	O
structure	O
,	O
conserved	O
sequence	O
patterns	O
or	O
motifs	O
,	O
evolutionary	O
origin	O
,	O
and	O
binding	O
and	O
active	O
sites	O
.	O

Novel	O
proteins	O
can	O
be	O
characterized	O
quickly	O
by	O
assigning	O
a	O
group	O
via	O
profile	O
search	O
methods	O
.	O

However	O
,	O
more	O
than	O
one	O
family	O
or	O
subfamily	O
may	O
exhibit	O
similarity	O
to	O
overlapping	O
sequence	O
intervals	O
and	O
to	O
a	O
degree	O
that	O
seems	O
convincing	O
(	O
Figure	O
1	O
)	O
.	O

Assigning	O
the	O
protein	O
to	O
the	O
correct	O
group	O
not	O
only	O
yields	O
the	O
correct	O
annotations	O
,	O
but	O
may	O
also	O
help	O
to	O
avoid	O
propagating	O
annotation	O
errors	O
and	O
alleviate	O
current	O
issues	O
with	O
mislabelling	O
in	O
protein	O
sequence	O
databases	O
[	O
1,2	O
]	O
.	O

Here	O
,	O
we	O
examine	O
the	O
problem	O
of	O
making	O
correct	O
domain	O
assignments	O
from	O
the	O
Conserved	O
Domain	O
Database	O
[	O
3,4	O
]	O
.	O

Domains	O
are	O
evolutionarily	O
conserved	O
units	O
in	O
proteins	O
and	O
frequently	O
correspond	O
to	O
recurrent	O
structural	O
and	O
functional	O
units	O
.	O

The	O
particular	O
function	O
of	O
a	O
protein	O
depends	O
on	O
its	O
combination	O
of	O
domains	O
;	O
two	O
-	O
thirds	O
of	O
prokaryotic	O
proteins	O
and	O
80	O
%	O
of	O
eukaryotic	O
proteins	O
have	O
more	O
than	O
one	O
domain	O
.	O

To	O
create	O
new	O
protein	O
functions	O
,	O
novel	O
domain	O
architectures	O
arise	O
through	O
domain	O
rearrangement	O
and	O
recombination	O
,	O
frequently	O
through	O
gene	O
duplication	O
and	O
fission	O
or	O
fusion	O
events	O
[	O
5,6	O
]	O
.	O

A	O
domain	O
may	O
be	O
represented	O
as	O
a	O
multiple	O
sequence	O
alignment	O
(	O
MSA	O
)	O
of	O
homologous	O
sequence	O
fragments	O
.	O

To	O
identify	O
the	O
domains	O
in	O
a	O
query	O
protein	O
sequence	O
,	O
the	O
MSAs	O
are	O
converted	O
into	O
scoring	O
models	O
such	O
as	O
hidden	O
Markov	O
model	O
or	O
position	O
-	O
specific	O
scoring	O
matrix	O
for	O
use	O
with	O
database	O
search	O
algorithms	O
such	O
HMMER	O
[	O
7	O
]	O
and	O
RPS	O
-	O
BLAST	O
[	O
8	O
]	O
.	O

To	O
refine	O
protein	O
annotation	O
,	O
domains	O
models	O
may	O
be	O
subdivided	O
to	O
represent	O
more	O
specific	O
functions	O
or	O
conserved	O
features	O
.	O

CDD	O
curators	O
apply	O
phylogenetic	O
and	O
structural	O
analysis	O
to	O
construct	O
hierarchies	O
of	O
homologous	O
domain	O
models	O
,	O
related	O
by	O
common	O
descent	O
,	O
to	O
reflect	O
aspects	O
of	O
their	O
evolutionary	O
histories	O
[	O
3,4	O
]	O
.	O

Curation	O
follows	O
an	O
iterative	O
procedure	O
to	O
split	O
domain	O
models	O
into	O
subfamilies	O
that	O
redistributes	O
sequences	O
into	O
more	O
narrowly	O
defined	O
models	O
.	O

In	O
the	O
hierarchy	O
tree	O
structure	O
,	O
the	O
leaf	O
domains	O
represent	O
highly	O
conserved	O
and	O
often	O
orthologous	O
protein	O
subgroups	O
.	O

Their	O
precursor	O
(	O
internal	O
)	O
domains	O
,	O
on	O
the	O
other	O
hand	O
,	O
reflect	O
ancient	O
gene	O
duplication	O
events	O
,	O
as	O
CDD	O
aims	O
to	O
categorize	O
ancient	O
conserved	O
domain	O
families	O
.	O

It	O
may	O
seem	O
natural	O
that	O
once	O
the	O
profiles	O
have	O
been	O
defined	O
,	O
the	O
most	O
significant	O
match	O
to	O
a	O
query	O
sequence	O
is	O
the	O
correct	O
one	O
.	O

Indeed	O
,	O
domains	O
from	O
Pfam	O
[	O
9,10	O
]	O
and	O
SMART	O
[	O
11	O
]	O
are	O
assigned	O
following	O
the	O
lowest	O
alignment	O
E	O
-	O
value	O
that	O
exceeds	O
a	O
family	O
-	O
specific	O
cutoff	O
[	O
12,13	O
]	O
.	O

This	O
straightforward	O
approach	O
works	O
well	O
when	O
the	O
candidate	O
domains	O
are	O
disjoint	O
.	O

Domain	O
subfamilies	O
may	O
be	O
obtained	O
through	O
automated	O
methods	O
such	O
as	O
the	O
SCI	O
-	O
PHY	O
algorithm	O
for	O
identifying	O
functional	O
subtypes	O
of	O
known	O
domain	O
families	O
[	O
14,15	O
]	O
or	O
by	O
mirroring	O
other	O
hierarchical	O
domain	O
classifications	O
such	O
as	O
SCOP	O
[	O
16	O
]	O
and	O
CATH	O
[	O
17	O
]	O
.	O

However	O
,	O
subfamily	O
assignment	O
methods	O
generally	O
attempt	O
to	O
classify	O
a	O
member	O
of	O
a	O
family	O
at	O
the	O
subfamily	O
level	O
given	O
that	O
the	O
family	O
is	O
known	O
,	O
as	O
in	O
a	O
statistical	O
pairwise	O
/	O
profile	O
method	O
proposed	O
for	O
SUPERFAMILY	O
[	O
18	O
-	O
20	O
]	O
.	O

The	O
systematic	O
arrangement	O
of	O
CDD	O
domains	O
requires	O
identifying	O
the	O
most	O
suitable	O
level	O
of	O
resolution	O
among	O
domain	O
models	O
that	O
offer	O
more	O
or	O
less	O
fine	O
-	O
grained	O
descriptions	O
of	O
a	O
protein	O
.	O

We	O
take	O
the	O
viewpoint	O
that	O
if	O
a	O
protein	O
can	O
not	O
be	O
associated	O
unambiguously	O
with	O
a	O
specific	O
subgroup	O
or	O
may	O
be	O
a	O
member	O
of	O
a	O
subgroup	O
that	O
has	O
not	O
been	O
defined	O
,	O
the	O
protein	O
can	O
be	O
assigned	O
a	O
more	O
generic	O
domain	O
model	O
or	O
the	O
superfamily	O
in	O
general	O
.	O

Consequently	O
the	O
ideal	O
domain	O
assignment	O
to	O
a	O
query	O
sequence	O
will	O
be	O
the	O
most	O
specific	O
domain	O
,	O
within	O
a	O
candidate	O
hierarchy	O
,	O
with	O
a	O
strong	O
match	O
to	O
the	O
sequence	O
.	O

Here	O
,	O
we	O
analyze	O
a	O
set	O
of	O
correct	O
domain	O
assignments	O
from	O
CDD	O
to	O
establish	O
an	O
improved	O
method	O
for	O
assigning	O
domains	O
to	O
query	O
sequences	O
.	O

The	O
effectiveness	O
of	O
a	O
traditional	O
alignment	O
score	O
and	O
domain	O
-	O
specific	O
threshold	O
is	O
of	O
particular	O
interest	O
,	O
as	O
this	O
method	O
is	O
efficient	O
and	O
makes	O
use	O
of	O
alignment	O
information	O
that	O
is	O
already	O
computed	O
for	O
CDD	O
.	O

Constructing	O
a	O
benchmark	O
set	O
of	O
correct	O
domain	O
assignments	O
To	O
benchmark	O
domain	O
assignment	O
heuristics	O
,	O
a	O
reference	O
set	O
of	O
domain	O
assignments	O
is	O
constructed	O
from	O
the	O
NCBI	O
-	O
curated	O
portion	O
of	O
CDD	O
v.	O
2.12	O
.	O

This	O
set	O
contains	O
every	O
sequence	O
fragment	O
present	O
among	O
the	O
MSAs	O
and	O
its	O
domain	O
assignment	O
.	O

The	O
NCBI	O
-	O
curated	O
domains	O
have	O
undergone	O
rigorous	O
testing	O
to	O
optimize	O
the	O
MSAs	O
and	O
distributions	O
of	O
representative	O
sequence	O
fragments	O
.	O

The	O
correct	O
or	O
most	O
specific	O
domain	O
for	O
each	O
sequence	O
in	O
a	O
hierarchy	O
is	O
defined	O
as	O
the	O
domain	O
having	O
no	O
descendant	O
that	O
contains	O
an	O
overlapping	O
sequence	O
interval	O
.	O

Two	O
sequence	O
intervals	O
from	O
one	O
protein	O
are	O
said	O
to	O
overlap	O
if	O
one	O
sequence	O
interval	O
contains	O
at	O
least	O
30	O
%	O
of	O
the	O
positions	O
of	O
the	O
other	O
.	O

While	O
each	O
sequence	O
has	O
been	O
placed	O
in	O
the	O
most	O
specific	O
domain	O
model	O
that	O
characterizes	O
it	O
,	O
this	O
step	O
is	O
required	O
as	O
parent	O
and	O
child	O
domains	O
share	O
overlapping	O
sequences	O
(	O
Figure	O
1	O
)	O
.	O

Sequences	O
with	O
overlapping	O
regions	O
from	O
more	O
than	O
one	O
hierarchy	O
are	O
counted	O
once	O
for	O
each	O
hierarchy	O
.	O

Non	O
-	O
overlapping	O
regions	O
of	O
a	O
protein	O
are	O
treated	O
independently	O
.	O

Alignments	O
between	O
all	O
NCBI	O
-	O
curated	O
domains	O
and	O
proteins	O
present	O
in	O
the	O
public	O
Entrez	O
protein	O
set	O
at	O
time	O
of	O
analysis	O
(	O
September	O
2007	O
)	O
[	O
21	O
]	O
have	O
been	O
pre	O
-	O
computed	O
using	O
RPS	O
-	O
BLAST	O
.	O

In	O
this	O
analysis	O
,	O
the	O
alignment	O
score	O
refers	O
to	O
the	O
bitscore	O
,	O
a	O
normalized	O
version	O
of	O
the	O
raw	O
alignment	O
score	O
between	O
the	O
query	O
sequence	O
and	O
the	O
PSSM	O
,	O
which	O
allows	O
alignments	O
from	O
different	O
searches	O
to	O
be	O
compared	O
.	O

The	O
bitscore	O
corresponds	O
roughly	O
to	O
the	O
alignment	O
E	O
-	O
value	O
and	O
is	O
used	O
instead	O
to	O
avoid	O
real	O
value	O
rounding	O
issues	O
.	O

A	O
significant	O
PSSM	O
-	O
sequence	O
alignment	O
is	O
called	O
a	O
hit	O
,	O
for	O
brevity	O
.	O

We	O
call	O
a	O
match	O
between	O
a	O
sequence	O
region	O
and	O
its	O
correct	O
domain	O
a	O
self	O
hit	O
to	O
distinguish	O
it	O
from	O
other	O
hits	O
to	O
overlapping	O
sequence	O
regions	O
.	O

Other	O
hits	O
to	O
the	O
sequences	O
in	O
the	O
reference	O
dataset	O
serve	O
as	O
examples	O
of	O
incorrect	O
domain	O
assignments	O
.	O

CDD	O
v	O
2.12	O
contains	O
3078	O
NCBI	O
-	O
curated	O
domains	O
in	O
495	O
hierarchies	O
,	O
including	O
298	O
single	O
-	O
domain	O
""""	O
hierarchies	O
""""	O
and	O
197	O
trees	O
with	O
2357	O
leaf	O
and	O
423	O
internal	O
domains	O
.	O

Many	O
sequence	O
fragments	O
used	O
to	O
construct	O
the	O
NCBI	O
-	O
curated	O
domain	O
profiles	O
come	O
from	O
proteins	O
that	O
have	O
been	O
replaced	O
with	O
newer	O
versions	O
or	O
declared	O
obsolete	O
.	O

Among	O
the	O
109186	O
representative	O
sequences	O
in	O
NCBI	O
-	O
curated	O
domain	O
hierarchies	O
,	O
over	O
21	O
%	O
have	O
no	O
hits	O
and	O
more	O
than	O
90	O
%	O
of	O
those	O
sequences	O
are	O
no	O
longer	O
present	O
in	O
Entrez	O
.	O

This	O
analysis	O
excludes	O
the	O
149	O
curated	O
domains	O
without	O
corresponding	O
live	O
data	O
in	O
Entrez	O
,	O
leaving	O
2929	O
domains	O
.	O

Performance	O
of	O
a	O
simple	O
high	O
-	O
score	O
assignment	O
method	O
We	O
begin	O
by	O
assessing	O
the	O
performance	O
of	O
the	O
previous	O
method	O
for	O
assigning	O
NCBI	O
-	O
curated	O
domains	O
from	O
CDD	O
.	O

The	O
NCBI	O
CD	O
-	O
Search	O
tool	O
[	O
22	O
]	O
has	O
historically	O
relied	O
on	O
alignment	O
E	O
-	O
value	O
and	O
properties	O
such	O
as	O
the	O
source	O
domain	O
database	O
to	O
highlight	O
one	O
or	O
a	O
few	O
most	O
likely	O
domain	O
assignments	O
,	O
without	O
claiming	O
to	O
pinpoint	O
the	O
correct	O
domain	O
assignment	O
.	O

Analysis	O
of	O
all	O
hits	O
to	O
the	O
sequences	O
in	O
the	O
benchmark	O
set	O
reveals	O
that	O
assigning	O
domains	O
by	O
high	O
alignment	O
score	O
alone	O
achieves	O
96	O
%	O
accuracy	O
over	O
all	O
sequences	O
and	O
100	O
%	O
accuracy	O
over	O
the	O
representative	O
sequences	O
for	O
91.5	O
%	O
of	O
domain	O
models	O
.	O

Further	O
,	O
categorizing	O
non	O
-	O
self	O
hits	O
by	O
their	O
hierarchical	O
relationships	O
to	O
the	O
correct	O
domain	O
reveals	O
that	O
assigning	O
to	O
a	O
subclass	O
of	O
the	O
correct	O
domain	O
is	O
the	O
most	O
common	O
type	O
of	O
error	O
when	O
a	O
sequence	O
matches	O
the	O
correct	O
domain	O
and	O
other	O
domains	O
(	O
Table	O
1	O
)	O
.	O

For	O
simplicity	O
,	O
all	O
non	O
-	O
self	O
hits	O
are	O
labelled	O
as	O
incorrect	O
hits	O
in	O
the	O
tables	O
although	O
some	O
child	O
/	O
descendant	O
and	O
parent	O
/	O
ancestor	O
assignments	O
may	O
not	O
be	O
regarded	O
as	O
actual	O
classification	O
errors	O
.	O

Child	O
/	O
descendant	O
domains	O
score	O
higher	O
than	O
the	O
self	O
hit	O
for	O
21.8	O
%	O
of	O
sequences	O
with	O
both	O
types	O
of	O
hits	O
.	O

These	O
higher	O
scores	O
may	O
reflect	O
computational	O
bias	O
from	O
longer	O
profiles	O
,	O
overly	O
cautious	O
assignment	O
of	O
a	O
sequence	O
to	O
a	O
more	O
generic	O
domain	O
,	O
or	O
missing	O
subfamilies	O
.	O

In	O
contrast	O
,	O
higher	O
scores	O
from	O
parent	O
/	O
ancestor	O
domains	O
or	O
domains	O
from	O
other	O
branches	O
of	O
a	O
hierarchy	O
are	O
rarely	O
observed	O
.	O

For	O
additional	O
data	O
and	O
discussion	O
of	O
all	O
analyses	O
described	O
in	O
this	O
document	O
,	O
see	O
[	O
Additional	O
file	O
1	O
]	O
.	O

We	O
define	O
a	O
score	O
threshold	O
for	O
each	O
domain	O
to	O
be	O
the	O
lowest	O
self	O
-	O
hit	O
score	O
to	O
that	O
domain	O
among	O
all	O
of	O
its	O
sequences	O
in	O
the	O
benchmark	O
set	O
.	O

This	O
additional	O
heuristic	O
,	O
in	O
particular	O
,	O
reduces	O
incorrect	O
assignments	O
to	O
subclasses	O
as	O
only	O
9.1	O
%	O
of	O
hits	O
to	O
subclasses	O
score	O
above	O
the	O
thresholds	O
for	O
those	O
subclasses	O
(	O
Table	O
2	O
)	O
.	O

The	O
threshold	O
definition	O
works	O
around	O
the	O
issue	O
of	O
small	O
data	O
size	O
–	O
over	O
60	O
%	O
of	O
domains	O
have	O
20	O
or	O
fewer	O
self	O
hits	O
–	O
and	O
addresses	O
variances	O
in	O
scores	O
between	O
domains	O
due	O
to	O
properties	O
such	O
as	O
length	O
and	O
residue	O
composition	O
,	O
or	O
practical	O
issues	O
such	O
as	O
incomplete	O
local	O
alignments	O
,	O
which	O
are	O
not	O
considered	O
by	O
simple	O
high	O
-	O
score	O
heuristics	O
.	O

The	O
definition	O
is	O
more	O
restrictive	O
than	O
its	O
Pfam	O
counterpart	O
,	O
the	O
minimum	O
alignment	O
score	O
among	O
all	O
sequences	O
in	O
the	O
automated	O
""""	O
full	O
alignment	O
""""	O
,	O
as	O
NCBI	O
-	O
curated	O
hierarchies	O
in	O
CDD	O
tend	O
to	O
present	O
a	O
finer	O
-	O
grained	O
classification	O
of	O
a	O
protein	O
domain	O
family	O
.	O

Proposed	O
rule	O
for	O
specific	O
domain	O
assignment	O
We	O
propose	O
to	O
label	O
a	O
single	O
domain	O
as	O
correct	O
or	O
specific	O
for	O
a	O
protein	O
sequence	O
region	O
if	O
its	O
alignment	O
score	O
is	O
highest	O
among	O
all	O
domains	O
that	O
align	O
to	O
overlapping	O
regions	O
of	O
the	O
protein	O
sequence	O
and	O
the	O
score	O
exceeds	O
a	O
pre	O
-	O
calculated	O
threshold	O
for	O
the	O
domain	O
,	O
defined	O
as	O
the	O
minimum	O
alignment	O
score	O
among	O
confirmed	O
members	O
of	O
the	O
domain	O
.	O

Sequence	O
intervals	O
that	O
are	O
difficult	O
to	O
group	O
with	O
a	O
specific	O
subclass	O
with	O
high	O
confidence	O
following	O
this	O
rule	O
may	O
receive	O
only	O
generic	O
domain	O
assignments	O
.	O

Assuming	O
that	O
the	O
set	O
of	O
overlapping	O
domains	O
represents	O
an	O
ancient	O
domain	O
superfamily	O
,	O
such	O
a	O
generic	O
assignment	O
would	O
be	O
characterized	O
as	O
membership	O
with	O
the	O
respective	O
superfamily	O
.	O

Reducing	O
misclassifications	O
and	O
errors	O
due	O
to	O
missing	O
subfamilies	O
A	O
more	O
concrete	O
picture	O
of	O
the	O
effect	O
of	O
the	O
proposed	O
rule	O
may	O
be	O
gleaned	O
by	O
quantifying	O
misclassifications	O
,	O
defined	O
to	O
be	O
either	O
descendants	O
of	O
the	O
correct	O
domain	O
or	O
domains	O
that	O
lie	O
in	O
other	O
branches	O
of	O
the	O
correct	O
hierarchy	O
.	O

Averaged	O
over	O
domains	O
in	O
multi	O
-	O
domain	O
hierarchies	O
and	O
counting	O
only	O
sequences	O
with	O
self	O
hits	O
,	O
the	O
misclassification	O
rate	O
using	O
high	O
scores	O
only	O
is	O
2.6	O
%	O
.	O

Incorporating	O
score	O
thresholds	O
to	O
eliminate	O
low	O
-	O
scoring	O
best	O
hits	O
reduces	O
the	O
misclassification	O
rate	O
to	O
0.85	O
%	O
.	O

Misclassifications	O
may	O
also	O
be	O
used	O
to	O
estimate	O
error	O
due	O
to	O
missing	O
subfamilies	O
.	O

Not	O
all	O
subclasses	O
in	O
a	O
domain	O
hierarchy	O
may	O
have	O
been	O
identified	O
as	O
the	O
available	O
sequence	O
databases	O
only	O
provide	O
a	O
terse	O
snapshot	O
of	O
protein	O
domain	O
diversity	O
.	O

We	O
simulate	O
a	O
cross	O
-	O
validation	O
experiment	O
to	O
ask	O
,	O
if	O
an	O
existing	O
domain	O
model	O
were	O
missing	O
from	O
a	O
hierarchy	O
,	O
what	O
fraction	O
of	O
its	O
sequence	O
intervals	O
have	O
best	O
hits	O
to	O
other	O
models	O
in	O
the	O
hierarchy	O
that	O
are	O
not	O
ancestors	O
of	O
the	O
correct	O
model	O
?	O

Averaged	O
over	O
leaf	O
domains	O
,	O
50.9	O
%	O
of	O
domain	O
assignments	O
made	O
from	O
high	O
alignment	O
score	O
alone	O
are	O
misclassifications	O
,	O
compared	O
to	O
6.0	O
%	O
of	O
domain	O
assignments	O
after	O
thresholds	O
are	O
used	O
to	O
screen	O
hits	O
.	O

Function	O
and	O
classification	O
through	O
specific	O
domain	O
assignments	O
:	O
Glycyl	O
radical	O
enzymes	O
To	O
illustrate	O
the	O
effect	O
of	O
our	O
proposed	O
method	O
,	O
we	O
examine	O
domain	O
assignments	O
from	O
the	O
glycyl	O
radical	O
enzymes	O
(	O
RNR_PFL	O
hierarchy	O
)	O
.	O

Its	O
subgroups	O
have	O
distinct	O
and	O
important	O
functions	O
,	O
including	O
ribonucleotide	O
reductases	O
(	O
RNRs	O
)	O
,	O
which	O
synthesize	O
deoxyribonucleotides	O
,	O
and	O
pyruvate	O
-	O
formate	O
lysases	O
(	O
PFLs	O
)	O
,	O
a	O
family	O
of	O
catabolic	O
enzymes	O
.	O

The	O
proposed	O
method	O
places	O
the	O
sequence	O
[	O
Entrez	O
:	O
CAA42118	O
]	O
into	O
RNR	O
class	O
1	O
and	O
places	O
[	O
Entrez	O
:	O
AAZ61477	O
]	O
into	O
RNR	O
class-1-like	O
domain	O
.	O

The	O
functions	O
of	O
these	O
proteins	O
are	O
inferred	O
by	O
their	O
subclass	O
.	O

Other	O
proteins	O
receive	O
generic	O
assignments	O
to	O
this	O
family	O
.	O

For	O
example	O
,	O
PFL2	O
(	O
cd01677	O
)	O
is	O
the	O
best	O
match	O
to	O
[	O
Entrez	O
:	O
ABX41552	O
]	O
and	O
[	O
Entrez	O
:	O
EDQ26237	O
]	O
with	O
alignment	O
scores	O
that	O
fall	O
short	O
of	O
the	O
PFL2	O
threshold	O
.	O

The	O
first	O
alignment	O
includes	O
a	O
long	O
insertion	O
(	O
gap	O
)	O
,	O
and	O
the	O
latter	O
exhibits	O
weak	O
sequence	O
similarity	O
;	O
in	O
both	O
of	O
these	O
scenarios	O
the	O
transfer	O
of	O
functional	O
annotation	O
may	O
not	O
be	O
straightforward	O
.	O

Domain	O
assignments	O
also	O
help	O
to	O
make	O
biological	O
insights	O
.	O

RNRs	O
fall	O
into	O
classes	O
that	O
use	O
different	O
mechanisms	O
and/or	O
cofactors	O
.	O

Class	O
1	O
is	O
oxygen	O
dependent	O
and	O
class	O
3	O
is	O
used	O
by	O
strictly	O
or	O
facultative	O
anaerobic	O
organisms	O
.	O

RNR_1_like	O
has	O
a	O
similar	O
active	O
site	O
to	O
class	O
1	O
and	O
at	O
the	O
time	O
of	O
curation	O
,	O
no	O
specific	O
literature	O
was	O
available	O
about	O
this	O
subclass	O
.	O

We	O
observed	O
that	O
the	O
strictly	O
anaerobic	O
organism	O
Chlorobium	B
limicola	I
DSM	O
24	O
has	O
RNR_3	O
proteins	O
(	O
e.g.	O
[	O
Entrez	O
:	O
ZP_00512827	O
]	O
)	O
as	O
well	O
as	O
an	O
enzyme	O
(	O
[	O
Entrez	O
:	O
ZP_00512727	O
]	O
)	O
that	O
matches	O
RNR_1_like	O
,	O
suggesting	O
that	O
RNR_1_like	O
,	O
a	O
subfamily	O
lacking	O
experimental	O
characterization	O
,	O
may	O
contain	O
non	O
-	O
oxygen	O
dependent	O
versions	O
of	O
RNR_1	O
.	O

Discussion	O
While	O
many	O
sequences	O
can	O
be	O
classified	O
by	O
sequence	O
similarity	O
,	O
profiles	O
of	O
protein	O
domain	O
families	O
make	O
it	O
possible	O
to	O
quickly	O
classify	O
more	O
distant	O
homologs	O
[	O
23	O
]	O
and	O
can	O
better	O
handle	O
multi	O
-	O
domain	O
proteins	O
.	O

An	O
important	O
step	O
in	O
transferring	O
annotations	O
from	O
known	O
protein	O
families	O
is	O
identifying	O
the	O
subclass	O
that	O
provides	O
the	O
best	O
characterization	O
for	O
the	O
protein	O
.	O

Here	O
,	O
we	O
conducted	O
the	O
first	O
focused	O
analysis	O
of	O
domain	O
assignments	O
from	O
CDD	O
in	O
order	O
to	O
assess	O
existing	O
methods	O
for	O
domain	O
and	O
domain	O
subfamily	O
assignment	O
and	O
identify	O
ways	O
to	O
improve	O
the	O
quality	O
of	O
assignments	O
.	O

We	O
find	O
that	O
best	O
-	O
scoring	O
hits	O
are	O
sometimes	O
too	O
specific	O
,	O
causing	O
a	O
sequence	O
to	O
be	O
mislabelled	O
by	O
a	O
subfamily	O
of	O
the	O
correct	O
domain	O
.	O

We	O
propose	O
a	O
subclass	O
assignment	O
procedure	O
that	O
enables	O
concrete	O
assignments	O
,	O
computed	O
quickly	O
using	O
existing	O
data	O
,	O
and	O
demonstrate	O
that	O
this	O
procedure	O
largely	O
avoids	O
over	O
-	O
predictions	O
or	O
false	O
positive	O
assignments	O
and	O
is	O
robust	O
enough	O
to	O
deal	O
with	O
situations	O
such	O
as	O
incomplete	O
hierarchies	O
in	O
which	O
not	O
all	O
subfamilies	O
have	O
been	O
identified	O
.	O

We	O
elected	O
to	O
not	O
employ	O
standard	O
jack	O
-	O
knife	O
or	O
cross	O
-	O
validation	O
testing	O
for	O
a	O
sequence	O
against	O
its	O
correct	O
domain	O
,	O
as	O
the	O
task	O
is	O
to	O
classify	O
sequence	O
fragments	O
that	O
are	O
very	O
similar	O
to	O
a	O
subfamily	O
,	O
where	O
the	O
subfamily	O
model	O
is	O
also	O
constructed	O
from	O
very	O
similar	O
sequences	O
.	O

Although	O
the	O
sequence	O
and	O
domain	O
databases	O
evolve	O
rapidly	O
,	O
we	O
expect	O
our	O
findings	O
to	O
provide	O
an	O
accurate	O
snapshot	O
for	O
some	O
time	O
.	O

A	O
version	O
of	O
our	O
proposed	O
method	O
has	O
been	O
incorporated	O
into	O
the	O
current	O
version	O
of	O
the	O
CD	O
-	O
Search	O
program	O
and	O
the	O
pre	O
-	O
calculated	O
annotation	O
of	O
proteins	O
with	O
domains	O
in	O
NCBI	O
's	O
Entrez	O
system	O
.	O

Domain	O
assignments	O
to	O
specific	O
orthologous	O
subfamilies	O
or	O
ancient	O
subfamilies	O
are	O
distinguished	O
from	O
non	O
-	O
specific	O
assignments	O
to	O
a	O
domain	O
superfamily	O
.	O

High	O
-	O
confidence	O
annotation	O
of	O
functional	O
sites	O
is	O
also	O
provided	O
following	O
these	O
results	O
.	O

We	O
hope	O
the	O
improved	O
ability	O
to	O
quickly	O
and	O
accurately	O
classify	O
proteins	O
will	O
be	O
a	O
valuable	O
step	O
toward	O
simplifying	O
protein	O
sequence	O
analysis	O
and	O
the	O
computational	O
annotation	O
of	O
genomes	O
.	O

Competing	O
interests	O
The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O
JF	O
carried	O
out	O
the	O
experiments	O
and	O
drafted	O
the	O
manuscript	O
.	O

AMB	O
conceived	O
the	O
study	O
,	O
participated	O
in	O
its	O
design	O
,	O
and	O
helped	O
to	O
draft	O
the	O
manuscript	O
.	O

Supplementary	O
Material	O

Tissue	O
remodeling	O
:	O
a	O
mating	O
-	O
induced	O
differentiation	O
program	O
for	O
the	O
Drosophila	B
oviduct	O
Abstract	O
Background	O
In	O
both	O
vertebrates	O
and	O
invertebrates	O
,	O
the	O
oviduct	O
is	O
an	O
epithelial	O
tube	O
surrounded	O
by	O
visceral	O
muscles	O
that	O
serves	O
as	O
a	O
conduit	O
for	O
gamete	O
transport	O
between	O
the	O
ovary	O
and	O
uterus	O
.	O

While	O
Drosophila	O
is	O
a	O
model	O
system	O
for	O
tubular	O
organ	O
development	O
,	O
few	O
studies	O
have	O
addressed	O
the	O
development	O
of	O
the	O
fly	B
's	O
oviduct	O
.	O

Recent	O
studies	O
in	O
Drosophila	O
have	O
identified	O
mating	O
-	O
responsive	O
genes	O
and	O
proteins	O
whose	O
levels	O
in	O
the	O
oviduct	O
are	O
altered	O
by	O
mating	O
.	O

Since	O
many	O
of	O
these	O
molecules	O
(	O
e.g.	O
Muscle	O
LIM	O
protein	O
84B	O
,	O
Coracle	O
,	O
Neuroglian	O
)	O
have	O
known	O
roles	O
in	O
the	O
differentiation	O
of	O
muscle	O
and	O
epithelia	O
of	O
other	O
organs	O
,	O
mating	O
may	O
trigger	O
similar	O
differentiation	O
events	O
in	O
the	O
oviduct	O
.	O

This	O
led	O
us	O
to	O
hypothesize	O
that	O
mating	O
mediates	O
the	O
last	O
stages	O
of	O
oviduct	O
differentiation	O
in	O
which	O
organ	O
-	O
specific	O
specializations	O
arise	O
.	O

Results	O
Using	O
electron-	O
and	O
confocal	O
-	O
microscopy	O
we	O
identified	O
tissue	O
-	O
wide	O
post	O
-	O
mating	O
changes	O
in	O
the	O
oviduct	O
including	O
differentiation	O
of	O
cellular	O
junctions	O
,	O
remodeling	O
of	O
extracellular	O
matrix	O
,	O
increased	O
myofibril	O
formation	O
,	O
and	O
increased	O
innervation	O
.	O

Analysis	O
of	O
once-	O
and	O
twice	O
-	O
mated	O
females	O
reveals	O
that	O
some	O
mating	O
-	O
responsive	O
proteins	O
respond	O
only	O
to	O
the	O
first	O
mating	O
,	O
while	O
others	O
respond	O
to	O
both	O
matings	O
.	O

Conclusion	O
We	O
uncovered	O
ultrastructural	O
changes	O
in	O
the	O
mated	O
oviduct	O
that	O
are	O
consistent	O
with	O
the	O
roles	O
that	O
mating	O
-	O
responsive	O
proteins	O
play	O
in	O
muscle	O
and	O
epithelial	O
differentiation	O
elsewhere	O
.	O

This	O
suggests	O
that	O
mating	O
triggers	O
the	O
late	O
differentiation	O
of	O
the	O
oviduct	O
.	O

Furthermore	O
,	O
we	O
suggest	O
that	O
mating	O
-	O
responsive	O
proteins	O
that	O
respond	O
only	O
to	O
the	O
first	O
mating	O
are	O
involved	O
in	O
the	O
final	O
maturation	O
of	O
the	O
oviduct	O
while	O
proteins	O
that	O
remain	O
responsive	O
to	O
later	O
matings	O
are	O
also	O
involved	O
in	O
maintenance	O
and	O
ongoing	O
function	O
of	O
the	O
oviduct	O
.	O

Taken	O
together	O
,	O
our	O
results	O
establish	O
the	O
oviduct	O
as	O
an	O
attractive	O
system	O
to	O
address	O
mechanisms	O
that	O
regulate	O
the	O
late	O
stages	O
of	O
differentiation	O
and	O
maintenance	O
of	O
a	O
tubular	O
organ	O
.	O

Background	O
Most	O
internal	O
organs	O
,	O
including	O
the	O
vascular	O
and	O
respiratory	O
systems	O
and	O
the	O
gastro	O
-	O
intestinal	O
and	O
urinary	O
-	O
genital	O
tracts	O
are	O
comprised	O
of	O
a	O
single	O
epithelial	O
tube	O
or	O
a	O
network	O
of	O
tubes	O
.	O

Tubular	O
organs	O
serve	O
as	O
conduits	O
for	O
the	O
transport	O
of	O
gases	O
,	O
liquids	O
,	O
or	O
solutes	O
,	O
and	O
serve	O
as	O
barriers	O
between	O
biological	O
compartments	O
.	O

To	O
create	O
tubes	O
with	O
specific	O
flow	O
and	O
barrier	O
properties	O
,	O
the	O
morphology	O
of	O
the	O
tube	O
must	O
be	O
precisely	O
specified	O
during	O
development	O
and	O
modulated	O
by	O
physiology	O
.	O

To	O
accommodate	O
specific	O
physiological	O
roles	O
,	O
tissue	O
-	O
specific	O
programs	O
for	O
differentiation	O
are	O
employed	O
at	O
the	O
last	O
stages	O
of	O
development	O
.	O

While	O
much	O
is	O
known	O
about	O
the	O
molecular	O
and	O
cellular	O
basis	O
of	O
tube	O
formation	O
[	O
1	O
-	O
6	O
]	O
,	O
little	O
is	O
known	O
about	O
the	O
mechanisms	O
that	O
regulate	O
the	O
late	O
stages	O
of	O
differentiation	O
in	O
which	O
organ	O
-	O
specific	O
specializations	O
arise	O
.	O

The	O
conservation	O
of	O
genes	O
and	O
similarity	O
in	O
tubular	O
organ	O
design	O
across	O
taxa	O
make	O
Drosophila	O
an	O
excellent	O
model	O
for	O
understanding	O
organogenesis	O
in	O
higher	O
animals	O
.	O

In	O
Drosophila	O
,	O
the	O
best	O
understood	O
tubular	O
organs	O
from	O
a	O
developmental	O
point	O
of	O
view	O
are	O
the	O
trachea	O
and	O
salivary	O
gland	O
.	O

Studies	O
of	O
these	O
organs	O
reveal	O
a	O
general	O
program	O
for	O
tubular	O
organ	O
development	O
,	O
in	O
which	O
combinatorial	O
expression	O
of	O
global	O
patterning	O
genes	O
specifies	O
positions	O
within	O
the	O
embryo	O
for	O
the	O
subsequent	O
activation	O
of	O
tissue	O
-	O
specific	O
early	O
genes	O
and	O
transcription	O
factors	O
.	O

This	O
program	O
results	O
in	O
the	O
activation	O
of	O
downstream	O
genes	O
involved	O
in	O
terminal	O
differentiation	O
of	O
organ	O
-	O
specific	O
specializations	O
such	O
as	O
the	O
cuticle	O
that	O
lines	O
the	O
tracheal	O
lumen	O
[	O
1,2,4,7	O
-	O
9	O
]	O
.	O

The	O
Drosophila	B
female	O
reproductive	O
tract	O
is	O
another	O
tubular	O
system	O
,	O
consisting	O
of	O
the	O
uterus	O
and	O
a	O
common	O
oviduct	O
(	O
the	O
main	O
tube	O
)	O
that	O
branches	O
into	O
two	O
lateral	O
oviducts	O
.	O

Regional	O
differences	O
in	O
function	O
are	O
observed	O
along	O
the	O
length	O
of	O
the	O
tract	O
,	O
with	O
egg	O
activation	O
occurring	O
largely	O
at	O
the	O
proximal	O
end	O
,	O
in	O
the	O
lateral	O
oviducts	O
,	O
and	O
fertilization	O
occurring	O
at	O
the	O
distal	O
end	O
,	O
in	O
the	O
uterus	O
[	O
10,11	O
]	O
.	O

Unlike	O
other	O
tubular	O
organs	O
,	O
little	O
is	O
known	O
about	O
the	O
development	O
of	O
the	O
female	O
reproductive	O
tract	O
.	O

However	O
,	O
regional	O
differences	O
in	O
function	O
suggest	O
the	O
presence	O
of	O
region	O
-	O
specific	O
differentiation	O
programs	O
within	O
the	O
female	O
reproductive	O
tract	O
.	O

In	O
Drosophila	O
,	O
mating	O
induces	O
changes	O
in	O
female	O
behavior	O
and	O
physiology	O
via	O
molecules	O
transmitted	O
in	O
the	O
seminal	O
fluid	O
.	O

These	O
changes	O
are	O
rapid	O
and	O
lead	O
to	O
a	O
mated	O
female	O
state	O
which	O
is	O
profoundly	O
different	O
from	O
the	O
unmated	O
female	O
state	O
.	O

While	O
an	O
unmated	O
female	O
lays	O
few	O
eggs	O
and	O
readily	O
accepts	O
the	O
courtship	O
efforts	O
of	O
a	O
male	O
,	O
a	O
mated	O
female	O
exhibits	O
increased	O
egg	O
-	O
laying	O
and	O
actively	O
rejects	O
males	O
[	O
12	O
-	O
19	O
]	O
.	O

Microarray	O
studies	O
of	O
whole	O
flies	B
reveal	O
that	O
the	O
changes	O
in	O
egg	O
-	O
laying	O
rate	O
are	O
accompanied	O
by	O
a	O
change	O
in	O
gene	O
expression	O
.	O

Within	O
three	O
hours	O
of	O
mating	O
there	O
is	O
an	O
increase	O
in	O
expression	O
of	O
a	O
small	O
number	O
of	O
genes	O
[	O
20,21	O
]	O
.	O

Rapid	O
changes	O
in	O
gene	O
expression	O
,	O
as	O
well	O
as	O
protein	O
abundance	O
,	O
have	O
also	O
been	O
observed	O
in	O
the	O
female	O
reproductive	O
tract	O
[	O
22,23	O
]	O
.	O

In	O
the	O
upper	O
reproductive	O
tract	O
(	O
lateral	O
and	O
common	O
oviducts	O
,	O
hereafter	O
,	O
oviduct	O
)	O
,	O
mating	O
induces	O
an	O
increase	O
in	O
immune	O
related	O
transcripts	O
and	O
down	O
regulates	O
transcription	O
factors	O
involved	O
in	O
cell	O
growth	O
and	O
differentiation	O
.	O

At	O
the	O
protein	O
level	O
mating	O
induces	O
increased	O
abundance	O
of	O
proteins	O
associated	O
with	O
muscle	O
assembly	O
and	O
function	O
and	O
cytoskeletal	O
proteins	O
associated	O
with	O
epithelial	O
morphogenesis	O
[	O
23	O
]	O
.	O

Since	O
many	O
of	O
these	O
mating	O
-	O
responsive	O
proteins	O
act	O
in	O
late	O
differentiation	O
pathways	O
of	O
muscle	O
and	O
epithelia	O
elsewhere	O
(	O
e.g.	O
Bent	O
,	O
Muscle	O
LIM	O
protein	O
84B	O
(	O
Mlp84B	O
)	O
,	O
Neuroglian	O
(	O
Nrg	O
)	O
,	O
Coracle	O
(	O
Cora	O
)	O
)	O
,	O
we	O
hypothesize	O
that	O
mating	O
triggers	O
similar	O
differentiation	O
in	O
the	O
oviduct	O
.	O

To	O
test	O
our	O
hypothesis	O
we	O
characterized	O
the	O
ultrastructure	O
of	O
oviduct	O
epithelia	O
and	O
muscle	O
,	O
as	O
well	O
as	O
the	O
pattern	O
of	O
innervation	O
before	O
and	O
after	O
mating	O
.	O

We	O
then	O
examined	O
the	O
effect	O
of	O
different	O
mating	O
regimes	O
on	O
oviduct	O
mating	O
-	O
responsive	O
cytoskeletal	O
proteins	O
and	O
on	O
female	O
reproductive	O
output	O
.	O

Our	O
results	O
suggest	O
that	O
active	O
tissue	O
remodeling	O
takes	O
place	O
in	O
the	O
oviduct	O
epithelia	O
and	O
musculature	O
in	O
response	O
to	O
mating	O
.	O

Furthermore	O
,	O
we	O
found	O
a	O
striking	O
increase	O
in	O
innervation	O
of	O
the	O
oviduct	O
after	O
mating	O
.	O

Our	O
results	O
show	O
that	O
the	O
reproductive	O
tract	O
is	O
an	O
attractive	O
system	O
to	O
address	O
mechanisms	O
that	O
regulate	O
the	O
late	O
stages	O
of	O
tissue	O
differentiation	O
in	O
a	O
tubular	O
organ	O
.	O

Unlike	O
other	O
tubular	O
organs	O
,	O
the	O
last	O
differentiation	O
stage	O
of	O
the	O
oviduct	O
is	O
triggered	O
by	O
an	O
extrinsic	O
cue	O
(	O
mating	O
)	O
.	O

This	O
makes	O
it	O
possible	O
to	O
experimentally	O
control	O
the	O
onset	O
of	O
differentiation	O
,	O
with	O
an	O
opportunity	O
to	O
independently	O
examine	O
the	O
effects	O
of	O
mating	O
and	O
age	O
.	O

In	O
addition	O
,	O
it	O
allows	O
us	O
to	O
examine	O
processes	O
essential	O
for	O
reproduction	O
.	O

Results	O
Mating	O
induces	O
changes	O
in	O
oviduct	O
lumen	O
Our	O
previous	O
molecular	O
profiling	O
showed	O
that	O
mating	O
promotes	O
changes	O
in	O
actin	O
-	O
based	O
cytoskeletal	O
molecules	O
and	O
suggests	O
that	O
mating	O
triggers	O
molecular	O
changes	O
and	O
tissue	O
remodeling	O
in	O
the	O
female	O
reproductive	O
tract	O
that	O
mediate	O
its	O
progression	O
to	O
a	O
mature	O
functional	O
stage	O
[	O
23	O
]	O
.	O

To	O
gain	O
insight	O
into	O
the	O
mechanisms	O
that	O
underlie	O
this	O
progression	O
,	O
we	O
used	O
light	O
and	O
electron	O
microscopy	O
to	O
determine	O
the	O
morphological	O
status	O
of	O
the	O
oviduct	O
in	O
unmated	O
and	O
mated	O
3-day	O
old	O
females	O
.	O

In	O
nearly	O
all	O
mated	O
reproductive	O
tracts	O
processed	O
for	O
microscopy	O
(	O
8	O
/	O
9	O
)	O
,	O
an	O
egg	O
was	O
located	O
in	O
one	O
of	O
the	O
lateral	O
oviducts	O
,	O
whereas	O
an	O
egg	O
was	O
never	O
observed	O
in	O
the	O
oviduct	O
of	O
unmated	O
reproductive	O
tracts	O
(	O
5	O
/	O
5	O
)	O
(	O
Figure	O
1	O
)	O
.	O

This	O
observation	O
is	O
consistent	O
with	O
previous	O
studies	O
that	O
report	O
increased	O
ovulation	O
and	O
egg	O
-	O
laying	O
at	O
6	O
h	O
post	O
-	O
mating	O
[	O
24	O
]	O
.	O

In	O
all	O
unmated	O
reproductive	O
tracts	O
examined	O
,	O
the	O
region	O
between	O
the	O
lateral	O
oviducts	O
and	O
the	O
middle	O
of	O
the	O
common	O
oviduct	O
was	O
either	O
tapered	O
or	O
constricted	O
,	O
whereas	O
this	O
region	O
appeared	O
relaxed	O
in	O
the	O
mated	O
reproductive	O
tract	O
(	O
Figure	O
1A	O
and	O
1D	O
)	O
.	O

These	O
observations	O
raise	O
the	O
possibility	O
that	O
the	O
lumen	O
is	O
narrow	O
in	O
the	O
unmated	O
oviduct	O
and	O
larger	O
in	O
the	O
mated	O
oviduct	O
.	O

To	O
address	O
this	O
possibility	O
,	O
we	O
collected	O
serial	O
1	O
μm	O
longitudinal	O
sections	O
through	O
the	O
reproductive	O
tracts	O
of	O
unmated	O
and	O
mated	O
females	O
and	O
stained	O
these	O
sections	O
with	O
toluidine	O
blue	O
to	O
survey	O
the	O
appearance	O
of	O
the	O
lumen	O
along	O
the	O
entire	O
length	O
of	O
the	O
oviduct	O
(	O
Figure	O
1B	O
and	O
1E	O
)	O
.	O

Our	O
examination	O
reveals	O
that	O
,	O
in	O
unmated	O
reproductive	O
tracts	O
,	O
the	O
lateral	O
oviduct	O
lumen	O
has	O
an	O
irregular	O
shape	O
,	O
while	O
the	O
common	O
oviduct	O
lumen	O
appears	O
straight	O
.	O

Moreover	O
,	O
in	O
all	O
the	O
unmated	O
reproductive	O
tracts	O
sectioned	O
,	O
we	O
detected	O
patches	O
of	O
darkly	O
stained	O
material	O
in	O
the	O
lumen	O
of	O
the	O
lower	O
common	O
oviduct	O
.	O

In	O
the	O
mated	O
reproductive	O
tract	O
,	O
the	O
lumen	O
of	O
the	O
upper	O
oviduct	O
(	O
defined	O
as	O
the	O
lateral	O
oviduct	O
and	O
upper	O
part	O
of	O
the	O
common	O
oviduct	O
)	O
has	O
an	O
irregular	O
shape	O
,	O
and	O
the	O
lumen	O
of	O
the	O
lower	O
oviduct	O
(	O
defined	O
as	O
the	O
lower	O
part	O
of	O
common	O
oviduct	O
)	O
appears	O
straight	O
.	O

In	O
addition	O
,	O
the	O
lumen	O
of	O
the	O
lower	O
oviduct	O
appears	O
wider	O
in	O
mated	O
than	O
unmated	O
reproductive	O
tracts	O
(	O
Figure	O
1C	O
and	O
1F	O
)	O
.	O

Interestingly	O
,	O
darkly	O
stained	O
material	O
was	O
not	O
detected	O
in	O
the	O
oviduct	O
lumen	O
of	O
mated	O
females	O
.	O

This	O
observation	O
appears	O
to	O
be	O
consistent	O
with	O
the	O
description	O
made	O
by	O
Mahowald	O
et	O
al.	O
[	O
25	O
]	O
,	O
who	O
reported	O
that	O
the	O
oviduct	O
lumen	O
of	O
unmated	O
females	O
is	O
nearly	O
filled	O
with	O
an	O
intima	O
-	O
like	O
matrix	O
and	O
that	O
this	O
matrix	O
is	O
reduced	O
after	O
mating	O
.	O

Because	O
3-day	O
-	O
old	O
mated	O
females	O
lay	O
eggs	O
,	O
it	O
is	O
unclear	O
whether	O
the	O
lack	O
of	O
lumenal	O
material	O
and	O
increase	O
in	O
lumen	O
size	O
in	O
mated	O
females	O
occurred	O
before	O
or	O
after	O
the	O
passage	O
of	O
eggs	O
.	O

We	O
suggest	O
that	O
mating	O
directly	O
or	O
indirectly	O
induces	O
morphological	O
changes	O
in	O
the	O
oviduct	O
that	O
facilitate	O
egg	O
passage	O
through	O
the	O
duct	O
.	O

Taken	O
together	O
,	O
our	O
observations	O
lead	O
us	O
to	O
propose	O
that	O
the	O
oviduct	O
lumen	O
is	O
closed	O
and/or	O
obstructed	O
in	O
the	O
unmated	O
reproductive	O
tract	O
,	O
and	O
that	O
mating	O
induces	O
changes	O
in	O
the	O
epithelia	O
and/or	O
muscle	O
that	O
""""	O
open	O
""""	O
the	O
oviduct	O
lumen	O
.	O

Initial	O
formation	O
of	O
cell	O
-	O
cell	O
junctions	O
in	O
oviduct	O
epithelia	O
is	O
mating	O
-	O
independent	O
To	O
determine	O
whether	O
mating	O
induces	O
specific	O
morphological	O
changes	O
in	O
the	O
oviduct	O
epithelia	O
post	O
-	O
mating	O
,	O
we	O
next	O
examined	O
the	O
ultrastructure	O
of	O
the	O
oviduct	O
epithelia	O
in	O
unmated	O
and	O
mated	O
reproductive	O
tracts	O
.	O

Since	O
molecular	O
profiling	O
demonstrates	O
that	O
proteins	O
associated	O
with	O
cellular	O
junctions	O
such	O
as	O
α-	O
and	O
β	O
-	O
Spectrin	O
(	O
Spec	O
)	O
,	O
Cora	O
,	O
and	O
Nrg	O
[	O
23	O
]	O
increase	O
post	O
-	O
mating	O
,	O
we	O
first	O
determined	O
the	O
status	O
of	O
the	O
cellular	O
junctions	O
in	O
the	O
oviduct	O
epithelia	O
of	O
unmated	O
females	O
,	O
and	O
whether	O
these	O
junctions	O
change	O
post	O
-	O
mating	O
.	O

In	O
Drosophila	O
,	O
most	O
ectodermally	O
derived	O
epithelia	O
(	O
such	O
as	O
the	O
epidermis	O
and	O
trachea	O
)	O
,	O
with	O
a	O
few	O
exceptions	O
,	O
are	O
joined	O
apically	O
by	O
a	O
belt	O
-	O
like	O
adherens	O
junction	O
called	O
the	O
zonal	O
adherens	O
junction	O
(	O
ZA	O
)	O
followed	O
basally	O
by	O
a	O
septate	O
junction	O
(	O
SJ	O
)	O
[	O
26	O
]	O
.	O

Our	O
analysis	O
reveals	O
that	O
the	O
oviduct	O
is	O
lined	O
,	O
along	O
its	O
entire	O
length	O
,	O
by	O
a	O
monolayered	O
epithelium	O
comprised	O
of	O
squamous	O
-	O
type	O
cells	O
.	O

Although	O
region	O
-	O
specific	O
differences	O
in	O
morphology	O
were	O
observed	O
,	O
all	O
oviduct	O
epithelia	O
examined	O
,	O
in	O
both	O
unmated	O
and	O
mated	O
females	O
,	O
are	O
joined	O
along	O
their	O
lateral	O
membranes	O
by	O
an	O
extensive	O
SJ	O
and	O
lack	O
an	O
apical	O
ZA	O
(	O
Figure	O
2	O
)	O
.	O

SJs	O
and	O
ZAs	O
form	O
complete	O
belts	O
that	O
surround	O
the	O
epithelial	O
cell	O
,	O
thus	O
making	O
these	O
junctions	O
easily	O
visible	O
in	O
transverse	O
sections	O
through	O
the	O
epithelium	O
.	O

Because	O
ZAs	O
were	O
not	O
detected	O
in	O
our	O
transverse	O
sections	O
through	O
the	O
oviduct	O
,	O
this	O
implies	O
that	O
ZAs	O
never	O
formed	O
,	O
or	O
developed	O
earlier	O
and	O
were	O
lost	O
(	O
Figure	O
2D	O
)	O
.	O

Interestingly	O
,	O
we	O
did	O
not	O
detect	O
any	O
ultrastructural	O
differences	O
in	O
the	O
SJs	O
at	O
6	O
h	O
post	O
-	O
mating	O
,	O
but	O
we	O
did	O
uncover	O
differences	O
in	O
SJ	O
ultrastructure	O
in	O
different	O
regions	O
of	O
the	O
oviduct	O
.	O

Based	O
on	O
their	O
ultrastructure	O
,	O
two	O
types	O
of	O
SJs	O
,	O
smooth	O
and	O
pleated	O
,	O
can	O
be	O
distinguished	O
in	O
Drosophila	O
[	O
26	O
]	O
.	O

Smooth	O
SJs	O
are	O
distinguished	O
by	O
the	O
lack	O
of	O
visible	O
septae	O
and	O
the	O
appearance	O
of	O
electron	O
dense	O
material	O
in	O
the	O
intercellular	O
space	O
,	O
while	O
pleated	O
SJs	O
are	O
distinguished	O
by	O
the	O
ladder	O
-	O
like	O
appearance	O
of	O
septae	O
.	O

In	O
the	O
lateral	O
oviducts	O
and	O
upper	O
common	O
oviduct	O
,	O
septa	O
were	O
not	O
detected	O
in	O
the	O
SJ	O
,	O
thus	O
these	O
SJs	O
represent	O
smooth	O
SJs	O
or	O
an	O
immature	O
stage	O
of	O
pleated	O
SJ	O
(	O
Figure	O
2A	O
,	O
2A	O
'	O
,	O
2A	O
""""	O
)	O
.	O

In	O
contrast	O
,	O
a	O
ladder	O
-	O
like	O
arrangement	O
of	O
septae	O
was	O
often	O
visible	O
in	O
the	O
SJs	O
of	O
the	O
lower	O
common	O
oviduct	O
(	O
Figure	O
2C	O
'	O
)	O
,	O
thus	O
these	O
SJs	O
can	O
be	O
classified	O
as	O
pleated	O
.	O

Unlike	O
the	O
smooth	O
-	O
like	O
SJs	O
of	O
the	O
upper	O
oviduct	O
,	O
the	O
pleated	O
SJs	O
of	O
the	O
lower	O
oviduct	O
are	O
followed	O
basally	O
by	O
spot	O
type	O
adherens	O
junction	O
(	O
spot	O
AJs	O
)	O
(	O
Figure	O
2B	O
,	O
2B	O
'	O
;	O
additional	O
file	O
1	O
)	O
.	O

Further	O
analysis	O
is	O
necessary	O
to	O
determine	O
if	O
the	O
SJs	O
of	O
the	O
upper	O
and	O
lower	O
oviduct	O
represent	O
different	O
types	O
or	O
different	O
developmental	O
stages	O
.	O

Our	O
findings	O
demonstrate	O
that	O
the	O
initial	O
formation	O
of	O
SJs	O
,	O
as	O
well	O
as	O
spot	O
AJs	O
in	O
the	O
lower	O
oviduct	O
,	O
are	O
mating	O
-	O
independent	O
.	O

This	O
raises	O
an	O
interesting	O
question	O
.	O

Why	O
are	O
SJ	O
proteins	O
such	O
as	O
Cora	O
and	O
Nrg	O
up	O
-	O
regulated	O
post	O
-	O
mating	O
if	O
SJs	O
are	O
formed	O
prior	O
to	O
mating	O
?	O

It	O
is	O
possible	O
that	O
the	O
increased	O
expression	O
of	O
SJ	O
proteins	O
is	O
associated	O
with	O
functional	O
changes	O
in	O
polarized	O
secretion	O
post	O
-	O
mating	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
SJs	O
play	O
an	O
unexpected	O
role	O
in	O
regulating	O
the	O
apical	O
secretion	O
of	O
specialized	O
extracellular	O
matrix	O
molecules	O
in	O
the	O
trachea	O
[	O
27,28	O
]	O
,	O
and	O
that	O
these	O
molecules	O
are	O
important	O
regulators	O
of	O
lumen	O
size	O
.	O

Mating	O
modulates	O
apical	O
secretory	O
activity	O
in	O
the	O
oviduct	O
Given	O
the	O
presence	O
of	O
extensive	O
SJs	O
in	O
the	O
oviduct	O
and	O
the	O
role	O
of	O
SJs	O
in	O
regulating	O
apical	O
secretion	O
of	O
extracellular	O
matrix	O
molecules	O
in	O
other	O
epithelia	O
(	O
e.g.	O
trachea	O
)	O
,	O
we	O
asked	O
if	O
mating	O
modulates	O
apical	O
secretion	O
in	O
the	O
oviduct	O
epithelia	O
.	O

Our	O
ultrastructural	O
analysis	O
reveals	O
that	O
different	O
regions	O
of	O
the	O
oviduct	O
display	O
different	O
apical	O
membrane	O
morphology	O
(	O
i.e	O
microvilli	O
or	O
pleats	O
)	O
(	O
see	O
Figures	O
2	O
and	O
additional	O
file	O
2A	O
and	O
2A	O
)	O
,	O
but	O
all	O
epithelia	O
are	O
covered	O
by	O
an	O
electron	O
dense	O
apical	O
extracellular	O
matrix	O
(	O
AECM	O
)	O
and	O
a	O
thin	O
layer	O
of	O
cuticle	O
.	O

We	O
found	O
that	O
mating	O
induces	O
ultrastructural	O
changes	O
in	O
the	O
AECM	O
and	O
cuticle	O
in	O
both	O
the	O
upper	O
and	O
lower	O
oviduct	O
.	O

In	O
the	O
upper	O
oviduct	O
of	O
the	O
unmated	O
female	O
,	O
the	O
AECM	O
varies	O
in	O
thickness	O
along	O
the	O
apical	O
surface	O
(	O
Figure	O
3A	O
)	O
.	O

Some	O
areas	O
have	O
little	O
AECM	O
,	O
while	O
other	O
areas	O
are	O
covered	O
by	O
a	O
distinct	O
layer	O
of	O
AECM	O
(	O
~1–2	O
μm	O
in	O
thickness	O
;	O
Figure	O
3B	O
)	O
.	O

However	O
,	O
the	O
AECM	O
of	O
mated	O
females	O
is	O
more	O
evenly	O
distributed	O
along	O
the	O
apical	O
surface	O
,	O
(	O
~2	O
μm	O
in	O
thickness	O
;	O
Figure	O
3E	O
)	O
.	O

Strikingly	O
,	O
the	O
AECM	O
and	O
cuticle	O
of	O
mated	O
females	O
have	O
a	O
ruffled	O
appearance	O
,	O
suggesting	O
that	O
the	O
AECM	O
and	O
cuticle	O
have	O
increased	O
in	O
surface	O
area	O
(	O
Figure	O
3F	O
)	O
.	O

Electron	O
dense	O
granules	O
up	O
to	O
~1.5	O
μm	O
in	O
diameter	O
were	O
occasionally	O
observed	O
in	O
both	O
the	O
AECM	O
and	O
cell	O
cytoplasm	O
(	O
Figure	O
3F	O
)	O
.	O

Although	O
further	O
analysis	O
is	O
needed	O
to	O
determine	O
the	O
role	O
of	O
these	O
granules	O
in	O
the	O
oviduct	O
epithelia	O
,	O
it	O
is	O
possible	O
that	O
these	O
granules	O
participate	O
in	O
the	O
secretion	O
and	O
deposition	O
of	O
the	O
AECM	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
suggest	O
that	O
polarized	O
secretion	O
via	O
the	O
AECM	O
,	O
while	O
ongoing	O
in	O
the	O
upper	O
oviduct	O
of	O
the	O
unmated	O
female	O
is	O
enhanced	O
and/or	O
modulated	O
post	O
-	O
mating	O
.	O

Post	O
-	O
mating	O
changes	O
in	O
AECM	O
ultrastructure	O
are	O
also	O
observed	O
in	O
the	O
lower	O
common	O
oviduct	O
.	O

However	O
,	O
unlike	O
the	O
AECM	O
of	O
the	O
upper	O
oviduct	O
,	O
the	O
AECM	O
of	O
the	O
lower	O
oviduct	O
is	O
well	O
developed	O
prior	O
to	O
mating	O
.	O

In	O
the	O
lower	O
oviduct	O
of	O
the	O
unmated	O
female	O
,	O
the	O
AECM	O
consists	O
of	O
an	O
amorphous	O
electron	O
dense	O
material	O
and	O
is	O
unevenly	O
distributed	O
,	O
forming	O
a	O
thick	O
,	O
bulbous	O
layer	O
above	O
the	O
plasma	O
membrane	O
in	O
some	O
regions	O
(	O
additional	O
file	O
2	O
)	O
.	O

Matrix	O
-	O
like	O
material	O
is	O
also	O
observed	O
in	O
the	O
lumen	O
,	O
but	O
this	O
material	O
is	O
more	O
electron	O
dense	O
than	O
the	O
AECM	O
(	O
additional	O
file	O
2A	O
and	O
2A	O
)	O
.	O

In	O
the	O
mated	O
female	O
,	O
the	O
AECM	O
is	O
flattened	O
against	O
the	O
plasma	O
membrane	O
and	O
is	O
uniformly	O
distributed	O
along	O
the	O
apical	O
surface	O
(	O
additional	O
file	O
2B	O
and	O
2B	O
)	O
.	O

Matrix	O
-	O
like	O
material	O
was	O
not	O
observed	O
in	O
the	O
center	O
of	O
the	O
lumen	O
,	O
but	O
small	O
pools	O
of	O
very	O
electron	O
dense	O
material	O
were	O
detected	O
in	O
the	O
spaces	O
between	O
the	O
epithelial	O
folds	O
(	O
additional	O
file	O
2C	O
and	O
2C	O
)	O
.	O

This	O
may	O
explain	O
why	O
lumenal	O
matrix	O
was	O
not	O
detected	O
at	O
the	O
light	O
microscopic	O
level	O
in	O
the	O
mated	O
female	O
oviduct	O
(	O
see	O
Figure	O
1E	O
and	O
1F	O
)	O
.	O

Taken	O
together	O
,	O
our	O
observations	O
suggest	O
that	O
the	O
lower	O
common	O
oviduct	O
is	O
a	O
site	O
of	O
active	O
apical	O
secretion	O
in	O
both	O
mated	O
and	O
unmated	O
females	O
,	O
and	O
that	O
matrix	O
secretion	O
,	O
particularly	O
in	O
the	O
lumen	O
,	O
is	O
reduced	O
post	O
-	O
mating	O
.	O

These	O
findings	O
raise	O
the	O
intriguing	O
possibility	O
that	O
the	O
AECM	O
and	O
lumenal	O
matrix	O
function	O
as	O
a	O
plug	O
in	O
the	O
lower	O
oviduct	O
,	O
and	O
that	O
mating	O
induces	O
the	O
breakdown	O
of	O
this	O
plug	O
.	O

Mating	O
induces	O
changes	O
in	O
hemi	O
-	O
adherens	O
junctions	O
in	O
upper	O
oviduct	O
In	O
addition	O
to	O
modulating	O
secretion	O
at	O
the	O
apical	O
membrane	O
,	O
mating	O
induces	O
changes	O
at	O
the	O
basolateral	O
membrane	O
.	O

In	O
many	O
epithelia	O
,	O
one	O
of	O
the	O
last	O
steps	O
of	O
differentiation	O
is	O
the	O
development	O
of	O
a	O
layer	O
of	O
extracellular	O
matrix	O
(	O
ECM	O
)	O
called	O
the	O
basal	O
lamina	O
that	O
covers	O
the	O
apical	O
and/or	O
basal	O
membranes	O
and	O
the	O
concomitant	O
development	O
of	O
hemi	O
-	O
adherens	O
junctions	O
(	O
HAJs	O
)	O
.	O

HAJs	O
connect	O
the	O
cell	O
cytoskeleton	O
with	O
the	O
ECM	O
and	O
are	O
formed	O
at	O
virtually	O
all	O
cell	O
surfaces	O
that	O
contact	O
an	O
ECM	O
.	O

HAJs	O
can	O
be	O
distinguished	O
at	O
the	O
ultrastructural	O
level	O
as	O
a	O
patch	O
-	O
like	O
,	O
electron	O
dense	O
undercoat	O
of	O
the	O
plasma	O
membrane	O
that	O
opposes	O
the	O
basal	O
lamina	O
(	O
[	O
26	O
]	O
;	O
Figure	O
3	O
G	O
,	O
3H	O
)	O
.	O

In	O
the	O
Drosophila	B
embryo	O
,	O
the	O
HAJs	O
and	O
basal	O
lamina	O
are	O
formed	O
at	O
the	O
same	O
time	O
[	O
26	O
]	O
.	O

Because	O
the	O
basal	O
lamina	O
is	O
established	O
at	O
a	O
time	O
when	O
the	O
majority	O
of	O
extracellular	O
matrix	O
molecules	O
are	O
actively	O
secreted	O
[	O
26,29	O
]	O
,	O
this	O
suggests	O
that	O
the	O
formation	O
of	O
HAJs	O
is	O
tightly	O
coordinated	O
with	O
the	O
secretion	O
of	O
the	O
ECM	O
.	O

One	O
of	O
the	O
most	O
striking	O
post	O
-	O
mating	O
changes	O
observed	O
in	O
the	O
oviduct	O
epithelia	O
was	O
the	O
appearance	O
of	O
numerous	O
HAJs	O
along	O
the	O
basolateral	O
membrane	O
in	O
the	O
upper	O
oviduct	O
(	O
Figure	O
3	O
)	O
.	O

The	O
importance	O
of	O
HAJs	O
,	O
particularly	O
in	O
the	O
upper	O
oviduct	O
,	O
is	O
underscored	O
by	O
the	O
extensive	O
infolding	O
of	O
the	O
basolateral	O
membrane	O
that	O
is	O
observed	O
in	O
both	O
unmated	O
and	O
mated	O
females	O
(	O
Figure	O
3A	O
and	O
3E	O
)	O
.	O

The	O
infolded	O
membrane	O
gives	O
rise	O
to	O
a	O
highly	O
branched	O
intercellular	O
space	O
that	O
is	O
filled	O
with	O
an	O
ECM	O
(	O
Figure	O
3C	O
and	O
3	O
G	O
)	O
.	O

This	O
ECM	O
is	O
contiguous	O
with	O
the	O
basal	O
lamina	O
that	O
surrounds	O
the	O
epithelia	O
.	O

Few	O
HAJs	O
were	O
observed	O
in	O
the	O
upper	O
oviduct	O
of	O
the	O
unmated	O
female	O
,	O
and	O
these	O
were	O
largely	O
restricted	O
to	O
the	O
basal	O
membrane	O
,	O
and	O
not	O
observed	O
along	O
the	O
basolateral	O
infolding	O
(	O
Figure	O
3C	O
)	O
.	O

In	O
contrast	O
,	O
numerous	O
HAJs	O
appear	O
along	O
the	O
basolateral	O
infolding	O
post	O
-	O
mating	O
in	O
this	O
region	O
of	O
the	O
oviduct	O
(	O
Figure	O
3F–3H	O
)	O
.	O

In	O
addition	O
,	O
the	O
intercellular	O
space	O
appears	O
wider	O
post	O
-	O
mating	O
(	O
Figure	O
3C–3D	O
and	O
3G–3H	O
)	O
,	O
suggesting	O
that	O
mating	O
induces	O
increased	O
secretion	O
and/or	O
deposition	O
of	O
the	O
ECM	O
in	O
this	O
cellular	O
compartment	O
and	O
brings	O
the	O
ECM	O
to	O
a	O
threshold	O
concentration	O
that	O
can	O
support	O
the	O
development	O
of	O
HAJs	O
.	O

HAJs	O
were	O
also	O
detected	O
along	O
the	O
basal	O
membrane	O
,	O
but	O
they	O
were	O
not	O
detected	O
along	O
the	O
apical	O
membrane	O
even	O
though	O
this	O
membrane	O
was	O
covered	O
by	O
an	O
ECM	O
.	O

Interestingly	O
,	O
while	O
the	O
basolateral	O
membrane	O
forms	O
very	O
shallow	O
folds	O
in	O
the	O
lower	O
oviduct	O
(	O
see	O
additional	O
file	O
2	O
)	O
,	O
HAJs	O
were	O
observed	O
along	O
this	O
membrane	O
in	O
unmated	O
reproductive	O
tracts	O
(	O
data	O
not	O
shown	O
)	O
,	O
thus	O
suggesting	O
that	O
the	O
epithelia	O
is	O
more	O
differentiated	O
in	O
this	O
region	O
of	O
the	O
oviduct	O
,	O
and	O
that	O
the	O
differentiation	O
of	O
the	O
upper	O
and	O
lower	O
oviduct	O
may	O
be	O
under	O
different	O
control	O
.	O

Muscle	O
differentiation	O
is	O
enhanced	O
post	O
-	O
mating	O
While	O
we	O
uncovered	O
post	O
-	O
mating	O
changes	O
in	O
the	O
oviduct	O
epithelia	O
that	O
might	O
facilitate	O
its	O
transition	O
to	O
a	O
high	O
egg	O
-	O
laying	O
state	O
,	O
this	O
transition	O
may	O
also	O
be	O
mediated	O
by	O
changes	O
in	O
oviduct	O
muscle	O
properties	O
and/or	O
activity	O
.	O

The	O
oviduct	O
is	O
lined	O
by	O
circular	O
muscle	O
fibers	O
with	O
supercontractile	O
characteristics	O
[	O
30	O
]	O
.	O

Our	O
previous	O
studies	O
showed	O
that	O
mef2	O
and	O
mlp84B	O
genes	O
that	O
regulate	O
muscle	O
differentiation	O
,	O
are	O
expressed	O
and	O
increased	O
post	O
-	O
mating	O
in	O
the	O
oviduct	O
,	O
as	O
well	O
as	O
in	O
the	O
sperm	O
storage	O
regions	O
of	O
the	O
reproductive	O
tract	O
[	O
22,23	O
]	O
.	O

This	O
suggests	O
that	O
mating	O
induces	O
muscle	O
differentiation	O
in	O
the	O
reproductive	O
tract	O
.	O

Muscle	O
differentiation	O
is	O
characterized	O
by	O
the	O
assembly	O
of	O
myofilaments	O
into	O
bundles	O
called	O
myofibrils	O
.	O

As	O
muscles	O
differentiate	O
,	O
myofibrils	O
and	O
z	O
-	O
bodies	O
appear	O
simultaneously	O
,	O
and	O
increase	O
in	O
number	O
until	O
the	O
cytoplasm	O
is	O
filled	O
with	O
myofibrils	O
[	O
31	O
]	O
.	O

Like	O
epithelia	O
,	O
one	O
of	O
the	O
last	O
steps	O
of	O
muscle	O
differentiation	O
is	O
the	O
secretion	O
of	O
a	O
basal	O
lamina	O
that	O
surrounds	O
the	O
muscle	O
fiber	O
.	O

To	O
determine	O
if	O
mating	O
induces	O
structural	O
changes	O
in	O
muscles	O
(	O
such	O
as	O
increased	O
myofibrils	O
)	O
we	O
examined	O
the	O
ultrastructure	O
of	O
muscle	O
fibers	O
in	O
the	O
upper	O
and	O
lower	O
parts	O
of	O
the	O
oviduct	O
.	O

Our	O
analysis	O
revealed	O
that	O
,	O
in	O
both	O
unmated	O
and	O
mated	O
reproductive	O
tracts	O
,	O
the	O
muscles	O
of	O
the	O
lower	O
oviduct	O
are	O
highly	O
differentiated	O
as	O
evidenced	O
by	O
the	O
high	O
density	O
of	O
myofibrils	O
,	O
well	O
developed	O
and	O
aligned	O
z	O
-	O
bodies	O
,	O
and	O
secretion	O
of	O
a	O
thick	O
,	O
electron	O
dense	O
basal	O
lamina	O
(	O
Figure	O
4E	O
and	O
4F	O
)	O
.	O

In	O
contrast	O
,	O
muscle	O
fibers	O
in	O
the	O
lateral	O
oviducts	O
and	O
upper	O
common	O
oviduct	O
appear	O
less	O
differentiated	O
than	O
muscles	O
in	O
the	O
lower	O
common	O
oviduct	O
,	O
as	O
evidenced	O
by	O
the	O
lesser	O
density	O
of	O
myofibrils	O
and	O
z	O
-	O
bodies	O
,	O
and	O
little	O
or	O
no	O
basal	O
lamina	O
(	O
Figure	O
4A	O
and	O
4B	O
)	O
.	O

Moreover	O
,	O
the	O
muscles	O
of	O
the	O
upper	O
oviduct	O
appear	O
more	O
differentiated	O
in	O
the	O
mated	O
than	O
in	O
unmated	O
reproductive	O
tracts	O
(	O
Figure	O
4A–4D	O
)	O
.	O

Interestingly	O
,	O
we	O
observed	O
neighboring	O
muscle	O
fibers	O
in	O
different	O
states	O
of	O
differentiation	O
in	O
the	O
lateral	O
oviducts	O
in	O
both	O
unmated	O
and	O
mated	O
reproductive	O
tracts	O
,	O
but	O
not	O
elsewhere	O
in	O
the	O
oviduct	O
(	O
Figure	O
4B	O
)	O
.	O

These	O
results	O
suggest	O
that	O
mating	O
enhances	O
the	O
rate	O
of	O
muscle	O
differentiation	O
in	O
the	O
upper	O
oviduct	O
,	O
and	O
that	O
muscle	O
differentiation	O
is	O
delayed	O
in	O
the	O
upper	O
as	O
compared	O
to	O
the	O
lower	O
oviduct	O
.	O

The	O
increased	O
muscle	O
differentiation	O
in	O
the	O
upper	O
oviduct	O
is	O
not	O
dramatic	O
and	O
likely	O
reflects	O
the	O
short	O
post	O
-	O
mating	O
period	O
examined	O
in	O
this	O
study	O
.	O

The	O
delayed	O
differentiation	O
of	O
the	O
upper	O
oviduct	O
muscles	O
resembles	O
the	O
delay	O
in	O
the	O
onset	O
of	O
development	O
between	O
the	O
adult	O
thoracic	O
muscles	O
and	O
abdominal	O
muscles	O
during	O
metamorphosis	O
[	O
32	O
]	O
.	O

Since	O
the	O
ovaries	O
and	O
the	O
other	O
parts	O
of	O
the	O
reproductive	O
tract	O
are	O
known	O
to	O
have	O
different	O
segmental	O
origins	O
[	O
33	O
]	O
,	O
we	O
hypothesize	O
that	O
different	O
parts	O
of	O
the	O
oviduct	O
develop	O
at	O
different	O
rates	O
or	O
begin	O
development	O
at	O
different	O
times	O
.	O

Increased	O
innervation	O
in	O
the	O
oviduct	O
post	O
-	O
mating	O
Nerve	O
-	O
muscle	O
interactions	O
play	O
an	O
important	O
role	O
in	O
regulating	O
adult	O
muscle	O
development	O
and	O
refining	O
the	O
final	O
pattern	O
of	O
innervation	O
[	O
34,35	O
]	O
.	O

Given	O
that	O
oviduct	O
muscle	O
differentiation	O
is	O
enhanced	O
post	O
-	O
mating	O
,	O
we	O
predicted	O
that	O
mating	O
either	O
directly	O
or	O
indirectly	O
induces	O
changes	O
in	O
innervation	O
.	O

To	O
address	O
this	O
prediction	O
,	O
we	O
quantified	O
the	O
number	O
of	O
nerve	O
terminals	O
or	O
boutons	O
innervating	O
the	O
lateral	O
oviducts	O
and	O
common	O
oviduct	O
in	O
unmated	O
and	O
mated	O
reproductive	O
tracts	O
.	O

Studies	O
of	O
oviduct	O
innervation	O
in	O
Drosophila	O
reveal	O
that	O
the	O
fly	B
's	O
oviduct	O
receives	O
aminergic	O
,	O
peptidergic	O
and	O
glutamatergic	O
input	O
[	O
30,36	O
-	O
39	O
]	O
.	O

In	O
both	O
larval	O
and	O
adult	O
Drosophila	O
,	O
different	O
types	O
of	O
boutons	O
are	O
formed	O
by	O
neurons	O
that	O
express	O
different	O
neurotransmitters	O
and	O
modulators	O
[	O
40	O
-	O
42	O
]	O
.	O

By	O
similarity	O
to	O
the	O
boutons	O
described	O
at	O
the	O
larval	O
and	O
adult	O
neuromuscular	O
junction	O
,	O
Middleton	O
et	O
al.	O
[	O
30	O
]	O
report	O
that	O
the	O
fly	B
's	O
oviduct	O
is	O
innervated	O
by	O
glutamatergic	O
type	O
I	O
boutons	O
and	O
tyraminergic	O
/	O
octopaminergic	O
type	O
II	O
boutons	O
.	O

Rodgriguez	O
-	O
Valentin	O
et	O
al.	O
[	O
43	O
]	O
further	O
report	O
that	O
the	O
oviduct	O
type	O
II	O
boutons	O
co	O
-	O
express	O
octopamine	O
and	O
glutamate	O
.	O

The	O
neurons	O
that	O
give	O
rise	O
to	O
the	O
type	O
I	O
innervation	O
have	O
not	O
been	O
identified	O
.	O

However	O
,	O
it	O
is	O
well	O
established	O
that	O
type	O
II	O
innervation	O
arises	O
from	O
octopaminergic	O
neurons	O
located	O
in	O
the	O
abdominal	O
ganglion	O
[	O
30,43	O
]	O
.	O

In	O
addition	O
,	O
it	O
has	O
been	O
shown	O
that	O
some	O
or	O
all	O
of	O
these	O
neurons	O
express	O
a	O
GAL4	O
insertion	O
line	O
for	O
the	O
bullwinkle	O
(	O
bwk	O
)	O
gene	O
[	O
43	O
]	O
.	O

Bwk	O
encodes	O
a	O
HMG	O
-	O
box	O
containing	O
putative	O
transcription	O
factor	O
[	O
44	O
]	O
.	O

To	O
determine	O
if	O
mating	O
induces	O
any	O
changes	O
in	O
the	O
number	O
of	O
type	O
I	O
and	O
II	O
boutons	O
innervating	O
the	O
oviduct	O
muscles	O
,	O
we	O
used	O
the	O
pan	O
-	O
neural	O
marker	O
,	O
anti	O
-	O
HRP	O
to	O
label	O
all	O
oviduct	O
boutons	O
in	O
unmated	O
and	O
mated	O
females	O
.	O

To	O
distinguish	O
between	O
type	O
I	O
and	O
II	O
boutons	O
we	O
used	O
an	O
antibody	O
against	O
the	O
Disc	O
Large	O
(	O
DLG	O
)	O
protein	O
[	O
45	O
]	O
.	O

Type	O
I	O
boutons	O
were	O
identified	O
by	O
their	O
DLG	O
postsynaptic	O
staining	O
and	O
large	O
size	O
(	O
>	O
8	O
μm	O
in	O
diameter	O
)	O
(	O
Figure	O
4	O
G	O
)	O
,	O
while	O
type	O
II	O
boutons	O
were	O
distinguished	O
by	O
their	O
absence	O
of	O
DLG	O
staining	O
and	O
smaller	O
size	O
(	O
<	O
2	O
μm	O
)	O
(	O
Figure	O
4H	O
)	O
.	O

We	O
find	O
that	O
type	O
I	O
and	O
II	O
boutons	O
innervate	O
the	O
lateral	O
oviducts	O
and	O
common	O
oviduct	O
,	O
and	O
that	O
the	O
type	O
I	O
innervation	O
is	O
restricted	O
to	O
a	O
few	O
axons	O
that	O
run	O
parallel	O
to	O
the	O
length	O
of	O
the	O
oviduct	O
,	O
while	O
the	O
type	O
II	O
innervation	O
is	O
more	O
widespread	O
.	O

We	O
quantified	O
the	O
number	O
of	O
boutons	O
in	O
the	O
lateral	O
oviducts	O
and	O
common	O
oviduct	O
and	O
observed	O
a	O
74	O
%	O
increase	O
in	O
bouton	O
number	O
in	O
the	O
lateral	O
oviduct	O
and	O
a	O
66	O
%	O
increase	O
in	O
the	O
common	O
oviduct	O
post	O
-	O
mating	O
(	O
Figure	O
4I	O
)	O
.	O

More	O
over	O
,	O
we	O
observed	O
no	O
significant	O
change	O
in	O
the	O
number	O
of	O
type	O
I	O
boutons	O
in	O
the	O
lateral	O
oviduct	O
and	O
common	O
oviduct	O
.	O

However	O
,	O
we	O
detected	O
a	O
1.5-fold	O
increase	O
in	O
the	O
number	O
of	O
type	O
II	O
boutons	O
in	O
the	O
lateral	O
oviduct	O
and	O
a	O
1.8-fold	O
increase	O
in	O
type	O
II	O
innervation	O
in	O
the	O
common	O
oviduct	O
.	O

Dramatic	O
increases	O
in	O
bouton	O
growth	O
are	O
also	O
observed	O
during	O
development	O
.	O

For	O
example	O
,	O
a	O
ten	O
-	O
fold	O
increase	O
in	O
bouton	O
number	O
is	O
observed	O
at	O
the	O
neuromuscular	O
junction	O
during	O
the	O
larval	O
period	O
[	O
46	O
]	O
.	O

To	O
determine	O
if	O
the	O
increase	O
in	O
type	O
II	O
innervation	O
was	O
specific	O
to	O
mating	O
or	O
reflected	O
normal	O
growth	O
in	O
3	O
day	O
-	O
old	O
females	O
,	O
we	O
quantified	O
type	O
I	O
and	O
II	O
innervation	O
in	O
the	O
oviducts	O
of	O
5	O
day	O
-	O
old	O
unmated	O
females	O
.	O

We	O
found	O
no	O
significant	O
difference	O
in	O
type	O
I	O
and	O
II	O
innervation	O
in	O
unmated	O
3	O
day	O
-	O
old	O
and	O
5-day	O
-	O
old	O
females	O
,	O
indicating	O
that	O
mating	O
,	O
either	O
directly	O
or	O
indirectly	O
,	O
induces	O
a	O
dramatic	O
increase	O
in	O
type	O
II	O
innervation	O
(	O
Figure	O
4I	O
)	O
.	O

To	O
determine	O
if	O
the	O
post	O
-	O
mating	O
increase	O
in	O
innervation	O
is	O
unique	O
to	O
the	O
oviduct	O
,	O
we	O
asked	O
if	O
mating	O
induces	O
a	O
global	O
change	O
in	O
innervation	O
.	O

We	O
quantified	O
bouton	O
number	O
in	O
the	O
adult	O
ventral	O
midline	O
muscles	O
of	O
the	O
5th	O
abdominal	O
segment	O
.	O

These	O
muscles	O
are	O
innervated	O
by	O
boutons	O
that	O
increase	O
in	O
number	O
during	O
metamorphosis	O
[	O
47	O
]	O
.	O

No	O
significant	O
difference	O
in	O
bouton	O
number	O
was	O
detected	O
at	O
these	O
muscles	O
in	O
unmated	O
and	O
mated	O
females	O
(	O
additional	O
file	O
3	O
)	O
.	O

Though	O
further	O
analysis	O
is	O
needed	O
,	O
this	O
suggests	O
that	O
the	O
post	O
-	O
mating	O
increase	O
in	O
innervation	O
is	O
oviduct	O
-	O
specific	O
.	O

Because	O
the	O
type	O
II	O
boutons	O
are	O
octopaminergic	O
,	O
the	O
increased	O
type	O
II	O
innervation	O
may	O
result	O
in	O
increased	O
octopamine	O
(	O
OA	O
)	O
release	O
in	O
the	O
oviduct	O
.	O

In	O
support	O
of	O
this	O
possibility	O
,	O
we	O
have	O
preliminary	O
evidence	O
that	O
OA	O
is	O
released	O
in	O
the	O
oviduct	O
post	O
-	O
mating	O
(	O
Heifetz	O
and	O
Wolfner	O
,	O
in	O
preparation	O
)	O
.	O

Studies	O
in	O
locust	O
and	O
Drosophila	O
demonstrate	O
that	O
OA	O
inhibits	O
oviduct	O
contraction	O
,	O
while	O
glutamate	O
activates	O
oviduct	O
contraction	O
[	O
30,43,48	O
]	O
.	O

In	O
Drosophila	O
,	O
electrical	O
stimulation	O
of	O
the	O
posterior	O
abdominal	O
nerve	O
gives	O
rise	O
to	O
a	O
series	O
of	O
muscle	O
contractions	O
in	O
the	O
oviduct	O
followed	O
by	O
a	O
period	O
of	O
muscle	O
fatigue	O
or	O
relaxation	O
[	O
43	O
]	O
.	O

This	O
pattern	O
of	O
muscle	O
contraction	O
and	O
relaxation	O
may	O
facilitate	O
the	O
proper	O
movement	O
of	O
the	O
egg	O
through	O
the	O
oviduct	O
.	O

In	O
their	O
study	O
of	O
bwk	O
expressing	O
neurons	O
that	O
innervate	O
the	O
oviduct	O
,	O
Rodriguez	O
-	O
Valentin	O
et	O
al.	O
[	O
43	O
]	O
show	O
that	O
OA	O
and	O
glutamate	O
interact	O
to	O
produce	O
the	O
pattern	O
of	O
oviduct	O
contraction	O
and	O
relaxation	O
described	O
above	O
.	O

It	O
is	O
therefore	O
possible	O
that	O
the	O
post	O
-	O
mating	O
increase	O
in	O
type	O
II	O
innervation	O
in	O
the	O
oviduct	O
plays	O
an	O
important	O
role	O
in	O
the	O
increased	O
rate	O
of	O
ovulation	O
and	O
egg	O
-	O
laying	O
observed	O
post	O
-	O
mating	O
.	O

Female	O
mating	O
history	O
affects	O
the	O
enrichment	O
of	O
cytosekeletal	O
proteins	O
in	O
the	O
oviduct	O
To	O
gain	O
insights	O
into	O
the	O
role	O
of	O
cytoskeletal	O
protein	O
enrichment	O
(	O
[	O
23	O
]	O
;	O
additional	O
file	O
4	O
)	O
in	O
mediating	O
the	O
morphological	O
changes	O
detected	O
in	O
this	O
study	O
,	O
we	O
examined	O
the	O
effect	O
of	O
different	O
mating	O
regimes	O
on	O
cytoskeletal	O
protein	O
abundance	O
.	O

We	O
focused	O
on	O
a	O
subset	O
of	O
mating	O
-	O
responsive	O
cytoskeletal	O
proteins	O
with	O
well	O
established	O
roles	O
in	O
the	O
differentiation	O
of	O
muscle	O
and	O
epithelia	O
.	O

These	O
include	O
:	O
(	O
i	O
)	O
Mlp84B	O
which	O
regulates	O
the	O
late	O
differentiation	O
pathway	O
of	O
muscle	O
[	O
49	O
]	O
;	O
(	O
ii	O
)	O
Cora	O
and	O
Nrg	O
which	O
are	O
required	O
for	O
the	O
formation	O
of	O
septate	O
junctions	O
in	O
epithelia	O
[	O
50	O
]	O
,	O
and	O
(	O
iii	O
)	O
Hu	O
-	O
li	O
tai	O
shao	O
(	O
Hts	O
)	O
,	O
also	O
known	O
as	O
adducin	O
-	O
like	O
protein	O
,	O
which	O
functions	O
in	O
assembly	O
of	O
the	O
cytoskeletal	O
network	O
.	O

Na+	O
pump	O
α	O
subunit	O
(	O
ATPα	O
)	O
,	O
another	O
protein	O
associated	O
with	O
septate	O
junctions	O
in	O
epithelia	O
,	O
is	O
not	O
a	O
mating	O
-	O
responsive	O
protein	O
and	O
was	O
used	O
as	O
a	O
control	O
.	O

Using	O
western	O
blots	O
,	O
we	O
first	O
determined	O
the	O
abundance	O
of	O
the	O
cytoskeletal	O
proteins	O
in	O
oviducts	O
of	O
3-day	O
-	O
old	O
unmated	O
and	O
mated	O
females	O
at	O
6	O
hrs	O
post	O
-	O
mating	O
.	O

We	O
confirmed	O
the	O
proteomic	O
results	O
of	O
Kalpenikov	O
et	O
al.	O
[	O
23	O
]	O
and	O
found	O
that	O
mating	O
increases	O
the	O
abundance	O
of	O
all	O
proteins	O
,	O
except	O
ATPα	O
in	O
mated	O
oviducts	O
relative	O
to	O
their	O
abundance	O
in	O
unmated	O
oviducts	O
(	O
Figure	O
5A	O
)	O
.	O

To	O
determine	O
whether	O
the	O
increased	O
abundance	O
of	O
mating	O
-	O
responsive	O
proteins	O
persists	O
for	O
longer	O
times	O
post	O
-	O
mating	O
,	O
we	O
examined	O
oviducts	O
of	O
10-day	O
-	O
old	O
females	O
that	O
mated	O
once	O
at	O
3	O
days	O
of	O
age	O
,	O
and	O
calculated	O
the	O
abundance	O
of	O
the	O
mating	O
-	O
responsive	O
proteins	O
relative	O
to	O
their	O
level	O
in	O
oviducts	O
of	O
3-day	O
-	O
old	O
unmated	O
females	O
.	O

We	O
found	O
no	O
change	O
or	O
a	O
slight	O
increase	O
in	O
the	O
relative	O
abundance	O
of	O
all	O
cytoskeletal	O
proteins	O
except	O
Mlp84B	O
at	O
7	O
days	O
post	O
-	O
mating	O
(	O
Figure	O
5A	O
)	O
.	O

Strikingly	O
,	O
the	O
level	O
of	O
Mlp84B	O
declines	O
by	O
7	O
days	O
post	O
-	O
mating	O
to	O
the	O
level	O
observed	O
prior	O
to	O
mating	O
.	O

Thus	O
Mlp84B	O
levels	O
rise	O
and	O
fall	O
after	O
mating	O
,	O
while	O
the	O
epithelial	O
-	O
related	O
proteins	O
rapidly	O
rise	O
and	O
are	O
maintained	O
at	O
a	O
high	O
level	O
after	O
mating	O
.	O

This	O
raises	O
the	O
possibility	O
that	O
a	O
second	O
mating	O
might	O
trigger	O
an	O
increase	O
in	O
Mlp84B	O
protein	O
expression	O
as	O
observed	O
in	O
3-day	O
-	O
old	O
females	O
at	O
6	O
h	O
post	O
-	O
mating	O
.	O

To	O
test	O
this	O
possibility	O
,	O
females	O
were	O
mated	O
twice	O
(	O
once	O
at	O
day	O
3	O
,	O
and	O
once	O
on	O
day	O
10	O
of	O
age	O
)	O
,	O
and	O
their	O
oviducts	O
were	O
examined	O
at	O
6	O
hrs	O
after	O
the	O
second	O
mating	O
.	O

We	O
calculated	O
the	O
abundance	O
of	O
the	O
cytoskeletal	O
proteins	O
in	O
the	O
twice	O
mated	O
oviducts	O
relative	O
to	O
their	O
abundance	O
in	O
oviducts	O
of	O
3-day	O
-	O
old	O
unmated	O
females	O
.	O

Our	O
results	O
show	O
that	O
a	O
second	O
mating	O
has	O
little	O
or	O
no	O
effect	O
on	O
Mlp84B	O
abundance	O
.	O

Thus	O
,	O
Mlp84B	O
may	O
represent	O
a	O
class	O
of	O
mating	O
-	O
responsive	O
proteins	O
that	O
is	O
only	O
needed	O
after	O
the	O
first	O
mating	O
.	O

Interestingly	O
,	O
the	O
effect	O
of	O
the	O
second	O
mating	O
on	O
the	O
epithelial	O
-	O
related	O
mating	O
-	O
responsive	O
proteins	O
appears	O
to	O
be	O
different	O
for	O
each	O
protein	O
.	O

While	O
Cora	O
levels	O
drop	O
to	O
the	O
level	O
observed	O
in	O
3-day	O
-	O
old	O
unmated	O
females	O
,	O
Nrg	O
and	O
Hts	O
are	O
maintained	O
at	O
a	O
high	O
level	O
.	O

To	O
determine	O
if	O
the	O
changes	O
in	O
cytoskeletal	O
protein	O
abundance	O
are	O
mating	O
-	O
dependent	O
we	O
measured	O
their	O
abundance	O
in	O
the	O
oviducts	O
of	O
unmated	O
5-	O
and	O
10-day	O
-	O
old	O
females	O
.	O

We	O
calculated	O
their	O
abundance	O
relative	O
to	O
their	O
level	O
in	O
oviducts	O
of	O
unmated	O
3-day	O
-	O
old	O
females	O
(	O
Figure	O
5B	O
)	O
.	O

We	O
rationalized	O
that	O
if	O
the	O
change	O
in	O
cytoskeletal	O
protein	O
abundance	O
is	O
mating	O
-	O
dependent	O
we	O
will	O
not	O
see	O
similar	O
changes	O
in	O
unmated	O
females	O
.	O

We	O
observed	O
a	O
slow	O
increase	O
in	O
the	O
relative	O
abundance	O
of	O
all	O
mating	O
-	O
responsive	O
proteins	O
with	O
time	O
post	O
-	O
eclosion	O
(	O
Figure	O
5B	O
)	O
.	O

Because	O
unmated	O
females	O
lay	O
more	O
eggs	O
as	O
they	O
age	O
(	O
see	O
additional	O
file	O
5C	O
)	O
one	O
possible	O
interpretation	O
of	O
the	O
increased	O
level	O
of	O
cytoskeletal	O
proteins	O
in	O
unmated	O
females	O
is	O
that	O
these	O
proteins	O
are	O
associated	O
with	O
an	O
intrinsic	O
program	O
for	O
oviduct	O
maturation	O
and	O
that	O
mating	O
accelerates	O
this	O
process	O
to	O
maximize	O
egg	O
-	O
laying	O
efficacy	O
.	O

Alternatively	O
,	O
it	O
is	O
possible	O
that	O
the	O
slow	O
increase	O
in	O
protein	O
abundance	O
observed	O
in	O
unmated	O
females	O
is	O
due	O
to	O
the	O
passage	O
of	O
eggs	O
through	O
the	O
oviduct	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
mating	O
is	O
essential	O
to	O
fine	O
-	O
tune	O
the	O
levels	O
of	O
the	O
mating	O
-	O
responsive	O
proteins	O
examined	O
in	O
this	O
study	O
.	O

Because	O
the	O
changes	O
in	O
cytoskeletal	O
protein	O
abundance	O
are	O
different	O
in	O
unmated	O
and	O
mated	O
females	O
,	O
this	O
suggests	O
that	O
the	O
post	O
-	O
mating	O
changes	O
are	O
mating	O
-	O
dependent	O
.	O

Furthermore	O
,	O
we	O
suggest	O
that	O
these	O
post	O
-	O
mating	O
changes	O
are	O
linked	O
to	O
changes	O
in	O
oviduct	O
function	O
.	O

Early	O
or	O
prior	O
mating	O
increases	O
fecundity	O
In	O
Drosophila	O
,	O
female	O
fecundity	O
decreases	O
with	O
age	O
[	O
51	O
-	O
54	O
]	O
.	O

It	O
has	O
been	O
proposed	O
that	O
this	O
decrease	O
is	O
due	O
,	O
in	O
part	O
,	O
to	O
the	O
loss	O
of	O
germline	O
and	O
somatic	O
stem	O
cells	O
[	O
55	O
]	O
.	O

Since	O
the	O
expression	O
of	O
the	O
oviduct	O
cytoskeletal	O
proteins	O
examined	O
in	O
this	O
study	O
change	O
with	O
age	O
and	O
mating	O
experience	O
,	O
the	O
state	O
of	O
the	O
oviduct	O
may	O
also	O
play	O
a	O
role	O
in	O
fecundity	O
.	O

To	O
separate	O
the	O
effects	O
of	O
age	O
and	O
mating	O
,	O
we	O
measured	O
the	O
fecundity	O
of	O
females	O
that	O
mated	O
twice	O
,	O
first	O
at	O
3	O
days	O
post	O
-	O
eclosion	O
and	O
again	O
at	O
10	O
days	O
,	O
and	O
compared	O
that	O
to	O
the	O
fecundity	O
of	O
females	O
that	O
mated	O
once	O
at	O
3	O
days	O
and	O
females	O
that	O
mated	O
once	O
at	O
10	O
days	O
.	O

Fecundity	O
was	O
measured	O
as	O
the	O
number	O
of	O
eggs	O
laid	O
per	O
day	O
per	O
female	O
during	O
the	O
first	O
three	O
days	O
after	O
mating	O
.	O

Once	O
-	O
mated	O
3-day	O
-	O
old	O
females	O
laid	O
nearly	O
twice	O
as	O
many	O
eggs	O
as	O
once	O
-	O
mated	O
10-day	O
-	O
old	O
females	O
during	O
the	O
three	O
days	O
examined	O
(	O
24.5	O
±	O
0.7	O
versus	O
13.3	O
±	O
0.9	O
,	O
p	O
<	O
0.0001	O
)	O
.	O

Twice	O
-	O
mated	O
10-day	O
-	O
old	O
females	O
also	O
laid	O
about	O
50	O
%	O
more	O
eggs	O
than	O
once	O
-	O
mated	O
females	O
of	O
the	O
same	O
age	O
(	O
19.3	O
±	O
0.9	O
versus	O
13.3	O
±	O
0.9	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
,	O
but	O
about	O
20	O
%	O
fewer	O
than	O
laid	O
by	O
once	O
-	O
mated	O
3-day	O
-	O
old	O
females	O
during	O
the	O
three	O
days	O
examined	O
(	O
19.3	O
±	O
0.9	O
versus	O
24.5	O
±	O
0.7	O
,	O
p	O
<	O
0.0001	O
)	O
(	O
Figure	O
6A	O
,	O
see	O
also	O
additional	O
file	O
5A	O
and	O
5B	O
)	O
.	O

Thus	O
,	O
the	O
difference	O
in	O
fecundity	O
between	O
once	O
-	O
mated	O
10-day	O
-	O
old	O
and	O
once	O
-	O
mated	O
3-day	O
-	O
old	O
females	O
is	O
not	O
a	O
result	O
of	O
age	O
alone	O
.	O

Rather	O
the	O
main	O
determinant	O
of	O
fecundity	O
at	O
10	O
days	O
is	O
whether	O
there	O
had	O
been	O
a	O
prior	O
mating	O
at	O
3	O
days	O
.	O

We	O
also	O
calculated	O
the	O
fertility	O
(	O
number	O
of	O
adults	O
eclosed	O
)	O
of	O
once-	O
and	O
twice	O
-	O
mated	O
females	O
.	O

Once	O
-	O
mated	O
3-day	O
-	O
old	O
females	O
are	O
more	O
fertile	O
than	O
once	O
-	O
mated	O
10-day	O
-	O
old	O
females	O
(	O
69.5	O
±	O
1.6	O
%	O
versus	O
56.1	O
±	O
3.0	O
%	O
,	O
p	O
<	O
0.0001	O
)	O
and	O
slightly	O
more	O
fertile	O
than	O
twice	O
-	O
mated	O
10-day	O
-	O
old	O
females	O
(	O
69.5	O
±	O
1.6	O
%	O
versus	O
62.7	O
±	O
2.4	O
%	O
,	O
p	O
<	O
0.015	O
)	O
(	O
Figure	O
6B	O
,	O
see	O
also	O
additional	O
file	O
5D	O
)	O
.	O

Because	O
there	O
is	O
no	O
significant	O
difference	O
in	O
fertility	O
between	O
once	O
-	O
mated	O
and	O
twice	O
-	O
mated	O
10-day	O
-	O
old	O
females	O
,	O
this	O
suggests	O
that	O
(	O
1	O
)	O
a	O
prior	O
mating	O
has	O
no	O
significant	O
effect	O
on	O
the	O
fertility	O
of	O
10-day	O
-	O
old	O
mated	O
females	O
and	O
(	O
2	O
)	O
fertility	O
decreases	O
with	O
age	O
.	O

One	O
intriguing	O
interpretation	O
of	O
these	O
results	O
is	O
that	O
an	O
early	O
mating	O
increases	O
fecundity	O
which	O
partially	O
compensates	O
for	O
the	O
age	O
-	O
related	O
decrease	O
in	O
fertility	O
.	O

Thus	O
,	O
cytoskeletal	O
mating	O
-	O
responsive	O
protein	O
changes	O
may	O
be	O
associated	O
with	O
structural	O
changes	O
in	O
the	O
oviduct	O
that	O
result	O
in	O
increased	O
fecundity	O
.	O

This	O
may	O
counteract	O
the	O
effects	O
of	O
decreased	O
fertility	O
on	O
the	O
reproductive	O
output	O
.	O

Discussion	O
Despite	O
the	O
use	O
of	O
Drosophila	O
as	O
a	O
model	O
system	O
for	O
organ	O
-	O
level	O
biology	O
and	O
the	O
emerging	O
parallels	O
between	O
mammalian	O
and	O
Drosophila	B
reproductive	O
biology	O
[	O
56	O
]	O
,	O
this	O
is	O
the	O
first	O
integrative	O
tissue	O
-	O
wide	O
study	O
of	O
post	O
-	O
mating	O
changes	O
in	O
the	O
Drosophila	B
oviduct	O
.	O

Our	O
results	O
provide	O
several	O
lines	O
of	O
evidence	O
at	O
the	O
molecular	O
,	O
morphological	O
and	O
physiological	O
levels	O
suggesting	O
that	O
mating	O
induces	O
tissue	O
-	O
wide	O
differentiation	O
in	O
the	O
oviduct	O
.	O

Moreover	O
,	O
we	O
identify	O
ultrastructural	O
changes	O
in	O
the	O
mated	O
oviduct	O
that	O
are	O
consistent	O
with	O
the	O
roles	O
that	O
some	O
of	O
the	O
mating	O
-	O
responsive	O
proteins	O
examined	O
in	O
this	O
study	O
(	O
e.g.	O
Mlp84B	O
,	O
Cora	O
,	O
Nrg	O
)	O
are	O
reported	O
to	O
play	O
in	O
muscle	O
and	O
epithelial	O
differentiation	O
elsewhere	O
.	O

For	O
example	O
,	O
the	O
increased	O
abundance	O
of	O
Mlp84B	O
,	O
a	O
major	O
regulator	O
of	O
the	O
late	O
differentiation	O
pathway	O
of	O
muscle	O
[	O
49	O
]	O
is	O
consistent	O
with	O
the	O
increased	O
muscle	O
differentiation	O
in	O
the	O
upper	O
oviduct	O
post	O
-	O
mating	O
(	O
Figure	O
4A–4F	O
)	O
.	O

Similarly	O
,	O
the	O
increased	O
abundance	O
of	O
Cora	O
and	O
Nrg	O
,	O
molecules	O
that	O
are	O
essential	O
for	O
SJ	O
development	O
and	O
function	O
[	O
50	O
]	O
is	O
consistent	O
with	O
the	O
observation	O
that	O
SJs	O
in	O
the	O
upper	O
oviduct	O
are	O
immature	O
and/or	O
that	O
mating	O
induces	O
changes	O
in	O
the	O
apical	O
extracellular	O
matrix	O
whose	O
secretion	O
may	O
be	O
regulated	O
,	O
in	O
part	O
,	O
by	O
SJs	O
as	O
occurs	O
in	O
the	O
trachea	O
[	O
27,28	O
]	O
.	O

Other	O
post	O
-	O
mating	O
changes	O
that	O
indicate	O
that	O
mating	O
induces	O
tissue	O
-	O
wide	O
differentiation	O
include	O
increased	O
HAJs	O
along	O
the	O
basolateral	O
membrane	O
and	O
increased	O
innervation	O
.	O

Analysis	O
of	O
protein	O
abundance	O
following	O
different	O
mating	O
regimes	O
(	O
unmated	O
,	O
once	O
-	O
mated	O
,	O
twice	O
-	O
mated	O
)	O
gave	O
us	O
further	O
insights	O
into	O
the	O
possible	O
roles	O
that	O
mating	O
-	O
responsive	O
proteins	O
play	O
in	O
the	O
oviduct	O
.	O

For	O
example	O
,	O
Mlp84B	O
is	O
only	O
responsive	O
to	O
the	O
first	O
mating	O
,	O
while	O
the	O
epithelial	O
proteins	O
examined	O
(	O
Cora	O
,	O
Nrg	O
and	O
Hts	O
)	O
are	O
responsive	O
to	O
the	O
first	O
and	O
second	O
mating	O
.	O

Furthermore	O
,	O
the	O
response	O
to	O
the	O
second	O
mating	O
is	O
different	O
from	O
the	O
response	O
to	O
the	O
first	O
mating	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
Mlp84B	O
is	O
required	O
for	O
the	O
final	O
maturation	O
of	O
the	O
oviduct	O
,	O
while	O
the	O
epithelial	O
proteins	O
examined	O
are	O
required	O
for	O
both	O
the	O
maturation	O
and	O
maintenance	O
of	O
the	O
oviduct	O
at	O
a	O
high	O
functional	O
state	O
.	O

Moreover	O
,	O
the	O
post	O
-	O
mating	O
pattern	O
of	O
Mlp84B	O
supports	O
the	O
idea	O
that	O
the	O
first	O
mating	O
induces	O
the	O
final	O
maturation	O
of	O
the	O
oviduct	O
.	O

The	O
rise	O
and	O
fall	O
of	O
Mlp84B	O
abundance	O
after	O
the	O
first	O
mating	O
(	O
Figure	O
5	O
)	O
parallels	O
the	O
expression	O
pattern	O
of	O
Mlp84B	O
during	O
development	O
where	O
peaks	O
in	O
Mlp84B	O
transcription	O
occur	O
during	O
periods	O
of	O
embryogenesis	O
and	O
metamorphosis	O
when	O
muscle	O
is	O
differentiating	O
[	O
49	O
]	O
.	O

Using	O
different	O
mating	O
regimes	O
we	O
tested	O
whether	O
the	O
first	O
/	O
early	O
mating	O
is	O
essential	O
for	O
maintenance	O
of	O
high	O
reproductive	O
output	O
in	O
the	O
second	O
mating	O
.	O

Our	O
results	O
suggest	O
that	O
mating	O
at	O
an	O
early	O
age	O
is	O
essential	O
to	O
achieve	O
maximum	O
reproductive	O
output	O
(	O
i.e.	O
high	O
fecundity	O
and	O
fertility	O
)	O
.	O

Since	O
the	O
first	O
mating	O
increases	O
reproductive	O
output	O
(	O
evidence	O
from	O
our	O
mating	O
regime	O
experiments	O
)	O
,	O
it	O
is	O
likely	O
that	O
the	O
ultrastructural	O
changes	O
detected	O
in	O
mated	O
3-day	O
-	O
old	O
females	O
lead	O
to	O
a	O
highly	O
functional	O
oviduct	O
.	O

We	O
suggest	O
that	O
the	O
final	O
maturation	O
of	O
the	O
oviduct	O
includes	O
a	O
mating	O
-	O
dependent	O
stage	O
.	O

We	O
propose	O
that	O
during	O
the	O
first	O
few	O
days	O
post	O
-	O
eclosion	O
,	O
the	O
oviduct	O
undergoes	O
the	O
first	O
phase	O
of	O
differentiation	O
,	O
after	O
which	O
the	O
oviduct	O
is	O
developmentally	O
poised	O
for	O
a	O
rapid	O
response	O
to	O
an	O
extrinsic	O
cue	O
(	O
mating	O
)	O
.	O

Mating	O
then	O
triggers	O
the	O
second	O
phase	O
of	O
maturation	O
(	O
tissue	O
remodeling	O
and	O
modulation	O
)	O
which	O
is	O
essential	O
for	O
proper	O
oviduct	O
function	O
(	O
Figure	O
7	O
)	O
.	O

We	O
further	O
propose	O
that	O
the	O
second	O
phase	O
of	O
maturation	O
consists	O
of	O
processes	O
that	O
are	O
mating	O
-	O
independent	O
and	O
-dependent	O
,	O
and	O
that	O
both	O
of	O
these	O
pathways	O
are	O
essential	O
to	O
produce	O
a	O
functional	O
oviduct	O
.	O

For	O
example	O
,	O
initial	O
formation	O
of	O
SJs	O
occurs	O
prior	O
to	O
mating	O
(	O
mating	O
-	O
independent	O
)	O
while	O
the	O
increased	O
apical	O
secretion	O
and	O
development	O
of	O
HAJs	O
are	O
mating	O
-	O
dependent	O
.	O

The	O
oviduct	O
musculature	O
is	O
an	O
example	O
where	O
both	O
mating	O
-	O
independent	O
and	O
-dependent	O
processes	O
play	O
a	O
role	O
.	O

Muscles	O
are	O
highly	O
differentiated	O
in	O
the	O
lower	O
oviduct	O
prior	O
to	O
mating	O
,	O
while	O
muscle	O
differentiation	O
is	O
ongoing	O
in	O
the	O
upper	O
oviduct	O
and	O
increases	O
after	O
mating	O
.	O

Although	O
the	O
onset	O
of	O
muscle	O
differentiation	O
in	O
both	O
regions	O
is	O
mating	O
-	O
independent	O
,	O
the	O
further	O
differentiation	O
of	O
muscle	O
in	O
the	O
upper	O
oviduct	O
is	O
mating	O
-	O
dependent	O
.	O

Another	O
possible	O
interpretation	O
of	O
the	O
role	O
of	O
mating	O
on	O
oviduct	O
maturation	O
is	O
that	O
mating	O
accelerates	O
and	O
synchronizes	O
processes	O
that	O
are	O
essential	O
for	O
the	O
functional	O
maturation	O
of	O
the	O
oviduct	O
.	O

It	O
will	O
therefore	O
be	O
interesting	O
to	O
examine	O
the	O
oviducts	O
of	O
older	O
females	O
to	O
determine	O
the	O
status	O
of	O
oviduct	O
maturation	O
.	O

What	O
is	O
the	O
benefit	O
of	O
mating	O
-	O
induced	O
differentiation	O
of	O
the	O
oviduct	O
tissues	O
?	O

Unmated	O
females	O
are	O
capable	O
of	O
laying	O
eggs	O
,	O
albeit	O
at	O
a	O
reduced	O
rate	O
as	O
compared	O
to	O
mated	O
females	O
of	O
the	O
same	O
age	O
.	O

One	O
possible	O
interpretation	O
is	O
that	O
reproduction	O
is	O
energetically	O
costly	O
,	O
thus	O
delaying	O
oviduct	O
maturation	O
until	O
sperm	O
is	O
available	O
is	O
advantageous	O
to	O
the	O
female	O
.	O

This	O
may	O
reflect	O
the	O
evolution	O
of	O
a	O
mechanism	O
to	O
optimize	O
reproductive	O
capacity	O
in	O
early	O
adulthood	O
in	O
short	O
-	O
lived	O
animals	O
.	O

In	O
summary	O
,	O
we	O
have	O
identified	O
events	O
at	O
the	O
cellular	O
,	O
molecular	O
and	O
physiological	O
levels	O
that	O
are	O
part	O
of	O
an	O
efficient	O
and	O
specific	O
program	O
for	O
reproduction	O
.	O

Drosophila	O
affords	O
us	O
the	O
opportunity	O
to	O
uncover	O
the	O
signaling	O
pathways	O
that	O
coordinate	O
these	O
events	O
to	O
produce	O
a	O
physiologically	O
functional	O
organ	O
.	O

Methods	O
Flies	O
Wild	O
-	O
type	O
Canton	O
-	O
S	O
flies	B
were	O
used	O
for	O
the	O
fecundity	O
/	O
fertility	O
experiments	O
and	O
confocal	O
analysis	O
.	O

Wild	O
-	O
type	O
Canton	O
-	O
S5	O
[	O
57	O
]	O
flies	B
were	O
used	O
for	O
electron	O
microscopy	O
.	O

All	O
flies	B
were	O
kept	O
in	O
a	O
12	O
hrs	O
light	O
/	O
dark	O
cycle	O
at	O
23	O
±	O
2	O
°	O
C	O
.	O

Upon	O
eclosion	O
,	O
females	O
and	O
males	O
were	O
collected	O
on	O
ice	O
and	O
held	O
separately	O
until	O
3	O
(	O
females	O
and	O
males	O
)	O
or	O
10	O
(	O
females	O
)	O
days	O
of	O
age	O
.	O

Sample	O
preparation	O
For	O
all	O
assays	O
(	O
unless	O
described	O
differently	O
)	O
unmated	O
females	O
were	O
placed	O
with	O
3-day	O
-	O
old	O
unmated	O
males	O
and	O
observed	O
until	O
mating	O
initiated	O
.	O

At	O
the	O
end	O
of	O
mating	O
,	O
females	O
were	O
aspirated	O
into	O
fresh	O
vials	O
and	O
held	O
for	O
6	O
hrs	O
.	O

At	O
6	O
hrs	O
after	O
the	O
start	O
of	O
mating	O
,	O
females	O
were	O
placed	O
on	O
ice	O
for	O
dissection	O
.	O

Previous	O
molecular	O
studies	O
indicate	O
changes	O
in	O
protein	O
abundance	O
at	O
3	O
hrs	O
post	O
-	O
mating	O
.	O

We	O
hypothesize	O
that	O
these	O
molecular	O
changes	O
will	O
translate	O
into	O
morphological	O
changes	O
in	O
the	O
next	O
few	O
hours	O
.	O

We	O
chose	O
to	O
analyze	O
the	O
morphology	O
of	O
mated	O
females	O
at	O
6	O
h	O
post	O
-	O
mating	O
as	O
opposed	O
to	O
later	O
times	O
post	O
-	O
mating	O
because	O
the	O
changes	O
observed	O
at	O
later	O
times	O
may	O
be	O
due	O
,	O
in	O
part	O
,	O
to	O
the	O
high	O
rate	O
of	O
eggs	O
passing	O
through	O
the	O
oviduct	O
.	O

Electron	O
microscopy	O
Reproductive	O
tracts	O
were	O
dissected	O
in	O
Schneider	O
's	O
Drosophila	B
medium	O
(	O
Sigma	O
)	O
on	O
ice	O
and	O
processed	O
for	O
electron	O
microscopy	O
as	O
described	O
in	O
[	O
42	O
]	O
.	O

Tracts	O
were	O
flat	O
-	O
embedded	O
between	O
two	O
sheets	O
of	O
Aclar	O
(	O
Electron	O
Microscopy	O
Sciences	O
)	O
,	O
which	O
allowed	O
us	O
to	O
image	O
the	O
entire	O
tract	O
at	O
the	O
light	O
microscopic	O
level	O
prior	O
to	O
sectioning	O
.	O

Sections	O
were	O
cut	O
on	O
a	O
Reichart	O
Ultracut	O
microtome	O
.	O

One	O
-	O
μm	O
thick	O
sections	O
were	O
stained	O
with	O
1	O
%	O
toluidine	O
blue	O
,	O
and	O
viewed	O
with	O
a	O
Zeiss	O
Axoplan	O
microscope	O
.	O

Ultrathin	O
sections	O
(	O
~100	O
nm	O
)	O
were	O
mounted	O
on	O
formvar	O
grids	O
,	O
stained	O
with	O
lead	O
citrate	O
,	O
and	O
viewed	O
with	O
a	O
Philips	O
/	O
FEI	O
Morgagni	O
268	O
TEM	O
at	O
80	O
kV.	O
Our	O
analysis	O
is	O
based	O
on	O
4	O
unmated	O
samples	O
and	O
3	O
mated	O
samples	O
.	O

Two	O
unmated	O
samples	O
were	O
cut	O
in	O
the	O
longitudinal	O
plane	O
and	O
two	O
additional	O
unmated	O
samples	O
were	O
cut	O
in	O
the	O
transverse	O
plane	O
,	O
while	O
one	O
mated	O
sample	O
was	O
cut	O
in	O
the	O
longitudinal	O
plane	O
and	O
two	O
additional	O
mated	O
samples	O
were	O
cut	O
in	O
the	O
transverse	O
plane	O
.	O

For	O
longitudinal	O
sections	O
,	O
the	O
entire	O
tract	O
was	O
re	O
-	O
embedded	O
and	O
cut	O
.	O

For	O
samples	O
cut	O
in	O
the	O
transverse	O
plane	O
,	O
the	O
flat	O
-	O
embedded	O
reproductive	O
tract	O
was	O
divided	O
into	O
three	O
regions	O
:	O
(	O
1	O
)	O
lateral	O
oviducts	O
and	O
upper	O
common	O
oviducts	O
,	O
(	O
2	O
)	O
middle	O
common	O
oviduct	O
,	O
and	O
(	O
3	O
)	O
lower	O
common	O
oviduct	O
.	O

Each	O
region	O
was	O
re	O
-	O
embedded	O
and	O
sectioned	O
.	O

It	O
is	O
beyond	O
the	O
scope	O
of	O
this	O
paper	O
to	O
describe	O
all	O
three	O
regions	O
,	O
and	O
our	O
analysis	O
focuses	O
on	O
the	O
uppermost	O
and	O
lowermost	O
regions	O
.	O

Immunocytochemistry	O
Reproductive	O
tracts	O
were	O
dissected	O
in	O
Yamamoto	O
's	O
Ringer	O
(	O
10	O
mM	O
MOPS	O
;	O
80	O
mM	O
NaCl	O
;	O
10	O
mM	O
KCL	O
;	O
0.2	O
mM	O
MgCl2	O
;	O
0.1	O
mM	O
CaCl2	O
)	O
with	O
5	O
%	O
(	O
w	O
/	O
v	O
)	O
sucrose	O
on	O
ice	O
,	O
fixed	O
in	O
4	O
%	O
paraphormaldehyde	O
in	O
PBS	O
(	O
phosphate	O
-	O
buffered	O
saline	O
;	O
0.85	O
%	O
NaCl	O
,	O
1.4	O
mM	O
KH2	O
PO4	O
,	O
8	O
mM	O
Na2	O
HPO4	O
,	O
pH	O
7.4	O
)	O
for	O
45	O
min	O
and	O
then	O
washed	O
in	O
PBS	O
.	O

The	O
reproductive	O
tracts	O
were	O
then	O
incubated	O
in	O
blocking	O
solution	O
(	O
0.5	O
%	O
Triton	O
x-100	O
,	O
3	O
%	O
NGS	O
,	O
0.1	O
%	O
BSA	O
)	O
for	O
2	O
hrs	O
at	O
room	O
temperature	O
.	O

The	O
following	O
primary	O
antibodies	O
,	O
reagents	O
,	O
and	O
dilutions	O
were	O
used	O
:	O
Cy3-conjugated	O
goat	B
anti	O
-	O
HRP	O
,	O
1:200	O
(	O
Jackson	O
Immunochemicals	O
,	O
West	O
Grove	O
,	O
PA	O
)	O
;	O
mouse	B
anti	O
-	O
Disc	O
Large	O
(	O
DLG	O
)	O
,	O
1:1000	O
(	O
Developmental	O
Hybridoma	O
Bank	O
)	O
,	O
Alexa	O
Fluor	O
488-phalloidin	O
,	O
1:200	O
(	O
Invitrogen	O
,	O
Molecular	O
Probes	O
,	O
Scotland	O
)	O
.	O

Secondary	O
antibodies	O
were	O
Alexa	O
Flour	O
488-conjugated	O
Goat	B
anti	O
-	O
mouse	B
,	O
1:200	O
and	O
Alexa	O
Flour	O
546-conjugated	O
Goat	B
anti	O
-	O
rabbit	B
,	O
1:200	O
(	O
Invitrogen	O
,	O
Molecular	O
Probes	O
,	O
Scotland	O
)	O
.	O

Reproductive	O
tracts	O
were	O
incubated	O
with	O
the	O
different	O
primary	O
antibodies	O
(	O
diluted	O
in	O
PBS	O
+	O
0.2	O
%	O
Triton	O
x-100	O
)	O
for	O
2	O
hr	O
at	O
room	O
temperature	O
,	O
washed	O
with	O
PBST	O
,	O
incubated	O
with	O
secondary	O
antibodies	O
for	O
2	O
hrs	O
at	O
room	O
temperature	O
and	O
washed	O
with	O
PBS	O
.	O

Reproductive	O
tracts	O
of	O
the	O
different	O
treatments	O
were	O
mounted	O
with	O
Antifade	O
media	O
[	O
58	O
]	O
on	O
a	O
multi	O
-	O
well	O
glass	O
slide	O
(	O
Hendley	O
-	O
Essex	O
,	O
UK	O
)	O
.	O

For	O
each	O
treatment	O
(	O
unmated	O
,	O
mated	O
)	O
and	O
antibody	O
/	O
reagent	O
(	O
HRP	O
,	O
DLG	O
,	O
phalloidin	O
)	O
a	O
minimum	O
of	O
ten	O
reproductive	O
tracts	O
from	O
at	O
least	O
two	O
independent	O
biological	O
replicates	O
were	O
prepared	O
.	O

Confocal	O
microscopy	O
Reproductive	O
tracts	O
were	O
viewed	O
with	O
a	O
Zeiss	O
510	O
laser	O
scanning	O
confocal	O
microscope	O
using	O
20	O
×	O
and	O
60	O
×	O
objective	O
with	O
additional	O
zooming	O
.	O

Optical	O
sections	O
from	O
different	O
focal	O
plans	O
of	O
each	O
reproductive	O
tract	O
region	O
(	O
lateral	O
oviducts	O
,	O
common	O
oviduct	O
,	O
uterus	O
)	O
were	O
collected	O
and	O
projected	O
as	O
a	O
reconstructed	O
three	O
-	O
dimensional	O
image	O
using	O
LSM	O
image	O
browser	O
(	O
version	O
3,5,0,376	O
)	O
software	O
.	O

Image	O
collections	O
were	O
identical	O
for	O
each	O
of	O
the	O
different	O
reproductive	O
tract	O
regions	O
analyzed	O
.	O

Quantitation	O
of	O
bouton	O
number	O
To	O
quantify	O
the	O
number	O
of	O
boutons	O
in	O
the	O
lateral	O
and	O
common	O
oviducts	O
we	O
used	O
ImageJ	O
software	O
(	O
1.37b	O
,	O
National	O
Institutes	O
of	O
Health	O
)	O
to	O
analyze	O
confocal	O
images	O
of	O
anti	O
-	O
HRP	O
and	O
anti	O
-	O
DLG	O
labeled	O
boutons	O
in	O
the	O
oviduct	O
.	O

The	O
number	O
of	O
boutons	O
per	O
unit	O
area	O
was	O
quantified	O
with	O
the	O
Particle	O
Analysis	O
Tool	O
.	O

Briefly	O
,	O
to	O
differentiate	O
between	O
the	O
boutons	O
,	O
the	O
particle	O
analysis	O
tool	O
requires	O
the	O
image	O
to	O
be	O
a	O
""""	O
binary	O
""""	O
image	O
(	O
i.e.	O
,	O
black	O
or	O
white	O
)	O
,	O
thus	O
we	O
first	O
converted	O
the	O
images	O
to	O
gray	O
scale	O
.	O

We	O
then	O
set	O
a	O
""""	O
threshold	O
""""	O
range	O
so	O
that	O
pixels	O
in	O
the	O
image	O
whose	O
value	O
lies	O
in	O
this	O
range	O
are	O
converted	O
to	O
black	O
;	O
pixels	O
with	O
values	O
outside	O
this	O
range	O
are	O
converted	O
to	O
white	O
.	O

We	O
next	O
defined	O
a	O
region	O
of	O
interest	O
(	O
ROI	O
)	O
within	O
the	O
oviduct	O
to	O
count	O
particles	O
(	O
i.e.	O
count	O
boutons	O
)	O
.	O

This	O
ROI	O
was	O
saved	O
and	O
served	O
to	O
measure	O
the	O
number	O
of	O
boutons	O
per	O
unit	O
area	O
in	O
each	O
treatment	O
.	O

For	O
each	O
oviduct	O
we	O
counted	O
the	O
number	O
of	O
anti	O
-	O
HRP	O
and	O
anti	O
-	O
DLG	O
labeled	O
boutons	O
in	O
two	O
ROIs	O
within	O
the	O
lateral	O
oviducts	O
and	O
two	O
ROIs	O
in	O
the	O
common	O
oviduct	O
.	O

One	O
-	O
way	O
ANOVA	O
(	O
SPSS	O
15.0	O
)	O
was	O
used	O
to	O
measure	O
the	O
difference	O
in	O
bouton	O
number	O
per	O
unit	O
area	O
in	O
different	O
regions	O
of	O
the	O
oviducts	O
,	O
in	O
both	O
unmated	O
and	O
mated	O
females	O
.	O

Quantitation	O
of	O
cytoskeleton	O
proteins	O
Sample	O
preparation	O
To	O
evaluate	O
the	O
effect	O
of	O
mating	O
on	O
the	O
abundance	O
of	O
the	O
cytoskeleton	O
proteins	O
tested	O
,	O
females	O
were	O
:	O
(	O
i	O
)	O
aged	O
for	O
3	O
days	O
,	O
mated	O
with	O
3-day	O
-	O
old	O
unmated	O
males	O
and	O
their	O
oviducts	O
were	O
dissected	O
after	O
6	O
hrs	O
post	O
-	O
mating	O
(	O
Once3	O
)	O
;	O
(	O
ii	O
)	O
aged	O
for	O
3	O
days	O
,	O
mated	O
with	O
3-day	O
-	O
old	O
unmated	O
males	O
and	O
their	O
oviducts	O
were	O
dissected	O
after	O
7	O
days	O
(	O
Once3	O
day10	O
)	O
;	O
(	O
iii	O
)	O
aged	O
for	O
3	O
days	O
,	O
mated	O
first	O
with	O
3-day	O
-	O
old	O
unmated	O
males	O
and	O
held	O
singly	O
for	O
7	O
days	O
.	O

At	O
10	O
days	O
of	O
age	O
,	O
female	O
were	O
mated	O
again	O
with	O
3-day	O
-	O
old	O
unmated	O
males	O
.	O

Oviducts	O
were	O
dissected	O
at	O
6	O
hrs	O
post	O
-	O
second	O
mating	O
(	O
Twice3&10	O
)	O
.	O

We	O
also	O
examined	O
5-day	O
-	O
old	O
and	O
10-day	O
-	O
old	O
unmated	O
females	O
(	O
UM5	O
,	O
UM10	O
respectively	O
)	O
.	O

SDS	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
SDS	O
-	O
PAGE	O
)	O
and	O
Western	O
blotting	O
For	O
each	O
mating	O
regime	O
,	O
sixty	O
oviducts	O
were	O
pooled	O
and	O
30	O
μl	O
of	O
SDS	O
-	O
PAGE	O
sample	O
buffer	O
was	O
added	O
as	O
described	O
in	O
[	O
59	O
]	O
.	O

Samples	O
were	O
boiled	O
,	O
and	O
then	O
frozen	O
at	O
-20	O
°	O
C	O
until	O
loading	O
.	O

SDS	O
-	O
PAGE	O
was	O
performed	O
on	O
12	O
%	O
polyacrylamide	O
gels	O
and	O
western	O
blotted	O
as	O
in	O
[	O
60	O
]	O
.	O

Proteins	O
were	O
cross	O
-	O
linked	O
to	O
the	O
filter	O
.	O

The	O
following	O
primary	O
antibodies	O
and	O
dilutions	O
were	O
used	O
:	O
mouse	B
anti	O
-	O
Neuroglian	O
(	O
kindly	O
provided	O
by	O
M.	O
Hortsch	O
)	O
1:250	O
;	O
Guinea	B
pig	I
anti	O
-	O
Coracle	O
(	O
kindly	O
provided	O
by	O
R.G.	O
Fehon	O
)	O
1:2500	O
;	O
rabbit	B
anti	O
-	O
Mlp84B	O
(	O
kindly	O
provided	O
by	O
M.	O
Beckerle	O
)	O
1:1000	O
;	O
mouse	B
anti	O
-	O
hts	O
(	O
1B1	O
,	O
Developmental	O
Studies	O
Hybridoma	O
Bank	O
,	O
DSHB	O
)	O
1:75	O
;	O
mouse	B
anti	O
-	O
Na	O
,	O
K	O
-	O
ATPase	O
(	O
α5	O
,	O
DSHB	O
)	O
1:100	O
.	O

Secondary	O
antibodies	O
included	O
:	O
anti	O
-	O
Guinea	B
pig	I
IgG	O
(	O
peroxidase	O
conjugated	O
)	O
,	O
anti	O
-	O
Rabbit	B
IgG	O
and	O
anti	O
-	O
Mouse	B
IgG	O
(	O
developed	O
in	O
goat	B
,	O
Sigma	O
,	O
Israel	O
)	O
1:10,000	O
.	O

Proteins	O
were	O
visualized	O
using	O
an	O
enhanced	O
chemiluminescence	O
(	O
ECL	O
)	O
detection	O
system	O
(	O
Amersham	O
Piscataway	O
,	O
NJ	O
)	O
.	O

Analysis	O
The	O
developed	O
film	O
was	O
scanned	O
and	O
the	O
signal	O
intensity	O
(	O
protein	O
abundance	O
)	O
of	O
each	O
band	O
was	O
determined	O
using	O
ImageJ	O
software	O
(	O
1.37d	O
,	O
National	O
Institutes	O
of	O
Health	O
)	O
.	O

We	O
evaluated	O
protein	O
abundance	O
by	O
measuring	O
the	O
mean	O
gray	O
value	O
of	O
a	O
specific	O
band	O
and	O
the	O
background	O
.	O

The	O
mean	O
gray	O
value	O
of	O
the	O
background	O
was	O
then	O
subtracted	O
from	O
that	O
of	O
the	O
measured	O
band	O
.	O

Relative	O
protein	O
abundance	O
in	O
mated	O
oviduct	O
vs.	O
3-day	O
-	O
old	O
unmated	O
oviduct	O
was	O
then	O
calculated	O
.	O

Four	O
independent	O
biological	O
replicates	O
were	O
prepared	O
for	O
each	O
mating	O
status	O
.	O

The	O
reported	O
abundance	O
(	O
see	O
Figure	O
5	O
)	O
is	O
the	O
relative	O
ratio	O
(	O
mated	O
/	O
unmated	O
or	O
unmated	O
/	O
unmated	O
)	O
of	O
at	O
least	O
three	O
replicates	O
that	O
showed	O
the	O
same	O
trend	O
.	O

Examination	O
of	O
female	O
reproductive	O
output	O
Mating	O
regimes	O
To	O
evaluate	O
the	O
effect	O
of	O
mating	O
on	O
reproductive	O
output	O
females	O
were	O
treated	O
as	O
follows	O
:	O
(	O
i	O
)	O
aged	O
for	O
3	O
days	O
and	O
mated	O
with	O
3-day	O
-	O
old	O
unmated	O
males	O
(	O
Once3	O
)	O
;	O
(	O
ii	O
)	O
aged	O
for	O
10	O
days	O
and	O
mated	O
with	O
3-day	O
-	O
old	O
unmated	O
males	O
(	O
Once10	O
)	O
;	O
(	O
iii	O
)	O
aged	O
for	O
3	O
days	O
,	O
mated	O
first	O
with	O
3-day	O
-	O
old	O
unmated	O
males	O
,	O
held	O
for	O
7	O
days	O
and	O
mated	O
again	O
with	O
3-day	O
-	O
old	O
unmated	O
males	O
(	O
Twice3&10	O
)	O
.	O

In	O
all	O
cases	O
male	O
and	O
female	O
pairs	O
were	O
observed	O
to	O
record	O
mating	O
initiation	O
and	O
termination	O
.	O

Analysis	O
Following	O
mating	O
,	O
females	O
were	O
aspirated	O
into	O
fresh	O
vials	O
,	O
held	O
singly	O
and	O
allowed	O
to	O
lay	O
eggs	O
for	O
6	O
hrs	O
,	O
then	O
transferred	O
daily	O
(	O
each	O
24	O
hrs	O
)	O
to	O
fresh	O
vials	O
.	O

The	O
number	O
of	O
eggs	O
laid	O
and	O
the	O
number	O
of	O
eclosed	O
adults	O
were	O
counted	O
from	O
vials	O
created	O
at	O
6	O
hrs	O
,	O
1	O
,	O
2	O
and	O
3	O
days	O
post	O
-	O
mating	O
.	O

To	O
ascertain	O
the	O
baseline	O
of	O
female	O
egg	O
-	O
laying	O
,	O
we	O
also	O
included	O
in	O
our	O
experiment	O
unmated	O
females	O
that	O
were	O
kept	O
in	O
the	O
same	O
conditions	O
as	O
mated	O
females	O
.	O

The	O
number	O
of	O
eggs	O
laid	O
by	O
unmated	O
females	O
was	O
counted	O
from	O
vials	O
created	O
at	O
6	O
hrs	O
,	O
1	O
,	O
2	O
and	O
3	O
days	O
after	O
placing	O
the	O
females	O
in	O
the	O
holding	O
vials	O
.	O

In	O
addition	O
,	O
we	O
also	O
recorded	O
the	O
pattern	O
of	O
unmated	O
female	O
egg	O
-	O
laying	O
for	O
10	O
days	O
.	O

To	O
determine	O
the	O
effect	O
of	O
different	O
mating	O
regimes	O
on	O
female	O
reproductive	O
output	O
(	O
i.e.	O
fecundity	O
and	O
fertility	O
)	O
,	O
we	O
used	O
One	O
-	O
way	O
ANOVA	O
(	O
SPSS	O
15.0	O
)	O
.	O

Abbreviations	O

Nrg	O
:	O
Neuroglian	O
;	O
Cora	O
:	O
Coracle	O
;	O

Spec	O
:	O
α-	O
and	O
β	O
-	O
Spectrin	O
;	O
SJ	O
:	O
septate	O
junction	O
;	O

SSJ	O
:	O
smooth	O
septate	O
junction	O
;	O
PSJ	O
:	O
pleated	O
septate	O
junction	O
;	O
ZA	O
:	O
zonal	O
adherens	O
junction	O
;	O
AJ	O
:	O
adherens	O
junction	O
;	O
AECM	O
:	O
apical	O
extracellular	O
matrix	O
;	O
ECM	O
:	O
extracellular	O
matrix	O
;	O
HAJ	O
:	O
hemi	O
-	O
adherens	O
junction	O
;	O
SAJ	O
:	O
spot	O
adherens	O
junction	O
;	O
OA	O
:	O
Octopamine	O
;	O
Hts	O
:	O
Hu	O
-	O
li	O
tai	O
shao	O
;	O
ATP	O
α	O
:	O
Na+	O
pump	O
α	O
subunit	O
;	O
Mlp84B	O
:	O
Muscle	O
LIM	O
protein	O
at	O
84B	O
;	O
DLG	O
:	O
Disc	O
Large	O
;	O
HRP	O
:	O
horseradish	B
peroxidas	O
;	O
UM	O
:	O
unmated	O
;	O
M	O
:	O
mated	O
.	O

Authors	O
'	O
contributions	O
AK	O
and	O
PKR	O
contributed	O
equally	O
to	O
this	O
manuscript	O
.	O

AK	O
,	O
PKR	O
and	O
YH	O
conceived	O
and	O
designed	O
the	O
project	O
and	O
analyzed	O
the	O
data	O
.	O

AK	O
performed	O
the	O
confocal	O
,	O
Western	O
blots	O
and	O
fertility	O
assays	O
.	O

PKR	O
and	O
AK	O
performed	O
the	O
light	O
microscopy	O
.	O

PKR	O
conducted	O
the	O
electron	O
microscopy	O
.	O

AK	O
,	O
PKR	O
and	O
YH	O
wrote	O
the	O
manuscript	O
.	O

RRH	O
contributed	O
to	O
design	O
of	O
the	O
study	O
and	O
revision	O
of	O
the	O
manuscript	O
.	O

All	O
authors	O
participated	O
in	O
the	O
discussion	O
and	O
approval	O
of	O
the	O
final	O
manuscript	O
.	O

Supplementary	O
Material	O

Identification	O
of	O
recruitment	O
and	O
retention	O
strategies	O
for	O
rehabilitation	O
professionals	O
in	O
Ontario	O
,	O
Canada	O
:	O
results	O
from	O
expert	O
panels	O

Abstract	O
Background	O
Demand	O
for	O
rehabilitation	O
services	O
is	O
expected	O
to	O
increase	O
due	O
to	O
factors	O
such	O
as	O
an	O
aging	O
population	O
,	O
workforce	O
pressures	O
,	O
rise	O
in	O
chronic	O
and	O
complex	O
multi	O
-	O
system	O
disorders	O
,	O
advances	O
in	O
technology	O
,	O
and	O
changes	O
in	O
interprofessional	O
health	O
service	O
delivery	O
models	O
.	O

However	O
,	O
health	O
human	B
resource	O
(	O
HHR	O
)	O
strategies	O
for	O
Canadian	O
rehabilitation	O
professionals	O
are	O
lagging	O
behind	O
other	O
professional	O
groups	O
such	O
as	O
physicians	O
and	O
nurses	O
.	O

The	O
objectives	O
of	O
this	O
study	O
were	O
:	O
1	O
)	O
to	O
identify	O
recruitment	O
and	O
retention	O
strategies	O
of	O
rehabilitation	O
professionals	O
including	O
occupational	O
therapists	O
,	O
physical	O
therapists	O
and	O
speech	O
language	O
pathologists	O
from	O
the	O
literature	O
;	O
and	O
2	O
)	O
to	O
investigate	O
both	O
the	O
importance	O
and	O
feasibility	O
of	O
the	O
identified	O
strategies	O
using	O
expert	O
panels	O
amongst	O
HHR	O
and	O
education	O
experts	O
.	O

Methods	O
A	O
review	O
of	O
the	O
literature	O
was	O
conducted	O
to	O
identify	O
recruitment	O
and	O
retention	O
strategies	O
for	O
rehabilitation	O
professionals	O
.	O

Two	O
expert	O
panels	O
,	O
one	O
on	O
Recruitment	O
and	O
Retention	O
and	O
the	O
other	O
on	O
Education	O
were	O
convened	O
to	O
determine	O
the	O
importance	O
and	O
feasibility	O
of	O
the	O
identified	O
strategies	O
.	O

A	O
modified	O
-	O
delphi	O
process	O
was	O
used	O
to	O
gain	O
consensus	O
and	O
to	O
rate	O
the	O
identified	O
strategies	O
along	O
these	O
two	O
dimensions	O
.	O

Results	O
A	O
total	O
of	O
34	O
strategies	O
were	O
identified	O
by	O
the	O
Recruitment	O
and	O
Retention	O
and	O
Education	O
expert	O
panels	O
as	O
being	O
important	O
and	O
feasible	O
for	O
the	O
development	O
of	O
a	O
HHR	O
plan	O
for	O
recruitment	O
and	O
retention	O
of	O
rehabilitation	O
professionals	O
.	O

Seven	O
were	O
categorized	O
under	O
the	O
Quality	O
of	O
Worklife	O
and	O
Work	O
Environment	O
theme	O
,	O
another	O
seven	O
in	O
Financial	O
Incentives	O
and	O
Marketing	O
,	O
two	O
in	O
Workload	O
and	O
Skill	O
Mix	O
,	O
thirteen	O
in	O
Professional	O
Development	O
and	O
five	O
in	O
Education	O
and	O
Training	O
.	O

Conclusion	O
Based	O
on	O
the	O
results	O
from	O
the	O
expert	O
panels	O
,	O
the	O
three	O
major	O
areas	O
of	O
focus	O
for	O
HHR	O
planning	O
in	O
the	O
rehabilitation	O
sector	O
should	O
include	O
strategies	O
addressing	O
Quality	O
of	O
Worklife	O
and	O
Work	O
Environment	O
,	O
Financial	O
Incentives	O
and	O
Marketing	O
and	O
Professional	O
Development	O
.	O

Background	O
Demand	O
for	O
rehabilitation	O
services	O
is	O
expected	O
to	O
increase	O
within	O
the	O
next	O
decade	O
primarily	O
due	O
to	O
factors	O
such	O
as	O
an	O
aging	O
population	O
,	O
workforce	O
pressures	O
,	O
rise	O
in	O
chronic	O
and	O
complex	O
multi	O
-	O
system	O
disorders	O
,	O
advances	O
in	O
technology	O
,	O
and	O
changes	O
in	O
health	O
service	O
delivery	O
models	O
[	O
1	O
-	O
4	O
]	O
.	O

In	O
Canada	O
,	O
rehabilitation	O
personnel	O
constitute	O
the	O
third	O
largest	O
health	O
professional	O
group	O
after	O
nurses	O
and	O
physicians	O
.	O

Despite	O
the	O
size	O
of	O
this	O
workforce	O
,	O
studies	O
have	O
consistently	O
reported	O
ongoing	O
shortages	O
of	O
physiotherapists	O
(	O
PTs	O
)	O
,	O
occupational	O
therapists	O
(	O
OTs	O
)	O
and	O
speech	O
-	O
language	O
pathologists	O
(	O
SLPs	O
)	O
across	O
all	O
jurisdictions	O
[	O
5	O
-	O
7	O
]	O
.	O

Similarly	O
,	O
recruitment	O
and	O
retention	O
of	O
rehabilitation	O
professionals	O
has	O
been	O
considered	O
a	O
challenge	O
internationally	O
,	O
nationally	O
and	O
provincially	O
.	O

At	O
the	O
international	O
level	O
,	O
the	O
literature	O
reports	O
recruitment	O
and	O
retention	O
difficulties	O
of	O
rehabilitation	O
therapists	O
in	O
countries	O
such	O
as	O
Australia	O
,	O
New	O
Zealand	O
,	O
United	O
Kingdom	O
and	O
the	O
United	O
States	O
[	O
8	O
-	O
13	O
]	O
.	O

Provinces	O
across	O
Canada	O
face	O
similar	O
issues	O
;	O
with	O
Ontario	O
projected	O
to	O
face	O
the	O
most	O
difficulty	O
due	O
to	O
its	O
population	O
growth	O
rate	O
[	O
14	O
]	O
.	O

Based	O
on	O
the	O
Canadian	O
Institute	O
for	O
Health	O
Information	O
's	O
Health	O
Personnel	O
Trends	O
in	O
Canada	O
from	O
1993	O
to	O
2002	O
report	O
,	O
numerous	O
factors	O
have	O
been	O
suggested	O
to	O
influence	O
demand	O
for	O
physiotherapy	O
and	O
occupational	O
therapy	O
services	O
.	O

Factors	O
that	O
may	O
influence	O
increase	O
demand	O
for	O
physiotherapy	O
include	O
:	O
shift	O
in	O
health	O
service	O
delivery	O
models	O
from	O
hospital	O
to	O
community	O
care	O
;	O
earlier	O
patient	O
discharge	O
;	O
increased	O
expectations	O
from	O
aging	O
Canadians	O
concerning	O
more	O
active	O
lifestyles	O
;	O
growing	O
private	O
practice	O
sector	O
and	O
continued	O
shortages	O
for	O
PTs	O
in	O
both	O
private	O
and	O
public	O
sectors	O
in	O
rural	O
,	O
remote	O
and	O
urban	O
settings	O
across	O
Canada	O
[	O
2	O
]	O
.	O

In	O
1993	O
,	O
an	O
Ontario	O
study	O
stated	O
that	O
in	O
order	O
to	O
meet	O
demands	O
of	O
changing	O
health	O
care	O
policy	O
,	O
medical	O
technology	O
and	O
demographic	O
changes	O
in	O
the	O
population	O
,	O
the	O
PT	O
profession	O
required	O
an	O
annual	O
growth	O
rate	O
of	O
4.4	O
%	O
until	O
the	O
year	O
2000	O
[	O
5	O
]	O
.	O

However	O
,	O
the	O
national	O
health	O
personnel	O
databases	O
revealed	O
that	O
the	O
actual	O
average	O
annual	O
growth	O
rate	O
of	O
active	O
PTs	O
in	O
Canada	O
from	O
1995	O
to	O
2004	O
was	O
only	O
2.5	O
%	O
,	O
approximately	O
half	O
of	O
the	O
projected	O
requirement	O
suggested	O
to	O
meet	O
demand	O
[	O
15	O
]	O
.	O

Similarly	O
,	O
in	O
Ontario	O
in	O
the	O
early	O
1990s	O
an	O
increase	O
in	O
demand	O
for	O
OTs	O
was	O
projected	O
because	O
of	O
the	O
reported	O
shortage	O
in	O
OTs	O
and	O
high	O
attrition	O
rate	O
[	O
16	O
]	O
.	O

The	O
shortage	O
of	O
OTs	O
was	O
explained	O
by	O
another	O
Ontario	O
study	O
to	O
be	O
the	O
result	O
of	O
the	O
changing	O
philosophies	O
of	O
care	O
and	O
management	O
for	O
the	O
disabled	O
,	O
and	O
a	O
clearer	O
understanding	O
of	O
the	O
role	O
of	O
OT	O
in	O
the	O
physical	O
and	O
mental	O
well	O
-	O
being	O
of	O
the	O
disabled	O
[	O
17	O
]	O
.	O

In	O
terms	O
of	O
actual	O
shortages	O
,	O
some	O
authors	O
have	O
reported	O
ongoing	O
vacancies	O
and	O
recruitment	O
difficulties	O
for	O
OTs	O
[	O
11,18	O
]	O
while	O
others	O
have	O
reported	O
an	O
increase	O
in	O
demand	O
for	O
both	O
PTs	O
[	O
19	O
]	O
and	O
OTs	O
[	O
20	O
]	O
.	O

Speech	O
language	O
pathology	O
is	O
facing	O
similar	O
service	O
demands	O
.	O

A	O
report	O
released	O
in	O
March	O
2003	O
by	O
the	O
College	O
of	O
Audiologists	O
and	O
Speech	O
-	O
Language	O
Pathologists	O
of	O
Ontario	O
(	O
CASLPO	O
)	O
concluded	O
that	O
based	O
on	O
prevalence	O
rates	O
for	O
Ontario	O
residents	O
with	O
speech	O
,	O
language	O
and	O
related	O
disorders	O
,	O
the	O
demand	O
for	O
service	O
would	O
increase	O
by	O
13	O
%	O
while	O
the	O
number	O
of	O
SLPs	O
would	O
decrease	O
by	O
4	O
%	O
resulting	O
in	O
an	O
overall	O
reduction	O
in	O
service	O
of	O
15	O
%	O
[	O
21	O
]	O
.	O

The	O
American	O
Speech	O
-	O
Language	O
-	O
Hearing	O
Association	O
(	O
ASHA	O
)	O
has	O
been	O
tracking	O
SLP	O
vacancies	O
.	O

In	O
their	O
2005	O
ASHA	O
Speech	O
-	O
Language	O
Pathology	O
Health	O
Care	O
survey	O
,	O
48	O
%	O
of	O
respondents	O
indicated	O
that	O
they	O
had	O
funded	O
unfilled	O
positions	O
for	O
SLPS	O
in	O
their	O
agency	O
[	O
22	O
]	O
.	O

The	O
same	O
survey	O
also	O
reported	O
that	O
65	O
%	O
of	O
respondents	O
in	O
home	O
care	O
indicated	O
that	O
job	O
openings	O
were	O
more	O
numerous	O
than	O
job	O
seekers	O
in	O
their	O
geographic	O
area	O
.	O

While	O
labour	O
market	O
demand	O
and	O
supply	O
are	O
influential	O
factors	O
on	O
recruitment	O
and	O
retention	O
decisions	O
,	O
the	O
development	O
of	O
strategies	O
requires	O
an	O
understanding	O
of	O
conceptual	O
frameworks	O
or	O
theories	O
to	O
categorise	O
and	O
explain	O
how	O
other	O
underlying	O
factors	O
impact	O
health	O
worker	O
's	O
mobility	O
.	O

For	O
example	O
,	O
Lehmann	O
et	O
al.	O
's	O
model	O
described	O
that	O
health	O
worker	O
's	O
decisions	O
to	O
accept	O
and	O
stay	O
in	O
remote	O
areas	O
in	O
the	O
public	O
sector	O
depends	O
on	O
two	O
interrelated	O
aspects	O
:	O
the	O
impact	O
of	O
the	O
different	O
environments	O
(	O
i.e.	O
individual	O
,	O
local	O
,	O
work	O
,	O
national	O
and	O
international	O
)	O
and	O
the	O
location	O
of	O
decision	O
-	O
makers	O
(	O
i.e.	O
local	O
government	O
,	O
Ministry	O
of	O
Health	O
,	O
HR	O
directorate	O
,	O
public	O
service	O
and	O
other	O
ministries	O
)	O
[	O
23	O
]	O
.	O

Behavioural	O
and	O
social	O
science	O
theories	O
,	O
such	O
as	O
those	O
explained	O
by	O
Tett	O
and	O
Meyer	O
,	O
found	O
that	O
job	O
satisfaction	O
and	O
organizational	O
commitment	O
each	O
contribute	O
independently	O
to	O
the	O
prediction	O
of	O
the	O
intention	O
to	O
resign	O
(	O
turnover	O
)	O
,	O
however	O
job	O
satisfaction	O
was	O
a	O
stronger	O
predictor	O
than	O
organizational	O
commitment	O
[	O
24	O
]	O
.	O

Based	O
on	O
this	O
notion	O
,	O
considerable	O
research	O
has	O
been	O
devoted	O
to	O
identifying	O
factors	O
that	O
affect	O
job	O
satisfaction	O
among	O
rehabilitation	O
professionals	O
.	O

While	O
there	O
is	O
no	O
single	O
,	O
agreed	O
upon	O
model	O
of	O
job	O
satisfaction	O
,	O
a	O
variety	O
of	O
theoretical	O
models	O
have	O
been	O
studied	O
to	O
explain	O
concepts	O
and	O
relationships	O
associated	O
with	O
overall	O
job	O
satisfaction	O
.	O

The	O
two	O
most	O
commonly	O
used	O
theories	O
of	O
job	O
satisfaction	O
for	O
rehabilitation	O
professionals	O
are	O
the	O
Herzberg	O
's	O
Motivation	O
-	O
Hygiene	O
Theory	O
[	O
25	O
]	O
and	O
Mottaz	O
's	O
concepts	O
of	O
work	O
values	O
and	O
work	O
rewards	O
[	O
26	O
]	O
.	O

A	O
number	O
of	O
rehabilitation	O
studies	O
have	O
used	O
the	O
Herzberg	O
's	O
Motivation	O
-	O
Hygiene	O
Theory	O
,	O
also	O
known	O
as	O
the	O
two	O
-	O
factor	O
theory	O
of	O
motivation	O
to	O
explain	O
associations	O
between	O
motivation	O
,	O
job	O
satisfaction	O
and	O
retention	O
factors	O
among	O
OTs	O
,	O
PTs	O
and	O
SLPs	O
[	O
27	O
-	O
31	O
]	O
.	O

Frederick	O
Herzberg	O
et	O
al.	O
explained	O
that	O
there	O
were	O
two	O
independent	O
incidents	O
occurring	O
at	O
peoples	O
'	O
jobs	O
:	O
one	O
that	O
made	O
them	O
feel	O
good	O
or	O
satisfied	O
,	O
and	O
another	O
that	O
made	O
them	O
feel	O
bad	O
or	O
dissatisfied	O
at	O
work	O
[	O
25	O
]	O
.	O

Intrinsic	O
factors	O
that	O
motivate	O
people	O
such	O
as	O
achievement	O
,	O
recognition	O
,	O
work	O
itself	O
,	O
responsibility	O
,	O
advancement	O
and	O
personal	O
growth	O
were	O
called	O
the	O
""""	O
motivators	O
""""	O
which	O
lead	O
to	O
feelings	O
of	O
satisfaction	O
.	O

Extrinsic	O
factors	O
such	O
as	O
work	O
conditions	O
,	O
company	O
policies	O
,	O
supervision	O
,	O
interpersonal	O
work	O
relations	O
,	O
salary	O
and	O
job	O
security	O
,	O
known	O
as	O
""""	O
hygiene	O
""""	O
factors	O
,	O
were	O
claimed	O
to	O
prevent	O
dissatisfaction	O
.	O

""""	O
Motivators	O
""""	O
directly	O
affect	O
a	O
person	O
's	O
motivational	O
drive	O
to	O
do	O
a	O
good	O
job	O
,	O
therefore	O
they	O
are	O
believed	O
to	O
be	O
more	O
important	O
than	O
hygiene	O
factors	O
.	O

Mottaz	O
on	O
the	O
other	O
hand	O
,	O
accounted	O
for	O
individual	O
differences	O
in	O
job	O
satisfaction	O
among	O
workers	O
and	O
based	O
his	O
study	O
on	O
two	O
dimensions	O
:	O
""""	O
work	O
rewards	O
""""	O
and	O
""""	O
work	O
"values"""	O
[	O
26	O
]	O
.	O
""""	O
Work	O
rewards	O
""""	O
are	O
perceived	O
characteristics	O
of	O
the	O
job	O
and	O
have	O
three	O
conceptual	O
clusters	O
which	O
include	O
task	O
,	O
social	O
and	O
organizational	O
rewards	O
[	O
26	O
]	O
.	O

Mottaz	O
describes	O
""""	O
task	O
rewards	O
""""	O
(	O
intrinsic	O
)	O
as	O
having	O
five	O
independent	O
characteristics	O
including	O
:	O
skill	O
variety	O
,	O
task	O
identity	O
,	O
task	O
significance	O
,	O
autonomy	O
and	O
feedback	O
.	O

Examples	O
include	O
interesting	O
and	O
challenging	O
work	O
,	O
self	O
-	O
direction	O
and	O
responsibility	O
,	O
creativity	O
,	O
opportunities	O
to	O
use	O
one	O
's	O
skills	O
and	O
feedback	O
.	O

In	O
the	O
same	O
study	O
,	O
Mottaz	O
stated	O
that	O
""""	O
social	O
rewards	O
""""	O
(	O
extrinsic	O
)	O
are	O
derived	O
from	O
the	O
interpersonal	O
relationships	O
established	O
with	O
others	O
at	O
work	O
.	O

Having	O
supportive	O
colleagues	O
and	O
supervisors	O
is	O
an	O
example	O
of	O
this	O
dimension	O
.	O

Lastly	O
,	O
""""	O
organizational	O
rewards	O
""""	O
(	O
extrinsic	O
)	O
are	O
tangible	O
rewards	O
that	O
are	O
provided	O
by	O
the	O
employer	O
/	O
organization	O
to	O
facilitate	O
performance	O
.	O

Such	O
factors	O
include	O
working	O
conditions	O
,	O
pay	O
and	O
fringe	O
benefits	O
,	O
career	O
advancement	O
and	O
security	O
.	O

The	O
second	O
dimension	O
of	O
job	O
satisfaction	O
is	O
based	O
on	O
""""	O
work	O
values	O
""""	O
,	O
which	O
is	O
the	O
importance	O
that	O
individuals	O
place	O
on	O
their	O
work	O
rewards	O
[	O
26	O
]	O
.	O

For	O
example	O
,	O
some	O
rehabilitation	O
therapists	O
may	O
value	O
extrinsic	O
rewards	O
such	O
as	O
pay	O
and	O
benefits	O
as	O
more	O
important	O
than	O
intrinsic	O
factors	O
like	O
clinical	O
autonomy	O
and	O
challenging	O
work	O
.	O

Although	O
the	O
Herzberg	O
and	O
Mottaz	O
conceptual	O
frameworks	O
are	O
organized	O
differently	O
,	O
their	O
job	O
satisfaction	O
variables	O
are	O
very	O
similar	O
(	O
i.e.	O
work	O
conditions	O
,	O
pay	O
,	O
interpersonal	O
relationships	O
,	O
etc	O
.	O
)	O

and	O
they	O
both	O
classify	O
these	O
factors	O
as	O
having	O
intrinsic	O
or	O
extrinsic	O
elements	O
.	O

Despite	O
the	O
growing	O
body	O
of	O
literature	O
on	O
recruitment	O
and	O
retention	O
factors	O
in	O
various	O
industries	O
,	O
there	O
is	O
a	O
minimal	O
amount	O
of	O
research	O
studying	O
these	O
factors	O
specifically	O
among	O
rehabilitation	O
professionals	O
.	O

One	O
published	O
study	O
however	O
,	O
did	O
look	O
at	O
extrinsic	O
and	O
intrinsic	O
job	O
satisfaction	O
factors	O
on	O
recruitment	O
and	O
retention	O
of	O
rehabilitation	O
professionals	O
(	O
OTs	O
,	O
PTs	O
and	O
SLPs	O
)	O
[	O
32	O
]	O
.	O

Results	O
from	O
this	O
study	O
showed	O
that	O
intrinsic	O
factors	O
such	O
as	O
professional	O
growth	O
and	O
having	O
a	O
work	O
environment	O
in	O
line	O
with	O
personal	O
values	O
are	O
more	O
significant	O
in	O
predicting	O
career	O
satisfaction	O
than	O
extrinsic	O
factors	O
such	O
as	O
pay	O
and	O
continuing	O
education	O
.	O

These	O
same	O
intrinsic	O
factors	O
are	O
also	O
significant	O
in	O
predicting	O
retention	O
in	O
rehabilitation	O
professionals	O
.	O

Another	O
study	O
looking	O
at	O
recruitment	O
and	O
retention	O
of	O
allied	O
health	O
professionals	O
in	O
the	O
rural	O
areas	O
in	O
New	O
South	O
Wales	O
identified	O
that	O
the	O
main	O
reasons	O
why	O
people	O
liked	O
working	O
in	O
rural	O
areas	O
were	O
because	O
of	O
the	O
attractive	O
environment	O
and	O
helpful	O
team	O
members	O
[	O
33	O
]	O
.	O

However	O
82	O
%	O
of	O
employees	O
reported	O
that	O
having	O
their	O
partner	O
move	O
away	O
was	O
the	O
number	O
one	O
reason	O
for	O
leaving	O
a	O
rural	O
job	O
.	O

A	O
similar	O
study	O
was	O
conducted	O
among	O
OTs	O
and	O
PTs	O
in	O
Northwestern	O
Ontario	O
[	O
34	O
]	O
.	O

Findings	O
from	O
this	O
study	O
indicated	O
that	O
factors	O
contributing	O
to	O
initial	O
decision	O
on	O
location	O
of	O
practice	O
include	O
availability	O
of	O
leisure	O
/	O
recreation	O
activities	O
,	O
proximity	O
of	O
family	O
origin	O
and	O
influences	O
of	O
spouse	O
/	O
partners	O
.	O

Study	O
results	O
also	O
showed	O
that	O
the	O
main	O
reasons	O
therapists	O
left	O
their	O
job	O
were	O
to	O
be	O
closer	O
to	O
their	O
family	O
,	O
lack	O
of	O
job	O
opportunity	O
and	O
spousal	O
influence	O
.	O

Solely	O
understanding	O
factors	O
that	O
influence	O
recruitment	O
and	O
retention	O
decisions	O
is	O
not	O
sufficient	O
in	O
the	O
development	O
of	O
a	O
HHR	O
plan	O
for	O
rehabilitation	O
professionals	O
.	O

In	O
order	O
for	O
the	O
plan	O
to	O
be	O
effective	O
and	O
sustainable	O
in	O
addressing	O
these	O
factors	O
,	O
the	O
most	O
important	O
and	O
feasible	O
workforce	O
strategies	O
needs	O
to	O
be	O
identified	O
.	O

There	O
have	O
been	O
a	O
number	O
of	O
reports	O
on	O
health	O
human	B
resources	O
(	O
HHR	O
)	O
planning	O
,	O
recruitment	O
and	O
retention	O
strategies	O
for	O
physicians	O
[	O
35,36	O
]	O
and	O
nurses	O
[	O
37	O
]	O
,	O
however	O
information	O
regarding	O
rehabilitation	O
professionals	O
is	O
lacking	O
.	O

Canadian	O
reports	O
indicate	O
that	O
the	O
main	O
reason	O
for	O
significant	O
gaps	O
in	O
this	O
field	O
is	O
the	O
absence	O
of	O
current	O
and	O
reliable	O
data	O
available	O
on	O
supply	O
,	O
demand	O
and	O
labour	O
force	O
participation	O
trends	O
for	O
rehabilitation	O
therapists	O
[	O
38	O
-	O
40	O
]	O
.	O

There	O
is	O
some	O
research	O
that	O
has	O
investigated	O
theoretical	O
models	O
of	O
job	O
satisfaction	O
on	O
recruitment	O
and	O
retention	O
[	O
28,32	O
]	O
;	O
however	O
few	O
studies	O
have	O
looked	O
at	O
how	O
these	O
models	O
have	O
been	O
implemented	O
.	O

Other	O
studies	O
have	O
examined	O
the	O
relationship	O
of	O
gender	O
,	O
workplace	O
setting	O
(	O
i.e.	O
hospital	O
,	O
ambulatory	O
,	O
rehabilitation	O
,	O
acute	O
and	O
long	O
-	O
term	O
care	O
)	O
and	O
geographical	O
location	O
(	O
i.e.	O
rural	O
or	O
urban	O
)	O
on	O
job	O
satisfaction	O
and	O
retention	O
among	O
rehabilitation	O
professionals	O
[	O
41	O
-	O
43	O
]	O
.	O

Furthermore	O
,	O
no	O
empirical	O
studies	O
have	O
examined	O
conceptual	O
frameworks	O
for	O
organizing	O
recruitment	O
and	O
retention	O
strategies	O
for	O
rehabilitation	O
therapists	O
.	O

To	O
address	O
this	O
gap	O
,	O
this	O
research	O
identified	O
recruitment	O
and	O
retention	O
strategies	O
from	O
the	O
literature	O
for	O
rehabilitation	O
professionals	O
and	O
determined	O
their	O
importance	O
and	O
feasibility	O
using	O
expert	O
panels	O
.	O

Methods	O
Phase	O
1	O
:	O
Literature	O
Review	O
Identification	O
of	O
recruitment	O
and	O
retention	O
strategies	O
A	O
review	O
of	O
the	O
literature	O
was	O
conducted	O
to	O
identify	O
recruitment	O
and	O
retention	O
strategies	O
for	O
rehabilitation	O
therapists	O
.	O

In	O
this	O
study	O
,	O
rehabilitation	O
professionals	O
were	O
defined	O
as	O
physical	O
therapists	O
(	O
PTs	O
)	O
,	O
occupational	O
therapists	O
(	O
OTs	O
)	O
and	O
speech	O
-	O
language	O
pathologists	O
(	O
SLPs	O
)	O
.	O

Both	O
published	O
and	O
non	O
-	O
empirical	O
literature	O
was	O
accessed	O
in	O
this	O
review	O
.	O

Keywords	O
used	O
to	O
search	O
for	O
relevant	O
published	O
studies	O
in	O
the	O
Consolidated	O
International	O
Nursing	O
and	O
Allied	O
Health	O
Sciences	O
Library	O
(	O
CINAHL	O
)	O
(	O
1982	O
to	O
2005	O
)	O
and	O
Medline	O
(	O
1996	O
to	O
2005	O
)	O
included	O
:	O
""""	O
health	O
human	B
resources	O
or	O
health	O
manpower	O
""""	O
,	O
""""	O
rehabilitation	O
or	O
rehabilitation	O
professionals	O
or	O
vocational	O
""""	O
,	O
""""	O
allied	O
health	O
professionals	O
or	O
personnel	O
""""	O
,	O
""""	O
recruitment	O
strategies	O
""""	O
,	O
""""	O
retention	O
strategies	O
""""	O
,	O
""""	O
physical	O
therapist	O
or	O
physiotherapist	O
""""	O
,	O
""""	O
occupational	O
therapy	O
or	O
occupational	O
therapist	O
""""	O
,	O
""""	O
speech	O
-	O
language	O
pathologist	O
or	O
speech	O
-	O
language	O
pathology	O
""""	O
.	O

Non	O
-	O
empirical	O
literature	O
searches	O
were	O
made	O
on	O
international	O
and	O
national	O
on	O
-	O
line	O
catalogues	O
and	O
publications	O
from	O
health	O
organizations	O
,	O
professional	O
associations	O
,	O
and	O
hospital	O
and	O
home	O
care	O
organizations	O
.	O

International	O
reports	O
were	O
limited	O
to	O
developed	O
countries	O
since	O
the	O
purpose	O
of	O
this	O
study	O
was	O
to	O
identify	O
strategies	O
appropriate	O
to	O
the	O
Ontario	O
setting	O
.	O

Organization	O
and	O
consolidation	O
of	O
strategies	O
There	O
was	O
a	O
paucity	O
of	O
peer	O
-	O
reviewed	O
studies	O
obtained	O
exploring	O
rehabilitation	O
HHR	O
strategies	O
,	O
therefore	O
the	O
majority	O
of	O
strategies	O
were	O
selected	O
from	O
grey	O
literature	O
reports	O
from	O
international	O
,	O
national	O
and	O
provincial	O
health	O
organizations	O
.	O

From	O
the	O
literature	O
review	O
,	O
107	O
potential	O
strategies	O
were	O
identified	O
according	O
to	O
their	O
relevance	O
to	O
HHR	O
issues	O
for	O
rehabilitation	O
in	O
Ontario	O
.	O

These	O
strategies	O
were	O
then	O
categorized	O
into	O
two	O
broad	O
groups	O
:	O
A	O
)	O
Recruitment	O
and	O
Retention	O
(	O
n	O
=	O
73	O
)	O
,	O
and	O
B	O
)	O
Education	O
(	O
n	O
=	O
34	O
)	O
.	O

The	O
majority	O
of	O
strategies	O
were	O
not	O
specific	O
to	O
rehabilitation	O
professionals	O
and	O
they	O
were	O
reviewed	O
by	O
a	O
group	O
of	O
three	O
individuals	O
collectively	O
(	O
rehabilitation	O
researcher	O
,	O
manager	O
,	O
and	O
clinician	O
)	O
for	O
duplication	O
,	O
clarity	O
,	O
action	O
focused	O
properties	O
and	O
appropriateness	O
to	O
the	O
Canadian	O
or	O
Ontario	O
setting	O
.	O

When	O
necessary	O
,	O
a	O
small	O
number	O
of	O
strategies	O
were	O
re	O
-	O
worded	O
to	O
be	O
relevant	O
to	O
a	O
rehabilitation	O
context	O
.	O

This	O
analysis	O
resulted	O
in	O
the	O
selection	O
of	O
40	O
Recruitment	O
and	O
Retention	O
and	O
24	O
Education	O
strategies	O
.	O

Only	O
14	O
recruitment	O
and	O
retention	O
and	O
six	O
education	O
strategies	O
were	O
obtained	O
from	O
peer	O
-	O
reviewed	O
articles	O
.	O

Since	O
the	O
majority	O
of	O
strategies	O
were	O
identified	O
from	O
the	O
grey	O
literature	O
,	O
it	O
was	O
not	O
surprising	O
that	O
there	O
was	O
no	O
apriori	O
peer	O
-	O
reviewed	O
conceptual	O
framework	O
that	O
reflected	O
the	O
breadth	O
of	O
the	O
strategies	O
obtained	O
from	O
the	O
literature	O
review	O
.	O

As	O
a	O
result	O
,	O
the	O
themes	O
used	O
by	O
the	O
Health	O
and	O
Community	O
Services	O
Human	B
Resources	O
Sector	O
Study	O
in	O
Newfoundland	O
and	O
Labrador	O
[	O
44	O
]	O
formed	O
the	O
basis	O
for	O
the	O
organizational	O
framework	O
for	O
this	O
study	O
since	O
they	O
aligned	O
with	O
the	O
identified	O
strategies	O
.	O

Each	O
group	O
was	O
further	O
categorized	O
into	O
the	O
five	O
themes	O
(	O
three	O
for	O
Recruitment	O
and	O
Retention	O
and	O
two	O
for	O
Education	O
)	O
.	O

The	O
three	O
Recruitment	O
and	O
Retention	O
strategy	O
themes	O
were	O
:	O
(	O
1	O
)	O
Quality	O
of	O
Worklife	O
and	O
Work	O
Environment	O
[	O
n	O
=	O
19	O
]	O
;	O
(	O
2	O
)	O
Workload	O
and	O
Skill	O
Mix	O
[	O
n	O
=	O
6	O
]	O
;	O
and	O
(	O
3	O
)	O
Financial	O
Incentives	O
and	O
Marketing	O
[	O
n	O
=	O
15	O
]	O
.	O

The	O
two	O
Education	O
strategy	O
themes	O
were	O
:	O
(	O
1	O
)	O
Education	O
and	O
Training	O
[	O
n	O
=	O
11	O
]	O
and	O
(	O
2	O
)	O
Professional	O
Development	O
(	O
n	O
=	O
13	O
)	O
.	O

Phase	O
2	O
:	O
Expert	O
Panel	O
Participant	O
Selection	O
Once	O
this	O
study	O
was	O
approved	O
by	O
the	O
Research	O
Ethics	O
Board	O
at	O
the	O
University	O
of	O
Toronto	O
,	O
key	O
informants	O
who	O
participated	O
in	O
a	O
previous	O
study	O
regarding	O
rehabilitation	O
supply	O
and	O
demand	O
at	O
the	O
University	O
of	O
Toronto	O
[	O
21	O
]	O
were	O
asked	O
to	O
nominate	O
potential	O
participants	O
for	O
the	O
panels	O
.	O

The	O
selection	O
criteria	O
considered	O
were	O
acknowledged	O
leadership	O
in	O
the	O
panel	O
member	O
's	O
specialty	O
,	O
expertise	O
in	O
recruitment	O
and	O
retention	O
or	O
education	O
and	O
training	O
of	O
rehabilitation	O
professionals	O
.	O

Absence	O
of	O
conflicts	O
of	O
interest	O
,	O
geographic	O
diversity	O
,	O
and	O
diversity	O
of	O
practice	O
setting	O
were	O
also	O
considered	O
.	O

After	O
purposefully	O
selecting	O
the	O
initial	O
list	O
of	O
candidates	O
from	O
among	O
the	O
nominations	O
,	O
each	O
nominee	O
was	O
contacted	O
to	O
establish	O
their	O
interest	O
and	O
availability	O
.	O

Those	O
who	O
expressed	O
an	O
interest	O
in	O
participating	O
were	O
asked	O
to	O
send	O
their	O
curriculum	O
vitae	O
to	O
help	O
the	O
research	O
team	O
evaluate	O
their	O
contributions	O
to	O
their	O
field	O
of	O
expertise	O
.	O

Once	O
candidate	O
panelists	O
were	O
selected	O
,	O
each	O
received	O
a	O
letter	O
explaining	O
the	O
expert	O
panel	O
process	O
and	O
consent	O
form	O
.	O

Two	O
separate	O
panels	O
were	O
constructed	O
:	O
one	O
for	O
Recruitment	O
and	O
Retention	O
(	O
n	O
=	O
8)	O
and	O
the	O
other	O
for	O
Education	O
(	O
n	O
=	O
9	O
)	O
(	O
Table	O
1	O
)	O
.	O

The	O
size	O
of	O
the	O
panel	O
was	O
large	O
enough	O
to	O
permit	O
diversity	O
of	O
representation	O
while	O
still	O
being	O
small	O
enough	O
to	O
allow	O
all	O
participants	O
to	O
be	O
involved	O
in	O
the	O
group	O
discussion	O
[	O
45	O
]	O
.	O

Expert	O
Panel	O
Process	O
:	O

Round	O
1	O
Survey	O
A	O
modified	O
-	O
delphi	O
technique	O
was	O
then	O
used	O
for	O
the	O
expert	O
panel	O
process	O
,	O
[	O
46,47	O
]	O
based	O
on	O
the	O
RAND	O
/	O
UCLA	O
appropriateness	O
method	O
[	O
45	O
]	O
.	O

In	O
round	O
1	O
,	O
members	O
of	O
the	O
Recruitment	O
and	O
Retention	O
panel	O
were	O
sent	O
an	O
electronic	O
survey	O
containing	O
the	O
40	O
strategies	O
identified	O
from	O
the	O
literature	O
review	O
and	O
the	O
Education	O
panelists	O
were	O
also	O
sent	O
an	O
electronic	O
survey	O
with	O
24	O
strategies	O
.	O

For	O
Round	O
1	O
,	O
each	O
panel	O
was	O
asked	O
to	O
rate	O
the	O
strategies	O
using	O
a	O
nine	O
-	O
point	O
Likert	O
-	O
type	O
rating	O
scale	O
that	O
ranged	O
from	O
""""	O
none	O
""""	O
(	O
1	O
)	O
to	O
""""	O
maximum	O
""""	O
(	O
9	O
)	O
,	O
on	O
two	O
key	O
dimensions	O
:	O
Feasibility	O
and	O
Importance	O
.	O

Feasibility	O
was	O
defined	O
as	O
the	O
practicality	O
and	O
cost	O
implications	O
of	O
the	O
strategy	O
and	O
was	O
rated	O
from	O
the	O
respondents	O
'	O
perspective	O
.	O

Importance	O
was	O
defined	O
as	O
how	O
valuable	O
,	O
appropriate	O
and	O
useful	O
the	O
strategy	O
could	O
be	O
for	O
rehabilitation	O
HHR	O
planning	O
in	O
Ontario	O
.	O

At	O
the	O
end	O
of	O
the	O
survey	O
,	O
panelists	O
were	O
given	O
the	O
opportunity	O
to	O
suggest	O
additional	O
strategies	O
that	O
they	O
felt	O
were	O
appropriate	O
to	O
consider	O
.	O

Once	O
completed	O
,	O
panelists	O
were	O
asked	O
to	O
return	O
the	O
survey	O
to	O
the	O
study	O
office	O
by	O
email	O
or	O
fax	O
prior	O
to	O
the	O
expert	O
panel	O
meeting	O
in	O
Round	O
2	O
.	O

Data	O
from	O
each	O
questionnaire	O
were	O
entered	O
into	O
a	O
spreadsheet	O
and	O
tabulated	O
.	O

Descriptive	O
statistics	O
were	O
calculated	O
for	O
each	O
strategy	O
using	O
frequency	O
distributions	O
and	O
proportional	O
percentages	O
of	O
respondents	O
.	O

Importance	O
and	O
feasibility	O
rankings	O
were	O
based	O
on	O
the	O
percentage	O
of	O
expert	O
panelists	O
'	O
low	O
,	O
medium	O
and	O
high	O
ratings	O
.	O

Expert	O
Panel	O
Process	O
Round	O
2	O
:	O

Expert	O
Panel	O
one	O
-	O
day	O
meeting	O
After	O
the	O
independent	O
completion	O
of	O
the	O
survey	O
,	O
each	O
panel	O
was	O
convened	O
separately	O
for	O
a	O
one	O
-	O
day	O
meeting	O
for	O
final	O
discussions	O
,	O
debates	O
and	O
consensus	O
voting	O
to	O
decide	O
on	O
strategies	O
[	O
48	O
]	O
.	O

A	O
strategy	O
that	O
had	O
been	O
scored	O
7	O
,	O
8	O
or	O
9	O
for	O
both	O
feasibility	O
and	O
importance	O
by	O
two	O
-	O
thirds	O
of	O
the	O
panel	O
was	O
considered	O
a	O
high	O
rating	O
.	O

Strategies	O
that	O
had	O
a	O
combination	O
of	O
medium	O
and	O
high	O
scores	O
between	O
4	O
and	O
9	O
in	O
either	O
of	O
the	O
two	O
dimensions	O
were	O
considered	O
medium	O
rated	O
strategies	O
,	O
while	O
low	O
rated	O
strategies	O
had	O
scores	O
between	O
1	O
and	O
3	O
for	O
both	O
dimensions	O
.	O

On	O
the	O
day	O
of	O
the	O
meeting	O
,	O
the	O
panelists	O
were	O
given	O
a	O
copy	O
of	O
the	O
aggregated	O
survey	O
results	O
indicating	O
the	O
ratings	O
of	O
all	O
of	O
the	O
strategies	O
.	O

High	O
and	O
low	O
rated	O
strategies	O
were	O
not	O
discussed	O
as	O
there	O
was	O
already	O
consensus	O
,	O
whereas	O
all	O
medium	O
rated	O
strategies	O
were	O
subject	O
to	O
discussion	O
.	O

Using	O
a	O
nominal	O
group	O
process	O
[	O
47	O
]	O
,	O
each	O
strategy	O
was	O
discussed	O
in	O
turn	O
,	O
and	O
panelists	O
were	O
given	O
an	O
opportunity	O
to	O
raise	O
any	O
issues	O
or	O
concerns	O
regarding	O
the	O
clarity	O
and	O
wording	O
of	O
each	O
strategy	O
.	O

Each	O
of	O
the	O
strategies	O
discussed	O
were	O
then	O
individually	O
rated	O
a	O
second	O
time	O
by	O
each	O
panelist	O
in	O
an	O
attempt	O
to	O
reach	O
further	O
consensus	O
.	O

Results	O
Selection	O
of	O
strategies	O
for	O
Round	O
1	O
:	O
Modified	O
Delphi	O
process	O
Following	O
Round	O
1	O
rating	O
of	O
the	O
40	O
identified	O
strategies	O
,	O
the	O
Recruitment	O
and	O
Retention	O
panel	O
reached	O
consensus	O
on	O
12	O
strategies	O
.	O

However	O
,	O
14	O
had	O
a	O
combination	O
of	O
high	O
/	O
medium	O
importance	O
and	O
feasibility	O
ratings	O
and	O
14	O
had	O
medium	O
ratings	O
on	O
both	O
dimensions	O
,	O
therefore	O
it	O
required	O
further	O
discussion	O
.	O

An	O
additional	O
strategy	O
regarding	O
family	O
relocation	O
programs	O
was	O
added	O
by	O
this	O
panel	O
.	O

The	O
Education	O
Panel	O
ranked	O
16	O
of	O
24	O
strategies	O
with	O
high	O
importance	O
and	O
feasibility	O
after	O
Round	O
1	O
.	O

Since	O
there	O
were	O
only	O
eight	O
strategies	O
with	O
medium	O
ratings	O
,	O
this	O
expert	O
panel	O
decided	O
to	O
review	O
all	O
the	O
strategies	O
at	O
the	O
face	O
-	O
to	O
-	O
face	O
meeting	O
to	O
discuss	O
the	O
rationale	O
that	O
would	O
explain	O
why	O
some	O
of	O
the	O
highly	O
rated	O
strategies	O
were	O
not	O
already	O
implemented	O
and	O
to	O
come	O
to	O
a	O
consensus	O
on	O
the	O
other	O
eight	O
medium	O
rated	O
strategies	O
.	O

They	O
also	O
added	O
an	O
additional	O
strategy	O
for	O
career	O
paths	O
.	O

Selection	O
of	O
strategies	O
for	O
Round	O
2	O
:	O
Face	O
-	O
to	O
-	O
face	O
meeting	O
A	O
total	O
of	O
34	O
strategies	O
were	O
identified	O
by	O
both	O
the	O
Recruitment	O
and	O
Retention	O
and	O
Education	O
expert	O
panels	O
as	O
being	O
important	O
and	O
feasible	O
for	O
the	O
development	O
of	O
a	O
HHR	O
plan	O
for	O
recruitment	O
and	O
retention	O
of	O
rehabilitation	O
professionals	O
.	O

Under	O
the	O
Recruitment	O
and	O
Retention	O
theme	O
,	O
seven	O
were	O
categorized	O
as	O
Quality	O
of	O
Worklife	O
and	O
Work	O
Environment	O
;	O
two	O
were	O
Workload	O
and	O
Skill	O
Mix	O
,	O
and	O
another	O
seven	O
were	O
Financial	O
Incentives	O
and	O
Marketing	O
.	O

As	O
for	O
the	O
Education	O
panel	O
,	O
five	O
were	O
categorized	O
as	O
Education	O
and	O
Training	O
strategies	O
while	O
the	O
other	O
thirteen	O
were	O
related	O
to	O
Professional	O
Development	O
.	O

As	O
indicated	O
in	O
Table	O
2	O
,	O
at	O
the	O
end	O
of	O
the	O
second	O
round	O
of	O
voting	O
,	O
the	O
Recruitment	O
and	O
Retention	O
panel	O
had	O
a	O
total	O
of	O
16	O
highly	O
important	O
and	O
feasible	O
strategies	O
,	O
8	O
high	O
/	O
medium	O
importance	O
and	O
feasibility	O
,	O
8	O
medium	O
and	O
9	O
low	O
ratings	O
for	O
both	O
dimensions	O
.	O

The	O
Education	O
panel	O
on	O
the	O
other	O
hand	O
had	O
a	O
total	O
of	O
18	O
high	O
,	O
1	O
high	O
/	O
medium	O
,	O
3	O
medium	O
and	O
3	O
low	O
rating	O
strategies	O
.	O

Recruitment	O
and	O
Retention	O
Strategy	O
Rankings	O
Table	O
3	O
provides	O
a	O
detailed	O
description	O
and	O
ranking	O
of	O
each	O
of	O
the	O
recruitment	O
and	O
retention	O
strategies	O
that	O
were	O
rated	O
highly	O
important	O
and	O
feasible	O
.	O

The	O
importance	O
and	O
feasibility	O
rankings	O
were	O
based	O
on	O
the	O
largest	O
proportion	O
of	O
panel	O
members	O
rating	O
a	O
strategy	O
a	O
7	O
,	O
8	O
or	O
9	O
.	O

The	O
overall	O
combined	O
ranking	O
was	O
based	O
on	O
the	O
average	O
of	O
the	O
proportion	O
of	O
these	O
two	O
dimensions	O
.	O

Among	O
these	O
selected	O
strategies	O
,	O
the	O
majority	O
were	O
classified	O
under	O
Quality	O
of	O
Worklife	O
and	O
Work	O
Environment	O
(	O
44	O
%	O
)	O
and	O
Financial	O
Incentives	O
and	O
Marketing	O
(	O
44	O
%	O
)	O
,	O
followed	O
by	O
Workload	O
and	O
Skill	O
Mix	O
(	O
12	O
%	O
)	O
.	O

It	O
should	O
be	O
noted	O
that	O
some	O
strategies	O
had	O
equal	O
rankings	O
;	O
therefore	O
the	O
total	O
number	O
of	O
rankings	O
did	O
not	O
equal	O
the	O
total	O
number	O
of	O
strategies	O
.	O

Recruitment	O
and	O
retention	O
strategies	O
that	O
had	O
a	O
combination	O
of	O
high	O
and	O
medium	O
ratings	O
in	O
either	O
of	O
the	O
two	O
dimensions	O
included	O
:	O
sense	O
of	O
empowerment	O
in	O
promoting	O
healthy	O
work	O
environments	O
;	O
team	O
-	O
building	O
exercises	O
;	O
developing	O
participatory	O
decision	O
-	O
making	O
systems	O
;	O
improving	O
rural	O
working	O
conditions	O
;	O
recognizing	O
work	O
-	O
life	O
balance	O
;	O
creating	O
an	O
environment	O
where	O
staff	O
are	O
valued	O
;	O
optimizing	O
scope	O
of	O
practice	O
and	O
work	O
-	O
management	O
autonomy	O
.	O

Strategies	O
that	O
had	O
medium	O
importance	O
and	O
feasibility	O
ratings	O
included	O
:	O
resolving	O
concerns	O
about	O
liability	O
and	O
accountability	O
in	O
collaborative	O
practice	O
;	O
recruiting	O
international	O
trained	O
therapists	O
;	O
opportunity	O
to	O
work	O
in	O
different	O
settings	O
;	O
interprofessional	O
payment	O
schemes	O
;	O
family	O
leave	O
;	O
staff	O
recognition	O
and	O
creating	O
a	O
position	O
for	O
a	O
provincial	O
health	O
professional	O
recruiter	O
.	O

Low	O
importance	O
and	O
feasibility	O
strategies	O
included	O
:	O
word	O
of	O
mouth	O
references	O
;	O
bursaries	O
and	O
retention	O
bonuses	O
;	O
exchange	O
employment	O
opportunities	O
;	O
health	O
promotion	O
;	O
retention	O
workshop	O
;	O
80–20	O
staffing	O
model	O
(	O
80	O
%	O
clinical	O
and	O
20	O
%	O
learning	O
new	O
skills	O
or	O
training	O
others	O
)	O
;	O
using	O
recruitment	O
agencies	O
and	O
providing	O
recruitment	O
bonuses	O
(	O
Table	O
4	O
)	O
.	O

Education	O
Strategy	O
Rankings	O
Education	O
strategies	O
that	O
were	O
rated	O
highly	O
important	O
and	O
feasible	O
are	O
described	O
in	O
Table	O
5	O
.	O

The	O
majority	O
of	O
strategies	O
in	O
this	O
group	O
tend	O
to	O
be	O
in	O
the	O
area	O
of	O
Professional	O
Development	O
(	O
72	O
%	O
)	O
,	O
more	O
so	O
than	O
Education	O
and	O
Training	O
(	O
28	O
%	O
)	O
.	O

The	O
medium	O
rated	O
education	O
strategies	O
included	O
:	O
expand	O
interprofessional	O
education	O
;	O
provide	O
incentives	O
for	O
students	O
interested	O
in	O
rural	O
practice	O
;	O
summer	O
mentorship	O
programs	O
for	O
high	O
school	O
students	O
;	O
and	O
aboriginal	O
student	O
support	O
program	O
.	O

The	O
strategies	O
that	O
were	O
considered	O
neither	O
feasible	O
nor	O
important	O
included	O
:	O
using	O
return	O
of	O
service	O
contracts	O
after	O
professional	O
development	O
;	O
create	O
a	O
tiered	O
pathway	O
approach	O
through	O
modular	O
education	O
and	O
laddered	O
credentialing	O
and	O
in	O
accreditation	O
standards	O
allow	O
greater	O
use	O
of	O
rural	O
practice	O
sites	O
(	O
Table	O
6	O
)	O
.	O

Since	O
the	O
purpose	O
of	O
the	O
panel	O
was	O
to	O
identify	O
recruitment	O
and	O
retention	O
and	O
education	O
strategies	O
that	O
could	O
inform	O
the	O
development	O
of	O
a	O
HHR	O
plan	O
for	O
rehabilitation	O
professionals	O
,	O
there	O
was	O
also	O
discussion	O
about	O
contextual	O
factors	O
that	O
would	O
influence	O
a	O
plan	O
.	O

Panelists	O
commented	O
that	O
key	O
factors	O
to	O
consider	O
prior	O
to	O
implementation	O
of	O
these	O
strategies	O
should	O
include	O
workplace	O
setting	O
,	O
geographical	O
location	O
(	O
i.e.	O
urban	O
and	O
rural	O
)	O
and	O
gender	O
issues	O
.	O

Discussion	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
identify	O
recruitment	O
and	O
retention	O
strategies	O
to	O
inform	O
the	O
development	O
of	O
HHR	O
planning	O
for	O
rehabilitation	O
professionals	O
in	O
Ontario	O
.	O

This	O
study	O
highlights	O
that	O
Quality	O
of	O
Worklife	O
and	O
Work	O
Environment	O
,	O
Financial	O
Incentives	O
and	O
Marketing	O
and	O
Professional	O
Development	O
are	O
the	O
three	O
major	O
areas	O
of	O
focus	O
when	O
developing	O
a	O
competitive	O
HR	O
plan	O
in	O
the	O
rehabilitation	O
sector	O
.	O

Quality	O
of	O
Worklife	O
and	O
Work	O
Environment	O
Quality	O
of	O
Worklife	O
and	O
Work	O
Environment	O
strategies	O
ranked	O
among	O
the	O
top	O
category	O
for	O
recruitment	O
and	O
retention	O
of	O
rehabilitation	O
therapists	O
.	O

This	O
has	O
also	O
been	O
found	O
among	O
nurses	O
[	O
44	O
]	O
where	O
it	O
was	O
reported	O
that	O
addressing	O
such	O
factors	O
can	O
affect	O
the	O
overall	O
success	O
of	O
the	O
program	O
[	O
49	O
]	O
.	O

Specifically	O
,	O
our	O
findings	O
showed	O
that	O
the	O
top	O
ranked	O
strategy	O
for	O
both	O
importance	O
and	O
feasibility	O
was	O
improving	O
and	O
maintaining	O
the	O
safety	O
of	O
rehabilitation	O
professionals	O
in	O
the	O
workplace	O
.	O

Specific	O
strategies	O
that	O
could	O
reduce	O
aggression	O
,	O
abuse	O
and	O
violence	O
in	O
the	O
workplace	O
include	O
:	O
zero	O
tolerance	O
policies	O
,	O
access	O
to	O
employee	O
support	O
programs	O
and	O
providing	O
assistance	O
to	O
rehabilitation	O
professionals	O
who	O
work	O
alone	O
(	O
i.e.	O
home	O
care	O
and	O
rural	O
and	O
remote	O
areas	O
)	O
.	O

Since	O
there	O
is	O
less	O
control	O
over	O
the	O
environment	O
in	O
the	O
home	O
care	O
setting	O
,	O
safety	O
may	O
become	O
a	O
greater	O
concern	O
in	O
one	O
practice	O
setting	O
over	O
another	O
.	O

This	O
might	O
suggest	O
that	O
because	O
there	O
is	O
less	O
control	O
in	O
environments	O
such	O
as	O
home	O
care	O
,	O
remote	O
areas	O
,	O
and	O
psychiatric	O
settings	O
,	O
maintaining	O
safety	O
will	O
be	O
more	O
difficult	O
and	O
that	O
solutions	O
will	O
need	O
to	O
be	O
tailored	O
to	O
these	O
settings	O
in	O
order	O
to	O
ensure	O
retention	O
of	O
providers	O
.	O

Although	O
no	O
studies	O
have	O
looked	O
at	O
implementing	O
personal	O
safety	O
strategies	O
for	O
home	O
care	O
therapists	O
,	O
written	O
policies	O
and	O
procedures	O
for	O
home	O
care	O
nurses	O
during	O
inclement	O
weather	O
and	O
for	O
dealing	O
with	O
abusive	O
or	O
dangerous	O
patients	O
,	O
families	O
and	O
neighbourhoods	O
have	O
been	O
reported	O
[	O
50	O
]	O
.	O

In	O
addition	O
to	O
the	O
above	O
,	O
ensuring	O
open	O
and	O
timely	O
communication	O
between	O
employer	O
and	O
worker	O
was	O
also	O
ranked	O
highly	O
among	O
the	O
recruitment	O
and	O
retention	O
strategies	O
.	O

Examples	O
of	O
strategies	O
include	O
:	O
open	O
door	O
policies	O
,	O
employee	O
advisory	O
committees	O
and	O
regular	O
staff	O
meetings	O
and	O
evaluations	O
.	O

Although	O
these	O
strategies	O
were	O
reported	O
to	O
be	O
used	O
among	O
organizations	O
providing	O
services	O
to	O
persons	O
with	O
developmental	O
disabilities	O
in	O
Alberta	O
,	O
there	O
was	O
no	O
description	O
of	O
the	O
organizations	O
,	O
sample	O
size	O
or	O
methodology	O
[	O
51	O
]	O
.	O

Similar	O
findings	O
were	O
found	O
in	O
a	O
qualitative	O
study	O
among	O
16	O
nurses	O
working	O
from	O
diverse	O
practice	O
settings	O
(	O
acute	O
,	O
long	O
-	O
term	O
care	O
,	O
rehabilitation	O
and	O
community	O
;	O
from	O
both	O
urban	O
and	O
rural	O
areas	O
)	O
in	O
a	O
health	O
region	O
in	O
western	O
Canada	O
.	O

From	O
the	O
semi	O
-	O
structured	O
interviews	O
,	O
study	O
participants	O
expressed	O
a	O
desire	O
for	O
improved	O
consultation	O
and	O
communication	O
with	O
nurses	O
regarding	O
changes	O
to	O
the	O
health	O
care	O
system	O
[	O
52	O
]	O
.	O

Financial	O
Incentives	O
and	O
Marketing	O
Another	O
area	O
that	O
was	O
ranked	O
highly	O
was	O
marketing	O
strategies	O
to	O
increase	O
high	O
school	O
student	O
and	O
public	O
awareness	O
of	O
rehabilitation	O
careers	O
.	O

These	O
specific	O
strategies	O
were	O
also	O
recommended	O
by	O
the	O
Ontario	O
Hospital	O
Association	O
(	O
OHA	O
)	O
in	O
order	O
to	O
establish	O
a	O
competitive	O
position	O
for	O
Ontario	O
hospitals	O
in	O
respect	O
of	O
recruitment	O
and	O
retention	O
of	O
health	O
care	O
professionals	O
[	O
53	O
]	O
.	O

Similar	O
strategies	O
have	O
been	O
developed	O
by	O
the	O
American	O
Physical	O
Therapy	O
Association	O
(	O
APTA	O
)	O
in	O
response	O
to	O
the	O
declining	O
number	O
of	O
students	O
applying	O
to	O
Physical	O
Therapy	O
Education	O
Programs	O
[	O
54	O
]	O
.	O

To	O
address	O
this	O
trend	O
,	O
APTA	O
developed	O
a	O
campaign	O
to	O
promote	O
Physical	O
Therapy	O
as	O
the	O
profession	O
of	O
choice	O
to	O
high	O
school	O
and	O
college	O
students	O
across	O
the	O
United	O
States	O
.	O

The	O
potential	O
components	O
of	O
their	O
plan	O
included	O
:	O
developing	O
a	O
""""	O
Recruiting	O
Kit	O
""""	O
for	O
educators	O
,	O
students	O
and	O
various	O
APTA	O
members	O
to	O
be	O
used	O
in	O
the	O
high	O
school	O
and	O
college	O
settings	O
to	O
introduce	O
Physical	O
Therapy	O
as	O
a	O
career	O
;	O
establishing	O
public	O
relations	O
initiatives	O
that	O
demonstrate	O
the	O
role	O
of	O
Physical	O
Therapy	O
in	O
the	O
public	O
arena	O
targeting	O
minority	O
groups	O
that	O
are	O
underrepresented	O
in	O
the	O
profession	O
;	O
and	O
creating	O
alliances	O
with	O
professional	O
associations	O
of	O
high	O
school	O
guidance	O
counsellors	O
and	O
educators	O
.	O

Based	O
on	O
our	O
finding	O
,	O
the	O
APTA	O
model	O
may	O
have	O
applicability	O
in	O
Ontario	O
.	O

Workload	O
and	O
Skill	O
Mix	O
Of	O
the	O
six	O
Workload	O
and	O
Skill	O
Mix	O
strategies	O
only	O
two	O
were	O
highly	O
rated	O
:	O
implementing	O
a	O
caseload	O
management	O
database	O
and	O
using	O
support	O
personnel	O
.	O

Caseload	O
management	O
has	O
been	O
identified	O
in	O
the	O
literature	O
as	O
an	O
issue	O
affecting	O
all	O
three	O
rehabilitation	O
professions	O
.	O

For	O
example	O
,	O
in	O
physiotherapy	O
,	O
Christie	O
's	O
study	O
[	O
55	O
]	O
found	O
that	O
caseload	O
expectations	O
tended	O
to	O
be	O
significantly	O
higher	O
than	O
the	O
reality	O
and	O
that	O
caseload	O
varies	O
across	O
different	O
programs	O
.	O

Similarly	O
,	O
the	O
Canadian	O
Association	O
of	O
Speech	O
-	O
Language	O
Pathologists	O
and	O
Audiologists	O
(	O
CASPLA	O
)	O
survey	O
indicated	O
that	O
factors	O
affecting	O
the	O
workload	O
of	O
SLPs	O
include	O
delivery	O
models	O
,	O
client	O
disorder	O
,	O
severity	O
and	O
work	O
setting	O
[	O
56	O
]	O
.	O

A	O
literature	O
review	O
and	O
environmental	O
scan	O
undertaken	O
by	O
the	O
Canadian	O
Association	O
of	O
Occupational	O
Therapists	O
(	O
CAOT	O
)	O
proposed	O
that	O
guiding	O
principles	O
for	O
caseload	O
management	O
should	O
include	O
:	O
evidence	O
-	O
based	O
occupational	O
therapy	O
,	O
cost	O
-	O
effectiveness	O
,	O
accountability	O
,	O
professional	O
leadership	O
and	O
expert	O
judgment	O
,	O
comprehensiveness	O
and	O
flexibility	O
[	O
57	O
]	O
.	O

Therefore	O
,	O
upon	O
implementation	O
of	O
a	O
caseload	O
management	O
database	O
for	O
rehabilitation	O
,	O
key	O
factors	O
to	O
consider	O
include	O
workplace	O
setting	O
and	O
client	O
service	O
delivery	O
models	O
.	O

The	O
other	O
highly	O
rated	O
Workload	O
and	O
Skill	O
Mix	O
strategy	O
was	O
the	O
use	O
of	O
support	O
personnel	O
(	O
i.e.	O
physiotherapy	O
assistants	O
or	O
exercise	O
therapists	O
)	O
to	O
increase	O
efficiency	O
of	O
utilization	O
of	O
scarcer	O
and	O
higher	O
order	O
rehabilitation	O
competencies	O
.	O

Considerations	O
for	O
implementing	O
this	O
strategy	O
include	O
addressing	O
key	O
issues	O
such	O
supply	O
,	O
standards	O
of	O
education	O
,	O
standards	O
of	O
practice	O
and	O
accreditation	O
.	O

These	O
are	O
highlighted	O
in	O
an	O
article	O
by	O
Salvatori	O
[	O
58	O
]	O
who	O
reported	O
that	O
the	O
actual	O
number	O
of	O
OT	O
personnel	O
delivering	O
OT	O
services	O
in	O
Canada	O
remains	O
unknown	O
and	O
that	O
there	O
are	O
no	O
national	O
standards	O
of	O
education	O
nor	O
accreditation	O
process	O
for	O
OT	O
assistants	O
.	O

CAOT	O
believes	O
that	O
in	O
order	O
to	O
utilize	O
support	O
personnel	O
appropriately	O
,	O
studies	O
on	O
human	B
resource	O
needs	O
for	O
occupational	O
therapy	O
and	O
support	O
personnel	O
are	O
first	O
needed	O
with	O
input	O
from	O
OTs	O
,	O
stakeholders	O
,	O
funders	O
,	O
decision	O
makers	O
and	O
health	O
policy	O
planners	O
[	O
59	O
]	O
.	O

Since	O
there	O
is	O
a	O
lack	O
of	O
competency	O
profiles	O
related	O
to	O
the	O
role	O
,	O
responsibilities	O
,	O
and	O
supervision	O
of	O
assistants	O
,	O
particularly	O
with	O
regards	O
to	O
delivering	O
services	O
in	O
unsupervised	O
community	O
-	O
based	O
settings	O
,	O
the	O
type	O
of	O
workplace	O
setting	O
where	O
this	O
strategy	O
may	O
be	O
implemented	O
should	O
be	O
considered	O
[	O
58	O
]	O
.	O

Education	O
and	O
Training	O
Given	O
that	O
60	O
%	O
of	O
highly	O
rated	O
Education	O
and	O
Training	O
strategies	O
targeted	O
rural	O
and	O
remote	O
practices	O
underscores	O
the	O
importance	O
of	O
specific	O
strategies	O
for	O
rural	O
and	O
remote	O
areas	O
in	O
the	O
development	O
of	O
a	O
HHR	O
plan	O
.	O

The	O
need	O
to	O
build	O
on	O
existing	O
mechanisms	O
to	O
expand	O
the	O
availability	O
of	O
rural	O
and	O
remote	O
clinical	O
placements	O
by	O
providing	O
financial	O
and	O
accommodation	O
support	O
was	O
ranked	O
among	O
the	O
top	O
two	O
most	O
important	O
and	O
feasible	O
education	O
strategies	O
for	O
rehabilitation	O
professionals	O
.	O

Not	O
only	O
has	O
this	O
strategy	O
been	O
used	O
as	O
a	O
recruitment	O
tool	O
for	O
rehabilitation	O
students	O
,	O
it	O
has	O
also	O
been	O
reported	O
by	O
Solomon	O
et	O
al.	O
[	O
34	O
]	O
to	O
be	O
effective	O
in	O
retaining	O
OTs	O
and	O
PTs	O
in	O
underserviced	O
Northwestern	O
Ontario	O
communities	O
.	O

Respondents	O
from	O
Solomon	O
et	O
al.	O
's	O
study	O
reported	O
that	O
the	O
top	O
three	O
benefits	O
of	O
supervising	O
students	O
were	O
that	O
it	O
stimulates	O
thinking	O
,	O
it	O
provides	O
opportunity	O
to	O
contribute	O
to	O
the	O
profession	O
and	O
that	O
it	O
provides	O
access	O
to	O
current	O
information	O
.	O

The	O
reported	O
disadvantages	O
however	O
was	O
that	O
it	O
was	O
time	O
-	O
consuming	O
and	O
students	O
contributed	O
stress	O
to	O
the	O
working	O
environment	O
.	O

Similarly	O
,	O
a	O
two	O
-	O
part	O
study	O
found	O
substantial	O
gaps	O
between	O
financial	O
incentives	O
students	O
deem	O
important	O
in	O
the	O
creation	O
of	O
an	O
appealing	O
clinical	O
placement	O
opportunity	O
and	O
the	O
actual	O
provisions	O
offered	O
to	O
them	O
by	O
Southeastern	O
Ontario	O
communities	O
[	O
60,61	O
]	O
.	O

Although	O
OT	O
and	O
PT	O
students	O
reported	O
that	O
they	O
were	O
more	O
willing	O
to	O
complete	O
a	O
clinical	O
placement	O
in	O
an	O
underserviced	O
community	O
if	O
provided	O
travel	O
stipends	O
,	O
rent	O
-	O
free	O
housing	O
and	O
interprofessional	O
education	O
opportunities	O
,	O
the	O
majority	O
of	O
these	O
incentives	O
were	O
only	O
available	O
to	O
medical	O
students	O
.	O

In	O
addition	O
to	O
training	O
students	O
for	O
rural	O
and	O
remote	O
practice	O
,	O
a	O
longitudinal	O
study	O
reported	O
that	O
perceived	O
opportunity	O
for	O
career	O
development	O
was	O
the	O
most	O
significant	O
factor	O
related	O
to	O
job	O
turnover	O
and	O
regional	O
attrition	O
among	O
physiotherapists	O
working	O
in	O
Northern	O
Ontario	O
[	O
5	O
]	O
.	O

Therefore	O
developing	O
workforce	O
strategies	O
for	O
rehabilitation	O
therapists	O
working	O
in	O
these	O
areas	O
should	O
be	O
among	O
one	O
of	O
the	O
priority	O
areas	O
in	O
HHR	O
planning	O
.	O

Professional	O
Development	O
Our	O
findings	O
indicate	O
that	O
the	O
theme	O
with	O
the	O
largest	O
number	O
of	O
strategies	O
that	O
were	O
considered	O
important	O
and	O
feasible	O
to	O
implement	O
as	O
part	O
of	O
HHR	O
planning	O
was	O
professional	O
development	O
.	O

Many	O
were	O
specific	O
to	O
rural	O
and	O
remote	O
areas	O
.	O

Although	O
the	O
importance	O
of	O
continuous	O
professional	O
development	O
(	O
CPD	O
)	O
in	O
recruitment	O
and	O
retention	O
is	O
well	O
recognized	O
,	O
a	O
Canadian	O
study	O
reported	O
several	O
barriers	O
to	O
its	O
implementation	O
[	O
62	O
]	O
.	O

In	O
the	O
case	O
of	O
OTs	O
employed	O
in	O
public	O
settings	O
in	O
Nova	O
Scotia	O
,	O
Townsend	O
et	O
al.	O
(	O
2006	O
)	O
found	O
that	O
the	O
most	O
powerful	O
deterrent	O
for	O
CPD	O
was	O
the	O
lack	O
of	O
support	O
from	O
workplace	O
policies	O
.	O

Based	O
on	O
their	O
study	O
results	O
,	O
the	O
use	O
of	O
CPD	O
as	O
a	O
recruitment	O
and	O
retention	O
strategy	O
was	O
highly	O
influenced	O
by	O
gender	O
issues	O
,	O
work	O
-	O
life	O
balance	O
,	O
career	O
advancement	O
,	O
working	O
conditions	O
,	O
geographical	O
location	O
,	O
professional	O
versus	O
employer	O
responsibility	O
,	O
and	O
employee	O
benefits	O
.	O

Although	O
occupational	O
therapy	O
is	O
a	O
female	O
-	O
dominated	O
profession	O
,	O
workplace	O
policies	O
did	O
not	O
address	O
issues	O
of	O
gender	O
.	O

For	O
example	O
,	O
therapists	O
in	O
this	O
study	O
indicated	O
that	O
CPD	O
competes	O
with	O
family	O
commitments	O
,	O
therefore	O
these	O
activities	O
are	O
""""	O
done	O
largely	O
during	O
personal	O
time	O
,	O
mainly	O
at	O
their	O
own	O
cost	O
,	O
and	O
on	O
top	O
of	O
childcare	O
,	O
eldercare	O
,	O
homemaking	O
and	O
other	O
family	O
responsibilities	O
""""	O
[	O
62	O
]	O
.	O

In	O
addition	O
,	O
heavy	O
workloads	O
,	O
lack	O
of	O
salary	O
and	O
career	O
incentives	O
,	O
and	O
lack	O
of	O
policy	O
and	O
funding	O
support	O
are	O
all	O
barriers	O
to	O
CPD	O
.	O

These	O
issues	O
become	O
more	O
pronounced	O
in	O
rural	O
and	O
remote	O
settings	O
because	O
smaller	O
communities	O
often	O
only	O
have	O
one	O
therapist	O
;	O
hence	O
the	O
systemic	O
pressure	O
of	O
workload	O
demands	O
makes	O
it	O
difficult	O
for	O
the	O
therapist	O
to	O
leave	O
patient	O
care	O
.	O

OTs	O
from	O
this	O
study	O
also	O
questioned	O
who	O
was	O
responsible	O
for	O
CPD	O
.	O

Some	O
felt	O
that	O
it	O
was	O
the	O
professional	O
's	O
responsibility	O
while	O
others	O
felt	O
that	O
it	O
was	O
the	O
responsibility	O
of	O
the	O
employer	O
to	O
provide	O
CPD	O
opportunities	O
.	O

The	O
primary	O
limitation	O
employers	O
faced	O
was	O
the	O
lack	O
of	O
financial	O
resources	O
,	O
however	O
giving	O
employees	O
time	O
off	O
without	O
pay	O
was	O
an	O
alternative	O
strategy	O
utilized	O
instead	O
of	O
funding	O
professional	O
development	O
activities	O
.	O

Although	O
there	O
are	O
professional	O
and	O
provincial	O
variations	O
in	O
funding	O
for	O
CPD	O
across	O
Canada	O
,	O
these	O
results	O
are	O
informative	O
in	O
that	O
it	O
highlights	O
the	O
need	O
for	O
employers	O
to	O
consider	O
how	O
workplace	O
policies	O
can	O
affect	O
recruitment	O
and	O
retention	O
strategies	O
.	O

Limitations	O
of	O
this	O
study	O
should	O
be	O
noted	O
.	O

First	O
,	O
the	O
majority	O
of	O
the	O
strategies	O
were	O
obtained	O
from	O
the	O
grey	O
literature	O
that	O
is	O
not	O
subject	O
to	O
the	O
same	O
scrutiny	O
as	O
the	O
peer	O
-	O
reviewed	O
literature	O
.	O

Second	O
,	O
almost	O
none	O
of	O
the	O
strategies	O
were	O
specifically	O
developed	O
for	O
rehabilitation	O
professionals	O
and	O
in	O
many	O
cases	O
had	O
to	O
be	O
re	O
-	O
worded	O
to	O
fit	O
the	O
rehabilitation	O
context	O
.	O

There	O
is	O
a	O
lack	O
of	O
research	O
on	O
rehabilitation	O
clinicians	O
'	O
perspectives	O
on	O
recruitment	O
and	O
retention	O
strategies	O
;	O
therefore	O
future	O
research	O
should	O
focus	O
on	O
investigating	O
this	O
area	O
.	O

Third	O
,	O
during	O
the	O
face	O
-	O
to	O
-	O
face	O
meeting	O
,	O
bias	O
could	O
have	O
resulted	O
from	O
panelists	O
whose	O
opinion	O
may	O
have	O
influenced	O
others	O
significantly	O
,	O
especially	O
if	O
members	O
came	O
from	O
similar	O
workplace	O
settings	O
.	O

The	O
facilitator	O
of	O
the	O
expert	O
panels	O
however	O
,	O
followed	O
a	O
strict	O
process	O
for	O
managing	O
the	O
discussion	O
and	O
ensured	O
that	O
all	O
panelists	O
were	O
given	O
the	O
opportunity	O
to	O
express	O
their	O
opinions	O
.	O

Finally	O
,	O
although	O
some	O
strategies	O
such	O
as	O
competitive	O
wage	O
packages	O
,	O
training	O
/	O
growth	O
opportunities	O
and	O
professional	O
development	O
are	O
viewed	O
as	O
both	O
a	O
recruitment	O
and	O
retention	O
incentive	O
,	O
other	O
strategies	O
do	O
not	O
overlap	O
and	O
are	O
appropriate	O
for	O
only	O
one	O
of	O
the	O
two	O
tasks	O
.	O

For	O
example	O
,	O
increasing	O
public	O
awareness	O
of	O
rehabilitation	O
careers	O
,	O
providing	O
rural	O
and	O
remote	O
orientation	O
packages	O
and	O
family	O
relocation	O
programs	O
are	O
only	O
appropriate	O
for	O
attracting	O
a	O
worker	O
while	O
ensuring	O
open	O
and	O
timely	O
communication	O
may	O
be	O
seen	O
as	O
a	O
strategy	O
only	O
for	O
retention	O
.	O

Future	O
research	O
should	O
therefore	O
consider	O
studying	O
recruitment	O
and	O
retention	O
strategies	O
separately	O
so	O
that	O
a	O
distinction	O
between	O
the	O
two	O
can	O
be	O
made	O
.	O

Conclusion	O
This	O
study	O
identified	O
34	O
strategies	O
that	O
should	O
be	O
considered	O
as	O
important	O
and	O
feasible	O
for	O
implementation	O
as	O
part	O
of	O
HHR	O
planning	O
for	O
rehabilitation	O
professionals	O
.	O

Although	O
the	O
highest	O
ranked	O
strategies	O
focused	O
on	O
areas	O
of	O
Quality	O
of	O
Worklife	O
and	O
Work	O
Environment	O
,	O
Financial	O
Incentives	O
and	O
Marketing	O
and	O
Professional	O
Development	O
,	O
key	O
factors	O
that	O
need	O
to	O
be	O
considered	O
in	O
the	O
context	O
of	O
implementation	O
include	O
:	O
workplace	O
setting	O
,	O
geographical	O
location	O
and	O
gender	O
issues	O
.	O

While	O
this	O
is	O
the	O
first	O
study	O
to	O
our	O
knowledge	O
that	O
provides	O
a	O
comprehensive	O
list	O
of	O
recruitment	O
and	O
retention	O
strategies	O
relevant	O
to	O
rehabilitation	O
professionals	O
,	O
more	O
information	O
is	O
needed	O
for	O
the	O
development	O
of	O
a	O
HHR	O
plan	O
.	O

Information	O
on	O
trends	O
in	O
labour	O
force	O
participation	O
as	O
well	O
as	O
knowledge	O
regarding	O
the	O
use	O
and	O
effectiveness	O
of	O
recruitment	O
and	O
retention	O
strategies	O
for	O
rehabilitation	O
professionals	O
is	O
needed	O
.	O

More	O
importantly	O
,	O
the	O
success	O
of	O
implementing	O
and	O
sustaining	O
such	O
strategies	O
requires	O
future	O
research	O
to	O
validate	O
these	O
strategies	O
from	O
the	O
perspective	O
of	O
rehabilitation	O
clinicians	O
and	O
human	B
resource	O
decisions	O
makers	O
(	O
i.e.	O
local	O
government	O
,	O
stakeholders	O
,	O
etc	O
.	O
)	O
so	O
that	O
specific	O
barriers	O
and	O
challenges	O
can	O
be	O
identified	O
.	O

Competing	O
interests	O
The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O
DT	O
participated	O
in	O
the	O
design	O
of	O
the	O
study	O
,	O
conducted	O
the	O
literature	O
review	O
,	O
analyzed	O
and	O
interpreted	O
the	O
results	O
and	O
drafted	O
the	O
manuscript	O
.	O

LMH	O
,	O
AD	O
,	O
DB	O
and	O
KB	O
were	O
involved	O
in	O
providing	O
feedback	O
and	O
editing	O
the	O
content	O
of	O
the	O
manuscript	O
.	O

MDL	O
recommended	O
participants	O
for	O
the	O
expert	O
panel	O
and	O
was	O
involved	O
in	O
providing	O
feedback	O
and	O
editing	O
the	O
content	O
of	O
the	O
manuscript	O
.	O

SJ	O
participated	O
in	O
the	O
design	O
of	O
the	O
study	O
,	O
recommended	O
participants	O
for	O
the	O
expert	O
panel	O
,	O
organized	O
and	O
consolidated	O
strategies	O
,	O
interpreted	O
the	O
data	O
and	O
edited	O
the	O
content	O
of	O
the	O
manuscript	O
.	O

Pre	O
-	O
publication	O
history	O
The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O

Structural	O
organization	O
of	O
a	O
17	O
KB	O
segment	O
of	O
the	O
alpha	O
2	O
collagen	O
gene	O
:	O
evaluation	O
by	O
R	O
loop	O
mapping	O
.	O

Abstract	O
A	O
recombinant	O
phage	O
,	O
SpC3	O
,	O
containing	O
a	O
17	O
kb	O
genomic	O
DNA	O
insert	O
representing	O
approximately	O
60	O
%	O
of	O
the	O
3	O
'	O
portion	O
of	O
the	O
sheep	B
collagen	O
alpha	O
2	O
gene	O
,	O
was	O
evaluated	O
by	O
electron	O
microscopic	O
R	O
loop	O
analysis	O
.	O

A	O
minimum	O
of	O
17	O
intervening	O
sequences	O
(	O
introns	O
)	O
and	O
18	O
alpha	O
2	O
coding	O
sequences	O
(	O
exons	O
)	O
were	O
mapped	O
.	O

With	O
the	O
exception	O
of	O
the	O
850	O
base	O
pair	O
exon	O
located	O
at	O
the	O
extreme	O
3	O
'	O
end	O
of	O
the	O
insert	O
,	O
all	O
exons	O
contained	O
250	O
base	O
pairs	O
or	O
less	O
.	O

The	O
total	O
length	O
of	O
all	O
the	O
exons	O
in	O
SpC3	O
was	O
3,014	O
base	O
pairs	O
.	O

The	O
length	O
distribution	O
of	O
the	O
17	O
introns	O
ranged	O
from	O
300	O
to	O
1600	O
base	O
pairs	O
;	O
together	O
,	O
all	O
of	O
the	O
introns	O
comprised	O
14,070	O
base	O
pairs	O
of	O
SpC3	O
DNA	O
.	O

Thus	O
,	O
the	O
DNA	O
region	O
required	O
for	O
coding	O
the	O
interspersed	O
3	O
kb	O
of	O
alpha	O
2	O
collagen	O
genetic	O
information	O
was	O
5.6	O
fold	O
longer	O
than	O
the	O
corresponding	O
alpha	O
2	O
mRNA	O
coding	O
sequences	O
.	O

Images	O
Nucleic	O
Acids	O
Research	O
Structural	O
organization	O
of	O
a	O
17	O
KB	O
segment	O
of	O
the	O
a2	O
collagen	O
gene	O
:	O
evaluation	O
by	O
R	O
loop	O
mapping	O
Millie	O
P.Schafer	O
,	O
Charles	O
D.Boyd	O
,	O
Paul	O
Tolstoshev	O
and	O
Ronald	O
G.Crystal	O
Pulmonary	O
Branch	O
,	O
National	O
Heart	O
,	O
Lung	O
and	O
Blood	O
Institute	O
,	O
National	O
Institutes	O
of	O
Health	O
,	O
Bethesda	O
,	O
MD	O
20205	O
,	O
USA	O
Received	O
13	O
February	O
1980	O
ABSTRACT	O
A	O
recombinant	O
phage	O
,	O
SpC3	O
,	O
containing	O
a	O
17	O
kb	O
genomic	O
DNA	O
insert	O
rep	O
resenting	O
approximately	O
60	O
%	O
of	O
the	O
3	O
'	O
portion	O
of	O
the	O
sheep	B
collagen	O
a2	O
gene	O
,	O
was	O
evaluated	O
by	O
electron	O
microscopic	O
R	O
loop	O
analysis	O
.	O

A	O
minimum	O
of	O
17	O
intervening	O
sequences	O
(	O
introns	O
)	O
and	O
18	O
a2	O
coding	O
sequences	O
(	O
exons	O
)	O
were	O
mapped	O
.	O

With	O
the	O
exception	O
of	O
the	O
850	O
base	O
pair	O
exon	O
located	O
at	O
the	O
extreme	O
3	O
'	O
end	O
of	O
the	O
insert	O
,	O
all	O
exons	O
contained	O
250	O
base	O
pairs	O
or	O
less	O
.	O

The	O
total	O
length	O
of	O
all	O
the	O
exons	O
in	O
SpC3	O
was	O
3,014	O
base	O
pairs	O
.	O

The	O
length	O
distribution	O
of	O
the	O
17	O
introns	O
ranged	O
from	O
300	O
to	O
1600	O
base	O
pairs	O
;	O
together	O
,	O
all	O
of	O
the	O
introns	O
comprised	O
14,070	O
base	O
pairs	O
of	O
SpC3	O
DNA	O
.	O

Thus	O
,	O
the	O
DNA	O
region	O
required	O
for	O
coding	O
the	O
interspersed	O
3	O
kb	O
of	O
a2	O
collagen	O
genetic	O
information	O
was	O
5.6	O
fold	O
longer	O
than	O
the	O
corresponding	O
a2	O
mRNA	O
coding	O
sequences	O
.	O

INTRODUCTION	O
Type	O
I	O
collagen	O
,	O
composed	O
of	O
two	O
al	O
(	O
I	O
)	O
and	O
one	O
a2	O
polypeptide	O
chains	O
,	O
is	O
the	O
most	O
abundant	O
of	O
the	O
five	O
known	O
mammalian	O
collagen	O
types	O
.	O

It	O
is	O
a	O
major	O
extracellular	O
constituent	O
of	O
tissues	O
such	O
as	O
bone	O
,	O
tendon	O
,	O
skin	O
and	O
lung	O
where	O
,	O
because	O
of	O
its	O
great	O
tensile	O
strength	O
,	O
it	O
plays	O
an	O
important	O
role	O
in	O
tissue	O
structure	O
and	O
function	O
.	O

The	O
polypeptides	O
comprising	O
type	O
I	O
collagen	O
are	O
synthesized	O
in	O
long	O
,	O
precursor	O
forms	O
,	O
referred	O
to	O
as	O
pro	O
al	O
(	O
I	O
)	O
and	O
pro	O
a2	O
chains,1	O
each	O
containing	O
approximately	O
1500	O
amino	O
acid	O
residues	O
(	O
1	O
)	O
.	O

1	O
The	O
terminology	O
for	O
the	O
primary	O
translation	O
products	O
of	O
the	O
various	O
collagen	O
messenger	O
RNAs	O
is	O
still	O
in	O
a	O
state	O
of	O
flux	O
.	O

It	O
is	O
known	O
that	O
al	O
(	O
I	O
)	O
and	O
a2	O
chains	O
are	O
synthesized	O
in	O
precursor	O
forms	O
;	O
these	O
are	O
currently	O
termed	O
pro	O
al	O
(	O
I	O
)	O
and	O
pro	O
a2	O
chains	O
(	O
1	O
)	O
.	O

However	O
,	O
recent	O
studies	O
(	O
43,44	O
)	O
have	O
shown	O
that	O
the	O
actual	O
primary	O
translation	O
product	O
of	O
al	O
(	O
I	O
)	O
mRNA	O
is	O
somewhat	O
larger	O
than	O
the	O
pro	O
al	O
(	O
I	O
)	O
chain	O
;	O
this	O
translation	O
product	O
has	O
been	O
termed	O
a	O
""""	O
pre	O
-	O
pro	O
al	O
(	O
I	O
)	O
chain	O
.	O
""""	O

Although	O
the	O
corresponding	O
""""	O
pre	O
-	O
pro	O
a2	O
chain	O
""""	O
likely	O
exists	O
,	O
it	O
has	O
not	O
yet	O
been	O
characterized	O
.	O

For	O
simplicity	O
,	O
therefore	O
,	O
until	O
the	O
proper	O
terminology	O
for	O
the	O
primary	O
translation	O
product	O
is	O
clarified	O
,	O
we	O
have	O
chosen	O
to	O
use	O
the	O
terms	O
""""	O
al	O
(	O
I	O
)	O
""""	O
and	O
""""	O
a2	O
""""	O
to	O
refer	O
to	O
the	O
type	O
I	O
collagen	O
mRNAs	O
and	O
collagen	O
structural	O
gene	O
sequences	O
.	O

?	O
)	O

IRL	O
Press	O
Umited	O
,	O
1	O
Falconberg	O
Court	O
,	O
London	O
W1V	O
5FG	O
,	O
U.K.	O
Volurne	O
8	O
Number	O
10	O
1980	O
2241	O

Nucleic	O
Acids	O
Research	O

There	O
is	O
increasing	O
evidence	O
that	O
the	O
quantities	O
of	O
al	O
(	O
I	O
)	O
and	O
a2	O
chains	O
produced	O
by	O
cells	O
may	O
be	O
regulated	O
,	O
in	O
part	O
,	O
at	O
the	O
genomic	O
level	O
(	O
1	O
)	O
.	O

However	O
,	O
to	O
understand	O
the	O
processes	O
which	O
mediate	O
their	O
expression	O
,	O
it	O
is	O
necessary	O
to	O
understand	O
the	O
structural	O
organization	O
of	O
these	O
collagen	O
genes	O
and	O
the	O
various	O
enzymes	O
that	O
modify	O
the	O
collagen	O
chains	O
after	O
its	O
synthesis	O
(	O
1	O
)	O
.	O

As	O
an	O
initial	O
approach	O
to	O
this	O
problem	O
,	O
we	O
have	O
recently	O
isolated	O
a	O
recombinant	O
bacteriophage	O
,	O
termed	O
SpC3	O
,	O
containing	O
approximately	O
60	O
%	O
of	O
the	O
a2	O
gene	O
for	O
type	O
I	O
collagen	O
.	O

Partial	O
characterization	O
of	O
this	O
a2	O
gene	O
demonstrated	O
that	O
,	O
like	O
most	O
other	O
structurally	O
evaluated	O
eukaryotic	O
genes	O
,	O
the	O
coding	O
sequences	O
are	O
interspersed	O
with	O
intervening	O
sequences	O
(	O
2	O
)	O
.	O

The	O
present	O
study	O
further	O
characterizes	O
this	O
portion	O
of	O
the	O
a2	O
gene	O
by	O
utilizing	O
electron	O
microscopic	O
R	O
loop	O
analysis	O
to	O
map	O
the	O
coding	O
regions	O
(	O
exons	O
)	O
and	O
intervening	O
sequences	O
(	O
introns	O
)	O
contained	O
within	O
the	O
sheep	B
genomic	O
insert	O
of	O
SpC3	O
.	O

The	O
data	O
suggests	O
that	O
the	O
structural	O
organization	O
of	O
this	O
portion	O
of	O
the	O
a2	O
collagen	O
gene	O
represents	O
3	O
kb	O
of	O
coding	O
information	O
that	O
is	O
interspersed	O
in	O
a	O
complex	O
fashion	O
with	O
17	O
introns	O
over	O
17	O
kb	O
of	O
genome	O
.	O

MATERIALS	O
AND	O
METHODS	O
Isolation	O
and	O
characterization	O
of	O
a2	O
collagen	O
recombinant	O
clone	O
,	O
SpC3	O
.	O

The	O
sheep	B
a2	O
collagen	O
recombinant	O
clone	O
,	O
SpC3	O
,	O
containing	O
a	O
portion	O
of	O
the	O
sheep	B
a2	O
gene	O
,	O
was	O
isolated	O
as	O
previously	O
described	O
(	O
2	O
)	O
.	O

Briefly	O
,	O
high	O
molecular	O
weight	O
fetal	O
sheep	B
liver	O
DNA	O
was	O
extracted	O
by	O
the	O
method	O
of	O
Blin	O
and	O
Stafford	O
(	O
3	O
)	O
,	O
and	O
15	O
-	O
20	O
kb	O
DNA	O
fragments	O
,	O
resulting	O
from	O
partial	O
Eco	O
RI	O
digestion	O
,	O
were	O
isolated	O
and	O
ligated	O
to	O
the	O
left	O
and	O
right	O
arms	O
of	O
Charon	O
4A	O
.	O

The	O
recombinant	O
DNA	O
was	O
then	O
packaged	O
in	O
vitro	O
and	O
the	O
sheep	B
genomic	O
library	O
amplified	O
(	O
4	O
-	O
6	O
)	O
.	O

Screening	O
of	O
the	O
sheep	B
genomic	O
library	O
was	O
conducted	O
utilizing	O
[	O
32	O
P	O
]	O
-labeled	O
fetal	O
sheep	B
tendon	O
type	O
I	O
collagen	O
cDNA	O
and	O
several	O
positive	O
recombinant	O
phages	O
were	O
isolated	O
.	O

One	O
recombinant	O
,	O
containing	O
a	O
17	O
kb	O
sheep	B
genomic	O
insert	O
,	O
was	O
demonstrated	O
to	O
have	O
coding	O
sequences	O
corresponding	O
to	O
60	O
%	O
of	O
the	O
3	O
'	O
end	O
of	O
a2	O
mRNA	O
.	O

Prior	O
studies	O
showed	O
that	O
the	O
insert	O
in	O
SpC3	O
was	O
not	O
due	O
to	O
ligation	O
of	O
noncontiguous	O
restriction	O
fragments	O
and/or	O
genetic	O
rearrangement	O
during	O
the	O
cloning	O
process	O
(	O
2	O
)	O
.	O

Electron	O
mi	O
croscopy	O
.	O

To	O
visualize	O
the	O
recombinant	O
bacteriophage	O
DNA	O
structure	O
complementary	O
to	O
a2	O
collagen	O
mRNA	O
,	O
1	O
iig	O
of	O
SpC3	O
DNA	O
was	O
lyophilized	O
with	O
1	O
ig	O
or	O
100	O
ng	O
of	O
mRNA	O
to	O
give	O
DNA	O
:	O
mRNA	O
ratios	O
of	O
1:1	O
and	O
10:1	O
,	O
respectively	O
.	O

These	O
were	O
then	O
dissolved	O
in	O
10	O
i1	O
of	O
R	O
loop	O
buffer	O
[	O
70	O
%	O
(	O
v	O
/	O
v	O
)	O
deionized	O
formamide	O
,	O
0.1	O
N-	O
[	O
tris	O
(	O
hydroxy	O
2242	O
Nucleic	O
Acids	O
Research	O
methyl	O
)	O
methyl	O
]	O
glycine	O
(	O
tricine	O
)	O
-NaOH	O
,	O
pH	O
8.0	O
,	O
0.5	O
M	O
NaCl	O
,	O
and	O
0.01	O
M	O
ethyl	O
enediaminetetraacetate	O
(	O
EDTA	O
)	O
]	O
,	O
incubated	O
in	O
sealed	O
capillary	O
tubes	O
at	O
520	O
for	O
14	O
hr	O
(	O
7	O
)	O
,	O
and	O
then	O
diluted	O
1:10	O
with	O
R	O
loop	O
buffer	O
.	O

Two	O
spreading	O
methods	O
were	O
used	O
to	O
subsequently	O
prepare	O
the	O
hybrids	O
for	O
visualization	O
in	O
the	O
electron	O
microscope	O
.	O

70	O
%	O
formamide	O
method	O
.	O

Immediately	O
before	O
spreading	O
onto	O
a	O
deionized	O
water	O
hypophase	O
,	O
the	O
nucleic	O
acid	O
mixtures	O
were	O
diluted	O
an	O
additional	O
10-fold	O
in	O
R	O
loop	O
buffer	O
and	O
cytochrome	O
c	O
,	O
100	O
vg	O
/	O
ml	O
,	O
was	O
added	O
.	O

Urea	O
-	O
formamide	O
method	O
.	O

The	O
nucleic	O
acid	O
solutions	O
were	O
spread	O
using	O
a	O
modification	O
of	O
the	O
method	O
of	O
Westphal	O
and	O
Lai	O
(	O
8,9	O
)	O
.	O

The	O
hyperphase	O
contained	O
55	O
%	O
formamide	O
,	O
2.6	O
M	O
urea	O
,	O
0.009	O
M	O
EDTA	O
,	O
0.09	O
M	O
tricine	O
-	O
NaOH	O
,	O
pH	O
8.0	O
,	O
and	O
the	O
nucleic	O
acid	O
mixture	O
(	O
approximately	O
0.1	O
to	O
1.0	O
ig	O
/	O
ml	O
)	O
.	O

The	O
mixture	O
was	O
heated	O
at	O
40	O
?	O
for	O
30	O
sec	O
,	O
placed	O
in	O
ice	O
water	O
,	O
and	O
then	O
allowed	O
to	O
reach	O
room	O
temperature	O
.	O

Cytochrome	O
c	O
,	O
100	O
pg	O
/	O
ml	O
,	O
was	O
added	O
immediately	O
before	O
spreading	O
onto	O
a	O
deionized	O
water	O
hypophase	O
.	O

The	O
nucleic	O
acid	O
-	O
protein	O
films	O
from	O
both	O
methods	O
were	O
absorbed	O
onto	O
parlodion	O
-	O
coated	O
grids	O
,	O
stained	O
with	O
uranyl	O
acetate	O
(	O
10	O
)	O
,	O
dehydrated	O
in	O
90	O
%	O
ethanol	O
and	O
rotary	O
-	O
shadowed	O
with	O
platinum	O
-	O
palladium	O
(	O
80:20	O
)	O
at	O
an	O
angle	O
of	O
50	O
.	O

Micrographs	O
were	O
taken	O
with	O
a	O
Siemens	O
Elmiskop	O
101	O
electron	O
microscope	O
at	O
an	O
original	O
magnification	O
of	O
10,000	O
and	O
an	O
accelerating	O
voltage	O
of	O
60	O
kv	O
.	O

Nucleic	O
acid	O
lengths	O
were	O
measured	O
at	O
a	O
final	O
magnification	O
of	O
43,000	O
with	O
a	O
Hewlett	O
-	O
Packard	O
9810A	O
calculator	O
equipped	O
with	O
a	O
9864A	O
digitizer	O
using	O
pBR322	O
and	O
fX-174	O
double	O
and	O
single	O
stranded	O
DNA	O
,	O
respectively	O
,	O
as	O
internal	O
length	O
standards	O
.	O

Approximately	O
10,000	O
hybrid	O
molecules	O
were	O
screened	O
for	O
these	O
studies	O
;	O
approximately	O
200	O
represented	O
molecules	O
containing	O
unambiguous	O
regions	O
appropriate	O
for	O
quantitative	O
analysis	O
.	O

The	O
mean	O
lengths	O
of	O
each	O
intron	O
and	O
exon	O
were	O
determined	O
for	O
each	O
method	O
and	O
the	O
data	O
expressed	O
as	O
mean	O
?	O

standard	O
deviation	O
.	O

Nucleic	O
acid	O
lengths	O
of	O
<	O
50	O
base	O
pairs	O
could	O
not	O
be	O
accurately	O
determined	O
using	O
the	O
methods	O
outlined	O
above	O
.	O

Thus	O
,	O
in	O
the	O
cases	O
where	O
introns	O
or	O
exons	O
were	O
of	O
this	O
length	O
or	O
less	O
,	O
accurate	O
error	O
estimates	O
could	O
not	O
be	O
made	O
.	O

Bi	O
ohazard	O
precauti	O
ons	O
.	O

The	O
construction	O
and	O
screening	O
of	O
the	O
sheep	B
genomic	O
library	O
together	O
with	O
amplification	O
of	O
pCg45	O
and	O
preparation	O
of	O
high	O
titre	O
lysates	O
of	O
chimaeric	O
Charon	O
4A	O
were	O
performed	O
under	O
the	O
physical	O
and	O
biological	O
containment	O
levels	O
specified	O
by	O
the	O
NIH	O
guidelines	O
for	O
recombinant	O
DNA	O
research	O
(	O
11	O
)	O
.	O

2243	O
Nucleic	O
Acids	O
Research	O
RESULTS	O
Location	O
and	O
orientation	O
of	O
the	O
intervening	O
and	O
a2	O
mRNA	O
coding	O
sequences	O
in	O
the	O
SpC3	O
recombinant	O
DNA	O
.	O

Hybridization	O
of	O
fetal	O
sheep	B
tendon	O
type	O
I	O
collagen	O
mRNA	O
to	O
SpC3	O
DNA	O
yielded	O
a	O
complex	O
R	O
loop	O
pattern	O
in	O
the	O
region	O
where	O
the	O
sheep	B
genomic	O
insert	O
was	O
expected	O
to	O
be	O
ligated	O
to	O
the	O
arms	O
of	O
the	O
lambda	O
vector	O
,	O
Charon	O
4A	O
.	O

To	O
confirm	O
that	O
these	O
hybridization	O
events	O
were	O
restricted	O
to	O
the	O
inserted	O
sheep	B
DNA	O
fragment	O
,	O
duplex	O
DNA	O
strands	O
on	O
both	O
sides	O
of	O
this	O
hybridization	O
area	O
were	O
measured	O
.	O

Using	O
pBR322	O
as	O
an	O
internal	O
length	O
standard	O
,	O
the	O
left	O
arm	O
of	O
the	O
phage	O
was	O
found	O
to	O
contain	O
21,780	O
?	O
1500	O
bp	O
,	O
and	O
the	O
right	O
arm	O
,	O
11,950	O
?	O

1030	O
bp	O
,	O
corresponding	O
to	O
the	O
report	O
values	O
for	O
the	O
left	O
and	O
right	O
arms	O
,	O
respectively	O
,	O
of	O
Charon	O
4A	O
DNA	O
(	O
5,6	O
)	O
.	O

The	O
hybridization	O
of	O
SpC3	O
to	O
a2	O
mRNA	O
resulted	O
in	O
the	O
destabilization	O
of	O
the	O
inserted	O
helical	O
duplex	O
DNA	O
fragment	O
such	O
that	O
one	O
DNA	O
strand	O
was	O
displaced	O
(	O
Figure	O
1	O
)	O
.	O

Occasionally	O
,	O
the	O
displaced	O
DNA	O
strand	O
was	O
mostly	O
absent	O
,	O
probably	O
due	O
to	O
fragmentation	O
induced	O
by	O
accidental	O
mechanical	O
shearing	O
.	O

This	O
event	O
considerably	O
enhanced	O
the	O
visualization	O
and	O
ordering	O
of	O
the	O
introns	O
.	O

As	O
the	O
a2	O
mRNA	O
annealed	O
to	O
complementary	O
DNA	O
regions	O
present	O
in	O
one	O
DNA	O
strand	O
,	O
numerous	O
single	O
-	O
stranded	O
loops	O
resulted	O
.	O

These	O
loops	O
,	O
referred	O
to	O
as	O
introns	O
,	O
represented	O
DNA	O
sequences	O
not	O
complementary	O
to	O
the	O
mRNA	O
.	O

Although	O
,	O
by	O
convention	O
,	O
introns	O
are	O
usually	O
sequentially	O
labeled	O
5	O
'	O
to	O
3	O
'	O
,	O
an	O
opposite	O
order	O
had	O
to	O
be	O
employed	O
in	O
this	O
case	O
as	O
SpC3	O
does	O
not	O
contain	O
the	O
sequences	O
coding	O
for	O
the	O
5	O
'	O
end	O
of	O
sheep	B
a2	O
mRNA	O
.	O

Infrequently	O
,	O
all	O
introns	O
were	O
clearly	O
observed	O
within	O
the	O
same	O
hybrid	O
molecule	O
(	O
Figure	O
1	O
)	O
.	O

The	O
largest	O
introns	O
were	O
towards	O
the	O
left	O
arm	O
of	O
Charon	O
4A	O
and	O
were	O
more	O
clustered	O
than	O
the	O
introns	O
at	O
the	O
opposite	O
end	O
of	O
the	O
hybrid	O
.	O

Thus	O
,	O
much	O
of	O
the	O
genetic	O
information	O
coding	O
for	O
the	O
a2	O
mRNA	O
was	O
contained	O
in	O
that	O
half	O
of	O
the	O
hybrid	O
attached	O
to	O
the	O
right	O
arm	O
.	O

A	O
small	O
non	O
-	O
hybridized	O
tail	O
was	O
consistently	O
found	O
in	O
the	O
region	O
where	O
the	O
right	O
arm	O
of	O
the	O
phage	O
was	O
ligated	O
to	O
the	O
sheep	B
genomic	O
insert	O
(	O
Figure	O
1	O
)	O
.	O

This	O
tail	O
likely	O
corresponded	O
to	O
the	O
3	O
'	O
poly	O
A	O
sequence	O
of	O
the	O
a2	O
mRNA	O
.	O

At	O
the	O
extreme	O
5	O
'	O
end	O
of	O
the	O
insert	O
,	O
a	O
variable	O
length	O
was	O
often	O
observed	O
for	O
the	O
remaining	O
unhybridized	O
mRNA	O
strand	O
.	O

This	O
was	O
most	O
likely	O
due	O
to	O
the	O
size	O
heterogeneity	O
of	O
the	O
a2	O
mRNA	O
used	O
in	O
these	O
studies	O
.	O

Size	O
determination	O
and	O
comparative	O
analysis	O
of	O
SpC3	O
introns	O
.	O

Although	O
localization	O
of	O
exon	O
and	O
intron	O
sequences	O
was	O
possible	O
with	O
both	O
the	O
70	O
%	O
formamide	O
and	O
urea	O
-	O
formamide	O
spreading	O
methods	O
,	O
the	O
probability	O
of	O
detecting	O
unambiguous	O
regions	O
in	O
a	O
hybrid	O
molecule	O
was	O
far	O
greater	O
with	O
the	O
2244	O
Nucleic	O
Acids	O
Research	O
A	O
B	O
'	O
,	O
:	O
'	O
14	O
.0	O
.	O

13	O
7	O
1	O
-5	O
13	O
.	O
.	O
.	O
.	O

,	O
4	O
x2	O
%	O
.	O

N1	O
9	O
>	O
10	O
R	O
4	O
Figure	O
1	O
.	O

Electron	O
microscopic	O
visualization	O
of	O
all	O
17	O
introns	O
and	O
18	O
exons	O
from	O
hybrid	O
molecules	O
formed	O
between	O
recombinant	O
clone	O
SpC3	O
DNA	O
and	O
fetal	O
sheep	B
tendon	O
a2	O
mRNA	O
.	O

(	O
A	O
,	O
B	O
)	O
Shown	O
are	O
the	O
double	O
-	O
stranded	O
segment	O
of	O
the	O
right	O
arm	O
CR	O
)	O
of	O
Charon	O
4A	O
;	O
double	O
-	O
stranded	O
segment	O
of	O
the	O
left	O
arm	O
CL	O
)	O
of	O
Charon	O
4A	O
;	O
the	O
displaced	O
single	O
-	O
stranded	O
DNA	O
segment	O
of	O
the	O
insert	O
(	O
5	O
)	O
;	O
single	O
-	O
stranded	O
DNA	O
loops	O
representing	O
introns	O
sequentially	O
labeled	O
1	O
through	O
17	O
in	O
the	O
3	O
'	O
to	O
5	O
'	O
direction	O
;	O
and	O
18	O
regions	O
of	O
insert	O
DNA	O
sequences	O
hybridized	O
to	O
ct2	O
mRNA	O
---	O
-	O
)	O
.	O

(	O
C	O
,	O
D	O
)	O
Similar	O
to	O
(	O
A	O
,	O
B	O
)	O
but	O
the	O
single	O
-	O
stranded	O
DNA	O
segment	O
(	O
5	O
)	O
of	O
the	O
insert	O
is	O
mostly	O
absent	O
.	O

The	O
urea	O
-	O
formamide	O
spreading	O
method	O
,	O
as	O
described	O
in	O
Materials	O
and	O
Methods	O
,	O
was	O
employed	O
.	O

2245	O
Nucleic	O
Acids	O
Research	O
urea	O
-	O
formamide	O
method	O
than	O
with	O
the	O
70	O
%	O
formamide	O
procedure	O
.	O

For	O
this	O
reason	O
,	O
most	O
measurements	O
were	O
made	O
with	O
the	O
urea	O
-	O
formamide	O
method	O
(	O
Tables	O
1,2	O
)	O
.	O

For	O
example	O
,	O
the	O
lowest	O
probability	O
event	O
,	O
the	O
detection	O
of	O
intron	O
17	O
and	O
the	O
surrounding	O
small	O
exons	O
,	O
""""	O
q	O
""""	O
and	O
""""	O
r	O
""""	O
,	O
was	O
only	O
observed	O
by	O
way	O
of	O
the	O
ureaformamide	O
spreading	O
procedure	O
.	O

The	O
smallest	O
introns	O
,	O
7	O
and	O
12	O
,	O
were	O
found	O
to	O
contain	O
approximately	O
the	O
same	O
number	O
of	O
bases	O
.	O

Introns	O
1	O
through	O
8	O
,	O
representing	O
the	O
DNA	O
sequences	O
which	O
split	O
the	O
a2	O
coding	O
sequence	O
corresponding	O
to	O
the	O
3	O
'	O
end	O
of	O
the	O
a2	O
mRNA	O
,	O
varied	O
in	O
length	O
over	O
approximately	O
a	O
2.4-fold	O
range	O
.	O

With	O
the	O
exception	O
of	O
Table	O
1	O
.	O

Electron	O
microscopic	O
R	O
loop	O
analysis	O
present	O
in	O
SpC3	O
DNA1	O
.	O

of	O
the	O
sheep	B
a2	O
introns	O
SpC3	O
was	O
hybridized	O
to	O
sheep	B
a2	O
mRNA	O
as	O
described	O
in	O
Materials	O
and	O
Methods	O
;	O
intron	O
lengths	O
were	O
determined	O
by	O
comparison	O
with	O
*	O
X-174	O
DNA	O
lengths	O
.	O

2	O
Introns	O
are	O
designated	O
sequentially	O
3	O
'	O
to	O
5	O
'	O
.	O

3	O
All	O
data	O
is	O
presented	O
as	O
mean	O
?	O

standard	O
deviation	O
.	O

4	O
Intron	O
17	O
was	O
visualized	O
only	O
by	O
the	O
urea	O
-	O
formamide	O
method	O
.	O

2246	O
70	O
%	O
Formamide	O
Method	O
Urea	O
-	O
Formamide	O
Method	O
Intron2	O
Number	O
of	O
Intron	O
length	O
Number	O
of	O
Intron	O
length	O
introns	O
analyzed	O
(	O
bases	O
)	O
introns	O
analyzed	O
(	O
bases	O
)	O
1	O
10	O
819	O
t	O
063	O
35	O
806	O
t	O
76	O
2	O
12	O
771	O
?	O
89	O
46	O
757	O
t	O
78	O
3	O
11	O
458	O
?	O
58	O
47	O
464	O
?	O
66	O
4	O
6	O
627	O
?	O
53	O

41	O
611	O
?	O

73	O
5	O
5	O
554	O
?	O

51	O

34	O

562	O
?	O
76	O

6	O
6	O
675	O
?	O
19	O

40	O
684	O
?	O

76	O
7	O
5	O
386	O
?	O
48	O

50	O
342	O
?	O
54	O
8	O
7	O
771	O
?	O
84	O

49	O
757	O
?	O

82	O
9	O
8	O
1,181	O
?	O
94	O

52	O
1,124	O
?	O

122	O
10	O
8	O
1,133	O
?	O
106	O

53	O
1,124	O
?	O

137	O
11	O
10	O
964	O
t?79	O
61	O

952	O
?	O

105	O
12	O
9	O
362	O
?	O

77	O

62	O
342	O
?	O

71	O
13	O
4	O
723	O
?	O

222	O

53	O
806	O
?	O

105	O
14	O
4	O
1,085	O
?	O

142	O
53	O
1,075	O
?	O

105	O
15	O
3	O
795	O

?	O
60	O

47	O
806	O
?	O

100	O
16	O
2	O
1,229	O
?	O
48	O

43	O
1,319	O
?	O
146	O

174	O
-	O
-	O
12	O
1,539	O
?	O

166	O
1	O
Nucleic	O
Acids	O
Research	O
Table	O
2	O
.	O

Electron	O
microscopic	O
R	O
loop	O
analysis	O
of	O
the	O
sheep	B
a2	O
exons	O
present	O
in	O
SpC3	O
DNA1	O
.	O

70	O
%	O
Formamide	O
Method	O
Urea	O
-	O
Formamide	O
Method	O
Exon2	O
Number	O
of	O
Exon	O
length	O
Number	O
of	O
Exon	O
length	O
exons	O
analyzed	O
(	O
base	O
pairs	O
)	O
exons	O
analyzed	O
(	O
base	O
pairs	O
)	O
a	O
7	O
807	O
?	O
883	O

26	O
883	O
?	O

132	O
b	O

10	O
252	O
?	O

35	O
41	O
234	O
?	O

49	O
c	O
11	O
151	O
?	O

25	O
48	O
182	O
?	O

42	O
d	O
6	O
252	O
?	O
60	O
44	O
234	O
?	O

62	O
e	O
5	O
126	O
?	O
45	O

37	O
129	O
?	O

47	O
f	O
5	O
126	O
?	O
38	O
35	O
104	O
?	O
41	O
9	O
5	O
176	O
?	O

48	O
40	O
182	O
?	O
54	O
h	O
5	O
100	O
?	O
43	O
47	O
104	O
?	O

31	O
7	O
100	O
?	O
35	O
50	O
104	O
?	O

28	O
j	O
7	O
126	O
?	O

48	O
45	O
130	O
?	O

47	O
k	O
8	O
50	O
?	O
48	O
51	O

52	O
?	O
39	O
1	O
9	O
75	O

?	O
10	O

60	O
52	O
?	O
44	O
m	O
6	O
126	O
?	O

43	O

51	O
182	O
?	O
54	O
n	O
4	O
100	O
?	O

45	O

53	O
52	O
?	O

42	O
o	O

3	O
<	O
504	O

50	O

78	O
?	O
36	O
p	O

2	O
126	O
?	O
71	O
47	O
104	O
?	O
36	O
q5	O
-	O
_	O
33	O
130?47	O
r5	O
r	O
6	O
78?36	O
SpC3	O
was	O
hybridized	O
to	O
sheep	B
a2	O
mRNA	O
as	O
described	O
in	O
M4aterials	O
and	O
Methods	O
;	O
exon	O
lengths	O
were	O
determined	O
by	O
comparison	O
with	O
pBR322	O
DNA	O
lengths	O
.	O

2	O
Exons	O
are	O
designated	O
sequentially	O
3	O
'	O
to	O
5	O
'	O
.	O

3	O
All	O
data	O
is	O
presented	O
as	O
mean	O
?	O

standard	O
deviation	O
.	O

4	O
5	O
No	O
statistical	O
evaluation	O
was	O
possible	O
because	O
of	O
the	O
size	O
of	O
the	O
exon	O
(	O
see	O
(	O
Materials	O
and	O
Methods	O
)	O
.	O

Exons	O
q	O
and	O
r	O
were	O
only	O
analyzed	O
by	O
the	O
urea	O
-	O
formamide	O
method	O
.	O

intron	O
1	O
,	O
the	O
nucleotide	O
size	O
of	O
these	O
introns	O
was	O
less	O
than	O
800	O
bases	O
.	O

In	O
contrast	O
,	O
introns	O
9	O
through	O
17	O
varied	O
over	O
a	O
4.5-fold	O
range	O
.	O

Except	O
for	O
intron	O
12	O
,	O
all	O
of	O
the	O
introns	O
9	O
through	O
17	O
contained	O
800	O
bases	O
or	O
more	O
.	O

Summation	O
of	O
introns	O
1	O
through	O
16	O
for	O
the	O
70	O
%	O
formamide	O
and	O
urea	O
formamide	O
spreading	O
methods	O
yielded	O
12,533	O
and	O
12,531	O
bases	O
,	O
respectively	O
.	O

However	O
,	O
detection	O
of	O
intron	O
17	O
by	O
the	O
urea	O
-	O
formamide	O
method	O
indicates	O
that	O
the	O
actual	O
summed	O
value	O
for	O
the	O
intervening	O
sequences	O
of	O
SpC3	O
is	O
14,070	O
bases	O
.	O

2247	O
1	O
Nucleic	O
Acids	O
Research	O
Size	O
determination	O
and	O
the	O
comparative	O
analysis	O
of	O
SpC3	O
exons	O
.	O

Eighteen	O
exons	O
,	O
""""	O
a	O
""""	O
through	O
""""	O
r	O
""""	O
,	O
were	O
mapped	O
(	O
Table	O
2	O
)	O
.	O

The	O
largest	O
exon	O
,	O
""""	O
a	O
""""	O
,	O
located	O
on	O
the	O
extreme	O
3	O
'	O
end	O
of	O
the	O
sheep	B
genomic	O
insert	O
,	O
contained	O
approximately	O
800	O
bp	O
.	O

With	O
the	O
exception	O
of	O
exon	O
""""	O
m	O
""""	O
,	O
exons	O
larger	O
than	O
150	O
base	O
pairs	O
were	O
confined	O
to	O
the	O
genetic	O
region	O
corresponding	O
to	O
the	O
far	O
3	O
'	O
end	O
of	O
the	O
a2	O
mRNA	O
.	O

Exon	O
""""	O
a	O
""""	O
and	O
exon	O
""""	O
b	O
""""	O
,	O
the	O
two	O
exons	O
situated	O
on	O
either	O
side	O
of	O
intron	O
1	O
,	O
coded	O
for	O
around	O
1000	O
bases	O
of	O
a2	O
collagen	O
information	O
;	O
these	O
two	O
exons	O
contained	O
one	O
-	O
third	O
of	O
the	O
mapped	O
3,014	O
DNA	O
bases	O
complementary	O
to	O
a2	O
mRNA	O
Length	O
distribution	O
and	O
organization	O
of	O
the	O
introns	O
and	O
exons	O
in	O
the	O
sheep	B
genomi	O
c	O
i	O
nsert	O
.	O

There	O
was	O
a	O
sharp	O
contrast	O
in	O
the	O
size	O
distribution	O
of	O
the	O
exons	O
and	O
introns	O
contained	O
within	O
SpC3	O
(	O
Figure	O
2	O
)	O
.	O

While	O
the	O
intron	O
sizes	O
varied	O
considerably	O
,	O
the	O
exons	O
,	O
in	O
general	O
,	O
showed	O
a	O
very	O
narrow	O
distribution	O
of	O
lengths	O
,	O
and	O
thus	O
tended	O
to	O
cluster	O
at	O
the	O
lowest	O
end	O
of	O
the	O
length	O
distri	O
A.	O
(	O
I	O
)	O
z	O
6	O
0	O
z	O
ZL4	O
0	O
021	O
z	O
10	O
B.	O
8	O
z	O
0	O
16	O
0	O
z	O
2	O
20	O
400	O
600	O
800	O
1000	O
1200	O
1400	O
1600	O
LENGTH	O
IN	O
NUCLEOTIDES	O
Figure	O
2	O
.	O

Length	O
distribution	O
of	O
the	O
intron	O
and	O
exon	O
mean	O
lengths	O
measured	O
from	O
micrographs	O
prepared	O
by	O
the	O
urea	O
-	O
formamide	O
method	O
.	O

(	O
A	O
)	O
Introns	O
;	O
(	O
b	O
)	O
Exons	O
.	O

See	O
Tables	O
1	O
and	O
2	O
for	O
details	O
.	O

2248	O
Nucleic	O
Acids	O
Research	O
bution	O
graph	O
.	O

The	O
exon	O
in	O
the	O
800	O
-	O
900	O
bp	O
region	O
was	O
unique	O
and	O
was	O
the	O
only	O
exon	O
which	O
exhibited	O
length	O
overlap	O
with	O
introns	O
.	O

The	O
maps	O
of	O
the	O
a2	O
collagen	O
gene	O
obtained	O
with	O
both	O
electron	O
micro	O
scopic	O
spreading	O
methods	O
were	O
almost	O
identical	O
(	O
Figure	O
3	O
)	O
,	O
except	O
that	O
the	O
region	O
at	O
the	O
extreme	O
5	O
'	O
end	O
of	O
the	O
insert	O
could	O
only	O
be	O
mapped	O
with	O
the	O
ureaformamide	O
method	O
.	O

From	O
these	O
measurements	O
we	O
concluded	O
that	O
the	O
length	O
of	O
the	O
a2	O
collagen	O
genetic	O
regi?on	O
in	O
SpC3	O
was	O
17,084	O
bases	O
long	O
with	O
only	O
3,014	O
bases	O
actually	O
coding	O
for	O
a2	O
mRNA	O
.	O

Therefore	O
,	O
only	O
18	O
%	O
of	O
the	O
mapped	O
17	O
kb	O
sheep	B
genetic	O
insert	O
actually	O
contained	O
a2	O
structural	O
information	O
.	O

DISCUSSION	O
The	O
organizational	O
structure	O
of	O
the	O
a2	O
collagen	O
gene	O
is	O
complex	O
.	O

A	O
minimum	O
of	O
17	O
introns	O
interrupt	O
the	O
3	O
kb	O
of	O
ca2	O
genetic	O
information	O
interspersed	O
as	O
18	O
exons	O
over	O
17	O
kb	O
of	O
sheep	B
DNA	O
.	O

With	O
the	O
exception	O
of	O
exon	O
""""	O
a	O
""""	O
located	O
at	O
the	O
extreme	O
3	O
'	O
end	O
of	O
the	O
inserted	O
a2	O
gene	O
,	O
all	O
other	O
mapped	O
exons	O
are	O
rather	O
small	O
,	O
exhibiting	O
a	O
size	O
distribution	O
range	O
of	O
50	O
to	O
250	O
bp	O
.	O

In	O
contrast	O
,	O
the	O
intron	O
sizes	O
range	O
from	O
340	O
to	O
1540	O
bases	O
occupying	O
a	O
total	O
of	O
14	O
kb	O
.	O

Thus	O
,	O
the	O
DNA	O
region	O
containing	O
the	O
3	O
kb	O
of	O
a2	O
collagen	O
genetic	O
information	O
is	O
5.6	O
fold	O
longer	O
than	O
the	O
corresponding	O
co2	O
mRNA	O
sequences	O
.	O

Although	O
the	O
total	O
number	O
of	O
introns	O
present	O
within	O
the	O
60	O
%	O
3	O
'	O
portion	O
of	O
the	O
a2	O
sheep	B
gene	O
was	O
determined	O
to	O
be	O
17	O
,	O
variation	O
in	O
the	O
precise	O
number	O
TRANSRIPTlO	O
A	O
5w	O
r	O
1	O
""""	O
2a4	O
133	O
112s	O
11.17	O
0	O
.	O

3O	O
2	O
715	O
6.2	O
313	O
04	O
4.2B	O
3.51	O
2.2	O
12	O
EXON0	O
p	O
o	O
n	O
5	O
Ik	O
h	O
f	O
d	O
4	O
.	O

b	O
WPM300	O
16	O
16	O
14	O
13	O
12	O
11	O
10	O
9	O
6	O
7	O
6	O
5	O
4	O
3	O
2	O
1	O
B	O
110	O
16	O
4.2	O
13111	O
112n	O
1113104	O
3.6	O
gm74	O
2	O
6	O
.	O

4	O
4	O
2	O
3.2	O
22	O
in	O
1	O
a1m03	O
133	O
1.2	O
11	O
10	O
01	O
341	O
6	O
.	O

1	O
117	O
6.2	O
4	O
12	O
417	O
3I5'm	O
2	O
DM00	O
1	O
q5	O
p	O
0	O
n	O
m	O
I	O
k.	O
j	O
i	O
h	O
g	O
f	O
d	O
c	O

b	O
a	O
147306	O
17	O
16	O
15	O
14	O
13	O
12	O
11	O
10	O
9	O
a	O
7	O
6	O
5	O
4	O
3	O
2	O
1	O
175	O
17.0	O
16.6	O
&	O
16'5.5	O
15.0	O
14.5	O
14	O
.	O

13.5	O
13.0	O
12.5	O
12.0	O
11.5	O
11	O
10.5	O
M	O
10.0	O
9.5	O
9.0	O
8	O
.	O
5.0	O
71	O
7.0	O
6.5	O
6	O
.	O

5.5	O
50	O
4.5	O
4.0	O
3.5	O
3.0	O
2.5	O
2.0	O
1.5	O
1.0	O
KILOBASE	O
Fiue3	O
Organization	O
of	O
60	O
%	O
of	O
the	O
3	O
'	O
end	O
of	O
the	O
sheep	B
a2	O
collagen	O
gene	O
.	O

(	O
A	O
)	O
}	O
The	O
exon	O
(	O
)	O
and	O
intron	O
(	O
CDJ	O
)	O
order	O
within	O
the	O
a2	O
gene	O
as	O
determined	O
by	O
R	O
loop	O
analysis	O
of	O
SpC3	O
DNA	O
-	O
a2	O
mRNA	O
hybrid	O
molecules	O
visualized	O
by	O
the	O
electron	O
microscopic	O
70	O
%	O
formamide	O
spreading	O
method	O
.	O

(	O
B	O
)	O
The	O
exon	O
Um	O
)	O
and	O
intron	O
(	O
Efl	O
)	O
order	O
within	O
the	O
a2	O
gene	O
as	O
determined	O
by	O
R	O
loop	O
analysis	O
of	O
SpC3	O
DNA	O
-	O
a2	O
mRNA	O
hybrid	O
molecules	O
evaluated	O
by	O
the	O
electron	O
microscopic	O
urea	O
-	O
formamide	O
spreading	O
method	O
.	O

Arrows	O
represent	O
the	O
approximate	O
location	O
of	O
intron	O
-	O
exon	O
junctions	O
.	O

All	O
values	O
are	O
presented	O
as	O
kilobase	O
pairs	O
.	O

2249	O
Nucleic	O
Acids	O
Research	O
of	O
introns	O
present	O
in	O
individual	O
hybrid	O
molecules	O
was	O
observed	O
.	O

The	O
reason	O
for	O
this	O
may	O
be	O
due	O
to	O
size	O
heterogeneity	O
of	O
the	O
a2	O
mRNA	O
used	O
as	O
a	O
complementary	O
probe	O
.	O

Although	O
the	O
a2	O
mRNA	O
was	O
extensively	O
purified	O
(	O
2	O
)	O
,	O
some	O
degradation	O
was	O
likely	O
present	O
.	O

It	O
is	O
also	O
possible	O
that	O
additional	O
introns	O
exist	O
that	O
are	O
too	O
small	O
to	O
be	O
detected	O
by	O
electron	O
microscopic	O
R	O
loop	O
analysis	O
.	O

The	O
most	O
likely	O
a2	O
genetic	O
regions	O
containing	O
such	O
introns	O
are	O
exons	O
""""	O
g	O
""""	O
and	O
""""	O
m	O
""""	O
.	O

Small	O
""""	O
protrusions	O
""""	O
were	O
sometimes	O
observed	O
within	O
these	O
exons	O
that	O
could	O
represent	O
small	O
introns	O
.	O

Very	O
small	O
introns	O
have	O
been	O
reported	O
for	O
tRNA	O
genes	O
(	O
12,13	O
)	O
,	O
and	O
it	O
will	O
be	O
necessary	O
to	O
sequence	O
these	O
regions	O
of	O
SpC3	O
to	O
determine	O
if	O
such	O
introns	O
are	O
present	O
within	O
the	O
a2	O
sheep	B
genome	O
.	O

The	O
existence	O
of	O
mRNAs	O
comprised	O
of	O
sequences	O
complementary	O
to	O
noncontiguous	O
regions	O
in	O
a	O
DNA	O
genome	O
was	O
first	O
described	O
for	O
adenovirus	B
(	O
14,15	O
)	O
and	O
simian	O
virus	O
(	O
16,17	O
)	O
genes	O
.	O

Similar	O
observations	O
were	O
soon	O
reported	O
for	O
eukaryotic	O
genes	O
,	O
including	O
serum	O
albumin	O
(	O
18	O
)	O
,	O
conalbumin	O
(	O
19	O
)	O
,	O
fibroin	O
(	O
20	O
)	O
,	O
s	O
globin	O
(	O
21,22	O
)	O
,	O
growth	O
hormones	O
(	O
23,24	O
)	O
,	O
immunoglobulin	O
(	O
25	O
)	O
,	O
lysozyme	O
(	O
26	O
)	O
,	O
ovalbumin	O
(	O
27	O
-	O
29	O
)	O
,	O
ovomucoid	O
(	O
30	O
)	O
,	O
rRNA	O
(	O
31	O
-	O
34	O
)	O
,	O
tRNA	O
(	O
12,13	O
)	O
,	O
and	O
vitellogenin	O
(	O
35	O
)	O
.	O

The	O
precise	O
number	O
or	O
occurrence	O
of	O
introns	O
within	O
these	O
genes	O
does	O
not	O
seem	O
to	O
follow	O
any	O
clear	O
pattern	O
.	O

However	O
,	O
the	O
genes	O
for	O
albumin	O
,	O
conalbumin	O
,	O
lysozyme	O
,	O
ovalbumin	O
,	O
and	O
ovomucoid	O
exhibit	O
a	O
structural	O
organization	O
comparable	O
to	O
the	O
a2	O
collagen	O
gene	O
.	O

All	O
of	O
these	O
genes	O
are	O
composed	O
of	O
numerous	O
small	O
exons	O
,	O
usually	O
less	O
than	O
250	O
base	O
pairs	O
,	O
and	O
introns	O
which	O
show	O
a	O
large	O
size	O
variation	O
within	O
an	O
individual	O
gene	O
.	O

Within	O
all	O
of	O
these	O
genomes	O
,	O
the	O
DNA	O
regions	O
required	O
for	O
coding	O
structural	O
formation	O
are	O
4	O
to	O
7	O
times	O
longer	O
than	O
the	O
corresponding	O
mRNA	O
coding	O
sequences	O
.	O

As	O
with	O
the	O
a2	O
collagen	O
gene	O
,	O
a	O
large	O
unique	O
exon	O
at	O
the	O
extreme	O
3	O
'	O
end	O
is	O
also	O
present	O
in	O
the	O
ovalbumin	O
gene	O
(	O
36,37	O
)	O
.	O

In	O
the	O
a2	O
gene	O
,	O
this	O
exon	O
was	O
800	O
to	O
900	O
nucleotides	O
in	O
length	O
,	O
while	O
in	O
the	O
ovalbumin	O
gene	O
the	O
exon	O
contained	O
1,030	O
base	O
pairs	O
.	O

Interestingly	O
,	O
this	O
ovalbumin	O
exon	O
contained	O
634	O
-	O
650	O
base	O
pairs	O
ot	O
DNA	O
sequence	O
to	O
the	O
3	O
'	O
side	O
of	O
the	O
terminator	O
triplet	O
,	O
suggesting	O
the	O
ovalbumin	O
mRNA	O
has	O
a	O
large	O
untranslated	O
region	O
at	O
the	O
3	O
'	O
end	O
.	O

The	O
consistent	O
appearance	O
of	O
a	O
small	O
non	O
-	O
hybridized	O
tail	O
,	O
approximately	O
100	O
nucleotides	O
in	O
length	O
,	O
in	O
the	O
region	O
where	O
the	O
right	O
arm	O
of	O
the	O
phage	O
was	O
ligated	O
to	O
the	O
sheep	B
genomic	O
insert	O
of	O
SpC3	O
very	O
likely	O
corresponded	O
to	O
the	O
3	O
'	O
poly	O
A	O
sequence	O
of	O
the	O
a2	O
mRNA	O
.	O

This	O
would	O
suggest	O
that	O
the	O
a2	O
mRNA	O
coding	O
sequence	O
terminates	O
very	O
near	O
or	O
at	O
this	O
point	O
in	O
the	O
genome	O
.	O

Previously	O
published	O
biochemical	O
evidence	O
(	O
2	O
)	O
obtained	O
from	O
restriction	O
mapping	O
and	O
Southern	O
blot	O
analysis	O
using	O
[	O
32P	O
]	O
-labeled	O
chick	O
a2	O
cDNA	O
probe	O
supports	O
2250	O
Nucleic	O
Acids	O
Research	O
this	O
observation	O
.	O

It	O
is	O
unclear	O
what	O
role	O
introns	O
play	O
in	O
genetic	O
expression	O
.	O

However	O
,	O
it	O
is	O
known	O
that	O
these	O
sequences	O
are	O
tranncribed	O
as	O
part	O
of	O
larger	O
precursor	O
mRNAs	O
and	O
the	O
introns	O
are	O
then	O
excised	O
and	O
the	O
fragmented	O
mRNA	O
chains	O
covalently	O
rejoined	O
(	O
38	O
)	O
.	O

Some	O
evidence	O
has	O
recently	O
accumulated	O
demonstrating	O
the	O
existence	O
of	O
precursor	O
a2	O
mRNAs	O
(	O
39,40	O
)	O
.	O

However	O
,	O
if	O
the	O
introns	O
in	O
the	O
a2	O
gene	O
are	O
transcribed	O
in	O
their	O
entirety	O
,	O
as	O
has	O
been	O
demonstrated	O
for	O
the	O
introns	O
in	O
ovalbumin	O
and	O
globin	O
(	O
41,42	O
)	O
,	O
much	O
larger	O
precursor	O
a2	O
mRNAs	O
may	O
exist	O
than	O
those	O
reported	O
to	O
date	O
.	O

For	O
if	O
the	O
re	O
mainder	O
of	O
the	O
a2	O
collagen	O
gene	O
has	O
a	O
structural	O
organization	O
comparable	O
to	O
the	O
60	O
%	O
3	O
'	O
portion	O
that	O
has	O
been	O
analyzed	O
,	O
it	O
is	O
probable	O
that	O
the	O
a2	O
collagen	O
gene	O
in	O
its	O
entirety	O
is	O
dispersed	O
throughout	O
a	O
30	O
kb	O
DNA	O
segment	O
.	O

ACKNOWLEDGMENTS	O
We	O
thank	O
Dr.	O
John	O
Dahlberg	O
and	O
Frances	O
Loebenstein	O
,	O
Laboratory	O
of	O
Cellular	O
and	O
Molecular	O
Biology	O
,	O
National	O
Cancer	O
Institute	O
,	O
for	O
the	O
generous	O
use	O
of	O
a	O
Siemens	O
Elmiskop	O
101	O
electron	O
microscope	O
;	O
Dr.	O
Ursula	O
Heine	O
and	O
Benjamin	O
Elliott	O
,	O
Laboratory	O
of	O
Viral	O
Carcinogenesis	O
,	O
National	O
Cancer	O
Institute	O
,	O
for	O
the	O
use	O
of	O
a	O
Hewlett	O
-	O
Packard	O
calculator	O
equipped	O
with	O
a	O
digitizer	O
and	O
a	O
Denton	O
vacuum	O
evaporator	O
,	O
and	O
Drs	O
.	O

Victor	O
Ferrans	O
and	O
Oichi	O
Kawanami	O
,	O
Laboratory	O
of	O
Pathology	O
,	O
National	O
Heart	O
,	O
Lung	O
,	O
and	O
Blood	O
Institute	O
,	O
for	O
expert	O
assistance	O
with	O
photography	O
.	O

We	O
are	O
also	O
grateful	O
to	O
Margery	O
Sullivan	O
,	O
Laboratory	O
of	O
Molecular	O
Genetics	O
,	O
National	O
Institute	O
of	O
Child	O
Health	O
and	O
Human	B
Development	O
,	O
for	O
helpful	O
discussions	O
and	O
to	O
Dr.	O
Helga	O
Boedtker	O
,	O
Department	O
of	O
Chemistry	O
,	O
Harvard	O
University	O
,	O
for	O
making	O
available	O
the	O
recombinant	O
plasmid	O
pCg45	O
.	O

References	O
1	O
.	O

Prockop	O
,	O
D.	O
J.	O
,	O
Kivirikko	O
,	O
k.	O
I.	O
,	O
Tuderman	O
,	O
L.	O
,	O
and	O
Guzman	O
,	O
N.	O
A.	O
(	O
1979	O
)	O
New	O
Engl	O
.	O

J.	O
Med	O
.	O

301	O
,	O
13	O
-	O
23	O
and	O
77	O
-	O
85	O
.	O

2	O
.	O

Boyd	O
,	O
C.	O
D.	O
,	O
Tolstoshev	O
,	O
P.	O
,	O
Schafer	O
,	O
M.	O
P.	O
,	O
Trapnell	O
,	O
B.	O
C.	O
,	O
Coon	O
,	O
H.	O
C.	O
,	O
Kretschmer	O
,	O
P.	O
J.	O
,	O
Nienhuis	O
,	O
A.	O
W.	O
,	O
and	O
Crystal	O
,	O
R.	O
G.	O
(	O
1980	O
)	O
J.	O
Biol	O
.	O

Chem	O
.	O
,	O
in	O
press	O
.	O

3	O
.	O

Blin	O
,	O
N.	O
,	O
and	O
Stafford	O
,	O
D.	O
W.	O
(	O
1976	O
)	O
Nucl	O
.	O

Acids	O
Res	O
.	O

3	O
,	O
2303	O
-	O
2308	O
.	O

4	O
.	O

Kretschmer	O
,	O
P.	O
J.	O
,	O
Kaufman	O
,	O
R.	O
E.	O
,	O
Coon	O
,	O
H.	O
C.	O
,	O
Chen	O
,	O
M.	O
JY	O
.	O
,	O
Geist	O
C.	O
E.	O
,	O
and	O
Nienhuis	O
,	O
A.	O
W.	O
(	O
1980	O
)	O
J.	O
Biol	O
.	O

Chem	O
.	O
,	O
in	O
press	O
.	O

5	O
.	O

Maniatis	O
,	O
T.	O
,	O
Hardison	O
,	O
R.	O
C.	O
,	O
Lacey	O
,	O
E.	O
,	O
Laver	O
,	O
H.	O
,	O
O'Connell	O
,	O
C.	O
,	O
Quon	O
,	O
D.	O
,	O
Sim	O
,	O
G.	O
K.	O
,	O
and	O
Efstratiadis	O
,	O
A.	O
(	O
1975	O
)	O
Cell	O
15	O
,	O
687	O
-	O
701	O
.	O

6	O
.	O

Blattner	O
,	O
F.	O
R.	O
,	O
Blechl	O
,	O
A.	O
E.	O
,	O
Denniston	O
-	O
Thompson	O
,	O
K.	O
,	O
Faber	O
,	O
H.	O
E.	O
,	O
Richards	O
,	O
J.	O
E.	O
,	O
Slightom	O
,	O
H.	O
L.	O
,	O
Tucker	O
,	O
P.	O
W.	O
,	O
and	O
Smithies	O
,	O
0	O
.	O
(	O
1978	O
)	O
Science	O
202	O
,	O
1279	O
-	O
1284	O
.	O

7	O
.	O

Meyer	O
,	O
J.	O
,	O
Neuwald	O
,	O
P.	O
D.	O
,	O
Lai	O
,	O
S.	O
,	O
Maizel	O
,	O
J.	O
V.	O
,	O
Jr.	O
,	O
and	O
Westphal	O
,	O
H.	O
(	O
1977	O
)	O
J.	O
Virol	O
.	O

21	O
,	O
1010	O
-	O
1014	O
.	O

2251	O
Nucleic	O
Acids	O
Research	O
8	O
.	O

Westphal	O
,	O
H.	O
,	O
and	O
Lai	O
,	O
S.	O
P.	O
(	O
1977	O
)	O
J.	O
Mol	O
.	O

Biol	O
.	O

116	O
,	O
525	O
-	O
548	O
.	O
9	O
.	O

Schafer	O
,	O
M.	O
P.	O
,	O
Rohrmann	O
,	O
G.	O
,	O
Heine	O
,	O
U.	O
,	O
and	O
Beaudreau	O
,	O
G.	O
S.	O
(	O
1979	O
)	O
Virol	O
.	O

95	O
,	O
176	O
-	O
184	O
.	O

10	O
.	O

Davis	O
,	O
R.	O
W.	O
,	O
Simon	O
,	O
M.	O
M.	O
,	O
and	O
Davison	O
,	O
N.	O
(	O
1971	O
)	O
in	O
Methods	O
in	O
Enzymology	O
(	O
Grossman	O
,	O
L.	O
and	O
Moldave	O
,	O
K.	O
,	O
eds	O
)	O
Vol	O
.	O

21	O
,	O
pp	O
.	O

413428	O
,	O
Academic	O
Press	O
,	O
New	O
York	O
.	O

11	O
.	O

Federal	O
Register	O
(	O
1978	O
)	O
43	O
,	O
60108	O
-	O
60131	O
.	O

12	O
.	O

Goodman	O
,	O
H.	O
M.	O
,	O
Olson	O
,	O
M.	O
V.	O
,	O
Hall	O
,	O
B.	O
D.	O
(	O
1977	O
)	O
Pro	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

U.S.A.	O
74	O
,	O
5453	O
-	O
5457	O
.	O

13	O
.	O

Valenzuela	O
,	O
P.	O
,	O
Venegas	O
,	O
A.	O
,	O
Weinberg	O
,	O
F.	O
,	O
Bishop	O
,	O
R.	O
,	O
Rutter	O
,	O
W.	O
J.	O
(	O
1978	O
)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

U.S.A.	O
75	O
,	O
190	O
-	O
194	O
.	O

14	O
.	O

Berget	O
,	O
S.	O
M.	O
,	O
Moore	O
,	O
C.	O
,	O
and	O
Sharp	O
,	O
P.	O
A.	O
(	O
1977	O
)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

U.S.A.	O
74	O
,	O
3171	O
-	O
3175	O
.	O

15	O
.	O

Chow	O
,	O
L.	O
T.	O
,	O
Gelinas	O
,	O
R.	O
E.	O
,	O
Broker	O
,	O
T.	O
,	O
and	O
Roberts	O
,	O
R.	O
J.	O
(	O
1977	O
)	O
Cell	O
12	O
,	O
1	O
-	O
8	O
.	O

16	O
.	O

Berk	O
,	O
A.	O
J.	O
,	O
and	O
Sharp	O
,	O
P.	O
A.	O
(	O
1978	O
)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

U.S.A.	O
75	O
,	O
1274	O
-	O
1278	O
.	O

17	O
.	O

Bratosin	O
,	O
S.	O
,	O
Horowitz	O
,	O
M.	O
,	O
Laub	O
,	O
0	O
.	O
,	O
and	O
Aloni	O
,	O
Y.	O
(	O
1978	O
)	O
Cell	O
13	O
,	O
783	O
-	O
790	O
.	O

18	O
.	O

Sargent	O
,	O
T.	O
D.	O
,	O
Wu	O
,	O
J.	O
R.	O
,	O
Sala	O
-	O
Trepat	O
,	O
J.	O
M.	O
,	O
Wallace	O
,	O
R.	O
B.	O
,	O
Reyes	O
,	O
A.	O
A.	O
,	O
and	O
Bonner	O
,	O
J.	O
(	O
1979	O
)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

U.S.A.	O
76	O
,	O
3256	O
-	O
3260	O
.	O

19	O
.	O

Perrin	O
,	O
F.	O
,	O
Cochet	O
,	O
M.	O
,	O
Gerlinger	O
,	O
P.	O
,	O
Cami	O
,	O
B.	O
,	O
LePennec	O
,	O
J.	O
P.	O
,	O
and	O
Chambon	O
,	O
P.	O
(	O
1979	O
)	O
Nucl	O
.	O

Acids	O
Res	O
.	O

6	O
2731	O
-	O
2748	O
.	O

20	O
.	O

Tsujimoto	O
,	O
Y.	O
,	O
and	O
Suzuki	O
,	O
Y.	O
(	O
1979	O
)	O
Cell	O
16	O
425	O
-	O
436	O
.	O

21	O
.	O

Jeffreys	O
,	O
A.	O
J.	O
,	O
and	O
Flavell	O
,	O
R.	O
A.	O
(	O
1977	O
)	O
Cell	O
12	O
,	O
1097	O
-	O
1108	O
.	O

22	O
.	O

Tilghman	O
,	O
S.	O
M.	O
,	O
Tiemeier	O
,	O
D.	O
C.	O
,	O
Seidman	O
,	O
J.	O
C.	O
,	O
Matija	O
Peterlin	O
,	O
B.	O
,	O
Sullivan	O
,	O
M.	O
,	O
Maizel	O
,	O
J.	O
V.	O
,	O
and	O
Leder	O
,	O
P.	O
(	O
1978	O
)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

U.S.A.	O
75	O
,	O
725	O
-	O
729	O
.	O

23	O
.	O

Fiddes	O
,	O
J.	O
C.	O
,	O
Seeburg	O
,	O
P.	O
H.	O
,	O
DeNoto	O
,	O
F.	O
M.	O
,	O
Hallewell	O
,	O
R.	O
A.	O
,	O
Baxter	O
,	O
J.	O
D.	O
,	O
and	O
Goodman	O
,	O
H.	O
M.	O
(	O
1979	O
)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

U.S.A.	O
76	O
,	O
4294	O
-	O
4298	O
.	O

24	O
.	O

Soreq	O
,	O
H.	O
,	O
Harpold	O
,	O
M.	O
,	O
Evans	O
,	O
R.	O
,	O
Darnell	O
,	O
Jr.	O
,	O
J.	O
E.	O
,	O
and	O
Bancroft	O
,	O
F.	O
C.	O
(	O
1979	O
)	O
Nucl	O
.	O

Acids	O
Res	O
.	O

6	O
,	O
2471	O
-	O
2482	O
.	O

25	O
.	O

Tonegawa	O
,	O
S.	O
,	O
Maxam	O
,	O
A.	O
M.	O
,	O
Tizard	O
,	O
R.	O
,	O
Bernard	O
,	O
0	O
.	O
,	O
and	O
Gilbert	O
,	O
W.	O
(	O
1978	O
)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

U.S.A.	O
75	O
,	O
1485	O
-	O
1489	O
.	O

26	O
.	O

Nguyen	O
-	O
Huu	O
,	O
M.	O
C.	O
,	O
Stratmann	O
,	O
M.	O
,	O
Groner	O
,	O
B.	O
,	O
Wurtz	O
,	O
T.	O
,	O
Land	O
,	O
M.	O
,	O
Glesecke	O
,	O
K.	O
,	O
Sippel	O
,	O
A.	O
F.	O
,	O
and	O
Schutz	O
,	O
G.	O
(	O
1979	O
)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

U.S.A.	O
76	O
,	O
76	O
-	O
80	O
.	O

27	O
.	O

Breathnach	O
,	O
R.	O
,	O
Mandel	O
,	O
J.	O
L.	O
,	O
and	O
Chambon	O
,	O
P.	O
(	O
1977	O
)	O
Nature	O
270	O
,	O
314	O
-	O
319	O
.	O

28	O
.	O

Dugaiczyk	O
,	O
A.	O
,	O
Woo	O
,	O
S.	O
L.	O
C.	O
,	O
Lai	O
,	O
E.	O
C.	O
,	O
Mace	O
,	O
M.	O
L.	O
,	O
Jr.	O
,	O
McReynolds	O
,	O
L.	O
,	O
and	O
O'Malley	O
,	O
B.	O
W.	O
(	O
1978	O
)	O
Nature	O
274	O
,	O
328	O
-	O
333	O
.	O
29	O
.	O

Weinstock	O
,	O
R.	O
,	O
Sweet	O
,	O
R.	O
,	O
Weiss	O
,	O
M.	O
,	O
Cedar	O
,	O
M.	O
,	O
and	O
Axel	O
,	O
R.	O
(	O
1978	O
)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

U.S.A.	O
75	O
,	O
1299	O
-	O
1303	O
.	O

30	O
.	O

Catterall	O
,	O
J.	O
F.	O
,	O
Stein	O
,	O
J.	O
P.	O
,	O
Lai	O
,	O
E.	O
C.	O
,	O
Woo	O
,	O
S.	O
L.	O
C.	O
,	O
Dugaiczyk	O
,	O
Mace	O
,	O
M.	O
L.	O
,	O
Means	O
,	O
A.	O
R.	O
,	O
and	O
O'Malley	O
,	O
B.	O
W.	O
(	O
1979	O
)	O
Nature	O
278	O
,	O
323	O
-	O
327	O
.	O

31	O
.	O

White	O
,	O
R.	O
L.	O
,	O
and	O
Hogness	O
,	O
D.	O
S.	O
(	O
1977	O
)	O
Cell	O
10	O
,	O
177	O
-	O
192	O
.	O

32	O
.	O

Glover	O
,	O
D.	O
M.	O
,	O
and	O
Hogness	O
,	O
D.	O
S.	O
(	O
1977	O
)	O
Cell	O
16	O
,	O
167	O
-	O
176	O
.	O
33	O
.	O

Wellauer	O
,	O
P.	O
K.	O
,	O
and	O
David	O
,	O
I.	O
B.	O
(	O
1977	O
)	O
Cell	O
10	O
,	O
193	O
-	O
212	O
.	O

34	O
.	O

Pellegrini	O
,	O
M.	O
,	O
Manning	O
,	O
J.	O
,	O
and	O
Davidson	O
,	O
N.	O
(	O
1977	O
)	O
Cell	O
10	O
,	O
213	O
-	O
214	O
.	O

35	O
.	O

Wahli	O
,	O
W.	O
,	O
David	O
,	O
I.	O
B.	O
,	O
Wyler	O
,	O
T.	O
,	O
Jaggi	O
,	O
R.	O
B.	O
,	O
Weber	O
,	O
R.	O
,	O
and	O
Ryffel	O
,	O
G.	O
V.	O
(	O
1979	O
)	O
Cell	O
16	O
,	O
535	O
-	O
549	O
.	O

36	O
.	O

McReynolds	O
,	O
L.	O
,	O
O'Malley	O
,	O
B.	O
W.	O
,	O
Nisbet	O
,	O
A.	O
D.	O
,	O
Fothergill	O
,	O
J.	O
E.	O
,	O
2252	O
Nucleic	O
Acids	O
Research	O
Givol	O
,	O
D.	O
,	O
Fields	O
,	O
S.	O
,	O
Robertson	O
,	O
M.	O
,	O
Brownlee	O
,	O
G.	O
G.	O
(	O
1978	O
)	O
Nature	O
273	O
,	O
723	O
-	O
728	O
.	O

37	O
.	O

O'Hare	O
,	O
K.	O
,	O
Breathnach	O
,	O
R.	O
,	O
Benoist	O
,	O
C.	O
,	O
Chambon	O
,	O
P.	O
(	O
1979	O
)	O
Nucl	O
.	O

Acids	O
Res	O
.	O

7	O
,	O
321	O
-	O
334	O
.	O

38	O
.	O

Abelson	O
,	O
J.	O
(	O
1979	O
)	O

Ann	O
.	O

Rev.	O
Biochem	O
.	O

48	O
,	O
1035	O
-	O
1069	O
.	O

39	O
.	O

Adams	O
,	O
S.	O
L.	O
,	O
Alwine	O
,	O
J.	O
C.	O
,	O
de	O
Chrombrugghe	O
,	O
B.	O
,	O
and	O
Pastan	O
,	O
I.	O
(	O
1979	O
)	O
J.	O
Biol	O
.	O

Chem	O
.	O
254	O
,	O
4935	O
-	O
4938	O
,	O
40	O
.	O

Rave	O
,	O
N.	O
,	O
Crkvenjakow	O
,	O
R.	O
,	O
and	O
Boedtker	O
,	O
H.	O
(	O
1979	O
)	O
Nucl	O
.	O

Acids	O
Res	O
.	O

6	O
,	O
3559	O
-	O
3567	O
.	O

41	O
.	O

Roop	O
,	O
D.	O
R.	O
,	O
Nordstrom	O
,	O
J.	O
L.	O
,	O
Tsai	O
,	O
S.	O
Y.	O
,	O
Tsai	O
,	O
M.	O
J.	O
,	O
and	O
O'Malley	O
,	O
B.	O
W.	O
(	O
1978	O
)	O
Cell	O
15	O
,	O
671	O
-	O
685	O
.	O

42	O
.	O

Tilghman	O
,	O
S.	O
M.	O
,	O
Curtis	O
,	O
P.	O
J.	O
,	O
Tiemeier	O
,	O
D.	O
C.	O
,	O
Leder	O
,	O
P.	O
,	O
and	O
Weissmann	O
,	O
C.	O
(	O
1978	O
)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

U.S.A.	O
75	O
,	O
1309	O
-	O
1313	O
.	O

43	O
.	O

Palmiter	O
,	O
R.	O
D.	O
,	O
Davidson	O
,	O
J.	O
M.	O
,	O
Gagnon	O
,	O
H.	O
,	O
Rowe	O
,	O
D.	O
W.	O
,	O
and	O
Bornstein	O
,	O
P.	O
(	O
1979	O
)	O
J.	O
Biol	O
.	O

Chem	O
.	O
254	O
,	O
1433	O
-	O
1436	O
.	O

44	O
.	O

Graves	O
,	O
P.	O
N.	O
,	O
Olsen	O
,	O
B.	O
R.	O
,	O
Feitzig	O
,	O
P.	O
P.	O
,	O
Monson	O
,	O
J.	O
M.	O
and	O
Prockop	O
,	O
D.	O
J.	O
(	O
1979	O
)	O
Fed	O
.	O

Proc	O
.	O
38	O
,	O
620	O
.	O

2253	O

Further	O
studies	O
on	O
partially	O
purified	O
calf	O
thymus	O
DNA	O
polymerase	O
a.	O
Abstract	O
Attempts	O
to	O
prevent	O
the	O
urea	O
conversion	O
of	O
a	O
200	O
-	O
230,000	O
molecular	O
weight	O
DNA	O
polymerase	O
alpha	O
to	O
a	O
150	O
-	O
170,000	O
molecular	O
weight	O
form	O
by	O
the	O
inclusion	O
of	O
protease	O
inhibitors	O
have	O
not	O
been	O
successful	O
.	O

No	O
other	O
method	O
has	O
been	O
found	O
capable	O
of	O
dissociating	O
a	O
50	O
-	O
70,000	O
fragment	O
or	O
subunit	O
from	O
the	O
DNA	O
polymerase	O
subunit	O
.	O

Addition	O
of	O
this	O
50	O
-	O
70,000	O
subunit	O
to	O
the	O
polymerase	O
subunit	O
does	O
not	O
aid	O
the	O
binding	O
of	O
the	O
enzyme	O
to	O
DNA	O
,	O
but	O
does	O
have	O
an	O
effect	O
on	O
the	O
utilisation	O
of	O
synthetic	O
template	O
-	O
initiator	O
complexes	O
by	O
the	O
polymerase	O
subunit	O
.	O

Volume	O
6	O
Number	O
10	O
1979	O
Nucleic	O
Acids	O
Research	O
Further	O
studies	O
on	O
partially	O
purified	O
calf	O
thymus	O
DNA	O
polymerase	O
a	O
Keith	O
McKune	O
and	O
Andrew	O
M.Holmes	O
*	O
Biochemistry	O
Department	O
,	O
Strathclyde	O
University	O
,	O
The	O
Todd	O
Centre	O
,	O
31	O
Taylor	O
Street	O
,	O
Glasgow	O
,	O
G4	O
ONR	O
,	O
UK	O
Received	O
I	O
June	O
1979	O
ABSTRACT	O
Attempts	O
to	O
prevent	O
the	O
urea	O
conversion	O
of	O
a	O
200	O
-	O
230	O
,	O
000	O
molecular	O
weight	O
DNA	O
polymerase	O
a	O
to	O
a	O
150	O
-	O
170	O
,	O
000	O
molecular	O
weight	O
form	O
by	O
the	O
inclusion	O
of	O
protease	O
inhibitors	O
have	O
not	O
been	O
successful	O
.	O

No	O
other	O
method	O
has	O
been	O
found	O
capable	O
of	O
dissociating	O
a	O
50	O
-	O
70	O
,	O
000	O
fragment	O
or	O
subunit	O
from	O
the	O
DNA	O
polymerase	O
subunit	O
.	O

Addition	O
of	O
this	O
50	O
-	O
70	O
,	O
000	O
subunit	O
to	O
the	O
polymerase	O
subunit	O
does	O
not	O
aid	O
the	O
binding	O
of	O
the	O
enzyme	O
to	O
DNA	O
,	O
but	O
does	O
have	O
an	O
effect	O
on	O
the	O
utilisation	O
of	O
synthetic	O
template	O
-	O
initiator	O
complexes	O
by	O
the	O
polymerase	O
subunit	O
.	O

INTRODUCTION	O
In	O
mammals	O
DNA	O
polymerase	O
a	O
is	O
thought	O
to	O
be	O
the	O
replicative	O
enzyme	O
,	O
but	O
due	O
to	O
low	O
levels	O
of	O
activity	O
,	O
even	O
in	O
tissues	O
actively	O
making	O
DNA	O
,	O
and	O
to	O
enzyme	O
heterogeneity	O
it	O
has	O
been	O
found	O
difficult	O
to	O
purify	O
However	O
,	O
small	O
samples	O
of	O
DNA	O
polymerase	O
a	O
have	O
been	O
highly	O
purified	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
from	O
several	O
sources	O
and	O
partially	O
characterised	O
Heterogeneity	O
has	O
been	O
observed	O
in	O
DNA	O
polymerase	O
a	O
from	O
a	O
var	O
6	O
7	O
iety	O
of	O
sources	O
,	O
including	O
rat	B
liver	O
and	O
spleen	O
,	O
Hela	O
cells	O
,	O
baby	O
hamster	O
8	O
9	O
,	O
10	O
11	O
kidney	O
cells	O
,	O
mouse	B
myeloma	O
,	O
Drosophila	B
embryos	O
and	O
calf	O
thymus	O
1,6	O
,	O
12	O
,	O
13	O
.	O

We	O
have	O
previously	O
observed	O
several	O
species	O
of	O
calf	O
thymus	O
DNA	O
polymerase	O
a	O
differing	O
in	O
size	O
and	O
charge	O
.	O

In	O
order	O
of	O
elution	O
from	O
DEAE	O
cellulose	O
they	O
are	O
enzyme	O
A1	O
(	O
200	O
-	O
230	O
,	O
000	O
molecular	O
weight	O
)	O
,	O
A2	O
(	O
200	O
-	O
230	O
,	O
000	O
)	O
,	O
B	O
(	O
100	O
-	O
110	O
,	O
000	O
)	O
and	O
C	O
(	O
150	O
-	O
170	O
,	O
000	O
)	O
.	O

A	O
poly	O
(	O
dA	O
)	O
.	O

oligo	O
(	O
dT	O
)	O
10	O
preferring	O
enzyme	O
,	O
enzyrrme	O
D	O
(	O
140	O
-	O
150	O
,	O
000	O
molecular	O
weight	O
)	O
elutes	O
just	O
after	O
enzyme	O
B.	O
The	O
A	O
enzymes	O
seem	O
identical	O
in	O
all	O
properties	O
except	O
their	O
charge	O
.	O

5.0	O
-	O
5	O
.	O

5S	O
enzymes	O
,	O
analagous	O
to	O
B	O
,	O
have	O
been	O
observed	O
to	O
C	O
Information	O
Retrieval	O
Limited	O
1	O
Falconberg	O
Court	O
London	O
Wl	O
V	O
5FG	O
England	O
3341	O
Nucleic	O
Acids	O
Research	O
arise	O
as	O
the	O
result	O
of	O
proteolytic	O
action	O
'	O
,	O
similarly	O
the	O
B	O
enzyme	O
above	O
14	O
,	O
but	O
the	O
relationship	O
of	O
the	O
other	O
observed	O
species	O
is	O
not	O
clear	O
,	O
nor	O
is	O
the	O
problem	O
of	O
which	O
,	O
if	O
any	O
,	O
of	O
these	O
species	O
is	O
the	O
replicative	O
enzyme	O
,	O
although	O
circumstantial	O
evidence	O
has	O
implicated	O
a	O
DNA	O
polymerase	O
a	O
to	O
be	O
15	O
the	O
replicative	O
enzyme	O
in	O
adenovirus	B
infected	O
KB	O
cells	O
We	O
have	O
previously	O
shown	O
that	O
several	O
of	O
these	O
enzymes	O
are	O
inter	O
16	O
convertible	O
.	O

In	O
particular	O
,	O
mild	O
urea	O
treatment	O
can	O
convert	O
both	O
A	O
enzymes	O
to	O
C	O
enzyme	O
,	O
with	O
the	O
loss	O
of	O
a	O
subunit	O
or	O
fragment	O
of	O
50	O
-	O
70	O
,	O
000	O
molecular	O
weight	O
.	O

The	O
C	O
enzyme	O
retains	O
DNA	O
polymerase	O
activity	O
,	O
but	O
does	O
show	O
differences	O
compared	O
to	O
A	O
enzyme	O
in	O
heat	O
sensitivity	O
and	O
sensitivity	O
to	O
N	O
-	O
ethylmaleimide	O
.	O

Highly	O
purified	O
samples	O
of	O
A	O
and	O
C	O
enzymes	O
when	O
subjected	O
to	O
sodium	O
dodecyl	O
sulphate	O
polyacrylamide	O
gel	O
electrophoresis	O
have	O
shown	O
a	O
corre	O
lation	O
of	O
DNA	O
polymerase	O
activity	O
with	O
a	O
polypeptide	O
band	O
155	O
,	O
000	O
molecular	O
weight	O
.	O

Contaminating	O
material	O
of	O
50	O
-	O
70	O
,	O
000	O
molecular	O
weight	O
appeared	O
to	O
obscure	O
the	O
putative	O
50	O
-	O
70	O
,	O
000	O
subunit	O
in	O
gels	O
of	O
A	O
enzyme	O
.	O

The	O
conclusions	O
drawn	O
were	O
that	O
DNA	O
polymerase	O
a	O
is	O
a	O
155	O
,	O
000	O
molecular	O
weight	O
polypeptide	O
(	O
C	O
enzyrrme	O
)	O
which	O
can	O
and	O
does	O
associated	O
with	O
material	O
of	O
50	O
70	O
,	O
000	O
molecular	O
weight	O
to	O
give	O
A	O
enzyme	O
,	O
and	O
that	O
enzyme	O
B	O
is	O
a	O
proteol	O
14	O
ytic	O
degradation	O
product	O
.	O

The	O
relationship	O
of	O
enzyme	O
D	O
to	O
the	O
others	O
is	O
not	O
clear	O
.	O

It	O
is	O
possible	O
that	O
during	O
the	O
enzyme	O
isolation	O
procedure	O
proteolytic	O
action	O
may	O
have	O
taken	O
place	O
on	O
a	O
200	O
-	O
230	O
,	O
000	O
molecular	O
weight	O
enzyme	O
releasing	O
155	O
,	O
000	O
and	O
50	O
-	O
70	O
,	O
000	O
fragments	O
which	O
remain	O
in	O
association	O
until	O
urea	O
treatment	O
separates	O
them	O
.	O

It	O
is	O
also	O
possible	O
that	O
urea	O
treatment	O
itself	O
renders	O
the	O
enzyme	O
susceptible	O
to	O
contaminating	O
proteases	O
.	O

Further	O
experiments	O
to	O
ascertain	O
whether	O
or	O
not	O
this	O
is	O
the	O
case	O
and	O
,	O
if	O
so	O
,	O
to	O
prevent	O
it	O
,	O
have	O
been	O
carried	O
out	O
.	O

A	O
enzyme	O
can	O
be	O
reconstituted	O
from	O
C	O
enzyme	O
formed	O
by	O
the	O
action	O
of	O
urea	O
on	O
A	O
enzyme	O
by	O
concentrating	O
it	O
with	O
the	O
50	O
-	O
70	O
,	O
000	O
molecular	O
weight	O
material	O
.	O

The	O
A	O
enzyrme	O
obtained	O
in	O
this	O
manner	O
is	O
highly	O
purified	O
,	O
as	O
is	O
the	O
C	O
enzyme	O
formed	O
by	O
the	O
urea	O
treatment	O
,	O
and	O
has	O
been	O
used	O
in	O
attempts	O
to	O
show	O
differences	O
in	O
synthetic	O
template	O
-	O
initiator	O
complex	O
utilisation	O
3342	O
Nucleic	O
Acids	O
Research	O
b	O
y	O
the	O
se	O
two	O
enzyme	O
s	O
.	O

MATERIALS	O
AND	O
METHODS	O
Calf	O
thymus	O
was	O
obtained	O
from	O
10	O
-	O
16	O
week	O
old	O
calves	O
and	O
frozen	O
at	O
-20?C	O
until	O
required	O
.	O

Chromatographic	O
media	O
and	O
chemicals	O
were	O
obtained	O
6	O
from	O
sources	O
previously	O
referred	O
to	O
.	O

Radioactive	O
deoxynucleoside	O
tri	O
phosphates	O
were	O
obtained	O
from	O
the	O
Radiochemical	O
Centre	O
,	O
Amersham	O
,	O
Bucks	O
.	O

Synthetic	O
oligo	O
and	O
polynucleotides	O
were	O
obtained	O
from	O
P.	O
L.	O
Biochemicals	O
Inc.	O
,	O
except	O
for	O
poly	O
(	O
dC	O
)	O
which	O
was	O
a	O
gift	O
from	O
Dr.	O
I.R.	O
Johnston	O
and	O
pre	O
17	O
pared	O
from	O
oligo	O
d	O
(	O
C	O
)	O
5	O
as	O
described	O
.	O

N	O
-	O
a	O
-	O
p	O
Tosyl	O
-	O
L	O
-	O
lysine	O
chloromethy	O
lketone	O
HCl	O
and	O
phenylmethylsulphonylfluoride	O
were	O
obtained	O
from	O
Sigma	O
and	O
Trasylol	O
from	O
Bayer	O
.	O

Except	O
where	O
indicated	O
all	O
buffers	O
contained	O
20	O
%	O
w	O
/	O
v	O
glycerol	O
and	O
1	O
mM	O
dithiothreitol	O
.	O

Standard	O
linear	O
phosphate	O
gradients	O
were	O
run	O
between	O
0.03	O
M	O
and	O
0.25	O
M	O
potassium	O
phosphate	O
,	O
pH	O
7.8	O
.	O

Gradient	O
salt	O
concentr	O
2	O
ations	O
were	O
measured	O
using	O
a	O
conductivity	O
meter	O
as	O
described	O
.	O

Urea	O
was	O
prepared	O
as	O
a	O
4	O
.	O
8	O
M	O
solution	O
in	O
20	O
%	O
w	O
/	O
v	O
glycerol	O
,	O
stirred	O
with	O
Amberlite	O
MB3	O
and	O
filtered	O
.	O

Dithiothreitol	O
was	O
added	O
to	O
a	O
final	O
concentration	O
of	O
1	O
mM	O
before	O
use	O
.	O

6	O
DNA	O
polymerase	O
was	O
assayed	O
using	O
activated	O
DNA	O
as	O
described	O
except	O
that	O
the	O
buffer	O
was	O
50	O
mM	O
tris	O
HC1	O
,	O
pH	O
7.8	O
.	O

One	O
unit	O
of	O
DNA	O
polymerase	O
activity	O
incorporates	O
ln	O
mol	O
[	O
H	O
]	O
dTMP	O
into	O
an	O
acid	O
insoluble	O
form	O
in	O
one	O
hour	O
at	O
370C	O
.	O

Assays	O
using	O
synthetic	O
template	O
-	O
initiator	O
complexes	O
were	O
carried	O
out	O
at	O
30?C	O
in	O
0	O
.	O
12	O
ml	O
.	O

The	O
template	O
-	O
initiator	O
complexes	O
6	O
were	O
prepared	O
and	O
assays	O
processed	O
as	O
described	O
.	O

All	O
assays	O
contained	O
1	O
mM	O
dithiothreitol	O
,	O
62	O
.	O
5	O
p.g	O
bovine	B
serum	O
albumin	O
,	O
1	O
,	O
ug	O
template	O
-	O
initiator	O
complex	O
,	O
enzyme	O
protein	O
and	O
the	O
relevant	O
[	O
H	O
]	O
deoxynucleoside	O
triphosphate	O
at	O
0.1	O
mM	O
and	O
12	O
-	O
15	O
cpm	O
/	O
pmol	O
.	O

These	O
assays	O
were	O
carried	O
out	O
at	O
either	O
pH	O
6.4	O
in	O
20	O
mM	O
sodium	O
-	O
potassium	O
phosphate	O
,	O
or	O
at	O
pH	O
7.8	O
in	O
50	O
mM	O
tris	O
HCl	O
and	O
contained	O
either	O
10	O
mM	O
MgCl2	O
or	O
1	O
mM	O
MnCl2	O
as	O
indicated	O
.	O

Preliminary	O
purification	O
of	O
DNA	O
polymerase	O
a	O
to	O
Fraction	O
IV	O
was	O
as	O
6	O
described	O
,	O
the	O
purification	O
steps	O
being	O
phosphocellulose	O
chromatography	O
,	O
ammonium	O
sulphate	O
precipitation	O
and	O
gel	O
filtration	O
on	O
Sepharose	O
6B	O
.	O

3343	O
Nucleic	O
Acids	O
Research	O
Enzyme	O
obtained	O
from	O
the	O
DEAE	O
cellulose	O
step	O
is	O
referred	O
to	O
as	O
Fraction	O
V	O
enzyme	O
.	O

Samples	O
were	O
prepared	O
for	O
sodium	O
dodecyl	O
sulphate	O
polyacrylamide	O
gel	O
electrophoresis	O
and	O
scanned	O
as	O
previously	O
described2	O
RESULTS	O
AND	O
DISCUSSION	O
(	O
a	O
)	O
Interconversion	O
Studies	O
A	O
enzyme	O
was	O
routinely	O
converted	O
to	O
C	O
enzyme	O
by	O
incubating	O
200500	O
units	O
/	O
ml	O
of	O
Fraction	O
V	O
A	O
enzyme	O
in	O
2.4	O
M	O
urea	O
in	O
0	O
.	O
02	O
M	O
potassium	O
phosphate	O
,	O
pH	O
7.8	O
,	O
for	O
60	O
minutes	O
at	O
0?C.	O
The	O
mixture	O
was	O
then	O
loaded	O
on	O
to	O
a	O
DEAE	O
cellulose	O
,	O
washed	O
with	O
0	O
.	O
03	O
M	O
potassium	O
phosphate	O
pH	O
7	O
.	O
8	O
,	O
and	O
enzyrme	O
eluted	O
either	O
with	O
the	O
standard	O
phosphate	O
gradient	O
or	O
batchwise	O
.	O

Under	O
these	O
conditions	O
usually	O
about	O
50	O
-	O
60	O
%	O
of	O
recovered	O
activity	O
was	O
enzyme	O
C	O
(	O
Fig	O
1	O
a	O
)	O
.	O

Overall	O
recovery	O
was	O
70	O
-	O
80	O
%	O
.	O

A	O
enzyme	O
was	O
recon	O
14	O
stituted	O
essentially	O
as	O
described	O
.	O

The	O
flow	O
through	O
material	O
from	O
the	O
DEAE	O
cellulose	O
column	O
after	O
the	O
urea	O
treatment	O
was	O
loaded	O
on	O
to	O
a	O
1	O
x	O
0	O
.	O

8	O
cm	O
phosphocellulose	O
column	O
,	O
washed	O
with	O
0.03	O
M	O
potassium	O
phosphate	O
,	O
pH	O
7.8	O
,	O
and	O
the	O
protein	O
eluted	O
with	O
0.25	O
M	O
potassium	O
phosphate	O
,	O
pH	O
7	O
.	O
8	O
.	O

This	O
material	O
,	O
the	O
putative	O
subunit	O
,	O
was	O
vacuum	O
dialysed	O
with	O
the	O
C	O
enzyme	O
produced	O
by	O
the	O
urea	O
treatment	O
,	O
rechromatographed	O
on	O
DEAE	O
cellulose	O
and	O
enzyme	O
eluted	O
batchwise	O
(	O
Fig	O
1	O
b	O
)	O
.	O

Recovery	O
from	O
this	O
procedure	O
was	O
usually	O
50	O
-	O
70	O
%	O
A	O
enzyme	O
.	O

Overall	O
recovery	O
was	O
30	O
-	O
40	O
%	O
of	O
the	O
C	O
enzyme	O
dialysed	O
.	O

If	O
the	O
material	O
eluted	O
from	O
the	O
phosphocellulose	O
by	O
the	O
0	O
.	O
25	O
M	O
potassium	O
phosphate	O
was	O
heated	O
to	O
90?C	O
for	O
5	O
minutes	O
prior	O
to	O
vacuum	O
dialysis	O
with	O
the	O
C	O
enzyme	O
the	O
recovery	O
from	O
the	O
DEAE	O
cellulose	O
column	O
was	O
significantly	O
higher	O
(	O
60	O
-	O
70	O
%	O
of	O
the	O
original	O
C	O
enzyme	O
activity	O
)	O
,	O
but	O
all	O
recoverable	O
DNA	O
polymerase	O
activity	O
was	O
C	O
enzyme	O
.	O

This	O
,	O
together	O
with	O
the	O
fact	O
that	O
the	O
60	O
minute	O
treatment	O
with	O
urea	O
has	O
,	O
on	O
occasions	O
,	O
given	O
rise	O
to	O
a	O
50	O
%	O
increase	O
in	O
DNA	O
polymerase	O
activity	O
prior	O
to	O
loading	O
on	O
to	O
the	O
DEAE	O
cellulose	O
column	O
,	O
would	O
indicate	O
that	O
A	O
enzyme	O
is	O
less	O
active	O
on	O
activated	O
DNA	O
than	O
is	O
C	O
enzyme	O
.	O

If	O
the	O
DEAE	O
cellulose	O
flow	O
through	O
material	O
came	O
from	O
urea	O
treatment	O
of	O
A2	O
enzyme	O
then	O
A2	O
was	O
produced	O
on	O
reconstitution	O
;	O
if	O
from	O
A1	O
then	O
A1	O
was	O
produced	O
.	O

Although	O
the	O
mild	O
urea	O
treatment	O
of	O
A	O
has	O
been	O
used	O
to	O
prepare	O
C	O
of	O
3344	O
Nucleic	O
Acids	O
Research	O
b	O

120	O
180	O
C	O
I	O
I	O
^	O
Figure	O
la	O
DEAE	O
cellulose	O
chromatography	O
after	O
2.4	O
M	O
urea	O
treatment	O
.	O

4	O
,	O
5000	O
units	O
,	O
4.4	O
mg	O
of	O
Fraction	O
II	O
A2	O
enzyme	O
were	O
incubated	O
with	O
urea	O
at	O
a	O
final	O
concentration	O
of	O
2.4	O
M	O
for	O
60	O
minutes	O
at	O
0?C	O
,	O
loaded	O
on	O
to	O
a	O
5	O
x	O
1.4	O
cm	O
DEAE	O
cellulose	O
column	O
,	O
the	O
column	O
was	O
washed	O
with	O
0	O
.	O
03	O
M	O
potassium	O
phosphate	O
,	O
pH	O
7.8	O
and	O
a	O
200	O
ml	O
standard	O
phosphate	O
gradient	O
applied	O
.	O

2.3	O
ml	O
fractions	O
were	O
collected	O
and	O
10	O
Rl	O
assayed	O
for	O
5	O
minutes	O
.	O

(	O
o	O
-	O
o	O
)	O
no	O
phenylmethylsulphonylfluoride	O
(	O
*	O
-	O
*	O
)	O
3	O
mM	O
phenylmethylsulphonylfluoride	O
(	O
-	O
)	O
phosphate	O
gradient	O
.	O

Figure	O
lb	O

The	O
reconstitution	O
of	O
A2	O
enzyme	O
.	O

3000	O
units	O
for	O
C	O
enzyme	O
derived	O
by	O
urea	O
treatment	O
of	O
A2	O
were	O
vacuum	O
dialysed	O
with	O
the	O
DEAE	O
cellulose	O
flow	O
through	O
material	O
after	O
phosphocellulose	O
chromatography	O
and	O
chromatographed	O
on	O
a	O
2	O
x	O
1	O
.	O

2	O
cm	O
DEAE	O
cellulose	O
column	O
.	O

After	O
washing	O
with	O
0.03	O
M	O
potassium	O
phosphate	O
,	O
pH	O
7.7	O
,	O
the	O
enzymes	O
were	O
eluted	O
batchwise	O
with	O
the	O
above	O
concentrations	O
of	O
potassium	O
phosphate	O
,	O
pH	O
7.8	O
.	O

1	O
ml	O
fractions	O
were	O
collected	O
and	O
10	O
.l	O
assayed	O
for	O
10	O
minutes	O
.	O

3345	O
Nucleic	O
Acids	O
Research	O
high	O
specific	O
activity	O
it	O
is	O
possible	O
that	O
conversion	O
of	O
the	O
200	O
-	O
230	O
,	O
000	O
molecular	O
weight	O
enzymes	O
to	O
a	O
155-	O
170	O
,	O
000	O
species	O
maybe	O
due	O
to	O
unfolding	O
of	O
the	O
molecule	O
to	O
allow	O
limited	O
attack	O
by	O
contaminating	O
proteases	O
.	O

Accord	O
ingly	O
the	O
urea	O
conversion	O
of	O
A	O
to	O
C	O
was	O
investigated	O
in	O
the	O
presence	O
of	O
certain	O
protease	O
inhibitors	O
.	O

The	O
presence	O
of	O
the	O
serine	O
protease	O
inhibitor	O
phenylmethylsulphonyl	O
-	O
fluoride	O
in	O
the	O
incubation	O
and	O
chromatography	O
buffers	O
did	O
not	O
affect	O
the	O
conversion	O
of	O
A2to	O
C	O
(	O
Fig	O
1	O
a	O
)	O
.	O

Likewise	O
trasylol	O
and	O
Na	O
-	O
p	O
Tosyl	O
-	O
L	O
-	O
lysine	O
chloromethylketone	O
HC1	O
had	O
no	O
effect	O
.	O

However	O
,	O
protease	O
action	O
could	O
have	O
occurred	O
earlier	O
in	O
the	O
purification	O
procedure	O
and	O
the	O
urea	O
could	O
be	O
separating	O
two	O
fragments	O
.	O

Usually	O
the	O
DEAE	O
cellulose	O
profile	O
shows	O
that	O
the	O
majority	O
of	O
the	O
enzyme	O
activity	O
is	O
present	O
as	O
A	O
enzyme	O
(	O
Fig	O
2	O
)	O
.	O

In	O
this	O
instance	O
A1	O
and	O
A2	O
have	O
not	O
been	O
separated	O
.	O

When	O
the	O
temperature	O
of	O
the	O
material	O
in	O
the	O
original	O
blending	O
procedure	O
was	O
kept	O
below	O
0?C	O
or	O
phenylmethylsulphonylfluoride	O
,	O
N	O
-	O
a	O
-	O
p	O
Tosyl	O
-	O
L	O
-	O
lysine	O
chloromethylketone	O
HCl	O
or	O
trasylol	O
was	O
included	O
in	O
the	O
isolation	O
buffers	O
the	O
DEAE	O
cellulose	O
profile	O
was	O
similar	O
.	O

The	O
A	O
enzymes	O
were	O
still	O
capable	O
of	O
conversion	O
by	O
mild	O
urea	O
treatment	O
to	O
C	O
enzyme	O
,	O
indicating	O
that	O
if	O
protease	O
activity	O
is	O
involved	O
then	O
it	O
is	O
not	O
susceptible	O
to	O
these	O
inhibitors	O
.	O

When	O
the	O
calf	O
20FI	O
:	O
Now	O
~	O
~	O
~	O
20	O
20Fr	O
Na	O
06	O
Figure	O
2	O
DEAE	O
cellulose	O
elution	O
profile	O
of	O
calf	O
thymus	O
DNA	O
polymerase	O
a.	O
47	O
,	O
000	O
units	O
,	O
97	O
mg	O
of	O
Fraction	O
IV	O
enzyme	O
prepared	O
from	O
415	O
g	O
of	O
calf	O
thymus	O
were	O
loaded	O
on	O
to	O
a	O
10	O
x	O
1.8	O
cm	O
DEAE	O
cellulose	O
column	O
,	O
after	O
washing	O
with	O
0	O
.	O
03	O
M	O
potassium	O
phosphate	O
,	O
pH	O
7	O
.	O
8	O
a	O
400	O
ml	O
standard	O
phosphate	O
gradient	O
was	O
applied	O
.	O

5	O
ml	O
fractions	O
were	O
collected	O
and	O
10	O
,	O
ul	O
assayed	O
for	O
5	O
minutes	O
.	O

3346	O
Nucleic	O
Acids	O
Research	O
thymus	O
was	O
allowed	O
to	O
warm	O
up	O
during	O
the	O
blending	O
procedure	O
,	O
or	O
the	O
supernatant	O
prior	O
to	O
phosphocellulose	O
chromatography	O
was	O
heated	O
to	O
37	O
?	O

C	O
for	O
30	O
minutes	O
,	O
there	O
was	O
a	O
marked	O
decrease	O
in	O
the	O
amount	O
of	O
A	O
enzyme	O
with	O
a	O
concomitant	O
increase	O
in	O
the	O
amount	O
of	O
B	O
and	O
C	O
(	O
unpublished	O
observation	O
)	O
.	O

The	O
presence	O
of	O
phenylmethylsulphonylfluoride	O
,	O
N-	O
a	O
-	O
p	O
T	O
osyl-	O
L	O
-	O
lysine	O
chloromethylketone	O
HCl	O
or	O
trasylol	O
under	O
these	O
conditions	O
only	O
had	O
a	O
marginal	O
effect	O
on	O
the	O
appearance	O
of	O
C	O
enzyme	O
,	O
but	O
did	O
reduce	O
the	O
amount	O
of	O
B	O
enzyme	O
.	O

Heating	O
the	O
enzyme	O
to	O
37?C	O
after	O
the	O
phosphocellulose	O
step	O
had	O
no	O
effect	O
on	O
the	O
DEAE	O
cellulose	O
elution	O
profile	O
.	O

Attempts	O
to	O
convert	O
A	O
enzyme	O
to	O
C	O
using	O
trypsin	O
have	O
not	O
been	O
successful	O
.	O

A	O
enzyme	O
activity	O
is	O
lost	O
without	O
the	O
appearance	O
of	O
any	O
other	O
species	O
(	O
unpublished	O
observation	O
)	O
,	O
although	O
14	O
the	O
action	O
of	O
trypsin	O
on	O
C	O
enzyme	O
can	O
give	O
rise	O
to	O
small	O
amounts	O
of	O
B	O
Although	O
the	O
conversion	O
of	O
A	O
enzyme	O
to	O
C	O
does	O
not	O
appear	O
to	O
be	O
the	O
result	O
of	O
serine	O
protease	O
action	O
,	O
proteases	O
other	O
than	O
serine	O
proteases	O
18	O
could	O
have	O
been	O
responsible	O
.	O

Also	O
,	O
the	O
fact	O
that	O
A	O
enzyme	O
can	O
be	O
recon	O
stituted	O
from	O
C	O
plus	O
the	O
flow	O
through	O
material	O
from	O
the	O
DEAE	O
cellulose	O
after	O
urea	O
treatment	O
does	O
not	O
necessarily	O
mean	O
we	O
are	O
dealing	O
with	O
two	O
subunits	O
as	O
fragments	O
produced	O
by	O
proteases	O
mray	O
be	O
reassembled	O
to	O
give	O
active	O
enzyme	O
9	O
.	O

However	O
,	O
the	O
fact	O
that	O
a	O
200	O
-	O
230	O
,	O
000	O
molecular	O
weight	O
polypeptide	O
band	O
has	O
never	O
been	O
observed	O
in	O
sodium	O
dodecylsulphate	O
polyacrylamride	O
gels	O
of	O
highly	O
purified	O
A	O
enzyme	O
,	O
or	O
even	O
cruder	O
fractions	O
of	O
A	O
enzyrre	O
(	O
unpublished	O
observation	O
)	O
,	O
may	O
be	O
significant	O
.	O

One	O
might	O
expect	O
some	O
of	O
the	O
enzyme	O
not	O
to	O
have	O
been	O
attacked	O
by	O
whatever	O
is	O
responsible	O
for	O
cleaving	O
the	O
molecule	O
,	O
if	O
,	O
indeed	O
,	O
this	O
does	O
happen	O
.	O

It	O
would	O
appear	O
,	O
therefore	O
,	O
that	O
the	O
A	O
enzyme	O
consists	O
of	O
subunits	O
of	O
155	O
,	O
000	O
and	O
50	O
-	O
70	O
,	O
000	O
molecular	O
weight	O
with	O
the	O
small	O
subunit	O
having	O
a	O
slightly	O
different	O
charge	O
in	O
the	O
case	O
of	O
A	O
and	O
A2	O
.	O

It	O
has	O
also	O
been	O
concluded	O
that	O
the	O
heterogeneity	O
in	O
the	O
1	O
~~~~~~~~~~~~~~~~~3	O
mouse	B
myeloma	O
DNA	O
polymerase	O
a	O
fraction	O
is	O
not	O
due	O
to	O
proteolysis	O
.	O

However	O
,	O
the	O
50	O
-	O
70	O
,	O
000	O
molecular	O
weight	O
subunit	O
has	O
not	O
yet	O
been	O
identified	O
.	O

Sodiurrm	O
dodecylsulphate	O
polyacrylamide	O
gels	O
of	O
reconstituted	O
A	O
enzyme	O
have	O
shown	O
polypeptide	O
bands	O
at	O
150	O
-	O
160	O
,	O
000	O
and	O
50	O
-	O
70	O
,	O
000	O
molecular	O
weight	O
(	O
Fig.	O
3	O
)	O
,	O
but	O
the	O
ratio	O
of	O
staining	O
intensity	O
of	O
the	O
bands	O
does	O
not	O
correspond	O
to	O
a	O
1	O
:	O
1	O
relationship	O
.	O

The	O
ratio	O
of	O
the	O
two	O
bands	O
is	O
variable	O
but	O
is	O
usually	O
between	O
1:2	O
and	O
1:3	O
,	O
indicating	O
,	O
perhaps	O
,	O
that	O
more	O
than	O
one	O
subunit	O
of	O
50	O
3347	O
Nucleic	O
Acids	O
Research	O
TOP	O
123	O
4	O
5	O
6	O
Figure	O
3	O
Scan	O
of	O
a	O
5	O
%	O
sodium	O
dodecyl	O
sulphate	O
polyacrylamide	O
gel	O
of	O
reconstituted	O
A2	O
enzyme	O
.	O

1500	O
units	O
of	O
reconstituted	O
A2	O
enzyme	O
were	O
subjected	O
to	O
polyacrylamide	O
gel	O
electrophoresis	O
under	O
non	O
-	O
denaturing	O
conditions	O
.	O

The	O
gels	O
were	O
sliced	O
,	O
enzyme	O
extracted	O
and	O
assayed	O
and	O
the	O
peak	O
fraction	O
of	O
DNA	O
polymerase	O
activity	O
from	O
three	O
gels	O
were	O
pooled	O
,	O
subjected	O
to	O
sodium	O
dodecyl	O
sulphate	O
polyacrylamide	O
gel	O
electrophoresis	O
on	O
a	O
single	O
gel	O
,	O
stained	O
and	O
scanned	O
at	O
2	O
volt	O
sensitivity	O
as	O
described2	O
.	O

The	O
molecular	O
weight	O
standards	O
were	O
:	O
(	O
1	O
)	O
bovine	B
serum	O
albumin	O
dimer	O
(	O
134	O
,	O
000	O
)	O
,	O
(	O
2	O
)	O
,	O
3	O
galactosidase	O
(	O
130	O
,	O
000	O
)	O
,	O
(	O
3	O
)	O
phosphorylase	O
a	O
(	O
94	O
,	O
000	O
)	O
,	O
(	O
4	O
)	O
bovine	B
serum	O
albumin	O
(	O
68	O
,	O
000	O
)	O
,	O
(	O
5	O
)	O
pyruvate	O
kinase	O
(	O
57	O
,	O
000	O
)	O
and	O
(	O
6	O
)	O
lactate	O
dehydrogenase	O
(	O
35	O
,	O
000	O
)	O
.	O

70	O
,	O
000	O
molecular	O
weight	O
can	O
associate	O
with	O
the	O
155	O
,	O
000	O
subunit	O
.	O

The	O
proportion	O
of	O
the	O
lower	O
molecular	O
weight	O
polypeptide	O
band	O
is	O
higher	O
in	O
the	O
reconstituted	O
A	O
enzyrrme	O
than	O
in	O
the	O
C	O
enzyme	O
preparation	O
from	O
which	O
it	O
was	O
formed	O
,	O
but	O
even	O
the	O
C	O
enzyme	O
contained	O
some	O
material	O
in	O
the	O
region	O
.	O

Breakdown	O
of	O
material	O
from	O
155	O
,	O
000	O
to	O
50	O
-	O
70	O
,	O
000	O
may	O
be	O
partly	O
responsible	O
for	O
the	O
contamination	O
,	O
but	O
the	O
presence	O
of	O
phenylmethylsulphonylfluoride	O
in	O
samples	O
in	O
preparation	O
for	O
sodium	O
dodecylsulphate	O
polyacrylamide	O
gel	O
electrophoresis	O
has	O
not	O
been	O
successful	O
in	O
preventing	O
it	O
.	O

The	O
human	B
KB	O
cell	O
DNA	O
polymerase	O
a	O
,	O
equivalent	O
to	O
the	O
C	O
enzyme	O
,	O
has	O
been	O
reported	O
to	O
consist	O
4	O
of	O
subunits	O
of	O
76	O
,	O
000	O
and	O
66	O
,	O
000	O
molecular	O
weight	O
,	O
but	O
at	O
no	O
time	O
have	O
we	O
observed	O
polypeptide	O
bands	O
at	O
76	O
,	O
000	O
and	O
66	O
,	O
000	O
rising	O
and	O
falling	O
with	O
enzyme	O
activity	O
in	O
any	O
gels	O
of	O
calf	O
thyrrmus	O
enzymes	O
A1	O
,	O
A	O
and	O
C	O
(	O
and	O
2	O
unpublished	O
observations	O
)	O
.	O

(	O
b	O
)	O
Template	O
Studies	O
Use	O
has	O
been	O
made	O
of	O
the	O
urea	O
conversion	O
of	O
A	O
to	O
C	O
and	O
of	O
the	O
reconstitution	O
of	O
A	O
enzyme	O
to	O
obtain	O
samples	O
of	O
highly	O
purified	O
DNA	O
polymerase	O
,	O
specific	O
activity	O
in	O
excess	O
of	O
50	O
,	O
000	O
units	O
/	O
mg	O
,	O
in	O
order	O
to	O
study	O
the	O
effect	O
of	O
this	O
50	O
-	O
70	O
,	O
000	O
molecular	O
weight	O
subunit	O
on	O
the	O
DNA	O
polymerase	O
subunit	O
.	O

Previous	O
results	O
have	O
indicated	O
that	O
A	O
enzyrrme	O
is	O
stabler	O
to	O
heat	O
and	O
less	O
3348	O
Nucleic	O
Acids	O
Research	O
14	O
,	O
21	O
susceptible	O
to	O
N	O
-	O
ethylmaleimide	O
than	O
C	O
enzyme	O
.	O

It	O
has	O
been	O
reported	O
that	O
highly	O
purified	O
DNA	O
polymerase	O
a	O
can	O
be	O
associated	O
with	O
a	O
protein	O
capable	O
of	O
binding	O
to	O
DNA	O
containing	O
no	O
3	O
'	O
OH	O
ends	O
and	O
capable	O
of	O
being	O
released	O
during	O
the	O
DNA	O
polymerase	O
assay	O
.	O

Attempts	O
to	O
dissociate	O
the	O
50	O
70	O
,	O
000	O
molecular	O
weight	O
subunit	O
from	O
the	O
polymerase	O
subunit	O
by	O
incubating	O
A2	O
with	O
DNA	O
polymerase	O
reaction	O
mixes	O
containing	O
activated	O
DNA	O
,	O
poly	O
(	O
dA	O
-	O
T	O
)	O
and	O
poly	O
(	O
dT	O
)	O
.	O

oligo	O
(	O
A	O
)	O
10	O
followed	O
by	O
ultracentrifugation	O
in	O
high	O
salt	O
have	O
been	O
unsuccessful	O
.	O

Similarly	O
A	O
absorbed	O
and	O
eluted	O
from	O
either	O
native	O
or	O
denatured	O
DNA	O
cellulose	O
remained	O
A	O
enzyme	O
.	O

Both	O
A	O
and	O
C	O
enzymes	O
were	O
eluted	O
from	O
the	O
DNA	O
celluloses	O
by	O
less	O
than	O
0	O
.	O
1	O
M	O
NaCl	O
so	O
it	O
does	O
not	O
appear	O
that	O
the	O
subunit	O
enhances	O
the	O
binding	O
of	O
the	O
DNA	O
polymerase	O
subunit	O
to	O
DNA	O
.	O

However	O
,	O
there	O
are	O
differences	O
in	O
the	O
response	O
of	O
A	O
and	O
C	O
enzymes	O
to	O
synthetic	O
template	O
-	O
initiator	O
complexes	O
(	O
Table	O
1	O
)	O
.	O

Even	O
if	O
one	O
takes	O
into	O
account	O
the	O
fact	O
that	O
A	O
enzyme	O
is	O
less	O
active	O
on	O
activated	O
DNA	O
than	O
C	O
enzyme	O
(	O
the	O
addition	O
of	O
the	O
50	O
-	O
70	O
,	O
000	O
subunit	O
to	O
the	O
polymerase	O
subunit	O
appears	O
to	O
result	O
in	O
a	O
decrease	O
of	O
about	O
30	O
%	O
of	O
polymerase	O
activity	O
on	O
activated	O
DNA	O
)	O
the	O
A	O
enzyme	O
is	O
still	O
more	O
active	O
on	O
these	O
templates	O
.	O

Although	O
there	O
is	O
a	O
variation	O
in	O
activity	O
on	O
these	O
template	O
-	O
initiator	O
comp	O
lexes	O
each	O
time	O
assays	O
are	O
carried	O
out	O
on	O
them	O
depending	O
on	O
the	O
method	O
of	O
preparing	O
the	O
complexes	O
and	O
the	O
base	O
ratio	O
of	O
template	O
to	O
initiator	O
,	O
A	O
enzyme	O
always	O
seems	O
to	O
be	O
significantly	O
more	O
active	O
than	O
C.	O
The	O
A2	O
enzyme	O
at	O
pH	O
7.8	O
,	O
with	O
extra	O
subunit	O
(	O
s	O
)	O
is	O
clearly	O
more	O
effective	O
on	O
the	O
oligoribonucleotide	O
initiator	O
,	O
oligo	O
(	O
A	O
)	O
10	O
than	O
is	O
enzyme	O
C.	O
In	O
view	O
of	O
the	O
proposed	O
RNA	O
initiation	O
of	O
Okazaki	O
pieces	O
this	O
may	O
indicate	O
a	O
role	O
of	O
this	O
subunit	O
in	O
Okazaki	O
piece	O
synthesis	O
,	O
in	O
that	O
it	O
may	O
aid	O
the	O
DNA	O
polymerase	O
to'take	O
over	O
'	O
from	O
the	O
RNA	O
polymerase	O
.	O

Using	O
poly	O
(	O
dA	O
)	O
.	O

oligo	O
(	O
dT	O
)	O
10	O
(	O
A	O
:	O
T=20	O
:	O
1	O
)	O
and	O
following	O
the	O
incorporation	O
of	O
[	O
H	O
]	O
dTMP	O
as	O
a	O
function	O
of	O
time	O
a	O
short	O
lag	O
was	O
observed	O
for	O
C	O
enzyme	O
,	O
but	O
not	O
for	O
A2	O
(	O
Fig.	O
4	O
)	O
.	O

Similar	O
re	O
sult	O
s	O
we	O
re	O
obtained	O
when	O
poly	O
(	O
dC	O
)	O
.	O

oligo	O
(	O
dG	O
)	O
1	O
0	O
(	O
C	O
:	O
G=	O
5	O
:	O
1	O
)	O
wa	O
s	O
used	O
as	O
temrrplate	O
-	O
initiator	O
,	O
but	O
not	O
when	O
poly	O
(	O
dT	O
)	O
.	O

oligo	O
(	O
A	O
)	O
10	O
(	O
T	O
:	O
A=1	O
:	O
1	O
)	O
was	O
used	O
.	O

Neither	O
enzyme	O
showed	O
a	O
lag	O
on	O
this	O
template	O
-	O
initiator	O
complex	O
or	O
on	O
activated	O
DNA	O
.	O

Incorporation	O
versus	O
enzyme	O
concentration	O
also	O
showed	O
this	O
lag	O
for	O
C	O
enzyme	O
on	O
poly	O
(	O
dA	O
)	O
.	O

oligo	O
(	O
dT	O
)	O
10	O
.	O

It	O
is	O
not	O
certain	O
what	O
causes	O
3349	O
Nucleic	O
Acids	O
Research	O
TABLE	O
1	O
Template	O
utilisation	O
by	O
reconstituted	O
A	O
and	O
C	O
derived	O
from	O
A.	O
3H	O
]	O
dNTP	O
Divalent	O
cation	O
A2	O
at	O
pH	O
C	O
at	O
pH	O
Template	O
_	O
6.4	O
7.8	O
6.4	O
7.8	O
Activated	O
DNA	O
dTTP	O
Mg++	O
100	O
100	O
Activated	O
DNA	O
dATP	O
Mg++	O
91	O
85	O
Activated	O
DNA	O
dGTP	O
Mg++	O
85	O
82	O
poly	O
(	O
dA	O
)	O
.oligo	O
(	O
dT	O
)	O
10	O
dTTP	O
Mg	O
66.0	O
4.0	O
20	O
91	O
(	O
A	O
:	O
T	O
=	O
20	O
:	O
1	O
)	O
poly	O
(	O
dA	O
)	O
.	O

oligo	O
(	O
dT	O
)	O
dTTP	O
Mu	O
19.0	O
4	O
.	O
5	O
6	O
.	O
5	O
2.5	O
poly	O
(	O
dA.	O
oig~10	O
(	O
A	O
:	O
T	O
=	O
20:1	O
)	O
poly	O
(	O
dT	O
)	O
.	O

oligo	O
(	O
dA	O
)	O
10	O
dATP	O
Mg	O
2.5	O
<	O
1	O
(	O
1	O
(	O
1	O
(	O
T	O
:	O
A	O
=	O
5:1	O
)	O
poly	O
(	O
dT	O
)	O
.oligo	O
(	O
dA	O
)	O
1	O

dATP	O
Mn	O
+	O
+	O
15.5	O
23.0	O
9	O
.	O

0	O
3	O
.	O
0	O
poly	O
(	O
dT	O
)	O
.	O

oligo	O
(	O
A	O
)	O
10	O
dATP	O
Mg	O

15.0	O
230.0	O
10.0	O
77	O
.	O

5	O
(	O
T	O
:	O
A	O
=	O
1:1	O
)	O
poly	O
(	O
dT	O
)	O
*	O
oligo	O
(	O
A	O
)	O
10	O
dATP	O
Mn	O
41.5	O
75	O
.	O
5	O
19.5	O
21.5	O
(	O
T	O
:	O
A	O
=	O
1:1	O
)	O
poly	O
(	O
dC	O
)	O
.	O

oligo	O
(	O
dG	O
)	O
dGTP	O
Mg++	O
6	O
.	O

0	O
15.5	O
4	O
.	O
5	O
7	O
.	O
5	O
(	O
C	O
:	O
G	O
=	O
5:1	O
)	O
10	O
poly	O
(	O
dC	O
)	O
.	O

oligo	O
(	O
dG	O
)	O
10	O
dGTP	O
Mn	O
+	O
6	O
.	O
0	O
29.5	O
5	O
.	O
0	O
6	O
.	O
5	O
(	O
C	O
:	O
G	O
=	O
5	O
:	O
1	O
)	O
.	O
.	O

Values	O
given	O
are	O
relative	O
to	O
incorporation	O
of	O
[	O
H	O
]	O
dTMP	O
at	O
pH	O
7	O
.	O
8	O
on	O
activated	O
DNA	O
.	O

For	O
A2	O
this	O
was	O
176.5	O
pmol	O
,	O
for	O
C	O
232	O
pmol	O
.	O

dATP	O
,	O
dCTP	O
,	O
dGTP	O
and	O
dTTP	O
were	O
included	O
for	O
assays	O
using	O
activated	O
DNA	O
,	O
only	O
the	O
deoxynucleoside	O
triphosphate	O
stated	O
was	O
used	O
in	O
the	O
synthetic	O
template	O
initiator	O
complex	O
assays	O
.	O

Assays	O
were	O
for	O
10	O
minutes	O
.	O

The	O
buffers	O
and	O
concentrations	O
of	O
the	O
divalent	O
cations	O
were	O
as	O
in	O
Materials	O
and	O
Methods	O
.	O

this	O
lag	O
,	O
but	O
the	O
annealing	O
of	O
template	O
to	O
initiator	O
is	O
only	O
transient	O
'	O
and	O
the	O
DNA	O
polymerase	O
subunit	O
may	O
have	O
difficulty	O
in	O
stabilising	O
the	O
complex	O
and	O
the	O
50	O
-	O
70	O
,	O
000	O
molecular	O
weight	O
subunit	O
may	O
be	O
able	O
to	O
help	O
the	O
poly	O
merase	O
subunit	O
to	O
overcome	O
this	O
.	O

Addition	O
of	O
the	O
50	O
-	O
70	O
,	O
000	O
subunit	O
to	O
the	O
polymerase	O
subunit	O
prior	O
to	O
assaying	O
with	O
these	O
templates	O
had	O
no	O
effect	O
on	O
activity	O
and	O
it	O
may	O
be	O
that	O
a	O
preincubation	O
period	O
is	O
required	O
before	O
the	O
two	O
3350	O
Nucleic	O
Acids	O
Research	O
Figure	O
4	O
Activity	O
of	O
A2	O
and	O
C	O
enzymes	O
on	O
poly	O
(	O
dA	O
)	O
.	O

oligo	O
(	O
dT	O
)	O
jO	O
(	O
A	O
:	O
T	O
=	O
20:1	O
)	O
as	O
a	O
function	O
of	O
time	O
.	O

50	O
,	O
ul	O
samples	O
were	O
withdrawn	O
at	O
various	O
times	O
from	O
a	O
0	O
.	O

6	O
inl	O
incubation	O
mix	O
at	O
30?C	O
and	O
added	O
to	O
0	O
.	O
5	O
ml	O
0	O
.	O

1	O
M	O
sodium	O
pyrophosphate	O
containing	O
100	O
,	O
ug	O
/	O
ml	O
native	O
calf	O
thymus	O
DNA	O
and	O
processed	O
for	O
counting	O
in	O
the	O
usual	O
manner6	O
.	O

The	O
mix	O
contained	O
1	O
mM	O
dithiothreitol	O
,	O
50	O
mM	O
tris	O
HC1	O
,	O
pH	O
7.8	O
10	O
mM	O
MgC12	O
,	O
0	O
.	O
1	O
mM	O
[	O
3H	O
]	O
dTTP	O
(	O
15	O
cpm	O
/	O
pmol	O
)	O
,	O
312.5	O
,	O
ug	O
bovine	B
serum	O
albumin	O
,	O
5	O
Fg	O
poly	O
(	O
dA	O
)	O
.	O

oligo	O
(	O
dT	O
)	O
(	O
A	O
:	O
T	O
=	O
20:1	O
)	O
and	O
enzyme	O
protein	O
(	O
*	O
-	O
*	O
)	O
3.3	O
units	O
reconstituted	O
A2	O
,	O
(	O
o	O
-	O
o	O
)	O
16	O
.	O
0	O
units	O
urea	O
derived	O
C	O
enzyme	O
.	O

subunits	O
become	O
fully	O
associated	O
.	O

After	O
the	O
lag	O
phase	O
is	O
over	O
the	O
C	O
enzyme	O
is	O
still	O
less	O
active	O
on	O
these	O
template	O
-	O
initiators	O
than	O
A	O
enzyme	O
.	O

That	O
is	O
the	O
A	O
enzyme	O
seems	O
capable	O
of	O
elongating	O
the	O
initiator	O
faster	O
than	O
the	O
C	O
enzyme	O
.	O

Experiments	O
to	O
determine	O
whether	O
the	O
differences	O
in	O
rates	O
of	O
elongation	O
of	O
these	O
template	O
-	O
initiator	O
complexes	O
are	O
differences	O
in	O
processivity	O
of	O
the	O
enzymes	O
under	O
the	O
different	O
pH	O
and	O
divalent	O
cation	O
conditions	O
are	O
under	O
way	O
.	O

ACKNOWLEDGEMENTS	O
We	O
thank	O
the	O
Medical	O
Research	O
Council	O
for	O
a	O
research	O
grant	O
.	O

Communications	O
concerning	O
the	O
paper	O
should	O
be	O
sent	O
to	O
:	O
Dr.	O
A.	O
M.	O
Holmes	O
,	O
Department	O
of	O
Biochemistry	O
,	O
University	O
of	O
Strathclyde	O
,	O
The	O
Todd	O
Centre	O
,	O
31	O
Taylor	O
Street	O
,	O
Glasgow	O
G4	O
ONR	O
,	O
U.K.	O
3351	O
Nucleic	O
Acids	O
Research	O
REFERENCES	O
(	O
1	O
)	O
Bollum	O
,	O
F.J.	O
(	O
1975	O
)	O
.	O

Prog	O
.	O

Nucleic	O
Acid	O
Res	O
.	O

Mol	O
.	O

Biol	O
.	O

15	O
,	O
109	O
-	O
144	O
.	O

(	O
2	O
)	O
Holmes	O
,	O
A.M.	O
,	O
Hesslewood	O
,	O
I.P.	O
and	O
Johnston	O
,	O
I.R.	O
(	O
1976	O
)	O
.	O

Eur	O
.	O

J.	O
Biochem	O
.	O

62	O
,	O
229	O
-	O
235	O
.	O

(	O
3	O
)	O
Matsukage	O
,	O
A.	O
,	O
Sivarajan	O
,	O
M.	O
and	O
Wilson	O
,	O
S.H.	O
(	O
1976	O
)	O
.	O

Biochem	O
istry	O
15	O
,	O
5305	O
-	O
5314	O
.	O

(	O
4	O
)	O
Fisher	O
,	O
P.A.	O
and	O
Korn	O
,	O
D.	O
(	O
1977	O
)	O
.	O

J.	O
Biol	O
.	O

Chem	O
.	O
252	O
,	O
6528	O
6535	O
.	O

(	O
5	O
)	O
Fichot	O
,	O
O.	O
,	O
Pascal	O
,	O
M.	O
,	O
Mechali	O
,	O
M.	O
and	O
De	O
Recondo	O
,	O
A	O
,	O
-M.	O
(	O
1979	O
)	O
.	O

Biochim	O
.	O

Biophys	O
.	O

Acta	O
,	O
561	O
,	O
28	O
-	O
41	O
.	O

(	O
6	O
)	O
Holmes	O
,	O
A.M.	O
,	O
Hesslewood	O
,	O
I.R.	O
and	O
Johnston	O
,	O
I.R.	O
(	O
1974	O
)	O
.	O

Eur	O
.	O

J.	O
Biochemn	O
.	O

43	O
,	O
487	O
-	O
499	O
.	O

(	O
7	O
)	O
Noy	O
,	O
G.P.	O
and	O
Weissbach	O
,	O
A.	O
(	O
1977	O
)	O
.	O

Biochim	O
.	O

Biophys	O
.	O

Acta	O
,	O
447	O
,	O
70	O
-	O
83	O
.	O

(	O
8)	O
Craig	O
,	O
R.K.	O
and	O
Keir	O
,	O
H.	O
M.	O
(	O
1975	O
)	O
.	O

Biochem	O
.	O

J.	O
145	O
,	O
225	O
-	O
232	O
.	O

(	O
9	O
)	O
Matsukage	O
,	O
A.	O
,	O
Bohn	O
,	O
E.W.	O
and	O
Wilson	O
,	O
S.H.	O
(	O
1974	O
)	O
.	O

Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

U.S.A.	O
71	O
,	O
578	O
-	O
582	O
.	O

110	O
)	O
Hachmann	O
,	O
H.J.	O
and	O
Lezius	O
,	O
A.G.	O
(	O
1975	O
)	O
.	O

Eur	O
.	O

J.	O
Biochem	O
.	O

50	O
,	O
357-	O
366	O
.	O

(	O
11	O
)	O
Brakel	O
,	O
C.L.	O
and	O
Blumenthal	O
,	O
A.B.	O
(	O
1977	O
)	O
.	O

Biochemistry	O
,	O
16	O
,	O
3137	O
-	O
3143	O
.	O

(	O
12	O
)	O
Momparler	O
,	O
R.L.	O
,	O
Rossi	O
,	O
M.	O
and	O
Labitan	O
,	O
A.	O
(	O
1973	O
)	O
.	O

J.	O
Biol	O
.	O

Chem	O
.	O

248	O
,	O
285	O
-	O
293	O
.	O

(	O
13	O
)	O
Yoshida	O
,	O
S.	O
,	O
Konda	O
,	O
T.	O
and	O
Ando	O
,	O
T.	O
(	O
1974	O
)	O
.	O

Biochim	O
.	O

Biophys	O
.	O

Acta	O
,	O
353	O
,	O
463	O
-	O
474	O
.	O

(	O
14	O
)	O
Holmes	O
,	O
A.M.	O
,	O
Hesslewood	O
,	O
I.P.	O
,	O
Wickremasinghe	O
,	O
R.G.	O
and	O
Johnston	O
,	O
I.R.	O
(	O
1977	O
)	O
.	O

Biochem	O
.	O

Soc	O
.	O

Symp	O
.	O
42	O
,	O
17	O
-	O
36	O
.	O

(	O
15	O
)	O
De	O
Jong	O
,	O
A.	O
,	O
Van	O
der	O
Vliet	O
,	O
P.	O
and	O
Jansz	O
,	O
H.S.	O
(	O
1977	O
)	O
.	O

Biochim	O
.	O

Biophys	O
.	O

Acta	O
,	O
476	O
,	O
156	O
-	O
165	O
.	O

(	O
16	O
)	O
Holmes	O
,	O
A.M.	O
,	O
Hesslewood	O
,	O
I.P.	O
and	O
Johnston	O
,	O
I.R.	O
(	O
1975	O
)	O
.	O

Nature	O
(	O
London	O
)	O
255	O
,	O
420	O
-	O
422	O
.	O

(	O
17	O
)	O
Bollum	O
,	O
F.	O
J.	O
(	O
1966	O
)	O
.	O

Procedures	O
in	O
Nucleic	O
Acid	O
Research	O
(	O
Cantoni	O
,	O
G.L.	O
and	O
Davis	O
,	O
D.R.	O
eds	O
)	O
.	O

pp	O
577	O
-	O
583	O
,	O
Harper	O
and	O
Row	O
,	O
New	O
York	O
.	O

(	O
18	O
)	O
Barrett	O
,	O
A.J.	O
(	O
1975	O
)	O
.	O

Proteases	O
and	O
Biological	O
Control	O
pp	O
467	O
-	O
482	O
,	O
Cold	O
Spring	O
Harbor	O
Laboratory	O
,	O
Cold	O
Spring	O
Harbor	O
.	O

(	O
19	O
)	O
Richards	O
,	O
F.	O
M.	O
and	O
Vithayathil	O
,	O
P.J.	O
(	O
1960	O
)	O
.	O

Brookhaven	O
Symp	O
.	O

Biol	O
.	O

13	O
,	O
115	O
-	O
134	O
.	O

(	O
20	O
)	O
Lowe	O
,	O
P.A.	O
,	O
and	O
Malcolm	O
,	O
A.B.D.	O
(	O
1976	O
)	O
.	O

Eur	O
.	O

J.	O
Biochem	O
.	O

64	O
,	O
177-	O
188	O
.	O

(	O
21	O
)	O
Hesslewood	O
,	O
I.P.	O
,	O
Holmes	O
,	O
A.M.	O
,	O
Wakeling	O
,	O
W.F.	O
and	O
Johnston	O
,	O
I.R.	O
(	O
1978	O
)	O
.	O

Eur	O
.	O

J.	O
Biochenr	O
..	O
84	O
,	O
123	O
-	O
131	O
.	O

(	O
22	O
)	O
Mechali	O
,	O
M.	O
and	O
De	O
Recondo	O
,	O
A.	O
-M.	O
(	O
1978	O
)	O
.	O

Biochim	O
.	O

Biophys	O
.	O

Res	O
.	O

Comm	O
,	O
82	O
,	O
255	O
-	O
264	O
.	O

(	O
23	O
)	O
Chang	O
,	O
L.M.S.	O
,	O
Cassani	O
,	O
G.R.	O
and	O
Bollum	O
,	O
F.J.	O
(	O
1972	O
)	O
.	O

J.	O
Biol	O
.	O

Che	O
.	O
247	O
,	O
7718	O
-	O
7723	O
.	O

(	O
24	O
)	O
Wickremasinghe	O
,	O
R.G.	O
and	O
Johnston	O
,	O
I.R.	O
(	O
1974	O
)	O
.	O

Biochim	O
.	O

Biophys	O
.	O

Acta	O
,	O
361	O
,	O
37	O
-	O
52	O
.	O

3352	O

Mapping	O
irradiation	O
hybrids	O
to	O
cosmid	O
and	O
yeast	B
artificial	O
chromosome	O
libraries	O
by	O
direct	O
hybridization	O
of	O
Alu	O
-	O
PCR	O
products	O
.	O

Abstract	O
A	O
direct	O
hybridization	O
protocol	O
is	O
described	O
for	O
screening	O
cosmid	O
and	O
yeast	B
artificial	O
chromosome	O
libraries	O
with	O
pools	O
of	O
Alu	O
-	O
PCR	O
products	O
from	O
somatic	O
cell	O
or	O
irradiation	O
hybrids	O
.	O

This	O
method	O
eliminates	O
purification	O
,	O
cloning	O
and	O
analysis	O
of	O
each	O
individual	O
Alu	O
-	O
PCR	O
product	O
before	O
library	O
screening	O
.	O

A	O
series	O
of	O
human	B
X	O
chromosome	O
irradiation	O
hybrids	O
were	O
mapped	O
by	O
this	O
method	O
,	O
using	O
a	O
cosmid	O
reference	O
library	O
for	O
comparisons	O
between	O
overlapping	O
hybrids	O
to	O
identify	O
interesting	O
clones	O
for	O
further	O
analysis	O
.	O

Images	O
Nucleic	O
Acids	O
Research	O
,	O
Vol	O
.	O

19	O
,	O
No.	O
12	O
3315	O
Mapping	O
irradiation	O
hybrids	O
to	O
cosmid	O
and	O
yeast	B
artificial	O
chromosome	O
libraries	O
by	O
direct	O
hybridization	O
of	O
Alu	O
-	O
PCR	O
products	O
Anthony	O
P.Monaco	O
*	O
,	O
Veronica	O
M.S.Lam2	O
,	O
Gunther	O
Zehetner	O
,	O
Gregory	O
G.Lennon	O
,	O
Christal	O
Douglas	O
,	O
Dean	O
Nizetic	O
,	O
Peter	O
N.Goodfellow1	O
and	O
Hans	O
Lehrach	O
Genome	O
Analysis	O
Laboratory	O
and	O
'	O
Molecular	O
Human	O
Genetics	O
Laboratory	O
,	O
Imperial	O
Cancer	O
Research	O
Fund	O
,	O
44	O
Lincoln	O
's	O
Inn	O
Fields	O
,	O
London	O
WC2A	O
3PX	O
,	O
UK	O
and	O
2Department	O
of	O
Biochemistry	O
,	O
Li	O
Shu	O
Fan	O
Building	O
,	O
Sassoon	O
Road	O
,	O
University	O
of	O
Hong	O
Kong	O
,	O
Hong	O
Kong	O
Received	O
March	O
12	O
,	O
1991	O
;	O
Revised	O
and	O
Accepted	O
May	O
16	O
,	O
1991	O
ABSTRACT	O
A	O
direct	O
hybridization	O
protocol	O
is	O
described	O
for	O
screening	O
cosmid	O
and	O
yeast	B
artificial	O
chromosome	O
libraries	O
with	O
pools	O
of	O
Alu	O
-	O
PCR	O
products	O
from	O
somatic	O
cell	O
or	O
irradiation	O
hybrids	O
.	O

This	O
method	O
eliminates	O
purification	O
,	O
cloning	O
and	O
analysis	O
of	O
each	O
individual	O
AluPCR	O
product	O
before	O
library	O
screening	O
.	O

A	O
series	O
of	O
human	B
X	O
chromosome	O
irradiation	O
hybrids	O
were	O
mapped	O
by	O
this	O
method	O
,	O
using	O
a	O
cosmid	O
reference	O
library	O
for	O
comparisons	O
between	O
overlapping	O
hybrids	O
to	O
identify	O
interesting	O
clones	O
for	O
further	O
analysis	O
.	O

INTRODUCTION	O
The	O
generation	O
of	O
human	B
DNA	O
probes	O
specific	O
for	O
individual	O
chromosomes	O
and	O
subregions	O
of	O
chromosomes	O
has	O
been	O
advanced	O
with	O
Alu	O
-	O
sequence	O
primed	O
polymerase	O
chain	O
reaction	O
amplification	O
(	O
Alu	O
-	O
PCR	O
,	O
1	O
-	O
3	O
)	O
.	O

This	O
method	O
specifically	O
amplifies	O
sequences	O
between	O
Alu	O
repeats	O
from	O
human	B
DNA	O
in	O
somatic	O
cell	O
hybrids	O
and	O
yeast	B
artificial	O
chromosomes	O
(	O
YACs	O
,	O
4	O
)	O
.	O

Individual	O
Alu	O
-	O
PCR	O
products	O
can	O
be	O
purified	O
from	O
agarose	O
gels	O
or	O
ligated	O
into	O
plasmid	O
vectors	O
to	O
screen	O
for	O
single	O
copy	O
sequences	O
.	O

Unique	O
Alu	O
-	O
PCR	O
products	O
are	O
then	O
localized	O
to	O
certain	O
chromosome	O
regions	O
using	O
DNA	O
blots	O
of	O
somatic	O
cell	O
hybrid	O
panels	O
.	O

Once	O
localized	O
,	O
Alu	O
-	O
PCR	O
fragments	O
can	O
be	O
screened	O
against	O
genomic	O
libraries	O
to	O
isolate	O
longer	O
DNA	O
fragments	O
from	O
the	O
region	O
of	O
interest	O
.	O

As	O
an	O
alternative	O
to	O
this	O
multistep	O
process	O
we	O
have	O
developed	O
a	O
hybridization	O
protocol	O
for	O
screening	O
of	O
cosmid	O
and	O
YAC	O
libraries	O
directly	O
with	O
pools	O
of	O
Alu	O
-	O
PCR	O
products	O
.	O

Two	O
new	O
human	B
specific	O
Alu	O
primers	O
were	O
used	O
to	O
generate	O
DNA	O
probes	O
from	O
a	O
series	O
of	O
irradiation	O
-	O
reduced	O
hybrids	O
containing	O
multiple	O
human	B
X	O
chromosome	O
fragments	O
of	O
1	O
-	O
2000	O
kb	O
on	O
a	O
hamster	O
chromosome	O
background	O
(	O
5	O
;	O
P.N.G.	O
,	O
unpublished	O
)	O
.	O

The	O
Alu	O
-	O
PCR	O
products	O
were	O
hybridized	O
as	O
a	O
pool	O
of	O
probes	O
to	O
X	O
-	O
specific	O
cosmid	O
and	O
YAC	O
libraries	O
,	O
after	O
competitive	O
reassociation	O
with	O
an	O
excess	O
of	O
human	B
DNA	O
to	O
both	O
the	O
library	O
filters	O
and	O
radioactively	O
labelled	O
Alu	O
-	O
PCR	O
products	O
.	O

Comparisons	O
were	O
made	O
between	O
clones	O
identified	O
by	O
overlapping	O
irradiation	O
hybrids	O
and	O
single	O
copy	O
DNA	O
probes	O
hybridized	O
to	O
the	O
cosmid	O
and	O
YAC	O
libraries	O
.	O

METHODS	O
Two	O
human	B
Alu	O
sequence	O
primers	O
were	O
generated	O
which	O
were	O
shown	O
to	O
be	O
human	B
specific	O
;	O
3144	O
from	O
the	O
3	O
'	O
end	O
of	O
Alu	O
:	O
5'-GAGCGAGACTCCGTCTCAAA-3	O
'	O
and	O
2729	O
from	O
the	O
5	O
'	O
end	O
of	O
Alu	O
:	O
5'-GTGGATCACCTGAGGTCAGGAGTTC-3	O
'	O
.	O

All	O
PCR	O
reactions	O
were	O
carried	O
out	O
with	O
100	O
ng	O
of	O
hybrid	O
DNA	O
and	O
0.7	O
,	O
^g	O
of	O
a	O
single	O
Alu	O
primer	O
in	O
100	O
d41	O
of	O
0.01	O
M	O
Tris	O
-	O
HCl	O
pH	O
8.3	O
,	O
0.0015	O
M	O
MgCl2	O
,	O
0.05	O
M	O
KCI	O
,	O
200	O
AtM	O
each	O
of	O
dNTPs	O
,	O
10	O
%	O
dimethlysulfoxide	O
,	O
and	O
2.5	O
units	O
of	O
Cetus	O
Taq	O
polymerase	O
.	O

Reactions	O
were	O
30	O
cycles	O
of	O
94?C	O
for	O
2	O
min	O
,	O
57?C	O
for	O
2	O
min	O
,	O
and	O
74?C	O
for	O
4	O
min	O
followed	O
by	O
a	O
final	O
extension	O
time	O
at	O
74?C	O
for	O
9	O
min	O
.	O

Reactions	O
products	O
were	O
analyzed	O
on	O
1	O
%	O
agarose	O
gels	O
and	O
shown	O
to	O
contain	O
between	O
five	O
and	O
twenty	O
fragments	O
,	O
with	O
sizes	O
ranging	O
from	O
0.1	O
to	O
2.0	O
kb	O
.	O

Chinese	B
hamster	I
DNA	O
and	O
no	O
DNA	O
PCR	O
reactions	O
were	O
done	O
to	O
control	O
for	O
non	O
-	O
human	B
products	O
(	O
data	O
not	O
shown	O
)	O
.	O

Alu	O
-	O
PCR	O
products	O
were	O
separated	O
from	O
Alu	O
oligomers	O
over	O
Qiagen	O
columns	O
,	O
and	O
approximately	O
50	O
-	O
100	O
ng	O
were	O
labelled	O
by	O
random	O
hexamer	O
priming	O
(	O
6	O
)	O
.	O

The	O
radioactively	O
labelled	O
pool	O
of	O
fragments	O
was	O
prehybridized	O
with	O
37.5	O
,	O
^g	O
of	O
total	O
human	B
DNA	O
and	O
12.5	O
tsg	O
of	O
hamster	O
DNA	O
immobilized	O
on	O
a	O
cellulose	O
support	O
matrix	O
,	O
prepared	O
as	O
previously	O
described	O
(	O
7	O
)	O
.	O

Reactions	O
were	O
at	O
65?C	O
in	O
1	O
ml	O
of	O
0.75	O
M	O
NaCl	O
,	O
0.05	O
M	O
sodium	O
phosphate	O
pH	O
7.2	O
,	O
0.005	O
M	O
EDTA	O
,	O
0.1	O
%	O
sodium	O
dodecyl	O
sulphate	O
(	O
SDS	O
)	O
,	O
0.5	O
mg	O
/	O
ml	O
heparin	O
,	O
and	O
100	O
jig	O
/	O
ml	O
denatured	O
salmon	O
sperm	O
DNA	O
.	O

The	O
cellulose	O
was	O
pelleted	O
and	O
the	O
supernatant	O
boiled	O
for	O
2	O
min	O
every	O
12	O
-	O
16	O
hours	O
(	O
three	O
times	O
in	O
two	O
days	O
)	O
.	O

Cosmid	O
and	O
YAC	O
library	O
filters	O
(	O
Hybond	O
N+	O
,	O
Amersham	O
)	O
were	O
prehybridized	O
at	O
42?C	O
for	O
16	O
hours	O
with	O
100	O
jig	O
/	O
ml	O
*	O
To	O
whom	O
correspondence	O
should	O
be	O
addressed	O
at	O
Human	O
Genetics	O
Laboratory	O
,	O
Imperial	O
Cancer	O
Research	O
Fund	O
,	O
Institute	O
of	O
Molecular	O
Medicine	O
,	O
John	O
Radcliffe	O
Hospital	O
,	O
Headington	O
,	O
Oxford	O
OX3	O
9DU	O
,	O
UK	O
1991	O
Oxford	O
University	O
Press	O
3316	O
Nucleic	O
Acids	O
Research	O
,	O
Vol	O
.	O

19	O
,	O
No.	O
12	O
Chromosome	O
X	O
.	O
,	O
..	O
,	O
.	O
,	O
<	O
_	O
.	O
,	O
.	O

<	O
.	O
,	O
*	O
2	O
.	O
'	O
1-	O
7-	O
_	O
_	O
-	O
_	O
1	O
.	O

J	O
,	O
.1	O
..	O
-	O
1	O
,	O
_	O
i	O
-	O
_	O
1	O
.	O
1	O
1	O
'	O
4	O
-	O
-1	O
+	O
1	O
1	O
L	O
L	O
.	O

i	O
.	O
1	O
.	O
_	O
1	O
1	O
1	O
s.	O
1	O
i	O
1	O
i	O
;	O
.	O

--r	O
'	O
F	O
1	O
-	O
1	O
-1-l	O
j	O
i-_1	O
.	O

1	O
-	O
_	O
1	O
..	O
s-	O
S	O
.	O

i	O
n	O
-	O
.	O

..	O
:	O
,	O
1	O
'	O
,	O
.	O

-1	O

_	O
E	O
I	O
i	O
?	O
,	O
.	O
.	O

_	O
_	O
_	O
G-	O
.	O

*	O
.-	O
.	O
,	O
.	O
,	O
z	O
_	O
_	O
,	O
z	O
;	O
-	O
[	O
X1	O
21	O
,	O
In	O
27	O
38	O
45	O
48	O
54	O
74	O
86	O
I	O
1	O

I	O
I	O

I	O
107	O

MD	O
I	O
:	O
I	O
I	O

I	O

I	O

I	O
I	O
Figur	O
2a	O
and	O
2b	O

:	O
Hybridization	O
of	O
Alu	O
-	O
PCR	O
products	O
generated	O
with	O
Alu	O
primer	O
3144	O
from	O
irradiation	O
hybrid	O
48	O
to	O
duplicate	O
copies	O
of	O
22	O
x22	O
cm	O
filters	O
containing	O
9216	O
human	B
X	O
chromosome	O
cosmids	O
(	O
8)	O
.	O

2c	O
:	O
Hybridization	O
of	O
Alu	O
-	O
PCR	O
products	O
generated	O
with	O
Alu	O
primer	O
3144	O
from	O
an	O
independent	O
hybrid	O
(	O
54	O
)	O
to	O
a	O
third	O
identical	O
cosmid	O
filter	O
.	O

Figure	O
1	O
:	O
A	O
schematic	O
diagram	O
of	O
the	O
human	B
X	O
chromosome	O
alongside	O
the	O
approximate	O
cytogenetic	O
location	O
of	O
fragments	O
identified	O
in	O
nine	O
irradiation	O
hybrids	O
(	O
numbers	O
across	O
the	O
top	O
)	O
.	O

The	O
human	B
X	O
fragments	O
were	O
identified	O
by	O
hybridization	O
of	O
27	O
known	O
DNA	O
markers	O
(	O
indicated	O
by	O
a	O
black	O
line	O
;	O
P.N.G	O
,	O
unpublished	O
)	O
or	O
by	O
cosmids	O
in	O
common	O
with	O
unique	O
X	O
chromosome	O
probes	O
in	O
the	O
reference	O
library	O
database	O
(	O
open	O
boxes	O
and	O
Table	O
1	O
)	O
.	O

The	O
size	O
of	O
the	O
lines	O
and	O
boxes	O
relate	O
to	O
the	O
best	O
cytogenetic	O
location	O
of	O
the	O
probes	O
used	O
according	O
to	O
Human	O
Gene	O
Mapping	O
10.5	O
(	O
14	O
)	O
and	O
does	O
not	O
indicate	O
the	O
physical	O
extent	O
of	O
the	O
irradiation	O
hybrid	O
fragments	O
.	O

denatured	O
and	O
sheared	O
total	O
human	B
DNA	O
in	O
50	O
%	O
formamide	O
,	O
4XSSC	O
,	O
0.05	O
M	O
sodium	O
phosphate	O
pH	O
7.2	O
,	O
0.001	O
M	O
EDTA	O
,	O
10	O
%	O
dextran	O
sulphate	O
,	O
1.0	O
%	O
SDS	O
,	O
50	O
isg	O
/	O
ml	O
denatured	O
salmon	O
sperm	O
DNA	O
and	O
OxDenhardt	O
's	O
solution	O
.	O

The	O
radioactively	O
labelled	O
Alu	O
-	O
PCR	O
products	O
were	O
denatured	O
and	O
added	O
to	O
fresh	O
hybridization	O
solution	O
without	O
human	B
DNA	O
competitor	O
at	O
1	O
x	O
106	O
cpm	O
/	O
ml	O
and	O
hybridized	O
at	O
42?C	O
for	O
16	O
hours	O
.	O

Filters	O
were	O
washed	O
in	O
0.1	O
xSSC	O
and	O
1.0	O
%	O
SDS	O
,	O
twice	O
at	O
room	O
temperature	O
and	O
twice	O
at	O
65?C	O
for	O
30	O
min	O
each	O
and	O
exposed	O
to	O
Kodak	O
X	O
-	O
OMAT	O
film	O
for	O
2	O
-	O
3	O
days	O
at	O
-70?C	O
with	O
an	O
intensifying	O
screen	O
.	O

For	O
each	O
hybridization	O
,	O
two	O
sets	O
of	O
duplicate	O
cosmid	O
filters	O
were	O
used	O
from	O
the	O
ICRF	O
reference	O
library	O
system	O
(	O
8)	O
,	O
each	O
containing	O
9216	O
flow	O
-	O
sorted	O
human	B
X	O
chromosome	O
cosmid	O
clones	O
or	O
approximately	O
2	O
chromosome	O
equivalents	O
on	O
a	O
22	O
x	O
22	O
cm	O
filter	O
(	O
9	O
)	O
.	O

The	O
coordinates	O
of	O
signals	O
positive	O
on	O
duplicate	O
cosmid	O
filters	O
were	O
entered	O
into	O
the	O
reference	O
library	O
database	O
(	O
G.	O
Z	O
,	O
unpublished	O
)	O
using	O
a	O
digitizing	O
tablet	O
.	O

For	O
the	O
X	O
chromosome	O
specific	O
YAC	O
library	O
(	O
A.P.M.	O
and	O
H.L.	O
,	O
unpublished	O
)	O
,	O
about	O
420	O
YAC	O
colonies	O
were	O
spotted	O
manually	O
onto	O
filters	O
from	O
96	O
well	O
microtiter	O
dishes	O
using	O
a	O
96	O
prong	O
device	O
.	O

After	O
growth	O
on	O
selective	O
media	O
for	O
3	O
days	O
,	O
YAC	O
filters	O
were	O
processed	O
for	O
hybridization	O
as	O
previously	O
described	O
(	O
10	O
)	O
.	O

RESULTS	O
A	O
panel	O
of	O
195	O
X	O
chromosome	O
irradiation	O
hybrids	O
was	O
constructed	O
(	O
50,000	O
rads	O
)	O
and	O
characterized	O
by	O
DNA	O
hybridization	O
using	O
27	O
X	O
chromosome	O
markers	O
and	O
flourescence	O
in	O
situ	O
hybridization	O
using	O
total	O
human	B
DNA	O
as	O
probe	O
(	O
Benham	O
et	O
al.	O
,	O
1989	O
;	O
P.N.G.	O
,	O
unpublished	O
)	O
.	O

This	O
analysis	O
indicated	O
that	O
the	O
hybrids	O
contained	O
multiple	O
small	O
fragments	O
(	O
4	O
-	O
10	O
fragments	O
of	O
1000	O
-	O
5000	O
kb	O
each	O
)	O
with	O
a	O
preferential	O
retaining	O
of	O
centromere	O
sequences	O
(	O
90	O
%	O
)	O
.	O

From	O
this	O
panel	O
,	O
nine	O
irradiation	O
hybrids	O
were	O
chosen	O
that	O
contained	O
less	O
than	O
five	O
different	O
regions	O
by	O
DNA	O
probe	O
hybridizations	O
,	O
mostly	O
from	O
the	O
short	O
arm	O
of	O
the	O
X	O
chromosome	O
(	O
Fig	O
1	O
)	O
.	O

All	O
nine	O
hybrids	O
were	O
used	O
in	O
PCR	O
reactions	O
with	O
3'-Alu	O
primer	O
3144	O
and	O
two	O
were	O
used	O
with	O
5'-Alu	O
Figure	O
3	O
:	O
Hybridization	O
of	O
Alu	O
-	O
PCR	O
products	O
generated	O
with	O
Alu	O
primer	O
3144	O
from	O
irradiation	O
hybrid	O
54	O
to	O
a	O
filter	O
containing	O
420	O
YAC	O
clones	O
from	O
the	O
human	B
X	O
chromosome	O
.	O

The	O
positive	O
YAC	O
was	O
also	O
identified	O
in	O
a	O
separate	O
hybridization	O
with	O
the	O
DMD	O
probe	O
P20	O
(	O
12	O
)	O
.	O

primer	O
2729	O
.	O

Example	O
hybridizations	O
to	O
a	O
human	B
X	O
chromosome	O
cosmid	O
filter	O
in	O
Fig	O
2	O
shows	O
the	O
intensity	O
and	O
reliability	O
of	O
positive	O
clones	O
identified	O
on	O
duplicate	O
filters	O
with	O
Alu	O
-	O
PCR	O
products	O
from	O
the	O
same	O
irradiation	O
hybrid	O
(	O
48	O
)	O
and	O
the	O
independence	O
of	O
clones	O
identified	O
with	O
Alu	O
-	O
PCR	O
products	O
from	O
a	O
different	O
hybrid	O
(	O
54	O
)	O
.	O

Fig	O
3	O
shows	O
a	O
single	O
positive	O
YAC	O
clone	O
after	O
hybridization	O
of	O
Alu	O
-	O
PCR	O
products	O
from	O
irradiation	O
hybrid	O
54	O
to	O
a	O
filter	O
containing	O
about	O
420	O
YAC	O
clones	O
specific	O
for	O
the	O
human	B
X	O
chromosome	O
.	O

The	O
total	O
number	O
of	O
cosmids	O
identified	O
with	O
each	O
pool	O
of	O
AluPCR	O
products	O
for	O
each	O
hybrid	O
is	O
shown	O
in	O
Table	O
1	O
.	O

From	O
the	O
average	O
number	O
of	O
cosmids	O
identified	O
(	O
24	O
)	O
in	O
four	O
chromosome	O
equivalents	O
screened	O
and	O
the	O
estimated	O
average	O
DNA	O
content	O
in	O
each	O
hybrid	O
(	O
3000	O
-	O
15000	O
kb	O
)	O
,	O
the	O
Alu	O
-	O
PCR	O
products	O
generated	O
by	O
a	O
single	O
primer	O
were	O
calculated	O
on	O
average	O
to	O
be	O
300	O
-	O
1500	O
kb	O
apart	O
,	O
similar	O
to	O
published	O
estimates	O
for	O
this	O
method	O
(	O
1,2	O
)	O
.	O

Only	O
3	O
-	O
4	O
cosmids	O
were	O
identified	O
in	O
common	O
using	O
Alu	O
-	O
PCR	O
products	O
generated	O
with	O
either	O
3	O
'	O
or	O
5	O
'	O
Alu	O
primers	O
(	O
3144	O
or	O
2729	O
)	O
from	O
two	O
hybrids	O
(	O
38	O
and	O
45	O
)	O
.	O

This	O
shows	O
that	O
separate	O
products	O
were	O
amplified	O
with	O
the	O
two	O
Alu	O
primers	O
since	O
they	O
prime	O
synthesis	O
from	O
opposite	O
ends	O
of	O
the	O
Alu	O
consensus	O
sequence	O
and	O
Alu	O
sequences	O
are	O
oriented	O
in	O
the	O
genome	O
either	O
head	O
to	O
head	O
,	O
A	O
B	O
C	O
El	O
I0	O
Nucleic	O
Acids	O
Research	O
,	O
Vol	O
.	O

19	O
,	O
No.	O
12	O
3317	O
Table	O
1	O
.	O

Cosmids	O
identified	O
by	O
hybrids	O
and	O
unique	O
probes	O
hybrids	O
21	O
27	O
38	O
38	O
45	O
45	O
48	O
54	O
74	O
86	O
107	O
unique	O
primer	O
3144	O
3144	O
3144	O
2729	O
3144	O
2729	O
3144	O
3144	O
3144	O
33144	O
3144	O
probes	O
21	O
3144	O

59	O
1	O
27	O
3144	O
7	O
14	O
2	O
38	O
3144	O
3	O
1	O
28	O
2	O
38	O
2729	O
0	O
0	O
4	O
25	O
0	O
45	O
3144	O
13	O

2	O
2	O
0	O
32	O
3	O
45	O
2729	O
1	O
0	O

0	O
0	O
3	O
31	O
0	O
48	O
3144	O
10	O
2	O
4	O
0	O
2	O
0	O
28	O
3	O
54	O
3144	O
11	O

3	O
0	O
0	O
5	O
0	O
5	O
30	O
2	O
74	O
3144	O
5	O
0	O
0	O

0	O
4	O
0	O
5	O
12	O
20	O
3	O
86	O
3144	O

3	O
1	O
0	O
0	O
4	O
1	O
3	O
4	O
3	O
17	O
0	O
107	O
3144	O
1	O
0	O
1	O

1	O
0	O
0	O
3	O
0	O
0	O
0	O
13	O
0	O
tail	O
to	O
tail	O
or	O
head	O
to	O
tail	O
relative	O
to	O
each	O
other	O
.	O

Therefore	O
,	O
by	O
using	O
the	O
3'-	O
and	O
5'-Alu	O
primers	O
in	O
separate	O
PCR	O
reactions	O
with	O
the	O
same	O
hybrid	O
DNA	O
,	O
the	O
total	O
number	O
of	O
products	O
and	O
cosmid	O
clones	O
identified	O
was	O
almost	O
doubled	O
.	O

Table	O
1	O
also	O
indicates	O
how	O
many	O
cosmids	O
were	O
identified	O
by	O
Alu	O
-	O
PCR	O
products	O
from	O
other	O
hybrids	O
,	O
and	O
16	O
cosmids	O
previously	O
identified	O
with	O
unique	O
DNA	O
probes	O
in	O
the	O
reference	O
library	O
database	O
.	O

As	O
can	O
be	O
seen	O
in	O
Fig	O
1	O
and	O
previous	O
irradiation	O
hybrid	O
analysis	O
,	O
there	O
is	O
a	O
preferential	O
retention	O
of	O
centromere	O
sequences	O
(	O
2,11	O
)	O
.	O

However	O
,	O
there	O
were	O
no	O
cosmids	O
identified	O
in	O
common	O
from	O
all	O
the	O
hybrids	O
positive	O
with	O
centromere	O
sequences	O
.	O

This	O
is	O
probably	O
due	O
to	O
a	O
paucity	O
of	O
Alu	O
repeats	O
in	O
the	O
correct	O
orientation	O
in	O
alphoid	O
centromere	O
sequences	O
and	O
thus	O
few	O
or	O
no	O
Alu	O
-	O
PCR	O
products	O
would	O
be	O
amplified	O
from	O
the	O
centromere	O
.	O

Cosmids	O
identified	O
in	O
common	O
by	O
several	O
irradiation	O
hybrids	O
(	O
Table	O
1	O
)	O
were	O
most	O
likely	O
from	O
regions	O
of	O
overlap	O
outside	O
the	O
centromere	O
area	O
as	O
shown	O
by	O
the	O
previous	O
DNA	O
probe	O
characterization	O
(	O
Fig	O
1	O
)	O
.	O

The	O
overlap	O
regions	O
between	O
hybrids	O
were	O
also	O
seen	O
by	O
16	O
cosmids	O
(	O
Table	O
1	O
,	O
Fig	O
1	O
)	O
that	O
were	O
hybridization	O
targets	O
of	O
unique	O
DNA	O
markers	O
in	O
the	O
reference	O
library	O
database	O
that	O
mapped	O
in	O
independent	O
experiments	O
to	O
the	O
overlap	O
region	O
.	O

At	O
least	O
for	O
several	O
cosmids	O
this	O
showed	O
that	O
the	O
Alu	O
-	O
PCR	O
products	O
identified	O
target	O
cosmids	O
that	O
were	O
definitely	O
from	O
the	O
expected	O
region	O
contained	O
in	O
the	O
hybrids	O
.	O

For	O
example	O
,	O
hybrids	O
21	O
and	O
54	O
were	O
both	O
shown	O
to	O
contain	O
part	O
of	O
the	O
Duchenne	O
muscular	O
dystrophy	O
(	O
DMD	O
)	O
locus	O
(	O
Fig	O
1	O
;	O
P.N.G.	O
,	O
unpublished	O
)	O
and	O
had	O
11	O
cosmids	O
in	O
common	O
,	O
including	O
one	O
identified	O
by	O
the	O
probe	O
P20	O
from	O
the	O
deletion	O
hotspot	O
region	O
of	O
the	O
DMD	O
gene	O
(	O
12	O
)	O
.	O

In	O
Fig	O
3	O
the	O
hybridization	O
of	O
Alu	O
-	O
PCR	O
products	O
from	O
hybrid	O
54	O
identified	O
a	O
YAC	O
clone	O
which	O
was	O
also	O
positive	O
for	O
the	O
DMD	O
probe	O
P20	O
(	O
data	O
not	O
shown	O
)	O
.	O

This	O
method	O
also	O
identified	O
fragments	O
in	O
the	O
hybrids	O
that	O
were	O
not	O
seen	O
in	O
the	O
initial	O
DNA	O
characterization	O
(	O
Fig	O
1	O
and	O
Table	O
1	O
)	O
.	O

Since	O
the	O
27	O
DNA	O
probes	O
were	O
not	O
close	O
enough	O
to	O
each	O
other	O
along	O
the	O
chromosome	O
to	O
detect	O
all	O
possible	O
hybrid	O
fragments	O
(	O
1000	O
-	O
5000	O
kb	O
)	O
,	O
many	O
regions	O
would	O
have	O
been	O
untested	O
.	O

For	O
example	O
,	O
AluPCR	O
products	O
from	O
hybrids	O
45	O
and	O
48	O
identified	O
several	O
cosmids	O
,	O
also	O
seen	O
by	O
the	O
cDNA	O
for	O
chronic	O
granulomatous	O
disease	O
gene	O
(	O
CYBB	O
,	O
13	O
)	O
in	O
Xp2	O
1.1	O
,	O
although	O
this	O
region	O
was	O
not	O
tested	O
in	O
the	O
original	O
hybrid	O
characterization	O
.	O

DISCUSSION	O
The	O
direct	O
hybridization	O
of	O
Alu	O
-	O
PCR	O
products	O
from	O
somatic	O
cell	O
hybrids	O
to	O
genomic	O
libraries	O
can	O
bypass	O
gel	O
purification	O
or	O
ligation	O
of	O
fragments	O
into	O
plasmid	O
vectors	O
and	O
individual	O
analysis	O
for	O
single	O
copy	O
sequences	O
.	O

Hybridization	O
of	O
Alu	O
-	O
PCR	O
products	O
as	O
a	O
pool	O
to	O
ordered	O
array	O
libraries	O
such	O
as	O
the	O
flow	O
-	O
sorted	O
X	O
chromosome	O
cosmid	O
library	O
(	O
9	O
)	O
,	O
allows	O
the	O
direct	O
comparison	O
of	O
overlapping	O
hybrids	O
to	O
pinpoint	O
cosmids	O
most	O
likely	O
to	O
be	O
from	O
the	O
region	O
of	O
interest	O
.	O

In	O
conjunction	O
with	O
the	O
reference	O
library	O
database	O
(	O
G.Z	O
,	O
unpublished	O
)	O
with	O
183	O
X	O
chromosome	O
probe	O
hybridization	O
entries	O
,	O
cosmids	O
identified	O
with	O
both	O
Alu	O
-	O
PCR	O
products	O
and	O
uniquely	O
mapped	O
X	O
probes	O
immediately	O
map	O
them	O
to	O
the	O
region	O
of	O
interest	O
and	O
proove	O
that	O
the	O
method	O
has	O
worked	O
.	O

Similar	O
hybridization	O
experiments	O
using	O
Alu	O
-	O
PCR	O
products	O
from	O
four	O
overlapping	O
irradiation	O
hybrids	O
identified	O
four	O
cosmids	O
in	O
common	O
that	O
mapped	O
to	O
the	O
region	O
of	O
overlap	O
by	O
independent	O
experiments	O
(	O
F.Muscatelli	O
,	O
A.P.M.	O
,	O
P.N.G.	O
,	O
H.L.	O
and	O
M.Fontes	O
,	O
in	O
preparation	O
)	O
.	O

Since	O
only	O
27	O
probes	O
from	O
the	O
X	O
chromosome	O
were	O
used	O
to	O
initially	O
characterize	O
the	O
hybrids	O
and	O
the	O
length	O
of	O
individual	O
human	B
fragments	O
in	O
the	O
irradiation	O
hybrids	O
is	O
about	O
1000	O
-	O
5000	O
kb	O
,	O
many	O
regions	O
could	O
have	O
been	O
undetected	O
in	O
the	O
original	O
analysis	O
.	O

The	O
direct	O
hybridization	O
of	O
Alu	O
-	O
PCR	O
products	O
to	O
the	O
cosmid	O
reference	O
library	O
detected	O
such	O
fragments	O
since	O
they	O
identified	O
cosmids	O
in	O
common	O
with	O
uniquely	O
mapped	O
probes	O
in	O
regions	O
not	O
tested	O
originally	O
(	O
Table	O
1	O
and	O
Fig	O
1	O
)	O
.	O

This	O
should	O
prove	O
to	O
be	O
a	O
sensitive	O
and	O
efficient	O
method	O
to	O
determine	O
content	O
and	O
overlap	O
of	O
irradiation	O
hybrids	O
in	O
conjunction	O
with	O
DNA	O
blot	O
hybridization	O
.	O

However	O
,	O
since	O
the	O
exact	O
length	O
of	O
the	O
human	B
DNA	O
fragments	O
for	O
each	O
hybrid	O
and	O
the	O
spacing	O
of	O
Alu	O
-	O
PCR	O
products	O
along	O
the	O
chromosome	O
is	O
not	O
known	O
,	O
it	O
is	O
difficult	O
to	O
directly	O
correlate	O
the	O
number	O
of	O
target	O
cosmids	O
to	O
the	O
DNA	O
content	O
of	O
the	O
hybrids	O
.	O

The	O
direct	O
hybridization	O
of	O
Alu	O
-	O
PCR	O
products	O
from	O
irradiation	O
or	O
somatic	O
cell	O
hybrids	O
to	O
total	O
genomic	O
YAC	O
libraries	O
will	O
be	O
especially	O
useful	O
to	O
construct	O
long	O
range	O
YAC	O
contigs	O
from	O
specific	O
subregions	O
of	O
chromosomes	O
.	O

The	O
dissection	O
of	O
a	O
total	O
genomic	O
YAC	O
library	O
by	O
this	O
method	O
may	O
be	O
more	O
efficient	O
than	O
generating	O
chromosome	O
specific	O
YAC	O
libraries	O
from	O
somatic	O
cell	O
hybrids	O
(	O
usually	O
a	O
haploid	O
human	B
chromosome	O
on	O
a	O
diploid	O
or	O
greater	O
rodent	O
background	O
)	O
or	O
flow	O
-	O
sorted	O
chromosomes	O
,	O
because	O
of	O
the	O
low	O
transformation	O
efficiency	O
of	O
yeast	B
.	O

ACKNOWLEDGEMENTS	O
We	O
would	O
like	O
to	O
thank	O
Gert	O
-	O
Jan	O
Van	O
Ommen	O
for	O
the	O
probe	O
P20	O
and	O
Stuart	O
Orkin	O
for	O
the	O
CYBB	O
cDNA	O
probe	O
.	O

A.P.M	O
is	O
supported	O
in	O
part	O
by	O
a	O
research	O
fellowship	O
from	O
the	O
Muscular	O
Dystrophy	O
Association	O
of	O
America	O
.	O

V.M.S.L.	O
is	O
supported	O
in	O
part	O
by	O
the	O
Medical	O
Research	O
Grant	O
of	O
the	O
University	O
of	O
Hong	O
Kong	O
.	O

Reference	O
library	O
filters	O
and	O
cosmids	O
identified	O
by	O
Alu	O
-	O
PCR	O
products	O
can	O
be	O
requested	O
from	O
the	O
Reference	O
Library	O
Database	O
,	O
ICRF	O
,	O
44	O
Lincoln	O
's	O
Inn	O
Fields	O
,	O
London	O
WC2A	O
3PX	O
,	O
U.K.	O
3318	O
Nucleic	O
Acids	O
Research	O
,	O
Vol	O
.	O

19	O
,	O
No.	O
12	O
REFERENCES	O
1	O
.	O

Nelson	O
,	O
D.L.	O
,	O
Ledbetter	O
,	O
S.A.	O
,	O
Corbo	O
,	O
L.	O
,	O
Victoria	O
,	O
M.F.	O
,	O
Ramirez	O
-	O
Solis	O
,	O
R.	O
,	O
Webster	O
,	O
T.D.	O
,	O
Ledbetter	O
,	O
D.H.	O
,	O
and	O
Caskey	O
,	O
C.T.	O
(	O
1989	O
)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

USA	O
,	O
86:6686	O
-	O
6690	O
.	O

2	O
.	O

Ledbetter	O
,	O
S.A.	O
,	O
Nelson	O
,	O
D.L.	O
,	O
Warren	O
,	O
S.T.	O
,	O
and	O
Ledbetter	O
,	O
D.H.	O
(	O
1990	O
)	O
Genomics	O
,	O
6:475	O
-	O
481	O
.	O

3	O
.	O

Cotter	O
,	O
F.E.	O
,	O
Hampton	O
,	O
G.M.	O
,	O
Nasipuri	O
,	O
S.	O
,	O
Bodmer	O
,	O
W.F.	O
,	O
and	O
Young	O
B.D.	O
(	O
1990	O
)	O
Genomics	O
,	O
7:257	O
-	O
263	O
.	O

4	O
.	O

Burke	O
,	O
D.T.	O
,	O
Carle	O
,	O
G.F.	O
,	O
and	O
Olson	O
,	O
M.V.	O
(	O
1987	O
)	O
Science	O
,	O
236:806	O
-	O
812	O
.	O

5	O
.	O

Benham	O
,	O
F.	O
,	O
Hart	O
,	O
K.	O
,	O
Crolla	O
,	O
J.	O
,	O
Bobrow	O
,	O
M.	O
,	O
Francavilla	O
,	O
M.	O
,	O
and	O
Goodfellow	O
,	O
P.N.	O
(	O
1989	O
)	O
Genomics	O
,	O
4:509	O
-	O
517	O
.	O

6	O
.	O

Feinberg	O
,	O
A.P.	O
,	O
and	O
Vogelstein	O
,	O
B.	O
(	O
1984	O
)	O
Anal	O
.	O

Biochem	O
.	O
,	O
137:266	O
-	O
267	O
.	O

7	O
.	O

Hochgeschwender	O
,	O
U.	O
,	O
Sutciffe	O
,	O
J.G.	O
,	O
and	O
Brennan	O
,	O
M.B.	O
(	O
1989	O
)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

USA	O
,	O
86:8482	O
-	O
8486	O
.	O

8	O
.	O

Lehrach	O
,	O
H.	O
,	O
Drmanac	O
,	O
R.	O
,	O
Hoheisel	O
,	O
J.	O
,	O
Larin	O
,	O
Z.	O
,	O
Lennon	O
,	O
G.	O
,	O
Monaco	O
,	O
A.P.	O
,	O
Nizetic	O
,	O
D.	O
,	O
Zehetner	O
,	O
G.	O
,	O
and	O
Poustka	O
,	O
A.	O
(	O
1990	O
)	O
In	O
Davies	O
,	O
K.E.	O
&	O
Tilghman	O
,	O
S.M.	O
(	O
eds	O
.	O
)	O
,	O
Genome	O
Analysis	O
Volume	O
1	O
:	O
Genetic	O
and	O
Physical	O
Mapping	O
.	O

Cold	O
Spring	O
Harbor	O
Laboratory	O
Press	O
,	O
Cold	O
Spring	O
Harbor	O
,	O
pp	O
.	O

39	O
-	O
81	O
.	O

9	O
.	O

Nizetic	O
,	O
D.	O
,	O
Zehetner	O
,	O
G.	O
,	O
Monaco	O
,	O
A.P.	O
,	O
Gellen	O
,	O
L.	O
,	O
Young	O
,	O
B.D.	O
,	O
and	O
Lehrach	O
,	O
H.	O
(	O
1991	O
)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

USA	O
,	O
88:3233	O
-	O
3237	O
.	O

10	O
.	O

Larin	O
,	O
Z.	O
and	O
Lehrach	O
,	O
H.	O
(	O
1990	O
)	O
Genet	O
.	O

Res	O
.	O

Camb	O
.	O
,	O
56:203	O
-	O
208	O
.	O

11	O
.	O

Cox	O
,	O
D	O
,	O
R.	O
,	O
Pritchard	O
,	O
C.A.	O
,	O
Uglum	O
,	O
E.	O
,	O
Casher	O
,	O
D.	O
,	O
Koborl	O
.	O

J.	O
and	O
Myers	O
,	O
R.M.	O
(	O
1989	O
)	O
Genomics	O
,	O
4:397	O
-	O
407	O
.	O

12	O
.	O

Wapenaar	O
,	O
M.C.	O
,	O
Kievits	O
,	O
T.	O
,	O
Hart	O
,	O
K.A.	O
,	O
Abbs	O
S.	O
,	O
Blonden	O
,	O
L.A.J.	O
,	O
denDunnen	O
,	O
J.T.	O
,	O
Grootscholten	O
,	O
P.M.	O
,	O
Bakker	O
,	O
E.	O
,	O
Verellen	O
-	O
Dumoulin	O
,	O
C.	O
,	O
Bobrow	O
,	O
M.	O
,	O
vanOmmen	O
,	O
G.J.B.	O
,	O
and	O
Pearson	O
,	O
P.L.	O
(	O
1988	O
)	O
Genomics	O
,	O
2:101	O
-	O
108	O
.	O

13	O
.	O

Royer	O
-	O
Pokora	O
,	O
B.	O
,	O
Kunkel	O
,	O
L.M.	O
,	O
Monaco	O
,	O
A.P.	O
,	O
Goff	O
,	O
S.C.	O
,	O
Newburger	O
,	O
P.E.	O
,	O
Baehner	O
,	O
R.L.	O
,	O
Cole	O
F.S.	O
,	O
Curnette	O
J.T.	O
,	O
and	O
Orkin	O
,	O
S.A.	O
(	O
1986	O
)	O
Nature	O
,	O
322	O
:	O
32	O
-	O
38	O
.	O

14	O
.	O

Davies	O
,	O
K.E.	O
,	O
Mandel	O
,	O
J.L.	O
,	O
Monaco	O
,	O
A.P.	O
,	O
Nussbaum	O
,	O
R.L.	O
and	O
Willard	O
,	O
H.F.	O
(	O
1990	O
)	O
Cytogenet	O
.	O

Cell	O
Genet	O
.	O

55	O
:	O
254	O
-	O
313	O
.	O

Primitive	O
Neuroectodermal	O
Tumor	O
(	O
PNET	O
)	O
of	O
the	O
kidney	O
:	O
a	O
case	O
report	O

Abstract	O
Background	O
A	O
case	O
of	O
Primitive	O
Neuroectodermal	O
Tumor	O
(	O
PNET	O
)	O
of	O
the	O
kidney	O
in	O
a	O
27-year	O
-	O
old	O
woman	O
is	O
presented	O
.	O

Few	O
cases	O
are	O
reported	O
in	O
the	O
literature	O
with	O
a	O
variable	O
,	O
nonspecific	O
presentation	O
and	O
an	O
aggressive	O
behaviour	O
.	O

In	O
our	O
case	O
,	O
a	O
radical	O
nephrectomy	O
with	O
lymphadenectomy	O
was	O
performed	O
and	O
there	O
was	O
no	O
residual	O
or	O
recurrent	O
tumour	O
at	O
24-month	O
follow	O
-	O
up	O
.	O

Methods	O
The	O
surgical	O
specimens	O
were	O
formalin	O
-	O
fixed	O
and	O
paraffin	O
embedded	O
.	O

The	O
sections	O
were	O
stained	O
with	O
routinary	O
H&E.	O
Immunohistochemistry	O
was	O
performed	O
.	O

Results	O
The	O
immunohistochemical	O
evaluation	O
revealed	O
a	O
diffuse	O
CD99	O
positivity	O
in	O
the	O
cytoplasm	O
of	O
the	O
neoplastic	O
cells	O
.	O

Pankeratin	O
,	O
cytokeratin	O
AE1	O
/	O
AE3	O
,	O
vimentin	O
,	O
desmin	O
,	O
S100	O
,	O
cromogranin	O
were	O
negative	O
.	O

The	O
clinical	O
presentation	O
and	O
the	O
macroscopic	O
aspect	O
,	O
together	O
with	O
the	O
histological	O
pattern	O
,	O
the	O
cytological	O
characteristic	O
and	O
the	O
cellular	O
immunophenotype	O
addressed	O
the	O
diagnosis	O
towards	O
primary	O
PNET	O
of	O
kidney	O
.	O

Conclusions	O

Since	O
sometimes	O
it	O
is	O
difficult	O
to	O
discriminate	O
between	O
PNET	O
and	O
Ewing	O
's	O
tumour	O
,	O
we	O
reviewed	O
the	O
difficulties	O
in	O
differential	O
diagnosis	O
.	O

These	O
tumors	O
have	O
a	O
common	O
precursor	O
but	O
the	O
stage	O
of	O
differentiation	O
in	O
which	O
it	O
is	O
blocked	O
is	O
probably	O
different	O
.	O

This	O
could	O
also	O
explain	O
their	O
different	O
biological	O
behaviour	O
and	O
prognosis	O
.	O

Background	O
The	O
peripheral	O
Primitive	O
Neuroectodermal	O
Tumor	O
(	O
PNET	O
)	O
,	O
firstly	O
recognized	O
by	O
Arthur	O
Purdy	O
Stout	O
in	O
1918	O
,	O
is	O
a	O
member	O
of	O
the	O
family	O
of	O
""""	O
small	O
round	O
-	O
cell	O
tumors	O
""""	O
.	O

Primitive	O
renal	O
localization	O
is	O
very	O
rare	O
.	O

There	O
are	O
almost	O
50	O
cases	O
reported	O
in	O
the	O
literature	O
,	O
although	O
it	O
is	O
difficult	O
to	O
estimate	O
the	O
exact	O
number	O
since	O
often	O
it	O
has	O
not	O
been	O
differentiated	O
from	O
Ewing	O
's	O
Sarcoma	O
[	O
1	O
-	O
13	O
]	O
.	O

Renal	O
PNET	O
is	O
more	O
aggressive	O
than	O
in	O
the	O
other	O
sites	O
.	O

It	O
frequently	O
arises	O
during	O
childhood	O
or	O
adolescence	O
,	O
having	O
an	O
aggressive	O
clinical	O
course	O
towards	O
metastatic	O
disease	O
and	O
death	O
.	O

It	O
often	O
recurs	O
locally	O
and	O
metastasises	O
early	O
to	O
regional	O
lymph	O
nodes	O
,	O
lungs	O
,	O
liver	O
,	O
bone	O
and	O
bone	O
marrow	O
,	O
resulting	O
in	O
a	O
poor	O
prognosis	O
.	O

The	O
5-year	O
disease	O
-	O
free	O
survival	O
rate	O
,	O
for	O
patients	O
presenting	O
well	O
confined	O
extra	O
-	O
skeletal	O
PNET	O
,	O
is	O
around	O
45–55	O
%	O
and	O
cases	O
with	O
advanced	O
disease	O
at	O
presentation	O
have	O
a	O
median	O
relapse	O
-	O
free	O
survival	O
of	O
only	O
2	O
years	O
[	O
1	O
]	O
.	O

Case	O
presentation	O
A	O
27-year	O
-	O
old	O
woman	O
was	O
referred	O
because	O
of	O
a	O
mild	O
left	O
flank	O
pain	O
and	O
haematuria	O
.	O

Ultrasonography	O
identified	O
a	O
left	O
renal	O
mass	O
homogeneously	O
hyperechogenic	O
in	O
comparison	O
with	O
renal	O
parenchyma	O
.	O

CT	O
scan	O
showed	O
a	O
11	O
mm	O
×	O
8	O
mm	O
×	O
6	O
mm	O
tumor	O
replacing	O
the	O
upper	O
half	O
of	O
the	O
left	O
kidney	O
with	O
extension	O
into	O
the	O
renal	O
vein	O
.	O

Chest	O
x	O
-	O
ray	O
was	O
negative	O
.	O

Pathological	O
stage	O
after	O
radical	O
nephrectomy	O
was	O
T3aN0Mx	O
.	O

The	O
surgical	O
specimens	O
were	O
formalin	O
-	O
fixed	O
and	O
paraffin	O
embedded	O
.	O

The	O
sections	O
were	O
stained	O
with	O
routinary	O
H&E.	O
Immunohistochemistry	O
was	O
performed	O
using	O
avidin	O
biotin	O
complex	O
technique	O
and	O
diaminobenzidine	O
as	O
chromogen	O
.	O

The	O
antibodies	O
used	O
included	O
CD99	O
(	O
Dako	O
,	O
M3601	O
)	O
,	O
pankeratin	O
(	O
Dako	O
,	O
M0821	O
)	O
,	O
cytokeratin	O
AE1	O
/	O
AE3	O
(	O
Dako	O
,	O
M3515	O
)	O
,	O
vimentin	O
(	O
Dako	O
,	O
M7010	O
)	O
,	O
desmin	O
(	O
Dako	O
,	O
M0760	O
)	O
,	O
S100	O
(	O
Dako	O
,	O
Z0311	O
)	O
,	O
and	O
chromogranin	O
A	O
(	O
Dako	O
,	O
M0869	O
)	O
,	O
at	O
suggested	O
dilution	O
.	O

We	O
performed	O
also	O
appropriate	O
routinely	O
positive	O
and	O
negative	O
controls	O
.	O

The	O
tumor	O
was	O
multilobular	O
,	O
grey	O
,	O
glistening	O
,	O
focally	O
hemorrhagic	O
,	O
surrounded	O
by	O
a	O
capsule	O
and	O
with	O
a	O
sharp	O
demarcation	O
from	O
the	O
uninvolved	O
kidney	O
.	O

Histologically	O
,	O
the	O
tumor	O
consisted	O
of	O
small	O
round	O
cells	O
with	O
round	O
nuclei	O
and	O
scant	O
cytoplasm	O
.	O

It	O
presented	O
different	O
patterns	O
,	O
with	O
cohesive	O
lobules	O
or	O
rosettes	O
and	O
perivascular	O
pseudo	O
-	O
rosettes	O
or	O
,	O
in	O
some	O
areas	O
,	O
spindle	O
cellular	O
elements	O
(	O
fig.	O
1	O
)	O
.	O

The	O
immunohistochemical	O
evaluation	O
revealed	O
a	O
diffuse	O
CD99	O
positivity	O
in	O
the	O
cytoplasm	O
of	O
the	O
neoplastic	O
cells	O
(	O
fig.	O
2	O
)	O
;	O
tumoral	O
cells	O
were	O
also	O
visible	O
in	O
the	O
vascular	O
lumens	O
(	O
fig.	O
3	O
)	O
.	O

By	O
contrast	O
,	O
pankeratin	O
,	O
cytokeratin	O
AE1	O
/	O
AE3	O
,	O
vimentin	O
,	O
desmin	O
,	O
S100	O
,	O
cromogranin	O
were	O
negative	O
.	O

The	O
clinical	O
presentation	O
and	O
the	O
macroscopic	O
aspect	O
,	O
together	O
with	O
the	O
histological	O
pattern	O
,	O
the	O
cytological	O
characteristic	O
and	O
the	O
cellular	O
immunophenotype	O
addressed	O
the	O
diagnosis	O
towards	O
primary	O
PNET	O
of	O
kidney	O
.	O

A	O
bone	O
scan	O
did	O
not	O
reveal	O
positive	O
areas	O
.	O

Eight	O
cycles	O
of	O
chemotherapy	O
with	O
Vincristine	O
,	O
Ifosfamide	O
and	O
Adriamycin	O
,	O
four	O
cycles	O
of	O
Ifosfamide	O
and	O
VP16	O
and	O
eight	O
sittings	O
of	O
local	O
radiotherapy	O
were	O
sequentially	O
performed	O
.	O

Follow	O
-	O
up	O
examinations	O
with	O
CT	O
and	O
bone	O
scan	O
failed	O
to	O
show	O
residual	O
or	O
recurrent	O
tumor	O
after	O
24	O
months	O
.	O

Conclusions	O
Primitive	O
Neuroectodermal	O
Tumor	O
of	O
the	O
kidney	O
is	O
a	O
rare	O
entity	O
.	O

The	O
few	O
cases	O
reported	O
revealed	O
a	O
variable	O
presentation	O
and	O
an	O
aggressive	O
behaviour	O
.	O

The	O
distinction	O
from	O
other	O
primary	O
malignancies	O
of	O
the	O
kidneys	O
is	O
crucial	O
for	O
prognosis	O
.	O

The	O
differential	O
diagnosis	O
includes	O
extra	O
-	O
osseous	O
Ewing	O
's	O
sarcoma	O
,	O
rhabdomyosarcoma	O
,	O
Wilm	O
's	O
tumor	O
,	O
carcinoid	O
,	O
neuroblastoma	O
,	O
clear	O
cell	O
sarcoma	O
of	O
the	O
kidney	O
,	O
lymphoma	O
,	O
the	O
small	O
cell	O
variant	O
of	O
osteosarcoma	O
,	O
desmoplastic	O
small	O
round	O
cell	O
tumor	O
and	O
nephroblastoma	O
[	O
5	O
]	O
.	O

The	O
Homer	O
-	O
Wright	O
type	O
rosettes	O
,	O
commonly	O
scarce	O
of	O
number	O
or	O
less	O
defined	O
in	O
extra	O
skeletal	O
Ewing	O
's	O
sarcoma	O
(	O
ES	O
)	O
,	O
are	O
a	O
typical	O
histological	O
feature	O
for	O
PNET	O
and	O
can	O
address	O
the	O
diagnosis	O
although	O
they	O
can	O
be	O
found	O
also	O
in	O
neuroblastoma	O
[	O
5	O
]	O
.	O

To	O
better	O
address	O
the	O
diagnosis	O
,	O
an	O
immunohistochemical	O
analysis	O
is	O
necessary	O
.	O

In	O
our	O
case	O
the	O
presence	O
of	O
MIC-2	O
gene	O
products	O
,	O
known	O
also	O
as	O
CD99	O
,	O
12E7	O
,	O
E2	O
,	O
013	O
and	O
HBA71	O
,	O
suggested	O
a	O
PNET	O
diagnosis	O
.	O

Primitive	O
neuroectodermal	O
tumors	O
only	O
immunorreactive	O
to	O
CD99	O
,	O
even	O
if	O
uncommon	O
,	O
are	O
reported	O
in	O
the	O
literature	O
[	O
13	O
]	O
.	O

The	O
reactivity	O
to	O
vimentin	O
,	O
NSE	O
and	O
S-100	O
may	O
facilitate	O
the	O
diagnosis	O
but	O
is	O
not	O
patognomonic	O
,	O
while	O
CD	O
99	O
positivity	O
is	O
nowadays	O
a	O
clue	O
for	O
the	O
diagnosis	O
.	O

Moreover	O
cytogenetic	O
studies	O
(	O
not	O
performed	O
in	O
our	O
case	O
)	O
demonstrated	O
that	O
PNET	O
and	O
Ewing	O
's	O
sarcoma	O
can	O
both	O
be	O
associated	O
to	O
a	O
translocation	O
of	O
the	O
long	O
arms	O
of	O
chromosome	O
11	O
and	O
22	O
,	O
t	O
(	O
11;22	O
)	O
(	O
q22;q12	O
)	O
[	O
5	O
]	O
.	O

Despite	O
their	O
genetic	O
and	O
antigenic	O
similarity	O
,	O
many	O
authors	O
currently	O
recognize	O
PNET	O
and	O
extra	O
-	O
skeletal	O
Ewing	O
's	O
sarcoma	O
of	O
the	O
kidney	O
as	O
separate	O
entities	O
.	O

It	O
is	O
also	O
important	O
to	O
keep	O
separate	O
renal	O
PNET	O
and	O
malignant	O
rhabdomyosarcoma	O
tumor	O
(	O
MRT	O
)	O
.	O

Weeks	O
et	O
al	O
reported	O
8	O
cases	O
suggestive	O
for	O
PNET	O
but	O
mimicking	O
MRT	O
[	O
14	O
]	O
.	O

Although	O
renal	O
PNET	O
and	O
MRT	O
show	O
similar	O
clinico	O
-	O
pathological	O
features	O
,	O
the	O
latter	O
usually	O
occurs	O
in	O
very	O
young	O
children	O
,	O
having	O
a	O
more	O
aggressive	O
prognosis	O
.	O

Rodriguez	O
et	O
al	O
postulated	O
that	O
these	O
two	O
renal	O
neoplasms	O
share	O
a	O
common	O
undifferentiated	O
precursor	O
to	O
explain	O
their	O
similarity	O
and	O
we	O
agree	O
with	O
these	O
Authors	O
[	O
12	O
]	O
.	O

Indeed	O
,	O
the	O
hypothesis	O
that	O
tumors	O
arise	O
from	O
stem	O
cells	O
(	O
SCs	O
)	O
as	O
a	O
consequence	O
of	O
a	O
maturative	O
arrest	O
is	O
now	O
growing	O
[	O
15	O
]	O
.	O

SCs	O
are	O
present	O
in	O
almost	O
all	O
tissues	O
and	O
may	O
originate	O
different	O
cellular	O
lineages	O
by	O
the	O
multi	O
-	O
step	O
process	O
named	O
""""	O
differentiation	O
""""	O
.	O

The	O
role	O
of	O
SCs	O
in	O
tumorigenesis	O
was	O
clearly	O
demonstrated	O
in	O
a	O
number	O
of	O
carcinogenic	O
models	O
showing	O
that	O
solid	O
and	O
haematopoietic	O
cancers	O
could	O
arise	O
from	O
tissue	O
-	O
specific	O
SCs	O
[	O
16	O
-	O
19	O
]	O
.	O

In	O
agreement	O
with	O
Sell	O
and	O
Pierce	O
,	O
we	O
retain	O
that	O
the	O
degree	O
of	O
malignancy	O
of	O
a	O
carcinoma	O
depends	O
by	O
the	O
stage	O
in	O
which	O
SCs	O
differentiation	O
stopped	O
during	O
carcinogenesis	O
[	O
19	O
]	O
.	O

In	O
particular	O
,	O
since	O
PNET	O
,	O
Ewing	O
's	O
tumour	O
and	O
MRT	O
have	O
a	O
similar	O
morphology	O
,	O
our	O
hypothesis	O
is	O
that	O
the	O
mesenchimal	O
stem	O
precursor	O
of	O
these	O
tumors	O
is	O
the	O
same	O
,	O
but	O
the	O
stage	O
of	O
differentiation	O
in	O
which	O
it	O
is	O
blocked	O
is	O
different	O
.	O

This	O
could	O
explain	O
why	O
sometimes	O
it	O
is	O
difficult	O
to	O
discriminate	O
between	O
these	O
tumors	O
,	O
notwithstanding	O
they	O
present	O
a	O
different	O
biological	O
behaviour	O
.	O

Competing	O
interests	O
None	O
declared	O
.	O

Authors	O
'	O
contribution	O
All	O
authors	O
contributed	O
.	O

Pre	O
-	O
publication	O
history	O
The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O

The	O
c1	O
genes	O
of	O
P1	O
and	O
P7	O
.	O

Abstract	O
The	O
c1	O
genes	O
of	O
the	O
heteroimmune	O
phages	O
P1	O
and	O
P7	O
were	O
sequenced	O
and	O
their	O
products	O
were	O
compared	O
.	O

P7c1	O
expression	O
was	O
correlated	O
with	O
the	O
translation	O
in	O
vitro	O
of	O
a	O
protein	O
whose	O
predicted	O
molecular	O
weight	O
(	O
33,000	O
daltons	O
)	O
is	O
indistinguishable	O
from	O
that	O
of	O
the	O
P1c1	O
repressor	O
.	O

The	O
c1	O
regions	O
from	O
both	O
P1	O
and	O
P7	O
were	O
found	O
to	O
contain	O
open	O
reading	O
frames	O
capable	O
of	O
coding	O
for	O
a	O
283-amino	O
acid	O
protein	O
whose	O
predicted	O
secondary	O
structure	O
lacks	O
the	O
helix	O
-	O
turn	O
-	O
helix	O
motif	O
commonly	O
associated	O
with	O
repressor	O
proteins	O
.	O

Two	O
P1c1	O
amber	O
mutations	O
were	O
localized	O
to	O
the	O
283-amino	O
acid	O
open	O
reading	O
frame	O
.	O

The	O
P1c1	O
and	O
P7c1	O
sequences	O
were	O
found	O
to	O
differ	O
at	O
only	O
18	O
positions	O
,	O
all	O
but	O
two	O
of	O
which	O
alter	O
the	O
third	O
position	O
of	O
the	O
affected	O
codon	O
and	O
do	O
not	O
alter	O
the	O
amino	O
acid	O
sequence	O
of	O
the	O
protein	O
.	O

Plasmids	O
expressing	O
the	O
c1	O
gene	O
from	O
either	O
phage	O
cause	O
the	O
repression	O
of	O
transcription	O
from	O
a	O
cloned	O
promoter	O
situated	O
upstream	O
of	O
P1c1.Images	O
Volme	O
7	O
Nmbe	O
19198	O
Nulei	O
Acds	O
eserc	O
The	O
cl	O
genes	O
of	O
P1	O
and	O
P7	O
Francis	O
A.Osborne	O
,	O
Sonja	O
R.Stovall	O
and	O
Barbara	O
R.Baumstark	O
*	O
Department	O
of	O
Biology	O
,	O
Georgia	O
State	O
University	O
,	O
Atlanta	O
,	O
GA	O
30303	O
,	O
USA	O
Received	O
July	O
11	O
,	O
1989	O
;	O
Revised	O
and	O
Accepted	O
August	O
29	O
,	O
1989	O
EMBL	O
accession	O
nos	O
X16005	O
,	O
X16006	O
ABSTRACT	O
The	O
cl	O
genes	O
of	O
the	O
heteroimmune	O
phages	O
P1	O
and	O
P7	O
were	O
sequenced	O
and	O
their	O
products	O
were	O
compared	O
.	O

P7cl	O
expression	O
was	O
correlated	O
with	O
the	O
translation	O
in	O
vitro	O
of	O
a	O
protein	O
whose	O
predicted	O
molecular	O
weight	O
(	O
33,000	O
daltons	O
)	O
is	O
indistinguishable	O
from	O
that	O
of	O
the	O
Plcl	O
repressor	O
.	O

The	O
cl	O
regions	O
from	O
both	O
P1	O
and	O
P7	O
were	O
found	O
to	O
contain	O
open	O
reading	O
frames	O
capable	O
of	O
coding	O
for	O
a	O
283-amino	O
acid	O
protein	O
whose	O
predicted	O
secondary	O
structure	O
lacks	O
the	O
helix	O
-	O
tum	O
-	O
helix	O
motif	O
commonly	O
associated	O
with	O
repressor	O
proteins	O
.	O

Two	O
Plcl	O
amber	O
mutations	O
were	O
localized	O
to	O
the	O
283-amino	O
acid	O
open	O
reading	O
frame	O
.	O

The	O
Plcl	O
and	O
P7cl	O
sequences	O
were	O
found	O
to	O
differ	O
at	O
only	O
18	O
positions	O
,	O
all	O
but	O
two	O
of	O
which	O
alter	O
the	O
third	O
position	O
of	O
the	O
affected	O
codon	O
and	O
do	O
not	O
alter	O
the	O
amino	O
acid	O
sequence	O
of	O
the	O
protein	O
.	O

Plasmids	O
expressing	O
the	O
cI	O
gene	O
from	O
either	O
phage	O
cause	O
the	O
repression	O
of	O
transcription	O
from	O
a	O
cloned	O
promoter	O
situated	O
upstream	O
of	O
Plcl	O
.	O

INTRODUCTION	O
The	O
cl	O
genes	O
of	O
the	O
plasmid	O
prophages	O
P1	O
and	O
P7	O
code	O
for	O
repressor	O
proteins	O
that	O
are	O
required	O
for	O
the	O
establishment	O
and	O
maintenance	O
of	O
lysogeny	O
(	O
reviewed	O
in	O
1	O
)	O
.	O

A	O
protein	O
corresponding	O
to	O
the	O
Plcl	O
repressor	O
has	O
been	O
isolated	O
and	O
shown	O
to	O
be	O
a	O
sequence	O
-	O
specific	O
DNA	O
binding	O
protein	O
that	O
recognizes	O
several	O
widely	O
dispersed	O
sites	O
on	O
the	O
phage	O
DNA	O
(	O
2	O
-	O
7	O
)	O
.	O

The	O
consensus	O
DNA	O
sequence	O
recognized	O
by	O
the	O
Plcl	O
repressor	O
(	O
ATTTATTAGAGCA	O
[	O
A	O
/	O
T	O
]	O
T	O
)	O
contains	O
no	O
discernable	O
bilateral	O
symmetry	O
,	O
a	O
feature	O
that	O
is	O
highly	O
unusual	O
among	O
prokaryotic	O
operator	O
sites	O
.	O

P1	O
and	O
P7	O
are	O
heteroimmune	O
;	O
that	O
is	O
,	O
each	O
phage	O
is	O
able	O
to	O
establish	O
a	O
lytic	O
infection	O
on	O
a	O
lysogen	O
of	O
the	O
other	O
phage	O
.	O

In	O
this	O
sense	O
,	O
their	O
relationship	O
is	O
analogous	O
to	O
that	O
of	O
phage	O
X	O
and	O
434	O
,	O
which	O
differ	O
in	O
the	O
DNA	O
specificity	O
of	O
their	O
cI	O
repressor	O
proteins	O
(	O
8)	O
.	O

However	O
,	O
genetic	O
studies	O
indicate	O
that	O
Plcl	O
and	O
P7cl	O
can	O
be	O
crossed	O
into	O
the	O
heterologous	O
phage	O
without	O
affecting	O
the	O
immunity	O
specificity	O
of	O
the	O
recipient	O
(	O
9	O
)	O
.	O

The	O
basis	O
for	O
P1	O
/	O
P7	O
heteroimmunity	O
has	O
been	O
localized	O
to	O
a	O
second	O
regulatory	O
gene	O
,	O
c4	O
,	O
that	O
is	O
unlinked	O
to	O
cl	O
.	O

The	O
c4	O
gene	O
products	O
prevent	O
the	O
expression	O
of	O
antireb	O
,	O
a	O
closely	O
linked	O
gene	O
that	O
interferes	O
with	O
cl	O
-	O
mediated	O
repression	O
(	O
10	O
,	O
11	O
)	O
.	O

According	O
to	O
current	O
models	O
,	O
P1	O
/	O
P7	O
heteroimmunity	O
results	O
from	O
the	O
inability	O
of	O
the	O
c4	O
repressor	O
of	O
one	O
phage	O
to	O
prevent	O
antireb	O
expression	O
from	O
the	O
heteroimmune	O
phage	O
genome	O
(	O
10	O
,	O
11	O
)	O
.	O

Because	O
the	O
cl	O
genes	O
of	O
P1	O
and	O
P7	O
are	O
genetically	O
interchangeable	O
,	O
it	O
is	O
anticipated	O
that	O
the	O
two	O
gene	O
products	O
carry	O
out	O
similar	O
or	O
identical	O
regulatory	O
functions	O
.	O

The	O
studies	O
presented	O
in	O
this	O
paper	O
were	O
undertaken	O
to	O
investigate	O
the	O
biochemical	O
basis	O
for	O
the	O
apparent	O
genetic	O
identity	O
of	O
the	O
two	O
cl	O
genes	O
.	O

In	O
this	O
paper	O
,	O
we	O
present	O
the	O
DNA	O
sequence	O
of	O
the	O
cl	O
genes	O
of	O
P1	O
and	O
P7	O
and	O
the	O
predicted	O
amino	O
acid	O
sequence	O
of	O
the	O
cl	O
repressor	O
proteins	O
.	O

We	O
report	O
that	O
Plcl	O
and	O
P7cl	O
code	O
for	O
proteins	O
of	O
identical	O
size	O
(	O
283	O
amino	O
acids	O
)	O
and	O
Nucleic	O
Acids	O
Research	O
Volume	O
17	O
Number	O
19	O
1989	O
767	O
1	O
(	O
r	O
IRL	O
Press	O
Nucleic	O
Acids	O
Research	O
nearly	O
identical	O
sequence	O
.	O

We	O
report	O
further	O
that	O
both	O
repressors	O
prevent	O
the	O
expression	O
of	O
a	O
promoter	O
located	O
immediately	O
upstream	O
of	O
the	O
Plc	O
1	O
open	O
reading	O
frame	O
,	O
an	O
observation	O
that	O
confirms	O
their	O
functional	O
similarity	O
and	O
suggests	O
an	O
autoregulatory	O
role	O
for	O
the	O
two	O
proteins	O
.	O

Analysis	O
of	O
the	O
secondary	O
structure	O
predicted	O
by	O
the	O
open	O
reading	O
frames	O
does	O
not	O
reveal	O
the	O
characteristic	O
helix	O
-	O
turn	O
-	O
helix	O
(	O
12	O
)	O
or	O
other	O
motifs	O
commonly	O
associated	O
with	O
DNA	O
binding	O
proteins	O
.	O

MATERIALS	O
AND	O
METHODS	O
Bacterial	O
and	O
phage	O
strains	O
.	O

E.	B
coli	I
K336	O
is	O
a	O
SuO	O
derivative	O
of	O
K140	O
(	O
13	O
)	O
.	O

E.	B
coli	I
CB454	O
is	O
a	O
recA-	O
,	O
lacZderivative	O
of	O
K-12	O
(	O
14	O
)	O
.	O

P1	O
+	O
is	O
described	O
by	O
Scott	O
(	O
13	O
)	O
.	O

P7	O
+	O
is	O
the	O
strain	O
of	O
Smith	O
(	O
15	O
)	O
,	O
as	O
described	O
by	O
Scott	O
(	O
16	O
)	O
.	O

P7cl	O
.	O

1	O
contains	O
a	O
missense	O
mutation	O
in	O
the	O
cl	O
gene	O
(	O
17	O
)	O
.	O

The	O
P7	O
phage	O
strains	O
and	O
the	O
cl	O
amber	O
mutant	O
phage	O
strains	O
PIci	O
.245Cm	O
,	O
Plc1	O
.	O

169	O
and	O
P	O
Ic	O
.55	O
(	O
11	O
)	O
were	O
generously	O
provided	O
by	O
June	O
Scott	O
.	O

Enzymes	O
and	O
reagents	O
.	O

Restriction	O
enzymes	O
,	O
T4	O
DNA	O
ligase	O
and	O
polymerase	O
,	O
and	O
the	O
Klenow	O
fragment	O
of	O
E.	B
coli	I
DNA	O
polymerase	O
were	O
purchased	O
from	O
Boehringer	O
Biochemicals	O
or	O
New	O
England	O
Biolabs	O
and	O
reactions	O
were	O
carried	O
out	O
according	O
to	O
the	O
manufacturers	O
'	O
instructions	O
.	O

DNA	O
sequencing	O
kits	O
and	O
in	O
vitro	O
transcription	O
-	O
translation	O
kits	O
were	O
purchased	O
from	O
Bethesda	O
Research	O
Laboratories	O
and	O
Amersham	O
Corporation	O
,	O
respectively	O
.	O

Synthetic	O
oligonucleotides	O
to	O
be	O
used	O
as	O
sequencing	O
primers	O
were	O
prepared	O
on	O
an	O
Applied	O
Biosystems	O
DNA	O
synthesizer	O
.	O

Plasmid	O
construction	O
.	O

pBRB7.2	O
.	O

pBRB7.2	O
(	O
2	O
)	O
contains	O
a	O
3.2	O
kb	O
EcoRI	O
/	O
PvuII	O
fragment	O
from	O
the	O
cl	O
region	O
of	O
P1	O
(	O
Figure	O
1	O
)	O
inserted	O
into	O
the	O
2.3	O
kb	O
EcoRIlPvuII	O
fragment	O
of	O
pBR322	O
that	O
contains	O
the	O
origin	O
of	O
replication	O
and	O
the	O
f3-lactamase	O
gene	O
.	O

pFA02	O
.	O

P7	O
plasmid	O
DNA	O
was	O
digested	O
with	O
PvuII	O
,	O
ligated	O
to	O
similarly	O
digested	O
pBR322	O
,	O
and	O
transformed	O
into	O
E.	B
coli	I
K336	O
.	O

Ampicillin	O
-	O
resistant	O
colonies	O
were	O
screened	O
for	O
cl	O
activity	O
by	O
cross	O
-	O
streak	O
complementation	O
analysis	O
against	O
P7cl.1	O
(	O
18	O
)	O
.	O

pFAO2	O
contains	O
a	O
3.5	O
kb	O
insert	O
of	O
P7	O
DNA	O
.	O

The	O
fragment	O
was	O
localized	O
to	O
the	O
cl	O
region	O
of	O
the	O
P7	O
genome	O
by	O
Southern	O
hybridization	O
against	O
P1	O
and	O
P7	O
DNA	O
that	O
had	O
been	O
digested	O
with	O
BamHI	O
and	O
BglII	O
(	O
data	O
not	O
shown	O
)	O
.	O

pBRBJ69	O
.	O

1	O
and	O
pBRB55	O
.	O

1	O
.	O

The	O
PI	O
cI	O
open	O
reading	O
frame	O
was	O
previously	O
localized	O
to	O
a	O
2.6	O
kb	O
EcoRlIBamHI	O
fragment	O
derived	O
from	O
PlEcoRI-7	O
(	O
2	O
)	O
.	O

This	O
fragment	O
also	O
contains	O
the	O
wildtype	O
allele	O
for	O
the	O
conditional	O
lethal	O
mutation	O
am43	O
(	O
19	O
,	O
20	O
)	O
.	O

To	O
clone	O
the	O
cl	O
reading	O
frame	O
from	O
the	O
amber	O
mutant	O
phage	O
Plc1.169	O
and	O
P	O
Ic	O
.55	O
,	O
we	O
digested	O
phage	O
DNA	O
with	O
EcoRI	O
and	O
BamHI	O
,	O
ligated	O
the	O
digestion	O
products	O
into	O
similarly	O
digested	O
pBR322	O
,	O
and	O
transformed	O
the	O
ligation	O
mixture	O
into	O
E.	B
coli	I
K336	O
.	O

Ampicillin	O
-	O
resistant	O
,	O
tetracyclinesensitive	O
colonies	O
were	O
screened	O
by	O
cross	O
-	O
streak	O
complementation	O
analysis	O
for	O
their	O
ability	O
to	O
support	O
the	O
growth	O
of	O
Plam43	O
.	O

Plasmid	O
DNA	O
isolated	O
from	O
complementation	O
-	O
positive	O
cells	O
was	O
shown	O
by	O
agarose	O
gel	O
electrophoresis	O
to	O
carry	O
plasmids	O
containing	O
the	O
2.6	O
kb	O
EcoRIlBamHI	O
fragment	O
from	O
the	O
cl	O
region	O
.	O

The	O
cl	O
mutant	O
open	O
reading	O
frames	O
were	O
placed	O
under	O
the	O
control	O
of	O
normal	O
regulatory	O
signals	O
present	O
in	O
the	O
cI	O
region	O
by	O
digesting	O
the	O
cl.55	O
and	O
cl	O
.	O

169-containing	O
plasmids	O
with	O
BamHI	O
and	O
PvuII	O
and	O
inserting	O
a	O
601	O
bp	O
BamHI	O
/	O
PvuH	O
fragment	O
containing	O
the	O
cl	O
promoter	O
region	O
(	O
2	O
)	O
.	O

The	O
resulting	O
plasmids	O
,	O
pBRB55.1	O
and	O
pBRB169.1	O
,	O
respectively	O
,	O
contain	O
the	O
3.2	O
kb	O
EcoRllPvuIl	O
fragment	O
analogous	O
to	O
that	O
present	O
in	O
pBRB7.2	O
(	O
Figure	O
1	O
)	O
.	O

pBCB2	O
.	O

13	O
-	O
2.18	O
.	O

To	O
identify	O
cl	O
-	O
repressible	O
promoters	O
,	O
we	O
introduced	O
selected	O
fragments	O
7672	O
Nucleic	O
Acids	O
Research	O
4	O
f	O
-	O
-	O
+	O
I	O
4	O
P1	O
4-	O
4-	O
4	O
ECAR	O
H	O
C	O
B	O
R	O
P	O
4	O
4.4,~	O
4	O
,	O
1	O
1	O
4	O
.	O

I	O
4	O
,	O
I	O
11	O
t	O
t	O
t	O
t	O
t	O
E	O
G	O
R	O
N	O
E	O
B	O
R	O
P	O
4	O
4	O
-	O
4	O
1	O
'	O
'	O

110z	O
I	O
I	O

I	O

I	O

I	O

I	O
1	O
3.2	O

1.5	O
1.0	O
0.5	O
0	O
P7	O
pBRB7.2	O
-------------------cl1	O
-	O
------------	O
r	O
~	O
/	O
>	O
'	O
pFAO2	O
*	O
-lacZ	O
pBCB2.13	O
<	O
-lacZ	O
Z	O
pBCB2.16	O
<	O
-lacZX	O
pBCB2.18	O
Fig.	O
1	O
.	O

The	O
cl	O
regions	O
of	O
P1	O
and	O
P7	O
.	O

A	O
restriction	O
map	O
is	O
indicated	O
by	O
the	O
solid	O
line	O
in	O
the	O
upper	O
part	O
of	O
the	O
figure	O
.	O

Sites	O
for	O
EcoRI	O
(	O
E	O
)	O
,	O
Pvul	O
(	O
P	O
)	O
,	O
NnrI	O
(	O
N	O
)	O
,	O
Bgll	O
(	O
G	O
)	O
,	O
BamHI	O
(	O
B	O
)	O
,	O
and	O
EcoRV	O
(	O
R	O
)	O
are	O
shown	O
.	O

The	O
sequencing	O
strategy	O
is	O
indicated	O
by	O
the	O
horizontal	O
arrows	O
.	O

Letters	O
and	O
arrows	O
above	O
and	O
below	O
the	O
map	O
refer	O
to	O
sites	O
and	O
sequence	O
analysis	O
for	O
P1	O
and	O
P7	O
,	O
respectively	O
.	O

The	O
size	O
of	O
this	O
region	O
(	O
in	O
kilobase	O
pairs	O
)	O
is	O
indicated	O
below	O
the	O
map	O
.	O

The	O
DNA	O
fragments	O
present	O
in	O
selected	O
plasmids	O
are	O
illustrated	O
by	O
boxes	O
at	O
the	O
bottom	O
of	O
the	O
figure	O
.	O

The	O
dashed	O
line	O
reveals	O
the	O
approximate	O
position	O
of	O
the	O
cl	O
gene	O
(	O
2	O
)	O
.	O

The	O
sites	O
of	O
the	O
-yb	O
mutations	O
introduced	O
into	O
pFA02	O
are	O
indicated	O
by	O
asterisks	O
.	O

pFA02.16	O
and	O
pFA02.26	O
contain	O
insertions	O
located	O
0.9	O
kb	O
and	O
1.4	O
kb	O
,	O
respectively	O
,	O
from	O
the	O
PvuIl	O
site	O
at	O
the	O
left	O
side	O
of	O
the	O
map	O
.	O

The	O
direction	O
of	O
the	O
lacZ	O
open	O
reading	O
frame	O
in	O
pBCB2.13	O
-	O
18	O
is	O
indicated	O
by	O
the	O
adjacent	O
arrow	O
.	O

from	O
the	O
cI	O
region	O
of	O
P1	O
into	O
pCB192	O
,	O
a	O
promoter	O
-	O
probe	O
vector	O
containing	O
promoterless	O
copies	O
of	O
lacZ	O
and	O
galK	O
extending	O
in	O
opposite	O
directions	O
from	O
a	O
multiple	O
cloning	O
site	O
(	O
21	O
)	O
.	O

The	O
source	O
of	O
P1	O
DNA	O
for	O
these	O
constructions	O
was	O
pZHA3	O
,	O
a	O
derivative	O
of	O
pBRB7.2	O
that	O
contains	O
a	O
HindIlI	O
linker	O
at	O
the	O
single	O
EcoRV	O
site	O
located	O
about	O
200	O
bps	O
upstream	O
of	O
the	O
cl	O
open	O
reading	O
frame	O
(	O
Figure	O
1	O
)	O
.	O

pBCB2.13	O
contains	O
a	O
460	O
bp	O
fragment	O
of	O
P1	O
DNA	O
extending	O
from	O
the	O
EcoRV	O
site	O
to	O
a	O
Bgll	O
site	O
within	O
the	O
cI	O
open	O
reading	O
frame	O
.	O

pBCB2	O
.	O

16	O
contains	O
a	O
130	O
bp	O
fragment	O
extending	O
from	O
the	O
EcoRV	O
site	O
to	O
a	O
BamHI	O
site	O
located	O
about	O
100	O
bps	O
upstream	O
of	O
the	O
cl	O
open	O
reading	O
frame	O
,	O
while	O
pBCB2.18	O
contains	O
the	O
region	O
extending	O
from	O
this	O
BamHI	O
site	O
to	O
the	O
Bglll	O
site	O
within	O
the	O
open	O
reading	O
frame	O
(	O
Figure	O
1	O
)	O
.	O

The	O
orientation	O
of	O
the	O
P1	O
DNA	O
fragments	O
within	O
these	O
plasmids	O
was	O
confirmed	O
by	O
restriction	O
mapping	O
and	O
DNA	O
sequencing	O
.	O

To	O
test	O
for	O
the	O
regulation	O
of	O
promoter	O
expression	O
by	O
cl	O
,	O
we	O
transformed	O
pBCB2.13	O
and	O
its	O
derivatives	O
into	O
CB454	O
(	O
pBRB7.152	O
)	O
and	O
CB454	O
(	O
pFAO2.152	O
)	O
,	O
two	O
strains	O
that	O
express	O
P7cl	O
and	O
Pll	O
,	O
respectively	O
,	O
from	O
the	O
pCB192-compatible	O
kanamycin	O
-	O
resistant	O
vector	O
pDPT152	O
(	O
22	O
)	O
.	O

Cells	O
harboring	O
both	O
plasmids	O
were	O
selected	O
by	O
their	O
resistance	O
to	O
both	O
ampicillin	O
and	O
kanamycin	O
.	O

lacZ	O
expression	O
was	O
measured	O
by	O
the	O
procedure	O
of	O
Miller	O
(	O
23	O
)	O
.	O

pBRB7.152	O
was	O
generated	O
by	O
introducing	O
PlEcoRI-7	O
into	O
pDPT152	O
.	O

pBRB7.152	O
has	O
sustained	O
a	O
spontaneous	O
deletion	O
within	O
the	O
EcoRI-7	O
fragment	O
that	O
results	O
in	O
the	O
loss	O
of	O
2.5	O
kb	O
of	O
P1	O
DNA	O
from	O
the	O
far	O
left	O
side	O
of	O
the	O
P1	O
genetic	O
map	O
,	O
but	O
retains	O
the	O
3.2	O
kb	O
PvuHlEcoRI	O
fragment	O
required	O
for	O
cl	O
expression	O
that	O
is	O
present	O
in	O
pBRB7.2	O
(	O
Figure	O
1	O
)	O
.	O

7673	O
z	O
I	O
011Z	O

I	O

e.	O
,	O
Nucleic	O
Acids	O
Research	O
Table	O
1	O
.	O

Complementation	O
of	O
PIci	O
.245	O
by	O
plasmids	O
that	O
contain	O
cI	O
genes	O
.	O

Phenotype	O
Efficiency	O
Relative	O
of	O
of	O
Efficiency	O
of	O
Plasmid	O
cI	O
gene	O
Lysogeny	O
Lysogeny	O
pBR322	O
1.5x	O
10	O
-	O
6	O
6.0x	O
10	O
-	O
6	O
pBRB7.2	O
Plcl+	O
2.5	O
x	O
10-	O
'	O
1.0	O
pBRB55.1	O
Plcl	O
-	O
am	O
1.4	O
x	O
10	O
-	O
6	O
5.6	O
x	O
10	O
-	O
6	O
pBRB169.1	O
PlCl	O
-	O
am	O
2.1	O
x	O
10	O
-	O
6	O
8.4	O
x	O
10	O
-	O
6	O
pFAO2	O
P7cl+	O
8.7	O
x	O
10	O
-	O
2	O
0.35	O
pFAO2.16	O
P7c	O
I-	O
,	O
4.7	O
x	O
10	O
-	O
6	O
1.9	O
X	O
10	O
-	O
5	O
pFAO2.26	O
P7cI	O
-1	O
3.1	O
x	O
10	O
-	O
6	O
1.2	O
x	O
10	O
-	O
5	O
Complementation	O
for	O
lysogeny	O
was	O
carried	O
out	O
as	O
described	O
by	O
Devlin	O
et	O
al.	O
(	O
26	O
)	O
.	O

The	O
plasmids	O
were	O
carried	O
by	O
E.	B
coli	I
K336	O
.	O

Cells	O
were	O
grown	O
to	O
mid	O
-	O
log	O
phase	O
at	O
370	O
in	O
LB	O
containing	O
50	O
tig	O
/	O
m1	O
sodium	O
ampicillin	O
and	O
infected	O
with	O
Plcl.245	O
at	O
a	O
multiplicity	O
of	O
infection	O
of	O
5	O
in	O
the	O
presence	O
of	O
50	O
mM	O
CaC12	O
.	O

After	O
10	O
minutes	O
,	O
non	O
-	O
absorbed	O
phage	O
were	O
removed	O
by	O
centrifugation	O
and	O
the	O
infection	O
was	O
allowed	O
to	O
proceed	O
for	O
2	O
hours	O
at	O
370	O
.	O

The	O
infected	O
cells	O
were	O
plated	O
on	O
LB	O
plates	O
containing	O
50	O
pLg	O
/	O
ml	O
sodium	O
ampicillin	O
,	O
50	O
pLg	O
/	O
ml	O
chloramphenicol	O
,	O
and	O
40	O
mM	O
sodium	O
citrate	O
.	O

The	O
efficiency	O
of	O
lysogeny	O
is	O
defined	O
as	O
the	O
number	O
of	O
ApRCmR	O
cells	O
at	O
the	O
end	O
of	O
infection	O
divided	O
by	O
the	O
number	O
of	O
ApR	O
cells	O
present	O
at	O
the	O
start	O
of	O
the	O
infection	O
.	O

To	O
construct	O
pFA02.152	O
,	O
we	O
introduced	O
a	O
2.8	O
kb	O
EcoRV	O
fragment	O
of	O
P7	O
DNA	O
containing	O
the	O
cl	O
gene	O
(	O
Figure	O
1	O
)	O
into	O
the	O
single	O
EcoRI	O
site	O
of	O
pDPT152	O
after	O
it	O
had	O
been	O
rendered	O
blunt	O
-	O
ended	O
by	O
extension	O
with	O
T4	O
DNA	O
polymerase	O
.	O

cl	O
expression	O
by	O
cells	O
harboring	O
either	O
pBRB7.152	O
or	O
pFA02.152	O
was	O
confirmed	O
by	O
measuring	O
their	O
ability	O
to	O
form	O
chloramphenicol	O
-	O
resistant	O
lysogens	O
when	O
infected	O
with	O
Plcl.245Cm	O
.	O
,	O
yb	O
insertional	O
mutagenesis	O
.	O

Insertional	O
mutagenesis	O
of	O
P7cl	O
was	O
carried	O
out	O
using	O
the	O
'	O
yb	O
transposon	O
of	O
F	O
(	O
24	O
)	O
as	O
described	O
by	O
Devlin	O
et	O
al.	O
(	O
25	O
)	O
.	O

E.	B
coli	I
W1485	O
(	O
pFA02	O
)	O
was	O
mated	O
with	O
the	O
F-	O
strain	O
MX648	O
and	O
subsequently	O
plated	O
on	O
ampicillin	O
(	O
to	O
select	O
for	O
the	O
plasmid	O
)	O
and	O
streptomycin	O
sulfate	O
(	O
to	O
select	O
for	O
the	O
recipient	O
strain	O
)	O
.	O

Transconjugants	O
which	O
could	O
support	O
only	O
lytic	O
growth	O
upon	O
infection	O
by	O
P7cl	O
.1	O
(	O
as	O
scored	O
by	O
cross	O
-	O
streak	O
analysis	O
;	O
18	O
)	O
were	O
assumed	O
to	O
have	O
lost	O
cl	O
-	O
complementing	O
activity	O
and	O
were	O
characterized	O
further	O
.	O

The	O
positions	O
of	O
two	O
cl	O
-	O
insertional	O
mutations	O
,	O
carried	O
by	O
pFA02.16	O
and	O
pFA02.26	O
,	O
were	O
identified	O
by	O
restriction	O
mapping	O
(	O
Figure	O
1	O
)	O
.	O

DNA	O
sequencing	O
.	O

DNA	O
sequence	O
analysis	O
was	O
carried	O
out	O
using	O
the	O
M13-dideoxy	O
technique	O
of	O
Sanger	O
et	O
al.	O
(	O
26	O
)	O
.	O

Selected	O
DNA	O
fragments	O
containing	O
the	O
cl	O
wildtype	O
or	O
mutant	O
genes	O
were	O
introduced	O
into	O
M13	O
mp8	O
or	O
mp9	O
.	O

18-nucleotide	O
oligomers	O
complementary	O
to	O
defined	O
sequences	O
within	O
the	O
cl	O
gene	O
were	O
extended	O
using	O
the	O
Klenow	O
fragment	O
of	O
DNA	O
polymerase	O
in	O
the	O
presence	O
of	O
dideoxynucleotide	O
triphosphates	O
and	O
analyzed	O
by	O
polyacrylamide	O
-	O
urea	O
gel	O
electrophoresis	O
.	O

The	O
sequencing	O
strategy	O
is	O
shown	O
in	O
Figure	O
1	O
.	O

RESULTS	O
Localization	O
of	O
the	O
P7cJ	O
gene	O
.	O

Initial	O
localization	O
of	O
the	O
P7cl	O
gene	O
was	O
undertaken	O
by	O
subjecting	O
pFA02	O
to	O
'	O
yb	O
mutagenesis	O
and	O
determining	O
the	O
map	O
position	O
of	O
inserts	O
which	O
destroy	O
the	O
ability	O
of	O
the	O
plasmids	O
to	O
complement	O
a	O
P7cl	O
-	O
mutation	O
(	O
as	O
determined	O
by	O
cross	O
-	O
streak	O
analysis	O
)	O
.	O

pFA02	O
and	O
the	O
-yb	O
insertion	O
mutants	O
were	O
tested	O
further	O
by	O
comparing	O
their	O
ability	O
to	O
complement	O
a	O
PIcI	O
amber	O
mutation	O
with	O
the	O
complementation	O
activity	O
of	O
plasmids	O
containing	O
cl	O
genes	O
isolated	O
7674	O
Nucleic	O
Acids	O
Research	O
B	O
C	O
D	O
E	O
F	O
G	O
*	O
.4	O

68	O
43	O
29-	O
_	O
-	O
=	O
I	O
=	O
Am~	O
W	O
_	O
18	O
14	O
p	O
Fig.	O
2	O
.	O

In	O
vitro	O
transcription	O
-	O
translation	O
of	O
plasmids	O
carrying	O
the	O
cl	O
region	O
of	O
P1	O
and	O
P7	O
.	O

Proteins	O
encoded	O
by	O
selected	O
plasmids	O
were	O
labeled	O
with	O
35S	O
methionine	O
according	O
to	O
the	O
procedure	O
of	O
DeVries	O
and	O
Zubay	O
(	O
27	O
)	O
,	O
using	O
a	O
commercial	O
in	O
vitro	O
transcription	O
/	O
tramnslation	O
kit	O
from	O
Amersham	O
Corporation	O
.	O

The	O
reaction	O
mixtures	O
were	O
subjected	O
to	O
electrophoresis	O
on	O
a	O
12.5	O
%	O
SDS	O
-	O
polyacrylamide	O
gel	O
and	O
the	O
labeled	O
proteins	O
were	O
visualized	O
by	O
autoradiography	O
.	O

The	O
migration	O
of	O
14C	O
-	O
labeled	O
protein	O
molecular	O
weight	O
standards	O
(	O
Bethesda	O
Research	O
Laboratories	O
)	O
is	O
indicated	O
at	O
the	O
left	O
side	O
of	O
the	O
figure	O
.	O

Plasmids	O
present	O
in	O
each	O
lane	O
are	O
:	O
A.	O
pBRB55.1	O
;	O
B.	O
pBRB169.1	O
;	O
C.	O
pBRB7.2	O
;	O
D.	O
pFAO2	O
;	O
E.	O
pFAO2.16	O
;	O
F.	O
pFAO2.26	O
;	O
G.	O
pBR322	O
.	O

from	O
P1	O
wildtype	O
and	O
amber	O
mutants	O
.	O

Lysogeny	O
by	O
cells	O
infected	O
with	O
Plcl.245Cm	O
was	O
scored	O
as	O
the	O
growth	O
of	O
infected	O
cells	O
on	O
ampicillin	O
(	O
to	O
select	O
for	O
the	O
resident	O
plasmid	O
)	O
and	O
chloramphenicol	O
(	O
to	O
select	O
for	O
the	O
phage	O
genome	O
)	O
.	O

The	O
values	O
observed	O
for	O
the	O
two	O
plasmids	O
containing	O
Plcl	O
and	O
P7cl	O
(	O
pBRB7.2	O
and	O
pFA02	O
,	O
respectively	O
)	O
are	O
very	O
similar	O
and	O
significantly	O
higher	O
than	O
those	O
obtained	O
for	O
pBR322	O
or	O
for	O
any	O
of	O
the	O
plasmids	O
carrying	O
Table	O
2	O
.	O

Assay	O
for	O
lacZ	O
expression	O
from	O
plasmids	O
containing	O
P1	O
DNA	O
fragments	O
.	O

,	O
3-galactosidase	O
activity	O
(	O
units	O
)	O
minus	O
cI	O
plus	O
Pici	O
plus	O
P7cl	O
relative	O
activity	O
(	O
pDPT152	O
)	O
(	O
pBB7	O
.	O
152	O
)	O
(	O
pFA02.152	O
)	O
+	O
PICJ	O
+	O
P7cJ	O
pCB192	O
0.58	O
0.55	O
0.54	O
0.95	O
0.93	O
pBCB2.13	O
154	O
15.2	O
13.6	O
0.10	O
0.09	O
pBCB2.16	O
1.1	O
1.2	O
1.1	O
1.1	O
1.0	O
pBCB2.18	O
4.0	O
3.4	O
3.9	O
0.9	O
1.0	O
Cells	O
containing	O
derivatives	O
of	O
the	O
ApR	O
promoter	O
-	O
probe	O
plasmid	O
pCB192	O
and	O
the	O
compatible	O
KnR	O
plasmid	O
pDPT152	O
were	O
grown	O
in	O
LB	O
at	O
37	O
?	O
.	O

When	O
they	O
reached	O
mid	O
-	O
log	O
phase	O
,	O
the	O
cells	O
were	O
chilled	O
,	O
lysed	O
,	O
and	O
assayed	O
for	O
(	O
3-galactosidase	O
activity	O
according	O
to	O
the	O
procedure	O
of	O
Miller	O
(	O
23	O
)	O
.	O

Plasmids	O
derived	O
from	O
pCB192	O
are	O
indicated	O
at	O
the	O
left	O
side	O
of	O
the	O
Table	O
.	O

Plasmids	O
derived	O
from	O
pDPT152	O
are	O
indicated	O
in	O
parentheses	O
across	O
the	O
top	O
of	O
the	O
Table	O
.	O

The	O
values	O
reported	O
are	O
the	O
average	O
of	O
two	O
independent	O
experiments	O
.	O

Relative	O
activity	O
is	O
defined	O
as	O
the	O
f3-galactosidase	O
activity	O
measured	O
in	O
cells	O
harboring	O
plasmids	O
expressing	O
cl	O
divided	O
by	O
the	O
activity	O
measured	O
in	O
cells	O
carrying	O
only	O
pDPT152	O
.	O

7675	O
Nucleic	O
Acids	O
Research	O
GATATCCAATCAGGAGTACC	O
GCATCACCCAAGACGACCTG	O
GATGATCTCACTGACACAAT	O
CGAATATCTCATGGCCACTA	O
ACCAGCCAGACTCACAATAAATGCA	O
105	O
v--	O
TtgAca	O
TATAATG	O
CTAATAAATCTATTATTTTC	O
GTTGGATCCTTCTATAATGG	O
TGGCCAACAACTCCCAGTGT	O
AATCCGCTGTGAGTTGTTGG	O
CCATGTCAATTCTGGAGGAGGATCA	O

210	O
b-----	O

I	O
I	O
GGAGGtG	O
ATG	O
ATA	O
AAT	O
TAT	O
GTC	O
TAC	O
GGC	O
GAA	O
CAA	O
CTG	O
TAC	O
CAG	O
GAG	O
TTC	O
GTC	O
AGC	O
TTC	O
AGG	O
GAT	O
CTC	O
TTT	O
CTA	O
AAA	O
AAA	O
GCT	O
GTT	O
GCA	O
CGC	O
GCC	O
CAA	O
300	O
MET	O
lIe	O
Asn	O
Tyr	O
Vat	O
Tyr	O
Gly	O
Glu	O
Gin	O
Leu	O
Tyr	O
Gin	O
Gtu	O
Phe	O
Vat	O
Ser	O
Phe	O
Arg	O
Asp	O
Leu	O

Phe	O
Leu	O

Lys	O
Lys	O
Ala	O
Val	O
Ala	O
Arg	O
Ala	O
Gtn	O
tag	O
(	O
cl	O
.55	O
)	O

CAC	O
GTT	O
GAT	O
GCC	O
GCC	O
AGC	O
GAC	O
GGT	O
CGT	O
CCT	O
GTT	O
CGC	O
CCG	O
GTT	O
GTC	O
GTT	O
CTG	O
CCG	O
TTC	O
AM	O
GM	O
ACG	O
GAC	O
AGC	O
ATT	O
CAG	O
GCT	O
GMA	O
ATT	O
GAT	O
390	O

His	O
Val	O
Asp	O
Ala	O
Ala	O
Ser	O
Asp	O
Gly	O

Arg	O
Pro	O
Vat	O
Arg	O
Pro	O
Vat	O
Vat	O
Vat	O
Leu	O

Pro	O
Phe	O
Lys	O
Glu	O
Thr	O
Asp	O
Ser	O
lIe	O
Gin	O
Ala	O
Glu	O
lie	O
Asp	O
T	O
A	O
C	O
A	O
G	O
AAA	O
TGG	O
ACA	O
TTA	O
ATG	O
GCG	O
CGG	O
GAA	O
CTG	O
GAG	O
CAG	O
TAC	O
CCA	O
GAT	O
CTC	O
MT	O
ATC	O
CCA	O
MG	O
ACT	O
ATT	O
TTA	O
TAT	O
CCT	O
GTA	O
CCT	O
AAC	O
ATC	O
CTT	O
CGC	O
480	O
9	O
Lys	O
Trp	O
Thr	O
Leu	O
MET	O
Ala	O
Arg	O
Glu	O
Leu	O
Gtu	O

Gin	O
Tyr	O
Pro	O
Asp	O
Leu	O
Asn	O
lIe	O
Pro	O
Lys	O
Thr	O
lie	O
Leu	O
Tyr	O
Pro	O
Vat	O
Pro	O
Asn	O
lIe	O
Leu	O
Arg	O
A	O
T	O
C	O
GGT	O
GTG	O
CGT	O
AAG	O
GTT	O
ACG	O
ACT	O
TAT	O
CAG	O
ACA	O
GAA	O
GCA	O
GTG	O
MC	O
AGC	O
GTC	O
AAT	O
ATG	O
ACC	O
GCT	O
GGC	O
CGC	O
ATT	O
ATT	O
CAT	O
CTG	O
ATT	O
GAT	O
AAG	O
GAC	O

570	O
Gly	O
Vat	O
Arg	O
Lys	O
Vat	O
Thr	O
Thr	O
Tyr	O
Gin	O
Thr	O
Glu	O
Ala	O
Vat	O
Asn	O
Ser	O
Vat	O
Asn	O
MET	O
Thr	O
Ala	O
Gly	O
Arg	O
lIe	O
lIe	O
His	O
Leu	O
lIe	O
Asp	O
Lys	O
Asp	O
G	O

ATT	O
CGC	O
ATC	O
CAA	O
AM	O
AGC	O
GCG	O
GGG	O
ATC	O
MT	O
GAG	O
CAC	O
AGT	O
GCG	O
AAA	O
TAC	O
ATA	O
GAG	O
MC	O
CTG	O
GAA	O
GCA	O
ACA	O
AM	O
GAG	O
CTA	O
ATG	O
AAG	O
CAG	O
TAC	O
660	O
lle	O
Arg	O
lIe	O
Gin	O
Lys	O
Ser	O
Ala	O
Gly	O
lIe	O
Asn	O

Gtu	O
His	O
Ser	O
Ala	O
Lys	O
Tyr	O
lIe	O
Gtu	O
Asn	O
Leu	O
Gtu	O
Ala	O
Thr	O
Lys	O
Gtu	O
Leu	O
MET	O
Lys	O
Gin	O
Tyr	O
T	O
T	O
CCG	O
GAG	O
GAT	O
GAA	O
AAA	O
TTC	O
CGT	O
ATG	O
CGC	O
GTA	O
CAC	O
GGC	O
TTT	O
AGC	O
GAA	O
ACA	O
ATG	O
CTG	O
CGC	O
GTC	O
CAT	O
TAC	O
ATT	O
TCC	O
AGT	O
AGC	O
CCT	O
AAC	O
TAC	O
AAT	O

750	O
Pro	O
Glu	O
Asp	O
Glu	O
Lys	O
Phe	O
Arg	O
MET	O

Arg	O
Vat	O

His	O
Gly	O
Phe	O
Ser	O

Gtu	O
Thr	O
MET	O
Leu	O

Arg	O
Vat	O
His	O
Tyr	O
lie	O
Ser	O
Ser	O
Ser	O
Pro	O
Asn	O
Tyr	O
Asn	O
Phe	O
T	O
C	O
G	O
T	O
T	O
I	O
~~~I	O
I	O
II	O
GAT	O
GGC	O
MA	O
TCA	O
GTT	O
AGT	O
TAC	O
CAT	O
GTG	O
CTG	O
CTA	O
TGT	O
GGC	O
GTG	O
TTT	O
ATC	O
TGC	O
GAT	O
GM	O
ACT	O
CTC	O
CGA	O
GAT	O
GGA	O
ATC	O
ATC	O
ATC	O
AAC	O
GGT	O
GAA	O
840	O
e	O
..	O

Asp	O
Gly	O
Lys	O
Ser	O
Vat	O
Ser	O
Tyr	O

His	O
Vat	O
Leu	O
Leu	O
Cys	O
Gly	O
Vat	O
Phe	O
lie	O
Cys	O
Asp	O
Glu	O
Thr	O
Leu	O
Arg	O
Asp	O
Gly	O
lIe	O
lie	O
lIe	O
Asn	O
Gly	O
Gtu	O
Pro	O
C	O
tag	O
(	O
cl	O
.169	O
)	O
TTT	O
GAG	O
AM	O
GCA	O
AAA	O
TTT	O
AGC	O
CTT	O
TAT	O
GAC	O
TCT	O
ATA	O
GM	O
CCG	O
ATC	O
ATC	O
TGC	O
GAC	O
CGC	O
TGG	O
CCG	O
CAG	O
GCA	O
AM	O
ATA	O
TAT	O
CGC	O
CTG	O
GCA	O
GAT	O
930	O
Phe	O
Gtu	O
Lys	O
Ala	O
Lys	O
Phe	O
Ser	O
Leu	O
Tyr	O
Asp	O
Ser	O
lIe	O
Glu	O
Pro	O
lie	O
lie	O
Cys	O
Asp	O
Arg	O
Trp	O
Pro	O
Gin	O
Ala	O
Lys	O
lIe	O
Tyr	O
Arg	O
Leu	O
Ala	O
Asp	O
T	O
ATT	O
GM	O
MT	O
GTA	O
AM	O
AM	O
CM	O
ATT	O
GCC	O
ATC	O
ACT	O
CGC	O
GM	O
GAG	O
AAA	O
G	O
GTC	O
AM	O
TCA	O
GCC	O
GCA	O
TCA	O
GTT	O
ACG	O
CGC	O
AGC	O
CGC	O
AAA	O
ACT	O
AAG	O
1020	O
n-----	O
lie	O
Glu	O
Asn	O
Vat	O
Lys	O
Lys	O
Gin	O
lIe	O
Ala	O
lie	O
Thr	O
Arg	O
Glu	O
Glu	O
Lys	O
Lys	O
Vat	O
Lys	O
Ser	O
Ala	O
Ala	O
Ser	O
Vat	O
Thr	O
Arg	O
Ser	O

Arg	O
Lys	O
Thr	O
Lys	O

AAG	O
GGG	O
CAG	O
CCA	O
GTA	O
AAC	O
GAC	O
MC	O
CCC	O
GAA	O
AGC	O
GCG	O
CM	O
TAG	O
Lys	O
Gly	O
Gin	O
Pro	O
Val	O
Asn	O
Asp	O
Asn	O
Pro	O
Glu	O
Ser	O

Ala	O
Gin	O
ter	O
Fig.	O
3	O
.	O

DNA	O
sequence	O
of	O
PIcI	O
and	O
P7cl	O
.	O

The	O
DNA	O
sequence	O
of	O
PIcI	O
is	O
indicated	O
.	O

Positions	O
where	O
the	O
sequence	O
of	O
P7cl	O
differs	O
from	O
that	O
of	O
Plcl	O
are	O
indicated	O
above	O
the	O
P1	O
sequence	O
.	O

The	O
amino	O
acid	O
sequence	O
predicted	O
by	O
the	O
open	O
reading	O
frame	O
is	O
given	O
below	O
the	O
sequence	O
.	O

The	O
two	O
amino	O
acid	O
substitutions	O
present	O
in	O
P7cl	O
are	O
shown	O
below	O
the	O
open	O
reading	O
frame	O
.	O

The	O
locations	O
of	O
the	O
amber	O
mutant	O
codons	O
in	O
cl.55	O
and	O
ci	O
.	O

169	O
are	O
indicated	O
by	O
small	O
letters	O
above	O
the	O
sequence	O
.	O

Sites	O
for	O
selected	O
restriction	O
enzymes	O
(	O
EcoRV	O
[	O
v	O
]	O
;	O
BamHI	O
[	O
b	O
]	O
;	O
Bgll	O
[	O
g	O
]	O
;	O
EcoRP	O
[	O
e	O
]	O
;	O
and	O
NruI	O
[	O
n	O
]	O
)	O
are	O
illustrated	O
by	O
dashed	O
lines	O
beneath	O
the	O
sequence	O
.	O

The	O
cl	O
repressor	O
binding	O
site	O
is	O
underlined	O
.	O

Inverted	O
arrows	O
beneath	O
the	O
sequence	O
illustrate	O
the	O
inverted	O
repeat	O
sequence	O
upstream	O
of	O
the	O
open	O
reading	O
frame	O
.	O

Predicted	O
promoter	O
ribosome	O
binding	O
sites	O
are	O
indicated	O
by	O
the	O
presence	O
of	O
the	O
consensus	O
sequences	O
above	O
and	O
below	O
the	O
line	O
,	O
respectively	O
.	O

The	O
DNA	O
sequences	O
of	O
Plcl	O
from	O
bp	O
1	O
-	O
134	O
and	O
bp	O
1	O
-	O
434	O
were	O
reported	O
previously	O
(	O
2,5	O
)	O
.	O

mutant	O
cl	O
genes	O
from	O
either	O
P1	O
or	O
P7	O
(	O
Table	O
1	O
)	O
.	O

The	O
efficiency	O
with	O
which	O
a	O
cloned	O
P7cl	O
gene	O
complements	O
a	O
PlcI	O
mutation	O
confirms	O
previous	O
genetic	O
studies	O
indicating	O
that	O
these	O
two	O
genes	O
are	O
functionally	O
interchangeable	O
(	O
9	O
)	O
.	O

The	O
location	O
of	O
the	O
'	O
y6	O
mutations	O
that	O
destroy	O
cl	O
-	O
complementing	O
activity	O
suggests	O
that	O
the	O
P7cl	O
open	O
reading	O
frame	O
occupies	O
a	O
map	O
position	O
similar	O
to	O
that	O
of	O
the	O
P1	O
open	O
reading	O
frame	O
(	O
Figure	O
1	O
)	O
.	O

7676	O
Nucleic	O
Acids	O
Research	O
Proteins	O
produced	O
by	O
fragments	O
containing	O
Plcl	O
.	O

As	O
an	O
initial	O
step	O
in	O
the	O
comparison	O
of	O
the	O
P1	O
and	O
P7	O
repressors	O
,	O
we	O
analyzed	O
the	O
gene	O
products	O
expressed	O
from	O
the	O
cloned	O
cl	O
regions	O
.	O

In	O
an	O
in	O
vitro	O
transcription	O
-	O
translation	O
reaction	O
,	O
plasmids	O
coding	O
for	O
the	O
wildtpe	O
alleles	O
of	O
either	O
PIcI	O
or	O
P7cl	O
direct	O
the	O
production	O
of	O
a	O
protein	O
with	O
an	O
estimated	O
molecular	O
weight	O
of	O
33,000	O
daltons	O
(	O
Figure	O
2	O
,	O
Lanes	O
C	O
and	O
D	O
)	O
,	O
a	O
size	O
that	O
agrees	O
closely	O
with	O
the	O
predicted	O
molecular	O
weight	O
of	O
the	O
PIcI	O
repressor	O
reported	O
previously	O
(	O
3,28	O
)	O
.	O

The	O
loss	O
of	O
the	O
33,000	O
dalton	O
protein	O
in	O
the	O
cl	O
-	O
'	O
ya	O
-	O
induced	O
P7	O
mutant	O
plasmids	O
(	O
Figure	O
2	O
,	O
Lanes	O
E	O
and	O
F	O
)	O
is	O
consistent	O
with	O
its	O
designation	O
as	O
the	O
P7cl	O
repressor	O
.	O

As	O
expected	O
,	O
the	O
33,000	O
dalton	O
protein	O
is	O
not	O
observed	O
when	O
reaction	O
mixtures	O
contain	O
DNA	O
from	O
Plcl	O
amber	O
mutants	O
(	O
Figure	O
2	O
,	O
Lanes	O
A	O
and	O
B	O
)	O
.	O

DNA	O
sequence	O
analysis	O
of	O
the	O
cl	O
genes	O
.	O

To	O
make	O
a	O
direct	O
comparison	O
between	O
the	O
Plcl	O
and	O
P7cl	O
DNA	O
sequences	O
and	O
to	O
predict	O
the	O
amino	O
acid	O
sequences	O
of	O
the	O
repressor	O
proteins	O
,	O
we	O
carried	O
out	O
M	O
13-dideoxy	O
sequence	O
analysis	O
of	O
cloned	O
fragments	O
carrying	O
the	O
cl	O
genes	O
.	O

The	O
sequences	O
of	O
about	O
1	O
kb	O
of	O
P1	O
and	O
P7	O
DNA	O
were	O
determined	O
starting	O
from	O
a	O
common	O
EcoRV	O
site	O
predicted	O
to	O
lie	O
approximately	O
200	O
bps	O
upstream	O
of	O
the	O
cl	O
genes	O
.	O

The	O
P1	O
and	O
P7	O
sequences	O
(	O
Figure	O
3	O
)	O
both	O
contain	O
an	O
ATG	O
initiation	O
codon	O
preceded	O
by	O
a	O
putative	O
ribosome	O
binding	O
sequence	O
(	O
29	O
)	O
situated	O
211	O
bps	O
downstream	O
of	O
the	O
EcoRV	O
site	O
.	O

In	O
each	O
case	O
,	O
the	O
initiation	O
codon	O
is	O
followed	O
by	O
an	O
open	O
reading	O
reading	O
frame	O
extending	O
for	O
283	O
codons	O
.	O

The	O
P1	O
and	O
P7	O
open	O
reading	O
frames	O
code	O
for	O
proteins	O
with	O
predicted	O
molecular	O
weights	O
(	O
32,515	O
and	O
32,499	O
daltons	O
,	O
respectively	O
)	O
that	O
agree	O
closely	O
with	O
the	O
values	O
of	O
the	O
proteins	O
expressed	O
from	O
the	O
cloned	O
DNA	O
fragments	O
(	O
Figure	O
2	O
)	O
and	O
with	O
results	O
predicted	O
independently	O
for	O
the	O
purified	O
PIcI	O
repressor	O
(	O
3	O
-	O
4	O
)	O
.	O

The	O
localization	O
of	O
two	O
PIcI	O
amber	O
mutations	O
to	O
the	O
P1	O
open	O
reading	O
frame	O
confirms	O
its	O
identification	O
as	O
the	O
cI	O
coding	O
sequence	O
.	O

cI.	O
169	O
contains	O
an	O
amber	O
mutation	O
that	O
would	O
result	O
in	O
a	O
protein	O
fragment	O
of	O
26,680	O
daltons	O
,	O
a	O
value	O
that	O
agrees	O
well	O
with	O
the	O
size	O
of	O
a	O
protein	O
fragment	O
observed	O
under	O
the	O
in	O
vitro	O
transcription	O
/	O
translation	O
reaction	O
conditions	O
(	O
Figure	O
2	O
,	O
Lane	O
B	O
)	O
.	O

The	O
cl.55	O
amber	O
mutation	O
lies	O
close	O
to	O
the	O
N	O
-	O
terminal	O
region	O
of	O
the	O
protein	O
,	O
resulting	O
in	O
the	O
production	O
of	O
a	O
fragment	O
of	O
55	O
amino	O
acids	O
that	O
is	O
apparently	O
too	O
small	O
to	O
resolve	O
under	O
the	O
electrophoretic	O
conditions	O
used	O
for	O
separation	O
of	O
the	O
proteins	O
.	O

Over	O
60	O
%	O
of	O
the	O
amino	O
acid	O
sequence	O
predicted	O
for	O
the	O
PIcI	O
open	O
reading	O
frame	O
has	O
been	O
verified	O
by	O
amino	O
acid	O
sequence	O
analysis	O
of	O
peptide	O
fragments	O
isolated	O
from	O
the	O
purified	O
repressor	O
protein	O
(	O
see	O
accompanying	O
paper	O
,	O
reference	O
3	O
)	O
.	O

The	O
DNA	O
sequences	O
of	O
P1	O
and	O
P7	O
are	O
identical	O
for	O
a	O
399-bp	O
region	O
that	O
extends	O
from	O
the	O
EcoRV	O
site	O
at	O
the	O
5	O
'	O
side	O
of	O
the	O
cl	O
gene	O
to	O
a	O
point	O
188	O
bps	O
within	O
the	O
open	O
reading	O
frame	O
.	O

The	O
sequences	O
within	O
the	O
Plcl	O
and	O
the	O
P7cl	O
open	O
reading	O
frames	O
differ	O
at	O
only	O
18	O
positions	O
,	O
all	O
but	O
two	O
of	O
which	O
occur	O
in	O
the	O
wobble	O
position	O
of	O
the	O
predicted	O
codon	O
.	O

From	O
these	O
results	O
,	O
we	O
conclude	O
that	O
the	O
functional	O
identity	O
of	O
the	O
P1	O
and	O
P7	O
cl	O
genes	O
is	O
a	O
consequence	O
of	O
their	O
nearly	O
identical	O
amino	O
acid	O
sequence	O
.	O

Analysis	O
of	O
promoters	O
upstream	O
of	O
the	O
cl	O
open	O
reading	O
frame	O
.	O

Expression	O
of	O
Plcl	O
was	O
shown	O
previously	O
to	O
require	O
sequences	O
on	O
the	O
distal	O
side	O
of	O
a	O
BamHI	O
site	O
(	O
2	O
,	O
5	O
)	O
located	O
about	O
100	O
bps	O
upstream	O
of	O
the	O
open	O
reading	O
frame	O
(	O
Figure	O
3	O
)	O
.	O

A	O
binding	O
site	O
for	O
the	O
cl	O
repressor	O
has	O
also	O
been	O
shown	O
to	O
exist	O
close	O
to	O
this	O
BamHI	O
site	O
(	O
2	O
,	O
5	O
,	O
6	O
)	O
.	O

To	O
determine	O
whether	O
this	O
region	O
contains	O
a	O
promoter	O
that	O
is	O
detectable	O
in	O
vivo	O
and	O
,	O
further	O
,	O
to	O
determine	O
whether	O
this	O
promoter	O
can	O
be	O
regulated	O
by	O
cl	O
repressor	O
proteins	O
from	O
either	O
P1	O
or	O
P7	O
,	O
we	O
introduced	O
several	O
DNA	O
fragments	O
from	O
this	O
region	O
into	O
the	O
promoter	O
probe	O
vector	O
pCB192	O
,	O
screened	O
for	O
promoter	O
activity	O
(	O
as	O
monitored	O
by	O
lacZ	O
expression	O
)	O
and	O
checked	O
for	O
repression	O
of	O
this	O
activity	O
in	O
the	O
presence	O
of	O
a	O
compatible	O
7677	O
Nucleic	O
Acids	O
Research	O
plasmid	O
expressing	O
Plcl	O
or	O
P7cl	O
.	O

Cells	O
harboring	O
pBCB2.13	O
(	O
a	O
plasmid	O
which	O
carries	O
a	O
460	O
bp	O
fragment	O
of	O
P1	O
DNA	O
that	O
extends	O
across	O
the	O
BamHI	O
site	O
upstream	O
of	O
cl	O
into	O
the	O
open	O
reading	O
frame	O
)	O
are	O
dark	O
blue	O
in	O
the	O
presence	O
of	O
Xgal	O
and	O
produce	O
significant	O
levels	O
of	O
3-galactosidase	O
(	O
Table	O
2	O
)	O
.	O

In	O
contrast	O
,	O
pBCB2.16	O
and	O
pBCB2.18	O
(	O
which	O
each	O
contain	O
DNA	O
from	O
only	O
one	O
side	O
of	O
the	O
BamHI	O
site	O
located	O
in	O
pBCB2	O
.	O

13	O
)	O
do	O
not	O
confer	O
a	O
blue	O
color	O
on	O
their	O
host	O
cell	O
in	O
the	O
presence	O
of	O
X	O
-	O
Gal	O
and	O
express	O
negligible	O
amounts	O
of	O
3-galactosidase	O
(	O
Table	O
2	O
)	O
.	O

These	O
observations	O
suggest	O
that	O
expression	O
from	O
the	O
promoter	O
identified	O
here	O
requires	O
sequences	O
that	O
span	O
the	O
BamHI	O
site	O
upstream	O
of	O
cl	O
.	O

Expression	O
of	O
cl	O
from	O
a	O
compatible	O
plasmid	O
in	O
the	O
presence	O
of	O
pBCB2	O
.	O

13	O
results	O
in	O
a	O
90	O
%	O
reduction	O
in	O
promoter	O
strength	O
(	O
Table	O
2	O
)	O
.	O

This	O
reduction	O
is	O
seen	O
in	O
the	O
presence	O
of	O
either	O
Plcl	O
or	O
P7cl	O
,	O
indicating	O
that	O
the	O
two	O
repressor	O
proteins	O
are	O
both	O
capable	O
of	O
repressing	O
expression	O
from	O
this	O
promoter	O
.	O

DISCUSSION	O
.	O

The	O
DNA	O
sequences	O
of	O
Plcl	O
and	O
P7cl	O
differ	O
at	O
only	O
18	O
sites	O
,	O
all	O
but	O
two	O
of	O
which	O
occur	O
at	O
the	O
third	O
position	O
of	O
the	O
affected	O
codon	O
.	O

This	O
observation	O
provides	O
biochemical	O
confirmation	O
of	O
the	O
functional	O
identity	O
predicted	O
on	O
the	O
basis	O
of	O
previous	O
genetic	O
analysis	O
(	O
9	O
)	O
.	O

A	O
number	O
of	O
DNA	O
binding	O
proteins	O
exhibit	O
a	O
common	O
structural	O
motif	O
in	O
which	O
two	O
helices	O
are	O
separated	O
by	O
a	O
glycine	O
residue	O
(	O
12	O
)	O
.	O

This	O
motif	O
is	O
not	O
observed	O
in	O
the	O
predicted	O
secondary	O
structures	O
(	O
30	O
)	O
of	O
the	O
Plcl	O
and	O
P7cl	O
amino	O
acid	O
sequences	O
.	O

A	O
sequence	O
with	O
some	O
similarity	O
to	O
the	O
XCro	O
helix	O
-	O
turn	O
-	O
helix	O
region	O
was	O
previously	O
reported	O
near	O
the	O
Nterminus	O
of	O
the	O
PIcI	O
protein	O
(	O
5	O
)	O
;	O
however	O
,	O
it	O
was	O
noted	O
that	O
the	O
potential	O
for	O
helix	O
formation	O
is	O
disrupted	O
by	O
the	O
presence	O
of	O
several	O
prolines	O
within	O
the	O
region	O
.	O

The	O
secondary	O
structure	O
predicted	O
for	O
the	O
Plcl	O
and	O
P7cl	O
repressor	O
proteins	O
(	O
30	O
)	O
does	O
not	O
reveal	O
other	O
structural	O
characteristics	O
(	O
e.g.	O
,	O
Zn	O
fingers	O
(	O
31	O
)	O
,	O
leucine	O
zippers	O
(	O
32	O
)	O
,	O
or	O
helix	O
-	O
loop	O
-	O
helix	O
motifs	O
(	O
33	O
)	O
)	O
that	O
have	O
been	O
associated	O
with	O
DNA	O
binding	O
activity	O
in	O
other	O
systems	O
.	O

A	O
search	O
of	O
the	O
GenBank	O
and	O
EMBL	O
databases	O
does	O
not	O
reveal	O
any	O
other	O
known	O
regulatory	O
proteins	O
with	O
significant	O
amino	O
acid	O
similarity	O
to	O
the	O
Plcl	O
or	O
the	O
P7cl	O
repressor	O
sequences	O
.	O

Since	O
the	O
Plcl	O
repressor	O
differs	O
from	O
most	O
other	O
repressors	O
in	O
DNA	O
binding	O
specificity	O
(	O
i.e.	O
,	O
in	O
its	O
recognition	O
of	O
an	O
asymmetric	O
operator	O
sequence	O
)	O
,	O
it	O
is	O
not	O
unexpected	O
to	O
find	O
that	O
the	O
protein	O
does	O
not	O
exhibit	O
common	O
structural	O
motifs	O
at	O
the	O
amino	O
acid	O
level	O
.	O

The	O
cl	O
-	O
repressible	O
promoter	O
described	O
in	O
this	O
report	O
is	O
located	O
in	O
a	O
region	O
just	O
upstream	O
of	O
the	O
cl	O
open	O
reading	O
frame	O
and	O
is	O
oriented	O
in	O
the	O
direction	O
of	O
cl	O
.	O

Because	O
the	O
promoter	O
is	O
present	O
on	O
a	O
multicopy	O
plasmid	O
,	O
it	O
is	O
not	O
possible	O
to	O
make	O
a	O
direct	O
calculation	O
of	O
promoter	O
strength	O
;	O
however	O
,	O
the	O
values	O
observed	O
are	O
about	O
five	O
-	O
fold	O
lower	O
than	O
the	O
levels	O
produced	O
by	O
a	O
derivative	O
of	O
pCB192	O
that	O
contains	O
the	O
plac	O
promoter	O
from	O
pUC19	O
(	O
34	O
)	O
.	O

Because	O
sequences	O
on	O
both	O
sides	O
of	O
the	O
BamHI	O
site	O
located	O
upstream	O
of	O
cl	O
are	O
required	O
for	O
promoter	O
activity	O
(	O
Table	O
2	O
)	O
,	O
we	O
suggest	O
that	O
the	O
promoter	O
spans	O
this	O
site	O
.	O

Less	O
than	O
10	O
bps	O
downstream	O
of	O
this	O
BamHI	O
site	O
is	O
a	O
heptanucleotide	O
sequence	O
(	O
TATAATG	O
)	O
that	O
is	O
identical	O
to	O
the	O
-10	O
consensus	O
sequence	O
for	O
RNA	O
polymerase	O
(	O
35	O
)	O
.	O

If	O
this	O
sequence	O
does	O
indeed	O
correspond	O
to	O
the	O
-10	O
region	O
of	O
the	O
promoter	O
,	O
the	O
-35	O
region	O
would	O
be	O
predicted	O
to	O
lie	O
on	O
the	O
other	O
side	O
of	O
the	O
BamHI	O
site	O
in	O
a	O
region	O
that	O
overlaps	O
a	O
known	O
cI	O
repressor	O
binding	O
site	O
(	O
2	O
-	O
5	O
)	O
.	O

Analysis	O
of	O
this	O
region	O
does	O
not	O
reveal	O
any	O
sequences	O
with	O
significant	O
similarity	O
to	O
the	O
-35	O
consensus	O
sequence	O
.	O

The	O
best	O
fit	O
is	O
the	O
sequence	O
TCTATT	O
(	O
Figure	O
3	O
)	O
,	O
which	O
matches	O
only	O
two	O
positions	O
of	O
the	O
-35	O
consensus	O
(	O
TTGACA	O
)	O
.	O

The	O
lack	O
of	O
a	O
strong	O
-35	O
region	O
is	O
often	O
observed	O
with	O
genes	O
that	O
require	O
an	O
activator	O
.	O

Although	O
a	O
pentanucleotide	O
sequence	O
corresponding	O
to	O
the	O
conserved	O
portion	O
of	O
the	O
CRP	O
protein	O
consensus	O
binding	O
site	O
(	O
36	O
)	O
7678	O
Nucleic	O
Acids	O
Research	O
is	O
located	O
just	O
upstream	O
of	O
the	O
predicted	O
-35	O
region	O
(	O
at	O
position	O
91	O
;	O
Figure	O
3	O
)	O
,	O
a	O
role	O
for	O
CRP	O
-	O
mediated	O
activation	O
in	O
cl	O
expression	O
has	O
not	O
previously	O
been	O
described	O
.	O

The	O
orientation	O
of	O
the	O
promoter	O
and	O
its	O
cl	O
-	O
repressible	O
character	O
raise	O
the	O
possibility	O
that	O
cl	O
expression	O
is	O
autoregulatory	O
.	O

If	O
this	O
is	O
so	O
,	O
one	O
potential	O
activator	O
would	O
be	O
the	O
cl	O
repressor	O
itself	O
.	O

Expression	O
can	O
not	O
be	O
absolutely	O
dependent	O
on	O
cl	O
-	O
mediated	O
activation	O
,	O
however	O
,	O
because	O
the	O
cloned	O
promoter	O
exhibits	O
significant	O
activity	O
in	O
the	O
absence	O
of	O
the	O
cl	O
gene	O
(	O
Table	O
2	O
)	O
.	O

Under	O
the	O
conditions	O
reported	O
here	O
,	O
the	O
presence	O
of	O
the	O
cl	O
gene	O
results	O
in	O
a	O
decrease	O
rather	O
than	O
an	O
increase	O
in	O
lacZ	O
expression	O
;	O
however	O
,	O
these	O
observations	O
do	O
not	O
rule	O
out	O
a	O
potential	O
activator	O
role	O
for	O
the	O
cl	O
protein	O
,	O
since	O
the	O
ratios	O
of	O
repressor	O
and	O
operator	O
provided	O
by	O
the	O
multicopy	O
plasmids	O
may	O
not	O
be	O
optimal	O
for	O
activation	O
.	O

Physiologically	O
,	O
the	O
role	O
of	O
additional	O
repressor	O
binding	O
sites	O
in	O
regulating	O
cl	O
expression	O
also	O
can	O
not	O
be	O
discounted	O
.	O

Three	O
potential	O
operator	O
sites	O
have	O
been	O
identified	O
several	O
hundred	O
bps	O
upstream	O
of	O
the	O
cI	O
open	O
reading	O
frame	O
(	O
2	O
-	O
5	O
)	O
;	O
one	O
or	O
more	O
of	O
these	O
could	O
be	O
involved	O
(	O
possibly	O
through	O
a	O
DNA	O
looping	O
mechanism	O
;	O
37	O
)	O
in	O
the	O
activation	O
or	O
repression	O
of	O
cl	O
expression	O
during	O
phage	O
growth	O
.	O

A	O
cl	O
-	O
repressible	O
promoter	O
oriented	O
in	O
the	O
direction	O
of	O
cl	O
was	O
previously	O
reported	O
(	O
38	O
)	O
to	O
be	O
located	O
entirely	O
within	O
PlBamHI-9	O
,	O
a	O
fragment	O
located	O
upstream	O
of	O
cl	O
which	O
is	O
bracketed	O
by	O
the	O
BamHI	O
site	O
within	O
pBCB2	O
.	O

13	O
.	O

Because	O
sequences	O
on	O
both	O
sides	O
of	O
this	O
BamHI	O
site	O
are	O
required	O
for	O
the	O
activity	O
of	O
the	O
promoter	O
in	O
pBCB2.13	O
,	O
we	O
suggest	O
that	O
the	O
previously	O
identified	O
promoter	O
is	O
distinct	O
from	O
the	O
one	O
reported	O
here	O
.	O

The	O
promoter	O
from	O
BamHI-9	O
could	O
correspond	O
to	O
a	O
consensus	O
promoter	O
sequence	O
that	O
is	O
situated	O
about	O
500	O
bps	O
upstream	O
of	O
cl	O
and	O
overlaps	O
a	O
cl	O
repressor	O
binding	O
site	O
(	O
2	O
)	O
.	O

If	O
so	O
,	O
cl	O
expression	O
is	O
likely	O
to	O
be	O
controlled	O
by	O
more	O
than	O
one	O
promoter	O
.	O

Located	O
between	O
this	O
promoter	O
sequence	O
and	O
the	O
promoter	O
encoded	O
on	O
pBCB2	O
.	O

13	O
is	O
an	O
open	O
reading	O
frame	O
whose	O
product	O
(	O
termed	O
coi	O
,	O
or	O
c	O
-	O
one	O
inactivator	O
)	O
has	O
been	O
implicated	O
in	O
the	O
establishment	O
of	O
lytic	O
growth	O
(	O
1	O
,	O
39	O
;	O
B.R.	O
Baumstark	O
,	O
unpublished	O
results	O
)	O
.	O

It	O
has	O
been	O
suggested	O
(	O
2	O
)	O
that	O
the	O
decision	O
to	O
enter	O
lytic	O
or	O
lysogenic	O
growth	O
is	O
influenced	O
by	O
the	O
level	O
of	O
transcription	O
initiated	O
from	O
the	O
distal	O
promoter	O
(	O
which	O
would	O
transcribe	O
coi	O
prior	O
to	O
the	O
transcription	O
of	O
cl	O
)	O
relative	O
to	O
that	O
of	O
the	O
promoter	O
located	O
immediately	O
upstream	O
of	O
the	O
cl	O
gene	O
(	O
which	O
would	O
transcribe	O
only	O
ci	O
)	O
.	O

A	O
32-nucleotide	O
hyphenated	O
inverted	O
repeat	O
sequence	O
is	O
located	O
just	O
upstream	O
of	O
the	O
cl	O
open	O
reading	O
frame	O
(	O
positions	O
146	O
-	O
188	O
;	O
Figure	O
3	O
)	O
.	O

It	O
is	O
not	O
currently	O
known	O
whether	O
this	O
sequence	O
has	O
any	O
regulatory	O
effect	O
on	O
cl	O
expression	O
.	O

Conceivably	O
,	O
the	O
sequence	O
could	O
serve	O
as	O
a	O
recognition	O
site	O
for	O
an	O
as	O
-	O
yet	O
-	O
unidentified	O
regulatory	O
protein	O
.	O

Alternatively	O
,	O
it	O
may	O
affect	O
the	O
secondary	O
structure	O
of	O
the	O
messenger	O
RNA	O
.	O

A	O
transcript	O
extending	O
from	O
a	O
promoter	O
located	O
upstream	O
of	O
the	O
putative	O
coi	O
open	O
reading	O
frame	O
would	O
be	O
capable	O
of	O
forming	O
a	O
stable	O
stem	O
-	O
loop	O
structure	O
containing	O
16	O
bps	O
with	O
a	O
single	O
bp	O
mismatch	O
(	O
AG	O
=	O
-33.6	O
Kcal	O
)	O
of	O
this	O
inverted	O
repeat	O
sequence	O
.	O

Such	O
a	O
structure	O
could	O
potentially	O
serve	O
as	O
a	O
recognition	O
site	O
for	O
a	O
regulatory	O
factor	O
or	O
,	O
alternatively	O
,	O
could	O
mask	O
such	O
a	O
site	O
.	O

On	O
the	O
other	O
hand	O
,	O
transcription	O
originating	O
from	O
the	O
promoter	O
spanning	O
the	O
BamHI	O
site	O
just	O
upstream	O
of	O
cl	O
would	O
start	O
at	O
a	O
site	O
within	O
the	O
inverted	O
repeat	O
sequence	O
,	O
forming	O
a	O
comparatively	O
less	O
stable	O
stem	O
-	O
loop	O
structure	O
of	O
about	O
8	O
bps	O
.	O

The	O
role	O
of	O
the	O
inverted	O
repeat	O
region	O
in	O
the	O
regulation	O
of	O
cl	O
expression	O
is	O
currently	O
under	O
investigation	O
.	O

ACKNOWLEDGEMENTS	O
We	O
thank	O
Heinz	O
Schuster	O
for	O
his	O
review	O
of	O
the	O
manuscript	O
.	O

This	O
work	O
was	O
supported	O
by	O
National	O
Science	O
Foundation	O
grant	O
DMB-8704146	O
.	O

7679	O
Nucleic	O
Acids	O
Research	O
Abbreviations	O
:	O
bp	O
,	O
basepairs	O
;	O
kb	O
,	O
kilobase	O
pairs	O
;	O
X	O
-	O
Gal	O
,	O
5-Bromo-4-Chloro-3-indolylbeta	O
-	O
D	O
-	O
galactopyranoside	O
.	O

*	O
To	O
whom	O
correspondence	O
should	O
be	O
addressed	O
REFERENCES	O
1	O
.	O

Yarmolinsky	O
,	O
M.B.	O
,	O
and	O
Steinberg	O
,	O
N.	O
(	O
1988	O
)	O
.	O

In	O
Calendar	O
,	O
R.	O
,	O
(	O
ed	O
.	O
)	O
,	O
The	O
Bacteriophages	O
,	O
Plenum	O
Publishing	O
Corp.	O
,	O
NY	O
,	O
Vol	O
.	O
1	O
,	O
pp	O
.	O

291	O
-	O
438	O
.	O

2	O
.	O

Baumstark	O
,	O
B.R.	O
,	O
Stovall	O
,	O
S.R.	O
,	O
and	O
Ashkar	O
,	O
S.	O
(	O
1987	O
)	O
.	O

Virology	O
156	O
,	O
404	O
-	O
413	O
.	O

3	O
.	O

Dreiseikelmann	O
,	O
B.	O
,	O
Velleman	O
,	O
M.	O
,	O
and	O
Schuster	O
,	O
H.	O
(	O
1988	O
)	O
.	O

J.	O
Biol	O
.	O

Chem	O
.	O

263	O
,	O
1391	O
-	O
1397	O
.	O

4	O
.	O

Heinrich	O
,	O
J.	O
,	O
Riedel	O
,	O
H	O
.-	O
D.	O
,	O
Baumstark	O
,	O
B.R.	O
,	O
Kimura	O
,	O
M.	O
,	O
and	O
Schuster	O
,	O
H.	O
(	O
1989	O
)	O
.	O

Nucleic	O
Acids	O
Res	O
,	O
this	O
volume	O
.	O

5	O
.	O

Eliason	O
,	O
J.L.	O
,	O
and	O
Stemnberg	O
,	O
N.	O
(	O
1987	O
)	O
.	O

J.	O
Mol	O
.	O

Biol	O
.	O

198	O
,	O
281	O
-	O
293	O
.	O

6	O
.	O

Velleman	O
,	O
M.	O
,	O
Dreiseikelmann	O
,	O
B.	O
,	O
and	O
Schuster	O
,	O
H.	O
(	O
1987	O
)	O
.	O

Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

USA	O
84	O
,	O
5570	O
-	O
5574	O
.	O

7	O
.	O

Citron	O
,	O
M.	O
,	O
Velleman	O
,	O
M.	O
,	O
and	O
Schuster	O
,	O
H.	O
(	O
1988	O
)	O
.	O

J.	O
Biol	O
.	O

Chem	O
.	O

264	O
,	O
3611	O
-	O
3617	O
.	O

8	O
.	O

Chadwick	O
,	O
P.	O
,	O
Pirotta	O
,	O
V.	O
,	O
Steinberg	O
,	O
R.	O
,	O
Hopkins	O
,	O
N.	O
,	O
and	O
Ptashne	O
,	O
M.	O
(	O
1970	O
)	O
.	O

Cold	O
Spring	O
Harbor	O
Symp	O
.	O

Quant	O
.	O

Biol	O
.	O

35	O
,	O
283	O
-	O
294	O
.	O

9	O
.	O

Chesney	O
,	O
R.H.	O
,	O
and	O
Scott	O
,	O
J.R.	O
(	O
1975	O
)	O
.	O

Virology	O
67	O
,	O
375	O
-	O
384	O
.	O

10	O
.	O

Wandersman	O
,	O
C.	O
,	O
and	O
Yarmolinsky	O
,	O
M.	O
(	O
1977	O
)	O
.	O

Virology	O
78	O
,	O
267	O
-	O
276	O
.	O

11	O
.	O

Scott	O
,	O
J.R.	O
,	O
West	O
,	O
B.W.	O
,	O
and	O
Laping	O
,	O
J.L.	O
(	O
1978	O
)	O
.	O

Virology	O
85	O
,	O
587	O
-	O
600	O
.	O
12	O
.	O

Pabo	O
,	O
C.O.	O
,	O
and	O
Sauer	O
,	O
R.	O
A.	O
(	O
1984	O
)	O
.	O

Ann	O
.	O

Rev.	O
Biochem	O
.	O

53	O
,	O
293	O
-	O
321	O
.	O
13	O
.	O

Scott	O
,	O
J.R.	O
(	O
1974	O
)	O
.	O

Virology	O
62	O
,	O
344	O
-	O
349	O
.	O

14	O
.	O

Schneider	O
,	O
K.	O
,	O
and	O
Beck	O
,	O
C.F.	O
(	O
1987	O
)	O
.	O

Methods	O
in	O
Enzymol	O
.	O

153	O
,	O
452	O
-	O
461	O
.	O
15	O
.	O

Smith	O
,	O
H.W.	O
(	O
1972	O
)	O
.	O

Nature	O
New	O
Biol	O
.	O

238	O
,	O
205	O
-	O
206	O
.	O
16	O
.	O

Scott	O
,	O
J.R.	O
(	O
1975	O
)	O
.	O

Virology	O
65	O
,	O
173	O
-	O
178	O
.	O

17	O
.	O

Scott	O
,	O
J.R.	O
,	O
Kropf	O
,	O
M.M.	O
,	O
and	O
Mendelson	O
,	O
L.	O
(	O
1977	O
)	O
.	O

Virology	O
76	O
,	O
39	O
-	O
46	O
.	O
18	O
.	O

Scott	O
,	O
J.R.	O
(	O
1968	O
)	O
.	O

Virology	O
36	O
,	O
564	O
-	O
574	O
.	O

19	O
.	O

Walker	O
,	O
D.H.	O
,	O
Jr.	O
,	O
and	O
Walker	O
,	O
J.T.	O
(	O
1976	O
)	O
.	O

J.	O
Virol	O
.	O

20	O
,	O
177	O
-	O
187	O
.	O
20	O
.	O

Stemnberg	O
,	O
N.	O
(	O
1979	O
)	O
.	O

Virology	O
96	O
,	O
129	O
-	O
142	O
.	O

21	O
.	O

Schneider	O
,	O
K.	O
,	O
and	O
Beck	O
,	O
C.F.	O
(	O
1986	O
)	O
.	O

Gene	O
42	O
,	O
37	O
-	O
48	O
.	O

22	O
.	O

Taylor	O
,	O
D.P.	O
,	O
and	O
Cohen	O
,	O
S.N.	O
(	O
1979	O
)	O
.	O

J.	O
Bacteriol	O
.	O

137	O
,	O
92	O
-	O
104	O
.	O

23	O
.	O

Miller	O
,	O
J.H.	O
(	O
1972	O
)	O
.	O

In	O
Experiments	O
in	O
Molecular	O
Genetics	O
,	O
Cold	O
Spring	O
Harbor	O
Laboratory	O
,	O
Cold	O
Spring	O
Harbor	O
,	O
N.Y.	O
352	O
-	O
355	O
.	O

24	O
.	O

Guyer	O
,	O
R.S.	O
(	O
1978	O
)	O
.	O

J.	O
Mol	O
.	O

Biol	O
.	O

126	O
,	O
347	O
-	O
365	O
.	O

25	O
.	O

Devlin	O
,	O
B.H.	O
,	O
Baumstark	O
,	O
B.R.	O
,	O
and	O
Scott	O
,	O
J.R.	O
(	O
1982	O
)	O
.	O

Virology	O
120	O
,	O
360	O
-	O
375	O
.	O

26	O
.	O

Sanger	O
,	O
F.	O
,	O
Nicklen	O
,	O
S.	O
,	O
and	O
Coulson	O
,	O
A.R.	O
(	O
1977	O
)	O
.	O

Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

USA	O
74	O
,	O
5463	O
-	O
5467	O
.	O
27	O
.	O

DeVries	O
,	O
J.K.	O
,	O
and	O
Zubay	O
,	O
G.	O
(	O
1967	O
)	O
.	O

Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

USA	O
57	O
,	O
1010	O
-	O
1012	O
.	O

28	O
.	O

Heilmann	O
,	O
H.	O
,	O
Reeve	O
,	O
J.R.	O
,	O
and	O
Puhler	O
,	O
A.	O
(	O
1980	O
)	O
.	O

Mol	O
.	O

Gen.	O
Genet	O
.	O

178	O
,	O
149	O
-	O
154	O
.	O
29	O
.	O

Shine	O
,	O
J.	O
,	O
and	O
Dalgarno	O
,	O
L.	O
(	O
1974	O
)	O
.	O

Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

USA	O
71	O
,	O
1342	O
-	O
1346	O
.	O

30	O
.	O

Chou	O
,	O
P.Y.	O
,	O
and	O
Fasman	O
,	O
G.D.	O
(	O
1978	O
)	O
.	O

Adv	O
.	O

Enzymol	O
.	O

47	O
,	O
45	O
-	O
148	O
.	O
31	O
.	O

Berg	O
,	O
J.M.	O
(	O
1986	O
)	O
.	O

Nature	O
319	O
,	O
264	O
-	O
265	O
.	O

32	O
.	O

Landschultz	O
,	O
W.H.	O
,	O
Johnson	O
,	O
P.F.	O
,	O
and	O
McKnight	O
,	O
S.L.	O
(	O
1988	O
)	O
.	O

Science	O
240	O
,	O
1759	O
-	O
1764	O
.	O
33	O
.	O

Murre	O
,	O
C.	O
,	O
McCaw	O
,	O
P.	O
,	O
and	O
Baltimore	O
,	O
D.	O
Cell	O
56	O
,	O
777	O
-	O
783	O
.	O

34	O
.	O

Anderson	O
,	O
B.E.	O
,	O
Baumstark	O
,	O
B.R.	O
,	O
and	O
Bellini	O
,	O
W.J.	O
(	O
1988	O
)	O
.	O

J.	O
Bacteriol	O
.	O

170	O
,	O
4493	O
-	O
4500	O
.	O
35	O
.	O

Rosenberg	O
,	O
M.	O
,	O
and	O
Court	O
,	O
D.	O
(	O
1979	O
)	O
.	O

Annu	O
.	O

Rev.	O
Genet	O
.	O

13	O
,	O
319	O
-	O
353	O
.	O

36	O
.	O

Ebright	O
,	O
R.H.	O
,	O
Cossart	O
,	O
P.	O
,	O
Gicquel	O
-	O
Sanzey	O
,	O
B.	O
,	O
and	O
Beckwith	O
,	O
J.	O
(	O
1984	O
)	O
.	O

Nature	O
311	O
,	O
232	O
-	O
235	O
.	O
37	O
.	O

Ptashne	O
,	O
M.	O
(	O
1986	O
)	O
.	O

Nature	O
322	O
,	O
697	O
-	O
701	O
.	O

38	O
.	O

Stemnberg	O
,	O
N.	O
,	O
and	O
Hoess	O
,	O
R.	O
(	O
1983	O
)	O
.	O

Annu	O
.	O

Rev.	O
Genet	O
.	O

17	O
,	O
123	O
-	O
154	O
.	O
39	O
.	O

Scott	O
,	O
J.R.	O
(	O
1980	O
)	O
.	O

Curr	O
.	O

Top	O
.	O

Microbiol	O
.	O

Immunol	O
.	O

90	O
,	O
49	O
-	O
65	O
.	O

7680	O
This	O
article	O
,	O
submitted	O
on	O
disc	O
,	O
has	O
been	O
automatically	O
converted	O
into	O
this	O
typeset	O
format	O
by	O
the	O
publisher	O
.	O

The	O
Caenorhabditis	B
elegans	I
genome	O
contains	O
monomorphic	O
minisatellites	O
and	O
simple	O
sequences	O
.	O

Abstract	O
Many	O
species	O
have	O
been	O
shown	O
to	O
contain	O
tandemly	O
repeated	O
short	O
sequence	O
DNA	O
known	O
as	O
minisatellites	O
and	O
simple	O
sequence	O
motifs	O
.	O

Due	O
to	O
allelic	O
variation	O
in	O
the	O
copy	O
number	O
of	O
the	O
repeat	O
unit	O
these	O
loci	O
are	O
usually	O
highly	O
polymorphic	O
.	O

Here	O
we	O
demonstrate	O
the	O
presence	O
of	O
sequences	O
in	O
the	O
genome	O
of	O
the	O
nematode	O
Caenorhabditis	B
elegans	I
which	O
are	O
homologous	O
to	O
two	O
sets	O
of	O
short	O
sequence	O
DNA	O
.	O

However	O
,	O
when	O
two	O
independent	O
strains	O
were	O
compared	O
no	O
polymorphism	O
for	O
these	O
sequences	O
could	O
be	O
detected	O
.	O

Images	O
Volume	O
17	O
Number	O
23	O
1989	O
Nucleic	O
Acids	O
Research	O

The	O
Caenorhabds	B
elegans	I
genome	O
contains	O
monomorphic	O
minisatellites	O
and	O
simple	O
sequences	O
Andrd	O
G.Uitterlinden	O
,	O
P.Eline	O
Slagboom	O
,	O
Thomas	O
E.Johnsonl	O
and	O
Jan	O
Vijg	O
Department	O
of	O
Molecular	O
Biology	O
,	O
TNO	O
Institute	O
for	O
Experimental	O
Gerontology	O
,	O
PO	O
Box	O
5815	O
,	O
2280	O
HV	O
Rijswijk	O
,	O
The	O
Netherlands	O
and	O
lInstitute	O
for	O
Behavioral	O
Genetics	O
,	O
University	O
of	O
Colorado	O
,	O
Boulder	O
,	O
CO	O
80309	O
,	O
USA	O
Received	O
October	O
27	O
,	O
1989	O
;	O
Accepted	O
November	O
3	O
,	O
1989	O
ABSTRACT	O
Many	O
species	O
have	O
been	O
shown	O
to	O
contain	O
tandemly	O
repeated	O
short	O
sequence	O
DNA	O
kinown	O
as	O
minisatellites	O
and	O
simple	O
sequence	O
motifs	O
.	O

Due	O
to	O
allelic	O
variation	O
in	O
the	O
copy	O
number	O
of	O
the	O
repeat	O
unit	O
these	O
loci	O
are	O
usually	O
highly	O
polymorphic	O
.	O

Here	O
we	O
demonstrate	O
the	O
presence	O
of	O
sequences	O
in	O
the	O
genome	O
of	O
the	O
nematode	O
Caenorhabditis	B
elegans	I
which	O
are	O
homologous	O
to	O
two	O
sets	O
of	O
short	O
sequence	O
DNA	O
.	O

However	O
,	O
when	O
two	O
independent	O
strains	O
were	O
compared	O
no	O
polymorphism	O
for	O
these	O
sequences	O
could	O
be	O
detected	O
.	O

INTRODUCTION	O
The	O
genome	O
of	O
many	O
species	O
,	O
including	O
lower	O
organisms	O
,	O
contain	O
minisatellite	O
sequences	O
and	O
so	O
-	O
called	O
simple	O
sequence	O
motifs	O
(	O
1,2,3	O
)	O
.	O

Due	O
to	O
extensive	O
variation	O
in	O
the	O
number	O
of	O
repeat	O
units	O
,	O
many	O
of	O
these	O
loci	O
have	O
been	O
shown	O
useful	O
as	O
polymorphic	O
markers	O
,	O
e.g.	O
for	O
genetic	O
linkage	O
studies	O
and	O
identification	O
purposes	O
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
genome	O
of	O
the	O
nematode	O
Caenorhabditis	B
elegans	I
contains	O
sequences	O
that	O
are	O
homologous	O
to	O
the	O
minisatellite	O
core	O
sequence	O
33.6	O
(	O
1	O
)	O
and	O
to	O
the	O
simple	O
sequence	O
motif	O
(	O
AGC	O
)	O
n	O
.	O

Surprisingly	O
,	O
these	O
sequences	O
did	O
not	O
display	O
polymorphism	O
when	O
two	O
independent	O
C.	B
elegans	I
strains	O
,	O
Bristol	O
and	O
Bergerac	O
,	O
were	O
compared	O
.	O

MATERIALS	O
AND	O
METHODS	O
Genomic	O
DNA	O
from	O
nematodes	O
Genomic	O
DNA	O
was	O
isolated	O
according	O
to	O
standard	O
procedures	O
from	O
the	O
two	O
strains	O
Bergerac	O
(	O
BO	O
)	O
and	O
Bristol	O
(	O
strain	O
N2	O
)	O
.	O

These	O
strains	O
are	O
derived	O
from	O
two	O
different	O
individual	O
worms	O
isolated	O
in	O
France	O
and	O
England	O
,	O
respectively	O
.	O

Southern	O
blotting	O
Genomic	O
DNA	O
digests	O
(	O
5	O
Ag	O
)	O
were	O
separated	O
in	O
a	O
1	O
%	O
agarose	O
gel	O
in	O
1	O
x	O
TAE	O
(	O
40	O
mM	O
Tris	O
.	O

HCl	O
,	O
pH	O
7.4	O
/	O
20	O
mM	O
sodium	O
acetate	O
/	O
I	O
mM	O
NaEDTA	O
)	O
by	O
electrophoresis	O
at	O
75	O
V	O
for	O
16	O
h.	O
Separation	O
patterns	O
were	O
transferred	O
to	O
Zetaprobe	O
membrane	O
(	O
BIORAD	O
)	O
in	O
0.4	O
N	O
NaOH	O
,	O
0.6	O
M	O
NaCl	O
in	O
a	O
vacu	O
-	O
blot	O
apparatus	O
(	O
LKB	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
.	O

The	O
minisatellite	O
and	O
simple	O
sequence	O
probes	O
used	O
were	O
prepared	O
essentially	O
as	O
described	O
(	O
5	O
)	O
.	O

The	O
Tcl	O
probe	O
is	O
a	O
plasmid	O
containing	O
an	O
insert	O
of	O
the	O
transposable	O
element	O
Tcl	O
(	O
4	O
)	O
.	O

All	O
probes	O
were	O
labelled	O
by	O
random	O
-	O
priming	O
.	O

Hybridization	O
was	O
performed	O
for	O
12	O
h	O
in	O
7	O
%	O
SDS	O
,	O
0.5	O
M	O
phosphate	O
buffer	O
,	O
1	O
mM	O
Na2EDTA	O
at	O
650C	O
.	O

Blots	O
were	O
washed	O
twice	O
in	O
2.5	O
x	O
SSC	O
at	O
650C	O
and	O
exposed	O
to	O
Kodak	O
XAR-5	O
film	O
with	O
intensifying	O
screens	O
.	O

Exposure	O
times	O
are	O
indicated	O
in	O
Fig.	O
1	O
.	O

(	O
IRL	O
Press	O
Nucleic	O
Acids	O
Research	O
Volume	O
17	O
Number	O
23	O
1989	O
9527	O
Nucleic	O
Acids	O
Research	O
C.	B
elegans	I
N	O
0	O
$	O
8	O
_	O
_	O
:	O
,	O
s	O
,	O
..	O

e	O
:	O
*	O
.	O
,	O
~	O
:	O
:	O
:	O
:	O
:	O
.	O

4i	O
.t	O
_	O
:	O
-::?J	O
?	O
.	O

:	O
i-	O

.a	O

E	O
?	O
:	O
<	O
.	O

:	O
:	O
y	O
:	O
*	O
01	O
4?j	O
*	O
.-I	O
kb	O
-	O
27	O
-	O
9A	O
-	O
:	O
.	O
:	O
:	O
.......	O

Mi	O
....	O
-	O
4v3	O
IC	O
.3	O
If.0r	O
MW	O
!	O

5	O
c6	O
I	O
""""	O
R	O
1d~	O
!	O

;	O
,	O
Figure	O
1	O
.	O

Southern	O
hybridization	O
analysis	O
of	O
Hae	O
III	O
,	O
Rsa	O
I	O
and	O
Eco	O
RI	O
digested	O
genomic	O
DNA	O
isolated	O
from	O
the	O
two	O
C.	B
elegans	I
strains	O
Bristol	O
(	O
N	O
)	O
and	O
Bergerac	O
(	O
B	O
)	O
.	O

The	O
probes	O
used	O
and	O
the	O
exposure	O
times	O
of	O
the	O
autoradiograph	O
are	O
indicated	O
below	O
the	O
figure	O
.	O

kb	O
=	O
kilo	O
basepairs	O
.	O

9528	O

*	O
:	O
..	O
?	O

.;.	O

.*.	O

i	O
...	O
:	O
""""	O
.	O

ANN	O
&	O
'	O
ROW	O
:	O
.	O

lwmwww	O
.	O

.Ammkw.l	O

4w	O
,	O
9	O
_	O
i	O
ob	O
Ill	O
a	O
Nucleic	O
Acids	O
Research	O
RESULTS	O
In	O
Figure	O
1	O
the	O
hybridization	O
patterns	O
are	O
shown	O
of	O
C.	B
elegans	I
genomic	O
DNA	O
digested	O
with	O
Hae	O
II	O
,	O
Rsa	O
I	O
and	O
Eco	O
RI	O
,	O
and	O
subsequently	O
hybridized	O
to	O
minisatellite	O
core	O
probe	O
33.6	O
,	O
the	O
simple	O
sequence	O
probe	O
(	O
AGC	O
)	O
n	O
and	O
Tcl	O
.	O

The	O
latter	O
probe	O
contains	O
a	O
member	O
of	O
the	O
Tcl	O
family	O
of	O
transposable	O
elements	O
which	O
is	O
present	O
in	O
different	O
copy	O
numbers	O
in	O
the	O
two	O
different	O
strains	O
(	O
4	O
)	O
.	O

The	O
hybridization	O
patterns	O
of	O
probes	O
33.6	O
and	O
(	O
AGC	O
)	O
n	O
obtained	O
after	O
Hae	O
I	O
m	O
and	O
Rsa	O
I	O
digestion	O
and	O
the	O
differences	O
in	O
intensities	O
of	O
the	O
hybridizing	O
bands	O
is	O
reminiscent	O
of	O
DNA	O
-	O
fingerprint	O
patterns	O
obtained	O
with	O
these	O
probes	O
in	O
other	O
species	O
(	O
1,2,3	O
)	O
.	O

However	O
,	O
identical	O
hybridization	O
patterns	O
for	O
the	O
two	O
strains	O
with	O
the	O
three	O
enzymes	O
tested	O
indicated	O
that	O
in	O
C.	B
elegans	I
these	O
sequences	O
are	O
monomorphic	O
(	O
Fig.	O
1	O
)	O
.	O

Based	O
on	O
the	O
number	O
of	O
hybridizing	O
bands	O
we	O
estimate	O
the	O
C.	B
elegans	I
genome	O
to	O
contain	O
about	O
30	O
33.6	O
homologous	O
loci	O
and	O
about	O
20	O
(	O
AGC	O
)	O
n	O
homologous	O
loci	O
.	O

Rehybridization	O
of	O
the	O
same	O
blot	O
with	O
a	O
Tcl	O
probe	O
revealed	O
extensive	O
RFLPs	O
due	O
to	O
the	O
different	O
copy	O
number	O
of	O
the	O
transposon	O
in	O
the	O
two	O
strains	O
,	O
a	O
phenomenon	O
which	O
has	O
been	O
described	O
previously	O
by	O
others	O
(	O
4	O
)	O
.	O

DISCUSSION	O
The	O
findings	O
presented	O
in	O
this	O
paper	O
indicate	O
that	O
polymorphism	O
of	O
minisatellite	O
sequences	O
and	O
simple	O
sequence	O
motifs	O
,	O
is	O
not	O
a	O
general	O
phenomenon	O
in	O
animal	O
species	O
.	O

So	O
far	O
,	O
only	O
some	O
species	O
of	O
whales	O
have	O
displayed	O
similar	O
high	O
levels	O
of	O
monomorphism	O
(	O
6	O
)	O
.	O

In	O
other	O
species	O
thus	O
far	O
tested	O
both	O
minisatellites	O
and	O
simple	O
sequences	O
display	O
high	O
to	O
very	O
high	O
levels	O
of	O
polymorphism	O
.	O

It	O
should	O
be	O
noted	O
,	O
however	O
,	O
that	O
at	O
least	O
in	O
humans	B
,	O
a	O
substantial	O
part	O
of	O
the	O
minisatellites	O
detected	O
by	O
core	O
probes	O
also	O
displays	O
high	O
levels	O
of	O
monomorphism	O
as	O
analysed	O
by	O
cloning	O
(	O
1	O
)	O
or	O
by	O
two	O
-	O
dimensional	O
DNA	O
fingerprinting	O
(	O
5	O
)	O
.	O

The	O
fact	O
that	O
nematodes	O
are	O
hermaphrodites	O
,	O
and	O
thus	O
inbred	O
,	O
might	O
be	O
a	O
contributing	O
factor	O
to	O
the	O
observed	O
lack	O
of	O
polymorphism	O
.	O

However	O
,	O
the	O
high	O
levels	O
of	O
polymorphism	O
detected	O
by	O
the	O
Tcl	O
probe	O
do	O
not	O
indicate	O
a	O
general	O
absence	O
of	O
events	O
causing	O
genetic	O
variation	O
.	O

Indeed	O
,	O
Eide	O
and	O
Anderson	O
(	O
7	O
)	O
showed	O
that	O
tandemly	O
repeated	O
duplications	O
in	O
the	O
unc-54	O
gene	O
of	O
C.	B
elegans	I
revert	O
at	O
high	O
frequencies	O
.	O

Since	O
in	O
all	O
cases	O
the	O
revertants	O
had	O
the	O
normal	O
genomic	O
configuration	O
this	O
suggests	O
that	O
unequal	O
crossing	O
-	O
over	O
does	O
occur	O
in	O
the	O
nematode	O
.	O

A	O
more	O
likely	O
explanation	O
for	O
the	O
monomorphic	O
nature	O
of	O
the	O
sequences	O
detected	O
with	O
33.6	O
and	O
(	O
AGC	O
)	O
n	O
in	O
C.	B
elegans	I
is	O
selection	O
against	O
sequence	O
variants	O
at	O
these	O
loci	O
.	O

This	O
might	O
be	O
the	O
result	O
of	O
the	O
presence	O
of	O
a	O
particular	O
subset	O
of	O
minisatellites	O
and/or	O
simple	O
sequences	O
at	O
sites	O
in	O
the	O
genome	O
of	O
this	O
organism	O
,	O
e.g.	O
in	O
coding	O
sequences	O
,	O
in	O
which	O
variation	O
in	O
copy	O
number	O
of	O
repeat	O
units	O
can	O
not	O
be	O
tolerated	O
.	O

An	O
example	O
of	O
such	O
a	O
coding	O
sequence	O
could	O
be	O
the	O
High	O
Mobility	O
Group	O
proteins	O
which	O
usually	O
have	O
stretches	O
of	O
identical	O
(	O
acidic	O
)	O
amino	O
acids	O
(	O
2,8	O
)	O
.	O

An	O
interesting	O
observation	O
in	O
this	O
respect	O
is	O
the	O
demonstration	O
of	O
the	O
absence	O
of	O
any	O
protein	O
polymorphisms	O
in	O
electrophoretic	O
comparisons	O
for	O
24	O
different	O
enzymes	O
between	O
the	O
Bristol	O
and	O
Bergerac	O
strains	O
(	O
9	O
)	O
.	O

An	O
important	O
step	O
in	O
understanding	O
this	O
phenomenon	O
will	O
therefore	O
be	O
the	O
isolation	O
and	O
analysis	O
of	O
individual	O
homologous	O
minisatellite	O
and	O
simple	O
sequence	O
loci	O
from	O
a	O
genomic	O
library	O
of	O
C.	B
elegans	I
.	O

REFERENCES	O
1	O
.	O

Jeffreys	O
,	O
A.J.	O
,	O
Wilson	O
,	O
V.	O
,	O
and	O
Thein	O
,	O
S.L.	O
(	O
1985	O
)	O
Nature	O
314	O
,	O
67	O
-	O
73	O
.	O

2	O
.	O

Tautz	O
,	O
D.	O
,	O
Trick	O
M.	O
,	O
and	O
Dover	O
,	O
G.A.	O
(	O
1986	O
)	O
Nature	O
322	O
,	O
652	O
-	O
656	O
.	O

3	O
.	O

Rogstad	O
,	O
S.H.	O
,	O
Herwaldt	O
,	O
B.L.	O
,	O
Schlesinger	O
,	O
P.H.	O
,	O
and	O
Krogstad	O
,	O
D.J.	O
(	O
1989	O
)	O

Nucleic	O
Acids	O
Res	O
.	O

17	O
,	O
9	O
,	O
3610	O
.	O

4	O
.	O

Emmons	O
,	O
S.W.	O
,	O
Yesner	O
,	O
L.	O
,	O
Ruan	O
,	O
K.	O
and	O
Katzenberg	O
,	O
D.	O
(	O
1983	O
)	O
Cell	O
32	O
,	O
55	O
-	O
65	O
.	O

9529	O
Nucleic	O
Acids	O
Research	O
5	O
.	O

Uitterlinden	O
,	O
A.G.	O
,	O
Slagboom	O
,	O
P.E.	O
,	O
Knook	O
,	O
D.L.	O
,	O
and	O
Vijg	O
,	O
J.	O
(	O
1989	O
)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

USA	O
86	O
,	O
2742	O
-	O
2746	O
.	O

6	O
.	O

Rus	O
Hoelzel	O
,	O
A.	O
,	O
and	O
Amos	O
,	O
W.	O
(	O
1988	O
)	O
Nature	O
333	O
,	O
305	O
.	O
7	O
.	O

Eide	O
,	O
D.	O
,	O
and	O
Anderson	O
,	O
P.	O
(	O
1985	O
)	O
Genetics	O
109	O
,	O
67	O
-	O
79	O
.	O

8	O
.	O

Pentecost	O
,	O
B.T.	O
,	O
Wright	O
,	O
J.M.	O
,	O
and	O
Dixon	O
,	O
G.H.	O
(	O
1985	O
)	O
Nucleic	O
Acids	O
Res	O
.	O

13	O
,	O
4871	O
-	O
4888	O
.	O

9	O
.	O

Butler	O
et	O
al.	O
(	O
1981	O
)	O
J.	O
Molec	O
.	O

Evolution	O
18	O
,	O
18	O
-	O
23	O
.	O

9530	O
This	O
article	O
,	O
submitted	O
on	O
disc	O
,	O
has	O
been	O
automatically	O
converted	O
into	O
this	O
typeset	O
format	O
by	O
the	O
publisher	O
.	O

SledgeHMMER	O
:	O
a	O
web	O
server	O
for	O
batch	O
searching	O
the	O
Pfam	O
database	O
Abstract	O
The	O
SledgeHMMER	O
web	O
server	O
is	O
intended	O
for	O
genome	O
-	O
scale	O
searching	O
of	O
the	O
Pfam	O
database	O
without	O
having	O
to	O
install	O
this	O
database	O
and	O
the	O
HMMER	O
software	O
locally	O
.	O

The	O
server	O
implements	O
a	O
parallelized	O
version	O
of	O
hmmpfam	O
,	O
the	O
program	O
used	O
for	O
searching	O
the	O
Pfam	O
HMM	O
database	O
.	O

Pfam	O
search	O
results	O
have	O
been	O
calculated	O
for	O
the	O
entire	O
Swiss	O
-	O
Prot	O
and	O
TrEmbl	O
database	O
sequences	O
(	O
∼1.2	O
million	O
)	O
on	O
256	O
processors	O
of	O
IA64-based	O
teragrid	O
machines	O
.	O

The	O
Pfam	O
database	O
can	O
be	O
searched	O
in	O
local	O
,	O
glocal	O
or	O
merged	O
mode	O
,	O
using	O
either	O
gathering	O
or	O
E	O
-	O
value	O
thresholds	O
.	O

Query	O
sequences	O
are	O
first	O
matched	O
against	O
the	O
pre	O
-	O
calculated	O
entries	O
to	O
retrieve	O
results	O
,	O
and	O
those	O
without	O
matches	O
are	O
processed	O
through	O
a	O
new	O
search	O
process	O
.	O

Results	O
are	O
emailed	O
in	O
a	O
space	O
-	O
delimited	O
tabular	O
format	O
upon	O
completion	O
of	O
the	O
search	O
.	O

While	O
most	O
other	O
Pfam	O
-	O
searching	O
web	O
servers	O
set	O
a	O
limit	O
of	O
one	O
sequence	O
per	O
query	O
,	O
this	O
server	O
processes	O
batch	O
sequences	O
with	O
no	O
limit	O
on	O
the	O
number	O
of	O
input	O
sequences	O
.	O

The	O
web	O
server	O
and	O
downloadable	O
data	O
are	O
accessible	O
from	O
http://SledgeHmmer.sdsc.edu	O
.	O

INTRODUCTION	O
Searching	O
for	O
conserved	O
domains	O
has	O
become	O
an	O
integral	O
part	O
of	O
several	O
bioinformatics	O
data	O
analysis	O
pipelines	O
.	O

The	O
Pfam	O
protein	O
families	O
database	O
[	O
(	O
1	O
)	O
;	O
http://pfam.wustl.edu	O
]	O
contains	O
the	O
single	O
largest	O
public	O
collection	O
of	O
conserved	O
functional	O
domains	O
and	O
hence	O
is	O
integrated	O
into	O
many	O
bioinformatics	O
resources	O
.	O

The	O
current	O
version	O
(	O
release	O
12	O
)	O
of	O
the	O
Pfam	O
-	O
A	O
database	O
contains	O
7316	O
HMM	O
domains	O
,	O
making	O
it	O
an	O
indispensable	O
resource	O
for	O
protein	O
functional	O
annotation	O
(	O
2	O
)	O
.	O

However	O
,	O
the	O
size	O
of	O
the	O
Pfam	O
database	O
is	O
quite	O
large	O
(	O
∼600	O
MB	O
)	O
and	O
genome	O
-	O
scale	O
searching	O
of	O
protein	O
sequences	O
against	O
this	O
database	O
is	O
a	O
highly	O
compute	O
-	O
intensive	O
task	O
.	O

Hence	O
,	O
with	O
the	O
exception	O
of	O
the	O
Sanger	O
Center	O
web	O
server	O
(	O
http://www.sanger.ac.uk/Software/Pfam	O
)	O
,	O
all	O
other	O
Pfam	O
-	O
searching	O
servers	O
permit	O
submission	O
of	O
only	O
one	O
protein	O
sequence	O
at	O
a	O
time	O
(	O
http://pfam.wustl.edu	O
,	O
http://pfam.jouy.inra.fr	O
,	O
http://pfam.cgb.ki.se	O
)	O
.	O

Currently	O
,	O
the	O
Sanger	O
Center	O
web	O
server	O
limits	O
batch	O
submission	O
to	O
1000	O
sequences	O
at	O
a	O
time	O
.	O

Other	O
than	O
this	O
,	O
for	O
batch	O
searching	O
,	O
users	O
are	O
required	O
to	O
install	O
the	O
Pfam	O
database	O
and	O
the	O
HMMER	O
software	O
[	O
(	O
3	O
)	O
;	O
http://hmmer.wustl.edu	O
)	O
locally	O
.	O

Given	O
the	O
size	O
and	O
dynamic	O
nature	O
of	O
this	O
database	O
(	O
14	O
updates	O
in	O
the	O
last	O
two	O
years	O
)	O
,	O
it	O
is	O
not	O
convenient	O
to	O
maintain	O
the	O
latest	O
versions	O
of	O
these	O
tools	O
locally	O
.	O

Moreover	O
,	O
the	O
hmmpfam	O
program	O
used	O
for	O
searching	O
the	O
Pfam	O
database	O
is	O
very	O
slow	O
and	O
memory	O
intensive	O
(	O
on	O
Solaris	O
machines	O
,	O
the	O
processing	O
speed	O
is	O
about	O
10	O
sequences	O
per	O
1	O
h	O
of	O
CPU	O
time	O
)	O
,	O
making	O
this	O
process	O
a	O
bottleneck	O
in	O
several	O
data	O
analysis	O
pipelines	O
.	O

Web	O
servers	O
that	O
enable	O
batch	O
searching	O
of	O
the	O
Pfam	O
database	O
are	O
extremely	O
beneficial	O
to	O
the	O
user	O
community	O
,	O
especially	O
to	O
those	O
without	O
local	O
access	O
to	O
high	O
-	O
end	O
computational	O
power	O
,	O
memory	O
and	O
disk	O
space	O
.	O

To	O
this	O
end	O
we	O
have	O
developed	O
a	O
parallelized	O
version	O
,	O
as	O
well	O
as	O
an	O
optimized	O
single	O
-	O
processor	O
version	O
,	O
of	O
hmmpfam	O
from	O
release	O
2.3.2	O
of	O
the	O
HMMER	O
software	O
,	O
as	O
described	O
in	O
the	O
next	O
section	O
.	O

Using	O
these	O
programs	O
,	O
we	O
present	O
the	O
SledgeHMMER	O
web	O
server	O
(	O
http://SledgeHmmer.sdsc.edu	O
)	O
,	O
which	O
is	O
capable	O
of	O
batch	O
searching	O
a	O
large	O
number	O
of	O
protein	O
sequences	O
concurrently	O
.	O

DESIGN	O
AND	O
IMPLEMENTATION	O
The	O
current	O
web	O
service	O
is	O
mainly	O
intended	O
for	O
genome	O
-	O
scale	O
searching	O
of	O
the	O
Pfam	O
-	O
A	O
database	O
.	O

Searches	O
are	O
possible	O
for	O
different	O
Pfam	O
-	O
searching	O
modes	O
such	O
as	O
local	O
,	O
glocal	O
and	O
merged	O
,	O
using	O
either	O
gathering	O
or	O
E	O
-	O
value	O
thresholds	O
.	O

To	O
expedite	O
the	O
response	O
time	O
,	O
we	O
developed	O
a	O
database	O
containing	O
pre	O
-	O
calculated	O
Pfam	O
search	O
results	O
.	O

Query	O
sequences	O
are	O
matched	O
against	O
the	O
pre	O
-	O
calculated	O
entries	O
using	O
hexadecimal	O
hashing	O
methods	O
from	O
the	O
MD5	O
Perl	O
module	O
,	O
and	O
those	O
without	O
matches	O
are	O
separated	O
out	O
.	O

Results	O
for	O
matching	O
sequences	O
are	O
retrieved	O
from	O
the	O
pre	O
-	O
calculated	O
database	O
while	O
,	O
for	O
other	O
sequences	O
,	O
a	O
new	O
search	O
process	O
is	O
initiated	O
using	O
our	O
improved	O
hmmpfam	O
program	O
.	O

Results	O
are	O
emailed	O
in	O
a	O
space	O
-	O
delimited	O
tabular	O
format	O
upon	O
completion	O
of	O
the	O
search	O
.	O

Parallelizing	O
the	O
hmmpfam	O
algorithm	O
Computing	O
batch	O
searches	O
against	O
the	O
Pfam	O
database	O
is	O
a	O
two	O
-	O
dimensional	O
(	O
2D	O
)	O
problem	O
,	O
i.e.	O
searching	O
N	O
query	O
sequences	O
against	O
M	O
Pfam	O
HMMs	O
.	O

Thus	O
,	O
this	O
problem	O
can	O
be	O
parallelized	O
across	O
any	O
dimension	O
or	O
across	O
both	O
dimensions	O
.	O

A	O
minor	O
disadvantage	O
of	O
parallelizing	O
across	O
the	O
M	O
dimension	O
is	O
that	O
a	O
global	O
gather	O
needs	O
to	O
be	O
performed	O
at	O
the	O
end	O
of	O
the	O
computation	O
to	O
identify	O
the	O
best	O
matched	O
HMM	O
models	O
.	O

Along	O
the	O
N	O
dimension	O
the	O
computation	O
is	O
completely	O
independent	O
,	O
however	O
;	O
due	O
to	O
the	O
variation	O
in	O
the	O
query	O
sequence	O
lengths	O
,	O
the	O
traditional	O
message	O
passing	O
interface	O
(	O
MPI	O
)	O
technique	O
of	O
splitting	O
the	O
file	O
into	O
equal	O
numbers	O
of	O
sequences	O
may	O
result	O
in	O
load	O
imbalance	O
.	O

Hence	O
,	O
the	O
best	O
way	O
to	O
parallelize	O
code	O
along	O
the	O
N	O
dimension	O
is	O
to	O
stripmine	O
the	O
query	O
sequences	O
as	O
the	O
processors	O
finish	O
working	O
on	O
their	O
previous	O
ones	O
.	O

This	O
can	O
be	O
achieved	O
using	O
an	O
MPI	O
technique	O
in	O
which	O
one	O
processor	O
reads	O
the	O
query	O
sequence	O
file	O
and	O
sends	O
the	O
sequences	O
to	O
all	O
others	O
.	O

Here	O
,	O
we	O
have	O
parallelized	O
the	O
HMMER	O
code	O
along	O
the	O
N	O
dimension	O
(	O
query	O
sequences	O
)	O
using	O
a	O
Unix	O
-	O
based	O
file	O
-	O
locking	O
technique	O
.	O

This	O
implementation	O
requires	O
all	O
the	O
processors	O
,	O
nodes	O
and	O
computers	O
working	O
on	O
a	O
single	O
problem	O
to	O
have	O
access	O
to	O
a	O
file	O
system	O
that	O
honors	O
Unix	O
file	O
locking	O
.	O

So	O
far	O
,	O
we	O
have	O
tested	O
the	O
implementation	O
on	O
AIX	O
,	O
Linux	O
,	O
NFS	O
and	O
GPFS	O
file	O
systems	O
and	O
found	O
our	O
program	O
to	O
work	O
correctly	O
.	O

The	O
advantages	O
of	O
parallelizing	O
with	O
file	O
locking	O
are	O
that	O
(	O
i	O
)	O
new	O
processes	O
can	O
join	O
or	O
leave	O
the	O
process	O
pool	O
in	O
the	O
middle	O
of	O
computing	O
;	O
(	O
ii	O
)	O
almost	O
perfect	O
load	O
balancing	O
can	O
be	O
achieved	O
;	O
(	O
iii	O
)	O
processors	O
with	O
different	O
clock	O
speeds	O
running	O
different	O
operating	O
systems	O
can	O
be	O
part	O
of	O
the	O
same	O
pool	O
;	O
and	O
(	O
iv	O
)	O
systems	O
do	O
not	O
need	O
to	O
have	O
MPI	O
or	O
parallel	O
virtual	O
machine	O
(	O
PVM	O
)	O
installed	O
.	O

Since	O
the	O
parallelized	O
subroutines	O
are	O
written	O
in	O
a	O
separate	O
file	O
as	O
function	O
calls	O
,	O
very	O
little	O
change	O
is	O
needed	O
to	O
the	O
original	O
HMMER	O
code	O
.	O

These	O
parallel	O
routines	O
are	O
generic	O
and	O
,	O
hence	O
,	O
can	O
be	O
used	O
to	O
parallelize	O
other	O
programs	O
with	O
similar	O
computational	O
requirements	O
,	O
such	O
as	O
the	O
BLAST	O
suite	O
of	O
programs	O
.	O

A	O
brief	O
description	O
of	O
the	O
parallel	O
function	O
calls	O
is	O
provided	O
below	O
.	O

All	O
the	O
processes	O
joining	O
the	O
work	O
pool	O
will	O
call	O
The	O
first	O
process	O
that	O
calls	O
this	O
subroutine	O
will	O
create	O
the	O
lockFile	O
and	O
write	O
the	O
starting	O
index	O
.	O

This	O
is	O
the	O
index	O
from	O
which	O
sequence	O
stripmining	O
happens	O
.	O

The	O
rest	O
of	O
the	O
processes	O
open	O
the	O
file	O
stream	O
to	O
the	O
lockFile	O
.	O

Then	O
,	O
inside	O
the	O
main	O
work	O
loop	O
,	O
every	O
process	O
calls	O
resulting	O
in	O
every	O
process	O
getting	O
a	O
unique	O
next	O
available	O
job	O
(	O
index	O
)	O
.	O

Each	O
process	O
computes	O
the	O
homology	O
search	O
for	O
the	O
sequence	O
index	O
matching	O
the	O
unique	O
index	O
obtained	O
.	O

These	O
steps	O
are	O
iterated	O
until	O
no	O
more	O
sequences	O
are	O
left	O
in	O
the	O
query	O
sequence	O
file	O
.	O

Outside	O
the	O
work	O
loop	O
at	O
the	O
end	O
,	O
all	O
the	O
processes	O
call	O
which	O
will	O
close	O
the	O
lockFile	O
.	O

The	O
user	O
has	O
to	O
ensure	O
a	O
unique	O
lockFile	O
for	O
each	O
new	O
query	O
sequence	O
file	O
.	O

If	O
for	O
some	O
reason	O
the	O
work	O
pool	O
is	O
stopped	O
in	O
the	O
middle	O
of	O
a	O
query	O
sequence	O
file	O
,	O
it	O
can	O
continue	O
from	O
the	O
same	O
point	O
by	O
using	O
the	O
same	O
lockFile	O
.	O

In	O
this	O
version	O
of	O
the	O
hmmpfam	O
program	O
,	O
all	O
processes	O
write	O
search	O
results	O
to	O
a	O
single	O
output	O
file	O
.	O

To	O
minimize	O
synchronization	O
overheads	O
,	O
each	O
process	O
writes	O
the	O
output	O
into	O
a	O
temporary	O
buffer	O
and	O
writes	O
once	O
per	O
sequence	O
into	O
the	O
output	O
file	O
.	O

For	O
the	O
sake	O
of	O
convenience	O
,	O
additional	O
synchronization	O
routines	O
are	O
provided	O
for	O
locking	O
and	O
unlocking	O
.	O

This	O
parallel	O
algorithm	O
has	O
been	O
tested	O
on	O
several	O
platforms	O
and	O
file	O
systems	O
including	O
Intel	O
IA32	O
,	O
IA64	O
Linux	O
platforms	O
,	O
power3	O
and	O
power4-based	O
AIX	O
platforms	O
and	O
Sparc4-based	O
Solaris	O
platforms	O
.	O

The	O
code	O
was	O
run	O
on	O
800	O
processors	O
of	O
power4-based	O
datastar	O
machines	O
and	O
256	O
processors	O
of	O
IA64-based	O
teragrid	O
machines	O
located	O
at	O
the	O
San	O
Diego	O
Supercomputer	O
Center	O
(	O
SDSC	O
)	O
to	O
test	O
scalability	O
issues	O
.	O

Single	O
-	O
processor	O
optimization	O
of	O
hmmpfam	O
Initially	O
,	O
we	O
utilized	O
version	O
2.2	O
g	O
of	O
HMMER	O
.	O

Performance	O
analysis	O
revealed	O
that	O
the	O
main	O
computational	O
kernel	O
was	O
accessing	O
the	O
2D	O
arrays	O
with	O
a	O
wrong	O
stride	O
.	O

Correcting	O
this	O
resulted	O
in	O
doubling	O
of	O
the	O
performance	O
;	O
however	O
,	O
the	O
HMMER	O
developer	O
has	O
rectified	O
this	O
issue	O
in	O
release	O
2.3.2	O
.	O

In	O
addition	O
,	O
HMMER	O
reads	O
the	O
database	O
file	O
from	O
disk	O
for	O
every	O
sequence	O
it	O
searches	O
.	O

This	O
is	O
extremely	O
inefficient	O
for	O
batch	O
searches	O
.	O

We	O
have	O
corrected	O
this	O
by	O
reading	O
the	O
whole	O
database	O
into	O
memory	O
once	O
and	O
conducting	O
searches	O
from	O
memory	O
.	O

Performance	O
testing	O
We	O
compared	O
our	O
improved	O
IA64	O
single	O
-	O
processor	O
hmmpfam	O
with	O
the	O
equivalent	O
program	O
from	O
the	O
original	O
HMMER	O
2.3.2	O
release	O
on	O
an	O
Itanium	O
II	O
IA64	O
processor	O
(	O
Figure	O
1	O
)	O
.	O

As	O
expected	O
,	O
the	O
per	O
sequence	O
CPU	O
time	O
for	O
our	O
program	O
is	O
reduced	O
up	O
to	O
10-fold	O
in	O
batch	O
searches	O
,	O
while	O
in	O
the	O
case	O
of	O
the	O
original	O
2.3.2	O
release	O
,	O
it	O
is	O
linear	O
to	O
the	O
number	O
of	O
sequences	O
.	O

Performance	O
difference	O
in	O
single	O
-	O
sequence	O
processing	O
could	O
be	O
attributed	O
to	O
compilation	O
differences	O
.	O

Performance	O
differences	O
resulting	O
in	O
the	O
slope	O
difference	O
of	O
the	O
two	O
plots	O
may	O
be	O
due	O
to	O
the	O
elimination	O
of	O
the	O
need	O
to	O
reload	O
the	O
Pfam	O
database	O
from	O
disk	O
for	O
every	O
sequence	O
in	O
our	O
case	O
.	O

Processing	O
data	O
from	O
disk	O
can	O
be	O
an	O
order	O
of	O
magnitude	O
slower	O
than	O
processing	O
in	O
memory	O
.	O

Scaling	O
tests	O
were	O
conducted	O
on	O
a	O
128-node	O
Itanium	O
II	O
IA64	O
cluster	O
.	O

We	O
used	O
a	O
fixed	O
set	O
of	O
500	O
sequences	O
as	O
the	O
test	O
set	O
and	O
ran	O
on	O
1–32	O
processors	O
.	O

As	O
expected	O
,	O
the	O
time	O
required	O
to	O
process	O
a	O
given	O
set	O
of	O
sequences	O
reduces	O
linearly	O
with	O
the	O
number	O
of	O
processors	O
(	O
data	O
not	O
shown	O
)	O
.	O

This	O
also	O
indicates	O
that	O
the	O
parallelization	O
overheads	O
using	O
our	O
method	O
are	O
minimal	O
.	O

However	O
,	O
as	O
the	O
ratio	O
of	O
the	O
number	O
of	O
sequences	O
to	O
the	O
number	O
of	O
processors	O
reduces	O
to	O
one	O
,	O
load	O
imbalances	O
due	O
to	O
the	O
processing	O
time	O
differences	O
between	O
different	O
sequences	O
start	O
to	O
dominate	O
,	O
reducing	O
parallel	O
efficiency	O
.	O

Pre	O
-	O
calculated	O
results	O
We	O
have	O
generated	O
pre	O
-	O
calculated	O
Pfam	O
search	O
results	O
for	O
the	O
entire	O
Swiss	O
-	O
Prot	O
and	O
TrEmbl	O
protein	O
sequences	O
(	O
∼1.2	O
million	O
)	O
,	O
using	O
our	O
parallelized	O
'	O
hmmpfam	O
'	O
on	O
256	O
processors	O
of	O
IA64-based	O
teragrid	O
machines	O
located	O
at	O
the	O
SDSC	O
.	O

Pfam	O
searches	O
have	O
been	O
performed	O
separately	O
,	O
using	O
either	O
gathering	O
thresholds	O
or	O
E	O
-	O
value	O
cutoffs	O
against	O
glocal	O
(	O
Pfam_ls	O
)	O
or	O
local	O
(	O
Pfam_fs	O
)	O
alignment	O
models	O
.	O

Glocal	O
and	O
local	O
search	O
results	O
were	O
parsed	O
and	O
merged	O
by	O
removing	O
all	O
local	O
search	O
hits	O
that	O
are	O
completely	O
overlapped	O
by	O
glocal	O
search	O
hits	O
.	O

Input	O
and	O
output	O
formats	O
The	O
program	O
takes	O
only	O
FASTA	O
-	O
formatted	O
sequences	O
as	O
input	O
and	O
searches	O
can	O
be	O
done	O
in	O
any	O
search	O
mode	O
,	O
i.e.	O
local	O
,	O
glocal	O
or	O
merged	O
.	O

The	O
maximum	O
E	O
-	O
value	O
allowed	O
for	O
searches	O
is	O
10	O
.	O

SledgeHMMER	O
results	O
are	O
emailed	O
to	O
the	O
user	O
in	O
a	O
space	O
-	O
delimited	O
,	O
one	O
hit	O
per	O
line	O
tabular	O
format	O
(	O
Figure	O
2	O
)	O
.	O

The	O
response	O
time	O
for	O
receiving	O
results	O
depends	O
on	O
the	O
number	O
of	O
query	O
sequences	O
and	O
the	O
fraction	O
of	O
these	O
existing	O
in	O
the	O
pre	O
-	O
calculated	O
entries	O
.	O

DISCUSSION	O
The	O
SledgeHMMER	O
server	O
provides	O
a	O
unique	O
service	O
to	O
the	O
scientific	O
community	O
wishing	O
to	O
batch	O
search	O
the	O
Pfam	O
database	O
on	O
the	O
web	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
only	O
such	O
server	O
that	O
has	O
no	O
limit	O
on	O
the	O
number	O
of	O
input	O
sequences	O
.	O

The	O
current	O
pre	O
-	O
calculated	O
database	O
covers	O
∼70	O
%	O
of	O
the	O
available	O
non	O
-	O
redundant	O
protein	O
sequence	O
space	O
,	O
and	O
we	O
plan	O
to	O
add	O
additional	O
new	O
sequences	O
from	O
other	O
resources	O
such	O
as	O
the	O
NR	O
database	O
from	O
GenBank	O
and	O
SEQRES	O
from	O
the	O
PDB	O
(	O
Protein	O
Data	O
Bank	O
)	O
in	O
the	O
future	O
.	O

Our	O
pre	O
-	O
calculated	O
database	O
is	O
updated	O
for	O
every	O
new	O
release	O
of	O
the	O
Pfam	O
database	O
or	O
SPTr	O
databases	O
(	O
Swiss	O
-	O
Prot	O
+	O
TrEMBL	O
)	O
in	O
order	O
to	O
provide	O
access	O
to	O
the	O
most	O
current	O
data	O
.	O

Single	O
-	O
processor	O
optimized	O
hmmpfam	O
binaries	O
and	O
the	O
source	O
code	O
can	O
be	O
downloaded	O
from	O
the	O
current	O
web	O
server	O
.	O

In	O
the	O
future	O
,	O
we	O
intend	O
to	O
make	O
such	O
binaries	O
available	O
for	O
many	O
additional	O
operating	O
systems	O
and	O
propagate	O
these	O
modifications	O
to	O
other	O
HMMER	O
programs	O
as	O
well	O
.	O

How	O
can	O
Health	O
Behavior	O
Theory	O
be	O
made	O
more	O
useful	O
for	O
intervention	O
research	O
?	O

Abstract	O
Background	O
The	O
present	O
paper	O
expresses	O
the	O
author	O
's	O
views	O
about	O
the	O
practical	O
utility	O
of	O
Health	O
Behavior	O
Theory	O
for	O
health	O
behavior	O
intervention	O
research	O
.	O

The	O
views	O
are	O
skeptical	O
and	O
perhaps	O
even	O
a	O
bit	O
exaggerated	O
.	O

They	O
are	O
,	O
however	O
,	O
also	O
based	O
on	O
20-plus	O
years	O
of	O
in	O
-	O
the	O
-	O
trenches	O
research	O
focused	O
on	O
improving	O
health	O
behavior	O
practice	O
through	O
research	O
.	O

Discussion	O
The	O
author	O
's	O
research	O
has	O
been	O
theoretically	O
driven	O
and	O
has	O
involved	O
measurement	O
of	O
varying	O
variables	O
considered	O
to	O
be	O
important	O
theoretical	O
mediators	O
and	O
moderators	O
of	O
health	O
behavior	O
.	O

Regretfully	O
,	O
much	O
of	O
this	O
work	O
has	O
found	O
these	O
variables	O
wanting	O
in	O
basic	O
scientific	O
merit	O
.	O

Health	O
Behavior	O
Theory	O
as	O
we	O
have	O
known	O
it	O
over	O
the	O
last	O
25	O
years	O
or	O
so	O
has	O
been	O
dominated	O
by	O
conceptualizations	O
of	O
behavior	O
change	O
processes	O
that	O
highlight	O
cognitive	O
decision	O
-	O
making	O
.	O

Although	O
much	O
of	O
health	O
behavior	O
practice	O
targets	O
what	O
people	O
do	O
rather	O
than	O
what	O
they	O
think	O
,	O
the	O
logic	O
of	O
focusing	O
on	O
thoughts	O
is	O
that	O
what	O
people	O
think	O
about	O
is	O
the	O
key	O
to	O
what	O
they	O
will	O
do	O
in	O
the	O
future	O
,	O
and	O
that	O
interventions	O
that	O
can	O
measure	O
and	O
harness	O
those	O
processes	O
will	O
succeed	O
to	O
a	O
greater	O
extent	O
than	O
those	O
that	O
do	O
not	O
.	O

Unfortunately	O
,	O
in	O
the	O
author	O
's	O
experience	O
,	O
the	O
premise	O
of	O
cognitive	O
theories	O
has	O
fallen	O
short	O
empirically	O
in	O
a	O
number	O
of	O
ways	O
.	O

The	O
cognitive	O
schemata	O
favored	O
by	O
most	O
health	O
behavior	O
theories	O
are	O
difficult	O
to	O
measure	O
,	O
they	O
do	O
not	O
predict	O
behavioral	O
outcomes	O
very	O
well	O
,	O
there	O
is	O
little	O
evidence	O
that	O
they	O
cause	O
behavior	O
,	O
and	O
they	O
are	O
hard	O
to	O
change	O
directly	O
.	O

Summary	O
It	O
is	O
suggested	O
that	O
health	O
behavior	O
researchers	O
reconsider	O
their	O
use	O
of	O
these	O
theories	O
in	O
favor	O
of	O
models	O
whose	O
variables	O
are	O
more	O
accessible	O
to	O
observation	O
and	O
experimental	O
manipulation	O
and	O
that	O
most	O
importantly	O
have	O
strong	O
empirical	O
support	O
.	O

Background	O
The	O
author	O
has	O
been	O
conducting	O
research	O
on	O
behavioral	O
treatment	O
of	O
obesity	O
for	O
about	O
25	O
years	O
.	O

During	O
that	O
time	O
,	O
the	O
dominant	O
conceptual	O
models	O
guiding	O
intervention	O
development	O
have	O
been	O
cognitive	O
behavior	O
models	O
that	O
have	O
their	O
origin	O
in	O
psychological	O
theory	O
.	O

Those	O
most	O
often	O
cited	O
include	O
the	O
Health	O
Belief	O
Model	O
[	O
1	O
]	O
,	O
Protection	O
Motivation	O
Theory	O
[	O
2	O
]	O
,	O
Subjective	O
Expected	O
Utility	O
Theory	O
[	O
3	O
]	O
,	O
the	O
Theory	O
of	O
Reasoned	O
Action	O
[	O
4	O
]	O
,	O
Social	O
Cognitive	O
Theory	O
[	O
5	O
]	O
,	O
and	O
the	O
Transtheoretical	O
Model	O
[	O
6	O
]	O
.	O

All	O
of	O
these	O
theories	O
are	O
concerned	O
with	O
how	O
people	O
make	O
behavioral	O
choices	O
and	O
the	O
general	O
idea	O
is	O
that	O
people	O
decide	O
what	O
to	O
do	O
based	O
on	O
the	O
extent	O
to	O
which	O
they	O
expect	O
that	O
their	O
choices	O
will	O
produce	O
results	O
that	O
they	O
value	O
.	O

Much	O
of	O
the	O
content	O
of	O
the	O
theories	O
is	O
concerned	O
with	O
factors	O
that	O
may	O
affect	O
value	O
/	O
expectancy	O
calculations	O
.	O

As	O
summarized	O
by	O
Weinstein	O
in	O
a	O
comparative	O
review	O
of	O
four	O
social	O
psychological	O
theories	O
[	O
7	O
]	O
,	O
variables	O
thought	O
to	O
influence	O
value	O
/	O
expectancy	O
judgments	O
include	O
such	O
factors	O
as	O
perceived	O
rewards	O
of	O
current	O
behavior	O
,	O
self	O
-	O
efficacy	O
,	O
normative	O
beliefs	O
,	O
motivation	O
,	O
and	O
the	O
perceived	O
consequences	O
of	O
not	O
changing	O
behavior	O
.	O

Weinstein	O
's	O
summary	O
is	O
illustrative	O
of	O
the	O
fact	O
that	O
Health	O
Behavior	O
Theory	O
has	O
tended	O
to	O
be	O
particularly	O
interested	O
in	O
understanding	O
people	O
's	O
motivation	O
to	O
change	O
behavior	O
rather	O
than	O
ability	O
to	O
change	O
.	O

Moreover	O
,	O
motivation	O
is	O
thought	O
to	O
be	O
the	O
result	O
of	O
a	O
relatively	O
complex	O
,	O
but	O
logical	O
,	O
interpretation	O
of	O
large	O
quantities	O
of	O
information	O
about	O
self	O
and	O
environment	O
.	O

The	O
theories	O
that	O
Weinstein	O
reviewed	O
deal	O
almost	O
exclusively	O
with	O
behavioral	O
decision	O
processes	O
in	O
people	O
's	O
minds	O
.	O

They	O
have	O
few	O
if	O
any	O
terms	O
relating	O
to	O
how	O
information	O
gets	O
into	O
peoples	O
minds	O
or	O
how	O
subsets	O
of	O
it	O
receive	O
more	O
or	O
less	O
attention	O
.	O

Broader	O
health	O
behavior	O
theories	O
such	O
as	O
Social	O
Cognitive	O
Theory	O
or	O
the	O
Transtheoretical	O
model	O
have	O
addressed	O
issues	O
and	O
variables	O
outside	O
the	O
person	O
to	O
a	O
greater	O
extent	O
,	O
but	O
the	O
fundamental	O
interest	O
in	O
and	O
belief	O
in	O
psychological	O
variables	O
as	O
the	O
key	O
force	O
in	O
determining	O
health	O
behavior	O
remains	O
.	O

The	O
implications	O
of	O
the	O
focus	O
of	O
health	O
behavior	O
theory	O
on	O
psychological	O
determinants	O
of	O
behavioral	O
decision	O
-	O
making	O
for	O
my	O
own	O
research	O
area	O
of	O
interest	O
,	O
obesity	O
treatment	O
,	O
are	O
several	O
.	O

One	O
is	O
the	O
inclusion	O
of	O
measures	O
of	O
psychological	O
characteristics	O
in	O
most	O
research	O
protocols	O
(	O
e.g.	O
,	O
assessment	O
of	O
behavioral	O
intentions	O
,	O
self	O
-	O
efficacy	O
,	O
perception	O
of	O
barriers	O
to	O
change	O
,	O
perception	O
of	O
social	O
support	O
,	O
and	O
outcome	O
expectations	O
)	O
.	O

A	O
second	O
is	O
the	O
inclusion	O
of	O
treatment	O
elements	O
that	O
specifically	O
target	O
psychological	O
perceptions	O
and	O
processes	O
independent	O
of	O
the	O
diet	O
and	O
physical	O
activity	O
behaviors	O
that	O
actually	O
produce	O
weight	O
change	O
(	O
e.g.	O
,	O
how	O
to	O
deal	O
with	O
emotional	O
eating	O
,	O
how	O
to	O
deal	O
with	O
the	O
frustration	O
of	O
lapses	O
and	O
relapses	O
,	O
and	O
how	O
to	O
talk	O
to	O
yourself	O
to	O
increase	O
self	O
-	O
motivation	O
)	O
.	O

A	O
third	O
is	O
the	O
belief	O
that	O
psychological	O
reactions	O
to	O
treatment	O
experiences	O
themselves	O
are	O
very	O
important	O
and	O
deserve	O
independent	O
attention	O
.	O

Common	O
behavioral	O
prescriptions	O
for	O
weight	O
-	O
loss	O
goals	O
and	O
frequency	O
of	O
self	O
-	O
weighing	O
are	O
exemplary	O
(	O
i.e.	O
,	O
recommending	O
infrequent	O
weighing	O
to	O
prevent	O
discouraging	O
feedback	O
about	O
progress	O
and	O
encouraging	O
smaller	O
and	O
thus	O
""""	O
more	O
attainable	O
""""	O
behavior	O
and	O
weight	O
-	O
loss	O
goals	O
in	O
the	O
belief	O
that	O
they	O
will	O
be	O
more	O
motivating	O
)	O
.	O

The	O
problem	O
with	O
the	O
emphasis	O
on	O
cognitive	O
variables	O
in	O
weight	O
-	O
control	O
research	O
is	O
that	O
they	O
have	O
so	O
far	O
failed	O
to	O
meet	O
fundamental	O
scientific	O
criteria	O
for	O
empirical	O
verification	O
.	O

Thus	O
,	O
they	O
also	O
have	O
not	O
led	O
to	O
a	O
better	O
understanding	O
of	O
the	O
weight	O
-	O
loss	O
process	O
,	O
have	O
not	O
improved	O
our	O
ability	O
to	O
predict	O
weight	O
-	O
loss	O
outcomes	O
,	O
and	O
have	O
not	O
led	O
to	O
improvement	O
in	O
treatment	O
methods	O
.	O

In	O
some	O
cases	O
it	O
is	O
even	O
arguable	O
that	O
they	O
have	O
made	O
treatment	O
worse	O
.	O

I	O
will	O
illustrate	O
these	O
problems	O
with	O
results	O
from	O
my	O
own	O
research	O
.	O

Discussion	O
Like	O
most	O
behavioral	O
researchers	O
in	O
the	O
obesity	O
area	O
,	O
I	O
have	O
attempted	O
to	O
measure	O
elements	O
of	O
health	O
behavior	O
theory	O
in	O
every	O
obesity	O
intervention	O
project	O
I	O
have	O
ever	O
conducted	O
.	O

I	O
have	O
assessed	O
weight	O
-	O
loss	O
goals	O
,	O
behavioral	O
and	O
weight	O
-	O
loss	O
self	O
-	O
efficacy	O
,	O
psychological	O
well	O
-	O
being	O
,	O
perceived	O
barriers	O
to	O
diet	O
and	O
physical	O
activity	O
change	O
,	O
stages	O
-	O
of	O
-	O
change	O
,	O
and	O
perceived	O
social	O
support	O
.	O

How	O
well	O
have	O
empirical	O
examinations	O
of	O
these	O
factors	O
fared	O
as	O
predictors	O
of	O
success	O
in	O
weight	O
control	O
?	O

Self	O
-	O
efficacy	O
We	O
have	O
examined	O
the	O
predictive	O
value	O
of	O
self	O
-	O
efficacy	O
assessments	O
in	O
several	O
of	O
our	O
studies	O
and	O
describe	O
the	O
results	O
from	O
three	O
of	O
these	O
here	O
in	O
more	O
detail	O
[	O
8	O
-	O
10	O
]	O
.	O

In	O
the	O
first	O
study	O
,	O
self	O
-	O
efficacy	O
was	O
assessed	O
at	O
baseline	O
,	O
posttreatment	O
,	O
and	O
one	O
year	O
later	O
in	O
85	O
men	O
participating	O
in	O
a	O
15-week	O
weight	O
-	O
loss	O
program	O
[	O
8	O
]	O
.	O

The	O
self	O
-	O
efficacy	O
instrument	O
had	O
subscales	O
for	O
emotional	O
states	O
(	O
e.g.	O
,	O
anxiety	O
)	O
and	O
situations	O
(	O
e.g.	O
,	O
eating	O
away	O
from	O
home	O
)	O
.	O

Higher	O
baseline	O
self	O
-	O
efficacy	O
on	O
both	O
subscales	O
was	O
associated	O
with	O
greater	O
weight	O
loss	O
in	O
treatment	O
and	O
at	O
1-	O
and	O
2-year	O
follow	O
-	O
up	O
.	O

Emotional	O
self	O
-	O
efficacy	O
at	O
posttreatment	O
did	O
not	O
predict	O
weight	O
loss	O
at	O
1-	O
or	O
2-year	O
follow	O
-	O
up	O
.	O

Situational	O
self	O
-	O
efficacy	O
at	O
posttreatment	O
predicted	O
weight	O
loss	O
at	O
1-year	O
but	O
not	O
2-year	O
follow	O
-	O
up	O
.	O

The	O
second	O
study	O
examined	O
mood	O
and	O
situational	O
self	O
-	O
efficacy	O
in	O
55	O
men	O
and	O
58	O
women	O
before	O
and	O
after	O
a	O
16-week	O
weight	O
-	O
loss	O
treatment	O
with	O
a	O
1-year	O
follow	O
-	O
up	O
[	O
9	O
]	O
.	O

Women	O
had	O
lower	O
pretreatment	O
self	O
-	O
efficacy	O
than	O
men	O
.	O

Self	O
-	O
efficacy	O
was	O
predictive	O
of	O
weight	O
loss	O
and	O
maintenance	O
in	O
men	O
but	O
not	O
in	O
women	O
.	O

Change	O
in	O
self	O
-	O
efficacy	O
over	O
time	O
was	O
positively	O
related	O
to	O
weight	O
change	O
in	O
women	O
but	O
not	O
in	O
men	O
.	O

The	O
third	O
study	O
examined	O
predictors	O
of	O
weight	O
change	O
over	O
a	O
2-year	O
period	O
in	O
460	O
men	O
and	O
1172	O
women	O
who	O
received	O
a	O
low	O
-	O
intensity	O
weight	O
-	O
loss	O
intervention	O
delivered	O
through	O
their	O
HMO	O
[	O
10	O
]	O
.	O

The	O
self	O
-	O
efficacy	O
measure	O
was	O
the	O
WEL	O
questionnaire	O
.	O

Men	O
again	O
were	O
found	O
to	O
have	O
higher	O
baseline	O
self	O
-	O
efficacy	O
than	O
women	O
.	O

Self	O
-	O
efficacy	O
did	O
not	O
predict	O
weight	O
change	O
in	O
men	O
but	O
was	O
positively	O
,	O
though	O
weakly	O
,	O
related	O
to	O
weight	O
change	O
at	O
6	O
months	O
only	O
in	O
women	O
.	O

Our	O
overall	O
conclusion	O
from	O
the	O
analyses	O
described	O
above	O
,	O
as	O
well	O
as	O
others	O
not	O
pursued	O
in	O
as	O
great	O
detail	O
,	O
is	O
that	O
self	O
-	O
efficacy	O
is	O
a	O
weak	O
predictor	O
of	O
weight	O
loss	O
and	O
is	O
inconsistent	O
across	O
study	O
populations	O
and	O
gender	O
.	O

It	O
tends	O
to	O
increase	O
with	O
weight	O
loss	O
.	O

However	O
,	O
treatment	O
-	O
induced	O
increases	O
in	O
efficacy	O
are	O
not	O
predictive	O
of	O
longer	O
-	O
term	O
weight	O
-	O
loss	O
success	O
.	O

Barriers	O
to	O
Adherence	O
We	O
have	O
also	O
attempted	O
to	O
measure	O
barriers	O
to	O
adherence	O
to	O
weight	O
-	O
control	O
behaviors	O
in	O
many	O
of	O
our	O
studies	O
[	O
11	O
-	O
14	O
]	O
.	O

The	O
instruments	O
used	O
for	O
this	O
have	O
typically	O
been	O
formatted	O
similarly	O
to	O
efficacy	O
questionnaires	O
in	O
that	O
people	O
are	O
asked	O
to	O
indicate	O
how	O
difficult	O
they	O
find	O
situational	O
,	O
knowledge	O
,	O
and	O
motivational	O
challenges	O
to	O
achieving	O
diet	O
and	O
exercise	O
changes	O
.	O

The	O
findings	O
in	O
these	O
studies	O
have	O
been	O
quite	O
consistent	O
.	O

Baseline	O
assessments	O
of	O
perceived	O
barriers	O
to	O
behavior	O
change	O
are	O
not	O
predictive	O
of	O
weight	O
change	O
.	O

Weight	O
loss	O
is	O
associated	O
with	O
reported	O
decreases	O
in	O
perceived	O
barriers	O
.	O

Treatment	O
-	O
induced	O
change	O
in	O
perceived	O
barriers	O
are	O
not	O
predictive	O
of	O
future	O
weight	O
change	O
.	O

In	O
other	O
words	O
,	O
barrier	O
perceptions	O
as	O
we	O
have	O
measured	O
them	O
do	O
not	O
appear	O
to	O
have	O
pragmatic	O
significance	O
.	O

Weight	O
Goals	O
Goal	O
-	O
setting	O
has	O
long	O
been	O
of	O
interest	O
to	O
health	O
behavior	O
theory	O
and	O
in	O
recent	O
years	O
has	O
attracted	O
attention	O
in	O
weight	O
-	O
loss	O
research	O
when	O
it	O
was	O
realized	O
that	O
most	O
people	O
who	O
enter	O
weight	O
-	O
loss	O
treatments	O
want	O
to	O
lose	O
a	O
lot	O
more	O
weight	O
than	O
is	O
realistic	O
given	O
the	O
potency	O
of	O
current	O
weight	O
-	O
loss	O
methodologies	O
[	O
15	O
]	O
.	O

When	O
asked	O
to	O
describe	O
weight	O
losses	O
they	O
deem	O
to	O
represent	O
""""	O
dream	O
,	O
happy	O
,	O
acceptable	O
,	O
and	O
disappointing	O
,	O
""""	O
many	O
individuals	O
in	O
treatment	O
fail	O
to	O
reach	O
even	O
""""	O
disappointing	O
""""	O
weight	O
losses	O
even	O
though	O
in	O
objective	O
medical	O
terms	O
the	O
results	O
are	O
positive	O
.	O

Based	O
on	O
the	O
argument	O
that	O
failure	O
to	O
reach	O
gratifying	O
weight	O
-	O
loss	O
goals	O
leads	O
to	O
psychological	O
distress	O
that	O
lowers	O
weight	O
self	O
-	O
efficacy	O
and	O
undermines	O
weight	O
-	O
loss	O
efforts	O
,	O
it	O
has	O
become	O
popular	O
to	O
recommend	O
counseling	O
in	O
weight	O
-	O
loss	O
treatments	O
specifically	O
targeting	O
the	O
lowering	O
of	O
weight	O
-	O
loss	O
goals	O
.	O

The	O
theoretical	O
argument	O
is	O
that	O
excessive	O
outcome	O
expectations	O
undermine	O
behavioral	O
efforts	O
.	O

We	O
have	O
now	O
completed	O
three	O
sets	O
of	O
formal	O
analyses	O
examining	O
whether	O
weight	O
goals	O
are	O
predictive	O
of	O
weight	O
-	O
loss	O
success	O
.	O

In	O
one	O
of	O
these	O
analyses	O
the	O
relationship	O
between	O
weight	O
-	O
loss	O
goals	O
,	O
weight	O
-	O
loss	O
goal	O
attainment	O
,	O
and	O
long	O
-	O
term	O
(	O
30	O
months	O
)	O
weight	O
-	O
loss	O
attainment	O
and	O
psychological	O
well	O
-	O
being	O
were	O
assessed	O
in	O
69	O
men	O
and	O
61	O
women	O
participating	O
in	O
an	O
intensive	O
behavioral	O
treatment	O
program	O
[	O
16	O
]	O
.	O

Results	O
indicated	O
that	O
weight	O
-	O
loss	O
goals	O
were	O
unrealistically	O
high	O
on	O
average	O
and	O
that	O
lower	O
goals	O
were	O
more	O
likely	O
to	O
be	O
reached	O
.	O

Nevertheless	O
,	O
weight	O
-	O
loss	O
goals	O
did	O
not	O
predict	O
either	O
short-	O
or	O
long	O
-	O
term	O
weight	O
losses	O
and	O
were	O
not	O
associated	O
with	O
elevated	O
psychological	O
distress	O
.	O

Two	O
more	O
recent	O
analyses	O
we	O
have	O
conducted	O
looking	O
at	O
weight	O
-	O
loss	O
goals	O
as	O
predictors	O
of	O
success	O
have	O
produced	O
similar	O
results	O
[	O
Linde	O
JA	O
,	O
Jeffery	O
RW	O
,	O
Levy	O
RL	O
,	O
Pronk	O
NP	O
and	O
Boyle	O
RG	O
,	O
unpublished	O
data	O
[	O
17	O
]	O
]	O
.	O

Weight	O
-	O
loss	O
goals	O
either	O
did	O
not	O
predict	O
weight	O
loss	O
at	O
all	O
or	O
were	O
slightly	O
positively	O
related	O
to	O
weight	O
-	O
loss	O
success	O
.	O

Perceived	O
Social	O
Support	O
Perceived	O
social	O
support	O
is	O
another	O
psychological	O
factor	O
thought	O
to	O
influence	O
health	O
behavior	O
decision	O
-	O
making	O
.	O

We	O
have	O
measured	O
social	O
support	O
in	O
a	O
variety	O
of	O
ways	O
in	O
our	O
studies	O
,	O
ranging	O
from	O
single	O
-	O
item	O
questions	O
to	O
multipaged	O
assessments	O
attempting	O
to	O
differentiate	O
among	O
informational	O
,	O
instrumental	O
,	O
and	O
emotional	O
support	O
.	O

The	O
results	O
,	O
unfortunately	O
,	O
have	O
closely	O
paralleled	O
those	O
we	O
have	O
seen	O
with	O
other	O
assessments	O
of	O
barriers	O
to	O
adherence	O
.	O

Assessments	O
of	O
social	O
support	O
prior	O
to	O
treatment	O
do	O
not	O
predict	O
weight	O
loss	O
.	O

Average	O
reports	O
of	O
social	O
support	O
tend	O
to	O
parallel	O
weight	O
loss	O
itself	O
.	O

When	O
people	O
lose	O
weight	O
they	O
report	O
more	O
social	O
support	O
.	O

When	O
they	O
regain	O
,	O
they	O
report	O
less	O
.	O

In	O
other	O
words	O
,	O
perceptions	O
of	O
social	O
support	O
are	O
not	O
predictive	O
of	O
success	O
in	O
weight	O
-	O
loss	O
treatments	O
.	O

Frequency	O
Weight	O
Self	O
-	O
monitoring	O
Self	O
-	O
monitoring	O
of	O
health	O
behavior	O
is	O
incorporated	O
into	O
many	O
health	O
behavior	O
theories	O
,	O
usually	O
as	O
part	O
of	O
a	O
person	O
's	O
assessment	O
of	O
achieved	O
outcomes	O
.	O

Although	O
self	O
-	O
monitoring	O
is	O
usually	O
considered	O
a	O
positive	O
element	O
in	O
the	O
adoption	O
of	O
health	O
behavior	O
,	O
in	O
obesity	O
treatment	O
frequent	O
self	O
-	O
monitoring	O
of	O
weight	O
has	O
tended	O
to	O
be	O
down	O
-	O
played	O
or	O
even	O
discouraged	O
on	O
the	O
grounds	O
that	O
disappointing	O
results	O
(	O
i.e.	O
,	O
less	O
than	O
desired	O
weight	O
change	O
)	O
may	O
undermine	O
motivation	O
.	O

This	O
is	O
another	O
example	O
in	O
which	O
health	O
behavior	O
theory	O
may	O
have	O
indirectly	O
led	O
to	O
incorrect	O
treatment	O
recommendations	O
.	O

In	O
weight	O
-	O
loss	O
treatments	O
,	O
active	O
discouragement	O
of	O
frequent	O
self	O
-	O
observation	O
of	O
weight	O
has	O
become	O
popular	O
based	O
on	O
the	O
premise	O
that	O
more	O
frequent	O
weighting	O
will	O
cause	O
psychological	O
stress	O
and	O
lower	O
self	O
-	O
efficacy	O
.	O

Recently	O
,	O
we	O
have	O
examined	O
the	O
relationship	O
between	O
frequency	O
of	O
self	O
-	O
weighing	O
and	O
body	O
weight	O
in	O
both	O
clinical	O
and	O
population	O
samples	O
and	O
have	O
found	O
,	O
somewhat	O
to	O
our	O
surprise	O
,	O
that	O
frequency	O
of	O
self	O
-	O
weighing	O
is	O
one	O
of	O
the	O
strongest	O
single	O
predictors	O
of	O
body	O
weight	O
cross	O
-	O
sectionally	O
,	O
and	O
change	O
in	O
the	O
frequency	O
of	O
self	O
-	O
weighing	O
is	O
one	O
of	O
the	O
strongest	O
predictors	O
of	O
weight	O
change	O
[	O
Linde	O
JA	O
,	O
Jeffery	O
RW	O
and	O
French	O
SA	O
,	O
unpublished	O
data	O
]	O
.	O

The	O
direction	O
of	O
predictions	O
,	O
however	O
,	O
is	O
opposite	O
that	O
derived	O
from	O
theory	O
.	O

People	O
who	O
weigh	O
themselves	O
more	O
weigh	O
less	O
and	O
are	O
more	O
successful	O
in	O
losing	O
weight	O
.	O

Stage	O
-	O
of	O
-	O
Change	O
A	O
final	O
failure	O
of	O
current	O
health	O
behavior	O
theory	O
to	O
prove	O
useful	O
in	O
weight	O
-	O
control	O
research	O
is	O
a	O
recent	O
examination	O
of	O
the	O
relationship	O
between	O
a	O
stage	O
-	O
of	O
-	O
change	O
measure	O
adopted	O
from	O
Prochaska	O
and	O
short-	O
and	O
long	O
-	O
term	O
weight	O
loss	O
[	O
18	O
]	O
.	O

Categories	O
of	O
precontemplation	O
,	O
contemplation	O
,	O
preparation	O
,	O
and	O
action	O
were	O
defined	O
based	O
on	O
questions	O
about	O
weight	O
-	O
loss	O
intentions	O
and	O
recent	O
weight	O
-	O
loss	O
attempts	O
.	O

Despite	O
a	O
large	O
sample	O
size	O
,	O
excellent	O
follow	O
-	O
up	O
rates	O
,	O
and	O
well	O
-	O
measured	O
objective	O
outcomes	O
,	O
we	O
were	O
unable	O
to	O
demonstrate	O
that	O
staging	O
algorithms	O
recommended	O
by	O
proponents	O
of	O
the	O
Transtheoretical	O
Model	O
could	O
predict	O
weight	O
-	O
loss	O
outcomes	O
.	O

Experimental	O
Modification	O
of	O
Expectations	O
Our	O
most	O
recent	O
effort	O
to	O
utilize	O
health	O
behavior	O
theory	O
in	O
obesity	O
intervention	O
research	O
is	O
a	O
study	O
that	O
attempted	O
to	O
examine	O
the	O
effectiveness	O
of	O
experimentally	O
-	O
induced	O
outcome	O
expectancies	O
on	O
weight	O
loss	O
[	O
Finch	O
EA	O
,	O
Linde	O
JA	O
,	O
Jeffery	O
RW	O
,	O
Rothman	O
AJ	O
and	O
King	O
CM	O
,	O
unpublished	O
data	O
]	O
.	O

Obese	O
men	O
and	O
women	O
participated	O
in	O
an	O
8-week	O
weight	O
-	O
loss	O
program	O
with	O
18-month	O
follow	O
-	O
up	O
in	O
which	O
they	O
were	O
assigned	O
to	O
one	O
of	O
two	O
expectancy	O
groups	O
.	O

The	O
optimistic	O
group	O
was	O
told	O
that	O
focusing	O
exclusively	O
on	O
the	O
positive	O
benefits	O
of	O
weight	O
loss	O
would	O
be	O
valuable	O
in	O
ensuring	O
that	O
they	O
remained	O
motivated	O
in	O
their	O
weight	O
-	O
loss	O
efforts	O
and	O
was	O
given	O
assignments	O
during	O
weekly	O
group	O
sessions	O
and	O
homework	O
between	O
sessions	O
to	O
reinforce	O
this	O
optimistic	O
mindset	O
.	O

A	O
""""	O
balanced	O
""""	O
expectancy	O
group	O
received	O
the	O
instructions	O
that	O
focusing	O
on	O
both	O
the	O
positive	O
and	O
negative	O
aspects	O
of	O
weight	O
loss	O
,	O
a	O
balanced	O
approach	O
,	O
would	O
be	O
most	O
conducive	O
to	O
maintaining	O
weight	O
-	O
loss	O
motivation	O
.	O

This	O
group	O
also	O
received	O
assignments	O
to	O
reinforce	O
their	O
message	O
.	O

Results	O
of	O
this	O
study	O
indicated	O
that	O
the	O
expectation	O
induction	O
was	O
successful	O
initially	O
but	O
difficult	O
to	O
maintain	O
in	O
the	O
face	O
of	O
real	O
weight	O
-	O
loss	O
experience	O
.	O

We	O
were	O
also	O
unable	O
to	O
show	O
that	O
experimentally	O
-	O
induced	O
expectations	O
influenced	O
weight	O
-	O
loss	O
success	O
.	O

Summary	O
and	O
Conclusion	O
To	O
summarize	O
the	O
findings	O
described	O
above	O
,	O
I	O
have	O
had	O
considerable	O
difficulty	O
over	O
the	O
last	O
25	O
years	O
in	O
confirming	O
that	O
the	O
psychosocial	O
variables	O
favored	O
by	O
health	O
behavior	O
theory	O
are	O
of	O
much	O
value	O
for	O
obesity	O
intervention	O
research	O
.	O

They	O
do	O
not	O
predict	O
weight	O
loss	O
well	O
,	O
either	O
as	O
mediators	O
or	O
moderators	O
.	O

There	O
is	O
little	O
evidence	O
to	O
support	O
the	O
idea	O
that	O
targeting	O
them	O
for	O
intervention	O
improves	O
weight	O
-	O
loss	O
outcomes	O
.	O

It	O
is	O
,	O
of	O
course	O
,	O
arguable	O
that	O
the	O
weak	O
findings	O
relating	O
to	O
health	O
behavior	O
theory	O
variables	O
are	O
due	O
in	O
large	O
part	O
to	O
methodological	O
weaknesses	O
,	O
either	O
in	O
measurement	O
tools	O
and/or	O
their	O
frequency	O
of	O
measurement	O
.	O

I	O
would	O
argue	O
,	O
however	O
,	O
that	O
25	O
years	O
is	O
long	O
enough	O
to	O
wait	O
for	O
improved	O
methods	O
and	O
that	O
it	O
is	O
time	O
to	O
look	O
elsewhere	O
for	O
variables	O
that	O
better	O
predict	O
weight	O
-	O
change	O
outcomes	O
and	O
that	O
,	O
therefore	O
,	O
may	O
form	O
a	O
better	O
basis	O
for	O
improving	O
future	O
treatments	O
.	O

Implication	O
for	O
Weight	O
-	O
Loss	O
Treatment	O
Given	O
the	O
lack	O
of	O
success	O
finding	O
support	O
for	O
cognitive	O
mediators	O
of	O
behavior	O
change	O
in	O
weight	O
loss	O
,	O
one	O
might	O
surmise	O
that	O
progress	O
in	O
improving	O
weight	O
-	O
loss	O
interventions	O
over	O
the	O
last	O
20	O
years	O
must	O
have	O
been	O
dreary	O
indeed	O
.	O

Somewhat	O
surprisingly	O
,	O
however	O
,	O
that	O
is	O
not	O
the	O
case	O
.	O

In	O
fact	O
,	O
the	O
short	O
-	O
term	O
(	O
6	O
to	O
12	O
months	O
)	O
success	O
of	O
weight	O
-	O
loss	O
treatments	O
has	O
approximately	O
doubled	O
over	O
that	O
time	O
and	O
several	O
variables	O
have	O
been	O
identified	O
that	O
reliably	O
enhance	O
treatment	O
outcomes	O
.	O

It	O
has	O
been	O
clearly	O
shown	O
experimentally	O
that	O
increasing	O
treatment	O
length	O
[	O
19	O
]	O
,	O
prescribing	O
low	O
-	O
energy	O
intakes	O
[	O
20	O
]	O
,	O
prescribing	O
high	O
-	O
energy	O
expenditure	O
[	O
21	O
]	O
,	O
using	O
a	O
deposit	O
contract	O
and	O
group	O
-	O
based	O
reward	O
systems	O
[	O
22	O
]	O
,	O
and	O
simplifying	O
adherence	O
to	O
diet	O
through	O
meal	O
substitutes	O
[	O
23	O
]	O
and	O
exercise	O
by	O
providing	O
exercise	O
equipment	O
[	O
24	O
]	O
all	O
improve	O
initial	O
weight	O
loss	O
.	O

From	O
a	O
theoretical	O
perspective	O
,	O
however	O
,	O
one	O
thing	O
is	O
noteworthy	O
about	O
these	O
successful	O
innovations	O
.	O

Although	O
not	O
incompatible	O
with	O
health	O
behavior	O
theory	O
,	O
none	O
of	O
them	O
are	O
specifically	O
derived	O
from	O
cognitive	O
decision	O
-	O
making	O
models	O
.	O

Indeed	O
,	O
health	O
behavior	O
theory	O
does	O
not	O
include	O
variables	O
like	O
these	O
in	O
its	O
models	O
.	O

Where	O
Do	O
We	O
Go	O
From	O
Here	O
?	O

The	O
argument	O
above	O
about	O
the	O
practical	O
limitations	O
of	O
many	O
popular	O
theories	O
of	O
health	O
behavior	O
is	O
not	O
meant	O
to	O
be	O
a	O
call	O
to	O
abandon	O
theory	O
.	O

Behavior	O
scientists	O
have	O
amassed	O
much	O
useful	O
information	O
about	O
the	O
principles	O
underlying	O
human	B
behavior	O
that	O
should	O
be	O
valuable	O
for	O
health	O
behavior	O
interventions	O
.	O

Much	O
is	O
known	O
about	O
human	B
perception	O
,	O
learning	O
,	O
motivation	O
,	O
and	O
responsiveness	O
to	O
environmental	O
opportunities	O
and	O
contingencies	O
.	O

Health	O
behavior	O
intervention	O
lies	O
at	O
the	O
interface	O
between	O
people	O
and	O
their	O
environment	O
.	O

Interventionists	O
change	O
aspects	O
of	O
the	O
environment	O
(	O
cues	O
,	O
information	O
,	O
behavioral	O
contingencies	O
)	O
with	O
the	O
intention	O
of	O
producing	O
changes	O
in	O
how	O
people	O
behave	O
.	O

What	O
is	O
needed	O
to	O
advance	O
health	O
behavior	O
intervention	O
is	O
theory	O
that	O
addresses	O
relationships	O
between	O
modifiable	O
aspects	O
of	O
the	O
environment	O
and	O
behavior	O
.	O

There	O
is	O
no	O
doubt	O
that	O
cognitive	O
processes	O
are	O
involved	O
in	O
these	O
relationships	O
.	O

However	O
,	O
the	O
extent	O
to	O
which	O
current	O
theories	O
capture	O
this	O
is	O
questionable	O
.	O

Data	O
now	O
available	O
suggest	O
that	O
easily	O
obtainable	O
information	O
about	O
people	O
's	O
cognitive	O
processes	O
adds	O
little	O
to	O
our	O
ability	O
to	O
predict	O
the	O
results	O
of	O
interventions	O
.	O

Thus	O
,	O
it	O
may	O
be	O
wise	O
to	O
pay	O
more	O
attention	O
to	O
applied	O
theories	O
like	O
classical	O
behavior	O
theory	O
[	O
25	O
]	O
,	O
communications	O
theory	O
[	O
26	O
]	O
,	O
and	O
learning	O
theory	O
[	O
27	O
]	O
than	O
to	O
those	O
coming	O
out	O
of	O
the	O
social	O
cognitive	O
traditions	O
.	O

Competing	O
interests	O
None	O
declared	O
.	O

Thumb	O
force	O
deficit	O
after	O
lower	O
median	O
nerve	O
block	O
Abstract	O
Purpose	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
characterize	O
thumb	O
motor	O
dysfunction	O
resulting	O
from	O
simulated	O
lower	O
median	O
nerve	O
lesions	O
at	O
the	O
wrist	O
.	O

Methods	O
Bupivacaine	O
hydrochloride	O
was	O
injected	O
into	O
the	O
carpal	O
tunnel	O
of	O
six	O
healthy	O
subjects	O
to	O
locally	O
anesthetize	O
the	O
median	O
nerve	O
.	O

Motor	O
function	O
was	O
subsequently	O
evaluated	O
by	O
measuring	O
maximal	O
force	O
production	O
in	O
all	O
directions	O
within	O
the	O
transverse	O
plane	O
perpendicular	O
to	O
the	O
longitudinal	O
axis	O
of	O
the	O
thumb	O
.	O

Force	O
envelopes	O
were	O
constructed	O
using	O
these	O
measured	O
multidirectional	O
forces	O
.	O

Results	O
Blockage	O
of	O
the	O
median	O
nerve	O
resulted	O
in	O
decreased	O
force	O
magnitudes	O
and	O
thus	O
smaller	O
force	O
envelopes	O
.	O

The	O
average	O
force	O
decrease	O
around	O
the	O
force	O
envelope	O
was	O
27.9	O
%	O
.	O

A	O
maximum	O
decrease	O
of	O
42.4	O
%	O
occurred	O
in	O
a	O
direction	O
combining	O
abduction	O
and	O
slight	O
flexion	O
,	O
while	O
a	O
minimum	O
decrease	O
of	O
10.5	O
%	O
occurred	O
in	O
a	O
direction	O
combining	O
adduction	O
and	O
slight	O
flexion	O
.	O

Relative	O
decreases	O
in	O
adduction	O
,	O
extension	O
,	O
abduction	O
,	O
and	O
flexion	O
were	O
17.3	O
%	O
,	O
21.2	O
%	O
,	O
41.2	O
%	O
and	O
33.5	O
%	O
,	O
respectively	O
.	O

Areas	O
enclosed	O
by	O
pre-	O
and	O
post	O
-	O
block	O
force	O
envelopes	O
were	O
20628	O
±	O
7747	O
N.N	O
,	O
and	O
10700	O
±	O
4474	O
N.N	O
,	O
respectively	O
,	O
representing	O
an	O
average	O
decrease	O
of	O
48.1	O
%	O
.	O

Relative	O
decreases	O
in	O
the	O
adduction	O
,	O
extension	O
,	O
abduction	O
,	O
and	O
flexion	O
quadrant	O
areas	O
were	O
31.5	O
%	O
,	O
42.3	O
%	O
,	O
60.9	O
%	O
,	O
and	O
52.3	O
%	O
,	O
respectively	O
.	O

Conclusion	O
Lower	O
median	O
nerve	O
lesion	O
,	O
simulated	O
by	O
a	O
nerve	O
block	O
at	O
the	O
wrist	O
,	O
compromise	O
normal	O
motor	O
function	O
of	O
the	O
thumb	O
.	O

A	O
median	O
nerve	O
block	O
results	O
in	O
force	O
deficits	O
in	O
all	O
directions	O
,	O
with	O
the	O
most	O
severe	O
impairment	O
in	O
abduction	O
and	O
flexion	O
.	O

From	O
our	O
results	O
,	O
such	O
a	O
means	O
of	O
motor	O
function	O
assessment	O
can	O
potentially	O
be	O
applied	O
to	O
functionally	O
evaluate	O
peripheral	O
neuropathies	O
.	O

Introduction	O
The	O
thumb	O
has	O
unique	O
anatomical	O
and	O
biomechanical	O
characteristics	O
that	O
are	O
required	O
to	O
perform	O
many	O
manipulative	O
tasks	O
.	O

Thumb	O
motor	O
dysfunction	O
resulting	O
from	O
neuromuscular	O
and	O
musculoskeletal	O
pathologies	O
severely	O
hinders	O
the	O
performance	O
of	O
these	O
daily	O
tasks	O
.	O

Clinical	O
treatment	O
,	O
prevention	O
protocols	O
,	O
and	O
rehabilitation	O
efficacy	O
requires	O
a	O
thorough	O
understanding	O
of	O
thumb	O
motor	O
capabilities	O
,	O
as	O
well	O
as	O
its	O
associated	O
functional	O
deficit	O
.	O

Investigations	O
of	O
underlying	O
pathological	O
mechanism	O
of	O
the	O
thumb	O
help	O
advance	O
clinical	O
treatments	O
such	O
as	O
tendon	O
transfers	O
[	O
1	O
]	O
,	O
functional	O
electrical	O
stimulation	O
[	O
2	O
]	O
and	O
plasticity	O
suppression	O
[	O
3	O
]	O
.	O

Measurement	O
of	O
strength	O
during	O
maximum	O
voluntary	O
contraction	O
is	O
a	O
simple	O
and	O
direct	O
means	O
of	O
assessing	O
neuromuscular	O
function	O
.	O

Popular	O
instruments	O
used	O
for	O
quantitative	O
assessment	O
of	O
thumb	O
strength	O
are	O
pinch	O
dynamometers	O
.	O

The	O
pinch	O
output	O
,	O
however	O
,	O
provides	O
limited	O
information	O
about	O
thumb	O
motor	O
function	O
in	O
that	O
it	O
offers	O
a	O
single	O
generic	O
force	O
in	O
one	O
specific	O
direction	O
.	O

Each	O
muscle	O
/	O
tendon	O
within	O
the	O
thumb	O
has	O
a	O
distinct	O
anatomical	O
origin	O
and	O
insertion	O
,	O
suggesting	O
its	O
external	O
force	O
potential	O
in	O
a	O
particular	O
direction	O
[	O
4	O
-	O
6	O
]	O
.	O

Hence	O
,	O
evaluation	O
of	O
strengths	O
in	O
multiple	O
directions	O
offers	O
insight	O
concerning	O
the	O
motor	O
capacity	O
of	O
individual	O
muscles	O
.	O

Force	O
production	O
of	O
a	O
digit	O
has	O
been	O
measured	O
in	O
various	O
directions	O
such	O
as	O
flexion	O
/	O
extension	O
[	O
7,8	O
]	O
,	O
abduction	O
/	O
adduction	O
[	O
9	O
-	O
14	O
]	O
,	O
or	O
in	O
combined	O
directions	O
[	O
15,16	O
]	O
.	O

Bourbonnais	O
et	O
al.	O
developed	O
an	O
apparatus	O
to	O
measure	O
thumb	O
force	O
production	O
in	O
eight	O
directions	O
in	O
the	O
transverse	O
plane	O
of	O
the	O
thumb	O
and	O
investigated	O
force	O
dependence	O
on	O
the	O
direction	O
of	O
effort	O
[	O
15	O
]	O
.	O

Yokogawa	O
and	O
Hara	O
measured	O
index	O
fingertip	O
forces	O
in	O
various	O
directions	O
within	O
the	O
flexion	O
/	O
extension	O
plane	O
[	O
8	O
]	O
.	O

Recently	O
,	O
we	O
developed	O
experimental	O
apparatuses	O
to	O
measure	O
multi	O
-	O
directional	O
forces	O
of	O
a	O
digit	O
in	O
its	O
transverse	O
plane	O
[	O
17	O
-	O
19	O
]	O
.	O

From	O
these	O
multi	O
-	O
directional	O
forces	O
we	O
constructed	O
force	O
envelopes	O
representative	O
of	O
the	O
characteristic	O
force	O
output	O
pattern	O
of	O
a	O
digit	O
[	O
17	O
-	O
19	O
]	O
.	O

Disorders	O
resulting	O
from	O
traumatic	O
injuries	O
to	O
and	O
various	O
diseases	O
of	O
these	O
nerves	O
are	O
common	O
in	O
clinical	O
practice	O
.	O

Clinical	O
manifestations	O
of	O
hand	O
dysfunction	O
are	O
distinctive	O
depending	O
on	O
the	O
nerve	O
involved	O
.	O

For	O
example	O
,	O
thenar	O
atrophy	O
is	O
a	O
major	O
clinical	O
observation	O
affecting	O
thumb	O
function	O
at	O
the	O
later	O
stages	O
of	O
compression	O
neuropathy	O
of	O
the	O
median	O
nerve	O
.	O

Several	O
studies	O
have	O
been	O
conducted	O
to	O
investigate	O
the	O
effects	O
of	O
simulated	O
peripheral	O
neuropathies	O
using	O
local	O
anesthetization	O
[	O
5,16,20,21	O
]	O
.	O

Kozin	O
et	O
al.	O
[	O
21	O
]	O
studied	O
the	O
effects	O
of	O
median	O
and	O
ulnar	O
nerve	O
blocks	O
on	O
grip	O
and	O
pinch	O
strength	O
and	O
showed	O
significant	O
decreases	O
following	O
nerve	O
blockage	O
[	O
21	O
]	O
.	O

Boatright	O
and	O
Kiebzak	O
[	O
20	O
]	O
investigated	O
the	O
effects	O
of	O
median	O
nerve	O
block	O
on	O
thumb	O
abduction	O
strength	O
.	O

Kaufman	O
et	O
al.	O
[	O
5	O
]	O
measured	O
isometric	O
thumb	O
forces	O
in	O
eight	O
directions	O
together	O
with	O
electromyographic	O
signals	O
of	O
thumb	O
muscles	O
after	O
block	O
of	O
the	O
median	O
nerve	O
.	O

Labosky	O
and	O
Waggy	O
[	O
22	O
]	O
studied	O
the	O
strength	O
related	O
to	O
grip	O
,	O
pinch	O
,	O
thumb	O
adduction	O
,	O
thumb	O
abduction	O
,	O
and	O
finger	O
flexion	O
after	O
radial	O
nerve	O
block	O
[	O
22	O
]	O
.	O

Kuxhaus	O
studied	O
the	O
three	O
dimensional	O
feasible	O
force	O
set	O
at	O
the	O
thumb	O
-	O
tip	O
before	O
and	O
after	O
ulnar	O
nerve	O
block	O
and	O
reported	O
this	O
to	O
be	O
a	O
reproducible	O
and	O
sensitive	O
means	O
to	O
detect	O
impairment	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
utilize	O
our	O
developed	O
apparatus	O
and	O
protocols	O
to	O
investigate	O
the	O
effects	O
of	O
lower	O
median	O
nerve	O
lesion	O
on	O
thumb	O
motor	O
function	O
.	O

The	O
lesion	O
was	O
simulated	O
by	O
blocking	O
the	O
median	O
nerve	O
at	O
the	O
wrist	O
using	O
an	O
anesthetic	O
.	O

We	O
hypothesized	O
that	O
a	O
median	O
nerve	O
block	O
would	O
cause	O
(	O
1	O
)	O
a	O
decrease	O
in	O
force	O
production	O
,	O
which	O
would	O
be	O
direction	O
-	O
dependent	O
with	O
the	O
most	O
severe	O
reduction	O
in	O
the	O
abduction	O
direction	O
,	O
and	O
(	O
2	O
)	O
a	O
decrease	O
in	O
the	O
force	O
envelope	O
area	O
and	O
force	O
quadrant	O
area	O
,	O
with	O
the	O
greatest	O
decrease	O
in	O
the	O
abduction	O
quadrant	O
.	O

Methods	O
Subjects	O
Six	O
healthy	O
male	O
subjects	O
(	O
mean	O
age	O
:	O
26.9	O
±	O
5.1	O
years	O
)	O
participated	O
in	O
this	O
study	O
.	O

The	O
subjects	O
had	O
no	O
previous	O
history	O
of	O
neuromuscular	O
or	O
musculoskeletal	O
disorders	O
of	O
the	O
upper	O
extremities	O
.	O

Each	O
subject	O
signed	O
an	O
informed	O
consent	O
form	O
approved	O
by	O
the	O
Institutional	O
Review	O
Board	O
prior	O
to	O
participating	O
in	O
the	O
experiment	O
.	O

Median	O
nerve	O
block	O
Injections	O
were	O
performed	O
under	O
aseptic	O
conditions	O
while	O
the	O
subjects	O
sat	O
with	O
the	O
forearm	O
supinated	O
and	O
the	O
wrist	O
slightly	O
extended	O
.	O

After	O
the	O
skin	O
at	O
the	O
palmer	O
area	O
of	O
the	O
wrist	O
was	O
cleaned	O
with	O
alcohol	O
,	O
4	O
mL	O
of	O
0.5	O
%	O
bupivacaine	O
hydrochloride	O
(	O
Astra	O
Pharmaceuticals	O
,	O
Westborough	O
,	O
MA	O
,	O
USA	O
)	O
was	O
injected	O
into	O
the	O
carpal	O
tunnel	O
with	O
a	O
sterile	O
25-gauge	O
short	O
-	O
bevel	O
needle	O
.	O

The	O
needle	O
was	O
inserted	O
through	O
the	O
transverse	O
carpal	O
ligament	O
in	O
line	O
with	O
the	O
radial	O
border	O
of	O
the	O
fourth	O
digit	O
slightly	O
ulnar	O
to	O
the	O
palmaris	O
longus	O
tendon	O
at	O
the	O
level	O
of	O
the	O
distal	O
wrist	O
crease	O
.	O

Forty	O
minutes	O
was	O
allowed	O
for	O
the	O
median	O
nerve	O
block	O
to	O
reach	O
complete	O
effectiveness	O
[	O
23	O
]	O
and	O
was	O
verified	O
using	O
the	O
Semmes	O
-	O
Weinstein	O
monofilament	O
test	O
.	O

The	O
average	O
monofilament	O
score	O
was	O
2.85	O
across	O
the	O
five	O
digits	O
before	O
nerve	O
block	O
.	O

About	O
40	O
minutes	O
after	O
nerve	O
injection	O
,	O
little	O
sensory	O
impairment	O
occurred	O
in	O
the	O
ulnar	O
distribution	O
(	O
score	O
=	O
3.22	O
)	O
,	O
while	O
the	O
sensory	O
score	O
in	O
the	O
median	O
distribution	O
was	O
greater	O
than	O
6.15	O
.	O

The	O
effects	O
of	O
nerve	O
block	O
lasted	O
more	O
than	O
6	O
hours	O
with	O
all	O
subjects	O
regaining	O
normal	O
hand	O
function	O
within	O
12	O
hours	O
.	O

Testing	O
apparatus	O
The	O
experimental	O
apparatus	O
was	O
designed	O
and	O
constructed	O
to	O
measure	O
maximum	O
voluntary	O
contraction	O
forces	O
of	O
any	O
digit	O
at	O
any	O
point	O
along	O
the	O
digit	O
.	O

Force	O
application	O
was	O
possible	O
in	O
any	O
direction	O
within	O
the	O
transverse	O
plane	O
of	O
the	O
longitudinal	O
axis	O
of	O
the	O
digit	O
.	O

The	O
apparatus	O
consisted	O
of	O
position	O
control	O
accessories	O
,	O
a	O
force	O
transducer	O
,	O
and	O
a	O
custom	O
fitted	O
aluminum	O
ring	O
attached	O
to	O
the	O
transducer	O
(	O
Figure	O
1A,1B	O
)	O
.	O

The	O
transducer	O
(	O
Mini40	O
,	O
ATI	O
Industrial	O
Automation	O
,	O
NC	O
,	O
USA	O
)	O
,	O
capable	O
of	O
measuring	O
6	O
degrees	O
of	O
freedom	O
forces	O
and	O
moments	O
,	O
was	O
attached	O
to	O
a	O
mounting	O
clamp	O
via	O
an	O
aluminum	O
adapter	O
plate	O
while	O
the	O
aluminum	O
ring	O
was	O
secured	O
to	O
the	O
tool	O
side	O
of	O
the	O
transducer	O
using	O
a	O
custom	O
adapter	O
.	O

The	O
ring	O
served	O
as	O
a	O
connection	O
anchor	O
for	O
the	O
transducer	O
and	O
the	O
digit	O
.	O

The	O
force	O
transducer	O
and	O
ring	O
attachment	O
were	O
positioned	O
in	O
a	O
desired	O
orientation	O
using	O
an	O
aluminum	O
slide	O
rail	O
,	O
tubing	O
,	O
and	O
lockable	O
mounting	O
clamps	O
(	O
80	O
/	O
20	O
Inc.	O
,	O
Columbia	O
City	O
,	O
IN	O
,	O
USA	O
)	O
.	O

The	O
slide	O
rail	O
was	O
secured	O
to	O
an	O
aluminum	O
base	O
plate	O
.	O

Foam	O
padded	O
wooden	O
blocks	O
with	O
two	O
locking	O
straps	O
secured	O
the	O
arm	O
to	O
the	O
base	O
plate	O
.	O

The	O
analog	O
outputs	O
from	O
the	O
transducer	O
were	O
digitized	O
using	O
a	O
16-bit	O
analog	O
-	O
to	O
-	O
digital	O
converter	O
(	O
PCI-6031	O
,	O
National	O
Instruments	O
,	O
TX	O
,	O
USA	O
)	O
.	O

The	O
X	O
(	O
abduction	O
/	O
adduction	O
)	O
and	O
Y	O
(	O
flexion	O
/	O
extension	O
)	O
force	O
components	O
in	O
the	O
transverse	O
plane	O
were	O
displayed	O
on	O
the	O
screen	O
while	O
the	O
subject	O
performed	O
a	O
force	O
production	O
task	O
.	O

The	O
resolutions	O
of	O
the	O
force	O
transducer	O
in	O
its	O
axial	O
(	O
flexion	O
/	O
extension	O
)	O
and	O
horizontal	O
(	O
abduction	O
/	O
adduction	O
)	O
directions	O
were	O
0.16	O
N	O
and	O
0.08	O
N	O
,	O
respectively	O
.	O

A	O
personal	O
computer	O
equipped	O
with	O
LabVIEW	O
(	O
National	O
Instrument	O
,	O
TX	O
,	O
USA	O
)	O
was	O
used	O
for	O
force	O
data	O
acquisition	O
,	O
display	O
,	O
and	O
processing	O
.	O

Experimental	O
procedures	O
Each	O
subject	O
was	O
tested	O
before	O
and	O
after	O
median	O
nerve	O
block	O
.	O

The	O
nerve	O
block	O
procedures	O
were	O
performed	O
immediately	O
after	O
the	O
completion	O
of	O
the	O
first	O
testing	O
session	O
.	O

Post	O
-	O
block	O
testing	O
started	O
after	O
the	O
verification	O
of	O
complete	O
median	O
nerve	O
block	O
,	O
approximately	O
40	O
minutes	O
after	O
the	O
injection	O
.	O

During	O
each	O
test	O
,	O
the	O
subject	O
was	O
seated	O
in	O
a	O
chair	O
adjacent	O
to	O
the	O
testing	O
station	O
modified	O
with	O
a	O
wooden	O
board	O
to	O
align	O
their	O
back	O
vertically	O
throughout	O
the	O
trials	O
.	O

The	O
subjects	O
rested	O
their	O
forearm	O
on	O
padded	O
wooden	O
blocks	O
positioning	O
their	O
shoulder	O
in	O
approximately	O
60	O
°	O
of	O
frontal	O
plane	O
abduction	O
.	O

Nylon	O
straps	O
fitted	O
with	O
plastic	O
snap	O
locking	O
mechanisms	O
secured	O
the	O
forearm	O
and	O
minimized	O
the	O
intervention	O
of	O
the	O
elbow	O
and	O
shoulder	O
during	O
thumb	O
force	O
application	O
.	O

Subjects	O
grasped	O
a	O
vertical	O
dowel	O
secured	O
to	O
the	O
distal	O
end	O
of	O
the	O
wooden	O
blocks	O
in	O
a	O
midprone	O
position	O
.	O

Formable	O
thermoplastic	O
braces	O
were	O
used	O
to	O
fix	O
the	O
elbow	O
in	O
90	O
°	O
of	O
flexion	O
,	O
and	O
the	O
wrist	O
in	O
20	O
°	O
of	O
extension	O
and	O
0	O
°	O
of	O
ulnar	O
deviation	O
.	O

A	O
metallic	O
brace	O
was	O
used	O
to	O
fix	O
the	O
interphalangeal	O
joint	O
of	O
the	O
thumb	O
in	O
full	O
extension	O
.	O

The	O
aluminum	O
ring	O
was	O
placed	O
around	O
the	O
middle	O
of	O
the	O
proximal	O
phalanx	O
and	O
oriented	O
to	O
accommodate	O
comfortable	O
thumb	O
position	O
with	O
the	O
metacarpophalangeal	O
joint	O
flexed	O
approximately	O
15	O
°	O
.	O

Prior	O
to	O
testing	O
,	O
a	O
line	O
was	O
drawn	O
on	O
the	O
proximal	O
phalange	O
at	O
the	O
midpoint	O
between	O
the	O
interphalangeal	O
and	O
metacarpophalangeal	O
joints	O
.	O

The	O
alignment	O
of	O
the	O
ring	O
with	O
the	O
circumferential	O
line	O
standardized	O
the	O
location	O
of	O
force	O
application	O
within	O
and	O
between	O
subjects	O
.	O

As	O
force	O
application	O
was	O
at	O
the	O
middle	O
of	O
the	O
proximal	O
phalanx	O
,	O
mechanical	O
action	O
pertains	O
to	O
both	O
the	O
metacarpophalangeal	O
and	O
carpometacarpal	O
joints	O
.	O

We	O
chose	O
the	O
terminology	O
of	O
flexion	O
/	O
extension	O
and	O
adduction	O
/	O
adduction	O
based	O
on	O
the	O
mechanical	O
action	O
with	O
respect	O
to	O
the	O
metacarpophalangeal	O
joint	O
.	O

With	O
the	O
thumb	O
in	O
the	O
ring	O
(	O
Figure	O
1B	O
)	O
,	O
extension	O
and	O
flexion	O
occurred	O
in	O
parallel	O
with	O
the	O
palm	O
,	O
and	O
abduction	O
and	O
adduction	O
occurred	O
in	O
a	O
plane	O
perpendicular	O
to	O
the	O
palm	O
.	O

Each	O
subject	O
performed	O
15	O
circumferential	O
MVC	O
trials	O
with	O
randomized	O
starting	O
directions	O
(	O
Figure	O
1C	O
)	O
.	O

The	O
subject	O
was	O
allotted	O
15	O
seconds	O
to	O
complete	O
each	O
circumferential	O
trial	O
,	O
and	O
was	O
instructed	O
to	O
use	O
the	O
entire	O
time	O
allotted	O
to	O
traverse	O
the	O
perimeter	O
of	O
the	O
ring	O
once	O
.	O

A	O
dot	O
generated	O
on	O
the	O
computer	O
screen	O
was	O
programmed	O
to	O
traverse	O
a	O
circle	O
within	O
15	O
seconds	O
to	O
provide	O
the	O
subject	O
with	O
directional	O
feedback	O
of	O
their	O
force	O
application	O
.	O

Subjects	O
were	O
given	O
60	O
seconds	O
of	O
rest	O
between	O
each	O
circumferential	O
trial	O
.	O

Each	O
subject	O
was	O
familiarized	O
with	O
the	O
task	O
with	O
a	O
few	O
practice	O
trials	O
.	O

Data	O
were	O
collected	O
from	O
each	O
subject	O
at	O
100	O
samples	O
per	O
second	O
producing	O
a	O
total	O
of	O
22,500	O
pairs	O
of	O
force	O
components	O
from	O
the	O
15	O
circumferential	O
trials	O
.	O

Our	O
previous	O
study	O
[	O
19	O
]	O
indicated	O
that	O
the	O
testing	O
protocol	O
did	O
not	O
cause	O
noticeable	O
fatigue	O
.	O

Force	O
envelope	O
and	O
quadrants	O
Data	O
from	O
multiple	O
circumferential	O
trials	O
were	O
accumulated	O
to	O
construct	O
a	O
force	O
envelope	O
.	O

The	O
procedures	O
to	O
generate	O
a	O
force	O
envelope	O
were	O
as	O
follows	O
:	O
Cartesian	O
force	O
coordinates	O
(	O
Xi	O
,	O
Yi	O
)	O
were	O
transformed	O
into	O
polar	O
coordinates	O
(	O
Rα	O
,	O
α	O
)	O
,	O
where	O
Rα	O
was	O
the	O
force	O
magnitude	O
at	O
an	O
angular	O
position	O
α	O
.	O

Each	O
α	O
was	O
rounded	O
to	O
the	O
nearest	O
integer	O
ranging	O
from	O
0	O
to	O
359	O
degrees	O
.	O

The	O
maximum	O
,	O
Fα	O
,	O
was	O
determined	O
from	O
a	O
string	O
of	O
N	O
data	O
points	O
along	O
each	O
radial	O
line	O
defined	O
by	O
α	O
.	O

At	O
the	O
completion	O
of	O
the	O
15	O
trials	O
,	O
there	O
were	O
,	O
on	O
average	O
,	O
N	O
=	O
63	O
data	O
points	O
on	O
each	O
radial	O
line	O
of	O
α	O
based	O
on	O
the	O
distribution	O
off	O
the	O
22,500	O
data	O
points	O
around	O
360	O
°	O
.	O

A	O
moving	O
average	O
with	O
an	O
interval	O
of	O
10	O
°	O
was	O
applied	O
to	O
the	O
maximal	O
series	O
data	O
Fα	O
(	O
α	O
=	O
0	O
,	O
1	O
,	O
2	O
,	O
...	O
,	O
359	O
)	O
to	O
obtain	O
filtered	O
maximal	O
forces	O
.	O

These	O
forces	O
formed	O
a	O
force	O
envelope	O
.	O

The	O
area	O
formed	O
by	O
a	O
force	O
envelope	O
was	O
divided	O
into	O
adduction	O
-	O
extension	O
,	O
extension	O
-	O
abduction	O
,	O
abduction	O
-	O
flexion	O
,	O
and	O
flexion	O
-	O
adduction	O
quadrants	O
by	O
radial	O
lines	O
oriented	O
at	O
0	O
°	O
,	O
90	O
°	O
,	O
180	O
°	O
,	O
and	O
270	O
°	O
A	O
quadrant	O
force	O
was	O
represented	O
using	O
the	O
mean	O
magnitude	O
of	O
the	O
forces	O
in	O
that	O
quadrant	O
.	O

The	O
areas	O
of	O
the	O
entire	O
envelope	O
and	O
each	O
quadrant	O
were	O
calculated	O
by	O
summing	O
the	O
areas	O
of	O
individual	O
arc	O
sections	O
formed	O
by	O
the	O
polar	O
coordinates	O
of	O
the	O
force	O
envelope	O
.	O

(	O
Figure	O
2	O
)	O
.	O

Statistical	O
Analyses	O
One-	O
and	O
two	O
-	O
factor	O
repeated	O
measures	O
analyses	O
of	O
variance	O
(	O
ANOVA	O
)	O
were	O
used	O
to	O
analyze	O
outcome	O
measures	O
.	O

The	O
independent	O
variables	O
were	O
testing	O
SESSION	O
(	O
n	O
=	O
2	O
,	O
i.e.	O
,	O
pre-	O
and	O
post	O
-	O
block	O
)	O
,	O
force	O
DIRECTION	O
(	O
n	O
=	O
16	O
)	O
,	O
and	O
force	O
QUADRANT	O
(	O
n	O
=	O
4	O
)	O
,	O
with	O
SESSION	O
as	O
a	O
repeated	O
variable	O
.	O

Dependent	O
variables	O
were	O
directional	O
force	O
,	O
individual	O
quadrant	O
area	O
and	O
force	O
envelope	O
area	O
.	O

Statistical	O
analyses	O
were	O
performed	O
using	O
SPSS	O
11	O
(	O
SPSS	O
Inc.	O
,	O
Illinois	O
)	O
with	O
statistical	O
significance	O
set	O
at	O
α	O
=	O
0.05	O
.	O

Results	O
Force	O
envelope	O
and	O
directional	O
forces	O
Figure	O
3	O
shows	O
the	O
force	O
envelopes	O
produced	O
by	O
each	O
subject	O
(	O
A	O
to	O
F	O
)	O
before	O
and	O
after	O
median	O
nerve	O
block	O
.	O

The	O
post	O
-	O
block	O
force	O
envelope	O
was	O
inside	O
the	O
pre	O
-	O
block	O
envelope	O
for	O
each	O
subject	O
,	O
indicating	O
a	O
decrease	O
in	O
force	O
magnitude	O
in	O
all	O
directions	O
after	O
nerve	O
block	O
.	O

Figure	O
4	O
shows	O
the	O
average	O
pre-	O
and	O
post	O
-	O
block	O
force	O
envelope	O
across	O
all	O
subjects	O
.	O

Force	O
magnitudes	O
were	O
significantly	O
reduced	O
after	O
nerve	O
block	O
(	O
p	O
<	O
0.001	O
)	O
resulting	O
in	O
significantly	O
smaller	O
force	O
envelopes	O
.	O

The	O
average	O
decrease	O
across	O
all	O
directions	O
was	O
27.9	O
%	O
.	O

A	O
maximum	O
decrease	O
of	O
42.4	O
%	O
occurred	O
at	O
199	O
°	O
,	O
corresponding	O
to	O
a	O
combined	O
direction	O
of	O
abduction	O
and	O
slight	O
flexion	O
,	O
while	O
a	O
minimum	O
decrease	O
of	O
10.5	O
%	O
occurred	O
at	O
328	O
°	O
corresponding	O
to	O
a	O
combined	O
direction	O
of	O
adduction	O
and	O
slight	O
flexion	O
.	O

Relative	O
decreases	O
at	O
0	O
°	O
(	O
adduction	O
)	O
,	O
90	O
°	O
(	O
extension	O
)	O
,	O
180	O
°	O
(	O
abduction	O
)	O
,	O
and	O
270	O
°	O
(	O
flexion	O
)	O
directions	O
were	O
17.3	O
%	O
,	O
21.2	O
%	O
,	O
41.2	O
%	O
and	O
33.5	O
%	O
,	O
respectively	O
.	O

A	O
single	O
force	O
in	O
each	O
quadrant	O
was	O
represented	O
using	O
the	O
mean	O
magnitude	O
of	O
the	O
forces	O
in	O
that	O
quadrant	O
(	O
see	O
description	O
in	O
the	O
Methods	O
)	O
.	O

The	O
average	O
quadrant	O
forces	O
were	O
significantly	O
decreased	O
after	O
nerve	O
block	O
(	O
p	O
<	O
0.001	O
;	O
Figure	O
5	O
)	O
.	O

The	O
amount	O
of	O
decrease	O
was	O
also	O
different	O
between	O
quadrants	O
(	O
p	O
<	O
0.005	O
)	O
.	O

Relative	O
decreases	O
in	O
mean	O
quadrant	O
forces	O
were	O
24.5	O
%	O
,	O
38.7	O
%	O
,	O
32.1	O
%	O
,	O
and	O
18.1	O
%	O
for	O
extension	O
,	O
abduction	O
,	O
flexion	O
,	O
and	O
adduction	O
,	O
respectively	O
.	O

The	O
maximal	O
decreases	O
in	O
mean	O
quadrant	O
force	O
,	O
38.7	O
%	O
,	O
occurred	O
in	O
the	O
abduction	O
quadrant	O
.	O

Force	O
envelope	O
areas	O
and	O
quadrant	O
areas	O
Areas	O
enclosed	O
by	O
the	O
post	O
-	O
block	O
envelopes	O
were	O
significantly	O
smaller	O
than	O
the	O
pre	O
-	O
block	O
envelopes	O
(	O
p	O
<	O
0.001	O
;	O
Figure	O
4	O
)	O
.	O

Post	O
-	O
block	O
force	O
envelope	O
area	O
,	O
10700	O
±	O
4474	O
N.N	O
,	O
was	O
51.9	O
%	O
of	O
pre	O
-	O
block	O
force	O
envelope	O
area	O
,	O
20628	O
±	O
7747	O
N.N.	O
Quadrant	O
area	O
decreased	O
significantly	O
(	O
p	O
<	O
0.001	O
;	O
Figure	O
6	O
)	O
.	O

The	O
maximal	O
percentage	O
decrease	O
in	O
area	O
after	O
nerve	O
block	O
was	O
60.9	O
%	O
in	O
the	O
abduction	O
quadrant	O
,	O
followed	O
by	O
a	O
52.3	O
%	O
area	O
decrease	O
in	O
the	O
flexion	O
quadrant	O
.	O

Discussion	O
In	O
this	O
study	O
we	O
simulated	O
a	O
lower	O
median	O
nerve	O
lesion	O
and	O
evaluated	O
the	O
resultant	O
thumb	O
motor	O
function	O
deficit	O
.	O

Our	O
internal	O
control	O
via	O
pre-	O
and	O
post	O
-	O
block	O
design	O
offered	O
a	O
particular	O
advantage	O
of	O
investigating	O
the	O
mechanical	O
role	O
of	O
muscles	O
innervated	O
by	O
a	O
targeted	O
nerve	O
.	O

The	O
testing	O
and	O
analytical	O
methods	O
employed	O
have	O
provided	O
advanced	O
quantification	O
of	O
thumb	O
motor	O
function	O
.	O

The	O
results	O
have	O
confirmed	O
our	O
initial	O
hypotheses	O
that	O
greatest	O
force	O
decreases	O
occurred	O
in	O
directions	O
related	O
to	O
abduction	O
,	O
and	O
that	O
the	O
post	O
-	O
block	O
thumb	O
force	O
envelope	O
area	O
was	O
smaller	O
than	O
the	O
pre	O
-	O
block	O
force	O
envelope	O
area	O
.	O

Preferential	O
force	O
attenuation	O
in	O
the	O
quadrants	O
of	O
abduction	O
and	O
flexion	O
after	O
median	O
nerve	O
block	O
are	O
in	O
agreement	O
with	O
anatomical	O
and	O
neuromuscular	O
features	O
of	O
the	O
thumb	O
.	O

The	O
median	O
nerve	O
innervates	O
the	O
abductor	O
pollicis	O
brevis	O
,	O
the	O
opponens	O
pollicis	O
and	O
superficial	O
head	O
of	O
the	O
flexor	O
pollicis	O
brevis	O
,	O
all	O
of	O
which	O
contribute	O
to	O
the	O
abduction	O
and	O
flexion	O
of	O
the	O
thumb	O
[	O
4	O
]	O
;	O
therefore	O
,	O
denervation	O
of	O
these	O
muscles	O
after	O
median	O
nerve	O
block	O
would	O
cause	O
the	O
greatest	O
force	O
deficit	O
related	O
to	O
median	O
nerve	O
function	O
[	O
5	O
]	O
.	O

Additionally	O
,	O
as	O
force	O
application	O
moved	O
towards	O
adduction	O
,	O
the	O
force	O
deficit	O
decreased	O
as	O
neuromuscular	O
control	O
shifted	O
from	O
the	O
median	O
nerve	O
to	O
the	O
ulnar	O
nerve	O
via	O
the	O
first	O
dorsal	O
interosseous	O
and	O
adductor	O
pollicis	O
brevis	O
.	O

Force	O
deficit	O
in	O
extension	O
was	O
also	O
comparably	O
small	O
as	O
extension	O
forces	O
are	O
mainly	O
produced	O
by	O
the	O
extensors	O
pollicis	O
brevis	O
and	O
longus	O
originating	O
in	O
the	O
forearm	O
.	O

Our	O
reported	O
force	O
decreases	O
following	O
a	O
median	O
nerve	O
block	O
(	O
40.9	O
%	O
in	O
abduction	O
,	O
34.1	O
%	O
in	O
flexion	O
)	O
were	O
smaller	O
than	O
those	O
reported	O
in	O
the	O
literature	O
.	O

Kozin	O
et	O
al.	O
[	O
21	O
]	O
reported	O
a	O
60	O
%	O
decrease	O
in	O
pinch	O
strength	O
after	O
a	O
median	O
nerve	O
block	O
using	O
mepivicaine	O
hydrochloride	O
[	O
21	O
]	O
.	O

Boatright	O
and	O
Kiebzak	O
[	O
20	O
]	O
reported	O
an	O
approximate	O
70	O
%	O
decrease	O
in	O
thumb	O
abduction	O
strength	O
after	O
median	O
nerve	O
block	O
using	O
Lidocaine	O
[	O
20	O
]	O
.	O

Kaufman	O
et	O
al.	O
[	O
5	O
]	O
stated	O
that	O
a	O
median	O
nerve	O
block	O
with	O
Lidocaine	O
almost	O
completely	O
diminished	O
force	O
production	O
in	O
the	O
abduction	O
direction	O
[	O
5	O
]	O
.	O

The	O
discrepancy	O
may	O
be	O
due	O
to	O
the	O
anesthetic	O
used	O
and	O
strength	O
testing	O
method	O
.	O

Although	O
the	O
sensory	O
block	O
appeared	O
to	O
be	O
complete	O
for	O
each	O
method	O
,	O
the	O
motor	O
capabilities	O
of	O
the	O
muscles	O
associated	O
with	O
the	O
median	O
nerve	O
might	O
or	O
might	O
not	O
be	O
completely	O
eliminated	O
.	O

Such	O
a	O
result	O
is	O
largely	O
dependent	O
on	O
a	O
particular	O
anesthetic	O
,	O
its	O
concentration	O
and	O
dosage	O
,	O
as	O
well	O
as	O
the	O
efficacy	O
of	O
the	O
injection	O
technique	O
at	O
immersing	O
the	O
nerve	O
.	O

The	O
methods	O
of	O
strength	O
testing	O
may	O
also	O
help	O
explain	O
the	O
different	O
magnitudes	O
of	O
strength	O
deficit	O
after	O
the	O
nerve	O
block	O
.	O

All	O
previous	O
results	O
were	O
based	O
on	O
forces	O
obtained	O
in	O
discrete	O
direction	O
(	O
s	O
)	O
,	O
and	O
focused	O
exertions	O
,	O
while	O
the	O
current	O
study	O
utilized	O
a	O
method	O
of	O
force	O
production	O
in	O
a	O
continuous	O
,	O
circumferential	O
and	O
dynamic	O
manner	O
.	O

Furthermore	O
,	O
thumb	O
motor	O
performance	O
can	O
be	O
maintained	O
despite	O
the	O
absence	O
of	O
certain	O
individual	O
muscles	O
.	O

For	O
example	O
,	O
Britto	O
and	O
Elliot	O
reported	O
that	O
the	O
loss	O
of	O
abductor	O
pollicis	O
longus	O
and	O
extensor	O
pollicis	O
brevis	O
in	O
their	O
two	O
patients	O
did	O
not	O
show	O
functional	O
compromise	O
of	O
strength	O
and	O
grip	O
strength	O
[	O
24	O
]	O
.	O

In	O
a	O
broader	O
sense	O
,	O
the	O
neuromuscular	O
system	O
has	O
remarkable	O
capabilities	O
to	O
accomplish	O
the	O
same	O
motor	O
function	O
goal	O
using	O
different	O
effectors	O
and	O
different	O
goals	O
using	O
the	O
same	O
effectors	O
,	O
a	O
phenomenon	O
so	O
called	O
""""	O
motor	O
equivalence	O
""""	O
[	O
25	O
]	O
.	O

An	O
unexpected	O
finding	O
from	O
this	O
study	O
was	O
that	O
the	O
force	O
deficit	O
occurred	O
in	O
all	O
directions	O
(	O
Figure	O
4	O
)	O
.	O

In	O
other	O
words	O
,	O
the	O
median	O
nerve	O
block	O
caused	O
reduced	O
force	O
production	O
by	O
those	O
muscles	O
not	O
associated	O
with	O
the	O
median	O
nerve	O
.	O

Several	O
potential	O
explanations	O
exist	O
to	O
describe	O
such	O
a	O
phenomenon	O
.	O

First	O
,	O
the	O
injection	O
into	O
the	O
carpal	O
tunnel	O
at	O
the	O
wrist	O
,	O
although	O
localized	O
,	O
potentially	O
diffused	O
into	O
the	O
intrinsic	O
fascia	O
of	O
the	O
hand	O
partially	O
compromising	O
function	O
of	O
the	O
ulnar	O
nerve	O
,	O
which	O
innervates	O
the	O
adductor	O
pollicis	O
.	O

Although	O
Semmes	O
-	O
Weinstein	O
monofilament	O
testing	O
confirmed	O
the	O
continued	O
sensation	O
of	O
the	O
digits	O
within	O
the	O
ulnar	O
nerve	O
distribution	O
,	O
it	O
is	O
not	O
inconceivable	O
that	O
the	O
injection	O
could	O
have	O
contaminated	O
the	O
ulnar	O
innervated	O
muscles	O
,	O
the	O
first	O
dorsal	O
interosseous	O
and	O
deep	O
head	O
of	O
the	O
flexor	O
pollicis	O
brevis	O
[	O
20	O
]	O
.	O

Secondly	O
,	O
thumb	O
force	O
in	O
any	O
direction	O
is	O
produced	O
by	O
synergistic	O
activation	O
of	O
the	O
many	O
intrinsic	O
muscles	O
,	O
and	O
as	O
a	O
result	O
,	O
the	O
muscular	O
deficiency	O
associated	O
with	O
one	O
direction	O
may	O
hinder	O
the	O
force	O
production	O
in	O
other	O
directions	O
by	O
other	O
muscles	O
[	O
5,22	O
]	O
.	O

For	O
example	O
,	O
Kaufman	O
et	O
al.	O
demonstrated	O
that	O
thumb	O
muscles	O
not	O
innervated	O
by	O
the	O
median	O
nerve	O
displayed	O
lower	O
electromyographical	O
activation	O
and	O
shifted	O
the	O
direction	O
of	O
maximum	O
activation	O
after	O
a	O
median	O
nerve	O
block	O
[	O
5	O
]	O
.	O

Labosky	O
and	O
Waggy	O
showed	O
that	O
a	O
radial	O
nerve	O
block	O
caused	O
a	O
53	O
%	O
decrease	O
in	O
thumb	O
abduction	O
strength	O
because	O
of	O
the	O
lack	O
of	O
stabilization	O
of	O
the	O
radial	O
innervated	O
extensor	O
muscles	O
[	O
22	O
]	O
.	O

Consequently	O
,	O
deficiency	O
of	O
median	O
innervated	O
muscles	O
inherently	O
limits	O
force	O
production	O
in	O
other	O
directions	O
as	O
neuromuscular	O
switching	O
is	O
necessary	O
to	O
produce	O
force	O
in	O
changing	O
directions	O
.	O

The	O
median	O
innervated	O
muscles	O
are	O
the	O
dominant	O
abductors	O
of	O
the	O
thumb	O
metacarpophalangeal	O
and	O
carpometacarpal	O
joint	O
.	O

The	O
more	O
than	O
50	O
%	O
residual	O
abduction	O
force	O
found	O
in	O
this	O
study	O
suggests	O
that	O
the	O
injection	O
did	O
not	O
totally	O
block	O
the	O
motor	O
function	O
of	O
these	O
muscles	O
,	O
even	O
though	O
a	O
complete	O
sensory	O
loss	O
was	O
verified	O
.	O

This	O
concurs	O
with	O
clinical	O
observations	O
of	O
median	O
compression	O
neuropathy	O
.	O

Individuals	O
with	O
carpal	O
tunnel	O
syndrome	O
complain	O
of	O
sensory	O
dysfunction	O
early	O
in	O
the	O
disease	O
process	O
(	O
at	O
the	O
beginning	O
)	O
,	O
while	O
motor	O
signs	O
of	O
thenar	O
wasting	O
and	O
thumb	O
weakness	O
occur	O
as	O
the	O
disease	O
advances	O
.	O

The	O
concept	O
that	O
the	O
motor	O
deficit	O
is	O
more	O
resistant	O
to	O
peripheral	O
median	O
neuropathy	O
than	O
sensory	O
loss	O
has	O
been	O
well	O
documented	O
[	O
23,26,27	O
]	O
.	O

Butterworth	O
et	O
al.	O
studied	O
the	O
temporal	O
effects	O
on	O
sensory	O
and	O
motor	O
blockade	O
after	O
injection	O
of	O
bupivacaine	O
or	O
mepivacaine	O
,	O
and	O
found	O
that	O
sensory	O
loss	O
was	O
complete	O
but	O
about	O
a	O
20	O
%	O
compound	O
motor	O
action	O
potential	O
remained	O
after	O
40	O
minutes	O
[	O
23	O
]	O
.	O

In	O
conclusion	O
,	O
we	O
have	O
incorporated	O
a	O
method	O
for	O
assessing	O
thumb	O
motor	O
deficit	O
based	O
on	O
strength	O
measurement	O
with	O
a	O
standard	O
local	O
anesthetic	O
to	O
investigate	O
the	O
effects	O
of	O
a	O
simulated	O
median	O
neuropathy	O
on	O
thumb	O
motor	O
function	O
.	O

Median	O
nerve	O
block	O
results	O
in	O
force	O
deficits	O
in	O
all	O
directions	O
,	O
with	O
the	O
most	O
severe	O
impairment	O
in	O
abduction	O
and	O
flexion	O
.	O

Future	O
endeavors	O
using	O
this	O
methodology	O
can	O
potentially	O
further	O
elucidate	O
underlying	O
pathomechanisms	O
of	O
peripheral	O
neuropathies	O
in	O
all	O
digits	O
of	O
the	O
hand	O
.	O

